can,reduce,the 1.0 0.00200688073394 14 0 14
reduce,the,natriuretic 1.0 0.00186353211009 13 0 13
inhibit,the,metabolism 1.0 0.00172018348624 12 0 12
enhance,the,effects 1.0 0.00172018348624 12 0 12
and,should,not 1.0 0.00157683486239 11 0 11
the,qt,interval 1.0 0.00143348623853 10 0 10
may,antagonize,the 1.0 0.00143348623853 10 0 10
increased,the,auc 1.0 0.00143348623853 10 0 10
increase,in,cmax 1.0 0.00143348623853 10 0 10
significant,increase,in 1.0 0.00129013761468 9 0 9
metabolism,of,resulting 1.0 0.00129013761468 9 0 9
in,a,decrease 1.0 0.00129013761468 9 0 9
elevated,serum,levels 1.0 0.00129013761468 9 0 9
auc,and,a 1.0 0.00129013761468 9 0 9
and,may,increase 1.0 0.00129013761468 9 0 9
and,a,increase 1.0 0.00129013761468 9 0 9
the,antihypertensive,effect 1.0 0.00114678899083 8 0 8
reported,to,reduce 1.0 0.00114678899083 8 0 8
of,the,qt 1.0 0.00114678899083 8 0 8
may,diminish,the 1.0 0.00114678899083 8 0 8
in,a,increase 1.0 0.00114678899083 8 0 8
buffered,tablets,or 1.0 0.00114678899083 8 0 8
been,reported,when 1.0 0.00114678899083 8 0 8
be,monitored,when 1.0 0.00114678899083 8 0 8
with,vardenafil,mg 1.0 0.00100344036697 7 0 7
when,and,are 1.0 0.00100344036697 7 0 7
this,interaction,should 1.0 0.00100344036697 7 0 7
the,natriuretic,and 1.0 0.00100344036697 7 0 7
the,hypotensive,effect 1.0 0.00100344036697 7 0 7
that,nsaids,may 1.0 0.00100344036697 7 0 7
suggest,that,nsaids 1.0 0.00100344036697 7 0 7
some,patients,the 1.0 0.00100344036697 7 0 7
shown,to,increase 1.0 0.00100344036697 7 0 7
renal,clearance,and 1.0 0.00100344036697 7 0 7
qt,interval,on 1.0 0.00100344036697 7 0 7
powder,for,oral 1.0 0.00100344036697 7 0 7
pediatric,powder,for 1.0 0.00100344036697 7 0 7
of,decreased,the 1.0 0.00100344036697 7 0 7
of,and,is 1.0 0.00100344036697 7 0 7
nsaids,may,diminish 1.0 0.00100344036697 7 0 7
levels,of,the 1.0 0.00100344036697 7 0 7
is,coadministered,with 1.0 0.00100344036697 7 0 7
initiation,of,treatment 1.0 0.00100344036697 7 0 7
initiation,of,therapy 1.0 0.00100344036697 7 0 7
in,a,hour 1.0 0.00100344036697 7 0 7
have,an,additive 1.0 0.00100344036697 7 0 7
given,consideration,in 1.0 0.00100344036697 7 0 7
for,oral,solution 1.0 0.00100344036697 7 0 7
doses,of,may 1.0 0.00100344036697 7 0 7
consideration,in,patients 1.0 0.00100344036697 7 0 7
chewable,buffered,tablets 1.0 0.00100344036697 7 0 7
by,and,respectively 1.0 0.00100344036697 7 0 7
be,given,consideration 1.0 0.00100344036697 7 0 7
an,additive,effect 1.0 0.00100344036697 7 0 7
a,hour,period 1.0 0.00100344036697 7 0 7
with,the,concomitant 1.0 0.000860091743119 6 0 6
with,may,increase 1.0 0.000860091743119 6 0 6
the,pediatric,powder 1.0 0.000860091743119 6 0 6
that,the,concomitant 1.0 0.000860091743119 6 0 6
taken,at,least 1.0 0.000860091743119 6 0 6
tablets,or,the 1.0 0.000860091743119 6 0 6
studies,as,well 1.0 0.000860091743119 6 0 6
severe,hypoglycemia,has 1.0 0.000860091743119 6 0 6
risk,of,serious 1.0 0.000860091743119 6 0 6
oxidase,inhibitors,and 1.0 0.000860091743119 6 0 6
or,the,pediatric 1.0 0.000860091743119 6 0 6
of,with,may 1.0 0.000860091743119 6 0 6
observations,have,shown 1.0 0.000860091743119 6 0 6
observation,of,the 1.0 0.000860091743119 6 0 6
nephrotoxicity,has,been 1.0 0.000860091743119 6 0 6
mean,cmax,and 1.0 0.000860091743119 6 0 6
may,delay,intestinal 1.0 0.000860091743119 6 0 6
levels,be,monitored 1.0 0.000860091743119 6 0 6
inhibits,the,metabolism 1.0 0.000860091743119 6 0 6
increase,in,mean 1.0 0.000860091743119 6 0 6
in,an,approximate 1.0 0.000860091743119 6 0 6
hypotensive,effect,of 1.0 0.000860091743119 6 0 6
elevated,plasma,levels 1.0 0.000860091743119 6 0 6
effects,of,loop 1.0 0.000860091743119 6 0 6
effect,when,given 1.0 0.000860091743119 6 0 6
during,therapy,with 1.0 0.000860091743119 6 0 6
caution,to,patients 1.0 0.000860091743119 6 0 6
blocking,action,of 1.0 0.000860091743119 6 0 6
be,used,if 1.0 0.000860091743119 6 0 6
be,taken,at 1.0 0.000860091743119 6 0 6
antihypertensive,effect,of 1.0 0.000860091743119 6 0 6
and,an,increase 1.0 0.000860091743119 6 0 6
and,add,a 1.0 0.000860091743119 6 0 6
and,a,fold 1.0 0.000860091743119 6 0 6
amphetamines,may,delay 1.0 0.000860091743119 6 0 6
add,a,high 1.0 0.000860091743119 6 0 6
a,high,risk 1.0 0.000860091743119 6 0 6
with,caution,to 1.0 0.000716743119266 5 0 5
with,b-blocking,properties 1.0 0.000716743119266 5 0 5
will,depend,on 1.0 0.000716743119266 5 0 5
when,is,added 1.0 0.000716743119266 5 0 5
when,given,with 1.0 0.000716743119266 5 0 5
videx,chewable,buffered 1.0 0.000716743119266 5 0 5
the,or,increasing 1.0 0.000716743119266 5 0 5
standing,systolic,blood 1.0 0.000716743119266 5 0 5
shown,to,interfere 1.0 0.000716743119266 5 0 5
result,in,elevated 1.0 0.000716743119266 5 0 5
reported,to,result 1.0 0.000716743119266 5 0 5
reduction,of,blood 1.0 0.000716743119266 5 0 5
problems,will,depend 1.0 0.000716743119266 5 0 5
possibility,of,hypotensive 1.0 0.000716743119266 5 0 5
pose,clinical,problems 1.0 0.000716743119266 5 0 5
pharmacokinetics,of,the 1.0 0.000716743119266 5 0 5
peak,plasma,levels 1.0 0.000716743119266 5 0 5
patients,the,administration 1.0 0.000716743119266 5 0 5
oxidase,inhibitors,or 1.0 0.000716743119266 5 0 5
on,the,degree 1.0 0.000716743119266 5 0 5
of,serious,infections 1.0 0.000716743119266 5 0 5
of,leading,to 1.0 0.000716743119266 5 0 5
of,inhibition,and 1.0 0.000716743119266 5 0 5
of,hypotensive,effects 1.0 0.000716743119266 5 0 5
of,and,can 1.0 0.000716743119266 5 0 5
nsaids,can,reduce 1.0 0.000716743119266 5 0 5
non-steroidal,anti-inflammatory,agents 1.0 0.000716743119266 5 0 5
minimized,by,either 1.0 0.000716743119266 5 0 5
may,produce,severe 1.0 0.000716743119266 5 0 5
may,pose,clinical 1.0 0.000716743119266 5 0 5
may,occasionally,experience 1.0 0.000716743119266 5 0 5
may,counteract,the 1.0 0.000716743119266 5 0 5
mao,inhibitors,prolong 1.0 0.000716743119266 5 0 5
lithium,generally,should 1.0 0.000716743119266 5 0 5
is,initiated,in 1.0 0.000716743119266 5 0 5
is,administered,concomitantly 1.0 0.000716743119266 5 0 5
inhibitors,prolong,and 1.0 0.000716743119266 5 0 5
inhibition,and,the 1.0 0.000716743119266 5 0 5
in,whom,therapy 1.0 0.000716743119266 5 0 5
in,prolongation,of 1.0 0.000716743119266 5 0 5
in,elevated,plasma 1.0 0.000716743119266 5 0 5
in,clearance,and 1.0 0.000716743119266 5 0 5
hormonal,may,increase 1.0 0.000716743119266 5 0 5
has,shown,a 1.0 0.000716743119266 5 0 5
generally,should,not 1.0 0.000716743119266 5 0 5
furosemide,clinical,studies 1.0 0.000716743119266 5 0 5
for,days,resulted 1.0 0.000716743119266 5 0 5
excretion,of,is 1.0 0.000716743119266 5 0 5
excessive,reduction,of 1.0 0.000716743119266 5 0 5
elevation,of,plasma 1.0 0.000716743119266 5 0 5
either,discontinuing,the 1.0 0.000716743119266 5 0 5
discontinuing,the,or 1.0 0.000716743119266 5 0 5
decreased,the,auc 1.0 0.000716743119266 5 0 5
days,resulted,in 1.0 0.000716743119266 5 0 5
concomitantly,with,or 1.0 0.000716743119266 5 0 5
clinical,problems,will 1.0 0.000716743119266 5 0 5
can,be,minimized 1.0 0.000716743119266 5 0 5
by,up,to 1.0 0.000716743119266 5 0 5
by,either,discontinuing 1.0 0.000716743119266 5 0 5
be,minimized,by 1.0 0.000716743119266 5 0 5
auc,of,by 1.0 0.000716743119266 5 0 5
antihypertensive,effects,of 1.0 0.000716743119266 5 0 5
and,the,pharmacokinetics 1.0 0.000716743119266 5 0 5
and,symptoms,of 1.0 0.000716743119266 5 0 5
and,prolongation,of 1.0 0.000716743119266 5 0 5
and,oral,hypoglycemic 1.0 0.000716743119266 5 0 5
and,or,other 1.0 0.000716743119266 5 0 5
and,may,cause 1.0 0.000716743119266 5 0 5
and,effects,of 1.0 0.000716743119266 5 0 5
and,adjustment,of 1.0 0.000716743119266 5 0 5
an,average,of 1.0 0.000716743119266 5 0 5
amphotericin,b,and 1.0 0.000716743119266 5 0 5
agents,with,b-blocking 1.0 0.000716743119266 5 0 5
agents,are,used 1.0 0.000716743119266 5 0 5
agent,can,reduce 1.0 0.000716743119266 5 0 5
additive,effects,on 1.0 0.000716743119266 5 0 5
additive,effect,when 1.0 0.000716743119266 5 0 5
with,monoamine,oxidase 1.0 0.000573394495413 4 0 4
with,mg,bid 1.0 0.000573394495413 4 0 4
with,mao,inhibitors 1.0 0.000573394495413 4 0 4
with,a,decrease 1.0 0.000573394495413 4 0 4
whom,therapy,was 1.0 0.000573394495413 4 0 4
which,ssri-tca,interactions 1.0 0.000573394495413 4 0 4
which,can,result 1.0 0.000573394495413 4 0 4
when,is,used 1.0 0.000573394495413 4 0 4
when,initiating,adjusting 1.0 0.000573394495413 4 0 4
was,recently,instituted 1.0 0.000573394495413 4 0 4
was,administered,hours 1.0 0.000573394495413 4 0 4
warranted,appropriate,observation 1.0 0.000573394495413 4 0 4
use,of,may 1.0 0.000573394495413 4 0 4
toxicity,have,been 1.0 0.000573394495413 4 0 4
toxicity,has,been 1.0 0.000573394495413 4 0 4
to,which,ssri-tca 1.0 0.000573394495413 4 0 4
to,increase,plasma 1.0 0.000573394495413 4 0 4
to,enhance,the 1.0 0.000573394495413 4 0 4
thus,inhibiting,the 1.0 0.000573394495413 4 0 4
those,in,whom 1.0 0.000573394495413 4 0 4
therefore,co-administration,of 1.0 0.000573394495413 4 0 4
therapy,with,a 1.0 0.000573394495413 4 0 4
therapy,was,recently 1.0 0.000573394495413 4 0 4
the,tubular,secretion 1.0 0.000573394495413 4 0 4
the,salt,intake 1.0 0.000573394495413 4 0 4
the,metabolic,clearance 1.0 0.000573394495413 4 0 4
the,hypoglycemic,action 1.0 0.000573394495413 4 0 4
the,central,stimulant 1.0 0.000573394495413 4 0 4
that,nsaids,can 1.0 0.000573394495413 4 0 4
that,are,highly 1.0 0.000573394495413 4 0 4
taking,nsaids,concomitantly 1.0 0.000573394495413 4 0 4
symptoms,of,toxicity 1.0 0.000573394495413 4 0 4
such,as,because 1.0 0.000573394495413 4 0 4
such,as,are 1.0 0.000573394495413 4 0 4
substantially,interfere,with 1.0 0.000573394495413 4 0 4
subjects,should,be 1.0 0.000573394495413 4 0 4
steady-state,serum,concentrations 1.0 0.000573394495413 4 0 4
ssri-tca,interactions,may 1.0 0.000573394495413 4 0 4
ssri,is,clinically 1.0 0.000573394495413 4 0 4
shown,that,nsaids 1.0 0.000573394495413 4 0 4
salt,intake,prior 1.0 0.000573394495413 4 0 4
resulting,in,lower 1.0 0.000573394495413 4 0 4
reports,of,patients 1.0 0.000573394495413 4 0 4
regimen,of,mg 1.0 0.000573394495413 4 0 4
produced,an,elevation 1.0 0.000573394495413 4 0 4
probenecid,as,with 1.0 0.000573394495413 4 0 4
pressure,after,initiation 1.0 0.000573394495413 4 0 4
plasma,auc,and 1.0 0.000573394495413 4 0 4
period,when,used 1.0 0.000573394495413 4 0 4
patients,taking,nsaids 1.0 0.000573394495413 4 0 4
patients,on,chronic 1.0 0.000573394495413 4 0 4
patients,concomitantly,receiving 1.0 0.000573394495413 4 0 4
oral,solution,may 1.0 0.000573394495413 4 0 4
oral,response,ie 1.0 0.000573394495413 4 0 4
or,its,derivatives 1.0 0.000573394495413 4 0 4
or,increasing,the 1.0 0.000573394495413 4 0 4
of,with,or 1.0 0.000573394495413 4 0 4
of,which,can 1.0 0.000573394495413 4 0 4
of,were,reduced 1.0 0.000573394495413 4 0 4
of,the,possibility 1.0 0.000573394495413 4 0 4
of,resulted,in 1.0 0.000573394495413 4 0 4
of,may,reduce 1.0 0.000573394495413 4 0 4
occasionally,experience,an 1.0 0.000573394495413 4 0 4
observed,carefully,for 1.0 0.000573394495413 4 0 4
natriuretic,and,effects 1.0 0.000573394495413 4 0 4
metabolism,of,which 1.0 0.000573394495413 4 0 4
metabolism,of,leading 1.0 0.000573394495413 4 0 4
may,be,inhibited 1.0 0.000573394495413 4 0 4
may,also,result 1.0 0.000573394495413 4 0 4
maximum,plasma,concentration 1.0 0.000573394495413 4 0 4
levels,and,prolongation 1.0 0.000573394495413 4 0 4
is,clinically,warranted 1.0 0.000573394495413 4 0 4
interactions,may,pose 1.0 0.000573394495413 4 0 4
interactions,for,vitamin 1.0 0.000573394495413 4 0 4
intake,prior,to 1.0 0.000573394495413 4 0 4
inhibitors,and,beta 1.0 0.000573394495413 4 0 4
inhibiting,the,central 1.0 0.000573394495413 4 0 4
indicate,that,oral 1.0 0.000573394495413 4 0 4
increasing,the,salt 1.0 0.000573394495413 4 0 4
increasing,the,dose 1.0 0.000573394495413 4 0 4
increase,the,concentration 1.0 0.000573394495413 4 0 4
increase,in,peak 1.0 0.000573394495413 4 0 4
in,the,area 1.0 0.000573394495413 4 0 4
in,peak,plasma 1.0 0.000573394495413 4 0 4
in,patients,undergoing 1.0 0.000573394495413 4 0 4
in,increases,in 1.0 0.000573394495413 4 0 4
in,cases,of 1.0 0.000573394495413 4 0 4
in,an,increased 1.0 0.000573394495413 4 0 4
in,a,reduction 1.0 0.000573394495413 4 0 4
if,concomitant,treatment 1.0 0.000573394495413 4 0 4
hypotensive,effects,with 1.0 0.000573394495413 4 0 4
hypoglycemic,action,of 1.0 0.000573394495413 4 0 4
hour,period,when 1.0 0.000573394495413 4 0 4
fold,and,the 1.0 0.000573394495413 4 0 4
experienced,a,standing 1.0 0.000573394495413 4 0 4
experience,an,excessive 1.0 0.000573394495413 4 0 4
especially,those,in 1.0 0.000573394495413 4 0 4
enhance,the,neuromuscular 1.0 0.000573394495413 4 0 4
effects,of,are 1.0 0.000573394495413 4 0 4
effects,affecting,the 1.0 0.000573394495413 4 0 4
dose,should,not 1.0 0.000573394495413 4 0 4
diminish,the,effect 1.0 0.000573394495413 4 0 4
decreased,the,plasma 1.0 0.000573394495413 4 0 4
day,of,a 1.0 0.000573394495413 4 0 4
cyp3a4,substrate,by 1.0 0.000573394495413 4 0 4
cyp3a4,inhibitors,such 1.0 0.000573394495413 4 0 4
course,of,at 1.0 0.000573394495413 4 0 4
concurrently,subjects,should 1.0 0.000573394495413 4 0 4
co-administered,with,vardenafil 1.0 0.000573394495413 4 0 4
cns,depressants,including 1.0 0.000573394495413 4 0 4
clinically,warranted,appropriate 1.0 0.000573394495413 4 0 4
clearance,and,add 1.0 0.000573394495413 4 0 4
certain,including,nonsteroidal 1.0 0.000573394495413 4 0 4
carefully,for,signs 1.0 0.000573394495413 4 0 4
blood,pressure,after 1.0 0.000573394495413 4 0 4
because,they,reduce 1.0 0.000573394495413 4 0 4
be,additive,with 1.0 0.000573394495413 4 0 4
auc,of,a 1.0 0.000573394495413 4 0 4
are,administered,concurrently 1.0 0.000573394495413 4 0 4
aprepitant,when,given 1.0 0.000573394495413 4 0 4
approximate,increase,in 1.0 0.000573394495413 4 0 4
approximate,decrease,in 1.0 0.000573394495413 4 0 4
appropriate,observation,of 1.0 0.000573394495413 4 0 4
and,type,c 1.0 0.000573394495413 4 0 4
and,renal,function 1.0 0.000573394495413 4 0 4
and,possibly,other 1.0 0.000573394495413 4 0 4
and,other,nsaids 1.0 0.000573394495413 4 0 4
and,or,the 1.0 0.000573394495413 4 0 4
and,mg,produced 1.0 0.000573394495413 4 0 4
and,mg,of 1.0 0.000573394495413 4 0 4
and,cmin,were 1.0 0.000573394495413 4 0 4
and,are,administered 1.0 0.000573394495413 4 0 4
and,an,ssri 1.0 0.000573394495413 4 0 4
and,a,reduction 1.0 0.000573394495413 4 0 4
an,ssri,is 1.0 0.000573394495413 4 0 4
an,excessive,reduction 1.0 0.000573394495413 4 0 4
an,elevation,of 1.0 0.000573394495413 4 0 4
an,approximate,increase 1.0 0.000573394495413 4 0 4
an,approximate,decrease 1.0 0.000573394495413 4 0 4
administered,concurrently,subjects 1.0 0.000573394495413 4 0 4
additive,or,potentiating 1.0 0.000573394495413 4 0 4
additive,cns,depressant 1.0 0.000573394495413 4 0 4
a,standing,systolic 1.0 0.000573394495413 4 0 4
with,the,combination 1.0 0.00043004587156 3 0 3
with,the,bactericidal 1.0 0.00043004587156 3 0 3
with,other,psychotropic 1.0 0.00043004587156 3 0 3
with,other,nsaids 1.0 0.00043004587156 3 0 3
with,other,cns 1.0 0.00043004587156 3 0 3
with,other,b-lactam 1.0 0.00043004587156 3 0 3
with,of,the 1.0 0.00043004587156 3 0 3
with,may,result 1.0 0.00043004587156 3 0 3
with,inhibitors,of 1.0 0.00043004587156 3 0 3
with,in,healthy 1.0 0.00043004587156 3 0 3
with,caution,because 1.0 0.00043004587156 3 0 3
with,care,in 1.0 0.00043004587156 3 0 3
with,because,they 1.0 0.00043004587156 3 0 3
with,as,hypercalcemia 1.0 0.00043004587156 3 0 3
with,and,an 1.0 0.00043004587156 3 0 3
who,are,on 1.0 0.00043004587156 3 0 3
which,promote,absorption 1.0 0.00043004587156 3 0 3
when,indocin,and 1.0 0.00043004587156 3 0 3
when,a,is 1.0 0.00043004587156 3 0 3
well,as,post-marketing 1.0 0.00043004587156 3 0 3
week,course,of 1.0 0.00043004587156 3 0 3
volunteers,concomitant,administration 1.0 0.00043004587156 3 0 3
vitamin,d3,calcitriol 1.0 0.00043004587156 3 0 3
vitamin,d2,vitamin 1.0 0.00043004587156 3 0 3
vitamin,d,dosage 1.0 0.00043004587156 3 0 3
vitamin,d,by 1.0 0.00043004587156 3 0 3
used,if,is 1.0 0.00043004587156 3 0 3
use,of,ergotamine-containing 1.0 0.00043004587156 3 0 3
urinary,acidifying,agents 1.0 0.00043004587156 3 0 3
upon,discontinuation,of 1.0 0.00043004587156 3 0 3
up,to,and 1.0 0.00043004587156 3 0 3
undergoing,treatment,with 1.0 0.00043004587156 3 0 3
treatment,with,as 1.0 0.00043004587156 3 0 3
treatment,with,and 1.0 0.00043004587156 3 0 3
to,severe,hypoglycemia 1.0 0.00043004587156 3 0 3
to,reduce,intestinal 1.0 0.00043004587156 3 0 3
to,lead,to 1.0 0.00043004587156 3 0 3
to,increased,plasma 1.0 0.00043004587156 3 0 3
to,exceed,a 1.0 0.00043004587156 3 0 3
to,elevated,serum 1.0 0.00043004587156 3 0 3
to,decrease,plasma 1.0 0.00043004587156 3 0 3
to,avoid,possible 1.0 0.00043004587156 3 0 3
they,reduce,its 1.0 0.00043004587156 3 0 3
therapy,with,vitamin 1.0 0.00043004587156 3 0 3
therapy,patients,on 1.0 0.00043004587156 3 0 3
the,vasodilating,effects 1.0 0.00043004587156 3 0 3
the,steady-state,auc 1.0 0.00043004587156 3 0 3
the,serum,levels 1.0 0.00043004587156 3 0 3
the,potent,cyp3a4 1.0 0.00043004587156 3 0 3
the,oral,or 1.0 0.00043004587156 3 0 3
the,oral,absorption 1.0 0.00043004587156 3 0 3
the,molecule,thereby 1.0 0.00043004587156 3 0 3
the,mean,cmax 1.0 0.00043004587156 3 0 3
the,maximum,plasma 1.0 0.00043004587156 3 0 3
the,hepatic,metabolism 1.0 0.00043004587156 3 0 3
the,half-life,of 1.0 0.00043004587156 3 0 3
the,first,few 1.0 0.00043004587156 3 0 3
the,dose,should 1.0 0.00043004587156 3 0 3
the,combination,may 1.0 0.00043004587156 3 0 3
the,cmax,of 1.0 0.00043004587156 3 0 3
the,cardiovascular,system 1.0 0.00043004587156 3 0 3
the,ace,inhibitor 1.0 0.00043004587156 3 0 3
that,the,dose 1.0 0.00043004587156 3 0 3
that,the,combination 1.0 0.00043004587156 3 0 3
that,levels,be 1.0 0.00043004587156 3 0 3
that,clearance,is 1.0 0.00043004587156 3 0 3
that,are,potent 1.0 0.00043004587156 3 0 3
than,when,either 1.0 0.00043004587156 3 0 3
tcas,with,any 1.0 0.00043004587156 3 0 3
taking,with,or 1.0 0.00043004587156 3 0 3
taken,during,therapy 1.0 0.00043004587156 3 0 3
t,i,d 1.0 0.00043004587156 3 0 3
synthetic,and,catabolic 1.0 0.00043004587156 3 0 3
suggest,a,possible 1.0 0.00043004587156 3 0 3
substrate,by,fold 1.0 0.00043004587156 3 0 3
steady-state,trough,concentrations 1.0 0.00043004587156 3 0 3
steady-state,cmax,a 1.0 0.00043004587156 3 0 3
species,of,the 1.0 0.00043004587156 3 0 3
some,resulting,in 1.0 0.00043004587156 3 0 3
some,reports,have 1.0 0.00043004587156 3 0 3
solutions,containing,or 1.0 0.00043004587156 3 0 3
since,there,have 1.0 0.00043004587156 3 0 3
signs,or,symptoms 1.0 0.00043004587156 3 0 3
should,therefore,not 1.0 0.00043004587156 3 0 3
should,elapse,between 1.0 0.00043004587156 3 0 3
should,be,withdrawn 1.0 0.00043004587156 3 0 3
should,be,undertaken 1.0 0.00043004587156 3 0 3
several,days,before 1.0 0.00043004587156 3 0 3
seizures,have,been 1.0 0.00043004587156 3 0 3
secretion,of,and 1.0 0.00043004587156 3 0 3
resulting,in,an 1.0 0.00043004587156 3 0 3
resulted,in,increases 1.0 0.00043004587156 3 0 3
result,in,prolongation 1.0 0.00043004587156 3 0 3
result,in,additive 1.0 0.00043004587156 3 0 3
response,in,man 1.0 0.00043004587156 3 0 3
requires,close,monitoring 1.0 0.00043004587156 3 0 3
reports,of,theophylline-related 1.0 0.00043004587156 3 0 3
reports,have,shown 1.0 0.00043004587156 3 0 3
reported,to,enhance 1.0 0.00043004587156 3 0 3
reported,in,a 1.0 0.00043004587156 3 0 3
reported,during,concomitant 1.0 0.00043004587156 3 0 3
relationship,of,functional 1.0 0.00043004587156 3 0 3
reduced,to,one-half 1.0 0.00043004587156 3 0 3
reduce,the,antihypertensive 1.0 0.00043004587156 3 0 3
reduce,plasma,concentrations 1.0 0.00043004587156 3 0 3
reduce,its,renal 1.0 0.00043004587156 3 0 3
reduce,intestinal,absorption 1.0 0.00043004587156 3 0 3
recommended,that,levels 1.0 0.00043004587156 3 0 3
recommended,due,to 1.0 0.00043004587156 3 0 3
recommended,because,of 1.0 0.00043004587156 3 0 3
recently,instituted,may 1.0 0.00043004587156 3 0 3
receiving,concomitantly,with 1.0 0.00043004587156 3 0 3
receiving,catecholamine-depleting,such 1.0 0.00043004587156 3 0 3
receiving,ace,inhibitors 1.0 0.00043004587156 3 0 3
qd,resulted,in 1.0 0.00043004587156 3 0 3
prothrombin,time,is 1.0 0.00043004587156 3 0 3
protein,bound,monoamine 1.0 0.00043004587156 3 0 3
promote,absorption,and 1.0 0.00043004587156 3 0 3
prior,to,a 1.0 0.00043004587156 3 0 3
preparations,eg,may 1.0 0.00043004587156 3 0 3
potentiated,by,certain 1.0 0.00043004587156 3 0 3
post-marketing,observations,have 1.0 0.00043004587156 3 0 3
possible,drug,interaction 1.0 0.00043004587156 3 0 3
plasma,concentrations,include 1.0 0.00043004587156 3 0 3
plasma,concentration,and 1.0 0.00043004587156 3 0 3
pharmacokinetic,analyses,indicate 1.0 0.00043004587156 3 0 3
period,in,patients 1.0 0.00043004587156 3 0 3
patients,taking,with 1.0 0.00043004587156 3 0 3
patients,receiving,other 1.0 0.00043004587156 3 0 3
patients,receiving,concomitantly 1.0 0.00043004587156 3 0 3
patients,receiving,catecholamine-depleting 1.0 0.00043004587156 3 0 3
patients,on,diuretic 1.0 0.00043004587156 3 0 3
patients,on,and 1.0 0.00043004587156 3 0 3
patients,may,precipitate 1.0 0.00043004587156 3 0 3
other,that,produce 1.0 0.00043004587156 3 0 3
other,should,be 1.0 0.00043004587156 3 0 3
oral,and,oral 1.0 0.00043004587156 3 0 3
or,without,other 1.0 0.00043004587156 3 0 3
or,videx,chewable 1.0 0.00043004587156 3 0 3
or,to,patients 1.0 0.00043004587156 3 0 3
or,the,side 1.0 0.00043004587156 3 0 3
or,proton,pump 1.0 0.00043004587156 3 0 3
or,potentiating,effect 1.0 0.00043004587156 3 0 3
or,may,produce 1.0 0.00043004587156 3 0 3
or,ergot-type,medications 1.0 0.00043004587156 3 0 3
or,bezalip,retard 1.0 0.00043004587156 3 0 3
or,are,expected 1.0 0.00043004587156 3 0 3
on,therapy,may 1.0 0.00043004587156 3 0 3
on,the,cardiovascular 1.0 0.00043004587156 3 0 3
on,diuretic,therapy 1.0 0.00043004587156 3 0 3
on,day,when 1.0 0.00043004587156 3 0 3
on,and,especially 1.0 0.00043004587156 3 0 3
of,with,mg 1.0 0.00043004587156 3 0 3
of,toxicity,have 1.0 0.00043004587156 3 0 3
of,the,molecule 1.0 0.00043004587156 3 0 3
of,tcas,with 1.0 0.00043004587156 3 0 3
of,oral,and 1.0 0.00043004587156 3 0 3
of,mg,with 1.0 0.00043004587156 3 0 3
of,mg,daily 1.0 0.00043004587156 3 0 3
of,may,decrease 1.0 0.00043004587156 3 0 3
of,local,solutions 1.0 0.00043004587156 3 0 3
of,is,recommended 1.0 0.00043004587156 3 0 3
of,is,impaired 1.0 0.00043004587156 3 0 3
of,increased,plasma 1.0 0.00043004587156 3 0 3
of,gi,ulceration 1.0 0.00043004587156 3 0 3
of,functional,antagonism 1.0 0.00043004587156 3 0 3
of,ergotamine-containing,or 1.0 0.00043004587156 3 0 3
of,by,decreased 1.0 0.00043004587156 3 0 3
of,by,but 1.0 0.00043004587156 3 0 3
of,by,approximately 1.0 0.00043004587156 3 0 3
of,by,a 1.0 0.00043004587156 3 0 3
of,angiotensin,converting 1.0 0.00043004587156 3 0 3
of,and,thus 1.0 0.00043004587156 3 0 3
of,a,strong 1.0 0.00043004587156 3 0 3
of,a,non-steroidal 1.0 0.00043004587156 3 0 3
of,a,known 1.0 0.00043004587156 3 0 3
of,a,cyp3a4 1.0 0.00043004587156 3 0 3
nsaids,have,produced 1.0 0.00043004587156 3 0 3
nsaids,concomitantly,with 1.0 0.00043004587156 3 0 3
nsaids,and,are 1.0 0.00043004587156 3 0 3
not,to,exceed 1.0 0.00043004587156 3 0 3
not,recommended,due 1.0 0.00043004587156 3 0 3
not,recommended,because 1.0 0.00043004587156 3 0 3
not,exceed,a 1.0 0.00043004587156 3 0 3
normal,volunteers,concomitant 1.0 0.00043004587156 3 0 3
natriuretic,and,antihypertensive 1.0 0.00043004587156 3 0 3
must,be,determined 1.0 0.00043004587156 3 0 3
monitoring,of,prothrombin 1.0 0.00043004587156 3 0 3
monitored,when,initiating 1.0 0.00043004587156 3 0 3
monitored,frequently,if 1.0 0.00043004587156 3 0 3
mg,vardenafil,dose 1.0 0.00043004587156 3 0 3
mg,t,i 1.0 0.00043004587156 3 0 3
mg,qd,resulted 1.0 0.00043004587156 3 0 3
mg,of,vardenafil 1.0 0.00043004587156 3 0 3
mg,in,a 1.0 0.00043004587156 3 0 3
mg,bid,with 1.0 0.00043004587156 3 0 3
metabolism,of,certain 1.0 0.00043004587156 3 0 3
medications,like,or 1.0 0.00043004587156 3 0 3
may,substantially,interfere 1.0 0.00043004587156 3 0 3
may,inhibit,both 1.0 0.00043004587156 3 0 3
may,have,additive 1.0 0.00043004587156 3 0 3
may,exacerbate,the 1.0 0.00043004587156 3 0 3
may,decrease,arterial 1.0 0.00043004587156 3 0 3
may,cause,hypermagnesemia 1.0 0.00043004587156 3 0 3
may,augment,the 1.0 0.00043004587156 3 0 3
may,also,decrease 1.0 0.00043004587156 3 0 3
maximum,of,mg 1.0 0.00043004587156 3 0 3
markedly,inhibit,the 1.0 0.00043004587156 3 0 3
magnesium-containing,preparations,eg 1.0 0.00043004587156 3 0 3
magnesium,magnesium-containing,preparations 1.0 0.00043004587156 3 0 3
lower,plasma,concentrations 1.0 0.00043004587156 3 0 3
local,solutions,containing 1.0 0.00043004587156 3 0 3
liver,and,or 1.0 0.00043004587156 3 0 3
lithium,nsaids,have 1.0 0.00043004587156 3 0 3
lithium,increased,serum 1.0 0.00043004587156 3 0 3
like,or,and 1.0 0.00043004587156 3 0 3
levels,were,increased 1.0 0.00043004587156 3 0 3
levels,of,increased 1.0 0.00043004587156 3 0 3
levels,and,symptoms 1.0 0.00043004587156 3 0 3
leading,to,severe 1.0 0.00043004587156 3 0 3
known,inhibitor,of 1.0 0.00043004587156 3 0 3
ketoconazole,may,inhibit 1.0 0.00043004587156 3 0 3
ketoconazole,ketoconazole,may 1.0 0.00043004587156 3 0 3
k,may,reduce 1.0 0.00043004587156 3 0 3
its,renal,clearance 1.0 0.00043004587156 3 0 3
isolated,reports,of 1.0 0.00043004587156 3 0 3
is,inhibited,by 1.0 0.00043004587156 3 0 3
is,increased,and 1.0 0.00043004587156 3 0 3
is,impaired,by 1.0 0.00043004587156 3 0 3
is,greater,in 1.0 0.00043004587156 3 0 3
interaction,between,oral 1.0 0.00043004587156 3 0 3
instituted,may,occasionally 1.0 0.00043004587156 3 0 3
initiating,adjusting,and 1.0 0.00043004587156 3 0 3
initiated,in,a 1.0 0.00043004587156 3 0 3
inhibitors,reports,suggest 1.0 0.00043004587156 3 0 3
inhibitors,or,may 1.0 0.00043004587156 3 0 3
inhibit,both,synthetic 1.0 0.00043004587156 3 0 3
inducers,such,as 1.0 0.00043004587156 3 0 3
indocin,and,are 1.0 0.00043004587156 3 0 3
indicate,that,clearance 1.0 0.00043004587156 3 0 3
increased,the,plasma 1.0 0.00043004587156 3 0 3
increased,the,cmax 1.0 0.00043004587156 3 0 3
increased,serum,levels 1.0 0.00043004587156 3 0 3
increased,prothrombin,time 1.0 0.00043004587156 3 0 3
increased,prothrombin,response 1.0 0.00043004587156 3 0 3
increased,levels,in 1.0 0.00043004587156 3 0 3
increased,by,and 1.0 0.00043004587156 3 0 3
increase,the,serum 1.0 0.00043004587156 3 0 3
increase,plasma,levels 1.0 0.00043004587156 3 0 3
including,nonsteroidal,agents 1.0 0.00043004587156 3 0 3
in,vivo,data 1.0 0.00043004587156 3 0 3
in,the,serum 1.0 0.00043004587156 3 0 3
in,mean,cmax 1.0 0.00043004587156 3 0 3
in,lower,plasma 1.0 0.00043004587156 3 0 3
in,elevated,serum 1.0 0.00043004587156 3 0 3
in,cmax,when 1.0 0.00043004587156 3 0 3
in,cmax,of 1.0 0.00043004587156 3 0 3
hypotension,patients,on 1.0 0.00043004587156 3 0 3
hypotension,has,been 1.0 0.00043004587156 3 0 3
hypoglycemic,agents,leading 1.0 0.00043004587156 3 0 3
hypoglycemia,has,been 1.0 0.00043004587156 3 0 3
hypermagnesemia,and,should 1.0 0.00043004587156 3 0 3
hypercalcemia,in,such 1.0 0.00043004587156 3 0 3
hours,of,each 1.0 0.00043004587156 3 0 3
hour,period,in 1.0 0.00043004587156 3 0 3
hmg-coa,reductase,inhibitor 1.0 0.00043004587156 3 0 3
higher,than,that 1.0 0.00043004587156 3 0 3
have,produced,an 1.0 0.00043004587156 3 0 3
have,been,isolated 1.0 0.00043004587156 3 0 3
has,led,to 1.0 0.00043004587156 3 0 3
h2,blockers,or 1.0 0.00043004587156 3 0 3
given,with,because 1.0 0.00043004587156 3 0 3
functional,antagonism,exists 1.0 0.00043004587156 3 0 3
from,its,binding 1.0 0.00043004587156 3 0 3
found,or,are 1.0 0.00043004587156 3 0 3
for,vitamin,d 1.0 0.00043004587156 3 0 3
for,several,days 1.0 0.00043004587156 3 0 3
for,days,increased 1.0 0.00043004587156 3 0 3
for,days,has 1.0 0.00043004587156 3 0 3
exposure,auc,to 1.0 0.00043004587156 3 0 3
exists,between,vitamin 1.0 0.00043004587156 3 0 3
exceed,a,single 1.0 0.00043004587156 3 0 3
exceed,a,maximum 1.0 0.00043004587156 3 0 3
ethinyl,estradiol,by 1.0 0.00043004587156 3 0 3
especially,in,the 1.0 0.00043004587156 3 0 3
erythromycin,has,been 1.0 0.00043004587156 3 0 3
ergotamine-containing,or,ergot-type 1.0 0.00043004587156 3 0 3
ergot-type,medications,like 1.0 0.00043004587156 3 0 3
enhance,the,action 1.0 0.00043004587156 3 0 3
eight-fold,increase,in 1.0 0.00043004587156 3 0 3
eg,may,cause 1.0 0.00043004587156 3 0 3
effects,and,may 1.0 0.00043004587156 3 0 3
during,the,concomitant 1.0 0.00043004587156 3 0 3
dose,of,vardenafil 1.0 0.00043004587156 3 0 3
dose,may,be 1.0 0.00043004587156 3 0 3
dose,increase,of 1.0 0.00043004587156 3 0 3
dosage,must,be 1.0 0.00043004587156 3 0 3
diuretic,therapy,patients 1.0 0.00043004587156 3 0 3
displaced,from,its 1.0 0.00043004587156 3 0 3
diminish,the,antihypertensive 1.0 0.00043004587156 3 0 3
digitalis,vitamin,d 1.0 0.00043004587156 3 0 3
determined,with,care 1.0 0.00043004587156 3 0 3
depressant,effects,when 1.0 0.00043004587156 3 0 3
decreased,clearance,by 1.0 0.00043004587156 3 0 3
decreased,by,and 1.0 0.00043004587156 3 0 3
decrease,the,hypotensive 1.0 0.00043004587156 3 0 3
decrease,the,absorption 1.0 0.00043004587156 3 0 3
decrease,in,plasma 1.0 0.00043004587156 3 0 3
decrease,in,cmax 1.0 0.00043004587156 3 0 3
decrease,in,clearance 1.0 0.00043004587156 3 0 3
daily,resulted,in 1.0 0.00043004587156 3 0 3
d3,calcitriol,and 1.0 0.00043004587156 3 0 3
d2,vitamin,d3 1.0 0.00043004587156 3 0 3
d,dosage,must 1.0 0.00043004587156 3 0 3
d,by,patients 1.0 0.00043004587156 3 0 3
d,analogues,which 1.0 0.00043004587156 3 0 3
d,analogues,vitamin 1.0 0.00043004587156 3 0 3
corticosteroids,a,relationship 1.0 0.00043004587156 3 0 3
containing,or,to 1.0 0.00043004587156 3 0 3
concomitantly,with,has 1.0 0.00043004587156 3 0 3
concentrations,of,should 1.0 0.00043004587156 3 0 3
concentration,of,the 1.0 0.00043004587156 3 0 3
concentration,of,by 1.0 0.00043004587156 3 0 3
combined,therapy,with 1.0 0.00043004587156 3 0 3
coadministered,with,or 1.0 0.00043004587156 3 0 3
co-administration,of,decreased 1.0 0.00043004587156 3 0 3
cmax,of,was 1.0 0.00043004587156 3 0 3
cmax,and,a 1.0 0.00043004587156 3 0 3
cmax,a,c 1.0 0.00043004587156 3 0 3
clearance,is,greater 1.0 0.00043004587156 3 0 3
cimetidine,has,been 1.0 0.00043004587156 3 0 3
cholestyramine,has,been 1.0 0.00043004587156 3 0 3
cholestyramine,cholestyramine,has 1.0 0.00043004587156 3 0 3
channel,blockers,and 1.0 0.00043004587156 3 0 3
causes,an,increase 1.0 0.00043004587156 3 0 3
cause,hypermagnesemia,and 1.0 0.00043004587156 3 0 3
cations,such,as 1.0 0.00043004587156 3 0 3
catecholamine-depleting,such,as 1.0 0.00043004587156 3 0 3
catabolic,enzymes,of 1.0 0.00043004587156 3 0 3
care,in,patients 1.0 0.00043004587156 3 0 3
can,interact,with 1.0 0.00043004587156 3 0 3
calcitriol,and,calcidiol 1.0 0.00043004587156 3 0 3
calcidiol,cholestyramine,cholestyramine 1.0 0.00043004587156 3 0 3
c,and,cmin 1.0 0.00043004587156 3 0 3
by,patients,on 1.0 0.00043004587156 3 0 3
by,fold,on 1.0 0.00043004587156 3 0 3
by,decreased,clearance 1.0 0.00043004587156 3 0 3
by,certain,including 1.0 0.00043004587156 3 0 3
by,approximately,when 1.0 0.00043004587156 3 0 3
by,and,increased 1.0 0.00043004587156 3 0 3
by,an,average 1.0 0.00043004587156 3 0 3
by,a,single 1.0 0.00043004587156 3 0 3
bound,monoamine,oxidase 1.0 0.00043004587156 3 0 3
both,synthetic,and 1.0 0.00043004587156 3 0 3
body,clearance,of 1.0 0.00043004587156 3 0 3
blood,pressure,below 1.0 0.00043004587156 3 0 3
blocking,agents,may 1.0 0.00043004587156 3 0 3
blockers,or,proton 1.0 0.00043004587156 3 0 3
bleeding,has,been 1.0 0.00043004587156 3 0 3
bile,acid,binding 1.0 0.00043004587156 3 0 3
bezalip,or,bezalip 1.0 0.00043004587156 3 0 3
between,vitamin,d 1.0 0.00043004587156 3 0 3
between,oral,and 1.0 0.00043004587156 3 0 3
between,and,is 1.0 0.00043004587156 3 0 3
been,isolated,reports 1.0 0.00043004587156 3 0 3
been,found,or 1.0 0.00043004587156 3 0 3
because,the,action 1.0 0.00043004587156 3 0 3
be,determined,with 1.0 0.00043004587156 3 0 3
avoid,possible,over- 1.0 0.00043004587156 3 0 3
auc,to,was 1.0 0.00043004587156 3 0 3
auc,of,and 1.0 0.00043004587156 3 0 3
auc,increased,by 1.0 0.00043004587156 3 0 3
at,mg,day 1.0 0.00043004587156 3 0 3
aspirin,concomitant,administration 1.0 0.00043004587156 3 0 3
as,post-marketing,observations 1.0 0.00043004587156 3 0 3
as,hypercalcemia,in 1.0 0.00043004587156 3 0 3
as,because,of 1.0 0.00043004587156 3 0 3
as,and,and 1.0 0.00043004587156 3 0 3
are,the,following 1.0 0.00043004587156 3 0 3
approximately,fold,and 1.0 0.00043004587156 3 0 3
apparent,oral,clearance 1.0 0.00043004587156 3 0 3
anti-inflammatory,agents,are 1.0 0.00043004587156 3 0 3
antagonize,the,hypotensive 1.0 0.00043004587156 3 0 3
antagonists,such,as 1.0 0.00043004587156 3 0 3
antagonism,exists,between 1.0 0.00043004587156 3 0 3
and,significantly,increased 1.0 0.00043004587156 3 0 3
and,should,therefore 1.0 0.00043004587156 3 0 3
and,respectively,and 1.0 0.00043004587156 3 0 3
and,other,may 1.0 0.00043004587156 3 0 3
and,or,has 1.0 0.00043004587156 3 0 3
and,non-steroidal,anti-inflammatory 1.0 0.00043004587156 3 0 3
and,k,may 1.0 0.00043004587156 3 0 3
and,especially,those 1.0 0.00043004587156 3 0 3
and,decreased,the 1.0 0.00043004587156 3 0 3
and,catabolic,enzymes 1.0 0.00043004587156 3 0 3
and,calcidiol,cholestyramine 1.0 0.00043004587156 3 0 3
and,beta,adrenergic 1.0 0.00043004587156 3 0 3
and,are,used 1.0 0.00043004587156 3 0 3
and,are,given 1.0 0.00043004587156 3 0 3
and,antihypertensive,effects 1.0 0.00043004587156 3 0 3
analogues,which,promote 1.0 0.00043004587156 3 0 3
analogues,vitamin,d2 1.0 0.00043004587156 3 0 3
an,additive,or 1.0 0.00043004587156 3 0 3
amphetamines,may,enhance 1.0 0.00043004587156 3 0 3
alter,the,metabolism 1.0 0.00043004587156 3 0 3
also,result,in 1.0 0.00043004587156 3 0 3
agents,that,are 1.0 0.00043004587156 3 0 3
agents,leading,to 1.0 0.00043004587156 3 0 3
affecting,the,liver 1.0 0.00043004587156 3 0 3
administration,of,local 1.0 0.00043004587156 3 0 3
administered,hours,prior 1.0 0.00043004587156 3 0 3
adjusting,and,discontinuing 1.0 0.00043004587156 3 0 3
additive,with,those 1.0 0.00043004587156 3 0 3
additive,effects,and 1.0 0.00043004587156 3 0 3
action,of,other 1.0 0.00043004587156 3 0 3
action,of,and 1.0 0.00043004587156 3 0 3
ace,inhibitors,reports 1.0 0.00043004587156 3 0 3
absorption,resulting,in 1.0 0.00043004587156 3 0 3
absorption,of,resulting 1.0 0.00043004587156 3 0 3
absorption,and,which 1.0 0.00043004587156 3 0 3
a,relationship,of 1.0 0.00043004587156 3 0 3
a,regimen,of 1.0 0.00043004587156 3 0 3
a,possible,drug 1.0 0.00043004587156 3 0 3
a,maximum,of 1.0 0.00043004587156 3 0 3
a,known,inhibitor 1.0 0.00043004587156 3 0 3
a,day,regimen 1.0 0.00043004587156 3 0 3
a,cyp2c9,substrate 1.0 0.00043004587156 3 0 3
a,c,and 1.0 0.00043004587156 3 0 3
you,may,need 1.0 0.000286697247706 2 0 2
without,other,enzyme- 1.0 0.000286697247706 2 0 2
withdrawn,at,least 1.0 0.000286697247706 2 0 2
with,which,cause 1.0 0.000286697247706 2 0 2
with,was,associated 1.0 0.000286697247706 2 0 2
with,transient,elevations 1.0 0.000286697247706 2 0 2
with,the,protein 1.0 0.000286697247706 2 0 2
with,the,ace 1.0 0.000286697247706 2 0 2
with,some,other 1.0 0.000286697247706 2 0 2
with,simultaneous,dosing 1.0 0.000286697247706 2 0 2
with,renal,impairment 1.0 0.000286697247706 2 0 2
with,proleukin,may 1.0 0.000286697247706 2 0 2
with,other,centrally 1.0 0.000286697247706 2 0 2
with,other,central 1.0 0.000286697247706 2 0 2
with,oral,carbonic 1.0 0.000286697247706 2 0 2
with,or,within 1.0 0.000286697247706 2 0 2
with,or,any 1.0 0.000286697247706 2 0 2
with,little,or 1.0 0.000286697247706 2 0 2
with,increased,serum 1.0 0.000286697247706 2 0 2
with,increased,levels 1.0 0.000286697247706 2 0 2
with,in,patients 1.0 0.000286697247706 2 0 2
with,for,the 1.0 0.000286697247706 2 0 2
with,compromised,renal 1.0 0.000286697247706 2 0 2
with,compared,to 1.0 0.000286697247706 2 0 2
with,cns,depressants 1.0 0.000286697247706 2 0 2
with,caution,as 1.0 0.000286697247706 2 0 2
with,bezalip,or 1.0 0.000286697247706 2 0 2
with,bextra,in 1.0 0.000286697247706 2 0 2
with,aprepitant,to 1.0 0.000286697247706 2 0 2
with,an,oral 1.0 0.000286697247706 2 0 2
with,an,intravenous 1.0 0.000286697247706 2 0 2
with,an,inhibitor 1.0 0.000286697247706 2 0 2
with,amphotericin,b 1.0 0.000286697247706 2 0 2
with,alphagan,p 1.0 0.000286697247706 2 0 2
with,agents,with 1.0 0.000286697247706 2 0 2
with,acute,toxicity 1.0 0.000286697247706 2 0 2
with,active,ra 1.0 0.000286697247706 2 0 2
with,ace,inhibitors 1.0 0.000286697247706 2 0 2
with,absorption,resulting 1.0 0.000286697247706 2 0 2
with,a,mg 1.0 0.000286697247706 2 0 2
with,a,increase 1.0 0.000286697247706 2 0 2
who,are,being 1.0 0.000286697247706 2 0 2
which,was,higher 1.0 0.000286697247706 2 0 2
which,patients,with 1.0 0.000286697247706 2 0 2
which,may,prolong 1.0 0.000286697247706 2 0 2
which,have,a 1.0 0.000286697247706 2 0 2
which,cause,elimination 1.0 0.000286697247706 2 0 2
where,gastric,ph 1.0 0.000286697247706 2 0 2
when,used,concomitantly 1.0 0.000286697247706 2 0 2
when,taxol,was 1.0 0.000286697247706 2 0 2
when,selecting,an 1.0 0.000286697247706 2 0 2
when,nsaids,and 1.0 0.000286697247706 2 0 2
when,multiple,doses 1.0 0.000286697247706 2 0 2
when,maleate,mg 1.0 0.000286697247706 2 0 2
when,itraconazole,and 1.0 0.000286697247706 2 0 2
when,is,initiated 1.0 0.000286697247706 2 0 2
when,is,coadministered 1.0 0.000286697247706 2 0 2
when,either,was 1.0 0.000286697247706 2 0 2
when,concomitant,administration 1.0 0.000286697247706 2 0 2
when,channel,blockers 1.0 0.000286697247706 2 0 2
when,bezalip,or 1.0 0.000286697247706 2 0 2
when,are,given 1.0 0.000286697247706 2 0 2
when,and,oral 1.0 0.000286697247706 2 0 2
when,an,oral 1.0 0.000286697247706 2 0 2
when,administering,to 1.0 0.000286697247706 2 0 2
when,administering,gleevec 1.0 0.000286697247706 2 0 2
when,a,mg 1.0 0.000286697247706 2 0 2
were,treated,for 1.0 0.000286697247706 2 0 2
were,supersensitive,to 1.0 0.000286697247706 2 0 2
were,indifferent,for 1.0 0.000286697247706 2 0 2
were,increased,about 1.0 0.000286697247706 2 0 2
weeks,with,concurrent 1.0 0.000286697247706 2 0 2
weeks,after,stopping 1.0 0.000286697247706 2 0 2
weaken,the,blood-glucose 1.0 0.000286697247706 2 0 2
was,used,in 1.0 0.000286697247706 2 0 2
was,significantly,higher 1.0 0.000286697247706 2 0 2
was,reduced,from 1.0 0.000286697247706 2 0 2
was,prevented,by 1.0 0.000286697247706 2 0 2
was,observed,which 1.0 0.000286697247706 2 0 2
was,observed,to 1.0 0.000286697247706 2 0 2
was,higher,than 1.0 0.000286697247706 2 0 2
was,decreased,an 1.0 0.000286697247706 2 0 2
wait,weeks,after 1.0 0.000286697247706 2 0 2
vitro,data,indicate 1.0 0.000286697247706 2 0 2
vitro,and,or 1.0 0.000286697247706 2 0 2
vitamin,k,antagonists 1.0 0.000286697247706 2 0 2
vision,have,been 1.0 0.000286697247706 2 0 2
vioxx,and,are 1.0 0.000286697247706 2 0 2
videx,didanosine,chewable 1.0 0.000286697247706 2 0 2
veratrum,alkaloids,amphetamines 1.0 0.000286697247706 2 0 2
vardenafil,with,mg 1.0 0.000286697247706 2 0 2
vardenafil,should,not 1.0 0.000286697247706 2 0 2
vardenafil,mg,resulted 1.0 0.000286697247706 2 0 2
vardenafil,mg,in 1.0 0.000286697247706 2 0 2
vardenafil,dose,should 1.0 0.000286697247706 2 0 2
vardenafil,dose,in 1.0 0.000286697247706 2 0 2
usp,should,not 1.0 0.000286697247706 2 0 2
users,of,both 1.0 0.000286697247706 2 0 2
used,to,control 1.0 0.000286697247706 2 0 2
use,of,two 1.0 0.000286697247706 2 0 2
use,of,l-glutamine 1.0 0.000286697247706 2 0 2
use,of,indocin 1.0 0.000286697247706 2 0 2
use,of,beta-adrenergic 1.0 0.000286697247706 2 0 2
use,of,argatroban 1.0 0.000286697247706 2 0 2
use,in,patients 1.0 0.000286697247706 2 0 2
up,to,weeks 1.0 0.000286697247706 2 0 2
unreliable,prothrombin,time 1.0 0.000286697247706 2 0 2
undertaken,with,caution 1.0 0.000286697247706 2 0 2
ulceration,or,other 1.0 0.000286697247706 2 0 2
type,c,should 1.0 0.000286697247706 2 0 2
twofold,increase,in 1.0 0.000286697247706 2 0 2
two,percent,of 1.0 0.000286697247706 2 0 2
two,patients,with 1.0 0.000286697247706 2 0 2
trough,plasma,levels 1.0 0.000286697247706 2 0 2
trivalent,cations,such 1.0 0.000286697247706 2 0 2
tricyclic,have,been 1.0 0.000286697247706 2 0 2
tricor,with,mg 1.0 0.000286697247706 2 0 2
treatment,with,axert 1.0 0.000286697247706 2 0 2
treatment,with,antithrombin 1.0 0.000286697247706 2 0 2
treated,with,oral 1.0 0.000286697247706 2 0 2
treated,with,monoamine 1.0 0.000286697247706 2 0 2
treated,with,may 1.0 0.000286697247706 2 0 2
treated,with,and 1.0 0.000286697247706 2 0 2
treated,for,up 1.0 0.000286697247706 2 0 2
transmission,curare-like,compounds 1.0 0.000286697247706 2 0 2
transdermal,and,implantable 1.0 0.000286697247706 2 0 2
toxicity,with,little 1.0 0.000286697247706 2 0 2
toxicity,should,be 1.0 0.000286697247706 2 0 2
toxicity,possibly,due 1.0 0.000286697247706 2 0 2
toxicity,may,be 1.0 0.000286697247706 2 0 2
took,min,for 1.0 0.000286697247706 2 0 2
tolerance,to,the 1.0 0.000286697247706 2 0 2
together,have,a 1.0 0.000286697247706 2 0 2
to,weeks,with 1.0 0.000286697247706 2 0 2
to,was,increased 1.0 0.000286697247706 2 0 2
to,use,of 1.0 0.000286697247706 2 0 2
to,two,patients 1.0 0.000286697247706 2 0 2
to,those,obtained 1.0 0.000286697247706 2 0 2
to,these,medicinal 1.0 0.000286697247706 2 0 2
to,the,same 1.0 0.000286697247706 2 0 2
to,the,package 1.0 0.000286697247706 2 0 2
to,the,inhibition 1.0 0.000286697247706 2 0 2
to,should,be 1.0 0.000286697247706 2 0 2
to,reduce,plasma 1.0 0.000286697247706 2 0 2
to,prevent,the 1.0 0.000286697247706 2 0 2
to,patients,not 1.0 0.000286697247706 2 0 2
to,patients,being 1.0 0.000286697247706 2 0 2
to,or,potentiate 1.0 0.000286697247706 2 0 2
to,one-half,of 1.0 0.000286697247706 2 0 2
to,normal,volunteers 1.0 0.000286697247706 2 0 2
to,mg,tricor 1.0 0.000286697247706 2 0 2
to,influence,the 1.0 0.000286697247706 2 0 2
to,in,the 1.0 0.000286697247706 2 0 2
to,hypoparathyroid,patients 1.0 0.000286697247706 2 0 2
to,have,neuromuscular 1.0 0.000286697247706 2 0 2
to,fold,and 1.0 0.000286697247706 2 0 2
to,diminish,oral 1.0 0.000286697247706 2 0 2
to,depress,plasma 1.0 0.000286697247706 2 0 2
to,decreased,synthesis 1.0 0.000286697247706 2 0 2
to,days,after 1.0 0.000286697247706 2 0 2
to,blunt,the 1.0 0.000286697247706 2 0 2
to,be,monitored 1.0 0.000286697247706 2 0 2
to,be,cyp 1.0 0.000286697247706 2 0 2
to,antagonize,the 1.0 0.000286697247706 2 0 2
to,an,increased 1.0 0.000286697247706 2 0 2
to,achieve,exposures 1.0 0.000286697247706 2 0 2
time,response,in 1.0 0.000286697247706 2 0 2
time,measured,as 1.0 0.000286697247706 2 0 2
time,is,recommended 1.0 0.000286697247706 2 0 2
time,have,been 1.0 0.000286697247706 2 0 2
thus,when,nsaids 1.0 0.000286697247706 2 0 2
thus,may,increase 1.0 0.000286697247706 2 0 2
those,obtained,when 1.0 0.000286697247706 2 0 2
this,interaction,has 1.0 0.000286697247706 2 0 2
this,has,not 1.0 0.000286697247706 2 0 2
thiazide,to,hypoparathyroid 1.0 0.000286697247706 2 0 2
therefore,when,and 1.0 0.000286697247706 2 0 2
therefore,the,combination 1.0 0.000286697247706 2 0 2
therefore,if,is 1.0 0.000286697247706 2 0 2
therefore,concurrent,use 1.0 0.000286697247706 2 0 2
therefore,concomitant,administration 1.0 0.000286697247706 2 0 2
thereby,delaying,elimination 1.0 0.000286697247706 2 0 2
therapy,with,flolan 1.0 0.000286697247706 2 0 2
therapy,urinary,excretion 1.0 0.000286697247706 2 0 2
therapy,omnicef,should 1.0 0.000286697247706 2 0 2
therapy,a,rate 1.0 0.000286697247706 2 0 2
theoretical,basis,that 1.0 0.000286697247706 2 0 2
theophylline-related,side,effects 1.0 0.000286697247706 2 0 2
the,usual,dose 1.0 0.000286697247706 2 0 2
the,toxic,effects 1.0 0.000286697247706 2 0 2
the,therapeutic,efficacy 1.0 0.000286697247706 2 0 2
the,same,dose 1.0 0.000286697247706 2 0 2
the,recommended,maximum 1.0 0.000286697247706 2 0 2
the,proliferation,of 1.0 0.000286697247706 2 0 2
the,pharmacokinetic,profile 1.0 0.000286697247706 2 0 2
the,ototoxic,potential 1.0 0.000286697247706 2 0 2
the,oral,bioavailability 1.0 0.000286697247706 2 0 2
the,oral,and 1.0 0.000286697247706 2 0 2
the,neuromuscular,blockade 1.0 0.000286697247706 2 0 2
the,muscle,relaxant 1.0 0.000286697247706 2 0 2
the,metabolic,effects 1.0 0.000286697247706 2 0 2
the,mean,terminal 1.0 0.000286697247706 2 0 2
the,mean,elimination 1.0 0.000286697247706 2 0 2
the,may,be 1.0 0.000286697247706 2 0 2
the,lowest,effective 1.0 0.000286697247706 2 0 2
the,ionized,species 1.0 0.000286697247706 2 0 2
the,increases,in 1.0 0.000286697247706 2 0 2
the,increased,possibility 1.0 0.000286697247706 2 0 2
the,increased,metabolism 1.0 0.000286697247706 2 0 2
the,including,produce 1.0 0.000286697247706 2 0 2
the,frequency,and 1.0 0.000286697247706 2 0 2
the,following,acetaminophen 1.0 0.000286697247706 2 0 2
the,electrolyte,loss 1.0 0.000286697247706 2 0 2
the,depression,of 1.0 0.000286697247706 2 0 2
the,danger,of 1.0 0.000286697247706 2 0 2
the,cyp3a4,inducer 1.0 0.000286697247706 2 0 2
the,biotransformation,system 1.0 0.000286697247706 2 0 2
the,beneficial,effects 1.0 0.000286697247706 2 0 2
the,bactericidal,action 1.0 0.000286697247706 2 0 2
the,auc,ss 1.0 0.000286697247706 2 0 2
the,antihypertensive,effects 1.0 0.000286697247706 2 0 2
that,users,of 1.0 0.000286697247706 2 0 2
that,these,effects 1.0 0.000286697247706 2 0 2
that,the,metabolism 1.0 0.000286697247706 2 0 2
that,serum,levels 1.0 0.000286697247706 2 0 2
that,reportedly,may 1.0 0.000286697247706 2 0 2
that,plasma,levels 1.0 0.000286697247706 2 0 2
that,oral,potently 1.0 0.000286697247706 2 0 2
that,may,interfere 1.0 0.000286697247706 2 0 2
that,may,alter 1.0 0.000286697247706 2 0 2
that,inhibit,this 1.0 0.000286697247706 2 0 2
that,could,cause 1.0 0.000286697247706 2 0 2
that,and,markedly 1.0 0.000286697247706 2 0 2
than,when,was 1.0 0.000286697247706 2 0 2
than,that,observed 1.0 0.000286697247706 2 0 2
than,suggest,a 1.0 0.000286697247706 2 0 2
tetracycline,a,bacteriostatic 1.0 0.000286697247706 2 0 2
taking,concomitantly,with 1.0 0.000286697247706 2 0 2
taking,and,renal 1.0 0.000286697247706 2 0 2
taking,and,concomitantly 1.0 0.000286697247706 2 0 2
tablets,results,in 1.0 0.000286697247706 2 0 2
tablets,or,pediatric 1.0 0.000286697247706 2 0 2
tablets,and,other 1.0 0.000286697247706 2 0 2
tablet,formulation,comparable 1.0 0.000286697247706 2 0 2
systemic,exposure,auc 1.0 0.000286697247706 2 0 2
system,responsible,for 1.0 0.000286697247706 2 0 2
system,depressants,including 1.0 0.000286697247706 2 0 2
synergistic,such,that 1.0 0.000286697247706 2 0 2
symptomatic,orthostatic,hypotension 1.0 0.000286697247706 2 0 2
supplements,and,potassium-sparing 1.0 0.000286697247706 2 0 2
suggest,that,exposure 1.0 0.000286697247706 2 0 2
such,that,users 1.0 0.000286697247706 2 0 2
such,as,videx 1.0 0.000286697247706 2 0 2
such,as,thiazide 1.0 0.000286697247706 2 0 2
subjects,experienced,a 1.0 0.000286697247706 2 0 2
study,with,in 1.0 0.000286697247706 2 0 2
study,in,six 1.0 0.000286697247706 2 0 2
study,has,shown 1.0 0.000286697247706 2 0 2
study,evaluating,the 1.0 0.000286697247706 2 0 2
study,coadministration,of 1.0 0.000286697247706 2 0 2
studies,of,other 1.0 0.000286697247706 2 0 2
studies,in,animals 1.0 0.000286697247706 2 0 2
strong,selective,cyp3a4 1.0 0.000286697247706 2 0 2
striking,and,sustained 1.0 0.000286697247706 2 0 2
stimulatory,effects,of 1.0 0.000286697247706 2 0 2
stimulation,is,potentiated 1.0 0.000286697247706 2 0 2
stimulant,effects,of 1.0 0.000286697247706 2 0 2
steroids,chloral,hydrate 1.0 0.000286697247706 2 0 2
steady-state,auc,of 1.0 0.000286697247706 2 0 2
steady,state,and 1.0 0.000286697247706 2 0 2
state,and,therefore 1.0 0.000286697247706 2 0 2
stadol,ns,was 1.0 0.000286697247706 2 0 2
stable,plasma,levels 1.0 0.000286697247706 2 0 2
ss,of,by 1.0 0.000286697247706 2 0 2
some,including,have 1.0 0.000286697247706 2 0 2
some,have,been 1.0 0.000286697247706 2 0 2
solution,should,not 1.0 0.000286697247706 2 0 2
solution,may,substantially 1.0 0.000286697247706 2 0 2
sodium,is,given 1.0 0.000286697247706 2 0 2
sodium,acid,etc 1.0 0.000286697247706 2 0 2
sites,during,the 1.0 0.000286697247706 2 0 2
single,mg,vardenafil 1.0 0.000286697247706 2 0 2
since,these,patients 1.0 0.000286697247706 2 0 2
since,the,toxic 1.0 0.000286697247706 2 0 2
since,may,reduce 1.0 0.000286697247706 2 0 2
simultaneous,dosing,of 1.0 0.000286697247706 2 0 2
similarly,decreased,the 1.0 0.000286697247706 2 0 2
significantly,reduced,the 1.0 0.000286697247706 2 0 2
significant,decreases,in 1.0 0.000286697247706 2 0 2
shown,to,reduce 1.0 0.000286697247706 2 0 2
shown,to,produce 1.0 0.000286697247706 2 0 2
shown,to,interact 1.0 0.000286697247706 2 0 2
shown,to,depress 1.0 0.000286697247706 2 0 2
shown,that,can 1.0 0.000286697247706 2 0 2
shown,a,significant 1.0 0.000286697247706 2 0 2
should,only,be 1.0 0.000286697247706 2 0 2
should,not,beadministered 1.0 0.000286697247706 2 0 2
should,be,cautious 1.0 0.000286697247706 2 0 2
should,be,aware 1.0 0.000286697247706 2 0 2
sgpt,alt,in 1.0 0.000286697247706 2 0 2
severe,dry,mouth 1.0 0.000286697247706 2 0 2
serum,levels,be 1.0 0.000286697247706 2 0 2
serum,creatinine,in 1.0 0.000286697247706 2 0 2
serum,creatinine,and 1.0 0.000286697247706 2 0 2
serum,concentration,and 1.0 0.000286697247706 2 0 2
serotonin,reuptake,inhibitor 1.0 0.000286697247706 2 0 2
serious,infections,was 1.0 0.000286697247706 2 0 2
serious,infections,and 1.0 0.000286697247706 2 0 2
serious,gi,bleeding 1.0 0.000286697247706 2 0 2
selecting,an,oral 1.0 0.000286697247706 2 0 2
seizures,in,susceptible 1.0 0.000286697247706 2 0 2
see,a,href 1.0 0.000286697247706 2 0 2
same,dose,of 1.0 0.000286697247706 2 0 2
salts,and,may 1.0 0.000286697247706 2 0 2
role,in,hemostasis 1.0 0.000286697247706 2 0 2
risk,of,neutropenia 1.0 0.000286697247706 2 0 2
risk,of,gastrointestinal 1.0 0.000286697247706 2 0 2
rifampin,coadministration,of 1.0 0.000286697247706 2 0 2
rhabdomyolysis,is,increased 1.0 0.000286697247706 2 0 2
rhabdomyolysis,has,been 1.0 0.000286697247706 2 0 2
reverse,the,pressor 1.0 0.000286697247706 2 0 2
reuptake,thus,inhibiting 1.0 0.000286697247706 2 0 2
retard,is,used 1.0 0.000286697247706 2 0 2
results,of,a 1.0 0.000286697247706 2 0 2
resulting,in,systemic 1.0 0.000286697247706 2 0 2
resulted,in,increased 1.0 0.000286697247706 2 0 2
resulted,in,elevated 1.0 0.000286697247706 2 0 2
result,in,decreased 1.0 0.000286697247706 2 0 2
response,ie,increased 1.0 0.000286697247706 2 0 2
response,ie,decreased 1.0 0.000286697247706 2 0 2
required,during,omnicef 1.0 0.000286697247706 2 0 2
require,downward,adjustment 1.0 0.000286697247706 2 0 2
reports,of,serious 1.0 0.000286697247706 2 0 2
reports,of,interactions 1.0 0.000286697247706 2 0 2
reports,indicate,that 1.0 0.000286697247706 2 0 2
reports,in,the 1.0 0.000286697247706 2 0 2
reportedly,may,increase 1.0 0.000286697247706 2 0 2
reported,when,is 1.0 0.000286697247706 2 0 2
reported,when,channel 1.0 0.000286697247706 2 0 2
reported,to,diminish 1.0 0.000286697247706 2 0 2
reported,to,blunt 1.0 0.000286697247706 2 0 2
reported,in,some 1.0 0.000286697247706 2 0 2
reported,among,patients 1.0 0.000286697247706 2 0 2
renal,function,who 1.0 0.000286697247706 2 0 2
renal,clearance,in 1.0 0.000286697247706 2 0 2
renal,and,cardiac 1.0 0.000286697247706 2 0 2
relaxants,and,may 1.0 0.000286697247706 2 0 2
reduction,of,to 1.0 0.000286697247706 2 0 2
reduction,of,plasma 1.0 0.000286697247706 2 0 2
reduction,in,renal 1.0 0.000286697247706 2 0 2
reduction,in,clearance 1.0 0.000286697247706 2 0 2
reductase,inhibitors,that 1.0 0.000286697247706 2 0 2
reduces,the,clearance 1.0 0.000286697247706 2 0 2
reduced,by,acidifying 1.0 0.000286697247706 2 0 2
reduce,the,renal 1.0 0.000286697247706 2 0 2
reduce,the,effect 1.0 0.000286697247706 2 0 2
reduce,or,reverse 1.0 0.000286697247706 2 0 2
recommended,when,administering 1.0 0.000286697247706 2 0 2
recommended,when,a 1.0 0.000286697247706 2 0 2
recommended,that,the 1.0 0.000286697247706 2 0 2
recommended,that,serum 1.0 0.000286697247706 2 0 2
recommended,during,coadministration 1.0 0.000286697247706 2 0 2
recommended,because,is 1.0 0.000286697247706 2 0 2
recommended,and,adjustment 1.0 0.000286697247706 2 0 2
receptors,thus,inhibiting 1.0 0.000286697247706 2 0 2
receiving,itraconazole,and 1.0 0.000286697247706 2 0 2
receiving,high,doses 1.0 0.000286697247706 2 0 2
receiving,concurrent,therapy 1.0 0.000286697247706 2 0 2
receiving,concomitant,and 1.0 0.000286697247706 2 0 2
receiving,both,and 1.0 0.000286697247706 2 0 2
receiving,beta-adrenergic,blocking 1.0 0.000286697247706 2 0 2
rate,of,serious 1.0 0.000286697247706 2 0 2
rate,of,gi 1.0 0.000286697247706 2 0 2
rarely,associated,with 1.0 0.000286697247706 2 0 2
rare,occasions,resulted 1.0 0.000286697247706 2 0 2
range,from,decrease 1.0 0.000286697247706 2 0 2
raise,the,serum 1.0 0.000286697247706 2 0 2
ra,were,treated 1.0 0.000286697247706 2 0 2
quinolones,including,may 1.0 0.000286697247706 2 0 2
quinolones,have,been 1.0 0.000286697247706 2 0 2
qt,interval,certain 1.0 0.000286697247706 2 0 2
qd,and,mg 1.0 0.000286697247706 2 0 2
psychomotor,performance,for 1.0 0.000286697247706 2 0 2
prothrombin,time,measured 1.0 0.000286697247706 2 0 2
prothrombin,time,have 1.0 0.000286697247706 2 0 2
prothrombin,time,determinations 1.0 0.000286697247706 2 0 2
prothrombin,time,be 1.0 0.000286697247706 2 0 2
prothrombin,response,in 1.0 0.000286697247706 2 0 2
prothrombin,activity,patients 1.0 0.000286697247706 2 0 2
prothrom-bin,time,response 1.0 0.000286697247706 2 0 2
propoxyphene,in,cases 1.0 0.000286697247706 2 0 2
properties,that,may 1.0 0.000286697247706 2 0 2
prolonged,the,half-life 1.0 0.000286697247706 2 0 2
products,containing,or 1.0 0.000286697247706 2 0 2
products,containing,and 1.0 0.000286697247706 2 0 2
production,of,hypotension 1.0 0.000286697247706 2 0 2
produces,an,increase 1.0 0.000286697247706 2 0 2
produced,by,without 1.0 0.000286697247706 2 0 2
produced,additive,effects 1.0 0.000286697247706 2 0 2
produced,a,increase 1.0 0.000286697247706 2 0 2
produced,a,fold 1.0 0.000286697247706 2 0 2
produce,clinically,significant 1.0 0.000286697247706 2 0 2
probenecid,may,decrease 1.0 0.000286697247706 2 0 2
prior,to,or 1.0 0.000286697247706 2 0 2
prior,to,dosing 1.0 0.000286697247706 2 0 2
previously,stable,plasma 1.0 0.000286697247706 2 0 2
pressure,of,less 1.0 0.000286697247706 2 0 2
presence,of,impaired 1.0 0.000286697247706 2 0 2
prescription,dose,co-administered 1.0 0.000286697247706 2 0 2
potently,inhibits,the 1.0 0.000286697247706 2 0 2
potentiating,effect,with 1.0 0.000286697247706 2 0 2
potentiated,by,monoamine 1.0 0.000286697247706 2 0 2
potentiated,and,fatal 1.0 0.000286697247706 2 0 2
potentiate,the,action 1.0 0.000286697247706 2 0 2
potentiate,or,weaken 1.0 0.000286697247706 2 0 2
potentially,resulting,in 1.0 0.000286697247706 2 0 2
potential,of,increased 1.0 0.000286697247706 2 0 2
potential,for,increased 1.0 0.000286697247706 2 0 2
potential,benefits,outweigh 1.0 0.000286697247706 2 0 2
potassium,supplements,and 1.0 0.000286697247706 2 0 2
post-marketing,experience,bleeding 1.0 0.000286697247706 2 0 2
possibly,other,cause 1.0 0.000286697247706 2 0 2
possible,that,the 1.0 0.000286697247706 2 0 2
possibility,of,gastrointestinal 1.0 0.000286697247706 2 0 2
possibility,of,an 1.0 0.000286697247706 2 0 2
play,an,important 1.0 0.000286697247706 2 0 2
platelet,function,as 1.0 0.000286697247706 2 0 2
plasmaconcentrations,may,reduce 1.0 0.000286697247706 2 0 2
plasma,prothrombin,activity 1.0 0.000286697247706 2 0 2
plasma,levels,increased 1.0 0.000286697247706 2 0 2
plasma,levels,by 1.0 0.000286697247706 2 0 2
plasma,level,of 1.0 0.000286697247706 2 0 2
plasma,exposure,of 1.0 0.000286697247706 2 0 2
plasma,exposure,auc 1.0 0.000286697247706 2 0 2
plasma,asparagine,levels 1.0 0.000286697247706 2 0 2
physicians,should,be 1.0 0.000286697247706 2 0 2
phenytoin,and,thus 1.0 0.000286697247706 2 0 2
phenytoin,amphetamines,may 1.0 0.000286697247706 2 0 2
phenothiazines,and,may 1.0 0.000286697247706 2 0 2
phenobarbital,amphetamines,may 1.0 0.000286697247706 2 0 2
pharmacologic,effects,of 1.0 0.000286697247706 2 0 2
pharmacokinetics,data,indicate 1.0 0.000286697247706 2 0 2
pharmacokinetic,data,indicate 1.0 0.000286697247706 2 0 2
ph,is,an 1.0 0.000286697247706 2 0 2
peripheral,blood,mononuclear 1.0 0.000286697247706 2 0 2
performed,with,caution 1.0 0.000286697247706 2 0 2
performance,for,to 1.0 0.000286697247706 2 0 2
percent,of,patients 1.0 0.000286697247706 2 0 2
patients,with,elevated 1.0 0.000286697247706 2 0 2
patients,with,compromised 1.0 0.000286697247706 2 0 2
patients,with,acute 1.0 0.000286697247706 2 0 2
patients,with,active 1.0 0.000286697247706 2 0 2
patients,the,metabolic 1.0 0.000286697247706 2 0 2
patients,taking,concomitantly 1.0 0.000286697247706 2 0 2
patients,taking,both 1.0 0.000286697247706 2 0 2
patients,receiving,hcl 1.0 0.000286697247706 2 0 2
patients,receiving,beta-adrenergic 1.0 0.000286697247706 2 0 2
patients,receiving,ace 1.0 0.000286697247706 2 0 2
patients,on,thiazide 1.0 0.000286697247706 2 0 2
patients,on,therapy 1.0 0.000286697247706 2 0 2
patients,on,may 1.0 0.000286697247706 2 0 2
patients,on,especially 1.0 0.000286697247706 2 0 2
patients,not,receiving 1.0 0.000286697247706 2 0 2
patients,in,a 1.0 0.000286697247706 2 0 2
patients,are,at 1.0 0.000286697247706 2 0 2
patient,who,has 1.0 0.000286697247706 2 0 2
patient,maintained,on 1.0 0.000286697247706 2 0 2
patient,is,recommended 1.0 0.000286697247706 2 0 2
patient,currently,receiving 1.0 0.000286697247706 2 0 2
particular,caution,is 1.0 0.000286697247706 2 0 2
partially,counteract,the 1.0 0.000286697247706 2 0 2
package,insert,for 1.0 0.000286697247706 2 0 2
p-450,isozymes,responsible 1.0 0.000286697247706 2 0 2
oxidase,inhibitors,maoi 1.0 0.000286697247706 2 0 2
overdosage,cns,stimulation 1.0 0.000286697247706 2 0 2
outweigh,the,risks 1.0 0.000286697247706 2 0 2
ototoxic,potential,of 1.0 0.000286697247706 2 0 2
other,which,may 1.0 0.000286697247706 2 0 2
other,than,suggest 1.0 0.000286697247706 2 0 2
other,psychotropic,medications 1.0 0.000286697247706 2 0 2
other,psychotropic,agents 1.0 0.000286697247706 2 0 2
other,nsaids,is 1.0 0.000286697247706 2 0 2
other,nsaids,concomitant 1.0 0.000286697247706 2 0 2
other,nsaids,can 1.0 0.000286697247706 2 0 2
other,multivalent,cations 1.0 0.000286697247706 2 0 2
other,may,increase 1.0 0.000286697247706 2 0 2
other,general,skeletal 1.0 0.000286697247706 2 0 2
other,general,or 1.0 0.000286697247706 2 0 2
other,cyp3a4,inhibitors 1.0 0.000286697247706 2 0 2
other,complications,compared 1.0 0.000286697247706 2 0 2
other,caution,is 1.0 0.000286697247706 2 0 2
other,cause,striking 1.0 0.000286697247706 2 0 2
other,agents,may 1.0 0.000286697247706 2 0 2
other,agents,interfering 1.0 0.000286697247706 2 0 2
orthostatic,hypotension,has 1.0 0.000286697247706 2 0 2
organic,were,used 1.0 0.000286697247706 2 0 2
orally,as,mg 1.0 0.000286697247706 2 0 2
oral,solution,should 1.0 0.000286697247706 2 0 2
oral,potently,inhibits 1.0 0.000286697247706 2 0 2
oral,or,intravenous 1.0 0.000286697247706 2 0 2
oral,injectable,transdermal 1.0 0.000286697247706 2 0 2
oral,inhibits,the 1.0 0.000286697247706 2 0 2
oral,has,not 1.0 0.000286697247706 2 0 2
oral,carbonic,anhydrase 1.0 0.000286697247706 2 0 2
oral,bioavailability,of 1.0 0.000286697247706 2 0 2
oral,absorption,of 1.0 0.000286697247706 2 0 2
or,within,hours 1.0 0.000286697247706 2 0 2
or,with,containing 1.0 0.000286697247706 2 0 2
or,weaken,the 1.0 0.000286697247706 2 0 2
or,that,inhibit 1.0 0.000286697247706 2 0 2
or,similar,agents 1.0 0.000286697247706 2 0 2
or,reverse,the 1.0 0.000286697247706 2 0 2
or,retinyl,acetate 1.0 0.000286697247706 2 0 2
or,potentiate,the 1.0 0.000286697247706 2 0 2
or,pediatric,powder 1.0 0.000286697247706 2 0 2
or,other,complications 1.0 0.000286697247706 2 0 2
or,other,caution 1.0 0.000286697247706 2 0 2
or,no,increase 1.0 0.000286697247706 2 0 2
or,may,potentiate 1.0 0.000286697247706 2 0 2
or,may,interact 1.0 0.000286697247706 2 0 2
or,in,vivo 1.0 0.000286697247706 2 0 2
or,has,resulted 1.0 0.000286697247706 2 0 2
or,has,been 1.0 0.000286697247706 2 0 2
or,halogenated,hydrocarbon 1.0 0.000286697247706 2 0 2
or,deleted,from 1.0 0.000286697247706 2 0 2
or,concurrent,with 1.0 0.000286697247706 2 0 2
or,are,used 1.0 0.000286697247706 2 0 2
or,any,known 1.0 0.000286697247706 2 0 2
or,and,possibly 1.0 0.000286697247706 2 0 2
onset,of,neuromuscular 1.0 0.000286697247706 2 0 2
only,be,performed 1.0 0.000286697247706 2 0 2
one-half,of,its 1.0 0.000286697247706 2 0 2
on,thiazide,and 1.0 0.000286697247706 2 0 2
on,should,be 1.0 0.000286697247706 2 0 2
on,reports,of 1.0 0.000286697247706 2 0 2
on,rare,occasions 1.0 0.000286697247706 2 0 2
on,gi,bleeding 1.0 0.000286697247706 2 0 2
on,especially,those 1.0 0.000286697247706 2 0 2
on,decreased,alertness 1.0 0.000286697247706 2 0 2
on,concomitant,therapy 1.0 0.000286697247706 2 0 2
omnicef,therapy,omnicef 1.0 0.000286697247706 2 0 2
omnicef,should,be 1.0 0.000286697247706 2 0 2
of,with,was 1.0 0.000286697247706 2 0 2
of,with,tablets 1.0 0.000286697247706 2 0 2
of,with,should 1.0 0.000286697247706 2 0 2
of,with,oral 1.0 0.000286697247706 2 0 2
of,with,increased 1.0 0.000286697247706 2 0 2
of,which,are 1.0 0.000286697247706 2 0 2
of,where,gastric 1.0 0.000286697247706 2 0 2
of,was,observed 1.0 0.000286697247706 2 0 2
of,was,lower 1.0 0.000286697247706 2 0 2
of,vioxx,with 1.0 0.000286697247706 2 0 2
of,vardenafil,mg 1.0 0.000286697247706 2 0 2
of,vardenafil,in 1.0 0.000286697247706 2 0 2
of,trileptal,with 1.0 0.000286697247706 2 0 2
of,to,micrograms 1.0 0.000286697247706 2 0 2
of,thiazide,to 1.0 0.000286697247706 2 0 2
of,these,have 1.0 0.000286697247706 2 0 2
of,theophylline-related,side 1.0 0.000286697247706 2 0 2
of,the,ionized 1.0 0.000286697247706 2 0 2
of,the,danger 1.0 0.000286697247706 2 0 2
of,the,administration 1.0 0.000286697247706 2 0 2
of,that,may 1.0 0.000286697247706 2 0 2
of,tablets,with 1.0 0.000286697247706 2 0 2
of,subjects,experienced 1.0 0.000286697247706 2 0 2
of,subjects,dosed 1.0 0.000286697247706 2 0 2
of,starlix,and 1.0 0.000286697247706 2 0 2
of,sodium,including 1.0 0.000286697247706 2 0 2
of,similar,to 1.0 0.000286697247706 2 0 2
of,similar,potential 1.0 0.000286697247706 2 0 2
of,serotonin,syndrome 1.0 0.000286697247706 2 0 2
of,serious,sometimes 1.0 0.000286697247706 2 0 2
of,serious,gi 1.0 0.000286697247706 2 0 2
of,robinul,injection 1.0 0.000286697247706 2 0 2
of,prolonged,prothrombin 1.0 0.000286697247706 2 0 2
of,overdosage,cns 1.0 0.000286697247706 2 0 2
of,other,than 1.0 0.000286697247706 2 0 2
of,other,neuromuscular 1.0 0.000286697247706 2 0 2
of,other,known 1.0 0.000286697247706 2 0 2
of,other,cyp3a4 1.0 0.000286697247706 2 0 2
of,only,in 1.0 0.000286697247706 2 0 2
of,once,daily 1.0 0.000286697247706 2 0 2
of,nondepolarizing,agents 1.0 0.000286697247706 2 0 2
of,neutropenia,and 1.0 0.000286697247706 2 0 2
of,myopathy,rhabdomyolysis 1.0 0.000286697247706 2 0 2
of,methotrexate-related,toxicity 1.0 0.000286697247706 2 0 2
of,metabolism,and 1.0 0.000286697247706 2 0 2
of,may,increase 1.0 0.000286697247706 2 0 2
of,loop,potassium-sparing 1.0 0.000286697247706 2 0 2
of,l-glutamine,and 1.0 0.000286697247706 2 0 2
of,itraconazole,with 1.0 0.000286697247706 2 0 2
of,is,increased 1.0 0.000286697247706 2 0 2
of,is,enhanced 1.0 0.000286697247706 2 0 2
of,interactions,of 1.0 0.000286697247706 2 0 2
of,indocin,and 1.0 0.000286697247706 2 0 2
of,increased,effects 1.0 0.000286697247706 2 0 2
of,increased,approximately 1.0 0.000286697247706 2 0 2
of,increased,and 1.0 0.000286697247706 2 0 2
of,hydrochloride,with 1.0 0.000286697247706 2 0 2
of,hexalen,and 1.0 0.000286697247706 2 0 2
of,hepatic,enzyme 1.0 0.000286697247706 2 0 2
of,h2,blockers 1.0 0.000286697247706 2 0 2
of,gastrointestinal,toxicity 1.0 0.000286697247706 2 0 2
of,felbatol,given 1.0 0.000286697247706 2 0 2
of,especially,in 1.0 0.000286697247706 2 0 2
of,equetrotm,are 1.0 0.000286697247706 2 0 2
of,elimination,of 1.0 0.000286697247706 2 0 2
of,decreased,with 1.0 0.000286697247706 2 0 2
of,decreased,approximately 1.0 0.000286697247706 2 0 2
of,cyp3a4,eg 1.0 0.000286697247706 2 0 2
of,combined,therapy 1.0 0.000286697247706 2 0 2
of,cmi,has 1.0 0.000286697247706 2 0 2
of,clinical,studies 1.0 0.000286697247706 2 0 2
of,central,nervous 1.0 0.000286697247706 2 0 2
of,buspirone,hcl 1.0 0.000286697247706 2 0 2
of,both,together 1.0 0.000286697247706 2 0 2
of,beta-adrenoceptor,blocking 1.0 0.000286697247706 2 0 2
of,beta,blockers 1.0 0.000286697247706 2 0 2
of,at,doses 1.0 0.000286697247706 2 0 2
of,are,decreased 1.0 0.000286697247706 2 0 2
of,are,antagonized 1.0 0.000286697247706 2 0 2
of,aprepitant,on 1.0 0.000286697247706 2 0 2
of,approximately,and 1.0 0.000286697247706 2 0 2
of,and,viracept 1.0 0.000286697247706 2 0 2
of,and,should 1.0 0.000286697247706 2 0 2
of,and,nsaids 1.0 0.000286697247706 2 0 2
of,and,k 1.0 0.000286697247706 2 0 2
of,and,increases 1.0 0.000286697247706 2 0 2
of,and,concurrent 1.0 0.000286697247706 2 0 2
of,and,coadministration 1.0 0.000286697247706 2 0 2
of,and,by 1.0 0.000286697247706 2 0 2
of,and,add 1.0 0.000286697247706 2 0 2
of,an,additive 1.0 0.000286697247706 2 0 2
of,a,previously 1.0 0.000286697247706 2 0 2
occurrence,of,torsade 1.0 0.000286697247706 2 0 2
occasions,resulted,in 1.0 0.000286697247706 2 0 2
obtained,when,it 1.0 0.000286697247706 2 0 2
observed,which,was 1.0 0.000286697247706 2 0 2
nsaids,should,be 1.0 0.000286697247706 2 0 2
nsaids,on,gi 1.0 0.000286697247706 2 0 2
nsaids,is,not 1.0 0.000286697247706 2 0 2
nsaids,have,been 1.0 0.000286697247706 2 0 2
nsaids,has,been 1.0 0.000286697247706 2 0 2
nsaids,concomitant,administration 1.0 0.000286697247706 2 0 2
ns,was,administered 1.0 0.000286697247706 2 0 2
not,receiving,these 1.0 0.000286697247706 2 0 2
not,indicate,a 1.0 0.000286697247706 2 0 2
not,generally,recommended 1.0 0.000286697247706 2 0 2
not,compensate,for 1.0 0.000286697247706 2 0 2
not,beadministered,concomitantly 1.0 0.000286697247706 2 0 2
not,be,exceeded 1.0 0.000286697247706 2 0 2
normal,volunteers,resulted 1.0 0.000286697247706 2 0 2
normal,volunteers,receiving 1.0 0.000286697247706 2 0 2
norepinephrine,amphetamines,enhance 1.0 0.000286697247706 2 0 2
nonsteroidal,antiinflammatory,agents 1.0 0.000286697247706 2 0 2
nonsteroidal,agents,have 1.0 0.000286697247706 2 0 2
nondepolarizing,neuromuscular,blocking 1.0 0.000286697247706 2 0 2
nondepolarizing,agents,such 1.0 0.000286697247706 2 0 2
non-steroidal,anti-inflammatory,drugs 1.0 0.000286697247706 2 0 2
non-steroidal,anti-inflammatory,agent 1.0 0.000286697247706 2 0 2
non-selective,mao,inhibitors 1.0 0.000286697247706 2 0 2
no,additional,benefit 1.0 0.000286697247706 2 0 2
ng,ml,with 1.0 0.000286697247706 2 0 2
nevirapine,and,should 1.0 0.000286697247706 2 0 2
neutropenia,and,no 1.0 0.000286697247706 2 0 2
neuromuscular,transmission,curare-like 1.0 0.000286697247706 2 0 2
neuromuscular,blocking,properties 1.0 0.000286697247706 2 0 2
neuromuscular,blocking,agents 1.0 0.000286697247706 2 0 2
neuromuscular,block,induced 1.0 0.000286697247706 2 0 2
need,to,take 1.0 0.000286697247706 2 0 2
nanm,but,not 1.0 0.000286697247706 2 0 2
n,compared,with 1.0 0.000286697247706 2 0 2
myopathy,rhabdomyolysis,is 1.0 0.000286697247706 2 0 2
myocardium,to,the 1.0 0.000286697247706 2 0 2
must,not,be 1.0 0.000286697247706 2 0 2
mouth,urinary,retention 1.0 0.000286697247706 2 0 2
monitored,when,itraconazole 1.0 0.000286697247706 2 0 2
monitored,if,a 1.0 0.000286697247706 2 0 2
monitored,closely,when 1.0 0.000286697247706 2 0 2
molecule,thereby,increasing 1.0 0.000286697247706 2 0 2
modest,effect,on 1.0 0.000286697247706 2 0 2
moderate,hypertension,administration 1.0 0.000286697247706 2 0 2
mm,hg,compared 1.0 0.000286697247706 2 0 2
minor,changes,in 1.0 0.000286697247706 2 0 2
minimum,alveolar,concentration 1.0 0.000286697247706 2 0 2
mg,was,coadministered 1.0 0.000286697247706 2 0 2
mg,tricor,with 1.0 0.000286697247706 2 0 2
mg,single,dose 1.0 0.000286697247706 2 0 2
mg,resulted,in 1.0 0.000286697247706 2 0 2
mg,qd,and 1.0 0.000286697247706 2 0 2
mg,produced,additive 1.0 0.000286697247706 2 0 2
mg,of,subjects 1.0 0.000286697247706 2 0 2
mg,kg,s 1.0 0.000286697247706 2 0 2
mg,increased,the 1.0 0.000286697247706 2 0 2
mg,day,and 1.0 0.000286697247706 2 0 2
mg,bid,the 1.0 0.000286697247706 2 0 2
mg,bid,a 1.0 0.000286697247706 2 0 2
mg,administered,once 1.0 0.000286697247706 2 0 2
methenamine,therapy,urinary 1.0 0.000286697247706 2 0 2
metabolite,which,may 1.0 0.000286697247706 2 0 2
metabolism,of,may 1.0 0.000286697247706 2 0 2
metabolism,of,ethinyl 1.0 0.000286697247706 2 0 2
metabolic,effects,of 1.0 0.000286697247706 2 0 2
meperidine,amphetamines,potentiate 1.0 0.000286697247706 2 0 2
medications,or,other 1.0 0.000286697247706 2 0 2
mean,terminal,half-life 1.0 0.000286697247706 2 0 2
mean,plasma,concentrations 1.0 0.000286697247706 2 0 2
mean,peak,plasma 1.0 0.000286697247706 2 0 2
mean,increase,in 1.0 0.000286697247706 2 0 2
mean,eight-fold,increase 1.0 0.000286697247706 2 0 2
may,require,downward 1.0 0.000286697247706 2 0 2
may,render,oral 1.0 0.000286697247706 2 0 2
may,reduce,or 1.0 0.000286697247706 2 0 2
may,prevent,the 1.0 0.000286697247706 2 0 2
may,partially,counteract 1.0 0.000286697247706 2 0 2
may,induce,the 1.0 0.000286697247706 2 0 2
may,increase,when 1.0 0.000286697247706 2 0 2
may,increase,oral 1.0 0.000286697247706 2 0 2
may,exhibit,an 1.0 0.000286697247706 2 0 2
may,either,potentiate 1.0 0.000286697247706 2 0 2
may,decrease,renal 1.0 0.000286697247706 2 0 2
may,decrease,blood 1.0 0.000286697247706 2 0 2
may,cause,changes 1.0 0.000286697247706 2 0 2
may,be,rarely 1.0 0.000286697247706 2 0 2
may,be,prolonged 1.0 0.000286697247706 2 0 2
may,be,blunted 1.0 0.000286697247706 2 0 2
may,add,to 1.0 0.000286697247706 2 0 2
may,accentuate,the 1.0 0.000286697247706 2 0 2
maximal,plasma,concentrations 1.0 0.000286697247706 2 0 2
markedly,inhibits,the 1.0 0.000286697247706 2 0 2
marked,symptomatic,orthostatic 1.0 0.000286697247706 2 0 2
maoi,as,well 1.0 0.000286697247706 2 0 2
mao,inhibitors,should 1.0 0.000286697247706 2 0 2
mao,inhibitors,maoi 1.0 0.000286697247706 2 0 2
man,significantly,include 1.0 0.000286697247706 2 0 2
maintenance,dose,of 1.0 0.000286697247706 2 0 2
magnitude,and,duration 1.0 0.000286697247706 2 0 2
mac,minimum,alveolar 1.0 0.000286697247706 2 0 2
maalox,tc,suspension 1.0 0.000286697247706 2 0 2
m,or,retinyl 1.0 0.000286697247706 2 0 2
lowered,the,plasma 1.0 0.000286697247706 2 0 2
lower,serum,and 1.0 0.000286697247706 2 0 2
lofexidine,may,enhance 1.0 0.000286697247706 2 0 2
lithium,toxicity,has 1.0 0.000286697247706 2 0 2
lithium,lithium,toxicity 1.0 0.000286697247706 2 0 2
lithium,carbonate,the 1.0 0.000286697247706 2 0 2
like,other,nonsteroidal 1.0 0.000286697247706 2 0 2
levels,of,when 1.0 0.000286697247706 2 0 2
levels,of,equetrotm 1.0 0.000286697247706 2 0 2
levels,it,is 1.0 0.000286697247706 2 0 2
levels,considerably,lower 1.0 0.000286697247706 2 0 2
led,to,increased 1.0 0.000286697247706 2 0 2
least,weeks,should 1.0 0.000286697247706 2 0 2
least,hours,prior 1.0 0.000286697247706 2 0 2
leading,to,possible 1.0 0.000286697247706 2 0 2
leading,to,elevated 1.0 0.000286697247706 2 0 2
labetalol,hcl,in 1.0 0.000286697247706 2 0 2
l-glutamine,at,a 1.0 0.000286697247706 2 0 2
known,cyp3a4,inducer 1.0 0.000286697247706 2 0 2
kinetics,and,renal 1.0 0.000286697247706 2 0 2
kg,s,c 1.0 0.000286697247706 2 0 2
kg,day,of 1.0 0.000286697247706 2 0 2
ketoconazole,coadministration,of 1.0 0.000286697247706 2 0 2
ketoconazole,co-administration,of 1.0 0.000286697247706 2 0 2
its,derivatives,and 1.0 0.000286697247706 2 0 2
its,binding,sites 1.0 0.000286697247706 2 0 2
isozymes,responsible,for 1.0 0.000286697247706 2 0 2
is,therefore,advised 1.0 0.000286697247706 2 0 2
is,potentiated,and 1.0 0.000286697247706 2 0 2
is,not,generally 1.0 0.000286697247706 2 0 2
is,displaced,from 1.0 0.000286697247706 2 0 2
is,combined,with 1.0 0.000286697247706 2 0 2
is,augmented,by 1.0 0.000286697247706 2 0 2
is,also,expected 1.0 0.000286697247706 2 0 2
is,administered,to 1.0 0.000286697247706 2 0 2
is,administered,concurrently 1.0 0.000286697247706 2 0 2
is,a,theoretical 1.0 0.000286697247706 2 0 2
ionized,species,of 1.0 0.000286697247706 2 0 2
intravenous,injection,of 1.0 0.000286697247706 2 0 2
interfering,with,neuromuscular 1.0 0.000286697247706 2 0 2
interaction,with,for 1.0 0.000286697247706 2 0 2
interact,with,of 1.0 0.000286697247706 2 0 2
insert,for,preparations 1.0 0.000286697247706 2 0 2
inotropic,effects,of 1.0 0.000286697247706 2 0 2
injection,usp,should 1.0 0.000286697247706 2 0 2
injection,of,at 1.0 0.000286697247706 2 0 2
injectable,transdermal,and 1.0 0.000286697247706 2 0 2
initiating,therapy,with 1.0 0.000286697247706 2 0 2
initiating,or,changing 1.0 0.000286697247706 2 0 2
initiated,in,patients 1.0 0.000286697247706 2 0 2
inhibitors,that,are 1.0 0.000286697247706 2 0 2
inhibitors,of,this 1.0 0.000286697247706 2 0 2
inhibitors,maoi,as 1.0 0.000286697247706 2 0 2
inhibitors,in,patients 1.0 0.000286697247706 2 0 2
inhibitors,and,has 1.0 0.000286697247706 2 0 2
inhibit,the,hypotensive 1.0 0.000286697247706 2 0 2
ingestion,of,may 1.0 0.000286697247706 2 0 2
infections,was,observed 1.0 0.000286697247706 2 0 2
inducers,of,clearance 1.0 0.000286697247706 2 0 2
inducer,should,be 1.0 0.000286697247706 2 0 2
indocin,can,reduce 1.0 0.000286697247706 2 0 2
increases,the,metabolic 1.0 0.000286697247706 2 0 2
increases,the,effect 1.0 0.000286697247706 2 0 2
increases,in,prothrombin 1.0 0.000286697247706 2 0 2
increases,in,heart 1.0 0.000286697247706 2 0 2
increases,in,cmax 1.0 0.000286697247706 2 0 2
increased,the,maximum 1.0 0.000286697247706 2 0 2
increased,the,exposure 1.0 0.000286697247706 2 0 2
increased,nephrotoxicity,has 1.0 0.000286697247706 2 0 2
increased,mean,plasma 1.0 0.000286697247706 2 0 2
increased,exposure,of 1.0 0.000286697247706 2 0 2
increased,effects,when 1.0 0.000286697247706 2 0 2
increased,by,about 1.0 0.000286697247706 2 0 2
increased,and,efficacy 1.0 0.000286697247706 2 0 2
increased,about,fold 1.0 0.000286697247706 2 0 2
increase,their,dose 1.0 0.000286697247706 2 0 2
increase,the,pharmacologic 1.0 0.000286697247706 2 0 2
increase,the,ototoxic 1.0 0.000286697247706 2 0 2
increase,the,mean 1.0 0.000286697247706 2 0 2
increase,the,frequency 1.0 0.000286697247706 2 0 2
increase,the,effect 1.0 0.000286697247706 2 0 2
increase,the,bioavailability 1.0 0.000286697247706 2 0 2
increase,plasma,concentration 1.0 0.000286697247706 2 0 2
increase,oral,response 1.0 0.000286697247706 2 0 2
increase,of,to 1.0 0.000286697247706 2 0 2
increase,in,cyclosporine-induced 1.0 0.000286697247706 2 0 2
increase,in,clearance 1.0 0.000286697247706 2 0 2
including,such,as 1.0 0.000286697247706 2 0 2
including,oral,injectable 1.0 0.000286697247706 2 0 2
including,may,enhance 1.0 0.000286697247706 2 0 2
including,concomitantly,with 1.0 0.000286697247706 2 0 2
include,certain,and 1.0 0.000286697247706 2 0 2
in,which,patients 1.0 0.000286697247706 2 0 2
in,well-controlled,patients 1.0 0.000286697247706 2 0 2
in,vivo,the 1.0 0.000286697247706 2 0 2
in,those,with 1.0 0.000286697247706 2 0 2
in,the,tail-flick 1.0 0.000286697247706 2 0 2
in,the,concentration 1.0 0.000286697247706 2 0 2
in,some,instances 1.0 0.000286697247706 2 0 2
in,serum,level 1.0 0.000286697247706 2 0 2
in,renal,clearance 1.0 0.000286697247706 2 0 2
in,plasmaconcentrations,may 1.0 0.000286697247706 2 0 2
in,patients,the 1.0 0.000286697247706 2 0 2
in,mean,peak 1.0 0.000286697247706 2 0 2
in,man,significantly 1.0 0.000286697247706 2 0 2
in,lower,serum 1.0 0.000286697247706 2 0 2
in,cyclosporine-induced,toxicity 1.0 0.000286697247706 2 0 2
in,additive,cns 1.0 0.000286697247706 2 0 2
in,a,greater 1.0 0.000286697247706 2 0 2
in,a,further 1.0 0.000286697247706 2 0 2
in,a,decreased 1.0 0.000286697247706 2 0 2
important,role,in 1.0 0.000286697247706 2 0 2
impaired,psychomotor,performance 1.0 0.000286697247706 2 0 2
immediate,release,capsules 1.0 0.000286697247706 2 0 2
if,the,two 1.0 0.000286697247706 2 0 2
if,is,co-administered 1.0 0.000286697247706 2 0 2
if,and,are 1.0 0.000286697247706 2 0 2
if,a,antimicrobial 1.0 0.000286697247706 2 0 2
ie,increased,prothrombin 1.0 0.000286697247706 2 0 2
ie,decreased,prothrom-bin 1.0 0.000286697247706 2 0 2
i,d,produced 1.0 0.000286697247706 2 0 2
i,d,co-administered 1.0 0.000286697247706 2 0 2
hypoparathyroid,patients,who 1.0 0.000286697247706 2 0 2
hypertension,administration,of 1.0 0.000286697247706 2 0 2
hydrochloride,has,been 1.0 0.000286697247706 2 0 2
human,pharmacokinetics,data 1.0 0.000286697247706 2 0 2
however,caution,should 1.0 0.000286697247706 2 0 2
however,because,some 1.0 0.000286697247706 2 0 2
hours,should,be 1.0 0.000286697247706 2 0 2
hours,of,the 1.0 0.000286697247706 2 0 2
hours,does,not 1.0 0.000286697247706 2 0 2
higher,occurrence,of 1.0 0.000286697247706 2 0 2
high,dose,of 1.0 0.000286697247706 2 0 2
healthy,volunteers,a 1.0 0.000286697247706 2 0 2
healthy,subjects,given 1.0 0.000286697247706 2 0 2
hcl,phenytoin,and 1.0 0.000286697247706 2 0 2
hcl,is,administered 1.0 0.000286697247706 2 0 2
have,neuromuscular,blocking 1.0 0.000286697247706 2 0 2
have,been,rarely 1.0 0.000286697247706 2 0 2
have,been,noted 1.0 0.000286697247706 2 0 2
have,been,greater 1.0 0.000286697247706 2 0 2
have,been,a 1.0 0.000286697247706 2 0 2
have,additive,effects 1.0 0.000286697247706 2 0 2
have,a,risk 1.0 0.000286697247706 2 0 2
has,on,rare 1.0 0.000286697247706 2 0 2
haloperidol,haloperidol,blocks 1.0 0.000286697247706 2 0 2
had,a,modest 1.0 0.000286697247706 2 0 2
h,ml,and 1.0 0.000286697247706 2 0 2
given,should,be 1.0 0.000286697247706 2 0 2
given,once,daily 1.0 0.000286697247706 2 0 2
given,in,conjunction 1.0 0.000286697247706 2 0 2
gi,ulceration,or 1.0 0.000286697247706 2 0 2
gi,bleeding,higher 1.0 0.000286697247706 2 0 2
gi,bleeding,are 1.0 0.000286697247706 2 0 2
generally,recommended,because 1.0 0.000286697247706 2 0 2
general,such,as 1.0 0.000286697247706 2 0 2
general,skeletal,muscle 1.0 0.000286697247706 2 0 2
general,or,other 1.0 0.000286697247706 2 0 2
gastrointestinal,toxicity,with 1.0 0.000286697247706 2 0 2
gastric,ph,is 1.0 0.000286697247706 2 0 2
further,deterioration,of 1.0 0.000286697247706 2 0 2
function,who,are 1.0 0.000286697247706 2 0 2
function,as,well 1.0 0.000286697247706 2 0 2
from,the,gastrointestinal 1.0 0.000286697247706 2 0 2
from,decrease,to 1.0 0.000286697247706 2 0 2
foscavir,and,intravenous 1.0 0.000286697247706 2 0 2
formulations,containing,divalent 1.0 0.000286697247706 2 0 2
formulation,with,mg 1.0 0.000286697247706 2 0 2
formulation,comparable,to 1.0 0.000286697247706 2 0 2
for,to,hours 1.0 0.000286697247706 2 0 2
for,the,increased 1.0 0.000286697247706 2 0 2
for,days,was 1.0 0.000286697247706 2 0 2
for,days,systemic 1.0 0.000286697247706 2 0 2
for,days,a 1.0 0.000286697247706 2 0 2
following,initiation,of 1.0 0.000286697247706 2 0 2
fold,on,day 1.0 0.000286697247706 2 0 2
first,few,days 1.0 0.000286697247706 2 0 2
few,days,after 1.0 0.000286697247706 2 0 2
felbatol,causes,an 1.0 0.000286697247706 2 0 2
felbatol,as,compared 1.0 0.000286697247706 2 0 2
extreme,caution,in 1.0 0.000286697247706 2 0 2
extended,release,tablets 1.0 0.000286697247706 2 0 2
exposures,of,similar 1.0 0.000286697247706 2 0 2
exposure,of,and 1.0 0.000286697247706 2 0 2
exposure,auc,of 1.0 0.000286697247706 2 0 2
experience,indicates,that 1.0 0.000286697247706 2 0 2
expected,to,reduce 1.0 0.000286697247706 2 0 2
exhibit,an,additive 1.0 0.000286697247706 2 0 2
every,hours,does 1.0 0.000286697247706 2 0 2
evaluated,but,should 1.0 0.000286697247706 2 0 2
ethosuximide,amphetamines,may 1.0 0.000286697247706 2 0 2
ethinyl,estradiol,may 1.0 0.000286697247706 2 0 2
etc,increase,the 1.0 0.000286697247706 2 0 2
estradiol,may,inhibit 1.0 0.000286697247706 2 0 2
equivalent,to,mg 1.0 0.000286697247706 2 0 2
equetrotm,are,the 1.0 0.000286697247706 2 0 2
enzyme,inhibitors,and 1.0 0.000286697247706 2 0 2
enzyme,inducers,and 1.0 0.000286697247706 2 0 2
enoxacin,is,a 1.0 0.000286697247706 2 0 2
enhanced,by,the 1.0 0.000286697247706 2 0 2
enhance,the,activity 1.0 0.000286697247706 2 0 2
elimination,of,sodium 1.0 0.000286697247706 2 0 2
elimination,of,by 1.0 0.000286697247706 2 0 2
elimination,and,increasing 1.0 0.000286697247706 2 0 2
elevations,in,the 1.0 0.000286697247706 2 0 2
electrolyte,loss,associated 1.0 0.000286697247706 2 0 2
elapse,between,discontinuation 1.0 0.000286697247706 2 0 2
either,potentiate,or 1.0 0.000286697247706 2 0 2
either,added,or 1.0 0.000286697247706 2 0 2
eg,and,other 1.0 0.000286697247706 2 0 2
eg,and,or 1.0 0.000286697247706 2 0 2
efficacy,of,oral 1.0 0.000286697247706 2 0 2
efficacy,is,reduced 1.0 0.000286697247706 2 0 2
effects,with,and 1.0 0.000286697247706 2 0 2
effects,when,coadministered 1.0 0.000286697247706 2 0 2
effects,when,and 1.0 0.000286697247706 2 0 2
effects,on,decreased 1.0 0.000286697247706 2 0 2
effects,of,when 1.0 0.000286697247706 2 0 2
effects,of,isosorbide 1.0 0.000286697247706 2 0 2
effects,of,ergomar 1.0 0.000286697247706 2 0 2
effects,of,but 1.0 0.000286697247706 2 0 2
effects,have,occurred 1.0 0.000286697247706 2 0 2
effects,and,the 1.0 0.000286697247706 2 0 2
effect,with,cns 1.0 0.000286697247706 2 0 2
effect,on,platelet 1.0 0.000286697247706 2 0 2
effect,of,only 1.0 0.000286697247706 2 0 2
effect,of,microdosed 1.0 0.000286697247706 2 0 2
effect,of,beta-adrenoceptor 1.0 0.000286697247706 2 0 2
effect,of,angiotensin 1.0 0.000286697247706 2 0 2
effect,in,some 1.0 0.000286697247706 2 0 2
effect,could,be 1.0 0.000286697247706 2 0 2
each,other,should 1.0 0.000286697247706 2 0 2
during,omnicef,therapy 1.0 0.000286697247706 2 0 2
during,coadministration,with 1.0 0.000286697247706 2 0 2
due,to,inhibition 1.0 0.000286697247706 2 0 2
dry,mouth,urinary 1.0 0.000286697247706 2 0 2
drugs,which,induce 1.0 0.000286697247706 2 0 2
drugs,that,reportedly 1.0 0.000286697247706 2 0 2
drugs,in,some 1.0 0.000286697247706 2 0 2
downward,adjustment,of 1.0 0.000286697247706 2 0 2
dosing,of,vardenafil 1.0 0.000286697247706 2 0 2
doses,of,hcl 1.0 0.000286697247706 2 0 2
doses,of,either 1.0 0.000286697247706 2 0 2
dose,range,of 1.0 0.000286697247706 2 0 2
dose,of,with 1.0 0.000286697247706 2 0 2
dose,of,be 1.0 0.000286697247706 2 0 2
dose,in,a 1.0 0.000286697247706 2 0 2
dose,co-administered,with 1.0 0.000286697247706 2 0 2
does,not,compensate 1.0 0.000286697247706 2 0 2
divalent,and,trivalent 1.0 0.000286697247706 2 0 2
diuretics,patients,on 1.0 0.000286697247706 2 0 2
diuretic,agents,reduce 1.0 0.000286697247706 2 0 2
discontinuing,to,avoid 1.0 0.000286697247706 2 0 2
discontinuation,of,and 1.0 0.000286697247706 2 0 2
diminish,oral,response 1.0 0.000286697247706 2 0 2
diflunisal,decreased,the 1.0 0.000286697247706 2 0 2
didanosine,chewable,buffered 1.0 0.000286697247706 2 0 2
diabetic,patients,the 1.0 0.000286697247706 2 0 2
dexbrompheniramine,can,interact 1.0 0.000286697247706 2 0 2
developed,neutropenia,anc 1.0 0.000286697247706 2 0 2
determinant,of,bioavailability 1.0 0.000286697247706 2 0 2
depressants,such,as 1.0 0.000286697247706 2 0 2
depressants,including,concomitantly 1.0 0.000286697247706 2 0 2
depress,plasma,prothrombin 1.0 0.000286697247706 2 0 2
depletions,of,striatal 1.0 0.000286697247706 2 0 2
demonstrated,to,be 1.0 0.000286697247706 2 0 2
delaying,elimination,and 1.0 0.000286697247706 2 0 2
decreased,with,coadministration 1.0 0.000286697247706 2 0 2
decreased,when,administered 1.0 0.000286697247706 2 0 2
decreased,the,renal 1.0 0.000286697247706 2 0 2
decreased,the,hyperuricemic 1.0 0.000286697247706 2 0 2
decreased,the,cmax 1.0 0.000286697247706 2 0 2
decreased,the,antinociceptive 1.0 0.000286697247706 2 0 2
decreased,synthesis,of 1.0 0.000286697247706 2 0 2
decreased,serum,levels 1.0 0.000286697247706 2 0 2
decreased,prothrom-bin,time 1.0 0.000286697247706 2 0 2
decreased,by,when 1.0 0.000286697247706 2 0 2
decreased,an,average 1.0 0.000286697247706 2 0 2
decreased,alertness,and 1.0 0.000286697247706 2 0 2
decrease,to,increase 1.0 0.000286697247706 2 0 2
decrease,the,tubular 1.0 0.000286697247706 2 0 2
decrease,the,effect 1.0 0.000286697247706 2 0 2
decrease,renal,tubular 1.0 0.000286697247706 2 0 2
decrease,in,mean 1.0 0.000286697247706 2 0 2
decrease,blood,glucose 1.0 0.000286697247706 2 0 2
days,systemic,exposure 1.0 0.000286697247706 2 0 2
days,increased,plasma 1.0 0.000286697247706 2 0 2
days,and,decreased 1.0 0.000286697247706 2 0 2
day,when,a 1.0 0.000286697247706 2 0 2
day,and,at 1.0 0.000286697247706 2 0 2
d,produced,a 1.0 0.000286697247706 2 0 2
d,for,days 1.0 0.000286697247706 2 0 2
d,co-administered,with 1.0 0.000286697247706 2 0 2
cytochrome,p-450,isozymes 1.0 0.000286697247706 2 0 2
cyp3a4,inducer,should 1.0 0.000286697247706 2 0 2
cyp3a4,eg,may 1.0 0.000286697247706 2 0 2
cyp3a4,activity,eg 1.0 0.000286697247706 2 0 2
cyp,a,inhibitors 1.0 0.000286697247706 2 0 2
cyclosporine-induced,toxicity,possibly 1.0 0.000286697247706 2 0 2
cyclosporine,elevated,serum 1.0 0.000286697247706 2 0 2
curare-like,compounds,should 1.0 0.000286697247706 2 0 2
crossover,study,in 1.0 0.000286697247706 2 0 2
creatinine,in,patients 1.0 0.000286697247706 2 0 2
could,exaggerate,the 1.0 0.000286697247706 2 0 2
corticotropin,may,accentuate 1.0 0.000286697247706 2 0 2
corresponding,increase,in 1.0 0.000286697247706 2 0 2
containing,or,with 1.0 0.000286697247706 2 0 2
containing,or,or 1.0 0.000286697247706 2 0 2
containing,divalent,and 1.0 0.000286697247706 2 0 2
containing,and,other 1.0 0.000286697247706 2 0 2
consequently,it,is 1.0 0.000286697247706 2 0 2
concurrently,being,treated 1.0 0.000286697247706 2 0 2
concomitantly,with,which 1.0 0.000286697247706 2 0 2
concomitantly,with,an 1.0 0.000286697247706 2 0 2
concomitantly,becausedecreases,in 1.0 0.000286697247706 2 0 2
concentrations,of,m 1.0 0.000286697247706 2 0 2
concentrations,of,felbatol 1.0 0.000286697247706 2 0 2
concentrations,and,a 1.0 0.000286697247706 2 0 2
concentration,of,synthetic 1.0 0.000286697247706 2 0 2
concentration,of,in 1.0 0.000286697247706 2 0 2
concentration,of,and 1.0 0.000286697247706 2 0 2
compromised,renal,function 1.0 0.000286697247706 2 0 2
compounds,should,only 1.0 0.000286697247706 2 0 2
complications,compared,to 1.0 0.000286697247706 2 0 2
compensate,for,the 1.0 0.000286697247706 2 0 2
compared,to,when 1.0 0.000286697247706 2 0 2
compared,to,use 1.0 0.000286697247706 2 0 2
compared,to,these 1.0 0.000286697247706 2 0 2
compared,to,dosing 1.0 0.000286697247706 2 0 2
comparable,to,mg 1.0 0.000286697247706 2 0 2
combination,of,and 1.0 0.000286697247706 2 0 2
combination,may,cause 1.0 0.000286697247706 2 0 2
coadministration,leads,to 1.0 0.000286697247706 2 0 2
coadministered,with,other 1.0 0.000286697247706 2 0 2
coadministered,with,aprepitant 1.0 0.000286697247706 2 0 2
co-administration,of,trileptal 1.0 0.000286697247706 2 0 2
co-administration,of,tcas 1.0 0.000286697247706 2 0 2
cns-active,drugs,ethanol 1.0 0.000286697247706 2 0 2
cns,stimulation,is 1.0 0.000286697247706 2 0 2
cns,depressants,such 1.0 0.000286697247706 2 0 2
cns,depressants,causing 1.0 0.000286697247706 2 0 2
cns,depressant,should 1.0 0.000286697247706 2 0 2
cmin,were,increased 1.0 0.000286697247706 2 0 2
cmin,were,decreased 1.0 0.000286697247706 2 0 2
cmi,has,been 1.0 0.000286697247706 2 0 2
cmax,when,co-administered 1.0 0.000286697247706 2 0 2
closely,monitored,if 1.0 0.000286697247706 2 0 2
close,observation,of 1.0 0.000286697247706 2 0 2
clinical,studies,involving 1.0 0.000286697247706 2 0 2
clinical,data,suggest 1.0 0.000286697247706 2 0 2
clinical,bleeding,has 1.0 0.000286697247706 2 0 2
clearance,of,by 1.0 0.000286697247706 2 0 2
clearance,by,and 1.0 0.000286697247706 2 0 2
clearance,and,significantly 1.0 0.000286697247706 2 0 2
clearance,and,an 1.0 0.000286697247706 2 0 2
class,of,may 1.0 0.000286697247706 2 0 2
cimetidine,cimetidine,has 1.0 0.000286697247706 2 0 2
chlorthalidone,and,related 1.0 0.000286697247706 2 0 2
chlorpromazine,chlorpromazine,blocks 1.0 0.000286697247706 2 0 2
chlorpromazine,blocks,and 1.0 0.000286697247706 2 0 2
chloride,sodium,acid 1.0 0.000286697247706 2 0 2
certain,and,sodium 1.0 0.000286697247706 2 0 2
central,stimulant,effects 1.0 0.000286697247706 2 0 2
cautiously,in,conjunction 1.0 0.000286697247706 2 0 2
cautious,when,administering 1.0 0.000286697247706 2 0 2
caution,is,therefore 1.0 0.000286697247706 2 0 2
caution,because,the 1.0 0.000286697247706 2 0 2
caution,as,the 1.0 0.000286697247706 2 0 2
causing,renin,release 1.0 0.000286697247706 2 0 2
causes,an,approximate 1.0 0.000286697247706 2 0 2
caused,a,dose-related 1.0 0.000286697247706 2 0 2
cause-and,effect,relationship 1.0 0.000286697247706 2 0 2
cause,striking,and 1.0 0.000286697247706 2 0 2
cause,elimination,of 1.0 0.000286697247706 2 0 2
cause,changes,in 1.0 0.000286697247706 2 0 2
cause,an,increase 1.0 0.000286697247706 2 0 2
catecholamine-depleting,may,have 1.0 0.000286697247706 2 0 2
cases,of,overdosage 1.0 0.000286697247706 2 0 2
carefully,monitored,when 1.0 0.000286697247706 2 0 2
cardiovascular,system,may 1.0 0.000286697247706 2 0 2
cardiac,output,and 1.0 0.000286697247706 2 0 2
capsule,formulation,with 1.0 0.000286697247706 2 0 2
can,occur,when 1.0 0.000286697247706 2 0 2
can,interfere,with 1.0 0.000286697247706 2 0 2
can,inhibit,the 1.0 0.000286697247706 2 0 2
can,decrease,plasma 1.0 0.000286697247706 2 0 2
can,attenuate,loss 1.0 0.000286697247706 2 0 2
can,antagonize,the 1.0 0.000286697247706 2 0 2
calcium,channel,blockers 1.0 0.000286697247706 2 0 2
c,should,be 1.0 0.000286697247706 2 0 2
by,pretreatment,with 1.0 0.000286697247706 2 0 2
by,on,day 1.0 0.000286697247706 2 0 2
by,high,doses 1.0 0.000286697247706 2 0 2
by,fold,and 1.0 0.000286697247706 2 0 2
by,cyp3a4,such 1.0 0.000286697247706 2 0 2
by,competing,for 1.0 0.000286697247706 2 0 2
by,approximately,and 1.0 0.000286697247706 2 0 2
by,antihypertensive,agents 1.0 0.000286697247706 2 0 2
by,and,decreased 1.0 0.000286697247706 2 0 2
by,acidifying,agents 1.0 0.000286697247706 2 0 2
by,about,when 1.0 0.000286697247706 2 0 2
by,about,in 1.0 0.000286697247706 2 0 2
by,about,and 1.0 0.000286697247706 2 0 2
by,a,mg 1.0 0.000286697247706 2 0 2
but,significantly,decreased 1.0 0.000286697247706 2 0 2
but,physicians,should 1.0 0.000286697247706 2 0 2
but,not,nanm 1.0 0.000286697247706 2 0 2
but,not,limited 1.0 0.000286697247706 2 0 2
but,not,by 1.0 0.000286697247706 2 0 2
brevibloc,were,concomitantly 1.0 0.000286697247706 2 0 2
both,together,have 1.0 0.000286697247706 2 0 2
bosentan,is,also 1.0 0.000286697247706 2 0 2
blurred,vision,have 1.0 0.000286697247706 2 0 2
blurred,vision,and 1.0 0.000286697247706 2 0 2
blunt,the,hypotensive 1.0 0.000286697247706 2 0 2
blood,pressure,of 1.0 0.000286697247706 2 0 2
blood,mononuclear,cells 1.0 0.000286697247706 2 0 2
blood,glucose,concentrations 1.0 0.000286697247706 2 0 2
blocks,and,reuptake 1.0 0.000286697247706 2 0 2
blocking,properties,that 1.0 0.000286697247706 2 0 2
blocking,agents,when 1.0 0.000286697247706 2 0 2
blocking,agents,by 1.0 0.000286697247706 2 0 2
blockers,should,be 1.0 0.000286697247706 2 0 2
blockers,may,exacerbate 1.0 0.000286697247706 2 0 2
blockers,and,organic 1.0 0.000286697247706 2 0 2
blockade,produced,by 1.0 0.000286697247706 2 0 2
block,may,be 1.0 0.000286697247706 2 0 2
bleeding,higher,than 1.0 0.000286697247706 2 0 2
bleeding,events,have 1.0 0.000286697247706 2 0 2
bleeding,are,synergistic 1.0 0.000286697247706 2 0 2
binding,to,avoid 1.0 0.000286697247706 2 0 2
binding,sites,during 1.0 0.000286697247706 2 0 2
binding,in,vitro 1.0 0.000286697247706 2 0 2
bid,a,potent 1.0 0.000286697247706 2 0 2
bezalip,retard,is 1.0 0.000286697247706 2 0 2
between,discontinuation,of 1.0 0.000286697247706 2 0 2
between,and,in 1.0 0.000286697247706 2 0 2
beta-blockers,salts,and 1.0 0.000286697247706 2 0 2
beta-adrenoceptor,blocking,agents 1.0 0.000286697247706 2 0 2
beta-adrenergic,antagonists,and 1.0 0.000286697247706 2 0 2
beta,blockers,may 1.0 0.000286697247706 2 0 2
benefits,outweigh,the 1.0 0.000286697247706 2 0 2
benefit,compared,to 1.0 0.000286697247706 2 0 2
before,the,gradual 1.0 0.000286697247706 2 0 2
been,studied,but 1.0 0.000286697247706 2 0 2
been,reported,among 1.0 0.000286697247706 2 0 2
been,rarely,reported 1.0 0.000286697247706 2 0 2
been,greater,than 1.0 0.000286697247706 2 0 2
been,evaluated,but 1.0 0.000286697247706 2 0 2
been,established,that 1.0 0.000286697247706 2 0 2
been,associated,in 1.0 0.000286697247706 2 0 2
becausedecreases,in,plasmaconcentrations 1.0 0.000286697247706 2 0 2
because,there,is 1.0 0.000286697247706 2 0 2
because,the,combination 1.0 0.000286697247706 2 0 2
because,some,have 1.0 0.000286697247706 2 0 2
because,of,similar 1.0 0.000286697247706 2 0 2
because,is,displaced 1.0 0.000286697247706 2 0 2
beadministered,concomitantly,becausedecreases 1.0 0.000286697247706 2 0 2
be,withdrawn,at 1.0 0.000286697247706 2 0 2
be,undertaken,with 1.0 0.000286697247706 2 0 2
be,rarely,associated 1.0 0.000286697247706 2 0 2
be,prolonged,by 1.0 0.000286697247706 2 0 2
be,performed,with 1.0 0.000286697247706 2 0 2
be,observed,when 1.0 0.000286697247706 2 0 2
be,monitored,particularly 1.0 0.000286697247706 2 0 2
be,monitored,carefully 1.0 0.000286697247706 2 0 2
be,increased,and 1.0 0.000286697247706 2 0 2
be,exacerbated,by 1.0 0.000286697247706 2 0 2
be,cyp,a 1.0 0.000286697247706 2 0 2
be,cautious,when 1.0 0.000286697247706 2 0 2
be,blunted,by 1.0 0.000286697247706 2 0 2
be,avoided,unless 1.0 0.000286697247706 2 0 2
be,approached,with 1.0 0.000286697247706 2 0 2
be,anticipated,with 1.0 0.000286697247706 2 0 2
be,alert,to 1.0 0.000286697247706 2 0 2
be,additive,use 1.0 0.000286697247706 2 0 2
basis,that,these 1.0 0.000286697247706 2 0 2
basis,of,clinical 1.0 0.000286697247706 2 0 2
bacteriostatic,may,antagonize 1.0 0.000286697247706 2 0 2
bactericidal,action,of 1.0 0.000286697247706 2 0 2
b-induced,hypokalemia,may 1.0 0.000286697247706 2 0 2
b-blocking,properties,may 1.0 0.000286697247706 2 0 2
b-blocking,properties,and 1.0 0.000286697247706 2 0 2
average,of,and 1.0 0.000286697247706 2 0 2
av,nodal,conduction 1.0 0.000286697247706 2 0 2
augmented,by,antihypertensive 1.0 0.000286697247706 2 0 2
augment,the,activity 1.0 0.000286697247706 2 0 2
auc,values,for 1.0 0.000286697247706 2 0 2
auc,ss,of 1.0 0.000286697247706 2 0 2
auc,of,were 1.0 0.000286697247706 2 0 2
auc,of,increased 1.0 0.000286697247706 2 0 2
attenuate,loss,caused 1.0 0.000286697247706 2 0 2
at,mg,twice 1.0 0.000286697247706 2 0 2
at,an,increased 1.0 0.000286697247706 2 0 2
associated,with,transient 1.0 0.000286697247706 2 0 2
associated,with,fatal 1.0 0.000286697247706 2 0 2
associated,in,some 1.0 0.000286697247706 2 0 2
aspirin,should,be 1.0 0.000286697247706 2 0 2
aspirin,concurrent,administration 1.0 0.000286697247706 2 0 2
as,with,some 1.0 0.000286697247706 2 0 2
as,videx,chewable 1.0 0.000286697247706 2 0 2
as,these,agents 1.0 0.000286697247706 2 0 2
as,the,effect 1.0 0.000286697247706 2 0 2
as,the,and 1.0 0.000286697247706 2 0 2
as,protease,inhibitors 1.0 0.000286697247706 2 0 2
as,and,can 1.0 0.000286697247706 2 0 2
as,a,tablet 1.0 0.000286697247706 2 0 2
as,a,regimen 1.0 0.000286697247706 2 0 2
as,a,metabolite 1.0 0.000286697247706 2 0 2
as,a,consequence 1.0 0.000286697247706 2 0 2
are,synergistic,such 1.0 0.000286697247706 2 0 2
are,required,during 1.0 0.000286697247706 2 0 2
are,reported,to 1.0 0.000286697247706 2 0 2
are,on,therapy 1.0 0.000286697247706 2 0 2
are,increased,by 1.0 0.000286697247706 2 0 2
are,given,in 1.0 0.000286697247706 2 0 2
are,decreased,when 1.0 0.000286697247706 2 0 2
are,concurrently,being 1.0 0.000286697247706 2 0 2
are,being,treated 1.0 0.000286697247706 2 0 2
aprepitant,to,achieve 1.0 0.000286697247706 2 0 2
aprepitant,increased,the 1.0 0.000286697247706 2 0 2
approximately,when,and 1.0 0.000286697247706 2 0 2
approximately,and,respectively 1.0 0.000286697247706 2 0 2
approached,with,caution 1.0 0.000286697247706 2 0 2
any,known,cyp3a4 1.0 0.000286697247706 2 0 2
antimicrobial,is,administered 1.0 0.000286697247706 2 0 2
antihypertensives,amphetamines,may 1.0 0.000286697247706 2 0 2
antihypertensive,medications,or 1.0 0.000286697247706 2 0 2
antihypertensive,agents,that 1.0 0.000286697247706 2 0 2
antihistamines,amphetamines,may 1.0 0.000286697247706 2 0 2
antidepressants,amphetamines,may 1.0 0.000286697247706 2 0 2
anticoagulants,there,have 1.0 0.000286697247706 2 0 2
anticipated,with,cmi 1.0 0.000286697247706 2 0 2
anti-inflammatory,drugs,in 1.0 0.000286697247706 2 0 2
anti-inflammatory,agents,in 1.0 0.000286697247706 2 0 2
anti-inflammatory,agent,can 1.0 0.000286697247706 2 0 2
antacids,in,a 1.0 0.000286697247706 2 0 2
animal,studies,indicate 1.0 0.000286697247706 2 0 2
and,which,have 1.0 0.000286697247706 2 0 2
and,were,indifferent 1.0 0.000286697247706 2 0 2
and,were,coadministered 1.0 0.000286697247706 2 0 2
and,vitamin,k 1.0 0.000286697247706 2 0 2
and,viracept,resulted 1.0 0.000286697247706 2 0 2
and,trivalent,cations 1.0 0.000286697247706 2 0 2
and,to,potentiate 1.0 0.000286697247706 2 0 2
and,thus,if 1.0 0.000286697247706 2 0 2
and,therapy,a 1.0 0.000286697247706 2 0 2
and,the,production 1.0 0.000286697247706 2 0 2
and,the,mean 1.0 0.000286697247706 2 0 2
and,the,cmax 1.0 0.000286697247706 2 0 2
and,tablets,may 1.0 0.000286697247706 2 0 2
and,such,an 1.0 0.000286697247706 2 0 2
and,reuptake,thus 1.0 0.000286697247706 2 0 2
and,retinyl,acetate 1.0 0.000286697247706 2 0 2
and,respectively,when 1.0 0.000286697247706 2 0 2
and,requires,close 1.0 0.000286697247706 2 0 2
and,related,may 1.0 0.000286697247706 2 0 2
and,reduces,the 1.0 0.000286697247706 2 0 2
and,prolong,the 1.0 0.000286697247706 2 0 2
and,potassium-sparing,diuretics 1.0 0.000286697247706 2 0 2
and,other,non-steroidal 1.0 0.000286697247706 2 0 2
and,other,multivalent 1.0 0.000286697247706 2 0 2
and,other,cns 1.0 0.000286697247706 2 0 2
and,organic,were 1.0 0.000286697247706 2 0 2
and,oral,were 1.0 0.000286697247706 2 0 2
and,or,that 1.0 0.000286697247706 2 0 2
and,or,bleeding 1.0 0.000286697247706 2 0 2
and,nsaids,on 1.0 0.000286697247706 2 0 2
and,non-selective,mao 1.0 0.000286697247706 2 0 2
and,no,additional 1.0 0.000286697247706 2 0 2
and,may,inhibit 1.0 0.000286697247706 2 0 2
and,may,either 1.0 0.000286697247706 2 0 2
and,markedly,inhibit 1.0 0.000286697247706 2 0 2
and,maois,may 1.0 0.000286697247706 2 0 2
and,it,has 1.0 0.000286697247706 2 0 2
and,is,likely 1.0 0.000286697247706 2 0 2
and,initiation,of 1.0 0.000286697247706 2 0 2
and,increases,the 1.0 0.000286697247706 2 0 2
and,increased,the 1.0 0.000286697247706 2 0 2
and,in,some 1.0 0.000286697247706 2 0 2
and,in,normal 1.0 0.000286697247706 2 0 2
and,in,dogs 1.0 0.000286697247706 2 0 2
and,impaired,psychomotor 1.0 0.000286697247706 2 0 2
and,half-life,increased 1.0 0.000286697247706 2 0 2
and,fatal,convulsions 1.0 0.000286697247706 2 0 2
and,efficacy,is 1.0 0.000286697247706 2 0 2
and,discontinuing,to 1.0 0.000286697247706 2 0 2
and,discontinuation,of 1.0 0.000286697247706 2 0 2
and,developed,neutropenia 1.0 0.000286697247706 2 0 2
and,decrease,in 1.0 0.000286697247706 2 0 2
and,concurrent,use 1.0 0.000286697247706 2 0 2
and,concomitantly,may 1.0 0.000286697247706 2 0 2
and,coadministration,of 1.0 0.000286697247706 2 0 2
and,channel,blockers 1.0 0.000286697247706 2 0 2
and,by,fold 1.0 0.000286697247706 2 0 2
and,brevibloc,were 1.0 0.000286697247706 2 0 2
and,auc,after 1.0 0.000286697247706 2 0 2
and,are,all 1.0 0.000286697247706 2 0 2
and,animal,studies 1.0 0.000286697247706 2 0 2
and,and,increase 1.0 0.000286697247706 2 0 2
and,a,dose 1.0 0.000286697247706 2 0 2
and,a,decrease 1.0 0.000286697247706 2 0 2
an,oral,for 1.0 0.000286697247706 2 0 2
an,interleukin-1,antagonist 1.0 0.000286697247706 2 0 2
an,increased,rate 1.0 0.000286697247706 2 0 2
an,eight-fold,increase 1.0 0.000286697247706 2 0 2
an,effect,may 1.0 0.000286697247706 2 0 2
an,decrease,in 1.0 0.000286697247706 2 0 2
an,approximate,doubling 1.0 0.000286697247706 2 0 2
amphotericin,b-induced,hypokalemia 1.0 0.000286697247706 2 0 2
amphetamines,potentiate,the 1.0 0.000286697247706 2 0 2
amphetamines,may,counteract 1.0 0.000286697247706 2 0 2
amphetamines,may,antagonize 1.0 0.000286697247706 2 0 2
amphetamines,inhibit,the 1.0 0.000286697247706 2 0 2
amphetamines,enhance,the 1.0 0.000286697247706 2 0 2
ammonium,chloride,sodium 1.0 0.000286697247706 2 0 2
aminosalicylic,acid,may 1.0 0.000286697247706 2 0 2
although,it,has 1.0 0.000286697247706 2 0 2
alternatives,to,should 1.0 0.000286697247706 2 0 2
also,expected,to 1.0 0.000286697247706 2 0 2
also,decrease,the 1.0 0.000286697247706 2 0 2
alone,had,no 1.0 0.000286697247706 2 0 2
alone,and,min 1.0 0.000286697247706 2 0 2
alkaloids,amphetamines,inhibit 1.0 0.000286697247706 2 0 2
alertness,and,impaired 1.0 0.000286697247706 2 0 2
alert,to,the 1.0 0.000286697247706 2 0 2
agents,that,cause 1.0 0.000286697247706 2 0 2
agents,reduce,the 1.0 0.000286697247706 2 0 2
agents,may,potentiate 1.0 0.000286697247706 2 0 2
agents,may,decrease 1.0 0.000286697247706 2 0 2
agents,interfering,with 1.0 0.000286697247706 2 0 2
agents,in,some 1.0 0.000286697247706 2 0 2
agents,causing,renin 1.0 0.000286697247706 2 0 2
agents,ammonium,chloride 1.0 0.000286697247706 2 0 2
after,a,week 1.0 0.000286697247706 2 0 2
after,a,bile 1.0 0.000286697247706 2 0 2
advised,in,the 1.0 0.000286697247706 2 0 2
adverse,effects,have 1.0 0.000286697247706 2 0 2
adrenergic,blockers,are 1.0 0.000286697247706 2 0 2
administration,with,may 1.0 0.000286697247706 2 0 2
administration,of,toradol 1.0 0.000286697247706 2 0 2
administration,of,thiazide 1.0 0.000286697247706 2 0 2
administration,of,resulting 1.0 0.000286697247706 2 0 2
administration,of,low-dose 1.0 0.000286697247706 2 0 2
administration,of,hepatic 1.0 0.000286697247706 2 0 2
administration,of,factive 1.0 0.000286697247706 2 0 2
administration,of,equivalent 1.0 0.000286697247706 2 0 2
administration,of,decreased 1.0 0.000286697247706 2 0 2
administration,of,buspirone 1.0 0.000286697247706 2 0 2
administration,of,because 1.0 0.000286697247706 2 0 2
administration,of,another 1.0 0.000286697247706 2 0 2
administering,gleevec,with 1.0 0.000286697247706 2 0 2
administered,with,oral 1.0 0.000286697247706 2 0 2
administered,with,extreme 1.0 0.000286697247706 2 0 2
administered,prior,to 1.0 0.000286697247706 2 0 2
administered,a,single 1.0 0.000286697247706 2 0 2
additive,use,of 1.0 0.000286697247706 2 0 2
additive,cns,depression 1.0 0.000286697247706 2 0 2
additional,benefit,compared 1.0 0.000286697247706 2 0 2
added,to,therapy 1.0 0.000286697247706 2 0 2
added,or,deleted 1.0 0.000286697247706 2 0 2
add,to,or 1.0 0.000286697247706 2 0 2
activity,such,as 1.0 0.000286697247706 2 0 2
activity,patients,who 1.0 0.000286697247706 2 0 2
active,ra,were 1.0 0.000286697247706 2 0 2
active,metabolite,which 1.0 0.000286697247706 2 0 2
action,of,starlix 1.0 0.000286697247706 2 0 2
action,of,it 1.0 0.000286697247706 2 0 2
acidifying,agents,used 1.0 0.000286697247706 2 0 2
acid,etc,increase 1.0 0.000286697247706 2 0 2
acid,combination,hormonal 1.0 0.000286697247706 2 0 2
acid,binding,to 1.0 0.000286697247706 2 0 2
achieve,exposures,of 1.0 0.000286697247706 2 0 2
ace-inhibitors,reports,suggest 1.0 0.000286697247706 2 0 2
ace,inhibitors,during 1.0 0.000286697247706 2 0 2
accordingly,in,patients 1.0 0.000286697247706 2 0 2
accentuate,the,electrolyte 1.0 0.000286697247706 2 0 2
absorption,of,where 1.0 0.000286697247706 2 0 2
absorption,of,may 1.0 0.000286697247706 2 0 2
about,a,increase 1.0 0.000286697247706 2 0 2
a,week,course 1.0 0.000286697247706 2 0 2
a,theoretical,basis 1.0 0.000286697247706 2 0 2
a,tablet,formulation 1.0 0.000286697247706 2 0 2
a,strong,cyp3a4 1.0 0.000286697247706 2 0 2
a,slight,decrease 1.0 0.000286697247706 2 0 2
a,rate,of 1.0 0.000286697247706 2 0 2
a,rapid,and 1.0 0.000286697247706 2 0 2
a,patient,with 1.0 0.000286697247706 2 0 2
a,patient,on 1.0 0.000286697247706 2 0 2
a,patient,currently 1.0 0.000286697247706 2 0 2
a,non-steroidal,anti-inflammatory 1.0 0.000286697247706 2 0 2
a,modest,effect 1.0 0.000286697247706 2 0 2
a,mg,single 1.0 0.000286697247706 2 0 2
a,mean,eight-fold 1.0 0.000286697247706 2 0 2
a,is,administered 1.0 0.000286697247706 2 0 2
a,higher,occurrence 1.0 0.000286697247706 2 0 2
a,further,deterioration 1.0 0.000286697247706 2 0 2
a,corresponding,increase 1.0 0.000286697247706 2 0 2
a,consequence,of 1.0 0.000286697247706 2 0 2
a,cause-and,effect 1.0 0.000286697247706 2 0 2
a,bile,acid 1.0 0.000286697247706 2 0 2
a,bacteriostatic,may 1.0 0.000286697247706 2 0 2
a,antimicrobial,is 1.0 0.000286697247706 2 0 2
zyvox,or,concomitant 1.0 0.000143348623853 1 0 1
zyvox,may,experience 1.0 0.000143348623853 1 0 1
zyvox,and,serotonergic 1.0 0.000143348623853 1 0 1
zyvox,and,concomitant 1.0 0.000143348623853 1 0 1
zone,and,dpcpx-induced 1.0 0.000143348623853 1 0 1
zidovudine,should,either 1.0 0.000143348623853 1 0 1
zidovudine,ribavirin,can 1.0 0.000143348623853 1 0 1
zebeta,should,not 1.0 0.000143348623853 1 0 1
zebeta,should,be 1.0 0.000143348623853 1 0 1
zebeta,resulting,in 1.0 0.000143348623853 1 0 1
zebeta,may,produce 1.0 0.000143348623853 1 0 1
zebeta,be,discontinued 1.0 0.000143348623853 1 0 1
zdv,as,shown 1.0 0.000143348623853 1 0 1
zarontin,may,interact 1.0 0.000143348623853 1 0 1
zaleplons,maximal,plasma 1.0 0.000143348623853 1 0 1
zalcitabine,inhibited,phosphorylation 1.0 0.000143348623853 1 0 1
zalcitabine,also,has 1.0 0.000143348623853 1 0 1
your,health,care 1.0 0.000143348623853 1 0 1
you,take,by 1.0 0.000143348623853 1 0 1
you,need,to 1.0 0.000143348623853 1 0 1
you,are,using 1.0 0.000143348623853 1 0 1
you,are,also 1.0 0.000143348623853 1 0 1
yields,a,net 1.0 0.000143348623853 1 0 1
years,who,were 1.0 0.000143348623853 1 0 1
xr,may,reduce 1.0 0.000143348623853 1 0 1
xanthine,derivatives,or 1.0 0.000143348623853 1 0 1
xanthine,and,other 1.0 0.000143348623853 1 0 1
xanthine,and,an 1.0 0.000143348623853 1 0 1
x,mg,tablets 1.0 0.000143348623853 1 0 1
x,mg,capsule 1.0 0.000143348623853 1 0 1
x,m,inhibits 1.0 0.000143348623853 1 0 1
x,m,enhance 1.0 0.000143348623853 1 0 1
x,h,ml 1.0 0.000143348623853 1 0 1
x,ed95,nimbex 1.0 0.000143348623853 1 0 1
wshow,that,given 1.0 0.000143348623853 1 0 1
would,worsen,the 1.0 0.000143348623853 1 0 1
would,seem,to 1.0 0.000143348623853 1 0 1
wort,theo-dur,and 1.0 0.000143348623853 1 0 1
worsened,by,especially 1.0 0.000143348623853 1 0 1
worsen,the,incidence 1.0 0.000143348623853 1 0 1
worsen,side,effects 1.0 0.000143348623853 1 0 1
without,to,l 1.0 0.000143348623853 1 0 1
without,preventing,its 1.0 0.000143348623853 1 0 1
without,clinical,bleeding 1.0 0.000143348623853 1 0 1
without,bleeding,in 1.0 0.000143348623853 1 0 1
without,an,agent 1.0 0.000143348623853 1 0 1
without,altering,prothrombin 1.0 0.000143348623853 1 0 1
without,a,functioning 1.0 0.000143348623853 1 0 1
within14,days,following 1.0 0.000143348623853 1 0 1
within,weeks,of 1.0 0.000143348623853 1 0 1
within,two,to 1.0 0.000143348623853 1 0 1
within,the,normal 1.0 0.000143348623853 1 0 1
within,minutes,of 1.0 0.000143348623853 1 0 1
within,days,because 1.0 0.000143348623853 1 0 1
within,a,period 1.0 0.000143348623853 1 0 1
withhold,during,dosing 1.0 0.000143348623853 1 0 1
withdrawn,several,days 1.0 0.000143348623853 1 0 1
withdrawn,from,treatment 1.0 0.000143348623853 1 0 1
withdrawal,syndrome,in 1.0 0.000143348623853 1 0 1
withdrawal,of,decreased 1.0 0.000143348623853 1 0 1
withdrawal,methadone,maintained 1.0 0.000143348623853 1 0 1
withdrawal,and,dose 1.0 0.000143348623853 1 0 1
with,zyvox,and 1.0 0.000143348623853 1 0 1
with,xanthine,derivatives 1.0 0.000143348623853 1 0 1
with,would,be 1.0 0.000143348623853 1 0 1
with,with,metal 1.0 0.000143348623853 1 0 1
with,with,and 1.0 0.000143348623853 1 0 1
with,were,not 1.0 0.000143348623853 1 0 1
with,wellbutrin,should 1.0 0.000143348623853 1 0 1
with,weakness,hyperreflexia 1.0 0.000143348623853 1 0 1
with,was,found 1.0 0.000143348623853 1 0 1
with,viracept,antiarrhythmics 1.0 0.000143348623853 1 0 1
with,vioxx,may 1.0 0.000143348623853 1 0 1
with,vioxx,is 1.0 0.000143348623853 1 0 1
with,videx,chewable 1.0 0.000143348623853 1 0 1
with,ventricular,fibrillation 1.0 0.000143348623853 1 0 1
with,various,containing 1.0 0.000143348623853 1 0 1
with,vaprisol,the 1.0 0.000143348623853 1 0 1
with,tylenol,chloromycetin 1.0 0.000143348623853 1 0 1
with,tuberculosis,showed 1.0 0.000143348623853 1 0 1
with,transdermal,may 1.0 0.000143348623853 1 0 1
with,topical,glaucoma 1.0 0.000143348623853 1 0 1
with,to,which 1.0 0.000143348623853 1 0 1
with,to,extend 1.0 0.000143348623853 1 0 1
with,tikosyn,as 1.0 0.000143348623853 1 0 1
with,those,produced 1.0 0.000143348623853 1 0 1
with,those,achieved 1.0 0.000143348623853 1 0 1
with,thiazide,may 1.0 0.000143348623853 1 0 1
with,these,or 1.0 0.000143348623853 1 0 1
with,these,disturbances 1.0 0.000143348623853 1 0 1
with,there,was 1.0 0.000143348623853 1 0 1
with,their,dosage 1.0 0.000143348623853 1 0 1
with,the,tricyclic 1.0 0.000143348623853 1 0 1
with,the,therapeutic 1.0 0.000143348623853 1 0 1
with,the,simultaneous 1.0 0.000143348623853 1 0 1
with,the,reversal 1.0 0.000143348623853 1 0 1
with,the,renal 1.0 0.000143348623853 1 0 1
with,the,preservative 1.0 0.000143348623853 1 0 1
with,the,preparation 1.0 0.000143348623853 1 0 1
with,the,potent 1.0 0.000143348623853 1 0 1
with,the,pharmacokinetics 1.0 0.000143348623853 1 0 1
with,the,modulation 1.0 0.000143348623853 1 0 1
with,the,levulan 1.0 0.000143348623853 1 0 1
with,the,label 1.0 0.000143348623853 1 0 1
with,the,iop 1.0 0.000143348623853 1 0 1
with,the,implication 1.0 0.000143348623853 1 0 1
with,the,hepatic 1.0 0.000143348623853 1 0 1
with,the,has 1.0 0.000143348623853 1 0 1
with,the,elimination 1.0 0.000143348623853 1 0 1
with,the,dose 1.0 0.000143348623853 1 0 1
with,the,cyp3a4 1.0 0.000143348623853 1 0 1
with,the,contraceptive 1.0 0.000143348623853 1 0 1
with,the,clearance 1.0 0.000143348623853 1 0 1
with,the,auc 1.0 0.000143348623853 1 0 1
with,the,anti-glaucoma 1.0 0.000143348623853 1 0 1
with,the,alternate 1.0 0.000143348623853 1 0 1
with,the,administration 1.0 0.000143348623853 1 0 1
with,the,action 1.0 0.000143348623853 1 0 1
with,that,strongly 1.0 0.000143348623853 1 0 1
with,that,observed 1.0 0.000143348623853 1 0 1
with,that,may 1.0 0.000143348623853 1 0 1
with,than,those 1.0 0.000143348623853 1 0 1
with,targretin,capsules 1.0 0.000143348623853 1 0 1
with,tambocor,unless 1.0 0.000143348623853 1 0 1
with,tambocor,are 1.0 0.000143348623853 1 0 1
with,tablets,usp 1.0 0.000143348623853 1 0 1
with,tablets,reduces 1.0 0.000143348623853 1 0 1
with,tablets,is 1.0 0.000143348623853 1 0 1
with,tablets,an 1.0 0.000143348623853 1 0 1
with,systemically-administered,oral 1.0 0.000143348623853 1 0 1
with,sustiva,mg 1.0 0.000143348623853 1 0 1
with,such,medications 1.0 0.000143348623853 1 0 1
with,strong,inhibitors 1.0 0.000143348623853 1 0 1
with,steady,state 1.0 0.000143348623853 1 0 1
with,sprycel,is 1.0 0.000143348623853 1 0 1
with,some,like 1.0 0.000143348623853 1 0 1
with,some,angiotensin 1.0 0.000143348623853 1 0 1
with,small,doses 1.0 0.000143348623853 1 0 1
with,since,these 1.0 0.000143348623853 1 0 1
with,since,interactions 1.0 0.000143348623853 1 0 1
with,since,an 1.0 0.000143348623853 1 0 1
with,similar,properties 1.0 0.000143348623853 1 0 1
with,signs,and 1.0 0.000143348623853 1 0 1
with,significantly,decreased 1.0 0.000143348623853 1 0 1
with,should,generally 1.0 0.000143348623853 1 0 1
with,severe,short 1.0 0.000143348623853 1 0 1
with,serotoninergic,agents 1.0 0.000143348623853 1 0 1
with,serotonin,reuptake 1.0 0.000143348623853 1 0 1
with,see,clinical 1.0 0.000143348623853 1 0 1
with,rr,microm 1.0 0.000143348623853 1 0 1
with,resulting,in 1.0 0.000143348623853 1 0 1
with,renal,tubular 1.0 0.000143348623853 1 0 1
with,renal,dysfunction 1.0 0.000143348623853 1 0 1
with,reduces,both 1.0 0.000143348623853 1 0 1
with,reduced,the 1.0 0.000143348623853 1 0 1
with,reduced,serum 1.0 0.000143348623853 1 0 1
with,reduce,both 1.0 0.000143348623853 1 0 1
with,racemic,mg 1.0 0.000143348623853 1 0 1
with,racemic,citalopram 1.0 0.000143348623853 1 0 1
with,proton,pump 1.0 0.000143348623853 1 0 1
with,prothrombin,time 1.0 0.000143348623853 1 0 1
with,propranolols,hypotensive 1.0 0.000143348623853 1 0 1
with,products,containing 1.0 0.000143348623853 1 0 1
with,produces,a 1.0 0.000143348623853 1 0 1
with,prinivil,can 1.0 0.000143348623853 1 0 1
with,prinivil,at 1.0 0.000143348623853 1 0 1
with,preparations,since 1.0 0.000143348623853 1 0 1
with,preparations,may 1.0 0.000143348623853 1 0 1
with,precedex,a 1.0 0.000143348623853 1 0 1
with,potentially,nephrotoxic 1.0 0.000143348623853 1 0 1
with,potent,loop 1.0 0.000143348623853 1 0 1
with,potent,cyp3a4 1.0 0.000143348623853 1 0 1
with,potassium-sparing,or 1.0 0.000143348623853 1 0 1
with,potassium-depleting,agents 1.0 0.000143348623853 1 0 1
with,possible,rapid 1.0 0.000143348623853 1 0 1
with,plus,catecholamine 1.0 0.000143348623853 1 0 1
with,platelet-aggregation,reactions 1.0 0.000143348623853 1 0 1
with,pivoxil,resulted 1.0 0.000143348623853 1 0 1
with,phenurone,since 1.0 0.000143348623853 1 0 1
with,peripheral,because 1.0 0.000143348623853 1 0 1
with,pegasys,once 1.0 0.000143348623853 1 0 1
with,patients,taking 1.0 0.000143348623853 1 0 1
with,patients,should 1.0 0.000143348623853 1 0 1
with,particularly,during 1.0 0.000143348623853 1 0 1
with,overdosage,or 1.0 0.000143348623853 1 0 1
with,ovcon-35,resulted 1.0 0.000143348623853 1 0 1
with,ototoxic,potential 1.0 0.000143348623853 1 0 1
with,other,tnf-blocking 1.0 0.000143348623853 1 0 1
with,other,should 1.0 0.000143348623853 1 0 1
with,other,monoamine 1.0 0.000143348623853 1 0 1
with,other,has 1.0 0.000143348623853 1 0 1
with,other,general 1.0 0.000143348623853 1 0 1
with,other,ergot 1.0 0.000143348623853 1 0 1
with,other,cyp3a4 1.0 0.000143348623853 1 0 1
with,other,cns-depressant 1.0 0.000143348623853 1 0 1
with,other,broad-spectrum 1.0 0.000143348623853 1 0 1
with,other,antipsychotic 1.0 0.000143348623853 1 0 1
with,other,antiepileptic 1.0 0.000143348623853 1 0 1
with,other,and 1.0 0.000143348623853 1 0 1
with,other,amphotericin 1.0 0.000143348623853 1 0 1
with,orencia,has 1.0 0.000143348623853 1 0 1
with,orencia,and 1.0 0.000143348623853 1 0 1
with,orally,administered 1.0 0.000143348623853 1 0 1
with,oral,was 1.0 0.000143348623853 1 0 1
with,oral,treatment 1.0 0.000143348623853 1 0 1
with,oral,the 1.0 0.000143348623853 1 0 1
with,oral,resulted 1.0 0.000143348623853 1 0 1
with,oral,may 1.0 0.000143348623853 1 0 1
with,oral,live 1.0 0.000143348623853 1 0 1
with,or,with 1.0 0.000143348623853 1 0 1
with,or,the 1.0 0.000143348623853 1 0 1
with,or,subsequent 1.0 0.000143348623853 1 0 1
with,or,sodium 1.0 0.000143348623853 1 0 1
with,or,potent 1.0 0.000143348623853 1 0 1
with,or,minutes 1.0 0.000143348623853 1 0 1
with,or,may 1.0 0.000143348623853 1 0 1
with,or,innovar 1.0 0.000143348623853 1 0 1
with,or,immediately 1.0 0.000143348623853 1 0 1
with,or,has 1.0 0.000143348623853 1 0 1
with,or,had 1.0 0.000143348623853 1 0 1
with,or,h2antagonists 1.0 0.000143348623853 1 0 1
with,or,glycoprotein 1.0 0.000143348623853 1 0 1
with,or,can 1.0 0.000143348623853 1 0 1
with,one,gram 1.0 0.000143348623853 1 0 1
with,on,the 1.0 0.000143348623853 1 0 1
with,oh,d3 1.0 0.000143348623853 1 0 1
with,occurs,dose 1.0 0.000143348623853 1 0 1
with,nsaids,has 1.0 0.000143348623853 1 0 1
with,norpace,or 1.0 0.000143348623853 1 0 1
with,nonsteroidal,the 1.0 0.000143348623853 1 0 1
with,nonsteroidal,anti-inflammatory 1.0 0.000143348623853 1 0 1
with,nonsteroidal,agents 1.0 0.000143348623853 1 0 1
with,nonselective,inhibitor 1.0 0.000143348623853 1 0 1
with,non-steroidal,the 1.0 0.000143348623853 1 0 1
with,nitrous,oxide 1.0 0.000143348623853 1 0 1
with,neurontin,mg 1.0 0.000143348623853 1 0 1
with,neoplastic,disease 1.0 0.000143348623853 1 0 1
with,nalfon,may 1.0 0.000143348623853 1 0 1
with,must,be 1.0 0.000143348623853 1 0 1
with,multivalent,cation-containing 1.0 0.000143348623853 1 0 1
with,multiple,effects 1.0 0.000143348623853 1 0 1
with,multiple,dosing 1.0 0.000143348623853 1 0 1
with,most,psychoactive 1.0 0.000143348623853 1 0 1
with,most,other 1.0 0.000143348623853 1 0 1
with,more,commonly 1.0 0.000143348623853 1 0 1
with,monurol,a 1.0 0.000143348623853 1 0 1
with,modest,increases 1.0 0.000143348623853 1 0 1
with,moderate,to 1.0 0.000143348623853 1 0 1
with,ml,maalox 1.0 0.000143348623853 1 0 1
with,mixed,agonist 1.0 0.000143348623853 1 0 1
with,microalbuminuria,inspra 1.0 0.000143348623853 1 0 1
with,mg,times 1.0 0.000143348623853 1 0 1
with,mg,tid 1.0 0.000143348623853 1 0 1
with,mg,sular 1.0 0.000143348623853 1 0 1
with,mg,p 1.0 0.000143348623853 1 0 1
with,mg,increased 1.0 0.000143348623853 1 0 1
with,metal,cations 1.0 0.000143348623853 1 0 1
with,mefloquine,although 1.0 0.000143348623853 1 0 1
with,medications,that 1.0 0.000143348623853 1 0 1
with,may,inhibit 1.0 0.000143348623853 1 0 1
with,may,enhance 1.0 0.000143348623853 1 0 1
with,may,change 1.0 0.000143348623853 1 0 1
with,may,alter 1.0 0.000143348623853 1 0 1
with,maxipime,because 1.0 0.000143348623853 1 0 1
with,maois,or 1.0 0.000143348623853 1 0 1
with,maleate,its 1.0 0.000143348623853 1 0 1
with,male,rats 1.0 0.000143348623853 1 0 1
with,major,psychotic 1.0 0.000143348623853 1 0 1
with,lowered,the 1.0 0.000143348623853 1 0 1
with,lowered,blood 1.0 0.000143348623853 1 0 1
with,lotensin,can 1.0 0.000143348623853 1 0 1
with,krm-1648,exhibited 1.0 0.000143348623853 1 0 1
with,known,microsomal 1.0 0.000143348623853 1 0 1
with,kineret,and 1.0 0.000143348623853 1 0 1
with,its,protein 1.0 0.000143348623853 1 0 1
with,itraconazole,has 1.0 0.000143348623853 1 0 1
with,iron,concomitant 1.0 0.000143348623853 1 0 1
with,intravascular,volume 1.0 0.000143348623853 1 0 1
with,intestinal,absorption 1.0 0.000143348623853 1 0 1
with,intact,endothelium 1.0 0.000143348623853 1 0 1
with,inomax,on 1.0 0.000143348623853 1 0 1
with,innovar,vet 1.0 0.000143348623853 1 0 1
with,injectable,an 1.0 0.000143348623853 1 0 1
with,inhibition,of 1.0 0.000143348623853 1 0 1
with,inducers,of 1.0 0.000143348623853 1 0 1
with,indicate,that 1.0 0.000143348623853 1 0 1
with,increasing,the 1.0 0.000143348623853 1 0 1
with,increases,in 1.0 0.000143348623853 1 0 1
with,increased,the 1.0 0.000143348623853 1 0 1
with,increased,risks 1.0 0.000143348623853 1 0 1
with,increased,exposure 1.0 0.000143348623853 1 0 1
with,in,some 1.0 0.000143348623853 1 0 1
with,in,five 1.0 0.000143348623853 1 0 1
with,in,causing 1.0 0.000143348623853 1 0 1
with,imidazole,and 1.0 0.000143348623853 1 0 1
with,if,therapy 1.0 0.000143348623853 1 0 1
with,hypertension,the 1.0 0.000143348623853 1 0 1
with,hydroxide,containing 1.0 0.000143348623853 1 0 1
with,hours,before 1.0 0.000143348623853 1 0 1
with,hormonal,may 1.0 0.000143348623853 1 0 1
with,higher,doses 1.0 0.000143348623853 1 0 1
with,high,doses 1.0 0.000143348623853 1 0 1
with,hereditary,antithrombin 1.0 0.000143348623853 1 0 1
with,hepatotoxicity,concomitant 1.0 0.000143348623853 1 0 1
with,hepatotoxic,potential 1.0 0.000143348623853 1 0 1
with,hepatic,enzyme 1.0 0.000143348623853 1 0 1
with,hemodynamic,compromise 1.0 0.000143348623853 1 0 1
with,have,identified 1.0 0.000143348623853 1 0 1
with,gram,absorption 1.0 0.000143348623853 1 0 1
with,glycosides,heart 1.0 0.000143348623853 1 0 1
with,glutathione,use 1.0 0.000143348623853 1 0 1
with,gastrointestinal,irritation 1.0 0.000143348623853 1 0 1
with,four,resulted 1.0 0.000143348623853 1 0 1
with,foscavir,and 1.0 0.000143348623853 1 0 1
with,formulations,containing 1.0 0.000143348623853 1 0 1
with,for,two 1.0 0.000143348623853 1 0 1
with,food,one 1.0 0.000143348623853 1 0 1
with,food,isrecommended 1.0 0.000143348623853 1 0 1
with,food,is 1.0 0.000143348623853 1 0 1
with,folate,utilization 1.0 0.000143348623853 1 0 1
with,fluvoxamine,tablets 1.0 0.000143348623853 1 0 1
with,fluothane,as 1.0 0.000143348623853 1 0 1
with,flolan,which 1.0 0.000143348623853 1 0 1
with,flolan,was 1.0 0.000143348623853 1 0 1
with,extracellular,rr 1.0 0.000143348623853 1 0 1
with,experimental,toxic 1.0 0.000143348623853 1 0 1
with,experienced,tremor 1.0 0.000143348623853 1 0 1
with,ethyl,mao 1.0 0.000143348623853 1 0 1
with,ethacrynic,acid 1.0 0.000143348623853 1 0 1
with,enhances,the 1.0 0.000143348623853 1 0 1
with,enbrel,and 1.0 0.000143348623853 1 0 1
with,elspar,or 1.0 0.000143348623853 1 0 1
with,elevations,of 1.0 0.000143348623853 1 0 1
with,elevated,plasma 1.0 0.000143348623853 1 0 1
with,either,secobarbitone 1.0 0.000143348623853 1 0 1
with,either,oral 1.0 0.000143348623853 1 0 1
with,either,enbrel 1.0 0.000143348623853 1 0 1
with,each,dose 1.0 0.000143348623853 1 0 1
with,dsm-iv,diagnosed 1.0 0.000143348623853 1 0 1
with,dilaudid,may 1.0 0.000143348623853 1 0 1
with,difluoro-2,propanol 1.0 0.000143348623853 1 0 1
with,depen,cuprimine 1.0 0.000143348623853 1 0 1
with,decreases,in 1.0 0.000143348623853 1 0 1
with,d2-antagonists,such 1.0 0.000143348623853 1 0 1
with,d,h 1.0 0.000143348623853 1 0 1
with,cyp3a4,substrates 1.0 0.000143348623853 1 0 1
with,cyp1a2,cyp3a 1.0 0.000143348623853 1 0 1
with,crohns,disease 1.0 0.000143348623853 1 0 1
with,coumarin-derivative,such 1.0 0.000143348623853 1 0 1
with,containing,or 1.0 0.000143348623853 1 0 1
with,containing,may 1.0 0.000143348623853 1 0 1
with,concurrently,administered 1.0 0.000143348623853 1 0 1
with,concurrent,kineret 1.0 0.000143348623853 1 0 1
with,concurrent,ingestion 1.0 0.000143348623853 1 0 1
with,concurrent,enbrel 1.0 0.000143348623853 1 0 1
with,compounds,that 1.0 0.000143348623853 1 0 1
with,combined,use 1.0 0.000143348623853 1 0 1
with,coadministration,whereas 1.0 0.000143348623853 1 0 1
with,coadministration,were 1.0 0.000143348623853 1 0 1
with,coadministration,up 1.0 0.000143348623853 1 0 1
with,coadministered,orally 1.0 0.000143348623853 1 0 1
with,co-administration,leading 1.0 0.000143348623853 1 0 1
with,co-administered,with 1.0 0.000143348623853 1 0 1
with,cmi,because 1.0 0.000143348623853 1 0 1
with,close,monitoring 1.0 0.000143348623853 1 0 1
with,citrate,may 1.0 0.000143348623853 1 0 1
with,channel,blockers 1.0 0.000143348623853 1 0 1
with,cgs,an 1.0 0.000143348623853 1 0 1
with,cerubidine,may 1.0 0.000143348623853 1 0 1
with,celebrex,mg 1.0 0.000143348623853 1 0 1
with,celebrex,may 1.0 0.000143348623853 1 0 1
with,cefizox,nephrotoxicity 1.0 0.000143348623853 1 0 1
with,caution,using 1.0 0.000143348623853 1 0 1
with,caution,should 1.0 0.000143348623853 1 0 1
with,caution,if 1.0 0.000143348623853 1 0 1
with,causes,an 1.0 0.000143348623853 1 0 1
with,care,when 1.0 0.000143348623853 1 0 1
with,care,as 1.0 0.000143348623853 1 0 1
with,carbamazepine,concomitant 1.0 0.000143348623853 1 0 1
with,cancidas,may 1.0 0.000143348623853 1 0 1
with,can,directly 1.0 0.000143348623853 1 0 1
with,camptosar,would 1.0 0.000143348623853 1 0 1
with,camptosar,and 1.0 0.000143348623853 1 0 1
with,camp,whereas 1.0 0.000143348623853 1 0 1
with,but,this 1.0 0.000143348623853 1 0 1
with,busulfex,may 1.0 0.000143348623853 1 0 1
with,breast,cancer 1.0 0.000143348623853 1 0 1
with,blood,thinners 1.0 0.000143348623853 1 0 1
with,betagan,and 1.0 0.000143348623853 1 0 1
with,beta-lactamtype,or 1.0 0.000143348623853 1 0 1
with,beta-blockers,concomitant 1.0 0.000143348623853 1 0 1
with,beta-adrenergic,blockers 1.0 0.000143348623853 1 0 1
with,because,plasma 1.0 0.000143348623853 1 0 1
with,axert,and 1.0 0.000143348623853 1 0 1
with,available,data 1.0 0.000143348623853 1 0 1
with,atacand,so 1.0 0.000143348623853 1 0 1
with,at,high 1.0 0.000143348623853 1 0 1
with,as,in 1.0 0.000143348623853 1 0 1
with,arimidex,as 1.0 0.000143348623853 1 0 1
with,aprepitant,reflects 1.0 0.000143348623853 1 0 1
with,any,significant 1.0 0.000143348623853 1 0 1
with,antithrombin,iii 1.0 0.000143348623853 1 0 1
with,antiplatelet,and 1.0 0.000143348623853 1 0 1
with,antiplatelet,agents 1.0 0.000143348623853 1 0 1
with,antihypertensive,agents 1.0 0.000143348623853 1 0 1
with,anticoagulation,levels 1.0 0.000143348623853 1 0 1
with,antagonists,of 1.0 0.000143348623853 1 0 1
with,antagonists,and 1.0 0.000143348623853 1 0 1
with,antacids,administration 1.0 0.000143348623853 1 0 1
with,another,and 1.0 0.000143348623853 1 0 1
with,anion-exchange,resins 1.0 0.000143348623853 1 0 1
with,angiotensln,converting 1.0 0.000143348623853 1 0 1
with,angina,pectoris 1.0 0.000143348623853 1 0 1
with,and,when 1.0 0.000143348623853 1 0 1
with,and,vitamin 1.0 0.000143348623853 1 0 1
with,and,valproic 1.0 0.000143348623853 1 0 1
with,and,therefore 1.0 0.000143348623853 1 0 1
with,and,tablets 1.0 0.000143348623853 1 0 1
with,and,special 1.0 0.000143348623853 1 0 1
with,and,respectively 1.0 0.000143348623853 1 0 1
with,and,requires 1.0 0.000143348623853 1 0 1
with,and,it 1.0 0.000143348623853 1 0 1
with,and,is 1.0 0.000143348623853 1 0 1
with,and,interfere 1.0 0.000143348623853 1 0 1
with,and,concurrently 1.0 0.000143348623853 1 0 1
with,and,antagonists 1.0 0.000143348623853 1 0 1
with,an,inhibition 1.0 0.000143348623853 1 0 1
with,an,in 1.0 0.000143348623853 1 0 1
with,an,hydroxide 1.0 0.000143348623853 1 0 1
with,an,average 1.0 0.000143348623853 1 0 1
with,an,appropriate 1.0 0.000143348623853 1 0 1
with,an,angiotensin-converting 1.0 0.000143348623853 1 0 1
with,amprenavir,and 1.0 0.000143348623853 1 0 1
with,altered,consciousness 1.0 0.000143348623853 1 0 1
with,allopurinol,the 1.0 0.000143348623853 1 0 1
with,all,nsaids 1.0 0.000143348623853 1 0 1
with,all,central 1.0 0.000143348623853 1 0 1
with,alfenta,can 1.0 0.000143348623853 1 0 1
with,agonists,only 1.0 0.000143348623853 1 0 1
with,agents,known 1.0 0.000143348623853 1 0 1
with,against,bacillus 1.0 0.000143348623853 1 0 1
with,administered,alone 1.0 0.000143348623853 1 0 1
with,acute,delirium 1.0 0.000143348623853 1 0 1
with,activity--such,as 1.0 0.000143348623853 1 0 1
with,activity,such 1.0 0.000143348623853 1 0 1
with,accutane,and 1.0 0.000143348623853 1 0 1
with,acamprosate,produced 1.0 0.000143348623853 1 0 1
with,absorption,and 1.0 0.000143348623853 1 0 1
with,a,toxicology 1.0 0.000143348623853 1 0 1
with,a,to 1.0 0.000143348623853 1 0 1
with,a,therapeutic 1.0 0.000143348623853 1 0 1
with,a,strong 1.0 0.000143348623853 1 0 1
with,a,separate 1.0 0.000143348623853 1 0 1
with,a,pure 1.0 0.000143348623853 1 0 1
with,a,positive 1.0 0.000143348623853 1 0 1
with,a,number 1.0 0.000143348623853 1 0 1
with,a,nonfunctioning 1.0 0.000143348623853 1 0 1
with,a,mean 1.0 0.000143348623853 1 0 1
with,a,may 1.0 0.000143348623853 1 0 1
with,a,has 1.0 0.000143348623853 1 0 1
with,a,decreased 1.0 0.000143348623853 1 0 1
with,a,corresponding 1.0 0.000143348623853 1 0 1
with,a,consequent 1.0 0.000143348623853 1 0 1
with,a,closely 1.0 0.000143348623853 1 0 1
with,a,agent 1.0 0.000143348623853 1 0 1
wish,to,withhold 1.0 0.000143348623853 1 0 1
window,such,as 1.0 0.000143348623853 1 0 1
window,is,different 1.0 0.000143348623853 1 0 1
will,require,a 1.0 0.000143348623853 1 0 1
will,need,to 1.0 0.000143348623853 1 0 1
will,interfere,with 1.0 0.000143348623853 1 0 1
will,increase,plasmaconcentration 1.0 0.000143348623853 1 0 1
will,have,erroneously 1.0 0.000143348623853 1 0 1
will,be,increased 1.0 0.000143348623853 1 0 1
will,be,augmented 1.0 0.000143348623853 1 0 1
will,affect,the 1.0 0.000143348623853 1 0 1
wide,interindividual,variability 1.0 0.000143348623853 1 0 1
whose,hypertension,was 1.0 0.000143348623853 1 0 1
whose,efficacy,is 1.0 0.000143348623853 1 0 1
whose,absorption,can 1.0 0.000143348623853 1 0 1
whom,therapy,with 1.0 0.000143348623853 1 0 1
whom,aminoglycoside,are 1.0 0.000143348623853 1 0 1
whole,blood,concentrations 1.0 0.000143348623853 1 0 1
whole,blood,area 1.0 0.000143348623853 1 0 1
who,were,on 1.0 0.000143348623853 1 0 1
who,were,extensive 1.0 0.000143348623853 1 0 1
who,were,drinking 1.0 0.000143348623853 1 0 1
who,received,mg 1.0 0.000143348623853 1 0 1
who,may,need 1.0 0.000143348623853 1 0 1
who,is,receiving 1.0 0.000143348623853 1 0 1
who,increase,their 1.0 0.000143348623853 1 0 1
who,inactivate,by 1.0 0.000143348623853 1 0 1
who,have,pre-existing 1.0 0.000143348623853 1 0 1
who,have,had 1.0 0.000143348623853 1 0 1
who,has,received 1.0 0.000143348623853 1 0 1
who,has,previously 1.0 0.000143348623853 1 0 1
who,discontinue,after 1.0 0.000143348623853 1 0 1
who,developed,increased 1.0 0.000143348623853 1 0 1
who,consume,and 1.0 0.000143348623853 1 0 1
who,begin,taking 1.0 0.000143348623853 1 0 1
who,are,treated 1.0 0.000143348623853 1 0 1
who,are,taking 1.0 0.000143348623853 1 0 1
who,are,not 1.0 0.000143348623853 1 0 1
who,are,hypersensitive 1.0 0.000143348623853 1 0 1
who,are,found 1.0 0.000143348623853 1 0 1
who,are,applying 1.0 0.000143348623853 1 0 1
while,you,are 1.0 0.000143348623853 1 0 1
while,under,treatment 1.0 0.000143348623853 1 0 1
while,the,effects 1.0 0.000143348623853 1 0 1
while,taking,or 1.0 0.000143348623853 1 0 1
while,taking,aminosalicylic 1.0 0.000143348623853 1 0 1
while,studies,have 1.0 0.000143348623853 1 0 1
while,plasma,exposure 1.0 0.000143348623853 1 0 1
while,only,additive 1.0 0.000143348623853 1 0 1
while,not,systematically 1.0 0.000143348623853 1 0 1
while,no,in 1.0 0.000143348623853 1 0 1
while,may,also 1.0 0.000143348623853 1 0 1
while,levels,of 1.0 0.000143348623853 1 0 1
while,attenuating,s 1.0 0.000143348623853 1 0 1
while,a,synergistic 1.0 0.000143348623853 1 0 1
which,were,considered 1.0 0.000143348623853 1 0 1
which,was,prevented 1.0 0.000143348623853 1 0 1
which,was,partially 1.0 0.000143348623853 1 0 1
which,themselves,produce 1.0 0.000143348623853 1 0 1
which,the,mg 1.0 0.000143348623853 1 0 1
which,suggests,that 1.0 0.000143348623853 1 0 1
which,suggest,that 1.0 0.000143348623853 1 0 1
which,ssri-tcainteractions,may 1.0 0.000143348623853 1 0 1
which,significantly,p 1.0 0.000143348623853 1 0 1
which,sensitize,the 1.0 0.000143348623853 1 0 1
which,resulted,in 1.0 0.000143348623853 1 0 1
which,require,a 1.0 0.000143348623853 1 0 1
which,may,require 1.0 0.000143348623853 1 0 1
which,may,predispose 1.0 0.000143348623853 1 0 1
which,may,lead 1.0 0.000143348623853 1 0 1
which,is,mediated 1.0 0.000143348623853 1 0 1
which,involved,concomitant 1.0 0.000143348623853 1 0 1
which,inhibits,the 1.0 0.000143348623853 1 0 1
which,inhibit,platelet 1.0 0.000143348623853 1 0 1
which,inhibit,cyp 1.0 0.000143348623853 1 0 1
which,induce,cytochrome 1.0 0.000143348623853 1 0 1
which,induce,cyp3a4 1.0 0.000143348623853 1 0 1
which,increases,gastrointestinal 1.0 0.000143348623853 1 0 1
which,increase,the 1.0 0.000143348623853 1 0 1
which,in,turn 1.0 0.000143348623853 1 0 1
which,healthy,volunteers 1.0 0.000143348623853 1 0 1
which,has,not 1.0 0.000143348623853 1 0 1
which,enbrel,was 1.0 0.000143348623853 1 0 1
which,d,h 1.0 0.000143348623853 1 0 1
which,contain,any 1.0 0.000143348623853 1 0 1
which,concomitant,use 1.0 0.000143348623853 1 0 1
which,competes,for 1.0 0.000143348623853 1 0 1
which,clearance,accelerated 1.0 0.000143348623853 1 0 1
which,causes,a 1.0 0.000143348623853 1 0 1
which,cause,a 1.0 0.000143348623853 1 0 1
which,can,lead 1.0 0.000143348623853 1 0 1
which,can,follow 1.0 0.000143348623853 1 0 1
which,are,very 1.0 0.000143348623853 1 0 1
which,are,vasoconstrictive 1.0 0.000143348623853 1 0 1
which,are,usually 1.0 0.000143348623853 1 0 1
which,are,reported 1.0 0.000143348623853 1 0 1
which,a,sulfonamide 1.0 0.000143348623853 1 0 1
whether,this,potentiation 1.0 0.000143348623853 1 0 1
whether,these,are 1.0 0.000143348623853 1 0 1
whether,the,dose 1.0 0.000143348623853 1 0 1
whether,the,desired 1.0 0.000143348623853 1 0 1
whereas,the,mean 1.0 0.000143348623853 1 0 1
whereas,it,had 1.0 0.000143348623853 1 0 1
where,iressa,and 1.0 0.000143348623853 1 0 1
where,definitely,indicated 1.0 0.000143348623853 1 0 1
when,you,are 1.0 0.000143348623853 1 0 1
when,was,used 1.0 0.000143348623853 1 0 1
when,was,applied 1.0 0.000143348623853 1 0 1
when,vioxx,and 1.0 0.000143348623853 1 0 1
when,videx,was 1.0 0.000143348623853 1 0 1
when,vardenafil,or 1.0 0.000143348623853 1 0 1
when,vardenafil,dosing 1.0 0.000143348623853 1 0 1
when,using,romazicon 1.0 0.000143348623853 1 0 1
when,using,or 1.0 0.000143348623853 1 0 1
when,using,doses 1.0 0.000143348623853 1 0 1
when,trisenox,is 1.0 0.000143348623853 1 0 1
when,trileptal,was 1.0 0.000143348623853 1 0 1
when,toradol,was 1.0 0.000143348623853 1 0 1
when,this,combination 1.0 0.000143348623853 1 0 1
when,these,were 1.0 0.000143348623853 1 0 1
when,the,treatment 1.0 0.000143348623853 1 0 1
when,the,stadol 1.0 0.000143348623853 1 0 1
when,the,recommended 1.0 0.000143348623853 1 0 1
when,the,orally 1.0 0.000143348623853 1 0 1
when,the,drug 1.0 0.000143348623853 1 0 1
when,taking,mg 1.0 0.000143348623853 1 0 1
when,taking,acarbose 1.0 0.000143348623853 1 0 1
when,taken,orally 1.0 0.000143348623853 1 0 1
when,taken,at 1.0 0.000143348623853 1 0 1
when,tagamet,is 1.0 0.000143348623853 1 0 1
when,systemic,vascular 1.0 0.000143348623853 1 0 1
when,suprax,is 1.0 0.000143348623853 1 0 1
when,sodium,is 1.0 0.000143348623853 1 0 1
when,potent,inhalational 1.0 0.000143348623853 1 0 1
when,possible,and 1.0 0.000143348623853 1 0 1
when,pletal,is 1.0 0.000143348623853 1 0 1
when,plasma,concentrations 1.0 0.000143348623853 1 0 1
when,plasma,asparagine 1.0 0.000143348623853 1 0 1
when,patients,take 1.0 0.000143348623853 1 0 1
when,other,potent 1.0 0.000143348623853 1 0 1
when,other,antiplatelet 1.0 0.000143348623853 1 0 1
when,or,its 1.0 0.000143348623853 1 0 1
when,nsaids,are 1.0 0.000143348623853 1 0 1
when,myocardial,depressants 1.0 0.000143348623853 1 0 1
when,midamor,and 1.0 0.000143348623853 1 0 1
when,mg,was 1.0 0.000143348623853 1 0 1
when,mg,every 1.0 0.000143348623853 1 0 1
when,mg,b 1.0 0.000143348623853 1 0 1
when,mesylate,was 1.0 0.000143348623853 1 0 1
when,mefloquine,is 1.0 0.000143348623853 1 0 1
when,meclofenamate,sodium 1.0 0.000143348623853 1 0 1
when,lodine,is 1.0 0.000143348623853 1 0 1
when,lexapro,and 1.0 0.000143348623853 1 0 1
when,levsin,is 1.0 0.000143348623853 1 0 1
when,k,antagonists 1.0 0.000143348623853 1 0 1
when,itraconazole,was 1.0 0.000143348623853 1 0 1
when,is,withdrawn 1.0 0.000143348623853 1 0 1
when,is,started 1.0 0.000143348623853 1 0 1
when,is,either 1.0 0.000143348623853 1 0 1
when,intravenous,and 1.0 0.000143348623853 1 0 1
when,inspra,and 1.0 0.000143348623853 1 0 1
when,initiating,or 1.0 0.000143348623853 1 0 1
when,initiating,extraneal 1.0 0.000143348623853 1 0 1
when,initiating,and 1.0 0.000143348623853 1 0 1
when,initiating,a 1.0 0.000143348623853 1 0 1
when,infection,and 1.0 0.000143348623853 1 0 1
when,indocin,is 1.0 0.000143348623853 1 0 1
when,hydrochlorothiazide,and 1.0 0.000143348623853 1 0 1
when,hydrochloride,has 1.0 0.000143348623853 1 0 1
when,ht1,agonists 1.0 0.000143348623853 1 0 1
when,heart,function 1.0 0.000143348623853 1 0 1
when,hcl,is 1.0 0.000143348623853 1 0 1
when,has,been 1.0 0.000143348623853 1 0 1
when,gleevec,is 1.0 0.000143348623853 1 0 1
when,gl,was 1.0 0.000143348623853 1 0 1
when,given,supplemental 1.0 0.000143348623853 1 0 1
when,given,simultaneously 1.0 0.000143348623853 1 0 1
when,given,once 1.0 0.000143348623853 1 0 1
when,flolan,is 1.0 0.000143348623853 1 0 1
when,eulexin,capsules 1.0 0.000143348623853 1 0 1
when,equetrotm,is 1.0 0.000143348623853 1 0 1
when,enablex,is 1.0 0.000143348623853 1 0 1
when,either,or 1.0 0.000143348623853 1 0 1
when,edecrin,and 1.0 0.000143348623853 1 0 1
when,doses,of 1.0 0.000143348623853 1 0 1
when,coumarin,anticoagulants 1.0 0.000143348623853 1 0 1
when,coreg,is 1.0 0.000143348623853 1 0 1
when,considering,the 1.0 0.000143348623853 1 0 1
when,concomitant,treatment 1.0 0.000143348623853 1 0 1
when,concomitant,therapy 1.0 0.000143348623853 1 0 1
when,combined,with 1.0 0.000143348623853 1 0 1
when,colestid,tablets 1.0 0.000143348623853 1 0 1
when,coadminstered,with 1.0 0.000143348623853 1 0 1
when,coadministering,these 1.0 0.000143348623853 1 0 1
when,clozapine,is 1.0 0.000143348623853 1 0 1
when,cime-tidine,therapy 1.0 0.000143348623853 1 0 1
when,central,nervous 1.0 0.000143348623853 1 0 1
when,celebrex,is 1.0 0.000143348623853 1 0 1
when,cancidas,is 1.0 0.000143348623853 1 0 1
when,cancidas,and 1.0 0.000143348623853 1 0 1
when,both,are 1.0 0.000143348623853 1 0 1
when,beginning,discontinuing 1.0 0.000143348623853 1 0 1
when,atromid-s,is 1.0 0.000143348623853 1 0 1
when,at,mg 1.0 0.000143348623853 1 0 1
when,at,an 1.0 0.000143348623853 1 0 1
when,are,started 1.0 0.000143348623853 1 0 1
when,arava,was 1.0 0.000143348623853 1 0 1
when,arava,and 1.0 0.000143348623853 1 0 1
when,any,additional 1.0 0.000143348623853 1 0 1
when,and,other 1.0 0.000143348623853 1 0 1
when,and,nonsteroidal 1.0 0.000143348623853 1 0 1
when,and,non-steroidal 1.0 0.000143348623853 1 0 1
when,and,mycophenolate 1.0 0.000143348623853 1 0 1
when,and,maalox 1.0 0.000143348623853 1 0 1
when,and,crixivan 1.0 0.000143348623853 1 0 1
when,and,certain 1.0 0.000143348623853 1 0 1
when,and,brevibloc 1.0 0.000143348623853 1 0 1
when,analgesia,must 1.0 0.000143348623853 1 0 1
when,anafranil,is 1.0 0.000143348623853 1 0 1
when,an,and 1.0 0.000143348623853 1 0 1
when,amines,have 1.0 0.000143348623853 1 0 1
when,alfenta,is 1.0 0.000143348623853 1 0 1
when,agents,such 1.0 0.000143348623853 1 0 1
when,administering,with 1.0 0.000143348623853 1 0 1
when,administering,peganone 1.0 0.000143348623853 1 0 1
when,administering,or 1.0 0.000143348623853 1 0 1
when,administering,hcl 1.0 0.000143348623853 1 0 1
when,administering,etopophos 1.0 0.000143348623853 1 0 1
when,administering,concurrently 1.0 0.000143348623853 1 0 1
when,administering,celebrex 1.0 0.000143348623853 1 0 1
when,administered,one 1.0 0.000143348623853 1 0 1
when,administered,in 1.0 0.000143348623853 1 0 1
when,abilify,is 1.0 0.000143348623853 1 0 1
were,very,strong 1.0 0.000143348623853 1 0 1
were,unaffected,given 1.0 0.000143348623853 1 0 1
were,transient,increases 1.0 0.000143348623853 1 0 1
were,to,fold 1.0 0.000143348623853 1 0 1
were,subsequently,administered 1.0 0.000143348623853 1 0 1
were,significantly,altered 1.0 0.000143348623853 1 0 1
were,potentiated,by 1.0 0.000143348623853 1 0 1
were,on,established 1.0 0.000143348623853 1 0 1
were,observed,with 1.0 0.000143348623853 1 0 1
were,noted,to 1.0 0.000143348623853 1 0 1
were,no,signs 1.0 0.000143348623853 1 0 1
were,neither,reversed 1.0 0.000143348623853 1 0 1
were,more,than 1.0 0.000143348623853 1 0 1
were,increased,over 1.0 0.000143348623853 1 0 1
were,increased,decreased 1.0 0.000143348623853 1 0 1
were,identified,in 1.0 0.000143348623853 1 0 1
were,given,on 1.0 0.000143348623853 1 0 1
were,extensive,metabolizers 1.0 0.000143348623853 1 0 1
were,experienced,more 1.0 0.000143348623853 1 0 1
were,equivocally,higher 1.0 0.000143348623853 1 0 1
were,drinking,during 1.0 0.000143348623853 1 0 1
were,decreased,on 1.0 0.000143348623853 1 0 1
were,considered,to 1.0 0.000143348623853 1 0 1
were,considerably,lower 1.0 0.000143348623853 1 0 1
were,conducted,between 1.0 0.000143348623853 1 0 1
were,completely,inhibited 1.0 0.000143348623853 1 0 1
were,comparable,to 1.0 0.000143348623853 1 0 1
were,coadministered,than 1.0 0.000143348623853 1 0 1
were,coadministered,steady-state 1.0 0.000143348623853 1 0 1
were,coadministered,plasma 1.0 0.000143348623853 1 0 1
were,co-administered,to 1.0 0.000143348623853 1 0 1
were,co-administered,has 1.0 0.000143348623853 1 0 1
were,approximately,twice 1.0 0.000143348623853 1 0 1
were,and,lower 1.0 0.000143348623853 1 0 1
were,also,higher 1.0 0.000143348623853 1 0 1
were,almost,fold 1.0 0.000143348623853 1 0 1
were,agonists,in 1.0 0.000143348623853 1 0 1
were,administered,a 1.0 0.000143348623853 1 0 1
were,above,or 1.0 0.000143348623853 1 0 1
were,about,higher 1.0 0.000143348623853 1 0 1
wellbutrin,tablets,to 1.0 0.000143348623853 1 0 1
wellbutrin,should,be 1.0 0.000143348623853 1 0 1
wellbutrin,and,that 1.0 0.000143348623853 1 0 1
wellbutrin,and,agents 1.0 0.000143348623853 1 0 1
well-controlled,patients,undergoing 1.0 0.000143348623853 1 0 1
well-controlled,patients,receiving 1.0 0.000143348623853 1 0 1
well,controlled,on 1.0 0.000143348623853 1 0 1
well,concurrent,therapy 1.0 0.000143348623853 1 0 1
well,concurent,therapy 1.0 0.000143348623853 1 0 1
well,as,random 1.0 0.000143348623853 1 0 1
well,as,pure 1.0 0.000143348623853 1 0 1
well,as,postmarketing 1.0 0.000143348623853 1 0 1
well,as,post 1.0 0.000143348623853 1 0 1
well,as,other 1.0 0.000143348623853 1 0 1
well,as,g 1.0 0.000143348623853 1 0 1
well,as,formulations 1.0 0.000143348623853 1 0 1
well,as,diminished 1.0 0.000143348623853 1 0 1
well,as,decreasing 1.0 0.000143348623853 1 0 1
welchol,decreased,the 1.0 0.000143348623853 1 0 1
weight,was,shown 1.0 0.000143348623853 1 0 1
weight,w,and 1.0 0.000143348623853 1 0 1
weight,to,erythro-fluorocitrate 1.0 0.000143348623853 1 0 1
weight,loss,compared 1.0 0.000143348623853 1 0 1
weight,gain,when 1.0 0.000143348623853 1 0 1
weight,gain,and 1.0 0.000143348623853 1 0 1
weighed,against,an 1.0 0.000143348623853 1 0 1
weeks,was,associated 1.0 0.000143348623853 1 0 1
weeks,should,elapse 1.0 0.000143348623853 1 0 1
weeks,should,be 1.0 0.000143348623853 1 0 1
weeks,plasma,concentrations 1.0 0.000143348623853 1 0 1
weeks,of,taking 1.0 0.000143348623853 1 0 1
weeks,may,produce 1.0 0.000143348623853 1 0 1
weeks,in,healthy 1.0 0.000143348623853 1 0 1
weeks,has,been 1.0 0.000143348623853 1 0 1
weeks,after,initiation 1.0 0.000143348623853 1 0 1
weeks,after,initiating 1.0 0.000143348623853 1 0 1
weekly,reduced,tysabri 1.0 0.000143348623853 1 0 1
weekly,dosage,schedule 1.0 0.000143348623853 1 0 1
week,prior,to 1.0 0.000143348623853 1 0 1
week,plasma,levels 1.0 0.000143348623853 1 0 1
week,period,particularly 1.0 0.000143348623853 1 0 1
wedge,pressure,than 1.0 0.000143348623853 1 0 1
weather,prolonged,long 1.0 0.000143348623853 1 0 1
weakness,may,be 1.0 0.000143348623853 1 0 1
weakness,lethargy,fever 1.0 0.000143348623853 1 0 1
weakness,in,patients 1.0 0.000143348623853 1 0 1
weak,effect,on 1.0 0.000143348623853 1 0 1
weak,acids,such 1.0 0.000143348623853 1 0 1
we,report,the 1.0 0.000143348623853 1 0 1
we,propose,these 1.0 0.000143348623853 1 0 1
we,observed,that 1.0 0.000143348623853 1 0 1
way,the,function 1.0 0.000143348623853 1 0 1
wax,matrix,may 1.0 0.000143348623853 1 0 1
watched,very,closely 1.0 0.000143348623853 1 0 1
was,with,alone 1.0 0.000143348623853 1 0 1
was,usually,reversible 1.0 0.000143348623853 1 0 1
was,used,with 1.0 0.000143348623853 1 0 1
was,the,ld50 1.0 0.000143348623853 1 0 1
was,separated,from 1.0 0.000143348623853 1 0 1
was,seen,but 1.0 0.000143348623853 1 0 1
was,responsible,for 1.0 0.000143348623853 1 0 1
was,reported,in 1.0 0.000143348623853 1 0 1
was,poorly,tolerated 1.0 0.000143348623853 1 0 1
was,only,observed 1.0 0.000143348623853 1 0 1
was,observed,with 1.0 0.000143348623853 1 0 1
was,observed,on 1.0 0.000143348623853 1 0 1
was,noted,even 1.0 0.000143348623853 1 0 1
was,not,substantially 1.0 0.000143348623853 1 0 1
was,ng,ml 1.0 0.000143348623853 1 0 1
was,necessary,to 1.0 0.000143348623853 1 0 1
was,necessary,for 1.0 0.000143348623853 1 0 1
was,more,profound 1.0 0.000143348623853 1 0 1
was,lower,when 1.0 0.000143348623853 1 0 1
was,lower,than 1.0 0.000143348623853 1 0 1
was,lower,and 1.0 0.000143348623853 1 0 1
was,longer,in 1.0 0.000143348623853 1 0 1
was,initiated,apparent 1.0 0.000143348623853 1 0 1
was,increased,when 1.0 0.000143348623853 1 0 1
was,increased,to 1.0 0.000143348623853 1 0 1
was,increased,fold 1.0 0.000143348623853 1 0 1
was,increased,about 1.0 0.000143348623853 1 0 1
was,higher,when 1.0 0.000143348623853 1 0 1
was,greater,when 1.0 0.000143348623853 1 0 1
was,greater,patients 1.0 0.000143348623853 1 0 1
was,given,at 1.0 0.000143348623853 1 0 1
was,generally,converted 1.0 0.000143348623853 1 0 1
was,found,that 1.0 0.000143348623853 1 0 1
was,for,alone 1.0 0.000143348623853 1 0 1
was,followed,by 1.0 0.000143348623853 1 0 1
was,effective,in 1.0 0.000143348623853 1 0 1
was,depressed,in 1.0 0.000143348623853 1 0 1
was,delayed,and 1.0 0.000143348623853 1 0 1
was,controlled,with 1.0 0.000143348623853 1 0 1
was,coadministered,on 1.0 0.000143348623853 1 0 1
was,coadministered,intravenously 1.0 0.000143348623853 1 0 1
was,applied,to 1.0 0.000143348623853 1 0 1
was,administered,minutes 1.0 0.000143348623853 1 0 1
was,administered,minute 1.0 0.000143348623853 1 0 1
was,administered,intravenously 1.0 0.000143348623853 1 0 1
was,administered,at 1.0 0.000143348623853 1 0 1
was,admini,stered 1.0 0.000143348623853 1 0 1
was,added,were 1.0 0.000143348623853 1 0 1
was,about,when 1.0 0.000143348623853 1 0 1
was,about,a 1.0 0.000143348623853 1 0 1
was,abolished,by 1.0 0.000143348623853 1 0 1
was,a,statistically 1.0 0.000143348623853 1 0 1
was,a,increase 1.0 0.000143348623853 1 0 1
was,a,decrease 1.0 0.000143348623853 1 0 1
warranted,and,therapeutic 1.0 0.000143348623853 1 0 1
warrant,dosage,adjustments 1.0 0.000143348623853 1 0 1
warfarin-vitamin,k,can 1.0 0.000143348623853 1 0 1
warfarin-type,therapy,may 1.0 0.000143348623853 1 0 1
warfarin-type,certain,and 1.0 0.000143348623853 1 0 1
warfarin,when,maleate 1.0 0.000143348623853 1 0 1
warfarin,quinolones,may 1.0 0.000143348623853 1 0 1
warfarin,quinolones,including 1.0 0.000143348623853 1 0 1
warfarin,quinolones,have 1.0 0.000143348623853 1 0 1
warfarin,meclofenamate,sodium 1.0 0.000143348623853 1 0 1
warfarin,increased,inr 1.0 0.000143348623853 1 0 1
warfarin,digoxin,salicylate 1.0 0.000143348623853 1 0 1
warfarin,co-administration,of 1.0 0.000143348623853 1 0 1
warfarin,anticoagulant,activity 1.0 0.000143348623853 1 0 1
warfarin,and,anticoagulants 1.0 0.000143348623853 1 0 1
wait,about,minutes 1.0 0.000143348623853 1 0 1
w,in,a 1.0 0.000143348623853 1 0 1
w,and,mg 1.0 0.000143348623853 1 0 1
vs,when,plasma 1.0 0.000143348623853 1 0 1
vs,serious,pneumonia 1.0 0.000143348623853 1 0 1
vs,serious,falls 1.0 0.000143348623853 1 0 1
vs,myocardial,infarction 1.0 0.000143348623853 1 0 1
vs,and,bone 1.0 0.000143348623853 1 0 1
vomiting,and,or 1.0 0.000143348623853 1 0 1
volunteers,with,multiple 1.0 0.000143348623853 1 0 1
volunteers,who,received 1.0 0.000143348623853 1 0 1
volunteers,treatment,potentiated 1.0 0.000143348623853 1 0 1
volunteers,the,auc 1.0 0.000143348623853 1 0 1
volunteers,the,administration 1.0 0.000143348623853 1 0 1
volunteers,taking,mg 1.0 0.000143348623853 1 0 1
volunteers,suggests,that 1.0 0.000143348623853 1 0 1
volunteers,significantly,reduced 1.0 0.000143348623853 1 0 1
volunteers,receiving,the 1.0 0.000143348623853 1 0 1
volunteers,receiving,low 1.0 0.000143348623853 1 0 1
volunteers,receiving,decreased 1.0 0.000143348623853 1 0 1
volunteers,of,subjects 1.0 0.000143348623853 1 0 1
volunteers,n,resulted 1.0 0.000143348623853 1 0 1
volunteers,n,pretreatment 1.0 0.000143348623853 1 0 1
volunteers,it,was 1.0 0.000143348623853 1 0 1
volunteers,ingesting,the 1.0 0.000143348623853 1 0 1
volunteers,hydrochloride,either 1.0 0.000143348623853 1 0 1
volunteers,had,no 1.0 0.000143348623853 1 0 1
volunteers,either,simultaneously 1.0 0.000143348623853 1 0 1
volunteers,developed,rash 1.0 0.000143348623853 1 0 1
volunteers,a,small 1.0 0.000143348623853 1 0 1
volunteers,a,six-day 1.0 0.000143348623853 1 0 1
volunteers,a,one-week 1.0 0.000143348623853 1 0 1
volume,depletion,may 1.0 0.000143348623853 1 0 1
volume,and,sodium 1.0 0.000143348623853 1 0 1
volatile,inhalation,are 1.0 0.000143348623853 1 0 1
vivo,the,primary 1.0 0.000143348623853 1 0 1
vivo,the,plasma 1.0 0.000143348623853 1 0 1
vivo,studies,nitrates 1.0 0.000143348623853 1 0 1
vivo,resulting,in 1.0 0.000143348623853 1 0 1
vivo,drug-drug,interaction 1.0 0.000143348623853 1 0 1
vivo,data,suggesting 1.0 0.000143348623853 1 0 1
vivo,data,show 1.0 0.000143348623853 1 0 1
vivo,data,indicate 1.0 0.000143348623853 1 0 1
vivo,as,indicated 1.0 0.000143348623853 1 0 1
vivo,animal,studies 1.0 0.000143348623853 1 0 1
vivo,and,to 1.0 0.000143348623853 1 0 1
vitro,upon,combination 1.0 0.000143348623853 1 0 1
vitro,study,in 1.0 0.000143348623853 1 0 1
vitro,studies,and 1.0 0.000143348623853 1 0 1
vitro,mixing,of 1.0 0.000143348623853 1 0 1
vitro,may,displace 1.0 0.000143348623853 1 0 1
vitro,interferes,minimally 1.0 0.000143348623853 1 0 1
vitro,interaction,of 1.0 0.000143348623853 1 0 1
vitro,interaction,between 1.0 0.000143348623853 1 0 1
vitro,in,peripheral 1.0 0.000143348623853 1 0 1
vitro,from,to 1.0 0.000143348623853 1 0 1
vitro,can,result 1.0 0.000143348623853 1 0 1
vitro,binding,of 1.0 0.000143348623853 1 0 1
vitro,appears,to 1.0 0.000143348623853 1 0 1
vitro,antiviral,activity 1.0 0.000143348623853 1 0 1
vitro,and,cyp3a4 1.0 0.000143348623853 1 0 1
vitro,and,animal 1.0 0.000143348623853 1 0 1
vitamin,supplements,containing 1.0 0.000143348623853 1 0 1
vitamin,k,the 1.0 0.000143348623853 1 0 1
vitamin,k,oral 1.0 0.000143348623853 1 0 1
vitamin,e,mg 1.0 0.000143348623853 1 0 1
vitamin,d3,administration 1.0 0.000143348623853 1 0 1
vitamin,c,g 1.0 0.000143348623853 1 0 1
vitamin,b3,niacin 1.0 0.000143348623853 1 0 1
vitamin,b12,which 1.0 0.000143348623853 1 0 1
vitamin,b12,supplement 1.0 0.000143348623853 1 0 1
vitamin,a,to 1.0 0.000143348623853 1 0 1
vitamin,a,because 1.0 0.000143348623853 1 0 1
vitamin,a,and 1.0 0.000143348623853 1 0 1
vistide,and,agents 1.0 0.000143348623853 1 0 1
vision,and,other 1.0 0.000143348623853 1 0 1
vision,and,in 1.0 0.000143348623853 1 0 1
virus,vaccine,inhalation 1.0 0.000143348623853 1 0 1
viracept,with,ovcon-35 1.0 0.000143348623853 1 0 1
viracept,should,not 1.0 0.000143348623853 1 0 1
viracept,should,also 1.0 0.000143348623853 1 0 1
viracept,astramorph,kadian 1.0 0.000143348623853 1 0 1
viracept,antiarrhythmics,antihistamines 1.0 0.000143348623853 1 0 1
viracept,and,should 1.0 0.000143348623853 1 0 1
vioxx,with,the 1.0 0.000143348623853 1 0 1
vioxx,with,mg 1.0 0.000143348623853 1 0 1
vioxx,therapy,in 1.0 0.000143348623853 1 0 1
vioxx,mg,administered 1.0 0.000143348623853 1 0 1
vioxx,may,result 1.0 0.000143348623853 1 0 1
vioxx,is,initiated 1.0 0.000143348623853 1 0 1
vioxx,concomitantly,with 1.0 0.000143348623853 1 0 1
videx,was,administered 1.0 0.000143348623853 1 0 1
videx,to,two 1.0 0.000143348623853 1 0 1
videx,hours,prior 1.0 0.000143348623853 1 0 1
videx,chewable,dispersible 1.0 0.000143348623853 1 0 1
via,this,route 1.0 0.000143348623853 1 0 1
via,p450,c9 1.0 0.000143348623853 1 0 1
via,organic,cationic 1.0 0.000143348623853 1 0 1
via,its,metabolism 1.0 0.000143348623853 1 0 1
via,dehydrogenase,inhibition 1.0 0.000143348623853 1 0 1
via,cyp3a4,should 1.0 0.000143348623853 1 0 1
via,conjugation,with 1.0 0.000143348623853 1 0 1
vet,or,the 1.0 0.000143348623853 1 0 1
very,weak,effect 1.0 0.000143348623853 1 0 1
very,strong,and 1.0 0.000143348623853 1 0 1
very,rarely,in 1.0 0.000143348623853 1 0 1
very,potent,inhibitors 1.0 0.000143348623853 1 0 1
very,little,change 1.0 0.000143348623853 1 0 1
very,closely,when 1.0 0.000143348623853 1 0 1
vertigo,syncope,presyncope 1.0 0.000143348623853 1 0 1
veratrum,alkaloids,may 1.0 0.000143348623853 1 0 1
verapamil,the,risk 1.0 0.000143348623853 1 0 1
verapamil,coadministration,of 1.0 0.000143348623853 1 0 1
verapamil,also,significantly 1.0 0.000143348623853 1 0 1
ventricular,tachycardia,was 1.0 0.000143348623853 1 0 1
ventricular,tachycardia,ventricular 1.0 0.000143348623853 1 0 1
ventricular,tachycardia,induced 1.0 0.000143348623853 1 0 1
ventricular,hypokinesia,and 1.0 0.000143348623853 1 0 1
ventricular,fibrulation,and 1.0 0.000143348623853 1 0 1
ventricular,fibrillation,when 1.0 0.000143348623853 1 0 1
ventricular,failure,have 1.0 0.000143348623853 1 0 1
ventricular,arrhythmias,during 1.0 0.000143348623853 1 0 1
ventricular,arrhythmias,and 1.0 0.000143348623853 1 0 1
velcade,treatment,may 1.0 0.000143348623853 1 0 1
vehicle-,progesterone-,and 1.0 0.000143348623853 1 0 1
vehicle,or,low-dose 1.0 0.000143348623853 1 0 1
vecuronium,when,used 1.0 0.000143348623853 1 0 1
vasospastic,reactions,have 1.0 0.000143348623853 1 0 1
vasospastic,effects,may 1.0 0.000143348623853 1 0 1
vasospasm,and,its 1.0 0.000143348623853 1 0 1
vasopressors,thyroxine,increases 1.0 0.000143348623853 1 0 1
vasopressor,for,the 1.0 0.000143348623853 1 0 1
vasodilators,the,following 1.0 0.000143348623853 1 0 1
vasodilator,activity,should 1.0 0.000143348623853 1 0 1
vasodilation,induced,with 1.0 0.000143348623853 1 0 1
vasoconstrictors,d,h 1.0 0.000143348623853 1 0 1
vasoconstrictor,can,combine 1.0 0.000143348623853 1 0 1
vasoconstrictive,and,inotropic 1.0 0.000143348623853 1 0 1
vasoconstrictive,action,of 1.0 0.000143348623853 1 0 1
vasoconstriction,in,some 1.0 0.000143348623853 1 0 1
vasoconstriction,caused,by 1.0 0.000143348623853 1 0 1
vasoconstriction,after,a 1.0 0.000143348623853 1 0 1
vasoconstricting,agents,such 1.0 0.000143348623853 1 0 1
vasoactive,resulting,in 1.0 0.000143348623853 1 0 1
vascular,response,to 1.0 0.000143348623853 1 0 1
vascular,dilation,associated 1.0 0.000143348623853 1 0 1
various,such,as 1.0 0.000143348623853 1 0 1
various,containing,regimens 1.0 0.000143348623853 1 0 1
various,antihypertensive,necessitating 1.0 0.000143348623853 1 0 1
variation,in,ultimate 1.0 0.000143348623853 1 0 1
variable,effects,an 1.0 0.000143348623853 1 0 1
variability,component,of 1.0 0.000143348623853 1 0 1
variability,and,individual 1.0 0.000143348623853 1 0 1
vardenafil,or,mg 1.0 0.000143348623853 1 0 1
vardenafil,mg,produced 1.0 0.000143348623853 1 0 1
vardenafil,in,healthy 1.0 0.000143348623853 1 0 1
vardenafil,in,a 1.0 0.000143348623853 1 0 1
vardenafil,experienced,a 1.0 0.000143348623853 1 0 1
vardenafil,dosing,was 1.0 0.000143348623853 1 0 1
vaprisol,the,clinician 1.0 0.000143348623853 1 0 1
values,of,both 1.0 0.000143348623853 1 0 1
values,of,approximately 1.0 0.000143348623853 1 0 1
values,for,n 1.0 0.000143348623853 1 0 1
values,for,by 1.0 0.000143348623853 1 0 1
valproic,acid,with 1.0 0.000143348623853 1 0 1
valproic,acid,using 1.0 0.000143348623853 1 0 1
valproic,acid,or 1.0 0.000143348623853 1 0 1
valproic,acid,has 1.0 0.000143348623853 1 0 1
valproic,acid,diminished 1.0 0.000143348623853 1 0 1
valproate,tiagabine,causes 1.0 0.000143348623853 1 0 1
valproate,the,addition 1.0 0.000143348623853 1 0 1
valproate,felbatol,causes 1.0 0.000143348623853 1 0 1
valproate,a,recent 1.0 0.000143348623853 1 0 1
valium,and,to 1.0 0.000143348623853 1 0 1
valid,prothrombin,time 1.0 0.000143348623853 1 0 1
valdecoxib,caused,a 1.0 0.000143348623853 1 0 1
vaccines,patients,on 1.0 0.000143348623853 1 0 1
vaccine,inhalation,mefenamic 1.0 0.000143348623853 1 0 1
utilization,including,medications 1.0 0.000143348623853 1 0 1
uterine,rupture,or 1.0 0.000143348623853 1 0 1
uterine,hypertonus,possibly 1.0 0.000143348623853 1 0 1
usually,within,the 1.0 0.000143348623853 1 0 1
usually,reversible,upon 1.0 0.000143348623853 1 0 1
usually,results,in 1.0 0.000143348623853 1 0 1
usually,does,not 1.0 0.000143348623853 1 0 1
usually,depresses,activity 1.0 0.000143348623853 1 0 1
usually,administered,hours 1.0 0.000143348623853 1 0 1
usually,a,lower 1.0 0.000143348623853 1 0 1
usual,prescription,dose 1.0 0.000143348623853 1 0 1
usual,dose,when 1.0 0.000143348623853 1 0 1
usual,daily,maintenance 1.0 0.000143348623853 1 0 1
usual,and,the 1.0 0.000143348623853 1 0 1
usp,to,subjects 1.0 0.000143348623853 1 0 1
usp,or,initiating 1.0 0.000143348623853 1 0 1
usp,is,a 1.0 0.000143348623853 1 0 1
using,tricor,with 1.0 0.000143348623853 1 0 1
using,the,tablets 1.0 0.000143348623853 1 0 1
using,the,following 1.0 0.000143348623853 1 0 1
using,such,as 1.0 0.000143348623853 1 0 1
using,small,initial 1.0 0.000143348623853 1 0 1
using,should,be 1.0 0.000143348623853 1 0 1
using,romazicon,in 1.0 0.000143348623853 1 0 1
using,or,concomitantly 1.0 0.000143348623853 1 0 1
using,morphological,markers 1.0 0.000143348623853 1 0 1
using,long-acting,or 1.0 0.000143348623853 1 0 1
using,labetalol,hcl 1.0 0.000143348623853 1 0 1
using,it,is 1.0 0.000143348623853 1 0 1
using,in,situ 1.0 0.000143348623853 1 0 1
using,higher,doses 1.0 0.000143348623853 1 0 1
using,escalating,doses 1.0 0.000143348623853 1 0 1
using,doses,of 1.0 0.000143348623853 1 0 1
using,cyp3a4,metabolized 1.0 0.000143348623853 1 0 1
using,bromocriptine,mesylate 1.0 0.000143348623853 1 0 1
using,an,experimental 1.0 0.000143348623853 1 0 1
using,acetate,with 1.0 0.000143348623853 1 0 1
using,a,inhaler 1.0 0.000143348623853 1 0 1
users,particularly,if 1.0 0.000143348623853 1 0 1
useof,a,potent 1.0 0.000143348623853 1 0 1
useful,in,combination 1.0 0.000143348623853 1 0 1
usedas,the,sole 1.0 0.000143348623853 1 0 1
used,with,peripheral 1.0 0.000143348623853 1 0 1
used,with,oral 1.0 0.000143348623853 1 0 1
used,with,in 1.0 0.000143348623853 1 0 1
used,with,extreme 1.0 0.000143348623853 1 0 1
used,with,care 1.0 0.000143348623853 1 0 1
used,with,arimidex 1.0 0.000143348623853 1 0 1
used,when,nsaids 1.0 0.000143348623853 1 0 1
used,when,equetrotm 1.0 0.000143348623853 1 0 1
used,when,and 1.0 0.000143348623853 1 0 1
used,when,abilify 1.0 0.000143348623853 1 0 1
used,together,with 1.0 0.000143348623853 1 0 1
used,together,the 1.0 0.000143348623853 1 0 1
used,together,during 1.0 0.000143348623853 1 0 1
used,it,may 1.0 0.000143348623853 1 0 1
used,in,therapeutic 1.0 0.000143348623853 1 0 1
used,in,any 1.0 0.000143348623853 1 0 1
used,in,addition 1.0 0.000143348623853 1 0 1
used,if,therapy 1.0 0.000143348623853 1 0 1
used,if,patients 1.0 0.000143348623853 1 0 1
used,if,indocin 1.0 0.000143348623853 1 0 1
used,for,management 1.0 0.000143348623853 1 0 1
used,concurrently,resulting 1.0 0.000143348623853 1 0 1
used,concurrently,increases 1.0 0.000143348623853 1 0 1
used,concomitantly,within14 1.0 0.000143348623853 1 0 1
used,concomitantly,there 1.0 0.000143348623853 1 0 1
used,concomitantly,serum 1.0 0.000143348623853 1 0 1
used,concomitantly,renal 1.0 0.000143348623853 1 0 1
used,concomitantly,patients 1.0 0.000143348623853 1 0 1
used,concomitantly,indicate 1.0 0.000143348623853 1 0 1
used,concomitantly,and 1.0 0.000143348623853 1 0 1
used,because,the 1.0 0.000143348623853 1 0 1
used,at,the 1.0 0.000143348623853 1 0 1
used,at,doses 1.0 0.000143348623853 1 0 1
used,as,alternatives 1.0 0.000143348623853 1 0 1
used,alone,has 1.0 0.000143348623853 1 0 1
used,alone,because 1.0 0.000143348623853 1 0 1
use,with,would 1.0 0.000143348623853 1 0 1
use,with,thiazide 1.0 0.000143348623853 1 0 1
use,with,or 1.0 0.000143348623853 1 0 1
use,with,angiotensln 1.0 0.000143348623853 1 0 1
use,with,allopurinol 1.0 0.000143348623853 1 0 1
use,short-acting,because 1.0 0.000143348623853 1 0 1
use,products,that 1.0 0.000143348623853 1 0 1
use,of,vasoconstricting 1.0 0.000143348623853 1 0 1
use,of,vardenafil 1.0 0.000143348623853 1 0 1
use,of,usually 1.0 0.000143348623853 1 0 1
use,of,trileptal 1.0 0.000143348623853 1 0 1
use,of,tricor 1.0 0.000143348623853 1 0 1
use,of,trazodone 1.0 0.000143348623853 1 0 1
use,of,transdermal 1.0 0.000143348623853 1 0 1
use,of,tablets 1.0 0.000143348623853 1 0 1
use,of,supplements 1.0 0.000143348623853 1 0 1
use,of,sprycel 1.0 0.000143348623853 1 0 1
use,of,sodium 1.0 0.000143348623853 1 0 1
use,of,selective 1.0 0.000143348623853 1 0 1
use,of,robinul 1.0 0.000143348623853 1 0 1
use,of,revia 1.0 0.000143348623853 1 0 1
use,of,psychotropic 1.0 0.000143348623853 1 0 1
use,of,prostaglandin 1.0 0.000143348623853 1 0 1
use,of,products 1.0 0.000143348623853 1 0 1
use,of,prior 1.0 0.000143348623853 1 0 1
use,of,prinivil 1.0 0.000143348623853 1 0 1
use,of,preparations 1.0 0.000143348623853 1 0 1
use,of,parenterally 1.0 0.000143348623853 1 0 1
use,of,pancreatic 1.0 0.000143348623853 1 0 1
use,of,nalfon 1.0 0.000143348623853 1 0 1
use,of,monoamine 1.0 0.000143348623853 1 0 1
use,of,mefloquine 1.0 0.000143348623853 1 0 1
use,of,levo-dromoran 1.0 0.000143348623853 1 0 1
use,of,l-tyrosine 1.0 0.000143348623853 1 0 1
use,of,l-phenylalanine 1.0 0.000143348623853 1 0 1
use,of,isocarboxazid 1.0 0.000143348623853 1 0 1
use,of,is 1.0 0.000143348623853 1 0 1
use,of,increases 1.0 0.000143348623853 1 0 1
use,of,hydrobromide 1.0 0.000143348623853 1 0 1
use,of,hmg-coa 1.0 0.000143348623853 1 0 1
use,of,h2 1.0 0.000143348623853 1 0 1
use,of,foscavir 1.0 0.000143348623853 1 0 1
use,of,fludara 1.0 0.000143348623853 1 0 1
use,of,enablex 1.0 0.000143348623853 1 0 1
use,of,ellence 1.0 0.000143348623853 1 0 1
use,of,duragesic 1.0 0.000143348623853 1 0 1
use,of,clozapine 1.0 0.000143348623853 1 0 1
use,of,cerubidine 1.0 0.000143348623853 1 0 1
use,of,by 1.0 0.000143348623853 1 0 1
use,of,buspirone 1.0 0.000143348623853 1 0 1
use,of,bromocriptine 1.0 0.000143348623853 1 0 1
use,of,brevibloc 1.0 0.000143348623853 1 0 1
use,of,antizol 1.0 0.000143348623853 1 0 1
use,of,anticholinesterase 1.0 0.000143348623853 1 0 1
use,of,angiotensin 1.0 0.000143348623853 1 0 1
use,of,an 1.0 0.000143348623853 1 0 1
use,of,amphotericin 1.0 0.000143348623853 1 0 1
use,of,adenocard 1.0 0.000143348623853 1 0 1
use,lowest,possible 1.0 0.000143348623853 1 0 1
use,in,conjunction 1.0 0.000143348623853 1 0 1
use,has,been 1.0 0.000143348623853 1 0 1
use,during,therapy 1.0 0.000143348623853 1 0 1
use,clinicians,should 1.0 0.000143348623853 1 0 1
uroxatral,should,not 1.0 0.000143348623853 1 0 1
urine,volume,in 1.0 0.000143348623853 1 0 1
urine,volume,and 1.0 0.000143348623853 1 0 1
urine,levels,considerably 1.0 0.000143348623853 1 0 1
urinary,uric,acid 1.0 0.000143348623853 1 0 1
urinary,retention,blurred 1.0 0.000143348623853 1 0 1
urinary,retention,and 1.0 0.000143348623853 1 0 1
urinary,excretion,is 1.0 0.000143348623853 1 0 1
urinary,and,chloride 1.0 0.000143348623853 1 0 1
uricosuric,such,as 1.0 0.000143348623853 1 0 1
uricosuric,medication,may 1.0 0.000143348623853 1 0 1
uricosuric,agents,which 1.0 0.000143348623853 1 0 1
uricosuric,agents,since 1.0 0.000143348623853 1 0 1
uricosuric,agents,aspirin 1.0 0.000143348623853 1 0 1
uricosuric,agents,and 1.0 0.000143348623853 1 0 1
uric,acid,level 1.0 0.000143348623853 1 0 1
uric,acid,excretion 1.0 0.000143348623853 1 0 1
ureidopenicillins,including,were 1.0 0.000143348623853 1 0 1
urate,uricosuric,agents 1.0 0.000143348623853 1 0 1
urate,are,also 1.0 0.000143348623853 1 0 1
upward,the,dose 1.0 0.000143348623853 1 0 1
uptake,to,be 1.0 0.000143348623853 1 0 1
uptake,of,sodium 1.0 0.000143348623853 1 0 1
uptake,may,occur 1.0 0.000143348623853 1 0 1
uptake,inhibitors,and 1.0 0.000143348623853 1 0 1
uptake,and,or 1.0 0.000143348623853 1 0 1
upper,gastrointestinal,bleeding 1.0 0.000143348623853 1 0 1
upon,the,reaction 1.0 0.000143348623853 1 0 1
upon,the,known 1.0 0.000143348623853 1 0 1
upon,concomitant,administration 1.0 0.000143348623853 1 0 1
upon,combination,with 1.0 0.000143348623853 1 0 1
upon,beginning,or 1.0 0.000143348623853 1 0 1
upon,administration,of 1.0 0.000143348623853 1 0 1
up,to,when 1.0 0.000143348623853 1 0 1
up,to,leading 1.0 0.000143348623853 1 0 1
up,to,hours 1.0 0.000143348623853 1 0 1
up,to,after 1.0 0.000143348623853 1 0 1
unusually,high,maintenance 1.0 0.000143348623853 1 0 1
until,therapy,is 1.0 0.000143348623853 1 0 1
until,the,relevance 1.0 0.000143348623853 1 0 1
until,data,on 1.0 0.000143348623853 1 0 1
until,a,patient 1.0 0.000143348623853 1 0 1
unsteady,gait,or 1.0 0.000143348623853 1 0 1
unsatisfactory,lipid,response 1.0 0.000143348623853 1 0 1
unrecognized,interaction,between 1.0 0.000143348623853 1 0 1
unpredictable,potentiation,by 1.0 0.000143348623853 1 0 1
unless,the,probable 1.0 0.000143348623853 1 0 1
unless,the,potential 1.0 0.000143348623853 1 0 1
unless,the,benefit 1.0 0.000143348623853 1 0 1
unless,in,the 1.0 0.000143348623853 1 0 1
unless,clinically,necessary 1.0 0.000143348623853 1 0 1
unknown,slightly,shorter 1.0 0.000143348623853 1 0 1
unknown,neither,nor 1.0 0.000143348623853 1 0 1
unknown,and,the 1.0 0.000143348623853 1 0 1
united,kingdom,with 1.0 0.000143348623853 1 0 1
uninfected,volunteers,developed 1.0 0.000143348623853 1 0 1
undertaken,only,with 1.0 0.000143348623853 1 0 1
underlying,mechanism,for 1.0 0.000143348623853 1 0 1
undergoing,ptca,pci 1.0 0.000143348623853 1 0 1
undergoing,concurrent,therapy 1.0 0.000143348623853 1 0 1
undergo,enterohepatic,circulation 1.0 0.000143348623853 1 0 1
under,therapy,should 1.0 0.000143348623853 1 0 1
under,the,serum 1.0 0.000143348623853 1 0 1
under,lying,the 1.0 0.000143348623853 1 0 1
under,acidic,conditions 1.0 0.000143348623853 1 0 1
unclear,how,soon 1.0 0.000143348623853 1 0 1
unchanged,alkaloids,and 1.0 0.000143348623853 1 0 1
unbound,by,hepatic 1.0 0.000143348623853 1 0 1
unaffected,given,the 1.0 0.000143348623853 1 0 1
unaffected,by,brevibloc 1.0 0.000143348623853 1 0 1
ulcerative,colitis,a 1.0 0.000143348623853 1 0 1
ulceration,and,may 1.0 0.000143348623853 1 0 1
ulceration,and,complications 1.0 0.000143348623853 1 0 1
u937,and,molt-4 1.0 0.000143348623853 1 0 1
typhoid,attenuation,of 1.0 0.000143348623853 1 0 1
types,of,adrenocortical 1.0 0.000143348623853 1 0 1
type,it,is 1.0 0.000143348623853 1 0 1
type,ii,diabetic 1.0 0.000143348623853 1 0 1
type,diabetes,used 1.0 0.000143348623853 1 0 1
type,caution,should 1.0 0.000143348623853 1 0 1
type,c,eg 1.0 0.000143348623853 1 0 1
type,c,and 1.0 0.000143348623853 1 0 1
tylenol,with,long-term 1.0 0.000143348623853 1 0 1
tylenol,such,as 1.0 0.000143348623853 1 0 1
tylenol,chloromycetin,local 1.0 0.000143348623853 1 0 1
two-way,interaction,between 1.0 0.000143348623853 1 0 1
two-second,increase,in 1.0 0.000143348623853 1 0 1
two-fold,or,more 1.0 0.000143348623853 1 0 1
two-fold,of,and 1.0 0.000143348623853 1 0 1
two-fold,increases,of 1.0 0.000143348623853 1 0 1
two-fold,increase,in 1.0 0.000143348623853 1 0 1
two,weeks,prior 1.0 0.000143348623853 1 0 1
two,weeks,plasma 1.0 0.000143348623853 1 0 1
two,to,three 1.0 0.000143348623853 1 0 1
two,studies,in 1.0 0.000143348623853 1 0 1
two,potentially,hepatotoxic 1.0 0.000143348623853 1 0 1
two,other,cell 1.0 0.000143348623853 1 0 1
two,of,subjects 1.0 0.000143348623853 1 0 1
two,of,four 1.0 0.000143348623853 1 0 1
two,mg,kg 1.0 0.000143348623853 1 0 1
two,medicines,since 1.0 0.000143348623853 1 0 1
two,instances,and 1.0 0.000143348623853 1 0 1
two,hormonal,components 1.0 0.000143348623853 1 0 1
two,drugs,can 1.0 0.000143348623853 1 0 1
two,clinical,studies 1.0 0.000143348623853 1 0 1
two,cases,in 1.0 0.000143348623853 1 0 1
two,are,coadministered 1.0 0.000143348623853 1 0 1
two,appear,to 1.0 0.000143348623853 1 0 1
two,agents,should 1.0 0.000143348623853 1 0 1
twitch,was,for 1.0 0.000143348623853 1 0 1
twitch,to,fade 1.0 0.000143348623853 1 0 1
twitch,from,to 1.0 0.000143348623853 1 0 1
twice-daily,with,resulted 1.0 0.000143348623853 1 0 1
twice,those,observed 1.0 0.000143348623853 1 0 1
twice,daily,with 1.0 0.000143348623853 1 0 1
twice,daily,taken 1.0 0.000143348623853 1 0 1
twice,daily,resulted 1.0 0.000143348623853 1 0 1
twice,daily,increased 1.0 0.000143348623853 1 0 1
twice,daily,followed 1.0 0.000143348623853 1 0 1
twelve,strains,of 1.0 0.000143348623853 1 0 1
turn,resulted,in 1.0 0.000143348623853 1 0 1
tumour,and,normal 1.0 0.000143348623853 1 0 1
tumors,and,it 1.0 0.000143348623853 1 0 1
tubular,transport,of 1.0 0.000143348623853 1 0 1
tubular,secretion,via 1.0 0.000143348623853 1 0 1
tubular,secretion,has 1.0 0.000143348623853 1 0 1
tubular,secretion,and 1.0 0.000143348623853 1 0 1
tubular,excretion,of 1.0 0.000143348623853 1 0 1
tuberculosis,showed,a 1.0 0.000143348623853 1 0 1
true,interaction,may 1.0 0.000143348623853 1 0 1
trough,concentrations,were 1.0 0.000143348623853 1 0 1
trough,concentrations,similar 1.0 0.000143348623853 1 0 1
trough,concentration,accompanied 1.0 0.000143348623853 1 0 1
tromethamine,control,vs 1.0 0.000143348623853 1 0 1
trisilicate,when,administered 1.0 0.000143348623853 1 0 1
trisenox,is,coadministered 1.0 0.000143348623853 1 0 1
trilisate,disalcid,others 1.0 0.000143348623853 1 0 1
trileptal,with,hormonal 1.0 0.000143348623853 1 0 1
trileptal,with,an 1.0 0.000143348623853 1 0 1
trileptal,was,given 1.0 0.000143348623853 1 0 1
trileptal,topamax,felbatol 1.0 0.000143348623853 1 0 1
trileptal,the,auc 1.0 0.000143348623853 1 0 1
trileptal,greater,than 1.0 0.000143348623853 1 0 1
trileptal,doses,in 1.0 0.000143348623853 1 0 1
triglycerides,sgot,ast 1.0 0.000143348623853 1 0 1
tricyclic,when,used 1.0 0.000143348623853 1 0 1
tricyclic,thereby,delaying 1.0 0.000143348623853 1 0 1
tricyclic,metabolism,may 1.0 0.000143348623853 1 0 1
tricyclic,may,enhance 1.0 0.000143348623853 1 0 1
tricyclic,may,block 1.0 0.000143348623853 1 0 1
tricyclic,may,antagonize 1.0 0.000143348623853 1 0 1
tricyclic,in,combination 1.0 0.000143348623853 1 0 1
tricyclic,flupenthixol,increases 1.0 0.000143348623853 1 0 1
tricyclic,antidepressants,use 1.0 0.000143348623853 1 0 1
tricyclic,antidepressants,foradil 1.0 0.000143348623853 1 0 1
tricyclic,and,may 1.0 0.000143348623853 1 0 1
tricyclic,and,in 1.0 0.000143348623853 1 0 1
tricor,with,and 1.0 0.000143348623853 1 0 1
tricor,there,is 1.0 0.000143348623853 1 0 1
tricor,at,least 1.0 0.000143348623853 1 0 1
tricor,and,hmg-coa 1.0 0.000143348623853 1 0 1
triclofos,sodium,unreliable 1.0 0.000143348623853 1 0 1
triazolopyridazines,and,others 1.0 0.000143348623853 1 0 1
triazolo-benzodiazepines,dihydropyridine,channel 1.0 0.000143348623853 1 0 1
triazolam,erythromycin,has 1.0 0.000143348623853 1 0 1
trials,with,these 1.0 0.000143348623853 1 0 1
trials,of,the 1.0 0.000143348623853 1 0 1
trials,flolan,was 1.0 0.000143348623853 1 0 1
trial,using,escalating 1.0 0.000143348623853 1 0 1
trial,should,not 1.0 0.000143348623853 1 0 1
trial,of,hexalen 1.0 0.000143348623853 1 0 1
trial,in,normal 1.0 0.000143348623853 1 0 1
trial,has,shown 1.0 0.000143348623853 1 0 1
trial,data,where 1.0 0.000143348623853 1 0 1
trial,as,with 1.0 0.000143348623853 1 0 1
tremulousness,and,confusion 1.0 0.000143348623853 1 0 1
tremor,as,compared 1.0 0.000143348623853 1 0 1
trecator,may,potentiate 1.0 0.000143348623853 1 0 1
trecator,has,been 1.0 0.000143348623853 1 0 1
treatment,with,xanthine 1.0 0.000143348623853 1 0 1
treatment,with,wellbutrin 1.0 0.000143348623853 1 0 1
treatment,with,there 1.0 0.000143348623853 1 0 1
treatment,with,tablets 1.0 0.000143348623853 1 0 1
treatment,with,suboxone 1.0 0.000143348623853 1 0 1
treatment,with,sodium 1.0 0.000143348623853 1 0 1
treatment,with,pegasys 1.0 0.000143348623853 1 0 1
treatment,with,oh 1.0 0.000143348623853 1 0 1
treatment,with,inhibitors 1.0 0.000143348623853 1 0 1
treatment,with,imidazole 1.0 0.000143348623853 1 0 1
treatment,with,can 1.0 0.000143348623853 1 0 1
treatment,with,bezalip 1.0 0.000143348623853 1 0 1
treatment,with,agents 1.0 0.000143348623853 1 0 1
treatment,with,accutane 1.0 0.000143348623853 1 0 1
treatment,which,causes 1.0 0.000143348623853 1 0 1
treatment,resulted,in 1.0 0.000143348623853 1 0 1
treatment,regimen,includes 1.0 0.000143348623853 1 0 1
treatment,potentiated,the 1.0 0.000143348623853 1 0 1
treatment,of,four 1.0 0.000143348623853 1 0 1
treatment,of,ewes 1.0 0.000143348623853 1 0 1
treatment,of,breast 1.0 0.000143348623853 1 0 1
treatment,of,anticholinesterase 1.0 0.000143348623853 1 0 1
treatment,of,anaphylactic 1.0 0.000143348623853 1 0 1
treatment,may,require 1.0 0.000143348623853 1 0 1
treatment,in,renal 1.0 0.000143348623853 1 0 1
treatment,following,the 1.0 0.000143348623853 1 0 1
treatment,folic,acid 1.0 0.000143348623853 1 0 1
treatment,dosage,adjustment 1.0 0.000143348623853 1 0 1
treatment,and,inhibits 1.0 0.000143348623853 1 0 1
treated,with,zyvox 1.0 0.000143348623853 1 0 1
treated,with,various 1.0 0.000143348623853 1 0 1
treated,with,systemically-administered 1.0 0.000143348623853 1 0 1
treated,with,proton 1.0 0.000143348623853 1 0 1
treated,with,plus 1.0 0.000143348623853 1 0 1
treated,with,or 1.0 0.000143348623853 1 0 1
treated,with,one 1.0 0.000143348623853 1 0 1
treated,with,nonsteroidal 1.0 0.000143348623853 1 0 1
treated,with,non-steroidal 1.0 0.000143348623853 1 0 1
treated,with,nalfon 1.0 0.000143348623853 1 0 1
treated,with,mao 1.0 0.000143348623853 1 0 1
treated,with,hours 1.0 0.000143348623853 1 0 1
treated,with,either 1.0 0.000143348623853 1 0 1
treated,with,difluoro-2 1.0 0.000143348623853 1 0 1
treated,with,coly-mycin 1.0 0.000143348623853 1 0 1
treated,with,co-administered 1.0 0.000143348623853 1 0 1
treated,with,an 1.0 0.000143348623853 1 0 1
treated,with,alone 1.0 0.000143348623853 1 0 1
treated,with,agonists 1.0 0.000143348623853 1 0 1
treated,rats,pd2 1.0 0.000143348623853 1 0 1
treat,strongyloidiasis,during 1.0 0.000143348623853 1 0 1
treat,pneumocystis,carinii 1.0 0.000143348623853 1 0 1
trazodone,hydrochloride,desyrel 1.0 0.000143348623853 1 0 1
travelers,receiving,comedication 1.0 0.000143348623853 1 0 1
traumatic,edemas,that 1.0 0.000143348623853 1 0 1
transport-related,effects,such 1.0 0.000143348623853 1 0 1
transport,of,may 1.0 0.000143348623853 1 0 1
transplant,recipients,a 1.0 0.000143348623853 1 0 1
transplant,patients,suffering 1.0 0.000143348623853 1 0 1
transplant,patients,receiving 1.0 0.000143348623853 1 0 1
transit,time,by 1.0 0.000143348623853 1 0 1
transient,dose-dependent,increase 1.0 0.000143348623853 1 0 1
transient,delirium,has 1.0 0.000143348623853 1 0 1
transient,cardiac,arrhythmias 1.0 0.000143348623853 1 0 1
transfusions,acute,pulmonary 1.0 0.000143348623853 1 0 1
transdermal,with,or 1.0 0.000143348623853 1 0 1
transdermal,system,with 1.0 0.000143348623853 1 0 1
transdermal,may,also 1.0 0.000143348623853 1 0 1
transcriptase,inhibitors,nnrtis 1.0 0.000143348623853 1 0 1
trans-3,dimethyl-4,hydroxyphenyl 1.0 0.000143348623853 1 0 1
tract,to,healthy 1.0 0.000143348623853 1 0 1
tract,hydoxide,hydrochloride 1.0 0.000143348623853 1 0 1
tract,by,up 1.0 0.000143348623853 1 0 1
tracrium,should,not 1.0 0.000143348623853 1 0 1
tracrium,include,certain 1.0 0.000143348623853 1 0 1
tracleer,is,initiated 1.0 0.000143348623853 1 0 1
tracleer,and,is 1.0 0.000143348623853 1 0 1
toxoids,should,be 1.0 0.000143348623853 1 0 1
toxoids,and,live 1.0 0.000143348623853 1 0 1
toxicology,studies,of 1.0 0.000143348623853 1 0 1
toxicity,when,given 1.0 0.000143348623853 1 0 1
toxicity,was,usually 1.0 0.000143348623853 1 0 1
toxicity,was,reported 1.0 0.000143348623853 1 0 1
toxicity,than,when 1.0 0.000143348623853 1 0 1
toxicity,of,is 1.0 0.000143348623853 1 0 1
toxicity,of,edetate 1.0 0.000143348623853 1 0 1
toxicity,of,by 1.0 0.000143348623853 1 0 1
toxicity,occur,when 1.0 0.000143348623853 1 0 1
toxicity,may,result 1.0 0.000143348623853 1 0 1
toxicity,may,occur 1.0 0.000143348623853 1 0 1
toxicity,may,have 1.0 0.000143348623853 1 0 1
toxicity,including,convulsions 1.0 0.000143348623853 1 0 1
toxicity,in,those 1.0 0.000143348623853 1 0 1
toxicity,in,these 1.0 0.000143348623853 1 0 1
toxicity,in,some 1.0 0.000143348623853 1 0 1
toxicity,in,a 1.0 0.000143348623853 1 0 1
toxicity,at,lower 1.0 0.000143348623853 1 0 1
toxicity,and,serial 1.0 0.000143348623853 1 0 1
toxicity,and,possible 1.0 0.000143348623853 1 0 1
toxicity,and,or 1.0 0.000143348623853 1 0 1
toxic,such,as 1.0 0.000143348623853 1 0 1
toxic,levels,of 1.0 0.000143348623853 1 0 1
toxic,effects,such 1.0 0.000143348623853 1 0 1
toxic,effect,in 1.0 0.000143348623853 1 0 1
toxic,concentrations,decreases 1.0 0.000143348623853 1 0 1
toxic,and,traumatic 1.0 0.000143348623853 1 0 1
totally,known,enzyme 1.0 0.000143348623853 1 0 1
total,formation,in 1.0 0.000143348623853 1 0 1
total,concentrations,increased 1.0 0.000143348623853 1 0 1
total,clearance,of 1.0 0.000143348623853 1 0 1
total,auc,increased 1.0 0.000143348623853 1 0 1
toradol,was,used 1.0 0.000143348623853 1 0 1
toradol,to,patients 1.0 0.000143348623853 1 0 1
toradol,therapy,have 1.0 0.000143348623853 1 0 1
toradol,oral,and 1.0 0.000143348623853 1 0 1
toradol,on,plasma 1.0 0.000143348623853 1 0 1
toradol,iv,im 1.0 0.000143348623853 1 0 1
toradol,and,or 1.0 0.000143348623853 1 0 1
topical,glaucoma,or 1.0 0.000143348623853 1 0 1
topamax,felbatol,gris-peg 1.0 0.000143348623853 1 0 1
tolerated,but,there 1.0 0.000143348623853 1 0 1
tolerated,and,of 1.0 0.000143348623853 1 0 1
tolerance,in,patients 1.0 0.000143348623853 1 0 1
tolerance,in,dogs 1.0 0.000143348623853 1 0 1
tolbutamide,aprepitant,when 1.0 0.000143348623853 1 0 1
tolazamide,a,case 1.0 0.000143348623853 1 0 1
together,with,rr 1.0 0.000143348623853 1 0 1
together,with,depen 1.0 0.000143348623853 1 0 1
together,with,bezalip 1.0 0.000143348623853 1 0 1
together,the,signs 1.0 0.000143348623853 1 0 1
together,may,increase 1.0 0.000143348623853 1 0 1
together,may,decrease 1.0 0.000143348623853 1 0 1
together,during,the 1.0 0.000143348623853 1 0 1
to,years,who 1.0 0.000143348623853 1 0 1
to,withhold,during 1.0 0.000143348623853 1 0 1
to,wide,interindividual 1.0 0.000143348623853 1 0 1
to,whom,aminoglycoside 1.0 0.000143348623853 1 0 1
to,which,ssri-tcainteractions 1.0 0.000143348623853 1 0 1
to,which,resulted 1.0 0.000143348623853 1 0 1
to,which,enbrel 1.0 0.000143348623853 1 0 1
to,when,trileptal 1.0 0.000143348623853 1 0 1
to,when,mg 1.0 0.000143348623853 1 0 1
to,when,it 1.0 0.000143348623853 1 0 1
to,when,gleevec 1.0 0.000143348623853 1 0 1
to,when,compared 1.0 0.000143348623853 1 0 1
to,was,not 1.0 0.000143348623853 1 0 1
to,was,necessary 1.0 0.000143348623853 1 0 1
to,warrant,dosage 1.0 0.000143348623853 1 0 1
to,vomiting,and 1.0 0.000143348623853 1 0 1
to,vehicle-,progesterone- 1.0 0.000143348623853 1 0 1
to,use,short-acting 1.0 0.000143348623853 1 0 1
to,treat,strongyloidiasis 1.0 0.000143348623853 1 0 1
to,transport-related,effects 1.0 0.000143348623853 1 0 1
to,toxoids,and 1.0 0.000143348623853 1 0 1
to,toxic,concentrations 1.0 0.000143348623853 1 0 1
to,took,min 1.0 0.000143348623853 1 0 1
to,three,weeks 1.0 0.000143348623853 1 0 1
to,three,cancer 1.0 0.000143348623853 1 0 1
to,those,with 1.0 0.000143348623853 1 0 1
to,those,seen 1.0 0.000143348623853 1 0 1
to,those,found 1.0 0.000143348623853 1 0 1
to,this,regimen 1.0 0.000143348623853 1 0 1
to,this,pharmacological 1.0 0.000143348623853 1 0 1
to,this,mechanism 1.0 0.000143348623853 1 0 1
to,therapy,plasma 1.0 0.000143348623853 1 0 1
to,therapy,dose 1.0 0.000143348623853 1 0 1
to,therapy,could 1.0 0.000143348623853 1 0 1
to,their,similar 1.0 0.000143348623853 1 0 1
to,the,vehicle 1.0 0.000143348623853 1 0 1
to,the,therapy 1.0 0.000143348623853 1 0 1
to,the,resolution 1.0 0.000143348623853 1 0 1
to,the,neuromuscular 1.0 0.000143348623853 1 0 1
to,the,muscle 1.0 0.000143348623853 1 0 1
to,the,lowest 1.0 0.000143348623853 1 0 1
to,the,induction 1.0 0.000143348623853 1 0 1
to,the,formation 1.0 0.000143348623853 1 0 1
to,the,enhancement 1.0 0.000143348623853 1 0 1
to,the,dosing 1.0 0.000143348623853 1 0 1
to,the,disruptive 1.0 0.000143348623853 1 0 1
to,the,cross-reactivity 1.0 0.000143348623853 1 0 1
to,the,combined 1.0 0.000143348623853 1 0 1
to,the,cautious 1.0 0.000143348623853 1 0 1
to,the,blood 1.0 0.000143348623853 1 0 1
to,the,action 1.0 0.000143348623853 1 0 1
to,temporarily,suspending 1.0 0.000143348623853 1 0 1
to,temporarily,raise 1.0 0.000143348623853 1 0 1
to,take,and 1.0 0.000143348623853 1 0 1
to,take,a 1.0 0.000143348623853 1 0 1
to,subjects,the 1.0 0.000143348623853 1 0 1
to,subjects,receiving 1.0 0.000143348623853 1 0 1
to,subjects,already 1.0 0.000143348623853 1 0 1
to,steady,state 1.0 0.000143348623853 1 0 1
to,slower,renal 1.0 0.000143348623853 1 0 1
to,slow,the 1.0 0.000143348623853 1 0 1
to,sinus,rhythm 1.0 0.000143348623853 1 0 1
to,significantly,alter 1.0 0.000143348623853 1 0 1
to,severe,cardiovascular 1.0 0.000143348623853 1 0 1
to,serum,proteins 1.0 0.000143348623853 1 0 1
to,serum,protein 1.0 0.000143348623853 1 0 1
to,see,whether 1.0 0.000143348623853 1 0 1
to,see,if 1.0 0.000143348623853 1 0 1
to,results,from 1.0 0.000143348623853 1 0 1
to,resulting,interference 1.0 0.000143348623853 1 0 1
to,require,replacement 1.0 0.000143348623853 1 0 1
to,representing,a 1.0 0.000143348623853 1 0 1
to,reported,to 1.0 0.000143348623853 1 0 1
to,release,from 1.0 0.000143348623853 1 0 1
to,reduce,proleukin-induced 1.0 0.000143348623853 1 0 1
to,reduce,hepatic 1.0 0.000143348623853 1 0 1
to,rats,treated 1.0 0.000143348623853 1 0 1
to,rachitic,chicks 1.0 0.000143348623853 1 0 1
to,protein,may 1.0 0.000143348623853 1 0 1
to,prolong,further 1.0 0.000143348623853 1 0 1
to,products,containing 1.0 0.000143348623853 1 0 1
to,produce,clinically 1.0 0.000143348623853 1 0 1
to,produce,any 1.0 0.000143348623853 1 0 1
to,produce,antabuse-like 1.0 0.000143348623853 1 0 1
to,produce,additive 1.0 0.000143348623853 1 0 1
to,prevent,symptoms 1.0 0.000143348623853 1 0 1
to,prevent,excessive 1.0 0.000143348623853 1 0 1
to,possibly,increase 1.0 0.000143348623853 1 0 1
to,possible,pharmacodynamic 1.0 0.000143348623853 1 0 1
to,phenytoin,intoxication 1.0 0.000143348623853 1 0 1
to,patients,anaesthetised 1.0 0.000143348623853 1 0 1
to,outweigh,the 1.0 0.000143348623853 1 0 1
to,other,general 1.0 0.000143348623853 1 0 1
to,or,the 1.0 0.000143348623853 1 0 1
to,or,slightly 1.0 0.000143348623853 1 0 1
to,or,oral 1.0 0.000143348623853 1 0 1
to,or,on 1.0 0.000143348623853 1 0 1
to,or,hours 1.0 0.000143348623853 1 0 1
to,or,concurrent 1.0 0.000143348623853 1 0 1
to,open,air 1.0 0.000143348623853 1 0 1
to,onset,of 1.0 0.000143348623853 1 0 1
to,one-half,the 1.0 0.000143348623853 1 0 1
to,one-fourth,of 1.0 0.000143348623853 1 0 1
to,one,third 1.0 0.000143348623853 1 0 1
to,occasionally,intensify 1.0 0.000143348623853 1 0 1
to,obtain,serum 1.0 0.000143348623853 1 0 1
to,ng,x 1.0 0.000143348623853 1 0 1
to,monitor,concentrations 1.0 0.000143348623853 1 0 1
to,minutes,p 1.0 0.000143348623853 1 0 1
to,might,decrease 1.0 0.000143348623853 1 0 1
to,micrograms,equally 1.0 0.000143348623853 1 0 1
to,micrograms,caused 1.0 0.000143348623853 1 0 1
to,mg,week 1.0 0.000143348623853 1 0 1
to,mg,twice 1.0 0.000143348623853 1 0 1
to,mg,to 1.0 0.000143348623853 1 0 1
to,mg,three 1.0 0.000143348623853 1 0 1
to,mg,or 1.0 0.000143348623853 1 0 1
to,mg,of 1.0 0.000143348623853 1 0 1
to,mg,led 1.0 0.000143348623853 1 0 1
to,mg,capsules 1.0 0.000143348623853 1 0 1
to,mechanisms,involving 1.0 0.000143348623853 1 0 1
to,may,be 1.0 0.000143348623853 1 0 1
to,marked,interference 1.0 0.000143348623853 1 0 1
to,maintain,trough 1.0 0.000143348623853 1 0 1
to,maintain,levels 1.0 0.000143348623853 1 0 1
to,m,markedly 1.0 0.000143348623853 1 0 1
to,m,g 1.0 0.000143348623853 1 0 1
to,leading,to 1.0 0.000143348623853 1 0 1
to,l,kg 1.0 0.000143348623853 1 0 1
to,its,nephrotoxicity 1.0 0.000143348623853 1 0 1
to,its,inhibitory 1.0 0.000143348623853 1 0 1
to,is,expected 1.0 0.000143348623853 1 0 1
to,iodinated,contrast 1.0 0.000143348623853 1 0 1
to,intravenous,and 1.0 0.000143348623853 1 0 1
to,inter-patient,variation 1.0 0.000143348623853 1 0 1
to,insure,that 1.0 0.000143348623853 1 0 1
to,initiating,combination 1.0 0.000143348623853 1 0 1
to,inhibit,phosphatase 1.0 0.000143348623853 1 0 1
to,inhibit,p450 1.0 0.000143348623853 1 0 1
to,infusions,of 1.0 0.000143348623853 1 0 1
to,induce,microsomal 1.0 0.000143348623853 1 0 1
to,indirect-acting,agents 1.0 0.000143348623853 1 0 1
to,increased,risk 1.0 0.000143348623853 1 0 1
to,increase,with 1.0 0.000143348623853 1 0 1
to,increase,when 1.0 0.000143348623853 1 0 1
to,increase,steadystate 1.0 0.000143348623853 1 0 1
to,increase,resulting 1.0 0.000143348623853 1 0 1
to,increase,respectively 1.0 0.000143348623853 1 0 1
to,increase,cmax 1.0 0.000143348623853 1 0 1
to,increase,awareness 1.0 0.000143348623853 1 0 1
to,increase,and 1.0 0.000143348623853 1 0 1
to,inactivate,the 1.0 0.000143348623853 1 0 1
to,in,of 1.0 0.000143348623853 1 0 1
to,in,normovolemic 1.0 0.000143348623853 1 0 1
to,in,healthy 1.0 0.000143348623853 1 0 1
to,hours,should 1.0 0.000143348623853 1 0 1
to,hours,or 1.0 0.000143348623853 1 0 1
to,higher,exposure 1.0 0.000143348623853 1 0 1
to,high,temperature 1.0 0.000143348623853 1 0 1
to,have,occurred 1.0 0.000143348623853 1 0 1
to,have,increased 1.0 0.000143348623853 1 0 1
to,has,a 1.0 0.000143348623853 1 0 1
to,half,the 1.0 0.000143348623853 1 0 1
to,groups,treated 1.0 0.000143348623853 1 0 1
to,fulminant,pancreatitis 1.0 0.000143348623853 1 0 1
to,form,or 1.0 0.000143348623853 1 0 1
to,form,a 1.0 0.000143348623853 1 0 1
to,for,the 1.0 0.000143348623853 1 0 1
to,fold,higher 1.0 0.000143348623853 1 0 1
to,fold,greater 1.0 0.000143348623853 1 0 1
to,fold,elevations 1.0 0.000143348623853 1 0 1
to,fold,elevation 1.0 0.000143348623853 1 0 1
to,fluctuate,significantly 1.0 0.000143348623853 1 0 1
to,fade,recovery 1.0 0.000143348623853 1 0 1
to,factrel,may 1.0 0.000143348623853 1 0 1
to,extend,the 1.0 0.000143348623853 1 0 1
to,establish,a 1.0 0.000143348623853 1 0 1
to,erythro-fluorocitrate,in 1.0 0.000143348623853 1 0 1
to,environmental,may 1.0 0.000143348623853 1 0 1
to,ensure,clinically 1.0 0.000143348623853 1 0 1
to,enhancing,absorption 1.0 0.000143348623853 1 0 1
to,enhance,in 1.0 0.000143348623853 1 0 1
to,emerge,if 1.0 0.000143348623853 1 0 1
to,eliminate,the 1.0 0.000143348623853 1 0 1
to,elevated,plasma 1.0 0.000143348623853 1 0 1
to,elevate,plasma 1.0 0.000143348623853 1 0 1
to,electrolyte,abnormalities 1.0 0.000143348623853 1 0 1
to,either,alone 1.0 0.000143348623853 1 0 1
to,during,or 1.0 0.000143348623853 1 0 1
to,double,the 1.0 0.000143348623853 1 0 1
to,dose-related,decrease 1.0 0.000143348623853 1 0 1
to,displace,from 1.0 0.000143348623853 1 0 1
to,discontinue,therapy 1.0 0.000143348623853 1 0 1
to,difluoroacetone,in 1.0 0.000143348623853 1 0 1
to,dictate,against 1.0 0.000143348623853 1 0 1
to,develop,a 1.0 0.000143348623853 1 0 1
to,decreased,serum 1.0 0.000143348623853 1 0 1
to,decreased,concentrations 1.0 0.000143348623853 1 0 1
to,decrease,glutathione 1.0 0.000143348623853 1 0 1
to,decrease,established 1.0 0.000143348623853 1 0 1
to,decrease,elimination 1.0 0.000143348623853 1 0 1
to,decrease,conduction 1.0 0.000143348623853 1 0 1
to,days,following 1.0 0.000143348623853 1 0 1
to,cytochrome,p450 1.0 0.000143348623853 1 0 1
to,cross,toxicity 1.0 0.000143348623853 1 0 1
to,convulsions,in 1.0 0.000143348623853 1 0 1
to,control,supraventricular 1.0 0.000143348623853 1 0 1
to,control,inflammation 1.0 0.000143348623853 1 0 1
to,control,hypertension 1.0 0.000143348623853 1 0 1
to,control,atrial 1.0 0.000143348623853 1 0 1
to,continue,treatment 1.0 0.000143348623853 1 0 1
to,continue,to 1.0 0.000143348623853 1 0 1
to,concurrent,administration 1.0 0.000143348623853 1 0 1
to,compromise,the 1.0 0.000143348623853 1 0 1
to,competitively,inhibit 1.0 0.000143348623853 1 0 1
to,compared,to 1.0 0.000143348623853 1 0 1
to,co-administer,and 1.0 0.000143348623853 1 0 1
to,check,coagulation 1.0 0.000143348623853 1 0 1
to,change,to 1.0 0.000143348623853 1 0 1
to,cause,ventricular 1.0 0.000143348623853 1 0 1
to,cause,tumors 1.0 0.000143348623853 1 0 1
to,cause,the 1.0 0.000143348623853 1 0 1
to,cause,renal 1.0 0.000143348623853 1 0 1
to,cause,decreased 1.0 0.000143348623853 1 0 1
to,cause,coronary 1.0 0.000143348623853 1 0 1
to,but,the 1.0 0.000143348623853 1 0 1
to,but,not 1.0 0.000143348623853 1 0 1
to,but,it 1.0 0.000143348623853 1 0 1
to,both,increase 1.0 0.000143348623853 1 0 1
to,block,the 1.0 0.000143348623853 1 0 1
to,bleeding,associated 1.0 0.000143348623853 1 0 1
to,beta-lactam,including 1.0 0.000143348623853 1 0 1
to,be,without 1.0 0.000143348623853 1 0 1
to,be,terminated 1.0 0.000143348623853 1 0 1
to,be,seen 1.0 0.000143348623853 1 0 1
to,be,reversed 1.0 0.000143348623853 1 0 1
to,be,receiving 1.0 0.000143348623853 1 0 1
to,be,maximal 1.0 0.000143348623853 1 0 1
to,be,markedly 1.0 0.000143348623853 1 0 1
to,be,ingested 1.0 0.000143348623853 1 0 1
to,be,greater 1.0 0.000143348623853 1 0 1
to,be,given 1.0 0.000143348623853 1 0 1
to,be,fatal 1.0 0.000143348623853 1 0 1
to,be,exacerbated 1.0 0.000143348623853 1 0 1
to,be,displaced 1.0 0.000143348623853 1 0 1
to,be,certain 1.0 0.000143348623853 1 0 1
to,be,antagonistic 1.0 0.000143348623853 1 0 1
to,baseline,values 1.0 0.000143348623853 1 0 1
to,avoid,while 1.0 0.000143348623853 1 0 1
to,avoid,this 1.0 0.000143348623853 1 0 1
to,avoid,giving 1.0 0.000143348623853 1 0 1
to,avoid,concurrent 1.0 0.000143348623853 1 0 1
to,avoid,bleeding 1.0 0.000143348623853 1 0 1
to,avoid,additive 1.0 0.000143348623853 1 0 1
to,as,these 1.0 0.000143348623853 1 0 1
to,approximately,to 1.0 0.000143348623853 1 0 1
to,approximately,one-third 1.0 0.000143348623853 1 0 1
to,approximately,fold 1.0 0.000143348623853 1 0 1
to,any,medication 1.0 0.000143348623853 1 0 1
to,antiepileptic,aeds 1.0 0.000143348623853 1 0 1
to,and,should 1.0 0.000143348623853 1 0 1
to,and,leading 1.0 0.000143348623853 1 0 1
to,an,enhancement 1.0 0.000143348623853 1 0 1
to,an,altered 1.0 0.000143348623853 1 0 1
to,amide-type,local 1.0 0.000143348623853 1 0 1
to,although,there 1.0 0.000143348623853 1 0 1
to,alter,cardiac 1.0 0.000143348623853 1 0 1
to,alert,clinicians 1.0 0.000143348623853 1 0 1
to,agents,may 1.0 0.000143348623853 1 0 1
to,affect,sinus 1.0 0.000143348623853 1 0 1
to,affect,bleeding 1.0 0.000143348623853 1 0 1
to,administering,disulfiram 1.0 0.000143348623853 1 0 1
to,adjust,the 1.0 0.000143348623853 1 0 1
to,achieve,mac 1.0 0.000143348623853 1 0 1
to,ace,inhibitors 1.0 0.000143348623853 1 0 1
to,about,one-third 1.0 0.000143348623853 1 0 1
to,a,theoretical 1.0 0.000143348623853 1 0 1
to,a,slight 1.0 0.000143348623853 1 0 1
to,a,regimen 1.0 0.000143348623853 1 0 1
to,a,prolongation 1.0 0.000143348623853 1 0 1
to,a,patients 1.0 0.000143348623853 1 0 1
to,a,non-matched 1.0 0.000143348623853 1 0 1
to,a,mg 1.0 0.000143348623853 1 0 1
to,a,marketed 1.0 0.000143348623853 1 0 1
to,a,five-fold 1.0 0.000143348623853 1 0 1
to,a,dose-dependent 1.0 0.000143348623853 1 0 1
to,a,digitalized 1.0 0.000143348623853 1 0 1
to,a,different 1.0 0.000143348623853 1 0 1
to,a,decreased 1.0 0.000143348623853 1 0 1
tnfa-blocking,agents,including 1.0 0.000143348623853 1 0 1
tnf-blocking,agents,including 1.0 0.000143348623853 1 0 1
tnf-blocking,agent,has 1.0 0.000143348623853 1 0 1
tnf,blocking,agent 1.0 0.000143348623853 1 0 1
tnf,antagonists,is 1.0 0.000143348623853 1 0 1
tnf,antagonist,with 1.0 0.000143348623853 1 0 1
tmax,by,and 1.0 0.000143348623853 1 0 1
titration,to,the 1.0 0.000143348623853 1 0 1
titration,of,their 1.0 0.000143348623853 1 0 1
titrated,with,caution 1.0 0.000143348623853 1 0 1
titrated,according,to 1.0 0.000143348623853 1 0 1
tissues,induced,by 1.0 0.000143348623853 1 0 1
tissues,from,the 1.0 0.000143348623853 1 0 1
tissue,damage,as 1.0 0.000143348623853 1 0 1
tissue,culture,the 1.0 0.000143348623853 1 0 1
tissue,culture,and 1.0 0.000143348623853 1 0 1
tinnitus,and,decreased 1.0 0.000143348623853 1 0 1
times,with,or 1.0 0.000143348623853 1 0 1
times,when,was 1.0 0.000143348623853 1 0 1
times,increase,in 1.0 0.000143348623853 1 0 1
times,daily,given 1.0 0.000143348623853 1 0 1
times,daily,for 1.0 0.000143348623853 1 0 1
time-curve,increased,from 1.0 0.000143348623853 1 0 1
time,within,the 1.0 0.000143348623853 1 0 1
time,with,or 1.0 0.000143348623853 1 0 1
time,window,is 1.0 0.000143348623853 1 0 1
time,when,was 1.0 0.000143348623853 1 0 1
time,to,onset 1.0 0.000143348623853 1 0 1
time,reported,as 1.0 0.000143348623853 1 0 1
time,pt,and 1.0 0.000143348623853 1 0 1
time,of,onset 1.0 0.000143348623853 1 0 1
time,monitored,and 1.0 0.000143348623853 1 0 1
time,may,occur 1.0 0.000143348623853 1 0 1
time,kill,curves 1.0 0.000143348623853 1 0 1
time,is,to 1.0 0.000143348623853 1 0 1
time,inr,should 1.0 0.000143348623853 1 0 1
time,in,healthy 1.0 0.000143348623853 1 0 1
time,in,all 1.0 0.000143348623853 1 0 1
time,for,hour 1.0 0.000143348623853 1 0 1
time,determinations,vitamin 1.0 0.000143348623853 1 0 1
time,by,means 1.0 0.000143348623853 1 0 1
time,beyond,the 1.0 0.000143348623853 1 0 1
time,be,monitored 1.0 0.000143348623853 1 0 1
time,be,determined 1.0 0.000143348623853 1 0 1
time,as,other 1.0 0.000143348623853 1 0 1
time,after,or 1.0 0.000143348623853 1 0 1
tikosyn,with,resulted 1.0 0.000143348623853 1 0 1
tikosyn,as,they 1.0 0.000143348623853 1 0 1
tikosyn,and,therapy 1.0 0.000143348623853 1 0 1
tid,was,administered 1.0 0.000143348623853 1 0 1
tid,the,cmax 1.0 0.000143348623853 1 0 1
tid,mg,qd 1.0 0.000143348623853 1 0 1
tiagabine,causes,a 1.0 0.000143348623853 1 0 1
thyroxine,increases,the 1.0 0.000143348623853 1 0 1
thyroiditis,bullous,pemphigoid 1.0 0.000143348623853 1 0 1
thyroidal,uptake,of 1.0 0.000143348623853 1 0 1
thyroid,preparations,may 1.0 0.000143348623853 1 0 1
thyroid,administration,to 1.0 0.000143348623853 1 0 1
thus,when,vioxx 1.0 0.000143348623853 1 0 1
thus,when,and 1.0 0.000143348623853 1 0 1
thus,the,results 1.0 0.000143348623853 1 0 1
thus,the,interaction 1.0 0.000143348623853 1 0 1
thus,smaller,doses 1.0 0.000143348623853 1 0 1
thus,should,not 1.0 0.000143348623853 1 0 1
thus,should,be 1.0 0.000143348623853 1 0 1
thus,requiring,an 1.0 0.000143348623853 1 0 1
thus,patients,receiving 1.0 0.000143348623853 1 0 1
thus,necessitating,an 1.0 0.000143348623853 1 0 1
thus,lower,the 1.0 0.000143348623853 1 0 1
thus,leading,to 1.0 0.000143348623853 1 0 1
thus,in,order 1.0 0.000143348623853 1 0 1
thus,impairing,absorption 1.0 0.000143348623853 1 0 1
thus,concomitant,administration 1.0 0.000143348623853 1 0 1
thus,careful,monitoring 1.0 0.000143348623853 1 0 1
thus,appeared,to 1.0 0.000143348623853 1 0 1
thus,an,enhancement 1.0 0.000143348623853 1 0 1
through,the,a-v 1.0 0.000143348623853 1 0 1
through,inhibition,of 1.0 0.000143348623853 1 0 1
through,increased,the 1.0 0.000143348623853 1 0 1
through,increased,metabolism 1.0 0.000143348623853 1 0 1
through,effects,on 1.0 0.000143348623853 1 0 1
through,an,effect 1.0 0.000143348623853 1 0 1
thrombus,formation,from 1.0 0.000143348623853 1 0 1
threshold,should,be 1.0 0.000143348623853 1 0 1
threshold,concurrent,administration 1.0 0.000143348623853 1 0 1
threefold,from,to 1.0 0.000143348623853 1 0 1
three,weeks,after 1.0 0.000143348623853 1 0 1
three,mg,capsules 1.0 0.000143348623853 1 0 1
three,cancer,patients 1.0 0.000143348623853 1 0 1
threatening,cardiac,dysrhythmias 1.0 0.000143348623853 1 0 1
though,this,has 1.0 0.000143348623853 1 0 1
though,reversible,impairment 1.0 0.000143348623853 1 0 1
those,with,severe 1.0 0.000143348623853 1 0 1
those,with,overdosage 1.0 0.000143348623853 1 0 1
those,with,intravascular 1.0 0.000143348623853 1 0 1
those,taking,therapy 1.0 0.000143348623853 1 0 1
those,seen,when 1.0 0.000143348623853 1 0 1
those,seen,prior 1.0 0.000143348623853 1 0 1
those,seen,in 1.0 0.000143348623853 1 0 1
those,required,to 1.0 0.000143348623853 1 0 1
those,receiving,crixivan 1.0 0.000143348623853 1 0 1
those,produced,by 1.0 0.000143348623853 1 0 1
those,patients,reveiving 1.0 0.000143348623853 1 0 1
those,patients,on 1.0 0.000143348623853 1 0 1
those,on,severe 1.0 0.000143348623853 1 0 1
those,of,the 1.0 0.000143348623853 1 0 1
those,of,class 1.0 0.000143348623853 1 0 1
those,obtained,after 1.0 0.000143348623853 1 0 1
those,observed,when 1.0 0.000143348623853 1 0 1
those,contained,in 1.0 0.000143348623853 1 0 1
this,was,prevented 1.0 0.000143348623853 1 0 1
this,time,window 1.0 0.000143348623853 1 0 1
this,study,demonstrates 1.0 0.000143348623853 1 0 1
this,study,demonstrated 1.0 0.000143348623853 1 0 1
this,study,adverse 1.0 0.000143348623853 1 0 1
this,small,decrease 1.0 0.000143348623853 1 0 1
this,route,and 1.0 0.000143348623853 1 0 1
this,regimen,did 1.0 0.000143348623853 1 0 1
this,reduction,is 1.0 0.000143348623853 1 0 1
this,protein,in 1.0 0.000143348623853 1 0 1
this,potentiation,of 1.0 0.000143348623853 1 0 1
this,pharmacological,interaction 1.0 0.000143348623853 1 0 1
this,parenteral,may 1.0 0.000143348623853 1 0 1
this,observed,increase 1.0 0.000143348623853 1 0 1
this,neurotoxic,effect 1.0 0.000143348623853 1 0 1
this,might,be 1.0 0.000143348623853 1 0 1
this,mechanism,may 1.0 0.000143348623853 1 0 1
this,may,occur 1.0 0.000143348623853 1 0 1
this,kind,with 1.0 0.000143348623853 1 0 1
this,isoenzyme,macrolide 1.0 0.000143348623853 1 0 1
this,interaction,which 1.0 0.000143348623853 1 0 1
this,interaction,probably 1.0 0.000143348623853 1 0 1
this,interaction,or 1.0 0.000143348623853 1 0 1
this,information,to 1.0 0.000143348623853 1 0 1
this,enzyme,should 1.0 0.000143348623853 1 0 1
this,enzyme,eg 1.0 0.000143348623853 1 0 1
this,effect,on 1.0 0.000143348623853 1 0 1
this,could,lead 1.0 0.000143348623853 1 0 1
this,combination,outweigh 1.0 0.000143348623853 1 0 1
this,combination,has 1.0 0.000143348623853 1 0 1
this,appears,to 1.0 0.000143348623853 1 0 1
this,antagonistic,effect 1.0 0.000143348623853 1 0 1
this,allows,to 1.0 0.000143348623853 1 0 1
third,of,the 1.0 0.000143348623853 1 0 1
thioxanthene,and,butyrophenone 1.0 0.000143348623853 1 0 1
thiosulfate,is,a 1.0 0.000143348623853 1 0 1
thioridazine,coadministration,of 1.0 0.000143348623853 1 0 1
thinners,may,decrease 1.0 0.000143348623853 1 0 1
thinners,decongestant,allergy 1.0 0.000143348623853 1 0 1
thiazides,may,decrease 1.0 0.000143348623853 1 0 1
thiazide,use,of 1.0 0.000143348623853 1 0 1
thiazide,may,prevent 1.0 0.000143348623853 1 0 1
thiazide,may,increase 1.0 0.000143348623853 1 0 1
thiazide,may,contribute 1.0 0.000143348623853 1 0 1
thiazide,diuretics,the 1.0 0.000143348623853 1 0 1
thiazide,can,be 1.0 0.000143348623853 1 0 1
thiazide,and,reducing 1.0 0.000143348623853 1 0 1
thiazide,and,might 1.0 0.000143348623853 1 0 1
thiazide,and,inhibitors 1.0 0.000143348623853 1 0 1
thiazide,and,even 1.0 0.000143348623853 1 0 1
thiazide,acidic,or 1.0 0.000143348623853 1 0 1
they,reduce,lithiums 1.0 0.000143348623853 1 0 1
they,modify,the 1.0 0.000143348623853 1 0 1
they,may,interfere 1.0 0.000143348623853 1 0 1
they,may,diminish 1.0 0.000143348623853 1 0 1
they,can,potentially 1.0 0.000143348623853 1 0 1
they,are,co-administered 1.0 0.000143348623853 1 0 1
they,are,begun 1.0 0.000143348623853 1 0 1
these,would,be 1.0 0.000143348623853 1 0 1
these,were,given 1.0 0.000143348623853 1 0 1
these,two,drugs 1.0 0.000143348623853 1 0 1
these,three,products 1.0 0.000143348623853 1 0 1
these,subjects,increased 1.0 0.000143348623853 1 0 1
these,studies,indicate 1.0 0.000143348623853 1 0 1
these,studies,do 1.0 0.000143348623853 1 0 1
these,results,would 1.0 0.000143348623853 1 0 1
these,results,do 1.0 0.000143348623853 1 0 1
these,resulting,in 1.0 0.000143348623853 1 0 1
these,reasons,it 1.0 0.000143348623853 1 0 1
these,products,may 1.0 0.000143348623853 1 0 1
these,potentially,resulting 1.0 0.000143348623853 1 0 1
these,patients,whose 1.0 0.000143348623853 1 0 1
these,patients,when 1.0 0.000143348623853 1 0 1
these,patients,demonstrated 1.0 0.000143348623853 1 0 1
these,oral,and 1.0 0.000143348623853 1 0 1
these,medicines,during 1.0 0.000143348623853 1 0 1
these,medicines,central 1.0 0.000143348623853 1 0 1
these,may,be 1.0 0.000143348623853 1 0 1
these,leading,to 1.0 0.000143348623853 1 0 1
these,larger,doses 1.0 0.000143348623853 1 0 1
these,is,likely 1.0 0.000143348623853 1 0 1
these,increases,should 1.0 0.000143348623853 1 0 1
these,have,not 1.0 0.000143348623853 1 0 1
these,have,negative 1.0 0.000143348623853 1 0 1
these,effects,is 1.0 0.000143348623853 1 0 1
these,doses,is 1.0 0.000143348623853 1 0 1
these,disturbances,have 1.0 0.000143348623853 1 0 1
these,data,vardenafil 1.0 0.000143348623853 1 0 1
these,cyp3a4,inducers 1.0 0.000143348623853 1 0 1
these,concomitant,n 1.0 0.000143348623853 1 0 1
these,categories,result 1.0 0.000143348623853 1 0 1
these,are,taken 1.0 0.000143348623853 1 0 1
these,alterations,in 1.0 0.000143348623853 1 0 1
these,agents,ammonium 1.0 0.000143348623853 1 0 1
these,actions,were 1.0 0.000143348623853 1 0 1
therophylline,a,recent 1.0 0.000143348623853 1 0 1
therefore,you,may 1.0 0.000143348623853 1 0 1
therefore,when,sodium 1.0 0.000143348623853 1 0 1
therefore,when,midamor 1.0 0.000143348623853 1 0 1
therefore,when,meclofenamate 1.0 0.000143348623853 1 0 1
therefore,when,inspra 1.0 0.000143348623853 1 0 1
therefore,when,hydrochlorothiazide 1.0 0.000143348623853 1 0 1
therefore,when,edecrin 1.0 0.000143348623853 1 0 1
therefore,when,central 1.0 0.000143348623853 1 0 1
therefore,viracept,should 1.0 0.000143348623853 1 0 1
therefore,use,of 1.0 0.000143348623853 1 0 1
therefore,to,hours 1.0 0.000143348623853 1 0 1
therefore,the,efficacy 1.0 0.000143348623853 1 0 1
therefore,the,concomitant 1.0 0.000143348623853 1 0 1
therefore,the,combined 1.0 0.000143348623853 1 0 1
therefore,such,use 1.0 0.000143348623853 1 0 1
therefore,such,combined 1.0 0.000143348623853 1 0 1
therefore,proton,pump 1.0 0.000143348623853 1 0 1
therefore,prothrombin,time 1.0 0.000143348623853 1 0 1
therefore,potentially,may 1.0 0.000143348623853 1 0 1
therefore,plasma,concentrations 1.0 0.000143348623853 1 0 1
therefore,patients,without 1.0 0.000143348623853 1 0 1
therefore,patients,under 1.0 0.000143348623853 1 0 1
therefore,patients,receiving 1.0 0.000143348623853 1 0 1
therefore,patients,on 1.0 0.000143348623853 1 0 1
therefore,or,other 1.0 0.000143348623853 1 0 1
therefore,may,interfere 1.0 0.000143348623853 1 0 1
therefore,mao,inhibitors 1.0 0.000143348623853 1 0 1
therefore,increased,monitoring 1.0 0.000143348623853 1 0 1
therefore,hormonal,including 1.0 0.000143348623853 1 0 1
therefore,extreme,caution 1.0 0.000143348623853 1 0 1
therefore,cyp3a4,substrates 1.0 0.000143348623853 1 0 1
therefore,consideration,should 1.0 0.000143348623853 1 0 1
therefore,be,observed 1.0 0.000143348623853 1 0 1
therefore,and,should 1.0 0.000143348623853 1 0 1
therefore,and,indocin 1.0 0.000143348623853 1 0 1
therefore,advised,when 1.0 0.000143348623853 1 0 1
therefore,advised,in 1.0 0.000143348623853 1 0 1
therefore,advisable,to 1.0 0.000143348623853 1 0 1
therefore,a,slower 1.0 0.000143348623853 1 0 1
thereby,potentially,aggravating 1.0 0.000143348623853 1 0 1
thereby,decreasing,the 1.0 0.000143348623853 1 0 1
thereafter,and,the 1.0 0.000143348623853 1 0 1
there,were,transient 1.0 0.000143348623853 1 0 1
there,was,about 1.0 0.000143348623853 1 0 1
there,is,some 1.0 0.000143348623853 1 0 1
there,is,insufficient 1.0 0.000143348623853 1 0 1
there,are,reports 1.0 0.000143348623853 1 0 1
there,are,rare 1.0 0.000143348623853 1 0 1
there,are,limited 1.0 0.000143348623853 1 0 1
there,are,conflicting 1.0 0.000143348623853 1 0 1
there,are,case 1.0 0.000143348623853 1 0 1
therapy,with,vioxx 1.0 0.000143348623853 1 0 1
therapy,with,to 1.0 0.000143348623853 1 0 1
therapy,with,small 1.0 0.000143348623853 1 0 1
therapy,with,should 1.0 0.000143348623853 1 0 1
therapy,with,prinivil 1.0 0.000143348623853 1 0 1
therapy,with,orencia 1.0 0.000143348623853 1 0 1
therapy,with,if 1.0 0.000143348623853 1 0 1
therapy,with,hcl 1.0 0.000143348623853 1 0 1
therapy,with,camptosar 1.0 0.000143348623853 1 0 1
therapy,with,betagan 1.0 0.000143348623853 1 0 1
therapy,with,antiplatelet 1.0 0.000143348623853 1 0 1
therapy,with,an 1.0 0.000143348623853 1 0 1
therapy,with,amprenavir 1.0 0.000143348623853 1 0 1
therapy,with,all 1.0 0.000143348623853 1 0 1
therapy,who,have 1.0 0.000143348623853 1 0 1
therapy,when,plasma 1.0 0.000143348623853 1 0 1
therapy,to,insure 1.0 0.000143348623853 1 0 1
therapy,to,avoid 1.0 0.000143348623853 1 0 1
therapy,the,prothrombin 1.0 0.000143348623853 1 0 1
therapy,the,patients 1.0 0.000143348623853 1 0 1
therapy,the,introduction 1.0 0.000143348623853 1 0 1
therapy,such,as 1.0 0.000143348623853 1 0 1
therapy,plasma,levels 1.0 0.000143348623853 1 0 1
therapy,on,the 1.0 0.000143348623853 1 0 1
therapy,of,ponstel 1.0 0.000143348623853 1 0 1
therapy,of,a 1.0 0.000143348623853 1 0 1
therapy,nicotinic,acid 1.0 0.000143348623853 1 0 1
therapy,may,need 1.0 0.000143348623853 1 0 1
therapy,may,exhibit 1.0 0.000143348623853 1 0 1
therapy,it,is 1.0 0.000143348623853 1 0 1
therapy,is,to 1.0 0.000143348623853 1 0 1
therapy,is,required 1.0 0.000143348623853 1 0 1
therapy,is,discontinued 1.0 0.000143348623853 1 0 1
therapy,if,diminished 1.0 0.000143348623853 1 0 1
therapy,free,may 1.0 0.000143348623853 1 0 1
therapy,eg,or 1.0 0.000143348623853 1 0 1
therapy,discontinuation,of 1.0 0.000143348623853 1 0 1
therapy,could,prolong 1.0 0.000143348623853 1 0 1
therapy,are,at 1.0 0.000143348623853 1 0 1
therapy,and,that 1.0 0.000143348623853 1 0 1
therapy,and,had 1.0 0.000143348623853 1 0 1
therapy,and,frequently 1.0 0.000143348623853 1 0 1
therapy,a,decrease 1.0 0.000143348623853 1 0 1
therapy,a,baseline 1.0 0.000143348623853 1 0 1
therapeutic,window,such 1.0 0.000143348623853 1 0 1
therapeutic,supplement,containing 1.0 0.000143348623853 1 0 1
therapeutic,range,in 1.0 0.000143348623853 1 0 1
therapeutic,monitoring,can 1.0 0.000143348623853 1 0 1
therapeutic,index,such 1.0 0.000143348623853 1 0 1
therapeutic,index,including 1.0 0.000143348623853 1 0 1
therapeutic,effects,are 1.0 0.000143348623853 1 0 1
therapeutic,doses,had 1.0 0.000143348623853 1 0 1
therapeutic,dose,of 1.0 0.000143348623853 1 0 1
therapeutic,concentration,monitoring 1.0 0.000143348623853 1 0 1
therapeutic,actions,and 1.0 0.000143348623853 1 0 1
therapeutic,action,of 1.0 0.000143348623853 1 0 1
theoretically,may,potentiate 1.0 0.000143348623853 1 0 1
theoretically,l-arginine,supplements 1.0 0.000143348623853 1 0 1
theoretically,coadministration,of 1.0 0.000143348623853 1 0 1
theoretically,affect,pharmacodynamics 1.0 0.000143348623853 1 0 1
theoretically,adversely,influence 1.0 0.000143348623853 1 0 1
theoretical,risk,of 1.0 0.000143348623853 1 0 1
theophylline-related,side-effects,in 1.0 0.000143348623853 1 0 1
theophylline-related,adverse,effects 1.0 0.000143348623853 1 0 1
theophylline,vioxx,and 1.0 0.000143348623853 1 0 1
theophylline,serum,levels 1.0 0.000143348623853 1 0 1
theophylline,grepafloxacin,is 1.0 0.000143348623853 1 0 1
theophylline,ethinyl,estradiol 1.0 0.000143348623853 1 0 1
theophylline,enoxacin,is 1.0 0.000143348623853 1 0 1
theophylline,decreased,the 1.0 0.000143348623853 1 0 1
theophylline,as,with 1.0 0.000143348623853 1 0 1
theobromine,grepafloxacin,like 1.0 0.000143348623853 1 0 1
theo-dur,key,pharmaceuticals 1.0 0.000143348623853 1 0 1
then,wait,about 1.0 0.000143348623853 1 0 1
then,titrated,according 1.0 0.000143348623853 1 0 1
then,careful,adjustment 1.0 0.000143348623853 1 0 1
their,vasospastic,effects 1.0 0.000143348623853 1 0 1
their,usual,dose 1.0 0.000143348623853 1 0 1
their,tolerance,to 1.0 0.000143348623853 1 0 1
their,similar,mechanism 1.0 0.000143348623853 1 0 1
their,prothrombin,times 1.0 0.000143348623853 1 0 1
their,prothrombin,time 1.0 0.000143348623853 1 0 1
their,metabolism,in 1.0 0.000143348623853 1 0 1
their,dose,or 1.0 0.000143348623853 1 0 1
their,dose,if 1.0 0.000143348623853 1 0 1
their,dosage,when 1.0 0.000143348623853 1 0 1
their,dosage,should 1.0 0.000143348623853 1 0 1
their,combined,use 1.0 0.000143348623853 1 0 1
their,combined,effects 1.0 0.000143348623853 1 0 1
their,coagulation,parameters 1.0 0.000143348623853 1 0 1
their,bioavailability,was 1.0 0.000143348623853 1 0 1
their,additive,effects 1.0 0.000143348623853 1 0 1
the-curve,after,a 1.0 0.000143348623853 1 0 1
the,within,a 1.0 0.000143348623853 1 0 1
the,with,the 1.0 0.000143348623853 1 0 1
the,weekly,dosage 1.0 0.000143348623853 1 0 1
the,week,period 1.0 0.000143348623853 1 0 1
the,volunteers,who 1.0 0.000143348623853 1 0 1
the,vehicle,or 1.0 0.000143348623853 1 0 1
the,vasoconstrictive,action 1.0 0.000143348623853 1 0 1
the,vascular,dilation 1.0 0.000143348623853 1 0 1
the,variability,component 1.0 0.000143348623853 1 0 1
the,usual,prescription 1.0 0.000143348623853 1 0 1
the,usual,daily 1.0 0.000143348623853 1 0 1
the,urine,volume 1.0 0.000143348623853 1 0 1
the,urinary,antiseptic 1.0 0.000143348623853 1 0 1
the,ureidopenicillins,including 1.0 0.000143348623853 1 0 1
the,uptake,inhibitors 1.0 0.000143348623853 1 0 1
the,united,kingdom 1.0 0.000143348623853 1 0 1
the,undesirable,effects 1.0 0.000143348623853 1 0 1
the,underlying,mechanism 1.0 0.000143348623853 1 0 1
the,unbound,by 1.0 0.000143348623853 1 0 1
the,type,caution 1.0 0.000143348623853 1 0 1
the,two,medicines 1.0 0.000143348623853 1 0 1
the,two,hormonal 1.0 0.000143348623853 1 0 1
the,tricyclic,when 1.0 0.000143348623853 1 0 1
the,treatment,with 1.0 0.000143348623853 1 0 1
the,toxicity,may 1.0 0.000143348623853 1 0 1
the,total,clearance 1.0 0.000143348623853 1 0 1
the,tmax,by 1.0 0.000143348623853 1 0 1
the,thioxanthene,and 1.0 0.000143348623853 1 0 1
the,they,should 1.0 0.000143348623853 1 0 1
the,therapy,of 1.0 0.000143348623853 1 0 1
the,therapeutic,effects 1.0 0.000143348623853 1 0 1
the,therapeutic,actions 1.0 0.000143348623853 1 0 1
the,therapeutic,action 1.0 0.000143348623853 1 0 1
the,theophylline-induced,anxiogenic 1.0 0.000143348623853 1 0 1
the,that,alter 1.0 0.000143348623853 1 0 1
the,test,results 1.0 0.000143348623853 1 0 1
the,test,period 1.0 0.000143348623853 1 0 1
the,tca,may 1.0 0.000143348623853 1 0 1
the,tardive,dyskinesia 1.0 0.000143348623853 1 0 1
the,tarceva,dose 1.0 0.000143348623853 1 0 1
the,tablets,as 1.0 0.000143348623853 1 0 1
the,systemic,circulation 1.0 0.000143348623853 1 0 1
the,systemic,administration 1.0 0.000143348623853 1 0 1
the,supraventricular,arrhythmia 1.0 0.000143348623853 1 0 1
the,substantial,interaction 1.0 0.000143348623853 1 0 1
the,striatum,and 1.0 0.000143348623853 1 0 1
the,strength,of 1.0 0.000143348623853 1 0 1
the,stomach,of 1.0 0.000143348623853 1 0 1
the,stomach,may 1.0 0.000143348623853 1 0 1
the,stomach,drugs 1.0 0.000143348623853 1 0 1
the,stimulatory,effects 1.0 0.000143348623853 1 0 1
the,steroidal,agent 1.0 0.000143348623853 1 0 1
the,steadystate,cmin 1.0 0.000143348623853 1 0 1
the,steady-state,serum 1.0 0.000143348623853 1 0 1
the,steady-state,epoxide 1.0 0.000143348623853 1 0 1
the,start,of 1.0 0.000143348623853 1 0 1
the,start,and 1.0 0.000143348623853 1 0 1
the,standard,dose 1.0 0.000143348623853 1 0 1
the,stadol,ns 1.0 0.000143348623853 1 0 1
the,specific,d1 1.0 0.000143348623853 1 0 1
the,sole,method 1.0 0.000143348623853 1 0 1
the,small,effect 1.0 0.000143348623853 1 0 1
the,sleeping,time 1.0 0.000143348623853 1 0 1
the,skeletal,muscle 1.0 0.000143348623853 1 0 1
the,sixth,day 1.0 0.000143348623853 1 0 1
the,sirolimus-diltiazem,interaction 1.0 0.000143348623853 1 0 1
the,severity,of 1.0 0.000143348623853 1 0 1
the,serum,uric 1.0 0.000143348623853 1 0 1
the,serum,sex 1.0 0.000143348623853 1 0 1
the,serum,half-life 1.0 0.000143348623853 1 0 1
the,serum,creatinine 1.0 0.000143348623853 1 0 1
the,serotonergic,effects 1.0 0.000143348623853 1 0 1
the,selective,mao 1.0 0.000143348623853 1 0 1
the,seizure,risk 1.0 0.000143348623853 1 0 1
the,sedative,effects 1.0 0.000143348623853 1 0 1
the,secretory,effect 1.0 0.000143348623853 1 0 1
the,second,day 1.0 0.000143348623853 1 0 1
the,same,evening 1.0 0.000143348623853 1 0 1
the,same,day 1.0 0.000143348623853 1 0 1
the,risks,to 1.0 0.000143348623853 1 0 1
the,risk,factors 1.0 0.000143348623853 1 0 1
the,reversal,of 1.0 0.000143348623853 1 0 1
the,results,suggest 1.0 0.000143348623853 1 0 1
the,results,raise 1.0 0.000143348623853 1 0 1
the,resulting,respiratory 1.0 0.000143348623853 1 0 1
the,resolution,of 1.0 0.000143348623853 1 0 1
the,residual,effects 1.0 0.000143348623853 1 0 1
the,requirements,in 1.0 0.000143348623853 1 0 1
the,requirement,of 1.0 0.000143348623853 1 0 1
the,required,infusion 1.0 0.000143348623853 1 0 1
the,reports,that 1.0 0.000143348623853 1 0 1
the,replication,of 1.0 0.000143348623853 1 0 1
the,renal,toxicity 1.0 0.000143348623853 1 0 1
the,relationship,of 1.0 0.000143348623853 1 0 1
the,reflex,tachycardia 1.0 0.000143348623853 1 0 1
the,reddish,color 1.0 0.000143348623853 1 0 1
the,rebound,hypertension 1.0 0.000143348623853 1 0 1
the,reaction,of 1.0 0.000143348623853 1 0 1
the,rate-decreasing,effects 1.0 0.000143348623853 1 0 1
the,rate,cmax 1.0 0.000143348623853 1 0 1
the,rat,stomach 1.0 0.000143348623853 1 0 1
the,proton,pump 1.0 0.000143348623853 1 0 1
the,protective,effect 1.0 0.000143348623853 1 0 1
the,prophylactic,and 1.0 0.000143348623853 1 0 1
the,pronounced,intersubject 1.0 0.000143348623853 1 0 1
the,probable,benefits 1.0 0.000143348623853 1 0 1
the,prior,administration 1.0 0.000143348623853 1 0 1
the,principal,pathway 1.0 0.000143348623853 1 0 1
the,primary,elimination 1.0 0.000143348623853 1 0 1
the,primary,effect 1.0 0.000143348623853 1 0 1
the,primary,and 1.0 0.000143348623853 1 0 1
the,pressor,response 1.0 0.000143348623853 1 0 1
the,preservative,in 1.0 0.000143348623853 1 0 1
the,prescription,of 1.0 0.000143348623853 1 0 1
the,preparation,causing 1.0 0.000143348623853 1 0 1
the,pr,interval 1.0 0.000143348623853 1 0 1
the,potentiating,action 1.0 0.000143348623853 1 0 1
the,potential,danger 1.0 0.000143348623853 1 0 1
the,potent,cytochrome 1.0 0.000143348623853 1 0 1
the,post-marketing,experience 1.0 0.000143348623853 1 0 1
the,possible,effectiveness 1.0 0.000143348623853 1 0 1
the,possible,complications 1.0 0.000143348623853 1 0 1
the,possible,benefits 1.0 0.000143348623853 1 0 1
the,possibility,nitric 1.0 0.000143348623853 1 0 1
the,positive,inotropic 1.0 0.000143348623853 1 0 1
the,plasma-level,of 1.0 0.000143348623853 1 0 1
the,plasma,level 1.0 0.000143348623853 1 0 1
the,plasma,clearance 1.0 0.000143348623853 1 0 1
the,physician,the 1.0 0.000143348623853 1 0 1
the,physician,may 1.0 0.000143348623853 1 0 1
the,photosensitivity,reaction 1.0 0.000143348623853 1 0 1
the,pharmacologically,predictable 1.0 0.000143348623853 1 0 1
the,pharmacologic,effects 1.0 0.000143348623853 1 0 1
the,pharmacologic,effect 1.0 0.000143348623853 1 0 1
the,ph,of 1.0 0.000143348623853 1 0 1
the,peripheral,vasoconstriction 1.0 0.000143348623853 1 0 1
the,perioperative,period 1.0 0.000143348623853 1 0 1
the,peak,plasma 1.0 0.000143348623853 1 0 1
the,patients,should 1.0 0.000143348623853 1 0 1
the,patients,liver 1.0 0.000143348623853 1 0 1
the,patient,to 1.0 0.000143348623853 1 0 1
the,overall,response 1.0 0.000143348623853 1 0 1
the,orally,disintegrating 1.0 0.000143348623853 1 0 1
the,oral,hormonal 1.0 0.000143348623853 1 0 1
the,oral,doses 1.0 0.000143348623853 1 0 1
the,oral,dose 1.0 0.000143348623853 1 0 1
the,oral,combination 1.0 0.000143348623853 1 0 1
the,or,type 1.0 0.000143348623853 1 0 1
the,or,may 1.0 0.000143348623853 1 0 1
the,onset,and 1.0 0.000143348623853 1 0 1
the,only,clinically 1.0 0.000143348623853 1 0 1
the,occurrence,has 1.0 0.000143348623853 1 0 1
the,normal,variability 1.0 0.000143348623853 1 0 1
the,non-ionized,species 1.0 0.000143348623853 1 0 1
the,non-depolarizing,muscle 1.0 0.000143348623853 1 0 1
the,neuron,blockade 1.0 0.000143348623853 1 0 1
the,net,effects 1.0 0.000143348623853 1 0 1
the,nephrotoxicity,of 1.0 0.000143348623853 1 0 1
the,natriuresis,and 1.0 0.000143348623853 1 0 1
the,nasal,spray 1.0 0.000143348623853 1 0 1
the,nad,dependent 1.0 0.000143348623853 1 0 1
the,myocardium,may 1.0 0.000143348623853 1 0 1
the,myasthenic,patient 1.0 0.000143348623853 1 0 1
the,muscle,to 1.0 0.000143348623853 1 0 1
the,muscle,in 1.0 0.000143348623853 1 0 1
the,mptp-induced,neuronal 1.0 0.000143348623853 1 0 1
the,mouth,and 1.0 0.000143348623853 1 0 1
the,most,commonly 1.0 0.000143348623853 1 0 1
the,mixing,of 1.0 0.000143348623853 1 0 1
the,mitogenic,effect 1.0 0.000143348623853 1 0 1
the,mitogenic,activity 1.0 0.000143348623853 1 0 1
the,mg,orally 1.0 0.000143348623853 1 0 1
the,mg,h 1.0 0.000143348623853 1 0 1
the,metabolism,or 1.0 0.000143348623853 1 0 1
the,median,of 1.0 0.000143348623853 1 0 1
the,mechanism,under 1.0 0.000143348623853 1 0 1
the,measurable,limit 1.0 0.000143348623853 1 0 1
the,mean,qt 1.0 0.000143348623853 1 0 1
the,mean,percentage 1.0 0.000143348623853 1 0 1
the,mean,half-life 1.0 0.000143348623853 1 0 1
the,mean,clearances 1.0 0.000143348623853 1 0 1
the,mean,apparent 1.0 0.000143348623853 1 0 1
the,may,occur 1.0 0.000143348623853 1 0 1
the,maximum,approved 1.0 0.000143348623853 1 0 1
the,mao,inhibitor 1.0 0.000143348623853 1 0 1
the,manifestation,of 1.0 0.000143348623853 1 0 1
the,major,are 1.0 0.000143348623853 1 0 1
the,maintenance,dose 1.0 0.000143348623853 1 0 1
the,main,hemostatic 1.0 0.000143348623853 1 0 1
the,macrolide,class 1.0 0.000143348623853 1 0 1
the,lowest,recommended 1.0 0.000143348623853 1 0 1
the,lower,rate 1.0 0.000143348623853 1 0 1
the,lower,intestine 1.0 0.000143348623853 1 0 1
the,lower,end 1.0 0.000143348623853 1 0 1
the,loss,of 1.0 0.000143348623853 1 0 1
the,literature,suggest 1.0 0.000143348623853 1 0 1
the,literature,revealed 1.0 0.000143348623853 1 0 1
the,levulan,kerastick 1.0 0.000143348623853 1 0 1
the,levels,or 1.0 0.000143348623853 1 0 1
the,leukopenic,activity 1.0 0.000143348623853 1 0 1
the,less,active 1.0 0.000143348623853 1 0 1
the,ld50,of 1.0 0.000143348623853 1 0 1
the,latter,agents 1.0 0.000143348623853 1 0 1
the,last,subcutaneous 1.0 0.000143348623853 1 0 1
the,last,intravenous 1.0 0.000143348623853 1 0 1
the,label,should 1.0 0.000143348623853 1 0 1
the,known,property 1.0 0.000143348623853 1 0 1
the,known,cyp3a4 1.0 0.000143348623853 1 0 1
the,judgment,of 1.0 0.000143348623853 1 0 1
the,iv,dose 1.0 0.000143348623853 1 0 1
the,introduction,of 1.0 0.000143348623853 1 0 1
the,intravenous,injection 1.0 0.000143348623853 1 0 1
the,intracellular,exposure 1.0 0.000143348623853 1 0 1
the,intestine,thus 1.0 0.000143348623853 1 0 1
the,interference,with 1.0 0.000143348623853 1 0 1
the,interactions,observed 1.0 0.000143348623853 1 0 1
the,interaction,study 1.0 0.000143348623853 1 0 1
the,interaction,observed 1.0 0.000143348623853 1 0 1
the,interaction,is 1.0 0.000143348623853 1 0 1
the,intake,of 1.0 0.000143348623853 1 0 1
the,initiate,therapy 1.0 0.000143348623853 1 0 1
the,initial,release 1.0 0.000143348623853 1 0 1
the,initial,presentation 1.0 0.000143348623853 1 0 1
the,initial,dosage 1.0 0.000143348623853 1 0 1
the,inhibitory,effects 1.0 0.000143348623853 1 0 1
the,inhibitory,effect 1.0 0.000143348623853 1 0 1
the,inhibitory,activity 1.0 0.000143348623853 1 0 1
the,ingested,being 1.0 0.000143348623853 1 0 1
the,increased,potential 1.0 0.000143348623853 1 0 1
the,incidence,or 1.0 0.000143348623853 1 0 1
the,implication,that 1.0 0.000143348623853 1 0 1
the,immediate,release 1.0 0.000143348623853 1 0 1
the,hypotension,seen 1.0 0.000143348623853 1 0 1
the,hypotension,induced 1.0 0.000143348623853 1 0 1
the,hypotension,caused 1.0 0.000143348623853 1 0 1
the,hypoglycemic,effect 1.0 0.000143348623853 1 0 1
the,hyperuricemia,present 1.0 0.000143348623853 1 0 1
the,hypertensive,response 1.0 0.000143348623853 1 0 1
the,hydantoin,antiepileptic 1.0 0.000143348623853 1 0 1
the,ht3,antagonist 1.0 0.000143348623853 1 0 1
the,hmg-coa,reductase 1.0 0.000143348623853 1 0 1
the,higher,serum 1.0 0.000143348623853 1 0 1
the,high-dose,mg 1.0 0.000143348623853 1 0 1
the,hepatoxicity,of 1.0 0.000143348623853 1 0 1
the,heart,rate 1.0 0.000143348623853 1 0 1
the,has,reduced 1.0 0.000143348623853 1 0 1
the,has,on 1.0 0.000143348623853 1 0 1
the,half-life,by 1.0 0.000143348623853 1 0 1
the,groups,receiving 1.0 0.000143348623853 1 0 1
the,gi,tract 1.0 0.000143348623853 1 0 1
the,gaba-ergic,system 1.0 0.000143348623853 1 0 1
the,function,of 1.0 0.000143348623853 1 0 1
the,from,protein 1.0 0.000143348623853 1 0 1
the,following,use 1.0 0.000143348623853 1 0 1
the,following,precautions 1.0 0.000143348623853 1 0 1
the,following,medicines 1.0 0.000143348623853 1 0 1
the,following,macrolide 1.0 0.000143348623853 1 0 1
the,following,eye 1.0 0.000143348623853 1 0 1
the,following,cisplatin 1.0 0.000143348623853 1 0 1
the,following,adverse 1.0 0.000143348623853 1 0 1
the,following,adrenocorticoids 1.0 0.000143348623853 1 0 1
the,following,acetazolamide 1.0 0.000143348623853 1 0 1
the,fluoride,and 1.0 0.000143348623853 1 0 1
the,first,sixty 1.0 0.000143348623853 1 0 1
the,fed,state 1.0 0.000143348623853 1 0 1
the,exposure,auc 1.0 0.000143348623853 1 0 1
the,ethanolysis,reaction 1.0 0.000143348623853 1 0 1
the,enzyme-inducing,properties 1.0 0.000143348623853 1 0 1
the,enzymatic,oxidation 1.0 0.000143348623853 1 0 1
the,enkephalinergic,neurons 1.0 0.000143348623853 1 0 1
the,endotoxin-treated,rats 1.0 0.000143348623853 1 0 1
the,elimination,half 1.0 0.000143348623853 1 0 1
the,elderly,may 1.0 0.000143348623853 1 0 1
the,elderly,in 1.0 0.000143348623853 1 0 1
the,effects,may 1.0 0.000143348623853 1 0 1
the,effect,should 1.0 0.000143348623853 1 0 1
the,effect,is 1.0 0.000143348623853 1 0 1
the,ed50,of 1.0 0.000143348623853 1 0 1
the,ecg,changes 1.0 0.000143348623853 1 0 1
the,early,components 1.0 0.000143348623853 1 0 1
the,during,and 1.0 0.000143348623853 1 0 1
the,duration,but 1.0 0.000143348623853 1 0 1
the,drug,is 1.0 0.000143348623853 1 0 1
the,dosing,of 1.0 0.000143348623853 1 0 1
the,dose,will 1.0 0.000143348623853 1 0 1
the,dose,reduced 1.0 0.000143348623853 1 0 1
the,dose,range 1.0 0.000143348623853 1 0 1
the,dose,adjustment 1.0 0.000143348623853 1 0 1
the,dosage,range 1.0 0.000143348623853 1 0 1
the,dosage,are 1.0 0.000143348623853 1 0 1
the,dopaminergic,renal 1.0 0.000143348623853 1 0 1
the,dmpge2,mg 1.0 0.000143348623853 1 0 1
the,divided,attention 1.0 0.000143348623853 1 0 1
the,diuretic,natriuretic 1.0 0.000143348623853 1 0 1
the,disruptive,effects 1.0 0.000143348623853 1 0 1
the,discontinuance,of 1.0 0.000143348623853 1 0 1
the,digit,symbol 1.0 0.000143348623853 1 0 1
the,diet,for 1.0 0.000143348623853 1 0 1
the,desired,lactulose-induced 1.0 0.000143348623853 1 0 1
the,depth,of 1.0 0.000143348623853 1 0 1
the,depressant,effect 1.0 0.000143348623853 1 0 1
the,decreases,in 1.0 0.000143348623853 1 0 1
the,day,of 1.0 0.000143348623853 1 0 1
the,danger,inherent 1.0 0.000143348623853 1 0 1
the,cytochrome,p450iiia4 1.0 0.000143348623853 1 0 1
the,cyp3a4,pathway 1.0 0.000143348623853 1 0 1
the,cyp2c9,isoenzyme 1.0 0.000143348623853 1 0 1
the,cyp2c9,catalyzed 1.0 0.000143348623853 1 0 1
the,curve,at 1.0 0.000143348623853 1 0 1
the,curve,after 1.0 0.000143348623853 1 0 1
the,curariform,effect 1.0 0.000143348623853 1 0 1
the,cross-reactivity,of 1.0 0.000143348623853 1 0 1
the,contrary,and 1.0 0.000143348623853 1 0 1
the,contraceptive,effect 1.0 0.000143348623853 1 0 1
the,consumption,of 1.0 0.000143348623853 1 0 1
the,concomitant,or 1.0 0.000143348623853 1 0 1
the,concomitant,intravenous 1.0 0.000143348623853 1 0 1
the,conclusion,that 1.0 0.000143348623853 1 0 1
the,committed,step 1.0 0.000143348623853 1 0 1
the,cognitive,and 1.0 0.000143348623853 1 0 1
the,coat-core,formulation 1.0 0.000143348623853 1 0 1
the,coadministration,with 1.0 0.000143348623853 1 0 1
the,cns-impairing,effects 1.0 0.000143348623853 1 0 1
the,cns-depressive,effects 1.0 0.000143348623853 1 0 1
the,cns-depressive,effect 1.0 0.000143348623853 1 0 1
the,cns-depressant,action 1.0 0.000143348623853 1 0 1
the,cns,effects 1.0 0.000143348623853 1 0 1
the,cns,depressive 1.0 0.000143348623853 1 0 1
the,cmax,by 1.0 0.000143348623853 1 0 1
the,cmax,auc 1.0 0.000143348623853 1 0 1
the,clinician,should 1.0 0.000143348623853 1 0 1
the,clinical,trials 1.0 0.000143348623853 1 0 1
the,chemical,resemblance 1.0 0.000143348623853 1 0 1
the,central,syndrome 1.0 0.000143348623853 1 0 1
the,central,effects 1.0 0.000143348623853 1 0 1
the,cautious,initiation 1.0 0.000143348623853 1 0 1
the,case-control,and 1.0 0.000143348623853 1 0 1
the,case,that 1.0 0.000143348623853 1 0 1
the,cardiovascular,action 1.0 0.000143348623853 1 0 1
the,carbachol-stimulated,intracellular 1.0 0.000143348623853 1 0 1
the,bumetanide-induced,increase 1.0 0.000143348623853 1 0 1
the,brief,psychiatric 1.0 0.000143348623853 1 0 1
the,body,via 1.0 0.000143348623853 1 0 1
the,blood-sugar,reducing 1.0 0.000143348623853 1 0 1
the,blood,which 1.0 0.000143348623853 1 0 1
the,blood,glucose 1.0 0.000143348623853 1 0 1
the,blood,auc0-12 1.0 0.000143348623853 1 0 1
the,blood,and 1.0 0.000143348623853 1 0 1
the,bleeding,tendency 1.0 0.000143348623853 1 0 1
the,biological,and 1.0 0.000143348623853 1 0 1
the,biologic,half-life 1.0 0.000143348623853 1 0 1
the,bioavailabillty,when 1.0 0.000143348623853 1 0 1
the,beta-adrenergic,blocker 1.0 0.000143348623853 1 0 1
the,beta,blocker 1.0 0.000143348623853 1 0 1
the,benzodiazepine,class 1.0 0.000143348623853 1 0 1
the,benefits,and 1.0 0.000143348623853 1 0 1
the,benefit,of 1.0 0.000143348623853 1 0 1
the,bad,general 1.0 0.000143348623853 1 0 1
the,bactericidal,effect 1.0 0.000143348623853 1 0 1
the,bactercidal,effect 1.0 0.000143348623853 1 0 1
the,b-blocking,agent 1.0 0.000143348623853 1 0 1
the,auc0-120hr,by 1.0 0.000143348623853 1 0 1
the,auc,for 1.0 0.000143348623853 1 0 1
the,auc,by 1.0 0.000143348623853 1 0 1
the,auc,but 1.0 0.000143348623853 1 0 1
the,auc,after 1.0 0.000143348623853 1 0 1
the,atac,trial 1.0 0.000143348623853 1 0 1
the,anxiogenic,effects 1.0 0.000143348623853 1 0 1
the,antitumor,effectiveness 1.0 0.000143348623853 1 0 1
the,antithrombotic,agent 1.0 0.000143348623853 1 0 1
the,antimuscarinic,effects 1.0 0.000143348623853 1 0 1
the,antimicrobial,combinations 1.0 0.000143348623853 1 0 1
the,antiepileptic,effect 1.0 0.000143348623853 1 0 1
the,antiedematous,action 1.0 0.000143348623853 1 0 1
the,antidepressant,single 1.0 0.000143348623853 1 0 1
the,anticoagulation,effects 1.0 0.000143348623853 1 0 1
the,anticholinesterase,effect 1.0 0.000143348623853 1 0 1
the,anti-inflammatory,activity 1.0 0.000143348623853 1 0 1
the,anti-glaucoma,action 1.0 0.000143348623853 1 0 1
the,antagonism,of 1.0 0.000143348623853 1 0 1
the,anorectic,and 1.0 0.000143348623853 1 0 1
the,and,reduce 1.0 0.000143348623853 1 0 1
the,and,increased 1.0 0.000143348623853 1 0 1
the,and,effects 1.0 0.000143348623853 1 0 1
the,and,classes 1.0 0.000143348623853 1 0 1
the,and,and 1.0 0.000143348623853 1 0 1
the,analgesic,effect 1.0 0.000143348623853 1 0 1
the,alternate,sequence 1.0 0.000143348623853 1 0 1
the,alkaloid,class 1.0 0.000143348623853 1 0 1
the,agents,employed 1.0 0.000143348623853 1 0 1
the,advice,of 1.0 0.000143348623853 1 0 1
the,added,beta-adrenergic 1.0 0.000143348623853 1 0 1
the,acute,locomotor 1.0 0.000143348623853 1 0 1
the,active,sulfide 1.0 0.000143348623853 1 0 1
the,active,isomer 1.0 0.000143348623853 1 0 1
the,above,effects 1.0 0.000143348623853 1 0 1
the,a-v,node 1.0 0.000143348623853 1 0 1
that,zebeta,be 1.0 0.000143348623853 1 0 1
that,your,health 1.0 0.000143348623853 1 0 1
that,you,need 1.0 0.000143348623853 1 0 1
that,you,are 1.0 0.000143348623853 1 0 1
that,when,compared 1.0 0.000143348623853 1 0 1
that,when,a 1.0 0.000143348623853 1 0 1
that,were,in 1.0 0.000143348623853 1 0 1
that,was,responsible 1.0 0.000143348623853 1 0 1
that,was,abolished 1.0 0.000143348623853 1 0 1
that,variable,effects 1.0 0.000143348623853 1 0 1
that,use,during 1.0 0.000143348623853 1 0 1
that,undergo,enterohepatic 1.0 0.000143348623853 1 0 1
that,there,may 1.0 0.000143348623853 1 0 1
that,the,prophylactic 1.0 0.000143348623853 1 0 1
that,the,potent 1.0 0.000143348623853 1 0 1
that,the,oral 1.0 0.000143348623853 1 0 1
that,the,neuromuscular 1.0 0.000143348623853 1 0 1
that,the,incidence 1.0 0.000143348623853 1 0 1
that,the,hepatoxicity 1.0 0.000143348623853 1 0 1
that,the,ethanolysis 1.0 0.000143348623853 1 0 1
that,the,cardiovascular 1.0 0.000143348623853 1 0 1
that,the,analgesic 1.0 0.000143348623853 1 0 1
that,the,administration 1.0 0.000143348623853 1 0 1
that,the,addition 1.0 0.000143348623853 1 0 1
that,the,acute 1.0 0.000143348623853 1 0 1
that,the,action 1.0 0.000143348623853 1 0 1
that,the,absorption 1.0 0.000143348623853 1 0 1
that,tam,significantly 1.0 0.000143348623853 1 0 1
that,strongly,induce 1.0 0.000143348623853 1 0 1
that,significantly,inhibited 1.0 0.000143348623853 1 0 1
that,sensitize,the 1.0 0.000143348623853 1 0 1
that,results,of 1.0 0.000143348623853 1 0 1
that,results,in 1.0 0.000143348623853 1 0 1
that,resulted,in 1.0 0.000143348623853 1 0 1
that,requirements,for 1.0 0.000143348623853 1 0 1
that,renal,function 1.0 0.000143348623853 1 0 1
that,reduce,the 1.0 0.000143348623853 1 0 1
that,range,of 1.0 0.000143348623853 1 0 1
that,protects,against 1.0 0.000143348623853 1 0 1
that,prolongs,the 1.0 0.000143348623853 1 0 1
that,patients,on 1.0 0.000143348623853 1 0 1
that,oral,markedly 1.0 0.000143348623853 1 0 1
that,oral,inhibits 1.0 0.000143348623853 1 0 1
that,oral,antagonists 1.0 0.000143348623853 1 0 1
that,or,co-administration 1.0 0.000143348623853 1 0 1
that,or,and 1.0 0.000143348623853 1 0 1
that,of,users 1.0 0.000143348623853 1 0 1
that,of,urate 1.0 0.000143348623853 1 0 1
that,of,most 1.0 0.000143348623853 1 0 1
that,obtained,with 1.0 0.000143348623853 1 0 1
that,observed,with 1.0 0.000143348623853 1 0 1
that,not,be 1.0 0.000143348623853 1 0 1
that,nonabsorbable,given 1.0 0.000143348623853 1 0 1
that,no,change 1.0 0.000143348623853 1 0 1
that,necessitated,changes 1.0 0.000143348623853 1 0 1
that,mptp,induced 1.0 0.000143348623853 1 0 1
that,modulates,in 1.0 0.000143348623853 1 0 1
that,might,increase 1.0 0.000143348623853 1 0 1
that,mg,kg 1.0 0.000143348623853 1 0 1
that,meth,caused 1.0 0.000143348623853 1 0 1
that,may,selectively 1.0 0.000143348623853 1 0 1
that,may,react 1.0 0.000143348623853 1 0 1
that,may,potentiate 1.0 0.000143348623853 1 0 1
that,may,inhibit 1.0 0.000143348623853 1 0 1
that,may,induce 1.0 0.000143348623853 1 0 1
that,may,impair 1.0 0.000143348623853 1 0 1
that,may,either 1.0 0.000143348623853 1 0 1
that,may,depress 1.0 0.000143348623853 1 0 1
that,lower,seizure 1.0 0.000143348623853 1 0 1
that,lodine,can 1.0 0.000143348623853 1 0 1
that,like,other 1.0 0.000143348623853 1 0 1
that,levels,may 1.0 0.000143348623853 1 0 1
that,itraconazole,enhances 1.0 0.000143348623853 1 0 1
that,it,is 1.0 0.000143348623853 1 0 1
that,iressa,may 1.0 0.000143348623853 1 0 1
that,interferes,with 1.0 0.000143348623853 1 0 1
that,inhibits,the 1.0 0.000143348623853 1 0 1
that,inhibits,metabolism 1.0 0.000143348623853 1 0 1
that,inhibit,both 1.0 0.000143348623853 1 0 1
that,ingestion,may 1.0 0.000143348623853 1 0 1
that,induce,inhibit 1.0 0.000143348623853 1 0 1
that,induce,hepatic 1.0 0.000143348623853 1 0 1
that,induce,cyp 1.0 0.000143348623853 1 0 1
that,increased,the 1.0 0.000143348623853 1 0 1
that,increase,or 1.0 0.000143348623853 1 0 1
that,include,extreme 1.0 0.000143348623853 1 0 1
that,in,most 1.0 0.000143348623853 1 0 1
that,in,addition 1.0 0.000143348623853 1 0 1
that,if,casodex 1.0 0.000143348623853 1 0 1
that,identify,chromatin 1.0 0.000143348623853 1 0 1
that,have,significant 1.0 0.000143348623853 1 0 1
that,have,secondary 1.0 0.000143348623853 1 0 1
that,have,demonstrated 1.0 0.000143348623853 1 0 1
that,has,been 1.0 0.000143348623853 1 0 1
that,haldol,may 1.0 0.000143348623853 1 0 1
that,given,with 1.0 0.000143348623853 1 0 1
that,gets,absorbed 1.0 0.000143348623853 1 0 1
that,fluvoxamine,tablets 1.0 0.000143348623853 1 0 1
that,exposure,to 1.0 0.000143348623853 1 0 1
that,exposure,of 1.0 0.000143348623853 1 0 1
that,elspar,can 1.0 0.000143348623853 1 0 1
that,ecg,and 1.0 0.000143348623853 1 0 1
that,dose,adjustment 1.0 0.000143348623853 1 0 1
that,dopamine-induced,ventricular 1.0 0.000143348623853 1 0 1
that,dopamine,antagonists 1.0 0.000143348623853 1 0 1
that,discontinuation,of 1.0 0.000143348623853 1 0 1
that,cyp1a2,is 1.0 0.000143348623853 1 0 1
that,could,enhance 1.0 0.000143348623853 1 0 1
that,contain,deet 1.0 0.000143348623853 1 0 1
that,concurrent,use 1.0 0.000143348623853 1 0 1
that,concurrent,administration 1.0 0.000143348623853 1 0 1
that,concomitan,administration 1.0 0.000143348623853 1 0 1
that,concentrations,be 1.0 0.000143348623853 1 0 1
that,clorazepate,dipotassium 1.0 0.000143348623853 1 0 1
that,chronic,concurrent 1.0 0.000143348623853 1 0 1
that,cause,significant 1.0 0.000143348623853 1 0 1
that,can,reduce 1.0 0.000143348623853 1 0 1
that,can,prolong 1.0 0.000143348623853 1 0 1
that,can,potentiate 1.0 0.000143348623853 1 0 1
that,can,deplete 1.0 0.000143348623853 1 0 1
that,can,be 1.0 0.000143348623853 1 0 1
that,buspirone,hydrochloride 1.0 0.000143348623853 1 0 1
that,both,and 1.0 0.000143348623853 1 0 1
that,be,taken 1.0 0.000143348623853 1 0 1
that,at,these 1.0 0.000143348623853 1 0 1
that,at,therapeutic 1.0 0.000143348623853 1 0 1
that,are,on 1.0 0.000143348623853 1 0 1
that,are,extensively 1.0 0.000143348623853 1 0 1
that,are,cytochrome 1.0 0.000143348623853 1 0 1
that,are,cyp3a4 1.0 0.000143348623853 1 0 1
that,are,cyp 1.0 0.000143348623853 1 0 1
that,are,actively 1.0 0.000143348623853 1 0 1
that,antagonized,evidently 1.0 0.000143348623853 1 0 1
that,and,significantly 1.0 0.000143348623853 1 0 1
that,and,oral 1.0 0.000143348623853 1 0 1
that,although,did 1.0 0.000143348623853 1 0 1
that,alter,platelet 1.0 0.000143348623853 1 0 1
that,alter,gastrointestinal 1.0 0.000143348623853 1 0 1
that,also,markedly 1.0 0.000143348623853 1 0 1
that,affect,hepatic 1.0 0.000143348623853 1 0 1
that,administration,attenuates 1.0 0.000143348623853 1 0 1
that,adl,prevents 1.0 0.000143348623853 1 0 1
that,act,on 1.0 0.000143348623853 1 0 1
that,accompany,high 1.0 0.000143348623853 1 0 1
that,a,smaller 1.0 0.000143348623853 1 0 1
that,a,small 1.0 0.000143348623853 1 0 1
that,a,satisfactory 1.0 0.000143348623853 1 0 1
that,a,potent 1.0 0.000143348623853 1 0 1
than,when,these 1.0 0.000143348623853 1 0 1
than,when,is 1.0 0.000143348623853 1 0 1
than,weeks,may 1.0 0.000143348623853 1 0 1
than,usual,and 1.0 0.000143348623853 1 0 1
than,users,of 1.0 0.000143348623853 1 0 1
than,two-second,increase 1.0 0.000143348623853 1 0 1
than,two-fold,of 1.0 0.000143348623853 1 0 1
than,two-fold,increases 1.0 0.000143348623853 1 0 1
than,times,higher 1.0 0.000143348623853 1 0 1
than,those,seen 1.0 0.000143348623853 1 0 1
than,those,required 1.0 0.000143348623853 1 0 1
than,those,receiving 1.0 0.000143348623853 1 0 1
than,reduction,in 1.0 0.000143348623853 1 0 1
than,recommended,doses 1.0 0.000143348623853 1 0 1
than,pediatrics,mean 1.0 0.000143348623853 1 0 1
than,one-tenth,of 1.0 0.000143348623853 1 0 1
than,might,be 1.0 0.000143348623853 1 0 1
than,mg,day 1.0 0.000143348623853 1 0 1
than,in,patients 1.0 0.000143348623853 1 0 1
than,for,other 1.0 0.000143348623853 1 0 1
than,for,exjade 1.0 0.000143348623853 1 0 1
than,for,auc 1.0 0.000143348623853 1 0 1
than,fold,increases 1.0 0.000143348623853 1 0 1
than,expected,antidepressant 1.0 0.000143348623853 1 0 1
than,and,a 1.0 0.000143348623853 1 0 1
than,additive,effects 1.0 0.000143348623853 1 0 1
th,day,provided 1.0 0.000143348623853 1 0 1
tetracyclines,since,both 1.0 0.000143348623853 1 0 1
tetracyclines,concomitant,treatment 1.0 0.000143348623853 1 0 1
tests,the,combination 1.0 0.000143348623853 1 0 1
testing,should,be 1.0 0.000143348623853 1 0 1
testing,and,reaction 1.0 0.000143348623853 1 0 1
test,results,and 1.0 0.000143348623853 1 0 1
test,period,will 1.0 0.000143348623853 1 0 1
test,for,hours 1.0 0.000143348623853 1 0 1
test,dsst,symbol 1.0 0.000143348623853 1 0 1
test,and,the 1.0 0.000143348623853 1 0 1
terminated,the,b-blocking 1.0 0.000143348623853 1 0 1
terminal,half-life,of 1.0 0.000143348623853 1 0 1
terminal,half-life,increased 1.0 0.000143348623853 1 0 1
terminal,half-life,decreased 1.0 0.000143348623853 1 0 1
termed,serotonin,syndrome 1.0 0.000143348623853 1 0 1
term,therapy,after 1.0 0.000143348623853 1 0 1
terfenadine,and,are 1.0 0.000143348623853 1 0 1
tendency,to,cause 1.0 0.000143348623853 1 0 1
tendency,to,antagonize 1.0 0.000143348623853 1 0 1
tendency,produced,by 1.0 0.000143348623853 1 0 1
tended,to,be 1.0 0.000143348623853 1 0 1
ten-subject,study,coadministration 1.0 0.000143348623853 1 0 1
temporarily,suspending,use 1.0 0.000143348623853 1 0 1
temporarily,reduced,creatinine 1.0 0.000143348623853 1 0 1
temporarily,raise,serum 1.0 0.000143348623853 1 0 1
temporarily,mask,the 1.0 0.000143348623853 1 0 1
temporarily,discontinued,or 1.0 0.000143348623853 1 0 1
temperature,was,decreased 1.0 0.000143348623853 1 0 1
tegretol,trileptal,topamax 1.0 0.000143348623853 1 0 1
tcatreatment,in,a 1.0 0.000143348623853 1 0 1
tcas,such,as 1.0 0.000143348623853 1 0 1
tcas,decrease,the 1.0 0.000143348623853 1 0 1
tca,may,need 1.0 0.000143348623853 1 0 1
tca,is,co-administered 1.0 0.000143348623853 1 0 1
tca,concentrations,may 1.0 0.000143348623853 1 0 1
tc,suspension,were 1.0 0.000143348623853 1 0 1
tc,suspension,reduces 1.0 0.000143348623853 1 0 1
tbars,levels,in 1.0 0.000143348623853 1 0 1
taxol,was,given 1.0 0.000143348623853 1 0 1
taxol,mg,m2 1.0 0.000143348623853 1 0 1
targretin,capsules,is 1.0 0.000143348623853 1 0 1
targretin,capsules,and 1.0 0.000143348623853 1 0 1
tardive,dyskinesia,side 1.0 0.000143348623853 1 0 1
tarceva,with,and 1.0 0.000143348623853 1 0 1
tarceva,dose,is 1.0 0.000143348623853 1 0 1
tambocor,unless,in 1.0 0.000143348623853 1 0 1
tambocor,to,healthy 1.0 0.000143348623853 1 0 1
tambocor,are,unknown 1.0 0.000143348623853 1 0 1
tambocor,and,on 1.0 0.000143348623853 1 0 1
tambocor,and,concurrently 1.0 0.000143348623853 1 0 1
tam,significantly,potentiates 1.0 0.000143348623853 1 0 1
tam,enhances,the 1.0 0.000143348623853 1 0 1
taking,while,taking 1.0 0.000143348623853 1 0 1
taking,while,on 1.0 0.000143348623853 1 0 1
taking,when,is 1.0 0.000143348623853 1 0 1
taking,vitamin,supplements 1.0 0.000143348623853 1 0 1
taking,vioxx,concomitantly 1.0 0.000143348623853 1 0 1
taking,tricyclic,in 1.0 0.000143348623853 1 0 1
taking,to,whom 1.0 0.000143348623853 1 0 1
taking,therapy,are 1.0 0.000143348623853 1 0 1
taking,the,effect 1.0 0.000143348623853 1 0 1
taking,tell,your 1.0 0.000143348623853 1 0 1
taking,tarceva,with 1.0 0.000143348623853 1 0 1
taking,since,the 1.0 0.000143348623853 1 0 1
taking,since,nevirapinemay 1.0 0.000143348623853 1 0 1
taking,revia,may 1.0 0.000143348623853 1 0 1
taking,prothrombin,time 1.0 0.000143348623853 1 0 1
taking,other,psychoactive 1.0 0.000143348623853 1 0 1
taking,or,within 1.0 0.000143348623853 1 0 1
taking,or,who 1.0 0.000143348623853 1 0 1
taking,or,may 1.0 0.000143348623853 1 0 1
taking,monoamine,oxidase 1.0 0.000143348623853 1 0 1
taking,mg,three 1.0 0.000143348623853 1 0 1
taking,mg,day 1.0 0.000143348623853 1 0 1
taking,mg,and 1.0 0.000143348623853 1 0 1
taking,mao,inhibitors 1.0 0.000143348623853 1 0 1
taking,lexapro,is 1.0 0.000143348623853 1 0 1
taking,labetalol,hcl 1.0 0.000143348623853 1 0 1
taking,coumarin-derivative,concomitantly 1.0 0.000143348623853 1 0 1
taking,concurrent,and 1.0 0.000143348623853 1 0 1
taking,celebrex,concomitantly 1.0 0.000143348623853 1 0 1
taking,both,and 1.0 0.000143348623853 1 0 1
taking,both,agents 1.0 0.000143348623853 1 0 1
taking,bextra,concomitantly 1.0 0.000143348623853 1 0 1
taking,beta,adrenergic 1.0 0.000143348623853 1 0 1
taking,another,class 1.0 0.000143348623853 1 0 1
taking,and,together 1.0 0.000143348623853 1 0 1
taking,and,a 1.0 0.000143348623853 1 0 1
taking,an,eg 1.0 0.000143348623853 1 0 1
taking,amyl,nitrite 1.0 0.000143348623853 1 0 1
taking,aminosalicylic,acid 1.0 0.000143348623853 1 0 1
taking,acarbose,due 1.0 0.000143348623853 1 0 1
taking,acamprosate,concomitantly 1.0 0.000143348623853 1 0 1
taking,a,rauwolfia 1.0 0.000143348623853 1 0 1
taking,a,or 1.0 0.000143348623853 1 0 1
taken,with,other 1.0 0.000143348623853 1 0 1
taken,with,food 1.0 0.000143348623853 1 0 1
taken,when,the 1.0 0.000143348623853 1 0 1
taken,when,enablex 1.0 0.000143348623853 1 0 1
taken,orally,imidazole 1.0 0.000143348623853 1 0 1
taken,on,the 1.0 0.000143348623853 1 0 1
taken,in,overdose 1.0 0.000143348623853 1 0 1
taken,if,is 1.0 0.000143348623853 1 0 1
taken,concomitantly,by 1.0 0.000143348623853 1 0 1
taken,closely,in 1.0 0.000143348623853 1 0 1
taken,and,hours 1.0 0.000143348623853 1 0 1
take,tricor,at 1.0 0.000143348623853 1 0 1
take,first,and 1.0 0.000143348623853 1 0 1
take,by,mouth 1.0 0.000143348623853 1 0 1
take,and,oral 1.0 0.000143348623853 1 0 1
take,a,vitamin 1.0 0.000143348623853 1 0 1
tail-flick,response,induced 1.0 0.000143348623853 1 0 1
tagamet,mg,q 1.0 0.000143348623853 1 0 1
tagamet,apparently,through 1.0 0.000143348623853 1 0 1
tadalafil,dose,should 1.0 0.000143348623853 1 0 1
tachypnea,lethargy,and 1.0 0.000143348623853 1 0 1
tachycardia,was,significantly 1.0 0.000143348623853 1 0 1
tachycardia,ventricular,fibrulation 1.0 0.000143348623853 1 0 1
tachycardia,produced,by 1.0 0.000143348623853 1 0 1
tachycardia,induced,by 1.0 0.000143348623853 1 0 1
tachycardia,in,the 1.0 0.000143348623853 1 0 1
tachycardia,have,been 1.0 0.000143348623853 1 0 1
tachycardia,dryness,of 1.0 0.000143348623853 1 0 1
tablets,with,or 1.0 0.000143348623853 1 0 1
tablets,with,may 1.0 0.000143348623853 1 0 1
tablets,usp,or 1.0 0.000143348623853 1 0 1
tablets,to,patients 1.0 0.000143348623853 1 0 1
tablets,the,initial 1.0 0.000143348623853 1 0 1
tablets,the,including 1.0 0.000143348623853 1 0 1
tablets,the,hypoglycemic 1.0 0.000143348623853 1 0 1
tablets,simultaneous,administration 1.0 0.000143348623853 1 0 1
tablets,should,have 1.0 0.000143348623853 1 0 1
tablets,reduces,the 1.0 0.000143348623853 1 0 1
tablets,not,be 1.0 0.000143348623853 1 0 1
tablets,may,reduce 1.0 0.000143348623853 1 0 1
tablets,may,exhibit 1.0 0.000143348623853 1 0 1
tablets,may,alter 1.0 0.000143348623853 1 0 1
tablets,injection,and 1.0 0.000143348623853 1 0 1
tablets,inhibit,the 1.0 0.000143348623853 1 0 1
tablets,in,epileptic 1.0 0.000143348623853 1 0 1
tablets,in,doses 1.0 0.000143348623853 1 0 1
tablets,at,least 1.0 0.000143348623853 1 0 1
tablets,as,well 1.0 0.000143348623853 1 0 1
tablets,are,either 1.0 0.000143348623853 1 0 1
tablets,and,is 1.0 0.000143348623853 1 0 1
tablets,an,can 1.0 0.000143348623853 1 0 1
tablets,administration,of 1.0 0.000143348623853 1 0 1
tablets,a,greater 1.0 0.000143348623853 1 0 1
tablet,was,given 1.0 0.000143348623853 1 0 1
tablet,was,administered 1.0 0.000143348623853 1 0 1
tablet,if,a 1.0 0.000143348623853 1 0 1
t3,in,the 1.0 0.000143348623853 1 0 1
t24,cells,but 1.0 0.000143348623853 1 0 1
t1,of,were 1.0 0.000143348623853 1 0 1
t,max,increased 1.0 0.000143348623853 1 0 1
t,a,with 1.0 0.000143348623853 1 0 1
systolic,diastolic,blood 1.0 0.000143348623853 1 0 1
systems,has,been 1.0 0.000143348623853 1 0 1
systemically-administered,oral,or 1.0 0.000143348623853 1 0 1
systemic,vascular,resistance 1.0 0.000143348623853 1 0 1
systemic,medications,were 1.0 0.000143348623853 1 0 1
systemic,levels,considerably 1.0 0.000143348623853 1 0 1
systemic,it,is 1.0 0.000143348623853 1 0 1
systemic,exposure,of 1.0 0.000143348623853 1 0 1
systemic,etc,that 1.0 0.000143348623853 1 0 1
systemic,concentrations,considerably 1.0 0.000143348623853 1 0 1
systemic,clearance,of 1.0 0.000143348623853 1 0 1
systemic,circulation,there 1.0 0.000143348623853 1 0 1
systemic,and,cardiac 1.0 0.000143348623853 1 0 1
systematically,studied,certain 1.0 0.000143348623853 1 0 1
systematically,evaluated,but 1.0 0.000143348623853 1 0 1
system,with,other 1.0 0.000143348623853 1 0 1
system,when,administered 1.0 0.000143348623853 1 0 1
system,though,this 1.0 0.000143348623853 1 0 1
system,regardless,of 1.0 0.000143348623853 1 0 1
system,or,should 1.0 0.000143348623853 1 0 1
system,notably,oral 1.0 0.000143348623853 1 0 1
system,mainly,responsible 1.0 0.000143348623853 1 0 1
system,ketoconazole,tablets 1.0 0.000143348623853 1 0 1
system,depression,or 1.0 0.000143348623853 1 0 1
system,depressants,the 1.0 0.000143348623853 1 0 1
system,depressants,such 1.0 0.000143348623853 1 0 1
system,depressants,eg 1.0 0.000143348623853 1 0 1
system,depressants,are 1.0 0.000143348623853 1 0 1
system,depressants,and 1.0 0.000143348623853 1 0 1
system,can,be 1.0 0.000143348623853 1 0 1
system,at,a 1.0 0.000143348623853 1 0 1
system,and,cardiovascular 1.0 0.000143348623853 1 0 1
system,and,brain 1.0 0.000143348623853 1 0 1
synthetic,possibly,by 1.0 0.000143348623853 1 0 1
synthetic,by,possibly 1.0 0.000143348623853 1 0 1
synthesis,it,has 1.0 0.000143348623853 1 0 1
synthesis,have,been 1.0 0.000143348623853 1 0 1
synthesis,and,may 1.0 0.000143348623853 1 0 1
synthase,inhibiting,eg 1.0 0.000143348623853 1 0 1
synergistic,relationship,with 1.0 0.000143348623853 1 0 1
synergistic,for,of 1.0 0.000143348623853 1 0 1
synergistic,elevation,of 1.0 0.000143348623853 1 0 1
synergistic,activity,while 1.0 0.000143348623853 1 0 1
synergistic,activity,if 1.0 0.000143348623853 1 0 1
synergism,was,observed 1.0 0.000143348623853 1 0 1
synergism,in,two 1.0 0.000143348623853 1 0 1
synergism,has,been 1.0 0.000143348623853 1 0 1
synergism,between,xanthine 1.0 0.000143348623853 1 0 1
syndrome,in,patients 1.0 0.000143348623853 1 0 1
syndrome,has,been 1.0 0.000143348623853 1 0 1
syndrome,cognitive,dysfunction 1.0 0.000143348623853 1 0 1
syndrome,characterized,by 1.0 0.000143348623853 1 0 1
syndrome,can,occur 1.0 0.000143348623853 1 0 1
syndrome,associated,with 1.0 0.000143348623853 1 0 1
syncope,presyncope,or 1.0 0.000143348623853 1 0 1
symptoms,that,accompany 1.0 0.000143348623853 1 0 1
symptoms,termed,serotonin 1.0 0.000143348623853 1 0 1
symptoms,suggestive,of 1.0 0.000143348623853 1 0 1
symptoms,severe,dry 1.0 0.000143348623853 1 0 1
symptoms,of,withdrawal 1.0 0.000143348623853 1 0 1
symptoms,of,serotonin 1.0 0.000143348623853 1 0 1
symptoms,of,methotrexate-related 1.0 0.000143348623853 1 0 1
symptoms,of,hyperlipidemia 1.0 0.000143348623853 1 0 1
symptoms,occur,physicians 1.0 0.000143348623853 1 0 1
symptoms,leukocytosis,elevated 1.0 0.000143348623853 1 0 1
symptoms,i,severe 1.0 0.000143348623853 1 0 1
symptoms,have,been 1.0 0.000143348623853 1 0 1
symptomatology,due,to 1.0 0.000143348623853 1 0 1
sympathomimetic,amines,may 1.0 0.000143348623853 1 0 1
sympathetic,effects,of 1.0 0.000143348623853 1 0 1
symbol,substitution,test 1.0 0.000143348623853 1 0 1
symbol,copying,test 1.0 0.000143348623853 1 0 1
sustiva,mg,once 1.0 0.000143348623853 1 0 1
sustiva,is,used 1.0 0.000143348623853 1 0 1
sustiva,has,the 1.0 0.000143348623853 1 0 1
sustained-release,calan,sr 1.0 0.000143348623853 1 0 1
sustained,elevation,in 1.0 0.000143348623853 1 0 1
suspension,were,coadministered 1.0 0.000143348623853 1 0 1
suspension,results,in 1.0 0.000143348623853 1 0 1
suspension,reduces,the 1.0 0.000143348623853 1 0 1
suspending,use,of 1.0 0.000143348623853 1 0 1
susceptible,patients,and 1.0 0.000143348623853 1 0 1
survey,of,patients 1.0 0.000143348623853 1 0 1
surgical,procedures,during 1.0 0.000143348623853 1 0 1
supraventricular,tachycardia,in 1.0 0.000143348623853 1 0 1
supraventricular,arrhythmia,and 1.0 0.000143348623853 1 0 1
suppression,of,the 1.0 0.000143348623853 1 0 1
suppression,of,gastric 1.0 0.000143348623853 1 0 1
suppression,by,of 1.0 0.000143348623853 1 0 1
suppression,by,and 1.0 0.000143348623853 1 0 1
suppress,the,dopaminergic 1.0 0.000143348623853 1 0 1
supporting,the,conclusion 1.0 0.000143348623853 1 0 1
supplements,use,of 1.0 0.000143348623853 1 0 1
supplements,theoretically,may 1.0 0.000143348623853 1 0 1
supplements,taken,concomitantly 1.0 0.000143348623853 1 0 1
supplements,may,give 1.0 0.000143348623853 1 0 1
supplements,containing,vitamin 1.0 0.000143348623853 1 0 1
supplements,are,required 1.0 0.000143348623853 1 0 1
supplements,and,l-lysine 1.0 0.000143348623853 1 0 1
supplements,and,foods 1.0 0.000143348623853 1 0 1
supplements,and,and 1.0 0.000143348623853 1 0 1
supplemented,with,mg 1.0 0.000143348623853 1 0 1
supplemental,l-glutamine,for 1.0 0.000143348623853 1 0 1
supplemental,l-glutamine,at 1.0 0.000143348623853 1 0 1
supplemental,in,a 1.0 0.000143348623853 1 0 1
supplement,while,taking 1.0 0.000143348623853 1 0 1
supplement,containing,mg 1.0 0.000143348623853 1 0 1
supine,systolic,diastolic 1.0 0.000143348623853 1 0 1
supersensitivity,to,the 1.0 0.000143348623853 1 0 1
supersensitive,to,when 1.0 0.000143348623853 1 0 1
supersensitive,to,compared 1.0 0.000143348623853 1 0 1
sunscreens,and,some 1.0 0.000143348623853 1 0 1
sumatriptan,there,have 1.0 0.000143348623853 1 0 1
sumatriptan,sumatriptan,has 1.0 0.000143348623853 1 0 1
sumatriptan,has,been 1.0 0.000143348623853 1 0 1
sumatriptan,and,d 1.0 0.000143348623853 1 0 1
sulindac,the,concomitant 1.0 0.000143348623853 1 0 1
sulfoxide,were,about 1.0 0.000143348623853 1 0 1
sulfoxide,concentrations,in 1.0 0.000143348623853 1 0 1
sulfoxide,by,about 1.0 0.000143348623853 1 0 1
sulfonate,soybean,flour 1.0 0.000143348623853 1 0 1
sulfide,metabolite,by 1.0 0.000143348623853 1 0 1
sulfate,sulfate,and 1.0 0.000143348623853 1 0 1
sulfate,sodium,polystyrene 1.0 0.000143348623853 1 0 1
sulfate,multivitamin,preparations 1.0 0.000143348623853 1 0 1
sulfate,may,interact 1.0 0.000143348623853 1 0 1
sulfate,may,enhance 1.0 0.000143348623853 1 0 1
sulfate,and,hc1 1.0 0.000143348623853 1 0 1
sulfapyridine,may,interact 1.0 0.000143348623853 1 0 1
sulfacetamide,preparations,are 1.0 0.000143348623853 1 0 1
sulfa,medicines,thiazide 1.0 0.000143348623853 1 0 1
sular,with,or 1.0 0.000143348623853 1 0 1
sular,tended,to 1.0 0.000143348623853 1 0 1
sular,tablets,in 1.0 0.000143348623853 1 0 1
suitable,anticoagulation,test 1.0 0.000143348623853 1 0 1
suggests,the,potential 1.0 0.000143348623853 1 0 1
suggests,that,renal 1.0 0.000143348623853 1 0 1
suggests,that,may 1.0 0.000143348623853 1 0 1
suggests,that,coadministration 1.0 0.000143348623853 1 0 1
suggestive,of,toxicity 1.0 0.000143348623853 1 0 1
suggesting,that,should 1.0 0.000143348623853 1 0 1
suggesting,that,may 1.0 0.000143348623853 1 0 1
suggesting,that,dose 1.0 0.000143348623853 1 0 1
suggesting,that,at 1.0 0.000143348623853 1 0 1
suggesting,an,inhibition 1.0 0.000143348623853 1 0 1
suggesting,a,modest 1.0 0.000143348623853 1 0 1
suggested,when,is 1.0 0.000143348623853 1 0 1
suggested,to,monitor 1.0 0.000143348623853 1 0 1
suggested,that,zebeta 1.0 0.000143348623853 1 0 1
suggested,that,the 1.0 0.000143348623853 1 0 1
suggested,that,or 1.0 0.000143348623853 1 0 1
suggested,that,may 1.0 0.000143348623853 1 0 1
suggested,that,in 1.0 0.000143348623853 1 0 1
suggest,that,when 1.0 0.000143348623853 1 0 1
suggest,that,tam 1.0 0.000143348623853 1 0 1
suggest,that,plasma 1.0 0.000143348623853 1 0 1
suggest,that,nonabsorbable 1.0 0.000143348623853 1 0 1
suggest,that,co-administration 1.0 0.000143348623853 1 0 1
suggest,that,both 1.0 0.000143348623853 1 0 1
suggest,that,also 1.0 0.000143348623853 1 0 1
suggest,a,higher 1.0 0.000143348623853 1 0 1
sugar,in,type 1.0 0.000143348623853 1 0 1
sugar,concentrations,during 1.0 0.000143348623853 1 0 1
sufficient,to,warrant 1.0 0.000143348623853 1 0 1
suffering,from,chronic 1.0 0.000143348623853 1 0 1
sudden,increase,in 1.0 0.000143348623853 1 0 1
sudden,death,potentially 1.0 0.000143348623853 1 0 1
sucralfate,should,not 1.0 0.000143348623853 1 0 1
sucralfate,and,containing 1.0 0.000143348623853 1 0 1
sucralfate,administered,hours 1.0 0.000143348623853 1 0 1
such,use,is 1.0 0.000143348623853 1 0 1
such,reduction,in 1.0 0.000143348623853 1 0 1
such,medicinal,products 1.0 0.000143348623853 1 0 1
such,combined,treatment 1.0 0.000143348623853 1 0 1
such,as,which 1.0 0.000143348623853 1 0 1
such,as,valium 1.0 0.000143348623853 1 0 1
such,as,triazolopyridazines 1.0 0.000143348623853 1 0 1
such,as,slowly 1.0 0.000143348623853 1 0 1
such,as,selective 1.0 0.000143348623853 1 0 1
such,as,protease 1.0 0.000143348623853 1 0 1
such,as,p-glycoprotein 1.0 0.000143348623853 1 0 1
such,as,nuromax 1.0 0.000143348623853 1 0 1
such,as,not 1.0 0.000143348623853 1 0 1
such,as,nonsteroidal 1.0 0.000143348623853 1 0 1
such,as,nimbex 1.0 0.000143348623853 1 0 1
such,as,narcotics 1.0 0.000143348623853 1 0 1
such,as,myelosuppression 1.0 0.000143348623853 1 0 1
such,as,might 1.0 0.000143348623853 1 0 1
such,as,loop 1.0 0.000143348623853 1 0 1
such,as,liver 1.0 0.000143348623853 1 0 1
such,as,inotropes 1.0 0.000143348623853 1 0 1
such,as,has 1.0 0.000143348623853 1 0 1
such,as,garlic 1.0 0.000143348623853 1 0 1
such,as,from 1.0 0.000143348623853 1 0 1
such,as,etc 1.0 0.000143348623853 1 0 1
such,as,cyp3a4 1.0 0.000143348623853 1 0 1
such,as,cough 1.0 0.000143348623853 1 0 1
such,as,convulsions 1.0 0.000143348623853 1 0 1
such,as,choline 1.0 0.000143348623853 1 0 1
such,as,certain 1.0 0.000143348623853 1 0 1
such,as,can 1.0 0.000143348623853 1 0 1
such,as,but 1.0 0.000143348623853 1 0 1
such,as,bradycardia 1.0 0.000143348623853 1 0 1
such,as,belladonna 1.0 0.000143348623853 1 0 1
such,as,antiparkinson 1.0 0.000143348623853 1 0 1
such,as,antineoplastic 1.0 0.000143348623853 1 0 1
such,as,amphotericin 1.0 0.000143348623853 1 0 1
such,as,akineton 1.0 0.000143348623853 1 0 1
such,a,potential 1.0 0.000143348623853 1 0 1
subutex,and,suboxone 1.0 0.000143348623853 1 0 1
substudy,in,patients 1.0 0.000143348623853 1 0 1
substrates,that,have 1.0 0.000143348623853 1 0 1
substrates,known,to 1.0 0.000143348623853 1 0 1
substrates,drugs,which 1.0 0.000143348623853 1 0 1
substrate,with,oral 1.0 0.000143348623853 1 0 1
substrate,trough,concentration 1.0 0.000143348623853 1 0 1
substrate,the,auc 1.0 0.000143348623853 1 0 1
substrate,resulted,in 1.0 0.000143348623853 1 0 1
substrate,for,cyp2d6 1.0 0.000143348623853 1 0 1
substrate,by,on 1.0 0.000143348623853 1 0 1
substrate,and,r-warfarin 1.0 0.000143348623853 1 0 1
substrate,and,its 1.0 0.000143348623853 1 0 1
substrate,and,fold 1.0 0.000143348623853 1 0 1
substitution,test,dsst 1.0 0.000143348623853 1 0 1
substantially,the,incidence 1.0 0.000143348623853 1 0 1
substantially,increased,following 1.0 0.000143348623853 1 0 1
substantially,decrease,the 1.0 0.000143348623853 1 0 1
substantial,increases,in 1.0 0.000143348623853 1 0 1
substantial,accumulation,of 1.0 0.000143348623853 1 0 1
substances,the,following 1.0 0.000143348623853 1 0 1
substances,demonstrated,to 1.0 0.000143348623853 1 0 1
substance,to,form 1.0 0.000143348623853 1 0 1
subsequently,treated,with 1.0 0.000143348623853 1 0 1
subsequently,administered,radiographic 1.0 0.000143348623853 1 0 1
subsequent,treatment,with 1.0 0.000143348623853 1 0 1
subsequent,to,increase 1.0 0.000143348623853 1 0 1
subsalicylate,given,concomitantly 1.0 0.000143348623853 1 0 1
suboxone,should,be 1.0 0.000143348623853 1 0 1
sublingual,mg,taken 1.0 0.000143348623853 1 0 1
subjects,with,steady 1.0 0.000143348623853 1 0 1
subjects,when,doses 1.0 0.000143348623853 1 0 1
subjects,was,associated 1.0 0.000143348623853 1 0 1
subjects,the,auc 1.0 0.000143348623853 1 0 1
subjects,stabilized,on 1.0 0.000143348623853 1 0 1
subjects,receiving,the 1.0 0.000143348623853 1 0 1
subjects,receiving,tambocor 1.0 0.000143348623853 1 0 1
subjects,receiving,multiple 1.0 0.000143348623853 1 0 1
subjects,receiving,mg 1.0 0.000143348623853 1 0 1
subjects,receiving,gm 1.0 0.000143348623853 1 0 1
subjects,receiving,either 1.0 0.000143348623853 1 0 1
subjects,receiving,a 1.0 0.000143348623853 1 0 1
subjects,no,effect 1.0 0.000143348623853 1 0 1
subjects,n,compared 1.0 0.000143348623853 1 0 1
subjects,mean,steady-state 1.0 0.000143348623853 1 0 1
subjects,ingesting,these 1.0 0.000143348623853 1 0 1
subjects,increased,the 1.0 0.000143348623853 1 0 1
subjects,increased,plasma 1.0 0.000143348623853 1 0 1
subjects,given,single 1.0 0.000143348623853 1 0 1
subjects,given,and 1.0 0.000143348623853 1 0 1
subjects,dosed,with 1.0 0.000143348623853 1 0 1
subjects,dosed,simultaneously 1.0 0.000143348623853 1 0 1
subjects,demonstrated,that 1.0 0.000143348623853 1 0 1
subjects,concurrent,administration 1.0 0.000143348623853 1 0 1
subjects,by,approximately 1.0 0.000143348623853 1 0 1
subjects,and,bioavailability 1.0 0.000143348623853 1 0 1
subjects,already,receiving 1.0 0.000143348623853 1 0 1
subjects,ages,to 1.0 0.000143348623853 1 0 1
subjects,aged,years 1.0 0.000143348623853 1 0 1
subjects,administered,a 1.0 0.000143348623853 1 0 1
subject,given,one 1.0 0.000143348623853 1 0 1
subcutaneous,dose,should 1.0 0.000143348623853 1 0 1
sub-therapeutic,concentrations,of 1.0 0.000143348623853 1 0 1
stupor,and,or 1.0 0.000143348623853 1 0 1
study,who,were 1.0 0.000143348623853 1 0 1
study,the,ureidopenicillins 1.0 0.000143348623853 1 0 1
study,rats,given 1.0 0.000143348623853 1 0 1
study,of,normal 1.0 0.000143348623853 1 0 1
study,of,mg 1.0 0.000143348623853 1 0 1
study,of,male 1.0 0.000143348623853 1 0 1
study,of,eleven 1.0 0.000143348623853 1 0 1
study,of,coadministration 1.0 0.000143348623853 1 0 1
study,of,arava 1.0 0.000143348623853 1 0 1
study,n,ingestion 1.0 0.000143348623853 1 0 1
study,maximum,plasma 1.0 0.000143348623853 1 0 1
study,involving,healthy 1.0 0.000143348623853 1 0 1
study,in,eight 1.0 0.000143348623853 1 0 1
study,in,diabetics 1.0 0.000143348623853 1 0 1
study,examining,mg 1.0 0.000143348623853 1 0 1
study,demonstrates,that 1.0 0.000143348623853 1 0 1
study,data,to 1.0 0.000143348623853 1 0 1
study,caused,a 1.0 0.000143348623853 1 0 1
study,adverse,effects 1.0 0.000143348623853 1 0 1
study,administration,of 1.0 0.000143348623853 1 0 1
study,a,single 1.0 0.000143348623853 1 0 1
studies,wshow,that 1.0 0.000143348623853 1 0 1
studies,with,or 1.0 0.000143348623853 1 0 1
studies,with,male 1.0 0.000143348623853 1 0 1
studies,with,aprepitant 1.0 0.000143348623853 1 0 1
studies,with,ace 1.0 0.000143348623853 1 0 1
studies,showed,that 1.0 0.000143348623853 1 0 1
studies,showed,higher 1.0 0.000143348623853 1 0 1
studies,one,mg 1.0 0.000143348623853 1 0 1
studies,of,suggest 1.0 0.000143348623853 1 0 1
studies,of,iopidine 1.0 0.000143348623853 1 0 1
studies,of,heroin-related 1.0 0.000143348623853 1 0 1
studies,nitrates,the 1.0 0.000143348623853 1 0 1
studies,involving,renal 1.0 0.000143348623853 1 0 1
studies,involving,metabolized 1.0 0.000143348623853 1 0 1
studies,involving,alprazolam 1.0 0.000143348623853 1 0 1
studies,in,steady-state 1.0 0.000143348623853 1 0 1
studies,in,rabbit 1.0 0.000143348623853 1 0 1
studies,in,peripheral 1.0 0.000143348623853 1 0 1
studies,do,not 1.0 0.000143348623853 1 0 1
studies,and,time 1.0 0.000143348623853 1 0 1
studies,adjuvant,treatment 1.0 0.000143348623853 1 0 1
studied,with,inhibition 1.0 0.000143348623853 1 0 1
studied,two,appear 1.0 0.000143348623853 1 0 1
studied,the,concomitant 1.0 0.000143348623853 1 0 1
studied,increased,exposures 1.0 0.000143348623853 1 0 1
studied,certain,may 1.0 0.000143348623853 1 0 1
studied,but,these 1.0 0.000143348623853 1 0 1
studied,but,cases 1.0 0.000143348623853 1 0 1
studied,and,coadministration 1.0 0.000143348623853 1 0 1
studied,alternative,or 1.0 0.000143348623853 1 0 1
structurally,related,to 1.0 0.000143348623853 1 0 1
structural,similarity,to 1.0 0.000143348623853 1 0 1
strongyloidiasis,during,the 1.0 0.000143348623853 1 0 1
strongly,induce,cyp3a4 1.0 0.000143348623853 1 0 1
strong,synergistic,activity 1.0 0.000143348623853 1 0 1
strong,likelihood,of 1.0 0.000143348623853 1 0 1
strong,cyp3a4,inhibitor 1.0 0.000143348623853 1 0 1
strong,cyp3a4,inducer 1.0 0.000143348623853 1 0 1
strong,and,completely 1.0 0.000143348623853 1 0 1
striatum,and,cortex 1.0 0.000143348623853 1 0 1
striatal,concentrations,and 1.0 0.000143348623853 1 0 1
striatal,but,these 1.0 0.000143348623853 1 0 1
stress,in,rat 1.0 0.000143348623853 1 0 1
strength,of,their 1.0 0.000143348623853 1 0 1
strattera,may,be 1.0 0.000143348623853 1 0 1
strains,and,synergistic 1.0 0.000143348623853 1 0 1
stopping,since,may 1.0 0.000143348623853 1 0 1
stopping,fluvoxamine,tablets 1.0 0.000143348623853 1 0 1
stopping,before,starting 1.0 0.000143348623853 1 0 1
stopping,an,mao 1.0 0.000143348623853 1 0 1
stopped,to,ensure 1.0 0.000143348623853 1 0 1
stopped,during,treatment 1.0 0.000143348623853 1 0 1
stomach,to,form 1.0 0.000143348623853 1 0 1
stomach,of,people 1.0 0.000143348623853 1 0 1
stomach,may,effect 1.0 0.000143348623853 1 0 1
stomach,drugs,such 1.0 0.000143348623853 1 0 1
stimulator,of,metabolism 1.0 0.000143348623853 1 0 1
stimulating,effect,in 1.0 0.000143348623853 1 0 1
stimulated,but,did 1.0 0.000143348623853 1 0 1
stimulate,egf-,or 1.0 0.000143348623853 1 0 1
stimulants,including,those 1.0 0.000143348623853 1 0 1
stimulants,and,their 1.0 0.000143348623853 1 0 1
still,kill,even 1.0 0.000143348623853 1 0 1
still,advisable,to 1.0 0.000143348623853 1 0 1
steroids,enhance,the 1.0 0.000143348623853 1 0 1
steroidal,antiinflammatory,agent 1.0 0.000143348623853 1 0 1
steroidal,anti-,inflammatory 1.0 0.000143348623853 1 0 1
steroidal,agent,can 1.0 0.000143348623853 1 0 1
steroid,hormones,such 1.0 0.000143348623853 1 0 1
stered,orally,prior 1.0 0.000143348623853 1 0 1
step,of,the 1.0 0.000143348623853 1 0 1
steadystate,cmin,to 1.0 0.000143348623853 1 0 1
steady-state,serum,antidepressant 1.0 0.000143348623853 1 0 1
steady-state,plasma,levels 1.0 0.000143348623853 1 0 1
steady-state,peak,serum 1.0 0.000143348623853 1 0 1
steady-state,cmin,to 1.0 0.000143348623853 1 0 1
steady-state,cmin,decreased 1.0 0.000143348623853 1 0 1
steady-state,blood,levels 1.0 0.000143348623853 1 0 1
steady-state,auc,and 1.0 0.000143348623853 1 0 1
steady,state,while 1.0 0.000143348623853 1 0 1
steady,state,auc 1.0 0.000143348623853 1 0 1
stavudine,and,zidovudine 1.0 0.000143348623853 1 0 1
status,is,warranted 1.0 0.000143348623853 1 0 1
status,changes,that 1.0 0.000143348623853 1 0 1
statistically,significant,decrease 1.0 0.000143348623853 1 0 1
statins,co-administration,of 1.0 0.000143348623853 1 0 1
states,to,emerge 1.0 0.000143348623853 1 0 1
state,while,levels 1.0 0.000143348623853 1 0 1
state,plasma,exposure 1.0 0.000143348623853 1 0 1
state,plasma,concentration 1.0 0.000143348623853 1 0 1
state,mg,kg 1.0 0.000143348623853 1 0 1
state,auc,ss 1.0 0.000143348623853 1 0 1
starting,and,frequently 1.0 0.000143348623853 1 0 1
starting,a,non-selective 1.0 0.000143348623853 1 0 1
started,or,stopped 1.0 0.000143348623853 1 0 1
started,in,patients 1.0 0.000143348623853 1 0 1
start,of,treatment 1.0 0.000143348623853 1 0 1
start,and,discontinuation 1.0 0.000143348623853 1 0 1
starlix,is,a 1.0 0.000143348623853 1 0 1
staphylococcus,aureus,a 1.0 0.000143348623853 1 0 1
standard,dose,and 1.0 0.000143348623853 1 0 1
standard,deviation,to 1.0 0.000143348623853 1 0 1
stadol,ns,may 1.0 0.000143348623853 1 0 1
stadol,ns,is 1.0 0.000143348623853 1 0 1
stabilized,on,should 1.0 0.000143348623853 1 0 1
stabilized,on,a 1.0 0.000143348623853 1 0 1
ssris,weakness,hyperreflexia 1.0 0.000143348623853 1 0 1
ssris,ssris,have 1.0 0.000143348623853 1 0 1
ssris,may,increase 1.0 0.000143348623853 1 0 1
ssris,and,agents 1.0 0.000143348623853 1 0 1
ssri-tcainteractions,may,pose 1.0 0.000143348623853 1 0 1
ss,of,o-desacetylrifabutin 1.0 0.000143348623853 1 0 1
sr,by,approximately 1.0 0.000143348623853 1 0 1
sprycel,with,should 1.0 0.000143348623853 1 0 1
sprycel,and,that 1.0 0.000143348623853 1 0 1
spray,the,auc 1.0 0.000143348623853 1 0 1
spray,but,by 1.0 0.000143348623853 1 0 1
sporanox,lipitor,atromid-s 1.0 0.000143348623853 1 0 1
sporadic,cases,of 1.0 0.000143348623853 1 0 1
spontaneous,motility,of 1.0 0.000143348623853 1 0 1
specific,interactions,with 1.0 0.000143348623853 1 0 1
specific,effects,of 1.0 0.000143348623853 1 0 1
specific,d1,antagonist 1.0 0.000143348623853 1 0 1
species,nanm,but 1.0 0.000143348623853 1 0 1
special,consideration,should 1.0 0.000143348623853 1 0 1
sparing,such,as 1.0 0.000143348623853 1 0 1
soon,after,administration 1.0 0.000143348623853 1 0 1
sonata,mg,potentiated 1.0 0.000143348623853 1 0 1
somnolence,have,been 1.0 0.000143348623853 1 0 1
sometimes,proves,to 1.0 0.000143348623853 1 0 1
sometimes,prescribed,to 1.0 0.000143348623853 1 0 1
sometimes,fatal,reactions 1.0 0.000143348623853 1 0 1
some,studies,and 1.0 0.000143348623853 1 0 1
some,pronestyl,sulfa 1.0 0.000143348623853 1 0 1
some,potential,for 1.0 0.000143348623853 1 0 1
some,patients,taking 1.0 0.000143348623853 1 0 1
some,patients,predisposing 1.0 0.000143348623853 1 0 1
some,patients,if 1.0 0.000143348623853 1 0 1
some,patients,have 1.0 0.000143348623853 1 0 1
some,patients,combined 1.0 0.000143348623853 1 0 1
some,patients,by 1.0 0.000143348623853 1 0 1
some,patients,and 1.0 0.000143348623853 1 0 1
some,oxytocic,may 1.0 0.000143348623853 1 0 1
some,other,nondepolarizing 1.0 0.000143348623853 1 0 1
some,other,concurrent 1.0 0.000143348623853 1 0 1
some,organisms,contained 1.0 0.000143348623853 1 0 1
some,of,which 1.0 0.000143348623853 1 0 1
some,nsaids,has 1.0 0.000143348623853 1 0 1
some,normal,volunteers 1.0 0.000143348623853 1 0 1
some,like,monoamine 1.0 0.000143348623853 1 0 1
some,leading,to 1.0 0.000143348623853 1 0 1
some,instances,resulted 1.0 0.000143348623853 1 0 1
some,instances,a 1.0 0.000143348623853 1 0 1
some,individuals,receiving 1.0 0.000143348623853 1 0 1
some,increase,the 1.0 0.000143348623853 1 0 1
some,have,also 1.0 0.000143348623853 1 0 1
some,has,been 1.0 0.000143348623853 1 0 1
some,further,antihypertensive 1.0 0.000143348623853 1 0 1
some,blockers,may 1.0 0.000143348623853 1 0 1
some,and,other 1.0 0.000143348623853 1 0 1
some,and,increase 1.0 0.000143348623853 1 0 1
solution,the,possibility 1.0 0.000143348623853 1 0 1
solution,one,study 1.0 0.000143348623853 1 0 1
solution,may,result 1.0 0.000143348623853 1 0 1
solution,may,potentiate 1.0 0.000143348623853 1 0 1
solution,can,form 1.0 0.000143348623853 1 0 1
sole,method,of 1.0 0.000143348623853 1 0 1
soft-gelatin,capsule,formulation 1.0 0.000143348623853 1 0 1
sodium,valproic,acid 1.0 0.000143348623853 1 0 1
sodium,unreliable,prothrombin 1.0 0.000143348623853 1 0 1
sodium,thiosulfate,is 1.0 0.000143348623853 1 0 1
sodium,polystyrene,sulfonate 1.0 0.000143348623853 1 0 1
sodium,plasma,levels 1.0 0.000143348623853 1 0 1
sodium,plasma,concentrations 1.0 0.000143348623853 1 0 1
sodium,or,other 1.0 0.000143348623853 1 0 1
sodium,may,reduce 1.0 0.000143348623853 1 0 1
sodium,may,enhance 1.0 0.000143348623853 1 0 1
sodium,kg,for 1.0 0.000143348623853 1 0 1
sodium,it,is 1.0 0.000143348623853 1 0 1
sodium,is,augmented 1.0 0.000143348623853 1 0 1
sodium,iodide,i131 1.0 0.000143348623853 1 0 1
sodium,from,the 1.0 0.000143348623853 1 0 1
sodium,excretion,seen 1.0 0.000143348623853 1 0 1
sodium,excretion,but 1.0 0.000143348623853 1 0 1
sodium,enhances,the 1.0 0.000143348623853 1 0 1
sodium,colistimethate,salts 1.0 0.000143348623853 1 0 1
sodium,colistemethate,salts 1.0 0.000143348623853 1 0 1
sodium,citrate,potentiate 1.0 0.000143348623853 1 0 1
sodium,can,attenuate 1.0 0.000143348623853 1 0 1
sodium,blood,levels 1.0 0.000143348623853 1 0 1
sodium,binding,to 1.0 0.000143348623853 1 0 1
sodium,bicarbonate,used 1.0 0.000143348623853 1 0 1
sodium,bicarbonate,etc 1.0 0.000143348623853 1 0 1
sodium,approximately,times 1.0 0.000143348623853 1 0 1
sodium,approximately,hours 1.0 0.000143348623853 1 0 1
sodium,and,urinary 1.0 0.000143348623853 1 0 1
sodium,and,other 1.0 0.000143348623853 1 0 1
sodium,and,may 1.0 0.000143348623853 1 0 1
sodium,and,g 1.0 0.000143348623853 1 0 1
sodium,and,coly-mycin 1.0 0.000143348623853 1 0 1
sodium,and,channel 1.0 0.000143348623853 1 0 1
sodium,absorption,the 1.0 0.000143348623853 1 0 1
sodium,a,period 1.0 0.000143348623853 1 0 1
so,that,intoxication 1.0 0.000143348623853 1 0 1
so,plasma,concentrations 1.0 0.000143348623853 1 0 1
so,careful,monitoring 1.0 0.000143348623853 1 0 1
smaller,initial,dose 1.0 0.000143348623853 1 0 1
smaller,doses,of 1.0 0.000143348623853 1 0 1
small,when,given 1.0 0.000143348623853 1 0 1
small,n,combination 1.0 0.000143348623853 1 0 1
small,initial,doses 1.0 0.000143348623853 1 0 1
small,but,statistically 1.0 0.000143348623853 1 0 1
slowly,over,several 1.0 0.000143348623853 1 0 1
slowly,dissolving,dosage 1.0 0.000143348623853 1 0 1
slower,renal,elimination 1.0 0.000143348623853 1 0 1
slower,onset,can 1.0 0.000143348623853 1 0 1
slower,absorption,mean 1.0 0.000143348623853 1 0 1
slow,the,metabolism 1.0 0.000143348623853 1 0 1
slightly,shorter,durations 1.0 0.000143348623853 1 0 1
slightly,reduced,by 1.0 0.000143348623853 1 0 1
slightly,greater,than 1.0 0.000143348623853 1 0 1
slightly,enhance,the 1.0 0.000143348623853 1 0 1
slight,reduction,in 1.0 0.000143348623853 1 0 1
slight,intrinsic,effect 1.0 0.000143348623853 1 0 1
slight,increases,in 1.0 0.000143348623853 1 0 1
slight,delay,in 1.0 0.000143348623853 1 0 1
slight,decreases,in 1.0 0.000143348623853 1 0 1
slight,decrease,in 1.0 0.000143348623853 1 0 1
slight,decrease,about 1.0 0.000143348623853 1 0 1
slight,but,not 1.0 0.000143348623853 1 0 1
sleeping,time,after 1.0 0.000143348623853 1 0 1
skin,rash,has 1.0 0.000143348623853 1 0 1
skeletal,muscle,relaxing 1.0 0.000143348623853 1 0 1
size,mydriasis,resulting 1.0 0.000143348623853 1 0 1
sixty,minutes,following 1.0 0.000143348623853 1 0 1
sixth,day,showed 1.0 0.000143348623853 1 0 1
six-day,course,of 1.0 0.000143348623853 1 0 1
six,subjects,demonstrated 1.0 0.000143348623853 1 0 1
six,of,these 1.0 0.000143348623853 1 0 1
six,healthy,volunteers 1.0 0.000143348623853 1 0 1
situation,when,analgesia 1.0 0.000143348623853 1 0 1
situ,hybridization,we 1.0 0.000143348623853 1 0 1
sites,or,a 1.0 0.000143348623853 1 0 1
sirolimus-diltiazem,interaction,whole 1.0 0.000143348623853 1 0 1
sinus,rhythm,following 1.0 0.000143348623853 1 0 1
sinus,node,function 1.0 0.000143348623853 1 0 1
sinus,medicines,diabetic 1.0 0.000143348623853 1 0 1
single-dose,crossover,study 1.0 0.000143348623853 1 0 1
single-dose,coadministration,leads 1.0 0.000143348623853 1 0 1
single,subject,given 1.0 0.000143348623853 1 0 1
single,study,rats 1.0 0.000143348623853 1 0 1
single,mg,doses 1.0 0.000143348623853 1 0 1
single,high,dose 1.0 0.000143348623853 1 0 1
single,case,report 1.0 0.000143348623853 1 0 1
single,and,multiple 1.0 0.000143348623853 1 0 1
since,zarontin,may 1.0 0.000143348623853 1 0 1
since,there,are 1.0 0.000143348623853 1 0 1
since,the,sedative 1.0 0.000143348623853 1 0 1
since,the,pharmacokinetics 1.0 0.000143348623853 1 0 1
since,the,excretion 1.0 0.000143348623853 1 0 1
since,the,effects 1.0 0.000143348623853 1 0 1
since,the,absorption 1.0 0.000143348623853 1 0 1
since,pletal,is 1.0 0.000143348623853 1 0 1
since,paranoid,symptoms 1.0 0.000143348623853 1 0 1
since,nsaids,and 1.0 0.000143348623853 1 0 1
since,nevirapinemay,lower 1.0 0.000143348623853 1 0 1
since,may,raise 1.0 0.000143348623853 1 0 1
since,may,prolong 1.0 0.000143348623853 1 0 1
since,may,antagonize 1.0 0.000143348623853 1 0 1
since,is,the 1.0 0.000143348623853 1 0 1
since,invirase,is 1.0 0.000143348623853 1 0 1
since,inhibits,platelet 1.0 0.000143348623853 1 0 1
since,in,high 1.0 0.000143348623853 1 0 1
since,higher,doses 1.0 0.000143348623853 1 0 1
since,exhibits,non-linear 1.0 0.000143348623853 1 0 1
since,bile,acid 1.0 0.000143348623853 1 0 1
since,bacteriostatic,such 1.0 0.000143348623853 1 0 1
since,bacteriostatic,may 1.0 0.000143348623853 1 0 1
since,are,potentiated 1.0 0.000143348623853 1 0 1
since,animal,studies 1.0 0.000143348623853 1 0 1
since,and,potassium-sparing 1.0 0.000143348623853 1 0 1
since,and,may 1.0 0.000143348623853 1 0 1
since,an,increase 1.0 0.000143348623853 1 0 1
simvastatin,and,other 1.0 0.000143348623853 1 0 1
simultaneously,with,vardenafil 1.0 0.000143348623853 1 0 1
simultaneously,with,or 1.0 0.000143348623853 1 0 1
simultaneously,or,hours 1.0 0.000143348623853 1 0 1
simultaneously,because,both 1.0 0.000143348623853 1 0 1
simultaneous,treatment,with 1.0 0.000143348623853 1 0 1
simultaneous,ingestion,of 1.0 0.000143348623853 1 0 1
simultaneous,fold,increase 1.0 0.000143348623853 1 0 1
simulect,was,reduced 1.0 0.000143348623853 1 0 1
similarly,to,or 1.0 0.000143348623853 1 0 1
similarly,the,effects 1.0 0.000143348623853 1 0 1
similarly,inhibit,and 1.0 0.000143348623853 1 0 1
similar,to,in 1.0 0.000143348623853 1 0 1
similar,study,with 1.0 0.000143348623853 1 0 1
similar,proportion,of 1.0 0.000143348623853 1 0 1
similar,properties,such 1.0 0.000143348623853 1 0 1
similar,mechanism,of 1.0 0.000143348623853 1 0 1
similar,length,of 1.0 0.000143348623853 1 0 1
similar,interaction,is 1.0 0.000143348623853 1 0 1
similar,agents,since 1.0 0.000143348623853 1 0 1
similar,agents,and 1.0 0.000143348623853 1 0 1
sildenafil,is,contraindicated 1.0 0.000143348623853 1 0 1
sildenafil,dose,should 1.0 0.000143348623853 1 0 1
sildenafil,citrate,theoretically 1.0 0.000143348623853 1 0 1
signs,of,hypotension 1.0 0.000143348623853 1 0 1
signs,of,atropinization 1.0 0.000143348623853 1 0 1
signs,and,mental 1.0 0.000143348623853 1 0 1
significantly,when,is 1.0 0.000143348623853 1 0 1
significantly,reduces,the 1.0 0.000143348623853 1 0 1
significantly,reduced,by 1.0 0.000143348623853 1 0 1
significantly,reduced,and 1.0 0.000143348623853 1 0 1
significantly,prolonged,the 1.0 0.000143348623853 1 0 1
significantly,potentiates,the 1.0 0.000143348623853 1 0 1
significantly,p,decreased 1.0 0.000143348623853 1 0 1
significantly,inhibited,the 1.0 0.000143348623853 1 0 1
significantly,inhibited,phosphorylation 1.0 0.000143348623853 1 0 1
significantly,inhibit,proliferation 1.0 0.000143348623853 1 0 1
significantly,inhibit,alfenta 1.0 0.000143348623853 1 0 1
significantly,increased,vasoconstriction 1.0 0.000143348623853 1 0 1
significantly,increased,plasma 1.0 0.000143348623853 1 0 1
significantly,include,adrenocortical 1.0 0.000143348623853 1 0 1
significantly,higher,when 1.0 0.000143348623853 1 0 1
significantly,higher,as 1.0 0.000143348623853 1 0 1
significantly,eliminated,by 1.0 0.000143348623853 1 0 1
significantly,elevating,duodenal 1.0 0.000143348623853 1 0 1
significantly,decreases,clearance 1.0 0.000143348623853 1 0 1
significantly,decreased,when 1.0 0.000143348623853 1 0 1
significantly,decreased,binding 1.0 0.000143348623853 1 0 1
significantly,altered,decrease 1.0 0.000143348623853 1 0 1
significant,sustained,elevation 1.0 0.000143348623853 1 0 1
significant,respiratory,depression 1.0 0.000143348623853 1 0 1
significant,reductions,in 1.0 0.000143348623853 1 0 1
significant,reduction,in 1.0 0.000143348623853 1 0 1
significant,protection,against 1.0 0.000143348623853 1 0 1
significant,metabolism,by 1.0 0.000143348623853 1 0 1
significant,in,patients 1.0 0.000143348623853 1 0 1
significant,hypotension,developed 1.0 0.000143348623853 1 0 1
significant,fluctuations,in 1.0 0.000143348623853 1 0 1
significant,alteration,of 1.0 0.000143348623853 1 0 1
significant,additional,efficacy 1.0 0.000143348623853 1 0 1
significant,accuracy,in 1.0 0.000143348623853 1 0 1
significance,on,the 1.0 0.000143348623853 1 0 1
side-effects,in,patients 1.0 0.000143348623853 1 0 1
side,reactions,of 1.0 0.000143348623853 1 0 1
side,effects,when 1.0 0.000143348623853 1 0 1
side,effects,particularly 1.0 0.000143348623853 1 0 1
side,effects,including 1.0 0.000143348623853 1 0 1
shown,to,prevent 1.0 0.000143348623853 1 0 1
shown,to,influence 1.0 0.000143348623853 1 0 1
shown,to,induce 1.0 0.000143348623853 1 0 1
shown,to,elevate 1.0 0.000143348623853 1 0 1
shown,to,double 1.0 0.000143348623853 1 0 1
shown,to,displace 1.0 0.000143348623853 1 0 1
shown,to,change 1.0 0.000143348623853 1 0 1
shown,to,affect 1.0 0.000143348623853 1 0 1
shown,that,lodine 1.0 0.000143348623853 1 0 1
shown,that,like 1.0 0.000143348623853 1 0 1
shown,that,concurrent 1.0 0.000143348623853 1 0 1
shown,that,concomitan 1.0 0.000143348623853 1 0 1
shown,that,antagonized 1.0 0.000143348623853 1 0 1
shown,that,administration 1.0 0.000143348623853 1 0 1
shown,in,vitro 1.0 0.000143348623853 1 0 1
shown,in,rats 1.0 0.000143348623853 1 0 1
shown,casodex,can 1.0 0.000143348623853 1 0 1
shown,between,and 1.0 0.000143348623853 1 0 1
shown,a,possible 1.0 0.000143348623853 1 0 1
shown,a,increase 1.0 0.000143348623853 1 0 1
shown,a,decrease 1.0 0.000143348623853 1 0 1
showed,that,was 1.0 0.000143348623853 1 0 1
showed,that,increased 1.0 0.000143348623853 1 0 1
showed,higher,concentrations 1.0 0.000143348623853 1 0 1
showed,an,increase 1.0 0.000143348623853 1 0 1
showed,a,reduction 1.0 0.000143348623853 1 0 1
showed,a,fold 1.0 0.000143348623853 1 0 1
show,that,and 1.0 0.000143348623853 1 0 1
show,elevations,of 1.0 0.000143348623853 1 0 1
should,take,tricor 1.0 0.000143348623853 1 0 1
should,receive,mg 1.0 0.000143348623853 1 0 1
should,receive,initial 1.0 0.000143348623853 1 0 1
should,not,ordinarily 1.0 0.000143348623853 1 0 1
should,not,concurrently 1.0 0.000143348623853 1 0 1
should,it,be 1.0 0.000143348623853 1 0 1
should,if,possible 1.0 0.000143348623853 1 0 1
should,have,cholesterol 1.0 0.000143348623853 1 0 1
should,have,a 1.0 0.000143348623853 1 0 1
should,either,be 1.0 0.000143348623853 1 0 1
should,consider,the 1.0 0.000143348623853 1 0 1
should,consider,discontinuation 1.0 0.000143348623853 1 0 1
should,be,watched 1.0 0.000143348623853 1 0 1
should,be,stopped 1.0 0.000143348623853 1 0 1
should,be,prescribed 1.0 0.000143348623853 1 0 1
should,be,minimized 1.0 0.000143348623853 1 0 1
should,be,maintained 1.0 0.000143348623853 1 0 1
should,be,introduced 1.0 0.000143348623853 1 0 1
should,be,halved 1.0 0.000143348623853 1 0 1
should,be,gradual 1.0 0.000143348623853 1 0 1
should,be,even 1.0 0.000143348623853 1 0 1
should,be,evaluated 1.0 0.000143348623853 1 0 1
should,be,deferred 1.0 0.000143348623853 1 0 1
should,be,continuously 1.0 0.000143348623853 1 0 1
should,be,continued 1.0 0.000143348623853 1 0 1
should,be,co-administered 1.0 0.000143348623853 1 0 1
should,be,checked 1.0 0.000143348623853 1 0 1
should,be,cautiously 1.0 0.000143348623853 1 0 1
should,be,at 1.0 0.000143348623853 1 0 1
should,be,allowed 1.0 0.000143348623853 1 0 1
should,also,not 1.0 0.000143348623853 1 0 1
shortly,after,nasal 1.0 0.000143348623853 1 0 1
shortened,in,patients 1.0 0.000143348623853 1 0 1
shortened,elimination,half-life 1.0 0.000143348623853 1 0 1
short-term,pharmacokinetic,studies 1.0 0.000143348623853 1 0 1
short-acting,because,the 1.0 0.000143348623853 1 0 1
short-acting,and,that 1.0 0.000143348623853 1 0 1
shock,can,in 1.0 0.000143348623853 1 0 1
sharp,fall,of 1.0 0.000143348623853 1 0 1
sgot,ast,and 1.0 0.000143348623853 1 0 1
sex,hormone,response 1.0 0.000143348623853 1 0 1
severity,of,side 1.0 0.000143348623853 1 0 1
severity,of,dry 1.0 0.000143348623853 1 0 1
severity,of,diarrhea 1.0 0.000143348623853 1 0 1
severity,of,chloride-induced 1.0 0.000143348623853 1 0 1
severity,and,or 1.0 0.000143348623853 1 0 1
severe,weakness,in 1.0 0.000143348623853 1 0 1
severe,toxicity,was 1.0 0.000143348623853 1 0 1
severe,toxicity,including 1.0 0.000143348623853 1 0 1
severe,rhabdomyolysis,appear 1.0 0.000143348623853 1 0 1
severe,prolonged,hypotension 1.0 0.000143348623853 1 0 1
severe,orthostatic,hypotension 1.0 0.000143348623853 1 0 1
severe,obstipation,even 1.0 0.000143348623853 1 0 1
severe,myopathy,rhabdomyolysis 1.0 0.000143348623853 1 0 1
severe,hypotension,or 1.0 0.000143348623853 1 0 1
severe,hypotension,has 1.0 0.000143348623853 1 0 1
severe,hypotension,and 1.0 0.000143348623853 1 0 1
severe,hyperkalemia,in 1.0 0.000143348623853 1 0 1
severe,high,blood 1.0 0.000143348623853 1 0 1
severe,enterocolitis,diarrhea 1.0 0.000143348623853 1 0 1
severe,dietary,salt 1.0 0.000143348623853 1 0 1
severe,cardiovascular,disease 1.0 0.000143348623853 1 0 1
severe,bronchospasm,in 1.0 0.000143348623853 1 0 1
severe,and,unpredictable 1.0 0.000143348623853 1 0 1
several,medicinal,products 1.0 0.000143348623853 1 0 1
several,hours,for 1.0 0.000143348623853 1 0 1
several,have,been 1.0 0.000143348623853 1 0 1
several,closely,related 1.0 0.000143348623853 1 0 1
several,aed,s 1.0 0.000143348623853 1 0 1
serum,slightly,about 1.0 0.000143348623853 1 0 1
serum,sex,hormone 1.0 0.000143348623853 1 0 1
serum,proteins,the 1.0 0.000143348623853 1 0 1
serum,proteins,or 1.0 0.000143348623853 1 0 1
serum,protein,the 1.0 0.000143348623853 1 0 1
serum,potassium,prinivil 1.0 0.000143348623853 1 0 1
serum,potassium,enalapril 1.0 0.000143348623853 1 0 1
serum,meq,l 1.0 0.000143348623853 1 0 1
serum,levels,were 1.0 0.000143348623853 1 0 1
serum,levels,the 1.0 0.000143348623853 1 0 1
serum,levels,or 1.0 0.000143348623853 1 0 1
serum,levels,is 1.0 0.000143348623853 1 0 1
serum,levels,in 1.0 0.000143348623853 1 0 1
serum,levels,have 1.0 0.000143348623853 1 0 1
serum,levels,has 1.0 0.000143348623853 1 0 1
serum,levels,carbamazepine 1.0 0.000143348623853 1 0 1
serum,level,that 1.0 0.000143348623853 1 0 1
serum,level,should 1.0 0.000143348623853 1 0 1
serum,level,has 1.0 0.000143348623853 1 0 1
serum,level,determinations 1.0 0.000143348623853 1 0 1
serum,half-life,or 1.0 0.000143348623853 1 0 1
serum,half-life,of 1.0 0.000143348623853 1 0 1
serum,exposure,compared 1.0 0.000143348623853 1 0 1
serum,enzymes,bun 1.0 0.000143348623853 1 0 1
serum,creatinine,level 1.0 0.000143348623853 1 0 1
serum,concentrations,increase 1.0 0.000143348623853 1 0 1
serum,concentration,has 1.0 0.000143348623853 1 0 1
serum,concentration,especially 1.0 0.000143348623853 1 0 1
serum,concentration,during 1.0 0.000143348623853 1 0 1
serum,concentration,due 1.0 0.000143348623853 1 0 1
serum,concentration,curve 1.0 0.000143348623853 1 0 1
serum,clearance,and 1.0 0.000143348623853 1 0 1
serum,by,a 1.0 0.000143348623853 1 0 1
serum,binding,proteins 1.0 0.000143348623853 1 0 1
serum,auc,cmax 1.0 0.000143348623853 1 0 1
serum,antidepressant,levels 1.0 0.000143348623853 1 0 1
serotoninergic,agents,there 1.0 0.000143348623853 1 0 1
serotonin,syndrome,has 1.0 0.000143348623853 1 0 1
serotonin,syndrome,cognitive 1.0 0.000143348623853 1 0 1
serotonin,syndrome,associated 1.0 0.000143348623853 1 0 1
serotonin,reuptake,and 1.0 0.000143348623853 1 0 1
serotonin,releaser,and 1.0 0.000143348623853 1 0 1
serotonergic,effects,of 1.0 0.000143348623853 1 0 1
serotonergic,agents,should 1.0 0.000143348623853 1 0 1
serotonergic,agents,including 1.0 0.000143348623853 1 0 1
serious,toxicity,may 1.0 0.000143348623853 1 0 1
serious,symptoms,severe 1.0 0.000143348623853 1 0 1
serious,symptoms,i 1.0 0.000143348623853 1 0 1
serious,sometimes,fatal 1.0 0.000143348623853 1 0 1
serious,reaction,to 1.0 0.000143348623853 1 0 1
serious,pneumonia,vs 1.0 0.000143348623853 1 0 1
serious,interactions,when 1.0 0.000143348623853 1 0 1
serious,infections,an 1.0 0.000143348623853 1 0 1
serious,falls,vs 1.0 0.000143348623853 1 0 1
serious,constellation,of 1.0 0.000143348623853 1 0 1
serious,clinical,bleeding 1.0 0.000143348623853 1 0 1
serious,cardiac,dysrhythmias 1.0 0.000143348623853 1 0 1
serial,measurement,of 1.0 0.000143348623853 1 0 1
sequestrants,may,bind 1.0 0.000143348623853 1 0 1
sequential,infusions,myelosuppression 1.0 0.000143348623853 1 0 1
sequential,high,dose 1.0 0.000143348623853 1 0 1
separating,the,doses 1.0 0.000143348623853 1 0 1
separately,by,different 1.0 0.000143348623853 1 0 1
separated,from,mg 1.0 0.000143348623853 1 0 1
separated,by,hours 1.0 0.000143348623853 1 0 1
separated,by,at 1.0 0.000143348623853 1 0 1
separate,group,of 1.0 0.000143348623853 1 0 1
sensitivity,to,the 1.0 0.000143348623853 1 0 1
sensitivity,and,enhance 1.0 0.000143348623853 1 0 1
sensitive,cyp3a4,substrate 1.0 0.000143348623853 1 0 1
sensipar,may,be 1.0 0.000143348623853 1 0 1
self-administration,of,while 1.0 0.000143348623853 1 0 1
selegiline,l-phenylalanine,and 1.0 0.000143348623853 1 0 1
selegiline,hydrochloride,in 1.0 0.000143348623853 1 0 1
selegiline,combination,hormonal 1.0 0.000143348623853 1 0 1
selectively,prevent,opioid-induced 1.0 0.000143348623853 1 0 1
selective,peripheral,anitagonism 1.0 0.000143348623853 1 0 1
selective,mao,inhibitor 1.0 0.000143348623853 1 0 1
selective,cyp3a4,inhibitors 1.0 0.000143348623853 1 0 1
selective,cyp3a4,inhibitor 1.0 0.000143348623853 1 0 1
seizure,threshold,should 1.0 0.000143348623853 1 0 1
seizure,threshold,concurrent 1.0 0.000143348623853 1 0 1
seizure,risk,in 1.0 0.000143348623853 1 0 1
seizure,control,by 1.0 0.000143348623853 1 0 1
seen,with,coadministration 1.0 0.000143348623853 1 0 1
seen,when,mg 1.0 0.000143348623853 1 0 1
seen,when,arava 1.0 0.000143348623853 1 0 1
seen,prior,to 1.0 0.000143348623853 1 0 1
seen,on,mtc-mdp 1.0 0.000143348623853 1 0 1
seen,in,difluoro-2 1.0 0.000143348623853 1 0 1
seen,in,cyp 1.0 0.000143348623853 1 0 1
seen,in,animals 1.0 0.000143348623853 1 0 1
seen,during,treatment 1.0 0.000143348623853 1 0 1
seen,during,coadministration 1.0 0.000143348623853 1 0 1
seen,but,brevibloc 1.0 0.000143348623853 1 0 1
seen,as,early 1.0 0.000143348623853 1 0 1
seem,to,dictate 1.0 0.000143348623853 1 0 1
see,whether,the 1.0 0.000143348623853 1 0 1
see,if,clearance 1.0 0.000143348623853 1 0 1
sedatives,hypnotics,opioids 1.0 0.000143348623853 1 0 1
sedative,effects,of 1.0 0.000143348623853 1 0 1
sedative,effects,and 1.0 0.000143348623853 1 0 1
sedation,when,is 1.0 0.000143348623853 1 0 1
sedation,or,potentially 1.0 0.000143348623853 1 0 1
sedation,if,is 1.0 0.000143348623853 1 0 1
sedation,hallucinations,and 1.0 0.000143348623853 1 0 1
secretory,effect,of 1.0 0.000143348623853 1 0 1
secretion,while,may 1.0 0.000143348623853 1 0 1
secretion,via,organic 1.0 0.000143348623853 1 0 1
secretion,of,when 1.0 0.000143348623853 1 0 1
secretion,of,resulting 1.0 0.000143348623853 1 0 1
secretion,of,in 1.0 0.000143348623853 1 0 1
secretion,of,certain 1.0 0.000143348623853 1 0 1
secretion,of,based 1.0 0.000143348623853 1 0 1
secretion,may,result 1.0 0.000143348623853 1 0 1
secretion,has,been 1.0 0.000143348623853 1 0 1
secretion,by,h2 1.0 0.000143348623853 1 0 1
secretion,and,reduces 1.0 0.000143348623853 1 0 1
secreted,via,this 1.0 0.000143348623853 1 0 1
secondary,to,vomiting 1.0 0.000143348623853 1 0 1
secondary,to,this 1.0 0.000143348623853 1 0 1
secondary,to,its 1.0 0.000143348623853 1 0 1
secondary,enzymes,respectively 1.0 0.000143348623853 1 0 1
secondary,actions,certain 1.0 0.000143348623853 1 0 1
second,study,administration 1.0 0.000143348623853 1 0 1
second,day,of 1.0 0.000143348623853 1 0 1
scores,on,the 1.0 0.000143348623853 1 0 1
schizophrenic,patients,treated 1.0 0.000143348623853 1 0 1
schizophrenic,patients,coadministered 1.0 0.000143348623853 1 0 1
schizophrenia,schizoaffective,disorder 1.0 0.000143348623853 1 0 1
schizoaffective,disorder,or 1.0 0.000143348623853 1 0 1
schedule,was,greater 1.0 0.000143348623853 1 0 1
schedule,of,indocin 1.0 0.000143348623853 1 0 1
sch-23390,but,not 1.0 0.000143348623853 1 0 1
scale,were,increased 1.0 0.000143348623853 1 0 1
satisfactory,hypotensive,effect 1.0 0.000143348623853 1 0 1
saquinavir,steady-state,cmax 1.0 0.000143348623853 1 0 1
saquinavir,coadministration,of 1.0 0.000143348623853 1 0 1
sandimmune,hiv,classified 1.0 0.000143348623853 1 0 1
same,time,as 1.0 0.000143348623853 1 0 1
same,evening,meal 1.0 0.000143348623853 1 0 1
same,day,as 1.0 0.000143348623853 1 0 1
salts,may,reduce 1.0 0.000143348623853 1 0 1
salt,restriction,or 1.0 0.000143348623853 1 0 1
salt,intake,approximately 1.0 0.000143348623853 1 0 1
salicylic,acid,decrease 1.0 0.000143348623853 1 0 1
salicylic,acid,combination 1.0 0.000143348623853 1 0 1
salicylate,and,heparin 1.0 0.000143348623853 1 0 1
safe,problem,associated 1.0 0.000143348623853 1 0 1
s-warfarin,and,respectively 1.0 0.000143348623853 1 0 1
s-warfarin,a,cyp2c9 1.0 0.000143348623853 1 0 1
s,that,are 1.0 0.000143348623853 1 0 1
s,regimen,particularly 1.0 0.000143348623853 1 0 1
s,influence,on 1.0 0.000143348623853 1 0 1
s,effect,will 1.0 0.000143348623853 1 0 1
s,determined,on 1.0 0.000143348623853 1 0 1
s,d,respectively 1.0 0.000143348623853 1 0 1
s,concomitantly,with 1.0 0.000143348623853 1 0 1
s,c,inhibited 1.0 0.000143348623853 1 0 1
s,c,completely 1.0 0.000143348623853 1 0 1
s,and,which 1.0 0.000143348623853 1 0 1
s,a,cyp2c9 1.0 0.000143348623853 1 0 1
rupture,or,cervical 1.0 0.000143348623853 1 0 1
rr,microm,inhibited 1.0 0.000143348623853 1 0 1
rr,microm,also 1.0 0.000143348623853 1 0 1
rpmi1640,containing,alone 1.0 0.000143348623853 1 0 1
routine,administration,of 1.0 0.000143348623853 1 0 1
routes,a,reduction 1.0 0.000143348623853 1 0 1
route,they,should 1.0 0.000143348623853 1 0 1
route,of,including 1.0 0.000143348623853 1 0 1
route,and,should 1.0 0.000143348623853 1 0 1
romazicon,in,cases 1.0 0.000143348623853 1 0 1
romazicon,exerts,a 1.0 0.000143348623853 1 0 1
romazicon,blocks,the 1.0 0.000143348623853 1 0 1
robinul,injection,with 1.0 0.000143348623853 1 0 1
robinul,injection,and 1.0 0.000143348623853 1 0 1
ritonavir,significantly,prolonged 1.0 0.000143348623853 1 0 1
ritonavir,mg,b 1.0 0.000143348623853 1 0 1
ritonavir,coadministration,of 1.0 0.000143348623853 1 0 1
ritonavir,and,upon 1.0 0.000143348623853 1 0 1
risks,of,severe 1.0 0.000143348623853 1 0 1
risks,of,major 1.0 0.000143348623853 1 0 1
risks,of,cns 1.0 0.000143348623853 1 0 1
risk,that,an 1.0 0.000143348623853 1 0 1
risk,of,prolonged 1.0 0.000143348623853 1 0 1
risk,of,neurotoxic 1.0 0.000143348623853 1 0 1
risk,of,hypoglycemia 1.0 0.000143348623853 1 0 1
risk,of,hyperkalemia 1.0 0.000143348623853 1 0 1
risk,of,hepatitis 1.0 0.000143348623853 1 0 1
risk,of,gi 1.0 0.000143348623853 1 0 1
risk,of,dehydration 1.0 0.000143348623853 1 0 1
risk,of,central 1.0 0.000143348623853 1 0 1
risk,of,are 1.0 0.000143348623853 1 0 1
risk,for,potentially 1.0 0.000143348623853 1 0 1
risk,factors,studied 1.0 0.000143348623853 1 0 1
rises,in,serum 1.0 0.000143348623853 1 0 1
rise,to,convulsions 1.0 0.000143348623853 1 0 1
rings,with,intact 1.0 0.000143348623853 1 0 1
rings,from,high-estradiol 1.0 0.000143348623853 1 0 1
rigidity,myoclonus,autonomic 1.0 0.000143348623853 1 0 1
rifampin,when,a 1.0 0.000143348623853 1 0 1
rifampin,significantly,decreased 1.0 0.000143348623853 1 0 1
rifampin,rifampin,increases 1.0 0.000143348623853 1 0 1
rifampin,reduced,plasma 1.0 0.000143348623853 1 0 1
rifampin,may,decrease 1.0 0.000143348623853 1 0 1
rifampin,markedly,increases 1.0 0.000143348623853 1 0 1
rifampin,increases,the 1.0 0.000143348623853 1 0 1
rifampin,has,been 1.0 0.000143348623853 1 0 1
rifampin,following,concomitant 1.0 0.000143348623853 1 0 1
rifampin,co-administration,of 1.0 0.000143348623853 1 0 1
rifampin,an,inducer 1.0 0.000143348623853 1 0 1
rifampicin,racemic,exposure 1.0 0.000143348623853 1 0 1
rifampicin,in,a 1.0 0.000143348623853 1 0 1
rifabutin,coadministration,of 1.0 0.000143348623853 1 0 1
ribavirin,can,antagonize 1.0 0.000143348623853 1 0 1
rhythm,following,administration 1.0 0.000143348623853 1 0 1
rheumatic,disease,may 1.0 0.000143348623853 1 0 1
rhabdomyolysis,secondary,to 1.0 0.000143348623853 1 0 1
rhabdomyolysis,appear,to 1.0 0.000143348623853 1 0 1
rhabdomyolysis,and,acute 1.0 0.000143348623853 1 0 1
reviewed,in,an 1.0 0.000143348623853 1 0 1
reviewed,for,additional 1.0 0.000143348623853 1 0 1
reviewed,and,the 1.0 0.000143348623853 1 0 1
review,of,the 1.0 0.000143348623853 1 0 1
revia,the,amount 1.0 0.000143348623853 1 0 1
revia,may,not 1.0 0.000143348623853 1 0 1
revia,and,is 1.0 0.000143348623853 1 0 1
reversible,upon,discontinuation 1.0 0.000143348623853 1 0 1
reversible,increases,in 1.0 0.000143348623853 1 0 1
reversible,impairment,of 1.0 0.000143348623853 1 0 1
reversible,enhancement,of 1.0 0.000143348623853 1 0 1
reversible,acute,renal 1.0 0.000143348623853 1 0 1
reversed,by,cgs 1.0 0.000143348623853 1 0 1
reveiving,phenytoin,and 1.0 0.000143348623853 1 0 1
revealed,that,significantly 1.0 0.000143348623853 1 0 1
revealed,that,range 1.0 0.000143348623853 1 0 1
reveal,frequent,involvement 1.0 0.000143348623853 1 0 1
reuptake,inhibitors,grapefruit 1.0 0.000143348623853 1 0 1
reuptake,inhibitor,should 1.0 0.000143348623853 1 0 1
reuptake,inhibitor,in 1.0 0.000143348623853 1 0 1
reuptake,and,the 1.0 0.000143348623853 1 0 1
returned,to,baseline 1.0 0.000143348623853 1 0 1
retinyl,acetate,x 1.0 0.000143348623853 1 0 1
retinyl,acetate,stimulated 1.0 0.000143348623853 1 0 1
retinyl,acetate,similarly 1.0 0.000143348623853 1 0 1
retinyl,acetate,at 1.0 0.000143348623853 1 0 1
retinyl,acetate,and 1.0 0.000143348623853 1 0 1
retinyl,acetate,affected 1.0 0.000143348623853 1 0 1
retention,of,was 1.0 0.000143348623853 1 0 1
retention,blurred,vision 1.0 0.000143348623853 1 0 1
retention,and,blurred 1.0 0.000143348623853 1 0 1
retard,may,enhance 1.0 0.000143348623853 1 0 1
retard,and,then 1.0 0.000143348623853 1 0 1
results,would,seem 1.0 0.000143348623853 1 0 1
results,the,geometric 1.0 0.000143348623853 1 0 1
results,regarding,the 1.0 0.000143348623853 1 0 1
results,raise,the 1.0 0.000143348623853 1 0 1
results,of,using 1.0 0.000143348623853 1 0 1
results,of,preliminary 1.0 0.000143348623853 1 0 1
results,in,reduced 1.0 0.000143348623853 1 0 1
results,in,prolongation 1.0 0.000143348623853 1 0 1
results,in,inhibition 1.0 0.000143348623853 1 0 1
results,in,increased 1.0 0.000143348623853 1 0 1
results,in,free 1.0 0.000143348623853 1 0 1
results,in,excessive 1.0 0.000143348623853 1 0 1
results,in,approximately 1.0 0.000143348623853 1 0 1
results,from,the 1.0 0.000143348623853 1 0 1
results,from,regression 1.0 0.000143348623853 1 0 1
results,for,the 1.0 0.000143348623853 1 0 1
results,during,treatment 1.0 0.000143348623853 1 0 1
results,do,not 1.0 0.000143348623853 1 0 1
results,and,pancreatic 1.0 0.000143348623853 1 0 1
resulting,respiratory,depression 1.0 0.000143348623853 1 0 1
resulting,interference,with 1.0 0.000143348623853 1 0 1
resulting,in,unexpectedly 1.0 0.000143348623853 1 0 1
resulting,in,toxicity 1.0 0.000143348623853 1 0 1
resulting,in,rare 1.0 0.000143348623853 1 0 1
resulting,in,qt 1.0 0.000143348623853 1 0 1
resulting,in,low 1.0 0.000143348623853 1 0 1
resulting,in,increases 1.0 0.000143348623853 1 0 1
resulting,in,excessive 1.0 0.000143348623853 1 0 1
resulting,in,death 1.0 0.000143348623853 1 0 1
resulting,in,concentrations 1.0 0.000143348623853 1 0 1
resulting,from,cholinergic 1.0 0.000143348623853 1 0 1
resulted,when,amines 1.0 0.000143348623853 1 0 1
resulted,in,substantial 1.0 0.000143348623853 1 0 1
resulted,in,slight 1.0 0.000143348623853 1 0 1
resulted,in,significantly 1.0 0.000143348623853 1 0 1
resulted,in,reversible 1.0 0.000143348623853 1 0 1
resulted,in,prolongation 1.0 0.000143348623853 1 0 1
resulted,in,previous 1.0 0.000143348623853 1 0 1
resulted,in,markedly 1.0 0.000143348623853 1 0 1
resulted,in,lowering 1.0 0.000143348623853 1 0 1
resulted,in,lower 1.0 0.000143348623853 1 0 1
resulted,in,interactions 1.0 0.000143348623853 1 0 1
resulted,in,induction 1.0 0.000143348623853 1 0 1
resulted,in,increase 1.0 0.000143348623853 1 0 1
resulted,in,greater 1.0 0.000143348623853 1 0 1
resulted,in,decreases 1.0 0.000143348623853 1 0 1
resulted,in,additive 1.0 0.000143348623853 1 0 1
resulted,in,about 1.0 0.000143348623853 1 0 1
result,of,a 1.0 0.000143348623853 1 0 1
result,in,uterine 1.0 0.000143348623853 1 0 1
result,in,substantial 1.0 0.000143348623853 1 0 1
result,in,sub-therapeutic 1.0 0.000143348623853 1 0 1
result,in,severe 1.0 0.000143348623853 1 0 1
result,in,lower 1.0 0.000143348623853 1 0 1
result,in,low 1.0 0.000143348623853 1 0 1
result,in,insufficient 1.0 0.000143348623853 1 0 1
result,in,fold 1.0 0.000143348623853 1 0 1
result,in,fatal 1.0 0.000143348623853 1 0 1
result,in,coma 1.0 0.000143348623853 1 0 1
result,in,advanced 1.0 0.000143348623853 1 0 1
result,if,is 1.0 0.000143348623853 1 0 1
result,i,n 1.0 0.000143348623853 1 0 1
result,from,the 1.0 0.000143348623853 1 0 1
result,from,combined 1.0 0.000143348623853 1 0 1
restriction,or,dialysis 1.0 0.000143348623853 1 0 1
restricted,antagonist,that 1.0 0.000143348623853 1 0 1
responsiveness,of,an 1.0 0.000143348623853 1 0 1
responsible,for,converting 1.0 0.000143348623853 1 0 1
responses,in,a 1.0 0.000143348623853 1 0 1
responses,have,been 1.0 0.000143348623853 1 0 1
responses,both,ca 1.0 0.000143348623853 1 0 1
response,to,toxoids 1.0 0.000143348623853 1 0 1
response,to,or 1.0 0.000143348623853 1 0 1
response,to,indirect-acting 1.0 0.000143348623853 1 0 1
response,to,factrel 1.0 0.000143348623853 1 0 1
response,to,either 1.0 0.000143348623853 1 0 1
response,to,although 1.0 0.000143348623853 1 0 1
response,to,agents 1.0 0.000143348623853 1 0 1
response,through,increased 1.0 0.000143348623853 1 0 1
response,of,male 1.0 0.000143348623853 1 0 1
response,is,less 1.0 0.000143348623853 1 0 1
response,duration,suggesting 1.0 0.000143348623853 1 0 1
response,by,displacing 1.0 0.000143348623853 1 0 1
responding,produced,by 1.0 0.000143348623853 1 0 1
responding,in,a 1.0 0.000143348623853 1 0 1
respiratory,depression,stupor 1.0 0.000143348623853 1 0 1
respectively,when,was 1.0 0.000143348623853 1 0 1
respectively,when,administered 1.0 0.000143348623853 1 0 1
respectively,were,added 1.0 0.000143348623853 1 0 1
respectively,suggesting,that 1.0 0.000143348623853 1 0 1
respectively,suggesting,an 1.0 0.000143348623853 1 0 1
respectively,resulted,in 1.0 0.000143348623853 1 0 1
respectively,on,the 1.0 0.000143348623853 1 0 1
respectively,of,those 1.0 0.000143348623853 1 0 1
respectively,compared,to 1.0 0.000143348623853 1 0 1
respectively,by,the 1.0 0.000143348623853 1 0 1
respectively,and,mean 1.0 0.000143348623853 1 0 1
respectively,and,in 1.0 0.000143348623853 1 0 1
respectively,and,for 1.0 0.000143348623853 1 0 1
respectively,and,did 1.0 0.000143348623853 1 0 1
respectively,after,days 1.0 0.000143348623853 1 0 1
respectively,a,strong 1.0 0.000143348623853 1 0 1
respectively,a,number 1.0 0.000143348623853 1 0 1
resolution,of,the 1.0 0.000143348623853 1 0 1
resistance,to,the 1.0 0.000143348623853 1 0 1
resins,since,bile 1.0 0.000143348623853 1 0 1
resins,an,interval 1.0 0.000143348623853 1 0 1
residual,effects,of 1.0 0.000143348623853 1 0 1
resemblance,of,and 1.0 0.000143348623853 1 0 1
requiring,increased,dosage 1.0 0.000143348623853 1 0 1
requiring,an,increase 1.0 0.000143348623853 1 0 1
requires,tikosyn,and 1.0 0.000143348623853 1 0 1
requirements,of,nimbex 1.0 0.000143348623853 1 0 1
requirements,in,human 1.0 0.000143348623853 1 0 1
requirements,for,volatile 1.0 0.000143348623853 1 0 1
requirement,of,our 1.0 0.000143348623853 1 0 1
requirement,i,mac 1.0 0.000143348623853 1 0 1
required,when,is 1.0 0.000143348623853 1 0 1
required,when,hydrochloride 1.0 0.000143348623853 1 0 1
required,when,anafranil 1.0 0.000143348623853 1 0 1
required,to,treat 1.0 0.000143348623853 1 0 1
required,to,prevent 1.0 0.000143348623853 1 0 1
required,to,antagonize 1.0 0.000143348623853 1 0 1
required,or,may 1.0 0.000143348623853 1 0 1
required,may,be 1.0 0.000143348623853 1 0 1
required,it,is 1.0 0.000143348623853 1 0 1
required,infusion,rate 1.0 0.000143348623853 1 0 1
required,concentrations,and 1.0 0.000143348623853 1 0 1
required,and,pth 1.0 0.000143348623853 1 0 1
require,that,the 1.0 0.000143348623853 1 0 1
require,replacement,therapy 1.0 0.000143348623853 1 0 1
require,increases,in 1.0 0.000143348623853 1 0 1
require,close,monitoring 1.0 0.000143348623853 1 0 1
require,additional,titration 1.0 0.000143348623853 1 0 1
require,a,reduction 1.0 0.000143348623853 1 0 1
require,a,dose 1.0 0.000143348623853 1 0 1
representing,a,potential 1.0 0.000143348623853 1 0 1
reports,there,may 1.0 0.000143348623853 1 0 1
reports,that,the 1.0 0.000143348623853 1 0 1
reports,that,may 1.0 0.000143348623853 1 0 1
reports,suggesting,that 1.0 0.000143348623853 1 0 1
reports,of,withdrawal 1.0 0.000143348623853 1 0 1
reports,of,significant 1.0 0.000143348623853 1 0 1
reports,of,serotonin 1.0 0.000143348623853 1 0 1
reports,of,prolonged 1.0 0.000143348623853 1 0 1
reports,of,prolongation 1.0 0.000143348623853 1 0 1
reports,of,profound 1.0 0.000143348623853 1 0 1
reports,of,enhanced 1.0 0.000143348623853 1 0 1
reports,of,both 1.0 0.000143348623853 1 0 1
reports,of,an 1.0 0.000143348623853 1 0 1
reports,of,adverse 1.0 0.000143348623853 1 0 1
reports,however,from 1.0 0.000143348623853 1 0 1
reports,describing,patients 1.0 0.000143348623853 1 0 1
reports,describe,modest 1.0 0.000143348623853 1 0 1
reportedly,resulted,in 1.0 0.000143348623853 1 0 1
reportedly,are,increased 1.0 0.000143348623853 1 0 1
reported,with,therapeutic 1.0 0.000143348623853 1 0 1
reported,with,cefizox 1.0 0.000143348623853 1 0 1
reported,with,caution 1.0 0.000143348623853 1 0 1
reported,when,was 1.0 0.000143348623853 1 0 1
reported,when,toradol 1.0 0.000143348623853 1 0 1
reported,when,and 1.0 0.000143348623853 1 0 1
reported,when,amitriptyline 1.0 0.000143348623853 1 0 1
reported,very,rarely 1.0 0.000143348623853 1 0 1
reported,upon,discontinuation 1.0 0.000143348623853 1 0 1
reported,to,significantly 1.0 0.000143348623853 1 0 1
reported,to,prolong 1.0 0.000143348623853 1 0 1
reported,to,lead 1.0 0.000143348623853 1 0 1
reported,to,inactivate 1.0 0.000143348623853 1 0 1
reported,to,fluctuate 1.0 0.000143348623853 1 0 1
reported,to,competitively 1.0 0.000143348623853 1 0 1
reported,to,both 1.0 0.000143348623853 1 0 1
reported,to,block 1.0 0.000143348623853 1 0 1
reported,to,affect 1.0 0.000143348623853 1 0 1
reported,that,when 1.0 0.000143348623853 1 0 1
reported,that,the 1.0 0.000143348623853 1 0 1
reported,that,results 1.0 0.000143348623853 1 0 1
reported,that,prolongs 1.0 0.000143348623853 1 0 1
reported,that,may 1.0 0.000143348623853 1 0 1
reported,that,itraconazole 1.0 0.000143348623853 1 0 1
reported,that,can 1.0 0.000143348623853 1 0 1
reported,resulting,in 1.0 0.000143348623853 1 0 1
reported,rarely,with 1.0 0.000143348623853 1 0 1
reported,rarely,when 1.0 0.000143348623853 1 0 1
reported,predominantly,in 1.0 0.000143348623853 1 0 1
reported,l-histidine,via 1.0 0.000143348623853 1 0 1
reported,in,which 1.0 0.000143348623853 1 0 1
reported,in,postmarketing 1.0 0.000143348623853 1 0 1
reported,in,organ 1.0 0.000143348623853 1 0 1
reported,in,elderly 1.0 0.000143348623853 1 0 1
reported,in,association 1.0 0.000143348623853 1 0 1
reported,from,the 1.0 0.000143348623853 1 0 1
reported,following,doses 1.0 0.000143348623853 1 0 1
reported,during,with 1.0 0.000143348623853 1 0 1
reported,during,therapy 1.0 0.000143348623853 1 0 1
reported,during,the 1.0 0.000143348623853 1 0 1
reported,due,to 1.0 0.000143348623853 1 0 1
reported,concomitant,use 1.0 0.000143348623853 1 0 1
reported,case,of 1.0 0.000143348623853 1 0 1
reported,both,weight 1.0 0.000143348623853 1 0 1
reported,as,international 1.0 0.000143348623853 1 0 1
report,which,suggests 1.0 0.000143348623853 1 0 1
report,the,case 1.0 0.000143348623853 1 0 1
report,that,may 1.0 0.000143348623853 1 0 1
report,suggesting,that 1.0 0.000143348623853 1 0 1
report,of,severe 1.0 0.000143348623853 1 0 1
report,of,prolonged 1.0 0.000143348623853 1 0 1
report,of,one 1.0 0.000143348623853 1 0 1
report,nine,patients 1.0 0.000143348623853 1 0 1
report,l-glutamine,at 1.0 0.000143348623853 1 0 1
report,describes,two 1.0 0.000143348623853 1 0 1
replication,of,some 1.0 0.000143348623853 1 0 1
replacing,by,therapy 1.0 0.000143348623853 1 0 1
replacement,therapy,should 1.0 0.000143348623853 1 0 1
replacement,therapy,free 1.0 0.000143348623853 1 0 1
repeated,doses,of 1.0 0.000143348623853 1 0 1
repeated,co-administration,of 1.0 0.000143348623853 1 0 1
renin,release,the 1.0 0.000143348623853 1 0 1
renin,release,captopril 1.0 0.000143348623853 1 0 1
renal,uptake,to 1.0 0.000143348623853 1 0 1
renal,tubular,transport 1.0 0.000143348623853 1 0 1
renal,tubular,excretion 1.0 0.000143348623853 1 0 1
renal,transplant,patients 1.0 0.000143348623853 1 0 1
renal,toxicity,of 1.0 0.000143348623853 1 0 1
renal,toxicity,bronchospasm 1.0 0.000143348623853 1 0 1
renal,prostaglandins,may 1.0 0.000143348623853 1 0 1
renal,insufficiency,hyperbilirubinemia 1.0 0.000143348623853 1 0 1
renal,impairment,the 1.0 0.000143348623853 1 0 1
renal,impairment,reportedly 1.0 0.000143348623853 1 0 1
renal,impairment,clcr 1.0 0.000143348623853 1 0 1
renal,function,the 1.0 0.000143348623853 1 0 1
renal,function,accompanied 1.0 0.000143348623853 1 0 1
renal,failure,in 1.0 0.000143348623853 1 0 1
renal,failure,and 1.0 0.000143348623853 1 0 1
renal,excretion,is 1.0 0.000143348623853 1 0 1
renal,elimination,but 1.0 0.000143348623853 1 0 1
renal,dysfunction,by 1.0 0.000143348623853 1 0 1
renal,clearances,by 1.0 0.000143348623853 1 0 1
renal,clearance,with 1.0 0.000143348623853 1 0 1
renal,clearance,measurements 1.0 0.000143348623853 1 0 1
removes,the,antiedematous 1.0 0.000143348623853 1 0 1
remicade,used,in 1.0 0.000143348623853 1 0 1
remedies,and,vasoconstrictive 1.0 0.000143348623853 1 0 1
reliable,when,tracleer 1.0 0.000143348623853 1 0 1
reliable,method,of 1.0 0.000143348623853 1 0 1
relevant,interaction,of 1.0 0.000143348623853 1 0 1
relevant,elevation,of 1.0 0.000143348623853 1 0 1
relevant,effect,was 1.0 0.000143348623853 1 0 1
relevant,consequences,for 1.0 0.000143348623853 1 0 1
releaser,and,reuptake 1.0 0.000143348623853 1 0 1
release,the,antihypertensive 1.0 0.000143348623853 1 0 1
release,tablets,the 1.0 0.000143348623853 1 0 1
release,tablets,administration 1.0 0.000143348623853 1 0 1
release,of,caused 1.0 0.000143348623853 1 0 1
release,from,the 1.0 0.000143348623853 1 0 1
release,captopril,s 1.0 0.000143348623853 1 0 1
release,capsules,there 1.0 0.000143348623853 1 0 1
release,capsules,since 1.0 0.000143348623853 1 0 1
release,but,not 1.0 0.000143348623853 1 0 1
relaxing,effect,of 1.0 0.000143348623853 1 0 1
relaxants,most,notably 1.0 0.000143348623853 1 0 1
relaxants,may,temporarily 1.0 0.000143348623853 1 0 1
relaxants,eg,and 1.0 0.000143348623853 1 0 1
relaxants,could,be 1.0 0.000143348623853 1 0 1
relaxants,and,the 1.0 0.000143348623853 1 0 1
relaxants,and,mac 1.0 0.000143348623853 1 0 1
relaxants,amphotericin,b-induced 1.0 0.000143348623853 1 0 1
relaxant,effect,of 1.0 0.000143348623853 1 0 1
relative,to,that 1.0 0.000143348623853 1 0 1
relationship,with,amphotericin 1.0 0.000143348623853 1 0 1
relationship,physicians,should 1.0 0.000143348623853 1 0 1
relationship,of,accutane 1.0 0.000143348623853 1 0 1
relationship,have,not 1.0 0.000143348623853 1 0 1
relationship,and,a 1.0 0.000143348623853 1 0 1
related,to,intravenous 1.0 0.000143348623853 1 0 1
related,to,cytochrome 1.0 0.000143348623853 1 0 1
related,to,amide-type 1.0 0.000143348623853 1 0 1
related,presumably,through 1.0 0.000143348623853 1 0 1
related,member,of 1.0 0.000143348623853 1 0 1
related,may,increase 1.0 0.000143348623853 1 0 1
related,may,decrease 1.0 0.000143348623853 1 0 1
related,have,been 1.0 0.000143348623853 1 0 1
related,compounds,eg 1.0 0.000143348623853 1 0 1
regulate,the,proliferation 1.0 0.000143348623853 1 0 1
regularly,for,alterations 1.0 0.000143348623853 1 0 1
regression,analyses,of 1.0 0.000143348623853 1 0 1
regimens,who,were 1.0 0.000143348623853 1 0 1
regimens,containing,sequential 1.0 0.000143348623853 1 0 1
regimen,particularly,in 1.0 0.000143348623853 1 0 1
regimen,of,oral 1.0 0.000143348623853 1 0 1
regimen,includes,both 1.0 0.000143348623853 1 0 1
regimen,did,not 1.0 0.000143348623853 1 0 1
regimen,consisting,of 1.0 0.000143348623853 1 0 1
regardless,of,whether 1.0 0.000143348623853 1 0 1
refractory,to,in 1.0 0.000143348623853 1 0 1
reflex,tachycardia,produced 1.0 0.000143348623853 1 0 1
reflects,an,approximate 1.0 0.000143348623853 1 0 1
reflected,in,urinary 1.0 0.000143348623853 1 0 1
reexacerbation,of,pulmonary 1.0 0.000143348623853 1 0 1
reductions,of,mm 1.0 0.000143348623853 1 0 1
reductions,in,elimination 1.0 0.000143348623853 1 0 1
reductions,in,blood 1.0 0.000143348623853 1 0 1
reduction,when,coadminstered 1.0 0.000143348623853 1 0 1
reduction,was,greater 1.0 0.000143348623853 1 0 1
reduction,of,oral 1.0 0.000143348623853 1 0 1
reduction,of,mean 1.0 0.000143348623853 1 0 1
reduction,of,dose 1.0 0.000143348623853 1 0 1
reduction,of,approximately 1.0 0.000143348623853 1 0 1
reduction,is,not 1.0 0.000143348623853 1 0 1
reduction,in,urinary 1.0 0.000143348623853 1 0 1
reduction,in,serum 1.0 0.000143348623853 1 0 1
reduction,in,levels 1.0 0.000143348623853 1 0 1
reduction,in,effect 1.0 0.000143348623853 1 0 1
reduction,in,cell 1.0 0.000143348623853 1 0 1
reduction,in,cardiac 1.0 0.000143348623853 1 0 1
reduction,in,blood 1.0 0.000143348623853 1 0 1
reduction,in,and 1.0 0.000143348623853 1 0 1
reductase,inhibitors,the 1.0 0.000143348623853 1 0 1
reductase,inhibitors,should 1.0 0.000143348623853 1 0 1
reductase,inhibitors,in 1.0 0.000143348623853 1 0 1
reductase,inhibitors,have 1.0 0.000143348623853 1 0 1
reductase,inhibitors,administered 1.0 0.000143348623853 1 0 1
reductase,inhibitor,is 1.0 0.000143348623853 1 0 1
reductase,inhibitor,has 1.0 0.000143348623853 1 0 1
reductase,inhibitor,class 1.0 0.000143348623853 1 0 1
reducing,the,plasma 1.0 0.000143348623853 1 0 1
reducing,the,number 1.0 0.000143348623853 1 0 1
reducing,effect,of 1.0 0.000143348623853 1 0 1
reducing,absorption,from 1.0 0.000143348623853 1 0 1
reduces,urinary,excretion 1.0 0.000143348623853 1 0 1
reduces,the,tubular 1.0 0.000143348623853 1 0 1
reduces,the,renal 1.0 0.000143348623853 1 0 1
reduces,the,rate 1.0 0.000143348623853 1 0 1
reduces,the,level 1.0 0.000143348623853 1 0 1
reduces,the,blood 1.0 0.000143348623853 1 0 1
reduces,both,the 1.0 0.000143348623853 1 0 1
reduced,while,the 1.0 0.000143348623853 1 0 1
reduced,when,it 1.0 0.000143348623853 1 0 1
reduced,when,given 1.0 0.000143348623853 1 0 1
reduced,upon,discontinuation 1.0 0.000143348623853 1 0 1
reduced,tysabri,clearance 1.0 0.000143348623853 1 0 1
reduced,tolerance,in 1.0 0.000143348623853 1 0 1
reduced,to,prevent 1.0 0.000143348623853 1 0 1
reduced,to,one 1.0 0.000143348623853 1 0 1
reduced,thus,necessitating 1.0 0.000143348623853 1 0 1
reduced,the,urine 1.0 0.000143348623853 1 0 1
reduced,the,response 1.0 0.000143348623853 1 0 1
reduced,the,rate 1.0 0.000143348623853 1 0 1
reduced,the,plasma 1.0 0.000143348623853 1 0 1
reduced,the,oral 1.0 0.000143348623853 1 0 1
reduced,the,blood 1.0 0.000143348623853 1 0 1
reduced,the,bioavailability 1.0 0.000143348623853 1 0 1
reduced,the,antitumour 1.0 0.000143348623853 1 0 1
reduced,serum,levels 1.0 0.000143348623853 1 0 1
reduced,protein,binding 1.0 0.000143348623853 1 0 1
reduced,or,the 1.0 0.000143348623853 1 0 1
reduced,or,eliminated 1.0 0.000143348623853 1 0 1
reduced,or,abolished 1.0 0.000143348623853 1 0 1
reduced,infusion,rates 1.0 0.000143348623853 1 0 1
reduced,if,a 1.0 0.000143348623853 1 0 1
reduced,from,ml 1.0 0.000143348623853 1 0 1
reduced,from,approximately 1.0 0.000143348623853 1 0 1
reduced,extent,of 1.0 0.000143348623853 1 0 1
reduced,dosage,of 1.0 0.000143348623853 1 0 1
reduced,creatinine,clearance 1.0 0.000143348623853 1 0 1
reduced,cmax,up 1.0 0.000143348623853 1 0 1
reduced,cmax,and 1.0 0.000143348623853 1 0 1
reduced,clearance,based 1.0 0.000143348623853 1 0 1
reduced,clearance,a 1.0 0.000143348623853 1 0 1
reduced,by,with 1.0 0.000143348623853 1 0 1
reduced,by,tromethamine 1.0 0.000143348623853 1 0 1
reduced,by,the 1.0 0.000143348623853 1 0 1
reduced,by,pretreatment 1.0 0.000143348623853 1 0 1
reduced,by,hepatic 1.0 0.000143348623853 1 0 1
reduced,by,concomitant 1.0 0.000143348623853 1 0 1
reduced,by,at 1.0 0.000143348623853 1 0 1
reduced,by,approx 1.0 0.000143348623853 1 0 1
reduced,by,an 1.0 0.000143348623853 1 0 1
reduced,by,about 1.0 0.000143348623853 1 0 1
reduced,and,signs 1.0 0.000143348623853 1 0 1
reduced,although,the 1.0 0.000143348623853 1 0 1
reduced,accordingly,in 1.0 0.000143348623853 1 0 1
reduce,the,tubular 1.0 0.000143348623853 1 0 1
reduce,the,therapeutic 1.0 0.000143348623853 1 0 1
reduce,the,oral 1.0 0.000143348623853 1 0 1
reduce,the,number 1.0 0.000143348623853 1 0 1
reduce,the,hepatic 1.0 0.000143348623853 1 0 1
reduce,the,gastrointestinal 1.0 0.000143348623853 1 0 1
reduce,the,effects 1.0 0.000143348623853 1 0 1
reduce,the,diuretic 1.0 0.000143348623853 1 0 1
reduce,the,clearance 1.0 0.000143348623853 1 0 1
reduce,the,antitumor 1.0 0.000143348623853 1 0 1
reduce,the,action 1.0 0.000143348623853 1 0 1
reduce,seizure,control 1.0 0.000143348623853 1 0 1
reduce,proleukin-induced,side 1.0 0.000143348623853 1 0 1
reduce,lithiums,renal 1.0 0.000143348623853 1 0 1
reduce,its,absorption 1.0 0.000143348623853 1 0 1
reduce,hepatic,metabolism 1.0 0.000143348623853 1 0 1
reduce,both,the 1.0 0.000143348623853 1 0 1
reddish,color,is 1.0 0.000143348623853 1 0 1
recovery,took,min 1.0 0.000143348623853 1 0 1
recovery,time,may 1.0 0.000143348623853 1 0 1
recovery,of,hoof 1.0 0.000143348623853 1 0 1
recovery,of,fade 1.0 0.000143348623853 1 0 1
recovery,from,twitch 1.0 0.000143348623853 1 0 1
recovery,following,an 1.0 0.000143348623853 1 0 1
recovered,from,succinylcholine-induced 1.0 0.000143348623853 1 0 1
recommended,when,used 1.0 0.000143348623853 1 0 1
recommended,when,initiating 1.0 0.000143348623853 1 0 1
recommended,when,and 1.0 0.000143348623853 1 0 1
recommended,when,administered 1.0 0.000143348623853 1 0 1
recommended,unless,the 1.0 0.000143348623853 1 0 1
recommended,to,be 1.0 0.000143348623853 1 0 1
recommended,to,avoid 1.0 0.000143348623853 1 0 1
recommended,that,they 1.0 0.000143348623853 1 0 1
recommended,that,plasma 1.0 0.000143348623853 1 0 1
recommended,that,not 1.0 0.000143348623853 1 0 1
recommended,that,in 1.0 0.000143348623853 1 0 1
recommended,that,if 1.0 0.000143348623853 1 0 1
recommended,that,fluvoxamine 1.0 0.000143348623853 1 0 1
recommended,that,ecg 1.0 0.000143348623853 1 0 1
recommended,that,concentrations 1.0 0.000143348623853 1 0 1
recommended,that,buspirone 1.0 0.000143348623853 1 0 1
recommended,since,may 1.0 0.000143348623853 1 0 1
recommended,maximum,human 1.0 0.000143348623853 1 0 1
recommended,maximum,cumulative 1.0 0.000143348623853 1 0 1
recommended,it,should 1.0 0.000143348623853 1 0 1
recommended,for,when 1.0 0.000143348623853 1 0 1
recommended,during,treatment 1.0 0.000143348623853 1 0 1
recommended,doses,vioxx 1.0 0.000143348623853 1 0 1
recommended,dose,in 1.0 0.000143348623853 1 0 1
recommended,dosages,or 1.0 0.000143348623853 1 0 1
reciprocal,interactions,may 1.0 0.000143348623853 1 0 1
recipients,a,reduction 1.0 0.000143348623853 1 0 1
receptors,such,as 1.0 0.000143348623853 1 0 1
receptor,antagonists,the 1.0 0.000143348623853 1 0 1
receptor,antagonists,hypertension 1.0 0.000143348623853 1 0 1
receptor,antagonists,cimetidine 1.0 0.000143348623853 1 0 1
recently,instituted,as 1.0 0.000143348623853 1 0 1
recent,study,has 1.0 0.000143348623853 1 0 1
recent,case,study 1.0 0.000143348623853 1 0 1
receiving,zyvox,may 1.0 0.000143348623853 1 0 1
receiving,with,agents 1.0 0.000143348623853 1 0 1
receiving,will,have 1.0 0.000143348623853 1 0 1
receiving,velcade,treatment 1.0 0.000143348623853 1 0 1
receiving,tricyclic,and 1.0 0.000143348623853 1 0 1
receiving,to,mg 1.0 0.000143348623853 1 0 1
receiving,these,concomitant 1.0 0.000143348623853 1 0 1
receiving,there,have 1.0 0.000143348623853 1 0 1
receiving,therapy,who 1.0 0.000143348623853 1 0 1
receiving,therapy,should 1.0 0.000143348623853 1 0 1
receiving,the,plasma 1.0 0.000143348623853 1 0 1
receiving,the,dosage 1.0 0.000143348623853 1 0 1
receiving,the,cyp3a4 1.0 0.000143348623853 1 0 1
receiving,the,administration 1.0 0.000143348623853 1 0 1
receiving,tambocor,and 1.0 0.000143348623853 1 0 1
receiving,revia,the 1.0 0.000143348623853 1 0 1
receiving,replacement,therapy 1.0 0.000143348623853 1 0 1
receiving,purinethol,or 1.0 0.000143348623853 1 0 1
receiving,prothrombin,times 1.0 0.000143348623853 1 0 1
receiving,prinivil,an 1.0 0.000143348623853 1 0 1
receiving,other,local 1.0 0.000143348623853 1 0 1
receiving,other,general 1.0 0.000143348623853 1 0 1
receiving,other,antianxiety 1.0 0.000143348623853 1 0 1
receiving,oral,and 1.0 0.000143348623853 1 0 1
receiving,oral,an 1.0 0.000143348623853 1 0 1
receiving,or,similar 1.0 0.000143348623853 1 0 1
receiving,or,monoamine 1.0 0.000143348623853 1 0 1
receiving,or,in 1.0 0.000143348623853 1 0 1
receiving,or,halogenated 1.0 0.000143348623853 1 0 1
receiving,or,concurrently 1.0 0.000143348623853 1 0 1
receiving,nonselective,monoamine 1.0 0.000143348623853 1 0 1
receiving,nalfon,and 1.0 0.000143348623853 1 0 1
receiving,multiple,doses 1.0 0.000143348623853 1 0 1
receiving,mg,fe 1.0 0.000143348623853 1 0 1
receiving,mg,bid 1.0 0.000143348623853 1 0 1
receiving,may,be 1.0 0.000143348623853 1 0 1
receiving,long-,term 1.0 0.000143348623853 1 0 1
receiving,known,enzyme 1.0 0.000143348623853 1 0 1
receiving,intravenous,amphotericin 1.0 0.000143348623853 1 0 1
receiving,in,combination 1.0 0.000143348623853 1 0 1
receiving,hydrochloride,is 1.0 0.000143348623853 1 0 1
receiving,hmg-coa,reductase 1.0 0.000143348623853 1 0 1
receiving,hctz,alone 1.0 0.000143348623853 1 0 1
receiving,hcl,has 1.0 0.000143348623853 1 0 1
receiving,hcl,alternatives 1.0 0.000143348623853 1 0 1
receiving,gm,daily 1.0 0.000143348623853 1 0 1
receiving,either,tagamet 1.0 0.000143348623853 1 0 1
receiving,either,or 1.0 0.000143348623853 1 0 1
receiving,decreased,the 1.0 0.000143348623853 1 0 1
receiving,coumarin-type,the 1.0 0.000143348623853 1 0 1
receiving,concurrently,with 1.0 0.000143348623853 1 0 1
receiving,concomitant,high-dose 1.0 0.000143348623853 1 0 1
receiving,concomitant,antihypertensive 1.0 0.000143348623853 1 0 1
receiving,comedication,particularly 1.0 0.000143348623853 1 0 1
receiving,combination,regimens 1.0 0.000143348623853 1 0 1
receiving,cautious,titration 1.0 0.000143348623853 1 0 1
receiving,careful,monitoring 1.0 0.000143348623853 1 0 1
receiving,camptosar,and 1.0 0.000143348623853 1 0 1
receiving,both,as 1.0 0.000143348623853 1 0 1
receiving,azole,agents 1.0 0.000143348623853 1 0 1
receiving,appeared,to 1.0 0.000143348623853 1 0 1
receiving,antihypertensive,medications 1.0 0.000143348623853 1 0 1
receiving,another,serotonin 1.0 0.000143348623853 1 0 1
receiving,and,which 1.0 0.000143348623853 1 0 1
receiving,and,serious 1.0 0.000143348623853 1 0 1
receiving,and,or 1.0 0.000143348623853 1 0 1
receiving,and,concurrently 1.0 0.000143348623853 1 0 1
receiving,and,concomitantly 1.0 0.000143348623853 1 0 1
receiving,a,cyp3a4 1.0 0.000143348623853 1 0 1
receiving,a,course 1.0 0.000143348623853 1 0 1
receiving,a,beta-adrenergic 1.0 0.000143348623853 1 0 1
received,the,recommended 1.0 0.000143348623853 1 0 1
received,or,is 1.0 0.000143348623853 1 0 1
received,muscle,relaxants 1.0 0.000143348623853 1 0 1
received,maoi,within 1.0 0.000143348623853 1 0 1
received,increases,the 1.0 0.000143348623853 1 0 1
receive,mg,of 1.0 0.000143348623853 1 0 1
receive,initial,doses 1.0 0.000143348623853 1 0 1
rebound,in,uptake 1.0 0.000143348623853 1 0 1
rebound,hypertension,which 1.0 0.000143348623853 1 0 1
rebound,hypertension,when 1.0 0.000143348623853 1 0 1
reasons,it,is 1.0 0.000143348623853 1 0 1
reactions,to,products 1.0 0.000143348623853 1 0 1
reactions,to,iodinated 1.0 0.000143348623853 1 0 1
reactions,the,main 1.0 0.000143348623853 1 0 1
reactions,patients,with 1.0 0.000143348623853 1 0 1
reactions,of,if 1.0 0.000143348623853 1 0 1
reactions,is,advised 1.0 0.000143348623853 1 0 1
reactions,including,hyperthermia 1.0 0.000143348623853 1 0 1
reactions,including,hypertensive 1.0 0.000143348623853 1 0 1
reactions,develop,in 1.0 0.000143348623853 1 0 1
reaction,to,any 1.0 0.000143348623853 1 0 1
reaction,time,for 1.0 0.000143348623853 1 0 1
reaction,of,placental 1.0 0.000143348623853 1 0 1
reaction,of,actinic 1.0 0.000143348623853 1 0 1
reaction,may,occur 1.0 0.000143348623853 1 0 1
reaction,between,a 1.0 0.000143348623853 1 0 1
reaction,and,lead 1.0 0.000143348623853 1 0 1
reaction,although,it 1.0 0.000143348623853 1 0 1
react,with,in 1.0 0.000143348623853 1 0 1
reached,after,administration 1.0 0.000143348623853 1 0 1
reach,to10,m 1.0 0.000143348623853 1 0 1
rauwolfia,alkaloid,while 1.0 0.000143348623853 1 0 1
rats,with,mg 1.0 0.000143348623853 1 0 1
rats,with,experimental 1.0 0.000143348623853 1 0 1
rats,were,supersensitive 1.0 0.000143348623853 1 0 1
rats,suggest,that 1.0 0.000143348623853 1 0 1
rats,simultaneous,ingestion 1.0 0.000143348623853 1 0 1
rats,results,in 1.0 0.000143348623853 1 0 1
rats,responding,in 1.0 0.000143348623853 1 0 1
rats,pd2,values 1.0 0.000143348623853 1 0 1
rats,in,a 1.0 0.000143348623853 1 0 1
rats,hydrochloride,was 1.0 0.000143348623853 1 0 1
rats,have,shown 1.0 0.000143348623853 1 0 1
rats,given,high 1.0 0.000143348623853 1 0 1
rats,epidural,injection 1.0 0.000143348623853 1 0 1
rats,decreased,by 1.0 0.000143348623853 1 0 1
rats,at,approximately 1.0 0.000143348623853 1 0 1
ratio,when,arava 1.0 0.000143348623853 1 0 1
ratio,or,inr 1.0 0.000143348623853 1 0 1
rating,scale,were 1.0 0.000143348623853 1 0 1
rates,of,nimbex 1.0 0.000143348623853 1 0 1
rate-decreasing,effects,of 1.0 0.000143348623853 1 0 1
rate,when,taken 1.0 0.000143348623853 1 0 1
rate,requirements,may 1.0 0.000143348623853 1 0 1
rate,of,metabolism 1.0 0.000143348623853 1 0 1
rate,of,excretion 1.0 0.000143348623853 1 0 1
rate,increase,following 1.0 0.000143348623853 1 0 1
rate,compared,with 1.0 0.000143348623853 1 0 1
rate,cmax,and 1.0 0.000143348623853 1 0 1
rat,stomach,to 1.0 0.000143348623853 1 0 1
rat,brain,and 1.0 0.000143348623853 1 0 1
rashes,is,due 1.0 0.000143348623853 1 0 1
rashes,in,patients 1.0 0.000143348623853 1 0 1
rash,while,receiving 1.0 0.000143348623853 1 0 1
rash,has,been 1.0 0.000143348623853 1 0 1
rarely,with,hemodynamic 1.0 0.000143348623853 1 0 1
rarely,with,concomitant 1.0 0.000143348623853 1 0 1
rarely,when,ht1 1.0 0.000143348623853 1 0 1
rarely,toxicity,may 1.0 0.000143348623853 1 0 1
rarely,reported,to 1.0 0.000143348623853 1 0 1
rarely,reported,due 1.0 0.000143348623853 1 0 1
rarely,in,patients 1.0 0.000143348623853 1 0 1
rare,reports,however 1.0 0.000143348623853 1 0 1
rare,but,serious 1.0 0.000143348623853 1 0 1
raptiva,should,not 1.0 0.000143348623853 1 0 1
rapid,fluctuations,of 1.0 0.000143348623853 1 0 1
rapid,and,transient 1.0 0.000143348623853 1 0 1
rapid,and,significant 1.0 0.000143348623853 1 0 1
ranitidine,in,normal 1.0 0.000143348623853 1 0 1
range,of,the 1.0 0.000143348623853 1 0 1
range,of,patients 1.0 0.000143348623853 1 0 1
range,mg,if 1.0 0.000143348623853 1 0 1
range,in,patients 1.0 0.000143348623853 1 0 1
randomized,trial,of 1.0 0.000143348623853 1 0 1
random,observations,have 1.0 0.000143348623853 1 0 1
raise,the,possibility 1.0 0.000143348623853 1 0 1
raise,serum,levels 1.0 0.000143348623853 1 0 1
radiographic,iodinated,contrast 1.0 0.000143348623853 1 0 1
radical-mediated,tissue,damage 1.0 0.000143348623853 1 0 1
rachitic,chicks,was 1.0 0.000143348623853 1 0 1
racemic,mg,given 1.0 0.000143348623853 1 0 1
racemic,mg,and 1.0 0.000143348623853 1 0 1
racemic,exposure,was 1.0 0.000143348623853 1 0 1
racemic,citalopram,citalopram 1.0 0.000143348623853 1 0 1
racemic,celexa,the 1.0 0.000143348623853 1 0 1
r-warfarin,the,less 1.0 0.000143348623853 1 0 1
r-warfarin,and,s-warfarin 1.0 0.000143348623853 1 0 1
r-warfarin,a,cyp3a4 1.0 0.000143348623853 1 0 1
quinolones,may,enhance 1.0 0.000143348623853 1 0 1
quinolones,including,nalidixic 1.0 0.000143348623853 1 0 1
quinolones,including,decrease 1.0 0.000143348623853 1 0 1
quinolones,have,also 1.0 0.000143348623853 1 0 1
quinolone,antibiotics,videx 1.0 0.000143348623853 1 0 1
quinolone,antibiotics,and 1.0 0.000143348623853 1 0 1
quinidine,immediate,release 1.0 0.000143348623853 1 0 1
quinidine,coadministration,of 1.0 0.000143348623853 1 0 1
quinidine,at,mg 1.0 0.000143348623853 1 0 1
quinidine,and,raise 1.0 0.000143348623853 1 0 1
quickens,the,onset 1.0 0.000143348623853 1 0 1
qtc,values,of 1.0 0.000143348623853 1 0 1
qtc,interval,must 1.0 0.000143348623853 1 0 1
qtc,interval,because 1.0 0.000143348623853 1 0 1
qt,prolongation,cardiac 1.0 0.000143348623853 1 0 1
qt,interval,observed 1.0 0.000143348623853 1 0 1
qid,n,the 1.0 0.000143348623853 1 0 1
qd,mg,tid 1.0 0.000143348623853 1 0 1
qd,increased,the 1.0 0.000143348623853 1 0 1
qd,for,days 1.0 0.000143348623853 1 0 1
qd,by,about 1.0 0.000143348623853 1 0 1
q12h,for,days 1.0 0.000143348623853 1 0 1
q,i,d 1.0 0.000143348623853 1 0 1
q,d,were 1.0 0.000143348623853 1 0 1
q,d,for 1.0 0.000143348623853 1 0 1
pyrazolone,derivatives,and 1.0 0.000143348623853 1 0 1
pyrantel,antiminth,taking 1.0 0.000143348623853 1 0 1
purinethol,or,imuran 1.0 0.000143348623853 1 0 1
pure,powders,showed 1.0 0.000143348623853 1 0 1
pure,agonist,such 1.0 0.000143348623853 1 0 1
pupil,size,mydriasis 1.0 0.000143348623853 1 0 1
pump,inhibitors,with 1.0 0.000143348623853 1 0 1
pump,inhibitors,was 1.0 0.000143348623853 1 0 1
pump,inhibitors,should 1.0 0.000143348623853 1 0 1
pump,inhibitors,long-term 1.0 0.000143348623853 1 0 1
pump,inhibitors,in 1.0 0.000143348623853 1 0 1
pump,inhibitors,eg 1.0 0.000143348623853 1 0 1
pump,inhibitors,and 1.0 0.000143348623853 1 0 1
pulmonary,wedge,pressure 1.0 0.000143348623853 1 0 1
pulmonary,toxicity,has 1.0 0.000143348623853 1 0 1
pulmonary,symptomatology,due 1.0 0.000143348623853 1 0 1
published,reports,describe 1.0 0.000143348623853 1 0 1
ptx,m,failed 1.0 0.000143348623853 1 0 1
pth,and,serum 1.0 0.000143348623853 1 0 1
ptca,pci,co-administration 1.0 0.000143348623853 1 0 1
pt,and,international 1.0 0.000143348623853 1 0 1
psychotropic,that,interfere 1.0 0.000143348623853 1 0 1
psychotropic,medications,the 1.0 0.000143348623853 1 0 1
psychotropic,medications,or 1.0 0.000143348623853 1 0 1
psychotropic,medications,and 1.0 0.000143348623853 1 0 1
psychotropic,have,not 1.0 0.000143348623853 1 0 1
psychotropic,agents,such 1.0 0.000143348623853 1 0 1
psychotropic,agents,is 1.0 0.000143348623853 1 0 1
psychotic,disorders,treated 1.0 0.000143348623853 1 0 1
psychomotor,performance,was 1.0 0.000143348623853 1 0 1
psychoactive,or,cns 1.0 0.000143348623853 1 0 1
psychoactive,medications,patients 1.0 0.000143348623853 1 0 1
psychoactive,drugs,hallucinations 1.0 0.000143348623853 1 0 1
psychiatric,rating,scale 1.0 0.000143348623853 1 0 1
psychiatric,patients,and 1.0 0.000143348623853 1 0 1
psychiatric,disorder,including 1.0 0.000143348623853 1 0 1
pseudotumor,cerebri,benign 1.0 0.000143348623853 1 0 1
prudent,medical,practice 1.0 0.000143348623853 1 0 1
provoke,vasoconstriction,in 1.0 0.000143348623853 1 0 1
provided,this,information 1.0 0.000143348623853 1 0 1
provided,significant,protection 1.0 0.000143348623853 1 0 1
proves,to,be 1.0 0.000143348623853 1 0 1
prothrombin,times,with 1.0 0.000143348623853 1 0 1
prothrombin,time,with 1.0 0.000143348623853 1 0 1
prothrombin,time,reported 1.0 0.000143348623853 1 0 1
prothrombin,time,pt 1.0 0.000143348623853 1 0 1
prothrombin,time,monitored 1.0 0.000143348623853 1 0 1
prothrombin,time,beyond 1.0 0.000143348623853 1 0 1
prothrombin,response,through 1.0 0.000143348623853 1 0 1
prothrombin,response,by 1.0 0.000143348623853 1 0 1
proteins,the,following 1.0 0.000143348623853 1 0 1
proteins,or,alter 1.0 0.000143348623853 1 0 1
proteins,is,only 1.0 0.000143348623853 1 0 1
proteins,and,related 1.0 0.000143348623853 1 0 1
protein-bound,with,narrow 1.0 0.000143348623853 1 0 1
protein,the,administration 1.0 0.000143348623853 1 0 1
protein,may,cause 1.0 0.000143348623853 1 0 1
protein,binding,is 1.0 0.000143348623853 1 0 1
protein,binding,in 1.0 0.000143348623853 1 0 1
protects,mouse,tumour 1.0 0.000143348623853 1 0 1
protective,effect,of 1.0 0.000143348623853 1 0 1
protection,against,the 1.0 0.000143348623853 1 0 1
protect,against,the 1.0 0.000143348623853 1 0 1
protease,inhibitors,serotonin 1.0 0.000143348623853 1 0 1
protease,inhibitors,indinavir 1.0 0.000143348623853 1 0 1
protease,inhibitors,amprenavir 1.0 0.000143348623853 1 0 1
protease,inhibitors,agenerase 1.0 0.000143348623853 1 0 1
protease,inhibitor,therapy 1.0 0.000143348623853 1 0 1
prostin,e2,may 1.0 0.000143348623853 1 0 1
prostatic,epithelium,in 1.0 0.000143348623853 1 0 1
prostate,epithelium,by 1.0 0.000143348623853 1 0 1
prostaglandins,play,an 1.0 0.000143348623853 1 0 1
prostaglandins,may,cause 1.0 0.000143348623853 1 0 1
prostaglandina,play,an 1.0 0.000143348623853 1 0 1
prostaglandin,synthesis,it 1.0 0.000143348623853 1 0 1
prostaglandin,synthesis,have 1.0 0.000143348623853 1 0 1
prostaglandin,synthase,inhibiting 1.0 0.000143348623853 1 0 1
proprietary,cold,remedies 1.0 0.000143348623853 1 0 1
propranolols,hypotensive,effect 1.0 0.000143348623853 1 0 1
propranolol,may,decrease 1.0 0.000143348623853 1 0 1
propranolol,increases,hydralazines 1.0 0.000143348623853 1 0 1
propranolol,attenuated,the 1.0 0.000143348623853 1 0 1
proposed,that,resulted 1.0 0.000143348623853 1 0 1
propose,these,pharmacokinetic 1.0 0.000143348623853 1 0 1
proportion,of,the 1.0 0.000143348623853 1 0 1
proportion,of,patients 1.0 0.000143348623853 1 0 1
prophylaxis,may,have 1.0 0.000143348623853 1 0 1
prophylactic,and,antidotal 1.0 0.000143348623853 1 0 1
property,of,to 1.0 0.000143348623853 1 0 1
properties,such,as 1.0 0.000143348623853 1 0 1
properties,of,the 1.0 0.000143348623853 1 0 1
properties,of,methylpyrazole 1.0 0.000143348623853 1 0 1
properties,may,potentiate 1.0 0.000143348623853 1 0 1
properties,may,enhance 1.0 0.000143348623853 1 0 1
properties,if,coreg 1.0 0.000143348623853 1 0 1
properties,and,the 1.0 0.000143348623853 1 0 1
properties,and,is 1.0 0.000143348623853 1 0 1
properties,and,a 1.0 0.000143348623853 1 0 1
propantheline,and,by 1.0 0.000143348623853 1 0 1
propanol,mg,kg 1.0 0.000143348623853 1 0 1
propanol,derive,from 1.0 0.000143348623853 1 0 1
pronounced,when,it 1.0 0.000143348623853 1 0 1
pronounced,though,reversible 1.0 0.000143348623853 1 0 1
pronounced,intersubject,variability 1.0 0.000143348623853 1 0 1
pronounced,if,a 1.0 0.000143348623853 1 0 1
pronounced,effect,on 1.0 0.000143348623853 1 0 1
pronestyl,sulfa,medicines 1.0 0.000143348623853 1 0 1
promethazine,coadministration,of 1.0 0.000143348623853 1 0 1
prolongs,the,sleeping 1.0 0.000143348623853 1 0 1
prolongs,the,half-life 1.0 0.000143348623853 1 0 1
prolonging,av,conduction 1.0 0.000143348623853 1 0 1
prolonged,sodation,of 1.0 0.000143348623853 1 0 1
prolonged,recovery,time 1.0 0.000143348623853 1 0 1
prolonged,prothrombin,times 1.0 0.000143348623853 1 0 1
prolonged,prothrombin,time 1.0 0.000143348623853 1 0 1
prolonged,or,delayed 1.0 0.000143348623853 1 0 1
prolonged,long,acting 1.0 0.000143348623853 1 0 1
prolonged,in,the 1.0 0.000143348623853 1 0 1
prolonged,hot,weather 1.0 0.000143348623853 1 0 1
prolonged,from,minutes 1.0 0.000143348623853 1 0 1
prolonged,by,therapy 1.0 0.000143348623853 1 0 1
prolonged,by,since 1.0 0.000143348623853 1 0 1
prolonged,by,concurrent 1.0 0.000143348623853 1 0 1
prolongation,ischemic,heart 1.0 0.000143348623853 1 0 1
prolongation,cardiac,arrythmias 1.0 0.000143348623853 1 0 1
prolong,the,serum 1.0 0.000143348623853 1 0 1
prolong,the,duration 1.0 0.000143348623853 1 0 1
prolong,further,the 1.0 0.000143348623853 1 0 1
prolong,adverse,effects 1.0 0.000143348623853 1 0 1
proliferation,of,prostatic 1.0 0.000143348623853 1 0 1
proliferation,of,prostate 1.0 0.000143348623853 1 0 1
proliferation,in,the 1.0 0.000143348623853 1 0 1
proleukin-induced,side,effects 1.0 0.000143348623853 1 0 1
proleukin,may,reduce 1.0 0.000143348623853 1 0 1
proleukin,may,increase 1.0 0.000143348623853 1 0 1
proleukin,including,crescentic 1.0 0.000143348623853 1 0 1
proleukin,and,thus 1.0 0.000143348623853 1 0 1
proleukin,and,antineoplastic 1.0 0.000143348623853 1 0 1
progressing,to,delirium 1.0 0.000143348623853 1 0 1
progestin-only,pills,is 1.0 0.000143348623853 1 0 1
progesterone-,and,high-estradiol 1.0 0.000143348623853 1 0 1
progesterone,preparations,micro-dosed 1.0 0.000143348623853 1 0 1
profound,when,taxol 1.0 0.000143348623853 1 0 1
profound,hypotensive,episodes 1.0 0.000143348623853 1 0 1
profound,hypotension,and 1.0 0.000143348623853 1 0 1
professional,know,if 1.0 0.000143348623853 1 0 1
products,with,similar 1.0 0.000143348623853 1 0 1
products,with,and 1.0 0.000143348623853 1 0 1
products,that,contain 1.0 0.000143348623853 1 0 1
products,may,interfere 1.0 0.000143348623853 1 0 1
products,including,and 1.0 0.000143348623853 1 0 1
products,could,theoretically 1.0 0.000143348623853 1 0 1
products,containing,ferrous 1.0 0.000143348623853 1 0 1
products,containing,cremophor 1.0 0.000143348623853 1 0 1
products,containing,containing 1.0 0.000143348623853 1 0 1
products,concurrent,administration 1.0 0.000143348623853 1 0 1
products,and,may 1.0 0.000143348623853 1 0 1
products,and,in 1.0 0.000143348623853 1 0 1
products,and,calcium-rich 1.0 0.000143348623853 1 0 1
produces,depression,of 1.0 0.000143348623853 1 0 1
produces,a,reduction 1.0 0.000143348623853 1 0 1
produces,a,complete 1.0 0.000143348623853 1 0 1
produced,significantly,increased 1.0 0.000143348623853 1 0 1
produced,significant,decreases 1.0 0.000143348623853 1 0 1
produced,only,minor 1.0 0.000143348623853 1 0 1
produced,minor,changes 1.0 0.000143348623853 1 0 1
produced,mean,additional 1.0 0.000143348623853 1 0 1
produced,in,the 1.0 0.000143348623853 1 0 1
produced,depletions,of 1.0 0.000143348623853 1 0 1
produced,by,subsequent 1.0 0.000143348623853 1 0 1
produced,by,resulting 1.0 0.000143348623853 1 0 1
produced,by,intermediate 1.0 0.000143348623853 1 0 1
produced,by,high 1.0 0.000143348623853 1 0 1
produced,by,explain 1.0 0.000143348623853 1 0 1
produced,by,any 1.0 0.000143348623853 1 0 1
produced,average,decreases 1.0 0.000143348623853 1 0 1
produced,an,increase 1.0 0.000143348623853 1 0 1
produced,an,approximate 1.0 0.000143348623853 1 0 1
produced,a,tolerance 1.0 0.000143348623853 1 0 1
produced,a,significant 1.0 0.000143348623853 1 0 1
produced,a,mean 1.0 0.000143348623853 1 0 1
produced,a,clinically 1.0 0.000143348623853 1 0 1
produce,significant,inhibition 1.0 0.000143348623853 1 0 1
produce,severe,weakness 1.0 0.000143348623853 1 0 1
produce,severe,prolonged 1.0 0.000143348623853 1 0 1
produce,severe,bronchospasm 1.0 0.000143348623853 1 0 1
produce,nephrotoxicity,with 1.0 0.000143348623853 1 0 1
produce,malabsorption,of 1.0 0.000143348623853 1 0 1
produce,excessive,reduction 1.0 0.000143348623853 1 0 1
produce,electrocardiographic,abnormalities 1.0 0.000143348623853 1 0 1
produce,cns-depressant,effects 1.0 0.000143348623853 1 0 1
produce,aucs,m 1.0 0.000143348623853 1 0 1
produce,any,additional 1.0 0.000143348623853 1 0 1
produce,antabuse-like,side 1.0 0.000143348623853 1 0 1
produce,an,additive 1.0 0.000143348623853 1 0 1
produce,additive,effects 1.0 0.000143348623853 1 0 1
produce,additive,cns 1.0 0.000143348623853 1 0 1
produce,a,stimulating 1.0 0.000143348623853 1 0 1
produce,a,less 1.0 0.000143348623853 1 0 1
procedures,during,or 1.0 0.000143348623853 1 0 1
problem,associated,with 1.0 0.000143348623853 1 0 1
probenecid,the,oral 1.0 0.000143348623853 1 0 1
probenecid,probenecid,interferes 1.0 0.000143348623853 1 0 1
probenecid,probenecid,increases 1.0 0.000143348623853 1 0 1
probenecid,pretreatment,with 1.0 0.000143348623853 1 0 1
probenecid,or,cimetidine 1.0 0.000143348623853 1 0 1
probenecid,is,known 1.0 0.000143348623853 1 0 1
probenecid,interferes,with 1.0 0.000143348623853 1 0 1
probenecid,increases,both 1.0 0.000143348623853 1 0 1
probenecid,given,concurrently 1.0 0.000143348623853 1 0 1
probenecid,depresses,tubular 1.0 0.000143348623853 1 0 1
probenecid,concomitant,administration 1.0 0.000143348623853 1 0 1
probably,secondary,to 1.0 0.000143348623853 1 0 1
probably,reduces,the 1.0 0.000143348623853 1 0 1
probably,is,adsorption 1.0 0.000143348623853 1 0 1
probably,at,least 1.0 0.000143348623853 1 0 1
probable,benefits,outweigh 1.0 0.000143348623853 1 0 1
prior,to,this 1.0 0.000143348623853 1 0 1
prior,to,initiating 1.0 0.000143348623853 1 0 1
prior,to,infusions 1.0 0.000143348623853 1 0 1
prior,to,hours 1.0 0.000143348623853 1 0 1
prior,to,during 1.0 0.000143348623853 1 0 1
prior,to,concurrent 1.0 0.000143348623853 1 0 1
prior,to,but 1.0 0.000143348623853 1 0 1
prior,to,administering 1.0 0.000143348623853 1 0 1
prior,ingestion,of 1.0 0.000143348623853 1 0 1
prinivil,with,potassium-sparing 1.0 0.000143348623853 1 0 1
prinivil,is,administered 1.0 0.000143348623853 1 0 1
prinivil,can,be 1.0 0.000143348623853 1 0 1
prinivil,attenuates,loss 1.0 0.000143348623853 1 0 1
prinivil,at,a 1.0 0.000143348623853 1 0 1
prinivil,an,additional 1.0 0.000143348623853 1 0 1
principal,pathway,for 1.0 0.000143348623853 1 0 1
primidone,population,pharmacokinetic 1.0 0.000143348623853 1 0 1
primary,elimination,route 1.0 0.000143348623853 1 0 1
primary,effect,of 1.0 0.000143348623853 1 0 1
primary,cns,effect 1.0 0.000143348623853 1 0 1
primarily,to,enhance 1.0 0.000143348623853 1 0 1
previously,unrecognized,interaction 1.0 0.000143348623853 1 0 1
previously,received,the 1.0 0.000143348623853 1 0 1
previously,received,increases 1.0 0.000143348623853 1 0 1
previous,studies,have 1.0 0.000143348623853 1 0 1
prevents,morphine-induced,increases 1.0 0.000143348623853 1 0 1
prevents,gastrointestinal,effects 1.0 0.000143348623853 1 0 1
prevented,by,and 1.0 0.000143348623853 1 0 1
prevent,the,urinary 1.0 0.000143348623853 1 0 1
prevent,the,from 1.0 0.000143348623853 1 0 1
prevent,the,development 1.0 0.000143348623853 1 0 1
prevent,the,conversion 1.0 0.000143348623853 1 0 1
prevent,symptoms,of 1.0 0.000143348623853 1 0 1
prevent,opioid-induced,gastrointestinal 1.0 0.000143348623853 1 0 1
prevent,excessive,prolongation 1.0 0.000143348623853 1 0 1
pretreatment,with,the 1.0 0.000143348623853 1 0 1
pretreatment,with,reduces 1.0 0.000143348623853 1 0 1
pretreatment,with,or 1.0 0.000143348623853 1 0 1
pretreatment,with,cgs 1.0 0.000143348623853 1 0 1
pretreatment,of,rats 1.0 0.000143348623853 1 0 1
pretreatment,of,megakaryocytes 1.0 0.000143348623853 1 0 1
pretreatment,of,healthy 1.0 0.000143348623853 1 0 1
pretreatment,augmented,the 1.0 0.000143348623853 1 0 1
pretreatment,attenuated,the 1.0 0.000143348623853 1 0 1
presyncope,or,orthostatic 1.0 0.000143348623853 1 0 1
presumably,through,inhibition 1.0 0.000143348623853 1 0 1
presumably,by,inhibition 1.0 0.000143348623853 1 0 1
presumably,because,both 1.0 0.000143348623853 1 0 1
presumably,acts,as 1.0 0.000143348623853 1 0 1
pressure,usually,within 1.0 0.000143348623853 1 0 1
pressure,their,combined 1.0 0.000143348623853 1 0 1
pressure,than,when 1.0 0.000143348623853 1 0 1
pressure,reductions,of 1.0 0.000143348623853 1 0 1
pressure,of,about 1.0 0.000143348623853 1 0 1
pressure,may,occur 1.0 0.000143348623853 1 0 1
pressure,lowering,effects 1.0 0.000143348623853 1 0 1
pressure,effect,of 1.0 0.000143348623853 1 0 1
pressure,caution,in 1.0 0.000143348623853 1 0 1
pressure,by,inhibiting 1.0 0.000143348623853 1 0 1
pressor,response,to 1.0 0.000143348623853 1 0 1
preservative,in,the 1.0 0.000143348623853 1 0 1
presentation,of,a 1.0 0.000143348623853 1 0 1
present,as,vertigo 1.0 0.000143348623853 1 0 1
presence,of,these 1.0 0.000143348623853 1 0 1
presence,of,that 1.0 0.000143348623853 1 0 1
presence,of,than 1.0 0.000143348623853 1 0 1
presence,of,high 1.0 0.000143348623853 1 0 1
presence,of,equetrotm 1.0 0.000143348623853 1 0 1
presence,of,both 1.0 0.000143348623853 1 0 1
presence,of,at 1.0 0.000143348623853 1 0 1
presence,of,agents 1.0 0.000143348623853 1 0 1
prescription,of,to 1.0 0.000143348623853 1 0 1
prescribed,with,caution 1.0 0.000143348623853 1 0 1
prescribed,to,control 1.0 0.000143348623853 1 0 1
preparations,sunscreens,and 1.0 0.000143348623853 1 0 1
preparations,such,as 1.0 0.000143348623853 1 0 1
preparations,since,there 1.0 0.000143348623853 1 0 1
preparations,minipills,that 1.0 0.000143348623853 1 0 1
preparations,micro-dosed,preparations 1.0 0.000143348623853 1 0 1
preparations,may,potentiate 1.0 0.000143348623853 1 0 1
preparations,may,increase 1.0 0.000143348623853 1 0 1
preparations,containing,carbohydrate-splitting 1.0 0.000143348623853 1 0 1
preparations,are,not 1.0 0.000143348623853 1 0 1
preparations,are,incompatible 1.0 0.000143348623853 1 0 1
preparation,this,parenteral 1.0 0.000143348623853 1 0 1
preparation,causing,a 1.0 0.000143348623853 1 0 1
prelone,st,johns 1.0 0.000143348623853 1 0 1
preliminary,studies,indicate 1.0 0.000143348623853 1 0 1
preliminary,studies,in 1.0 0.000143348623853 1 0 1
preliminary,data,which 1.0 0.000143348623853 1 0 1
preliminary,clinical,data 1.0 0.000143348623853 1 0 1
preferentially,blocked,the 1.0 0.000143348623853 1 0 1
prednisolone,ethinyl,estradiol 1.0 0.000143348623853 1 0 1
predisposing,to,a 1.0 0.000143348623853 1 0 1
predispose,the,patient 1.0 0.000143348623853 1 0 1
predictable,sympathetic,effects 1.0 0.000143348623853 1 0 1
precipitous,reduction,of 1.0 0.000143348623853 1 0 1
precipitate,seizures,in 1.0 0.000143348623853 1 0 1
precedex,with,and 1.0 0.000143348623853 1 0 1
precedex,on,the 1.0 0.000143348623853 1 0 1
precedex,a,reduction 1.0 0.000143348623853 1 0 1
precautions,should,be 1.0 0.000143348623853 1 0 1
pre-treatment,with,the 1.0 0.000143348623853 1 0 1
pre-existing,cardiac,abnormalities 1.0 0.000143348623853 1 0 1
praziquantel,in,the 1.0 0.000143348623853 1 0 1
practice,has,been 1.0 0.000143348623853 1 0 1
practice,dictates,careful 1.0 0.000143348623853 1 0 1
pr,interval,were 1.0 0.000143348623853 1 0 1
powders,showed,that 1.0 0.000143348623853 1 0 1
powder,or,products 1.0 0.000143348623853 1 0 1
potentiation,of,rashes 1.0 0.000143348623853 1 0 1
potentiation,by,mao 1.0 0.000143348623853 1 0 1
potentiating,effect,on 1.0 0.000143348623853 1 0 1
potentiating,cns,depressants 1.0 0.000143348623853 1 0 1
potentiating,action,of 1.0 0.000143348623853 1 0 1
potentiates,the,reduction 1.0 0.000143348623853 1 0 1
potentiates,the,muscle 1.0 0.000143348623853 1 0 1
potentiates,the,effect 1.0 0.000143348623853 1 0 1
potentiates,the,acute 1.0 0.000143348623853 1 0 1
potentiates,other,cholinesterase 1.0 0.000143348623853 1 0 1
potentiated,the,risk 1.0 0.000143348623853 1 0 1
potentiated,the,positive 1.0 0.000143348623853 1 0 1
potentiated,the,cns-impairing 1.0 0.000143348623853 1 0 1
potentiated,the,blood 1.0 0.000143348623853 1 0 1
potentiated,resulting,in 1.0 0.000143348623853 1 0 1
potentiated,by,which 1.0 0.000143348623853 1 0 1
potentiated,by,the 1.0 0.000143348623853 1 0 1
potentiated,by,nonbarbiturate 1.0 0.000143348623853 1 0 1
potentiated,by,a 1.0 0.000143348623853 1 0 1
potentiate,the,vasoconstrictive 1.0 0.000143348623853 1 0 1
potentiate,the,undesirable 1.0 0.000143348623853 1 0 1
potentiate,the,toxic 1.0 0.000143348623853 1 0 1
potentiate,the,therapeutic 1.0 0.000143348623853 1 0 1
potentiate,the,tardive 1.0 0.000143348623853 1 0 1
potentiate,the,side 1.0 0.000143348623853 1 0 1
potentiate,the,replication 1.0 0.000143348623853 1 0 1
potentiate,the,neuromuscular 1.0 0.000143348623853 1 0 1
potentiate,the,hypotension 1.0 0.000143348623853 1 0 1
potentiate,the,hypoglycemic 1.0 0.000143348623853 1 0 1
potentiate,the,effect 1.0 0.000143348623853 1 0 1
potentiate,the,cognitive 1.0 0.000143348623853 1 0 1
potentiate,the,cns-depressive 1.0 0.000143348623853 1 0 1
potentiate,the,analgesic 1.0 0.000143348623853 1 0 1
potentiate,the,adverse 1.0 0.000143348623853 1 0 1
potentiate,blood-pressure,and 1.0 0.000143348623853 1 0 1
potentiate,any,hypokalemic 1.0 0.000143348623853 1 0 1
potentiate,amphotericin,b- 1.0 0.000143348623853 1 0 1
potentiate,adverse,events 1.0 0.000143348623853 1 0 1
potentiate,a,possible 1.0 0.000143348623853 1 0 1
potentially,toxic,such 1.0 0.000143348623853 1 0 1
potentially,significant,interactions 1.0 0.000143348623853 1 0 1
potentially,serious,cardiovascular 1.0 0.000143348623853 1 0 1
potentially,result,in 1.0 0.000143348623853 1 0 1
potentially,nephrotoxic,such 1.0 0.000143348623853 1 0 1
potentially,nephrotoxic,agents 1.0 0.000143348623853 1 0 1
potentially,leading,to 1.0 0.000143348623853 1 0 1
potentially,important,drug 1.0 0.000143348623853 1 0 1
potentially,hepatotoxic,medications 1.0 0.000143348623853 1 0 1
potentially,fatal,prolongation 1.0 0.000143348623853 1 0 1
potentially,associated,with 1.0 0.000143348623853 1 0 1
potentially,arise,from 1.0 0.000143348623853 1 0 1
potential,twofold,increase 1.0 0.000143348623853 1 0 1
potential,to,sensitize 1.0 0.000143348623853 1 0 1
potential,to,result 1.0 0.000143348623853 1 0 1
potential,to,increase 1.0 0.000143348623853 1 0 1
potential,to,enhance 1.0 0.000143348623853 1 0 1
potential,risk,of 1.0 0.000143348623853 1 0 1
potential,of,other 1.0 0.000143348623853 1 0 1
potential,of,nephrotoxicity 1.0 0.000143348623853 1 0 1
potential,of,especially 1.0 0.000143348623853 1 0 1
potential,of,binding 1.0 0.000143348623853 1 0 1
potential,must,not 1.0 0.000143348623853 1 0 1
potential,intravenous,and 1.0 0.000143348623853 1 0 1
potential,interactions,for 1.0 0.000143348623853 1 0 1
potential,interaction,involving 1.0 0.000143348623853 1 0 1
potential,inhibitor,of 1.0 0.000143348623853 1 0 1
potential,for,renal 1.0 0.000143348623853 1 0 1
potential,for,reexacerbation 1.0 0.000143348623853 1 0 1
potential,for,reduction 1.0 0.000143348623853 1 0 1
potential,for,ototoxicity 1.0 0.000143348623853 1 0 1
potential,for,flolan 1.0 0.000143348623853 1 0 1
potential,for,arava 1.0 0.000143348623853 1 0 1
potential,especially,in 1.0 0.000143348623853 1 0 1
potential,effects,on 1.0 0.000143348623853 1 0 1
potential,danger,of 1.0 0.000143348623853 1 0 1
potent,parental,such 1.0 0.000143348623853 1 0 1
potent,loop,such 1.0 0.000143348623853 1 0 1
potent,inhalational,such 1.0 0.000143348623853 1 0 1
potent,iiia4,inhibitor 1.0 0.000143348623853 1 0 1
potent,cytochrome,p450 1.0 0.000143348623853 1 0 1
potent,cyp3a,inducers 1.0 0.000143348623853 1 0 1
potent,a4,inhibitors 1.0 0.000143348623853 1 0 1
potassium-sparing,with,nsaids 1.0 0.000143348623853 1 0 1
potassium-sparing,on,kinetics 1.0 0.000143348623853 1 0 1
potassium-sparing,including,midamor 1.0 0.000143348623853 1 0 1
potassium-sparing,diuretics,lotensin 1.0 0.000143348623853 1 0 1
potassium-sparing,diuretics,fosinopril 1.0 0.000143348623853 1 0 1
potassium-depleting,are,a 1.0 0.000143348623853 1 0 1
potassium-depleting,agents,when 1.0 0.000143348623853 1 0 1
potassium-depleting,agents,amphotericin 1.0 0.000143348623853 1 0 1
potassium,prinivil,attenuates 1.0 0.000143348623853 1 0 1
potassium,levels,the 1.0 0.000143348623853 1 0 1
potassium,kinetics,and 1.0 0.000143348623853 1 0 1
potassium,enalapril,and 1.0 0.000143348623853 1 0 1
postmarketing,reports,describing 1.0 0.000143348623853 1 0 1
postmarketing,observations,have 1.0 0.000143348623853 1 0 1
postmarketing,experience,when 1.0 0.000143348623853 1 0 1
postdose,a,similar 1.0 0.000143348623853 1 0 1
post-marketing,experience,of 1.0 0.000143348623853 1 0 1
post-heparin,lipolytic,activity 1.0 0.000143348623853 1 0 1
post,marketing,observations 1.0 0.000143348623853 1 0 1
possibly,related,to 1.0 0.000143348623853 1 0 1
possibly,other,macrolide 1.0 0.000143348623853 1 0 1
possibly,other,and 1.0 0.000143348623853 1 0 1
possibly,increasing,the 1.0 0.000143348623853 1 0 1
possibly,increasing,its 1.0 0.000143348623853 1 0 1
possibly,increase,the 1.0 0.000143348623853 1 0 1
possibly,concomitant,administration 1.0 0.000143348623853 1 0 1
possibly,causing,uterine 1.0 0.000143348623853 1 0 1
possibly,by,competing 1.0 0.000143348623853 1 0 1
possible,that,may 1.0 0.000143348623853 1 0 1
possible,that,dopamine 1.0 0.000143348623853 1 0 1
possible,that,concomitant 1.0 0.000143348623853 1 0 1
possible,rapid,fluctuations 1.0 0.000143348623853 1 0 1
possible,pharmacokinetic,interactions 1.0 0.000143348623853 1 0 1
possible,pharmacodynamic,interactions 1.0 0.000143348623853 1 0 1
possible,interactions,of 1.0 0.000143348623853 1 0 1
possible,interaction,of 1.0 0.000143348623853 1 0 1
possible,increase,in 1.0 0.000143348623853 1 0 1
possible,effectiveness,of 1.0 0.000143348623853 1 0 1
possible,dose,of 1.0 0.000143348623853 1 0 1
possible,complications,of 1.0 0.000143348623853 1 0 1
possible,benefits,of 1.0 0.000143348623853 1 0 1
possible,be,discontinued 1.0 0.000143348623853 1 0 1
possible,atrioventricular,conduction 1.0 0.000143348623853 1 0 1
possible,anticholinesterase,agents 1.0 0.000143348623853 1 0 1
possible,and,alternative 1.0 0.000143348623853 1 0 1
possibility,that,the 1.0 0.000143348623853 1 0 1
possibility,that,might 1.0 0.000143348623853 1 0 1
possibility,that,may 1.0 0.000143348623853 1 0 1
possibility,that,a 1.0 0.000143348623853 1 0 1
possibility,of,toxicity 1.0 0.000143348623853 1 0 1
possibility,of,increases 1.0 0.000143348623853 1 0 1
possibility,of,additive 1.0 0.000143348623853 1 0 1
possibility,nitric,oxide 1.0 0.000143348623853 1 0 1
possessing,nephrotoxic,myelotoxic 1.0 0.000143348623853 1 0 1
positive,level,to 1.0 0.000143348623853 1 0 1
positive,inotropic,effects 1.0 0.000143348623853 1 0 1
porpranolol,may,exacerbate 1.0 0.000143348623853 1 0 1
populations,the,concomitant 1.0 0.000143348623853 1 0 1
population,pharmacokinetic,studies 1.0 0.000143348623853 1 0 1
poorly,tolerated,and 1.0 0.000143348623853 1 0 1
poor,metabolizers,suggesting 1.0 0.000143348623853 1 0 1
ponstel,with,the 1.0 0.000143348623853 1 0 1
ponstel,and,is 1.0 0.000143348623853 1 0 1
polystyrene,sulfonate,soybean 1.0 0.000143348623853 1 0 1
poisoning,although,they 1.0 0.000143348623853 1 0 1
pointes,most,like 1.0 0.000143348623853 1 0 1
pneumonia,vs,serious 1.0 0.000143348623853 1 0 1
pneumonia,treatment,with 1.0 0.000143348623853 1 0 1
pneumocystis,carinii,pneumonia 1.0 0.000143348623853 1 0 1
plus,was,poorly 1.0 0.000143348623853 1 0 1
plus,experienced,severe 1.0 0.000143348623853 1 0 1
plus,catecholamine,depletors 1.0 0.000143348623853 1 0 1
pletal,is,extensively 1.0 0.000143348623853 1 0 1
pletal,is,coadministered 1.0 0.000143348623853 1 0 1
platelets,by,causing 1.0 0.000143348623853 1 0 1
platelet-aggregation,reactions,the 1.0 0.000143348623853 1 0 1
platelet,inhibitors,drugs 1.0 0.000143348623853 1 0 1
platelet,function,there 1.0 0.000143348623853 1 0 1
platelet,function,such 1.0 0.000143348623853 1 0 1
platelet,function,eg 1.0 0.000143348623853 1 0 1
platelet,aggregation,inhibitors 1.0 0.000143348623853 1 0 1
platelet,aggregation,but 1.0 0.000143348623853 1 0 1
plasmaconcentration,of,other 1.0 0.000143348623853 1 0 1
plasma,tca,concentrations 1.0 0.000143348623853 1 0 1
plasma,protein-bound,with 1.0 0.000143348623853 1 0 1
plasma,mean,cmax 1.0 0.000143348623853 1 0 1
plasma,m1,the 1.0 0.000143348623853 1 0 1
plasma,levels,total 1.0 0.000143348623853 1 0 1
plasma,levels,suggesting 1.0 0.000143348623853 1 0 1
plasma,levels,resulting 1.0 0.000143348623853 1 0 1
plasma,levels,possibly 1.0 0.000143348623853 1 0 1
plasma,levels,occurred 1.0 0.000143348623853 1 0 1
plasma,levels,mcg 1.0 0.000143348623853 1 0 1
plasma,levels,during 1.0 0.000143348623853 1 0 1
plasma,levels,be 1.0 0.000143348623853 1 0 1
plasma,has,not 1.0 0.000143348623853 1 0 1
plasma,half-life,may 1.0 0.000143348623853 1 0 1
plasma,exposures,of 1.0 0.000143348623853 1 0 1
plasma,exposure,when 1.0 0.000143348623853 1 0 1
plasma,concentrations,which 1.0 0.000143348623853 1 0 1
plasma,concentrations,reach 1.0 0.000143348623853 1 0 1
plasma,concentrations,peak 1.0 0.000143348623853 1 0 1
plasma,concentrations,drugs 1.0 0.000143348623853 1 0 1
plasma,concentrations,caution 1.0 0.000143348623853 1 0 1
plasma,concentrations,by 1.0 0.000143348623853 1 0 1
plasma,concentrations,below 1.0 0.000143348623853 1 0 1
plasma,concentration,time-curve 1.0 0.000143348623853 1 0 1
plasma,concentration,should 1.0 0.000143348623853 1 0 1
plasma,clearance,of 1.0 0.000143348623853 1 0 1
plasma,clearance,from 1.0 0.000143348623853 1 0 1
plasma,and,renal 1.0 0.000143348623853 1 0 1
plasma,and,reduction 1.0 0.000143348623853 1 0 1
plasma,and,brain 1.0 0.000143348623853 1 0 1
plasma,albumin,binding 1.0 0.000143348623853 1 0 1
placental,vessels,to 1.0 0.000143348623853 1 0 1
placebo-controlled,trial,in 1.0 0.000143348623853 1 0 1
placebo-controlled,crossover,study 1.0 0.000143348623853 1 0 1
place,of,h2 1.0 0.000143348623853 1 0 1
pivoxil,resulted,in 1.0 0.000143348623853 1 0 1
pivoxil,administered,following 1.0 0.000143348623853 1 0 1
pipracil,produces,an 1.0 0.000143348623853 1 0 1
piperidine,prevents,gastrointestinal 1.0 0.000143348623853 1 0 1
piperacillin,sodium,may 1.0 0.000143348623853 1 0 1
pimozide,and,celexa 1.0 0.000143348623853 1 0 1
pills,is,reduced 1.0 0.000143348623853 1 0 1
pigeons,but,did 1.0 0.000143348623853 1 0 1
physostigmine,pretreatment,augmented 1.0 0.000143348623853 1 0 1
physiologic,activity,thus 1.0 0.000143348623853 1 0 1
physicians,are,provided 1.0 0.000143348623853 1 0 1
physicians,are,advised 1.0 0.000143348623853 1 0 1
physician,the,benefits 1.0 0.000143348623853 1 0 1
physician,or,are 1.0 0.000143348623853 1 0 1
physician,may,wish 1.0 0.000143348623853 1 0 1
photosensitizing,agents,such 1.0 0.000143348623853 1 0 1
photosensitivity,reaction,of 1.0 0.000143348623853 1 0 1
phosphorylation,of,zdv 1.0 0.000143348623853 1 0 1
phosphorylation,of,this 1.0 0.000143348623853 1 0 1
phosphorylation,inhibition,of 1.0 0.000143348623853 1 0 1
phosphorylation,in,t24 1.0 0.000143348623853 1 0 1
phosphorylation,in,a 1.0 0.000143348623853 1 0 1
phosphorylation,at,high 1.0 0.000143348623853 1 0 1
phosphorylated,which,may 1.0 0.000143348623853 1 0 1
phospholine,iodide,potentiates 1.0 0.000143348623853 1 0 1
phenytoin,therapy,a 1.0 0.000143348623853 1 0 1
phenytoin,steady,state 1.0 0.000143348623853 1 0 1
phenytoin,serum,levels 1.0 0.000143348623853 1 0 1
phenytoin,serum,level 1.0 0.000143348623853 1 0 1
phenytoin,population,pharmacokinetic 1.0 0.000143348623853 1 0 1
phenytoin,phenytoin,causes 1.0 0.000143348623853 1 0 1
phenytoin,isoniazid,may 1.0 0.000143348623853 1 0 1
phenytoin,intoxication,prior 1.0 0.000143348623853 1 0 1
phenytoin,increases,the 1.0 0.000143348623853 1 0 1
phenytoin,in,post-marketing 1.0 0.000143348623853 1 0 1
phenytoin,if,is 1.0 0.000143348623853 1 0 1
phenytoin,felbatol,causes 1.0 0.000143348623853 1 0 1
phenytoin,dilantin,use 1.0 0.000143348623853 1 0 1
phenytoin,causes,an 1.0 0.000143348623853 1 0 1
phenytoin,and,may 1.0 0.000143348623853 1 0 1
phenytoin,altered,serum 1.0 0.000143348623853 1 0 1
phenylbutazone,phenylbutazone,causes 1.0 0.000143348623853 1 0 1
phenylbutazone,causes,increase 1.0 0.000143348623853 1 0 1
phenurone,since,paranoid 1.0 0.000143348623853 1 0 1
phenothiazines,taking,and 1.0 0.000143348623853 1 0 1
phenothiazine-related,compounds,and 1.0 0.000143348623853 1 0 1
phenobarbital,toxicity,has 1.0 0.000143348623853 1 0 1
phenobarbital,tegretol,trileptal 1.0 0.000143348623853 1 0 1
phenobarbital,primidone,population 1.0 0.000143348623853 1 0 1
phenobarbital,it,appears 1.0 0.000143348623853 1 0 1
phenobarbital,decreases,effectiveness 1.0 0.000143348623853 1 0 1
phenobarbital,coadministration,of 1.0 0.000143348623853 1 0 1
phase,ii,clinical 1.0 0.000143348623853 1 0 1
pharmacology,study,coadministration 1.0 0.000143348623853 1 0 1
pharmacology,drug,interactions 1.0 0.000143348623853 1 0 1
pharmacology,coadministration,of 1.0 0.000143348623853 1 0 1
pharmacology,clinical,studies 1.0 0.000143348623853 1 0 1
pharmacologically,with,orally 1.0 0.000143348623853 1 0 1
pharmacologically,predictable,sympathetic 1.0 0.000143348623853 1 0 1
pharmacological,pharmacodynamic,interactions 1.0 0.000143348623853 1 0 1
pharmacological,interaction,this 1.0 0.000143348623853 1 0 1
pharmacological,effect,when 1.0 0.000143348623853 1 0 1
pharmacologic,studies,indicate 1.0 0.000143348623853 1 0 1
pharmacokinetics,produced,by 1.0 0.000143348623853 1 0 1
pharmacokinetics,parameters,auc 1.0 0.000143348623853 1 0 1
pharmacokinetics,over,the 1.0 0.000143348623853 1 0 1
pharmacokinetics,of,which 1.0 0.000143348623853 1 0 1
pharmacokinetics,of,that 1.0 0.000143348623853 1 0 1
pharmacokinetics,of,intravenous 1.0 0.000143348623853 1 0 1
pharmacokinetics,of,busulfex 1.0 0.000143348623853 1 0 1
pharmacokinetics,except,that 1.0 0.000143348623853 1 0 1
pharmacokinetics,but,significantly 1.0 0.000143348623853 1 0 1
pharmacokinetic,substudy,in 1.0 0.000143348623853 1 0 1
pharmacokinetic,study,maximum 1.0 0.000143348623853 1 0 1
pharmacokinetic,study,evaluating 1.0 0.000143348623853 1 0 1
pharmacokinetic,studies,showed 1.0 0.000143348623853 1 0 1
pharmacokinetic,results,from 1.0 0.000143348623853 1 0 1
pharmacokinetic,effects,seen 1.0 0.000143348623853 1 0 1
pharmacokinetic,data,from 1.0 0.000143348623853 1 0 1
pharmacokinetic,changes,to 1.0 0.000143348623853 1 0 1
pharmacodynamics,arecoline,eproxindine 1.0 0.000143348623853 1 0 1
pharmacodynamic,interactions,with 1.0 0.000143348623853 1 0 1
pharmacodynamic,interactions,when 1.0 0.000143348623853 1 0 1
pharmacodynamic,interactions,the 1.0 0.000143348623853 1 0 1
pharmacodynamic,interaction,use 1.0 0.000143348623853 1 0 1
pharmacodynamic,effects,prothrombin 1.0 0.000143348623853 1 0 1
pharmaceuticals,inc,demonstrated 1.0 0.000143348623853 1 0 1
ph,was,significantly 1.0 0.000143348623853 1 0 1
ph,of,the 1.0 0.000143348623853 1 0 1
ph,h2-receptor,antagonists 1.0 0.000143348623853 1 0 1
pgf2alpha,upon,the 1.0 0.000143348623853 1 0 1
pgf2alpha,produced,significantly 1.0 0.000143348623853 1 0 1
persists,as,long 1.0 0.000143348623853 1 0 1
persistent,inhibition,of 1.0 0.000143348623853 1 0 1
peroxidation,which,was 1.0 0.000143348623853 1 0 1
permits,at,least 1.0 0.000143348623853 1 0 1
peripherally,restricted,antagonist 1.0 0.000143348623853 1 0 1
peripheral,vasoconstriction,caused 1.0 0.000143348623853 1 0 1
peripheral,neuropathy,or 1.0 0.000143348623853 1 0 1
peripheral,because,the 1.0 0.000143348623853 1 0 1
peripheral,anitagonism,without 1.0 0.000143348623853 1 0 1
perioperative,period,has 1.0 0.000143348623853 1 0 1
periods,of,active 1.0 0.000143348623853 1 0 1
periodic,serum,level 1.0 0.000143348623853 1 0 1
periodic,intervals,or 1.0 0.000143348623853 1 0 1
period,will,affect 1.0 0.000143348623853 1 0 1
period,particularly,at 1.0 0.000143348623853 1 0 1
period,of,min 1.0 0.000143348623853 1 0 1
period,of,concurrent 1.0 0.000143348623853 1 0 1
period,of,at 1.0 0.000143348623853 1 0 1
period,in,which 1.0 0.000143348623853 1 0 1
period,has,been 1.0 0.000143348623853 1 0 1
period,following,elspar 1.0 0.000143348623853 1 0 1
perhexiline,hydrogen,maleate 1.0 0.000143348623853 1 0 1
performed,when,initiating 1.0 0.000143348623853 1 0 1
performed,coadministration,with 1.0 0.000143348623853 1 0 1
performed,based,on 1.0 0.000143348623853 1 0 1
performance,was,seen 1.0 0.000143348623853 1 0 1
percentage,of,endotoxin-induced 1.0 0.000143348623853 1 0 1
per,kg,diet 1.0 0.000143348623853 1 0 1
per,day,will 1.0 0.000143348623853 1 0 1
per,day,in 1.0 0.000143348623853 1 0 1
per,day,ig 1.0 0.000143348623853 1 0 1
per,day,decreases 1.0 0.000143348623853 1 0 1
people,who,consume 1.0 0.000143348623853 1 0 1
penthrane,has,been 1.0 0.000143348623853 1 0 1
penicillin-type,are,administered 1.0 0.000143348623853 1 0 1
pegasys,once,weekly 1.0 0.000143348623853 1 0 1
peganone,is,administered 1.0 0.000143348623853 1 0 1
pediatrics,mean,increase 1.0 0.000143348623853 1 0 1
pediatric,powder,or 1.0 0.000143348623853 1 0 1
pediatric,patients,there 1.0 0.000143348623853 1 0 1
pectoris,additional,effects 1.0 0.000143348623853 1 0 1
peak,serum,levels 1.0 0.000143348623853 1 0 1
peak,serum,level 1.0 0.000143348623853 1 0 1
peak,plasma,level 1.0 0.000143348623853 1 0 1
peak,plasma,concentration 1.0 0.000143348623853 1 0 1
peak,levels,were 1.0 0.000143348623853 1 0 1
peak,blood,concentration 1.0 0.000143348623853 1 0 1
pcp,or,either 1.0 0.000143348623853 1 0 1
pci,co-administration,of 1.0 0.000143348623853 1 0 1
patients,without,a 1.0 0.000143348623853 1 0 1
patients,with,weakness 1.0 0.000143348623853 1 0 1
patients,with,tuberculosis 1.0 0.000143348623853 1 0 1
patients,with,neoplastic 1.0 0.000143348623853 1 0 1
patients,with,moderate 1.0 0.000143348623853 1 0 1
patients,with,major 1.0 0.000143348623853 1 0 1
patients,with,hypertension 1.0 0.000143348623853 1 0 1
patients,with,hereditary 1.0 0.000143348623853 1 0 1
patients,with,dsm-iv 1.0 0.000143348623853 1 0 1
patients,with,depressed 1.0 0.000143348623853 1 0 1
patients,with,breast 1.0 0.000143348623853 1 0 1
patients,with,angina 1.0 0.000143348623853 1 0 1
patients,whose,hypertension 1.0 0.000143348623853 1 0 1
patients,who,inactivate 1.0 0.000143348623853 1 0 1
patients,who,discontinue 1.0 0.000143348623853 1 0 1
patients,who,developed 1.0 0.000143348623853 1 0 1
patients,who,begin 1.0 0.000143348623853 1 0 1
patients,when,was 1.0 0.000143348623853 1 0 1
patients,when,and 1.0 0.000143348623853 1 0 1
patients,using,should 1.0 0.000143348623853 1 0 1
patients,using,long-acting 1.0 0.000143348623853 1 0 1
patients,using,cyp3a4 1.0 0.000143348623853 1 0 1
patients,undergoing,ptca 1.0 0.000143348623853 1 0 1
patients,undergoing,concurrent 1.0 0.000143348623853 1 0 1
patients,under,therapy 1.0 0.000143348623853 1 0 1
patients,treated,concomitantly 1.0 0.000143348623853 1 0 1
patients,to,whom 1.0 0.000143348623853 1 0 1
patients,to,be 1.0 0.000143348623853 1 0 1
patients,the,steroidal 1.0 0.000143348623853 1 0 1
patients,the,steady-state 1.0 0.000143348623853 1 0 1
patients,the,prothrombin 1.0 0.000143348623853 1 0 1
patients,the,concomitant 1.0 0.000143348623853 1 0 1
patients,the,combined 1.0 0.000143348623853 1 0 1
patients,that,are 1.0 0.000143348623853 1 0 1
patients,taking,while 1.0 0.000143348623853 1 0 1
patients,taking,to 1.0 0.000143348623853 1 0 1
patients,taking,since 1.0 0.000143348623853 1 0 1
patients,taking,revia 1.0 0.000143348623853 1 0 1
patients,taking,prothrombin 1.0 0.000143348623853 1 0 1
patients,taking,monoamine 1.0 0.000143348623853 1 0 1
patients,taking,lexapro 1.0 0.000143348623853 1 0 1
patients,taking,labetalol 1.0 0.000143348623853 1 0 1
patients,taking,either 1.0 0.000143348623853 1 0 1
patients,taking,coumarin-derivative 1.0 0.000143348623853 1 0 1
patients,taking,concurrent 1.0 0.000143348623853 1 0 1
patients,taking,bextra 1.0 0.000143348623853 1 0 1
patients,taking,beta 1.0 0.000143348623853 1 0 1
patients,taking,another 1.0 0.000143348623853 1 0 1
patients,taking,an 1.0 0.000143348623853 1 0 1
patients,taking,acamprosate 1.0 0.000143348623853 1 0 1
patients,taking,a 1.0 0.000143348623853 1 0 1
patients,suffering,from 1.0 0.000143348623853 1 0 1
patients,steady-state,auc 1.0 0.000143348623853 1 0 1
patients,stabilized,on 1.0 0.000143348623853 1 0 1
patients,reveiving,phenytoin 1.0 0.000143348623853 1 0 1
patients,receiving,with 1.0 0.000143348623853 1 0 1
patients,receiving,will 1.0 0.000143348623853 1 0 1
patients,receiving,vioxx 1.0 0.000143348623853 1 0 1
patients,receiving,tricyclic 1.0 0.000143348623853 1 0 1
patients,receiving,to 1.0 0.000143348623853 1 0 1
patients,receiving,purinethol 1.0 0.000143348623853 1 0 1
patients,receiving,proleukin 1.0 0.000143348623853 1 0 1
patients,receiving,nonselective 1.0 0.000143348623853 1 0 1
patients,receiving,nalfon 1.0 0.000143348623853 1 0 1
patients,receiving,may 1.0 0.000143348623853 1 0 1
patients,receiving,long- 1.0 0.000143348623853 1 0 1
patients,receiving,known 1.0 0.000143348623853 1 0 1
patients,receiving,itraconazole 1.0 0.000143348623853 1 0 1
patients,receiving,intravenous 1.0 0.000143348623853 1 0 1
patients,receiving,in 1.0 0.000143348623853 1 0 1
patients,receiving,hmg-coa 1.0 0.000143348623853 1 0 1
patients,receiving,high 1.0 0.000143348623853 1 0 1
patients,receiving,hctz 1.0 0.000143348623853 1 0 1
patients,receiving,coumarin-type 1.0 0.000143348623853 1 0 1
patients,receiving,concurrently 1.0 0.000143348623853 1 0 1
patients,receiving,combination 1.0 0.000143348623853 1 0 1
patients,receiving,camptosar 1.0 0.000143348623853 1 0 1
patients,receiving,antihypertensive 1.0 0.000143348623853 1 0 1
patients,receiving,antabuse 1.0 0.000143348623853 1 0 1
patients,receiving,another 1.0 0.000143348623853 1 0 1
patients,predisposing,to 1.0 0.000143348623853 1 0 1
patients,over,a 1.0 0.000143348623853 1 0 1
patients,on,warfarin-type 1.0 0.000143348623853 1 0 1
patients,on,treatment 1.0 0.000143348623853 1 0 1
patients,on,than 1.0 0.000143348623853 1 0 1
patients,on,such 1.0 0.000143348623853 1 0 1
patients,on,oral 1.0 0.000143348623853 1 0 1
patients,on,or 1.0 0.000143348623853 1 0 1
patients,on,no 1.0 0.000143348623853 1 0 1
patients,on,long-term 1.0 0.000143348623853 1 0 1
patients,on,has 1.0 0.000143348623853 1 0 1
patients,on,coumarin-type 1.0 0.000143348623853 1 0 1
patients,n,and 1.0 0.000143348623853 1 0 1
patients,may,require 1.0 0.000143348623853 1 0 1
patients,may,induce 1.0 0.000143348623853 1 0 1
patients,may,experience 1.0 0.000143348623853 1 0 1
patients,lowered,the 1.0 0.000143348623853 1 0 1
patients,liver,which 1.0 0.000143348623853 1 0 1
patients,is,limited 1.0 0.000143348623853 1 0 1
patients,if,dosage 1.0 0.000143348623853 1 0 1
patients,have,been 1.0 0.000143348623853 1 0 1
patients,given,very 1.0 0.000143348623853 1 0 1
patients,given,both 1.0 0.000143348623853 1 0 1
patients,experiencing,increases 1.0 0.000143348623853 1 0 1
patients,demonstrated,a 1.0 0.000143348623853 1 0 1
patients,currently,receiving 1.0 0.000143348623853 1 0 1
patients,consuming,while 1.0 0.000143348623853 1 0 1
patients,concurrently,treated 1.0 0.000143348623853 1 0 1
patients,combined,use 1.0 0.000143348623853 1 0 1
patients,coadministered,oral 1.0 0.000143348623853 1 0 1
patients,by,inhibiting 1.0 0.000143348623853 1 0 1
patients,beginning,therapy 1.0 0.000143348623853 1 0 1
patients,are,to 1.0 0.000143348623853 1 0 1
patients,and,result 1.0 0.000143348623853 1 0 1
patients,and,normal 1.0 0.000143348623853 1 0 1
patients,and,dosage 1.0 0.000143348623853 1 0 1
patients,and,cerebyx 1.0 0.000143348623853 1 0 1
patients,anaesthetised,with 1.0 0.000143348623853 1 0 1
patients,already,stabilized 1.0 0.000143348623853 1 0 1
patients,already,receiving 1.0 0.000143348623853 1 0 1
patients,administered,prior 1.0 0.000143348623853 1 0 1
patient,with,acute 1.0 0.000143348623853 1 0 1
patient,with,a 1.0 0.000143348623853 1 0 1
patient,taking,mg 1.0 0.000143348623853 1 0 1
patient,requires,tikosyn 1.0 0.000143348623853 1 0 1
patient,receiving,revia 1.0 0.000143348623853 1 0 1
patient,receiving,prinivil 1.0 0.000143348623853 1 0 1
patient,receiving,hydrochloride 1.0 0.000143348623853 1 0 1
patient,populations,the 1.0 0.000143348623853 1 0 1
patient,pharmacokinetic,data 1.0 0.000143348623853 1 0 1
patient,only,where 1.0 0.000143348623853 1 0 1
patient,on,phenytoin 1.0 0.000143348623853 1 0 1
patient,on,chronic 1.0 0.000143348623853 1 0 1
patient,monitoring,and 1.0 0.000143348623853 1 0 1
patient,may,increase 1.0 0.000143348623853 1 0 1
patient,initiates,or 1.0 0.000143348623853 1 0 1
patient,has,recovered 1.0 0.000143348623853 1 0 1
patient,has,recently 1.0 0.000143348623853 1 0 1
patient,appeared,to 1.0 0.000143348623853 1 0 1
pathway,showed,a 1.0 0.000143348623853 1 0 1
pathway,for,detoxification 1.0 0.000143348623853 1 0 1
passages,increasing,the 1.0 0.000143348623853 1 0 1
parvum,growth,in 1.0 0.000143348623853 1 0 1
parts,of,the 1.0 0.000143348623853 1 0 1
partly,antagonized,the 1.0 0.000143348623853 1 0 1
particularly,with,higher 1.0 0.000143348623853 1 0 1
particularly,the,elderly 1.0 0.000143348623853 1 0 1
particularly,since,exhibits 1.0 0.000143348623853 1 0 1
particularly,of,the 1.0 0.000143348623853 1 0 1
particularly,in,the 1.0 0.000143348623853 1 0 1
particularly,in,subjects 1.0 0.000143348623853 1 0 1
particularly,if,their 1.0 0.000143348623853 1 0 1
particularly,have,been 1.0 0.000143348623853 1 0 1
particularly,diabetics,or 1.0 0.000143348623853 1 0 1
particularly,at,to 1.0 0.000143348623853 1 0 1
particular,convulsions,have 1.0 0.000143348623853 1 0 1
particular,caution,in 1.0 0.000143348623853 1 0 1
partially,related,to 1.0 0.000143348623853 1 0 1
part,to,mechanisms 1.0 0.000143348623853 1 0 1
paroxetine,produced,only 1.0 0.000143348623853 1 0 1
paroxetine,mg,qd 1.0 0.000143348623853 1 0 1
parkinsons,disease,have 1.0 0.000143348623853 1 0 1
parenterally,administered,in 1.0 0.000143348623853 1 0 1
parenteral,may,cause 1.0 0.000143348623853 1 0 1
parental,such,as 1.0 0.000143348623853 1 0 1
paranoid,symptoms,have 1.0 0.000143348623853 1 0 1
parameters,in,patients 1.0 0.000143348623853 1 0 1
parameters,auc,cmax 1.0 0.000143348623853 1 0 1
parameters,and,or 1.0 0.000143348623853 1 0 1
paralytic,ileus,may 1.0 0.000143348623853 1 0 1
para-aminosalicylic,acid,and 1.0 0.000143348623853 1 0 1
para-aminobenzoic,acid,paba 1.0 0.000143348623853 1 0 1
panretin,gel,should 1.0 0.000143348623853 1 0 1
pancreatitis,possibly,related 1.0 0.000143348623853 1 0 1
pancreatic,supplements,use 1.0 0.000143348623853 1 0 1
pancreatic,supplements,may 1.0 0.000143348623853 1 0 1
pah,cannot,be 1.0 0.000143348623853 1 0 1
paclitaxel,in,one 1.0 0.000143348623853 1 0 1
pacemaker,activity,can 1.0 0.000143348623853 1 0 1
paba,containing,preparations 1.0 0.000143348623853 1 0 1
p450iiia4,isozyme,and 1.0 0.000143348623853 1 0 1
p450iid6,such,as 1.0 0.000143348623853 1 0 1
p450,system,though 1.0 0.000143348623853 1 0 1
p450,inducers,can 1.0 0.000143348623853 1 0 1
p450,enzymes,the 1.0 0.000143348623853 1 0 1
p450,enzyme-inducer,did 1.0 0.000143348623853 1 0 1
p450,c9,decreased 1.0 0.000143348623853 1 0 1
p450,c9,by 1.0 0.000143348623853 1 0 1
p450,a4,would 1.0 0.000143348623853 1 0 1
p450,a4,such 1.0 0.000143348623853 1 0 1
p450,a4,may 1.0 0.000143348623853 1 0 1
p450,a4,increased 1.0 0.000143348623853 1 0 1
p450,a4,grapefruit 1.0 0.000143348623853 1 0 1
p450,a4,cyp 1.0 0.000143348623853 1 0 1
p450,a2,and 1.0 0.000143348623853 1 0 1
p450,a2,an 1.0 0.000143348623853 1 0 1
p-glycoprotein,substrate,with 1.0 0.000143348623853 1 0 1
p-glycoprotein,in,vivo 1.0 0.000143348623853 1 0 1
p-450iie1,in,the 1.0 0.000143348623853 1 0 1
p-450,isoenzymes,caution 1.0 0.000143348623853 1 0 1
p-450,inducers,such 1.0 0.000143348623853 1 0 1
p-450,for,days 1.0 0.000143348623853 1 0 1
p-450,a,family 1.0 0.000143348623853 1 0 1
p,this,was 1.0 0.000143348623853 1 0 1
p,the,possibility 1.0 0.000143348623853 1 0 1
p,o,induced 1.0 0.000143348623853 1 0 1
p,o,every 1.0 0.000143348623853 1 0 1
p,in,humans 1.0 0.000143348623853 1 0 1
p,decreased,mean 1.0 0.000143348623853 1 0 1
p,but,not 1.0 0.000143348623853 1 0 1
p,and,a 1.0 0.000143348623853 1 0 1
p,a,such 1.0 0.000143348623853 1 0 1
oxytocin,or,other 1.0 0.000143348623853 1 0 1
oxytocic,may,result 1.0 0.000143348623853 1 0 1
oxypurines,hypoxanthine,and 1.0 0.000143348623853 1 0 1
oxolinic,acid,prolonged 1.0 0.000143348623853 1 0 1
oxide,to,achieve 1.0 0.000143348623853 1 0 1
oxide,donor,compounds 1.0 0.000143348623853 1 0 1
oxidation,responsible,for 1.0 0.000143348623853 1 0 1
oxidation,of,and 1.0 0.000143348623853 1 0 1
oxidation,elc,should 1.0 0.000143348623853 1 0 1
oxidase,inhibitors,should 1.0 0.000143348623853 1 0 1
oxidase,inhibitors,psychotropic 1.0 0.000143348623853 1 0 1
oxidase,inhibitors,nalidixic 1.0 0.000143348623853 1 0 1
oxidase,inhibitors,maois 1.0 0.000143348623853 1 0 1
oxidase,inhibitors,hypertensive 1.0 0.000143348623853 1 0 1
oxidase,inhibitors,coadministration 1.0 0.000143348623853 1 0 1
oxidase,inhibiting,may 1.0 0.000143348623853 1 0 1
oxidase,in,vitro 1.0 0.000143348623853 1 0 1
oxidase,and,cyp3a4 1.0 0.000143348623853 1 0 1
overdose,with,a 1.0 0.000143348623853 1 0 1
overdose,especially,cyclic 1.0 0.000143348623853 1 0 1
overdosage,since,the 1.0 0.000143348623853 1 0 1
overdosage,or,in 1.0 0.000143348623853 1 0 1
overall,response,is 1.0 0.000143348623853 1 0 1
overall,exposure,to 1.0 0.000143348623853 1 0 1
over,use,of 1.0 0.000143348623853 1 0 1
over,those,seen 1.0 0.000143348623853 1 0 1
over,the,dosage 1.0 0.000143348623853 1 0 1
over,several,days 1.0 0.000143348623853 1 0 1
over,patients,in 1.0 0.000143348623853 1 0 1
over,a,dose 1.0 0.000143348623853 1 0 1
ovcon-35,resulted,in 1.0 0.000143348623853 1 0 1
ovarian,cancer,indicated 1.0 0.000143348623853 1 0 1
outweigh,the,increased 1.0 0.000143348623853 1 0 1
output,and,usually 1.0 0.000143348623853 1 0 1
output,and,an 1.0 0.000143348623853 1 0 1
our,patient,appeared 1.0 0.000143348623853 1 0 1
our,data,suggest 1.0 0.000143348623853 1 0 1
ototoxicity,is,enhanced 1.0 0.000143348623853 1 0 1
ototoxic,potential,especially 1.0 0.000143348623853 1 0 1
otherwise,healthy,male 1.0 0.000143348623853 1 0 1
others,that,interfere 1.0 0.000143348623853 1 0 1
others,choline,arthropan 1.0 0.000143348623853 1 0 1
others,are,also 1.0 0.000143348623853 1 0 1
other,with,potent 1.0 0.000143348623853 1 0 1
other,when,is 1.0 0.000143348623853 1 0 1
other,vasoconstrictor,can 1.0 0.000143348623853 1 0 1
other,tnfa-blocking,agents 1.0 0.000143348623853 1 0 1
other,tnf-blocking,agents 1.0 0.000143348623853 1 0 1
other,the,renal 1.0 0.000143348623853 1 0 1
other,that,sensitize 1.0 0.000143348623853 1 0 1
other,that,act 1.0 0.000143348623853 1 0 1
other,taken,in 1.0 0.000143348623853 1 0 1
other,systemic,etc 1.0 0.000143348623853 1 0 1
other,suitable,anticoagulation 1.0 0.000143348623853 1 0 1
other,substances,demonstrated 1.0 0.000143348623853 1 0 1
other,strong,selective 1.0 0.000143348623853 1 0 1
other,strong,cyp3a4 1.0 0.000143348623853 1 0 1
other,statins,co-administration 1.0 0.000143348623853 1 0 1
other,significantly,eliminated 1.0 0.000143348623853 1 0 1
other,schizophrenic,patients 1.0 0.000143348623853 1 0 1
other,related,presumably 1.0 0.000143348623853 1 0 1
other,related,compounds 1.0 0.000143348623853 1 0 1
other,published,reports 1.0 0.000143348623853 1 0 1
other,psychotropic,have 1.0 0.000143348623853 1 0 1
other,psychoactive,or 1.0 0.000143348623853 1 0 1
other,products,containing 1.0 0.000143348623853 1 0 1
other,potentially,nephrotoxic 1.0 0.000143348623853 1 0 1
other,potentially,important 1.0 0.000143348623853 1 0 1
other,potent,parental 1.0 0.000143348623853 1 0 1
other,potent,cyp3a4 1.0 0.000143348623853 1 0 1
other,potent,a4 1.0 0.000143348623853 1 0 1
other,potassium-sparing,with 1.0 0.000143348623853 1 0 1
other,pharmacokinetics,parameters 1.0 0.000143348623853 1 0 1
other,oral,with 1.0 0.000143348623853 1 0 1
other,oral,hypoglycemic 1.0 0.000143348623853 1 0 1
other,oral,formulations 1.0 0.000143348623853 1 0 1
other,or,medications 1.0 0.000143348623853 1 0 1
other,or,as 1.0 0.000143348623853 1 0 1
other,nsaids,through 1.0 0.000143348623853 1 0 1
other,nsaids,have 1.0 0.000143348623853 1 0 1
other,nsaid,while 1.0 0.000143348623853 1 0 1
other,nonsteroidal,that 1.0 0.000143348623853 1 0 1
other,nonsteroidal,probably 1.0 0.000143348623853 1 0 1
other,nonsteroidal,has 1.0 0.000143348623853 1 0 1
other,nonsteroidal,can 1.0 0.000143348623853 1 0 1
other,nonsteroidal,antiinflammatory 1.0 0.000143348623853 1 0 1
other,non-steroidal,anti-inflammatory 1.0 0.000143348623853 1 0 1
other,non-steroidal,and 1.0 0.000143348623853 1 0 1
other,narcotic,general 1.0 0.000143348623853 1 0 1
other,monoamine,oxidase 1.0 0.000143348623853 1 0 1
other,metal,cations 1.0 0.000143348623853 1 0 1
other,medicines,or 1.0 0.000143348623853 1 0 1
other,may,potentiate 1.0 0.000143348623853 1 0 1
other,may,inhibit 1.0 0.000143348623853 1 0 1
other,macrolide,and 1.0 0.000143348623853 1 0 1
other,local,or 1.0 0.000143348623853 1 0 1
other,known,photosensitizing 1.0 0.000143348623853 1 0 1
other,injectable,produces 1.0 0.000143348623853 1 0 1
other,inhibitors,of 1.0 0.000143348623853 1 0 1
other,including,when 1.0 0.000143348623853 1 0 1
other,including,ether 1.0 0.000143348623853 1 0 1
other,hypotensive,including 1.0 0.000143348623853 1 0 1
other,hydroxymethylglutaryl,coenzyme 1.0 0.000143348623853 1 0 1
other,hormonalmethods,of 1.0 0.000143348623853 1 0 1
other,hivid-associated,adverse 1.0 0.000143348623853 1 0 1
other,hepatic,enzyme 1.0 0.000143348623853 1 0 1
other,having,vasodilator 1.0 0.000143348623853 1 0 1
other,have,demonstrated 1.0 0.000143348623853 1 0 1
other,have,been 1.0 0.000143348623853 1 0 1
other,hand,intrathecal 1.0 0.000143348623853 1 0 1
other,given,concurrently 1.0 0.000143348623853 1 0 1
other,ergot,alkaloids 1.0 0.000143348623853 1 0 1
other,drugs,which 1.0 0.000143348623853 1 0 1
other,depressasnts,such 1.0 0.000143348623853 1 0 1
other,cyp3a4,metabolized 1.0 0.000143348623853 1 0 1
other,coumarin-like,should 1.0 0.000143348623853 1 0 1
other,concurrent,use 1.0 0.000143348623853 1 0 1
other,concurrent,administration 1.0 0.000143348623853 1 0 1
other,cns-depressant,should 1.0 0.000143348623853 1 0 1
other,cns-active,should 1.0 0.000143348623853 1 0 1
other,cns,agents 1.0 0.000143348623853 1 0 1
other,cholinesterase,inhibitors 1.0 0.000143348623853 1 0 1
other,channel,blockers 1.0 0.000143348623853 1 0 1
other,certain,such 1.0 0.000143348623853 1 0 1
other,cell,lines 1.0 0.000143348623853 1 0 1
other,cardioactive,compounds 1.0 0.000143348623853 1 0 1
other,bronchodilators,has 1.0 0.000143348623853 1 0 1
other,broad-spectrum,augmentin 1.0 0.000143348623853 1 0 1
other,beta2,agonists 1.0 0.000143348623853 1 0 1
other,b-lactam,renal 1.0 0.000143348623853 1 0 1
other,b-lactam,inhibits 1.0 0.000143348623853 1 0 1
other,b-lactam,co-administration 1.0 0.000143348623853 1 0 1
other,as,used 1.0 0.000143348623853 1 0 1
other,antiretroviral,drugs 1.0 0.000143348623853 1 0 1
other,antipsychotic,agents 1.0 0.000143348623853 1 0 1
other,antiplatelet,agents 1.0 0.000143348623853 1 0 1
other,antineoplastic,agents 1.0 0.000143348623853 1 0 1
other,antianxiety,agents 1.0 0.000143348623853 1 0 1
other,and,type 1.0 0.000143348623853 1 0 1
other,and,may 1.0 0.000143348623853 1 0 1
other,and,antiparkinsonian 1.0 0.000143348623853 1 0 1
other,amphotericin,b 1.0 0.000143348623853 1 0 1
other,agents,with 1.0 0.000143348623853 1 0 1
other,agents,the 1.0 0.000143348623853 1 0 1
other,ace,inhibitors 1.0 0.000143348623853 1 0 1
otc,dose,resulted 1.0 0.000143348623853 1 0 1
orthostatic,hypotension,cimetidine 1.0 0.000143348623853 1 0 1
orthostatic,changes,in 1.0 0.000143348623853 1 0 1
ortho-novum,produced,average 1.0 0.000143348623853 1 0 1
ortho-novum,increased,the 1.0 0.000143348623853 1 0 1
orlistat-orlistat,may,decrease 1.0 0.000143348623853 1 0 1
organisms,contained,in 1.0 0.000143348623853 1 0 1
organic,l-arginine,supplements 1.0 0.000143348623853 1 0 1
organ,transplant,patients 1.0 0.000143348623853 1 0 1
orencia,has,been 1.0 0.000143348623853 1 0 1
orencia,and,tnf 1.0 0.000143348623853 1 0 1
orencia,administered,concurrently 1.0 0.000143348623853 1 0 1
ordinarily,recommended,unless 1.0 0.000143348623853 1 0 1
order,to,produce 1.0 0.000143348623853 1 0 1
orally,with,channel 1.0 0.000143348623853 1 0 1
orally,prior,to 1.0 0.000143348623853 1 0 1
orally,imidazole,compounds 1.0 0.000143348623853 1 0 1
orally,for,days 1.0 0.000143348623853 1 0 1
orally,disintegrating,tablet 1.0 0.000143348623853 1 0 1
orally,because,of 1.0 0.000143348623853 1 0 1
orally,administered,agents 1.0 0.000143348623853 1 0 1
oral-dose,clearance,by 1.0 0.000143348623853 1 0 1
oral,with,must 1.0 0.000143348623853 1 0 1
oral,with,may 1.0 0.000143348623853 1 0 1
oral,who,are 1.0 0.000143348623853 1 0 1
oral,was,associated 1.0 0.000143348623853 1 0 1
oral,upon,beginning 1.0 0.000143348623853 1 0 1
oral,unreliable,prothrombin 1.0 0.000143348623853 1 0 1
oral,twice,daily 1.0 0.000143348623853 1 0 1
oral,treatment,folic 1.0 0.000143348623853 1 0 1
oral,the,prothrombin 1.0 0.000143348623853 1 0 1
oral,the,need 1.0 0.000143348623853 1 0 1
oral,sulfate,may 1.0 0.000143348623853 1 0 1
oral,such,as 1.0 0.000143348623853 1 0 1
oral,solution,one 1.0 0.000143348623853 1 0 1
oral,solution,can 1.0 0.000143348623853 1 0 1
oral,resulted,in 1.0 0.000143348623853 1 0 1
oral,produced,minor 1.0 0.000143348623853 1 0 1
oral,phenytoin,protease 1.0 0.000143348623853 1 0 1
oral,or,has 1.0 0.000143348623853 1 0 1
oral,mg,twice 1.0 0.000143348623853 1 0 1
oral,medications,containing 1.0 0.000143348623853 1 0 1
oral,medication,such 1.0 0.000143348623853 1 0 1
oral,may,render 1.0 0.000143348623853 1 0 1
oral,may,potentiate 1.0 0.000143348623853 1 0 1
oral,may,interfere 1.0 0.000143348623853 1 0 1
oral,markedly,inhibits 1.0 0.000143348623853 1 0 1
oral,markedly,inhibit 1.0 0.000143348623853 1 0 1
oral,live,typhoid 1.0 0.000143348623853 1 0 1
oral,is,significantly 1.0 0.000143348623853 1 0 1
oral,increased,the 1.0 0.000143348623853 1 0 1
oral,increased,auc 1.0 0.000143348623853 1 0 1
oral,including,or 1.0 0.000143348623853 1 0 1
oral,hypoglycemics,agents 1.0 0.000143348623853 1 0 1
oral,hormonal,ortho-novum 1.0 0.000143348623853 1 0 1
oral,has,led 1.0 0.000143348623853 1 0 1
oral,formulations,of 1.0 0.000143348623853 1 0 1
oral,form,a 1.0 0.000143348623853 1 0 1
oral,for,a 1.0 0.000143348623853 1 0 1
oral,estrogens,may 1.0 0.000143348623853 1 0 1
oral,during,administration 1.0 0.000143348623853 1 0 1
oral,doses,should 1.0 0.000143348623853 1 0 1
oral,dose,should 1.0 0.000143348623853 1 0 1
oral,dose,followed 1.0 0.000143348623853 1 0 1
oral,diabetes,medicine 1.0 0.000143348623853 1 0 1
oral,contraceptives,coadministration 1.0 0.000143348623853 1 0 1
oral,containing,mcg 1.0 0.000143348623853 1 0 1
oral,containing,may 1.0 0.000143348623853 1 0 1
oral,concomitant,administration 1.0 0.000143348623853 1 0 1
oral,combination,of 1.0 0.000143348623853 1 0 1
oral,co-administration,of 1.0 0.000143348623853 1 0 1
oral,clearance,values 1.0 0.000143348623853 1 0 1
oral,clearance,of 1.0 0.000143348623853 1 0 1
oral,clearance,and 1.0 0.000143348623853 1 0 1
oral,certain,and 1.0 0.000143348623853 1 0 1
oral,ccnu,by 1.0 0.000143348623853 1 0 1
oral,azole,inhibits 1.0 0.000143348623853 1 0 1
oral,aprepitant,when 1.0 0.000143348623853 1 0 1
oral,antifungal,agents 1.0 0.000143348623853 1 0 1
oral,anticoagulants,in 1.0 0.000143348623853 1 0 1
oral,anticoagulants,caution 1.0 0.000143348623853 1 0 1
oral,antagonists,may 1.0 0.000143348623853 1 0 1
oral,antagonist,was 1.0 0.000143348623853 1 0 1
oral,and,you 1.0 0.000143348623853 1 0 1
oral,and,vitamin 1.0 0.000143348623853 1 0 1
oral,and,to 1.0 0.000143348623853 1 0 1
oral,and,supplemental 1.0 0.000143348623853 1 0 1
oral,and,resulted 1.0 0.000143348623853 1 0 1
oral,and,plasma 1.0 0.000143348623853 1 0 1
oral,and,other 1.0 0.000143348623853 1 0 1
oral,and,its 1.0 0.000143348623853 1 0 1
oral,and,fluvoxamine 1.0 0.000143348623853 1 0 1
oral,and,discontinuation 1.0 0.000143348623853 1 0 1
oral,and,are 1.0 0.000143348623853 1 0 1
oral,an,and 1.0 0.000143348623853 1 0 1
oral,agents,receiving 1.0 0.000143348623853 1 0 1
oral,a,potent 1.0 0.000143348623853 1 0 1
or,without,clinical 1.0 0.000143348623853 1 0 1
or,without,bleeding 1.0 0.000143348623853 1 0 1
or,within,days 1.0 0.000143348623853 1 0 1
or,with,with 1.0 0.000143348623853 1 0 1
or,with,videx 1.0 0.000143348623853 1 0 1
or,with,preparations 1.0 0.000143348623853 1 0 1
or,with,particularly 1.0 0.000143348623853 1 0 1
or,with,other 1.0 0.000143348623853 1 0 1
or,with,formulations 1.0 0.000143348623853 1 0 1
or,with,cancidas 1.0 0.000143348623853 1 0 1
or,who,may 1.0 0.000143348623853 1 0 1
or,who,increase 1.0 0.000143348623853 1 0 1
or,which,inhibit 1.0 0.000143348623853 1 0 1
or,was,associated 1.0 0.000143348623853 1 0 1
or,vitamin,e 1.0 0.000143348623853 1 0 1
or,verapamil,the 1.0 0.000143348623853 1 0 1
or,use,of 1.0 0.000143348623853 1 0 1
or,type,it 1.0 0.000143348623853 1 0 1
or,two,mg 1.0 0.000143348623853 1 0 1
or,toxoids,should 1.0 0.000143348623853 1 0 1
or,to,two 1.0 0.000143348623853 1 0 1
or,to,those 1.0 0.000143348623853 1 0 1
or,those,taking 1.0 0.000143348623853 1 0 1
or,thiazide,can 1.0 0.000143348623853 1 0 1
or,therapy,on 1.0 0.000143348623853 1 0 1
or,the,strength 1.0 0.000143348623853 1 0 1
or,the,initial 1.0 0.000143348623853 1 0 1
or,the,hyperuricemia 1.0 0.000143348623853 1 0 1
or,the,dosage 1.0 0.000143348623853 1 0 1
or,the,concomitant 1.0 0.000143348623853 1 0 1
or,the,auc 1.0 0.000143348623853 1 0 1
or,the,administration 1.0 0.000143348623853 1 0 1
or,than,in 1.0 0.000143348623853 1 0 1
or,taking,tarceva 1.0 0.000143348623853 1 0 1
or,systemic,medications 1.0 0.000143348623853 1 0 1
or,symptoms,of 1.0 0.000143348623853 1 0 1
or,symptoms,occur 1.0 0.000143348623853 1 0 1
or,supplemented,with 1.0 0.000143348623853 1 0 1
or,substrates,of 1.0 0.000143348623853 1 0 1
or,substantially,interfere 1.0 0.000143348623853 1 0 1
or,substances,the 1.0 0.000143348623853 1 0 1
or,stopping,since 1.0 0.000143348623853 1 0 1
or,stopped,to 1.0 0.000143348623853 1 0 1
or,st,john 1.0 0.000143348623853 1 0 1
or,some,leading 1.0 0.000143348623853 1 0 1
or,sodium,a 1.0 0.000143348623853 1 0 1
or,slightly,greater 1.0 0.000143348623853 1 0 1
or,should,not 1.0 0.000143348623853 1 0 1
or,serum,levels 1.0 0.000143348623853 1 0 1
or,s,determined 1.0 0.000143348623853 1 0 1
or,resulted,in 1.0 0.000143348623853 1 0 1
or,renal,tubular 1.0 0.000143348623853 1 0 1
or,reduced,tolerance 1.0 0.000143348623853 1 0 1
or,reduced,infusion 1.0 0.000143348623853 1 0 1
or,recovery,following 1.0 0.000143348623853 1 0 1
or,prolong,adverse 1.0 0.000143348623853 1 0 1
or,products,containing 1.0 0.000143348623853 1 0 1
or,potentiating,effects 1.0 0.000143348623853 1 0 1
or,potentiated,the 1.0 0.000143348623853 1 0 1
or,potentially,result 1.0 0.000143348623853 1 0 1
or,pcp,were 1.0 0.000143348623853 1 0 1
or,pcp,in 1.0 0.000143348623853 1 0 1
or,patients,using 1.0 0.000143348623853 1 0 1
or,other,significantly 1.0 0.000143348623853 1 0 1
or,other,should 1.0 0.000143348623853 1 0 1
or,other,products 1.0 0.000143348623853 1 0 1
or,other,potent 1.0 0.000143348623853 1 0 1
or,other,oral 1.0 0.000143348623853 1 0 1
or,other,nonsteroidal 1.0 0.000143348623853 1 0 1
or,other,metal 1.0 0.000143348623853 1 0 1
or,other,metabolized 1.0 0.000143348623853 1 0 1
or,other,hivid-associated 1.0 0.000143348623853 1 0 1
or,other,hepatic 1.0 0.000143348623853 1 0 1
or,other,having 1.0 0.000143348623853 1 0 1
or,other,drugs 1.0 0.000143348623853 1 0 1
or,other,coumarin-like 1.0 0.000143348623853 1 0 1
or,other,concurrent 1.0 0.000143348623853 1 0 1
or,other,beta2 1.0 0.000143348623853 1 0 1
or,other,as 1.0 0.000143348623853 1 0 1
or,orthostatic,changes 1.0 0.000143348623853 1 0 1
or,organophosphate,and 1.0 0.000143348623853 1 0 1
or,oral,hypoglycemic 1.0 0.000143348623853 1 0 1
or,or,with 1.0 0.000143348623853 1 0 1
or,or,should 1.0 0.000143348623853 1 0 1
or,or,lead 1.0 0.000143348623853 1 0 1
or,not,at 1.0 0.000143348623853 1 0 1
or,norpace,cr 1.0 0.000143348623853 1 0 1
or,near,mg 1.0 0.000143348623853 1 0 1
or,n,compared 1.0 0.000143348623853 1 0 1
or,more,with 1.0 0.000143348623853 1 0 1
or,more,than 1.0 0.000143348623853 1 0 1
or,more,possibly 1.0 0.000143348623853 1 0 1
or,more,in 1.0 0.000143348623853 1 0 1
or,monoamine,oxidase 1.0 0.000143348623853 1 0 1
or,ml,twice 1.0 0.000143348623853 1 0 1
or,minutes,following 1.0 0.000143348623853 1 0 1
or,minus,in 1.0 0.000143348623853 1 0 1
or,mg,with 1.0 0.000143348623853 1 0 1
or,mg,was 1.0 0.000143348623853 1 0 1
or,mg,m2 1.0 0.000143348623853 1 0 1
or,mg,h 1.0 0.000143348623853 1 0 1
or,medications,with 1.0 0.000143348623853 1 0 1
or,may,substantially 1.0 0.000143348623853 1 0 1
or,may,result 1.0 0.000143348623853 1 0 1
or,may,reduce 1.0 0.000143348623853 1 0 1
or,may,partially 1.0 0.000143348623853 1 0 1
or,may,interfere 1.0 0.000143348623853 1 0 1
or,may,intensify 1.0 0.000143348623853 1 0 1
or,may,impair 1.0 0.000143348623853 1 0 1
or,may,diminish 1.0 0.000143348623853 1 0 1
or,may,develop 1.0 0.000143348623853 1 0 1
or,may,cause 1.0 0.000143348623853 1 0 1
or,marked,changes 1.0 0.000143348623853 1 0 1
or,mao-inhibitors,with 1.0 0.000143348623853 1 0 1
or,magnesium-containing,concomitant 1.0 0.000143348623853 1 0 1
or,low-dose,microg 1.0 0.000143348623853 1 0 1
or,less,frequent 1.0 0.000143348623853 1 0 1
or,led,to 1.0 0.000143348623853 1 0 1
or,lead,to 1.0 0.000143348623853 1 0 1
or,known,to 1.0 0.000143348623853 1 0 1
or,its,breakdown 1.0 0.000143348623853 1 0 1
or,is,used 1.0 0.000143348623853 1 0 1
or,is,receiving 1.0 0.000143348623853 1 0 1
or,intravenous,or 1.0 0.000143348623853 1 0 1
or,intravenous,antagonists 1.0 0.000143348623853 1 0 1
or,insulin-induced,proliferation 1.0 0.000143348623853 1 0 1
or,inr,days 1.0 0.000143348623853 1 0 1
or,initiating,therapy 1.0 0.000143348623853 1 0 1
or,increasing,salt 1.0 0.000143348623853 1 0 1
or,increased,prothrombin 1.0 0.000143348623853 1 0 1
or,increased,metabolic 1.0 0.000143348623853 1 0 1
or,increase,the 1.0 0.000143348623853 1 0 1
or,inactivated,due 1.0 0.000143348623853 1 0 1
or,in,whom 1.0 0.000143348623853 1 0 1
or,in,volume 1.0 0.000143348623853 1 0 1
or,in,two 1.0 0.000143348623853 1 0 1
or,imuran,the 1.0 0.000143348623853 1 0 1
or,impairing,its 1.0 0.000143348623853 1 0 1
or,immediately,following 1.0 0.000143348623853 1 0 1
or,if,any 1.0 0.000143348623853 1 0 1
or,ibuprofen,and 1.0 0.000143348623853 1 0 1
or,hypotension,with 1.0 0.000143348623853 1 0 1
or,hypotension,which 1.0 0.000143348623853 1 0 1
or,hypokalemia,that 1.0 0.000143348623853 1 0 1
or,hours,before 1.0 0.000143348623853 1 0 1
or,hepatotoxic,effects 1.0 0.000143348623853 1 0 1
or,hepatic,enzyme 1.0 0.000143348623853 1 0 1
or,has,led 1.0 0.000143348623853 1 0 1
or,had,a 1.0 0.000143348623853 1 0 1
or,h2antagonists,reduced 1.0 0.000143348623853 1 0 1
or,h1-blocking,agents 1.0 0.000143348623853 1 0 1
or,h,receptor 1.0 0.000143348623853 1 0 1
or,glycoprotein,iib 1.0 0.000143348623853 1 0 1
or,from,their 1.0 0.000143348623853 1 0 1
or,fr,responding 1.0 0.000143348623853 1 0 1
or,excess,may 1.0 0.000143348623853 1 0 1
or,estrogen-containing,oral 1.0 0.000143348623853 1 0 1
or,ergot,alkaloids 1.0 0.000143348623853 1 0 1
or,eliminated,the 1.0 0.000143348623853 1 0 1
or,elevated,serum 1.0 0.000143348623853 1 0 1
or,elevated,liver 1.0 0.000143348623853 1 0 1
or,either,stereoisomer 1.0 0.000143348623853 1 0 1
or,discontinues,therapy 1.0 0.000143348623853 1 0 1
or,diarrhea,induced 1.0 0.000143348623853 1 0 1
or,dialysis,may 1.0 0.000143348623853 1 0 1
or,decreases,the 1.0 0.000143348623853 1 0 1
or,decreased,by 1.0 0.000143348623853 1 0 1
or,decrease,plasma 1.0 0.000143348623853 1 0 1
or,cyp2d6,eg 1.0 0.000143348623853 1 0 1
or,consider,hmg-coa 1.0 0.000143348623853 1 0 1
or,concurrently,with 1.0 0.000143348623853 1 0 1
or,concurrently,should 1.0 0.000143348623853 1 0 1
or,co-administration,enhances 1.0 0.000143348623853 1 0 1
or,cns,depressants 1.0 0.000143348623853 1 0 1
or,cimetidine,concomitant 1.0 0.000143348623853 1 0 1
or,channel,blockers 1.0 0.000143348623853 1 0 1
or,changing,vioxx 1.0 0.000143348623853 1 0 1
or,changing,therapy 1.0 0.000143348623853 1 0 1
or,changing,the 1.0 0.000143348623853 1 0 1
or,changed,in 1.0 0.000143348623853 1 0 1
or,cervical,laceration 1.0 0.000143348623853 1 0 1
or,careful,consideration 1.0 0.000143348623853 1 0 1
or,can,inhibit 1.0 0.000143348623853 1 0 1
or,can,be 1.0 0.000143348623853 1 0 1
or,camp-stimulated,acid 1.0 0.000143348623853 1 0 1
or,but,not 1.0 0.000143348623853 1 0 1
or,bleeding,have 1.0 0.000143348623853 1 0 1
or,bleeding,events 1.0 0.000143348623853 1 0 1
or,bind,the 1.0 0.000143348623853 1 0 1
or,because,the 1.0 0.000143348623853 1 0 1
or,basic,as 1.0 0.000143348623853 1 0 1
or,back-up,methods 1.0 0.000143348623853 1 0 1
or,avoided,also 1.0 0.000143348623853 1 0 1
or,av,nodal 1.0 0.000143348623853 1 0 1
or,as,well 1.0 0.000143348623853 1 0 1
or,as,these 1.0 0.000143348623853 1 0 1
or,are,taken 1.0 0.000143348623853 1 0 1
or,are,enhanced 1.0 0.000143348623853 1 0 1
or,another,such 1.0 0.000143348623853 1 0 1
or,and,within 1.0 0.000143348623853 1 0 1
or,and,hydroxides 1.0 0.000143348623853 1 0 1
or,and,frova 1.0 0.000143348623853 1 0 1
or,and,axert 1.0 0.000143348623853 1 0 1
or,an,oral 1.0 0.000143348623853 1 0 1
or,aluminum-containing,products 1.0 0.000143348623853 1 0 1
or,alter,the 1.0 0.000143348623853 1 0 1
or,agents,such 1.0 0.000143348623853 1 0 1
or,agents,structurally 1.0 0.000143348623853 1 0 1
or,after,ethyl 1.0 0.000143348623853 1 0 1
or,administered,with 1.0 0.000143348623853 1 0 1
or,activated,in 1.0 0.000143348623853 1 0 1
or,above,of 1.0 0.000143348623853 1 0 1
or,abolished,as 1.0 0.000143348623853 1 0 1
or,abolish,the 1.0 0.000143348623853 1 0 1
or,a,diminished 1.0 0.000143348623853 1 0 1
or,a,antidepressant 1.0 0.000143348623853 1 0 1
opposite,way,the 1.0 0.000143348623853 1 0 1
opioids,co-administration,of 1.0 0.000143348623853 1 0 1
opioid-induced,gastrointestinal,effects 1.0 0.000143348623853 1 0 1
opioid,analgesics,agonist 1.0 0.000143348623853 1 0 1
ophthalmic,solution,the 1.0 0.000143348623853 1 0 1
open,air,passages 1.0 0.000143348623853 1 0 1
onto,the,surface 1.0 0.000143348623853 1 0 1
onset,of,maximum 1.0 0.000143348623853 1 0 1
onset,can,be 1.0 0.000143348623853 1 0 1
onset,and,may 1.0 0.000143348623853 1 0 1
only,where,definitely 1.0 0.000143348623853 1 0 1
only,to,slower 1.0 0.000143348623853 1 0 1
only,slightly,reduced 1.0 0.000143348623853 1 0 1
only,observed,in 1.0 0.000143348623853 1 0 1
only,minor,changes 1.0 0.000143348623853 1 0 1
only,enhances,cocaine-induced 1.0 0.000143348623853 1 0 1
only,clinically,relevant 1.0 0.000143348623853 1 0 1
only,block,the 1.0 0.000143348623853 1 0 1
only,additive,effects 1.0 0.000143348623853 1 0 1
only,a,very 1.0 0.000143348623853 1 0 1
only,a,increase 1.0 0.000143348623853 1 0 1
one-week,course,of 1.0 0.000143348623853 1 0 1
one-third,to,one-fourth 1.0 0.000143348623853 1 0 1
one-third,as,well 1.0 0.000143348623853 1 0 1
one-half,the,usual 1.0 0.000143348623853 1 0 1
one-fourth,of,the 1.0 0.000143348623853 1 0 1
one,week,prior 1.0 0.000143348623853 1 0 1
one,week,plasma 1.0 0.000143348623853 1 0 1
one,week,course 1.0 0.000143348623853 1 0 1
one,third,of 1.0 0.000143348623853 1 0 1
one,survey,of 1.0 0.000143348623853 1 0 1
one,study,or 1.0 0.000143348623853 1 0 1
one,study,in 1.0 0.000143348623853 1 0 1
one,reported,case 1.0 0.000143348623853 1 0 1
one,report,that 1.0 0.000143348623853 1 0 1
one,report,suggesting 1.0 0.000143348623853 1 0 1
one,report,l-glutamine 1.0 0.000143348623853 1 0 1
one,patient,taking 1.0 0.000143348623853 1 0 1
one,mg,kg 1.0 0.000143348623853 1 0 1
one,mg,dose 1.0 0.000143348623853 1 0 1
one,man,the 1.0 0.000143348623853 1 0 1
one,hour,apart 1.0 0.000143348623853 1 0 1
one,gram,of 1.0 0.000143348623853 1 0 1
one,dose,of 1.0 0.000143348623853 1 0 1
one,controlled,clinical 1.0 0.000143348623853 1 0 1
once,weekly,reduced 1.0 0.000143348623853 1 0 1
once,weekly,for 1.0 0.000143348623853 1 0 1
once,daily,the 1.0 0.000143348623853 1 0 1
once,daily,resulted 1.0 0.000143348623853 1 0 1
once,daily,produced 1.0 0.000143348623853 1 0 1
once,daily,doses 1.0 0.000143348623853 1 0 1
on,warfarin-type,therapy 1.0 0.000143348623853 1 0 1
on,valproic,acid 1.0 0.000143348623853 1 0 1
on,tyrosine,phosphorylation 1.0 0.000143348623853 1 0 1
on,treatment,should 1.0 0.000143348623853 1 0 1
on,travelers,receiving 1.0 0.000143348623853 1 0 1
on,these,data 1.0 0.000143348623853 1 0 1
on,therapy,the 1.0 0.000143348623853 1 0 1
on,the,tail-flick 1.0 0.000143348623853 1 0 1
on,the,sixth 1.0 0.000143348623853 1 0 1
on,the,second 1.0 0.000143348623853 1 0 1
on,the,risk 1.0 0.000143348623853 1 0 1
on,the,retention 1.0 0.000143348623853 1 0 1
on,the,requirement 1.0 0.000143348623853 1 0 1
on,the,pr 1.0 0.000143348623853 1 0 1
on,the,maintenance 1.0 0.000143348623853 1 0 1
on,the,involvement 1.0 0.000143348623853 1 0 1
on,the,gi 1.0 0.000143348623853 1 0 1
on,the,early 1.0 0.000143348623853 1 0 1
on,the,digit 1.0 0.000143348623853 1 0 1
on,the,day 1.0 0.000143348623853 1 0 1
on,the,contrary 1.0 0.000143348623853 1 0 1
on,the,concomitant 1.0 0.000143348623853 1 0 1
on,the,cmax 1.0 0.000143348623853 1 0 1
on,the,chemical 1.0 0.000143348623853 1 0 1
on,the,brief 1.0 0.000143348623853 1 0 1
on,the,biotransformation 1.0 0.000143348623853 1 0 1
on,the,advice 1.0 0.000143348623853 1 0 1
on,the,action 1.0 0.000143348623853 1 0 1
on,than,in 1.0 0.000143348623853 1 0 1
on,such,combined 1.0 0.000143348623853 1 0 1
on,sodium,excretion 1.0 0.000143348623853 1 0 1
on,should,receive 1.0 0.000143348623853 1 0 1
on,sgpt,alt 1.0 0.000143348623853 1 0 1
on,severe,dietary 1.0 0.000143348623853 1 0 1
on,renal,tubular 1.0 0.000143348623853 1 0 1
on,renal,prostaglandins 1.0 0.000143348623853 1 0 1
on,receiving,concurrent 1.0 0.000143348623853 1 0 1
on,pupil,size 1.0 0.000143348623853 1 0 1
on,psychomotor,performance 1.0 0.000143348623853 1 0 1
on,prolonging,atrioventricular 1.0 0.000143348623853 1 0 1
on,potassium,kinetics 1.0 0.000143348623853 1 0 1
on,possible,interactions 1.0 0.000143348623853 1 0 1
on,platelet,aggregation 1.0 0.000143348623853 1 0 1
on,plasma,has 1.0 0.000143348623853 1 0 1
on,phenytoin,therapy 1.0 0.000143348623853 1 0 1
on,pharmacokinetics,but 1.0 0.000143348623853 1 0 1
on,other,antiepileptic 1.0 0.000143348623853 1 0 1
on,oral,who 1.0 0.000143348623853 1 0 1
on,oral,agents 1.0 0.000143348623853 1 0 1
on,or,other 1.0 0.000143348623853 1 0 1
on,natriuresis,is 1.0 0.000143348623853 1 0 1
on,metabolism,in 1.0 0.000143348623853 1 0 1
on,may,show 1.0 0.000143348623853 1 0 1
on,may,be 1.0 0.000143348623853 1 0 1
on,malignant,cells 1.0 0.000143348623853 1 0 1
on,long-term,therapy 1.0 0.000143348623853 1 0 1
on,kinetics,and 1.0 0.000143348623853 1 0 1
on,indicates,that 1.0 0.000143348623853 1 0 1
on,histamine-,or 1.0 0.000143348623853 1 0 1
on,hepatotoxicity,are 1.0 0.000143348623853 1 0 1
on,has,been 1.0 0.000143348623853 1 0 1
on,half-life,the 1.0 0.000143348623853 1 0 1
on,gm,day 1.0 0.000143348623853 1 0 1
on,gabitril,carbamazepine 1.0 0.000143348623853 1 0 1
on,fi,and 1.0 0.000143348623853 1 0 1
on,felbatol,phenytoin 1.0 0.000143348623853 1 0 1
on,established,therapy 1.0 0.000143348623853 1 0 1
on,equetrotm,and 1.0 0.000143348623853 1 0 1
on,days,through 1.0 0.000143348623853 1 0 1
on,day9,of 1.0 0.000143348623853 1 0 1
on,day5,of 1.0 0.000143348623853 1 0 1
on,day,relative 1.0 0.000143348623853 1 0 1
on,day,of 1.0 0.000143348623853 1 0 1
on,coumarin-type,the 1.0 0.000143348623853 1 0 1
on,concomitant,treatment 1.0 0.000143348623853 1 0 1
on,components,p2 1.0 0.000143348623853 1 0 1
on,clinical,and 1.0 0.000143348623853 1 0 1
on,chronic,treatment 1.0 0.000143348623853 1 0 1
on,certain,microsomal 1.0 0.000143348623853 1 0 1
on,cas,but 1.0 0.000143348623853 1 0 1
on,balance,testing 1.0 0.000143348623853 1 0 1
on,average,by 1.0 0.000143348623853 1 0 1
on,av,node 1.0 0.000143348623853 1 0 1
on,arterial,thrombus 1.0 0.000143348623853 1 0 1
on,anecdotal,reports 1.0 0.000143348623853 1 0 1
on,adult,data 1.0 0.000143348623853 1 0 1
on,administration,of 1.0 0.000143348623853 1 0 1
on,activity,persists 1.0 0.000143348623853 1 0 1
on,absorption,when 1.0 0.000143348623853 1 0 1
on,a,preparation 1.0 0.000143348623853 1 0 1
on,a,maintenance 1.0 0.000143348623853 1 0 1
olanzapine,coadministration,of 1.0 0.000143348623853 1 0 1
oil-concomitant,intake,of 1.0 0.000143348623853 1 0 1
oil,interferes,with 1.0 0.000143348623853 1 0 1
oil,and,k 1.0 0.000143348623853 1 0 1
of,zyvox,and 1.0 0.000143348623853 1 0 1
of,zebeta,resulting 1.0 0.000143348623853 1 0 1
of,zebeta,may 1.0 0.000143348623853 1 0 1
of,zdv,as 1.0 0.000143348623853 1 0 1
of,x,mg 1.0 0.000143348623853 1 0 1
of,withdrawal,syndrome 1.0 0.000143348623853 1 0 1
of,withdrawal,methadone 1.0 0.000143348623853 1 0 1
of,with,with 1.0 0.000143348623853 1 0 1
of,with,targretin 1.0 0.000143348623853 1 0 1
of,with,strong 1.0 0.000143348623853 1 0 1
of,with,products 1.0 0.000143348623853 1 0 1
of,with,pivoxil 1.0 0.000143348623853 1 0 1
of,with,of 1.0 0.000143348623853 1 0 1
of,with,occurs 1.0 0.000143348623853 1 0 1
of,with,lowered 1.0 0.000143348623853 1 0 1
of,with,itraconazole 1.0 0.000143348623853 1 0 1
of,with,is 1.0 0.000143348623853 1 0 1
of,with,hydroxide 1.0 0.000143348623853 1 0 1
of,with,elspar 1.0 0.000143348623853 1 0 1
of,with,containing 1.0 0.000143348623853 1 0 1
of,with,central 1.0 0.000143348623853 1 0 1
of,with,celebrex 1.0 0.000143348623853 1 0 1
of,with,causes 1.0 0.000143348623853 1 0 1
of,with,careful 1.0 0.000143348623853 1 0 1
of,with,atacand 1.0 0.000143348623853 1 0 1
of,with,alfenta 1.0 0.000143348623853 1 0 1
of,with,agents 1.0 0.000143348623853 1 0 1
of,with,ace 1.0 0.000143348623853 1 0 1
of,with,acamprosate 1.0 0.000143348623853 1 0 1
of,while,under 1.0 0.000143348623853 1 0 1
of,which,may 1.0 0.000143348623853 1 0 1
of,which,involved 1.0 0.000143348623853 1 0 1
of,which,d 1.0 0.000143348623853 1 0 1
of,whether,these 1.0 0.000143348623853 1 0 1
of,when,used 1.0 0.000143348623853 1 0 1
of,when,it 1.0 0.000143348623853 1 0 1
of,when,is 1.0 0.000143348623853 1 0 1
of,when,has 1.0 0.000143348623853 1 0 1
of,when,co 1.0 0.000143348623853 1 0 1
of,when,both 1.0 0.000143348623853 1 0 1
of,were,significantly 1.0 0.000143348623853 1 0 1
of,were,considerably 1.0 0.000143348623853 1 0 1
of,were,approximately 1.0 0.000143348623853 1 0 1
of,were,and 1.0 0.000143348623853 1 0 1
of,were,almost 1.0 0.000143348623853 1 0 1
of,were,administered 1.0 0.000143348623853 1 0 1
of,wellbutrin,tablets 1.0 0.000143348623853 1 0 1
of,wellbutrin,and 1.0 0.000143348623853 1 0 1
of,was,ng 1.0 0.000143348623853 1 0 1
of,was,lowered 1.0 0.000143348623853 1 0 1
of,was,higher 1.0 0.000143348623853 1 0 1
of,warfarin-type,certain 1.0 0.000143348623853 1 0 1
of,vitamin,k 1.0 0.000143348623853 1 0 1
of,vitamin,b12 1.0 0.000143348623853 1 0 1
of,vitamin,a 1.0 0.000143348623853 1 0 1
of,vital,signs 1.0 0.000143348623853 1 0 1
of,vistide,and 1.0 0.000143348623853 1 0 1
of,viracept,with 1.0 0.000143348623853 1 0 1
of,videx,to 1.0 0.000143348623853 1 0 1
of,videx,hours 1.0 0.000143348623853 1 0 1
of,vasopressor,for 1.0 0.000143348623853 1 0 1
of,vasoconstricting,agents 1.0 0.000143348623853 1 0 1
of,various,such 1.0 0.000143348623853 1 0 1
of,various,antihypertensive 1.0 0.000143348623853 1 0 1
of,vardenafil,should 1.0 0.000143348623853 1 0 1
of,vardenafil,experienced 1.0 0.000143348623853 1 0 1
of,vardenafil,and 1.0 0.000143348623853 1 0 1
of,v,oral 1.0 0.000143348623853 1 0 1
of,usually,depresses 1.0 0.000143348623853 1 0 1
of,using,tricor 1.0 0.000143348623853 1 0 1
of,using,bromocriptine 1.0 0.000143348623853 1 0 1
of,using,an 1.0 0.000143348623853 1 0 1
of,users,of 1.0 0.000143348623853 1 0 1
of,uricosuric,medication 1.0 0.000143348623853 1 0 1
of,uricosuric,agents 1.0 0.000143348623853 1 0 1
of,urate,uricosuric 1.0 0.000143348623853 1 0 1
of,urate,are 1.0 0.000143348623853 1 0 1
of,unsteady,gait 1.0 0.000143348623853 1 0 1
of,unchanged,alkaloids 1.0 0.000143348623853 1 0 1
of,two,potentially 1.0 0.000143348623853 1 0 1
of,two,or 1.0 0.000143348623853 1 0 1
of,trileptal,the 1.0 0.000143348623853 1 0 1
of,trileptal,greater 1.0 0.000143348623853 1 0 1
of,tricyclic,and 1.0 0.000143348623853 1 0 1
of,tricor,and 1.0 0.000143348623853 1 0 1
of,treatment,in 1.0 0.000143348623853 1 0 1
of,trazodone,hydrochloride 1.0 0.000143348623853 1 0 1
of,transdermal,with 1.0 0.000143348623853 1 0 1
of,tracrium,include 1.0 0.000143348623853 1 0 1
of,tracleer,and 1.0 0.000143348623853 1 0 1
of,toxicity,when 1.0 0.000143348623853 1 0 1
of,toxicity,were 1.0 0.000143348623853 1 0 1
of,toxicity,should 1.0 0.000143348623853 1 0 1
of,toxicity,occur 1.0 0.000143348623853 1 0 1
of,toxicity,in 1.0 0.000143348623853 1 0 1
of,toxicity,associated 1.0 0.000143348623853 1 0 1
of,toxic,levels 1.0 0.000143348623853 1 0 1
of,total,formation 1.0 0.000143348623853 1 0 1
of,toradol,to 1.0 0.000143348623853 1 0 1
of,toradol,oral 1.0 0.000143348623853 1 0 1
of,toradol,and 1.0 0.000143348623853 1 0 1
of,tolerance,in 1.0 0.000143348623853 1 0 1
of,to,treat 1.0 0.000143348623853 1 0 1
of,to,subjects 1.0 0.000143348623853 1 0 1
of,to,plasma 1.0 0.000143348623853 1 0 1
of,to,normal 1.0 0.000143348623853 1 0 1
of,to,induce 1.0 0.000143348623853 1 0 1
of,to,increase 1.0 0.000143348623853 1 0 1
of,to,human 1.0 0.000143348623853 1 0 1
of,to,half 1.0 0.000143348623853 1 0 1
of,to,decrease 1.0 0.000143348623853 1 0 1
of,to,approximately 1.0 0.000143348623853 1 0 1
of,to,about 1.0 0.000143348623853 1 0 1
of,to,a 1.0 0.000143348623853 1 0 1
of,tikosyn,with 1.0 0.000143348623853 1 0 1
of,those,obtained 1.0 0.000143348623853 1 0 1
of,this,reduction 1.0 0.000143348623853 1 0 1
of,this,protein 1.0 0.000143348623853 1 0 1
of,this,kind 1.0 0.000143348623853 1 0 1
of,these,three 1.0 0.000143348623853 1 0 1
of,these,subjects 1.0 0.000143348623853 1 0 1
of,these,resulting 1.0 0.000143348623853 1 0 1
of,these,potentially 1.0 0.000143348623853 1 0 1
of,these,oral 1.0 0.000143348623853 1 0 1
of,these,may 1.0 0.000143348623853 1 0 1
of,these,leading 1.0 0.000143348623853 1 0 1
of,these,larger 1.0 0.000143348623853 1 0 1
of,these,could 1.0 0.000143348623853 1 0 1
of,thereby,raising 1.0 0.000143348623853 1 0 1
of,thereby,decreasing 1.0 0.000143348623853 1 0 1
of,there,is 1.0 0.000143348623853 1 0 1
of,theophylline-related,side-effects 1.0 0.000143348623853 1 0 1
of,theo-dur,key 1.0 0.000143348623853 1 0 1
of,their,usual 1.0 0.000143348623853 1 0 1
of,their,dosage 1.0 0.000143348623853 1 0 1
of,their,blood 1.0 0.000143348623853 1 0 1
of,the,with 1.0 0.000143348623853 1 0 1
of,the,weekly 1.0 0.000143348623853 1 0 1
of,the,unbound 1.0 0.000143348623853 1 0 1
of,the,type 1.0 0.000143348623853 1 0 1
of,the,tnf 1.0 0.000143348623853 1 0 1
of,the,therapeutic 1.0 0.000143348623853 1 0 1
of,the,theophylline-induced 1.0 0.000143348623853 1 0 1
of,the,tca 1.0 0.000143348623853 1 0 1
of,the,systemic 1.0 0.000143348623853 1 0 1
of,the,supraventricular 1.0 0.000143348623853 1 0 1
of,the,stomach 1.0 0.000143348623853 1 0 1
of,the,sirolimus-diltiazem 1.0 0.000143348623853 1 0 1
of,the,r 1.0 0.000143348623853 1 0 1
of,the,qtc 1.0 0.000143348623853 1 0 1
of,the,proton 1.0 0.000143348623853 1 0 1
of,the,protective 1.0 0.000143348623853 1 0 1
of,the,pronounced 1.0 0.000143348623853 1 0 1
of,the,potent 1.0 0.000143348623853 1 0 1
of,the,physician 1.0 0.000143348623853 1 0 1
of,the,non-ionized 1.0 0.000143348623853 1 0 1
of,the,non-depolarizing 1.0 0.000143348623853 1 0 1
of,the,neuromuscular 1.0 0.000143348623853 1 0 1
of,the,muscle 1.0 0.000143348623853 1 0 1
of,the,mouth 1.0 0.000143348623853 1 0 1
of,the,metabolism 1.0 0.000143348623853 1 0 1
of,the,mao 1.0 0.000143348623853 1 0 1
of,the,macrolide 1.0 0.000143348623853 1 0 1
of,the,literature 1.0 0.000143348623853 1 0 1
of,the,intravenous 1.0 0.000143348623853 1 0 1
of,the,inhibition 1.0 0.000143348623853 1 0 1
of,the,ingested 1.0 0.000143348623853 1 0 1
of,the,induction 1.0 0.000143348623853 1 0 1
of,the,hypotensive 1.0 0.000143348623853 1 0 1
of,the,hypotension 1.0 0.000143348623853 1 0 1
of,the,hypoglycemic 1.0 0.000143348623853 1 0 1
of,the,ht3 1.0 0.000143348623853 1 0 1
of,the,first-pass 1.0 0.000143348623853 1 0 1
of,the,enkephalinergic 1.0 0.000143348623853 1 0 1
of,the,endotoxin-treated 1.0 0.000143348623853 1 0 1
of,the,during 1.0 0.000143348623853 1 0 1
of,the,divided 1.0 0.000143348623853 1 0 1
of,the,cyp2c9 1.0 0.000143348623853 1 0 1
of,the,clearance 1.0 0.000143348623853 1 0 1
of,the,central 1.0 0.000143348623853 1 0 1
of,the,case-control 1.0 0.000143348623853 1 0 1
of,the,beta-adrenergic 1.0 0.000143348623853 1 0 1
of,the,benzodiazepine 1.0 0.000143348623853 1 0 1
of,the,alkaloid 1.0 0.000143348623853 1 0 1
of,the,activity 1.0 0.000143348623853 1 0 1
of,the,ace 1.0 0.000143348623853 1 0 1
of,the,above 1.0 0.000143348623853 1 0 1
of,that,undergo 1.0 0.000143348623853 1 0 1
of,that,necessitated 1.0 0.000143348623853 1 0 1
of,that,increase 1.0 0.000143348623853 1 0 1
of,than,when 1.0 0.000143348623853 1 0 1
of,tbars,levels 1.0 0.000143348623853 1 0 1
of,taxol,mg 1.0 0.000143348623853 1 0 1
of,targretin,capsules 1.0 0.000143348623853 1 0 1
of,tambocor,to 1.0 0.000143348623853 1 0 1
of,taking,mao 1.0 0.000143348623853 1 0 1
of,tablets,in 1.0 0.000143348623853 1 0 1
of,tablets,and 1.0 0.000143348623853 1 0 1
of,t,a 1.0 0.000143348623853 1 0 1
of,systemic,it 1.0 0.000143348623853 1 0 1
of,synthetic,possibly 1.0 0.000143348623853 1 0 1
of,synthetic,by 1.0 0.000143348623853 1 0 1
of,symptoms,termed 1.0 0.000143348623853 1 0 1
of,symptom,control 1.0 0.000143348623853 1 0 1
of,sustained-release,calan 1.0 0.000143348623853 1 0 1
of,supplements,and 1.0 0.000143348623853 1 0 1
of,supplemental,l-glutamine 1.0 0.000143348623853 1 0 1
of,sulfoxide,were 1.0 0.000143348623853 1 0 1
of,sulfoxide,by 1.0 0.000143348623853 1 0 1
of,sular,with 1.0 0.000143348623853 1 0 1
of,sular,tended 1.0 0.000143348623853 1 0 1
of,suggest,a 1.0 0.000143348623853 1 0 1
of,substantial,accumulation 1.0 0.000143348623853 1 0 1
of,sublingual,mg 1.0 0.000143348623853 1 0 1
of,subjects,who 1.0 0.000143348623853 1 0 1
of,subjects,n 1.0 0.000143348623853 1 0 1
of,striatal,concentrations 1.0 0.000143348623853 1 0 1
of,striatal,but 1.0 0.000143348623853 1 0 1
of,strattera,may 1.0 0.000143348623853 1 0 1
of,sprycel,with 1.0 0.000143348623853 1 0 1
of,sprycel,and 1.0 0.000143348623853 1 0 1
of,some,resulting 1.0 0.000143348623853 1 0 1
of,some,organisms 1.0 0.000143348623853 1 0 1
of,some,has 1.0 0.000143348623853 1 0 1
of,some,and 1.0 0.000143348623853 1 0 1
of,sodium,or 1.0 0.000143348623853 1 0 1
of,sodium,kg 1.0 0.000143348623853 1 0 1
of,sodium,is 1.0 0.000143348623853 1 0 1
of,sodium,iodide 1.0 0.000143348623853 1 0 1
of,sodium,from 1.0 0.000143348623853 1 0 1
of,sodium,capsules 1.0 0.000143348623853 1 0 1
of,sodium,and 1.0 0.000143348623853 1 0 1
of,single,oral 1.0 0.000143348623853 1 0 1
of,simulect,was 1.0 0.000143348623853 1 0 1
of,significantly,decreased 1.0 0.000143348623853 1 0 1
of,significant,respiratory 1.0 0.000143348623853 1 0 1
of,significant,hypotension 1.0 0.000143348623853 1 0 1
of,should,therefore 1.0 0.000143348623853 1 0 1
of,should,not 1.0 0.000143348623853 1 0 1
of,should,also 1.0 0.000143348623853 1 0 1
of,severe,toxicity 1.0 0.000143348623853 1 0 1
of,severe,myopathy 1.0 0.000143348623853 1 0 1
of,severe,hypoglycemia 1.0 0.000143348623853 1 0 1
of,several,closely 1.0 0.000143348623853 1 0 1
of,serum,concentrations 1.0 0.000143348623853 1 0 1
of,serum,concentration 1.0 0.000143348623853 1 0 1
of,serum,binding 1.0 0.000143348623853 1 0 1
of,serious,ventricular 1.0 0.000143348623853 1 0 1
of,serious,reaction 1.0 0.000143348623853 1 0 1
of,sensipar,may 1.0 0.000143348623853 1 0 1
of,selective,serotonin 1.0 0.000143348623853 1 0 1
of,selective,peripheral 1.0 0.000143348623853 1 0 1
of,seizures,in 1.0 0.000143348623853 1 0 1
of,seizures,have 1.0 0.000143348623853 1 0 1
of,see,warnings 1.0 0.000143348623853 1 0 1
of,sedation,hallucinations 1.0 0.000143348623853 1 0 1
of,salicylic,acid 1.0 0.000143348623853 1 0 1
of,s,and 1.0 0.000143348623853 1 0 1
of,results,in 1.0 0.000143348623853 1 0 1
of,response,to 1.0 0.000143348623853 1 0 1
of,required,to 1.0 0.000143348623853 1 0 1
of,required,may 1.0 0.000143348623853 1 0 1
of,reports,of 1.0 0.000143348623853 1 0 1
of,reports,in 1.0 0.000143348623853 1 0 1
of,reportedly,are 1.0 0.000143348623853 1 0 1
of,renal,tubular 1.0 0.000143348623853 1 0 1
of,reduced,cmax 1.0 0.000143348623853 1 0 1
of,rats,with 1.0 0.000143348623853 1 0 1
of,rats,results 1.0 0.000143348623853 1 0 1
of,rashes,is 1.0 0.000143348623853 1 0 1
of,rashes,in 1.0 0.000143348623853 1 0 1
of,ranging,from 1.0 0.000143348623853 1 0 1
of,racemic,celexa 1.0 0.000143348623853 1 0 1
of,r-warfarin,the 1.0 0.000143348623853 1 0 1
of,r-warfarin,and 1.0 0.000143348623853 1 0 1
of,q12h,for 1.0 0.000143348623853 1 0 1
of,pulmonary,symptomatology 1.0 0.000143348623853 1 0 1
of,psychotropic,that 1.0 0.000143348623853 1 0 1
of,psychiatric,disorder 1.0 0.000143348623853 1 0 1
of,pseudotumor,cerebri 1.0 0.000143348623853 1 0 1
of,prostatic,epithelium 1.0 0.000143348623853 1 0 1
of,prostate,epithelium 1.0 0.000143348623853 1 0 1
of,prostaglandin,synthesis 1.0 0.000143348623853 1 0 1
of,prostaglandin,synthase 1.0 0.000143348623853 1 0 1
of,prolonged,or 1.0 0.000143348623853 1 0 1
of,prolongation,of 1.0 0.000143348623853 1 0 1
of,proleukin,and 1.0 0.000143348623853 1 0 1
of,progestin-only,pills 1.0 0.000143348623853 1 0 1
of,profound,hypotension 1.0 0.000143348623853 1 0 1
of,products,with 1.0 0.000143348623853 1 0 1
of,produced,a 1.0 0.000143348623853 1 0 1
of,probably,at 1.0 0.000143348623853 1 0 1
of,prior,to 1.0 0.000143348623853 1 0 1
of,prinivil,with 1.0 0.000143348623853 1 0 1
of,previously,stable 1.0 0.000143348623853 1 0 1
of,preparations,such 1.0 0.000143348623853 1 0 1
of,preparations,in 1.0 0.000143348623853 1 0 1
of,preparations,by 1.0 0.000143348623853 1 0 1
of,preliminary,studies 1.0 0.000143348623853 1 0 1
of,precedex,with 1.0 0.000143348623853 1 0 1
of,precedex,on 1.0 0.000143348623853 1 0 1
of,potentiating,cns 1.0 0.000143348623853 1 0 1
of,potentially,leading 1.0 0.000143348623853 1 0 1
of,potential,to 1.0 0.000143348623853 1 0 1
of,potent,inducer 1.0 0.000143348623853 1 0 1
of,post-heparin,lipolytic 1.0 0.000143348623853 1 0 1
of,ponstel,with 1.0 0.000143348623853 1 0 1
of,ponstel,and 1.0 0.000143348623853 1 0 1
of,plasma,and 1.0 0.000143348623853 1 0 1
of,placental,vessels 1.0 0.000143348623853 1 0 1
of,pipracil,produces 1.0 0.000143348623853 1 0 1
of,pharmacologic,effects 1.0 0.000143348623853 1 0 1
of,pgf2alpha,upon 1.0 0.000143348623853 1 0 1
of,permits,at 1.0 0.000143348623853 1 0 1
of,people,who 1.0 0.000143348623853 1 0 1
of,pcp,treatment 1.0 0.000143348623853 1 0 1
of,pcp,or 1.0 0.000143348623853 1 0 1
of,patients,to 1.0 0.000143348623853 1 0 1
of,patients,taking 1.0 0.000143348623853 1 0 1
of,patients,on 1.0 0.000143348623853 1 0 1
of,patients,experiencing 1.0 0.000143348623853 1 0 1
of,patient,pharmacokinetic 1.0 0.000143348623853 1 0 1
of,particularly,with 1.0 0.000143348623853 1 0 1
of,parenterally,administered 1.0 0.000143348623853 1 0 1
of,pancreatic,supplements 1.0 0.000143348623853 1 0 1
of,pah,cannot 1.0 0.000143348623853 1 0 1
of,p450,a2 1.0 0.000143348623853 1 0 1
of,p-450iie1,in 1.0 0.000143348623853 1 0 1
of,p,and 1.0 0.000143348623853 1 0 1
of,oxypurines,hypoxanthine 1.0 0.000143348623853 1 0 1
of,our,patient 1.0 0.000143348623853 1 0 1
of,other,with 1.0 0.000143348623853 1 0 1
of,other,taken 1.0 0.000143348623853 1 0 1
of,other,related 1.0 0.000143348623853 1 0 1
of,other,potassium-sparing 1.0 0.000143348623853 1 0 1
of,other,oral 1.0 0.000143348623853 1 0 1
of,other,narcotic 1.0 0.000143348623853 1 0 1
of,other,inducers 1.0 0.000143348623853 1 0 1
of,other,including 1.0 0.000143348623853 1 0 1
of,other,folic 1.0 0.000143348623853 1 0 1
of,other,channel 1.0 0.000143348623853 1 0 1
of,other,central 1.0 0.000143348623853 1 0 1
of,other,antituberculous 1.0 0.000143348623853 1 0 1
of,other,antiepileptic 1.0 0.000143348623853 1 0 1
of,other,antiepilepsy 1.0 0.000143348623853 1 0 1
of,organic,if 1.0 0.000143348623853 1 0 1
of,orencia,administered 1.0 0.000143348623853 1 0 1
of,oral,with 1.0 0.000143348623853 1 0 1
of,oral,upon 1.0 0.000143348623853 1 0 1
of,oral,the 1.0 0.000143348623853 1 0 1
of,oral,such 1.0 0.000143348623853 1 0 1
of,oral,mg 1.0 0.000143348623853 1 0 1
of,oral,is 1.0 0.000143348623853 1 0 1
of,oral,increased 1.0 0.000143348623853 1 0 1
of,oral,including 1.0 0.000143348623853 1 0 1
of,oral,form 1.0 0.000143348623853 1 0 1
of,oral,during 1.0 0.000143348623853 1 0 1
of,oral,certain 1.0 0.000143348623853 1 0 1
of,oral,administration 1.0 0.000143348623853 1 0 1
of,or,toxoids 1.0 0.000143348623853 1 0 1
of,or,similar 1.0 0.000143348623853 1 0 1
of,or,oral 1.0 0.000143348623853 1 0 1
of,or,nsaids 1.0 0.000143348623853 1 0 1
of,or,hepatic 1.0 0.000143348623853 1 0 1
of,or,decreases 1.0 0.000143348623853 1 0 1
of,or,activated 1.0 0.000143348623853 1 0 1
of,onto,the 1.0 0.000143348623853 1 0 1
of,onset,of 1.0 0.000143348623853 1 0 1
of,one,patient 1.0 0.000143348623853 1 0 1
of,on,valproic 1.0 0.000143348623853 1 0 1
of,on,oral 1.0 0.000143348623853 1 0 1
of,on,natriuresis 1.0 0.000143348623853 1 0 1
of,on,malignant 1.0 0.000143348623853 1 0 1
of,on,indicates 1.0 0.000143348623853 1 0 1
of,on,fi 1.0 0.000143348623853 1 0 1
of,of,approximately 1.0 0.000143348623853 1 0 1
of,norpace,and 1.0 0.000143348623853 1 0 1
of,normal,subjects 1.0 0.000143348623853 1 0 1
of,norfloxacin,in 1.0 0.000143348623853 1 0 1
of,nonsteroial,anti-inflammatory 1.0 0.000143348623853 1 0 1
of,nonsedating,and 1.0 0.000143348623853 1 0 1
of,nondepolarizing,neuromuscular 1.0 0.000143348623853 1 0 1
of,nonbenzodiazepine,agonists 1.0 0.000143348623853 1 0 1
of,non-steroidal,concomitantly 1.0 0.000143348623853 1 0 1
of,non-potassium,sparing 1.0 0.000143348623853 1 0 1
of,non-depolarising,muscle 1.0 0.000143348623853 1 0 1
of,nimbex,were 1.0 0.000143348623853 1 0 1
of,nimbex,may 1.0 0.000143348623853 1 0 1
of,nimbex,in 1.0 0.000143348623853 1 0 1
of,nimbex,are 1.0 0.000143348623853 1 0 1
of,neuromuscular,blockade 1.0 0.000143348623853 1 0 1
of,nephrolithiasis,is 1.0 0.000143348623853 1 0 1
of,needed,to 1.0 0.000143348623853 1 0 1
of,nanm,were 1.0 0.000143348623853 1 0 1
of,nanm,but 1.0 0.000143348623853 1 0 1
of,nalfon,to 1.0 0.000143348623853 1 0 1
of,nalfon,the 1.0 0.000143348623853 1 0 1
of,nalfon,may 1.0 0.000143348623853 1 0 1
of,nalfon,and 1.0 0.000143348623853 1 0 1
of,n-acetyltransferase,may 1.0 0.000143348623853 1 0 1
of,myobloc,and 1.0 0.000143348623853 1 0 1
of,myalgia,and 1.0 0.000143348623853 1 0 1
of,multiple,oral 1.0 0.000143348623853 1 0 1
of,most,other 1.0 0.000143348623853 1 0 1
of,most,likely 1.0 0.000143348623853 1 0 1
of,more,than 1.0 0.000143348623853 1 0 1
of,mm,hg 1.0 0.000143348623853 1 0 1
of,mixed,overdosage 1.0 0.000143348623853 1 0 1
of,mineral,oil 1.0 0.000143348623853 1 0 1
of,min,before 1.0 0.000143348623853 1 0 1
of,min,after 1.0 0.000143348623853 1 0 1
of,microsomal,drug 1.0 0.000143348623853 1 0 1
of,micrograms,completely 1.0 0.000143348623853 1 0 1
of,microdosed,progestin-containing 1.0 0.000143348623853 1 0 1
of,mg,twice-daily 1.0 0.000143348623853 1 0 1
of,mg,sodium 1.0 0.000143348623853 1 0 1
of,mg,per 1.0 0.000143348623853 1 0 1
of,mg,oral 1.0 0.000143348623853 1 0 1
of,mg,once 1.0 0.000143348623853 1 0 1
of,mg,increased 1.0 0.000143348623853 1 0 1
of,mg,co-administered 1.0 0.000143348623853 1 0 1
of,mg,capsules 1.0 0.000143348623853 1 0 1
of,mg,a 1.0 0.000143348623853 1 0 1
of,methylpyrazole,seen 1.0 0.000143348623853 1 0 1
of,metabolism,via 1.0 0.000143348623853 1 0 1
of,metabolism,decreased 1.0 0.000143348623853 1 0 1
of,megakaryocytes,with 1.0 0.000143348623853 1 0 1
of,mefloquine,on 1.0 0.000143348623853 1 0 1
of,mefloquine,may 1.0 0.000143348623853 1 0 1
of,mefloquine,and 1.0 0.000143348623853 1 0 1
of,medicinal,products 1.0 0.000143348623853 1 0 1
of,mean,serum 1.0 0.000143348623853 1 0 1
of,may,therefore 1.0 0.000143348623853 1 0 1
of,may,render 1.0 0.000143348623853 1 0 1
of,may,potentiate 1.0 0.000143348623853 1 0 1
of,may,occur 1.0 0.000143348623853 1 0 1
of,may,lower 1.0 0.000143348623853 1 0 1
of,may,even 1.0 0.000143348623853 1 0 1
of,may,antagonize 1.0 0.000143348623853 1 0 1
of,maximum,block 1.0 0.000143348623853 1 0 1
of,marked,bradycardia 1.0 0.000143348623853 1 0 1
of,many,angiotensin-converting 1.0 0.000143348623853 1 0 1
of,malignant,hyperthermia 1.0 0.000143348623853 1 0 1
of,male,subjects 1.0 0.000143348623853 1 0 1
of,major,clinical 1.0 0.000143348623853 1 0 1
of,major,bleeding 1.0 0.000143348623853 1 0 1
of,macrolide,and 1.0 0.000143348623853 1 0 1
of,m1,peak 1.0 0.000143348623853 1 0 1
of,m,ptx 1.0 0.000143348623853 1 0 1
of,m,or 1.0 0.000143348623853 1 0 1
of,lymphatic,invasion 1.0 0.000143348623853 1 0 1
of,low-dose,with 1.0 0.000143348623853 1 0 1
of,low-dose,hcl 1.0 0.000143348623853 1 0 1
of,loop,potassium- 1.0 0.000143348623853 1 0 1
of,lodine,and 1.0 0.000143348623853 1 0 1
of,life-,threatening 1.0 0.000143348623853 1 0 1
of,levo-dromoran,with 1.0 0.000143348623853 1 0 1
of,levels,it 1.0 0.000143348623853 1 0 1
of,level,however 1.0 0.000143348623853 1 0 1
of,lanoxin,lanoxicaps 1.0 0.000143348623853 1 0 1
of,lamprene,have 1.0 0.000143348623853 1 0 1
of,l-tyrosine,and 1.0 0.000143348623853 1 0 1
of,l-phenylalanine,and 1.0 0.000143348623853 1 0 1
of,kg,was 1.0 0.000143348623853 1 0 1
of,ketoconazole,and 1.0 0.000143348623853 1 0 1
of,its,structural 1.0 0.000143348623853 1 0 1
of,its,primary 1.0 0.000143348623853 1 0 1
of,its,normal 1.0 0.000143348623853 1 0 1
of,its,active 1.0 0.000143348623853 1 0 1
of,its,action 1.0 0.000143348623853 1 0 1
of,itraconazole,therapy 1.0 0.000143348623853 1 0 1
of,isosorbide,mononitrate 1.0 0.000143348623853 1 0 1
of,isosorbide,dinitrate 1.0 0.000143348623853 1 0 1
of,isocarboxazid,and 1.0 0.000143348623853 1 0 1
of,is,to 1.0 0.000143348623853 1 0 1
of,is,similar 1.0 0.000143348623853 1 0 1
of,is,potentiated 1.0 0.000143348623853 1 0 1
of,is,inhibited 1.0 0.000143348623853 1 0 1
of,is,approximately 1.0 0.000143348623853 1 0 1
of,iressa,and 1.0 0.000143348623853 1 0 1
of,iopidine,ophthalmic 1.0 0.000143348623853 1 0 1
of,intravenously,administered 1.0 0.000143348623853 1 0 1
of,intravenous,without 1.0 0.000143348623853 1 0 1
of,intravenous,and 1.0 0.000143348623853 1 0 1
of,interfere,with 1.0 0.000143348623853 1 0 1
of,interactions,have 1.0 0.000143348623853 1 0 1
of,insufficient,to 1.0 0.000143348623853 1 0 1
of,inspra,to 1.0 0.000143348623853 1 0 1
of,inspra,mg 1.0 0.000143348623853 1 0 1
of,innovar,or 1.0 0.000143348623853 1 0 1
of,injection,and 1.0 0.000143348623853 1 0 1
of,initial,and 1.0 0.000143348623853 1 0 1
of,inhibition,are 1.0 0.000143348623853 1 0 1
of,infection,in 1.0 0.000143348623853 1 0 1
of,indocin,with 1.0 0.000143348623853 1 0 1
of,indocin,resulted 1.0 0.000143348623853 1 0 1
of,indocin,can 1.0 0.000143348623853 1 0 1
of,indigestion,remedies 1.0 0.000143348623853 1 0 1
of,increasing,its 1.0 0.000143348623853 1 0 1
of,increases,the 1.0 0.000143348623853 1 0 1
of,increased,when 1.0 0.000143348623853 1 0 1
of,increased,the 1.0 0.000143348623853 1 0 1
of,increased,prothrombin 1.0 0.000143348623853 1 0 1
of,increased,metabolism 1.0 0.000143348623853 1 0 1
of,increased,by 1.0 0.000143348623853 1 0 1
of,including,with 1.0 0.000143348623853 1 0 1
of,including,tricor 1.0 0.000143348623853 1 0 1
of,including,ethacrynic 1.0 0.000143348623853 1 0 1
of,inapsine,the 1.0 0.000143348623853 1 0 1
of,in,well-controlled 1.0 0.000143348623853 1 0 1
of,in,some 1.0 0.000143348623853 1 0 1
of,in,rats 1.0 0.000143348623853 1 0 1
of,in,plasma 1.0 0.000143348623853 1 0 1
of,in,parkinsons 1.0 0.000143348623853 1 0 1
of,in,nonfailing 1.0 0.000143348623853 1 0 1
of,in,combination 1.0 0.000143348623853 1 0 1
of,in,by 1.0 0.000143348623853 1 0 1
of,in,both 1.0 0.000143348623853 1 0 1
of,in,anhydrous 1.0 0.000143348623853 1 0 1
of,in,an 1.0 0.000143348623853 1 0 1
of,in,alcoholic 1.0 0.000143348623853 1 0 1
of,impaired,renal 1.0 0.000143348623853 1 0 1
of,immunization,cannot 1.0 0.000143348623853 1 0 1
of,iiia4,blocks 1.0 0.000143348623853 1 0 1
of,if,used 1.0 0.000143348623853 1 0 1
of,hypotension,will 1.0 0.000143348623853 1 0 1
of,hypoglycemic,medications 1.0 0.000143348623853 1 0 1
of,hypoglycemic,agents 1.0 0.000143348623853 1 0 1
of,hypoglycemia,secondary 1.0 0.000143348623853 1 0 1
of,hyperlipidemia,or 1.0 0.000143348623853 1 0 1
of,hyperkalemia,serum 1.0 0.000143348623853 1 0 1
of,hyperkalemia,may 1.0 0.000143348623853 1 0 1
of,hydroxyzine,must 1.0 0.000143348623853 1 0 1
of,hydroxylated,in 1.0 0.000143348623853 1 0 1
of,hydroxide,with 1.0 0.000143348623853 1 0 1
of,hydrochloride,x 1.0 0.000143348623853 1 0 1
of,hydrochloride,on 1.0 0.000143348623853 1 0 1
of,hydrochloride,given 1.0 0.000143348623853 1 0 1
of,hydrochloride,concomitantly 1.0 0.000143348623853 1 0 1
of,hydrobromide,may 1.0 0.000143348623853 1 0 1
of,humorsol,with 1.0 0.000143348623853 1 0 1
of,human,breast 1.0 0.000143348623853 1 0 1
of,however,serum 1.0 0.000143348623853 1 0 1
of,hours,after 1.0 0.000143348623853 1 0 1
of,hoof,twitch 1.0 0.000143348623853 1 0 1
of,heroin-related,deaths 1.0 0.000143348623853 1 0 1
of,hepatitis,has 1.0 0.000143348623853 1 0 1
of,heparinized,patients 1.0 0.000143348623853 1 0 1
of,hcl,should 1.0 0.000143348623853 1 0 1
of,hcl,no 1.0 0.000143348623853 1 0 1
of,hcl,is 1.0 0.000143348623853 1 0 1
of,had,plasma 1.0 0.000143348623853 1 0 1
of,h1,and 1.0 0.000143348623853 1 0 1
of,h-triglyceride,fractional 1.0 0.000143348623853 1 0 1
of,grams,three 1.0 0.000143348623853 1 0 1
of,gleevec,increased 1.0 0.000143348623853 1 0 1
of,given,later 1.0 0.000143348623853 1 0 1
of,gastrointestinal,ulceration 1.0 0.000143348623853 1 0 1
of,gastric,acid 1.0 0.000143348623853 1 0 1
of,ganglionic,blocking 1.0 0.000143348623853 1 0 1
of,g,of 1.0 0.000143348623853 1 0 1
of,g,hour 1.0 0.000143348623853 1 0 1
of,g,and 1.0 0.000143348623853 1 0 1
of,further,alterations 1.0 0.000143348623853 1 0 1
of,from,plasma 1.0 0.000143348623853 1 0 1
of,from,ml 1.0 0.000143348623853 1 0 1
of,free,is 1.0 0.000143348623853 1 0 1
of,four,patients 1.0 0.000143348623853 1 0 1
of,foscavir,should 1.0 0.000143348623853 1 0 1
of,foscavir,and 1.0 0.000143348623853 1 0 1
of,foscarnets,tendency 1.0 0.000143348623853 1 0 1
of,for,patients 1.0 0.000143348623853 1 0 1
of,followed,by 1.0 0.000143348623853 1 0 1
of,fold,in 1.0 0.000143348623853 1 0 1
of,fluvoxamine,tablets 1.0 0.000143348623853 1 0 1
of,fluorouracil,is 1.0 0.000143348623853 1 0 1
of,fludrocortisone,acetate 1.0 0.000143348623853 1 0 1
of,fludara,for 1.0 0.000143348623853 1 0 1
of,femara,and 1.0 0.000143348623853 1 0 1
of,fell,by 1.0 0.000143348623853 1 0 1
of,felbatol,to 1.0 0.000143348623853 1 0 1
of,fe,per 1.0 0.000143348623853 1 0 1
of,fat-soluble,including 1.0 0.000143348623853 1 0 1
of,fade,hoof 1.0 0.000143348623853 1 0 1
of,factive,with 1.0 0.000143348623853 1 0 1
of,factive,and 1.0 0.000143348623853 1 0 1
of,excretion,of 1.0 0.000143348623853 1 0 1
of,ewes,with 1.0 0.000143348623853 1 0 1
of,ethyol,in 1.0 0.000143348623853 1 0 1
of,etc,but 1.0 0.000143348623853 1 0 1
of,erythrocyte,acetylcholinesterase 1.0 0.000143348623853 1 0 1
of,ergotamine-containing,when 1.0 0.000143348623853 1 0 1
of,ergomar,may 1.0 0.000143348623853 1 0 1
of,ergomar,and 1.0 0.000143348623853 1 0 1
of,equetrotm,due 1.0 0.000143348623853 1 0 1
of,epidural,local 1.0 0.000143348623853 1 0 1
of,enhanced,as 1.0 0.000143348623853 1 0 1
of,endotoxin-induced,deaths 1.0 0.000143348623853 1 0 1
of,endogenous,steroid 1.0 0.000143348623853 1 0 1
of,endogenous,prostaglandin 1.0 0.000143348623853 1 0 1
of,enablex,with 1.0 0.000143348623853 1 0 1
of,enablex,should 1.0 0.000143348623853 1 0 1
of,ellence,with 1.0 0.000143348623853 1 0 1
of,elimination,the 1.0 0.000143348623853 1 0 1
of,elemental,reduced 1.0 0.000143348623853 1 0 1
of,elemental,as 1.0 0.000143348623853 1 0 1
of,either,one 1.0 0.000143348623853 1 0 1
of,either,nanm 1.0 0.000143348623853 1 0 1
of,either,medicine 1.0 0.000143348623853 1 0 1
of,edetate,disodium 1.0 0.000143348623853 1 0 1
of,each,to 1.0 0.000143348623853 1 0 1
of,during,treatment 1.0 0.000143348623853 1 0 1
of,during,therapy 1.0 0.000143348623853 1 0 1
of,duragesic,transdermal 1.0 0.000143348623853 1 0 1
of,duloxetine,and 1.0 0.000143348623853 1 0 1
of,dry,mouth 1.0 0.000143348623853 1 0 1
of,drugs,possessing 1.0 0.000143348623853 1 0 1
of,doubled,the 1.0 0.000143348623853 1 0 1
of,dose,ranging 1.0 0.000143348623853 1 0 1
of,discontinuing,treatment 1.0 0.000143348623853 1 0 1
of,didanosine-placebo,tablets 1.0 0.000143348623853 1 0 1
of,diarrhea,but 1.0 0.000143348623853 1 0 1
of,diamox,may 1.0 0.000143348623853 1 0 1
of,diamox,in 1.0 0.000143348623853 1 0 1
of,developing,peripheral 1.0 0.000143348623853 1 0 1
of,developing,an 1.0 0.000143348623853 1 0 1
of,dehydration,secondary 1.0 0.000143348623853 1 0 1
of,decreases,the 1.0 0.000143348623853 1 0 1
of,decreased,slightly 1.0 0.000143348623853 1 0 1
of,decreased,protein 1.0 0.000143348623853 1 0 1
of,decreased,plasma 1.0 0.000143348623853 1 0 1
of,decreased,by 1.0 0.000143348623853 1 0 1
of,dcg-iv,were 1.0 0.000143348623853 1 0 1
of,day-old,chick 1.0 0.000143348623853 1 0 1
of,daily,increases 1.0 0.000143348623853 1 0 1
of,cytochrome,p-450 1.0 0.000143348623853 1 0 1
of,cyp3a4,the 1.0 0.000143348623853 1 0 1
of,cyp3a4,substrate 1.0 0.000143348623853 1 0 1
of,cyp3a4,mg 1.0 0.000143348623853 1 0 1
of,cyp3a4,increased 1.0 0.000143348623853 1 0 1
of,cyp3a,compounds 1.0 0.000143348623853 1 0 1
of,cyp2d6,increased 1.0 0.000143348623853 1 0 1
of,cyp2d6,i 1.0 0.000143348623853 1 0 1
of,cyp2a6,hydroxylation 1.0 0.000143348623853 1 0 1
of,cyp1a2,results 1.0 0.000143348623853 1 0 1
of,cyp1a2,concomitant 1.0 0.000143348623853 1 0 1
of,cyp,enzymes 1.0 0.000143348623853 1 0 1
of,cromolyn,sodium 1.0 0.000143348623853 1 0 1
of,could,pose 1.0 0.000143348623853 1 0 1
of,corneal,lesions 1.0 0.000143348623853 1 0 1
of,copegus,and 1.0 0.000143348623853 1 0 1
of,contraception,should 1.0 0.000143348623853 1 0 1
of,contraception,inwomen 1.0 0.000143348623853 1 0 1
of,contraception,during 1.0 0.000143348623853 1 0 1
of,containing,or 1.0 0.000143348623853 1 0 1
of,consciousness,when 1.0 0.000143348623853 1 0 1
of,congestive,heart 1.0 0.000143348623853 1 0 1
of,conduction,disturbance 1.0 0.000143348623853 1 0 1
of,concurrent,use 1.0 0.000143348623853 1 0 1
of,concomitant,oral 1.0 0.000143348623853 1 0 1
of,concentrations,after 1.0 0.000143348623853 1 0 1
of,compounds,that 1.0 0.000143348623853 1 0 1
of,compounds,taken 1.0 0.000143348623853 1 0 1
of,compounds,are 1.0 0.000143348623853 1 0 1
of,competitive,renal 1.0 0.000143348623853 1 0 1
of,coma,and 1.0 0.000143348623853 1 0 1
of,coadministration,with 1.0 0.000143348623853 1 0 1
of,cns,stimulation 1.0 0.000143348623853 1 0 1
of,clozapine,potentially 1.0 0.000143348623853 1 0 1
of,clozapine,caution 1.0 0.000143348623853 1 0 1
of,clozapine,and 1.0 0.000143348623853 1 0 1
of,clinical,status 1.0 0.000143348623853 1 0 1
of,clearance,such 1.0 0.000143348623853 1 0 1
of,clearance,or 1.0 0.000143348623853 1 0 1
of,class,ia 1.0 0.000143348623853 1 0 1
of,ci,when 1.0 0.000143348623853 1 0 1
of,chronic,or 1.0 0.000143348623853 1 0 1
of,cholinesterase,inhibitors 1.0 0.000143348623853 1 0 1
of,cholinesterase,activity 1.0 0.000143348623853 1 0 1
of,cholesterol,and 1.0 0.000143348623853 1 0 1
of,chloride-induced,gastrointestinal 1.0 0.000143348623853 1 0 1
of,changed,the 1.0 0.000143348623853 1 0 1
of,cerubidine,in 1.0 0.000143348623853 1 0 1
of,certain,weak 1.0 0.000143348623853 1 0 1
of,certain,tricyclic 1.0 0.000143348623853 1 0 1
of,certain,thereby 1.0 0.000143348623853 1 0 1
of,certain,intravenously 1.0 0.000143348623853 1 0 1
of,certain,compounds 1.0 0.000143348623853 1 0 1
of,certain,by 1.0 0.000143348623853 1 0 1
of,cefditoren,with 1.0 0.000143348623853 1 0 1
of,causes,an 1.0 0.000143348623853 1 0 1
of,cases,of 1.0 0.000143348623853 1 0 1
of,cardiac,function 1.0 0.000143348623853 1 0 1
of,cardiac,contractility 1.0 0.000143348623853 1 0 1
of,carbimazole,and 1.0 0.000143348623853 1 0 1
of,carbamazepine,equetrotm 1.0 0.000143348623853 1 0 1
of,cancidas,should 1.0 0.000143348623853 1 0 1
of,cancidas,mg 1.0 0.000143348623853 1 0 1
of,camptosar,such 1.0 0.000143348623853 1 0 1
of,by,up 1.0 0.000143348623853 1 0 1
of,by,the 1.0 0.000143348623853 1 0 1
of,by,possibly 1.0 0.000143348623853 1 0 1
of,by,patients 1.0 0.000143348623853 1 0 1
of,by,or 1.0 0.000143348623853 1 0 1
of,by,on 1.0 0.000143348623853 1 0 1
of,by,m 1.0 0.000143348623853 1 0 1
of,by,is 1.0 0.000143348623853 1 0 1
of,by,inhibiting 1.0 0.000143348623853 1 0 1
of,by,increasing 1.0 0.000143348623853 1 0 1
of,by,fold 1.0 0.000143348623853 1 0 1
of,by,cytochrome 1.0 0.000143348623853 1 0 1
of,by,concomitant 1.0 0.000143348623853 1 0 1
of,by,competitive 1.0 0.000143348623853 1 0 1
of,by,blocking 1.0 0.000143348623853 1 0 1
of,by,and 1.0 0.000143348623853 1 0 1
of,by,an 1.0 0.000143348623853 1 0 1
of,but,there 1.0 0.000143348623853 1 0 1
of,but,significantly 1.0 0.000143348623853 1 0 1
of,but,no 1.0 0.000143348623853 1 0 1
of,but,does 1.0 0.000143348623853 1 0 1
of,busulfex,were 1.0 0.000143348623853 1 0 1
of,busulfex,at 1.0 0.000143348623853 1 0 1
of,brovana,may 1.0 0.000143348623853 1 0 1
of,bromocriptine,mesylate 1.0 0.000143348623853 1 0 1
of,botox,and 1.0 0.000143348623853 1 0 1
of,both,species 1.0 0.000143348623853 1 0 1
of,both,s-warfarin 1.0 0.000143348623853 1 0 1
of,both,resorptions 1.0 0.000143348623853 1 0 1
of,both,increases 1.0 0.000143348623853 1 0 1
of,both,first 1.0 0.000143348623853 1 0 1
of,bombesin-enhanced,peritoneal 1.0 0.000143348623853 1 0 1
of,blood,platelets 1.0 0.000143348623853 1 0 1
of,blocking,hepatic 1.0 0.000143348623853 1 0 1
of,blocking,cardiac 1.0 0.000143348623853 1 0 1
of,block,is 1.0 0.000143348623853 1 0 1
of,bleeding,when 1.0 0.000143348623853 1 0 1
of,bleeding,particularly 1.0 0.000143348623853 1 0 1
of,bleeding,if 1.0 0.000143348623853 1 0 1
of,birth,control 1.0 0.000143348623853 1 0 1
of,bioavailability,eg 1.0 0.000143348623853 1 0 1
of,binding,thiazide 1.0 0.000143348623853 1 0 1
of,bezalip,or 1.0 0.000143348623853 1 0 1
of,betaseron,on 1.0 0.000143348623853 1 0 1
of,beta-adrenergic,antagonists 1.0 0.000143348623853 1 0 1
of,before,intramuscular 1.0 0.000143348623853 1 0 1
of,because,they 1.0 0.000143348623853 1 0 1
of,because,these 1.0 0.000143348623853 1 0 1
of,because,of 1.0 0.000143348623853 1 0 1
of,be,reduced 1.0 0.000143348623853 1 0 1
of,be,adjusted 1.0 0.000143348623853 1 0 1
of,based,on 1.0 0.000143348623853 1 0 1
of,barrier,contraception 1.0 0.000143348623853 1 0 1
of,azole,agents 1.0 0.000143348623853 1 0 1
of,averaged,s 1.0 0.000143348623853 1 0 1
of,av,nodal 1.0 0.000143348623853 1 0 1
of,av,conduction 1.0 0.000143348623853 1 0 1
of,autoimmune,and 1.0 0.000143348623853 1 0 1
of,auc,and 1.0 0.000143348623853 1 0 1
of,atropinization,flushing 1.0 0.000143348623853 1 0 1
of,as,reflected 1.0 0.000143348623853 1 0 1
of,as,antiemetic 1.0 0.000143348623853 1 0 1
of,are,to 1.0 0.000143348623853 1 0 1
of,are,the 1.0 0.000143348623853 1 0 1
of,are,reported 1.0 0.000143348623853 1 0 1
of,are,increased 1.0 0.000143348623853 1 0 1
of,are,due 1.0 0.000143348623853 1 0 1
of,are,altered 1.0 0.000143348623853 1 0 1
of,arava,with 1.0 0.000143348623853 1 0 1
of,arava,to 1.0 0.000143348623853 1 0 1
of,aprepitant,mg 1.0 0.000143348623853 1 0 1
of,aprepitant,may 1.0 0.000143348623853 1 0 1
of,aprepitant,given 1.0 0.000143348623853 1 0 1
of,approximately,when 1.0 0.000143348623853 1 0 1
of,approximately,was 1.0 0.000143348623853 1 0 1
of,approximately,times 1.0 0.000143348623853 1 0 1
of,approximately,msec 1.0 0.000143348623853 1 0 1
of,apparent,total 1.0 0.000143348623853 1 0 1
of,apoptosis,assessed 1.0 0.000143348623853 1 0 1
of,antizol,mg 1.0 0.000143348623853 1 0 1
of,antizol,by 1.0 0.000143348623853 1 0 1
of,antizol,and 1.0 0.000143348623853 1 0 1
of,antipsychotic,agents 1.0 0.000143348623853 1 0 1
of,antihypertensive,and 1.0 0.000143348623853 1 0 1
of,antidepressant,when 1.0 0.000143348623853 1 0 1
of,anticholinesterase,poisoning 1.0 0.000143348623853 1 0 1
of,anticholinesterase,agents 1.0 0.000143348623853 1 0 1
of,another,tnf 1.0 0.000143348623853 1 0 1
of,another,botulinum 1.0 0.000143348623853 1 0 1
of,angiomax,with 1.0 0.000143348623853 1 0 1
of,angina,or 1.0 0.000143348623853 1 0 1
of,and,which 1.0 0.000143348623853 1 0 1
of,and,when 1.0 0.000143348623853 1 0 1
of,and,veratrum 1.0 0.000143348623853 1 0 1
of,and,usually 1.0 0.000143348623853 1 0 1
of,and,thiazide 1.0 0.000143348623853 1 0 1
of,and,tablets 1.0 0.000143348623853 1 0 1
of,and,subsalicylate 1.0 0.000143348623853 1 0 1
of,and,strong 1.0 0.000143348623853 1 0 1
of,and,some 1.0 0.000143348623853 1 0 1
of,and,similarly 1.0 0.000143348623853 1 0 1
of,and,significantly 1.0 0.000143348623853 1 0 1
of,and,significant 1.0 0.000143348623853 1 0 1
of,and,results 1.0 0.000143348623853 1 0 1
of,and,resulting 1.0 0.000143348623853 1 0 1
of,and,require 1.0 0.000143348623853 1 0 1
of,and,reached 1.0 0.000143348623853 1 0 1
of,and,prolongation 1.0 0.000143348623853 1 0 1
of,and,proleukin 1.0 0.000143348623853 1 0 1
of,and,produces 1.0 0.000143348623853 1 0 1
of,and,plasma 1.0 0.000143348623853 1 0 1
of,and,penthrane 1.0 0.000143348623853 1 0 1
of,and,partly 1.0 0.000143348623853 1 0 1
of,and,ortho-novum 1.0 0.000143348623853 1 0 1
of,and,occurred 1.0 0.000143348623853 1 0 1
of,and,o-desacetylrifabutin 1.0 0.000143348623853 1 0 1
of,and,monitoring 1.0 0.000143348623853 1 0 1
of,and,moderate 1.0 0.000143348623853 1 0 1
of,and,minimizes 1.0 0.000143348623853 1 0 1
of,and,metabolite 1.0 0.000143348623853 1 0 1
of,and,mepron 1.0 0.000143348623853 1 0 1
of,and,mean 1.0 0.000143348623853 1 0 1
of,and,lodine 1.0 0.000143348623853 1 0 1
of,and,iv 1.0 0.000143348623853 1 0 1
of,and,initiation 1.0 0.000143348623853 1 0 1
of,and,hypoglycemic 1.0 0.000143348623853 1 0 1
of,and,g 1.0 0.000143348623853 1 0 1
of,and,extended 1.0 0.000143348623853 1 0 1
of,and,enhance 1.0 0.000143348623853 1 0 1
of,and,as 1.0 0.000143348623853 1 0 1
of,and,also 1.0 0.000143348623853 1 0 1
of,and,agents 1.0 0.000143348623853 1 0 1
of,and,acetylsalicylic 1.0 0.000143348623853 1 0 1
of,anaphylactic,shock 1.0 0.000143348623853 1 0 1
of,anafranil,to 1.0 0.000143348623853 1 0 1
of,an,with 1.0 0.000143348623853 1 0 1
of,an,nsaid 1.0 0.000143348623853 1 0 1
of,an,mao 1.0 0.000143348623853 1 0 1
of,an,interleukin-1 1.0 0.000143348623853 1 0 1
of,an,hydroxide 1.0 0.000143348623853 1 0 1
of,an,containing 1.0 0.000143348623853 1 0 1
of,an,and 1.0 0.000143348623853 1 0 1
of,an,adolescent 1.0 0.000143348623853 1 0 1
of,amprenavir,and 1.0 0.000143348623853 1 0 1
of,among,patients 1.0 0.000143348623853 1 0 1
of,although,overall 1.0 0.000143348623853 1 0 1
of,although,it 1.0 0.000143348623853 1 0 1
of,alternate-day,administration 1.0 0.000143348623853 1 0 1
of,already,accumulated 1.0 0.000143348623853 1 0 1
of,allergic,reaction 1.0 0.000143348623853 1 0 1
of,all,muscle 1.0 0.000143348623853 1 0 1
of,albendazole,mg 1.0 0.000143348623853 1 0 1
of,akathisia,in 1.0 0.000143348623853 1 0 1
of,agents,which 1.0 0.000143348623853 1 0 1
of,agents,simultaneous 1.0 0.000143348623853 1 0 1
of,aeds,in 1.0 0.000143348623853 1 0 1
of,adverse,neuropsychiatric 1.0 0.000143348623853 1 0 1
of,adverse,experiences 1.0 0.000143348623853 1 0 1
of,adrenocortical,dependent 1.0 0.000143348623853 1 0 1
of,adrenergic,agonists 1.0 0.000143348623853 1 0 1
of,administered,in 1.0 0.000143348623853 1 0 1
of,adenocard,in 1.0 0.000143348623853 1 0 1
of,adenocarcinomas,which 1.0 0.000143348623853 1 0 1
of,additive,negative 1.0 0.000143348623853 1 0 1
of,active,vomiting 1.0 0.000143348623853 1 0 1
of,active,phosphorylated 1.0 0.000143348623853 1 0 1
of,action,it 1.0 0.000143348623853 1 0 1
of,actinic,keratoses 1.0 0.000143348623853 1 0 1
of,acidity,in 1.0 0.000143348623853 1 0 1
of,acetate,in 1.0 0.000143348623853 1 0 1
of,accutane,to 1.0 0.000143348623853 1 0 1
of,acarbose,and 1.0 0.000143348623853 1 0 1
of,absorption,mean 1.0 0.000143348623853 1 0 1
of,absorption,in 1.0 0.000143348623853 1 0 1
of,absorption,by 1.0 0.000143348623853 1 0 1
of,about,when 1.0 0.000143348623853 1 0 1
of,about,mm 1.0 0.000143348623853 1 0 1
of,a,tnf 1.0 0.000143348623853 1 0 1
of,a,study 1.0 0.000143348623853 1 0 1
of,a,slower 1.0 0.000143348623853 1 0 1
of,a,sensitive 1.0 0.000143348623853 1 0 1
of,a,regimen 1.0 0.000143348623853 1 0 1
of,a,potentially 1.0 0.000143348623853 1 0 1
of,a,physician 1.0 0.000143348623853 1 0 1
of,a,pharmacodynamic 1.0 0.000143348623853 1 0 1
of,a,p-glycoprotein 1.0 0.000143348623853 1 0 1
of,a,number 1.0 0.000143348623853 1 0 1
of,a,nonsteroidal 1.0 0.000143348623853 1 0 1
of,a,nonabsorbable 1.0 0.000143348623853 1 0 1
of,a,non- 1.0 0.000143348623853 1 0 1
of,a,mao 1.0 0.000143348623853 1 0 1
of,a,large 1.0 0.000143348623853 1 0 1
of,a,increase 1.0 0.000143348623853 1 0 1
of,a,including 1.0 0.000143348623853 1 0 1
of,a,four-day 1.0 0.000143348623853 1 0 1
of,a,daily 1.0 0.000143348623853 1 0 1
of,a,cyp2d6 1.0 0.000143348623853 1 0 1
of,a,cyp2c9 1.0 0.000143348623853 1 0 1
of,a,clinical 1.0 0.000143348623853 1 0 1
of,a,beta 1.0 0.000143348623853 1 0 1
of,a,agonist 1.0 0.000143348623853 1 0 1
of,a,a 1.0 0.000143348623853 1 0 1
ocupress,should,be 1.0 0.000143348623853 1 0 1
oculo-bulbar,myasthenia,gravis 1.0 0.000143348623853 1 0 1
occurs,dose,should 1.0 0.000143348623853 1 0 1
occurring,interactions,are 1.0 0.000143348623853 1 0 1
occurrence,of,upper 1.0 0.000143348623853 1 0 1
occurrence,has,not 1.0 0.000143348623853 1 0 1
occurred,following,simultaneous 1.0 0.000143348623853 1 0 1
occurred,at,six 1.0 0.000143348623853 1 0 1
occur,with,labetalol 1.0 0.000143348623853 1 0 1
occur,with,concomitant 1.0 0.000143348623853 1 0 1
occur,when,the 1.0 0.000143348623853 1 0 1
occur,when,levsin 1.0 0.000143348623853 1 0 1
occur,when,infection 1.0 0.000143348623853 1 0 1
occur,when,flolan 1.0 0.000143348623853 1 0 1
occur,when,cime-tidine 1.0 0.000143348623853 1 0 1
occur,when,are 1.0 0.000143348623853 1 0 1
occur,when,and 1.0 0.000143348623853 1 0 1
occur,when,an 1.0 0.000143348623853 1 0 1
occur,when,agents 1.0 0.000143348623853 1 0 1
occur,up,to 1.0 0.000143348623853 1 0 1
occur,physicians,should 1.0 0.000143348623853 1 0 1
occur,if,and 1.0 0.000143348623853 1 0 1
occur,earlier,than 1.0 0.000143348623853 1 0 1
occur,between,epa 1.0 0.000143348623853 1 0 1
occur,because,competitively 1.0 0.000143348623853 1 0 1
occasionally,intensify,the 1.0 0.000143348623853 1 0 1
occasionally,experience,a 1.0 0.000143348623853 1 0 1
occasional,literature,reports 1.0 0.000143348623853 1 0 1
obtained,with,alone 1.0 0.000143348623853 1 0 1
obtained,should,not 1.0 0.000143348623853 1 0 1
obtained,after,co-treatment 1.0 0.000143348623853 1 0 1
obtain,serum,levels 1.0 0.000143348623853 1 0 1
obstipation,even,ileus 1.0 0.000143348623853 1 0 1
observed,with,preparations 1.0 0.000143348623853 1 0 1
observed,with,concomitant 1.0 0.000143348623853 1 0 1
observed,when,was 1.0 0.000143348623853 1 0 1
observed,when,videx 1.0 0.000143348623853 1 0 1
observed,when,this 1.0 0.000143348623853 1 0 1
observed,when,they 1.0 0.000143348623853 1 0 1
observed,when,therapy 1.0 0.000143348623853 1 0 1
observed,when,multiple 1.0 0.000143348623853 1 0 1
observed,when,is 1.0 0.000143348623853 1 0 1
observed,when,gl 1.0 0.000143348623853 1 0 1
observed,when,coreg 1.0 0.000143348623853 1 0 1
observed,when,colestid 1.0 0.000143348623853 1 0 1
observed,to,occasionally 1.0 0.000143348623853 1 0 1
observed,to,enhance 1.0 0.000143348623853 1 0 1
observed,to,determine 1.0 0.000143348623853 1 0 1
observed,that,mptp 1.0 0.000143348623853 1 0 1
observed,that,meth 1.0 0.000143348623853 1 0 1
observed,on,the 1.0 0.000143348623853 1 0 1
observed,increase,in 1.0 0.000143348623853 1 0 1
observed,in,this 1.0 0.000143348623853 1 0 1
observed,in,these 1.0 0.000143348623853 1 0 1
observed,for,several 1.0 0.000143348623853 1 0 1
observed,for,alterations 1.0 0.000143348623853 1 0 1
observed,following,initiation 1.0 0.000143348623853 1 0 1
observed,following,concurrent 1.0 0.000143348623853 1 0 1
observed,during,studies 1.0 0.000143348623853 1 0 1
observations,on,hepatotoxicity 1.0 0.000143348623853 1 0 1
observation,is,required 1.0 0.000143348623853 1 0 1
o-desacetylrifabutin,and,the 1.0 0.000143348623853 1 0 1
o,induced,diarrhea 1.0 0.000143348623853 1 0 1
o,every,hours 1.0 0.000143348623853 1 0 1
nutrition,herb,interactions 1.0 0.000143348623853 1 0 1
nutrient,absorption,in 1.0 0.000143348623853 1 0 1
nuromax,is,lengthened 1.0 0.000143348623853 1 0 1
nuromax,include,certain 1.0 0.000143348623853 1 0 1
number,of,reports 1.0 0.000143348623853 1 0 1
number,of,including 1.0 0.000143348623853 1 0 1
number,of,human 1.0 0.000143348623853 1 0 1
number,of,compounds 1.0 0.000143348623853 1 0 1
number,of,cases 1.0 0.000143348623853 1 0 1
number,of,blood 1.0 0.000143348623853 1 0 1
number,of,autoimmune 1.0 0.000143348623853 1 0 1
number,induced,by 1.0 0.000143348623853 1 0 1
nucleoside,analogues,didanosine 1.0 0.000143348623853 1 0 1
nsaids,through,effects 1.0 0.000143348623853 1 0 1
nsaids,the,concomitant 1.0 0.000143348623853 1 0 1
nsaids,suggests,the 1.0 0.000143348623853 1 0 1
nsaids,monoamine,oxidase 1.0 0.000143348623853 1 0 1
nsaids,may,decrease 1.0 0.000143348623853 1 0 1
nsaids,may,cause 1.0 0.000143348623853 1 0 1
nsaids,like,aleve 1.0 0.000143348623853 1 0 1
nsaids,including,and 1.0 0.000143348623853 1 0 1
nsaids,in,patients 1.0 0.000143348623853 1 0 1
nsaids,concomitant,use 1.0 0.000143348623853 1 0 1
nsaids,can,inhibit 1.0 0.000143348623853 1 0 1
nsaids,are,used 1.0 0.000143348623853 1 0 1
nsaids,are,administered 1.0 0.000143348623853 1 0 1
nsaids,and,may 1.0 0.000143348623853 1 0 1
nsaids,affect,platelet 1.0 0.000143348623853 1 0 1
nsaid,while,taking 1.0 0.000143348623853 1 0 1
nsaid,or,potentiated 1.0 0.000143348623853 1 0 1
ns,may,be 1.0 0.000143348623853 1 0 1
ns,is,administered 1.0 0.000143348623853 1 0 1
novel,peripherally,restricted 1.0 0.000143348623853 1 0 1
novel,chemical,reaction 1.0 0.000143348623853 1 0 1
noted,to,possibly 1.0 0.000143348623853 1 0 1
noted,to,develop 1.0 0.000143348623853 1 0 1
noted,that,haldol 1.0 0.000143348623853 1 0 1
noted,that,discontinuation 1.0 0.000143348623853 1 0 1
noted,in,patients 1.0 0.000143348623853 1 0 1
noted,even,when 1.0 0.000143348623853 1 0 1
notably,oral,antifungal 1.0 0.000143348623853 1 0 1
notably,nondepolarizing,muscle 1.0 0.000143348623853 1 0 1
not,when,the 1.0 0.000143348623853 1 0 1
not,totally,known 1.0 0.000143348623853 1 0 1
not,the,coat-core 1.0 0.000143348623853 1 0 1
not,systematically,studied 1.0 0.000143348623853 1 0 1
not,substantially,increased 1.0 0.000143348623853 1 0 1
not,studied,with 1.0 0.000143348623853 1 0 1
not,statistically,significant 1.0 0.000143348623853 1 0 1
not,shown,to 1.0 0.000143348623853 1 0 1
not,reported,l-histidine 1.0 0.000143348623853 1 0 1
not,recommended,when 1.0 0.000143348623853 1 0 1
not,recommended,to 1.0 0.000143348623853 1 0 1
not,recommended,since 1.0 0.000143348623853 1 0 1
not,recommended,it 1.0 0.000143348623853 1 0 1
not,primarily,metabolized 1.0 0.000143348623853 1 0 1
not,outweigh,the 1.0 0.000143348623853 1 0 1
not,ordinarily,recommended 1.0 0.000143348623853 1 0 1
not,only,to 1.0 0.000143348623853 1 0 1
not,only,block 1.0 0.000143348623853 1 0 1
not,needed,when 1.0 0.000143348623853 1 0 1
not,nanm,or 1.0 0.000143348623853 1 0 1
not,nanm,antagonized 1.0 0.000143348623853 1 0 1
not,known,hence 1.0 0.000143348623853 1 0 1
not,known,caution 1.0 0.000143348623853 1 0 1
not,in,rats 1.0 0.000143348623853 1 0 1
not,in,functional 1.0 0.000143348623853 1 0 1
not,in,and 1.0 0.000143348623853 1 0 1
not,exhibit,monoamine 1.0 0.000143348623853 1 0 1
not,exceed,mg 1.0 0.000143348623853 1 0 1
not,established,a 1.0 0.000143348623853 1 0 1
not,contain,an 1.0 0.000143348623853 1 0 1
not,concurrently,use 1.0 0.000143348623853 1 0 1
not,by,n6-cyclopentyladenosine 1.0 0.000143348623853 1 0 1
not,benefit,from 1.0 0.000143348623853 1 0 1
not,been,systematically 1.0 0.000143348623853 1 0 1
not,been,investigated 1.0 0.000143348623853 1 0 1
not,been,fully 1.0 0.000143348623853 1 0 1
not,been,definitively 1.0 0.000143348623853 1 0 1
not,bear,directly 1.0 0.000143348623853 1 0 1
not,be,usedas 1.0 0.000143348623853 1 0 1
not,be,treated 1.0 0.000143348623853 1 0 1
not,be,reliable 1.0 0.000143348623853 1 0 1
not,at,all 1.0 0.000143348623853 1 0 1
not,antagonize,the 1.0 0.000143348623853 1 0 1
not,after,administration 1.0 0.000143348623853 1 0 1
not,affect,pharmacokinetics 1.0 0.000143348623853 1 0 1
not,advisable,to 1.0 0.000143348623853 1 0 1
not,a,true 1.0 0.000143348623853 1 0 1
not,a,short-acting 1.0 0.000143348623853 1 0 1
nose,may,occur 1.0 0.000143348623853 1 0 1
norvir,viracept,astramorph 1.0 0.000143348623853 1 0 1
norpace,or,norpace 1.0 0.000143348623853 1 0 1
norpace,cr,lower 1.0 0.000143348623853 1 0 1
norpace,and,resulted 1.0 0.000143348623853 1 0 1
normovolemic,healthy,subjects 1.0 0.000143348623853 1 0 1
normalized,ratio,when 1.0 0.000143348623853 1 0 1
normalized,ratio,or 1.0 0.000143348623853 1 0 1
normal,volunteers,it 1.0 0.000143348623853 1 0 1
normal,volunteers,had 1.0 0.000143348623853 1 0 1
normal,volunteers,a 1.0 0.000143348623853 1 0 1
normal,variability,and 1.0 0.000143348623853 1 0 1
normal,tissues,from 1.0 0.000143348623853 1 0 1
normal,subjects,with 1.0 0.000143348623853 1 0 1
normal,subjects,no 1.0 0.000143348623853 1 0 1
normal,subjects,concurrent 1.0 0.000143348623853 1 0 1
normal,male,and 1.0 0.000143348623853 1 0 1
normal,dose,when 1.0 0.000143348623853 1 0 1
normal,but,should 1.0 0.000143348623853 1 0 1
norfloxacin,in,the 1.0 0.000143348623853 1 0 1
norethindrone,coadministration,of 1.0 0.000143348623853 1 0 1
nor,should,be 1.0 0.000143348623853 1 0 1
nor,retinyl,acetate 1.0 0.000143348623853 1 0 1
nonsteroidal,the,co-administration 1.0 0.000143348623853 1 0 1
nonsteroidal,that,inhibit 1.0 0.000143348623853 1 0 1
nonsteroidal,probably,reduces 1.0 0.000143348623853 1 0 1
nonsteroidal,has,been 1.0 0.000143348623853 1 0 1
nonsteroidal,can,interfere 1.0 0.000143348623853 1 0 1
nonsteroidal,anti-inflammatory,have 1.0 0.000143348623853 1 0 1
nonsteroidal,anti,inflammatory 1.0 0.000143348623853 1 0 1
nonsteroidal,agents,some 1.0 0.000143348623853 1 0 1
nonsteroidal,agents,nsaids 1.0 0.000143348623853 1 0 1
nonsteroidal,agents,including 1.0 0.000143348623853 1 0 1
nonsteroidal,agents,are 1.0 0.000143348623853 1 0 1
nonsteroidal,agents,and 1.0 0.000143348623853 1 0 1
nonsteroial,anti-inflammatory,concomitantly 1.0 0.000143348623853 1 0 1
nonselective,monoamine,oxidase 1.0 0.000143348623853 1 0 1
nonsedating,and,when 1.0 0.000143348623853 1 0 1
nonfunctioning,gland,who 1.0 0.000143348623853 1 0 1
nonfailing,myocardium,p 1.0 0.000143348623853 1 0 1
nonetheless,individual,patients 1.0 0.000143348623853 1 0 1
noncardioselective,porpranolol,may 1.0 0.000143348623853 1 0 1
nonbenzodiazepine,agonists,at 1.0 0.000143348623853 1 0 1
nonbarbiturate,antianxiety,agents 1.0 0.000143348623853 1 0 1
nonabsorbable,given,concurrently 1.0 0.000143348623853 1 0 1
nonabsorbable,complex,between 1.0 0.000143348623853 1 0 1
non-steroidal,the,co-administration 1.0 0.000143348623853 1 0 1
non-steroidal,concomitantly,with 1.0 0.000143348623853 1 0 1
non-steroidal,antiinflammatory,including 1.0 0.000143348623853 1 0 1
non-steroidal,anti-inflammatory,may 1.0 0.000143348623853 1 0 1
non-steroidal,and,herbs 1.0 0.000143348623853 1 0 1
non-steroidal,agents,seizures 1.0 0.000143348623853 1 0 1
non-steroidal,agents,are 1.0 0.000143348623853 1 0 1
non-steroidal,agent,can 1.0 0.000143348623853 1 0 1
non-selective,beta-adrenergic,blocking 1.0 0.000143348623853 1 0 1
non-potassium,sparing,such 1.0 0.000143348623853 1 0 1
non-matched,historicalcontrol,group 1.0 0.000143348623853 1 0 1
non-linear,pharmacokinetics,over 1.0 0.000143348623853 1 0 1
non-ionized,species,of 1.0 0.000143348623853 1 0 1
non-depolarizing,muscle,relaxants 1.0 0.000143348623853 1 0 1
non-depolarising,muscle,relaxants 1.0 0.000143348623853 1 0 1
non-comparative,clinical,trial 1.0 0.000143348623853 1 0 1
non-,steroidal,antiinflammatory 1.0 0.000143348623853 1 0 1
non-,steroidal,anti- 1.0 0.000143348623853 1 0 1
node,higher,degrees 1.0 0.000143348623853 1 0 1
node,function,or 1.0 0.000143348623853 1 0 1
node,conduction,can 1.0 0.000143348623853 1 0 1
nodal,conduction,observed 1.0 0.000143348623853 1 0 1
nodal,conduction,channel 1.0 0.000143348623853 1 0 1
no,study,data 1.0 0.000143348623853 1 0 1
no,specific,interactions 1.0 0.000143348623853 1 0 1
no,signs,or 1.0 0.000143348623853 1 0 1
no,significant,impact 1.0 0.000143348623853 1 0 1
no,significant,alteration 1.0 0.000143348623853 1 0 1
no,significant,additional 1.0 0.000143348623853 1 0 1
no,interaction,between 1.0 0.000143348623853 1 0 1
no,in,vivo 1.0 0.000143348623853 1 0 1
no,greater,than 1.0 0.000143348623853 1 0 1
no,effect,one 1.0 0.000143348623853 1 0 1
nnrtis,nevirapine,may 1.0 0.000143348623853 1 0 1
nizoral,tablets,with 1.0 0.000143348623853 1 0 1
nizoral,sporanox,lipitor 1.0 0.000143348623853 1 0 1
nitrous,oxide,to 1.0 0.000143348623853 1 0 1
nitrofurantoin,interferes,with 1.0 0.000143348623853 1 0 1
nitrite,after,drinking 1.0 0.000143348623853 1 0 1
nitric,oxide,donor 1.0 0.000143348623853 1 0 1
nitrates,the,blood 1.0 0.000143348623853 1 0 1
nine,patients,with 1.0 0.000143348623853 1 0 1
nimotop,was,observed 1.0 0.000143348623853 1 0 1
nimbex,were,comparable 1.0 0.000143348623853 1 0 1
nimbex,is,approximately 1.0 0.000143348623853 1 0 1
nimbex,include,certain 1.0 0.000143348623853 1 0 1
nimbex,in,patients 1.0 0.000143348623853 1 0 1
nimbex,at,or 1.0 0.000143348623853 1 0 1
nimbex,are,unknown 1.0 0.000143348623853 1 0 1
nimbex,and,decrease 1.0 0.000143348623853 1 0 1
nicotinic,acid,may 1.0 0.000143348623853 1 0 1
nicotine-induced,release,in 1.0 0.000143348623853 1 0 1
nicotine,nicotine,may 1.0 0.000143348623853 1 0 1
nicotine,may,provoke 1.0 0.000143348623853 1 0 1
nicardipine,hcl,usually 1.0 0.000143348623853 1 0 1
niacin,antihypertensive,therapy 1.0 0.000143348623853 1 0 1
ng,x,h 1.0 0.000143348623853 1 0 1
ng,ml,administered 1.0 0.000143348623853 1 0 1
nevirapinemay,lower,the 1.0 0.000143348623853 1 0 1
nevirapine,may,decrease 1.0 0.000143348623853 1 0 1
nevertheless,the,prothrombin 1.0 0.000143348623853 1 0 1
nevertheless,the,possibility 1.0 0.000143348623853 1 0 1
nevertheless,the,effects 1.0 0.000143348623853 1 0 1
nevertheless,clinical,studies 1.0 0.000143348623853 1 0 1
neutrophil,counts,in 1.0 0.000143348623853 1 0 1
neutralizing,agent,for 1.0 0.000143348623853 1 0 1
neurotoxic,effect,could 1.0 0.000143348623853 1 0 1
neuropsychiatric,events,or 1.0 0.000143348623853 1 0 1
neuropathy,or,other 1.0 0.000143348623853 1 0 1
neurontin,mg,appears 1.0 0.000143348623853 1 0 1
neurontin,capsule,n 1.0 0.000143348623853 1 0 1
neurons,and,the 1.0 0.000143348623853 1 0 1
neuronal,damage,produced 1.0 0.000143348623853 1 0 1
neuron,blockade,produced 1.0 0.000143348623853 1 0 1
neuromuscular,weakness,may 1.0 0.000143348623853 1 0 1
neuromuscular,blocking,effect 1.0 0.000143348623853 1 0 1
neuromuscular,blockade,produced 1.0 0.000143348623853 1 0 1
neuromuscular,blockade,of 1.0 0.000143348623853 1 0 1
neuromuscular,blockade,by 1.0 0.000143348623853 1 0 1
neuromuscular,block,may 1.0 0.000143348623853 1 0 1
neuroleptic,drugs,l-phenylalanine 1.0 0.000143348623853 1 0 1
netilmicin,should,not 1.0 0.000143348623853 1 0 1
net,decrease,in 1.0 0.000143348623853 1 0 1
nervous,system,when 1.0 0.000143348623853 1 0 1
nervous,system,regardless 1.0 0.000143348623853 1 0 1
nervous,system,or 1.0 0.000143348623853 1 0 1
nervous,system,and 1.0 0.000143348623853 1 0 1
nephrotoxicity,with,decreases 1.0 0.000143348623853 1 0 1
nephrotoxicity,of,coly-mycin 1.0 0.000143348623853 1 0 1
nephrotoxicity,may,cause 1.0 0.000143348623853 1 0 1
nephrotoxic,such,as 1.0 0.000143348623853 1 0 1
nephrotoxic,potential,intravenous 1.0 0.000143348623853 1 0 1
nephrotoxic,myelotoxic,chemotherapy 1.0 0.000143348623853 1 0 1
nephrotoxic,agents,should 1.0 0.000143348623853 1 0 1
nephrotoxic,agents,concomitant 1.0 0.000143348623853 1 0 1
nephrolithiasis,is,higher 1.0 0.000143348623853 1 0 1
neoral,sandimmune,hiv 1.0 0.000143348623853 1 0 1
neoplastic,disease,except 1.0 0.000143348623853 1 0 1
nelfinavir,steady-state,cmax 1.0 0.000143348623853 1 0 1
neither,reversed,by 1.0 0.000143348623853 1 0 1
neither,nor,should 1.0 0.000143348623853 1 0 1
neither,nor,retinyl 1.0 0.000143348623853 1 0 1
negative,inotropic,properties 1.0 0.000143348623853 1 0 1
negative,inotropic,effects 1.0 0.000143348623853 1 0 1
negative,inotropic,agents 1.0 0.000143348623853 1 0 1
needed,when,is 1.0 0.000143348623853 1 0 1
needed,to,cause 1.0 0.000143348623853 1 0 1
needed,the,dose 1.0 0.000143348623853 1 0 1
needed,following,coadministration 1.0 0.000143348623853 1 0 1
need,to,use 1.0 0.000143348623853 1 0 1
need,to,increase 1.0 0.000143348623853 1 0 1
need,for,therapy 1.0 0.000143348623853 1 0 1
need,for,an 1.0 0.000143348623853 1 0 1
necessitating,an,increase 1.0 0.000143348623853 1 0 1
necessitating,a,reduction 1.0 0.000143348623853 1 0 1
necessitated,changes,in 1.0 0.000143348623853 1 0 1
necessary,when,using 1.0 0.000143348623853 1 0 1
necessary,when,tagamet 1.0 0.000143348623853 1 0 1
necessary,when,eulexin 1.0 0.000143348623853 1 0 1
necessary,when,coadministered 1.0 0.000143348623853 1 0 1
necessary,to,adjust 1.0 0.000143348623853 1 0 1
necessary,the,dosage 1.0 0.000143348623853 1 0 1
necessary,for,eight 1.0 0.000143348623853 1 0 1
necessary,eg,may 1.0 0.000143348623853 1 0 1
necessary,during,and 1.0 0.000143348623853 1 0 1
necessary,because,of 1.0 0.000143348623853 1 0 1
near,mg,dl 1.0 0.000143348623853 1 0 1
nc,denotes,a 1.0 0.000143348623853 1 0 1
natriuresis,is,not 1.0 0.000143348623853 1 0 1
natriuresis,and,hyperreninemia 1.0 0.000143348623853 1 0 1
nasal,spray,the 1.0 0.000143348623853 1 0 1
nasal,spray,but 1.0 0.000143348623853 1 0 1
narrow,therapeutic,window 1.0 0.000143348623853 1 0 1
narcotics,non-narcotic,analgesics 1.0 0.000143348623853 1 0 1
narcotic,such,as 1.0 0.000143348623853 1 0 1
narcotic,may,potentiate 1.0 0.000143348623853 1 0 1
narcotic,general,such 1.0 0.000143348623853 1 0 1
naproxen,the,concomitant 1.0 0.000143348623853 1 0 1
naproxen,sodium,and 1.0 0.000143348623853 1 0 1
naproxen,coadministration,n 1.0 0.000143348623853 1 0 1
naproxen,and,other 1.0 0.000143348623853 1 0 1
nanm,were,more 1.0 0.000143348623853 1 0 1
nanm,antagonized,the 1.0 0.000143348623853 1 0 1
nalidixic,acid,oxolinic 1.0 0.000143348623853 1 0 1
nalidixic,acid,may 1.0 0.000143348623853 1 0 1
nalfon,to,therapy 1.0 0.000143348623853 1 0 1
nalfon,the,concomitant 1.0 0.000143348623853 1 0 1
nalfon,may,be 1.0 0.000143348623853 1 0 1
nalfon,has,not 1.0 0.000143348623853 1 0 1
nalfon,and,is 1.0 0.000143348623853 1 0 1
nalfon,and,a 1.0 0.000143348623853 1 0 1
nafazodone,consider,xanax 1.0 0.000143348623853 1 0 1
nabilone,should,be 1.0 0.000143348623853 1 0 1
nabilone,has,been 1.0 0.000143348623853 1 0 1
n6-cyclopentyladenosine,cpa,an 1.0 0.000143348623853 1 0 1
n1,while,attenuating 1.0 0.000143348623853 1 0 1
n-diethyl,m-toluamide,a 1.0 0.000143348623853 1 0 1
n-desmethyldiazepam,there,is 1.0 0.000143348623853 1 0 1
n-acetyltransferase,may,have 1.0 0.000143348623853 1 0 1
n,were,decreased 1.0 0.000143348623853 1 0 1
n,the,mean 1.0 0.000143348623853 1 0 1
n,resulted,in 1.0 0.000143348623853 1 0 1
n,pretreatment,with 1.0 0.000143348623853 1 0 1
n,of,sodium 1.0 0.000143348623853 1 0 1
n,n-diethyl,m-toluamide 1.0 0.000143348623853 1 0 1
n,mean,auc 1.0 0.000143348623853 1 0 1
n,ingestion,of 1.0 0.000143348623853 1 0 1
n,hypotension,vs 1.0 0.000143348623853 1 0 1
n,compared,to 1.0 0.000143348623853 1 0 1
n,combination,study 1.0 0.000143348623853 1 0 1
n,and,volunteers 1.0 0.000143348623853 1 0 1
n,and,n 1.0 0.000143348623853 1 0 1
myopathy,rhabdomyolysis,and 1.0 0.000143348623853 1 0 1
myoclonus,autonomic,instability 1.0 0.000143348623853 1 0 1
myocardium,to,effects 1.0 0.000143348623853 1 0 1
myocardium,p,but 1.0 0.000143348623853 1 0 1
myocardium,may,induce 1.0 0.000143348623853 1 0 1
myocarditis,ventricular,hypokinesia 1.0 0.000143348623853 1 0 1
myocardial,injury,including 1.0 0.000143348623853 1 0 1
myocardial,infarction,vs 1.0 0.000143348623853 1 0 1
myocardial,infarction,myocarditis 1.0 0.000143348623853 1 0 1
myocardial,depressants,or 1.0 0.000143348623853 1 0 1
myobloc,and,or 1.0 0.000143348623853 1 0 1
myelotoxic,chemotherapy,cardiotoxic 1.0 0.000143348623853 1 0 1
myelosuppression,was,more 1.0 0.000143348623853 1 0 1
myelosuppression,and,diarrhea 1.0 0.000143348623853 1 0 1
mydriasis,tachycardia,dryness 1.0 0.000143348623853 1 0 1
mydriasis,resulting,from 1.0 0.000143348623853 1 0 1
mycophenolate,mofetil,respectively 1.0 0.000143348623853 1 0 1
myasthenic,patient,only 1.0 0.000143348623853 1 0 1
myasthenia,gravis,inflammatory 1.0 0.000143348623853 1 0 1
myalgia,and,arthralgia 1.0 0.000143348623853 1 0 1
must,be,weighed 1.0 0.000143348623853 1 0 1
must,be,taken 1.0 0.000143348623853 1 0 1
must,be,directed 1.0 0.000143348623853 1 0 1
must,be,considered 1.0 0.000143348623853 1 0 1
must,be,avoided 1.0 0.000143348623853 1 0 1
muscle,to,m 1.0 0.000143348623853 1 0 1
muscle,relaxing,effect 1.0 0.000143348623853 1 0 1
muscle,relaxants,most 1.0 0.000143348623853 1 0 1
muscle,relaxants,may 1.0 0.000143348623853 1 0 1
muscle,relaxants,eg 1.0 0.000143348623853 1 0 1
muscle,relaxants,could 1.0 0.000143348623853 1 0 1
muscle,relaxants,amphotericin 1.0 0.000143348623853 1 0 1
muscle,relaxant,effect 1.0 0.000143348623853 1 0 1
muscle,in,the 1.0 0.000143348623853 1 0 1
mumol,liter,potentiated 1.0 0.000143348623853 1 0 1
multivitamins,or,other 1.0 0.000143348623853 1 0 1
multivitamin,preparations,containing 1.0 0.000143348623853 1 0 1
multivalent,cations,such 1.0 0.000143348623853 1 0 1
multivalent,cations,likely 1.0 0.000143348623853 1 0 1
multivalent,cations,including 1.0 0.000143348623853 1 0 1
multivalent,cation-containing,products 1.0 0.000143348623853 1 0 1
multiple-dose,study,caused 1.0 0.000143348623853 1 0 1
multiple,effects,on 1.0 0.000143348623853 1 0 1
multiple,dosing,caution 1.0 0.000143348623853 1 0 1
multiple,dosing,beta-1a 1.0 0.000143348623853 1 0 1
multiple,doses,mg 1.0 0.000143348623853 1 0 1
multiple,dose,study 1.0 0.000143348623853 1 0 1
multiple,dose,studies 1.0 0.000143348623853 1 0 1
multi-day,course,of 1.0 0.000143348623853 1 0 1
mucosa,caused,an 1.0 0.000143348623853 1 0 1
much,as,hours 1.0 0.000143348623853 1 0 1
msec,was,with 1.0 0.000143348623853 1 0 1
msec,compared,to 1.0 0.000143348623853 1 0 1
ms,contin,prelone 1.0 0.000143348623853 1 0 1
mrna,level,in 1.0 0.000143348623853 1 0 1
mptp-induced,neuronal,damage 1.0 0.000143348623853 1 0 1
mptp,produced,depletions 1.0 0.000143348623853 1 0 1
mptp,induced,long 1.0 0.000143348623853 1 0 1
mouth,use,of 1.0 0.000143348623853 1 0 1
mouth,constipation,blurred 1.0 0.000143348623853 1 0 1
mouth,and,nose 1.0 0.000143348623853 1 0 1
mouth,and,associated 1.0 0.000143348623853 1 0 1
mouse,tumour,and 1.0 0.000143348623853 1 0 1
motor,effects,of 1.0 0.000143348623853 1 0 1
motility,of,day-old 1.0 0.000143348623853 1 0 1
motility,lowers,the 1.0 0.000143348623853 1 0 1
most,subjects,who 1.0 0.000143348623853 1 0 1
most,psychoactive,medications 1.0 0.000143348623853 1 0 1
most,other,psychotropic 1.0 0.000143348623853 1 0 1
most,other,hypotensive 1.0 0.000143348623853 1 0 1
most,notably,nondepolarizing 1.0 0.000143348623853 1 0 1
most,likely,by 1.0 0.000143348623853 1 0 1
most,like,due 1.0 0.000143348623853 1 0 1
most,instances,synergism 1.0 0.000143348623853 1 0 1
most,commonly,occurring 1.0 0.000143348623853 1 0 1
most,are,contraindicated 1.0 0.000143348623853 1 0 1
morphological,markers,that 1.0 0.000143348623853 1 0 1
morphine-induced,increases,in 1.0 0.000143348623853 1 0 1
morphine-induced,and,nicotine-induced 1.0 0.000143348623853 1 0 1
morphine,combination,hormonal 1.0 0.000143348623853 1 0 1
morphine,a,literature 1.0 0.000143348623853 1 0 1
moreover,as,noted 1.0 0.000143348623853 1 0 1
more,with,activity--such 1.0 0.000143348623853 1 0 1
more,than,two 1.0 0.000143348623853 1 0 1
more,than,times 1.0 0.000143348623853 1 0 1
more,than,for 1.0 0.000143348623853 1 0 1
more,pronounced,when 1.0 0.000143348623853 1 0 1
more,pronounced,if 1.0 0.000143348623853 1 0 1
more,profound,when 1.0 0.000143348623853 1 0 1
more,possibly,due 1.0 0.000143348623853 1 0 1
more,in,some 1.0 0.000143348623853 1 0 1
more,conservatively,adjusted 1.0 0.000143348623853 1 0 1
more,commonly,reported 1.0 0.000143348623853 1 0 1
more,commonly,in 1.0 0.000143348623853 1 0 1
monurol,a,which 1.0 0.000143348623853 1 0 1
mononuclear,cells,u937 1.0 0.000143348623853 1 0 1
mononuclear,cells,or 1.0 0.000143348623853 1 0 1
mononitrate,may,be 1.0 0.000143348623853 1 0 1
monoamine,oxidase,inhibiting 1.0 0.000143348623853 1 0 1
monkeys,the,effects 1.0 0.000143348623853 1 0 1
monitoring,or,consider 1.0 0.000143348623853 1 0 1
monitoring,of,their 1.0 0.000143348623853 1 0 1
monitoring,of,methotrexate-related 1.0 0.000143348623853 1 0 1
monitoring,of,liver 1.0 0.000143348623853 1 0 1
monitoring,of,is 1.0 0.000143348623853 1 0 1
monitoring,of,clinical 1.0 0.000143348623853 1 0 1
monitoring,of,cardiac 1.0 0.000143348623853 1 0 1
monitoring,is,recommended 1.0 0.000143348623853 1 0 1
monitoring,for,known 1.0 0.000143348623853 1 0 1
monitoring,for,adverse 1.0 0.000143348623853 1 0 1
monitoring,can,avoid 1.0 0.000143348623853 1 0 1
monitoring,and,dose 1.0 0.000143348623853 1 0 1
monitored,when,or 1.0 0.000143348623853 1 0 1
monitored,when,it 1.0 0.000143348623853 1 0 1
monitored,when,is 1.0 0.000143348623853 1 0 1
monitored,when,concomitant 1.0 0.000143348623853 1 0 1
monitored,when,celebrex 1.0 0.000143348623853 1 0 1
monitored,when,and 1.0 0.000143348623853 1 0 1
monitored,to,ensure 1.0 0.000143348623853 1 0 1
monitored,particularly,in 1.0 0.000143348623853 1 0 1
monitored,particularly,during 1.0 0.000143348623853 1 0 1
monitored,in,the 1.0 0.000143348623853 1 0 1
monitored,forevidence,of 1.0 0.000143348623853 1 0 1
monitored,for,possible 1.0 0.000143348623853 1 0 1
monitored,for,loss 1.0 0.000143348623853 1 0 1
monitored,for,increases 1.0 0.000143348623853 1 0 1
monitored,especially,when 1.0 0.000143348623853 1 0 1
monitored,during,and 1.0 0.000143348623853 1 0 1
monitored,closely,if 1.0 0.000143348623853 1 0 1
monitored,closely,after 1.0 0.000143348623853 1 0 1
monitored,carefully,if 1.0 0.000143348623853 1 0 1
monitored,carefully,and 1.0 0.000143348623853 1 0 1
monitored,because,the 1.0 0.000143348623853 1 0 1
monitored,because,nephrotoxicity 1.0 0.000143348623853 1 0 1
monitored,and,their 1.0 0.000143348623853 1 0 1
monitored,and,its 1.0 0.000143348623853 1 0 1
monitored,and,if 1.0 0.000143348623853 1 0 1
monitored,and,adjustment 1.0 0.000143348623853 1 0 1
monitored,after,tracleer 1.0 0.000143348623853 1 0 1
monitor,concentrations,in 1.0 0.000143348623853 1 0 1
molt-4,cells,revealed 1.0 0.000143348623853 1 0 1
molecule,thereby,decreasing 1.0 0.000143348623853 1 0 1
mofetil,respectively,were 1.0 0.000143348623853 1 0 1
modulation,of,allergic 1.0 0.000143348623853 1 0 1
modulates,in,an 1.0 0.000143348623853 1 0 1
modify,the,mitogenic 1.0 0.000143348623853 1 0 1
modifies,metabolism,with 1.0 0.000143348623853 1 0 1
modified,by,the 1.0 0.000143348623853 1 0 1
modification,of,the 1.0 0.000143348623853 1 0 1
modest,increases,in 1.0 0.000143348623853 1 0 1
modest,increases,about 1.0 0.000143348623853 1 0 1
modest,elevations,less 1.0 0.000143348623853 1 0 1
modest,cyp2d6,inhibitory 1.0 0.000143348623853 1 0 1
moderate,to,severe 1.0 0.000143348623853 1 0 1
moderate,to,marked 1.0 0.000143348623853 1 0 1
moderate,cyp3a4,inhibitors 1.0 0.000143348623853 1 0 1
moderate,cyp1a2,inhibitors 1.0 0.000143348623853 1 0 1
model,possibly,increasing 1.0 0.000143348623853 1 0 1
ml,with,coadministration 1.0 0.000143348623853 1 0 1
ml,with,alone 1.0 0.000143348623853 1 0 1
ml,twice,daily 1.0 0.000143348623853 1 0 1
ml,the,binding 1.0 0.000143348623853 1 0 1
ml,min,mean 1.0 0.000143348623853 1 0 1
ml,maalox,tc 1.0 0.000143348623853 1 0 1
ml,h,among 1.0 0.000143348623853 1 0 1
ml,and,terminal 1.0 0.000143348623853 1 0 1
ml,and,maximum 1.0 0.000143348623853 1 0 1
ml,administered,with 1.0 0.000143348623853 1 0 1
mixing,of,with 1.0 0.000143348623853 1 0 1
mixing,of,an 1.0 0.000143348623853 1 0 1
mixed,overdosage,since 1.0 0.000143348623853 1 0 1
mitogenic,effect,of 1.0 0.000143348623853 1 0 1
misuse,of,and 1.0 0.000143348623853 1 0 1
misonidazole,reduced,the 1.0 0.000143348623853 1 0 1
misonidazole,protects,mouse 1.0 0.000143348623853 1 0 1
misonidazole,has,a 1.0 0.000143348623853 1 0 1
minutes,p,this 1.0 0.000143348623853 1 0 1
minutes,of,an 1.0 0.000143348623853 1 0 1
minutes,following,alfenta 1.0 0.000143348623853 1 0 1
minutes,following,administration 1.0 0.000143348623853 1 0 1
minutes,faster,with 1.0 0.000143348623853 1 0 1
minutes,before,using 1.0 0.000143348623853 1 0 1
minutes,before,any 1.0 0.000143348623853 1 0 1
minutes,any,such 1.0 0.000143348623853 1 0 1
minutes,after,the 1.0 0.000143348623853 1 0 1
minute,after,a 1.0 0.000143348623853 1 0 1
minus,in,ovarian 1.0 0.000143348623853 1 0 1
minor,increase,in 1.0 0.000143348623853 1 0 1
minipills,that,do 1.0 0.000143348623853 1 0 1
minipill,preparations,are 1.0 0.000143348623853 1 0 1
minimizes,this,decrease 1.0 0.000143348623853 1 0 1
minimized,or,avoided 1.0 0.000143348623853 1 0 1
minimally,or,not 1.0 0.000143348623853 1 0 1
minimally,absorbed,into 1.0 0.000143348623853 1 0 1
mineral,oil-concomitant,intake 1.0 0.000143348623853 1 0 1
mineral,oil,interferes 1.0 0.000143348623853 1 0 1
mineral,oil,and 1.0 0.000143348623853 1 0 1
mind,that,ingestion 1.0 0.000143348623853 1 0 1
mind,in,the 1.0 0.000143348623853 1 0 1
min,mean,standard 1.0 0.000143348623853 1 0 1
min,interval,significantly 1.0 0.000143348623853 1 0 1
min,before,a 1.0 0.000143348623853 1 0 1
min,after,m-tco 1.0 0.000143348623853 1 0 1
milk,products,and 1.0 0.000143348623853 1 0 1
milk,milk,products 1.0 0.000143348623853 1 0 1
mildly,reduced,approximately 1.0 0.000143348623853 1 0 1
mild,decrease,in 1.0 0.000143348623853 1 0 1
migraine,therapy,such 1.0 0.000143348623853 1 0 1
might,decrease,the 1.0 0.000143348623853 1 0 1
might,be,explained 1.0 0.000143348623853 1 0 1
might,be,expected 1.0 0.000143348623853 1 0 1
might,also,contribute 1.0 0.000143348623853 1 0 1
midazolam,used,at 1.0 0.000143348623853 1 0 1
midazolam,aprepitant,increased 1.0 0.000143348623853 1 0 1
midamor,may,each 1.0 0.000143348623853 1 0 1
midamor,and,non-steroidal 1.0 0.000143348623853 1 0 1
microsomes,inhibition,of 1.0 0.000143348623853 1 0 1
microsomal,enzymes,and 1.0 0.000143348623853 1 0 1
microsomal,enzyme,system 1.0 0.000143348623853 1 0 1
microsomal,enzyme,inducer 1.0 0.000143348623853 1 0 1
microsomal,drug,metabolism 1.0 0.000143348623853 1 0 1
micromol,l,and 1.0 0.000143348623853 1 0 1
microm,preferentially,blocked 1.0 0.000143348623853 1 0 1
microm,inhibited,insp 1.0 0.000143348623853 1 0 1
microm,also,inhibited 1.0 0.000143348623853 1 0 1
micrograms,had,only 1.0 0.000143348623853 1 0 1
micrograms,equally,antagonized 1.0 0.000143348623853 1 0 1
micrograms,completely,blocked 1.0 0.000143348623853 1 0 1
micrograms,caused,a 1.0 0.000143348623853 1 0 1
microdosed,minipill,preparations 1.0 0.000143348623853 1 0 1
microalbuminuria,inspra,mg 1.0 0.000143348623853 1 0 1
micro-dosed,progesterone,preparations 1.0 0.000143348623853 1 0 1
micro-dosed,preparations,minipills 1.0 0.000143348623853 1 0 1
mg,with,viracept 1.0 0.000143348623853 1 0 1
mg,with,neurontin 1.0 0.000143348623853 1 0 1
mg,with,multiple 1.0 0.000143348623853 1 0 1
mg,with,coadministered 1.0 0.000143348623853 1 0 1
mg,when,coadministered 1.0 0.000143348623853 1 0 1
mg,week,for 1.0 0.000143348623853 1 0 1
mg,was,admini 1.0 0.000143348623853 1 0 1
mg,twice-daily,with 1.0 0.000143348623853 1 0 1
mg,to,ace 1.0 0.000143348623853 1 0 1
mg,tid,was 1.0 0.000143348623853 1 0 1
mg,tid,the 1.0 0.000143348623853 1 0 1
mg,tid,mg 1.0 0.000143348623853 1 0 1
mg,three,mg 1.0 0.000143348623853 1 0 1
mg,taken,and 1.0 0.000143348623853 1 0 1
mg,tablets,results 1.0 0.000143348623853 1 0 1
mg,sular,tablets 1.0 0.000143348623853 1 0 1
mg,sodium,approximately 1.0 0.000143348623853 1 0 1
mg,sodium,and 1.0 0.000143348623853 1 0 1
mg,separated,by 1.0 0.000143348623853 1 0 1
mg,respectively,resulted 1.0 0.000143348623853 1 0 1
mg,respectively,a 1.0 0.000143348623853 1 0 1
mg,reduced,the 1.0 0.000143348623853 1 0 1
mg,qid,n 1.0 0.000143348623853 1 0 1
mg,qd,mg 1.0 0.000143348623853 1 0 1
mg,qd,is 1.0 0.000143348623853 1 0 1
mg,qd,increased 1.0 0.000143348623853 1 0 1
mg,qd,by 1.0 0.000143348623853 1 0 1
mg,q,i 1.0 0.000143348623853 1 0 1
mg,produced,mean 1.0 0.000143348623853 1 0 1
mg,produced,an 1.0 0.000143348623853 1 0 1
mg,produced,a 1.0 0.000143348623853 1 0 1
mg,potentiated,the 1.0 0.000143348623853 1 0 1
mg,p,o 1.0 0.000143348623853 1 0 1
mg,orally,disintegrating 1.0 0.000143348623853 1 0 1
mg,oral,twice 1.0 0.000143348623853 1 0 1
mg,on,days 1.0 0.000143348623853 1 0 1
mg,of,sodium 1.0 0.000143348623853 1 0 1
mg,of,q12h 1.0 0.000143348623853 1 0 1
mg,of,mefenamic 1.0 0.000143348623853 1 0 1
mg,of,hydrochloride 1.0 0.000143348623853 1 0 1
mg,of,fe 1.0 0.000143348623853 1 0 1
mg,of,elemental 1.0 0.000143348623853 1 0 1
mg,of,decreased 1.0 0.000143348623853 1 0 1
mg,of,daily 1.0 0.000143348623853 1 0 1
mg,of,cancidas 1.0 0.000143348623853 1 0 1
mg,of,betaseron 1.0 0.000143348623853 1 0 1
mg,neurontin,capsule 1.0 0.000143348623853 1 0 1
mg,m2,given 1.0 0.000143348623853 1 0 1
mg,m2,and 1.0 0.000143348623853 1 0 1
mg,led,to 1.0 0.000143348623853 1 0 1
mg,l,to 1.0 0.000143348623853 1 0 1
mg,kg,x 1.0 0.000143348623853 1 0 1
mg,kg,with 1.0 0.000143348623853 1 0 1
mg,kg,weight 1.0 0.000143348623853 1 0 1
mg,kg,w 1.0 0.000143348623853 1 0 1
mg,kg,via 1.0 0.000143348623853 1 0 1
mg,kg,removes 1.0 0.000143348623853 1 0 1
mg,kg,ip 1.0 0.000143348623853 1 0 1
mg,kg,injected 1.0 0.000143348623853 1 0 1
mg,kg,increased 1.0 0.000143348623853 1 0 1
mg,kg,hours 1.0 0.000143348623853 1 0 1
mg,kg,enhanced 1.0 0.000143348623853 1 0 1
mg,kg,doses 1.0 0.000143348623853 1 0 1
mg,kg,decreased 1.0 0.000143348623853 1 0 1
mg,initial,oral 1.0 0.000143348623853 1 0 1
mg,increased,exposure 1.0 0.000143348623853 1 0 1
mg,if,is 1.0 0.000143348623853 1 0 1
mg,h,s 1.0 0.000143348623853 1 0 1
mg,given,once 1.0 0.000143348623853 1 0 1
mg,for,weeks 1.0 0.000143348623853 1 0 1
mg,fe,instead 1.0 0.000143348623853 1 0 1
mg,experienced,a 1.0 0.000143348623853 1 0 1
mg,each,administered 1.0 0.000143348623853 1 0 1
mg,doses,of 1.0 0.000143348623853 1 0 1
mg,dl,dose 1.0 0.000143348623853 1 0 1
mg,decreased,the 1.0 0.000143348623853 1 0 1
mg,day,with 1.0 0.000143348623853 1 0 1
mg,day,orally 1.0 0.000143348623853 1 0 1
mg,day,lexapro 1.0 0.000143348623853 1 0 1
mg,day,increased 1.0 0.000143348623853 1 0 1
mg,day,followed 1.0 0.000143348623853 1 0 1
mg,day,during 1.0 0.000143348623853 1 0 1
mg,day,divided 1.0 0.000143348623853 1 0 1
mg,day,a 1.0 0.000143348623853 1 0 1
mg,daily,the 1.0 0.000143348623853 1 0 1
mg,daily,resulted 1.0 0.000143348623853 1 0 1
mg,daily,of 1.0 0.000143348623853 1 0 1
mg,daily,may 1.0 0.000143348623853 1 0 1
mg,daily,dose 1.0 0.000143348623853 1 0 1
mg,daily,a 1.0 0.000143348623853 1 0 1
mg,controlled-release,capsule 1.0 0.000143348623853 1 0 1
mg,combined,with 1.0 0.000143348623853 1 0 1
mg,co-administered,with 1.0 0.000143348623853 1 0 1
mg,capsules,with 1.0 0.000143348623853 1 0 1
mg,capsules,or 1.0 0.000143348623853 1 0 1
mg,capsules,every 1.0 0.000143348623853 1 0 1
mg,capsule,within 1.0 0.000143348623853 1 0 1
mg,capsule,with 1.0 0.000143348623853 1 0 1
mg,by,hours 1.0 0.000143348623853 1 0 1
mg,bid,was 1.0 0.000143348623853 1 0 1
mg,bid,resulted 1.0 0.000143348623853 1 0 1
mg,bid,otc 1.0 0.000143348623853 1 0 1
mg,bid,mg 1.0 0.000143348623853 1 0 1
mg,bid,in 1.0 0.000143348623853 1 0 1
mg,bid,decreased 1.0 0.000143348623853 1 0 1
mg,bid,as 1.0 0.000143348623853 1 0 1
mg,appears,to 1.0 0.000143348623853 1 0 1
mg,and,a 1.0 0.000143348623853 1 0 1
mg,a,substrate 1.0 0.000143348623853 1 0 1
mexate,use,of 1.0 0.000143348623853 1 0 1
metoprolol,administration,of 1.0 0.000143348623853 1 0 1
metoclopramide,when,coadministered 1.0 0.000143348623853 1 0 1
metoclopramide,bioavailability,is 1.0 0.000143348623853 1 0 1
methylxanthines,and,diuretics 1.0 0.000143348623853 1 0 1
methylpyrazole,seen,in 1.0 0.000143348623853 1 0 1
methyldopa,aldomet,use 1.0 0.000143348623853 1 0 1
methotrexate-related,toxicity,when 1.0 0.000143348623853 1 0 1
methotrexate-related,toxicity,should 1.0 0.000143348623853 1 0 1
methotrexate,there,is 1.0 0.000143348623853 1 0 1
methotrexate,there,has 1.0 0.000143348623853 1 0 1
methotrexate,renal,tubular 1.0 0.000143348623853 1 0 1
methotrexate,piperacillin,sodium 1.0 0.000143348623853 1 0 1
methotrexate,nsaids,have 1.0 0.000143348623853 1 0 1
methotrexate,mexate,use 1.0 0.000143348623853 1 0 1
methotrexate,lodine,like 1.0 0.000143348623853 1 0 1
methotrexate,ketoprofen,like 1.0 0.000143348623853 1 0 1
methotrexate,ibuprofen,as 1.0 0.000143348623853 1 0 1
methotrexate,concomitant,administration 1.0 0.000143348623853 1 0 1
methotrexate,caution,should 1.0 0.000143348623853 1 0 1
methotrexate,an,increased 1.0 0.000143348623853 1 0 1
method,of,barrier 1.0 0.000143348623853 1 0 1
methionine,may,protect 1.0 0.000143348623853 1 0 1
methamphetamine,like,mptp 1.0 0.000143348623853 1 0 1
methadone,maintained,patients 1.0 0.000143348623853 1 0 1
methadone,levels,may 1.0 0.000143348623853 1 0 1
methadone,coadministration,of 1.0 0.000143348623853 1 0 1
meth,caused,a 1.0 0.000143348623853 1 0 1
metformin,in,healthy 1.0 0.000143348623853 1 0 1
metal,cations,such 1.0 0.000143348623853 1 0 1
metal,cations,or 1.0 0.000143348623853 1 0 1
metabolizers,suggesting,that 1.0 0.000143348623853 1 0 1
metabolizers,of,the 1.0 0.000143348623853 1 0 1
metabolizers,of,interactions 1.0 0.000143348623853 1 0 1
metabolized,via,cyp3a4 1.0 0.000143348623853 1 0 1
metabolized,triazolo-benzodiazepines,dihydropyridine 1.0 0.000143348623853 1 0 1
metabolized,similarly,to 1.0 0.000143348623853 1 0 1
metabolized,should,have 1.0 0.000143348623853 1 0 1
metabolites,with,a 1.0 0.000143348623853 1 0 1
metabolite,n-desmethyldiazepam,there 1.0 0.000143348623853 1 0 1
metabolite,may,be 1.0 0.000143348623853 1 0 1
metabolite,exposure,by 1.0 0.000143348623853 1 0 1
metabolite,concentrations,when 1.0 0.000143348623853 1 0 1
metabolite,concentration,and 1.0 0.000143348623853 1 0 1
metabolism,with,increased 1.0 0.000143348623853 1 0 1
metabolism,which,is 1.0 0.000143348623853 1 0 1
metabolism,via,p450 1.0 0.000143348623853 1 0 1
metabolism,to,might 1.0 0.000143348623853 1 0 1
metabolism,rifampin,reduced 1.0 0.000143348623853 1 0 1
metabolism,produced,an 1.0 0.000143348623853 1 0 1
metabolism,or,renal 1.0 0.000143348623853 1 0 1
metabolism,of,warfarin-type 1.0 0.000143348623853 1 0 1
metabolism,of,toxic 1.0 0.000143348623853 1 0 1
metabolism,of,these 1.0 0.000143348623853 1 0 1
metabolism,of,s 1.0 0.000143348623853 1 0 1
metabolism,of,one 1.0 0.000143348623853 1 0 1
metabolism,of,nonsedating 1.0 0.000143348623853 1 0 1
metabolism,of,increasing 1.0 0.000143348623853 1 0 1
metabolism,of,hmg-coa 1.0 0.000143348623853 1 0 1
metabolism,of,etc 1.0 0.000143348623853 1 0 1
metabolism,of,combination 1.0 0.000143348623853 1 0 1
metabolism,inhibitors,of 1.0 0.000143348623853 1 0 1
metabolism,increased,altretamines 1.0 0.000143348623853 1 0 1
metabolism,in,the 1.0 0.000143348623853 1 0 1
metabolism,in,ms 1.0 0.000143348623853 1 0 1
metabolism,decreased,the 1.0 0.000143348623853 1 0 1
metabolism,causing,an 1.0 0.000143348623853 1 0 1
metabolism,and,higher 1.0 0.000143348623853 1 0 1
metabolism,and,has 1.0 0.000143348623853 1 0 1
metabolic,clearance,that 1.0 0.000143348623853 1 0 1
mesylate,with,other 1.0 0.000143348623853 1 0 1
mesylate,was,administered 1.0 0.000143348623853 1 0 1
mesylate,may,interact 1.0 0.000143348623853 1 0 1
mesylate,in,combination 1.0 0.000143348623853 1 0 1
mesenteric,vasodilation,induced 1.0 0.000143348623853 1 0 1
mercaptopurine,azathioprine,allopurinol 1.0 0.000143348623853 1 0 1
meq,l,from 1.0 0.000143348623853 1 0 1
mepron,suspension,results 1.0 0.000143348623853 1 0 1
mental,status,changes 1.0 0.000143348623853 1 0 1
member,of,the 1.0 0.000143348623853 1 0 1
member,have,been 1.0 0.000143348623853 1 0 1
megakaryocytes,with,extracellular 1.0 0.000143348623853 1 0 1
mefloquine,on,travelers 1.0 0.000143348623853 1 0 1
mefloquine,may,reduce 1.0 0.000143348623853 1 0 1
mefloquine,is,taken 1.0 0.000143348623853 1 0 1
mefloquine,and,other 1.0 0.000143348623853 1 0 1
mefloquine,although,theoretically 1.0 0.000143348623853 1 0 1
mefenamic,acid,monoamine 1.0 0.000143348623853 1 0 1
mefenamic,acid,increased 1.0 0.000143348623853 1 0 1
mefenamic,acid,by 1.0 0.000143348623853 1 0 1
medroxyprogesterone,acetate,l-histidine 1.0 0.000143348623853 1 0 1
medicines,with,may 1.0 0.000143348623853 1 0 1
medicines,thiazide,use 1.0 0.000143348623853 1 0 1
medicines,such,as 1.0 0.000143348623853 1 0 1
medicines,since,the 1.0 0.000143348623853 1 0 1
medicines,or,substances 1.0 0.000143348623853 1 0 1
medicines,or,another 1.0 0.000143348623853 1 0 1
medicines,during,the 1.0 0.000143348623853 1 0 1
medicines,diabetic,nsaids 1.0 0.000143348623853 1 0 1
medicines,central,nervous 1.0 0.000143348623853 1 0 1
medicine,you,take 1.0 0.000143348623853 1 0 1
medicine,that,you 1.0 0.000143348623853 1 0 1
medicine,may,cause 1.0 0.000143348623853 1 0 1
medicine,blood,thinners 1.0 0.000143348623853 1 0 1
medicinal,products,with 1.0 0.000143348623853 1 0 1
medicinal,products,including 1.0 0.000143348623853 1 0 1
medicinal,products,could 1.0 0.000143348623853 1 0 1
medications,were,identified 1.0 0.000143348623853 1 0 1
medications,tylenol,such 1.0 0.000143348623853 1 0 1
medications,the,use 1.0 0.000143348623853 1 0 1
medications,that,can 1.0 0.000143348623853 1 0 1
medications,that,affect 1.0 0.000143348623853 1 0 1
medications,patients,should 1.0 0.000143348623853 1 0 1
medications,or,n 1.0 0.000143348623853 1 0 1
medications,is,not 1.0 0.000143348623853 1 0 1
medications,containing,multivalent 1.0 0.000143348623853 1 0 1
medications,can,interfere 1.0 0.000143348623853 1 0 1
medications,and,vasodilators 1.0 0.000143348623853 1 0 1
medications,and,other 1.0 0.000143348623853 1 0 1
medication,must,be 1.0 0.000143348623853 1 0 1
medication,including,solganal 1.0 0.000143348623853 1 0 1
medical,practice,dictates 1.0 0.000143348623853 1 0 1
mediated,by,cimetidines 1.0 0.000143348623853 1 0 1
median,of,the 1.0 0.000143348623853 1 0 1
median,gastric,ph 1.0 0.000143348623853 1 0 1
media,experienced,acute 1.0 0.000143348623853 1 0 1
media,a,review 1.0 0.000143348623853 1 0 1
meclofenamate,sodium,plasma 1.0 0.000143348623853 1 0 1
meclofenamate,sodium,enhances 1.0 0.000143348623853 1 0 1
mechanisms,involving,inhibition 1.0 0.000143348623853 1 0 1
mechanism,under,lying 1.0 0.000143348623853 1 0 1
mechanism,of,interaction 1.0 0.000143348623853 1 0 1
mechanism,may,be 1.0 0.000143348623853 1 0 1
mechanism,and,a 1.0 0.000143348623853 1 0 1
measurements,of,pah 1.0 0.000143348623853 1 0 1
measured,as,inr 1.0 0.000143348623853 1 0 1
means,of,selective 1.0 0.000143348623853 1 0 1
mean,steady-state,plasma 1.0 0.000143348623853 1 0 1
mean,standard,deviation 1.0 0.000143348623853 1 0 1
mean,sodium,and 1.0 0.000143348623853 1 0 1
mean,serum,slightly 1.0 0.000143348623853 1 0 1
mean,serum,concentrations 1.0 0.000143348623853 1 0 1
mean,scores,on 1.0 0.000143348623853 1 0 1
mean,renal,clearance 1.0 0.000143348623853 1 0 1
mean,qt,c 1.0 0.000143348623853 1 0 1
mean,percentage,increase 1.0 0.000143348623853 1 0 1
mean,of,and 1.0 0.000143348623853 1 0 1
mean,neutrophil,counts 1.0 0.000143348623853 1 0 1
mean,maximum,plasma 1.0 0.000143348623853 1 0 1
mean,half-life,and 1.0 0.000143348623853 1 0 1
mean,fold,increase 1.0 0.000143348623853 1 0 1
mean,confidence,interval 1.0 0.000143348623853 1 0 1
mean,cmax,a 1.0 0.000143348623853 1 0 1
mean,clearances,of 1.0 0.000143348623853 1 0 1
mean,change,of 1.0 0.000143348623853 1 0 1
mean,auc,of 1.0 0.000143348623853 1 0 1
mean,auc,increased 1.0 0.000143348623853 1 0 1
mean,auc,decreased 1.0 0.000143348623853 1 0 1
mean,arterial,pressure 1.0 0.000143348623853 1 0 1
mean,apparent,oral 1.0 0.000143348623853 1 0 1
mean,additional,supine 1.0 0.000143348623853 1 0 1
meal,resulted,in 1.0 0.000143348623853 1 0 1
meal,h,following 1.0 0.000143348623853 1 0 1
meal,as,evidenced 1.0 0.000143348623853 1 0 1
meal,and,mg 1.0 0.000143348623853 1 0 1
mc,potentiates,the 1.0 0.000143348623853 1 0 1
mc,block,morphine-induced 1.0 0.000143348623853 1 0 1
may,worsen,side 1.0 0.000143348623853 1 0 1
may,wish,to 1.0 0.000143348623853 1 0 1
may,temporarily,mask 1.0 0.000143348623853 1 0 1
may,substantially,decrease 1.0 0.000143348623853 1 0 1
may,still,kill 1.0 0.000143348623853 1 0 1
may,significantly,decrease 1.0 0.000143348623853 1 0 1
may,show,elevations 1.0 0.000143348623853 1 0 1
may,sensitize,the 1.0 0.000143348623853 1 0 1
may,selectively,prevent 1.0 0.000143348623853 1 0 1
may,result,if 1.0 0.000143348623853 1 0 1
may,require,increases 1.0 0.000143348623853 1 0 1
may,require,close 1.0 0.000143348623853 1 0 1
may,require,additional 1.0 0.000143348623853 1 0 1
may,render,these 1.0 0.000143348623853 1 0 1
may,regulate,the 1.0 0.000143348623853 1 0 1
may,reduce,serum 1.0 0.000143348623853 1 0 1
may,reduce,seizure 1.0 0.000143348623853 1 0 1
may,react,with 1.0 0.000143348623853 1 0 1
may,raise,serum 1.0 0.000143348623853 1 0 1
may,provoke,vasoconstriction 1.0 0.000143348623853 1 0 1
may,protect,against 1.0 0.000143348623853 1 0 1
may,produce,malabsorption 1.0 0.000143348623853 1 0 1
may,produce,excessive 1.0 0.000143348623853 1 0 1
may,produce,electrocardiographic 1.0 0.000143348623853 1 0 1
may,produce,aucs 1.0 0.000143348623853 1 0 1
may,produce,an 1.0 0.000143348623853 1 0 1
may,present,as 1.0 0.000143348623853 1 0 1
may,predispose,the 1.0 0.000143348623853 1 0 1
may,precipitate,seizures 1.0 0.000143348623853 1 0 1
may,potentiate,vecuronium-induced 1.0 0.000143348623853 1 0 1
may,potentiate,renal 1.0 0.000143348623853 1 0 1
may,potentiate,blood-pressure 1.0 0.000143348623853 1 0 1
may,potentiate,any 1.0 0.000143348623853 1 0 1
may,potentiate,amphotericin 1.0 0.000143348623853 1 0 1
may,potentiate,adverse 1.0 0.000143348623853 1 0 1
may,potentiate,a 1.0 0.000143348623853 1 0 1
may,occur,up 1.0 0.000143348623853 1 0 1
may,occur,if 1.0 0.000143348623853 1 0 1
may,occur,earlier 1.0 0.000143348623853 1 0 1
may,occur,between 1.0 0.000143348623853 1 0 1
may,occur,because 1.0 0.000143348623853 1 0 1
may,not,benefit 1.0 0.000143348623853 1 0 1
may,necessitate,raising 1.0 0.000143348623853 1 0 1
may,lower,meclofenamate 1.0 0.000143348623853 1 0 1
may,intensify,the 1.0 0.000143348623853 1 0 1
may,induce,fungal 1.0 0.000143348623853 1 0 1
may,induce,bleeding 1.0 0.000143348623853 1 0 1
may,increase,two-fold 1.0 0.000143348623853 1 0 1
may,increase,slightly 1.0 0.000143348623853 1 0 1
may,increase,respiratory 1.0 0.000143348623853 1 0 1
may,increase,exposure 1.0 0.000143348623853 1 0 1
may,increase,cyp 1.0 0.000143348623853 1 0 1
may,increase,blood 1.0 0.000143348623853 1 0 1
may,increase,absorption 1.0 0.000143348623853 1 0 1
may,have,synergistic 1.0 0.000143348623853 1 0 1
may,have,resulted 1.0 0.000143348623853 1 0 1
may,have,life-threatening 1.0 0.000143348623853 1 0 1
may,have,enhanced 1.0 0.000143348623853 1 0 1
may,have,elevated 1.0 0.000143348623853 1 0 1
may,have,clinically 1.0 0.000143348623853 1 0 1
may,have,caused 1.0 0.000143348623853 1 0 1
may,give,false 1.0 0.000143348623853 1 0 1
may,experience,toxicity 1.0 0.000143348623853 1 0 1
may,experience,enhanced 1.0 0.000143348623853 1 0 1
may,experience,a 1.0 0.000143348623853 1 0 1
may,exhibit,a 1.0 0.000143348623853 1 0 1
may,exacerbate,rebound 1.0 0.000143348623853 1 0 1
may,even,be 1.0 0.000143348623853 1 0 1
may,enhance,nutrient 1.0 0.000143348623853 1 0 1
may,enhance,cns 1.0 0.000143348623853 1 0 1
may,emerge,with 1.0 0.000143348623853 1 0 1
may,elevate,serum 1.0 0.000143348623853 1 0 1
may,either,inhibit 1.0 0.000143348623853 1 0 1
may,either,increase 1.0 0.000143348623853 1 0 1
may,effect,the 1.0 0.000143348623853 1 0 1
may,each,be 1.0 0.000143348623853 1 0 1
may,displace,less 1.0 0.000143348623853 1 0 1
may,displace,acidic 1.0 0.000143348623853 1 0 1
may,diminish,its 1.0 0.000143348623853 1 0 1
may,diminish,adrenal 1.0 0.000143348623853 1 0 1
may,develop,toxicity 1.0 0.000143348623853 1 0 1
may,develop,increased 1.0 0.000143348623853 1 0 1
may,develop,delirium 1.0 0.000143348623853 1 0 1
may,depress,the 1.0 0.000143348623853 1 0 1
may,decrease,vascular 1.0 0.000143348623853 1 0 1
may,decrease,thyroidal 1.0 0.000143348623853 1 0 1
may,decrease,clozapine 1.0 0.000143348623853 1 0 1
may,decrease,anti-inflammatory 1.0 0.000143348623853 1 0 1
may,compete,for 1.0 0.000143348623853 1 0 1
may,cause,synergistic 1.0 0.000143348623853 1 0 1
may,cause,serious 1.0 0.000143348623853 1 0 1
may,cause,respiratory 1.0 0.000143348623853 1 0 1
may,cause,hypertension 1.0 0.000143348623853 1 0 1
may,cause,hypercalcemia 1.0 0.000143348623853 1 0 1
may,cause,elevated 1.0 0.000143348623853 1 0 1
may,cause,adrenal 1.0 0.000143348623853 1 0 1
may,cause,abnormal 1.0 0.000143348623853 1 0 1
may,block,the 1.0 0.000143348623853 1 0 1
may,bind,and 1.0 0.000143348623853 1 0 1
may,become,subtherapeutic 1.0 0.000143348623853 1 0 1
may,be,seen 1.0 0.000143348623853 1 0 1
may,be,resistant 1.0 0.000143348623853 1 0 1
may,be,refractory 1.0 0.000143348623853 1 0 1
may,be,modified 1.0 0.000143348623853 1 0 1
may,be,lower 1.0 0.000143348623853 1 0 1
may,be,ineffective 1.0 0.000143348623853 1 0 1
may,be,effective 1.0 0.000143348623853 1 0 1
may,be,diminished 1.0 0.000143348623853 1 0 1
may,be,deeper 1.0 0.000143348623853 1 0 1
may,be,compromised 1.0 0.000143348623853 1 0 1
may,be,capable 1.0 0.000143348623853 1 0 1
may,be,aggravated 1.0 0.000143348623853 1 0 1
may,be,active 1.0 0.000143348623853 1 0 1
may,ameliorate,increased 1.0 0.000143348623853 1 0 1
may,alter,plasma 1.0 0.000143348623853 1 0 1
may,alter,a 1.0 0.000143348623853 1 0 1
may,also,potentiate 1.0 0.000143348623853 1 0 1
may,also,interfere 1.0 0.000143348623853 1 0 1
may,also,adversely 1.0 0.000143348623853 1 0 1
may,affect,gastrointestinal 1.0 0.000143348623853 1 0 1
maxipime,because,of 1.0 0.000143348623853 1 0 1
maximum,plasma,concentrations 1.0 0.000143348623853 1 0 1
maximum,human,therapeutic 1.0 0.000143348623853 1 0 1
maximum,cumulative,doses 1.0 0.000143348623853 1 0 1
maximum,concentration,increased 1.0 0.000143348623853 1 0 1
maximum,block,following 1.0 0.000143348623853 1 0 1
maximum,approved,prescription 1.0 0.000143348623853 1 0 1
maximal,to,days 1.0 0.000143348623853 1 0 1
max,of,was 1.0 0.000143348623853 1 0 1
max,is,about 1.0 0.000143348623853 1 0 1
max,decreased,by 1.0 0.000143348623853 1 0 1
max,by,and 1.0 0.000143348623853 1 0 1
matrix,may,increase 1.0 0.000143348623853 1 0 1
mask,the,residual 1.0 0.000143348623853 1 0 1
marrow,suppression,by 1.0 0.000143348623853 1 0 1
marrow,depression,such 1.0 0.000143348623853 1 0 1
marketing,observations,have 1.0 0.000143348623853 1 0 1
marketing,experiences,of 1.0 0.000143348623853 1 0 1
marketed,chewable,dispersible 1.0 0.000143348623853 1 0 1
markers,that,identify 1.0 0.000143348623853 1 0 1
markedly,reduced,or 1.0 0.000143348623853 1 0 1
markedly,increases,the 1.0 0.000143348623853 1 0 1
markedly,increased,the 1.0 0.000143348623853 1 0 1
markedly,increased,plasma 1.0 0.000143348623853 1 0 1
markedly,decreased,even 1.0 0.000143348623853 1 0 1
marked,interference,with 1.0 0.000143348623853 1 0 1
marked,hypertension,and 1.0 0.000143348623853 1 0 1
marked,effect,on 1.0 0.000143348623853 1 0 1
marked,changes,in 1.0 0.000143348623853 1 0 1
marked,bradycardia,or 1.0 0.000143348623853 1 0 1
marked,and,persistent 1.0 0.000143348623853 1 0 1
maois,selegiline,hydrochloride 1.0 0.000143348623853 1 0 1
maois,or,within 1.0 0.000143348623853 1 0 1
maois,may,increase 1.0 0.000143348623853 1 0 1
maois,may,enhance 1.0 0.000143348623853 1 0 1
maoi,within,days 1.0 0.000143348623853 1 0 1
maoi,there,have 1.0 0.000143348623853 1 0 1
maoi,maoi,could 1.0 0.000143348623853 1 0 1
maoi,could,theoretically 1.0 0.000143348623853 1 0 1
mao-inhibitors,with,hepatotoxic 1.0 0.000143348623853 1 0 1
mao,inhibitors,within 1.0 0.000143348623853 1 0 1
mao,inhibitors,studies 1.0 0.000143348623853 1 0 1
mao,inhibitors,or 1.0 0.000143348623853 1 0 1
mao,inhibitors,in 1.0 0.000143348623853 1 0 1
mao,inhibitors,has 1.0 0.000143348623853 1 0 1
mao,inhibitors,duragesic 1.0 0.000143348623853 1 0 1
mao,inhibitors,because 1.0 0.000143348623853 1 0 1
mao,inhibitor,plus 1.0 0.000143348623853 1 0 1
mao,inhibitor,may 1.0 0.000143348623853 1 0 1
mao,inhibitor,class 1.0 0.000143348623853 1 0 1
mao,inhibitor,and 1.0 0.000143348623853 1 0 1
many,angiotensin-converting,enzyme 1.0 0.000143348623853 1 0 1
manner,when,was 1.0 0.000143348623853 1 0 1
manner,the,tail-flick 1.0 0.000143348623853 1 0 1
manifestation,of,corneal 1.0 0.000143348623853 1 0 1
management,of,malignant 1.0 0.000143348623853 1 0 1
management,of,angina 1.0 0.000143348623853 1 0 1
man,the,c 1.0 0.000143348623853 1 0 1
man,include,aminosalicylic 1.0 0.000143348623853 1 0 1
malignant,hyperthermia,crisis 1.0 0.000143348623853 1 0 1
malignant,cells,this 1.0 0.000143348623853 1 0 1
males,and,in 1.0 0.000143348623853 1 0 1
maleate,or,mao-inhibitors 1.0 0.000143348623853 1 0 1
maleate,mg,tid 1.0 0.000143348623853 1 0 1
maleate,mg,qd 1.0 0.000143348623853 1 0 1
maleate,its,dose 1.0 0.000143348623853 1 0 1
male,volunteers,treatment 1.0 0.000143348623853 1 0 1
male,volunteers,ingesting 1.0 0.000143348623853 1 0 1
male,subjects,increased 1.0 0.000143348623853 1 0 1
male,subjects,ages 1.0 0.000143348623853 1 0 1
male,rats,hydrochloride 1.0 0.000143348623853 1 0 1
major,psychotic,disorders 1.0 0.000143348623853 1 0 1
major,enzyme,responsible 1.0 0.000143348623853 1 0 1
major,contributing,factor 1.0 0.000143348623853 1 0 1
major,clinical,importance 1.0 0.000143348623853 1 0 1
major,bleeding,events 1.0 0.000143348623853 1 0 1
major,are,also 1.0 0.000143348623853 1 0 1
maintenance,schedule,of 1.0 0.000143348623853 1 0 1
maintenance,dosing,lower 1.0 0.000143348623853 1 0 1
maintenance,doses,or 1.0 0.000143348623853 1 0 1
maintenance,dose,should 1.0 0.000143348623853 1 0 1
maintenance,dose,and 1.0 0.000143348623853 1 0 1
maintained,patients,beginning 1.0 0.000143348623853 1 0 1
maintained,on,the 1.0 0.000143348623853 1 0 1
maintained,on,gm 1.0 0.000143348623853 1 0 1
maintained,between,the 1.0 0.000143348623853 1 0 1
maintain,trough,concentrations 1.0 0.000143348623853 1 0 1
maintain,levels,limit 1.0 0.000143348623853 1 0 1
mainly,responsible,for 1.0 0.000143348623853 1 0 1
mainly,metabolized,by 1.0 0.000143348623853 1 0 1
main,hemostatic,defense 1.0 0.000143348623853 1 0 1
magnitude,of,changes 1.0 0.000143348623853 1 0 1
magnesium-containing,concomitant,administration 1.0 0.000143348623853 1 0 1
magnesium-,and,or 1.0 0.000143348623853 1 0 1
magnesium-,and,aluminum-containing 1.0 0.000143348623853 1 0 1
made,with,any 1.0 0.000143348623853 1 0 1
macrolide,inhibit,the 1.0 0.000143348623853 1 0 1
macrolide,have,been 1.0 0.000143348623853 1 0 1
macrolide,class,resulting 1.0 0.000143348623853 1 0 1
macrolide,azole,antifungal 1.0 0.000143348623853 1 0 1
macrolide,antibiotics,such 1.0 0.000143348623853 1 0 1
macrolide,and,other 1.0 0.000143348623853 1 0 1
macrolide,and,may 1.0 0.000143348623853 1 0 1
mac,was,depressed 1.0 0.000143348623853 1 0 1
maalox,reduced,the 1.0 0.000143348623853 1 0 1
maalox,maalox,reduced 1.0 0.000143348623853 1 0 1
maalox,decreased,auc 1.0 0.000143348623853 1 0 1
m2,given,as 1.0 0.000143348623853 1 0 1
m2,basis,to 1.0 0.000143348623853 1 0 1
m2,basis,appears 1.0 0.000143348623853 1 0 1
m2,and,or 1.0 0.000143348623853 1 0 1
m1,the,active 1.0 0.000143348623853 1 0 1
m1,peak,levels 1.0 0.000143348623853 1 0 1
m-toluamide,a,common 1.0 0.000143348623853 1 0 1
m-tco,injection,with 1.0 0.000143348623853 1 0 1
m,ptx,m 1.0 0.000143348623853 1 0 1
m,parenteral,should 1.0 0.000143348623853 1 0 1
m,min,in 1.0 0.000143348623853 1 0 1
m,markedly,increased 1.0 0.000143348623853 1 0 1
m,m,m 1.0 0.000143348623853 1 0 1
m,m,i 1.0 0.000143348623853 1 0 1
m,inhibits,proliferation 1.0 0.000143348623853 1 0 1
m,i,mg 1.0 0.000143348623853 1 0 1
m,g,ml 1.0 0.000143348623853 1 0 1
m,g,h 1.0 0.000143348623853 1 0 1
m,failed,to 1.0 0.000143348623853 1 0 1
m,enhance,the 1.0 0.000143348623853 1 0 1
lymphocytopenia,has,been 1.0 0.000143348623853 1 0 1
lymphatic,invasion,of 1.0 0.000143348623853 1 0 1
lying,the,interference 1.0 0.000143348623853 1 0 1
lowest,recommended,dose 1.0 0.000143348623853 1 0 1
lowest,possible,dose 1.0 0.000143348623853 1 0 1
lowest,effective,dose 1.0 0.000143348623853 1 0 1
lowers,the,serum 1.0 0.000143348623853 1 0 1
lowering,the,rate 1.0 0.000143348623853 1 0 1
lowering,the,plasma 1.0 0.000143348623853 1 0 1
lowering,of,the 1.0 0.000143348623853 1 0 1
lowering,effects,of 1.0 0.000143348623853 1 0 1
lowered,blood,levels 1.0 0.000143348623853 1 0 1
lower,when,the 1.0 0.000143348623853 1 0 1
lower,the,plasma 1.0 0.000143348623853 1 0 1
lower,the,degree 1.0 0.000143348623853 1 0 1
lower,than,those 1.0 0.000143348623853 1 0 1
lower,seizure,threshold 1.0 0.000143348623853 1 0 1
lower,rate,of 1.0 0.000143348623853 1 0 1
lower,pulmonary,wedge 1.0 0.000143348623853 1 0 1
lower,plasma,levels 1.0 0.000143348623853 1 0 1
lower,meclofenamate,sodium 1.0 0.000143348623853 1 0 1
lower,maintenance,doses 1.0 0.000143348623853 1 0 1
lower,intestine,so 1.0 0.000143348623853 1 0 1
lower,in,patients 1.0 0.000143348623853 1 0 1
lower,in,epileptic 1.0 0.000143348623853 1 0 1
lower,end,of 1.0 0.000143348623853 1 0 1
lower,doses,because 1.0 0.000143348623853 1 0 1
lower,and,the 1.0 0.000143348623853 1 0 1
lower,and,exposure 1.0 0.000143348623853 1 0 1
lower,affinity,for 1.0 0.000143348623853 1 0 1
low-dose,with,vioxx 1.0 0.000143348623853 1 0 1
low-dose,microg,kg 1.0 0.000143348623853 1 0 1
low-dose,hcl,and 1.0 0.000143348623853 1 0 1
low-dose,has,been 1.0 0.000143348623853 1 0 1
low,erpf,and 1.0 0.000143348623853 1 0 1
lotensin,can,be 1.0 0.000143348623853 1 0 1
lotensin,can,attenuate 1.0 0.000143348623853 1 0 1
loss,of,symptom 1.0 0.000143348623853 1 0 1
loss,compared,with 1.0 0.000143348623853 1 0 1
lorazepam,injection,like 1.0 0.000143348623853 1 0 1
loop,such,as 1.0 0.000143348623853 1 0 1
loop,potassium-,sparing 1.0 0.000143348623853 1 0 1
loop,or,thiazide 1.0 0.000143348623853 1 0 1
longer,than,weeks 1.0 0.000143348623853 1 0 1
longer,intervals,between 1.0 0.000143348623853 1 0 1
long-term,therapy,eg 1.0 0.000143348623853 1 0 1
long-term,suppression,of 1.0 0.000143348623853 1 0 1
long-acting,or,who 1.0 0.000143348623853 1 0 1
long-,term,therapy 1.0 0.000143348623853 1 0 1
long,surgical,procedures 1.0 0.000143348623853 1 0 1
long,lasting,depletions 1.0 0.000143348623853 1 0 1
long,as,plasma 1.0 0.000143348623853 1 0 1
long,acting,triclofos 1.0 0.000143348623853 1 0 1
lodine,like,other 1.0 0.000143348623853 1 0 1
lodine,is,administered 1.0 0.000143348623853 1 0 1
lodine,capsules,and 1.0 0.000143348623853 1 0 1
lodine,can,reduce 1.0 0.000143348623853 1 0 1
lodine,and,is 1.0 0.000143348623853 1 0 1
local,which,contain 1.0 0.000143348623853 1 0 1
local,since,the 1.0 0.000143348623853 1 0 1
local,or,agents 1.0 0.000143348623853 1 0 1
local,including,both 1.0 0.000143348623853 1 0 1
local,and,para-aminobenzoic 1.0 0.000143348623853 1 0 1
liver,which,in 1.0 0.000143348623853 1 0 1
liver,microsomes,inhibition 1.0 0.000143348623853 1 0 1
liver,is,prevented 1.0 0.000143348623853 1 0 1
liver,enzymes,was 1.0 0.000143348623853 1 0 1
liver,enzymes,is 1.0 0.000143348623853 1 0 1
liver,enzyme,abnormalities 1.0 0.000143348623853 1 0 1
liver,and,in 1.0 0.000143348623853 1 0 1
liver,alt,and 1.0 0.000143348623853 1 0 1
live-attenuated,should,not 1.0 0.000143348623853 1 0 1
live,typhoid,attenuation 1.0 0.000143348623853 1 0 1
live,or,inactivated 1.0 0.000143348623853 1 0 1
live,and,live-attenuated 1.0 0.000143348623853 1 0 1
little,change,in 1.0 0.000143348623853 1 0 1
lithiums,renal,clearance 1.0 0.000143348623853 1 0 1
lithium,valdecoxib,mg 1.0 0.000143348623853 1 0 1
lithium,toxicity,was 1.0 0.000143348623853 1 0 1
lithium,should,generally 1.0 0.000143348623853 1 0 1
lithium,serum,concentrations 1.0 0.000143348623853 1 0 1
lithium,reversible,increases 1.0 0.000143348623853 1 0 1
lithium,nonsteroidal,agents 1.0 0.000143348623853 1 0 1
lithium,lithium,should 1.0 0.000143348623853 1 0 1
lithium,in,a 1.0 0.000143348623853 1 0 1
lithium,ibuprofen,produced 1.0 0.000143348623853 1 0 1
lithium,diclofenac,decreases 1.0 0.000143348623853 1 0 1
literature,suggest,that 1.0 0.000143348623853 1 0 1
literature,revealed,that 1.0 0.000143348623853 1 0 1
literature,reports,suggesting 1.0 0.000143348623853 1 0 1
literature,reports,indicate 1.0 0.000143348623853 1 0 1
literature,article,reported 1.0 0.000143348623853 1 0 1
liter,potentiated,the 1.0 0.000143348623853 1 0 1
listed,below,drugs 1.0 0.000143348623853 1 0 1
lipolytic,activity,and 1.0 0.000143348623853 1 0 1
lipitor,atromid-s,neoral 1.0 0.000143348623853 1 0 1
lipid,peroxidation,which 1.0 0.000143348623853 1 0 1
lipid,levels,is 1.0 0.000143348623853 1 0 1
lincomycin,has,been 1.0 0.000143348623853 1 0 1
limited,to,other 1.0 0.000143348623853 1 0 1
limited,therefore,consideration 1.0 0.000143348623853 1 0 1
limited,in,vivo 1.0 0.000143348623853 1 0 1
limited,data,in 1.0 0.000143348623853 1 0 1
limited,clinical,experience 1.0 0.000143348623853 1 0 1
limit,adverse,experiences 1.0 0.000143348623853 1 0 1
likely,will,interfere 1.0 0.000143348623853 1 0 1
likely,viracept,should 1.0 0.000143348623853 1 0 1
likely,to,outweigh 1.0 0.000143348623853 1 0 1
likely,to,lead 1.0 0.000143348623853 1 0 1
likely,to,interfere 1.0 0.000143348623853 1 0 1
likely,to,increase 1.0 0.000143348623853 1 0 1
likely,that,the 1.0 0.000143348623853 1 0 1
likely,by,inhibition 1.0 0.000143348623853 1 0 1
likelihood,of,substantial 1.0 0.000143348623853 1 0 1
likelihood,of,congestive 1.0 0.000143348623853 1 0 1
like,other,may 1.0 0.000143348623853 1 0 1
like,other,injectable 1.0 0.000143348623853 1 0 1
like,other,ace 1.0 0.000143348623853 1 0 1
like,mptp,produced 1.0 0.000143348623853 1 0 1
like,monoamine,oxidase 1.0 0.000143348623853 1 0 1
like,may,enhance 1.0 0.000143348623853 1 0 1
like,due,to 1.0 0.000143348623853 1 0 1
like,aleve,or 1.0 0.000143348623853 1 0 1
light,zone,and 1.0 0.000143348623853 1 0 1
light,meal,h 1.0 0.000143348623853 1 0 1
life-threatening,interactions,with 1.0 0.000143348623853 1 0 1
life-,threatening,cardiac 1.0 0.000143348623853 1 0 1
life,of,and 1.0 0.000143348623853 1 0 1
lexapro,for,days 1.0 0.000143348623853 1 0 1
lexapro,did,not 1.0 0.000143348623853 1 0 1
levsin,is,administered 1.0 0.000143348623853 1 0 1
levothyroxine,sodium,absorption 1.0 0.000143348623853 1 0 1
levodopa,and,amantadine 1.0 0.000143348623853 1 0 1
levo-dromoran,with,all 1.0 0.000143348623853 1 0 1
levo-dromoran,has,been 1.0 0.000143348623853 1 0 1
levels,with,co-administration 1.0 0.000143348623853 1 0 1
levels,were,unaffected 1.0 0.000143348623853 1 0 1
levels,were,seen 1.0 0.000143348623853 1 0 1
levels,were,decreased 1.0 0.000143348623853 1 0 1
levels,were,also 1.0 0.000143348623853 1 0 1
levels,was,seen 1.0 0.000143348623853 1 0 1
levels,was,observed 1.0 0.000143348623853 1 0 1
levels,total,auc 1.0 0.000143348623853 1 0 1
levels,to,continue 1.0 0.000143348623853 1 0 1
levels,to,below 1.0 0.000143348623853 1 0 1
levels,the,potential 1.0 0.000143348623853 1 0 1
levels,the,dose 1.0 0.000143348623853 1 0 1
levels,suggesting,that 1.0 0.000143348623853 1 0 1
levels,resulting,in 1.0 0.000143348623853 1 0 1
levels,possibly,by 1.0 0.000143348623853 1 0 1
levels,or,may 1.0 0.000143348623853 1 0 1
levels,or,increase 1.0 0.000143348623853 1 0 1
levels,or,activity 1.0 0.000143348623853 1 0 1
levels,of,unchanged 1.0 0.000143348623853 1 0 1
levels,of,tricyclic 1.0 0.000143348623853 1 0 1
levels,of,to 1.0 0.000143348623853 1 0 1
levels,of,several 1.0 0.000143348623853 1 0 1
levels,of,if 1.0 0.000143348623853 1 0 1
levels,of,however 1.0 0.000143348623853 1 0 1
levels,of,duloxetine 1.0 0.000143348623853 1 0 1
levels,of,clozapine 1.0 0.000143348623853 1 0 1
levels,of,but 1.0 0.000143348623853 1 0 1
levels,of,are 1.0 0.000143348623853 1 0 1
levels,of,antidepressant 1.0 0.000143348623853 1 0 1
levels,of,although 1.0 0.000143348623853 1 0 1
levels,of,agents 1.0 0.000143348623853 1 0 1
levels,occurred,at 1.0 0.000143348623853 1 0 1
levels,monitored,after 1.0 0.000143348623853 1 0 1
levels,limit,adverse 1.0 0.000143348623853 1 0 1
levels,is,likely 1.0 0.000143348623853 1 0 1
levels,increased,by 1.0 0.000143348623853 1 0 1
levels,increased,approximately 1.0 0.000143348623853 1 0 1
levels,in,of 1.0 0.000143348623853 1 0 1
levels,in,cerebral 1.0 0.000143348623853 1 0 1
levels,in,all 1.0 0.000143348623853 1 0 1
levels,has,been 1.0 0.000143348623853 1 0 1
levels,during,toradol 1.0 0.000143348623853 1 0 1
levels,carbamazepine,levels 1.0 0.000143348623853 1 0 1
levels,by,compared 1.0 0.000143348623853 1 0 1
levels,at,some 1.0 0.000143348623853 1 0 1
levels,and,weight 1.0 0.000143348623853 1 0 1
levels,and,valproic 1.0 0.000143348623853 1 0 1
levels,and,urinary 1.0 0.000143348623853 1 0 1
levels,and,there 1.0 0.000143348623853 1 0 1
levels,and,slight 1.0 0.000143348623853 1 0 1
levels,and,prolong 1.0 0.000143348623853 1 0 1
levels,and,lessened 1.0 0.000143348623853 1 0 1
levels,and,increase 1.0 0.000143348623853 1 0 1
levels,and,extends 1.0 0.000143348623853 1 0 1
levels,and,efficacy 1.0 0.000143348623853 1 0 1
levels,and,compromise 1.0 0.000143348623853 1 0 1
levels,and,cardiovascular 1.0 0.000143348623853 1 0 1
levels,and,area-under 1.0 0.000143348623853 1 0 1
levels,and,adjustment 1.0 0.000143348623853 1 0 1
level,to,alert 1.0 0.000143348623853 1 0 1
level,that,has 1.0 0.000143348623853 1 0 1
level,of,when 1.0 0.000143348623853 1 0 1
level,of,was 1.0 0.000143348623853 1 0 1
level,of,exposure 1.0 0.000143348623853 1 0 1
level,of,acidity 1.0 0.000143348623853 1 0 1
level,in,the 1.0 0.000143348623853 1 0 1
level,however,is 1.0 0.000143348623853 1 0 1
level,has,been 1.0 0.000143348623853 1 0 1
level,dosage,adjustment 1.0 0.000143348623853 1 0 1
level,determinations,of 1.0 0.000143348623853 1 0 1
levamisole,hydrochloride,has 1.0 0.000143348623853 1 0 1
leukopenic,activity,of 1.0 0.000143348623853 1 0 1
leukocytosis,elevated,serum 1.0 0.000143348623853 1 0 1
leukocyte,transfusions,acute 1.0 0.000143348623853 1 0 1
leukemia,in,the 1.0 0.000143348623853 1 0 1
leucovorin,the,concentration 1.0 0.000143348623853 1 0 1
leucovorin,may,enhance 1.0 0.000143348623853 1 0 1
lethargy,fever,tremulousness 1.0 0.000143348623853 1 0 1
lethargy,and,somnolence 1.0 0.000143348623853 1 0 1
lethargy,and,coma 1.0 0.000143348623853 1 0 1
lesser,extent,of 1.0 0.000143348623853 1 0 1
lessened,physiologic,activity 1.0 0.000143348623853 1 0 1
less,than,two-second 1.0 0.000143348623853 1 0 1
less,than,two-fold 1.0 0.000143348623853 1 0 1
less,than,pediatrics 1.0 0.000143348623853 1 0 1
less,than,additive 1.0 0.000143348623853 1 0 1
less,pronounced,effect 1.0 0.000143348623853 1 0 1
less,frequent,maintenance 1.0 0.000143348623853 1 0 1
less,effective,while 1.0 0.000143348623853 1 0 1
less,alteration,in 1.0 0.000143348623853 1 0 1
less,active,isomer 1.0 0.000143348623853 1 0 1
lesions,in,rats 1.0 0.000143348623853 1 0 1
lesions,as,a 1.0 0.000143348623853 1 0 1
leprosy-associated,inflammatory,reactions 1.0 0.000143348623853 1 0 1
lengthened,and,the 1.0 0.000143348623853 1 0 1
led,to,elevated 1.0 0.000143348623853 1 0 1
led,to,an 1.0 0.000143348623853 1 0 1
led,to,a 1.0 0.000143348623853 1 0 1
least,two,weeks 1.0 0.000143348623853 1 0 1
least,partially,related 1.0 0.000143348623853 1 0 1
least,minutes,before 1.0 0.000143348623853 1 0 1
least,hours,following 1.0 0.000143348623853 1 0 1
least,halved,and 1.0 0.000143348623853 1 0 1
least,days,should 1.0 0.000143348623853 1 0 1
least,a,twofold 1.0 0.000143348623853 1 0 1
leads,to,higher 1.0 0.000143348623853 1 0 1
leads,to,an 1.0 0.000143348623853 1 0 1
leading,to,inter-patient 1.0 0.000143348623853 1 0 1
leading,to,alterations 1.0 0.000143348623853 1 0 1
lead,to,resulting 1.0 0.000143348623853 1 0 1
lead,to,phenytoin 1.0 0.000143348623853 1 0 1
lead,to,hypotension 1.0 0.000143348623853 1 0 1
lead,to,elevated 1.0 0.000143348623853 1 0 1
lead,to,electrolyte 1.0 0.000143348623853 1 0 1
lead,to,decreased 1.0 0.000143348623853 1 0 1
ld50,of,with 1.0 0.000143348623853 1 0 1
latter,agents,when 1.0 0.000143348623853 1 0 1
later,also,produces 1.0 0.000143348623853 1 0 1
lasting,depletions,of 1.0 0.000143348623853 1 0 1
last,subcutaneous,dose 1.0 0.000143348623853 1 0 1
last,intravenous,dose 1.0 0.000143348623853 1 0 1
large,reduction,in 1.0 0.000143348623853 1 0 1
large,amounts,may 1.0 0.000143348623853 1 0 1
lanoxin,lanoxicaps,that 1.0 0.000143348623853 1 0 1
lanoxicaps,that,gets 1.0 0.000143348623853 1 0 1
lamprene,have,not 1.0 0.000143348623853 1 0 1
lamivudine,in,vitro 1.0 0.000143348623853 1 0 1
lamivudine,and,may 1.0 0.000143348623853 1 0 1
lactulose-induced,drop,in 1.0 0.000143348623853 1 0 1
laceration,especially,in 1.0 0.000143348623853 1 0 1
laboratory,tests,the 1.0 0.000143348623853 1 0 1
laboratory,testing,should 1.0 0.000143348623853 1 0 1
labetalol,hcl,is 1.0 0.000143348623853 1 0 1
labetalol,hcl,blunts 1.0 0.000143348623853 1 0 1
label,should,be 1.0 0.000143348623853 1 0 1
l-tyrosine,and,non-selective 1.0 0.000143348623853 1 0 1
l-phenylalanine,may,potentiate 1.0 0.000143348623853 1 0 1
l-phenylalanine,and,the 1.0 0.000143348623853 1 0 1
l-phenylalanine,and,non-selective 1.0 0.000143348623853 1 0 1
l-methionine,may,decrease 1.0 0.000143348623853 1 0 1
l-histidine,was,observed 1.0 0.000143348623853 1 0 1
l-histidine,via,its 1.0 0.000143348623853 1 0 1
l-glutamine,and,may 1.0 0.000143348623853 1 0 1
l-glutamine,and,human 1.0 0.000143348623853 1 0 1
l-arginine,supplements,theoretically 1.0 0.000143348623853 1 0 1
l-arginine,supplements,taken 1.0 0.000143348623853 1 0 1
l-arginine,may,increase 1.0 0.000143348623853 1 0 1
l-arginine,may,counteract 1.0 0.000143348623853 1 0 1
l,kg,h 1.0 0.000143348623853 1 0 1
l,from,on 1.0 0.000143348623853 1 0 1
l,and,by 1.0 0.000143348623853 1 0 1
krm-1648,exhibited,strong 1.0 0.000143348623853 1 0 1
known,to,slow 1.0 0.000143348623853 1 0 1
known,to,raise 1.0 0.000143348623853 1 0 1
known,to,alter 1.0 0.000143348623853 1 0 1
known,that,patients 1.0 0.000143348623853 1 0 1
known,that,cyp1a2 1.0 0.000143348623853 1 0 1
known,side,effects 1.0 0.000143348623853 1 0 1
known,property,of 1.0 0.000143348623853 1 0 1
known,photosensitizing,agents 1.0 0.000143348623853 1 0 1
known,microsomal,enzyme 1.0 0.000143348623853 1 0 1
known,if,the 1.0 0.000143348623853 1 0 1
known,hence,is 1.0 0.000143348623853 1 0 1
known,enzyme,induction 1.0 0.000143348623853 1 0 1
known,enzyme,inducers 1.0 0.000143348623853 1 0 1
known,enzyme,inducer 1.0 0.000143348623853 1 0 1
known,cyp3a4,inducers 1.0 0.000143348623853 1 0 1
known,caution,is 1.0 0.000143348623853 1 0 1
know,if,you 1.0 0.000143348623853 1 0 1
kingdom,with,foscavir 1.0 0.000143348623853 1 0 1
kineret,and,therapy 1.0 0.000143348623853 1 0 1
kineret,and,developed 1.0 0.000143348623853 1 0 1
kind,with,mefloquine 1.0 0.000143348623853 1 0 1
kill,even,experienced 1.0 0.000143348623853 1 0 1
kill,curves,with 1.0 0.000143348623853 1 0 1
kg,x,ed95 1.0 0.000143348623853 1 0 1
kg,with,an 1.0 0.000143348623853 1 0 1
kg,weight,w 1.0 0.000143348623853 1 0 1
kg,was,significantly 1.0 0.000143348623853 1 0 1
kg,w,in 1.0 0.000143348623853 1 0 1
kg,via,dehydrogenase 1.0 0.000143348623853 1 0 1
kg,removes,the 1.0 0.000143348623853 1 0 1
kg,on,the 1.0 0.000143348623853 1 0 1
kg,on,balance 1.0 0.000143348623853 1 0 1
kg,ip,or 1.0 0.000143348623853 1 0 1
kg,injected,with 1.0 0.000143348623853 1 0 1
kg,increased,mean 1.0 0.000143348623853 1 0 1
kg,hours,apart 1.0 0.000143348623853 1 0 1
kg,h,without 1.0 0.000143348623853 1 0 1
kg,for,up 1.0 0.000143348623853 1 0 1
kg,enhanced,and 1.0 0.000143348623853 1 0 1
kg,doses,increased 1.0 0.000143348623853 1 0 1
kg,diet,resulted 1.0 0.000143348623853 1 0 1
kg,decreased,the 1.0 0.000143348623853 1 0 1
kg,day,n 1.0 0.000143348623853 1 0 1
kg,day,groups 1.0 0.000143348623853 1 0 1
kg,day,group 1.0 0.000143348623853 1 0 1
key,pharmaceuticals,inc 1.0 0.000143348623853 1 0 1
ketoprofen,like,other 1.0 0.000143348623853 1 0 1
ketoconazole,tablets,may 1.0 0.000143348623853 1 0 1
ketoconazole,tablets,inhibit 1.0 0.000143348623853 1 0 1
ketoconazole,potential,interaction 1.0 0.000143348623853 1 0 1
ketoconazole,mg,once 1.0 0.000143348623853 1 0 1
ketoconazole,ketoconazole,has 1.0 0.000143348623853 1 0 1
ketoconazole,increased,mean 1.0 0.000143348623853 1 0 1
ketoconazole,in,healthy 1.0 0.000143348623853 1 0 1
ketoconazole,has,been 1.0 0.000143348623853 1 0 1
ketoconazole,combined,administration 1.0 0.000143348623853 1 0 1
ketoconazole,at,mg 1.0 0.000143348623853 1 0 1
ketoconazole,and,isoniazid 1.0 0.000143348623853 1 0 1
ketamine,when,administered 1.0 0.000143348623853 1 0 1
ketamine,marked,hypertension 1.0 0.000143348623853 1 0 1
keratoses,treated,with 1.0 0.000143348623853 1 0 1
kaolin-pectin,certain,anticancer 1.0 0.000143348623853 1 0 1
kaletra,norvir,viracept 1.0 0.000143348623853 1 0 1
kadian,ms,contin 1.0 0.000143348623853 1 0 1
k,the,net 1.0 0.000143348623853 1 0 1
k,oral,unreliable 1.0 0.000143348623853 1 0 1
k,can,antagonize 1.0 0.000143348623853 1 0 1
k,antagonists,should 1.0 0.000143348623853 1 0 1
k,antagonists,drugs 1.0 0.000143348623853 1 0 1
k,antagonists,are 1.0 0.000143348623853 1 0 1
juices,etc,lower 1.0 0.000143348623853 1 0 1
juice,and,other 1.0 0.000143348623853 1 0 1
judgment,of,the 1.0 0.000143348623853 1 0 1
johns,wort,theo-dur 1.0 0.000143348623853 1 0 1
iv,is,augmented 1.0 0.000143348623853 1 0 1
iv,injection,of 1.0 0.000143348623853 1 0 1
iv,im,reduced 1.0 0.000143348623853 1 0 1
iv,dose,should 1.0 0.000143348623853 1 0 1
iv,attenuate,loss 1.0 0.000143348623853 1 0 1
its,toxicity,may 1.0 0.000143348623853 1 0 1
its,synergism,with 1.0 0.000143348623853 1 0 1
its,structural,similarity 1.0 0.000143348623853 1 0 1
its,serum,levels 1.0 0.000143348623853 1 0 1
its,protein,binding 1.0 0.000143348623853 1 0 1
its,primary,cns 1.0 0.000143348623853 1 0 1
its,normal,dose 1.0 0.000143348623853 1 0 1
its,nephrotoxicity,may 1.0 0.000143348623853 1 0 1
its,metabolism,to 1.0 0.000143348623853 1 0 1
its,inhibitory,effect 1.0 0.000143348623853 1 0 1
its,effect,could 1.0 0.000143348623853 1 0 1
its,dose,should 1.0 0.000143348623853 1 0 1
its,dosage,reduced 1.0 0.000143348623853 1 0 1
its,derivatives,prothrombin 1.0 0.000143348623853 1 0 1
its,derivatives,or 1.0 0.000143348623853 1 0 1
its,derivatives,in 1.0 0.000143348623853 1 0 1
its,cellular,uptake 1.0 0.000143348623853 1 0 1
its,breakdown,products 1.0 0.000143348623853 1 0 1
its,active,hydroxy 1.0 0.000143348623853 1 0 1
its,action,on 1.0 0.000143348623853 1 0 1
its,absorption,from 1.0 0.000143348623853 1 0 1
its,abrupt,suppression 1.0 0.000143348623853 1 0 1
its,ability,to 1.0 0.000143348623853 1 0 1
itraconazole,with,oral 1.0 0.000143348623853 1 0 1
itraconazole,was,coadministered 1.0 0.000143348623853 1 0 1
itraconazole,therapy,and 1.0 0.000143348623853 1 0 1
itraconazole,plasma,concentrations 1.0 0.000143348623853 1 0 1
itraconazole,has,led 1.0 0.000143348623853 1 0 1
itraconazole,enhances,the 1.0 0.000143348623853 1 0 1
itraconazole,decreases,clearance 1.0 0.000143348623853 1 0 1
itraconazole,and,oral 1.0 0.000143348623853 1 0 1
itraconazole,and,or 1.0 0.000143348623853 1 0 1
itraconazole,and,may 1.0 0.000143348623853 1 0 1
it,was,found 1.0 0.000143348623853 1 0 1
it,was,co-administered 1.0 0.000143348623853 1 0 1
it,is,unclear 1.0 0.000143348623853 1 0 1
it,is,still 1.0 0.000143348623853 1 0 1
it,is,inadvisable 1.0 0.000143348623853 1 0 1
it,is,however 1.0 0.000143348623853 1 0 1
it,is,felt 1.0 0.000143348623853 1 0 1
it,is,believed 1.0 0.000143348623853 1 0 1
it,be,decided 1.0 0.000143348623853 1 0 1
it,appears,that 1.0 0.000143348623853 1 0 1
it,adversely,affected 1.0 0.000143348623853 1 0 1
isuprel,should,be 1.0 0.000143348623853 1 0 1
isozyme,including,and 1.0 0.000143348623853 1 0 1
isozyme,and,which 1.0 0.000143348623853 1 0 1
isozyme,and,it 1.0 0.000143348623853 1 0 1
isosorbide,mononitrate,may 1.0 0.000143348623853 1 0 1
isosorbide,dinitrate,may 1.0 0.000143348623853 1 0 1
isoproterenol,hydrochloride,injection 1.0 0.000143348623853 1 0 1
isoniazid,may,increase 1.0 0.000143348623853 1 0 1
isoniazid,is,known 1.0 0.000143348623853 1 0 1
isoniazid,is,also 1.0 0.000143348623853 1 0 1
isomer,of,racemic 1.0 0.000143348623853 1 0 1
isolated,cases,of 1.0 0.000143348623853 1 0 1
isolated,cases,a 1.0 0.000143348623853 1 0 1
isoform,also,involved 1.0 0.000143348623853 1 0 1
isoflurane,potentiates,the 1.0 0.000143348623853 1 0 1
isoflurane,or,administered 1.0 0.000143348623853 1 0 1
isoflurane,and,decrease 1.0 0.000143348623853 1 0 1
isoenzymes,caution,should 1.0 0.000143348623853 1 0 1
isoenzyme,macrolide,azole 1.0 0.000143348623853 1 0 1
isoenzyme,including,other 1.0 0.000143348623853 1 0 1
isoenzyme,including,certain 1.0 0.000143348623853 1 0 1
isoenzyme,in,vivo 1.0 0.000143348623853 1 0 1
isoenzyme,daily,doses 1.0 0.000143348623853 1 0 1
isocarboxazid,should,be 1.0 0.000143348623853 1 0 1
isocarboxazid,and,other 1.0 0.000143348623853 1 0 1
is,warranted,when 1.0 0.000143348623853 1 0 1
is,used,concurrently 1.0 0.000143348623853 1 0 1
is,used,at 1.0 0.000143348623853 1 0 1
is,used,alone 1.0 0.000143348623853 1 0 1
is,unknown,and 1.0 0.000143348623853 1 0 1
is,unclear,how 1.0 0.000143348623853 1 0 1
is,to,decrease 1.0 0.000143348623853 1 0 1
is,therefore,advisable 1.0 0.000143348623853 1 0 1
is,the,active 1.0 0.000143348623853 1 0 1
is,taken,with 1.0 0.000143348623853 1 0 1
is,suggested,to 1.0 0.000143348623853 1 0 1
is,still,advisable 1.0 0.000143348623853 1 0 1
is,started,or 1.0 0.000143348623853 1 0 1
is,started,in 1.0 0.000143348623853 1 0 1
is,some,potential 1.0 0.000143348623853 1 0 1
is,small,when 1.0 0.000143348623853 1 0 1
is,similar,to 1.0 0.000143348623853 1 0 1
is,significantly,reduced 1.0 0.000143348623853 1 0 1
is,shortened,in 1.0 0.000143348623853 1 0 1
is,required,concentrations 1.0 0.000143348623853 1 0 1
is,reduced,although 1.0 0.000143348623853 1 0 1
is,receiving,replacement 1.0 0.000143348623853 1 0 1
is,receiving,a 1.0 0.000143348623853 1 0 1
is,probably,secondary 1.0 0.000143348623853 1 0 1
is,prevented,by 1.0 0.000143348623853 1 0 1
is,potentiated,by 1.0 0.000143348623853 1 0 1
is,only,slightly 1.0 0.000143348623853 1 0 1
is,one,reported 1.0 0.000143348623853 1 0 1
is,not,totally 1.0 0.000143348623853 1 0 1
is,not,ordinarily 1.0 0.000143348623853 1 0 1
is,not,needed 1.0 0.000143348623853 1 0 1
is,not,due 1.0 0.000143348623853 1 0 1
is,not,advisable 1.0 0.000143348623853 1 0 1
is,normal,but 1.0 0.000143348623853 1 0 1
is,no,effect 1.0 0.000143348623853 1 0 1
is,minimally,absorbed 1.0 0.000143348623853 1 0 1
is,mildly,reduced 1.0 0.000143348623853 1 0 1
is,markedly,decreased 1.0 0.000143348623853 1 0 1
is,limited,therefore 1.0 0.000143348623853 1 0 1
is,likely,viracept 1.0 0.000143348623853 1 0 1
is,lengthened,and 1.0 0.000143348623853 1 0 1
is,insufficient,experience 1.0 0.000143348623853 1 0 1
is,initiated,to 1.0 0.000143348623853 1 0 1
is,initiated,adjusted 1.0 0.000143348623853 1 0 1
is,indicated,reduction 1.0 0.000143348623853 1 0 1
is,increased,when 1.0 0.000143348623853 1 0 1
is,increased,by 1.0 0.000143348623853 1 0 1
is,inadvisable,to 1.0 0.000143348623853 1 0 1
is,impaired,in 1.0 0.000143348623853 1 0 1
is,however,possible 1.0 0.000143348623853 1 0 1
is,given,should 1.0 0.000143348623853 1 0 1
is,generally,not 1.0 0.000143348623853 1 0 1
is,felt,that 1.0 0.000143348623853 1 0 1
is,eliminated,from 1.0 0.000143348623853 1 0 1
is,either,added 1.0 0.000143348623853 1 0 1
is,drawn,if 1.0 0.000143348623853 1 0 1
is,different,than 1.0 0.000143348623853 1 0 1
is,derived,from 1.0 0.000143348623853 1 0 1
is,contraindicated,and 1.0 0.000143348623853 1 0 1
is,co-administered,particularly 1.0 0.000143348623853 1 0 1
is,changed,by 1.0 0.000143348623853 1 0 1
is,believed,that 1.0 0.000143348623853 1 0 1
is,approximately,to 1.0 0.000143348623853 1 0 1
is,approximately,minutes 1.0 0.000143348623853 1 0 1
is,antagonized,by 1.0 0.000143348623853 1 0 1
is,an,interaction 1.0 0.000143348623853 1 0 1
is,also,taking 1.0 0.000143348623853 1 0 1
is,also,reported 1.0 0.000143348623853 1 0 1
is,advised,and 1.0 0.000143348623853 1 0 1
is,adsorption,of 1.0 0.000143348623853 1 0 1
is,administered,or 1.0 0.000143348623853 1 0 1
is,administered,in 1.0 0.000143348623853 1 0 1
is,administered,immediately 1.0 0.000143348623853 1 0 1
is,administered,at 1.0 0.000143348623853 1 0 1
is,adjusted,upward 1.0 0.000143348623853 1 0 1
is,added,of 1.0 0.000143348623853 1 0 1
is,accelerated,when 1.0 0.000143348623853 1 0 1
is,about,to 1.0 0.000143348623853 1 0 1
is,a,weak 1.0 0.000143348623853 1 0 1
is,a,single 1.0 0.000143348623853 1 0 1
is,a,significant 1.0 0.000143348623853 1 0 1
is,a,serotonin 1.0 0.000143348623853 1 0 1
is,a,risk 1.0 0.000143348623853 1 0 1
is,a,possible 1.0 0.000143348623853 1 0 1
is,a,novel 1.0 0.000143348623853 1 0 1
is,a,neutralizing 1.0 0.000143348623853 1 0 1
is,a,member 1.0 0.000143348623853 1 0 1
is,a,consequence 1.0 0.000143348623853 1 0 1
is,a,competitive 1.0 0.000143348623853 1 0 1
is,a,agonist 1.0 0.000143348623853 1 0 1
irritation,caution,should 1.0 0.000143348623853 1 0 1
irritability,and,may 1.0 0.000143348623853 1 0 1
irreversible,brain,damage 1.0 0.000143348623853 1 0 1
irrational,behavior,has 1.0 0.000143348623853 1 0 1
iron,supplements,and 1.0 0.000143348623853 1 0 1
iron,salts,may 1.0 0.000143348623853 1 0 1
iron,concomitant,administration 1.0 0.000143348623853 1 0 1
iressa,may,exacerbate 1.0 0.000143348623853 1 0 1
iressa,and,therefore 1.0 0.000143348623853 1 0 1
iressa,and,have 1.0 0.000143348623853 1 0 1
ipratropium,bromide,is 1.0 0.000143348623853 1 0 1
ip,the,effect 1.0 0.000143348623853 1 0 1
ip,or,vitamin 1.0 0.000143348623853 1 0 1
iodine,or,excess 1.0 0.000143348623853 1 0 1
iodinated,contrast,media 1.0 0.000143348623853 1 0 1
iodide,potentiates,other 1.0 0.000143348623853 1 0 1
iodide,i131,a 1.0 0.000143348623853 1 0 1
inwomen,taking,since 1.0 0.000143348623853 1 0 1
involving,the,latter 1.0 0.000143348623853 1 0 1
involving,renal,and 1.0 0.000143348623853 1 0 1
involving,nizoral,tablets 1.0 0.000143348623853 1 0 1
involving,metabolized,similarly 1.0 0.000143348623853 1 0 1
involving,inhibition,of 1.0 0.000143348623853 1 0 1
involving,healthy,subjects 1.0 0.000143348623853 1 0 1
involving,alprazolam,caution 1.0 0.000143348623853 1 0 1
involvement,of,the 1.0 0.000143348623853 1 0 1
involvement,of,other 1.0 0.000143348623853 1 0 1
invirase,kaletra,norvir 1.0 0.000143348623853 1 0 1
invirase,is,coadministered 1.0 0.000143348623853 1 0 1
investigated,using,higher 1.0 0.000143348623853 1 0 1
invasion,of,adenocarcinomas 1.0 0.000143348623853 1 0 1
intubating,dose,of 1.0 0.000143348623853 1 0 1
introduction,of,oral 1.0 0.000143348623853 1 0 1
introduction,of,beta 1.0 0.000143348623853 1 0 1
introduced,at,the 1.0 0.000143348623853 1 0 1
intrinsic,effect,its 1.0 0.000143348623853 1 0 1
intravenously,to,normal 1.0 0.000143348623853 1 0 1
intravenously,as,mg 1.0 0.000143348623853 1 0 1
intravenously,administered,mg 1.0 0.000143348623853 1 0 1
intravenous,was,shown 1.0 0.000143348623853 1 0 1
intravenous,unless,the 1.0 0.000143348623853 1 0 1
intravenous,or,other 1.0 0.000143348623853 1 0 1
intravenous,misuse,of 1.0 0.000143348623853 1 0 1
intravenous,may,have 1.0 0.000143348623853 1 0 1
intravenous,iv,injection 1.0 0.000143348623853 1 0 1
intravenous,is,required 1.0 0.000143348623853 1 0 1
intravenous,dose,or 1.0 0.000143348623853 1 0 1
intravenous,antagonists,should 1.0 0.000143348623853 1 0 1
intravenous,and,non-steroidal 1.0 0.000143348623853 1 0 1
intravenous,and,hivid 1.0 0.000143348623853 1 0 1
intravenous,and,brevibloc 1.0 0.000143348623853 1 0 1
intravenous,and,amphotericin 1.0 0.000143348623853 1 0 1
intravenous,amphotericin,b 1.0 0.000143348623853 1 0 1
intravascular,volume,depletion 1.0 0.000143348623853 1 0 1
intrathecal,micrograms,had 1.0 0.000143348623853 1 0 1
intrathecal,injection,of 1.0 0.000143348623853 1 0 1
intraperitoneally,ip,the 1.0 0.000143348623853 1 0 1
intraperitoneal,doses,of 1.0 0.000143348623853 1 0 1
intramuscular,injection,of 1.0 0.000143348623853 1 0 1
intracranial,pressure,their 1.0 0.000143348623853 1 0 1
intracranial,hypertension,some 1.0 0.000143348623853 1 0 1
intracellular,exposure,to 1.0 0.000143348623853 1 0 1
intoxication,prior,to 1.0 0.000143348623853 1 0 1
into,three,doses 1.0 0.000143348623853 1 0 1
into,the,systemic 1.0 0.000143348623853 1 0 1
into,consideration,when 1.0 0.000143348623853 1 0 1
into,account,bezalip 1.0 0.000143348623853 1 0 1
intestine,thus,impairing 1.0 0.000143348623853 1 0 1
intestine,so,that 1.0 0.000143348623853 1 0 1
intestinal,mucosa,caused 1.0 0.000143348623853 1 0 1
intestinal,adsorbents,and 1.0 0.000143348623853 1 0 1
intestinal,absorption,resulting 1.0 0.000143348623853 1 0 1
intervals,or,if 1.0 0.000143348623853 1 0 1
intervals,between,doses 1.0 0.000143348623853 1 0 1
interval,whole,blood 1.0 0.000143348623853 1 0 1
interval,were,less 1.0 0.000143348623853 1 0 1
interval,significantly,increased 1.0 0.000143348623853 1 0 1
interval,prolongation,ischemic 1.0 0.000143348623853 1 0 1
interval,must,not 1.0 0.000143348623853 1 0 1
interval,msec,was 1.0 0.000143348623853 1 0 1
interval,certain,or 1.0 0.000143348623853 1 0 1
interval,certain,including 1.0 0.000143348623853 1 0 1
interval,because,the 1.0 0.000143348623853 1 0 1
intersubject,variability,in 1.0 0.000143348623853 1 0 1
interleukin-1,antagonist,has 1.0 0.000143348623853 1 0 1
interleukin-1,antagonist,and 1.0 0.000143348623853 1 0 1
interindividual,variability,in 1.0 0.000143348623853 1 0 1
interfering,with,the 1.0 0.000143348623853 1 0 1
interferes,with,renal 1.0 0.000143348623853 1 0 1
interferes,minimally,or 1.0 0.000143348623853 1 0 1
interference,with,propranolols 1.0 0.000143348623853 1 0 1
interfere,with,serotonin 1.0 0.000143348623853 1 0 1
interfere,with,platelet-aggregation 1.0 0.000143348623853 1 0 1
interfere,with,intestinal 1.0 0.000143348623853 1 0 1
interfere,with,in 1.0 0.000143348623853 1 0 1
interfere,with,folate 1.0 0.000143348623853 1 0 1
interfere,with,blood 1.0 0.000143348623853 1 0 1
interactions,with,topical 1.0 0.000143348623853 1 0 1
interactions,with,mixed 1.0 0.000143348623853 1 0 1
interactions,with,carbamazepine 1.0 0.000143348623853 1 0 1
interactions,with,beta-blockers 1.0 0.000143348623853 1 0 1
interactions,with,antacids 1.0 0.000143348623853 1 0 1
interactions,when,is 1.0 0.000143348623853 1 0 1
interactions,when,co-administered 1.0 0.000143348623853 1 0 1
interactions,toxicity,associated 1.0 0.000143348623853 1 0 1
interactions,the,cns-depressant 1.0 0.000143348623853 1 0 1
interactions,the,central 1.0 0.000143348623853 1 0 1
interactions,of,humorsol 1.0 0.000143348623853 1 0 1
interactions,of,and 1.0 0.000143348623853 1 0 1
interactions,observed,in 1.0 0.000143348623853 1 0 1
interactions,must,be 1.0 0.000143348623853 1 0 1
interactions,may,be 1.0 0.000143348623853 1 0 1
interactions,given,the 1.0 0.000143348623853 1 0 1
interactions,for,include 1.0 0.000143348623853 1 0 1
interactions,food,cns 1.0 0.000143348623853 1 0 1
interactions,flupenthixol,may 1.0 0.000143348623853 1 0 1
interactions,benzodiazepines,benzodiazepines 1.0 0.000143348623853 1 0 1
interactions,attributed,to 1.0 0.000143348623853 1 0 1
interactions,and,clinical 1.0 0.000143348623853 1 0 1
interactions,albuterol,strattera 1.0 0.000143348623853 1 0 1
interaction,with,its 1.0 0.000143348623853 1 0 1
interaction,with,concomitantly 1.0 0.000143348623853 1 0 1
interaction,will,lead 1.0 0.000143348623853 1 0 1
interaction,whole,blood 1.0 0.000143348623853 1 0 1
interaction,which,has 1.0 0.000143348623853 1 0 1
interaction,use,of 1.0 0.000143348623853 1 0 1
interaction,this,report 1.0 0.000143348623853 1 0 1
interaction,study,evaluating 1.0 0.000143348623853 1 0 1
interaction,study,demonstrated 1.0 0.000143348623853 1 0 1
interaction,probably,is 1.0 0.000143348623853 1 0 1
interaction,or,should 1.0 0.000143348623853 1 0 1
interaction,of,this 1.0 0.000143348623853 1 0 1
interaction,of,ketoconazole 1.0 0.000143348623853 1 0 1
interaction,of,foscavir 1.0 0.000143348623853 1 0 1
interaction,observed,between 1.0 0.000143348623853 1 0 1
interaction,may,precipitate 1.0 0.000143348623853 1 0 1
interaction,is,likely 1.0 0.000143348623853 1 0 1
interaction,is,a 1.0 0.000143348623853 1 0 1
interaction,involving,the 1.0 0.000143348623853 1 0 1
interaction,for,the 1.0 0.000143348623853 1 0 1
interaction,between,wellbutrin 1.0 0.000143348623853 1 0 1
interaction,between,toradol 1.0 0.000143348623853 1 0 1
interaction,between,single 1.0 0.000143348623853 1 0 1
interaction,between,mao 1.0 0.000143348623853 1 0 1
interaction,between,clozapine 1.0 0.000143348623853 1 0 1
interaction,between,b12 1.0 0.000143348623853 1 0 1
interact,with,tylenol 1.0 0.000143348623853 1 0 1
interact,with,some 1.0 0.000143348623853 1 0 1
interact,with,mao 1.0 0.000143348623853 1 0 1
interact,with,increasing 1.0 0.000143348623853 1 0 1
interact,with,concurrently 1.0 0.000143348623853 1 0 1
interact,with,blood 1.0 0.000143348623853 1 0 1
interact,with,beta-adrenergic 1.0 0.000143348623853 1 0 1
interact,with,any 1.0 0.000143348623853 1 0 1
interact,with,antagonists 1.0 0.000143348623853 1 0 1
interact,with,amphotericin 1.0 0.000143348623853 1 0 1
interact,pharmacologically,with 1.0 0.000143348623853 1 0 1
inter-patient,variation,in 1.0 0.000143348623853 1 0 1
intentional,or,unintentional 1.0 0.000143348623853 1 0 1
intensify,the,effect 1.0 0.000143348623853 1 0 1
intensify,the,drying 1.0 0.000143348623853 1 0 1
intensify,the,antimuscarinic 1.0 0.000143348623853 1 0 1
intake,of,mineral 1.0 0.000143348623853 1 0 1
intake,for,longer 1.0 0.000143348623853 1 0 1
intake,approximately,one 1.0 0.000143348623853 1 0 1
intact,endothelium,from 1.0 0.000143348623853 1 0 1
insure,that,no 1.0 0.000143348623853 1 0 1
insulin-induced,proliferation,of 1.0 0.000143348623853 1 0 1
insufficient,to,produce 1.0 0.000143348623853 1 0 1
insufficient,plasma,and 1.0 0.000143348623853 1 0 1
insufficient,experience,to 1.0 0.000143348623853 1 0 1
insufficiency,hyperbilirubinemia,confusion 1.0 0.000143348623853 1 0 1
instituted,as,well 1.0 0.000143348623853 1 0 1
instead,of,mg 1.0 0.000143348623853 1 0 1
instances,synergism,in 1.0 0.000143348623853 1 0 1
instances,resulted,in 1.0 0.000143348623853 1 0 1
instances,of,life- 1.0 0.000143348623853 1 0 1
instances,of,interactions 1.0 0.000143348623853 1 0 1
instances,and,antagonism 1.0 0.000143348623853 1 0 1
instances,a,slight 1.0 0.000143348623853 1 0 1
instability,with,possible 1.0 0.000143348623853 1 0 1
inspra,mg,with 1.0 0.000143348623853 1 0 1
inspra,mg,combined 1.0 0.000143348623853 1 0 1
inspra,is,administered 1.0 0.000143348623853 1 0 1
inspra,and,nsaids 1.0 0.000143348623853 1 0 1
insp,together,with 1.0 0.000143348623853 1 0 1
inr,was,increased 1.0 0.000143348623853 1 0 1
inr,should,be 1.0 0.000143348623853 1 0 1
inr,international,normalized 1.0 0.000143348623853 1 0 1
inr,days,after 1.0 0.000143348623853 1 0 1
inotropic,such,as 1.0 0.000143348623853 1 0 1
inotropic,properties,and 1.0 0.000143348623853 1 0 1
inotropes,and,may 1.0 0.000143348623853 1 0 1
inomax,on,the 1.0 0.000143348623853 1 0 1
innovar,vet,or 1.0 0.000143348623853 1 0 1
innovar,or,but 1.0 0.000143348623853 1 0 1
injury,including,myocardial 1.0 0.000143348623853 1 0 1
injection,with,other 1.0 0.000143348623853 1 0 1
injection,with,a 1.0 0.000143348623853 1 0 1
injection,usp,to 1.0 0.000143348623853 1 0 1
injection,usp,is 1.0 0.000143348623853 1 0 1
injection,of,pipracil 1.0 0.000143348623853 1 0 1
injection,of,min 1.0 0.000143348623853 1 0 1
injection,of,mg 1.0 0.000143348623853 1 0 1
injection,of,insufficient 1.0 0.000143348623853 1 0 1
injection,of,in 1.0 0.000143348623853 1 0 1
injection,of,given 1.0 0.000143348623853 1 0 1
injection,lorazepam,injection 1.0 0.000143348623853 1 0 1
injection,like,other 1.0 0.000143348623853 1 0 1
injection,concentrate,should 1.0 0.000143348623853 1 0 1
injection,concentrate,and 1.0 0.000143348623853 1 0 1
injection,clonidine,may 1.0 0.000143348623853 1 0 1
injection,and,should 1.0 0.000143348623853 1 0 1
injection,and,potassium-depleting 1.0 0.000143348623853 1 0 1
injection,and,oral 1.0 0.000143348623853 1 0 1
injection,and,epidural 1.0 0.000143348623853 1 0 1
injection,and,chloride 1.0 0.000143348623853 1 0 1
injected,with,was 1.0 0.000143348623853 1 0 1
injectable,produces,depression 1.0 0.000143348623853 1 0 1
injectable,an,increased 1.0 0.000143348623853 1 0 1
initiation,of,the 1.0 0.000143348623853 1 0 1
initiation,of,itraconazole 1.0 0.000143348623853 1 0 1
initiation,of,combined 1.0 0.000143348623853 1 0 1
initiation,of,and 1.0 0.000143348623853 1 0 1
initiating,tcatreatment,in 1.0 0.000143348623853 1 0 1
initiating,extraneal,in 1.0 0.000143348623853 1 0 1
initiating,combination,therapy 1.0 0.000143348623853 1 0 1
initiating,and,discontinuing 1.0 0.000143348623853 1 0 1
initiating,adjusting,or 1.0 0.000143348623853 1 0 1
initiating,a,multi-day 1.0 0.000143348623853 1 0 1
initiates,or,discontinues 1.0 0.000143348623853 1 0 1
initiated,to,see 1.0 0.000143348623853 1 0 1
initiated,or,changed 1.0 0.000143348623853 1 0 1
initiated,at,the 1.0 0.000143348623853 1 0 1
initiated,as,a 1.0 0.000143348623853 1 0 1
initiated,apparent,oral 1.0 0.000143348623853 1 0 1
initiate,therapy,with 1.0 0.000143348623853 1 0 1
initial,release,of 1.0 0.000143348623853 1 0 1
initial,presentation,of 1.0 0.000143348623853 1 0 1
initial,oral,dose 1.0 0.000143348623853 1 0 1
initial,doses,and 1.0 0.000143348623853 1 0 1
initial,dose,until 1.0 0.000143348623853 1 0 1
initial,dosage,should 1.0 0.000143348623853 1 0 1
initial,and,maintenance 1.0 0.000143348623853 1 0 1
inhibits,the,renal 1.0 0.000143348623853 1 0 1
inhibits,the,gastrointestinal 1.0 0.000143348623853 1 0 1
inhibits,the,enzymatic 1.0 0.000143348623853 1 0 1
inhibits,the,effects 1.0 0.000143348623853 1 0 1
inhibits,the,cyp2c9 1.0 0.000143348623853 1 0 1
inhibits,the,bumetanide-induced 1.0 0.000143348623853 1 0 1
inhibits,the,biotransformation 1.0 0.000143348623853 1 0 1
inhibits,proliferation,stimulated 1.0 0.000143348623853 1 0 1
inhibits,platelet,function 1.0 0.000143348623853 1 0 1
inhibits,metabolism,which 1.0 0.000143348623853 1 0 1
inhibits,both,aldehyde 1.0 0.000143348623853 1 0 1
inhibitory,effect,for 1.0 0.000143348623853 1 0 1
inhibitory,activity,which 1.0 0.000143348623853 1 0 1
inhibitors,within,two 1.0 0.000143348623853 1 0 1
inhibitors,with,sprycel 1.0 0.000143348623853 1 0 1
inhibitors,was,delayed 1.0 0.000143348623853 1 0 1
inhibitors,was,associated 1.0 0.000143348623853 1 0 1
inhibitors,to,control 1.0 0.000143348623853 1 0 1
inhibitors,thereby,potentially 1.0 0.000143348623853 1 0 1
inhibitors,the,use 1.0 0.000143348623853 1 0 1
inhibitors,the,combined 1.0 0.000143348623853 1 0 1
inhibitors,that,have 1.0 0.000143348623853 1 0 1
inhibitors,studies,in 1.0 0.000143348623853 1 0 1
inhibitors,ssris,ssris 1.0 0.000143348623853 1 0 1
inhibitors,ssris,may 1.0 0.000143348623853 1 0 1
inhibitors,serotonin,reuptake 1.0 0.000143348623853 1 0 1
inhibitors,result,in 1.0 0.000143348623853 1 0 1
inhibitors,rare,instances 1.0 0.000143348623853 1 0 1
inhibitors,psychotropic,medications 1.0 0.000143348623853 1 0 1
inhibitors,or,with 1.0 0.000143348623853 1 0 1
inhibitors,or,substrates 1.0 0.000143348623853 1 0 1
inhibitors,or,known 1.0 0.000143348623853 1 0 1
inhibitors,or,because 1.0 0.000143348623853 1 0 1
inhibitors,of,possible 1.0 0.000143348623853 1 0 1
inhibitors,of,endogenous 1.0 0.000143348623853 1 0 1
inhibitors,of,cyp1a2 1.0 0.000143348623853 1 0 1
inhibitors,of,c 1.0 0.000143348623853 1 0 1
inhibitors,of,av 1.0 0.000143348623853 1 0 1
inhibitors,nnrtis,nevirapine 1.0 0.000143348623853 1 0 1
inhibitors,nalidixic,acid 1.0 0.000143348623853 1 0 1
inhibitors,mg,bid 1.0 0.000143348623853 1 0 1
inhibitors,may,potentiate 1.0 0.000143348623853 1 0 1
inhibitors,maois,selegiline 1.0 0.000143348623853 1 0 1
inhibitors,maoi,there 1.0 0.000143348623853 1 0 1
inhibitors,maoi,maoi 1.0 0.000143348623853 1 0 1
inhibitors,long-term,suppression 1.0 0.000143348623853 1 0 1
inhibitors,indinavir,mg 1.0 0.000143348623853 1 0 1
inhibitors,including,quinolone 1.0 0.000143348623853 1 0 1
inhibitors,in,studies 1.0 0.000143348623853 1 0 1
inhibitors,in,combination 1.0 0.000143348623853 1 0 1
inhibitors,hypertensive,reactions 1.0 0.000143348623853 1 0 1
inhibitors,have,resulted 1.0 0.000143348623853 1 0 1
inhibitors,has,had 1.0 0.000143348623853 1 0 1
inhibitors,has,been 1.0 0.000143348623853 1 0 1
inhibitors,eg,and 1.0 0.000143348623853 1 0 1
inhibitors,duragesic,is 1.0 0.000143348623853 1 0 1
inhibitors,drugs,such 1.0 0.000143348623853 1 0 1
inhibitors,dipyridamole,may 1.0 0.000143348623853 1 0 1
inhibitors,coadministration,of 1.0 0.000143348623853 1 0 1
inhibitors,because,the 1.0 0.000143348623853 1 0 1
inhibitors,as,anorexia 1.0 0.000143348623853 1 0 1
inhibitors,and,with 1.0 0.000143348623853 1 0 1
inhibitors,and,tricyclic 1.0 0.000143348623853 1 0 1
inhibitors,and,the 1.0 0.000143348623853 1 0 1
inhibitors,and,substrates 1.0 0.000143348623853 1 0 1
inhibitors,and,other 1.0 0.000143348623853 1 0 1
inhibitors,and,non-selective 1.0 0.000143348623853 1 0 1
inhibitors,and,mumol 1.0 0.000143348623853 1 0 1
inhibitors,and,levo-dromoran 1.0 0.000143348623853 1 0 1
inhibitors,and,have 1.0 0.000143348623853 1 0 1
inhibitors,and,fentanyl 1.0 0.000143348623853 1 0 1
inhibitors,and,decreased 1.0 0.000143348623853 1 0 1
inhibitors,and,decrease 1.0 0.000143348623853 1 0 1
inhibitors,and,concomitantly 1.0 0.000143348623853 1 0 1
inhibitors,amprenavir,and 1.0 0.000143348623853 1 0 1
inhibitors,aminosalicylic,acid 1.0 0.000143348623853 1 0 1
inhibitors,agenerase,crixivan 1.0 0.000143348623853 1 0 1
inhibitors,administered,alone 1.0 0.000143348623853 1 0 1
inhibitor,which,also 1.0 0.000143348623853 1 0 1
inhibitor,to,mg 1.0 0.000143348623853 1 0 1
inhibitor,therapy,should 1.0 0.000143348623853 1 0 1
inhibitor,the,risk 1.0 0.000143348623853 1 0 1
inhibitor,the,auc 1.0 0.000143348623853 1 0 1
inhibitor,should,not 1.0 0.000143348623853 1 0 1
inhibitor,produced,a 1.0 0.000143348623853 1 0 1
inhibitor,plus,experienced 1.0 0.000143348623853 1 0 1
inhibitor,of,microsomal 1.0 0.000143348623853 1 0 1
inhibitor,of,iiia4 1.0 0.000143348623853 1 0 1
inhibitor,of,c 1.0 0.000143348623853 1 0 1
inhibitor,mg,q 1.0 0.000143348623853 1 0 1
inhibitor,mg,increased 1.0 0.000143348623853 1 0 1
inhibitor,may,have 1.0 0.000143348623853 1 0 1
inhibitor,it,is 1.0 0.000143348623853 1 0 1
inhibitor,is,administered 1.0 0.000143348623853 1 0 1
inhibitor,increased,the 1.0 0.000143348623853 1 0 1
inhibitor,has,been 1.0 0.000143348623853 1 0 1
inhibitor,class,see 1.0 0.000143348623853 1 0 1
inhibitor,class,may 1.0 0.000143348623853 1 0 1
inhibitor,can,be 1.0 0.000143348623853 1 0 1
inhibitor,at,mg 1.0 0.000143348623853 1 0 1
inhibitor,and,initiation 1.0 0.000143348623853 1 0 1
inhibition,significantly,reduced 1.0 0.000143348623853 1 0 1
inhibition,of,total 1.0 0.000143348623853 1 0 1
inhibition,of,response 1.0 0.000143348623853 1 0 1
inhibition,of,prostaglandin 1.0 0.000143348623853 1 0 1
inhibition,of,platelet 1.0 0.000143348623853 1 0 1
inhibition,of,p450 1.0 0.000143348623853 1 0 1
inhibition,of,n-acetyltransferase 1.0 0.000143348623853 1 0 1
inhibition,of,erythrocyte 1.0 0.000143348623853 1 0 1
inhibition,of,elimination 1.0 0.000143348623853 1 0 1
inhibition,of,each 1.0 0.000143348623853 1 0 1
inhibition,of,cyp3a 1.0 0.000143348623853 1 0 1
inhibition,of,cyp2a6 1.0 0.000143348623853 1 0 1
inhibition,of,cholinesterase 1.0 0.000143348623853 1 0 1
inhibition,are,expected 1.0 0.000143348623853 1 0 1
inhibiting,their,metabolism 1.0 0.000143348623853 1 0 1
inhibiting,parts,of 1.0 0.000143348623853 1 0 1
inhibiting,may,result 1.0 0.000143348623853 1 0 1
inhibiting,eg,may 1.0 0.000143348623853 1 0 1
inhibiting,cryptosporidium,parvum 1.0 0.000143348623853 1 0 1
inhibited,the,dmpge2 1.0 0.000143348623853 1 0 1
inhibited,the,carbachol-stimulated 1.0 0.000143348623853 1 0 1
inhibited,the,absorption 1.0 0.000143348623853 1 0 1
inhibited,phosphorylation,in 1.0 0.000143348623853 1 0 1
inhibited,phosphorylation,at 1.0 0.000143348623853 1 0 1
inhibited,insp,induced 1.0 0.000143348623853 1 0 1
inhibited,by,several 1.0 0.000143348623853 1 0 1
inhibited,by,concomitant 1.0 0.000143348623853 1 0 1
inhibited,by,combination 1.0 0.000143348623853 1 0 1
inhibited,by,and 1.0 0.000143348623853 1 0 1
inhibit,the,nad 1.0 0.000143348623853 1 0 1
inhibit,the,intracellular 1.0 0.000143348623853 1 0 1
inhibit,the,in 1.0 0.000143348623853 1 0 1
inhibit,the,desired 1.0 0.000143348623853 1 0 1
inhibit,the,anti-inflammatory 1.0 0.000143348623853 1 0 1
inhibit,sodium,binding 1.0 0.000143348623853 1 0 1
inhibit,renal,tubular 1.0 0.000143348623853 1 0 1
inhibit,proliferation,in 1.0 0.000143348623853 1 0 1
inhibit,platelet,function 1.0 0.000143348623853 1 0 1
inhibit,phosphatase,activities 1.0 0.000143348623853 1 0 1
inhibit,p450,a2 1.0 0.000143348623853 1 0 1
inhibit,elimination,and 1.0 0.000143348623853 1 0 1
inhibit,cytochrome,p450iid6 1.0 0.000143348623853 1 0 1
inhibit,cyp3a4,eg 1.0 0.000143348623853 1 0 1
inhibit,cyp,a4 1.0 0.000143348623853 1 0 1
inhibit,both,aldehyde 1.0 0.000143348623853 1 0 1
inhibit,and,stimulate 1.0 0.000143348623853 1 0 1
inhibit,alfenta,clearance 1.0 0.000143348623853 1 0 1
inhibit,adrenal,synthesis 1.0 0.000143348623853 1 0 1
inhibit,accumulation,in 1.0 0.000143348623853 1 0 1
inherent,in,any 1.0 0.000143348623853 1 0 1
inhaler,take,first 1.0 0.000143348623853 1 0 1
inhalational,such,as 1.0 0.000143348623853 1 0 1
inhalation,mefenamic,acid 1.0 0.000143348623853 1 0 1
inhalation,are,reduced 1.0 0.000143348623853 1 0 1
inhalation,aerosol,with 1.0 0.000143348623853 1 0 1
inh,isoniazid,is 1.0 0.000143348623853 1 0 1
ingestion,of,and 1.0 0.000143348623853 1 0 1
ingestion,of,an 1.0 0.000143348623853 1 0 1
ingestion,may,increase 1.0 0.000143348623853 1 0 1
ingested,being,converted 1.0 0.000143348623853 1 0 1
infusions,of,nimbex 1.0 0.000143348623853 1 0 1
infusions,myelosuppression,was 1.0 0.000143348623853 1 0 1
infusion,requirements,of 1.0 0.000143348623853 1 0 1
infusion,rates,of 1.0 0.000143348623853 1 0 1
infusion,rate,requirements 1.0 0.000143348623853 1 0 1
information,to,increase 1.0 0.000143348623853 1 0 1
influenza,virus,vaccine 1.0 0.000143348623853 1 0 1
influence,the,percentage 1.0 0.000143348623853 1 0 1
influence,on,components 1.0 0.000143348623853 1 0 1
inflammatory,with,a 1.0 0.000143348623853 1 0 1
inflammatory,reactions,develop 1.0 0.000143348623853 1 0 1
inflammatory,disorders,has 1.0 0.000143348623853 1 0 1
inflammatory,arthritis,thyroiditis 1.0 0.000143348623853 1 0 1
inflammatory,agents,are 1.0 0.000143348623853 1 0 1
inflammation,associated,with 1.0 0.000143348623853 1 0 1
infections,and,no 1.0 0.000143348623853 1 0 1
infections,and,increased 1.0 0.000143348623853 1 0 1
infections,an,increased 1.0 0.000143348623853 1 0 1
infection,in,but 1.0 0.000143348623853 1 0 1
infection,and,are 1.0 0.000143348623853 1 0 1
infarction,vs,serious 1.0 0.000143348623853 1 0 1
infarction,myocarditis,ventricular 1.0 0.000143348623853 1 0 1
ineffective,if,the 1.0 0.000143348623853 1 0 1
induction,thus,leading 1.0 0.000143348623853 1 0 1
induction,the,concomitant 1.0 0.000143348623853 1 0 1
induction,of,p-450iie1 1.0 0.000143348623853 1 0 1
induction,of,cyp 1.0 0.000143348623853 1 0 1
induction,and,displacement 1.0 0.000143348623853 1 0 1
inducers,that,have 1.0 0.000143348623853 1 0 1
inducers,of,cyp3a 1.0 0.000143348623853 1 0 1
inducers,it,is 1.0 0.000143348623853 1 0 1
inducers,inhibitors,and 1.0 0.000143348623853 1 0 1
inducers,indicate,only 1.0 0.000143348623853 1 0 1
inducers,can,decrease 1.0 0.000143348623853 1 0 1
inducers,are,taken 1.0 0.000143348623853 1 0 1
inducers,and,such 1.0 0.000143348623853 1 0 1
inducers,and,inhibitors 1.0 0.000143348623853 1 0 1
inducers,and,adjustment 1.0 0.000143348623853 1 0 1
inducer,with,mg 1.0 0.000143348623853 1 0 1
inducer,the,auc 1.0 0.000143348623853 1 0 1
inducer,or,to 1.0 0.000143348623853 1 0 1
inducer,of,metabolism 1.0 0.000143348623853 1 0 1
inducer,of,cytochrome 1.0 0.000143348623853 1 0 1
inducer,mg,every 1.0 0.000143348623853 1 0 1
inducer,may,be 1.0 0.000143348623853 1 0 1
inducer,decreased,auc 1.0 0.000143348623853 1 0 1
inducer,at,mg 1.0 0.000143348623853 1 0 1
induced,with,low 1.0 0.000143348623853 1 0 1
induced,responses,both 1.0 0.000143348623853 1 0 1
induced,long,lasting 1.0 0.000143348623853 1 0 1
induced,hypokalemia,which 1.0 0.000143348623853 1 0 1
induced,diarrhea,in 1.0 0.000143348623853 1 0 1
induced,by,was 1.0 0.000143348623853 1 0 1
induced,by,single 1.0 0.000143348623853 1 0 1
induced,by,oh 1.0 0.000143348623853 1 0 1
induced,by,nuromax 1.0 0.000143348623853 1 0 1
induced,by,in 1.0 0.000143348623853 1 0 1
induced,by,camptosar 1.0 0.000143348623853 1 0 1
induce,microsomal,enzymes 1.0 0.000143348623853 1 0 1
induce,metabolism,causing 1.0 0.000143348623853 1 0 1
induce,inhibit,or 1.0 0.000143348623853 1 0 1
induce,hepatic,enzymes 1.0 0.000143348623853 1 0 1
induce,fungal,resistance 1.0 0.000143348623853 1 0 1
induce,cyp3a4,rifampicin 1.0 0.000143348623853 1 0 1
induce,cyp3a4,eg 1.0 0.000143348623853 1 0 1
induce,cyp,a4 1.0 0.000143348623853 1 0 1
induce,bleeding,and 1.0 0.000143348623853 1 0 1
indomethacin,indomethacin,blunts 1.0 0.000143348623853 1 0 1
indomethacin,concomitant,use 1.0 0.000143348623853 1 0 1
indomethacin,blunts,the 1.0 0.000143348623853 1 0 1
indocin,with,other 1.0 0.000143348623853 1 0 1
indocin,should,not 1.0 0.000143348623853 1 0 1
indocin,resulted,in 1.0 0.000143348623853 1 0 1
indocin,mg,t 1.0 0.000143348623853 1 0 1
indocin,is,given 1.0 0.000143348623853 1 0 1
indocin,is,administered 1.0 0.000143348623853 1 0 1
indocin,is,added 1.0 0.000143348623853 1 0 1
indocin,has,been 1.0 0.000143348623853 1 0 1
indocin,given,concomitantly 1.0 0.000143348623853 1 0 1
indocin,and,should 1.0 0.000143348623853 1 0 1
indocin,and,has 1.0 0.000143348623853 1 0 1
individuals,treated,with 1.0 0.000143348623853 1 0 1
individuals,receiving,zyvox 1.0 0.000143348623853 1 0 1
individuals,plasma,concentrations 1.0 0.000143348623853 1 0 1
individual,patients,may 1.0 0.000143348623853 1 0 1
individual,glucose,concentrations 1.0 0.000143348623853 1 0 1
indirect-acting,agents,or 1.0 0.000143348623853 1 0 1
indinavir,steady-state,cmax 1.0 0.000143348623853 1 0 1
indinavir,mg,t 1.0 0.000143348623853 1 0 1
indinavir,may,be 1.0 0.000143348623853 1 0 1
indinavir,has,been 1.0 0.000143348623853 1 0 1
indinavir,concentrations,may 1.0 0.000143348623853 1 0 1
indinavir,coadministration,of 1.0 0.000143348623853 1 0 1
indinavir,and,formulations 1.0 0.000143348623853 1 0 1
indifferent,for,strains 1.0 0.000143348623853 1 0 1
indifferent,for,and 1.0 0.000143348623853 1 0 1
indicates,that,requirements 1.0 0.000143348623853 1 0 1
indicates,that,inhibits 1.0 0.000143348623853 1 0 1
indicates,that,clorazepate 1.0 0.000143348623853 1 0 1
indicated,that,significantly 1.0 0.000143348623853 1 0 1
indicated,reduction,of 1.0 0.000143348623853 1 0 1
indicated,by,its 1.0 0.000143348623853 1 0 1
indicated,by,elevated 1.0 0.000143348623853 1 0 1
indicated,and,then 1.0 0.000143348623853 1 0 1
indicate,that,there 1.0 0.000143348623853 1 0 1
indicate,that,or 1.0 0.000143348623853 1 0 1
indicate,that,may 1.0 0.000143348623853 1 0 1
indicate,that,levels 1.0 0.000143348623853 1 0 1
indicate,that,iressa 1.0 0.000143348623853 1 0 1
indicate,that,elspar 1.0 0.000143348623853 1 0 1
indicate,that,dopamine-induced 1.0 0.000143348623853 1 0 1
indicate,that,could 1.0 0.000143348623853 1 0 1
indicate,that,coadministration 1.0 0.000143348623853 1 0 1
indicate,that,at 1.0 0.000143348623853 1 0 1
indicate,only,a 1.0 0.000143348623853 1 0 1
indicate,a,significant 1.0 0.000143348623853 1 0 1
indicate,a,safe 1.0 0.000143348623853 1 0 1
index,such,as 1.0 0.000143348623853 1 0 1
index,including,certain 1.0 0.000143348623853 1 0 1
indeed,have,a 1.0 0.000143348623853 1 0 1
indanyl,sodium,blood 1.0 0.000143348623853 1 0 1
indandione,derivatives,and 1.0 0.000143348623853 1 0 1
increasing,the,non-renal 1.0 0.000143348623853 1 0 1
increasing,the,effectiveness 1.0 0.000143348623853 1 0 1
increasing,steady-state,concentrations 1.0 0.000143348623853 1 0 1
increasing,salt,intake 1.0 0.000143348623853 1 0 1
increasing,its,cellular 1.0 0.000143348623853 1 0 1
increasing,gastric,emptying 1.0 0.000143348623853 1 0 1
increasing,blood,levels 1.0 0.000143348623853 1 0 1
increases,the,rate 1.0 0.000143348623853 1 0 1
increases,the,plasma 1.0 0.000143348623853 1 0 1
increases,the,metabolism 1.0 0.000143348623853 1 0 1
increases,the,mean 1.0 0.000143348623853 1 0 1
increases,the,inhibitory 1.0 0.000143348623853 1 0 1
increases,the,clearance 1.0 0.000143348623853 1 0 1
increases,the,auc 1.0 0.000143348623853 1 0 1
increases,substantially,the 1.0 0.000143348623853 1 0 1
increases,of,previously 1.0 0.000143348623853 1 0 1
increases,in,urine 1.0 0.000143348623853 1 0 1
increases,in,previously 1.0 0.000143348623853 1 0 1
increases,in,mean 1.0 0.000143348623853 1 0 1
increases,in,gastrointestinal 1.0 0.000143348623853 1 0 1
increases,in,concentrations 1.0 0.000143348623853 1 0 1
increases,gastrointestinal,motility 1.0 0.000143348623853 1 0 1
increases,excretion,and 1.0 0.000143348623853 1 0 1
increases,both,free 1.0 0.000143348623853 1 0 1
increases,anion,plasma 1.0 0.000143348623853 1 0 1
increases,and,decreases 1.0 0.000143348623853 1 0 1
increases,about,two 1.0 0.000143348623853 1 0 1
increased,with,mao 1.0 0.000143348623853 1 0 1
increased,when,was 1.0 0.000143348623853 1 0 1
increased,when,either 1.0 0.000143348623853 1 0 1
increased,when,and 1.0 0.000143348623853 1 0 1
increased,vasoconstriction,after 1.0 0.000143348623853 1 0 1
increased,to,fold 1.0 0.000143348623853 1 0 1
increased,to,approximately 1.0 0.000143348623853 1 0 1
increased,the,systemic 1.0 0.000143348623853 1 0 1
increased,the,steadystate 1.0 0.000143348623853 1 0 1
increased,the,steady-state 1.0 0.000143348623853 1 0 1
increased,the,intracellular 1.0 0.000143348623853 1 0 1
increased,the,frequency 1.0 0.000143348623853 1 0 1
increased,the,concentration 1.0 0.000143348623853 1 0 1
increased,the,c 1.0 0.000143348623853 1 0 1
increased,the,area 1.0 0.000143348623853 1 0 1
increased,the,activation 1.0 0.000143348623853 1 0 1
increased,severity,and 1.0 0.000143348623853 1 0 1
increased,serum,potassium 1.0 0.000143348623853 1 0 1
increased,sedation,when 1.0 0.000143348623853 1 0 1
increased,sedation,if 1.0 0.000143348623853 1 0 1
increased,risk,for 1.0 0.000143348623853 1 0 1
increased,potential,of 1.0 0.000143348623853 1 0 1
increased,plasma,clearance 1.0 0.000143348623853 1 0 1
increased,peak,plasma 1.0 0.000143348623853 1 0 1
increased,over,those 1.0 0.000143348623853 1 0 1
increased,monitoring,of 1.0 0.000143348623853 1 0 1
increased,metabolism,of 1.0 0.000143348623853 1 0 1
increased,metabolism,due 1.0 0.000143348623853 1 0 1
increased,metabolism,and 1.0 0.000143348623853 1 0 1
increased,metabolic,clearance 1.0 0.000143348623853 1 0 1
increased,mean,serum 1.0 0.000143348623853 1 0 1
increased,mean,maximum 1.0 0.000143348623853 1 0 1
increased,intracranial,pressure 1.0 0.000143348623853 1 0 1
increased,intestinal,permeability 1.0 0.000143348623853 1 0 1
increased,inr,international 1.0 0.000143348623853 1 0 1
increased,if,and 1.0 0.000143348623853 1 0 1
increased,hepatotoxicity,of 1.0 0.000143348623853 1 0 1
increased,half-life,by 1.0 0.000143348623853 1 0 1
increased,gleevec,oral-dose 1.0 0.000143348623853 1 0 1
increased,following,administration 1.0 0.000143348623853 1 0 1
increased,fold,during 1.0 0.000143348623853 1 0 1
increased,fold,by 1.0 0.000143348623853 1 0 1
increased,exposures,to 1.0 0.000143348623853 1 0 1
increased,exposures,of 1.0 0.000143348623853 1 0 1
increased,exposure,following 1.0 0.000143348623853 1 0 1
increased,exposure,and 1.0 0.000143348623853 1 0 1
increased,ectopic,pacemaker 1.0 0.000143348623853 1 0 1
increased,during,concomitant 1.0 0.000143348623853 1 0 1
increased,dose,mg 1.0 0.000143348623853 1 0 1
increased,dosages,may 1.0 0.000143348623853 1 0 1
increased,dosage,of 1.0 0.000143348623853 1 0 1
increased,decreased,and 1.0 0.000143348623853 1 0 1
increased,cns,depressant 1.0 0.000143348623853 1 0 1
increased,clinical,effects 1.0 0.000143348623853 1 0 1
increased,central,nervous 1.0 0.000143348623853 1 0 1
increased,by,up 1.0 0.000143348623853 1 0 1
increased,by,in 1.0 0.000143348623853 1 0 1
increased,by,hour 1.0 0.000143348623853 1 0 1
increased,by,following 1.0 0.000143348623853 1 0 1
increased,by,concomitant 1.0 0.000143348623853 1 0 1
increased,by,compared 1.0 0.000143348623853 1 0 1
increased,by,chronic 1.0 0.000143348623853 1 0 1
increased,by,an 1.0 0.000143348623853 1 0 1
increased,bun,serum 1.0 0.000143348623853 1 0 1
increased,auc,values 1.0 0.000143348623853 1 0 1
increased,approximately,with 1.0 0.000143348623853 1 0 1
increased,approximately,twofold 1.0 0.000143348623853 1 0 1
increased,approximately,threefold 1.0 0.000143348623853 1 0 1
increased,approximately,in 1.0 0.000143348623853 1 0 1
increased,approximately,fold 1.0 0.000143348623853 1 0 1
increased,approximately,and 1.0 0.000143348623853 1 0 1
increased,and,prolonged 1.0 0.000143348623853 1 0 1
increased,and,more 1.0 0.000143348623853 1 0 1
increased,and,its 1.0 0.000143348623853 1 0 1
increased,and,because 1.0 0.000143348623853 1 0 1
increased,an,average 1.0 0.000143348623853 1 0 1
increased,altretamines,half-life 1.0 0.000143348623853 1 0 1
increased,about,compared 1.0 0.000143348623853 1 0 1
increased,about,and 1.0 0.000143348623853 1 0 1
increase,with,multiple 1.0 0.000143348623853 1 0 1
increase,when,the 1.0 0.000143348623853 1 0 1
increase,when,patients 1.0 0.000143348623853 1 0 1
increase,when,is 1.0 0.000143348623853 1 0 1
increase,when,atromid-s 1.0 0.000143348623853 1 0 1
increase,two-fold,or 1.0 0.000143348623853 1 0 1
increase,toxicity,in 1.0 0.000143348623853 1 0 1
increase,the,severity 1.0 0.000143348623853 1 0 1
increase,the,risks 1.0 0.000143348623853 1 0 1
increase,the,requirements 1.0 0.000143348623853 1 0 1
increase,the,rate 1.0 0.000143348623853 1 0 1
increase,the,plasma-level 1.0 0.000143348623853 1 0 1
increase,the,photosensitivity 1.0 0.000143348623853 1 0 1
increase,the,incidence 1.0 0.000143348623853 1 0 1
increase,the,hypotensive 1.0 0.000143348623853 1 0 1
increase,the,excretion 1.0 0.000143348623853 1 0 1
increase,the,effects 1.0 0.000143348623853 1 0 1
increase,the,depth 1.0 0.000143348623853 1 0 1
increase,the,danger 1.0 0.000143348623853 1 0 1
increase,the,bleeding 1.0 0.000143348623853 1 0 1
increase,the,amount 1.0 0.000143348623853 1 0 1
increase,the,action 1.0 0.000143348623853 1 0 1
increase,the,absorption 1.0 0.000143348623853 1 0 1
increase,slightly,the 1.0 0.000143348623853 1 0 1
increase,sensitivity,and 1.0 0.000143348623853 1 0 1
increase,resulting,in 1.0 0.000143348623853 1 0 1
increase,respiratory,and 1.0 0.000143348623853 1 0 1
increase,respectively,in 1.0 0.000143348623853 1 0 1
increase,respectively,and 1.0 0.000143348623853 1 0 1
increase,plasmaconcentration,of 1.0 0.000143348623853 1 0 1
increase,or,inhibit 1.0 0.000143348623853 1 0 1
increase,of,the 1.0 0.000143348623853 1 0 1
increase,of,level 1.0 0.000143348623853 1 0 1
increase,of,h-triglyceride 1.0 0.000143348623853 1 0 1
increase,of,crixivan 1.0 0.000143348623853 1 0 1
increase,of,auc 1.0 0.000143348623853 1 0 1
increase,of,apparent 1.0 0.000143348623853 1 0 1
increase,its,serum 1.0 0.000143348623853 1 0 1
increase,is,due 1.0 0.000143348623853 1 0 1
increase,in,zaleplons 1.0 0.000143348623853 1 0 1
increase,in,urinary 1.0 0.000143348623853 1 0 1
increase,in,unbound 1.0 0.000143348623853 1 0 1
increase,in,systemic 1.0 0.000143348623853 1 0 1
increase,in,symptoms 1.0 0.000143348623853 1 0 1
increase,in,steady-state 1.0 0.000143348623853 1 0 1
increase,in,qtc 1.0 0.000143348623853 1 0 1
increase,in,prothrombin 1.0 0.000143348623853 1 0 1
increase,in,metabolic 1.0 0.000143348623853 1 0 1
increase,in,dose 1.0 0.000143348623853 1 0 1
increase,in,clozapine 1.0 0.000143348623853 1 0 1
increase,in,central 1.0 0.000143348623853 1 0 1
increase,in,auc0-12 1.0 0.000143348623853 1 0 1
increase,in,area 1.0 0.000143348623853 1 0 1
increase,in,arc 1.0 0.000143348623853 1 0 1
increase,in,adults 1.0 0.000143348623853 1 0 1
increase,for,equetrotm 1.0 0.000143348623853 1 0 1
increase,following,administration 1.0 0.000143348623853 1 0 1
increase,exposure,to 1.0 0.000143348623853 1 0 1
increase,due,to 1.0 0.000143348623853 1 0 1
increase,cyp,metabolism 1.0 0.000143348623853 1 0 1
increase,cmax,by 1.0 0.000143348623853 1 0 1
increase,cardiac,autonomic 1.0 0.000143348623853 1 0 1
increase,by,about 1.0 0.000143348623853 1 0 1
increase,blood,glucose 1.0 0.000143348623853 1 0 1
increase,awareness,of 1.0 0.000143348623853 1 0 1
increase,and,range 1.0 0.000143348623853 1 0 1
increase,absorption,in 1.0 0.000143348623853 1 0 1
incoordination,have,been 1.0 0.000143348623853 1 0 1
incoordination,following,the 1.0 0.000143348623853 1 0 1
including,yields,a 1.0 0.000143348623853 1 0 1
including,with,multivalent 1.0 0.000143348623853 1 0 1
including,with,a 1.0 0.000143348623853 1 0 1
including,when,hydrochloride 1.0 0.000143348623853 1 0 1
including,were,reported 1.0 0.000143348623853 1 0 1
including,tricor,there 1.0 0.000143348623853 1 0 1
including,those,of 1.0 0.000143348623853 1 0 1
including,those,contained 1.0 0.000143348623853 1 0 1
including,sodium,and 1.0 0.000143348623853 1 0 1
including,remicade,used 1.0 0.000143348623853 1 0 1
including,quinolone,antibiotics 1.0 0.000143348623853 1 0 1
including,products,and 1.0 0.000143348623853 1 0 1
including,produce,cns-depressant 1.0 0.000143348623853 1 0 1
including,produce,additive 1.0 0.000143348623853 1 0 1
including,other,and 1.0 0.000143348623853 1 0 1
including,oral,estrogens 1.0 0.000143348623853 1 0 1
including,or,its 1.0 0.000143348623853 1 0 1
including,nonsteroidal,anti-inflammatory 1.0 0.000143348623853 1 0 1
including,nalidixic,acid 1.0 0.000143348623853 1 0 1
including,myocardial,infarction 1.0 0.000143348623853 1 0 1
including,midamor,may 1.0 0.000143348623853 1 0 1
including,medications,such 1.0 0.000143348623853 1 0 1
including,manic-depressive,illness 1.0 0.000143348623853 1 0 1
including,indocin,is 1.0 0.000143348623853 1 0 1
including,indocin,has 1.0 0.000143348623853 1 0 1
including,hyperthermia,rigidity 1.0 0.000143348623853 1 0 1
including,hypertensive,crises 1.0 0.000143348623853 1 0 1
including,hyperglycemia,and 1.0 0.000143348623853 1 0 1
including,humira,may 1.0 0.000143348623853 1 0 1
including,have,been 1.0 0.000143348623853 1 0 1
including,have,also 1.0 0.000143348623853 1 0 1
including,has,additive 1.0 0.000143348623853 1 0 1
including,ganglionic,blocking 1.0 0.000143348623853 1 0 1
including,for,example 1.0 0.000143348623853 1 0 1
including,fever,renal 1.0 0.000143348623853 1 0 1
including,ether,and 1.0 0.000143348623853 1 0 1
including,ethacrynic,acid 1.0 0.000143348623853 1 0 1
including,dry,mouth 1.0 0.000143348623853 1 0 1
including,derivatives,indandione 1.0 0.000143348623853 1 0 1
including,decrease,the 1.0 0.000143348623853 1 0 1
including,crescentic,iga 1.0 0.000143348623853 1 0 1
including,certain,tcas 1.0 0.000143348623853 1 0 1
including,certain,and 1.0 0.000143348623853 1 0 1
including,but,not 1.0 0.000143348623853 1 0 1
including,both,sensory 1.0 0.000143348623853 1 0 1
including,based,on 1.0 0.000143348623853 1 0 1
including,and,type 1.0 0.000143348623853 1 0 1
including,and,such 1.0 0.000143348623853 1 0 1
including,and,requires 1.0 0.000143348623853 1 0 1
including,and,or 1.0 0.000143348623853 1 0 1
include,vaiproic,acid 1.0 0.000143348623853 1 0 1
include,increased,sedation 1.0 0.000143348623853 1 0 1
include,extreme,agitation 1.0 0.000143348623853 1 0 1
include,certain,especially 1.0 0.000143348623853 1 0 1
include,aminosalicylic,acid 1.0 0.000143348623853 1 0 1
include,adrenocortical,steroids 1.0 0.000143348623853 1 0 1
include,acute,intake 1.0 0.000143348623853 1 0 1
incidence,or,severity 1.0 0.000143348623853 1 0 1
incidence,of,sedation 1.0 0.000143348623853 1 0 1
incidence,of,rashes 1.0 0.000143348623853 1 0 1
incidence,of,nephrolithiasis 1.0 0.000143348623853 1 0 1
incidence,of,lymphatic 1.0 0.000143348623853 1 0 1
incidence,of,both 1.0 0.000143348623853 1 0 1
incidence,of,adverse 1.0 0.000143348623853 1 0 1
inc,demonstrated,less 1.0 0.000143348623853 1 0 1
inapsine,the,dose 1.0 0.000143348623853 1 0 1
inadvisable,to,co-administer 1.0 0.000143348623853 1 0 1
inadequate,method,of 1.0 0.000143348623853 1 0 1
inactivated,due,to 1.0 0.000143348623853 1 0 1
inactivate,the,activity 1.0 0.000143348623853 1 0 1
inactivate,by,bacterial 1.0 0.000143348623853 1 0 1
in,zaleplons,maximal 1.0 0.000143348623853 1 0 1
in,which,concomitant 1.0 0.000143348623853 1 0 1
in,which,clearance 1.0 0.000143348623853 1 0 1
in,volume,of 1.0 0.000143348623853 1 0 1
in,vivo,resulting 1.0 0.000143348623853 1 0 1
in,vivo,as 1.0 0.000143348623853 1 0 1
in,vivo,animal 1.0 0.000143348623853 1 0 1
in,vitro,upon 1.0 0.000143348623853 1 0 1
in,vitro,mixing 1.0 0.000143348623853 1 0 1
in,vitro,may 1.0 0.000143348623853 1 0 1
in,vitro,interferes 1.0 0.000143348623853 1 0 1
in,vitro,from 1.0 0.000143348623853 1 0 1
in,vitro,can 1.0 0.000143348623853 1 0 1
in,vitro,appears 1.0 0.000143348623853 1 0 1
in,vitro,antiviral 1.0 0.000143348623853 1 0 1
in,vitamin,k 1.0 0.000143348623853 1 0 1
in,uterine,hypertonus 1.0 0.000143348623853 1 0 1
in,using,such 1.0 0.000143348623853 1 0 1
in,urine,volume 1.0 0.000143348623853 1 0 1
in,urinary,uric 1.0 0.000143348623853 1 0 1
in,urinary,excretion 1.0 0.000143348623853 1 0 1
in,urinary,and 1.0 0.000143348623853 1 0 1
in,uptake,may 1.0 0.000143348623853 1 0 1
in,uninfected,volunteers 1.0 0.000143348623853 1 0 1
in,unexpectedly,low 1.0 0.000143348623853 1 0 1
in,type,diabetes 1.0 0.000143348623853 1 0 1
in,two,other 1.0 0.000143348623853 1 0 1
in,two,instances 1.0 0.000143348623853 1 0 1
in,two,clinical 1.0 0.000143348623853 1 0 1
in,turn,resulted 1.0 0.000143348623853 1 0 1
in,toxicity,in 1.0 0.000143348623853 1 0 1
in,tissue,culture 1.0 0.000143348623853 1 0 1
in,time,with 1.0 0.000143348623853 1 0 1
in,these,studies 1.0 0.000143348623853 1 0 1
in,these,categories 1.0 0.000143348623853 1 0 1
in,therapeutic,doses 1.0 0.000143348623853 1 0 1
in,their,prothrombin 1.0 0.000143348623853 1 0 1
in,their,dosage 1.0 0.000143348623853 1 0 1
in,their,coagulation 1.0 0.000143348623853 1 0 1
in,the,within 1.0 0.000143348623853 1 0 1
in,the,week 1.0 0.000143348623853 1 0 1
in,the,time 1.0 0.000143348623853 1 0 1
in,the,striatum 1.0 0.000143348623853 1 0 1
in,the,prothrombin 1.0 0.000143348623853 1 0 1
in,the,prolongation 1.0 0.000143348623853 1 0 1
in,the,preparation 1.0 0.000143348623853 1 0 1
in,the,post-marketing 1.0 0.000143348623853 1 0 1
in,the,ph 1.0 0.000143348623853 1 0 1
in,the,perioperative 1.0 0.000143348623853 1 0 1
in,the,oral 1.0 0.000143348623853 1 0 1
in,the,need 1.0 0.000143348623853 1 0 1
in,the,myasthenic 1.0 0.000143348623853 1 0 1
in,the,median 1.0 0.000143348623853 1 0 1
in,the,lower 1.0 0.000143348623853 1 0 1
in,the,loss 1.0 0.000143348623853 1 0 1
in,the,judgment 1.0 0.000143348623853 1 0 1
in,the,fed 1.0 0.000143348623853 1 0 1
in,the,excretion 1.0 0.000143348623853 1 0 1
in,the,doses 1.0 0.000143348623853 1 0 1
in,the,dosage 1.0 0.000143348623853 1 0 1
in,the,concomitant 1.0 0.000143348623853 1 0 1
in,the,committed 1.0 0.000143348623853 1 0 1
in,the,apparent 1.0 0.000143348623853 1 0 1
in,t24,cells 1.0 0.000143348623853 1 0 1
in,systemic,levels 1.0 0.000143348623853 1 0 1
in,systemic,concentrations 1.0 0.000143348623853 1 0 1
in,symptoms,that 1.0 0.000143348623853 1 0 1
in,substantial,increases 1.0 0.000143348623853 1 0 1
in,substantial,inactivation 1.0 0.000143348623853 1 0 1
in,subjects,aged 1.0 0.000143348623853 1 0 1
in,sub-therapeutic,concentrations 1.0 0.000143348623853 1 0 1
in,steady-state,serum 1.0 0.000143348623853 1 0 1
in,steady-state,peak 1.0 0.000143348623853 1 0 1
in,standing,systolic 1.0 0.000143348623853 1 0 1
in,some,studies 1.0 0.000143348623853 1 0 1
in,some,normal 1.0 0.000143348623853 1 0 1
in,slight,increases 1.0 0.000143348623853 1 0 1
in,six,subjects 1.0 0.000143348623853 1 0 1
in,six,of 1.0 0.000143348623853 1 0 1
in,six,healthy 1.0 0.000143348623853 1 0 1
in,situ,hybridization 1.0 0.000143348623853 1 0 1
in,single,and 1.0 0.000143348623853 1 0 1
in,simultaneous,treatment 1.0 0.000143348623853 1 0 1
in,significantly,increased 1.0 0.000143348623853 1 0 1
in,significantly,elevating 1.0 0.000143348623853 1 0 1
in,significant,reductions 1.0 0.000143348623853 1 0 1
in,severe,hyperkalemia 1.0 0.000143348623853 1 0 1
in,serum,half-life 1.0 0.000143348623853 1 0 1
in,serum,clearance 1.0 0.000143348623853 1 0 1
in,serum,auc 1.0 0.000143348623853 1 0 1
in,s,a 1.0 0.000143348623853 1 0 1
in,rpmi1640,containing 1.0 0.000143348623853 1 0 1
in,rheumatic,disease 1.0 0.000143348623853 1 0 1
in,reversible,acute 1.0 0.000143348623853 1 0 1
in,renal,transplant 1.0 0.000143348623853 1 0 1
in,renal,and 1.0 0.000143348623853 1 0 1
in,reducing,the 1.0 0.000143348623853 1 0 1
in,reduced,protein 1.0 0.000143348623853 1 0 1
in,reduced,clearance 1.0 0.000143348623853 1 0 1
in,rats,with 1.0 0.000143348623853 1 0 1
in,rats,simultaneous 1.0 0.000143348623853 1 0 1
in,rats,responding 1.0 0.000143348623853 1 0 1
in,rats,in 1.0 0.000143348623853 1 0 1
in,rats,have 1.0 0.000143348623853 1 0 1
in,rats,epidural 1.0 0.000143348623853 1 0 1
in,rat,brain 1.0 0.000143348623853 1 0 1
in,rare,instances 1.0 0.000143348623853 1 0 1
in,qtc,values 1.0 0.000143348623853 1 0 1
in,qt,prolongation 1.0 0.000143348623853 1 0 1
in,psychiatric,patients 1.0 0.000143348623853 1 0 1
in,proprietary,cold 1.0 0.000143348623853 1 0 1
in,prolonging,av 1.0 0.000143348623853 1 0 1
in,previously,stable 1.0 0.000143348623853 1 0 1
in,plasma,m1 1.0 0.000143348623853 1 0 1
in,plasma,exposures 1.0 0.000143348623853 1 0 1
in,plasma,exposure 1.0 0.000143348623853 1 0 1
in,plasma,and 1.0 0.000143348623853 1 0 1
in,place,of 1.0 0.000143348623853 1 0 1
in,pigeons,but 1.0 0.000143348623853 1 0 1
in,phosphorylation,inhibition 1.0 0.000143348623853 1 0 1
in,pharmacological,effect 1.0 0.000143348623853 1 0 1
in,pharmacokinetics,produced 1.0 0.000143348623853 1 0 1
in,peak,serum 1.0 0.000143348623853 1 0 1
in,patients,when 1.0 0.000143348623853 1 0 1
in,patients,that 1.0 0.000143348623853 1 0 1
in,patients,suffering 1.0 0.000143348623853 1 0 1
in,patients,prone 1.0 0.000143348623853 1 0 1
in,patients,not 1.0 0.000143348623853 1 0 1
in,patients,n 1.0 0.000143348623853 1 0 1
in,patients,is 1.0 0.000143348623853 1 0 1
in,patients,consuming 1.0 0.000143348623853 1 0 1
in,patients,chronically 1.0 0.000143348623853 1 0 1
in,patients,already 1.0 0.000143348623853 1 0 1
in,patients,administered 1.0 0.000143348623853 1 0 1
in,particular,convulsions 1.0 0.000143348623853 1 0 1
in,parkinsons,disease 1.0 0.000143348623853 1 0 1
in,overdose,especially 1.0 0.000143348623853 1 0 1
in,over,patients 1.0 0.000143348623853 1 0 1
in,ovarian,cancer 1.0 0.000143348623853 1 0 1
in,other,schizophrenic 1.0 0.000143348623853 1 0 1
in,organ,transplant 1.0 0.000143348623853 1 0 1
in,one,survey 1.0 0.000143348623853 1 0 1
in,one,report 1.0 0.000143348623853 1 0 1
in,one,man 1.0 0.000143348623853 1 0 1
in,normovolemic,healthy 1.0 0.000143348623853 1 0 1
in,normal,male 1.0 0.000143348623853 1 0 1
in,nonfailing,myocardium 1.0 0.000143348623853 1 0 1
in,most,subjects 1.0 0.000143348623853 1 0 1
in,most,instances 1.0 0.000143348623853 1 0 1
in,monkeys,the 1.0 0.000143348623853 1 0 1
in,mind,that 1.0 0.000143348623853 1 0 1
in,mind,in 1.0 0.000143348623853 1 0 1
in,metabolism,inhibitors 1.0 0.000143348623853 1 0 1
in,metabolic,clearance 1.0 0.000143348623853 1 0 1
in,mean,trough 1.0 0.000143348623853 1 0 1
in,mean,neutrophil 1.0 0.000143348623853 1 0 1
in,mean,arterial 1.0 0.000143348623853 1 0 1
in,mean,area 1.0 0.000143348623853 1 0 1
in,maximal,plasma 1.0 0.000143348623853 1 0 1
in,markedly,increased 1.0 0.000143348623853 1 0 1
in,males,and 1.0 0.000143348623853 1 0 1
in,lowering,the 1.0 0.000143348623853 1 0 1
in,lowering,of 1.0 0.000143348623853 1 0 1
in,long,surgical 1.0 0.000143348623853 1 0 1
in,liver,enzymes 1.0 0.000143348623853 1 0 1
in,liver,alt 1.0 0.000143348623853 1 0 1
in,lipid,levels 1.0 0.000143348623853 1 0 1
in,levels,with 1.0 0.000143348623853 1 0 1
in,levels,was 1.0 0.000143348623853 1 0 1
in,levels,to 1.0 0.000143348623853 1 0 1
in,large,amounts 1.0 0.000143348623853 1 0 1
in,isolated,cases 1.0 0.000143348623853 1 0 1
in,interactions,toxicity 1.0 0.000143348623853 1 0 1
in,insufficient,plasma 1.0 0.000143348623853 1 0 1
in,inhibition,of 1.0 0.000143348623853 1 0 1
in,inhibiting,cryptosporidium 1.0 0.000143348623853 1 0 1
in,induction,of 1.0 0.000143348623853 1 0 1
in,increased,levels 1.0 0.000143348623853 1 0 1
in,increased,cns 1.0 0.000143348623853 1 0 1
in,increased,clinical 1.0 0.000143348623853 1 0 1
in,increased,central 1.0 0.000143348623853 1 0 1
in,increased,blood 1.0 0.000143348623853 1 0 1
in,increased,and 1.0 0.000143348623853 1 0 1
in,increase,in 1.0 0.000143348623853 1 0 1
in,hypercholesterolemic,patients 1.0 0.000143348623853 1 0 1
in,hydatid,cyst 1.0 0.000143348623853 1 0 1
in,humans,show 1.0 0.000143348623853 1 0 1
in,humans,may 1.0 0.000143348623853 1 0 1
in,humans,can 1.0 0.000143348623853 1 0 1
in,human,trials 1.0 0.000143348623853 1 0 1
in,higher,increases 1.0 0.000143348623853 1 0 1
in,high,doses 1.0 0.000143348623853 1 0 1
in,healthy,individuals 1.0 0.000143348623853 1 0 1
in,greater,gastrointestinal 1.0 0.000143348623853 1 0 1
in,glucose,concentrations 1.0 0.000143348623853 1 0 1
in,gastrointestinal,transit 1.0 0.000143348623853 1 0 1
in,gastric,ph 1.0 0.000143348623853 1 0 1
in,free,radical-mediated 1.0 0.000143348623853 1 0 1
in,free,fraction 1.0 0.000143348623853 1 0 1
in,fold,increase 1.0 0.000143348623853 1 0 1
in,five,normal 1.0 0.000143348623853 1 0 1
in,fi,or 1.0 0.000143348623853 1 0 1
in,exposure,with 1.0 0.000143348623853 1 0 1
in,exposure,to 1.0 0.000143348623853 1 0 1
in,excretion,of 1.0 0.000143348623853 1 0 1
in,excessive,widening 1.0 0.000143348623853 1 0 1
in,excessive,effects 1.0 0.000143348623853 1 0 1
in,ewes,given 1.0 0.000143348623853 1 0 1
in,europe,nimotop 1.0 0.000143348623853 1 0 1
in,etodolac-treated,patients 1.0 0.000143348623853 1 0 1
in,ethinyl,estradiol 1.0 0.000143348623853 1 0 1
in,em,individuals 1.0 0.000143348623853 1 0 1
in,elimination,half-life 1.0 0.000143348623853 1 0 1
in,eight,hiv-infected 1.0 0.000143348623853 1 0 1
in,eight,healthy 1.0 0.000143348623853 1 0 1
in,effects,of 1.0 0.000143348623853 1 0 1
in,effectiveness,of 1.0 0.000143348623853 1 0 1
in,effect,should 1.0 0.000143348623853 1 0 1
in,dose,and 1.0 0.000143348623853 1 0 1
in,dosage,should 1.0 0.000143348623853 1 0 1
in,dosage,of 1.0 0.000143348623853 1 0 1
in,dogs,the 1.0 0.000143348623853 1 0 1
in,dogs,but 1.0 0.000143348623853 1 0 1
in,dogs,anesthetized 1.0 0.000143348623853 1 0 1
in,diabetics,with 1.0 0.000143348623853 1 0 1
in,decreases,of 1.0 0.000143348623853 1 0 1
in,decreased,efficacy 1.0 0.000143348623853 1 0 1
in,decreased,effectiveness 1.0 0.000143348623853 1 0 1
in,decreased,clearance 1.0 0.000143348623853 1 0 1
in,decreased,blood 1.0 0.000143348623853 1 0 1
in,decreased,antihypertensive 1.0 0.000143348623853 1 0 1
in,death,have 1.0 0.000143348623853 1 0 1
in,cyp,d6 1.0 0.000143348623853 1 0 1
in,creatinine,clearance 1.0 0.000143348623853 1 0 1
in,controlled,studies 1.0 0.000143348623853 1 0 1
in,concentrations,from 1.0 0.000143348623853 1 0 1
in,concentrations,above 1.0 0.000143348623853 1 0 1
in,common,with 1.0 0.000143348623853 1 0 1
in,combining,with 1.0 0.000143348623853 1 0 1
in,combination,to 1.0 0.000143348623853 1 0 1
in,cmax,leading 1.0 0.000143348623853 1 0 1
in,clinical,practice 1.0 0.000143348623853 1 0 1
in,clearance,when 1.0 0.000143348623853 1 0 1
in,clearance,of 1.0 0.000143348623853 1 0 1
in,cell,number 1.0 0.000143348623853 1 0 1
in,cardiac,output 1.0 0.000143348623853 1 0 1
in,by,decreasing 1.0 0.000143348623853 1 0 1
in,but,not 1.0 0.000143348623853 1 0 1
in,both,species 1.0 0.000143348623853 1 0 1
in,blood,sugar 1.0 0.000143348623853 1 0 1
in,bioavailability,was 1.0 0.000143348623853 1 0 1
in,binding,decrease 1.0 0.000143348623853 1 0 1
in,bile,and 1.0 0.000143348623853 1 0 1
in,average,steady- 1.0 0.000143348623853 1 0 1
in,auc0-12,and 1.0 0.000143348623853 1 0 1
in,auc,values 1.0 0.000143348623853 1 0 1
in,auc,by 1.0 0.000143348623853 1 0 1
in,auc,a 1.0 0.000143348623853 1 0 1
in,area,under 1.0 0.000143348623853 1 0 1
in,arc,mrna 1.0 0.000143348623853 1 0 1
in,approximately,decrease 1.0 0.000143348623853 1 0 1
in,approximately,a 1.0 0.000143348623853 1 0 1
in,any,intentional 1.0 0.000143348623853 1 0 1
in,any,condition 1.0 0.000143348623853 1 0 1
in,anti-inflammatory,activity 1.0 0.000143348623853 1 0 1
in,another,report 1.0 0.000143348623853 1 0 1
in,another,interaction 1.0 0.000143348623853 1 0 1
in,animals,treated 1.0 0.000143348623853 1 0 1
in,animals,indicate 1.0 0.000143348623853 1 0 1
in,animals,edetate 1.0 0.000143348623853 1 0 1
in,animals,demonstrate 1.0 0.000143348623853 1 0 1
in,anhydrous,and 1.0 0.000143348623853 1 0 1
in,and,or 1.0 0.000143348623853 1 0 1
in,and,addicts 1.0 0.000143348623853 1 0 1
in,an,opposite 1.0 0.000143348623853 1 0 1
in,an,emergency 1.0 0.000143348623853 1 0 1
in,an,eight-fold 1.0 0.000143348623853 1 0 1
in,an,decrease 1.0 0.000143348623853 1 0 1
in,an,attempt 1.0 0.000143348623853 1 0 1
in,an,approximately 1.0 0.000143348623853 1 0 1
in,an,animal 1.0 0.000143348623853 1 0 1
in,an,analysis 1.0 0.000143348623853 1 0 1
in,an,additive 1.0 0.000143348623853 1 0 1
in,all,subjects 1.0 0.000143348623853 1 0 1
in,alcoholic,beverages 1.0 0.000143348623853 1 0 1
in,advanced,or 1.0 0.000143348623853 1 0 1
in,adults,at 1.0 0.000143348623853 1 0 1
in,additive,effect 1.0 0.000143348623853 1 0 1
in,additive,central 1.0 0.000143348623853 1 0 1
in,addition,that 1.0 0.000143348623853 1 0 1
in,addition,results 1.0 0.000143348623853 1 0 1
in,addition,other 1.0 0.000143348623853 1 0 1
in,addition,most 1.0 0.000143348623853 1 0 1
in,addition,interfere 1.0 0.000143348623853 1 0 1
in,addition,higher-than 1.0 0.000143348623853 1 0 1
in,addition,deaths 1.0 0.000143348623853 1 0 1
in,addition,alone 1.0 0.000143348623853 1 0 1
in,about,a 1.0 0.000143348623853 1 0 1
in,a,wax 1.0 0.000143348623853 1 0 1
in,a,type 1.0 0.000143348623853 1 0 1
in,a,two-fold 1.0 0.000143348623853 1 0 1
in,a,to 1.0 0.000143348623853 1 0 1
in,a,times 1.0 0.000143348623853 1 0 1
in,a,ten-subject 1.0 0.000143348623853 1 0 1
in,a,substantial 1.0 0.000143348623853 1 0 1
in,a,slower 1.0 0.000143348623853 1 0 1
in,a,shortened 1.0 0.000143348623853 1 0 1
in,a,schedule 1.0 0.000143348623853 1 0 1
in,a,reduced 1.0 0.000143348623853 1 0 1
in,a,rapid 1.0 0.000143348623853 1 0 1
in,a,potentiation 1.0 0.000143348623853 1 0 1
in,a,phase 1.0 0.000143348623853 1 0 1
in,a,non-comparative 1.0 0.000143348623853 1 0 1
in,a,multiple-dose 1.0 0.000143348623853 1 0 1
in,a,multiple 1.0 0.000143348623853 1 0 1
in,a,min 1.0 0.000143348623853 1 0 1
in,a,higher 1.0 0.000143348623853 1 0 1
in,a,comparison 1.0 0.000143348623853 1 0 1
in,a,c 1.0 0.000143348623853 1 0 1
imuran,the,concomitant 1.0 0.000143348623853 1 0 1
important,that,your 1.0 0.000143348623853 1 0 1
important,drug,interactions 1.0 0.000143348623853 1 0 1
importance,brevibloc,should 1.0 0.000143348623853 1 0 1
implications,of,interactions 1.0 0.000143348623853 1 0 1
implication,that,intoxication 1.0 0.000143348623853 1 0 1
implantable,forms,may 1.0 0.000143348623853 1 0 1
implantable,contraceptives,an 1.0 0.000143348623853 1 0 1
impairment,the,use 1.0 0.000143348623853 1 0 1
impairment,reportedly,resulted 1.0 0.000143348623853 1 0 1
impairment,of,renal 1.0 0.000143348623853 1 0 1
impairment,clcr,and 1.0 0.000143348623853 1 0 1
impairing,absorption,of 1.0 0.000143348623853 1 0 1
impaired,in,the 1.0 0.000143348623853 1 0 1
impaired,by,include 1.0 0.000143348623853 1 0 1
impaired,by,containing 1.0 0.000143348623853 1 0 1
impair,the,absorption 1.0 0.000143348623853 1 0 1
immediately,following,or 1.0 0.000143348623853 1 0 1
immediately,following,a 1.0 0.000143348623853 1 0 1
immediately,beginning,depletion 1.0 0.000143348623853 1 0 1
immediate,release,but 1.0 0.000143348623853 1 0 1
immediate,and,extended 1.0 0.000143348623853 1 0 1
imipramine,hydrochloride,may 1.0 0.000143348623853 1 0 1
imipramine,coadministration,of 1.0 0.000143348623853 1 0 1
imidazoles,etc,in 1.0 0.000143348623853 1 0 1
imidazole,compounds,like 1.0 0.000143348623853 1 0 1
imidazole,and,the 1.0 0.000143348623853 1 0 1
im,reduced,the 1.0 0.000143348623853 1 0 1
ileus,may,occur 1.0 0.000143348623853 1 0 1
iiia4,inhibitor,it 1.0 0.000143348623853 1 0 1
iiia4,blocks,the 1.0 0.000143348623853 1 0 1
iiia,inhibitors,was 1.0 0.000143348623853 1 0 1
iii,human,in 1.0 0.000143348623853 1 0 1
iib,iiia,inhibitors 1.0 0.000143348623853 1 0 1
ii,may,be 1.0 0.000143348623853 1 0 1
ii,diabetic,patient 1.0 0.000143348623853 1 0 1
ii,clinical,trial 1.0 0.000143348623853 1 0 1
ii,antagonists,increased 1.0 0.000143348623853 1 0 1
iga,glomerulonephritis,oculo-bulbar 1.0 0.000143348623853 1 0 1
ig,for,days 1.0 0.000143348623853 1 0 1
if,vioxx,and 1.0 0.000143348623853 1 0 1
if,treatment,with 1.0 0.000143348623853 1 0 1
if,these,agents 1.0 0.000143348623853 1 0 1
if,their,tolerance 1.0 0.000143348623853 1 0 1
if,the,tarceva 1.0 0.000143348623853 1 0 1
if,the,effects 1.0 0.000143348623853 1 0 1
if,supplements,are 1.0 0.000143348623853 1 0 1
if,stadol,ns 1.0 0.000143348623853 1 0 1
if,signs,and 1.0 0.000143348623853 1 0 1
if,replacing,by 1.0 0.000143348623853 1 0 1
if,prinivil,is 1.0 0.000143348623853 1 0 1
if,possible,be 1.0 0.000143348623853 1 0 1
if,possible,anticholinesterase 1.0 0.000143348623853 1 0 1
if,peganone,is 1.0 0.000143348623853 1 0 1
if,patients,are 1.0 0.000143348623853 1 0 1
if,or,other 1.0 0.000143348623853 1 0 1
if,or,estrogen-containing 1.0 0.000143348623853 1 0 1
if,necessary,the 1.0 0.000143348623853 1 0 1
if,leprosy-associated,inflammatory 1.0 0.000143348623853 1 0 1
if,labetalol,hcl 1.0 0.000143348623853 1 0 1
if,is,used 1.0 0.000143348623853 1 0 1
if,is,combined 1.0 0.000143348623853 1 0 1
if,is,coadministered 1.0 0.000143348623853 1 0 1
if,intravenous,is 1.0 0.000143348623853 1 0 1
if,inspra,is 1.0 0.000143348623853 1 0 1
if,indocin,is 1.0 0.000143348623853 1 0 1
if,hydrochloride,is 1.0 0.000143348623853 1 0 1
if,high,doses 1.0 0.000143348623853 1 0 1
if,dosage,is 1.0 0.000143348623853 1 0 1
if,diminished,renal 1.0 0.000143348623853 1 0 1
if,coreg,is 1.0 0.000143348623853 1 0 1
if,combination,hormonal 1.0 0.000143348623853 1 0 1
if,clearance,is 1.0 0.000143348623853 1 0 1
if,cefotan,and 1.0 0.000143348623853 1 0 1
if,casodex,is 1.0 0.000143348623853 1 0 1
if,are,required 1.0 0.000143348623853 1 0 1
if,any,signs 1.0 0.000143348623853 1 0 1
if,any,clinical 1.0 0.000143348623853 1 0 1
if,and,or 1.0 0.000143348623853 1 0 1
if,an,hmg-coa 1.0 0.000143348623853 1 0 1
if,administered,prior 1.0 0.000143348623853 1 0 1
if,additional,adrenergic 1.0 0.000143348623853 1 0 1
if,a,valid 1.0 0.000143348623853 1 0 1
if,a,tca 1.0 0.000143348623853 1 0 1
if,a,mg 1.0 0.000143348623853 1 0 1
identify,chromatin,and 1.0 0.000143348623853 1 0 1
identified,potentially,significant 1.0 0.000143348623853 1 0 1
identified,involving,nizoral 1.0 0.000143348623853 1 0 1
identified,in,clinical 1.0 0.000143348623853 1 0 1
ibuprofen,produced,an 1.0 0.000143348623853 1 0 1
ibuprofen,l-arginine,may 1.0 0.000143348623853 1 0 1
ibuprofen,as,well 1.0 0.000143348623853 1 0 1
ibuprofen,and,high 1.0 0.000143348623853 1 0 1
ibogaine,attenuates,but 1.0 0.000143348623853 1 0 1
ibandronate,should,be 1.0 0.000143348623853 1 0 1
iatrogenic,alterations,caused 1.0 0.000143348623853 1 0 1
ia,such,as 1.0 0.000143348623853 1 0 1
i131,a,rebound 1.0 0.000143348623853 1 0 1
i,trial,using 1.0 0.000143348623853 1 0 1
i,severe,dry 1.0 0.000143348623853 1 0 1
i,selective,serotonin 1.0 0.000143348623853 1 0 1
i,mac,was 1.0 0.000143348623853 1 0 1
i,increase,due 1.0 0.000143348623853 1 0 1
i,d,with 1.0 0.000143348623853 1 0 1
i,d,was 1.0 0.000143348623853 1 0 1
i,d,for 1.0 0.000143348623853 1 0 1
i,d,dosage 1.0 0.000143348623853 1 0 1
i,coadministration,of 1.0 0.000143348623853 1 0 1
hypoxanthine,and,xanthine 1.0 0.000143348623853 1 0 1
hypothyroid,patient,may 1.0 0.000143348623853 1 0 1
hypotensive,using,labetalol 1.0 0.000143348623853 1 0 1
hypotensive,including,ganglionic 1.0 0.000143348623853 1 0 1
hypotensive,episodes,may 1.0 0.000143348623853 1 0 1
hypotensive,effects,can 1.0 0.000143348623853 1 0 1
hypotensive,effect,has 1.0 0.000143348623853 1 0 1
hypotensite,effects,due 1.0 0.000143348623853 1 0 1
hypotension,with,the 1.0 0.000143348623853 1 0 1
hypotension,will,be 1.0 0.000143348623853 1 0 1
hypotension,which,may 1.0 0.000143348623853 1 0 1
hypotension,vs,myocardial 1.0 0.000143348623853 1 0 1
hypotension,or,exacerbation 1.0 0.000143348623853 1 0 1
hypotension,developed,in 1.0 0.000143348623853 1 0 1
hypotension,cimetidine,an 1.0 0.000143348623853 1 0 1
hypotension,caused,by 1.0 0.000143348623853 1 0 1
hypotension,av,conduction 1.0 0.000143348623853 1 0 1
hypotension,and,loss 1.0 0.000143348623853 1 0 1
hypokinesia,and,severe 1.0 0.000143348623853 1 0 1
hypokalemic,effect,of 1.0 0.000143348623853 1 0 1
hypokalemia,which,may 1.0 0.000143348623853 1 0 1
hypokalemia,that,may 1.0 0.000143348623853 1 0 1
hypokalemia,may,enhance 1.0 0.000143348623853 1 0 1
hypoglycemics,agents,with 1.0 0.000143348623853 1 0 1
hypoglycemic,medications,may 1.0 0.000143348623853 1 0 1
hypoglycemic,effect,of 1.0 0.000143348623853 1 0 1
hypoglycemic,agents,there 1.0 0.000143348623853 1 0 1
hypoglycemic,agents,that 1.0 0.000143348623853 1 0 1
hypoglycemic,agents,such 1.0 0.000143348623853 1 0 1
hypoglycemic,agents,should 1.0 0.000143348623853 1 0 1
hypoglycemic,agents,eg 1.0 0.000143348623853 1 0 1
hypoglycemia,secondary,to 1.0 0.000143348623853 1 0 1
hypoglycemia,have,been 1.0 0.000143348623853 1 0 1
hypnotics,opioids,co-administration 1.0 0.000143348623853 1 0 1
hyperuricemia,present,in 1.0 0.000143348623853 1 0 1
hypertonus,possibly,causing 1.0 0.000143348623853 1 0 1
hyperthermia,rigidity,myoclonus 1.0 0.000143348623853 1 0 1
hyperthermia,crisis,until 1.0 0.000143348623853 1 0 1
hypertensive,responses,have 1.0 0.000143348623853 1 0 1
hypertensive,response,seen 1.0 0.000143348623853 1 0 1
hypertensive,reactions,including 1.0 0.000143348623853 1 0 1
hypertensive,crises,have 1.0 0.000143348623853 1 0 1
hypertension,which,can 1.0 0.000143348623853 1 0 1
hypertension,was,controlled 1.0 0.000143348623853 1 0 1
hypertension,the,addition 1.0 0.000143348623853 1 0 1
hypertension,some,of 1.0 0.000143348623853 1 0 1
hypertension,in,patients 1.0 0.000143348623853 1 0 1
hypertension,in,clinical 1.0 0.000143348623853 1 0 1
hypertension,and,tachycardia 1.0 0.000143348623853 1 0 1
hypersensitivity,reactions,to 1.0 0.000143348623853 1 0 1
hypersensitivity,reactions,patients 1.0 0.000143348623853 1 0 1
hypersensitivity,reactions,have 1.0 0.000143348623853 1 0 1
hypersensitive,to,nonsteroidal 1.0 0.000143348623853 1 0 1
hyperpyrexia,has,been 1.0 0.000143348623853 1 0 1
hyperlipidemia,or,elevated 1.0 0.000143348623853 1 0 1
hyperkalemia,serum,meq 1.0 0.000143348623853 1 0 1
hyperkalemia,in,patients 1.0 0.000143348623853 1 0 1
hyperglycemia,and,hypoglycemia 1.0 0.000143348623853 1 0 1
hypercholesterolemic,patients,steady-state 1.0 0.000143348623853 1 0 1
hypercalcemia,too,much 1.0 0.000143348623853 1 0 1
hyperbilirubinemia,confusion,and 1.0 0.000143348623853 1 0 1
hydroxyzine,must,be 1.0 0.000143348623853 1 0 1
hydroxyphenyl,piperidine,prevents 1.0 0.000143348623853 1 0 1
hydroxymethylglutaryl,coenzyme,a 1.0 0.000143348623853 1 0 1
hydroxylation,of,by 1.0 0.000143348623853 1 0 1
hydroxy-iso,by,range 1.0 0.000143348623853 1 0 1
hydroxy-1,on,a 1.0 0.000143348623853 1 0 1
hydroxy,acid,metabolite 1.0 0.000143348623853 1 0 1
hydroxides,be,used 1.0 0.000143348623853 1 0 1
hydroxide,with,mg 1.0 0.000143348623853 1 0 1
hydroxide,reduce,the 1.0 0.000143348623853 1 0 1
hydroxide,hydroxide,and 1.0 0.000143348623853 1 0 1
hydroxide,containing,to 1.0 0.000143348623853 1 0 1
hydroxide,containing,for 1.0 0.000143348623853 1 0 1
hydroxide,and,with 1.0 0.000143348623853 1 0 1
hydrogen,maleate,or 1.0 0.000143348623853 1 0 1
hydrocodone,increases,auc 1.0 0.000143348623853 1 0 1
hydrochlorothiazide,in,normal 1.0 0.000143348623853 1 0 1
hydrochlorothiazide,given,concomitantly 1.0 0.000143348623853 1 0 1
hydrochlorothiazide,and,non-steroidal 1.0 0.000143348623853 1 0 1
hydrochloride,x,mg 1.0 0.000143348623853 1 0 1
hydrochloride,with,in 1.0 0.000143348623853 1 0 1
hydrochloride,with,either 1.0 0.000143348623853 1 0 1
hydrochloride,was,found 1.0 0.000143348623853 1 0 1
hydrochloride,therapy,to 1.0 0.000143348623853 1 0 1
hydrochloride,on,the 1.0 0.000143348623853 1 0 1
hydrochloride,not,be 1.0 0.000143348623853 1 0 1
hydrochloride,may,potentiate 1.0 0.000143348623853 1 0 1
hydrochloride,may,enhance 1.0 0.000143348623853 1 0 1
hydrochloride,is,to 1.0 0.000143348623853 1 0 1
hydrochloride,is,also 1.0 0.000143348623853 1 0 1
hydrochloride,injection,and 1.0 0.000143348623853 1 0 1
hydrochloride,in,combination 1.0 0.000143348623853 1 0 1
hydrochloride,has,additive 1.0 0.000143348623853 1 0 1
hydrochloride,given,prior 1.0 0.000143348623853 1 0 1
hydrochloride,ferrous,sulfate 1.0 0.000143348623853 1 0 1
hydrochloride,either,had 1.0 0.000143348623853 1 0 1
hydrochloride,desyrel,and 1.0 0.000143348623853 1 0 1
hydrocarbon,increase,cardiac 1.0 0.000143348623853 1 0 1
hydrocarbon,general,such 1.0 0.000143348623853 1 0 1
hydrobromide,may,result 1.0 0.000143348623853 1 0 1
hydrate,may,cause 1.0 0.000143348623853 1 0 1
hydrate,dietary,deficiencies 1.0 0.000143348623853 1 0 1
hydrate,diet,high 1.0 0.000143348623853 1 0 1
hydrate,and,interact 1.0 0.000143348623853 1 0 1
hydoxide,hydrochloride,ferrous 1.0 0.000143348623853 1 0 1
hydatid,cyst,patients 1.0 0.000143348623853 1 0 1
hydantoin,antiepileptic,and 1.0 0.000143348623853 1 0 1
hybridization,we,observed 1.0 0.000143348623853 1 0 1
humorsol,with,or 1.0 0.000143348623853 1 0 1
humira,may,also 1.0 0.000143348623853 1 0 1
humans,show,that 1.0 0.000143348623853 1 0 1
humans,may,result 1.0 0.000143348623853 1 0 1
humans,can,lead 1.0 0.000143348623853 1 0 1
humans,and,rats 1.0 0.000143348623853 1 0 1
human,trials,have 1.0 0.000143348623853 1 0 1
human,therapeutic,dose 1.0 0.000143348623853 1 0 1
human,subjects,ingesting 1.0 0.000143348623853 1 0 1
human,serum,by 1.0 0.000143348623853 1 0 1
human,pharmacokinetic,data 1.0 0.000143348623853 1 0 1
human,in,patients 1.0 0.000143348623853 1 0 1
human,growth,hormone 1.0 0.000143348623853 1 0 1
human,breast,cancer 1.0 0.000143348623853 1 0 1
ht3,antagonists,based 1.0 0.000143348623853 1 0 1
ht3,antagonist,class 1.0 0.000143348623853 1 0 1
ht1,agonists,within 1.0 0.000143348623853 1 0 1
ht1,agonists,have 1.0 0.000143348623853 1 0 1
hrs,of,decreased 1.0 0.000143348623853 1 0 1
href,frova_od,htm 1.0 0.000143348623853 1 0 1
href,bupropz_od,htm 1.0 0.000143348623853 1 0 1
however,when,any 1.0 0.000143348623853 1 0 1
however,there,has 1.0 0.000143348623853 1 0 1
however,the,systemic 1.0 0.000143348623853 1 0 1
however,the,peak 1.0 0.000143348623853 1 0 1
however,the,concomitant 1.0 0.000143348623853 1 0 1
however,the,antagonism 1.0 0.000143348623853 1 0 1
however,since,nsaids 1.0 0.000143348623853 1 0 1
however,serum,levels 1.0 0.000143348623853 1 0 1
however,retinyl,acetate 1.0 0.000143348623853 1 0 1
however,requirement,i 1.0 0.000143348623853 1 0 1
however,reports,suggest 1.0 0.000143348623853 1 0 1
however,reduced,cmax 1.0 0.000143348623853 1 0 1
however,prudent,medical 1.0 0.000143348623853 1 0 1
however,possible,that 1.0 0.000143348623853 1 0 1
however,patients,with 1.0 0.000143348623853 1 0 1
however,patients,on 1.0 0.000143348623853 1 0 1
however,other,published 1.0 0.000143348623853 1 0 1
however,mg,of 1.0 0.000143348623853 1 0 1
however,it,has 1.0 0.000143348623853 1 0 1
however,it,adversely 1.0 0.000143348623853 1 0 1
however,is,small 1.0 0.000143348623853 1 0 1
however,interactions,may 1.0 0.000143348623853 1 0 1
however,in,patients 1.0 0.000143348623853 1 0 1
however,in,another 1.0 0.000143348623853 1 0 1
however,high,doses 1.0 0.000143348623853 1 0 1
however,has,the 1.0 0.000143348623853 1 0 1
however,from,marketing 1.0 0.000143348623853 1 0 1
however,due,to 1.0 0.000143348623853 1 0 1
however,co,administration 1.0 0.000143348623853 1 0 1
however,careful,attention 1.0 0.000143348623853 1 0 1
however,because,bleeding 1.0 0.000143348623853 1 0 1
however,as,with 1.0 0.000143348623853 1 0 1
however,appropriate,monitoring 1.0 0.000143348623853 1 0 1
however,another,hmg-coa 1.0 0.000143348623853 1 0 1
however,a,crossover 1.0 0.000143348623853 1 0 1
how,soon,after 1.0 0.000143348623853 1 0 1
hours,were,potentiated 1.0 0.000143348623853 1 0 1
hours,was,given 1.0 0.000143348623853 1 0 1
hours,q24h,for 1.0 0.000143348623853 1 0 1
hours,postdose,a 1.0 0.000143348623853 1 0 1
hours,or,concurrent 1.0 0.000143348623853 1 0 1
hours,of,treatment 1.0 0.000143348623853 1 0 1
hours,of,subjects 1.0 0.000143348623853 1 0 1
hours,is,recommended 1.0 0.000143348623853 1 0 1
hours,for,any 1.0 0.000143348623853 1 0 1
hours,experienced,a 1.0 0.000143348623853 1 0 1
hours,competes,for 1.0 0.000143348623853 1 0 1
hours,before,resulted 1.0 0.000143348623853 1 0 1
hours,before,dosing 1.0 0.000143348623853 1 0 1
hours,before,conducting 1.0 0.000143348623853 1 0 1
hours,are,recommended 1.0 0.000143348623853 1 0 1
hours,apart,was 1.0 0.000143348623853 1 0 1
hours,and,as 1.0 0.000143348623853 1 0 1
hours,after,receiving 1.0 0.000143348623853 1 0 1
hours,after,or 1.0 0.000143348623853 1 0 1
hours,after,injection 1.0 0.000143348623853 1 0 1
hours,after,and 1.0 0.000143348623853 1 0 1
hour,prior,to 1.0 0.000143348623853 1 0 1
hour,blood,concentration 1.0 0.000143348623853 1 0 1
hour,before,the 1.0 0.000143348623853 1 0 1
hour,apart,on 1.0 0.000143348623853 1 0 1
hour,and,a 1.0 0.000143348623853 1 0 1
hour,after,receiving 1.0 0.000143348623853 1 0 1
hour,after,or 1.0 0.000143348623853 1 0 1
hour,after,administration 1.0 0.000143348623853 1 0 1
hot,weather,prolonged 1.0 0.000143348623853 1 0 1
hormones,and,estrogen-containing 1.0 0.000143348623853 1 0 1
hormone,response,of 1.0 0.000143348623853 1 0 1
hormone,may,enhance 1.0 0.000143348623853 1 0 1
hormone,concomitant,use 1.0 0.000143348623853 1 0 1
hormonalmethods,of,birth 1.0 0.000143348623853 1 0 1
hormonal,ortho-novum,produced 1.0 0.000143348623853 1 0 1
hormonal,may,render 1.0 0.000143348623853 1 0 1
hormonal,may,inhibit 1.0 0.000143348623853 1 0 1
hormonal,may,decrease 1.0 0.000143348623853 1 0 1
hormonal,increasing,plasma 1.0 0.000143348623853 1 0 1
hormonal,including,oral 1.0 0.000143348623853 1 0 1
hormonal,contraceptives,including 1.0 0.000143348623853 1 0 1
hormonal,components,ee 1.0 0.000143348623853 1 0 1
hormonal,co-administration,of 1.0 0.000143348623853 1 0 1
hormonal,are,used 1.0 0.000143348623853 1 0 1
hoof,twitch,from 1.0 0.000143348623853 1 0 1
hivid-associated,adverse,events 1.0 0.000143348623853 1 0 1
hivid,with,is 1.0 0.000143348623853 1 0 1
hiv-infected,patients,the 1.0 0.000143348623853 1 0 1
hiv,classified,as 1.0 0.000143348623853 1 0 1
history,of,serious 1.0 0.000143348623853 1 0 1
history,of,psychiatric 1.0 0.000143348623853 1 0 1
historicalcontrol,group,resulted 1.0 0.000143348623853 1 0 1
histamine-,or,camp-stimulated 1.0 0.000143348623853 1 0 1
histamine,h2,antagonists 1.0 0.000143348623853 1 0 1
highly,potent,cyp3a4 1.0 0.000143348623853 1 0 1
highly,plasma,protein-bound 1.0 0.000143348623853 1 0 1
higher-than,expected,steady-state 1.0 0.000143348623853 1 0 1
higher,when,was 1.0 0.000143348623853 1 0 1
higher,when,mg 1.0 0.000143348623853 1 0 1
higher,when,it 1.0 0.000143348623853 1 0 1
higher,when,given 1.0 0.000143348623853 1 0 1
higher,when,and 1.0 0.000143348623853 1 0 1
higher,than,users 1.0 0.000143348623853 1 0 1
higher,than,those 1.0 0.000143348623853 1 0 1
higher,than,recommended 1.0 0.000143348623853 1 0 1
higher,than,in 1.0 0.000143348623853 1 0 1
higher,serum,exposure 1.0 0.000143348623853 1 0 1
higher,serum,concentrations 1.0 0.000143348623853 1 0 1
higher,increases,in 1.0 0.000143348623853 1 0 1
higher,exposure,presumably 1.0 0.000143348623853 1 0 1
higher,doses,may 1.0 0.000143348623853 1 0 1
higher,degrees,of 1.0 0.000143348623853 1 0 1
higher,cardiac,output 1.0 0.000143348623853 1 0 1
higher,as,was 1.0 0.000143348623853 1 0 1
high-estradiol,treated,rats 1.0 0.000143348623853 1 0 1
high-estradiol,rats,were 1.0 0.000143348623853 1 0 1
high-dose,with,sodium 1.0 0.000143348623853 1 0 1
high-dose,mg,kg 1.0 0.000143348623853 1 0 1
high-dose,and,carbonic 1.0 0.000143348623853 1 0 1
high-dose,a,resulting 1.0 0.000143348623853 1 0 1
high,trileptal,doses 1.0 0.000143348623853 1 0 1
high,to,toxic 1.0 0.000143348623853 1 0 1
high,temperature,and 1.0 0.000143348623853 1 0 1
high,maintenance,dose 1.0 0.000143348623853 1 0 1
high,intraperitoneal,doses 1.0 0.000143348623853 1 0 1
high,in,vitamin 1.0 0.000143348623853 1 0 1
high,fever,severe 1.0 0.000143348623853 1 0 1
high,doses,mg 1.0 0.000143348623853 1 0 1
high,doses,has 1.0 0.000143348623853 1 0 1
high,dose,proleukin 1.0 0.000143348623853 1 0 1
high,concentrations,or 1.0 0.000143348623853 1 0 1
hg,compared,to 1.0 0.000143348623853 1 0 1
hexalen,and,plus 1.0 0.000143348623853 1 0 1
hexalen,and,of 1.0 0.000143348623853 1 0 1
heroin-related,deaths,reveal 1.0 0.000143348623853 1 0 1
herbs,such,as 1.0 0.000143348623853 1 0 1
herb,interactions,food 1.0 0.000143348623853 1 0 1
hepatoxicity,of,in 1.0 0.000143348623853 1 0 1
hepatotoxicity,of,by 1.0 0.000143348623853 1 0 1
hepatotoxicity,concomitant,administration 1.0 0.000143348623853 1 0 1
hepatotoxicity,are,suggested 1.0 0.000143348623853 1 0 1
hepatotoxic,potential,must 1.0 0.000143348623853 1 0 1
hepatotoxic,medications,is 1.0 0.000143348623853 1 0 1
hepatotoxic,influenza,virus 1.0 0.000143348623853 1 0 1
hepatotoxic,effects,with 1.0 0.000143348623853 1 0 1
hepatic,tissues,induced 1.0 0.000143348623853 1 0 1
hepatic,oxidation,elc 1.0 0.000143348623853 1 0 1
hepatic,metabolism,rifampin 1.0 0.000143348623853 1 0 1
hepatic,metabolism,produced 1.0 0.000143348623853 1 0 1
hepatic,lipid,peroxidation 1.0 0.000143348623853 1 0 1
hepatic,enzymes,such 1.0 0.000143348623853 1 0 1
hepatic,enzyme-inducing,such 1.0 0.000143348623853 1 0 1
hepatic,enzyme,induction 1.0 0.000143348623853 1 0 1
heparinized,patients,may 1.0 0.000143348623853 1 0 1
heparin,the,in 1.0 0.000143348623853 1 0 1
heparin,effect,digitalis 1.0 0.000143348623853 1 0 1
hence,is,not 1.0 0.000143348623853 1 0 1
hemostatic,defense,of 1.0 0.000143348623853 1 0 1
hemostasis,and,nsaids 1.0 0.000143348623853 1 0 1
hemostasis,and,has 1.0 0.000143348623853 1 0 1
hemodynamic,compromise,have 1.0 0.000143348623853 1 0 1
hemabate,may,augment 1.0 0.000143348623853 1 0 1
heavy,intake,for 1.0 0.000143348623853 1 0 1
heart,rate,when 1.0 0.000143348623853 1 0 1
heart,rate,increase 1.0 0.000143348623853 1 0 1
heart,medicine,may 1.0 0.000143348623853 1 0 1
heart,function,is 1.0 0.000143348623853 1 0 1
heart,failure,severe 1.0 0.000143348623853 1 0 1
heart,failure,receiving 1.0 0.000143348623853 1 0 1
heart,failure,etc 1.0 0.000143348623853 1 0 1
heart,failure,channel 1.0 0.000143348623853 1 0 1
heart,disease,has 1.0 0.000143348623853 1 0 1
heart,disease,congestive 1.0 0.000143348623853 1 0 1
heart,block,may 1.0 0.000143348623853 1 0 1
hearing,have,been 1.0 0.000143348623853 1 0 1
healthy,volunteers,with 1.0 0.000143348623853 1 0 1
healthy,volunteers,taking 1.0 0.000143348623853 1 0 1
healthy,volunteers,significantly 1.0 0.000143348623853 1 0 1
healthy,volunteers,receiving 1.0 0.000143348623853 1 0 1
healthy,volunteers,of 1.0 0.000143348623853 1 0 1
healthy,volunteers,in 1.0 0.000143348623853 1 0 1
healthy,volunteers,hydrochloride 1.0 0.000143348623853 1 0 1
healthy,volunteers,either 1.0 0.000143348623853 1 0 1
healthy,subjects,when 1.0 0.000143348623853 1 0 1
healthy,subjects,was 1.0 0.000143348623853 1 0 1
healthy,subjects,stabilized 1.0 0.000143348623853 1 0 1
healthy,subjects,n 1.0 0.000143348623853 1 0 1
healthy,subjects,mean 1.0 0.000143348623853 1 0 1
healthy,subjects,administered 1.0 0.000143348623853 1 0 1
healthy,individuals,plasma 1.0 0.000143348623853 1 0 1
health,care,professional 1.0 0.000143348623853 1 0 1
hctz,alone,auc 1.0 0.000143348623853 1 0 1
hcl,with,other 1.0 0.000143348623853 1 0 1
hcl,with,most 1.0 0.000143348623853 1 0 1
hcl,usually,does 1.0 0.000143348623853 1 0 1
hcl,to,patients 1.0 0.000143348623853 1 0 1
hcl,should,receive 1.0 0.000143348623853 1 0 1
hcl,no,greater 1.0 0.000143348623853 1 0 1
hcl,may,have 1.0 0.000143348623853 1 0 1
hcl,is,used 1.0 0.000143348623853 1 0 1
hcl,is,antagonized 1.0 0.000143348623853 1 0 1
hcl,in,combination 1.0 0.000143348623853 1 0 1
hcl,in,association 1.0 0.000143348623853 1 0 1
hcl,has,been 1.0 0.000143348623853 1 0 1
hcl,blunts,the 1.0 0.000143348623853 1 0 1
hcl,ascorbic,acid 1.0 0.000143348623853 1 0 1
hcl,and,sulfate 1.0 0.000143348623853 1 0 1
hcl,and,resulted 1.0 0.000143348623853 1 0 1
hcl,and,agents 1.0 0.000143348623853 1 0 1
hcl,alternatives,to 1.0 0.000143348623853 1 0 1
hc1,concomitant,use 1.0 0.000143348623853 1 0 1
have,synergistic,activity 1.0 0.000143348623853 1 0 1
have,significant,metabolism 1.0 0.000143348623853 1 0 1
have,shown,casodex 1.0 0.000143348623853 1 0 1
have,secondary,actions 1.0 0.000143348623853 1 0 1
have,resulted,when 1.0 0.000143348623853 1 0 1
have,resulted,in 1.0 0.000143348623853 1 0 1
have,resulted,from 1.0 0.000143348623853 1 0 1
have,received,muscle 1.0 0.000143348623853 1 0 1
have,received,maoi 1.0 0.000143348623853 1 0 1
have,pre-existing,cardiac 1.0 0.000143348623853 1 0 1
have,not,established 1.0 0.000143348623853 1 0 1
have,negative,inotropic 1.0 0.000143348623853 1 0 1
have,life-threatening,interactions 1.0 0.000143348623853 1 0 1
have,increased,the 1.0 0.000143348623853 1 0 1
have,in,some 1.0 0.000143348623853 1 0 1
have,identified,potentially 1.0 0.000143348623853 1 0 1
have,had,an 1.0 0.000143348623853 1 0 1
have,erroneously,low 1.0 0.000143348623853 1 0 1
have,enhanced,the 1.0 0.000143348623853 1 0 1
have,elevated,plasma 1.0 0.000143348623853 1 0 1
have,demonstrated,moderate 1.0 0.000143348623853 1 0 1
have,demonstrated,an 1.0 0.000143348623853 1 0 1
have,demonstrated,a 1.0 0.000143348623853 1 0 1
have,decreased,symptoms 1.0 0.000143348623853 1 0 1
have,cholesterol,levels 1.0 0.000143348623853 1 0 1
have,caused,to 1.0 0.000143348623853 1 0 1
have,been,treated 1.0 0.000143348623853 1 0 1
have,been,some 1.0 0.000143348623853 1 0 1
have,been,reviewed 1.0 0.000143348623853 1 0 1
have,been,postmarketing 1.0 0.000143348623853 1 0 1
have,been,occasional 1.0 0.000143348623853 1 0 1
have,been,conflicting 1.0 0.000143348623853 1 0 1
have,been,co-administered 1.0 0.000143348623853 1 0 1
have,been,cases 1.0 0.000143348623853 1 0 1
have,also,shown 1.0 0.000143348623853 1 0 1
have,additive,or 1.0 0.000143348623853 1 0 1
have,additive,hypotensite 1.0 0.000143348623853 1 0 1
have,a,marked 1.0 0.000143348623853 1 0 1
have,a,dose 1.0 0.000143348623853 1 0 1
has,reduced,or 1.0 0.000143348623853 1 0 1
has,recovered,from 1.0 0.000143348623853 1 0 1
has,recently,received 1.0 0.000143348623853 1 0 1
has,received,or 1.0 0.000143348623853 1 0 1
has,previously,received 1.0 0.000143348623853 1 0 1
has,occurred,in 1.0 0.000143348623853 1 0 1
has,little,or 1.0 0.000143348623853 1 0 1
has,had,less 1.0 0.000143348623853 1 0 1
has,been,seen 1.0 0.000143348623853 1 0 1
has,been,one 1.0 0.000143348623853 1 0 1
has,been,filtrated 1.0 0.000143348623853 1 0 1
has,been,concern 1.0 0.000143348623853 1 0 1
has,additive,effects 1.0 0.000143348623853 1 0 1
has,a,tendency 1.0 0.000143348623853 1 0 1
has,a,synergistic 1.0 0.000143348623853 1 0 1
has,a,lower 1.0 0.000143348623853 1 0 1
has,a,less 1.0 0.000143348623853 1 0 1
has,a,considerable 1.0 0.000143348623853 1 0 1
has,a,complex 1.0 0.000143348623853 1 0 1
hand,intrathecal,micrograms 1.0 0.000143348623853 1 0 1
halved,for,the 1.0 0.000143348623853 1 0 1
halved,and,titration 1.0 0.000143348623853 1 0 1
haloperidol,reduced,or 1.0 0.000143348623853 1 0 1
haloperidol,blocks,receptors 1.0 0.000143348623853 1 0 1
haloperidol,blocks,and 1.0 0.000143348623853 1 0 1
halogenated,hydrocarbon,increase 1.0 0.000143348623853 1 0 1
halogenated,hydrocarbon,general 1.0 0.000143348623853 1 0 1
hallucinations,have,been 1.0 0.000143348623853 1 0 1
hallucinations,and,irrational 1.0 0.000143348623853 1 0 1
half-life,the,coadministration 1.0 0.000143348623853 1 0 1
half-life,or,serum 1.0 0.000143348623853 1 0 1
half-life,of,thereby 1.0 0.000143348623853 1 0 1
half-life,of,is 1.0 0.000143348623853 1 0 1
half-life,of,increased 1.0 0.000143348623853 1 0 1
half-life,of,in 1.0 0.000143348623853 1 0 1
half-life,of,decreased 1.0 0.000143348623853 1 0 1
half-life,of,by 1.0 0.000143348623853 1 0 1
half-life,of,because 1.0 0.000143348623853 1 0 1
half-life,may,be 1.0 0.000143348623853 1 0 1
half-life,increased,to 1.0 0.000143348623853 1 0 1
half-life,increased,approximately 1.0 0.000143348623853 1 0 1
half-life,by,and 1.0 0.000143348623853 1 0 1
half-life,and,toxicity 1.0 0.000143348623853 1 0 1
half-life,and,the 1.0 0.000143348623853 1 0 1
half-life,and,an 1.0 0.000143348623853 1 0 1
half,the,standard 1.0 0.000143348623853 1 0 1
half,life,of 1.0 0.000143348623853 1 0 1
haldol,may,be 1.0 0.000143348623853 1 0 1
had,returned,to 1.0 0.000143348623853 1 0 1
had,plasma,concentrations 1.0 0.000143348623853 1 0 1
had,only,a 1.0 0.000143348623853 1 0 1
had,less,than 1.0 0.000143348623853 1 0 1
had,an,unsatisfactory 1.0 0.000143348623853 1 0 1
h2antagonists,reduced,plasma 1.0 0.000143348623853 1 0 1
h2-receptor,antagonists,such 1.0 0.000143348623853 1 0 1
h2-receptor,antagonists,co-administration 1.0 0.000143348623853 1 0 1
h2,receptor,antagonists 1.0 0.000143348623853 1 0 1
h2,blockers,proton 1.0 0.000143348623853 1 0 1
h2,blockers,although 1.0 0.000143348623853 1 0 1
h2,antagonists,cimetidine 1.0 0.000143348623853 1 0 1
h1-blocking,agents,and 1.0 0.000143348623853 1 0 1
h1,and,h2 1.0 0.000143348623853 1 0 1
h-triglyceride,fractional,clearance 1.0 0.000143348623853 1 0 1
h,without,to 1.0 0.000143348623853 1 0 1
h,s,regimen 1.0 0.000143348623853 1 0 1
h,s,concomitantly 1.0 0.000143348623853 1 0 1
h,receptor,antagonists 1.0 0.000143348623853 1 0 1
h,following,the 1.0 0.000143348623853 1 0 1
h,antagonists,when 1.0 0.000143348623853 1 0 1
h,among,the 1.0 0.000143348623853 1 0 1
gut,motility,may 1.0 0.000143348623853 1 0 1
guide,to,further 1.0 0.000143348623853 1 0 1
growth,in,vitro 1.0 0.000143348623853 1 0 1
growth,hormone,may 1.0 0.000143348623853 1 0 1
growth,hormone,concomitant 1.0 0.000143348623853 1 0 1
groups,treated,with 1.0 0.000143348623853 1 0 1
groups,receiving,mg 1.0 0.000143348623853 1 0 1
groups,pd2,values 1.0 0.000143348623853 1 0 1
group,were,supersensitive 1.0 0.000143348623853 1 0 1
group,resulted,in 1.0 0.000143348623853 1 0 1
group,of,subjects 1.0 0.000143348623853 1 0 1
gritty,substance,to 1.0 0.000143348623853 1 0 1
griseofulvin,may,induce 1.0 0.000143348623853 1 0 1
griseofulvin,griseofulvin,may 1.0 0.000143348623853 1 0 1
gris-peg,nizoral,sporanox 1.0 0.000143348623853 1 0 1
grepafloxacin,like,other 1.0 0.000143348623853 1 0 1
grepafloxacin,is,a 1.0 0.000143348623853 1 0 1
greater,when,and 1.0 0.000143348623853 1 0 1
greater,than,when 1.0 0.000143348623853 1 0 1
greater,than,usual 1.0 0.000143348623853 1 0 1
greater,than,two-fold 1.0 0.000143348623853 1 0 1
greater,than,reduction 1.0 0.000143348623853 1 0 1
greater,than,one-tenth 1.0 0.000143348623853 1 0 1
greater,than,fold 1.0 0.000143348623853 1 0 1
greater,proportion,of 1.0 0.000143348623853 1 0 1
greater,patients,when 1.0 0.000143348623853 1 0 1
greater,ischemic,response 1.0 0.000143348623853 1 0 1
greater,gastrointestinal,toxicity 1.0 0.000143348623853 1 0 1
greater,degrees,of 1.0 0.000143348623853 1 0 1
greater,amount,of 1.0 0.000143348623853 1 0 1
gravis,inflammatory,arthritis 1.0 0.000143348623853 1 0 1
grapefruit,juice,and 1.0 0.000143348623853 1 0 1
grams,three,times 1.0 0.000143348623853 1 0 1
gram,of,hydroxide 1.0 0.000143348623853 1 0 1
gram,of,and 1.0 0.000143348623853 1 0 1
gram,absorption,of 1.0 0.000143348623853 1 0 1
gradual,in,order 1.0 0.000143348623853 1 0 1
gm,day,days 1.0 0.000143348623853 1 0 1
gm,daily,for 1.0 0.000143348623853 1 0 1
glycosides,heart,medicine 1.0 0.000143348623853 1 0 1
glycosides,could,exaggerate 1.0 0.000143348623853 1 0 1
glycosides,amphotericin,b-induced 1.0 0.000143348623853 1 0 1
glycoprotein,iib,iiia 1.0 0.000143348623853 1 0 1
glyburide,the,concomitant 1.0 0.000143348623853 1 0 1
glutathione,use,of 1.0 0.000143348623853 1 0 1
glutathione,levels,in 1.0 0.000143348623853 1 0 1
glutamic,acid,hcl 1.0 0.000143348623853 1 0 1
glucose,should,be 1.0 0.000143348623853 1 0 1
glucose,lowering,effect 1.0 0.000143348623853 1 0 1
glucose,levels,and 1.0 0.000143348623853 1 0 1
glucose,including,hyperglycemia 1.0 0.000143348623853 1 0 1
glucose,concentrations,with 1.0 0.000143348623853 1 0 1
glucose,concentrations,were 1.0 0.000143348623853 1 0 1
glucose,concentrations,should 1.0 0.000143348623853 1 0 1
glucose,concentrations,dosage 1.0 0.000143348623853 1 0 1
glomerulonephritis,oculo-bulbar,myasthenia 1.0 0.000143348623853 1 0 1
glibenclamide,in,a 1.0 0.000143348623853 1 0 1
gleevec,with,inhibitors 1.0 0.000143348623853 1 0 1
gleevec,with,cyp3a4 1.0 0.000143348623853 1 0 1
gleevec,will,increase 1.0 0.000143348623853 1 0 1
gleevec,oral-dose,clearance 1.0 0.000143348623853 1 0 1
gleevec,is,coadministered 1.0 0.000143348623853 1 0 1
gleevec,increases,the 1.0 0.000143348623853 1 0 1
gleevec,increased,gleevec 1.0 0.000143348623853 1 0 1
gleevec,gleevec,increases 1.0 0.000143348623853 1 0 1
glaucoma,or,systemic 1.0 0.000143348623853 1 0 1
gland,who,is 1.0 0.000143348623853 1 0 1
gland,who,are 1.0 0.000143348623853 1 0 1
gl,was,combined 1.0 0.000143348623853 1 0 1
given,with,sustiva 1.0 0.000143348623853 1 0 1
given,with,such 1.0 0.000143348623853 1 0 1
given,with,nonsteroidal 1.0 0.000143348623853 1 0 1
given,with,either 1.0 0.000143348623853 1 0 1
given,with,compared 1.0 0.000143348623853 1 0 1
given,with,but 1.0 0.000143348623853 1 0 1
given,with,beta 1.0 0.000143348623853 1 0 1
given,very,high 1.0 0.000143348623853 1 0 1
given,to,temporarily 1.0 0.000143348623853 1 0 1
given,to,a 1.0 0.000143348623853 1 0 1
given,the,substantial 1.0 0.000143348623853 1 0 1
given,the,enzyme-inducing 1.0 0.000143348623853 1 0 1
given,supplemental,l-glutamine 1.0 0.000143348623853 1 0 1
given,single,mg 1.0 0.000143348623853 1 0 1
given,simultaneously,with 1.0 0.000143348623853 1 0 1
given,one,dose 1.0 0.000143348623853 1 0 1
given,on,separate 1.0 0.000143348623853 1 0 1
given,mg,of 1.0 0.000143348623853 1 0 1
given,later,also 1.0 0.000143348623853 1 0 1
given,hours,prior 1.0 0.000143348623853 1 0 1
given,hour,prior 1.0 0.000143348623853 1 0 1
given,high,intraperitoneal 1.0 0.000143348623853 1 0 1
given,concurrently,patients 1.0 0.000143348623853 1 0 1
given,concurrently,increases 1.0 0.000143348623853 1 0 1
given,concomitantly,the 1.0 0.000143348623853 1 0 1
given,concomitantly,physicians 1.0 0.000143348623853 1 0 1
given,concomitantly,in 1.0 0.000143348623853 1 0 1
given,at,doses 1.0 0.000143348623853 1 0 1
given,as,sequential 1.0 0.000143348623853 1 0 1
given,and,didanosine-placebo 1.0 0.000143348623853 1 0 1
given,after,than 1.0 0.000143348623853 1 0 1
gi,ulceration,and 1.0 0.000143348623853 1 0 1
gi,tract,to 1.0 0.000143348623853 1 0 1
gets,absorbed,into 1.0 0.000143348623853 1 0 1
geometric,mean,confidence 1.0 0.000143348623853 1 0 1
geocillin,carbenicillin,indanyl 1.0 0.000143348623853 1 0 1
gentamicin,methionine,may 1.0 0.000143348623853 1 0 1
generally,not,recommended 1.0 0.000143348623853 1 0 1
generally,converted,to 1.0 0.000143348623853 1 0 1
general,have,additive 1.0 0.000143348623853 1 0 1
general,exaggeration,of 1.0 0.000143348623853 1 0 1
general,clinical,conditions 1.0 0.000143348623853 1 0 1
gel,should,not 1.0 0.000143348623853 1 0 1
gastrointestinal,ulceration,and 1.0 0.000143348623853 1 0 1
gastrointestinal,tract,hydoxide 1.0 0.000143348623853 1 0 1
gastrointestinal,tract,by 1.0 0.000143348623853 1 0 1
gastrointestinal,toxicity,than 1.0 0.000143348623853 1 0 1
gastrointestinal,secretion,while 1.0 0.000143348623853 1 0 1
gastrointestinal,motility,lowers 1.0 0.000143348623853 1 0 1
gastrointestinal,lesions,as 1.0 0.000143348623853 1 0 1
gastrointestinal,irritation,caution 1.0 0.000143348623853 1 0 1
gastrointestinal,effects,without 1.0 0.000143348623853 1 0 1
gastrointestinal,effects,of 1.0 0.000143348623853 1 0 1
gastrointestinal,bleeding,have 1.0 0.000143348623853 1 0 1
gastrointestinal,alkalinizing,agents 1.0 0.000143348623853 1 0 1
gastrointestinal,acidifying,agents 1.0 0.000143348623853 1 0 1
gastric,ph,was 1.0 0.000143348623853 1 0 1
gastric,ph,h2-receptor 1.0 0.000143348623853 1 0 1
gastric,emptying,may 1.0 0.000143348623853 1 0 1
garlic,allium,sativum 1.0 0.000143348623853 1 0 1
ganciclovir,administration,of 1.0 0.000143348623853 1 0 1
gait,or,marked 1.0 0.000143348623853 1 0 1
gain,when,was 1.0 0.000143348623853 1 0 1
gain,and,weight 1.0 0.000143348623853 1 0 1
gabitril,carbamazepine,population 1.0 0.000143348623853 1 0 1
gaba-ergic,system,and 1.0 0.000143348623853 1 0 1
g,resulted,in 1.0 0.000143348623853 1 0 1
g,of,per 1.0 0.000143348623853 1 0 1
g,ml,the 1.0 0.000143348623853 1 0 1
g,kg,on 1.0 0.000143348623853 1 0 1
g,kg,for 1.0 0.000143348623853 1 0 1
g,hour,before 1.0 0.000143348623853 1 0 1
g,h,ml 1.0 0.000143348623853 1 0 1
g,day,have 1.0 0.000143348623853 1 0 1
g,and,was 1.0 0.000143348623853 1 0 1
g,and,preparations 1.0 0.000143348623853 1 0 1
furthermore,it,has 1.0 0.000143348623853 1 0 1
furthermore,and,other 1.0 0.000143348623853 1 0 1
further,the,duration 1.0 0.000143348623853 1 0 1
further,antihypertensive,effect 1.0 0.000143348623853 1 0 1
further,alterations,in 1.0 0.000143348623853 1 0 1
furosemide,when,was 1.0 0.000143348623853 1 0 1
furosemide,toradol,iv 1.0 0.000143348623853 1 0 1
furosemide,should,not 1.0 0.000143348623853 1 0 1
furosemide,may,increase 1.0 0.000143348623853 1 0 1
furosemide,may,decrease 1.0 0.000143348623853 1 0 1
furosemide,may,add 1.0 0.000143348623853 1 0 1
furosemide,has,a 1.0 0.000143348623853 1 0 1
fungal,resistance,to 1.0 0.000143348623853 1 0 1
functioning,gland,who 1.0 0.000143348623853 1 0 1
function,there,is 1.0 0.000143348623853 1 0 1
function,the,use 1.0 0.000143348623853 1 0 1
function,tests,occur 1.0 0.000143348623853 1 0 1
function,such,as 1.0 0.000143348623853 1 0 1
function,or,av 1.0 0.000143348623853 1 0 1
function,is,normal 1.0 0.000143348623853 1 0 1
function,eg,and 1.0 0.000143348623853 1 0 1
function,and,in 1.0 0.000143348623853 1 0 1
function,accompanied,by 1.0 0.000143348623853 1 0 1
fulminant,rhabdomyolysis,has 1.0 0.000143348623853 1 0 1
fulminant,pancreatitis,possibly 1.0 0.000143348623853 1 0 1
fully,characterized,a 1.0 0.000143348623853 1 0 1
fruit,juices,etc 1.0 0.000143348623853 1 0 1
frova,within,hours 1.0 0.000143348623853 1 0 1
from,twitch,to 1.0 0.000143348623853 1 0 1
from,treatment,dosage 1.0 0.000143348623853 1 0 1
from,to,which 1.0 0.000143348623853 1 0 1
from,to,was 1.0 0.000143348623853 1 0 1
from,to,took 1.0 0.000143348623853 1 0 1
from,to,ng 1.0 0.000143348623853 1 0 1
from,to,minutes 1.0 0.000143348623853 1 0 1
from,to,m 1.0 0.000143348623853 1 0 1
from,to,fold 1.0 0.000143348623853 1 0 1
from,these,patients 1.0 0.000143348623853 1 0 1
from,the,toxicity 1.0 0.000143348623853 1 0 1
from,the,results 1.0 0.000143348623853 1 0 1
from,the,high-dose 1.0 0.000143348623853 1 0 1
from,the,combined 1.0 0.000143348623853 1 0 1
from,the,body 1.0 0.000143348623853 1 0 1
from,the,atac 1.0 0.000143348623853 1 0 1
from,the,administration 1.0 0.000143348623853 1 0 1
from,severe,enterocolitis 1.0 0.000143348623853 1 0 1
from,regression,analyses 1.0 0.000143348623853 1 0 1
from,protein,binding 1.0 0.000143348623853 1 0 1
from,plasma,albumin 1.0 0.000143348623853 1 0 1
from,ml,min 1.0 0.000143348623853 1 0 1
from,mg,l 1.0 0.000143348623853 1 0 1
from,mg,by 1.0 0.000143348623853 1 0 1
from,marketing,experiences 1.0 0.000143348623853 1 0 1
from,l,kg 1.0 0.000143348623853 1 0 1
from,its,capacity 1.0 0.000143348623853 1 0 1
from,high-estradiol,rats 1.0 0.000143348623853 1 0 1
from,containing,medicines 1.0 0.000143348623853 1 0 1
from,concomitant,therapy 1.0 0.000143348623853 1 0 1
from,combined,use 1.0 0.000143348623853 1 0 1
from,combined,therapy 1.0 0.000143348623853 1 0 1
from,co-administration,of 1.0 0.000143348623853 1 0 1
from,cholinergic,blockade 1.0 0.000143348623853 1 0 1
from,approximately,to 1.0 0.000143348623853 1 0 1
from,a,randomized 1.0 0.000143348623853 1 0 1
from,a,previously 1.0 0.000143348623853 1 0 1
from,a,control 1.0 0.000143348623853 1 0 1
frequently,thereafter,and 1.0 0.000143348623853 1 0 1
frequently,if,prinivil 1.0 0.000143348623853 1 0 1
frequently,if,is 1.0 0.000143348623853 1 0 1
frequently,if,inspra 1.0 0.000143348623853 1 0 1
frequently,enough,during 1.0 0.000143348623853 1 0 1
frequent,maintenance,dosing 1.0 0.000143348623853 1 0 1
frequent,involvement,of 1.0 0.000143348623853 1 0 1
frequent,cause,of 1.0 0.000143348623853 1 0 1
frequency,of,skin 1.0 0.000143348623853 1 0 1
frequency,of,seizures 1.0 0.000143348623853 1 0 1
frequency,of,hyperkalemia 1.0 0.000143348623853 1 0 1
frequency,and,severity 1.0 0.000143348623853 1 0 1
frequency,and,or 1.0 0.000143348623853 1 0 1
free,radical-mediated,tissue 1.0 0.000143348623853 1 0 1
free,may,be 1.0 0.000143348623853 1 0 1
free,fraction,fdf 1.0 0.000143348623853 1 0 1
free,and,bound 1.0 0.000143348623853 1 0 1
fraction,fdf,at 1.0 0.000143348623853 1 0 1
fr,responding,produced 1.0 0.000143348623853 1 0 1
four-day,regimen,of 1.0 0.000143348623853 1 0 1
four,resulted,in 1.0 0.000143348623853 1 0 1
four,patients,in 1.0 0.000143348623853 1 0 1
found,to,temporarily 1.0 0.000143348623853 1 0 1
found,to,require 1.0 0.000143348623853 1 0 1
found,to,inhibit 1.0 0.000143348623853 1 0 1
found,to,decrease 1.0 0.000143348623853 1 0 1
found,that,chronic 1.0 0.000143348623853 1 0 1
found,in,vivo 1.0 0.000143348623853 1 0 1
fosinopril,sodium,can 1.0 0.000143348623853 1 0 1
foscavir,should,be 1.0 0.000143348623853 1 0 1
foscarnets,tendency,to 1.0 0.000143348623853 1 0 1
foscarnet,and,aminoglycosides 1.0 0.000143348623853 1 0 1
fortovase,invirase,kaletra 1.0 0.000143348623853 1 0 1
fortified,with,iron 1.0 0.000143348623853 1 0 1
formulations,of,which 1.0 0.000143348623853 1 0 1
formulations,containing,buffer 1.0 0.000143348623853 1 0 1
formulation,of,mg 1.0 0.000143348623853 1 0 1
formulation,of,increased 1.0 0.000143348623853 1 0 1
forms,may,not 1.0 0.000143348623853 1 0 1
formed,with,concurrent 1.0 0.000143348623853 1 0 1
formation,of,a 1.0 0.000143348623853 1 0 1
formation,in,u937 1.0 0.000143348623853 1 0 1
formation,from,combined 1.0 0.000143348623853 1 0 1
form,or,may 1.0 0.000143348623853 1 0 1
form,chelation,complexes 1.0 0.000143348623853 1 0 1
form,a,sudden 1.0 0.000143348623853 1 0 1
form,a,nitrosamine 1.0 0.000143348623853 1 0 1
forevidence,of,withdrawal 1.0 0.000143348623853 1 0 1
for,when,coadministered 1.0 0.000143348623853 1 0 1
for,weeks,was 1.0 0.000143348623853 1 0 1
for,weeks,has 1.0 0.000143348623853 1 0 1
for,volatile,inhalation 1.0 0.000143348623853 1 0 1
for,vitamin,b3 1.0 0.000143348623853 1 0 1
for,use,with 1.0 0.000143348623853 1 0 1
for,two,weeks 1.0 0.000143348623853 1 0 1
for,tubular,secretion 1.0 0.000143348623853 1 0 1
for,these,reasons 1.0 0.000143348623853 1 0 1
for,therapy,should 1.0 0.000143348623853 1 0 1
for,the,reduction 1.0 0.000143348623853 1 0 1
for,the,period 1.0 0.000143348623853 1 0 1
for,the,inhibitory 1.0 0.000143348623853 1 0 1
for,the,following 1.0 0.000143348623853 1 0 1
for,the,first 1.0 0.000143348623853 1 0 1
for,the,effect 1.0 0.000143348623853 1 0 1
for,the,appearance 1.0 0.000143348623853 1 0 1
for,that,protects 1.0 0.000143348623853 1 0 1
for,than,for 1.0 0.000143348623853 1 0 1
for,strains,and 1.0 0.000143348623853 1 0 1
for,signs,and 1.0 0.000143348623853 1 0 1
for,serious,interactions 1.0 0.000143348623853 1 0 1
for,renal,toxicity 1.0 0.000143348623853 1 0 1
for,reexacerbation,of 1.0 0.000143348623853 1 0 1
for,reduction,in 1.0 0.000143348623853 1 0 1
for,potentially,serious 1.0 0.000143348623853 1 0 1
for,possible,atrioventricular 1.0 0.000143348623853 1 0 1
for,patients,given 1.0 0.000143348623853 1 0 1
for,ototoxicity,is 1.0 0.000143348623853 1 0 1
for,other,oral 1.0 0.000143348623853 1 0 1
for,one,week 1.0 0.000143348623853 1 0 1
for,n,and 1.0 0.000143348623853 1 0 1
for,migraine,therapy 1.0 0.000143348623853 1 0 1
for,mg,qd 1.0 0.000143348623853 1 0 1
for,management,of 1.0 0.000143348623853 1 0 1
for,longer,than 1.0 0.000143348623853 1 0 1
for,known,side 1.0 0.000143348623853 1 0 1
for,injection,in 1.0 0.000143348623853 1 0 1
for,injection,concentrate 1.0 0.000143348623853 1 0 1
for,increased,sedation 1.0 0.000143348623853 1 0 1
for,increased,risk 1.0 0.000143348623853 1 0 1
for,include,increased 1.0 0.000143348623853 1 0 1
for,i,coadministration 1.0 0.000143348623853 1 0 1
for,hydroxy-iso,by 1.0 0.000143348623853 1 0 1
for,hour,after 1.0 0.000143348623853 1 0 1
for,flolan,to 1.0 0.000143348623853 1 0 1
for,exjade,should 1.0 0.000143348623853 1 0 1
for,excretion,in 1.0 0.000143348623853 1 0 1
for,example,when 1.0 0.000143348623853 1 0 1
for,example,since 1.0 0.000143348623853 1 0 1
for,example,and 1.0 0.000143348623853 1 0 1
for,eight,of 1.0 0.000143348623853 1 0 1
for,drugs,such 1.0 0.000143348623853 1 0 1
for,detoxification,of 1.0 0.000143348623853 1 0 1
for,days,while 1.0 0.000143348623853 1 0 1
for,days,results 1.0 0.000143348623853 1 0 1
for,days,intraperitoneally 1.0 0.000143348623853 1 0 1
for,days,however 1.0 0.000143348623853 1 0 1
for,days,decreased 1.0 0.000143348623853 1 0 1
for,days,as 1.0 0.000143348623853 1 0 1
for,cyp2d6,resulted 1.0 0.000143348623853 1 0 1
for,converting,difluoro-2 1.0 0.000143348623853 1 0 1
for,cmax,when 1.0 0.000143348623853 1 0 1
for,by,range 1.0 0.000143348623853 1 0 1
for,auc,and 1.0 0.000143348623853 1 0 1
for,arava,levels 1.0 0.000143348623853 1 0 1
for,any,excessive 1.0 0.000143348623853 1 0 1
for,and,synergistic 1.0 0.000143348623853 1 0 1
for,and,ethinyl 1.0 0.000143348623853 1 0 1
for,an,unusually 1.0 0.000143348623853 1 0 1
for,an,additive 1.0 0.000143348623853 1 0 1
for,alterations,of 1.0 0.000143348623853 1 0 1
for,alterations,in 1.0 0.000143348623853 1 0 1
for,adult-onset,diabetics 1.0 0.000143348623853 1 0 1
for,additional,that 1.0 0.000143348623853 1 0 1
for,a,interaction 1.0 0.000143348623853 1 0 1
for,a,change 1.0 0.000143348623853 1 0 1
foods,or,may 1.0 0.000143348623853 1 0 1
foods,fortified,with 1.0 0.000143348623853 1 0 1
food,one,hour 1.0 0.000143348623853 1 0 1
food,isrecommended,in 1.0 0.000143348623853 1 0 1
food,is,recommended 1.0 0.000143348623853 1 0 1
food,cns,effects 1.0 0.000143348623853 1 0 1
following,use,with 1.0 0.000143348623853 1 0 1
following,use,of 1.0 0.000143348623853 1 0 1
following,the,initiation 1.0 0.000143348623853 1 0 1
following,simultaneous,administration 1.0 0.000143348623853 1 0 1
following,precautions,should 1.0 0.000143348623853 1 0 1
following,or,h 1.0 0.000143348623853 1 0 1
following,nimbex,is 1.0 0.000143348623853 1 0 1
following,medicines,or 1.0 0.000143348623853 1 0 1
following,medications,tylenol 1.0 0.000143348623853 1 0 1
following,macrolide,antibiotics 1.0 0.000143348623853 1 0 1
following,interactions,must 1.0 0.000143348623853 1 0 1
following,eye,product 1.0 0.000143348623853 1 0 1
following,elspar,therapy 1.0 0.000143348623853 1 0 1
following,concurrent,use 1.0 0.000143348623853 1 0 1
following,cisplatin,hcl 1.0 0.000143348623853 1 0 1
following,an,intubating 1.0 0.000143348623853 1 0 1
following,alfenta,induction 1.0 0.000143348623853 1 0 1
following,agents,clomipramine 1.0 0.000143348623853 1 0 1
following,adverse,events 1.0 0.000143348623853 1 0 1
following,adrenocorticoids,cortisone-like 1.0 0.000143348623853 1 0 1
following,administration,decreased 1.0 0.000143348623853 1 0 1
following,acetazolamide,azole 1.0 0.000143348623853 1 0 1
following,acetaminophen,tylenol 1.0 0.000143348623853 1 0 1
following,acetaminophen,oral 1.0 0.000143348623853 1 0 1
following,a,meal 1.0 0.000143348623853 1 0 1
followed,by,irreversible 1.0 0.000143348623853 1 0 1
followed,by,cardiac 1.0 0.000143348623853 1 0 1
folic,acid,in 1.0 0.000143348623853 1 0 1
folic,acid,antagonists 1.0 0.000143348623853 1 0 1
fold,which,significantly 1.0 0.000143348623853 1 0 1
fold,when,at 1.0 0.000143348623853 1 0 1
fold,respectively,suggesting 1.0 0.000143348623853 1 0 1
fold,of,control 1.0 0.000143348623853 1 0 1
fold,lower,than 1.0 0.000143348623853 1 0 1
fold,increase,of 1.0 0.000143348623853 1 0 1
fold,in,hydatid 1.0 0.000143348623853 1 0 1
fold,in,healthy 1.0 0.000143348623853 1 0 1
fold,elevations,on 1.0 0.000143348623853 1 0 1
fold,elevation,in 1.0 0.000143348623853 1 0 1
fold,by,coadministration 1.0 0.000143348623853 1 0 1
fold,at,steady 1.0 0.000143348623853 1 0 1
fold,and,prolonged 1.0 0.000143348623853 1 0 1
fold,and,css 1.0 0.000143348623853 1 0 1
fold,and,auc 1.0 0.000143348623853 1 0 1
folate,utilization,including 1.0 0.000143348623853 1 0 1
fluvoxamine,tablets,the 1.0 0.000143348623853 1 0 1
fluvoxamine,tablets,should 1.0 0.000143348623853 1 0 1
fluvoxamine,tablets,not 1.0 0.000143348623853 1 0 1
fluvoxamine,tablets,at 1.0 0.000143348623853 1 0 1
fluvoxamine,tablets,and 1.0 0.000143348623853 1 0 1
fluvoxamine,inhibits,the 1.0 0.000143348623853 1 0 1
fluvoxamine,increased,mean 1.0 0.000143348623853 1 0 1
fluvoxamine,has,also 1.0 0.000143348623853 1 0 1
flushing,mydriasis,tachycardia 1.0 0.000143348623853 1 0 1
flurbiprofen,pretreatment,attenuated 1.0 0.000143348623853 1 0 1
flurbiprofen,like,other 1.0 0.000143348623853 1 0 1
flupenthixol,may,interact 1.0 0.000143348623853 1 0 1
flupenthixol,increases,the 1.0 0.000143348623853 1 0 1
flupenthixol,and,ethanol 1.0 0.000143348623853 1 0 1
fluothane,may,augment 1.0 0.000143348623853 1 0 1
fluothane,augments,the 1.0 0.000143348623853 1 0 1
fluothane,as,arrhythmias 1.0 0.000143348623853 1 0 1
fluorouracil,is,increased 1.0 0.000143348623853 1 0 1
fluoroquinolone,has,been 1.0 0.000143348623853 1 0 1
fluoride,and,citrate 1.0 0.000143348623853 1 0 1
fluid,were,increased 1.0 0.000143348623853 1 0 1
fludrocortisone,acetate,because 1.0 0.000143348623853 1 0 1
fludara,for,injection 1.0 0.000143348623853 1 0 1
flucytosine,while,a 1.0 0.000143348623853 1 0 1
fluctuations,of,vital 1.0 0.000143348623853 1 0 1
fluctuations,in,steady-state 1.0 0.000143348623853 1 0 1
fluctuate,significantly,when 1.0 0.000143348623853 1 0 1
fluconazole,concomitant,administration 1.0 0.000143348623853 1 0 1
fluconazole,an,inhibitor 1.0 0.000143348623853 1 0 1
flolan,which,may 1.0 0.000143348623853 1 0 1
flolan,was,used 1.0 0.000143348623853 1 0 1
flolan,was,initiated 1.0 0.000143348623853 1 0 1
flolan,to,increase 1.0 0.000143348623853 1 0 1
flolan,is,administered 1.0 0.000143348623853 1 0 1
flexeril,may,have 1.0 0.000143348623853 1 0 1
flexeril,may,enhance 1.0 0.000143348623853 1 0 1
flavoridin,alone,was 1.0 0.000143348623853 1 0 1
five-fold,increase,in 1.0 0.000143348623853 1 0 1
five,normal,volunteers 1.0 0.000143348623853 1 0 1
first,study,concomitant 1.0 0.000143348623853 1 0 1
first,sixty,minutes 1.0 0.000143348623853 1 0 1
first,hour,after 1.0 0.000143348623853 1 0 1
first,few,weeks 1.0 0.000143348623853 1 0 1
first,and,then 1.0 0.000143348623853 1 0 1
findings,to,humans 1.0 0.000143348623853 1 0 1
filtrated,to,a 1.0 0.000143348623853 1 0 1
fibrulation,and,torsades 1.0 0.000143348623853 1 0 1
fibrillation,when,combined 1.0 0.000143348623853 1 0 1
fibrillation,their,additive 1.0 0.000143348623853 1 0 1
fi,responding,produced 1.0 0.000143348623853 1 0 1
fi,or,fr 1.0 0.000143348623853 1 0 1
few,weeks,after 1.0 0.000143348623853 1 0 1
few,spontaneous,reports 1.0 0.000143348623853 1 0 1
few,patients,treated 1.0 0.000143348623853 1 0 1
few,patients,taking 1.0 0.000143348623853 1 0 1
fever,tremulousness,and 1.0 0.000143348623853 1 0 1
fever,severe,obstipation 1.0 0.000143348623853 1 0 1
fever,renal,insufficiency 1.0 0.000143348623853 1 0 1
feso4,or,supplemented 1.0 0.000143348623853 1 0 1
ferrous,sulfate,sodium 1.0 0.000143348623853 1 0 1
ferrous,sulfate,multivitamin 1.0 0.000143348623853 1 0 1
fentanyl,in,patients 1.0 0.000143348623853 1 0 1
fentanyl,anesthesia,severe 1.0 0.000143348623853 1 0 1
fenfluramine,may,increase 1.0 0.000143348623853 1 0 1
femara,and,mg 1.0 0.000143348623853 1 0 1
females,and,auc 1.0 0.000143348623853 1 0 1
female,volunteers,suggests 1.0 0.000143348623853 1 0 1
felt,that,in 1.0 0.000143348623853 1 0 1
fell,by,and 1.0 0.000143348623853 1 0 1
felbatol,to,antiepileptic 1.0 0.000143348623853 1 0 1
felbatol,phenytoin,phenytoin 1.0 0.000143348623853 1 0 1
felbatol,on,other 1.0 0.000143348623853 1 0 1
felbatol,gris-peg,nizoral 1.0 0.000143348623853 1 0 1
felbatol,causes,a 1.0 0.000143348623853 1 0 1
felbamate,treatment,resulted 1.0 0.000143348623853 1 0 1
fed,state,mg 1.0 0.000143348623853 1 0 1
fe,per,kg 1.0 0.000143348623853 1 0 1
fe,instead,of 1.0 0.000143348623853 1 0 1
fdf,at,micromol 1.0 0.000143348623853 1 0 1
fbs,followed,by 1.0 0.000143348623853 1 0 1
fatal,when,used 1.0 0.000143348623853 1 0 1
fatal,reactions,including 1.0 0.000143348623853 1 0 1
fatal,prolongation,of 1.0 0.000143348623853 1 0 1
fat-soluble,including,vitamin 1.0 0.000143348623853 1 0 1
faster,with,prior 1.0 0.000143348623853 1 0 1
fashion,as,much 1.0 0.000143348623853 1 0 1
family,in,metabolism 1.0 0.000143348623853 1 0 1
falls,vs,and 1.0 0.000143348623853 1 0 1
fall,of,the 1.0 0.000143348623853 1 0 1
failure,severe,hypotension 1.0 0.000143348623853 1 0 1
failure,receiving,or 1.0 0.000143348623853 1 0 1
failure,in,two 1.0 0.000143348623853 1 0 1
failure,have,been 1.0 0.000143348623853 1 0 1
failure,etc,or 1.0 0.000143348623853 1 0 1
failure,channel,blockers 1.0 0.000143348623853 1 0 1
failure,and,dosage 1.0 0.000143348623853 1 0 1
failed,to,cause 1.0 0.000143348623853 1 0 1
fade,recovery,took 1.0 0.000143348623853 1 0 1
fade,hoof,twitch 1.0 0.000143348623853 1 0 1
factrel,may,be 1.0 0.000143348623853 1 0 1
factors,studied,two 1.0 0.000143348623853 1 0 1
factive,with,resulted 1.0 0.000143348623853 1 0 1
factive,and,carbonate 1.0 0.000143348623853 1 0 1
f2alpha,and,in 1.0 0.000143348623853 1 0 1
eye,product,containing 1.0 0.000143348623853 1 0 1
extremely,cautiously,and 1.0 0.000143348623853 1 0 1
extreme,caution,to 1.0 0.000143348623853 1 0 1
extreme,agitation,progressing 1.0 0.000143348623853 1 0 1
extrapyramidal,symptoms,leukocytosis 1.0 0.000143348623853 1 0 1
extraneal,in,diabetic 1.0 0.000143348623853 1 0 1
extracellular,rr,microm 1.0 0.000143348623853 1 0 1
extent,auc,of 1.0 0.000143348623853 1 0 1
extensive,metabolizers,of 1.0 0.000143348623853 1 0 1
extends,its,plasma 1.0 0.000143348623853 1 0 1
extended,a,similar 1.0 0.000143348623853 1 0 1
extend,the,half-life 1.0 0.000143348623853 1 0 1
exposures,to,may 1.0 0.000143348623853 1 0 1
exposures,of,r-warfarin 1.0 0.000143348623853 1 0 1
exposures,of,and 1.0 0.000143348623853 1 0 1
exposure,with,a 1.0 0.000143348623853 1 0 1
exposure,when,coadministered 1.0 0.000143348623853 1 0 1
exposure,was,significantly 1.0 0.000143348623853 1 0 1
exposure,was,decreased 1.0 0.000143348623853 1 0 1
exposure,to,when 1.0 0.000143348623853 1 0 1
exposure,to,was 1.0 0.000143348623853 1 0 1
exposure,to,is 1.0 0.000143348623853 1 0 1
exposure,to,environmental 1.0 0.000143348623853 1 0 1
exposure,to,but 1.0 0.000143348623853 1 0 1
exposure,presumably,by 1.0 0.000143348623853 1 0 1
exposure,of,under 1.0 0.000143348623853 1 0 1
exposure,of,rats 1.0 0.000143348623853 1 0 1
exposure,of,mg 1.0 0.000143348623853 1 0 1
exposure,of,cefditoren 1.0 0.000143348623853 1 0 1
exposure,following,a 1.0 0.000143348623853 1 0 1
exposure,by,approximately 1.0 0.000143348623853 1 0 1
exposure,auc,higher 1.0 0.000143348623853 1 0 1
exposure,and,active 1.0 0.000143348623853 1 0 1
exposed,to,high 1.0 0.000143348623853 1 0 1
explain,the,increase 1.0 0.000143348623853 1 0 1
experimental,toxic,and 1.0 0.000143348623853 1 0 1
experimental,soft-gelatin,capsule 1.0 0.000143348623853 1 0 1
experiencing,increases,in 1.0 0.000143348623853 1 0 1
experiences,of,changes 1.0 0.000143348623853 1 0 1
experiences,in,patients 1.0 0.000143348623853 1 0 1
experiences,and,achieve 1.0 0.000143348623853 1 0 1
experienced,users,particularly 1.0 0.000143348623853 1 0 1
experienced,tremor,as 1.0 0.000143348623853 1 0 1
experienced,severe,toxicity 1.0 0.000143348623853 1 0 1
experienced,more,commonly 1.0 0.000143348623853 1 0 1
experienced,acute,atypical 1.0 0.000143348623853 1 0 1
experienced,a,decrease 1.0 0.000143348623853 1 0 1
experience,with,nonsteroidal 1.0 0.000143348623853 1 0 1
experience,when,suprax 1.0 0.000143348623853 1 0 1
experience,toxicity,at 1.0 0.000143348623853 1 0 1
experience,to,assess 1.0 0.000143348623853 1 0 1
experience,of,coma 1.0 0.000143348623853 1 0 1
experience,in,over 1.0 0.000143348623853 1 0 1
experience,enhanced,side 1.0 0.000143348623853 1 0 1
experience,bleeding,has 1.0 0.000143348623853 1 0 1
experience,bleeding,events 1.0 0.000143348623853 1 0 1
experience,a,reversible 1.0 0.000143348623853 1 0 1
experience,a,precipitous 1.0 0.000143348623853 1 0 1
expected,with,higher 1.0 0.000143348623853 1 0 1
expected,when,is 1.0 0.000143348623853 1 0 1
expected,to,prolong 1.0 0.000143348623853 1 0 1
expected,to,lead 1.0 0.000143348623853 1 0 1
expected,to,decrease 1.0 0.000143348623853 1 0 1
expected,to,compromise 1.0 0.000143348623853 1 0 1
expected,that,use 1.0 0.000143348623853 1 0 1
expected,that,the 1.0 0.000143348623853 1 0 1
expected,than,when 1.0 0.000143348623853 1 0 1
expected,steady-state,serum 1.0 0.000143348623853 1 0 1
expected,antidepressant,levels 1.0 0.000143348623853 1 0 1
expected,and,uroxatral 1.0 0.000143348623853 1 0 1
exogenous,also,appeared 1.0 0.000143348623853 1 0 1
exists,for,a 1.0 0.000143348623853 1 0 1
exhibits,non-linear,pharmacokinetics 1.0 0.000143348623853 1 0 1
exhibited,strong,synergistic 1.0 0.000143348623853 1 0 1
exhibit,a,diminished 1.0 0.000143348623853 1 0 1
exerts,a,slight 1.0 0.000143348623853 1 0 1
exert,particular,caution 1.0 0.000143348623853 1 0 1
exercised,when,pletal 1.0 0.000143348623853 1 0 1
exercised,when,lexapro 1.0 0.000143348623853 1 0 1
exercised,when,is 1.0 0.000143348623853 1 0 1
exercised,when,indocin 1.0 0.000143348623853 1 0 1
exercised,when,coumarin 1.0 0.000143348623853 1 0 1
exercised,when,considering 1.0 0.000143348623853 1 0 1
exercised,when,are 1.0 0.000143348623853 1 0 1
exercised,nonetheless,since 1.0 0.000143348623853 1 0 1
exercised,if,peganone 1.0 0.000143348623853 1 0 1
exercised,if,and 1.0 0.000143348623853 1 0 1
exercised,if,an 1.0 0.000143348623853 1 0 1
exercised,during,the 1.0 0.000143348623853 1 0 1
exercised,because,there 1.0 0.000143348623853 1 0 1
excretion,seen,during 1.0 0.000143348623853 1 0 1
excretion,of,urate 1.0 0.000143348623853 1 0 1
excretion,of,resulting 1.0 0.000143348623853 1 0 1
excretion,of,oxypurines 1.0 0.000143348623853 1 0 1
excretion,of,of 1.0 0.000143348623853 1 0 1
excretion,of,nalfon 1.0 0.000143348623853 1 0 1
excretion,of,many 1.0 0.000143348623853 1 0 1
excretion,of,has 1.0 0.000143348623853 1 0 1
excretion,of,by 1.0 0.000143348623853 1 0 1
excretion,of,as 1.0 0.000143348623853 1 0 1
excretion,is,the 1.0 0.000143348623853 1 0 1
excretion,is,markedly 1.0 0.000143348623853 1 0 1
excretion,in,the 1.0 0.000143348623853 1 0 1
excretion,in,chronic 1.0 0.000143348623853 1 0 1
excretion,compared,with 1.0 0.000143348623853 1 0 1
excretion,but,is 1.0 0.000143348623853 1 0 1
excretion,and,the 1.0 0.000143348623853 1 0 1
excessive,prolongation,of 1.0 0.000143348623853 1 0 1
excessive,neuromuscular,weakness 1.0 0.000143348623853 1 0 1
excessive,fall,in 1.0 0.000143348623853 1 0 1
excessive,effects,including 1.0 0.000143348623853 1 0 1
excess,may,decrease 1.0 0.000143348623853 1 0 1
except,that,a 1.0 0.000143348623853 1 0 1
except,leukemia,in 1.0 0.000143348623853 1 0 1
exceeded,when,used 1.0 0.000143348623853 1 0 1
exceeded,in,a 1.0 0.000143348623853 1 0 1
exceed,mg,when 1.0 0.000143348623853 1 0 1
examples,of,known 1.0 0.000143348623853 1 0 1
example,when,k 1.0 0.000143348623853 1 0 1
example,since,may 1.0 0.000143348623853 1 0 1
examining,mg,and 1.0 0.000143348623853 1 0 1
exaggeration,of,the 1.0 0.000143348623853 1 0 1
exaggerated,hypertensive,responses 1.0 0.000143348623853 1 0 1
exaggerate,the,prolongation 1.0 0.000143348623853 1 0 1
exaggerate,the,depression 1.0 0.000143348623853 1 0 1
exacerbation,or,the 1.0 0.000143348623853 1 0 1
exacerbated,by,other 1.0 0.000143348623853 1 0 1
exacerbated,by,administration 1.0 0.000143348623853 1 0 1
exacerbate,the,rebound 1.0 0.000143348623853 1 0 1
exacerbate,the,neutropenic 1.0 0.000143348623853 1 0 1
exacerbate,the,hypertensive 1.0 0.000143348623853 1 0 1
exacerbate,rebound,hypertension 1.0 0.000143348623853 1 0 1
ewes,with,an 1.0 0.000143348623853 1 0 1
ewes,given,mg 1.0 0.000143348623853 1 0 1
evidently,the,antinociceptive 1.0 0.000143348623853 1 0 1
evidenced,by,a 1.0 0.000143348623853 1 0 1
evidence,supporting,the 1.0 0.000143348623853 1 0 1
evidence,of,marked 1.0 0.000143348623853 1 0 1
evidence,of,decreased 1.0 0.000143348623853 1 0 1
evidence,has,shown 1.0 0.000143348623853 1 0 1
every,hours,was 1.0 0.000143348623853 1 0 1
every,hours,q24h 1.0 0.000143348623853 1 0 1
every,hours,is 1.0 0.000143348623853 1 0 1
every,hours,competes 1.0 0.000143348623853 1 0 1
every,hours,are 1.0 0.000143348623853 1 0 1
events,were,experienced 1.0 0.000143348623853 1 0 1
events,or,reduced 1.0 0.000143348623853 1 0 1
events,compared,to 1.0 0.000143348623853 1 0 1
events,by,interfering 1.0 0.000143348623853 1 0 1
events,associated,with 1.0 0.000143348623853 1 0 1
evening,meal,resulted 1.0 0.000143348623853 1 0 1
evening,meal,and 1.0 0.000143348623853 1 0 1
even,when,was 1.0 0.000143348623853 1 0 1
even,when,an 1.0 0.000143348623853 1 0 1
even,when,administered 1.0 0.000143348623853 1 0 1
even,so,plasma 1.0 0.000143348623853 1 0 1
even,more,conservatively 1.0 0.000143348623853 1 0 1
even,in,the 1.0 0.000143348623853 1 0 1
even,experienced,users 1.0 0.000143348623853 1 0 1
even,be,more 1.0 0.000143348623853 1 0 1
evaluating,the,effect 1.0 0.000143348623853 1 0 1
evaluating,the,administration 1.0 0.000143348623853 1 0 1
evaluated,but,may 1.0 0.000143348623853 1 0 1
evaluated,and,concomitant 1.0 0.000143348623853 1 0 1
evaluated,after,concomitant 1.0 0.000143348623853 1 0 1
evaluate,the,possibility 1.0 0.000143348623853 1 0 1
europe,nimotop,was 1.0 0.000143348623853 1 0 1
eulexin,capsules,are 1.0 0.000143348623853 1 0 1
etopophos,with,that 1.0 0.000143348623853 1 0 1
etonogestrel,may,interact 1.0 0.000143348623853 1 0 1
etofibrate,elicited,enhancement 1.0 0.000143348623853 1 0 1
etodolac-treated,patients,receiving 1.0 0.000143348623853 1 0 1
ethyol,in,patients 1.0 0.000143348623853 1 0 1
ethyl,mao,inhibitors 1.0 0.000143348623853 1 0 1
ethyl,increases,the 1.0 0.000143348623853 1 0 1
ethoxzolamide,may,increase 1.0 0.000143348623853 1 0 1
ethopropazine,may,interact 1.0 0.000143348623853 1 0 1
ethopropazine,can,interact 1.0 0.000143348623853 1 0 1
ethinyl,estradiol,should 1.0 0.000143348623853 1 0 1
ethinyl,estradiol,levels 1.0 0.000143348623853 1 0 1
ether,and,sodium 1.0 0.000143348623853 1 0 1
ethanolysis,reaction,may 1.0 0.000143348623853 1 0 1
ethanolysis,of,in 1.0 0.000143348623853 1 0 1
ethanol,sonata,mg 1.0 0.000143348623853 1 0 1
ethanol,nutrition,herb 1.0 0.000143348623853 1 0 1
ethanol,flupenthixol,and 1.0 0.000143348623853 1 0 1
ethanol,clinical,evidence 1.0 0.000143348623853 1 0 1
ethanol,cause,additive 1.0 0.000143348623853 1 0 1
ethanol,an,additive 1.0 0.000143348623853 1 0 1
ethacrynic,acid,hepatotoxic 1.0 0.000143348623853 1 0 1
ethacrynic,acid,have 1.0 0.000143348623853 1 0 1
ethacrynic,acid,because 1.0 0.000143348623853 1 0 1
ethacrynic,acid,as 1.0 0.000143348623853 1 0 1
etc,that,lower 1.0 0.000143348623853 1 0 1
etc,is,indicated 1.0 0.000143348623853 1 0 1
etc,in,vitro 1.0 0.000143348623853 1 0 1
etc,but,physicians 1.0 0.000143348623853 1 0 1
estrogens,may,decrease 1.0 0.000143348623853 1 0 1
estrogens,including,oral 1.0 0.000143348623853 1 0 1
estrogen-containing,therapies,should 1.0 0.000143348623853 1 0 1
estrogen-containing,compounds,meclofenamic 1.0 0.000143348623853 1 0 1
estradiol,should,be 1.0 0.000143348623853 1 0 1
estradiol,levels,of 1.0 0.000143348623853 1 0 1
estradiol,by,and 1.0 0.000143348623853 1 0 1
estradiol,and,some 1.0 0.000143348623853 1 0 1
estradiol,and,or 1.0 0.000143348623853 1 0 1
estradiol,and,norethindrone 1.0 0.000143348623853 1 0 1
estradiol,and,an 1.0 0.000143348623853 1 0 1
established,therapy,with 1.0 0.000143348623853 1 0 1
established,that,there 1.0 0.000143348623853 1 0 1
established,that,interferes 1.0 0.000143348623853 1 0 1
established,steady-state,serum 1.0 0.000143348623853 1 0 1
established,current,evidence 1.0 0.000143348623853 1 0 1
established,but,physicians 1.0 0.000143348623853 1 0 1
established,a,cause 1.0 0.000143348623853 1 0 1
establish,a,cause-and 1.0 0.000143348623853 1 0 1
especially,when,therapy 1.0 0.000143348623853 1 0 1
especially,when,the 1.0 0.000143348623853 1 0 1
especially,those,with 1.0 0.000143348623853 1 0 1
especially,the,and 1.0 0.000143348623853 1 0 1
especially,in,cases 1.0 0.000143348623853 1 0 1
especially,important,that 1.0 0.000143348623853 1 0 1
especially,cyclic,may 1.0 0.000143348623853 1 0 1
escalating,doses,of 1.0 0.000143348623853 1 0 1
erythromycin,use,in 1.0 0.000143348623853 1 0 1
erythromycin,mg,t 1.0 0.000143348623853 1 0 1
erythromycin,in,hypercholesterolemic 1.0 0.000143348623853 1 0 1
erythromycin,in,healthy 1.0 0.000143348623853 1 0 1
erythromycin,and,and 1.0 0.000143348623853 1 0 1
erythrocyte,acetylcholinesterase,ache 1.0 0.000143348623853 1 0 1
erythro-fluorocitrate,in,vivo 1.0 0.000143348623853 1 0 1
erroneously,low,erpf 1.0 0.000143348623853 1 0 1
erpf,and,tm 1.0 0.000143348623853 1 0 1
ergotamine-containing,when,co-administered 1.0 0.000143348623853 1 0 1
ergotamine,concurrent,use 1.0 0.000143348623853 1 0 1
ergot,alkaloids,should 1.0 0.000143348623853 1 0 1
ergot,alkaloids,is 1.0 0.000143348623853 1 0 1
ergomar,may,be 1.0 0.000143348623853 1 0 1
ergomar,and,other 1.0 0.000143348623853 1 0 1
ergamisol,levamisole,hydrochloride 1.0 0.000143348623853 1 0 1
equivocally,higher,when 1.0 0.000143348623853 1 0 1
equetrotm,is,taken 1.0 0.000143348623853 1 0 1
equetrotm,increases,the 1.0 0.000143348623853 1 0 1
equetrotm,due,to 1.0 0.000143348623853 1 0 1
equally,antagonized,in 1.0 0.000143348623853 1 0 1
eproxindine,ethanol,flupenthixol 1.0 0.000143348623853 1 0 1
epithelium,in,rpmi1640 1.0 0.000143348623853 1 0 1
epithelium,by,a 1.0 0.000143348623853 1 0 1
episodes,may,occur 1.0 0.000143348623853 1 0 1
epinephrine,should,not 1.0 0.000143348623853 1 0 1
epinephrine,may,antagonize 1.0 0.000143348623853 1 0 1
epinephrine,also,should 1.0 0.000143348623853 1 0 1
epileptic,patients,on 1.0 0.000143348623853 1 0 1
epileptic,patients,lowered 1.0 0.000143348623853 1 0 1
epidural,may,prolong 1.0 0.000143348623853 1 0 1
epidural,local,including 1.0 0.000143348623853 1 0 1
epidural,injection,clonidine 1.0 0.000143348623853 1 0 1
epidural,include,hypotension 1.0 0.000143348623853 1 0 1
epidemiological,studies,of 1.0 0.000143348623853 1 0 1
ephedrine,may,enhance 1.0 0.000143348623853 1 0 1
ephedrine,ephedrine,may 1.0 0.000143348623853 1 0 1
enzymes,was,seen 1.0 0.000143348623853 1 0 1
enzymes,the,interaction 1.0 0.000143348623853 1 0 1
enzymes,respectively,responsible 1.0 0.000143348623853 1 0 1
enzymes,may,reduce 1.0 0.000143348623853 1 0 1
enzymes,is,recommended 1.0 0.000143348623853 1 0 1
enzymes,bun,and 1.0 0.000143348623853 1 0 1
enzymes,are,the 1.0 0.000143348623853 1 0 1
enzymes,and,thus 1.0 0.000143348623853 1 0 1
enzyme-inducing,such,as 1.0 0.000143348623853 1 0 1
enzyme-inducing,properties,of 1.0 0.000143348623853 1 0 1
enzyme-inducer,did,indeed 1.0 0.000143348623853 1 0 1
enzyme,systems,has 1.0 0.000143348623853 1 0 1
enzyme,system,responsible 1.0 0.000143348623853 1 0 1
enzyme,system,notably 1.0 0.000143348623853 1 0 1
enzyme,system,ketoconazole 1.0 0.000143348623853 1 0 1
enzyme,system,at 1.0 0.000143348623853 1 0 1
enzyme,should,be 1.0 0.000143348623853 1 0 1
enzyme,preparations,containing 1.0 0.000143348623853 1 0 1
enzyme,inhibitors,to 1.0 0.000143348623853 1 0 1
enzyme,inhibitors,the 1.0 0.000143348623853 1 0 1
enzyme,inhibitors,aminosalicylic 1.0 0.000143348623853 1 0 1
enzyme,inhibitor,the 1.0 0.000143348623853 1 0 1
enzyme,induction,thus 1.0 0.000143348623853 1 0 1
enzyme,induction,and 1.0 0.000143348623853 1 0 1
enzyme,inducers,inhibitors 1.0 0.000143348623853 1 0 1
enzyme,inducers,indicate 1.0 0.000143348623853 1 0 1
enzyme,inducers,are 1.0 0.000143348623853 1 0 1
enzyme,inducer,or 1.0 0.000143348623853 1 0 1
enzyme,inducer,may 1.0 0.000143348623853 1 0 1
enzyme,eg,should 1.0 0.000143348623853 1 0 1
enzyme,activity,may 1.0 0.000143348623853 1 0 1
enzyme,abnormalities,and 1.0 0.000143348623853 1 0 1
enzymatic,oxidation,of 1.0 0.000143348623853 1 0 1
environmental,may,alter 1.0 0.000143348623853 1 0 1
enterohepatic,circulation,the 1.0 0.000143348623853 1 0 1
enterocolitis,diarrhea,and 1.0 0.000143348623853 1 0 1
enteric,coating,of 1.0 0.000143348623853 1 0 1
enteric,coated,aspirin 1.0 0.000143348623853 1 0 1
ensure,that,a 1.0 0.000143348623853 1 0 1
ensure,clinically,effective 1.0 0.000143348623853 1 0 1
enoxacin,may,raise 1.0 0.000143348623853 1 0 1
enoxacin,interferes,with 1.0 0.000143348623853 1 0 1
enough,during,early 1.0 0.000143348623853 1 0 1
enlargement,and,congestive 1.0 0.000143348623853 1 0 1
enkephalinergic,neurons,and 1.0 0.000143348623853 1 0 1
enhancing,absorption,decreases 1.0 0.000143348623853 1 0 1
enhances,the,manifestation 1.0 0.000143348623853 1 0 1
enhances,the,effect 1.0 0.000143348623853 1 0 1
enhances,the,degree 1.0 0.000143348623853 1 0 1
enhances,cocaine-induced,increases 1.0 0.000143348623853 1 0 1
enhancement,of,toxicity 1.0 0.000143348623853 1 0 1
enhancement,of,post-heparin 1.0 0.000143348623853 1 0 1
enhancement,effect,of 1.0 0.000143348623853 1 0 1
enhanced,when,alfenta 1.0 0.000143348623853 1 0 1
enhanced,the,likelihood 1.0 0.000143348623853 1 0 1
enhanced,side,effects 1.0 0.000143348623853 1 0 1
enhanced,if,combination 1.0 0.000143348623853 1 0 1
enhanced,clearance,secondary 1.0 0.000143348623853 1 0 1
enhanced,by,monoamine 1.0 0.000143348623853 1 0 1
enhanced,by,interaction 1.0 0.000143348623853 1 0 1
enhanced,by,concurrent 1.0 0.000143348623853 1 0 1
enhanced,by,bezalip 1.0 0.000143348623853 1 0 1
enhanced,bone,marrow 1.0 0.000143348623853 1 0 1
enhanced,as,well 1.0 0.000143348623853 1 0 1
enhanced,and,excretion 1.0 0.000143348623853 1 0 1
enhance,the,serotonergic 1.0 0.000143348623853 1 0 1
enhance,the,seizure 1.0 0.000143348623853 1 0 1
enhance,the,renal 1.0 0.000143348623853 1 0 1
enhance,the,possibility 1.0 0.000143348623853 1 0 1
enhance,the,nephrotoxicity 1.0 0.000143348623853 1 0 1
enhance,the,mitogenic 1.0 0.000143348623853 1 0 1
enhance,the,metabolism 1.0 0.000143348623853 1 0 1
enhance,the,metabolic 1.0 0.000143348623853 1 0 1
enhance,the,magnitude 1.0 0.000143348623853 1 0 1
enhance,the,inhibition 1.0 0.000143348623853 1 0 1
enhance,the,duration 1.0 0.000143348623853 1 0 1
enhance,the,curariform 1.0 0.000143348623853 1 0 1
enhance,the,cns-depressive 1.0 0.000143348623853 1 0 1
enhance,the,cns 1.0 0.000143348623853 1 0 1
enhance,the,blood-sugar 1.0 0.000143348623853 1 0 1
enhance,the,adrenergic 1.0 0.000143348623853 1 0 1
enhance,nutrient,absorption 1.0 0.000143348623853 1 0 1
enhance,in,tissue 1.0 0.000143348623853 1 0 1
enhance,cns,depression 1.0 0.000143348623853 1 0 1
enhance,activity,transient 1.0 0.000143348623853 1 0 1
endotoxin-treated,rats,increased 1.0 0.000143348623853 1 0 1
endotoxin-treated,rats,decreased 1.0 0.000143348623853 1 0 1
endotoxin-induced,deaths,in 1.0 0.000143348623853 1 0 1
endothelium-intact,aortic,rings 1.0 0.000143348623853 1 0 1
endothelium,from,the 1.0 0.000143348623853 1 0 1
endogenous,steroid,hormones 1.0 0.000143348623853 1 0 1
endogenous,prostaglandin,synthesis 1.0 0.000143348623853 1 0 1
endogenous,marker,of 1.0 0.000143348623853 1 0 1
encephalopathic,syndrome,characterized 1.0 0.000143348623853 1 0 1
enbrel,was,added 1.0 0.000143348623853 1 0 1
enbrel,and,therapy 1.0 0.000143348623853 1 0 1
enbrel,and,developed 1.0 0.000143348623853 1 0 1
enablex,with,other 1.0 0.000143348623853 1 0 1
enablex,should,not 1.0 0.000143348623853 1 0 1
enablex,is,used 1.0 0.000143348623853 1 0 1
emptying,may,also 1.0 0.000143348623853 1 0 1
employed,since,the 1.0 0.000143348623853 1 0 1
employed,because,of 1.0 0.000143348623853 1 0 1
emergency,situation,when 1.0 0.000143348623853 1 0 1
emerge,with,the 1.0 0.000143348623853 1 0 1
emerge,if,is 1.0 0.000143348623853 1 0 1
embryos,in,comparison 1.0 0.000143348623853 1 0 1
em,individuals,treated 1.0 0.000143348623853 1 0 1
elspar,therapy,when 1.0 0.000143348623853 1 0 1
elspar,or,during 1.0 0.000143348623853 1 0 1
elspar,can,diminish 1.0 0.000143348623853 1 0 1
ellence,with,other 1.0 0.000143348623853 1 0 1
elimination,the,effect 1.0 0.000143348623853 1 0 1
elimination,route,of 1.0 0.000143348623853 1 0 1
elimination,of,these 1.0 0.000143348623853 1 0 1
elimination,of,most 1.0 0.000143348623853 1 0 1
elimination,of,leading 1.0 0.000143348623853 1 0 1
elimination,of,its 1.0 0.000143348623853 1 0 1
elimination,of,antizol 1.0 0.000143348623853 1 0 1
elimination,half-life,and 1.0 0.000143348623853 1 0 1
elimination,half,life 1.0 0.000143348623853 1 0 1
elimination,but,also 1.0 0.000143348623853 1 0 1
elimination,and,cause 1.0 0.000143348623853 1 0 1
elimination,and,and 1.0 0.000143348623853 1 0 1
eliminated,the,increases 1.0 0.000143348623853 1 0 1
eliminated,from,the 1.0 0.000143348623853 1 0 1
eliminated,by,active 1.0 0.000143348623853 1 0 1
eliminate,the,fluoride 1.0 0.000143348623853 1 0 1
elicited,enhancement,of 1.0 0.000143348623853 1 0 1
elevations,seen,in 1.0 0.000143348623853 1 0 1
elevations,on,sgpt 1.0 0.000143348623853 1 0 1
elevations,of,concentrations 1.0 0.000143348623853 1 0 1
elevations,of,cholesterol 1.0 0.000143348623853 1 0 1
elevations,less,than 1.0 0.000143348623853 1 0 1
elevations,and,or 1.0 0.000143348623853 1 0 1
elevation,of,tbars 1.0 0.000143348623853 1 0 1
elevation,in,liver 1.0 0.000143348623853 1 0 1
elevation,in,gastric 1.0 0.000143348623853 1 0 1
elevating,duodenal,absorption 1.0 0.000143348623853 1 0 1
elevated,serum,enzymes 1.0 0.000143348623853 1 0 1
elevated,serum,concentrations 1.0 0.000143348623853 1 0 1
elevated,liver,function 1.0 0.000143348623853 1 0 1
elevated,levels,it 1.0 0.000143348623853 1 0 1
elevated,levels,have 1.0 0.000143348623853 1 0 1
elevated,levels,and 1.0 0.000143348623853 1 0 1
elevated,cerebral,and 1.0 0.000143348623853 1 0 1
elevate,serum,levels 1.0 0.000143348623853 1 0 1
elevate,plasma,concentrations 1.0 0.000143348623853 1 0 1
elements,ethacrynic,acid 1.0 0.000143348623853 1 0 1
elemental,reduced,extent 1.0 0.000143348623853 1 0 1
elemental,as,feso4 1.0 0.000143348623853 1 0 1
electrolyte,disturbances,were 1.0 0.000143348623853 1 0 1
electrolyte,abnormalities,such 1.0 0.000143348623853 1 0 1
electrocardiographic,abnormalities,and 1.0 0.000143348623853 1 0 1
elderly,patients,receiving 1.0 0.000143348623853 1 0 1
elderly,may,develop 1.0 0.000143348623853 1 0 1
elderly,in,association 1.0 0.000143348623853 1 0 1
elc,should,be 1.0 0.000143348623853 1 0 1
elapse,between,administration 1.0 0.000143348623853 1 0 1
elapse,before,blood 1.0 0.000143348623853 1 0 1
el,eg,for 1.0 0.000143348623853 1 0 1
either,tagamet,mg 1.0 0.000143348623853 1 0 1
either,simultaneously,or 1.0 0.000143348623853 1 0 1
either,oral,or 1.0 0.000143348623853 1 0 1
either,or,led 1.0 0.000143348623853 1 0 1
either,or,is 1.0 0.000143348623853 1 0 1
either,or,concurrently 1.0 0.000143348623853 1 0 1
either,or,bind 1.0 0.000143348623853 1 0 1
either,one,or 1.0 0.000143348623853 1 0 1
either,nanm,or 1.0 0.000143348623853 1 0 1
either,medicine,that 1.0 0.000143348623853 1 0 1
either,inhibit,sodium 1.0 0.000143348623853 1 0 1
either,increase,or 1.0 0.000143348623853 1 0 1
either,had,no 1.0 0.000143348623853 1 0 1
either,enbrel,ci 1.0 0.000143348623853 1 0 1
either,be,temporarily 1.0 0.000143348623853 1 0 1
either,alone,the 1.0 0.000143348623853 1 0 1
eight-fold,increase,of 1.0 0.000143348623853 1 0 1
eight,hiv-infected,patients 1.0 0.000143348623853 1 0 1
egf-,or,insulin-induced 1.0 0.000143348623853 1 0 1
eg,would,be 1.0 0.000143348623853 1 0 1
eg,valproic,acid 1.0 0.000143348623853 1 0 1
eg,should,be 1.0 0.000143348623853 1 0 1
eg,other,general 1.0 0.000143348623853 1 0 1
eg,or,than 1.0 0.000143348623853 1 0 1
eg,or,cyp2d6 1.0 0.000143348623853 1 0 1
eg,or,can 1.0 0.000143348623853 1 0 1
eg,or,beta-adrenergic 1.0 0.000143348623853 1 0 1
eg,may,result 1.0 0.000143348623853 1 0 1
eg,may,increase 1.0 0.000143348623853 1 0 1
eg,may,have 1.0 0.000143348623853 1 0 1
eg,may,elevate 1.0 0.000143348623853 1 0 1
eg,may,decrease 1.0 0.000143348623853 1 0 1
eg,for,injection 1.0 0.000143348623853 1 0 1
eg,could,cause 1.0 0.000143348623853 1 0 1
eg,commonly,results 1.0 0.000143348623853 1 0 1
eg,channel,blockers 1.0 0.000143348623853 1 0 1
eg,and,should 1.0 0.000143348623853 1 0 1
eg,and,may 1.0 0.000143348623853 1 0 1
eg,and,is 1.0 0.000143348623853 1 0 1
eg,and,decrease 1.0 0.000143348623853 1 0 1
eg,and,by 1.0 0.000143348623853 1 0 1
eg,an,antiparkinsonian 1.0 0.000143348623853 1 0 1
efficacy,over,use 1.0 0.000143348623853 1 0 1
efficacy,of,the 1.0 0.000143348623853 1 0 1
efficacy,of,orencia 1.0 0.000143348623853 1 0 1
efficacy,of,may 1.0 0.000143348623853 1 0 1
efficacy,of,h1 1.0 0.000143348623853 1 0 1
efficacy,is,impaired 1.0 0.000143348623853 1 0 1
effects,with,those 1.0 0.000143348623853 1 0 1
effects,with,proleukin 1.0 0.000143348623853 1 0 1
effects,with,prinivil 1.0 0.000143348623853 1 0 1
effects,with,or 1.0 0.000143348623853 1 0 1
effects,with,lotensin 1.0 0.000143348623853 1 0 1
effects,with,can 1.0 0.000143348623853 1 0 1
effects,with,beta-adrenergic 1.0 0.000143348623853 1 0 1
effects,when,given 1.0 0.000143348623853 1 0 1
effects,when,co-administered 1.0 0.000143348623853 1 0 1
effects,when,administered 1.0 0.000143348623853 1 0 1
effects,were,neither 1.0 0.000143348623853 1 0 1
effects,seen,during 1.0 0.000143348623853 1 0 1
effects,resulting,from 1.0 0.000143348623853 1 0 1
effects,prothrombin,time 1.0 0.000143348623853 1 0 1
effects,prolonged,sodation 1.0 0.000143348623853 1 0 1
effects,particularly,have 1.0 0.000143348623853 1 0 1
effects,on,renal 1.0 0.000143348623853 1 0 1
effects,on,prolonging 1.0 0.000143348623853 1 0 1
effects,on,potassium 1.0 0.000143348623853 1 0 1
effects,on,av 1.0 0.000143348623853 1 0 1
effects,on,arterial 1.0 0.000143348623853 1 0 1
effects,of,veratrum 1.0 0.000143348623853 1 0 1
effects,of,that 1.0 0.000143348623853 1 0 1
effects,of,sublingual 1.0 0.000143348623853 1 0 1
effects,of,organic 1.0 0.000143348623853 1 0 1
effects,of,nonbenzodiazepine 1.0 0.000143348623853 1 0 1
effects,of,mefloquine 1.0 0.000143348623853 1 0 1
effects,of,medicinal 1.0 0.000143348623853 1 0 1
effects,of,intravenous 1.0 0.000143348623853 1 0 1
effects,of,indocin 1.0 0.000143348623853 1 0 1
effects,of,increased 1.0 0.000143348623853 1 0 1
effects,of,ganglionic 1.0 0.000143348623853 1 0 1
effects,of,g 1.0 0.000143348623853 1 0 1
effects,of,for 1.0 0.000143348623853 1 0 1
effects,of,epidural 1.0 0.000143348623853 1 0 1
effects,of,clozapine 1.0 0.000143348623853 1 0 1
effects,of,chronic 1.0 0.000143348623853 1 0 1
effects,of,camptosar 1.0 0.000143348623853 1 0 1
effects,of,by 1.0 0.000143348623853 1 0 1
effects,of,brovana 1.0 0.000143348623853 1 0 1
effects,of,beta 1.0 0.000143348623853 1 0 1
effects,of,antihypertensive 1.0 0.000143348623853 1 0 1
effects,of,a 1.0 0.000143348623853 1 0 1
effects,is,not 1.0 0.000143348623853 1 0 1
effects,including,fever 1.0 0.000143348623853 1 0 1
effects,including,dry 1.0 0.000143348623853 1 0 1
effects,in,prolonging 1.0 0.000143348623853 1 0 1
effects,divalproex,sodium 1.0 0.000143348623853 1 0 1
effects,could,potentially 1.0 0.000143348623853 1 0 1
effects,concerning,have 1.0 0.000143348623853 1 0 1
effects,by,cgs21680 1.0 0.000143348623853 1 0 1
effects,are,likely 1.0 0.000143348623853 1 0 1
effects,and,confusional 1.0 0.000143348623853 1 0 1
effects,an,blood 1.0 0.000143348623853 1 0 1
effectiveness,of,supplemental 1.0 0.000143348623853 1 0 1
effectiveness,of,proleukin 1.0 0.000143348623853 1 0 1
effectiveness,of,progestin-only 1.0 0.000143348623853 1 0 1
effectiveness,of,oral 1.0 0.000143348623853 1 0 1
effectiveness,of,a 1.0 0.000143348623853 1 0 1
effectiveness,and,increased 1.0 0.000143348623853 1 0 1
effective,while,you 1.0 0.000143348623853 1 0 1
effective,in,the 1.0 0.000143348623853 1 0 1
effective,in,significantly 1.0 0.000143348623853 1 0 1
effect,with,inomax 1.0 0.000143348623853 1 0 1
effect,with,in 1.0 0.000143348623853 1 0 1
effect,will,be 1.0 0.000143348623853 1 0 1
effect,when,initiating 1.0 0.000143348623853 1 0 1
effect,was,noted 1.0 0.000143348623853 1 0 1
effect,to,but 1.0 0.000143348623853 1 0 1
effect,the,enteric 1.0 0.000143348623853 1 0 1
effect,relationship,physicians 1.0 0.000143348623853 1 0 1
effect,relationship,have 1.0 0.000143348623853 1 0 1
effect,relationship,and 1.0 0.000143348623853 1 0 1
effect,one,study 1.0 0.000143348623853 1 0 1
effect,on,tyrosine 1.0 0.000143348623853 1 0 1
effect,on,renal 1.0 0.000143348623853 1 0 1
effect,on,pupil 1.0 0.000143348623853 1 0 1
effect,on,psychomotor 1.0 0.000143348623853 1 0 1
effect,on,oral 1.0 0.000143348623853 1 0 1
effect,on,histamine- 1.0 0.000143348623853 1 0 1
effect,on,half-life 1.0 0.000143348623853 1 0 1
effect,on,certain 1.0 0.000143348623853 1 0 1
effect,on,cas 1.0 0.000143348623853 1 0 1
effect,on,activity 1.0 0.000143348623853 1 0 1
effect,on,absorption 1.0 0.000143348623853 1 0 1
effect,of,systemic 1.0 0.000143348623853 1 0 1
effect,of,sular 1.0 0.000143348623853 1 0 1
effect,of,such 1.0 0.000143348623853 1 0 1
effect,of,stadol 1.0 0.000143348623853 1 0 1
effect,of,skeletal 1.0 0.000143348623853 1 0 1
effect,of,pgf2alpha 1.0 0.000143348623853 1 0 1
effect,of,norfloxacin 1.0 0.000143348623853 1 0 1
effect,of,levels 1.0 0.000143348623853 1 0 1
effect,of,hydrochloride 1.0 0.000143348623853 1 0 1
effect,of,especially 1.0 0.000143348623853 1 0 1
effect,of,either 1.0 0.000143348623853 1 0 1
effect,of,each 1.0 0.000143348623853 1 0 1
effect,of,compounds 1.0 0.000143348623853 1 0 1
effect,of,cholinesterase 1.0 0.000143348623853 1 0 1
effect,of,certain 1.0 0.000143348623853 1 0 1
effect,of,carbimazole 1.0 0.000143348623853 1 0 1
effect,of,aprepitant 1.0 0.000143348623853 1 0 1
effect,of,alternate-day 1.0 0.000143348623853 1 0 1
effect,of,all 1.0 0.000143348623853 1 0 1
effect,of,aeds 1.0 0.000143348623853 1 0 1
effect,of,acetate 1.0 0.000143348623853 1 0 1
effect,of,ace 1.0 0.000143348623853 1 0 1
effect,of,acarbose 1.0 0.000143348623853 1 0 1
effect,its,abrupt 1.0 0.000143348623853 1 0 1
effect,in,most 1.0 0.000143348623853 1 0 1
effect,in,lowering 1.0 0.000143348623853 1 0 1
effect,for,i 1.0 0.000143348623853 1 0 1
effect,digitalis,or 1.0 0.000143348623853 1 0 1
effect,caution,should 1.0 0.000143348623853 1 0 1
effect,beyond,that 1.0 0.000143348623853 1 0 1
effect,and,should 1.0 0.000143348623853 1 0 1
effect,and,requiring 1.0 0.000143348623853 1 0 1
edetate,disodium,interferes 1.0 0.000143348623853 1 0 1
edetate,disodium,in 1.0 0.000143348623853 1 0 1
edemas,that,mg 1.0 0.000143348623853 1 0 1
edema,it,has 1.0 0.000143348623853 1 0 1
edema,has,been 1.0 0.000143348623853 1 0 1
edecrin,may,increase 1.0 0.000143348623853 1 0 1
edecrin,and,non- 1.0 0.000143348623853 1 0 1
ed95,nimbex,at 1.0 0.000143348623853 1 0 1
ed50,of,nuromax 1.0 0.000143348623853 1 0 1
ectopic,pacemaker,activity 1.0 0.000143348623853 1 0 1
echistatin,alone,had 1.0 0.000143348623853 1 0 1
ecg,and,blood 1.0 0.000143348623853 1 0 1
early,therapy,to 1.0 0.000143348623853 1 0 1
early,components,p1 1.0 0.000143348623853 1 0 1
early,as,three 1.0 0.000143348623853 1 0 1
earlier,than,might 1.0 0.000143348623853 1 0 1
each,to,mg 1.0 0.000143348623853 1 0 1
each,other,when 1.0 0.000143348623853 1 0 1
each,other,is 1.0 0.000143348623853 1 0 1
each,dose,of 1.0 0.000143348623853 1 0 1
each,be,associated 1.0 0.000143348623853 1 0 1
each,administered,alone 1.0 0.000143348623853 1 0 1
e2,may,augment 1.0 0.000143348623853 1 0 1
e,mg,kg 1.0 0.000143348623853 1 0 1
dysrhythmias,some,resulting 1.0 0.000143348623853 1 0 1
dysrhythmias,of,other 1.0 0.000143348623853 1 0 1
dyspnea,concomitant,administration 1.0 0.000143348623853 1 0 1
dyskinesia,side,reactions 1.0 0.000143348623853 1 0 1
dysfunction,by,increasing 1.0 0.000143348623853 1 0 1
during,with,concomitant 1.0 0.000143348623853 1 0 1
during,treatment,and 1.0 0.000143348623853 1 0 1
during,toradol,therapy 1.0 0.000143348623853 1 0 1
during,the,test 1.0 0.000143348623853 1 0 1
during,the,management 1.0 0.000143348623853 1 0 1
during,studies,involving 1.0 0.000143348623853 1 0 1
during,periods,of 1.0 0.000143348623853 1 0 1
during,or,less 1.0 0.000143348623853 1 0 1
during,or,after 1.0 0.000143348623853 1 0 1
during,early,therapy 1.0 0.000143348623853 1 0 1
during,dosing,with 1.0 0.000143348623853 1 0 1
during,controlled,hypotensive 1.0 0.000143348623853 1 0 1
during,concomitant,treatment 1.0 0.000143348623853 1 0 1
during,concomitant,protease 1.0 0.000143348623853 1 0 1
during,coadministration,can 1.0 0.000143348623853 1 0 1
during,can,be 1.0 0.000143348623853 1 0 1
during,and,for 1.0 0.000143348623853 1 0 1
during,administration,systemic 1.0 0.000143348623853 1 0 1
during,adjunctive,therapy 1.0 0.000143348623853 1 0 1
durations,of,neuromuscular 1.0 0.000143348623853 1 0 1
duration,suggesting,that 1.0 0.000143348623853 1 0 1
duration,of,pharmacologic 1.0 0.000143348623853 1 0 1
duration,of,its 1.0 0.000143348623853 1 0 1
duration,of,central 1.0 0.000143348623853 1 0 1
duration,of,block 1.0 0.000143348623853 1 0 1
duration,but,quickens 1.0 0.000143348623853 1 0 1
duragesic,transdermal,system 1.0 0.000143348623853 1 0 1
duragesic,is,not 1.0 0.000143348623853 1 0 1
duodenal,absorption,acting 1.0 0.000143348623853 1 0 1
duloxetine,with,other 1.0 0.000143348623853 1 0 1
duloxetine,and,should 1.0 0.000143348623853 1 0 1
due,to,wide 1.0 0.000143348623853 1 0 1
due,to,transport-related 1.0 0.000143348623853 1 0 1
due,to,release 1.0 0.000143348623853 1 0 1
due,to,or 1.0 0.000143348623853 1 0 1
due,to,lowered 1.0 0.000143348623853 1 0 1
due,to,fulminant 1.0 0.000143348623853 1 0 1
due,not,only 1.0 0.000143348623853 1 0 1
dsst,symbol,copying 1.0 0.000143348623853 1 0 1
dsm-iv,diagnosed,schizophrenia 1.0 0.000143348623853 1 0 1
dryness,of,the 1.0 0.000143348623853 1 0 1
dry,mouth,constipation 1.0 0.000143348623853 1 0 1
drugs,with,ototoxic 1.0 0.000143348623853 1 0 1
drugs,whose,efficacy 1.0 0.000143348623853 1 0 1
drugs,which,themselves 1.0 0.000143348623853 1 0 1
drugs,which,require 1.0 0.000143348623853 1 0 1
drugs,the,administration 1.0 0.000143348623853 1 0 1
drugs,the,addition 1.0 0.000143348623853 1 0 1
drugs,that,reduce 1.0 0.000143348623853 1 0 1
drugs,that,lower 1.0 0.000143348623853 1 0 1
drugs,that,could 1.0 0.000143348623853 1 0 1
drugs,that,cause 1.0 0.000143348623853 1 0 1
drugs,sporadic,cases 1.0 0.000143348623853 1 0 1
drugs,significant,decreases 1.0 0.000143348623853 1 0 1
drugs,possessing,nephrotoxic 1.0 0.000143348623853 1 0 1
drugs,phenytoin,felbatol 1.0 0.000143348623853 1 0 1
drugs,on,felbatol 1.0 0.000143348623853 1 0 1
drugs,nsaids,the 1.0 0.000143348623853 1 0 1
drugs,l-phenylalanine,may 1.0 0.000143348623853 1 0 1
drugs,hallucinations,have 1.0 0.000143348623853 1 0 1
drugs,ethanol,sonata 1.0 0.000143348623853 1 0 1
drugs,ethanol,an 1.0 0.000143348623853 1 0 1
drugs,demonstrated,to 1.0 0.000143348623853 1 0 1
drugs,decreasing,heparin 1.0 0.000143348623853 1 0 1
drugs,can,lead 1.0 0.000143348623853 1 0 1
drugs,and,other 1.0 0.000143348623853 1 0 1
drugs,aeds,on 1.0 0.000143348623853 1 0 1
drug-drug,interactions,given 1.0 0.000143348623853 1 0 1
drug-drug,interactions,albuterol 1.0 0.000143348623853 1 0 1
drug,metabolism,increased 1.0 0.000143348623853 1 0 1
drug,is,used 1.0 0.000143348623853 1 0 1
drug,interactions,the 1.0 0.000143348623853 1 0 1
drug,interactions,flupenthixol 1.0 0.000143348623853 1 0 1
drug,interactions,benzodiazepines 1.0 0.000143348623853 1 0 1
drug,interactions,and 1.0 0.000143348623853 1 0 1
drug,interaction,for 1.0 0.000143348623853 1 0 1
drug,eg,and 1.0 0.000143348623853 1 0 1
drinking,may,worsen 1.0 0.000143348623853 1 0 1
drinking,during,treatment 1.0 0.000143348623853 1 0 1
drawn,if,a 1.0 0.000143348623853 1 0 1
dpcpx-induced,anxiogenic,effects 1.0 0.000143348623853 1 0 1
doxylamine,may,enhance 1.0 0.000143348623853 1 0 1
doxorubicin,doxorubicin,caused 1.0 0.000143348623853 1 0 1
doxorubicin,caused,a 1.0 0.000143348623853 1 0 1
downward,dose,adjustment 1.0 0.000143348623853 1 0 1
doubling,of,the 1.0 0.000143348623853 1 0 1
doubling,in,a 1.0 0.000143348623853 1 0 1
double,the,bioavailability 1.0 0.000143348623853 1 0 1
dostinex,should,not 1.0 0.000143348623853 1 0 1
dosing,with,camptosar 1.0 0.000143348623853 1 0 1
dosing,with,because 1.0 0.000143348623853 1 0 1
dosing,was,separated 1.0 0.000143348623853 1 0 1
dosing,of,aprepitant 1.0 0.000143348623853 1 0 1
dosing,lower,maintenance 1.0 0.000143348623853 1 0 1
dosing,caution,should 1.0 0.000143348623853 1 0 1
dosing,beta-1a,avonex 1.0 0.000143348623853 1 0 1
doses,vioxx,mg 1.0 0.000143348623853 1 0 1
doses,or,reduced 1.0 0.000143348623853 1 0 1
doses,of,with 1.0 0.000143348623853 1 0 1
doses,of,were 1.0 0.000143348623853 1 0 1
doses,of,trileptal 1.0 0.000143348623853 1 0 1
doses,of,taxol 1.0 0.000143348623853 1 0 1
doses,of,tambocor 1.0 0.000143348623853 1 0 1
doses,of,see 1.0 0.000143348623853 1 0 1
doses,of,required 1.0 0.000143348623853 1 0 1
doses,of,pcp 1.0 0.000143348623853 1 0 1
doses,of,m1 1.0 0.000143348623853 1 0 1
doses,of,hydrochloride 1.0 0.000143348623853 1 0 1
doses,of,given 1.0 0.000143348623853 1 0 1
doses,of,followed 1.0 0.000143348623853 1 0 1
doses,of,ergotamine-containing 1.0 0.000143348623853 1 0 1
doses,of,concomitantly 1.0 0.000143348623853 1 0 1
doses,of,as 1.0 0.000143348623853 1 0 1
doses,of,are 1.0 0.000143348623853 1 0 1
doses,of,antizol 1.0 0.000143348623853 1 0 1
doses,of,an 1.0 0.000143348623853 1 0 1
doses,mg,qd 1.0 0.000143348623853 1 0 1
doses,mg,of 1.0 0.000143348623853 1 0 1
doses,may,be 1.0 0.000143348623853 1 0 1
doses,is,a 1.0 0.000143348623853 1 0 1
doses,increased,the 1.0 0.000143348623853 1 0 1
doses,in,vivo 1.0 0.000143348623853 1 0 1
doses,has,been 1.0 0.000143348623853 1 0 1
doses,had,a 1.0 0.000143348623853 1 0 1
doses,because,of 1.0 0.000143348623853 1 0 1
doses,and,small 1.0 0.000143348623853 1 0 1
dosed,with,vardenafil 1.0 0.000143348623853 1 0 1
dosed,simultaneously,with 1.0 0.000143348623853 1 0 1
dose-response,curves,derived 1.0 0.000143348623853 1 0 1
dose-related,increase,in 1.0 0.000143348623853 1 0 1
dose-related,decrease,in 1.0 0.000143348623853 1 0 1
dose-related,blockade,of 1.0 0.000143348623853 1 0 1
dose-dependently,inhibits,the 1.0 0.000143348623853 1 0 1
dose-dependent,modification,of 1.0 0.000143348623853 1 0 1
dose-dependent,manner,when 1.0 0.000143348623853 1 0 1
dose-dependent,manner,the 1.0 0.000143348623853 1 0 1
dose-dependent,inhibition,of 1.0 0.000143348623853 1 0 1
dose-dependent,increase,in 1.0 0.000143348623853 1 0 1
dose-dependent,fashion,as 1.0 0.000143348623853 1 0 1
dose,will,need 1.0 0.000143348623853 1 0 1
dose,when,concomitant 1.0 0.000143348623853 1 0 1
dose,when,administered 1.0 0.000143348623853 1 0 1
dose,until,blood 1.0 0.000143348623853 1 0 1
dose,to,approximately 1.0 0.000143348623853 1 0 1
dose,to,achieve 1.0 0.000143348623853 1 0 1
dose,study,of 1.0 0.000143348623853 1 0 1
dose,study,n 1.0 0.000143348623853 1 0 1
dose,studies,in 1.0 0.000143348623853 1 0 1
dose,should,elapse 1.0 0.000143348623853 1 0 1
dose,reduction,when 1.0 0.000143348623853 1 0 1
dose,reduced,by 1.0 0.000143348623853 1 0 1
dose,ranging,from 1.0 0.000143348623853 1 0 1
dose,proleukin,and 1.0 0.000143348623853 1 0 1
dose,or,two 1.0 0.000143348623853 1 0 1
dose,or,hours 1.0 0.000143348623853 1 0 1
dose,or,any 1.0 0.000143348623853 1 0 1
dose,of,x 1.0 0.000143348623853 1 0 1
dose,of,videx 1.0 0.000143348623853 1 0 1
dose,of,these 1.0 0.000143348623853 1 0 1
dose,of,their 1.0 0.000143348623853 1 0 1
dose,of,stadol 1.0 0.000143348623853 1 0 1
dose,of,sodium 1.0 0.000143348623853 1 0 1
dose,of,significant 1.0 0.000143348623853 1 0 1
dose,of,sensipar 1.0 0.000143348623853 1 0 1
dose,of,resulted 1.0 0.000143348623853 1 0 1
dose,of,other 1.0 0.000143348623853 1 0 1
dose,of,micrograms 1.0 0.000143348623853 1 0 1
dose,of,intravenously 1.0 0.000143348623853 1 0 1
dose,of,inspra 1.0 0.000143348623853 1 0 1
dose,of,increased 1.0 0.000143348623853 1 0 1
dose,of,hours 1.0 0.000143348623853 1 0 1
dose,of,grams 1.0 0.000143348623853 1 0 1
dose,of,gram 1.0 0.000143348623853 1 0 1
dose,of,gleevec 1.0 0.000143348623853 1 0 1
dose,of,enablex 1.0 0.000143348623853 1 0 1
dose,of,each 1.0 0.000143348623853 1 0 1
dose,of,didanosine-placebo 1.0 0.000143348623853 1 0 1
dose,of,diamox 1.0 0.000143348623853 1 0 1
dose,of,changed 1.0 0.000143348623853 1 0 1
dose,of,cefditoren 1.0 0.000143348623853 1 0 1
dose,of,arava 1.0 0.000143348623853 1 0 1
dose,of,albendazole 1.0 0.000143348623853 1 0 1
dose,modifying,factors 1.0 0.000143348623853 1 0 1
dose,mg,every 1.0 0.000143348623853 1 0 1
dose,is,co-administered 1.0 0.000143348623853 1 0 1
dose,is,adjusted 1.0 0.000143348623853 1 0 1
dose,if,or 1.0 0.000143348623853 1 0 1
dose,followed,by 1.0 0.000143348623853 1 0 1
dose,decrease,for 1.0 0.000143348623853 1 0 1
dose,and,total 1.0 0.000143348623853 1 0 1
dose,and,plasma 1.0 0.000143348623853 1 0 1
dose,and,longer 1.0 0.000143348623853 1 0 1
dose,adjustments,considered 1.0 0.000143348623853 1 0 1
dose,adjustment,required 1.0 0.000143348623853 1 0 1
dosages,or,concomitantly 1.0 0.000143348623853 1 0 1
dosage,when,is 1.0 0.000143348623853 1 0 1
dosage,schedule,was 1.0 0.000143348623853 1 0 1
dosage,reduced,accordingly 1.0 0.000143348623853 1 0 1
dosage,range,mg 1.0 0.000143348623853 1 0 1
dosage,on,equetrotm 1.0 0.000143348623853 1 0 1
dosage,of,vitamin 1.0 0.000143348623853 1 0 1
dosage,of,theo-dur 1.0 0.000143348623853 1 0 1
dosage,of,precedex 1.0 0.000143348623853 1 0 1
dosage,of,needed 1.0 0.000143348623853 1 0 1
dosage,may,need 1.0 0.000143348623853 1 0 1
dosage,levels,should 1.0 0.000143348623853 1 0 1
dosage,adjustments,patients 1.0 0.000143348623853 1 0 1
dopaminergic,renal,and 1.0 0.000143348623853 1 0 1
dopamine-induced,ventricular,arrhythmias 1.0 0.000143348623853 1 0 1
dopamine,d2,antagonists 1.0 0.000143348623853 1 0 1
dopamine,antagonists,such 1.0 0.000143348623853 1 0 1
dopamine,antagonists,since 1.0 0.000143348623853 1 0 1
donor,compounds,including 1.0 0.000143348623853 1 0 1
done,to,see 1.0 0.000143348623853 1 0 1
done,extremely,cautiously 1.0 0.000143348623853 1 0 1
dogs,the,intravenous 1.0 0.000143348623853 1 0 1
dogs,but,not 1.0 0.000143348623853 1 0 1
dogs,anesthetized,with 1.0 0.000143348623853 1 0 1
do,not,outweigh 1.0 0.000143348623853 1 0 1
do,not,indicate 1.0 0.000143348623853 1 0 1
do,not,contain 1.0 0.000143348623853 1 0 1
do,not,bear 1.0 0.000143348623853 1 0 1
dl,dose,adjustment 1.0 0.000143348623853 1 0 1
divided,attention,test 1.0 0.000143348623853 1 0 1
divalproex,sodium,valproic 1.0 0.000143348623853 1 0 1
diuretics,the,reports 1.0 0.000143348623853 1 0 1
diuretics,studies,in 1.0 0.000143348623853 1 0 1
diuretics,lotensin,can 1.0 0.000143348623853 1 0 1
diuretics,fosinopril,sodium 1.0 0.000143348623853 1 0 1
diuretics,diclofenac,and 1.0 0.000143348623853 1 0 1
diuretics,concomitant,treatment 1.0 0.000143348623853 1 0 1
diuretic,natriuretic,and 1.0 0.000143348623853 1 0 1
diuretic,hydrochlorothiazide,given 1.0 0.000143348623853 1 0 1
diuretic,agents,may 1.0 0.000143348623853 1 0 1
disulfiram,to,a 1.0 0.000143348623853 1 0 1
disulfiram,should,be 1.0 0.000143348623853 1 0 1
disturbances,were,not 1.0 0.000143348623853 1 0 1
disturbances,of,blood 1.0 0.000143348623853 1 0 1
disturbances,left,ventricular 1.0 0.000143348623853 1 0 1
disturbances,have,been 1.0 0.000143348623853 1 0 1
disturbances,and,left 1.0 0.000143348623853 1 0 1
disturbance,rarely,with 1.0 0.000143348623853 1 0 1
distribution,of,decreased 1.0 0.000143348623853 1 0 1
disruptive,effects,of 1.0 0.000143348623853 1 0 1
displacing,the,from 1.0 0.000143348623853 1 0 1
displaces,from,protein 1.0 0.000143348623853 1 0 1
displacement,of,from 1.0 0.000143348623853 1 0 1
displace,such,as 1.0 0.000143348623853 1 0 1
displace,less,firmly 1.0 0.000143348623853 1 0 1
displace,acidic,such 1.0 0.000143348623853 1 0 1
dispersible,tablet,formulation 1.0 0.000143348623853 1 0 1
dispersible,buffered,tablets 1.0 0.000143348623853 1 0 1
disorders,treated,with 1.0 0.000143348623853 1 0 1
disorders,has,been 1.0 0.000143348623853 1 0 1
disorder,including,manic-depressive 1.0 0.000143348623853 1 0 1
disodium,interferes,with 1.0 0.000143348623853 1 0 1
disodium,in,animals 1.0 0.000143348623853 1 0 1
disintegrating,tablet,was 1.0 0.000143348623853 1 0 1
disease,or,those 1.0 0.000143348623853 1 0 1
disease,may,experience 1.0 0.000143348623853 1 0 1
disease,have,been 1.0 0.000143348623853 1 0 1
disease,has,not 1.0 0.000143348623853 1 0 1
disease,except,leukemia 1.0 0.000143348623853 1 0 1
disease,control,by 1.0 0.000143348623853 1 0 1
disease,congestive,heart 1.0 0.000143348623853 1 0 1
disease,and,ulcerative 1.0 0.000143348623853 1 0 1
discussion,clarithromycin,is 1.0 0.000143348623853 1 0 1
discontinuing,treatment,with 1.0 0.000143348623853 1 0 1
discontinuing,or,changing 1.0 0.000143348623853 1 0 1
discontinuing,hydrochloride,therapy 1.0 0.000143348623853 1 0 1
discontinues,therapy,with 1.0 0.000143348623853 1 0 1
discontinued,slowly,over 1.0 0.000143348623853 1 0 1
discontinued,or,decreased 1.0 0.000143348623853 1 0 1
discontinued,it,is 1.0 0.000143348623853 1 0 1
discontinued,for,several 1.0 0.000143348623853 1 0 1
discontinue,therapy,in 1.0 0.000143348623853 1 0 1
discontinue,after,concurrent 1.0 0.000143348623853 1 0 1
discontinuation,of,which 1.0 0.000143348623853 1 0 1
discontinuation,of,therapy 1.0 0.000143348623853 1 0 1
discontinuation,of,produced 1.0 0.000143348623853 1 0 1
discontinuation,of,or 1.0 0.000143348623853 1 0 1
discontinuation,of,in 1.0 0.000143348623853 1 0 1
discontinuation,of,has 1.0 0.000143348623853 1 0 1
discontinuation,of,either 1.0 0.000143348623853 1 0 1
discontinuation,of,concomitant 1.0 0.000143348623853 1 0 1
discontinuation,of,a 1.0 0.000143348623853 1 0 1
discontinuance,of,could 1.0 0.000143348623853 1 0 1
disalcid,others,choline 1.0 0.000143348623853 1 0 1
directly,on,the 1.0 0.000143348623853 1 0 1
directly,interfere,with 1.0 0.000143348623853 1 0 1
directed,to,cross 1.0 0.000143348623853 1 0 1
direct,causal,relationship 1.0 0.000143348623853 1 0 1
direct,cardiac,stimulants 1.0 0.000143348623853 1 0 1
dipyridamole,may,counteract 1.0 0.000143348623853 1 0 1
dipyridamole,has,been 1.0 0.000143348623853 1 0 1
dipotassium,prolongs,the 1.0 0.000143348623853 1 0 1
diphenoxylate,hcl,and 1.0 0.000143348623853 1 0 1
diphenhydramine,hydrochloride,has 1.0 0.000143348623853 1 0 1
dinitrate,may,be 1.0 0.000143348623853 1 0 1
diminishes,the,effect 1.0 0.000143348623853 1 0 1
diminished,when,it 1.0 0.000143348623853 1 0 1
diminished,urinary,excretion 1.0 0.000143348623853 1 0 1
diminished,the,binding 1.0 0.000143348623853 1 0 1
diminished,response,to 1.0 0.000143348623853 1 0 1
diminished,renal,function 1.0 0.000143348623853 1 0 1
diminished,prothrombin,response 1.0 0.000143348623853 1 0 1
diminished,effects,of 1.0 0.000143348623853 1 0 1
diminished,binding,of 1.0 0.000143348623853 1 0 1
diminish,the,effectiveness 1.0 0.000143348623853 1 0 1
diminish,or,abolish 1.0 0.000143348623853 1 0 1
dimethyl-4,hydroxyphenyl,piperidine 1.0 0.000143348623853 1 0 1
dimenhydrinate,may,decrease 1.0 0.000143348623853 1 0 1
diltiazem,in,patients 1.0 0.000143348623853 1 0 1
dilaudid,may,exhibit 1.0 0.000143348623853 1 0 1
dilation,associated,with 1.0 0.000143348623853 1 0 1
dilantin,use,of 1.0 0.000143348623853 1 0 1
dilantin,phenobarbital,tegretol 1.0 0.000143348623853 1 0 1
dihydropyridine,channel,blockers 1.0 0.000143348623853 1 0 1
digoxin,when,multiple 1.0 0.000143348623853 1 0 1
digoxin,some,blockers 1.0 0.000143348623853 1 0 1
digoxin,salicylate,and 1.0 0.000143348623853 1 0 1
digoxin,methotrexate,lodine 1.0 0.000143348623853 1 0 1
digoxin,in,controlled 1.0 0.000143348623853 1 0 1
digoxin,enoxacin,may 1.0 0.000143348623853 1 0 1
digoxin,digoxin,concentrations 1.0 0.000143348623853 1 0 1
digoxin,concentrations,are 1.0 0.000143348623853 1 0 1
digoxin,coadministration,of 1.0 0.000143348623853 1 0 1
digoxin,and,use 1.0 0.000143348623853 1 0 1
digitalized,hypothyroid,patient 1.0 0.000143348623853 1 0 1
digitalis,toxicity,may 1.0 0.000143348623853 1 0 1
digitalis,thyroid,preparations 1.0 0.000143348623853 1 0 1
digitalis,or,may 1.0 0.000143348623853 1 0 1
digitalis,immediate,release 1.0 0.000143348623853 1 0 1
digitalis,glycosides,amphotericin 1.0 0.000143348623853 1 0 1
digit,symbol,substitution 1.0 0.000143348623853 1 0 1
digestive,enzyme,preparations 1.0 0.000143348623853 1 0 1
difluoroacetone,in,the 1.0 0.000143348623853 1 0 1
difluoro-2,propanol,mg 1.0 0.000143348623853 1 0 1
difluoro-2,propanol,derive 1.0 0.000143348623853 1 0 1
different,type,of 1.0 0.000143348623853 1 0 1
different,than,for 1.0 0.000143348623853 1 0 1
different,routes,a 1.0 0.000143348623853 1 0 1
dietary,salt,restriction 1.0 0.000143348623853 1 0 1
dietary,deficiencies,affecting 1.0 0.000143348623853 1 0 1
diet,resulted,in 1.0 0.000143348623853 1 0 1
diet,for,weeks 1.0 0.000143348623853 1 0 1
didrex,should,not 1.0 0.000143348623853 1 0 1
didanosine-placebo,tablets,a 1.0 0.000143348623853 1 0 1
didanosine,co-administration,of 1.0 0.000143348623853 1 0 1
did,slightly,enhance 1.0 0.000143348623853 1 0 1
did,not,indicate 1.0 0.000143348623853 1 0 1
did,not,antagonize 1.0 0.000143348623853 1 0 1
did,indeed,have 1.0 0.000143348623853 1 0 1
did,augment,the 1.0 0.000143348623853 1 0 1
dicumarol,it,has 1.0 0.000143348623853 1 0 1
dictates,careful,monitoring 1.0 0.000143348623853 1 0 1
dictate,against,the 1.0 0.000143348623853 1 0 1
diclofenac,decreases,renal 1.0 0.000143348623853 1 0 1
diclofenac,and,other 1.0 0.000143348623853 1 0 1
diazepam,the,co-administration 1.0 0.000143348623853 1 0 1
diazepam,at,doses 1.0 0.000143348623853 1 0 1
diastolic,blood,pressure 1.0 0.000143348623853 1 0 1
diarrhea,would,be 1.0 0.000143348623853 1 0 1
diarrhea,induced,by 1.0 0.000143348623853 1 0 1
diarrhea,but,this 1.0 0.000143348623853 1 0 1
diarrhea,and,dehydration 1.0 0.000143348623853 1 0 1
diamox,modifies,metabolism 1.0 0.000143348623853 1 0 1
diamox,may,decrease 1.0 0.000143348623853 1 0 1
diamond,patient,populations 1.0 0.000143348623853 1 0 1
dialysis,may,occasionally 1.0 0.000143348623853 1 0 1
diagnosed,schizophrenia,schizoaffective 1.0 0.000143348623853 1 0 1
diabetics,with,microalbuminuria 1.0 0.000143348623853 1 0 1
diabetics,or,patients 1.0 0.000143348623853 1 0 1
diabetics,dosage,adjustment 1.0 0.000143348623853 1 0 1
diabetic,patients,and 1.0 0.000143348623853 1 0 1
diabetic,patient,s 1.0 0.000143348623853 1 0 1
diabetic,patient,maintained 1.0 0.000143348623853 1 0 1
diabetic,nsaids,like 1.0 0.000143348623853 1 0 1
diabetes,used,to 1.0 0.000143348623853 1 0 1
diabetes,medicine,you 1.0 0.000143348623853 1 0 1
dexfenfluramine,should,not 1.0 0.000143348623853 1 0 1
dexamethasone,steady-state,trough 1.0 0.000143348623853 1 0 1
dexamethasone,at,m 1.0 0.000143348623853 1 0 1
dexamethasone,aprepitant,when 1.0 0.000143348623853 1 0 1
dexamethasone,and,retinyl 1.0 0.000143348623853 1 0 1
deviation,to,ml 1.0 0.000143348623853 1 0 1
development,of,spontaneous 1.0 0.000143348623853 1 0 1
development,of,myalgia 1.0 0.000143348623853 1 0 1
developing,peripheral,neuropathy 1.0 0.000143348623853 1 0 1
developed,rash,while 1.0 0.000143348623853 1 0 1
developed,increased,bun 1.0 0.000143348623853 1 0 1
developed,in,a 1.0 0.000143348623853 1 0 1
develop,toxicity,characteristics 1.0 0.000143348623853 1 0 1
develop,increased,serum 1.0 0.000143348623853 1 0 1
develop,in,patients 1.0 0.000143348623853 1 0 1
develop,delirium,high 1.0 0.000143348623853 1 0 1
develop,a,mild 1.0 0.000143348623853 1 0 1
detoxification,of,is 1.0 0.000143348623853 1 0 1
determined,prior,to 1.0 0.000143348623853 1 0 1
determined,on,day 1.0 0.000143348623853 1 0 1
determined,before,starting 1.0 0.000143348623853 1 0 1
determinations,vitamin,c 1.0 0.000143348623853 1 0 1
determinations,of,these 1.0 0.000143348623853 1 0 1
desyrel,and,buspirone 1.0 0.000143348623853 1 0 1
desired,lactulose-induced,drop 1.0 0.000143348623853 1 0 1
desired,effect,on 1.0 0.000143348623853 1 0 1
design,that,have 1.0 0.000143348623853 1 0 1
describing,patients,with 1.0 0.000143348623853 1 0 1
describes,two,cases 1.0 0.000143348623853 1 0 1
describes,a,novel 1.0 0.000143348623853 1 0 1
describe,modest,elevations 1.0 0.000143348623853 1 0 1
derived,from,the 1.0 0.000143348623853 1 0 1
derived,from,a 1.0 0.000143348623853 1 0 1
derive,from,its 1.0 0.000143348623853 1 0 1
derivatives,prothrombin,time 1.0 0.000143348623853 1 0 1
derivatives,or,may 1.0 0.000143348623853 1 0 1
derivatives,indandione,derivatives 1.0 0.000143348623853 1 0 1
derivatives,in,patients 1.0 0.000143348623853 1 0 1
derivatives,antimycobacterial,agents 1.0 0.000143348623853 1 0 1
derivatives,and,possibly 1.0 0.000143348623853 1 0 1
derivatives,and,platelet 1.0 0.000143348623853 1 0 1
derivatives,and,may 1.0 0.000143348623853 1 0 1
derivatives,and,has 1.0 0.000143348623853 1 0 1
derivatives,and,are 1.0 0.000143348623853 1 0 1
depth,of,neuromuscular 1.0 0.000143348623853 1 0 1
depressive,effects,of 1.0 0.000143348623853 1 0 1
depression,tricyclic,flupenthixol 1.0 0.000143348623853 1 0 1
depression,such,as 1.0 0.000143348623853 1 0 1
depression,stupor,and 1.0 0.000143348623853 1 0 1
depression,or,may 1.0 0.000143348623853 1 0 1
depression,of,the 1.0 0.000143348623853 1 0 1
depression,of,cardiac 1.0 0.000143348623853 1 0 1
depression,of,av 1.0 0.000143348623853 1 0 1
depression,may,occur 1.0 0.000143348623853 1 0 1
depresses,tubular,secretion 1.0 0.000143348623853 1 0 1
depresses,activity,and 1.0 0.000143348623853 1 0 1
depressed,in,a 1.0 0.000143348623853 1 0 1
depressasnts,such,as 1.0 0.000143348623853 1 0 1
depressants,using,these 1.0 0.000143348623853 1 0 1
depressants,the,concomitant 1.0 0.000143348623853 1 0 1
depressants,or,should 1.0 0.000143348623853 1 0 1
depressants,or,inhibitors 1.0 0.000143348623853 1 0 1
depressants,may,still 1.0 0.000143348623853 1 0 1
depressants,including,such 1.0 0.000143348623853 1 0 1
depressants,including,has 1.0 0.000143348623853 1 0 1
depressants,including,but 1.0 0.000143348623853 1 0 1
depressants,including,and 1.0 0.000143348623853 1 0 1
depressants,eg,other 1.0 0.000143348623853 1 0 1
depressants,causing,increased 1.0 0.000143348623853 1 0 1
depressants,are,administered 1.0 0.000143348623853 1 0 1
depressants,and,may 1.0 0.000143348623853 1 0 1
depressant,should,be 1.0 0.000143348623853 1 0 1
depressant,effects,divalproex 1.0 0.000143348623853 1 0 1
depressant,effect,of 1.0 0.000143348623853 1 0 1
depressant,and,general 1.0 0.000143348623853 1 0 1
depress,the,nervous 1.0 0.000143348623853 1 0 1
depletors,should,therefore 1.0 0.000143348623853 1 0 1
depletion,of,already 1.0 0.000143348623853 1 0 1
depletion,may,occasionally 1.0 0.000143348623853 1 0 1
deplete,and,monoamine 1.0 0.000143348623853 1 0 1
dependent,oxidation,responsible 1.0 0.000143348623853 1 0 1
dependent,hypertension,including 1.0 0.000143348623853 1 0 1
depen,cuprimine,another 1.0 0.000143348623853 1 0 1
dental,complications,blurred 1.0 0.000143348623853 1 0 1
denotes,a,mean 1.0 0.000143348623853 1 0 1
demonstrates,that,concurrent 1.0 0.000143348623853 1 0 1
demonstrated,to,interfere 1.0 0.000143348623853 1 0 1
demonstrated,that,is 1.0 0.000143348623853 1 0 1
demonstrated,that,concomitant 1.0 0.000143348623853 1 0 1
demonstrated,that,co-administration 1.0 0.000143348623853 1 0 1
demonstrated,moderate,to 1.0 0.000143348623853 1 0 1
demonstrated,less,alteration 1.0 0.000143348623853 1 0 1
demonstrated,in,a 1.0 0.000143348623853 1 0 1
demonstrated,between,and 1.0 0.000143348623853 1 0 1
demonstrated,an,association 1.0 0.000143348623853 1 0 1
demonstrated,a,significant 1.0 0.000143348623853 1 0 1
demonstrated,a,decrease 1.0 0.000143348623853 1 0 1
delirium,high,fever 1.0 0.000143348623853 1 0 1
delirium,has,been 1.0 0.000143348623853 1 0 1
delirium,associated,with 1.0 0.000143348623853 1 0 1
deleted,from,a 1.0 0.000143348623853 1 0 1
delayed,for,several 1.0 0.000143348623853 1 0 1
delayed,and,their 1.0 0.000143348623853 1 0 1
delayed,adverse,reactions 1.0 0.000143348623853 1 0 1
dehydrogenase,inhibition,significantly 1.0 0.000143348623853 1 0 1
dehydration,secondary,to 1.0 0.000143348623853 1 0 1
dehydration,have,been 1.0 0.000143348623853 1 0 1
degrees,of,inhibition 1.0 0.000143348623853 1 0 1
degrees,of,heart 1.0 0.000143348623853 1 0 1
degree,of,hypotension 1.0 0.000143348623853 1 0 1
degree,of,apoptosis 1.0 0.000143348623853 1 0 1
definitively,demonstrated,that 1.0 0.000143348623853 1 0 1
definitely,indicated,and 1.0 0.000143348623853 1 0 1
deficiency,can,increase 1.0 0.000143348623853 1 0 1
deficiencies,affecting,blood 1.0 0.000143348623853 1 0 1
deferred,until,therapy 1.0 0.000143348623853 1 0 1
defense,of,heparinized 1.0 0.000143348623853 1 0 1
deet,n,n-diethyl 1.0 0.000143348623853 1 0 1
decreasing,the,gastrointestinal 1.0 0.000143348623853 1 0 1
decreasing,the,clearance 1.0 0.000143348623853 1 0 1
decreasing,heparin,effect 1.0 0.000143348623853 1 0 1
decreasing,gut,motility 1.0 0.000143348623853 1 0 1
decreases,urinary,excretion 1.0 0.000143348623853 1 0 1
decreases,the,elimination 1.0 0.000143348623853 1 0 1
decreases,the,biologic 1.0 0.000143348623853 1 0 1
decreases,the,binding 1.0 0.000143348623853 1 0 1
decreases,renal,clearance 1.0 0.000143348623853 1 0 1
decreases,of,more 1.0 0.000143348623853 1 0 1
decreases,of,and 1.0 0.000143348623853 1 0 1
decreases,in,the 1.0 0.000143348623853 1 0 1
decreases,in,plasma 1.0 0.000143348623853 1 0 1
decreases,in,levels 1.0 0.000143348623853 1 0 1
decreases,in,fi 1.0 0.000143348623853 1 0 1
decreases,in,creatinine 1.0 0.000143348623853 1 0 1
decreases,gastrointestinal,secretion 1.0 0.000143348623853 1 0 1
decreases,effectiveness,by 1.0 0.000143348623853 1 0 1
decreases,clearance,of 1.0 0.000143348623853 1 0 1
decreases,clearance,by 1.0 0.000143348623853 1 0 1
decreased,with,and 1.0 0.000143348623853 1 0 1
decreased,when,given 1.0 0.000143348623853 1 0 1
decreased,when,are 1.0 0.000143348623853 1 0 1
decreased,to,micrograms 1.0 0.000143348623853 1 0 1
decreased,the,urinary 1.0 0.000143348623853 1 0 1
decreased,the,tmax 1.0 0.000143348623853 1 0 1
decreased,the,rate 1.0 0.000143348623853 1 0 1
decreased,the,maximum 1.0 0.000143348623853 1 0 1
decreased,the,concentrations 1.0 0.000143348623853 1 0 1
decreased,the,bioavailability 1.0 0.000143348623853 1 0 1
decreased,the,binding 1.0 0.000143348623853 1 0 1
decreased,symptoms,of 1.0 0.000143348623853 1 0 1
decreased,slightly,from 1.0 0.000143348623853 1 0 1
decreased,protein,binding 1.0 0.000143348623853 1 0 1
decreased,on,average 1.0 0.000143348623853 1 0 1
decreased,mean,cmax 1.0 0.000143348623853 1 0 1
decreased,increased,dosages 1.0 0.000143348623853 1 0 1
decreased,in,rats 1.0 0.000143348623853 1 0 1
decreased,hearing,have 1.0 0.000143348623853 1 0 1
decreased,have,been 1.0 0.000143348623853 1 0 1
decreased,even,when 1.0 0.000143348623853 1 0 1
decreased,efficacy,of 1.0 0.000143348623853 1 0 1
decreased,effectiveness,and 1.0 0.000143348623853 1 0 1
decreased,concentrations,in 1.0 0.000143348623853 1 0 1
decreased,clearance,of 1.0 0.000143348623853 1 0 1
decreased,by,while 1.0 0.000143348623853 1 0 1
decreased,by,the 1.0 0.000143348623853 1 0 1
decreased,by,concomitant 1.0 0.000143348623853 1 0 1
decreased,by,about 1.0 0.000143348623853 1 0 1
decreased,by,a 1.0 0.000143348623853 1 0 1
decreased,blood,levels 1.0 0.000143348623853 1 0 1
decreased,binding,in 1.0 0.000143348623853 1 0 1
decreased,auc,by 1.0 0.000143348623853 1 0 1
decreased,approximately,when 1.0 0.000143348623853 1 0 1
decreased,approximately,fold 1.0 0.000143348623853 1 0 1
decreased,antihypertensive,effect 1.0 0.000143348623853 1 0 1
decreased,and,decreased 1.0 0.000143348623853 1 0 1
decreased,active,metabolite 1.0 0.000143348623853 1 0 1
decrease,vascular,response 1.0 0.000143348623853 1 0 1
decrease,thyroidal,uptake 1.0 0.000143348623853 1 0 1
decrease,the,response 1.0 0.000143348623853 1 0 1
decrease,the,required 1.0 0.000143348623853 1 0 1
decrease,the,possible 1.0 0.000143348623853 1 0 1
decrease,the,metabolic 1.0 0.000143348623853 1 0 1
decrease,the,hepatic 1.0 0.000143348623853 1 0 1
decrease,the,hemodynamic 1.0 0.000143348623853 1 0 1
decrease,the,efficacy 1.0 0.000143348623853 1 0 1
decrease,the,ed50 1.0 0.000143348623853 1 0 1
decrease,the,cyp3a4-mediated 1.0 0.000143348623853 1 0 1
decrease,the,antinociceptive 1.0 0.000143348623853 1 0 1
decrease,the,amount 1.0 0.000143348623853 1 0 1
decrease,serum,concentrations 1.0 0.000143348623853 1 0 1
decrease,serum,concentration 1.0 0.000143348623853 1 0 1
decrease,range,from 1.0 0.000143348623853 1 0 1
decrease,in,standing 1.0 0.000143348623853 1 0 1
decrease,in,s 1.0 0.000143348623853 1 0 1
decrease,in,phosphorylation 1.0 0.000143348623853 1 0 1
decrease,in,levels 1.0 0.000143348623853 1 0 1
decrease,in,excretion 1.0 0.000143348623853 1 0 1
decrease,in,ethinyl 1.0 0.000143348623853 1 0 1
decrease,in,effectiveness 1.0 0.000143348623853 1 0 1
decrease,in,bioavailability 1.0 0.000143348623853 1 0 1
decrease,in,binding 1.0 0.000143348623853 1 0 1
decrease,in,average 1.0 0.000143348623853 1 0 1
decrease,in,anti-inflammatory 1.0 0.000143348623853 1 0 1
decrease,glutathione,levels 1.0 0.000143348623853 1 0 1
decrease,for,the 1.0 0.000143348623853 1 0 1
decrease,established,steady-state 1.0 0.000143348623853 1 0 1
decrease,elimination,and 1.0 0.000143348623853 1 0 1
decrease,conduction,through 1.0 0.000143348623853 1 0 1
decrease,clozapine,plasma 1.0 0.000143348623853 1 0 1
decrease,by,concomitant 1.0 0.000143348623853 1 0 1
decrease,blood,levels 1.0 0.000143348623853 1 0 1
decrease,anti-inflammatory,action 1.0 0.000143348623853 1 0 1
decrease,absorption,of 1.0 0.000143348623853 1 0 1
decrease,about,in 1.0 0.000143348623853 1 0 1
decongestant,allergy,cold 1.0 0.000143348623853 1 0 1
decided,to,discontinue 1.0 0.000143348623853 1 0 1
deaths,reveal,frequent 1.0 0.000143348623853 1 0 1
deaths,in,a 1.0 0.000143348623853 1 0 1
deaths,have,been 1.0 0.000143348623853 1 0 1
deaths,from,severe 1.0 0.000143348623853 1 0 1
death,potentially,associated 1.0 0.000143348623853 1 0 1
death,have,occurred 1.0 0.000143348623853 1 0 1
death,due,to 1.0 0.000143348623853 1 0 1
death,associated,with 1.0 0.000143348623853 1 0 1
de,pointes,most 1.0 0.000143348623853 1 0 1
dcg-iv,were,very 1.0 0.000143348623853 1 0 1
days,with,the 1.0 0.000143348623853 1 0 1
days,with,co-administration 1.0 0.000143348623853 1 0 1
days,with,a 1.0 0.000143348623853 1 0 1
days,while,plasma 1.0 0.000143348623853 1 0 1
days,was,decreased 1.0 0.000143348623853 1 0 1
days,was,associated 1.0 0.000143348623853 1 0 1
days,through,increased 1.0 0.000143348623853 1 0 1
days,should,elapse 1.0 0.000143348623853 1 0 1
days,results,in 1.0 0.000143348623853 1 0 1
days,produced,significant 1.0 0.000143348623853 1 0 1
days,of,discontinuing 1.0 0.000143348623853 1 0 1
days,of,a 1.0 0.000143348623853 1 0 1
days,intraperitoneally,ip 1.0 0.000143348623853 1 0 1
days,increased,the 1.0 0.000143348623853 1 0 1
days,in,healthy 1.0 0.000143348623853 1 0 1
days,however,reduced 1.0 0.000143348623853 1 0 1
days,following,use 1.0 0.000143348623853 1 0 1
days,following,initiation 1.0 0.000143348623853 1 0 1
days,decreased,the 1.0 0.000143348623853 1 0 1
days,because,severe 1.0 0.000143348623853 1 0 1
days,as,a 1.0 0.000143348623853 1 0 1
days,and,increased 1.0 0.000143348623853 1 0 1
days,and,a 1.0 0.000143348623853 1 0 1
days,after,sudden 1.0 0.000143348623853 1 0 1
days,after,initiating 1.0 0.000143348623853 1 0 1
days,after,completion 1.0 0.000143348623853 1 0 1
days,after,administration 1.0 0.000143348623853 1 0 1
days,a,potent 1.0 0.000143348623853 1 0 1
days,a,decrease 1.0 0.000143348623853 1 0 1
day9,of,a 1.0 0.000143348623853 1 0 1
day5,of,a 1.0 0.000143348623853 1 0 1
day-old,chick,embryos 1.0 0.000143348623853 1 0 1
day,with,coadministered 1.0 0.000143348623853 1 0 1
day,will,require 1.0 0.000143348623853 1 0 1
day,when,was 1.0 0.000143348623853 1 0 1
day,was,coadministered 1.0 0.000143348623853 1 0 1
day,there,was 1.0 0.000143348623853 1 0 1
day,showed,an 1.0 0.000143348623853 1 0 1
day,resulted,in 1.0 0.000143348623853 1 0 1
day,relative,to 1.0 0.000143348623853 1 0 1
day,provided,significant 1.0 0.000143348623853 1 0 1
day,orally,for 1.0 0.000143348623853 1 0 1
day,on,day 1.0 0.000143348623853 1 0 1
day,of,were 1.0 0.000143348623853 1 0 1
day,of,therapy 1.0 0.000143348623853 1 0 1
day,of,resulted 1.0 0.000143348623853 1 0 1
day,of,cromolyn 1.0 0.000143348623853 1 0 1
day,of,cancidas 1.0 0.000143348623853 1 0 1
day,of,approximately 1.0 0.000143348623853 1 0 1
day,n,compared 1.0 0.000143348623853 1 0 1
day,lexapro,for 1.0 0.000143348623853 1 0 1
day,increased,the 1.0 0.000143348623853 1 0 1
day,in,six 1.0 0.000143348623853 1 0 1
day,in,order 1.0 0.000143348623853 1 0 1
day,in,eight 1.0 0.000143348623853 1 0 1
day,ig,for 1.0 0.000143348623853 1 0 1
day,have,been 1.0 0.000143348623853 1 0 1
day,groups,pd2 1.0 0.000143348623853 1 0 1
day,group,were 1.0 0.000143348623853 1 0 1
day,followed,by 1.0 0.000143348623853 1 0 1
day,during,adjunctive 1.0 0.000143348623853 1 0 1
day,divided,into 1.0 0.000143348623853 1 0 1
day,decreases,blood 1.0 0.000143348623853 1 0 1
day,days,after 1.0 0.000143348623853 1 0 1
day,as,camptosar 1.0 0.000143348623853 1 0 1
day,and,orally 1.0 0.000143348623853 1 0 1
day,and,on 1.0 0.000143348623853 1 0 1
day,and,fold 1.0 0.000143348623853 1 0 1
day,and,decreased 1.0 0.000143348623853 1 0 1
day,and,day 1.0 0.000143348623853 1 0 1
day,and,by 1.0 0.000143348623853 1 0 1
day,and,aprepitant 1.0 0.000143348623853 1 0 1
day,and,a 1.0 0.000143348623853 1 0 1
day,a,dose 1.0 0.000143348623853 1 0 1
data,which,suggest 1.0 0.000143348623853 1 0 1
data,where,iressa 1.0 0.000143348623853 1 0 1
data,vardenafil,should 1.0 0.000143348623853 1 0 1
data,to,evaluate 1.0 0.000143348623853 1 0 1
data,suggesting,a 1.0 0.000143348623853 1 0 1
data,suggest,a 1.0 0.000143348623853 1 0 1
data,show,that 1.0 0.000143348623853 1 0 1
data,on,possible 1.0 0.000143348623853 1 0 1
data,lower,doses 1.0 0.000143348623853 1 0 1
data,from,these 1.0 0.000143348623853 1 0 1
danger,of,the 1.0 0.000143348623853 1 0 1
danger,of,blocking 1.0 0.000143348623853 1 0 1
danger,of,a 1.0 0.000143348623853 1 0 1
danger,inherent,in 1.0 0.000143348623853 1 0 1
danazol,the,risk 1.0 0.000143348623853 1 0 1
damage,produced,a 1.0 0.000143348623853 1 0 1
damage,has,occurred 1.0 0.000143348623853 1 0 1
damage,as,indicated 1.0 0.000143348623853 1 0 1
daily,with,food 1.0 0.000143348623853 1 0 1
daily,the,maximum 1.0 0.000143348623853 1 0 1
daily,the,auc 1.0 0.000143348623853 1 0 1
daily,taken,with 1.0 0.000143348623853 1 0 1
daily,produced,a 1.0 0.000143348623853 1 0 1
daily,of,vioxx 1.0 0.000143348623853 1 0 1
daily,may,result 1.0 0.000143348623853 1 0 1
daily,maintenance,dose 1.0 0.000143348623853 1 0 1
daily,increases,in 1.0 0.000143348623853 1 0 1
daily,increased,the 1.0 0.000143348623853 1 0 1
daily,given,hours 1.0 0.000143348623853 1 0 1
daily,followed,by 1.0 0.000143348623853 1 0 1
daily,dose,is 1.0 0.000143348623853 1 0 1
daily,as,a 1.0 0.000143348623853 1 0 1
daily,and,provide 1.0 0.000143348623853 1 0 1
daily,and,one 1.0 0.000143348623853 1 0 1
daily,a,potent 1.0 0.000143348623853 1 0 1
d6,poor,metabolizers 1.0 0.000143348623853 1 0 1
d3,and,tam 1.0 0.000143348623853 1 0 1
d3,administration,to 1.0 0.000143348623853 1 0 1
d2,antagonists,and 1.0 0.000143348623853 1 0 1
d1,antagonist,sch-23390 1.0 0.000143348623853 1 0 1
d,with,a 1.0 0.000143348623853 1 0 1
d,were,co-administered 1.0 0.000143348623853 1 0 1
d,respectively,of 1.0 0.000143348623853 1 0 1
d,inhibited,the 1.0 0.000143348623853 1 0 1
d,dosage,of 1.0 0.000143348623853 1 0 1
d,at,microm 1.0 0.000143348623853 1 0 1
d,and,a 1.0 0.000143348623853 1 0 1
d,agonists,concomitant 1.0 0.000143348623853 1 0 1
cytotoxic,agents,enhanced 1.0 0.000143348623853 1 0 1
cytostatic,agent,has 1.0 0.000143348623853 1 0 1
cytosine,arabinoside,a 1.0 0.000143348623853 1 0 1
cytochrome,p450iiia4,isozyme 1.0 0.000143348623853 1 0 1
cytochrome,p450iid6,such 1.0 0.000143348623853 1 0 1
cytochrome,p450,inducers 1.0 0.000143348623853 1 0 1
cytochrome,p450,enzyme-inducer 1.0 0.000143348623853 1 0 1
cytochrome,p-450,inducers 1.0 0.000143348623853 1 0 1
cytochrome,p-450,for 1.0 0.000143348623853 1 0 1
cytochrome,p-450,a 1.0 0.000143348623853 1 0 1
cytochalasin,d,inhibited 1.0 0.000143348623853 1 0 1
cytochalasin,d,at 1.0 0.000143348623853 1 0 1
cytadren,accelerates,the 1.0 0.000143348623853 1 0 1
cystic,fluid,were 1.0 0.000143348623853 1 0 1
cyst,patients,treated 1.0 0.000143348623853 1 0 1
cypermethrin-induced,oxidative,stress 1.0 0.000143348623853 1 0 1
cyp3a4,the,major 1.0 0.000143348623853 1 0 1
cyp3a4,such,as 1.0 0.000143348623853 1 0 1
cyp3a4,substrates,that 1.0 0.000143348623853 1 0 1
cyp3a4,substrates,known 1.0 0.000143348623853 1 0 1
cyp3a4,should,be 1.0 0.000143348623853 1 0 1
cyp3a4,rifampicin,racemic 1.0 0.000143348623853 1 0 1
cyp3a4,pathway,showed 1.0 0.000143348623853 1 0 1
cyp3a4,mg,daily 1.0 0.000143348623853 1 0 1
cyp3a4,metabolized,triazolo-benzodiazepines 1.0 0.000143348623853 1 0 1
cyp3a4,metabolized,should 1.0 0.000143348623853 1 0 1
cyp3a4,inhibitors,that 1.0 0.000143348623853 1 0 1
cyp3a4,inhibitors,result 1.0 0.000143348623853 1 0 1
cyp3a4,inhibitors,mg 1.0 0.000143348623853 1 0 1
cyp3a4,inhibitor,which 1.0 0.000143348623853 1 0 1
cyp3a4,inhibitor,the 1.0 0.000143348623853 1 0 1
cyp3a4,inhibitor,produced 1.0 0.000143348623853 1 0 1
cyp3a4,inhibitor,mg 1.0 0.000143348623853 1 0 1
cyp3a4,inhibitor,increases 1.0 0.000143348623853 1 0 1
cyp3a4,inhibitor,increased 1.0 0.000143348623853 1 0 1
cyp3a4,inhibitor,at 1.0 0.000143348623853 1 0 1
cyp3a4,inducers,it 1.0 0.000143348623853 1 0 1
cyp3a4,inducer,with 1.0 0.000143348623853 1 0 1
cyp3a4,inducer,the 1.0 0.000143348623853 1 0 1
cyp3a4,inducer,mg 1.0 0.000143348623853 1 0 1
cyp3a4,inducer,decreased 1.0 0.000143348623853 1 0 1
cyp3a4,inducer,at 1.0 0.000143348623853 1 0 1
cyp3a4,increased,exposure 1.0 0.000143348623853 1 0 1
cyp3a4,eg,or 1.0 0.000143348623853 1 0 1
cyp3a4,eg,could 1.0 0.000143348623853 1 0 1
cyp3a4,eg,channel 1.0 0.000143348623853 1 0 1
cyp3a4,cimetidine,cimetidine 1.0 0.000143348623853 1 0 1
cyp3a4,and,can 1.0 0.000143348623853 1 0 1
cyp3a4,activity,such 1.0 0.000143348623853 1 0 1
cyp3a4,activity,in 1.0 0.000143348623853 1 0 1
cyp3a,inducers,such 1.0 0.000143348623853 1 0 1
cyp3a,compounds,that 1.0 0.000143348623853 1 0 1
cyp3a,a,minor 1.0 0.000143348623853 1 0 1
cyp2d6,substrate,the 1.0 0.000143348623853 1 0 1
cyp2d6,resulted,in 1.0 0.000143348623853 1 0 1
cyp2d6,isoenzyme,including 1.0 0.000143348623853 1 0 1
cyp2d6,isoenzyme,daily 1.0 0.000143348623853 1 0 1
cyp2d6,inhibitory,effect 1.0 0.000143348623853 1 0 1
cyp2d6,increased,the 1.0 0.000143348623853 1 0 1
cyp2d6,i,selective 1.0 0.000143348623853 1 0 1
cyp2d6,eg,or 1.0 0.000143348623853 1 0 1
cyp2d6,and,which 1.0 0.000143348623853 1 0 1
cyp2c9,such,as 1.0 0.000143348623853 1 0 1
cyp2c9,substrate,trough 1.0 0.000143348623853 1 0 1
cyp2c9,substrate,by 1.0 0.000143348623853 1 0 1
cyp2c9,substrate,and 1.0 0.000143348623853 1 0 1
cyp2c9,isoenzyme,in 1.0 0.000143348623853 1 0 1
cyp2c19,substrate,resulted 1.0 0.000143348623853 1 0 1
cyp2a6,hydroxylation,of 1.0 0.000143348623853 1 0 1
cyp1a2,results,in 1.0 0.000143348623853 1 0 1
cyp1a2,is,inhibited 1.0 0.000143348623853 1 0 1
cyp1a2,inhibitors,including 1.0 0.000143348623853 1 0 1
cyp1a2,cyp3a,a 1.0 0.000143348623853 1 0 1
cyp1a2,concomitant,use 1.0 0.000143348623853 1 0 1
cyp,metabolism,of 1.0 0.000143348623853 1 0 1
cyp,inducers,that 1.0 0.000143348623853 1 0 1
cyp,enzymes,are 1.0 0.000143348623853 1 0 1
cyp,d6,poor 1.0 0.000143348623853 1 0 1
cyp,a4,or 1.0 0.000143348623853 1 0 1
cyp,a4,macrolide 1.0 0.000143348623853 1 0 1
cyp,a4,enzyme 1.0 0.000143348623853 1 0 1
cyclosporine,modest,increases 1.0 0.000143348623853 1 0 1
cyclosporine,l-arginine,may 1.0 0.000143348623853 1 0 1
cyclosporine,increased,activity 1.0 0.000143348623853 1 0 1
cyclosporine,digoxin,methotrexate 1.0 0.000143348623853 1 0 1
cyclosporine,combination,hormonal 1.0 0.000143348623853 1 0 1
cyclosporine,because,can 1.0 0.000143348623853 1 0 1
cyclosporine,and,concentrations 1.0 0.000143348623853 1 0 1
cyclosporine,administration,of 1.0 0.000143348623853 1 0 1
cyclosporin,reports,indicate 1.0 0.000143348623853 1 0 1
cyclosporin,after,introduction 1.0 0.000143348623853 1 0 1
cyclopropane,or,halogenated 1.0 0.000143348623853 1 0 1
cyclophosphamide,used,concurrently 1.0 0.000143348623853 1 0 1
cyclophosphamide,treatment,which 1.0 0.000143348623853 1 0 1
cyclopentolate,may,interfere 1.0 0.000143348623853 1 0 1
cyclic,may,emerge 1.0 0.000143348623853 1 0 1
curves,with,enteric 1.0 0.000143348623853 1 0 1
curves,derived,from 1.0 0.000143348623853 1 0 1
curve,of,sulfoxide 1.0 0.000143348623853 1 0 1
curve,at,steady 1.0 0.000143348623853 1 0 1
curve,and,maximal 1.0 0.000143348623853 1 0 1
curve,after,a 1.0 0.000143348623853 1 0 1
currently,receiving,therapy 1.0 0.000143348623853 1 0 1
currently,receiving,cautious 1.0 0.000143348623853 1 0 1
currently,receiving,careful 1.0 0.000143348623853 1 0 1
current,responses,in 1.0 0.000143348623853 1 0 1
cure,and,the 1.0 0.000143348623853 1 0 1
curariform,muscle,relaxants 1.0 0.000143348623853 1 0 1
curariform,effect,of 1.0 0.000143348623853 1 0 1
cumulative,doses,of 1.0 0.000143348623853 1 0 1
culture,the,effect 1.0 0.000143348623853 1 0 1
culture,and,animal 1.0 0.000143348623853 1 0 1
css,max,is 1.0 0.000143348623853 1 0 1
cryptosporidium,parvum,growth 1.0 0.000143348623853 1 0 1
crossover,study,examining 1.0 0.000143348623853 1 0 1
cross-reactivity,of,with 1.0 0.000143348623853 1 0 1
cross,toxicity,and 1.0 0.000143348623853 1 0 1
cromolyn,sodium,approximately 1.0 0.000143348623853 1 0 1
crohns,disease,and 1.0 0.000143348623853 1 0 1
crixivan,may,not 1.0 0.000143348623853 1 0 1
crixivan,fortovase,invirase 1.0 0.000143348623853 1 0 1
crixivan,and,is 1.0 0.000143348623853 1 0 1
crisis,until,the 1.0 0.000143348623853 1 0 1
crises,have,resulted 1.0 0.000143348623853 1 0 1
crescentic,iga,glomerulonephritis 1.0 0.000143348623853 1 0 1
cremophor,el,eg 1.0 0.000143348623853 1 0 1
creatinine,level,has 1.0 0.000143348623853 1 0 1
creatinine,clearance,in 1.0 0.000143348623853 1 0 1
creatinine,clearance,and 1.0 0.000143348623853 1 0 1
creatinine,and,serum 1.0 0.000143348623853 1 0 1
creatinine,and,because 1.0 0.000143348623853 1 0 1
creatinine,an,endogenous 1.0 0.000143348623853 1 0 1
cr,lower,plasma 1.0 0.000143348623853 1 0 1
course,of,therapy 1.0 0.000143348623853 1 0 1
course,of,pcp 1.0 0.000143348623853 1 0 1
course,of,in 1.0 0.000143348623853 1 0 1
counts,in,comparison 1.0 0.000143348623853 1 0 1
counteract,the,antinaturetic 1.0 0.000143348623853 1 0 1
counteract,the,antiepileptic 1.0 0.000143348623853 1 0 1
counteract,the,anticoagulation 1.0 0.000143348623853 1 0 1
counteract,the,anticholinesterase 1.0 0.000143348623853 1 0 1
counteract,the,action 1.0 0.000143348623853 1 0 1
coumarin-type,the,physician 1.0 0.000143348623853 1 0 1
coumarin-type,the,addition 1.0 0.000143348623853 1 0 1
coumarin-like,should,be 1.0 0.000143348623853 1 0 1
coumarin-derivative,concomitantly,with 1.0 0.000143348623853 1 0 1
coumarin,anticoagulants,there 1.0 0.000143348623853 1 0 1
coumarin,anticoagulants,are 1.0 0.000143348623853 1 0 1
coumarin,anticoagulants,altered 1.0 0.000143348623853 1 0 1
could,theoretically,affect 1.0 0.000143348623853 1 0 1
could,theoretically,adversely 1.0 0.000143348623853 1 0 1
could,prolong,the 1.0 0.000143348623853 1 0 1
could,potentially,arise 1.0 0.000143348623853 1 0 1
could,cause,or 1.0 0.000143348623853 1 0 1
could,cause,heart 1.0 0.000143348623853 1 0 1
could,cause,an 1.0 0.000143348623853 1 0 1
could,be,prolonged 1.0 0.000143348623853 1 0 1
could,be,prevented 1.0 0.000143348623853 1 0 1
could,be,enhanced 1.0 0.000143348623853 1 0 1
could,be,additive 1.0 0.000143348623853 1 0 1
cortisone-like,medicine,blood 1.0 0.000143348623853 1 0 1
corticotropin,acth,may 1.0 0.000143348623853 1 0 1
corticosteroids,methylxanthines,and 1.0 0.000143348623853 1 0 1
corticosteroids,may,increase 1.0 0.000143348623853 1 0 1
corticosteroids,may,also 1.0 0.000143348623853 1 0 1
corticosteroids,dexamethasone,aprepitant 1.0 0.000143348623853 1 0 1
corticosteroids,concomitant,administration 1.0 0.000143348623853 1 0 1
corticosteroids,and,corticotropin 1.0 0.000143348623853 1 0 1
cortex,that,was 1.0 0.000143348623853 1 0 1
coronary,artery,vasospasm 1.0 0.000143348623853 1 0 1
corneal,lesions,in 1.0 0.000143348623853 1 0 1
coreg,is,to 1.0 0.000143348623853 1 0 1
core,temperature,was 1.0 0.000143348623853 1 0 1
copying,test,and 1.0 0.000143348623853 1 0 1
copegus,and,is 1.0 0.000143348623853 1 0 1
convulsions,and,cardiac 1.0 0.000143348623853 1 0 1
converting,difluoro-2,propanol 1.0 0.000143348623853 1 0 1
converted,to,the 1.0 0.000143348623853 1 0 1
converted,to,sinus 1.0 0.000143348623853 1 0 1
conversely,the,have 1.0 0.000143348623853 1 0 1
conversely,may,interfere 1.0 0.000143348623853 1 0 1
conversely,decreases,in 1.0 0.000143348623853 1 0 1
controlled-release,capsule,was 1.0 0.000143348623853 1 0 1
controlled,with,vardenafil 1.0 0.000143348623853 1 0 1
controlled,study,a 1.0 0.000143348623853 1 0 1
controlled,studies,in 1.0 0.000143348623853 1 0 1
controlled,on,receiving 1.0 0.000143348623853 1 0 1
controlled,hypotensive,using 1.0 0.000143348623853 1 0 1
controlled,clinical,study 1.0 0.000143348623853 1 0 1
control,vs,when 1.0 0.000143348623853 1 0 1
control,supraventricular,tachycardia 1.0 0.000143348623853 1 0 1
control,should,not 1.0 0.000143348623853 1 0 1
control,period,in 1.0 0.000143348623853 1 0 1
control,inflammation,associated 1.0 0.000143348623853 1 0 1
control,hypertension,in 1.0 0.000143348623853 1 0 1
control,by,lowering 1.0 0.000143348623853 1 0 1
control,by,its 1.0 0.000143348623853 1 0 1
control,blood,sugar 1.0 0.000143348623853 1 0 1
control,atrial,fibrillation 1.0 0.000143348623853 1 0 1
control,and,half-life 1.0 0.000143348623853 1 0 1
contribute,to,a 1.0 0.000143348623853 1 0 1
contrast,media,experienced 1.0 0.000143348623853 1 0 1
contrast,media,a 1.0 0.000143348623853 1 0 1
contrary,and,were 1.0 0.000143348623853 1 0 1
contraindicated,and,alternative 1.0 0.000143348623853 1 0 1
contractility,when,systemic 1.0 0.000143348623853 1 0 1
contractility,conductivity,and 1.0 0.000143348623853 1 0 1
contraceptives,including,oral 1.0 0.000143348623853 1 0 1
contraceptives,coadministration,of 1.0 0.000143348623853 1 0 1
contraceptives,an,interaction 1.0 0.000143348623853 1 0 1
contraceptive,effect,of 1.0 0.000143348623853 1 0 1
contraception,should,be 1.0 0.000143348623853 1 0 1
contraception,inwomen,taking 1.0 0.000143348623853 1 0 1
contortrostatin-induced,phosphorylation,of 1.0 0.000143348623853 1 0 1
continuously,observed,for 1.0 0.000143348623853 1 0 1
continued,if,vioxx 1.0 0.000143348623853 1 0 1
continue,to,increase 1.0 0.000143348623853 1 0 1
continue,the,initiate 1.0 0.000143348623853 1 0 1
contin,prelone,st 1.0 0.000143348623853 1 0 1
containing,vitamin,a 1.0 0.000143348623853 1 0 1
containing,trisilicate,when 1.0 0.000143348623853 1 0 1
containing,to,patients 1.0 0.000143348623853 1 0 1
containing,sequential,high 1.0 0.000143348623853 1 0 1
containing,regimens,who 1.0 0.000143348623853 1 0 1
containing,preparations,sunscreens 1.0 0.000143348623853 1 0 1
containing,or,videx 1.0 0.000143348623853 1 0 1
containing,or,other 1.0 0.000143348623853 1 0 1
containing,or,may 1.0 0.000143348623853 1 0 1
containing,or,as 1.0 0.000143348623853 1 0 1
containing,or,and 1.0 0.000143348623853 1 0 1
containing,multivalent,cations 1.0 0.000143348623853 1 0 1
containing,medicines,such 1.0 0.000143348623853 1 0 1
containing,mcg,of 1.0 0.000143348623853 1 0 1
containing,may,substantially 1.0 0.000143348623853 1 0 1
containing,may,decrease 1.0 0.000143348623853 1 0 1
containing,maalox,decreased 1.0 0.000143348623853 1 0 1
containing,hydroxide,and 1.0 0.000143348623853 1 0 1
containing,gram,of 1.0 0.000143348623853 1 0 1
containing,for,at 1.0 0.000143348623853 1 0 1
containing,ferrous,sulfate 1.0 0.000143348623853 1 0 1
containing,cremophor,el 1.0 0.000143348623853 1 0 1
containing,containing,or 1.0 0.000143348623853 1 0 1
containing,carbohydrate-splitting,enzymes 1.0 0.000143348623853 1 0 1
containing,buffer,should 1.0 0.000143348623853 1 0 1
containing,alone,they 1.0 0.000143348623853 1 0 1
contained,in,proprietary 1.0 0.000143348623853 1 0 1
contain,deet,n 1.0 0.000143348623853 1 0 1
contain,any,amine 1.0 0.000143348623853 1 0 1
contain,an,may 1.0 0.000143348623853 1 0 1
consumption,of,during 1.0 0.000143348623853 1 0 1
consuming,while,on 1.0 0.000143348623853 1 0 1
consume,and,hydroxy-1 1.0 0.000143348623853 1 0 1
constipation,blurred,vision 1.0 0.000143348623853 1 0 1
constellation,of,symptoms 1.0 0.000143348623853 1 0 1
consisting,of,usp 1.0 0.000143348623853 1 0 1
considering,the,use 1.0 0.000143348623853 1 0 1
considered,when,therapy 1.0 0.000143348623853 1 0 1
considered,when,the 1.0 0.000143348623853 1 0 1
considered,when,taking 1.0 0.000143348623853 1 0 1
considered,when,selecting 1.0 0.000143348623853 1 0 1
considered,when,coadministering 1.0 0.000143348623853 1 0 1
considered,prior,to 1.0 0.000143348623853 1 0 1
considered,in,place 1.0 0.000143348623853 1 0 1
considered,if,the 1.0 0.000143348623853 1 0 1
considered,during,the 1.0 0.000143348623853 1 0 1
considered,and,the 1.0 0.000143348623853 1 0 1
consideration,when,selecting 1.0 0.000143348623853 1 0 1
considerably,lower,in 1.0 0.000143348623853 1 0 1
considerable,effect,in 1.0 0.000143348623853 1 0 1
considerable,caution,should 1.0 0.000143348623853 1 0 1
consider,the,possibility 1.0 0.000143348623853 1 0 1
consider,hmg-coa,reductase 1.0 0.000143348623853 1 0 1
consider,discontinuation,of 1.0 0.000143348623853 1 0 1
consider,additive,sedative 1.0 0.000143348623853 1 0 1
conservatively,adjusted,in 1.0 0.000143348623853 1 0 1
consequently,the,effect 1.0 0.000143348623853 1 0 1
consequently,the,combination 1.0 0.000143348623853 1 0 1
consequently,should,be 1.0 0.000143348623853 1 0 1
consequently,concomitant,administration 1.0 0.000143348623853 1 0 1
consequent,possible,decrease 1.0 0.000143348623853 1 0 1
consequences,for,drugs 1.0 0.000143348623853 1 0 1
consequence,when,indocin 1.0 0.000143348623853 1 0 1
consequence,of,increased 1.0 0.000143348623853 1 0 1
consequence,of,blocking 1.0 0.000143348623853 1 0 1
consciousness,when,was 1.0 0.000143348623853 1 0 1
consciousness,caused,by 1.0 0.000143348623853 1 0 1
conjunction,with,in 1.0 0.000143348623853 1 0 1
conjunction,with,central 1.0 0.000143348623853 1 0 1
conjunction,with,a 1.0 0.000143348623853 1 0 1
conjugation,with,glutathione 1.0 0.000143348623853 1 0 1
confusional,states,to 1.0 0.000143348623853 1 0 1
confusion,extrapyramidal,symptoms 1.0 0.000143348623853 1 0 1
confusion,and,dyspnea 1.0 0.000143348623853 1 0 1
conflicting,results,regarding 1.0 0.000143348623853 1 0 1
conflicting,results,for 1.0 0.000143348623853 1 0 1
confidence,interval,whole 1.0 0.000143348623853 1 0 1
conductivity,and,automaticity 1.0 0.000143348623853 1 0 1
conduction,when,using 1.0 0.000143348623853 1 0 1
conduction,through,the 1.0 0.000143348623853 1 0 1
conduction,such,as 1.0 0.000143348623853 1 0 1
conduction,eg,or 1.0 0.000143348623853 1 0 1
conduction,disturbances,left 1.0 0.000143348623853 1 0 1
conduction,disturbance,rarely 1.0 0.000143348623853 1 0 1
conduction,can,result 1.0 0.000143348623853 1 0 1
conducting,an,arbutamine-mediated 1.0 0.000143348623853 1 0 1
conducted,with,alphagan 1.0 0.000143348623853 1 0 1
conducted,it,is 1.0 0.000143348623853 1 0 1
conducted,in,healthy 1.0 0.000143348623853 1 0 1
conducted,concomitant,administration 1.0 0.000143348623853 1 0 1
conducted,between,and 1.0 0.000143348623853 1 0 1
conditions,similar,to 1.0 0.000143348623853 1 0 1
condition,in,which 1.0 0.000143348623853 1 0 1
concurrently,with,the 1.0 0.000143348623853 1 0 1
concurrently,with,tambocor 1.0 0.000143348623853 1 0 1
concurrently,with,since 1.0 0.000143348623853 1 0 1
concurrently,with,reduced 1.0 0.000143348623853 1 0 1
concurrently,with,phenurone 1.0 0.000143348623853 1 0 1
concurrently,with,oral 1.0 0.000143348623853 1 0 1
concurrently,with,norpace 1.0 0.000143348623853 1 0 1
concurrently,with,may 1.0 0.000143348623853 1 0 1
concurrently,with,kineret 1.0 0.000143348623853 1 0 1
concurrently,with,enbrel 1.0 0.000143348623853 1 0 1
concurrently,with,d2-antagonists 1.0 0.000143348623853 1 0 1
concurrently,with,compared 1.0 0.000143348623853 1 0 1
concurrently,with,cerubidine 1.0 0.000143348623853 1 0 1
concurrently,with,central 1.0 0.000143348623853 1 0 1
concurrently,with,anion-exchange 1.0 0.000143348623853 1 0 1
concurrently,use,products 1.0 0.000143348623853 1 0 1
concurrently,treated,with 1.0 0.000143348623853 1 0 1
concurrently,the,should 1.0 0.000143348623853 1 0 1
concurrently,resulting,in 1.0 0.000143348623853 1 0 1
concurrently,plasma,levels 1.0 0.000143348623853 1 0 1
concurrently,patients,should 1.0 0.000143348623853 1 0 1
concurrently,increases,the 1.0 0.000143348623853 1 0 1
concurrently,increases,anion 1.0 0.000143348623853 1 0 1
concurrently,concentrations,should 1.0 0.000143348623853 1 0 1
concurrently,and,evidence 1.0 0.000143348623853 1 0 1
concurrently,administered,antiepileptic 1.0 0.000143348623853 1 0 1
concurrent,with,oral 1.0 0.000143348623853 1 0 1
concurrent,with,busulfex 1.0 0.000143348623853 1 0 1
concurrent,therapy,discontinuation 1.0 0.000143348623853 1 0 1
concurrent,kineret,and 1.0 0.000143348623853 1 0 1
concurrent,enbrel,and 1.0 0.000143348623853 1 0 1
concurrent,and,sodium 1.0 0.000143348623853 1 0 1
concurrent,administration,with 1.0 0.000143348623853 1 0 1
concurent,therapy,with 1.0 0.000143348623853 1 0 1
concomitantly,within14,days 1.0 0.000143348623853 1 0 1
concomitantly,with,their 1.0 0.000143348623853 1 0 1
concomitantly,with,tablets 1.0 0.000143348623853 1 0 1
concomitantly,with,significantly 1.0 0.000143348623853 1 0 1
concomitantly,with,should 1.0 0.000143348623853 1 0 1
concomitantly,with,reduce 1.0 0.000143348623853 1 0 1
concomitantly,with,prothrombin 1.0 0.000143348623853 1 0 1
concomitantly,with,produces 1.0 0.000143348623853 1 0 1
concomitantly,with,potassium-depleting 1.0 0.000143348623853 1 0 1
concomitantly,with,more 1.0 0.000143348623853 1 0 1
concomitantly,with,medications 1.0 0.000143348623853 1 0 1
concomitantly,with,mao 1.0 0.000143348623853 1 0 1
concomitantly,with,injectable 1.0 0.000143348623853 1 0 1
concomitantly,with,hepatic 1.0 0.000143348623853 1 0 1
concomitantly,with,gram 1.0 0.000143348623853 1 0 1
concomitantly,with,ethacrynic 1.0 0.000143348623853 1 0 1
concomitantly,with,dilaudid 1.0 0.000143348623853 1 0 1
concomitantly,with,cyp1a2 1.0 0.000143348623853 1 0 1
concomitantly,with,coumarin-derivative 1.0 0.000143348623853 1 0 1
concomitantly,with,citrate 1.0 0.000143348623853 1 0 1
concomitantly,with,as 1.0 0.000143348623853 1 0 1
concomitantly,with,antagonists 1.0 0.000143348623853 1 0 1
concomitantly,to,patients 1.0 0.000143348623853 1 0 1
concomitantly,there,is 1.0 0.000143348623853 1 0 1
concomitantly,should,have 1.0 0.000143348623853 1 0 1
concomitantly,serum,levels 1.0 0.000143348623853 1 0 1
concomitantly,renal,function 1.0 0.000143348623853 1 0 1
concomitantly,receiving,oral 1.0 0.000143348623853 1 0 1
concomitantly,receiving,itraconazole 1.0 0.000143348623853 1 0 1
concomitantly,receiving,azole 1.0 0.000143348623853 1 0 1
concomitantly,physicians,are 1.0 0.000143348623853 1 0 1
concomitantly,patients,should 1.0 0.000143348623853 1 0 1
concomitantly,may,need 1.0 0.000143348623853 1 0 1
concomitantly,may,develop 1.0 0.000143348623853 1 0 1
concomitantly,indicate,that 1.0 0.000143348623853 1 0 1
concomitantly,in,the 1.0 0.000143348623853 1 0 1
concomitantly,by,patients 1.0 0.000143348623853 1 0 1
concomitantly,any,reduction 1.0 0.000143348623853 1 0 1
concomitantly,and,channel 1.0 0.000143348623853 1 0 1
concomitantly,administered,intravenously 1.0 0.000143348623853 1 0 1
concomitant,useof,a 1.0 0.000143348623853 1 0 1
concomitant,use,may 1.0 0.000143348623853 1 0 1
concomitant,treatment,of 1.0 0.000143348623853 1 0 1
concomitant,therapy,of 1.0 0.000143348623853 1 0 1
concomitant,single,dose 1.0 0.000143348623853 1 0 1
concomitant,serotonergic,agents 1.0 0.000143348623853 1 0 1
concomitant,protease,inhibitor 1.0 0.000143348623853 1 0 1
concomitant,oral,medication 1.0 0.000143348623853 1 0 1
concomitant,oral,administration 1.0 0.000143348623853 1 0 1
concomitant,or,may 1.0 0.000143348623853 1 0 1
concomitant,n,hypotension 1.0 0.000143348623853 1 0 1
concomitant,may,decrease 1.0 0.000143348623853 1 0 1
concomitant,intravenous,misuse 1.0 0.000143348623853 1 0 1
concomitant,high-dose,and 1.0 0.000143348623853 1 0 1
concomitant,antihypertensive,medications 1.0 0.000143348623853 1 0 1
concomitant,and,should 1.0 0.000143348623853 1 0 1
concomitant,and,ace 1.0 0.000143348623853 1 0 1
concomitant,administration,should 1.0 0.000143348623853 1 0 1
concomitant,administration,may 1.0 0.000143348623853 1 0 1
concomitan,administration,of 1.0 0.000143348623853 1 0 1
conclusions,single-dose,coadministration 1.0 0.000143348623853 1 0 1
conclusions,macrolide,inhibit 1.0 0.000143348623853 1 0 1
conclusion,that,it 1.0 0.000143348623853 1 0 1
concluded,that,modulates 1.0 0.000143348623853 1 0 1
concluded,that,is 1.0 0.000143348623853 1 0 1
concluded,that,although 1.0 0.000143348623853 1 0 1
conclude,that,the 1.0 0.000143348623853 1 0 1
conclude,that,adl 1.0 0.000143348623853 1 0 1
concerning,have,been 1.0 0.000143348623853 1 0 1
concern,about,the 1.0 0.000143348623853 1 0 1
concentrations,with,coadministration 1.0 0.000143348623853 1 0 1
concentrations,which,could 1.0 0.000143348623853 1 0 1
concentrations,when,was 1.0 0.000143348623853 1 0 1
concentrations,were,to 1.0 0.000143348623853 1 0 1
concentrations,were,observed 1.0 0.000143348623853 1 0 1
concentrations,were,equivocally 1.0 0.000143348623853 1 0 1
concentrations,were,above 1.0 0.000143348623853 1 0 1
concentrations,similar,to 1.0 0.000143348623853 1 0 1
concentrations,reach,to10 1.0 0.000143348623853 1 0 1
concentrations,peak,plasma 1.0 0.000143348623853 1 0 1
concentrations,or,above 1.0 0.000143348623853 1 0 1
concentrations,of,that 1.0 0.000143348623853 1 0 1
concentrations,of,sulfoxide 1.0 0.000143348623853 1 0 1
concentrations,of,serum 1.0 0.000143348623853 1 0 1
concentrations,of,probably 1.0 0.000143348623853 1 0 1
concentrations,of,iressa 1.0 0.000143348623853 1 0 1
concentrations,of,interfere 1.0 0.000143348623853 1 0 1
concentrations,of,increased 1.0 0.000143348623853 1 0 1
concentrations,of,decreased 1.0 0.000143348623853 1 0 1
concentrations,of,concomitant 1.0 0.000143348623853 1 0 1
concentrations,of,but 1.0 0.000143348623853 1 0 1
concentrations,of,both 1.0 0.000143348623853 1 0 1
concentrations,of,azole 1.0 0.000143348623853 1 0 1
concentrations,of,among 1.0 0.000143348623853 1 0 1
concentrations,of,active 1.0 0.000143348623853 1 0 1
concentrations,may,need 1.0 0.000143348623853 1 0 1
concentrations,increased,the 1.0 0.000143348623853 1 0 1
concentrations,increased,by 1.0 0.000143348623853 1 0 1
concentrations,increase,when 1.0 0.000143348623853 1 0 1
concentrations,include,vaiproic 1.0 0.000143348623853 1 0 1
concentrations,include,acute 1.0 0.000143348623853 1 0 1
concentrations,in,otherwise 1.0 0.000143348623853 1 0 1
concentrations,in,bile 1.0 0.000143348623853 1 0 1
concentrations,from,mg 1.0 0.000143348623853 1 0 1
concentrations,during,concomitant 1.0 0.000143348623853 1 0 1
concentrations,drugs,that 1.0 0.000143348623853 1 0 1
concentrations,dosage,adjustments 1.0 0.000143348623853 1 0 1
concentrations,decreases,the 1.0 0.000143348623853 1 0 1
concentrations,considerably,lower 1.0 0.000143348623853 1 0 1
concentrations,caution,is 1.0 0.000143348623853 1 0 1
concentrations,by,as 1.0 0.000143348623853 1 0 1
concentrations,below,the 1.0 0.000143348623853 1 0 1
concentrations,be,monitored 1.0 0.000143348623853 1 0 1
concentrations,auc,by 1.0 0.000143348623853 1 0 1
concentrations,auc,approximately 1.0 0.000143348623853 1 0 1
concentrations,are,increased 1.0 0.000143348623853 1 0 1
concentrations,and,urinary 1.0 0.000143348623853 1 0 1
concentrations,and,toxicity 1.0 0.000143348623853 1 0 1
concentrations,and,this 1.0 0.000143348623853 1 0 1
concentrations,and,therapeutic 1.0 0.000143348623853 1 0 1
concentrations,and,significant 1.0 0.000143348623853 1 0 1
concentrations,and,peak 1.0 0.000143348623853 1 0 1
concentrations,and,an 1.0 0.000143348623853 1 0 1
concentrations,after,initiation 1.0 0.000143348623853 1 0 1
concentrations,above,ng 1.0 0.000143348623853 1 0 1
concentration-time,curve,and 1.0 0.000143348623853 1 0 1
concentration,time-curve,increased 1.0 0.000143348623853 1 0 1
concentration,of,when 1.0 0.000143348623853 1 0 1
concentration,of,preparations 1.0 0.000143348623853 1 0 1
concentration,of,mg 1.0 0.000143348623853 1 0 1
concentration,of,may 1.0 0.000143348623853 1 0 1
concentration,of,fluorouracil 1.0 0.000143348623853 1 0 1
concentration,of,cmi 1.0 0.000143348623853 1 0 1
concentration,monitoring,is 1.0 0.000143348623853 1 0 1
concentration,may,prolong 1.0 0.000143348623853 1 0 1
concentration,is,reduced 1.0 0.000143348623853 1 0 1
concentration,increased,from 1.0 0.000143348623853 1 0 1
concentration,especially,in 1.0 0.000143348623853 1 0 1
concentration,during,concomitant 1.0 0.000143348623853 1 0 1
concentration,due,to 1.0 0.000143348623853 1 0 1
concentration,curve,of 1.0 0.000143348623853 1 0 1
concentration,cmax,by 1.0 0.000143348623853 1 0 1
concentration,c12hr,by 1.0 0.000143348623853 1 0 1
concentration,and,urinary 1.0 0.000143348623853 1 0 1
concentration,and,prolong 1.0 0.000143348623853 1 0 1
concentration,and,other 1.0 0.000143348623853 1 0 1
concentration,accompanied,by 1.0 0.000143348623853 1 0 1
concentrate,should,not 1.0 0.000143348623853 1 0 1
concentrate,and,for 1.0 0.000143348623853 1 0 1
compromised,in,these 1.0 0.000143348623853 1 0 1
compromise,the,beneficial 1.0 0.000143348623853 1 0 1
compromise,have,been 1.0 0.000143348623853 1 0 1
compounds,that,induce 1.0 0.000143348623853 1 0 1
compounds,that,could 1.0 0.000143348623853 1 0 1
compounds,taken,concomitantly 1.0 0.000143348623853 1 0 1
compounds,such,as 1.0 0.000143348623853 1 0 1
compounds,meclofenamic,acid 1.0 0.000143348623853 1 0 1
compounds,like,may 1.0 0.000143348623853 1 0 1
compounds,including,sodium 1.0 0.000143348623853 1 0 1
compounds,in,these 1.0 0.000143348623853 1 0 1
compounds,eg,and 1.0 0.000143348623853 1 0 1
compounds,are,inhibitors 1.0 0.000143348623853 1 0 1
compounds,and,beta-adrenergic 1.0 0.000143348623853 1 0 1
component,of,the 1.0 0.000143348623853 1 0 1
component,of,insect 1.0 0.000143348623853 1 0 1
complications,blurred,vision 1.0 0.000143348623853 1 0 1
complexes,with,and 1.0 0.000143348623853 1 0 1
complex,effect,on 1.0 0.000143348623853 1 0 1
complex,between,or 1.0 0.000143348623853 1 0 1
completion,of,dosing 1.0 0.000143348623853 1 0 1
completely,inhibited,by 1.0 0.000143348623853 1 0 1
completely,depressed,the 1.0 0.000143348623853 1 0 1
completely,blocked,the 1.0 0.000143348623853 1 0 1
completely,block,contortrostatin-induced 1.0 0.000143348623853 1 0 1
completely,antagonized,the 1.0 0.000143348623853 1 0 1
complete,and,immediately 1.0 0.000143348623853 1 0 1
competitively,inhibit,accumulation 1.0 0.000143348623853 1 0 1
competitively,displaces,from 1.0 0.000143348623853 1 0 1
competitive,interaction,at 1.0 0.000143348623853 1 0 1
competitive,inhibitor,of 1.0 0.000143348623853 1 0 1
competing,for,the 1.0 0.000143348623853 1 0 1
competes,for,tubular 1.0 0.000143348623853 1 0 1
competes,for,active 1.0 0.000143348623853 1 0 1
compete,for,excretion 1.0 0.000143348623853 1 0 1
comparison,to,groups 1.0 0.000143348623853 1 0 1
comparison,of,tolerance 1.0 0.000143348623853 1 0 1
compared,with,patients 1.0 0.000143348623853 1 0 1
compared,with,administered 1.0 0.000143348623853 1 0 1
compared,with,a 1.0 0.000143348623853 1 0 1
compared,to,vehicle- 1.0 0.000143348623853 1 0 1
compared,to,subjects 1.0 0.000143348623853 1 0 1
compared,to,results 1.0 0.000143348623853 1 0 1
compared,to,reported 1.0 0.000143348623853 1 0 1
compared,to,has 1.0 0.000143348623853 1 0 1
compared,to,ace 1.0 0.000143348623853 1 0 1
comparable,to,or 1.0 0.000143348623853 1 0 1
commonly,results,in 1.0 0.000143348623853 1 0 1
commonly,reported,both 1.0 0.000143348623853 1 0 1
commonly,occurring,interactions 1.0 0.000143348623853 1 0 1
commonly,in,patients 1.0 0.000143348623853 1 0 1
common,with,other 1.0 0.000143348623853 1 0 1
common,component,of 1.0 0.000143348623853 1 0 1
committed,step,of 1.0 0.000143348623853 1 0 1
comedication,particularly,diabetics 1.0 0.000143348623853 1 0 1
combining,with,other 1.0 0.000143348623853 1 0 1
combined,with,these 1.0 0.000143348623853 1 0 1
combined,with,the 1.0 0.000143348623853 1 0 1
combined,with,krm-1648 1.0 0.000143348623853 1 0 1
combined,with,against 1.0 0.000143348623853 1 0 1
combined,use,clinicians 1.0 0.000143348623853 1 0 1
combined,treatment,with 1.0 0.000143348623853 1 0 1
combined,treatment,should 1.0 0.000143348623853 1 0 1
combined,therapy,if 1.0 0.000143348623853 1 0 1
combine,to,cause 1.0 0.000143348623853 1 0 1
combinations,of,these 1.0 0.000143348623853 1 0 1
combination,with,than 1.0 0.000143348623853 1 0 1
combination,with,serotoninergic 1.0 0.000143348623853 1 0 1
combination,with,potentially 1.0 0.000143348623853 1 0 1
combination,with,patients 1.0 0.000143348623853 1 0 1
combination,with,monoamine 1.0 0.000143348623853 1 0 1
combination,with,maois 1.0 0.000143348623853 1 0 1
combination,with,indicate 1.0 0.000143348623853 1 0 1
combination,with,experienced 1.0 0.000143348623853 1 0 1
combination,with,enhances 1.0 0.000143348623853 1 0 1
combination,with,close 1.0 0.000143348623853 1 0 1
combination,with,beta-adrenergic 1.0 0.000143348623853 1 0 1
combination,to,control 1.0 0.000143348623853 1 0 1
combination,therapy,with 1.0 0.000143348623853 1 0 1
combination,study,of 1.0 0.000143348623853 1 0 1
combination,regimens,containing 1.0 0.000143348623853 1 0 1
combination,of,systemic 1.0 0.000143348623853 1 0 1
combination,of,intravenous 1.0 0.000143348623853 1 0 1
combination,of,before 1.0 0.000143348623853 1 0 1
combination,of,amprenavir 1.0 0.000143348623853 1 0 1
combination,of,amphotericin 1.0 0.000143348623853 1 0 1
combination,may,increase 1.0 0.000143348623853 1 0 1
combination,hormonal,increasing 1.0 0.000143348623853 1 0 1
combination,hormonal,causing 1.0 0.000143348623853 1 0 1
combination,hormonal,are 1.0 0.000143348623853 1 0 1
combination,has,been 1.0 0.000143348623853 1 0 1
coma,have,been 1.0 0.000143348623853 1 0 1
coma,and,death 1.0 0.000143348623853 1 0 1
color,is,due 1.0 0.000143348623853 1 0 1
colitis,a,methotrexate 1.0 0.000143348623853 1 0 1
colestipol-concomitant,intake,of 1.0 0.000143348623853 1 0 1
colestipol,plasma,concentrations 1.0 0.000143348623853 1 0 1
colestid,tablets,are 1.0 0.000143348623853 1 0 1
cold,remedies,and 1.0 0.000143348623853 1 0 1
cold,preparations,antidiarrheal 1.0 0.000143348623853 1 0 1
cold,and,sinus 1.0 0.000143348623853 1 0 1
colchicine,para-aminosalicylic,acid 1.0 0.000143348623853 1 0 1
colchicine,may,increase 1.0 0.000143348623853 1 0 1
colchicine,is,inhibited 1.0 0.000143348623853 1 0 1
coingestion,of,with 1.0 0.000143348623853 1 0 1
cohort,design,that 1.0 0.000143348623853 1 0 1
cognitive,dysfunction,hyperpyrexia 1.0 0.000143348623853 1 0 1
cognitive,and,motor 1.0 0.000143348623853 1 0 1
coenzyme,a,hmg-coa 1.0 0.000143348623853 1 0 1
codeine,in,combination 1.0 0.000143348623853 1 0 1
cocaine,sometimes,proves 1.0 0.000143348623853 1 0 1
coated,aspirin,should 1.0 0.000143348623853 1 0 1
coat-core,formulation,of 1.0 0.000143348623853 1 0 1
coagulation,time,within 1.0 0.000143348623853 1 0 1
coagulation,parameters,pt 1.0 0.000143348623853 1 0 1
coagulation,parameters,and 1.0 0.000143348623853 1 0 1
coagulation,have,been 1.0 0.000143348623853 1 0 1
coadminstered,with,viracept 1.0 0.000143348623853 1 0 1
coadministration,with,to 1.0 0.000143348623853 1 0 1
coadministration,with,that 1.0 0.000143348623853 1 0 1
coadministration,with,tambocor 1.0 0.000143348623853 1 0 1
coadministration,with,mg 1.0 0.000143348623853 1 0 1
coadministration,with,increased 1.0 0.000143348623853 1 0 1
coadministration,with,compounds 1.0 0.000143348623853 1 0 1
coadministration,with,coadministration 1.0 0.000143348623853 1 0 1
coadministration,with,available 1.0 0.000143348623853 1 0 1
coadministration,whereas,the 1.0 0.000143348623853 1 0 1
coadministration,were,within 1.0 0.000143348623853 1 0 1
coadministration,up,to 1.0 0.000143348623853 1 0 1
coadministration,of,which 1.0 0.000143348623853 1 0 1
coadministration,of,using 1.0 0.000143348623853 1 0 1
coadministration,of,that 1.0 0.000143348623853 1 0 1
coadministration,of,tcas 1.0 0.000143348623853 1 0 1
coadministration,of,sular 1.0 0.000143348623853 1 0 1
coadministration,of,significantly 1.0 0.000143348623853 1 0 1
coadministration,of,resulted 1.0 0.000143348623853 1 0 1
coadministration,of,relative 1.0 0.000143348623853 1 0 1
coadministration,of,potent 1.0 0.000143348623853 1 0 1
coadministration,of,once 1.0 0.000143348623853 1 0 1
coadministration,of,may 1.0 0.000143348623853 1 0 1
coadministration,of,it 1.0 0.000143348623853 1 0 1
coadministration,of,decreases 1.0 0.000143348623853 1 0 1
coadministration,of,decreased 1.0 0.000143348623853 1 0 1
coadministration,of,atrovent 1.0 0.000143348623853 1 0 1
coadministration,of,an 1.0 0.000143348623853 1 0 1
coadministration,n,of 1.0 0.000143348623853 1 0 1
coadministration,can,result 1.0 0.000143348623853 1 0 1
coadministering,these,agents 1.0 0.000143348623853 1 0 1
coadministered,with,were 1.0 0.000143348623853 1 0 1
coadministered,with,viracept 1.0 0.000143348623853 1 0 1
coadministered,with,tikosyn 1.0 0.000143348623853 1 0 1
coadministered,with,the 1.0 0.000143348623853 1 0 1
coadministered,with,resulting 1.0 0.000143348623853 1 0 1
coadministered,with,potent 1.0 0.000143348623853 1 0 1
coadministered,with,nonselective 1.0 0.000143348623853 1 0 1
coadministered,with,monurol 1.0 0.000143348623853 1 0 1
coadministered,with,monoamine 1.0 0.000143348623853 1 0 1
coadministered,with,inhibitors 1.0 0.000143348623853 1 0 1
coadministered,with,each 1.0 0.000143348623853 1 0 1
coadministered,with,cyp2d6 1.0 0.000143348623853 1 0 1
coadministered,the,beta 1.0 0.000143348623853 1 0 1
coadministered,than,when 1.0 0.000143348623853 1 0 1
coadministered,steady-state,plasma 1.0 0.000143348623853 1 0 1
coadministered,plasma,concentrations 1.0 0.000143348623853 1 0 1
coadministered,orally,as 1.0 0.000143348623853 1 0 1
coadministered,oral,and 1.0 0.000143348623853 1 0 1
coadministered,on,day 1.0 0.000143348623853 1 0 1
coadministered,intravenously,as 1.0 0.000143348623853 1 0 1
co-treatment,with,the 1.0 0.000143348623853 1 0 1
co-administration,with,or 1.0 0.000143348623853 1 0 1
co-administration,with,high 1.0 0.000143348623853 1 0 1
co-administration,of,zyvox 1.0 0.000143348623853 1 0 1
co-administration,of,vioxx 1.0 0.000143348623853 1 0 1
co-administration,of,tikosyn 1.0 0.000143348623853 1 0 1
co-administration,of,t 1.0 0.000143348623853 1 0 1
co-administration,of,resulted 1.0 0.000143348623853 1 0 1
co-administration,of,reduced 1.0 0.000143348623853 1 0 1
co-administration,of,precedex 1.0 0.000143348623853 1 0 1
co-administration,of,other 1.0 0.000143348623853 1 0 1
co-administration,of,myobloc 1.0 0.000143348623853 1 0 1
co-administration,of,hmg-coa 1.0 0.000143348623853 1 0 1
co-administration,of,fluvoxamine 1.0 0.000143348623853 1 0 1
co-administration,of,copegus 1.0 0.000143348623853 1 0 1
co-administration,of,botox 1.0 0.000143348623853 1 0 1
co-administration,leading,to 1.0 0.000143348623853 1 0 1
co-administration,concomitant,use 1.0 0.000143348623853 1 0 1
co-administered,with,the 1.0 0.000143348623853 1 0 1
co-administered,with,racemic 1.0 0.000143348623853 1 0 1
co-administered,with,precedex 1.0 0.000143348623853 1 0 1
co-administered,with,multiple 1.0 0.000143348623853 1 0 1
co-administered,with,maleate 1.0 0.000143348623853 1 0 1
co-administered,with,inducers 1.0 0.000143348623853 1 0 1
co-administered,with,fluvoxamine 1.0 0.000143348623853 1 0 1
co-administered,with,care 1.0 0.000143348623853 1 0 1
co-administered,with,anticoagulation 1.0 0.000143348623853 1 0 1
co-administered,which,may 1.0 0.000143348623853 1 0 1
co-administered,to,steady 1.0 0.000143348623853 1 0 1
co-administered,particularly,since 1.0 0.000143348623853 1 0 1
co-administered,has,been 1.0 0.000143348623853 1 0 1
co-administer,and,is 1.0 0.000143348623853 1 0 1
co,administration,of 1.0 0.000143348623853 1 0 1
co,administered,and 1.0 0.000143348623853 1 0 1
cns-impairing,effects,of 1.0 0.000143348623853 1 0 1
cns-depressive,effects,of 1.0 0.000143348623853 1 0 1
cns-depressive,effect,of 1.0 0.000143348623853 1 0 1
cns-depressant,effects,when 1.0 0.000143348623853 1 0 1
cns-depressant,action,of 1.0 0.000143348623853 1 0 1
cns-active,should,be 1.0 0.000143348623853 1 0 1
cns,effect,caution 1.0 0.000143348623853 1 0 1
cns,depressive,effects 1.0 0.000143348623853 1 0 1
cns,depression,when 1.0 0.000143348623853 1 0 1
cns,depression,tricyclic 1.0 0.000143348623853 1 0 1
cns,depression,may 1.0 0.000143348623853 1 0 1
cns,depressants,using 1.0 0.000143348623853 1 0 1
cns,depressants,should 1.0 0.000143348623853 1 0 1
cns,depressants,or 1.0 0.000143348623853 1 0 1
cns,depressant,effect 1.0 0.000143348623853 1 0 1
cns,agents,concurrent 1.0 0.000143348623853 1 0 1
cmin,decreased,to 1.0 0.000143348623853 1 0 1
cmi,because,of 1.0 0.000143348623853 1 0 1
cmax,when,compared 1.0 0.000143348623853 1 0 1
cmax,when,a 1.0 0.000143348623853 1 0 1
cmax,up,to 1.0 0.000143348623853 1 0 1
cmax,t1,of 1.0 0.000143348623853 1 0 1
cmax,of,were 1.0 0.000143348623853 1 0 1
cmax,of,ranging 1.0 0.000143348623853 1 0 1
cmax,of,by 1.0 0.000143348623853 1 0 1
cmax,of,averaged 1.0 0.000143348623853 1 0 1
cmax,of,and 1.0 0.000143348623853 1 0 1
cmax,of,about 1.0 0.000143348623853 1 0 1
cmax,leading,to 1.0 0.000143348623853 1 0 1
cmax,increased,approximately 1.0 0.000143348623853 1 0 1
cmax,by,in 1.0 0.000143348623853 1 0 1
cmax,by,fold 1.0 0.000143348623853 1 0 1
cmax,by,approximately 1.0 0.000143348623853 1 0 1
cmax,by,and 1.0 0.000143348623853 1 0 1
cmax,auc,and 1.0 0.000143348623853 1 0 1
cmax,and,mean 1.0 0.000143348623853 1 0 1
cmax,and,increase 1.0 0.000143348623853 1 0 1
cmax,and,extent 1.0 0.000143348623853 1 0 1
cmax,a,increase 1.0 0.000143348623853 1 0 1
clozapine,potentially,resulting 1.0 0.000143348623853 1 0 1
clozapine,plasma,levels 1.0 0.000143348623853 1 0 1
clozapine,may,potentiate 1.0 0.000143348623853 1 0 1
clozapine,is,combined 1.0 0.000143348623853 1 0 1
clozapine,caution,is 1.0 0.000143348623853 1 0 1
clozapine,and,or 1.0 0.000143348623853 1 0 1
clozapine,and,is 1.0 0.000143348623853 1 0 1
closely,when,initiating 1.0 0.000143348623853 1 0 1
closely,when,clozapine 1.0 0.000143348623853 1 0 1
closely,related,member 1.0 0.000143348623853 1 0 1
closely,related,have 1.0 0.000143348623853 1 0 1
closely,monitored,when 1.0 0.000143348623853 1 0 1
closely,monitored,during 1.0 0.000143348623853 1 0 1
closely,monitored,because 1.0 0.000143348623853 1 0 1
closely,in,time 1.0 0.000143348623853 1 0 1
closely,if,a 1.0 0.000143348623853 1 0 1
closely,for,development 1.0 0.000143348623853 1 0 1
closely,after,initiation 1.0 0.000143348623853 1 0 1
clorazepate,dipotassium,prolongs 1.0 0.000143348623853 1 0 1
clonidine,may,potentiate 1.0 0.000143348623853 1 0 1
clonidine,hydrochloride,may 1.0 0.000143348623853 1 0 1
clonidine,concomitant,administration 1.0 0.000143348623853 1 0 1
clomipramine,hcl,phenytoin 1.0 0.000143348623853 1 0 1
clofibric,acid,combination 1.0 0.000143348623853 1 0 1
clinicians,to,the 1.0 0.000143348623853 1 0 1
clinicians,should,be 1.0 0.000143348623853 1 0 1
clinician,should,be 1.0 0.000143348623853 1 0 1
clinically,significant,in 1.0 0.000143348623853 1 0 1
clinically,significant,fluctuations 1.0 0.000143348623853 1 0 1
clinically,relevant,interaction 1.0 0.000143348623853 1 0 1
clinically,relevant,elevation 1.0 0.000143348623853 1 0 1
clinically,relevant,effect 1.0 0.000143348623853 1 0 1
clinically,relevant,consequences 1.0 0.000143348623853 1 0 1
clinically,necessary,because 1.0 0.000143348623853 1 0 1
clinically,meaningful,reductions 1.0 0.000143348623853 1 0 1
clinical,trials,in 1.0 0.000143348623853 1 0 1
clinical,trials,flolan 1.0 0.000143348623853 1 0 1
clinical,trial,has 1.0 0.000143348623853 1 0 1
clinical,trial,data 1.0 0.000143348623853 1 0 1
clinical,trial,as 1.0 0.000143348623853 1 0 1
clinical,study,who 1.0 0.000143348623853 1 0 1
clinical,study,the 1.0 0.000143348623853 1 0 1
clinical,study,did 1.0 0.000143348623853 1 0 1
clinical,studies,one 1.0 0.000143348623853 1 0 1
clinical,studies,adjuvant 1.0 0.000143348623853 1 0 1
clinical,status,is 1.0 0.000143348623853 1 0 1
clinical,signs,or 1.0 0.000143348623853 1 0 1
clinical,significance,on 1.0 0.000143348623853 1 0 1
clinical,practice,has 1.0 0.000143348623853 1 0 1
clinical,pharmacology,drug 1.0 0.000143348623853 1 0 1
clinical,pharmacology,coadministration 1.0 0.000143348623853 1 0 1
clinical,pharmacology,clinical 1.0 0.000143348623853 1 0 1
clinical,importance,brevibloc 1.0 0.000143348623853 1 0 1
clinical,implications,of 1.0 0.000143348623853 1 0 1
clinical,experience,indicates 1.0 0.000143348623853 1 0 1
clinical,evidence,has 1.0 0.000143348623853 1 0 1
clinical,effects,prolonged 1.0 0.000143348623853 1 0 1
clinical,and,pharmacokinetic 1.0 0.000143348623853 1 0 1
clindamycin,has,been 1.0 0.000143348623853 1 0 1
clidinium,may,decrease 1.0 0.000143348623853 1 0 1
clearances,of,were 1.0 0.000143348623853 1 0 1
clearance,with,a 1.0 0.000143348623853 1 0 1
clearance,when,administered 1.0 0.000143348623853 1 0 1
clearance,values,for 1.0 0.000143348623853 1 0 1
clearance,that,results 1.0 0.000143348623853 1 0 1
clearance,such,as 1.0 0.000143348623853 1 0 1
clearance,rate,compared 1.0 0.000143348623853 1 0 1
clearance,or,with 1.0 0.000143348623853 1 0 1
clearance,of,zebeta 1.0 0.000143348623853 1 0 1
clearance,of,when 1.0 0.000143348623853 1 0 1
clearance,of,to 1.0 0.000143348623853 1 0 1
clearance,of,these 1.0 0.000143348623853 1 0 1
clearance,of,thereby 1.0 0.000143348623853 1 0 1
clearance,of,some 1.0 0.000143348623853 1 0 1
clearance,of,simulect 1.0 0.000143348623853 1 0 1
clearance,of,should 1.0 0.000143348623853 1 0 1
clearance,of,r-warfarin 1.0 0.000143348623853 1 0 1
clearance,of,may 1.0 0.000143348623853 1 0 1
clearance,of,from 1.0 0.000143348623853 1 0 1
clearance,of,free 1.0 0.000143348623853 1 0 1
clearance,of,fludrocortisone 1.0 0.000143348623853 1 0 1
clearance,of,fell 1.0 0.000143348623853 1 0 1
clearance,of,enhancing 1.0 0.000143348623853 1 0 1
clearance,of,decreased 1.0 0.000143348623853 1 0 1
clearance,of,compared 1.0 0.000143348623853 1 0 1
clearance,of,chronic 1.0 0.000143348623853 1 0 1
clearance,of,caused 1.0 0.000143348623853 1 0 1
clearance,of,busulfex 1.0 0.000143348623853 1 0 1
clearance,of,both 1.0 0.000143348623853 1 0 1
clearance,of,approximately 1.0 0.000143348623853 1 0 1
clearance,measurements,of 1.0 0.000143348623853 1 0 1
clearance,is,changed 1.0 0.000143348623853 1 0 1
clearance,in,psychiatric 1.0 0.000143348623853 1 0 1
clearance,in,a 1.0 0.000143348623853 1 0 1
clearance,from,l 1.0 0.000143348623853 1 0 1
clearance,by,up 1.0 0.000143348623853 1 0 1
clearance,by,increased 1.0 0.000143348623853 1 0 1
clearance,by,fold 1.0 0.000143348623853 1 0 1
clearance,based,upon 1.0 0.000143348623853 1 0 1
clearance,and,volume 1.0 0.000143348623853 1 0 1
clearance,and,rises 1.0 0.000143348623853 1 0 1
clearance,and,renal 1.0 0.000143348623853 1 0 1
clearance,and,or 1.0 0.000143348623853 1 0 1
clearance,and,may 1.0 0.000143348623853 1 0 1
clearance,and,lower 1.0 0.000143348623853 1 0 1
clearance,and,increases 1.0 0.000143348623853 1 0 1
clearance,and,a 1.0 0.000143348623853 1 0 1
clearance,accelerated,markedly 1.0 0.000143348623853 1 0 1
clearance,a,prolongation 1.0 0.000143348623853 1 0 1
classified,as,protease 1.0 0.000143348623853 1 0 1
classes,or,agents 1.0 0.000143348623853 1 0 1
classes,of,antipsychotic 1.0 0.000143348623853 1 0 1
class,see,warnings 1.0 0.000143348623853 1 0 1
class,resulting,in 1.0 0.000143348623853 1 0 1
class,of,which 1.0 0.000143348623853 1 0 1
class,may,cause 1.0 0.000143348623853 1 0 1
class,including,for 1.0 0.000143348623853 1 0 1
class,ia,such 1.0 0.000143348623853 1 0 1
class,antimicrobial,and 1.0 0.000143348623853 1 0 1
clarithromycin,is,a 1.0 0.000143348623853 1 0 1
clarithromycin,exposure,was 1.0 0.000143348623853 1 0 1
citrate,theoretically,l-arginine 1.0 0.000143348623853 1 0 1
citrate,potentiate,the 1.0 0.000143348623853 1 0 1
citrate,may,potentiate 1.0 0.000143348623853 1 0 1
citrate,elevations,seen 1.0 0.000143348623853 1 0 1
citalopram,since,is 1.0 0.000143348623853 1 0 1
citalopram,citalopram,since 1.0 0.000143348623853 1 0 1
cisplatin,hcl,phenytoin 1.0 0.000143348623853 1 0 1
cisapride,should,not 1.0 0.000143348623853 1 0 1
circulation,there,is 1.0 0.000143348623853 1 0 1
circulation,the,discontinuance 1.0 0.000143348623853 1 0 1
cimetidines,known,inhibition 1.0 0.000143348623853 1 0 1
cimetidine,treatment,should 1.0 0.000143348623853 1 0 1
cimetidine,reduces,the 1.0 0.000143348623853 1 0 1
cimetidine,ranitidine,in 1.0 0.000143348623853 1 0 1
cimetidine,is,reported 1.0 0.000143348623853 1 0 1
cimetidine,inhibits,cyp3a4 1.0 0.000143348623853 1 0 1
cimetidine,inhibits,both 1.0 0.000143348623853 1 0 1
cimetidine,increases,hcl 1.0 0.000143348623853 1 0 1
cimetidine,increased,the 1.0 0.000143348623853 1 0 1
cimetidine,in,the 1.0 0.000143348623853 1 0 1
cimetidine,in,subjects 1.0 0.000143348623853 1 0 1
cimetidine,in,a 1.0 0.000143348623853 1 0 1
cimetidine,concomitant,administration 1.0 0.000143348623853 1 0 1
cimetidine,coadministration,leads 1.0 0.000143348623853 1 0 1
cimetidine,co-administration,with 1.0 0.000143348623853 1 0 1
cimetidine,cimetidine,inhibits 1.0 0.000143348623853 1 0 1
cimetidine,cimetidine,increases 1.0 0.000143348623853 1 0 1
cimetidine,cimetidine,can 1.0 0.000143348623853 1 0 1
cimetidine,can,inhibit 1.0 0.000143348623853 1 0 1
cimetidine,at,mg 1.0 0.000143348623853 1 0 1
cimetidine,at,doses 1.0 0.000143348623853 1 0 1
cimetidine,and,may 1.0 0.000143348623853 1 0 1
cimetidine,an,inhibitor 1.0 0.000143348623853 1 0 1
cimetidine,albendazole,sulfoxide 1.0 0.000143348623853 1 0 1
cimetidine,a,study 1.0 0.000143348623853 1 0 1
ci,when,was 1.0 0.000143348623853 1 0 1
chronic,treatment,following 1.0 0.000143348623853 1 0 1
chronic,therapy,the 1.0 0.000143348623853 1 0 1
chronic,or,therapy 1.0 0.000143348623853 1 0 1
chronic,concurrent,administration 1.0 0.000143348623853 1 0 1
chromatin,and,nuclear 1.0 0.000143348623853 1 0 1
cholinesterase,inhibitors,thereby 1.0 0.000143348623853 1 0 1
cholinesterase,inhibitors,such 1.0 0.000143348623853 1 0 1
cholinesterase,inhibitors,dipyridamole 1.0 0.000143348623853 1 0 1
cholinesterase,activity,potentiates 1.0 0.000143348623853 1 0 1
cholinergic,blockade,may 1.0 0.000143348623853 1 0 1
choline,trilisate,disalcid 1.0 0.000143348623853 1 0 1
choline,arthropan,magan 1.0 0.000143348623853 1 0 1
cholestytamine,and,have 1.0 0.000143348623853 1 0 1
cholestyramine-concomitant,intake,of 1.0 0.000143348623853 1 0 1
cholestyramine,may,interfere 1.0 0.000143348623853 1 0 1
cholestyramine,may,increase 1.0 0.000143348623853 1 0 1
cholestyramine,may,delay 1.0 0.000143348623853 1 0 1
cholestyramine,cholestyramine,may 1.0 0.000143348623853 1 0 1
cholestyramine,cholestyramine,binds 1.0 0.000143348623853 1 0 1
cholestyramine,binds,both 1.0 0.000143348623853 1 0 1
cholestyramine,and,cholestytamine 1.0 0.000143348623853 1 0 1
cholestyramine,and,charcoal 1.0 0.000143348623853 1 0 1
cholestyramine,and,absorption 1.0 0.000143348623853 1 0 1
cholestyramine,an,anionic-binding 1.0 0.000143348623853 1 0 1
cholesterol,levels,monitored 1.0 0.000143348623853 1 0 1
cholesterol,and,triglycerides 1.0 0.000143348623853 1 0 1
chlorthalidone,may,add 1.0 0.000143348623853 1 0 1
chlorprothixene,may,increase 1.0 0.000143348623853 1 0 1
chlorpropamides,plasma,half-life 1.0 0.000143348623853 1 0 1
chlorpropamide,chlorpropamides,plasma 1.0 0.000143348623853 1 0 1
chlorotrianisene,may,interact 1.0 0.000143348623853 1 0 1
chloromycetin,local,and 1.0 0.000143348623853 1 0 1
chloride-induced,gastrointestinal,lesions 1.0 0.000143348623853 1 0 1
chloride,in,a 1.0 0.000143348623853 1 0 1
chloride,excretion,compared 1.0 0.000143348623853 1 0 1
chloramphenicol,or,may 1.0 0.000143348623853 1 0 1
chloramphenicol,has,been 1.0 0.000143348623853 1 0 1
chloral,hydrate,may 1.0 0.000143348623853 1 0 1
chloral,hydrate,dietary 1.0 0.000143348623853 1 0 1
chloral,hydrate,diet 1.0 0.000143348623853 1 0 1
chirocaine,should,be 1.0 0.000143348623853 1 0 1
chicks,was,effective 1.0 0.000143348623853 1 0 1
chick,embryos,in 1.0 0.000143348623853 1 0 1
chewable,dispersible,tablet 1.0 0.000143348623853 1 0 1
chewable,dispersible,buffered 1.0 0.000143348623853 1 0 1
chemotherapy,cardiotoxic,or 1.0 0.000143348623853 1 0 1
chemical,resemblance,of 1.0 0.000143348623853 1 0 1
chemical,reaction,between 1.0 0.000143348623853 1 0 1
chelation,complexes,with 1.0 0.000143348623853 1 0 1
check,coagulation,time 1.0 0.000143348623853 1 0 1
charcoal,administration,of 1.0 0.000143348623853 1 0 1
characterized,by,weakness 1.0 0.000143348623853 1 0 1
characterized,a,reliable 1.0 0.000143348623853 1 0 1
channel,blockers,such 1.0 0.000143348623853 1 0 1
channel,blockers,should 1.0 0.000143348623853 1 0 1
channel,blockers,requires 1.0 0.000143348623853 1 0 1
channel,blockers,or 1.0 0.000143348623853 1 0 1
channel,blockers,of 1.0 0.000143348623853 1 0 1
channel,blockers,isolated 1.0 0.000143348623853 1 0 1
channel,blockers,derivatives 1.0 0.000143348623853 1 0 1
channel,blockers,could 1.0 0.000143348623853 1 0 1
channel,blockers,certain 1.0 0.000143348623853 1 0 1
changing,vioxx,therapy 1.0 0.000143348623853 1 0 1
changing,therapy,with 1.0 0.000143348623853 1 0 1
changing,the,dose 1.0 0.000143348623853 1 0 1
changes,to,be 1.0 0.000143348623853 1 0 1
changes,that,include 1.0 0.000143348623853 1 0 1
changes,in,glucose 1.0 0.000143348623853 1 0 1
changes,in,effects 1.0 0.000143348623853 1 0 1
changes,in,blood 1.0 0.000143348623853 1 0 1
changes,and,or 1.0 0.000143348623853 1 0 1
changed,the,serum 1.0 0.000143348623853 1 0 1
changed,by,coadministration 1.0 0.000143348623853 1 0 1
change,to,a 1.0 0.000143348623853 1 0 1
change,the,bioavailabillty 1.0 0.000143348623853 1 0 1
change,the,amount 1.0 0.000143348623853 1 0 1
change,of,less 1.0 0.000143348623853 1 0 1
change,in,their 1.0 0.000143348623853 1 0 1
change,in,plasma 1.0 0.000143348623853 1 0 1
change,in,pharmacological 1.0 0.000143348623853 1 0 1
chance,of,developing 1.0 0.000143348623853 1 0 1
cgs21680,was,only 1.0 0.000143348623853 1 0 1
cgs,an,a2-selective 1.0 0.000143348623853 1 0 1
cervical,laceration,especially 1.0 0.000143348623853 1 0 1
cerubidine,should,not 1.0 0.000143348623853 1 0 1
cerubidine,may,also 1.0 0.000143348623853 1 0 1
cerubidine,in,a 1.0 0.000143348623853 1 0 1
certainly,during,periods 1.0 0.000143348623853 1 0 1
certain,weak,acids 1.0 0.000143348623853 1 0 1
certain,types,of 1.0 0.000143348623853 1 0 1
certain,tricyclic,thereby 1.0 0.000143348623853 1 0 1
certain,thereby,increasing 1.0 0.000143348623853 1 0 1
certain,that,no 1.0 0.000143348623853 1 0 1
certain,tcas,such 1.0 0.000143348623853 1 0 1
certain,such,as 1.0 0.000143348623853 1 0 1
certain,or,or 1.0 0.000143348623853 1 0 1
certain,nonsteroidal,anti-inflammatory 1.0 0.000143348623853 1 0 1
certain,narcotic,such 1.0 0.000143348623853 1 0 1
certain,microsomal,enzyme 1.0 0.000143348623853 1 0 1
certain,may,induce 1.0 0.000143348623853 1 0 1
certain,intravenously,administered 1.0 0.000143348623853 1 0 1
certain,including,those 1.0 0.000143348623853 1 0 1
certain,including,products 1.0 0.000143348623853 1 0 1
certain,hmg-coa,reductase 1.0 0.000143348623853 1 0 1
certain,especially,the 1.0 0.000143348623853 1 0 1
certain,compounds,such 1.0 0.000143348623853 1 0 1
certain,by,up 1.0 0.000143348623853 1 0 1
certain,anticancer,and 1.0 0.000143348623853 1 0 1
certain,antagonists,particularly 1.0 0.000143348623853 1 0 1
certain,and,type 1.0 0.000143348623853 1 0 1
certain,and,thereby 1.0 0.000143348623853 1 0 1
cerebyx,dosage,may 1.0 0.000143348623853 1 0 1
cerebri,benign,intracranial 1.0 0.000143348623853 1 0 1
central,syndrome,can 1.0 0.000143348623853 1 0 1
central,effects,of 1.0 0.000143348623853 1 0 1
cellular,uptake,and 1.0 0.000143348623853 1 0 1
cells,u937,and 1.0 0.000143348623853 1 0 1
cells,this,effect 1.0 0.000143348623853 1 0 1
cells,that,were 1.0 0.000143348623853 1 0 1
cells,revealed,that 1.0 0.000143348623853 1 0 1
cells,or,in 1.0 0.000143348623853 1 0 1
cells,but,dose-dependently 1.0 0.000143348623853 1 0 1
cell,number,induced 1.0 0.000143348623853 1 0 1
cell,lines,u937 1.0 0.000143348623853 1 0 1
celexa,the,two 1.0 0.000143348623853 1 0 1
celexa,in,a 1.0 0.000143348623853 1 0 1
celebrex,with,since 1.0 0.000143348623853 1 0 1
celebrex,should,be 1.0 0.000143348623853 1 0 1
celebrex,mg,bid 1.0 0.000143348623853 1 0 1
celebrex,may,result 1.0 0.000143348623853 1 0 1
celebrex,is,introduced 1.0 0.000143348623853 1 0 1
celebrex,can,be 1.0 0.000143348623853 1 0 1
cefotan,and,an 1.0 0.000143348623853 1 0 1
cefizox,nephrotoxicity,has 1.0 0.000143348623853 1 0 1
cefditoren,with,a 1.0 0.000143348623853 1 0 1
cefditoren,pivoxil,administered 1.0 0.000143348623853 1 0 1
ccnu,by,dose 1.0 0.000143348623853 1 0 1
cautiously,with,other 1.0 0.000143348623853 1 0 1
cautiously,with,careful 1.0 0.000143348623853 1 0 1
cautiously,in,the 1.0 0.000143348623853 1 0 1
cautiously,coadministered,with 1.0 0.000143348623853 1 0 1
cautiously,and,patients 1.0 0.000143348623853 1 0 1
cautious,initiation,of 1.0 0.000143348623853 1 0 1
caution,using,small 1.0 0.000143348623853 1 0 1
caution,is,necessary 1.0 0.000143348623853 1 0 1
caution,in,those 1.0 0.000143348623853 1 0 1
caution,in,combining 1.0 0.000143348623853 1 0 1
caution,if,at 1.0 0.000143348623853 1 0 1
caution,because,of 1.0 0.000143348623853 1 0 1
caution,and,should 1.0 0.000143348623853 1 0 1
caution,and,patients 1.0 0.000143348623853 1 0 1
causing,uterine,rupture 1.0 0.000143348623853 1 0 1
causing,bone,marrow 1.0 0.000143348623853 1 0 1
causing,an,approximately 1.0 0.000143348623853 1 0 1
causing,a,toxic 1.0 0.000143348623853 1 0 1
causing,a,gritty 1.0 0.000143348623853 1 0 1
causes,increase,by 1.0 0.000143348623853 1 0 1
causes,a,slight 1.0 0.000143348623853 1 0 1
causes,a,marked 1.0 0.000143348623853 1 0 1
causes,a,decrease 1.0 0.000143348623853 1 0 1
caused,to,fold 1.0 0.000143348623853 1 0 1
caused,by,overdose 1.0 0.000143348623853 1 0 1
caused,by,mtc-methylene 1.0 0.000143348623853 1 0 1
caused,by,increased 1.0 0.000143348623853 1 0 1
caused,by,high 1.0 0.000143348623853 1 0 1
caused,by,bretylium 1.0 0.000143348623853 1 0 1
caused,by,a 1.0 0.000143348623853 1 0 1
caused,an,eight-fold 1.0 0.000143348623853 1 0 1
caused,a,statistically 1.0 0.000143348623853 1 0 1
caused,a,rapid 1.0 0.000143348623853 1 0 1
caused,a,decrease 1.0 0.000143348623853 1 0 1
cause,ventricular,tachycardia 1.0 0.000143348623853 1 0 1
cause,tumors,and 1.0 0.000143348623853 1 0 1
cause,synergistic,elevation 1.0 0.000143348623853 1 0 1
cause,significant,sustained 1.0 0.000143348623853 1 0 1
cause,severe,orthostatic 1.0 0.000143348623853 1 0 1
cause,severe,hypotension 1.0 0.000143348623853 1 0 1
cause,respiratory,depression 1.0 0.000143348623853 1 0 1
cause,renal,impairment 1.0 0.000143348623853 1 0 1
cause,of,infection 1.0 0.000143348623853 1 0 1
cause,increased,intracranial 1.0 0.000143348623853 1 0 1
cause,hypercalcemia,too 1.0 0.000143348623853 1 0 1
cause,heart,failure 1.0 0.000143348623853 1 0 1
cause,elevated,plasma 1.0 0.000143348623853 1 0 1
cause,decreased,serum 1.0 0.000143348623853 1 0 1
cause,coronary,artery 1.0 0.000143348623853 1 0 1
cause,and,effect 1.0 0.000143348623853 1 0 1
cause,an,increased 1.0 0.000143348623853 1 0 1
cause,adrenal,insufficiency 1.0 0.000143348623853 1 0 1
cause,additive,cns 1.0 0.000143348623853 1 0 1
cause,abnormal,renal 1.0 0.000143348623853 1 0 1
cause,a,sharp 1.0 0.000143348623853 1 0 1
cause,a,severe 1.0 0.000143348623853 1 0 1
cause,a,rise 1.0 0.000143348623853 1 0 1
cause,a,reduction 1.0 0.000143348623853 1 0 1
causal,mechanism,and 1.0 0.000143348623853 1 0 1
cations,or,videx 1.0 0.000143348623853 1 0 1
cations,likely,will 1.0 0.000143348623853 1 0 1
cation-containing,products,such 1.0 0.000143348623853 1 0 1
cation-containing,products,concurrent 1.0 0.000143348623853 1 0 1
categories,result,in 1.0 0.000143348623853 1 0 1
catecholamine-depleting,eg,may 1.0 0.000143348623853 1 0 1
catecholamine-depleting,drugs,such 1.0 0.000143348623853 1 0 1
catecholamine-depleting,agents,patients 1.0 0.000143348623853 1 0 1
catecholamine,depletors,should 1.0 0.000143348623853 1 0 1
casodex,is,started 1.0 0.000143348623853 1 0 1
casodex,can,displace 1.0 0.000143348623853 1 0 1
cases,reported,in 1.0 0.000143348623853 1 0 1
cases,of,seizures 1.0 0.000143348623853 1 0 1
cases,of,pseudotumor 1.0 0.000143348623853 1 0 1
cases,of,mixed 1.0 0.000143348623853 1 0 1
cases,of,low 1.0 0.000143348623853 1 0 1
cases,of,increased 1.0 0.000143348623853 1 0 1
cases,of,conduction 1.0 0.000143348623853 1 0 1
cases,in,which 1.0 0.000143348623853 1 0 1
cases,a,pronounced 1.0 0.000143348623853 1 0 1
case-control,and,cohort 1.0 0.000143348623853 1 0 1
case,that,you 1.0 0.000143348623853 1 0 1
case,study,has 1.0 0.000143348623853 1 0 1
case,report,which 1.0 0.000143348623853 1 0 1
case,report,of 1.0 0.000143348623853 1 0 1
case,of,toxicity 1.0 0.000143348623853 1 0 1
case,of,an 1.0 0.000143348623853 1 0 1
case,of,a 1.0 0.000143348623853 1 0 1
cas,but,can 1.0 0.000143348623853 1 0 1
carinii,pneumonia,treatment 1.0 0.000143348623853 1 0 1
carefully,monitored,in 1.0 0.000143348623853 1 0 1
carefully,monitored,because 1.0 0.000143348623853 1 0 1
carefully,monitored,and 1.0 0.000143348623853 1 0 1
carefully,if,high 1.0 0.000143348623853 1 0 1
carefully,considered,and 1.0 0.000143348623853 1 0 1
carefully,and,the 1.0 0.000143348623853 1 0 1
careful,observations,on 1.0 0.000143348623853 1 0 1
careful,observation,is 1.0 0.000143348623853 1 0 1
careful,adjustment,should 1.0 0.000143348623853 1 0 1
care,when,myocardial 1.0 0.000143348623853 1 0 1
care,professional,know 1.0 0.000143348623853 1 0 1
care,as,they 1.0 0.000143348623853 1 0 1
cardiovascular,system,can 1.0 0.000143348623853 1 0 1
cardiovascular,effects,may 1.0 0.000143348623853 1 0 1
cardiovascular,disease,or 1.0 0.000143348623853 1 0 1
cardiovascular,adverse,effects 1.0 0.000143348623853 1 0 1
cardiovascular,action,of 1.0 0.000143348623853 1 0 1
cardiotoxic,or,hepatotoxic 1.0 0.000143348623853 1 0 1
cardioactive,compounds,that 1.0 0.000143348623853 1 0 1
cardiac,transplant,recipients 1.0 0.000143348623853 1 0 1
cardiac,stimulants,and 1.0 0.000143348623853 1 0 1
cardiac,glycosides,could 1.0 0.000143348623853 1 0 1
cardiac,enlargement,and 1.0 0.000143348623853 1 0 1
cardiac,effects,of 1.0 0.000143348623853 1 0 1
cardiac,dysrhythmias,some 1.0 0.000143348623853 1 0 1
cardiac,dysrhythmias,of 1.0 0.000143348623853 1 0 1
cardiac,dysrhythmias,and 1.0 0.000143348623853 1 0 1
cardiac,contractility,when 1.0 0.000143348623853 1 0 1
cardiac,contractility,conductivity 1.0 0.000143348623853 1 0 1
cardiac,conduction,eg 1.0 0.000143348623853 1 0 1
cardiac,autonomic,irritability 1.0 0.000143348623853 1 0 1
cardiac,arrythmias,ventricular 1.0 0.000143348623853 1 0 1
cardiac,arrhythmias,have 1.0 0.000143348623853 1 0 1
cardiac,abnormalities,arrhythmia 1.0 0.000143348623853 1 0 1
carbonate,the,stimulatory 1.0 0.000143348623853 1 0 1
carbonate,the,anorectic 1.0 0.000143348623853 1 0 1
carbonate,or,an 1.0 0.000143348623853 1 0 1
carbohydrate-splitting,enzymes,may 1.0 0.000143348623853 1 0 1
carbimazole,and,an 1.0 0.000143348623853 1 0 1
carbenicillin,indanyl,sodium 1.0 0.000143348623853 1 0 1
carbamazepine,population,pharmacokinetic 1.0 0.000143348623853 1 0 1
carbamazepine,levels,should 1.0 0.000143348623853 1 0 1
carbamazepine,isoniazid,is 1.0 0.000143348623853 1 0 1
carbamazepine,in,healthy 1.0 0.000143348623853 1 0 1
carbamazepine,felbatol,causes 1.0 0.000143348623853 1 0 1
carbamazepine,equetrotm,increases 1.0 0.000143348623853 1 0 1
carbamazepine,elevated,levels 1.0 0.000143348623853 1 0 1
carbamazepine,concomitant,administration 1.0 0.000143348623853 1 0 1
carbamazepine,coadministration,of 1.0 0.000143348623853 1 0 1
carbamazepine,causes,an 1.0 0.000143348623853 1 0 1
carbamazepine,carbamazepine,causes 1.0 0.000143348623853 1 0 1
carbachol-stimulated,intracellular,ca 1.0 0.000143348623853 1 0 1
captopril,s,effect 1.0 0.000143348623853 1 0 1
capsules,with,ml 1.0 0.000143348623853 1 0 1
capsules,there,have 1.0 0.000143348623853 1 0 1
capsules,since,there 1.0 0.000143348623853 1 0 1
capsules,or,ml 1.0 0.000143348623853 1 0 1
capsules,mg,with 1.0 0.000143348623853 1 0 1
capsules,indocin,mg 1.0 0.000143348623853 1 0 1
capsules,every,hours 1.0 0.000143348623853 1 0 1
capsules,are,administered 1.0 0.000143348623853 1 0 1
capsules,and,tablets 1.0 0.000143348623853 1 0 1
capsules,and,resulted 1.0 0.000143348623853 1 0 1
capsule,within,minutes 1.0 0.000143348623853 1 0 1
capsule,with,an 1.0 0.000143348623853 1 0 1
capsule,was,administered 1.0 0.000143348623853 1 0 1
capsule,n,mean 1.0 0.000143348623853 1 0 1
capable,of,potentiating 1.0 0.000143348623853 1 0 1
cannot,be,made 1.0 0.000143348623853 1 0 1
cancidas,reduced,the 1.0 0.000143348623853 1 0 1
cancidas,mg,daily 1.0 0.000143348623853 1 0 1
cancidas,may,result 1.0 0.000143348623853 1 0 1
cancidas,is,co-administered 1.0 0.000143348623853 1 0 1
cancer,were,reported 1.0 0.000143348623853 1 0 1
cancer,patients,over 1.0 0.000143348623853 1 0 1
cancer,indicated,that 1.0 0.000143348623853 1 0 1
cancer,in,postmenopausal 1.0 0.000143348623853 1 0 1
cancer,cells,that 1.0 0.000143348623853 1 0 1
can,suppress,the 1.0 0.000143348623853 1 0 1
can,significantly,inhibit 1.0 0.000143348623853 1 0 1
can,prolong,the 1.0 0.000143348623853 1 0 1
can,produce,nephrotoxicity 1.0 0.000143348623853 1 0 1
can,produce,clinically 1.0 0.000143348623853 1 0 1
can,potentiate,the 1.0 0.000143348623853 1 0 1
can,not,be 1.0 0.000143348623853 1 0 1
can,inhibit,renal 1.0 0.000143348623853 1 0 1
can,inhibit,elimination 1.0 0.000143348623853 1 0 1
can,inhibit,adrenal 1.0 0.000143348623853 1 0 1
can,in,addition 1.0 0.000143348623853 1 0 1
can,form,chelation 1.0 0.000143348623853 1 0 1
can,follow,the 1.0 0.000143348623853 1 0 1
can,displace,such 1.0 0.000143348623853 1 0 1
can,directly,interfere 1.0 0.000143348623853 1 0 1
can,diminish,or 1.0 0.000143348623853 1 0 1
can,deplete,and 1.0 0.000143348623853 1 0 1
can,completely,block 1.0 0.000143348623853 1 0 1
can,combine,to 1.0 0.000143348623853 1 0 1
can,cause,increased 1.0 0.000143348623853 1 0 1
can,be,reduced 1.0 0.000143348623853 1 0 1
can,be,potentiated 1.0 0.000143348623853 1 0 1
can,be,formed 1.0 0.000143348623853 1 0 1
can,be,anticipated 1.0 0.000143348623853 1 0 1
can,be,affected 1.0 0.000143348623853 1 0 1
can,be,acutely 1.0 0.000143348623853 1 0 1
can,avoid,iatrogenic 1.0 0.000143348623853 1 0 1
can,also,be 1.0 0.000143348623853 1 0 1
camptosar,would,worsen 1.0 0.000143348623853 1 0 1
camptosar,the,physician 1.0 0.000143348623853 1 0 1
camptosar,than,when 1.0 0.000143348623853 1 0 1
camptosar,such,as 1.0 0.000143348623853 1 0 1
camptosar,and,it 1.0 0.000143348623853 1 0 1
camptosar,and,certainly 1.0 0.000143348623853 1 0 1
camp-stimulated,acid,secretion 1.0 0.000143348623853 1 0 1
camp,whereas,it 1.0 0.000143348623853 1 0 1
calcium-rich,foods,or 1.0 0.000143348623853 1 0 1
calcium,antagonists,after 1.0 0.000143348623853 1 0 1
calan,sr,by 1.0 0.000143348623853 1 0 1
caffeine-related,adverse,effects 1.0 0.000143348623853 1 0 1
caffeine,theobromine,grepafloxacin 1.0 0.000143348623853 1 0 1
caffeine,enoxacin,is 1.0 0.000143348623853 1 0 1
caffeine,administered,concurrently 1.0 0.000143348623853 1 0 1
ca,i,increase 1.0 0.000143348623853 1 0 1
ca,and,current 1.0 0.000143348623853 1 0 1
c9,decreased,active 1.0 0.000143348623853 1 0 1
c9,by,see 1.0 0.000143348623853 1 0 1
c12hr,by,in 1.0 0.000143348623853 1 0 1
c,max,of 1.0 0.000143348623853 1 0 1
c,max,decreased 1.0 0.000143348623853 1 0 1
c,interval,prolongation 1.0 0.000143348623853 1 0 1
c,interval,msec 1.0 0.000143348623853 1 0 1
c,inhibited,the 1.0 0.000143348623853 1 0 1
c,g,day 1.0 0.000143348623853 1 0 1
c,eg,and 1.0 0.000143348623853 1 0 1
c,completely,antagonized 1.0 0.000143348623853 1 0 1
c,and,or 1.0 0.000143348623853 1 0 1
c,a,increase 1.0 0.000143348623853 1 0 1
by,without,preventing 1.0 0.000143348623853 1 0 1
by,without,altering 1.0 0.000143348623853 1 0 1
by,while,those 1.0 0.000143348623853 1 0 1
by,which,inhibits 1.0 0.000143348623853 1 0 1
by,when,coadministered 1.0 0.000143348623853 1 0 1
by,when,co-administered 1.0 0.000143348623853 1 0 1
by,weakness,lethargy 1.0 0.000143348623853 1 0 1
by,was,unaffected 1.0 0.000143348623853 1 0 1
by,was,generally 1.0 0.000143348623853 1 0 1
by,tromethamine,control 1.0 0.000143348623853 1 0 1
by,to,in 1.0 0.000143348623853 1 0 1
by,to,for 1.0 0.000143348623853 1 0 1
by,therapy,with 1.0 0.000143348623853 1 0 1
by,therapy,the 1.0 0.000143348623853 1 0 1
by,the,they 1.0 0.000143348623853 1 0 1
by,the,simultaneous 1.0 0.000143348623853 1 0 1
by,the,level 1.0 0.000143348623853 1 0 1
by,the,initial 1.0 0.000143348623853 1 0 1
by,the,ganglionic-blocking 1.0 0.000143348623853 1 0 1
by,the,auc0-120hr 1.0 0.000143348623853 1 0 1
by,the,ability 1.0 0.000143348623853 1 0 1
by,that,of 1.0 0.000143348623853 1 0 1
by,subsequent,treatment 1.0 0.000143348623853 1 0 1
by,single,high 1.0 0.000143348623853 1 0 1
by,since,and 1.0 0.000143348623853 1 0 1
by,several,medicinal 1.0 0.000143348623853 1 0 1
by,see,clinical 1.0 0.000143348623853 1 0 1
by,range,from 1.0 0.000143348623853 1 0 1
by,possibly,increasing 1.0 0.000143348623853 1 0 1
by,possibly,by 1.0 0.000143348623853 1 0 1
by,patients,with 1.0 0.000143348623853 1 0 1
by,patients,taking 1.0 0.000143348623853 1 0 1
by,patients,suffering 1.0 0.000143348623853 1 0 1
by,overdose,with 1.0 0.000143348623853 1 0 1
by,other,antineoplastic 1.0 0.000143348623853 1 0 1
by,or,more 1.0 0.000143348623853 1 0 1
by,of,the 1.0 0.000143348623853 1 0 1
by,of,bombesin-enhanced 1.0 0.000143348623853 1 0 1
by,nuromax,is 1.0 0.000143348623853 1 0 1
by,nonsteroidal,anti-inflammatory 1.0 0.000143348623853 1 0 1
by,nonbarbiturate,antianxiety 1.0 0.000143348623853 1 0 1
by,non-steroidal,antiinflammatory 1.0 0.000143348623853 1 0 1
by,n6-cyclopentyladenosine,cpa 1.0 0.000143348623853 1 0 1
by,mtc-methylene,diphosphonate 1.0 0.000143348623853 1 0 1
by,mouth,use 1.0 0.000143348623853 1 0 1
by,minutes,any 1.0 0.000143348623853 1 0 1
by,mg,day 1.0 0.000143348623853 1 0 1
by,mao,inhibitors 1.0 0.000143348623853 1 0 1
by,m,m 1.0 0.000143348623853 1 0 1
by,lowering,the 1.0 0.000143348623853 1 0 1
by,its,ability 1.0 0.000143348623853 1 0 1
by,is,not 1.0 0.000143348623853 1 0 1
by,irreversible,brain 1.0 0.000143348623853 1 0 1
by,intraventricular,injection 1.0 0.000143348623853 1 0 1
by,intermediate,doses 1.0 0.000143348623853 1 0 1
by,interfering,with 1.0 0.000143348623853 1 0 1
by,interaction,with 1.0 0.000143348623853 1 0 1
by,inhibiting,their 1.0 0.000143348623853 1 0 1
by,inhibiting,parts 1.0 0.000143348623853 1 0 1
by,increasing,gastric 1.0 0.000143348623853 1 0 1
by,increased,half-life 1.0 0.000143348623853 1 0 1
by,increased,exposure 1.0 0.000143348623853 1 0 1
by,in,the 1.0 0.000143348623853 1 0 1
by,in,males 1.0 0.000143348623853 1 0 1
by,in,healthy 1.0 0.000143348623853 1 0 1
by,hours,of 1.0 0.000143348623853 1 0 1
by,hours,experienced 1.0 0.000143348623853 1 0 1
by,hour,and 1.0 0.000143348623853 1 0 1
by,hepatic,oxidation 1.0 0.000143348623853 1 0 1
by,hepatic,enzyme-inducing 1.0 0.000143348623853 1 0 1
by,hepatic,enzyme 1.0 0.000143348623853 1 0 1
by,h2,blockers 1.0 0.000143348623853 1 0 1
by,gleevec,gleevec 1.0 0.000143348623853 1 0 1
by,following,administration 1.0 0.000143348623853 1 0 1
by,fold,which 1.0 0.000143348623853 1 0 1
by,fold,compared 1.0 0.000143348623853 1 0 1
by,explain,the 1.0 0.000143348623853 1 0 1
by,especially,when 1.0 0.000143348623853 1 0 1
by,elevated,cerebral 1.0 0.000143348623853 1 0 1
by,dose,modifying 1.0 0.000143348623853 1 0 1
by,displacing,the 1.0 0.000143348623853 1 0 1
by,different,routes 1.0 0.000143348623853 1 0 1
by,decreasing,the 1.0 0.000143348623853 1 0 1
by,decreasing,gut 1.0 0.000143348623853 1 0 1
by,cyp3a4,eg 1.0 0.000143348623853 1 0 1
by,cyp2d6,isoenzyme 1.0 0.000143348623853 1 0 1
by,cyp2c9,such 1.0 0.000143348623853 1 0 1
by,containing,or 1.0 0.000143348623853 1 0 1
by,concurrent,treatment 1.0 0.000143348623853 1 0 1
by,concomitant,useof 1.0 0.000143348623853 1 0 1
by,concomitant,medications 1.0 0.000143348623853 1 0 1
by,competitive,interaction 1.0 0.000143348623853 1 0 1
by,compared,with 1.0 0.000143348623853 1 0 1
by,compared,to 1.0 0.000143348623853 1 0 1
by,combination,hormonal 1.0 0.000143348623853 1 0 1
by,cimetidines,known 1.0 0.000143348623853 1 0 1
by,chronic,administration 1.0 0.000143348623853 1 0 1
by,cgs21680,was 1.0 0.000143348623853 1 0 1
by,cgs,nor 1.0 0.000143348623853 1 0 1
by,causing,bone 1.0 0.000143348623853 1 0 1
by,cardiac,enlargement 1.0 0.000143348623853 1 0 1
by,camptosar,the 1.0 0.000143348623853 1 0 1
by,but,not 1.0 0.000143348623853 1 0 1
by,but,had 1.0 0.000143348623853 1 0 1
by,but,decreased 1.0 0.000143348623853 1 0 1
by,brevibloc,but 1.0 0.000143348623853 1 0 1
by,blocking,the 1.0 0.000143348623853 1 0 1
by,bezalip,or 1.0 0.000143348623853 1 0 1
by,beta-adrenergic,blocking 1.0 0.000143348623853 1 0 1
by,bacterial,metabolism 1.0 0.000143348623853 1 0 1
by,at,the 1.0 0.000143348623853 1 0 1
by,at,least 1.0 0.000143348623853 1 0 1
by,as,measured 1.0 0.000143348623853 1 0 1
by,approximately,peak 1.0 0.000143348623853 1 0 1
by,approximately,of 1.0 0.000143348623853 1 0 1
by,approximately,mean 1.0 0.000143348623853 1 0 1
by,approximately,given 1.0 0.000143348623853 1 0 1
by,approximately,fold 1.0 0.000143348623853 1 0 1
by,approximately,by 1.0 0.000143348623853 1 0 1
by,approx,because 1.0 0.000143348623853 1 0 1
by,any,route 1.0 0.000143348623853 1 0 1
by,and,resulted 1.0 0.000143348623853 1 0 1
by,and,reduced 1.0 0.000143348623853 1 0 1
by,and,prothrombin 1.0 0.000143348623853 1 0 1
by,and,other 1.0 0.000143348623853 1 0 1
by,and,mean 1.0 0.000143348623853 1 0 1
by,and,hour 1.0 0.000143348623853 1 0 1
by,and,creatinine 1.0 0.000143348623853 1 0 1
by,and,antagonists 1.0 0.000143348623853 1 0 1
by,active,renal 1.0 0.000143348623853 1 0 1
by,a,dose-dependent 1.0 0.000143348623853 1 0 1
by,a,corresponding 1.0 0.000143348623853 1 0 1
by,a,blockade 1.0 0.000143348623853 1 0 1
butyrophenones,such,as 1.0 0.000143348623853 1 0 1
butyrophenone,classes,of 1.0 0.000143348623853 1 0 1
butalbital,and,may 1.0 0.000143348623853 1 0 1
but,this,is 1.0 0.000143348623853 1 0 1
but,this,has 1.0 0.000143348623853 1 0 1
but,these,would 1.0 0.000143348623853 1 0 1
but,these,actions 1.0 0.000143348623853 1 0 1
but,there,was 1.0 0.000143348623853 1 0 1
but,the,overall 1.0 0.000143348623853 1 0 1
but,the,effect 1.0 0.000143348623853 1 0 1
but,the,duration 1.0 0.000143348623853 1 0 1
but,statistically,significant 1.0 0.000143348623853 1 0 1
but,serious,constellation 1.0 0.000143348623853 1 0 1
but,quickens,the 1.0 0.000143348623853 1 0 1
but,not,when 1.0 0.000143348623853 1 0 1
but,not,statistically 1.0 0.000143348623853 1 0 1
but,not,after 1.0 0.000143348623853 1 0 1
but,no,clinically 1.0 0.000143348623853 1 0 1
but,no,change 1.0 0.000143348623853 1 0 1
but,mc,potentiates 1.0 0.000143348623853 1 0 1
but,may,produce 1.0 0.000143348623853 1 0 1
but,may,potentiate 1.0 0.000143348623853 1 0 1
but,is,probably 1.0 0.000143348623853 1 0 1
but,had,no 1.0 0.000143348623853 1 0 1
but,dose-dependently,inhibits 1.0 0.000143348623853 1 0 1
but,did,slightly 1.0 0.000143348623853 1 0 1
but,decreased,the 1.0 0.000143348623853 1 0 1
but,cases,of 1.0 0.000143348623853 1 0 1
but,can,completely 1.0 0.000143348623853 1 0 1
but,by,minutes 1.0 0.000143348623853 1 0 1
but,brevibloc,steady-state 1.0 0.000143348623853 1 0 1
but,also,to 1.0 0.000143348623853 1 0 1
busulfex,were,studied 1.0 0.000143348623853 1 0 1
busulfex,may,result 1.0 0.000143348623853 1 0 1
busulfex,at,the 1.0 0.000143348623853 1 0 1
buspirone,hydrochloride,not 1.0 0.000143348623853 1 0 1
buspirone,hcl,with 1.0 0.000143348623853 1 0 1
buspirone,hcl,may 1.0 0.000143348623853 1 0 1
buspirone,hcl,and 1.0 0.000143348623853 1 0 1
bun,serum,creatinine 1.0 0.000143348623853 1 0 1
bun,and,fbs 1.0 0.000143348623853 1 0 1
bumetanide-induced,increase,in 1.0 0.000143348623853 1 0 1
bumetanide,may,potentiate 1.0 0.000143348623853 1 0 1
bullous,pemphigoid,and 1.0 0.000143348623853 1 0 1
buforin,ii,may 1.0 0.000143348623853 1 0 1
buffer,should,be 1.0 0.000143348623853 1 0 1
brovana,may,interfere 1.0 0.000143348623853 1 0 1
brovana,as,with 1.0 0.000143348623853 1 0 1
bromocriptine,mesylate,with 1.0 0.000143348623853 1 0 1
bromocriptine,mesylate,may 1.0 0.000143348623853 1 0 1
bromocriptine,mesylate,in 1.0 0.000143348623853 1 0 1
bromide,is,minimally 1.0 0.000143348623853 1 0 1
broad-spectrum,augmentin,xr 1.0 0.000143348623853 1 0 1
brief,psychiatric,rating 1.0 0.000143348623853 1 0 1
brevibloc,steady-state,blood 1.0 0.000143348623853 1 0 1
brevibloc,should,not 1.0 0.000143348623853 1 0 1
brevibloc,should,be 1.0 0.000143348623853 1 0 1
brevibloc,concentrations,were 1.0 0.000143348623853 1 0 1
brevibloc,but,the 1.0 0.000143348623853 1 0 1
brevibloc,and,in 1.0 0.000143348623853 1 0 1
breast,cancer,were 1.0 0.000143348623853 1 0 1
breast,cancer,in 1.0 0.000143348623853 1 0 1
breakdown,products,and 1.0 0.000143348623853 1 0 1
brain,was,longer 1.0 0.000143348623853 1 0 1
brain,edema,it 1.0 0.000143348623853 1 0 1
brain,damage,has 1.0 0.000143348623853 1 0 1
brain,and,liver 1.0 0.000143348623853 1 0 1
bradycardia,qt,c 1.0 0.000143348623853 1 0 1
bradycardia,or,hypotension 1.0 0.000143348623853 1 0 1
bradycardia,and,av 1.0 0.000143348623853 1 0 1
bound,to,protein 1.0 0.000143348623853 1 0 1
bound,by,reducing 1.0 0.000143348623853 1 0 1
botulinum,prior,to 1.0 0.000143348623853 1 0 1
botox,and,or 1.0 0.000143348623853 1 0 1
both,weight,gain 1.0 0.000143348623853 1 0 1
both,the,oral 1.0 0.000143348623853 1 0 1
both,the,natriuresis 1.0 0.000143348623853 1 0 1
both,the,magnitude 1.0 0.000143348623853 1 0 1
both,the,and 1.0 0.000143348623853 1 0 1
both,t4,and 1.0 0.000143348623853 1 0 1
both,species,nanm 1.0 0.000143348623853 1 0 1
both,species,during 1.0 0.000143348623853 1 0 1
both,sensory,and 1.0 0.000143348623853 1 0 1
both,s-warfarin,a 1.0 0.000143348623853 1 0 1
both,lower,blood 1.0 0.000143348623853 1 0 1
both,increases,and 1.0 0.000143348623853 1 0 1
both,increase,and 1.0 0.000143348623853 1 0 1
both,free,and 1.0 0.000143348623853 1 0 1
both,first,and 1.0 0.000143348623853 1 0 1
both,ca,and 1.0 0.000143348623853 1 0 1
both,as,compared 1.0 0.000143348623853 1 0 1
both,are,direct 1.0 0.000143348623853 1 0 1
both,and,should 1.0 0.000143348623853 1 0 1
both,and,retinyl 1.0 0.000143348623853 1 0 1
both,and,prothrombin 1.0 0.000143348623853 1 0 1
both,and,may 1.0 0.000143348623853 1 0 1
both,and,creatinine 1.0 0.000143348623853 1 0 1
both,and,coreg 1.0 0.000143348623853 1 0 1
both,and,can 1.0 0.000143348623853 1 0 1
both,and,a 1.0 0.000143348623853 1 0 1
both,aldehyde,oxidase 1.0 0.000143348623853 1 0 1
both,agents,zyvox 1.0 0.000143348623853 1 0 1
both,agents,with 1.0 0.000143348623853 1 0 1
boric,acid,may 1.0 0.000143348623853 1 0 1
bone,and,joint 1.0 0.000143348623853 1 0 1
bombesin-enhanced,peritoneal,metastasis 1.0 0.000143348623853 1 0 1
body,via,conjugation 1.0 0.000143348623853 1 0 1
blunts,the,reflex 1.0 0.000143348623853 1 0 1
blunts,the,increases 1.0 0.000143348623853 1 0 1
blunted,by,and 1.0 0.000143348623853 1 0 1
blood-sugar,reducing,effect 1.0 0.000143348623853 1 0 1
blood-pressure,and,heart-rate 1.0 0.000143348623853 1 0 1
blood,which,could 1.0 0.000143348623853 1 0 1
blood,thinners,may 1.0 0.000143348623853 1 0 1
blood,thinners,decongestant 1.0 0.000143348623853 1 0 1
blood,sugar,in 1.0 0.000143348623853 1 0 1
blood,sugar,concentrations 1.0 0.000143348623853 1 0 1
blood,pressure,without 1.0 0.000143348623853 1 0 1
blood,pressure,usually 1.0 0.000143348623853 1 0 1
blood,pressure,reductions 1.0 0.000143348623853 1 0 1
blood,pressure,may 1.0 0.000143348623853 1 0 1
blood,pressure,lowering 1.0 0.000143348623853 1 0 1
blood,pressure,effect 1.0 0.000143348623853 1 0 1
blood,pressure,caution 1.0 0.000143348623853 1 0 1
blood,pressure,by 1.0 0.000143348623853 1 0 1
blood,platelets,by 1.0 0.000143348623853 1 0 1
blood,levels,was 1.0 0.000143348623853 1 0 1
blood,levels,may 1.0 0.000143348623853 1 0 1
blood,levels,at 1.0 0.000143348623853 1 0 1
blood,is,drawn 1.0 0.000143348623853 1 0 1
blood,glucose,should 1.0 0.000143348623853 1 0 1
blood,glucose,lowering 1.0 0.000143348623853 1 0 1
blood,glucose,including 1.0 0.000143348623853 1 0 1
blood,elements,ethacrynic 1.0 0.000143348623853 1 0 1
blood,concentrations,should 1.0 0.000143348623853 1 0 1
blood,concentration,cmax 1.0 0.000143348623853 1 0 1
blood,concentration,c12hr 1.0 0.000143348623853 1 0 1
blood,coagulation,have 1.0 0.000143348623853 1 0 1
blood,auc0-12,of 1.0 0.000143348623853 1 0 1
blood,area,under 1.0 0.000143348623853 1 0 1
blood,and,or 1.0 0.000143348623853 1 0 1
blocks,the,metabolism 1.0 0.000143348623853 1 0 1
blocks,the,central 1.0 0.000143348623853 1 0 1
blocks,receptors,thus 1.0 0.000143348623853 1 0 1
blocks,and,receptors 1.0 0.000143348623853 1 0 1
blocking,the,vasodilating 1.0 0.000143348623853 1 0 1
blocking,hepatic,metabolism 1.0 0.000143348623853 1 0 1
blocking,effect,and 1.0 0.000143348623853 1 0 1
blocking,cardiac,contractility 1.0 0.000143348623853 1 0 1
blocking,agents,with 1.0 0.000143348623853 1 0 1
blocking,agents,negative 1.0 0.000143348623853 1 0 1
blocking,agents,has 1.0 0.000143348623853 1 0 1
blocking,agents,experience 1.0 0.000143348623853 1 0 1
blocking,agents,channel 1.0 0.000143348623853 1 0 1
blocking,agents,anesthetics 1.0 0.000143348623853 1 0 1
blocking,agents,along 1.0 0.000143348623853 1 0 1
blocking,agent,orally 1.0 0.000143348623853 1 0 1
blocking,agent,and 1.0 0.000143348623853 1 0 1
blocking,add,some 1.0 0.000143348623853 1 0 1
blockers,requires,close 1.0 0.000143348623853 1 0 1
blockers,proton,pump 1.0 0.000143348623853 1 0 1
blockers,presumably,because 1.0 0.000143348623853 1 0 1
blockers,or,h1-blocking 1.0 0.000143348623853 1 0 1
blockers,or,channel 1.0 0.000143348623853 1 0 1
blockers,of,the 1.0 0.000143348623853 1 0 1
blockers,may,increase 1.0 0.000143348623853 1 0 1
blockers,may,also 1.0 0.000143348623853 1 0 1
blockers,isolated,cases 1.0 0.000143348623853 1 0 1
blockers,derivatives,and 1.0 0.000143348623853 1 0 1
blockers,could,be 1.0 0.000143348623853 1 0 1
blockers,certain,hmg-coa 1.0 0.000143348623853 1 0 1
blockers,and,should 1.0 0.000143348623853 1 0 1
blockers,and,may 1.0 0.000143348623853 1 0 1
blockers,although,the 1.0 0.000143348623853 1 0 1
blockers,although,not 1.0 0.000143348623853 1 0 1
blocker,should,be 1.0 0.000143348623853 1 0 1
blocker,given,in 1.0 0.000143348623853 1 0 1
blocker,and,a 1.0 0.000143348623853 1 0 1
blocked,the,tail-flick 1.0 0.000143348623853 1 0 1
blocked,the,secretory 1.0 0.000143348623853 1 0 1
blockade,was,prolonged 1.0 0.000143348623853 1 0 1
blockade,may,occur 1.0 0.000143348623853 1 0 1
blockade,by,was 1.0 0.000143348623853 1 0 1
blockade,by,of 1.0 0.000143348623853 1 0 1
block,the,therapeutic 1.0 0.000143348623853 1 0 1
block,the,pharmacologic 1.0 0.000143348623853 1 0 1
block,the,antihypertensive 1.0 0.000143348623853 1 0 1
block,morphine-induced,and 1.0 0.000143348623853 1 0 1
block,is,shortened 1.0 0.000143348623853 1 0 1
block,induced,by 1.0 0.000143348623853 1 0 1
block,following,nimbex 1.0 0.000143348623853 1 0 1
block,contortrostatin-induced,phosphorylation 1.0 0.000143348623853 1 0 1
block,caution,is 1.0 0.000143348623853 1 0 1
bleeding,when,administered 1.0 0.000143348623853 1 0 1
bleeding,tendency,produced 1.0 0.000143348623853 1 0 1
bleeding,reduced,dosage 1.0 0.000143348623853 1 0 1
bleeding,particularly,in 1.0 0.000143348623853 1 0 1
bleeding,parameters,in 1.0 0.000143348623853 1 0 1
bleeding,in,etodolac-treated 1.0 0.000143348623853 1 0 1
bleeding,if,administered 1.0 0.000143348623853 1 0 1
bleeding,have,been 1.0 0.000143348623853 1 0 1
bleeding,have,also 1.0 0.000143348623853 1 0 1
bleeding,events,compared 1.0 0.000143348623853 1 0 1
bleeding,associated,with 1.0 0.000143348623853 1 0 1
bleeding,and,should 1.0 0.000143348623853 1 0 1
bleeding,and,or 1.0 0.000143348623853 1 0 1
bismuth,subsalicylate,given 1.0 0.000143348623853 1 0 1
bismuth,bismuth,subsalicylate 1.0 0.000143348623853 1 0 1
birth,control,should 1.0 0.000143348623853 1 0 1
biotransformation,system,responsible 1.0 0.000143348623853 1 0 1
biotransformation,system,mainly 1.0 0.000143348623853 1 0 1
biological,and,behavioral 1.0 0.000143348623853 1 0 1
biologic,half-life,of 1.0 0.000143348623853 1 0 1
bioavailabillty,when,they 1.0 0.000143348623853 1 0 1
bioavailability,was,reduced 1.0 0.000143348623853 1 0 1
bioavailability,was,about 1.0 0.000143348623853 1 0 1
bioavailability,of,n 1.0 0.000143348623853 1 0 1
bioavailability,of,may 1.0 0.000143348623853 1 0 1
bioavailability,of,by 1.0 0.000143348623853 1 0 1
bioavailability,is,mildly 1.0 0.000143348623853 1 0 1
binds,both,t4 1.0 0.000143348623853 1 0 1
binding,to,serum 1.0 0.000143348623853 1 0 1
binding,thiazide,and 1.0 0.000143348623853 1 0 1
binding,sites,or 1.0 0.000143348623853 1 0 1
binding,proteins,and 1.0 0.000143348623853 1 0 1
binding,of,salicylic 1.0 0.000143348623853 1 0 1
binding,of,may 1.0 0.000143348623853 1 0 1
binding,of,but 1.0 0.000143348623853 1 0 1
binding,may,also 1.0 0.000143348623853 1 0 1
binding,is,reduced 1.0 0.000143348623853 1 0 1
binding,decrease,in 1.0 0.000143348623853 1 0 1
binding,and,increased 1.0 0.000143348623853 1 0 1
bind,the,and 1.0 0.000143348623853 1 0 1
bind,other,given 1.0 0.000143348623853 1 0 1
bind,and,decrease 1.0 0.000143348623853 1 0 1
bile,and,cystic 1.0 0.000143348623853 1 0 1
bid,with,resulted 1.0 0.000143348623853 1 0 1
bid,with,coadministration 1.0 0.000143348623853 1 0 1
bid,with,celebrex 1.0 0.000143348623853 1 0 1
bid,was,not 1.0 0.000143348623853 1 0 1
bid,was,increased 1.0 0.000143348623853 1 0 1
bid,the,usual 1.0 0.000143348623853 1 0 1
bid,the,cmax 1.0 0.000143348623853 1 0 1
bid,resulted,in 1.0 0.000143348623853 1 0 1
bid,otc,dose 1.0 0.000143348623853 1 0 1
bid,mg,qd 1.0 0.000143348623853 1 0 1
bid,in,conjunction 1.0 0.000143348623853 1 0 1
bid,decreased,the 1.0 0.000143348623853 1 0 1
bid,as,compared 1.0 0.000143348623853 1 0 1
bicarbonate,used,concurrently 1.0 0.000143348623853 1 0 1
bicarbonate,etc,increase 1.0 0.000143348623853 1 0 1
bezalip,retard,may 1.0 0.000143348623853 1 0 1
bezalip,retard,and 1.0 0.000143348623853 1 0 1
bezalip,and,bezalip 1.0 0.000143348623853 1 0 1
beyond,the,therapeutic 1.0 0.000143348623853 1 0 1
beyond,that,obtained 1.0 0.000143348623853 1 0 1
bextra,in,patients 1.0 0.000143348623853 1 0 1
beverages,is,enhanced 1.0 0.000143348623853 1 0 1
between,xanthine,and 1.0 0.000143348623853 1 0 1
between,wellbutrin,and 1.0 0.000143348623853 1 0 1
between,use,of 1.0 0.000143348623853 1 0 1
between,toradol,and 1.0 0.000143348623853 1 0 1
between,the,hydantoin 1.0 0.000143348623853 1 0 1
between,single,oral 1.0 0.000143348623853 1 0 1
between,or,its 1.0 0.000143348623853 1 0 1
between,mao,inhibitors 1.0 0.000143348623853 1 0 1
between,epa,supplements 1.0 0.000143348623853 1 0 1
between,doses,may 1.0 0.000143348623853 1 0 1
between,clozapine,and 1.0 0.000143348623853 1 0 1
between,b12,and 1.0 0.000143348623853 1 0 1
between,and,with 1.0 0.000143348623853 1 0 1
between,and,it 1.0 0.000143348623853 1 0 1
between,and,intravenously 1.0 0.000143348623853 1 0 1
between,and,inducers 1.0 0.000143348623853 1 0 1
between,and,are 1.0 0.000143348623853 1 0 1
between,and,a 1.0 0.000143348623853 1 0 1
between,a,and 1.0 0.000143348623853 1 0 1
betaseron,on,metabolism 1.0 0.000143348623853 1 0 1
betaseron,administration,to 1.0 0.000143348623853 1 0 1
betagan,used,alone 1.0 0.000143348623853 1 0 1
beta2,agonists,because 1.0 0.000143348623853 1 0 1
beta-lactamtype,or,may 1.0 0.000143348623853 1 0 1
beta-lactam,including,based 1.0 0.000143348623853 1 0 1
beta-blockers,not,only 1.0 0.000143348623853 1 0 1
beta-blockers,concomitant,use 1.0 0.000143348623853 1 0 1
beta-blockers,and,other 1.0 0.000143348623853 1 0 1
beta-adrenergic,blocking,add 1.0 0.000143348623853 1 0 1
beta-adrenergic,blocking,action 1.0 0.000143348623853 1 0 1
beta-adrenergic,blockers,presumably 1.0 0.000143348623853 1 0 1
beta-adrenergic,blockers,or 1.0 0.000143348623853 1 0 1
beta-adrenergic,blocker,given 1.0 0.000143348623853 1 0 1
beta,blockers,should 1.0 0.000143348623853 1 0 1
beta,blockers,and 1.0 0.000143348623853 1 0 1
beta,blockers,although 1.0 0.000143348623853 1 0 1
beta,blocker,should 1.0 0.000143348623853 1 0 1
beta,blocker,and 1.0 0.000143348623853 1 0 1
beta,adrenergic,antagonists 1.0 0.000143348623853 1 0 1
benzthiazide,may,interact 1.0 0.000143348623853 1 0 1
benzodiazepines,metabolized,by 1.0 0.000143348623853 1 0 1
benzodiazepines,combination,hormonal 1.0 0.000143348623853 1 0 1
benzodiazepines,benzodiazepines,metabolized 1.0 0.000143348623853 1 0 1
benzodiazepine,class,of 1.0 0.000143348623853 1 0 1
bentiromide,may,interact 1.0 0.000143348623853 1 0 1
benign,intracranial,hypertension 1.0 0.000143348623853 1 0 1
benefits,of,this 1.0 0.000143348623853 1 0 1
benefits,of,combined 1.0 0.000143348623853 1 0 1
benefits,and,risks 1.0 0.000143348623853 1 0 1
benefit,of,further 1.0 0.000143348623853 1 0 1
benefit,from,containing 1.0 0.000143348623853 1 0 1
beneficial,effects,on 1.0 0.000143348623853 1 0 1
beneficial,effects,of 1.0 0.000143348623853 1 0 1
benazepril,like,other 1.0 0.000143348623853 1 0 1
below,the,measurable 1.0 0.000143348623853 1 0 1
below,drugs,that 1.0 0.000143348623853 1 0 1
belladonna,alkaloids,and 1.0 0.000143348623853 1 0 1
believed,that,the 1.0 0.000143348623853 1 0 1
being,treated,concurrently 1.0 0.000143348623853 1 0 1
being,given,should 1.0 0.000143348623853 1 0 1
being,converted,to 1.0 0.000143348623853 1 0 1
behavioral,responsiveness,of 1.0 0.000143348623853 1 0 1
begun,in,patients 1.0 0.000143348623853 1 0 1
beginning,therapy,should 1.0 0.000143348623853 1 0 1
beginning,or,stopping 1.0 0.000143348623853 1 0 1
beginning,discontinuing,or 1.0 0.000143348623853 1 0 1
beginning,depletion,of 1.0 0.000143348623853 1 0 1
begin,taking,or 1.0 0.000143348623853 1 0 1
before,taking,tell 1.0 0.000143348623853 1 0 1
before,starting,and 1.0 0.000143348623853 1 0 1
before,starting,a 1.0 0.000143348623853 1 0 1
before,resulted,in 1.0 0.000143348623853 1 0 1
before,or,after 1.0 0.000143348623853 1 0 1
before,intramuscular,injection 1.0 0.000143348623853 1 0 1
before,initiating,tcatreatment 1.0 0.000143348623853 1 0 1
before,dosing,with 1.0 0.000143348623853 1 0 1
before,conducting,an 1.0 0.000143348623853 1 0 1
before,blood,is 1.0 0.000143348623853 1 0 1
before,any,oral 1.0 0.000143348623853 1 0 1
before,a,nonlethal 1.0 0.000143348623853 1 0 1
been,systematically,evaluated 1.0 0.000143348623853 1 0 1
been,suggested,that 1.0 0.000143348623853 1 0 1
been,studied,the 1.0 0.000143348623853 1 0 1
been,studied,increased 1.0 0.000143348623853 1 0 1
been,studied,and 1.0 0.000143348623853 1 0 1
been,studied,alternative 1.0 0.000143348623853 1 0 1
been,shown,between 1.0 0.000143348623853 1 0 1
been,seen,as 1.0 0.000143348623853 1 0 1
been,reviewed,in 1.0 0.000143348623853 1 0 1
been,reports,that 1.0 0.000143348623853 1 0 1
been,reported,very 1.0 0.000143348623853 1 0 1
been,reported,upon 1.0 0.000143348623853 1 0 1
been,reported,resulting 1.0 0.000143348623853 1 0 1
been,reported,predominantly 1.0 0.000143348623853 1 0 1
been,reported,from 1.0 0.000143348623853 1 0 1
been,reported,concomitant 1.0 0.000143348623853 1 0 1
been,proposed,that 1.0 0.000143348623853 1 0 1
been,postmarketing,reports 1.0 0.000143348623853 1 0 1
been,performed,coadministration 1.0 0.000143348623853 1 0 1
been,performed,based 1.0 0.000143348623853 1 0 1
been,one,report 1.0 0.000143348623853 1 0 1
been,occasional,literature 1.0 0.000143348623853 1 0 1
been,observed,it 1.0 0.000143348623853 1 0 1
been,noted,to 1.0 0.000143348623853 1 0 1
been,noted,in 1.0 0.000143348623853 1 0 1
been,investigated,using 1.0 0.000143348623853 1 0 1
been,identified,involving 1.0 0.000143348623853 1 0 1
been,fully,characterized 1.0 0.000143348623853 1 0 1
been,filtrated,to 1.0 0.000143348623853 1 0 1
been,established,current 1.0 0.000143348623853 1 0 1
been,done,to 1.0 0.000143348623853 1 0 1
been,demonstrated,to 1.0 0.000143348623853 1 0 1
been,definitively,demonstrated 1.0 0.000143348623853 1 0 1
been,conflicting,results 1.0 0.000143348623853 1 0 1
been,conducted,it 1.0 0.000143348623853 1 0 1
been,conducted,concomitant 1.0 0.000143348623853 1 0 1
been,concern,about 1.0 0.000143348623853 1 0 1
been,cases,reported 1.0 0.000143348623853 1 0 1
been,attributed,at 1.0 0.000143348623853 1 0 1
been,a,number 1.0 0.000143348623853 1 0 1
been,a,few 1.0 0.000143348623853 1 0 1
because,these,products 1.0 0.000143348623853 1 0 1
because,there,have 1.0 0.000143348623853 1 0 1
because,their,vasospastic 1.0 0.000143348623853 1 0 1
because,the,potential 1.0 0.000143348623853 1 0 1
because,the,pharmacologically 1.0 0.000143348623853 1 0 1
because,the,have 1.0 0.000143348623853 1 0 1
because,the,effects 1.0 0.000143348623853 1 0 1
because,the,degree 1.0 0.000143348623853 1 0 1
because,the,clearance 1.0 0.000143348623853 1 0 1
because,the,added 1.0 0.000143348623853 1 0 1
because,severe,hypoglycemia 1.0 0.000143348623853 1 0 1
because,severe,and 1.0 0.000143348623853 1 0 1
because,renal,excretion 1.0 0.000143348623853 1 0 1
because,reduces,the 1.0 0.000143348623853 1 0 1
because,prostaglandins,play 1.0 0.000143348623853 1 0 1
because,prostaglandina,play 1.0 0.000143348623853 1 0 1
because,plasma,concentrations 1.0 0.000143348623853 1 0 1
because,oral,may 1.0 0.000143348623853 1 0 1
because,of,reports 1.0 0.000143348623853 1 0 1
because,of,potential 1.0 0.000143348623853 1 0 1
because,of,foscarnets 1.0 0.000143348623853 1 0 1
because,of,competitive 1.0 0.000143348623853 1 0 1
because,nephrotoxicity,may 1.0 0.000143348623853 1 0 1
because,nalfon,has 1.0 0.000143348623853 1 0 1
because,moderate,cyp3a4 1.0 0.000143348623853 1 0 1
because,may,potentiate 1.0 0.000143348623853 1 0 1
because,may,interfere 1.0 0.000143348623853 1 0 1
because,may,increase 1.0 0.000143348623853 1 0 1
because,may,enhance 1.0 0.000143348623853 1 0 1
because,is,a 1.0 0.000143348623853 1 0 1
because,increases,the 1.0 0.000143348623853 1 0 1
because,have,been 1.0 0.000143348623853 1 0 1
because,competitively,displaces 1.0 0.000143348623853 1 0 1
because,changes,in 1.0 0.000143348623853 1 0 1
because,can,produce 1.0 0.000143348623853 1 0 1
because,both,lower 1.0 0.000143348623853 1 0 1
because,both,are 1.0 0.000143348623853 1 0 1
because,bleeding,has 1.0 0.000143348623853 1 0 1
because,anafranil,is 1.0 0.000143348623853 1 0 1
because,amplifies,the 1.0 0.000143348623853 1 0 1
because,accutane,use 1.0 0.000143348623853 1 0 1
because,a,similar 1.0 0.000143348623853 1 0 1
bear,directly,on 1.0 0.000143348623853 1 0 1
be,withdrawn,several 1.0 0.000143348623853 1 0 1
be,well,controlled 1.0 0.000143348623853 1 0 1
be,watched,very 1.0 0.000143348623853 1 0 1
be,usedas,the 1.0 0.000143348623853 1 0 1
be,used,because 1.0 0.000143348623853 1 0 1
be,undertaken,only 1.0 0.000143348623853 1 0 1
be,titrated,with 1.0 0.000143348623853 1 0 1
be,the,underlying 1.0 0.000143348623853 1 0 1
be,the,only 1.0 0.000143348623853 1 0 1
be,terminated,the 1.0 0.000143348623853 1 0 1
be,taken,closely 1.0 0.000143348623853 1 0 1
be,stopped,during 1.0 0.000143348623853 1 0 1
be,separated,by 1.0 0.000143348623853 1 0 1
be,seen,on 1.0 0.000143348623853 1 0 1
be,seen,after 1.0 0.000143348623853 1 0 1
be,reviewed,for 1.0 0.000143348623853 1 0 1
be,reviewed,and 1.0 0.000143348623853 1 0 1
be,resistant,to 1.0 0.000143348623853 1 0 1
be,required,or 1.0 0.000143348623853 1 0 1
be,reliable,when 1.0 0.000143348623853 1 0 1
be,refractory,to 1.0 0.000143348623853 1 0 1
be,reduced,while 1.0 0.000143348623853 1 0 1
be,reduced,when 1.0 0.000143348623853 1 0 1
be,reduced,upon 1.0 0.000143348623853 1 0 1
be,reduced,thus 1.0 0.000143348623853 1 0 1
be,receiving,both 1.0 0.000143348623853 1 0 1
be,prolonged,in 1.0 0.000143348623853 1 0 1
be,produced,in 1.0 0.000143348623853 1 0 1
be,prescribed,with 1.0 0.000143348623853 1 0 1
be,potentiated,resulting 1.0 0.000143348623853 1 0 1
be,of,major 1.0 0.000143348623853 1 0 1
be,observed,with 1.0 0.000143348623853 1 0 1
be,observed,to 1.0 0.000143348623853 1 0 1
be,needed,following 1.0 0.000143348623853 1 0 1
be,necessary,eg 1.0 0.000143348623853 1 0 1
be,necessary,during 1.0 0.000143348623853 1 0 1
be,monitored,forevidence 1.0 0.000143348623853 1 0 1
be,monitored,especially 1.0 0.000143348623853 1 0 1
be,modified,by 1.0 0.000143348623853 1 0 1
be,minimized,or 1.0 0.000143348623853 1 0 1
be,maximal,to 1.0 0.000143348623853 1 0 1
be,markedly,reduced 1.0 0.000143348623853 1 0 1
be,maintained,between 1.0 0.000143348623853 1 0 1
be,made,with 1.0 0.000143348623853 1 0 1
be,made,of 1.0 0.000143348623853 1 0 1
be,lower,and 1.0 0.000143348623853 1 0 1
be,introduced,at 1.0 0.000143348623853 1 0 1
be,initiated,as 1.0 0.000143348623853 1 0 1
be,ingested,simultaneously 1.0 0.000143348623853 1 0 1
be,ineffective,if 1.0 0.000143348623853 1 0 1
be,increased,with 1.0 0.000143348623853 1 0 1
be,increased,if 1.0 0.000143348623853 1 0 1
be,increased,an 1.0 0.000143348623853 1 0 1
be,halved,for 1.0 0.000143348623853 1 0 1
be,greater,than 1.0 0.000143348623853 1 0 1
be,gradual,in 1.0 0.000143348623853 1 0 1
be,given,simultaneously 1.0 0.000143348623853 1 0 1
be,given,hour 1.0 0.000143348623853 1 0 1
be,given,concurrently 1.0 0.000143348623853 1 0 1
be,formed,with 1.0 0.000143348623853 1 0 1
be,fatal,when 1.0 0.000143348623853 1 0 1
be,expected,when 1.0 0.000143348623853 1 0 1
be,expected,than 1.0 0.000143348623853 1 0 1
be,expected,and 1.0 0.000143348623853 1 0 1
be,exercised,nonetheless 1.0 0.000143348623853 1 0 1
be,exercised,during 1.0 0.000143348623853 1 0 1
be,exceeded,when 1.0 0.000143348623853 1 0 1
be,exceeded,in 1.0 0.000143348623853 1 0 1
be,even,more 1.0 0.000143348623853 1 0 1
be,evaluated,after 1.0 0.000143348623853 1 0 1
be,enhanced,when 1.0 0.000143348623853 1 0 1
be,enhanced,if 1.0 0.000143348623853 1 0 1
be,effective,in 1.0 0.000143348623853 1 0 1
be,done,extremely 1.0 0.000143348623853 1 0 1
be,displaced,from 1.0 0.000143348623853 1 0 1
be,discontinued,slowly 1.0 0.000143348623853 1 0 1
be,discontinued,it 1.0 0.000143348623853 1 0 1
be,discontinued,for 1.0 0.000143348623853 1 0 1
be,directed,to 1.0 0.000143348623853 1 0 1
be,diminished,when 1.0 0.000143348623853 1 0 1
be,determined,prior 1.0 0.000143348623853 1 0 1
be,determined,before 1.0 0.000143348623853 1 0 1
be,delayed,for 1.0 0.000143348623853 1 0 1
be,deferred,until 1.0 0.000143348623853 1 0 1
be,deeper,and 1.0 0.000143348623853 1 0 1
be,decreased,increased 1.0 0.000143348623853 1 0 1
be,decided,to 1.0 0.000143348623853 1 0 1
be,continuously,observed 1.0 0.000143348623853 1 0 1
be,continued,if 1.0 0.000143348623853 1 0 1
be,considered,prior 1.0 0.000143348623853 1 0 1
be,considered,during 1.0 0.000143348623853 1 0 1
be,compromised,in 1.0 0.000143348623853 1 0 1
be,certain,that 1.0 0.000143348623853 1 0 1
be,cautiously,coadministered 1.0 0.000143348623853 1 0 1
be,carefully,titrated 1.0 0.000143348623853 1 0 1
be,carefully,considered 1.0 0.000143348623853 1 0 1
be,capable,of 1.0 0.000143348623853 1 0 1
be,aware,when 1.0 0.000143348623853 1 0 1
be,aware,that 1.0 0.000143348623853 1 0 1
be,avoided,when 1.0 0.000143348623853 1 0 1
be,avoided,see 1.0 0.000143348623853 1 0 1
be,avoided,except 1.0 0.000143348623853 1 0 1
be,avoided,beta-blockers 1.0 0.000143348623853 1 0 1
be,avoided,and 1.0 0.000143348623853 1 0 1
be,augmented,by 1.0 0.000143348623853 1 0 1
be,at,least 1.0 0.000143348623853 1 0 1
be,anticipated,if 1.0 0.000143348623853 1 0 1
be,anticipated,and 1.0 0.000143348623853 1 0 1
be,antagonistic,to 1.0 0.000143348623853 1 0 1
be,an,interaction 1.0 0.000143348623853 1 0 1
be,an,inadequate 1.0 0.000143348623853 1 0 1
be,allowed,before 1.0 0.000143348623853 1 0 1
be,aggravated,by 1.0 0.000143348623853 1 0 1
be,administered,within 1.0 0.000143348623853 1 0 1
be,administered,until 1.0 0.000143348623853 1 0 1
be,administered,together 1.0 0.000143348623853 1 0 1
be,administered,simultaneously 1.0 0.000143348623853 1 0 1
be,administered,orally 1.0 0.000143348623853 1 0 1
be,administered,during 1.0 0.000143348623853 1 0 1
be,administered,by 1.0 0.000143348623853 1 0 1
be,adjusted,accordingly 1.0 0.000143348623853 1 0 1
be,additive,effects 1.0 0.000143348623853 1 0 1
be,additive,coadministration 1.0 0.000143348623853 1 0 1
be,acutely,worsened 1.0 0.000143348623853 1 0 1
be,active,in 1.0 0.000143348623853 1 0 1
basis,to,mg 1.0 0.000143348623853 1 0 1
basis,of,in 1.0 0.000143348623853 1 0 1
basis,for,this 1.0 0.000143348623853 1 0 1
basis,appears,to 1.0 0.000143348623853 1 0 1
basic,as,well 1.0 0.000143348623853 1 0 1
baseline,phenytoin,serum 1.0 0.000143348623853 1 0 1
based,upon,the 1.0 0.000143348623853 1 0 1
based,on,total 1.0 0.000143348623853 1 0 1
based,on,reports 1.0 0.000143348623853 1 0 1
based,on,clinical 1.0 0.000143348623853 1 0 1
based,on,anecdotal 1.0 0.000143348623853 1 0 1
based,on,adult 1.0 0.000143348623853 1 0 1
barrier,contraception,should 1.0 0.000143348623853 1 0 1
barbiturates,or,increased 1.0 0.000143348623853 1 0 1
barbiturates,may,decrease 1.0 0.000143348623853 1 0 1
barbiturates,and,should 1.0 0.000143348623853 1 0 1
barbiturates,and,decrease 1.0 0.000143348623853 1 0 1
balance,testing,and 1.0 0.000143348623853 1 0 1
bad,general,clinical 1.0 0.000143348623853 1 0 1
bacteriostatic,such,as 1.0 0.000143348623853 1 0 1
bacteriostatic,may,interfere 1.0 0.000143348623853 1 0 1
bacteriostatic,antibiotics,chloramphenicol 1.0 0.000143348623853 1 0 1
bactericidal,effect,of 1.0 0.000143348623853 1 0 1
bacterial,metabolism,in 1.0 0.000143348623853 1 0 1
bactercidal,effect,of 1.0 0.000143348623853 1 0 1
back-up,methods,of 1.0 0.000143348623853 1 0 1
bacillus,subtilis,and 1.0 0.000143348623853 1 0 1
b3,niacin,antihypertensive 1.0 0.000143348623853 1 0 1
b12,which,can 1.0 0.000143348623853 1 0 1
b12,supplement,while 1.0 0.000143348623853 1 0 1
b-lactam,renal,excretion 1.0 0.000143348623853 1 0 1
b-lactam,inhibits,the 1.0 0.000143348623853 1 0 1
b-lactam,co-administration,of 1.0 0.000143348623853 1 0 1
b-blocking,properties,if 1.0 0.000143348623853 1 0 1
b-blocking,agent,should 1.0 0.000143348623853 1 0 1
b-,induced,hypokalemia 1.0 0.000143348623853 1 0 1
b,patients,should 1.0 0.000143348623853 1 0 1
b,intravenous,and 1.0 0.000143348623853 1 0 1
b,injection,and 1.0 0.000143348623853 1 0 1
b,has,been 1.0 0.000143348623853 1 0 1
b,antineoplastic,agents 1.0 0.000143348623853 1 0 1
b,and,was 1.0 0.000143348623853 1 0 1
b,and,suggest 1.0 0.000143348623853 1 0 1
b,and,may 1.0 0.000143348623853 1 0 1
b,and,intravenous 1.0 0.000143348623853 1 0 1
azole,inhibits,the 1.0 0.000143348623853 1 0 1
azole,antifungals,grapefruit 1.0 0.000143348623853 1 0 1
azole,antifungal,agents 1.0 0.000143348623853 1 0 1
azole,agents,are 1.0 0.000143348623853 1 0 1
azole,agents,and 1.0 0.000143348623853 1 0 1
azlocillin,should,not 1.0 0.000143348623853 1 0 1
azathioprine,allopurinol,inhibits 1.0 0.000143348623853 1 0 1
axert,within,hours 1.0 0.000143348623853 1 0 1
axert,and,an 1.0 0.000143348623853 1 0 1
awareness,of,the 1.0 0.000143348623853 1 0 1
aware,when,is 1.0 0.000143348623853 1 0 1
aware,that,variable 1.0 0.000143348623853 1 0 1
avoided,when,possible 1.0 0.000143348623853 1 0 1
avoided,unless,the 1.0 0.000143348623853 1 0 1
avoided,unless,clinically 1.0 0.000143348623853 1 0 1
avoided,see,a 1.0 0.000143348623853 1 0 1
avoided,in,combination 1.0 0.000143348623853 1 0 1
avoided,except,in 1.0 0.000143348623853 1 0 1
avoided,by,patients 1.0 0.000143348623853 1 0 1
avoided,beta-blockers,and 1.0 0.000143348623853 1 0 1
avoided,because,of 1.0 0.000143348623853 1 0 1
avoided,because,accutane 1.0 0.000143348623853 1 0 1
avoided,and,alternative 1.0 0.000143348623853 1 0 1
avoided,also,see 1.0 0.000143348623853 1 0 1
avoid,this,interaction 1.0 0.000143348623853 1 0 1
avoid,the,use 1.0 0.000143348623853 1 0 1
avoid,the,possible 1.0 0.000143348623853 1 0 1
avoid,the,concomitant 1.0 0.000143348623853 1 0 1
avoid,iatrogenic,alterations 1.0 0.000143348623853 1 0 1
avoid,giving,in 1.0 0.000143348623853 1 0 1
avoid,concurrent,administration 1.0 0.000143348623853 1 0 1
avoid,bleeding,reduced 1.0 0.000143348623853 1 0 1
average,steady-,state 1.0 0.000143348623853 1 0 1
average,of,fold 1.0 0.000143348623853 1 0 1
average,of,ci 1.0 0.000143348623853 1 0 1
average,of,approximately 1.0 0.000143348623853 1 0 1
average,increase,in 1.0 0.000143348623853 1 0 1
average,decreases,of 1.0 0.000143348623853 1 0 1
average,by,and 1.0 0.000143348623853 1 0 1
average,and,when 1.0 0.000143348623853 1 0 1
available,data,from 1.0 0.000143348623853 1 0 1
av,node,conduction 1.0 0.000143348623853 1 0 1
av,conduction,when 1.0 0.000143348623853 1 0 1
av,conduction,such 1.0 0.000143348623853 1 0 1
av,block,caution 1.0 0.000143348623853 1 0 1
autonomic,irritability,and 1.0 0.000143348623853 1 0 1
autonomic,instability,with 1.0 0.000143348623853 1 0 1
automaticity,as,well 1.0 0.000143348623853 1 0 1
autoimmune,and,inflammatory 1.0 0.000143348623853 1 0 1
aureus,a,frequent 1.0 0.000143348623853 1 0 1
auranofin,should,not 1.0 0.000143348623853 1 0 1
auranofin,should,be 1.0 0.000143348623853 1 0 1
augments,the,action 1.0 0.000143348623853 1 0 1
augmentin,xr,may 1.0 0.000143348623853 1 0 1
augmented,the,depressant 1.0 0.000143348623853 1 0 1
augmented,by,that 1.0 0.000143348623853 1 0 1
augment,the,neuromuscular 1.0 0.000143348623853 1 0 1
augment,the,hypotension 1.0 0.000143348623853 1 0 1
aucs,m,min 1.0 0.000143348623853 1 0 1
auc0-120hr,by,and 1.0 0.000143348623853 1 0 1
auc0-12,of,by 1.0 0.000143348623853 1 0 1
auc0-12,and,a 1.0 0.000143348623853 1 0 1
auc,of,there 1.0 0.000143348623853 1 0 1
auc,of,sustained-release 1.0 0.000143348623853 1 0 1
auc,of,r 1.0 0.000143348623853 1 0 1
auc,of,p 1.0 0.000143348623853 1 0 1
auc,of,mg 1.0 0.000143348623853 1 0 1
auc,of,mefenamic 1.0 0.000143348623853 1 0 1
auc,of,less 1.0 0.000143348623853 1 0 1
auc,of,its 1.0 0.000143348623853 1 0 1
auc,of,is 1.0 0.000143348623853 1 0 1
auc,of,ethinyl 1.0 0.000143348623853 1 0 1
auc,of,decreased 1.0 0.000143348623853 1 0 1
auc,of,cyp3a4 1.0 0.000143348623853 1 0 1
auc,of,although 1.0 0.000143348623853 1 0 1
auc,of,absorption 1.0 0.000143348623853 1 0 1
auc,increased,approximately 1.0 0.000143348623853 1 0 1
auc,higher,in 1.0 0.000143348623853 1 0 1
auc,cmax,t1 1.0 0.000143348623853 1 0 1
auc,by,to 1.0 0.000143348623853 1 0 1
auc,by,in 1.0 0.000143348623853 1 0 1
auc,by,approximately 1.0 0.000143348623853 1 0 1
auc,but,no 1.0 0.000143348623853 1 0 1
auc,approximately,fold 1.0 0.000143348623853 1 0 1
auc,and,very 1.0 0.000143348623853 1 0 1
auc,and,of 1.0 0.000143348623853 1 0 1
auc,and,for 1.0 0.000143348623853 1 0 1
auc,and,decrease 1.0 0.000143348623853 1 0 1
auc,and,cmin 1.0 0.000143348623853 1 0 1
auc,and,about 1.0 0.000143348623853 1 0 1
auc,after,administration 1.0 0.000143348623853 1 0 1
auc,after,a 1.0 0.000143348623853 1 0 1
auc,a,single 1.0 0.000143348623853 1 0 1
auc,a,fold 1.0 0.000143348623853 1 0 1
attributed,to,the 1.0 0.000143348623853 1 0 1
attributed,at,least 1.0 0.000143348623853 1 0 1
attenuation,of,immunization 1.0 0.000143348623853 1 0 1
attenuating,s,influence 1.0 0.000143348623853 1 0 1
attenuates,loss,caused 1.0 0.000143348623853 1 0 1
attenuates,certain,types 1.0 0.000143348623853 1 0 1
attenuates,but,mc 1.0 0.000143348623853 1 0 1
attenuated,the,hypotensive 1.0 0.000143348623853 1 0 1
attenuated,the,heart 1.0 0.000143348623853 1 0 1
attention,test,for 1.0 0.000143348623853 1 0 1
attempt,to,establish 1.0 0.000143348623853 1 0 1
atropinization,flushing,mydriasis 1.0 0.000143348623853 1 0 1
atromid-s,neoral,sandimmune 1.0 0.000143348623853 1 0 1
atromid-s,may,displace 1.0 0.000143348623853 1 0 1
atrioventricular,conduction,disturbances 1.0 0.000143348623853 1 0 1
atrial,fibrillation,their 1.0 0.000143348623853 1 0 1
atorvastatin,increases,the 1.0 0.000143348623853 1 0 1
atorvastatin,atorvastatin,increases 1.0 0.000143348623853 1 0 1
atacand,so,careful 1.0 0.000143348623853 1 0 1
atac,trial,should 1.0 0.000143348623853 1 0 1
at,to,days 1.0 0.000143348623853 1 0 1
at,these,doses 1.0 0.000143348623853 1 0 1
at,the,start 1.0 0.000143348623853 1 0 1
at,the,lowest 1.0 0.000143348623853 1 0 1
at,the,lower 1.0 0.000143348623853 1 0 1
at,recovery,of 1.0 0.000143348623853 1 0 1
at,recommended,dosages 1.0 0.000143348623853 1 0 1
at,receptors,such 1.0 0.000143348623853 1 0 1
at,periodic,intervals 1.0 0.000143348623853 1 0 1
at,or,recovery 1.0 0.000143348623853 1 0 1
at,micromol,l 1.0 0.000143348623853 1 0 1
at,microm,preferentially 1.0 0.000143348623853 1 0 1
at,mg,qid 1.0 0.000143348623853 1 0 1
at,mg,qd 1.0 0.000143348623853 1 0 1
at,mg,per 1.0 0.000143348623853 1 0 1
at,mg,daily 1.0 0.000143348623853 1 0 1
at,mg,b 1.0 0.000143348623853 1 0 1
at,m,or 1.0 0.000143348623853 1 0 1
at,lower,doses 1.0 0.000143348623853 1 0 1
at,least,partially 1.0 0.000143348623853 1 0 1
at,least,halved 1.0 0.000143348623853 1 0 1
at,least,a 1.0 0.000143348623853 1 0 1
at,hours,postdose 1.0 0.000143348623853 1 0 1
at,higher,than 1.0 0.000143348623853 1 0 1
at,high,trileptal 1.0 0.000143348623853 1 0 1
at,high,to 1.0 0.000143348623853 1 0 1
at,high,concentration 1.0 0.000143348623853 1 0 1
at,doses,above 1.0 0.000143348623853 1 0 1
at,all,with 1.0 0.000143348623853 1 0 1
at,all,when 1.0 0.000143348623853 1 0 1
at,about,x 1.0 0.000143348623853 1 0 1
astramorph,kadian,ms 1.0 0.000143348623853 1 0 1
ast,when,cancidas 1.0 0.000143348623853 1 0 1
ast,and,sgpt 1.0 0.000143348623853 1 0 1
association,with,increases 1.0 0.000143348623853 1 0 1
association,with,high 1.0 0.000143348623853 1 0 1
association,with,concomitant 1.0 0.000143348623853 1 0 1
association,between,use 1.0 0.000143348623853 1 0 1
associated,with,ventricular 1.0 0.000143348623853 1 0 1
associated,with,modest 1.0 0.000143348623853 1 0 1
associated,with,hepatotoxicity 1.0 0.000143348623853 1 0 1
associated,with,gastrointestinal 1.0 0.000143348623853 1 0 1
associated,with,crohns 1.0 0.000143348623853 1 0 1
associated,with,co-administration 1.0 0.000143348623853 1 0 1
associated,with,and 1.0 0.000143348623853 1 0 1
associated,dental,complications 1.0 0.000143348623853 1 0 1
assessed,using,morphological 1.0 0.000143348623853 1 0 1
assess,the,safety 1.0 0.000143348623853 1 0 1
aspirin,when,lodine 1.0 0.000143348623853 1 0 1
aspirin,should,not 1.0 0.000143348623853 1 0 1
aspirin,may,decrease 1.0 0.000143348623853 1 0 1
aspirin,is,contraindicated 1.0 0.000143348623853 1 0 1
aspirin,in,normal 1.0 0.000143348623853 1 0 1
aspirin,concomitant,may 1.0 0.000143348623853 1 0 1
aspirin,celebrex,can 1.0 0.000143348623853 1 0 1
aspirin,as,with 1.0 0.000143348623853 1 0 1
aspirin,animal,studies 1.0 0.000143348623853 1 0 1
asparagine,levels,are 1.0 0.000143348623853 1 0 1
ascorbic,acid,vitamin 1.0 0.000143348623853 1 0 1
ascorbic,acid,fruit 1.0 0.000143348623853 1 0 1
ascorbic,acid,doses 1.0 0.000143348623853 1 0 1
as,with,most 1.0 0.000143348623853 1 0 1
as,which,sensitize 1.0 0.000143348623853 1 0 1
as,well,concurrent 1.0 0.000143348623853 1 0 1
as,well,concurent 1.0 0.000143348623853 1 0 1
as,was,the 1.0 0.000143348623853 1 0 1
as,vertigo,syncope 1.0 0.000143348623853 1 0 1
as,valium,and 1.0 0.000143348623853 1 0 1
as,used,for 1.0 0.000143348623853 1 0 1
as,triazolopyridazines,and 1.0 0.000143348623853 1 0 1
as,three,weeks 1.0 0.000143348623853 1 0 1
as,those,on 1.0 0.000143348623853 1 0 1
as,thiazide,and 1.0 0.000143348623853 1 0 1
as,thiazide,acidic 1.0 0.000143348623853 1 0 1
as,they,might 1.0 0.000143348623853 1 0 1
as,they,can 1.0 0.000143348623853 1 0 1
as,the,vascular 1.0 0.000143348623853 1 0 1
as,the,primary 1.0 0.000143348623853 1 0 1
as,the,potential 1.0 0.000143348623853 1 0 1
as,the,or 1.0 0.000143348623853 1 0 1
as,the,class 1.0 0.000143348623853 1 0 1
as,slowly,dissolving 1.0 0.000143348623853 1 0 1
as,shown,in 1.0 0.000143348623853 1 0 1
as,sequential,infusions 1.0 0.000143348623853 1 0 1
as,selective,serotonin 1.0 0.000143348623853 1 0 1
as,reflected,in 1.0 0.000143348623853 1 0 1
as,random,observations 1.0 0.000143348623853 1 0 1
as,pure,powders 1.0 0.000143348623853 1 0 1
as,postmarketing,observations 1.0 0.000143348623853 1 0 1
as,post,marketing 1.0 0.000143348623853 1 0 1
as,plasma,asparagine 1.0 0.000143348623853 1 0 1
as,p-glycoprotein,in 1.0 0.000143348623853 1 0 1
as,other,nonsteroidal 1.0 0.000143348623853 1 0 1
as,other,medicines 1.0 0.000143348623853 1 0 1
as,or,with 1.0 0.000143348623853 1 0 1
as,or,videx 1.0 0.000143348623853 1 0 1
as,or,use 1.0 0.000143348623853 1 0 1
as,or,other 1.0 0.000143348623853 1 0 1
as,or,organophosphate 1.0 0.000143348623853 1 0 1
as,or,may 1.0 0.000143348623853 1 0 1
as,or,from 1.0 0.000143348623853 1 0 1
as,or,ergot 1.0 0.000143348623853 1 0 1
as,or,careful 1.0 0.000143348623853 1 0 1
as,or,are 1.0 0.000143348623853 1 0 1
as,nuromax,include 1.0 0.000143348623853 1 0 1
as,noted,with 1.0 0.000143348623853 1 0 1
as,not,be 1.0 0.000143348623853 1 0 1
as,nonsteroidal,anti-inflammatory 1.0 0.000143348623853 1 0 1
as,nimbex,include 1.0 0.000143348623853 1 0 1
as,narcotics,non-narcotic 1.0 0.000143348623853 1 0 1
as,myelosuppression,and 1.0 0.000143348623853 1 0 1
as,might,increase 1.0 0.000143348623853 1 0 1
as,mg,twice 1.0 0.000143348623853 1 0 1
as,mg,day 1.0 0.000143348623853 1 0 1
as,may,result 1.0 0.000143348623853 1 0 1
as,may,have 1.0 0.000143348623853 1 0 1
as,loop,or 1.0 0.000143348623853 1 0 1
as,long,as 1.0 0.000143348623853 1 0 1
as,liver,enzyme 1.0 0.000143348623853 1 0 1
as,international,normalized 1.0 0.000143348623853 1 0 1
as,inr,was 1.0 0.000143348623853 1 0 1
as,inotropes,and 1.0 0.000143348623853 1 0 1
as,in,rheumatic 1.0 0.000143348623853 1 0 1
as,hours,and 1.0 0.000143348623853 1 0 1
as,hours,after 1.0 0.000143348623853 1 0 1
as,have,the 1.0 0.000143348623853 1 0 1
as,have,been 1.0 0.000143348623853 1 0 1
as,garlic,allium 1.0 0.000143348623853 1 0 1
as,g,and 1.0 0.000143348623853 1 0 1
as,from,their 1.0 0.000143348623853 1 0 1
as,formulations,containing 1.0 0.000143348623853 1 0 1
as,feso4,or 1.0 0.000143348623853 1 0 1
as,etc,is 1.0 0.000143348623853 1 0 1
as,early,as 1.0 0.000143348623853 1 0 1
as,diminished,effects 1.0 0.000143348623853 1 0 1
as,decreasing,its 1.0 0.000143348623853 1 0 1
as,cyp3a4,inhibitors 1.0 0.000143348623853 1 0 1
as,cough,and 1.0 0.000143348623853 1 0 1
as,convulsions,and 1.0 0.000143348623853 1 0 1
as,compared,with 1.0 0.000143348623853 1 0 1
as,choline,trilisate 1.0 0.000143348623853 1 0 1
as,certain,antagonists 1.0 0.000143348623853 1 0 1
as,can,also 1.0 0.000143348623853 1 0 1
as,camptosar,than 1.0 0.000143348623853 1 0 1
as,but,not 1.0 0.000143348623853 1 0 1
as,bradycardia,and 1.0 0.000143348623853 1 0 1
as,belladonna,alkaloids 1.0 0.000143348623853 1 0 1
as,because,they 1.0 0.000143348623853 1 0 1
as,arrhythmias,may 1.0 0.000143348623853 1 0 1
as,are,used 1.0 0.000143348623853 1 0 1
as,are,likely 1.0 0.000143348623853 1 0 1
as,are,employed 1.0 0.000143348623853 1 0 1
as,antiparkinson,or 1.0 0.000143348623853 1 0 1
as,antineoplastic,agents 1.0 0.000143348623853 1 0 1
as,anorexia,tachypnea 1.0 0.000143348623853 1 0 1
as,and,would 1.0 0.000143348623853 1 0 1
as,and,with 1.0 0.000143348623853 1 0 1
as,and,sometimes 1.0 0.000143348623853 1 0 1
as,and,some 1.0 0.000143348623853 1 0 1
as,and,should 1.0 0.000143348623853 1 0 1
as,and,see 1.0 0.000143348623853 1 0 1
as,and,or 1.0 0.000143348623853 1 0 1
as,and,maois 1.0 0.000143348623853 1 0 1
as,and,local 1.0 0.000143348623853 1 0 1
as,and,induce 1.0 0.000143348623853 1 0 1
as,and,ethacrynic 1.0 0.000143348623853 1 0 1
as,and,dilantin 1.0 0.000143348623853 1 0 1
as,and,because 1.0 0.000143348623853 1 0 1
as,an,antipsychotic 1.0 0.000143348623853 1 0 1
as,amphotericin,b 1.0 0.000143348623853 1 0 1
as,alternatives,to 1.0 0.000143348623853 1 0 1
as,akineton,are 1.0 0.000143348623853 1 0 1
as,a,stimulator 1.0 0.000143348623853 1 0 1
as,a,guide 1.0 0.000143348623853 1 0 1
article,reported,that 1.0 0.000143348623853 1 0 1
arthropan,magan,or 1.0 0.000143348623853 1 0 1
arthritis,thyroiditis,bullous 1.0 0.000143348623853 1 0 1
artery,vasospasm,and 1.0 0.000143348623853 1 0 1
arterial,thrombus,formation 1.0 0.000143348623853 1 0 1
arterial,pressure,of 1.0 0.000143348623853 1 0 1
arrythmias,ventricular,tachycardia 1.0 0.000143348623853 1 0 1
arrhythmias,during,can 1.0 0.000143348623853 1 0 1
arrhythmias,and,sudden 1.0 0.000143348623853 1 0 1
arrhythmia,bradycardia,qt 1.0 0.000143348623853 1 0 1
arrhythmia,and,diamond 1.0 0.000143348623853 1 0 1
arise,from,co-administration 1.0 0.000143348623853 1 0 1
aripiprazole,dose,should 1.0 0.000143348623853 1 0 1
arimidex,as,they 1.0 0.000143348623853 1 0 1
argatroban,with,antiplatelet 1.0 0.000143348623853 1 0 1
arecoline,eproxindine,ethanol 1.0 0.000143348623853 1 0 1
area-under,the-curve,after 1.0 0.000143348623853 1 0 1
are,very,potent 1.0 0.000143348623853 1 0 1
are,vasoconstrictive,and 1.0 0.000143348623853 1 0 1
are,usually,administered 1.0 0.000143348623853 1 0 1
are,using,the 1.0 0.000143348623853 1 0 1
are,using,it 1.0 0.000143348623853 1 0 1
are,used,in 1.0 0.000143348623853 1 0 1
are,unknown,slightly 1.0 0.000143348623853 1 0 1
are,unknown,neither 1.0 0.000143348623853 1 0 1
are,treated,with 1.0 0.000143348623853 1 0 1
are,the,prescription 1.0 0.000143348623853 1 0 1
are,taking,while 1.0 0.000143348623853 1 0 1
are,taking,other 1.0 0.000143348623853 1 0 1
are,taking,or 1.0 0.000143348623853 1 0 1
are,taken,on 1.0 0.000143348623853 1 0 1
are,taken,concurrently 1.0 0.000143348623853 1 0 1
are,taken,as 1.0 0.000143348623853 1 0 1
are,suggested,when 1.0 0.000143348623853 1 0 1
are,started,thus 1.0 0.000143348623853 1 0 1
are,reports,of 1.0 0.000143348623853 1 0 1
are,reduced,when 1.0 0.000143348623853 1 0 1
are,reduced,by 1.0 0.000143348623853 1 0 1
are,recommended,when 1.0 0.000143348623853 1 0 1
are,receiving,or 1.0 0.000143348623853 1 0 1
are,receiving,high 1.0 0.000143348623853 1 0 1
are,receiving,ace 1.0 0.000143348623853 1 0 1
are,receiving,a 1.0 0.000143348623853 1 0 1
are,rare,reports 1.0 0.000143348623853 1 0 1
are,provided,this 1.0 0.000143348623853 1 0 1
are,potentiated,by 1.0 0.000143348623853 1 0 1
are,potent,inhibitors 1.0 0.000143348623853 1 0 1
are,potent,inducers 1.0 0.000143348623853 1 0 1
are,potent,cyp3a 1.0 0.000143348623853 1 0 1
are,on,replacement 1.0 0.000143348623853 1 0 1
are,obtained,should 1.0 0.000143348623853 1 0 1
are,not,receiving 1.0 0.000143348623853 1 0 1
are,not,primarily 1.0 0.000143348623853 1 0 1
are,no,study 1.0 0.000143348623853 1 0 1
are,listed,below 1.0 0.000143348623853 1 0 1
are,limited,in 1.0 0.000143348623853 1 0 1
are,increased,with 1.0 0.000143348623853 1 0 1
are,hypersensitive,to 1.0 0.000143348623853 1 0 1
are,highly,bound 1.0 0.000143348623853 1 0 1
are,given,to 1.0 0.000143348623853 1 0 1
are,found,to 1.0 0.000143348623853 1 0 1
are,extensively,metabolized 1.0 0.000143348623853 1 0 1
are,expected,with 1.0 0.000143348623853 1 0 1
are,enhanced,by 1.0 0.000143348623853 1 0 1
are,employed,because 1.0 0.000143348623853 1 0 1
are,either,added 1.0 0.000143348623853 1 0 1
are,due,not 1.0 0.000143348623853 1 0 1
are,direct,cardiac 1.0 0.000143348623853 1 0 1
are,cytochrome,p450 1.0 0.000143348623853 1 0 1
are,cyp3a4,inhibitors 1.0 0.000143348623853 1 0 1
are,cyp,inducers 1.0 0.000143348623853 1 0 1
are,contraindicated,in 1.0 0.000143348623853 1 0 1
are,conflicting,results 1.0 0.000143348623853 1 0 1
are,coadministered,the 1.0 0.000143348623853 1 0 1
are,co-administered,which 1.0 0.000143348623853 1 0 1
are,co,administered 1.0 0.000143348623853 1 0 1
are,case,reports 1.0 0.000143348623853 1 0 1
are,begun,in 1.0 0.000143348623853 1 0 1
are,at,an 1.0 0.000143348623853 1 0 1
are,applying,panretin 1.0 0.000143348623853 1 0 1
are,altered,by 1.0 0.000143348623853 1 0 1
are,also,using 1.0 0.000143348623853 1 0 1
are,also,likely 1.0 0.000143348623853 1 0 1
are,also,blocked 1.0 0.000143348623853 1 0 1
are,also,additive 1.0 0.000143348623853 1 0 1
are,all,metabolized 1.0 0.000143348623853 1 0 1
are,all,associated 1.0 0.000143348623853 1 0 1
are,administered,separately 1.0 0.000143348623853 1 0 1
are,actively,secreted 1.0 0.000143348623853 1 0 1
are,a,major 1.0 0.000143348623853 1 0 1
arc,mrna,level 1.0 0.000143348623853 1 0 1
arava,with,a 1.0 0.000143348623853 1 0 1
arava,to,subjects 1.0 0.000143348623853 1 0 1
arava,levels,to 1.0 0.000143348623853 1 0 1
arava,and,were 1.0 0.000143348623853 1 0 1
arabinoside,a,cytostatic 1.0 0.000143348623853 1 0 1
aprepitant,with,these 1.0 0.000143348623853 1 0 1
aprepitant,with,each 1.0 0.000143348623853 1 0 1
aprepitant,reflects,an 1.0 0.000143348623853 1 0 1
aprepitant,on,the 1.0 0.000143348623853 1 0 1
aprepitant,mg,on 1.0 0.000143348623853 1 0 1
aprepitant,has,been 1.0 0.000143348623853 1 0 1
aprepitant,given,concomitantly 1.0 0.000143348623853 1 0 1
apraclonidine,should,not 1.0 0.000143348623853 1 0 1
approximately,with,coadministration 1.0 0.000143348623853 1 0 1
approximately,when,taxol 1.0 0.000143348623853 1 0 1
approximately,when,taking 1.0 0.000143348623853 1 0 1
approximately,was,necessary 1.0 0.000143348623853 1 0 1
approximately,twofold,from 1.0 0.000143348623853 1 0 1
approximately,twice,those 1.0 0.000143348623853 1 0 1
approximately,to,the 1.0 0.000143348623853 1 0 1
approximately,to,representing 1.0 0.000143348623853 1 0 1
approximately,to,fold 1.0 0.000143348623853 1 0 1
approximately,threefold,from 1.0 0.000143348623853 1 0 1
approximately,peak,blood 1.0 0.000143348623853 1 0 1
approximately,one-third,to 1.0 0.000143348623853 1 0 1
approximately,one,week 1.0 0.000143348623853 1 0 1
approximately,msec,compared 1.0 0.000143348623853 1 0 1
approximately,minutes,faster 1.0 0.000143348623853 1 0 1
approximately,mean,sodium 1.0 0.000143348623853 1 0 1
approximately,increase,in 1.0 0.000143348623853 1 0 1
approximately,in,subjects 1.0 0.000143348623853 1 0 1
approximately,in,cyp2d6 1.0 0.000143348623853 1 0 1
approximately,hours,after 1.0 0.000143348623853 1 0 1
approximately,given,to 1.0 0.000143348623853 1 0 1
approximately,fold,of 1.0 0.000143348623853 1 0 1
approximately,fold,at 1.0 0.000143348623853 1 0 1
approximately,decrease,range 1.0 0.000143348623853 1 0 1
approximately,decrease,in 1.0 0.000143348623853 1 0 1
approximately,by,the 1.0 0.000143348623853 1 0 1
approximately,and,the 1.0 0.000143348623853 1 0 1
approximately,and,cmax 1.0 0.000143348623853 1 0 1
approximately,a,fold 1.0 0.000143348623853 1 0 1
approximate,reduction,of 1.0 0.000143348623853 1 0 1
approximate,doubling,of 1.0 0.000143348623853 1 0 1
approximate,doubling,in 1.0 0.000143348623853 1 0 1
approx,because,amplifies 1.0 0.000143348623853 1 0 1
approved,prescription,dose 1.0 0.000143348623853 1 0 1
appropriate,monitoring,of 1.0 0.000143348623853 1 0 1
appropriate,laboratory,testing 1.0 0.000143348623853 1 0 1
appropriate,dosage,adjustment 1.0 0.000143348623853 1 0 1
applying,panretin,gel 1.0 0.000143348623853 1 0 1
appears,to,increase 1.0 0.000143348623853 1 0 1
appears,that,may 1.0 0.000143348623853 1 0 1
appeared,to,produce 1.0 0.000143348623853 1 0 1
appeared,to,prevent 1.0 0.000143348623853 1 0 1
appeared,to,influence 1.0 0.000143348623853 1 0 1
appeared,to,alter 1.0 0.000143348623853 1 0 1
appearance,of,unsteady 1.0 0.000143348623853 1 0 1
apparently,through,an 1.0 0.000143348623853 1 0 1
apparent,total,body 1.0 0.000143348623853 1 0 1
apoptosis,assessed,using 1.0 0.000143348623853 1 0 1
apart,was,administered 1.0 0.000143348623853 1 0 1
apart,on,an 1.0 0.000143348623853 1 0 1
aortic,rings,from 1.0 0.000143348623853 1 0 1
any,such,reduction 1.0 0.000143348623853 1 0 1
any,signs,or 1.0 0.000143348623853 1 0 1
any,significant,accuracy 1.0 0.000143348623853 1 0 1
any,route,they 1.0 0.000143348623853 1 0 1
any,reduction,in 1.0 0.000143348623853 1 0 1
any,oral,medications 1.0 0.000143348623853 1 0 1
any,medication,including 1.0 0.000143348623853 1 0 1
any,intentional,or 1.0 0.000143348623853 1 0 1
any,hypokalemic,effect 1.0 0.000143348623853 1 0 1
any,excessive,fall 1.0 0.000143348623853 1 0 1
any,condition,in 1.0 0.000143348623853 1 0 1
any,clinical,signs 1.0 0.000143348623853 1 0 1
any,amine,since 1.0 0.000143348623853 1 0 1
any,additional,including 1.0 0.000143348623853 1 0 1
any,additional,effect 1.0 0.000143348623853 1 0 1
anxiogenic,effects,of 1.0 0.000143348623853 1 0 1
anxiogenic,effects,by 1.0 0.000143348623853 1 0 1
antizol,mg,kg 1.0 0.000143348623853 1 0 1
antizol,by,approximately 1.0 0.000143348623853 1 0 1
antizol,and,that 1.0 0.000143348623853 1 0 1
antiviral,activity,of 1.0 0.000143348623853 1 0 1
antitumour,activity,of 1.0 0.000143348623853 1 0 1
antitumor,effectiveness,of 1.0 0.000143348623853 1 0 1
antithyroid,agents,may 1.0 0.000143348623853 1 0 1
antithrombin,iii,human 1.0 0.000143348623853 1 0 1
antiretroviral,drugs,significant 1.0 0.000143348623853 1 0 1
antipsychotic,eg,an 1.0 0.000143348623853 1 0 1
antipsychotic,agents,monoamine 1.0 0.000143348623853 1 0 1
antipsychotic,agents,it 1.0 0.000143348623853 1 0 1
antiplatelet,and,medication 1.0 0.000143348623853 1 0 1
antiplatelet,agents,or 1.0 0.000143348623853 1 0 1
antiplatelet,agents,and 1.0 0.000143348623853 1 0 1
antiparkinsonian,drug,eg 1.0 0.000143348623853 1 0 1
antiparkinsonian,agents,particularly 1.0 0.000143348623853 1 0 1
antiparkinson,or,may 1.0 0.000143348623853 1 0 1
antinociceptive,effect,between 1.0 0.000143348623853 1 0 1
antineoplastic,agents,or 1.0 0.000143348623853 1 0 1
antineoplastic,agents,may 1.0 0.000143348623853 1 0 1
antineoplastic,agents,having 1.0 0.000143348623853 1 0 1
antimycobacterial,agents,benzodiazepines 1.0 0.000143348623853 1 0 1
antimuscarinic,effects,and 1.0 0.000143348623853 1 0 1
antiminth,taking,and 1.0 0.000143348623853 1 0 1
antimigraine,derivatives,antimycobacterial 1.0 0.000143348623853 1 0 1
antimicrobial,and,the 1.0 0.000143348623853 1 0 1
antiinflammatory,including,indocin 1.0 0.000143348623853 1 0 1
antiinflammatory,agents,aspirin 1.0 0.000143348623853 1 0 1
antiinflammatory,agents,and 1.0 0.000143348623853 1 0 1
antiinflammatory,agent,can 1.0 0.000143348623853 1 0 1
antihypertensives,bumetanide,may 1.0 0.000143348623853 1 0 1
antihypertensive,therapy,nicotinic 1.0 0.000143348623853 1 0 1
antihypertensive,necessitating,a 1.0 0.000143348623853 1 0 1
antihypertensive,medications,and 1.0 0.000143348623853 1 0 1
antihypertensive,effect,to 1.0 0.000143348623853 1 0 1
antihypertensive,effect,in 1.0 0.000143348623853 1 0 1
antihypertensive,effect,and 1.0 0.000143348623853 1 0 1
antihypertensive,and,the 1.0 0.000143348623853 1 0 1
antihypertensive,action,of 1.0 0.000143348623853 1 0 1
antihistamines,may,partially 1.0 0.000143348623853 1 0 1
antihistamines,may,have 1.0 0.000143348623853 1 0 1
antihistamines,may,enhance 1.0 0.000143348623853 1 0 1
antihistamines,antimigraine,derivatives 1.0 0.000143348623853 1 0 1
antifungals,in,vitro 1.0 0.000143348623853 1 0 1
antifungals,grapefruit,juice 1.0 0.000143348623853 1 0 1
antifungal,agents,should 1.0 0.000143348623853 1 0 1
antifungal,agents,protease 1.0 0.000143348623853 1 0 1
antiepileptic,periodic,serum 1.0 0.000143348623853 1 0 1
antiepileptic,effect,of 1.0 0.000143348623853 1 0 1
antiepileptic,drugs,the 1.0 0.000143348623853 1 0 1
antiepileptic,drugs,sporadic 1.0 0.000143348623853 1 0 1
antiepileptic,drugs,phenytoin 1.0 0.000143348623853 1 0 1
antiepileptic,drugs,on 1.0 0.000143348623853 1 0 1
antiepileptic,and,the 1.0 0.000143348623853 1 0 1
antiepileptic,aeds,affects 1.0 0.000143348623853 1 0 1
antiemetic,prophylaxis,may 1.0 0.000143348623853 1 0 1
antiedematous,action,of 1.0 0.000143348623853 1 0 1
antidotal,properties,of 1.0 0.000143348623853 1 0 1
antidiabetics,oral,diabetes 1.0 0.000143348623853 1 0 1
antidiabetics,because,may 1.0 0.000143348623853 1 0 1
antidiabetic,agents,disturbances 1.0 0.000143348623853 1 0 1
antidepressants,use,of 1.0 0.000143348623853 1 0 1
antidepressants,in,vitro 1.0 0.000143348623853 1 0 1
antidepressants,foradil,should 1.0 0.000143348623853 1 0 1
antidepressant,when,therapy 1.0 0.000143348623853 1 0 1
antidepressant,single,dose 1.0 0.000143348623853 1 0 1
antidepressant,levels,have 1.0 0.000143348623853 1 0 1
antidepressant,levels,and 1.0 0.000143348623853 1 0 1
antidepressant,eg,commonly 1.0 0.000143348623853 1 0 1
anticonvulsants,phenytoin,steady 1.0 0.000143348623853 1 0 1
anticonvulsants,increase,the 1.0 0.000143348623853 1 0 1
anticonvulsants,in,a 1.0 0.000143348623853 1 0 1
anticoagulation,test,should 1.0 0.000143348623853 1 0 1
anticoagulation,levels,should 1.0 0.000143348623853 1 0 1
anticoagulants,while,studies 1.0 0.000143348623853 1 0 1
anticoagulants,oral,co-administration 1.0 0.000143348623853 1 0 1
anticoagulants,increased,prothrombin 1.0 0.000143348623853 1 0 1
anticoagulants,including,derivatives 1.0 0.000143348623853 1 0 1
anticoagulants,in,some 1.0 0.000143348623853 1 0 1
anticoagulants,flurbiprofen,like 1.0 0.000143348623853 1 0 1
anticoagulants,combination,hormonal 1.0 0.000143348623853 1 0 1
anticoagulants,caution,should 1.0 0.000143348623853 1 0 1
anticoagulants,are,given 1.0 0.000143348623853 1 0 1
anticoagulants,altered,coagulation 1.0 0.000143348623853 1 0 1
anticoagulant,therapy,should 1.0 0.000143348623853 1 0 1
anticoagulant,activity,should 1.0 0.000143348623853 1 0 1
anticipated,if,stadol 1.0 0.000143348623853 1 0 1
anticipated,and,infusion 1.0 0.000143348623853 1 0 1
anticholinesterases,concomitant,use 1.0 0.000143348623853 1 0 1
anticholinesterase,poisoning,although 1.0 0.000143348623853 1 0 1
anticholinesterase,effect,of 1.0 0.000143348623853 1 0 1
anticholinesterase,agents,should 1.0 0.000143348623853 1 0 1
anticholinesterase,agents,and 1.0 0.000143348623853 1 0 1
anticholinergics,concurrent,administration 1.0 0.000143348623853 1 0 1
anticholinergic,may,antagonize 1.0 0.000143348623853 1 0 1
anticholinergic,agents,although 1.0 0.000143348623853 1 0 1
anticancer,and,may 1.0 0.000143348623853 1 0 1
antibiotics,videx,should 1.0 0.000143348623853 1 0 1
antibiotics,such,as 1.0 0.000143348623853 1 0 1
antibiotics,macrolide,have 1.0 0.000143348623853 1 0 1
antibiotics,in,vitro 1.0 0.000143348623853 1 0 1
antibiotics,chloramphenicol,or 1.0 0.000143348623853 1 0 1
antibiotics,and,has 1.0 0.000143348623853 1 0 1
antibiotics,and,agents 1.0 0.000143348623853 1 0 1
antiarrhythmics,antihistamines,antimigraine 1.0 0.000143348623853 1 0 1
antianxiety,agents,the 1.0 0.000143348623853 1 0 1
antianxiety,agents,or 1.0 0.000143348623853 1 0 1
anti-malarial,such,as 1.0 0.000143348623853 1 0 1
anti-inflammatory,nsaids,suggests 1.0 0.000143348623853 1 0 1
anti-inflammatory,nsaids,and 1.0 0.000143348623853 1 0 1
anti-inflammatory,may,increase 1.0 0.000143348623853 1 0 1
anti-inflammatory,have,been 1.0 0.000143348623853 1 0 1
anti-inflammatory,drugs,the 1.0 0.000143348623853 1 0 1
anti-inflammatory,drugs,has 1.0 0.000143348623853 1 0 1
anti-inflammatory,concomitantly,with 1.0 0.000143348623853 1 0 1
anti-inflammatory,agents,nsaids 1.0 0.000143348623853 1 0 1
anti-inflammatory,agents,and 1.0 0.000143348623853 1 0 1
anti-inflammatory,activity,with 1.0 0.000143348623853 1 0 1
anti-inflammatory,activity,of 1.0 0.000143348623853 1 0 1
anti-inflammatory,action,by 1.0 0.000143348623853 1 0 1
anti-depressants,could,exaggerate 1.0 0.000143348623853 1 0 1
anti-arrhythmics,and,anti-depressants 1.0 0.000143348623853 1 0 1
anti-,inflammatory,agents 1.0 0.000143348623853 1 0 1
anti,inflammatory,with 1.0 0.000143348623853 1 0 1
antagonized,the,rate-decreasing 1.0 0.000143348623853 1 0 1
antagonized,the,inhibitory 1.0 0.000143348623853 1 0 1
antagonized,in,a 1.0 0.000143348623853 1 0 1
antagonized,evidently,the 1.0 0.000143348623853 1 0 1
antagonized,by,such 1.0 0.000143348623853 1 0 1
antagonized,by,beta-adrenergic 1.0 0.000143348623853 1 0 1
antagonized,by,alpha-adrenergic 1.0 0.000143348623853 1 0 1
antagonize,the,skeletal 1.0 0.000143348623853 1 0 1
antagonize,the,neuron 1.0 0.000143348623853 1 0 1
antagonize,the,in 1.0 0.000143348623853 1 0 1
antagonize,the,effect 1.0 0.000143348623853 1 0 1
antagonize,the,decreases 1.0 0.000143348623853 1 0 1
antagonize,the,bactericidal 1.0 0.000143348623853 1 0 1
antagonize,the,bactercidal 1.0 0.000143348623853 1 0 1
antagonize,the,anorectic 1.0 0.000143348623853 1 0 1
antagonists,which,cause 1.0 0.000143348623853 1 0 1
antagonists,when,is 1.0 0.000143348623853 1 0 1
antagonists,the,absorption 1.0 0.000143348623853 1 0 1
antagonists,since,is 1.0 0.000143348623853 1 0 1
antagonists,should,be 1.0 0.000143348623853 1 0 1
antagonists,particularly,of 1.0 0.000143348623853 1 0 1
antagonists,may,have 1.0 0.000143348623853 1 0 1
antagonists,may,be 1.0 0.000143348623853 1 0 1
antagonists,increased,mean 1.0 0.000143348623853 1 0 1
antagonists,hypertension,in 1.0 0.000143348623853 1 0 1
antagonists,drugs,that 1.0 0.000143348623853 1 0 1
antagonists,co-administration,of 1.0 0.000143348623853 1 0 1
antagonists,cimetidine,inhibits 1.0 0.000143348623853 1 0 1
antagonists,cimetidine,coadministration 1.0 0.000143348623853 1 0 1
antagonists,because,of 1.0 0.000143348623853 1 0 1
antagonists,based,on 1.0 0.000143348623853 1 0 1
antagonists,are,administered 1.0 0.000143348623853 1 0 1
antagonists,and,may 1.0 0.000143348623853 1 0 1
antagonists,and,certain 1.0 0.000143348623853 1 0 1
antagonists,and,brovana 1.0 0.000143348623853 1 0 1
antagonists,and,alpha-adrenergic 1.0 0.000143348623853 1 0 1
antagonists,after,repeated 1.0 0.000143348623853 1 0 1
antagonistic,to,beta-lactam 1.0 0.000143348623853 1 0 1
antagonistic,effect,of 1.0 0.000143348623853 1 0 1
antagonist,with,orencia 1.0 0.000143348623853 1 0 1
antagonist,was,added 1.0 0.000143348623853 1 0 1
antagonist,that,may 1.0 0.000143348623853 1 0 1
antagonist,sch-23390,but 1.0 0.000143348623853 1 0 1
antagonist,opioid,analgesics 1.0 0.000143348623853 1 0 1
antagonist,has,been 1.0 0.000143348623853 1 0 1
antagonist,eg,and 1.0 0.000143348623853 1 0 1
antagonist,class,including 1.0 0.000143348623853 1 0 1
antagonist,and,another 1.0 0.000143348623853 1 0 1
antagonism,of,the 1.0 0.000143348623853 1 0 1
antagonism,has,the 1.0 0.000143348623853 1 0 1
antagonism,has,been 1.0 0.000143348623853 1 0 1
antagonism,between,and 1.0 0.000143348623853 1 0 1
antacids,or,substantially 1.0 0.000143348623853 1 0 1
antacids,may,interfere 1.0 0.000143348623853 1 0 1
antacids,kaolin-pectin,certain 1.0 0.000143348623853 1 0 1
antacids,increase,the 1.0 0.000143348623853 1 0 1
antacids,enteric,coated 1.0 0.000143348623853 1 0 1
antacids,containing,trisilicate 1.0 0.000143348623853 1 0 1
antacids,containing,hydroxide 1.0 0.000143348623853 1 0 1
antacids,and,sucralfate 1.0 0.000143348623853 1 0 1
antacids,and,can 1.0 0.000143348623853 1 0 1
antacids,and,antacids 1.0 0.000143348623853 1 0 1
antacids,aluminum-,or 1.0 0.000143348623853 1 0 1
antacid,when,and 1.0 0.000143348623853 1 0 1
antacid,maalox,maalox 1.0 0.000143348623853 1 0 1
antabuse-like,side,effects 1.0 0.000143348623853 1 0 1
another,tnf-blocking,agent 1.0 0.000143348623853 1 0 1
another,tnf,blocking 1.0 0.000143348623853 1 0 1
another,such,as 1.0 0.000143348623853 1 0 1
another,study,in 1.0 0.000143348623853 1 0 1
another,serotonin,reuptake 1.0 0.000143348623853 1 0 1
another,report,nine 1.0 0.000143348623853 1 0 1
another,oral,azole 1.0 0.000143348623853 1 0 1
another,interaction,study 1.0 0.000143348623853 1 0 1
another,hmg-coa,reductase 1.0 0.000143348623853 1 0 1
another,class,antimicrobial 1.0 0.000143348623853 1 0 1
another,botulinum,prior 1.0 0.000143348623853 1 0 1
another,and,but 1.0 0.000143348623853 1 0 1
anorexia,tachypnea,lethargy 1.0 0.000143348623853 1 0 1
anorectic,and,stimulatory 1.0 0.000143348623853 1 0 1
anitagonism,without,affecting 1.0 0.000143348623853 1 0 1
anionic-binding,has,a 1.0 0.000143348623853 1 0 1
anion-exchange,resins,an 1.0 0.000143348623853 1 0 1
anion,plasma,levels 1.0 0.000143348623853 1 0 1
animals,treated,with 1.0 0.000143348623853 1 0 1
animals,indicate,that 1.0 0.000143348623853 1 0 1
animals,edetate,disodium 1.0 0.000143348623853 1 0 1
animals,demonstrate,that 1.0 0.000143348623853 1 0 1
animal,studies,wshow 1.0 0.000143348623853 1 0 1
animal,studies,with 1.0 0.000143348623853 1 0 1
animal,studies,suggest 1.0 0.000143348623853 1 0 1
animal,model,possibly 1.0 0.000143348623853 1 0 1
animal,experience,indicates 1.0 0.000143348623853 1 0 1
anhydrase,inhibitors,rare 1.0 0.000143348623853 1 0 1
anhydrase,inhibitors,as 1.0 0.000143348623853 1 0 1
anhydrase,inhibitors,and 1.0 0.000143348623853 1 0 1
angiotensln,converting,enzyme 1.0 0.000143348623853 1 0 1
angiotensin-converting,enzyme,inhibitors 1.0 0.000143348623853 1 0 1
angiotensin-converting,enzyme,inhibitor 1.0 0.000143348623853 1 0 1
angiomax,with,or 1.0 0.000143348623853 1 0 1
angina,pectoris,additional 1.0 0.000143348623853 1 0 1
angina,or,other 1.0 0.000143348623853 1 0 1
anesthetized,with,innovar 1.0 0.000143348623853 1 0 1
anesthetics,sedatives,hypnotics 1.0 0.000143348623853 1 0 1
anesthetics,general,exaggeration 1.0 0.000143348623853 1 0 1
anesthesia,severe,hypotension 1.0 0.000143348623853 1 0 1
anecdotal,reports,there 1.0 0.000143348623853 1 0 1
and,zidovudine,ribavirin 1.0 0.000143348623853 1 0 1
and,you,may 1.0 0.000143348623853 1 0 1
and,xanthine,and 1.0 0.000143348623853 1 0 1
and,without,an 1.0 0.000143348623853 1 0 1
and,within,hours 1.0 0.000143348623853 1 0 1
and,with,transdermal 1.0 0.000143348623853 1 0 1
and,with,some 1.0 0.000143348623853 1 0 1
and,with,reduced 1.0 0.000143348623853 1 0 1
and,with,a 1.0 0.000143348623853 1 0 1
and,which,inhibit 1.0 0.000143348623853 1 0 1
and,which,competes 1.0 0.000143348623853 1 0 1
and,when,and 1.0 0.000143348623853 1 0 1
and,when,administered 1.0 0.000143348623853 1 0 1
and,were,co-administered 1.0 0.000143348623853 1 0 1
and,were,agonists 1.0 0.000143348623853 1 0 1
and,weight,loss 1.0 0.000143348623853 1 0 1
and,weight,gain 1.0 0.000143348623853 1 0 1
and,was,followed 1.0 0.000143348623853 1 0 1
and,volunteers,n 1.0 0.000143348623853 1 0 1
and,volume,of 1.0 0.000143348623853 1 0 1
and,videx,didanosine 1.0 0.000143348623853 1 0 1
and,very,little 1.0 0.000143348623853 1 0 1
and,veratrum,alkaloids 1.0 0.000143348623853 1 0 1
and,vasodilators,the 1.0 0.000143348623853 1 0 1
and,vasoactive,resulting 1.0 0.000143348623853 1 0 1
and,usually,results 1.0 0.000143348623853 1 0 1
and,usually,a 1.0 0.000143348623853 1 0 1
and,use,may 1.0 0.000143348623853 1 0 1
and,uroxatral,should 1.0 0.000143348623853 1 0 1
and,urine,levels 1.0 0.000143348623853 1 0 1
and,upon,concomitant 1.0 0.000143348623853 1 0 1
and,unpredictable,potentiation 1.0 0.000143348623853 1 0 1
and,under,acidic 1.0 0.000143348623853 1 0 1
and,ulcerative,colitis 1.0 0.000143348623853 1 0 1
and,triglycerides,sgot 1.0 0.000143348623853 1 0 1
and,tricyclic,antidepressants 1.0 0.000143348623853 1 0 1
and,traumatic,edemas 1.0 0.000143348623853 1 0 1
and,transient,dose-dependent 1.0 0.000143348623853 1 0 1
and,toxicity,in 1.0 0.000143348623853 1 0 1
and,toxicity,have 1.0 0.000143348623853 1 0 1
and,together,may 1.0 0.000143348623853 1 0 1
and,to,eliminate 1.0 0.000143348623853 1 0 1
and,tnf,antagonists 1.0 0.000143348623853 1 0 1
and,titration,to 1.0 0.000143348623853 1 0 1
and,time,kill 1.0 0.000143348623853 1 0 1
and,thus,should 1.0 0.000143348623853 1 0 1
and,thus,lower 1.0 0.000143348623853 1 0 1
and,thus,decrease 1.0 0.000143348623853 1 0 1
and,this,neurotoxic 1.0 0.000143348623853 1 0 1
and,thiazide,may 1.0 0.000143348623853 1 0 1
and,therefore,such 1.0 0.000143348623853 1 0 1
and,therefore,potentially 1.0 0.000143348623853 1 0 1
and,thereby,delaying 1.0 0.000143348623853 1 0 1
and,there,is 1.0 0.000143348623853 1 0 1
and,therapy,it 1.0 0.000143348623853 1 0 1
and,therapeutic,effects 1.0 0.000143348623853 1 0 1
and,therapeutic,concentration 1.0 0.000143348623853 1 0 1
and,then,wait 1.0 0.000143348623853 1 0 1
and,then,titrated 1.0 0.000143348623853 1 0 1
and,then,careful 1.0 0.000143348623853 1 0 1
and,their,combined 1.0 0.000143348623853 1 0 1
and,their,bioavailability 1.0 0.000143348623853 1 0 1
and,the,variability 1.0 0.000143348623853 1 0 1
and,the,selective 1.0 0.000143348623853 1 0 1
and,the,resulting 1.0 0.000143348623853 1 0 1
and,the,potent 1.0 0.000143348623853 1 0 1
and,the,occurrence 1.0 0.000143348623853 1 0 1
and,the,nonsteroidal 1.0 0.000143348623853 1 0 1
and,the,muscle 1.0 0.000143348623853 1 0 1
and,the,may 1.0 0.000143348623853 1 0 1
and,the,lowest 1.0 0.000143348623853 1 0 1
and,the,leukopenic 1.0 0.000143348623853 1 0 1
and,the,has 1.0 0.000143348623853 1 0 1
and,the,combination 1.0 0.000143348623853 1 0 1
and,the,central 1.0 0.000143348623853 1 0 1
and,the,bad 1.0 0.000143348623853 1 0 1
and,the,auc 1.0 0.000143348623853 1 0 1
and,the,area 1.0 0.000143348623853 1 0 1
and,the,antithrombotic 1.0 0.000143348623853 1 0 1
and,the,and 1.0 0.000143348623853 1 0 1
and,that,the 1.0 0.000143348623853 1 0 1
and,that,increase 1.0 0.000143348623853 1 0 1
and,that,concomitant 1.0 0.000143348623853 1 0 1
and,terminal,half-life 1.0 0.000143348623853 1 0 1
and,tam,enhances 1.0 0.000143348623853 1 0 1
and,tachycardia,have 1.0 0.000143348623853 1 0 1
and,tablets,results 1.0 0.000143348623853 1 0 1
and,t3,in 1.0 0.000143348623853 1 0 1
and,synergistic,for 1.0 0.000143348623853 1 0 1
and,symptoms,suggestive 1.0 0.000143348623853 1 0 1
and,supplemental,in 1.0 0.000143348623853 1 0 1
and,sulfate,may 1.0 0.000143348623853 1 0 1
and,sudden,death 1.0 0.000143348623853 1 0 1
and,sucralfate,and 1.0 0.000143348623853 1 0 1
and,such,medicinal 1.0 0.000143348623853 1 0 1
and,substrates,drugs 1.0 0.000143348623853 1 0 1
and,subsequently,treated 1.0 0.000143348623853 1 0 1
and,subsalicylate,should 1.0 0.000143348623853 1 0 1
and,suboxone,should 1.0 0.000143348623853 1 0 1
and,strong,cyp3a4 1.0 0.000143348623853 1 0 1
and,stimulatory,effects 1.0 0.000143348623853 1 0 1
and,stimulate,egf- 1.0 0.000143348623853 1 0 1
and,special,care 1.0 0.000143348623853 1 0 1
and,somnolence,have 1.0 0.000143348623853 1 0 1
and,sometimes,prescribed 1.0 0.000143348623853 1 0 1
and,some,resulting 1.0 0.000143348623853 1 0 1
and,some,pronestyl 1.0 0.000143348623853 1 0 1
and,some,oxytocic 1.0 0.000143348623853 1 0 1
and,some,nsaids 1.0 0.000143348623853 1 0 1
and,sodium,plasma 1.0 0.000143348623853 1 0 1
and,sodium,it 1.0 0.000143348623853 1 0 1
and,sodium,excretion 1.0 0.000143348623853 1 0 1
and,sodium,colistimethate 1.0 0.000143348623853 1 0 1
and,sodium,colistemethate 1.0 0.000143348623853 1 0 1
and,sodium,citrate 1.0 0.000143348623853 1 0 1
and,sodium,bicarbonate 1.0 0.000143348623853 1 0 1
and,slight,decreases 1.0 0.000143348623853 1 0 1
and,sinus,medicines 1.0 0.000143348623853 1 0 1
and,signs,of 1.0 0.000143348623853 1 0 1
and,significantly,reduces 1.0 0.000143348623853 1 0 1
and,significant,increases 1.0 0.000143348623853 1 0 1
and,significant,increase 1.0 0.000143348623853 1 0 1
and,significant,decrease 1.0 0.000143348623853 1 0 1
and,sgpt,alt 1.0 0.000143348623853 1 0 1
and,severity,of 1.0 0.000143348623853 1 0 1
and,severe,rhabdomyolysis 1.0 0.000143348623853 1 0 1
and,serum,concentrations 1.0 0.000143348623853 1 0 1
and,serious,clinical 1.0 0.000143348623853 1 0 1
and,serial,measurement 1.0 0.000143348623853 1 0 1
and,secondary,enzymes 1.0 0.000143348623853 1 0 1
and,s-warfarin,and 1.0 0.000143348623853 1 0 1
and,s,d 1.0 0.000143348623853 1 0 1
and,risks,of 1.0 0.000143348623853 1 0 1
and,rises,in 1.0 0.000143348623853 1 0 1
and,reuptake,inhibitor 1.0 0.000143348623853 1 0 1
and,results,in 1.0 0.000143348623853 1 0 1
and,resulting,in 1.0 0.000143348623853 1 0 1
and,respectively,suggesting 1.0 0.000143348623853 1 0 1
and,respectively,on 1.0 0.000143348623853 1 0 1
and,respectively,compared 1.0 0.000143348623853 1 0 1
and,respectively,by 1.0 0.000143348623853 1 0 1
and,respectively,after 1.0 0.000143348623853 1 0 1
and,respectively,a 1.0 0.000143348623853 1 0 1
and,requiring,increased 1.0 0.000143348623853 1 0 1
and,require,that 1.0 0.000143348623853 1 0 1
and,renal,clearances 1.0 0.000143348623853 1 0 1
and,reduction,in 1.0 0.000143348623853 1 0 1
and,reducing,absorption 1.0 0.000143348623853 1 0 1
and,reduced,the 1.0 0.000143348623853 1 0 1
and,receptors,thus 1.0 0.000143348623853 1 0 1
and,reaction,time 1.0 0.000143348623853 1 0 1
and,reached,after 1.0 0.000143348623853 1 0 1
and,rats,suggest 1.0 0.000143348623853 1 0 1
and,range,from 1.0 0.000143348623853 1 0 1
and,raise,the 1.0 0.000143348623853 1 0 1
and,r-warfarin,a 1.0 0.000143348623853 1 0 1
and,pth,and 1.0 0.000143348623853 1 0 1
and,provide,close 1.0 0.000143348623853 1 0 1
and,prolonged,the 1.0 0.000143348623853 1 0 1
and,prolonged,by 1.0 0.000143348623853 1 0 1
and,proleukin,including 1.0 0.000143348623853 1 0 1
and,produces,an 1.0 0.000143348623853 1 0 1
and,potassium-sparing,on 1.0 0.000143348623853 1 0 1
and,potassium-sparing,including 1.0 0.000143348623853 1 0 1
and,potassium-depleting,agents 1.0 0.000143348623853 1 0 1
and,possibly,concomitant 1.0 0.000143348623853 1 0 1
and,possible,pharmacokinetic 1.0 0.000143348623853 1 0 1
and,plus,or 1.0 0.000143348623853 1 0 1
and,platelet,aggregation 1.0 0.000143348623853 1 0 1
and,plasma,mean 1.0 0.000143348623853 1 0 1
and,pharmacokinetic,results 1.0 0.000143348623853 1 0 1
and,persistent,inhibition 1.0 0.000143348623853 1 0 1
and,penthrane,has 1.0 0.000143348623853 1 0 1
and,partly,antagonized 1.0 0.000143348623853 1 0 1
and,para-aminobenzoic,acid 1.0 0.000143348623853 1 0 1
and,pancreatic,supplements 1.0 0.000143348623853 1 0 1
and,others,that 1.0 0.000143348623853 1 0 1
and,others,are 1.0 0.000143348623853 1 0 1
and,other,when 1.0 0.000143348623853 1 0 1
and,other,vasoconstrictor 1.0 0.000143348623853 1 0 1
and,other,substances 1.0 0.000143348623853 1 0 1
and,other,strong 1.0 0.000143348623853 1 0 1
and,other,statins 1.0 0.000143348623853 1 0 1
and,other,related 1.0 0.000143348623853 1 0 1
and,other,psychotropic 1.0 0.000143348623853 1 0 1
and,other,potent 1.0 0.000143348623853 1 0 1
and,other,pharmacokinetics 1.0 0.000143348623853 1 0 1
and,other,nonsteroidal 1.0 0.000143348623853 1 0 1
and,other,metabolized 1.0 0.000143348623853 1 0 1
and,other,medications 1.0 0.000143348623853 1 0 1
and,other,inhibitors 1.0 0.000143348623853 1 0 1
and,other,including 1.0 0.000143348623853 1 0 1
and,other,hydroxymethylglutaryl 1.0 0.000143348623853 1 0 1
and,other,ht1 1.0 0.000143348623853 1 0 1
and,other,hormonalmethods 1.0 0.000143348623853 1 0 1
and,other,drugs 1.0 0.000143348623853 1 0 1
and,other,certain 1.0 0.000143348623853 1 0 1
and,other,bronchodilators 1.0 0.000143348623853 1 0 1
and,ortho-novum,increased 1.0 0.000143348623853 1 0 1
and,orally,as 1.0 0.000143348623853 1 0 1
and,oral,solution 1.0 0.000143348623853 1 0 1
and,oral,markedly 1.0 0.000143348623853 1 0 1
and,oral,containing 1.0 0.000143348623853 1 0 1
and,oral,concomitant 1.0 0.000143348623853 1 0 1
and,oral,a 1.0 0.000143348623853 1 0 1
and,or,to 1.0 0.000143348623853 1 0 1
and,or,some 1.0 0.000143348623853 1 0 1
and,or,resulted 1.0 0.000143348623853 1 0 1
and,or,increased 1.0 0.000143348623853 1 0 1
and,or,impairing 1.0 0.000143348623853 1 0 1
and,or,hypotension 1.0 0.000143348623853 1 0 1
and,or,hypokalemia 1.0 0.000143348623853 1 0 1
and,or,frequency 1.0 0.000143348623853 1 0 1
and,or,elevated 1.0 0.000143348623853 1 0 1
and,or,diarrhea 1.0 0.000143348623853 1 0 1
and,or,are 1.0 0.000143348623853 1 0 1
and,or,aluminum-containing 1.0 0.000143348623853 1 0 1
and,or,a 1.0 0.000143348623853 1 0 1
and,one,mg 1.0 0.000143348623853 1 0 1
and,on,day 1.0 0.000143348623853 1 0 1
and,of,the 1.0 0.000143348623853 1 0 1
and,of,subjects 1.0 0.000143348623853 1 0 1
and,of,by 1.0 0.000143348623853 1 0 1
and,occurred,following 1.0 0.000143348623853 1 0 1
and,o-desacetylrifabutin,and 1.0 0.000143348623853 1 0 1
and,nuclear,matrix 1.0 0.000143348623853 1 0 1
and,nsaids,are 1.0 0.000143348623853 1 0 1
and,nsaids,affect 1.0 0.000143348623853 1 0 1
and,nose,may 1.0 0.000143348623853 1 0 1
and,normal,tissues 1.0 0.000143348623853 1 0 1
and,normal,subjects 1.0 0.000143348623853 1 0 1
and,norethindrone,coadministration 1.0 0.000143348623853 1 0 1
and,nonsteroidal,agents 1.0 0.000143348623853 1 0 1
and,non-steroidal,agents 1.0 0.000143348623853 1 0 1
and,non-selective,beta-adrenergic 1.0 0.000143348623853 1 0 1
and,non-,steroidal 1.0 0.000143348623853 1 0 1
and,nicotine-induced,release 1.0 0.000143348623853 1 0 1
and,ng,ml 1.0 0.000143348623853 1 0 1
and,n1,while 1.0 0.000143348623853 1 0 1
and,n,were 1.0 0.000143348623853 1 0 1
and,mycophenolate,mofetil 1.0 0.000143348623853 1 0 1
and,mumol,liter 1.0 0.000143348623853 1 0 1
and,motor,effects 1.0 0.000143348623853 1 0 1
and,more,prolonged 1.0 0.000143348623853 1 0 1
and,monitoring,of 1.0 0.000143348623853 1 0 1
and,molt-4,cells 1.0 0.000143348623853 1 0 1
and,moderate,cyp1a2 1.0 0.000143348623853 1 0 1
and,minimizes,this 1.0 0.000143348623853 1 0 1
and,min,for 1.0 0.000143348623853 1 0 1
and,might,increase 1.0 0.000143348623853 1 0 1
and,might,also 1.0 0.000143348623853 1 0 1
and,mg,twice 1.0 0.000143348623853 1 0 1
and,mg,three 1.0 0.000143348623853 1 0 1
and,mg,sodium 1.0 0.000143348623853 1 0 1
and,mg,separated 1.0 0.000143348623853 1 0 1
and,mg,q 1.0 0.000143348623853 1 0 1
and,mg,once 1.0 0.000143348623853 1 0 1
and,mg,initial 1.0 0.000143348623853 1 0 1
and,mg,experienced 1.0 0.000143348623853 1 0 1
and,mg,decreased 1.0 0.000143348623853 1 0 1
and,mg,bid 1.0 0.000143348623853 1 0 1
and,mg,administered 1.0 0.000143348623853 1 0 1
and,metabolite,concentrations 1.0 0.000143348623853 1 0 1
and,mepron,suspension 1.0 0.000143348623853 1 0 1
and,mental,status 1.0 0.000143348623853 1 0 1
and,medication,must 1.0 0.000143348623853 1 0 1
and,mean,t 1.0 0.000143348623853 1 0 1
and,mean,scores 1.0 0.000143348623853 1 0 1
and,mean,renal 1.0 0.000143348623853 1 0 1
and,mc,block 1.0 0.000143348623853 1 0 1
and,may,sensitize 1.0 0.000143348623853 1 0 1
and,may,regulate 1.0 0.000143348623853 1 0 1
and,may,potentiate 1.0 0.000143348623853 1 0 1
and,may,occur 1.0 0.000143348623853 1 0 1
and,may,necessitate 1.0 0.000143348623853 1 0 1
and,may,interfere 1.0 0.000143348623853 1 0 1
and,may,compete 1.0 0.000143348623853 1 0 1
and,may,antagonize 1.0 0.000143348623853 1 0 1
and,may,ameliorate 1.0 0.000143348623853 1 0 1
and,maximal,plasma 1.0 0.000143348623853 1 0 1
and,maintenance,doses 1.0 0.000143348623853 1 0 1
and,mac,minimum 1.0 0.000143348623853 1 0 1
and,maalox,tc 1.0 0.000143348623853 1 0 1
and,lower,in 1.0 0.000143348623853 1 0 1
and,low-dose,has 1.0 0.000143348623853 1 0 1
and,loss,of 1.0 0.000143348623853 1 0 1
and,longer,intervals 1.0 0.000143348623853 1 0 1
and,lodine,capsules 1.0 0.000143348623853 1 0 1
and,local,which 1.0 0.000143348623853 1 0 1
and,liver,is 1.0 0.000143348623853 1 0 1
and,live-attenuated,should 1.0 0.000143348623853 1 0 1
and,live,or 1.0 0.000143348623853 1 0 1
and,levo-dromoran,has 1.0 0.000143348623853 1 0 1
and,levels,were 1.0 0.000143348623853 1 0 1
and,lessened,physiologic 1.0 0.000143348623853 1 0 1
and,left,ventricular 1.0 0.000143348623853 1 0 1
and,lead,to 1.0 0.000143348623853 1 0 1
and,l-methionine,may 1.0 0.000143348623853 1 0 1
and,l-lysine,may 1.0 0.000143348623853 1 0 1
and,iv,is 1.0 0.000143348623853 1 0 1
and,iv,attenuate 1.0 0.000143348623853 1 0 1
and,its,toxicity 1.0 0.000143348623853 1 0 1
and,its,synergism 1.0 0.000143348623853 1 0 1
and,its,dosage 1.0 0.000143348623853 1 0 1
and,its,derivatives 1.0 0.000143348623853 1 0 1
and,is,unknown 1.0 0.000143348623853 1 0 1
and,is,to 1.0 0.000143348623853 1 0 1
and,is,therefore 1.0 0.000143348623853 1 0 1
and,is,generally 1.0 0.000143348623853 1 0 1
and,is,derived 1.0 0.000143348623853 1 0 1
and,is,contraindicated 1.0 0.000143348623853 1 0 1
and,is,accelerated 1.0 0.000143348623853 1 0 1
and,irrational,behavior 1.0 0.000143348623853 1 0 1
and,intravenously,administered 1.0 0.000143348623853 1 0 1
and,intravenous,unless 1.0 0.000143348623853 1 0 1
and,intravenous,may 1.0 0.000143348623853 1 0 1
and,intravenous,has 1.0 0.000143348623853 1 0 1
and,international,normalized 1.0 0.000143348623853 1 0 1
and,interfere,with 1.0 0.000143348623853 1 0 1
and,interact,pharmacologically 1.0 0.000143348623853 1 0 1
and,inotropic,such 1.0 0.000143348623853 1 0 1
and,inhibits,the 1.0 0.000143348623853 1 0 1
and,infusion,rate 1.0 0.000143348623853 1 0 1
and,inflammatory,disorders 1.0 0.000143348623853 1 0 1
and,inducers,of 1.0 0.000143348623853 1 0 1
and,induce,metabolism 1.0 0.000143348623853 1 0 1
and,indocin,should 1.0 0.000143348623853 1 0 1
and,individual,glucose 1.0 0.000143348623853 1 0 1
and,increasing,steady-state 1.0 0.000143348623853 1 0 1
and,increasing,blood 1.0 0.000143348623853 1 0 1
and,increases,substantially 1.0 0.000143348623853 1 0 1
and,increased,risk 1.0 0.000143348623853 1 0 1
and,increased,plasma 1.0 0.000143348623853 1 0 1
and,increase,of 1.0 0.000143348623853 1 0 1
and,increase,its 1.0 0.000143348623853 1 0 1
and,increase,in 1.0 0.000143348623853 1 0 1
and,incoordination,have 1.0 0.000143348623853 1 0 1
and,incoordination,following 1.0 0.000143348623853 1 0 1
and,in,females 1.0 0.000143348623853 1 0 1
and,in,clinical 1.0 0.000143348623853 1 0 1
and,in,absorption 1.0 0.000143348623853 1 0 1
and,implantable,forms 1.0 0.000143348623853 1 0 1
and,implantable,contraceptives 1.0 0.000143348623853 1 0 1
and,immediately,beginning 1.0 0.000143348623853 1 0 1
and,hypoglycemic,agents 1.0 0.000143348623853 1 0 1
and,hypoglycemia,have 1.0 0.000143348623853 1 0 1
and,hydroxy-1,on 1.0 0.000143348623853 1 0 1
and,hydroxides,be 1.0 0.000143348623853 1 0 1
and,hydroxide,reduce 1.0 0.000143348623853 1 0 1
and,human,growth 1.0 0.000143348623853 1 0 1
and,hours,were 1.0 0.000143348623853 1 0 1
and,hour,blood 1.0 0.000143348623853 1 0 1
and,hmg-coa,reductase 1.0 0.000143348623853 1 0 1
and,hivid,has 1.0 0.000143348623853 1 0 1
and,higher,doses 1.0 0.000143348623853 1 0 1
and,high-estradiol,treated 1.0 0.000143348623853 1 0 1
and,high,blood 1.0 0.000143348623853 1 0 1
and,herbs,such 1.0 0.000143348623853 1 0 1
and,hepatic,lipid 1.0 0.000143348623853 1 0 1
and,heparin,the 1.0 0.000143348623853 1 0 1
and,heavy,intake 1.0 0.000143348623853 1 0 1
and,hearing,impairment 1.0 0.000143348623853 1 0 1
and,hc1,concomitant 1.0 0.000143348623853 1 0 1
and,have,the 1.0 0.000143348623853 1 0 1
and,have,in 1.0 0.000143348623853 1 0 1
and,has,an 1.0 0.000143348623853 1 0 1
and,had,returned 1.0 0.000143348623853 1 0 1
and,h2,blockers 1.0 0.000143348623853 1 0 1
and,greater,degrees 1.0 0.000143348623853 1 0 1
and,general,have 1.0 0.000143348623853 1 0 1
and,g,resulted 1.0 0.000143348623853 1 0 1
and,g,kg 1.0 0.000143348623853 1 0 1
and,frova,within 1.0 0.000143348623853 1 0 1
and,frequently,thereafter 1.0 0.000143348623853 1 0 1
and,frequently,enough 1.0 0.000143348623853 1 0 1
and,formulations,containing 1.0 0.000143348623853 1 0 1
and,for,several 1.0 0.000143348623853 1 0 1
and,for,injection 1.0 0.000143348623853 1 0 1
and,for,hydroxy-iso 1.0 0.000143348623853 1 0 1
and,for,cmax 1.0 0.000143348623853 1 0 1
and,foods,fortified 1.0 0.000143348623853 1 0 1
and,fold,respectively 1.0 0.000143348623853 1 0 1
and,fold,on 1.0 0.000143348623853 1 0 1
and,fluvoxamine,tablets 1.0 0.000143348623853 1 0 1
and,fentanyl,in 1.0 0.000143348623853 1 0 1
and,fbs,followed 1.0 0.000143348623853 1 0 1
and,extent,auc 1.0 0.000143348623853 1 0 1
and,extends,its 1.0 0.000143348623853 1 0 1
and,extended,release 1.0 0.000143348623853 1 0 1
and,extended,a 1.0 0.000143348623853 1 0 1
and,exposure,auc 1.0 0.000143348623853 1 0 1
and,excretion,in 1.0 0.000143348623853 1 0 1
and,evidence,of 1.0 0.000143348623853 1 0 1
and,even,in 1.0 0.000143348623853 1 0 1
and,ethanol,cause 1.0 0.000143348623853 1 0 1
and,ethacrynic,acid 1.0 0.000143348623853 1 0 1
and,estrogen-containing,compounds 1.0 0.000143348623853 1 0 1
and,epidural,include 1.0 0.000143348623853 1 0 1
and,enhance,activity 1.0 0.000143348623853 1 0 1
and,electrolyte,disturbances 1.0 0.000143348623853 1 0 1
and,effect,relationship 1.0 0.000143348623853 1 0 1
and,dyspnea,concomitant 1.0 0.000143348623853 1 0 1
and,dpcpx-induced,anxiogenic 1.0 0.000143348623853 1 0 1
and,downward,dose 1.0 0.000143348623853 1 0 1
and,dose,should 1.0 0.000143348623853 1 0 1
and,dose,adjustment 1.0 0.000143348623853 1 0 1
and,dosage,should 1.0 0.000143348623853 1 0 1
and,dosage,levels 1.0 0.000143348623853 1 0 1
and,diuretics,concomitant 1.0 0.000143348623853 1 0 1
and,displacement,of 1.0 0.000143348623853 1 0 1
and,discontinuing,hydrochloride 1.0 0.000143348623853 1 0 1
and,dilantin,phenobarbital 1.0 0.000143348623853 1 0 1
and,digestive,enzyme 1.0 0.000143348623853 1 0 1
and,diarrhea,would 1.0 0.000143348623853 1 0 1
and,diamond,patient 1.0 0.000143348623853 1 0 1
and,dehydration,have 1.0 0.000143348623853 1 0 1
and,decreased,with 1.0 0.000143348623853 1 0 1
and,decreased,respectively 1.0 0.000143348623853 1 0 1
and,decreased,measured 1.0 0.000143348623853 1 0 1
and,decreased,hearing 1.0 0.000143348623853 1 0 1
and,decreased,have 1.0 0.000143348623853 1 0 1
and,decreased,by 1.0 0.000143348623853 1 0 1
and,decrease,metabolism 1.0 0.000143348623853 1 0 1
and,decrease,by 1.0 0.000143348623853 1 0 1
and,decrease,absorption 1.0 0.000143348623853 1 0 1
and,death,associated 1.0 0.000143348623853 1 0 1
and,day,of 1.0 0.000143348623853 1 0 1
and,cystic,fluid 1.0 0.000143348623853 1 0 1
and,cyp3a4,in 1.0 0.000143348623853 1 0 1
and,cyp3a4,cimetidine 1.0 0.000143348623853 1 0 1
and,current,responses 1.0 0.000143348623853 1 0 1
and,css,max 1.0 0.000143348623853 1 0 1
and,creatinine,clearance 1.0 0.000143348623853 1 0 1
and,creatinine,an 1.0 0.000143348623853 1 0 1
and,corticotropin,acth 1.0 0.000143348623853 1 0 1
and,cortex,that 1.0 0.000143348623853 1 0 1
and,coreg,slow 1.0 0.000143348623853 1 0 1
and,containing,or 1.0 0.000143348623853 1 0 1
and,containing,maalox 1.0 0.000143348623853 1 0 1
and,confusional,states 1.0 0.000143348623853 1 0 1
and,confusion,extrapyramidal 1.0 0.000143348623853 1 0 1
and,concurrently,the 1.0 0.000143348623853 1 0 1
and,concurrently,plasma 1.0 0.000143348623853 1 0 1
and,concurrently,and 1.0 0.000143348623853 1 0 1
and,concomitantly,with 1.0 0.000143348623853 1 0 1
and,concomitantly,toxicity 1.0 0.000143348623853 1 0 1
and,concomitantly,should 1.0 0.000143348623853 1 0 1
and,concomitant,serotonergic 1.0 0.000143348623853 1 0 1
and,concentrations,should 1.0 0.000143348623853 1 0 1
and,compromise,their 1.0 0.000143348623853 1 0 1
and,complications,compared 1.0 0.000143348623853 1 0 1
and,completely,depressed 1.0 0.000143348623853 1 0 1
and,coma,have 1.0 0.000143348623853 1 0 1
and,coly-mycin,m 1.0 0.000143348623853 1 0 1
and,cohort,design 1.0 0.000143348623853 1 0 1
and,cmax,increased 1.0 0.000143348623853 1 0 1
and,clinical,pharmacology 1.0 0.000143348623853 1 0 1
and,classes,or 1.0 0.000143348623853 1 0 1
and,class,iii 1.0 0.000143348623853 1 0 1
and,citrate,elevations 1.0 0.000143348623853 1 0 1
and,cholestytamine,and 1.0 0.000143348623853 1 0 1
and,chloride,in 1.0 0.000143348623853 1 0 1
and,chloride,excretion 1.0 0.000143348623853 1 0 1
and,charcoal,administration 1.0 0.000143348623853 1 0 1
and,certainly,during 1.0 0.000143348623853 1 0 1
and,certain,nonsteroidal 1.0 0.000143348623853 1 0 1
and,cerebyx,dosage 1.0 0.000143348623853 1 0 1
and,celexa,in 1.0 0.000143348623853 1 0 1
and,cause,increased 1.0 0.000143348623853 1 0 1
and,cardiovascular,effects 1.0 0.000143348623853 1 0 1
and,cardiac,transplant 1.0 0.000143348623853 1 0 1
and,cardiac,dysrhythmias 1.0 0.000143348623853 1 0 1
and,carbonic,anhydrase 1.0 0.000143348623853 1 0 1
and,carbonate,or 1.0 0.000143348623853 1 0 1
and,can,suppress 1.0 0.000143348623853 1 0 1
and,can,reduce 1.0 0.000143348623853 1 0 1
and,can,produce 1.0 0.000143348623853 1 0 1
and,can,inhibit 1.0 0.000143348623853 1 0 1
and,can,increase 1.0 0.000143348623853 1 0 1
and,can,decrease 1.0 0.000143348623853 1 0 1
and,can,cause 1.0 0.000143348623853 1 0 1
and,calcium-rich,foods 1.0 0.000143348623853 1 0 1
and,by,inhibition 1.0 0.000143348623853 1 0 1
and,by,inhibiting 1.0 0.000143348623853 1 0 1
and,by,decreasing 1.0 0.000143348623853 1 0 1
and,by,a 1.0 0.000143348623853 1 0 1
and,butyrophenone,classes 1.0 0.000143348623853 1 0 1
and,but,may 1.0 0.000143348623853 1 0 1
and,buspirone,hcl 1.0 0.000143348623853 1 0 1
and,brovana,may 1.0 0.000143348623853 1 0 1
and,brain,was 1.0 0.000143348623853 1 0 1
and,brain,edema 1.0 0.000143348623853 1 0 1
and,bound,by 1.0 0.000143348623853 1 0 1
and,bone,and 1.0 0.000143348623853 1 0 1
and,blurred,vision 1.0 0.000143348623853 1 0 1
and,bioavailability,of 1.0 0.000143348623853 1 0 1
and,bezalip,retard 1.0 0.000143348623853 1 0 1
and,beta-adrenergic,blocking 1.0 0.000143348623853 1 0 1
and,behavioral,responsiveness 1.0 0.000143348623853 1 0 1
and,because,renal 1.0 0.000143348623853 1 0 1
and,because,increases 1.0 0.000143348623853 1 0 1
and,axert,within 1.0 0.000143348623853 1 0 1
and,av,block 1.0 0.000143348623853 1 0 1
and,automaticity,as 1.0 0.000143348623853 1 0 1
and,auc,increased 1.0 0.000143348623853 1 0 1
and,auc,from 1.0 0.000143348623853 1 0 1
and,auc,by 1.0 0.000143348623853 1 0 1
and,auc,a 1.0 0.000143348623853 1 0 1
and,at,periodic 1.0 0.000143348623853 1 0 1
and,at,mg 1.0 0.000143348623853 1 0 1
and,ast,when 1.0 0.000143348623853 1 0 1
and,associated,dental 1.0 0.000143348623853 1 0 1
and,as,much 1.0 0.000143348623853 1 0 1
and,as,compared 1.0 0.000143348623853 1 0 1
and,arthralgia,adverse 1.0 0.000143348623853 1 0 1
and,area-under,the-curve 1.0 0.000143348623853 1 0 1
and,are,obtained 1.0 0.000143348623853 1 0 1
and,are,co 1.0 0.000143348623853 1 0 1
and,aprepitant,when 1.0 0.000143348623853 1 0 1
and,appropriate,dose 1.0 0.000143348623853 1 0 1
and,antiparkinsonian,agents 1.0 0.000143348623853 1 0 1
and,antineoplastic,agents 1.0 0.000143348623853 1 0 1
and,antidotal,properties 1.0 0.000143348623853 1 0 1
and,anticoagulants,increased 1.0 0.000143348623853 1 0 1
and,anti-depressants,could 1.0 0.000143348623853 1 0 1
and,antagonists,which 1.0 0.000143348623853 1 0 1
and,antagonists,may 1.0 0.000143348623853 1 0 1
and,antagonism,in 1.0 0.000143348623853 1 0 1
and,antacids,and 1.0 0.000143348623853 1 0 1
and,another,tnf-blocking 1.0 0.000143348623853 1 0 1
and,and,type 1.0 0.000143348623853 1 0 1
and,and,thus 1.0 0.000143348623853 1 0 1
and,and,reduces 1.0 0.000143348623853 1 0 1
and,and,possibly 1.0 0.000143348623853 1 0 1
and,and,other 1.0 0.000143348623853 1 0 1
and,and,higher 1.0 0.000143348623853 1 0 1
and,and,class 1.0 0.000143348623853 1 0 1
and,and,at 1.0 0.000143348623853 1 0 1
and,and,a 1.0 0.000143348623853 1 0 1
and,an,oral 1.0 0.000143348623853 1 0 1
and,an,interleukin-1 1.0 0.000143348623853 1 0 1
and,an,deficiency 1.0 0.000143348623853 1 0 1
and,an,decrease 1.0 0.000143348623853 1 0 1
and,an,are 1.0 0.000143348623853 1 0 1
and,amphotericin,b 1.0 0.000143348623853 1 0 1
and,aminoglycosides,drugs 1.0 0.000143348623853 1 0 1
and,amantadine,limited 1.0 0.000143348623853 1 0 1
and,aluminum-containing,administered 1.0 0.000143348623853 1 0 1
and,alternative,therapy 1.0 0.000143348623853 1 0 1
and,alternative,hypoglycemic 1.0 0.000143348623853 1 0 1
and,also,increased 1.0 0.000143348623853 1 0 1
and,alpha-adrenergic,stimulants 1.0 0.000143348623853 1 0 1
and,agents,with 1.0 0.000143348623853 1 0 1
and,agents,other 1.0 0.000143348623853 1 0 1
and,agents,of 1.0 0.000143348623853 1 0 1
and,agents,may 1.0 0.000143348623853 1 0 1
and,agents,is 1.0 0.000143348623853 1 0 1
and,agents,for 1.0 0.000143348623853 1 0 1
and,addicts,were 1.0 0.000143348623853 1 0 1
and,achieve,the 1.0 0.000143348623853 1 0 1
and,absorption,of 1.0 0.000143348623853 1 0 1
and,about,a 1.0 0.000143348623853 1 0 1
and,abciximab,may 1.0 0.000143348623853 1 0 1
and,a,together 1.0 0.000143348623853 1 0 1
and,a,that 1.0 0.000143348623853 1 0 1
and,a,supersensitivity 1.0 0.000143348623853 1 0 1
and,a,subsequent 1.0 0.000143348623853 1 0 1
and,a,slight 1.0 0.000143348623853 1 0 1
and,a,single 1.0 0.000143348623853 1 0 1
and,a,simultaneous 1.0 0.000143348623853 1 0 1
and,a,should 1.0 0.000143348623853 1 0 1
and,a,penicillin-type 1.0 0.000143348623853 1 0 1
and,a,molecular 1.0 0.000143348623853 1 0 1
and,a,mechanism 1.0 0.000143348623853 1 0 1
and,a,lesser 1.0 0.000143348623853 1 0 1
and,a,known 1.0 0.000143348623853 1 0 1
and,a,high 1.0 0.000143348623853 1 0 1
and,a,fluoroquinolone 1.0 0.000143348623853 1 0 1
and,a,do 1.0 0.000143348623853 1 0 1
and,a,delay 1.0 0.000143348623853 1 0 1
and,a,cyp2c19 1.0 0.000143348623853 1 0 1
and,a,concomitantly 1.0 0.000143348623853 1 0 1
and,a,cause-and 1.0 0.000143348623853 1 0 1
anaphylactic,shock,can 1.0 0.000143348623853 1 0 1
anaphylactic,reaction,although 1.0 0.000143348623853 1 0 1
analyses,of,patient 1.0 0.000143348623853 1 0 1
analogues,didanosine,co-administration 1.0 0.000143348623853 1 0 1
analgesics,agonist,antagonist 1.0 0.000143348623853 1 0 1
analgesic,effect,of 1.0 0.000143348623853 1 0 1
analgesia,must,be 1.0 0.000143348623853 1 0 1
anakinra,concurrent,administration 1.0 0.000143348623853 1 0 1
anagrelide,alone,had 1.0 0.000143348623853 1 0 1
anafranil,to,patients 1.0 0.000143348623853 1 0 1
anafranil,should,not 1.0 0.000143348623853 1 0 1
anafranil,is,highly 1.0 0.000143348623853 1 0 1
anafranil,is,administered 1.0 0.000143348623853 1 0 1
anaesthetised,with,fluothane 1.0 0.000143348623853 1 0 1
anabolic,steroids,chloral 1.0 0.000143348623853 1 0 1
anabolic,hormones,and 1.0 0.000143348623853 1 0 1
an,with,beta-lactamtype 1.0 0.000143348623853 1 0 1
an,unusually,high 1.0 0.000143348623853 1 0 1
an,unsatisfactory,lipid 1.0 0.000143348623853 1 0 1
an,oral,produced 1.0 0.000143348623853 1 0 1
an,oral,increased 1.0 0.000143348623853 1 0 1
an,oral,has 1.0 0.000143348623853 1 0 1
an,oral,antagonist 1.0 0.000143348623853 1 0 1
an,oral,and 1.0 0.000143348623853 1 0 1
an,opposite,way 1.0 0.000143348623853 1 0 1
an,nsaid,or 1.0 0.000143348623853 1 0 1
an,may,be 1.0 0.000143348623853 1 0 1
an,isoform,also 1.0 0.000143348623853 1 0 1
an,intubating,dose 1.0 0.000143348623853 1 0 1
an,intravenous,iv 1.0 0.000143348623853 1 0 1
an,intravenous,injection 1.0 0.000143348623853 1 0 1
an,interaction,will 1.0 0.000143348623853 1 0 1
an,increased,severity 1.0 0.000143348623853 1 0 1
an,increased,prothrombin 1.0 0.000143348623853 1 0 1
an,increased,plasma 1.0 0.000143348623853 1 0 1
an,increased,peak 1.0 0.000143348623853 1 0 1
an,inadequate,method 1.0 0.000143348623853 1 0 1
an,hydroxide,hydroxide 1.0 0.000143348623853 1 0 1
an,hydroxide,containing 1.0 0.000143348623853 1 0 1
an,hmg-coa,reductase 1.0 0.000143348623853 1 0 1
an,experimental,soft-gelatin 1.0 0.000143348623853 1 0 1
an,enhancement,effect 1.0 0.000143348623853 1 0 1
an,endogenous,marker 1.0 0.000143348623853 1 0 1
an,encephalopathic,syndrome 1.0 0.000143348623853 1 0 1
an,emergency,situation 1.0 0.000143348623853 1 0 1
an,eg,valproic 1.0 0.000143348623853 1 0 1
an,deficiency,can 1.0 0.000143348623853 1 0 1
an,containing,gram 1.0 0.000143348623853 1 0 1
an,can,not 1.0 0.000143348623853 1 0 1
an,blood,coagulation 1.0 0.000143348623853 1 0 1
an,average,increase 1.0 0.000143348623853 1 0 1
an,average,and 1.0 0.000143348623853 1 0 1
an,attempt,to 1.0 0.000143348623853 1 0 1
an,are,used 1.0 0.000143348623853 1 0 1
an,approximately,increase 1.0 0.000143348623853 1 0 1
an,approximately,decrease 1.0 0.000143348623853 1 0 1
an,approximate,reduction 1.0 0.000143348623853 1 0 1
an,appropriate,adjustment 1.0 0.000143348623853 1 0 1
an,antipsychotic,eg 1.0 0.000143348623853 1 0 1
an,antiparkinsonian,drug 1.0 0.000143348623853 1 0 1
an,anionic-binding,has 1.0 0.000143348623853 1 0 1
an,animal,model 1.0 0.000143348623853 1 0 1
an,angiotensin-converting,enzyme 1.0 0.000143348623853 1 0 1
an,and,oral 1.0 0.000143348623853 1 0 1
an,and,containing 1.0 0.000143348623853 1 0 1
an,and,a 1.0 0.000143348623853 1 0 1
an,analysis,of 1.0 0.000143348623853 1 0 1
an,altered,distribution 1.0 0.000143348623853 1 0 1
an,agent,with 1.0 0.000143348623853 1 0 1
an,adolescent,with 1.0 0.000143348623853 1 0 1
an,additive,interaction 1.0 0.000143348623853 1 0 1
an,additive,hypotensive 1.0 0.000143348623853 1 0 1
an,additive,cns 1.0 0.000143348623853 1 0 1
an,additional,effect 1.0 0.000143348623853 1 0 1
an,a2-selective,agonist 1.0 0.000143348623853 1 0 1
amyl,nitrite,after 1.0 0.000143348623853 1 0 1
amprenavir,significantly,increased 1.0 0.000143348623853 1 0 1
amprenavir,significantly,decreases 1.0 0.000143348623853 1 0 1
amprenavir,and,low-dose 1.0 0.000143348623853 1 0 1
amprenavir,and,have 1.0 0.000143348623853 1 0 1
amprenavir,and,and 1.0 0.000143348623853 1 0 1
amplifies,the,therapeutic 1.0 0.000143348623853 1 0 1
ampicillin,in,a 1.0 0.000143348623853 1 0 1
ampicillin,amoxicillin,an 1.0 0.000143348623853 1 0 1
amphotericin,foscarnet,and 1.0 0.000143348623853 1 0 1
amphotericin,b-,induced 1.0 0.000143348623853 1 0 1
amphotericin,b,patients 1.0 0.000143348623853 1 0 1
amphotericin,b,intravenous 1.0 0.000143348623853 1 0 1
amphotericin,b,injection 1.0 0.000143348623853 1 0 1
amphotericin,b,has 1.0 0.000143348623853 1 0 1
amphotericin,b,antineoplastic 1.0 0.000143348623853 1 0 1
amphetamines,may,decrease 1.0 0.000143348623853 1 0 1
amoxicillin,an,increase 1.0 0.000143348623853 1 0 1
amounts,may,counteract 1.0 0.000143348623853 1 0 1
amount,of,required 1.0 0.000143348623853 1 0 1
amount,of,lanoxin 1.0 0.000143348623853 1 0 1
amount,of,hydroxylated 1.0 0.000143348623853 1 0 1
amount,of,either 1.0 0.000143348623853 1 0 1
among,the,volunteers 1.0 0.000143348623853 1 0 1
among,the,risk 1.0 0.000143348623853 1 0 1
among,patients,with 1.0 0.000143348623853 1 0 1
among,patients,receiving 1.0 0.000143348623853 1 0 1
among,patients,concurrently 1.0 0.000143348623853 1 0 1
amitriptyline,in,combination 1.0 0.000143348623853 1 0 1
amitriptyline,concurrent,administration 1.0 0.000143348623853 1 0 1
amiodarone,or,verapamil 1.0 0.000143348623853 1 0 1
amiodarone,is,known 1.0 0.000143348623853 1 0 1
aminosalicylic,acid,nonsteroidal 1.0 0.000143348623853 1 0 1
aminosalicylic,acid,higher 1.0 0.000143348623853 1 0 1
aminosalicylic,acid,anabolic 1.0 0.000143348623853 1 0 1
aminoglycosides,the,mixing 1.0 0.000143348623853 1 0 1
aminoglycosides,drugs,such 1.0 0.000143348623853 1 0 1
aminoglycoside,are,also 1.0 0.000143348623853 1 0 1
aminoglutethimide,may,increase 1.0 0.000143348623853 1 0 1
aminoglutethimide,may,diminish 1.0 0.000143348623853 1 0 1
aminoglutethimide,diminishes,the 1.0 0.000143348623853 1 0 1
aminoglutethimide,aminoglutethimide,may 1.0 0.000143348623853 1 0 1
amines,may,reduce 1.0 0.000143348623853 1 0 1
amines,have,been 1.0 0.000143348623853 1 0 1
amine,since,it 1.0 0.000143348623853 1 0 1
amide-type,local,since 1.0 0.000143348623853 1 0 1
ameliorate,increased,intestinal 1.0 0.000143348623853 1 0 1
amantadine,limited,clinical 1.0 0.000143348623853 1 0 1
amantadine,and,maois 1.0 0.000143348623853 1 0 1
alveolar,concentration,may 1.0 0.000143348623853 1 0 1
alveolar,concentration,is 1.0 0.000143348623853 1 0 1
aluminum-containing,products,containing 1.0 0.000143348623853 1 0 1
aluminum-containing,administered,concomitantly 1.0 0.000143348623853 1 0 1
aluminum-,or,magnesium-containing 1.0 0.000143348623853 1 0 1
altretamines,half-life,and 1.0 0.000143348623853 1 0 1
although,trough,plasma 1.0 0.000143348623853 1 0 1
although,this,interaction 1.0 0.000143348623853 1 0 1
although,this,effect 1.0 0.000143348623853 1 0 1
although,they,do 1.0 0.000143348623853 1 0 1
although,these,results 1.0 0.000143348623853 1 0 1
although,there,are 1.0 0.000143348623853 1 0 1
although,theoretically,coadministration 1.0 0.000143348623853 1 0 1
although,the,results 1.0 0.000143348623853 1 0 1
although,the,mechanism 1.0 0.000143348623853 1 0 1
although,the,magnitude 1.0 0.000143348623853 1 0 1
although,the,interactions 1.0 0.000143348623853 1 0 1
although,the,interaction 1.0 0.000143348623853 1 0 1
although,the,clearance 1.0 0.000143348623853 1 0 1
although,specific,studies 1.0 0.000143348623853 1 0 1
although,romazicon,exerts 1.0 0.000143348623853 1 0 1
although,overall,exposure 1.0 0.000143348623853 1 0 1
although,not,reported 1.0 0.000143348623853 1 0 1
although,not,observed 1.0 0.000143348623853 1 0 1
although,no,studies 1.0 0.000143348623853 1 0 1
although,no,specific 1.0 0.000143348623853 1 0 1
although,no,interaction 1.0 0.000143348623853 1 0 1
although,neither,nor 1.0 0.000143348623853 1 0 1
although,may,increase 1.0 0.000143348623853 1 0 1
although,lexapro,did 1.0 0.000143348623853 1 0 1
although,it,significantly 1.0 0.000143348623853 1 0 1
although,ipratropium,bromide 1.0 0.000143348623853 1 0 1
although,in,vivo 1.0 0.000143348623853 1 0 1
although,have,been 1.0 0.000143348623853 1 0 1
although,has,a 1.0 0.000143348623853 1 0 1
although,did,augment 1.0 0.000143348623853 1 0 1
although,concomitant,use 1.0 0.000143348623853 1 0 1
although,betagan,used 1.0 0.000143348623853 1 0 1
although,beta-adrenergic,blockers 1.0 0.000143348623853 1 0 1
although,acid-base,and 1.0 0.000143348623853 1 0 1
although,a,dose 1.0 0.000143348623853 1 0 1
although,a,day 1.0 0.000143348623853 1 0 1
although,a,causal 1.0 0.000143348623853 1 0 1
alternatives,to,as 1.0 0.000143348623853 1 0 1
alternative,or,back-up 1.0 0.000143348623853 1 0 1
alternative,hypoglycemic,agents 1.0 0.000143348623853 1 0 1
alternate-day,administration,of 1.0 0.000143348623853 1 0 1
alternate,sequence,ie 1.0 0.000143348623853 1 0 1
altered,serum,levels 1.0 0.000143348623853 1 0 1
altered,distribution,in 1.0 0.000143348623853 1 0 1
altered,decrease,in 1.0 0.000143348623853 1 0 1
altered,consciousness,caused 1.0 0.000143348623853 1 0 1
altered,coagulation,parameters 1.0 0.000143348623853 1 0 1
altered,by,gleevec 1.0 0.000143348623853 1 0 1
altered,by,concomitant 1.0 0.000143348623853 1 0 1
alterations,of,the 1.0 0.000143348623853 1 0 1
alterations,in,their 1.0 0.000143348623853 1 0 1
alterations,in,pharmacokinetics 1.0 0.000143348623853 1 0 1
alterations,in,lipid 1.0 0.000143348623853 1 0 1
alterations,caused,by 1.0 0.000143348623853 1 0 1
alteration,of,prothrombin 1.0 0.000143348623853 1 0 1
alteration,in,steady-state 1.0 0.000143348623853 1 0 1
alter,the,concentrations 1.0 0.000143348623853 1 0 1
alter,the,biological 1.0 0.000143348623853 1 0 1
alter,platelet,function 1.0 0.000143348623853 1 0 1
alter,plasma,concentrations 1.0 0.000143348623853 1 0 1
alter,gastrointestinal,motility 1.0 0.000143348623853 1 0 1
alter,cardiac,conduction 1.0 0.000143348623853 1 0 1
alter,a,diabetic 1.0 0.000143348623853 1 0 1
alt,in,a 1.0 0.000143348623853 1 0 1
alt,and,ast 1.0 0.000143348623853 1 0 1
also,using,a 1.0 0.000143348623853 1 0 1
also,used,it 1.0 0.000143348623853 1 0 1
also,to,an 1.0 0.000143348623853 1 0 1
also,taking,the 1.0 0.000143348623853 1 0 1
also,significantly,decreased 1.0 0.000143348623853 1 0 1
also,should,be 1.0 0.000143348623853 1 0 1
also,see,a 1.0 0.000143348623853 1 0 1
also,result,i 1.0 0.000143348623853 1 0 1
also,produces,a 1.0 0.000143348623853 1 0 1
also,potentiate,the 1.0 0.000143348623853 1 0 1
also,not,be 1.0 0.000143348623853 1 0 1
also,markedly,inhibits 1.0 0.000143348623853 1 0 1
also,likely,to 1.0 0.000143348623853 1 0 1
also,interfere,with 1.0 0.000143348623853 1 0 1
also,inhibited,insp 1.0 0.000143348623853 1 0 1
also,increased,fold 1.0 0.000143348623853 1 0 1
also,higher,when 1.0 0.000143348623853 1 0 1
also,have,an 1.0 0.000143348623853 1 0 1
also,due,to 1.0 0.000143348623853 1 0 1
also,contribute,to 1.0 0.000143348623853 1 0 1
also,concomitant,administration 1.0 0.000143348623853 1 0 1
also,bleeding,and 1.0 0.000143348623853 1 0 1
also,be,monitored 1.0 0.000143348623853 1 0 1
also,be,expected 1.0 0.000143348623853 1 0 1
also,be,approached 1.0 0.000143348623853 1 0 1
also,appeared,to 1.0 0.000143348623853 1 0 1
also,adversely,affect 1.0 0.000143348623853 1 0 1
also,additive,to 1.0 0.000143348623853 1 0 1
already,receiving,there 1.0 0.000143348623853 1 0 1
already,receiving,prothrombin 1.0 0.000143348623853 1 0 1
already,accumulated,in 1.0 0.000143348623853 1 0 1
alprazolam,when,maleate 1.0 0.000143348623853 1 0 1
alprazolam,caution,is 1.0 0.000143348623853 1 0 1
alphagan,p,the 1.0 0.000143348623853 1 0 1
alphagan,p,in 1.0 0.000143348623853 1 0 1
alpha-blockers,when,vardenafil 1.0 0.000143348623853 1 0 1
alpha-adrenergic,stimulants,including 1.0 0.000143348623853 1 0 1
along,with,either 1.0 0.000143348623853 1 0 1
alone,was,found 1.0 0.000143348623853 1 0 1
alone,they,modify 1.0 0.000143348623853 1 0 1
alone,the,possible 1.0 0.000143348623853 1 0 1
alone,suggesting,that 1.0 0.000143348623853 1 0 1
alone,has,little 1.0 0.000143348623853 1 0 1
alone,can,inhibit 1.0 0.000143348623853 1 0 1
alone,because,may 1.0 0.000143348623853 1 0 1
alone,auc,increased 1.0 0.000143348623853 1 0 1
alone,at,recommended 1.0 0.000143348623853 1 0 1
alone,and,subsequently 1.0 0.000143348623853 1 0 1
alone,and,ng 1.0 0.000143348623853 1 0 1
alone,and,concomitantly 1.0 0.000143348623853 1 0 1
alone,and,because 1.0 0.000143348623853 1 0 1
almost,fold,lower 1.0 0.000143348623853 1 0 1
allows,to,open 1.0 0.000143348623853 1 0 1
allowed,before,starting 1.0 0.000143348623853 1 0 1
allopurinol,the,principal 1.0 0.000143348623853 1 0 1
allopurinol,the,auc 1.0 0.000143348623853 1 0 1
allopurinol,inhibits,the 1.0 0.000143348623853 1 0 1
allium,sativum,and 1.0 0.000143348623853 1 0 1
allergy,cold,and 1.0 0.000143348623853 1 0 1
allergic,reaction,and 1.0 0.000143348623853 1 0 1
allegra,should,not 1.0 0.000143348623853 1 0 1
all,with,the 1.0 0.000143348623853 1 0 1
all,when,potent 1.0 0.000143348623853 1 0 1
all,subjects,and 1.0 0.000143348623853 1 0 1
all,should,be 1.0 0.000143348623853 1 0 1
all,nsaids,including 1.0 0.000143348623853 1 0 1
all,muscle,relaxants 1.0 0.000143348623853 1 0 1
all,metabolized,by 1.0 0.000143348623853 1 0 1
all,central,nervous 1.0 0.000143348623853 1 0 1
all,associated,with 1.0 0.000143348623853 1 0 1
alkaloids,should,be 1.0 0.000143348623853 1 0 1
alkaloids,may,be 1.0 0.000143348623853 1 0 1
alkaloids,and,would 1.0 0.000143348623853 1 0 1
alkaloid,while,you 1.0 0.000143348623853 1 0 1
alkaloid,class,of 1.0 0.000143348623853 1 0 1
alkalinizing,agents,some 1.0 0.000143348623853 1 0 1
alkalinizing,agents,sodium 1.0 0.000143348623853 1 0 1
alkalinizing,agents,gastrointestinal 1.0 0.000143348623853 1 0 1
alfenta,is,administered 1.0 0.000143348623853 1 0 1
alfenta,induction,the 1.0 0.000143348623853 1 0 1
alfenta,clearance,and 1.0 0.000143348623853 1 0 1
alfenta,can,significantly 1.0 0.000143348623853 1 0 1
aleve,or,ibuprofen 1.0 0.000143348623853 1 0 1
alert,clinicians,to 1.0 0.000143348623853 1 0 1
aldomet,use,of 1.0 0.000143348623853 1 0 1
aldehyde,oxidase,and 1.0 0.000143348623853 1 0 1
alcoholic,beverages,is 1.0 0.000143348623853 1 0 1
alcohol,it,should 1.0 0.000143348623853 1 0 1
alcohol,in,post-marketing 1.0 0.000143348623853 1 0 1
alcohol,has,a 1.0 0.000143348623853 1 0 1
alcohol,although,lexapro 1.0 0.000143348623853 1 0 1
albuterol,strattera,should 1.0 0.000143348623853 1 0 1
albumin,binding,sites 1.0 0.000143348623853 1 0 1
albendazole,sulfoxide,concentrations 1.0 0.000143348623853 1 0 1
albendazole,mg,kg 1.0 0.000143348623853 1 0 1
akineton,are,administered 1.0 0.000143348623853 1 0 1
akathisia,in,clinical 1.0 0.000143348623853 1 0 1
air,passages,increasing 1.0 0.000143348623853 1 0 1
agonists,only,if 1.0 0.000143348623853 1 0 1
agonists,on,the 1.0 0.000143348623853 1 0 1
agonists,in,induction 1.0 0.000143348623853 1 0 1
agonists,have,been 1.0 0.000143348623853 1 0 1
agonists,concomitant,use 1.0 0.000143348623853 1 0 1
agonists,because,the 1.0 0.000143348623853 1 0 1
agonists,at,receptors 1.0 0.000143348623853 1 0 1
agonist,it,is 1.0 0.000143348623853 1 0 1
agonist,can,give 1.0 0.000143348623853 1 0 1
agonist,but,not 1.0 0.000143348623853 1 0 1
agonist,antagonist,opioid 1.0 0.000143348623853 1 0 1
agonist,antagonist,eg 1.0 0.000143348623853 1 0 1
agitation,progressing,to 1.0 0.000143348623853 1 0 1
aggregation,inhibitors,such 1.0 0.000143348623853 1 0 1
aggregation,but,did 1.0 0.000143348623853 1 0 1
aggravated,by,the 1.0 0.000143348623853 1 0 1
ages,to,years 1.0 0.000143348623853 1 0 1
agents,zyvox,or 1.0 0.000143348623853 1 0 1
agents,with,proleukin 1.0 0.000143348623853 1 0 1
agents,with,nephrotoxic 1.0 0.000143348623853 1 0 1
agents,with,increased 1.0 0.000143348623853 1 0 1
agents,with,and 1.0 0.000143348623853 1 0 1
agents,with,alphagan 1.0 0.000143348623853 1 0 1
agents,which,increase 1.0 0.000143348623853 1 0 1
agents,when,used 1.0 0.000143348623853 1 0 1
agents,when,heart 1.0 0.000143348623853 1 0 1
agents,when,are 1.0 0.000143348623853 1 0 1
agents,these,agents 1.0 0.000143348623853 1 0 1
agents,there,were 1.0 0.000143348623853 1 0 1
agents,there,have 1.0 0.000143348623853 1 0 1
agents,the,time 1.0 0.000143348623853 1 0 1
agents,the,thioxanthene 1.0 0.000143348623853 1 0 1
agents,the,antihypertensive 1.0 0.000143348623853 1 0 1
agents,that,have 1.0 0.000143348623853 1 0 1
agents,such,a 1.0 0.000143348623853 1 0 1
agents,structurally,related 1.0 0.000143348623853 1 0 1
agents,some,individuals 1.0 0.000143348623853 1 0 1
agents,some,increase 1.0 0.000143348623853 1 0 1
agents,some,and 1.0 0.000143348623853 1 0 1
agents,sodium,bicarbonate 1.0 0.000143348623853 1 0 1
agents,since,these 1.0 0.000143348623853 1 0 1
agents,since,the 1.0 0.000143348623853 1 0 1
agents,simultaneous,use 1.0 0.000143348623853 1 0 1
agents,seizures,have 1.0 0.000143348623853 1 0 1
agents,receiving,velcade 1.0 0.000143348623853 1 0 1
agents,protease,inhibitors 1.0 0.000143348623853 1 0 1
agents,patients,taking 1.0 0.000143348623853 1 0 1
agents,particularly,the 1.0 0.000143348623853 1 0 1
agents,other,systemic 1.0 0.000143348623853 1 0 1
agents,or,with 1.0 0.000143348623853 1 0 1
agents,or,which 1.0 0.000143348623853 1 0 1
agents,or,other 1.0 0.000143348623853 1 0 1
agents,or,are 1.0 0.000143348623853 1 0 1
agents,of,the 1.0 0.000143348623853 1 0 1
agents,nsaids,monoamine 1.0 0.000143348623853 1 0 1
agents,nsaids,concomitant 1.0 0.000143348623853 1 0 1
agents,negative,inotropic 1.0 0.000143348623853 1 0 1
agents,monoamine,oxidase 1.0 0.000143348623853 1 0 1
agents,may,produce 1.0 0.000143348623853 1 0 1
agents,may,have 1.0 0.000143348623853 1 0 1
agents,may,enhance 1.0 0.000143348623853 1 0 1
agents,may,either 1.0 0.000143348623853 1 0 1
agents,may,bind 1.0 0.000143348623853 1 0 1
agents,may,become 1.0 0.000143348623853 1 0 1
agents,may,affect 1.0 0.000143348623853 1 0 1
agents,it,should 1.0 0.000143348623853 1 0 1
agents,is,usually 1.0 0.000143348623853 1 0 1
agents,is,generally 1.0 0.000143348623853 1 0 1
agents,including,yields 1.0 0.000143348623853 1 0 1
agents,including,such 1.0 0.000143348623853 1 0 1
agents,including,remicade 1.0 0.000143348623853 1 0 1
agents,including,humira 1.0 0.000143348623853 1 0 1
agents,having,similar 1.0 0.000143348623853 1 0 1
agents,have,no 1.0 0.000143348623853 1 0 1
agents,glutamic,acid 1.0 0.000143348623853 1 0 1
agents,gastrointestinal,alkalinizing 1.0 0.000143348623853 1 0 1
agents,gastrointestinal,acidifying 1.0 0.000143348623853 1 0 1
agents,for,migraine 1.0 0.000143348623853 1 0 1
agents,experience,in 1.0 0.000143348623853 1 0 1
agents,enhanced,bone 1.0 0.000143348623853 1 0 1
agents,employed,since 1.0 0.000143348623853 1 0 1
agents,eg,and 1.0 0.000143348623853 1 0 1
agents,disturbances,of 1.0 0.000143348623853 1 0 1
agents,decrease,blood 1.0 0.000143348623853 1 0 1
agents,concomitant,administration 1.0 0.000143348623853 1 0 1
agents,clomipramine,hcl 1.0 0.000143348623853 1 0 1
agents,channel,blockers 1.0 0.000143348623853 1 0 1
agents,by,nonsteroidal 1.0 0.000143348623853 1 0 1
agents,by,non-steroidal 1.0 0.000143348623853 1 0 1
agents,but,the 1.0 0.000143348623853 1 0 1
agents,benzodiazepines,gi 1.0 0.000143348623853 1 0 1
agents,aspirin,may 1.0 0.000143348623853 1 0 1
agents,aspirin,is 1.0 0.000143348623853 1 0 1
agents,are,to 1.0 0.000143348623853 1 0 1
agents,are,reduced 1.0 0.000143348623853 1 0 1
agents,anesthetics,general 1.0 0.000143348623853 1 0 1
agents,and,vasoactive 1.0 0.000143348623853 1 0 1
agents,and,such 1.0 0.000143348623853 1 0 1
agents,and,oral 1.0 0.000143348623853 1 0 1
agents,and,might 1.0 0.000143348623853 1 0 1
agents,and,may 1.0 0.000143348623853 1 0 1
agents,and,increases 1.0 0.000143348623853 1 0 1
agents,amphotericin,b 1.0 0.000143348623853 1 0 1
agents,although,ipratropium 1.0 0.000143348623853 1 0 1
agents,along,with 1.0 0.000143348623853 1 0 1
agent,with,multiple 1.0 0.000143348623853 1 0 1
agent,orally,because 1.0 0.000143348623853 1 0 1
agent,has,on 1.0 0.000143348623853 1 0 1
agent,for,that 1.0 0.000143348623853 1 0 1
agent,and,an 1.0 0.000143348623853 1 0 1
agenerase,crixivan,fortovase 1.0 0.000143348623853 1 0 1
against,the,ototoxic 1.0 0.000143348623853 1 0 1
against,the,elevation 1.0 0.000143348623853 1 0 1
against,the,concurrent 1.0 0.000143348623853 1 0 1
against,the,clinical 1.0 0.000143348623853 1 0 1
against,taking,vitamin 1.0 0.000143348623853 1 0 1
against,bacillus,subtilis 1.0 0.000143348623853 1 0 1
against,an,increased 1.0 0.000143348623853 1 0 1
after,tracleer,is 1.0 0.000143348623853 1 0 1
after,the,start 1.0 0.000143348623853 1 0 1
after,the,same 1.0 0.000143348623853 1 0 1
after,the,nasal 1.0 0.000143348623853 1 0 1
after,the,initiation 1.0 0.000143348623853 1 0 1
after,the,dose 1.0 0.000143348623853 1 0 1
after,the,coadministration 1.0 0.000143348623853 1 0 1
after,than,with 1.0 0.000143348623853 1 0 1
after,sudden,withdrawal 1.0 0.000143348623853 1 0 1
after,stopping,fluvoxamine 1.0 0.000143348623853 1 0 1
after,stopping,before 1.0 0.000143348623853 1 0 1
after,stopping,an 1.0 0.000143348623853 1 0 1
after,repeated,co-administration 1.0 0.000143348623853 1 0 1
after,receiving,the 1.0 0.000143348623853 1 0 1
after,receiving,appeared 1.0 0.000143348623853 1 0 1
after,or,more 1.0 0.000143348623853 1 0 1
after,or,hours 1.0 0.000143348623853 1 0 1
after,or,after 1.0 0.000143348623853 1 0 1
after,nasal,spray 1.0 0.000143348623853 1 0 1
after,multiple,dosing 1.0 0.000143348623853 1 0 1
after,m-tco,injection 1.0 0.000143348623853 1 0 1
after,introduction,of 1.0 0.000143348623853 1 0 1
after,injection,of 1.0 0.000143348623853 1 0 1
after,initiating,therapy 1.0 0.000143348623853 1 0 1
after,initiating,or 1.0 0.000143348623853 1 0 1
after,ethyl,increases 1.0 0.000143348623853 1 0 1
after,drinking,may 1.0 0.000143348623853 1 0 1
after,days,with 1.0 0.000143348623853 1 0 1
after,concomitant,therapy 1.0 0.000143348623853 1 0 1
after,completion,of 1.0 0.000143348623853 1 0 1
after,and,increases 1.0 0.000143348623853 1 0 1
after,administration,was 1.0 0.000143348623853 1 0 1
after,administration,may 1.0 0.000143348623853 1 0 1
after,administration,and 1.0 0.000143348623853 1 0 1
after,a,one 1.0 0.000143348623853 1 0 1
after,a,dose 1.0 0.000143348623853 1 0 1
affinity,for,than 1.0 0.000143348623853 1 0 1
affects,the,steady-state 1.0 0.000143348623853 1 0 1
affecting,the,blood 1.0 0.000143348623853 1 0 1
affecting,blood,elements 1.0 0.000143348623853 1 0 1
affected,the,proliferation 1.0 0.000143348623853 1 0 1
affected,response,duration 1.0 0.000143348623853 1 0 1
affect,the,test 1.0 0.000143348623853 1 0 1
affect,the,cyp2b6 1.0 0.000143348623853 1 0 1
affect,sinus,node 1.0 0.000143348623853 1 0 1
affect,pharmacokinetics,except 1.0 0.000143348623853 1 0 1
affect,pharmacodynamics,arecoline 1.0 0.000143348623853 1 0 1
affect,hepatic,metabolism 1.0 0.000143348623853 1 0 1
affect,gastrointestinal,absorption 1.0 0.000143348623853 1 0 1
affect,disease,control 1.0 0.000143348623853 1 0 1
affect,bleeding,parameters 1.0 0.000143348623853 1 0 1
aeds,on,gabitril 1.0 0.000143348623853 1 0 1
aeds,in,pediatric 1.0 0.000143348623853 1 0 1
aeds,affects,the 1.0 0.000143348623853 1 0 1
aed,s,that 1.0 0.000143348623853 1 0 1
advised,when,trisenox 1.0 0.000143348623853 1 0 1
advised,when,is 1.0 0.000143348623853 1 0 1
advised,when,beginning 1.0 0.000143348623853 1 0 1
advised,to,obtain 1.0 0.000143348623853 1 0 1
advised,to,avoid 1.0 0.000143348623853 1 0 1
advised,and,downward 1.0 0.000143348623853 1 0 1
advised,against,taking 1.0 0.000143348623853 1 0 1
advisable,to,monitor 1.0 0.000143348623853 1 0 1
advisable,to,continue 1.0 0.000143348623853 1 0 1
advisable,to,check 1.0 0.000143348623853 1 0 1
advisable,to,avoid 1.0 0.000143348623853 1 0 1
advisable,to,administer 1.0 0.000143348623853 1 0 1
advice,of,a 1.0 0.000143348623853 1 0 1
adversely,influence,the 1.0 0.000143348623853 1 0 1
adversely,affected,response 1.0 0.000143348623853 1 0 1
adversely,affect,disease 1.0 0.000143348623853 1 0 1
adverse,reactions,is 1.0 0.000143348623853 1 0 1
adverse,neuropsychiatric,events 1.0 0.000143348623853 1 0 1
adverse,experiences,and 1.0 0.000143348623853 1 0 1
adverse,events,were 1.0 0.000143348623853 1 0 1
adverse,events,by 1.0 0.000143348623853 1 0 1
adverse,events,associated 1.0 0.000143348623853 1 0 1
adverse,effects,resulting 1.0 0.000143348623853 1 0 1
adverse,effects,could 1.0 0.000143348623853 1 0 1
advanced,or,complete 1.0 0.000143348623853 1 0 1
adults,at,high 1.0 0.000143348623853 1 0 1
adult-onset,diabetics,dosage 1.0 0.000143348623853 1 0 1
adult,data,lower 1.0 0.000143348623853 1 0 1
adsorption,of,onto 1.0 0.000143348623853 1 0 1
adsorbents,and,digestive 1.0 0.000143348623853 1 0 1
adrenocorticoids,cortisone-like,medicine 1.0 0.000143348623853 1 0 1
adrenocortical,steroids,chloral 1.0 0.000143348623853 1 0 1
adrenocortical,dependent,hypertension 1.0 0.000143348623853 1 0 1
adrenergic,are,to 1.0 0.000143348623853 1 0 1
adrenergic,antagonists,because 1.0 0.000143348623853 1 0 1
adrenergic,antagonism,has 1.0 0.000143348623853 1 0 1
adrenergic,agonists,on 1.0 0.000143348623853 1 0 1
adrenergic,agents,some 1.0 0.000143348623853 1 0 1
adrenal,synthesis,and 1.0 0.000143348623853 1 0 1
adolescent,with,altered 1.0 0.000143348623853 1 0 1
administration,with,signs 1.0 0.000143348623853 1 0 1
administration,with,racemic 1.0 0.000143348623853 1 0 1
administration,to,three 1.0 0.000143348623853 1 0 1
administration,to,rachitic 1.0 0.000143348623853 1 0 1
administration,systemic,clearance 1.0 0.000143348623853 1 0 1
administration,should,also 1.0 0.000143348623853 1 0 1
administration,of,vitamin 1.0 0.000143348623853 1 0 1
administration,of,vistide 1.0 0.000143348623853 1 0 1
administration,of,videx 1.0 0.000143348623853 1 0 1
administration,of,uricosuric 1.0 0.000143348623853 1 0 1
administration,of,tracleer 1.0 0.000143348623853 1 0 1
administration,of,targretin 1.0 0.000143348623853 1 0 1
administration,of,tambocor 1.0 0.000143348623853 1 0 1
administration,of,sprycel 1.0 0.000143348623853 1 0 1
administration,of,some 1.0 0.000143348623853 1 0 1
administration,of,robinul 1.0 0.000143348623853 1 0 1
administration,of,potentially 1.0 0.000143348623853 1 0 1
administration,of,ponstel 1.0 0.000143348623853 1 0 1
administration,of,permits 1.0 0.000143348623853 1 0 1
administration,of,particularly 1.0 0.000143348623853 1 0 1
administration,of,once 1.0 0.000143348623853 1 0 1
administration,of,norpace 1.0 0.000143348623853 1 0 1
administration,of,nonsteroial 1.0 0.000143348623853 1 0 1
administration,of,non-steroidal 1.0 0.000143348623853 1 0 1
administration,of,non-potassium 1.0 0.000143348623853 1 0 1
administration,of,multiple 1.0 0.000143348623853 1 0 1
administration,of,mefloquine 1.0 0.000143348623853 1 0 1
administration,of,macrolide 1.0 0.000143348623853 1 0 1
administration,of,lodine 1.0 0.000143348623853 1 0 1
administration,of,innovar 1.0 0.000143348623853 1 0 1
administration,of,indocin 1.0 0.000143348623853 1 0 1
administration,of,indigestion 1.0 0.000143348623853 1 0 1
administration,of,including 1.0 0.000143348623853 1 0 1
administration,of,inapsine 1.0 0.000143348623853 1 0 1
administration,of,hexalen 1.0 0.000143348623853 1 0 1
administration,of,hcl 1.0 0.000143348623853 1 0 1
administration,of,ethyol 1.0 0.000143348623853 1 0 1
administration,of,during 1.0 0.000143348623853 1 0 1
administration,of,doubled 1.0 0.000143348623853 1 0 1
administration,of,does 1.0 0.000143348623853 1 0 1
administration,of,d 1.0 0.000143348623853 1 0 1
administration,of,containing 1.0 0.000143348623853 1 0 1
administration,of,compounds 1.0 0.000143348623853 1 0 1
administration,of,cmi 1.0 0.000143348623853 1 0 1
administration,of,certain 1.0 0.000143348623853 1 0 1
administration,of,as 1.0 0.000143348623853 1 0 1
administration,of,are 1.0 0.000143348623853 1 0 1
administration,of,anafranil 1.0 0.000143348623853 1 0 1
administration,may,result 1.0 0.000143348623853 1 0 1
administration,may,be 1.0 0.000143348623853 1 0 1
administration,decreased,bioavailability 1.0 0.000143348623853 1 0 1
administration,attenuates,certain 1.0 0.000143348623853 1 0 1
administration,and,on 1.0 0.000143348623853 1 0 1
administering,with,since 1.0 0.000143348623853 1 0 1
administering,peganone,to 1.0 0.000143348623853 1 0 1
administering,or,taking 1.0 0.000143348623853 1 0 1
administering,insp,together 1.0 0.000143348623853 1 0 1
administering,hcl,to 1.0 0.000143348623853 1 0 1
administering,etopophos,with 1.0 0.000143348623853 1 0 1
administering,disulfiram,to 1.0 0.000143348623853 1 0 1
administering,concurrently,with 1.0 0.000143348623853 1 0 1
administering,celebrex,with 1.0 0.000143348623853 1 0 1
administered,within,hours 1.0 0.000143348623853 1 0 1
administered,with,vaprisol 1.0 0.000143348623853 1 0 1
administered,with,the 1.0 0.000143348623853 1 0 1
administered,with,such 1.0 0.000143348623853 1 0 1
administered,with,see 1.0 0.000143348623853 1 0 1
administered,with,other 1.0 0.000143348623853 1 0 1
administered,with,or 1.0 0.000143348623853 1 0 1
administered,with,nitrous 1.0 0.000143348623853 1 0 1
administered,with,maxipime 1.0 0.000143348623853 1 0 1
administered,with,its 1.0 0.000143348623853 1 0 1
administered,with,hexalen 1.0 0.000143348623853 1 0 1
administered,with,ethyl 1.0 0.000143348623853 1 0 1
administered,with,antihypertensive 1.0 0.000143348623853 1 0 1
administered,with,agents 1.0 0.000143348623853 1 0 1
administered,until,a 1.0 0.000143348623853 1 0 1
administered,to,rats 1.0 0.000143348623853 1 0 1
administered,simultaneously,because 1.0 0.000143348623853 1 0 1
administered,separately,by 1.0 0.000143348623853 1 0 1
administered,radiographic,iodinated 1.0 0.000143348623853 1 0 1
administered,orally,with 1.0 0.000143348623853 1 0 1
administered,or,discontinued 1.0 0.000143348623853 1 0 1
administered,one,hour 1.0 0.000143348623853 1 0 1
administered,on,day9 1.0 0.000143348623853 1 0 1
administered,minutes,after 1.0 0.000143348623853 1 0 1
administered,minute,after 1.0 0.000143348623853 1 0 1
administered,mg,reduced 1.0 0.000143348623853 1 0 1
administered,intravenously,to 1.0 0.000143348623853 1 0 1
administered,in,patients 1.0 0.000143348623853 1 0 1
administered,in,normal 1.0 0.000143348623853 1 0 1
administered,immediately,following 1.0 0.000143348623853 1 0 1
administered,following,a 1.0 0.000143348623853 1 0 1
administered,concurrently,concentrations 1.0 0.000143348623853 1 0 1
administered,concomitantly,to 1.0 0.000143348623853 1 0 1
administered,by,any 1.0 0.000143348623853 1 0 1
administered,antiepileptic,periodic 1.0 0.000143348623853 1 0 1
administered,and,appropriate 1.0 0.000143348623853 1 0 1
administered,alone,suggesting 1.0 0.000143348623853 1 0 1
administered,alone,at 1.0 0.000143348623853 1 0 1
administered,agents,but 1.0 0.000143348623853 1 0 1
admini,stered,orally 1.0 0.000143348623853 1 0 1
adl-8,is,a 1.0 0.000143348623853 1 0 1
adl,prevents,morphine-induced 1.0 0.000143348623853 1 0 1
adl,a,trans-3 1.0 0.000143348623853 1 0 1
adjuvant,treatment,of 1.0 0.000143348623853 1 0 1
adjustments,patients,may 1.0 0.000143348623853 1 0 1
adjustments,of,agents 1.0 0.000143348623853 1 0 1
adjustments,considered,for 1.0 0.000143348623853 1 0 1
adjustment,should,be 1.0 0.000143348623853 1 0 1
adjustment,required,it 1.0 0.000143348623853 1 0 1
adjustment,of,uricosuric 1.0 0.000143348623853 1 0 1
adjustment,of,strattera 1.0 0.000143348623853 1 0 1
adjustment,of,sensipar 1.0 0.000143348623853 1 0 1
adjustment,of,nalfon 1.0 0.000143348623853 1 0 1
adjustment,of,hypoglycemic 1.0 0.000143348623853 1 0 1
adjustment,for,mg 1.0 0.000143348623853 1 0 1
adjusted,upward,the 1.0 0.000143348623853 1 0 1
adjusted,in,those 1.0 0.000143348623853 1 0 1
adjusted,accordingly,in 1.0 0.000143348623853 1 0 1
adjust,the,dosage 1.0 0.000143348623853 1 0 1
adjunctive,therapy,a 1.0 0.000143348623853 1 0 1
adequate,monitoring,of 1.0 0.000143348623853 1 0 1
adenosine,effects,are 1.0 0.000143348623853 1 0 1
adenosine,dipyridamole,has 1.0 0.000143348623853 1 0 1
adenocard,in,patients 1.0 0.000143348623853 1 0 1
adenocarcinomas,which,was 1.0 0.000143348623853 1 0 1
additive,with,d 1.0 0.000143348623853 1 0 1
additive,sedative,effects 1.0 0.000143348623853 1 0 1
additive,negative,inotropic 1.0 0.000143348623853 1 0 1
additive,interaction,with 1.0 0.000143348623853 1 0 1
additive,hypotensive,effect 1.0 0.000143348623853 1 0 1
additive,hypotensite,effects 1.0 0.000143348623853 1 0 1
additive,effects,were 1.0 0.000143348623853 1 0 1
additive,effects,such 1.0 0.000143348623853 1 0 1
additive,effects,in 1.0 0.000143348623853 1 0 1
additive,effect,with 1.0 0.000143348623853 1 0 1
additive,effect,on 1.0 0.000143348623853 1 0 1
additive,effect,in 1.0 0.000143348623853 1 0 1
additive,coadministration,of 1.0 0.000143348623853 1 0 1
additive,central,nervous 1.0 0.000143348623853 1 0 1
additive,adverse,effects 1.0 0.000143348623853 1 0 1
additionally,higher,than 1.0 0.000143348623853 1 0 1
additionally,brevibloc,should 1.0 0.000143348623853 1 0 1
additionally,anti-malarial,such 1.0 0.000143348623853 1 0 1
additional,titration,of 1.0 0.000143348623853 1 0 1
additional,that,should 1.0 0.000143348623853 1 0 1
additional,supine,systolic 1.0 0.000143348623853 1 0 1
additional,significantly,inhibited 1.0 0.000143348623853 1 0 1
additional,reductions,in 1.0 0.000143348623853 1 0 1
additional,including,indocin 1.0 0.000143348623853 1 0 1
additional,efficacy,over 1.0 0.000143348623853 1 0 1
additional,effect,is 1.0 0.000143348623853 1 0 1
additional,effect,beyond 1.0 0.000143348623853 1 0 1
additional,adrenergic,are 1.0 0.000143348623853 1 0 1
addition,to,this 1.0 0.000143348623853 1 0 1
addition,to,enhancing 1.0 0.000143348623853 1 0 1
addition,to,bleeding 1.0 0.000143348623853 1 0 1
addition,there,have 1.0 0.000143348623853 1 0 1
addition,the,beneficial 1.0 0.000143348623853 1 0 1
addition,that,are 1.0 0.000143348623853 1 0 1
addition,several,aed 1.0 0.000143348623853 1 0 1
addition,results,from 1.0 0.000143348623853 1 0 1
addition,other,have 1.0 0.000143348623853 1 0 1
addition,of,results 1.0 0.000143348623853 1 0 1
addition,of,nalfon 1.0 0.000143348623853 1 0 1
addition,of,mg 1.0 0.000143348623853 1 0 1
addition,of,inspra 1.0 0.000143348623853 1 0 1
addition,of,felbatol 1.0 0.000143348623853 1 0 1
addition,of,causes 1.0 0.000143348623853 1 0 1
addition,most,are 1.0 0.000143348623853 1 0 1
addition,interfere,with 1.0 0.000143348623853 1 0 1
addition,higher-than,expected 1.0 0.000143348623853 1 0 1
addition,deaths,have 1.0 0.000143348623853 1 0 1
addition,alone,can 1.0 0.000143348623853 1 0 1
addicts,were,completely 1.0 0.000143348623853 1 0 1
added,were,noted 1.0 0.000143348623853 1 0 1
added,to,or 1.0 0.000143348623853 1 0 1
added,to,a 1.0 0.000143348623853 1 0 1
added,of,the 1.0 0.000143348623853 1 0 1
added,beta-adrenergic,blocking 1.0 0.000143348623853 1 0 1
add,some,further 1.0 0.000143348623853 1 0 1
acutely,worsened,by 1.0 0.000143348623853 1 0 1
acute,toxicity,of 1.0 0.000143348623853 1 0 1
acute,renal,failure 1.0 0.000143348623853 1 0 1
acute,pulmonary,toxicity 1.0 0.000143348623853 1 0 1
acute,delirium,associated 1.0 0.000143348623853 1 0 1
acts,as,a 1.0 0.000143348623853 1 0 1
activity--such,as,an 1.0 0.000143348623853 1 0 1
activity,with,lowered 1.0 0.000143348623853 1 0 1
activity,while,only 1.0 0.000143348623853 1 0 1
activity,which,was 1.0 0.000143348623853 1 0 1
activity,transient,cardiac 1.0 0.000143348623853 1 0 1
activity,thus,requiring 1.0 0.000143348623853 1 0 1
activity,should,if 1.0 0.000143348623853 1 0 1
activity,should,be 1.0 0.000143348623853 1 0 1
activity,potentiates,the 1.0 0.000143348623853 1 0 1
activity,persists,as 1.0 0.000143348623853 1 0 1
activity,of,reportedly 1.0 0.000143348623853 1 0 1
activity,of,other 1.0 0.000143348623853 1 0 1
activity,of,oral 1.0 0.000143348623853 1 0 1
activity,of,lamprene 1.0 0.000143348623853 1 0 1
activity,of,endogenous 1.0 0.000143348623853 1 0 1
activity,of,by 1.0 0.000143348623853 1 0 1
activity,of,both 1.0 0.000143348623853 1 0 1
activity,of,and 1.0 0.000143348623853 1 0 1
activity,may,enhance 1.0 0.000143348623853 1 0 1
activity,in,the 1.0 0.000143348623853 1 0 1
activity,eg,would 1.0 0.000143348623853 1 0 1
activity,eg,and 1.0 0.000143348623853 1 0 1
activity,can,occur 1.0 0.000143348623853 1 0 1
activity,appeared,to 1.0 0.000143348623853 1 0 1
activity,and,may 1.0 0.000143348623853 1 0 1
activity,and,increase 1.0 0.000143348623853 1 0 1
actively,secreted,via 1.0 0.000143348623853 1 0 1
active,sulfide,metabolite 1.0 0.000143348623853 1 0 1
active,renal,tubular 1.0 0.000143348623853 1 0 1
active,phosphorylated,which 1.0 0.000143348623853 1 0 1
active,metabolite,n-desmethyldiazepam 1.0 0.000143348623853 1 0 1
active,metabolite,may 1.0 0.000143348623853 1 0 1
active,metabolite,exposure 1.0 0.000143348623853 1 0 1
active,metabolite,concentration 1.0 0.000143348623853 1 0 1
active,metabolite,by 1.0 0.000143348623853 1 0 1
active,isomer,of 1.0 0.000143348623853 1 0 1
active,in,inhibiting 1.0 0.000143348623853 1 0 1
active,hydroxy,acid 1.0 0.000143348623853 1 0 1
activated,in,patients 1.0 0.000143348623853 1 0 1
actions,were,potentiated 1.0 0.000143348623853 1 0 1
actions,certain,narcotic 1.0 0.000143348623853 1 0 1
actions,and,side-effects 1.0 0.000143348623853 1 0 1
action,on,the 1.0 0.000143348623853 1 0 1
action,on,sodium 1.0 0.000143348623853 1 0 1
action,of,zebeta 1.0 0.000143348623853 1 0 1
action,of,tracrium 1.0 0.000143348623853 1 0 1
action,of,preparations 1.0 0.000143348623853 1 0 1
action,of,of 1.0 0.000143348623853 1 0 1
action,of,non-depolarising 1.0 0.000143348623853 1 0 1
action,of,nimbex 1.0 0.000143348623853 1 0 1
action,of,is 1.0 0.000143348623853 1 0 1
action,of,hypoglycemic 1.0 0.000143348623853 1 0 1
action,of,hydroxyzine 1.0 0.000143348623853 1 0 1
action,of,certain 1.0 0.000143348623853 1 0 1
action,of,by 1.0 0.000143348623853 1 0 1
action,of,adrenergic 1.0 0.000143348623853 1 0 1
action,it,is 1.0 0.000143348623853 1 0 1
action,by,competing 1.0 0.000143348623853 1 0 1
actinic,keratoses,treated 1.0 0.000143348623853 1 0 1
acting,triclofos,sodium 1.0 0.000143348623853 1 0 1
acting,primarily,to 1.0 0.000143348623853 1 0 1
acth,may,potentiate 1.0 0.000143348623853 1 0 1
acitretin,interferes,with 1.0 0.000143348623853 1 0 1
acidity,in,the 1.0 0.000143348623853 1 0 1
acidifying,agents,these 1.0 0.000143348623853 1 0 1
acidifying,agents,glutamic 1.0 0.000143348623853 1 0 1
acidifying,agents,gastrointestinal 1.0 0.000143348623853 1 0 1
acidifying,agents,decrease 1.0 0.000143348623853 1 0 1
acidifying,agents,ammonium 1.0 0.000143348623853 1 0 1
acidic,such,as 1.0 0.000143348623853 1 0 1
acidic,or,basic 1.0 0.000143348623853 1 0 1
acidic,conditions,similar 1.0 0.000143348623853 1 0 1
acid-catalyzed,ethanolysis,of 1.0 0.000143348623853 1 0 1
acid,with,at 1.0 0.000143348623853 1 0 1
acid,vitamin,c 1.0 0.000143348623853 1 0 1
acid,using,these 1.0 0.000143348623853 1 0 1
acid,temporarily,reduced 1.0 0.000143348623853 1 0 1
acid,sequestrants,may 1.0 0.000143348623853 1 0 1
acid,secretion,by 1.0 0.000143348623853 1 0 1
acid,prolonged,hot 1.0 0.000143348623853 1 0 1
acid,paba,containing 1.0 0.000143348623853 1 0 1
acid,oxolinic,acid 1.0 0.000143348623853 1 0 1
acid,or,the 1.0 0.000143348623853 1 0 1
acid,nonsteroidal,anti-inflammatory 1.0 0.000143348623853 1 0 1
acid,monoamine,oxidase 1.0 0.000143348623853 1 0 1
acid,may,potentiate 1.0 0.000143348623853 1 0 1
acid,may,interact 1.0 0.000143348623853 1 0 1
acid,may,enhance 1.0 0.000143348623853 1 0 1
acid,may,decrease 1.0 0.000143348623853 1 0 1
acid,may,also 1.0 0.000143348623853 1 0 1
acid,level,dosage 1.0 0.000143348623853 1 0 1
acid,increased,the 1.0 0.000143348623853 1 0 1
acid,in,large 1.0 0.000143348623853 1 0 1
acid,higher,doses 1.0 0.000143348623853 1 0 1
acid,hepatotoxic,influenza 1.0 0.000143348623853 1 0 1
acid,hcl,ascorbic 1.0 0.000143348623853 1 0 1
acid,have,been 1.0 0.000143348623853 1 0 1
acid,has,been 1.0 0.000143348623853 1 0 1
acid,fruit,juices 1.0 0.000143348623853 1 0 1
acid,excretion,compared 1.0 0.000143348623853 1 0 1
acid,doses,of 1.0 0.000143348623853 1 0 1
acid,diminished,binding 1.0 0.000143348623853 1 0 1
acid,decrease,in 1.0 0.000143348623853 1 0 1
acid,by,and 1.0 0.000143348623853 1 0 1
acid,binding,may 1.0 0.000143348623853 1 0 1
acid,because,of 1.0 0.000143348623853 1 0 1
acid,as,the 1.0 0.000143348623853 1 0 1
acid,antagonists,such 1.0 0.000143348623853 1 0 1
acid,and,sodium 1.0 0.000143348623853 1 0 1
acid,and,others 1.0 0.000143348623853 1 0 1
acid,and,heavy 1.0 0.000143348623853 1 0 1
acid,and,abciximab 1.0 0.000143348623853 1 0 1
acid,anabolic,steroids 1.0 0.000143348623853 1 0 1
achieve,the,dose 1.0 0.000143348623853 1 0 1
achieve,mac,minimum 1.0 0.000143348623853 1 0 1
ache,activity,appeared 1.0 0.000143348623853 1 0 1
acetylsalicylic,acid,temporarily 1.0 0.000143348623853 1 0 1
acetylcholinesterase,ache,activity 1.0 0.000143348623853 1 0 1
acetazolamide,reduces,urinary 1.0 0.000143348623853 1 0 1
acetazolamide,may,prevent 1.0 0.000143348623853 1 0 1
acetazolamide,increases,excretion 1.0 0.000143348623853 1 0 1
acetazolamide,decreases,urinary 1.0 0.000143348623853 1 0 1
acetazolamide,azole,antifungals 1.0 0.000143348623853 1 0 1
acetazolamide,and,sodium 1.0 0.000143348623853 1 0 1
acetate,x,m 1.0 0.000143348623853 1 0 1
acetate,with,glycosides 1.0 0.000143348623853 1 0 1
acetate,stimulated,but 1.0 0.000143348623853 1 0 1
acetate,similarly,inhibit 1.0 0.000143348623853 1 0 1
acetate,l-histidine,was 1.0 0.000143348623853 1 0 1
acetate,in,reducing 1.0 0.000143348623853 1 0 1
acetate,because,of 1.0 0.000143348623853 1 0 1
acetate,at,about 1.0 0.000143348623853 1 0 1
acetate,and,possibly 1.0 0.000143348623853 1 0 1
acetate,affected,the 1.0 0.000143348623853 1 0 1
acetaminophen,tylenol,with 1.0 0.000143348623853 1 0 1
acetaminophen,oral,phenytoin 1.0 0.000143348623853 1 0 1
acetaminophen,may,increase 1.0 0.000143348623853 1 0 1
acetaminophen,in,normal 1.0 0.000143348623853 1 0 1
acetaminophen,diminished,the 1.0 0.000143348623853 1 0 1
acetaminophen,and,l-methionine 1.0 0.000143348623853 1 0 1
acetaminophen,a,report 1.0 0.000143348623853 1 0 1
acellular,live,and 1.0 0.000143348623853 1 0 1
ace,inhibitors,in 1.0 0.000143348623853 1 0 1
ace,inhibitor,to 1.0 0.000143348623853 1 0 1
ace,inhibitor,mg 1.0 0.000143348623853 1 0 1
ace,inhibitor,can 1.0 0.000143348623853 1 0 1
accutane,use,has 1.0 0.000143348623853 1 0 1
accutane,to,a 1.0 0.000143348623853 1 0 1
accutane,and,should 1.0 0.000143348623853 1 0 1
accuracy,in,patients 1.0 0.000143348623853 1 0 1
accumulation,of,both 1.0 0.000143348623853 1 0 1
accumulation,in,rabbit 1.0 0.000143348623853 1 0 1
accumulated,in,the 1.0 0.000143348623853 1 0 1
account,bezalip,and 1.0 0.000143348623853 1 0 1
accordingly,when,is 1.0 0.000143348623853 1 0 1
accordingly,careful,patient 1.0 0.000143348623853 1 0 1
accordingly,and,should 1.0 0.000143348623853 1 0 1
accelerated,when,they 1.0 0.000143348623853 1 0 1
accelerated,markedly,with 1.0 0.000143348623853 1 0 1
acarbose,has,been 1.0 0.000143348623853 1 0 1
acarbose,due,to 1.0 0.000143348623853 1 0 1
acarbose,and,should 1.0 0.000143348623853 1 0 1
acamprosate,produced,a 1.0 0.000143348623853 1 0 1
absorption,when,it 1.0 0.000143348623853 1 0 1
absorption,the,following 1.0 0.000143348623853 1 0 1
absorption,of,while 1.0 0.000143348623853 1 0 1
absorption,of,vitamin 1.0 0.000143348623853 1 0 1
absorption,of,various 1.0 0.000143348623853 1 0 1
absorption,of,v 1.0 0.000143348623853 1 0 1
absorption,of,the 1.0 0.000143348623853 1 0 1
absorption,of,sodium 1.0 0.000143348623853 1 0 1
absorption,of,if 1.0 0.000143348623853 1 0 1
absorption,of,g 1.0 0.000143348623853 1 0 1
absorption,of,fat-soluble 1.0 0.000143348623853 1 0 1
absorption,of,diamox 1.0 0.000143348623853 1 0 1
absorption,of,both 1.0 0.000143348623853 1 0 1
absorption,of,bezalip 1.0 0.000143348623853 1 0 1
absorption,of,and 1.0 0.000143348623853 1 0 1
absorption,of,agents 1.0 0.000143348623853 1 0 1
absorption,mean,c 1.0 0.000143348623853 1 0 1
absorption,mean,auc 1.0 0.000143348623853 1 0 1
absorption,in,those 1.0 0.000143348623853 1 0 1
absorption,in,the 1.0 0.000143348623853 1 0 1
absorption,in,patients 1.0 0.000143348623853 1 0 1
absorption,decreases,gastrointestinal 1.0 0.000143348623853 1 0 1
absorption,can,be 1.0 0.000143348623853 1 0 1
absorption,and,result 1.0 0.000143348623853 1 0 1
absorption,acting,primarily 1.0 0.000143348623853 1 0 1
absorbed,into,the 1.0 0.000143348623853 1 0 1
absence,of,renal 1.0 0.000143348623853 1 0 1
absence,of,adequate 1.0 0.000143348623853 1 0 1
abrupt,suppression,of 1.0 0.000143348623853 1 0 1
above,or,near 1.0 0.000143348623853 1 0 1
above,of,should 1.0 0.000143348623853 1 0 1
above,ng,ml 1.0 0.000143348623853 1 0 1
above,effects,concerning 1.0 0.000143348623853 1 0 1
about,x,m 1.0 0.000143348623853 1 0 1
about,when,was 1.0 0.000143348623853 1 0 1
about,when,mesylate 1.0 0.000143348623853 1 0 1
about,when,compared 1.0 0.000143348623853 1 0 1
about,when,and 1.0 0.000143348623853 1 0 1
about,two,studies 1.0 0.000143348623853 1 0 1
about,to,fold 1.0 0.000143348623853 1 0 1
about,one-third,as 1.0 0.000143348623853 1 0 1
about,mm,hg 1.0 0.000143348623853 1 0 1
about,minutes,before 1.0 0.000143348623853 1 0 1
about,in,the 1.0 0.000143348623853 1 0 1
about,in,healthy 1.0 0.000143348623853 1 0 1
about,higher,when 1.0 0.000143348623853 1 0 1
about,fold,when 1.0 0.000143348623853 1 0 1
about,fold,in 1.0 0.000143348623853 1 0 1
about,compared,to 1.0 0.000143348623853 1 0 1
about,and,levels 1.0 0.000143348623853 1 0 1
about,and,half-life 1.0 0.000143348623853 1 0 1
about,and,greater 1.0 0.000143348623853 1 0 1
about,a,fold 1.0 0.000143348623853 1 0 1
abolished,by,pretreatment 1.0 0.000143348623853 1 0 1
abolished,as,a 1.0 0.000143348623853 1 0 1
abolish,the,effect 1.0 0.000143348623853 1 0 1
abnormalities,such,as 1.0 0.000143348623853 1 0 1
abnormalities,arrhythmia,bradycardia 1.0 0.000143348623853 1 0 1
abnormalities,and,increase 1.0 0.000143348623853 1 0 1
abnormalities,and,hearing 1.0 0.000143348623853 1 0 1
abnormal,renal,uptake 1.0 0.000143348623853 1 0 1
ability,to,inhibit 1.0 0.000143348623853 1 0 1
ability,of,to 1.0 0.000143348623853 1 0 1
abilify,is,taken 1.0 0.000143348623853 1 0 1
abciximab,may,increase 1.0 0.000143348623853 1 0 1
abased,on,reports 1.0 0.000143348623853 1 0 1
a4,would,be 1.0 0.000143348623853 1 0 1
a4,or,st 1.0 0.000143348623853 1 0 1
a4,may,cause 1.0 0.000143348623853 1 0 1
a4,macrolide,such 1.0 0.000143348623853 1 0 1
a4,increased,the 1.0 0.000143348623853 1 0 1
a4,grapefruit,juice 1.0 0.000143348623853 1 0 1
a4,enzyme,activity 1.0 0.000143348623853 1 0 1
a4,cyp,a4 1.0 0.000143348623853 1 0 1
a2-selective,agonist,but 1.0 0.000143348623853 1 0 1
a2,and,a 1.0 0.000143348623853 1 0 1
a2,an,isoform 1.0 0.000143348623853 1 0 1
a-v,node,higher 1.0 0.000143348623853 1 0 1
a,with,any 1.0 0.000143348623853 1 0 1
a,which,increases 1.0 0.000143348623853 1 0 1
a,wax,matrix 1.0 0.000143348623853 1 0 1
a,vitamin,b12 1.0 0.000143348623853 1 0 1
a,very,weak 1.0 0.000143348623853 1 0 1
a,valid,prothrombin 1.0 0.000143348623853 1 0 1
a,type,ii 1.0 0.000143348623853 1 0 1
a,twofold,increase 1.0 0.000143348623853 1 0 1
a,two-way,interaction 1.0 0.000143348623853 1 0 1
a,two-fold,increase 1.0 0.000143348623853 1 0 1
a,true,interaction 1.0 0.000143348623853 1 0 1
a,trans-3,dimethyl-4 1.0 0.000143348623853 1 0 1
a,toxic,effect 1.0 0.000143348623853 1 0 1
a,tolerance,to 1.0 0.000143348623853 1 0 1
a,together,may 1.0 0.000143348623853 1 0 1
a,to,increase 1.0 0.000143348623853 1 0 1
a,to,fold 1.0 0.000143348623853 1 0 1
a,to,dose-related 1.0 0.000143348623853 1 0 1
a,to,avoid 1.0 0.000143348623853 1 0 1
a,tnf,antagonist 1.0 0.000143348623853 1 0 1
a,times,increase 1.0 0.000143348623853 1 0 1
a,therapeutic,supplement 1.0 0.000143348623853 1 0 1
a,theoretical,risk 1.0 0.000143348623853 1 0 1
a,that,can 1.0 0.000143348623853 1 0 1
a,tendency,to 1.0 0.000143348623853 1 0 1
a,ten-subject,study 1.0 0.000143348623853 1 0 1
a,synergistic,relationship 1.0 0.000143348623853 1 0 1
a,supersensitivity,to 1.0 0.000143348623853 1 0 1
a,sulfonamide,is 1.0 0.000143348623853 1 0 1
a,sudden,increase 1.0 0.000143348623853 1 0 1
a,substantial,number 1.0 0.000143348623853 1 0 1
a,subsequent,to 1.0 0.000143348623853 1 0 1
a,study,conducted 1.0 0.000143348623853 1 0 1
a,strong,selective 1.0 0.000143348623853 1 0 1
a,strong,likelihood 1.0 0.000143348623853 1 0 1
a,strong,inhibitor 1.0 0.000143348623853 1 0 1
a,stimulator,of 1.0 0.000143348623853 1 0 1
a,stimulating,effect 1.0 0.000143348623853 1 0 1
a,smaller,initial 1.0 0.000143348623853 1 0 1
a,small,n 1.0 0.000143348623853 1 0 1
a,small,but 1.0 0.000143348623853 1 0 1
a,slower,onset 1.0 0.000143348623853 1 0 1
a,slower,gastrointestinal 1.0 0.000143348623853 1 0 1
a,slower,absorption 1.0 0.000143348623853 1 0 1
a,slight,reduction 1.0 0.000143348623853 1 0 1
a,slight,intrinsic 1.0 0.000143348623853 1 0 1
a,slight,delay 1.0 0.000143348623853 1 0 1
a,slight,but 1.0 0.000143348623853 1 0 1
a,six-day,course 1.0 0.000143348623853 1 0 1
a,single-dose,crossover 1.0 0.000143348623853 1 0 1
a,single,subject 1.0 0.000143348623853 1 0 1
a,single,study 1.0 0.000143348623853 1 0 1
a,single,case 1.0 0.000143348623853 1 0 1
a,simultaneous,fold 1.0 0.000143348623853 1 0 1
a,similar,to 1.0 0.000143348623853 1 0 1
a,similar,proportion 1.0 0.000143348623853 1 0 1
a,similar,length 1.0 0.000143348623853 1 0 1
a,significant,reduction 1.0 0.000143348623853 1 0 1
a,significant,interaction 1.0 0.000143348623853 1 0 1
a,should,be 1.0 0.000143348623853 1 0 1
a,shortened,elimination 1.0 0.000143348623853 1 0 1
a,short-acting,and 1.0 0.000143348623853 1 0 1
a,sharp,fall 1.0 0.000143348623853 1 0 1
a,severe,high 1.0 0.000143348623853 1 0 1
a,serotonin,releaser 1.0 0.000143348623853 1 0 1
a,separate,group 1.0 0.000143348623853 1 0 1
a,sensitive,cyp3a4 1.0 0.000143348623853 1 0 1
a,satisfactory,hypotensive 1.0 0.000143348623853 1 0 1
a,safe,problem 1.0 0.000143348623853 1 0 1
a,risk,that 1.0 0.000143348623853 1 0 1
a,review,of 1.0 0.000143348623853 1 0 1
a,reversible,enhancement 1.0 0.000143348623853 1 0 1
a,resulting,in 1.0 0.000143348623853 1 0 1
a,report,of 1.0 0.000143348623853 1 0 1
a,reliable,method 1.0 0.000143348623853 1 0 1
a,regimen,consisting 1.0 0.000143348623853 1 0 1
a,reduced,clearance 1.0 0.000143348623853 1 0 1
a,recent,study 1.0 0.000143348623853 1 0 1
a,recent,case 1.0 0.000143348623853 1 0 1
a,rebound,in 1.0 0.000143348623853 1 0 1
a,rauwolfia,alkaloid 1.0 0.000143348623853 1 0 1
a,rare,but 1.0 0.000143348623853 1 0 1
a,randomized,trial 1.0 0.000143348623853 1 0 1
a,pure,agonist 1.0 0.000143348623853 1 0 1
a,pronounced,though 1.0 0.000143348623853 1 0 1
a,prolongation,in 1.0 0.000143348623853 1 0 1
a,previously,unrecognized 1.0 0.000143348623853 1 0 1
a,previously,effective 1.0 0.000143348623853 1 0 1
a,previously,administered 1.0 0.000143348623853 1 0 1
a,preparation,this 1.0 0.000143348623853 1 0 1
a,precipitous,reduction 1.0 0.000143348623853 1 0 1
a,potentiation,of 1.0 0.000143348623853 1 0 1
a,potentially,fatal 1.0 0.000143348623853 1 0 1
a,potential,twofold 1.0 0.000143348623853 1 0 1
a,potential,inhibitor 1.0 0.000143348623853 1 0 1
a,potent,iiia4 1.0 0.000143348623853 1 0 1
a,possible,increase 1.0 0.000143348623853 1 0 1
a,possible,hypokalemic 1.0 0.000143348623853 1 0 1
a,positive,level 1.0 0.000143348623853 1 0 1
a,placebo-controlled,trial 1.0 0.000143348623853 1 0 1
a,placebo-controlled,crossover 1.0 0.000143348623853 1 0 1
a,physician,or 1.0 0.000143348623853 1 0 1
a,phase,i 1.0 0.000143348623853 1 0 1
a,pharmacokinetic,substudy 1.0 0.000143348623853 1 0 1
a,pharmacodynamic,interaction 1.0 0.000143348623853 1 0 1
a,penicillin-type,are 1.0 0.000143348623853 1 0 1
a,patients,should 1.0 0.000143348623853 1 0 1
a,patient,requires 1.0 0.000143348623853 1 0 1
a,patient,maintained 1.0 0.000143348623853 1 0 1
a,patient,initiates 1.0 0.000143348623853 1 0 1
a,p-glycoprotein,substrate 1.0 0.000143348623853 1 0 1
a,or,any 1.0 0.000143348623853 1 0 1
a,one-week,course 1.0 0.000143348623853 1 0 1
a,one,week 1.0 0.000143348623853 1 0 1
a,novel,peripherally 1.0 0.000143348623853 1 0 1
a,novel,chemical 1.0 0.000143348623853 1 0 1
a,nonsteroidal,anti 1.0 0.000143348623853 1 0 1
a,nonfunctioning,gland 1.0 0.000143348623853 1 0 1
a,nonabsorbable,complex 1.0 0.000143348623853 1 0 1
a,non-steroidal,agent 1.0 0.000143348623853 1 0 1
a,non-matched,historicalcontrol 1.0 0.000143348623853 1 0 1
a,non-comparative,clinical 1.0 0.000143348623853 1 0 1
a,non-,steroidal 1.0 0.000143348623853 1 0 1
a,nitrosamine,which 1.0 0.000143348623853 1 0 1
a,neutralizing,agent 1.0 0.000143348623853 1 0 1
a,net,decrease 1.0 0.000143348623853 1 0 1
a,multiple,dose 1.0 0.000143348623853 1 0 1
a,multi-day,course 1.0 0.000143348623853 1 0 1
a,molecular,basis 1.0 0.000143348623853 1 0 1
a,modest,cyp2d6 1.0 0.000143348623853 1 0 1
a,minor,increase 1.0 0.000143348623853 1 0 1
a,min,interval 1.0 0.000143348623853 1 0 1
a,mild,decrease 1.0 0.000143348623853 1 0 1
a,mg,vardenafil 1.0 0.000143348623853 1 0 1
a,mg,neurontin 1.0 0.000143348623853 1 0 1
a,mg,daily 1.0 0.000143348623853 1 0 1
a,mg,controlled-release 1.0 0.000143348623853 1 0 1
a,mg,capsule 1.0 0.000143348623853 1 0 1
a,mg,b 1.0 0.000143348623853 1 0 1
a,methotrexate,there 1.0 0.000143348623853 1 0 1
a,member,have 1.0 0.000143348623853 1 0 1
a,mean,increase 1.0 0.000143348623853 1 0 1
a,mean,fold 1.0 0.000143348623853 1 0 1
a,mean,change 1.0 0.000143348623853 1 0 1
a,meal,as 1.0 0.000143348623853 1 0 1
a,may,increase 1.0 0.000143348623853 1 0 1
a,marketed,chewable 1.0 0.000143348623853 1 0 1
a,marked,effect 1.0 0.000143348623853 1 0 1
a,marked,and 1.0 0.000143348623853 1 0 1
a,mao,inhibitor 1.0 0.000143348623853 1 0 1
a,major,contributing 1.0 0.000143348623853 1 0 1
a,maintenance,schedule 1.0 0.000143348623853 1 0 1
a,maintenance,dose 1.0 0.000143348623853 1 0 1
a,lower,pulmonary 1.0 0.000143348623853 1 0 1
a,lower,affinity 1.0 0.000143348623853 1 0 1
a,literature,article 1.0 0.000143348623853 1 0 1
a,less,pronounced 1.0 0.000143348623853 1 0 1
a,large,reduction 1.0 0.000143348623853 1 0 1
a,known,enzyme 1.0 0.000143348623853 1 0 1
a,is,added 1.0 0.000143348623853 1 0 1
a,interaction,between 1.0 0.000143348623853 1 0 1
a,inhibitors,on 1.0 0.000143348623853 1 0 1
a,inhibitors,of 1.0 0.000143348623853 1 0 1
a,inhaler,take 1.0 0.000143348623853 1 0 1
a,increase,of 1.0 0.000143348623853 1 0 1
a,including,with 1.0 0.000143348623853 1 0 1
a,href,frova_od 1.0 0.000143348623853 1 0 1
a,href,bupropz_od 1.0 0.000143348623853 1 0 1
a,hmg-coa,reductase 1.0 0.000143348623853 1 0 1
a,highly,potent 1.0 0.000143348623853 1 0 1
a,higher,serum 1.0 0.000143348623853 1 0 1
a,higher,cardiac 1.0 0.000143348623853 1 0 1
a,high,dose 1.0 0.000143348623853 1 0 1
a,has,been 1.0 0.000143348623853 1 0 1
a,guide,to 1.0 0.000143348623853 1 0 1
a,gritty,substance 1.0 0.000143348623853 1 0 1
a,greater,than 1.0 0.000143348623853 1 0 1
a,greater,proportion 1.0 0.000143348623853 1 0 1
a,greater,ischemic 1.0 0.000143348623853 1 0 1
a,greater,amount 1.0 0.000143348623853 1 0 1
a,functioning,gland 1.0 0.000143348623853 1 0 1
a,frequent,cause 1.0 0.000143348623853 1 0 1
a,four-day,regimen 1.0 0.000143348623853 1 0 1
a,fluoroquinolone,has 1.0 0.000143348623853 1 0 1
a,five-fold,increase 1.0 0.000143348623853 1 0 1
a,few,spontaneous 1.0 0.000143348623853 1 0 1
a,family,in 1.0 0.000143348623853 1 0 1
a,dose-related,increase 1.0 0.000143348623853 1 0 1
a,dose-related,blockade 1.0 0.000143348623853 1 0 1
a,dose-dependent,modification 1.0 0.000143348623853 1 0 1
a,dose-dependent,inhibition 1.0 0.000143348623853 1 0 1
a,dose,range 1.0 0.000143348623853 1 0 1
a,dose,decrease 1.0 0.000143348623853 1 0 1
a,do,not 1.0 0.000143348623853 1 0 1
a,direct,causal 1.0 0.000143348623853 1 0 1
a,diminished,response 1.0 0.000143348623853 1 0 1
a,diminished,prothrombin 1.0 0.000143348623853 1 0 1
a,digitalized,hypothyroid 1.0 0.000143348623853 1 0 1
a,different,type 1.0 0.000143348623853 1 0 1
a,diabetic,patient 1.0 0.000143348623853 1 0 1
a,delay,in 1.0 0.000143348623853 1 0 1
a,decreased,renal 1.0 0.000143348623853 1 0 1
a,decreased,plasma 1.0 0.000143348623853 1 0 1
a,decreased,efficacy 1.0 0.000143348623853 1 0 1
a,day,resulted 1.0 0.000143348623853 1 0 1
a,cytostatic,agent 1.0 0.000143348623853 1 0 1
a,cyp2d6,substrate 1.0 0.000143348623853 1 0 1
a,cyp2c19,substrate 1.0 0.000143348623853 1 0 1
a,crossover,study 1.0 0.000143348623853 1 0 1
a,controlled,study 1.0 0.000143348623853 1 0 1
a,control,period 1.0 0.000143348623853 1 0 1
a,considerable,effect 1.0 0.000143348623853 1 0 1
a,consequent,possible 1.0 0.000143348623853 1 0 1
a,consequence,when 1.0 0.000143348623853 1 0 1
a,concomitantly,any 1.0 0.000143348623853 1 0 1
a,complex,effect 1.0 0.000143348623853 1 0 1
a,complete,and 1.0 0.000143348623853 1 0 1
a,competitive,inhibitor 1.0 0.000143348623853 1 0 1
a,common,component 1.0 0.000143348623853 1 0 1
a,closely,related 1.0 0.000143348623853 1 0 1
a,clinically,relevant 1.0 0.000143348623853 1 0 1
a,cause,and 1.0 0.000143348623853 1 0 1
a,causal,mechanism 1.0 0.000143348623853 1 0 1
a,case,report 1.0 0.000143348623853 1 0 1
a,c,a 1.0 0.000143348623853 1 0 1
a,blockade,by 1.0 0.000143348623853 1 0 1
a,beta,blocker 1.0 0.000143348623853 1 0 1
a,because,of 1.0 0.000143348623853 1 0 1
a,baseline,phenytoin 1.0 0.000143348623853 1 0 1
a,antidepressant,eg 1.0 0.000143348623853 1 0 1
a,and,under 1.0 0.000143348623853 1 0 1
a,and,oral 1.0 0.000143348623853 1 0 1
a,and,or 1.0 0.000143348623853 1 0 1
a,and,decrease 1.0 0.000143348623853 1 0 1
a,agonist,it 1.0 0.000143348623853 1 0 1
a,agonist,can 1.0 0.000143348623853 1 0 1
a,agent,has 1.0 0.000143348623853 1 0 1
a,a,cyp3a4 1.0 0.000143348623853 1 0 1
zone,in,this 1.0 0.000143348623853 0 1 -1
zollinger-ellison,ze,patients 1.0 0.000143348623853 0 1 -1
zofran,and,kytril 1.0 0.000143348623853 0 1 -1
zmax,have,not 1.0 0.000143348623853 0 1 -1
zinecard,on,the 1.0 0.000143348623853 0 1 -1
zinecard,does,not 1.0 0.000143348623853 0 1 -1
zidovudine,there,is 1.0 0.000143348623853 0 1 -1
zevalin,therapeutic,regimen 1.0 0.000143348623853 0 1 -1
zero,to,h 1.0 0.000143348623853 0 1 -1
zebeta,on,prothrombin 1.0 0.000143348623853 0 1 -1
ze,patients,no 1.0 0.000143348623853 0 1 -1
zdv,has,been 1.0 0.000143348623853 0 1 -1
zdv,and,which 1.0 0.000143348623853 0 1 -1
zaleplon,is,not 1.0 0.000143348623853 0 1 -1
your,skin,that 1.0 0.000143348623853 0 1 -1
your,physician,to 1.0 0.000143348623853 0 1 -1
your,doctor,or 1.0 0.000286697247706 0 2 -2
your,doctor,may 1.0 0.000143348623853 0 1 -1
your,doctor,before 1.0 0.000286697247706 0 2 -2
your,doctor,and 1.0 0.000143348623853 0 1 -1
your,condition,worse 1.0 0.000143348623853 0 1 -1
your,bodys,ability 1.0 0.000143348623853 0 1 -1
your,b12,status 1.0 0.000143348623853 0 1 -1
younger,patients,have 1.0 0.000143348623853 0 1 -1
younger,patients,but 1.0 0.000143348623853 0 1 -1
young,healthy,male 1.0 0.000143348623853 0 1 -1
you,think,you 1.0 0.000143348623853 0 1 -1
you,take,a 1.0 0.000143348623853 0 1 -1
you,more,information 1.0 0.000143348623853 0 1 -1
you,may,use 1.0 0.000143348623853 0 1 -1
you,may,require 1.0 0.000143348623853 0 1 -1
you,are,years 1.0 0.000143348623853 0 1 -1
york,heart,association 1.0 0.000143348623853 0 1 -1
yielded,similar,serum 1.0 0.000143348623853 0 1 -1
yielded,a,significantly 1.0 0.000143348623853 0 1 -1
yet,statistically,significant 1.0 0.000143348623853 0 1 -1
yeast,and,for 1.0 0.000143348623853 0 1 -1
years,with,severe 1.0 0.000143348623853 0 1 -1
years,weight,range 1.0 0.000143348623853 0 1 -1
years,total,cholesterol 1.0 0.000143348623853 0 1 -1
years,on,multiple 1.0 0.000143348623853 0 1 -1
years,old,participated 1.0 0.000143348623853 0 1 -1
years,of,age 1.0 0.000573394495413 0 4 -4
years,have,not 1.0 0.000143348623853 0 1 -1
years,at,doses 1.0 0.000143348623853 0 1 -1
year-old,african-american,man 1.0 0.000143348623853 0 1 -1
year,risk,of 1.0 0.000143348623853 0 1 -1
year,pharmacokinetics,exposure-response 1.0 0.000143348623853 0 1 -1
year,monthly,comparison 1.0 0.000143348623853 0 1 -1
year,indicating,strong 1.0 0.000143348623853 0 1 -1
year,controlled,study 1.0 0.000143348623853 0 1 -1
y1,cells,stably 1.0 0.000143348623853 0 1 -1
xr,was,given 1.0 0.000143348623853 0 1 -1
xr,should,be 1.0 0.000286697247706 0 2 -2
xr,patients,received 1.0 0.000143348623853 0 1 -1
xii,vii-x,complex 1.0 0.000286697247706 0 2 -2
xigris,present,in 1.0 0.000286697247706 0 2 -2
xigris,may,affect 1.0 0.000143348623853 0 1 -1
xigris,is,used 1.0 0.000143348623853 0 1 -1
xigris,have,not 1.0 0.000286697247706 0 2 -2
xigris,caution,should 1.0 0.000143348623853 0 1 -1
xenobiotic,metabolism,using 1.0 0.000143348623853 0 1 -1
xanthine-derived,antagonists,tested 1.0 0.000143348623853 0 1 -1
xanthine,oxidase,from 1.0 0.000143348623853 0 1 -1
xanthine,derivatives,in 1.0 0.000143348623853 0 1 -1
xa,and,antithrombin 1.0 0.000286697247706 0 2 -2
x-ray,diffraction,differential 1.0 0.000143348623853 0 1 -1
x,xii,vii-x 1.0 0.000286697247706 0 2 -2
x,use,with 1.0 0.000143348623853 0 1 -1
x,l,with 1.0 0.000143348623853 0 1 -1
x,kg,in 1.0 0.000143348623853 0 1 -1
x,kg,and 1.0 0.000143348623853 0 1 -1
x,c3h,hen 1.0 0.000143348623853 0 1 -1
www,rxlist,com 1.0 0.000143348623853 0 1 -1
wshow,that,significantly 1.0 0.000143348623853 0 1 -1
wshow,no,evidence 1.0 0.000143348623853 0 1 -1
wshow,an,effect 1.0 0.000143348623853 0 1 -1
would,warrant,alteration 1.0 0.000143348623853 0 1 -1
would,therefore,not 1.0 0.000143348623853 0 1 -1
would,play,a 1.0 0.000143348623853 0 1 -1
would,permit,larger 1.0 0.000143348623853 0 1 -1
would,occur,when 1.0 0.000143348623853 0 1 -1
would,not,result 1.0 0.000143348623853 0 1 -1
would,not,be 1.0 0.000573394495413 0 4 -4
would,not,affect 1.0 0.000143348623853 0 1 -1
would,include,a 1.0 0.000143348623853 0 1 -1
would,coincide,duloxetine 1.0 0.000143348623853 0 1 -1
would,cause,direct 1.0 0.000143348623853 0 1 -1
would,be,useful 1.0 0.000143348623853 0 1 -1
would,be,unlikely 1.0 0.000143348623853 0 1 -1
would,affect,this 1.0 0.000143348623853 0 1 -1
wort,should,be 1.0 0.000143348623853 0 1 -1
wort,may,increase 1.0 0.000143348623853 0 1 -1
wort,may,decrease 1.0 0.000143348623853 0 1 -1
wort,in,patients 1.0 0.000143348623853 0 1 -1
wort,hypericum,perforatum 1.0 0.00043004587156 0 3 -3
wort,because,of 1.0 0.000143348623853 0 1 -1
wort,based,on 1.0 0.000143348623853 0 1 -1
worsening,renal,failure 1.0 0.000143348623853 0 1 -1
worsening,asthma,decreased 1.0 0.000143348623853 0 1 -1
worsened,glucose,control 1.0 0.000143348623853 0 1 -1
worsened,by,the 1.0 0.000143348623853 0 1 -1
worsen,the,tremor 1.0 0.000143348623853 0 1 -1
worse,and,prevent 1.0 0.000143348623853 0 1 -1
world,medical,literature 1.0 0.000143348623853 0 1 -1
world,health,organization 1.0 0.000143348623853 0 1 -1
works,differently,from 1.0 0.000143348623853 0 1 -1
working,properly,and 1.0 0.000143348623853 0 1 -1
workers,involved,in 1.0 0.000143348623853 0 1 -1
work,involved,the 1.0 0.000143348623853 0 1 -1
work,has,focused 1.0 0.000143348623853 0 1 -1
work,exists,in 1.0 0.000143348623853 0 1 -1
women,with,sexual 1.0 0.000143348623853 0 1 -1
women,who,use 1.0 0.000143348623853 0 1 -1
women,who,have 1.0 0.000143348623853 0 1 -1
women,who,are 1.0 0.000143348623853 0 1 -1
women,were,not 1.0 0.000143348623853 0 1 -1
women,should,practice 1.0 0.000143348623853 0 1 -1
women,receiving,the 1.0 0.000143348623853 0 1 -1
women,of,childbearing 1.0 0.00043004587156 0 3 -3
without,using,effective 1.0 0.000143348623853 0 1 -1
without,the,other 1.0 0.000143348623853 0 1 -1
without,the,need 1.0 0.000143348623853 0 1 -1
without,the,addition 1.0 0.000143348623853 0 1 -1
without,tdp,in 1.0 0.000143348623853 0 1 -1
without,significantly,lowering 1.0 0.000143348623853 0 1 -1
without,replacement,may 1.0 0.000143348623853 0 1 -1
without,mg,of 1.0 0.000143348623853 0 1 -1
without,indicated,that 1.0 0.000143348623853 0 1 -1
without,evidence,of 1.0 0.00129013761468 0 9 -9
without,endothelium,were 1.0 0.000143348623853 0 1 -1
without,doctor,or 1.0 0.000143348623853 0 1 -1
without,disturbing,the 1.0 0.000143348623853 0 1 -1
without,difficulty,once 1.0 0.000143348623853 0 1 -1
without,consulting,the 1.0 0.000143348623853 0 1 -1
without,coadministration,of 1.0 0.000143348623853 0 1 -1
without,co-administered,avonex 1.0 0.000143348623853 0 1 -1
without,climbing,paperhanging 1.0 0.000143348623853 0 1 -1
without,changes,in 1.0 0.000143348623853 0 1 -1
without,any,evidence 1.0 0.000286697247706 0 2 -2
without,any,change 1.0 0.000143348623853 0 1 -1
without,and,with 1.0 0.000143348623853 0 1 -1
without,alterations,of 1.0 0.000143348623853 0 1 -1
without,additional,caution 1.0 0.000143348623853 0 1 -1
without,a,significant 1.0 0.000143348623853 0 1 -1
within,weeks,and 1.0 0.000143348623853 0 1 -1
within,weeks,after 1.0 0.000143348623853 0 1 -1
within,the,two-hour 1.0 0.000143348623853 0 1 -1
within,the,two 1.0 0.000143348623853 0 1 -1
within,the,therapeutic 1.0 0.000286697247706 0 2 -2
within,the,recommended 1.0 0.000143348623853 0 1 -1
within,the,range 1.0 0.00043004587156 0 3 -3
within,the,limits 1.0 0.000143348623853 0 1 -1
within,several,months 1.0 0.000143348623853 0 1 -1
within,minutes,after 1.0 0.000143348623853 0 1 -1
within,less,than 1.0 0.000143348623853 0 1 -1
within,hours,most 1.0 0.000143348623853 0 1 -1
within,hours,after 1.0 0.000143348623853 0 1 -1
within,five,days 1.0 0.000143348623853 0 1 -1
within,class,not 1.0 0.000143348623853 0 1 -1
within,a,week 1.0 0.000143348623853 0 1 -1
withdrawn,within,hours 1.0 0.000143348623853 0 1 -1
withdrawn,in,conjunction 1.0 0.000143348623853 0 1 -1
withdrawn,from,patients 1.0 0.000286697247706 0 2 -2
withdrawn,from,cotherapy 1.0 0.000143348623853 0 1 -1
withdrawn,from,co-therapy 1.0 0.000573394495413 0 4 -4
withdrawn,from,a 1.0 0.000860091743119 0 6 -6
withdrawn,and,recurred 1.0 0.000143348623853 0 1 -1
withdrawal,the,sst 1.0 0.000143348623853 0 1 -1
withdrawal,the,most 1.0 0.000143348623853 0 1 -1
withdrawal,the,lst 1.0 0.000143348623853 0 1 -1
withdrawal,symptoms,may 1.0 0.000143348623853 0 1 -1
withdrawal,period,mg 1.0 0.000286697247706 0 2 -2
withdrawal,period,after 1.0 0.000143348623853 0 1 -1
withdrawal,of,the 1.0 0.000143348623853 0 1 -1
withdrawal,of,or 1.0 0.000143348623853 0 1 -1
withdrawal,from,dependence 1.0 0.000143348623853 0 1 -1
withdrawal,and,their 1.0 0.000143348623853 0 1 -1
with,your,bodys 1.0 0.000143348623853 0 1 -1
with,xigris,have 1.0 0.000143348623853 0 1 -1
with,xigris,caution 1.0 0.000143348623853 0 1 -1
with,wthionamide,trecator-sc 1.0 0.000143348623853 0 1 -1
with,wshow,no 1.0 0.000143348623853 0 1 -1
with,would,not 1.0 0.000143348623853 0 1 -1
with,without,evidence 1.0 0.000143348623853 0 1 -1
with,without,coadministered 1.0 0.000143348623853 0 1 -1
with,within,days 1.0 0.000143348623853 0 1 -1
with,with,respectto 1.0 0.000143348623853 0 1 -1
with,with,no 1.0 0.000143348623853 0 1 -1
with,whose,metabolism 1.0 0.000143348623853 0 1 -1
with,whole-cell,recording 1.0 0.000143348623853 0 1 -1
with,who,are 1.0 0.000143348623853 0 1 -1
with,which,to 1.0 0.000143348623853 0 1 -1
with,which,may 1.0 0.000143348623853 0 1 -1
with,which,it 1.0 0.000143348623853 0 1 -1
with,were,performed 1.0 0.000143348623853 0 1 -1
with,water-miscible,or 1.0 0.000143348623853 0 1 -1
with,was,evaluated 1.0 0.000286697247706 0 2 -2
with,videx,should 1.0 0.000143348623853 0 1 -1
with,very,high 1.0 0.000143348623853 0 1 -1
with,various,oral 1.0 0.000143348623853 0 1 -1
with,varapamil,and 1.0 0.000143348623853 0 1 -1
with,used,in 1.0 0.000143348623853 0 1 -1
with,use,of 1.0 0.000286697247706 0 2 -2
with,uricosuric,agents 1.0 0.000143348623853 0 1 -1
with,type,i 1.0 0.000143348623853 0 1 -1
with,type,diabetes 1.0 0.000286697247706 0 2 -2
with,two,doses 1.0 0.000143348623853 0 1 -1
with,tuberculosis,andusing 1.0 0.000143348623853 0 1 -1
with,triamterene,concomitant 1.0 0.000143348623853 0 1 -1
with,treatment,in 1.0 0.000143348623853 0 1 -1
with,torsades,de 1.0 0.000143348623853 0 1 -1
with,to,patients 1.0 0.000143348623853 0 1 -1
with,tikosyn,or 1.0 0.000143348623853 0 1 -1
with,tikosyn,and 1.0 0.000143348623853 0 1 -1
with,thus,support 1.0 0.000143348623853 0 1 -1
with,thrombolytic,agents 1.0 0.000143348623853 0 1 -1
with,those,of 1.0 0.000143348623853 0 1 -1
with,those,in 1.0 0.000143348623853 0 1 -1
with,this,organism 1.0 0.000143348623853 0 1 -1
with,this,combination 1.0 0.000143348623853 0 1 -1
with,thioridizine,or 1.0 0.000143348623853 0 1 -1
with,these,when 1.0 0.000143348623853 0 1 -1
with,these,on 1.0 0.000143348623853 0 1 -1
with,these,medicines 1.0 0.00043004587156 0 3 -3
with,these,does 1.0 0.000143348623853 0 1 -1
with,these,compounds 1.0 0.000143348623853 0 1 -1
with,their,physicians 1.0 0.000143348623853 0 1 -1
with,the,use 1.0 0.000573394495413 0 4 -4
with,the,urine 1.0 0.000143348623853 0 1 -1
with,the,supplied 1.0 0.000143348623853 0 1 -1
with,the,serum 1.0 0.00043004587156 0 3 -3
with,the,same 1.0 0.000143348623853 0 1 -1
with,the,release 1.0 0.000143348623853 0 1 -1
with,the,rate 1.0 0.000143348623853 0 1 -1
with,the,potential 1.0 0.000143348623853 0 1 -1
with,the,pi 1.0 0.000143348623853 0 1 -1
with,the,pharmacology-related 1.0 0.000143348623853 0 1 -1
with,the,patients 1.0 0.000143348623853 0 1 -1
with,the,patch-clamp 1.0 0.000143348623853 0 1 -1
with,the,other 1.0 0.000143348623853 0 1 -1
with,the,oral 1.0 0.000286697247706 0 2 -2
with,the,nerve 1.0 0.000143348623853 0 1 -1
with,the,negative 1.0 0.000143348623853 0 1 -1
with,the,morning 1.0 0.000143348623853 0 1 -1
with,the,mao-b 1.0 0.000143348623853 0 1 -1
with,the,listed 1.0 0.000286697247706 0 2 -2
with,the,lipid-lowering 1.0 0.000143348623853 0 1 -1
with,the,known 1.0 0.000286697247706 0 2 -2
with,the,intravenous 1.0 0.00043004587156 0 3 -3
with,the,initiation 1.0 0.000143348623853 0 1 -1
with,the,individual 1.0 0.000143348623853 0 1 -1
with,the,in 1.0 0.000143348623853 0 1 -1
with,the,hydroalcoholic 1.0 0.000143348623853 0 1 -1
with,the,hour 1.0 0.000143348623853 0 1 -1
with,the,highest 1.0 0.000143348623853 0 1 -1
with,the,growth 1.0 0.000143348623853 0 1 -1
with,the,glucose 1.0 0.000143348623853 0 1 -1
with,the,first 1.0 0.000143348623853 0 1 -1
with,the,extent 1.0 0.000143348623853 0 1 -1
with,the,exception 1.0 0.00043004587156 0 3 -3
with,the,evening 1.0 0.000143348623853 0 1 -1
with,the,disposition 1.0 0.000143348623853 0 1 -1
with,the,digi- 1.0 0.000143348623853 0 1 -1
with,the,differences 1.0 0.000143348623853 0 1 -1
with,the,determination 1.0 0.000143348623853 0 1 -1
with,the,data 1.0 0.000143348623853 0 1 -1
with,the,conversion 1.0 0.000143348623853 0 1 -1
with,the,conventional 1.0 0.000143348623853 0 1 -1
with,the,commonly 1.0 0.000143348623853 0 1 -1
with,the,coadministration 1.0 0.000286697247706 0 2 -2
with,the,clinical 1.0 0.000286697247706 0 2 -2
with,the,blood 1.0 0.000143348623853 0 1 -1
with,the,bio-rad 1.0 0.000143348623853 0 1 -1
with,the,assay 1.0 0.000286697247706 0 2 -2
with,the,and 1.0 0.000143348623853 0 1 -1
with,the,ames 1.0 0.000143348623853 0 1 -1
with,the,adverse 1.0 0.000143348623853 0 1 -1
with,the,addition 1.0 0.000143348623853 0 1 -1
with,the,activity 1.0 0.000143348623853 0 1 -1
with,that,reduce 1.0 0.000143348623853 0 1 -1
with,that,prolong 1.0 0.000143348623853 0 1 -1
with,that,potentiate 1.0 0.000143348623853 0 1 -1
with,that,inhibit 1.0 0.000573394495413 0 4 -4
with,that,induce 1.0 0.000143348623853 0 1 -1
with,that,in 1.0 0.000143348623853 0 1 -1
with,that,either 1.0 0.000143348623853 0 1 -1
with,that,can 1.0 0.000716743119266 0 5 -5
with,that,associated 1.0 0.000143348623853 0 1 -1
with,that,after 1.0 0.000143348623853 0 1 -1
with,tests,using 1.0 0.000286697247706 0 2 -2
with,tenormin,plus 1.0 0.000143348623853 0 1 -1
with,taxol,should 1.0 0.000143348623853 0 1 -1
with,tam,induces 1.0 0.000143348623853 0 1 -1
with,systemic,antiretroviral 1.0 0.000143348623853 0 1 -1
with,synthetic,hydroalcoholic 1.0 0.000143348623853 0 1 -1
with,synergistically,augmented 1.0 0.000143348623853 0 1 -1
with,symptoms,of 1.0 0.000143348623853 0 1 -1
with,sustiva,is 1.0 0.000143348623853 0 1 -1
with,sustiva,in 1.0 0.000143348623853 0 1 -1
with,sustiva,are 1.0 0.000143348623853 0 1 -1
with,sustiva,and 1.0 0.000286697247706 0 2 -2
with,sustained-release,channel 1.0 0.000143348623853 0 1 -1
with,suspension,yielded 1.0 0.000143348623853 0 1 -1
with,supplements,may 1.0 0.000143348623853 0 1 -1
with,sulfamethoxazole,concomitant 1.0 0.000143348623853 0 1 -1
with,such,the 1.0 0.000143348623853 0 1 -1
with,such,medication 1.0 0.000143348623853 0 1 -1
with,subsequent,diagnostic 1.0 0.000143348623853 0 1 -1
with,subsequent,cycles 1.0 0.000143348623853 0 1 -1
with,standard,cystic 1.0 0.000143348623853 0 1 -1
with,standard,clinical 1.0 0.000143348623853 0 1 -1
with,st,johns 1.0 0.000143348623853 0 1 -1
with,sprycel,in 1.0 0.000286697247706 0 2 -2
with,sprycel,close 1.0 0.000143348623853 0 1 -1
with,spectrophotometrically,determined 1.0 0.000143348623853 0 1 -1
with,specific,neurobiological 1.0 0.000143348623853 0 1 -1
with,some,urinary 1.0 0.000143348623853 0 1 -1
with,some,the 1.0 0.000143348623853 0 1 -1
with,some,colorimetric 1.0 0.000143348623853 0 1 -1
with,some,agents 1.0 0.000286697247706 0 2 -2
with,somatic,disease 1.0 0.000143348623853 0 1 -1
with,solid,phase 1.0 0.000143348623853 0 1 -1
with,sodium,and 1.0 0.000143348623853 0 1 -1
with,slow-release,mg 1.0 0.000143348623853 0 1 -1
with,skin,products 1.0 0.000143348623853 0 1 -1
with,single,metal 1.0 0.000143348623853 0 1 -1
with,simultaneous,use 1.0 0.000143348623853 0 1 -1
with,simultaneous,reduction 1.0 0.000143348623853 0 1 -1
with,simulect,with 1.0 0.000143348623853 0 1 -1
with,similar,responses 1.0 0.000143348623853 0 1 -1
with,similar,frequency 1.0 0.000143348623853 0 1 -1
with,significantly,fewer 1.0 0.000143348623853 0 1 -1
with,showed,no 1.0 0.000143348623853 0 1 -1
with,should,not 1.0 0.000143348623853 0 1 -1
with,short,s 1.0 0.000143348623853 0 1 -1
with,sexual,dysfunction 1.0 0.000143348623853 0 1 -1
with,severely,impaired 1.0 0.000143348623853 0 1 -1
with,severe,recalcitrant 1.0 0.000143348623853 0 1 -1
with,severe,bradycardia 1.0 0.000143348623853 0 1 -1
with,several,which 1.0 0.000143348623853 0 1 -1
with,serum,total 1.0 0.000143348623853 0 1 -1
with,serum,measurements 1.0 0.000143348623853 0 1 -1
with,serum,creatinine 1.0 0.000143348623853 0 1 -1
with,serotonin,syndrome 1.0 0.000143348623853 0 1 -1
with,serious,toxicity 1.0 0.000143348623853 0 1 -1
with,serial,pharmacokinetic 1.0 0.000143348623853 0 1 -1
with,schizophrenia,or 1.0 0.000286697247706 0 2 -2
with,schizophrenia,and 1.0 0.000143348623853 0 1 -1
with,salts,with 1.0 0.000143348623853 0 1 -1
with,ribavirin,see 1.0 0.000143348623853 0 1 -1
with,ribavirin,ribavirin 1.0 0.000143348623853 0 1 -1
with,rheumatoid,arthritis 1.0 0.000143348623853 0 1 -1
with,restricted,pulmonary 1.0 0.000143348623853 0 1 -1
with,respectto,safety 1.0 0.000143348623853 0 1 -1
with,respect,to 1.0 0.00100344036697 0 7 -7
with,resistance,which 1.0 0.000143348623853 0 1 -1
with,resistance,or 1.0 0.000143348623853 0 1 -1
with,reports,of 1.0 0.000143348623853 0 1 -1
with,reported,musculoskeletal 1.0 0.000143348623853 0 1 -1
with,repeated,dosing 1.0 0.000143348623853 0 1 -1
with,renal,insufficiency 1.0 0.00043004587156 0 3 -3
with,renal,and 1.0 0.000286697247706 0 2 -2
with,regimens,and 1.0 0.000143348623853 0 1 -1
with,regard,to 1.0 0.000573394495413 0 4 -4
with,reduced,requirements 1.0 0.000143348623853 0 1 -1
with,radiotherapy,may 1.0 0.000143348623853 0 1 -1
with,radiation,therapy 1.0 0.000143348623853 0 1 -1
with,quantitative,and 1.0 0.000143348623853 0 1 -1
with,qt-interval,prolongation 1.0 0.000143348623853 0 1 -1
with,pulmonary,arterial 1.0 0.000143348623853 0 1 -1
with,prostatectomy,radiation 1.0 0.000143348623853 0 1 -1
with,proscar,mg 1.0 0.000143348623853 0 1 -1
with,propecia,mg 1.0 0.000143348623853 0 1 -1
with,prolonged,administration 1.0 0.000143348623853 0 1 -1
with,prolongation,of 1.0 0.000143348623853 0 1 -1
with,produced,approximately 1.0 0.000143348623853 0 1 -1
with,primarily,metabolized 1.0 0.000143348623853 0 1 -1
with,previous,findings 1.0 0.000143348623853 0 1 -1
with,practically,only 1.0 0.000143348623853 0 1 -1
with,potentiates,a 1.0 0.000143348623853 0 1 -1
with,potentially,important 1.0 0.000143348623853 0 1 -1
with,potential,risk 1.0 0.000143348623853 0 1 -1
with,potent,inhibitors 1.0 0.000143348623853 0 1 -1
with,potent,inducers 1.0 0.000143348623853 0 1 -1
with,potassium-sparing,may 1.0 0.000143348623853 0 1 -1
with,plus,without 1.0 0.000143348623853 0 1 -1
with,plendil,the 1.0 0.000143348623853 0 1 -1
with,plenaxis,and 1.0 0.000143348623853 0 1 -1
with,platelet,function 1.0 0.00043004587156 0 3 -3
with,physicians,should 1.0 0.000143348623853 0 1 -1
with,phenyl-butazone,sodium 1.0 0.000143348623853 0 1 -1
with,peripheral,neuropathy 1.0 0.000286697247706 0 2 -2
with,pegasys,in 1.0 0.000143348623853 0 1 -1
with,pcp,dcg-iv 1.0 0.000143348623853 0 1 -1
with,parasympathomimetic,effects 1.0 0.000143348623853 0 1 -1
with,parasite,reduction 1.0 0.000143348623853 0 1 -1
with,other,will 1.0 0.000143348623853 0 1 -1
with,other,which 1.0 0.000143348623853 0 1 -1
with,other,was 1.0 0.000143348623853 0 1 -1
with,other,topical 1.0 0.000286697247706 0 2 -2
with,other,through 1.0 0.000286697247706 0 2 -2
with,other,therapy 1.0 0.000143348623853 0 1 -1
with,other,than 1.0 0.000143348623853 0 1 -1
with,other,products 1.0 0.000143348623853 0 1 -1
with,other,primarily 1.0 0.000143348623853 0 1 -1
with,other,pressor 1.0 0.000143348623853 0 1 -1
with,other,potent 1.0 0.000143348623853 0 1 -1
with,other,oxytocic 1.0 0.000286697247706 0 2 -2
with,other,oral 1.0 0.000143348623853 0 1 -1
with,other,nonsteroidal 1.0 0.000143348623853 0 1 -1
with,other,metabolized 1.0 0.00114678899083 0 8 -8
with,other,may 1.0 0.000143348623853 0 1 -1
with,other,including 1.0 0.000286697247706 0 2 -2
with,other,in 1.0 0.000143348623853 0 1 -1
with,other,ht1 1.0 0.000143348623853 0 1 -1
with,other,high 1.0 0.000143348623853 0 1 -1
with,other,have 1.0 0.000573394495413 0 4 -4
with,other,drugs 1.0 0.000286697247706 0 2 -2
with,other,dialysis 1.0 0.000143348623853 0 1 -1
with,other,diagnostic 1.0 0.000143348623853 0 1 -1
with,other,creams 1.0 0.000143348623853 0 1 -1
with,other,combinations 1.0 0.000143348623853 0 1 -1
with,other,clinically 1.0 0.000143348623853 0 1 -1
with,other,chelator 1.0 0.000143348623853 0 1 -1
with,other,carbonic 1.0 0.000143348623853 0 1 -1
with,other,calcium-containing 1.0 0.000143348623853 0 1 -1
with,other,by 1.0 0.000143348623853 0 1 -1
with,other,anti-asthma 1.0 0.000143348623853 0 1 -1
with,other,administered 1.0 0.000143348623853 0 1 -1
with,other,acting 1.0 0.000286697247706 0 2 -2
with,organ,transplants 1.0 0.000143348623853 0 1 -1
with,orencia,mtx 1.0 0.000143348623853 0 1 -1
with,oral,in 1.0 0.000143348623853 0 1 -1
with,or,to 1.0 0.000143348623853 0 1 -1
with,or,substituted 1.0 0.000143348623853 0 1 -1
with,or,since 1.0 0.000143348623853 0 1 -1
with,or,prolongation 1.0 0.000143348623853 0 1 -1
with,or,placebo 1.0 0.000143348623853 0 1 -1
with,or,patients 1.0 0.000143348623853 0 1 -1
with,or,might 1.0 0.000143348623853 0 1 -1
with,or,clinically 1.0 0.000143348623853 0 1 -1
with,or,carbidopa-levodopa 1.0 0.000143348623853 0 1 -1
with,or,affect 1.0 0.000143348623853 0 1 -1
with,opioid-evoked,hyperpolarization 1.0 0.000143348623853 0 1 -1
with,only,n3 1.0 0.000143348623853 0 1 -1
with,only,bodyweight 1.0 0.000143348623853 0 1 -1
with,one-stage,factor 1.0 0.000143348623853 0 1 -1
with,one-stage,coagulation 1.0 0.000143348623853 0 1 -1
with,on,performance 1.0 0.000143348623853 0 1 -1
with,of,this 1.0 0.000143348623853 0 1 -1
with,of,low 1.0 0.000143348623853 0 1 -1
with,of,animal 1.0 0.000143348623853 0 1 -1
with,of,a 1.0 0.000143348623853 0 1 -1
with,occasional,doses 1.0 0.000143348623853 0 1 -1
with,nutrition,or 1.0 0.000143348623853 0 1 -1
with,nucleophosmin,b23 1.0 0.000143348623853 0 1 -1
with,nsaids,the 1.0 0.000143348623853 0 1 -1
with,nph,human 1.0 0.000286697247706 0 2 -2
with,normal,subjects 1.0 0.000143348623853 0 1 -1
with,normal,renal 1.0 0.000286697247706 0 2 -2
with,normal,fat 1.0 0.000143348623853 0 1 -1
with,non-pegylated,alfa-2a 1.0 0.000143348623853 0 1 -1
with,non-aspergillus,polysaccharides 1.0 0.000143348623853 0 1 -1
with,no,specific 1.0 0.000143348623853 0 1 -1
with,no,increase 1.0 0.000143348623853 0 1 -1
with,no,evidence 1.0 0.000143348623853 0 1 -1
with,no,clinically 1.0 0.000286697247706 0 2 -2
with,no,alteration 1.0 0.000286697247706 0 2 -2
with,nnrtis,occur 1.0 0.000143348623853 0 1 -1
with,nm,oh 1.0 0.000143348623853 0 1 -1
with,nevirapine-,or 1.0 0.000143348623853 0 1 -1
with,neurons,recorded 1.0 0.000143348623853 0 1 -1
with,natrecor,were 1.0 0.000143348623853 0 1 -1
with,natrecor,in 1.0 0.000143348623853 0 1 -1
with,n,or 1.0 0.000286697247706 0 2 -2
with,myopathy,underlying 1.0 0.000143348623853 0 1 -1
with,muscle,relaxants 1.0 0.000143348623853 0 1 -1
with,mtx,have 1.0 0.000143348623853 0 1 -1
with,more,than 1.0 0.000143348623853 0 1 -1
with,moieties,significantly 1.0 0.000143348623853 0 1 -1
with,moderate,renal 1.0 0.000143348623853 0 1 -1
with,mild,uncomplicated 1.0 0.000143348623853 0 1 -1
with,micromol,l 1.0 0.000143348623853 0 1 -1
with,mhd,and 1.0 0.000143348623853 0 1 -1
with,mg,vardenafil 1.0 0.000143348623853 0 1 -1
with,mg,three 1.0 0.000143348623853 0 1 -1
with,mg,tablets 1.0 0.000143348623853 0 1 -1
with,mg,m2 1.0 0.000143348623853 0 1 -1
with,mg,followed 1.0 0.000143348623853 0 1 -1
with,mg,every 1.0 0.000286697247706 0 2 -2
with,mg,d 1.0 0.000143348623853 0 1 -1
with,mg,b 1.0 0.000143348623853 0 1 -1
with,metabolized,by 1.0 0.000286697247706 0 2 -2
with,metabolism,very 1.0 0.000143348623853 0 1 -1
with,membranes,and 1.0 0.000143348623853 0 1 -1
with,mefloquine,have 1.0 0.000143348623853 0 1 -1
with,medications,with 1.0 0.000286697247706 0 2 -2
with,medication,iodine-containing 1.0 0.000143348623853 0 1 -1
with,measurement,of 1.0 0.00043004587156 0 3 -3
with,may,intensify 1.0 0.000143348623853 0 1 -1
with,may,have 1.0 0.000143348623853 0 1 -1
with,may,cause 1.0 0.000143348623853 0 1 -1
with,maximum,levels 1.0 0.000143348623853 0 1 -1
with,many,without 1.0 0.000143348623853 0 1 -1
with,m-dinitrobenzene,used 1.0 0.000143348623853 0 1 -1
with,m,g 1.0 0.000143348623853 0 1 -1
with,lymphoma,on 1.0 0.000143348623853 0 1 -1
with,long-,and 1.0 0.000143348623853 0 1 -1
with,lodosyn,carbidopa 1.0 0.000143348623853 0 1 -1
with,lodosyn,and 1.0 0.000143348623853 0 1 -1
with,lodine,as 1.0 0.000143348623853 0 1 -1
with,local,close 1.0 0.000143348623853 0 1 -1
with,lipid-lowering,that 1.0 0.000143348623853 0 1 -1
with,likewise,further 1.0 0.000143348623853 0 1 -1
with,likely,to 1.0 0.000143348623853 0 1 -1
with,life-threatening,ventricular 1.0 0.000143348623853 0 1 -1
with,less,than 1.0 0.000143348623853 0 1 -1
with,less,enzyme 1.0 0.000286697247706 0 2 -2
with,left,ventricular 1.0 0.000143348623853 0 1 -1
with,lean,rats 1.0 0.000143348623853 0 1 -1
with,larger,doses 1.0 0.000286697247706 0 2 -2
with,laboratory,tests 1.0 0.000143348623853 0 1 -1
with,l-tryptophan,may 1.0 0.000143348623853 0 1 -1
with,known,to 1.0 0.000286697247706 0 2 -2
with,known,substrates 1.0 0.000143348623853 0 1 -1
with,knowledge,of 1.0 0.000143348623853 0 1 -1
with,kerlone,and 1.0 0.000143348623853 0 1 -1
with,kemstrotm,was 1.0 0.000143348623853 0 1 -1
with,joint,action 1.0 0.000143348623853 0 1 -1
with,iv,such 1.0 0.000143348623853 0 1 -1
with,its,congeners 1.0 0.000143348623853 0 1 -1
with,it,is 1.0 0.000143348623853 0 1 -1
with,it,has 1.0 0.000143348623853 0 1 -1
with,isocarboxazid,and 1.0 0.000143348623853 0 1 -1
with,is,thus 1.0 0.000143348623853 0 1 -1
with,irradiation,has 1.0 0.000143348623853 0 1 -1
with,iopidine,ophthalmic 1.0 0.000143348623853 0 1 -1
with,invirase,and 1.0 0.000143348623853 0 1 -1
with,intravenous,hydration 1.0 0.000143348623853 0 1 -1
with,intravenous,at 1.0 0.000143348623853 0 1 -1
with,intravenous,administration 1.0 0.000143348623853 0 1 -1
with,intramuscular,doses 1.0 0.000143348623853 0 1 -1
with,interferon,beta 1.0 0.000143348623853 0 1 -1
with,inhibitors,or 1.0 0.000143348623853 0 1 -1
with,inhibiting,cyp3a 1.0 0.000143348623853 0 1 -1
with,infusion,solutions 1.0 0.000143348623853 0 1 -1
with,indocin,have 1.0 0.000143348623853 0 1 -1
with,increasing,concentration 1.0 0.000143348623853 0 1 -1
with,increases,the 1.0 0.00043004587156 0 3 -3
with,increases,serum 1.0 0.000143348623853 0 1 -1
with,increased,concentrations 1.0 0.000143348623853 0 1 -1
with,incisive,by 1.0 0.000143348623853 0 1 -1
with,in,several 1.0 0.000143348623853 0 1 -1
with,in,or 1.0 0.000143348623853 0 1 -1
with,in,man 1.0 0.000143348623853 0 1 -1
with,in,clinical 1.0 0.000143348623853 0 1 -1
with,in,an 1.0 0.000143348623853 0 1 -1
with,in,all 1.0 0.000143348623853 0 1 -1
with,in,adults 1.0 0.000143348623853 0 1 -1
with,in,a 1.0 0.000286697247706 0 2 -2
with,impaired,ventricular 1.0 0.000143348623853 0 1 -1
with,impaired,liver 1.0 0.000143348623853 0 1 -1
with,impaired,cardiac 1.0 0.000143348623853 0 1 -1
with,ibandronate,was 1.0 0.000143348623853 0 1 -1
with,ibandronate,mg 1.0 0.000143348623853 0 1 -1
with,hypokalemia,or 1.0 0.000143348623853 0 1 -1
with,hyperthyroidism,hypertension 1.0 0.000143348623853 0 1 -1
with,hypercholesterolemia,concomitant 1.0 0.000143348623853 0 1 -1
with,hydrochloride,mg 1.0 0.000143348623853 0 1 -1
with,humira,has 1.0 0.000143348623853 0 1 -1
with,human,volunteers 1.0 0.000143348623853 0 1 -1
with,human,serum 1.0 0.000143348623853 0 1 -1
with,human,liver 1.0 0.000143348623853 0 1 -1
with,human,immunodeficiency 1.0 0.000286697247706 0 2 -2
with,hormonal,since 1.0 0.000143348623853 0 1 -1
with,hormonal,and 1.0 0.000143348623853 0 1 -1
with,hiv-related,systemic 1.0 0.000143348623853 0 1 -1
with,hiv-nhl,who 1.0 0.000143348623853 0 1 -1
with,highly,protein-bound 1.0 0.000143348623853 0 1 -1
with,highly,protein 1.0 0.000143348623853 0 1 -1
with,high,viral 1.0 0.000143348623853 0 1 -1
with,high,affinity 1.0 0.000143348623853 0 1 -1
with,hepatic,or 1.0 0.000143348623853 0 1 -1
with,hepatic,insufficiency 1.0 0.000143348623853 0 1 -1
with,hepatic,injury 1.0 0.000143348623853 0 1 -1
with,hepatic,impairment 1.0 0.000143348623853 0 1 -1
with,heparin-induced,thrombocytopenia 1.0 0.000143348623853 0 1 -1
with,hemostasis,nsaids 1.0 0.000143348623853 0 1 -1
with,heart,failure 1.0 0.00043004587156 0 3 -3
with,healthy,male 1.0 0.000143348623853 0 1 -1
with,hcl,an 1.0 0.000143348623853 0 1 -1
with,hcl,a 1.0 0.000143348623853 0 1 -1
with,have,not 1.0 0.000286697247706 0 2 -2
with,have,been 1.0 0.000143348623853 0 1 -1
with,have,a 1.0 0.000143348623853 0 1 -1
with,has,not 1.0 0.000573394495413 0 4 -4
with,has,also 1.0 0.000143348623853 0 1 -1
with,hard,gelatin 1.0 0.000143348623853 0 1 -1
with,had,no 1.0 0.000286697247706 0 2 -2
with,haca,titers 1.0 0.000143348623853 0 1 -1
with,habituating,potential 1.0 0.000143348623853 0 1 -1
with,greater,than 1.0 0.000143348623853 0 1 -1
with,grapefruit,juice 1.0 0.000143348623853 0 1 -1
with,glutathione,or 1.0 0.000143348623853 0 1 -1
with,glucuronidation,being 1.0 0.000143348623853 0 1 -1
with,glucose,intolerance 1.0 0.000143348623853 0 1 -1
with,general,may 1.0 0.000143348623853 0 1 -1
with,general,antianxiety 1.0 0.000143348623853 0 1 -1
with,gastric,fistulas 1.0 0.000143348623853 0 1 -1
with,ganglionic,peripheral 1.0 0.000143348623853 0 1 -1
with,ganglionic,or 1.0 0.000143348623853 0 1 -1
with,g,kg 1.0 0.000143348623853 0 1 -1
with,further,enhanced 1.0 0.000143348623853 0 1 -1
with,full,recovery 1.0 0.000143348623853 0 1 -1
with,fruit,juices 1.0 0.000143348623853 0 1 -1
with,frequent,monitoring 1.0 0.00043004587156 0 3 -3
with,four,kinds 1.0 0.000143348623853 0 1 -1
with,fortovase,may 1.0 0.000143348623853 0 1 -1
with,for,less 1.0 0.000143348623853 0 1 -1
with,food,see 1.0 0.000143348623853 0 1 -1
with,food,or 1.0 0.000143348623853 0 1 -1
with,fondaparinux,the 1.0 0.000143348623853 0 1 -1
with,fluoxetine,a 1.0 0.000143348623853 0 1 -1
with,first-episode,or 1.0 0.000143348623853 0 1 -1
with,few,individuals 1.0 0.000143348623853 0 1 -1
with,fentanyl,cyp3a4 1.0 0.000143348623853 0 1 -1
with,features,resembling 1.0 0.000143348623853 0 1 -1
with,faslodex,in 1.0 0.000143348623853 0 1 -1
with,failed,to 1.0 0.000143348623853 0 1 -1
with,expected,physiologic 1.0 0.000143348623853 0 1 -1
with,erythromycin,and 1.0 0.000143348623853 0 1 -1
with,erectile,dysfunction 1.0 0.000143348623853 0 1 -1
with,equal,concentrations 1.0 0.000143348623853 0 1 -1
with,epilepsy,ingesting 1.0 0.00043004587156 0 3 -3
with,epilepsy,also 1.0 0.000143348623853 0 1 -1
with,enzyme-based,tests 1.0 0.00043004587156 0 3 -3
with,enzyme,based 1.0 0.000143348623853 0 1 -1
with,enzymatic-based,assays 1.0 0.000143348623853 0 1 -1
with,emtriva,has 1.0 0.000143348623853 0 1 -1
with,emphasis,on 1.0 0.000143348623853 0 1 -1
with,elemental,primarily 1.0 0.000143348623853 0 1 -1
with,either,single 1.0 0.000143348623853 0 1 -1
with,either,of 1.0 0.000286697247706 0 2 -2
with,either,mg 1.0 0.000143348623853 0 1 -1
with,either,grapefruit 1.0 0.000143348623853 0 1 -1
with,eg,rt-pa 1.0 0.000143348623853 0 1 -1
with,early-phase,schizophrenia 1.0 0.000143348623853 0 1 -1
with,each,successive 1.0 0.000143348623853 0 1 -1
with,each,of 1.0 0.000143348623853 0 1 -1
with,dynacirc,an 1.0 0.000143348623853 0 1 -1
with,dual,therapy 1.0 0.000143348623853 0 1 -1
with,drugs,that 1.0 0.000286697247706 0 2 -2
with,drugs,or 1.0 0.000143348623853 0 1 -1
with,drugs,administered 1.0 0.000143348623853 0 1 -1
with,double,strength 1.0 0.000143348623853 0 1 -1
with,doses,of 1.0 0.000143348623853 0 1 -1
with,doses,higher 1.0 0.000286697247706 0 2 -2
with,doses,corresponding 1.0 0.000143348623853 0 1 -1
with,dose,reduction 1.0 0.000143348623853 0 1 -1
with,dosage,adjustment 1.0 0.000286697247706 0 2 -2
with,dopa,decarboxylase 1.0 0.000143348623853 0 1 -1
with,does,not 1.0 0.000143348623853 0 1 -1
with,divalent,or 1.0 0.000143348623853 0 1 -1
with,disease,states 1.0 0.000143348623853 0 1 -1
with,difluoroacetone,did 1.0 0.000143348623853 0 1 -1
with,differin,gel 1.0 0.000143348623853 0 1 -1
with,diethyl,pyrocarbonate 1.0 0.000143348623853 0 1 -1
with,did,not 1.0 0.000286697247706 0 2 -2
with,diagnostic,or 1.0 0.000143348623853 0 1 -1
with,diabetes,mellitus 1.0 0.000143348623853 0 1 -1
with,desirable,antimuscarinic 1.0 0.000143348623853 0 1 -1
with,described,as 1.0 0.000143348623853 0 1 -1
with,derivatives,k 1.0 0.000143348623853 0 1 -1
with,depression,in 1.0 0.000143348623853 0 1 -1
with,demonstrated,no 1.0 0.000143348623853 0 1 -1
with,demonstrated,efficacy 1.0 0.000143348623853 0 1 -1
with,decreased,levels 1.0 0.000143348623853 0 1 -1
with,daily,dosing 1.0 0.000143348623853 0 1 -1
with,daily,doses 1.0 0.000143348623853 0 1 -1
with,cytochalasin,d 1.0 0.000143348623853 0 1 -1
with,cyp3a4,substrate 1.0 0.000143348623853 0 1 -1
with,cyp3a4,inhibitors 1.0 0.000143348623853 0 1 -1
with,cyp2c19,the 1.0 0.000143348623853 0 1 -1
with,cyp1a2,and 1.0 0.000143348623853 0 1 -1
with,crohn,s 1.0 0.000143348623853 0 1 -1
with,creatinine,clearance 1.0 0.000143348623853 0 1 -1
with,coronary,artery 1.0 0.000286697247706 0 2 -2
with,cordarone,i 1.0 0.000143348623853 0 1 -1
with,copper,sulfate 1.0 0.000143348623853 0 1 -1
with,copper,reduction 1.0 0.000286697247706 0 2 -2
with,copegus,pegasys 1.0 0.000143348623853 0 1 -1
with,copegus,in 1.0 0.000143348623853 0 1 -1
with,copegus,did 1.0 0.000143348623853 0 1 -1
with,copd,should 1.0 0.000143348623853 0 1 -1
with,conventional,it 1.0 0.000143348623853 0 1 -1
with,continuation,of 1.0 0.000286697247706 0 2 -2
with,constant,values 1.0 0.000143348623853 0 1 -1
with,conditions,that 1.0 0.000143348623853 0 1 -1
with,conditions,such 1.0 0.000143348623853 0 1 -1
with,concurrent,administration 1.0 0.000143348623853 0 1 -1
with,concomitantly,administered 1.0 0.000143348623853 0 1 -1
with,concomitant,treatment 1.0 0.000143348623853 0 1 -1
with,concomitant,medications 1.0 0.000143348623853 0 1 -1
with,concomitant,medication 1.0 0.000143348623853 0 1 -1
with,concomitant,augmentin 1.0 0.000143348623853 0 1 -1
with,concomitant,agents 1.0 0.000143348623853 0 1 -1
with,concentrations,at 1.0 0.000143348623853 0 1 -1
with,complex,renal 1.0 0.000143348623853 0 1 -1
with,commonly,used 1.0 0.000143348623853 0 1 -1
with,commonly,employed 1.0 0.00043004587156 0 3 -3
with,combination,therapy 1.0 0.000143348623853 0 1 -1
with,coly-mycin,m 1.0 0.000143348623853 0 1 -1
with,colorectal,cancer 1.0 0.000143348623853 0 1 -1
with,coenzyme,a 1.0 0.000143348623853 0 1 -1
with,coadministered,with 1.0 0.000143348623853 0 1 -1
with,co-administered,avonex 1.0 0.000143348623853 0 1 -1
with,cns-active,has 1.0 0.000143348623853 0 1 -1
with,clomiphene,citrate 1.0 0.000143348623853 0 1 -1
with,clinitest,tablets 1.0 0.00043004587156 0 3 -3
with,clinical,laboratory 1.0 0.000143348623853 0 1 -1
with,chronic,hepatitis 1.0 0.000143348623853 0 1 -1
with,chop,chemotherapy 1.0 0.000143348623853 0 1 -1
with,cholesterol,synthesis 1.0 0.000143348623853 0 1 -1
with,chirocaine,that 1.0 0.000143348623853 0 1 -1
with,chemical,color 1.0 0.000143348623853 0 1 -1
with,changes,in 1.0 0.000143348623853 0 1 -1
with,cefamandole,naftate 1.0 0.000143348623853 0 1 -1
with,caution,when 1.0 0.000143348623853 0 1 -1
with,caution,since 1.0 0.000143348623853 0 1 -1
with,caution,especially 1.0 0.000143348623853 0 1 -1
with,caution,dose 1.0 0.000143348623853 0 1 -1
with,cardiovascular,disease 1.0 0.000286697247706 0 2 -2
with,cardiac,conduction 1.0 0.000143348623853 0 1 -1
with,cardiac,channel 1.0 0.000143348623853 0 1 -1
with,can,lead 1.0 0.000143348623853 0 1 -1
with,camp,in 1.0 0.000143348623853 0 1 -1
with,c-cholesteryl,oleate 1.0 0.000143348623853 0 1 -1
with,c,diethyl 1.0 0.000143348623853 0 1 -1
with,by,about 1.0 0.000143348623853 0 1 -1
with,but,there 1.0 0.000143348623853 0 1 -1
with,brovana,at 1.0 0.000143348623853 0 1 -1
with,brevibloc,esmolol 1.0 0.000143348623853 0 1 -1
with,brain,levels 1.0 0.000143348623853 0 1 -1
with,both,invirase 1.0 0.000143348623853 0 1 -1
with,blood,liver 1.0 0.000143348623853 0 1 -1
with,bleeding,or 1.0 0.000143348623853 0 1 -1
with,biocytin,with 1.0 0.000143348623853 0 1 -1
with,bioavailability,parameters 1.0 0.000143348623853 0 1 -1
with,bioassay,procedures 1.0 0.000143348623853 0 1 -1
with,biliary,excretion 1.0 0.000143348623853 0 1 -1
with,bextra,is 1.0 0.000143348623853 0 1 -1
with,beta-receptor,blockers 1.0 0.000143348623853 0 1 -1
with,beta,adrenergic-blocking 1.0 0.000143348623853 0 1 -1
with,benedicts,solution 1.0 0.000143348623853 0 1 -1
with,benedict,s 1.0 0.000286697247706 0 2 -2
with,be,temporarily 1.0 0.000143348623853 0 1 -1
with,baseline,neutrophil 1.0 0.000143348623853 0 1 -1
with,based,on 1.0 0.000143348623853 0 1 -1
with,avastin,when 1.0 0.000143348623853 0 1 -1
with,auc,was 1.0 0.000143348623853 0 1 -1
with,attenuated,live 1.0 0.000143348623853 0 1 -1
with,at,three 1.0 0.000143348623853 0 1 -1
with,at,least 1.0 0.000143348623853 0 1 -1
with,at,a 1.0 0.000143348623853 0 1 -1
with,as,this 1.0 0.000143348623853 0 1 -1
with,as,a 1.0 0.000143348623853 0 1 -1
with,are,used 1.0 0.000143348623853 0 1 -1
with,are,illustrated 1.0 0.000143348623853 0 1 -1
with,are,bodyweight 1.0 0.000143348623853 0 1 -1
with,appropriate,adjustment 1.0 0.000143348623853 0 1 -1
with,any,that 1.0 0.000143348623853 0 1 -1
with,any,routine 1.0 0.000143348623853 0 1 -1
with,any,other 1.0 0.000286697247706 0 2 -2
with,any,one 1.0 0.000143348623853 0 1 -1
with,any,antineoplastic 1.0 0.000143348623853 0 1 -1
with,antifungal,agents 1.0 0.000143348623853 0 1 -1
with,anti-neoplastic,agents 1.0 0.000143348623853 0 1 -1
with,another,positively-charged 1.0 0.000143348623853 0 1 -1
with,another,known 1.0 0.000573394495413 0 4 -4
with,another,drug 1.0 0.000143348623853 0 1 -1
with,another,agent 1.0 0.000143348623853 0 1 -1
with,angiotensin-,converting 1.0 0.000143348623853 0 1 -1
with,and,were 1.0 0.000143348623853 0 1 -1
with,and,the 1.0 0.000286697247706 0 2 -2
with,and,tenofovir 1.0 0.000143348623853 0 1 -1
with,and,subsequent 1.0 0.000143348623853 0 1 -1
with,and,several 1.0 0.000143348623853 0 1 -1
with,and,placebo 1.0 0.000143348623853 0 1 -1
with,and,or 1.0 0.000143348623853 0 1 -1
with,and,no 1.0 0.000143348623853 0 1 -1
with,and,lodine 1.0 0.000143348623853 0 1 -1
with,and,laboratory 1.0 0.000143348623853 0 1 -1
with,and,indicated 1.0 0.000143348623853 0 1 -1
with,and,including 1.0 0.000143348623853 0 1 -1
with,and,in 1.0 0.000143348623853 0 1 -1
with,and,have 1.0 0.000143348623853 0 1 -1
with,and,has 1.0 0.000143348623853 0 1 -1
with,and,following 1.0 0.000143348623853 0 1 -1
with,and,failed 1.0 0.000143348623853 0 1 -1
with,and,dopa 1.0 0.000143348623853 0 1 -1
with,and,between 1.0 0.000143348623853 0 1 -1
with,and,and 1.0 0.000143348623853 0 1 -1
with,and,against 1.0 0.000143348623853 0 1 -1
with,anaesthesia,for 1.0 0.000143348623853 0 1 -1
with,an,nsaid 1.0 0.000143348623853 0 1 -1
with,an,interval 1.0 0.000143348623853 0 1 -1
with,an,indication 1.0 0.000143348623853 0 1 -1
with,an,i-labelled 1.0 0.000143348623853 0 1 -1
with,an,erection 1.0 0.000143348623853 0 1 -1
with,an,an 1.0 0.000143348623853 0 1 -1
with,an,adjustment 1.0 0.000143348623853 0 1 -1
with,an,active 1.0 0.000143348623853 0 1 -1
with,amevive,before 1.0 0.000143348623853 0 1 -1
with,amenorrhea,the 1.0 0.000143348623853 0 1 -1
with,aluminum-,and 1.0 0.000143348623853 0 1 -1
with,altered,renal 1.0 0.000143348623853 0 1 -1
with,alt,and 1.0 0.000143348623853 0 1 -1
with,all,the 1.0 0.000143348623853 0 1 -1
with,all,in 1.0 0.000143348623853 0 1 -1
with,all,care 1.0 0.000143348623853 0 1 -1
with,alkaline,earth 1.0 0.000286697247706 0 2 -2
with,agents,that 1.0 0.00043004587156 0 3 -3
with,agents,such 1.0 0.000143348623853 0 1 -1
with,age-dependent,alterations 1.0 0.000143348623853 0 1 -1
with,affected,by 1.0 0.000143348623853 0 1 -1
with,advanced,hiv 1.0 0.000143348623853 0 1 -1
with,adrenergic,blockers 1.0 0.000143348623853 0 1 -1
with,administration,of 1.0 0.000143348623853 0 1 -1
with,administration,at 1.0 0.000143348623853 0 1 -1
with,adefovir,dipivoxil 1.0 0.000143348623853 0 1 -1
with,addictive,medications 1.0 0.000143348623853 0 1 -1
with,activase,for 1.0 0.000143348623853 0 1 -1
with,acetylsalicylic,acid 1.0 0.000143348623853 0 1 -1
with,acamprosate,concomitantly 1.0 0.000143348623853 0 1 -1
with,absorption,of 1.0 0.000143348623853 0 1 -1
with,abciximab,have 1.0 0.000143348623853 0 1 -1
with,a,very 1.0 0.000143348623853 0 1 -1
with,a,that 1.0 0.000143348623853 0 1 -1
with,a,steady 1.0 0.000143348623853 0 1 -1
with,a,small 1.0 0.000143348623853 0 1 -1
with,a,similar 1.0 0.000286697247706 0 2 -2
with,a,short-acting 1.0 0.000143348623853 0 1 -1
with,a,sensitivity 1.0 0.000143348623853 0 1 -1
with,a,risk 1.0 0.000143348623853 0 1 -1
with,a,reduced 1.0 0.000143348623853 0 1 -1
with,a,predisposition 1.0 0.000143348623853 0 1 -1
with,a,pharmacological 1.0 0.000143348623853 0 1 -1
with,a,partially 1.0 0.000143348623853 0 1 -1
with,a,non-specific 1.0 0.000143348623853 0 1 -1
with,a,narrow 1.0 0.00043004587156 0 3 -3
with,a,median 1.0 0.000143348623853 0 1 -1
with,a,meal 1.0 0.000143348623853 0 1 -1
with,a,main 1.0 0.000143348623853 0 1 -1
with,a,luciferase 1.0 0.000143348623853 0 1 -1
with,a,low 1.0 0.000143348623853 0 1 -1
with,a,hydroalcoholic 1.0 0.000143348623853 0 1 -1
with,a,half-life 1.0 0.000143348623853 0 1 -1
with,a,group 1.0 0.000143348623853 0 1 -1
with,a,glucose-specific 1.0 0.000143348623853 0 1 -1
with,a,genetic 1.0 0.000143348623853 0 1 -1
with,a,focus 1.0 0.000143348623853 0 1 -1
with,a,false-positive 1.0 0.000143348623853 0 1 -1
with,a,dopa 1.0 0.000143348623853 0 1 -1
with,a,cyp3a4 1.0 0.000143348623853 0 1 -1
with,a,broad 1.0 0.000286697247706 0 2 -2
with,a,beta-adrenergic 1.0 0.000143348623853 0 1 -1
with,a,balanced 1.0 0.000143348623853 0 1 -1
wistar,rats,were 1.0 0.000286697247706 0 2 -2
wistar,rats,in 1.0 0.000143348623853 0 1 -1
wishing,to,terminate 1.0 0.000143348623853 0 1 -1
windows,that,are 1.0 0.000286697247706 0 2 -2
will,result,in 1.0 0.000286697247706 0 2 -2
will,occur,in 1.0 0.000143348623853 0 1 -1
will,not,increase 1.0 0.000143348623853 0 1 -1
will,not,correct 1.0 0.000143348623853 0 1 -1
will,inhibit,the 1.0 0.000143348623853 0 1 -1
will,increase,the 1.0 0.000143348623853 0 1 -1
will,have,a 1.0 0.000143348623853 0 1 -1
will,describe,the 1.0 0.000143348623853 0 1 -1
will,become,more 1.0 0.000143348623853 0 1 -1
will,be,required 1.0 0.000143348623853 0 1 -1
will,be,reduced 1.0 0.00043004587156 0 3 -3
will,be,longer 1.0 0.000143348623853 0 1 -1
will,be,less 1.0 0.000143348623853 0 1 -1
will,be,decreased 1.0 0.000143348623853 0 1 -1
will,aid,in 1.0 0.000143348623853 0 1 -1
wild-type,alleles,cyp2c9 1.0 0.000143348623853 0 1 -1
widespread,effects,for 1.0 0.000143348623853 0 1 -1
wide,variety,of 1.0 0.000286697247706 0 2 -2
wide,distribution,of 1.0 0.000143348623853 0 1 -1
whose,pulmonary,disease 1.0 0.000143348623853 0 1 -1
whose,plasma,levels 1.0 0.000143348623853 0 1 -1
whose,mothers,received 1.0 0.000143348623853 0 1 -1
whose,mothers,have 1.0 0.000143348623853 0 1 -1
whose,metabolism,is 1.0 0.000143348623853 0 1 -1
whose,absorption,is 1.0 0.000143348623853 0 1 -1
whom,this,effect 1.0 0.000143348623853 0 1 -1
whom,renal,insufficiency 1.0 0.000143348623853 0 1 -1
whom,either,long-acting 1.0 0.000143348623853 0 1 -1
whom,died,compared 1.0 0.000143348623853 0 1 -1
whom,cyp3a4,inducers 1.0 0.000143348623853 0 1 -1
whole-cell,tight,seal 1.0 0.000286697247706 0 2 -2
whole-cell,recording,technique 1.0 0.000143348623853 0 1 -1
whole-cell,recording,higher 1.0 0.000143348623853 0 1 -1
whole,body,tremors 1.0 0.000143348623853 0 1 -1
who,were,to 1.0 0.000143348623853 0 1 -1
who,were,stabilized 1.0 0.000286697247706 0 2 -2
who,were,receiving 1.0 0.000286697247706 0 2 -2
who,were,randomly 1.0 0.000143348623853 0 1 -1
who,were,already 1.0 0.000143348623853 0 1 -1
who,was,taking 1.0 0.000143348623853 0 1 -1
who,use,only 1.0 0.000143348623853 0 1 -1
who,take,lodine 1.0 0.000143348623853 0 1 -1
who,take,epa 1.0 0.000286697247706 0 2 -2
who,switched,from 1.0 0.000143348623853 0 1 -1
who,require,the 1.0 0.000143348623853 0 1 -1
who,require,anticoagulation 1.0 0.000143348623853 0 1 -1
who,require,additional 1.0 0.000143348623853 0 1 -1
who,received,under 1.0 0.000143348623853 0 1 -1
who,received,tended 1.0 0.000143348623853 0 1 -1
who,received,chop-haart 1.0 0.000143348623853 0 1 -1
who,received,chop 1.0 0.000143348623853 0 1 -1
who,received,both 1.0 0.000143348623853 0 1 -1
who,received,angiomax 1.0 0.000143348623853 0 1 -1
who,received,amevive 1.0 0.000143348623853 0 1 -1
who,must,receive 1.0 0.000143348623853 0 1 -1
who,may,subject 1.0 0.000143348623853 0 1 -1
who,may,be 1.0 0.000143348623853 0 1 -1
who,is,stable 1.0 0.000716743119266 0 5 -5
who,have,used 1.0 0.000143348623853 0 1 -1
who,have,discontinued 1.0 0.000143348623853 0 1 -1
who,have,developed 1.0 0.000143348623853 0 1 -1
who,have,congenital 1.0 0.000143348623853 0 1 -1
who,have,benign 1.0 0.000143348623853 0 1 -1
who,had,initial 1.0 0.000143348623853 0 1 -1
who,had,had 1.0 0.000143348623853 0 1 -1
who,had,depleting 1.0 0.000143348623853 0 1 -1
who,had,achieved 1.0 0.000143348623853 0 1 -1
who,do,not 1.0 0.000143348623853 0 1 -1
who,consume,greater 1.0 0.000143348623853 0 1 -1
who,become,pregnant 1.0 0.000143348623853 0 1 -1
who,are,pregnant 1.0 0.000143348623853 0 1 -1
who,are,incompletely 1.0 0.000143348623853 0 1 -1
who,are,given 1.0 0.000143348623853 0 1 -1
who,are,generally 1.0 0.000143348623853 0 1 -1
who,are,concomitantly 1.0 0.000286697247706 0 2 -2
who,are,also 1.0 0.000286697247706 0 2 -2
who,also,used 1.0 0.000286697247706 0 2 -2
white,male,rats 1.0 0.000143348623853 0 1 -1
white,female,volunteers 1.0 0.000143348623853 0 1 -1
while,using,pocs 1.0 0.000143348623853 0 1 -1
while,transfer,from 1.0 0.000143348623853 0 1 -1
while,they,cause 1.0 0.000143348623853 0 1 -1
while,the,recognition 1.0 0.000143348623853 0 1 -1
while,the,rats 1.0 0.000143348623853 0 1 -1
while,the,fraction 1.0 0.000143348623853 0 1 -1
while,taking,this 1.0 0.000143348623853 0 1 -1
while,taking,the 1.0 0.000143348623853 0 1 -1
while,taking,patients 1.0 0.00043004587156 0 3 -3
while,taking,fortovase 1.0 0.000143348623853 0 1 -1
while,taking,beta 1.0 0.000286697247706 0 2 -2
while,taking,amevive 1.0 0.000143348623853 0 1 -1
while,taking,acarbose 1.0 0.000143348623853 0 1 -1
while,other,studies 1.0 0.000143348623853 0 1 -1
while,only,a 1.0 0.000143348623853 0 1 -1
while,on,accutane 1.0 0.000143348623853 0 1 -1
while,no,formal 1.0 0.000143348623853 0 1 -1
while,no,clinical 1.0 0.000143348623853 0 1 -1
while,minimizing,the 1.0 0.000143348623853 0 1 -1
while,mean,inr 1.0 0.000143348623853 0 1 -1
while,mc,and 1.0 0.000143348623853 0 1 -1
while,left,ventricular 1.0 0.000143348623853 0 1 -1
while,it,is 1.0 0.000143348623853 0 1 -1
while,in,the 1.0 0.000143348623853 0 1 -1
while,gallic,acid 1.0 0.000143348623853 0 1 -1
while,fractional,transfer 1.0 0.000143348623853 0 1 -1
while,decreasing,components 1.0 0.000143348623853 0 1 -1
while,corresponding,values 1.0 0.000143348623853 0 1 -1
while,all,the 1.0 0.000716743119266 0 5 -5
while,additional,research 1.0 0.000143348623853 0 1 -1
which,were,submitted 1.0 0.000143348623853 0 1 -1
which,were,due 1.0 0.000143348623853 0 1 -1
which,we,call 1.0 0.000143348623853 0 1 -1
which,was,preceded 1.0 0.000143348623853 0 1 -1
which,was,far 1.0 0.000143348623853 0 1 -1
which,was,also 1.0 0.000143348623853 0 1 -1
which,was,administered 1.0 0.000286697247706 0 2 -2
which,to,examine 1.0 0.000143348623853 0 1 -1
which,they,are 1.0 0.000143348623853 0 1 -1
which,the,use 1.0 0.000143348623853 0 1 -1
which,the,rate 1.0 0.000143348623853 0 1 -1
which,the,effects 1.0 0.000143348623853 0 1 -1
which,the,doses 1.0 0.000143348623853 0 1 -1
which,support,these 1.0 0.000143348623853 0 1 -1
which,suggested,that 1.0 0.000143348623853 0 1 -1
which,requires,more 1.0 0.000143348623853 0 1 -1
which,requires,an 1.0 0.000143348623853 0 1 -1
which,required,the 1.0 0.000143348623853 0 1 -1
which,prolong,ecg 1.0 0.000143348623853 0 1 -1
which,plasma,concentrations 1.0 0.000286697247706 0 2 -2
which,only,requires 1.0 0.000143348623853 0 1 -1
which,must,be 1.0 0.000143348623853 0 1 -1
which,metabolizes,may 1.0 0.000143348623853 0 1 -1
which,may,sometimes 1.0 0.000286697247706 0 2 -2
which,may,potentiate 1.0 0.000143348623853 0 1 -1
which,may,not 1.0 0.000143348623853 0 1 -1
which,may,interfere 1.0 0.000143348623853 0 1 -1
which,may,intensify 1.0 0.000143348623853 0 1 -1
which,may,induce 1.0 0.000143348623853 0 1 -1
which,may,increase 1.0 0.000143348623853 0 1 -1
which,may,change 1.0 0.000143348623853 0 1 -1
which,may,also 1.0 0.000143348623853 0 1 -1
which,may,affect 1.0 0.000143348623853 0 1 -1
which,may,accentuate 1.0 0.000143348623853 0 1 -1
which,leads,to 1.0 0.000143348623853 0 1 -1
which,it,was 1.0 0.000143348623853 0 1 -1
which,it,might 1.0 0.000143348623853 0 1 -1
which,is,totally 1.0 0.000143348623853 0 1 -1
which,is,not 1.0 0.000143348623853 0 1 -1
which,is,manifested 1.0 0.000143348623853 0 1 -1
which,is,important 1.0 0.000143348623853 0 1 -1
which,is,further 1.0 0.000143348623853 0 1 -1
which,is,catalyzed 1.0 0.000143348623853 0 1 -1
which,is,about 1.0 0.000143348623853 0 1 -1
which,is,a 1.0 0.000286697247706 0 2 -2
which,interfere,with 1.0 0.000143348623853 0 1 -1
which,inhibits,cyp3a4 1.0 0.000143348623853 0 1 -1
which,inhibit,this 1.0 0.000143348623853 0 1 -1
which,inhibit,neuronal 1.0 0.000143348623853 0 1 -1
which,inhibit,cyp2d6 1.0 0.000143348623853 0 1 -1
which,inflammation,is 1.0 0.000143348623853 0 1 -1
which,indicate,that 1.0 0.000143348623853 0 1 -1
which,increased,with 1.0 0.000143348623853 0 1 -1
which,includes,anafranil 1.0 0.000143348623853 0 1 -1
which,impair,glomerular 1.0 0.000143348623853 0 1 -1
which,healthy,subjects 1.0 0.000143348623853 0 1 -1
which,have,been 1.0 0.000143348623853 0 1 -1
which,has,proven 1.0 0.000143348623853 0 1 -1
which,has,been 1.0 0.000143348623853 0 1 -1
which,had,a 1.0 0.000143348623853 0 1 -1
which,erbitux,was 1.0 0.000143348623853 0 1 -1
which,eight,hiv-infected 1.0 0.000143348623853 0 1 -1
which,effectiveness,is 1.0 0.000143348623853 0 1 -1
which,directly,affect 1.0 0.000143348623853 0 1 -1
which,could,decrease 1.0 0.000143348623853 0 1 -1
which,could,contribute 1.0 0.000143348623853 0 1 -1
which,could,cause 1.0 0.000143348623853 0 1 -1
which,confirms,the 1.0 0.000143348623853 0 1 -1
which,concurrent,therapy 1.0 0.000143348623853 0 1 -1
which,clearance,mechanism 1.0 0.000143348623853 0 1 -1
which,certain,are 1.0 0.000143348623853 0 1 -1
which,can,cause 1.0 0.000143348623853 0 1 -1
which,can,be 1.0 0.000143348623853 0 1 -1
which,can,affect 1.0 0.000286697247706 0 2 -2
which,blood,levels 1.0 0.000143348623853 0 1 -1
which,becomes,complete 1.0 0.000143348623853 0 1 -1
which,are,thought 1.0 0.000143348623853 0 1 -1
which,are,substrates 1.0 0.000143348623853 0 1 -1
which,are,not 1.0 0.000143348623853 0 1 -1
which,are,highly 1.0 0.000143348623853 0 1 -1
which,are,capable 1.0 0.000143348623853 0 1 -1
which,are,activated 1.0 0.000143348623853 0 1 -1
which,alterations,in 1.0 0.000143348623853 0 1 -1
which,also,lowers 1.0 0.000143348623853 0 1 -1
which,also,induces 1.0 0.000143348623853 0 1 -1
which,affect,hepatic 1.0 0.000143348623853 0 1 -1
which,adds,to 1.0 0.000143348623853 0 1 -1
which,a,single 1.0 0.000143348623853 0 1 -1
whether,would,cause 1.0 0.000143348623853 0 1 -1
whether,to,discontinue 1.0 0.00043004587156 0 3 -3
whether,this,was 1.0 0.000143348623853 0 1 -1
whether,this,represents 1.0 0.000143348623853 0 1 -1
whether,this,observation 1.0 0.000143348623853 0 1 -1
whether,this,interaction 1.0 0.000573394495413 0 4 -4
whether,this,could 1.0 0.000143348623853 0 1 -1
whether,they,respond 1.0 0.000143348623853 0 1 -1
whether,these,same 1.0 0.000143348623853 0 1 -1
whether,these,compounds 1.0 0.000143348623853 0 1 -1
whether,the,insulin-sensitizing 1.0 0.000143348623853 0 1 -1
whether,the,concomitant 1.0 0.000286697247706 0 2 -2
whether,the,are 1.0 0.000286697247706 0 2 -2
whether,similar,increases 1.0 0.000143348623853 0 1 -1
whether,other,progestational 1.0 0.000143348623853 0 1 -1
whether,or,or 1.0 0.000143348623853 0 1 -1
whether,or,not 1.0 0.000143348623853 0 1 -1
whether,might,induce 1.0 0.000143348623853 0 1 -1
whether,meth,administration 1.0 0.000143348623853 0 1 -1
whether,is,the 1.0 0.000143348623853 0 1 -1
whether,injection,of 1.0 0.000143348623853 0 1 -1
whether,has,a 1.0 0.000143348623853 0 1 -1
whether,ginsenosides-induced,inhibition 1.0 0.000143348623853 0 1 -1
whether,an,alteration 1.0 0.000143348623853 0 1 -1
whether,amevive,is 1.0 0.000143348623853 0 1 -1
whether,also,fulfils 1.0 0.000143348623853 0 1 -1
whether,abnormal,topoisomerase 1.0 0.000143348623853 0 1 -1
whereas,urinary,excretion 1.0 0.000143348623853 0 1 -1
whereas,the,medial 1.0 0.000143348623853 0 1 -1
whereas,the,first 1.0 0.000143348623853 0 1 -1
whereas,the,effects 1.0 0.000143348623853 0 1 -1
whereas,the,colonic 1.0 0.000143348623853 0 1 -1
whereas,none,of 1.0 0.000143348623853 0 1 -1
whereas,in,pigeons 1.0 0.000143348623853 0 1 -1
whereas,in,an 1.0 0.000143348623853 0 1 -1
whereas,h-spiroperidol,binding 1.0 0.000143348623853 0 1 -1
whereas,exogenous,respiration 1.0 0.000143348623853 0 1 -1
whereas,b,was 1.0 0.000143348623853 0 1 -1
where,the,effects 1.0 0.000143348623853 0 1 -1
where,survival,was 1.0 0.000143348623853 0 1 -1
where,serious,ventricular 1.0 0.000143348623853 0 1 -1
where,patients,were 1.0 0.000143348623853 0 1 -1
where,or,other 1.0 0.000143348623853 0 1 -1
where,is,given 1.0 0.000143348623853 0 1 -1
where,endothelial,function 1.0 0.000143348623853 0 1 -1
where,appropriate,plasma 1.0 0.000143348623853 0 1 -1
where,and,were 1.0 0.000143348623853 0 1 -1
where,abuse,of 1.0 0.000143348623853 0 1 -1
whenever,these,agents 1.0 0.000143348623853 0 1 -1
whenever,possible,before 1.0 0.000143348623853 0 1 -1
whenever,one,of 1.0 0.000716743119266 0 5 -5
whenever,increased,thioether 1.0 0.000143348623853 0 1 -1
whenever,an,agent 1.0 0.000143348623853 0 1 -1
whenever,a,tca 1.0 0.000573394495413 0 4 -4
when,xigris,is 1.0 0.000143348623853 0 1 -1
when,was,withdrawn 1.0 0.000143348623853 0 1 -1
when,viracept,was 1.0 0.000143348623853 0 1 -1
when,vioxx,is 1.0 0.000143348623853 0 1 -1
when,vardenafil,mg 1.0 0.000143348623853 0 1 -1
when,using,these 1.0 0.000143348623853 0 1 -1
when,using,immunoanalytical 1.0 0.000143348623853 0 1 -1
when,using,for 1.0 0.000143348623853 0 1 -1
when,using,clinitest 1.0 0.000143348623853 0 1 -1
when,used,with 1.0 0.000143348623853 0 1 -1
when,two,single 1.0 0.000143348623853 0 1 -1
when,tumor,response 1.0 0.000143348623853 0 1 -1
when,treatment,is 1.0 0.000143348623853 0 1 -1
when,treating,patients 1.0 0.00043004587156 0 3 -3
when,treated,with 1.0 0.000143348623853 0 1 -1
when,this,is 1.0 0.000286697247706 0 2 -2
when,these,two 1.0 0.000143348623853 0 1 -1
when,these,products 1.0 0.000716743119266 0 5 -5
when,these,drugs 1.0 0.000143348623853 0 1 -1
when,these,are 1.0 0.000716743119266 0 5 -5
when,therapeutic,concentrations 1.0 0.000143348623853 0 1 -1
when,their,main 1.0 0.000143348623853 0 1 -1
when,the,were 1.0 0.000143348623853 0 1 -1
when,the,use 1.0 0.000143348623853 0 1 -1
when,the,thioether 1.0 0.000143348623853 0 1 -1
when,the,test 1.0 0.000143348623853 0 1 -1
when,the,preceding 1.0 0.000143348623853 0 1 -1
when,the,patient 1.0 0.000143348623853 0 1 -1
when,the,nerves 1.0 0.000143348623853 0 1 -1
when,the,muscle 1.0 0.000143348623853 0 1 -1
when,the,medication 1.0 0.000143348623853 0 1 -1
when,the,following 1.0 0.000143348623853 0 1 -1
when,the,dose 1.0 0.000143348623853 0 1 -1
when,the,decision 1.0 0.000143348623853 0 1 -1
when,the,cyp3a4 1.0 0.000143348623853 0 1 -1
when,the,cyp2d6 1.0 0.000143348623853 0 1 -1
when,the,concentration 1.0 0.000143348623853 0 1 -1
when,the,are 1.0 0.000143348623853 0 1 -1
when,tested,up 1.0 0.000143348623853 0 1 -1
when,tested,in 1.0 0.000143348623853 0 1 -1
when,taking,this 1.0 0.000143348623853 0 1 -1
when,taking,placebo 1.0 0.000143348623853 0 1 -1
when,taken,with 1.0 0.000143348623853 0 1 -1
when,taken,concurrently 1.0 0.000286697247706 0 2 -2
when,such,drugs 1.0 0.000286697247706 0 2 -2
when,such,combined 1.0 0.00043004587156 0 3 -3
when,such,are 1.0 0.00172018348624 0 12 -12
when,subjects,were 1.0 0.000143348623853 0 1 -1
when,starting,or 1.0 0.000286697247706 0 2 -2
when,starlix,mg 1.0 0.000286697247706 0 2 -2
when,simulect,is 1.0 0.000143348623853 0 1 -1
when,serious,drug 1.0 0.000143348623853 0 1 -1
when,screening,urine 1.0 0.000143348623853 0 1 -1
when,romazicon,was 1.0 0.000143348623853 0 1 -1
when,rebif,is 1.0 0.000143348623853 0 1 -1
when,proquin,xr 1.0 0.000143348623853 0 1 -1
when,prinivil,was 1.0 0.000143348623853 0 1 -1
when,prescribing,for 1.0 0.000143348623853 0 1 -1
when,prescribing,concomitantly 1.0 0.000143348623853 0 1 -1
when,possible,interactions 1.0 0.000143348623853 0 1 -1
when,ponstel,is 1.0 0.000143348623853 0 1 -1
when,placed,on 1.0 0.000143348623853 0 1 -1
when,patients,receive 1.0 0.000143348623853 0 1 -1
when,patients,have 1.0 0.000143348623853 0 1 -1
when,patients,being 1.0 0.000143348623853 0 1 -1
when,parenteral,are 1.0 0.000143348623853 0 1 -1
when,orudis,doses 1.0 0.000143348623853 0 1 -1
when,oral,therapy 1.0 0.000143348623853 0 1 -1
when,or,were 1.0 0.000143348623853 0 1 -1
when,or,nitrous 1.0 0.000143348623853 0 1 -1
when,norpace,was 1.0 0.000143348623853 0 1 -1
when,nimbex,is 1.0 0.000143348623853 0 1 -1
when,new,agents 1.0 0.000143348623853 0 1 -1
when,measured,by 1.0 0.000143348623853 0 1 -1
when,macrolide,or 1.0 0.000143348623853 0 1 -1
when,lotensin,was 1.0 0.000143348623853 0 1 -1
when,known,to 1.0 0.000143348623853 0 1 -1
when,it,combines 1.0 0.000143348623853 0 1 -1
when,is,the 1.0 0.000143348623853 0 1 -1
when,is,concurrently 1.0 0.000143348623853 0 1 -1
when,is,co 1.0 0.000143348623853 0 1 -1
when,increases,in 1.0 0.000143348623853 0 1 -1
when,hypothyroid,patients 1.0 0.000143348623853 0 1 -1
when,hydrochloride,was 1.0 0.000286697247706 0 2 -2
when,healthy,subjects 1.0 0.000143348623853 0 1 -1
when,grown,in 1.0 0.000143348623853 0 1 -1
when,giving,these 1.0 0.000286697247706 0 2 -2
when,given,together 1.0 0.000143348623853 0 1 -1
when,given,one 1.0 0.000716743119266 0 5 -5
when,given,in 1.0 0.00043004587156 0 3 -3
when,given,i 1.0 0.000143348623853 0 1 -1
when,given,concurrently 1.0 0.000286697247706 0 2 -2
when,given,concomitantly 1.0 0.000286697247706 0 2 -2
when,eye,drops 1.0 0.000143348623853 0 1 -1
when,extended,sodium 1.0 0.000143348623853 0 1 -1
when,evaluating,serum 1.0 0.000143348623853 0 1 -1
when,evaluating,plasma 1.0 0.000143348623853 0 1 -1
when,evaluating,men 1.0 0.000143348623853 0 1 -1
when,encountered,such 1.0 0.000143348623853 0 1 -1
when,duragesic,is 1.0 0.000143348623853 0 1 -1
when,duloxetine,and 1.0 0.000143348623853 0 1 -1
when,dosing,concurrently 1.0 0.000143348623853 0 1 -1
when,dosed,with 1.0 0.000143348623853 0 1 -1
when,deet,was 1.0 0.000143348623853 0 1 -1
when,d2o,was 1.0 0.000143348623853 0 1 -1
when,cyp3a4,inhibitors 1.0 0.000143348623853 0 1 -1
when,contrast,media 1.0 0.000286697247706 0 2 -2
when,concurrent,therapy 1.0 0.000286697247706 0 2 -2
when,compared,with 1.0 0.000286697247706 0 2 -2
when,combining,with 1.0 0.000143348623853 0 1 -1
when,combined,therapy 1.0 0.000143348623853 0 1 -1
when,coadministering,medications 1.0 0.000143348623853 0 1 -1
when,coadministered,in 1.0 0.000143348623853 0 1 -1
when,changing,from 1.0 0.000143348623853 0 1 -1
when,cefotan,was 1.0 0.000143348623853 0 1 -1
when,briefly,exposed 1.0 0.000143348623853 0 1 -1
when,bleeding,times 1.0 0.000143348623853 0 1 -1
when,baraclude,is 1.0 0.000143348623853 0 1 -1
when,bactericidal,activity 1.0 0.000143348623853 0 1 -1
when,assessed,on 1.0 0.000143348623853 0 1 -1
when,are,used 1.0 0.000143348623853 0 1 -1
when,any,of 1.0 0.000143348623853 0 1 -1
when,anti-globulin,tests 1.0 0.000143348623853 0 1 -1
when,another,drug 1.0 0.000143348623853 0 1 -1
when,animals,are 1.0 0.000143348623853 0 1 -1
when,and,viracept 1.0 0.000143348623853 0 1 -1
when,and,these 1.0 0.000143348623853 0 1 -1
when,and,cerebyx 1.0 0.000143348623853 0 1 -1
when,an,adequate 1.0 0.000143348623853 0 1 -1
when,administering,this 1.0 0.000143348623853 0 1 -1
when,administering,taxol 1.0 0.000286697247706 0 2 -2
when,administering,other 1.0 0.000286697247706 0 2 -2
when,administering,mepron 1.0 0.000143348623853 0 1 -1
when,administering,cyp3a4 1.0 0.000143348623853 0 1 -1
when,administering,cerebyx 1.0 0.000143348623853 0 1 -1
when,administered,neonatally 1.0 0.000143348623853 0 1 -1
when,administered,minutes 1.0 0.000143348623853 0 1 -1
when,administered,during 1.0 0.000286697247706 0 2 -2
when,administered,alone 1.0 0.000143348623853 0 1 -1
when,adjustment,of 1.0 0.000143348623853 0 1 -1
when,addiction,is 1.0 0.000143348623853 0 1 -1
when,a,potent 1.0 0.000143348623853 0 1 -1
when,a,patient 1.0 0.000143348623853 0 1 -1
when,a,hypothyroid 1.0 0.000143348623853 0 1 -1
when,a,euthyroid 1.0 0.000143348623853 0 1 -1
wheals,and,flares 1.0 0.000143348623853 0 1 -1
wheal,and,flare 1.0 0.000143348623853 0 1 -1
what,to,do 1.0 0.000143348623853 0 1 -1
what,modern,medications 1.0 0.000143348623853 0 1 -1
west,midlands,a 1.0 0.000143348623853 0 1 -1
were,well,matched 1.0 0.000143348623853 0 1 -1
were,variable,and 1.0 0.000143348623853 0 1 -1
were,usually,mild 1.0 0.000143348623853 0 1 -1
were,used,to 1.0 0.00043004587156 0 3 -3
were,used,in 1.0 0.000143348623853 0 1 -1
were,undetectable,ng 1.0 0.000143348623853 0 1 -1
were,unchanged,hours 1.0 0.000143348623853 0 1 -1
were,unchanged,following 1.0 0.000286697247706 0 2 -2
were,unchanged,after 1.0 0.000143348623853 0 1 -1
were,unaffected,following 1.0 0.000143348623853 0 1 -1
were,unaffected,by 1.0 0.000286697247706 0 2 -2
were,treated,concurrently 1.0 0.000143348623853 0 1 -1
were,to,years 1.0 0.000143348623853 0 1 -1
were,to,times 1.0 0.000143348623853 0 1 -1
were,to,elucidate 1.0 0.000143348623853 0 1 -1
were,to,avoid 1.0 0.000143348623853 0 1 -1
were,thus,dosed 1.0 0.000143348623853 0 1 -1
were,there,any 1.0 0.000143348623853 0 1 -1
were,the,same 1.0 0.000286697247706 0 2 -2
were,the,pharmacokinetics 1.0 0.000143348623853 0 1 -1
were,tested,for 1.0 0.000143348623853 0 1 -1
were,taken,by 1.0 0.000286697247706 0 2 -2
were,taken,before 1.0 0.000143348623853 0 1 -1
were,systematically,investigated 1.0 0.000143348623853 0 1 -1
were,subsequently,found 1.0 0.000143348623853 0 1 -1
were,submitted,to 1.0 0.000286697247706 0 2 -2
were,studied,with 1.0 0.000143348623853 0 1 -1
were,studied,following 1.0 0.000143348623853 0 1 -1
were,stabilized,on 1.0 0.000286697247706 0 2 -2
were,similar,with 1.0 0.000143348623853 0 1 -1
were,similar,regardless 1.0 0.000143348623853 0 1 -1
were,similar,in 1.0 0.000143348623853 0 1 -1
were,similar,between 1.0 0.000143348623853 0 1 -1
were,significantly,lower 1.0 0.000143348623853 0 1 -1
were,significantly,larger 1.0 0.000143348623853 0 1 -1
were,significantly,greater 1.0 0.000143348623853 0 1 -1
were,short-lasting,as 1.0 0.000143348623853 0 1 -1
were,several,factors 1.0 0.000143348623853 0 1 -1
were,separated,by 1.0 0.000143348623853 0 1 -1
were,seen,on 1.0 0.000143348623853 0 1 -1
were,seen,in 1.0 0.00043004587156 0 3 -3
were,seen,after 1.0 0.000143348623853 0 1 -1
were,sampled,at 1.0 0.000143348623853 0 1 -1
were,sacrificed,and 1.0 0.000143348623853 0 1 -1
were,resistant,to 1.0 0.000143348623853 0 1 -1
were,reported,with 1.0 0.000143348623853 0 1 -1
were,reported,in 1.0 0.000573394495413 0 4 -4
were,reflected,in 1.0 0.000143348623853 0 1 -1
were,reduced,in 1.0 0.000143348623853 0 1 -1
were,recorded,while 1.0 0.000143348623853 0 1 -1
were,recorded,from 1.0 0.000143348623853 0 1 -1
were,recorded,at 1.0 0.000143348623853 0 1 -1
were,receiving,intravenous 1.0 0.000143348623853 0 1 -1
were,receiving,beta 1.0 0.000143348623853 0 1 -1
were,randomly,assigned 1.0 0.00043004587156 0 3 -3
were,randomized,to 1.0 0.000143348623853 0 1 -1
were,randomized,in 1.0 0.000143348623853 0 1 -1
were,prohibited,in 1.0 0.000143348623853 0 1 -1
were,prohibited,from 1.0 0.000143348623853 0 1 -1
were,precise,and 1.0 0.000143348623853 0 1 -1
were,positive,for 1.0 0.000143348623853 0 1 -1
were,picr,detected 1.0 0.000143348623853 0 1 -1
were,pi,with 1.0 0.000143348623853 0 1 -1
were,pharmacokinetic,parameters 1.0 0.000143348623853 0 1 -1
were,performed,with 1.0 0.000143348623853 0 1 -1
were,performed,on 1.0 0.000143348623853 0 1 -1
were,performed,both 1.0 0.000143348623853 0 1 -1
were,only,slightly 1.0 0.000143348623853 0 1 -1
were,only,observed 1.0 0.000143348623853 0 1 -1
were,on,chronic 1.0 0.000143348623853 0 1 -1
were,on,average 1.0 0.000143348623853 0 1 -1
were,of,maternal 1.0 0.000143348623853 0 1 -1
were,obtained,from 1.0 0.00043004587156 0 3 -3
were,observed,when 1.0 0.00043004587156 0 3 -3
were,observed,to 1.0 0.000143348623853 0 1 -1
were,observed,there 1.0 0.000143348623853 0 1 -1
were,observed,in 1.0 0.00186353211009 0 13 -13
were,observed,hours 1.0 0.000143348623853 0 1 -1
were,observed,for 1.0 0.000143348623853 0 1 -1
were,observed,by 1.0 0.000143348623853 0 1 -1
were,observed,but 1.0 0.000286697247706 0 2 -2
were,observed,between 1.0 0.000286697247706 0 2 -2
were,observed,after 1.0 0.000143348623853 0 1 -1
were,noted,with 1.0 0.000143348623853 0 1 -1
were,noted,in 1.0 0.00043004587156 0 3 -3
were,noted,during 1.0 0.000143348623853 0 1 -1
were,noted,at 1.0 0.000143348623853 0 1 -1
were,not,tested 1.0 0.000143348623853 0 1 -1
were,not,studied 1.0 0.000143348623853 0 1 -1
were,not,significantly 1.0 0.00100344036697 0 7 -7
were,not,significant 1.0 0.000143348623853 0 1 -1
were,not,seen 1.0 0.000143348623853 0 1 -1
were,not,quantitatively 1.0 0.000143348623853 0 1 -1
were,not,performed 1.0 0.000286697247706 0 2 -2
were,not,observed 1.0 0.000143348623853 0 1 -1
were,not,noted 1.0 0.000143348623853 0 1 -1
were,not,measured 1.0 0.000143348623853 0 1 -1
were,not,inhibited 1.0 0.000143348623853 0 1 -1
were,not,excluded 1.0 0.000143348623853 0 1 -1
were,not,different 1.0 0.000143348623853 0 1 -1
were,not,considered 1.0 0.000143348623853 0 1 -1
were,not,co-administered 1.0 0.000143348623853 0 1 -1
were,not,attenuated 1.0 0.000143348623853 0 1 -1
were,not,altered 1.0 0.000573394495413 0 4 -4
were,not,affected 1.0 0.0021502293578 0 15 -15
were,nonsteroidal,agents 1.0 0.000143348623853 0 1 -1
were,no,significant 1.0 0.00043004587156 0 3 -3
were,no,reports 1.0 0.000143348623853 0 1 -1
were,no,observed 1.0 0.000143348623853 0 1 -1
were,no,differential 1.0 0.000143348623853 0 1 -1
were,no,differences 1.0 0.000143348623853 0 1 -1
were,no,clinically 1.0 0.00143348623853 0 10 -10
were,no,changes 1.0 0.000143348623853 0 1 -1
were,no,alterations 1.0 0.000143348623853 0 1 -1
were,negative,on 1.0 0.000143348623853 0 1 -1
were,mp,aza 1.0 0.000143348623853 0 1 -1
were,more,pronounced 1.0 0.000143348623853 0 1 -1
were,more,likely 1.0 0.000143348623853 0 1 -1
were,more,efficiently 1.0 0.000143348623853 0 1 -1
were,measured,using 1.0 0.000143348623853 0 1 -1
were,measured,four 1.0 0.000143348623853 0 1 -1
were,measured,during 1.0 0.000143348623853 0 1 -1
were,measured,by 1.0 0.000143348623853 0 1 -1
were,maintained,on 1.0 0.000143348623853 0 1 -1
were,maintained,at 1.0 0.000143348623853 0 1 -1
were,mainly,receiving 1.0 0.000143348623853 0 1 -1
were,lowered,from 1.0 0.000143348623853 0 1 -1
were,killed,at 1.0 0.000143348623853 0 1 -1
were,kept,in 1.0 0.000143348623853 0 1 -1
were,investigated,in 1.0 0.000286697247706 0 2 -2
were,investigated,against 1.0 0.000143348623853 0 1 -1
were,intravenously,injected 1.0 0.000143348623853 0 1 -1
were,inhibited,by 1.0 0.000286697247706 0 2 -2
were,increased,in 1.0 0.000143348623853 0 1 -1
were,increased,fold 1.0 0.000143348623853 0 1 -1
were,increased,because 1.0 0.000143348623853 0 1 -1
were,increased,approximately 1.0 0.000143348623853 0 1 -1
were,inconclusive,with 1.0 0.000143348623853 0 1 -1
were,in,excess 1.0 0.000143348623853 0 1 -1
were,identified,through 1.0 0.000143348623853 0 1 -1
were,identified,as 1.0 0.000143348623853 0 1 -1
were,homozygous,for 1.0 0.000143348623853 0 1 -1
were,grouped,as 1.0 0.000143348623853 0 1 -1
were,given,weekly 1.0 0.000143348623853 0 1 -1
were,given,mg 1.0 0.000143348623853 0 1 -1
were,given,injections 1.0 0.000143348623853 0 1 -1
were,given,fu 1.0 0.000143348623853 0 1 -1
were,generated,from 1.0 0.000143348623853 0 1 -1
were,found,to 1.0 0.000286697247706 0 2 -2
were,found,but 1.0 0.000143348623853 0 1 -1
were,found,between 1.0 0.000143348623853 0 1 -1
were,followed,for 1.0 0.000143348623853 0 1 -1
were,fasted,and 1.0 0.000143348623853 0 1 -1
were,explored,with 1.0 0.000143348623853 0 1 -1
were,experienced,by 1.0 0.000143348623853 0 1 -1
were,examined,in 1.0 0.000143348623853 0 1 -1
were,evident,on 1.0 0.000143348623853 0 1 -1
were,evident,in 1.0 0.000143348623853 0 1 -1
were,evaluated,and 1.0 0.000143348623853 0 1 -1
were,enrolled,in 1.0 0.000143348623853 0 1 -1
were,elevated,with 1.0 0.000143348623853 0 1 -1
were,each,significantly 1.0 0.000143348623853 0 1 -1
were,each,found 1.0 0.000143348623853 0 1 -1
were,due,to 1.0 0.000143348623853 0 1 -1
were,dry,mouth 1.0 0.000143348623853 0 1 -1
were,drawn,at 1.0 0.000143348623853 0 1 -1
were,drawn,and 1.0 0.000143348623853 0 1 -1
were,dosed,weekly 1.0 0.000143348623853 0 1 -1
were,dose,proportional 1.0 0.000143348623853 0 1 -1
were,done,at 1.0 0.000143348623853 0 1 -1
were,divided,into 1.0 0.000286697247706 0 2 -2
were,determined,in 1.0 0.000143348623853 0 1 -1
were,determined,by 1.0 0.000286697247706 0 2 -2
were,determined,after 1.0 0.000143348623853 0 1 -1
were,detected,except 1.0 0.000143348623853 0 1 -1
were,demonstrated,only 1.0 0.000143348623853 0 1 -1
were,deaths,in 1.0 0.000143348623853 0 1 -1
were,conducted,with 1.0 0.000143348623853 0 1 -1
were,conducted,to 1.0 0.000143348623853 0 1 -1
were,conducted,on 1.0 0.000286697247706 0 2 -2
were,conducted,in 1.0 0.00043004587156 0 3 -3
were,conducted,although 1.0 0.000143348623853 0 1 -1
were,concurrently,administered 1.0 0.000286697247706 0 2 -2
were,concomitantly,used 1.0 0.000143348623853 0 1 -1
were,compared,with 1.0 0.000143348623853 0 1 -1
were,compared,to 1.0 0.000143348623853 0 1 -1
were,common,findings 1.0 0.000143348623853 0 1 -1
were,collected,through 1.0 0.000143348623853 0 1 -1
were,coadministered,with 1.0 0.000143348623853 0 1 -1
were,challenged,with 1.0 0.000143348623853 0 1 -1
were,carried,out 1.0 0.00043004587156 0 3 -3
were,cardiac,two 1.0 0.000143348623853 0 1 -1
were,cardiac,and 1.0 0.000143348623853 0 1 -1
were,between,given 1.0 0.000143348623853 0 1 -1
were,below,the 1.0 0.000143348623853 0 1 -1
were,assessed,in 1.0 0.000716743119266 0 5 -5
were,as,much 1.0 0.000143348623853 0 1 -1
were,approximately,bpm 1.0 0.000143348623853 0 1 -1
were,antagonized,by 1.0 0.000143348623853 0 1 -1
were,and,with 1.0 0.000143348623853 0 1 -1
were,and,micrograms 1.0 0.000143348623853 0 1 -1
were,and,increases 1.0 0.000143348623853 0 1 -1
were,and,both 1.0 0.000143348623853 0 1 -1
were,also,reported 1.0 0.000143348623853 0 1 -1
were,also,not 1.0 0.000286697247706 0 2 -2
were,also,decreased 1.0 0.000143348623853 0 1 -1
were,also,collected 1.0 0.000143348623853 0 1 -1
were,also,assessed 1.0 0.000143348623853 0 1 -1
were,already,seen 1.0 0.000143348623853 0 1 -1
were,already,receiving 1.0 0.000143348623853 0 1 -1
were,allowed,in 1.0 0.000143348623853 0 1 -1
were,administered,together 1.0 0.000143348623853 0 1 -1
were,administered,to 1.0 0.000143348623853 0 1 -1
were,administered,starlix 1.0 0.000143348623853 0 1 -1
were,administered,several 1.0 0.000143348623853 0 1 -1
were,administered,orally 1.0 0.000143348623853 0 1 -1
were,administered,one 1.0 0.000143348623853 0 1 -1
were,administered,mg 1.0 0.000143348623853 0 1 -1
were,administered,in 1.0 0.000143348623853 0 1 -1
were,administered,hydrochloride 1.0 0.000143348623853 0 1 -1
were,administered,following 1.0 0.000143348623853 0 1 -1
were,administered,during 1.0 0.000143348623853 0 1 -1
were,administered,concomitantly 1.0 0.000286697247706 0 2 -2
were,additive,when 1.0 0.000143348623853 0 1 -1
were,accompanied,by 1.0 0.000286697247706 0 2 -2
were,about,fold 1.0 0.000143348623853 0 1 -1
were,a,dihydropyridine 1.0 0.000143348623853 0 1 -1
wellbutrin,on,the 1.0 0.000143348623853 0 1 -1
wellbutrin,following,concomitant 1.0 0.000143348623853 0 1 -1
well-known,potential,to 1.0 0.000143348623853 0 1 -1
well-known,interactions,with 1.0 0.000143348623853 0 1 -1
well-defined,pharmacokinetic-pharmacodynamic,relationship 1.0 0.000143348623853 0 1 -1
well-controlled,study,of 1.0 0.000143348623853 0 1 -1
well-controlled,studies,was 1.0 0.000143348623853 0 1 -1
well-controlled,studies,of 1.0 0.000143348623853 0 1 -1
well-controlled,studies,in 1.0 0.000143348623853 0 1 -1
well-controlled,studies,caused 1.0 0.000143348623853 0 1 -1
well,tolerated,when 1.0 0.000143348623853 0 1 -1
well,tolerated,in 1.0 0.000143348623853 0 1 -1
well,studied,than 1.0 0.000143348623853 0 1 -1
well,matched,with 1.0 0.000143348623853 0 1 -1
well,defined,physical 1.0 0.000143348623853 0 1 -1
well,correlated,with 1.0 0.000143348623853 0 1 -1
well,controlled,trials 1.0 0.000143348623853 0 1 -1
well,as,urinary 1.0 0.000143348623853 0 1 -1
well,as,topical 1.0 0.000143348623853 0 1 -1
well,as,subsequent 1.0 0.000143348623853 0 1 -1
well,as,retention 1.0 0.000143348623853 0 1 -1
well,as,peripheral 1.0 0.000143348623853 0 1 -1
well,as,normal 1.0 0.000143348623853 0 1 -1
well,as,nonsteroidal 1.0 0.000143348623853 0 1 -1
well,as,minimal 1.0 0.000143348623853 0 1 -1
well,as,increasing 1.0 0.000143348623853 0 1 -1
well,as,in 1.0 0.000143348623853 0 1 -1
well,as,for 1.0 0.000286697247706 0 2 -2
well,as,effects 1.0 0.000143348623853 0 1 -1
well,as,complications 1.0 0.000143348623853 0 1 -1
well,and,the 1.0 0.000143348623853 0 1 -1
well,after,clinical 1.0 0.000143348623853 0 1 -1
well,acquainted,with 1.0 0.000143348623853 0 1 -1
well,above,cmax 1.0 0.000143348623853 0 1 -1
welfare,of,those 1.0 0.000143348623853 0 1 -1
welchol,with,or 1.0 0.000143348623853 0 1 -1
welchol,was,found 1.0 0.000143348623853 0 1 -1
welchol,has,been 1.0 0.000143348623853 0 1 -1
weighted,least,squares 1.0 0.000143348623853 0 1 -1
weight,were,administered 1.0 0.000143348623853 0 1 -1
weight,was,ineffective 1.0 0.000143348623853 0 1 -1
weight,was,found 1.0 0.000143348623853 0 1 -1
weight,to,rats 1.0 0.000286697247706 0 2 -2
weight,range,kg 1.0 0.000143348623853 0 1 -1
weight,heparins,as 1.0 0.000143348623853 0 1 -1
weight,for,days 1.0 0.000143348623853 0 1 -1
weight,every,other 1.0 0.000143348623853 0 1 -1
weight,approximately,ml 1.0 0.000143348623853 0 1 -1
weight,and,subcutaneous 1.0 0.000143348623853 0 1 -1
weight,and,post-implantation 1.0 0.000143348623853 0 1 -1
weight,and,have 1.0 0.000143348623853 0 1 -1
weight,and,body 1.0 0.000143348623853 0 1 -1
weighed,against,the 1.0 0.000286697247706 0 2 -2
weeks,with,intravenous 1.0 0.000143348623853 0 1 -1
weeks,were,found 1.0 0.000143348623853 0 1 -1
weeks,oral,cordarone 1.0 0.000143348623853 0 1 -1
weeks,of,escalating 1.0 0.000143348623853 0 1 -1
weeks,of,and 1.0 0.000143348623853 0 1 -1
weeks,in,rats 1.0 0.000143348623853 0 1 -1
weeks,in,dogs 1.0 0.000143348623853 0 1 -1
weeks,following,completion 1.0 0.000143348623853 0 1 -1
weeks,as,initial 1.0 0.000143348623853 0 1 -1
weeks,and,half 1.0 0.000143348623853 0 1 -1
weeks,and,and 1.0 0.000143348623853 0 1 -1
weeks,after,the 1.0 0.000143348623853 0 1 -1
weeks,after,cessation 1.0 0.000143348623853 0 1 -1
weeks,after,bilateral 1.0 0.000143348623853 0 1 -1
weekly,subcutaneous,injections 1.0 0.000143348623853 0 1 -1
weekly,or,glatiramer 1.0 0.000143348623853 0 1 -1
weekly,or,every 1.0 0.000143348623853 0 1 -1
weekly,or,biweekly 1.0 0.000286697247706 0 2 -2
weekly,human,dose 1.0 0.000143348623853 0 1 -1
weekly,during,the 1.0 0.000143348623853 0 1 -1
weekly,during,five 1.0 0.000143348623853 0 1 -1
weekly,doses,of 1.0 0.000143348623853 0 1 -1
weekly,dose,resulted 1.0 0.000143348623853 0 1 -1
week,until,the 1.0 0.000143348623853 0 1 -1
week,trial,showed 1.0 0.000143348623853 0 1 -1
week,study,has 1.0 0.000143348623853 0 1 -1
week,placebo,controlled 1.0 0.000143348623853 0 1 -1
week,of,and 1.0 0.000143348623853 0 1 -1
week,leaving,only 1.0 0.000143348623853 0 1 -1
week,intraperitoneal,injections 1.0 0.000143348623853 0 1 -1
week,intervals,until 1.0 0.000143348623853 0 1 -1
week,following,mating 1.0 0.000143348623853 0 1 -1
week,endoscopy,study 1.0 0.000143348623853 0 1 -1
week,controlled,study 1.0 0.000143348623853 0 1 -1
week,about,times 1.0 0.000143348623853 0 1 -1
wear,off,before 1.0 0.000143348623853 0 1 -1
weakness,who,are 1.0 0.000143348623853 0 1 -1
weakness,their,condition 1.0 0.000143348623853 0 1 -1
weakness,myoclonus,tremor 1.0 0.000143348623853 0 1 -1
weakness,lethargy,drowsiness 1.0 0.000143348623853 0 1 -1
weakness,associated,with 1.0 0.000143348623853 0 1 -1
weaker,inhibitors,grapefruit 1.0 0.000143348623853 0 1 -1
weaken,or,antagonise 1.0 0.000143348623853 0 1 -1
weak,inhibitory,effects 1.0 0.000143348623853 0 1 -1
weak,inhibitors,of 1.0 0.000143348623853 0 1 -1
weak,inhibitor,of 1.0 0.000286697247706 0 2 -2
weak,inducer,of 1.0 0.000143348623853 0 1 -1
weak,c19,weak 1.0 0.000143348623853 0 1 -1
weak,b6,weak 1.0 0.000143348623853 0 1 -1
we,show,that 1.0 0.000286697247706 0 2 -2
we,reviewed,the 1.0 0.000143348623853 0 1 -1
we,previously,reported 1.0 0.000143348623853 0 1 -1
we,present,clearly 1.0 0.000143348623853 0 1 -1
we,obtained,evidence 1.0 0.000143348623853 0 1 -1
we,noted,a 1.0 0.000143348623853 0 1 -1
we,investigated,whether 1.0 0.000143348623853 0 1 -1
we,investigated,the 1.0 0.000573394495413 0 4 -4
we,incorporate,the 1.0 0.000143348623853 0 1 -1
we,have,shown 1.0 0.00043004587156 0 3 -3
we,have,selected 1.0 0.000143348623853 0 1 -1
we,have,examined 1.0 0.000143348623853 0 1 -1
we,have,carried 1.0 0.000143348623853 0 1 -1
we,examined,the 1.0 0.000286697247706 0 2 -2
we,evaluated,the 1.0 0.000143348623853 0 1 -1
we,describe,a 1.0 0.000143348623853 0 1 -1
we,demonstrate,that 1.0 0.000286697247706 0 2 -2
we,could,observe 1.0 0.000143348623853 0 1 -1
we,compared,pharmacokinetics 1.0 0.000143348623853 0 1 -1
we,carried,out 1.0 0.000143348623853 0 1 -1
we,call,that 1.0 0.000143348623853 0 1 -1
we,assessed,the 1.0 0.000143348623853 0 1 -1
ways,to,avoid 1.0 0.000143348623853 0 1 -1
ways,of,improving 1.0 0.000143348623853 0 1 -1
way,crossover,studies 1.0 0.000143348623853 0 1 -1
watery,stool,in 1.0 0.00043004587156 0 3 -3
water-miscible,or,parenteral 1.0 0.000143348623853 0 1 -1
water,pill,such 1.0 0.000143348623853 0 1 -1
water,orange,juice 1.0 0.000143348623853 0 1 -1
water,from,a 1.0 0.000143348623853 0 1 -1
water,for,days 1.0 0.000143348623853 0 1 -1
watched,during,initiation 1.0 0.000143348623853 0 1 -1
wasting,facial,wasting 1.0 0.000143348623853 0 1 -1
wasting,breast,enlargement 1.0 0.000143348623853 0 1 -1
washout,period,was 1.0 0.000143348623853 0 1 -1
washout,period,followed 1.0 0.000143348623853 0 1 -1
washed,out,and 1.0 0.000143348623853 0 1 -1
was,withdrawn,and 1.0 0.000143348623853 0 1 -1
was,well,tolerated 1.0 0.000143348623853 0 1 -1
was,washed,out 1.0 0.000143348623853 0 1 -1
was,variably,increased 1.0 0.000143348623853 0 1 -1
was,usually,observed 1.0 0.000143348623853 0 1 -1
was,used,to 1.0 0.000286697247706 0 2 -2
was,used,concurrently 1.0 0.000143348623853 0 1 -1
was,used,concomitantly 1.0 0.000286697247706 0 2 -2
was,undertaken,with 1.0 0.000143348623853 0 1 -1
was,unaltered,by 1.0 0.000143348623853 0 1 -1
was,treated,with 1.0 0.000143348623853 0 1 -1
was,treated,aggressively 1.0 0.000143348623853 0 1 -1
was,treated,according 1.0 0.000143348623853 0 1 -1
was,totally,inhibited 1.0 0.000143348623853 0 1 -1
was,too,low 1.0 0.000143348623853 0 1 -1
was,to,study 1.0 0.000143348623853 0 1 -1
was,to,investigate 1.0 0.000143348623853 0 1 -1
was,to,examine 1.0 0.000143348623853 0 1 -1
was,to,evaluate 1.0 0.000143348623853 0 1 -1
was,to,determine 1.0 0.000143348623853 0 1 -1
was,to,cite 1.0 0.000143348623853 0 1 -1
was,to,characterize 1.0 0.000143348623853 0 1 -1
was,times,maximum 1.0 0.000143348623853 0 1 -1
was,times,less 1.0 0.000143348623853 0 1 -1
was,thus,not 1.0 0.000143348623853 0 1 -1
was,the,most 1.0 0.000143348623853 0 1 -1
was,tested,in 1.0 0.000286697247706 0 2 -2
was,tested,by 1.0 0.000143348623853 0 1 -1
was,taking,a 1.0 0.000143348623853 0 1 -1
was,taken,in 1.0 0.000143348623853 0 1 -1
was,taken,hours 1.0 0.000143348623853 0 1 -1
was,superior,to 1.0 0.000143348623853 0 1 -1
was,studied,in 1.0 0.000860091743119 0 6 -6
was,strongly,suppressed 1.0 0.000143348623853 0 1 -1
was,started,on 1.0 0.000143348623853 0 1 -1
was,similar,to 1.0 0.000860091743119 0 6 -6
was,similar,in 1.0 0.000143348623853 0 1 -1
was,similar,between 1.0 0.000143348623853 0 1 -1
was,similar,among 1.0 0.000143348623853 0 1 -1
was,significantly,superior 1.0 0.000143348623853 0 1 -1
was,significantly,lower 1.0 0.000143348623853 0 1 -1
was,significantly,increased 1.0 0.000143348623853 0 1 -1
was,significantly,impaired 1.0 0.000143348623853 0 1 -1
was,significantly,greater 1.0 0.000286697247706 0 2 -2
was,shown,on 1.0 0.000143348623853 0 1 -1
was,shown,in 1.0 0.000143348623853 0 1 -1
was,separated,by 1.0 0.000143348623853 0 1 -1
was,seen,when 1.0 0.000143348623853 0 1 -1
was,seen,on 1.0 0.000143348623853 0 1 -1
was,sacrificed,in 1.0 0.000143348623853 0 1 -1
was,resistant,to 1.0 0.000143348623853 0 1 -1
was,replaced,by 1.0 0.000143348623853 0 1 -1
was,related,to 1.0 0.000143348623853 0 1 -1
was,reduced,about 1.0 0.000143348623853 0 1 -1
was,reached,on 1.0 0.000143348623853 0 1 -1
was,present,in 1.0 0.000286697247706 0 2 -2
was,present,for 1.0 0.000143348623853 0 1 -1
was,prepared,in 1.0 0.000143348623853 0 1 -1
was,preceded,by 1.0 0.000143348623853 0 1 -1
was,potentiated,by 1.0 0.000143348623853 0 1 -1
was,possible,to 1.0 0.000143348623853 0 1 -1
was,pharmacodynamic,with 1.0 0.000286697247706 0 2 -2
was,performed,within 1.0 0.000143348623853 0 1 -1
was,performed,on 1.0 0.000143348623853 0 1 -1
was,performed,in 1.0 0.000143348623853 0 1 -1
was,only,significantly 1.0 0.000143348623853 0 1 -1
was,only,half 1.0 0.000143348623853 0 1 -1
was,obtained,from 1.0 0.000286697247706 0 2 -2
was,obtained,for 1.0 0.000143348623853 0 1 -1
was,observed,in 1.0 0.000716743119266 0 5 -5
was,observed,for 1.0 0.000143348623853 0 1 -1
was,observed,during 1.0 0.000143348623853 0 1 -1
was,observed,at 1.0 0.000143348623853 0 1 -1
was,noted,with 1.0 0.000143348623853 0 1 -1
was,noted,when 1.0 0.000143348623853 0 1 -1
was,noted,that 1.0 0.000143348623853 0 1 -1
was,noted,in 1.0 0.000143348623853 0 1 -1
was,not,studied 1.0 0.000286697247706 0 2 -2
was,not,so 1.0 0.000143348623853 0 1 -1
was,not,reached 1.0 0.000143348623853 0 1 -1
was,not,observed 1.0 0.000143348623853 0 1 -1
was,not,mutagenic 1.0 0.000286697247706 0 2 -2
was,not,inhibitory 1.0 0.000143348623853 0 1 -1
was,not,due 1.0 0.000143348623853 0 1 -1
was,not,detected 1.0 0.000143348623853 0 1 -1
was,not,considered 1.0 0.000143348623853 0 1 -1
was,not,associated 1.0 0.000143348623853 0 1 -1
was,not,altered 1.0 0.000286697247706 0 2 -2
was,not,affected 1.0 0.00043004587156 0 3 -3
was,not,accompanied 1.0 0.000143348623853 0 1 -1
was,not,a 1.0 0.000143348623853 0 1 -1
was,no,significant 1.0 0.00043004587156 0 3 -3
was,no,pharmacodynamic 1.0 0.000286697247706 0 2 -2
was,no,interaction 1.0 0.000143348623853 0 1 -1
was,no,evidence 1.0 0.000860091743119 0 6 -6
was,no,difference 1.0 0.000143348623853 0 1 -1
was,no,clinically 1.0 0.000143348623853 0 1 -1
was,no,clinical 1.0 0.000143348623853 0 1 -1
was,no,apparent 1.0 0.000143348623853 0 1 -1
was,no,alteration 1.0 0.000143348623853 0 1 -1
was,more,than 1.0 0.000143348623853 0 1 -1
was,more,pronounced 1.0 0.000143348623853 0 1 -1
was,more,potent 1.0 0.000143348623853 0 1 -1
was,more,likely 1.0 0.000143348623853 0 1 -1
was,monitored,by 1.0 0.000143348623853 0 1 -1
was,misused,by 1.0 0.000143348623853 0 1 -1
was,measured,near 1.0 0.000143348623853 0 1 -1
was,measured,in 1.0 0.000143348623853 0 1 -1
was,measured,from 1.0 0.000143348623853 0 1 -1
was,measured,by 1.0 0.000286697247706 0 2 -2
was,markedly,sensitive 1.0 0.000143348623853 0 1 -1
was,maintained,at 1.0 0.000143348623853 0 1 -1
was,made,of 1.0 0.000143348623853 0 1 -1
was,investigated,in 1.0 0.00043004587156 0 3 -3
was,investigated,as 1.0 0.000143348623853 0 1 -1
was,inserted,between 1.0 0.000143348623853 0 1 -1
was,inhibited,by 1.0 0.000143348623853 0 1 -1
was,ineffective,in 1.0 0.000286697247706 0 2 -2
was,independent,of 1.0 0.000143348623853 0 1 -1
was,increased,indicating 1.0 0.000143348623853 0 1 -1
was,increased,in 1.0 0.000143348623853 0 1 -1
was,increased,above 1.0 0.000143348623853 0 1 -1
was,included,with 1.0 0.000143348623853 0 1 -1
was,included,in 1.0 0.000143348623853 0 1 -1
was,included,as 1.0 0.000143348623853 0 1 -1
was,inappropriate,being 1.0 0.000143348623853 0 1 -1
was,inadequate,to 1.0 0.000143348623853 0 1 -1
was,in,respect 1.0 0.000143348623853 0 1 -1
was,improved,when 1.0 0.000143348623853 0 1 -1
was,identical,but 1.0 0.000143348623853 0 1 -1
was,hypercholesterolemia,was 1.0 0.000143348623853 0 1 -1
was,hours,for 1.0 0.000143348623853 0 1 -1
was,greater,after 1.0 0.000143348623853 0 1 -1
was,grams,daily 1.0 0.000143348623853 0 1 -1
was,given,within 1.0 0.000143348623853 0 1 -1
was,given,several 1.0 0.000143348623853 0 1 -1
was,given,prior 1.0 0.000143348623853 0 1 -1
was,given,intravenously 1.0 0.000143348623853 0 1 -1
was,given,concomitantly 1.0 0.000286697247706 0 2 -2
was,given,as 1.0 0.000143348623853 0 1 -1
was,given,alone 1.0 0.000286697247706 0 2 -2
was,gathered,for 1.0 0.000143348623853 0 1 -1
was,found,minutes 1.0 0.000143348623853 0 1 -1
was,found,between 1.0 0.000143348623853 0 1 -1
was,fold,greater 1.0 0.000143348623853 0 1 -1
was,far,more 1.0 0.000143348623853 0 1 -1
was,extensive,concomitant 1.0 0.000143348623853 0 1 -1
was,expressed,by 1.0 0.000143348623853 0 1 -1
was,exposed,to 1.0 0.000143348623853 0 1 -1
was,explored,further 1.0 0.000143348623853 0 1 -1
was,expected,because 1.0 0.000143348623853 0 1 -1
was,evident,in 1.0 0.000143348623853 0 1 -1
was,evident,following 1.0 0.000143348623853 0 1 -1
was,evident,by 1.0 0.000143348623853 0 1 -1
was,evidence,for 1.0 0.000143348623853 0 1 -1
was,evaluated,using 1.0 0.000143348623853 0 1 -1
was,evaluated,in 1.0 0.00100344036697 0 7 -7
was,evaluated,by 1.0 0.000143348623853 0 1 -1
was,evaluated,as 1.0 0.000143348623853 0 1 -1
was,estimated,as 1.0 0.000143348623853 0 1 -1
was,established,that 1.0 0.000143348623853 0 1 -1
was,especially,resistant 1.0 0.000143348623853 0 1 -1
was,enhanced,when 1.0 0.000143348623853 0 1 -1
was,due,to 1.0 0.00043004587156 0 3 -3
was,documented,however 1.0 0.000143348623853 0 1 -1
was,discussed,in 1.0 0.000143348623853 0 1 -1
was,discontinued,from 1.0 0.000143348623853 0 1 -1
was,discontinued,and 1.0 0.000143348623853 0 1 -1
was,determined,by 1.0 0.000143348623853 0 1 -1
was,determined,after 1.0 0.000143348623853 0 1 -1
was,detected,although 1.0 0.000143348623853 0 1 -1
was,detected,after 1.0 0.000143348623853 0 1 -1
was,designed,to 1.0 0.000286697247706 0 2 -2
was,demonstrated,that 1.0 0.000143348623853 0 1 -1
was,delayed,until 1.0 0.000143348623853 0 1 -1
was,delayed,by 1.0 0.000143348623853 0 1 -1
was,decrease,of 1.0 0.000143348623853 0 1 -1
was,covalently,linked 1.0 0.000143348623853 0 1 -1
was,correlated,with 1.0 0.000143348623853 0 1 -1
was,continued,for 1.0 0.000143348623853 0 1 -1
was,considered,by 1.0 0.000143348623853 0 1 -1
was,conducted,to 1.0 0.000143348623853 0 1 -1
was,conducted,in 1.0 0.000143348623853 0 1 -1
was,compared,directly 1.0 0.000143348623853 0 1 -1
was,comparable,in 1.0 0.000143348623853 0 1 -1
was,coadministered,for 1.0 0.000143348623853 0 1 -1
was,coadministered,although 1.0 0.000143348623853 0 1 -1
was,co-administered,but 1.0 0.000143348623853 0 1 -1
was,changed,as 1.0 0.000143348623853 0 1 -1
was,carried,out 1.0 0.000286697247706 0 2 -2
was,calculated,by 1.0 0.000143348623853 0 1 -1
was,bioequivalent,when 1.0 0.000143348623853 0 1 -1
was,bioequivalent,to 1.0 0.000143348623853 0 1 -1
was,between,and 1.0 0.000143348623853 0 1 -1
was,assessed,in 1.0 0.000143348623853 0 1 -1
was,as,stable 1.0 0.000143348623853 0 1 -1
was,approximately,twofold 1.0 0.000143348623853 0 1 -1
was,approximately,doubled 1.0 0.000143348623853 0 1 -1
was,and,that 1.0 0.000143348623853 0 1 -1
was,and,micrograms 1.0 0.000143348623853 0 1 -1
was,and,intraindividual 1.0 0.000143348623853 0 1 -1
was,and,hours 1.0 0.000143348623853 0 1 -1
was,analyzed,in 1.0 0.000143348623853 0 1 -1
was,analyzed,for 1.0 0.000143348623853 0 1 -1
was,an,increasing 1.0 0.000143348623853 0 1 -1
was,altered,in 1.0 0.000143348623853 0 1 -1
was,altered,by 1.0 0.000143348623853 0 1 -1
was,also,verified 1.0 0.000143348623853 0 1 -1
was,also,shown 1.0 0.000143348623853 0 1 -1
was,also,reduced 1.0 0.000143348623853 0 1 -1
was,also,ineffective 1.0 0.000143348623853 0 1 -1
was,also,diminished 1.0 0.000143348623853 0 1 -1
was,also,conducted 1.0 0.000143348623853 0 1 -1
was,also,chronically 1.0 0.000143348623853 0 1 -1
was,again,given 1.0 0.000143348623853 0 1 -1
was,again,allowed 1.0 0.000143348623853 0 1 -1
was,admitted,to 1.0 0.000143348623853 0 1 -1
was,administered,together 1.0 0.000143348623853 0 1 -1
was,administered,over 1.0 0.000143348623853 0 1 -1
was,administered,one 1.0 0.000143348623853 0 1 -1
was,administered,intraperitoneally 1.0 0.000143348623853 0 1 -1
was,administered,in 1.0 0.00043004587156 0 3 -3
was,administered,concurrently 1.0 0.000143348623853 0 1 -1
was,administered,after 1.0 0.000143348623853 0 1 -1
was,added,one 1.0 0.000143348623853 0 1 -1
was,added,in 1.0 0.000143348623853 0 1 -1
was,achieved,indicating 1.0 0.000143348623853 0 1 -1
was,about,times 1.0 0.000143348623853 0 1 -1
was,about,equipotent 1.0 0.000143348623853 0 1 -1
was,a,tendency 1.0 0.000143348623853 0 1 -1
was,a,reduction 1.0 0.000286697247706 0 2 -2
was,a,multicenter 1.0 0.000143348623853 0 1 -1
warranted,in,the 1.0 0.000143348623853 0 1 -1
warranted,and,clinical 1.0 0.000143348623853 0 1 -1
warrant,alteration,of 1.0 0.000143348623853 0 1 -1
warnings,and,should 1.0 0.000143348623853 0 1 -1
warning,signs,irrespective 1.0 0.000143348623853 0 1 -1
warning,potential,for 1.0 0.000143348623853 0 1 -1
warning,coadministration,may 1.0 0.000143348623853 0 1 -1
warned,of,this 1.0 0.000286697247706 0 2 -2
warfarin-type,cyp2c9,and 1.0 0.000143348623853 0 1 -1
warfarin,when,healthy 1.0 0.000143348623853 0 1 -1
warfarin,the,effect 1.0 0.000286697247706 0 2 -2
warfarin,no,significant 1.0 0.000143348623853 0 1 -1
warfarin,multiple,oral 1.0 0.000143348623853 0 1 -1
warfarin,keppra,mg 1.0 0.000143348623853 0 1 -1
warfarin,in,subjects 1.0 0.000143348623853 0 1 -1
warfarin,in,a 1.0 0.000286697247706 0 2 -2
warfarin,eszopiclone,mg 1.0 0.000143348623853 0 1 -1
warfarin,concomitant,administration 1.0 0.000143348623853 0 1 -1
warfarin,co-,administration 1.0 0.000143348623853 0 1 -1
warfarin,atorvastatin,had 1.0 0.000143348623853 0 1 -1
warfarin,administration,of 1.0 0.000143348623853 0 1 -1
warfarin,a,single 1.0 0.000143348623853 0 1 -1
want,to,know 1.0 0.000143348623853 0 1 -1
want,to,change 1.0 0.000143348623853 0 1 -1
wallerian,degeneration,of 1.0 0.000143348623853 0 1 -1
walking,without,climbing 1.0 0.000143348623853 0 1 -1
vs,spared,by 1.0 0.000143348623853 0 1 -1
vs,respectively,p 1.0 0.000143348623853 0 1 -1
vs,placebo,n 1.0 0.000143348623853 0 1 -1
vs,logs,of 1.0 0.000143348623853 0 1 -1
vs,end,of 1.0 0.000143348623853 0 1 -1
vs,cmax,vs 1.0 0.000143348623853 0 1 -1
vs,and,tmax 1.0 0.000143348623853 0 1 -1
vre,is,a 1.0 0.000143348623853 0 1 -1
vr,pediatric,and 1.0 0.000143348623853 0 1 -1
vomiting,pruritus,rash 1.0 0.000143348623853 0 1 -1
vomiting,diarrhea,and 1.0 0.000143348623853 0 1 -1
volunteers,with,oral 1.0 0.000143348623853 0 1 -1
volunteers,who,had 1.0 0.000143348623853 0 1 -1
volunteers,when,administered 1.0 0.000143348623853 0 1 -1
volunteers,were,randomly 1.0 0.000143348623853 0 1 -1
volunteers,were,randomized 1.0 0.000143348623853 0 1 -1
volunteers,were,administered 1.0 0.000143348623853 0 1 -1
volunteers,under,steady-state 1.0 0.000143348623853 0 1 -1
volunteers,under,fasting 1.0 0.000143348623853 0 1 -1
volunteers,treatment,with 1.0 0.000143348623853 0 1 -1
volunteers,toradoloral,was 1.0 0.000143348623853 0 1 -1
volunteers,took,mg 1.0 0.000143348623853 0 1 -1
volunteers,there,were 1.0 0.000143348623853 0 1 -1
volunteers,show,that 1.0 0.000143348623853 0 1 -1
volunteers,resulting,in 1.0 0.000143348623853 0 1 -1
volunteers,received,alone 1.0 0.000143348623853 0 1 -1
volunteers,or,given 1.0 0.000143348623853 0 1 -1
volunteers,no,significant 1.0 0.000143348623853 0 1 -1
volunteers,no,clinically 1.0 0.000143348623853 0 1 -1
volunteers,n,in 1.0 0.000143348623853 0 1 -1
volunteers,n,demonstrated 1.0 0.000143348623853 0 1 -1
volunteers,mg,times 1.0 0.000143348623853 0 1 -1
volunteers,increased,auc 1.0 0.000143348623853 0 1 -1
volunteers,in,the 1.0 0.000143348623853 0 1 -1
volunteers,in,a 1.0 0.000143348623853 0 1 -1
volunteers,hormone,replacement 1.0 0.000143348623853 0 1 -1
volunteers,have,failed 1.0 0.000143348623853 0 1 -1
volunteers,has,been 1.0 0.000143348623853 0 1 -1
volunteers,for,days 1.0 0.000143348623853 0 1 -1
volunteers,exjade,had 1.0 0.000143348623853 0 1 -1
volunteers,established,on 1.0 0.000143348623853 0 1 -1
volunteers,did,not 1.0 0.00043004587156 0 3 -3
volunteers,coadministration,of 1.0 0.000143348623853 0 1 -1
volunteers,co-administration,of 1.0 0.000143348623853 0 1 -1
volunteers,administration,of 1.0 0.000143348623853 0 1 -1
volunteer,was,administered 1.0 0.000143348623853 0 1 -1
volunteer,showed,hormonal 1.0 0.000143348623853 0 1 -1
volunteer,reported,intermenstrual 1.0 0.000143348623853 0 1 -1
volunteer,received,a 1.0 0.000143348623853 0 1 -1
volume,of,circulating 1.0 0.000286697247706 0 2 -2
volume,of,an 1.0 0.000143348623853 0 1 -1
volume,fewer,interactions 1.0 0.000143348623853 0 1 -1
voltaren,cataflam,lodine 1.0 0.000143348623853 0 1 -1
voltage-dependent,ca,subtypes 1.0 0.000143348623853 0 1 -1
voltage-dependent,ca,currents 1.0 0.000143348623853 0 1 -1
voltage-dependent,ca,channels 1.0 0.000143348623853 0 1 -1
voltage-dependent,ca,channel 1.0 0.000286697247706 0 2 -2
volatile,agent,known 1.0 0.000143348623853 0 1 -1
volatile,agent,has 1.0 0.000143348623853 0 1 -1
vivo,tests,of 1.0 0.000143348623853 0 1 -1
vivo,studies,to 1.0 0.000143348623853 0 1 -1
vivo,studies,suggest 1.0 0.000143348623853 0 1 -1
vivo,studies,it 1.0 0.000143348623853 0 1 -1
vivo,studies,cytochrome 1.0 0.000143348623853 0 1 -1
vivo,rodent,study 1.0 0.000143348623853 0 1 -1
vivo,resulted,in 1.0 0.000143348623853 0 1 -1
vivo,platelet,aggregation 1.0 0.000143348623853 0 1 -1
vivo,particularly,when 1.0 0.000143348623853 0 1 -1
vivo,micronucleus,test 1.0 0.000143348623853 0 1 -1
vivo,metabolic,probe 1.0 0.000286697247706 0 2 -2
vivo,it,is 1.0 0.000143348623853 0 1 -1
vivo,interaction,with 1.0 0.000143348623853 0 1 -1
vivo,interaction,study 1.0 0.000143348623853 0 1 -1
vivo,interaction,studies 1.0 0.000573394495413 0 4 -4
vivo,evidence,suggest 1.0 0.000143348623853 0 1 -1
vivo,effects,when 1.0 0.000143348623853 0 1 -1
vivo,drug-drug,interactions 1.0 0.000143348623853 0 1 -1
vivo,clinically,in 1.0 0.000143348623853 0 1 -1
vivo,by,inhibition 1.0 0.000143348623853 0 1 -1
vivo,and,in 1.0 0.000143348623853 0 1 -1
vivo,and,clinically 1.0 0.000143348623853 0 1 -1
vitro,was,only 1.0 0.000143348623853 0 1 -1
vitro,was,altered 1.0 0.000143348623853 0 1 -1
vitro,to,a 1.0 0.000143348623853 0 1 -1
vitro,therefore,this 1.0 0.000143348623853 0 1 -1
vitro,the,udp-glucuronyl 1.0 0.000143348623853 0 1 -1
vitro,the,plasma 1.0 0.000143348623853 0 1 -1
vitro,tests,with 1.0 0.000143348623853 0 1 -1
vitro,study,cytochrome 1.0 0.000143348623853 0 1 -1
vitro,studies,were 1.0 0.000143348623853 0 1 -1
vitro,studies,vardenafil 1.0 0.000143348623853 0 1 -1
vitro,studies,using 1.0 0.000143348623853 0 1 -1
vitro,studies,translates 1.0 0.000143348623853 0 1 -1
vitro,studies,studies 1.0 0.000143348623853 0 1 -1
vitro,studies,show 1.0 0.000143348623853 0 1 -1
vitro,studies,m1 1.0 0.000286697247706 0 2 -2
vitro,studies,it 1.0 0.000143348623853 0 1 -1
vitro,studies,indicated 1.0 0.000143348623853 0 1 -1
vitro,studies,evaluating 1.0 0.000143348623853 0 1 -1
vitro,studies,did 1.0 0.000143348623853 0 1 -1
vitro,studies,demonstrated 1.0 0.000286697247706 0 2 -2
vitro,studies,demonstrate 1.0 0.000143348623853 0 1 -1
vitro,studies,cytochrome 1.0 0.000143348623853 0 1 -1
vitro,studies,angiomax 1.0 0.000143348623853 0 1 -1
vitro,studies,also 1.0 0.000143348623853 0 1 -1
vitro,sodium,is 1.0 0.000143348623853 0 1 -1
vitro,showed,no 1.0 0.000143348623853 0 1 -1
vitro,show,that 1.0 0.000143348623853 0 1 -1
vitro,results,are 1.0 0.000143348623853 0 1 -1
vitro,perfused,pancreases 1.0 0.000143348623853 0 1 -1
vitro,on,the 1.0 0.000143348623853 0 1 -1
vitro,metabolism,studies 1.0 0.000716743119266 0 5 -5
vitro,metabolic,reactions 1.0 0.000143348623853 0 1 -1
vitro,interaction,studies 1.0 0.000143348623853 0 1 -1
vitro,in,situ 1.0 0.000143348623853 0 1 -1
vitro,human,liver 1.0 0.000143348623853 0 1 -1
vitro,however,the 1.0 0.000143348623853 0 1 -1
vitro,have,shown 1.0 0.000143348623853 0 1 -1
vitro,has,been 1.0 0.000143348623853 0 1 -1
vitro,glucuronidation,of 1.0 0.000143348623853 0 1 -1
vitro,gleevec,inhibits 1.0 0.000286697247706 0 2 -2
vitro,finding,that 1.0 0.000143348623853 0 1 -1
vitro,experiments,demonstrated 1.0 0.000143348623853 0 1 -1
vitro,excystment,rates 1.0 0.000143348623853 0 1 -1
vitro,excystment,of 1.0 0.000143348623853 0 1 -1
vitro,evaluation,of 1.0 0.000143348623853 0 1 -1
vitro,effect,occurs 1.0 0.000143348623853 0 1 -1
vitro,does,not 1.0 0.000143348623853 0 1 -1
vitro,displacement,studies 1.0 0.000143348623853 0 1 -1
vitro,data,showed 1.0 0.000143348623853 0 1 -1
vitro,data,on 1.0 0.000143348623853 0 1 -1
vitro,data,no 1.0 0.000143348623853 0 1 -1
vitro,data,is 1.0 0.000143348623853 0 1 -1
vitro,data,in 1.0 0.000143348623853 0 1 -1
vitro,cytogenetics,study 1.0 0.000143348623853 0 1 -1
vitro,concentrations,found 1.0 0.000143348623853 0 1 -1
vitro,chromosomal,aberration 1.0 0.000143348623853 0 1 -1
vitro,binding,studies 1.0 0.000143348623853 0 1 -1
vitro,at,total 1.0 0.000143348623853 0 1 -1
vitro,at,clinically 1.0 0.000143348623853 0 1 -1
vitro,aspirin-mediated,inhibition 1.0 0.000143348623853 0 1 -1
vitro,anti-cryptosporidial,activity 1.0 0.000143348623853 0 1 -1
vitro,and,to 1.0 0.000143348623853 0 1 -1
vitro,and,its 1.0 0.000143348623853 0 1 -1
vitro,and,decrease 1.0 0.000143348623853 0 1 -1
vitro,against,two 1.0 0.000143348623853 0 1 -1
vitro,against,gram 1.0 0.000143348623853 0 1 -1
vitro,activity,of 1.0 0.000143348623853 0 1 -1
vitamin-d,mediated,signalling 1.0 0.000143348623853 0 1 -1
vitamin,k,aquamephyton 1.0 0.000143348623853 0 1 -1
vitamin,d,the 1.0 0.00043004587156 0 3 -3
vitamin,d,have 1.0 0.00043004587156 0 3 -3
vitamin,d,concentrations 1.0 0.00043004587156 0 3 -3
vitamin,d,also 1.0 0.00043004587156 0 3 -3
vitamin,c,up 1.0 0.000143348623853 0 1 -1
vitamin,c,has 1.0 0.000143348623853 0 1 -1
vitamin,b12,diagnostic 1.0 0.000143348623853 0 1 -1
vital,signs,salivary 1.0 0.000143348623853 0 1 -1
vital,sign,monitoring 1.0 0.000143348623853 0 1 -1
visual,cortex,of 1.0 0.000286697247706 0 2 -2
visual,analogue,scales 1.0 0.000143348623853 0 1 -1
vision,nystagmus,strabismus 1.0 0.000143348623853 0 1 -1
virus-positive,patients,by 1.0 0.000143348623853 0 1 -1
virus,also,known 1.0 0.000143348623853 0 1 -1
virtually,complete,across 1.0 0.000143348623853 0 1 -1
virtually,all,research 1.0 0.000143348623853 0 1 -1
virologic,response,rates 1.0 0.000143348623853 0 1 -1
virologic,response,and 1.0 0.00043004587156 0 3 -3
viral,loads,treated 1.0 0.000143348623853 0 1 -1
viracept,was,coadministered 1.0 0.000143348623853 0 1 -1
viracept,may,not 1.0 0.000143348623853 0 1 -1
viracept,and,that 1.0 0.000286697247706 0 2 -2
viracept,and,primarily 1.0 0.000143348623853 0 1 -1
vioxx,should,be 1.0 0.000143348623853 0 1 -1
vioxx,mg,once 1.0 0.000143348623853 0 1 -1
vioxx,mg,daily 1.0 0.000143348623853 0 1 -1
vioxx,is,not 1.0 0.000143348623853 0 1 -1
vioxx,is,co-administered 1.0 0.000143348623853 0 1 -1
vioxx,antiplatelet,therapies 1.0 0.000143348623853 0 1 -1
vioxx,and,have 1.0 0.000143348623853 0 1 -1
viii,ix,and 1.0 0.000143348623853 0 1 -1
viii,coagulant,activity 1.0 0.000286697247706 0 2 -2
viii,antigen,viii 1.0 0.000286697247706 0 2 -2
vii-x,complex,ii-vii 1.0 0.000286697247706 0 2 -2
vii,when,compared 1.0 0.000143348623853 0 1 -1
vii,viii,ix 1.0 0.000286697247706 0 2 -2
vii,antigen,viii 1.0 0.000286697247706 0 2 -2
vigorous,physical,activity 1.0 0.000143348623853 0 1 -1
view,however,the 1.0 0.000143348623853 0 1 -1
videx,with,that 1.0 0.000143348623853 0 1 -1
videx,therapy,see 1.0 0.000143348623853 0 1 -1
vidaza,and,other 1.0 0.000143348623853 0 1 -1
viable,counts,were 1.0 0.000143348623853 0 1 -1
viable,counts,for 1.0 0.000143348623853 0 1 -1
via,the,same 1.0 0.000143348623853 0 1 -1
via,the,organic 1.0 0.000143348623853 0 1 -1
via,the,human 1.0 0.000143348623853 0 1 -1
via,the,cytochrome 1.0 0.000286697247706 0 2 -2
via,the,biliary 1.0 0.000143348623853 0 1 -1
via,the,bile 1.0 0.000143348623853 0 1 -1
via,the,activation 1.0 0.000143348623853 0 1 -1
via,cytochrome,p450 1.0 0.00043004587156 0 3 -3
via,cyp3a4,in 1.0 0.000143348623853 0 1 -1
via,cyp,a4 1.0 0.000143348623853 0 1 -1
via,a,different 1.0 0.000143348623853 0 1 -1
vi,of,the 1.0 0.000143348623853 0 1 -1
vessels,was,studied 1.0 0.000143348623853 0 1 -1
very,unlikely,to 1.0 0.000143348623853 0 1 -1
very,sensitive,to 1.0 0.000143348623853 0 1 -1
very,rapidly,to 1.0 0.000143348623853 0 1 -1
very,low,compared 1.0 0.000143348623853 0 1 -1
very,low,cardiac 1.0 0.000143348623853 0 1 -1
very,little,progression 1.0 0.000143348623853 0 1 -1
very,high,concentrations 1.0 0.000143348623853 0 1 -1
vertebrae,at,mg 1.0 0.000143348623853 0 1 -1
vertebra,at,doses 1.0 0.000143348623853 0 1 -1
versus,normal,cells 1.0 0.000143348623853 0 1 -1
versus,mg,of 1.0 0.000143348623853 0 1 -1
verified,by,equilibrium 1.0 0.000143348623853 0 1 -1
verapamil,produced,a 1.0 0.000143348623853 0 1 -1
verapamil,concomitant,use 1.0 0.000143348623853 0 1 -1
ventricular,tachycardia,and 1.0 0.000143348623853 0 1 -1
ventricular,function,or 1.0 0.000143348623853 0 1 -1
ventricular,fibrillation,and 1.0 0.000143348623853 0 1 -1
ventricular,failure,and 1.0 0.000143348623853 0 1 -1
ventricular,dysfunction,or 1.0 0.000143348623853 0 1 -1
ventricular,cardiac,preparations 1.0 0.000143348623853 0 1 -1
ventricular,arrhythmias,who 1.0 0.000143348623853 0 1 -1
ventricular,arrhythmias,qt 1.0 0.000143348623853 0 1 -1
ventricular,arrhythmias,in 1.0 0.000143348623853 0 1 -1
ventricular,arrhythmias,have 1.0 0.000143348623853 0 1 -1
ventral,tubercle,of 1.0 0.000143348623853 0 1 -1
venlafaxine,coadministration,of 1.0 0.000143348623853 0 1 -1
velcade,and,that 1.0 0.000143348623853 0 1 -1
vehicle-controlled,studies,of 1.0 0.000143348623853 0 1 -1
vehicle,corn,oil 1.0 0.000143348623853 0 1 -1
vectors,containing,a 1.0 0.000143348623853 0 1 -1
vasospasm,and,ischemia 1.0 0.000286697247706 0 2 -2
vasorelaxation,in,resistance 1.0 0.000143348623853 0 1 -1
vasorelaxation,differs,in 1.0 0.000143348623853 0 1 -1
vasopressor,and,of 1.0 0.000143348623853 0 1 -1
vasopressin,was,found 1.0 0.000143348623853 0 1 -1
vasodilator,properties,on 1.0 0.000143348623853 0 1 -1
vasodilator,effects,on 1.0 0.000143348623853 0 1 -1
vasodilator,and,platelet 1.0 0.000143348623853 0 1 -1
vasodilator,activity,data 1.0 0.000143348623853 0 1 -1
vasodilation,is,not 1.0 0.000143348623853 0 1 -1
vasoconstrictor,thromboxane,a2 1.0 0.000143348623853 0 1 -1
vasoconstrictor,but,the 1.0 0.000143348623853 0 1 -1
vasculopathy,and,ultimately 1.0 0.000143348623853 0 1 -1
vasculature,without,disturbing 1.0 0.000143348623853 0 1 -1
vascularity,of,intestinal 1.0 0.000143348623853 0 1 -1
vascular,or,urinary 1.0 0.000143348623853 0 1 -1
vascular,lesions,characterized 1.0 0.000143348623853 0 1 -1
varying,degrees,of 1.0 0.000143348623853 0 1 -1
vary,in,the 1.0 0.000716743119266 0 5 -5
vary,from,those 1.0 0.000143348623853 0 1 -1
vary,by,such 1.0 0.000143348623853 0 1 -1
vary,as,a 1.0 0.000143348623853 0 1 -1
vary,and,is 1.0 0.000143348623853 0 1 -1
various,temperatures,in 1.0 0.000143348623853 0 1 -1
various,pesticides,this 1.0 0.000143348623853 0 1 -1
various,oral,anticoagulents 1.0 0.000143348623853 0 1 -1
various,dual-memory,theories 1.0 0.000143348623853 0 1 -1
various,doses,of 1.0 0.000143348623853 0 1 -1
various,cytochrome,p450 1.0 0.000143348623853 0 1 -1
various,combinations,of 1.0 0.000143348623853 0 1 -1
various,chemotherapy,agents 1.0 0.000143348623853 0 1 -1
various,ca,channel 1.0 0.000143348623853 0 1 -1
variety,of,toxic 1.0 0.000143348623853 0 1 -1
variety,of,settings 1.0 0.000143348623853 0 1 -1
variety,of,preparations 1.0 0.000143348623853 0 1 -1
variety,of,parametric 1.0 0.000143348623853 0 1 -1
variety,of,other 1.0 0.000143348623853 0 1 -1
variety,of,neurological 1.0 0.000143348623853 0 1 -1
variety,of,infections 1.0 0.000143348623853 0 1 -1
variety,of,hepatic 1.0 0.000143348623853 0 1 -1
variety,of,factors 1.0 0.000143348623853 0 1 -1
variety,of,allergens 1.0 0.000860091743119 0 6 -6
varied,from,study 1.0 0.000143348623853 0 1 -1
variations,of,glycemic 1.0 0.000143348623853 0 1 -1
variations,in,rabbits 1.0 0.000143348623853 0 1 -1
variation,in,metabolism 1.0 0.000143348623853 0 1 -1
variation,also,occurs 1.0 0.000143348623853 0 1 -1
variably,increased,when 1.0 0.000143348623853 0 1 -1
variables,of,compared 1.0 0.000143348623853 0 1 -1
variables,for,were 1.0 0.000143348623853 0 1 -1
variable,half-life,of 1.0 0.000143348623853 0 1 -1
variable,elevations,in 1.0 0.000143348623853 0 1 -1
variable,degrees,of 1.0 0.000143348623853 0 1 -1
variability,of,these 1.0 0.000143348623853 0 1 -1
variability,of,individual 1.0 0.000143348623853 0 1 -1
variability,of,effect 1.0 0.000143348623853 0 1 -1
variability,in,individual 1.0 0.000143348623853 0 1 -1
variability,however,somepatients 1.0 0.000143348623853 0 1 -1
variability,for,auc 1.0 0.000143348623853 0 1 -1
variability,and,limited 1.0 0.000143348623853 0 1 -1
vardenafil,with,has 1.0 0.000143348623853 0 1 -1
vardenafil,when,taken 1.0 0.000143348623853 0 1 -1
vardenafil,mg,when 1.0 0.000143348623853 0 1 -1
vardenafil,mg,was 1.0 0.000143348623853 0 1 -1
vardenafil,mg,did 1.0 0.000143348623853 0 1 -1
vardenafil,had,no 1.0 0.000143348623853 0 1 -1
vardenafil,and,its 1.0 0.000143348623853 0 1 -1
varapamil,and,sodium 1.0 0.000143348623853 0 1 -1
vanillylmandelic,acid,when 1.0 0.000143348623853 0 1 -1
vanh,promoter-vana,antisense 1.0 0.000143348623853 0 1 -1
vancomycin-resistant,strains,of 1.0 0.000143348623853 0 1 -1
vancomycin,resistance,reversal 1.0 0.000143348623853 0 1 -1
values,were,only 1.0 0.000143348623853 0 1 -1
values,were,not 1.0 0.000286697247706 0 2 -2
values,were,in 1.0 0.000143348623853 0 1 -1
values,similar,to 1.0 0.000143348623853 0 1 -1
values,of,the 1.0 0.000143348623853 0 1 -1
values,of,lng 1.0 0.000143348623853 0 1 -1
values,of,ee 1.0 0.000143348623853 0 1 -1
values,of,and 1.0 0.000143348623853 0 1 -1
values,it,has 1.0 0.000143348623853 0 1 -1
values,in,the 1.0 0.000143348623853 0 1 -1
values,in,a 1.0 0.000143348623853 0 1 -1
values,for,which 1.0 0.000143348623853 0 1 -1
values,for,ketogenic 1.0 0.000143348623853 0 1 -1
values,for,in 1.0 0.000143348623853 0 1 -1
values,for,free 1.0 0.000143348623853 0 1 -1
values,for,any 1.0 0.000143348623853 0 1 -1
values,being,reached 1.0 0.000143348623853 0 1 -1
values,are,to 1.0 0.000143348623853 0 1 -1
values,all,three 1.0 0.000143348623853 0 1 -1
values,after,an 1.0 0.000143348623853 0 1 -1
value,prescribed,daily 1.0 0.000143348623853 0 1 -1
value,one,must 1.0 0.000143348623853 0 1 -1
value,of,the 1.0 0.000286697247706 0 2 -2
value,of,serum 1.0 0.000143348623853 0 1 -1
value,of,m 1.0 0.000143348623853 0 1 -1
value,of,b 1.0 0.000143348623853 0 1 -1
value,is,not 1.0 0.000143348623853 0 1 -1
value,abstract,truncated 1.0 0.000143348623853 0 1 -1
valproic,acid,were 1.0 0.000143348623853 0 1 -1
valproic,acid,the 1.0 0.000143348623853 0 1 -1
valproic,acid,depakene 1.0 0.000143348623853 0 1 -1
valproic,acid,concentrations 1.0 0.000143348623853 0 1 -1
valproate,mg,twice 1.0 0.000143348623853 0 1 -1
valproate,keppra,mg 1.0 0.000143348623853 0 1 -1
valproate,available,data 1.0 0.000143348623853 0 1 -1
valium,is,a 1.0 0.000143348623853 0 1 -1
validation,of,method 1.0 0.000143348623853 0 1 -1
valid,in,cardioplegic 1.0 0.000143348623853 0 1 -1
valdecoxib,steady,state 1.0 0.000143348623853 0 1 -1
valdecoxib,did,not 1.0 0.000143348623853 0 1 -1
vaginal,preparations,of 1.0 0.00043004587156 0 3 -3
vacuolation,were,seen 1.0 0.000143348623853 0 1 -1
vaccines,neurological,complications 1.0 0.000143348623853 0 1 -1
vaccinations,with,attenuated 1.0 0.000143348623853 0 1 -1
v,vii,and 1.0 0.000143348623853 0 1 -1
v,v,solution 1.0 0.000143348623853 0 1 -1
v,to,m 1.0 0.000143348623853 0 1 -1
v,solution,of 1.0 0.000143348623853 0 1 -1
v,significantly,improved 1.0 0.000143348623853 0 1 -1
v,remains,constant 1.0 0.000143348623853 0 1 -1
v,readily,penetrates 1.0 0.000143348623853 0 1 -1
v,patients,should 1.0 0.000143348623853 0 1 -1
v,nacmc,conjugated 1.0 0.000143348623853 0 1 -1
v,in,the 1.0 0.000143348623853 0 1 -1
v,has,been 1.0 0.000143348623853 0 1 -1
v,did,not 1.0 0.000143348623853 0 1 -1
v,decreased,the 1.0 0.000143348623853 0 1 -1
v,concentrations,up 1.0 0.000143348623853 0 1 -1
v,concentrations,greater 1.0 0.000143348623853 0 1 -1
v,concentration,mm 1.0 0.000143348623853 0 1 -1
v,cmc-cys7,a 1.0 0.000143348623853 0 1 -1
v,as,these 1.0 0.000143348623853 0 1 -1
v,and,vii 1.0 0.000143348623853 0 1 -1
v,and,that 1.0 0.000143348623853 0 1 -1
utilizing,commercially,available 1.0 0.000143348623853 0 1 -1
utilizing,a,volatile 1.0 0.000143348623853 0 1 -1
utilization,with,simultaneous 1.0 0.000143348623853 0 1 -1
utilization,of,for 1.0 0.000143348623853 0 1 -1
utility,of,using 1.0 0.000143348623853 0 1 -1
utero,serum,levels 1.0 0.000143348623853 0 1 -1
utero,exposure,in 1.0 0.000143348623853 0 1 -1
usually,this,has 1.0 0.000143348623853 0 1 -1
usually,the,dosage 1.0 0.000143348623853 0 1 -1
usually,such,inactivation 1.0 0.000143348623853 0 1 -1
usually,severe,abdominal 1.0 0.000143348623853 0 1 -1
usually,recommended,for 1.0 0.000143348623853 0 1 -1
usually,prescribed,for 1.0 0.00100344036697 0 7 -7
usually,only,in 1.0 0.000143348623853 0 1 -1
usually,occurred,within 1.0 0.000143348623853 0 1 -1
usually,observed,only 1.0 0.000143348623853 0 1 -1
usually,mild,and 1.0 0.000143348623853 0 1 -1
usually,involves,depression 1.0 0.000143348623853 0 1 -1
usually,in,close 1.0 0.000143348623853 0 1 -1
usually,give,little 1.0 0.000143348623853 0 1 -1
usually,clear,within 1.0 0.000143348623853 0 1 -1
usual,recommended,dose 1.0 0.000143348623853 0 1 -1
usual,doses,of 1.0 0.000860091743119 0 6 -6
usual,dose,with 1.0 0.000143348623853 0 1 -1
usual,dosage,may 1.0 0.000143348623853 0 1 -1
usual,concentrations,following 1.0 0.000143348623853 0 1 -1
usual,amounts,of 1.0 0.000286697247706 0 2 -2
usp,have,not 1.0 0.000143348623853 0 1 -1
usp,has,not 1.0 0.000143348623853 0 1 -1
using,two,different 1.0 0.000143348623853 0 1 -1
using,this,technique 1.0 0.000143348623853 0 1 -1
using,this,medication 1.0 0.000143348623853 0 1 -1
using,these,techniques 1.0 0.000143348623853 0 1 -1
using,these,blocking 1.0 0.000143348623853 0 1 -1
using,these,agents 1.0 0.000143348623853 0 1 -1
using,their,selective 1.0 0.000143348623853 0 1 -1
using,the,uptake 1.0 0.000143348623853 0 1 -1
using,the,terms 1.0 0.000143348623853 0 1 -1
using,the,tail-flick 1.0 0.000143348623853 0 1 -1
using,the,scale 1.0 0.000143348623853 0 1 -1
using,the,paraaminohippurate 1.0 0.000143348623853 0 1 -1
using,the,intravenous 1.0 0.000143348623853 0 1 -1
using,the,commercially 1.0 0.000143348623853 0 1 -1
using,the,bio-rad 1.0 0.000143348623853 0 1 -1
using,stadol,ns 1.0 0.000143348623853 0 1 -1
using,red,cells 1.0 0.000143348623853 0 1 -1
using,rat,fibroblast 1.0 0.000143348623853 0 1 -1
using,preparations,containing 1.0 0.000143348623853 0 1 -1
using,pocs,and 1.0 0.000143348623853 0 1 -1
using,pcp,combination 1.0 0.000143348623853 0 1 -1
using,more,specific 1.0 0.000143348623853 0 1 -1
using,isoform,selective 1.0 0.000143348623853 0 1 -1
using,induced,skin 1.0 0.000143348623853 0 1 -1
using,in,combination 1.0 0.000143348623853 0 1 -1
using,immunoanalytical,methods 1.0 0.000143348623853 0 1 -1
using,human,liver 1.0 0.000143348623853 0 1 -1
using,four,diets 1.0 0.000143348623853 0 1 -1
using,for,example 1.0 0.000286697247706 0 2 -2
using,effective,forms 1.0 0.000143348623853 0 1 -1
using,effective,contraception 1.0 0.000143348623853 0 1 -1
using,duloxetine,in 1.0 0.000143348623853 0 1 -1
using,concomitant,such 1.0 0.000143348623853 0 1 -1
using,comparisons,to 1.0 0.000143348623853 0 1 -1
using,clozapine,in 1.0 0.000143348623853 0 1 -1
using,clinitest,tablets 1.0 0.000143348623853 0 1 -1
using,clinitest,benedicts 1.0 0.000143348623853 0 1 -1
using,clinitest,benedict 1.0 0.000286697247706 0 2 -2
using,cardiovascular,concurrently 1.0 0.000143348623853 0 1 -1
using,cardiac,and 1.0 0.000143348623853 0 1 -1
using,but,not 1.0 0.000286697247706 0 2 -2
using,anafranil,in 1.0 0.000143348623853 0 1 -1
using,an,i-labelled 1.0 0.000143348623853 0 1 -1
users,the,incidence 1.0 0.000143348623853 0 1 -1
users,of,which 1.0 0.000143348623853 0 1 -1
users,of,intravenous 1.0 0.000143348623853 0 1 -1
users,of,combined 1.0 0.000286697247706 0 2 -2
users,is,at 1.0 0.000143348623853 0 1 -1
users,experiencing,breakthrough 1.0 0.000143348623853 0 1 -1
users,develop,physiological 1.0 0.000143348623853 0 1 -1
user,such,as 1.0 0.000143348623853 0 1 -1
useful,tool,for 1.0 0.000143348623853 0 1 -1
useful,to,monitor 1.0 0.000143348623853 0 1 -1
useful,pharmacological,tool 1.0 0.000143348623853 0 1 -1
useful,in,therapy 1.0 0.000143348623853 0 1 -1
useful,in,cases 1.0 0.000143348623853 0 1 -1
useful,for,peroral 1.0 0.000143348623853 0 1 -1
used,with,the 1.0 0.000143348623853 0 1 -1
used,with,other 1.0 0.00043004587156 0 3 -3
used,with,general 1.0 0.000143348623853 0 1 -1
used,with,described 1.0 0.000143348623853 0 1 -1
used,with,agents 1.0 0.000143348623853 0 1 -1
used,while,taking 1.0 0.000143348623853 0 1 -1
used,when,it 1.0 0.000143348623853 0 1 -1
used,when,cyp3a4 1.0 0.000143348623853 0 1 -1
used,when,coadministering 1.0 0.000143348623853 0 1 -1
used,together,even 1.0 0.000143348623853 0 1 -1
used,together,caution 1.0 0.000143348623853 0 1 -1
used,together,at 1.0 0.000143348623853 0 1 -1
used,to,treat 1.0 0.00157683486239 0 11 -11
used,to,test 1.0 0.000143348623853 0 1 -1
used,to,study 1.0 0.000143348623853 0 1 -1
used,to,sensitize 1.0 0.000143348623853 0 1 -1
used,to,measure 1.0 0.000143348623853 0 1 -1
used,to,improve 1.0 0.000143348623853 0 1 -1
used,to,generate 1.0 0.000143348623853 0 1 -1
used,to,determine 1.0 0.00043004587156 0 3 -3
used,to,detect 1.0 0.000143348623853 0 1 -1
used,to,chemically 1.0 0.000143348623853 0 1 -1
used,to,characterize 1.0 0.000143348623853 0 1 -1
used,to,aid 1.0 0.000143348623853 0 1 -1
used,they,should 1.0 0.000143348623853 0 1 -1
used,the,length 1.0 0.000143348623853 0 1 -1
used,such,as 1.0 0.000143348623853 0 1 -1
used,successfully,concurrently 1.0 0.000286697247706 0 2 -2
used,some,form 1.0 0.000286697247706 0 2 -2
used,preanesthetic,or 1.0 0.000143348623853 0 1 -1
used,physiological,oral 1.0 0.000143348623853 0 1 -1
used,only,with 1.0 0.000143348623853 0 1 -1
used,only,as 1.0 0.000143348623853 0 1 -1
used,on,a 1.0 0.000143348623853 0 1 -1
used,many,patients 1.0 0.000143348623853 0 1 -1
used,it,is 1.0 0.000143348623853 0 1 -1
used,inconcomitant,administration 1.0 0.000143348623853 0 1 -1
used,in,turn 1.0 0.000143348623853 0 1 -1
used,in,treating 1.0 0.000143348623853 0 1 -1
used,in,surgery 1.0 0.000143348623853 0 1 -1
used,in,relation 1.0 0.000143348623853 0 1 -1
used,in,older 1.0 0.000143348623853 0 1 -1
used,in,ms 1.0 0.000143348623853 0 1 -1
used,in,interpreting 1.0 0.000143348623853 0 1 -1
used,in,hospitals 1.0 0.000143348623853 0 1 -1
used,in,external 1.0 0.000143348623853 0 1 -1
used,in,establishing 1.0 0.000143348623853 0 1 -1
used,in,diabetic 1.0 0.000143348623853 0 1 -1
used,in,dentistry 1.0 0.000143348623853 0 1 -1
used,in,clinical 1.0 0.000143348623853 0 1 -1
used,in,chemotherapy 1.0 0.000286697247706 0 2 -2
used,in,caution 1.0 0.000143348623853 0 1 -1
used,in,a 1.0 0.000143348623853 0 1 -1
used,general,and 1.0 0.000143348623853 0 1 -1
used,for,therapeutic 1.0 0.000143348623853 0 1 -1
used,for,relief 1.0 0.000143348623853 0 1 -1
used,for,l-glutamine 1.0 0.000143348623853 0 1 -1
used,during,therapy 1.0 0.000143348623853 0 1 -1
used,during,the 1.0 0.000143348623853 0 1 -1
used,during,pregnancy 1.0 0.000286697247706 0 2 -2
used,during,muscle 1.0 0.000143348623853 0 1 -1
used,concurrently,patient 1.0 0.000143348623853 0 1 -1
used,concomitantly,only 1.0 0.000143348623853 0 1 -1
used,concomitantly,closely 1.0 0.000143348623853 0 1 -1
used,concomitantly,careful 1.0 0.000143348623853 0 1 -1
used,combined,oral 1.0 0.000143348623853 0 1 -1
used,clinically,because 1.0 0.000143348623853 0 1 -1
used,cautiously,if 1.0 0.000143348623853 0 1 -1
used,by,millions 1.0 0.000143348623853 0 1 -1
used,as,sole 1.0 0.000143348623853 0 1 -1
used,as,a 1.0 0.000143348623853 0 1 -1
used,anti-peptic,agents 1.0 0.000143348623853 0 1 -1
used,and,blood 1.0 0.000143348623853 0 1 -1
used,after,insertion 1.0 0.000143348623853 0 1 -1
use,younger,patients 1.0 0.000143348623853 0 1 -1
use,with,supplements 1.0 0.000143348623853 0 1 -1
use,with,ribavirin 1.0 0.000286697247706 0 2 -2
use,with,other 1.0 0.000573394495413 0 4 -4
use,with,is 1.0 0.000143348623853 0 1 -1
use,with,general 1.0 0.000143348623853 0 1 -1
use,with,caution 1.0 0.000286697247706 0 2 -2
use,with,activase 1.0 0.000143348623853 0 1 -1
use,with,a 1.0 0.000143348623853 0 1 -1
use,when,tumor 1.0 0.000143348623853 0 1 -1
use,were,common 1.0 0.000143348623853 0 1 -1
use,was,present 1.0 0.000143348623853 0 1 -1
use,unless,necessary 1.0 0.000143348623853 0 1 -1
use,to,avoid 1.0 0.000143348623853 0 1 -1
use,the,safety 1.0 0.000286697247706 0 2 -2
use,the,pharmacological 1.0 0.000143348623853 0 1 -1
use,such,methods 1.0 0.000143348623853 0 1 -1
use,should,be 1.0 0.000143348623853 0 1 -1
use,resulted,in 1.0 0.000143348623853 0 1 -1
use,only,a 1.0 0.000143348623853 0 1 -1
use,of,when 1.0 0.000143348623853 0 1 -1
use,of,was 1.0 0.000143348623853 0 1 -1
use,of,tricyclic 1.0 0.000143348623853 0 1 -1
use,of,this 1.0 0.000286697247706 0 2 -2
use,of,st 1.0 0.000143348623853 0 1 -1
use,of,romazicon 1.0 0.000286697247706 0 2 -2
use,of,retinal 1.0 0.000143348623853 0 1 -1
use,of,repeated 1.0 0.000143348623853 0 1 -1
use,of,regranex 1.0 0.000143348623853 0 1 -1
use,of,prophylactic 1.0 0.000143348623853 0 1 -1
use,of,potassium-sparing 1.0 0.000143348623853 0 1 -1
use,of,pegasys 1.0 0.000143348623853 0 1 -1
use,of,orally 1.0 0.000143348623853 0 1 -1
use,of,one 1.0 0.000143348623853 0 1 -1
use,of,nuromax 1.0 0.000286697247706 0 2 -2
use,of,nimbex 1.0 0.000143348623853 0 1 -1
use,of,mg 1.0 0.000143348623853 0 1 -1
use,of,medications 1.0 0.000143348623853 0 1 -1
use,of,intravenously 1.0 0.000143348623853 0 1 -1
use,of,hydrochloride 1.0 0.000143348623853 0 1 -1
use,of,hormone 1.0 0.000143348623853 0 1 -1
use,of,herbal 1.0 0.00043004587156 0 3 -3
use,of,hctz 1.0 0.000143348623853 0 1 -1
use,of,have 1.0 0.000143348623853 0 1 -1
use,of,genetic 1.0 0.000143348623853 0 1 -1
use,of,from 1.0 0.000143348623853 0 1 -1
use,of,for 1.0 0.000143348623853 0 1 -1
use,of,femara 1.0 0.000143348623853 0 1 -1
use,of,erection-supporting 1.0 0.000143348623853 0 1 -1
use,of,does 1.0 0.000143348623853 0 1 -1
use,of,creams 1.0 0.000143348623853 0 1 -1
use,of,concurrently 1.0 0.000143348623853 0 1 -1
use,of,certain 1.0 0.000143348623853 0 1 -1
use,of,bepridil 1.0 0.000286697247706 0 2 -2
use,of,barrier 1.0 0.000143348623853 0 1 -1
use,of,ascorbic 1.0 0.000143348623853 0 1 -1
use,of,antithrombotics 1.0 0.000143348623853 0 1 -1
use,of,antifibrinolytic 1.0 0.000143348623853 0 1 -1
use,of,alone 1.0 0.000143348623853 0 1 -1
use,of,agents 1.0 0.000143348623853 0 1 -1
use,of,after 1.0 0.000143348623853 0 1 -1
use,of,aerosolized 1.0 0.000143348623853 0 1 -1
use,of,aczone 1.0 0.000143348623853 0 1 -1
use,of,activated 1.0 0.000143348623853 0 1 -1
use,of,ace 1.0 0.000143348623853 0 1 -1
use,may,potentiate 1.0 0.000143348623853 0 1 -1
use,may,blunt 1.0 0.000143348623853 0 1 -1
use,is,associated 1.0 0.000143348623853 0 1 -1
use,instructions,and 1.0 0.000143348623853 0 1 -1
use,in,women 1.0 0.000143348623853 0 1 -1
use,in,the 1.0 0.000286697247706 0 2 -2
use,in,spite 1.0 0.000143348623853 0 1 -1
use,in,combination 1.0 0.000143348623853 0 1 -1
use,in,ambulatory 1.0 0.000143348623853 0 1 -1
use,in,a 1.0 0.000143348623853 0 1 -1
use,if,possible 1.0 0.000143348623853 0 1 -1
use,however,pharmacokinetic 1.0 0.000143348623853 0 1 -1
use,glucose,dehydrogenase 1.0 0.000143348623853 0 1 -1
use,forms,of 1.0 0.000143348623853 0 1 -1
use,foradil,fumarate 1.0 0.000143348623853 0 1 -1
use,for,oral 1.0 0.000143348623853 0 1 -1
use,for,diabetic 1.0 0.000143348623853 0 1 -1
use,folate,may 1.0 0.000143348623853 0 1 -1
use,especially,of 1.0 0.000143348623853 0 1 -1
use,caution,when 1.0 0.000143348623853 0 1 -1
use,cannot,be 1.0 0.000143348623853 0 1 -1
use,by,the 1.0 0.000143348623853 0 1 -1
use,both,and 1.0 0.000143348623853 0 1 -1
use,as,part 1.0 0.000143348623853 0 1 -1
use,and,has 1.0 0.000143348623853 0 1 -1
usage,of,and 1.0 0.000143348623853 0 1 -1
us,food,and 1.0 0.000143348623853 0 1 -1
us,a,comprehensive 1.0 0.000143348623853 0 1 -1
urticaria,require,immediate 1.0 0.000143348623853 0 1 -1
uroxatral,and,other 1.0 0.000143348623853 0 1 -1
urobilin,due,to 1.0 0.000143348623853 0 1 -1
urine,which,may 1.0 0.000143348623853 0 1 -1
urine,when,using 1.0 0.000286697247706 0 2 -2
urine,were,sampled 1.0 0.000143348623853 0 1 -1
urine,was,analyzed 1.0 0.000143348623853 0 1 -1
urine,using,clinitest 1.0 0.00043004587156 0 3 -3
urine,using,a 1.0 0.000143348623853 0 1 -1
urine,test,for 1.0 0.000286697247706 0 2 -2
urine,sampling,were 1.0 0.000143348623853 0 1 -1
urine,samples,for 1.0 0.000143348623853 0 1 -1
urine,red-orange,which 1.0 0.000143348623853 0 1 -1
urine,or,serum 1.0 0.000286697247706 0 2 -2
urine,of,patients 1.0 0.000143348623853 0 1 -1
urine,of,both 1.0 0.000143348623853 0 1 -1
urine,may,result 1.0 0.000143348623853 0 1 -1
urine,may,occur 1.0 0.000860091743119 0 6 -6
urine,may,interfere 1.0 0.000143348623853 0 1 -1
urine,immunoreactive,concentrations 1.0 0.000143348623853 0 1 -1
urine,has,resulted 1.0 0.000143348623853 0 1 -1
urine,glucose,levels 1.0 0.000143348623853 0 1 -1
urine,for,the 1.0 0.000143348623853 0 1 -1
urine,creatinine,levels 1.0 0.000286697247706 0 2 -2
urine,creatinine,by 1.0 0.000143348623853 0 1 -1
urine,by,active 1.0 0.000143348623853 0 1 -1
urine,as,mercapturic 1.0 0.000143348623853 0 1 -1
urine,allow,development 1.0 0.000143348623853 0 1 -1
urine,after,exposure 1.0 0.000143348623853 0 1 -1
urinary,values,for 1.0 0.000143348623853 0 1 -1
urinary,tract,obstruction 1.0 0.000143348623853 0 1 -1
urinary,tract,infections 1.0 0.000286697247706 0 2 -2
urinary,thioether,assay 1.0 0.000143348623853 0 1 -1
urinary,retention,dysuria 1.0 0.000143348623853 0 1 -1
urinary,recovery,of 1.0 0.000143348623853 0 1 -1
urinary,protein,when 1.0 0.000143348623853 0 1 -1
urinary,metanephrine,normetanephrine 1.0 0.000143348623853 0 1 -1
urinary,levels,could 1.0 0.000143348623853 0 1 -1
urinary,hydroxy-corticosteroids,by 1.0 0.000143348623853 0 1 -1
urinary,homocysteine,following 1.0 0.000143348623853 0 1 -1
urinary,excretion,was 1.0 0.000143348623853 0 1 -1
urinary,excretion,as 1.0 0.000143348623853 0 1 -1
urinary,excretion,and 1.0 0.000143348623853 0 1 -1
urinary,catecholamine,levels 1.0 0.000143348623853 0 1 -1
urinary,bilirubin,urobilin 1.0 0.000143348623853 0 1 -1
urinary,assays,of 1.0 0.000143348623853 0 1 -1
urinary,alkalinizers,decrease 1.0 0.000143348623853 0 1 -1
uricosuric,agents,the 1.0 0.000143348623853 0 1 -1
uric,acid,levels 1.0 0.000143348623853 0 1 -1
urgently,to,be 1.0 0.000143348623853 0 1 -1
uremic,patients,serum 1.0 0.000143348623853 0 1 -1
uptakes,which,may 1.0 0.000143348623853 0 1 -1
uptake-1,were,reduced 1.0 0.000143348623853 0 1 -1
uptake-1,was,studied 1.0 0.000143348623853 0 1 -1
uptake-1,occurs,is 1.0 0.000143348623853 0 1 -1
uptake-1,in,human 1.0 0.000143348623853 0 1 -1
uptake-1,in,functional 1.0 0.000143348623853 0 1 -1
uptake-1,carrier,density 1.0 0.000143348623853 0 1 -1
uptake,sites,in 1.0 0.000143348623853 0 1 -1
uptake,producing,low 1.0 0.000143348623853 0 1 -1
uptake,of,uptake-1 1.0 0.000143348623853 0 1 -1
uptake,of,radiolabeled 1.0 0.000143348623853 0 1 -1
uptake,is,decreased 1.0 0.000573394495413 0 4 -4
uptake,inhibitor,hydrogen-3 1.0 0.000143348623853 0 1 -1
uptake,blocking,agents 1.0 0.000143348623853 0 1 -1
upper,limit,of 1.0 0.000286697247706 0 2 -2
upper,gastrointestinal,events 1.0 0.000143348623853 0 1 -1
upper,gastrointestinal,adverse 1.0 0.00043004587156 0 3 -3
upon,the,particular 1.0 0.000143348623853 0 1 -1
upon,the,metabolism 1.0 0.000143348623853 0 1 -1
upon,pcp,induced 1.0 0.000143348623853 0 1 -1
upon,cytochrome,p450 1.0 0.000143348623853 0 1 -1
upon,chylomicron,metabolism 1.0 0.000143348623853 0 1 -1
upon,a,variety 1.0 0.000143348623853 0 1 -1
updated,review,of 1.0 0.000143348623853 0 1 -1
up-titration,presumably,resulting 1.0 0.000143348623853 0 1 -1
up,to,years 1.0 0.000143348623853 0 1 -1
up,to,year 1.0 0.000143348623853 0 1 -1
up,to,x 1.0 0.000143348623853 0 1 -1
up,to,units 1.0 0.000143348623853 0 1 -1
up,to,the 1.0 0.000143348623853 0 1 -1
up,to,of 1.0 0.000286697247706 0 2 -2
up,to,nearly 1.0 0.000143348623853 0 1 -1
up,to,mm 1.0 0.000143348623853 0 1 -1
up,to,increase3 1.0 0.000143348623853 0 1 -1
up,to,doses 1.0 0.000143348623853 0 1 -1
up,smoking,adapting 1.0 0.000143348623853 0 1 -1
up,and,proposed 1.0 0.000143348623853 0 1 -1
up,a,considerable 1.0 0.000143348623853 0 1 -1
unwanted,effects,ways 1.0 0.000143348623853 0 1 -1
unusual,and,requires 1.0 0.000143348623853 0 1 -1
untreated,hypothyroidism,may 1.0 0.000143348623853 0 1 -1
until,the,volatile 1.0 0.000143348623853 0 1 -1
until,the,response 1.0 0.000143348623853 0 1 -1
until,the,lipid 1.0 0.000286697247706 0 2 -2
until,the,end 1.0 0.000143348623853 0 1 -1
until,the,effects 1.0 0.000143348623853 0 1 -1
until,stable,and 1.0 0.000143348623853 0 1 -1
until,specific,compatibility 1.0 0.000143348623853 0 1 -1
until,reaching,a 1.0 0.000143348623853 0 1 -1
until,neutrophils,recover 1.0 0.000143348623853 0 1 -1
until,it,has 1.0 0.000286697247706 0 2 -2
until,his,death 1.0 0.000143348623853 0 1 -1
until,further,data 1.0 0.000286697247706 0 2 -2
until,clinical,data 1.0 0.000143348623853 0 1 -1
until,after,chemotherapy 1.0 0.000143348623853 0 1 -1
unstable,with,a 1.0 0.000143348623853 0 1 -1
unrestricted,use,of 1.0 0.000143348623853 0 1 -1
unresponsive,to,the 1.0 0.000860091743119 0 6 -6
unrelated,to,sexual 1.0 0.000143348623853 0 1 -1
unrecognized,interactions,between 1.0 0.000143348623853 0 1 -1
unprotected,sexual,intercourse 1.0 0.000143348623853 0 1 -1
unprotected,by,the 1.0 0.000143348623853 0 1 -1
unmodified,nacmc,m 1.0 0.000143348623853 0 1 -1
unlikely,to,produce 1.0 0.000143348623853 0 1 -1
unlikely,to,interact 1.0 0.000143348623853 0 1 -1
unlikely,to,inhibit 1.0 0.000286697247706 0 2 -2
unlikely,to,have 1.0 0.000716743119266 0 5 -5
unlikely,to,compete 1.0 0.000143348623853 0 1 -1
unlikely,to,cause 1.0 0.000143348623853 0 1 -1
unlikely,to,be 1.0 0.000573394495413 0 4 -4
unlikely,to,affect 1.0 0.000143348623853 0 1 -1
unlikely,that,would 1.0 0.000143348623853 0 1 -1
unlikely,that,will 1.0 0.000143348623853 0 1 -1
unlikely,that,this 1.0 0.000143348623853 0 1 -1
unlikely,that,co-administration 1.0 0.000143348623853 0 1 -1
unlike,nucleolin,c23 1.0 0.000143348623853 0 1 -1
unlike,mc,does 1.0 0.000143348623853 0 1 -1
unless,there,are 1.0 0.000143348623853 0 1 -1
unless,really,needed 1.0 0.000143348623853 0 1 -1
unless,otherwise,specified 1.0 0.000286697247706 0 2 -2
unless,necessary,to 1.0 0.000143348623853 0 1 -1
unless,absolute,abstinence 1.0 0.000143348623853 0 1 -1
unknown,whether,this 1.0 0.000143348623853 0 1 -1
unknown,whether,the 1.0 0.000143348623853 0 1 -1
unknown,in,patients 1.0 0.000143348623853 0 1 -1
unknown,how,the 1.0 0.000143348623853 0 1 -1
unknown,but,the 1.0 0.000143348623853 0 1 -1
unknown,but,may 1.0 0.000286697247706 0 2 -2
unknown,amevive,should 1.0 0.000143348623853 0 1 -1
units,with,careful 1.0 0.000143348623853 0 1 -1
units,day,or 1.0 0.000143348623853 0 1 -1
united,states,but 1.0 0.000143348623853 0 1 -1
united,states,at 1.0 0.000286697247706 0 2 -2
united,states,and 1.0 0.000143348623853 0 1 -1
unique,biopharmaceutical,properties 1.0 0.000143348623853 0 1 -1
uniformity,and,time 1.0 0.000143348623853 0 1 -1
unfractionated,up,to 1.0 0.000143348623853 0 1 -1
unfortunately,folic,acid 1.0 0.000143348623853 0 1 -1
unexplored,area,and 1.0 0.000143348623853 0 1 -1
unexpectedly,high,plasma 1.0 0.000143348623853 0 1 -1
unexpected,hypotension,could 1.0 0.000143348623853 0 1 -1
unexpected,adverse,reactions 1.0 0.000143348623853 0 1 -1
unexpected,adverse,effects 1.0 0.000143348623853 0 1 -1
undetectable,release,in 1.0 0.000143348623853 0 1 -1
undetectable,ng,ml 1.0 0.000143348623853 0 1 -1
undesirable,involving,even 1.0 0.000286697247706 0 2 -2
underwent,trans-placental,passage 1.0 0.000143348623853 0 1 -1
underway,to,examine 1.0 0.000143348623853 0 1 -1
undertaken,with,equal 1.0 0.000143348623853 0 1 -1
understood,and,depend 1.0 0.000143348623853 0 1 -1
understanding,the,breadth 1.0 0.000143348623853 0 1 -1
understanding,of,pain 1.0 0.000143348623853 0 1 -1
understanding,of,its 1.0 0.000143348623853 0 1 -1
understanding,of,drug 1.0 0.000143348623853 0 1 -1
understanding,and,identifications 1.0 0.000143348623853 0 1 -1
understandable,because,the 1.0 0.000143348623853 0 1 -1
understand,how,to 1.0 0.000143348623853 0 1 -1
underlying,the,link 1.0 0.000143348623853 0 1 -1
underlying,the,development 1.0 0.000143348623853 0 1 -1
underlying,renal,insufficiency 1.0 0.000143348623853 0 1 -1
underlying,neural,plasticity 1.0 0.000143348623853 0 1 -1
underlying,many,of 1.0 0.000143348623853 0 1 -1
underlying,disease,rather 1.0 0.000143348623853 0 1 -1
underlying,conditions,and 1.0 0.000143348623853 0 1 -1
underlies,the,antipsychotic 1.0 0.000143348623853 0 1 -1
underlie,its,long-lasting 1.0 0.000143348623853 0 1 -1
undergoing,vigorous,physical 1.0 0.000143348623853 0 1 -1
undergoing,systemic,anticholinesterase 1.0 0.000143348623853 0 1 -1
undergoing,strenuous,physical 1.0 0.000143348623853 0 1 -1
undergoes,extensive,metabolism 1.0 0.000143348623853 0 1 -1
undergo,tyrosine,phosphorylation 1.0 0.000143348623853 0 1 -1
undergo,renal,tubular 1.0 0.000143348623853 0 1 -1
undergo,hydrolysis,to 1.0 0.000143348623853 0 1 -1
underestimates,the,degree 1.0 0.000143348623853 0 1 -1
underdosage,myasthenic,weakness 1.0 0.000143348623853 0 1 -1
under,years,of 1.0 0.000143348623853 0 1 -1
under,the,transcriptional 1.0 0.000143348623853 0 1 -1
under,the,influence 1.0 0.000286697247706 0 2 -2
under,the,concentration-time 1.0 0.000143348623853 0 1 -1
under,the,blood 1.0 0.000143348623853 0 1 -1
under,steady-state,conditions 1.0 0.000286697247706 0 2 -2
under,steady,state 1.0 0.000286697247706 0 2 -2
under,similar,conditions 1.0 0.000143348623853 0 1 -1
under,fasting,conditions 1.0 0.000143348623853 0 1 -1
under,certain,conditions 1.0 0.000143348623853 0 1 -1
under,certain,circumstances 1.0 0.000143348623853 0 1 -1
under,a,multiple 1.0 0.000143348623853 0 1 -1
uncontrolled,study,of 1.0 0.000143348623853 0 1 -1
uncontrolled,intake,of 1.0 0.00043004587156 0 3 -3
uncontrolled,domestic,studies 1.0 0.000143348623853 0 1 -1
uncontrolled,data,suggest 1.0 0.000143348623853 0 1 -1
unconjugated,nacmc,m 1.0 0.000143348623853 0 1 -1
uncompromised,elderly,patients 1.0 0.000143348623853 0 1 -1
uncomplicated,urinary,tract 1.0 0.000143348623853 0 1 -1
unclear,patients,on 1.0 0.000143348623853 0 1 -1
unchanged,when,they 1.0 0.000143348623853 0 1 -1
unchanged,the,secretion 1.0 0.000143348623853 0 1 -1
unchanged,or,only 1.0 0.000143348623853 0 1 -1
unchanged,in,the 1.0 0.000143348623853 0 1 -1
unchanged,following,coadministration 1.0 0.000143348623853 0 1 -1
unchanged,following,a 1.0 0.000143348623853 0 1 -1
unchanged,and,its 1.0 0.000143348623853 0 1 -1
unchanged,after,coadministration 1.0 0.000143348623853 0 1 -1
unchanged,accounts,for 1.0 0.000143348623853 0 1 -1
uncertain,mechanism,and 1.0 0.000143348623853 0 1 -1
unbound,to,the 1.0 0.000143348623853 0 1 -1
unbound,free,hormone 1.0 0.000143348623853 0 1 -1
unbound,bound,to 1.0 0.000143348623853 0 1 -1
unavailable,a,tarceva 1.0 0.000143348623853 0 1 -1
unaltered,in,the 1.0 0.000143348623853 0 1 -1
unaltered,by,concomitant 1.0 0.000143348623853 0 1 -1
unaffected,following,co-administration 1.0 0.000143348623853 0 1 -1
unaffected,by,the 1.0 0.000286697247706 0 2 -2
unaffected,by,indicating 1.0 0.000143348623853 0 1 -1
unaffected,by,concurrent 1.0 0.000143348623853 0 1 -1
unaffected,by,baseline 1.0 0.000143348623853 0 1 -1
unaffected,by,adl 1.0 0.000143348623853 0 1 -1
um,toward,cyp3a4 1.0 0.000143348623853 0 1 -1
ultracentrifugation,indicated,that 1.0 0.000143348623853 0 1 -1
ultimately,however,up 1.0 0.000143348623853 0 1 -1
ultimate,effect,of 1.0 0.000143348623853 0 1 -1
ulcers,in,patients 1.0 0.000143348623853 0 1 -1
ulcerans,was,measured 1.0 0.000143348623853 0 1 -1
ulcerans,was,between 1.0 0.000143348623853 0 1 -1
ugt,enzymes,in 1.0 0.000143348623853 0 1 -1
uganda,since,the 1.0 0.000143348623853 0 1 -1
udp-glucuronyl,transferase,level 1.0 0.000143348623853 0 1 -1
udp-glucuronyl,transferase,it 1.0 0.000143348623853 0 1 -1
ucb,l057,was 1.0 0.000143348623853 0 1 -1
ucb,l057,in 1.0 0.000143348623853 0 1 -1
u,of,to 1.0 0.000143348623853 0 1 -1
tysabri,dose,to 1.0 0.000143348623853 0 1 -1
tysabri,associated,adverse 1.0 0.000143348623853 0 1 -1
tysabri,and,concomitant 1.0 0.000143348623853 0 1 -1
tyrosine,phosphorylation,status 1.0 0.000143348623853 0 1 -1
typically,nonlinear,in 1.0 0.000143348623853 0 1 -1
typical,side,effect 1.0 0.000143348623853 0 1 -1
typhimurium,and,escherichia 1.0 0.000143348623853 0 1 -1
types,of,therapy 1.0 0.000143348623853 0 1 -1
types,of,studies 1.0 0.000143348623853 0 1 -1
types,of,liver 1.0 0.000143348623853 0 1 -1
types,of,interferences 1.0 0.000143348623853 0 1 -1
types,of,indications 1.0 0.000143348623853 0 1 -1
types,of,channels 1.0 0.000143348623853 0 1 -1
types,is,unknown 1.0 0.000143348623853 0 1 -1
type-specific,differences,may 1.0 0.000143348623853 0 1 -1
type,strains,and 1.0 0.000143348623853 0 1 -1
type,strain,of 1.0 0.000143348623853 0 1 -1
type,of,preparations 1.0 0.000143348623853 0 1 -1
type,may,be 1.0 0.000143348623853 0 1 -1
type,inositol,trisphosphate 1.0 0.000143348623853 0 1 -1
type,i,insulin-dependent 1.0 0.000143348623853 0 1 -1
type,diabetics,die 1.0 0.000143348623853 0 1 -1
type,diabetes,were 1.0 0.000143348623853 0 1 -1
type,diabetes,there 1.0 0.000143348623853 0 1 -1
type,diabetes,mellitus 1.0 0.000286697247706 0 2 -2
type,depth,of 1.0 0.000143348623853 0 1 -1
type,c,antiarrhythrnics 1.0 0.000143348623853 0 1 -1
type,and,may 1.0 0.000143348623853 0 1 -1
tykerb,is,administered 1.0 0.000286697247706 0 2 -2
txb2,generation,in 1.0 0.000143348623853 0 1 -1
twofold,greater,antitumour 1.0 0.000143348623853 0 1 -1
twofold,at,the 1.0 0.000143348623853 0 1 -1
two-year,carcinogenesis,study 1.0 0.000143348623853 0 1 -1
two-way,crossover,study 1.0 0.000143348623853 0 1 -1
two-lever,discrimination,and 1.0 0.000143348623853 0 1 -1
two-hour,period,after 1.0 0.000143348623853 0 1 -1
two,were,cardiac 1.0 0.000143348623853 0 1 -1
two,weeks,after 1.0 0.000143348623853 0 1 -1
two,type,strains 1.0 0.000143348623853 0 1 -1
two,treatment,groups 1.0 0.000143348623853 0 1 -1
two,times,the 1.0 0.000143348623853 0 1 -1
two,studies,were 1.0 0.000143348623853 0 1 -1
two,strains,of 1.0 0.000143348623853 0 1 -1
two,single,oral 1.0 0.000143348623853 0 1 -1
two,should,not 1.0 0.000286697247706 0 2 -2
two,sequential,trials 1.0 0.000143348623853 0 1 -1
two,reverse,transcriptase 1.0 0.000143348623853 0 1 -1
two,retrospective,studies 1.0 0.000143348623853 0 1 -1
two,regimens,was 1.0 0.000143348623853 0 1 -1
two,outbreaks,of 1.0 0.000143348623853 0 1 -1
two,on,certain 1.0 0.000143348623853 0 1 -1
two,of,the 1.0 0.000143348623853 0 1 -1
two,multiple-dose,interaction 1.0 0.000143348623853 0 1 -1
two,mg,tablets 1.0 0.000143348623853 0 1 -1
two,mg,sustained-release 1.0 0.000143348623853 0 1 -1
two,metabolites,hydroxytolbutamide 1.0 0.000143348623853 0 1 -1
two,isoenzymes,will 1.0 0.000143348623853 0 1 -1
two,inhibitors,of 1.0 0.000143348623853 0 1 -1
two,hundred,mg 1.0 0.000143348623853 0 1 -1
two,hours,of 1.0 0.000143348623853 0 1 -1
two,hours,between 1.0 0.000143348623853 0 1 -1
two,hours,and 1.0 0.000143348623853 0 1 -1
two,hour,period 1.0 0.000143348623853 0 1 -1
two,hepatic,and 1.0 0.000143348623853 0 1 -1
two,groups,sh 1.0 0.000143348623853 0 1 -1
two,groups,but 1.0 0.000143348623853 0 1 -1
two,groups,achieving 1.0 0.000143348623853 0 1 -1
two,elements,only 1.0 0.000143348623853 0 1 -1
two,doses,of 1.0 0.000143348623853 0 1 -1
two,different,way 1.0 0.000143348623853 0 1 -1
two,different,types 1.0 0.000143348623853 0 1 -1
two,different,tasks 1.0 0.000143348623853 0 1 -1
two,different,medicines 1.0 0.000143348623853 0 1 -1
two,differ,and 1.0 0.000143348623853 0 1 -1
two,controlled,crossover 1.0 0.000143348623853 0 1 -1
two,concomitantly,should 1.0 0.000143348623853 0 1 -1
two,compounds,was 1.0 0.000143348623853 0 1 -1
two,combined,week 1.0 0.000143348623853 0 1 -1
two,capsules,twice 1.0 0.000143348623853 0 1 -1
two,are,given 1.0 0.000143348623853 0 1 -1
two,agents,were 1.0 0.000143348623853 0 1 -1
twitch,was,maintained 1.0 0.000143348623853 0 1 -1
twitch,was,again 1.0 0.000143348623853 0 1 -1
twitch,strength,from 1.0 0.000143348623853 0 1 -1
twitch,gradually,returned 1.0 0.000143348623853 0 1 -1
twitch,for,a 1.0 0.000143348623853 0 1 -1
twitch,allowed,to 1.0 0.000143348623853 0 1 -1
twice-a,day,administration 1.0 0.000143348623853 0 1 -1
twice,the,human 1.0 0.00043004587156 0 3 -3
twice,daily,morning 1.0 0.000143348623853 0 1 -1
twice,daily,mg 1.0 0.000143348623853 0 1 -1
twice,daily,mcg 1.0 0.000143348623853 0 1 -1
twice,daily,dose 1.0 0.000143348623853 0 1 -1
twice,daily,did 1.0 0.000860091743119 0 6 -6
twice,a,day 1.0 0.00043004587156 0 3 -3
twenty-four,healthy,male 1.0 0.000143348623853 0 1 -1
twenty-four,h,exposures 1.0 0.000143348623853 0 1 -1
twenty,four,male 1.0 0.000143348623853 0 1 -1
twelve,healthy,male 1.0 0.000143348623853 0 1 -1
turn,out,to 1.0 0.000143348623853 0 1 -1
turn,discussing,the 1.0 0.000143348623853 0 1 -1
turn,controls,levels 1.0 0.000143348623853 0 1 -1
tumour,total,peak 1.0 0.000143348623853 0 1 -1
tumour,the,peak 1.0 0.000143348623853 0 1 -1
tumors,when,administered 1.0 0.000143348623853 0 1 -1
tumors,was,evident 1.0 0.000143348623853 0 1 -1
tumors,seen,in 1.0 0.000143348623853 0 1 -1
tumors,of,more 1.0 0.000143348623853 0 1 -1
tumors,is,consistent 1.0 0.000143348623853 0 1 -1
tumors,and,testicular 1.0 0.000143348623853 0 1 -1
tumors,and,cancer 1.0 0.000143348623853 0 1 -1
tumor,versus,normal 1.0 0.000143348623853 0 1 -1
tumor,vascularity,of 1.0 0.000143348623853 0 1 -1
tumor,types,is 1.0 0.000143348623853 0 1 -1
tumor,that,results 1.0 0.000143348623853 0 1 -1
tumor,response,was 1.0 0.000143348623853 0 1 -1
tumor,phenotype,and 1.0 0.000143348623853 0 1 -1
tumor,cells,by 1.0 0.000143348623853 0 1 -1
tumor,cell,resistance 1.0 0.000143348623853 0 1 -1
tumor,cell,killing 1.0 0.000143348623853 0 1 -1
tumor,and,normal 1.0 0.000143348623853 0 1 -1
tubules,seminiferous,tubular 1.0 0.000143348623853 0 1 -1
tubular,secretion,by 1.0 0.000143348623853 0 1 -1
tubular,secretion,blocking 1.0 0.000143348623853 0 1 -1
tubular,atrophy,and 1.0 0.000143348623853 0 1 -1
tuberculosis,andusing,a 1.0 0.000143348623853 0 1 -1
tuberculosa,caused,a 1.0 0.000143348623853 0 1 -1
tubercle,of,the 1.0 0.000143348623853 0 1 -1
tsh,secretion,p-aminosalicylic 1.0 0.000143348623853 0 1 -1
tsh,levels,generally 1.0 0.000143348623853 0 1 -1
trypanosomiasis,uganda,since 1.0 0.000143348623853 0 1 -1
trypanosomiasis,in,the 1.0 0.000143348623853 0 1 -1
truly,hypothyroid,it 1.0 0.000143348623853 0 1 -1
true,in,patients 1.0 0.000143348623853 0 1 -1
true,decrease,in 1.0 0.000143348623853 0 1 -1
trough,serum,valproic 1.0 0.000143348623853 0 1 -1
trough,plasma,concentrations 1.0 0.000143348623853 0 1 -1
trough,plasma,and 1.0 0.000143348623853 0 1 -1
trough,concentrations,and 1.0 0.000143348623853 0 1 -1
trough,cmin,plasma 1.0 0.000286697247706 0 2 -2
trisphosphate-induced,responses,in 1.0 0.000143348623853 0 1 -1
trisphosphate,the,major 1.0 0.000143348623853 0 1 -1
trisphosphate,insp,induced 1.0 0.000143348623853 0 1 -1
trisenox,and,other 1.0 0.000143348623853 0 1 -1
triple-immunosuppression,regimens,including 1.0 0.000143348623853 0 1 -1
triple,therapy,with 1.0 0.000143348623853 0 1 -1
triphosphate,metabolite,was 1.0 0.000143348623853 0 1 -1
trinitrate,isosorbide,dinitrate 1.0 0.000143348623853 0 1 -1
trimethyl,lead,tml 1.0 0.000143348623853 0 1 -1
trimethoprim,alone,or 1.0 0.000143348623853 0 1 -1
trileptal,on,aed 1.0 0.000143348623853 0 1 -1
trileptal,and,other 1.0 0.000143348623853 0 1 -1
trilafon,compazine,sparine 1.0 0.000143348623853 0 1 -1
triiodothyronine,levels,but 1.0 0.000143348623853 0 1 -1
triglycerides,or,bone 1.0 0.000143348623853 0 1 -1
triglycerides,mg,dl 1.0 0.000143348623853 0 1 -1
triglyceride,plasma,levels 1.0 0.000143348623853 0 1 -1
tricyclic,with,that 1.0 0.000143348623853 0 1 -1
tricyclic,which,can 1.0 0.000143348623853 0 1 -1
tricyclic,tcas,when 1.0 0.000143348623853 0 1 -1
tricyclic,may,potentiate 1.0 0.000143348623853 0 1 -1
tricyclic,antidepressants,concurrent 1.0 0.000143348623853 0 1 -1
tricyclic,antidepressant,or 1.0 0.000286697247706 0 2 -2
tricyclic,antidepressant,may 1.0 0.000143348623853 0 1 -1
tricyclic,antidepressant,agent 1.0 0.000143348623853 0 1 -1
tricky,using,for 1.0 0.000143348623853 0 1 -1
triazole,have,not 1.0 0.000143348623853 0 1 -1
triazolam,no,significant 1.0 0.000143348623853 0 1 -1
triazolam,combined,administration 1.0 0.000143348623853 0 1 -1
triamterene,concomitant,use 1.0 0.000143348623853 0 1 -1
trials,with,simulect 1.0 0.000143348623853 0 1 -1
trials,were,maintained 1.0 0.000143348623853 0 1 -1
trials,were,administered 1.0 0.000143348623853 0 1 -1
trials,was,used 1.0 0.000143348623853 0 1 -1
trials,using,the 1.0 0.000143348623853 0 1 -1
trials,to,examine 1.0 0.000143348623853 0 1 -1
trials,the,safety 1.0 0.000143348623853 0 1 -1
trials,the,patients 1.0 0.000143348623853 0 1 -1
trials,the,concomitant 1.0 0.000143348623853 0 1 -1
trials,that,included 1.0 0.000143348623853 0 1 -1
trials,suggest,no 1.0 0.000143348623853 0 1 -1
trials,suggest,comparable 1.0 0.000143348623853 0 1 -1
trials,specifically,examining 1.0 0.000143348623853 0 1 -1
trials,similar,changes 1.0 0.000143348623853 0 1 -1
trials,showed,that 1.0 0.000143348623853 0 1 -1
trials,performed,at 1.0 0.000143348623853 0 1 -1
trials,patients,who 1.0 0.000143348623853 0 1 -1
trials,patients,were 1.0 0.000143348623853 0 1 -1
trials,of,such 1.0 0.000143348623853 0 1 -1
trials,of,postoperative 1.0 0.000143348623853 0 1 -1
trials,of,interactions 1.0 0.000143348623853 0 1 -1
trials,of,epirubicin-containing 1.0 0.000143348623853 0 1 -1
trials,of,chloral 1.0 0.000143348623853 0 1 -1
trials,of,augmentin 1.0 0.000143348623853 0 1 -1
trials,no,interactions 1.0 0.000143348623853 0 1 -1
trials,no,clinically 1.0 0.000143348623853 0 1 -1
trials,mesylate,tablets 1.0 0.000143348623853 0 1 -1
trials,mean,decreases 1.0 0.000143348623853 0 1 -1
trials,hypoglycemia,and 1.0 0.000143348623853 0 1 -1
trials,however,beta 1.0 0.000143348623853 0 1 -1
trials,heart,rate 1.0 0.000143348623853 0 1 -1
trials,have,used 1.0 0.000143348623853 0 1 -1
trials,have,investigated 1.0 0.000143348623853 0 1 -1
trials,have,indicated 1.0 0.000143348623853 0 1 -1
trials,due,to 1.0 0.000143348623853 0 1 -1
trials,database,three 1.0 0.000143348623853 0 1 -1
trials,currently,exist 1.0 0.000143348623853 0 1 -1
trials,concomitant,medications 1.0 0.000143348623853 0 1 -1
trials,and,were 1.0 0.000143348623853 0 1 -1
trials,and,studies 1.0 0.000143348623853 0 1 -1
trials,and,hepatitis 1.0 0.000143348623853 0 1 -1
trials,a,total 1.0 0.000143348623853 0 1 -1
trial,there,have 1.0 0.000143348623853 0 1 -1
trial,that,included 1.0 0.000143348623853 0 1 -1
trial,showed,comparable 1.0 0.000143348623853 0 1 -1
trial,of,pediatric 1.0 0.000143348623853 0 1 -1
trial,in,which 1.0 0.000286697247706 0 2 -2
trial,a,reduction 1.0 0.000143348623853 0 1 -1
triacylglycerol,synthesis,to 1.0 0.000143348623853 0 1 -1
trexan,with,long-term 1.0 0.000143348623853 0 1 -1
trend,to,increase 1.0 0.000143348623853 0 1 -1
tremors,and,at 1.0 0.000143348623853 0 1 -1
tremor,rigidity,dystonia 1.0 0.000143348623853 0 1 -1
tremor,in,elderly 1.0 0.000143348623853 0 1 -1
tremor,hemiballismus,hyperreflexia 1.0 0.000143348623853 0 1 -1
treatpatients,co-infected,with 1.0 0.000143348623853 0 1 -1
treatments,with,constant 1.0 0.000143348623853 0 1 -1
treatments,with,an 1.0 0.000143348623853 0 1 -1
treatments,to,this 1.0 0.000143348623853 0 1 -1
treatments,of,depletion 1.0 0.000143348623853 0 1 -1
treatments,lacking,cyp3a4 1.0 0.000143348623853 0 1 -1
treatments,corrective,measures 1.0 0.000143348623853 0 1 -1
treatments,and,no 1.0 0.000143348623853 0 1 -1
treatment-naive,patients,the 1.0 0.000143348623853 0 1 -1
treatment-experienced,patients,have 1.0 0.000143348623853 0 1 -1
treatment-experienced,patients,available 1.0 0.000143348623853 0 1 -1
treatment,with,the 1.0 0.000143348623853 0 1 -1
treatment,with,synthetic 1.0 0.000143348623853 0 1 -1
treatment,with,sprycel 1.0 0.000143348623853 0 1 -1
treatment,with,soriatane 1.0 0.000143348623853 0 1 -1
treatment,with,potassium-sparing 1.0 0.000143348623853 0 1 -1
treatment,with,plenaxis 1.0 0.000143348623853 0 1 -1
treatment,with,other 1.0 0.000286697247706 0 2 -2
treatment,with,of 1.0 0.000143348623853 0 1 -1
treatment,with,isocarboxazid 1.0 0.000143348623853 0 1 -1
treatment,with,is 1.0 0.000143348623853 0 1 -1
treatment,with,incisive 1.0 0.000143348623853 0 1 -1
treatment,with,eg 1.0 0.000143348623853 0 1 -1
treatment,with,did 1.0 0.000143348623853 0 1 -1
treatment,with,derivatives 1.0 0.000143348623853 0 1 -1
treatment,with,daily 1.0 0.000143348623853 0 1 -1
treatment,with,coadministered 1.0 0.000143348623853 0 1 -1
treatment,with,amevive 1.0 0.000143348623853 0 1 -1
treatment,there,was 1.0 0.000143348623853 0 1 -1
treatment,the,dose 1.0 0.000143348623853 0 1 -1
treatment,study,and 1.0 0.000143348623853 0 1 -1
treatment,studies,evaluating 1.0 0.000143348623853 0 1 -1
treatment,regimen,of 1.0 0.000143348623853 0 1 -1
treatment,produced,either 1.0 0.000143348623853 0 1 -1
treatment,practices,in 1.0 0.000143348623853 0 1 -1
treatment,plans,for 1.0 0.000143348623853 0 1 -1
treatment,period,was 1.0 0.000143348623853 0 1 -1
treatment,or,during 1.0 0.000143348623853 0 1 -1
treatment,on,patient 1.0 0.000143348623853 0 1 -1
treatment,of,trypanosomiasis 1.0 0.000143348623853 0 1 -1
treatment,of,the 1.0 0.00043004587156 0 3 -3
treatment,of,some 1.0 0.000286697247706 0 2 -2
treatment,of,severe 1.0 0.000143348623853 0 1 -1
treatment,of,relapses 1.0 0.000143348623853 0 1 -1
treatment,of,ras-3t3 1.0 0.000143348623853 0 1 -1
treatment,of,psychotic 1.0 0.000286697247706 0 2 -2
treatment,of,pregnant 1.0 0.000143348623853 0 1 -1
treatment,of,positive 1.0 0.000143348623853 0 1 -1
treatment,of,osteoarthritis 1.0 0.000143348623853 0 1 -1
treatment,of,negative 1.0 0.000286697247706 0 2 -2
treatment,of,induced 1.0 0.000143348623853 0 1 -1
treatment,of,hypoxic 1.0 0.000143348623853 0 1 -1
treatment,of,erection 1.0 0.000143348623853 0 1 -1
treatment,of,depressive 1.0 0.000143348623853 0 1 -1
treatment,of,depression 1.0 0.000286697247706 0 2 -2
treatment,of,crohn 1.0 0.000143348623853 0 1 -1
treatment,of,complicated 1.0 0.000143348623853 0 1 -1
treatment,of,chronic 1.0 0.000143348623853 0 1 -1
treatment,of,both 1.0 0.000143348623853 0 1 -1
treatment,of,angina 1.0 0.000143348623853 0 1 -1
treatment,of,addiction 1.0 0.000143348623853 0 1 -1
treatment,of,acute 1.0 0.000143348623853 0 1 -1
treatment,of,a 1.0 0.000143348623853 0 1 -1
treatment,occurred,in 1.0 0.000143348623853 0 1 -1
treatment,may,delay 1.0 0.000143348623853 0 1 -1
treatment,is,unavailable 1.0 0.000143348623853 0 1 -1
treatment,is,group 1.0 0.000143348623853 0 1 -1
treatment,is,followed 1.0 0.000143348623853 0 1 -1
treatment,is,essential 1.0 0.000143348623853 0 1 -1
treatment,is,continued 1.0 0.000286697247706 0 2 -2
treatment,is,cas 1.0 0.000143348623853 0 1 -1
treatment,is,associated 1.0 0.000143348623853 0 1 -1
treatment,in,some 1.0 0.000143348623853 0 1 -1
treatment,in,patients 1.0 0.000286697247706 0 2 -2
treatment,in,a 1.0 0.000716743119266 0 5 -5
treatment,improves,quality 1.0 0.000143348623853 0 1 -1
treatment,i,the 1.0 0.000143348623853 0 1 -1
treatment,groups,were 1.0 0.000286697247706 0 2 -2
treatment,for,weeks 1.0 0.000143348623853 0 1 -1
treatment,for,up 1.0 0.000143348623853 0 1 -1
treatment,for,patients 1.0 0.000143348623853 0 1 -1
treatment,for,multiple 1.0 0.000143348623853 0 1 -1
treatment,for,extravasation 1.0 0.000143348623853 0 1 -1
treatment,for,anaphylactic 1.0 0.000143348623853 0 1 -1
treatment,for,a 1.0 0.000143348623853 0 1 -1
treatment,dyspnea,requiring 1.0 0.000143348623853 0 1 -1
treatment,during,the 1.0 0.000143348623853 0 1 -1
treatment,discontinued,promptly 1.0 0.000143348623853 0 1 -1
treatment,discontinuation,is 1.0 0.000143348623853 0 1 -1
treatment,did,not 1.0 0.000286697247706 0 2 -2
treatment,costs,of 1.0 0.000143348623853 0 1 -1
treatment,costs,inpatient 1.0 0.000143348623853 0 1 -1
treatment,costs,despite 1.0 0.000143348623853 0 1 -1
treatment,cessation,such 1.0 0.000143348623853 0 1 -1
treatment,ataxia,a 1.0 0.000143348623853 0 1 -1
treatment,arm,was 1.0 0.000143348623853 0 1 -1
treatment,and,prevention 1.0 0.000143348623853 0 1 -1
treatment,and,gi 1.0 0.000143348623853 0 1 -1
treatment,and,aftercare 1.0 0.000143348623853 0 1 -1
treatment,age,sex 1.0 0.000143348623853 0 1 -1
treating,patients,with 1.0 0.000286697247706 0 2 -2
treating,patients,receiving 1.0 0.000143348623853 0 1 -1
treated,with,within 1.0 0.000143348623853 0 1 -1
treated,with,who 1.0 0.000143348623853 0 1 -1
treated,with,tikosyn 1.0 0.000143348623853 0 1 -1
treated,with,tenormin 1.0 0.000143348623853 0 1 -1
treated,with,taxol 1.0 0.000143348623853 0 1 -1
treated,with,pegasys 1.0 0.000143348623853 0 1 -1
treated,with,pcp 1.0 0.000143348623853 0 1 -1
treated,with,other 1.0 0.000286697247706 0 2 -2
treated,with,non-pegylated 1.0 0.000143348623853 0 1 -1
treated,with,nm 1.0 0.000143348623853 0 1 -1
treated,with,nevirapine- 1.0 0.000143348623853 0 1 -1
treated,with,intramuscular 1.0 0.000143348623853 0 1 -1
treated,with,indocin 1.0 0.000143348623853 0 1 -1
treated,with,ibandronate 1.0 0.000286697247706 0 2 -2
treated,with,hcl 1.0 0.000143348623853 0 1 -1
treated,with,have 1.0 0.000286697247706 0 2 -2
treated,with,faslodex 1.0 0.000143348623853 0 1 -1
treated,with,cordarone 1.0 0.000143348623853 0 1 -1
treated,with,chop 1.0 0.000143348623853 0 1 -1
treated,with,appropriate 1.0 0.000143348623853 0 1 -1
treated,with,acamprosate 1.0 0.000143348623853 0 1 -1
treated,with,a 1.0 0.00043004587156 0 3 -3
treated,subjects,received 1.0 0.000286697247706 0 2 -2
treated,simultaneously,with 1.0 0.000143348623853 0 1 -1
treated,patients,no 1.0 0.000143348623853 0 1 -1
treated,for,months 1.0 0.000143348623853 0 1 -1
treated,by,during 1.0 0.000143348623853 0 1 -1
treated,at,mg 1.0 0.000143348623853 0 1 -1
treated,animals,than 1.0 0.000143348623853 0 1 -1
treated,aggressively,with 1.0 0.000143348623853 0 1 -1
treated,according,to 1.0 0.000143348623853 0 1 -1
treat,hypertension,patients 1.0 0.000143348623853 0 1 -1
treat,anxiety,associated 1.0 0.000143348623853 0 1 -1
treat,an,overactive 1.0 0.000143348623853 0 1 -1
treat,aggressively,is 1.0 0.000143348623853 0 1 -1
treat,achlorhydria,and 1.0 0.000143348623853 0 1 -1
treat,a,wide 1.0 0.000143348623853 0 1 -1
tranxene,tablets,are 1.0 0.000143348623853 0 1 -1
tranxene,is,to 1.0 0.000143348623853 0 1 -1
transporter,as,demonstrated 1.0 0.000143348623853 0 1 -1
transport,systems,lapatinib 1.0 0.000286697247706 0 2 -2
transport,ratio,r 1.0 0.000143348623853 0 1 -1
transport,pathway,in 1.0 0.000143348623853 0 1 -1
transport,of,or 1.0 0.000143348623853 0 1 -1
transport,of,noradrenaline 1.0 0.000143348623853 0 1 -1
transport,in,the 1.0 0.00043004587156 0 3 -3
transplants,malignancy,and 1.0 0.000143348623853 0 1 -1
transplant,recipients,over 1.0 0.000143348623853 0 1 -1
transmission,should,be 1.0 0.000143348623853 0 1 -1
transmission,at,the 1.0 0.000143348623853 0 1 -1
translocation,of,phosphatidate 1.0 0.000286697247706 0 2 -2
translocating,action,of 1.0 0.000143348623853 0 1 -1
transits,were,the 1.0 0.000143348623853 0 1 -1
transits,or,in 1.0 0.000143348623853 0 1 -1
transitory,changes,in 1.0 0.000143348623853 0 1 -1
transit-enhancing,effect,of 1.0 0.000143348623853 0 1 -1
transit,time,hydrogen 1.0 0.000143348623853 0 1 -1
transiently,elevated,by 1.0 0.000143348623853 0 1 -1
transient,thrombocytopenia,or 1.0 0.000143348623853 0 1 -1
transient,peak,plasma 1.0 0.000143348623853 0 1 -1
transient,outward,rectification 1.0 0.000143348623853 0 1 -1
transient,increase,in 1.0 0.000143348623853 0 1 -1
transient,hypotensive,response 1.0 0.000143348623853 0 1 -1
transient,drowsiness,was 1.0 0.000143348623853 0 1 -1
transient,asymptomatic,liver 1.0 0.000143348623853 0 1 -1
transient,and,minor 1.0 0.000143348623853 0 1 -1
transfusion,practices,for 1.0 0.000143348623853 0 1 -1
transfusion,cross-matching,procedures 1.0 0.000143348623853 0 1 -1
transfers,were,the 1.0 0.000143348623853 0 1 -1
transferring,the,phosphohydrolase 1.0 0.000143348623853 0 1 -1
transferred,to,the 1.0 0.000143348623853 0 1 -1
transferase,level,was 1.0 0.000143348623853 0 1 -1
transferase,it,is 1.0 0.000143348623853 0 1 -1
transferase,gst,activity 1.0 0.000143348623853 0 1 -1
transferase,enzyme,activity 1.0 0.000143348623853 0 1 -1
transfer,to,the 1.0 0.000143348623853 0 1 -1
transfer,to,reverse 1.0 0.000143348623853 0 1 -1
transfer,to,oral 1.0 0.000143348623853 0 1 -1
transfer,from,the 1.0 0.000143348623853 0 1 -1
transfected,with,a 1.0 0.000143348623853 0 1 -1
transcriptional,regulation,of 1.0 0.000143348623853 0 1 -1
transcriptional,activator,binding 1.0 0.000143348623853 0 1 -1
transcription,was,strongly 1.0 0.000143348623853 0 1 -1
transcription,replication,etc 1.0 0.000143348623853 0 1 -1
transcription,factor,iegs 1.0 0.000143348623853 0 1 -1
transcriptase,inhibitors,and 1.0 0.000143348623853 0 1 -1
transcriptase,inhibitor,nnrti 1.0 0.000143348623853 0 1 -1
transaminases,have,been 1.0 0.000143348623853 0 1 -1
transaminases,bilirubin,and 1.0 0.000143348623853 0 1 -1
transaminase,levels,should 1.0 0.000143348623853 0 1 -1
trans-placental,passage,and 1.0 0.000143348623853 0 1 -1
tranexamic,acid,aminocaproic 1.0 0.000143348623853 0 1 -1
training-induced,neurobiological,alterations 1.0 0.000143348623853 0 1 -1
training,dose,in 1.0 0.000143348623853 0 1 -1
traditional,agents,for 1.0 0.000143348623853 0 1 -1
trademark,of,ames 1.0 0.000143348623853 0 1 -1
traction,of,metabolized 1.0 0.000143348623853 0 1 -1
tract,where,the 1.0 0.000143348623853 0 1 -1
tract,obstruction,and 1.0 0.000143348623853 0 1 -1
tracleer,is,not 1.0 0.000143348623853 0 1 -1
trace,pathways,which 1.0 0.000143348623853 0 1 -1
trace,elements,were 1.0 0.000143348623853 0 1 -1
toxicology,study,male 1.0 0.000143348623853 0 1 -1
toxicology,studies,showed 1.0 0.000143348623853 0 1 -1
toxicology,studies,have 1.0 0.000143348623853 0 1 -1
toxicology,of,difluoroacetone 1.0 0.000143348623853 0 1 -1
toxicologic,profile,of 1.0 0.000143348623853 0 1 -1
toxicologic,and,toxicokinetic 1.0 0.000143348623853 0 1 -1
toxicokinetic,studies,in 1.0 0.000143348623853 0 1 -1
toxicokinetic,interferences,between 1.0 0.000143348623853 0 1 -1
toxicodynamic,interference,between 1.0 0.000143348623853 0 1 -1
toxicity,where,survival 1.0 0.000143348623853 0 1 -1
toxicity,when,deet 1.0 0.000143348623853 0 1 -1
toxicity,was,also 1.0 0.000143348623853 0 1 -1
toxicity,to,miracidia 1.0 0.000143348623853 0 1 -1
toxicity,to,hatching 1.0 0.000143348623853 0 1 -1
toxicity,tests,showed 1.0 0.000143348623853 0 1 -1
toxicity,study,cynomolgus 1.0 0.000143348623853 0 1 -1
toxicity,since,it 1.0 0.000143348623853 0 1 -1
toxicity,see,warnings 1.0 0.000143348623853 0 1 -1
toxicity,resulting,from 1.0 0.000143348623853 0 1 -1
toxicity,of,various 1.0 0.000143348623853 0 1 -1
toxicity,of,patients 1.0 0.000143348623853 0 1 -1
toxicity,of,cadmium 1.0 0.000573394495413 0 4 -4
toxicity,of,b 1.0 0.000143348623853 0 1 -1
toxicity,of,and 1.0 0.000143348623853 0 1 -1
toxicity,is,encountered 1.0 0.000143348623853 0 1 -1
toxicity,investigation,was 1.0 0.000143348623853 0 1 -1
toxicity,including,adverse 1.0 0.000143348623853 0 1 -1
toxicity,in,the 1.0 0.000143348623853 0 1 -1
toxicity,from,normal 1.0 0.000143348623853 0 1 -1
toxicity,especially,hematologic 1.0 0.000143348623853 0 1 -1
toxicity,cns,depression 1.0 0.000143348623853 0 1 -1
toxicity,but,only 1.0 0.000143348623853 0 1 -1
toxicity,brain,hemorrhage 1.0 0.000143348623853 0 1 -1
toxicity,because,of 1.0 0.000143348623853 0 1 -1
toxicity,and,treatment 1.0 0.000143348623853 0 1 -1
toxicity,and,the 1.0 0.000286697247706 0 2 -2
toxicity,and,should 1.0 0.000143348623853 0 1 -1
toxicity,and,pharmacokinetics 1.0 0.000143348623853 0 1 -1
toxicity,and,mechanisms 1.0 0.000143348623853 0 1 -1
toxicity,and,effectiveness 1.0 0.000143348623853 0 1 -1
toxicity,and,cause 1.0 0.000143348623853 0 1 -1
toxicity,and,a 1.0 0.000143348623853 0 1 -1
toxic,when,given 1.0 0.000716743119266 0 5 -5
toxic,to,normal 1.0 0.000143348623853 0 1 -1
toxic,that,is 1.0 0.000143348623853 0 1 -1
toxic,reactions,to 1.0 0.000143348623853 0 1 -1
toxic,product,erythro-fluorocitrate 1.0 0.000143348623853 0 1 -1
toxic,neurological,effects 1.0 0.000143348623853 0 1 -1
toxic,metabolites,in 1.0 0.000143348623853 0 1 -1
toxic,medications,that 1.0 0.000143348623853 0 1 -1
toxic,levels,with 1.0 0.000143348623853 0 1 -1
toxic,epidermal,necrolysis 1.0 0.000143348623853 0 1 -1
toxic,effects,and 1.0 0.000143348623853 0 1 -1
toxic,action,of 1.0 0.000143348623853 0 1 -1
toxi-lab,a,thin-layer 1.0 0.000143348623853 0 1 -1
towards,the,major 1.0 0.000143348623853 0 1 -1
toward,other,isoforms 1.0 0.000143348623853 0 1 -1
toward,normal,when 1.0 0.000143348623853 0 1 -1
toward,cyp3a4,which 1.0 0.000143348623853 0 1 -1
toward,a,more 1.0 0.000143348623853 0 1 -1
totally,inhibited,at 1.0 0.000143348623853 0 1 -1
totally,atoxic,since 1.0 0.000143348623853 0 1 -1
total,were,and 1.0 0.000143348623853 0 1 -1
total,were,about 1.0 0.000143348623853 0 1 -1
total,rna,from 1.0 0.000143348623853 0 1 -1
total,picr,could 1.0 0.000143348623853 0 1 -1
total,peak,concentrations 1.0 0.000143348623853 0 1 -1
total,mucosal,accumulation 1.0 0.000143348623853 0 1 -1
total,hormone,levels 1.0 0.000286697247706 0 2 -2
total,hormone,as 1.0 0.000143348623853 0 1 -1
total,gsh,and 1.0 0.000143348623853 0 1 -1
total,glutathione,total 1.0 0.000143348623853 0 1 -1
total,exposure,for 1.0 0.000143348623853 0 1 -1
total,drug,concentrations 1.0 0.000143348623853 0 1 -1
total,daily,dose 1.0 0.000143348623853 0 1 -1
total,daily,dosage 1.0 0.000143348623853 0 1 -1
total,concentrations,of 1.0 0.000143348623853 0 1 -1
total,concentrations,just 1.0 0.000143348623853 0 1 -1
total,circulating,and 1.0 0.000286697247706 0 2 -2
total,cholesterol,mg 1.0 0.000143348623853 0 1 -1
total,cholesterol,low-density 1.0 0.000143348623853 0 1 -1
total,cholesterol,and 1.0 0.000143348623853 0 1 -1
total,bioavailability,of 1.0 0.000143348623853 0 1 -1
total,bilirubin,times 1.0 0.000143348623853 0 1 -1
total,bilirubin,elevations 1.0 0.000143348623853 0 1 -1
total,amount,of 1.0 0.000143348623853 0 1 -1
tot,the,sexological 1.0 0.000143348623853 0 1 -1
tosylate,these,are 1.0 0.000143348623853 0 1 -1
torsades,de,pointes-type 1.0 0.000143348623853 0 1 -1
torsades,de,pointe 1.0 0.000143348623853 0 1 -1
toradoloral,was,coadministered 1.0 0.000143348623853 0 1 -1
toradoliv,im,was 1.0 0.000143348623853 0 1 -1
toradoliv,im,has 1.0 0.000143348623853 0 1 -1
toradoliv,im,and 1.0 0.000143348623853 0 1 -1
toradol,with,muscle 1.0 0.000143348623853 0 1 -1
toradol,on,clearance 1.0 0.000143348623853 0 1 -1
toradol,induces,or 1.0 0.000143348623853 0 1 -1
toradol,and,in 1.0 0.000143348623853 0 1 -1
topoisomerases,is,no 1.0 0.000143348623853 0 1 -1
topoisomerases,in,proliferating 1.0 0.000143348623853 0 1 -1
topoisomerase-targeted,chemotherapy,in 1.0 0.000143348623853 0 1 -1
topoisomerase,quantity,and 1.0 0.000143348623853 0 1 -1
topoisomerase,activity,level 1.0 0.000143348623853 0 1 -1
topo,in,particular 1.0 0.000143348623853 0 1 -1
topo,i,expression 1.0 0.000143348623853 0 1 -1
topical,solution,with 1.0 0.000143348623853 0 1 -1
topical,products,medicated 1.0 0.000143348623853 0 1 -1
topical,or,vaginal 1.0 0.00043004587156 0 3 -3
topical,medications,applied 1.0 0.000143348623853 0 1 -1
topical,injectable,implantable 1.0 0.000143348623853 0 1 -1
topical,has,not 1.0 0.000143348623853 0 1 -1
topical,dose,is 1.0 0.000143348623853 0 1 -1
tool,with,which 1.0 0.000143348623853 0 1 -1
tool,for,studying 1.0 0.000143348623853 0 1 -1
tool,for,establishing 1.0 0.000143348623853 0 1 -1
tool,for,diagnosis 1.0 0.000143348623853 0 1 -1
took,mg,of 1.0 0.000143348623853 0 1 -1
took,either,mg 1.0 0.000143348623853 0 1 -1
too,was,increased 1.0 0.000143348623853 0 1 -1
too,small,to 1.0 0.000143348623853 0 1 -1
too,low,to 1.0 0.000143348623853 0 1 -1
too,low,as 1.0 0.000143348623853 0 1 -1
too,little,experience 1.0 0.000143348623853 0 1 -1
too,high,or 1.0 0.000143348623853 0 1 -1
too,frequent,doses 1.0 0.000143348623853 0 1 -1
tonic,convulsion,was 1.0 0.000143348623853 0 1 -1
tonevirapine,caution,should 1.0 0.000143348623853 0 1 -1
tolerated,when,administered 1.0 0.000143348623853 0 1 -1
tolerated,in,zollinger-ellison 1.0 0.000143348623853 0 1 -1
tolerated,in,patients 1.0 0.000286697247706 0 2 -2
tolerated,dose,of 1.0 0.000143348623853 0 1 -1
tolerated,but,available 1.0 0.000143348623853 0 1 -1
tolerant,patients,or 1.0 0.000143348623853 0 1 -1
tolerance,secretion,or 1.0 0.000143348623853 0 1 -1
tolerance,and,sensitization 1.0 0.000143348623853 0 1 -1
tolerance,allowing,gradually 1.0 0.000143348623853 0 1 -1
tolerability,of,nnrtis 1.0 0.000143348623853 0 1 -1
tolbutamides,conversion,to 1.0 0.000143348623853 0 1 -1
tolbutamide,in,in 1.0 0.000143348623853 0 1 -1
tolbutamide,in,diabetic 1.0 0.000143348623853 0 1 -1
together,with,with 1.0 0.000143348623853 0 1 -1
together,with,the 1.0 0.000143348623853 0 1 -1
together,with,that 1.0 0.000143348623853 0 1 -1
together,with,previous 1.0 0.000143348623853 0 1 -1
together,with,adrenergic 1.0 0.000143348623853 0 1 -1
together,these,results 1.0 0.000143348623853 0 1 -1
together,these,findings 1.0 0.000143348623853 0 1 -1
together,the,effects 1.0 0.000143348623853 0 1 -1
together,even,if 1.0 0.000143348623853 0 1 -1
together,especially,in 1.0 0.000143348623853 0 1 -1
together,caution,should 1.0 0.000143348623853 0 1 -1
together,at,all 1.0 0.000143348623853 0 1 -1
together,as,a 1.0 0.000143348623853 0 1 -1
today,pharmacological,therapy 1.0 0.000143348623853 0 1 -1
to,your,doctor 1.0 0.000716743119266 0 5 -5
to,years,with 1.0 0.000143348623853 0 1 -1
to,years,old 1.0 0.000143348623853 0 1 -1
to,years,at 1.0 0.000143348623853 0 1 -1
to,x,iu 1.0 0.000143348623853 0 1 -1
to,wshow,that 1.0 0.000143348623853 0 1 -1
to,wshow,an 1.0 0.000143348623853 0 1 -1
to,worsen,the 1.0 0.000143348623853 0 1 -1
to,which,the 1.0 0.000143348623853 0 1 -1
to,were,not 1.0 0.000143348623853 0 1 -1
to,week,intervals 1.0 0.000143348623853 0 1 -1
to,volunteers,under 1.0 0.000143348623853 0 1 -1
to,various,combinations 1.0 0.000143348623853 0 1 -1
to,values,similar 1.0 0.000143348623853 0 1 -1
to,use,the 1.0 0.000143348623853 0 1 -1
to,use,such 1.0 0.000143348623853 0 1 -1
to,use,forms 1.0 0.000143348623853 0 1 -1
to,use,foradil 1.0 0.000143348623853 0 1 -1
to,use,folate 1.0 0.000143348623853 0 1 -1
to,units,day 1.0 0.000143348623853 0 1 -1
to,unique,biopharmaceutical 1.0 0.000143348623853 0 1 -1
to,triple-immunosuppression,regimens 1.0 0.000143348623853 0 1 -1
to,triple,therapy 1.0 0.000143348623853 0 1 -1
to,treatpatients,co-infected 1.0 0.000143348623853 0 1 -1
to,treatment,with 1.0 0.000286697247706 0 2 -2
to,treatment,is 1.0 0.000143348623853 0 1 -1
to,treatment,for 1.0 0.000143348623853 0 1 -1
to,treated,patients 1.0 0.000143348623853 0 1 -1
to,treat,the 1.0 0.000143348623853 0 1 -1
to,treat,hypertension 1.0 0.000286697247706 0 2 -2
to,treat,anxiety 1.0 0.000143348623853 0 1 -1
to,treat,an 1.0 0.000143348623853 0 1 -1
to,treat,aggressively 1.0 0.000143348623853 0 1 -1
to,treat,achlorhydria 1.0 0.000143348623853 0 1 -1
to,treat,a 1.0 0.000143348623853 0 1 -1
to,trace,pathways 1.0 0.000143348623853 0 1 -1
to,topoisomerase-targeted,chemotherapy 1.0 0.000143348623853 0 1 -1
to,topo,in 1.0 0.000143348623853 0 1 -1
to,to,mg 1.0 0.000286697247706 0 2 -2
to,to,cups 1.0 0.000143348623853 0 1 -1
to,times,the 1.0 0.000143348623853 0 1 -1
to,times,rat 1.0 0.000143348623853 0 1 -1
to,times,mouse 1.0 0.000143348623853 0 1 -1
to,three,types 1.0 0.000143348623853 0 1 -1
to,those,that 1.0 0.000143348623853 0 1 -1
to,those,taking 1.0 0.000143348623853 0 1 -1
to,those,prior 1.0 0.000143348623853 0 1 -1
to,those,of 1.0 0.000286697247706 0 2 -2
to,those,observed 1.0 0.000143348623853 0 1 -1
to,those,in 1.0 0.000143348623853 0 1 -1
to,this,therapy 1.0 0.000143348623853 0 1 -1
to,this,effort 1.0 0.000143348623853 0 1 -1
to,this,adverse 1.0 0.000143348623853 0 1 -1
to,these,effects 1.0 0.000143348623853 0 1 -1
to,their,practitioners 1.0 0.000143348623853 0 1 -1
to,their,possible 1.0 0.000143348623853 0 1 -1
to,their,increased 1.0 0.000143348623853 0 1 -1
to,their,efficacy 1.0 0.000143348623853 0 1 -1
to,their,differential 1.0 0.000143348623853 0 1 -1
to,their,corresponding 1.0 0.000143348623853 0 1 -1
to,their,concomitant 1.0 0.000143348623853 0 1 -1
to,the,zevalin 1.0 0.000143348623853 0 1 -1
to,the,world 1.0 0.000143348623853 0 1 -1
to,the,usual 1.0 0.000860091743119 0 6 -6
to,the,use 1.0 0.000286697247706 0 2 -2
to,the,underlying 1.0 0.000143348623853 0 1 -1
to,the,trans-diol 1.0 0.000143348623853 0 1 -1
to,the,stress 1.0 0.000143348623853 0 1 -1
to,the,role 1.0 0.000143348623853 0 1 -1
to,the,release 1.0 0.000143348623853 0 1 -1
to,the,receptor-binding 1.0 0.000143348623853 0 1 -1
to,the,rbc 1.0 0.000143348623853 0 1 -1
to,the,rat 1.0 0.000143348623853 0 1 -1
to,the,presence 1.0 0.000143348623853 0 1 -1
to,the,prescribing 1.0 0.000143348623853 0 1 -1
to,the,potassium-depleted 1.0 0.000143348623853 0 1 -1
to,the,platelets 1.0 0.000143348623853 0 1 -1
to,the,pharmacologic 1.0 0.000143348623853 0 1 -1
to,the,pharmacokinetics 1.0 0.000143348623853 0 1 -1
to,the,patient 1.0 0.000143348623853 0 1 -1
to,the,parental 1.0 0.000143348623853 0 1 -1
to,the,other 1.0 0.000143348623853 0 1 -1
to,the,number 1.0 0.000143348623853 0 1 -1
to,the,normal 1.0 0.000143348623853 0 1 -1
to,the,need 1.0 0.000143348623853 0 1 -1
to,the,nature 1.0 0.000143348623853 0 1 -1
to,the,mucosal 1.0 0.000143348623853 0 1 -1
to,the,monomeric 1.0 0.000143348623853 0 1 -1
to,the,microsomal 1.0 0.00043004587156 0 3 -3
to,the,maximum 1.0 0.000143348623853 0 1 -1
to,the,manufacturer 1.0 0.000143348623853 0 1 -1
to,the,major 1.0 0.000143348623853 0 1 -1
to,the,locomotor 1.0 0.000143348623853 0 1 -1
to,the,level 1.0 0.000143348623853 0 1 -1
to,the,lack 1.0 0.000143348623853 0 1 -1
to,the,interactions 1.0 0.000143348623853 0 1 -1
to,the,interaction 1.0 0.000143348623853 0 1 -1
to,the,initial 1.0 0.000143348623853 0 1 -1
to,the,identification 1.0 0.000143348623853 0 1 -1
to,the,human 1.0 0.000143348623853 0 1 -1
to,the,hospital 1.0 0.000143348623853 0 1 -1
to,the,heat 1.0 0.000143348623853 0 1 -1
to,the,general 1.0 0.000286697247706 0 2 -2
to,the,frequent 1.0 0.000143348623853 0 1 -1
to,the,following 1.0 0.000286697247706 0 2 -2
to,the,fetus 1.0 0.000143348623853 0 1 -1
to,the,female 1.0 0.000143348623853 0 1 -1
to,the,expected 1.0 0.000286697247706 0 2 -2
to,the,efficacy 1.0 0.000143348623853 0 1 -1
to,the,dose 1.0 0.000143348623853 0 1 -1
to,the,differences 1.0 0.000143348623853 0 1 -1
to,the,dietary 1.0 0.000143348623853 0 1 -1
to,the,development 1.0 0.000286697247706 0 2 -2
to,the,degree 1.0 0.000143348623853 0 1 -1
to,the,copegus 1.0 0.000143348623853 0 1 -1
to,the,contents 1.0 0.000143348623853 0 1 -1
to,the,considerable 1.0 0.000143348623853 0 1 -1
to,the,concentrations 1.0 0.000143348623853 0 1 -1
to,the,complete 1.0 0.000143348623853 0 1 -1
to,the,combination 1.0 0.000143348623853 0 1 -1
to,the,clinical 1.0 0.000143348623853 0 1 -1
to,the,class 1.0 0.00043004587156 0 3 -3
to,the,characteristics 1.0 0.000143348623853 0 1 -1
to,the,changes 1.0 0.000143348623853 0 1 -1
to,the,central 1.0 0.000143348623853 0 1 -1
to,the,brain 1.0 0.000143348623853 0 1 -1
to,the,body 1.0 0.00043004587156 0 3 -3
to,the,aucs 1.0 0.000143348623853 0 1 -1
to,the,amount 1.0 0.000143348623853 0 1 -1
to,the,additive 1.0 0.000286697247706 0 2 -2
to,the,added 1.0 0.000143348623853 0 1 -1
to,the,active 1.0 0.000286697247706 0 2 -2
to,the,actions 1.0 0.000286697247706 0 2 -2
to,that,seen 1.0 0.000143348623853 0 1 -1
to,that,in 1.0 0.000573394495413 0 4 -4
to,terminate,treatment 1.0 0.000143348623853 0 1 -1
to,survive,in 1.0 0.000143348623853 0 1 -1
to,supraspinal,brain 1.0 0.000143348623853 0 1 -1
to,suppression,of 1.0 0.000143348623853 0 1 -1
to,suppress,bone 1.0 0.000143348623853 0 1 -1
to,suggest,that 1.0 0.000143348623853 0 1 -1
to,such,patients 1.0 0.000143348623853 0 1 -1
to,such,doses 1.0 0.000143348623853 0 1 -1
to,such,as 1.0 0.000286697247706 0 2 -2
to,substrates,of 1.0 0.000143348623853 0 1 -1
to,substantially,decrease 1.0 0.000143348623853 0 1 -1
to,substances,of 1.0 0.000143348623853 0 1 -1
to,study,the 1.0 0.000573394495413 0 4 -4
to,study,effects 1.0 0.000143348623853 0 1 -1
to,study,cocaine-induced 1.0 0.000143348623853 0 1 -1
to,starting,therapy 1.0 0.000143348623853 0 1 -1
to,start,therapy 1.0 0.000143348623853 0 1 -1
to,solvents,this 1.0 0.000143348623853 0 1 -1
to,situate,the 1.0 0.000143348623853 0 1 -1
to,similar,effects 1.0 0.000143348623853 0 1 -1
to,significantly,interact 1.0 0.000143348623853 0 1 -1
to,significant,shifts 1.0 0.000143348623853 0 1 -1
to,show,that 1.0 0.000143348623853 0 1 -1
to,share,a 1.0 0.000143348623853 0 1 -1
to,sexual,dysfunction 1.0 0.000143348623853 0 1 -1
to,several-,fold 1.0 0.000143348623853 0 1 -1
to,several,days 1.0 0.000143348623853 0 1 -1
to,serum,plasma 1.0 0.000143348623853 0 1 -1
to,sensitize,resistant 1.0 0.000143348623853 0 1 -1
to,select,and 1.0 0.000143348623853 0 1 -1
to,screen,for 1.0 0.000143348623853 0 1 -1
to,screen,compounds 1.0 0.000143348623853 0 1 -1
to,saline,values 1.0 0.000143348623853 0 1 -1
to,rule,out 1.0 0.000286697247706 0 2 -2
to,reverse,resistance 1.0 0.000143348623853 0 1 -1
to,report,a 1.0 0.000143348623853 0 1 -1
to,replicate,this 1.0 0.000143348623853 0 1 -1
to,repeated,exposure 1.0 0.000143348623853 0 1 -1
to,repeated,challenge 1.0 0.000573394495413 0 4 -4
to,relieve,acute 1.0 0.000143348623853 0 1 -1
to,relevant,plasma 1.0 0.000143348623853 0 1 -1
to,regimen,efficacy 1.0 0.000143348623853 0 1 -1
to,refrain,from 1.0 0.000143348623853 0 1 -1
to,reductions,in 1.0 0.000143348623853 0 1 -1
to,reduced,clearance 1.0 0.000716743119266 0 5 -5
to,receive,tablets 1.0 0.000143348623853 0 1 -1
to,receive,oral 1.0 0.000143348623853 0 1 -1
to,receive,mg 1.0 0.000143348623853 0 1 -1
to,receive,intermittent 1.0 0.000143348623853 0 1 -1
to,receive,adl 1.0 0.000143348623853 0 1 -1
to,reassess,the 1.0 0.000143348623853 0 1 -1
to,reach,maximum 1.0 0.000143348623853 0 1 -1
to,reach,cmax 1.0 0.000143348623853 0 1 -1
to,rats,in 1.0 0.000143348623853 0 1 -1
to,rats,hours 1.0 0.000143348623853 0 1 -1
to,rats,and 1.0 0.000143348623853 0 1 -1
to,pursue,qualification 1.0 0.000143348623853 0 1 -1
to,published,accounts 1.0 0.000143348623853 0 1 -1
to,ptx,was 1.0 0.000143348623853 0 1 -1
to,ptx,have 1.0 0.000143348623853 0 1 -1
to,provoke,convulsions 1.0 0.000143348623853 0 1 -1
to,provide,therapeutic 1.0 0.000143348623853 0 1 -1
to,provide,information 1.0 0.000143348623853 0 1 -1
to,provide,a 1.0 0.000143348623853 0 1 -1
to,proleukin,treatment 1.0 0.000143348623853 0 1 -1
to,progression,as 1.0 0.000143348623853 0 1 -1
to,produce,some 1.0 0.000143348623853 0 1 -1
to,produce,scintigraphic 1.0 0.000143348623853 0 1 -1
to,produce,persistently 1.0 0.000143348623853 0 1 -1
to,produce,or 1.0 0.000143348623853 0 1 -1
to,produce,local 1.0 0.000143348623853 0 1 -1
to,produce,hyperglycemia 1.0 0.000573394495413 0 4 -4
to,produce,adverse 1.0 0.000143348623853 0 1 -1
to,prinivil,given 1.0 0.000143348623853 0 1 -1
to,prevent,stomach 1.0 0.000143348623853 0 1 -1
to,prevent,maltose 1.0 0.000143348623853 0 1 -1
to,prevent,folic 1.0 0.000143348623853 0 1 -1
to,pressor,amines 1.0 0.000286697247706 0 2 -2
to,pressor,activity 1.0 0.000143348623853 0 1 -1
to,prescribe,this 1.0 0.000143348623853 0 1 -1
to,premature,ventricular 1.0 0.000143348623853 0 1 -1
to,predict,the 1.0 0.00043004587156 0 3 -3
to,predict,specific 1.0 0.000143348623853 0 1 -1
to,preclude,effectiveness 1.0 0.000286697247706 0 2 -2
to,pre-gentamycin,strength 1.0 0.000143348623853 0 1 -1
to,potentiate,the 1.0 0.000143348623853 0 1 -1
to,potential,for 1.0 0.00143348623853 0 10 -10
to,possible,interaction 1.0 0.000143348623853 0 1 -1
to,possible,deleterious 1.0 0.000143348623853 0 1 -1
to,possible,cns 1.0 0.000143348623853 0 1 -1
to,pooled,human 1.0 0.000143348623853 0 1 -1
to,pms,will 1.0 0.000143348623853 0 1 -1
to,plus,or 1.0 0.000143348623853 0 1 -1
to,plenaxis,should 1.0 0.000143348623853 0 1 -1
to,play,a 1.0 0.000143348623853 0 1 -1
to,platelet,activation 1.0 0.000143348623853 0 1 -1
to,plasma,protein 1.0 0.000573394495413 0 4 -4
to,pi-based,regimens 1.0 0.000143348623853 0 1 -1
to,ph,may 1.0 0.000143348623853 0 1 -1
to,pentobarbital-induced,sedation 1.0 0.000143348623853 0 1 -1
to,peak,and 1.0 0.000143348623853 0 1 -1
to,patients,n 1.0 0.000143348623853 0 1 -1
to,patients,already 1.0 0.000143348623853 0 1 -1
to,patients,along 1.0 0.000143348623853 0 1 -1
to,patient,demographics 1.0 0.000143348623853 0 1 -1
to,p450-based,metabolic 1.0 0.000143348623853 0 1 -1
to,overlap,to 1.0 0.000143348623853 0 1 -1
to,other,fruit 1.0 0.000143348623853 0 1 -1
to,other,asthma 1.0 0.000143348623853 0 1 -1
to,other,antiepileptic 1.0 0.000143348623853 0 1 -1
to,orders,of 1.0 0.000143348623853 0 1 -1
to,oral,the 1.0 0.000143348623853 0 1 -1
to,oral,may 1.0 0.000143348623853 0 1 -1
to,one-half,and 1.0 0.000143348623853 0 1 -1
to,one,or 1.0 0.000143348623853 0 1 -1
to,one,of 1.0 0.000286697247706 0 2 -2
to,offer,patients 1.0 0.000143348623853 0 1 -1
to,of,type 1.0 0.000143348623853 0 1 -1
to,of,total 1.0 0.000143348623853 0 1 -1
to,of,those 1.0 0.000143348623853 0 1 -1
to,of,the 1.0 0.000286697247706 0 2 -2
to,of,caucasians 1.0 0.000286697247706 0 2 -2
to,of,a 1.0 0.000143348623853 0 1 -1
to,occur,when 1.0 0.000286697247706 0 2 -2
to,occur,if 1.0 0.000143348623853 0 1 -1
to,occasionally,induce 1.0 0.00043004587156 0 3 -3
to,observations,which 1.0 0.000143348623853 0 1 -1
to,normal,within 1.0 0.000143348623853 0 1 -1
to,normal,tissue 1.0 0.000143348623853 0 1 -1
to,normal,minutes 1.0 0.000143348623853 0 1 -1
to,normal,menstrual 1.0 0.000143348623853 0 1 -1
to,normal,levels 1.0 0.000143348623853 0 1 -1
to,normal,healthy 1.0 0.000286697247706 0 2 -2
to,nonopioid,tolerant 1.0 0.000143348623853 0 1 -1
to,nonlethal,and 1.0 0.000143348623853 0 1 -1
to,need,expensive 1.0 0.000143348623853 0 1 -1
to,nearly,times 1.0 0.000143348623853 0 1 -1
to,mouse,bone 1.0 0.000143348623853 0 1 -1
to,monitor,the 1.0 0.000286697247706 0 2 -2
to,monitor,tcaplasma 1.0 0.000143348623853 0 1 -1
to,monitor,tca 1.0 0.000573394495413 0 4 -4
to,monitor,plasma 1.0 0.000143348623853 0 1 -1
to,modify,acth 1.0 0.000143348623853 0 1 -1
to,model,the 1.0 0.000143348623853 0 1 -1
to,mm,declining 1.0 0.000143348623853 0 1 -1
to,miracidia,of 1.0 0.000143348623853 0 1 -1
to,miracidia,are 1.0 0.000143348623853 0 1 -1
to,minutes,of 1.0 0.000143348623853 0 1 -1
to,minutes,from 1.0 0.000143348623853 0 1 -1
to,minimize,risks 1.0 0.000143348623853 0 1 -1
to,minimise,the 1.0 0.000143348623853 0 1 -1
to,min,for 1.0 0.000143348623853 0 1 -1
to,min,compared 1.0 0.000143348623853 0 1 -1
to,midcycle,day 1.0 0.000143348623853 0 1 -1
to,microg,ml 1.0 0.000143348623853 0 1 -1
to,microg,l 1.0 0.000286697247706 0 2 -2
to,mice,with 1.0 0.000143348623853 0 1 -1
to,mice,min 1.0 0.000143348623853 0 1 -1
to,mg,were 1.0 0.000143348623853 0 1 -1
to,mg,per 1.0 0.000143348623853 0 1 -1
to,mg,ml 1.0 0.000143348623853 0 1 -1
to,mg,m2 1.0 0.000143348623853 0 1 -1
to,mg,dl 1.0 0.000143348623853 0 1 -1
to,mg,daily 1.0 0.000143348623853 0 1 -1
to,mg,b 1.0 0.000286697247706 0 2 -2
to,mg,also 1.0 0.000143348623853 0 1 -1
to,measure,plasma 1.0 0.000143348623853 0 1 -1
to,measure,over 1.0 0.000143348623853 0 1 -1
to,measure,glucose 1.0 0.000143348623853 0 1 -1
to,maximizing,therapy 1.0 0.000143348623853 0 1 -1
to,maximizing,benefit 1.0 0.000143348623853 0 1 -1
to,maximize,the 1.0 0.000286697247706 0 2 -2
to,match,an 1.0 0.000143348623853 0 1 -1
to,maintain,twitch 1.0 0.000143348623853 0 1 -1
to,maintain,the 1.0 0.000573394495413 0 4 -4
to,maintain,satisfactory 1.0 0.000286697247706 0 2 -2
to,maintain,pregnancy 1.0 0.000143348623853 0 1 -1
to,maintain,optimum 1.0 0.000286697247706 0 2 -2
to,maintain,inhibition 1.0 0.000143348623853 0 1 -1
to,maintain,concentrations 1.0 0.000143348623853 0 1 -1
to,maintain,barpress 1.0 0.000143348623853 0 1 -1
to,maintain,an 1.0 0.000143348623853 0 1 -1
to,mac,or 1.0 0.000143348623853 0 1 -1
to,m,v 1.0 0.000143348623853 0 1 -1
to,lower,the 1.0 0.000143348623853 0 1 -1
to,lower,respectively 1.0 0.000143348623853 0 1 -1
to,low,serum 1.0 0.000143348623853 0 1 -1
to,loss,of 1.0 0.000716743119266 0 5 -5
to,lose,the 1.0 0.000143348623853 0 1 -1
to,limited,renal 1.0 0.000143348623853 0 1 -1
to,lie,in 1.0 0.000143348623853 0 1 -1
to,lessen,the 1.0 0.000143348623853 0 1 -1
to,less,than 1.0 0.000143348623853 0 1 -1
to,know,how 1.0 0.000143348623853 0 1 -1
to,its,three 1.0 0.000143348623853 0 1 -1
to,its,proposed 1.0 0.000143348623853 0 1 -1
to,its,potential 1.0 0.000143348623853 0 1 -1
to,its,enantiomer 1.0 0.000143348623853 0 1 -1
to,its,antidiuretic 1.0 0.000143348623853 0 1 -1
to,its,active 1.0 0.000143348623853 0 1 -1
to,is,catalyzed 1.0 0.000143348623853 0 1 -1
to,invirase,or 1.0 0.000143348623853 0 1 -1
to,investigate,the 1.0 0.000716743119266 0 5 -5
to,interference,with 1.0 0.000143348623853 0 1 -1
to,interactions,of 1.0 0.000286697247706 0 2 -2
to,insulin-induced,hypoglycemia 1.0 0.000143348623853 0 1 -1
to,inhibitory,interactions 1.0 0.000143348623853 0 1 -1
to,inhibitors,of 1.0 0.000143348623853 0 1 -1
to,inhibit,or 1.0 0.000143348623853 0 1 -1
to,inhibit,cyps 1.0 0.000143348623853 0 1 -1
to,inhibit,cyp3a4 1.0 0.000143348623853 0 1 -1
to,inhibit,c9 1.0 0.000143348623853 0 1 -1
to,influence,serum 1.0 0.000143348623853 0 1 -1
to,influence,limbic 1.0 0.000143348623853 0 1 -1
to,induce,hypercalcemia 1.0 0.00043004587156 0 3 -3
to,induce,hepatic 1.0 0.000143348623853 0 1 -1
to,induce,cytochrome 1.0 0.000143348623853 0 1 -1
to,induce,cyp1a2 1.0 0.000143348623853 0 1 -1
to,induce,cyp 1.0 0.000143348623853 0 1 -1
to,induce,both 1.0 0.000143348623853 0 1 -1
to,induce,abnormalities 1.0 0.000143348623853 0 1 -1
to,increases,in 1.0 0.000143348623853 0 1 -1
to,increased,total 1.0 0.000286697247706 0 2 -2
to,increased,effects 1.0 0.000143348623853 0 1 -1
to,increased,circulating 1.0 0.00043004587156 0 3 -3
to,increase3,ci 1.0 0.000143348623853 0 1 -1
to,increase,serum 1.0 0.000286697247706 0 2 -2
to,increase,levels 1.0 0.000143348623853 0 1 -1
to,increase,high-density 1.0 0.000143348623853 0 1 -1
to,increase,fi 1.0 0.000143348623853 0 1 -1
to,increase,catabolism 1.0 0.000143348623853 0 1 -1
to,inactive,metabolites 1.0 0.000143348623853 0 1 -1
to,in-creased,circulating 1.0 0.000143348623853 0 1 -1
to,in,rat 1.0 0.000143348623853 0 1 -1
to,improve,this 1.0 0.000143348623853 0 1 -1
to,improve,the 1.0 0.000143348623853 0 1 -1
to,iii,and 1.0 0.000286697247706 0 2 -2
to,identify,the 1.0 0.000286697247706 0 2 -2
to,identify,any 1.0 0.000143348623853 0 1 -1
to,hypoglycemia,oral 1.0 0.000286697247706 0 2 -2
to,hypertensive,patients 1.0 0.000143348623853 0 1 -1
to,hypertensive,nephropathy 1.0 0.000143348623853 0 1 -1
to,hyperglycemia,in 1.0 0.000143348623853 0 1 -1
to,hydrochloride,including 1.0 0.000143348623853 0 1 -1
to,humans,is 1.0 0.000143348623853 0 1 -1
to,human,plasma 1.0 0.000573394495413 0 4 -4
to,human,lymphocytes 1.0 0.000143348623853 0 1 -1
to,hours,p 1.0 0.000143348623853 0 1 -1
to,hours,following 1.0 0.000143348623853 0 1 -1
to,hours,after 1.0 0.000143348623853 0 1 -1
to,hormone,is 1.0 0.000143348623853 0 1 -1
to,highintersubject,variability 1.0 0.000143348623853 0 1 -1
to,higher,free 1.0 0.000143348623853 0 1 -1
to,high,intraluminal 1.0 0.000143348623853 0 1 -1
to,high,inter-patient 1.0 0.000143348623853 0 1 -1
to,healthy,men 1.0 0.000143348623853 0 1 -1
to,healthy,male 1.0 0.000286697247706 0 2 -2
to,have,similar 1.0 0.00043004587156 0 3 -3
to,have,significant 1.0 0.000143348623853 0 1 -1
to,have,negative 1.0 0.000143348623853 0 1 -1
to,have,clinically 1.0 0.000143348623853 0 1 -1
to,have,centroblast 1.0 0.000143348623853 0 1 -1
to,hatching,survival 1.0 0.000143348623853 0 1 -1
to,groups,of 1.0 0.000143348623853 0 1 -1
to,gonadotropin-releasing,hormone 1.0 0.000143348623853 0 1 -1
to,generate,the 1.0 0.000143348623853 0 1 -1
to,generate,concentration-response 1.0 0.000143348623853 0 1 -1
to,g,hr 1.0 0.000143348623853 0 1 -1
to,further,doses 1.0 0.000143348623853 0 1 -1
to,function,normally 1.0 0.000143348623853 0 1 -1
to,function,as 1.0 0.000143348623853 0 1 -1
to,fully,define 1.0 0.000143348623853 0 1 -1
to,fivefold,increase 1.0 0.000143348623853 0 1 -1
to,first-pass,metabolism 1.0 0.000143348623853 0 1 -1
to,find,out 1.0 0.000143348623853 0 1 -1
to,extravasation,were 1.0 0.000143348623853 0 1 -1
to,exposures,similar 1.0 0.000143348623853 0 1 -1
to,exposure,to 1.0 0.000143348623853 0 1 -1
to,exposure,in 1.0 0.000143348623853 0 1 -1
to,explain,the 1.0 0.000143348623853 0 1 -1
to,experience,fewer 1.0 0.000143348623853 0 1 -1
to,existing,therapy 1.0 0.000143348623853 0 1 -1
to,exhibit,minimal 1.0 0.000143348623853 0 1 -1
to,exhibit,additive 1.0 0.00043004587156 0 3 -3
to,examine,the 1.0 0.000573394495413 0 4 -4
to,examine,some 1.0 0.000143348623853 0 1 -1
to,examine,interactions 1.0 0.000143348623853 0 1 -1
to,exaggerated,leukopenia 1.0 0.000143348623853 0 1 -1
to,evaluate,potential 1.0 0.000143348623853 0 1 -1
to,evaluate,possible 1.0 0.000143348623853 0 1 -1
to,evaluate,interactions 1.0 0.000143348623853 0 1 -1
to,established,interactions 1.0 0.000143348623853 0 1 -1
to,establish,strategies 1.0 0.000143348623853 0 1 -1
to,establish,corrective 1.0 0.000143348623853 0 1 -1
to,escalate,the 1.0 0.000143348623853 0 1 -1
to,enroll,patients 1.0 0.000143348623853 0 1 -1
to,enhanced,drug 1.0 0.000143348623853 0 1 -1
to,encystment,and 1.0 0.000143348623853 0 1 -1
to,elucidate,metal 1.0 0.000143348623853 0 1 -1
to,electrophilic,agents 1.0 0.000143348623853 0 1 -1
to,electrolyte,and 1.0 0.000143348623853 0 1 -1
to,either,was 1.0 0.000143348623853 0 1 -1
to,efficacy,and 1.0 0.000716743119266 0 5 -5
to,effects,on 1.0 0.000143348623853 0 1 -1
to,effect,the 1.0 0.000143348623853 0 1 -1
to,each,preparation 1.0 0.000143348623853 0 1 -1
to,during,short-term 1.0 0.000143348623853 0 1 -1
to,dosing,should 1.0 0.000143348623853 0 1 -1
to,doses,that 1.0 0.000143348623853 0 1 -1
to,do,if 1.0 0.000143348623853 0 1 -1
to,displacement,of 1.0 0.000143348623853 0 1 -1
to,diseases,such 1.0 0.000143348623853 0 1 -1
to,discriminate,between 1.0 0.000143348623853 0 1 -1
to,discontinue,the 1.0 0.000286697247706 0 2 -2
to,discontinue,nursing 1.0 0.00043004587156 0 3 -3
to,difluoroacetone,mg 1.0 0.000143348623853 0 1 -1
to,difluoroacetone,by 1.0 0.000143348623853 0 1 -1
to,diethylnitrosamine,during 1.0 0.000143348623853 0 1 -1
to,determine,therapy 1.0 0.000143348623853 0 1 -1
to,determine,the 1.0 0.000573394495413 0 4 -4
to,determine,its 1.0 0.000143348623853 0 1 -1
to,determine,blood 1.0 0.000286697247706 0 2 -2
to,detect,ketone 1.0 0.000143348623853 0 1 -1
to,designing,experiments 1.0 0.000143348623853 0 1 -1
to,desbutyl,levobupivacaine 1.0 0.000143348623853 0 1 -1
to,depress,prolactin 1.0 0.000143348623853 0 1 -1
to,define,the 1.0 0.000143348623853 0 1 -1
to,decreased,plasma 1.0 0.000143348623853 0 1 -1
to,decrease,serum 1.0 0.000143348623853 0 1 -1
to,decrease,prior 1.0 0.000143348623853 0 1 -1
to,decrease,platelet 1.0 0.000143348623853 0 1 -1
to,decrease,overall 1.0 0.000143348623853 0 1 -1
to,decrease,in 1.0 0.000143348623853 0 1 -1
to,deaths,among 1.0 0.000143348623853 0 1 -1
to,days,the 1.0 0.000143348623853 0 1 -1
to,days,has 1.0 0.000143348623853 0 1 -1
to,days,for 1.0 0.000143348623853 0 1 -1
to,date,show 1.0 0.000143348623853 0 1 -1
to,date,on 1.0 0.000286697247706 0 2 -2
to,date,levosimendan 1.0 0.000143348623853 0 1 -1
to,date,in 1.0 0.000143348623853 0 1 -1
to,date,has 1.0 0.000143348623853 0 1 -1
to,daily,treatment 1.0 0.000143348623853 0 1 -1
to,cups,of 1.0 0.000143348623853 0 1 -1
to,crixivan,or 1.0 0.000286697247706 0 2 -2
to,copaxone,did 1.0 0.000143348623853 0 1 -1
to,controls,was 1.0 0.000143348623853 0 1 -1
to,control,symptoms 1.0 0.000143348623853 0 1 -1
to,control,side 1.0 0.000143348623853 0 1 -1
to,control,hyperuricemia 1.0 0.000143348623853 0 1 -1
to,consult,the 1.0 0.000286697247706 0 2 -2
to,confirm,that 1.0 0.000286697247706 0 2 -2
to,concomitant,therapy 1.0 0.000286697247706 0 2 -2
to,competitive,inhibition 1.0 0.000143348623853 0 1 -1
to,compete,for 1.0 0.000143348623853 0 1 -1
to,co-administration,of 1.0 0.000143348623853 0 1 -1
to,closely,monitor 1.0 0.000143348623853 0 1 -1
to,cite,primary 1.0 0.000143348623853 0 1 -1
to,chemotherapy,can 1.0 0.000143348623853 0 1 -1
to,chemically,modify 1.0 0.000143348623853 0 1 -1
to,chelated,extracellular 1.0 0.000143348623853 0 1 -1
to,check,your 1.0 0.000143348623853 0 1 -1
to,characterize,the 1.0 0.000286697247706 0 2 -2
to,changes,in 1.0 0.000143348623853 0 1 -1
to,cause,prolonged 1.0 0.00043004587156 0 3 -3
to,cause,peripheral 1.0 0.000143348623853 0 1 -1
to,cause,pancreatitis 1.0 0.000286697247706 0 2 -2
to,cause,or 1.0 0.000143348623853 0 1 -1
to,cause,neutropenia 1.0 0.000143348623853 0 1 -1
to,cause,increases 1.0 0.000286697247706 0 2 -2
to,cause,increased 1.0 0.000143348623853 0 1 -1
to,cause,immunosuppression 1.0 0.000143348623853 0 1 -1
to,cause,clinically 1.0 0.000143348623853 0 1 -1
to,cause,an 1.0 0.000143348623853 0 1 -1
to,cardiac,patients 1.0 0.000143348623853 0 1 -1
to,cardiac,arrhythmias 1.0 0.000143348623853 0 1 -1
to,campath,may 1.0 0.000143348623853 0 1 -1
to,cadmium,mixtures 1.0 0.000143348623853 0 1 -1
to,c,p 1.0 0.000143348623853 0 1 -1
to,by,the 1.0 0.000286697247706 0 2 -2
to,by,cytochrome 1.0 0.000143348623853 0 1 -1
to,but,have 1.0 0.000143348623853 0 1 -1
to,but,are 1.0 0.000143348623853 0 1 -1
to,bruising,nosebleeds 1.0 0.000143348623853 0 1 -1
to,broadly,the 1.0 0.000143348623853 0 1 -1
to,bovine,thyroglobulin 1.0 0.000143348623853 0 1 -1
to,both,minimal 1.0 0.000143348623853 0 1 -1
to,bind,other 1.0 0.000143348623853 0 1 -1
to,beta-adrenergic,stimulating 1.0 0.000143348623853 0 1 -1
to,benefits,should 1.0 0.000143348623853 0 1 -1
to,be,used 1.0 0.00043004587156 0 3 -3
to,be,unlikely 1.0 0.000143348623853 0 1 -1
to,be,unaffected 1.0 0.000143348623853 0 1 -1
to,be,susceptible 1.0 0.000143348623853 0 1 -1
to,be,significantly 1.0 0.000143348623853 0 1 -1
to,be,sensitive 1.0 0.000286697247706 0 2 -2
to,be,related 1.0 0.000286697247706 0 2 -2
to,be,provided 1.0 0.000143348623853 0 1 -1
to,be,produced 1.0 0.000143348623853 0 1 -1
to,be,patient 1.0 0.000143348623853 0 1 -1
to,be,particularly 1.0 0.000143348623853 0 1 -1
to,be,no 1.0 0.000143348623853 0 1 -1
to,be,necessary 1.0 0.000143348623853 0 1 -1
to,be,more 1.0 0.000143348623853 0 1 -1
to,be,modified 1.0 0.000286697247706 0 2 -2
to,be,mediated 1.0 0.000143348623853 0 1 -1
to,be,lower 1.0 0.000286697247706 0 2 -2
to,be,low 1.0 0.000143348623853 0 1 -1
to,be,less 1.0 0.000143348623853 0 1 -1
to,be,involved 1.0 0.000143348623853 0 1 -1
to,be,initiated 1.0 0.000143348623853 0 1 -1
to,be,inhibited 1.0 0.000286697247706 0 2 -2
to,be,highly 1.0 0.000286697247706 0 2 -2
to,be,free 1.0 0.000143348623853 0 1 -1
to,be,formed 1.0 0.000143348623853 0 1 -1
to,be,falsely 1.0 0.000143348623853 0 1 -1
to,be,evaluated 1.0 0.000143348623853 0 1 -1
to,be,due 1.0 0.000143348623853 0 1 -1
to,be,drawn 1.0 0.000143348623853 0 1 -1
to,be,demonstrated 1.0 0.000143348623853 0 1 -1
to,be,deficient 1.0 0.000143348623853 0 1 -1
to,be,consistent 1.0 0.000143348623853 0 1 -1
to,be,considered 1.0 0.000143348623853 0 1 -1
to,be,concomitantly 1.0 0.000143348623853 0 1 -1
to,be,coadministered 1.0 0.000286697247706 0 2 -2
to,be,co-administered 1.0 0.000573394495413 0 4 -4
to,be,clastogenic 1.0 0.000143348623853 0 1 -1
to,be,catalyzed 1.0 0.000143348623853 0 1 -1
to,be,aware 1.0 0.000143348623853 0 1 -1
to,be,associated 1.0 0.000143348623853 0 1 -1
to,be,artifactually 1.0 0.000143348623853 0 1 -1
to,be,approved 1.0 0.000143348623853 0 1 -1
to,be,an 1.0 0.00114678899083 0 8 -8
to,be,adjusted 1.0 0.000143348623853 0 1 -1
to,be,above 1.0 0.000143348623853 0 1 -1
to,be,abnormal 1.0 0.000143348623853 0 1 -1
to,be,a 1.0 0.000286697247706 0 2 -2
to,b-cell,lymphomas 1.0 0.000143348623853 0 1 -1
to,avoid,them 1.0 0.000143348623853 0 1 -1
to,avoid,potentiation 1.0 0.000143348623853 0 1 -1
to,avoid,potential 1.0 0.000143348623853 0 1 -1
to,avoid,intoxication 1.0 0.000286697247706 0 2 -2
to,avoid,administration 1.0 0.000143348623853 0 1 -1
to,attenuate,some 1.0 0.000286697247706 0 2 -2
to,assist,the 1.0 0.000143348623853 0 1 -1
to,assess,if 1.0 0.000286697247706 0 2 -2
to,ascertain,when 1.0 0.000143348623853 0 1 -1
to,as,poor 1.0 0.000286697247706 0 2 -2
to,as,nsaids 1.0 0.000143348623853 0 1 -1
to,as,is 1.0 0.000143348623853 0 1 -1
to,approximately,times 1.0 0.000143348623853 0 1 -1
to,approximately,of 1.0 0.000143348623853 0 1 -1
to,approximately,and 1.0 0.000286697247706 0 2 -2
to,approximate,the 1.0 0.000143348623853 0 1 -1
to,any,procedure 1.0 0.000143348623853 0 1 -1
to,any,nonlinear 1.0 0.000143348623853 0 1 -1
to,any,great 1.0 0.000143348623853 0 1 -1
to,and,was 1.0 0.000143348623853 0 1 -1
to,and,the 1.0 0.000143348623853 0 1 -1
to,and,st 1.0 0.000143348623853 0 1 -1
to,and,m 1.0 0.000143348623853 0 1 -1
to,and,its 1.0 0.000143348623853 0 1 -1
to,and,for 1.0 0.000143348623853 0 1 -1
to,and,during 1.0 0.000143348623853 0 1 -1
to,and,and 1.0 0.000143348623853 0 1 -1
to,an,insufficient 1.0 0.000143348623853 0 1 -1
to,an,improved 1.0 0.000143348623853 0 1 -1
to,an,earlier 1.0 0.000143348623853 0 1 -1
to,alter,behaviors 1.0 0.000143348623853 0 1 -1
to,alpha,interferons 1.0 0.000143348623853 0 1 -1
to,allow,for 1.0 0.000143348623853 0 1 -1
to,all,physciains 1.0 0.000143348623853 0 1 -1
to,albumin,could 1.0 0.000143348623853 0 1 -1
to,aid,sleep 1.0 0.000143348623853 0 1 -1
to,after,exposure 1.0 0.000143348623853 0 1 -1
to,affect,the 1.0 0.000716743119266 0 5 -5
to,affect,safety 1.0 0.000143348623853 0 1 -1
to,affect,renal 1.0 0.000286697247706 0 2 -2
to,affect,protein 1.0 0.000143348623853 0 1 -1
to,affect,other 1.0 0.000286697247706 0 2 -2
to,affect,its 1.0 0.000143348623853 0 1 -1
to,affect,duloxetine 1.0 0.000143348623853 0 1 -1
to,affect,conversion 1.0 0.000143348623853 0 1 -1
to,affect,cardiac 1.0 0.000143348623853 0 1 -1
to,affect,abilify 1.0 0.000143348623853 0 1 -1
to,adversely,affect 1.0 0.000143348623853 0 1 -1
to,adverse,events 1.0 0.000143348623853 0 1 -1
to,adult,diabetics 1.0 0.000143348623853 0 1 -1
to,admission,the 1.0 0.000143348623853 0 1 -1
to,administration,on 1.0 0.000143348623853 0 1 -1
to,administration,of 1.0 0.000286697247706 0 2 -2
to,additive,potentiation 1.0 0.000143348623853 0 1 -1
to,additional,pharmacokinetic 1.0 0.000143348623853 0 1 -1
to,acute,release 1.0 0.000143348623853 0 1 -1
to,active,metabolite 1.0 0.000143348623853 0 1 -1
to,activation,of 1.0 0.000143348623853 0 1 -1
to,achieve,or 1.0 0.000143348623853 0 1 -1
to,accutane,has 1.0 0.000143348623853 0 1 -1
to,accident,suicide 1.0 0.000143348623853 0 1 -1
to,accelerate,the 1.0 0.000143348623853 0 1 -1
to,about,absorption 1.0 0.000143348623853 0 1 -1
to,abnormal,bleeding 1.0 0.000143348623853 0 1 -1
to,a,variety 1.0 0.000860091743119 0 6 -6
to,a,survey 1.0 0.000143348623853 0 1 -1
to,a,small 1.0 0.000143348623853 0 1 -1
to,a,significant 1.0 0.000143348623853 0 1 -1
to,a,release 1.0 0.000143348623853 0 1 -1
to,a,relatively 1.0 0.000143348623853 0 1 -1
to,a,randomized 1.0 0.000143348623853 0 1 -1
to,a,mean 1.0 0.000143348623853 0 1 -1
to,a,level 1.0 0.000286697247706 0 2 -2
to,a,lesser 1.0 0.000716743119266 0 5 -5
to,a,far 1.0 0.000143348623853 0 1 -1
to,a,dysregulation 1.0 0.000143348623853 0 1 -1
to,a,clinically 1.0 0.000143348623853 0 1 -1
tnf,blocking,agents 1.0 0.000143348623853 0 1 -1
tmp,smx,such 1.0 0.000143348623853 0 1 -1
tmp,and,smx 1.0 0.000143348623853 0 1 -1
tml,or,mg 1.0 0.000143348623853 0 1 -1
tml,manifested,significantly 1.0 0.000143348623853 0 1 -1
tmax,was,hours 1.0 0.000143348623853 0 1 -1
tmax,vs,for 1.0 0.000143348623853 0 1 -1
tmax,of,were 1.0 0.000143348623853 0 1 -1
tmax,at,daily 1.0 0.000143348623853 0 1 -1
tizoxanide,is,highly 1.0 0.000143348623853 0 1 -1
titration,should,be 1.0 0.000143348623853 0 1 -1
titration,of,the 1.0 0.000143348623853 0 1 -1
titration,are,warranted 1.0 0.000143348623853 0 1 -1
titrated,to,mg 1.0 0.000286697247706 0 2 -2
titrated,to,achieve 1.0 0.000143348623853 0 1 -1
titers,may,have 1.0 0.000143348623853 0 1 -1
tissues,to,the 1.0 0.000143348623853 0 1 -1
tissues,of,rats 1.0 0.000143348623853 0 1 -1
tissues,of,mice 1.0 0.000143348623853 0 1 -1
tissues,metabolism,or 1.0 0.000143348623853 0 1 -1
tissues,either,or 1.0 0.000143348623853 0 1 -1
tissue,culture,medium 1.0 0.000143348623853 0 1 -1
tissue,although,the 1.0 0.000143348623853 0 1 -1
tinnitus,slurred,speech 1.0 0.000143348623853 0 1 -1
tindal,thorazine,prolixin 1.0 0.000143348623853 0 1 -1
timi-ii,isis-2,currently 1.0 0.000143348623853 0 1 -1
times,without,clinically 1.0 0.000143348623853 0 1 -1
times,when,administered 1.0 0.000143348623853 0 1 -1
times,were,observed 1.0 0.000143348623853 0 1 -1
times,were,not 1.0 0.000143348623853 0 1 -1
times,were,measured 1.0 0.000143348623853 0 1 -1
times,were,increased 1.0 0.000143348623853 0 1 -1
times,weekly,during 1.0 0.000143348623853 0 1 -1
times,the,upper 1.0 0.000286697247706 0 2 -2
times,the,human 1.0 0.00043004587156 0 3 -3
times,the,daily 1.0 0.000143348623853 0 1 -1
times,the,control 1.0 0.000143348623853 0 1 -1
times,the,cmax 1.0 0.000143348623853 0 1 -1
times,rat,the 1.0 0.000143348623853 0 1 -1
times,or,a 1.0 0.000143348623853 0 1 -1
times,mouse,and 1.0 0.000143348623853 0 1 -1
times,more,potent 1.0 0.000143348623853 0 1 -1
times,maximum,recommended 1.0 0.000143348623853 0 1 -1
times,long-sedation,time 1.0 0.000143348623853 0 1 -1
times,less,toxic 1.0 0.000143348623853 0 1 -1
times,have,been 1.0 0.000143348623853 0 1 -1
times,day,days 1.0 0.000143348623853 0 1 -1
times,daily,to 1.0 0.000286697247706 0 2 -2
times,daily,before 1.0 0.000286697247706 0 2 -2
times,comparable,to 1.0 0.000143348623853 0 1 -1
times,can,be 1.0 0.000143348623853 0 1 -1
times,as,well 1.0 0.000143348623853 0 1 -1
times,as,high 1.0 0.000143348623853 0 1 -1
times,and,a 1.0 0.000143348623853 0 1 -1
time,zero,to 1.0 0.000143348623853 0 1 -1
time,when,administered 1.0 0.000143348623853 0 1 -1
time,were,recorded 1.0 0.000143348623853 0 1 -1
time,were,assessed 1.0 0.000143348623853 0 1 -1
time,was,observed 1.0 0.000143348623853 0 1 -1
time,was,not 1.0 0.000143348623853 0 1 -1
time,was,increased 1.0 0.000143348623853 0 1 -1
time,to,reach 1.0 0.000286697247706 0 2 -2
time,to,peak 1.0 0.000143348623853 0 1 -1
time,the,plasma 1.0 0.000143348623853 0 1 -1
time,sst,and 1.0 0.000143348623853 0 1 -1
time,scale,of 1.0 0.000143348623853 0 1 -1
time,responses,have 1.0 0.000143348623853 0 1 -1
time,response,to 1.0 0.000143348623853 0 1 -1
time,ratio,or 1.0 0.000143348623853 0 1 -1
time,profiles,in 1.0 0.000143348623853 0 1 -1
time,points,after 1.0 0.000143348623853 0 1 -1
time,point,in 1.0 0.000143348623853 0 1 -1
time,plasma,thrombin 1.0 0.000143348623853 0 1 -1
time,plasma,or 1.0 0.000143348623853 0 1 -1
time,partial,thromboplastin 1.0 0.00043004587156 0 3 -3
time,or,within 1.0 0.000286697247706 0 2 -2
time,or,clotting 1.0 0.000143348623853 0 1 -1
time,of,were 1.0 0.000143348623853 0 1 -1
time,of,the 1.0 0.000143348623853 0 1 -1
time,of,minutes 1.0 0.000143348623853 0 1 -1
time,necessitating,an 1.0 0.000143348623853 0 1 -1
time,may,vary 1.0 0.000143348623853 0 1 -1
time,may,lead 1.0 0.000143348623853 0 1 -1
time,lst,short 1.0 0.000143348623853 0 1 -1
time,it,has 1.0 0.000143348623853 0 1 -1
time,inr,determinations 1.0 0.000143348623853 0 1 -1
time,inr,at 1.0 0.000143348623853 0 1 -1
time,hydrogen,breath 1.0 0.000143348623853 0 1 -1
time,have,not 1.0 0.000143348623853 0 1 -1
time,has,been 1.0 0.000286697247706 0 2 -2
time,for,recovery 1.0 0.000143348623853 0 1 -1
time,for,heparins 1.0 0.000143348623853 0 1 -1
time,following,a 1.0 0.000286697247706 0 2 -2
time,course,of 1.0 0.000143348623853 0 1 -1
time,concomitant,supplementation 1.0 0.000143348623853 0 1 -1
time,caused,by 1.0 0.000143348623853 0 1 -1
time,by,approximately 1.0 0.000143348623853 0 1 -1
time,by,after 1.0 0.000143348623853 0 1 -1
time,but,does 1.0 0.000143348623853 0 1 -1
time,at,the 1.0 0.000143348623853 0 1 -1
time,and,platelet 1.0 0.000286697247706 0 2 -2
time,and,close 1.0 0.000143348623853 0 1 -1
time,and,by 1.0 0.000286697247706 0 2 -2
time,and,an 1.0 0.000143348623853 0 1 -1
tilade,has,been 1.0 0.000143348623853 0 1 -1
tikosyn,or,the 1.0 0.000143348623853 0 1 -1
tikosyn,had,a 1.0 0.000143348623853 0 1 -1
tikosyn,does,not 1.0 0.000286697247706 0 2 -2
tikosyn,and,concomitantly 1.0 0.000143348623853 0 1 -1
tightly,bound,like 1.0 0.000143348623853 0 1 -1
tight,seal,recordings 1.0 0.000286697247706 0 2 -2
tid,were,coadministered 1.0 0.000143348623853 0 1 -1
tid,study,of 1.0 0.000143348623853 0 1 -1
tid,no,dose 1.0 0.000143348623853 0 1 -1
tiagabine,has,shown 1.0 0.000143348623853 0 1 -1
tiagabine,had,no 1.0 0.000286697247706 0 2 -2
thyroxine-binding,prealbumin,tbpa 1.0 0.000143348623853 0 1 -1
thyroid-stimulating,hormone,or 1.0 0.000143348623853 0 1 -1
thyroid-binding,globulin,tbg 1.0 0.00043004587156 0 3 -3
thyroid,products,oral 1.0 0.000143348623853 0 1 -1
thyroid,physiology,the 1.0 0.000143348623853 0 1 -1
thyroid,hormones,appear 1.0 0.000143348623853 0 1 -1
thyroid,hormone,activity 1.0 0.000143348623853 0 1 -1
thyroid,hormonal,replacement 1.0 0.000143348623853 0 1 -1
thyroglobulin,in,an 1.0 0.000143348623853 0 1 -1
thus,this,interaction 1.0 0.000143348623853 0 1 -1
thus,there,was 1.0 0.000143348623853 0 1 -1
thus,the,selective 1.0 0.000143348623853 0 1 -1
thus,the,hypothesis 1.0 0.000143348623853 0 1 -1
thus,the,exogenous 1.0 0.000143348623853 0 1 -1
thus,support,its 1.0 0.000143348623853 0 1 -1
thus,results,of 1.0 0.000286697247706 0 2 -2
thus,patients,should 1.0 0.000143348623853 0 1 -1
thus,not,proliferation-dependent 1.0 0.000143348623853 0 1 -1
thus,no,dosing 1.0 0.000143348623853 0 1 -1
thus,may,prevent 1.0 0.000143348623853 0 1 -1
thus,may,make 1.0 0.000286697247706 0 2 -2
thus,it,is 1.0 0.000143348623853 0 1 -1
thus,in,addition 1.0 0.000143348623853 0 1 -1
thus,if,such 1.0 0.000143348623853 0 1 -1
thus,dosed,to 1.0 0.000143348623853 0 1 -1
thus,could,lead 1.0 0.000143348623853 0 1 -1
thus,concomitant,therapy 1.0 0.000143348623853 0 1 -1
thus,concentrations,which 1.0 0.000143348623853 0 1 -1
thus,certain,factors 1.0 0.000143348623853 0 1 -1
thus,agents,likely 1.0 0.000143348623853 0 1 -1
through,various,cytochrome 1.0 0.000143348623853 0 1 -1
through,udp-glucuronyl,transferase 1.0 0.000143348623853 0 1 -1
through,the,modulation 1.0 0.000143348623853 0 1 -1
through,the,increase 1.0 0.000143348623853 0 1 -1
through,the,cytochrome 1.0 0.000143348623853 0 1 -1
through,the,cyp3a 1.0 0.000143348623853 0 1 -1
through,searches,of 1.0 0.000143348623853 0 1 -1
through,redundancy,at 1.0 0.000143348623853 0 1 -1
through,pharmacokinetic,screening 1.0 0.000143348623853 0 1 -1
through,hours,following 1.0 0.000143348623853 0 1 -1
through,cyp3a4,ingestion 1.0 0.000143348623853 0 1 -1
through,competition,for 1.0 0.000286697247706 0 2 -2
through,actions,that 1.0 0.000143348623853 0 1 -1
through,a,combined 1.0 0.000143348623853 0 1 -1
thromboxane,a2,are 1.0 0.000143348623853 0 1 -1
thromboplastin,times,have 1.0 0.000143348623853 0 1 -1
thromboplastin,time,or 1.0 0.000143348623853 0 1 -1
thromboplastin,time,and 1.0 0.000286697247706 0 2 -2
thrombolytic,agents,the 1.0 0.000143348623853 0 1 -1
thrombolytic,agents,have 1.0 0.000143348623853 0 1 -1
thrombocytopenia,the,potential 1.0 0.000143348623853 0 1 -1
thrombocytopenia,the,co-administration 1.0 0.000143348623853 0 1 -1
thrombocytopenia,or,x 1.0 0.000143348623853 0 1 -1
thrombin,or,red 1.0 0.000143348623853 0 1 -1
thrombin,clotting,time 1.0 0.000143348623853 0 1 -1
threshold,voltage-dependent,ca 1.0 0.00043004587156 0 3 -3
three-period,randomized,crossover 1.0 0.000143348623853 0 1 -1
three-fold,compared,to 1.0 0.000143348623853 0 1 -1
three-,to,fivefold 1.0 0.000143348623853 0 1 -1
three,well-controlled,studies 1.0 0.000143348623853 0 1 -1
three,types,of 1.0 0.000286697247706 0 2 -2
three,study,periods 1.0 0.000143348623853 0 1 -1
three,strains,of 1.0 0.000286697247706 0 2 -2
three,separate,controlled 1.0 0.000143348623853 0 1 -1
three,pharmacokinetic,studies 1.0 0.000143348623853 0 1 -1
three,patients,met 1.0 0.000143348623853 0 1 -1
three,metabolites,including 1.0 0.000143348623853 0 1 -1
three,lines,divergently 1.0 0.000143348623853 0 1 -1
three,hours,concurrently 1.0 0.000143348623853 0 1 -1
three,groups,which 1.0 0.000143348623853 0 1 -1
three,equal,groups 1.0 0.000143348623853 0 1 -1
three,duloxetine-treated,patients 1.0 0.000143348623853 0 1 -1
three,different,concentrations 1.0 0.000143348623853 0 1 -1
three,concentrations,was 1.0 0.000143348623853 0 1 -1
three,concentrations,ranging 1.0 0.000143348623853 0 1 -1
three,clinical,trials 1.0 0.000143348623853 0 1 -1
three,cases,of 1.0 0.000143348623853 0 1 -1
three,agents,produced 1.0 0.000143348623853 0 1 -1
thought,to,play 1.0 0.000143348623853 0 1 -1
thought,to,be 1.0 0.000286697247706 0 2 -2
though,such,interactions 1.0 0.000286697247706 0 2 -2
though,less,marked 1.0 0.000286697247706 0 2 -2
though,individual,levels 1.0 0.000143348623853 0 1 -1
though,has,been 1.0 0.000286697247706 0 2 -2
those,with,moderate 1.0 0.000143348623853 0 1 -1
those,with,conditions 1.0 0.000143348623853 0 1 -1
those,who,are 1.0 0.000143348623853 0 1 -1
those,used,to 1.0 0.000286697247706 0 2 -2
those,undergoing,strenuous 1.0 0.000143348623853 0 1 -1
those,that,demonstrate 1.0 0.000143348623853 0 1 -1
those,that,can 1.0 0.000143348623853 0 1 -1
those,taking,mg 1.0 0.000143348623853 0 1 -1
those,such,as 1.0 0.000143348623853 0 1 -1
those,receiving,tablets 1.0 0.000143348623853 0 1 -1
those,receiving,including 1.0 0.000143348623853 0 1 -1
those,prior,to 1.0 0.000143348623853 0 1 -1
those,patients,with 1.0 0.000143348623853 0 1 -1
those,patients,in 1.0 0.000143348623853 0 1 -1
those,off,medications 1.0 0.000143348623853 0 1 -1
those,of,pcp 1.0 0.000286697247706 0 2 -2
those,of,other 1.0 0.000286697247706 0 2 -2
those,of,low 1.0 0.000143348623853 0 1 -1
those,of,endotoxin-treated 1.0 0.000143348623853 0 1 -1
those,listed,here 1.0 0.000143348623853 0 1 -1
those,in,the 1.0 0.000286697247706 0 2 -2
those,in,patients 1.0 0.000143348623853 0 1 -1
those,for,which 1.0 0.000143348623853 0 1 -1
those,enzymes,would 1.0 0.000143348623853 0 1 -1
those,elevations,of 1.0 0.000143348623853 0 1 -1
those,concomitant,medications 1.0 0.000143348623853 0 1 -1
those,changes,induced 1.0 0.000143348623853 0 1 -1
those,aspects,that 1.0 0.000143348623853 0 1 -1
thorough,medication,review 1.0 0.000143348623853 0 1 -1
thorazine,prolixin,serentil 1.0 0.000143348623853 0 1 -1
thorazine,prolixin,permitil 1.0 0.000143348623853 0 1 -1
this,was,seen 1.0 0.000143348623853 0 1 -1
this,was,expected 1.0 0.000143348623853 0 1 -1
this,was,due 1.0 0.000286697247706 0 2 -2
this,treatment,arm 1.0 0.000143348623853 0 1 -1
this,transient,hypotensive 1.0 0.000143348623853 0 1 -1
this,toxicity,see 1.0 0.000143348623853 0 1 -1
this,to,patients 1.0 0.000143348623853 0 1 -1
this,therapy,may 1.0 0.000143348623853 0 1 -1
this,the,dosage 1.0 0.000143348623853 0 1 -1
this,test,which 1.0 0.000143348623853 0 1 -1
this,technique,it 1.0 0.000143348623853 0 1 -1
this,table,is 1.0 0.000286697247706 0 2 -2
this,suggests,that 1.0 0.000286697247706 0 2 -2
this,study,were 1.0 0.000143348623853 0 1 -1
this,study,we 1.0 0.00043004587156 0 3 -3
this,study,was 1.0 0.00100344036697 0 7 -7
this,study,there 1.0 0.000143348623853 0 1 -1
this,study,the 1.0 0.000143348623853 0 1 -1
this,study,suggest 1.0 0.000143348623853 0 1 -1
this,study,investigated 1.0 0.000143348623853 0 1 -1
this,study,indicates 1.0 0.000143348623853 0 1 -1
this,study,and 1.0 0.000143348623853 0 1 -1
this,strategy,can 1.0 0.000143348623853 0 1 -1
this,specificity,we 1.0 0.000143348623853 0 1 -1
this,slowing,potentiates 1.0 0.000286697247706 0 2 -2
this,situation,special 1.0 0.000143348623853 0 1 -1
this,should,be 1.0 0.00043004587156 0 3 -3
this,setting,cardioselective 1.0 0.000143348623853 0 1 -1
this,sequence,initiation 1.0 0.000143348623853 0 1 -1
this,sequence,however 1.0 0.000143348623853 0 1 -1
this,section,were 1.0 0.00043004587156 0 3 -3
this,section,as 1.0 0.000143348623853 0 1 -1
this,secretory,diarrhea 1.0 0.000143348623853 0 1 -1
this,sample,size 1.0 0.000143348623853 0 1 -1
this,risk,is 1.0 0.000143348623853 0 1 -1
this,review,was 1.0 0.000143348623853 0 1 -1
this,review,discusses 1.0 0.000143348623853 0 1 -1
this,response,has 1.0 0.000860091743119 0 6 -6
this,represents,an 1.0 0.000143348623853 0 1 -1
this,reported,activity 1.0 0.000143348623853 0 1 -1
this,product,with 1.0 0.000143348623853 0 1 -1
this,product,can 1.0 0.000143348623853 0 1 -1
this,process,can 1.0 0.000143348623853 0 1 -1
this,procedure,it 1.0 0.000143348623853 0 1 -1
this,problem,has 1.0 0.000143348623853 0 1 -1
this,practice,resulted 1.0 0.000143348623853 0 1 -1
this,possibility,and 1.0 0.000143348623853 0 1 -1
this,phenomenon,was 1.0 0.000143348623853 0 1 -1
this,phenomenon,has 1.0 0.000143348623853 0 1 -1
this,pharmacodynamic,interaction 1.0 0.000143348623853 0 1 -1
this,period,of 1.0 0.000143348623853 0 1 -1
this,patients,should 1.0 0.000143348623853 0 1 -1
this,patient,group 1.0 0.000143348623853 0 1 -1
this,particular,sulphydryl-containing 1.0 0.000143348623853 0 1 -1
this,paper,we 1.0 0.000143348623853 0 1 -1
this,paper,was 1.0 0.000143348623853 0 1 -1
this,paper,reviews 1.0 0.000143348623853 0 1 -1
this,paper,lists 1.0 0.000143348623853 0 1 -1
this,paper,is 1.0 0.000143348623853 0 1 -1
this,paper,critically 1.0 0.000143348623853 0 1 -1
this,paper,attempts 1.0 0.000143348623853 0 1 -1
this,oxidation,which 1.0 0.000143348623853 0 1 -1
this,organism,and 1.0 0.000143348623853 0 1 -1
this,oral,did 1.0 0.000143348623853 0 1 -1
this,observation,is 1.0 0.000143348623853 0 1 -1
this,number,fell 1.0 0.000143348623853 0 1 -1
this,might,increase 1.0 0.000143348623853 0 1 -1
this,metabolism,in 1.0 0.000143348623853 0 1 -1
this,metabolic,pathway 1.0 0.000143348623853 0 1 -1
this,medicine,with 1.0 0.000286697247706 0 2 -2
this,medicine,should 1.0 0.000286697247706 0 2 -2
this,medicine,due 1.0 0.000143348623853 0 1 -1
this,medicine,certain 1.0 0.000143348623853 0 1 -1
this,medication,tell 1.0 0.000143348623853 0 1 -1
this,medication,should 1.0 0.000143348623853 0 1 -1
this,medication,may 1.0 0.000143348623853 0 1 -1
this,may,result 1.0 0.000143348623853 0 1 -1
this,may,potentiate 1.0 0.000286697247706 0 2 -2
this,may,lead 1.0 0.00100344036697 0 7 -7
this,may,interact 1.0 0.000286697247706 0 2 -2
this,may,increase 1.0 0.000143348623853 0 1 -1
this,may,have 1.0 0.000143348623853 0 1 -1
this,may,enhance 1.0 0.000143348623853 0 1 -1
this,may,be 1.0 0.000143348623853 0 1 -1
this,loss,of 1.0 0.000143348623853 0 1 -1
this,isoenzyme,family 1.0 0.000143348623853 0 1 -1
this,isoenzyme,and 1.0 0.000286697247706 0 2 -2
this,is,given 1.0 0.000286697247706 0 2 -2
this,is,especially 1.0 0.00043004587156 0 3 -3
this,is,demonstrated 1.0 0.000143348623853 0 1 -1
this,is,based 1.0 0.000143348623853 0 1 -1
this,is,also 1.0 0.000143348623853 0 1 -1
this,is,administered 1.0 0.000143348623853 0 1 -1
this,interference,may 1.0 0.000143348623853 0 1 -1
this,interference,has 1.0 0.000143348623853 0 1 -1
this,interaction,with 1.0 0.000143348623853 0 1 -1
this,interaction,was 1.0 0.000143348623853 0 1 -1
this,interaction,occurs 1.0 0.000143348623853 0 1 -1
this,interaction,may 1.0 0.000286697247706 0 2 -2
this,interaction,is 1.0 0.000860091743119 0 6 -6
this,interaction,including 1.0 0.000143348623853 0 1 -1
this,interaction,include 1.0 0.000286697247706 0 2 -2
this,interaction,in 1.0 0.000286697247706 0 2 -2
this,interaction,appears 1.0 0.000286697247706 0 2 -2
this,interaction,also 1.0 0.00043004587156 0 3 -3
this,inhibitory,action 1.0 0.000143348623853 0 1 -1
this,inhibition,can 1.0 0.000143348623853 0 1 -1
this,information,should 1.0 0.000143348623853 0 1 -1
this,indicates,that 1.0 0.000286697247706 0 2 -2
this,increased,incidence 1.0 0.000143348623853 0 1 -1
this,increased,bioavailability 1.0 0.000143348623853 0 1 -1
this,increase,may 1.0 0.000143348623853 0 1 -1
this,increase,in 1.0 0.000143348623853 0 1 -1
this,included,post 1.0 0.000143348623853 0 1 -1
this,in,vitro 1.0 0.000143348623853 0 1 -1
this,hit,may 1.0 0.000143348623853 0 1 -1
this,has,been 1.0 0.000716743119266 0 5 -5
this,formal,interaction 1.0 0.000143348623853 0 1 -1
this,finding,to 1.0 0.000143348623853 0 1 -1
this,finding,no 1.0 0.000143348623853 0 1 -1
this,finding,is 1.0 0.000143348623853 0 1 -1
this,enzyme,prolongs 1.0 0.000143348623853 0 1 -1
this,enzyme,may 1.0 0.000143348623853 0 1 -1
this,enzyme,could 1.0 0.000143348623853 0 1 -1
this,effort,optimal 1.0 0.000143348623853 0 1 -1
this,effect,should 1.0 0.000143348623853 0 1 -1
this,effect,of 1.0 0.000143348623853 0 1 -1
this,effect,is 1.0 0.000286697247706 0 2 -2
this,effect,has 1.0 0.000286697247706 0 2 -2
this,effect,did 1.0 0.000143348623853 0 1 -1
this,drug,interaction 1.0 0.000143348623853 0 1 -1
this,dose,was 1.0 0.000143348623853 0 1 -1
this,disease,can 1.0 0.000143348623853 0 1 -1
this,diminution,is 1.0 0.000286697247706 0 2 -2
this,did,not 1.0 0.000286697247706 0 2 -2
this,defect,is 1.0 0.000143348623853 0 1 -1
this,defect,in 1.0 0.000143348623853 0 1 -1
this,decrease,of 1.0 0.000143348623853 0 1 -1
this,could,result 1.0 0.000143348623853 0 1 -1
this,could,facilitate 1.0 0.000143348623853 0 1 -1
this,could,create 1.0 0.00043004587156 0 3 -3
this,could,be 1.0 0.000143348623853 0 1 -1
this,conjugated,system 1.0 0.000143348623853 0 1 -1
this,conference,reviews 1.0 0.000143348623853 0 1 -1
this,combinational,action 1.0 0.000143348623853 0 1 -1
this,combination,with 1.0 0.000716743119266 0 5 -5
this,combination,should 1.0 0.000143348623853 0 1 -1
this,combination,of 1.0 0.000143348623853 0 1 -1
this,combination,in 1.0 0.000143348623853 0 1 -1
this,combination,have 1.0 0.000143348623853 0 1 -1
this,combination,arenot 1.0 0.000286697247706 0 2 -2
this,combination,are 1.0 0.000143348623853 0 1 -1
this,cluster,of 1.0 0.000143348623853 0 1 -1
this,class,produced 1.0 0.000143348623853 0 1 -1
this,class,of 1.0 0.000143348623853 0 1 -1
this,class,is 1.0 0.000143348623853 0 1 -1
this,change,was 1.0 0.000143348623853 0 1 -1
this,can,cause 1.0 0.000286697247706 0 2 -2
this,can,be 1.0 0.000143348623853 0 1 -1
this,being,the 1.0 0.000143348623853 0 1 -1
this,article,will 1.0 0.000143348623853 0 1 -1
this,article,reviews 1.0 0.000143348623853 0 1 -1
this,article,review 1.0 0.000143348623853 0 1 -1
this,article,looks 1.0 0.000143348623853 0 1 -1
this,alteration,in 1.0 0.000143348623853 0 1 -1
this,agent,should 1.0 0.000143348623853 0 1 -1
this,agent,and 1.0 0.000143348623853 0 1 -1
this,adverse,reaction 1.0 0.000143348623853 0 1 -1
this,activity,enough 1.0 0.000143348623853 0 1 -1
this,acid-catalyzed,ethanolysis 1.0 0.000143348623853 0 1 -1
thirty,male,rats 1.0 0.000143348623853 0 1 -1
thirst,weakness,lethargy 1.0 0.000143348623853 0 1 -1
third,hour,and 1.0 0.000143348623853 0 1 -1
third,group,sh 1.0 0.000143348623853 0 1 -1
thioridizine,or,within 1.0 0.000143348623853 0 1 -1
thiolated,carboxymethylcellulose,in 1.0 0.000143348623853 0 1 -1
thioethers,in,urine 1.0 0.000143348623853 0 1 -1
thioether,excretion,is 1.0 0.000143348623853 0 1 -1
thioether,concentration,ranges 1.0 0.000143348623853 0 1 -1
thioether,assay,as 1.0 0.000143348623853 0 1 -1
thioether,assay,appears 1.0 0.000143348623853 0 1 -1
thiobarbituric,acid,reactive 1.0 0.000143348623853 0 1 -1
thio,compounds,in 1.0 0.000143348623853 0 1 -1
thinners,coumadin,other 1.0 0.000143348623853 0 1 -1
think,you,are 1.0 0.000143348623853 0 1 -1
thin-layer,chromatographic,assay 1.0 0.000143348623853 0 1 -1
thienobenzodiazepine,derivative,is 1.0 0.000143348623853 0 1 -1
thiazides,thiazides,are 1.0 0.00043004587156 0 3 -3
thiazides,should,be 1.0 0.000286697247706 0 2 -2
thiazides,are,known 1.0 0.00043004587156 0 3 -3
thiazide,substrates,and 1.0 0.000143348623853 0 1 -1
thiazide,may,raise 1.0 0.000286697247706 0 2 -2
thiazide,for,hypertension 1.0 0.000143348623853 0 1 -1
thiazide,agents,and 1.0 0.000143348623853 0 1 -1
they,should,not 1.0 0.000286697247706 0 2 -2
they,respond,differently 1.0 0.000143348623853 0 1 -1
they,relate,to 1.0 0.000143348623853 0 1 -1
they,occur,they 1.0 0.000143348623853 0 1 -1
they,may,vary 1.0 0.000716743119266 0 5 -5
they,may,share 1.0 0.000143348623853 0 1 -1
they,may,provoke 1.0 0.000143348623853 0 1 -1
they,may,lead 1.0 0.000143348623853 0 1 -1
they,may,enhance 1.0 0.000143348623853 0 1 -1
they,may,be 1.0 0.000286697247706 0 2 -2
they,have,focused 1.0 0.000143348623853 0 1 -1
they,have,been 1.0 0.000143348623853 0 1 -1
they,do,occur 1.0 0.000143348623853 0 1 -1
they,could,enhance 1.0 0.000143348623853 0 1 -1
they,cause,much 1.0 0.000143348623853 0 1 -1
they,can,be 1.0 0.000143348623853 0 1 -1
they,bring,into 1.0 0.000143348623853 0 1 -1
they,are,weak 1.0 0.000143348623853 0 1 -1
they,are,using 1.0 0.000143348623853 0 1 -1
they,are,part 1.0 0.000143348623853 0 1 -1
they,are,being 1.0 0.000143348623853 0 1 -1
they,are,at 1.0 0.000143348623853 0 1 -1
they,are,administered 1.0 0.000143348623853 0 1 -1
they,also,suggest 1.0 0.000143348623853 0 1 -1
these,would,include 1.0 0.000143348623853 0 1 -1
these,with,respect 1.0 0.000143348623853 0 1 -1
these,with,lodosyn 1.0 0.000143348623853 0 1 -1
these,with,hivid 1.0 0.000143348623853 0 1 -1
these,who,are 1.0 0.000143348623853 0 1 -1
these,when,treating 1.0 0.000143348623853 0 1 -1
these,were,not 1.0 0.000286697247706 0 2 -2
these,usually,clear 1.0 0.000143348623853 0 1 -1
these,two,should 1.0 0.000143348623853 0 1 -1
these,two,isoenzymes 1.0 0.000143348623853 0 1 -1
these,two,differ 1.0 0.000143348623853 0 1 -1
these,two,compounds 1.0 0.000143348623853 0 1 -1
these,two,are 1.0 0.000143348623853 0 1 -1
these,trials,heart 1.0 0.000143348623853 0 1 -1
these,trace,elements 1.0 0.000143348623853 0 1 -1
these,together,especially 1.0 0.000143348623853 0 1 -1
these,tests,be 1.0 0.00043004587156 0 3 -3
these,techniques,confirmation 1.0 0.000143348623853 0 1 -1
these,supplements,with 1.0 0.000143348623853 0 1 -1
these,subjects,r 1.0 0.000143348623853 0 1 -1
these,subjects,did 1.0 0.000143348623853 0 1 -1
these,studies,it 1.0 0.000143348623853 0 1 -1
these,studies,did 1.0 0.000143348623853 0 1 -1
these,studies,are 1.0 0.000143348623853 0 1 -1
these,strategies,will 1.0 0.000143348623853 0 1 -1
these,stimulants,are 1.0 0.000143348623853 0 1 -1
these,steps,include 1.0 0.000143348623853 0 1 -1
these,small,changes 1.0 0.000143348623853 0 1 -1
these,six,volunteers 1.0 0.000143348623853 0 1 -1
these,six,cases 1.0 0.000143348623853 0 1 -1
these,should,not 1.0 0.000143348623853 0 1 -1
these,same,interactions 1.0 0.000143348623853 0 1 -1
these,results,together 1.0 0.000143348623853 0 1 -1
these,results,that 1.0 0.000143348623853 0 1 -1
these,results,show 1.0 0.000143348623853 0 1 -1
these,results,indicate 1.0 0.00043004587156 0 3 -3
these,results,confirm 1.0 0.000143348623853 0 1 -1
these,results,are 1.0 0.000286697247706 0 2 -2
these,reports,concerned 1.0 0.000143348623853 0 1 -1
these,reports,are 1.0 0.000143348623853 0 1 -1
these,reports,and 1.0 0.000143348623853 0 1 -1
these,recommendations,are 1.0 0.000143348623853 0 1 -1
these,reactions,resemble 1.0 0.000143348623853 0 1 -1
these,reactions,include 1.0 0.000143348623853 0 1 -1
these,reactions,have 1.0 0.000286697247706 0 2 -2
these,reactions,consisted 1.0 0.000143348623853 0 1 -1
these,purposes,cannot 1.0 0.000143348623853 0 1 -1
these,products,are 1.0 0.000860091743119 0 6 -6
these,problems,and 1.0 0.000143348623853 0 1 -1
these,preparations,have 1.0 0.000143348623853 0 1 -1
these,precautions,probably 1.0 0.000143348623853 0 1 -1
these,potential,interactions 1.0 0.000143348623853 0 1 -1
these,polyene,showed 1.0 0.000143348623853 0 1 -1
these,peptides,in 1.0 0.000143348623853 0 1 -1
these,patients,the 1.0 0.000286697247706 0 2 -2
these,patients,should 1.0 0.000143348623853 0 1 -1
these,patients,may 1.0 0.000143348623853 0 1 -1
these,patients,have 1.0 0.000143348623853 0 1 -1
these,patients,approximately 1.0 0.000143348623853 0 1 -1
these,patients,and 1.0 0.000143348623853 0 1 -1
these,other,is 1.0 0.000573394495413 0 4 -4
these,or,others 1.0 0.000143348623853 0 1 -1
these,on,the 1.0 0.000143348623853 0 1 -1
these,on,plasma 1.0 0.000143348623853 0 1 -1
these,observations,suggest 1.0 0.000143348623853 0 1 -1
these,observations,strongly 1.0 0.000143348623853 0 1 -1
these,observations,are 1.0 0.000143348623853 0 1 -1
these,monkeys,were 1.0 0.000143348623853 0 1 -1
these,models,are 1.0 0.000143348623853 0 1 -1
these,medicines,should 1.0 0.000143348623853 0 1 -1
these,medicines,may 1.0 0.000573394495413 0 4 -4
these,medications,should 1.0 0.000143348623853 0 1 -1
these,medications,have 1.0 0.000143348623853 0 1 -1
these,medications,at 1.0 0.000143348623853 0 1 -1
these,may,also 1.0 0.000143348623853 0 1 -1
these,lines,showed 1.0 0.000143348623853 0 1 -1
these,levels,then 1.0 0.000143348623853 0 1 -1
these,isozymes,may 1.0 0.000143348623853 0 1 -1
these,isoenzymes,may 1.0 0.000286697247706 0 2 -2
these,is,withdrawn 1.0 0.000143348623853 0 1 -1
these,is,taken 1.0 0.000143348623853 0 1 -1
these,interactions,the 1.0 0.000143348623853 0 1 -1
these,interactions,on 1.0 0.000143348623853 0 1 -1
these,interactions,is 1.0 0.000143348623853 0 1 -1
these,interactions,has 1.0 0.000143348623853 0 1 -1
these,instances,has 1.0 0.000143348623853 0 1 -1
these,inhibiting,as 1.0 0.000716743119266 0 5 -5
these,individuals,may 1.0 0.000286697247706 0 2 -2
these,increases,is 1.0 0.000143348623853 0 1 -1
these,increases,in 1.0 0.000143348623853 0 1 -1
these,included,seven 1.0 0.000143348623853 0 1 -1
these,include,the 1.0 0.00043004587156 0 3 -3
these,include,and 1.0 0.000143348623853 0 1 -1
these,in,vivo 1.0 0.000143348623853 0 1 -1
these,in,normal 1.0 0.000143348623853 0 1 -1
these,in,combination 1.0 0.00043004587156 0 3 -3
these,imidazole,and 1.0 0.000143348623853 0 1 -1
these,if,given 1.0 0.000143348623853 0 1 -1
these,hormones,were 1.0 0.000143348623853 0 1 -1
these,have,been 1.0 0.000143348623853 0 1 -1
these,groups,is 1.0 0.000143348623853 0 1 -1
these,functions,as 1.0 0.000143348623853 0 1 -1
these,findings,suggest 1.0 0.00043004587156 0 3 -3
these,findings,should 1.0 0.000143348623853 0 1 -1
these,findings,indicate 1.0 0.000143348623853 0 1 -1
these,findings,has 1.0 0.000143348623853 0 1 -1
these,facts,should 1.0 0.000143348623853 0 1 -1
these,factors,in 1.0 0.000143348623853 0 1 -1
these,experiences,have 1.0 0.000143348623853 0 1 -1
these,events,were 1.0 0.000143348623853 0 1 -1
these,events,required 1.0 0.000143348623853 0 1 -1
these,events,is 1.0 0.000143348623853 0 1 -1
these,events,are 1.0 0.000143348623853 0 1 -1
these,events,and 1.0 0.000143348623853 0 1 -1
these,enzymes,would 1.0 0.000143348623853 0 1 -1
these,enzymes,or 1.0 0.000143348623853 0 1 -1
these,enzymes,may 1.0 0.000143348623853 0 1 -1
these,enzymes,are 1.0 0.000143348623853 0 1 -1
these,enzyme,systems 1.0 0.000143348623853 0 1 -1
these,effects,were 1.0 0.00043004587156 0 3 -3
these,effects,of 1.0 0.000143348623853 0 1 -1
these,effects,not 1.0 0.000143348623853 0 1 -1
these,effects,have 1.0 0.00043004587156 0 3 -3
these,effects,are 1.0 0.000286697247706 0 2 -2
these,effects,although 1.0 0.000143348623853 0 1 -1
these,drugs,is 1.0 0.000143348623853 0 1 -1
these,drugs,include 1.0 0.000143348623853 0 1 -1
these,drugs,have 1.0 0.000143348623853 0 1 -1
these,doses,were 1.0 0.000143348623853 0 1 -1
these,doses,correspond 1.0 0.000286697247706 0 2 -2
these,doses,are 1.0 0.000143348623853 0 1 -1
these,does,not 1.0 0.000143348623853 0 1 -1
these,disorders,can 1.0 0.000143348623853 0 1 -1
these,differences,were 1.0 0.000143348623853 0 1 -1
these,differences,are 1.0 0.000143348623853 0 1 -1
these,data,suggest 1.0 0.000573394495413 0 4 -4
these,data,raise 1.0 0.000143348623853 0 1 -1
these,data,indicate 1.0 0.000143348623853 0 1 -1
these,data,emphasize 1.0 0.000143348623853 0 1 -1
these,data,appeared 1.0 0.000143348623853 0 1 -1
these,cyp3a4,or 1.0 0.000143348623853 0 1 -1
these,cyp,enzymes 1.0 0.000143348623853 0 1 -1
these,concurrently,should 1.0 0.000143348623853 0 1 -1
these,concomitantly,plasma 1.0 0.000143348623853 0 1 -1
these,conclusions,are 1.0 0.000143348623853 0 1 -1
these,compounds,interfere 1.0 0.000143348623853 0 1 -1
these,compounds,have 1.0 0.00043004587156 0 3 -3
these,compounds,caution 1.0 0.000143348623853 0 1 -1
these,compounds,block 1.0 0.000143348623853 0 1 -1
these,compounds,are 1.0 0.000143348623853 0 1 -1
these,components,may 1.0 0.000143348623853 0 1 -1
these,combinations,should 1.0 0.000286697247706 0 2 -2
these,changes,were 1.0 0.000143348623853 0 1 -1
these,changes,has 1.0 0.000143348623853 0 1 -1
these,cells,express 1.0 0.000143348623853 0 1 -1
these,cases,your 1.0 0.000143348623853 0 1 -1
these,cases,was 1.0 0.000143348623853 0 1 -1
these,cases,and 1.0 0.000143348623853 0 1 -1
these,case,reports 1.0 0.000143348623853 0 1 -1
these,blocking,agents 1.0 0.000143348623853 0 1 -1
these,behavioral,changes 1.0 0.000143348623853 0 1 -1
these,areas,examines 1.0 0.000143348623853 0 1 -1
these,are,used 1.0 0.000143348623853 0 1 -1
these,are,unchanged 1.0 0.000143348623853 0 1 -1
these,are,to 1.0 0.000143348623853 0 1 -1
these,are,that 1.0 0.000143348623853 0 1 -1
these,are,often 1.0 0.000143348623853 0 1 -1
these,are,inhibitors 1.0 0.000143348623853 0 1 -1
these,are,incompatible 1.0 0.000143348623853 0 1 -1
these,are,administered 1.0 0.000143348623853 0 1 -1
these,and,therefore 1.0 0.000143348623853 0 1 -1
these,and,perhaps 1.0 0.000143348623853 0 1 -1
these,and,other 1.0 0.000143348623853 0 1 -1
these,and,may 1.0 0.000143348623853 0 1 -1
these,also,resolved 1.0 0.000143348623853 0 1 -1
these,agents,should 1.0 0.00143348623853 0 10 -10
these,agents,is 1.0 0.000573394495413 0 4 -4
these,agents,into 1.0 0.000143348623853 0 1 -1
these,agents,including 1.0 0.000143348623853 0 1 -1
these,agents,include 1.0 0.000143348623853 0 1 -1
these,agents,contribute 1.0 0.000143348623853 0 1 -1
these,agents,and 1.0 0.000286697247706 0 2 -2
these,aeds,during 1.0 0.000143348623853 0 1 -1
these,aeds,do 1.0 0.000143348623853 0 1 -1
these,above,findings 1.0 0.000143348623853 0 1 -1
thermal,analysis,and 1.0 0.000143348623853 0 1 -1
thereof,are,suggested 1.0 0.000143348623853 0 1 -1
therefore,we,investigated 1.0 0.000143348623853 0 1 -1
therefore,unless,otherwise 1.0 0.000286697247706 0 2 -2
therefore,to,maximize 1.0 0.000143348623853 0 1 -1
therefore,this,conjugated 1.0 0.000143348623853 0 1 -1
therefore,these,combinations 1.0 0.000143348623853 0 1 -1
therefore,there,is 1.0 0.000286697247706 0 2 -2
therefore,the,use 1.0 0.000286697247706 0 2 -2
therefore,the,simultaneous 1.0 0.000143348623853 0 1 -1
therefore,the,dose 1.0 0.000143348623853 0 1 -1
therefore,the,disposition 1.0 0.000286697247706 0 2 -2
therefore,the,assay 1.0 0.000143348623853 0 1 -1
therefore,that,affect 1.0 0.000143348623853 0 1 -1
therefore,subtle,cell 1.0 0.000143348623853 0 1 -1
therefore,smaller,alfenta 1.0 0.000143348623853 0 1 -1
therefore,simultaneous,use 1.0 0.000143348623853 0 1 -1
therefore,signs,of 1.0 0.000143348623853 0 1 -1
therefore,serum,levels 1.0 0.000573394495413 0 4 -4
therefore,precaution,should 1.0 0.00043004587156 0 3 -3
therefore,potentiate,the 1.0 0.000143348623853 0 1 -1
therefore,potential,interactions 1.0 0.000143348623853 0 1 -1
therefore,positive,test 1.0 0.000143348623853 0 1 -1
therefore,periodic,liver 1.0 0.000143348623853 0 1 -1
therefore,patients,with 1.0 0.000143348623853 0 1 -1
therefore,patients,who 1.0 0.000143348623853 0 1 -1
therefore,patients,concurrently 1.0 0.000143348623853 0 1 -1
therefore,omnicef,for 1.0 0.000143348623853 0 1 -1
therefore,no,adjustment 1.0 0.000143348623853 0 1 -1
therefore,necessary,to 1.0 0.000143348623853 0 1 -1
therefore,more,frequent 1.0 0.000143348623853 0 1 -1
therefore,monitoring,of 1.0 0.000716743119266 0 5 -5
therefore,may,reduce 1.0 0.000143348623853 0 1 -1
therefore,may,increase 1.0 0.000143348623853 0 1 -1
therefore,little,is 1.0 0.000143348623853 0 1 -1
therefore,it,would 1.0 0.000143348623853 0 1 -1
therefore,it,should 1.0 0.000573394495413 0 4 -4
therefore,it,can 1.0 0.000143348623853 0 1 -1
therefore,interactions,mediated 1.0 0.000143348623853 0 1 -1
therefore,interactions,could 1.0 0.000143348623853 0 1 -1
therefore,intake,of 1.0 0.000143348623853 0 1 -1
therefore,injection,of 1.0 0.000143348623853 0 1 -1
therefore,inhibitors,of 1.0 0.000143348623853 0 1 -1
therefore,in,patients 1.0 0.000286697247706 0 2 -2
therefore,if,replacement 1.0 0.000143348623853 0 1 -1
therefore,if,concomitant 1.0 0.000860091743119 0 6 -6
therefore,foradil,should 1.0 0.000143348623853 0 1 -1
therefore,exposure,may 1.0 0.000143348623853 0 1 -1
therefore,doses,greater 1.0 0.000143348623853 0 1 -1
therefore,dose,adjustments 1.0 0.000143348623853 0 1 -1
therefore,concurrent,administration 1.0 0.000143348623853 0 1 -1
therefore,colestld,tablets 1.0 0.000143348623853 0 1 -1
therefore,coagulation,indices 1.0 0.000286697247706 0 2 -2
therefore,clozapine,should 1.0 0.000143348623853 0 1 -1
therefore,change,with 1.0 0.000143348623853 0 1 -1
therefore,caution,is 1.0 0.000143348623853 0 1 -1
therefore,careful,monitoring 1.0 0.000143348623853 0 1 -1
therefore,can,generally 1.0 0.000143348623853 0 1 -1
therefore,be,completed 1.0 0.000143348623853 0 1 -1
therefore,based,on 1.0 0.000143348623853 0 1 -1
therefore,appropriate,dose 1.0 0.000143348623853 0 1 -1
therefore,agents,affecting 1.0 0.000143348623853 0 1 -1
therefore,administration,of 1.0 0.00043004587156 0 3 -3
therefore,a,starting 1.0 0.000143348623853 0 1 -1
therefore,a,potent 1.0 0.000143348623853 0 1 -1
therefore,a,possible 1.0 0.000143348623853 0 1 -1
therefore,a,lower 1.0 0.000143348623853 0 1 -1
thereby,providing,for 1.0 0.000143348623853 0 1 -1
thereby,increasing,the 1.0 0.000143348623853 0 1 -1
thereby,cause,arrhythmias 1.0 0.000143348623853 0 1 -1
thereafter,at,intervals 1.0 0.000143348623853 0 1 -1
there,were,several 1.0 0.000143348623853 0 1 -1
there,were,pi 1.0 0.000143348623853 0 1 -1
there,were,not 1.0 0.000143348623853 0 1 -1
there,were,deaths 1.0 0.000143348623853 0 1 -1
there,were,and 1.0 0.000143348623853 0 1 -1
there,was,not 1.0 0.000143348623853 0 1 -1
there,was,extensive 1.0 0.000143348623853 0 1 -1
there,was,evidence 1.0 0.000143348623853 0 1 -1
there,was,decrease 1.0 0.000143348623853 0 1 -1
there,was,an 1.0 0.000143348623853 0 1 -1
there,may,remain 1.0 0.000143348623853 0 1 -1
there,is,such 1.0 0.000143348623853 0 1 -1
there,is,strong 1.0 0.000143348623853 0 1 -1
there,is,rapid 1.0 0.000143348623853 0 1 -1
there,is,now 1.0 0.000143348623853 0 1 -1
there,is,more 1.0 0.000143348623853 0 1 -1
there,is,little 1.0 0.00043004587156 0 3 -3
there,is,limited 1.0 0.00043004587156 0 3 -3
there,is,inadequate 1.0 0.000143348623853 0 1 -1
there,is,however 1.0 0.000143348623853 0 1 -1
there,is,evidence 1.0 0.000286697247706 0 2 -2
there,is,currently 1.0 0.000143348623853 0 1 -1
there,is,considerable 1.0 0.000143348623853 0 1 -1
there,exists,the 1.0 0.000143348623853 0 1 -1
there,does,not 1.0 0.000143348623853 0 1 -1
there,are,types 1.0 0.000143348623853 0 1 -1
there,are,several 1.0 0.000143348623853 0 1 -1
there,are,other 1.0 0.000143348623853 0 1 -1
there,are,multiple 1.0 0.000143348623853 0 1 -1
there,are,few 1.0 0.000143348623853 0 1 -1
there,are,currently 1.0 0.000286697247706 0 2 -2
there,are,compelling 1.0 0.000143348623853 0 1 -1
there,are,at 1.0 0.000143348623853 0 1 -1
there,are,a 1.0 0.000143348623853 0 1 -1
there,appears,to 1.0 0.000143348623853 0 1 -1
there,any,changes 1.0 0.000143348623853 0 1 -1
there,also,was 1.0 0.000143348623853 0 1 -1
therapy,with,the 1.0 0.000286697247706 0 2 -2
therapy,with,similar 1.0 0.000143348623853 0 1 -1
therapy,with,other 1.0 0.00043004587156 0 3 -3
therapy,with,nsaids 1.0 0.000143348623853 0 1 -1
therapy,with,is 1.0 0.000143348623853 0 1 -1
therapy,with,interferon 1.0 0.000143348623853 0 1 -1
therapy,with,differin 1.0 0.000143348623853 0 1 -1
therapy,with,be 1.0 0.000143348623853 0 1 -1
therapy,with,are 1.0 0.000143348623853 0 1 -1
therapy,which,may 1.0 0.000143348623853 0 1 -1
therapy,which,adds 1.0 0.000143348623853 0 1 -1
therapy,were,treated 1.0 0.000143348623853 0 1 -1
therapy,were,increased 1.0 0.000143348623853 0 1 -1
therapy,the,patient 1.0 0.000143348623853 0 1 -1
therapy,the,initial 1.0 0.000143348623853 0 1 -1
therapy,such,agents 1.0 0.000143348623853 0 1 -1
therapy,standard,in 1.0 0.000143348623853 0 1 -1
therapy,should,not 1.0 0.000143348623853 0 1 -1
therapy,resulted,in 1.0 0.000143348623853 0 1 -1
therapy,particularly,for 1.0 0.000143348623853 0 1 -1
therapy,oral,containing 1.0 0.000143348623853 0 1 -1
therapy,or,daily 1.0 0.000143348623853 0 1 -1
therapy,of,human 1.0 0.000143348623853 0 1 -1
therapy,may,not 1.0 0.000143348623853 0 1 -1
therapy,may,induce 1.0 0.000143348623853 0 1 -1
therapy,may,increase 1.0 0.000143348623853 0 1 -1
therapy,may,cause 1.0 0.000143348623853 0 1 -1
therapy,may,be 1.0 0.000143348623853 0 1 -1
therapy,mainly,concerns 1.0 0.000143348623853 0 1 -1
therapy,lies,in 1.0 0.000143348623853 0 1 -1
therapy,is,prolonged 1.0 0.000143348623853 0 1 -1
therapy,is,necessary 1.0 0.00043004587156 0 3 -3
therapy,is,contraindicated 1.0 0.000143348623853 0 1 -1
therapy,is,contemplated 1.0 0.000716743119266 0 5 -5
therapy,is,begun 1.0 0.000143348623853 0 1 -1
therapy,indicate,no 1.0 0.000143348623853 0 1 -1
therapy,including,more 1.0 0.000143348623853 0 1 -1
therapy,including,and 1.0 0.000143348623853 0 1 -1
therapy,includes,such 1.0 0.000143348623853 0 1 -1
therapy,in,healthy 1.0 0.000143348623853 0 1 -1
therapy,have,experienced 1.0 0.000143348623853 0 1 -1
therapy,has,not 1.0 0.000286697247706 0 2 -2
therapy,had,no 1.0 0.000143348623853 0 1 -1
therapy,haart,is 1.0 0.000143348623853 0 1 -1
therapy,for,maintenance 1.0 0.000143348623853 0 1 -1
therapy,for,initial 1.0 0.000143348623853 0 1 -1
therapy,for,erectile 1.0 0.000143348623853 0 1 -1
therapy,eg,selective 1.0 0.000143348623853 0 1 -1
therapy,ect,there 1.0 0.000143348623853 0 1 -1
therapy,did,not 1.0 0.000286697247706 0 2 -2
therapy,diabetes,mellitus 1.0 0.000143348623853 0 1 -1
therapy,depends,not 1.0 0.000143348623853 0 1 -1
therapy,compliance,especially 1.0 0.000143348623853 0 1 -1
therapy,can,then 1.0 0.000143348623853 0 1 -1
therapy,but,had 1.0 0.000143348623853 0 1 -1
therapy,at,to 1.0 0.000143348623853 0 1 -1
therapy,any,form 1.0 0.000143348623853 0 1 -1
therapy,and,the 1.0 0.000286697247706 0 2 -2
therapy,and,overuse 1.0 0.000143348623853 0 1 -1
therapy,and,concerns 1.0 0.000143348623853 0 1 -1
therapy,and,bone 1.0 0.000143348623853 0 1 -1
therapy,although,specific 1.0 0.000286697247706 0 2 -2
therapy,although,no 1.0 0.000143348623853 0 1 -1
therapy,alone,can 1.0 0.000143348623853 0 1 -1
therapy,allow,sufficient 1.0 0.000143348623853 0 1 -1
therapy,administration,of 1.0 0.000143348623853 0 1 -1
therapy,a,reduction 1.0 0.000143348623853 0 1 -1
therapy,a,combination 1.0 0.000143348623853 0 1 -1
theraputic,agents,have 1.0 0.000143348623853 0 1 -1
therapies,that,take 1.0 0.000143348623853 0 1 -1
therapies,standard,monitoring 1.0 0.000143348623853 0 1 -1
therapies,may,affect 1.0 0.000143348623853 0 1 -1
therapies,including,oral 1.0 0.000143348623853 0 1 -1
therapies,in,clinical 1.0 0.000143348623853 0 1 -1
therapies,i,tranexamic 1.0 0.000143348623853 0 1 -1
therapies,for,type 1.0 0.000143348623853 0 1 -1
therapies,commonly,used 1.0 0.000143348623853 0 1 -1
therapies,as,safety 1.0 0.000143348623853 0 1 -1
therapies,are,effective 1.0 0.000143348623853 0 1 -1
therapeutic,windows,that 1.0 0.000286697247706 0 2 -2
therapeutic,value,of 1.0 0.000143348623853 0 1 -1
therapeutic,to,human 1.0 0.000286697247706 0 2 -2
therapeutic,superiority,compared 1.0 0.000143348623853 0 1 -1
therapeutic,response,and 1.0 0.000143348623853 0 1 -1
therapeutic,regimes,against 1.0 0.000143348623853 0 1 -1
therapeutic,regimen,of 1.0 0.000143348623853 0 1 -1
therapeutic,regimen,be 1.0 0.000143348623853 0 1 -1
therapeutic,regimen,as 1.0 0.000143348623853 0 1 -1
therapeutic,ratio,or 1.0 0.000286697247706 0 2 -2
therapeutic,range,while 1.0 0.000143348623853 0 1 -1
therapeutic,range,of 1.0 0.000143348623853 0 1 -1
therapeutic,monitoring,the 1.0 0.000143348623853 0 1 -1
therapeutic,monitoring,tdm 1.0 0.000143348623853 0 1 -1
therapeutic,margin,such 1.0 0.000143348623853 0 1 -1
therapeutic,levels,of 1.0 0.000143348623853 0 1 -1
therapeutic,levels,did 1.0 0.000143348623853 0 1 -1
therapeutic,interval,and 1.0 0.000143348623853 0 1 -1
therapeutic,index,digoxin 1.0 0.000286697247706 0 2 -2
therapeutic,index,and 1.0 0.000143348623853 0 1 -1
therapeutic,hypermagnesaemia,high 1.0 0.000143348623853 0 1 -1
therapeutic,efficacy,and 1.0 0.000143348623853 0 1 -1
therapeutic,effect,has 1.0 0.000143348623853 0 1 -1
therapeutic,effect,for 1.0 0.000143348623853 0 1 -1
therapeutic,effect,and 1.0 0.000143348623853 0 1 -1
therapeutic,dose,range 1.0 0.000143348623853 0 1 -1
therapeutic,concentrations,in 1.0 0.000143348623853 0 1 -1
therapeutic,concentrations,has 1.0 0.000143348623853 0 1 -1
therapeutic,benefit,of 1.0 0.000143348623853 0 1 -1
therapeutic,and,toxic 1.0 0.000143348623853 0 1 -1
therapeutic,agents,with 1.0 0.000143348623853 0 1 -1
therapeutic,advantage,when 1.0 0.000143348623853 0 1 -1
theories,have,been 1.0 0.000143348623853 0 1 -1
theories,assume,that 1.0 0.000143348623853 0 1 -1
theoretically,the,anion 1.0 0.000143348623853 0 1 -1
theoretically,occur,if 1.0 0.000143348623853 0 1 -1
theoretically,might,blunt 1.0 0.000143348623853 0 1 -1
theoretically,it,may 1.0 0.000143348623853 0 1 -1
theoretically,interfere,with 1.0 0.000143348623853 0 1 -1
theoretically,could,likewise 1.0 0.000143348623853 0 1 -1
theophylline,twelve,healthy 1.0 0.000143348623853 0 1 -1
theophylline,theophylline,clearance 1.0 0.000143348623853 0 1 -1
theophylline,the,pharmacokinetics 1.0 0.000143348623853 0 1 -1
theophylline,the,effect 1.0 0.000143348623853 0 1 -1
theophylline,mg,as 1.0 0.000143348623853 0 1 -1
theophylline,in,three 1.0 0.000143348623853 0 1 -1
theophylline,following,co-administration 1.0 0.000143348623853 0 1 -1
theophylline,combined,administration 1.0 0.000143348623853 0 1 -1
theophylline,clearance,may 1.0 0.000143348623853 0 1 -1
theophylline,alone,caused 1.0 0.000143348623853 0 1 -1
theophylline,a,single 1.0 0.000143348623853 0 1 -1
then,with,caution 1.0 0.000143348623853 0 1 -1
then,took,mg 1.0 0.000143348623853 0 1 -1
then,the,effects 1.0 0.000143348623853 0 1 -1
then,remained,stable 1.0 0.000143348623853 0 1 -1
then,received,plus 1.0 0.000143348623853 0 1 -1
then,mg,kg 1.0 0.000143348623853 0 1 -1
then,hoof,twitch 1.0 0.000143348623853 0 1 -1
then,be,discontinued 1.0 0.000143348623853 0 1 -1
then,analysing,the 1.0 0.000143348623853 0 1 -1
themselves,to,an 1.0 0.000143348623853 0 1 -1
them,are,less 1.0 0.000143348623853 0 1 -1
them,and,what 1.0 0.000143348623853 0 1 -1
their,usual,recommended 1.0 0.000143348623853 0 1 -1
their,serum,half-life 1.0 0.000143348623853 0 1 -1
their,selective,ca 1.0 0.000143348623853 0 1 -1
their,relevance,continues 1.0 0.000143348623853 0 1 -1
their,relative,avidities 1.0 0.000143348623853 0 1 -1
their,reappearance,on 1.0 0.000143348623853 0 1 -1
their,practitioners,any 1.0 0.000143348623853 0 1 -1
their,potential,to 1.0 0.000143348623853 0 1 -1
their,possible,role 1.0 0.000143348623853 0 1 -1
their,physicians,and 1.0 0.000143348623853 0 1 -1
their,pharmacological,actions 1.0 0.000143348623853 0 1 -1
their,patients,are 1.0 0.000143348623853 0 1 -1
their,o-desacetyl,metabolites 1.0 0.000143348623853 0 1 -1
their,need,for 1.0 0.000143348623853 0 1 -1
their,metabolites,may 1.0 0.000143348623853 0 1 -1
their,main,route 1.0 0.000143348623853 0 1 -1
their,increased,renal 1.0 0.000143348623853 0 1 -1
their,guardians,carefully 1.0 0.000143348623853 0 1 -1
their,efficacy,in 1.0 0.000143348623853 0 1 -1
their,effects,by 1.0 0.000143348623853 0 1 -1
their,effectiveness,when 1.0 0.000143348623853 0 1 -1
their,effect,on 1.0 0.000286697247706 0 2 -2
their,dose,should 1.0 0.000143348623853 0 1 -1
their,dose,of 1.0 0.000143348623853 0 1 -1
their,dose,increased 1.0 0.000143348623853 0 1 -1
their,dosages,may 1.0 0.000143348623853 0 1 -1
their,differential,effects 1.0 0.000143348623853 0 1 -1
their,condition,may 1.0 0.000143348623853 0 1 -1
their,concurrent,use 1.0 0.000143348623853 0 1 -1
their,concomitant,medications 1.0 0.000143348623853 0 1 -1
their,clearance,resulting 1.0 0.000143348623853 0 1 -1
their,capacity,for 1.0 0.000143348623853 0 1 -1
their,binding,sites 1.0 0.000286697247706 0 2 -2
their,associated,side-effect 1.0 0.000143348623853 0 1 -1
their,antiseizure,medication 1.0 0.000143348623853 0 1 -1
their,action,may 1.0 0.000143348623853 0 1 -1
thedosage,of,may 1.0 0.000286697247706 0 2 -2
theasinensin,a,potently 1.0 0.000143348623853 0 1 -1
the-curve,auc,hours 1.0 0.000143348623853 0 1 -1
the,zevalin,therapeutic 1.0 0.000143348623853 0 1 -1
the,year,risk 1.0 0.000143348623853 0 1 -1
the,year,monthly 1.0 0.000143348623853 0 1 -1
the,world,medical 1.0 0.000143348623853 0 1 -1
the,world,health 1.0 0.000143348623853 0 1 -1
the,wild-type,alleles 1.0 0.000143348623853 0 1 -1
the,west,midlands 1.0 0.000143348623853 0 1 -1
the,were,administered 1.0 0.000143348623853 0 1 -1
the,welfare,of 1.0 0.000143348623853 0 1 -1
the,washout,period 1.0 0.000143348623853 0 1 -1
the,was,fold 1.0 0.000143348623853 0 1 -1
the,was,carried 1.0 0.000143348623853 0 1 -1
the,volunteers,were 1.0 0.000143348623853 0 1 -1
the,volume,of 1.0 0.000143348623853 0 1 -1
the,volatile,agent 1.0 0.000143348623853 0 1 -1
the,vitamin,d 1.0 0.00043004587156 0 3 -3
the,visual,cortex 1.0 0.000143348623853 0 1 -1
the,vehicle-controlled,studies 1.0 0.000143348623853 0 1 -1
the,various,dual-memory 1.0 0.000143348623853 0 1 -1
the,various,ca 1.0 0.000143348623853 0 1 -1
the,variability,of 1.0 0.000286697247706 0 2 -2
the,value,of 1.0 0.000143348623853 0 1 -1
the,v,v 1.0 0.000143348623853 0 1 -1
the,utilization,of 1.0 0.000143348623853 0 1 -1
the,utility,of 1.0 0.000143348623853 0 1 -1
the,usual,doses 1.0 0.000860091743119 0 6 -6
the,usual,dosage 1.0 0.000143348623853 0 1 -1
the,usual,concentrations 1.0 0.000143348623853 0 1 -1
the,usual,amounts 1.0 0.000286697247706 0 2 -2
the,user,such 1.0 0.000143348623853 0 1 -1
the,us,food 1.0 0.000143348623853 0 1 -1
the,us,a 1.0 0.000143348623853 0 1 -1
the,urine,when 1.0 0.000286697247706 0 2 -2
the,urine,using 1.0 0.00043004587156 0 3 -3
the,urine,test 1.0 0.000143348623853 0 1 -1
the,urine,remained 1.0 0.000143348623853 0 1 -1
the,urine,of 1.0 0.000286697247706 0 2 -2
the,urine,may 1.0 0.00114678899083 0 8 -8
the,urine,by 1.0 0.000143348623853 0 1 -1
the,urine,as 1.0 0.000143348623853 0 1 -1
the,urinary,thioether 1.0 0.000143348623853 0 1 -1
the,urinary,recovery 1.0 0.000143348623853 0 1 -1
the,uptake,inhibitor 1.0 0.000143348623853 0 1 -1
the,upper,limit 1.0 0.000286697247706 0 2 -2
the,unrestricted,use 1.0 0.000143348623853 0 1 -1
the,united,states 1.0 0.000573394495413 0 4 -4
the,understanding,and 1.0 0.000143348623853 0 1 -1
the,underlying,disease 1.0 0.000143348623853 0 1 -1
the,unbound,free 1.0 0.000143348623853 0 1 -1
the,ultimate,effect 1.0 0.000143348623853 0 1 -1
the,udp-glucuronyl,transferase 1.0 0.000143348623853 0 1 -1
the,tysabri,dose 1.0 0.000143348623853 0 1 -1
the,tysabri,associated 1.0 0.000143348623853 0 1 -1
the,tyrosine,phosphorylation 1.0 0.000143348623853 0 1 -1
the,types,of 1.0 0.000286697247706 0 2 -2
the,type,c 1.0 0.000143348623853 0 1 -1
the,two-hour,period 1.0 0.000143348623853 0 1 -1
the,two,treatment 1.0 0.000143348623853 0 1 -1
the,two,should 1.0 0.000143348623853 0 1 -1
the,two,regimens 1.0 0.000143348623853 0 1 -1
the,two,on 1.0 0.000143348623853 0 1 -1
the,two,hour 1.0 0.000143348623853 0 1 -1
the,two,groups 1.0 0.000286697247706 0 2 -2
the,two,elements 1.0 0.000143348623853 0 1 -1
the,two,concomitantly 1.0 0.000143348623853 0 1 -1
the,two,at 1.0 0.000143348623853 0 1 -1
the,tricyclic,antidepressant 1.0 0.00043004587156 0 3 -3
the,trials,of 1.0 0.000143348623853 0 1 -1
the,trials,due 1.0 0.000143348623853 0 1 -1
the,tremor,in 1.0 0.000143348623853 0 1 -1
the,treatments,to 1.0 0.000143348623853 0 1 -1
the,treatment,is 1.0 0.000143348623853 0 1 -1
the,treated,animals 1.0 0.000143348623853 0 1 -1
the,transport,ratio 1.0 0.000143348623853 0 1 -1
the,transport,of 1.0 0.000143348623853 0 1 -1
the,translocation,when 1.0 0.000143348623853 0 1 -1
the,translocation,of 1.0 0.000286697247706 0 2 -2
the,translocating,action 1.0 0.000143348623853 0 1 -1
the,transfusion,practices 1.0 0.000143348623853 0 1 -1
the,transcriptional,regulation 1.0 0.000143348623853 0 1 -1
the,trans-diol,by 1.0 0.000143348623853 0 1 -1
the,training,dose 1.0 0.000143348623853 0 1 -1
the,traction,of 1.0 0.000143348623853 0 1 -1
the,toxicokinetic,interferences 1.0 0.000143348623853 0 1 -1
the,toxicity,and 1.0 0.000143348623853 0 1 -1
the,toxic,product 1.0 0.000143348623853 0 1 -1
the,toxic,metabolites 1.0 0.000143348623853 0 1 -1
the,total,were 1.0 0.000143348623853 0 1 -1
the,total,picr 1.0 0.000143348623853 0 1 -1
the,total,exposure 1.0 0.000143348623853 0 1 -1
the,total,bioavailability 1.0 0.000143348623853 0 1 -1
the,total,amount 1.0 0.000143348623853 0 1 -1
the,tolerability,of 1.0 0.000143348623853 0 1 -1
the,to,nonopioid 1.0 0.000143348623853 0 1 -1
the,to,bind 1.0 0.000143348623853 0 1 -1
the,time,scale 1.0 0.000143348623853 0 1 -1
the,time,for 1.0 0.000143348623853 0 1 -1
the,three,types 1.0 0.000143348623853 0 1 -1
the,three,study 1.0 0.000143348623853 0 1 -1
the,three,groups 1.0 0.000143348623853 0 1 -1
the,three,concentrations 1.0 0.000143348623853 0 1 -1
the,third,group 1.0 0.000143348623853 0 1 -1
the,thioether,concentration 1.0 0.000143348623853 0 1 -1
the,thioether,assay 1.0 0.000143348623853 0 1 -1
the,therapy,standard 1.0 0.000143348623853 0 1 -1
the,therapeutic,value 1.0 0.000143348623853 0 1 -1
the,therapeutic,regimen 1.0 0.000286697247706 0 2 -2
the,therapeutic,interval 1.0 0.000143348623853 0 1 -1
the,therapeutic,doses 1.0 0.000143348623853 0 1 -1
the,therapeutic,dose 1.0 0.000143348623853 0 1 -1
the,therapeutic,benefit 1.0 0.000143348623853 0 1 -1
the,therapeutic,and 1.0 0.000143348623853 0 1 -1
the,that,inhibit 1.0 0.000716743119266 0 5 -5
the,that,could 1.0 0.000286697247706 0 2 -2
the,th,week 1.0 0.000143348623853 0 1 -1
the,th,generation 1.0 0.000143348623853 0 1 -1
the,th,and 1.0 0.000143348623853 0 1 -1
the,testes,and 1.0 0.000143348623853 0 1 -1
the,test,sample 1.0 0.000143348623853 0 1 -1
the,terms,viagra 1.0 0.000143348623853 0 1 -1
the,template,bleeding 1.0 0.000143348623853 0 1 -1
the,task,considered 1.0 0.000143348623853 0 1 -1
the,target,cell 1.0 0.000143348623853 0 1 -1
the,taking,into 1.0 0.000143348623853 0 1 -1
the,tail-flick,and 1.0 0.000143348623853 0 1 -1
the,synthesis,of 1.0 0.000286697247706 0 2 -2
the,syndrome,requires 1.0 0.000143348623853 0 1 -1
the,sympathetic,reflex 1.0 0.000143348623853 0 1 -1
the,sympathetic,nervous 1.0 0.000286697247706 0 2 -2
the,survanta,and 1.0 0.000143348623853 0 1 -1
the,suppression,test 1.0 0.000286697247706 0 2 -2
the,supplied,aerolizertm 1.0 0.000143348623853 0 1 -1
the,supplements,affect 1.0 0.000143348623853 0 1 -1
the,superiority,of 1.0 0.000143348623853 0 1 -1
the,sum,of 1.0 0.000143348623853 0 1 -1
the,suitability,of 1.0 0.000143348623853 0 1 -1
the,substrate,are 1.0 0.000143348623853 0 1 -1
the,substances,the 1.0 0.000143348623853 0 1 -1
the,subjective,and 1.0 0.000286697247706 0 2 -2
the,study,with 1.0 0.000143348623853 0 1 -1
the,study,were 1.0 0.000143348623853 0 1 -1
the,study,was 1.0 0.000143348623853 0 1 -1
the,study,regardless 1.0 0.000143348623853 0 1 -1
the,study,had 1.0 0.000143348623853 0 1 -1
the,study,dosed 1.0 0.000143348623853 0 1 -1
the,study,at 1.0 0.000143348623853 0 1 -1
the,study,and 1.0 0.000143348623853 0 1 -1
the,stress,of 1.0 0.000143348623853 0 1 -1
the,str,was 1.0 0.000143348623853 0 1 -1
the,str,or 1.0 0.000143348623853 0 1 -1
the,str,may 1.0 0.000143348623853 0 1 -1
the,store,from 1.0 0.000143348623853 0 1 -1
the,stomach,does 1.0 0.000143348623853 0 1 -1
the,stimulant,action 1.0 0.000143348623853 0 1 -1
the,stereoisomers,of 1.0 0.000143348623853 0 1 -1
the,steadystate,trough 1.0 0.000143348623853 0 1 -1
the,steady-state,pharmacokinetics 1.0 0.000573394495413 0 4 -4
the,steady-state,concentrations 1.0 0.000143348623853 0 1 -1
the,starting,dose 1.0 0.000286697247706 0 2 -2
the,sst,were 1.0 0.000143348623853 0 1 -1
the,sst,mice 1.0 0.000143348623853 0 1 -1
the,sst,and 1.0 0.000143348623853 0 1 -1
the,spleen,following 1.0 0.000143348623853 0 1 -1
the,spleen,and 1.0 0.000143348623853 0 1 -1
the,spinal,endorphinergic 1.0 0.000143348623853 0 1 -1
the,specific,toxicities 1.0 0.000143348623853 0 1 -1
the,specific,pharmacokinetic 1.0 0.000143348623853 0 1 -1
the,specific,objectives 1.0 0.000143348623853 0 1 -1
the,specific,isoenzyme 1.0 0.000143348623853 0 1 -1
the,specific,interaction 1.0 0.000143348623853 0 1 -1
the,soluble,to 1.0 0.000286697247706 0 2 -2
the,solubility,of 1.0 0.000143348623853 0 1 -1
the,sole,protease 1.0 0.000143348623853 0 1 -1
the,sole,indication 1.0 0.000143348623853 0 1 -1
the,smallest,effective 1.0 0.000143348623853 0 1 -1
the,small,magnitude 1.0 0.000143348623853 0 1 -1
the,small,gtp-binding 1.0 0.000143348623853 0 1 -1
the,slow,phasic 1.0 0.000143348623853 0 1 -1
the,sleeping,sickness 1.0 0.000143348623853 0 1 -1
the,size,of 1.0 0.000143348623853 0 1 -1
the,site,of 1.0 0.000286697247706 0 2 -2
the,single-dose,nature 1.0 0.000143348623853 0 1 -1
the,single,dose 1.0 0.000143348623853 0 1 -1
the,simplest,inference 1.0 0.000143348623853 0 1 -1
the,similarity,of 1.0 0.000143348623853 0 1 -1
the,signs,and 1.0 0.000143348623853 0 1 -1
the,significantly,affects 1.0 0.000143348623853 0 1 -1
the,significant,findings 1.0 0.000143348623853 0 1 -1
the,short-acting,adrenergic 1.0 0.000143348623853 0 1 -1
the,sexological,psychological 1.0 0.000143348623853 0 1 -1
the,several-fold,higher 1.0 0.000143348623853 0 1 -1
the,serum,supplemented 1.0 0.000143348623853 0 1 -1
the,serum,protein 1.0 0.000286697247706 0 2 -2
the,serotype,o11 1.0 0.000143348623853 0 1 -1
the,sensitivity,of 1.0 0.000286697247706 0 2 -2
the,seminiferous,tubules 1.0 0.000143348623853 0 1 -1
the,selective,toxicity 1.0 0.000143348623853 0 1 -1
the,selective,serotonin 1.0 0.000716743119266 0 5 -5
the,selective,regulation 1.0 0.000143348623853 0 1 -1
the,selection,of 1.0 0.000143348623853 0 1 -1
the,secretion,of 1.0 0.000143348623853 0 1 -1
the,second,test 1.0 0.000143348623853 0 1 -1
the,second,response 1.0 0.000143348623853 0 1 -1
the,second,pregnancy 1.0 0.000143348623853 0 1 -1
the,second,experiment 1.0 0.000143348623853 0 1 -1
the,second,contraction 1.0 0.000286697247706 0 2 -2
the,scale,of 1.0 0.000143348623853 0 1 -1
the,same,target 1.0 0.000143348623853 0 1 -1
the,same,study 1.0 0.000143348623853 0 1 -1
the,same,proportions 1.0 0.000143348623853 0 1 -1
the,same,procedures 1.0 0.000143348623853 0 1 -1
the,same,procedure 1.0 0.000286697247706 0 2 -2
the,same,pharmacological 1.0 0.000143348623853 0 1 -1
the,same,metabolic 1.0 0.000143348623853 0 1 -1
the,same,in 1.0 0.00043004587156 0 3 -3
the,same,group 1.0 0.000143348623853 0 1 -1
the,same,episode 1.0 0.000143348623853 0 1 -1
the,same,enzyme 1.0 0.000143348623853 0 1 -1
the,same,efficacy 1.0 0.000143348623853 0 1 -1
the,same,effects 1.0 0.000143348623853 0 1 -1
the,same,degree 1.0 0.000143348623853 0 1 -1
the,same,cytochrome 1.0 0.000143348623853 0 1 -1
the,same,areas 1.0 0.000143348623853 0 1 -1
the,same,age 1.0 0.000143348623853 0 1 -1
the,safety,profile 1.0 0.00043004587156 0 3 -3
the,safety,or 1.0 0.00043004587156 0 3 -3
the,safety,of 1.0 0.000286697247706 0 2 -2
the,sa,and 1.0 0.000143348623853 0 1 -1
the,roughly,twofold 1.0 0.000143348623853 0 1 -1
the,role,of 1.0 0.000716743119266 0 5 -5
the,risks,arising 1.0 0.000143348623853 0 1 -1
the,risk,to 1.0 0.000143348623853 0 1 -1
the,risk,and 1.0 0.000143348623853 0 1 -1
the,righting,reflex 1.0 0.000286697247706 0 2 -2
the,review,of 1.0 0.000143348623853 0 1 -1
the,results,we 1.0 0.000143348623853 0 1 -1
the,results,indicate 1.0 0.00043004587156 0 3 -3
the,results,generated 1.0 0.000143348623853 0 1 -1
the,results,from 1.0 0.00043004587156 0 3 -3
the,results,demonstrate 1.0 0.000143348623853 0 1 -1
the,resulting,mixture 1.0 0.000143348623853 0 1 -1
the,resulting,increase 1.0 0.000286697247706 0 2 -2
the,result,of 1.0 0.000143348623853 0 1 -1
the,result,is 1.0 0.000143348623853 0 1 -1
the,rest,were 1.0 0.000143348623853 0 1 -1
the,response,rates 1.0 0.000143348623853 0 1 -1
the,response,of 1.0 0.000286697247706 0 2 -2
the,resistance,or 1.0 0.000143348623853 0 1 -1
the,reservoir,function 1.0 0.000143348623853 0 1 -1
the,reported,dose 1.0 0.000143348623853 0 1 -1
the,reported,association 1.0 0.000143348623853 0 1 -1
the,repeat,dose 1.0 0.000143348623853 0 1 -1
the,renal,plasma 1.0 0.000143348623853 0 1 -1
the,renal,elimination 1.0 0.000143348623853 0 1 -1
the,renal,effects 1.0 0.000143348623853 0 1 -1
the,renal,and 1.0 0.000286697247706 0 2 -2
the,remaining,ci 1.0 0.000143348623853 0 1 -1
the,remaining,cases 1.0 0.000143348623853 0 1 -1
the,remainder,were 1.0 0.000143348623853 0 1 -1
the,remainder,no 1.0 0.000143348623853 0 1 -1
the,reluctance,to 1.0 0.000143348623853 0 1 -1
the,relevance,to 1.0 0.000143348623853 0 1 -1
the,release,whereas 1.0 0.000143348623853 0 1 -1
the,release,of 1.0 0.000860091743119 0 6 -6
the,release,but 1.0 0.000143348623853 0 1 -1
the,relative,risk 1.0 0.000143348623853 0 1 -1
the,relative,bioavailability 1.0 0.000143348623853 0 1 -1
the,relationship,to 1.0 0.000143348623853 0 1 -1
the,relationship,between 1.0 0.000143348623853 0 1 -1
the,relation,with 1.0 0.000143348623853 0 1 -1
the,relation,between 1.0 0.000143348623853 0 1 -1
the,regulation,of 1.0 0.000286697247706 0 2 -2
the,reduction,depending 1.0 0.000143348623853 0 1 -1
the,reduced,risk 1.0 0.000143348623853 0 1 -1
the,reduced,interaction 1.0 0.000143348623853 0 1 -1
the,reduced,absorption 1.0 0.000143348623853 0 1 -1
the,recording,pipette 1.0 0.000143348623853 0 1 -1
the,recommended,weekly 1.0 0.000143348623853 0 1 -1
the,recommended,twice 1.0 0.000143348623853 0 1 -1
the,recommended,human 1.0 0.000143348623853 0 1 -1
the,recommended,dosage 1.0 0.000143348623853 0 1 -1
the,recommendation,to 1.0 0.000143348623853 0 1 -1
the,recognition,of 1.0 0.000143348623853 0 1 -1
the,receptor-binding,activity 1.0 0.000143348623853 0 1 -1
the,reaction,after 1.0 0.000143348623853 0 1 -1
the,rd,th 1.0 0.000143348623853 0 1 -1
the,rbc,mice 1.0 0.000286697247706 0 2 -2
the,rats,were 1.0 0.000286697247706 0 2 -2
the,rats,treated 1.0 0.000143348623853 0 1 -1
the,ratios,of 1.0 0.000143348623853 0 1 -1
the,ratio,between 1.0 0.000143348623853 0 1 -1
the,rate-limiting,step 1.0 0.000143348623853 0 1 -1
the,rate,or 1.0 0.00043004587156 0 3 -3
the,rate,but 1.0 0.000286697247706 0 2 -2
the,rate,at 1.0 0.000143348623853 0 1 -1
the,rat,were 1.0 0.000143348623853 0 1 -1
the,rat,s 1.0 0.000143348623853 0 1 -1
the,range,reported 1.0 0.000143348623853 0 1 -1
the,range,of 1.0 0.000716743119266 0 5 -5
the,range,observed 1.0 0.000143348623853 0 1 -1
the,rabbit,following 1.0 0.000143348623853 0 1 -1
the,r-value,of 1.0 0.000286697247706 0 2 -2
the,r,and 1.0 0.000143348623853 0 1 -1
the,question,of 1.0 0.000143348623853 0 1 -1
the,qt0,on 1.0 0.000143348623853 0 1 -1
the,qt,qtc 1.0 0.000143348623853 0 1 -1
the,q-t,interval 1.0 0.000143348623853 0 1 -1
the,purpose,of 1.0 0.000286697247706 0 2 -2
the,purification,of 1.0 0.000143348623853 0 1 -1
the,pt,such 1.0 0.000143348623853 0 1 -1
the,psychostimulant,effects 1.0 0.000143348623853 0 1 -1
the,provide,close 1.0 0.000143348623853 0 1 -1
the,prothrombin,level 1.0 0.000143348623853 0 1 -1
the,proteins,that 1.0 0.000143348623853 0 1 -1
the,proposed,topical 1.0 0.000143348623853 0 1 -1
the,proposed,methodology 1.0 0.000143348623853 0 1 -1
the,proposed,mechanisms 1.0 0.000143348623853 0 1 -1
the,proportion,of 1.0 0.000143348623853 0 1 -1
the,properties,of 1.0 0.000143348623853 0 1 -1
the,promotion,of 1.0 0.000143348623853 0 1 -1
the,prolonged,survival 1.0 0.000143348623853 0 1 -1
the,profile,of 1.0 0.000143348623853 0 1 -1
the,problems,that 1.0 0.000143348623853 0 1 -1
the,problems,encountered 1.0 0.000143348623853 0 1 -1
the,principles,of 1.0 0.000143348623853 0 1 -1
the,principles,observed 1.0 0.000143348623853 0 1 -1
the,principal,given 1.0 0.000143348623853 0 1 -1
the,primary,metabolite 1.0 0.000143348623853 0 1 -1
the,primary,enzymes 1.0 0.000143348623853 0 1 -1
the,primary,addiction 1.0 0.000143348623853 0 1 -1
the,prevention,and 1.0 0.000143348623853 0 1 -1
the,prevalence,of 1.0 0.000716743119266 0 5 -5
the,pressor,agent 1.0 0.000286697247706 0 2 -2
the,pressor,activity 1.0 0.000143348623853 0 1 -1
the,preservation,of 1.0 0.000143348623853 0 1 -1
the,present,work 1.0 0.000143348623853 0 1 -1
the,present,study 1.0 0.000573394495413 0 4 -4
the,presence,or 1.0 0.00043004587156 0 3 -3
the,prescribing,information 1.0 0.000286697247706 0 2 -2
the,prescriber,when 1.0 0.000143348623853 0 1 -1
the,predominant,sterol 1.0 0.000143348623853 0 1 -1
the,predominant,plasma 1.0 0.000143348623853 0 1 -1
the,precipitate,is 1.0 0.000143348623853 0 1 -1
the,preceding,lists 1.0 0.000143348623853 0 1 -1
the,preceding,effect 1.0 0.000143348623853 0 1 -1
the,potentiation,resulted 1.0 0.000143348623853 0 1 -1
the,potentiation,of 1.0 0.000143348623853 0 1 -1
the,potential,that 1.0 0.000143348623853 0 1 -1
the,potential,nephrotoxicity 1.0 0.000143348623853 0 1 -1
the,potential,increased 1.0 0.000143348623853 0 1 -1
the,potential,effect 1.0 0.000143348623853 0 1 -1
the,potential,benefit 1.0 0.000143348623853 0 1 -1
the,potency,of 1.0 0.000143348623853 0 1 -1
the,potassium-depleted,solution 1.0 0.000143348623853 0 1 -1
the,possible,potentiation 1.0 0.000143348623853 0 1 -1
the,possible,effects 1.0 0.000143348623853 0 1 -1
the,possible,adverse 1.0 0.000286697247706 0 2 -2
the,possible,administration 1.0 0.000143348623853 0 1 -1
the,possibility,should 1.0 0.000143348623853 0 1 -1
the,positive,and 1.0 0.000143348623853 0 1 -1
the,porter-silber,test 1.0 0.000143348623853 0 1 -1
the,porter-silber,reaction 1.0 0.000143348623853 0 1 -1
the,population,pharmacokinetics 1.0 0.000143348623853 0 1 -1
the,population,has 1.0 0.000286697247706 0 2 -2
the,polymorphic,p450 1.0 0.000143348623853 0 1 -1
the,polymer,conjugates 1.0 0.000143348623853 0 1 -1
the,polyene,many 1.0 0.000143348623853 0 1 -1
the,platelets,in 1.0 0.000143348623853 0 1 -1
the,plasma,was 1.0 0.000143348623853 0 1 -1
the,plasma,protein 1.0 0.000286697247706 0 2 -2
the,plasma,pharmacokinetics 1.0 0.000143348623853 0 1 -1
the,plasma,of 1.0 0.000143348623853 0 1 -1
the,plasma,maximum 1.0 0.000143348623853 0 1 -1
the,plasma,lipid 1.0 0.000143348623853 0 1 -1
the,plasma,kinetics 1.0 0.000143348623853 0 1 -1
the,plasma,half-life 1.0 0.000143348623853 0 1 -1
the,plasma,enzymes 1.0 0.000143348623853 0 1 -1
the,placental,margin 1.0 0.000143348623853 0 1 -1
the,placebo-controlled,clinical 1.0 0.000143348623853 0 1 -1
the,pk,properties 1.0 0.000143348623853 0 1 -1
the,pituitary-gonadal,axis 1.0 0.000143348623853 0 1 -1
the,pituitary,secretion 1.0 0.000143348623853 0 1 -1
the,picr,so 1.0 0.000143348623853 0 1 -1
the,pi,over 1.0 0.000143348623853 0 1 -1
the,physiological,behavioral 1.0 0.000143348623853 0 1 -1
the,physician,wishing 1.0 0.000143348623853 0 1 -1
the,physician,is 1.0 0.000286697247706 0 2 -2
the,physician,even 1.0 0.000143348623853 0 1 -1
the,phosphohydrolase,from 1.0 0.000143348623853 0 1 -1
the,phosphohydrolase,becomes 1.0 0.000143348623853 0 1 -1
the,phenotype,of 1.0 0.000143348623853 0 1 -1
the,phase,study 1.0 0.000143348623853 0 1 -1
the,pharmacology-related,endocrine 1.0 0.000143348623853 0 1 -1
the,pharmacological,properties 1.0 0.000143348623853 0 1 -1
the,pharmacological,interactions 1.0 0.000143348623853 0 1 -1
the,pharmacological,action 1.0 0.000143348623853 0 1 -1
the,pharmacologic,mechanism 1.0 0.000143348623853 0 1 -1
the,pharmacokinetits,of 1.0 0.000143348623853 0 1 -1
the,pharmacokinetics,pharmacodynamics 1.0 0.000143348623853 0 1 -1
the,pharmacokinetics,or 1.0 0.000286697247706 0 2 -2
the,pharmacokinetics,exposure 1.0 0.000143348623853 0 1 -1
the,pharmacokinetics,and 1.0 0.000573394495413 0 4 -4
the,pharmacokinetic,variables 1.0 0.000143348623853 0 1 -1
the,pharmacokinetic,or 1.0 0.000143348623853 0 1 -1
the,pharmacokinetic,interactions 1.0 0.000143348623853 0 1 -1
the,pharmacokinetic,interaction 1.0 0.000143348623853 0 1 -1
the,pharmacokinetic,disposition 1.0 0.000143348623853 0 1 -1
the,pharmacokinetic,basis 1.0 0.000143348623853 0 1 -1
the,pharmacokinetic,and 1.0 0.000143348623853 0 1 -1
the,pharmacodynamics,prothrombin 1.0 0.000143348623853 0 1 -1
the,pharmacodynamics,or 1.0 0.000143348623853 0 1 -1
the,pharmacodynamics,of 1.0 0.000716743119266 0 5 -5
the,pharmacodynamics,blood 1.0 0.000143348623853 0 1 -1
the,pharmacodynamic,profile 1.0 0.000143348623853 0 1 -1
the,pharmacodynamic,effect 1.0 0.00043004587156 0 3 -3
the,pharmacodynamic,consequences 1.0 0.000143348623853 0 1 -1
the,pesticide,the 1.0 0.000143348623853 0 1 -1
the,pesticide,gliftor 1.0 0.000143348623853 0 1 -1
the,persistence,of 1.0 0.000143348623853 0 1 -1
the,permeation,however 1.0 0.000143348623853 0 1 -1
the,permeability,of 1.0 0.000143348623853 0 1 -1
the,peritoneal,cavity 1.0 0.000143348623853 0 1 -1
the,peripheral,vascular 1.0 0.000143348623853 0 1 -1
the,perfused,pancreas 1.0 0.000143348623853 0 1 -1
the,pelvic,girdle 1.0 0.000143348623853 0 1 -1
the,peak,levels 1.0 0.000143348623853 0 1 -1
the,peak,concentration 1.0 0.00043004587156 0 3 -3
the,peak,b 1.0 0.000143348623853 0 1 -1
the,pd2,values 1.0 0.000143348623853 0 1 -1
the,pattern,of 1.0 0.000143348623853 0 1 -1
the,patients,who 1.0 0.00043004587156 0 3 -3
the,patients,were 1.0 0.000143348623853 0 1 -1
the,patients,treated 1.0 0.00043004587156 0 3 -3
the,patients,serum 1.0 0.000143348623853 0 1 -1
the,patients,receiving 1.0 0.000143348623853 0 1 -1
the,patients,on 1.0 0.000143348623853 0 1 -1
the,patients,in 1.0 0.000143348623853 0 1 -1
the,patients,gland 1.0 0.000143348623853 0 1 -1
the,patients,as 1.0 0.000143348623853 0 1 -1
the,patient,with 1.0 0.000286697247706 0 2 -2
the,patient,was 1.0 0.000573394495413 0 4 -4
the,patient,s 1.0 0.000143348623853 0 1 -1
the,patient,population 1.0 0.000143348623853 0 1 -1
the,patient,or 1.0 0.000143348623853 0 1 -1
the,patient,must 1.0 0.000143348623853 0 1 -1
the,patient,interferes 1.0 0.000143348623853 0 1 -1
the,patient,in 1.0 0.000143348623853 0 1 -1
the,patient,had 1.0 0.000143348623853 0 1 -1
the,patient,for 1.0 0.000286697247706 0 2 -2
the,patient,feels 1.0 0.000143348623853 0 1 -1
the,patient,continued 1.0 0.000143348623853 0 1 -1
the,pathway,that 1.0 0.000143348623853 0 1 -1
the,pathophysiologic,consequences 1.0 0.000143348623853 0 1 -1
the,pathogenic,species 1.0 0.000143348623853 0 1 -1
the,patch-clamp,whole-cell 1.0 0.000143348623853 0 1 -1
the,patch,pipette 1.0 0.000143348623853 0 1 -1
the,particular,mao 1.0 0.000143348623853 0 1 -1
the,parietal,cell 1.0 0.000143348623853 0 1 -1
the,parenteral,route 1.0 0.000143348623853 0 1 -1
the,parental,mcf-7 1.0 0.000143348623853 0 1 -1
the,parameters,and 1.0 0.000143348623853 0 1 -1
the,paraaminohippurate,method 1.0 0.000143348623853 0 1 -1
the,para-aminobenzoic,acid 1.0 0.000143348623853 0 1 -1
the,pancreatic,effects 1.0 0.000143348623853 0 1 -1
the,pancreatic,alpha 1.0 0.000143348623853 0 1 -1
the,palytoxin-induced,contraction 1.0 0.000143348623853 0 1 -1
the,package,inserts 1.0 0.000143348623853 0 1 -1
the,p-glycoprotein,transporter 1.0 0.000143348623853 0 1 -1
the,overall,direct 1.0 0.000143348623853 0 1 -1
the,outset,of 1.0 0.000143348623853 0 1 -1
the,outcome,of 1.0 0.000143348623853 0 1 -1
the,other,which 1.0 0.000143348623853 0 1 -1
the,other,that 1.0 0.000143348623853 0 1 -1
the,other,isozymes 1.0 0.000143348623853 0 1 -1
the,other,isoforms 1.0 0.000143348623853 0 1 -1
the,other,drug 1.0 0.000143348623853 0 1 -1
the,other,currently 1.0 0.000143348623853 0 1 -1
the,other,agents 1.0 0.000143348623853 0 1 -1
the,other,agent 1.0 0.000143348623853 0 1 -1
the,other,added 1.0 0.000143348623853 0 1 -1
the,original,medication 1.0 0.000143348623853 0 1 -1
the,organic,cationic 1.0 0.000143348623853 0 1 -1
the,order,of 1.0 0.000143348623853 0 1 -1
the,oral,self-administration 1.0 0.000143348623853 0 1 -1
the,oral,route 1.0 0.000143348623853 0 1 -1
the,oral,has 1.0 0.000143348623853 0 1 -1
the,oral,formulation 1.0 0.000143348623853 0 1 -1
the,oral,contraceptive 1.0 0.000143348623853 0 1 -1
the,oral,compared 1.0 0.000143348623853 0 1 -1
the,or,mg 1.0 0.000143348623853 0 1 -1
the,optimal,therapeutic 1.0 0.000143348623853 0 1 -1
the,optimal,dosing 1.0 0.000143348623853 0 1 -1
the,optimal,dose 1.0 0.000286697247706 0 2 -2
the,only,protein 1.0 0.000143348623853 0 1 -1
the,offspring,delivered 1.0 0.000143348623853 0 1 -1
the,odontoid,and 1.0 0.000143348623853 0 1 -1
the,octapeptide,cholecystokinin--of 1.0 0.000143348623853 0 1 -1
the,obstetrical,cardiological 1.0 0.000143348623853 0 1 -1
the,observed,training-induced 1.0 0.000143348623853 0 1 -1
the,objective,of 1.0 0.000143348623853 0 1 -1
the,nursing,infant 1.0 0.000143348623853 0 1 -1
the,nueronal,cell 1.0 0.000143348623853 0 1 -1
the,nucleus,accumbens 1.0 0.000143348623853 0 1 -1
the,nrtis,are 1.0 0.000143348623853 0 1 -1
the,not,only 1.0 0.000143348623853 0 1 -1
the,normal,value 1.0 0.000143348623853 0 1 -1
the,normal,range 1.0 0.000143348623853 0 1 -1
the,normal,or 1.0 0.000143348623853 0 1 -1
the,normal,cells 1.0 0.000143348623853 0 1 -1
the,normal,antiasthmatic 1.0 0.000143348623853 0 1 -1
the,nonpredisposed,strain 1.0 0.000143348623853 0 1 -1
the,nonlinear,kinetic 1.0 0.000143348623853 0 1 -1
the,non-myelinated,axons 1.0 0.000286697247706 0 2 -2
the,nitrobluetetrazolium,test 1.0 0.000143348623853 0 1 -1
the,ninth,day 1.0 0.000143348623853 0 1 -1
the,ninds,t-pa 1.0 0.000143348623853 0 1 -1
the,next,chapter 1.0 0.000286697247706 0 2 -2
the,new,anaesthetic 1.0 0.000143348623853 0 1 -1
the,neutrophil,count 1.0 0.000143348623853 0 1 -1
the,neuronal,apparatus 1.0 0.000143348623853 0 1 -1
the,neurochemical,and 1.0 0.000143348623853 0 1 -1
the,net,effect 1.0 0.000143348623853 0 1 -1
the,nerves,and 1.0 0.000143348623853 0 1 -1
the,nerve,transmission 1.0 0.000143348623853 0 1 -1
the,nephrotoxicity,and 1.0 0.000143348623853 0 1 -1
the,negative,symptoms 1.0 0.000143348623853 0 1 -1
the,negative,chronotropic 1.0 0.000143348623853 0 1 -1
the,need,to 1.0 0.00043004587156 0 3 -3
the,nature,of 1.0 0.000286697247706 0 2 -2
the,nac,decreased 1.0 0.000143348623853 0 1 -1
the,nac,and 1.0 0.000143348623853 0 1 -1
the,myelotoxicity,of 1.0 0.000143348623853 0 1 -1
the,muscle,was 1.0 0.000143348623853 0 1 -1
the,mucosal,cells 1.0 0.000143348623853 0 1 -1
the,mucosal,and 1.0 0.000143348623853 0 1 -1
the,mucocutaneous,and 1.0 0.000143348623853 0 1 -1
the,mouse,mammary 1.0 0.000143348623853 0 1 -1
the,most,significant 1.0 0.000143348623853 0 1 -1
the,most,potent 1.0 0.00043004587156 0 3 -3
the,most,out 1.0 0.000143348623853 0 1 -1
the,most,effective 1.0 0.000143348623853 0 1 -1
the,most,common 1.0 0.00043004587156 0 3 -3
the,mortality,rate 1.0 0.000143348623853 0 1 -1
the,morning,dose 1.0 0.000143348623853 0 1 -1
the,more,specific 1.0 0.000143348623853 0 1 -1
the,morbidity,from 1.0 0.000143348623853 0 1 -1
the,months,after 1.0 0.000143348623853 0 1 -1
the,monomeric,disintegrins 1.0 0.000143348623853 0 1 -1
the,monoamine,oxidase 1.0 0.000143348623853 0 1 -1
the,modulatory,effect 1.0 0.000143348623853 0 1 -1
the,modified,histidine 1.0 0.000143348623853 0 1 -1
the,model,peptide 1.0 0.000143348623853 0 1 -1
the,mode,of 1.0 0.000286697247706 0 2 -2
the,minor,side 1.0 0.000143348623853 0 1 -1
the,minimum,inhibitory 1.0 0.000143348623853 0 1 -1
the,minimum,effective 1.0 0.000143348623853 0 1 -1
the,minimal,inhibitory 1.0 0.000286697247706 0 2 -2
the,milk,secretion 1.0 0.000143348623853 0 1 -1
the,microvascular,complications 1.0 0.000143348623853 0 1 -1
the,microtubules,was 1.0 0.000143348623853 0 1 -1
the,microsomal,metabolizing 1.0 0.000143348623853 0 1 -1
the,microsomal,fraction 1.0 0.00043004587156 0 3 -3
the,mg,oral 1.0 0.000143348623853 0 1 -1
the,mg,kg 1.0 0.000143348623853 0 1 -1
the,mg,dosage 1.0 0.000143348623853 0 1 -1
the,metabolizing,isozyme 1.0 0.000573394495413 0 4 -4
the,metabolite,ucb 1.0 0.000143348623853 0 1 -1
the,metabolite,of 1.0 0.000143348623853 0 1 -1
the,metabolism,may 1.0 0.000143348623853 0 1 -1
the,metabolism,and 1.0 0.00043004587156 0 3 -3
the,mesenteric,resistance 1.0 0.000143348623853 0 1 -1
the,mentioned,above 1.0 0.000143348623853 0 1 -1
the,menstrual,period 1.0 0.000143348623853 0 1 -1
the,medium,blocked 1.0 0.000143348623853 0 1 -1
the,medications,most 1.0 0.000143348623853 0 1 -1
the,medication,interferes 1.0 0.000143348623853 0 1 -1
the,medication,authorization 1.0 0.000143348623853 0 1 -1
the,mediation,of 1.0 0.000143348623853 0 1 -1
the,mediated,reduction 1.0 0.000143348623853 0 1 -1
the,median,tmax 1.0 0.000143348623853 0 1 -1
the,median,survival 1.0 0.000143348623853 0 1 -1
the,medial,survival 1.0 0.000143348623853 0 1 -1
the,mechanisms,underlying 1.0 0.000143348623853 0 1 -1
the,mechanisms,of 1.0 0.000143348623853 0 1 -1
the,mechanism,underlying 1.0 0.000143348623853 0 1 -1
the,mechanism,s 1.0 0.000286697247706 0 2 -2
the,mechanism,and 1.0 0.000143348623853 0 1 -1
the,mean,values 1.0 0.000143348623853 0 1 -1
the,mean,value 1.0 0.000143348623853 0 1 -1
the,mean,t 1.0 0.000143348623853 0 1 -1
the,mean,steady-state 1.0 0.000143348623853 0 1 -1
the,mean,sd 1.0 0.000143348623853 0 1 -1
the,mean,reduction 1.0 0.000143348623853 0 1 -1
the,mean,minimum 1.0 0.00043004587156 0 3 -3
the,mean,estimates 1.0 0.000143348623853 0 1 -1
the,mean,drug 1.0 0.000143348623853 0 1 -1
the,mean,distribution 1.0 0.000143348623853 0 1 -1
the,mean,daily 1.0 0.000143348623853 0 1 -1
the,mean,concentrations 1.0 0.000143348623853 0 1 -1
the,mean,changes 1.0 0.000143348623853 0 1 -1
the,mean,c 1.0 0.000143348623853 0 1 -1
the,mean,auc 1.0 0.000573394495413 0 4 -4
the,mean,area 1.0 0.000143348623853 0 1 -1
the,may,require 1.0 0.000286697247706 0 2 -2
the,may,however 1.0 0.000143348623853 0 1 -1
the,maximum,tolerated 1.0 0.000143348623853 0 1 -1
the,maximum,human 1.0 0.000143348623853 0 1 -1
the,maximum,concentration 1.0 0.000143348623853 0 1 -1
the,maximal,effects 1.0 0.000143348623853 0 1 -1
the,marrow,toxicity 1.0 0.000143348623853 0 1 -1
the,mao-b,inhibitor 1.0 0.000143348623853 0 1 -1
the,manufacturer,or 1.0 0.000143348623853 0 1 -1
the,management,and 1.0 0.000143348623853 0 1 -1
the,mammary,gland 1.0 0.000286697247706 0 2 -2
the,male,partners 1.0 0.000143348623853 0 1 -1
the,majority,of 1.0 0.000573394495413 0 4 -4
the,major,subtype 1.0 0.000143348623853 0 1 -1
the,major,serum 1.0 0.000143348623853 0 1 -1
the,major,metabolites 1.0 0.000143348623853 0 1 -1
the,major,membrane 1.0 0.000143348623853 0 1 -1
the,major,ingredient 1.0 0.000143348623853 0 1 -1
the,major,cytochrome 1.0 0.000573394495413 0 4 -4
the,major,cyp 1.0 0.000143348623853 0 1 -1
the,major,circulating 1.0 0.000143348623853 0 1 -1
the,maintenance,of 1.0 0.000143348623853 0 1 -1
the,main,non-infection 1.0 0.000143348623853 0 1 -1
the,main,indications 1.0 0.000143348623853 0 1 -1
the,magnitude,or 1.0 0.000143348623853 0 1 -1
the,m1,cmax 1.0 0.000143348623853 0 1 -1
the,lysate,of 1.0 0.000143348623853 0 1 -1
the,lysate,derived 1.0 0.000143348623853 0 1 -1
the,lymphoid,malignancy 1.0 0.000143348623853 0 1 -1
the,luteinizing,hormone 1.0 0.000143348623853 0 1 -1
the,lumen,at 1.0 0.000143348623853 0 1 -1
the,lst,mice 1.0 0.00043004587156 0 3 -3
the,low,dietary 1.0 0.000143348623853 0 1 -1
the,longterm,treatment 1.0 0.000143348623853 0 1 -1
the,long-term,safety 1.0 0.000143348623853 0 1 -1
the,long-term,administration 1.0 0.000143348623853 0 1 -1
the,long,and 1.0 0.000143348623853 0 1 -1
the,locomotor,and 1.0 0.000143348623853 0 1 -1
the,locomotor,activities 1.0 0.000143348623853 0 1 -1
the,location,histologic 1.0 0.000143348623853 0 1 -1
the,liver,weight 1.0 0.000143348623853 0 1 -1
the,liver,was 1.0 0.000143348623853 0 1 -1
the,liver,via 1.0 0.000143348623853 0 1 -1
the,liver,to 1.0 0.000143348623853 0 1 -1
the,liver,microsomes 1.0 0.000143348623853 0 1 -1
the,liver,gallbladder 1.0 0.000143348623853 0 1 -1
the,liver,by 1.0 0.000286697247706 0 2 -2
the,literature,that 1.0 0.000143348623853 0 1 -1
the,literature,suggests 1.0 0.000143348623853 0 1 -1
the,literature,reports 1.0 0.000143348623853 0 1 -1
the,literature,provides 1.0 0.000143348623853 0 1 -1
the,listed,isoforms 1.0 0.000143348623853 0 1 -1
the,listed,below 1.0 0.000143348623853 0 1 -1
the,lipid-lowering,activity 1.0 0.000143348623853 0 1 -1
the,lipid,response 1.0 0.000286697247706 0 2 -2
the,link,between 1.0 0.000143348623853 0 1 -1
the,limits,of 1.0 0.000143348623853 0 1 -1
the,limbic,system 1.0 0.000286697247706 0 2 -2
the,light,dark 1.0 0.000143348623853 0 1 -1
the,levorotatory,isomer 1.0 0.000143348623853 0 1 -1
the,levels,shown 1.0 0.000143348623853 0 1 -1
the,levels,effects 1.0 0.000143348623853 0 1 -1
the,length,of 1.0 0.000143348623853 0 1 -1
the,lectin,and 1.0 0.000143348623853 0 1 -1
the,leakage,of 1.0 0.000143348623853 0 1 -1
the,latter,might 1.0 0.000143348623853 0 1 -1
the,latency,to 1.0 0.000143348623853 0 1 -1
the,last,years 1.0 0.000143348623853 0 1 -1
the,last,two 1.0 0.000143348623853 0 1 -1
the,last,morning 1.0 0.000143348623853 0 1 -1
the,last,day 1.0 0.000143348623853 0 1 -1
the,last,chapters 1.0 0.000143348623853 0 1 -1
the,last,act 1.0 0.000143348623853 0 1 -1
the,large,placebo-controlled 1.0 0.000143348623853 0 1 -1
the,lack,of 1.0 0.00043004587156 0 3 -3
the,labeling,index 1.0 0.000143348623853 0 1 -1
the,known,relationships 1.0 0.000143348623853 0 1 -1
the,known,inhibition 1.0 0.000286697247706 0 2 -2
the,known,cytochrome 1.0 0.000143348623853 0 1 -1
the,kidneys,coadministration 1.0 0.000143348623853 0 1 -1
the,kidneys,along 1.0 0.000143348623853 0 1 -1
the,kidney,which 1.0 0.000143348623853 0 1 -1
the,kidney,by 1.0 0.000143348623853 0 1 -1
the,kidney,and 1.0 0.000143348623853 0 1 -1
the,key,to 1.0 0.000143348623853 0 1 -1
the,kd,of 1.0 0.000143348623853 0 1 -1
the,kd,and 1.0 0.000143348623853 0 1 -1
the,k,contribution 1.0 0.000143348623853 0 1 -1
the,joint,dose-response 1.0 0.000143348623853 0 1 -1
the,jaffe,reaction 1.0 0.000143348623853 0 1 -1
the,jaff,reaction 1.0 0.000143348623853 0 1 -1
the,is,required 1.0 0.000143348623853 0 1 -1
the,is,only 1.0 0.000143348623853 0 1 -1
the,is,maintained 1.0 0.000143348623853 0 1 -1
the,is,clinically 1.0 0.000143348623853 0 1 -1
the,is,administered 1.0 0.000143348623853 0 1 -1
the,inulin,method 1.0 0.000143348623853 0 1 -1
the,introductory,chapter 1.0 0.000143348623853 0 1 -1
the,intravenous,topical 1.0 0.00043004587156 0 3 -3
the,intravenous,route 1.0 0.000143348623853 0 1 -1
the,intravenous,prodrug 1.0 0.000286697247706 0 2 -2
the,intravenous,application 1.0 0.000143348623853 0 1 -1
the,intestine,kidneys 1.0 0.00043004587156 0 3 -3
the,intestinal,permeation 1.0 0.000286697247706 0 2 -2
the,intestinal,lumen 1.0 0.000143348623853 0 1 -1
the,intestinal,absorption 1.0 0.000143348623853 0 1 -1
the,intervals,usually 1.0 0.000143348623853 0 1 -1
the,interval,between 1.0 0.000143348623853 0 1 -1
the,interpretation,of 1.0 0.000143348623853 0 1 -1
the,international,literature 1.0 0.000143348623853 0 1 -1
the,interindividual,pharmacokinetic 1.0 0.000143348623853 0 1 -1
the,interference,of 1.0 0.000143348623853 0 1 -1
the,interactions,of 1.0 0.000143348623853 0 1 -1
the,interactions,noted 1.0 0.000143348623853 0 1 -1
the,interactions,between 1.0 0.000143348623853 0 1 -1
the,interaction,was 1.0 0.000286697247706 0 2 -2
the,interaction,studies 1.0 0.000143348623853 0 1 -1
the,interaction,on 1.0 0.000143348623853 0 1 -1
the,interaction,of 1.0 0.00129013761468 0 9 -9
the,interaction,may 1.0 0.000143348623853 0 1 -1
the,interaction,effects 1.0 0.000143348623853 0 1 -1
the,interaction,data 1.0 0.00043004587156 0 3 -3
the,interaction,can 1.0 0.000143348623853 0 1 -1
the,interaction,began 1.0 0.000143348623853 0 1 -1
the,intensity,uniformity 1.0 0.000143348623853 0 1 -1
the,intake,and 1.0 0.000143348623853 0 1 -1
the,insulin-sensitizing,effects 1.0 0.000143348623853 0 1 -1
the,insp,or 1.0 0.000143348623853 0 1 -1
the,insp,mediated 1.0 0.000143348623853 0 1 -1
the,inr,was 1.0 0.000143348623853 0 1 -1
the,injection,site 1.0 0.000143348623853 0 1 -1
the,injection,should 1.0 0.000143348623853 0 1 -1
the,initiated,cells 1.0 0.000143348623853 0 1 -1
the,initial,treatment 1.0 0.000143348623853 0 1 -1
the,initial,step 1.0 0.000143348623853 0 1 -1
the,initial,clinical 1.0 0.000143348623853 0 1 -1
the,inhibits,the 1.0 0.000143348623853 0 1 -1
the,inhibitory,potential 1.0 0.000143348623853 0 1 -1
the,inhibitory,action 1.0 0.000143348623853 0 1 -1
the,inhibitor,on 1.0 0.000143348623853 0 1 -1
the,inhibiting,effects 1.0 0.000143348623853 0 1 -1
the,infusion,site 1.0 0.000143348623853 0 1 -1
the,influence,of 1.0 0.000860091743119 0 6 -6
the,individual,compounds 1.0 0.000143348623853 0 1 -1
the,individual,case 1.0 0.000143348623853 0 1 -1
the,individual,and 1.0 0.000143348623853 0 1 -1
the,increased,regional 1.0 0.000143348623853 0 1 -1
the,increased,plasma 1.0 0.000143348623853 0 1 -1
the,in,the 1.0 0.000143348623853 0 1 -1
the,in,situ 1.0 0.000143348623853 0 1 -1
the,in,nursing 1.0 0.000143348623853 0 1 -1
the,importance,of 1.0 0.00043004587156 0 3 -3
the,implications,of 1.0 0.000143348623853 0 1 -1
the,impairment,of 1.0 0.000143348623853 0 1 -1
the,impact,of 1.0 0.00043004587156 0 3 -3
the,immunodepressant--the,sandimmune--on 1.0 0.000143348623853 0 1 -1
the,immune,system 1.0 0.000143348623853 0 1 -1
the,immune,response 1.0 0.000143348623853 0 1 -1
the,immediate,side 1.0 0.000143348623853 0 1 -1
the,identity,of 1.0 0.000143348623853 0 1 -1
the,identification,of 1.0 0.000286697247706 0 2 -2
the,ic,was 1.0 0.000143348623853 0 1 -1
the,ibandronate,osteoporosis 1.0 0.000143348623853 0 1 -1
the,iatrogenic,alteration 1.0 0.000143348623853 0 1 -1
the,hypothesis,that 1.0 0.000143348623853 0 1 -1
the,hypothesis,of 1.0 0.000143348623853 0 1 -1
the,hypothalamic-pituitary,testicular 1.0 0.000143348623853 0 1 -1
the,hypoprothrombinemic,effect 1.0 0.000143348623853 0 1 -1
the,hyperplasia,observed 1.0 0.000143348623853 0 1 -1
the,hydroxytamoxifen,tam 1.0 0.000143348623853 0 1 -1
the,hydroxylation,during 1.0 0.000143348623853 0 1 -1
the,hydrophilic,molecule 1.0 0.000143348623853 0 1 -1
the,hydroalcoholic,solutions 1.0 0.000143348623853 0 1 -1
the,human,weekly 1.0 0.000143348623853 0 1 -1
the,human,recommended 1.0 0.000286697247706 0 2 -2
the,human,plasma 1.0 0.000143348623853 0 1 -1
the,human,liver 1.0 0.000143348623853 0 1 -1
the,human,dose 1.0 0.00114678899083 0 8 -8
the,human,cytochrome 1.0 0.000286697247706 0 2 -2
the,human,auc 1.0 0.000143348623853 0 1 -1
the,ht3,zofran 1.0 0.000143348623853 0 1 -1
the,hplc,peak 1.0 0.000143348623853 0 1 -1
the,hour,observation 1.0 0.000143348623853 0 1 -1
the,hour,lag 1.0 0.000143348623853 0 1 -1
the,hour,infusion 1.0 0.000143348623853 0 1 -1
the,hospital,for 1.0 0.000143348623853 0 1 -1
the,horses,from 1.0 0.000143348623853 0 1 -1
the,homodimeric,structure 1.0 0.000143348623853 0 1 -1
the,homodimeric,disintegrin 1.0 0.000143348623853 0 1 -1
the,homocysteine,excretion 1.0 0.000143348623853 0 1 -1
the,history,prior 1.0 0.000143348623853 0 1 -1
the,histology,of 1.0 0.000143348623853 0 1 -1
the,histidine,residues 1.0 0.000143348623853 0 1 -1
the,hippocampus,would 1.0 0.000143348623853 0 1 -1
the,hippocampus,is 1.0 0.000143348623853 0 1 -1
the,hippocampus,and 1.0 0.000143348623853 0 1 -1
the,hind,paw 1.0 0.000143348623853 0 1 -1
the,highest,dose 1.0 0.000143348623853 0 1 -1
the,higher,end 1.0 0.000143348623853 0 1 -1
the,higher,concentrations 1.0 0.000143348623853 0 1 -1
the,higher,and 1.0 0.000143348623853 0 1 -1
the,high,dose 1.0 0.000143348623853 0 1 -1
the,high,acquisition 1.0 0.000143348623853 0 1 -1
the,herbal,supplement 1.0 0.000143348623853 0 1 -1
the,hepatic,metabolic 1.0 0.000143348623853 0 1 -1
the,hematopoietic,system 1.0 0.000143348623853 0 1 -1
the,heat,stimulus 1.0 0.000143348623853 0 1 -1
the,hazards,of 1.0 0.000143348623853 0 1 -1
the,hatching,of 1.0 0.000143348623853 0 1 -1
the,has,been 1.0 0.000143348623853 0 1 -1
the,harmonic,mean 1.0 0.000143348623853 0 1 -1
the,half-life,increased 1.0 0.000143348623853 0 1 -1
the,growth,response 1.0 0.000143348623853 0 1 -1
the,growth,of 1.0 0.00043004587156 0 3 -3
the,groups,then 1.0 0.000143348623853 0 1 -1
the,groups,fed 1.0 0.000143348623853 0 1 -1
the,group,the 1.0 0.000143348623853 0 1 -1
the,group,that 1.0 0.000286697247706 0 2 -2
the,greatest,value 1.0 0.000143348623853 0 1 -1
the,gradual,withdrawal 1.0 0.000143348623853 0 1 -1
the,gonadotropin,levels 1.0 0.000143348623853 0 1 -1
the,goal,of 1.0 0.000286697247706 0 2 -2
the,glucosylation,of 1.0 0.000143348623853 0 1 -1
the,glucosyl,transferase 1.0 0.000143348623853 0 1 -1
the,glucose,oxidase 1.0 0.000286697247706 0 2 -2
the,glucocorticoid-induced,gene 1.0 0.000286697247706 0 2 -2
the,glands,with 1.0 0.000286697247706 0 2 -2
the,germinal,centers 1.0 0.000143348623853 0 1 -1
the,geriatric,population 1.0 0.000286697247706 0 2 -2
the,genotypes,of 1.0 0.000143348623853 0 1 -1
the,genetically,nervous 1.0 0.000143348623853 0 1 -1
the,genetically,diabetic 1.0 0.000143348623853 0 1 -1
the,general,public 1.0 0.000143348623853 0 1 -1
the,general,population 1.0 0.00043004587156 0 3 -3
the,general,conditions 1.0 0.000143348623853 0 1 -1
the,general,concern 1.0 0.000143348623853 0 1 -1
the,gastrointestinal,ph 1.0 0.000143348623853 0 1 -1
the,functional,integrity 1.0 0.000143348623853 0 1 -1
the,function,as 1.0 0.000286697247706 0 2 -2
the,full,duration 1.0 0.000143348623853 0 1 -1
the,full,dose 1.0 0.000143348623853 0 1 -1
the,frontal,cortex 1.0 0.000143348623853 0 1 -1
the,frequent,occurrence 1.0 0.000143348623853 0 1 -1
the,french,non-governmental 1.0 0.000143348623853 0 1 -1
the,free,fraction 1.0 0.000286697247706 0 2 -2
the,free,concentration 1.0 0.000143348623853 0 1 -1
the,fractional,inhibitory 1.0 0.000143348623853 0 1 -1
the,fraction,of 1.0 0.000860091743119 0 6 -6
the,fraction,containing 1.0 0.000143348623853 0 1 -1
the,fourth,group 1.0 0.000143348623853 0 1 -1
the,force,of 1.0 0.000143348623853 0 1 -1
the,for,urinary 1.0 0.000143348623853 0 1 -1
the,following,was 1.0 0.000143348623853 0 1 -1
the,following,table 1.0 0.000286697247706 0 2 -2
the,following,symptoms 1.0 0.000143348623853 0 1 -1
the,following,specific 1.0 0.000143348623853 0 1 -1
the,following,six 1.0 0.000143348623853 0 1 -1
the,following,situations 1.0 0.000143348623853 0 1 -1
the,following,similar 1.0 0.000286697247706 0 2 -2
the,following,protease 1.0 0.000143348623853 0 1 -1
the,following,other 1.0 0.000143348623853 0 1 -1
the,following,or 1.0 0.000143348623853 0 1 -1
the,following,observations 1.0 0.000143348623853 0 1 -1
the,following,nicotinic 1.0 0.000143348623853 0 1 -1
the,following,lipid-lowering 1.0 0.000143348623853 0 1 -1
the,following,laboratory 1.0 0.000143348623853 0 1 -1
the,following,information 1.0 0.000286697247706 0 2 -2
the,following,immunosuppressives 1.0 0.000143348623853 0 1 -1
the,following,have 1.0 0.000143348623853 0 1 -1
the,following,enzymes 1.0 0.000143348623853 0 1 -1
the,following,eight 1.0 0.000143348623853 0 1 -1
the,following,drug 1.0 0.000143348623853 0 1 -1
the,following,cyclosporine 1.0 0.000143348623853 0 1 -1
the,following,concomitant 1.0 0.000143348623853 0 1 -1
the,following,blood 1.0 0.000143348623853 0 1 -1
the,following,beta-adrenergic 1.0 0.000143348623853 0 1 -1
the,following,antibiotics 1.0 0.000143348623853 0 1 -1
the,following,anti-anxiety 1.0 0.000143348623853 0 1 -1
the,flavonoids,alone 1.0 0.000143348623853 0 1 -1
the,fischer-344,strain 1.0 0.000143348623853 0 1 -1
the,first,year 1.0 0.000143348623853 0 1 -1
the,first,test 1.0 0.000143348623853 0 1 -1
the,first,synthetic 1.0 0.000143348623853 0 1 -1
the,first,step 1.0 0.000143348623853 0 1 -1
the,first,response 1.0 0.000143348623853 0 1 -1
the,first,post-transplant 1.0 0.000143348623853 0 1 -1
the,first,phase 1.0 0.000143348623853 0 1 -1
the,first,month 1.0 0.000143348623853 0 1 -1
the,first,hours 1.0 0.000143348623853 0 1 -1
the,first,double-blind 1.0 0.000143348623853 0 1 -1
the,first,dose 1.0 0.000143348623853 0 1 -1
the,first,days 1.0 0.000143348623853 0 1 -1
the,first,day 1.0 0.000143348623853 0 1 -1
the,first,contractile 1.0 0.000143348623853 0 1 -1
the,first,cervical 1.0 0.000143348623853 0 1 -1
the,first,and 1.0 0.000143348623853 0 1 -1
the,findings,suggest 1.0 0.000143348623853 0 1 -1
the,findings,of 1.0 0.000143348623853 0 1 -1
the,fetus,due 1.0 0.000143348623853 0 1 -1
the,fetal,immune 1.0 0.000143348623853 0 1 -1
the,fertility,of 1.0 0.00043004587156 0 3 -3
the,ferricyanide,test 1.0 0.000286697247706 0 2 -2
the,female,patient 1.0 0.000143348623853 0 1 -1
the,feasibility,and 1.0 0.000143348623853 0 1 -1
the,fda,have 1.0 0.000143348623853 0 1 -1
the,failing,heart 1.0 0.000143348623853 0 1 -1
the,factrel,test 1.0 0.000143348623853 0 1 -1
the,extremities,and 1.0 0.000286697247706 0 2 -2
the,extent,and 1.0 0.000143348623853 0 1 -1
the,experiments,reported 1.0 0.000143348623853 0 1 -1
the,experiment,rats 1.0 0.000143348623853 0 1 -1
the,experience,gained 1.0 0.000143348623853 0 1 -1
the,expected,magnitude 1.0 0.000286697247706 0 2 -2
the,exogenous,respiration 1.0 0.000143348623853 0 1 -1
the,existence,of 1.0 0.000143348623853 0 1 -1
the,excreted,levels 1.0 0.000143348623853 0 1 -1
the,exception,of 1.0 0.00043004587156 0 3 -3
the,exact,place 1.0 0.000143348623853 0 1 -1
the,exact,length 1.0 0.000143348623853 0 1 -1
the,evidence,for 1.0 0.000143348623853 0 1 -1
the,event,of 1.0 0.000143348623853 0 1 -1
the,european,and 1.0 0.000143348623853 0 1 -1
the,estrogenic,component 1.0 0.000143348623853 0 1 -1
the,estimated,number 1.0 0.000143348623853 0 1 -1
the,escalating,use 1.0 0.000143348623853 0 1 -1
the,ermbt,and 1.0 0.000143348623853 0 1 -1
the,ermbt,after 1.0 0.000143348623853 0 1 -1
the,epa,dose 1.0 0.000143348623853 0 1 -1
the,enzymes,responsible 1.0 0.000143348623853 0 1 -1
the,environment,and 1.0 0.000143348623853 0 1 -1
the,enhanced,secretion 1.0 0.000143348623853 0 1 -1
the,endometrium,and 1.0 0.000143348623853 0 1 -1
the,end,of 1.0 0.000143348623853 0 1 -1
the,end,fo 1.0 0.000143348623853 0 1 -1
the,emerging,roles 1.0 0.000143348623853 0 1 -1
the,embryogenesis,of 1.0 0.000143348623853 0 1 -1
the,elimination,rate 1.0 0.000286697247706 0 2 -2
the,elimination,and 1.0 0.000143348623853 0 1 -1
the,elevated,plasma 1.0 0.000143348623853 0 1 -1
the,electrocardiographic,qt 1.0 0.000143348623853 0 1 -1
the,electrocardiographic,parameters 1.0 0.000143348623853 0 1 -1
the,elderly,population 1.0 0.000143348623853 0 1 -1
the,elderly,basic 1.0 0.000143348623853 0 1 -1
the,elderly,and 1.0 0.000286697247706 0 2 -2
the,efflux,transporter 1.0 0.000143348623853 0 1 -1
the,efficacy,and 1.0 0.000286697247706 0 2 -2
the,effects,seen 1.0 0.000143348623853 0 1 -1
the,effects,on 1.0 0.000143348623853 0 1 -1
the,effects,noted 1.0 0.000143348623853 0 1 -1
the,effects,if 1.0 0.000143348623853 0 1 -1
the,effect,was 1.0 0.000143348623853 0 1 -1
the,effect,seen 1.0 0.000143348623853 0 1 -1
the,effect,on 1.0 0.000573394495413 0 4 -4
the,effect,measured 1.0 0.000143348623853 0 1 -1
the,ec50,values 1.0 0.000143348623853 0 1 -1
the,e-strain,subjects 1.0 0.000143348623853 0 1 -1
the,duodenum,and 1.0 0.000143348623853 0 1 -1
the,duloxetine,clinical 1.0 0.000143348623853 0 1 -1
the,dst,should 1.0 0.000286697247706 0 2 -2
the,drug,to 1.0 0.000286697247706 0 2 -2
the,drug,taking 1.0 0.000143348623853 0 1 -1
the,drug,should 1.0 0.000143348623853 0 1 -1
the,drug,or 1.0 0.000143348623853 0 1 -1
the,drug,metabolizing 1.0 0.000143348623853 0 1 -1
the,dose-limiting,organ 1.0 0.000143348623853 0 1 -1
the,dose,that 1.0 0.000143348623853 0 1 -1
the,dose,required 1.0 0.000143348623853 0 1 -1
the,dose,or 1.0 0.000286697247706 0 2 -2
the,dose,levels 1.0 0.000143348623853 0 1 -1
the,dose,in 1.0 0.000286697247706 0 2 -2
the,dose,during 1.0 0.000143348623853 0 1 -1
the,dose,at 1.0 0.000143348623853 0 1 -1
the,dosage,was 1.0 0.000143348623853 0 1 -1
the,dosage,may 1.0 0.000286697247706 0 2 -2
the,dosage,and 1.0 0.000143348623853 0 1 -1
the,dog,whelk 1.0 0.000143348623853 0 1 -1
the,disulfiram-ethanol,reaction 1.0 0.000143348623853 0 1 -1
the,district,of 1.0 0.000143348623853 0 1 -1
the,distribution,of 1.0 0.000143348623853 0 1 -1
the,dissolution,rate 1.0 0.000286697247706 0 2 -2
the,disposition,of 1.0 0.000860091743119 0 6 -6
the,displacing,effect 1.0 0.000143348623853 0 1 -1
the,direction,of 1.0 0.000143348623853 0 1 -1
the,direction,and 1.0 0.000143348623853 0 1 -1
the,dimethylprostaglandin,e2 1.0 0.000143348623853 0 1 -1
the,digitalized,patient 1.0 0.000143348623853 0 1 -1
the,digi-,tab 1.0 0.000143348623853 0 1 -1
the,differential,diagnosis 1.0 0.000143348623853 0 1 -1
the,different,responses 1.0 0.000143348623853 0 1 -1
the,differences,in 1.0 0.000286697247706 0 2 -2
the,difference,was 1.0 0.000143348623853 0 1 -1
the,difference,between 1.0 0.000143348623853 0 1 -1
the,diets,no 1.0 0.000143348623853 0 1 -1
the,dietary,treatments 1.0 0.000143348623853 0 1 -1
the,diet,or 1.0 0.000143348623853 0 1 -1
the,diarrhea-inducing,effects 1.0 0.000143348623853 0 1 -1
the,diamond,trials 1.0 0.000286697247706 0 2 -2
the,diabetics,and 1.0 0.000143348623853 0 1 -1
the,diabetic,chinese 1.0 0.000286697247706 0 2 -2
the,diabectics,than 1.0 0.000143348623853 0 1 -1
the,dextrorotatory,isomer 1.0 0.000143348623853 0 1 -1
the,determination,of 1.0 0.000286697247706 0 2 -2
the,detection,of 1.0 0.000143348623853 0 1 -1
the,desired,therapeutic 1.0 0.000143348623853 0 1 -1
the,desired,level 1.0 0.000286697247706 0 2 -2
the,design,of 1.0 0.000143348623853 0 1 -1
the,dermatologist,and 1.0 0.000143348623853 0 1 -1
the,derivative,implications 1.0 0.000143348623853 0 1 -1
the,dependency,of 1.0 0.000143348623853 0 1 -1
the,dependence,of 1.0 0.000143348623853 0 1 -1
the,density,of 1.0 0.000143348623853 0 1 -1
the,decreased,urinary 1.0 0.000143348623853 0 1 -1
the,decreased,free 1.0 0.000143348623853 0 1 -1
the,decrease,of 1.0 0.000143348623853 0 1 -1
the,decrease,in 1.0 0.000143348623853 0 1 -1
the,decision,to 1.0 0.000143348623853 0 1 -1
the,decision,is 1.0 0.000143348623853 0 1 -1
the,deaths,due 1.0 0.000143348623853 0 1 -1
the,day-to,day 1.0 0.000143348623853 0 1 -1
the,day,preferably 1.0 0.000143348623853 0 1 -1
the,data,suggest 1.0 0.000286697247706 0 2 -2
the,data,presented 1.0 0.000143348623853 0 1 -1
the,data,intables 1.0 0.000143348623853 0 1 -1
the,data,from 1.0 0.000143348623853 0 1 -1
the,data,do 1.0 0.000143348623853 0 1 -1
the,daily,dosage 1.0 0.000143348623853 0 1 -1
the,d,and 1.0 0.000143348623853 0 1 -1
the,cytosol,to 1.0 0.000143348623853 0 1 -1
the,cytochrome,p450-linked 1.0 0.000143348623853 0 1 -1
the,cyp450,isoenzymes 1.0 0.000143348623853 0 1 -1
the,cyp3a4,substrate 1.0 0.000143348623853 0 1 -1
the,cyp3a4,metabolism 1.0 0.000143348623853 0 1 -1
the,cyp3a4,isoenzyme 1.0 0.00043004587156 0 3 -3
the,cyp3a4,inhibitor 1.0 0.000143348623853 0 1 -1
the,cyp3a,and 1.0 0.000143348623853 0 1 -1
the,cyp2d6,pathway 1.0 0.000143348623853 0 1 -1
the,cyp2d6,inhibitor 1.0 0.000143348623853 0 1 -1
the,cyp1a2,substrate 1.0 0.000143348623853 0 1 -1
the,cyp,enzymes 1.0 0.000286697247706 0 2 -2
the,cyp,c9 1.0 0.000143348623853 0 1 -1
the,cyclooxygenase-2,cox-2 1.0 0.000143348623853 0 1 -1
the,currently,available 1.0 0.000143348623853 0 1 -1
the,current,theories 1.0 0.000143348623853 0 1 -1
the,current,study 1.0 0.000143348623853 0 1 -1
the,cumulative,incidence 1.0 0.000143348623853 0 1 -1
the,csf,primarily 1.0 0.000143348623853 0 1 -1
the,cpk,elevations 1.0 0.000143348623853 0 1 -1
the,coumarin,type 1.0 0.000143348623853 0 1 -1
the,cost-risk,benefit 1.0 0.000143348623853 0 1 -1
the,cortex,which 1.0 0.000143348623853 0 1 -1
the,corrected,qt 1.0 0.000143348623853 0 1 -1
the,core,temperature 1.0 0.000143348623853 0 1 -1
the,copegus,pregnancy 1.0 0.000143348623853 0 1 -1
the,conventional,formulation 1.0 0.000143348623853 0 1 -1
the,control,of 1.0 0.000286697247706 0 2 -2
the,control,mechanisms 1.0 0.000143348623853 0 1 -1
the,control,group 1.0 0.000143348623853 0 1 -1
the,control,at 1.0 0.000143348623853 0 1 -1
the,contribution,of 1.0 0.000143348623853 0 1 -1
the,continuing,surveillance 1.0 0.000143348623853 0 1 -1
the,continued,need 1.0 0.000143348623853 0 1 -1
the,context,of 1.0 0.000143348623853 0 1 -1
the,contents,of 1.0 0.000286697247706 0 2 -2
the,constituents,of 1.0 0.000143348623853 0 1 -1
the,considerable,variability 1.0 0.000143348623853 0 1 -1
the,consequences,of 1.0 0.000143348623853 0 1 -1
the,conjugates,so 1.0 0.000143348623853 0 1 -1
the,condition,corrected 1.0 0.000143348623853 0 1 -1
the,concomitant,substrate 1.0 0.000143348623853 0 1 -1
the,concomitant,intake 1.0 0.000143348623853 0 1 -1
the,concentrations,producing 1.0 0.000143348623853 0 1 -1
the,concentrations,fo 1.0 0.000143348623853 0 1 -1
the,concentration-time,curve 1.0 0.000143348623853 0 1 -1
the,concentration,or 1.0 0.000143348623853 0 1 -1
the,compromised,cardiovascular 1.0 0.000143348623853 0 1 -1
the,components,with 1.0 0.000143348623853 0 1 -1
the,complete,prescribing 1.0 0.000143348623853 0 1 -1
the,compatibility,of 1.0 0.000143348623853 0 1 -1
the,community,or 1.0 0.000143348623853 0 1 -1
the,commonly,used 1.0 0.000143348623853 0 1 -1
the,commercially,available 1.0 0.000143348623853 0 1 -1
the,combined,moieties 1.0 0.000143348623853 0 1 -1
the,combined,data 1.0 0.000143348623853 0 1 -1
the,combined,chemotherapy 1.0 0.000143348623853 0 1 -1
the,combination,oral 1.0 0.000143348623853 0 1 -1
the,color,reverses 1.0 0.000143348623853 0 1 -1
the,colonic,transit-enhancing 1.0 0.000143348623853 0 1 -1
the,cold,binding 1.0 0.000143348623853 0 1 -1
the,cocaine-treated,sst 1.0 0.000143348623853 0 1 -1
the,cocaine-treated,animals 1.0 0.000143348623853 0 1 -1
the,coat-a,count 1.0 0.000143348623853 0 1 -1
the,coagulation,times 1.0 0.000143348623853 0 1 -1
the,co-administered,dose 1.0 0.000143348623853 0 1 -1
the,cns,and 1.0 0.000143348623853 0 1 -1
the,cmax,values 1.0 0.000143348623853 0 1 -1
the,cmax,at 1.0 0.000143348623853 0 1 -1
the,clinician,to 1.0 0.000143348623853 0 1 -1
the,clinician,responsible 1.0 0.000143348623853 0 1 -1
the,clinician,in 1.0 0.000143348623853 0 1 -1
the,clinician,depends 1.0 0.000143348623853 0 1 -1
the,clinical,studies 1.0 0.000143348623853 0 1 -1
the,clinical,situation 1.0 0.000143348623853 0 1 -1
the,clinical,relevance 1.0 0.00100344036697 0 7 -7
the,clinical,presentation 1.0 0.000143348623853 0 1 -1
the,clinical,effects 1.0 0.000143348623853 0 1 -1
the,clinical,effect 1.0 0.000143348623853 0 1 -1
the,clinical,dose 1.0 0.000143348623853 0 1 -1
the,clinical,differences 1.0 0.000143348623853 0 1 -1
the,clinical,data 1.0 0.000143348623853 0 1 -1
the,clinical,course 1.0 0.000143348623853 0 1 -1
the,clinical,basis 1.0 0.000143348623853 0 1 -1
the,clinical,and 1.0 0.000143348623853 0 1 -1
the,clinic,is 1.0 0.000143348623853 0 1 -1
the,clearance,or 1.0 0.000143348623853 0 1 -1
the,clearance,by 1.0 0.000143348623853 0 1 -1
the,classes,of 1.0 0.000143348623853 0 1 -1
the,chronically,ill 1.0 0.000143348623853 0 1 -1
the,chosen,method 1.0 0.000143348623853 0 1 -1
the,chop-haart,patients 1.0 0.000143348623853 0 1 -1
the,chop-haart,group 1.0 0.000143348623853 0 1 -1
the,chop,patients 1.0 0.000286697247706 0 2 -2
the,choice,of 1.0 0.000143348623853 0 1 -1
the,chick,by 1.0 0.000143348623853 0 1 -1
the,characteristics,of 1.0 0.000143348623853 0 1 -1
the,channel,blocker 1.0 0.000143348623853 0 1 -1
the,changes,in 1.0 0.000573394495413 0 4 -4
the,change,in 1.0 0.000143348623853 0 1 -1
the,central,importance 1.0 0.000143348623853 0 1 -1
the,cellular,permeability 1.0 0.000143348623853 0 1 -1
the,cellular,basis 1.0 0.000143348623853 0 1 -1
the,cellular,and 1.0 0.000143348623853 0 1 -1
the,cell,membrane 1.0 0.000143348623853 0 1 -1
the,cecum,in 1.0 0.000143348623853 0 1 -1
the,cecum,and 1.0 0.000143348623853 0 1 -1
the,ccnu,is 1.0 0.000143348623853 0 1 -1
the,cause,of 1.0 0.000286697247706 0 2 -2
the,caucasian,population 1.0 0.000573394495413 0 4 -4
the,cases,of 1.0 0.000143348623853 0 1 -1
the,case,in 1.0 0.000143348623853 0 1 -1
the,carpophores,of 1.0 0.000143348623853 0 1 -1
the,cardiovascular,effects 1.0 0.000143348623853 0 1 -1
the,cardiotoxicity,associated 1.0 0.000143348623853 0 1 -1
the,carcinogenic,potential 1.0 0.000286697247706 0 2 -2
the,can,prevent 1.0 0.000143348623853 0 1 -1
the,calcium-entry,blocking 1.0 0.000143348623853 0 1 -1
the,ca,store 1.0 0.000143348623853 0 1 -1
the,ca,dependent 1.0 0.000143348623853 0 1 -1
the,brovana,treated 1.0 0.000143348623853 0 1 -1
the,bronchodilator,effect 1.0 0.000143348623853 0 1 -1
the,broadening,indications 1.0 0.000143348623853 0 1 -1
the,breadth,of 1.0 0.000143348623853 0 1 -1
the,brain,memory 1.0 0.000143348623853 0 1 -1
the,brain,although 1.0 0.000143348623853 0 1 -1
the,bowel,and 1.0 0.000143348623853 0 1 -1
the,body,occurs 1.0 0.000143348623853 0 1 -1
the,body,it 1.0 0.000143348623853 0 1 -1
the,body,increase 1.0 0.000143348623853 0 1 -1
the,body,by 1.0 0.000143348623853 0 1 -1
the,bmax,of 1.0 0.000143348623853 0 1 -1
the,blood,or 1.0 0.000143348623853 0 1 -1
the,blood,level 1.0 0.000143348623853 0 1 -1
the,blood,concentration-time 1.0 0.000143348623853 0 1 -1
the,blood,concentration 1.0 0.000143348623853 0 1 -1
the,blood,coagulation 1.0 0.000143348623853 0 1 -1
the,blockade,of 1.0 0.000143348623853 0 1 -1
the,block,with 1.0 0.000143348623853 0 1 -1
the,biotransformation,of 1.0 0.000143348623853 0 1 -1
the,biological,levels 1.0 0.000143348623853 0 1 -1
the,biological,indicators 1.0 0.000143348623853 0 1 -1
the,biological,half-lives 1.0 0.000143348623853 0 1 -1
the,biogen,pregnancy 1.0 0.000143348623853 0 1 -1
the,biochemical,toxicology 1.0 0.000143348623853 0 1 -1
the,biochemical,activity 1.0 0.000716743119266 0 5 -5
the,bioavailability,and 1.0 0.000143348623853 0 1 -1
the,bio-rad,laboratories 1.0 0.000286697247706 0 2 -2
the,binding,is 1.0 0.000143348623853 0 1 -1
the,biliary,route 1.0 0.000143348623853 0 1 -1
the,bile-acidsequestering,agent 1.0 0.000143348623853 0 1 -1
the,bile,caution 1.0 0.000143348623853 0 1 -1
the,best,tool 1.0 0.000143348623853 0 1 -1
the,best,choice 1.0 0.000143348623853 0 1 -1
the,best,approach 1.0 0.000143348623853 0 1 -1
the,best,adaptive 1.0 0.000143348623853 0 1 -1
the,behaviour,of 1.0 0.000286697247706 0 2 -2
the,behavioral,response 1.0 0.000143348623853 0 1 -1
the,behavioral,effects 1.0 0.000573394495413 0 4 -4
the,behavioral,changes 1.0 0.000143348623853 0 1 -1
the,beginning,of 1.0 0.000286697247706 0 2 -2
the,basal,colonic 1.0 0.000143348623853 0 1 -1
the,basal,and 1.0 0.000143348623853 0 1 -1
the,balance,technique 1.0 0.000143348623853 0 1 -1
the,aviano,cancer 1.0 0.000143348623853 0 1 -1
the,average,infusion 1.0 0.000143348623853 0 1 -1
the,average,for 1.0 0.000143348623853 0 1 -1
the,available,agents 1.0 0.000143348623853 0 1 -1
the,availability,of 1.0 0.000286697247706 0 2 -2
the,authors,investigated 1.0 0.000143348623853 0 1 -1
the,authors,examined 1.0 0.000143348623853 0 1 -1
the,authors,compared 1.0 0.000143348623853 0 1 -1
the,augmentation,persisted 1.0 0.000143348623853 0 1 -1
the,aucs,of 1.0 0.000143348623853 0 1 -1
the,aucasian,population 1.0 0.000143348623853 0 1 -1
the,auc,more 1.0 0.000143348623853 0 1 -1
the,atypical,antipsychotic 1.0 0.000143348623853 0 1 -1
the,atropine-like,effects 1.0 0.000143348623853 0 1 -1
the,at,a 1.0 0.000143348623853 0 1 -1
the,association,of 1.0 0.000143348623853 0 1 -1
the,assay,result 1.0 0.000143348623853 0 1 -1
the,assay,of 1.0 0.000286697247706 0 2 -2
the,assay,and 1.0 0.000143348623853 0 1 -1
the,arrival,of 1.0 0.000143348623853 0 1 -1
the,are,used 1.0 0.000143348623853 0 1 -1
the,are,to 1.0 0.000143348623853 0 1 -1
the,are,also 1.0 0.000143348623853 0 1 -1
the,are,administered 1.0 0.000286697247706 0 2 -2
the,are,a 1.0 0.000286697247706 0 2 -2
the,aqueous,extract 1.0 0.000143348623853 0 1 -1
the,aptt,to 1.0 0.000143348623853 0 1 -1
the,aptt,such 1.0 0.000143348623853 0 1 -1
the,aptt,assay 1.0 0.000143348623853 0 1 -1
the,appropriate,package 1.0 0.000143348623853 0 1 -1
the,appropriate,interval 1.0 0.000143348623853 0 1 -1
the,appropriate,doses 1.0 0.000716743119266 0 5 -5
the,appropriate,dose 1.0 0.000143348623853 0 1 -1
the,approach,is 1.0 0.000143348623853 0 1 -1
the,applied,to 1.0 0.000143348623853 0 1 -1
the,apparent,volume 1.0 0.000143348623853 0 1 -1
the,apoptosis,induced 1.0 0.000143348623853 0 1 -1
the,antitumor,activity 1.0 0.000143348623853 0 1 -1
the,antipsychotic,action 1.0 0.000143348623853 0 1 -1
the,antiprothrombinemic,effect 1.0 0.000143348623853 0 1 -1
the,antioxidative,gallates 1.0 0.000143348623853 0 1 -1
the,antinonciceptive,effect 1.0 0.000143348623853 0 1 -1
the,antimicrobial,effect 1.0 0.000143348623853 0 1 -1
the,antimicrobial,activity 1.0 0.000286697247706 0 2 -2
the,antidepressant,was 1.0 0.000143348623853 0 1 -1
the,antidepressant,or 1.0 0.000143348623853 0 1 -1
the,antidepressant,class 1.0 0.000286697247706 0 2 -2
the,anticoagulants,should 1.0 0.000143348623853 0 1 -1
the,antianginal,effectiveness 1.0 0.000143348623853 0 1 -1
the,anti-platelet,activity 1.0 0.000143348623853 0 1 -1
the,anti-glaucoma,and 1.0 0.000143348623853 0 1 -1
the,anti-coagulant,effect 1.0 0.000143348623853 0 1 -1
the,antagonist,were 1.0 0.000143348623853 0 1 -1
the,anion,itself 1.0 0.000143348623853 0 1 -1
the,animals,were 1.0 0.000143348623853 0 1 -1
the,animal,literature 1.0 0.000143348623853 0 1 -1
the,anesthesiologist,should 1.0 0.000286697247706 0 2 -2
the,anemia,associated 1.0 0.000143348623853 0 1 -1
the,and,this 1.0 0.000143348623853 0 1 -1
the,and,properties 1.0 0.000143348623853 0 1 -1
the,and,or 1.0 0.000143348623853 0 1 -1
the,and,chop 1.0 0.000143348623853 0 1 -1
the,and,a 1.0 0.000286697247706 0 2 -2
the,analyte,is 1.0 0.000143348623853 0 1 -1
the,analysis,and 1.0 0.000143348623853 0 1 -1
the,amplitudes,of 1.0 0.00043004587156 0 3 -3
the,amplitude,of 1.0 0.000143348623853 0 1 -1
the,amplitude,data 1.0 0.000143348623853 0 1 -1
the,amount,absorbed 1.0 0.000143348623853 0 1 -1
the,ames,test 1.0 0.000143348623853 0 1 -1
the,ames,n-multistix 1.0 0.000143348623853 0 1 -1
the,ames,bacterial 1.0 0.000143348623853 0 1 -1
the,alveoli,of 1.0 0.000143348623853 0 1 -1
the,alters,the 1.0 0.000143348623853 0 1 -1
the,aldehyde,oxidase 1.0 0.000143348623853 0 1 -1
the,aim,of 1.0 0.000286697247706 0 2 -2
the,agents,to 1.0 0.000143348623853 0 1 -1
the,agent,was 1.0 0.000143348623853 0 1 -1
the,agent,has 1.0 0.000143348623853 0 1 -1
the,age,of 1.0 0.000143348623853 0 1 -1
the,affinity,kd 1.0 0.000143348623853 0 1 -1
the,aerosol,particles 1.0 0.00043004587156 0 3 -3
the,adverse,reaction 1.0 0.000143348623853 0 1 -1
the,adverse,experience 1.0 0.000143348623853 0 1 -1
the,adverse,events 1.0 0.000143348623853 0 1 -1
the,advantages,and 1.0 0.000143348623853 0 1 -1
the,adrenergic,from 1.0 0.000143348623853 0 1 -1
the,administrative,arrangements 1.0 0.000143348623853 0 1 -1
the,adequacy,of 1.0 0.000143348623853 0 1 -1
the,additive,effects 1.0 0.000286697247706 0 2 -2
the,additive,and 1.0 0.000143348623853 0 1 -1
the,additional,stimulus 1.0 0.000143348623853 0 1 -1
the,added,concentration 1.0 0.000143348623853 0 1 -1
the,acute,phase 1.0 0.000143348623853 0 1 -1
the,acute,myocardial 1.0 0.000143348623853 0 1 -1
the,activity,and 1.0 0.000143348623853 0 1 -1
the,active,triphosphate 1.0 0.000143348623853 0 1 -1
the,active,s-isomer 1.0 0.000143348623853 0 1 -1
the,active,epoxide 1.0 0.000143348623853 0 1 -1
the,actions,and 1.0 0.000143348623853 0 1 -1
the,acquisition,of 1.0 0.000143348623853 0 1 -1
the,acquired,behavioral 1.0 0.000143348623853 0 1 -1
the,acid-catalyzed,ethanol-drug 1.0 0.000143348623853 0 1 -1
the,acid,metabolite 1.0 0.000143348623853 0 1 -1
the,acceleration,of 1.0 0.000143348623853 0 1 -1
the,abundance,and 1.0 0.000143348623853 0 1 -1
the,absorption,site 1.0 0.000143348623853 0 1 -1
the,absorption,or 1.0 0.000143348623853 0 1 -1
the,absolute,number 1.0 0.000143348623853 0 1 -1
the,above,or 1.0 0.000143348623853 0 1 -1
the,above,listed 1.0 0.000143348623853 0 1 -1
the,above,experiments 1.0 0.000143348623853 0 1 -1
the,above,data 1.0 0.000143348623853 0 1 -1
the,above,behavioral 1.0 0.000143348623853 0 1 -1
the,ability,to 1.0 0.000143348623853 0 1 -1
the,aberrant,and 1.0 0.000143348623853 0 1 -1
that,xanthine-derived,antagonists 1.0 0.000143348623853 0 1 -1
that,would,warrant 1.0 0.000143348623853 0 1 -1
that,would,affect 1.0 0.000143348623853 0 1 -1
that,with,serial 1.0 0.000143348623853 0 1 -1
that,will,inhibit 1.0 0.000143348623853 0 1 -1
that,was,too 1.0 0.000143348623853 0 1 -1
that,was,sacrificed 1.0 0.000143348623853 0 1 -1
that,was,detected 1.0 0.000143348623853 0 1 -1
that,use,of 1.0 0.000143348623853 0 1 -1
that,use,glucose 1.0 0.000143348623853 0 1 -1
that,undergo,tyrosine 1.0 0.000143348623853 0 1 -1
that,transferred,to 1.0 0.000143348623853 0 1 -1
that,toradol,induces 1.0 0.000143348623853 0 1 -1
that,topoisomerase,activity 1.0 0.000143348623853 0 1 -1
that,time,the 1.0 0.000143348623853 0 1 -1
that,tikosyn,does 1.0 0.000286697247706 0 2 -2
that,this,decrease 1.0 0.000143348623853 0 1 -1
that,this,can 1.0 0.000143348623853 0 1 -1
that,this,alteration 1.0 0.000143348623853 0 1 -1
that,they,could 1.0 0.000143348623853 0 1 -1
that,these,tests 1.0 0.00043004587156 0 3 -3
that,these,reactions 1.0 0.000143348623853 0 1 -1
that,these,compounds 1.0 0.000143348623853 0 1 -1
that,these,are 1.0 0.000143348623853 0 1 -1
that,these,aeds 1.0 0.000143348623853 0 1 -1
that,there,were 1.0 0.000143348623853 0 1 -1
that,there,are 1.0 0.000286697247706 0 2 -2
that,therapy,with 1.0 0.000143348623853 0 1 -1
that,their,patients 1.0 0.000143348623853 0 1 -1
that,the,use 1.0 0.000286697247706 0 2 -2
that,the,time 1.0 0.000143348623853 0 1 -1
that,the,solubility 1.0 0.000143348623853 0 1 -1
that,the,site 1.0 0.000143348623853 0 1 -1
that,the,response 1.0 0.000143348623853 0 1 -1
that,the,presence 1.0 0.000143348623853 0 1 -1
that,the,precipitate 1.0 0.000143348623853 0 1 -1
that,the,possible 1.0 0.000143348623853 0 1 -1
that,the,plasma 1.0 0.000143348623853 0 1 -1
that,the,phosphohydrolase 1.0 0.000143348623853 0 1 -1
that,the,phenotype 1.0 0.000143348623853 0 1 -1
that,the,pharmacokinetics 1.0 0.00043004587156 0 3 -3
that,the,patients 1.0 0.000143348623853 0 1 -1
that,the,pancreatic 1.0 0.000143348623853 0 1 -1
that,the,myelotoxicity 1.0 0.000143348623853 0 1 -1
that,the,modulatory 1.0 0.000143348623853 0 1 -1
that,the,involvement 1.0 0.000143348623853 0 1 -1
that,the,hypothalamic-pituitary 1.0 0.000143348623853 0 1 -1
that,the,homodimeric 1.0 0.000143348623853 0 1 -1
that,the,histidine 1.0 0.000143348623853 0 1 -1
that,the,hippocampus 1.0 0.000143348623853 0 1 -1
that,the,first 1.0 0.000143348623853 0 1 -1
that,the,extent 1.0 0.000143348623853 0 1 -1
that,the,effect 1.0 0.000143348623853 0 1 -1
that,the,diabetic 1.0 0.000143348623853 0 1 -1
that,the,desired 1.0 0.000143348623853 0 1 -1
that,the,conversion 1.0 0.000286697247706 0 2 -2
that,the,coadministration 1.0 0.000143348623853 0 1 -1
that,the,changes 1.0 0.000143348623853 0 1 -1
that,the,bioavailability 1.0 0.000143348623853 0 1 -1
that,the,binding 1.0 0.000143348623853 0 1 -1
that,the,applied 1.0 0.000143348623853 0 1 -1
that,the,alters 1.0 0.000143348623853 0 1 -1
that,the,agent 1.0 0.000143348623853 0 1 -1
that,tests,to 1.0 0.000143348623853 0 1 -1
that,taking,the 1.0 0.000143348623853 0 1 -1
that,take,advantage 1.0 0.000143348623853 0 1 -1
that,suppress,the 1.0 0.000143348623853 0 1 -1
that,such,doses 1.0 0.000143348623853 0 1 -1
that,starlix,is 1.0 0.000143348623853 0 1 -1
that,some,of 1.0 0.000143348623853 0 1 -1
that,small,quantities 1.0 0.000143348623853 0 1 -1
that,significantly,bind 1.0 0.000143348623853 0 1 -1
that,significantly,affected 1.0 0.000143348623853 0 1 -1
that,several,but 1.0 0.000143348623853 0 1 -1
that,seeds,of 1.0 0.000143348623853 0 1 -1
that,same,study 1.0 0.000143348623853 0 1 -1
that,s,augmentation 1.0 0.000143348623853 0 1 -1
that,rr,is 1.0 0.000143348623853 0 1 -1
that,revlimid,is 1.0 0.000143348623853 0 1 -1
that,results,from 1.0 0.000143348623853 0 1 -1
that,result,from 1.0 0.000286697247706 0 2 -2
that,resists,dissolution 1.0 0.000143348623853 0 1 -1
that,resistance,is 1.0 0.000143348623853 0 1 -1
that,require,careful 1.0 0.000143348623853 0 1 -1
that,reduce,renal 1.0 0.000143348623853 0 1 -1
that,received,one 1.0 0.000143348623853 0 1 -1
that,received,mg 1.0 0.000286697247706 0 2 -2
that,reached,borderline 1.0 0.000143348623853 0 1 -1
that,raise,the 1.0 0.000143348623853 0 1 -1
that,pulmozyme,can 1.0 0.000143348623853 0 1 -1
that,prolonged,administration 1.0 0.000143348623853 0 1 -1
that,prolong,the 1.0 0.000143348623853 0 1 -1
that,produces,cardiopulmonary 1.0 0.000143348623853 0 1 -1
that,produced,plasma 1.0 0.000143348623853 0 1 -1
that,produced,pharmacological 1.0 0.000143348623853 0 1 -1
that,pretreatment,with 1.0 0.000143348623853 0 1 -1
that,precipitation,occurs 1.0 0.000143348623853 0 1 -1
that,potentiate,the 1.0 0.000143348623853 0 1 -1
that,poor,d6 1.0 0.000143348623853 0 1 -1
that,polyamines,might 1.0 0.000143348623853 0 1 -1
that,platelet,function 1.0 0.000143348623853 0 1 -1
that,physicians,query 1.0 0.000143348623853 0 1 -1
that,peak,concentrations 1.0 0.000143348623853 0 1 -1
that,patients,understand 1.0 0.000143348623853 0 1 -1
that,patients,take 1.0 0.000143348623853 0 1 -1
that,oral,ccnu 1.0 0.000143348623853 0 1 -1
that,oral,and 1.0 0.000143348623853 0 1 -1
that,oral,administration 1.0 0.000143348623853 0 1 -1
that,or,acth 1.0 0.000143348623853 0 1 -1
that,of,subjects 1.0 0.000143348623853 0 1 -1
that,of,n-desmethyldiazepam 1.0 0.000143348623853 0 1 -1
that,of,decreased 1.0 0.000143348623853 0 1 -1
that,of,crude 1.0 0.000143348623853 0 1 -1
that,occurred,three 1.0 0.000143348623853 0 1 -1
that,occur,with 1.0 0.000143348623853 0 1 -1
that,observed,in 1.0 0.000143348623853 0 1 -1
that,no,relevant 1.0 0.000143348623853 0 1 -1
that,no,igg 1.0 0.000143348623853 0 1 -1
that,neither,nor 1.0 0.000143348623853 0 1 -1
that,mtx,nsaids 1.0 0.000143348623853 0 1 -1
that,more,than 1.0 0.000143348623853 0 1 -1
that,mixing,novolog 1.0 0.000143348623853 0 1 -1
that,might,occur 1.0 0.000143348623853 0 1 -1
that,might,be 1.0 0.000143348623853 0 1 -1
that,mesylate,has 1.0 0.000143348623853 0 1 -1
that,mediate,and 1.0 0.000143348623853 0 1 -1
that,mcf-7,cells 1.0 0.000143348623853 0 1 -1
that,mc,has 1.0 0.000143348623853 0 1 -1
that,may,underlie 1.0 0.000143348623853 0 1 -1
that,may,slow 1.0 0.000143348623853 0 1 -1
that,may,reach 1.0 0.000143348623853 0 1 -1
that,may,produce 1.0 0.000143348623853 0 1 -1
that,may,make 1.0 0.000143348623853 0 1 -1
that,may,cause 1.0 0.000143348623853 0 1 -1
that,may,arise 1.0 0.000143348623853 0 1 -1
that,may,affect 1.0 0.000286697247706 0 2 -2
that,maximally,suppresses 1.0 0.000143348623853 0 1 -1
that,m,was 1.0 0.000143348623853 0 1 -1
that,lung,has 1.0 0.000143348623853 0 1 -1
that,larger,doses 1.0 0.000143348623853 0 1 -1
that,krm-1648,has 1.0 0.000143348623853 0 1 -1
that,keppra,is 1.0 0.000143348623853 0 1 -1
that,its,metabolism 1.0 0.000143348623853 0 1 -1
that,is,unlikely 1.0 0.000286697247706 0 2 -2
that,is,significantly 1.0 0.000143348623853 0 1 -1
that,is,rapidly 1.0 0.000143348623853 0 1 -1
that,is,primarily 1.0 0.00043004587156 0 3 -3
that,is,metabolized 1.0 0.000286697247706 0 2 -2
that,is,lower 1.0 0.000143348623853 0 1 -1
that,is,known 1.0 0.000143348623853 0 1 -1
that,is,highly 1.0 0.00043004587156 0 3 -3
that,is,cleared 1.0 0.000143348623853 0 1 -1
that,is,bound 1.0 0.000143348623853 0 1 -1
that,is,both 1.0 0.000143348623853 0 1 -1
that,intraventricular,and 1.0 0.000143348623853 0 1 -1
that,intracellular,ca 1.0 0.000143348623853 0 1 -1
that,interacts,with 1.0 0.000143348623853 0 1 -1
that,interactions,between 1.0 0.000143348623853 0 1 -1
that,intensive,control 1.0 0.000143348623853 0 1 -1
that,inhibits,cyp3a4 1.0 0.000143348623853 0 1 -1
that,inhibits,cyp2d6 1.0 0.000143348623853 0 1 -1
that,inhibits,cancer 1.0 0.000143348623853 0 1 -1
that,inhibits,c9 1.0 0.000143348623853 0 1 -1
that,inhibited,the 1.0 0.000143348623853 0 1 -1
that,inhibited,high 1.0 0.000143348623853 0 1 -1
that,inhibit,these 1.0 0.000143348623853 0 1 -1
that,inhibit,the 1.0 0.000286697247706 0 2 -2
that,inhibit,pgp 1.0 0.000143348623853 0 1 -1
that,inhibit,or 1.0 0.000573394495413 0 4 -4
that,inhibit,metabolism 1.0 0.000143348623853 0 1 -1
that,inhibit,high 1.0 0.000143348623853 0 1 -1
that,inhibit,drug 1.0 0.000143348623853 0 1 -1
that,inhibit,cyp3a 1.0 0.000143348623853 0 1 -1
that,inhibit,alprazolam 1.0 0.000143348623853 0 1 -1
that,inhibit,aldehyde 1.0 0.000143348623853 0 1 -1
that,induce,or 1.0 0.000143348623853 0 1 -1
that,induce,cytochrome 1.0 0.000143348623853 0 1 -1
that,induce,cyp3a 1.0 0.000143348623853 0 1 -1
that,induce,a4 1.0 0.000143348623853 0 1 -1
that,indocin,does 1.0 0.000143348623853 0 1 -1
that,increased,stability 1.0 0.000143348623853 0 1 -1
that,increased,interaction 1.0 0.000143348623853 0 1 -1
that,increase,gastrointestinal 1.0 0.000143348623853 0 1 -1
that,includes,most 1.0 0.000143348623853 0 1 -1
that,included,brovana 1.0 0.000143348623853 0 1 -1
that,included,a 1.0 0.000143348623853 0 1 -1
that,incidence,of 1.0 0.000143348623853 0 1 -1
that,in,the 1.0 0.000143348623853 0 1 -1
that,in,serum-supplemented 1.0 0.000143348623853 0 1 -1
that,in,control 1.0 0.000143348623853 0 1 -1
that,in,combination 1.0 0.000143348623853 0 1 -1
that,in,alcoholics 1.0 0.000143348623853 0 1 -1
that,in,acutely 1.0 0.000143348623853 0 1 -1
that,in,a 1.0 0.000143348623853 0 1 -1
that,impairment,of 1.0 0.000143348623853 0 1 -1
that,impact,on 1.0 0.000143348623853 0 1 -1
that,iga,is 1.0 0.000143348623853 0 1 -1
that,hydrochloride,binds 1.0 0.000143348623853 0 1 -1
that,homocysteine,may 1.0 0.000143348623853 0 1 -1
that,histaminergic,and 1.0 0.000143348623853 0 1 -1
that,hippocampal,lesions 1.0 0.000143348623853 0 1 -1
that,herbal,remedy 1.0 0.000143348623853 0 1 -1
that,health,care 1.0 0.000143348623853 0 1 -1
that,have,the 1.0 0.000143348623853 0 1 -1
that,have,renal 1.0 0.000143348623853 0 1 -1
that,have,one 1.0 0.000143348623853 0 1 -1
that,has,the 1.0 0.000143348623853 0 1 -1
that,has,no 1.0 0.000143348623853 0 1 -1
that,has,benefits 1.0 0.000143348623853 0 1 -1
that,had,no 1.0 0.000143348623853 0 1 -1
that,had,a 1.0 0.000143348623853 0 1 -1
that,glucose,tests 1.0 0.000860091743119 0 6 -6
that,given,as 1.0 0.000143348623853 0 1 -1
that,genetic,factors 1.0 0.000143348623853 0 1 -1
that,gaba-positive,be 1.0 0.000143348623853 0 1 -1
that,functional,coupling 1.0 0.000143348623853 0 1 -1
that,from,the 1.0 0.000143348623853 0 1 -1
that,frequent,peripheral 1.0 0.000143348623853 0 1 -1
that,falsely,identify 1.0 0.000143348623853 0 1 -1
that,experience,significantly 1.0 0.000143348623853 0 1 -1
that,exogenous,co-factors 1.0 0.000143348623853 0 1 -1
that,epa,supplements 1.0 0.000286697247706 0 2 -2
that,encodes,a 1.0 0.000143348623853 0 1 -1
that,either,the 1.0 0.000286697247706 0 2 -2
that,either,are 1.0 0.000143348623853 0 1 -1
that,doxil,be 1.0 0.000143348623853 0 1 -1
that,dosage,adjustment 1.0 0.000143348623853 0 1 -1
that,does,not 1.0 0.00157683486239 0 11 -11
that,does,induce 1.0 0.000143348623853 0 1 -1
that,disease,states 1.0 0.000143348623853 0 1 -1
that,did,not 1.0 0.000143348623853 0 1 -1
that,depending,on 1.0 0.000143348623853 0 1 -1
that,demonstrate,very 1.0 0.000143348623853 0 1 -1
that,decreases,stomach 1.0 0.000143348623853 0 1 -1
that,d1,receptors 1.0 0.000143348623853 0 1 -1
that,cyp3a4,and 1.0 0.000143348623853 0 1 -1
that,could,increase 1.0 0.00043004587156 0 3 -3
that,could,have 1.0 0.000143348623853 0 1 -1
that,conclusively,establish 1.0 0.000143348623853 0 1 -1
that,coadministration,with 1.0 0.000143348623853 0 1 -1
that,chloral,hydrate 1.0 0.000143348623853 0 1 -1
that,caution,may 1.0 0.000143348623853 0 1 -1
that,causative,factors 1.0 0.000143348623853 0 1 -1
that,caspofungin,acetate 1.0 0.000143348623853 0 1 -1
that,can,speed-up 1.0 0.000143348623853 0 1 -1
that,can,progress 1.0 0.000143348623853 0 1 -1
that,can,modulate 1.0 0.000143348623853 0 1 -1
that,can,inhibit 1.0 0.000716743119266 0 5 -5
that,can,either 1.0 0.000143348623853 0 1 -1
that,can,cause 1.0 0.000143348623853 0 1 -1
that,both,products 1.0 0.000143348623853 0 1 -1
that,both,angiotensins 1.0 0.000143348623853 0 1 -1
that,blockers,also 1.0 0.000143348623853 0 1 -1
that,block,angiotensin 1.0 0.000143348623853 0 1 -1
that,binds,differently 1.0 0.000143348623853 0 1 -1
that,because,of 1.0 0.000286697247706 0 2 -2
that,be,administered 1.0 0.000143348623853 0 1 -1
that,at,high 1.0 0.000143348623853 0 1 -1
that,as,v 1.0 0.000143348623853 0 1 -1
that,are,supported 1.0 0.000143348623853 0 1 -1
that,are,substrates 1.0 0.00200688073394 0 14 -14
that,are,specific 1.0 0.000143348623853 0 1 -1
that,are,renally 1.0 0.000143348623853 0 1 -1
that,are,negatively 1.0 0.000143348623853 0 1 -1
that,are,likely 1.0 0.000143348623853 0 1 -1
that,are,inhibitors 1.0 0.000143348623853 0 1 -1
that,are,inducers 1.0 0.000286697247706 0 2 -2
that,are,impaired 1.0 0.000143348623853 0 1 -1
that,are,facilitated 1.0 0.000143348623853 0 1 -1
that,are,either 1.0 0.000143348623853 0 1 -1
that,are,dose 1.0 0.000143348623853 0 1 -1
that,are,contraindicated 1.0 0.000143348623853 0 1 -1
that,are,associated 1.0 0.000143348623853 0 1 -1
that,are,applicable 1.0 0.000143348623853 0 1 -1
that,are,also 1.0 0.000143348623853 0 1 -1
that,appears,to 1.0 0.000143348623853 0 1 -1
that,apoptosis,can 1.0 0.000143348623853 0 1 -1
that,anion,because 1.0 0.000143348623853 0 1 -1
that,and,its 1.0 0.000286697247706 0 2 -2
that,and,have 1.0 0.000143348623853 0 1 -1
that,and,had 1.0 0.000143348623853 0 1 -1
that,and,fenofibric 1.0 0.000143348623853 0 1 -1
that,and,do 1.0 0.000143348623853 0 1 -1
that,and,cause 1.0 0.000143348623853 0 1 -1
that,an,agent 1.0 0.000143348623853 0 1 -1
that,an,acute 1.0 0.000143348623853 0 1 -1
that,an,ability 1.0 0.000143348623853 0 1 -1
that,although,not 1.0 0.000143348623853 0 1 -1
that,alters,hormone 1.0 0.000143348623853 0 1 -1
that,alter,renal 1.0 0.000143348623853 0 1 -1
that,allegra,should 1.0 0.000143348623853 0 1 -1
that,alcoholic,beverages 1.0 0.000143348623853 0 1 -1
that,after,the 1.0 0.000143348623853 0 1 -1
that,after,days 1.0 0.000143348623853 0 1 -1
that,affect,platelet 1.0 0.000143348623853 0 1 -1
that,affect,gastric 1.0 0.000143348623853 0 1 -1
that,affect,cyp3a4 1.0 0.000143348623853 0 1 -1
that,administration,of 1.0 0.000286697247706 0 2 -2
that,acute,dosing 1.0 0.000143348623853 0 1 -1
that,acarbose,has 1.0 0.000143348623853 0 1 -1
that,absorption,metabolism 1.0 0.000143348623853 0 1 -1
that,a,the 1.0 0.000143348623853 0 1 -1
that,a,statistically 1.0 0.000143348623853 0 1 -1
that,a,spinal 1.0 0.000143348623853 0 1 -1
that,a,single 1.0 0.000286697247706 0 2 -2
that,a,reduction 1.0 0.000143348623853 0 1 -1
that,a,positive 1.0 0.00043004587156 0 3 -3
that,a,number 1.0 0.000143348623853 0 1 -1
that,a,exerts 1.0 0.000143348623853 0 1 -1
that,a,dosing 1.0 0.000143348623853 0 1 -1
that,a,combination 1.0 0.000143348623853 0 1 -1
than,with,no 1.0 0.000143348623853 0 1 -1
than,with,based 1.0 0.000143348623853 0 1 -1
than,when,or 1.0 0.000143348623853 0 1 -1
than,usually,prescribed 1.0 0.00100344036697 0 7 -7
than,usual,of 1.0 0.000143348623853 0 1 -1
than,usual,dose 1.0 0.000143348623853 0 1 -1
than,to,mg 1.0 0.000143348623853 0 1 -1
than,thrombin,or 1.0 0.000143348623853 0 1 -1
than,those,listed 1.0 0.000143348623853 0 1 -1
than,the,usual 1.0 0.000286697247706 0 2 -2
than,the,therapeutic 1.0 0.000143348623853 0 1 -1
than,the,stable 1.0 0.000143348623853 0 1 -1
than,the,prescription 1.0 0.000143348623853 0 1 -1
than,the,number 1.0 0.000143348623853 0 1 -1
than,the,normal 1.0 0.000143348623853 0 1 -1
than,the,mean 1.0 0.000286697247706 0 2 -2
than,the,m1 1.0 0.000143348623853 0 1 -1
than,the,in 1.0 0.000143348623853 0 1 -1
than,the,cytochrome 1.0 0.000143348623853 0 1 -1
than,that,in 1.0 0.000143348623853 0 1 -1
than,seven,days 1.0 0.000143348623853 0 1 -1
than,second,in 1.0 0.000143348623853 0 1 -1
than,plasma,after 1.0 0.000143348623853 0 1 -1
than,peak,plasma 1.0 0.000143348623853 0 1 -1
than,patients,were 1.0 0.000143348623853 0 1 -1
than,parkinsons,disease 1.0 0.000143348623853 0 1 -1
than,or,equal 1.0 0.000143348623853 0 1 -1
than,one,treatment 1.0 0.000143348623853 0 1 -1
than,one,mechanism 1.0 0.000143348623853 0 1 -1
than,of,this 1.0 0.000143348623853 0 1 -1
than,of,the 1.0 0.000143348623853 0 1 -1
than,normal,daily 1.0 0.000143348623853 0 1 -1
than,nanm,in 1.0 0.000143348623853 0 1 -1
than,myopathy,and 1.0 0.000143348623853 0 1 -1
than,mug,ml 1.0 0.000143348623853 0 1 -1
than,months,of 1.0 0.000143348623853 0 1 -1
than,mm,fractional 1.0 0.000143348623853 0 1 -1
than,mg,should 1.0 0.000143348623853 0 1 -1
than,mg,qd 1.0 0.000143348623853 0 1 -1
than,mg,of 1.0 0.000143348623853 0 1 -1
than,mg,mg 1.0 0.000143348623853 0 1 -1
than,mg,m2 1.0 0.000143348623853 0 1 -1
than,mg,considered 1.0 0.000143348623853 0 1 -1
than,mg,as 1.0 0.000143348623853 0 1 -1
than,in,control 1.0 0.000286697247706 0 2 -2
than,have,not 1.0 0.000143348623853 0 1 -1
than,has,not 1.0 0.000143348623853 0 1 -1
than,for,strains 1.0 0.000143348623853 0 1 -1
than,for,nmda 1.0 0.000143348623853 0 1 -1
than,fold,increase 1.0 0.000286697247706 0 2 -2
than,expected,plasma 1.0 0.00100344036697 0 7 -7
than,expected,lasma 1.0 0.000143348623853 0 1 -1
than,episodes,of 1.0 0.000143348623853 0 1 -1
than,doubled,in 1.0 0.000143348623853 0 1 -1
than,dose,levels 1.0 0.000143348623853 0 1 -1
than,changes,seen 1.0 0.000143348623853 0 1 -1
than,atiii,no 1.0 0.000143348623853 0 1 -1
than,and,would 1.0 0.000143348623853 0 1 -1
than,and,to 1.0 0.000143348623853 0 1 -1
than,and,nonrenal 1.0 0.000143348623853 0 1 -1
than,and,does 1.0 0.000143348623853 0 1 -1
thalidomide,co-administration,with 1.0 0.000143348623853 0 1 -1
th,week,of 1.0 0.000143348623853 0 1 -1
th,generation,of 1.0 0.000143348623853 0 1 -1
th,days,of 1.0 0.000143348623853 0 1 -1
th,and,the 1.0 0.000143348623853 0 1 -1
th,and,th 1.0 0.000143348623853 0 1 -1
tests,with,and 1.0 0.000143348623853 0 1 -1
tests,with,a 1.0 0.000143348623853 0 1 -1
tests,were,negative 1.0 0.000143348623853 0 1 -1
tests,vital,signs 1.0 0.000286697247706 0 2 -2
tests,using,but 1.0 0.000286697247706 0 2 -2
tests,to,rule 1.0 0.000143348623853 0 1 -1
tests,such,as 1.0 0.000143348623853 0 1 -1
tests,since,elevations 1.0 0.000143348623853 0 1 -1
tests,showed,that 1.0 0.000143348623853 0 1 -1
tests,should,be 1.0 0.000573394495413 0 4 -4
tests,response,to 1.0 0.000143348623853 0 1 -1
tests,pregnancy,test 1.0 0.000143348623853 0 1 -1
tests,performed,in 1.0 0.000143348623853 0 1 -1
tests,of,radio-iodine 1.0 0.000143348623853 0 1 -1
tests,may,be 1.0 0.000286697247706 0 2 -2
tests,interactions,there 1.0 0.000143348623853 0 1 -1
tests,interactions,no 1.0 0.000143348623853 0 1 -1
tests,interactions,hyperaminotransferasemia 1.0 0.000143348623853 0 1 -1
tests,interactions,because 1.0 0.000143348623853 0 1 -1
tests,if,significant 1.0 0.000143348623853 0 1 -1
tests,have,not 1.0 0.000143348623853 0 1 -1
tests,have,been 1.0 0.00043004587156 0 3 -3
tests,for,glycosuria 1.0 0.000143348623853 0 1 -1
tests,elevations,of 1.0 0.000143348623853 0 1 -1
tests,corticosteroids,may 1.0 0.000143348623853 0 1 -1
tests,common,side 1.0 0.000143348623853 0 1 -1
tests,benedicts,solution 1.0 0.000143348623853 0 1 -1
tests,benedicts,or 1.0 0.000143348623853 0 1 -1
tests,benedict,s 1.0 0.000143348623853 0 1 -1
tests,be,performed 1.0 0.00043004587156 0 3 -3
tests,based,on 1.0 0.000860091743119 0 6 -6
tests,are,performed 1.0 0.000286697247706 0 2 -2
tests,are,carried 1.0 0.000143348623853 0 1 -1
testing,transaminases,bilirubin 1.0 0.000143348623853 0 1 -1
testing,of,newborns 1.0 0.000143348623853 0 1 -1
testing,a,maneuver 1.0 0.000143348623853 0 1 -1
testicular,leydig,cell 1.0 0.000143348623853 0 1 -1
testicular,axis,was 1.0 0.000143348623853 0 1 -1
testicular,atrophy,was 1.0 0.000143348623853 0 1 -1
testes,and,epididymides 1.0 0.000143348623853 0 1 -1
tested,was,observed 1.0 0.000143348623853 0 1 -1
tested,up,to 1.0 0.000143348623853 0 1 -1
tested,to,determine 1.0 0.000143348623853 0 1 -1
tested,the,antimicrobial 1.0 0.000143348623853 0 1 -1
tested,more,frequently 1.0 0.000143348623853 0 1 -1
tested,in,vitro 1.0 0.000143348623853 0 1 -1
tested,in,the 1.0 0.000143348623853 0 1 -1
tested,in,man 1.0 0.000286697247706 0 2 -2
tested,in,combination 1.0 0.000143348623853 0 1 -1
tested,here,commonly 1.0 0.000143348623853 0 1 -1
tested,for,subjects 1.0 0.000143348623853 0 1 -1
tested,for,its 1.0 0.000143348623853 0 1 -1
tested,cyp1a2,cyp2c9 1.0 0.000143348623853 0 1 -1
tested,by,determination 1.0 0.000143348623853 0 1 -1
tested,and,no 1.0 0.000143348623853 0 1 -1
test,which,suggested 1.0 0.000143348623853 0 1 -1
test,was,measured 1.0 0.000143348623853 0 1 -1
test,strips,that 1.0 0.000143348623853 0 1 -1
test,sample,is 1.0 0.000143348623853 0 1 -1
test,results,using 1.0 0.000143348623853 0 1 -1
test,results,in 1.0 0.000143348623853 0 1 -1
test,results,for 1.0 0.000143348623853 0 1 -1
test,results,during 1.0 0.000143348623853 0 1 -1
test,must,be 1.0 0.000143348623853 0 1 -1
test,monitoring,during 1.0 0.000143348623853 0 1 -1
test,may,be 1.0 0.000286697247706 0 2 -2
test,it,is 1.0 0.000286697247706 0 2 -2
test,is,to 1.0 0.000143348623853 0 1 -1
test,is,obtained 1.0 0.000143348623853 0 1 -1
test,interferences,dicumarol 1.0 0.000143348623853 0 1 -1
test,interactions,with 1.0 0.000143348623853 0 1 -1
test,interactions,thiazides 1.0 0.000143348623853 0 1 -1
test,interactions,there 1.0 0.00100344036697 0 7 -7
test,interactions,the 1.0 0.000860091743119 0 6 -6
test,interactions,serum 1.0 0.000143348623853 0 1 -1
test,interactions,see 1.0 0.000143348623853 0 1 -1
test,interactions,prolongation 1.0 0.000143348623853 0 1 -1
test,interactions,positive 1.0 0.000143348623853 0 1 -1
test,interactions,phenytoin 1.0 0.000143348623853 0 1 -1
test,interactions,no 1.0 0.000286697247706 0 2 -2
test,interactions,naproxen 1.0 0.000143348623853 0 1 -1
test,interactions,measurement 1.0 0.000143348623853 0 1 -1
test,interactions,it 1.0 0.000143348623853 0 1 -1
test,interactions,interactions 1.0 0.000143348623853 0 1 -1
test,interactions,increases 1.0 0.000143348623853 0 1 -1
test,interactions,frova 1.0 0.000143348623853 0 1 -1
test,interactions,finasteride 1.0 0.000143348623853 0 1 -1
test,interactions,false 1.0 0.000143348623853 0 1 -1
test,interactions,effect 1.0 0.000286697247706 0 2 -2
test,interactions,corticosteroids 1.0 0.000143348623853 0 1 -1
test,interactions,certain 1.0 0.000143348623853 0 1 -1
test,interactions,cephalosporins 1.0 0.000286697247706 0 2 -2
test,interactions,blood 1.0 0.000143348623853 0 1 -1
test,interactions,as 1.0 0.000573394495413 0 4 -4
test,interactions,amerge 1.0 0.000143348623853 0 1 -1
test,interactions,acetaminophen 1.0 0.000143348623853 0 1 -1
test,interactions,a 1.0 0.000573394495413 0 4 -4
test,interaction,studies 1.0 0.000143348623853 0 1 -1
test,interaction,fosinopril 1.0 0.000143348623853 0 1 -1
test,interaction,captopril 1.0 0.000143348623853 0 1 -1
test,interaction,because 1.0 0.000143348623853 0 1 -1
test,interaction,after 1.0 0.000143348623853 0 1 -1
test,in,patients 1.0 0.000143348623853 0 1 -1
test,in,mice 1.0 0.000143348623853 0 1 -1
test,in,clinical 1.0 0.000143348623853 0 1 -1
test,has,been 1.0 0.000143348623853 0 1 -1
test,for,when 1.0 0.000143348623853 0 1 -1
test,for,using 1.0 0.000143348623853 0 1 -1
test,for,urinary 1.0 0.000143348623853 0 1 -1
test,for,occult 1.0 0.000143348623853 0 1 -1
test,for,ketones 1.0 0.000143348623853 0 1 -1
test,for,bacterial 1.0 0.000143348623853 0 1 -1
test,findings,asymptomatic 1.0 0.000143348623853 0 1 -1
test,female,patients 1.0 0.000143348623853 0 1 -1
test,dst,in 1.0 0.000286697247706 0 2 -2
test,dst,false-negative 1.0 0.000143348623853 0 1 -1
test,do,not 1.0 0.000143348623853 0 1 -1
test,could,be 1.0 0.000143348623853 0 1 -1
test,but,was 1.0 0.000143348623853 0 1 -1
test,alterations,associated 1.0 0.000143348623853 0 1 -1
test,agent,for 1.0 0.000143348623853 0 1 -1
test,abnormalities,were 1.0 0.000143348623853 0 1 -1
test,abnormalities,related 1.0 0.000143348623853 0 1 -1
test,a,confirmation 1.0 0.000143348623853 0 1 -1
terms,viagra,and 1.0 0.000143348623853 0 1 -1
terms,of,safety 1.0 0.000143348623853 0 1 -1
terms,of,proportionate 1.0 0.000143348623853 0 1 -1
terms,of,pregnancy 1.0 0.000143348623853 0 1 -1
terminate,treatment,with 1.0 0.000143348623853 0 1 -1
termed,the,resistance 1.0 0.000143348623853 0 1 -1
term,therapy,particularly 1.0 0.000143348623853 0 1 -1
terfenadine,no,clinically 1.0 0.000143348623853 0 1 -1
terfenadine,in,a 1.0 0.000143348623853 0 1 -1
terfenadine,astemizole,and 1.0 0.000143348623853 0 1 -1
terfenadine,administration,of 1.0 0.000143348623853 0 1 -1
teratogenic,effects,were 1.0 0.000286697247706 0 2 -2
teratogenic,and,or 1.0 0.000143348623853 0 1 -1
tentatively,supports,the 1.0 0.000143348623853 0 1 -1
tension,hoof,twitch 1.0 0.000143348623853 0 1 -1
tenormin,sectral,lopressor 1.0 0.000143348623853 0 1 -1
tenormin,plus,a 1.0 0.000143348623853 0 1 -1
tenofovir,disoproxil,fumarate 1.0 0.000143348623853 0 1 -1
tendon,reflexes,hourly 1.0 0.000143348623853 0 1 -1
tenderness,skin,discoloration 1.0 0.000143348623853 0 1 -1
tendency,toward,a 1.0 0.000143348623853 0 1 -1
tended,to,experience 1.0 0.000143348623853 0 1 -1
tend,to,produce 1.0 0.000716743119266 0 5 -5
tend,to,increase 1.0 0.000143348623853 0 1 -1
ten,patients,who 1.0 0.000143348623853 0 1 -1
temporary,decrease,in 1.0 0.000143348623853 0 1 -1
temporarily,discontinued,hours 1.0 0.000143348623853 0 1 -1
temporal,patterns,during 1.0 0.000143348623853 0 1 -1
template,bleeding,time 1.0 0.000286697247706 0 2 -2
temperatures,on,microtubules 1.0 0.000143348623853 0 1 -1
temperatures,in,eagles 1.0 0.000143348623853 0 1 -1
temperature,returned,to 1.0 0.000143348623853 0 1 -1
temperature,in,female 1.0 0.000143348623853 0 1 -1
temperature,changes,on 1.0 0.000143348623853 0 1 -1
temperature,began,within 1.0 0.000143348623853 0 1 -1
telithromycin,hiv,protease 1.0 0.000143348623853 0 1 -1
tegretol,tagamet,prozac 1.0 0.000143348623853 0 1 -1
techniques,confirmation,should 1.0 0.000143348623853 0 1 -1
technique,it,was 1.0 0.000143348623853 0 1 -1
technique,in,combination 1.0 0.000143348623853 0 1 -1
technique,and,by 1.0 0.000143348623853 0 1 -1
tea,polyphenols,as 1.0 0.000143348623853 0 1 -1
tea,gallocatechins,epigallocatechin-3 1.0 0.000143348623853 0 1 -1
tdp,in,patients 1.0 0.000143348623853 0 1 -1
tdm,of,therapy 1.0 0.000143348623853 0 1 -1
tcas,when,given 1.0 0.000716743119266 0 5 -5
tcaplasma,levels,whenever 1.0 0.000143348623853 0 1 -1
tcamay,become,abruptly 1.0 0.000143348623853 0 1 -1
tca5,with,any 1.0 0.000143348623853 0 1 -1
tca,treatment,in 1.0 0.000573394495413 0 4 -4
tca,plasma,levels 1.0 0.000573394495413 0 4 -4
tca,may,become 1.0 0.000573394495413 0 4 -4
tca,is,going 1.0 0.000573394495413 0 4 -4
tc99m,uptake,of 1.0 0.000143348623853 0 1 -1
tc,had,no 1.0 0.000143348623853 0 1 -1
tbg,may,also 1.0 0.000143348623853 0 1 -1
tbg,levels,leading 1.0 0.000143348623853 0 1 -1
tbg,leading,to 1.0 0.00043004587156 0 3 -3
tbg,concentrations,are 1.0 0.000143348623853 0 1 -1
tbg,concentration,should 1.0 0.000143348623853 0 1 -1
tbars,in,both 1.0 0.000143348623853 0 1 -1
taxotere,as,there 1.0 0.000143348623853 0 1 -1
taxol,until,neutrophils 1.0 0.000143348623853 0 1 -1
taxol,to,such 1.0 0.000143348623853 0 1 -1
taxol,therapy,should 1.0 0.000143348623853 0 1 -1
taxol,therapy,a 1.0 0.000143348623853 0 1 -1
taxol,should,be 1.0 0.000143348623853 0 1 -1
taxol,may,be 1.0 0.000143348623853 0 1 -1
taxol,is,catalyzed 1.0 0.000143348623853 0 1 -1
taxol,infusions,must 1.0 0.000143348623853 0 1 -1
taxol,contains,dehydrated 1.0 0.000143348623853 0 1 -1
taxol,concomitantly,with 1.0 0.000143348623853 0 1 -1
taxol,but,generally 1.0 0.000143348623853 0 1 -1
taxol,at,the 1.0 0.000143348623853 0 1 -1
taxol,at,a 1.0 0.000143348623853 0 1 -1
taxol,and,aggressive 1.0 0.000143348623853 0 1 -1
taxol,a,substrate 1.0 0.000143348623853 0 1 -1
taste,disorder,abdominal 1.0 0.000143348623853 0 1 -1
tasks,that,are 1.0 0.000143348623853 0 1 -1
tasks,in,mice 1.0 0.000143348623853 0 1 -1
task,it,substituted 1.0 0.000143348623853 0 1 -1
task,induced,significant 1.0 0.000143348623853 0 1 -1
task,considered,the 1.0 0.000143348623853 0 1 -1
tarsal,flexure,of 1.0 0.000143348623853 0 1 -1
targets,and,has 1.0 0.000143348623853 0 1 -1
target,tissues,metabolism 1.0 0.000143348623853 0 1 -1
target,sites,in 1.0 0.000143348623853 0 1 -1
target,of,inhibitor 1.0 0.000143348623853 0 1 -1
target,cell,or 1.0 0.000143348623853 0 1 -1
target,added,drug 1.0 0.000143348623853 0 1 -1
tarceva,should,be 1.0 0.000143348623853 0 1 -1
tarceva,dose,greater 1.0 0.000143348623853 0 1 -1
tapering,of,the 1.0 0.000143348623853 0 1 -1
tamponades,in,conjunction 1.0 0.000143348623853 0 1 -1
tambocor,with,or 1.0 0.000143348623853 0 1 -1
tambocor,has,been 1.0 0.000286697247706 0 2 -2
tambocor,clinical,trials 1.0 0.000143348623853 0 1 -1
tambocor,and,were 1.0 0.000143348623853 0 1 -1
tam,which,also 1.0 0.000143348623853 0 1 -1
tam,induces,apoptosis 1.0 0.000143348623853 0 1 -1
talk,to,your 1.0 0.000716743119266 0 5 -5
taking,which,prolong 1.0 0.000143348623853 0 1 -1
taking,which,can 1.0 0.000143348623853 0 1 -1
taking,when,macrolide 1.0 0.000143348623853 0 1 -1
taking,vioxx,antiplatelet 1.0 0.000143348623853 0 1 -1
taking,tysabri,and 1.0 0.000143348623853 0 1 -1
taking,tricyclic,which 1.0 0.000143348623853 0 1 -1
taking,this,medicine 1.0 0.000286697247706 0 2 -2
taking,these,with 1.0 0.000143348623853 0 1 -1
taking,the,significantly 1.0 0.000143348623853 0 1 -1
taking,the,highest 1.0 0.000143348623853 0 1 -1
taking,the,drug 1.0 0.000143348623853 0 1 -1
taking,that,inhibit 1.0 0.000143348623853 0 1 -1
taking,placebo,with 1.0 0.000143348623853 0 1 -1
taking,placebo,as 1.0 0.000143348623853 0 1 -1
taking,patients,with 1.0 0.00043004587156 0 3 -3
taking,other,psychotropic 1.0 0.000143348623853 0 1 -1
taking,or,other 1.0 0.000143348623853 0 1 -1
taking,or,oral 1.0 0.000143348623853 0 1 -1
taking,or,nsaids 1.0 0.000143348623853 0 1 -1
taking,on,a 1.0 0.000143348623853 0 1 -1
taking,most,and 1.0 0.000143348623853 0 1 -1
taking,mg,daily 1.0 0.000143348623853 0 1 -1
taking,metabolized,by 1.0 0.000143348623853 0 1 -1
taking,medications,for 1.0 0.000143348623853 0 1 -1
taking,medications,associated 1.0 0.000143348623853 0 1 -1
taking,low-dose,plus 1.0 0.000143348623853 0 1 -1
taking,low-dose,mg 1.0 0.000143348623853 0 1 -1
taking,into,account 1.0 0.000286697247706 0 2 -2
taking,fortovase,as 1.0 0.000143348623853 0 1 -1
taking,cyp3a4,inducers 1.0 0.000143348623853 0 1 -1
taking,certain,such 1.0 0.000143348623853 0 1 -1
taking,celebrex,did 1.0 0.000143348623853 0 1 -1
taking,can,in 1.0 0.000143348623853 0 1 -1
taking,beta,blockers 1.0 0.000286697247706 0 2 -2
taking,are,at 1.0 0.000143348623853 0 1 -1
taking,any,prescription 1.0 0.000143348623853 0 1 -1
taking,antiseizure,medication 1.0 0.000143348623853 0 1 -1
taking,another,that 1.0 0.00043004587156 0 3 -3
taking,and,hepatic 1.0 0.000143348623853 0 1 -1
taking,an,mao 1.0 0.000143348623853 0 1 -1
taking,amevive,who 1.0 0.000143348623853 0 1 -1
taking,amevive,continued 1.0 0.000143348623853 0 1 -1
taking,ace,inhibitors 1.0 0.000143348623853 0 1 -1
taking,acarbose,was 1.0 0.000143348623853 0 1 -1
taking,a,talk 1.0 0.000143348623853 0 1 -1
taken,within,the 1.0 0.000143348623853 0 1 -1
taken,when,using 1.0 0.000143348623853 0 1 -1
taken,when,coadministration 1.0 0.00043004587156 0 3 -3
taken,together,these 1.0 0.000286697247706 0 2 -2
taken,on,an 1.0 0.000143348623853 0 1 -1
taken,in,patients 1.0 0.000143348623853 0 1 -1
taken,in,dose 1.0 0.000143348623853 0 1 -1
taken,in,divided 1.0 0.000143348623853 0 1 -1
taken,in,conjunction 1.0 0.000143348623853 0 1 -1
taken,in,concurrent 1.0 0.000286697247706 0 2 -2
taken,if,necessary 1.0 0.000143348623853 0 1 -1
taken,hours,before 1.0 0.000143348623853 0 1 -1
taken,hour,before 1.0 0.000143348623853 0 1 -1
taken,for,hours 1.0 0.000143348623853 0 1 -1
taken,during,treatment 1.0 0.000143348623853 0 1 -1
taken,concurrently,and 1.0 0.000143348623853 0 1 -1
taken,by,of 1.0 0.000286697247706 0 2 -2
taken,before,morning 1.0 0.000143348623853 0 1 -1
taken,as,directed 1.0 0.000143348623853 0 1 -1
take,to,ensure 1.0 0.000143348623853 0 1 -1
take,this,medicine 1.0 0.000286697247706 0 2 -2
take,place,at 1.0 0.000143348623853 0 1 -1
take,other,drugs 1.0 0.000143348623853 0 1 -1
take,other,at 1.0 0.000143348623853 0 1 -1
take,lodine,can 1.0 0.000143348623853 0 1 -1
take,into,account 1.0 0.000143348623853 0 1 -1
take,epa,supplements 1.0 0.000286697247706 0 2 -2
take,advantage,of 1.0 0.000143348623853 0 1 -1
take,a,supplement 1.0 0.000143348623853 0 1 -1
tail-flick,response,to 1.0 0.000143348623853 0 1 -1
tail-flick,inhibition,and 1.0 0.000143348623853 0 1 -1
tagamet,to,maintain 1.0 0.000143348623853 0 1 -1
tagamet,prozac,sporanox 1.0 0.000143348623853 0 1 -1
tacrolimus,felodipine,may 1.0 0.000143348623853 0 1 -1
tacrolimus,co-administration,of 1.0 0.000143348623853 0 1 -1
tachycardia,do,not 1.0 0.000143348623853 0 1 -1
tachycardia,and,gastrointestinal 1.0 0.000143348623853 0 1 -1
tablets,with,and 1.0 0.000143348623853 0 1 -1
tablets,was,not 1.0 0.000143348623853 0 1 -1
tablets,usp,have 1.0 0.000143348623853 0 1 -1
tablets,to,avoid 1.0 0.000143348623853 0 1 -1
tablets,should,be 1.0 0.000143348623853 0 1 -1
tablets,may,delay 1.0 0.000143348623853 0 1 -1
tablets,have,been 1.0 0.000286697247706 0 2 -2
tablets,for,oral 1.0 0.000143348623853 0 1 -1
tablets,containing,mg 1.0 0.000143348623853 0 1 -1
tablets,compared,to 1.0 0.000143348623853 0 1 -1
tablets,but,not 1.0 0.000573394495413 0 4 -4
tablets,benedicts,solution 1.0 0.000143348623853 0 1 -1
tablets,at,doses 1.0 0.000143348623853 0 1 -1
tablets,are,used 1.0 0.000143348623853 0 1 -1
tablets,are,not 1.0 0.000143348623853 0 1 -1
tablets,and,primarily 1.0 0.000143348623853 0 1 -1
tablets,and,any 1.0 0.000143348623853 0 1 -1
tablets,administered,twice 1.0 0.000143348623853 0 1 -1
tablets,administered,once 1.0 0.000143348623853 0 1 -1
tablet,volume,fewer 1.0 0.000143348623853 0 1 -1
table,table,summary 1.0 0.000143348623853 0 1 -1
table,summary,of 1.0 0.000143348623853 0 1 -1
table,potential,drug 1.0 0.000143348623853 0 1 -1
table,is,not 1.0 0.000143348623853 0 1 -1
table,established,drug 1.0 0.000143348623853 0 1 -1
table,effects,on 1.0 0.000286697247706 0 2 -2
table,changes,in 1.0 0.000143348623853 0 1 -1
table,additional,clinical 1.0 0.000143348623853 0 1 -1
table,a,drugs 1.0 0.000143348623853 0 1 -1
tab,ria,kit 1.0 0.000143348623853 0 1 -1
t4,levels,by 1.0 0.000286697247706 0 2 -2
t4,concentration,is 1.0 0.000143348623853 0 1 -1
t4,by,column 1.0 0.000286697247706 0 2 -2
t4,and,free 1.0 0.000143348623853 0 1 -1
t3,uptake,is 1.0 0.000573394495413 0 4 -4
t24,human,bladder 1.0 0.000143348623853 0 1 -1
t,max,were 1.0 0.000143348623853 0 1 -1
t,max,and 1.0 0.00043004587156 0 3 -3
t,max,although 1.0 0.000143348623853 0 1 -1
t,cell-independent,activator 1.0 0.000143348623853 0 1 -1
t,cell,mitogen 1.0 0.000143348623853 0 1 -1
systems,responsible,for 1.0 0.000143348623853 0 1 -1
systems,most,of 1.0 0.000143348623853 0 1 -1
systems,may,have 1.0 0.000143348623853 0 1 -1
systems,lapatinib,is 1.0 0.000143348623853 0 1 -1
systems,lapatinib,inhibits 1.0 0.000143348623853 0 1 -1
systems,inhibition,of 1.0 0.000143348623853 0 1 -1
systems,for,and 1.0 0.000143348623853 0 1 -1
systems,at,the 1.0 0.000143348623853 0 1 -1
systems,and,the 1.0 0.000143348623853 0 1 -1
systems,and,have 1.0 0.000143348623853 0 1 -1
systemically,administered,enter 1.0 0.000143348623853 0 1 -1
systemic,non-hodgkin,lymphoma 1.0 0.000143348623853 0 1 -1
systemic,may,inhibit 1.0 0.000143348623853 0 1 -1
systemic,levels,of 1.0 0.000143348623853 0 1 -1
systemic,levels,may 1.0 0.000143348623853 0 1 -1
systemic,exposure,is 1.0 0.000143348623853 0 1 -1
systemic,exposure,for 1.0 0.000143348623853 0 1 -1
systemic,exposure,auc0-30 1.0 0.000286697247706 0 2 -2
systemic,exposure,auc0-12 1.0 0.000143348623853 0 1 -1
systemic,exposure,approximately 1.0 0.000143348623853 0 1 -1
systemic,eg,flu-like 1.0 0.000143348623853 0 1 -1
systemic,data,have 1.0 0.000143348623853 0 1 -1
systemic,corticosteroids,systemic 1.0 0.000143348623853 0 1 -1
systemic,are,known 1.0 0.000143348623853 0 1 -1
systemic,antiretroviral,agents 1.0 0.000143348623853 0 1 -1
systemic,antimicrobial,agents 1.0 0.000143348623853 0 1 -1
systemic,anticholinesterase,treatment 1.0 0.000143348623853 0 1 -1
systemic,and,or 1.0 0.000143348623853 0 1 -1
systematically,investigated,in 1.0 0.000143348623853 0 1 -1
systematically,in,clinical 1.0 0.000143348623853 0 1 -1
systematically,between,june 1.0 0.000143348623853 0 1 -1
systematically,alter,the 1.0 0.000143348623853 0 1 -1
systematic,experience,with 1.0 0.000143348623853 0 1 -1
systematic,changes,in 1.0 0.000143348623853 0 1 -1
system,that,result 1.0 0.000143348623853 0 1 -1
system,that,in 1.0 0.000143348623853 0 1 -1
system,such,as 1.0 0.000143348623853 0 1 -1
system,specifically,through 1.0 0.000143348623853 0 1 -1
system,should,be 1.0 0.000286697247706 0 2 -2
system,probably,responsible 1.0 0.000143348623853 0 1 -1
system,particularly,the 1.0 0.000143348623853 0 1 -1
system,or,the 1.0 0.000143348623853 0 1 -1
system,of,primary 1.0 0.000143348623853 0 1 -1
system,maybe,useful 1.0 0.000143348623853 0 1 -1
system,may,result 1.0 0.000286697247706 0 2 -2
system,may,have 1.0 0.000143348623853 0 1 -1
system,leading,to 1.0 0.000143348623853 0 1 -1
system,is,less 1.0 0.000143348623853 0 1 -1
system,is,involved 1.0 0.000143348623853 0 1 -1
system,inhibitors,of 1.0 0.000143348623853 0 1 -1
system,have,not 1.0 0.000143348623853 0 1 -1
system,fentanyl,is 1.0 0.000143348623853 0 1 -1
system,development,was 1.0 0.000143348623853 0 1 -1
system,development,is 1.0 0.000143348623853 0 1 -1
system,derived,from 1.0 0.000143348623853 0 1 -1
system,depression,produced 1.0 0.000143348623853 0 1 -1
system,depressants,other 1.0 0.000143348623853 0 1 -1
system,depressants,but 1.0 0.000143348623853 0 1 -1
system,depressant,cns 1.0 0.000143348623853 0 1 -1
system,decreased,effect 1.0 0.000143348623853 0 1 -1
system,cyp3a4,therefore 1.0 0.000143348623853 0 1 -1
system,careful,consideration 1.0 0.000286697247706 0 2 -2
system,by,intrathecal 1.0 0.000143348623853 0 1 -1
system,and,result 1.0 0.000143348623853 0 1 -1
system,and,postnatal 1.0 0.000143348623853 0 1 -1
system,and,at 1.0 0.000143348623853 0 1 -1
system,although,the 1.0 0.000143348623853 0 1 -1
synthetic,steroidal,and 1.0 0.000143348623853 0 1 -1
synthetic,on,placental 1.0 0.000143348623853 0 1 -1
synthetic,hydroxy-3,methylglutaryl 1.0 0.000143348623853 0 1 -1
synthetic,hydroalcoholic,solutions 1.0 0.000143348623853 0 1 -1
synthetic,galloyl,esters 1.0 0.000143348623853 0 1 -1
synthetic,analogue,d-ala2 1.0 0.000143348623853 0 1 -1
synthetase,inhibitors,also 1.0 0.000143348623853 0 1 -1
synthetase,inhibitor,however 1.0 0.000143348623853 0 1 -1
synthesis,to,match 1.0 0.000143348623853 0 1 -1
synthesis,secretion,distribution 1.0 0.000286697247706 0 2 -2
synthesis,or,in 1.0 0.000143348623853 0 1 -1
synthesis,of,the 1.0 0.000143348623853 0 1 -1
synthesis,of,cyp3a4 1.0 0.000143348623853 0 1 -1
synthesis,interfere,with 1.0 0.000143348623853 0 1 -1
synthesis,in,the 1.0 0.000143348623853 0 1 -1
synthesis,and,theoretically 1.0 0.000143348623853 0 1 -1
synthesis,and,release 1.0 0.000143348623853 0 1 -1
synthesis,and,did 1.0 0.000143348623853 0 1 -1
synkayvite,use,of 1.0 0.000143348623853 0 1 -1
synergy,was,usually 1.0 0.000143348623853 0 1 -1
synergistically,to,increase 1.0 0.000143348623853 0 1 -1
synergistically,augmented,the 1.0 0.000143348623853 0 1 -1
synergistic,or,antagonist 1.0 0.000143348623853 0 1 -1
synergistic,effect,compared 1.0 0.000143348623853 0 1 -1
synergistic,depressant,effects 1.0 0.000143348623853 0 1 -1
syndrome,requires,immediate 1.0 0.000143348623853 0 1 -1
syndrome,in,phase 1.0 0.000143348623853 0 1 -1
synaptic,concentration,of 1.0 0.000143348623853 0 1 -1
symptoms,usually,occurred 1.0 0.000143348623853 0 1 -1
symptoms,support,the 1.0 0.000143348623853 0 1 -1
symptoms,such,as 1.0 0.000143348623853 0 1 -1
symptoms,should,be 1.0 0.000143348623853 0 1 -1
symptoms,resolved,within 1.0 0.000143348623853 0 1 -1
symptoms,resolved,when 1.0 0.000143348623853 0 1 -1
symptoms,p,although 1.0 0.000143348623853 0 1 -1
symptoms,of,myasthenic 1.0 0.000143348623853 0 1 -1
symptoms,of,anticholinesterase 1.0 0.000143348623853 0 1 -1
symptoms,of,aggression 1.0 0.000143348623853 0 1 -1
symptoms,may,be 1.0 0.000143348623853 0 1 -1
symptoms,may,also 1.0 0.000143348623853 0 1 -1
symptoms,indicates,deterioration 1.0 0.000143348623853 0 1 -1
symptoms,excitement,hypomania 1.0 0.000143348623853 0 1 -1
symptoms,but,not 1.0 0.000143348623853 0 1 -1
symptoms,appear,before 1.0 0.000143348623853 0 1 -1
symptoms,and,was 1.0 0.000143348623853 0 1 -1
symptoms,and,extra 1.0 0.000143348623853 0 1 -1
symptomatology,is,unusual 1.0 0.000143348623853 0 1 -1
symptomatic,pharmaceutical,treatment 1.0 0.000143348623853 0 1 -1
symptomatic,hypotension,in 1.0 0.000143348623853 0 1 -1
symptomatic,hyperlactatemia,lactic 1.0 0.000143348623853 0 1 -1
symptom,onset,were 1.0 0.000143348623853 0 1 -1
sympathomimetic,agents,possible 1.0 0.000143348623853 0 1 -1
sympatholytic,medicinal,products 1.0 0.000286697247706 0 2 -2
sympathetic,nervous,system 1.0 0.000286697247706 0 2 -2
sympathetic,activity,the 1.0 0.000143348623853 0 1 -1
sympathetic,activity,ganglionic 1.0 0.000143348623853 0 1 -1
switched,from,therapy 1.0 0.000143348623853 0 1 -1
swine,has,resulted 1.0 0.000143348623853 0 1 -1
swelling,at,the 1.0 0.000143348623853 0 1 -1
sustivahas,the,potential 1.0 0.000143348623853 0 1 -1
sustiva,mg,all 1.0 0.000143348623853 0 1 -1
sustiva,is,recommended 1.0 0.000143348623853 0 1 -1
sustiva,is,given 1.0 0.000143348623853 0 1 -1
sustiva,in,treatment-naive 1.0 0.000143348623853 0 1 -1
sustiva,are,summarized 1.0 0.000143348623853 0 1 -1
sustiva,and,these 1.0 0.000143348623853 0 1 -1
sustiva,and,nrtis 1.0 0.000143348623853 0 1 -1
sustiva,and,in 1.0 0.000143348623853 0 1 -1
sustained-release,with,no 1.0 0.000143348623853 0 1 -1
sustained-release,tablets,with 1.0 0.000143348623853 0 1 -1
sustained-release,channel,blockers 1.0 0.000143348623853 0 1 -1
sustain,plasma,levels 1.0 0.000143348623853 0 1 -1
suspension,yielded,similar 1.0 0.000143348623853 0 1 -1
suspension,contains,a 1.0 0.000143348623853 0 1 -1
suspension,can,be 1.0 0.000286697247706 0 2 -2
suspected,to,be 1.0 0.000286697247706 0 2 -2
suspected,of,having 1.0 0.000143348623853 0 1 -1
susceptible,to,the 1.0 0.000143348623853 0 1 -1
susceptible,to,inhibitory 1.0 0.000143348623853 0 1 -1
susceptible,to,diethylnitrosamine 1.0 0.000143348623853 0 1 -1
susceptible,to,a 1.0 0.000143348623853 0 1 -1
susceptible,patients,or 1.0 0.000143348623853 0 1 -1
susceptible,patients,following 1.0 0.000143348623853 0 1 -1
susceptibility,to,progression 1.0 0.000143348623853 0 1 -1
susceptibility,to,hypoglycemia 1.0 0.000286697247706 0 2 -2
susceptibility,to,cardiac 1.0 0.000143348623853 0 1 -1
susceptibility,to,bruising 1.0 0.000143348623853 0 1 -1
susceptibility,through,a 1.0 0.000143348623853 0 1 -1
susceptibility,in,enterococcus 1.0 0.000143348623853 0 1 -1
survive,in,and 1.0 0.000143348623853 0 1 -1
survival,were,evident 1.0 0.000143348623853 0 1 -1
survival,was,increased 1.0 0.000143348623853 0 1 -1
survival,of,miracidia 1.0 0.000143348623853 0 1 -1
survival,of,chop 1.0 0.000143348623853 0 1 -1
survival,needs,urgently 1.0 0.000143348623853 0 1 -1
survival,in,conditions 1.0 0.000143348623853 0 1 -1
survival,in,and 1.0 0.000143348623853 0 1 -1
survival,for,chop-haart 1.0 0.000143348623853 0 1 -1
survival,and,avoidance 1.0 0.000143348623853 0 1 -1
survey,of,hospital 1.0 0.000143348623853 0 1 -1
survanta,on,the 1.0 0.000143348623853 0 1 -1
survanta,increased,the 1.0 0.000143348623853 0 1 -1
survanta,also,increased 1.0 0.000143348623853 0 1 -1
surprisingly,green,tea 1.0 0.000143348623853 0 1 -1
surgery,or,skeletal-muscle 1.0 0.000143348623853 0 1 -1
surgery,because,is 1.0 0.000143348623853 0 1 -1
surfaces,of,the 1.0 0.000143348623853 0 1 -1
surface,histidine,residues 1.0 0.000143348623853 0 1 -1
surface,area,bsa 1.0 0.000286697247706 0 2 -2
surface,area,basis 1.0 0.000143348623853 0 1 -1
suprax,may,result 1.0 0.000143348623853 0 1 -1
supraventricular,arrhythmias,may 1.0 0.000143348623853 0 1 -1
supraspinal,brain,sites 1.0 0.000143348623853 0 1 -1
suppression,test,dst 1.0 0.000286697247706 0 2 -2
suppression,of,release 1.0 0.000143348623853 0 1 -1
suppression,of,organs 1.0 0.000143348623853 0 1 -1
suppression,of,midcycle 1.0 0.000143348623853 0 1 -1
suppression,of,in 1.0 0.000143348623853 0 1 -1
suppression,of,growth 1.0 0.000143348623853 0 1 -1
suppressed,by,synthetic 1.0 0.000143348623853 0 1 -1
suppress,the,immune 1.0 0.000143348623853 0 1 -1
suppress,reactions,to 1.0 0.000143348623853 0 1 -1
suppress,certain,cyp450 1.0 0.000143348623853 0 1 -1
supports,the,hypothesis 1.0 0.000143348623853 0 1 -1
supporting,blood,pressure 1.0 0.000143348623853 0 1 -1
supported,by,separate 1.0 0.000143348623853 0 1 -1
support,was,significantly 1.0 0.000143348623853 0 1 -1
support,these,conclusions 1.0 0.000143348623853 0 1 -1
support,the,effectiveness 1.0 0.000143348623853 0 1 -1
support,the,choice 1.0 0.000143348623853 0 1 -1
support,its,use 1.0 0.000143348623853 0 1 -1
supplied,aerolizertm,inhalation 1.0 0.000143348623853 0 1 -1
supplements,with,their 1.0 0.000143348623853 0 1 -1
supplements,uncontrolled,intake 1.0 0.00043004587156 0 3 -3
supplements,should,be 1.0 0.000286697247706 0 2 -2
supplements,oral,or 1.0 0.000143348623853 0 1 -1
supplements,or,salt 1.0 0.000143348623853 0 1 -1
supplements,on,glycemic 1.0 0.000143348623853 0 1 -1
supplements,might,have 1.0 0.000143348623853 0 1 -1
supplements,may,result 1.0 0.000143348623853 0 1 -1
supplements,have,detrimental 1.0 0.000143348623853 0 1 -1
supplements,has,been 1.0 0.000143348623853 0 1 -1
supplements,can,increase 1.0 0.000286697247706 0 2 -2
supplements,can,correct 1.0 0.000143348623853 0 1 -1
supplements,and,the 1.0 0.000143348623853 0 1 -1
supplements,affect,their 1.0 0.000143348623853 0 1 -1
supplemented,with,the 1.0 0.000143348623853 0 1 -1
supplemented,with,coenzyme 1.0 0.000143348623853 0 1 -1
supplementation,with,water-miscible 1.0 0.000143348623853 0 1 -1
supplementation,which,is 1.0 0.000143348623853 0 1 -1
supplementation,mg,kg 1.0 0.000143348623853 0 1 -1
supplementation,and,depletion 1.0 0.000143348623853 0 1 -1
supplementary,oral,and 1.0 0.000143348623853 0 1 -1
supplemental,folic,acid 1.0 0.000143348623853 0 1 -1
supplement,that,contains 1.0 0.000143348623853 0 1 -1
supplement,st,johns 1.0 0.000143348623853 0 1 -1
supplement,food,or 1.0 0.000286697247706 0 2 -2
supine,position,and 1.0 0.000143348623853 0 1 -1
supervision,of,diabetic 1.0 0.000143348623853 0 1 -1
supervision,for,at 1.0 0.000143348623853 0 1 -1
superiority,over,in 1.0 0.000143348623853 0 1 -1
superiority,of,over 1.0 0.000143348623853 0 1 -1
superiority,compared,with 1.0 0.000143348623853 0 1 -1
superior,to,to 1.0 0.000286697247706 0 2 -2
superior,antipsychotic,efficacy 1.0 0.000143348623853 0 1 -1
summary,of,aed 1.0 0.000143348623853 0 1 -1
summary,a,year-old 1.0 0.000143348623853 0 1 -1
summarized,in,the 1.0 0.000286697247706 0 2 -2
summarized,in,table 1.0 0.000143348623853 0 1 -1
sum,of,desethylzaleplon 1.0 0.000143348623853 0 1 -1
sulphydryl-containing,amino,acid 1.0 0.000143348623853 0 1 -1
sulfoxide,plasma,concentrations 1.0 0.000143348623853 0 1 -1
sulfosalicylic,acid,precipitation 1.0 0.000143348623853 0 1 -1
sulfonylureas,requirements,for 1.0 0.000143348623853 0 1 -1
sulfate,tests,benedicts 1.0 0.000143348623853 0 1 -1
sulfate,prednisolone,sodium 1.0 0.000143348623853 0 1 -1
sulfamethoxazole-trimethoprim,bactrim,septra 1.0 0.000143348623853 0 1 -1
sulfamethoxazole,concomitant,use 1.0 0.000143348623853 0 1 -1
sulfa-based,such,as 1.0 0.000143348623853 0 1 -1
suitable,for,evaluating 1.0 0.000143348623853 0 1 -1
suitable,coagulation,tests 1.0 0.000573394495413 0 4 -4
suitability,of,the 1.0 0.000143348623853 0 1 -1
suggests,that,more 1.0 0.000143348623853 0 1 -1
suggests,that,interactions 1.0 0.000143348623853 0 1 -1
suggests,that,does 1.0 0.000143348623853 0 1 -1
suggests,that,an 1.0 0.000143348623853 0 1 -1
suggesting,that,is 1.0 0.000143348623853 0 1 -1
suggesting,that,histaminergic 1.0 0.000143348623853 0 1 -1
suggesting,that,coadministration 1.0 0.000143348623853 0 1 -1
suggesting,no,clinically 1.0 0.000143348623853 0 1 -1
suggesting,a,metabolite 1.0 0.000143348623853 0 1 -1
suggesting,a,dissociation 1.0 0.000143348623853 0 1 -1
suggested,with,sodium 1.0 0.000143348623853 0 1 -1
suggested,with,phenyl-butazone 1.0 0.000143348623853 0 1 -1
suggested,with,hormonal 1.0 0.000143348623853 0 1 -1
suggested,to,mg 1.0 0.000143348623853 0 1 -1
suggested,the,mediation 1.0 0.000143348623853 0 1 -1
suggested,that,these 1.0 0.000143348623853 0 1 -1
suggested,that,there 1.0 0.000143348623853 0 1 -1
suggested,that,therapy 1.0 0.000143348623853 0 1 -1
suggested,that,is 1.0 0.000143348623853 0 1 -1
suggested,may,be 1.0 0.000143348623853 0 1 -1
suggested,in,the 1.0 0.000143348623853 0 1 -1
suggested,by,induction 1.0 0.000143348623853 0 1 -1
suggest,these,agents 1.0 0.000143348623853 0 1 -1
suggest,the,need 1.0 0.000143348623853 0 1 -1
suggest,the,modified 1.0 0.000143348623853 0 1 -1
suggest,that,there 1.0 0.000143348623853 0 1 -1
suggest,that,s 1.0 0.000143348623853 0 1 -1
suggest,that,mc 1.0 0.000143348623853 0 1 -1
suggest,that,krm-1648 1.0 0.000143348623853 0 1 -1
suggest,that,is 1.0 0.00043004587156 0 3 -3
suggest,that,intraventricular 1.0 0.000143348623853 0 1 -1
suggest,that,intracellular 1.0 0.000143348623853 0 1 -1
suggest,that,interacts 1.0 0.000143348623853 0 1 -1
suggest,that,genetic 1.0 0.000143348623853 0 1 -1
suggest,that,exogenous 1.0 0.000143348623853 0 1 -1
suggest,that,d1 1.0 0.000143348623853 0 1 -1
suggest,that,blockers 1.0 0.000143348623853 0 1 -1
suggest,that,are 1.0 0.000143348623853 0 1 -1
suggest,that,an 1.0 0.000143348623853 0 1 -1
suggest,that,alcoholic 1.0 0.000143348623853 0 1 -1
suggest,that,affect 1.0 0.000143348623853 0 1 -1
suggest,that,acute 1.0 0.000143348623853 0 1 -1
suggest,that,absorption 1.0 0.000143348623853 0 1 -1
suggest,similar,effects 1.0 0.000143348623853 0 1 -1
suggest,no,significant 1.0 0.000143348623853 0 1 -1
suggest,comparable,activity 1.0 0.000143348623853 0 1 -1
suggest,any,clinical 1.0 0.000143348623853 0 1 -1
suggest,an,increased 1.0 0.000286697247706 0 2 -2
sugar,some,patients 1.0 0.000143348623853 0 1 -1
sugar,level,hyperlipidaemia 1.0 0.000143348623853 0 1 -1
sufficient,to,rule 1.0 0.000143348623853 0 1 -1
sufficient,to,predict 1.0 0.000143348623853 0 1 -1
sufficient,to,preclude 1.0 0.000573394495413 0 4 -4
sufficient,time,for 1.0 0.000143348623853 0 1 -1
sufficient,numbers,of 1.0 0.000143348623853 0 1 -1
sufficient,however,to 1.0 0.000143348623853 0 1 -1
sufficient,function,the 1.0 0.000143348623853 0 1 -1
sufficient,data,to 1.0 0.000143348623853 0 1 -1
suffer,from,these 1.0 0.000143348623853 0 1 -1
suddenly,exceeded,of 1.0 0.000143348623853 0 1 -1
sudden,extrusion,of 1.0 0.000143348623853 0 1 -1
sudden,cardiac,deaths 1.0 0.000143348623853 0 1 -1
sucralfate,metal,cations 1.0 0.000143348623853 0 1 -1
sucralfate,and,quinolones 1.0 0.000143348623853 0 1 -1
such,without,a 1.0 0.000143348623853 0 1 -1
such,users,is 1.0 0.000143348623853 0 1 -1
such,tumors,is 1.0 0.000143348623853 0 1 -1
such,treatment,is 1.0 0.000143348623853 0 1 -1
such,the,dose 1.0 0.000286697247706 0 2 -2
such,reactions,have 1.0 0.000143348623853 0 1 -1
such,preparations,to 1.0 0.000143348623853 0 1 -1
such,preparations,in 1.0 0.000143348623853 0 1 -1
such,patients,with 1.0 0.000143348623853 0 1 -1
such,patients,the 1.0 0.000143348623853 0 1 -1
such,patients,careful 1.0 0.000143348623853 0 1 -1
such,methods,for 1.0 0.000143348623853 0 1 -1
such,medication,and 1.0 0.000143348623853 0 1 -1
such,measurements,are 1.0 0.000143348623853 0 1 -1
such,it,may 1.0 0.00043004587156 0 3 -3
such,interactions,were 1.0 0.000143348623853 0 1 -1
such,interactions,should 1.0 0.000143348623853 0 1 -1
such,interactions,might 1.0 0.000143348623853 0 1 -1
such,interactions,have 1.0 0.000143348623853 0 1 -1
such,interaction,should 1.0 0.000143348623853 0 1 -1
such,information,assists 1.0 0.000143348623853 0 1 -1
such,individuals,are 1.0 0.000286697247706 0 2 -2
such,inactivation,of 1.0 0.000143348623853 0 1 -1
such,factors,as 1.0 0.000143348623853 0 1 -1
such,drugs,are 1.0 0.00043004587156 0 3 -3
such,doses,of 1.0 0.000286697247706 0 2 -2
such,data,are 1.0 0.000143348623853 0 1 -1
such,considerations,as 1.0 0.000143348623853 0 1 -1
such,concurrent,use 1.0 0.000143348623853 0 1 -1
such,concomitant,use 1.0 0.000143348623853 0 1 -1
such,combinations,should 1.0 0.000143348623853 0 1 -1
such,combinations,has 1.0 0.000143348623853 0 1 -1
such,cases,therefore 1.0 0.000143348623853 0 1 -1
such,cases,the 1.0 0.000143348623853 0 1 -1
such,cases,should 1.0 0.000143348623853 0 1 -1
such,cases,of 1.0 0.000143348623853 0 1 -1
such,as,uncompromised 1.0 0.000143348623853 0 1 -1
such,as,tolerance 1.0 0.000143348623853 0 1 -1
such,as,those 1.0 0.000143348623853 0 1 -1
such,as,thorazine 1.0 0.000143348623853 0 1 -1
such,as,sulfamethoxazole-trimethoprim 1.0 0.000143348623853 0 1 -1
such,as,should 1.0 0.00043004587156 0 3 -3
such,as,salicylic 1.0 0.000143348623853 0 1 -1
such,as,risk 1.0 0.000286697247706 0 2 -2
such,as,renal 1.0 0.000143348623853 0 1 -1
such,as,reinforcing 1.0 0.000143348623853 0 1 -1
such,as,psoriasis 1.0 0.000143348623853 0 1 -1
such,as,prolonged 1.0 0.000286697247706 0 2 -2
such,as,platelet 1.0 0.000143348623853 0 1 -1
such,as,phlebitis 1.0 0.000143348623853 0 1 -1
such,as,palpitations 1.0 0.000143348623853 0 1 -1
such,as,operating 1.0 0.000143348623853 0 1 -1
such,as,nausea 1.0 0.000143348623853 0 1 -1
such,as,motrin 1.0 0.000143348623853 0 1 -1
such,as,mg 1.0 0.000143348623853 0 1 -1
such,as,marplan 1.0 0.000286697247706 0 2 -2
such,as,k 1.0 0.000143348623853 0 1 -1
such,as,ironing 1.0 0.000143348623853 0 1 -1
such,as,inderal 1.0 0.000143348623853 0 1 -1
such,as,impulsivity 1.0 0.000143348623853 0 1 -1
such,as,implants 1.0 0.000143348623853 0 1 -1
such,as,hypotension 1.0 0.000143348623853 0 1 -1
such,as,high-dose 1.0 0.000143348623853 0 1 -1
such,as,hctz 1.0 0.000143348623853 0 1 -1
such,as,grapefruit 1.0 0.000143348623853 0 1 -1
such,as,flushing 1.0 0.000143348623853 0 1 -1
such,as,factor 1.0 0.000286697247706 0 2 -2
such,as,dose 1.0 0.000143348623853 0 1 -1
such,as,diphen-hydramine 1.0 0.000143348623853 0 1 -1
such,as,deltasone 1.0 0.000143348623853 0 1 -1
such,as,colostrum 1.0 0.000143348623853 0 1 -1
such,as,cns 1.0 0.000143348623853 0 1 -1
such,as,clinistix 1.0 0.000716743119266 0 5 -5
such,as,channel-blockers 1.0 0.000143348623853 0 1 -1
such,as,beta-adrenergic 1.0 0.000143348623853 0 1 -1
such,as,back 1.0 0.000143348623853 0 1 -1
such,as,acute 1.0 0.000286697247706 0 2 -2
such,as,a 1.0 0.00043004587156 0 3 -3
such,arrhythmias,may 1.0 0.000143348623853 0 1 -1
such,are,withdrawn 1.0 0.000860091743119 0 6 -6
such,are,used 1.0 0.000143348623853 0 1 -1
such,are,given 1.0 0.000143348623853 0 1 -1
such,are,administered 1.0 0.000860091743119 0 6 -6
such,an,interaction 1.0 0.00043004587156 0 3 -3
such,an,action 1.0 0.000143348623853 0 1 -1
such,agents,should 1.0 0.000286697247706 0 2 -2
such,agents,must 1.0 0.000143348623853 0 1 -1
such,agents,is 1.0 0.000286697247706 0 2 -2
such,a,similar 1.0 0.000143348623853 0 1 -1
such,a,nonlinear 1.0 0.000143348623853 0 1 -1
such,a,fall 1.0 0.000143348623853 0 1 -1
such,a,case 1.0 0.000143348623853 0 1 -1
succinylcholine-induced,neuromuscular,blockade 1.0 0.000143348623853 0 1 -1
succinylcholine,may,cause 1.0 0.000143348623853 0 1 -1
successive,generation,more 1.0 0.000143348623853 0 1 -1
successfully,concurrently,with 1.0 0.000286697247706 0 2 -2
successful,prophylaxis,of 1.0 0.000143348623853 0 1 -1
subtypes,using,their 1.0 0.000143348623853 0 1 -1
subtypes,in,bovine 1.0 0.000143348623853 0 1 -1
subtypes,by,in 1.0 0.000143348623853 0 1 -1
subtypes,although,it 1.0 0.000143348623853 0 1 -1
subtype,in,the 1.0 0.000143348623853 0 1 -1
subtle,cell,type-specific 1.0 0.000143348623853 0 1 -1
substrates,or,inhibitors 1.0 0.000143348623853 0 1 -1
substrates,of,pgp 1.0 0.000143348623853 0 1 -1
substrates,of,cyp450 1.0 0.000143348623853 0 1 -1
substrates,of,cyp3a4 1.0 0.000286697247706 0 2 -2
substrates,of,c 1.0 0.000143348623853 0 1 -1
substrates,inhibitors,or 1.0 0.00043004587156 0 3 -3
substrates,in,vitro 1.0 0.000143348623853 0 1 -1
substrates,has,not 1.0 0.000143348623853 0 1 -1
substrates,for,the 1.0 0.000143348623853 0 1 -1
substrates,for,p450 1.0 0.000716743119266 0 5 -5
substrates,for,human 1.0 0.000143348623853 0 1 -1
substrates,for,cyp3a4 1.0 0.000143348623853 0 1 -1
substrates,for,cyp1a2 1.0 0.000143348623853 0 1 -1
substrates,dasatinib,is 1.0 0.000143348623853 0 1 -1
substrates,and,or 1.0 0.000143348623853 0 1 -1
substrates,and,inhibitors 1.0 0.000143348623853 0 1 -1
substrates,and,human 1.0 0.000143348623853 0 1 -1
substrate,single,dose 1.0 0.000286697247706 0 2 -2
substrate,should,be 1.0 0.000143348623853 0 1 -1
substrate,response,is 1.0 0.000143348623853 0 1 -1
substrate,of,the 1.0 0.000143348623853 0 1 -1
substrate,of,cyp3a4 1.0 0.000286697247706 0 2 -2
substrate,of,cyp2d6 1.0 0.000143348623853 0 1 -1
substrate,of,cyp1a1 1.0 0.000143348623853 0 1 -1
substrate,is,only 1.0 0.000143348623853 0 1 -1
substrate,is,an 1.0 0.000143348623853 0 1 -1
substrate,in,combination 1.0 0.000286697247706 0 2 -2
substrate,for,uptake-1 1.0 0.000143348623853 0 1 -1
substrate,for,the 1.0 0.000143348623853 0 1 -1
substrate,for,p-glycoprotein 1.0 0.000286697247706 0 2 -2
substrate,for,many 1.0 0.000143348623853 0 1 -1
substrate,for,deoxycytidine 1.0 0.000143348623853 0 1 -1
substrate,for,cytochrome 1.0 0.000286697247706 0 2 -2
substrate,for,cyp3a4 1.0 0.000286697247706 0 2 -2
substrate,for,both 1.0 0.000143348623853 0 1 -1
substrate,are,likely 1.0 0.000143348623853 0 1 -1
substrate,and,cyp 1.0 0.000143348623853 0 1 -1
substrate,and,an 1.0 0.000143348623853 0 1 -1
substrate,and,a 1.0 0.000286697247706 0 2 -2
substrate,agent,may 1.0 0.000143348623853 0 1 -1
substrate,administered,in 1.0 0.000143348623853 0 1 -1
substrate,a,moderate 1.0 0.000143348623853 0 1 -1
substitutes,containing,should 1.0 0.000143348623853 0 1 -1
substitutes,containing,may 1.0 0.000143348623853 0 1 -1
substituted,for,the 1.0 0.000143348623853 0 1 -1
substituted,for,other 1.0 0.000143348623853 0 1 -1
substitute,for,oral 1.0 0.000143348623853 0 1 -1
substitute,for,for 1.0 0.00043004587156 0 3 -3
substantive,effect,on 1.0 0.000143348623853 0 1 -1
substantially,greater,therapeutic 1.0 0.000143348623853 0 1 -1
substantially,decrease,plasma 1.0 0.000143348623853 0 1 -1
substantial,period,after 1.0 0.000143348623853 0 1 -1
substantial,intercurrent,use 1.0 0.000143348623853 0 1 -1
substantia,gelatinosa,neurons 1.0 0.000143348623853 0 1 -1
substances,the,types 1.0 0.000143348623853 0 1 -1
substances,that,may 1.0 0.000716743119266 0 5 -5
substances,that,inhibit 1.0 0.000286697247706 0 2 -2
substances,tbars,in 1.0 0.000143348623853 0 1 -1
substances,including,herbal 1.0 0.000143348623853 0 1 -1
substances,grapefruit,juice 1.0 0.000143348623853 0 1 -1
substances,are,known 1.0 0.000143348623853 0 1 -1
substances,affect,glucose 1.0 0.000286697247706 0 2 -2
subset,to,of 1.0 0.000143348623853 0 1 -1
subset,of,the 1.0 0.00100344036697 0 7 -7
subset,of,patients 1.0 0.000143348623853 0 1 -1
subsequently,increase,with 1.0 0.000143348623853 0 1 -1
subsequently,found,to 1.0 0.000143348623853 0 1 -1
subsequent,to,initiation 1.0 0.000286697247706 0 2 -2
subsequent,synthesis,and 1.0 0.000143348623853 0 1 -1
subsequent,recovery,of 1.0 0.000143348623853 0 1 -1
subsequent,diagnostic,serum 1.0 0.000143348623853 0 1 -1
subsequent,cycles,of 1.0 0.000143348623853 0 1 -1
subsequent,courses,of 1.0 0.000143348623853 0 1 -1
subsequent,adjustment,of 1.0 0.000143348623853 0 1 -1
subpopulations,of,initiated 1.0 0.000143348623853 0 1 -1
subnormal,release,and 1.0 0.000143348623853 0 1 -1
subnormal,pancreatic,release 1.0 0.000143348623853 0 1 -1
submitted,to,treatment 1.0 0.000143348623853 0 1 -1
submitted,to,daily 1.0 0.000143348623853 0 1 -1
submitted,to,a 1.0 0.000143348623853 0 1 -1
sublingual,may,be 1.0 0.000143348623853 0 1 -1
subjects,with,specific 1.0 0.000143348623853 0 1 -1
subjects,with,normal 1.0 0.000143348623853 0 1 -1
subjects,with,mg 1.0 0.000143348623853 0 1 -1
subjects,with,epilepsy 1.0 0.000573394495413 0 4 -4
subjects,who,were 1.0 0.000286697247706 0 2 -2
subjects,who,do 1.0 0.000143348623853 0 1 -1
subjects,were,randomized 1.0 0.000143348623853 0 1 -1
subjects,were,administered 1.0 0.000286697247706 0 2 -2
subjects,twelve,healthy 1.0 0.000143348623853 0 1 -1
subjects,treated,with 1.0 0.000286697247706 0 2 -2
subjects,to,determine 1.0 0.000143348623853 0 1 -1
subjects,to,assess 1.0 0.000143348623853 0 1 -1
subjects,to,a 1.0 0.000143348623853 0 1 -1
subjects,there,were 1.0 0.000143348623853 0 1 -1
subjects,the,steady-state 1.0 0.000143348623853 0 1 -1
subjects,the,concurrent 1.0 0.000143348623853 0 1 -1
subjects,than,for 1.0 0.000143348623853 0 1 -1
subjects,taking,placebo 1.0 0.000143348623853 0 1 -1
subjects,single-dose,administration 1.0 0.000143348623853 0 1 -1
subjects,reports,of 1.0 0.000143348623853 0 1 -1
subjects,receiving,no 1.0 0.000143348623853 0 1 -1
subjects,receiving,daily 1.0 0.000143348623853 0 1 -1
subjects,received,rantidine 1.0 0.000143348623853 0 1 -1
subjects,received,mg 1.0 0.000286697247706 0 2 -2
subjects,received,in 1.0 0.000143348623853 0 1 -1
subjects,received,concomitant 1.0 0.000286697247706 0 2 -2
subjects,received,alone 1.0 0.000143348623853 0 1 -1
subjects,r,b 1.0 0.000143348623853 0 1 -1
subjects,or,patients 1.0 0.000143348623853 0 1 -1
subjects,on,stable 1.0 0.000143348623853 0 1 -1
subjects,on,concomitant 1.0 0.000143348623853 0 1 -1
subjects,nor,does 1.0 0.000143348623853 0 1 -1
subjects,no,significant 1.0 0.000143348623853 0 1 -1
subjects,no,evidence 1.0 0.000143348623853 0 1 -1
subjects,n,there 1.0 0.000143348623853 0 1 -1
subjects,have,not 1.0 0.000143348623853 0 1 -1
subjects,had,treatment-emergent 1.0 0.000143348623853 0 1 -1
subjects,did,not 1.0 0.000143348623853 0 1 -1
subjects,decreases,in 1.0 0.000143348623853 0 1 -1
subjects,clearance,and 1.0 0.000143348623853 0 1 -1
subjects,by,coadministration 1.0 0.000143348623853 0 1 -1
subjects,but,also 1.0 0.000143348623853 0 1 -1
subjects,aged,or 1.0 0.000143348623853 0 1 -1
subjective,responses,to 1.0 0.000143348623853 0 1 -1
subjective,effects,addiction 1.0 0.000143348623853 0 1 -1
subjective,and,behavioral 1.0 0.000286697247706 0 2 -2
subject,was,treated 1.0 0.000143348623853 0 1 -1
subject,to,p450-based 1.0 0.000143348623853 0 1 -1
subject,to,first-pass 1.0 0.000143348623853 0 1 -1
subject,themselves,to 1.0 0.000143348623853 0 1 -1
subject,received,an 1.0 0.000143348623853 0 1 -1
subject,n,received 1.0 0.000143348623853 0 1 -1
subject,demonstrated,clinical 1.0 0.000143348623853 0 1 -1
subject,before,and 1.0 0.000143348623853 0 1 -1
subgroup,of,the 1.0 0.000143348623853 0 1 -1
subfraction,concentrations,reduced 1.0 0.000286697247706 0 2 -2
subcutaneous,injections,of 1.0 0.000143348623853 0 1 -1
subcutaneous,injections,in 1.0 0.000143348623853 0 1 -1
subcutaneous,injection,q12h 1.0 0.000143348623853 0 1 -1
subcutaneous,infusion,pumps 1.0 0.000143348623853 0 1 -1
subcortical,structures,whereas 1.0 0.000143348623853 0 1 -1
subcortical,structures,of 1.0 0.000143348623853 0 1 -1
subclone,of,mcf-7 1.0 0.000143348623853 0 1 -1
subacute,hepatitis,and 1.0 0.000143348623853 0 1 -1
sub-,for,in 1.0 0.000143348623853 0 1 -1
studying,of,serum 1.0 0.000143348623853 0 1 -1
study,without,co-administered 1.0 0.000143348623853 0 1 -1
study,with,without 1.0 0.000143348623853 0 1 -1
study,with,showed 1.0 0.000143348623853 0 1 -1
study,with,intravenous 1.0 0.000143348623853 0 1 -1
study,with,healthy 1.0 0.000143348623853 0 1 -1
study,with,concomitant 1.0 0.000143348623853 0 1 -1
study,with,co-administered 1.0 0.000143348623853 0 1 -1
study,with,bioavailability 1.0 0.000143348623853 0 1 -1
study,with,and 1.0 0.000143348623853 0 1 -1
study,with,administration 1.0 0.000143348623853 0 1 -1
study,which,confirms 1.0 0.000143348623853 0 1 -1
study,were,to 1.0 0.000143348623853 0 1 -1
study,were,positive 1.0 0.000143348623853 0 1 -1
study,week,of 1.0 0.000143348623853 0 1 -1
study,we,investigated 1.0 0.00043004587156 0 3 -3
study,we,evaluated 1.0 0.000143348623853 0 1 -1
study,was,to 1.0 0.00043004587156 0 3 -3
study,was,performed 1.0 0.000143348623853 0 1 -1
study,was,inadequate 1.0 0.000143348623853 0 1 -1
study,was,identical 1.0 0.000143348623853 0 1 -1
study,was,given 1.0 0.000143348623853 0 1 -1
study,was,designed 1.0 0.000286697247706 0 2 -2
study,was,conducted 1.0 0.000286697247706 0 2 -2
study,was,carried 1.0 0.000143348623853 0 1 -1
study,was,also 1.0 0.000143348623853 0 1 -1
study,was,a 1.0 0.000143348623853 0 1 -1
study,volunteers,mg 1.0 0.000143348623853 0 1 -1
study,toradoliv,im 1.0 0.000143348623853 0 1 -1
study,to,study 1.0 0.000143348623853 0 1 -1
study,to,receive 1.0 0.000143348623853 0 1 -1
study,there,were 1.0 0.000143348623853 0 1 -1
study,there,was 1.0 0.000143348623853 0 1 -1
study,the,pancreatic 1.0 0.000143348623853 0 1 -1
study,the,nonpredisposed 1.0 0.000143348623853 0 1 -1
study,the,interaction 1.0 0.000143348623853 0 1 -1
study,the,influence 1.0 0.000143348623853 0 1 -1
study,the,effects 1.0 0.000143348623853 0 1 -1
study,the,effect 1.0 0.000143348623853 0 1 -1
study,the,concomitant 1.0 0.000143348623853 0 1 -1
study,the,bioavailability 1.0 0.000143348623853 0 1 -1
study,the,atypical 1.0 0.000143348623853 0 1 -1
study,tentatively,supports 1.0 0.000143348623853 0 1 -1
study,tambocor,and 1.0 0.000143348623853 0 1 -1
study,suggested,to 1.0 0.000143348623853 0 1 -1
study,suggest,that 1.0 0.000143348623853 0 1 -1
study,showed,that 1.0 0.000143348623853 0 1 -1
study,regardless,of 1.0 0.000143348623853 0 1 -1
study,received,either 1.0 0.000143348623853 0 1 -1
study,periods,were 1.0 0.000143348623853 0 1 -1
study,patients,with 1.0 0.000286697247706 0 2 -2
study,patients,receiving 1.0 0.000143348623853 0 1 -1
study,one,hyperglycaemic 1.0 0.000143348623853 0 1 -1
study,of,young 1.0 0.000143348623853 0 1 -1
study,of,with 1.0 0.000286697247706 0 2 -2
study,of,the 1.0 0.000286697247706 0 2 -2
study,of,rheumatoid 1.0 0.000143348623853 0 1 -1
study,of,patients 1.0 0.000573394495413 0 4 -4
study,of,over 1.0 0.000143348623853 0 1 -1
study,of,neurontin 1.0 0.000143348623853 0 1 -1
study,of,interaction 1.0 0.000143348623853 0 1 -1
study,of,in 1.0 0.000143348623853 0 1 -1
study,objective,to 1.0 0.000143348623853 0 1 -1
study,male,rats 1.0 0.000143348623853 0 1 -1
study,it,was 1.0 0.000143348623853 0 1 -1
study,it,is 1.0 0.000143348623853 0 1 -1
study,involving,six-healthy 1.0 0.000143348623853 0 1 -1
study,involving,concomitant 1.0 0.000143348623853 0 1 -1
study,involving,adult 1.0 0.000143348623853 0 1 -1
study,investigated,the 1.0 0.000143348623853 0 1 -1
study,indicates,that 1.0 0.000143348623853 0 1 -1
study,in,this 1.0 0.000143348623853 0 1 -1
study,in,seven 1.0 0.000143348623853 0 1 -1
study,in,rats 1.0 0.000143348623853 0 1 -1
study,in,patients 1.0 0.000286697247706 0 2 -2
study,in,niddm 1.0 0.000143348623853 0 1 -1
study,in,insulin-dependent 1.0 0.000143348623853 0 1 -1
study,in,hypertensive 1.0 0.000143348623853 0 1 -1
study,in,humans 1.0 0.000143348623853 0 1 -1
study,healthy,female 1.0 0.000286697247706 0 2 -2
study,has,suggested 1.0 0.000143348623853 0 1 -1
study,had,no 1.0 0.000143348623853 0 1 -1
study,following,chronic 1.0 0.000143348623853 0 1 -1
study,evoked,potentials 1.0 0.000143348623853 0 1 -1
study,evaluated,the 1.0 0.000143348623853 0 1 -1
study,effects,have 1.0 0.000143348623853 0 1 -1
study,dosed,subjects 1.0 0.000143348623853 0 1 -1
study,denileukin,diftitox 1.0 0.000143348623853 0 1 -1
study,cytochrome,p450 1.0 0.000143348623853 0 1 -1
study,cynomolgus,monkeys 1.0 0.000143348623853 0 1 -1
study,comparing,the 1.0 0.000143348623853 0 1 -1
study,comparing,once-monthly 1.0 0.000143348623853 0 1 -1
study,by,the 1.0 0.000143348623853 0 1 -1
study,both,agents 1.0 0.000143348623853 0 1 -1
study,baboons,given 1.0 0.000143348623853 0 1 -1
study,attempting,to 1.0 0.000143348623853 0 1 -1
study,at,doses 1.0 0.000143348623853 0 1 -1
study,and,those 1.0 0.000143348623853 0 1 -1
study,and,the 1.0 0.000143348623853 0 1 -1
study,and,nonsteroidal 1.0 0.000286697247706 0 2 -2
study,and,ci 1.0 0.000286697247706 0 2 -2
study,alone,produced 1.0 0.000143348623853 0 1 -1
study,a,nd 1.0 0.000143348623853 0 1 -1
studies,with,xigris 1.0 0.000143348623853 0 1 -1
studies,with,were 1.0 0.000143348623853 0 1 -1
studies,with,thus 1.0 0.000143348623853 0 1 -1
studies,with,sustiva 1.0 0.000143348623853 0 1 -1
studies,with,sprycel 1.0 0.000286697247706 0 2 -2
studies,with,several 1.0 0.000143348623853 0 1 -1
studies,with,proscar 1.0 0.000143348623853 0 1 -1
studies,with,propecia 1.0 0.000143348623853 0 1 -1
studies,with,plenaxis 1.0 0.000143348623853 0 1 -1
studies,with,other 1.0 0.000286697247706 0 2 -2
studies,with,normal 1.0 0.000143348623853 0 1 -1
studies,with,no 1.0 0.000143348623853 0 1 -1
studies,with,in 1.0 0.000286697247706 0 2 -2
studies,with,human 1.0 0.00043004587156 0 3 -3
studies,with,highly 1.0 0.000143348623853 0 1 -1
studies,with,hcl 1.0 0.000143348623853 0 1 -1
studies,with,fortovase 1.0 0.000143348623853 0 1 -1
studies,with,dynacirc 1.0 0.000143348623853 0 1 -1
studies,with,anti-neoplastic 1.0 0.000143348623853 0 1 -1
studies,with,and 1.0 0.000573394495413 0 4 -4
studies,with,acetylsalicylic 1.0 0.000143348623853 0 1 -1
studies,with,abciximab 1.0 0.000143348623853 0 1 -1
studies,which,support 1.0 0.000143348623853 0 1 -1
studies,where,patients 1.0 0.000143348623853 0 1 -1
studies,when,was 1.0 0.000143348623853 0 1 -1
studies,were,prohibited 1.0 0.000143348623853 0 1 -1
studies,were,performed 1.0 0.000286697247706 0 2 -2
studies,were,not 1.0 0.000286697247706 0 2 -2
studies,were,carried 1.0 0.000143348623853 0 1 -1
studies,was,given 1.0 0.000143348623853 0 1 -1
studies,was,administered 1.0 0.000143348623853 0 1 -1
studies,vardenafil,and 1.0 0.000143348623853 0 1 -1
studies,using,induced 1.0 0.000143348623853 0 1 -1
studies,using,human 1.0 0.000143348623853 0 1 -1
studies,used,anti-peptic 1.0 0.000143348623853 0 1 -1
studies,translates,into 1.0 0.000143348623853 0 1 -1
studies,to,mg 1.0 0.000143348623853 0 1 -1
studies,to,evaluate 1.0 0.000573394495413 0 4 -4
studies,to,determine 1.0 0.000143348623853 0 1 -1
studies,to,date 1.0 0.000143348623853 0 1 -1
studies,tilade,has 1.0 0.000143348623853 0 1 -1
studies,these,results 1.0 0.000143348623853 0 1 -1
studies,the,incidence 1.0 0.000143348623853 0 1 -1
studies,the,consequences 1.0 0.000143348623853 0 1 -1
studies,that,toradol 1.0 0.000143348623853 0 1 -1
studies,studies,in 1.0 0.000143348623853 0 1 -1
studies,strongly,support 1.0 0.000143348623853 0 1 -1
studies,some,associated 1.0 0.000143348623853 0 1 -1
studies,sodium,was 1.0 0.000143348623853 0 1 -1
studies,showed,increased 1.0 0.000143348623853 0 1 -1
studies,show,that 1.0 0.000143348623853 0 1 -1
studies,show,significant 1.0 0.000143348623853 0 1 -1
studies,should,focus 1.0 0.000143348623853 0 1 -1
studies,received,one 1.0 0.000286697247706 0 2 -2
studies,performed,with 1.0 0.000143348623853 0 1 -1
studies,other,than 1.0 0.000143348623853 0 1 -1
studies,oral,and 1.0 0.000143348623853 0 1 -1
studies,or,predicted 1.0 0.000143348623853 0 1 -1
studies,or,in 1.0 0.000143348623853 0 1 -1
studies,on,two 1.0 0.000143348623853 0 1 -1
studies,on,the 1.0 0.00043004587156 0 3 -3
studies,on,patients 1.0 0.000143348623853 0 1 -1
studies,on,concomitant 1.0 0.000143348623853 0 1 -1
studies,of,with 1.0 0.00043004587156 0 3 -3
studies,of,pegasys 1.0 0.000286697247706 0 2 -2
studies,of,mevacor 1.0 0.000143348623853 0 1 -1
studies,of,mefenamic 1.0 0.000143348623853 0 1 -1
studies,of,indicate 1.0 0.000143348623853 0 1 -1
studies,of,human 1.0 0.000143348623853 0 1 -1
studies,of,drug 1.0 0.000143348623853 0 1 -1
studies,of,concomitant 1.0 0.000143348623853 0 1 -1
studies,of,candesartan 1.0 0.000143348623853 0 1 -1
studies,of,aranesp 1.0 0.000143348623853 0 1 -1
studies,no,dosage 1.0 0.000143348623853 0 1 -1
studies,m1,was 1.0 0.000286697247706 0 2 -2
studies,it,is 1.0 0.00043004587156 0 3 -3
studies,is,metabolized 1.0 0.000143348623853 0 1 -1
studies,involving,otherwise 1.0 0.000143348623853 0 1 -1
studies,involving,healthy 1.0 0.000143348623853 0 1 -1
studies,involving,either 1.0 0.000143348623853 0 1 -1
studies,investigating,possible 1.0 0.000143348623853 0 1 -1
studies,intravenous,has 1.0 0.000143348623853 0 1 -1
studies,indicated,that 1.0 0.000286697247706 0 2 -2
studies,indicate,cyp3a4 1.0 0.000143348623853 0 1 -1
studies,including,normal 1.0 0.000143348623853 0 1 -1
studies,including,interactions 1.0 0.000143348623853 0 1 -1
studies,in,which 1.0 0.000286697247706 0 2 -2
studies,in,vitro 1.0 0.000143348623853 0 1 -1
studies,in,these 1.0 0.000143348623853 0 1 -1
studies,in,multiple 1.0 0.000143348623853 0 1 -1
studies,in,mice 1.0 0.000143348623853 0 1 -1
studies,in,human 1.0 0.000860091743119 0 6 -6
studies,in,hiv-1 1.0 0.000143348623853 0 1 -1
studies,in,female 1.0 0.000143348623853 0 1 -1
studies,ie,timi-ii 1.0 0.000143348623853 0 1 -1
studies,hydrochloride,mg 1.0 0.000143348623853 0 1 -1
studies,however,have 1.0 0.000143348623853 0 1 -1
studies,however,are 1.0 0.000143348623853 0 1 -1
studies,have,suggested 1.0 0.000143348623853 0 1 -1
studies,have,indicated 1.0 0.000143348623853 0 1 -1
studies,have,excluded 1.0 0.000286697247706 0 2 -2
studies,have,confirmed 1.0 0.000143348623853 0 1 -1
studies,had,no 1.0 0.000143348623853 0 1 -1
studies,fully,evaluating 1.0 0.000143348623853 0 1 -1
studies,failed,to 1.0 0.000286697247706 0 2 -2
studies,evaluating,the 1.0 0.000286697247706 0 2 -2
studies,document,no 1.0 0.000143348623853 0 1 -1
studies,did,not 1.0 0.000573394495413 0 4 -4
studies,designed,to 1.0 0.000143348623853 0 1 -1
studies,demonstrated,that 1.0 0.000143348623853 0 1 -1
studies,demonstrated,no 1.0 0.000143348623853 0 1 -1
studies,demonstrate,that 1.0 0.000286697247706 0 2 -2
studies,cytochrome,p450 1.0 0.000143348623853 0 1 -1
studies,conducted,in 1.0 0.000143348623853 0 1 -1
studies,coadministration,of 1.0 0.000143348623853 0 1 -1
studies,caution,should 1.0 0.000143348623853 0 1 -1
studies,caused,no 1.0 0.000143348623853 0 1 -1
studies,case,reports 1.0 0.000143348623853 0 1 -1
studies,beta-receptor,blockers 1.0 0.000143348623853 0 1 -1
studies,at,the 1.0 0.000143348623853 0 1 -1
studies,as,a 1.0 0.000143348623853 0 1 -1
studies,are,summarized 1.0 0.000143348623853 0 1 -1
studies,are,needed 1.0 0.000143348623853 0 1 -1
studies,angiomax,exhibited 1.0 0.000143348623853 0 1 -1
studies,and,the 1.0 0.000143348623853 0 1 -1
studies,and,nonclinical 1.0 0.000143348623853 0 1 -1
studies,and,no 1.0 0.000143348623853 0 1 -1
studies,and,consensus 1.0 0.000143348623853 0 1 -1
studies,and,an 1.0 0.000143348623853 0 1 -1
studies,also,indicate 1.0 0.000143348623853 0 1 -1
studied,with,doses 1.0 0.000143348623853 0 1 -1
studied,than,the 1.0 0.000143348623853 0 1 -1
studied,systematically,in 1.0 0.000143348623853 0 1 -1
studied,of,the 1.0 0.000143348623853 0 1 -1
studied,in,vivo 1.0 0.000143348623853 0 1 -1
studied,in,six 1.0 0.000143348623853 0 1 -1
studied,in,several 1.0 0.000143348623853 0 1 -1
studied,in,rheumatoid 1.0 0.000143348623853 0 1 -1
studied,in,rat 1.0 0.000143348623853 0 1 -1
studied,in,healthy 1.0 0.000286697247706 0 2 -2
studied,in,electrically 1.0 0.000143348623853 0 1 -1
studied,in,combination 1.0 0.00043004587156 0 3 -3
studied,in,cat 1.0 0.000143348623853 0 1 -1
studied,in,adequate 1.0 0.000143348623853 0 1 -1
studied,in,a 1.0 0.000286697247706 0 2 -2
studied,for,its 1.0 0.000143348623853 0 1 -1
studied,following,subcutaneous 1.0 0.000143348623853 0 1 -1
studied,extensively,in 1.0 0.000143348623853 0 1 -1
studied,but,would 1.0 0.000143348623853 0 1 -1
studied,but,in 1.0 0.000143348623853 0 1 -1
studied,as,triple 1.0 0.000143348623853 0 1 -1
studied,and,is 1.0 0.000286697247706 0 2 -2
studied,and,have 1.0 0.000143348623853 0 1 -1
structures,whereas,h-spiroperidol 1.0 0.000143348623853 0 1 -1
structures,and,nonzero 1.0 0.000143348623853 0 1 -1
structure,of,functionally 1.0 0.000143348623853 0 1 -1
structurally,similar,to 1.0 0.000143348623853 0 1 -1
structurally,distinct,from 1.0 0.000143348623853 0 1 -1
structural,heart,disease 1.0 0.000286697247706 0 2 -2
structural,alterations,underlying 1.0 0.000143348623853 0 1 -1
strongly,suppressed,by 1.0 0.000143348623853 0 1 -1
strongly,support,the 1.0 0.000143348623853 0 1 -1
strongly,suggest,that 1.0 0.000143348623853 0 1 -1
strong,inhibitors,or 1.0 0.000286697247706 0 2 -2
strong,inducers,of 1.0 0.000286697247706 0 2 -2
strong,in,vitro 1.0 0.000143348623853 0 1 -1
strong,evidence,that 1.0 0.000286697247706 0 2 -2
strong,drying,effect 1.0 0.000143348623853 0 1 -1
strong,cyp,a4 1.0 0.000143348623853 0 1 -1
strong,central,nervous 1.0 0.000143348623853 0 1 -1
strong,affinity,for 1.0 0.000143348623853 0 1 -1
strips,that,use 1.0 0.000143348623853 0 1 -1
striatum,str,or 1.0 0.000143348623853 0 1 -1
stress,of,the 1.0 0.000143348623853 0 1 -1
stress,may,influence 1.0 0.000143348623853 0 1 -1
stress,induction,by 1.0 0.000143348623853 0 1 -1
stress,in,cerebral 1.0 0.000143348623853 0 1 -1
stress,and,on 1.0 0.000143348623853 0 1 -1
stress,and,facilitate 1.0 0.000143348623853 0 1 -1
streptozotocin-induced,diabetic,rats 1.0 0.000143348623853 0 1 -1
streptococcus,pyogenes,and 1.0 0.000143348623853 0 1 -1
strenuous,physical,activity 1.0 0.000143348623853 0 1 -1
strength,over,the 1.0 0.000143348623853 0 1 -1
strength,mg,mg 1.0 0.000143348623853 0 1 -1
strength,from,mean 1.0 0.000143348623853 0 1 -1
strategy,can,result 1.0 0.000143348623853 0 1 -1
strategies,will,become 1.0 0.000143348623853 0 1 -1
strategies,to,minimise 1.0 0.000143348623853 0 1 -1
strategies,during,conversion 1.0 0.000143348623853 0 1 -1
strains,of,salmonella 1.0 0.000143348623853 0 1 -1
strains,of,pointer 1.0 0.000143348623853 0 1 -1
strains,of,escherichia 1.0 0.000143348623853 0 1 -1
strains,of,enterococcus 1.0 0.000286697247706 0 2 -2
strains,of,enterococci 1.0 0.000143348623853 0 1 -1
strains,of,enterobacteriaceae 1.0 0.000143348623853 0 1 -1
strains,of,clostridium 1.0 0.000286697247706 0 2 -2
strains,from,normal 1.0 0.000143348623853 0 1 -1
strains,from,addicts 1.0 0.000286697247706 0 2 -2
strains,and,six 1.0 0.000143348623853 0 1 -1
strain,were,divided 1.0 0.000143348623853 0 1 -1
strain,of,proteus 1.0 0.000143348623853 0 1 -1
strain,of,enterococci 1.0 0.000143348623853 0 1 -1
strain,c57bl,n 1.0 0.000143348623853 0 1 -1
strabismus,miosis,mydriasis 1.0 0.000143348623853 0 1 -1
str,was,significantly 1.0 0.000143348623853 0 1 -1
str,or,nucleus 1.0 0.000143348623853 0 1 -1
str,may,contribute 1.0 0.000143348623853 0 1 -1
store,from,the 1.0 0.000143348623853 0 1 -1
store,and,the 1.0 0.000143348623853 0 1 -1
storage,vesicles,along 1.0 0.000143348623853 0 1 -1
stopping,concomitantly,administered 1.0 0.000286697247706 0 2 -2
stopped,without,consulting 1.0 0.000143348623853 0 1 -1
stop,any,medicine 1.0 0.000143348623853 0 1 -1
stools,in,patients 1.0 0.000143348623853 0 1 -1
stool,in,cecectomized 1.0 0.000143348623853 0 1 -1
stomach,irritation,subjects 1.0 0.000143348623853 0 1 -1
stomach,does,not 1.0 0.000143348623853 0 1 -1
stomach,acidity,does 1.0 0.000143348623853 0 1 -1
stimulus-induced,neural,plasticity 1.0 0.000143348623853 0 1 -1
stimulus,response,in 1.0 0.000143348623853 0 1 -1
stimulus,of,dietary 1.0 0.000143348623853 0 1 -1
stimulation,study,of 1.0 0.000143348623853 0 1 -1
stimulation,of,the 1.0 0.000286697247706 0 2 -2
stimulation,is,critical 1.0 0.000143348623853 0 1 -1
stimulation,is,a 1.0 0.000143348623853 0 1 -1
stimulation,by,cerulein--an 1.0 0.000143348623853 0 1 -1
stimulation,and,inhibition 1.0 0.000143348623853 0 1 -1
stimulating,the,synthesis 1.0 0.000143348623853 0 1 -1
stimulating,properties,of 1.0 0.000143348623853 0 1 -1
stimulating,factor,support 1.0 0.000143348623853 0 1 -1
stimulated,with,greater 1.0 0.000143348623853 0 1 -1
stimulated,hz,degrees 1.0 0.000143348623853 0 1 -1
stimulated,gastric,secretion 1.0 0.000143348623853 0 1 -1
stimulated,by,but 1.0 0.000143348623853 0 1 -1
stimulants,are,commonly 1.0 0.000143348623853 0 1 -1
stimulant,type,may 1.0 0.000143348623853 0 1 -1
stimulant,action,on 1.0 0.000143348623853 0 1 -1
still,valid,in 1.0 0.000143348623853 0 1 -1
still,unknown,in 1.0 0.000143348623853 0 1 -1
still,significant,degree 1.0 0.000143348623853 0 1 -1
still,other,pathways 1.0 0.000143348623853 0 1 -1
sterol,in,human 1.0 0.000143348623853 0 1 -1
steroidal,and,progestogen 1.0 0.000143348623853 0 1 -1
sterilize,the,bowel 1.0 0.000143348623853 0 1 -1
stereoselectivity,in,the 1.0 0.000143348623853 0 1 -1
stereoselective,behavioral,effects 1.0 0.000143348623853 0 1 -1
stereoisomers,of,n-allylnormetazocine 1.0 0.000143348623853 0 1 -1
steps,physicians,can 1.0 0.000143348623853 0 1 -1
steps,include,regular 1.0 0.000143348623853 0 1 -1
step,in,the 1.0 0.000143348623853 0 1 -1
step,in,metabolism 1.0 0.000143348623853 0 1 -1
steadystate,trough,cmin 1.0 0.000143348623853 0 1 -1
steady-state,were,not 1.0 0.000143348623853 0 1 -1
steady-state,trough,serum 1.0 0.000143348623853 0 1 -1
steady-state,trough,plasma 1.0 0.000286697247706 0 2 -2
steady-state,plasma,concentration 1.0 0.000143348623853 0 1 -1
steady-state,pharmacokinetics,of 1.0 0.000573394495413 0 4 -4
steady-state,pharmacokinetics,after 1.0 0.000143348623853 0 1 -1
steady-state,pharmacokinetic,variables 1.0 0.000143348623853 0 1 -1
steady-state,pharmacokinetic,parameters 1.0 0.000143348623853 0 1 -1
steady-state,maximum,concentration 1.0 0.000143348623853 0 1 -1
steady-state,levels,of 1.0 0.000143348623853 0 1 -1
steady-state,l50,mg 1.0 0.000143348623853 0 1 -1
steady-state,exposure,to 1.0 0.000143348623853 0 1 -1
steady-state,conditions,to 1.0 0.000143348623853 0 1 -1
steady-state,conditions,had 1.0 0.000143348623853 0 1 -1
steady-state,concentrations,of 1.0 0.000143348623853 0 1 -1
steady-state,cmin,increased 1.0 0.000286697247706 0 2 -2
steady-state,cmin,concentrations 1.0 0.000143348623853 0 1 -1
steady-state,cmin,concentration 1.0 0.000143348623853 0 1 -1
steady-state,blood,concentrations 1.0 0.000143348623853 0 1 -1
steady,state,was 1.0 0.000143348623853 0 1 -1
steady,state,vioxx 1.0 0.000143348623853 0 1 -1
steady,state,therefore 1.0 0.000143348623853 0 1 -1
steady,state,serum 1.0 0.000143348623853 0 1 -1
steady,state,on 1.0 0.000143348623853 0 1 -1
steady,state,levels 1.0 0.000143348623853 0 1 -1
steady,state,level 1.0 0.000143348623853 0 1 -1
steady,state,in 1.0 0.000143348623853 0 1 -1
steady,state,following 1.0 0.000143348623853 0 1 -1
steady,state,conditions 1.0 0.000286697247706 0 2 -2
steady,partner,causes 1.0 0.000143348623853 0 1 -1
status,which,requires 1.0 0.000143348623853 0 1 -1
status,of,several 1.0 0.000143348623853 0 1 -1
status,in,an 1.0 0.000143348623853 0 1 -1
status,before,you 1.0 0.000143348623853 0 1 -1
status,at,the 1.0 0.000143348623853 0 1 -1
status,and,treatment 1.0 0.000143348623853 0 1 -1
status,and,mixed--pharmacological 1.0 0.000143348623853 0 1 -1
statistically,significant,effect 1.0 0.00043004587156 0 3 -3
statistically,significant,differences 1.0 0.000286697247706 0 2 -2
statistically,significant,difference 1.0 0.000143348623853 0 1 -1
statistically,significant,changes 1.0 0.000143348623853 0 1 -1
statistically,or,clinically 1.0 0.000143348623853 0 1 -1
statistical,work,has 1.0 0.000143348623853 0 1 -1
statistical,significance,in 1.0 0.000143348623853 0 1 -1
states,underlying,conditions 1.0 0.000143348623853 0 1 -1
states,or,concomitant 1.0 0.000143348623853 0 1 -1
states,of,disease 1.0 0.000143348623853 0 1 -1
states,careful,attention 1.0 0.000143348623853 0 1 -1
states,but,also 1.0 0.000143348623853 0 1 -1
states,associated,with 1.0 0.000143348623853 0 1 -1
states,and,these 1.0 0.000143348623853 0 1 -1
states,and,a 1.0 0.000143348623853 0 1 -1
state,was,reached 1.0 0.000143348623853 0 1 -1
state,vioxx,mg 1.0 0.000143348623853 0 1 -1
state,therefore,the 1.0 0.000143348623853 0 1 -1
state,serum,levels 1.0 0.000143348623853 0 1 -1
state,on,the 1.0 0.000143348623853 0 1 -1
state,levels,of 1.0 0.000143348623853 0 1 -1
state,level,serum 1.0 0.000143348623853 0 1 -1
state,following,dosing 1.0 0.000143348623853 0 1 -1
state,conditions,to 1.0 0.000143348623853 0 1 -1
state,conditions,or 1.0 0.000143348623853 0 1 -1
starting,treatment,with 1.0 0.000143348623853 0 1 -1
starting,the,or 1.0 0.000143348623853 0 1 -1
starting,other,therapy 1.0 0.000143348623853 0 1 -1
starting,or,stopping 1.0 0.000286697247706 0 2 -2
starting,dose,should 1.0 0.000286697247706 0 2 -2
starting,daily,dose 1.0 0.000143348623853 0 1 -1
start,therapy,with 1.0 0.000143348623853 0 1 -1
start,or,stop 1.0 0.000143348623853 0 1 -1
starlix,three,times 1.0 0.000143348623853 0 1 -1
starlix,the,patient 1.0 0.000143348623853 0 1 -1
starlix,mg,three 1.0 0.000286697247706 0 2 -2
starlix,mg,in 1.0 0.000143348623853 0 1 -1
starlix,mg,before 1.0 0.000143348623853 0 1 -1
starlix,is,predominantly 1.0 0.000143348623853 0 1 -1
staphylococcus,aureus,diplococcus 1.0 0.000143348623853 0 1 -1
standard,therapy,includes 1.0 0.000143348623853 0 1 -1
standard,in,neonates 1.0 0.000143348623853 0 1 -1
standard,cystic,fibrosis 1.0 0.000143348623853 0 1 -1
stadol,ns,were 1.0 0.000286697247706 0 2 -2
stadol,ns,mg 1.0 0.000143348623853 0 1 -1
stadol,ns,and 1.0 0.000143348623853 0 1 -1
stadol,ns,absorbed 1.0 0.000143348623853 0 1 -1
stably,transfected,with 1.0 0.000143348623853 0 1 -1
stable,therapy,were 1.0 0.000143348623853 0 1 -1
stable,prothrombin,time 1.0 0.000143348623853 0 1 -1
stable,on,a 1.0 0.000716743119266 0 5 -5
stable,for,up 1.0 0.000143348623853 0 1 -1
stable,exposure,during 1.0 0.000143348623853 0 1 -1
stable,dosage,of 1.0 0.000143348623853 0 1 -1
stable,as,v 1.0 0.000143348623853 0 1 -1
stable,as,that 1.0 0.000143348623853 0 1 -1
stable,and,thereafter 1.0 0.000143348623853 0 1 -1
stabilized,see,dosage 1.0 0.000143348623853 0 1 -1
stabilized,on,maintenance 1.0 0.000143348623853 0 1 -1
stabilized,for,at 1.0 0.000143348623853 0 1 -1
stability,over,time 1.0 0.000143348623853 0 1 -1
stability,of,nucleophosmin 1.0 0.000286697247706 0 2 -2
stability,in,auc 1.0 0.000143348623853 0 1 -1
sst,were,not 1.0 0.000143348623853 0 1 -1
sst,mice,showed 1.0 0.000143348623853 0 1 -1
sst,and,the 1.0 0.000143348623853 0 1 -1
sst,and,randomly 1.0 0.000143348623853 0 1 -1
ssris,seriraline,and 1.0 0.000143348623853 0 1 -1
ssris,many,and 1.0 0.000143348623853 0 1 -1
ssris,and,inhibit 1.0 0.000573394495413 0 4 -4
ssris,and,d 1.0 0.000143348623853 0 1 -1
squirrel,monkeys,responding 1.0 0.000143348623853 0 1 -1
squares,approach,can 1.0 0.000143348623853 0 1 -1
sprycel,should,not 1.0 0.000143348623853 0 1 -1
sprycel,must,be 1.0 0.000143348623853 0 1 -1
sprycel,in,patients 1.0 0.000286697247706 0 2 -2
sprycel,dose,reduction 1.0 0.000143348623853 0 1 -1
sprycel,close,monitoring 1.0 0.000143348623853 0 1 -1
spray,during,the 1.0 0.000143348623853 0 1 -1
sprague-dawley,rats,fasted 1.0 0.000143348623853 0 1 -1
sporanox,nizoral,muscle 1.0 0.000143348623853 0 1 -1
spontaneous,action,potentials 1.0 0.000143348623853 0 1 -1
spleen,following,a 1.0 0.000143348623853 0 1 -1
spite,of,the 1.0 0.000143348623853 0 1 -1
spite,of,adverse 1.0 0.000143348623853 0 1 -1
spite,of,adequate 1.0 0.000143348623853 0 1 -1
spinal,substantia,gelatinosa 1.0 0.000143348623853 0 1 -1
spinal,naloxone-sensitive,endorphinergic 1.0 0.000143348623853 0 1 -1
spinal,endorphinergic,system 1.0 0.000143348623853 0 1 -1
spinal,cord,injuries 1.0 0.000143348623853 0 1 -1
spices,or,lime 1.0 0.000143348623853 0 1 -1
spermine,promotes,the 1.0 0.000143348623853 0 1 -1
spermine,mm,promoted 1.0 0.000143348623853 0 1 -1
spermine,and,to 1.0 0.000143348623853 0 1 -1
spermatozoa,from,the 1.0 0.000143348623853 0 1 -1
speed-up,this,process 1.0 0.000143348623853 0 1 -1
speech,coordination,disorder 1.0 0.000143348623853 0 1 -1
spectrum,of,activity 1.0 0.000143348623853 0 1 -1
spectrum,of,actions 1.0 0.000143348623853 0 1 -1
spectrum,may,sterilize 1.0 0.000143348623853 0 1 -1
spectrophotometrically,determined,urinary 1.0 0.000143348623853 0 1 -1
specified,time,points 1.0 0.000143348623853 0 1 -1
specified,appropriate,dosage 1.0 0.000286697247706 0 2 -2
specificity,we,describe 1.0 0.000143348623853 0 1 -1
specifically,through,the 1.0 0.000143348623853 0 1 -1
specifically,they,have 1.0 0.000143348623853 0 1 -1
specifically,lipid,metabolism 1.0 0.000143348623853 0 1 -1
specifically,examining,potential 1.0 0.000143348623853 0 1 -1
specifically,due,to 1.0 0.000143348623853 0 1 -1
specifically,cytochromes,p450 1.0 0.000143348623853 0 1 -1
specifically,been,described 1.0 0.000143348623853 0 1 -1
specifically,been,attributed 1.0 0.000143348623853 0 1 -1
specific,treatment,for 1.0 0.000143348623853 0 1 -1
specific,sulfosalicylic,acid 1.0 0.000143348623853 0 1 -1
specific,substrates,inhibitors 1.0 0.000143348623853 0 1 -1
specific,studies,with 1.0 0.000143348623853 0 1 -1
specific,studies,in 1.0 0.000143348623853 0 1 -1
specific,regulation,of 1.0 0.000143348623853 0 1 -1
specific,rare,defect 1.0 0.000143348623853 0 1 -1
specific,pharmacokinetic,or 1.0 0.000143348623853 0 1 -1
specific,pharmacokinetic,changes 1.0 0.000143348623853 0 1 -1
specific,patient,populations 1.0 0.000143348623853 0 1 -1
specific,objectives,of 1.0 0.000143348623853 0 1 -1
specific,neurobiological,alterations 1.0 0.000143348623853 0 1 -1
specific,molecular,differences 1.0 0.000143348623853 0 1 -1
specific,methods,such 1.0 0.000143348623853 0 1 -1
specific,method,such 1.0 0.000143348623853 0 1 -1
specific,isoenzyme,cyp3a4 1.0 0.000143348623853 0 1 -1
specific,interactions,have 1.0 0.000143348623853 0 1 -1
specific,interaction,was 1.0 0.000143348623853 0 1 -1
specific,information,processing 1.0 0.000143348623853 0 1 -1
specific,for,the 1.0 0.000143348623853 0 1 -1
specific,drug,interaction 1.0 0.000143348623853 0 1 -1
specific,compatibility,data 1.0 0.000143348623853 0 1 -1
specific,clinical,interaction 1.0 0.000143348623853 0 1 -1
specific,blockade,of 1.0 0.000143348623853 0 1 -1
specific,applications,of 1.0 0.000143348623853 0 1 -1
specific,and,may 1.0 0.000143348623853 0 1 -1
specific,and,aspecific 1.0 0.000143348623853 0 1 -1
specific,activity,are 1.0 0.000143348623853 0 1 -1
species,was,totally 1.0 0.000143348623853 0 1 -1
species,ros,has 1.0 0.000143348623853 0 1 -1
species,of,bacteria 1.0 0.000143348623853 0 1 -1
species,including,man 1.0 0.000143348623853 0 1 -1
special,precautions,appear 1.0 0.000143348623853 0 1 -1
special,precaution,is 1.0 0.000286697247706 0 2 -2
special,populations,such 1.0 0.000143348623853 0 1 -1
special,patient,care 1.0 0.000143348623853 0 1 -1
special,monitoring,if 1.0 0.000143348623853 0 1 -1
special,care,is 1.0 0.000143348623853 0 1 -1
special,attention,should 1.0 0.000143348623853 0 1 -1
sparing,thiazide,substrates 1.0 0.000143348623853 0 1 -1
sparing,pharmacological,doses 1.0 0.000143348623853 0 1 -1
sparing,agents,should 1.0 0.000286697247706 0 2 -2
sparine,phenergan,mellaril 1.0 0.000143348623853 0 1 -1
spared,by,lesions 1.0 0.000143348623853 0 1 -1
spaces,have,been 1.0 0.000143348623853 0 1 -1
sources,for,virtually 1.0 0.000143348623853 0 1 -1
source,or,preparations 1.0 0.000143348623853 0 1 -1
soriatane,therapy,at 1.0 0.000143348623853 0 1 -1
sores,or,unusual 1.0 0.000143348623853 0 1 -1
sonata,to,a 1.0 0.000143348623853 0 1 -1
sonata,reflecting,the 1.0 0.000143348623853 0 1 -1
sonata,mg,q24h 1.0 0.000143348623853 0 1 -1
sonata,mg,did 1.0 0.000143348623853 0 1 -1
somnolence,dizziness,effects 1.0 0.000143348623853 0 1 -1
sometimes,used,for 1.0 0.000143348623853 0 1 -1
sometimes,mcg,per 1.0 0.000143348623853 0 1 -1
sometimes,been,observed 1.0 0.000143348623853 0 1 -1
sometimes,be,followed 1.0 0.000286697247706 0 2 -2
somepatients,may,experience 1.0 0.000143348623853 0 1 -1
some,would,be 1.0 0.000143348623853 0 1 -1
some,urinary,assays 1.0 0.000143348623853 0 1 -1
some,the,dependency 1.0 0.000143348623853 0 1 -1
some,that,are 1.0 0.000716743119266 0 5 -5
some,substances,are 1.0 0.000143348623853 0 1 -1
some,strains,combinations 1.0 0.000143348623853 0 1 -1
some,reports,of 1.0 0.000143348623853 0 1 -1
some,preliminary,data 1.0 0.000143348623853 0 1 -1
some,physicians,are 1.0 0.000143348623853 0 1 -1
some,patients,undergoing 1.0 0.000286697247706 0 2 -2
some,patients,treated 1.0 0.000143348623853 0 1 -1
some,patients,this 1.0 0.000143348623853 0 1 -1
some,patients,nor 1.0 0.000143348623853 0 1 -1
some,patients,may 1.0 0.000143348623853 0 1 -1
some,patients,concomitant 1.0 0.000143348623853 0 1 -1
some,patients,a 1.0 0.000143348623853 0 1 -1
some,of,the 1.0 0.00100344036697 0 7 -7
some,of,agents 1.0 0.000143348623853 0 1 -1
some,of,a 1.0 0.000143348623853 0 1 -1
some,molecular,mechanisms 1.0 0.000143348623853 0 1 -1
some,medications,may 1.0 0.000143348623853 0 1 -1
some,inhibiting,activity 1.0 0.000143348623853 0 1 -1
some,indications,of 1.0 0.000143348623853 0 1 -1
some,general,agents 1.0 0.000143348623853 0 1 -1
some,forms,of 1.0 0.000143348623853 0 1 -1
some,form,of 1.0 0.000286697247706 0 2 -2
some,early,studies 1.0 0.000143348623853 0 1 -1
some,dysrhythmias,torsades 1.0 0.000143348623853 0 1 -1
some,disorders,unrelated 1.0 0.000143348623853 0 1 -1
some,concomitantly,administered 1.0 0.000143348623853 0 1 -1
some,colorimetric,complexometric 1.0 0.000143348623853 0 1 -1
some,clinicians,have 1.0 0.000143348623853 0 1 -1
some,cases,where 1.0 0.000143348623853 0 1 -1
some,cases,the 1.0 0.000143348623853 0 1 -1
some,cases,presented 1.0 0.000143348623853 0 1 -1
some,attenuation,in 1.0 0.000143348623853 0 1 -1
some,associated,with 1.0 0.000286697247706 0 2 -2
some,are,analgesic 1.0 0.000143348623853 0 1 -1
some,agents,the 1.0 0.000143348623853 0 1 -1
some,agents,such 1.0 0.000143348623853 0 1 -1
somatropin,excessive,concurrent 1.0 0.000143348623853 0 1 -1
somatrem,somatropin,excessive 1.0 0.000143348623853 0 1 -1
somatic,disease,states 1.0 0.000143348623853 0 1 -1
solvents,this,article 1.0 0.000143348623853 0 1 -1
solvents,have,generally 1.0 0.000143348623853 0 1 -1
solvents,can,give 1.0 0.000143348623853 0 1 -1
solutions,with,quantitative 1.0 0.000143348623853 0 1 -1
solutions,until,clinical 1.0 0.000143348623853 0 1 -1
solutions,should,be 1.0 0.000143348623853 0 1 -1
solutions,containing,higher 1.0 0.000143348623853 0 1 -1
solutions,but,not 1.0 0.000143348623853 0 1 -1
solutions,blood,concentrations 1.0 0.000143348623853 0 1 -1
solutions,and,for 1.0 0.000143348623853 0 1 -1
solutions,and,also 1.0 0.000143348623853 0 1 -1
solution,with,any 1.0 0.000143348623853 0 1 -1
solution,was,given 1.0 0.000143348623853 0 1 -1
solution,the,first 1.0 0.000143348623853 0 1 -1
solution,should,have 1.0 0.000143348623853 0 1 -1
solution,or,with 1.0 0.00043004587156 0 3 -3
solution,or,fehling 1.0 0.000143348623853 0 1 -1
solution,or,clinitest 1.0 0.000143348623853 0 1 -1
solution,of,was 1.0 0.000143348623853 0 1 -1
solution,fehlings,solution 1.0 0.000286697247706 0 2 -2
solution,dried,and 1.0 0.000143348623853 0 1 -1
soluble,to,the 1.0 0.000286697247706 0 2 -2
soluble,such,as 1.0 0.000143348623853 0 1 -1
soluble,particularly,during 1.0 0.000143348623853 0 1 -1
solubility,of,is 1.0 0.000143348623853 0 1 -1
solid,phase,extraction 1.0 0.000143348623853 0 1 -1
sole,protease,inhibitor 1.0 0.000286697247706 0 2 -2
sole,indication,of 1.0 0.000143348623853 0 1 -1
soft,and,watery 1.0 0.000143348623853 0 1 -1
sodium,was,used 1.0 0.000143348623853 0 1 -1
sodium,was,evaluated 1.0 0.000143348623853 0 1 -1
sodium,the,bioavailability 1.0 0.000143348623853 0 1 -1
sodium,sulfate,prednisolone 1.0 0.000143348623853 0 1 -1
sodium,succinate,and 1.0 0.000143348623853 0 1 -1
sodium,should,be 1.0 0.000143348623853 0 1 -1
sodium,pertechnetate,tc99m 1.0 0.000143348623853 0 1 -1
sodium,perchlorate,in 1.0 0.000143348623853 0 1 -1
sodium,nor,its 1.0 0.000143348623853 0 1 -1
sodium,may,prolong 1.0 0.000143348623853 0 1 -1
sodium,levels,may 1.0 0.000143348623853 0 1 -1
sodium,is,unaffected 1.0 0.000143348623853 0 1 -1
sodium,is,not 1.0 0.000143348623853 0 1 -1
sodium,iodide,i 1.0 0.000143348623853 0 1 -1
sodium,injection,should 1.0 0.000143348623853 0 1 -1
sodium,given,at 1.0 0.000143348623853 0 1 -1
sodium,following,oral 1.0 0.000143348623853 0 1 -1
sodium,fluorescein,naflu 1.0 0.000143348623853 0 1 -1
sodium,does,not 1.0 0.000286697247706 0 2 -2
sodium,channels,and 1.0 0.000143348623853 0 1 -1
sodium,carboxymethylcellulose,nacmc 1.0 0.000143348623853 0 1 -1
sodium,are,known 1.0 0.000143348623853 0 1 -1
sodium,and,were 1.0 0.000143348623853 0 1 -1
sodium,and,possibly 1.0 0.000286697247706 0 2 -2
sodium,and,in 1.0 0.000143348623853 0 1 -1
sodium,an,inducer 1.0 0.000143348623853 0 1 -1
sodium,alone,in 1.0 0.000143348623853 0 1 -1
socioeconomic,factors,involved 1.0 0.000143348623853 0 1 -1
soaps,and,cosmetics 1.0 0.000143348623853 0 1 -1
soaps,and,cleansers 1.0 0.000143348623853 0 1 -1
so,that,peak 1.0 0.000143348623853 0 1 -1
so,formed,often 1.0 0.000143348623853 0 1 -1
so,for,the 1.0 0.000143348623853 0 1 -1
so,as,to 1.0 0.000286697247706 0 2 -2
so,active,suggesting 1.0 0.000143348623853 0 1 -1
sn38,the,active 1.0 0.000143348623853 0 1 -1
sn38,levels,in 1.0 0.000143348623853 0 1 -1
smx,such,as 1.0 0.000143348623853 0 1 -1
smooth,muscle,cell 1.0 0.000143348623853 0 1 -1
smoking,cessation,with 1.0 0.000143348623853 0 1 -1
smoking,adapting,of 1.0 0.000143348623853 0 1 -1
smokers,have,an 1.0 0.000143348623853 0 1 -1
smokers,and,industrial 1.0 0.000143348623853 0 1 -1
smallest,effective,dose 1.0 0.000143348623853 0 1 -1
smaller,week,study 1.0 0.000143348623853 0 1 -1
smaller,proportion,of 1.0 0.000143348623853 0 1 -1
smaller,alfenta,doses 1.0 0.000143348623853 0 1 -1
small,yet,statistically 1.0 0.000143348623853 0 1 -1
small,with,occasional 1.0 0.000143348623853 0 1 -1
small,volume,of 1.0 0.000143348623853 0 1 -1
small,to,allow 1.0 0.000143348623853 0 1 -1
small,study,of 1.0 0.000143348623853 0 1 -1
small,quantities,of 1.0 0.000143348623853 0 1 -1
small,pulse,of 1.0 0.000143348623853 0 1 -1
small,or,quite 1.0 0.000716743119266 0 5 -5
small,number,of 1.0 0.000143348623853 0 1 -1
small,magnitude,and 1.0 0.000143348623853 0 1 -1
small,intestinal,transits 1.0 0.000143348623853 0 1 -1
small,intestinal,mucosa 1.0 0.000143348623853 0 1 -1
small,increase,in 1.0 0.000143348623853 0 1 -1
small,gtp-binding,proteins 1.0 0.000143348623853 0 1 -1
small,groups,of 1.0 0.000143348623853 0 1 -1
small,gradual,dose 1.0 0.000143348623853 0 1 -1
small,extent,by 1.0 0.000143348623853 0 1 -1
small,differences,in 1.0 0.000143348623853 0 1 -1
small,clinical,trial 1.0 0.000143348623853 0 1 -1
small,changes,are 1.0 0.000143348623853 0 1 -1
slurred,speech,coordination 1.0 0.000143348623853 0 1 -1
slows,the,renal 1.0 0.000143348623853 0 1 -1
slowing,potentiates,increasing 1.0 0.000286697247706 0 2 -2
slow-release,mg,or 1.0 0.000143348623853 0 1 -1
slow-channel,blockers,such 1.0 0.000143348623853 0 1 -1
slow,phasic,contraction 1.0 0.000143348623853 0 1 -1
slow,metabolizers,which 1.0 0.000143348623853 0 1 -1
slow,gastric,emptying 1.0 0.000143348623853 0 1 -1
slow,chylomicron,intravascular 1.0 0.000143348623853 0 1 -1
slow,alterations,in 1.0 0.000143348623853 0 1 -1
slightly,increased,with 1.0 0.000143348623853 0 1 -1
slight,effects,on 1.0 0.000143348623853 0 1 -1
slight,degree,of 1.0 0.000143348623853 0 1 -1
sleeping,sickness,center 1.0 0.000143348623853 0 1 -1
sleep,time,were 1.0 0.000143348623853 0 1 -1
sleep,drowsiness-causing,any 1.0 0.000143348623853 0 1 -1
skin,wheals,and 1.0 0.000143348623853 0 1 -1
skin,that,you 1.0 0.000143348623853 0 1 -1
skin,tests,corticosteroids 1.0 0.000143348623853 0 1 -1
skin,reactions,dyspnea 1.0 0.000143348623853 0 1 -1
skin,reactions,at 1.0 0.000143348623853 0 1 -1
skin,rash,particularly 1.0 0.000143348623853 0 1 -1
skin,products,or 1.0 0.000143348623853 0 1 -1
skin,medicines,when 1.0 0.000143348623853 0 1 -1
skin,exfoliation,necrosis 1.0 0.000143348623853 0 1 -1
skin,discoloration,or 1.0 0.000143348623853 0 1 -1
skills,or,stimulus 1.0 0.000143348623853 0 1 -1
skeletal-muscle,relaxants,nondepolarizing 1.0 0.000143348623853 0 1 -1
skeletal,myopathy,in 1.0 0.000143348623853 0 1 -1
size,to,the 1.0 0.000143348623853 0 1 -1
size,of,wheal 1.0 0.000143348623853 0 1 -1
size,is,too 1.0 0.000143348623853 0 1 -1
sixty-two,of,strains 1.0 0.000143348623853 0 1 -1
six-healthy,male,volunteers 1.0 0.000143348623853 0 1 -1
six,volunteers,received 1.0 0.000143348623853 0 1 -1
six,sudden,cardiac 1.0 0.000143348623853 0 1 -1
six,patients,five 1.0 0.000143348623853 0 1 -1
six,hours,following 1.0 0.000143348623853 0 1 -1
six,cytochrome,p450 1.0 0.000143348623853 0 1 -1
six,clinical,isolates 1.0 0.000143348623853 0 1 -1
six,cases,it 1.0 0.000143348623853 0 1 -1
situations,when,concurrent 1.0 0.000286697247706 0 2 -2
situations,occur,which 1.0 0.000143348623853 0 1 -1
situations,in,which 1.0 0.000143348623853 0 1 -1
situation,special,patient 1.0 0.000143348623853 0 1 -1
situation,has,the 1.0 0.000143348623853 0 1 -1
situation,and,in 1.0 0.000143348623853 0 1 -1
situate,the,exact 1.0 0.000143348623853 0 1 -1
situ,ligated,duodenal 1.0 0.000143348623853 0 1 -1
situ,and,in 1.0 0.000143348623853 0 1 -1
sites,produced,their 1.0 0.000143348623853 0 1 -1
sites,other,which 1.0 0.000143348623853 0 1 -1
sites,other,that 1.0 0.000143348623853 0 1 -1
sites,may,be 1.0 0.000143348623853 0 1 -1
sites,in,the 1.0 0.00043004587156 0 3 -3
sites,for,on 1.0 0.000143348623853 0 1 -1
sites,for,increased 1.0 0.000143348623853 0 1 -1
sites,for,in 1.0 0.000143348623853 0 1 -1
sites,between,cerebral 1.0 0.000143348623853 0 1 -1
site,reactions,including 1.0 0.000143348623853 0 1 -1
site,reaction,either 1.0 0.000143348623853 0 1 -1
site,of,the 1.0 0.000143348623853 0 1 -1
site,of,previous 1.0 0.000143348623853 0 1 -1
site,ie,recall 1.0 0.000143348623853 0 1 -1
site,for,possible 1.0 0.000143348623853 0 1 -1
site,fecal,and 1.0 0.000143348623853 0 1 -1
sirolimus,works,differently 1.0 0.000143348623853 0 1 -1
sirolimus,mammalian,target 1.0 0.000143348623853 0 1 -1
sinus,bradycardia,has 1.0 0.000143348623853 0 1 -1
sinus,arrest,and 1.0 0.000143348623853 0 1 -1
singly,or,in 1.0 0.000143348623853 0 1 -1
singly,and,in 1.0 0.000143348623853 0 1 -1
single-dose,study,with 1.0 0.000143348623853 0 1 -1
single-dose,pharmacokinetic,study 1.0 0.000143348623853 0 1 -1
single-dose,nature,of 1.0 0.000143348623853 0 1 -1
single-dose,interaction,study 1.0 0.000143348623853 0 1 -1
single-dose,administration,of 1.0 0.000143348623853 0 1 -1
single,weekly,doses 1.0 0.000143348623853 0 1 -1
single,tonic,convulsion 1.0 0.000143348623853 0 1 -1
single,small,pulse 1.0 0.000143348623853 0 1 -1
single,pancreatic,acinar 1.0 0.000143348623853 0 1 -1
single,oral,mg 1.0 0.000143348623853 0 1 -1
single,or,repeated 1.0 0.000143348623853 0 1 -1
single,or,multiple 1.0 0.000143348623853 0 1 -1
single,mg,subcutaneous 1.0 0.000143348623853 0 1 -1
single,mg,oral 1.0 0.000573394495413 0 4 -4
single,mg,kg 1.0 0.000143348623853 0 1 -1
single,mg,and 1.0 0.000143348623853 0 1 -1
single,metal,toxicity 1.0 0.000286697247706 0 2 -2
single,intravenous,infusion 1.0 0.000143348623853 0 1 -1
single,in,vivo 1.0 0.000143348623853 0 1 -1
single,enzyme,may 1.0 0.000143348623853 0 1 -1
single,doses,or 1.0 0.000143348623853 0 1 -1
single,dose,pharmacokinetics 1.0 0.000143348623853 0 1 -1
single,dose,or 1.0 0.000143348623853 0 1 -1
single,dose,mg 1.0 0.000143348623853 0 1 -1
single,dose,in 1.0 0.000143348623853 0 1 -1
single,dose,bioavailability 1.0 0.000143348623853 0 1 -1
single,dose,at 1.0 0.000143348623853 0 1 -1
single,dosage,of 1.0 0.000143348623853 0 1 -1
single,daily,oral 1.0 0.000143348623853 0 1 -1
single,compound,is 1.0 0.000143348623853 0 1 -1
single,agent,or 1.0 0.000143348623853 0 1 -1
since,vitamin,d 1.0 0.00043004587156 0 3 -3
since,this,could 1.0 0.000143348623853 0 1 -1
since,they,may 1.0 0.000143348623853 0 1 -1
since,there,is 1.0 0.000286697247706 0 2 -2
since,the,therapeutic 1.0 0.000143348623853 0 1 -1
since,the,renal 1.0 0.000143348623853 0 1 -1
since,the,nrtis 1.0 0.000143348623853 0 1 -1
since,the,french 1.0 0.000143348623853 0 1 -1
since,the,effect 1.0 0.00043004587156 0 3 -3
since,the,coadministration 1.0 0.000143348623853 0 1 -1
since,the,arrival 1.0 0.000143348623853 0 1 -1
since,symptoms,of 1.0 0.000143348623853 0 1 -1
since,some,patients 1.0 0.000143348623853 0 1 -1
since,some,medications 1.0 0.000143348623853 0 1 -1
since,sodium,does 1.0 0.000143348623853 0 1 -1
since,photic,evoked 1.0 0.000143348623853 0 1 -1
since,its,approval 1.0 0.000143348623853 0 1 -1
since,it,palliates 1.0 0.000143348623853 0 1 -1
since,it,creates 1.0 0.000143348623853 0 1 -1
since,is,primarily 1.0 0.000143348623853 0 1 -1
since,is,frequently 1.0 0.000143348623853 0 1 -1
since,is,contraindicated 1.0 0.000143348623853 0 1 -1
since,hydrochloride,is 1.0 0.000143348623853 0 1 -1
since,has,a 1.0 0.000143348623853 0 1 -1
since,foscavir,decreases 1.0 0.000143348623853 0 1 -1
since,falsely,elevated 1.0 0.000143348623853 0 1 -1
since,elevations,of 1.0 0.000143348623853 0 1 -1
since,drowsiness,may 1.0 0.000143348623853 0 1 -1
since,does,not 1.0 0.000143348623853 0 1 -1
since,decreases,aldosterone 1.0 0.000143348623853 0 1 -1
since,chronic,dosing 1.0 0.000143348623853 0 1 -1
since,cholestyramine,resin 1.0 0.000143348623853 0 1 -1
since,blood,level 1.0 0.00043004587156 0 3 -3
since,ancobon,does 1.0 0.000143348623853 0 1 -1
since,aminotransferase,determinations 1.0 0.000143348623853 0 1 -1
since,a,decline 1.0 0.000143348623853 0 1 -1
since,a,clinically 1.0 0.000143348623853 0 1 -1
simvastatin,cyp3a4,substrate 1.0 0.000143348623853 0 1 -1
simultaneously,with,varapamil 1.0 0.000143348623853 0 1 -1
simultaneously,or,mg 1.0 0.000143348623853 0 1 -1
simultaneously,it,is 1.0 0.000143348623853 0 1 -1
simultaneously,at,least 1.0 0.000143348623853 0 1 -1
simultaneous,use,should 1.0 0.000143348623853 0 1 -1
simulect,with,no 1.0 0.000143348623853 0 1 -1
simulect,use,in 1.0 0.000143348623853 0 1 -1
simulect,is,added 1.0 0.000143348623853 0 1 -1
simulect,clearance,values 1.0 0.000143348623853 0 1 -1
simply,normalizing,the 1.0 0.000143348623853 0 1 -1
simplest,inference,is 1.0 0.000143348623853 0 1 -1
simple,and,reliable 1.0 0.000143348623853 0 1 -1
similarly,there,is 1.0 0.000143348623853 0 1 -1
similarly,the,acute 1.0 0.000143348623853 0 1 -1
similarly,patients,receiving 1.0 0.000143348623853 0 1 -1
similarly,of,over 1.0 0.000143348623853 0 1 -1
similarly,might,also 1.0 0.000143348623853 0 1 -1
similarly,metabolized,particularly 1.0 0.000143348623853 0 1 -1
similarly,in,the 1.0 0.000143348623853 0 1 -1
similarly,had,no 1.0 0.000143348623853 0 1 -1
similarly,dialyzed,were 1.0 0.000143348623853 0 1 -1
similarity,of,the 1.0 0.000143348623853 0 1 -1
similar,with,and 1.0 0.000143348623853 0 1 -1
similar,to,the 1.0 0.000143348623853 0 1 -1
similar,to,sodium 1.0 0.000143348623853 0 1 -1
similar,to,hydrochloride 1.0 0.000143348623853 0 1 -1
similar,to,controls 1.0 0.000143348623853 0 1 -1
similar,to,and 1.0 0.000143348623853 0 1 -1
similar,temporal,patterns 1.0 0.000143348623853 0 1 -1
similar,study,attempting 1.0 0.000143348623853 0 1 -1
similar,serum,time 1.0 0.000143348623853 0 1 -1
similar,responses,being 1.0 0.000143348623853 0 1 -1
similar,regardless,of 1.0 0.000143348623853 0 1 -1
similar,personality,characteristics 1.0 0.000143348623853 0 1 -1
similar,metabolism,may 1.0 0.000143348623853 0 1 -1
similar,median,follow-up 1.0 0.000143348623853 0 1 -1
similar,interaction,between 1.0 0.000143348623853 0 1 -1
similar,increases,will 1.0 0.000143348623853 0 1 -1
similar,in,this 1.0 0.000143348623853 0 1 -1
similar,in,patients 1.0 0.000286697247706 0 2 -2
similar,frequency,on 1.0 0.000143348623853 0 1 -1
similar,events,have 1.0 0.000143348623853 0 1 -1
similar,efficacy,on 1.0 0.000143348623853 0 1 -1
similar,effects,would 1.0 0.000143348623853 0 1 -1
similar,effects,of 1.0 0.000143348623853 0 1 -1
similar,effects,and 1.0 0.00043004587156 0 3 -3
similar,effect,would 1.0 0.000143348623853 0 1 -1
similar,effect,on 1.0 0.000143348623853 0 1 -1
similar,effect,in 1.0 0.000143348623853 0 1 -1
similar,decreases,in 1.0 0.000143348623853 0 1 -1
similar,conditions,concentrations 1.0 0.000143348623853 0 1 -1
similar,concentrations,that 1.0 0.000143348623853 0 1 -1
similar,compounds,enhanced 1.0 0.000143348623853 0 1 -1
similar,changes,may 1.0 0.000286697247706 0 2 -2
similar,changes,in 1.0 0.000143348623853 0 1 -1
similar,between,the 1.0 0.000286697247706 0 2 -2
similar,association,though 1.0 0.000286697247706 0 2 -2
similar,among,bosentan- 1.0 0.000143348623853 0 1 -1
similar,affinities,for 1.0 0.000143348623853 0 1 -1
sildenafil,is,an 1.0 0.000143348623853 0 1 -1
sildenafil,has,demonstrated 1.0 0.000143348623853 0 1 -1
sildenafil,citrate,a 1.0 0.000143348623853 0 1 -1
signs,salivary,cortisol 1.0 0.000143348623853 0 1 -1
signs,of,withdrawal 1.0 0.000143348623853 0 1 -1
signs,of,sedation 1.0 0.000143348623853 0 1 -1
signs,of,hypoglycemia 1.0 0.000286697247706 0 2 -2
signs,irrespective,of 1.0 0.000143348623853 0 1 -1
significantly,without,changes 1.0 0.000143348623853 0 1 -1
significantly,with,multiple 1.0 0.000143348623853 0 1 -1
significantly,with,auc 1.0 0.000143348623853 0 1 -1
significantly,while,those 1.0 0.000143348623853 0 1 -1
significantly,when,administered 1.0 0.000143348623853 0 1 -1
significantly,underestimates,the 1.0 0.000143348623853 0 1 -1
significantly,to,plasma 1.0 0.000143348623853 0 1 -1
significantly,superior,to 1.0 0.000143348623853 0 1 -1
significantly,smaller,proportion 1.0 0.000143348623853 0 1 -1
significantly,reduced,when 1.0 0.000143348623853 0 1 -1
significantly,reduced,in 1.0 0.000143348623853 0 1 -1
significantly,reduce,exposure 1.0 0.000143348623853 0 1 -1
significantly,reduce,and 1.0 0.000143348623853 0 1 -1
significantly,potentiated,the 1.0 0.000143348623853 0 1 -1
significantly,more,frequently 1.0 0.000143348623853 0 1 -1
significantly,more,effective 1.0 0.000143348623853 0 1 -1
significantly,metabolized,by 1.0 0.000143348623853 0 1 -1
significantly,lowering,their 1.0 0.000143348623853 0 1 -1
significantly,lowered,numbers 1.0 0.000143348623853 0 1 -1
significantly,lower,with 1.0 0.000143348623853 0 1 -1
significantly,lower,in 1.0 0.000143348623853 0 1 -1
significantly,longer,latencies 1.0 0.000143348623853 0 1 -1
significantly,larger,when 1.0 0.000143348623853 0 1 -1
significantly,interfere,with 1.0 0.000143348623853 0 1 -1
significantly,interact,with 1.0 0.000143348623853 0 1 -1
significantly,inhibit,the 1.0 0.000143348623853 0 1 -1
significantly,influence,the 1.0 0.000143348623853 0 1 -1
significantly,increased,in 1.0 0.000143348623853 0 1 -1
significantly,increase,and 1.0 0.000143348623853 0 1 -1
significantly,in,either 1.0 0.000143348623853 0 1 -1
significantly,improves,the 1.0 0.000143348623853 0 1 -1
significantly,improved,the 1.0 0.000143348623853 0 1 -1
significantly,improved,permeation 1.0 0.000143348623853 0 1 -1
significantly,improve,the 1.0 0.000143348623853 0 1 -1
significantly,impaired,by 1.0 0.000143348623853 0 1 -1
significantly,higher,than 1.0 0.000143348623853 0 1 -1
significantly,higher,proportion 1.0 0.000143348623853 0 1 -1
significantly,higher,approximately 1.0 0.000143348623853 0 1 -1
significantly,greater,than 1.0 0.000143348623853 0 1 -1
significantly,greater,in 1.0 0.000286697247706 0 2 -2
significantly,fewer,extrapyramidal 1.0 0.000143348623853 0 1 -1
significantly,different,in 1.0 0.000143348623853 0 1 -1
significantly,different,from 1.0 0.000143348623853 0 1 -1
significantly,different,before 1.0 0.000143348623853 0 1 -1
significantly,decreased,in 1.0 0.000143348623853 0 1 -1
significantly,bound,to 1.0 0.000143348623853 0 1 -1
significantly,bind,to 1.0 0.000143348623853 0 1 -1
significantly,altered,for 1.0 0.000143348623853 0 1 -1
significantly,altered,by 1.0 0.000143348623853 0 1 -1
significantly,affects,prothrombin 1.0 0.000143348623853 0 1 -1
significantly,affected,prothrombin 1.0 0.000143348623853 0 1 -1
significantly,affected,by 1.0 0.000286697247706 0 2 -2
significantly,affect,steady-state 1.0 0.000143348623853 0 1 -1
significant,when,are 1.0 0.000143348623853 0 1 -1
significant,teratogenic,and 1.0 0.000143348623853 0 1 -1
significant,shifts,in 1.0 0.000143348623853 0 1 -1
significant,qtc,prolongation 1.0 0.000143348623853 0 1 -1
significant,pharmacokinetic,or 1.0 0.000143348623853 0 1 -1
significant,pharmacokinetic,interactions 1.0 0.000286697247706 0 2 -2
significant,pharmacokinetic,interaction 1.0 0.000286697247706 0 2 -2
significant,p,endothelial 1.0 0.000143348623853 0 1 -1
significant,oxidative,stress 1.0 0.000143348623853 0 1 -1
significant,only,in 1.0 0.000143348623853 0 1 -1
significant,lengthening,of 1.0 0.000143348623853 0 1 -1
significant,interference,with 1.0 0.000143348623853 0 1 -1
significant,interactions,would 1.0 0.000143348623853 0 1 -1
significant,interactions,with 1.0 0.000716743119266 0 5 -5
significant,interactions,when 1.0 0.000143348623853 0 1 -1
significant,interactions,were 1.0 0.000143348623853 0 1 -1
significant,interactions,of 1.0 0.000143348623853 0 1 -1
significant,interactions,may 1.0 0.000143348623853 0 1 -1
significant,interactions,have 1.0 0.000286697247706 0 2 -2
significant,interactions,for 1.0 0.000143348623853 0 1 -1
significant,interactions,following 1.0 0.000143348623853 0 1 -1
significant,interactions,between 1.0 0.000143348623853 0 1 -1
significant,interactions,are 1.0 0.000143348623853 0 1 -1
significant,interaction,would 1.0 0.000143348623853 0 1 -1
significant,interaction,with 1.0 0.000143348623853 0 1 -1
significant,interaction,may 1.0 0.000143348623853 0 1 -1
significant,interaction,has 1.0 0.000143348623853 0 1 -1
significant,inhibitory,effect 1.0 0.000143348623853 0 1 -1
significant,inhibitors,of 1.0 0.000143348623853 0 1 -1
significant,hyperprolactinaemia,as 1.0 0.000143348623853 0 1 -1
significant,findings,and 1.0 0.000143348623853 0 1 -1
significant,elevations,of 1.0 0.000143348623853 0 1 -1
significant,effects,were 1.0 0.000286697247706 0 2 -2
significant,effects,on 1.0 0.000716743119266 0 5 -5
significant,effects,caution 1.0 0.000143348623853 0 1 -1
significant,effect,of 1.0 0.00043004587156 0 3 -3
significant,effect,in 1.0 0.000143348623853 0 1 -1
significant,effect,after 1.0 0.000143348623853 0 1 -1
significant,drug-drug,pharmacokinetic 1.0 0.000286697247706 0 2 -2
significant,drug-drug,interactions 1.0 0.000143348623853 0 1 -1
significant,drug-drug,interaction 1.0 0.000143348623853 0 1 -1
significant,drug,or 1.0 0.000143348623853 0 1 -1
significant,drug,interactions 1.0 0.000143348623853 0 1 -1
significant,differences,were 1.0 0.00043004587156 0 3 -3
significant,differences,in 1.0 0.00043004587156 0 3 -3
significant,differences,between 1.0 0.000286697247706 0 2 -2
significant,differences,among 1.0 0.000143348623853 0 1 -1
significant,difference,was 1.0 0.000143348623853 0 1 -1
significant,difference,p 1.0 0.000143348623853 0 1 -1
significant,difference,in 1.0 0.00043004587156 0 3 -3
significant,difference,exists 1.0 0.000143348623853 0 1 -1
significant,difference,between 1.0 0.000143348623853 0 1 -1
significant,deterioration,in 1.0 0.000143348623853 0 1 -1
significant,degree,when 1.0 0.000143348623853 0 1 -1
significant,degree,should 1.0 0.000143348623853 0 1 -1
significant,decrease,of 1.0 0.000143348623853 0 1 -1
significant,decrease,by 1.0 0.000143348623853 0 1 -1
significant,changes,to 1.0 0.000143348623853 0 1 -1
significant,changes,occurred 1.0 0.000143348623853 0 1 -1
significant,changes,in 1.0 0.00100344036697 0 7 -7
significant,change,in 1.0 0.000573394495413 0 4 -4
significant,and,no 1.0 0.000286697247706 0 2 -2
significant,alterations,in 1.0 0.000143348623853 0 1 -1
significant,adverse,interactions 1.0 0.000143348623853 0 1 -1
significant,abnormal,laboratory 1.0 0.000143348623853 0 1 -1
significance,these,two 1.0 0.000143348623853 0 1 -1
significance,the,two 1.0 0.000143348623853 0 1 -1
significance,of,which 1.0 0.000143348623853 0 1 -1
significance,of,reduced 1.0 0.000143348623853 0 1 -1
significance,in,the 1.0 0.000143348623853 0 1 -1
significance,if,any 1.0 0.000143348623853 0 1 -1
significance,as,is 1.0 0.000143348623853 0 1 -1
signalling,or,disruption 1.0 0.000143348623853 0 1 -1
signalled-unsignalled,differential-reinforcement,of-low 1.0 0.000143348623853 0 1 -1
sign,of,seriously 1.0 0.000143348623853 0 1 -1
sign,monitoring,particularly 1.0 0.000143348623853 0 1 -1
sigma-2,receptors,sodium 1.0 0.000143348623853 0 1 -1
side-effect,profiles,and 1.0 0.000143348623853 0 1 -1
side,or,in 1.0 0.000143348623853 0 1 -1
side,effects,may 1.0 0.000143348623853 0 1 -1
side,effects,kemstro 1.0 0.000143348623853 0 1 -1
side,effects,breast 1.0 0.000143348623853 0 1 -1
side,effect,of 1.0 0.000143348623853 0 1 -1
side,chains,of 1.0 0.000143348623853 0 1 -1
side,chain,is 1.0 0.000143348623853 0 1 -1
sickness,medications,muscle 1.0 0.000143348623853 0 1 -1
shuttle,vectors,containing 1.0 0.000143348623853 0 1 -1
shows,no,signs 1.0 0.000143348623853 0 1 -1
shown,to,result 1.0 0.000143348623853 0 1 -1
shown,to,provoke 1.0 0.000143348623853 0 1 -1
shown,to,exhibit 1.0 0.000143348623853 0 1 -1
shown,to,cause 1.0 0.000286697247706 0 2 -2
shown,to,bind 1.0 0.000143348623853 0 1 -1
shown,to,alter 1.0 0.000143348623853 0 1 -1
shown,that,tikosyn 1.0 0.000286697247706 0 2 -2
shown,that,small 1.0 0.000143348623853 0 1 -1
shown,that,rr 1.0 0.000143348623853 0 1 -1
shown,that,precipitation 1.0 0.000143348623853 0 1 -1
shown,that,mcf-7 1.0 0.000143348623853 0 1 -1
shown,that,is 1.0 0.000143348623853 0 1 -1
shown,that,inhibit 1.0 0.000143348623853 0 1 -1
shown,that,indocin 1.0 0.000143348623853 0 1 -1
shown,that,herbal 1.0 0.000143348623853 0 1 -1
shown,that,does 1.0 0.00043004587156 0 3 -3
shown,that,because 1.0 0.000286697247706 0 2 -2
shown,that,at 1.0 0.000143348623853 0 1 -1
shown,that,anion 1.0 0.000143348623853 0 1 -1
shown,that,and 1.0 0.000143348623853 0 1 -1
shown,that,after 1.0 0.000143348623853 0 1 -1
shown,that,acarbose 1.0 0.000143348623853 0 1 -1
shown,on,the 1.0 0.000143348623853 0 1 -1
shown,on,furosemide-stimulated 1.0 0.000143348623853 0 1 -1
shown,not,to 1.0 0.000143348623853 0 1 -1
shown,no,significant 1.0 0.000143348623853 0 1 -1
shown,no,effect 1.0 0.000143348623853 0 1 -1
shown,no,clinically 1.0 0.000143348623853 0 1 -1
shown,no,binding 1.0 0.000143348623853 0 1 -1
shown,increased,sedation 1.0 0.000143348623853 0 1 -1
shown,in,vivo 1.0 0.000143348623853 0 1 -1
shown,in,a 1.0 0.000143348623853 0 1 -1
shown,consistent,effects 1.0 0.000143348623853 0 1 -1
shown,by,rats 1.0 0.000143348623853 0 1 -1
showing,that,hippocampal 1.0 0.000143348623853 0 1 -1
showing,a,higher 1.0 0.000143348623853 0 1 -1
showed,variable,degrees 1.0 0.000143348623853 0 1 -1
showed,the,most 1.0 0.000143348623853 0 1 -1
showed,the,flavonoids 1.0 0.000143348623853 0 1 -1
showed,that,the 1.0 0.000286697247706 0 2 -2
showed,that,poor 1.0 0.000143348623853 0 1 -1
showed,that,oral 1.0 0.000143348623853 0 1 -1
showed,that,is 1.0 0.000286697247706 0 2 -2
showed,that,inhibited 1.0 0.000143348623853 0 1 -1
showed,that,had 1.0 0.000143348623853 0 1 -1
showed,that,depending 1.0 0.000143348623853 0 1 -1
showed,that,concomitant 1.0 0.000143348623853 0 1 -1
showed,significant,p 1.0 0.000143348623853 0 1 -1
showed,no,positive 1.0 0.000143348623853 0 1 -1
showed,no,influence 1.0 0.000143348623853 0 1 -1
showed,no,clinically 1.0 0.000143348623853 0 1 -1
showed,moderate,activity 1.0 0.000143348623853 0 1 -1
showed,increased,deet 1.0 0.000143348623853 0 1 -1
showed,hormonal,evidence 1.0 0.000143348623853 0 1 -1
showed,good,inhibition 1.0 0.000143348623853 0 1 -1
showed,differential,effects 1.0 0.000143348623853 0 1 -1
showed,comparable,cognitive 1.0 0.000143348623853 0 1 -1
showed,behavioral,sensitization 1.0 0.000143348623853 0 1 -1
showed,anxiogenic,effects 1.0 0.000143348623853 0 1 -1
showed,a,loss 1.0 0.000143348623853 0 1 -1
show,whether,ginsenosides-induced 1.0 0.000143348623853 0 1 -1
show,that,taking 1.0 0.000143348623853 0 1 -1
show,that,revlimid 1.0 0.000143348623853 0 1 -1
show,that,lung 1.0 0.000143348623853 0 1 -1
show,that,disease 1.0 0.000143348623853 0 1 -1
show,that,caspofungin 1.0 0.000143348623853 0 1 -1
show,that,a 1.0 0.000143348623853 0 1 -1
show,subnormal,pancreatic 1.0 0.000143348623853 0 1 -1
show,significant,inhibition 1.0 0.000143348623853 0 1 -1
show,potential,for 1.0 0.000143348623853 0 1 -1
show,on-treatment,additive 1.0 0.000143348623853 0 1 -1
show,clinically,relevant 1.0 0.000143348623853 0 1 -1
show,any,changes 1.0 0.000143348623853 0 1 -1
show,a,significant 1.0 0.000143348623853 0 1 -1
show,a,change 1.0 0.000143348623853 0 1 -1
should,take,other 1.0 0.000143348623853 0 1 -1
should,report,to 1.0 0.000143348623853 0 1 -1
should,refer,to 1.0 0.000143348623853 0 1 -1
should,receive,low-molecular 1.0 0.000143348623853 0 1 -1
should,provide,the 1.0 0.000143348623853 0 1 -1
should,precede,dosing 1.0 0.000143348623853 0 1 -1
should,practice,additional 1.0 0.000143348623853 0 1 -1
should,not,take 1.0 0.000143348623853 0 1 -1
should,not,require 1.0 0.000143348623853 0 1 -1
should,not,normally 1.0 0.000143348623853 0 1 -1
should,not,cause 1.0 0.000286697247706 0 2 -2
should,include,such 1.0 0.000143348623853 0 1 -1
should,if,necessary 1.0 0.000143348623853 0 1 -1
should,have,the 1.0 0.000286697247706 0 2 -2
should,have,pulse 1.0 0.000143348623853 0 1 -1
should,have,more 1.0 0.000143348623853 0 1 -1
should,have,frequent 1.0 0.000143348623853 0 1 -1
should,focus,on 1.0 0.000143348623853 0 1 -1
should,discuss,the 1.0 0.000143348623853 0 1 -1
should,consider,starting 1.0 0.000143348623853 0 1 -1
should,consider,monitoring 1.0 0.000143348623853 0 1 -1
should,be,weighed 1.0 0.000286697247706 0 2 -2
should,be,under 1.0 0.000143348623853 0 1 -1
should,be,the 1.0 0.000143348623853 0 1 -1
should,be,tested 1.0 0.000143348623853 0 1 -1
should,be,restricted 1.0 0.000143348623853 0 1 -1
should,be,reserved 1.0 0.000143348623853 0 1 -1
should,be,reported 1.0 0.000143348623853 0 1 -1
should,be,recognized 1.0 0.00043004587156 0 3 -3
should,be,reassessed 1.0 0.000286697247706 0 2 -2
should,be,premedicated 1.0 0.000143348623853 0 1 -1
should,be,placed 1.0 0.000143348623853 0 1 -1
should,be,particularly 1.0 0.000143348623853 0 1 -1
should,be,obtained 1.0 0.00043004587156 0 3 -3
should,be,notified 1.0 0.000143348623853 0 1 -1
should,be,necessary 1.0 0.000143348623853 0 1 -1
should,be,lowered 1.0 0.000143348623853 0 1 -1
should,be,interrupted 1.0 0.000143348623853 0 1 -1
should,be,interpreted 1.0 0.000573394495413 0 4 -4
should,be,informed 1.0 0.000286697247706 0 2 -2
should,be,individualized 1.0 0.000143348623853 0 1 -1
should,be,increased 1.0 0.000143348623853 0 1 -1
should,be,guided 1.0 0.000143348623853 0 1 -1
should,be,followed 1.0 0.000143348623853 0 1 -1
should,be,flexible 1.0 0.000143348623853 0 1 -1
should,be,drawn 1.0 0.000286697247706 0 2 -2
should,be,conducted 1.0 0.000143348623853 0 1 -1
should,be,coadministered 1.0 0.000286697247706 0 2 -2
should,be,coad-ministered 1.0 0.000143348623853 0 1 -1
should,be,cautioned 1.0 0.00043004587156 0 3 -3
should,be,based 1.0 0.000143348623853 0 1 -1
should,be,assumed 1.0 0.000143348623853 0 1 -1
should,be,as 1.0 0.000143348623853 0 1 -1
should,be,approximately 1.0 0.000143348623853 0 1 -1
should,be,alerted 1.0 0.000143348623853 0 1 -1
should,be,accompanied 1.0 0.000286697247706 0 2 -2
should,be,a 1.0 0.000143348623853 0 1 -1
should,apply,to 1.0 0.000143348623853 0 1 -1
should,also,refer 1.0 0.000143348623853 0 1 -1
should,allow,for 1.0 0.000143348623853 0 1 -1
should,achieve,and 1.0 0.000143348623853 0 1 -1
shortly,after,starting 1.0 0.000143348623853 0 1 -1
shortly,after,initiation 1.0 0.000143348623853 0 1 -1
shorter,withdrawal,period 1.0 0.000143348623853 0 1 -1
short-term,controlled,study 1.0 0.000143348623853 0 1 -1
short-term,controlled,studies 1.0 0.000286697247706 0 2 -2
short-lasting,as,compared 1.0 0.000143348623853 0 1 -1
short-acting,such,as 1.0 0.000143348623853 0 1 -1
short-acting,inhaled,such 1.0 0.000143348623853 0 1 -1
short-acting,has,been 1.0 0.000143348623853 0 1 -1
short-acting,aerosol,of 1.0 0.000143348623853 0 1 -1
short-acting,adrenergic,stimulant 1.0 0.000143348623853 0 1 -1
short,sedation,time 1.0 0.000143348623853 0 1 -1
short,s,interresponse 1.0 0.000143348623853 0 1 -1
shock,in,a 1.0 0.000143348623853 0 1 -1
shivering,pupillary,dilation 1.0 0.000143348623853 0 1 -1
shifts,in,treatment 1.0 0.000143348623853 0 1 -1
sheep,interactions,of 1.0 0.000143348623853 0 1 -1
shbg,leading,to 1.0 0.000286697247706 0 2 -2
share,or,partly 1.0 0.000143348623853 0 1 -1
share,a,common 1.0 0.000143348623853 0 1 -1
shampoos,for,dandruff 1.0 0.000143348623853 0 1 -1
sh,fa,were 1.0 0.000143348623853 0 1 -1
sh,ea,was 1.0 0.000143348623853 0 1 -1
sh,da,sh 1.0 0.000143348623853 0 1 -1
sgpt,s-alt,levels 1.0 0.000143348623853 0 1 -1
sgpt,or,ldh 1.0 0.000143348623853 0 1 -1
sgot,s-ast,and 1.0 0.000143348623853 0 1 -1
sgot,elevated,alkaline 1.0 0.000143348623853 0 1 -1
sgot,alt,sgpt 1.0 0.000143348623853 0 1 -1
sg,dipstick,test 1.0 0.000143348623853 0 1 -1
sexual,intercourse,without 1.0 0.000143348623853 0 1 -1
sexual,intercourse,with 1.0 0.000143348623853 0 1 -1
sexual,dysfunction,with 1.0 0.000143348623853 0 1 -1
sexual,dysfunction,eg 1.0 0.000143348623853 0 1 -1
sexual,activity,is 1.0 0.000286697247706 0 2 -2
sexological,psychological,and 1.0 0.000143348623853 0 1 -1
sex,number,of 1.0 0.000143348623853 0 1 -1
sex,men,and 1.0 0.000143348623853 0 1 -1
sex,hormone-binding,globulin 1.0 0.000143348623853 0 1 -1
sex,hormone,binding 1.0 0.000143348623853 0 1 -1
severity,of,bone 1.0 0.000143348623853 0 1 -1
severely,depressed,at 1.0 0.000143348623853 0 1 -1
severe,symptomatology,is 1.0 0.000143348623853 0 1 -1
severe,structural,heart 1.0 0.000143348623853 0 1 -1
severe,recalcitrant,nodular 1.0 0.000143348623853 0 1 -1
severe,reactions,such 1.0 0.000143348623853 0 1 -1
severe,reaction,on 1.0 0.000143348623853 0 1 -1
severe,or,prolonged 1.0 0.000143348623853 0 1 -1
severe,neutropenia,cells 1.0 0.000143348623853 0 1 -1
severe,myelosuppression,following 1.0 0.000143348623853 0 1 -1
severe,malaria,mefloquine 1.0 0.000143348623853 0 1 -1
severe,in,the 1.0 0.000143348623853 0 1 -1
severe,events,such 1.0 0.000143348623853 0 1 -1
severe,bradycardia,or 1.0 0.000143348623853 0 1 -1
severe,autonomic,neurotoxicity 1.0 0.000143348623853 0 1 -1
severe,anemia,grade 1.0 0.000143348623853 0 1 -1
severe,and,prolonged 1.0 0.000143348623853 0 1 -1
severe,anaphylactic,reaction 1.0 0.000573394495413 0 4 -4
severe,allergic,reactions 1.0 0.000143348623853 0 1 -1
severe,adverse,reaction 1.0 0.000143348623853 0 1 -1
severe,abdominal,symptoms 1.0 0.000143348623853 0 1 -1
several-fold,higher,daily 1.0 0.000143348623853 0 1 -1
several-,fold,increases 1.0 0.000143348623853 0 1 -1
several,with,which 1.0 0.000143348623853 0 1 -1
several,which,may 1.0 0.000143348623853 0 1 -1
several,well-controlled,studies 1.0 0.000143348623853 0 1 -1
several,transcription,factor 1.0 0.000143348623853 0 1 -1
several,studies,indicate 1.0 0.000143348623853 0 1 -1
several,studies,ie 1.0 0.000143348623853 0 1 -1
several,short-term,controlled 1.0 0.000143348623853 0 1 -1
several,proteins,in 1.0 0.000143348623853 0 1 -1
several,of,the 1.0 0.000143348623853 0 1 -1
several,months,of 1.0 0.000143348623853 0 1 -1
several,interaction,studies 1.0 0.000143348623853 0 1 -1
several,interacting,simultaneously 1.0 0.000143348623853 0 1 -1
several,instances,in 1.0 0.000143348623853 0 1 -1
several,human,interaction 1.0 0.000143348623853 0 1 -1
several,hours,following 1.0 0.000143348623853 0 1 -1
several,hours,apart 1.0 0.000143348623853 0 1 -1
several,factors,that 1.0 0.000143348623853 0 1 -1
several,dose,fractions 1.0 0.000143348623853 0 1 -1
several,days,later 1.0 0.000143348623853 0 1 -1
several,clinically,important 1.0 0.000143348623853 0 1 -1
several,clinical,trials 1.0 0.000143348623853 0 1 -1
several,classes,of 1.0 0.000143348623853 0 1 -1
several,cardiovascular,directly 1.0 0.000143348623853 0 1 -1
several,but,not 1.0 0.000143348623853 0 1 -1
several,beta-adrenergic,neuroeffector 1.0 0.000143348623853 0 1 -1
several,advantages,over 1.0 0.000143348623853 0 1 -1
seventeen,percent,of 1.0 0.000143348623853 0 1 -1
seven,experiments,reactions 1.0 0.000143348623853 0 1 -1
seven,days,prior 1.0 0.000143348623853 0 1 -1
seven,days,or 1.0 0.000143348623853 0 1 -1
seven,days,increases 1.0 0.000143348623853 0 1 -1
seven,cerebrovascular,accidents 1.0 0.000143348623853 0 1 -1
seven,cases,of 1.0 0.000143348623853 0 1 -1
settings,commonly,associated 1.0 0.000143348623853 0 1 -1
setting,rural,primary 1.0 0.000143348623853 0 1 -1
setting,cardioselective,could 1.0 0.000143348623853 0 1 -1
served,as,his 1.0 0.000143348623853 0 1 -1
served,as,control 1.0 0.000143348623853 0 1 -1
serum-supplemented,nih-3t3,or 1.0 0.000143348623853 0 1 -1
serum-deprived,serum,nih-3t3 1.0 0.000143348623853 0 1 -1
serum-deprived,ras-transformed,ras-3t3 1.0 0.000143348623853 0 1 -1
serum-deprived,ras-3t3,cells 1.0 0.000143348623853 0 1 -1
serum,without,the 1.0 0.000143348623853 0 1 -1
serum,with,concomitant 1.0 0.000143348623853 0 1 -1
serum,valproic,acid 1.0 0.000143348623853 0 1 -1
serum,txb2,generation 1.0 0.000143348623853 0 1 -1
serum,triglyceride,and 1.0 0.000286697247706 0 2 -2
serum,transaminase,levels 1.0 0.000143348623853 0 1 -1
serum,total,concentrations 1.0 0.000143348623853 0 1 -1
serum,total,bilirubin 1.0 0.000143348623853 0 1 -1
serum,time,profiles 1.0 0.000143348623853 0 1 -1
serum,supplemented,with 1.0 0.000143348623853 0 1 -1
serum,should,be 1.0 0.000286697247706 0 2 -2
serum,samples,from 1.0 0.000143348623853 0 1 -1
serum,salicylate,assays 1.0 0.000143348623853 0 1 -1
serum,reverse,triiodothyronine 1.0 0.000143348623853 0 1 -1
serum,psa,when 1.0 0.000143348623853 0 1 -1
serum,psa,levels 1.0 0.000143348623853 0 1 -1
serum,proteins,indicate 1.0 0.000143348623853 0 1 -1
serum,protein-bound,pbi 1.0 0.000143348623853 0 1 -1
serum,protein,binding 1.0 0.000143348623853 0 1 -1
serum,protein,added 1.0 0.000143348623853 0 1 -1
serum,prostate-specific,antigen 1.0 0.000143348623853 0 1 -1
serum,pregnancy,tests 1.0 0.000143348623853 0 1 -1
serum,potassium,since 1.0 0.000143348623853 0 1 -1
serum,plasma,proteins 1.0 0.000143348623853 0 1 -1
serum,nih-3t3,cells 1.0 0.000143348623853 0 1 -1
serum,measurements,with 1.0 0.000143348623853 0 1 -1
serum,levels,utilizing 1.0 0.000143348623853 0 1 -1
serum,levels,using 1.0 0.000143348623853 0 1 -1
serum,levels,for 1.0 0.000143348623853 0 1 -1
serum,levels,at 1.0 0.000143348623853 0 1 -1
serum,levels,after 1.0 0.000143348623853 0 1 -1
serum,level,is 1.0 0.000143348623853 0 1 -1
serum,in,vitro 1.0 0.000143348623853 0 1 -1
serum,i,corticosteroid 1.0 0.000143348623853 0 1 -1
serum,i,binding 1.0 0.000143348623853 0 1 -1
serum,hormone,levels 1.0 0.000143348623853 0 1 -1
serum,half-life,leading 1.0 0.000143348623853 0 1 -1
serum,enzyme,activities 1.0 0.000143348623853 0 1 -1
serum,endogenous,vitamin 1.0 0.00043004587156 0 3 -3
serum,electrolytes,and 1.0 0.000143348623853 0 1 -1
serum,deprivation,in 1.0 0.000143348623853 0 1 -1
serum,creatinine,levels 1.0 0.000143348623853 0 1 -1
serum,creatinine,have 1.0 0.000143348623853 0 1 -1
serum,creatinine,concentration 1.0 0.000143348623853 0 1 -1
serum,constituent,precipitated 1.0 0.000143348623853 0 1 -1
serum,concentrations,or 1.0 0.000143348623853 0 1 -1
serum,concentrations,lower 1.0 0.000143348623853 0 1 -1
serum,concentrations,appeared 1.0 0.000143348623853 0 1 -1
serum,concentration,that 1.0 0.000143348623853 0 1 -1
serum,concentration,should 1.0 0.000143348623853 0 1 -1
serum,concentration,by 1.0 0.000286697247706 0 2 -2
serum,bilirubin,levels 1.0 0.000143348623853 0 1 -1
serum,assays,when 1.0 0.000143348623853 0 1 -1
serum,and,with 1.0 0.000143348623853 0 1 -1
serum,and,sodium 1.0 0.000143348623853 0 1 -1
serum,amylase,an 1.0 0.000143348623853 0 1 -1
serum,activity,has 1.0 0.000143348623853 0 1 -1
sertraline,neutralized,the 1.0 0.000143348623853 0 1 -1
serotypes,at,the 1.0 0.000286697247706 0 2 -2
serotype,o11,strains 1.0 0.000286697247706 0 2 -2
serotoninergic,central,pathways 1.0 0.000143348623853 0 1 -1
serotonin2-receptors,underlies,the 1.0 0.000143348623853 0 1 -1
serotonin,syndrome,in 1.0 0.000143348623853 0 1 -1
serotonin,release,by 1.0 0.000143348623853 0 1 -1
serotonin,in,the 1.0 0.000143348623853 0 1 -1
serotonin,ht2a,than 1.0 0.000143348623853 0 1 -1
serotonin,and,the 1.0 0.000143348623853 0 1 -1
serotonergic,agents,was 1.0 0.000143348623853 0 1 -1
serotonergic,agents,co-administration 1.0 0.000143348623853 0 1 -1
serosal,surfaces,of 1.0 0.000143348623853 0 1 -1
seroquel,is,a 1.0 0.000143348623853 0 1 -1
seropositive,subjects,unless 1.0 0.000143348623853 0 1 -1
seropositive,subjects,have 1.0 0.000143348623853 0 1 -1
seriraline,and,inhibit 1.0 0.000143348623853 0 1 -1
seriously,worsening,asthma 1.0 0.000143348623853 0 1 -1
serious,toxicity,such 1.0 0.000143348623853 0 1 -1
serious,side,effects 1.0 0.000143348623853 0 1 -1
serious,resedation,at 1.0 0.000143348623853 0 1 -1
serious,reactions,such 1.0 0.000286697247706 0 2 -2
serious,or,fatal 1.0 0.000143348623853 0 1 -1
serious,opportunistic,infections 1.0 0.000143348623853 0 1 -1
serious,events,or 1.0 0.000143348623853 0 1 -1
serious,drug,toxicity 1.0 0.000143348623853 0 1 -1
serious,arrhythmias,in 1.0 0.000143348623853 0 1 -1
serious,and,unexpected 1.0 0.000143348623853 0 1 -1
serious,and,life-threatening 1.0 0.000143348623853 0 1 -1
serious,adverse,reactions 1.0 0.00043004587156 0 3 -3
serious,adverse,events 1.0 0.000143348623853 0 1 -1
serious,adverse,effects 1.0 0.000143348623853 0 1 -1
series,of,visual 1.0 0.000143348623853 0 1 -1
series,of,treatments 1.0 0.000143348623853 0 1 -1
serial,use,of 1.0 0.000286697247706 0 2 -2
serial,plasma,and 1.0 0.000143348623853 0 1 -1
serial,pharmacokinetic,dosing 1.0 0.000286697247706 0 2 -2
serial,broth,dilution 1.0 0.000143348623853 0 1 -1
serentil,trilafon,compazine 1.0 0.000143348623853 0 1 -1
sera,from,patients 1.0 0.000143348623853 0 1 -1
sequestrants,have,been 1.0 0.000143348623853 0 1 -1
sequestered,in,fat 1.0 0.000143348623853 0 1 -1
sequential,trials,performed 1.0 0.000143348623853 0 1 -1
sequence,initiation,is 1.0 0.000143348623853 0 1 -1
sequence,however,usually 1.0 0.000143348623853 0 1 -1
septic,shock,in 1.0 0.000143348623853 0 1 -1
separated,by,a 1.0 0.000143348623853 0 1 -1
separate,study,concomitant 1.0 0.000143348623853 0 1 -1
separate,study,baboons 1.0 0.000143348623853 0 1 -1
separate,studies,of 1.0 0.000143348623853 0 1 -1
separate,studies,hydrochloride 1.0 0.000143348623853 0 1 -1
separate,single,or 1.0 0.000143348623853 0 1 -1
separate,controlled,parallel 1.0 0.000143348623853 0 1 -1
separate,brain,systems 1.0 0.000143348623853 0 1 -1
sensitize,tissues,to 1.0 0.000143348623853 0 1 -1
sensitize,resistant,strains 1.0 0.000143348623853 0 1 -1
sensitization,to,the 1.0 0.000143348623853 0 1 -1
sensitization,similar,to 1.0 0.000143348623853 0 1 -1
sensitivity,to,topoisomerase-targeted 1.0 0.000143348623853 0 1 -1
sensitivity,to,chemotherapy 1.0 0.000143348623853 0 1 -1
sensitivity,of,tumor 1.0 0.000143348623853 0 1 -1
sensitivity,of,rat 1.0 0.000143348623853 0 1 -1
sensitivity,of,at 1.0 0.000143348623853 0 1 -1
sensitivity,and,glycemic 1.0 0.000143348623853 0 1 -1
sensitive,to,ph 1.0 0.000143348623853 0 1 -1
sensitive,to,c 1.0 0.000143348623853 0 1 -1
sensitive,to,alterations 1.0 0.000286697247706 0 2 -2
sensitive,assay,system 1.0 0.000143348623853 0 1 -1
sensitive,and,inhibited 1.0 0.000143348623853 0 1 -1
sensipar,sensipar,is 1.0 0.000143348623853 0 1 -1
sensipar,on,other 1.0 0.000143348623853 0 1 -1
sensipar,is,metabolized 1.0 0.000286697247706 0 2 -2
sensipar,is,a 1.0 0.000143348623853 0 1 -1
seminiferous,tubules,seminiferous 1.0 0.000143348623853 0 1 -1
seminiferous,tubular,atrophy 1.0 0.000143348623853 0 1 -1
sem,to,within 1.0 0.000143348623853 0 1 -1
self-reported,mood,and 1.0 0.000143348623853 0 1 -1
self-injection,of,crushed 1.0 0.000143348623853 0 1 -1
self-administration,of,and 1.0 0.000143348623853 0 1 -1
selectively,bred,for 1.0 0.000143348623853 0 1 -1
selective,tumor,cell 1.0 0.000143348623853 0 1 -1
selective,toxicity,of 1.0 0.000143348623853 0 1 -1
selective,survival,in 1.0 0.000143348623853 0 1 -1
selective,regulation,of 1.0 0.000143348623853 0 1 -1
selective,methods,that 1.0 0.000143348623853 0 1 -1
selective,marker,substrates 1.0 0.000143348623853 0 1 -1
selective,inhibitors,of 1.0 0.000143348623853 0 1 -1
selective,ca,channel 1.0 0.000143348623853 0 1 -1
selective,agonists,compared 1.0 0.000143348623853 0 1 -1
selection,of,and 1.0 0.000143348623853 0 1 -1
selection,and,it 1.0 0.000143348623853 0 1 -1
selected,patient,data 1.0 0.000143348623853 0 1 -1
selected,for,response 1.0 0.000143348623853 0 1 -1
selected,a,subclone 1.0 0.000143348623853 0 1 -1
select,and,commit 1.0 0.000143348623853 0 1 -1
seizures,when,these 1.0 0.000286697247706 0 2 -2
seizures,may,be 1.0 0.000143348623853 0 1 -1
seizure,associated,with 1.0 0.000143348623853 0 1 -1
segment,of,the 1.0 0.000286697247706 0 2 -2
seen,with,treatment 1.0 0.000143348623853 0 1 -1
seen,with,other 1.0 0.000143348623853 0 1 -1
seen,with,or 1.0 0.000143348623853 0 1 -1
seen,with,kemstrotm 1.0 0.000143348623853 0 1 -1
seen,with,doses 1.0 0.000143348623853 0 1 -1
seen,with,administration 1.0 0.000143348623853 0 1 -1
seen,when,two 1.0 0.000143348623853 0 1 -1
seen,when,romazicon 1.0 0.000143348623853 0 1 -1
seen,on,the 1.0 0.000143348623853 0 1 -1
seen,on,plasma 1.0 0.000143348623853 0 1 -1
seen,in,these 1.0 0.000143348623853 0 1 -1
seen,in,the 1.0 0.000286697247706 0 2 -2
seen,in,patients 1.0 0.000143348623853 0 1 -1
seen,in,non-specialist 1.0 0.000143348623853 0 1 -1
seen,in,livers 1.0 0.000143348623853 0 1 -1
seen,in,each 1.0 0.000143348623853 0 1 -1
seen,in,diabetic 1.0 0.000143348623853 0 1 -1
seen,in,clinical 1.0 0.000143348623853 0 1 -1
seen,in,another 1.0 0.000143348623853 0 1 -1
seen,in,and 1.0 0.000143348623853 0 1 -1
seen,in,a 1.0 0.000143348623853 0 1 -1
seen,during,clinical 1.0 0.000143348623853 0 1 -1
seen,as,an 1.0 0.000143348623853 0 1 -1
seen,are,poorly 1.0 0.000143348623853 0 1 -1
seen,after,the 1.0 0.000143348623853 0 1 -1
seemingly,adequate,treatment 1.0 0.000143348623853 0 1 -1
seem,to,influence 1.0 0.000143348623853 0 1 -1
seem,to,change 1.0 0.000143348623853 0 1 -1
seeds,of,artocarpus 1.0 0.000143348623853 0 1 -1
see,warnings,congestive 1.0 0.000143348623853 0 1 -1
see,warnings,and 1.0 0.000143348623853 0 1 -1
see,illustrated,information 1.0 0.000143348623853 0 1 -1
see,drug,interactions 1.0 0.000143348623853 0 1 -1
see,contraindications,significant 1.0 0.000143348623853 0 1 -1
see,clinical,pharmacology-pharmacokinetics 1.0 0.000143348623853 0 1 -1
sedatives,hypnotics,contraindicated 1.0 0.000143348623853 0 1 -1
sedation,within,hours 1.0 0.000143348623853 0 1 -1
sedation,with,concurrent 1.0 0.000143348623853 0 1 -1
sedation,times,long-sedation 1.0 0.000143348623853 0 1 -1
sedation,time,sst 1.0 0.000143348623853 0 1 -1
sedation,or,coma 1.0 0.000143348623853 0 1 -1
section,were,obtained 1.0 0.00043004587156 0 3 -3
section,as,they 1.0 0.000143348623853 0 1 -1
secretory,diarrhea,model 1.0 0.000143348623853 0 1 -1
secretory,diarrhea,in 1.0 0.000143348623853 0 1 -1
secretions,such,as 1.0 0.000143348623853 0 1 -1
secretion,via,the 1.0 0.000143348623853 0 1 -1
secretion,stimulated,by 1.0 0.000143348623853 0 1 -1
secretion,p-aminosalicylic,acid 1.0 0.000143348623853 0 1 -1
secretion,or,resistance 1.0 0.000143348623853 0 1 -1
secretion,of,colonic 1.0 0.000143348623853 0 1 -1
secretion,of,a 1.0 0.000143348623853 0 1 -1
secretion,may,increase 1.0 0.000143348623853 0 1 -1
secretion,may,impair 1.0 0.000143348623853 0 1 -1
secretion,in,isolated 1.0 0.000143348623853 0 1 -1
secretion,distribution,metabolism 1.0 0.000143348623853 0 1 -1
secretion,distribution,effect 1.0 0.000143348623853 0 1 -1
secretion,chronic,experiments 1.0 0.000143348623853 0 1 -1
secretion,by,the 1.0 0.000143348623853 0 1 -1
secretion,by,alveoli 1.0 0.000143348623853 0 1 -1
secretion,blocking,agent 1.0 0.000143348623853 0 1 -1
secretion,are,contraindicated 1.0 0.000143348623853 0 1 -1
secretion,are,antagonized 1.0 0.000143348623853 0 1 -1
secretion,and,increase 1.0 0.000143348623853 0 1 -1
secondary,to,proleukin 1.0 0.000143348623853 0 1 -1
secondary,to,hypertensive 1.0 0.000143348623853 0 1 -1
secondary,to,high 1.0 0.000143348623853 0 1 -1
secondary,to,extravasation 1.0 0.000143348623853 0 1 -1
secondary,prevention,of 1.0 0.000143348623853 0 1 -1
secondary,deficiencies,constitute 1.0 0.000143348623853 0 1 -1
second,test,should 1.0 0.000143348623853 0 1 -1
second,study,was 1.0 0.000143348623853 0 1 -1
second,study,by 1.0 0.000143348623853 0 1 -1
second,response,is 1.0 0.000143348623853 0 1 -1
second,pregnancy,test 1.0 0.000143348623853 0 1 -1
second,in,both 1.0 0.000143348623853 0 1 -1
second,hour,then 1.0 0.000143348623853 0 1 -1
second,generation,atypical 1.0 0.000143348623853 0 1 -1
second,experiment,non-diabetic 1.0 0.000143348623853 0 1 -1
second,contraction,was 1.0 0.000143348623853 0 1 -1
searches,of,medline 1.0 0.000143348623853 0 1 -1
seal,recordings,of 1.0 0.000286697247706 0 2 -2
sd,cumulative,urinary 1.0 0.000143348623853 0 1 -1
screening,urine,for 1.0 0.000143348623853 0 1 -1
screening,patients,suspected 1.0 0.000143348623853 0 1 -1
screening,in,the 1.0 0.000143348623853 0 1 -1
screening,for,that 1.0 0.000143348623853 0 1 -1
screen,compounds,for 1.0 0.000143348623853 0 1 -1
scotland,were,accompanied 1.0 0.000143348623853 0 1 -1
sclerosis,patients,taking 1.0 0.000143348623853 0 1 -1
scintigraphy,employing,mtc-mdp 1.0 0.000143348623853 0 1 -1
scintigraphic,results,that 1.0 0.000143348623853 0 1 -1
schizophrenic,patients,who 1.0 0.000143348623853 0 1 -1
schizophrenia,were,significantly 1.0 0.000143348623853 0 1 -1
schizophrenia,or,related 1.0 0.000143348623853 0 1 -1
schizophrenia,in,the 1.0 0.000143348623853 0 1 -1
schizophrenia,and,related 1.0 0.000143348623853 0 1 -1
schizophrenia,and,in 1.0 0.000143348623853 0 1 -1
schedule,of,sodium 1.0 0.000143348623853 0 1 -1
scanning,electron,microscopy 1.0 0.000143348623853 0 1 -1
scanning,calorimetry,differential 1.0 0.000143348623853 0 1 -1
scales,vital,signs 1.0 0.000143348623853 0 1 -1
scales,and,in 1.0 0.000143348623853 0 1 -1
scale,of,hansten 1.0 0.000143348623853 0 1 -1
scale,of,displacement 1.0 0.000143348623853 0 1 -1
sc,or,the 1.0 0.000143348623853 0 1 -1
sc,injections,of 1.0 0.000143348623853 0 1 -1
saw,palmetto,red 1.0 0.000143348623853 0 1 -1
sarcoma,taxol,at 1.0 0.000143348623853 0 1 -1
saquinavir,the,combination 1.0 0.000143348623853 0 1 -1
sans,fronti,res 1.0 0.000143348623853 0 1 -1
sandimmune--on,hepatic,microsomal 1.0 0.000143348623853 0 1 -1
sampling,were,conducted 1.0 0.000143348623853 0 1 -1
sampling,the,extent 1.0 0.000143348623853 0 1 -1
sampling,for,the 1.0 0.000143348623853 0 1 -1
samples,were,drawn 1.0 0.000286697247706 0 2 -2
samples,may,interfere 1.0 0.000143348623853 0 1 -1
samples,from,patients 1.0 0.000143348623853 0 1 -1
samples,for,plasma 1.0 0.000143348623853 0 1 -1
samples,for,measurement 1.0 0.000143348623853 0 1 -1
samples,does,not 1.0 0.000143348623853 0 1 -1
samples,also,were 1.0 0.000143348623853 0 1 -1
sample,size,is 1.0 0.000143348623853 0 1 -1
sample,of,mac 1.0 0.000143348623853 0 1 -1
sample,is,acidified 1.0 0.000143348623853 0 1 -1
same,time,or 1.0 0.000286697247706 0 2 -2
same,target,sites 1.0 0.000143348623853 0 1 -1
same,study,it 1.0 0.000143348623853 0 1 -1
same,study,alone 1.0 0.000143348623853 0 1 -1
same,proportions,as 1.0 0.000143348623853 0 1 -1
same,procedures,were 1.0 0.000143348623853 0 1 -1
same,procedure,the 1.0 0.000143348623853 0 1 -1
same,procedure,should 1.0 0.000143348623853 0 1 -1
same,pharmacological,treatment 1.0 0.000143348623853 0 1 -1
same,metabolic,enzymes 1.0 0.000143348623853 0 1 -1
same,in,cecectomized 1.0 0.000286697247706 0 2 -2
same,in,both 1.0 0.000143348623853 0 1 -1
same,group,did 1.0 0.000143348623853 0 1 -1
same,episode,of 1.0 0.000143348623853 0 1 -1
same,enzyme,and 1.0 0.000143348623853 0 1 -1
same,efficacy,although 1.0 0.000143348623853 0 1 -1
same,effects,may 1.0 0.000143348623853 0 1 -1
same,degree,of 1.0 0.000143348623853 0 1 -1
same,cytochrome,isozymes 1.0 0.000143348623853 0 1 -1
same,areas,of 1.0 0.000143348623853 0 1 -1
same,age,and 1.0 0.000143348623853 0 1 -1
salts,with,practically 1.0 0.000143348623853 0 1 -1
salts,medicine,for 1.0 0.000143348623853 0 1 -1
salt,substitutes,containing 1.0 0.000286697247706 0 2 -2
salmonella,typhimurium,and 1.0 0.000143348623853 0 1 -1
salivary,cortisol,levels 1.0 0.000143348623853 0 1 -1
salivary,cortisol,and 1.0 0.000143348623853 0 1 -1
saline,was,low 1.0 0.000143348623853 0 1 -1
saline,values,all 1.0 0.000143348623853 0 1 -1
saline,g,kg 1.0 0.000143348623853 0 1 -1
salicylic,acid,indicating 1.0 0.000143348623853 0 1 -1
salicylic,acid,in 1.0 0.000143348623853 0 1 -1
salicylates-salicylates,in,large 1.0 0.000143348623853 0 1 -1
salicylate,levels,have 1.0 0.000143348623853 0 1 -1
salicylate,assays,caution 1.0 0.000143348623853 0 1 -1
sali-cylates,nsaids,including 1.0 0.000143348623853 0 1 -1
safety,studies,was 1.0 0.000143348623853 0 1 -1
safety,profiles,comparable 1.0 0.000143348623853 0 1 -1
safety,profile,of 1.0 0.000286697247706 0 2 -2
safety,profile,in 1.0 0.000143348623853 0 1 -1
safety,or,efficacy 1.0 0.000716743119266 0 5 -5
safety,of,using 1.0 0.000143348623853 0 1 -1
safety,of,such 1.0 0.000286697247706 0 2 -2
safety,of,pharmacologic 1.0 0.000143348623853 0 1 -1
safety,of,at 1.0 0.000143348623853 0 1 -1
safety,however,its 1.0 0.000143348623853 0 1 -1
safety,have,not 1.0 0.000716743119266 0 5 -5
safety,concern,thus 1.0 0.000143348623853 0 1 -1
safety,and,effectiveness 1.0 0.00043004587156 0 3 -3
safely,without,additional 1.0 0.000143348623853 0 1 -1
safely,with,such 1.0 0.000143348623853 0 1 -1
safely,used,in 1.0 0.000286697247706 0 2 -2
safely,used,concomitantly 1.0 0.000286697247706 0 2 -2
safely,tolerated,in 1.0 0.000143348623853 0 1 -1
safely,to,patients 1.0 0.000143348623853 0 1 -1
safely,coadministered,with 1.0 0.000286697247706 0 2 -2
safely,co-administered,with 1.0 0.000143348623853 0 1 -1
safe,sexual,activity 1.0 0.000143348623853 0 1 -1
safe,dosing,regimens 1.0 0.000143348623853 0 1 -1
sacrificed,in,moribund 1.0 0.000143348623853 0 1 -1
sacrificed,and,aortic 1.0 0.000143348623853 0 1 -1
sa,and,av 1.0 0.000143348623853 0 1 -1
s-warfarin,with,the 1.0 0.000143348623853 0 1 -1
s-isomer,and,changes 1.0 0.000143348623853 0 1 -1
s-ast,and,sgpt 1.0 0.000143348623853 0 1 -1
s-alt,levels,have 1.0 0.000143348623853 0 1 -1
s-,enantiomers,or 1.0 0.000143348623853 0 1 -1
s,wort,should 1.0 0.000143348623853 0 1 -1
s,wort,in 1.0 0.000143348623853 0 1 -1
s,wort,hypericum 1.0 0.000286697247706 0 2 -2
s,solutions,but 1.0 0.000143348623853 0 1 -1
s,solutions,and 1.0 0.000143348623853 0 1 -1
s,solution,or 1.0 0.00043004587156 0 3 -3
s,serum,should 1.0 0.000143348623853 0 1 -1
s,sarcoma,taxol 1.0 0.000143348623853 0 1 -1
s,or,fehling 1.0 0.000143348623853 0 1 -1
s,of,resveratrol-induced 1.0 0.000143348623853 0 1 -1
s,of,altered 1.0 0.000143348623853 0 1 -1
s,nor,were 1.0 0.000143348623853 0 1 -1
s,nephrotoxicity,and 1.0 0.000143348623853 0 1 -1
s,isomers,of 1.0 0.000143348623853 0 1 -1
s,interresponse,times 1.0 0.000143348623853 0 1 -1
s,effects,on 1.0 0.000143348623853 0 1 -1
s,disease,who 1.0 0.000143348623853 0 1 -1
s,disease,medications 1.0 0.000143348623853 0 1 -1
s,disease,including 1.0 0.000143348623853 0 1 -1
s,disease,clinical 1.0 0.000143348623853 0 1 -1
s,diet,did 1.0 0.000143348623853 0 1 -1
s,bioavailability,auc 1.0 0.000143348623853 0 1 -1
s,augmentation,of 1.0 0.000143348623853 0 1 -1
s,and,fehling 1.0 0.000286697247706 0 2 -2
s,alpha,and 1.0 0.000143348623853 0 1 -1
rxlist,com,cgi 1.0 0.000143348623853 0 1 -1
ruthenium,red,rr 1.0 0.000143348623853 0 1 -1
ruthenium,red,on 1.0 0.000143348623853 0 1 -1
rural,health,objectives 1.0 0.000143348623853 0 1 -1
running,a,control 1.0 0.000143348623853 0 1 -1
rule,out,possible 1.0 0.000143348623853 0 1 -1
rule,out,decreased 1.0 0.000143348623853 0 1 -1
rt-pa,or,may 1.0 0.000143348623853 0 1 -1
rr,reduced,adp-induced 1.0 0.000143348623853 0 1 -1
rr,on,inositol 1.0 0.000143348623853 0 1 -1
rr,is,at 1.0 0.000143348623853 0 1 -1
rr,is,a 1.0 0.000143348623853 0 1 -1
rr,had,no 1.0 0.000143348623853 0 1 -1
rpmi1640,containing,microgram 1.0 0.000143348623853 0 1 -1
routine,monitoring,should 1.0 0.000143348623853 0 1 -1
routine,dosage,adjustment 1.0 0.000143348623853 0 1 -1
route,with,less 1.0 0.000143348623853 0 1 -1
route,than,and 1.0 0.000143348623853 0 1 -1
route,of,elimination 1.0 0.000143348623853 0 1 -1
route,may,produce 1.0 0.000143348623853 0 1 -1
route,is,suitable 1.0 0.000143348623853 0 1 -1
route,in,man 1.0 0.000143348623853 0 1 -1
roughly,twofold,greater 1.0 0.000143348623853 0 1 -1
ros,has,been 1.0 0.000143348623853 0 1 -1
romazicon,was,administered 1.0 0.000143348623853 0 1 -1
romazicon,may,wear 1.0 0.000143348623853 0 1 -1
romazicon,is,not 1.0 0.000143348623853 0 1 -1
roles,of,non-nucleoside 1.0 0.000143348623853 0 1 -1
role,of,uptake-1 1.0 0.000143348623853 0 1 -1
role,of,neuronal 1.0 0.000143348623853 0 1 -1
role,of,cyp2d6 1.0 0.000143348623853 0 1 -1
role,of,amevive 1.0 0.000143348623853 0 1 -1
role,in,the 1.0 0.000143348623853 0 1 -1
role,in,s 1.0 0.000143348623853 0 1 -1
role,in,mediating 1.0 0.000143348623853 0 1 -1
role,in,determining 1.0 0.000143348623853 0 1 -1
role,in,addressing 1.0 0.000143348623853 0 1 -1
role,for,and 1.0 0.000143348623853 0 1 -1
rofecoxib,mg,once 1.0 0.000143348623853 0 1 -1
rofecoxib,did,not 1.0 0.00043004587156 0 3 -3
roegnik,grade,i 1.0 0.000143348623853 0 1 -1
rodent,study,denileukin 1.0 0.000143348623853 0 1 -1
rodent,studies,these 1.0 0.000143348623853 0 1 -1
rodent,pups,from 1.0 0.000143348623853 0 1 -1
rocaltrol,may,be 1.0 0.00043004587156 0 3 -3
robust,induction,of 1.0 0.000143348623853 0 1 -1
rna,from,prefrontal 1.0 0.000143348623853 0 1 -1
ritonavir,combined,administration 1.0 0.000143348623853 0 1 -1
risks,of,bleeding 1.0 0.000143348623853 0 1 -1
risks,maximize,benefits 1.0 0.000143348623853 0 1 -1
risks,arising,from 1.0 0.000143348623853 0 1 -1
risk,to,the 1.0 0.000143348623853 0 1 -1
risk,than,normal 1.0 0.000143348623853 0 1 -1
risk,relative,to 1.0 0.000143348623853 0 1 -1
risk,of,toxic 1.0 0.000143348623853 0 1 -1
risk,of,this 1.0 0.00043004587156 0 3 -3
risk,of,theophylline-related 1.0 0.000143348623853 0 1 -1
risk,of,relapse 1.0 0.000143348623853 0 1 -1
risk,of,rashes 1.0 0.000143348623853 0 1 -1
risk,of,precipitating 1.0 0.000143348623853 0 1 -1
risk,of,neuropathy 1.0 0.000143348623853 0 1 -1
risk,of,nephrotoxicity 1.0 0.000143348623853 0 1 -1
risk,of,myocardial 1.0 0.000143348623853 0 1 -1
risk,of,methaemoglobinaemia 1.0 0.000143348623853 0 1 -1
risk,of,metabolic 1.0 0.000143348623853 0 1 -1
risk,of,malignant 1.0 0.000143348623853 0 1 -1
risk,of,increased 1.0 0.000143348623853 0 1 -1
risk,of,hemorrhage 1.0 0.000286697247706 0 2 -2
risk,of,having 1.0 0.000143348623853 0 1 -1
risk,of,habituation 1.0 0.000143348623853 0 1 -1
risk,of,elevated 1.0 0.000143348623853 0 1 -1
risk,of,depression 1.0 0.000143348623853 0 1 -1
risk,of,decreased 1.0 0.000143348623853 0 1 -1
risk,of,coronary 1.0 0.000143348623853 0 1 -1
risk,of,convulsions 1.0 0.000143348623853 0 1 -1
risk,of,cardiac 1.0 0.000143348623853 0 1 -1
risk,of,arrhythmias 1.0 0.000143348623853 0 1 -1
risk,of,agranulocytosis 1.0 0.000143348623853 0 1 -1
risk,of,adverse 1.0 0.000573394495413 0 4 -4
risk,is,present 1.0 0.000143348623853 0 1 -1
risk,for,loss 1.0 0.000143348623853 0 1 -1
risk,for,further 1.0 0.000143348623853 0 1 -1
risk,for,developing 1.0 0.000143348623853 0 1 -1
risk,for,death 1.0 0.000143348623853 0 1 -1
risk,factors,is 1.0 0.000143348623853 0 1 -1
risk,and,or 1.0 0.000143348623853 0 1 -1
rises,that,might 1.0 0.000143348623853 0 1 -1
rise,to,additive 1.0 0.000143348623853 0 1 -1
rings,with,or 1.0 0.000143348623853 0 1 -1
rigidity,dystonia,ataxia 1.0 0.000143348623853 0 1 -1
righting,reflex,and 1.0 0.000286697247706 0 2 -2
rifampin,is,a 1.0 0.000143348623853 0 1 -1
rifampin,cyp3a4,is 1.0 0.000143348623853 0 1 -1
rifabutin,did,not 1.0 0.000143348623853 0 1 -1
rifabutin,another,is 1.0 0.000143348623853 0 1 -1
rifabutin,and,its 1.0 0.000143348623853 0 1 -1
ribavirin,see,contraindications 1.0 0.000143348623853 0 1 -1
ribavirin,ribavirin,is 1.0 0.000143348623853 0 1 -1
ribavirin,is,genotoxic 1.0 0.000143348623853 0 1 -1
ria,kit,may 1.0 0.000143348623853 0 1 -1
rhythm,followed,cessation 1.0 0.000143348623853 0 1 -1
rheumatoid,arthritis,patients 1.0 0.000286697247706 0 2 -2
rheumatoid,arthritis,or 1.0 0.000143348623853 0 1 -1
rheumatoid,arthritis,n 1.0 0.000143348623853 0 1 -1
rheumatoid,arthritis,concomitant 1.0 0.000143348623853 0 1 -1
rheumatoid,arthritis,and 1.0 0.000143348623853 0 1 -1
rhesus,monkeys,treated 1.0 0.000143348623853 0 1 -1
rhesus,monkeys,at 1.0 0.000143348623853 0 1 -1
rhabdomyolysis,were,reported 1.0 0.000143348623853 0 1 -1
rhabdomyolysis,some,associated 1.0 0.000143348623853 0 1 -1
rhabdomyolysis,resulting,from 1.0 0.000143348623853 0 1 -1
rhabdomyolysis,particularly,in 1.0 0.000143348623853 0 1 -1
rhabdomyolysis,including,chronic 1.0 0.000143348623853 0 1 -1
rhabdomyolysis,have,occasionally 1.0 0.000143348623853 0 1 -1
rhabdomyolysis,have,been 1.0 0.000143348623853 0 1 -1
rewarming,was,a 1.0 0.000143348623853 0 1 -1
revlimid,is,neither 1.0 0.000143348623853 0 1 -1
reviews,the,suitability 1.0 0.000143348623853 0 1 -1
reviews,the,impact 1.0 0.000143348623853 0 1 -1
reviews,recent,studies 1.0 0.000143348623853 0 1 -1
reviews,recent,developments 1.0 0.000143348623853 0 1 -1
reviewed,the,clinical 1.0 0.000143348623853 0 1 -1
reviewed,after,the 1.0 0.000143348623853 0 1 -1
review,was,to 1.0 0.000143348623853 0 1 -1
review,was,made 1.0 0.000143348623853 0 1 -1
review,papers,published 1.0 0.000143348623853 0 1 -1
review,of,these 1.0 0.000143348623853 0 1 -1
review,of,its 1.0 0.000143348623853 0 1 -1
review,of,all 1.0 0.000143348623853 0 1 -1
review,is,presented 1.0 0.000143348623853 0 1 -1
review,in,evaluating 1.0 0.000143348623853 0 1 -1
review,discusses,the 1.0 0.000143348623853 0 1 -1
revia,and,other 1.0 0.000286697247706 0 2 -2
reversing,resistance,of 1.0 0.000143348623853 0 1 -1
reversible,reduction,in 1.0 0.000143348623853 0 1 -1
reversible,nonselective,inhibitor 1.0 0.000143348623853 0 1 -1
reverses,when,the 1.0 0.000143348623853 0 1 -1
reverse,triiodothyronine,levels 1.0 0.000143348623853 0 1 -1
reverse,transcriptase,inhibitor 1.0 0.000143348623853 0 1 -1
reverse,resistance,in 1.0 0.000143348623853 0 1 -1
reversal,in,enterococci 1.0 0.000143348623853 0 1 -1
revealed,that,mtx 1.0 0.000143348623853 0 1 -1
revealed,no,significant 1.0 0.000143348623853 0 1 -1
revealed,no,evidence 1.0 0.000143348623853 0 1 -1
revealed,necrotizing,myopathy 1.0 0.000143348623853 0 1 -1
revealed,concentration,dependent 1.0 0.000143348623853 0 1 -1
revealed,a,significant 1.0 0.000143348623853 0 1 -1
reveal,other,affected 1.0 0.000143348623853 0 1 -1
reveal,an,inhibitory 1.0 0.000143348623853 0 1 -1
reuptake,of,disrupts 1.0 0.000143348623853 0 1 -1
reuptake,inhibitors,and 1.0 0.000286697247706 0 2 -2
returned,to,pre-gentamycin 1.0 0.000143348623853 0 1 -1
returned,to,normal 1.0 0.000716743119266 0 5 -5
return,toward,normal 1.0 0.000143348623853 0 1 -1
return,to,normal 1.0 0.000143348623853 0 1 -1
rettgeri,were,resistant 1.0 0.000143348623853 0 1 -1
retrospectively,a,group 1.0 0.000143348623853 0 1 -1
retrospective,studies,were 1.0 0.000143348623853 0 1 -1
retrospective,analysis,of 1.0 0.000143348623853 0 1 -1
retinogeniculate,fibers,in 1.0 0.000143348623853 0 1 -1
retinal,tamponades,in 1.0 0.000143348623853 0 1 -1
retention,was,calculated 1.0 0.000143348623853 0 1 -1
retention,tend,to 1.0 0.000143348623853 0 1 -1
retention,of,these 1.0 0.000143348623853 0 1 -1
retention,in,the 1.0 0.000143348623853 0 1 -1
retention,dysuria,impotence 1.0 0.000143348623853 0 1 -1
retard,the,microvascular 1.0 0.000143348623853 0 1 -1
resveratrol-induced,vasorelaxation,in 1.0 0.000143348623853 0 1 -1
resveratrol-induced,vasorelaxation,differs 1.0 0.000143348623853 0 1 -1
resveratrol,micromol,l 1.0 0.000143348623853 0 1 -1
resveratrol,has,been 1.0 0.000143348623853 0 1 -1
resumed,during,therapy 1.0 0.000143348623853 0 1 -1
results,with,wshow 1.0 0.000143348623853 0 1 -1
results,we,present 1.0 0.000143348623853 0 1 -1
results,using,the 1.0 0.000143348623853 0 1 -1
results,together,with 1.0 0.000143348623853 0 1 -1
results,the,two 1.0 0.000143348623853 0 1 -1
results,that,the 1.0 0.000143348623853 0 1 -1
results,that,falsely 1.0 0.000143348623853 0 1 -1
results,that,are 1.0 0.000143348623853 0 1 -1
results,sildenafil,has 1.0 0.000143348623853 0 1 -1
results,showed,that 1.0 0.000143348623853 0 1 -1
results,show,that 1.0 0.000143348623853 0 1 -1
results,of,these 1.0 0.000143348623853 0 1 -1
results,of,the 1.0 0.000573394495413 0 4 -4
results,of,serum 1.0 0.000143348623853 0 1 -1
results,of,interaction 1.0 0.000286697247706 0 2 -2
results,of,in 1.0 0.000143348623853 0 1 -1
results,of,clinical 1.0 0.000286697247706 0 2 -2
results,of,certain 1.0 0.000143348623853 0 1 -1
results,of,assays 1.0 0.000143348623853 0 1 -1
results,of,an 1.0 0.000143348623853 0 1 -1
results,obtained,with 1.0 0.000143348623853 0 1 -1
results,insulin,increased 1.0 0.000143348623853 0 1 -1
results,indicate,that 1.0 0.000860091743119 0 6 -6
results,indicate,important 1.0 0.000143348623853 0 1 -1
results,in,the 1.0 0.00043004587156 0 3 -3
results,in,patients 1.0 0.000143348623853 0 1 -1
results,in,or 1.0 0.000143348623853 0 1 -1
results,in,december 1.0 0.000143348623853 0 1 -1
results,hydrocortisone,elevated 1.0 0.000143348623853 0 1 -1
results,have,varied 1.0 0.000143348623853 0 1 -1
results,have,been 1.0 0.000143348623853 0 1 -1
results,generated,to 1.0 0.000143348623853 0 1 -1
results,from,urine 1.0 0.000143348623853 0 1 -1
results,from,trials 1.0 0.000143348623853 0 1 -1
results,from,in 1.0 0.000143348623853 0 1 -1
results,from,human 1.0 0.000143348623853 0 1 -1
results,from,existing 1.0 0.000143348623853 0 1 -1
results,from,concomitant 1.0 0.000143348623853 0 1 -1
results,from,clinical 1.0 0.000143348623853 0 1 -1
results,from,an 1.0 0.000286697247706 0 2 -2
results,for,urinary 1.0 0.000143348623853 0 1 -1
results,everolimus,steady 1.0 0.000143348623853 0 1 -1
results,during,the 1.0 0.000143348623853 0 1 -1
results,demonstrate,that 1.0 0.000143348623853 0 1 -1
results,demonstrate,a 1.0 0.000143348623853 0 1 -1
results,confirm,that 1.0 0.000143348623853 0 1 -1
results,bombesin,significantly 1.0 0.000143348623853 0 1 -1
results,blood,samples 1.0 0.000143348623853 0 1 -1
results,are,obtained 1.0 0.000143348623853 0 1 -1
results,are,discussed 1.0 0.000143348623853 0 1 -1
results,are,consistent 1.0 0.000143348623853 0 1 -1
resulting,increase,in 1.0 0.000286697247706 0 2 -2
resulting,in,vitamin 1.0 0.000143348623853 0 1 -1
resulting,in,inaccurately 1.0 0.000143348623853 0 1 -1
resulting,in,adverse 1.0 0.000143348623853 0 1 -1
resulting,from,vasodilating 1.0 0.000143348623853 0 1 -1
resulting,from,smoking 1.0 0.000143348623853 0 1 -1
resulting,from,intravenous 1.0 0.000143348623853 0 1 -1
resulting,from,interactions 1.0 0.000143348623853 0 1 -1
resulted,in,ventricular 1.0 0.000143348623853 0 1 -1
resulted,in,r-values 1.0 0.000143348623853 0 1 -1
resulted,in,no 1.0 0.000716743119266 0 5 -5
resulted,in,more 1.0 0.000143348623853 0 1 -1
resulted,in,levels 1.0 0.000143348623853 0 1 -1
resulted,in,false-positive 1.0 0.000143348623853 0 1 -1
resulted,in,erythro-fluorocitrate 1.0 0.000143348623853 0 1 -1
result,when,giving 1.0 0.000143348623853 0 1 -1
result,that,are 1.0 0.000143348623853 0 1 -1
result,of,which 1.0 0.000143348623853 0 1 -1
result,of,the 1.0 0.000143348623853 0 1 -1
result,of,specific 1.0 0.000143348623853 0 1 -1
result,of,inhibition 1.0 0.000143348623853 0 1 -1
result,of,coadministration 1.0 0.000143348623853 0 1 -1
result,of,administration 1.0 0.000143348623853 0 1 -1
result,may,occur 1.0 0.000286697247706 0 2 -2
result,is,true 1.0 0.000143348623853 0 1 -1
result,is,erroneous 1.0 0.000143348623853 0 1 -1
result,in,vertigo 1.0 0.000143348623853 0 1 -1
result,in,unexpectedly 1.0 0.000143348623853 0 1 -1
result,in,serious 1.0 0.000286697247706 0 2 -2
result,in,prolonged 1.0 0.000143348623853 0 1 -1
result,in,myopathy 1.0 0.000143348623853 0 1 -1
result,in,incomplete 1.0 0.000143348623853 0 1 -1
result,in,high 1.0 0.000143348623853 0 1 -1
result,in,falsely 1.0 0.000143348623853 0 1 -1
result,in,deficits 1.0 0.000143348623853 0 1 -1
result,in,decreases 1.0 0.000143348623853 0 1 -1
result,in,clinically- 1.0 0.000143348623853 0 1 -1
result,in,any 1.0 0.000716743119266 0 5 -5
result,in,altered 1.0 0.000286697247706 0 2 -2
result,from,this 1.0 0.000143348623853 0 1 -1
result,from,inhibition 1.0 0.000143348623853 0 1 -1
result,from,displacement 1.0 0.000143348623853 0 1 -1
result,from,at 1.0 0.000143348623853 0 1 -1
result,from,a 1.0 0.000143348623853 0 1 -1
result,at,least 1.0 0.000143348623853 0 1 -1
restricted,pulmonary,or 1.0 0.000143348623853 0 1 -1
restricted,and,an 1.0 0.000143348623853 0 1 -1
restored,susceptibility,through 1.0 0.000143348623853 0 1 -1
restoration,of,susceptibility 1.0 0.000143348623853 0 1 -1
restoration,of,female 1.0 0.000143348623853 0 1 -1
restlessness,muscle,pains 1.0 0.000143348623853 0 1 -1
restlessness,loss,of 1.0 0.000143348623853 0 1 -1
resting,membrane,potential 1.0 0.000143348623853 0 1 -1
responsiveness,to,the 1.0 0.000286697247706 0 2 -2
responsiveness,to,after 1.0 0.000143348623853 0 1 -1
responsive,to,a 1.0 0.000143348623853 0 1 -1
responsible,for,of 1.0 0.000143348623853 0 1 -1
responsible,for,metabolism 1.0 0.000143348623853 0 1 -1
responses,with,short 1.0 0.000143348623853 0 1 -1
responses,were,studied 1.0 0.000143348623853 0 1 -1
responses,were,seen 1.0 0.000143348623853 0 1 -1
responses,to,were 1.0 0.000143348623853 0 1 -1
responses,to,repeated 1.0 0.000143348623853 0 1 -1
responses,to,of 1.0 0.000143348623853 0 1 -1
responses,to,exposure 1.0 0.000143348623853 0 1 -1
responses,to,acth 1.0 0.000143348623853 0 1 -1
responses,in,locomotor 1.0 0.000143348623853 0 1 -1
responses,being,observed 1.0 0.000143348623853 0 1 -1
responses,associated,with 1.0 0.000143348623853 0 1 -1
responses,and,other 1.0 0.000143348623853 0 1 -1
responses,alternative,error 1.0 0.000143348623853 0 1 -1
response,was,not 1.0 0.000143348623853 0 1 -1
response,was,considered 1.0 0.000143348623853 0 1 -1
response,to,various 1.0 0.000143348623853 0 1 -1
response,to,treatment 1.0 0.000286697247706 0 2 -2
response,to,the 1.0 0.000286697247706 0 2 -2
response,to,soriatane 1.0 0.000143348623853 0 1 -1
response,to,ptx 1.0 0.000143348623853 0 1 -1
response,to,plenaxis 1.0 0.000143348623853 0 1 -1
response,to,pentobarbital-induced 1.0 0.000143348623853 0 1 -1
response,to,oral 1.0 0.000143348623853 0 1 -1
response,to,may 1.0 0.000143348623853 0 1 -1
response,to,insulin-induced 1.0 0.000143348623853 0 1 -1
response,to,campath 1.0 0.000143348623853 0 1 -1
response,to,and 1.0 0.000143348623853 0 1 -1
response,to,additional 1.0 0.000143348623853 0 1 -1
response,to,accutane 1.0 0.000286697247706 0 2 -2
response,to,a 1.0 0.000143348623853 0 1 -1
response,suggest,that 1.0 0.000143348623853 0 1 -1
response,rates,were 1.0 0.000143348623853 0 1 -1
response,rates,than 1.0 0.000143348623853 0 1 -1
response,rates,in 1.0 0.000143348623853 0 1 -1
response,of,the 1.0 0.000286697247706 0 2 -2
response,of,lh 1.0 0.000143348623853 0 1 -1
response,of,cancer 1.0 0.000143348623853 0 1 -1
response,multiple,interacting 1.0 0.000143348623853 0 1 -1
response,is,not 1.0 0.000143348623853 0 1 -1
response,is,due 1.0 0.000143348623853 0 1 -1
response,is,almost 1.0 0.000143348623853 0 1 -1
response,in,this 1.0 0.000143348623853 0 1 -1
response,in,the 1.0 0.000143348623853 0 1 -1
response,has,been 1.0 0.000860091743119 0 6 -6
response,and,there 1.0 0.000143348623853 0 1 -1
response,and,the 1.0 0.000143348623853 0 1 -1
response,and,possible 1.0 0.00043004587156 0 3 -3
response,and,adverse 1.0 0.000143348623853 0 1 -1
response,against,sera 1.0 0.000143348623853 0 1 -1
responds,excessively,to 1.0 0.000143348623853 0 1 -1
responding,whereas,in 1.0 0.000143348623853 0 1 -1
responding,under,a 1.0 0.000143348623853 0 1 -1
responding,significantly,in 1.0 0.000143348623853 0 1 -1
responding,in,monkeys 1.0 0.000143348623853 0 1 -1
responding,for,a 1.0 0.000143348623853 0 1 -1
responded,to,the 1.0 0.000143348623853 0 1 -1
respond,to,administration 1.0 0.000143348623853 0 1 -1
respond,normally,to 1.0 0.000143348623853 0 1 -1
respond,differently,from 1.0 0.000143348623853 0 1 -1
respiratory,failure,cannot 1.0 0.000143348623853 0 1 -1
respiratory,arrest,cardiac 1.0 0.000143348623853 0 1 -1
respiratory,and,or 1.0 0.000143348623853 0 1 -1
respiration,was,unaffected 1.0 0.000143348623853 0 1 -1
respiration,was,markedly 1.0 0.000143348623853 0 1 -1
respiration,becomes,sensitive 1.0 0.000143348623853 0 1 -1
respiration,and,cell 1.0 0.000143348623853 0 1 -1
respectto,safety,and 1.0 0.000143348623853 0 1 -1
respectively,which,could 1.0 0.000143348623853 0 1 -1
respectively,p,and 1.0 0.000143348623853 0 1 -1
respectively,of,the 1.0 0.000143348623853 0 1 -1
respectively,in,the 1.0 0.000143348623853 0 1 -1
respectively,in,subjects 1.0 0.000143348623853 0 1 -1
respectively,have,been 1.0 0.000143348623853 0 1 -1
respectively,after,administration 1.0 0.000143348623853 0 1 -1
respect,to,their 1.0 0.000143348623853 0 1 -1
respect,to,observations 1.0 0.000143348623853 0 1 -1
respect,to,efficacy 1.0 0.000716743119266 0 5 -5
respect,of,competitive 1.0 0.000143348623853 0 1 -1
resolved,within,a 1.0 0.000143348623853 0 1 -1
resolved,with,continuation 1.0 0.000286697247706 0 2 -2
resolved,when,was 1.0 0.000143348623853 0 1 -1
resists,dissolution,until 1.0 0.000143348623853 0 1 -1
resistant,to,oh 1.0 0.000143348623853 0 1 -1
resistant,to,chelated 1.0 0.000143348623853 0 1 -1
resistant,to,both 1.0 0.000143348623853 0 1 -1
resistant,strains,of 1.0 0.000143348623853 0 1 -1
resistant,mcf-7,cells 1.0 0.000143348623853 0 1 -1
resistant,clinical,isolates 1.0 0.000143348623853 0 1 -1
resistance,which,is 1.0 0.000143348623853 0 1 -1
resistance,was,measured 1.0 0.000143348623853 0 1 -1
resistance,to,invirase 1.0 0.000143348623853 0 1 -1
resistance,to,hormone 1.0 0.000143348623853 0 1 -1
resistance,to,crixivan 1.0 0.000286697247706 0 2 -2
resistance,reversal,in 1.0 0.000143348623853 0 1 -1
resistance,or,sensitivity 1.0 0.000143348623853 0 1 -1
resistance,or,cardiovascular 1.0 0.000143348623853 0 1 -1
resistance,or,by 1.0 0.000143348623853 0 1 -1
resistance,of,enterococci 1.0 0.000143348623853 0 1 -1
resistance,mesenteric,arteries 1.0 0.000143348623853 0 1 -1
resistance,is,involved 1.0 0.000143348623853 0 1 -1
resistance,in,class 1.0 0.000143348623853 0 1 -1
resistance,arteries,of 1.0 0.000143348623853 0 1 -1
resistance,arteries,from 1.0 0.000143348623853 0 1 -1
resin,or,at 1.0 0.000143348623853 0 1 -1
resin,may,bind 1.0 0.000143348623853 0 1 -1
residues,on,a 1.0 0.000143348623853 0 1 -1
residues,may,be 1.0 0.000143348623853 0 1 -1
residues,abolishes,the 1.0 0.000143348623853 0 1 -1
reservoir,function,of 1.0 0.000143348623853 0 1 -1
reserved,for,patients 1.0 0.000143348623853 0 1 -1
resemble,the,immediate 1.0 0.000143348623853 0 1 -1
resemble,poor,metabolizers 1.0 0.000286697247706 0 2 -2
resedation,at,a 1.0 0.000143348623853 0 1 -1
resecting,the,cecum 1.0 0.000143348623853 0 1 -1
researchers,have,investigated 1.0 0.000143348623853 0 1 -1
research,specific,to 1.0 0.000143348623853 0 1 -1
research,is,needed 1.0 0.000143348623853 0 1 -1
research,has,shown 1.0 0.000143348623853 0 1 -1
research,center,inventory 1.0 0.000143348623853 0 1 -1
res,is,running 1.0 0.000143348623853 0 1 -1
res,have,reported 1.0 0.000143348623853 0 1 -1
requiring,treatment,dyspnea 1.0 0.000143348623853 0 1 -1
requiring,complete,mental 1.0 0.000143348623853 0 1 -1
requiring,any,combination 1.0 0.000143348623853 0 1 -1
requiring,angioedema,or 1.0 0.000143348623853 0 1 -1
requires,oral,physiological 1.0 0.000143348623853 0 1 -1
requires,more,than 1.0 0.000143348623853 0 1 -1
requires,more,or 1.0 0.000143348623853 0 1 -1
requires,maintaining,a 1.0 0.000143348623853 0 1 -1
requires,immediate,medical 1.0 0.000143348623853 0 1 -1
requires,an,increase 1.0 0.000143348623853 0 1 -1
requires,a,dose 1.0 0.000143348623853 0 1 -1
requirements,may,be 1.0 0.000143348623853 0 1 -1
requirements,in,diabetic 1.0 0.000143348623853 0 1 -1
requirements,i,may 1.0 0.000143348623853 0 1 -1
requirements,for,or 1.0 0.000143348623853 0 1 -1
requirements,but,also 1.0 0.000143348623853 0 1 -1
requirement,may,be 1.0 0.000143348623853 0 1 -1
required,with,prolonged 1.0 0.000143348623853 0 1 -1
required,will,be 1.0 0.000143348623853 0 1 -1
required,when,used 1.0 0.000143348623853 0 1 -1
required,when,this 1.0 0.000286697247706 0 2 -2
required,when,administering 1.0 0.000143348623853 0 1 -1
required,to,maintain 1.0 0.000143348623853 0 1 -1
required,to,alleviate 1.0 0.000143348623853 0 1 -1
required,to,achieve 1.0 0.000143348623853 0 1 -1
required,the,additional 1.0 0.000143348623853 0 1 -1
required,since,the 1.0 0.000286697247706 0 2 -2
required,medical,intervention 1.0 0.000143348623853 0 1 -1
required,in,patients 1.0 0.000143348623853 0 1 -1
required,if,this 1.0 0.000143348623853 0 1 -1
required,if,such 1.0 0.000286697247706 0 2 -2
required,if,rebif 1.0 0.000143348623853 0 1 -1
required,if,or 1.0 0.000143348623853 0 1 -1
required,for,therapeutic 1.0 0.000143348623853 0 1 -1
required,for,the 1.0 0.000143348623853 0 1 -1
required,for,blood 1.0 0.000143348623853 0 1 -1
required,except,for 1.0 0.000143348623853 0 1 -1
required,and,increased 1.0 0.000143348623853 0 1 -1
require,the,use 1.0 0.000143348623853 0 1 -1
require,reduction,in 1.0 0.000286697247706 0 2 -2
require,lower,doses 1.0 0.00100344036697 0 7 -7
require,immediate,discontinuation 1.0 0.000143348623853 0 1 -1
require,higher,doses 1.0 0.000286697247706 0 2 -2
require,exogenous,enhancement 1.0 0.000143348623853 0 1 -1
require,empiric,adjustment 1.0 0.000143348623853 0 1 -1
require,dose,adjustment 1.0 0.00043004587156 0 3 -3
require,careful,titration 1.0 0.000143348623853 0 1 -1
require,anticoagulation,should 1.0 0.000143348623853 0 1 -1
require,adjustment,when 1.0 0.000143348623853 0 1 -1
require,additional,therapy 1.0 0.000143348623853 0 1 -1
require,a,dosage 1.0 0.000143348623853 0 1 -1
reproductive,toxicology,studies 1.0 0.000143348623853 0 1 -1
reproduction,studies,however 1.0 0.000143348623853 0 1 -1
reproducible,pattern,of 1.0 0.000143348623853 0 1 -1
represents,an,interaction 1.0 0.000143348623853 0 1 -1
representative,metabolized,by 1.0 0.000143348623853 0 1 -1
representations,of,neural 1.0 0.000143348623853 0 1 -1
represent,the,best 1.0 0.000143348623853 0 1 -1
reports,we,have 1.0 0.000143348623853 0 1 -1
reports,the,same 1.0 0.000143348623853 0 1 -1
reports,regarding,the 1.0 0.000143348623853 0 1 -1
reports,of,skeletal 1.0 0.000143348623853 0 1 -1
reports,of,sedation 1.0 0.000143348623853 0 1 -1
reports,of,rhabdomyolysis 1.0 0.000143348623853 0 1 -1
reports,of,reddish 1.0 0.000143348623853 0 1 -1
reports,of,qtc 1.0 0.000143348623853 0 1 -1
reports,of,pregnancy 1.0 0.000143348623853 0 1 -1
reports,of,positive 1.0 0.000143348623853 0 1 -1
reports,of,oral 1.0 0.000143348623853 0 1 -1
reports,of,more 1.0 0.000143348623853 0 1 -1
reports,of,interaction 1.0 0.000143348623853 0 1 -1
reports,of,increases 1.0 0.000143348623853 0 1 -1
reports,of,fatal 1.0 0.000143348623853 0 1 -1
reports,of,deaths 1.0 0.000143348623853 0 1 -1
reports,of,changes 1.0 0.000143348623853 0 1 -1
reports,of,bleeding 1.0 0.000143348623853 0 1 -1
reports,of,a 1.0 0.000143348623853 0 1 -1
reports,indicates,that 1.0 0.000143348623853 0 1 -1
reports,have,expanded 1.0 0.000143348623853 0 1 -1
reports,concerned,variable 1.0 0.000143348623853 0 1 -1
reports,are,more 1.0 0.000143348623853 0 1 -1
reports,and,commentaries 1.0 0.000143348623853 0 1 -1
reports,and,any 1.0 0.000143348623853 0 1 -1
reporter,gene,under 1.0 0.000143348623853 0 1 -1
reported,with,this 1.0 0.000143348623853 0 1 -1
reported,with,some 1.0 0.000143348623853 0 1 -1
reported,with,are 1.0 0.000143348623853 0 1 -1
reported,to,worsen 1.0 0.000143348623853 0 1 -1
reported,to,the 1.0 0.000286697247706 0 2 -2
reported,to,interfere 1.0 0.000143348623853 0 1 -1
reported,that,these 1.0 0.000143348623853 0 1 -1
reported,that,seeds 1.0 0.000143348623853 0 1 -1
reported,that,a 1.0 0.000143348623853 0 1 -1
reported,significantly,more 1.0 0.000143348623853 0 1 -1
reported,regarding,the 1.0 0.000143348623853 0 1 -1
reported,pretreatment,and 1.0 0.000143348623853 0 1 -1
reported,neuropsychiatric,confusion 1.0 0.000143348623853 0 1 -1
reported,musculoskeletal,adverse 1.0 0.000143348623853 0 1 -1
reported,itraconazole,co-administration 1.0 0.000143348623853 0 1 -1
reported,intermenstrual,bleeding 1.0 0.000143348623853 0 1 -1
reported,interactions,with 1.0 0.000143348623853 0 1 -1
reported,in,this 1.0 0.000143348623853 0 1 -1
reported,in,studies 1.0 0.000143348623853 0 1 -1
reported,in,seriously 1.0 0.000143348623853 0 1 -1
reported,in,diabetic 1.0 0.000143348623853 0 1 -1
reported,in,clinical 1.0 0.000286697247706 0 2 -2
reported,here,we 1.0 0.000143348623853 0 1 -1
reported,for,use 1.0 0.000143348623853 0 1 -1
reported,for,other 1.0 0.000143348623853 0 1 -1
reported,for,combined 1.0 0.000143348623853 0 1 -1
reported,following,the 1.0 0.000143348623853 0 1 -1
reported,examples,of 1.0 0.000286697247706 0 2 -2
reported,examples,include 1.0 0.000143348623853 0 1 -1
reported,during,treatment 1.0 0.00043004587156 0 3 -3
reported,during,continuous 1.0 0.000143348623853 0 1 -1
reported,dose,used 1.0 0.000143348623853 0 1 -1
reported,chiefly,with 1.0 0.000143348623853 0 1 -1
reported,cases,from 1.0 0.000143348623853 0 1 -1
reported,by,users 1.0 0.000286697247706 0 2 -2
reported,between,zoladex 1.0 0.000143348623853 0 1 -1
reported,between,prostin 1.0 0.000143348623853 0 1 -1
reported,association,has 1.0 0.000143348623853 0 1 -1
reported,activity,they 1.0 0.000143348623853 0 1 -1
report,to,their 1.0 0.000143348623853 0 1 -1
report,of,cardiopulmonary 1.0 0.000143348623853 0 1 -1
report,any,serious 1.0 0.000143348623853 0 1 -1
report,a,case 1.0 0.000143348623853 0 1 -1
replication,etc,and 1.0 0.000143348623853 0 1 -1
replicate,this,finding 1.0 0.000143348623853 0 1 -1
replacement,therapy,a 1.0 0.000143348623853 0 1 -1
replacement,may,alter 1.0 0.000143348623853 0 1 -1
replacement,is,needed 1.0 0.000143348623853 0 1 -1
replacement,indicates,either 1.0 0.000143348623853 0 1 -1
replacement,increases,metabolic 1.0 0.000143348623853 0 1 -1
replaced,by,the 1.0 0.000143348623853 0 1 -1
repeating,the,study 1.0 0.000143348623853 0 1 -1
repeated,oral,administration 1.0 0.000143348623853 0 1 -1
repeated,mg,kg 1.0 0.000143348623853 0 1 -1
repeated,injection,of 1.0 0.000143348623853 0 1 -1
repeated,if,the 1.0 0.000143348623853 0 1 -1
repeated,exposure,in 1.0 0.000143348623853 0 1 -1
repeated,each,month 1.0 0.000143348623853 0 1 -1
repeated,dosing,or 1.0 0.000143348623853 0 1 -1
repeated,courses,of 1.0 0.000143348623853 0 1 -1
repeated,challenge,or 1.0 0.000143348623853 0 1 -1
repeated,challenge,either 1.0 0.000716743119266 0 5 -5
repeat,treatment,studies 1.0 0.000143348623853 0 1 -1
repeat,testing,was 1.0 0.000143348623853 0 1 -1
repeat,doses,of 1.0 0.000143348623853 0 1 -1
repeat,dose,pharmacokinetics 1.0 0.000143348623853 0 1 -1
renin,substrate,alpha-1 1.0 0.000286697247706 0 2 -2
renin,levels,aldosterone 1.0 0.000143348623853 0 1 -1
renin,activity,pra 1.0 0.000143348623853 0 1 -1
renin,activity,in 1.0 0.000143348623853 0 1 -1
renally,eliminated,or 1.0 0.000143348623853 0 1 -1
renal,vasodilator,effects 1.0 0.000143348623853 0 1 -1
renal,vascular,or 1.0 0.000143348623853 0 1 -1
renal,transplant,recipients 1.0 0.000143348623853 0 1 -1
renal,toxicity,and 1.0 0.000143348623853 0 1 -1
renal,secretion,via 1.0 0.000143348623853 0 1 -1
renal,retention,tend 1.0 0.000143348623853 0 1 -1
renal,prostaglandins,and 1.0 0.000143348623853 0 1 -1
renal,prostaglandin,synthesis 1.0 0.000286697247706 0 2 -2
renal,precipitation,of 1.0 0.000143348623853 0 1 -1
renal,plasma,flow 1.0 0.000286697247706 0 2 -2
renal,nonrenal,and 1.0 0.000143348623853 0 1 -1
renal,insufficiency,was 1.0 0.000143348623853 0 1 -1
renal,insufficiency,or 1.0 0.000286697247706 0 2 -2
renal,insufficiency,are 1.0 0.000143348623853 0 1 -1
renal,insufficiency,and 1.0 0.000143348623853 0 1 -1
renal,impairment,there 1.0 0.000143348623853 0 1 -1
renal,impairment,particularly 1.0 0.000143348623853 0 1 -1
renal,impairment,and 1.0 0.000143348623853 0 1 -1
renal,function,since 1.0 0.000143348623853 0 1 -1
renal,function,secondary 1.0 0.000143348623853 0 1 -1
renal,function,or 1.0 0.000143348623853 0 1 -1
renal,function,is 1.0 0.000143348623853 0 1 -1
renal,function,in 1.0 0.000143348623853 0 1 -1
renal,function,have 1.0 0.000143348623853 0 1 -1
renal,function,clinical 1.0 0.000143348623853 0 1 -1
renal,function,care 1.0 0.000143348623853 0 1 -1
renal,function,are 1.0 0.000286697247706 0 2 -2
renal,failure,secondary 1.0 0.000143348623853 0 1 -1
renal,failure,may 1.0 0.000143348623853 0 1 -1
renal,failure,elevated 1.0 0.000143348623853 0 1 -1
renal,excretion,ibuprofen 1.0 0.000143348623853 0 1 -1
renal,excretion,a 1.0 0.000143348623853 0 1 -1
renal,elimination,of 1.0 0.000286697247706 0 2 -2
renal,effects,of 1.0 0.000143348623853 0 1 -1
renal,disease,on 1.0 0.000143348623853 0 1 -1
renal,clearance,were 1.0 0.000143348623853 0 1 -1
renal,clearance,was 1.0 0.000286697247706 0 2 -2
renal,clearance,mechanisms 1.0 0.000143348623853 0 1 -1
renal,clearance,leading 1.0 0.000286697247706 0 2 -2
renal,clearance,from 1.0 0.000143348623853 0 1 -1
renal,cationic,secretion 1.0 0.000143348623853 0 1 -1
renal,calculi,the 1.0 0.000143348623853 0 1 -1
renal,blood,flow 1.0 0.000143348623853 0 1 -1
renal,and,or 1.0 0.000286697247706 0 2 -2
renal,and,ocular 1.0 0.000286697247706 0 2 -2
removal,was,achieved 1.0 0.000143348623853 0 1 -1
remnant,removal,was 1.0 0.000143348623853 0 1 -1
remedy,use,may 1.0 0.000143348623853 0 1 -1
remedies,with,complex 1.0 0.000143348623853 0 1 -1
remedies,nephropathies,and 1.0 0.000143348623853 0 1 -1
remedies,may,be 1.0 0.000143348623853 0 1 -1
remedies,is,becoming 1.0 0.000143348623853 0 1 -1
remains,constant,while 1.0 0.000143348623853 0 1 -1
remaining,ci,by 1.0 0.000143348623853 0 1 -1
remaining,cases,two 1.0 0.000143348623853 0 1 -1
remained,the,same 1.0 0.000143348623853 0 1 -1
remained,stable,for 1.0 0.000143348623853 0 1 -1
remainder,were,of 1.0 0.000143348623853 0 1 -1
remainder,no,adjustment 1.0 0.000143348623853 0 1 -1
remain,to,orders 1.0 0.000143348623853 0 1 -1
remain,some,indications 1.0 0.000143348623853 0 1 -1
rely,on,hormonal 1.0 0.000143348623853 0 1 -1
reluctance,to,treat 1.0 0.000143348623853 0 1 -1
relieve,acute,asthma 1.0 0.000143348623853 0 1 -1
relief,of,breakthrough 1.0 0.000143348623853 0 1 -1
reliable,increases,in 1.0 0.000143348623853 0 1 -1
reliable,estimates,of 1.0 0.000716743119266 0 5 -5
reliable,affinity,chromatography 1.0 0.000143348623853 0 1 -1
relevant,significant,changes 1.0 0.000143348623853 0 1 -1
relevant,plasma,levels 1.0 0.000143348623853 0 1 -1
relevant,pharmacokinetic,or 1.0 0.000143348623853 0 1 -1
relevant,pharmacokinetic,interactions 1.0 0.000143348623853 0 1 -1
relevant,pharmacokinetic,and 1.0 0.000143348623853 0 1 -1
relevant,laboratory,test 1.0 0.000143348623853 0 1 -1
relevant,interactions,with 1.0 0.000286697247706 0 2 -2
relevant,inhibitory,effect 1.0 0.000143348623853 0 1 -1
relevant,inhibition,of 1.0 0.000143348623853 0 1 -1
relevant,effects,on 1.0 0.000143348623853 0 1 -1
relevant,effect,on 1.0 0.000143348623853 0 1 -1
relevant,drug-drug,interactions 1.0 0.000143348623853 0 1 -1
relevant,concentrations,in 1.0 0.000143348623853 0 1 -1
relevant,changes,in 1.0 0.00100344036697 0 7 -7
relevant,as,adverse 1.0 0.000143348623853 0 1 -1
relevant,alterations,in 1.0 0.000143348623853 0 1 -1
relevance,to,humans 1.0 0.000143348623853 0 1 -1
relevance,picr,in 1.0 0.000143348623853 0 1 -1
relevance,of,this 1.0 0.000573394495413 0 4 -4
relevance,of,the 1.0 0.000143348623853 0 1 -1
relevance,continues,to 1.0 0.000143348623853 0 1 -1
release,whereas,the 1.0 0.000143348623853 0 1 -1
release,was,measured 1.0 0.000143348623853 0 1 -1
release,or,the 1.0 0.000143348623853 0 1 -1
release,of,vasoconstrictor 1.0 0.000143348623853 0 1 -1
release,of,neutrophils 1.0 0.000143348623853 0 1 -1
release,of,in 1.0 0.000143348623853 0 1 -1
release,of,from 1.0 0.000286697247706 0 2 -2
release,of,atp 1.0 0.000143348623853 0 1 -1
release,of,arachidonic 1.0 0.000143348623853 0 1 -1
release,of,and 1.0 0.000286697247706 0 2 -2
release,mg,did 1.0 0.000143348623853 0 1 -1
release,in,either 1.0 0.000143348623853 0 1 -1
release,in,diabetics 1.0 0.000143348623853 0 1 -1
release,formulation,of 1.0 0.000143348623853 0 1 -1
release,by,platelets 1.0 0.000143348623853 0 1 -1
release,by,cholinergic 1.0 0.000143348623853 0 1 -1
release,but,presumably 1.0 0.000143348623853 0 1 -1
release,but,nearly 1.0 0.000143348623853 0 1 -1
release,and,thromboxane 1.0 0.000143348623853 0 1 -1
release,and,less 1.0 0.000143348623853 0 1 -1
release,and,impaired 1.0 0.000143348623853 0 1 -1
relaxation,of,mesenteric 1.0 0.000143348623853 0 1 -1
relaxation,of,at 1.0 0.000143348623853 0 1 -1
relaxants,that,resulted 1.0 0.000143348623853 0 1 -1
relaxants,nondepolarizing,used 1.0 0.000143348623853 0 1 -1
relaxants,nondepolarizing,possible 1.0 0.000286697247706 0 2 -2
relaxants,is,augmented 1.0 0.000143348623853 0 1 -1
relaxants,intravenous,agents 1.0 0.000143348623853 0 1 -1
relaxants,in,postmarketing 1.0 0.000143348623853 0 1 -1
relaxants,has,not 1.0 0.000143348623853 0 1 -1
relaxants,birth,control 1.0 0.000143348623853 0 1 -1
relaxants,are,used 1.0 0.000143348623853 0 1 -1
relaxants,are,given 1.0 0.000143348623853 0 1 -1
relaxants,and,muscle 1.0 0.000143348623853 0 1 -1
relaxant,antagonists,administered 1.0 0.000143348623853 0 1 -1
relatively,unexplored,area 1.0 0.000143348623853 0 1 -1
relatively,specific,blockade 1.0 0.000143348623853 0 1 -1
relatively,little,work 1.0 0.000143348623853 0 1 -1
relative,to,published 1.0 0.000143348623853 0 1 -1
relative,to,benefits 1.0 0.000143348623853 0 1 -1
relative,to,administration 1.0 0.000143348623853 0 1 -1
relative,risk,of 1.0 0.000143348623853 0 1 -1
relative,risk,for 1.0 0.000143348623853 0 1 -1
relative,importance,of 1.0 0.000143348623853 0 1 -1
relative,bioavailability,auc 1.0 0.000143348623853 0 1 -1
relative,avidities,for 1.0 0.000143348623853 0 1 -1
relative,absorption,as 1.0 0.000143348623853 0 1 -1
relationships,between,area 1.0 0.000143348623853 0 1 -1
relationships,between,and 1.0 0.000143348623853 0 1 -1
relationships,among,ras 1.0 0.000143348623853 0 1 -1
relationship,to,therapy 1.0 0.000143348623853 0 1 -1
relationship,to,their 1.0 0.000143348623853 0 1 -1
relationship,measurement,of 1.0 0.000143348623853 0 1 -1
relationship,between,these 1.0 0.000143348623853 0 1 -1
relationship,between,folic 1.0 0.000143348623853 0 1 -1
relational,the,hippocampus 1.0 0.000143348623853 0 1 -1
relation,to,the 1.0 0.000286697247706 0 2 -2
relation,to,other 1.0 0.000143348623853 0 1 -1
relation,between,plasma 1.0 0.000143348623853 0 1 -1
relating,to,the 1.0 0.000143348623853 0 1 -1
related,with,the 1.0 0.000143348623853 0 1 -1
related,to,the 1.0 0.00100344036697 0 7 -7
related,to,platelet 1.0 0.000143348623853 0 1 -1
related,to,interactions 1.0 0.000143348623853 0 1 -1
related,to,during 1.0 0.000143348623853 0 1 -1
related,to,dose 1.0 0.000143348623853 0 1 -1
related,to,diseases 1.0 0.000143348623853 0 1 -1
related,to,competitive 1.0 0.000143348623853 0 1 -1
related,to,alpha 1.0 0.000143348623853 0 1 -1
related,to,acute 1.0 0.000143348623853 0 1 -1
related,to,a 1.0 0.000143348623853 0 1 -1
related,psychoses,to 1.0 0.000286697247706 0 2 -2
related,metabolic,disturbances 1.0 0.000143348623853 0 1 -1
related,ethacrynic,acid 1.0 0.000143348623853 0 1 -1
related,changes,were 1.0 0.000143348623853 0 1 -1
related,both,to 1.0 0.000143348623853 0 1 -1
relate,to,the 1.0 0.000143348623853 0 1 -1
relapses,for,periods 1.0 0.000143348623853 0 1 -1
relapse,rehospitalisation,was 1.0 0.000143348623853 0 1 -1
relafen,daypro,and 1.0 0.000143348623853 0 1 -1
rejection,episodes,permit 1.0 0.000143348623853 0 1 -1
reinstate,psychostimulant,self-administration 1.0 0.000143348623853 0 1 -1
reinforcing,effects,conditioning 1.0 0.000143348623853 0 1 -1
rehospitalisation,was,significantly 1.0 0.000143348623853 0 1 -1
regulation,of,voltage-dependent 1.0 0.000143348623853 0 1 -1
regulation,of,tyrosine 1.0 0.000143348623853 0 1 -1
regulation,of,topoisomerases 1.0 0.000143348623853 0 1 -1
regulation,of,the 1.0 0.000286697247706 0 2 -2
regulation,of,its 1.0 0.000143348623853 0 1 -1
regulation,of,blood 1.0 0.000143348623853 0 1 -1
regulated,by,movement 1.0 0.000143348623853 0 1 -1
regularly,results,in 1.0 0.000143348623853 0 1 -1
regularly,for,changes 1.0 0.000286697247706 0 2 -2
regularly,during,simultaneous 1.0 0.000143348623853 0 1 -1
regular,users,of 1.0 0.000143348623853 0 1 -1
regular,users,develop 1.0 0.000143348623853 0 1 -1
regular,reevaluations,of 1.0 0.000143348623853 0 1 -1
regular,monitoring,of 1.0 0.000143348623853 0 1 -1
regular,basis,it 1.0 0.000143348623853 0 1 -1
regression,model,primary 1.0 0.000143348623853 0 1 -1
regranex,gel,with 1.0 0.000143348623853 0 1 -1
regranex,gel,interacts 1.0 0.000143348623853 0 1 -1
registered,trademark,of 1.0 0.000143348623853 0 1 -1
regional,perfusion,in 1.0 0.000143348623853 0 1 -1
regimens,where,is 1.0 0.000143348623853 0 1 -1
regimens,prediction,of 1.0 0.000143348623853 0 1 -1
regimens,of,of 1.0 0.000143348623853 0 1 -1
regimens,may,have 1.0 0.000143348623853 0 1 -1
regimens,lower,tablet 1.0 0.000143348623853 0 1 -1
regimens,including,and 1.0 0.000143348623853 0 1 -1
regimens,in,patients 1.0 0.000143348623853 0 1 -1
regimens,has,been 1.0 0.000143348623853 0 1 -1
regimens,for,therapy 1.0 0.000143348623853 0 1 -1
regimens,consisted,of 1.0 0.000143348623853 0 1 -1
regimens,and,superiority 1.0 0.000143348623853 0 1 -1
regimen,reduces,the 1.0 0.000143348623853 0 1 -1
regimen,plus,haart 1.0 0.000143348623853 0 1 -1
regimen,of,patients 1.0 0.000286697247706 0 2 -2
regimen,may,be 1.0 0.000286697247706 0 2 -2
regimen,i,and 1.0 0.000143348623853 0 1 -1
regimen,efficacy,in 1.0 0.000143348623853 0 1 -1
regimen,containing,mg 1.0 0.000143348623853 0 1 -1
regimen,be,altered 1.0 0.000143348623853 0 1 -1
regimen,as,well 1.0 0.000143348623853 0 1 -1
regardless,of,the 1.0 0.000286697247706 0 2 -2
regarding,the,risk 1.0 0.000143348623853 0 1 -1
regarding,the,potential 1.0 0.000143348623853 0 1 -1
regarding,the,effects 1.0 0.000286697247706 0 2 -2
regarding,the,coadministration 1.0 0.000143348623853 0 1 -1
regarding,protease,inhibitor 1.0 0.000143348623853 0 1 -1
regarding,potential,adverse 1.0 0.000143348623853 0 1 -1
regarding,interactions,with 1.0 0.000143348623853 0 1 -1
regarding,interactions,when 1.0 0.000143348623853 0 1 -1
regarding,interactions,associated 1.0 0.000143348623853 0 1 -1
regarding,asthma,therapy 1.0 0.000143348623853 0 1 -1
regard,to,the 1.0 0.000143348623853 0 1 -1
regard,to,patient 1.0 0.000143348623853 0 1 -1
regard,to,designing 1.0 0.000143348623853 0 1 -1
regard,to,concomitant 1.0 0.000286697247706 0 2 -2
refrain,from,treatment 1.0 0.000143348623853 0 1 -1
reformed,microtubules,appeared 1.0 0.000143348623853 0 1 -1
reflexes,hourly,diuresis 1.0 0.000143348623853 0 1 -1
reflex,and,shorter 1.0 0.000143348623853 0 1 -1
reflex,and,duration 1.0 0.000143348623853 0 1 -1
reflective,of,a 1.0 0.000143348623853 0 1 -1
reflecting,the,absence 1.0 0.000143348623853 0 1 -1
reflected,in,the 1.0 0.000143348623853 0 1 -1
reflect,the,interaction 1.0 0.000143348623853 0 1 -1
referred,to,as 1.0 0.00043004587156 0 3 -3
reference,to,possible 1.0 0.000143348623853 0 1 -1
reevaluations,of,dosages 1.0 0.000143348623853 0 1 -1
redundancy,at,many 1.0 0.000143348623853 0 1 -1
reductions,in,the 1.0 0.000143348623853 0 1 -1
reductions,in,serum 1.0 0.00043004587156 0 3 -3
reductions,in,other 1.0 0.000143348623853 0 1 -1
reductions,in,or 1.0 0.000143348623853 0 1 -1
reductions,in,both 1.0 0.000143348623853 0 1 -1
reduction,with,careful 1.0 0.000143348623853 0 1 -1
reduction,were,not 1.0 0.000143348623853 0 1 -1
reduction,that,reached 1.0 0.000143348623853 0 1 -1
reduction,tests,benedicts 1.0 0.000143348623853 0 1 -1
reduction,tests,benedict 1.0 0.000143348623853 0 1 -1
reduction,should,be 1.0 0.000143348623853 0 1 -1
reduction,or,interruption 1.0 0.000143348623853 0 1 -1
reduction,of,uptake 1.0 0.000143348623853 0 1 -1
reduction,of,growth 1.0 0.000143348623853 0 1 -1
reduction,of,for 1.0 0.000143348623853 0 1 -1
reduction,of,excretion 1.0 0.00043004587156 0 3 -3
reduction,of,cerubidine 1.0 0.000143348623853 0 1 -1
reduction,in,order 1.0 0.000286697247706 0 2 -2
reduction,in,mac 1.0 0.000143348623853 0 1 -1
reduction,in,low-density 1.0 0.000143348623853 0 1 -1
reduction,in,iop 1.0 0.000143348623853 0 1 -1
reduction,in,fertility 1.0 0.000143348623853 0 1 -1
reduction,in,female 1.0 0.000143348623853 0 1 -1
reduction,for,equetrotm 1.0 0.000143348623853 0 1 -1
reduction,depending,on 1.0 0.000143348623853 0 1 -1
reduction,at,the 1.0 0.000143348623853 0 1 -1
reduction,at,hr 1.0 0.000143348623853 0 1 -1
reduction,as,recommended 1.0 0.000143348623853 0 1 -1
reductase,resulting,in 1.0 0.000143348623853 0 1 -1
reductase,may,cause 1.0 0.000143348623853 0 1 -1
reductase,inhibitors,warning 1.0 0.000143348623853 0 1 -1
reductase,inhibitors,simvastatin 1.0 0.000143348623853 0 1 -1
reductase,inhibitors,prostaglandin 1.0 0.000143348623853 0 1 -1
reductase,inhibitors,on 1.0 0.000143348623853 0 1 -1
reductase,inhibitors,interfere 1.0 0.000143348623853 0 1 -1
reductase,inhibitors,inhibitors 1.0 0.000143348623853 0 1 -1
reductase,inhibitor,to 1.0 0.000143348623853 0 1 -1
reducing,hunger,and 1.0 0.000143348623853 0 1 -1
reduces,the,plasma 1.0 0.000143348623853 0 1 -1
reduces,basal,plasma 1.0 0.000143348623853 0 1 -1
reduced,twitch,strength 1.0 0.000143348623853 0 1 -1
reduced,to,maintain 1.0 0.000143348623853 0 1 -1
reduced,to,approximately 1.0 0.000143348623853 0 1 -1
reduced,the,number 1.0 0.000143348623853 0 1 -1
reduced,the,amplitudes 1.0 0.000143348623853 0 1 -1
reduced,the,amplitude 1.0 0.000143348623853 0 1 -1
reduced,subjects,reports 1.0 0.000143348623853 0 1 -1
reduced,significantly,when 1.0 0.000143348623853 0 1 -1
reduced,risk,of 1.0 0.000143348623853 0 1 -1
reduced,response,to 1.0 0.000573394495413 0 4 -4
reduced,requirements,but 1.0 0.000143348623853 0 1 -1
reduced,relative,risk 1.0 0.000143348623853 0 1 -1
reduced,p450,d6 1.0 0.000716743119266 0 5 -5
reduced,ligand,binding 1.0 0.000143348623853 0 1 -1
reduced,levels,up 1.0 0.000143348623853 0 1 -1
reduced,ldl,cholesterol 1.0 0.000286697247706 0 2 -2
reduced,kidney,and 1.0 0.000143348623853 0 1 -1
reduced,it,by 1.0 0.000143348623853 0 1 -1
reduced,interaction,between 1.0 0.000143348623853 0 1 -1
reduced,in,order 1.0 0.000143348623853 0 1 -1
reduced,in,myocardium 1.0 0.000143348623853 0 1 -1
reduced,in,hypothyroid 1.0 0.000143348623853 0 1 -1
reduced,in,both 1.0 0.000143348623853 0 1 -1
reduced,in,a 1.0 0.000716743119266 0 5 -5
reduced,if,is 1.0 0.000143348623853 0 1 -1
reduced,higher,doses 1.0 0.00043004587156 0 3 -3
reduced,efficacy,should 1.0 0.000143348623853 0 1 -1
reduced,efficacy,and 1.0 0.000286697247706 0 2 -2
reduced,clozapine,dose 1.0 0.000143348623853 0 1 -1
reduced,clearance,prolongation 1.0 0.000143348623853 0 1 -1
reduced,clearance,of 1.0 0.000573394495413 0 4 -4
reduced,by,one-third 1.0 0.000286697247706 0 2 -2
reduced,by,one-half 1.0 0.000143348623853 0 1 -1
reduced,by,increasing 1.0 0.000143348623853 0 1 -1
reduced,by,factors 1.0 0.000143348623853 0 1 -1
reduced,as,much 1.0 0.000143348623853 0 1 -1
reduced,antihypertensive,effect 1.0 0.000143348623853 0 1 -1
reduced,and,titrated 1.0 0.000143348623853 0 1 -1
reduced,and,the 1.0 0.000143348623853 0 1 -1
reduced,adp-induced,increases 1.0 0.000143348623853 0 1 -1
reduced,activity,of 1.0 0.000286697247706 0 2 -2
reduced,activity,against 1.0 0.000143348623853 0 1 -1
reduced,about,in 1.0 0.000143348623853 0 1 -1
reduce,the,morbidity 1.0 0.000143348623853 0 1 -1
reduce,the,metabolism 1.0 0.000143348623853 0 1 -1
reduce,the,function 1.0 0.000143348623853 0 1 -1
reduce,the,frequency 1.0 0.000143348623853 0 1 -1
reduce,the,blood-glucose 1.0 0.000286697247706 0 2 -2
reduce,renal,function 1.0 0.000143348623853 0 1 -1
reduce,plasma,clearance 1.0 0.000143348623853 0 1 -1
reduce,its,serum 1.0 0.000143348623853 0 1 -1
reduce,basal,plasma 1.0 0.000143348623853 0 1 -1
reduce,and,retard 1.0 0.000143348623853 0 1 -1
redistribution,redistribution,accumulation 1.0 0.000143348623853 0 1 -1
redistribution,accumulation,of 1.0 0.000143348623853 0 1 -1
redistributed,type,inositol 1.0 0.000143348623853 0 1 -1
reddish,stools,in 1.0 0.000143348623853 0 1 -1
red-orange,which,may 1.0 0.000143348623853 0 1 -1
red,rr,on 1.0 0.000143348623853 0 1 -1
red,on,inositol 1.0 0.000143348623853 0 1 -1
red,cells,from 1.0 0.000143348623853 0 1 -1
red,blood,cells 1.0 0.000143348623853 0 1 -1
recurrence,relative,to 1.0 0.000143348623853 0 1 -1
recurrence,of,skin 1.0 0.000143348623853 0 1 -1
recurred,when,the 1.0 0.000143348623853 0 1 -1
rectification,were,each 1.0 0.000143348623853 0 1 -1
recovery,programs,should 1.0 0.000143348623853 0 1 -1
recovery,of,the 1.0 0.000143348623853 0 1 -1
recovery,in,a 1.0 0.000143348623853 0 1 -1
recovery,from,single 1.0 0.000143348623853 0 1 -1
recovery,from,neuromuscular 1.0 0.000143348623853 0 1 -1
recovery,and,the 1.0 0.000143348623853 0 1 -1
recovery,and,define 1.0 0.000143348623853 0 1 -1
recovered,weeks,after 1.0 0.000143348623853 0 1 -1
recover,to,a 1.0 0.000143348623853 0 1 -1
recordings,of,rat 1.0 0.000143348623853 0 1 -1
recording,technique,in 1.0 0.000143348623853 0 1 -1
recording,pipette,compared 1.0 0.000143348623853 0 1 -1
recording,higher,concentrations 1.0 0.000143348623853 0 1 -1
recorded,with,but 1.0 0.000143348623853 0 1 -1
recorded,while,the 1.0 0.000143348623853 0 1 -1
recorded,from,the 1.0 0.000143348623853 0 1 -1
recorded,at,and 1.0 0.000143348623853 0 1 -1
recommended,when,these 1.0 0.000286697247706 0 2 -2
recommended,when,is 1.0 0.000143348623853 0 1 -1
recommended,weekly,human 1.0 0.000143348623853 0 1 -1
recommended,twice,daily 1.0 0.000143348623853 0 1 -1
recommended,to,determine 1.0 0.000143348623853 0 1 -1
recommended,that,these 1.0 0.00043004587156 0 3 -3
recommended,that,patients 1.0 0.000143348623853 0 1 -1
recommended,that,glucose 1.0 0.000860091743119 0 6 -6
recommended,that,gaba-positive 1.0 0.000143348623853 0 1 -1
recommended,that,frequent 1.0 0.000143348623853 0 1 -1
recommended,that,either 1.0 0.000286697247706 0 2 -2
recommended,that,doxil 1.0 0.000143348623853 0 1 -1
recommended,that,allegra 1.0 0.000143348623853 0 1 -1
recommended,levetiracetam,had 1.0 0.000143348623853 0 1 -1
recommended,in,such 1.0 0.000143348623853 0 1 -1
recommended,in,epileptic 1.0 0.000143348623853 0 1 -1
recommended,in,dosage 1.0 0.000143348623853 0 1 -1
recommended,human,hour 1.0 0.000143348623853 0 1 -1
recommended,human,dose 1.0 0.000286697247706 0 2 -2
recommended,for,patients 1.0 0.000143348623853 0 1 -1
recommended,for,coadministration 1.0 0.000143348623853 0 1 -1
recommended,during,the 1.0 0.000143348623853 0 1 -1
recommended,dose,ranges 1.0 0.000143348623853 0 1 -1
recommended,dose,for 1.0 0.000143348623853 0 1 -1
recommended,dose,based 1.0 0.000286697247706 0 2 -2
recommended,dosage,one 1.0 0.000143348623853 0 1 -1
recommended,depending,on 1.0 0.000143348623853 0 1 -1
recommended,based,on 1.0 0.000286697247706 0 2 -2
recommended,as,they 1.0 0.000143348623853 0 1 -1
recommended,and,if 1.0 0.000143348623853 0 1 -1
recommendations,were,to 1.0 0.000143348623853 0 1 -1
recommendations,for,sustiva 1.0 0.000143348623853 0 1 -1
recommendations,are,based 1.0 0.000143348623853 0 1 -1
recommendation,to,lower 1.0 0.000143348623853 0 1 -1
recombinant,shuttle,vectors 1.0 0.000143348623853 0 1 -1
recognized,that,a 1.0 0.00043004587156 0 3 -3
recognized,as,increasingly 1.0 0.000143348623853 0 1 -1
recognition,of,toxicity 1.0 0.000143348623853 0 1 -1
recognition,and,understanding 1.0 0.000143348623853 0 1 -1
recipients,suggest,that 1.0 0.000143348623853 0 1 -1
recipients,over,the 1.0 0.000143348623853 0 1 -1
recipients,during,the 1.0 0.000143348623853 0 1 -1
receptors,to,these 1.0 0.000143348623853 0 1 -1
receptors,sodium,channels 1.0 0.000143348623853 0 1 -1
receptors,mc,has 1.0 0.000143348623853 0 1 -1
receptors,in,the 1.0 0.000143348623853 0 1 -1
receptors,are,coupled 1.0 0.000143348623853 0 1 -1
receptor,blockers,calcium 1.0 0.000143348623853 0 1 -1
receptor,antagonists,congestive 1.0 0.000143348623853 0 1 -1
recently,identified,case 1.0 0.000143348623853 0 1 -1
recently,been,demonstrated 1.0 0.000143348623853 0 1 -1
recent,studies,of 1.0 0.000143348623853 0 1 -1
recent,studies,and 1.0 0.000143348623853 0 1 -1
recent,radiation,treatment 1.0 0.000143348623853 0 1 -1
recent,developments,in 1.0 0.000143348623853 0 1 -1
recent,better,designed 1.0 0.000143348623853 0 1 -1
receiving,velcade,and 1.0 0.000143348623853 0 1 -1
receiving,treatment,with 1.0 0.000143348623853 0 1 -1
receiving,treatment,for 1.0 0.000143348623853 0 1 -1
receiving,thiazide,for 1.0 0.000143348623853 0 1 -1
receiving,thiazide,agents 1.0 0.000143348623853 0 1 -1
receiving,these,who 1.0 0.000143348623853 0 1 -1
receiving,these,in 1.0 0.000143348623853 0 1 -1
receiving,these,concurrently 1.0 0.000143348623853 0 1 -1
receiving,therapy,administration 1.0 0.000143348623853 0 1 -1
receiving,the,two 1.0 0.000143348623853 0 1 -1
receiving,the,recommended 1.0 0.000143348623853 0 1 -1
receiving,the,patient 1.0 0.000573394495413 0 4 -4
receiving,the,and 1.0 0.000143348623853 0 1 -1
receiving,taxotere,as 1.0 0.000143348623853 0 1 -1
receiving,tablets,compared 1.0 0.000143348623853 0 1 -1
receiving,such,combined 1.0 0.000143348623853 0 1 -1
receiving,starlix,the 1.0 0.000143348623853 0 1 -1
receiving,sprycel,should 1.0 0.000143348623853 0 1 -1
receiving,single,weekly 1.0 0.000143348623853 0 1 -1
receiving,similar,combination 1.0 0.000143348623853 0 1 -1
receiving,resulted,in 1.0 0.000143348623853 0 1 -1
receiving,preparations,or 1.0 0.000143348623853 0 1 -1
receiving,preparations,increases 1.0 0.000143348623853 0 1 -1
receiving,oral,the 1.0 0.000143348623853 0 1 -1
receiving,oral,may 1.0 0.000143348623853 0 1 -1
receiving,or,should 1.0 0.000143348623853 0 1 -1
receiving,or,oral 1.0 0.000143348623853 0 1 -1
receiving,no,significant 1.0 0.000143348623853 0 1 -1
receiving,narrow,therapeutic 1.0 0.000143348623853 0 1 -1
receiving,n,n 1.0 0.000143348623853 0 1 -1
receiving,micronase,the 1.0 0.000573394495413 0 4 -4
receiving,mg,to 1.0 0.000143348623853 0 1 -1
receiving,mg,of 1.0 0.000143348623853 0 1 -1
receiving,medications,that 1.0 0.000143348623853 0 1 -1
receiving,maintenance,doses 1.0 0.000143348623853 0 1 -1
receiving,low,therapeutic 1.0 0.000143348623853 0 1 -1
receiving,inspra,to 1.0 0.000143348623853 0 1 -1
receiving,injection,who 1.0 0.000143348623853 0 1 -1
receiving,infusions,of 1.0 0.000143348623853 0 1 -1
receiving,increased,sgot 1.0 0.000143348623853 0 1 -1
receiving,including,antiparkinsonism 1.0 0.000143348623853 0 1 -1
receiving,hydrochloride,concomitantly 1.0 0.000143348623853 0 1 -1
receiving,have,experienced 1.0 0.000143348623853 0 1 -1
receiving,growth,factor 1.0 0.000143348623853 0 1 -1
receiving,ganglion,blocking 1.0 0.000143348623853 0 1 -1
receiving,foradil,other 1.0 0.000143348623853 0 1 -1
receiving,for,heart 1.0 0.000143348623853 0 1 -1
receiving,for,approximately 1.0 0.000143348623853 0 1 -1
receiving,either,concomitant 1.0 0.000143348623853 0 1 -1
receiving,diabinese,the 1.0 0.000573394495413 0 4 -4
receiving,daily,doses 1.0 0.000143348623853 0 1 -1
receiving,could,result 1.0 0.000143348623853 0 1 -1
receiving,concurrent,and 1.0 0.000143348623853 0 1 -1
receiving,concurrent,administration 1.0 0.000143348623853 0 1 -1
receiving,concomitant,treatment 1.0 0.000143348623853 0 1 -1
receiving,concomitant,therapy 1.0 0.000143348623853 0 1 -1
receiving,concomitant,hydrochloride 1.0 0.000143348623853 0 1 -1
receiving,brovana,has 1.0 0.000143348623853 0 1 -1
receiving,both,therapies 1.0 0.000143348623853 0 1 -1
receiving,both,should 1.0 0.000286697247706 0 2 -2
receiving,both,agents 1.0 0.000143348623853 0 1 -1
receiving,bolus-ifl,plus 1.0 0.000143348623853 0 1 -1
receiving,bolus-ifl,in 1.0 0.000143348623853 0 1 -1
receiving,bolus-ifl,alone 1.0 0.000143348623853 0 1 -1
receiving,blocking,agents 1.0 0.000143348623853 0 1 -1
receiving,beta,blockers 1.0 0.000143348623853 0 1 -1
receiving,and,no 1.0 0.000143348623853 0 1 -1
receiving,and,can 1.0 0.000143348623853 0 1 -1
receiving,accutane,have 1.0 0.000143348623853 0 1 -1
receiving,acarbose,the 1.0 0.000143348623853 0 1 -1
receiving,acarbose,in 1.0 0.000143348623853 0 1 -1
receiving,a,potent 1.0 0.000286697247706 0 2 -2
receiving,a,metabolized 1.0 0.000143348623853 0 1 -1
received,under,steady 1.0 0.000143348623853 0 1 -1
received,tended,to 1.0 0.000143348623853 0 1 -1
received,such,the 1.0 0.000143348623853 0 1 -1
received,rantidine,hydrochloride 1.0 0.000143348623853 0 1 -1
received,plus,for 1.0 0.000143348623853 0 1 -1
received,pelvic,abdominal 1.0 0.000143348623853 0 1 -1
received,one,or 1.0 0.000286697247706 0 2 -2
received,one,dose 1.0 0.000143348623853 0 1 -1
received,mg,twice 1.0 0.000286697247706 0 2 -2
received,mg,once 1.0 0.000143348623853 0 1 -1
received,mg,day 1.0 0.000143348623853 0 1 -1
received,in,escalating 1.0 0.000143348623853 0 1 -1
received,general,utilizing 1.0 0.000143348623853 0 1 -1
received,epirubicin-based,chemotherapy 1.0 0.000143348623853 0 1 -1
received,either,prophylactic 1.0 0.000143348623853 0 1 -1
received,concomitant,at 1.0 0.000286697247706 0 2 -2
received,concomitant,and 1.0 0.000143348623853 0 1 -1
received,chop-haart,compared 1.0 0.000143348623853 0 1 -1
received,chop,alone 1.0 0.000143348623853 0 1 -1
received,cephalosporin,before 1.0 0.000143348623853 0 1 -1
received,both,and 1.0 0.000143348623853 0 1 -1
received,as,part 1.0 0.000143348623853 0 1 -1
received,angiomax,in 1.0 0.000143348623853 0 1 -1
received,an,individualized 1.0 0.000143348623853 0 1 -1
received,an,equivalent 1.0 0.000143348623853 0 1 -1
received,among,patients 1.0 0.000143348623853 0 1 -1
received,amevive,in 1.0 0.000143348623853 0 1 -1
received,alone,mg 1.0 0.000143348623853 0 1 -1
received,alone,and 1.0 0.000143348623853 0 1 -1
received,ace,inhibitors 1.0 0.000143348623853 0 1 -1
received,a,single 1.0 0.000143348623853 0 1 -1
receive,tablets,at 1.0 0.000143348623853 0 1 -1
receive,oral,and 1.0 0.000143348623853 0 1 -1
receive,low-molecular,weight 1.0 0.000143348623853 0 1 -1
receive,large,doses 1.0 0.000143348623853 0 1 -1
receive,intermittent,hemodialysis 1.0 0.000143348623853 0 1 -1
receive,concomitant,strong 1.0 0.000143348623853 0 1 -1
receive,an,intravenous 1.0 0.000143348623853 0 1 -1
receive,adl,mg 1.0 0.000143348623853 0 1 -1
recall,reaction,at 1.0 0.000143348623853 0 1 -1
recall,has,been 1.0 0.000143348623853 0 1 -1
recalcitrant,nodular,acne 1.0 0.000143348623853 0 1 -1
rebif,is,used 1.0 0.000143348623853 0 1 -1
rebif,is,given 1.0 0.000143348623853 0 1 -1
reassessed,periodically,in 1.0 0.000143348623853 0 1 -1
reassessed,and,where 1.0 0.000143348623853 0 1 -1
reassess,the,patient 1.0 0.000143348623853 0 1 -1
rearrangements,of,genomes 1.0 0.000143348623853 0 1 -1
reappearance,on,rewarming 1.0 0.000143348623853 0 1 -1
really,needed,agents 1.0 0.000143348623853 0 1 -1
realization,of,this 1.0 0.000143348623853 0 1 -1
readings,were,reported 1.0 0.000143348623853 0 1 -1
readily,penetrates,both 1.0 0.000143348623853 0 1 -1
read,circulars,for 1.0 0.000573394495413 0 4 -4
reactive,to,repeated 1.0 0.000573394495413 0 4 -4
reactive,substances,tbars 1.0 0.000143348623853 0 1 -1
reactive,species,ros 1.0 0.000143348623853 0 1 -1
reactive,encephalopathy,are 1.0 0.000143348623853 0 1 -1
reactions,when,treated 1.0 0.000143348623853 0 1 -1
reactions,was,not 1.0 0.000143348623853 0 1 -1
reactions,to,this 1.0 0.000143348623853 0 1 -1
reactions,to,such 1.0 0.000143348623853 0 1 -1
reactions,to,and 1.0 0.000143348623853 0 1 -1
reactions,thought,to 1.0 0.000143348623853 0 1 -1
reactions,such,as 1.0 0.0021502293578 0 15 -15
reactions,should,not 1.0 0.000143348623853 0 1 -1
reactions,secondary,to 1.0 0.000143348623853 0 1 -1
reactions,resemble,the 1.0 0.000143348623853 0 1 -1
reactions,related,to 1.0 0.000143348623853 0 1 -1
reactions,of,parietal 1.0 0.000143348623853 0 1 -1
reactions,is,unknown 1.0 0.000143348623853 0 1 -1
reactions,including,reactions 1.0 0.000143348623853 0 1 -1
reactions,including,anaphylaxis 1.0 0.000143348623853 0 1 -1
reactions,include,fever 1.0 0.000143348623853 0 1 -1
reactions,in,vitro 1.0 0.000143348623853 0 1 -1
reactions,in,patients 1.0 0.000143348623853 0 1 -1
reactions,in,nursing 1.0 0.000143348623853 0 1 -1
reactions,have,also 1.0 0.000143348623853 0 1 -1
reactions,from,the 1.0 0.000143348623853 0 1 -1
reactions,from,faslodex 1.0 0.000143348623853 0 1 -1
reactions,dyspnea,hypotension 1.0 0.000143348623853 0 1 -1
reactions,consisted,of 1.0 0.000143348623853 0 1 -1
reactions,compared,to 1.0 0.000143348623853 0 1 -1
reactions,catalyzed,by 1.0 0.000143348623853 0 1 -1
reactions,atg,alg 1.0 0.000143348623853 0 1 -1
reactions,at,a 1.0 0.000143348623853 0 1 -1
reactions,are,dizziness 1.0 0.000143348623853 0 1 -1
reactions,and,repeat 1.0 0.000143348623853 0 1 -1
reactions,all,patients 1.0 0.000143348623853 0 1 -1
reactions,after,therapy 1.0 0.000143348623853 0 1 -1
reaction,with,glutathione 1.0 0.000143348623853 0 1 -1
reaction,while,taking 1.0 0.00043004587156 0 3 -3
reaction,to,have 1.0 0.000143348623853 0 1 -1
reaction,to,a 1.0 0.000716743119266 0 5 -5
reaction,since,ancobon 1.0 0.000143348623853 0 1 -1
reaction,profile,of 1.0 0.000143348623853 0 1 -1
reaction,on,repeated 1.0 0.000143348623853 0 1 -1
reaction,may,be 1.0 0.000143348623853 0 1 -1
reaction,is,unknown 1.0 0.000143348623853 0 1 -1
reaction,is,a 1.0 0.000143348623853 0 1 -1
reaction,injection,site 1.0 0.000143348623853 0 1 -1
reaction,had,increased 1.0 0.000143348623853 0 1 -1
reaction,for,urinary 1.0 0.000143348623853 0 1 -1
reaction,for,ketones 1.0 0.000286697247706 0 2 -2
reaction,for,glucose 1.0 0.00186353211009 0 13 -13
reaction,either,occurred 1.0 0.000143348623853 0 1 -1
reaction,during,treatment 1.0 0.000143348623853 0 1 -1
reaction,at,the 1.0 0.000143348623853 0 1 -1
reaction,at,concentrations 1.0 0.000143348623853 0 1 -1
reaction,and,produce 1.0 0.00043004587156 0 3 -3
reaction,and,clinical 1.0 0.000143348623853 0 1 -1
reaction,after,remained 1.0 0.000143348623853 0 1 -1
reaching,epidemic,proportions 1.0 0.000143348623853 0 1 -1
reaching,a,segment 1.0 0.000143348623853 0 1 -1
reaching,a,maximal 1.0 0.000143348623853 0 1 -1
reached,whereas,the 1.0 0.000143348623853 0 1 -1
reached,on,or 1.0 0.000143348623853 0 1 -1
reached,by,to 1.0 0.000143348623853 0 1 -1
reached,borderline,statistical 1.0 0.000143348623853 0 1 -1
reached,after,approximately 1.0 0.000143348623853 0 1 -1
reach,toxic,levels 1.0 0.000143348623853 0 1 -1
reach,maximum,concentration 1.0 0.000143348623853 0 1 -1
reach,cmax,is 1.0 0.000143348623853 0 1 -1
re-treated,with,subsequent 1.0 0.000143348623853 0 1 -1
re-results,in,almost 1.0 0.000143348623853 0 1 -1
re-exposure,in,in 1.0 0.000143348623853 0 1 -1
rd,th,and 1.0 0.000143348623853 0 1 -1
rbc,were,used 1.0 0.000143348623853 0 1 -1
rbc,mice,in 1.0 0.000143348623853 0 1 -1
rbc,mice,but 1.0 0.000143348623853 0 1 -1
rats,with,the 1.0 0.000143348623853 0 1 -1
rats,whereas,the 1.0 0.000143348623853 0 1 -1
rats,were,sacrificed 1.0 0.000143348623853 0 1 -1
rats,were,kept 1.0 0.000143348623853 0 1 -1
rats,were,given 1.0 0.000143348623853 0 1 -1
rats,were,fasted 1.0 0.000286697247706 0 2 -2
rats,were,divided 1.0 0.000143348623853 0 1 -1
rats,was,more 1.0 0.000143348623853 0 1 -1
rats,was,investigated 1.0 0.000143348623853 0 1 -1
rats,to,assess 1.0 0.000143348623853 0 1 -1
rats,the,human 1.0 0.000143348623853 0 1 -1
rats,that,prolonged 1.0 0.000143348623853 0 1 -1
rats,tarsal,flexure 1.0 0.000143348623853 0 1 -1
rats,showed,significant 1.0 0.000143348623853 0 1 -1
rats,responses,to 1.0 0.000143348623853 0 1 -1
rats,received,a 1.0 0.000143348623853 0 1 -1
rats,probably,due 1.0 0.000143348623853 0 1 -1
rats,prepared,by 1.0 0.000143348623853 0 1 -1
rats,of,the 1.0 0.000143348623853 0 1 -1
rats,in,vivo 1.0 0.000143348623853 0 1 -1
rats,in,vitro 1.0 0.000143348623853 0 1 -1
rats,in,basal 1.0 0.000143348623853 0 1 -1
rats,hours,prior 1.0 0.000143348623853 0 1 -1
rats,giving,superimposed 1.0 0.000143348623853 0 1 -1
rats,followed,by 1.0 0.000143348623853 0 1 -1
rats,fasted,for 1.0 0.000143348623853 0 1 -1
rats,did,not 1.0 0.000286697247706 0 2 -2
rats,at,intramuscular 1.0 0.000143348623853 0 1 -1
rats,at,doses 1.0 0.000286697247706 0 2 -2
rats,at,but 1.0 0.000143348623853 0 1 -1
rats,as,was 1.0 0.000143348623853 0 1 -1
rats,arteries,from 1.0 0.000143348623853 0 1 -1
rats,are,not 1.0 0.000143348623853 0 1 -1
rats,are,mediated 1.0 0.000143348623853 0 1 -1
rats,appear,to 1.0 0.000143348623853 0 1 -1
rats,and,the 1.0 0.000286697247706 0 2 -2
rats,and,blood 1.0 0.000143348623853 0 1 -1
rats,administered,at 1.0 0.000143348623853 0 1 -1
ratios,of,the 1.0 0.000143348623853 0 1 -1
ratios,confidence,interval 1.0 0.000143348623853 0 1 -1
rationalized,at,the 1.0 0.000143348623853 0 1 -1
rationale,stress,and 1.0 0.000143348623853 0 1 -1
ratio,r,p 1.0 0.000143348623853 0 1 -1
ratio,or,other 1.0 0.000143348623853 0 1 -1
ratio,or,in 1.0 0.000143348623853 0 1 -1
ratio,or,enantiomer 1.0 0.000143348623853 0 1 -1
ratio,between,the 1.0 0.000143348623853 0 1 -1
ratio,and,potential 1.0 0.000143348623853 0 1 -1
rating,scales,and 1.0 0.000143348623853 0 1 -1
rather,than,dose 1.0 0.000143348623853 0 1 -1
rates,were,similar 1.0 0.000143348623853 0 1 -1
rates,over,a 1.0 0.000143348623853 0 1 -1
rates,of,patients 1.0 0.000143348623853 0 1 -1
rates,in,the 1.0 0.000143348623853 0 1 -1
rates,compliance,and 1.0 0.000143348623853 0 1 -1
rates,and,therefore 1.0 0.000143348623853 0 1 -1
rates,and,mortality 1.0 0.000143348623853 0 1 -1
rate-limiting,step,in 1.0 0.000143348623853 0 1 -1
rate,which,requires 1.0 0.000143348623853 0 1 -1
rate,was,greater 1.0 0.000143348623853 0 1 -1
rate,requirement,may 1.0 0.000143348623853 0 1 -1
rate,or,extent 1.0 0.00043004587156 0 3 -3
rate,or,corrected 1.0 0.000143348623853 0 1 -1
rate,or,blood 1.0 0.000143348623853 0 1 -1
rate,of,the 1.0 0.000143348623853 0 1 -1
rate,of,dizziness 1.0 0.000143348623853 0 1 -1
rate,of,dissolution 1.0 0.000143348623853 0 1 -1
rate,of,aerosol 1.0 0.000143348623853 0 1 -1
rate,increased,initially 1.0 0.000143348623853 0 1 -1
rate,in,such 1.0 0.000143348623853 0 1 -1
rate,constant,was 1.0 0.000143348623853 0 1 -1
rate,constant,volume 1.0 0.000143348623853 0 1 -1
rate,but,not 1.0 0.000143348623853 0 1 -1
rate,but,no 1.0 0.000143348623853 0 1 -1
rate,at,which 1.0 0.000143348623853 0 1 -1
rate,and,systolic 1.0 0.000143348623853 0 1 -1
rate,and,pulsatile 1.0 0.000143348623853 0 1 -1
rat,were,evaluated 1.0 0.000143348623853 0 1 -1
rat,the,human 1.0 0.000143348623853 0 1 -1
rat,spinal,substantia 1.0 0.000286697247706 0 2 -2
rat,s,diet 1.0 0.000143348623853 0 1 -1
rat,milk,at 1.0 0.000143348623853 0 1 -1
rat,liver,but 1.0 0.000143348623853 0 1 -1
rat,liver,and 1.0 0.000143348623853 0 1 -1
rat,kidney,homogenates 1.0 0.000143348623853 0 1 -1
rat,fibroblast,y1 1.0 0.000143348623853 0 1 -1
rat,days,showed 1.0 0.000143348623853 0 1 -1
rat,days,or 1.0 0.000143348623853 0 1 -1
rat,days,and 1.0 0.000286697247706 0 2 -2
rat,bone,marrow 1.0 0.000143348623853 0 1 -1
rashes,with,concomitant 1.0 0.000143348623853 0 1 -1
rashes,were,reported 1.0 0.000143348623853 0 1 -1
rashes,itching,mouth 1.0 0.000143348623853 0 1 -1
rash,pruritus,ankle 1.0 0.000143348623853 0 1 -1
rash,peripheral,edema 1.0 0.000143348623853 0 1 -1
rash,particularly,in 1.0 0.000143348623853 0 1 -1
rash,diarrhea,hypotension 1.0 0.000143348623853 0 1 -1
ras-transformed,ras-3t3,cells 1.0 0.000143348623853 0 1 -1
ras-3t3,cells,with 1.0 0.000143348623853 0 1 -1
ras-3t3,cells,was 1.0 0.000143348623853 0 1 -1
ras-3t3,cells,compared 1.0 0.000143348623853 0 1 -1
ras,nucleophosmin,b23 1.0 0.000143348623853 0 1 -1
rarely,euphoria,excitement 1.0 0.000143348623853 0 1 -1
rarely,enuresis,urinary 1.0 0.000143348623853 0 1 -1
rarely,dry,mouth 1.0 0.000143348623853 0 1 -1
rare,defect,in 1.0 0.000143348623853 0 1 -1
rare,cases,of 1.0 0.00043004587156 0 3 -3
rare,cases,approximately 1.0 0.000143348623853 0 1 -1
rapidly,to,fully 1.0 0.000143348623853 0 1 -1
rapidly,identified,and 1.0 0.000143348623853 0 1 -1
rapidly,hydrolyzed,intravenous 1.0 0.000143348623853 0 1 -1
rapidly,growing,class 1.0 0.000143348623853 0 1 -1
rapidly,by,the 1.0 0.000143348623853 0 1 -1
rapidly,and,essentially 1.0 0.000143348623853 0 1 -1
rapid,while,transfer 1.0 0.000143348623853 0 1 -1
rapid,progression,in 1.0 0.000143348623853 0 1 -1
rapid,equilibration,of 1.0 0.000143348623853 0 1 -1
rapid,contraction,followed 1.0 0.000143348623853 0 1 -1
rapid,avoidance,behaviour 1.0 0.000143348623853 0 1 -1
rantidine,hydrochloride,before 1.0 0.000143348623853 0 1 -1
ranitidine,produced,smaller 1.0 0.000286697247706 0 2 -2
ranitidine,mg,twice 1.0 0.000143348623853 0 1 -1
ranitidine,also,has 1.0 0.000143348623853 0 1 -1
ranging,from,therapeutic 1.0 0.000143348623853 0 1 -1
ranging,from,in 1.0 0.000286697247706 0 2 -2
ranges,within,the 1.0 0.000143348623853 0 1 -1
ranges,of,either 1.0 0.000143348623853 0 1 -1
ranged,from,to 1.0 0.000143348623853 0 1 -1
range,years,weight 1.0 0.000143348623853 0 1 -1
range,while,in 1.0 0.000143348623853 0 1 -1
range,when,assessed 1.0 0.000143348623853 0 1 -1
range,reported,for 1.0 0.000143348623853 0 1 -1
range,of,plasma 1.0 0.000143348623853 0 1 -1
range,of,observed 1.0 0.000143348623853 0 1 -1
range,of,medications 1.0 0.000143348623853 0 1 -1
range,of,is 1.0 0.000143348623853 0 1 -1
range,of,individual 1.0 0.000143348623853 0 1 -1
range,of,doses 1.0 0.000143348623853 0 1 -1
range,of,concentrations 1.0 0.000143348623853 0 1 -1
range,observed,with 1.0 0.000143348623853 0 1 -1
range,kg,and 1.0 0.000143348623853 0 1 -1
range,are,neither 1.0 0.000143348623853 0 1 -1
range,and,or 1.0 0.000143348623853 0 1 -1
randomly,bred,control 1.0 0.000143348623853 0 1 -1
randomly,assigned,to 1.0 0.000286697247706 0 2 -2
randomly,assigned,in 1.0 0.000143348623853 0 1 -1
randomized,to,one 1.0 0.000143348623853 0 1 -1
randomized,multiple-dose,crossover 1.0 0.000143348623853 0 1 -1
randomized,in,an 1.0 0.000143348623853 0 1 -1
randomized,double-blind,study 1.0 0.000143348623853 0 1 -1
randomized,crossover,study 1.0 0.000143348623853 0 1 -1
randomized,crossover,double-blind 1.0 0.000143348623853 0 1 -1
randomized,crossover,design 1.0 0.000143348623853 0 1 -1
randomized,balanced,two-period 1.0 0.000143348623853 0 1 -1
random,sample,of 1.0 0.000143348623853 0 1 -1
raise,the,question 1.0 0.000143348623853 0 1 -1
raise,the,level 1.0 0.000143348623853 0 1 -1
raise,the,gastrointestinal 1.0 0.000143348623853 0 1 -1
radiotherapy,may,sensitize 1.0 0.000143348623853 0 1 -1
radioligand,binding,experiments 1.0 0.000143348623853 0 1 -1
radiolabeled,ions,may 1.0 0.000143348623853 0 1 -1
radioimmunoassay,or,t3 1.0 0.000286697247706 0 2 -2
radioactive,derivative,of 1.0 0.000143348623853 0 1 -1
radio-iodine,uptake,producing 1.0 0.000143348623853 0 1 -1
radiation,treatment,or 1.0 0.000143348623853 0 1 -1
radiation,therapy,may 1.0 0.000286697247706 0 2 -2
radiation,therapy,diabetes 1.0 0.000143348623853 0 1 -1
radiation,therapy,but 1.0 0.000143348623853 0 1 -1
racemic,were,not 1.0 0.000143348623853 0 1 -1
racemic,was,seen 1.0 0.000143348623853 0 1 -1
racemic,titrated,to 1.0 0.000143348623853 0 1 -1
racemic,nor,binding 1.0 0.000143348623853 0 1 -1
racemic,mg,day 1.0 0.00043004587156 0 3 -3
racemic,for,days 1.0 0.000143348623853 0 1 -1
racemic,did,not 1.0 0.000143348623853 0 1 -1
race,intercurrent,illnesses 1.0 0.000143348623853 0 1 -1
rabbits,failed,to 1.0 0.000143348623853 0 1 -1
rabbits,dosed,at 1.0 0.000143348623853 0 1 -1
rabbits,backwards,displacement 1.0 0.000143348623853 0 1 -1
rabbit,kidney,cell 1.0 0.000143348623853 0 1 -1
rabbit,gastric,glands 1.0 0.000143348623853 0 1 -1
rabbit,following,doses 1.0 0.000143348623853 0 1 -1
ra,clinical,studies 1.0 0.000143348623853 0 1 -1
r-warfarin,or,s-warfarin 1.0 0.000143348623853 0 1 -1
r-value,of,naflu 1.0 0.000286697247706 0 2 -2
r,p,app 1.0 0.000143348623853 0 1 -1
r,or,s- 1.0 0.000143348623853 0 1 -1
r,b,the 1.0 0.000143348623853 0 1 -1
r,and,s 1.0 0.000143348623853 0 1 -1
quite,large,fold 1.0 0.000716743119266 0 5 -5
quinolones,form,chelates 1.0 0.00043004587156 0 3 -3
quinidine,and,doses 1.0 0.000143348623853 0 1 -1
quetiapine,fumarate,seroquel 1.0 0.000143348623853 0 1 -1
question,the,utility 1.0 0.000143348623853 0 1 -1
question,of,whether 1.0 0.000143348623853 0 1 -1
query,patients,or 1.0 0.000143348623853 0 1 -1
quantity,and,specific 1.0 0.000143348623853 0 1 -1
quantities,of,systemically 1.0 0.000143348623853 0 1 -1
quantities,of,grapefruit 1.0 0.000143348623853 0 1 -1
quantitatively,related,to 1.0 0.000143348623853 0 1 -1
quantitative,approach,to 1.0 0.000143348623853 0 1 -1
quantitative,and,qualitative 1.0 0.000143348623853 0 1 -1
quality,of,life 1.0 0.000143348623853 0 1 -1
qualitative,differences,between 1.0 0.000143348623853 0 1 -1
qualification,of,the 1.0 0.000143348623853 0 1 -1
quai,and,black 1.0 0.000143348623853 0 1 -1
qtc,prolongation,with 1.0 0.000143348623853 0 1 -1
qtc,prolongation,has 1.0 0.000143348623853 0 1 -1
qtc,prolongation,and 1.0 0.000143348623853 0 1 -1
qtc,intervals,in 1.0 0.000143348623853 0 1 -1
qtc,intervals,and 1.0 0.000143348623853 0 1 -1
qtc,interval,were 1.0 0.000143348623853 0 1 -1
qtc,interval,prolongation 1.0 0.000143348623853 0 1 -1
qtc,interval,have 1.0 0.000143348623853 0 1 -1
qtc,interval,caution 1.0 0.000143348623853 0 1 -1
qtc,increase,over 1.0 0.000286697247706 0 2 -2
qt0,on,ecg 1.0 0.000143348623853 0 1 -1
qt-interval,prolongation,and 1.0 0.000143348623853 0 1 -1
qt,qtc,interval 1.0 0.000286697247706 0 2 -2
qt,prolongation,which 1.0 0.000143348623853 0 1 -1
qt,prolongation,and 1.0 0.000286697247706 0 2 -2
qt,intervals,or 1.0 0.000143348623853 0 1 -1
qt,intervals,during 1.0 0.000143348623853 0 1 -1
qt,interval,clinical 1.0 0.000143348623853 0 1 -1
qid,did,not 1.0 0.000143348623853 0 1 -1
qd,was,co-administered 1.0 0.000143348623853 0 1 -1
qd,or,mg 1.0 0.000143348623853 0 1 -1
qd,or,hctz 1.0 0.000143348623853 0 1 -1
qd,of,are 1.0 0.000143348623853 0 1 -1
qd,has,not 1.0 0.000143348623853 0 1 -1
qd,for,five 1.0 0.000143348623853 0 1 -1
qd,did,not 1.0 0.000143348623853 0 1 -1
qd,cohort,or 1.0 0.000143348623853 0 1 -1
q4h,and,mg 1.0 0.000143348623853 0 1 -1
q12h,for,four 1.0 0.000143348623853 0 1 -1
q-t,interval,may 1.0 0.000143348623853 0 1 -1
q,d,doses 1.0 0.000143348623853 0 1 -1
pyrroloquinolinequinone,gdh,pqq 1.0 0.000143348623853 0 1 -1
pyrocarbonate,revealed,concentration 1.0 0.000143348623853 0 1 -1
pyrocarbonate,could,be 1.0 0.000143348623853 0 1 -1
pyrocarbonate,at,ph 1.0 0.000143348623853 0 1 -1
pyrocarbonate,abolished,both 1.0 0.000143348623853 0 1 -1
pyogenes,and,anaerobic 1.0 0.000143348623853 0 1 -1
pyknotic,nuclei,chromatin 1.0 0.000143348623853 0 1 -1
pursue,qualification,of 1.0 0.000143348623853 0 1 -1
purposes,cannot,be 1.0 0.000143348623853 0 1 -1
purpose,of,this 1.0 0.000143348623853 0 1 -1
purification,protocol,for 1.0 0.000143348623853 0 1 -1
purification,of,both 1.0 0.000143348623853 0 1 -1
pups,from,fulvestrant-treated 1.0 0.000143348623853 0 1 -1
pupillary,dilation,diaphoresis 1.0 0.000143348623853 0 1 -1
pupil,constriction,were 1.0 0.000143348623853 0 1 -1
pumps,for,novolog 1.0 0.000143348623853 0 1 -1
pulse,of,carcinogen 1.0 0.000143348623853 0 1 -1
pulse,of,a 1.0 0.000143348623853 0 1 -1
pulse,arterial,pressure 1.0 0.000143348623853 0 1 -1
pulsation,amplitude,but 1.0 0.000143348623853 0 1 -1
pulsatile,choroidal,blood 1.0 0.000143348623853 0 1 -1
pulmozyme,can,be 1.0 0.000143348623853 0 1 -1
pulmonary,or,systemic 1.0 0.000143348623853 0 1 -1
pulmonary,granulomata,subacute 1.0 0.000143348623853 0 1 -1
pulmonary,function,or 1.0 0.000143348623853 0 1 -1
pulmonary,extract,from 1.0 0.000143348623853 0 1 -1
pulmonary,emboli,rises 1.0 0.000143348623853 0 1 -1
pulmonary,disease,requires 1.0 0.000143348623853 0 1 -1
pulmonary,arterial,hypertension 1.0 0.000143348623853 0 1 -1
published,over,the 1.0 0.000143348623853 0 1 -1
published,information,on 1.0 0.000143348623853 0 1 -1
published,in,the 1.0 0.000143348623853 0 1 -1
published,accounts,in 1.0 0.000143348623853 0 1 -1
public,feels,that 1.0 0.000143348623853 0 1 -1
ptx,was,discussed 1.0 0.000143348623853 0 1 -1
ptx,have,entirely 1.0 0.000143348623853 0 1 -1
ptx,caused,the 1.0 0.000143348623853 0 1 -1
ptx,c129h223n3o54,isolated 1.0 0.000143348623853 0 1 -1
pt,such,as 1.0 0.000143348623853 0 1 -1
pt,and,inr 1.0 0.000143348623853 0 1 -1
psychotropic,or,even 1.0 0.000143348623853 0 1 -1
psychotomimetic,effects,in 1.0 0.000143348623853 0 1 -1
psychotic,reaction,has 1.0 0.000143348623853 0 1 -1
psychotic,patients,with 1.0 0.000286697247706 0 2 -2
psychostimulant,effects,of 1.0 0.000143348623853 0 1 -1
psychoses,to,mg 1.0 0.000143348623853 0 1 -1
psychoses,to,a 1.0 0.000143348623853 0 1 -1
psychopathology,rating,scales 1.0 0.000143348623853 0 1 -1
psychological,and,medical 1.0 0.000143348623853 0 1 -1
psoriatic,arthritis,clinical 1.0 0.000143348623853 0 1 -1
psoriasis,rheumatoid,arthritis 1.0 0.000143348623853 0 1 -1
pseudomonas,strains,from 1.0 0.000143348623853 0 1 -1
pseudomonas,aeruginosa,were 1.0 0.000143348623853 0 1 -1
pseudomonas,aeruginosa,serotype 1.0 0.000143348623853 0 1 -1
pseudomonas,aeruginosa,particularly 1.0 0.000143348623853 0 1 -1
psa,when,evaluating 1.0 0.000143348623853 0 1 -1
psa,levels,may 1.0 0.000143348623853 0 1 -1
psa,levels,are 1.0 0.000143348623853 0 1 -1
psa,decreased,from 1.0 0.000143348623853 0 1 -1
pruritus,rash,diarrhea 1.0 0.000143348623853 0 1 -1
pruritus,ankle,edema 1.0 0.000143348623853 0 1 -1
pruritus,and,should 1.0 0.000143348623853 0 1 -1
pruritus,and,hypotension 1.0 0.000143348623853 0 1 -1
prudent,evaluation,of 1.0 0.000143348623853 0 1 -1
prozac,sporanox,nizoral 1.0 0.000143348623853 0 1 -1
provoke,toxicity,because 1.0 0.000143348623853 0 1 -1
provoke,convulsions,in 1.0 0.000143348623853 0 1 -1
providing,for,results 1.0 0.000143348623853 0 1 -1
provides,considerable,evidence 1.0 0.000143348623853 0 1 -1
providers,are,encouraged 1.0 0.000143348623853 0 1 -1
provided,to,the 1.0 0.000143348623853 0 1 -1
provided,to,assist 1.0 0.000143348623853 0 1 -1
provided,for,any 1.0 0.000143348623853 0 1 -1
provided,a,proper 1.0 0.000143348623853 0 1 -1
provide,therapeutic,levels 1.0 0.000143348623853 0 1 -1
provide,the,patient 1.0 0.000143348623853 0 1 -1
provide,misleading,information 1.0 0.000143348623853 0 1 -1
provide,medical,supervision 1.0 0.000143348623853 0 1 -1
provide,information,for 1.0 0.000143348623853 0 1 -1
provide,a,basis 1.0 0.000143348623853 0 1 -1
proven,efficacy,against 1.0 0.000143348623853 0 1 -1
proved,to,be 1.0 0.000143348623853 0 1 -1
protocol,for,a 1.0 0.000143348623853 0 1 -1
prothrombin,times,without 1.0 0.000143348623853 0 1 -1
prothrombin,times,were 1.0 0.00043004587156 0 3 -3
prothrombin,times,or 1.0 0.000143348623853 0 1 -1
prothrombin,times,can 1.0 0.000143348623853 0 1 -1
prothrombin,time,was 1.0 0.00043004587156 0 3 -3
prothrombin,time,responses 1.0 0.000143348623853 0 1 -1
prothrombin,time,response 1.0 0.000143348623853 0 1 -1
prothrombin,time,ratio 1.0 0.000143348623853 0 1 -1
prothrombin,time,partial 1.0 0.00043004587156 0 3 -3
prothrombin,time,of 1.0 0.000143348623853 0 1 -1
prothrombin,time,necessitating 1.0 0.000143348623853 0 1 -1
prothrombin,time,may 1.0 0.000143348623853 0 1 -1
prothrombin,time,has 1.0 0.000143348623853 0 1 -1
prothrombin,time,following 1.0 0.000286697247706 0 2 -2
prothrombin,time,by 1.0 0.000143348623853 0 1 -1
prothrombin,time,at 1.0 0.000143348623853 0 1 -1
prothrombin,time,and 1.0 0.000286697247706 0 2 -2
prothrombin,test,results 1.0 0.000143348623853 0 1 -1
prothrombin,test,monitoring 1.0 0.000143348623853 0 1 -1
prothrombin,or,other 1.0 0.000143348623853 0 1 -1
prothrombin,measures,have 1.0 0.000143348623853 0 1 -1
prothrombin,levels,and 1.0 0.000143348623853 0 1 -1
prothrombin,level,has 1.0 0.000143348623853 0 1 -1
prothrombin,determinations,are 1.0 0.000143348623853 0 1 -1
prothrombin,complex,concentrates 1.0 0.000143348623853 0 1 -1
prothrombin,and,partial 1.0 0.000143348623853 0 1 -1
prothrombin,and,factors 1.0 0.000286697247706 0 2 -2
proteus,rettgeri,were 1.0 0.000143348623853 0 1 -1
proteins,that,undergo 1.0 0.000143348623853 0 1 -1
proteins,other,than 1.0 0.000286697247706 0 2 -2
proteins,of,the 1.0 0.000143348623853 0 1 -1
proteins,may,be 1.0 0.000573394495413 0 4 -4
proteins,is,reduced 1.0 0.000143348623853 0 1 -1
proteins,is,low 1.0 0.000143348623853 0 1 -1
proteins,is,either 1.0 0.000143348623853 0 1 -1
proteins,interacting,with 1.0 0.000143348623853 0 1 -1
proteins,indicate,that 1.0 0.000143348623853 0 1 -1
proteins,in,vitro 1.0 0.000143348623853 0 1 -1
proteins,in,the 1.0 0.000143348623853 0 1 -1
proteins,in,t24 1.0 0.000143348623853 0 1 -1
proteins,at,c 1.0 0.000143348623853 0 1 -1
proteins,and,is 1.0 0.000143348623853 0 1 -1
protein-bound,would,not 1.0 0.000143348623853 0 1 -1
protein-bound,such,as 1.0 0.000143348623853 0 1 -1
protein-bound,pbi,t4 1.0 0.000286697247706 0 2 -2
protein-bound,pbi,levels 1.0 0.000143348623853 0 1 -1
protein-bound,have,essentially 1.0 0.000143348623853 0 1 -1
protein-bound,from,their 1.0 0.000143348623853 0 1 -1
protein-bound,anafranil,by 1.0 0.000143348623853 0 1 -1
protein-,bound,with 1.0 0.000143348623853 0 1 -1
protein,zaleplon,is 1.0 0.000143348623853 0 1 -1
protein,with,homology 1.0 0.000143348623853 0 1 -1
protein,when,was 1.0 0.000143348623853 0 1 -1
protein,tyrosine,phosphorylation 1.0 0.000143348623853 0 1 -1
protein,synthesis,within 1.0 0.000143348623853 0 1 -1
protein,mna,may 1.0 0.000143348623853 0 1 -1
protein,may,displace 1.0 0.000143348623853 0 1 -1
protein,kinase,c 1.0 0.000143348623853 0 1 -1
protein,is,not 1.0 0.000143348623853 0 1 -1
protein,involved,in 1.0 0.000143348623853 0 1 -1
protein,eszopiclone,is 1.0 0.000143348623853 0 1 -1
protein,carbamazepine,is 1.0 0.000143348623853 0 1 -1
protein,bound,would 1.0 0.000143348623853 0 1 -1
protein,bound,should 1.0 0.000286697247706 0 2 -2
protein,bound,from 1.0 0.000143348623853 0 1 -1
protein,bound,drugs 1.0 0.000143348623853 0 1 -1
protein,binding,entacapone 1.0 0.000143348623853 0 1 -1
protein,and,therefore 1.0 0.000143348623853 0 1 -1
protein,added,to 1.0 0.000143348623853 0 1 -1
protease,inhibitors,the 1.0 0.000143348623853 0 1 -1
protease,inhibitors,protease 1.0 0.000143348623853 0 1 -1
protease,inhibitors,or 1.0 0.000143348623853 0 1 -1
protease,inhibitors,nefazodone 1.0 0.000143348623853 0 1 -1
protease,inhibitors,macrolide 1.0 0.000143348623853 0 1 -1
protease,inhibitors,are 1.0 0.000143348623853 0 1 -1
protease,inhibitor,pi 1.0 0.000143348623853 0 1 -1
protease,inhibitor,in 1.0 0.000143348623853 0 1 -1
protease,inhibitor,due 1.0 0.000143348623853 0 1 -1
prostin,vr,pediatric 1.0 0.000143348623853 0 1 -1
prostigmin,may,have 1.0 0.000143348623853 0 1 -1
prostatic,hyperplasia,bph 1.0 0.000143348623853 0 1 -1
prostatic,epithelium,proliferates 1.0 0.000143348623853 0 1 -1
prostatectomy,radiation,therapy 1.0 0.000143348623853 0 1 -1
prostate-specific,antigen,psa 1.0 0.000143348623853 0 1 -1
prostate,cancer,diabetes 1.0 0.000143348623853 0 1 -1
prostaglandins,and,increase 1.0 0.000143348623853 0 1 -1
prostaglandin,synthetase,inhibitors 1.0 0.000143348623853 0 1 -1
prostaglandin,synthetase,inhibitor 1.0 0.000143348623853 0 1 -1
prostaglandin,synthesis,interfere 1.0 0.000143348623853 0 1 -1
prostaglandin,synthesis,by 1.0 0.000286697247706 0 2 -2
prostacyclin,which,could 1.0 0.000143348623853 0 1 -1
prospective,study,involving 1.0 0.000143348623853 0 1 -1
prospective,studies,on 1.0 0.000143348623853 0 1 -1
prospective,long-term,studies 1.0 0.000143348623853 0 1 -1
prospective,clinical,trials 1.0 0.000143348623853 0 1 -1
prosom,is,given 1.0 0.000143348623853 0 1 -1
proscar,mg,when 1.0 0.000143348623853 0 1 -1
proquin,xr,was 1.0 0.000143348623853 0 1 -1
proquin,xr,should 1.0 0.000286697247706 0 2 -2
propranolol,in,normal 1.0 0.000143348623853 0 1 -1
propranolol,in,a 1.0 0.000143348623853 0 1 -1
propoxyphene,the,concurrent 1.0 0.000143348623853 0 1 -1
proposed,topical,dose 1.0 0.000143348623853 0 1 -1
proposed,that,the 1.0 0.000286697247706 0 2 -2
proposed,specific,information 1.0 0.000143348623853 0 1 -1
proposed,methodology,for 1.0 0.000143348623853 0 1 -1
proposed,mechanisms,of 1.0 0.000143348623853 0 1 -1
proposed,mechanism,for 1.0 0.000143348623853 0 1 -1
proposed,by,barton 1.0 0.000143348623853 0 1 -1
proposed,as,a 1.0 0.000286697247706 0 2 -2
proportions,in,the 1.0 0.000143348623853 0 1 -1
proportions,as,those 1.0 0.000143348623853 0 1 -1
proportionate,responses,associated 1.0 0.000143348623853 0 1 -1
proportional,over,the 1.0 0.000143348623853 0 1 -1
proportion,to,the 1.0 0.000143348623853 0 1 -1
proportion,of,neurons 1.0 0.00043004587156 0 3 -3
prophylaxis,of,manic-depressive 1.0 0.000143348623853 0 1 -1
prophylaxis,contributed,to 1.0 0.000143348623853 0 1 -1
prophylaxis,after,myocardial 1.0 0.000143348623853 0 1 -1
prophylactic,low,dose 1.0 0.000286697247706 0 2 -2
prophylactic,doses,of 1.0 0.000143348623853 0 1 -1
properties,relative,to 1.0 0.000143348623853 0 1 -1
properties,on,renal 1.0 0.000143348623853 0 1 -1
properties,of,these 1.0 0.000143348623853 0 1 -1
properties,of,rat 1.0 0.000143348623853 0 1 -1
properties,of,nor 1.0 0.000143348623853 0 1 -1
properties,of,non 1.0 0.000143348623853 0 1 -1
properties,of,is 1.0 0.000143348623853 0 1 -1
properties,of,induced 1.0 0.000143348623853 0 1 -1
properties,of,equetrotm 1.0 0.000143348623853 0 1 -1
properties,during,whole-cell 1.0 0.000143348623853 0 1 -1
properties,can,blunt 1.0 0.000143348623853 0 1 -1
properly,and,and 1.0 0.000143348623853 0 1 -1
proper,monitoring,of 1.0 0.000143348623853 0 1 -1
proper,interval,has 1.0 0.000143348623853 0 1 -1
proper,interpretation,of 1.0 0.000143348623853 0 1 -1
propecia,mg,in 1.0 0.000143348623853 0 1 -1
propanolol,the,pharmacokinetics 1.0 0.000143348623853 0 1 -1
propanol,was,investigated 1.0 0.000143348623853 0 1 -1
proof,by,c 1.0 0.000143348623853 0 1 -1
pronounced,than,in 1.0 0.000143348623853 0 1 -1
pronounced,secretory,diarrhea 1.0 0.000143348623853 0 1 -1
pronounced,inhibition,of 1.0 0.000143348623853 0 1 -1
pronounced,in,cecectomized 1.0 0.000143348623853 0 1 -1
promptly,if,such 1.0 0.000143348623853 0 1 -1
promotes,the,translocation 1.0 0.000143348623853 0 1 -1
promoter-vana,antisense,gene 1.0 0.000143348623853 0 1 -1
promoted,the,translocation 1.0 0.000143348623853 0 1 -1
promoted,significant,decrease 1.0 0.000143348623853 0 1 -1
prolongs,and,potentiates 1.0 0.000143348623853 0 1 -1
prolonging,the,qt 1.0 0.000143348623853 0 1 -1
prolonged,use,for 1.0 0.000143348623853 0 1 -1
prolonged,thrombocytopenia,the 1.0 0.000143348623853 0 1 -1
prolonged,therapy,including 1.0 0.000143348623853 0 1 -1
prolonged,survival,in 1.0 0.000143348623853 0 1 -1
prolonged,or,increased 1.0 0.000286697247706 0 2 -2
prolonged,menstrual,cycles 1.0 0.000143348623853 0 1 -1
prolonged,infusion,or 1.0 0.000143348623853 0 1 -1
prolonged,from,to 1.0 0.000143348623853 0 1 -1
prolonged,diarrhea,or 1.0 0.000143348623853 0 1 -1
prolonged,daily,administration 1.0 0.000143348623853 0 1 -1
prolonged,concurrent,use 1.0 0.000143348623853 0 1 -1
prolonged,because,of 1.0 0.000143348623853 0 1 -1
prolonged,administration,twice 1.0 0.000143348623853 0 1 -1
prolonged,administration,of 1.0 0.000143348623853 0 1 -1
prolonged,administration,and 1.0 0.000143348623853 0 1 -1
prolongation,with,or 1.0 0.000143348623853 0 1 -1
prolongation,which,could 1.0 0.000143348623853 0 1 -1
prolongation,has,not 1.0 0.000143348623853 0 1 -1
prolongation,cardiac,arrest 1.0 0.000143348623853 0 1 -1
prolongation,and,torsades 1.0 0.000143348623853 0 1 -1
prolongation,and,increase 1.0 0.000143348623853 0 1 -1
prolongation,and,have 1.0 0.000143348623853 0 1 -1
prolongation,and,an 1.0 0.000143348623853 0 1 -1
prolong,the,one-stage 1.0 0.000143348623853 0 1 -1
prolong,the,biological 1.0 0.000286697247706 0 2 -2
prolong,its,therapeutic 1.0 0.000143348623853 0 1 -1
prolong,ecg,intervals 1.0 0.000143348623853 0 1 -1
prolong,both,therapeutic 1.0 0.000286697247706 0 2 -2
prolong,both,its 1.0 0.000143348623853 0 1 -1
prolong,bleeding,time 1.0 0.000143348623853 0 1 -1
prolong,and,effects 1.0 0.000143348623853 0 1 -1
prolixin,serentil,trilafon 1.0 0.000143348623853 0 1 -1
prolixin,permitil,compazine 1.0 0.000143348623853 0 1 -1
proliferation-dependent,but,caspase-3 1.0 0.000143348623853 0 1 -1
proliferation,in,b-cell 1.0 0.000143348623853 0 1 -1
proliferation,and,b-cell 1.0 0.000143348623853 0 1 -1
proliferating,cell,functions 1.0 0.000143348623853 0 1 -1
proliferates,in,a 1.0 0.000143348623853 0 1 -1
proleukin,treatment,may 1.0 0.000143348623853 0 1 -1
proleukin,may,affect 1.0 0.000143348623853 0 1 -1
proleukin,in,combination 1.0 0.000143348623853 0 1 -1
prolactin,secretion,and 1.0 0.000143348623853 0 1 -1
prohibited,in,the 1.0 0.000143348623853 0 1 -1
prohibited,from,receiving 1.0 0.000143348623853 0 1 -1
progression,in,cell 1.0 0.000143348623853 0 1 -1
progression,as,an 1.0 0.000143348623853 0 1 -1
progress,very,rapidly 1.0 0.000143348623853 0 1 -1
programs,should,be 1.0 0.000143348623853 0 1 -1
program,of,human 1.0 0.000143348623853 0 1 -1
progestin-only,oral,poc 1.0 0.000143348623853 0 1 -1
progestin-only,oral,contraception 1.0 0.000143348623853 0 1 -1
progestational,such,as 1.0 0.000143348623853 0 1 -1
progestational,eg,implants 1.0 0.000143348623853 0 1 -1
profound,effect,on 1.0 0.000143348623853 0 1 -1
profound,collapse,and 1.0 0.000143348623853 0 1 -1
profound,and,long 1.0 0.000143348623853 0 1 -1
profiles,of,and 1.0 0.000143348623853 0 1 -1
profiles,in,young 1.0 0.000143348623853 0 1 -1
profiles,comparable,to 1.0 0.000143348623853 0 1 -1
profiles,clinically,significant 1.0 0.000143348623853 0 1 -1
profiles,and,interactions 1.0 0.000143348623853 0 1 -1
profile,total,cholesterol 1.0 0.000143348623853 0 1 -1
profile,seen,with 1.0 0.000143348623853 0 1 -1
profile,prothrombin,time 1.0 0.000143348623853 0 1 -1
profile,or,renal 1.0 0.000143348623853 0 1 -1
profile,of,mood 1.0 0.000143348623853 0 1 -1
profile,of,mg 1.0 0.000143348623853 0 1 -1
profile,of,in 1.0 0.000143348623853 0 1 -1
profile,of,does 1.0 0.000143348623853 0 1 -1
profile,of,as 1.0 0.000286697247706 0 2 -2
profile,in,subjects 1.0 0.000143348623853 0 1 -1
profile,between,study 1.0 0.000143348623853 0 1 -1
professionals,be,aware 1.0 0.000143348623853 0 1 -1
products,you,may 1.0 0.000143348623853 0 1 -1
products,with,high 1.0 0.000143348623853 0 1 -1
products,that,are 1.0 0.000143348623853 0 1 -1
products,st,john 1.0 0.000286697247706 0 2 -2
products,should,be 1.0 0.000143348623853 0 1 -1
products,oral,nicotinic 1.0 0.000573394495413 0 4 -4
products,or,shampoos 1.0 0.000143348623853 0 1 -1
products,medicated,or 1.0 0.000143348623853 0 1 -1
products,h2-antagonists,and 1.0 0.000143348623853 0 1 -1
products,associated,with 1.0 0.000143348623853 0 1 -1
products,are,needed 1.0 0.000143348623853 0 1 -1
products,are,capable 1.0 0.000143348623853 0 1 -1
products,are,administered 1.0 0.000716743119266 0 5 -5
products,ace,inhibitors 1.0 0.000286697247706 0 2 -2
products,absorption,of 1.0 0.000143348623853 0 1 -1
production,of,tail-flick 1.0 0.000143348623853 0 1 -1
production,of,catecholamines 1.0 0.000143348623853 0 1 -1
production,of,but 1.0 0.000143348623853 0 1 -1
production,including,may 1.0 0.000143348623853 0 1 -1
production,elevation,of 1.0 0.000143348623853 0 1 -1
product,with,in 1.0 0.000143348623853 0 1 -1
product,erythro-fluorocitrate,from 1.0 0.000143348623853 0 1 -1
product,can,affect 1.0 0.000143348623853 0 1 -1
producing,transient,increases 1.0 0.000143348623853 0 1 -1
producing,of,the 1.0 0.000143348623853 0 1 -1
producing,medications,concurrent 1.0 0.000286697247706 0 2 -2
producing,low,uptakes 1.0 0.000143348623853 0 1 -1
produces,whole,body 1.0 0.000143348623853 0 1 -1
produces,psychotomimetic,effects 1.0 0.000143348623853 0 1 -1
produces,cardiopulmonary,stimulation 1.0 0.000143348623853 0 1 -1
produced,transient,increases 1.0 0.000143348623853 0 1 -1
produced,their,effects 1.0 0.000143348623853 0 1 -1
produced,some,attenuation 1.0 0.000143348623853 0 1 -1
produced,reliable,increases 1.0 0.000143348623853 0 1 -1
produced,plasma,drug 1.0 0.000143348623853 0 1 -1
produced,optic,nerve 1.0 0.000143348623853 0 1 -1
produced,no,statistically 1.0 0.000143348623853 0 1 -1
produced,no,pharmacokinetic 1.0 0.000143348623853 0 1 -1
produced,modest,dysphoria 1.0 0.000143348623853 0 1 -1
produced,less,than 1.0 0.000143348623853 0 1 -1
produced,in,utero 1.0 0.000143348623853 0 1 -1
produced,enhanced,learning 1.0 0.000143348623853 0 1 -1
produced,either,a 1.0 0.000143348623853 0 1 -1
produced,distinctive,effects 1.0 0.000143348623853 0 1 -1
produced,by,the 1.0 0.000286697247706 0 2 -2
produced,by,other 1.0 0.000143348623853 0 1 -1
produced,approximately,the 1.0 0.000143348623853 0 1 -1
produced,an,inhibition 1.0 0.000143348623853 0 1 -1
produced,a,similar 1.0 0.000143348623853 0 1 -1
produced,a,marked 1.0 0.000143348623853 0 1 -1
produce,ventricular,arrhythmias 1.0 0.000143348623853 0 1 -1
produce,toxicity,of 1.0 0.000143348623853 0 1 -1
produce,some,inhibiting 1.0 0.000143348623853 0 1 -1
produce,significant,oxidative 1.0 0.000143348623853 0 1 -1
produce,significant,increases 1.0 0.000143348623853 0 1 -1
produce,serious,arrhythmias 1.0 0.000143348623853 0 1 -1
produce,scintigraphic,results 1.0 0.000143348623853 0 1 -1
produce,persistently,elevated 1.0 0.000143348623853 0 1 -1
produce,or,be 1.0 0.000143348623853 0 1 -1
produce,local,irritation 1.0 0.000143348623853 0 1 -1
produce,inhibition,of 1.0 0.000143348623853 0 1 -1
produce,hyperglycemia,and 1.0 0.000573394495413 0 4 -4
produce,false-positive,test 1.0 0.000143348623853 0 1 -1
produce,false,increases 1.0 0.00043004587156 0 3 -3
produce,artifactually,low 1.0 0.000143348623853 0 1 -1
produce,any,interaction 1.0 0.000143348623853 0 1 -1
produce,additive,inotropic 1.0 0.000143348623853 0 1 -1
produce,a,well 1.0 0.000143348623853 0 1 -1
produce,a,watery 1.0 0.000143348623853 0 1 -1
produce,a,satisfactory 1.0 0.000143348623853 0 1 -1
produce,a,modest 1.0 0.000143348623853 0 1 -1
produce,a,false 1.0 0.000143348623853 0 1 -1
prodrug,form,of 1.0 0.000143348623853 0 1 -1
prodrug,are,reported 1.0 0.000143348623853 0 1 -1
procrit,with,other 1.0 0.000143348623853 0 1 -1
processing,functions,i 1.0 0.000143348623853 0 1 -1
processes,automatic,behavior 1.0 0.000143348623853 0 1 -1
procedures,when,anti-globulin 1.0 0.000143348623853 0 1 -1
procedures,were,followed 1.0 0.000143348623853 0 1 -1
procedures,in,animals 1.0 0.000143348623853 0 1 -1
procedures,for,the 1.0 0.000143348623853 0 1 -1
procedure,the,possibility 1.0 0.000143348623853 0 1 -1
procedure,it,was 1.0 0.000143348623853 0 1 -1
procedure,is,recommended 1.0 0.000143348623853 0 1 -1
procedure,in,which 1.0 0.000143348623853 0 1 -1
procedure,for,the 1.0 0.000143348623853 0 1 -1
procedure,even,when 1.0 0.000143348623853 0 1 -1
problems,with,blood 1.0 0.000143348623853 0 1 -1
problems,that,may 1.0 0.000143348623853 0 1 -1
problems,in,the 1.0 0.000143348623853 0 1 -1
problems,encountered,during 1.0 0.000143348623853 0 1 -1
problems,and,if 1.0 0.000143348623853 0 1 -1
problem,not,only 1.0 0.000143348623853 0 1 -1
problem,has,been 1.0 0.000143348623853 0 1 -1
probenecid,slows,the 1.0 0.000143348623853 0 1 -1
probenecid,probenecid,slows 1.0 0.000143348623853 0 1 -1
probenecid,probenecid,a 1.0 0.000143348623853 0 1 -1
probenecid,is,a 1.0 0.000143348623853 0 1 -1
probenecid,a,renal 1.0 0.000143348623853 0 1 -1
probe,study,did 1.0 0.000143348623853 0 1 -1
probe,study,demonstrated 1.0 0.000143348623853 0 1 -1
probably,the,major 1.0 0.000143348623853 0 1 -1
probably,should,apply 1.0 0.000143348623853 0 1 -1
probably,responsible,for 1.0 0.000143348623853 0 1 -1
probably,related,to 1.0 0.000143348623853 0 1 -1
probably,has,an 1.0 0.000143348623853 0 1 -1
probably,for,as 1.0 0.000143348623853 0 1 -1
probably,due,to 1.0 0.000143348623853 0 1 -1
probably,accomplished,through 1.0 0.000143348623853 0 1 -1
probable,that,given 1.0 0.000143348623853 0 1 -1
probability,distribution,have 1.0 0.000143348623853 0 1 -1
prior,to,starting 1.0 0.000143348623853 0 1 -1
prior,to,difluoroacetone 1.0 0.000143348623853 0 1 -1
prior,to,any 1.0 0.000143348623853 0 1 -1
prior,to,and 1.0 0.00043004587156 0 3 -3
prior,to,admission 1.0 0.000143348623853 0 1 -1
prior,to,administration 1.0 0.000286697247706 0 2 -2
prinivil,was,used 1.0 0.000143348623853 0 1 -1
prinivil,has,been 1.0 0.000143348623853 0 1 -1
prinivil,given,concomitantly 1.0 0.000143348623853 0 1 -1
prinivil,alone,were 1.0 0.000143348623853 0 1 -1
principles,of,recovery 1.0 0.000143348623853 0 1 -1
principles,observed,the 1.0 0.000143348623853 0 1 -1
principally,metabolized,by 1.0 0.000143348623853 0 1 -1
principal,given,number 1.0 0.000143348623853 0 1 -1
primidone,no,formal 1.0 0.000143348623853 0 1 -1
primates,and,the 1.0 0.000143348623853 0 1 -1
primate,gammaherpes,virus 1.0 0.000143348623853 0 1 -1
primary,sources,for 1.0 0.000143348623853 0 1 -1
primary,rabbit,kidney 1.0 0.000143348623853 0 1 -1
primary,form,unless 1.0 0.000143348623853 0 1 -1
primary,focus,is 1.0 0.000143348623853 0 1 -1
primary,enzymes,involved 1.0 0.000143348623853 0 1 -1
primary,addiction,after 1.0 0.000143348623853 0 1 -1
primarily,metabolized,to 1.0 0.000143348623853 0 1 -1
primarily,metabolized,and 1.0 0.000143348623853 0 1 -1
primarily,iron-fortified,breakfast 1.0 0.000143348623853 0 1 -1
primarily,h2,blockers 1.0 0.000143348623853 0 1 -1
primarily,eliminated,by 1.0 0.000143348623853 0 1 -1
primarily,degraded,by 1.0 0.000143348623853 0 1 -1
primarily,cyp3a4,cyp2d6 1.0 0.000143348623853 0 1 -1
primarily,by,p450 1.0 0.000143348623853 0 1 -1
primarily,by,cytochrome 1.0 0.000143348623853 0 1 -1
primarily,being,metabolized 1.0 0.000143348623853 0 1 -1
primarily,as,methyltetrahydro-folate 1.0 0.000143348623853 0 1 -1
primarily,a,substrate 1.0 0.000143348623853 0 1 -1
previously,reported,that 1.0 0.000143348623853 0 1 -1
previously,received,pelvic 1.0 0.000143348623853 0 1 -1
previously,been,reported 1.0 0.000143348623853 0 1 -1
previously,administered,agents 1.0 0.000143348623853 0 1 -1
previous,reports,we 1.0 0.000143348623853 0 1 -1
previous,radiation,therapy 1.0 0.000143348623853 0 1 -1
previous,findings,these 1.0 0.000143348623853 0 1 -1
previous,extravasation,following 1.0 0.000143348623853 0 1 -1
previous,experience,as 1.0 0.000143348623853 0 1 -1
prevention,studies,used 1.0 0.000143348623853 0 1 -1
prevention,of,atherosclerotic 1.0 0.000143348623853 0 1 -1
prevention,in,a 1.0 0.000143348623853 0 1 -1
prevention,and,treatment 1.0 0.000143348623853 0 1 -1
preventing,erythro-fluorocitrate,synthesis 1.0 0.000143348623853 0 1 -1
prevent,the,adrenergic 1.0 0.000143348623853 0 1 -1
prevent,stomach,irritation 1.0 0.000143348623853 0 1 -1
prevent,or,delay 1.0 0.000143348623853 0 1 -1
prevent,maltose,interference 1.0 0.000143348623853 0 1 -1
prevent,folic,acid 1.0 0.000143348623853 0 1 -1
prevent,absorption,of 1.0 0.000143348623853 0 1 -1
prevalence,of,reduced 1.0 0.000716743119266 0 5 -5
pretreatment,with,potentiates 1.0 0.000143348623853 0 1 -1
pretreatment,with,likewise 1.0 0.000143348623853 0 1 -1
pretreatment,period,with 1.0 0.000143348623853 0 1 -1
pretreatment,on,the 1.0 0.000143348623853 0 1 -1
pretreatment,did,not 1.0 0.000143348623853 0 1 -1
pretreatment,and,follow-up 1.0 0.00043004587156 0 3 -3
preterm,neonates,is 1.0 0.000143348623853 0 1 -1
presynaptic,defect,in 1.0 0.000143348623853 0 1 -1
presumably,to,a 1.0 0.000143348623853 0 1 -1
presumably,resulting,from 1.0 0.000143348623853 0 1 -1
presumably,a,threshold 1.0 0.000143348623853 0 1 -1
pressure,were,approximately 1.0 0.000143348623853 0 1 -1
pressure,strattera,should 1.0 0.000143348623853 0 1 -1
pressure,should,be 1.0 0.000143348623853 0 1 -1
pressure,response,to 1.0 0.000143348623853 0 1 -1
pressure,or,on 1.0 0.000143348623853 0 1 -1
pressure,or,metabolic 1.0 0.000143348623853 0 1 -1
pressure,medications,motion 1.0 0.000143348623853 0 1 -1
pressure,may,be 1.0 0.000143348623853 0 1 -1
pressure,in,patients 1.0 0.000143348623853 0 1 -1
pressure,has,stabilized 1.0 0.000286697247706 0 2 -2
pressure,has,increased 1.0 0.000143348623853 0 1 -1
pressure,deep,tendon 1.0 0.000143348623853 0 1 -1
pressure,control,in 1.0 0.000143348623853 0 1 -1
pressure,carotid,cannulation 1.0 0.000143348623853 0 1 -1
pressure,beyond,those 1.0 0.000143348623853 0 1 -1
pressure,and,increased 1.0 0.000143348623853 0 1 -1
pressure,and,blood 1.0 0.000143348623853 0 1 -1
pressor,amines,possible 1.0 0.000286697247706 0 2 -2
pressor,amines,but 1.0 0.000286697247706 0 2 -2
pressor,agents,only 1.0 0.000143348623853 0 1 -1
pressor,agents,because 1.0 0.000143348623853 0 1 -1
pressor,agent,for 1.0 0.000286697247706 0 2 -2
pressor,activity,of 1.0 0.000143348623853 0 1 -1
pressor,activity,and 1.0 0.000143348623853 0 1 -1
preservation,of,the 1.0 0.000143348623853 0 1 -1
presents,information,on 1.0 0.000143348623853 0 1 -1
presents,findings,on 1.0 0.000143348623853 0 1 -1
presents,a,diagnostic 1.0 0.000143348623853 0 1 -1
presently,not,known 1.0 0.000143348623853 0 1 -1
presented,with,features 1.0 0.000143348623853 0 1 -1
presented,of,some 1.0 0.000143348623853 0 1 -1
presented,here,demonstrate 1.0 0.000143348623853 0 1 -1
presentation,and,natural 1.0 0.000143348623853 0 1 -1
present,work,involved 1.0 0.000143348623853 0 1 -1
present,whether,the 1.0 0.000143348623853 0 1 -1
present,study,we 1.0 0.000143348623853 0 1 -1
present,study,the 1.0 0.000143348623853 0 1 -1
present,study,it 1.0 0.000143348623853 0 1 -1
present,study,evoked 1.0 0.000143348623853 0 1 -1
present,in,the 1.0 0.000286697247706 0 2 -2
present,in,plasma 1.0 0.000286697247706 0 2 -2
present,in,each 1.0 0.000143348623853 0 1 -1
present,in,both 1.0 0.000143348623853 0 1 -1
present,for,at 1.0 0.000143348623853 0 1 -1
present,clearly,show 1.0 0.000143348623853 0 1 -1
presence,or,the 1.0 0.000143348623853 0 1 -1
presence,or,absence 1.0 0.000143348623853 0 1 -1
presence,of,while 1.0 0.000143348623853 0 1 -1
presence,of,using 1.0 0.000143348623853 0 1 -1
presence,of,therapeutic 1.0 0.000143348623853 0 1 -1
presence,of,the 1.0 0.000143348623853 0 1 -1
presence,of,phenolic 1.0 0.000143348623853 0 1 -1
presence,of,other 1.0 0.000143348623853 0 1 -1
presence,of,more 1.0 0.000143348623853 0 1 -1
presence,of,ml 1.0 0.000143348623853 0 1 -1
presence,of,microg 1.0 0.000143348623853 0 1 -1
presence,of,metabolites 1.0 0.000143348623853 0 1 -1
presence,of,increased 1.0 0.000143348623853 0 1 -1
presence,of,hydrophobic 1.0 0.000143348623853 0 1 -1
presence,of,from 1.0 0.000143348623853 0 1 -1
presence,of,free 1.0 0.000143348623853 0 1 -1
presence,of,food 1.0 0.000143348623853 0 1 -1
presence,of,exogenously 1.0 0.000143348623853 0 1 -1
presence,of,enflurane 1.0 0.000143348623853 0 1 -1
presence,of,decreased 1.0 0.000143348623853 0 1 -1
presence,of,caused 1.0 0.000143348623853 0 1 -1
presence,of,and 1.0 0.000286697247706 0 2 -2
presence,of,an 1.0 0.000143348623853 0 1 -1
presence,of,a 1.0 0.000143348623853 0 1 -1
prescription,or,over-the 1.0 0.000143348623853 0 1 -1
prescription,and,nonprescription 1.0 0.000143348623853 0 1 -1
prescribing,information,for 1.0 0.000286697247706 0 2 -2
prescribing,for,older 1.0 0.000143348623853 0 1 -1
prescribing,concomitantly,with 1.0 0.000143348623853 0 1 -1
prescribing,a,symptomatic 1.0 0.000143348623853 0 1 -1
prescribers,should,also 1.0 0.000143348623853 0 1 -1
prescribers,are,advised 1.0 0.000286697247706 0 2 -2
prescriber,when,the 1.0 0.000143348623853 0 1 -1
prescribed,to,each 1.0 0.000143348623853 0 1 -1
prescribed,foradil,should 1.0 0.000143348623853 0 1 -1
prescribed,for,either 1.0 0.00100344036697 0 7 -7
prescribed,daily,dose 1.0 0.000143348623853 0 1 -1
prescribe,this,agent 1.0 0.000143348623853 0 1 -1
prepared,to,treat 1.0 0.000143348623853 0 1 -1
prepared,in,water 1.0 0.000143348623853 0 1 -1
prepared,by,resecting 1.0 0.000143348623853 0 1 -1
preparations,to,control 1.0 0.000143348623853 0 1 -1
preparations,st,john 1.0 0.000143348623853 0 1 -1
preparations,produced,by 1.0 0.000143348623853 0 1 -1
preparations,or,beta-adrenergic 1.0 0.000143348623853 0 1 -1
preparations,of,is 1.0 0.00043004587156 0 3 -3
preparations,nsaids,antigout 1.0 0.000143348623853 0 1 -1
preparations,novolog,should 1.0 0.000143348623853 0 1 -1
preparations,incubated,at 1.0 0.000143348623853 0 1 -1
preparations,increases,the 1.0 0.000143348623853 0 1 -1
preparations,in,the 1.0 0.000143348623853 0 1 -1
preparations,have,been 1.0 0.000143348623853 0 1 -1
preparations,has,not 1.0 0.000143348623853 0 1 -1
preparations,glyceryl,trinitrate 1.0 0.000143348623853 0 1 -1
preparations,and,the 1.0 0.000143348623853 0 1 -1
preparations,and,isolated 1.0 0.000143348623853 0 1 -1
preparations,and,endocrine 1.0 0.000143348623853 0 1 -1
preparation,was,added 1.0 0.000143348623853 0 1 -1
preparation,before,use 1.0 0.000143348623853 0 1 -1
premedline,and,international 1.0 0.000143348623853 0 1 -1
premedicated,with,such 1.0 0.000143348623853 0 1 -1
premature,ventricular,arrhythmias 1.0 0.000143348623853 0 1 -1
premature,atherosclerotic,cardiovascular 1.0 0.000143348623853 0 1 -1
prelone,pediapred,others 1.0 0.000143348623853 0 1 -1
preliminary,whole-cell,tight 1.0 0.000143348623853 0 1 -1
preliminary,results,from 1.0 0.000286697247706 0 2 -2
preliminary,investigations,indicate 1.0 0.000143348623853 0 1 -1
preliminary,data,suggest 1.0 0.000143348623853 0 1 -1
preliminary,animal,and 1.0 0.000143348623853 0 1 -1
pregnant,rhesus,monkeys 1.0 0.000143348623853 0 1 -1
pregnant,into,the 1.0 0.000143348623853 0 1 -1
pregnant,and,in 1.0 0.000143348623853 0 1 -1
pregnancy,when,dosed 1.0 0.000143348623853 0 1 -1
pregnancy,tests,with 1.0 0.000143348623853 0 1 -1
pregnancy,test,must 1.0 0.000143348623853 0 1 -1
pregnancy,test,female 1.0 0.000143348623853 0 1 -1
pregnancy,test,a 1.0 0.000143348623853 0 1 -1
pregnancy,registry,by 1.0 0.000143348623853 0 1 -1
pregnancy,rates,compliance 1.0 0.000143348623853 0 1 -1
pregnancy,pregnancy,category 1.0 0.000143348623853 0 1 -1
pregnancy,outcomes,in 1.0 0.000143348623853 0 1 -1
pregnancy,only,if 1.0 0.000286697247706 0 2 -2
pregnancy,occurs,while 1.0 0.000143348623853 0 1 -1
pregnancy,occurs,in 1.0 0.000143348623853 0 1 -1
pregnancy,has,been 1.0 0.000143348623853 0 1 -1
pregnancy,from,women 1.0 0.000143348623853 0 1 -1
pregnancy,cromolyn,sodium 1.0 0.000143348623853 0 1 -1
pregnancy,could,not 1.0 0.000143348623853 0 1 -1
pregnancy,category,x 1.0 0.000143348623853 0 1 -1
pregnancy,category,c 1.0 0.000143348623853 0 1 -1
pregnancy,and,fetal 1.0 0.000143348623853 0 1 -1
pregnancy,and,estrogen-containing 1.0 0.000143348623853 0 1 -1
pregnancies,the,outcome 1.0 0.000143348623853 0 1 -1
pregnancies,have,been 1.0 0.000286697247706 0 2 -2
pregnancies,conceived,while 1.0 0.000143348623853 0 1 -1
prefrontal,cortical,tissues 1.0 0.000143348623853 0 1 -1
predominantly,mediated,via 1.0 0.000286697247706 0 2 -2
predominantly,eliminated,in 1.0 0.000143348623853 0 1 -1
predominantly,cyp,a4 1.0 0.000143348623853 0 1 -1
predominantly,by,cytochrome 1.0 0.000143348623853 0 1 -1
predominant,sterol,in 1.0 0.000143348623853 0 1 -1
predominant,plasma,substrate 1.0 0.000143348623853 0 1 -1
prednisone,rofecoxib,did 1.0 0.000143348623853 0 1 -1
prednisolone,sodium,succinate 1.0 0.000143348623853 0 1 -1
predisposition,for,glucose 1.0 0.000143348623853 0 1 -1
predisposing,to,adenylyl 1.0 0.000143348623853 0 1 -1
predisposed,mice,one 1.0 0.000143348623853 0 1 -1
predisposed,mice,c57bl 1.0 0.000143348623853 0 1 -1
predispose,to,premature 1.0 0.000143348623853 0 1 -1
predispose,a,patient 1.0 0.000143348623853 0 1 -1
predictive,of,human 1.0 0.000143348623853 0 1 -1
prediction,of,abnormal 1.0 0.000143348623853 0 1 -1
predicted,interactions,due 1.0 0.000143348623853 0 1 -1
predictable,and,manageable 1.0 0.000143348623853 0 1 -1
predict,the,effects 1.0 0.000286697247706 0 2 -2
predict,the,direction 1.0 0.000143348623853 0 1 -1
precursor,to,this 1.0 0.000143348623853 0 1 -1
preconstricted,with,micromol 1.0 0.000143348623853 0 1 -1
preclude,effectiveness,of 1.0 0.000286697247706 0 2 -2
preclinical,researchers,have 1.0 0.000143348623853 0 1 -1
precise,and,not 1.0 0.000143348623853 0 1 -1
precipitation,procedure,is 1.0 0.000143348623853 0 1 -1
precipitation,of,oxypurines 1.0 0.000143348623853 0 1 -1
precipitation,occurs,when 1.0 0.000143348623853 0 1 -1
precipitation,in,cell 1.0 0.000143348623853 0 1 -1
precipitating,factor,in 1.0 0.000143348623853 0 1 -1
precipitating,coronary,insufficiency 1.0 0.000143348623853 0 1 -1
precipitated,by,the 1.0 0.000143348623853 0 1 -1
precipitated,by,similar 1.0 0.000143348623853 0 1 -1
precipitate,is,formed 1.0 0.000143348623853 0 1 -1
preceding,the,beginning 1.0 0.000143348623853 0 1 -1
preceding,lists,of 1.0 0.000143348623853 0 1 -1
preceding,effect,of 1.0 0.000143348623853 0 1 -1
precedex,for,minutes 1.0 0.000143348623853 0 1 -1
preceded,by,an 1.0 0.000143348623853 0 1 -1
precede,dosing,by 1.0 0.000143348623853 0 1 -1
precautions,probably,should 1.0 0.000143348623853 0 1 -1
precautions,appear,to 1.0 0.000143348623853 0 1 -1
precautions,and,contraindications 1.0 0.000143348623853 0 1 -1
precaution,should,be 1.0 0.00043004587156 0 3 -3
precaution,is,required 1.0 0.000286697247706 0 2 -2
preanesthetic,or,used 1.0 0.000143348623853 0 1 -1
preanesthetic,and,agents 1.0 0.000143348623853 0 1 -1
prealbumin,tbpa,is 1.0 0.000143348623853 0 1 -1
pre-sacral,vertebrae,at 1.0 0.000143348623853 0 1 -1
pre-gentamycin,strength,over 1.0 0.000143348623853 0 1 -1
pre-,and,postsedative 1.0 0.000143348623853 0 1 -1
practitioners,any,new 1.0 0.000143348623853 0 1 -1
practices,for,such 1.0 0.000143348623853 0 1 -1
practice,the,greatest 1.0 0.000143348623853 0 1 -1
practice,resulted,in 1.0 0.000143348623853 0 1 -1
practice,additional,methods 1.0 0.000143348623853 0 1 -1
practically,only,one 1.0 0.000143348623853 0 1 -1
pra,induced,by 1.0 0.000143348623853 0 1 -1
pra,as,well 1.0 0.000143348623853 0 1 -1
pqq-based,methods,should 1.0 0.000143348623853 0 1 -1
pqq,based,methods 1.0 0.000143348623853 0 1 -1
powder,x-ray,diffraction 1.0 0.000143348623853 0 1 -1
potently,enhanced,the 1.0 0.000143348623853 0 1 -1
potentiation,the,physician 1.0 0.000143348623853 0 1 -1
potentiation,resulted,from 1.0 0.000143348623853 0 1 -1
potentiation,of,warfarin-type 1.0 0.000143348623853 0 1 -1
potentiation,of,otthostatic 1.0 0.000143348623853 0 1 -1
potentiation,of,orthostatic 1.0 0.000143348623853 0 1 -1
potentiation,of,coumarin-type 1.0 0.000143348623853 0 1 -1
potentiation,of,camp-mediated 1.0 0.000143348623853 0 1 -1
potentiation,of,bradycardia 1.0 0.000143348623853 0 1 -1
potentiation,occurs,with 1.0 0.000286697247706 0 2 -2
potentiation,effects,have 1.0 0.000143348623853 0 1 -1
potentiating,the,central 1.0 0.000143348623853 0 1 -1
potentiates,increasing,their 1.0 0.000286697247706 0 2 -2
potentiates,a,cetaminophen 1.0 0.000143348623853 0 1 -1
potentiated,when,used 1.0 0.000143348623853 0 1 -1
potentiated,the,apoptosis 1.0 0.000143348623853 0 1 -1
potentiated,by,through 1.0 0.000143348623853 0 1 -1
potentiated,by,co-administration 1.0 0.000143348623853 0 1 -1
potentiated,apparently,by 1.0 0.000143348623853 0 1 -1
potentiate,the,release 1.0 0.000143348623853 0 1 -1
potentiate,the,increase 1.0 0.000143348623853 0 1 -1
potentiate,the,cardiovascular 1.0 0.000143348623853 0 1 -1
potentiate,sulfate,neuromuscular 1.0 0.000143348623853 0 1 -1
potentiate,and,prolong 1.0 0.000286697247706 0 2 -2
potentials,with,either 1.0 0.000143348623853 0 1 -1
potentials,were,recorded 1.0 0.000286697247706 0 2 -2
potentials,in,visual 1.0 0.000143348623853 0 1 -1
potentially,toxic,to 1.0 0.000143348623853 0 1 -1
potentially,toxic,that 1.0 0.000143348623853 0 1 -1
potentially,toxic,medications 1.0 0.000143348623853 0 1 -1
potentially,significant,drug 1.0 0.000143348623853 0 1 -1
potentially,serious,adverse 1.0 0.000143348623853 0 1 -1
potentially,lead,to 1.0 0.000143348623853 0 1 -1
potentially,irritating,topical 1.0 0.000143348623853 0 1 -1
potentially,interfere,with 1.0 0.000143348623853 0 1 -1
potentially,increased,or 1.0 0.000143348623853 0 1 -1
potentially,important,effects 1.0 0.000143348623853 0 1 -1
potentially,favorable,effects 1.0 0.000143348623853 0 1 -1
potentially,fatal,interactions 1.0 0.000143348623853 0 1 -1
potentially,clinically,significant 1.0 0.000143348623853 0 1 -1
potentially,alter,the 1.0 0.000143348623853 0 1 -1
potential,treatment,for 1.0 0.000143348623853 0 1 -1
potential,to,suppress 1.0 0.000143348623853 0 1 -1
potential,to,select 1.0 0.000143348623853 0 1 -1
potential,to,reduce 1.0 0.000143348623853 0 1 -1
potential,to,prolong 1.0 0.000143348623853 0 1 -1
potential,to,produce 1.0 0.000143348623853 0 1 -1
potential,to,interact 1.0 0.000286697247706 0 2 -2
potential,to,cause 1.0 0.000573394495413 0 4 -4
potential,there,has 1.0 0.000143348623853 0 1 -1
potential,that,the 1.0 0.000143348623853 0 1 -1
potential,terfenadine,astemizole 1.0 0.000143348623853 0 1 -1
potential,risk,to 1.0 0.000143348623853 0 1 -1
potential,prolonged,concurrent 1.0 0.000143348623853 0 1 -1
potential,pharmacokinetic,interactions 1.0 0.000286697247706 0 2 -2
potential,only,when 1.0 0.000143348623853 0 1 -1
potential,on,the 1.0 0.000143348623853 0 1 -1
potential,of,to 1.0 0.000143348623853 0 1 -1
potential,of,on 1.0 0.000143348623853 0 1 -1
potential,of,has 1.0 0.000143348623853 0 1 -1
potential,of,enhancing 1.0 0.000143348623853 0 1 -1
potential,nephrotoxicity,and 1.0 0.000143348623853 0 1 -1
potential,must,have 1.0 0.000143348623853 0 1 -1
potential,make,up 1.0 0.000143348623853 0 1 -1
potential,interactions,with 1.0 0.000143348623853 0 1 -1
potential,interactions,may 1.0 0.000143348623853 0 1 -1
potential,interactions,in 1.0 0.000143348623853 0 1 -1
potential,interactions,between 1.0 0.000573394495413 0 4 -4
potential,interactions,are 1.0 0.000143348623853 0 1 -1
potential,input,impedance 1.0 0.000143348623853 0 1 -1
potential,increased,risks 1.0 0.000143348623853 0 1 -1
potential,in,the 1.0 0.000143348623853 0 1 -1
potential,for,to 1.0 0.000286697247706 0 2 -2
potential,for,such 1.0 0.000286697247706 0 2 -2
potential,for,seizures 1.0 0.000286697247706 0 2 -2
potential,for,protein 1.0 0.000143348623853 0 1 -1
potential,for,pharmacokinetic 1.0 0.000143348623853 0 1 -1
potential,for,other 1.0 0.00043004587156 0 3 -3
potential,for,medications 1.0 0.000143348623853 0 1 -1
potential,for,increases 1.0 0.000143348623853 0 1 -1
potential,for,hepatic 1.0 0.000143348623853 0 1 -1
potential,for,duloxetine 1.0 0.000143348623853 0 1 -1
potential,for,drug-induced 1.0 0.000143348623853 0 1 -1
potential,for,drug-drug 1.0 0.000143348623853 0 1 -1
potential,for,drug 1.0 0.000143348623853 0 1 -1
potential,for,clinically 1.0 0.000286697247706 0 2 -2
potential,for,binding 1.0 0.000143348623853 0 1 -1
potential,for,arrhythmias 1.0 0.000143348623853 0 1 -1
potential,for,altering 1.0 0.000143348623853 0 1 -1
potential,for,adverse 1.0 0.000143348623853 0 1 -1
potential,for,abilify 1.0 0.000143348623853 0 1 -1
potential,for,a 1.0 0.000143348623853 0 1 -1
potential,effect,of 1.0 0.000143348623853 0 1 -1
potential,drug,interactions 1.0 0.000286697247706 0 2 -2
potential,differences,in 1.0 0.000143348623853 0 1 -1
potential,components,in 1.0 0.000143348623853 0 1 -1
potential,components,are 1.0 0.000143348623853 0 1 -1
potential,bleeding,international 1.0 0.000143348623853 0 1 -1
potential,benefits,of 1.0 0.000143348623853 0 1 -1
potential,benefit,justifies 1.0 0.000143348623853 0 1 -1
potential,adverse,cardiovascular 1.0 0.000143348623853 0 1 -1
potent,than,that 1.0 0.000143348623853 0 1 -1
potent,than,nanm 1.0 0.000143348623853 0 1 -1
potent,t,cell 1.0 0.000143348623853 0 1 -1
potent,of,glucocorticoid-induced 1.0 0.000143348623853 0 1 -1
potent,non-nucleoside,reverse 1.0 0.000143348623853 0 1 -1
potent,inhibitory,activity 1.0 0.000143348623853 0 1 -1
potent,inhibition,inhibition 1.0 0.000143348623853 0 1 -1
potent,in,lysing 1.0 0.000143348623853 0 1 -1
potent,in,inhibiting 1.0 0.000143348623853 0 1 -1
potent,effect,of 1.0 0.000143348623853 0 1 -1
potent,cyp3a4,enzyme 1.0 0.000143348623853 0 1 -1
potent,against,micrococcus 1.0 0.000143348623853 0 1 -1
potency,of,was 1.0 0.000143348623853 0 1 -1
potassium-sparing,supplements,or 1.0 0.000143348623853 0 1 -1
potassium-sparing,such,as 1.0 0.000143348623853 0 1 -1
potassium-sparing,may,be 1.0 0.000143348623853 0 1 -1
potassium-sparing,each,may 1.0 0.000143348623853 0 1 -1
potassium-sparing,and,others 1.0 0.000286697247706 0 2 -2
potassium-depleting,and,related 1.0 0.000143348623853 0 1 -1
potassium-depleted,solution,the 1.0 0.000143348623853 0 1 -1
potassium,sparing,agents 1.0 0.000286697247706 0 2 -2
potassium,since,decreases 1.0 0.000143348623853 0 1 -1
potassium,levels,should 1.0 0.000143348623853 0 1 -1
potassium,levels,and 1.0 0.000143348623853 0 1 -1
postulated,that,some 1.0 0.000143348623853 0 1 -1
postoperatively,patients,were 1.0 0.000143348623853 0 1 -1
postoperative,respiratory,depression 1.0 0.000143348623853 0 1 -1
postoperative,pain,without 1.0 0.000143348623853 0 1 -1
postnatal,immune,function 1.0 0.000143348623853 0 1 -1
postmarketing,experience,there 1.0 0.000143348623853 0 1 -1
post-transplant,year,pharmacokinetics 1.0 0.000143348623853 0 1 -1
post-myocardial,infarction,in 1.0 0.000143348623853 0 1 -1
post-marketing,reports,of 1.0 0.000143348623853 0 1 -1
post-implantation,loss,were 1.0 0.000143348623853 0 1 -1
post,myocardial,infarction 1.0 0.000143348623853 0 1 -1
post,and,returned 1.0 0.000143348623853 0 1 -1
possibly,nicotinic,receptors 1.0 0.000143348623853 0 1 -1
possibly,have,some 1.0 0.000143348623853 0 1 -1
possible,with,some 1.0 0.000143348623853 0 1 -1
possible,when,administered 1.0 0.000143348623853 0 1 -1
possible,toxicity,from 1.0 0.000143348623853 0 1 -1
possible,to,escalate 1.0 0.000143348623853 0 1 -1
possible,to,avoid 1.0 0.000143348623853 0 1 -1
possible,the,starting 1.0 0.000286697247706 0 2 -2
possible,that,larger 1.0 0.000143348623853 0 1 -1
possible,that,its 1.0 0.000143348623853 0 1 -1
possible,role,in 1.0 0.000143348623853 0 1 -1
possible,resistance,to 1.0 0.00043004587156 0 3 -3
possible,potentiation,of 1.0 0.000143348623853 0 1 -1
possible,or,closely 1.0 0.000143348623853 0 1 -1
possible,lack,of 1.0 0.000143348623853 0 1 -1
possible,interactions,particularly 1.0 0.000143348623853 0 1 -1
possible,interaction,with 1.0 0.000143348623853 0 1 -1
possible,interaction,has 1.0 0.000143348623853 0 1 -1
possible,index,of 1.0 0.000143348623853 0 1 -1
possible,increases,in 1.0 0.000143348623853 0 1 -1
possible,increased,risk 1.0 0.000143348623853 0 1 -1
possible,increased,responsiveness 1.0 0.000286697247706 0 2 -2
possible,extrarenal,mechanisms 1.0 0.000143348623853 0 1 -1
possible,explanation,for 1.0 0.000143348623853 0 1 -1
possible,enhancement,of 1.0 0.000143348623853 0 1 -1
possible,effects,on 1.0 0.000143348623853 0 1 -1
possible,effects,deriving 1.0 0.000143348623853 0 1 -1
possible,dosage,modifications 1.0 0.000143348623853 0 1 -1
possible,diminished,effect 1.0 0.000143348623853 0 1 -1
possible,deleterious,effects 1.0 0.000143348623853 0 1 -1
possible,decreased,response 1.0 0.000286697247706 0 2 -2
possible,combined,actions 1.0 0.000286697247706 0 2 -2
possible,cns,and 1.0 0.000143348623853 0 1 -1
possible,before,being 1.0 0.000143348623853 0 1 -1
possible,adverse,effects 1.0 0.000286697247706 0 2 -2
possible,administration,of 1.0 0.000143348623853 0 1 -1
possible,adjustment,of 1.0 0.000143348623853 0 1 -1
possibility,that,causative 1.0 0.000143348623853 0 1 -1
possibility,should,be 1.0 0.000143348623853 0 1 -1
possibility,of,worsened 1.0 0.000143348623853 0 1 -1
possibility,of,skin 1.0 0.000143348623853 0 1 -1
possibility,of,reduced 1.0 0.000143348623853 0 1 -1
possibility,of,oxidative 1.0 0.000143348623853 0 1 -1
possibility,of,interactions 1.0 0.000143348623853 0 1 -1
possibility,of,increased 1.0 0.000286697247706 0 2 -2
possibility,of,extravasation 1.0 0.000143348623853 0 1 -1
possibility,of,clinical 1.0 0.000143348623853 0 1 -1
possibility,of,arrhythmias 1.0 0.000143348623853 0 1 -1
possibility,of,antagonism 1.0 0.000143348623853 0 1 -1
possibility,of,altered 1.0 0.000143348623853 0 1 -1
possibility,of,adverse 1.0 0.000143348623853 0 1 -1
possibility,and,cautioned 1.0 0.000143348623853 0 1 -1
possessing,properties,can 1.0 0.000143348623853 0 1 -1
positive,urine,test 1.0 0.000143348623853 0 1 -1
positive,tests,were 1.0 0.000143348623853 0 1 -1
positive,test,results 1.0 0.000286697247706 0 2 -2
positive,test,for 1.0 0.000286697247706 0 2 -2
positive,readings,were 1.0 0.000143348623853 0 1 -1
positive,reaction,for 1.0 0.000286697247706 0 2 -2
positive,reaction,at 1.0 0.000143348623853 0 1 -1
positive,for,an 1.0 0.000143348623853 0 1 -1
positive,direct,coombs 1.0 0.000143348623853 0 1 -1
positive,direct,and 1.0 0.000143348623853 0 1 -1
positive,coombs,test 1.0 0.00043004587156 0 3 -3
positive,and,negative 1.0 0.000286697247706 0 2 -2
positive,and,gram 1.0 0.000143348623853 0 1 -1
positive,and,constructive 1.0 0.000143348623853 0 1 -1
positive,and,anxiety 1.0 0.000143348623853 0 1 -1
position,and,if 1.0 0.000143348623853 0 1 -1
posing,a,safety 1.0 0.000143348623853 0 1 -1
posed,by,and 1.0 0.000143348623853 0 1 -1
porter-silber,test,is 1.0 0.000143348623853 0 1 -1
porter-silber,test,do 1.0 0.000143348623853 0 1 -1
porter-silber,reaction,and 1.0 0.000143348623853 0 1 -1
populations,such,as 1.0 0.000143348623853 0 1 -1
populations,prostate,cancer 1.0 0.000143348623853 0 1 -1
populations,are,not 1.0 0.000716743119266 0 5 -5
population,with,hepatic 1.0 0.000143348623853 0 1 -1
population,who,are 1.0 0.000143348623853 0 1 -1
population,plasma,concentrations 1.0 0.000143348623853 0 1 -1
population,pharmacokinetics,analysis 1.0 0.000143348623853 0 1 -1
population,of,the 1.0 0.000143348623853 0 1 -1
population,is,susceptible 1.0 0.000143348623853 0 1 -1
population,is,considered 1.0 0.000143348623853 0 1 -1
population,in,general 1.0 0.000143348623853 0 1 -1
population,has,reduced 1.0 0.000286697247706 0 2 -2
population,chronically,receiving 1.0 0.000143348623853 0 1 -1
population,about,to 1.0 0.000286697247706 0 2 -2
population,about,of 1.0 0.00043004587156 0 3 -3
popular,in,the 1.0 0.000143348623853 0 1 -1
poorly,understood,and 1.0 0.000143348623853 0 1 -1
poor-risk,aids-related,kaposi 1.0 0.000143348623853 0 1 -1
poor,substrate,for 1.0 0.000143348623853 0 1 -1
poor,patient,compliance 1.0 0.000143348623853 0 1 -1
poor,metabolizers,with 1.0 0.000286697247706 0 2 -2
poor,metabolizers,have 1.0 0.000716743119266 0 5 -5
poor,metabolizers,and 1.0 0.000143348623853 0 1 -1
poor,d6,metabolizers 1.0 0.000143348623853 0 1 -1
poor,absorption,excessive 1.0 0.000143348623853 0 1 -1
pooled,human,serum 1.0 0.000143348623853 0 1 -1
ponstel,is,used 1.0 0.000143348623853 0 1 -1
polysaccharides,and,polyfuranoses 1.0 0.000143348623853 0 1 -1
polyphenols,as,potent 1.0 0.000143348623853 0 1 -1
polymorphic,proliferation,and 1.0 0.000143348623853 0 1 -1
polymorphic,p450,d6 1.0 0.000143348623853 0 1 -1
polymer,p,app 1.0 0.000143348623853 0 1 -1
polymer,conjugates,was 1.0 0.000143348623853 0 1 -1
polyfuranoses,with,the 1.0 0.000143348623853 0 1 -1
polyenes,are,determined 1.0 0.000143348623853 0 1 -1
polyene,showed,differential 1.0 0.000143348623853 0 1 -1
polyene,many,like 1.0 0.000143348623853 0 1 -1
polyamines,might,help 1.0 0.000143348623853 0 1 -1
poisonings,of,uncertain 1.0 0.000143348623853 0 1 -1
points,after,the 1.0 0.000143348623853 0 1 -1
pointes-type,ventricular,tachycardia 1.0 0.000143348623853 0 1 -1
pointes,have,occurred 1.0 0.000143348623853 0 1 -1
pointes,and,other 1.0 0.000143348623853 0 1 -1
pointer,dogs,have 1.0 0.000143348623853 0 1 -1
pointe,particularly,and 1.0 0.000143348623853 0 1 -1
point,in,cerebral 1.0 0.000143348623853 0 1 -1
pocs,and,the 1.0 0.000143348623853 0 1 -1
pocs,and,fertility 1.0 0.000143348623853 0 1 -1
poc,in,the 1.0 0.000143348623853 0 1 -1
pneumoniae,streptococcus,pyogenes 1.0 0.000143348623853 0 1 -1
pms,will,not 1.0 0.000143348623853 0 1 -1
plus,vioxx,mg 1.0 0.000143348623853 0 1 -1
plus,to,those 1.0 0.000143348623853 0 1 -1
plus,highly,active 1.0 0.000143348623853 0 1 -1
plus,haart,with 1.0 0.000143348623853 0 1 -1
plus,haart,treatment 1.0 0.000143348623853 0 1 -1
plus,haart,on 1.0 0.000143348623853 0 1 -1
plus,haart,is 1.0 0.000143348623853 0 1 -1
plus,for,days 1.0 0.000143348623853 0 1 -1
plus,avastin,had 1.0 0.000143348623853 0 1 -1
plus,a,catecholamine 1.0 0.000286697247706 0 2 -2
pletal,does,not 1.0 0.000143348623853 0 1 -1
plendil,with,resulted 1.0 0.000143348623853 0 1 -1
plendil,the,pharmacokinetics 1.0 0.000143348623853 0 1 -1
plenaxis,should,be 1.0 0.000143348623853 0 1 -1
plenaxis,is,highly 1.0 0.000143348623853 0 1 -1
plenaxis,and,periodically 1.0 0.000143348623853 0 1 -1
plays,an,important 1.0 0.000143348623853 0 1 -1
play,a,role 1.0 0.000286697247706 0 2 -2
play,a,critical 1.0 0.000143348623853 0 1 -1
platelia,aspergillus,eia 1.0 0.000286697247706 0 2 -2
platelets,recover,to 1.0 0.000143348623853 0 1 -1
platelets,plays,an 1.0 0.000143348623853 0 1 -1
platelets,leukocytes,and 1.0 0.000143348623853 0 1 -1
platelets,in,a 1.0 0.000143348623853 0 1 -1
platelets,and,regulates 1.0 0.000143348623853 0 1 -1
platelet,nucleotide,release 1.0 0.000143348623853 0 1 -1
platelet,inhibitors,including 1.0 0.000143348623853 0 1 -1
platelet,inhibitors,acetylsalicylic 1.0 0.000143348623853 0 1 -1
platelet,function,to 1.0 0.000143348623853 0 1 -1
platelet,function,studies 1.0 0.000143348623853 0 1 -1
platelet,function,or 1.0 0.000143348623853 0 1 -1
platelet,function,may 1.0 0.000143348623853 0 1 -1
platelet,function,and 1.0 0.000573394495413 0 4 -4
platelet,effects,vioxx 1.0 0.000143348623853 0 1 -1
platelet,effects,celebrex 1.0 0.000143348623853 0 1 -1
platelet,count,prothrombin 1.0 0.000143348623853 0 1 -1
platelet,antiaggregant,prostacyclin 1.0 0.000143348623853 0 1 -1
platelet,aggregation,time 1.0 0.000143348623853 0 1 -1
platelet,aggregation,the 1.0 0.000143348623853 0 1 -1
platelet,aggregation,response 1.0 0.000143348623853 0 1 -1
platelet,aggregation,in 1.0 0.000143348623853 0 1 -1
platelet,aggregation,and 1.0 0.000286697247706 0 2 -2
platelet,agents,are 1.0 0.000143348623853 0 1 -1
platelet,activation,in 1.0 0.000143348623853 0 1 -1
platelet,activation,and 1.0 0.000143348623853 0 1 -1
plate,counts,and 1.0 0.000143348623853 0 1 -1
plasticity,ieg,response 1.0 0.000143348623853 0 1 -1
plasmacytic,hyperplasia,polymorphic 1.0 0.000143348623853 0 1 -1
plasma,was,approximately 1.0 0.000143348623853 0 1 -1
plasma,was,analyzed 1.0 0.000143348623853 0 1 -1
plasma,thrombin,clotting 1.0 0.000143348623853 0 1 -1
plasma,substrate,is 1.0 0.000143348623853 0 1 -1
plasma,samples,may 1.0 0.000143348623853 0 1 -1
plasma,samples,does 1.0 0.000143348623853 0 1 -1
plasma,renin,levels 1.0 0.000143348623853 0 1 -1
plasma,renin,activity 1.0 0.000286697247706 0 2 -2
plasma,proteins,other 1.0 0.000286697247706 0 2 -2
plasma,proteins,may 1.0 0.000286697247706 0 2 -2
plasma,proteins,in 1.0 0.000143348623853 0 1 -1
plasma,proteins,at 1.0 0.000143348623853 0 1 -1
plasma,proteins,are 1.0 0.000143348623853 0 1 -1
plasma,proteins,and 1.0 0.000143348623853 0 1 -1
plasma,protein-,bound 1.0 0.000143348623853 0 1 -1
plasma,protein,zaleplon 1.0 0.000143348623853 0 1 -1
plasma,protein,is 1.0 0.000143348623853 0 1 -1
plasma,protein,eszopiclone 1.0 0.000143348623853 0 1 -1
plasma,protein,carbamazepine 1.0 0.000143348623853 0 1 -1
plasma,protein,bound 1.0 0.000143348623853 0 1 -1
plasma,protein,binding 1.0 0.000573394495413 0 4 -4
plasma,protein,and 1.0 0.000143348623853 0 1 -1
plasma,pharmacokinetics,or 1.0 0.000143348623853 0 1 -1
plasma,or,the 1.0 0.000143348623853 0 1 -1
plasma,or,factors 1.0 0.000143348623853 0 1 -1
plasma,of,dogs 1.0 0.000143348623853 0 1 -1
plasma,membrane,and 1.0 0.000143348623853 0 1 -1
plasma,maximum,concentration 1.0 0.000143348623853 0 1 -1
plasma,lipid,profile 1.0 0.000143348623853 0 1 -1
plasma,levels,whenever 1.0 0.000573394495413 0 4 -4
plasma,levels,when 1.0 0.000143348623853 0 1 -1
plasma,levels,should 1.0 0.000860091743119 0 6 -6
plasma,levels,or 1.0 0.000143348623853 0 1 -1
plasma,levels,is 1.0 0.000143348623853 0 1 -1
plasma,levels,have 1.0 0.000143348623853 0 1 -1
plasma,levels,are 1.0 0.000286697247706 0 2 -2
plasma,levels,achieved 1.0 0.000143348623853 0 1 -1
plasma,kinetics,of 1.0 0.000143348623853 0 1 -1
plasma,is,not 1.0 0.000143348623853 0 1 -1
plasma,indicate,that 1.0 0.000143348623853 0 1 -1
plasma,in,vitro 1.0 0.000143348623853 0 1 -1
plasma,hdl,and 1.0 0.000286697247706 0 2 -2
plasma,half-life,of 1.0 0.000143348623853 0 1 -1
plasma,glucose,levels 1.0 0.000286697247706 0 2 -2
plasma,flow,glomerular 1.0 0.000143348623853 0 1 -1
plasma,flow,and 1.0 0.000143348623853 0 1 -1
plasma,exposure,or 1.0 0.000143348623853 0 1 -1
plasma,enzymes,or 1.0 0.000143348623853 0 1 -1
plasma,elimination,half-life 1.0 0.000143348623853 0 1 -1
plasma,drug,levels 1.0 0.000143348623853 0 1 -1
plasma,cortisol,concentration 1.0 0.000143348623853 0 1 -1
plasma,concentrations,substances 1.0 0.000143348623853 0 1 -1
plasma,concentrations,resulted 1.0 0.000143348623853 0 1 -1
plasma,concentrations,recognition 1.0 0.000143348623853 0 1 -1
plasma,concentrations,observed 1.0 0.000143348623853 0 1 -1
plasma,concentrations,mg 1.0 0.000143348623853 0 1 -1
plasma,concentrations,may 1.0 0.000573394495413 0 4 -4
plasma,concentrations,has 1.0 0.000286697247706 0 2 -2
plasma,concentrations,following 1.0 0.000143348623853 0 1 -1
plasma,concentrations,did 1.0 0.000143348623853 0 1 -1
plasma,concentrations,decreased 1.0 0.000143348623853 0 1 -1
plasma,concentrations,cyp3a4 1.0 0.000286697247706 0 2 -2
plasma,concentrations,c 1.0 0.000143348623853 0 1 -1
plasma,concentrations,achieved 1.0 0.000143348623853 0 1 -1
plasma,concentration,was 1.0 0.000286697247706 0 2 -2
plasma,concentration,profile 1.0 0.000143348623853 0 1 -1
plasma,concentration,may 1.0 0.000716743119266 0 5 -5
plasma,concentration,has 1.0 0.000143348623853 0 1 -1
plasma,concentration,for 1.0 0.000143348623853 0 1 -1
plasma,concentration,data 1.0 0.000143348623853 0 1 -1
plasma,clearance,or 1.0 0.000143348623853 0 1 -1
plasma,clearance,and 1.0 0.000143348623853 0 1 -1
plasma,auc,was 1.0 0.000143348623853 0 1 -1
plasma,area-under,the-curve 1.0 0.000143348623853 0 1 -1
plasma,and,urine 1.0 0.00043004587156 0 3 -3
plasma,and,tumour 1.0 0.000143348623853 0 1 -1
plasma,and,kht 1.0 0.000143348623853 0 1 -1
plasma,and,epoxide 1.0 0.000143348623853 0 1 -1
plasma,after,administration 1.0 0.000143348623853 0 1 -1
plans,for,patients 1.0 0.000143348623853 0 1 -1
placental,weight,and 1.0 0.000143348623853 0 1 -1
placental,vessels,was 1.0 0.000143348623853 0 1 -1
placental,margin,after 1.0 0.000143348623853 0 1 -1
placed,on,the 1.0 0.000143348623853 0 1 -1
placed,in,a 1.0 0.000143348623853 0 1 -1
placebo-controlled,study,with 1.0 0.000143348623853 0 1 -1
placebo-controlled,phase,i 1.0 0.000143348623853 0 1 -1
placebo-controlled,osteoporosis,treatment 1.0 0.000143348623853 0 1 -1
placebo-controlled,clinical,studies 1.0 0.000143348623853 0 1 -1
placebo,with,these 1.0 0.000143348623853 0 1 -1
placebo,was,and 1.0 0.000143348623853 0 1 -1
placebo,oral,placebo 1.0 0.000143348623853 0 1 -1
placebo,or,dose 1.0 0.000143348623853 0 1 -1
placebo,n,had 1.0 0.000143348623853 0 1 -1
placebo,for,days 1.0 0.000143348623853 0 1 -1
placebo,day,for 1.0 0.000143348623853 0 1 -1
placebo,controlled,trials 1.0 0.000143348623853 0 1 -1
placebo,coadministered,with 1.0 0.000143348623853 0 1 -1
placebo,as,indicated 1.0 0.000143348623853 0 1 -1
placebo,and,treatments 1.0 0.000143348623853 0 1 -1
placebo,and,intravenous 1.0 0.000286697247706 0 2 -2
place,of,the 1.0 0.000143348623853 0 1 -1
place,at,the 1.0 0.000143348623853 0 1 -1
pk,properties,of 1.0 0.000143348623853 0 1 -1
pk,and,or 1.0 0.000143348623853 0 1 -1
pivoxil,had,no 1.0 0.000143348623853 0 1 -1
pituitary-gonadal,axis,in 1.0 0.000143348623853 0 1 -1
pituitary,secretion,of 1.0 0.000143348623853 0 1 -1
pipracil,may,result 1.0 0.000143348623853 0 1 -1
pipette,yielded,a 1.0 0.000143348623853 0 1 -1
pipette,compared,with 1.0 0.000143348623853 0 1 -1
pill,such,as 1.0 0.000143348623853 0 1 -1
pigeons,nanm,was 1.0 0.000143348623853 0 1 -1
pigeons,did,not 1.0 0.000143348623853 0 1 -1
pigeons,and,squirrel 1.0 0.000143348623853 0 1 -1
pigeons,and,mixed 1.0 0.000143348623853 0 1 -1
pig,small,intestinal 1.0 0.000143348623853 0 1 -1
picr,so,as 1.0 0.000143348623853 0 1 -1
picr,in,the 1.0 0.000143348623853 0 1 -1
picr,detected,in 1.0 0.000143348623853 0 1 -1
picr,could,be 1.0 0.000143348623853 0 1 -1
pi-based,therapy,for 1.0 0.000143348623853 0 1 -1
pi-based,regimens,in 1.0 0.000143348623853 0 1 -1
pi,with,of 1.0 0.000143348623853 0 1 -1
pi,was,related 1.0 0.000143348623853 0 1 -1
pi,related,metabolic 1.0 0.000143348623853 0 1 -1
pi,over,weeks 1.0 0.000143348623853 0 1 -1
pi,classified,using 1.0 0.000143348623853 0 1 -1
pi,affecting,patients 1.0 0.000143348623853 0 1 -1
physostigmine,briefly,reduced 1.0 0.000143348623853 0 1 -1
physiology,the,following 1.0 0.000143348623853 0 1 -1
physiological,tolerance,allowing 1.0 0.000143348623853 0 1 -1
physiological,supplementation,and 1.0 0.000143348623853 0 1 -1
physiological,oral,supplementation 1.0 0.000286697247706 0 2 -2
physiological,oral,load 1.0 0.000143348623853 0 1 -1
physiological,doses,of 1.0 0.000143348623853 0 1 -1
physiological,changes,resulting 1.0 0.000143348623853 0 1 -1
physiological,behavioral,or 1.0 0.000143348623853 0 1 -1
physiologic,effects,blood 1.0 0.000143348623853 0 1 -1
physicians,to,minimize 1.0 0.000143348623853 0 1 -1
physicians,should,refer 1.0 0.000143348623853 0 1 -1
physicians,query,patients 1.0 0.000143348623853 0 1 -1
physicians,needing,to 1.0 0.000143348623853 0 1 -1
physicians,can,take 1.0 0.000143348623853 0 1 -1
physicians,are,overly 1.0 0.000143348623853 0 1 -1
physicians,and,note 1.0 0.000143348623853 0 1 -1
physician,wishing,to 1.0 0.000143348623853 0 1 -1
physician,to,check 1.0 0.000143348623853 0 1 -1
physician,should,provide 1.0 0.000143348623853 0 1 -1
physician,is,advised 1.0 0.000286697247706 0 2 -2
physician,even,if 1.0 0.000143348623853 0 1 -1
physical,dependency,and 1.0 0.000143348623853 0 1 -1
physical,activity,while 1.0 0.000143348623853 0 1 -1
physical,activity,in 1.0 0.000143348623853 0 1 -1
physciains,it,is 1.0 0.000143348623853 0 1 -1
photic,stimulation,study 1.0 0.000143348623853 0 1 -1
photic,evoked,potentials 1.0 0.000143348623853 0 1 -1
photic,evoked,potential 1.0 0.000143348623853 0 1 -1
phosphorylation,status,of 1.0 0.000143348623853 0 1 -1
phosphorylation,of,to 1.0 0.000143348623853 0 1 -1
phosphorylation,of,proteins 1.0 0.000143348623853 0 1 -1
phosphorylation,of,in 1.0 0.000143348623853 0 1 -1
phosphorylation,in,tumor 1.0 0.000143348623853 0 1 -1
phosphorylation,in,response 1.0 0.000143348623853 0 1 -1
phosphorylated,concentration,is 1.0 0.000143348623853 0 1 -1
phospholipids,as,well 1.0 0.000143348623853 0 1 -1
phosphokinase,diffuse,muscle 1.0 0.000143348623853 0 1 -1
phosphohydrolase,from,the 1.0 0.00043004587156 0 3 -3
phosphohydrolase,becomes,metabolically 1.0 0.000143348623853 0 1 -1
phosphatidate,phosphohydrolase,from 1.0 0.000286697247706 0 2 -2
phosphate-binding,agents,since 1.0 0.00043004587156 0 3 -3
phosphate-binding,agents,must 1.0 0.00043004587156 0 3 -3
phosphate,transport,in 1.0 0.00043004587156 0 3 -3
phosphatases,in,the 1.0 0.000143348623853 0 1 -1
phosphatase,and,gamma 1.0 0.000143348623853 0 1 -1
phosphatase,and,elevation 1.0 0.000143348623853 0 1 -1
phosphatase,activity,but 1.0 0.000143348623853 0 1 -1
phlebitis,cellulitis,induration 1.0 0.000143348623853 0 1 -1
pheochromocytoma,and,being 1.0 0.000143348623853 0 1 -1
phenytoin,tiagabine,had 1.0 0.000143348623853 0 1 -1
phenytoin,should,be 1.0 0.000143348623853 0 1 -1
phenytoin,phenobarbitol,rifabutin 1.0 0.000143348623853 0 1 -1
phenytoin,no,significant 1.0 0.000143348623853 0 1 -1
phenytoin,may,decrease 1.0 0.000143348623853 0 1 -1
phenytoin,may,also 1.0 0.000143348623853 0 1 -1
phenytoin,levels,should 1.0 0.000143348623853 0 1 -1
phenytoin,keppra,mg 1.0 0.000143348623853 0 1 -1
phenytoin,is,metabolized 1.0 0.000143348623853 0 1 -1
phenytoin,is,known 1.0 0.000143348623853 0 1 -1
phenytoin,is,extensively 1.0 0.000143348623853 0 1 -1
phenytoin,is,a 1.0 0.000143348623853 0 1 -1
phenytoin,in,a 1.0 0.000143348623853 0 1 -1
phenytoin,etodolac,has 1.0 0.000143348623853 0 1 -1
phenytoin,and,are 1.0 0.000143348623853 0 1 -1
phenytoin,accutane,has 1.0 0.000143348623853 0 1 -1
phenyltheophylline,and,cyclopentyl-1 1.0 0.000143348623853 0 1 -1
phenyl-butazone,sodium,and 1.0 0.000143348623853 0 1 -1
phenotypic,subset,of 1.0 0.000143348623853 0 1 -1
phenotype,were,demonstrated 1.0 0.000143348623853 0 1 -1
phenotype,of,a 1.0 0.000143348623853 0 1 -1
phenotype,and,susceptibility 1.0 0.000143348623853 0 1 -1
phenothiazines,tindal,thorazine 1.0 0.000143348623853 0 1 -1
phenomenon,was,not 1.0 0.000143348623853 0 1 -1
phenomenon,has,not 1.0 0.000143348623853 0 1 -1
phenobarbitol,rifabutin,rifampin 1.0 0.000143348623853 0 1 -1
phenobarbital,or,primidone 1.0 0.000143348623853 0 1 -1
phenobarbital,estimates,of 1.0 0.000143348623853 0 1 -1
phenergan,mellaril,stelazine 1.0 0.000143348623853 0 1 -1
phencyclidine,pcp,produces 1.0 0.000143348623853 0 1 -1
phe-nothiazines,products,oral 1.0 0.000143348623853 0 1 -1
phasic,contraction,of 1.0 0.000143348623853 0 1 -1
phase,was,detected 1.0 0.000143348623853 0 1 -1
phase,study,received 1.0 0.000143348623853 0 1 -1
phase,schizophrenia,and 1.0 0.000143348623853 0 1 -1
phase,of,this 1.0 0.000143348623853 0 1 -1
phase,in,either 1.0 0.000143348623853 0 1 -1
phase,extraction,j 1.0 0.000143348623853 0 1 -1
phase,days,mg 1.0 0.000286697247706 0 2 -2
phase,and,for 1.0 0.000143348623853 0 1 -1
pharmacotherapy,of,cardiovascular 1.0 0.000143348623853 0 1 -1
pharmacology-related,endocrine,feedback 1.0 0.000143348623853 0 1 -1
pharmacology-pharmacokinetics,drug-drug,interactions 1.0 0.000143348623853 0 1 -1
pharmacology,study,or 1.0 0.000143348623853 0 1 -1
pharmacology,studies,in 1.0 0.000286697247706 0 2 -2
pharmacology,studies,at 1.0 0.000143348623853 0 1 -1
pharmacology,pharmacokinetics,pharmacodynamics 1.0 0.000143348623853 0 1 -1
pharmacology,pharmacokinetics,and 1.0 0.000143348623853 0 1 -1
pharmacology,of,all 1.0 0.000143348623853 0 1 -1
pharmacology,and,pharmacotherapy 1.0 0.000143348623853 0 1 -1
pharmacologically,active,monohydroxy 1.0 0.000143348623853 0 1 -1
pharmacological,treatment,produced 1.0 0.000143348623853 0 1 -1
pharmacological,treatment,of 1.0 0.000143348623853 0 1 -1
pharmacological,tool,with 1.0 0.000143348623853 0 1 -1
pharmacological,therapy,which 1.0 0.000143348623853 0 1 -1
pharmacological,therapy,mainly 1.0 0.000143348623853 0 1 -1
pharmacological,properties,of 1.0 0.000143348623853 0 1 -1
pharmacological,interactions,pi 1.0 0.000143348623853 0 1 -1
pharmacological,interactions,of 1.0 0.000143348623853 0 1 -1
pharmacological,interaction,may 1.0 0.000143348623853 0 1 -1
pharmacological,i,without 1.0 0.000143348623853 0 1 -1
pharmacological,doses,of 1.0 0.000143348623853 0 1 -1
pharmacological,analysis,of 1.0 0.000143348623853 0 1 -1
pharmacological,actions,via 1.0 0.000143348623853 0 1 -1
pharmacologic,mechanism,of 1.0 0.000143348623853 0 1 -1
pharmacologic,interactions,in 1.0 0.000143348623853 0 1 -1
pharmacologic,effects,may 1.0 0.000143348623853 0 1 -1
pharmacologic,doses,of 1.0 0.000143348623853 0 1 -1
pharmacologic,activities,similar 1.0 0.000143348623853 0 1 -1
pharmacokinetits,of,sodium 1.0 0.000143348623853 0 1 -1
pharmacokinetics,were,unaltered 1.0 0.000143348623853 0 1 -1
pharmacokinetics,were,observed 1.0 0.000143348623853 0 1 -1
pharmacokinetics,were,not 1.0 0.000143348623853 0 1 -1
pharmacokinetics,were,assessed 1.0 0.000143348623853 0 1 -1
pharmacokinetics,therapeutic,efficacy 1.0 0.000143348623853 0 1 -1
pharmacokinetics,pharmacodynamics,and 1.0 0.000143348623853 0 1 -1
pharmacokinetics,or,renal 1.0 0.000143348623853 0 1 -1
pharmacokinetics,or,pharmacodynamics 1.0 0.000286697247706 0 2 -2
pharmacokinetics,of,when 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,was 1.0 0.00043004587156 0 3 -3
pharmacokinetics,of,sonata 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,see 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,representative 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,r-warfarin 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,r- 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,r 1.0 0.00043004587156 0 3 -3
pharmacokinetics,of,other 1.0 0.000286697247706 0 2 -2
pharmacokinetics,of,oral 1.0 0.000286697247706 0 2 -2
pharmacokinetics,of,or 1.0 0.00043004587156 0 3 -3
pharmacokinetics,of,mg 1.0 0.000716743119266 0 5 -5
pharmacokinetics,of,measured 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,interactions 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,in 1.0 0.000860091743119 0 6 -6
pharmacokinetics,of,higher 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,have 1.0 0.00043004587156 0 3 -3
pharmacokinetics,of,gemzar 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,following 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,fenofibric 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,ethinyl 1.0 0.000286697247706 0 2 -2
pharmacokinetics,of,enbrel 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,either 1.0 0.00043004587156 0 3 -3
pharmacokinetics,of,d 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,cmax 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,clonazepam 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,certain 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,cardiovascular 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,cancidas 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,at 1.0 0.000286697247706 0 2 -2
pharmacokinetics,of,are 1.0 0.000286697247706 0 2 -2
pharmacokinetics,of,and 1.0 0.00114678899083 0 8 -8
pharmacokinetics,of,an 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,amphotericin 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,affected 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,administered 1.0 0.000143348623853 0 1 -1
pharmacokinetics,of,a 1.0 0.00114678899083 0 8 -8
pharmacokinetics,in,subjects 1.0 0.000143348623853 0 1 -1
pharmacokinetics,in,patients 1.0 0.000143348623853 0 1 -1
pharmacokinetics,in,healthy 1.0 0.000143348623853 0 1 -1
pharmacokinetics,if,the 1.0 0.000143348623853 0 1 -1
pharmacokinetics,have,not 1.0 0.000143348623853 0 1 -1
pharmacokinetics,has,not 1.0 0.000143348623853 0 1 -1
pharmacokinetics,exposure-response,relationships 1.0 0.000143348623853 0 1 -1
pharmacokinetics,exposure,or 1.0 0.000143348623853 0 1 -1
pharmacokinetics,effectiveness,against 1.0 0.000143348623853 0 1 -1
pharmacokinetics,during,concurrent 1.0 0.000143348623853 0 1 -1
pharmacokinetics,auc,c 1.0 0.000143348623853 0 1 -1
pharmacokinetics,at,different 1.0 0.000143348623853 0 1 -1
pharmacokinetics,and,qtc 1.0 0.000143348623853 0 1 -1
pharmacokinetics,and,protein 1.0 0.000143348623853 0 1 -1
pharmacokinetics,and,pharmacodynamics 1.0 0.000143348623853 0 1 -1
pharmacokinetics,and,or 1.0 0.000143348623853 0 1 -1
pharmacokinetics,and,gastric 1.0 0.000143348623853 0 1 -1
pharmacokinetics,and,cardiovascular 1.0 0.000143348623853 0 1 -1
pharmacokinetics,analysis,of 1.0 0.000143348623853 0 1 -1
pharmacokinetics,after,days 1.0 0.000143348623853 0 1 -1
pharmacokinetic-related,interactions,clozapine 1.0 0.000143348623853 0 1 -1
pharmacokinetic-pharmacodynamic,relationship,measurement 1.0 0.000143348623853 0 1 -1
pharmacokinetic-based,drug-drug,interaction 1.0 0.000143348623853 0 1 -1
pharmacokinetic,variables,of 1.0 0.000143348623853 0 1 -1
pharmacokinetic,variables,for 1.0 0.000143348623853 0 1 -1
pharmacokinetic,variability,for 1.0 0.000143348623853 0 1 -1
pharmacokinetic,study,of 1.0 0.000143348623853 0 1 -1
pharmacokinetic,study,healthy 1.0 0.000286697247706 0 2 -2
pharmacokinetic,study,did 1.0 0.000143348623853 0 1 -1
pharmacokinetic,studies,with 1.0 0.000143348623853 0 1 -1
pharmacokinetic,studies,were 1.0 0.000143348623853 0 1 -1
pharmacokinetic,studies,oral 1.0 0.000143348623853 0 1 -1
pharmacokinetic,studies,of 1.0 0.000143348623853 0 1 -1
pharmacokinetic,studies,indicate 1.0 0.000143348623853 0 1 -1
pharmacokinetic,studies,including 1.0 0.000143348623853 0 1 -1
pharmacokinetic,studies,document 1.0 0.000143348623853 0 1 -1
pharmacokinetic,screening,in 1.0 0.000143348623853 0 1 -1
pharmacokinetic,profiles,of 1.0 0.000143348623853 0 1 -1
pharmacokinetic,parameters,without 1.0 0.000143348623853 0 1 -1
pharmacokinetic,parameters,is 1.0 0.000143348623853 0 1 -1
pharmacokinetic,parameters,for 1.0 0.000143348623853 0 1 -1
pharmacokinetic,parameters,affected 1.0 0.000143348623853 0 1 -1
pharmacokinetic,parameter,values 1.0 0.000143348623853 0 1 -1
pharmacokinetic,or,pharmacodynamic 1.0 0.000716743119266 0 5 -5
pharmacokinetic,or,other 1.0 0.000143348623853 0 1 -1
pharmacokinetic,interactions,with 1.0 0.00043004587156 0 3 -3
pharmacokinetic,interactions,were 1.0 0.000286697247706 0 2 -2
pharmacokinetic,interactions,occurred 1.0 0.000286697247706 0 2 -2
pharmacokinetic,interactions,mediated 1.0 0.000143348623853 0 1 -1
pharmacokinetic,interactions,listed 1.0 0.000143348623853 0 1 -1
pharmacokinetic,interactions,have 1.0 0.000143348623853 0 1 -1
pharmacokinetic,interaction,when 1.0 0.000573394495413 0 4 -4
pharmacokinetic,interaction,study 1.0 0.000143348623853 0 1 -1
pharmacokinetic,interaction,studies 1.0 0.000286697247706 0 2 -2
pharmacokinetic,interaction,occurred 1.0 0.000143348623853 0 1 -1
pharmacokinetic,evaluation,of 1.0 0.000143348623853 0 1 -1
pharmacokinetic,effects,did 1.0 0.000143348623853 0 1 -1
pharmacokinetic,drug-drug,interactions 1.0 0.00043004587156 0 3 -3
pharmacokinetic,drug-drug,interaction 1.0 0.000143348623853 0 1 -1
pharmacokinetic,dosing,of 1.0 0.000143348623853 0 1 -1
pharmacokinetic,dosing,has 1.0 0.000143348623853 0 1 -1
pharmacokinetic,disposition,of 1.0 0.000143348623853 0 1 -1
pharmacokinetic,changes,that 1.0 0.000143348623853 0 1 -1
pharmacokinetic,changes,are 1.0 0.000143348623853 0 1 -1
pharmacokinetic,captopril-digoxin,interaction 1.0 0.000143348623853 0 1 -1
pharmacokinetic,basis,of 1.0 0.000143348623853 0 1 -1
pharmacokinetic,and,pharmacodynamic 1.0 0.000143348623853 0 1 -1
pharmacokinetic,analyses,were 1.0 0.000143348623853 0 1 -1
pharmacokinetic,analyses,revealed 1.0 0.000143348623853 0 1 -1
pharmacogenetics,pharmacogenetics,deals 1.0 0.000143348623853 0 1 -1
pharmacogenetics,deals,with 1.0 0.000143348623853 0 1 -1
pharmacoeconomic,analyses,indicate 1.0 0.000143348623853 0 1 -1
pharmacodynamics,prothrombin,time 1.0 0.000143348623853 0 1 -1
pharmacodynamics,or,pharmacokinetics 1.0 0.000143348623853 0 1 -1
pharmacodynamics,of,prothrombin 1.0 0.000143348623853 0 1 -1
pharmacodynamics,of,or 1.0 0.000143348623853 0 1 -1
pharmacodynamics,of,glucose 1.0 0.000143348623853 0 1 -1
pharmacodynamics,of,coadministration 1.0 0.000143348623853 0 1 -1
pharmacodynamics,of,and 1.0 0.000143348623853 0 1 -1
pharmacodynamics,of,acetylsalicylic 1.0 0.000143348623853 0 1 -1
pharmacodynamics,ecg,of 1.0 0.000143348623853 0 1 -1
pharmacodynamics,blood,glucose 1.0 0.000143348623853 0 1 -1
pharmacodynamics,and,potency 1.0 0.000143348623853 0 1 -1
pharmacodynamic-related,interactions,the 1.0 0.000143348623853 0 1 -1
pharmacodynamic,with,no 1.0 0.000286697247706 0 2 -2
pharmacodynamic,profile,prothrombin 1.0 0.000143348623853 0 1 -1
pharmacodynamic,profile,of 1.0 0.000143348623853 0 1 -1
pharmacodynamic,interactions,have 1.0 0.000143348623853 0 1 -1
pharmacodynamic,interactions,between 1.0 0.000143348623853 0 1 -1
pharmacodynamic,interaction,with 1.0 0.000143348623853 0 1 -1
pharmacodynamic,interaction,is 1.0 0.000143348623853 0 1 -1
pharmacodynamic,interaction,between 1.0 0.000286697247706 0 2 -2
pharmacodynamic,interaction,as 1.0 0.000143348623853 0 1 -1
pharmacodynamic,effects,of 1.0 0.000286697247706 0 2 -2
pharmacodynamic,effects,can 1.0 0.000143348623853 0 1 -1
pharmacodynamic,effect,reduction 1.0 0.000143348623853 0 1 -1
pharmacodynamic,effect,of 1.0 0.000143348623853 0 1 -1
pharmacodynamic,effect,increased 1.0 0.000286697247706 0 2 -2
pharmacodynamic,drug-drug,interactions 1.0 0.000143348623853 0 1 -1
pharmacodynamic,consequences,of 1.0 0.000143348623853 0 1 -1
pharmaco-dynamic,effects,makes 1.0 0.000143348623853 0 1 -1
pharmacist,of,all 1.0 0.000143348623853 0 1 -1
pharmacist,can,give 1.0 0.000143348623853 0 1 -1
pharmacist,before,taking 1.0 0.000143348623853 0 1 -1
pharmaceutical,treatment,for 1.0 0.000143348623853 0 1 -1
pharmaceutical,abstracts,using 1.0 0.000143348623853 0 1 -1
ph,was,used 1.0 0.000143348623853 0 1 -1
ph,on,the 1.0 0.000143348623853 0 1 -1
ph,may,lead 1.0 0.000143348623853 0 1 -1
ph,may,be 1.0 0.000143348623853 0 1 -1
ph,may,affect 1.0 0.000143348623853 0 1 -1
ph,in,human 1.0 0.000143348623853 0 1 -1
pgp,may,modify 1.0 0.000143348623853 0 1 -1
pgp,increased,concentrations 1.0 0.000286697247706 0 2 -2
pesticides,this,study 1.0 0.000143348623853 0 1 -1
pesticide,the,metabolism 1.0 0.000143348623853 0 1 -1
pesticide,gliftor,difluoro-2 1.0 0.000143348623853 0 1 -1
pertechnetate,tc99m,uptake 1.0 0.000143348623853 0 1 -1
perspiration,weight,gain 1.0 0.000143348623853 0 1 -1
persons,taking,most 1.0 0.000143348623853 0 1 -1
personality,characteristics,in 1.0 0.000143348623853 0 1 -1
person,based,on 1.0 0.000143348623853 0 1 -1
person,and,plasma 1.0 0.000143348623853 0 1 -1
persistently,elevated,plasma 1.0 0.000143348623853 0 1 -1
persistence,of,clinical 1.0 0.000143348623853 0 1 -1
persisted,even,after 1.0 0.000143348623853 0 1 -1
persist,for,a 1.0 0.000143348623853 0 1 -1
peroral,administration,of 1.0 0.000143348623853 0 1 -1
permitil,compazine,phenergan 1.0 0.000143348623853 0 1 -1
permit,reductions,in 1.0 0.000143348623853 0 1 -1
permit,larger,doses 1.0 0.000143348623853 0 1 -1
permeation,studies,were 1.0 0.000143348623853 0 1 -1
permeation,of,the 1.0 0.000143348623853 0 1 -1
permeation,of,sodium 1.0 0.000143348623853 0 1 -1
permeation,however,in 1.0 0.000143348623853 0 1 -1
permeation,enhancing,effect 1.0 0.000143348623853 0 1 -1
permeable,caspase-3,inhibitor 1.0 0.000143348623853 0 1 -1
permeability,of,the 1.0 0.000143348623853 0 1 -1
permeability,and,thus 1.0 0.000143348623853 0 1 -1
permanent,nerve,damage 1.0 0.000143348623853 0 1 -1
perivascular,spaces,have 1.0 0.000143348623853 0 1 -1
perivascular,hemorrhages,edema 1.0 0.000143348623853 0 1 -1
peritoneal,cavity,or 1.0 0.000143348623853 0 1 -1
peripheral,wasting,facial 1.0 0.000143348623853 0 1 -1
peripheral,vasospasm,and 1.0 0.000286697247706 0 2 -2
peripheral,vascular,resistance 1.0 0.000143348623853 0 1 -1
peripheral,neuropathy,the 1.0 0.000143348623853 0 1 -1
peripheral,neuropathy,should 1.0 0.000143348623853 0 1 -1
peripheral,neuropathy,pancreatitis 1.0 0.000143348623853 0 1 -1
peripheral,neuropathy,is 1.0 0.000143348623853 0 1 -1
peripheral,neuropathy,include 1.0 0.000143348623853 0 1 -1
peripheral,mononuclear,cells 1.0 0.000143348623853 0 1 -1
peripheral,edema,nausea 1.0 0.000143348623853 0 1 -1
peripheral,blood,cell 1.0 0.000143348623853 0 1 -1
perioperative,administration,of 1.0 0.000143348623853 0 1 -1
periods,with,alone 1.0 0.000143348623853 0 1 -1
periods,were,separated 1.0 0.000143348623853 0 1 -1
periods,of,up 1.0 0.000143348623853 0 1 -1
periods,of,time 1.0 0.000143348623853 0 1 -1
periods,blood,and 1.0 0.000143348623853 0 1 -1
periodically,in,patients 1.0 0.000143348623853 0 1 -1
periodic,monitoring,of 1.0 0.000143348623853 0 1 -1
periodic,measurement,of 1.0 0.000143348623853 0 1 -1
periodic,liver,function 1.0 0.000143348623853 0 1 -1
period,with,n 1.0 0.000143348623853 0 1 -1
period,was,separated 1.0 0.000143348623853 0 1 -1
period,was,inserted 1.0 0.000143348623853 0 1 -1
period,of,organogenesis 1.0 0.000143348623853 0 1 -1
period,of,observation 1.0 0.000143348623853 0 1 -1
period,of,days 1.0 0.000143348623853 0 1 -1
period,mg,kg 1.0 0.000286697247706 0 2 -2
period,in,healthy 1.0 0.000143348623853 0 1 -1
period,immediately,preceding 1.0 0.000143348623853 0 1 -1
period,following,treatment 1.0 0.000143348623853 0 1 -1
period,followed,by 1.0 0.000143348623853 0 1 -1
period,demonstrated,widespread 1.0 0.000143348623853 0 1 -1
period,before,or 1.0 0.000143348623853 0 1 -1
period,b,the 1.0 0.000143348623853 0 1 -1
period,after,nalidixic 1.0 0.000143348623853 0 1 -1
period,after,dosing 1.0 0.000143348623853 0 1 -1
period,after,discontinuation 1.0 0.000143348623853 0 1 -1
period,a,all 1.0 0.000143348623853 0 1 -1
perhaps,other,medications 1.0 0.000143348623853 0 1 -1
perfusion,in,diabetes 1.0 0.000143348623853 0 1 -1
perfusion,did,not 1.0 0.000143348623853 0 1 -1
perfused,pancreases,of 1.0 0.000143348623853 0 1 -1
perfused,pancreas,of 1.0 0.000143348623853 0 1 -1
performed,within,h 1.0 0.000143348623853 0 1 -1
performed,with,sustiva 1.0 0.000143348623853 0 1 -1
performed,with,fondaparinux 1.0 0.000143348623853 0 1 -1
performed,with,and 1.0 0.000286697247706 0 2 -2
performed,when,therapy 1.0 0.000143348623853 0 1 -1
performed,weekly,or 1.0 0.000143348623853 0 1 -1
performed,to,evaluate 1.0 0.000143348623853 0 1 -1
performed,prior,to 1.0 0.000143348623853 0 1 -1
performed,on,the 1.0 0.000143348623853 0 1 -1
performed,on,guinea 1.0 0.000143348623853 0 1 -1
performed,on,day 1.0 0.000143348623853 0 1 -1
performed,on,all 1.0 0.000143348623853 0 1 -1
performed,in,which 1.0 0.000143348623853 0 1 -1
performed,in,patients 1.0 0.000286697247706 0 2 -2
performed,in,cynomolgus 1.0 0.000143348623853 0 1 -1
performed,in,clinical 1.0 0.000143348623853 0 1 -1
performed,if,the 1.0 0.000143348623853 0 1 -1
performed,examining,the 1.0 0.000143348623853 0 1 -1
performed,doses,of 1.0 0.000143348623853 0 1 -1
performed,both,with 1.0 0.000143348623853 0 1 -1
performed,at,weekly 1.0 0.000286697247706 0 2 -2
performed,at,the 1.0 0.000143348623853 0 1 -1
performed,at,specified 1.0 0.000143348623853 0 1 -1
performed,and,caution 1.0 0.000286697247706 0 2 -2
performed,and,a 1.0 0.000143348623853 0 1 -1
performance,of,gross 1.0 0.000143348623853 0 1 -1
performance,liquid,chromatographic 1.0 0.000143348623853 0 1 -1
perforatum,warning,coadministration 1.0 0.000143348623853 0 1 -1
perforatum,may,decrease 1.0 0.000143348623853 0 1 -1
perchlorate,in,several 1.0 0.000143348623853 0 1 -1
percentage,of,patients 1.0 0.000143348623853 0 1 -1
percentage,of,neurons 1.0 0.000143348623853 0 1 -1
percentage,of,binding 1.0 0.000143348623853 0 1 -1
percent,of,chop-haart 1.0 0.000143348623853 0 1 -1
per,patients,be 1.0 0.000143348623853 0 1 -1
per,day,to 1.0 0.000143348623853 0 1 -1
per,day,or 1.0 0.000286697247706 0 2 -2
per,day,for 1.0 0.000286697247706 0 2 -2
per,day,are 1.0 0.000143348623853 0 1 -1
peptides,in,mice 1.0 0.000143348623853 0 1 -1
peptide,that,is 1.0 0.000143348623853 0 1 -1
peptide,and,in 1.0 0.000143348623853 0 1 -1
peptidase,and,not 1.0 0.000143348623853 0 1 -1
people,use,both 1.0 0.000143348623853 0 1 -1
people,are,becoming 1.0 0.000143348623853 0 1 -1
pentobarbital-induced,sedation,times 1.0 0.000143348623853 0 1 -1
pentamidine,treatment,with 1.0 0.000143348623853 0 1 -1
pentamidine,may,cause 1.0 0.000286697247706 0 2 -2
pentagastrin-,and,histamine-induced 1.0 0.000143348623853 0 1 -1
penetrates,both,the 1.0 0.000143348623853 0 1 -1
pelvic,girdle,and 1.0 0.000143348623853 0 1 -1
pelvic,abdominal,irradiation 1.0 0.000143348623853 0 1 -1
pegasys,treatment,did 1.0 0.000143348623853 0 1 -1
pegasys,should,be 1.0 0.000286697247706 0 2 -2
pegasys,on,male 1.0 0.000143348623853 0 1 -1
pegasys,may,impair 1.0 0.000143348623853 0 1 -1
pegasys,is,to 1.0 0.000143348623853 0 1 -1
pegasys,is,recommended 1.0 0.000143348623853 0 1 -1
pegasys,in,combination 1.0 0.000143348623853 0 1 -1
pegasys,has,not 1.0 0.000286697247706 0 2 -2
pegasys,every,other 1.0 0.000143348623853 0 1 -1
pegasys,equivalent,to 1.0 0.000143348623853 0 1 -1
pegasys,did,not 1.0 0.000143348623853 0 1 -1
pegasys,and,copegus 1.0 0.000143348623853 0 1 -1
pegasys,alone,or 1.0 0.000286697247706 0 2 -2
peganone,used,in 1.0 0.000143348623853 0 1 -1
pediatric,use,the 1.0 0.000286697247706 0 2 -2
pediatric,patients,to 1.0 0.000143348623853 0 1 -1
pediatric,patients,have 1.0 0.000286697247706 0 2 -2
pediatric,and,the 1.0 0.000143348623853 0 1 -1
peak,levels,and 1.0 0.000143348623853 0 1 -1
peak,latency,for 1.0 0.000143348623853 0 1 -1
peak,concentrations,were 1.0 0.000143348623853 0 1 -1
peak,concentrations,of 1.0 0.000143348623853 0 1 -1
peak,concentration,reached 1.0 0.000143348623853 0 1 -1
peak,concentration,of 1.0 0.000143348623853 0 1 -1
peak,b,estradiol 1.0 0.000143348623853 0 1 -1
peak,as,being 1.0 0.000143348623853 0 1 -1
peak,and,the 1.0 0.000143348623853 0 1 -1
pd2,values,for 1.0 0.000143348623853 0 1 -1
pd,studies,investigating 1.0 0.000143348623853 0 1 -1
pcp-induced,behavioral,changes 1.0 0.000143348623853 0 1 -1
pcp,were,observed 1.0 0.000143348623853 0 1 -1
pcp,produces,psychotomimetic 1.0 0.000143348623853 0 1 -1
pcp,produced,transient 1.0 0.000143348623853 0 1 -1
pcp,produced,distinctive 1.0 0.000143348623853 0 1 -1
pcp,induced,locomotion 1.0 0.000143348623853 0 1 -1
pcp,in,two-lever 1.0 0.000143348623853 0 1 -1
pcp,in,either 1.0 0.000143348623853 0 1 -1
pcp,for,days 1.0 0.000143348623853 0 1 -1
pcp,discrimination,and 1.0 0.000143348623853 0 1 -1
pcp,dcg-iv,and 1.0 0.000143348623853 0 1 -1
pcp,combination,procedures 1.0 0.000143348623853 0 1 -1
pbi,t4,levels 1.0 0.000286697247706 0 2 -2
pbi,t4,by 1.0 0.000286697247706 0 2 -2
pbi,levels,may 1.0 0.000143348623853 0 1 -1
paw,at,mg 1.0 0.000143348623853 0 1 -1
patterns,during,the 1.0 0.000143348623853 0 1 -1
pattern,of,use 1.0 0.000143348623853 0 1 -1
pattern,of,efficacy 1.0 0.000143348623853 0 1 -1
pattern,of,deficit 1.0 0.000143348623853 0 1 -1
patients,years,of 1.0 0.000143348623853 0 1 -1
patients,without,significantly 1.0 0.000143348623853 0 1 -1
patients,with,type 1.0 0.00043004587156 0 3 -3
patients,with,symptoms 1.0 0.000143348623853 0 1 -1
patients,with,stable 1.0 0.000286697247706 0 2 -2
patients,with,severely 1.0 0.000143348623853 0 1 -1
patients,with,severe 1.0 0.000286697247706 0 2 -2
patients,with,serum 1.0 0.000286697247706 0 2 -2
patients,with,serious 1.0 0.000143348623853 0 1 -1
patients,with,schizophrenia 1.0 0.00043004587156 0 3 -3
patients,with,rheumatoid 1.0 0.000143348623853 0 1 -1
patients,with,pulmonary 1.0 0.000143348623853 0 1 -1
patients,with,parkinson 1.0 0.000143348623853 0 1 -1
patients,with,organ 1.0 0.000143348623853 0 1 -1
patients,with,maximum 1.0 0.000143348623853 0 1 -1
patients,with,lymphoma 1.0 0.000143348623853 0 1 -1
patients,with,life-threatening 1.0 0.000143348623853 0 1 -1
patients,with,left 1.0 0.000143348623853 0 1 -1
patients,with,hypokalemia 1.0 0.000143348623853 0 1 -1
patients,with,hyperthyroidism 1.0 0.000143348623853 0 1 -1
patients,with,hypercholesterolemia 1.0 0.000143348623853 0 1 -1
patients,with,human 1.0 0.000286697247706 0 2 -2
patients,with,hiv-related 1.0 0.000143348623853 0 1 -1
patients,with,hiv-nhl 1.0 0.000143348623853 0 1 -1
patients,with,high 1.0 0.000286697247706 0 2 -2
patients,with,hepatic 1.0 0.000286697247706 0 2 -2
patients,with,heparin-induced 1.0 0.000143348623853 0 1 -1
patients,with,heart 1.0 0.000573394495413 0 4 -4
patients,with,haca 1.0 0.000143348623853 0 1 -1
patients,with,first-episode 1.0 0.000143348623853 0 1 -1
patients,with,either 1.0 0.000143348623853 0 1 -1
patients,with,early-phase 1.0 0.000143348623853 0 1 -1
patients,with,dose 1.0 0.000143348623853 0 1 -1
patients,with,disease 1.0 0.000143348623853 0 1 -1
patients,with,diabetes 1.0 0.000143348623853 0 1 -1
patients,with,crohn 1.0 0.000143348623853 0 1 -1
patients,with,creatinine 1.0 0.000143348623853 0 1 -1
patients,with,coronary 1.0 0.000860091743119 0 6 -6
patients,with,copd 1.0 0.000143348623853 0 1 -1
patients,with,conditions 1.0 0.000143348623853 0 1 -1
patients,with,concentrations 1.0 0.000143348623853 0 1 -1
patients,with,colorectal 1.0 0.000143348623853 0 1 -1
patients,with,cardiovascular 1.0 0.000286697247706 0 2 -2
patients,with,cardiac 1.0 0.000143348623853 0 1 -1
patients,with,blood 1.0 0.000143348623853 0 1 -1
patients,with,baseline 1.0 0.000143348623853 0 1 -1
patients,with,are 1.0 0.000143348623853 0 1 -1
patients,with,an 1.0 0.000286697247706 0 2 -2
patients,with,amenorrhea 1.0 0.000143348623853 0 1 -1
patients,with,altered 1.0 0.000143348623853 0 1 -1
patients,with,alt 1.0 0.000143348623853 0 1 -1
patients,with,advanced 1.0 0.000143348623853 0 1 -1
patients,whose,pulmonary 1.0 0.000143348623853 0 1 -1
patients,whose,plasma 1.0 0.000143348623853 0 1 -1
patients,who,take 1.0 0.000143348623853 0 1 -1
patients,who,switched 1.0 0.000143348623853 0 1 -1
patients,who,successfully 1.0 0.000143348623853 0 1 -1
patients,who,require 1.0 0.00043004587156 0 3 -3
patients,who,received 1.0 0.00043004587156 0 3 -3
patients,who,must 1.0 0.000143348623853 0 1 -1
patients,who,may 1.0 0.00043004587156 0 3 -3
patients,who,had 1.0 0.00043004587156 0 3 -3
patients,where,or 1.0 0.000143348623853 0 1 -1
patients,were,treated 1.0 0.000143348623853 0 1 -1
patients,were,randomly 1.0 0.000143348623853 0 1 -1
patients,were,on 1.0 0.000143348623853 0 1 -1
patients,were,mainly 1.0 0.000143348623853 0 1 -1
patients,were,intravenously 1.0 0.000143348623853 0 1 -1
patients,were,enrolled 1.0 0.000143348623853 0 1 -1
patients,were,dry 1.0 0.000143348623853 0 1 -1
patients,were,diagnosed 1.0 0.000143348623853 0 1 -1
patients,was,not 1.0 0.000143348623853 0 1 -1
patients,want,to 1.0 0.000143348623853 0 1 -1
patients,vs,respectively 1.0 0.000143348623853 0 1 -1
patients,using,these 1.0 0.000143348623853 0 1 -1
patients,using,cardiovascular 1.0 0.000143348623853 0 1 -1
patients,using,cardiac 1.0 0.000143348623853 0 1 -1
patients,understand,how 1.0 0.000143348623853 0 1 -1
patients,undergoing,vigorous 1.0 0.000143348623853 0 1 -1
patients,undergoing,systemic 1.0 0.000143348623853 0 1 -1
patients,under,years 1.0 0.000143348623853 0 1 -1
patients,under,treatment 1.0 0.000143348623853 0 1 -1
patients,treated,simultaneously 1.0 0.000143348623853 0 1 -1
patients,treated,by 1.0 0.000143348623853 0 1 -1
patients,transient,drowsiness 1.0 0.000143348623853 0 1 -1
patients,to,years 1.0 0.000143348623853 0 1 -1
patients,those,with 1.0 0.000143348623853 0 1 -1
patients,this,may 1.0 0.000143348623853 0 1 -1
patients,the,recommended 1.0 0.000143348623853 0 1 -1
patients,the,mean 1.0 0.000143348623853 0 1 -1
patients,the,incidence 1.0 0.000286697247706 0 2 -2
patients,the,effects 1.0 0.000143348623853 0 1 -1
patients,the,dose 1.0 0.000143348623853 0 1 -1
patients,than,in 1.0 0.000143348623853 0 1 -1
patients,taking,which 1.0 0.000286697247706 0 2 -2
patients,taking,tysabri 1.0 0.000143348623853 0 1 -1
patients,taking,that 1.0 0.000143348623853 0 1 -1
patients,taking,or 1.0 0.000286697247706 0 2 -2
patients,taking,mg 1.0 0.000143348623853 0 1 -1
patients,taking,low-dose 1.0 0.000286697247706 0 2 -2
patients,taking,cyp3a4 1.0 0.000143348623853 0 1 -1
patients,taking,can 1.0 0.000286697247706 0 2 -2
patients,taking,as 1.0 0.000143348623853 0 1 -1
patients,taking,are 1.0 0.000143348623853 0 1 -1
patients,taking,ace 1.0 0.000143348623853 0 1 -1
patients,take,other 1.0 0.000143348623853 0 1 -1
patients,suspected,of 1.0 0.000143348623853 0 1 -1
patients,some,physicians 1.0 0.000143348623853 0 1 -1
patients,should,report 1.0 0.000143348623853 0 1 -1
patients,should,not 1.0 0.000143348623853 0 1 -1
patients,serum,should 1.0 0.000143348623853 0 1 -1
patients,serum,protein-bound 1.0 0.000143348623853 0 1 -1
patients,response,to 1.0 0.000143348623853 0 1 -1
patients,requiring,any 1.0 0.000143348623853 0 1 -1
patients,receiving,without 1.0 0.000143348623853 0 1 -1
patients,receiving,treatment 1.0 0.000143348623853 0 1 -1
patients,receiving,thiazide 1.0 0.000143348623853 0 1 -1
patients,receiving,these 1.0 0.00043004587156 0 3 -3
patients,receiving,taxotere 1.0 0.000143348623853 0 1 -1
patients,receiving,such 1.0 0.000143348623853 0 1 -1
patients,receiving,starlix 1.0 0.000143348623853 0 1 -1
patients,receiving,sprycel 1.0 0.000143348623853 0 1 -1
patients,receiving,single 1.0 0.000143348623853 0 1 -1
patients,receiving,similar 1.0 0.000143348623853 0 1 -1
patients,receiving,preparations 1.0 0.000286697247706 0 2 -2
patients,receiving,narrow 1.0 0.000143348623853 0 1 -1
patients,receiving,mg 1.0 0.000143348623853 0 1 -1
patients,receiving,medications 1.0 0.000143348623853 0 1 -1
patients,receiving,maintenance 1.0 0.000143348623853 0 1 -1
patients,receiving,low 1.0 0.000143348623853 0 1 -1
patients,receiving,inspra 1.0 0.000143348623853 0 1 -1
patients,receiving,injection 1.0 0.000143348623853 0 1 -1
patients,receiving,infusions 1.0 0.000143348623853 0 1 -1
patients,receiving,increased 1.0 0.000143348623853 0 1 -1
patients,receiving,hydrochloride 1.0 0.000143348623853 0 1 -1
patients,receiving,have 1.0 0.000143348623853 0 1 -1
patients,receiving,ganglion 1.0 0.000143348623853 0 1 -1
patients,receiving,foradil 1.0 0.000143348623853 0 1 -1
patients,receiving,for 1.0 0.000143348623853 0 1 -1
patients,receiving,could 1.0 0.000143348623853 0 1 -1
patients,receiving,chronic 1.0 0.000143348623853 0 1 -1
patients,receiving,brovana 1.0 0.000143348623853 0 1 -1
patients,receiving,bolus-ifl 1.0 0.00043004587156 0 3 -3
patients,receiving,blocking 1.0 0.000143348623853 0 1 -1
patients,receiving,azopt 1.0 0.000143348623853 0 1 -1
patients,receiving,alone 1.0 0.000143348623853 0 1 -1
patients,receiving,accutane 1.0 0.000143348623853 0 1 -1
patients,receiving,acarbose 1.0 0.000143348623853 0 1 -1
patients,receiving,a 1.0 0.000143348623853 0 1 -1
patients,received,epirubicin-based 1.0 0.000143348623853 0 1 -1
patients,received,concomitant 1.0 0.000143348623853 0 1 -1
patients,receive,these 1.0 0.000143348623853 0 1 -1
patients,receive,large 1.0 0.000143348623853 0 1 -1
patients,random,sample 1.0 0.000143348623853 0 1 -1
patients,or,their 1.0 0.000143348623853 0 1 -1
patients,or,the 1.0 0.000143348623853 0 1 -1
patients,or,in 1.0 0.000143348623853 0 1 -1
patients,optimal,care 1.0 0.000143348623853 0 1 -1
patients,on,tikosyn 1.0 0.000143348623853 0 1 -1
patients,on,these 1.0 0.000143348623853 0 1 -1
patients,on,stable 1.0 0.000143348623853 0 1 -1
patients,on,replacement 1.0 0.000286697247706 0 2 -2
patients,on,immunosuppression 1.0 0.000143348623853 0 1 -1
patients,on,hormone 1.0 0.000143348623853 0 1 -1
patients,on,glycosides 1.0 0.000143348623853 0 1 -1
patients,of,childbearing 1.0 0.000143348623853 0 1 -1
patients,observed,for 1.0 0.000143348623853 0 1 -1
patients,nor,other 1.0 0.000143348623853 0 1 -1
patients,no,effect 1.0 0.000143348623853 0 1 -1
patients,no,dose 1.0 0.000143348623853 0 1 -1
patients,n,maintained 1.0 0.000143348623853 0 1 -1
patients,must,take 1.0 0.000143348623853 0 1 -1
patients,mixed,agonist 1.0 0.000143348623853 0 1 -1
patients,met,acr 1.0 0.000143348623853 0 1 -1
patients,mean,age 1.0 0.000143348623853 0 1 -1
patients,may,turn 1.0 0.000143348623853 0 1 -1
patients,may,need 1.0 0.000143348623853 0 1 -1
patients,may,be 1.0 0.00129013761468 0 9 -9
patients,is,required 1.0 0.000143348623853 0 1 -1
patients,is,advised 1.0 0.000143348623853 0 1 -1
patients,interaction,study 1.0 0.000143348623853 0 1 -1
patients,including,those 1.0 0.000143348623853 0 1 -1
patients,including,the 1.0 0.000143348623853 0 1 -1
patients,in,whom 1.0 0.00043004587156 0 3 -3
patients,in,three 1.0 0.000143348623853 0 1 -1
patients,in,rheumatoid 1.0 0.000143348623853 0 1 -1
patients,in,ra 1.0 0.000143348623853 0 1 -1
patients,in,parentheses 1.0 0.000143348623853 0 1 -1
patients,in,clinical 1.0 0.00043004587156 0 3 -3
patients,have,received 1.0 0.000143348623853 0 1 -1
patients,have,not 1.0 0.000573394495413 0 4 -4
patients,have,higher 1.0 0.000143348623853 0 1 -1
patients,have,a 1.0 0.000143348623853 0 1 -1
patients,had,liver 1.0 0.000143348623853 0 1 -1
patients,guardians,should 1.0 0.000143348623853 0 1 -1
patients,gland,has 1.0 0.000143348623853 0 1 -1
patients,given,oral 1.0 0.000143348623853 0 1 -1
patients,following,the 1.0 0.000143348623853 0 1 -1
patients,five,lacking 1.0 0.000143348623853 0 1 -1
patients,experiencing,severe 1.0 0.000143348623853 0 1 -1
patients,enrolled,in 1.0 0.000286697247706 0 2 -2
patients,either,on 1.0 0.000143348623853 0 1 -1
patients,does,not 1.0 0.000143348623853 0 1 -1
patients,developed,severe 1.0 0.000143348623853 0 1 -1
patients,demonstrated,no 1.0 0.000143348623853 0 1 -1
patients,currently,taking 1.0 0.000143348623853 0 1 -1
patients,concurrently,taking 1.0 0.000286697247706 0 2 -2
patients,concomitantly,taking 1.0 0.000143348623853 0 1 -1
patients,concomitant,use 1.0 0.000143348623853 0 1 -1
patients,careful,tapering 1.0 0.000143348623853 0 1 -1
patients,by,use 1.0 0.000143348623853 0 1 -1
patients,but,there 1.0 0.000143348623853 0 1 -1
patients,below,the 1.0 0.000143348623853 0 1 -1
patients,before,the 1.0 0.000143348623853 0 1 -1
patients,be,accompanied 1.0 0.000143348623853 0 1 -1
patients,available,uncontrolled 1.0 0.000143348623853 0 1 -1
patients,as,well 1.0 0.000286697247706 0 2 -2
patients,are,not 1.0 0.000143348623853 0 1 -1
patients,are,more 1.0 0.000143348623853 0 1 -1
patients,approximately,half 1.0 0.000143348623853 0 1 -1
patients,and,return 1.0 0.000143348623853 0 1 -1
patients,and,may 1.0 0.000143348623853 0 1 -1
patients,and,increased 1.0 0.000143348623853 0 1 -1
patients,and,in 1.0 0.000143348623853 0 1 -1
patients,and,healthy 1.0 0.000143348623853 0 1 -1
patients,and,greater 1.0 0.000143348623853 0 1 -1
patients,although,combining 1.0 0.000143348623853 0 1 -1
patients,already,on 1.0 0.000143348623853 0 1 -1
patients,along,with 1.0 0.000143348623853 0 1 -1
patients,addition,of 1.0 0.000143348623853 0 1 -1
patients,a,disulfiram-like 1.0 0.000143348623853 0 1 -1
patient,with,such 1.0 0.000143348623853 0 1 -1
patient,with,compromised 1.0 0.000143348623853 0 1 -1
patient,who,was 1.0 0.000143348623853 0 1 -1
patient,was,started 1.0 0.000143348623853 0 1 -1
patient,was,also 1.0 0.000143348623853 0 1 -1
patient,taking,another 1.0 0.00043004587156 0 3 -3
patient,survival,needs 1.0 0.000143348623853 0 1 -1
patient,specific,and 1.0 0.000143348623853 0 1 -1
patient,slow,alterations 1.0 0.000143348623853 0 1 -1
patient,shows,no 1.0 0.000143348623853 0 1 -1
patient,s,serum 1.0 0.000143348623853 0 1 -1
patient,response,multiple 1.0 0.000143348623853 0 1 -1
patient,receiving,micronase 1.0 0.000573394495413 0 4 -4
patient,receiving,diabinese 1.0 0.000573394495413 0 4 -4
patient,receiving,acarbose 1.0 0.000143348623853 0 1 -1
patient,populations,prostate 1.0 0.000143348623853 0 1 -1
patient,population,with 1.0 0.000143348623853 0 1 -1
patient,population,chronically 1.0 0.000143348623853 0 1 -1
patient,population,affected 1.0 0.000143348623853 0 1 -1
patient,or,partner 1.0 0.000143348623853 0 1 -1
patient,or,guardian 1.0 0.000143348623853 0 1 -1
patient,must,have 1.0 0.000143348623853 0 1 -1
patient,is,truly 1.0 0.000143348623853 0 1 -1
patient,is,essential 1.0 0.000143348623853 0 1 -1
patient,interferes,with 1.0 0.000143348623853 0 1 -1
patient,in,whom 1.0 0.000143348623853 0 1 -1
patient,in,on 1.0 0.000143348623853 0 1 -1
patient,in,how 1.0 0.000143348623853 0 1 -1
patient,has,undergone 1.0 0.000143348623853 0 1 -1
patient,had,intoxication 1.0 0.000143348623853 0 1 -1
patient,had,been 1.0 0.000143348623853 0 1 -1
patient,group,is 1.0 0.000143348623853 0 1 -1
patient,for,possible 1.0 0.000143348623853 0 1 -1
patient,for,accutane 1.0 0.000143348623853 0 1 -1
patient,feels,better 1.0 0.000143348623853 0 1 -1
patient,during,treatment 1.0 0.000143348623853 0 1 -1
patient,died,with 1.0 0.000143348623853 0 1 -1
patient,demographics,nhl 1.0 0.000143348623853 0 1 -1
patient,data,from 1.0 0.000143348623853 0 1 -1
patient,continued,to 1.0 0.000143348623853 0 1 -1
patient,compliance,poor 1.0 0.000143348623853 0 1 -1
patient,care,and 1.0 0.000143348623853 0 1 -1
patient,already,stabilized 1.0 0.000143348623853 0 1 -1
patient,already,receiving 1.0 0.000143348623853 0 1 -1
patient,access,distribution 1.0 0.000143348623853 0 1 -1
pathways,which,are 1.0 0.000143348623853 0 1 -1
pathways,on,exposure 1.0 0.000143348623853 0 1 -1
pathways,are,involved 1.0 0.000143348623853 0 1 -1
pathways,and,prescription 1.0 0.000143348623853 0 1 -1
pathway,that,is 1.0 0.000143348623853 0 1 -1
pathway,suggesting,that 1.0 0.000143348623853 0 1 -1
pathway,may,have 1.0 0.000143348623853 0 1 -1
pathway,in,the 1.0 0.000143348623853 0 1 -1
pathway,for,the 1.0 0.000143348623853 0 1 -1
pathophysiologic,consequences,could 1.0 0.000143348623853 0 1 -1
pathophysiologic,abnormality,in 1.0 0.000143348623853 0 1 -1
pathogens,of,addicts 1.0 0.000143348623853 0 1 -1
pathogenic,species,was 1.0 0.000143348623853 0 1 -1
patch-clamp,whole-cell,recording 1.0 0.000143348623853 0 1 -1
patch,pipette,yielded 1.0 0.000143348623853 0 1 -1
passage,and,produced 1.0 0.000143348623853 0 1 -1
pass,secondary,to 1.0 0.000143348623853 0 1 -1
parturition,it,should 1.0 0.000143348623853 0 1 -1
partners,of,women 1.0 0.000143348623853 0 1 -1
partner,of,a 1.0 0.000143348623853 0 1 -1
partner,causes,no 1.0 0.000143348623853 0 1 -1
particularly,when,their 1.0 0.000143348623853 0 1 -1
particularly,when,bactericidal 1.0 0.000143348623853 0 1 -1
particularly,those,patients 1.0 0.000143348623853 0 1 -1
particularly,those,of 1.0 0.000143348623853 0 1 -1
particularly,the,hippocampus 1.0 0.000143348623853 0 1 -1
particularly,susceptible,to 1.0 0.000143348623853 0 1 -1
particularly,serotype,o11 1.0 0.000143348623853 0 1 -1
particularly,in,infants 1.0 0.000143348623853 0 1 -1
particularly,in,hyperuricemic 1.0 0.000143348623853 0 1 -1
particularly,important,that 1.0 0.000143348623853 0 1 -1
particularly,if,renal 1.0 0.000143348623853 0 1 -1
particularly,if,administered 1.0 0.000143348623853 0 1 -1
particularly,for,those 1.0 0.000143348623853 0 1 -1
particularly,for,gout 1.0 0.000143348623853 0 1 -1
particularly,dangerous,because 1.0 0.000143348623853 0 1 -1
particularly,cautious,in 1.0 0.000143348623853 0 1 -1
particularly,carefully,monitored 1.0 0.000143348623853 0 1 -1
particularly,c-17,alkylated 1.0 0.000143348623853 0 1 -1
particular,sulphydryl-containing,amino 1.0 0.000143348623853 0 1 -1
particular,mao,inhibitor 1.0 0.000143348623853 0 1 -1
particular,low,doses 1.0 0.000143348623853 0 1 -1
particular,has,been 1.0 0.00043004587156 0 3 -3
particular,and,dna-damaging 1.0 0.000143348623853 0 1 -1
particular,a2,d6 1.0 0.000143348623853 0 1 -1
particles,of,were 1.0 0.000143348623853 0 1 -1
particles,of,in 1.0 0.000143348623853 0 1 -1
particles,in,saline 1.0 0.000143348623853 0 1 -1
particles,appeared,to 1.0 0.000143348623853 0 1 -1
participated,in,an 1.0 0.000143348623853 0 1 -1
partially,impaired,renal 1.0 0.000143348623853 0 1 -1
partial,thromboplastin,times 1.0 0.000143348623853 0 1 -1
partial,thromboplastin,time 1.0 0.00043004587156 0 3 -3
part,to,their 1.0 0.000143348623853 0 1 -1
part,of,the 1.0 0.00043004587156 0 3 -3
part,from,alterations 1.0 0.000143348623853 0 1 -1
part,a,shift 1.0 0.000143348623853 0 1 -1
parorchis,acanthus,obtained 1.0 0.000143348623853 0 1 -1
parnate,using,these 1.0 0.000143348623853 0 1 -1
parkinsons,disease,patients 1.0 0.000143348623853 0 1 -1
parietal,cells,in 1.0 0.000143348623853 0 1 -1
parietal,cell,from 1.0 0.000143348623853 0 1 -1
parietal,cell,activation 1.0 0.000143348623853 0 1 -1
paresthesia,muscle,pain 1.0 0.000143348623853 0 1 -1
paresthesia,and,laboratory 1.0 0.000143348623853 0 1 -1
parentheses,were,cardiac 1.0 0.000143348623853 0 1 -1
parenterally,special,precaution 1.0 0.000286697247706 0 2 -2
parenteral,route,is 1.0 0.000143348623853 0 1 -1
parenteral,forms,of 1.0 0.000143348623853 0 1 -1
parenteral,except,with 1.0 0.000143348623853 0 1 -1
parenteral,enzyme,supplements 1.0 0.000143348623853 0 1 -1
parental,mcf-7,cells 1.0 0.000143348623853 0 1 -1
parental,and,resistant 1.0 0.000143348623853 0 1 -1
parathyroid-function,tests,are 1.0 0.000143348623853 0 1 -1
parasympathomimetic,effects,administered 1.0 0.000143348623853 0 1 -1
parasite,reduction,at 1.0 0.000143348623853 0 1 -1
parametric,dose-response,models 1.0 0.000143348623853 0 1 -1
parameters,without,and 1.0 0.000143348623853 0 1 -1
parameters,the,degree 1.0 0.000143348623853 0 1 -1
parameters,should,if 1.0 0.000143348623853 0 1 -1
parameters,should,be 1.0 0.000143348623853 0 1 -1
parameters,of,either 1.0 0.000143348623853 0 1 -1
parameters,of,cmax 1.0 0.000143348623853 0 1 -1
parameters,including,the 1.0 0.000143348623853 0 1 -1
parameters,for,or 1.0 0.000143348623853 0 1 -1
parameters,clinical,laboratory 1.0 0.000143348623853 0 1 -1
parameters,and,as 1.0 0.000143348623853 0 1 -1
parameters,affected,by 1.0 0.000143348623853 0 1 -1
parameter,values,were 1.0 0.000143348623853 0 1 -1
paralysis,may,be 1.0 0.000143348623853 0 1 -1
parallel,group,interaction 1.0 0.000143348623853 0 1 -1
parallel,group,clinical 1.0 0.000143348623853 0 1 -1
paraclinical,pattern,of 1.0 0.000143348623853 0 1 -1
paraaminohippurate,method,the 1.0 0.000143348623853 0 1 -1
para-aminobenzoic,acid,metabolite 1.0 0.000143348623853 0 1 -1
papers,published,over 1.0 0.000143348623853 0 1 -1
paperhanging,playing,golf 1.0 0.000143348623853 0 1 -1
paper,we,show 1.0 0.000143348623853 0 1 -1
paper,was,to 1.0 0.000143348623853 0 1 -1
paper,reviews,recent 1.0 0.000143348623853 0 1 -1
paper,lists,of 1.0 0.000143348623853 0 1 -1
paper,is,a 1.0 0.000143348623853 0 1 -1
paper,critically,reviews 1.0 0.000143348623853 0 1 -1
paper,attempts,to 1.0 0.000143348623853 0 1 -1
panretin,gel,on 1.0 0.000143348623853 0 1 -1
panretin,gel,and 1.0 0.000143348623853 0 1 -1
pancreatitis,may,increase 1.0 0.000143348623853 0 1 -1
pancreatitis,in,patients 1.0 0.000143348623853 0 1 -1
pancreatitis,and,symptomatic 1.0 0.000143348623853 0 1 -1
pancreatic,release,and 1.0 0.000143348623853 0 1 -1
pancreatic,effects,of 1.0 0.000143348623853 0 1 -1
pancreatic,content,after 1.0 0.000143348623853 0 1 -1
pancreatic,alpha,cell 1.0 0.000143348623853 0 1 -1
pancreatic,acinar,cells 1.0 0.000143348623853 0 1 -1
pancreases,of,normal 1.0 0.000143348623853 0 1 -1
pancreas,of,the 1.0 0.000143348623853 0 1 -1
palytoxin-induced,contraction,and 1.0 0.000143348623853 0 1 -1
palytoxin,ptx,c129h223n3o54 1.0 0.000143348623853 0 1 -1
palythoa,tuberculosa,caused 1.0 0.000143348623853 0 1 -1
palliates,deficiencies,by 1.0 0.000143348623853 0 1 -1
pains,or,cramps 1.0 0.000143348623853 0 1 -1
pain,without,evidence 1.0 0.000143348623853 0 1 -1
pain,vomiting,diarrhea 1.0 0.000143348623853 0 1 -1
pain,tinnitus,slurred 1.0 0.000143348623853 0 1 -1
pain,or,weakness 1.0 0.000143348623853 0 1 -1
pain,medication,used 1.0 0.000143348623853 0 1 -1
pain,mechanisms,will 1.0 0.000143348623853 0 1 -1
pain,arthralgia,limb 1.0 0.000143348623853 0 1 -1
pain,and,severe 1.0 0.000143348623853 0 1 -1
paid,to,possible 1.0 0.000143348623853 0 1 -1
package,inserts,of 1.0 0.000143348623853 0 1 -1
package,insert,of 1.0 0.000143348623853 0 1 -1
package,insert,labeling 1.0 0.000143348623853 0 1 -1
pacemaker,in,patients 1.0 0.000143348623853 0 1 -1
p53,mouse,carcinogenicity 1.0 0.000143348623853 0 1 -1
p450iid6,may,require 1.0 0.000143348623853 0 1 -1
p450iid6,cyp2d6,many 1.0 0.000143348623853 0 1 -1
p450iid6,a,subset 1.0 0.000143348623853 0 1 -1
p4502d6,in,vitro 1.0 0.000143348623853 0 1 -1
p450-mediated,metabolism,of 1.0 0.000143348623853 0 1 -1
p450-mediated,interactions,that 1.0 0.000143348623853 0 1 -1
p450-based,metabolic,interactions 1.0 0.000143348623853 0 1 -1
p450,with,the 1.0 0.000143348623853 0 1 -1
p450,system,such 1.0 0.000143348623853 0 1 -1
p450,system,specifically 1.0 0.000143348623853 0 1 -1
p450,system,should 1.0 0.000143348623853 0 1 -1
p450,system,may 1.0 0.000143348623853 0 1 -1
p450,system,inhibitors 1.0 0.000143348623853 0 1 -1
p450,system,and 1.0 0.000143348623853 0 1 -1
p450,substrates,has 1.0 0.000143348623853 0 1 -1
p450,pathway,suggesting 1.0 0.000143348623853 0 1 -1
p450,metabolism,would 1.0 0.000143348623853 0 1 -1
p450,isozymes,may 1.0 0.000143348623853 0 1 -1
p450,isozymes,including 1.0 0.000143348623853 0 1 -1
p450,isozymes,a2 1.0 0.000143348623853 0 1 -1
p450,isozymes,a1 1.0 0.000143348623853 0 1 -1
p450,isozyme,cyp2c9 1.0 0.000143348623853 0 1 -1
p450,isoforms,epoxide 1.0 0.000143348623853 0 1 -1
p450,isoforms,cyp3a4 1.0 0.000143348623853 0 1 -1
p450,isoforms,cyp1a2 1.0 0.000143348623853 0 1 -1
p450,isoenzymes,cyp2c9 1.0 0.000143348623853 0 1 -1
p450,isoenzymes,cyp2c8 1.0 0.000143348623853 0 1 -1
p450,isoenzymes,carbamazepine 1.0 0.000143348623853 0 1 -1
p450,isoenzymes,and 1.0 0.000143348623853 0 1 -1
p450,isoenzymes,a4 1.0 0.000143348623853 0 1 -1
p450,isoenzyme,cyp3a4 1.0 0.000143348623853 0 1 -1
p450,isoenzyme,cyp2d6 1.0 0.000143348623853 0 1 -1
p450,isoen-zymes,cyp2c8 1.0 0.000143348623853 0 1 -1
p450,inhibitors,to 1.0 0.000143348623853 0 1 -1
p450,inhibitors,and 1.0 0.000143348623853 0 1 -1
p450,enzymes,responsible 1.0 0.000143348623853 0 1 -1
p450,enzymes,primarily 1.0 0.000143348623853 0 1 -1
p450,enzymes,may 1.0 0.000286697247706 0 2 -2
p450,enzymes,interactions 1.0 0.000143348623853 0 1 -1
p450,enzymes,i 1.0 0.000143348623853 0 1 -1
p450,enzymes,evaluated 1.0 0.000143348623853 0 1 -1
p450,enzymes,cyp1a2 1.0 0.000143348623853 0 1 -1
p450,enzymes,carbamazepine 1.0 0.000143348623853 0 1 -1
p450,enzymes,and 1.0 0.000143348623853 0 1 -1
p450,d6,they 1.0 0.000716743119266 0 5 -5
p450,d6,the 1.0 0.00143348623853 0 10 -10
p450,d6,may 1.0 0.000860091743119 0 6 -6
p450,d6,many 1.0 0.000716743119266 0 5 -5
p450,d6,isozyme 1.0 0.000716743119266 0 5 -5
p450,d6,include 1.0 0.000716743119266 0 5 -5
p450,d6,in 1.0 0.000143348623853 0 1 -1
p450,d6,hydroxylase 1.0 0.000573394495413 0 4 -4
p450,d6,debrisoquin 1.0 0.000143348623853 0 1 -1
p450,d6,cyp2d6 1.0 0.000143348623853 0 1 -1
p450,d6,and 1.0 0.000143348623853 0 1 -1
p450,cyp450,enzyme 1.0 0.000143348623853 0 1 -1
p450,cyp,isoforms 1.0 0.000286697247706 0 2 -2
p450,cyp,drug 1.0 0.000143348623853 0 1 -1
p450,cyp,at 1.0 0.000143348623853 0 1 -1
p450,cyp,a4 1.0 0.000143348623853 0 1 -1
p450,c9,in 1.0 0.000143348623853 0 1 -1
p450,c9,have 1.0 0.000143348623853 0 1 -1
p450,c9,c19 1.0 0.000143348623853 0 1 -1
p450,c9,and 1.0 0.000143348623853 0 1 -1
p450,c,p 1.0 0.000143348623853 0 1 -1
p450,a6,or 1.0 0.000143348623853 0 1 -1
p450,a4,should 1.0 0.000143348623853 0 1 -1
p450,a4,isozyme 1.0 0.000143348623853 0 1 -1
p450,a4,isoenzyme 1.0 0.000143348623853 0 1 -1
p450,a4,inhibitors 1.0 0.000143348623853 0 1 -1
p450,a4,have 1.0 0.000143348623853 0 1 -1
p450,a4,had 1.0 0.000143348623853 0 1 -1
p450,a4,enzymes 1.0 0.000143348623853 0 1 -1
p450,a4,cyp3a4 1.0 0.000143348623853 0 1 -1
p450,a4,c19 1.0 0.000143348623853 0 1 -1
p450,a2,cyp1a2 1.0 0.000143348623853 0 1 -1
p450,a2,c8 1.0 0.000143348623853 0 1 -1
p450,a,the 1.0 0.000143348623853 0 1 -1
p450,a,family 1.0 0.000143348623853 0 1 -1
p450,a,cyp3a 1.0 0.000143348623853 0 1 -1
p2,while,decreasing 1.0 0.000143348623853 0 1 -1
p2,may,result 1.0 0.000143348623853 0 1 -1
p2,however,was 1.0 0.000143348623853 0 1 -1
p1,and,p2 1.0 0.000143348623853 0 1 -1
p-type,in,bovine 1.0 0.000143348623853 0 1 -1
p-type,channel,and 1.0 0.000143348623853 0 1 -1
p-glycoprotein,transporter,as 1.0 0.000143348623853 0 1 -1
p-glycoprotein,mediated,transport 1.0 0.000143348623853 0 1 -1
p-glycoprotein,mediated,clearance 1.0 0.000143348623853 0 1 -1
p-glycoprotein,loop,sparing 1.0 0.000143348623853 0 1 -1
p-glycoprotein,and,is 1.0 0.000143348623853 0 1 -1
p-aminosalicylic,acid,and 1.0 0.000143348623853 0 1 -1
p-450iie1,a,mixed-function 1.0 0.000143348623853 0 1 -1
p-450,linked,drug-metabolizing 1.0 0.000143348623853 0 1 -1
p-450,isoenzymes,and 1.0 0.000143348623853 0 1 -1
p-450,is,not 1.0 0.000143348623853 0 1 -1
p-450,enzymes,and 1.0 0.000143348623853 0 1 -1
p-,by,which 1.0 0.000143348623853 0 1 -1
p,less,than 1.0 0.000143348623853 0 1 -1
p,in,auc 1.0 0.000143348623853 0 1 -1
p,endothelial,dysfunction 1.0 0.000143348623853 0 1 -1
p,dmpge2,mg 1.0 0.000143348623853 0 1 -1
p,app,polymer 1.0 0.000143348623853 0 1 -1
p,app,control 1.0 0.000143348623853 0 1 -1
p,and,vs 1.0 0.000143348623853 0 1 -1
p,although,consistent 1.0 0.000143348623853 0 1 -1
p,a,were 1.0 0.000143348623853 0 1 -1
p,a,substrates 1.0 0.000143348623853 0 1 -1
p,a,metabolism 1.0 0.000143348623853 0 1 -1
oz,has,no 1.0 0.000143348623853 0 1 -1
oxytocic,agents,is 1.0 0.000286697247706 0 2 -2
oxypurines,in,patients 1.0 0.000143348623853 0 1 -1
oxo-desethylzaleplon,glucuronide,account 1.0 0.000143348623853 0 1 -1
oxo-desethylzaleplon,and,oxo-desethylzaleplon 1.0 0.000143348623853 0 1 -1
oxidized,metabolites,with 1.0 0.000143348623853 0 1 -1
oxide,with,a 1.0 0.000143348623853 0 1 -1
oxidative,stress,induction 1.0 0.000143348623853 0 1 -1
oxidative,metabolites,appear 1.0 0.000143348623853 0 1 -1
oxidation,which,is 1.0 0.000143348623853 0 1 -1
oxidation,system,decreased 1.0 0.000143348623853 0 1 -1
oxidation,is,the 1.0 0.000143348623853 0 1 -1
oxidases,and,on 1.0 0.000143348623853 0 1 -1
oxidase,the,aldehyde 1.0 0.000143348623853 0 1 -1
oxidase,reactions,such 1.0 0.000573394495413 0 4 -4
oxidase,or,hexokinase 1.0 0.000286697247706 0 2 -2
oxidase,mao,inhibition 1.0 0.000143348623853 0 1 -1
oxidase,inhibitory,effects 1.0 0.000143348623853 0 1 -1
oxidase,inhibitors,guanethidine 1.0 0.000143348623853 0 1 -1
oxidase,inhibitor,maoi 1.0 0.000143348623853 0 1 -1
oxidase,inhibition,linezolid 1.0 0.000143348623853 0 1 -1
oxidase,in,rat 1.0 0.000143348623853 0 1 -1
oxidase,enzyme,that 1.0 0.000143348623853 0 1 -1
oxidase,enzyme,system 1.0 0.000143348623853 0 1 -1
oxcarbazepine,was,evaluated 1.0 0.000143348623853 0 1 -1
oxcarbazepine,can,inhibit 1.0 0.000143348623853 0 1 -1
oxc,and,mhd 1.0 0.000286697247706 0 2 -2
oxaloacetate,and,mg2 1.0 0.000143348623853 0 1 -1
own,pre-,and 1.0 0.000143348623853 0 1 -1
ovulation,but,one 1.0 0.000143348623853 0 1 -1
overly,cautious,and 1.0 0.000143348623853 0 1 -1
overload,of,ml 1.0 0.000143348623853 0 1 -1
overload,both,in 1.0 0.000143348623853 0 1 -1
overlapping,administration,of 1.0 0.000143348623853 0 1 -1
overlap,to,any 1.0 0.000143348623853 0 1 -1
overdose,recognized,by 1.0 0.000143348623853 0 1 -1
overdose,cholinergic,crisis 1.0 0.000143348623853 0 1 -1
overcoming,tumor,cell 1.0 0.000143348623853 0 1 -1
overallactivity,against,this 1.0 0.000143348623853 0 1 -1
overall,treatment,costs 1.0 0.000143348623853 0 1 -1
overall,response,rates 1.0 0.000143348623853 0 1 -1
overall,improvements,in 1.0 0.000143348623853 0 1 -1
overall,direct,treatment 1.0 0.000143348623853 0 1 -1
overactive,pain,medication 1.0 0.000143348623853 0 1 -1
over-the,counter,medicines 1.0 0.000143348623853 0 1 -1
over-the,counter,cough 1.0 0.000143348623853 0 1 -1
over,weeks,as 1.0 0.000143348623853 0 1 -1
over,to,determine 1.0 0.000143348623853 0 1 -1
over,time,were 1.0 0.000143348623853 0 1 -1
over,time,and 1.0 0.000286697247706 0 2 -2
over,three,hours 1.0 0.000143348623853 0 1 -1
over,the,last 1.0 0.000286697247706 0 2 -2
over,the,full 1.0 0.000143348623853 0 1 -1
over,the,first 1.0 0.000143348623853 0 1 -1
over,the,course 1.0 0.000286697247706 0 2 -2
over,pi-based,therapy 1.0 0.000143348623853 0 1 -1
over,patients,with 1.0 0.000143348623853 0 1 -1
over,patients,enrolled 1.0 0.000286697247706 0 2 -2
over,of,the 1.0 0.000143348623853 0 1 -1
over,minutes,were 1.0 0.000143348623853 0 1 -1
over,indinavir-based,regimens 1.0 0.000143348623853 0 1 -1
over,in,nucleoside-experienced 1.0 0.000143348623853 0 1 -1
over,hours,or 1.0 0.000143348623853 0 1 -1
over,a,period 1.0 0.000143348623853 0 1 -1
over,a,h 1.0 0.000143348623853 0 1 -1
ovariectomy,female,rats 1.0 0.000143348623853 0 1 -1
ovarian,granulosa,cell 1.0 0.000143348623853 0 1 -1
ovarian,cervical,breast 1.0 0.000143348623853 0 1 -1
outward,rectification,were 1.0 0.000143348623853 0 1 -1
outside,the,range 1.0 0.000143348623853 0 1 -1
outset,of,such 1.0 0.000143348623853 0 1 -1
outcomes,in,terms 1.0 0.000143348623853 0 1 -1
outcome,of,pregnancies 1.0 0.000143348623853 0 1 -1
outbreaks,of,arsenical 1.0 0.000143348623853 0 1 -1
out,whether,this 1.0 0.000143348623853 0 1 -1
out,two,different 1.0 0.000143348623853 0 1 -1
out,to,study 1.0 0.000143348623853 0 1 -1
out,to,need 1.0 0.000143348623853 0 1 -1
out,tests,for 1.0 0.000286697247706 0 2 -2
out,studies,in 1.0 0.000143348623853 0 1 -1
out,possible,increases 1.0 0.000143348623853 0 1 -1
out,of,what 1.0 0.000143348623853 0 1 -1
out,of,a 1.0 0.000143348623853 0 1 -1
out,mainly,on 1.0 0.000143348623853 0 1 -1
out,in,the 1.0 0.000143348623853 0 1 -1
out,during,placebo 1.0 0.000143348623853 0 1 -1
out,decreased,renal 1.0 0.000143348623853 0 1 -1
out,as,an 1.0 0.000143348623853 0 1 -1
out,and,was 1.0 0.000143348623853 0 1 -1
out,and,serum 1.0 0.000143348623853 0 1 -1
our,understanding,of 1.0 0.000143348623853 0 1 -1
our,results,indicate 1.0 0.000143348623853 0 1 -1
our,objective,was 1.0 0.000286697247706 0 2 -2
our,laboratory,preliminary 1.0 0.000143348623853 0 1 -1
ototoxicity,were,not 1.0 0.000143348623853 0 1 -1
ototoxicity,and,potentiate 1.0 0.000143348623853 0 1 -1
otherwise,specified,appropriate 1.0 0.000286697247706 0 2 -2
otherwise,healthy,subjects 1.0 0.00043004587156 0 3 -3
otherwise,healthy,adults 1.0 0.000143348623853 0 1 -1
others,with,a 1.0 0.000143348623853 0 1 -1
others,reported,neuropsychiatric 1.0 0.000143348623853 0 1 -1
others,prelone,pediapred 1.0 0.000143348623853 0 1 -1
others,plasma,levels 1.0 0.000143348623853 0 1 -1
others,orudis,orudis 1.0 0.000143348623853 0 1 -1
others,or,supplements 1.0 0.000286697247706 0 2 -2
others,medrol,others 1.0 0.000143348623853 0 1 -1
others,may,inhibit 1.0 0.000286697247706 0 2 -2
other,will,result 1.0 0.000143348623853 0 1 -1
other,which,directly 1.0 0.000143348623853 0 1 -1
other,which,could 1.0 0.000143348623853 0 1 -1
other,which,are 1.0 0.00043004587156 0 3 -3
other,week,until 1.0 0.000143348623853 0 1 -1
other,was,observed 1.0 0.000143348623853 0 1 -1
other,ventricular,arrhythmias 1.0 0.000143348623853 0 1 -1
other,treatment,costs 1.0 0.000143348623853 0 1 -1
other,traditional,agents 1.0 0.000143348623853 0 1 -1
other,topical,medications 1.0 0.000143348623853 0 1 -1
other,topical,has 1.0 0.000143348623853 0 1 -1
other,thyroid,products 1.0 0.000143348623853 0 1 -1
other,through,competition 1.0 0.000286697247706 0 2 -2
other,there,appears 1.0 0.000143348623853 0 1 -1
other,therapy,should 1.0 0.000143348623853 0 1 -1
other,therapy,has 1.0 0.000143348623853 0 1 -1
other,therapies,commonly 1.0 0.000143348623853 0 1 -1
other,the,administration 1.0 0.000143348623853 0 1 -1
other,that,significantly 1.0 0.000143348623853 0 1 -1
other,that,require 1.0 0.000143348623853 0 1 -1
other,that,may 1.0 0.000286697247706 0 2 -2
other,that,interfere 1.0 0.000143348623853 0 1 -1
other,that,inhibit 1.0 0.000286697247706 0 2 -2
other,that,increase 1.0 0.000143348623853 0 1 -1
other,that,could 1.0 0.000143348623853 0 1 -1
other,that,block 1.0 0.000143348623853 0 1 -1
other,than,with 1.0 0.000286697247706 0 2 -2
other,than,thrombin 1.0 0.000143348623853 0 1 -1
other,than,those 1.0 0.000143348623853 0 1 -1
other,than,the 1.0 0.000143348623853 0 1 -1
other,than,myopathy 1.0 0.000143348623853 0 1 -1
other,than,have 1.0 0.000143348623853 0 1 -1
other,than,has 1.0 0.000143348623853 0 1 -1
other,than,atiii 1.0 0.000143348623853 0 1 -1
other,tegretol,tagamet 1.0 0.000143348623853 0 1 -1
other,substances,including 1.0 0.000143348623853 0 1 -1
other,substances,grapefruit 1.0 0.000143348623853 0 1 -1
other,studies,strongly 1.0 0.000143348623853 0 1 -1
other,strong,inhibitors 1.0 0.000286697247706 0 2 -2
other,specific,drug 1.0 0.000143348623853 0 1 -1
other,similarly,metabolized 1.0 0.000143348623853 0 1 -1
other,signs,of 1.0 0.000286697247706 0 2 -2
other,significant,inhibitors 1.0 0.000143348623853 0 1 -1
other,reported,interactions 1.0 0.000143348623853 0 1 -1
other,psychotropic,or 1.0 0.000143348623853 0 1 -1
other,protein-bound,from 1.0 0.000143348623853 0 1 -1
other,progestational,such 1.0 0.000143348623853 0 1 -1
other,progestational,eg 1.0 0.000143348623853 0 1 -1
other,products,oral 1.0 0.000286697247706 0 2 -2
other,products,associated 1.0 0.000143348623853 0 1 -1
other,produce,a 1.0 0.000143348623853 0 1 -1
other,primarily,being 1.0 0.000143348623853 0 1 -1
other,pressor,agents 1.0 0.000143348623853 0 1 -1
other,precautions,may 1.0 0.000143348623853 0 1 -1
other,potentially,significant 1.0 0.000143348623853 0 1 -1
other,potentially,irritating 1.0 0.000143348623853 0 1 -1
other,potentially,clinically 1.0 0.000143348623853 0 1 -1
other,potential,hepatotoxic 1.0 0.000143348623853 0 1 -1
other,possible,interactions 1.0 0.000143348623853 0 1 -1
other,populations,are 1.0 0.000716743119266 0 5 -5
other,plasma,proteins 1.0 0.000286697247706 0 2 -2
other,phe-nothiazines,products 1.0 0.000143348623853 0 1 -1
other,pharmacokinetic,parameters 1.0 0.000143348623853 0 1 -1
other,pathways,on 1.0 0.000143348623853 0 1 -1
other,pathways,have 1.0 0.000143348623853 0 1 -1
other,oxytocic,agents 1.0 0.000286697247706 0 2 -2
other,oral,or 1.0 0.000143348623853 0 1 -1
other,or,maois 1.0 0.000143348623853 0 1 -1
other,or,alternatively 1.0 0.000143348623853 0 1 -1
other,on,sensipar 1.0 0.000143348623853 0 1 -1
other,nsaid,and 1.0 0.000143348623853 0 1 -1
other,nonsteroidal,given 1.0 0.000143348623853 0 1 -1
other,nonsteroidal,anti-inflammatory 1.0 0.000143348623853 0 1 -1
other,no,clinically 1.0 0.000143348623853 0 1 -1
other,niacin,nicotinic 1.0 0.000143348623853 0 1 -1
other,neurotoxic,and 1.0 0.000143348623853 0 1 -1
other,nephrotoxic,medications 1.0 0.000143348623853 0 1 -1
other,neither,sodium 1.0 0.000143348623853 0 1 -1
other,myelosuppressive,agents 1.0 0.000143348623853 0 1 -1
other,muscle,relaxants 1.0 0.000143348623853 0 1 -1
other,monomeric,members 1.0 0.000143348623853 0 1 -1
other,monoamines,from 1.0 0.000286697247706 0 2 -2
other,membrane,properties 1.0 0.000143348623853 0 1 -1
other,medicines,may 1.0 0.000143348623853 0 1 -1
other,medicines,although 1.0 0.000143348623853 0 1 -1
other,medicinal,products 1.0 0.000143348623853 0 1 -1
other,medications,used 1.0 0.000143348623853 0 1 -1
other,medications,to 1.0 0.000143348623853 0 1 -1
other,medications,or 1.0 0.000143348623853 0 1 -1
other,medications,may 1.0 0.000143348623853 0 1 -1
other,medication,should 1.0 0.000143348623853 0 1 -1
other,medical,considerations 1.0 0.000143348623853 0 1 -1
other,may,show 1.0 0.000143348623853 0 1 -1
other,may,be 1.0 0.000143348623853 0 1 -1
other,may,affect 1.0 0.000143348623853 0 1 -1
other,manufacturers,have 1.0 0.000143348623853 0 1 -1
other,macrolide,such 1.0 0.000143348623853 0 1 -1
other,likely,to 1.0 0.000143348623853 0 1 -1
other,lesions,resulting 1.0 0.000143348623853 0 1 -1
other,kits,such 1.0 0.000143348623853 0 1 -1
other,isozymes,evaluated 1.0 0.000143348623853 0 1 -1
other,isoforms,tested 1.0 0.000143348623853 0 1 -1
other,isoforms,cyp2c8 1.0 0.000143348623853 0 1 -1
other,is,withdrawn 1.0 0.000573394495413 0 4 -4
other,is,catalyzed 1.0 0.000143348623853 0 1 -1
other,interactions,vardenafil 1.0 0.000143348623853 0 1 -1
other,interactions,should 1.0 0.000143348623853 0 1 -1
other,interactions,cimetidine 1.0 0.000143348623853 0 1 -1
other,instances,of 1.0 0.000143348623853 0 1 -1
other,inhaled,medications 1.0 0.000143348623853 0 1 -1
other,including,preparations 1.0 0.000143348623853 0 1 -1
other,including,and 1.0 0.000143348623853 0 1 -1
other,in,vivo 1.0 0.000143348623853 0 1 -1
other,in,patients 1.0 0.000143348623853 0 1 -1
other,hormonal,are 1.0 0.000143348623853 0 1 -1
other,hiv,protease 1.0 0.000143348623853 0 1 -1
other,highly,protein-bound 1.0 0.000143348623853 0 1 -1
other,highly,protein 1.0 0.000143348623853 0 1 -1
other,highly,bound 1.0 0.000143348623853 0 1 -1
other,high,concentrations 1.0 0.000143348623853 0 1 -1
other,have,not 1.0 0.00157683486239 0 11 -11
other,hand,the 1.0 0.000286697247706 0 2 -2
other,hand,surprisingly 1.0 0.000143348623853 0 1 -1
other,hand,promoted 1.0 0.000143348623853 0 1 -1
other,hand,had 1.0 0.000143348623853 0 1 -1
other,fruit,juices 1.0 0.000143348623853 0 1 -1
other,formal,interaction 1.0 0.000143348623853 0 1 -1
other,for,which 1.0 0.000143348623853 0 1 -1
other,factors,such 1.0 0.000143348623853 0 1 -1
other,factors,may 1.0 0.000143348623853 0 1 -1
other,factors,like 1.0 0.000143348623853 0 1 -1
other,especially,or 1.0 0.000143348623853 0 1 -1
other,eg,have 1.0 0.000143348623853 0 1 -1
other,drugs,to 1.0 0.000286697247706 0 2 -2
other,drugs,on 1.0 0.000286697247706 0 2 -2
other,drugs,metabolized 1.0 0.000143348623853 0 1 -1
other,drugs,in 1.0 0.000286697247706 0 2 -2
other,drugs,given 1.0 0.000143348623853 0 1 -1
other,drugs,drugs 1.0 0.000286697247706 0 2 -2
other,drugs,clonazepam 1.0 0.000143348623853 0 1 -1
other,drugs,cimetidine 1.0 0.000143348623853 0 1 -1
other,drugs,based 1.0 0.000143348623853 0 1 -1
other,drugs,at 1.0 0.000143348623853 0 1 -1
other,drugs,aripiprazole 1.0 0.000143348623853 0 1 -1
other,drugs,and 1.0 0.000143348623853 0 1 -1
other,drugs,aliskiren 1.0 0.000143348623853 0 1 -1
other,drugs,alcohol 1.0 0.000143348623853 0 1 -1
other,drug,interaction 1.0 0.000143348623853 0 1 -1
other,drug,classes 1.0 0.000143348623853 0 1 -1
other,drug,at 1.0 0.000143348623853 0 1 -1
other,doses,is 1.0 0.000286697247706 0 2 -2
other,dialysis,solutions 1.0 0.000143348623853 0 1 -1
other,diagnostic,or 1.0 0.000143348623853 0 1 -1
other,day,until 1.0 0.000143348623853 0 1 -1
other,day,for 1.0 0.000143348623853 0 1 -1
other,day,dosing 1.0 0.000143348623853 0 1 -1
other,day,and 1.0 0.000143348623853 0 1 -1
other,cytochrome,p450 1.0 0.000143348623853 0 1 -1
other,cyp3a4,inducers 1.0 0.000286697247706 0 2 -2
other,currently,available 1.0 0.000143348623853 0 1 -1
other,creams,lotions 1.0 0.000143348623853 0 1 -1
other,coumarin-derivative,should 1.0 0.000143348623853 0 1 -1
other,concomitant,therapy 1.0 0.00043004587156 0 3 -3
other,concomitant,therapies 1.0 0.000143348623853 0 1 -1
other,concomitant,or 1.0 0.000143348623853 0 1 -1
other,compounds,that 1.0 0.000143348623853 0 1 -1
other,components,of 1.0 0.000143348623853 0 1 -1
other,complications,in 1.0 0.000143348623853 0 1 -1
other,commonly,used 1.0 0.000143348623853 0 1 -1
other,common,adverse 1.0 0.000143348623853 0 1 -1
other,combinations,or 1.0 0.000143348623853 0 1 -1
other,coadministration,of 1.0 0.000143348623853 0 1 -1
other,cns-active,has 1.0 0.000143348623853 0 1 -1
other,clotting,factors 1.0 0.000143348623853 0 1 -1
other,chemotherapy,agents 1.0 0.000143348623853 0 1 -1
other,chelator,therapies 1.0 0.000143348623853 0 1 -1
other,centrally,acting 1.0 0.000143348623853 0 1 -1
other,cases,two 1.0 0.000143348623853 0 1 -1
other,cardiovascular,agents 1.0 0.000143348623853 0 1 -1
other,cardioactive,or 1.0 0.000143348623853 0 1 -1
other,cardioactive,drugs 1.0 0.000143348623853 0 1 -1
other,carbonic,anhydrase 1.0 0.000143348623853 0 1 -1
other,calcium-containing,medicines 1.0 0.000143348623853 0 1 -1
other,by,mouth 1.0 0.000143348623853 0 1 -1
other,by,a 1.0 0.000143348623853 0 1 -1
other,binding,proteins 1.0 0.000286697247706 0 2 -2
other,at,least 1.0 0.000143348623853 0 1 -1
other,asthma,or 1.0 0.000143348623853 0 1 -1
other,are,listed 1.0 0.000143348623853 0 1 -1
other,antiretroviral,medications 1.0 0.000143348623853 0 1 -1
other,antihypertensive,additive 1.0 0.000143348623853 0 1 -1
other,antiepileptic,the 1.0 0.000143348623853 0 1 -1
other,anti-asthma,medications 1.0 0.000143348623853 0 1 -1
other,and,the 1.0 0.000716743119266 0 5 -5
other,and,have 1.0 0.000143348623853 0 1 -1
other,and,for 1.0 0.000143348623853 0 1 -1
other,and,because 1.0 0.000143348623853 0 1 -1
other,and,anti 1.0 0.000143348623853 0 1 -1
other,alternatives,are 1.0 0.000143348623853 0 1 -1
other,agents,which 1.0 0.000143348623853 0 1 -1
other,agents,that 1.0 0.000143348623853 0 1 -1
other,agents,prinivil 1.0 0.000143348623853 0 1 -1
other,agents,or 1.0 0.000143348623853 0 1 -1
other,agents,on 1.0 0.000143348623853 0 1 -1
other,agents,of 1.0 0.000143348623853 0 1 -1
other,agents,known 1.0 0.000143348623853 0 1 -1
other,agents,having 1.0 0.000143348623853 0 1 -1
other,agents,have 1.0 0.000286697247706 0 2 -2
other,agents,given 1.0 0.000143348623853 0 1 -1
other,agents,dynamic 1.0 0.000143348623853 0 1 -1
other,agents,affecting 1.0 0.000143348623853 0 1 -1
other,agent,should 1.0 0.000143348623853 0 1 -1
other,affected,by 1.0 0.000143348623853 0 1 -1
other,aeds,were 1.0 0.000143348623853 0 1 -1
other,aeds,and 1.0 0.000286697247706 0 2 -2
other,administered,concurrently 1.0 0.000143348623853 0 1 -1
other,additive,effect 1.0 0.000143348623853 0 1 -1
other,added,as 1.0 0.000143348623853 0 1 -1
other,acting,on 1.0 0.000286697247706 0 2 -2
osteoporosis,treatment,study 1.0 0.000143348623853 0 1 -1
osteoporosis,treatment,and 1.0 0.000143348623853 0 1 -1
osteomalacia,in,some 1.0 0.000143348623853 0 1 -1
osteoarthritis,when,vioxx 1.0 0.000143348623853 0 1 -1
oruvail,voltaren,cataflam 1.0 0.000143348623853 0 1 -1
orudis,orudis,kt 1.0 0.000143348623853 0 1 -1
orudis,kt,oruvail 1.0 0.000143348623853 0 1 -1
orudis,doses,greater 1.0 0.000143348623853 0 1 -1
orthostatic,hypotension,in 1.0 0.000143348623853 0 1 -1
orphan,status,for 1.0 0.000143348623853 0 1 -1
original,medication,should 1.0 0.000143348623853 0 1 -1
organs,actively,concentrating 1.0 0.000143348623853 0 1 -1
organophosphorous,compound,and 1.0 0.000143348623853 0 1 -1
organometals,also,compromise 1.0 0.000143348623853 0 1 -1
organoleads,are,present 1.0 0.000143348623853 0 1 -1
organization,criteria,was 1.0 0.000143348623853 0 1 -1
organisms,but,it 1.0 0.000143348623853 0 1 -1
organisms,and,oral 1.0 0.000143348623853 0 1 -1
organism,and,abuse 1.0 0.000143348623853 0 1 -1
organisation,m,decins 1.0 0.000143348623853 0 1 -1
organic,cation,transport 1.0 0.000143348623853 0 1 -1
organ,transplants,malignancy 1.0 0.000143348623853 0 1 -1
organ,may,be 1.0 0.000143348623853 0 1 -1
orencia,mtx,nsaids 1.0 0.000143348623853 0 1 -1
ordinarily,a,minor 1.0 0.000143348623853 0 1 -1
orders,of,magnitude 1.0 0.000143348623853 0 1 -1
order,to,use 1.0 0.000143348623853 0 1 -1
order,to,provide 1.0 0.000143348623853 0 1 -1
order,to,monitor 1.0 0.000143348623853 0 1 -1
order,to,lessen 1.0 0.000143348623853 0 1 -1
order,to,examine 1.0 0.000143348623853 0 1 -1
order,to,confirm 1.0 0.000143348623853 0 1 -1
order,to,approximate 1.0 0.000143348623853 0 1 -1
order,of,application 1.0 0.000143348623853 0 1 -1
orasone,others,medrol 1.0 0.000143348623853 0 1 -1
orange,juices,studies 1.0 0.000143348623853 0 1 -1
orange,juices,compared 1.0 0.000143348623853 0 1 -1
orange,juice,or 1.0 0.000143348623853 0 1 -1
orange,and,apple 1.0 0.000143348623853 0 1 -1
orally,to,healthy 1.0 0.000143348623853 0 1 -1
orally,min,before 1.0 0.000143348623853 0 1 -1
orally,ingested,or 1.0 0.000143348623853 0 1 -1
orally,has,not 1.0 0.000143348623853 0 1 -1
orally,given,and 1.0 0.000143348623853 0 1 -1
orally,administered,could 1.0 0.000143348623853 0 1 -1
orally,administered,by 1.0 0.000143348623853 0 1 -1
oral,were,given 1.0 0.000143348623853 0 1 -1
oral,users,experiencing 1.0 0.000143348623853 0 1 -1
oral,to,maintain 1.0 0.000143348623853 0 1 -1
oral,therapy,is 1.0 0.000143348623853 0 1 -1
oral,therapies,for 1.0 0.000143348623853 0 1 -1
oral,the,hypoprothrombinemic 1.0 0.000143348623853 0 1 -1
oral,the,dose 1.0 0.000143348623853 0 1 -1
oral,the,coagulation 1.0 0.000143348623853 0 1 -1
oral,suspension,can 1.0 0.000286697247706 0 2 -2
oral,supplements,has 1.0 0.000143348623853 0 1 -1
oral,supplementation,which 1.0 0.000143348623853 0 1 -1
oral,supplementation,mg 1.0 0.000143348623853 0 1 -1
oral,should,be 1.0 0.000143348623853 0 1 -1
oral,self-administration,of 1.0 0.000143348623853 0 1 -1
oral,route,in 1.0 0.000143348623853 0 1 -1
oral,resulting,in 1.0 0.000143348623853 0 1 -1
oral,regularly,results 1.0 0.000143348623853 0 1 -1
oral,regular,monitoring 1.0 0.000143348623853 0 1 -1
oral,regimen,containing 1.0 0.000143348623853 0 1 -1
oral,products,ace 1.0 0.000143348623853 0 1 -1
oral,product,in 1.0 0.000143348623853 0 1 -1
oral,poc,in 1.0 0.000143348623853 0 1 -1
oral,platelet,inhibitors 1.0 0.000143348623853 0 1 -1
oral,placebo,and 1.0 0.000143348623853 0 1 -1
oral,physiological,supplementation 1.0 0.000143348623853 0 1 -1
oral,parenteral,or 1.0 0.000143348623853 0 1 -1
oral,overload,of 1.0 0.000143348623853 0 1 -1
oral,or,other 1.0 0.000143348623853 0 1 -1
oral,or,implant 1.0 0.000143348623853 0 1 -1
oral,or,have 1.0 0.000143348623853 0 1 -1
oral,or,did 1.0 0.000143348623853 0 1 -1
oral,on,the 1.0 0.000143348623853 0 1 -1
oral,on,acth 1.0 0.000143348623853 0 1 -1
oral,nicotinic,acid 1.0 0.000573394495413 0 4 -4
oral,mg,dose 1.0 0.000286697247706 0 2 -2
oral,mg,daily 1.0 0.000143348623853 0 1 -1
oral,may,affect 1.0 0.000143348623853 0 1 -1
oral,load,constitutes 1.0 0.000143348623853 0 1 -1
oral,inhaled,and 1.0 0.000143348623853 0 1 -1
oral,increased,about 1.0 0.000143348623853 0 1 -1
oral,includes,longer 1.0 0.000143348623853 0 1 -1
oral,in,patients 1.0 0.000143348623853 0 1 -1
oral,in,healthy 1.0 0.000286697247706 0 2 -2
oral,in,combination 1.0 0.000143348623853 0 1 -1
oral,hypoglycemics,initiating 1.0 0.000143348623853 0 1 -1
oral,hypoglycemics,diclofenac 1.0 0.000143348623853 0 1 -1
oral,hypoglycemics,bepridil 1.0 0.000143348623853 0 1 -1
oral,heparin,sodium 1.0 0.000143348623853 0 1 -1
oral,formulation,the 1.0 0.000143348623853 0 1 -1
oral,ethinyl,estradiol 1.0 0.000143348623853 0 1 -1
oral,erection-supporting,medication 1.0 0.000143348623853 0 1 -1
oral,doses,besides 1.0 0.000143348623853 0 1 -1
oral,dose,have 1.0 0.000143348623853 0 1 -1
oral,dose,had 1.0 0.000143348623853 0 1 -1
oral,dose,for 1.0 0.000143348623853 0 1 -1
oral,dose,even 1.0 0.000143348623853 0 1 -1
oral,did,not 1.0 0.000143348623853 0 1 -1
oral,decreased,prothrombin 1.0 0.000143348623853 0 1 -1
oral,cough,and 1.0 0.000143348623853 0 1 -1
oral,cordarone,administration 1.0 0.000143348623853 0 1 -1
oral,contraceptives,valdecoxib 1.0 0.000143348623853 0 1 -1
oral,contraceptives,the 1.0 0.000143348623853 0 1 -1
oral,contraceptives,rofecoxib 1.0 0.000143348623853 0 1 -1
oral,contraceptives,multiple 1.0 0.000286697247706 0 2 -2
oral,contraceptives,may 1.0 0.000143348623853 0 1 -1
oral,contraceptives,keppra 1.0 0.000143348623853 0 1 -1
oral,contraceptives,estrogens 1.0 0.000143348623853 0 1 -1
oral,contraceptives,a 1.0 0.000143348623853 0 1 -1
oral,contraceptive,based 1.0 0.000143348623853 0 1 -1
oral,contraceptive,agents 1.0 0.000143348623853 0 1 -1
oral,contraception,a 1.0 0.000143348623853 0 1 -1
oral,containing,mg 1.0 0.000143348623853 0 1 -1
oral,containing,iodine-containing 1.0 0.000143348623853 0 1 -1
oral,compared,to 1.0 0.000143348623853 0 1 -1
oral,clearance,was 1.0 0.000143348623853 0 1 -1
oral,channel,blockers 1.0 0.000143348623853 0 1 -1
oral,ccnu,was 1.0 0.000143348623853 0 1 -1
oral,ccnu,either 1.0 0.000143348623853 0 1 -1
oral,birth,control 1.0 0.000143348623853 0 1 -1
oral,bioavailability,low 1.0 0.000143348623853 0 1 -1
oral,as,well 1.0 0.000143348623853 0 1 -1
oral,are,also 1.0 0.000143348623853 0 1 -1
oral,antidiabetes,products 1.0 0.000143348623853 0 1 -1
oral,anticoagulents,may 1.0 0.000143348623853 0 1 -1
oral,anticoagulants,thyroid 1.0 0.000143348623853 0 1 -1
oral,anticoagulants,interaction 1.0 0.000143348623853 0 1 -1
oral,and,through 1.0 0.000143348623853 0 1 -1
oral,and,intravenous 1.0 0.000286697247706 0 2 -2
oral,and,inhaled 1.0 0.000143348623853 0 1 -1
oral,and,as 1.0 0.000143348623853 0 1 -1
oral,an,inhibitor 1.0 0.000143348623853 0 1 -1
oral,agents,pharmacokinetic 1.0 0.000143348623853 0 1 -1
oral,agents,may 1.0 0.000143348623853 0 1 -1
oral,agents,and 1.0 0.000573394495413 0 4 -4
oral,administration,even 1.0 0.000143348623853 0 1 -1
oral,administration,appeared 1.0 0.000143348623853 0 1 -1
oral,adl,mg 1.0 0.000143348623853 0 1 -1
or,x,l 1.0 0.000143348623853 0 1 -1
or,would,be 1.0 0.000143348623853 0 1 -1
or,without,tdp 1.0 0.000143348623853 0 1 -1
or,without,replacement 1.0 0.000143348623853 0 1 -1
or,without,evidence 1.0 0.000143348623853 0 1 -1
or,without,endothelium 1.0 0.000143348623853 0 1 -1
or,within,the 1.0 0.000143348623853 0 1 -1
or,within,several 1.0 0.000143348623853 0 1 -1
or,within,less 1.0 0.000143348623853 0 1 -1
or,withdrawn,in 1.0 0.000143348623853 0 1 -1
or,with,the 1.0 0.000143348623853 0 1 -1
or,with,suspension 1.0 0.000143348623853 0 1 -1
or,with,salts 1.0 0.000143348623853 0 1 -1
or,with,parasite 1.0 0.000143348623853 0 1 -1
or,with,mg 1.0 0.000143348623853 0 1 -1
or,with,had 1.0 0.000143348623853 0 1 -1
or,with,clinitest 1.0 0.00043004587156 0 3 -3
or,with,changes 1.0 0.000143348623853 0 1 -1
or,when,proquin 1.0 0.000143348623853 0 1 -1
or,when,new 1.0 0.000143348623853 0 1 -1
or,when,a 1.0 0.000143348623853 0 1 -1
or,were,observed 1.0 0.000143348623853 0 1 -1
or,were,administered 1.0 0.000143348623853 0 1 -1
or,were,added 1.0 0.000143348623853 0 1 -1
or,weakness,associated 1.0 0.000143348623853 0 1 -1
or,was,seen 1.0 0.000143348623853 0 1 -1
or,was,delayed 1.0 0.000143348623853 0 1 -1
or,was,administered 1.0 0.000143348623853 0 1 -1
or,was,added 1.0 0.000143348623853 0 1 -1
or,volume,of 1.0 0.000143348623853 0 1 -1
or,vaginal,preparations 1.0 0.00043004587156 0 3 -3
or,used,during 1.0 0.000143348623853 0 1 -1
or,use,may 1.0 0.000143348623853 0 1 -1
or,urine,which 1.0 0.000143348623853 0 1 -1
or,urinary,tract 1.0 0.000143348623853 0 1 -1
or,unusual,taste 1.0 0.000143348623853 0 1 -1
or,undesirable,involving 1.0 0.000286697247706 0 2 -2
or,uncomplicated,urinary 1.0 0.000143348623853 0 1 -1
or,ugt,enzymes 1.0 0.000143348623853 0 1 -1
or,two,capsules 1.0 0.000143348623853 0 1 -1
or,tumor,vascularity 1.0 0.000143348623853 0 1 -1
or,tubular,secretion 1.0 0.000143348623853 0 1 -1
or,tsh,levels 1.0 0.000143348623853 0 1 -1
or,trivalent,cations 1.0 0.000286697247706 0 2 -2
or,triazolam,no 1.0 0.000143348623853 0 1 -1
or,treatment,discontinuation 1.0 0.000143348623853 0 1 -1
or,toxicologic,profile 1.0 0.000143348623853 0 1 -1
or,toxicity,associated 1.0 0.000143348623853 0 1 -1
or,total,body 1.0 0.000143348623853 0 1 -1
or,total,bilirubin 1.0 0.000143348623853 0 1 -1
or,too,low 1.0 0.000143348623853 0 1 -1
or,too,frequent 1.0 0.000143348623853 0 1 -1
or,to,the 1.0 0.000573394495413 0 4 -4
or,to,recommend 1.0 0.000143348623853 0 1 -1
or,to,receive 1.0 0.000143348623853 0 1 -1
or,to,hours 1.0 0.000143348623853 0 1 -1
or,to,discontinue 1.0 0.000286697247706 0 2 -2
or,to,be 1.0 0.000143348623853 0 1 -1
or,tmax,at 1.0 0.000143348623853 0 1 -1
or,those,who 1.0 0.000143348623853 0 1 -1
or,therapeutic,agents 1.0 0.000143348623853 0 1 -1
or,their,metabolites 1.0 0.000143348623853 0 1 -1
or,their,guardians 1.0 0.000143348623853 0 1 -1
or,the,therapeutic 1.0 0.000143348623853 0 1 -1
or,the,simultaneous 1.0 0.000143348623853 0 1 -1
or,the,presence 1.0 0.000143348623853 0 1 -1
or,the,polymorphic 1.0 0.000143348623853 0 1 -1
or,the,pharmacokinetics 1.0 0.000143348623853 0 1 -1
or,the,pharmacodynamics 1.0 0.000286697247706 0 2 -2
or,the,patient 1.0 0.000143348623853 0 1 -1
or,the,mean 1.0 0.000286697247706 0 2 -2
or,the,level 1.0 0.000143348623853 0 1 -1
or,the,fda 1.0 0.000143348623853 0 1 -1
or,the,dose 1.0 0.000143348623853 0 1 -1
or,the,area 1.0 0.000143348623853 0 1 -1
or,the,antiprothrombinemic 1.0 0.000143348623853 0 1 -1
or,the,active 1.0 0.000143348623853 0 1 -1
or,the,absence 1.0 0.000143348623853 0 1 -1
or,teratogenic,effects 1.0 0.000143348623853 0 1 -1
or,tenofovir,disoproxil 1.0 0.000143348623853 0 1 -1
or,tachycardia,do 1.0 0.000143348623853 0 1 -1
or,t3,levels 1.0 0.000286697247706 0 2 -2
or,t,max 1.0 0.000286697247706 0 2 -2
or,systolic,blood 1.0 0.000143348623853 0 1 -1
or,synergistic,depressant 1.0 0.000143348623853 0 1 -1
or,swelling,at 1.0 0.000143348623853 0 1 -1
or,suspected,to 1.0 0.000286697247706 0 2 -2
or,surgery,because 1.0 0.000143348623853 0 1 -1
or,supplements,should 1.0 0.000143348623853 0 1 -1
or,supplements,can 1.0 0.000286697247706 0 2 -2
or,substituted,for 1.0 0.000143348623853 0 1 -1
or,substances,that 1.0 0.000143348623853 0 1 -1
or,structural,alterations 1.0 0.000143348623853 0 1 -1
or,stopping,concomitantly 1.0 0.000286697247706 0 2 -2
or,stop,any 1.0 0.000143348623853 0 1 -1
or,stimulus,response 1.0 0.000143348623853 0 1 -1
or,stereotypic,effects 1.0 0.000143348623853 0 1 -1
or,statistically,significant 1.0 0.000143348623853 0 1 -1
or,special,monitoring 1.0 0.000143348623853 0 1 -1
or,skin,medicines 1.0 0.000143348623853 0 1 -1
or,skeletal-muscle,relaxants 1.0 0.000143348623853 0 1 -1
or,since,it 1.0 0.000143348623853 0 1 -1
or,side,effects 1.0 0.000143348623853 0 1 -1
or,shampoos,for 1.0 0.000143348623853 0 1 -1
or,serum,pregnancy 1.0 0.000143348623853 0 1 -1
or,serial,use 1.0 0.000286697247706 0 2 -2
or,sensitivity,to 1.0 0.000143348623853 0 1 -1
or,seen,in 1.0 0.000143348623853 0 1 -1
or,salt,substitutes 1.0 0.000143348623853 0 1 -1
or,salt,or 1.0 0.000143348623853 0 1 -1
or,salicylic,acid 1.0 0.000286697247706 0 2 -2
or,s-warfarin,with 1.0 0.000143348623853 0 1 -1
or,s-,enantiomers 1.0 0.000143348623853 0 1 -1
or,s,nor 1.0 0.000143348623853 0 1 -1
or,resistance,in 1.0 0.000143348623853 0 1 -1
or,repeated,mg 1.0 0.000143348623853 0 1 -1
or,repeated,doses 1.0 0.000143348623853 0 1 -1
or,renal,failure 1.0 0.000143348623853 0 1 -1
or,renal,elimination 1.0 0.000286697247706 0 2 -2
or,related,psychoses 1.0 0.000143348623853 0 1 -1
or,regimen,may 1.0 0.000286697247706 0 2 -2
or,radiation,therapy 1.0 0.000143348623853 0 1 -1
or,quite,large 1.0 0.000716743119266 0 5 -5
or,qtc,interval 1.0 0.000143348623853 0 1 -1
or,qt,interval 1.0 0.000143348623853 0 1 -1
or,prothrombin,times 1.0 0.000143348623853 0 1 -1
or,prothrombin,complex 1.0 0.000143348623853 0 1 -1
or,prophylactic,doses 1.0 0.000143348623853 0 1 -1
or,prolonged,therapy 1.0 0.000143348623853 0 1 -1
or,prolonged,diarrhea 1.0 0.000143348623853 0 1 -1
or,prolonged,by 1.0 0.000143348623853 0 1 -1
or,prolong,its 1.0 0.000143348623853 0 1 -1
or,prolong,both 1.0 0.00043004587156 0 3 -3
or,primidone,no 1.0 0.000143348623853 0 1 -1
or,preparations,produced 1.0 0.000143348623853 0 1 -1
or,predicted,interactions 1.0 0.000143348623853 0 1 -1
or,preanesthetic,and 1.0 0.000143348623853 0 1 -1
or,potentiation,of 1.0 0.000286697247706 0 2 -2
or,potentially,toxic 1.0 0.000143348623853 0 1 -1
or,potassium-depleting,and 1.0 0.000143348623853 0 1 -1
or,placebo,was 1.0 0.000143348623853 0 1 -1
or,placebo,for 1.0 0.000143348623853 0 1 -1
or,placebo,and 1.0 0.000143348623853 0 1 -1
or,pharmacokinetics,during 1.0 0.000143348623853 0 1 -1
or,pharmacodynamics,of 1.0 0.000286697247706 0 2 -2
or,pharmacodynamic,profile 1.0 0.000143348623853 0 1 -1
or,pharmacodynamic,interactions 1.0 0.000143348623853 0 1 -1
or,pharmacodynamic,interaction 1.0 0.000286697247706 0 2 -2
or,pharmacodynamic,drug-drug 1.0 0.000143348623853 0 1 -1
or,pharmacist,of 1.0 0.000143348623853 0 1 -1
or,pharmacist,can 1.0 0.000143348623853 0 1 -1
or,pgp,may 1.0 0.000143348623853 0 1 -1
or,pd,studies 1.0 0.000143348623853 0 1 -1
or,pcp,produced 1.0 0.000143348623853 0 1 -1
or,patients,should 1.0 0.000143348623853 0 1 -1
or,partner,of 1.0 0.000143348623853 0 1 -1
or,partly,share 1.0 0.000143348623853 0 1 -1
or,parenteral,forms 1.0 0.000143348623853 0 1 -1
or,parenteral,enzyme 1.0 0.000143348623853 0 1 -1
or,overlapping,administration 1.0 0.000143348623853 0 1 -1
or,over-the,counter 1.0 0.000286697247706 0 2 -2
or,over,to 1.0 0.000143348623853 0 1 -1
or,outpatient,services 1.0 0.000143348623853 0 1 -1
or,ototoxicity,and 1.0 0.000143348623853 0 1 -1
or,others,with 1.0 0.000143348623853 0 1 -1
or,other,precautions 1.0 0.000143348623853 0 1 -1
or,other,or 1.0 0.000143348623853 0 1 -1
or,other,highly 1.0 0.000143348623853 0 1 -1
or,other,formal 1.0 0.000143348623853 0 1 -1
or,other,factors 1.0 0.000143348623853 0 1 -1
or,other,cyp3a4 1.0 0.000143348623853 0 1 -1
or,other,coumarin-derivative 1.0 0.000143348623853 0 1 -1
or,other,coadministered 1.0 0.000143348623853 0 1 -1
or,orange,juices 1.0 0.000143348623853 0 1 -1
or,orally,administered 1.0 0.000143348623853 0 1 -1
or,oral,should 1.0 0.000143348623853 0 1 -1
or,oral,regular 1.0 0.000143348623853 0 1 -1
or,oral,agents 1.0 0.000143348623853 0 1 -1
or,or,supplements 1.0 0.000143348623853 0 1 -1
or,or,mg 1.0 0.000143348623853 0 1 -1
or,or,its 1.0 0.000143348623853 0 1 -1
or,operating,dangerous 1.0 0.000143348623853 0 1 -1
or,on,plasma 1.0 0.000143348623853 0 1 -1
or,on,insulins 1.0 0.000143348623853 0 1 -1
or,omega-agatoxin,iva 1.0 0.000143348623853 0 1 -1
or,older,ask 1.0 0.000143348623853 0 1 -1
or,oils,should 1.0 0.000143348623853 0 1 -1
or,of,the 1.0 0.000143348623853 0 1 -1
or,of,patients 1.0 0.000143348623853 0 1 -1
or,nucleus,accumbens 1.0 0.000143348623853 0 1 -1
or,nsaids,was 1.0 0.000143348623853 0 1 -1
or,nsaid,users 1.0 0.000143348623853 0 1 -1
or,not,an 1.0 0.000143348623853 0 1 -1
or,nor,did 1.0 0.000143348623853 0 1 -1
or,non-opioid,analgesics 1.0 0.000143348623853 0 1 -1
or,no,first-pass 1.0 0.000143348623853 0 1 -1
or,no,change 1.0 0.000143348623853 0 1 -1
or,no,capacity 1.0 0.000143348623853 0 1 -1
or,nitrous,oxide 1.0 0.000143348623853 0 1 -1
or,neurotoxic,therapy 1.0 0.000143348623853 0 1 -1
or,neuromuscular,blockade 1.0 0.000143348623853 0 1 -1
or,nephrotoxic,because 1.0 0.000143348623853 0 1 -1
or,mycophenolate,mofetil 1.0 0.000143348623853 0 1 -1
or,multiple,dose 1.0 0.000143348623853 0 1 -1
or,more,when 1.0 0.000143348623853 0 1 -1
or,more,were 1.0 0.000143348623853 0 1 -1
or,more,pharmacologic 1.0 0.000143348623853 0 1 -1
or,more,of 1.0 0.00043004587156 0 3 -3
or,more,during 1.0 0.000143348623853 0 1 -1
or,more,competing 1.0 0.000143348623853 0 1 -1
or,monitoring,of 1.0 0.000286697247706 0 2 -2
or,moieties,are 1.0 0.000143348623853 0 1 -1
or,minus,s 1.0 0.000286697247706 0 2 -2
or,mimic,certain 1.0 0.000143348623853 0 1 -1
or,milk,there 1.0 0.000143348623853 0 1 -1
or,might,have 1.0 0.000143348623853 0 1 -1
or,micrograms,kg 1.0 0.000143348623853 0 1 -1
or,mg,twice 1.0 0.000143348623853 0 1 -1
or,mg,rat 1.0 0.000143348623853 0 1 -1
or,mg,qd 1.0 0.000143348623853 0 1 -1
or,mg,q 1.0 0.000143348623853 0 1 -1
or,mg,per 1.0 0.000143348623853 0 1 -1
or,mg,orally 1.0 0.000286697247706 0 2 -2
or,mg,once 1.0 0.000286697247706 0 2 -2
or,mg,ml 1.0 0.000286697247706 0 2 -2
or,mg,every 1.0 0.000143348623853 0 1 -1
or,mg,day 1.0 0.000143348623853 0 1 -1
or,mg,bid 1.0 0.000143348623853 0 1 -1
or,methylthiadiazole,can 1.0 0.000143348623853 0 1 -1
or,metabolite,i 1.0 0.000143348623853 0 1 -1
or,metabolic,responses 1.0 0.000143348623853 0 1 -1
or,may,increase 1.0 0.000143348623853 0 1 -1
or,maximum,concentration 1.0 0.000143348623853 0 1 -1
or,maois,which 1.0 0.000143348623853 0 1 -1
or,maintenance,bolus 1.0 0.000143348623853 0 1 -1
or,maintain,the 1.0 0.000143348623853 0 1 -1
or,m,and 1.0 0.000143348623853 0 1 -1
or,logistic,probability 1.0 0.000143348623853 0 1 -1
or,lime,should 1.0 0.000143348623853 0 1 -1
or,life-threatening,reactions 1.0 0.00100344036697 0 7 -7
or,less,specific 1.0 0.000143348623853 0 1 -1
or,less,of 1.0 0.000286697247706 0 2 -2
or,ldh,were 1.0 0.000143348623853 0 1 -1
or,large,doses 1.0 0.000143348623853 0 1 -1
or,laboratory,test 1.0 0.000143348623853 0 1 -1
or,kineret,when 1.0 0.000143348623853 0 1 -1
or,kidney,diseases 1.0 0.000143348623853 0 1 -1
or,kcl,mmol 1.0 0.000143348623853 0 1 -1
or,iv,ace 1.0 0.000143348623853 0 1 -1
or,its,synthetic 1.0 0.000143348623853 0 1 -1
or,its,plasma 1.0 0.000143348623853 0 1 -1
or,its,metabolites 1.0 0.000143348623853 0 1 -1
or,its,metabolite 1.0 0.000143348623853 0 1 -1
or,its,epoxide 1.0 0.000143348623853 0 1 -1
or,its,effects 1.0 0.000143348623853 0 1 -1
or,its,components 1.0 0.000143348623853 0 1 -1
or,its,closely 1.0 0.000143348623853 0 1 -1
or,interruption,of 1.0 0.000143348623853 0 1 -1
or,interaction,study 1.0 0.000143348623853 0 1 -1
or,inhibits,hepatic 1.0 0.000143348623853 0 1 -1
or,inhibition,of 1.0 0.000286697247706 0 2 -2
or,inhibit,this 1.0 0.000143348623853 0 1 -1
or,inhibit,cytochrome 1.0 0.000143348623853 0 1 -1
or,induction,potential 1.0 0.000143348623853 0 1 -1
or,induces,the 1.0 0.000143348623853 0 1 -1
or,inducers,of 1.0 0.000860091743119 0 6 -6
or,induce,cytochromes 1.0 0.000143348623853 0 1 -1
or,induce,cytochrome 1.0 0.000286697247706 0 2 -2
or,induce,cyp 1.0 0.000143348623853 0 1 -1
or,increased,sedation 1.0 0.000286697247706 0 2 -2
or,including,combined 1.0 0.000143348623853 0 1 -1
or,inactivity,of 1.0 0.000143348623853 0 1 -1
or,in,transfusion 1.0 0.000143348623853 0 1 -1
or,in,those 1.0 0.000286697247706 0 2 -2
or,in,rats 1.0 0.000143348623853 0 1 -1
or,in,patients 1.0 0.00043004587156 0 3 -3
or,in,metabolite 1.0 0.000143348623853 0 1 -1
or,in,dmpge2 1.0 0.000143348623853 0 1 -1
or,in,coombs 1.0 0.000143348623853 0 1 -1
or,in,conjunction 1.0 0.000143348623853 0 1 -1
or,in,citrate 1.0 0.000143348623853 0 1 -1
or,implant,have 1.0 0.000143348623853 0 1 -1
or,igm,can 1.0 0.000143348623853 0 1 -1
or,if,therapy 1.0 0.000143348623853 0 1 -1
or,hypomagnesemia,should 1.0 0.000143348623853 0 1 -1
or,hypo-thyroxine,binding-globulinemias 1.0 0.000143348623853 0 1 -1
or,hypersensitivity,reactions 1.0 0.000143348623853 0 1 -1
or,human,studies 1.0 0.000143348623853 0 1 -1
or,hot,drinks 1.0 0.000143348623853 0 1 -1
or,hits,are 1.0 0.000143348623853 0 1 -1
or,higher,was 1.0 0.000143348623853 0 1 -1
or,hexokinase,method 1.0 0.000286697247706 0 2 -2
or,herbs,do 1.0 0.000143348623853 0 1 -1
or,herbal,product 1.0 0.000143348623853 0 1 -1
or,herb,interactions 1.0 0.000286697247706 0 2 -2
or,hepatic,impairment 1.0 0.000286697247706 0 2 -2
or,hctz,mg 1.0 0.000143348623853 0 1 -1
or,harm,to 1.0 0.000143348623853 0 1 -1
or,had,minimal 1.0 0.000143348623853 0 1 -1
or,guardian,see 1.0 0.000143348623853 0 1 -1
or,grapefruit,juice 1.0 0.000143348623853 0 1 -1
or,glycosides,concurrent 1.0 0.000143348623853 0 1 -1
or,glatiramer,acetate 1.0 0.000143348623853 0 1 -1
or,given,with 1.0 0.000143348623853 0 1 -1
or,generalized,urticaria 1.0 0.000143348623853 0 1 -1
or,from,breast 1.0 0.000143348623853 0 1 -1
or,four,hours 1.0 0.000143348623853 0 1 -1
or,fortovase,and 1.0 0.000143348623853 0 1 -1
or,for,hours 1.0 0.000143348623853 0 1 -1
or,for,a 1.0 0.000143348623853 0 1 -1
or,follow,dosing 1.0 0.000143348623853 0 1 -1
or,fertility,studies 1.0 0.000143348623853 0 1 -1
or,female,have 1.0 0.000143348623853 0 1 -1
or,fehlings,solution 1.0 0.000143348623853 0 1 -1
or,fehling,s 1.0 0.000143348623853 0 1 -1
or,fec-100,chemotherapies 1.0 0.000143348623853 0 1 -1
or,fatal,adverse 1.0 0.000143348623853 0 1 -1
or,factors,v 1.0 0.000143348623853 0 1 -1
or,extent,of 1.0 0.00043004587156 0 3 -3
or,excessive,bradycardia 1.0 0.000143348623853 0 1 -1
or,evidence,of 1.0 0.000143348623853 0 1 -1
or,every,other 1.0 0.000143348623853 0 1 -1
or,even,clozapine 1.0 0.000143348623853 0 1 -1
or,equal,to 1.0 0.000143348623853 0 1 -1
or,epoxide,hydrolase 1.0 0.000286697247706 0 2 -2
or,enzyme,function 1.0 0.000143348623853 0 1 -1
or,enhance,the 1.0 0.000143348623853 0 1 -1
or,enantiomer,pharmacokinetics 1.0 0.000143348623853 0 1 -1
or,embryocidal,effects 1.0 0.000143348623853 0 1 -1
or,elimination,or 1.0 0.000143348623853 0 1 -1
or,elimination,may 1.0 0.000143348623853 0 1 -1
or,efficacy,were 1.0 0.000143348623853 0 1 -1
or,efficacy,physicians 1.0 0.000143348623853 0 1 -1
or,efficacy,of 1.0 0.00043004587156 0 3 -3
or,dysfunction,is 1.0 0.000143348623853 0 1 -1
or,duloxetine,with 1.0 0.000143348623853 0 1 -1
or,due,to 1.0 0.000286697247706 0 2 -2
or,drug,laboratory 1.0 0.000143348623853 0 1 -1
or,driving,a 1.0 0.000143348623853 0 1 -1
or,dosing,requirements 1.0 0.000143348623853 0 1 -1
or,dose,mu 1.0 0.000143348623853 0 1 -1
or,dose,baseline 1.0 0.000143348623853 0 1 -1
or,dosage,and 1.0 0.000143348623853 0 1 -1
or,does,not 1.0 0.000286697247706 0 2 -2
or,divalent,or 1.0 0.000143348623853 0 1 -1
or,disruption,of 1.0 0.000143348623853 0 1 -1
or,disposition,of 1.0 0.000143348623853 0 1 -1
or,discontinued,because 1.0 0.000143348623853 0 1 -1
or,discontinue,pegasys 1.0 0.000143348623853 0 1 -1
or,dihydroxyflavone,with 1.0 0.000143348623853 0 1 -1
or,dietary,interferes 1.0 0.000143348623853 0 1 -1
or,depresses,bone 1.0 0.000143348623853 0 1 -1
or,deletion,of 1.0 0.000143348623853 0 1 -1
or,delay,premature 1.0 0.000143348623853 0 1 -1
or,delavirdine-based,regimens 1.0 0.000143348623853 0 1 -1
or,decrease,blood 1.0 0.000143348623853 0 1 -1
or,daily,alternating 1.0 0.000143348623853 0 1 -1
or,cyp3a4,in 1.0 0.000143348623853 0 1 -1
or,cyp-mediated,drug 1.0 0.000143348623853 0 1 -1
or,crohn,s 1.0 0.000143348623853 0 1 -1
or,cramps,muscular 1.0 0.000143348623853 0 1 -1
or,corticosteroids,or 1.0 0.000143348623853 0 1 -1
or,corrected,qt 1.0 0.000143348623853 0 1 -1
or,copd,symptoms 1.0 0.000143348623853 0 1 -1
or,copd,medications 1.0 0.000143348623853 0 1 -1
or,concurrent,use 1.0 0.000143348623853 0 1 -1
or,concomitant,strong 1.0 0.000143348623853 0 1 -1
or,concomitant,administration 1.0 0.000143348623853 0 1 -1
or,concentrations,when 1.0 0.000143348623853 0 1 -1
or,compounds,which 1.0 0.000143348623853 0 1 -1
or,compete,for 1.0 0.000143348623853 0 1 -1
or,coagulation,should 1.0 0.000143348623853 0 1 -1
or,cns,depression 1.0 0.000143348623853 0 1 -1
or,clotting,factor 1.0 0.000143348623853 0 1 -1
or,closely,monitor 1.0 0.000143348623853 0 1 -1
or,clinitest,tablets 1.0 0.000143348623853 0 1 -1
or,clinically,significant 1.0 0.000143348623853 0 1 -1
or,clinically,relevant 1.0 0.000143348623853 0 1 -1
or,clinical,effects 1.0 0.000143348623853 0 1 -1
or,clastogenic,in 1.0 0.000143348623853 0 1 -1
or,citrate,accumulation 1.0 0.000143348623853 0 1 -1
or,chronic,administration 1.0 0.000143348623853 0 1 -1
or,channel,antagonists 1.0 0.000143348623853 0 1 -1
or,cerebroactive,drugs 1.0 0.000143348623853 0 1 -1
or,caused,excessive 1.0 0.000143348623853 0 1 -1
or,cardiac,glycosides 1.0 0.000143348623853 0 1 -1
or,carbidopa-levodopa,combination 1.0 0.000143348623853 0 1 -1
or,by,radioimmunoassay 1.0 0.000286697247706 0 2 -2
or,by,protecting 1.0 0.000143348623853 0 1 -1
or,by,injection 1.0 0.000143348623853 0 1 -1
or,by,an 1.0 0.000143348623853 0 1 -1
or,by,a 1.0 0.000143348623853 0 1 -1
or,both,which 1.0 0.000143348623853 0 1 -1
or,blood,pressure 1.0 0.000143348623853 0 1 -1
or,biweekly,intervals 1.0 0.000286697247706 0 2 -2
or,biocytin,was 1.0 0.000143348623853 0 1 -1
or,biocytin,compared 1.0 0.000143348623853 0 1 -1
or,before,day 1.0 0.000143348623853 0 1 -1
or,be,subject 1.0 0.000286697247706 0 2 -2
or,azoles,were 1.0 0.000143348623853 0 1 -1
or,at,least 1.0 0.000143348623853 0 1 -1
or,at,bedtime 1.0 0.000143348623853 0 1 -1
or,at,as 1.0 0.000143348623853 0 1 -1
or,at,any 1.0 0.000143348623853 0 1 -1
or,ast,times 1.0 0.000143348623853 0 1 -1
or,are,known 1.0 0.000143348623853 0 1 -1
or,are,given 1.0 0.000143348623853 0 1 -1
or,anticoagulation,should 1.0 0.000143348623853 0 1 -1
or,antagonist,effect 1.0 0.000143348623853 0 1 -1
or,antagonise,the 1.0 0.000143348623853 0 1 -1
or,angiotensin,ii 1.0 0.000143348623853 0 1 -1
or,and,to 1.0 0.000143348623853 0 1 -1
or,and,that 1.0 0.000143348623853 0 1 -1
or,anaphylactic,reactions 1.0 0.000143348623853 0 1 -1
or,an,levonorgestrol 1.0 0.000143348623853 0 1 -1
or,an,impairment 1.0 0.000143348623853 0 1 -1
or,an,equivalent 1.0 0.000143348623853 0 1 -1
or,amenorrhea,were 1.0 0.000143348623853 0 1 -1
or,alternatively,the 1.0 0.000143348623853 0 1 -1
or,altering,their 1.0 0.000143348623853 0 1 -1
or,altered,tsh 1.0 0.000143348623853 0 1 -1
or,adrenergic,neuron 1.0 0.000143348623853 0 1 -1
or,administration,for 1.0 0.000143348623853 0 1 -1
or,additional,method 1.0 0.000143348623853 0 1 -1
or,additional,measures 1.0 0.000143348623853 0 1 -1
or,acute,ergot 1.0 0.000143348623853 0 1 -1
or,activase,may 1.0 0.000143348623853 0 1 -1
or,acth,treatment 1.0 0.000143348623853 0 1 -1
or,acquired,immunodeficiencies 1.0 0.000143348623853 0 1 -1
or,accumulation,during 1.0 0.000143348623853 0 1 -1
or,accidental,contact 1.0 0.000143348623853 0 1 -1
or,absence,of 1.0 0.000143348623853 0 1 -1
or,abrasive,soaps 1.0 0.000143348623853 0 1 -1
or,a,variety 1.0 0.000143348623853 0 1 -1
or,a,dose 1.0 0.000143348623853 0 1 -1
or,a,chop-like 1.0 0.000143348623853 0 1 -1
or,a,cardioselective 1.0 0.000143348623853 0 1 -1
option,in,the 1.0 0.000143348623853 0 1 -1
optimal,therapeutic,dose 1.0 0.000143348623853 0 1 -1
optimal,pulmonary,function 1.0 0.000143348623853 0 1 -1
optimal,pharmacokinetics,effectiveness 1.0 0.000143348623853 0 1 -1
optimal,dosing,interval 1.0 0.000143348623853 0 1 -1
optimal,dose,of 1.0 0.000286697247706 0 2 -2
optimal,designs,for 1.0 0.000143348623853 0 1 -1
optimal,conditions,kinetics 1.0 0.000143348623853 0 1 -1
optimal,care,in 1.0 0.000143348623853 0 1 -1
optimal,and,minimal 1.0 0.000143348623853 0 1 -1
optic,nerve,vacuolation 1.0 0.000143348623853 0 1 -1
optic,nerve,degeneration 1.0 0.000143348623853 0 1 -1
opportunistic,infections,have 1.0 0.000143348623853 0 1 -1
opportunistic,infection,oi 1.0 0.000143348623853 0 1 -1
opioids,are,strong 1.0 0.000143348623853 0 1 -1
opioid-evoked,hyperpolarization,and 1.0 0.000143348623853 0 1 -1
opioid-dependent,patients,mixed 1.0 0.000143348623853 0 1 -1
opioid-antagonist,and,non-opioid 1.0 0.000143348623853 0 1 -1
ophthalmic,suspension,contains 1.0 0.000143348623853 0 1 -1
ophthalmic,solution,should 1.0 0.000143348623853 0 1 -1
operating,machinery,or 1.0 0.000143348623853 0 1 -1
operating,dangerous,machinery 1.0 0.000143348623853 0 1 -1
open-label,two-way,crossover 1.0 0.000143348623853 0 1 -1
open,three-period,randomized 1.0 0.000143348623853 0 1 -1
open,randomized,crossover 1.0 0.000143348623853 0 1 -1
ontario,the,mortality 1.0 0.000143348623853 0 1 -1
ontario,alone,in 1.0 0.000143348623853 0 1 -1
onset,were,prohibited 1.0 0.000143348623853 0 1 -1
onset,of,the 1.0 0.000286697247706 0 2 -2
onset,of,symptoms 1.0 0.000143348623853 0 1 -1
onset,of,of 1.0 0.000143348623853 0 1 -1
onset,of,action 1.0 0.000143348623853 0 1 -1
only,with,knowledge 1.0 0.000143348623853 0 1 -1
only,with,concomitant 1.0 0.000143348623853 0 1 -1
only,with,caution 1.0 0.000143348623853 0 1 -1
only,with,careful 1.0 0.000143348623853 0 1 -1
only,when,they 1.0 0.000143348623853 0 1 -1
only,take,place 1.0 0.000143348623853 0 1 -1
only,slightly,increased 1.0 0.000143348623853 0 1 -1
only,significantly,affected 1.0 0.000143348623853 0 1 -1
only,requires,oral 1.0 0.000143348623853 0 1 -1
only,re-results,in 1.0 0.000143348623853 0 1 -1
only,one,contra-indication 1.0 0.000143348623853 0 1 -1
only,on,clinical 1.0 0.000143348623853 0 1 -1
only,of,the 1.0 0.000143348623853 0 1 -1
only,observed,between 1.0 0.000143348623853 0 1 -1
only,n3,showing 1.0 0.000143348623853 0 1 -1
only,increases,extracellular 1.0 0.000143348623853 0 1 -1
only,in,patients 1.0 0.000286697247706 0 2 -2
only,in,genetically 1.0 0.000143348623853 0 1 -1
only,improve,sensitivity 1.0 0.000143348623853 0 1 -1
only,if,other 1.0 0.000143348623853 0 1 -1
only,hyperglycemia,but 1.0 0.000143348623853 0 1 -1
only,half,of 1.0 0.000143348623853 0 1 -1
only,for,documented 1.0 0.000143348623853 0 1 -1
only,bodyweight,gain 1.0 0.000143348623853 0 1 -1
only,be,envisaged 1.0 0.000143348623853 0 1 -1
only,at,very 1.0 0.000143348623853 0 1 -1
only,at,the 1.0 0.000143348623853 0 1 -1
only,at,relatively 1.0 0.000143348623853 0 1 -1
only,at,concentrations 1.0 0.000143348623853 0 1 -1
only,as,directed 1.0 0.000143348623853 0 1 -1
only,about,bound 1.0 0.000143348623853 0 1 -1
only,a,weak 1.0 0.000143348623853 0 1 -1
only,a,single 1.0 0.000143348623853 0 1 -1
only,a,limited 1.0 0.000143348623853 0 1 -1
one-thousandth,of,the 1.0 0.000143348623853 0 1 -1
one-third,when,either 1.0 0.000143348623853 0 1 -1
one-third,to,one-half 1.0 0.000143348623853 0 1 -1
one-stage,factor,assays 1.0 0.000143348623853 0 1 -1
one-stage,coagulation,assays 1.0 0.000143348623853 0 1 -1
one-hundredth,of,the 1.0 0.000286697247706 0 2 -2
one-half,the,human 1.0 0.000286697247706 0 2 -2
one-half,depending,on 1.0 0.000143348623853 0 1 -1
one-half,and,prothrombin 1.0 0.000143348623853 0 1 -1
one,with,a 1.0 0.000143348623853 0 1 -1
one,volunteer,reported 1.0 0.000143348623853 0 1 -1
one,treatment,age 1.0 0.000143348623853 0 1 -1
one,treated,at 1.0 0.000143348623853 0 1 -1
one,study,was 1.0 0.000143348623853 0 1 -1
one,study,tentatively 1.0 0.000143348623853 0 1 -1
one,study,of 1.0 0.000143348623853 0 1 -1
one,study,following 1.0 0.000143348623853 0 1 -1
one,study,and 1.0 0.000286697247706 0 2 -2
one,strain,of 1.0 0.000143348623853 0 1 -1
one,should,consider 1.0 0.000143348623853 0 1 -1
one,possible,index 1.0 0.000143348623853 0 1 -1
one,patient,died 1.0 0.000143348623853 0 1 -1
one,or,two 1.0 0.000143348623853 0 1 -1
one,or,more 1.0 0.000860091743119 0 6 -6
one,of,which 1.0 0.000143348623853 0 1 -1
one,ng,ml 1.0 0.000143348623853 0 1 -1
one,must,not 1.0 0.000143348623853 0 1 -1
one,month,at 1.0 0.000143348623853 0 1 -1
one,mg,capsule 1.0 0.000143348623853 0 1 -1
one,mechanism,of 1.0 0.000143348623853 0 1 -1
one,hyperglycaemic,clamps 1.0 0.000143348623853 0 1 -1
one,hour,before 1.0 0.000143348623853 0 1 -1
one,event,in 1.0 0.000143348623853 0 1 -1
one,day,fecal 1.0 0.000143348623853 0 1 -1
one,day,and 1.0 0.000143348623853 0 1 -1
one,controlled,study 1.0 0.000143348623853 0 1 -1
one,contra-indication,overt 1.0 0.000143348623853 0 1 -1
one,at,mg 1.0 0.000143348623853 0 1 -1
one,animal,in 1.0 0.000143348623853 0 1 -1
one,additional,at 1.0 0.000143348623853 0 1 -1
once-monthly,with,daily 1.0 0.000143348623853 0 1 -1
once-daily,dose,was 1.0 0.000143348623853 0 1 -1
once,weekly,or 1.0 0.000143348623853 0 1 -1
once,the,blood 1.0 0.000143348623853 0 1 -1
once,monthly,was 1.0 0.000143348623853 0 1 -1
once,every,hours 1.0 0.000286697247706 0 2 -2
once,daily,with 1.0 0.000143348623853 0 1 -1
once,daily,was 1.0 0.000143348623853 0 1 -1
once,daily,under 1.0 0.000143348623853 0 1 -1
once,daily,or 1.0 0.000143348623853 0 1 -1
once,daily,of 1.0 0.000143348623853 0 1 -1
once,daily,has 1.0 0.000143348623853 0 1 -1
once,daily,had 1.0 0.000143348623853 0 1 -1
once,daily,did 1.0 0.000143348623853 0 1 -1
once,daily,brovana 1.0 0.000143348623853 0 1 -1
once,a,stable 1.0 0.000143348623853 0 1 -1
once,a,day 1.0 0.000143348623853 0 1 -1
on-treatment,additive,toxicity 1.0 0.000143348623853 0 1 -1
on,without,evidence 1.0 0.000143348623853 0 1 -1
on,white,male 1.0 0.000143348623853 0 1 -1
on,weeks,and 1.0 0.000143348623853 0 1 -1
on,voltage-dependent,ca 1.0 0.000143348623853 0 1 -1
on,two,strains 1.0 0.000143348623853 0 1 -1
on,tikosyn,had 1.0 0.000143348623853 0 1 -1
on,those,aspects 1.0 0.000143348623853 0 1 -1
on,this,reported 1.0 0.000143348623853 0 1 -1
on,this,inhibitory 1.0 0.000143348623853 0 1 -1
on,these,pharmacokinetic 1.0 0.000143348623853 0 1 -1
on,these,medications 1.0 0.000143348623853 0 1 -1
on,these,in 1.0 0.000286697247706 0 2 -2
on,these,components 1.0 0.000143348623853 0 1 -1
on,them,are 1.0 0.000143348623853 0 1 -1
on,the,various 1.0 0.000143348623853 0 1 -1
on,the,variability 1.0 0.000143348623853 0 1 -1
on,the,tyrosine 1.0 0.000143348623853 0 1 -1
on,the,translocation 1.0 0.000143348623853 0 1 -1
on,the,traction 1.0 0.000143348623853 0 1 -1
on,the,task 1.0 0.000143348623853 0 1 -1
on,the,subjective 1.0 0.000286697247706 0 2 -2
on,the,steady-state 1.0 0.000860091743119 0 6 -6
on,the,single 1.0 0.000143348623853 0 1 -1
on,the,serum 1.0 0.000286697247706 0 2 -2
on,the,sensitivity 1.0 0.000143348623853 0 1 -1
on,the,sa 1.0 0.000143348623853 0 1 -1
on,the,results 1.0 0.000716743119266 0 5 -5
on,the,response 1.0 0.000143348623853 0 1 -1
on,the,repeat 1.0 0.000143348623853 0 1 -1
on,the,release 1.0 0.000286697247706 0 2 -2
on,the,relation 1.0 0.000143348623853 0 1 -1
on,the,rd 1.0 0.000143348623853 0 1 -1
on,the,rate 1.0 0.000286697247706 0 2 -2
on,the,r-value 1.0 0.000143348623853 0 1 -1
on,the,pt 1.0 0.000143348623853 0 1 -1
on,the,prothrombin 1.0 0.000143348623853 0 1 -1
on,the,protein 1.0 0.000286697247706 0 2 -2
on,the,production 1.0 0.000143348623853 0 1 -1
on,the,potential 1.0 0.000143348623853 0 1 -1
on,the,population 1.0 0.000143348623853 0 1 -1
on,the,pituitary-gonadal 1.0 0.000143348623853 0 1 -1
on,the,pharmacokinetits 1.0 0.000143348623853 0 1 -1
on,the,pharmacodynamics 1.0 0.000573394495413 0 4 -4
on,the,palytoxin-induced 1.0 0.000143348623853 0 1 -1
on,the,order 1.0 0.000143348623853 0 1 -1
on,the,nursing 1.0 0.000143348623853 0 1 -1
on,the,number 1.0 0.000143348623853 0 1 -1
on,the,ninth 1.0 0.000143348623853 0 1 -1
on,the,neuromuscular 1.0 0.000143348623853 0 1 -1
on,the,minor 1.0 0.000143348623853 0 1 -1
on,the,minimum 1.0 0.000143348623853 0 1 -1
on,the,milk 1.0 0.000143348623853 0 1 -1
on,the,microsomal 1.0 0.000143348623853 0 1 -1
on,the,mechanisms 1.0 0.000143348623853 0 1 -1
on,the,mechanism 1.0 0.000143348623853 0 1 -1
on,the,mean 1.0 0.000143348623853 0 1 -1
on,the,maximum 1.0 0.000286697247706 0 2 -2
on,the,management 1.0 0.000143348623853 0 1 -1
on,the,major 1.0 0.000143348623853 0 1 -1
on,the,location 1.0 0.000143348623853 0 1 -1
on,the,literature 1.0 0.000143348623853 0 1 -1
on,the,level 1.0 0.000286697247706 0 2 -2
on,the,last 1.0 0.000143348623853 0 1 -1
on,the,intestinal 1.0 0.000143348623853 0 1 -1
on,the,individual 1.0 0.000143348623853 0 1 -1
on,the,incidence 1.0 0.000143348623853 0 1 -1
on,the,glucosyl 1.0 0.000143348623853 0 1 -1
on,the,fraction 1.0 0.000573394495413 0 4 -4
on,the,fertility 1.0 0.00043004587156 0 3 -3
on,the,extent 1.0 0.000573394495413 0 4 -4
on,the,enhancement 1.0 0.000143348623853 0 1 -1
on,the,electrocardiographic 1.0 0.000143348623853 0 1 -1
on,the,efficacy 1.0 0.000286697247706 0 2 -2
on,the,effect 1.0 0.000716743119266 0 5 -5
on,the,duration 1.0 0.000860091743119 0 6 -6
on,the,dosage 1.0 0.000143348623853 0 1 -1
on,the,distribution 1.0 0.000143348623853 0 1 -1
on,the,dissolution 1.0 0.000143348623853 0 1 -1
on,the,disposition 1.0 0.000286697247706 0 2 -2
on,the,cytochrome 1.0 0.000143348623853 0 1 -1
on,the,concurrent 1.0 0.000143348623853 0 1 -1
on,the,compromised 1.0 0.000143348623853 0 1 -1
on,the,compatibility 1.0 0.000143348623853 0 1 -1
on,the,clinical 1.0 0.000286697247706 0 2 -2
on,the,clearance 1.0 0.000143348623853 0 1 -1
on,the,changes 1.0 0.000143348623853 0 1 -1
on,the,breath 1.0 0.000143348623853 0 1 -1
on,the,blood 1.0 0.000143348623853 0 1 -1
on,the,bioavailability 1.0 0.000286697247706 0 2 -2
on,the,binding 1.0 0.000286697247706 0 2 -2
on,the,average 1.0 0.000143348623853 0 1 -1
on,the,aptt 1.0 0.000286697247706 0 2 -2
on,the,apparent 1.0 0.000143348623853 0 1 -1
on,the,antitumour 1.0 0.000143348623853 0 1 -1
on,the,antinonciceptive 1.0 0.000143348623853 0 1 -1
on,the,anti-platelet 1.0 0.000143348623853 0 1 -1
on,the,anti-coagulant 1.0 0.000143348623853 0 1 -1
on,the,activity 1.0 0.000143348623853 0 1 -1
on,the,absorption 1.0 0.000143348623853 0 1 -1
on,the,above 1.0 0.000286697247706 0 2 -2
on,that,are 1.0 0.000143348623853 0 1 -1
on,target,tissues 1.0 0.000143348623853 0 1 -1
on,stimulated,gastric 1.0 0.000143348623853 0 1 -1
on,steady-state,pharmacokinetics 1.0 0.000143348623853 0 1 -1
on,stable,therapy 1.0 0.000143348623853 0 1 -1
on,specific,patient 1.0 0.000143348623853 0 1 -1
on,some,reports 1.0 0.000143348623853 0 1 -1
on,smooth,muscle 1.0 0.000143348623853 0 1 -1
on,should,have 1.0 0.000143348623853 0 1 -1
on,sensipar,sensipar 1.0 0.000143348623853 0 1 -1
on,safety,or 1.0 0.000143348623853 0 1 -1
on,rewarming,was 1.0 0.000143348623853 0 1 -1
on,responses,and 1.0 0.000143348623853 0 1 -1
on,respiration,and 1.0 0.000143348623853 0 1 -1
on,resistance,arteries 1.0 0.000143348623853 0 1 -1
on,repeated,challenge 1.0 0.000143348623853 0 1 -1
on,renal,and 1.0 0.000143348623853 0 1 -1
on,recovery,and 1.0 0.000143348623853 0 1 -1
on,qtc,intervals 1.0 0.000143348623853 0 1 -1
on,prothrombin,time 1.0 0.00043004587156 0 3 -3
on,protein,binding 1.0 0.000143348623853 0 1 -1
on,previous,experience 1.0 0.000143348623853 0 1 -1
on,pregnancy,and 1.0 0.000143348623853 0 1 -1
on,precautions,and 1.0 0.000143348623853 0 1 -1
on,potential,interactions 1.0 0.000143348623853 0 1 -1
on,plasma,levels 1.0 0.000286697247706 0 2 -2
on,plasma,concentrations 1.0 0.00100344036697 0 7 -7
on,plasma,concentration 1.0 0.000143348623853 0 1 -1
on,placental,vessels 1.0 0.000143348623853 0 1 -1
on,placebo,and 1.0 0.000143348623853 0 1 -1
on,phosphate,transport 1.0 0.00043004587156 0 3 -3
on,pharmacokinetics,of 1.0 0.000143348623853 0 1 -1
on,pharmacokinetics,in 1.0 0.000143348623853 0 1 -1
on,pharmacokinetics,if 1.0 0.000143348623853 0 1 -1
on,pharmacokinetics,have 1.0 0.000143348623853 0 1 -1
on,pharmacokinetics,and 1.0 0.000143348623853 0 1 -1
on,performance,of 1.0 0.000143348623853 0 1 -1
on,pentagastrin-,and 1.0 0.000143348623853 0 1 -1
on,patients,with 1.0 0.000286697247706 0 2 -2
on,patient,survival 1.0 0.000143348623853 0 1 -1
on,p450,enzymes 1.0 0.000143348623853 0 1 -1
on,over,of 1.0 0.000143348623853 0 1 -1
on,other,progestational 1.0 0.000143348623853 0 1 -1
on,other,drugs 1.0 0.000286697247706 0 2 -2
on,other,components 1.0 0.000143348623853 0 1 -1
on,other,antiepilepsy 1.0 0.000143348623853 0 1 -1
on,oral,were 1.0 0.000143348623853 0 1 -1
on,or,before 1.0 0.000143348623853 0 1 -1
on,multiple,occupational 1.0 0.000143348623853 0 1 -1
on,monotherapy,for 1.0 0.000143348623853 0 1 -1
on,monoamine,oxidases 1.0 0.000143348623853 0 1 -1
on,milk,ejection 1.0 0.000143348623853 0 1 -1
on,microtubules,in 1.0 0.000143348623853 0 1 -1
on,mhd,concentration 1.0 0.000143348623853 0 1 -1
on,metabolism,or 1.0 0.000286697247706 0 2 -2
on,metabolism,by 1.0 0.000143348623853 0 1 -1
on,metabolic,interactions 1.0 0.000143348623853 0 1 -1
on,metabolic,effects 1.0 0.000143348623853 0 1 -1
on,measures,of 1.0 0.000143348623853 0 1 -1
on,mean,aucs 1.0 0.000143348623853 0 1 -1
on,male,fertility 1.0 0.000286697247706 0 2 -2
on,low-dose,combination 1.0 0.000143348623853 0 1 -1
on,known,metabolic 1.0 0.000143348623853 0 1 -1
on,its,rate 1.0 0.000143348623853 0 1 -1
on,investigation,of 1.0 0.000143348623853 0 1 -1
on,intestinal,first 1.0 0.000143348623853 0 1 -1
on,interactions,with 1.0 0.000143348623853 0 1 -1
on,intact,liver 1.0 0.000143348623853 0 1 -1
on,insulins,ability 1.0 0.000143348623853 0 1 -1
on,inositol,trisphosphate-induced 1.0 0.000143348623853 0 1 -1
on,inositol,trisphosphate 1.0 0.000143348623853 0 1 -1
on,in-vitro,studies 1.0 0.000143348623853 0 1 -1
on,immunosuppression,are 1.0 0.000143348623853 0 1 -1
on,immune,system 1.0 0.000143348623853 0 1 -1
on,how,age 1.0 0.000143348623853 0 1 -1
on,hormone,therapy 1.0 0.000143348623853 0 1 -1
on,hormone,synthesis 1.0 0.000143348623853 0 1 -1
on,hormonal,contraception 1.0 0.000143348623853 0 1 -1
on,high,threshold 1.0 0.000143348623853 0 1 -1
on,hepatic,transaminases 1.0 0.000143348623853 0 1 -1
on,hepatic,cytochrome 1.0 0.000143348623853 0 1 -1
on,guinea,pig 1.0 0.000143348623853 0 1 -1
on,glycosides,may 1.0 0.000143348623853 0 1 -1
on,glycemic,control 1.0 0.000143348623853 0 1 -1
on,glycemia,in 1.0 0.000143348623853 0 1 -1
on,glucose,tolerance 1.0 0.000143348623853 0 1 -1
on,glucocorticoid-induced,gene 1.0 0.000143348623853 0 1 -1
on,gastric,hydrochloric 1.0 0.000143348623853 0 1 -1
on,furosemide-stimulated,diuresis 1.0 0.000143348623853 0 1 -1
on,fetal,development 1.0 0.000143348623853 0 1 -1
on,fertility,were 1.0 0.000143348623853 0 1 -1
on,female,fertility 1.0 0.000143348623853 0 1 -1
on,felbatol,the 1.0 0.000286697247706 0 2 -2
on,exposure,to 1.0 0.000286697247706 0 2 -2
on,exjade,pharmacokinetics 1.0 0.000143348623853 0 1 -1
on,excystment,rates 1.0 0.000143348623853 0 1 -1
on,evoked,potentials 1.0 0.000143348623853 0 1 -1
on,enzymatic,glucose 1.0 0.000860091743119 0 6 -6
on,endotoxin-induced,changes 1.0 0.000143348623853 0 1 -1
on,endometrial,ovarian 1.0 0.000143348623853 0 1 -1
on,embryo,fetal 1.0 0.000143348623853 0 1 -1
on,either,the 1.0 0.000860091743119 0 6 -6
on,either,s 1.0 0.000143348623853 0 1 -1
on,either,levels 1.0 0.000143348623853 0 1 -1
on,either,interaction 1.0 0.000143348623853 0 1 -1
on,efficacy,and 1.0 0.000143348623853 0 1 -1
on,ecg,taken 1.0 0.000143348623853 0 1 -1
on,drug,metabolizing 1.0 0.000143348623853 0 1 -1
on,drug,interaction 1.0 0.000143348623853 0 1 -1
on,dopamine2-,and 1.0 0.000143348623853 0 1 -1
on,dogs,with 1.0 0.000143348623853 0 1 -1
on,discrimination,and 1.0 0.000143348623853 0 1 -1
on,different,days 1.0 0.000143348623853 0 1 -1
on,diastolic,or 1.0 0.000143348623853 0 1 -1
on,developing,mathematical 1.0 0.000143348623853 0 1 -1
on,day,was 1.0 0.000143348623853 0 1 -1
on,day,each 1.0 0.000143348623853 0 1 -1
on,day,as 1.0 0.000143348623853 0 1 -1
on,cyp450,isoenzymes 1.0 0.000143348623853 0 1 -1
on,cyp1a2,was 1.0 0.000143348623853 0 1 -1
on,cyp1a2,a6 1.0 0.000143348623853 0 1 -1
on,cyp,a4 1.0 0.000143348623853 0 1 -1
on,cycle,duration 1.0 0.000143348623853 0 1 -1
on,cure,rates 1.0 0.000143348623853 0 1 -1
on,cooling,the 1.0 0.000143348623853 0 1 -1
on,concurrent,usage 1.0 0.000143348623853 0 1 -1
on,concomitant,use 1.0 0.000143348623853 0 1 -1
on,concomitant,compared 1.0 0.000143348623853 0 1 -1
on,concomitant,administration 1.0 0.00043004587156 0 3 -3
on,concentration,of 1.0 0.000143348623853 0 1 -1
on,combination,therapy 1.0 0.000143348623853 0 1 -1
on,clonidines,analgesic 1.0 0.000143348623853 0 1 -1
on,clinical,evaluation 1.0 0.000143348623853 0 1 -1
on,clinical,acumen 1.0 0.000143348623853 0 1 -1
on,clearance,this 1.0 0.000143348623853 0 1 -1
on,clearance,or 1.0 0.000143348623853 0 1 -1
on,clearance,has 1.0 0.000143348623853 0 1 -1
on,circulating,levels 1.0 0.000143348623853 0 1 -1
on,certain,brain 1.0 0.000143348623853 0 1 -1
on,bsa,when 1.0 0.000286697247706 0 2 -2
on,bsa,increases 1.0 0.000143348623853 0 1 -1
on,bsa,during 1.0 0.000143348623853 0 1 -1
on,bsa,and 1.0 0.000143348623853 0 1 -1
on,both,chylomicron 1.0 0.000143348623853 0 1 -1
on,bone,loss 1.0 0.000286697247706 0 2 -2
on,body,weight 1.0 0.000143348623853 0 1 -1
on,body,surface 1.0 0.000286697247706 0 2 -2
on,blood,coagulation 1.0 0.000286697247706 0 2 -2
on,blocking,the 1.0 0.000143348623853 0 1 -1
on,bleeding,time 1.0 0.000143348623853 0 1 -1
on,bioavailability,auc 1.0 0.000143348623853 0 1 -1
on,bar-press,behavior 1.0 0.000143348623853 0 1 -1
on,average,higher 1.0 0.000143348623853 0 1 -1
on,auc,and 1.0 0.000143348623853 0 1 -1
on,aspects,of 1.0 0.000143348623853 0 1 -1
on,arteries,from 1.0 0.000143348623853 0 1 -1
on,application,mode 1.0 0.000143348623853 0 1 -1
on,any,cyp 1.0 0.000143348623853 0 1 -1
on,antinociceptive,effect 1.0 0.000143348623853 0 1 -1
on,and,transport 1.0 0.000143348623853 0 1 -1
on,an,oral 1.0 0.000143348623853 0 1 -1
on,an,individual 1.0 0.000143348623853 0 1 -1
on,an,empty 1.0 0.000143348623853 0 1 -1
on,alone,or 1.0 0.000143348623853 0 1 -1
on,all,patients 1.0 0.000143348623853 0 1 -1
on,aliskiren,based 1.0 0.000143348623853 0 1 -1
on,aed,concentration 1.0 0.000143348623853 0 1 -1
on,acth,induced 1.0 0.000143348623853 0 1 -1
on,accutane,therapy 1.0 0.000143348623853 0 1 -1
on,absorption,has 1.0 0.000143348623853 0 1 -1
on,absorption,from 1.0 0.000143348623853 0 1 -1
on,absorption,and 1.0 0.000143348623853 0 1 -1
on,a,with 1.0 0.000143348623853 0 1 -1
on,a,variety 1.0 0.000143348623853 0 1 -1
on,a,regular 1.0 0.000143348623853 0 1 -1
on,a,patient 1.0 0.000143348623853 0 1 -1
on,a,given 1.0 0.000716743119266 0 5 -5
on,a,body 1.0 0.000143348623853 0 1 -1
on,a,are 1.0 0.000286697247706 0 2 -2
omniscan,interferes,with 1.0 0.000143348623853 0 1 -1
omnicef,for,oral 1.0 0.000143348623853 0 1 -1
omeprazole,the,rate 1.0 0.000143348623853 0 1 -1
omeprazole,should,be 1.0 0.000143348623853 0 1 -1
omeprazole,omeprazole,is 1.0 0.000143348623853 0 1 -1
omeprazole,no,clinically 1.0 0.000143348623853 0 1 -1
omeprazole,is,a 1.0 0.000143348623853 0 1 -1
omega-conotoxin,gvia-sensitive,n-type 1.0 0.000143348623853 0 1 -1
omega-conotoxin,gvia,omega-agatoxin 1.0 0.000143348623853 0 1 -1
omega-conotoxin,gvia,n-type 1.0 0.000143348623853 0 1 -1
omega-agatoxin,via-resistant,presumptive 1.0 0.000143348623853 0 1 -1
omega-agatoxin,iva-sensitive,p-type 1.0 0.000143348623853 0 1 -1
omega-agatoxin,iva,p-type 1.0 0.000143348623853 0 1 -1
oliguria,tachycardia,and 1.0 0.000143348623853 0 1 -1
oligomer,significantly,potentiated 1.0 0.000143348623853 0 1 -1
oleate,and,increased 1.0 0.000143348623853 0 1 -1
oleate,and,h-triolein 1.0 0.000143348623853 0 1 -1
older,who,were 1.0 0.000143348623853 0 1 -1
older,patients,some 1.0 0.000143348623853 0 1 -1
older,men,who 1.0 0.000143348623853 0 1 -1
older,ask,your 1.0 0.000143348623853 0 1 -1
older,and,younger 1.0 0.000143348623853 0 1 -1
older,adults,to 1.0 0.000143348623853 0 1 -1
old,participated,in 1.0 0.000143348623853 0 1 -1
olanzapine,treatment,improves 1.0 0.000143348623853 0 1 -1
olanzapine,is,associated 1.0 0.000143348623853 0 1 -1
olanzapine,demonstrated,superior 1.0 0.000143348623853 0 1 -1
olanzapine,an,updated 1.0 0.000143348623853 0 1 -1
olanzapine,a,thienobenzodiazepine 1.0 0.000143348623853 0 1 -1
ointments,or,oils 1.0 0.000143348623853 0 1 -1
oil,ml,kg 1.0 0.000143348623853 0 1 -1
oil,ml,day 1.0 0.000143348623853 0 1 -1
oi,rates,and 1.0 0.000143348623853 0 1 -1
oh,metabolite,concentrations 1.0 0.000143348623853 0 1 -1
oh,d3,the 1.0 0.000143348623853 0 1 -1
oh,d3,exhibit 1.0 0.000143348623853 0 1 -1
often,used,in 1.0 0.000143348623853 0 1 -1
often,applied,to 1.0 0.000143348623853 0 1 -1
often,appear,in 1.0 0.000143348623853 0 1 -1
often,administered,concurrently 1.0 0.000143348623853 0 1 -1
offset,by,reductions 1.0 0.000143348623853 0 1 -1
offers,advantages,in 1.0 0.000143348623853 0 1 -1
offered,by,this 1.0 0.000143348623853 0 1 -1
offer,patients,optimal 1.0 0.000143348623853 0 1 -1
off,medications,varied 1.0 0.000143348623853 0 1 -1
off,before,a 1.0 0.000143348623853 0 1 -1
of,zmax,have 1.0 0.000143348623853 0 1 -1
of,zinecard,on 1.0 0.000143348623853 0 1 -1
of,zebeta,on 1.0 0.000143348623853 0 1 -1
of,your,skin 1.0 0.000143348623853 0 1 -1
of,young,healthy 1.0 0.000143348623853 0 1 -1
of,years,have 1.0 0.000143348623853 0 1 -1
of,xigris,have 1.0 0.000143348623853 0 1 -1
of,xanthine,derivatives 1.0 0.000143348623853 0 1 -1
of,would,permit 1.0 0.000143348623853 0 1 -1
of,worsened,glucose 1.0 0.000143348623853 0 1 -1
of,women,who 1.0 0.000143348623853 0 1 -1
of,within,the 1.0 0.000143348623853 0 1 -1
of,withdrawal,symptoms 1.0 0.000143348623853 0 1 -1
of,withdrawal,of 1.0 0.000143348623853 0 1 -1
of,with,various 1.0 0.000143348623853 0 1 -1
of,with,these 1.0 0.000573394495413 0 4 -4
of,with,resulted 1.0 0.000143348623853 0 1 -1
of,with,radiotherapy 1.0 0.000143348623853 0 1 -1
of,with,primarily 1.0 0.000143348623853 0 1 -1
of,with,potent 1.0 0.000143348623853 0 1 -1
of,with,mhd 1.0 0.000143348623853 0 1 -1
of,with,known 1.0 0.000143348623853 0 1 -1
of,with,its 1.0 0.000143348623853 0 1 -1
of,with,inhibitors 1.0 0.000143348623853 0 1 -1
of,with,increases 1.0 0.000143348623853 0 1 -1
of,with,grapefruit 1.0 0.000143348623853 0 1 -1
of,with,either 1.0 0.000143348623853 0 1 -1
of,with,each 1.0 0.000143348623853 0 1 -1
of,with,doses 1.0 0.000286697247706 0 2 -2
of,with,did 1.0 0.000143348623853 0 1 -1
of,with,blood 1.0 0.000143348623853 0 1 -1
of,with,any 1.0 0.000143348623853 0 1 -1
of,with,and 1.0 0.000143348623853 0 1 -1
of,with,adefovir 1.0 0.000143348623853 0 1 -1
of,whom,died 1.0 0.000143348623853 0 1 -1
of,while,the 1.0 0.000143348623853 0 1 -1
of,while,minimizing 1.0 0.000143348623853 0 1 -1
of,which,required 1.0 0.000143348623853 0 1 -1
of,which,must 1.0 0.000143348623853 0 1 -1
of,which,is 1.0 0.000143348623853 0 1 -1
of,which,also 1.0 0.000143348623853 0 1 -1
of,whether,is 1.0 0.000143348623853 0 1 -1
of,when,coadministered 1.0 0.000143348623853 0 1 -1
of,when,co-administered 1.0 0.000143348623853 0 1 -1
of,when,any 1.0 0.000143348623853 0 1 -1
of,wheal,and 1.0 0.000143348623853 0 1 -1
of,what,modern 1.0 0.000143348623853 0 1 -1
of,were,unchanged 1.0 0.000143348623853 0 1 -1
of,were,unaffected 1.0 0.000143348623853 0 1 -1
of,were,on 1.0 0.000143348623853 0 1 -1
of,were,observed 1.0 0.000143348623853 0 1 -1
of,were,noted 1.0 0.000143348623853 0 1 -1
of,were,not 1.0 0.000860091743119 0 6 -6
of,were,more 1.0 0.000143348623853 0 1 -1
of,were,increased 1.0 0.000143348623853 0 1 -1
of,were,generated 1.0 0.000143348623853 0 1 -1
of,were,below 1.0 0.000143348623853 0 1 -1
of,were,also 1.0 0.000286697247706 0 2 -2
of,wellbutrin,on 1.0 0.000143348623853 0 1 -1
of,wellbutrin,following 1.0 0.000143348623853 0 1 -1
of,welchol,with 1.0 0.000143348623853 0 1 -1
of,water,for 1.0 0.000143348623853 0 1 -1
of,was,variably 1.0 0.000143348623853 0 1 -1
of,was,studied 1.0 0.000286697247706 0 2 -2
of,was,prepared 1.0 0.000143348623853 0 1 -1
of,was,not 1.0 0.000716743119266 0 5 -5
of,was,investigated 1.0 0.000143348623853 0 1 -1
of,was,given 1.0 0.000143348623853 0 1 -1
of,was,generally 1.0 0.000143348623853 0 1 -1
of,was,found 1.0 0.000143348623853 0 1 -1
of,was,evaluated 1.0 0.000286697247706 0 2 -2
of,was,coadministered 1.0 0.000143348623853 0 1 -1
of,was,bioequivalent 1.0 0.000143348623853 0 1 -1
of,was,associated 1.0 0.000143348623853 0 1 -1
of,warfarin-type,cyp2c9 1.0 0.000143348623853 0 1 -1
of,walking,without 1.0 0.000143348623853 0 1 -1
of,voltage-dependent,ca 1.0 0.000143348623853 0 1 -1
of,vitamin-d,mediated 1.0 0.000143348623853 0 1 -1
of,vitamin,c 1.0 0.000143348623853 0 1 -1
of,visual,analogue 1.0 0.000143348623853 0 1 -1
of,virologic,response 1.0 0.00043004587156 0 3 -3
of,viracept,and 1.0 0.00043004587156 0 3 -3
of,vioxx,should 1.0 0.000143348623853 0 1 -1
of,vioxx,and 1.0 0.000143348623853 0 1 -1
of,videx,with 1.0 0.000143348623853 0 1 -1
of,vehicle,corn 1.0 0.000143348623853 0 1 -1
of,vasopressor,and 1.0 0.000143348623853 0 1 -1
of,vasodilator,and 1.0 0.000143348623853 0 1 -1
of,vasoconstrictor,thromboxane 1.0 0.000143348623853 0 1 -1
of,various,pesticides 1.0 0.000143348623853 0 1 -1
of,various,doses 1.0 0.000143348623853 0 1 -1
of,variability,in 1.0 0.000143348623853 0 1 -1
of,vardenafil,when 1.0 0.000143348623853 0 1 -1
of,using,stadol 1.0 0.000143348623853 0 1 -1
of,using,pcp 1.0 0.000143348623853 0 1 -1
of,using,in 1.0 0.000143348623853 0 1 -1
of,using,clozapine 1.0 0.000143348623853 0 1 -1
of,using,anafranil 1.0 0.000143348623853 0 1 -1
of,used,to 1.0 0.000860091743119 0 6 -6
of,used,in 1.0 0.000143348623853 0 1 -1
of,use,in 1.0 0.000143348623853 0 1 -1
of,use,for 1.0 0.000143348623853 0 1 -1
of,use,at 1.0 0.000143348623853 0 1 -1
of,urinary,metanephrine 1.0 0.000143348623853 0 1 -1
of,urinary,hydroxy-corticosteroids 1.0 0.000143348623853 0 1 -1
of,urinary,catecholamine 1.0 0.000143348623853 0 1 -1
of,uptake-1,was 1.0 0.000143348623853 0 1 -1
of,uptake-1,in 1.0 0.000143348623853 0 1 -1
of,uptake,sites 1.0 0.000143348623853 0 1 -1
of,uptake,blocking 1.0 0.000143348623853 0 1 -1
of,upon,the 1.0 0.000143348623853 0 1 -1
of,upon,chylomicron 1.0 0.000143348623853 0 1 -1
of,up,to 1.0 0.000286697247706 0 2 -2
of,unprotected,sexual 1.0 0.000143348623853 0 1 -1
of,unchanged,and 1.0 0.000143348623853 0 1 -1
of,unchanged,accounts 1.0 0.000143348623853 0 1 -1
of,uncertain,mechanism 1.0 0.000143348623853 0 1 -1
of,unbound,was 1.0 0.000143348623853 0 1 -1
of,unbound,to 1.0 0.000143348623853 0 1 -1
of,um,toward 1.0 0.000143348623853 0 1 -1
of,udp-glucuronyl,transferase 1.0 0.000143348623853 0 1 -1
of,ucb,l057 1.0 0.000143348623853 0 1 -1
of,u,of 1.0 0.000143348623853 0 1 -1
of,tyrosine,phosphorylation 1.0 0.000143348623853 0 1 -1
of,type,diabetics 1.0 0.000143348623853 0 1 -1
of,two,reverse 1.0 0.000143348623853 0 1 -1
of,two,of 1.0 0.000143348623853 0 1 -1
of,two,mg 1.0 0.000286697247706 0 2 -2
of,two,consecutive 1.0 0.000143348623853 0 1 -1
of,twice,daily 1.0 0.000143348623853 0 1 -1
of,tumors,by 1.0 0.000143348623853 0 1 -1
of,tumor,versus 1.0 0.000143348623853 0 1 -1
of,trypanosomiasis,uganda 1.0 0.000143348623853 0 1 -1
of,trimethyl,lead 1.0 0.000143348623853 0 1 -1
of,trileptal,on 1.0 0.000143348623853 0 1 -1
of,tricyclic,with 1.0 0.000143348623853 0 1 -1
of,tricyclic,tcas 1.0 0.000143348623853 0 1 -1
of,tricyclic,antidepressant 1.0 0.000143348623853 0 1 -1
of,treatments,given 1.0 0.000143348623853 0 1 -1
of,treatment,should 1.0 0.000143348623853 0 1 -1
of,treatment,measures 1.0 0.000143348623853 0 1 -1
of,treatment,did 1.0 0.000143348623853 0 1 -1
of,treatment,and 1.0 0.000143348623853 0 1 -1
of,transient,thrombocytopenia 1.0 0.000143348623853 0 1 -1
of,toxicity,resulting 1.0 0.000143348623853 0 1 -1
of,toxic,reactions 1.0 0.000143348623853 0 1 -1
of,toxic,neurological 1.0 0.000143348623853 0 1 -1
of,toxic,action 1.0 0.000143348623853 0 1 -1
of,total,rna 1.0 0.000143348623853 0 1 -1
of,total,glutathione 1.0 0.000143348623853 0 1 -1
of,total,cholesterol 1.0 0.000143348623853 0 1 -1
of,toradol,with 1.0 0.000143348623853 0 1 -1
of,topoisomerases,is 1.0 0.000143348623853 0 1 -1
of,topoisomerases,in 1.0 0.000143348623853 0 1 -1
of,tolerance,min 1.0 0.000143348623853 0 1 -1
of,to,volunteers 1.0 0.000143348623853 0 1 -1
of,to,the 1.0 0.000286697247706 0 2 -2
of,to,regimens 1.0 0.000143348623853 0 1 -1
of,to,modify 1.0 0.000143348623853 0 1 -1
of,to,less 1.0 0.000143348623853 0 1 -1
of,to,its 1.0 0.000286697247706 0 2 -2
of,to,inhibit 1.0 0.000143348623853 0 1 -1
of,to,healthy 1.0 0.000286697247706 0 2 -2
of,to,existing 1.0 0.000143348623853 0 1 -1
of,to,desbutyl 1.0 0.000143348623853 0 1 -1
of,to,bovine 1.0 0.000143348623853 0 1 -1
of,to,be 1.0 0.000143348623853 0 1 -1
of,to,alleviate 1.0 0.000143348623853 0 1 -1
of,tmp,smx 1.0 0.000143348623853 0 1 -1
of,tmp,and 1.0 0.000143348623853 0 1 -1
of,tml,manifested 1.0 0.000143348623853 0 1 -1
of,time,may 1.0 0.000143348623853 0 1 -1
of,time,it 1.0 0.000143348623853 0 1 -1
of,time,concomitant 1.0 0.000143348623853 0 1 -1
of,three,lines 1.0 0.000143348623853 0 1 -1
of,those,receiving 1.0 0.000143348623853 0 1 -1
of,those,in 1.0 0.000286697247706 0 2 -2
of,this,toxicity 1.0 0.000143348623853 0 1 -1
of,this,the 1.0 0.000143348623853 0 1 -1
of,this,study 1.0 0.000716743119266 0 5 -5
of,this,specificity 1.0 0.000143348623853 0 1 -1
of,this,sequence 1.0 0.000286697247706 0 2 -2
of,this,review 1.0 0.000143348623853 0 1 -1
of,this,property 1.0 0.000143348623853 0 1 -1
of,this,product 1.0 0.000143348623853 0 1 -1
of,this,possibility 1.0 0.000143348623853 0 1 -1
of,this,pharmacodynamic 1.0 0.000143348623853 0 1 -1
of,this,patients 1.0 0.000143348623853 0 1 -1
of,this,particular 1.0 0.000143348623853 0 1 -1
of,this,paper 1.0 0.000143348623853 0 1 -1
of,this,oral 1.0 0.000143348623853 0 1 -1
of,this,observation 1.0 0.000143348623853 0 1 -1
of,this,medication 1.0 0.000143348623853 0 1 -1
of,this,isozyme 1.0 0.000860091743119 0 6 -6
of,this,interaction 1.0 0.00129013761468 0 9 -9
of,this,increased 1.0 0.000143348623853 0 1 -1
of,this,increase 1.0 0.000143348623853 0 1 -1
of,this,in 1.0 0.000143348623853 0 1 -1
of,this,finding 1.0 0.00100344036697 0 7 -7
of,this,drug 1.0 0.000143348623853 0 1 -1
of,this,difference 1.0 0.000143348623853 0 1 -1
of,this,class 1.0 0.000143348623853 0 1 -1
of,this,being 1.0 0.000143348623853 0 1 -1
of,this,agent 1.0 0.000143348623853 0 1 -1
of,this,acid-catalyzed 1.0 0.000143348623853 0 1 -1
of,thioethers,in 1.0 0.000143348623853 0 1 -1
of,thiobarbituric,acid 1.0 0.000143348623853 0 1 -1
of,thio,compounds 1.0 0.000143348623853 0 1 -1
of,these,with 1.0 0.000143348623853 0 1 -1
of,these,trace 1.0 0.000143348623853 0 1 -1
of,these,supplements 1.0 0.000143348623853 0 1 -1
of,these,studies 1.0 0.000286697247706 0 2 -2
of,these,strategies 1.0 0.000143348623853 0 1 -1
of,these,results 1.0 0.000143348623853 0 1 -1
of,these,reports 1.0 0.000286697247706 0 2 -2
of,these,peptides 1.0 0.000143348623853 0 1 -1
of,these,other 1.0 0.000573394495413 0 4 -4
of,these,or 1.0 0.000286697247706 0 2 -2
of,these,on 1.0 0.000143348623853 0 1 -1
of,these,observations 1.0 0.000286697247706 0 2 -2
of,these,medications 1.0 0.000143348623853 0 1 -1
of,these,isoenzymes 1.0 0.000143348623853 0 1 -1
of,these,interactions 1.0 0.000573394495413 0 4 -4
of,these,inhibiting 1.0 0.000716743119266 0 5 -5
of,these,increases 1.0 0.000143348623853 0 1 -1
of,these,increased 1.0 0.000143348623853 0 1 -1
of,these,in 1.0 0.00043004587156 0 3 -3
of,these,if 1.0 0.000143348623853 0 1 -1
of,these,functions 1.0 0.000143348623853 0 1 -1
of,these,events 1.0 0.000286697247706 0 2 -2
of,these,enzymes 1.0 0.00043004587156 0 3 -3
of,these,drugs 1.0 0.000143348623853 0 1 -1
of,these,differences 1.0 0.000143348623853 0 1 -1
of,these,compounds 1.0 0.000143348623853 0 1 -1
of,these,changes 1.0 0.000286697247706 0 2 -2
of,these,cases 1.0 0.000286697247706 0 2 -2
of,these,case 1.0 0.000143348623853 0 1 -1
of,these,birth 1.0 0.000143348623853 0 1 -1
of,these,are 1.0 0.000143348623853 0 1 -1
of,these,and 1.0 0.00043004587156 0 3 -3
of,these,also 1.0 0.000143348623853 0 1 -1
of,there,are 1.0 0.000143348623853 0 1 -1
of,therapy,which 1.0 0.000143348623853 0 1 -1
of,therapy,the 1.0 0.000143348623853 0 1 -1
of,therapy,allow 1.0 0.000143348623853 0 1 -1
of,therapeutic,to 1.0 0.000286697247706 0 2 -2
of,therapeutic,response 1.0 0.000143348623853 0 1 -1
of,therapeutic,doses 1.0 0.000143348623853 0 1 -1
of,therapeutic,concentrations 1.0 0.000143348623853 0 1 -1
of,theophylline,mg 1.0 0.000143348623853 0 1 -1
of,their,antiseizure 1.0 0.000143348623853 0 1 -1
of,the,west 1.0 0.000143348623853 0 1 -1
of,the,week 1.0 0.000143348623853 0 1 -1
of,the,washout 1.0 0.000143348623853 0 1 -1
of,the,volume 1.0 0.000143348623853 0 1 -1
of,the,vitamin 1.0 0.00043004587156 0 3 -3
of,the,variability 1.0 0.000143348623853 0 1 -1
of,the,use 1.0 0.000286697247706 0 2 -2
of,the,urinary 1.0 0.000286697247706 0 2 -2
of,the,ultimate 1.0 0.000143348623853 0 1 -1
of,the,tysabri 1.0 0.000143348623853 0 1 -1
of,the,treatments 1.0 0.000143348623853 0 1 -1
of,the,toxic 1.0 0.000143348623853 0 1 -1
of,the,to 1.0 0.000286697247706 0 2 -2
of,the,three 1.0 0.000143348623853 0 1 -1
of,the,thioether 1.0 0.000143348623853 0 1 -1
of,the,th 1.0 0.000143348623853 0 1 -1
of,the,template 1.0 0.000143348623853 0 1 -1
of,the,target 1.0 0.000143348623853 0 1 -1
of,the,sympathetic 1.0 0.000143348623853 0 1 -1
of,the,substrate 1.0 0.000143348623853 0 1 -1
of,the,substances 1.0 0.000143348623853 0 1 -1
of,the,study 1.0 0.000286697247706 0 2 -2
of,the,store 1.0 0.000143348623853 0 1 -1
of,the,stereoisomers 1.0 0.000143348623853 0 1 -1
of,the,stable 1.0 0.000143348623853 0 1 -1
of,the,sst 1.0 0.000143348623853 0 1 -1
of,the,spleen 1.0 0.000286697247706 0 2 -2
of,the,spinal 1.0 0.000143348623853 0 1 -1
of,the,specific 1.0 0.000143348623853 0 1 -1
of,the,side 1.0 0.000286697247706 0 2 -2
of,the,short-acting 1.0 0.000143348623853 0 1 -1
of,the,serotype 1.0 0.000143348623853 0 1 -1
of,the,same 1.0 0.000286697247706 0 2 -2
of,the,righting 1.0 0.000143348623853 0 1 -1
of,the,reservoir 1.0 0.000143348623853 0 1 -1
of,the,reported 1.0 0.000143348623853 0 1 -1
of,the,remaining 1.0 0.000143348623853 0 1 -1
of,the,reduction 1.0 0.000143348623853 0 1 -1
of,the,q-t 1.0 0.000143348623853 0 1 -1
of,the,problems 1.0 0.000143348623853 0 1 -1
of,the,principles 1.0 0.000143348623853 0 1 -1
of,the,primary 1.0 0.000143348623853 0 1 -1
of,the,prevalence 1.0 0.000716743119266 0 5 -5
of,the,presence 1.0 0.000143348623853 0 1 -1
of,the,population 1.0 0.000286697247706 0 2 -2
of,the,polymer 1.0 0.000143348623853 0 1 -1
of,the,physiological 1.0 0.000143348623853 0 1 -1
of,the,pharmacological 1.0 0.000143348623853 0 1 -1
of,the,pharmacokinetics 1.0 0.000573394495413 0 4 -4
of,the,pharmacodynamic 1.0 0.000143348623853 0 1 -1
of,the,pesticide 1.0 0.000286697247706 0 2 -2
of,the,period 1.0 0.000143348623853 0 1 -1
of,the,perfused 1.0 0.000143348623853 0 1 -1
of,the,pelvic 1.0 0.000143348623853 0 1 -1
of,the,patients 1.0 0.000716743119266 0 5 -5
of,the,pathogenic 1.0 0.000143348623853 0 1 -1
of,the,other 1.0 0.000716743119266 0 5 -5
of,the,original 1.0 0.000143348623853 0 1 -1
of,the,odontoid 1.0 0.000143348623853 0 1 -1
of,the,octapeptide 1.0 0.000143348623853 0 1 -1
of,the,observed 1.0 0.000143348623853 0 1 -1
of,the,nueronal 1.0 0.000143348623853 0 1 -1
of,the,not 1.0 0.000143348623853 0 1 -1
of,the,normal 1.0 0.000286697247706 0 2 -2
of,the,new 1.0 0.000143348623853 0 1 -1
of,the,nephrotoxicity 1.0 0.000143348623853 0 1 -1
of,the,mucocutaneous 1.0 0.000143348623853 0 1 -1
of,the,mouse 1.0 0.000143348623853 0 1 -1
of,the,microtubules 1.0 0.000143348623853 0 1 -1
of,the,metabolizing 1.0 0.000573394495413 0 4 -4
of,the,metabolite 1.0 0.000143348623853 0 1 -1
of,the,mentioned 1.0 0.000143348623853 0 1 -1
of,the,menstrual 1.0 0.000143348623853 0 1 -1
of,the,medicines 1.0 0.000143348623853 0 1 -1
of,the,maximal 1.0 0.000143348623853 0 1 -1
of,the,mammary 1.0 0.000286697247706 0 2 -2
of,the,lymphoid 1.0 0.000143348623853 0 1 -1
of,the,luteinizing 1.0 0.000143348623853 0 1 -1
of,the,low 1.0 0.000143348623853 0 1 -1
of,the,long 1.0 0.000143348623853 0 1 -1
of,the,liver 1.0 0.00043004587156 0 3 -3
of,the,limbic 1.0 0.000143348623853 0 1 -1
of,the,level 1.0 0.000286697247706 0 2 -2
of,the,is 1.0 0.00043004587156 0 3 -3
of,the,interaction 1.0 0.000573394495413 0 4 -4
of,the,injection 1.0 0.000143348623853 0 1 -1
of,the,inhibitory 1.0 0.000143348623853 0 1 -1
of,the,influence 1.0 0.000143348623853 0 1 -1
of,the,increase 1.0 0.000286697247706 0 2 -2
of,the,in 1.0 0.000573394495413 0 4 -4
of,the,immunodepressant--the 1.0 0.000143348623853 0 1 -1
of,the,iatrogenic 1.0 0.000143348623853 0 1 -1
of,the,hydroxylation 1.0 0.000143348623853 0 1 -1
of,the,hydrophilic 1.0 0.000143348623853 0 1 -1
of,the,human 1.0 0.000716743119266 0 5 -5
of,the,hplc 1.0 0.000143348623853 0 1 -1
of,the,horses 1.0 0.000143348623853 0 1 -1
of,the,homocysteine 1.0 0.000143348623853 0 1 -1
of,the,history 1.0 0.000143348623853 0 1 -1
of,the,hind 1.0 0.000143348623853 0 1 -1
of,the,higher 1.0 0.000143348623853 0 1 -1
of,the,hepatic 1.0 0.000143348623853 0 1 -1
of,the,glucocorticoid-induced 1.0 0.000143348623853 0 1 -1
of,the,glands 1.0 0.000286697247706 0 2 -2
of,the,genetically 1.0 0.000286697247706 0 2 -2
of,the,gastrointestinal 1.0 0.000143348623853 0 1 -1
of,the,formation 1.0 0.000143348623853 0 1 -1
of,the,fischer-344 1.0 0.000143348623853 0 1 -1
of,the,first 1.0 0.000143348623853 0 1 -1
of,the,fetal 1.0 0.000143348623853 0 1 -1
of,the,extremities 1.0 0.000286697247706 0 2 -2
of,the,extent 1.0 0.000143348623853 0 1 -1
of,the,exposure 1.0 0.000143348623853 0 1 -1
of,the,experiment 1.0 0.000143348623853 0 1 -1
of,the,evidence 1.0 0.000143348623853 0 1 -1
of,the,estimated 1.0 0.000143348623853 0 1 -1
of,the,ermbt 1.0 0.000143348623853 0 1 -1
of,the,enzyme 1.0 0.000143348623853 0 1 -1
of,the,efflux 1.0 0.000143348623853 0 1 -1
of,the,efficacy 1.0 0.000143348623853 0 1 -1
of,the,dst 1.0 0.000286697247706 0 2 -2
of,the,drug 1.0 0.000573394495413 0 4 -4
of,the,disulfiram-ethanol 1.0 0.000286697247706 0 2 -2
of,the,displacing 1.0 0.000143348623853 0 1 -1
of,the,diets 1.0 0.000143348623853 0 1 -1
of,the,diabetic 1.0 0.000143348623853 0 1 -1
of,the,day-to 1.0 0.000143348623853 0 1 -1
of,the,cyp 1.0 0.000143348623853 0 1 -1
of,the,cyclooxygenase-2 1.0 0.000143348623853 0 1 -1
of,the,current 1.0 0.000143348623853 0 1 -1
of,the,cpk 1.0 0.000143348623853 0 1 -1
of,the,coumarin 1.0 0.000143348623853 0 1 -1
of,the,cortex 1.0 0.000143348623853 0 1 -1
of,the,controlled 1.0 0.000143348623853 0 1 -1
of,the,control 1.0 0.000143348623853 0 1 -1
of,the,continuing 1.0 0.000143348623853 0 1 -1
of,the,constituents 1.0 0.000143348623853 0 1 -1
of,the,concomitant 1.0 0.000143348623853 0 1 -1
of,the,concentration 1.0 0.000143348623853 0 1 -1
of,the,components 1.0 0.000143348623853 0 1 -1
of,the,combined 1.0 0.000573394495413 0 4 -4
of,the,combination 1.0 0.000143348623853 0 1 -1
of,the,co-administered 1.0 0.000143348623853 0 1 -1
of,the,cns 1.0 0.000143348623853 0 1 -1
of,the,clinical 1.0 0.000286697247706 0 2 -2
of,the,chronically 1.0 0.000143348623853 0 1 -1
of,the,chop 1.0 0.000143348623853 0 1 -1
of,the,cell 1.0 0.000143348623853 0 1 -1
of,the,cecum 1.0 0.000143348623853 0 1 -1
of,the,caucasian 1.0 0.000573394495413 0 4 -4
of,the,cases 1.0 0.000143348623853 0 1 -1
of,the,cardiovascular 1.0 0.000143348623853 0 1 -1
of,the,can 1.0 0.000143348623853 0 1 -1
of,the,calculated 1.0 0.000143348623853 0 1 -1
of,the,brovana 1.0 0.000143348623853 0 1 -1
of,the,broadening 1.0 0.000143348623853 0 1 -1
of,the,block 1.0 0.000143348623853 0 1 -1
of,the,biological 1.0 0.000286697247706 0 2 -2
of,the,bile-acidsequestering 1.0 0.000143348623853 0 1 -1
of,the,available 1.0 0.000143348623853 0 1 -1
of,the,aucs 1.0 0.000143348623853 0 1 -1
of,the,aucasian 1.0 0.000143348623853 0 1 -1
of,the,assay 1.0 0.000143348623853 0 1 -1
of,the,are 1.0 0.000143348623853 0 1 -1
of,the,antidepressant 1.0 0.000143348623853 0 1 -1
of,the,anticoagulants 1.0 0.000143348623853 0 1 -1
of,the,analyte 1.0 0.000143348623853 0 1 -1
of,the,aerosol 1.0 0.000143348623853 0 1 -1
of,the,adverse 1.0 0.000143348623853 0 1 -1
of,the,additive 1.0 0.000143348623853 0 1 -1
of,the,action 1.0 0.000143348623853 0 1 -1
of,the,acid 1.0 0.000143348623853 0 1 -1
of,the,absorption 1.0 0.000143348623853 0 1 -1
of,the,absence 1.0 0.000143348623853 0 1 -1
of,the,a-blocking 1.0 0.000143348623853 0 1 -1
of,that,observed 1.0 0.000143348623853 0 1 -1
of,that,induce 1.0 0.000143348623853 0 1 -1
of,that,in 1.0 0.000143348623853 0 1 -1
of,that,from 1.0 0.000143348623853 0 1 -1
of,temperature,changes 1.0 0.000143348623853 0 1 -1
of,tcas,when 1.0 0.000573394495413 0 4 -4
of,tcamay,become 1.0 0.000143348623853 0 1 -1
of,tca5,with 1.0 0.000143348623853 0 1 -1
of,tca,may 1.0 0.000573394495413 0 4 -4
of,tbg,deficiency 1.0 0.000143348623853 0 1 -1
of,taxotere,with 1.0 0.000143348623853 0 1 -1
of,taxol,until 1.0 0.000143348623853 0 1 -1
of,taxol,therapy 1.0 0.000143348623853 0 1 -1
of,taxol,may 1.0 0.000143348623853 0 1 -1
of,taxol,is 1.0 0.000143348623853 0 1 -1
of,taxol,infusion 1.0 0.000143348623853 0 1 -1
of,taxol,but 1.0 0.000143348623853 0 1 -1
of,taxol,at 1.0 0.000143348623853 0 1 -1
of,taxol,and 1.0 0.000143348623853 0 1 -1
of,tasks,that 1.0 0.000143348623853 0 1 -1
of,tarceva,should 1.0 0.000143348623853 0 1 -1
of,tambocor,with 1.0 0.000143348623853 0 1 -1
of,tail-flick,inhibition 1.0 0.000143348623853 0 1 -1
of,tachyarrhythmias,as 1.0 0.000143348623853 0 1 -1
of,tablets,containing 1.0 0.000143348623853 0 1 -1
of,t4,and 1.0 0.000143348623853 0 1 -1
of,systemically,administered 1.0 0.000143348623853 0 1 -1
of,systemic,antimicrobial 1.0 0.000143348623853 0 1 -1
of,symptoms,usually 1.0 0.000143348623853 0 1 -1
of,sympatholytic,medicinal 1.0 0.000286697247706 0 2 -2
of,sustiva,is 1.0 0.000143348623853 0 1 -1
of,susceptibility,in 1.0 0.000143348623853 0 1 -1
of,surface,histidine 1.0 0.000143348623853 0 1 -1
of,suprax,may 1.0 0.000143348623853 0 1 -1
of,supplementary,oral 1.0 0.000143348623853 0 1 -1
of,supplemental,folic 1.0 0.000143348623853 0 1 -1
of,suggesting,that 1.0 0.000143348623853 0 1 -1
of,suggested,the 1.0 0.000143348623853 0 1 -1
of,such,tumors 1.0 0.000143348623853 0 1 -1
of,such,concurrently 1.0 0.000143348623853 0 1 -1
of,such,concomitant 1.0 0.000143348623853 0 1 -1
of,such,combinations 1.0 0.000286697247706 0 2 -2
of,such,agents 1.0 0.00043004587156 0 3 -3
of,such,a 1.0 0.000143348623853 0 1 -1
of,succinylcholine-induced,neuromuscular 1.0 0.000143348623853 0 1 -1
of,subutex,or 1.0 0.000143348623853 0 1 -1
of,substrates,of 1.0 0.000143348623853 0 1 -1
of,substances,that 1.0 0.000573394495413 0 4 -4
of,substances,affect 1.0 0.000286697247706 0 2 -2
of,subpopulations,of 1.0 0.000143348623853 0 1 -1
of,subjects,taking 1.0 0.000143348623853 0 1 -1
of,subjects,aged 1.0 0.000143348623853 0 1 -1
of,studies,which 1.0 0.000143348623853 0 1 -1
of,strong,inhibitors 1.0 0.000143348623853 0 1 -1
of,strong,cyp 1.0 0.000143348623853 0 1 -1
of,stress,and 1.0 0.000143348623853 0 1 -1
of,strains,of 1.0 0.000143348623853 0 1 -1
of,stimulation,and 1.0 0.000143348623853 0 1 -1
of,stereoselectivity,in 1.0 0.000143348623853 0 1 -1
of,steps,physicians 1.0 0.000143348623853 0 1 -1
of,steady-state,pharmacokinetic 1.0 0.000143348623853 0 1 -1
of,steady-state,l50 1.0 0.000143348623853 0 1 -1
of,status,which 1.0 0.000143348623853 0 1 -1
of,status,and 1.0 0.000143348623853 0 1 -1
of,starlix,mg 1.0 0.000143348623853 0 1 -1
of,st,john 1.0 0.000143348623853 0 1 -1
of,spermatozoa,from 1.0 0.000143348623853 0 1 -1
of,soriatane,therapy 1.0 0.000143348623853 0 1 -1
of,sonata,to 1.0 0.000143348623853 0 1 -1
of,sonata,reflecting 1.0 0.000143348623853 0 1 -1
of,some,patients 1.0 0.000143348623853 0 1 -1
of,some,of 1.0 0.000286697247706 0 2 -2
of,some,forms 1.0 0.000143348623853 0 1 -1
of,some,concomitantly 1.0 0.000143348623853 0 1 -1
of,sodium,was 1.0 0.000143348623853 0 1 -1
of,sodium,perchlorate 1.0 0.000143348623853 0 1 -1
of,sodium,given 1.0 0.000143348623853 0 1 -1
of,sodium,fluorescein 1.0 0.000143348623853 0 1 -1
of,sodium,carboxymethylcellulose 1.0 0.000143348623853 0 1 -1
of,sn38,the 1.0 0.000143348623853 0 1 -1
of,sleep,time 1.0 0.000143348623853 0 1 -1
of,sleep,than 1.0 0.000143348623853 0 1 -1
of,skin,reactions 1.0 0.000143348623853 0 1 -1
of,skeletal,myopathy 1.0 0.000143348623853 0 1 -1
of,sites,may 1.0 0.000143348623853 0 1 -1
of,single,mg 1.0 0.000143348623853 0 1 -1
of,short-acting,such 1.0 0.000143348623853 0 1 -1
of,severe,symptomatology 1.0 0.000143348623853 0 1 -1
of,severe,neutropenia 1.0 0.000143348623853 0 1 -1
of,severe,myelosuppression 1.0 0.000143348623853 0 1 -1
of,severe,malaria 1.0 0.000143348623853 0 1 -1
of,severe,and 1.0 0.000143348623853 0 1 -1
of,severe,anaphylactic 1.0 0.000573394495413 0 4 -4
of,severe,adverse 1.0 0.000143348623853 0 1 -1
of,several,transcription 1.0 0.000143348623853 0 1 -1
of,several,species 1.0 0.000143348623853 0 1 -1
of,several,proteins 1.0 0.000143348623853 0 1 -1
of,several,interacting 1.0 0.000143348623853 0 1 -1
of,settings,commonly 1.0 0.000143348623853 0 1 -1
of,serum,psa 1.0 0.000286697247706 0 2 -2
of,serum,prostate-specific 1.0 0.000143348623853 0 1 -1
of,serum,level 1.0 0.000143348623853 0 1 -1
of,serum,creatinine 1.0 0.000143348623853 0 1 -1
of,serum,assays 1.0 0.000143348623853 0 1 -1
of,serum,and 1.0 0.000573394495413 0 4 -4
of,serotonin,in 1.0 0.000143348623853 0 1 -1
of,seriously,worsening 1.0 0.000143348623853 0 1 -1
of,serious,resedation 1.0 0.000143348623853 0 1 -1
of,serious,or 1.0 0.000143348623853 0 1 -1
of,serious,cardiovascular 1.0 0.000143348623853 0 1 -1
of,serious,adverse 1.0 0.000143348623853 0 1 -1
of,septic,shock 1.0 0.000143348623853 0 1 -1
of,sensipar,on 1.0 0.000143348623853 0 1 -1
of,selective,methods 1.0 0.000143348623853 0 1 -1
of,see,clinical 1.0 0.000143348623853 0 1 -1
of,sedation,within 1.0 0.000143348623853 0 1 -1
of,scotland,were 1.0 0.000143348623853 0 1 -1
of,schizophrenia,in 1.0 0.000143348623853 0 1 -1
of,salmonella,typhimurium 1.0 0.000143348623853 0 1 -1
of,saline,g 1.0 0.000143348623853 0 1 -1
of,safety,is 1.0 0.000143348623853 0 1 -1
of,safe,dosing 1.0 0.000143348623853 0 1 -1
of,ruthenium,red 1.0 0.000286697247706 0 2 -2
of,rural,health 1.0 0.000143348623853 0 1 -1
of,rr,reduced 1.0 0.000143348623853 0 1 -1
of,rr,is 1.0 0.000143348623853 0 1 -1
of,romazicon,may 1.0 0.000143348623853 0 1 -1
of,romazicon,is 1.0 0.000143348623853 0 1 -1
of,rocaltrol,may 1.0 0.00043004587156 0 3 -3
of,rheumatoid,arthritis 1.0 0.000143348623853 0 1 -1
of,rhabdomyolysis,were 1.0 0.000143348623853 0 1 -1
of,rhabdomyolysis,some 1.0 0.000143348623853 0 1 -1
of,rhabdomyolysis,resulting 1.0 0.000143348623853 0 1 -1
of,rhabdomyolysis,have 1.0 0.000143348623853 0 1 -1
of,retinopathy,nephropathy 1.0 0.000143348623853 0 1 -1
of,retinogeniculate,fibers 1.0 0.000143348623853 0 1 -1
of,retinal,tamponades 1.0 0.000143348623853 0 1 -1
of,resveratrol-induced,vasorelaxation 1.0 0.000286697247706 0 2 -2
of,responses,with 1.0 0.000143348623853 0 1 -1
of,resistant,clinical 1.0 0.000143348623853 0 1 -1
of,representative,metabolized 1.0 0.000143348623853 0 1 -1
of,repeated,courses 1.0 0.000143348623853 0 1 -1
of,repeat,doses 1.0 0.000143348623853 0 1 -1
of,renal,prostaglandin 1.0 0.00043004587156 0 3 -3
of,renal,impairment 1.0 0.000143348623853 0 1 -1
of,renal,disease 1.0 0.000143348623853 0 1 -1
of,renal,clearance 1.0 0.000286697247706 0 2 -2
of,renal,cationic 1.0 0.000143348623853 0 1 -1
of,relevant,significant 1.0 0.000143348623853 0 1 -1
of,relevant,pharmacokinetic 1.0 0.000143348623853 0 1 -1
of,release,in 1.0 0.000143348623853 0 1 -1
of,relapses,for 1.0 0.000143348623853 0 1 -1
of,relapse,rehospitalisation 1.0 0.000143348623853 0 1 -1
of,rejection,episodes 1.0 0.000143348623853 0 1 -1
of,regular,users 1.0 0.000143348623853 0 1 -1
of,regranex,gel 1.0 0.000143348623853 0 1 -1
of,refludan,on 1.0 0.000143348623853 0 1 -1
of,reduction,at 1.0 0.000143348623853 0 1 -1
of,reducing,hunger 1.0 0.000143348623853 0 1 -1
of,reduced,p450 1.0 0.000716743119266 0 5 -5
of,reduced,efficacy 1.0 0.000143348623853 0 1 -1
of,reddish,stools 1.0 0.000143348623853 0 1 -1
of,recovery,from 1.0 0.000143348623853 0 1 -1
of,recovery,and 1.0 0.000143348623853 0 1 -1
of,receptors,to 1.0 0.000143348623853 0 1 -1
of,reactive,species 1.0 0.000143348623853 0 1 -1
of,reaction,had 1.0 0.000143348623853 0 1 -1
of,rats,followed 1.0 0.000143348623853 0 1 -1
of,rats,as 1.0 0.000143348623853 0 1 -1
of,rat,thoracic 1.0 0.000143348623853 0 1 -1
of,rat,spinal 1.0 0.000286697247706 0 2 -2
of,rat,liver 1.0 0.000143348623853 0 1 -1
of,rashes,with 1.0 0.000143348623853 0 1 -1
of,rash,pruritus 1.0 0.000143348623853 0 1 -1
of,ras-3t3,cells 1.0 0.000143348623853 0 1 -1
of,ras,during 1.0 0.000286697247706 0 2 -2
of,radiolabeled,ions 1.0 0.000143348623853 0 1 -1
of,radio-iodine,uptake 1.0 0.000143348623853 0 1 -1
of,racemic,were 1.0 0.000143348623853 0 1 -1
of,racemic,titrated 1.0 0.000143348623853 0 1 -1
of,r-warfarin,or 1.0 0.000143348623853 0 1 -1
of,qtc,prolongation 1.0 0.000286697247706 0 2 -2
of,pulse,arterial 1.0 0.000143348623853 0 1 -1
of,ptx,was 1.0 0.000143348623853 0 1 -1
of,pt,and 1.0 0.000143348623853 0 1 -1
of,psychotic,patients 1.0 0.000286697247706 0 2 -2
of,pseudomonas,aeruginosa 1.0 0.000286697247706 0 2 -2
of,proton,pump 1.0 0.000143348623853 0 1 -1
of,proteus,rettgeri 1.0 0.000143348623853 0 1 -1
of,proteins,in 1.0 0.000143348623853 0 1 -1
of,protein-bound,anafranil 1.0 0.000143348623853 0 1 -1
of,protein,synthesis 1.0 0.000143348623853 0 1 -1
of,protein,binding 1.0 0.000143348623853 0 1 -1
of,protease,inhibitors 1.0 0.000143348623853 0 1 -1
of,prostigmin,may 1.0 0.000143348623853 0 1 -1
of,proportionate,responses 1.0 0.000143348623853 0 1 -1
of,prophylactic,low 1.0 0.000143348623853 0 1 -1
of,proleukin,in 1.0 0.000143348623853 0 1 -1
of,progestin-only,oral 1.0 0.000143348623853 0 1 -1
of,producing,transient 1.0 0.000143348623853 0 1 -1
of,procrit,with 1.0 0.000143348623853 0 1 -1
of,probenecid,probenecid 1.0 0.000143348623853 0 1 -1
of,prinivil,alone 1.0 0.000143348623853 0 1 -1
of,primary,rabbit 1.0 0.000143348623853 0 1 -1
of,previously,administered 1.0 0.000143348623853 0 1 -1
of,previous,extravasation 1.0 0.000143348623853 0 1 -1
of,prescribed,to 1.0 0.000143348623853 0 1 -1
of,preparations,which 1.0 0.000143348623853 0 1 -1
of,preparations,and 1.0 0.000143348623853 0 1 -1
of,pregnant,rhesus 1.0 0.000143348623853 0 1 -1
of,pregnancy,rates 1.0 0.000143348623853 0 1 -1
of,pregnancy,from 1.0 0.000143348623853 0 1 -1
of,pregnancies,conceived 1.0 0.000143348623853 0 1 -1
of,predisposing,to 1.0 0.000143348623853 0 1 -1
of,precipitating,coronary 1.0 0.000143348623853 0 1 -1
of,precedex,for 1.0 0.000143348623853 0 1 -1
of,pra,induced 1.0 0.000143348623853 0 1 -1
of,potentially,serious 1.0 0.000143348623853 0 1 -1
of,potential,for 1.0 0.000143348623853 0 1 -1
of,potent,non-nucleoside 1.0 0.000143348623853 0 1 -1
of,potassium-sparing,supplements 1.0 0.000143348623853 0 1 -1
of,postoperative,pain 1.0 0.000143348623853 0 1 -1
of,possible,enhancement 1.0 0.000143348623853 0 1 -1
of,possible,effects 1.0 0.000143348623853 0 1 -1
of,positive,test 1.0 0.000143348623853 0 1 -1
of,positive,and 1.0 0.000143348623853 0 1 -1
of,polyenes,are 1.0 0.000143348623853 0 1 -1
of,pointer,dogs 1.0 0.000143348623853 0 1 -1
of,pocs,and 1.0 0.000143348623853 0 1 -1
of,plendil,with 1.0 0.000143348623853 0 1 -1
of,platelet,effects 1.0 0.000286697247706 0 2 -2
of,platelet,aggregation 1.0 0.000143348623853 0 1 -1
of,plasma,protein 1.0 0.000143348623853 0 1 -1
of,plasma,is 1.0 0.000143348623853 0 1 -1
of,placebo,day 1.0 0.000143348623853 0 1 -1
of,pipracil,may 1.0 0.000143348623853 0 1 -1
of,pi,was 1.0 0.000143348623853 0 1 -1
of,phosphorylation,of 1.0 0.000143348623853 0 1 -1
of,phosphorylated,concentration 1.0 0.000143348623853 0 1 -1
of,phosphatidate,phosphohydrolase 1.0 0.000286697247706 0 2 -2
of,phosphate-binding,agents 1.0 0.00043004587156 0 3 -3
of,phosphatases,in 1.0 0.000143348623853 0 1 -1
of,phosphatase,activity 1.0 0.000143348623853 0 1 -1
of,phenytoin,should 1.0 0.000143348623853 0 1 -1
of,pharmacologic,doses 1.0 0.000143348623853 0 1 -1
of,pharmacokinetics,in 1.0 0.000143348623853 0 1 -1
of,pharmacokinetic,parameters 1.0 0.000143348623853 0 1 -1
of,pharmacokinetic,drug-drug 1.0 0.000143348623853 0 1 -1
of,pharmacogenetics,pharmacogenetics 1.0 0.000143348623853 0 1 -1
of,ph,may 1.0 0.000143348623853 0 1 -1
of,pgp,increased 1.0 0.000143348623853 0 1 -1
of,perivascular,spaces 1.0 0.000143348623853 0 1 -1
of,peritoneal,metastasis 1.0 0.000143348623853 0 1 -1
of,peripheral,neuropathy 1.0 0.000143348623853 0 1 -1
of,per,mac 1.0 0.000143348623853 0 1 -1
of,peptide,in 1.0 0.000143348623853 0 1 -1
of,pegasys,to 1.0 0.000143348623853 0 1 -1
of,pegasys,on 1.0 0.000143348623853 0 1 -1
of,pegasys,in 1.0 0.000286697247706 0 2 -2
of,pegasys,every 1.0 0.000143348623853 0 1 -1
of,pegasys,alone 1.0 0.000286697247706 0 2 -2
of,pediatric,patients 1.0 0.000143348623853 0 1 -1
of,pcp-induced,behavioral 1.0 0.000143348623853 0 1 -1
of,pcp,were 1.0 0.000143348623853 0 1 -1
of,pcp,in 1.0 0.000573394495413 0 4 -4
of,pcp,for 1.0 0.000143348623853 0 1 -1
of,patients,years 1.0 0.000143348623853 0 1 -1
of,patients,were 1.0 0.000143348623853 0 1 -1
of,patients,used 1.0 0.000143348623853 0 1 -1
of,patients,under 1.0 0.000143348623853 0 1 -1
of,patients,transient 1.0 0.000143348623853 0 1 -1
of,patients,the 1.0 0.000143348623853 0 1 -1
of,patients,receiving 1.0 0.00043004587156 0 3 -3
of,patients,received 1.0 0.000143348623853 0 1 -1
of,patients,is 1.0 0.000286697247706 0 2 -2
of,patients,interaction 1.0 0.000143348623853 0 1 -1
of,patients,including 1.0 0.000143348623853 0 1 -1
of,patients,in 1.0 0.000573394495413 0 4 -4
of,patients,before 1.0 0.000143348623853 0 1 -1
of,patients,and 1.0 0.000143348623853 0 1 -1
of,patients,already 1.0 0.000286697247706 0 2 -2
of,parorchis,acanthus 1.0 0.000286697247706 0 2 -2
of,parietal,cells 1.0 0.000143348623853 0 1 -1
of,parametric,dose-response 1.0 0.000143348623853 0 1 -1
of,panretin,gel 1.0 0.000286697247706 0 2 -2
of,pancreatitis,in 1.0 0.000143348623853 0 1 -1
of,palythoa,tuberculosa 1.0 0.000143348623853 0 1 -1
of,pain,mechanisms 1.0 0.000143348623853 0 1 -1
of,p450,d6 1.0 0.000143348623853 0 1 -1
of,p450,a4 1.0 0.000143348623853 0 1 -1
of,p-glycoprotein,mediated 1.0 0.000143348623853 0 1 -1
of,p-glycoprotein,loop 1.0 0.000143348623853 0 1 -1
of,oxypurines,in 1.0 0.000143348623853 0 1 -1
of,oxidized,metabolites 1.0 0.000143348623853 0 1 -1
of,oxidative,stress 1.0 0.000143348623853 0 1 -1
of,ovulation,but 1.0 0.000143348623853 0 1 -1
of,over,patients 1.0 0.00043004587156 0 3 -3
of,over,indinavir-based 1.0 0.000143348623853 0 1 -1
of,otthostatic,hypotension 1.0 0.000143348623853 0 1 -1
of,other,which 1.0 0.000286697247706 0 2 -2
of,other,traditional 1.0 0.000143348623853 0 1 -1
of,other,potentially 1.0 0.000143348623853 0 1 -1
of,other,potential 1.0 0.000143348623853 0 1 -1
of,other,pathways 1.0 0.000143348623853 0 1 -1
of,other,on 1.0 0.000286697247706 0 2 -2
of,other,nonsteroidal 1.0 0.000143348623853 0 1 -1
of,other,neurotoxic 1.0 0.000143348623853 0 1 -1
of,other,methods 1.0 0.000143348623853 0 1 -1
of,other,metabolized 1.0 0.00043004587156 0 3 -3
of,other,medications 1.0 0.000143348623853 0 1 -1
of,other,medical 1.0 0.000143348623853 0 1 -1
of,other,may 1.0 0.000286697247706 0 2 -2
of,other,is 1.0 0.000143348623853 0 1 -1
of,other,in 1.0 0.000143348623853 0 1 -1
of,other,hiv 1.0 0.000143348623853 0 1 -1
of,other,highly 1.0 0.000143348623853 0 1 -1
of,other,have 1.0 0.000143348623853 0 1 -1
of,other,has 1.0 0.000286697247706 0 2 -2
of,other,drugs 1.0 0.00043004587156 0 3 -3
of,other,cytochrome 1.0 0.000143348623853 0 1 -1
of,other,clotting 1.0 0.000143348623853 0 1 -1
of,other,cardioactive 1.0 0.000143348623853 0 1 -1
of,other,and 1.0 0.000143348623853 0 1 -1
of,other,aeds 1.0 0.000143348623853 0 1 -1
of,osteomalacia,in 1.0 0.000143348623853 0 1 -1
of,osteoarthritis,when 1.0 0.000143348623853 0 1 -1
of,orthostatic,hypotension 1.0 0.000143348623853 0 1 -1
of,organs,actively 1.0 0.000143348623853 0 1 -1
of,orally,ingested 1.0 0.000143348623853 0 1 -1
of,orally,administered 1.0 0.000143348623853 0 1 -1
of,oral,users 1.0 0.000143348623853 0 1 -1
of,oral,to 1.0 0.000143348623853 0 1 -1
of,oral,supplements 1.0 0.000143348623853 0 1 -1
of,oral,regularly 1.0 0.000143348623853 0 1 -1
of,oral,platelet 1.0 0.000143348623853 0 1 -1
of,oral,or 1.0 0.000286697247706 0 2 -2
of,oral,on 1.0 0.000286697247706 0 2 -2
of,oral,may 1.0 0.000143348623853 0 1 -1
of,oral,in 1.0 0.000143348623853 0 1 -1
of,oral,hypoglycemic 1.0 0.000143348623853 0 1 -1
of,oral,erection-supporting 1.0 0.000143348623853 0 1 -1
of,oral,agents 1.0 0.000143348623853 0 1 -1
of,or,with 1.0 0.000143348623853 0 1 -1
of,or,were 1.0 0.000143348623853 0 1 -1
of,or,was 1.0 0.000143348623853 0 1 -1
of,or,use 1.0 0.000143348623853 0 1 -1
of,or,the 1.0 0.00043004587156 0 3 -3
of,or,should 1.0 0.000143348623853 0 1 -1
of,or,metabolite 1.0 0.000143348623853 0 1 -1
of,or,during 1.0 0.000143348623853 0 1 -1
of,or,does 1.0 0.000143348623853 0 1 -1
of,or,dihydroxyflavone 1.0 0.000143348623853 0 1 -1
of,or,caused 1.0 0.000143348623853 0 1 -1
of,or,and 1.0 0.000143348623853 0 1 -1
of,or,an 1.0 0.000286697247706 0 2 -2
of,or,affect 1.0 0.000143348623853 0 1 -1
of,or,administration 1.0 0.000143348623853 0 1 -1
of,or,a 1.0 0.000143348623853 0 1 -1
of,one,of 1.0 0.000143348623853 0 1 -1
of,one,ng 1.0 0.000143348623853 0 1 -1
of,on,was 1.0 0.000143348623853 0 1 -1
of,on,voltage-dependent 1.0 0.000143348623853 0 1 -1
of,on,total 1.0 0.000143348623853 0 1 -1
of,on,these 1.0 0.000143348623853 0 1 -1
of,on,them 1.0 0.000143348623853 0 1 -1
of,on,stimulated 1.0 0.000143348623853 0 1 -1
of,on,respiration 1.0 0.000143348623853 0 1 -1
of,on,resistance 1.0 0.000143348623853 0 1 -1
of,on,plasma 1.0 0.000143348623853 0 1 -1
of,on,pharmacokinetics 1.0 0.000573394495413 0 4 -4
of,on,monoamine 1.0 0.000143348623853 0 1 -1
of,on,milk 1.0 0.000143348623853 0 1 -1
of,on,high 1.0 0.000143348623853 0 1 -1
of,on,hepatic 1.0 0.000143348623853 0 1 -1
of,on,gastric 1.0 0.000143348623853 0 1 -1
of,on,exjade 1.0 0.000143348623853 0 1 -1
of,on,endotoxin-induced 1.0 0.000143348623853 0 1 -1
of,on,diastolic 1.0 0.000143348623853 0 1 -1
of,on,cyp450 1.0 0.000143348623853 0 1 -1
of,on,clonidines 1.0 0.000143348623853 0 1 -1
of,on,both 1.0 0.000143348623853 0 1 -1
of,on,blood 1.0 0.000143348623853 0 1 -1
of,on,arteries 1.0 0.000143348623853 0 1 -1
of,on,and 1.0 0.000143348623853 0 1 -1
of,on,absorption 1.0 0.000143348623853 0 1 -1
of,oleate,in 1.0 0.000143348623853 0 1 -1
of,oleate,and 1.0 0.000143348623853 0 1 -1
of,offers,advantages 1.0 0.000143348623853 0 1 -1
of,of,the 1.0 0.000143348623853 0 1 -1
of,of,patients 1.0 0.000143348623853 0 1 -1
of,of,mg 1.0 0.000143348623853 0 1 -1
of,observation,must 1.0 0.000143348623853 0 1 -1
of,nuromax,before 1.0 0.000143348623853 0 1 -1
of,nuromax,and 1.0 0.000143348623853 0 1 -1
of,nucleophosmin,b23 1.0 0.000573394495413 0 4 -4
of,nucleolin,c23 1.0 0.000143348623853 0 1 -1
of,novolog,were 1.0 0.000143348623853 0 1 -1
of,novolog,but 1.0 0.000143348623853 0 1 -1
of,novolog,and 1.0 0.000143348623853 0 1 -1
of,not,only 1.0 0.000143348623853 0 1 -1
of,normal,and 1.0 0.000143348623853 0 1 -1
of,noradrenaline,storage 1.0 0.000143348623853 0 1 -1
of,nor,high 1.0 0.000143348623853 0 1 -1
of,nor,does 1.0 0.000143348623853 0 1 -1
of,nonsmoking,healthy 1.0 0.000143348623853 0 1 -1
of,nondepolarizing,relaxants 1.0 0.000286697247706 0 2 -2
of,non-nucleoside,reverse 1.0 0.000143348623853 0 1 -1
of,non,soluble 1.0 0.000143348623853 0 1 -1
of,nociception,was 1.0 0.000143348623853 0 1 -1
of,nnrtis,appears 1.0 0.000143348623853 0 1 -1
of,nmda-ergic,activation 1.0 0.000143348623853 0 1 -1
of,nmda,receptors 1.0 0.000143348623853 0 1 -1
of,nm,absorbing 1.0 0.000143348623853 0 1 -1
of,nimbex,before 1.0 0.000143348623853 0 1 -1
of,newly,diagnosed 1.0 0.000143348623853 0 1 -1
of,newborns,whose 1.0 0.000143348623853 0 1 -1
of,new,therapeutic 1.0 0.000143348623853 0 1 -1
of,nevirapine,or 1.0 0.000143348623853 0 1 -1
of,neutrophils,such 1.0 0.000143348623853 0 1 -1
of,neuropathy,or 1.0 0.000143348623853 0 1 -1
of,neuropathy,during 1.0 0.000143348623853 0 1 -1
of,neurontin,in 1.0 0.000143348623853 0 1 -1
of,neurons,hyperpolarized 1.0 0.000286697247706 0 2 -2
of,neurons,fired 1.0 0.000143348623853 0 1 -1
of,neurons,displaying 1.0 0.000143348623853 0 1 -1
of,neuronal,uptake 1.0 0.000143348623853 0 1 -1
of,neurological,toxicity 1.0 0.000143348623853 0 1 -1
of,neurological,toxic 1.0 0.000143348623853 0 1 -1
of,neurological,and 1.0 0.000143348623853 0 1 -1
of,neural,pathways 1.0 0.000143348623853 0 1 -1
of,nephrotoxic,compounds 1.0 0.000143348623853 0 1 -1
of,neoplasia,are 1.0 0.000143348623853 0 1 -1
of,negative,and 1.0 0.000286697247706 0 2 -2
of,necessary,while 1.0 0.000143348623853 0 1 -1
of,natural,and 1.0 0.000143348623853 0 1 -1
of,natrecor,with 1.0 0.000143348623853 0 1 -1
of,nanm,or 1.0 0.000143348623853 0 1 -1
of,nanm,nanm 1.0 0.000143348623853 0 1 -1
of,naflu,to 1.0 0.000143348623853 0 1 -1
of,naflu,compared 1.0 0.000143348623853 0 1 -1
of,n-methylthiotetrazole,or 1.0 0.000143348623853 0 1 -1
of,n-desmethyldiazepam,to 1.0 0.000143348623853 0 1 -1
of,n-allylnormetazocine,nanm 1.0 0.000143348623853 0 1 -1
of,n-allylnormetazocine,in 1.0 0.000143348623853 0 1 -1
of,n,later 1.0 0.000143348623853 0 1 -1
of,myopathy,is 1.0 0.000143348623853 0 1 -1
of,myopathy,during 1.0 0.000143348623853 0 1 -1
of,myopathy,by 1.0 0.000143348623853 0 1 -1
of,myocardial,infarction 1.0 0.000286697247706 0 2 -2
of,myelotoxicity,it 1.0 0.000143348623853 0 1 -1
of,myasthenic,weakness 1.0 0.000143348623853 0 1 -1
of,multipledose,treatment 1.0 0.000143348623853 0 1 -1
of,multiple,exposure 1.0 0.000143348623853 0 1 -1
of,multiple,doses 1.0 0.000143348623853 0 1 -1
of,mouth,thirst 1.0 0.000143348623853 0 1 -1
of,most,evoked 1.0 0.000143348623853 0 1 -1
of,most,components 1.0 0.000143348623853 0 1 -1
of,mortality,in 1.0 0.000143348623853 0 1 -1
of,morning,and 1.0 0.000143348623853 0 1 -1
of,more,severe 1.0 0.000286697247706 0 2 -2
of,more,malignant 1.0 0.000143348623853 0 1 -1
of,more,highly 1.0 0.000143348623853 0 1 -1
of,mood,states 1.0 0.000143348623853 0 1 -1
of,months,the 1.0 0.000143348623853 0 1 -1
of,monitoring,serum 1.0 0.000143348623853 0 1 -1
of,modest,degree 1.0 0.000286697247706 0 2 -2
of,mna,in 1.0 0.000143348623853 0 1 -1
of,mmol,l 1.0 0.000143348623853 0 1 -1
of,mm,or 1.0 0.000143348623853 0 1 -1
of,ml,of 1.0 0.000143348623853 0 1 -1
of,ml,h 1.0 0.000143348623853 0 1 -1
of,mixing,novolog 1.0 0.000143348623853 0 1 -1
of,mixed-function,mono-oxidases 1.0 0.000143348623853 0 1 -1
of,miracidia,was 1.0 0.000143348623853 0 1 -1
of,miracidia,from 1.0 0.000143348623853 0 1 -1
of,minutes,to 1.0 0.000143348623853 0 1 -1
of,milk,ejection 1.0 0.000143348623853 0 1 -1
of,migraine,has 1.0 0.000143348623853 0 1 -1
of,microtubules,on 1.0 0.000143348623853 0 1 -1
of,microtubules,in 1.0 0.000143348623853 0 1 -1
of,microsomal,enzymes 1.0 0.000143348623853 0 1 -1
of,micrograms,ml 1.0 0.000143348623853 0 1 -1
of,microg,ml 1.0 0.000143348623853 0 1 -1
of,microg,l 1.0 0.00043004587156 0 3 -3
of,microg,kg 1.0 0.000143348623853 0 1 -1
of,mice,treated 1.0 0.000143348623853 0 1 -1
of,mice,induced 1.0 0.000143348623853 0 1 -1
of,mhd,to 1.0 0.000143348623853 0 1 -1
of,mg,times 1.0 0.000143348623853 0 1 -1
of,mg,tid 1.0 0.000143348623853 0 1 -1
of,mg,should 1.0 0.000143348623853 0 1 -1
of,mg,qhs 1.0 0.000143348623853 0 1 -1
of,mg,q24h 1.0 0.000143348623853 0 1 -1
of,mg,neurontin 1.0 0.000143348623853 0 1 -1
of,mg,mg 1.0 0.000143348623853 0 1 -1
of,mg,l 1.0 0.000143348623853 0 1 -1
of,mg,has 1.0 0.000143348623853 0 1 -1
of,mg,four 1.0 0.000143348623853 0 1 -1
of,mg,five 1.0 0.000143348623853 0 1 -1
of,mg,did 1.0 0.000573394495413 0 4 -4
of,mg,causing 1.0 0.000143348623853 0 1 -1
of,mg,both 1.0 0.000143348623853 0 1 -1
of,mevacor,in 1.0 0.000143348623853 0 1 -1
of,method,and 1.0 0.000143348623853 0 1 -1
of,methaemoglobinaemia,particularly 1.0 0.000143348623853 0 1 -1
of,metal,toxicity 1.0 0.000143348623853 0 1 -1
of,metabotropic,glutamate 1.0 0.000143348623853 0 1 -1
of,metabolizing,itself 1.0 0.000143348623853 0 1 -1
of,metabolized,by 1.0 0.00129013761468 0 9 -9
of,metabolites,in 1.0 0.000143348623853 0 1 -1
of,metabolite,i 1.0 0.000143348623853 0 1 -1
of,metabolism,mediated 1.0 0.000143348623853 0 1 -1
of,metabolism,may 1.0 0.000143348623853 0 1 -1
of,metabolism,by 1.0 0.000143348623853 0 1 -1
of,metabolic,interactions 1.0 0.000143348623853 0 1 -1
of,metabolic,abnormalities 1.0 0.000143348623853 0 1 -1
of,mesenteric,arteries 1.0 0.000143348623853 0 1 -1
of,mental,and 1.0 0.000143348623853 0 1 -1
of,men,for 1.0 0.000143348623853 0 1 -1
of,memory,that 1.0 0.000143348623853 0 1 -1
of,mefloquineuine,on 1.0 0.000143348623853 0 1 -1
of,mefloquineuine,and 1.0 0.000143348623853 0 1 -1
of,mefloquine,therapy 1.0 0.000143348623853 0 1 -1
of,medline,premedline 1.0 0.000143348623853 0 1 -1
of,medications,which 1.0 0.000143348623853 0 1 -1
of,medications,used 1.0 0.000143348623853 0 1 -1
of,medications,for 1.0 0.000143348623853 0 1 -1
of,medication,administered 1.0 0.000286697247706 0 2 -2
of,medical,examinations 1.0 0.000143348623853 0 1 -1
of,medical,complications 1.0 0.000143348623853 0 1 -1
of,meclofenamate,sodium 1.0 0.000143348623853 0 1 -1
of,measured,at 1.0 0.000143348623853 0 1 -1
of,mcg,twice 1.0 0.000143348623853 0 1 -1
of,mcg,ml 1.0 0.000143348623853 0 1 -1
of,mcf-7,cells 1.0 0.000143348623853 0 1 -1
of,may,produce 1.0 0.000573394495413 0 4 -4
of,manic-depressive,disorder 1.0 0.000143348623853 0 1 -1
of,malignant,disease 1.0 0.000143348623853 0 1 -1
of,male,dogs 1.0 0.000143348623853 0 1 -1
of,male,animals 1.0 0.000143348623853 0 1 -1
of,magnitude,lower 1.0 0.000143348623853 0 1 -1
of,mac,out 1.0 0.000143348623853 0 1 -1
of,maalox,tc 1.0 0.000143348623853 0 1 -1
of,m,v 1.0 0.000143348623853 0 1 -1
of,m,the 1.0 0.000143348623853 0 1 -1
of,m,at 1.0 0.000143348623853 0 1 -1
of,lower,doses 1.0 0.000143348623853 0 1 -1
of,low-dose,mg 1.0 0.000143348623853 0 1 -1
of,low,therapeutic 1.0 0.000143348623853 0 1 -1
of,low,temperatures 1.0 0.000143348623853 0 1 -1
of,low,molecular 1.0 0.000143348623853 0 1 -1
of,low,intrinsic 1.0 0.000143348623853 0 1 -1
of,low,and 1.0 0.000143348623853 0 1 -1
of,loratadine,and 1.0 0.000143348623853 0 1 -1
of,locomotor,activities 1.0 0.000143348623853 0 1 -1
of,lng,were 1.0 0.000143348623853 0 1 -1
of,liver,tumors 1.0 0.000143348623853 0 1 -1
of,liver,cytochrome 1.0 0.000143348623853 0 1 -1
of,listed,in 1.0 0.000143348623853 0 1 -1
of,liquid,did 1.0 0.000143348623853 0 1 -1
of,linear,regression 1.0 0.000143348623853 0 1 -1
of,limit,values 1.0 0.000143348623853 0 1 -1
of,lifestyle,giving 1.0 0.000143348623853 0 1 -1
of,life,in 1.0 0.000143348623853 0 1 -1
of,lh,and 1.0 0.000143348623853 0 1 -1
of,lexapro,and 1.0 0.000143348623853 0 1 -1
of,levulan,kerastick 1.0 0.000143348623853 0 1 -1
of,levels,and 1.0 0.000143348623853 0 1 -1
of,lessened,active 1.0 0.000143348623853 0 1 -1
of,learning,and 1.0 0.000143348623853 0 1 -1
of,lean,and 1.0 0.000143348623853 0 1 -1
of,large,size 1.0 0.000143348623853 0 1 -1
of,large,initial 1.0 0.000143348623853 0 1 -1
of,lapatinib,on 1.0 0.000143348623853 0 1 -1
of,labetalol,hcl 1.0 0.000143348623853 0 1 -1
of,l-ccg,were 1.0 0.000143348623853 0 1 -1
of,krm-1648,either 1.0 0.000143348623853 0 1 -1
of,kidney,function 1.0 0.000143348623853 0 1 -1
of,kg,of 1.0 0.000143348623853 0 1 -1
of,kg,for 1.0 0.000143348623853 0 1 -1
of,kerlone,with 1.0 0.000143348623853 0 1 -1
of,keppra,on 1.0 0.000143348623853 0 1 -1
of,keflex,a 1.0 0.000143348623853 0 1 -1
of,its,use 1.0 0.000143348623853 0 1 -1
of,its,permeation 1.0 0.000143348623853 0 1 -1
of,its,lack 1.0 0.00043004587156 0 3 -3
of,its,efficacy 1.0 0.000286697247706 0 2 -2
of,its,affinity 1.0 0.00043004587156 0 3 -3
of,its,adverse 1.0 0.000143348623853 0 1 -1
of,itraconazole,mg 1.0 0.000143348623853 0 1 -1
of,it,has 1.0 0.000143348623853 0 1 -1
of,isocarboxazid,may 1.0 0.000143348623853 0 1 -1
of,is,virtually 1.0 0.000143348623853 0 1 -1
of,is,still 1.0 0.000143348623853 0 1 -1
of,is,offset 1.0 0.000143348623853 0 1 -1
of,is,negligible 1.0 0.000143348623853 0 1 -1
of,is,necessary 1.0 0.000143348623853 0 1 -1
of,is,narrow 1.0 0.000143348623853 0 1 -1
of,is,moderately 1.0 0.000143348623853 0 1 -1
of,is,minimized 1.0 0.000143348623853 0 1 -1
of,is,mg 1.0 0.000143348623853 0 1 -1
of,is,mediated 1.0 0.000143348623853 0 1 -1
of,is,excreted 1.0 0.000143348623853 0 1 -1
of,is,evidently 1.0 0.000143348623853 0 1 -1
of,is,changed 1.0 0.000143348623853 0 1 -1
of,ions,are 1.0 0.000143348623853 0 1 -1
of,ionized,concurrent 1.0 0.000143348623853 0 1 -1
of,involvement,labeling 1.0 0.000143348623853 0 1 -1
of,invirase,or 1.0 0.000143348623853 0 1 -1
of,intrinsic,value 1.0 0.000143348623853 0 1 -1
of,intravenously,or 1.0 0.000143348623853 0 1 -1
of,intravenous,in 1.0 0.000143348623853 0 1 -1
of,intrathecal,on 1.0 0.000143348623853 0 1 -1
of,intramuscularly,injected 1.0 0.000143348623853 0 1 -1
of,intestinal,tumors 1.0 0.000143348623853 0 1 -1
of,intestinal,carcinogenesis 1.0 0.000143348623853 0 1 -1
of,intestinal,cancers 1.0 0.000286697247706 0 2 -2
of,interferences,and 1.0 0.000143348623853 0 1 -1
of,interference,of 1.0 0.000143348623853 0 1 -1
of,interference,by 1.0 0.000143348623853 0 1 -1
of,interactions,with 1.0 0.00043004587156 0 3 -3
of,interactions,resulting 1.0 0.000143348623853 0 1 -1
of,interactions,in 1.0 0.000143348623853 0 1 -1
of,interaction,within 1.0 0.000143348623853 0 1 -1
of,interaction,with 1.0 0.000286697247706 0 2 -2
of,interaction,studies 1.0 0.000286697247706 0 2 -2
of,interaction,of 1.0 0.000286697247706 0 2 -2
of,interaction,depends 1.0 0.000143348623853 0 1 -1
of,interaction,at 1.0 0.000286697247706 0 2 -2
of,interaction,and 1.0 0.000286697247706 0 2 -2
of,insp,microm 1.0 0.000143348623853 0 1 -1
of,innovar,on 1.0 0.000143348623853 0 1 -1
of,injection,use 1.0 0.000143348623853 0 1 -1
of,injection,in 1.0 0.000143348623853 0 1 -1
of,initial,or 1.0 0.000143348623853 0 1 -1
of,initial,doses 1.0 0.000143348623853 0 1 -1
of,inhibitor,to 1.0 0.000143348623853 0 1 -1
of,influence,through 1.0 0.000143348623853 0 1 -1
of,infections,caused 1.0 0.000143348623853 0 1 -1
of,infections,and 1.0 0.000143348623853 0 1 -1
of,infection,is 1.0 0.000143348623853 0 1 -1
of,induction,or 1.0 0.000143348623853 0 1 -1
of,induction,of 1.0 0.000143348623853 0 1 -1
of,induced,therapeutic 1.0 0.000143348623853 0 1 -1
of,induced,hypotension 1.0 0.000143348623853 0 1 -1
of,indocin,may 1.0 0.000143348623853 0 1 -1
of,indocin,are 1.0 0.000143348623853 0 1 -1
of,individual,simulect 1.0 0.000143348623853 0 1 -1
of,individual,patient 1.0 0.000143348623853 0 1 -1
of,individual,cases 1.0 0.000143348623853 0 1 -1
of,indications,specific 1.0 0.000143348623853 0 1 -1
of,indicate,that 1.0 0.000143348623853 0 1 -1
of,incubation,in 1.0 0.000143348623853 0 1 -1
of,increases,in 1.0 0.000143348623853 0 1 -1
of,increased,steady-state 1.0 0.000143348623853 0 1 -1
of,increased,risk 1.0 0.000143348623853 0 1 -1
of,increased,intraocular 1.0 0.000143348623853 0 1 -1
of,increased,interaction 1.0 0.000143348623853 0 1 -1
of,increased,gastric 1.0 0.000143348623853 0 1 -1
of,increased,frequency 1.0 0.000143348623853 0 1 -1
of,increased,exposure 1.0 0.000143348623853 0 1 -1
of,increased,dramatically 1.0 0.000143348623853 0 1 -1
of,incompatibility,of 1.0 0.000286697247706 0 2 -2
of,include,optimal 1.0 0.000143348623853 0 1 -1
of,inapsine,required 1.0 0.000143348623853 0 1 -1
of,in,vivo 1.0 0.000143348623853 0 1 -1
of,in,therapy 1.0 0.000143348623853 0 1 -1
of,in,the 1.0 0.00100344036697 0 7 -7
of,in,survanta 1.0 0.000143348623853 0 1 -1
of,in,states 1.0 0.000143348623853 0 1 -1
of,in,sheep 1.0 0.000143348623853 0 1 -1
of,in,rodent 1.0 0.000143348623853 0 1 -1
of,in,renally 1.0 0.000143348623853 0 1 -1
of,in,proportion 1.0 0.000143348623853 0 1 -1
of,in,peripheral 1.0 0.000143348623853 0 1 -1
of,in,lean 1.0 0.000143348623853 0 1 -1
of,in,increasing 1.0 0.000143348623853 0 1 -1
of,in,healthy 1.0 0.00043004587156 0 3 -3
of,in,each 1.0 0.000143348623853 0 1 -1
of,in,dependence 1.0 0.000143348623853 0 1 -1
of,in,de 1.0 0.000143348623853 0 1 -1
of,in,cyp3a4 1.0 0.000143348623853 0 1 -1
of,in,conjunction 1.0 0.000143348623853 0 1 -1
of,improving,the 1.0 0.000143348623853 0 1 -1
of,importance,to 1.0 0.000143348623853 0 1 -1
of,impaired,fertility 1.0 0.000143348623853 0 1 -1
of,immunoreactive,after 1.0 0.000143348623853 0 1 -1
of,immobilised,cmc-cys7 1.0 0.000143348623853 0 1 -1
of,hypoxic,respiratory 1.0 0.000143348623853 0 1 -1
of,hypothyroidism,in 1.0 0.000143348623853 0 1 -1
of,hypotension,or 1.0 0.000286697247706 0 2 -2
of,hypoglycemia,may 1.0 0.000286697247706 0 2 -2
of,hypertriglyceridemia,was 1.0 0.000143348623853 0 1 -1
of,hypertriglyceridemia,is 1.0 0.000143348623853 0 1 -1
of,hyperpyrexia,eight 1.0 0.000143348623853 0 1 -1
of,hydroxytolbutamide,and 1.0 0.000143348623853 0 1 -1
of,hydroxylamine,dha 1.0 0.000143348623853 0 1 -1
of,hydroxylamine,a 1.0 0.000143348623853 0 1 -1
of,hydroxy,indoleacetic 1.0 0.000143348623853 0 1 -1
of,hydroxide,and 1.0 0.000143348623853 0 1 -1
of,hydrophobic,side 1.0 0.000143348623853 0 1 -1
of,hydrochloride,does 1.0 0.000143348623853 0 1 -1
of,hydrochloride,and 1.0 0.000286697247706 0 2 -2
of,humans,and 1.0 0.000143348623853 0 1 -1
of,human,response 1.0 0.000143348623853 0 1 -1
of,human,fungal 1.0 0.000143348623853 0 1 -1
of,human,cyp 1.0 0.000143348623853 0 1 -1
of,human,b 1.0 0.000143348623853 0 1 -1
of,human,african 1.0 0.000143348623853 0 1 -1
of,however,were 1.0 0.000143348623853 0 1 -1
of,hormone,may 1.0 0.000143348623853 0 1 -1
of,homocysteine,in 1.0 0.000143348623853 0 1 -1
of,hivid,and 1.0 0.000143348623853 0 1 -1
of,histidine,residues 1.0 0.000143348623853 0 1 -1
of,higher,doses 1.0 0.000143348623853 0 1 -1
of,hexanal-induced,sleep 1.0 0.000143348623853 0 1 -1
of,herbal,therapy 1.0 0.000143348623853 0 1 -1
of,herbal,remedy 1.0 0.000143348623853 0 1 -1
of,herbal,remedies 1.0 0.00043004587156 0 3 -3
of,hepatic,microsomal 1.0 0.000143348623853 0 1 -1
of,hepatic,k 1.0 0.000143348623853 0 1 -1
of,hepatic,extraction 1.0 0.000143348623853 0 1 -1
of,hepatic,cyp 1.0 0.000143348623853 0 1 -1
of,hemorrhage,should 1.0 0.000286697247706 0 2 -2
of,healthy,subjects 1.0 0.000143348623853 0 1 -1
of,healthy,males 1.0 0.000143348623853 0 1 -1
of,hctz,alone 1.0 0.000143348623853 0 1 -1
of,hcl,was 1.0 0.000143348623853 0 1 -1
of,having,a 1.0 0.000286697247706 0 2 -2
of,have,not 1.0 0.000286697247706 0 2 -2
of,have,demonstrated 1.0 0.000143348623853 0 1 -1
of,have,also 1.0 0.000143348623853 0 1 -1
of,has,not 1.0 0.000573394495413 0 4 -4
of,has,no 1.0 0.000286697247706 0 2 -2
of,hansten,into 1.0 0.000143348623853 0 1 -1
of,had,to 1.0 0.000143348623853 0 1 -1
of,had,no 1.0 0.000716743119266 0 5 -5
of,had,a 1.0 0.000143348623853 0 1 -1
of,habituation,or 1.0 0.000143348623853 0 1 -1
of,growth,to 1.0 0.000143348623853 0 1 -1
of,growth,caused 1.0 0.000143348623853 0 1 -1
of,gross,motor 1.0 0.000143348623853 0 1 -1
of,great,interest 1.0 0.000143348623853 0 1 -1
of,grapefruit,or 1.0 0.000143348623853 0 1 -1
of,grapefruit,juice 1.0 0.00043004587156 0 3 -3
of,grade,diarrhea 1.0 0.000143348623853 0 1 -1
of,goal-directed,behavior 1.0 0.000143348623853 0 1 -1
of,glycemic,levels 1.0 0.000143348623853 0 1 -1
of,glycemia,induced 1.0 0.000143348623853 0 1 -1
of,gly-buride,and 1.0 0.000143348623853 0 1 -1
of,glucose,intolerance 1.0 0.000143348623853 0 1 -1
of,glucose,and 1.0 0.000143348623853 0 1 -1
of,glucose,alkaline 1.0 0.000143348623853 0 1 -1
of,glucocorticoid-induced,mouse 1.0 0.000143348623853 0 1 -1
of,gl,was 1.0 0.000143348623853 0 1 -1
of,gl,the 1.0 0.000143348623853 0 1 -1
of,genomes,have 1.0 0.000143348623853 0 1 -1
of,genetically,predisposed 1.0 0.000143348623853 0 1 -1
of,genetic,data 1.0 0.000143348623853 0 1 -1
of,general,the 1.0 0.000143348623853 0 1 -1
of,gene,transfer 1.0 0.000143348623853 0 1 -1
of,gemzar,and 1.0 0.000143348623853 0 1 -1
of,gastric,emptying 1.0 0.000143348623853 0 1 -1
of,ganoderma,lucidum 1.0 0.000286697247706 0 2 -2
of,gabitril,with 1.0 0.000286697247706 0 2 -2
of,gabitril,on 1.0 0.000143348623853 0 1 -1
of,g,per 1.0 0.000143348623853 0 1 -1
of,future,studies 1.0 0.000143348623853 0 1 -1
of,fundus,pulsation 1.0 0.000143348623853 0 1 -1
of,functionally,distinguishes 1.0 0.000143348623853 0 1 -1
of,fully,formed 1.0 0.000143348623853 0 1 -1
of,frova,treatment 1.0 0.000143348623853 0 1 -1
of,from,these 1.0 0.000143348623853 0 1 -1
of,from,nerves 1.0 0.000143348623853 0 1 -1
of,from,muscle 1.0 0.000143348623853 0 1 -1
of,from,midcycle 1.0 0.000143348623853 0 1 -1
of,free,ions 1.0 0.000143348623853 0 1 -1
of,free,had 1.0 0.000143348623853 0 1 -1
of,four,chemotherapeutic 1.0 0.000143348623853 0 1 -1
of,formal,clinical 1.0 0.000143348623853 0 1 -1
of,for,which 1.0 0.000143348623853 0 1 -1
of,for,up 1.0 0.000143348623853 0 1 -1
of,for,the 1.0 0.000143348623853 0 1 -1
of,for,such 1.0 0.000143348623853 0 1 -1
of,for,all 1.0 0.000143348623853 0 1 -1
of,foods,highly 1.0 0.000143348623853 0 1 -1
of,food,on 1.0 0.000143348623853 0 1 -1
of,food,in 1.0 0.000143348623853 0 1 -1
of,following,ultracentrifugation 1.0 0.000143348623853 0 1 -1
of,following,a 1.0 0.000143348623853 0 1 -1
of,flushing,and 1.0 0.000143348623853 0 1 -1
of,fluorescence,labelled 1.0 0.000143348623853 0 1 -1
of,flucoxacillin,and 1.0 0.000143348623853 0 1 -1
of,flolan,in 1.0 0.000143348623853 0 1 -1
of,fibrinolysis,is 1.0 0.000143348623853 0 1 -1
of,fibrinogen,to 1.0 0.000143348623853 0 1 -1
of,fibric,acid 1.0 0.000143348623853 0 1 -1
of,fetal,variations 1.0 0.000143348623853 0 1 -1
of,fetal,toxicity 1.0 0.000143348623853 0 1 -1
of,fetal,abnormalities 1.0 0.000143348623853 0 1 -1
of,fertility,pegasys 1.0 0.000143348623853 0 1 -1
of,fertility,no 1.0 0.000143348623853 0 1 -1
of,fertility,carcinogenesis 1.0 0.000143348623853 0 1 -1
of,fertility,a 1.0 0.000143348623853 0 1 -1
of,fenofibric,acid 1.0 0.000143348623853 0 1 -1
of,femara,with 1.0 0.000143348623853 0 1 -1
of,femara,in 1.0 0.000143348623853 0 1 -1
of,female,rats 1.0 0.000143348623853 0 1 -1
of,female,fertility 1.0 0.000143348623853 0 1 -1
of,felbatol,therapy 1.0 0.000143348623853 0 1 -1
of,fe,over 1.0 0.000143348623853 0 1 -1
of,fatty,acids 1.0 0.000143348623853 0 1 -1
of,fatal,hepatic 1.0 0.000143348623853 0 1 -1
of,fat-soluble,should 1.0 0.000143348623853 0 1 -1
of,fat,soluble 1.0 0.000143348623853 0 1 -1
of,faslodex,in 1.0 0.000143348623853 0 1 -1
of,factors,such 1.0 0.000143348623853 0 1 -1
of,factive,had 1.0 0.000143348623853 0 1 -1
of,extravasation,it 1.0 0.000143348623853 0 1 -1
of,extraneals,effects 1.0 0.000143348623853 0 1 -1
of,extraneal,on 1.0 0.000143348623853 0 1 -1
of,exposure,were 1.0 0.000143348623853 0 1 -1
of,exposure,the 1.0 0.000143348623853 0 1 -1
of,exposure,in 1.0 0.000143348623853 0 1 -1
of,exposure,compared 1.0 0.000143348623853 0 1 -1
of,exogenously,infused 1.0 0.000143348623853 0 1 -1
of,exogenous,on 1.0 0.000143348623853 0 1 -1
of,exjade,with 1.0 0.000143348623853 0 1 -1
of,exjade,and 1.0 0.000286697247706 0 2 -2
of,excreted,unchanged 1.0 0.000143348623853 0 1 -1
of,events,or 1.0 0.000143348623853 0 1 -1
of,escherichia,coli 1.0 0.000286697247706 0 2 -2
of,escalating,doses 1.0 0.000143348623853 0 1 -1
of,erythromycin,on 1.0 0.000143348623853 0 1 -1
of,erythema,tenderness 1.0 0.000143348623853 0 1 -1
of,erythema,pruritus 1.0 0.000143348623853 0 1 -1
of,ergot-type,oxytocic 1.0 0.000143348623853 0 1 -1
of,ergocalcitriol,will 1.0 0.00043004587156 0 3 -3
of,erection-supporting,medication 1.0 0.000143348623853 0 1 -1
of,erection,disorders 1.0 0.000143348623853 0 1 -1
of,er,extended 1.0 0.000143348623853 0 1 -1
of,equetrotm,to 1.0 0.000143348623853 0 1 -1
of,equetrotm,may 1.0 0.000143348623853 0 1 -1
of,equetrotm,and 1.0 0.000143348623853 0 1 -1
of,epirubicin-containing,cef-120 1.0 0.000143348623853 0 1 -1
of,epa,supplements 1.0 0.000143348623853 0 1 -1
of,enterococcus,three 1.0 0.000143348623853 0 1 -1
of,enterococcus,faecalis 1.0 0.000143348623853 0 1 -1
of,enterococci,were 1.0 0.000143348623853 0 1 -1
of,enterococci,vre 1.0 0.000143348623853 0 1 -1
of,enterococci,highlights 1.0 0.000143348623853 0 1 -1
of,enterobacteriaceae,and 1.0 0.000143348623853 0 1 -1
of,enhancing,selective 1.0 0.000143348623853 0 1 -1
of,enhancement,of 1.0 0.000143348623853 0 1 -1
of,enflurane,than 1.0 0.000143348623853 0 1 -1
of,endoscopic,gastroduodenal 1.0 0.000143348623853 0 1 -1
of,enbrel,was 1.0 0.000143348623853 0 1 -1
of,ellence,after 1.0 0.000143348623853 0 1 -1
of,elixir,was 1.0 0.000143348623853 0 1 -1
of,elimination,was 1.0 0.000143348623853 0 1 -1
of,elimination,is 1.0 0.000286697247706 0 2 -2
of,elevated,plasma 1.0 0.000143348623853 0 1 -1
of,elevated,liver 1.0 0.000143348623853 0 1 -1
of,either,was 1.0 0.000143348623853 0 1 -1
of,either,the 1.0 0.000143348623853 0 1 -1
of,either,protein 1.0 0.000143348623853 0 1 -1
of,either,is 1.0 0.000286697247706 0 2 -2
of,either,humira 1.0 0.000143348623853 0 1 -1
of,either,h2 1.0 0.000143348623853 0 1 -1
of,either,due 1.0 0.000143348623853 0 1 -1
of,either,class 1.0 0.000286697247706 0 2 -2
of,either,agent 1.0 0.000286697247706 0 2 -2
of,either,age 1.0 0.000143348623853 0 1 -1
of,efficacy,the 1.0 0.000143348623853 0 1 -1
of,efficacy,has 1.0 0.000143348623853 0 1 -1
of,effective,contraception 1.0 0.000143348623853 0 1 -1
of,effect,of 1.0 0.000143348623853 0 1 -1
of,ee,were 1.0 0.000143348623853 0 1 -1
of,ect,and 1.0 0.000143348623853 0 1 -1
of,each,year 1.0 0.000143348623853 0 1 -1
of,each,would 1.0 0.000143348623853 0 1 -1
of,each,of 1.0 0.000286697247706 0 2 -2
of,each,agent 1.0 0.000143348623853 0 1 -1
of,dyspnea,palpitation 1.0 0.000143348623853 0 1 -1
of,dynacirc,and 1.0 0.000286697247706 0 2 -2
of,during,the 1.0 0.000286697247706 0 2 -2
of,duloxetine,it 1.0 0.000143348623853 0 1 -1
of,drugs,metabolized 1.0 0.000143348623853 0 1 -1
of,drugs,in 1.0 0.000286697247706 0 2 -2
of,drugs,affecting 1.0 0.000143348623853 0 1 -1
of,drug-metabolizing,enzymes 1.0 0.000143348623853 0 1 -1
of,drug-induced,cns-related 1.0 0.000143348623853 0 1 -1
of,drug-drug,interactions 1.0 0.000143348623853 0 1 -1
of,drug,side 1.0 0.000143348623853 0 1 -1
of,drug,metabolized 1.0 0.000143348623853 0 1 -1
of,drug,interactions 1.0 0.000143348623853 0 1 -1
of,dosing,reduced 1.0 0.000143348623853 0 1 -1
of,doses,there 1.0 0.000143348623853 0 1 -1
of,doses,of 1.0 0.000143348623853 0 1 -1
of,dosages,and 1.0 0.000143348623853 0 1 -1
of,dosage,should 1.0 0.000143348623853 0 1 -1
of,dosage,or 1.0 0.000143348623853 0 1 -1
of,dosage,of 1.0 0.000286697247706 0 2 -2
of,dosage,may 1.0 0.000143348623853 0 1 -1
of,dosage,is 1.0 0.000286697247706 0 2 -2
of,dogs,deprived 1.0 0.000143348623853 0 1 -1
of,do,not 1.0 0.000143348623853 0 1 -1
of,dmpge2,were 1.0 0.000143348623853 0 1 -1
of,dmpge2,induces 1.0 0.000143348623853 0 1 -1
of,dmpge2,in 1.0 0.000143348623853 0 1 -1
of,dizziness,during 1.0 0.000143348623853 0 1 -1
of,distribution,was 1.0 0.000143348623853 0 1 -1
of,distribution,or 1.0 0.000143348623853 0 1 -1
of,distribution,and 1.0 0.000286697247706 0 2 -2
of,dissolution,of 1.0 0.000286697247706 0 2 -2
of,dissolution,in 1.0 0.000143348623853 0 1 -1
of,disrupts,the 1.0 0.000143348623853 0 1 -1
of,displacement,of 1.0 0.000143348623853 0 1 -1
of,disease,states 1.0 0.000143348623853 0 1 -1
of,disease,and 1.0 0.000143348623853 0 1 -1
of,dimethylprostaglandin,e2-induced 1.0 0.000143348623853 0 1 -1
of,difluoroacetone,mg 1.0 0.000143348623853 0 1 -1
of,difluoroacetone,a 1.0 0.000143348623853 0 1 -1
of,diffusible,treatment 1.0 0.000143348623853 0 1 -1
of,different,on 1.0 0.000143348623853 0 1 -1
of,different,descending 1.0 0.000286697247706 0 2 -2
of,diethyl,pyrocarbonate 1.0 0.000143348623853 0 1 -1
of,diet,and 1.0 0.000143348623853 0 1 -1
of,did,not 1.0 0.00100344036697 0 7 -7
of,dialyzable,may 1.0 0.000143348623853 0 1 -1
of,diabetic,patients 1.0 0.000143348623853 0 1 -1
of,diabetic,and 1.0 0.000143348623853 0 1 -1
of,diabetes,mellitus 1.0 0.000143348623853 0 1 -1
of,diabetes,have 1.0 0.000286697247706 0 2 -2
of,developing,renal 1.0 0.000143348623853 0 1 -1
of,desmopressin,tablets 1.0 0.000143348623853 0 1 -1
of,desmopressin,is 1.0 0.000143348623853 0 1 -1
of,desired,effect 1.0 0.000143348623853 0 1 -1
of,desethylzaleplon,formed 1.0 0.000143348623853 0 1 -1
of,depressive,and 1.0 0.000143348623853 0 1 -1
of,depression,the 1.0 0.000143348623853 0 1 -1
of,depression,than 1.0 0.000143348623853 0 1 -1
of,depression,in 1.0 0.000143348623853 0 1 -1
of,depletion,are 1.0 0.000143348623853 0 1 -1
of,dependence,may 1.0 0.000143348623853 0 1 -1
of,deoxy,to 1.0 0.000143348623853 0 1 -1
of,demonstrated,hypokalemia 1.0 0.00043004587156 0 3 -3
of,deficit,i 1.0 0.000143348623853 0 1 -1
of,deficit,and 1.0 0.000143348623853 0 1 -1
of,deficiency,and 1.0 0.000143348623853 0 1 -1
of,defecation,episodes 1.0 0.000143348623853 0 1 -1
of,deep-seated,infection 1.0 0.000143348623853 0 1 -1
of,decreased,probably 1.0 0.000143348623853 0 1 -1
of,deaths,induced 1.0 0.000143348623853 0 1 -1
of,deaths,in 1.0 0.000143348623853 0 1 -1
of,deaths,associated 1.0 0.000143348623853 0 1 -1
of,dcg-iv,and 1.0 0.000143348623853 0 1 -1
of,days,in 1.0 0.000143348623853 0 1 -1
of,daily,administration 1.0 0.000143348623853 0 1 -1
of,d2,in 1.0 0.000286697247706 0 2 -2
of,d2,binding 1.0 0.000143348623853 0 1 -1
of,d-penicillamine,or 1.0 0.000143348623853 0 1 -1
of,d,is 1.0 0.000143348623853 0 1 -1
of,cytochrome,p450-mediated 1.0 0.000286697247706 0 2 -2
of,cytochrome,cyp 1.0 0.000143348623853 0 1 -1
of,cyp450,enzyme 1.0 0.000143348623853 0 1 -1
of,cyp450,a4 1.0 0.000143348623853 0 1 -1
of,cyp3a4-eplerenone,metabolism 1.0 0.000143348623853 0 1 -1
of,cyp3a4,would 1.0 0.000286697247706 0 2 -2
of,cyp3a4,substrates 1.0 0.000143348623853 0 1 -1
of,cyp3a4,or 1.0 0.000143348623853 0 1 -1
of,cyp3a4,nor 1.0 0.000143348623853 0 1 -1
of,cyp3a4,metabolic 1.0 0.000143348623853 0 1 -1
of,cyp3a4,may 1.0 0.000143348623853 0 1 -1
of,cyp3a4,major 1.0 0.000143348623853 0 1 -1
of,cyp3a4,inhibitors 1.0 0.000143348623853 0 1 -1
of,cyp3a4,in 1.0 0.000143348623853 0 1 -1
of,cyp3a4,have 1.0 0.000143348623853 0 1 -1
of,cyp3a4,did 1.0 0.000143348623853 0 1 -1
of,cyp3a4,can 1.0 0.000143348623853 0 1 -1
of,cyp3a4,below 1.0 0.000143348623853 0 1 -1
of,cyp3a4,and 1.0 0.000286697247706 0 2 -2
of,cyp3a4,alter 1.0 0.000143348623853 0 1 -1
of,cyp3a,cytochrome 1.0 0.000143348623853 0 1 -1
of,cyp2d6,was 1.0 0.000143348623853 0 1 -1
of,cyp2d6,minor 1.0 0.000143348623853 0 1 -1
of,cyp2d6,may 1.0 0.000143348623853 0 1 -1
of,cyp2d6,is 1.0 0.000143348623853 0 1 -1
of,cyp2d6,increase 1.0 0.000143348623853 0 1 -1
of,cyp2d6,in 1.0 0.000143348623853 0 1 -1
of,cyp2d6,because 1.0 0.000143348623853 0 1 -1
of,cyp2c9,at 1.0 0.000143348623853 0 1 -1
of,cyp2c9,and 1.0 0.000143348623853 0 1 -1
of,cyp2c19,and 1.0 0.000143348623853 0 1 -1
of,cyp1a2,and 1.0 0.000143348623853 0 1 -1
of,cyp1a1,cyp1a2 1.0 0.000143348623853 0 1 -1
of,cyp-2c19,by 1.0 0.000143348623853 0 1 -1
of,cyp,isoenzymes 1.0 0.000143348623853 0 1 -1
of,cyp,d6 1.0 0.000143348623853 0 1 -1
of,cyp,c19 1.0 0.000143348623853 0 1 -1
of,cyp,a4 1.0 0.000286697247706 0 2 -2
of,cyclic,amp 1.0 0.000143348623853 0 1 -1
of,cycles,and 1.0 0.000143348623853 0 1 -1
of,crohn,s 1.0 0.000143348623853 0 1 -1
of,creatinine,values 1.0 0.000143348623853 0 1 -1
of,creatinine,makes 1.0 0.000143348623853 0 1 -1
of,creams,ointments 1.0 0.000143348623853 0 1 -1
of,coumarin-type,has 1.0 0.000143348623853 0 1 -1
of,cortisol,thyroid-stimulating 1.0 0.000143348623853 0 1 -1
of,corticosteroid-binding,globulin 1.0 0.000143348623853 0 1 -1
of,correlation,between 1.0 0.000143348623853 0 1 -1
of,coronary,insufficiency 1.0 0.000143348623853 0 1 -1
of,convulsions,occurring 1.0 0.000143348623853 0 1 -1
of,contrast,reactions 1.0 0.000143348623853 0 1 -1
of,contraction,was 1.0 0.000143348623853 0 1 -1
of,contraception,is 1.0 0.000143348623853 0 1 -1
of,contraception,and 1.0 0.000143348623853 0 1 -1
of,consciousness,confusion 1.0 0.000143348623853 0 1 -1
of,conjugated,dienes 1.0 0.000143348623853 0 1 -1
of,conjugated,and 1.0 0.000143348623853 0 1 -1
of,concurrently,with 1.0 0.000143348623853 0 1 -1
of,concomitant,treatment 1.0 0.000143348623853 0 1 -1
of,concomitant,on 1.0 0.000143348623853 0 1 -1
of,concomitant,medications 1.0 0.000716743119266 0 5 -5
of,concomitant,medication 1.0 0.000143348623853 0 1 -1
of,concomitant,chemotherapy 1.0 0.000143348623853 0 1 -1
of,concentrations,tested 1.0 0.000143348623853 0 1 -1
of,concentrations,or 1.0 0.000143348623853 0 1 -1
of,compounds,requiring 1.0 0.000143348623853 0 1 -1
of,compounds,metabolized 1.0 0.000143348623853 0 1 -1
of,components,p1 1.0 0.000286697247706 0 2 -2
of,component,p2 1.0 0.000143348623853 0 1 -1
of,complicated,or 1.0 0.000143348623853 0 1 -1
of,competitive,suppression 1.0 0.000143348623853 0 1 -1
of,competitive,displacement 1.0 0.000143348623853 0 1 -1
of,compared,with 1.0 0.000143348623853 0 1 -1
of,combined,treatment 1.0 0.000143348623853 0 1 -1
of,combined,hyperglycaemia 1.0 0.000143348623853 0 1 -1
of,combined,hormonal 1.0 0.000286697247706 0 2 -2
of,combined,administration 1.0 0.000143348623853 0 1 -1
of,colony,forming 1.0 0.000143348623853 0 1 -1
of,colonic,fluid 1.0 0.000143348623853 0 1 -1
of,collapse,respiratory 1.0 0.000143348623853 0 1 -1
of,colestid,tablets 1.0 0.000143348623853 0 1 -1
of,coagulation,alterations 1.0 0.000143348623853 0 1 -1
of,coadministration,loratadine 1.0 0.000143348623853 0 1 -1
of,coadministered,medicinal 1.0 0.000143348623853 0 1 -1
of,coadministered,and 1.0 0.000286697247706 0 2 -2
of,co-administration,with 1.0 0.000143348623853 0 1 -1
of,co-administration,mean 1.0 0.000143348623853 0 1 -1
of,co-administered,drug 1.0 0.000143348623853 0 1 -1
of,co,and 1.0 0.000143348623853 0 1 -1
of,cmc-cys,exhibiting 1.0 0.000143348623853 0 1 -1
of,cmax,cmin 1.0 0.000143348623853 0 1 -1
of,cmax,and 1.0 0.000143348623853 0 1 -1
of,clozapine,induced 1.0 0.000143348623853 0 1 -1
of,clostridium,were 1.0 0.000143348623853 0 1 -1
of,clostridium,three 1.0 0.000143348623853 0 1 -1
of,clonazepam,on 1.0 0.000143348623853 0 1 -1
of,clonazepam,literature 1.0 0.000143348623853 0 1 -1
of,clolar,with 1.0 0.000143348623853 0 1 -1
of,clinically,significant 1.0 0.000716743119266 0 5 -5
of,clinically,important 1.0 0.000143348623853 0 1 -1
of,clinical,vancomycin-resistant 1.0 0.000143348623853 0 1 -1
of,clinical,toxicity 1.0 0.000143348623853 0 1 -1
of,clinical,significance 1.0 0.000143348623853 0 1 -1
of,clinical,relevance 1.0 0.000143348623853 0 1 -1
of,clinical,laboratory 1.0 0.000286697247706 0 2 -2
of,clinical,interest 1.0 0.000143348623853 0 1 -1
of,clinical,importance 1.0 0.000143348623853 0 1 -1
of,clinical,and 1.0 0.000143348623853 0 1 -1
of,cleavable,complex 1.0 0.000143348623853 0 1 -1
of,clearance,in 1.0 0.000143348623853 0 1 -1
of,circulating,fluids 1.0 0.000286697247706 0 2 -2
of,circulating,catecholamines 1.0 0.000143348623853 0 1 -1
of,circulating,after 1.0 0.000143348623853 0 1 -1
of,circulating,active 1.0 0.000143348623853 0 1 -1
of,ci,of 1.0 0.000143348623853 0 1 -1
of,chylomicron-like,emulsions 1.0 0.000143348623853 0 1 -1
of,chronically,implanted 1.0 0.000143348623853 0 1 -1
of,chronic,obstructive 1.0 0.000143348623853 0 1 -1
of,chronic,dosing 1.0 0.000143348623853 0 1 -1
of,chop-haart,patients 1.0 0.000143348623853 0 1 -1
of,chop,plus 1.0 0.000143348623853 0 1 -1
of,chop,patients 1.0 0.000143348623853 0 1 -1
of,cholino-,and 1.0 0.000143348623853 0 1 -1
of,cholinergic,reactions 1.0 0.000143348623853 0 1 -1
of,cholecystokinin,octapeptide 1.0 0.000143348623853 0 1 -1
of,chloroprocaine,inhibits 1.0 0.000143348623853 0 1 -1
of,children,who 1.0 0.000143348623853 0 1 -1
of,childbearing,potential 1.0 0.000573394495413 0 4 -4
of,chemotherapy,plus 1.0 0.000143348623853 0 1 -1
of,chemicals,that 1.0 0.000143348623853 0 1 -1
of,channels,in 1.0 0.000143348623853 0 1 -1
of,channel,blockers 1.0 0.000143348623853 0 1 -1
of,cerubidine,may 1.0 0.000143348623853 0 1 -1
of,certain,with 1.0 0.000143348623853 0 1 -1
of,certain,metabolizing 1.0 0.000286697247706 0 2 -2
of,certain,concomitant 1.0 0.000143348623853 0 1 -1
of,cerebyx,are 1.0 0.000143348623853 0 1 -1
of,cellular,sensitivity 1.0 0.000143348623853 0 1 -1
of,cefotan,may 1.0 0.000143348623853 0 1 -1
of,caused,subnormal 1.0 0.000143348623853 0 1 -1
of,cause,are 1.0 0.000143348623853 0 1 -1
of,caucasians,are 1.0 0.000716743119266 0 5 -5
of,catecholamines,in 1.0 0.000143348623853 0 1 -1
of,caspase-3,and 1.0 0.000143348623853 0 1 -1
of,cardiovascular,morbidity 1.0 0.000143348623853 0 1 -1
of,cardiovascular,in 1.0 0.000143348623853 0 1 -1
of,cardiovascular,are 1.0 0.000143348623853 0 1 -1
of,cardiovascular,and 1.0 0.000143348623853 0 1 -1
of,cardiopulmonary,arrest 1.0 0.000143348623853 0 1 -1
of,cardiac,arrhythmias 1.0 0.000143348623853 0 1 -1
of,carcinogen,can 1.0 0.000143348623853 0 1 -1
of,carbamazepine,due 1.0 0.000143348623853 0 1 -1
of,candesartan,cilexetil 1.0 0.000143348623853 0 1 -1
of,cancidas,are 1.0 0.000143348623853 0 1 -1
of,cancer,increases 1.0 0.000143348623853 0 1 -1
of,camptosar,with 1.0 0.000143348623853 0 1 -1
of,camp-mediated,acid 1.0 0.000143348623853 0 1 -1
of,calcium-channel,blockers 1.0 0.000143348623853 0 1 -1
of,cadmium,and 1.0 0.000716743119266 0 5 -5
of,ca,currents 1.0 0.000143348623853 0 1 -1
of,by,thyroxine-binding 1.0 0.000143348623853 0 1 -1
of,by,stimulating 1.0 0.000143348623853 0 1 -1
of,by,sodium 1.0 0.000143348623853 0 1 -1
of,by,confidence 1.0 0.000143348623853 0 1 -1
of,but,not 1.0 0.000143348623853 0 1 -1
of,but,increased 1.0 0.000143348623853 0 1 -1
of,buforin,ii 1.0 0.000286697247706 0 2 -2
of,brovana,treated 1.0 0.000143348623853 0 1 -1
of,brovana,are 1.0 0.000143348623853 0 1 -1
of,bronchodilator,may 1.0 0.000143348623853 0 1 -1
of,brevibloc,on 1.0 0.000143348623853 0 1 -1
of,breakthrough,symptoms 1.0 0.000143348623853 0 1 -1
of,breakthrough,bleeding 1.0 0.000286697247706 0 2 -2
of,bradycardia,sinus 1.0 0.000143348623853 0 1 -1
of,both,than 1.0 0.000143348623853 0 1 -1
of,both,possibly 1.0 0.000143348623853 0 1 -1
of,both,parental 1.0 0.000143348623853 0 1 -1
of,both,human 1.0 0.000143348623853 0 1 -1
of,both,ethynyl 1.0 0.000143348623853 0 1 -1
of,both,elements 1.0 0.000143348623853 0 1 -1
of,both,cyp2c9 1.0 0.000143348623853 0 1 -1
of,both,cyp1a2 1.0 0.000143348623853 0 1 -1
of,both,control 1.0 0.000143348623853 0 1 -1
of,both,agents 1.0 0.000143348623853 0 1 -1
of,bone,marrow 1.0 0.000286697247706 0 2 -2
of,body,weight 1.0 0.000143348623853 0 1 -1
of,body,fat 1.0 0.000143348623853 0 1 -1
of,blood,levels 1.0 0.000143348623853 0 1 -1
of,blood,concentrations 1.0 0.000143348623853 0 1 -1
of,blood,can 1.0 0.000143348623853 0 1 -1
of,blockers,on 1.0 0.000143348623853 0 1 -1
of,bleeding,with 1.0 0.000143348623853 0 1 -1
of,bleeding,events 1.0 0.000143348623853 0 1 -1
of,bleeding,complications 1.0 0.000143348623853 0 1 -1
of,biocytin,with 1.0 0.000143348623853 0 1 -1
of,biocytin,inclusion 1.0 0.000143348623853 0 1 -1
of,bioavailability,relative 1.0 0.000143348623853 0 1 -1
of,bioavailability,of 1.0 0.000143348623853 0 1 -1
of,bioavailability,area 1.0 0.000143348623853 0 1 -1
of,binding,to 1.0 0.000143348623853 0 1 -1
of,binding,in 1.0 0.000143348623853 0 1 -1
of,bextra,mg 1.0 0.000143348623853 0 1 -1
of,between,the 1.0 0.000143348623853 0 1 -1
of,beta-receptor,agonist 1.0 0.000143348623853 0 1 -1
of,bepridil,with 1.0 0.000143348623853 0 1 -1
of,bepridil,and 1.0 0.000143348623853 0 1 -1
of,benign,ovarian 1.0 0.000143348623853 0 1 -1
of,because,the 1.0 0.000143348623853 0 1 -1
of,baseline,for 1.0 0.000143348623853 0 1 -1
of,basal,medium 1.0 0.000143348623853 0 1 -1
of,barrier,form 1.0 0.000143348623853 0 1 -1
of,baraclude,with 1.0 0.000286697247706 0 2 -2
of,bar-press,response 1.0 0.000143348623853 0 1 -1
of,bacteria,tested 1.0 0.000143348623853 0 1 -1
of,b6,physiological 1.0 0.000143348623853 0 1 -1
of,b,were 1.0 0.000143348623853 0 1 -1
of,b,for 1.0 0.000143348623853 0 1 -1
of,b,can 1.0 0.000143348623853 0 1 -1
of,augmentin,xr 1.0 0.000143348623853 0 1 -1
of,atp,and 1.0 0.000143348623853 0 1 -1
of,atherosclerotic,risk 1.0 0.000143348623853 0 1 -1
of,atherosclerotic,disease 1.0 0.000143348623853 0 1 -1
of,at,therapeutic 1.0 0.000143348623853 0 1 -1
of,at,their 1.0 0.000143348623853 0 1 -1
of,at,the 1.0 0.000143348623853 0 1 -1
of,at,steady 1.0 0.000143348623853 0 1 -1
of,at,h 1.0 0.000143348623853 0 1 -1
of,at,concentrations 1.0 0.000143348623853 0 1 -1
of,at,a 1.0 0.000143348623853 0 1 -1
of,astringents,spices 1.0 0.000143348623853 0 1 -1
of,asthma,control 1.0 0.000143348623853 0 1 -1
of,ast,sgot 1.0 0.000143348623853 0 1 -1
of,assistance,in 1.0 0.000143348623853 0 1 -1
of,assays,using 1.0 0.000143348623853 0 1 -1
of,as,v 1.0 0.00043004587156 0 3 -3
of,as,measured 1.0 0.000143348623853 0 1 -1
of,as,determined 1.0 0.000143348623853 0 1 -1
of,as,assessed 1.0 0.000286697247706 0 2 -2
of,artocarpus,integrifolia 1.0 0.000143348623853 0 1 -1
of,arsenical,reactive 1.0 0.000143348623853 0 1 -1
of,arsenical,encephalopathy 1.0 0.000143348623853 0 1 -1
of,arrhythmias,or 1.0 0.000143348623853 0 1 -1
of,arrhythmias,due 1.0 0.000143348623853 0 1 -1
of,arimidex,with 1.0 0.000143348623853 0 1 -1
of,arimidex,and 1.0 0.000143348623853 0 1 -1
of,argatroban,g 1.0 0.000143348623853 0 1 -1
of,are,unaltered 1.0 0.000143348623853 0 1 -1
of,are,tolerated 1.0 0.000143348623853 0 1 -1
of,are,suddenly 1.0 0.000143348623853 0 1 -1
of,are,reviewed 1.0 0.000143348623853 0 1 -1
of,are,not 1.0 0.000143348623853 0 1 -1
of,arc,gene 1.0 0.000143348623853 0 1 -1
of,aranesp,have 1.0 0.000143348623853 0 1 -1
of,arachidonic,acid 1.0 0.000143348623853 0 1 -1
of,arachidonate-,or 1.0 0.000143348623853 0 1 -1
of,approximately,um 1.0 0.000143348623853 0 1 -1
of,apoptosis,in 1.0 0.000143348623853 0 1 -1
of,aom,mg 1.0 0.000143348623853 0 1 -1
of,any,pharmacokinetic 1.0 0.000143348623853 0 1 -1
of,any,of 1.0 0.00114678899083 0 8 -8
of,any,from 1.0 0.000143348623853 0 1 -1
of,any,enzyme 1.0 0.000143348623853 0 1 -1
of,antithrombotics,aspirin 1.0 0.000143348623853 0 1 -1
of,antistress,effects 1.0 0.000143348623853 0 1 -1
of,antimicrobial,combinations 1.0 0.000143348623853 0 1 -1
of,antigout,medications 1.0 0.000143348623853 0 1 -1
of,antifibrinolytic,therapies 1.0 0.000143348623853 0 1 -1
of,antidepressant,may 1.0 0.000286697247706 0 2 -2
of,antidepressant,agent 1.0 0.000143348623853 0 1 -1
of,anticoagulation,may 1.0 0.000143348623853 0 1 -1
of,anticoagulation,levels 1.0 0.000143348623853 0 1 -1
of,anticholinesterase,overdose 1.0 0.000143348623853 0 1 -1
of,antiaddictive,efficacy 1.0 0.000143348623853 0 1 -1
of,anti-platelet,effect 1.0 0.000143348623853 0 1 -1
of,anti-factor,xa 1.0 0.000286697247706 0 2 -2
of,antagonists,phenyltheophylline 1.0 0.000143348623853 0 1 -1
of,antagonists,and 1.0 0.000143348623853 0 1 -1
of,antagonism,in 1.0 0.000143348623853 0 1 -1
of,antacids,on 1.0 0.000143348623853 0 1 -1
of,another,extended 1.0 0.000143348623853 0 1 -1
of,animals,dosed 1.0 0.000143348623853 0 1 -1
of,animal,source 1.0 0.000143348623853 0 1 -1
of,angiotensin,and 1.0 0.000143348623853 0 1 -1
of,angiomax,and 1.0 0.000143348623853 0 1 -1
of,angina,myocardial 1.0 0.000143348623853 0 1 -1
of,andtolbutamide,did 1.0 0.000143348623853 0 1 -1
of,and,was 1.0 0.000143348623853 0 1 -1
of,and,treatment 1.0 0.000143348623853 0 1 -1
of,and,those 1.0 0.000143348623853 0 1 -1
of,and,these 1.0 0.000143348623853 0 1 -1
of,and,therapy 1.0 0.000143348623853 0 1 -1
of,and,their 1.0 0.000143348623853 0 1 -1
of,and,sodium 1.0 0.000143348623853 0 1 -1
of,and,single 1.0 0.000143348623853 0 1 -1
of,and,signs 1.0 0.000143348623853 0 1 -1
of,and,served 1.0 0.000143348623853 0 1 -1
of,and,serotonergic 1.0 0.000143348623853 0 1 -1
of,and,one 1.0 0.000143348623853 0 1 -1
of,and,on 1.0 0.000573394495413 0 4 -4
of,and,of 1.0 0.000286697247706 0 2 -2
of,and,no 1.0 0.000143348623853 0 1 -1
of,and,n-acetyl 1.0 0.000143348623853 0 1 -1
of,and,must 1.0 0.000143348623853 0 1 -1
of,and,micrograms 1.0 0.000143348623853 0 1 -1
of,and,metabolized 1.0 0.000143348623853 0 1 -1
of,and,inn 1.0 0.000143348623853 0 1 -1
of,and,inhibitors 1.0 0.000143348623853 0 1 -1
of,and,hydroxydesloratadine 1.0 0.000143348623853 0 1 -1
of,and,hydroxides 1.0 0.000143348623853 0 1 -1
of,and,hydrochloride 1.0 0.000143348623853 0 1 -1
of,and,haldol 1.0 0.000143348623853 0 1 -1
of,and,had 1.0 0.00043004587156 0 3 -3
of,and,for 1.0 0.000143348623853 0 1 -1
of,and,following 1.0 0.000143348623853 0 1 -1
of,and,effects 1.0 0.000143348623853 0 1 -1
of,and,during 1.0 0.000143348623853 0 1 -1
of,and,did 1.0 0.00043004587156 0 3 -3
of,and,decrease 1.0 0.000143348623853 0 1 -1
of,and,concomitant 1.0 0.000143348623853 0 1 -1
of,and,cns-active 1.0 0.000143348623853 0 1 -1
of,and,caused 1.0 0.000143348623853 0 1 -1
of,and,cause 1.0 0.000143348623853 0 1 -1
of,and,bretylium 1.0 0.000143348623853 0 1 -1
of,and,at 1.0 0.000286697247706 0 2 -2
of,and,asa 1.0 0.000143348623853 0 1 -1
of,and,alone 1.0 0.000143348623853 0 1 -1
of,and,acamprosate 1.0 0.000143348623853 0 1 -1
of,anafranil,caution 1.0 0.000143348623853 0 1 -1
of,an,oral 1.0 0.000143348623853 0 1 -1
of,an,isocaloric 1.0 0.000143348623853 0 1 -1
of,an,in 1.0 0.000143348623853 0 1 -1
of,an,effector 1.0 0.000286697247706 0 2 -2
of,an,effect 1.0 0.000143348623853 0 1 -1
of,an,analog 1.0 0.000143348623853 0 1 -1
of,an,aluminum-containing 1.0 0.000143348623853 0 1 -1
of,an,aluminum 1.0 0.000143348623853 0 1 -1
of,an,adverse 1.0 0.000143348623853 0 1 -1
of,an,active 1.0 0.000143348623853 0 1 -1
of,aminotransferase,sgot 1.0 0.000143348623853 0 1 -1
of,amicar,transient 1.0 0.000143348623853 0 1 -1
of,amicar,necessary 1.0 0.000143348623853 0 1 -1
of,amicar,may 1.0 0.000143348623853 0 1 -1
of,amicar,at 1.0 0.000143348623853 0 1 -1
of,amevive,on 1.0 0.000143348623853 0 1 -1
of,amevive,in 1.0 0.000286697247706 0 2 -2
of,amevive,administered 1.0 0.000143348623853 0 1 -1
of,ames,company 1.0 0.000143348623853 0 1 -1
of,american,coffee 1.0 0.000143348623853 0 1 -1
of,altered,topo 1.0 0.000143348623853 0 1 -1
of,altered,safety 1.0 0.000143348623853 0 1 -1
of,also,appears 1.0 0.000143348623853 0 1 -1
of,alone,versus 1.0 0.000143348623853 0 1 -1
of,alone,or 1.0 0.000286697247706 0 2 -2
of,alone,markedly 1.0 0.000143348623853 0 1 -1
of,allergic,or 1.0 0.000143348623853 0 1 -1
of,allergens,may 1.0 0.000716743119266 0 5 -5
of,allergens,either 1.0 0.000143348623853 0 1 -1
of,all,prescription 1.0 0.000143348623853 0 1 -1
of,all,agents 1.0 0.000143348623853 0 1 -1
of,alkalinization,of 1.0 0.000143348623853 0 1 -1
of,aliskiren,on 1.0 0.000143348623853 0 1 -1
of,alfenta,my 1.0 0.000143348623853 0 1 -1
of,aldehyde,oxidase 1.0 0.000143348623853 0 1 -1
of,alcoholic,beverages 1.0 0.000143348623853 0 1 -1
of,alcohol-related,deaths 1.0 0.000143348623853 0 1 -1
of,akathisia,however 1.0 0.000143348623853 0 1 -1
of,agranulocytosis,as 1.0 0.000143348623853 0 1 -1
of,aggression,and 1.0 0.000143348623853 0 1 -1
of,agents,such 1.0 0.000143348623853 0 1 -1
of,agents,of 1.0 0.000143348623853 0 1 -1
of,agents,lower 1.0 0.000286697247706 0 2 -2
of,agents,increase 1.0 0.000143348623853 0 1 -1
of,agents,in 1.0 0.000143348623853 0 1 -1
of,agents,derivatives 1.0 0.000143348623853 0 1 -1
of,age,the 1.0 0.000143348623853 0 1 -1
of,age,or 1.0 0.000143348623853 0 1 -1
of,age,and 1.0 0.000286697247706 0 2 -2
of,against,of 1.0 0.000143348623853 0 1 -1
of,after,their 1.0 0.000143348623853 0 1 -1
of,after,mefloquineuine 1.0 0.000143348623853 0 1 -1
of,after,being 1.0 0.000143348623853 0 1 -1
of,after,a 1.0 0.000143348623853 0 1 -1
of,affected,by 1.0 0.000286697247706 0 2 -2
of,aerosolized,has 1.0 0.000143348623853 0 1 -1
of,aerosol,particles 1.0 0.000286697247706 0 2 -2
of,aed,on 1.0 0.000143348623853 0 1 -1
of,aed,interactions 1.0 0.000143348623853 0 1 -1
of,adverse,reactions 1.0 0.000143348623853 0 1 -1
of,adverse,events 1.0 0.000573394495413 0 4 -4
of,adverse,effects 1.0 0.00043004587156 0 3 -3
of,adverse,consequences 1.0 0.000143348623853 0 1 -1
of,adverse,clinical 1.0 0.000143348623853 0 1 -1
of,adrenocorticoids,is 1.0 0.000143348623853 0 1 -1
of,admissions,for 1.0 0.000143348623853 0 1 -1
of,administration,with 1.0 0.000143348623853 0 1 -1
of,administration,one 1.0 0.000143348623853 0 1 -1
of,administration,of 1.0 0.000286697247706 0 2 -2
of,administering,different 1.0 0.000286697247706 0 2 -2
of,administered,to 1.0 0.000143348623853 0 1 -1
of,administered,orally 1.0 0.000143348623853 0 1 -1
of,administered,h 1.0 0.000143348623853 0 1 -1
of,administered,concomitantly 1.0 0.000143348623853 0 1 -1
of,administered,as 1.0 0.000286697247706 0 2 -2
of,administered,alone 1.0 0.000143348623853 0 1 -1
of,adequate,dosage 1.0 0.000143348623853 0 1 -1
of,additional,calcium-containing 1.0 0.00043004587156 0 3 -3
of,addicts,in 1.0 0.000143348623853 0 1 -1
of,addiction,while 1.0 0.000143348623853 0 1 -1
of,aczone,gel 1.0 0.000143348623853 0 1 -1
of,acute,pretreatment 1.0 0.000143348623853 0 1 -1
of,acute,phase 1.0 0.000143348623853 0 1 -1
of,acute,myocardial 1.0 0.000143348623853 0 1 -1
of,acute,ischemic 1.0 0.000143348623853 0 1 -1
of,acute,angina 1.0 0.000143348623853 0 1 -1
of,activity,against 1.0 0.000143348623853 0 1 -1
of,activated,prothrombin 1.0 0.000143348623853 0 1 -1
of,activase,with 1.0 0.000143348623853 0 1 -1
of,activase,in 1.0 0.000143348623853 0 1 -1
of,actions,and 1.0 0.000143348623853 0 1 -1
of,action,or 1.0 0.000143348623853 0 1 -1
of,action,including 1.0 0.000143348623853 0 1 -1
of,action,exists 1.0 0.000143348623853 0 1 -1
of,action,by 1.0 0.000143348623853 0 1 -1
of,action,are 1.0 0.000143348623853 0 1 -1
of,acetylsalicylic,acid 1.0 0.000286697247706 0 2 -2
of,acetate,and 1.0 0.000143348623853 0 1 -1
of,ace,inhibitors 1.0 0.000143348623853 0 1 -1
of,accumulation,that 1.0 0.000143348623853 0 1 -1
of,absorption,or 1.0 0.000143348623853 0 1 -1
of,absorption,but 1.0 0.000143348623853 0 1 -1
of,absorption,after 1.0 0.000143348623853 0 1 -1
of,absorbed,while 1.0 0.000143348623853 0 1 -1
of,absolute,in 1.0 0.000143348623853 0 1 -1
of,abnormal,handling 1.0 0.000143348623853 0 1 -1
of,a,with 1.0 0.000286697247706 0 2 -2
of,a,tumor 1.0 0.000143348623853 0 1 -1
of,a,true 1.0 0.000143348623853 0 1 -1
of,a,thorough 1.0 0.000143348623853 0 1 -1
of,a,that 1.0 0.00043004587156 0 3 -3
of,a,test 1.0 0.000143348623853 0 1 -1
of,a,synergistic 1.0 0.000143348623853 0 1 -1
of,a,solution 1.0 0.000143348623853 0 1 -1
of,a,role 1.0 0.000143348623853 0 1 -1
of,a,pulmonary 1.0 0.000143348623853 0 1 -1
of,a,potential 1.0 0.000143348623853 0 1 -1
of,a,possible 1.0 0.000286697247706 0 2 -2
of,a,pacemaker 1.0 0.000143348623853 0 1 -1
of,a,novel 1.0 0.000143348623853 0 1 -1
of,a,nonhormonal 1.0 0.000860091743119 0 6 -6
of,a,nd 1.0 0.000143348623853 0 1 -1
of,a,nasal 1.0 0.000143348623853 0 1 -1
of,a,mammalian 1.0 0.000143348623853 0 1 -1
of,a,krm-1648 1.0 0.000143348623853 0 1 -1
of,a,interaction 1.0 0.000143348623853 0 1 -1
of,a,hot 1.0 0.000143348623853 0 1 -1
of,a,higher 1.0 0.000143348623853 0 1 -1
of,a,group 1.0 0.000143348623853 0 1 -1
of,a,g 1.0 0.000143348623853 0 1 -1
of,a,false-positive 1.0 0.000143348623853 0 1 -1
of,a,facilitates 1.0 0.000143348623853 0 1 -1
of,a,disulfiram-like 1.0 0.000143348623853 0 1 -1
of,a,direct 1.0 0.000143348623853 0 1 -1
of,a,chylomicron-like 1.0 0.000143348623853 0 1 -1
of,a,chemical 1.0 0.000143348623853 0 1 -1
of,a,blunting 1.0 0.000143348623853 0 1 -1
odontoid,and,ventral 1.0 0.000143348623853 0 1 -1
ocular,blood,flow 1.0 0.000143348623853 0 1 -1
ocular,and,renal 1.0 0.000143348623853 0 1 -1
october,of,each 1.0 0.000143348623853 0 1 -1
octapeptide,was,replaced 1.0 0.000143348623853 0 1 -1
octapeptide,is,a 1.0 0.000143348623853 0 1 -1
octapeptide,cholecystokinin--of,h-spiroperidol 1.0 0.000143348623853 0 1 -1
ocs,macrolide,antibiotics 1.0 0.000143348623853 0 1 -1
occurs,with,the 1.0 0.00043004587156 0 3 -3
occurs,with,other 1.0 0.000143348623853 0 1 -1
occurs,with,ganglionic 1.0 0.000286697247706 0 2 -2
occurs,while,taking 1.0 0.000143348623853 0 1 -1
occurs,when,the 1.0 0.000143348623853 0 1 -1
occurs,when,eye 1.0 0.000143348623853 0 1 -1
occurs,the,patient 1.0 0.000143348623853 0 1 -1
occurs,in,proteins 1.0 0.000143348623853 0 1 -1
occurs,in,a 1.0 0.000143348623853 0 1 -1
occurring,in,susceptible 1.0 0.000143348623853 0 1 -1
occurrence,of,severe 1.0 0.000286697247706 0 2 -2
occurrence,of,peripheral 1.0 0.000143348623853 0 1 -1
occurrence,of,osteomalacia 1.0 0.000143348623853 0 1 -1
occurrence,of,myelotoxicity 1.0 0.000143348623853 0 1 -1
occurred,within,hours 1.0 0.000286697247706 0 2 -2
occurred,with,similar 1.0 0.000143348623853 0 1 -1
occurred,with,concomitant 1.0 0.000143348623853 0 1 -1
occurred,when,was 1.0 0.000143348623853 0 1 -1
occurred,when,prinivil 1.0 0.000143348623853 0 1 -1
occurred,when,lotensin 1.0 0.000143348623853 0 1 -1
occurred,when,cefotan 1.0 0.000143348623853 0 1 -1
occurred,when,and 1.0 0.000143348623853 0 1 -1
occurred,three,months 1.0 0.000143348623853 0 1 -1
occurred,significantly,more 1.0 0.000143348623853 0 1 -1
occurred,more,frequently 1.0 0.000143348623853 0 1 -1
occurred,in,the 1.0 0.000143348623853 0 1 -1
occurred,in,heart 1.0 0.000143348623853 0 1 -1
occurred,during,a 1.0 0.000143348623853 0 1 -1
occurred,between,the 1.0 0.000143348623853 0 1 -1
occur,within,the 1.0 0.000143348623853 0 1 -1
occur,with,use 1.0 0.000143348623853 0 1 -1
occur,with,that 1.0 0.000143348623853 0 1 -1
occur,with,tests 1.0 0.000286697247706 0 2 -2
occur,with,copper 1.0 0.00043004587156 0 3 -3
occur,with,co-administration 1.0 0.000143348623853 0 1 -1
occur,with,benedicts 1.0 0.000143348623853 0 1 -1
occur,which,may 1.0 0.000143348623853 0 1 -1
occur,when,duragesic 1.0 0.000143348623853 0 1 -1
occur,when,contrast 1.0 0.000286697247706 0 2 -2
occur,when,coadministered 1.0 0.000143348623853 0 1 -1
occur,the,epa 1.0 0.000143348623853 0 1 -1
occur,sometimes,with 1.0 0.000286697247706 0 2 -2
occur,potentiating,the 1.0 0.000143348623853 0 1 -1
occur,in,therapeutic 1.0 0.000143348623853 0 1 -1
occur,in,neonates 1.0 0.000143348623853 0 1 -1
occur,if,the 1.0 0.000143348623853 0 1 -1
occur,if,b12 1.0 0.000143348623853 0 1 -1
occur,following,concomitant 1.0 0.000143348623853 0 1 -1
occur,due,to 1.0 0.000143348623853 0 1 -1
occur,at,high 1.0 0.000143348623853 0 1 -1
occupational,exposure,to 1.0 0.000143348623853 0 1 -1
occasionally,taxol,infusions 1.0 0.000143348623853 0 1 -1
occasionally,induce,a 1.0 0.00043004587156 0 3 -3
occasionally,been,used 1.0 0.000143348623853 0 1 -1
occasionally,been,associated 1.0 0.000143348623853 0 1 -1
occasional,susceptible,patients 1.0 0.000143348623853 0 1 -1
occasional,doses,of 1.0 0.000143348623853 0 1 -1
occasion,in,the 1.0 0.000143348623853 0 1 -1
obtained,with,a 1.0 0.000143348623853 0 1 -1
obtained,in,vivo 1.0 0.000143348623853 0 1 -1
obtained,in,a 1.0 0.000143348623853 0 1 -1
obtained,from,the 1.0 0.000143348623853 0 1 -1
obtained,from,studies 1.0 0.00043004587156 0 3 -3
obtained,from,controlled 1.0 0.000143348623853 0 1 -1
obtained,for,any 1.0 0.000143348623853 0 1 -1
obtained,evidence,that 1.0 0.000143348623853 0 1 -1
obtained,either,dosage 1.0 0.000143348623853 0 1 -1
obtained,by,the 1.0 0.000143348623853 0 1 -1
obtained,before,starting 1.0 0.000143348623853 0 1 -1
obstruction,and,even 1.0 0.000143348623853 0 1 -1
obstetrical,cardiological,and 1.0 0.000143348623853 0 1 -1
observed,with,regimens 1.0 0.000143348623853 0 1 -1
observed,with,prolongation 1.0 0.000143348623853 0 1 -1
observed,with,likely 1.0 0.000143348623853 0 1 -1
observed,with,dual 1.0 0.000143348623853 0 1 -1
observed,with,co-administration 1.0 0.000143348623853 0 1 -1
observed,with,clinitest 1.0 0.000143348623853 0 1 -1
observed,with,blood 1.0 0.000143348623853 0 1 -1
observed,with,beta-receptor 1.0 0.000143348623853 0 1 -1
observed,with,benedict 1.0 0.000286697247706 0 2 -2
observed,with,another 1.0 0.000143348623853 0 1 -1
observed,when,viracept 1.0 0.000143348623853 0 1 -1
observed,when,vardenafil 1.0 0.000143348623853 0 1 -1
observed,when,subjects 1.0 0.000143348623853 0 1 -1
observed,when,or 1.0 0.000143348623853 0 1 -1
observed,when,norpace 1.0 0.000143348623853 0 1 -1
observed,when,and 1.0 0.000143348623853 0 1 -1
observed,when,a 1.0 0.000143348623853 0 1 -1
observed,training-induced,neurobiological 1.0 0.000143348623853 0 1 -1
observed,to,be 1.0 0.000143348623853 0 1 -1
observed,there,were 1.0 0.000143348623853 0 1 -1
observed,the,concentrations 1.0 0.000143348623853 0 1 -1
observed,that,the 1.0 0.000143348623853 0 1 -1
observed,that,is 1.0 0.000143348623853 0 1 -1
observed,that,had 1.0 0.000143348623853 0 1 -1
observed,only,at 1.0 0.000143348623853 0 1 -1
observed,more,frequently 1.0 0.000143348623853 0 1 -1
observed,in,tarceva 1.0 0.000143348623853 0 1 -1
observed,in,some 1.0 0.000143348623853 0 1 -1
observed,in,of 1.0 0.000286697247706 0 2 -2
observed,in,north 1.0 0.000143348623853 0 1 -1
observed,in,non-human 1.0 0.000143348623853 0 1 -1
observed,in,nephrosis 1.0 0.000143348623853 0 1 -1
observed,in,mice 1.0 0.000143348623853 0 1 -1
observed,in,mean 1.0 0.000143348623853 0 1 -1
observed,in,man 1.0 0.000143348623853 0 1 -1
observed,in,male 1.0 0.000143348623853 0 1 -1
observed,in,liver 1.0 0.000143348623853 0 1 -1
observed,in,female 1.0 0.000143348623853 0 1 -1
observed,in,dogs 1.0 0.000143348623853 0 1 -1
observed,in,cynomolgus 1.0 0.000143348623853 0 1 -1
observed,in,comparative 1.0 0.000143348623853 0 1 -1
observed,in,arthritic 1.0 0.000143348623853 0 1 -1
observed,in,any 1.0 0.000143348623853 0 1 -1
observed,in,a 1.0 0.000286697247706 0 2 -2
observed,hours,after 1.0 0.000143348623853 0 1 -1
observed,for,metabolite 1.0 0.000143348623853 0 1 -1
observed,for,loss 1.0 0.000716743119266 0 5 -5
observed,for,increased 1.0 0.000143348623853 0 1 -1
observed,for,evidence 1.0 0.00043004587156 0 3 -3
observed,for,clinical 1.0 0.000143348623853 0 1 -1
observed,for,any 1.0 0.000143348623853 0 1 -1
observed,following,the 1.0 0.00043004587156 0 3 -3
observed,following,coadministration 1.0 0.000143348623853 0 1 -1
observed,effects,on 1.0 0.000143348623853 0 1 -1
observed,during,the 1.0 0.000143348623853 0 1 -1
observed,during,clinical 1.0 0.000143348623853 0 1 -1
observed,during,administration 1.0 0.000143348623853 0 1 -1
observed,closely,particularly 1.0 0.000143348623853 0 1 -1
observed,carefully,in 1.0 0.000143348623853 0 1 -1
observed,by,measuring 1.0 0.000143348623853 0 1 -1
observed,but,were 1.0 0.000143348623853 0 1 -1
observed,but,there 1.0 0.000143348623853 0 1 -1
observed,between,older 1.0 0.000143348623853 0 1 -1
observed,between,both 1.0 0.000143348623853 0 1 -1
observed,between,argatroban 1.0 0.000143348623853 0 1 -1
observed,at,concentrations 1.0 0.000143348623853 0 1 -1
observed,and,the 1.0 0.000143348623853 0 1 -1
observed,and,no 1.0 0.000143348623853 0 1 -1
observed,after,concomitant 1.0 0.000143348623853 0 1 -1
observed,after,administration 1.0 0.000143348623853 0 1 -1
observe,the,patient 1.0 0.000143348623853 0 1 -1
observe,that,inhibited 1.0 0.000143348623853 0 1 -1
observations,which,indicate 1.0 0.000143348623853 0 1 -1
observations,suggest,that 1.0 0.000143348623853 0 1 -1
observations,strongly,suggest 1.0 0.000143348623853 0 1 -1
observations,now,appearing 1.0 0.000143348623853 0 1 -1
observations,i,these 1.0 0.000143348623853 0 1 -1
observations,from,interaction 1.0 0.000143348623853 0 1 -1
observations,are,discussed 1.0 0.000143348623853 0 1 -1
observation,period,in 1.0 0.000143348623853 0 1 -1
observation,must,be 1.0 0.000143348623853 0 1 -1
observation,is,related 1.0 0.000143348623853 0 1 -1
objectives,to,identify 1.0 0.000143348623853 0 1 -1
objectives,to,examine 1.0 0.000143348623853 0 1 -1
objectives,of,this 1.0 0.000143348623853 0 1 -1
objective,was,to 1.0 0.000286697247706 0 2 -2
objective,to,report 1.0 0.000143348623853 0 1 -1
objective,to,evaluate 1.0 0.000143348623853 0 1 -1
objective,this,paper 1.0 0.000143348623853 0 1 -1
objective,responses,were 1.0 0.000143348623853 0 1 -1
objective,our,objective 1.0 0.000286697247706 0 2 -2
objective,of,this 1.0 0.000143348623853 0 1 -1
obesity,dorsocervical,fat 1.0 0.000143348623853 0 1 -1
obesity,as,well 1.0 0.000143348623853 0 1 -1
oa,patients,there 1.0 0.000143348623853 0 1 -1
o11,strains,from 1.0 0.000143348623853 0 1 -1
o11,strains,but 1.0 0.000143348623853 0 1 -1
o-glucuronidation,ki,value 1.0 0.000143348623853 0 1 -1
o-gallate,and,theasinensin 1.0 0.000143348623853 0 1 -1
o-desacetyl,metabolites,were 1.0 0.000143348623853 0 1 -1
nystagmus,strabismus,miosis 1.0 0.000143348623853 0 1 -1
nyha,class,ii 1.0 0.000143348623853 0 1 -1
nutritional,supplement,food 1.0 0.000286697247706 0 2 -2
nutrition,or,depresses 1.0 0.000143348623853 0 1 -1
nutraceutical,st,johns 1.0 0.000143348623853 0 1 -1
nursing,while,taking 1.0 0.000143348623853 0 1 -1
nursing,or,to 1.0 0.000143348623853 0 1 -1
nursing,or,discontinue 1.0 0.000143348623853 0 1 -1
nursing,mothers,it 1.0 0.000143348623853 0 1 -1
nursing,mothers,fulvestrant 1.0 0.000143348623853 0 1 -1
nursing,infants,from 1.0 0.000143348623853 0 1 -1
nursing,infants,a 1.0 0.000286697247706 0 2 -2
nursing,infant,has 1.0 0.000143348623853 0 1 -1
nuromax,before,to 1.0 0.000143348623853 0 1 -1
nuromax,and,other 1.0 0.000143348623853 0 1 -1
nuprin,others,orudis 1.0 0.000143348623853 0 1 -1
numerous,potentiation,effects 1.0 0.000143348623853 0 1 -1
numerous,liver,tumors 1.0 0.000143348623853 0 1 -1
numerous,interactions,are 1.0 0.000143348623853 0 1 -1
numbers,of,two 1.0 0.000143348623853 0 1 -1
numbers,of,subjects 1.0 0.000143348623853 0 1 -1
numbers,of,colony 1.0 0.000143348623853 0 1 -1
number,of,substances 1.0 0.000286697247706 0 2 -2
number,of,steps 1.0 0.000143348623853 0 1 -1
number,of,sites 1.0 0.000143348623853 0 1 -1
number,of,responses 1.0 0.000143348623853 0 1 -1
number,of,regular 1.0 0.000143348623853 0 1 -1
number,of,prescribed 1.0 0.000143348623853 0 1 -1
number,of,per 1.0 0.000143348623853 0 1 -1
number,of,patients 1.0 0.000573394495413 0 4 -4
number,of,microtubules 1.0 0.000143348623853 0 1 -1
number,of,intrinsic 1.0 0.000143348623853 0 1 -1
number,of,in 1.0 0.000143348623853 0 1 -1
number,of,events 1.0 0.000143348623853 0 1 -1
number,of,defecation 1.0 0.000143348623853 0 1 -1
number,of,deaths 1.0 0.000286697247706 0 2 -2
number,of,cycles 1.0 0.000143348623853 0 1 -1
number,of,alcohol-related 1.0 0.000143348623853 0 1 -1
number,of,adverse 1.0 0.000143348623853 0 1 -1
number,fell,to 1.0 0.000143348623853 0 1 -1
nueronal,cell,body 1.0 0.000143348623853 0 1 -1
nucleus,accumbens,nac 1.0 0.000143348623853 0 1 -1
nucleus,accumbens,but 1.0 0.000143348623853 0 1 -1
nucleotide,release,and 1.0 0.000143348623853 0 1 -1
nucleoside-experienced,patients,although 1.0 0.000143348623853 0 1 -1
nucleophosmin,b23,was 1.0 0.000143348623853 0 1 -1
nucleophosmin,b23,is 1.0 0.000143348623853 0 1 -1
nucleophosmin,b23,in 1.0 0.00043004587156 0 3 -3
nucleophosmin,b23,antisense 1.0 0.000143348623853 0 1 -1
nucleophosmin,b23,and 1.0 0.000143348623853 0 1 -1
nucleophosmin,b23,activation 1.0 0.000143348623853 0 1 -1
nucleolin,c23,in 1.0 0.000143348623853 0 1 -1
nucleolin,c23,down-regulation 1.0 0.000143348623853 0 1 -1
nuclei,chromatin,and 1.0 0.000143348623853 0 1 -1
nuclear,matrix,protein 1.0 0.000143348623853 0 1 -1
nsclc,patients,and 1.0 0.000143348623853 0 1 -1
nsaids,without,evidence 1.0 0.000143348623853 0 1 -1
nsaids,was,similar 1.0 0.000143348623853 0 1 -1
nsaids,tnf,blocking 1.0 0.000143348623853 0 1 -1
nsaids,the,patient 1.0 0.000143348623853 0 1 -1
nsaids,may,affect 1.0 0.000143348623853 0 1 -1
nsaids,including,ketorolac 1.0 0.000143348623853 0 1 -1
nsaids,in,in 1.0 0.000143348623853 0 1 -1
nsaids,in,clinical 1.0 0.000143348623853 0 1 -1
nsaids,antigout,oral 1.0 0.000143348623853 0 1 -1
nsaids,and,tnf 1.0 0.000143348623853 0 1 -1
nsaids,and,did 1.0 0.000143348623853 0 1 -1
nsaids,and,anti-infectives 1.0 0.000143348623853 0 1 -1
nsaids,a,interaction 1.0 0.000143348623853 0 1 -1
nsaid,users,the 1.0 0.000143348623853 0 1 -1
nsaid,such,as 1.0 0.000143348623853 0 1 -1
nsaid,has,not 1.0 0.000143348623853 0 1 -1
nsaid,and,particularly 1.0 0.000143348623853 0 1 -1
ns,were,not 1.0 0.000286697247706 0 2 -2
ns,mg,qid 1.0 0.000143348623853 0 1 -1
ns,and,imitrex 1.0 0.000143348623853 0 1 -1
ns,absorbed,is 1.0 0.000143348623853 0 1 -1
nrtis,are,metabolized 1.0 0.000143348623853 0 1 -1
nph,human,novolog 1.0 0.000143348623853 0 1 -1
nph,human,immediately 1.0 0.000143348623853 0 1 -1
now,strong,evidence 1.0 0.000143348623853 0 1 -1
now,difficult,to 1.0 0.000143348623853 0 1 -1
now,clear,that 1.0 0.000143348623853 0 1 -1
now,cared,for 1.0 0.000143348623853 0 1 -1
now,available,in 1.0 0.000143348623853 0 1 -1
now,appearing,on 1.0 0.000143348623853 0 1 -1
novoseven,should,not 1.0 0.000143348623853 0 1 -1
novoseven,and,coagulation 1.0 0.000143348623853 0 1 -1
novolog,with,of 1.0 0.000143348623853 0 1 -1
novolog,with,nph 1.0 0.000143348623853 0 1 -1
novolog,were,not 1.0 0.000143348623853 0 1 -1
novolog,should,not 1.0 0.000286697247706 0 2 -2
novolog,should,be 1.0 0.000143348623853 0 1 -1
novolog,is,mixed 1.0 0.000143348623853 0 1 -1
novolog,but,that 1.0 0.000143348623853 0 1 -1
novolog,and,crystalline 1.0 0.000143348623853 0 1 -1
novo,renal,transplant 1.0 0.000143348623853 0 1 -1
novo,kidney,allograft 1.0 0.000143348623853 0 1 -1
novel,targets,and 1.0 0.000143348623853 0 1 -1
novel,purification,protocol 1.0 0.000143348623853 0 1 -1
novel,iboga,alkaloid 1.0 0.000143348623853 0 1 -1
notified,immediately,if 1.0 0.000143348623853 0 1 -1
noted,with,other 1.0 0.000143348623853 0 1 -1
noted,when,was 1.0 0.000143348623853 0 1 -1
noted,when,is 1.0 0.000143348623853 0 1 -1
noted,when,hydrochloride 1.0 0.000143348623853 0 1 -1
noted,that,these 1.0 0.000143348623853 0 1 -1
noted,that,or 1.0 0.000143348623853 0 1 -1
noted,that,incidence 1.0 0.000143348623853 0 1 -1
noted,that,both 1.0 0.000143348623853 0 1 -1
noted,in,the 1.0 0.000286697247706 0 2 -2
noted,in,study 1.0 0.000143348623853 0 1 -1
noted,during,any 1.0 0.000143348623853 0 1 -1
noted,below,are 1.0 0.000143348623853 0 1 -1
noted,below,a 1.0 0.000143348623853 0 1 -1
noted,at,the 1.0 0.000143348623853 0 1 -1
noted,above,chronic 1.0 0.000143348623853 0 1 -1
noted,a,massive 1.0 0.000143348623853 0 1 -1
note,if,the 1.0 0.000143348623853 0 1 -1
note,dissolution,of 1.0 0.000143348623853 0 1 -1
note,all,patients 1.0 0.000143348623853 0 1 -1
notably,systemic,exposure 1.0 0.000143348623853 0 1 -1
notable,that,xanthine-derived 1.0 0.000143348623853 0 1 -1
not,with,the 1.0 0.000143348623853 0 1 -1
not,with,enzyme-based 1.0 0.00043004587156 0 3 -3
not,with,enzyme 1.0 0.000143348623853 0 1 -1
not,vary,as 1.0 0.000143348623853 0 1 -1
not,undergo,renal 1.0 0.000143348623853 0 1 -1
not,to,use 1.0 0.000143348623853 0 1 -1
not,to,start 1.0 0.000143348623853 0 1 -1
not,to,potentiate 1.0 0.000143348623853 0 1 -1
not,to,be 1.0 0.000143348623853 0 1 -1
not,these,in 1.0 0.000143348623853 0 1 -1
not,the,glomerular 1.0 0.000143348623853 0 1 -1
not,the,extent 1.0 0.000143348623853 0 1 -1
not,tested,to 1.0 0.000143348623853 0 1 -1
not,take,this 1.0 0.000286697247706 0 2 -2
not,take,st 1.0 0.000143348623853 0 1 -1
not,systematically,alter 1.0 0.000143348623853 0 1 -1
not,suggest,the 1.0 0.000143348623853 0 1 -1
not,suggest,any 1.0 0.000143348623853 0 1 -1
not,sufficient,however 1.0 0.000143348623853 0 1 -1
not,sufficient,data 1.0 0.000143348623853 0 1 -1
not,suffer,from 1.0 0.000143348623853 0 1 -1
not,studied,systematically 1.0 0.000143348623853 0 1 -1
not,studied,in 1.0 0.000143348623853 0 1 -1
not,studied,but 1.0 0.000286697247706 0 2 -2
not,start,or 1.0 0.000143348623853 0 1 -1
not,so,active 1.0 0.000143348623853 0 1 -1
not,significantly,metabolized 1.0 0.000143348623853 0 1 -1
not,significantly,interfere 1.0 0.000143348623853 0 1 -1
not,significantly,influence 1.0 0.000143348623853 0 1 -1
not,significantly,increase 1.0 0.000143348623853 0 1 -1
not,significantly,improve 1.0 0.000143348623853 0 1 -1
not,significantly,higher 1.0 0.000143348623853 0 1 -1
not,significantly,different 1.0 0.00043004587156 0 3 -3
not,significantly,altered 1.0 0.000286697247706 0 2 -2
not,significantly,alter 1.0 0.000143348623853 0 1 -1
not,significantly,affected 1.0 0.000143348623853 0 1 -1
not,significant,contributors 1.0 0.000143348623853 0 1 -1
not,shown,consistent 1.0 0.000143348623853 0 1 -1
not,show,whether 1.0 0.000143348623853 0 1 -1
not,show,potential 1.0 0.000143348623853 0 1 -1
not,show,clinically 1.0 0.000143348623853 0 1 -1
not,show,any 1.0 0.000143348623853 0 1 -1
not,show,a 1.0 0.000286697247706 0 2 -2
not,seen,during 1.0 0.000143348623853 0 1 -1
not,seem,to 1.0 0.000143348623853 0 1 -1
not,reveal,an 1.0 0.000143348623853 0 1 -1
not,required,except 1.0 0.000143348623853 0 1 -1
not,require,interruption 1.0 0.000143348623853 0 1 -1
not,require,exogenous 1.0 0.000143348623853 0 1 -1
not,require,empiric 1.0 0.000143348623853 0 1 -1
not,require,dosage 1.0 0.000143348623853 0 1 -1
not,reported,these 1.0 0.000143348623853 0 1 -1
not,report,any 1.0 0.000143348623853 0 1 -1
not,rely,on 1.0 0.000143348623853 0 1 -1
not,related,to 1.0 0.000143348623853 0 1 -1
not,reduce,basal 1.0 0.000143348623853 0 1 -1
not,recovered,weeks 1.0 0.000143348623853 0 1 -1
not,recommended,levetiracetam 1.0 0.000143348623853 0 1 -1
not,recommended,in 1.0 0.000143348623853 0 1 -1
not,recommended,as 1.0 0.000143348623853 0 1 -1
not,readily,obtainable 1.0 0.000143348623853 0 1 -1
not,reached,whereas 1.0 0.000143348623853 0 1 -1
not,quantitatively,related 1.0 0.000143348623853 0 1 -1
not,proliferation-dependent,but 1.0 0.000143348623853 0 1 -1
not,produce,any 1.0 0.000143348623853 0 1 -1
not,produce,a 1.0 0.000286697247706 0 2 -2
not,predispose,to 1.0 0.000143348623853 0 1 -1
not,potent,cyp3a4 1.0 0.000143348623853 0 1 -1
not,possible,the 1.0 0.000286697247706 0 2 -2
not,posing,a 1.0 0.000143348623853 0 1 -1
not,performed,in 1.0 0.000143348623853 0 1 -1
not,performed,doses 1.0 0.000143348623853 0 1 -1
not,particularly,dangerous 1.0 0.000143348623853 0 1 -1
not,only,with 1.0 0.000143348623853 0 1 -1
not,only,re-results 1.0 0.000143348623853 0 1 -1
not,only,on 1.0 0.000143348623853 0 1 -1
not,only,in 1.0 0.000143348623853 0 1 -1
not,only,improve 1.0 0.000143348623853 0 1 -1
not,only,hyperglycemia 1.0 0.000143348623853 0 1 -1
not,on,overall 1.0 0.000143348623853 0 1 -1
not,observed,when 1.0 0.000143348623853 0 1 -1
not,noted,when 1.0 0.000143348623853 0 1 -1
not,normally,be 1.0 0.000143348623853 0 1 -1
not,necessitate,reduction 1.0 0.000143348623853 0 1 -1
not,necessitate,an 1.0 0.000143348623853 0 1 -1
not,necessary,when 1.0 0.000143348623853 0 1 -1
not,mutagenic,or 1.0 0.000143348623853 0 1 -1
not,mutagenic,in 1.0 0.000143348623853 0 1 -1
not,morphine-induced,tail-flick 1.0 0.000143348623853 0 1 -1
not,modify,the 1.0 0.000286697247706 0 2 -2
not,mix,toradol 1.0 0.000143348623853 0 1 -1
not,metabolized,by 1.0 0.00100344036697 0 7 -7
not,metabolize,to 1.0 0.000143348623853 0 1 -1
not,measured,toxicity 1.0 0.000143348623853 0 1 -1
not,meant,to 1.0 0.000143348623853 0 1 -1
not,meaningfully,alter 1.0 0.000143348623853 0 1 -1
not,mc,decreases 1.0 0.000143348623853 0 1 -1
not,materially,different 1.0 0.000143348623853 0 1 -1
not,markedly,inhibit 1.0 0.000143348623853 0 1 -1
not,lead,to 1.0 0.000143348623853 0 1 -1
not,known,which 1.0 0.000143348623853 0 1 -1
not,known,to 1.0 0.000716743119266 0 5 -5
not,known,health 1.0 0.000143348623853 0 1 -1
not,known,at 1.0 0.000143348623853 0 1 -1
not,interfere,with 1.0 0.00143348623853 0 10 -10
not,interact,significantly 1.0 0.000143348623853 0 1 -1
not,inhibitory,towards 1.0 0.000143348623853 0 1 -1
not,inhibitors,of 1.0 0.000143348623853 0 1 -1
not,inhibited,by 1.0 0.000143348623853 0 1 -1
not,inhibit,the 1.0 0.00043004587156 0 3 -3
not,inhibit,p450 1.0 0.000143348623853 0 1 -1
not,inhibit,p-glycoprotein 1.0 0.000143348623853 0 1 -1
not,inhibit,or 1.0 0.000143348623853 0 1 -1
not,inhibit,metabolism 1.0 0.000143348623853 0 1 -1
not,inhibit,cyp2e1 1.0 0.000143348623853 0 1 -1
not,inhibit,cyp2d6 1.0 0.000143348623853 0 1 -1
not,inhibit,cyp 1.0 0.000143348623853 0 1 -1
not,influence,the 1.0 0.00129013761468 0 9 -9
not,influence,recovery 1.0 0.000143348623853 0 1 -1
not,induce,the 1.0 0.000286697247706 0 2 -2
not,induce,metabolic 1.0 0.000143348623853 0 1 -1
not,induce,cyp1a2 1.0 0.000143348623853 0 1 -1
not,indicated,for 1.0 0.000143348623853 0 1 -1
not,increase,the 1.0 0.000573394495413 0 4 -4
not,include,sufficient 1.0 0.000143348623853 0 1 -1
not,in,dietary-obese 1.0 0.000143348623853 0 1 -1
not,impaired,but 1.0 0.000143348623853 0 1 -1
not,however,appear 1.0 0.000143348623853 0 1 -1
not,highly,bound 1.0 0.00043004587156 0 3 -3
not,higher,among 1.0 0.000143348623853 0 1 -1
not,have,effects 1.0 0.000143348623853 0 1 -1
not,have,clinically 1.0 0.000573394495413 0 4 -4
not,have,any 1.0 0.000860091743119 0 6 -6
not,have,a 1.0 0.000286697247706 0 2 -2
not,extensively,bound 1.0 0.000143348623853 0 1 -1
not,extend,outside 1.0 0.000143348623853 0 1 -1
not,experience,an 1.0 0.000143348623853 0 1 -1
not,expected,in 1.0 0.000143348623853 0 1 -1
not,expected,between 1.0 0.000143348623853 0 1 -1
not,exhibit,binding 1.0 0.000143348623853 0 1 -1
not,excluded,from 1.0 0.000143348623853 0 1 -1
not,exceed,micrograms 1.0 0.000143348623853 0 1 -1
not,equivalent,in 1.0 0.000143348623853 0 1 -1
not,effected,by 1.0 0.000143348623853 0 1 -1
not,display,the 1.0 0.000143348623853 0 1 -1
not,displace,tightly 1.0 0.000143348623853 0 1 -1
not,diminish,fluoride 1.0 0.000143348623853 0 1 -1
not,different,and 1.0 0.000143348623853 0 1 -1
not,differ,significantly 1.0 0.000143348623853 0 1 -1
not,differ,from 1.0 0.000143348623853 0 1 -1
not,detected,in 1.0 0.000143348623853 0 1 -1
not,detect,an 1.0 0.000143348623853 0 1 -1
not,depend,on 1.0 0.000143348623853 0 1 -1
not,demonstrated,renal 1.0 0.000143348623853 0 1 -1
not,demonstrated,any 1.0 0.000286697247706 0 2 -2
not,demonstrate,any 1.0 0.000286697247706 0 2 -2
not,correlate,with 1.0 0.000143348623853 0 1 -1
not,correct,changes 1.0 0.000143348623853 0 1 -1
not,considered,clinically 1.0 0.000143348623853 0 1 -1
not,confirm,the 1.0 0.000143348623853 0 1 -1
not,conclude,that 1.0 0.000143348623853 0 1 -1
not,co-administered,with 1.0 0.000143348623853 0 1 -1
not,clinically,significant 1.0 0.000143348623853 0 1 -1
not,clear,whether 1.0 0.000286697247706 0 2 -2
not,change,the 1.0 0.000143348623853 0 1 -1
not,change,significantly 1.0 0.000143348623853 0 1 -1
not,change,fasting 1.0 0.000143348623853 0 1 -1
not,cause,transient 1.0 0.000143348623853 0 1 -1
not,cause,significant 1.0 0.000143348623853 0 1 -1
not,cause,induction 1.0 0.000143348623853 0 1 -1
not,cause,increased 1.0 0.000143348623853 0 1 -1
not,cause,dna 1.0 0.000143348623853 0 1 -1
not,by,cytochrome 1.0 0.000143348623853 0 1 -1
not,bind,significantly 1.0 0.000143348623853 0 1 -1
not,been,well 1.0 0.000143348623853 0 1 -1
not,been,tested 1.0 0.000143348623853 0 1 -1
not,been,seen 1.0 0.000143348623853 0 1 -1
not,been,observed 1.0 0.000573394495413 0 4 -4
not,been,found 1.0 0.000143348623853 0 1 -1
not,been,formally 1.0 0.000143348623853 0 1 -1
not,been,explored 1.0 0.000143348623853 0 1 -1
not,been,demonstrated 1.0 0.000143348623853 0 1 -1
not,been,completely 1.0 0.000143348623853 0 1 -1
not,been,associated 1.0 0.000286697247706 0 2 -2
not,been,as 1.0 0.000143348623853 0 1 -1
not,been,adequately 1.0 0.000286697247706 0 2 -2
not,be,stopped 1.0 0.000143348623853 0 1 -1
not,be,reflective 1.0 0.000143348623853 0 1 -1
not,be,rechallenged 1.0 0.000143348623853 0 1 -1
not,be,re-treated 1.0 0.000143348623853 0 1 -1
not,be,predictive 1.0 0.000143348623853 0 1 -1
not,be,mixed 1.0 0.000573394495413 0 4 -4
not,be,maintained 1.0 0.000143348623853 0 1 -1
not,be,expected 1.0 0.000716743119266 0 5 -5
not,be,discontinued 1.0 0.000143348623853 0 1 -1
not,be,confirmed 1.0 0.000143348623853 0 1 -1
not,be,changed 1.0 0.000143348623853 0 1 -1
not,be,analyzed 1.0 0.000143348623853 0 1 -1
not,available,and 1.0 0.000143348623853 0 1 -1
not,attenuated,by 1.0 0.000143348623853 0 1 -1
not,at,min 1.0 0.000143348623853 0 1 -1
not,associated,with 1.0 0.000286697247706 0 2 -2
not,approved,in 1.0 0.000286697247706 0 2 -2
not,appreciably,metabolized 1.0 0.000143348623853 0 1 -1
not,antagonized,by 1.0 0.000143348623853 0 1 -1
not,an,inhibitor 1.0 0.00043004587156 0 3 -3
not,an,aed 1.0 0.000143348623853 0 1 -1
not,always,predictive 1.0 0.000143348623853 0 1 -1
not,altered,when 1.0 0.000286697247706 0 2 -2
not,altered,to 1.0 0.000143348623853 0 1 -1
not,altered,its 1.0 0.000143348623853 0 1 -1
not,altered,in 1.0 0.000143348623853 0 1 -1
not,altered,by 1.0 0.000573394495413 0 4 -4
not,alter,tromethamine 1.0 0.000143348623853 0 1 -1
not,alter,glucose 1.0 0.000143348623853 0 1 -1
not,all,inclusive 1.0 0.000143348623853 0 1 -1
not,all,are 1.0 0.000143348623853 0 1 -1
not,affected,when 1.0 0.000286697247706 0 2 -2
not,affected,significantly 1.0 0.000143348623853 0 1 -1
not,affected,during 1.0 0.000286697247706 0 2 -2
not,affected,by 1.0 0.00229357798165 0 16 -16
not,affect,subjective 1.0 0.000143348623853 0 1 -1
not,affect,responding 1.0 0.000143348623853 0 1 -1
not,affect,renal 1.0 0.000143348623853 0 1 -1
not,affect,idv 1.0 0.000143348623853 0 1 -1
not,affect,either 1.0 0.000143348623853 0 1 -1
not,affect,distribution 1.0 0.000143348623853 0 1 -1
not,affect,bleeding 1.0 0.000143348623853 0 1 -1
not,affect,behaviors 1.0 0.000143348623853 0 1 -1
not,affect,any 1.0 0.000143348623853 0 1 -1
not,administered,but 1.0 0.000143348623853 0 1 -1
not,act,on 1.0 0.000143348623853 0 1 -1
not,accompanied,by 1.0 0.000143348623853 0 1 -1
not,a,substrate 1.0 0.000860091743119 0 6 -6
not,a,substitute 1.0 0.00043004587156 0 3 -3
not,a,significant 1.0 0.000143348623853 0 1 -1
not,a,contraindication 1.0 0.000143348623853 0 1 -1
nosebleeds,hemoptysis,hematemesis 1.0 0.000143348623853 0 1 -1
northern,blot,analysis 1.0 0.000143348623853 0 1 -1
norpace,was,coadministered 1.0 0.000143348623853 0 1 -1
norpace,does,not 1.0 0.000143348623853 0 1 -1
normetanephrine,and,vanillylmandelic 1.0 0.000143348623853 0 1 -1
normally,with,respect 1.0 0.000143348623853 0 1 -1
normally,to,but 1.0 0.000143348623853 0 1 -1
normalizing,the,intake 1.0 0.000143348623853 0 1 -1
normalized,ratio,and 1.0 0.000143348623853 0 1 -1
normal,within,weeks 1.0 0.000143348623853 0 1 -1
normal,when,a 1.0 0.000143348623853 0 1 -1
normal,volunteers,has 1.0 0.000143348623853 0 1 -1
normal,volunteers,did 1.0 0.000143348623853 0 1 -1
normal,volunteers,coadministration 1.0 0.000143348623853 0 1 -1
normal,value,one 1.0 0.000143348623853 0 1 -1
normal,tissue,although 1.0 0.000143348623853 0 1 -1
normal,subjects,the 1.0 0.000143348623853 0 1 -1
normal,subjects,than 1.0 0.000143348623853 0 1 -1
normal,subjects,single-dose 1.0 0.000143348623853 0 1 -1
normal,subjects,nor 1.0 0.000143348623853 0 1 -1
normal,renal,function 1.0 0.000286697247706 0 2 -2
normal,release,in 1.0 0.000143348623853 0 1 -1
normal,range,and 1.0 0.000143348623853 0 1 -1
normal,or,logistic 1.0 0.000143348623853 0 1 -1
normal,metabolizers,resemble 1.0 0.000860091743119 0 6 -6
normal,metab-olizers,resemble 1.0 0.000143348623853 0 1 -1
normal,menstrual,rhythm 1.0 0.000143348623853 0 1 -1
normal,levels,when 1.0 0.000143348623853 0 1 -1
normal,healthy,volunteers 1.0 0.000286697247706 0 2 -2
normal,healthy,subjects 1.0 0.000143348623853 0 1 -1
normal,healthy,male 1.0 0.000143348623853 0 1 -1
normal,fat,digestion 1.0 0.000143348623853 0 1 -1
normal,dogs,in 1.0 0.000143348623853 0 1 -1
normal,daily,activities 1.0 0.000143348623853 0 1 -1
normal,cells,to 1.0 0.000143348623853 0 1 -1
normal,cells,that 1.0 0.000143348623853 0 1 -1
normal,cells,are 1.0 0.000143348623853 0 1 -1
normal,antiasthmatic,dose 1.0 0.000143348623853 0 1 -1
normal,and,genetically 1.0 0.000143348623853 0 1 -1
normal,and,diabetic 1.0 0.000143348623853 0 1 -1
norfluoxe-tine,have,long 1.0 0.000143348623853 0 1 -1
noradrenaline-precontracted,arteries,from 1.0 0.000143348623853 0 1 -1
noradrenaline,storage,vesicles 1.0 0.000143348623853 0 1 -1
nor,were,there 1.0 0.000143348623853 0 1 -1
nor,the,pharmacokinetics 1.0 0.000143348623853 0 1 -1
nor,other,possible 1.0 0.000143348623853 0 1 -1
nor,of,other 1.0 0.000143348623853 0 1 -1
nor,its,metabolites 1.0 0.000286697247706 0 2 -2
nor,is,the 1.0 0.000143348623853 0 1 -1
nor,inhibits,or 1.0 0.000143348623853 0 1 -1
nor,high,affinity 1.0 0.000143348623853 0 1 -1
nor,does,it 1.0 0.000286697247706 0 2 -2
nor,does,affect 1.0 0.000143348623853 0 1 -1
nor,did,it 1.0 0.000143348623853 0 1 -1
nor,binding,to 1.0 0.000143348623853 0 1 -1
nor,appears,to 1.0 0.000143348623853 0 1 -1
nonsteroidal,were,taken 1.0 0.000286697247706 0 2 -2
nonsteroidal,nsaid,such 1.0 0.000143348623853 0 1 -1
nonsteroidal,given,with 1.0 0.000143348623853 0 1 -1
nonsteroidal,antiinflammatories,and 1.0 0.000143348623853 0 1 -1
nonsteroidal,agents,of 1.0 0.000143348623853 0 1 -1
nonsteroidal,agents,folic 1.0 0.000286697247706 0 2 -2
nonsmoking,healthy,white 1.0 0.000143348623853 0 1 -1
nonrenal,clearance,from 1.0 0.000143348623853 0 1 -1
nonrenal,and,total 1.0 0.000143348623853 0 1 -1
nonprescription,products,you 1.0 0.000143348623853 0 1 -1
nonpredisposed,strain,c57bl 1.0 0.000143348623853 0 1 -1
nonopioid,tolerant,patients 1.0 0.000143348623853 0 1 -1
nonlinear,weighted,least 1.0 0.000143348623853 0 1 -1
nonlinear,regression,model 1.0 0.000143348623853 0 1 -1
nonlinear,kinetic,characteristics 1.0 0.000143348623853 0 1 -1
nonlinear,in,the 1.0 0.000143348623853 0 1 -1
nonlethal,mg,kg 1.0 0.000143348623853 0 1 -1
nonlethal,and,lethal 1.0 0.000143348623853 0 1 -1
nonketotic,genetically,diabetic 1.0 0.000143348623853 0 1 -1
noninsulin,dependent,diabetic 1.0 0.000143348623853 0 1 -1
nonetheless,they,have 1.0 0.000143348623853 0 1 -1
nonetheless,their,relevance 1.0 0.000143348623853 0 1 -1
nonetheless,the,range 1.0 0.000143348623853 0 1 -1
nonetheless,the,possibility 1.0 0.000143348623853 0 1 -1
none,of,the 1.0 0.000143348623853 0 1 -1
nondepolarizing,relaxants,is 1.0 0.000143348623853 0 1 -1
nondepolarizing,relaxants,are 1.0 0.000143348623853 0 1 -1
nondepolarizing,possible,increased 1.0 0.000286697247706 0 2 -2
nondepolarizing,blocking,action 1.0 0.000143348623853 0 1 -1
nonclinical,studies,show 1.0 0.000143348623853 0 1 -1
nonclinical,data,demonstrate 1.0 0.000143348623853 0 1 -1
nonadditive,independent,joint 1.0 0.000143348623853 0 1 -1
non-steroidal,anti-inflammatory,but 1.0 0.000143348623853 0 1 -1
non-specific,cyp-450,inhibitor 1.0 0.000143348623853 0 1 -1
non-specialist,hospitals,usually 1.0 0.000143348623853 0 1 -1
non-significantly,reduced,relative 1.0 0.000143348623853 0 1 -1
non-selective,monoamine,oxidase 1.0 0.000143348623853 0 1 -1
non-pegylated,alfa-2a,treatment 1.0 0.000143348623853 0 1 -1
non-pegylated,alfa-2a,for 1.0 0.000143348623853 0 1 -1
non-ossification,of,the 1.0 0.000143348623853 0 1 -1
non-opioid,analgesics,was 1.0 0.000143348623853 0 1 -1
non-opioid,agonist,effects 1.0 0.000143348623853 0 1 -1
non-myelinated,axons,of 1.0 0.000143348623853 0 1 -1
non-myelinated,axons,has 1.0 0.000143348623853 0 1 -1
non-myelinated,axons,contained 1.0 0.000143348623853 0 1 -1
non-infection,unwanted,effects 1.0 0.000143348623853 0 1 -1
non-human,primates,and 1.0 0.000143348623853 0 1 -1
non-hodgkin,lymphoma,hiv-nhl 1.0 0.000143348623853 0 1 -1
non-governmental,organisation,m 1.0 0.000143348623853 0 1 -1
non-gastrointestinal,bleedings,have 1.0 0.000143348623853 0 1 -1
non-diabetics,with,glucose 1.0 0.000143348623853 0 1 -1
non-diabetic,and,streptozotocin-induced 1.0 0.000143348623853 0 1 -1
non-cyp3a4,substrate,agent 1.0 0.000143348623853 0 1 -1
non-aspergillus,polysaccharides,and 1.0 0.000143348623853 0 1 -1
non,soluble,particularly 1.0 0.000143348623853 0 1 -1
nodular,acne,transient 1.0 0.000143348623853 0 1 -1
nodes,however,adenocard 1.0 0.000143348623853 0 1 -1
nociception,was,performed 1.0 0.000143348623853 0 1 -1
nociception,and,that 1.0 0.000143348623853 0 1 -1
no,well-known,interactions 1.0 0.000143348623853 0 1 -1
no,volunteer,showed 1.0 0.000143348623853 0 1 -1
no,trials,specifically 1.0 0.000143348623853 0 1 -1
no,treatment-related,pattern 1.0 0.000143348623853 0 1 -1
no,teratogenic,effects 1.0 0.000143348623853 0 1 -1
no,systematic,changes 1.0 0.000143348623853 0 1 -1
no,substantive,effect 1.0 0.000143348623853 0 1 -1
no,statistically,significant 1.0 0.000286697247706 0 2 -2
no,specific,studies 1.0 0.000286697247706 0 2 -2
no,specific,pharmacokinetic 1.0 0.000143348623853 0 1 -1
no,specific,interaction 1.0 0.000286697247706 0 2 -2
no,specific,clinical 1.0 0.000143348623853 0 1 -1
no,special,precautions 1.0 0.000143348623853 0 1 -1
no,signs,of 1.0 0.000143348623853 0 1 -1
no,significant,pharmacokinetic 1.0 0.00043004587156 0 3 -3
no,significant,interference 1.0 0.000143348623853 0 1 -1
no,significant,interactions 1.0 0.000573394495413 0 4 -4
no,significant,interaction 1.0 0.000286697247706 0 2 -2
no,significant,inhibitory 1.0 0.000143348623853 0 1 -1
no,significant,effects 1.0 0.00100344036697 0 7 -7
no,significant,drug-drug 1.0 0.00043004587156 0 3 -3
no,significant,differences 1.0 0.000860091743119 0 6 -6
no,significant,difference 1.0 0.000716743119266 0 5 -5
no,significant,changes 1.0 0.000286697247706 0 2 -2
no,significant,change 1.0 0.00043004587156 0 3 -3
no,safety,and 1.0 0.00043004587156 0 3 -3
no,reports,of 1.0 0.000286697247706 0 2 -2
no,reported,laboratory 1.0 0.000143348623853 0 1 -1
no,reported,drug-laboratory 1.0 0.000286697247706 0 2 -2
no,reported,cases 1.0 0.000143348623853 0 1 -1
no,relevant,inhibitory 1.0 0.000143348623853 0 1 -1
no,relevant,inhibition 1.0 0.000143348623853 0 1 -1
no,relevant,effect 1.0 0.000143348623853 0 1 -1
no,related,changes 1.0 0.000143348623853 0 1 -1
no,rashes,were 1.0 0.000143348623853 0 1 -1
no,prolongation,in 1.0 0.000143348623853 0 1 -1
no,potentiation,of 1.0 0.000143348623853 0 1 -1
no,potential,for 1.0 0.000143348623853 0 1 -1
no,positive,reaction 1.0 0.000143348623853 0 1 -1
no,platelet,aggregation 1.0 0.000143348623853 0 1 -1
no,pharmacokinetic-based,drug-drug 1.0 0.000143348623853 0 1 -1
no,pharmacokinetic,or 1.0 0.000143348623853 0 1 -1
no,pharmacokinetic,interactions 1.0 0.000286697247706 0 2 -2
no,pharmacokinetic,interaction 1.0 0.000573394495413 0 4 -4
no,pharmacokinetic,drug-drug 1.0 0.000143348623853 0 1 -1
no,pharmacokinetic,data 1.0 0.000143348623853 0 1 -1
no,pharmacodynamic,interaction 1.0 0.000286697247706 0 2 -2
no,pharmacodynamic,effects 1.0 0.000143348623853 0 1 -1
no,other,specific 1.0 0.000143348623853 0 1 -1
no,other,pharmacokinetic 1.0 0.000143348623853 0 1 -1
no,other,interactions 1.0 0.000143348623853 0 1 -1
no,observed,effects 1.0 0.000143348623853 0 1 -1
no,nutritional,supplement 1.0 0.000143348623853 0 1 -1
no,more,cardiovascular 1.0 0.000143348623853 0 1 -1
no,measurable,effect 1.0 0.000143348623853 0 1 -1
no,longer,marketed 1.0 0.000143348623853 0 1 -1
no,long-term,carcinogenicity 1.0 0.000143348623853 0 1 -1
no,laboratory,test 1.0 0.000143348623853 0 1 -1
no,known,interference 1.0 0.000143348623853 0 1 -1
no,known,interactions 1.0 0.000573394495413 0 4 -4
no,known,drug 1.0 0.000143348623853 0 1 -1
no,known,clinically 1.0 0.000143348623853 0 1 -1
no,interactive,effect 1.0 0.000143348623853 0 1 -1
no,interactions,with 1.0 0.000143348623853 0 1 -1
no,interactions,were 1.0 0.000286697247706 0 2 -2
no,interactions,of 1.0 0.000143348623853 0 1 -1
no,interactions,have 1.0 0.000716743119266 0 5 -5
no,interactions,by 1.0 0.000143348623853 0 1 -1
no,interaction,would 1.0 0.000143348623853 0 1 -1
no,interaction,with 1.0 0.000286697247706 0 2 -2
no,interaction,was 1.0 0.000143348623853 0 1 -1
no,interaction,trials 1.0 0.000143348623853 0 1 -1
no,interaction,studies 1.0 0.000143348623853 0 1 -1
no,inhibitory,or 1.0 0.000143348623853 0 1 -1
no,inhibition,of 1.0 0.000286697247706 0 2 -2
no,information,regarding 1.0 0.000143348623853 0 1 -1
no,information,on 1.0 0.000143348623853 0 1 -1
no,information,is 1.0 0.000286697247706 0 2 -2
no,influence,on 1.0 0.000286697247706 0 2 -2
no,influence,in 1.0 0.000143348623853 0 1 -1
no,increase,in 1.0 0.000573394495413 0 4 -4
no,in,vitro 1.0 0.000143348623853 0 1 -1
no,important,interactions 1.0 0.000143348623853 0 1 -1
no,igg,or 1.0 0.000143348623853 0 1 -1
no,human,interaction 1.0 0.000286697247706 0 2 -2
no,formal,studies 1.0 0.00043004587156 0 3 -3
no,formal,pharmacokinetic 1.0 0.000143348623853 0 1 -1
no,formal,laboratory 1.0 0.000143348623853 0 1 -1
no,formal,interaction 1.0 0.00229357798165 0 16 -16
no,formal,drug-interaction 1.0 0.000286697247706 0 2 -2
no,formal,drug-drug 1.0 0.000286697247706 0 2 -2
no,formal,drug 1.0 0.000286697247706 0 2 -2
no,formal,clinical 1.0 0.00043004587156 0 3 -3
no,formal,assessments 1.0 0.000286697247706 0 2 -2
no,first-pass,metabolism 1.0 0.000143348623853 0 1 -1
no,experience,with 1.0 0.000143348623853 0 1 -1
no,experience,on 1.0 0.000143348623853 0 1 -1
no,evidence,was 1.0 0.000143348623853 0 1 -1
no,evidence,that 1.0 0.000143348623853 0 1 -1
no,evidence,of 1.0 0.0021502293578 0 15 -15
no,evidence,in 1.0 0.000286697247706 0 2 -2
no,evaluation,of 1.0 0.000143348623853 0 1 -1
no,effects,were 1.0 0.000143348623853 0 1 -1
no,effects,on 1.0 0.000573394495413 0 4 -4
no,effect,was 1.0 0.000143348623853 0 1 -1
no,drug-specific,interactions 1.0 0.000143348623853 0 1 -1
no,drug-drug,interaction 1.0 0.000286697247706 0 2 -2
no,drug,nutritional 1.0 0.000143348623853 0 1 -1
no,drug,interactions 1.0 0.000143348623853 0 1 -1
no,drug,interaction 1.0 0.000573394495413 0 4 -4
no,doubt,complex 1.0 0.000143348623853 0 1 -1
no,dosing,adjustments 1.0 0.000143348623853 0 1 -1
no,dose,relationship 1.0 0.000143348623853 0 1 -1
no,dose,adjustments 1.0 0.000143348623853 0 1 -1
no,dose,adjustment 1.0 0.00114678899083 0 8 -8
no,dosage,adjustment 1.0 0.000716743119266 0 5 -5
no,documentation,of 1.0 0.000143348623853 0 1 -1
no,discernible,changes 1.0 0.000143348623853 0 1 -1
no,differential,effects 1.0 0.000143348623853 0 1 -1
no,differential,effect 1.0 0.000143348623853 0 1 -1
no,differences,in 1.0 0.000286697247706 0 2 -2
no,differences,between 1.0 0.000143348623853 0 1 -1
no,difference,in 1.0 0.000286697247706 0 2 -2
no,detectable,effect 1.0 0.000143348623853 0 1 -1
no,depressant,effect 1.0 0.000143348623853 0 1 -1
no,deleterious,interactions 1.0 0.000143348623853 0 1 -1
no,data,that 1.0 0.000143348623853 0 1 -1
no,data,on 1.0 0.000573394495413 0 4 -4
no,data,from 1.0 0.000143348623853 0 1 -1
no,data,are 1.0 0.00043004587156 0 3 -3
no,controlled,studies 1.0 0.000143348623853 0 1 -1
no,confirmed,interactions 1.0 0.000143348623853 0 1 -1
no,complications,have 1.0 0.000143348623853 0 1 -1
no,cns,lesions 1.0 0.000143348623853 0 1 -1
no,clinically,significant 1.0 0.00301032110092 0 21 -21
no,clinically,or 1.0 0.000143348623853 0 1 -1
no,clinically,meaningful 1.0 0.00043004587156 0 3 -3
no,clinically,important 1.0 0.000716743119266 0 5 -5
no,clinical,or 1.0 0.000143348623853 0 1 -1
no,clinical,interaction 1.0 0.000286697247706 0 2 -2
no,clinical,experience 1.0 0.000143348623853 0 1 -1
no,clinical,evidence 1.0 0.000286697247706 0 2 -2
no,clinical,drug-drug 1.0 0.000143348623853 0 1 -1
no,clinical,data 1.0 0.000143348623853 0 1 -1
no,clear,reproducible 1.0 0.000143348623853 0 1 -1
no,chemical,or 1.0 0.000143348623853 0 1 -1
no,changes,were 1.0 0.000143348623853 0 1 -1
no,changes,in 1.0 0.000143348623853 0 1 -1
no,change,after 1.0 0.000143348623853 0 1 -1
no,causal,relationship 1.0 0.000143348623853 0 1 -1
no,cases,of 1.0 0.000143348623853 0 1 -1
no,carcinogenicity,or 1.0 0.000143348623853 0 1 -1
no,capacity,to 1.0 0.000143348623853 0 1 -1
no,binding,displacement 1.0 0.000143348623853 0 1 -1
no,autoinduction,has 1.0 0.000143348623853 0 1 -1
no,are,known 1.0 0.000143348623853 0 1 -1
no,apparent,pharmacokinetic 1.0 0.000573394495413 0 4 -4
no,apparent,increase 1.0 0.000143348623853 0 1 -1
no,apparent,effect 1.0 0.000143348623853 0 1 -1
no,alterations,in 1.0 0.000143348623853 0 1 -1
no,alteration,of 1.0 0.000286697247706 0 2 -2
no,alteration,in 1.0 0.000143348623853 0 1 -1
no,adverse,effects 1.0 0.000286697247706 0 2 -2
no,adjustment,to 1.0 0.000143348623853 0 1 -1
no,adjustment,of 1.0 0.000143348623853 0 1 -1
no,adequate,and 1.0 0.000286697247706 0 2 -2
no,acceptable,alternatives 1.0 0.000143348623853 0 1 -1
no,abortifacient,or 1.0 0.000143348623853 0 1 -1
nnrtis,occur,within 1.0 0.000143348623853 0 1 -1
nnrtis,appears,generally 1.0 0.000143348623853 0 1 -1
nnrti-based,regimens,may 1.0 0.000143348623853 0 1 -1
nnrti,based,regimens 1.0 0.000143348623853 0 1 -1
nmda-ergic,activation,of 1.0 0.000143348623853 0 1 -1
nmda,receptors,in 1.0 0.000143348623853 0 1 -1
nmda,and,sigma-2 1.0 0.000143348623853 0 1 -1
nm,oh,d3 1.0 0.000143348623853 0 1 -1
nm,absorbing,materials 1.0 0.000143348623853 0 1 -1
nizoral,muscle,relaxants 1.0 0.000143348623853 0 1 -1
nizatidine,does,not 1.0 0.000143348623853 0 1 -1
nitrous,oxide,with 1.0 0.000143348623853 0 1 -1
nitroglycerin,dynacirc,has 1.0 0.000143348623853 0 1 -1
nitrogen,mustard,etc 1.0 0.000143348623853 0 1 -1
nitrobluetetrazolium,test,for 1.0 0.000143348623853 0 1 -1
nitrates,the,concomitant 1.0 0.000143348623853 0 1 -1
nitrates,nifedipine,may 1.0 0.000143348623853 0 1 -1
ninth,day,the 1.0 0.000143348623853 0 1 -1
nine,otherwise,healthy 1.0 0.000143348623853 0 1 -1
nine,additional,patients 1.0 0.000143348623853 0 1 -1
nimodipine,had,no 1.0 0.000143348623853 0 1 -1
nimodipine,and,losartan 1.0 0.000143348623853 0 1 -1
nimbex,is,administered 1.0 0.000143348623853 0 1 -1
nimbex,before,to 1.0 0.000143348623853 0 1 -1
nimbex,and,therefore 1.0 0.000143348623853 0 1 -1
nih-3t3,cells,was 1.0 0.000143348623853 0 1 -1
nih-3t3,cells,during 1.0 0.000143348623853 0 1 -1
nifedipine,vardenafil,mg 1.0 0.000143348623853 0 1 -1
nifedipine,may,be 1.0 0.000143348623853 0 1 -1
nifedipine,did,not 1.0 0.000143348623853 0 1 -1
niddm,subjects,decreases 1.0 0.000143348623853 0 1 -1
nicotinic,receptors,mc 1.0 0.000143348623853 0 1 -1
nicotinic,acid,sympathomimet-ics 1.0 0.000143348623853 0 1 -1
nicotinic,acid,erythromycin 1.0 0.000143348623853 0 1 -1
nicotinic,acid,channel 1.0 0.000286697247706 0 2 -2
nicotinic,acid,calcium 1.0 0.000143348623853 0 1 -1
niacin,nicotinic,acid 1.0 0.000286697247706 0 2 -2
nhl,characteristics,hiv 1.0 0.000143348623853 0 1 -1
ng,ml,throughout 1.0 0.000143348623853 0 1 -1
ng,ml,resulted 1.0 0.000143348623853 0 1 -1
ng,ml,at 1.0 0.000143348623853 0 1 -1
ng,ml,and 1.0 0.000143348623853 0 1 -1
next,chapter,presents 1.0 0.000143348623853 0 1 -1
next,chapter,and 1.0 0.000143348623853 0 1 -1
newly,introduced,atypical 1.0 0.000143348623853 0 1 -1
newly,diagnosed,subjects 1.0 0.000143348623853 0 1 -1
newborns,whose,mothers 1.0 0.000143348623853 0 1 -1
new,york,heart 1.0 0.000143348623853 0 1 -1
new,therapeutic,regimes 1.0 0.000143348623853 0 1 -1
new,rashes,itching 1.0 0.000143348623853 0 1 -1
new,oral,therapies 1.0 0.000143348623853 0 1 -1
new,combination,therapies 1.0 0.000143348623853 0 1 -1
new,class,of 1.0 0.000143348623853 0 1 -1
new,cases,of 1.0 0.000286697247706 0 2 -2
new,anaesthetic,agents 1.0 0.000143348623853 0 1 -1
new,agents,are 1.0 0.000143348623853 0 1 -1
new,acute,episode 1.0 0.000143348623853 0 1 -1
nevirapine-,or,delavirdine-based 1.0 0.000143348623853 0 1 -1
nevirapine,is,principally 1.0 0.000143348623853 0 1 -1
nevirapine,is,known 1.0 0.000143348623853 0 1 -1
nevertheless,there,may 1.0 0.000143348623853 0 1 -1
nevertheless,plasma,levels 1.0 0.000143348623853 0 1 -1
nevertheless,caution,should 1.0 0.000143348623853 0 1 -1
nevertheless,associated,in 1.0 0.000143348623853 0 1 -1
neutrophils,such,as 1.0 0.000143348623853 0 1 -1
neutrophils,recover,to 1.0 0.000143348623853 0 1 -1
neutrophil,counts,of 1.0 0.000143348623853 0 1 -1
neutrophil,count,is 1.0 0.000143348623853 0 1 -1
neutropenia,cells,mm3 1.0 0.000143348623853 0 1 -1
neutropenia,and,lymphopenia 1.0 0.000143348623853 0 1 -1
neutralized,the,increase 1.0 0.000286697247706 0 2 -2
neurotransmitter,systems,and 1.0 0.000143348623853 0 1 -1
neurotoxin,serotypes,at 1.0 0.000286697247706 0 2 -2
neurotoxicity,whereas,none 1.0 0.000143348623853 0 1 -1
neurotoxic,therapy,including 1.0 0.000143348623853 0 1 -1
neurotoxic,and,or 1.0 0.000143348623853 0 1 -1
neuropathy,the,concomitant 1.0 0.000143348623853 0 1 -1
neuropathy,should,be 1.0 0.000143348623853 0 1 -1
neuropathy,pancreatitis,and 1.0 0.000143348623853 0 1 -1
neuropathy,or,neurotoxic 1.0 0.000143348623853 0 1 -1
neuropathy,is,frequent 1.0 0.000143348623853 0 1 -1
neuropathy,include,nucleoside 1.0 0.000143348623853 0 1 -1
neuropathy,has,occurred 1.0 0.000143348623853 0 1 -1
neuropathy,during,videx 1.0 0.000143348623853 0 1 -1
neurontin,in,epileptic 1.0 0.000143348623853 0 1 -1
neurontin,and,to 1.0 0.000143348623853 0 1 -1
neurons,recorded,with 1.0 0.000143348623853 0 1 -1
neurons,including,biocytin 1.0 0.000143348623853 0 1 -1
neurons,hyperpolarized,by 1.0 0.000286697247706 0 2 -2
neurons,fired,spontaneous 1.0 0.000143348623853 0 1 -1
neurons,displaying,transient 1.0 0.000143348623853 0 1 -1
neuronal,uptake,of 1.0 0.000143348623853 0 1 -1
neuronal,reuptake,of 1.0 0.000143348623853 0 1 -1
neuronal,apparatus,of 1.0 0.000143348623853 0 1 -1
neuron,blocking,agents 1.0 0.000143348623853 0 1 -1
neuromuscular,transmission,should 1.0 0.000143348623853 0 1 -1
neuromuscular,paralysis,may 1.0 0.000143348623853 0 1 -1
neuromuscular,blockers,in 1.0 0.000143348623853 0 1 -1
neuromuscular,blockade,will 1.0 0.000143348623853 0 1 -1
neuromuscular,blockade,associated 1.0 0.000143348623853 0 1 -1
neuromuscular,block,following 1.0 0.000143348623853 0 1 -1
neurological,toxicity,and 1.0 0.000143348623853 0 1 -1
neurological,toxic,effects 1.0 0.000143348623853 0 1 -1
neurological,effects,and 1.0 0.000143348623853 0 1 -1
neurological,complications,and 1.0 0.000143348623853 0 1 -1
neurological,and,other 1.0 0.000143348623853 0 1 -1
neurologic,disorders,and 1.0 0.000143348623853 0 1 -1
neuroeffector,defects,occur 1.0 0.000143348623853 0 1 -1
neurochemical,and,functional 1.0 0.000286697247706 0 2 -2
neurobiological,alterations,might 1.0 0.000143348623853 0 1 -1
neurobiological,alterations,in 1.0 0.000143348623853 0 1 -1
neural,plasticity,triggered 1.0 0.000143348623853 0 1 -1
neural,plasticity,ieg 1.0 0.000143348623853 0 1 -1
neural,pathways,which 1.0 0.000143348623853 0 1 -1
neupogen,and,other 1.0 0.000143348623853 0 1 -1
net,fluid,transfers 1.0 0.000143348623853 0 1 -1
net,effect,of 1.0 0.000143348623853 0 1 -1
nervous,system,that 1.0 0.000143348623853 0 1 -1
nervous,system,may 1.0 0.000143348623853 0 1 -1
nervous,system,leading 1.0 0.000143348623853 0 1 -1
nervous,system,depressant 1.0 0.000143348623853 0 1 -1
nervous,system,careful 1.0 0.000286697247706 0 2 -2
nervous,system,although 1.0 0.000143348623853 0 1 -1
nervous,e-strain,subjects 1.0 0.000143348623853 0 1 -1
nerves,and,was 1.0 0.000143348623853 0 1 -1
nerves,and,their 1.0 0.000143348623853 0 1 -1
nerve,vacuolation,were 1.0 0.000143348623853 0 1 -1
nerve,transmission,at 1.0 0.000143348623853 0 1 -1
nerve,preparations,incubated 1.0 0.000143348623853 0 1 -1
nerve,degeneration,wallerian 1.0 0.000143348623853 0 1 -1
nerve,damage,could 1.0 0.000143348623853 0 1 -1
nerally,classified,as 1.0 0.000143348623853 0 1 -1
nephrotoxicity,frequently,limits 1.0 0.000143348623853 0 1 -1
nephrotoxicity,associated,with 1.0 0.000143348623853 0 1 -1
nephrotoxicity,and,the 1.0 0.000143348623853 0 1 -1
nephrotoxicity,and,or 1.0 0.000286697247706 0 2 -2
nephrotoxic,potential,there 1.0 0.000143348623853 0 1 -1
nephrotoxic,medications,agents 1.0 0.000143348623853 0 1 -1
nephrotoxic,compounds,may 1.0 0.000143348623853 0 1 -1
nephrotoxic,because,of 1.0 0.000143348623853 0 1 -1
nephrosis,acromegaly,and 1.0 0.000143348623853 0 1 -1
nephropathy,were,not 1.0 0.000143348623853 0 1 -1
neostgmine,can,enhance 1.0 0.000143348623853 0 1 -1
neoplasia,are,also 1.0 0.000143348623853 0 1 -1
neonates,with,restricted 1.0 0.000143348623853 0 1 -1
neonates,whose,mothers 1.0 0.000143348623853 0 1 -1
neonates,and,infants 1.0 0.000143348623853 0 1 -1
neonatally,to,mice 1.0 0.000143348623853 0 1 -1
neomycin,has,no 1.0 0.000143348623853 0 1 -1
nelfinavir,is,metabolized 1.0 0.000143348623853 0 1 -1
nelfinavir,is,an 1.0 0.000143348623853 0 1 -1
neither,were,pharmacokinetic 1.0 0.000143348623853 0 1 -1
neither,sufficient,to 1.0 0.000143348623853 0 1 -1
neither,subject,demonstrated 1.0 0.000143348623853 0 1 -1
neither,sodium,nor 1.0 0.000143348623853 0 1 -1
neither,racemic,nor 1.0 0.000143348623853 0 1 -1
neither,nor,its 1.0 0.000143348623853 0 1 -1
neither,nor,appears 1.0 0.000143348623853 0 1 -1
neither,metabolized,by 1.0 0.000143348623853 0 1 -1
neither,inhibitors,of 1.0 0.000143348623853 0 1 -1
neither,influenced,the 1.0 0.000143348623853 0 1 -1
neither,case,were 1.0 0.000143348623853 0 1 -1
negligible,interactions,due 1.0 0.000143348623853 0 1 -1
neglect,of,therapy 1.0 0.000143348623853 0 1 -1
negatively,impacted,by 1.0 0.000143348623853 0 1 -1
negatively,coupled,to 1.0 0.000143348623853 0 1 -1
negative,symptoms,and 1.0 0.000143348623853 0 1 -1
negative,results,from 1.0 0.000143348623853 0 1 -1
negative,result,from 1.0 0.000143348623853 0 1 -1
negative,chronotropic,effects 1.0 0.000143348623853 0 1 -1
negative,bacteria,by 1.0 0.000143348623853 0 1 -1
negative,and,depressive 1.0 0.000286697247706 0 2 -2
nefazodone,cyclosporine,large 1.0 0.000143348623853 0 1 -1
needs,urgently,to 1.0 0.000143348623853 0 1 -1
needing,to,treatpatients 1.0 0.000143348623853 0 1 -1
needed,when,and 1.0 0.000143348623853 0 1 -1
needed,to,determine 1.0 0.000143348623853 0 1 -1
needed,they,should 1.0 0.000143348623853 0 1 -1
needed,their,dose 1.0 0.000143348623853 0 1 -1
needed,the,initial 1.0 0.000143348623853 0 1 -1
needed,due,to 1.0 0.000143348623853 0 1 -1
needed,careful,consideration 1.0 0.000143348623853 0 1 -1
needed,agents,which 1.0 0.000143348623853 0 1 -1
need,to,reassess 1.0 0.000143348623853 0 1 -1
need,to,decrease 1.0 0.000143348623853 0 1 -1
need,for,the 1.0 0.000143348623853 0 1 -1
need,for,or 1.0 0.000143348623853 0 1 -1
need,for,more 1.0 0.000143348623853 0 1 -1
need,for,dose 1.0 0.000286697247706 0 2 -2
need,for,dosage 1.0 0.000143348623853 0 1 -1
need,expensive,or 1.0 0.000143348623853 0 1 -1
necrotizing,myopathy,secondary 1.0 0.000143348623853 0 1 -1
necrosis,and,fibrosis 1.0 0.000143348623853 0 1 -1
necrolysis,has,been 1.0 0.000143348623853 0 1 -1
necessitating,an,increased 1.0 0.000143348623853 0 1 -1
necessitate,reduction,of 1.0 0.000143348623853 0 1 -1
necessitate,an,adjustment 1.0 0.000143348623853 0 1 -1
necessary,when,the 1.0 0.000286697247706 0 2 -2
necessary,when,simulect 1.0 0.000143348623853 0 1 -1
necessary,when,patient 1.0 0.000143348623853 0 1 -1
necessary,when,oral 1.0 0.000143348623853 0 1 -1
necessary,when,nimbex 1.0 0.000143348623853 0 1 -1
necessary,to,control 1.0 0.000286697247706 0 2 -2
necessary,to,be 1.0 0.000143348623853 0 1 -1
necessary,the,use 1.0 0.000143348623853 0 1 -1
necessary,receive,an 1.0 0.000143348623853 0 1 -1
necessary,in,order 1.0 0.000143348623853 0 1 -1
necessary,if,these 1.0 0.00043004587156 0 3 -3
necessary,for,the 1.0 0.000143348623853 0 1 -1
necessary,factor,for 1.0 0.000143348623853 0 1 -1
necessary,during,concomitant 1.0 0.000143348623853 0 1 -1
necessary,careful,patient 1.0 0.00043004587156 0 3 -3
necessary,can,continue 1.0 0.000143348623853 0 1 -1
necessary,but,increased 1.0 0.000143348623853 0 1 -1
nearly,times,the 1.0 0.000143348623853 0 1 -1
nearly,normal,release 1.0 0.000143348623853 0 1 -1
near,the,placental 1.0 0.000143348623853 0 1 -1
nd,series,of 1.0 0.000143348623853 0 1 -1
nd,female,n 1.0 0.000143348623853 0 1 -1
nc1,decrease,ci 1.0 0.00043004587156 0 3 -3
nausea,vomiting,pruritus 1.0 0.000143348623853 0 1 -1
nausea,paresthesia,and 1.0 0.000143348623853 0 1 -1
nature,of,this 1.0 0.000143348623853 0 1 -1
nature,of,the 1.0 0.000143348623853 0 1 -1
natural,history,of 1.0 0.000143348623853 0 1 -1
natural,and,synthetic 1.0 0.000143348623853 0 1 -1
natrecor,with,iv 1.0 0.000143348623853 0 1 -1
natrecor,were,conducted 1.0 0.000143348623853 0 1 -1
nateglinide,is,highly 1.0 0.000143348623853 0 1 -1
nasal,vasoconstrictor,but 1.0 0.000143348623853 0 1 -1
nasal,spray,during 1.0 0.000143348623853 0 1 -1
narrower,spectrum,of 1.0 0.000143348623853 0 1 -1
narrow,therapeutic,windows 1.0 0.000286697247706 0 2 -2
narrow,therapeutic,ratio 1.0 0.000143348623853 0 1 -1
narrow,serum,levels 1.0 0.000143348623853 0 1 -1
nardil,matulane,eldepryl 1.0 0.000143348623853 0 1 -1
naproxen,may,interfere 1.0 0.000143348623853 0 1 -1
naproxen,may,decrease 1.0 0.000143348623853 0 1 -1
naproxen,had,no 1.0 0.000143348623853 0 1 -1
nanm,were,compared 1.0 0.000143348623853 0 1 -1
nanm,was,about 1.0 0.000143348623853 0 1 -1
nanm,in,decreasing 1.0 0.000143348623853 0 1 -1
nanm,failed,to 1.0 0.000143348623853 0 1 -1
nanm,decreased,fi 1.0 0.000143348623853 0 1 -1
naltrexone,trexan,with 1.0 0.000143348623853 0 1 -1
naloxone-sensitive,endorphinergic,system 1.0 0.000143348623853 0 1 -1
naftate,cephalothin,sodium 1.0 0.000143348623853 0 1 -1
naflu,to,and 1.0 0.000143348623853 0 1 -1
naflu,compared,to 1.0 0.000143348623853 0 1 -1
naflu,and,the 1.0 0.000143348623853 0 1 -1
naflu,and,model 1.0 0.000143348623853 0 1 -1
nafarelin,acetate,is 1.0 0.000143348623853 0 1 -1
nacmc,with,moieties 1.0 0.000143348623853 0 1 -1
nacmc,m,v 1.0 0.000286697247706 0 2 -2
nacmc,conjugated,with 1.0 0.000143348623853 0 1 -1
nacmc,at,m 1.0 0.000143348623853 0 1 -1
nacmc,and,cmc-cys 1.0 0.000143348623853 0 1 -1
nac,for,the 1.0 0.000143348623853 0 1 -1
nac,decreased,significantly 1.0 0.000143348623853 0 1 -1
nac,and,the 1.0 0.000143348623853 0 1 -1
n3,for,varying 1.0 0.000143348623853 0 1 -1
n2,and,n3 1.0 0.000143348623853 0 1 -1
n1,n2,and 1.0 0.000143348623853 0 1 -1
n1,and,produced 1.0 0.000143348623853 0 1 -1
n-type,or,omega-agatoxin 1.0 0.000143348623853 0 1 -1
n-type,channel,an 1.0 0.000143348623853 0 1 -1
n-oxide,were,elevated 1.0 0.000143348623853 0 1 -1
n-octyl,and,n-cetyl 1.0 0.000143348623853 0 1 -1
n-multistix,sg,dipstick 1.0 0.000143348623853 0 1 -1
n-methylthiotetrazole,or,methylthiadiazole 1.0 0.000143348623853 0 1 -1
n-dodecyl,gallate,showed 1.0 0.000143348623853 0 1 -1
n-desmethyldiazepam,to,a 1.0 0.000143348623853 0 1 -1
n-desmethylclozapine,and,n-oxide 1.0 0.000143348623853 0 1 -1
n-demethylated,metabolite,metabolite 1.0 0.000143348623853 0 1 -1
n-cetyl,gallate,also 1.0 0.000143348623853 0 1 -1
n-allylnormetazocine,nanm,were 1.0 0.000143348623853 0 1 -1
n-allylnormetazocine,in,pigeons 1.0 0.000143348623853 0 1 -1
n,x,c3h 1.0 0.000143348623853 0 1 -1
n,with,n 1.0 0.000143348623853 0 1 -1
n,were,not 1.0 0.000143348623853 0 1 -1
n,was,also 1.0 0.000143348623853 0 1 -1
n,vs,placebo 1.0 0.000143348623853 0 1 -1
n,under,steady 1.0 0.000143348623853 0 1 -1
n,there,was 1.0 0.000143348623853 0 1 -1
n,received,mg 1.0 0.000143348623853 0 1 -1
n,or,with 1.0 0.000143348623853 0 1 -1
n,n,with 1.0 0.000143348623853 0 1 -1
n,maintained,on 1.0 0.000143348623853 0 1 -1
n,later,changed 1.0 0.000143348623853 0 1 -1
n,in,each 1.0 0.000286697247706 0 2 -2
n,had,no 1.0 0.000143348623853 0 1 -1
n,for,days 1.0 0.000143348623853 0 1 -1
n,did,not 1.0 0.000143348623853 0 1 -1
n,demonstrated,that 1.0 0.000143348623853 0 1 -1
n,demonstrated,large 1.0 0.000143348623853 0 1 -1
n,cmax,and 1.0 0.000143348623853 0 1 -1
n,as,well 1.0 0.000143348623853 0 1 -1
n,are,identical 1.0 0.000143348623853 0 1 -1
myopathy,which,is 1.0 0.000143348623853 0 1 -1
myopathy,underlying,renal 1.0 0.000143348623853 0 1 -1
myopathy,is,also 1.0 0.000143348623853 0 1 -1
myopathy,in,a 1.0 0.000143348623853 0 1 -1
myopathy,during,treatment 1.0 0.000143348623853 0 1 -1
myopathy,by,reducing 1.0 0.000143348623853 0 1 -1
myopathy,and,rhabdomyolysis 1.0 0.000286697247706 0 2 -2
myoclonus,tremor,hemiballismus 1.0 0.000143348623853 0 1 -1
myocardium,versus,nonfailing 1.0 0.000143348623853 0 1 -1
myocardium,to,administration 1.0 0.000143348623853 0 1 -1
myocardium,in,functional 1.0 0.000143348623853 0 1 -1
myocardial,infarction,there 1.0 0.000143348623853 0 1 -1
myocardial,infarction,patients 1.0 0.000143348623853 0 1 -1
myocardial,infarction,or 1.0 0.000143348623853 0 1 -1
myocardial,infarction,liver 1.0 0.000143348623853 0 1 -1
myocardial,infarction,during 1.0 0.000143348623853 0 1 -1
mylotarg,is,not 1.0 0.000143348623853 0 1 -1
myelotoxicity,of,taxol 1.0 0.000143348623853 0 1 -1
myelotoxicity,it,is 1.0 0.000143348623853 0 1 -1
myelosuppressive,agents,or 1.0 0.000143348623853 0 1 -1
myelosuppression,following,the 1.0 0.000143348623853 0 1 -1
myelopoesis,drugs,which 1.0 0.000143348623853 0 1 -1
mydriasis,diplopia,dysarthria 1.0 0.000143348623853 0 1 -1
mycophenolate,mofetil,ml 1.0 0.000143348623853 0 1 -1
mycobacteriumavium-intracellulare,complex,overallactivity 1.0 0.000143348623853 0 1 -1
myasthenic,weakness,who 1.0 0.000143348623853 0 1 -1
myasthenic,weakness,their 1.0 0.000143348623853 0 1 -1
mutation,assay,in 1.0 0.000143348623853 0 1 -1
mutagenicity,studies,were 1.0 0.000143348623853 0 1 -1
mutagenicity,assay,and 1.0 0.000143348623853 0 1 -1
mutagenic,or,clastogenic 1.0 0.000143348623853 0 1 -1
mutagenic,in,the 1.0 0.000143348623853 0 1 -1
mutagenesis,pegasys,did 1.0 0.000143348623853 0 1 -1
mutagenesis,impairment,of 1.0 0.00043004587156 0 3 -3
mutagenesis,and,impairment 1.0 0.000143348623853 0 1 -1
mustard,etc,should 1.0 0.000143348623853 0 1 -1
must,take,into 1.0 0.000143348623853 0 1 -1
must,receive,concomitant 1.0 0.000143348623853 0 1 -1
must,not,conclude 1.0 0.000143348623853 0 1 -1
must,have,negative 1.0 0.000143348623853 0 1 -1
must,have,a 1.0 0.000143348623853 0 1 -1
must,be,repeated 1.0 0.000143348623853 0 1 -1
must,be,provided 1.0 0.000143348623853 0 1 -1
must,be,paid 1.0 0.000143348623853 0 1 -1
must,be,made 1.0 0.000143348623853 0 1 -1
must,be,interrupted 1.0 0.000143348623853 0 1 -1
must,be,exercised 1.0 0.000143348623853 0 1 -1
must,be,done 1.0 0.000143348623853 0 1 -1
must,be,discontinued 1.0 0.000143348623853 0 1 -1
must,be,adjusted 1.0 0.00043004587156 0 3 -3
must,be,a 1.0 0.000143348623853 0 1 -1
musculoskeletal,adverse,events 1.0 0.000143348623853 0 1 -1
muscular,fatigue,hypotension 1.0 0.000143348623853 0 1 -1
muscle,was,exposed 1.0 0.000143348623853 0 1 -1
muscle,relaxants,that 1.0 0.000143348623853 0 1 -1
muscle,relaxants,sleeping 1.0 0.000143348623853 0 1 -1
muscle,relaxants,nondepolarizing 1.0 0.000286697247706 0 2 -2
muscle,relaxants,intravenous 1.0 0.000143348623853 0 1 -1
muscle,relaxants,in 1.0 0.000143348623853 0 1 -1
muscle,relaxants,has 1.0 0.000143348623853 0 1 -1
muscle,relaxants,birth 1.0 0.000143348623853 0 1 -1
muscle,relaxants,are 1.0 0.000143348623853 0 1 -1
muscle,relaxant,antagonists 1.0 0.000143348623853 0 1 -1
muscle,pains,or 1.0 0.000143348623853 0 1 -1
muscle,pain,tinnitus 1.0 0.000143348623853 0 1 -1
muscle,pain,or 1.0 0.000143348623853 0 1 -1
muscle,pain,and 1.0 0.000143348623853 0 1 -1
muscle,cells,and 1.0 0.000143348623853 0 1 -1
muscle,cell,and 1.0 0.000143348623853 0 1 -1
muscle,biopsy,revealed 1.0 0.000143348623853 0 1 -1
multivitamins,quinolones,form 1.0 0.000143348623853 0 1 -1
multipledose,treatment,with 1.0 0.000143348623853 0 1 -1
multiple-dose,suggesting,no 1.0 0.000143348623853 0 1 -1
multiple-dose,study,was 1.0 0.000143348623853 0 1 -1
multiple-dose,pharmacokinetic,profiles 1.0 0.000143348623853 0 1 -1
multiple-dose,interaction,studies 1.0 0.000143348623853 0 1 -1
multiple-dose,crossover,study 1.0 0.000143348623853 0 1 -1
multiple,sclerosis,patients 1.0 0.000143348623853 0 1 -1
multiple,occupational,exposure 1.0 0.000143348623853 0 1 -1
multiple,interacting,mechanisms 1.0 0.000143348623853 0 1 -1
multiple,in,vitro 1.0 0.000143348623853 0 1 -1
multiple,forms,of 1.0 0.000143348623853 0 1 -1
multiple,fixed-interval,fixed-ratio 1.0 0.000143348623853 0 1 -1
multiple,exposure,in 1.0 0.000143348623853 0 1 -1
multiple,exposure,be 1.0 0.000143348623853 0 1 -1
multiple,enzyme,systems 1.0 0.000143348623853 0 1 -1
multiple,dose,pharmacokinetic 1.0 0.000143348623853 0 1 -1
multiple,dose,mg 1.0 0.000143348623853 0 1 -1
multiple,dose,administration 1.0 0.000143348623853 0 1 -1
multiple,cytochrome,p450 1.0 0.000143348623853 0 1 -1
multifaceted,and,is 1.0 0.000143348623853 0 1 -1
multidrug-resistant,organisms,and 1.0 0.000143348623853 0 1 -1
multicenter,randomized,double-blind 1.0 0.000143348623853 0 1 -1
mug,or,less 1.0 0.000286697247706 0 2 -2
mug,ml,whereas 1.0 0.000143348623853 0 1 -1
mug,ml,and 1.0 0.000143348623853 0 1 -1
mucus,the,endometrium 1.0 0.000143348623853 0 1 -1
mucosal,cells,to 1.0 0.000143348623853 0 1 -1
mucosal,cells,at 1.0 0.000143348623853 0 1 -1
mucosal,cell,accumulation 1.0 0.000143348623853 0 1 -1
mucosal,and,serosal 1.0 0.000143348623853 0 1 -1
mucosal,accumulation,of 1.0 0.000143348623853 0 1 -1
mucosa,the,systemic 1.0 0.000143348623853 0 1 -1
mucosa,mounted,in 1.0 0.000143348623853 0 1 -1
mucocutaneous,and,cytoprotective 1.0 0.000143348623853 0 1 -1
much,statistical,work 1.0 0.000143348623853 0 1 -1
much,more,severe 1.0 0.000143348623853 0 1 -1
much,lower,affinities 1.0 0.000143348623853 0 1 -1
much,less,caspase-3 1.0 0.000143348623853 0 1 -1
much,higher,changes 1.0 0.000143348623853 0 1 -1
much,as,possible 1.0 0.000143348623853 0 1 -1
much,as,and 1.0 0.000143348623853 0 1 -1
mu-,delta,and 1.0 0.000143348623853 0 1 -1
mu,systems,for 1.0 0.000143348623853 0 1 -1
mu,kg,min 1.0 0.000143348623853 0 1 -1
mtx,were,nonsteroidal 1.0 0.000143348623853 0 1 -1
mtx,nsaids,tnf 1.0 0.000143348623853 0 1 -1
mtx,nsaids,and 1.0 0.000143348623853 0 1 -1
mtx,in,approximately 1.0 0.000143348623853 0 1 -1
mtx,have,not 1.0 0.000143348623853 0 1 -1
mtc-mdp,as,the 1.0 0.000143348623853 0 1 -1
ms,patients,including 1.0 0.000143348623853 0 1 -1
mrna,in,layers 1.0 0.000143348623853 0 1 -1
mptp,administration,to 1.0 0.000143348623853 0 1 -1
mouth,thirst,weakness 1.0 0.000143348623853 0 1 -1
mouth,sores,or 1.0 0.000143348623853 0 1 -1
mouth,or,by 1.0 0.000143348623853 0 1 -1
mouth,bodyweight,gain 1.0 0.000143348623853 0 1 -1
mouth,anorexia,taste 1.0 0.000143348623853 0 1 -1
mouth,and,transient 1.0 0.000143348623853 0 1 -1
mouse,model,using 1.0 0.000143348623853 0 1 -1
mouse,mammary,tumor 1.0 0.000143348623853 0 1 -1
mouse,lymphoma,cells 1.0 0.000143348623853 0 1 -1
mouse,carcinogenicity,study 1.0 0.000143348623853 0 1 -1
mouse,bone,marrow 1.0 0.000143348623853 0 1 -1
mouse,and,to 1.0 0.000143348623853 0 1 -1
motrin,advil,nuprin 1.0 0.000143348623853 0 1 -1
motor,weakness,myoclonus 1.0 0.000143348623853 0 1 -1
motor,skills,or 1.0 0.000143348623853 0 1 -1
motion,sickness,medications 1.0 0.000143348623853 0 1 -1
motility,may,produce 1.0 0.000143348623853 0 1 -1
motility,in,chick 1.0 0.000143348623853 0 1 -1
motility,dysfunction,may 1.0 0.000143348623853 0 1 -1
motility,agent,contraindicated 1.0 0.000143348623853 0 1 -1
mothers,it,is 1.0 0.000143348623853 0 1 -1
mothers,have,received 1.0 0.000143348623853 0 1 -1
mothers,fulvestrant,is 1.0 0.000143348623853 0 1 -1
most,who,take 1.0 0.000143348623853 0 1 -1
most,ssris,many 1.0 0.000143348623853 0 1 -1
most,significant,interactions 1.0 0.000143348623853 0 1 -1
most,potent,inhibitory 1.0 0.000143348623853 0 1 -1
most,potent,inhibition 1.0 0.000143348623853 0 1 -1
most,potent,against 1.0 0.000143348623853 0 1 -1
most,patients,treated 1.0 0.000143348623853 0 1 -1
most,out,of 1.0 0.000143348623853 0 1 -1
most,of,plasma 1.0 0.000143348623853 0 1 -1
most,genotoxic,compounds--can 1.0 0.000143348623853 0 1 -1
most,excretion,is 1.0 0.000143348623853 0 1 -1
most,evoked,potential 1.0 0.000143348623853 0 1 -1
most,events,were 1.0 0.000143348623853 0 1 -1
most,effective,treatment 1.0 0.000143348623853 0 1 -1
most,commonly,to 1.0 0.000143348623853 0 1 -1
most,commonly,involved 1.0 0.000143348623853 0 1 -1
most,common,medications 1.0 0.000143348623853 0 1 -1
most,common,distilled 1.0 0.000143348623853 0 1 -1
most,common,adverse 1.0 0.000286697247706 0 2 -2
most,closely,associated 1.0 0.000143348623853 0 1 -1
most,cases,of 1.0 0.000143348623853 0 1 -1
most,automated,equipment 1.0 0.000143348623853 0 1 -1
most,and,invalidate 1.0 0.000143348623853 0 1 -1
mortality,were,significantly 1.0 0.000143348623853 0 1 -1
mortality,was,observed 1.0 0.000143348623853 0 1 -1
mortality,rate,in 1.0 0.000143348623853 0 1 -1
mortality,is,not 1.0 0.000143348623853 0 1 -1
mortality,in,patients 1.0 0.000143348623853 0 1 -1
morphology,pyknotic,nuclei 1.0 0.000143348623853 0 1 -1
morphine-induced,tail-flick,inhibition 1.0 0.000143348623853 0 1 -1
morphine-induced,locomotion,in 1.0 0.000143348623853 0 1 -1
morphine,toradoliv,im 1.0 0.000143348623853 0 1 -1
morphine,pharmacokinetic,parameter 1.0 0.000143348623853 0 1 -1
morphine,analgesia,and 1.0 0.000143348623853 0 1 -1
morning,doses,on 1.0 0.000143348623853 0 1 -1
morning,dose,of 1.0 0.000286697247706 0 2 -2
morning,and,lunch 1.0 0.000143348623853 0 1 -1
morning,and,evening 1.0 0.000143348623853 0 1 -1
moribund,condition,after 1.0 0.000143348623853 0 1 -1
moreover,the,mechanisms 1.0 0.000143348623853 0 1 -1
moreover,the,basal 1.0 0.000143348623853 0 1 -1
moreover,the,acquisition 1.0 0.000143348623853 0 1 -1
moreover,its,activity 1.0 0.000143348623853 0 1 -1
moreover,each,task 1.0 0.000143348623853 0 1 -1
moreover,additional,interaction 1.0 0.000143348623853 0 1 -1
more,when,it 1.0 0.000143348623853 0 1 -1
more,were,concomitantly 1.0 0.000143348623853 0 1 -1
more,than,the 1.0 0.000143348623853 0 1 -1
more,than,patients 1.0 0.000143348623853 0 1 -1
more,than,parkinsons 1.0 0.000143348623853 0 1 -1
more,than,one 1.0 0.000286697247706 0 2 -2
more,than,fold 1.0 0.000286697247706 0 2 -2
more,than,episodes 1.0 0.000143348623853 0 1 -1
more,than,doubled 1.0 0.000143348623853 0 1 -1
more,susceptible,to 1.0 0.000143348623853 0 1 -1
more,specific,sulfosalicylic 1.0 0.000143348623853 0 1 -1
more,specific,methods 1.0 0.000143348623853 0 1 -1
more,specific,applications 1.0 0.000143348623853 0 1 -1
more,severely,depressed 1.0 0.000143348623853 0 1 -1
more,severe,structural 1.0 0.000143348623853 0 1 -1
more,severe,reaction 1.0 0.000143348623853 0 1 -1
more,severe,in 1.0 0.000143348623853 0 1 -1
more,severe,events 1.0 0.000143348623853 0 1 -1
more,reactive,to 1.0 0.000573394495413 0 4 -4
more,rapid,progression 1.0 0.000143348623853 0 1 -1
more,pronounced,than 1.0 0.000143348623853 0 1 -1
more,pronounced,secretory 1.0 0.000143348623853 0 1 -1
more,pronounced,inhibition 1.0 0.000143348623853 0 1 -1
more,pronounced,in 1.0 0.00043004587156 0 3 -3
more,potent,than 1.0 0.000286697247706 0 2 -2
more,potent,in 1.0 0.000143348623853 0 1 -1
more,pharmacologic,activities 1.0 0.000143348623853 0 1 -1
more,people,are 1.0 0.000143348623853 0 1 -1
more,or,less 1.0 0.000143348623853 0 1 -1
more,of,the 1.0 0.000286697247706 0 2 -2
more,malignant,phenotype 1.0 0.000143348623853 0 1 -1
more,likely,to 1.0 0.000286697247706 0 2 -2
more,inhalations,than 1.0 0.000143348623853 0 1 -1
more,information,on 1.0 0.000143348623853 0 1 -1
more,importantly,we 1.0 0.000143348623853 0 1 -1
more,highly,protein 1.0 0.000143348623853 0 1 -1
more,frequently,with 1.0 0.000286697247706 0 2 -2
more,frequently,in 1.0 0.000143348623853 0 1 -1
more,frequently,and 1.0 0.000143348623853 0 1 -1
more,frequent,laboratory 1.0 0.000143348623853 0 1 -1
more,frequent,for 1.0 0.000143348623853 0 1 -1
more,frequent,dosing 1.0 0.000143348623853 0 1 -1
more,feasible,as 1.0 0.000143348623853 0 1 -1
more,efficiently,inhibited 1.0 0.000143348623853 0 1 -1
more,efficient,substrate 1.0 0.000143348623853 0 1 -1
more,effective,than 1.0 0.000143348623853 0 1 -1
more,during,a 1.0 0.000143348623853 0 1 -1
more,convenient,administration 1.0 0.000143348623853 0 1 -1
more,competing,memory 1.0 0.000143348623853 0 1 -1
more,cardiovascular,risk 1.0 0.000143348623853 0 1 -1
morbidity,from,ois 1.0 0.000143348623853 0 1 -1
morbidity,and,mortality 1.0 0.000143348623853 0 1 -1
mood,states,and 1.0 0.000143348623853 0 1 -1
mood,and,subjective 1.0 0.000143348623853 0 1 -1
months,the,combination 1.0 0.000143348623853 0 1 -1
months,received,mg 1.0 0.000143348623853 0 1 -1
months,of,each 1.0 0.000286697247706 0 2 -2
months,had,no 1.0 0.000143348623853 0 1 -1
months,at,mg 1.0 0.000143348623853 0 1 -1
months,at,doses 1.0 0.000143348623853 0 1 -1
months,after,treatment 1.0 0.000143348623853 0 1 -1
monthly,was,similar 1.0 0.000143348623853 0 1 -1
monthly,comparison,study 1.0 0.000143348623853 0 1 -1
month,washout,period 1.0 0.000143348623853 0 1 -1
month,toxicology,study 1.0 0.000143348623853 0 1 -1
month,prior,to 1.0 0.000143348623853 0 1 -1
month,of,therapy 1.0 0.000143348623853 0 1 -1
month,controlled,trial 1.0 0.000143348623853 0 1 -1
month,at,approximately 1.0 0.000143348623853 0 1 -1
month,and,are 1.0 0.000143348623853 0 1 -1
monotherapy,given,as 1.0 0.000143348623853 0 1 -1
monotherapy,for,at 1.0 0.000143348623853 0 1 -1
monotherapy,did,not 1.0 0.000143348623853 0 1 -1
mononuclear,cells,were 1.0 0.000143348623853 0 1 -1
mononuclear,cell,infiltration 1.0 0.000143348623853 0 1 -1
monomeric,members,of 1.0 0.000143348623853 0 1 -1
monomeric,disintegrins,and 1.0 0.000143348623853 0 1 -1
monohydroxy,metabolite,mhd 1.0 0.000143348623853 0 1 -1
monoamines,from,adrenergic 1.0 0.000143348623853 0 1 -1
monoamine,oxidases,and 1.0 0.000143348623853 0 1 -1
monoamine,oxidase,inhibitory 1.0 0.000143348623853 0 1 -1
monoamine,oxidase,inhibitor 1.0 0.000143348623853 0 1 -1
monoamine,oxidase,inhibition 1.0 0.000143348623853 0 1 -1
mono-oxidases,in,the 1.0 0.000143348623853 0 1 -1
monkeys,were,of 1.0 0.000143348623853 0 1 -1
monkeys,were,dosed 1.0 0.000143348623853 0 1 -1
monkeys,treated,with 1.0 0.000143348623853 0 1 -1
monkeys,responding,under 1.0 0.000143348623853 0 1 -1
monkeys,nanm,was 1.0 0.000143348623853 0 1 -1
monkeys,given,sc 1.0 0.000143348623853 0 1 -1
monkeys,following,intravenous 1.0 0.000143348623853 0 1 -1
monkeys,at,doses 1.0 0.000143348623853 0 1 -1
monkeys,at,approximately 1.0 0.000143348623853 0 1 -1
monkeys,and,sustained 1.0 0.000143348623853 0 1 -1
monitoring,with,dosage 1.0 0.000143348623853 0 1 -1
monitoring,the,problems 1.0 0.000143348623853 0 1 -1
monitoring,tdm,of 1.0 0.000143348623853 0 1 -1
monitoring,should,be 1.0 0.000143348623853 0 1 -1
monitoring,serum,concentration 1.0 0.000143348623853 0 1 -1
monitoring,particularly,during 1.0 0.000143348623853 0 1 -1
monitoring,or,treatment 1.0 0.000143348623853 0 1 -1
monitoring,of,the 1.0 0.000143348623853 0 1 -1
monitoring,of,renal 1.0 0.000143348623853 0 1 -1
monitoring,of,pulse 1.0 0.000143348623853 0 1 -1
monitoring,of,pancreatitis 1.0 0.000143348623853 0 1 -1
monitoring,of,levels 1.0 0.000143348623853 0 1 -1
monitoring,of,anticoagulation 1.0 0.000143348623853 0 1 -1
monitoring,may,be 1.0 0.000286697247706 0 2 -2
monitoring,is,not 1.0 0.000143348623853 0 1 -1
monitoring,if,you 1.0 0.000143348623853 0 1 -1
monitoring,for,bleeding 1.0 0.000143348623853 0 1 -1
monitoring,devices,and 1.0 0.000143348623853 0 1 -1
monitoring,and,follow-up 1.0 0.000143348623853 0 1 -1
monitoring,allows,physicians 1.0 0.000143348623853 0 1 -1
monitored,with,dosage 1.0 0.000143348623853 0 1 -1
monitored,with,appropriate 1.0 0.000143348623853 0 1 -1
monitored,to,maintain 1.0 0.000143348623853 0 1 -1
monitored,they,should 1.0 0.000143348623853 0 1 -1
monitored,see,clinical 1.0 0.000143348623853 0 1 -1
monitored,regularly,during 1.0 0.000143348623853 0 1 -1
monitored,in,these 1.0 0.000143348623853 0 1 -1
monitored,frequently,to 1.0 0.000143348623853 0 1 -1
monitored,for,signs 1.0 0.000286697247706 0 2 -2
monitored,for,either 1.0 0.000143348623853 0 1 -1
monitored,for,adverse 1.0 0.000143348623853 0 1 -1
monitored,especially,if 1.0 0.000143348623853 0 1 -1
monitored,closely,for 1.0 0.00043004587156 0 3 -3
monitored,by,the 1.0 0.000143348623853 0 1 -1
monitored,by,measuring 1.0 0.000143348623853 0 1 -1
monitored,appropriately,regardless 1.0 0.000143348623853 0 1 -1
monitored,and,patients 1.0 0.000143348623853 0 1 -1
monitored,and,dosage 1.0 0.000143348623853 0 1 -1
monitored,and,any 1.0 0.000143348623853 0 1 -1
monitor,the,plasma 1.0 0.000143348623853 0 1 -1
monitor,the,occurrence 1.0 0.000143348623853 0 1 -1
monitor,the,infusion 1.0 0.000143348623853 0 1 -1
monitor,tcaplasma,levels 1.0 0.000143348623853 0 1 -1
monitor,tca,plasma 1.0 0.000573394495413 0 4 -4
monitor,serum,electrolytes 1.0 0.000143348623853 0 1 -1
monitor,prothrombin,levels 1.0 0.000143348623853 0 1 -1
monitor,plasma,levels 1.0 0.000143348623853 0 1 -1
monitor,levels,or 1.0 0.000143348623853 0 1 -1
monitor,for,symptoms 1.0 0.000143348623853 0 1 -1
monitor,closely,for 1.0 0.000143348623853 0 1 -1
monitor,cardiovascular,status 1.0 0.000143348623853 0 1 -1
molecule,naflu,and 1.0 0.000143348623853 0 1 -1
molecular,weight,heparins 1.0 0.000143348623853 0 1 -1
molecular,mechanisms,of 1.0 0.000143348623853 0 1 -1
molecular,level,by 1.0 0.000143348623853 0 1 -1
molecular,differences,between 1.0 0.000143348623853 0 1 -1
moieties,significantly,improves 1.0 0.000143348623853 0 1 -1
moieties,are,known 1.0 0.000143348623853 0 1 -1
mofetil,ml,h 1.0 0.000143348623853 0 1 -1
modulatory,effect,of 1.0 0.000143348623853 0 1 -1
modulation,of,cholinergic 1.0 0.000143348623853 0 1 -1
modify,the,rate 1.0 0.000143348623853 0 1 -1
modify,the,pharmacokinetics 1.0 0.000143348623853 0 1 -1
modify,the,effect 1.0 0.000143348623853 0 1 -1
modify,exposed,histidine 1.0 0.000143348623853 0 1 -1
modify,acth,induced 1.0 0.000143348623853 0 1 -1
modified,if,they 1.0 0.000143348623853 0 1 -1
modified,histidine,residues 1.0 0.000143348623853 0 1 -1
modified,given,the 1.0 0.000143348623853 0 1 -1
modifications,in,special 1.0 0.000143348623853 0 1 -1
modifications,based,on 1.0 0.000143348623853 0 1 -1
modification,of,surface 1.0 0.000143348623853 0 1 -1
modification,of,a 1.0 0.000143348623853 0 1 -1
modification,is,recommended 1.0 0.000143348623853 0 1 -1
modification,is,generally 1.0 0.000143348623853 0 1 -1
modification,had,no 1.0 0.000143348623853 0 1 -1
modification,abolished,the 1.0 0.000143348623853 0 1 -1
modest,inhibition,of 1.0 0.000143348623853 0 1 -1
modest,dysphoria,and 1.0 0.000143348623853 0 1 -1
modest,degree,in 1.0 0.000286697247706 0 2 -2
modern,medications,can 1.0 0.000143348623853 0 1 -1
moderately,reduced,approximately 1.0 0.000143348623853 0 1 -1
moderate,renal,impairment 1.0 0.000143348623853 0 1 -1
moderate,inhibitors,of 1.0 0.000143348623853 0 1 -1
moderate,inhibitor,of 1.0 0.00043004587156 0 3 -3
moderate,inhibitor,and 1.0 0.000143348623853 0 1 -1
moderate,inducer,of 1.0 0.000143348623853 0 1 -1
moderate,hypertension,where 1.0 0.000143348623853 0 1 -1
moderate,activity,which 1.0 0.000143348623853 0 1 -1
models,for,individual 1.0 0.000143348623853 0 1 -1
models,based,on 1.0 0.000143348623853 0 1 -1
models,are,typically 1.0 0.000143348623853 0 1 -1
models,and,in 1.0 0.000143348623853 0 1 -1
model,using,the 1.0 0.000143348623853 0 1 -1
model,the,joint 1.0 0.000143348623853 0 1 -1
model,primary,focus 1.0 0.000143348623853 0 1 -1
model,peptide,and 1.0 0.000143348623853 0 1 -1
model,is,suitable 1.0 0.000143348623853 0 1 -1
model,in,patients 1.0 0.000143348623853 0 1 -1
mode,of,toxic 1.0 0.000143348623853 0 1 -1
mode,of,action 1.0 0.000143348623853 0 1 -1
mobilization,of,ions 1.0 0.000143348623853 0 1 -1
mna,may,displace 1.0 0.000143348623853 0 1 -1
mna,in,the 1.0 0.000143348623853 0 1 -1
mmol,mmol,l 1.0 0.000143348623853 0 1 -1
mmol,l,were 1.0 0.000143348623853 0 1 -1
mmol,l,or 1.0 0.00043004587156 0 3 -3
mmol,l,mmol 1.0 0.000143348623853 0 1 -1
mmol,l,from 1.0 0.000143348623853 0 1 -1
mmol,day,for 1.0 0.000143348623853 0 1 -1
mm3,for,seven 1.0 0.000143348623853 0 1 -1
mm3,and,platelets 1.0 0.000143348623853 0 1 -1
mm,was,a 1.0 0.000143348623853 0 1 -1
mm,promoted,the 1.0 0.000143348623853 0 1 -1
mm,or,mg 1.0 0.000143348623853 0 1 -1
mm,is,rapid 1.0 0.000143348623853 0 1 -1
mm,hg,higher 1.0 0.000143348623853 0 1 -1
mm,had,no 1.0 0.000143348623853 0 1 -1
mm,fractional,mucosal 1.0 0.000143348623853 0 1 -1
mm,declining,to 1.0 0.000143348623853 0 1 -1
mm,and,mm 1.0 0.000143348623853 0 1 -1
ml,with,the 1.0 0.000143348623853 0 1 -1
ml,whereas,exogenous 1.0 0.000143348623853 0 1 -1
ml,when,was 1.0 0.000143348623853 0 1 -1
ml,sc,or 1.0 0.000143348623853 0 1 -1
ml,resulted,in 1.0 0.000143348623853 0 1 -1
ml,or,m 1.0 0.000143348623853 0 1 -1
ml,or,dihydroxyflavone 1.0 0.000143348623853 0 1 -1
ml,of,absolute 1.0 0.000143348623853 0 1 -1
ml,of,a 1.0 0.000143348623853 0 1 -1
ml,nor,is 1.0 0.000143348623853 0 1 -1
ml,min,and 1.0 0.000143348623853 0 1 -1
ml,may,interfere 1.0 0.000143348623853 0 1 -1
ml,in,the 1.0 0.000143348623853 0 1 -1
ml,h,or 1.0 0.000143348623853 0 1 -1
ml,h,in 1.0 0.000143348623853 0 1 -1
ml,h,did 1.0 0.000143348623853 0 1 -1
ml,for,h 1.0 0.000143348623853 0 1 -1
ml,for,and 1.0 0.000143348623853 0 1 -1
ml,egf,ng 1.0 0.000143348623853 0 1 -1
ml,day,microg 1.0 0.000143348623853 0 1 -1
ml,before,receiving 1.0 0.000143348623853 0 1 -1
ml,at,baseline 1.0 0.000143348623853 0 1 -1
ml,approximately,times 1.0 0.000143348623853 0 1 -1
ml,and,minimal 1.0 0.000143348623853 0 1 -1
ml,and,micrograms 1.0 0.000143348623853 0 1 -1
ml,and,greater 1.0 0.000143348623853 0 1 -1
mixtures,should,not 1.0 0.000143348623853 0 1 -1
mixtures,of,cadmium 1.0 0.000143348623853 0 1 -1
mixtures,had,no 1.0 0.000143348623853 0 1 -1
mixtures,at,concentrations 1.0 0.000286697247706 0 2 -2
mixture,toxicity,investigation 1.0 0.000143348623853 0 1 -1
mixing,novolog,with 1.0 0.000286697247706 0 2 -2
mixed-function,oxidase,enzyme 1.0 0.000143348623853 0 1 -1
mixed-function,mono-oxidases,in 1.0 0.000143348623853 0 1 -1
mixed--pharmacological,and,aetiopathogenic-- 1.0 0.000143348623853 0 1 -1
mixed,with,or 1.0 0.000143348623853 0 1 -1
mixed,with,nph 1.0 0.000143348623853 0 1 -1
mixed,with,infusion 1.0 0.000143348623853 0 1 -1
mixed,with,any 1.0 0.000143348623853 0 1 -1
mixed,signalled-unsignalled,differential-reinforcement 1.0 0.000143348623853 0 1 -1
mixed,agonist-antagonist,effects 1.0 0.000143348623853 0 1 -1
mix,toradol,and 1.0 0.000143348623853 0 1 -1
miu,ml,before 1.0 0.000143348623853 0 1 -1
mitogen,and,an 1.0 0.000143348623853 0 1 -1
misused,by,self-injection 1.0 0.000143348623853 0 1 -1
missing,a,pill 1.0 0.000143348623853 0 1 -1
misonidazole,also,reduced 1.0 0.000143348623853 0 1 -1
misleading,information,that 1.0 0.000143348623853 0 1 -1
miracidia,was,reduced 1.0 0.000143348623853 0 1 -1
miracidia,from,eggs 1.0 0.000143348623853 0 1 -1
miracidia,demonstrated,a 1.0 0.000143348623853 0 1 -1
miotic,actions,of 1.0 0.000143348623853 0 1 -1
miosis,mydriasis,diplopia 1.0 0.000143348623853 0 1 -1
minutes,were,unchanged 1.0 0.000143348623853 0 1 -1
minutes,to,min 1.0 0.000143348623853 0 1 -1
minutes,post,and 1.0 0.000143348623853 0 1 -1
minutes,of,exposure 1.0 0.000143348623853 0 1 -1
minutes,at,a 1.0 0.000143348623853 0 1 -1
minutes,after,administration 1.0 0.000143348623853 0 1 -1
minor,symptoms,such 1.0 0.000143348623853 0 1 -1
minor,side,or 1.0 0.000143348623853 0 1 -1
minor,metabolic,pathway 1.0 0.000143348623853 0 1 -1
minor,contribution,of 1.0 0.000143348623853 0 1 -1
minor,adverse,events 1.0 0.000143348623853 0 1 -1
minimum,inhibitory,concentrations 1.0 0.000143348623853 0 1 -1
minimum,inhibitory,concentration 1.0 0.000143348623853 0 1 -1
minimum,effective,concentration 1.0 0.000143348623853 0 1 -1
minimum,concentration,increased 1.0 0.00043004587156 0 3 -3
minimizing,the,risk 1.0 0.000143348623853 0 1 -1
minimized,to,mg 1.0 0.000143348623853 0 1 -1
minimize,risks,maximize 1.0 0.000143348623853 0 1 -1
minimise,the,risks 1.0 0.000143348623853 0 1 -1
minimally,excreted,via 1.0 0.000143348623853 0 1 -1
minimally,elevated,by 1.0 0.000143348623853 0 1 -1
minimal,inhibitory,concentrations 1.0 0.000143348623853 0 1 -1
minimal,inhibitory,concentration 1.0 0.000286697247706 0 2 -2
minimal,experimental,designs 1.0 0.000143348623853 0 1 -1
minimal,essential,tissue 1.0 0.000143348623853 0 1 -1
minimal,effects,on 1.0 0.000143348623853 0 1 -1
minimal,bactericidal,concentration 1.0 0.000143348623853 0 1 -1
minimal,alterations,of 1.0 0.000143348623853 0 1 -1
mind,when,orudis 1.0 0.000143348623853 0 1 -1
mind,when,bleeding 1.0 0.000143348623853 0 1 -1
mind,when,another 1.0 0.000143348623853 0 1 -1
min,p,less 1.0 0.000143348623853 0 1 -1
min,over,hours 1.0 0.000143348623853 0 1 -1
min,or,t 1.0 0.000143348623853 0 1 -1
min,following,ip 1.0 0.000143348623853 0 1 -1
min,fasting,glycemia 1.0 0.000143348623853 0 1 -1
min,dose,mu 1.0 0.000143348623853 0 1 -1
min,compared,to 1.0 0.000143348623853 0 1 -1
min,before,the 1.0 0.000143348623853 0 1 -1
min,and,copegus 1.0 0.000143348623853 0 1 -1
mimicked,by,the 1.0 0.000143348623853 0 1 -1
mimic,underdosage,myasthenic 1.0 0.000143348623853 0 1 -1
millions,of,men 1.0 0.000143348623853 0 1 -1
milk,there,is 1.0 0.000143348623853 0 1 -1
milk,secretion,by 1.0 0.000143348623853 0 1 -1
milk,on,the 1.0 0.000143348623853 0 1 -1
milk,ejection,by 1.0 0.000286697247706 0 2 -2
milk,at,levels 1.0 0.000143348623853 0 1 -1
milk,and,because 1.0 0.000286697247706 0 2 -2
mild-to,moderate,inhibitors 1.0 0.000143348623853 0 1 -1
mild,but,definite 1.0 0.000143348623853 0 1 -1
mild,and,consisted 1.0 0.000143348623853 0 1 -1
migraines,such,as 1.0 0.000143348623853 0 1 -1
migraine,has,not 1.0 0.000143348623853 0 1 -1
might,reflect,the 1.0 0.000143348623853 0 1 -1
might,occur,with 1.0 0.000143348623853 0 1 -1
might,interfere,with 1.0 0.000143348623853 0 1 -1
might,help,to 1.0 0.000143348623853 0 1 -1
might,have,the 1.0 0.000143348623853 0 1 -1
might,have,detrimental 1.0 0.000143348623853 0 1 -1
might,blunt,adrenal 1.0 0.000143348623853 0 1 -1
might,be,required 1.0 0.000286697247706 0 2 -2
might,be,manifested 1.0 0.000143348623853 0 1 -1
might,be,caused 1.0 0.000143348623853 0 1 -1
might,arise,from 1.0 0.000143348623853 0 1 -1
might,also,modify 1.0 0.000143348623853 0 1 -1
midlands,a,large 1.0 0.000143348623853 0 1 -1
midcycle,day,to 1.0 0.000143348623853 0 1 -1
midcycle,day,of 1.0 0.000143348623853 0 1 -1
mics,of,against 1.0 0.000143348623853 0 1 -1
mics,and,viable 1.0 0.000143348623853 0 1 -1
microvascular,complications,of 1.0 0.000143348623853 0 1 -1
microtubules,was,improved 1.0 0.000143348623853 0 1 -1
microtubules,on,cooling 1.0 0.000143348623853 0 1 -1
microtubules,in,the 1.0 0.000143348623853 0 1 -1
microtubules,in,non-myelinated 1.0 0.000143348623853 0 1 -1
microtubules,appeared,to 1.0 0.000143348623853 0 1 -1
microsomes,to,determine 1.0 0.000143348623853 0 1 -1
microsomes,the,effects 1.0 0.000143348623853 0 1 -1
microsomes,suggest,that 1.0 0.000143348623853 0 1 -1
microsomes,showed,that 1.0 0.000143348623853 0 1 -1
microsomes,indicate,that 1.0 0.00043004587156 0 3 -3
microsomes,demonstrated,no 1.0 0.000143348623853 0 1 -1
microsomes,cyp1a2,cyp2c9 1.0 0.000143348623853 0 1 -1
microsomes,appears,to 1.0 0.000143348623853 0 1 -1
microsome,studies,and 1.0 0.000143348623853 0 1 -1
microsomal,monooxygenase,activities 1.0 0.000143348623853 0 1 -1
microsomal,fraction,suggesting 1.0 0.000143348623853 0 1 -1
microsomal,fraction,of 1.0 0.000143348623853 0 1 -1
microsomal,fraction,in 1.0 0.000143348623853 0 1 -1
microsomal,ethoxycoumarine,deethylase 1.0 0.000143348623853 0 1 -1
microsomal,enzymes,were 1.0 0.000143348623853 0 1 -1
microsomal,enzymes,cytochrome 1.0 0.000143348623853 0 1 -1
microsomal,enzyme,oxidation 1.0 0.000143348623853 0 1 -1
microscopy,were,used 1.0 0.000143348623853 0 1 -1
micronase,the,patient 1.0 0.000573394495413 0 4 -4
micromol,l,or 1.0 0.000143348623853 0 1 -1
micromol,l,induced 1.0 0.000143348623853 0 1 -1
micromol,l,did 1.0 0.000143348623853 0 1 -1
microm,which,was 1.0 0.000143348623853 0 1 -1
microm,increased,intracellular 1.0 0.000143348623853 0 1 -1
micrograms,ml,with 1.0 0.000143348623853 0 1 -1
micrograms,ml,or 1.0 0.000143348623853 0 1 -1
micrograms,ml,may 1.0 0.000143348623853 0 1 -1
micrograms,ml,for 1.0 0.000143348623853 0 1 -1
micrograms,kg,of 1.0 0.000143348623853 0 1 -1
micrograms,g,sometimes 1.0 0.000143348623853 0 1 -1
microgram,ml,egf 1.0 0.000143348623853 0 1 -1
microg,ml,when 1.0 0.000143348623853 0 1 -1
microg,ml,or 1.0 0.000143348623853 0 1 -1
microg,ml,in 1.0 0.000143348623853 0 1 -1
microg,l,were 1.0 0.000143348623853 0 1 -1
microg,l,or 1.0 0.000143348623853 0 1 -1
microg,l,of 1.0 0.000143348623853 0 1 -1
microg,l,for 1.0 0.000143348623853 0 1 -1
microg,kg,body 1.0 0.000143348623853 0 1 -1
microdilution,method,for 1.0 0.000143348623853 0 1 -1
micrococcus,luteus,mic 1.0 0.000143348623853 0 1 -1
mice,with,a 1.0 0.000143348623853 0 1 -1
mice,treated,with 1.0 0.000143348623853 0 1 -1
mice,showed,behavioral 1.0 0.000143348623853 0 1 -1
mice,selectively,bred 1.0 0.000143348623853 0 1 -1
mice,one,of 1.0 0.000143348623853 0 1 -1
mice,on,the 1.0 0.000143348623853 0 1 -1
mice,min,before 1.0 0.000143348623853 0 1 -1
mice,induced,lower 1.0 0.000143348623853 0 1 -1
mice,induced,by 1.0 0.000143348623853 0 1 -1
mice,in,the 1.0 0.000143348623853 0 1 -1
mice,from,the 1.0 0.000143348623853 0 1 -1
mice,did,not 1.0 0.000286697247706 0 2 -2
mice,c57bl,n 1.0 0.000143348623853 0 1 -1
mice,but,the 1.0 0.000143348623853 0 1 -1
mice,and,the 1.0 0.000143348623853 0 1 -1
mice,after,chronic 1.0 0.000143348623853 0 1 -1
mice,a,bar-press 1.0 0.000143348623853 0 1 -1
mic,of,flucoxacillin 1.0 0.000143348623853 0 1 -1
mhd,to,plasma 1.0 0.000143348623853 0 1 -1
mhd,the,predominant 1.0 0.000143348623853 0 1 -1
mhd,induce,a 1.0 0.000143348623853 0 1 -1
mhd,however,is 1.0 0.000143348623853 0 1 -1
mhd,have,little 1.0 0.000143348623853 0 1 -1
mhd,did,occur 1.0 0.000143348623853 0 1 -1
mhd,concentration,mean 1.0 0.000143348623853 0 1 -1
mhd,and,with 1.0 0.000143348623853 0 1 -1
mglur,agonists,dcg-iv 1.0 0.000143348623853 0 1 -1
mg2,converted,difluoroacetone 1.0 0.000143348623853 0 1 -1
mg,x,kg 1.0 0.000143348623853 0 1 -1
mg,with,the 1.0 0.000143348623853 0 1 -1
mg,when,used 1.0 0.000143348623853 0 1 -1
mg,when,given 1.0 0.000143348623853 0 1 -1
mg,when,co-administered 1.0 0.000143348623853 0 1 -1
mg,were,allowed 1.0 0.000143348623853 0 1 -1
mg,were,administered 1.0 0.000143348623853 0 1 -1
mg,was,taken 1.0 0.000143348623853 0 1 -1
mg,was,in 1.0 0.000143348623853 0 1 -1
mg,was,evaluated 1.0 0.000143348623853 0 1 -1
mg,vardenafil,in 1.0 0.000143348623853 0 1 -1
mg,twice,a 1.0 0.000143348623853 0 1 -1
mg,total,daily 1.0 0.000143348623853 0 1 -1
mg,to,a 1.0 0.000143348623853 0 1 -1
mg,times,the 1.0 0.000143348623853 0 1 -1
mg,times,day 1.0 0.000143348623853 0 1 -1
mg,tid,were 1.0 0.000143348623853 0 1 -1
mg,tid,study 1.0 0.000143348623853 0 1 -1
mg,tid,no 1.0 0.000143348623853 0 1 -1
mg,tablets,administered 1.0 0.000143348623853 0 1 -1
mg,sustained-release,tablets 1.0 0.000143348623853 0 1 -1
mg,starlix,three 1.0 0.000143348623853 0 1 -1
mg,single,oral 1.0 0.000286697247706 0 2 -2
mg,should,be 1.0 0.000286697247706 0 2 -2
mg,result,in 1.0 0.000143348623853 0 1 -1
mg,rat,days 1.0 0.00043004587156 0 3 -3
mg,qid,did 1.0 0.000143348623853 0 1 -1
mg,qhs,after 1.0 0.000143348623853 0 1 -1
mg,qd,was 1.0 0.000143348623853 0 1 -1
mg,qd,or 1.0 0.000286697247706 0 2 -2
mg,qd,of 1.0 0.000143348623853 0 1 -1
mg,qd,in 1.0 0.000143348623853 0 1 -1
mg,qd,has 1.0 0.000143348623853 0 1 -1
mg,qd,did 1.0 0.000143348623853 0 1 -1
mg,qd,cohort 1.0 0.000143348623853 0 1 -1
mg,q24h,for 1.0 0.000143348623853 0 1 -1
mg,per,ml 1.0 0.000143348623853 0 1 -1
mg,orally,min 1.0 0.000143348623853 0 1 -1
mg,orally,given 1.0 0.000143348623853 0 1 -1
mg,oral,dose 1.0 0.00043004587156 0 3 -3
mg,or,placebo 1.0 0.000143348623853 0 1 -1
mg,or,of 1.0 0.000143348623853 0 1 -1
mg,or,more 1.0 0.000143348623853 0 1 -1
mg,once-daily,dose 1.0 0.000143348623853 0 1 -1
mg,once,monthly 1.0 0.000143348623853 0 1 -1
mg,once,a 1.0 0.000143348623853 0 1 -1
mg,on,the 1.0 0.000286697247706 0 2 -2
mg,of,vioxx 1.0 0.000143348623853 0 1 -1
mg,of,twice 1.0 0.000143348623853 0 1 -1
mg,of,or 1.0 0.000143348623853 0 1 -1
mg,of,have 1.0 0.000143348623853 0 1 -1
mg,of,equivalent 1.0 0.000143348623853 0 1 -1
mg,of,as 1.0 0.000286697247706 0 2 -2
mg,of,alone 1.0 0.000143348623853 0 1 -1
mg,of,administered 1.0 0.000143348623853 0 1 -1
mg,of,acetate 1.0 0.000143348623853 0 1 -1
mg,of,a 1.0 0.000143348623853 0 1 -1
mg,neurontin,and 1.0 0.000143348623853 0 1 -1
mg,ml,have 1.0 0.000143348623853 0 1 -1
mg,ml,approximately 1.0 0.000143348623853 0 1 -1
mg,ml,and 1.0 0.000143348623853 0 1 -1
mg,mg,or 1.0 0.000143348623853 0 1 -1
mg,mg,bid 1.0 0.000143348623853 0 1 -1
mg,m2,without 1.0 0.000143348623853 0 1 -1
mg,m2,plus 1.0 0.000143348623853 0 1 -1
mg,m2,before 1.0 0.000143348623853 0 1 -1
mg,m,basis 1.0 0.000143348623853 0 1 -1
mg,l,while 1.0 0.000143348623853 0 1 -1
mg,l,and 1.0 0.000143348623853 0 1 -1
mg,kg,weekly 1.0 0.000143348623853 0 1 -1
mg,kg,week 1.0 0.000143348623853 0 1 -1
mg,kg,was 1.0 0.000143348623853 0 1 -1
mg,kg,twice 1.0 0.000143348623853 0 1 -1
mg,kg,the 1.0 0.000143348623853 0 1 -1
mg,kg,such 1.0 0.000143348623853 0 1 -1
mg,kg,subcutaneous 1.0 0.000143348623853 0 1 -1
mg,kg,results 1.0 0.000143348623853 0 1 -1
mg,kg,resulted 1.0 0.000143348623853 0 1 -1
mg,kg,or 1.0 0.000573394495413 0 4 -4
mg,kg,once 1.0 0.000286697247706 0 2 -2
mg,kg,of 1.0 0.000286697247706 0 2 -2
mg,kg,ml 1.0 0.000143348623853 0 1 -1
mg,kg,mg 1.0 0.000286697247706 0 2 -2
mg,kg,mc 1.0 0.000143348623853 0 1 -1
mg,kg,infused 1.0 0.000143348623853 0 1 -1
mg,kg,induced 1.0 0.000143348623853 0 1 -1
mg,kg,every 1.0 0.000143348623853 0 1 -1
mg,kg,decreases 1.0 0.000143348623853 0 1 -1
mg,kg,days 1.0 0.000286697247706 0 2 -2
mg,kg,daily 1.0 0.000143348623853 0 1 -1
mg,kg,bwt 1.0 0.000143348623853 0 1 -1
mg,iv,was 1.0 0.000143348623853 0 1 -1
mg,intravenous,dose 1.0 0.000143348623853 0 1 -1
mg,in,men 1.0 0.000143348623853 0 1 -1
mg,in,combination 1.0 0.000143348623853 0 1 -1
mg,has,been 1.0 0.000143348623853 0 1 -1
mg,four,times 1.0 0.000143348623853 0 1 -1
mg,for,at 1.0 0.000143348623853 0 1 -1
mg,followed,by 1.0 0.000143348623853 0 1 -1
mg,five,times 1.0 0.000143348623853 0 1 -1
mg,ethinyl,estradiol 1.0 0.000286697247706 0 2 -2
mg,enteric,coated 1.0 0.000143348623853 0 1 -1
mg,elemental,oz 1.0 0.000143348623853 0 1 -1
mg,each,dose 1.0 0.000143348623853 0 1 -1
mg,dose,had 1.0 0.000143348623853 0 1 -1
mg,dose,achieves 1.0 0.000143348623853 0 1 -1
mg,dosage,inhibited 1.0 0.000143348623853 0 1 -1
mg,dl,were 1.0 0.000143348623853 0 1 -1
mg,dl,triglycerides 1.0 0.000143348623853 0 1 -1
mg,dl,submitted 1.0 0.000143348623853 0 1 -1
mg,did,not 1.0 0.00143348623853 0 10 -10
mg,day,to 1.0 0.000573394495413 0 4 -4
mg,day,proved 1.0 0.000143348623853 0 1 -1
mg,day,n 1.0 0.000143348623853 0 1 -1
mg,day,monotherapy 1.0 0.000143348623853 0 1 -1
mg,day,mg 1.0 0.000143348623853 0 1 -1
mg,day,has 1.0 0.000143348623853 0 1 -1
mg,day,doses 1.0 0.000143348623853 0 1 -1
mg,day,against 1.0 0.000143348623853 0 1 -1
mg,day,after 1.0 0.000143348623853 0 1 -1
mg,daily,was 1.0 0.000143348623853 0 1 -1
mg,daily,should 1.0 0.000143348623853 0 1 -1
mg,daily,had 1.0 0.000143348623853 0 1 -1
mg,daily,for 1.0 0.00043004587156 0 3 -3
mg,daily,did 1.0 0.000143348623853 0 1 -1
mg,d,of 1.0 0.000143348623853 0 1 -1
mg,d,but 1.0 0.000143348623853 0 1 -1
mg,considered,for 1.0 0.000143348623853 0 1 -1
mg,clo-4,simultaneously 1.0 0.000143348623853 0 1 -1
mg,causing,no 1.0 0.000143348623853 0 1 -1
mg,capsule,twice 1.0 0.000143348623853 0 1 -1
mg,both,a 1.0 0.000143348623853 0 1 -1
mg,bid,were 1.0 0.000143348623853 0 1 -1
mg,bid,on 1.0 0.000286697247706 0 2 -2
mg,bid,n 1.0 0.000143348623853 0 1 -1
mg,bid,have 1.0 0.000143348623853 0 1 -1
mg,bid,did 1.0 0.00043004587156 0 3 -3
mg,before,meals 1.0 0.000143348623853 0 1 -1
mg,as,mg 1.0 0.000143348623853 0 1 -1
mg,as,a 1.0 0.000143348623853 0 1 -1
mg,and,sustiva 1.0 0.000143348623853 0 1 -1
mg,and,multiple 1.0 0.000286697247706 0 2 -2
mg,and,intravenous 1.0 0.000143348623853 0 1 -1
mg,also,received 1.0 0.000143348623853 0 1 -1
mg,administered,daily 1.0 0.000143348623853 0 1 -1
mg,a,potent 1.0 0.000143348623853 0 1 -1
mevacor,in,hypercholesterolemic 1.0 0.000143348623853 0 1 -1
methyltransferase,comt,hormone 1.0 0.000143348623853 0 1 -1
methylthiadiazole,can,cause 1.0 0.000143348623853 0 1 -1
methyltetrahydro-folate,and,in 1.0 0.000143348623853 0 1 -1
methylglutaryl,coenzyme,a 1.0 0.000143348623853 0 1 -1
methyl-4,phenyl-1,tetrahydropyridine 1.0 0.000143348623853 0 1 -1
methoxycoronaridine,mc,and 1.0 0.000143348623853 0 1 -1
methotrexate,vioxx,and 1.0 0.000143348623853 0 1 -1
methotrexate,valdecoxib,mg 1.0 0.000143348623853 0 1 -1
methotrexate,in,an 1.0 0.000143348623853 0 1 -1
methotrexate,humira,has 1.0 0.000143348623853 0 1 -1
methotrexate,cyclosporine,diclofenac 1.0 0.000143348623853 0 1 -1
methods,we,carried 1.0 0.000143348623853 0 1 -1
methods,toxi-lab,a 1.0 0.000143348623853 0 1 -1
methods,to,measure 1.0 0.000143348623853 0 1 -1
methods,the,study 1.0 0.000143348623853 0 1 -1
methods,that,may 1.0 0.000143348623853 0 1 -1
methods,such,as 1.0 0.000143348623853 0 1 -1
methods,should,not 1.0 0.000143348623853 0 1 -1
methods,hydrocortisone,mg 1.0 0.000143348623853 0 1 -1
methods,healthy,subjects 1.0 0.000143348623853 0 1 -1
methods,gdh,pqq-based 1.0 0.000143348623853 0 1 -1
methods,from,the 1.0 0.000143348623853 0 1 -1
methods,for,hours 1.0 0.000143348623853 0 1 -1
methods,commonly,used 1.0 0.000143348623853 0 1 -1
methods,clinical,studies 1.0 0.000143348623853 0 1 -1
methods,all,patients 1.0 0.000143348623853 0 1 -1
methodology,used,to 1.0 0.000143348623853 0 1 -1
methodology,for,deriving 1.0 0.000143348623853 0 1 -1
method,to,prevent 1.0 0.000143348623853 0 1 -1
method,to,maximize 1.0 0.000143348623853 0 1 -1
method,to,accomplish 1.0 0.000143348623853 0 1 -1
method,this,study 1.0 0.000143348623853 0 1 -1
method,the,inulin 1.0 0.000143348623853 0 1 -1
method,such,as 1.0 0.000143348623853 0 1 -1
method,or,the 1.0 0.000143348623853 0 1 -1
method,for,the 1.0 0.000143348623853 0 1 -1
method,for,aerobic 1.0 0.000143348623853 0 1 -1
method,be,used 1.0 0.000286697247706 0 2 -2
method,and,the 1.0 0.000143348623853 0 1 -1
method,and,observations 1.0 0.000143348623853 0 1 -1
method,and,a 1.0 0.000143348623853 0 1 -1
methaemoglobinaemia,particularly,in 1.0 0.000143348623853 0 1 -1
methadone,dose,was 1.0 0.000143348623853 0 1 -1
meth,induced,arc 1.0 0.000143348623853 0 1 -1
meth,has,been 1.0 0.000143348623853 0 1 -1
meth,administration,affects 1.0 0.000143348623853 0 1 -1
metformin,when,starlix 1.0 0.000143348623853 0 1 -1
metformin,in,a 1.0 0.000143348623853 0 1 -1
metenkephalinamide,or,on 1.0 0.000143348623853 0 1 -1
metastasis,through,actions 1.0 0.000143348623853 0 1 -1
metanephrine,normetanephrine,and 1.0 0.000143348623853 0 1 -1
metal,toxicity,where 1.0 0.000143348623853 0 1 -1
metal,toxicity,to 1.0 0.000286697247706 0 2 -2
metal,toxicity,but 1.0 0.000143348623853 0 1 -1
metal,mixtures,had 1.0 0.000143348623853 0 1 -1
metal,mixture,toxicity 1.0 0.000143348623853 0 1 -1
metal,concentration,except 1.0 0.000143348623853 0 1 -1
metal,cations,multivitamins 1.0 0.000143348623853 0 1 -1
metacercariae,of,parorchis 1.0 0.000143348623853 0 1 -1
metabotropic,glutamate,mglur 1.0 0.000143348623853 0 1 -1
metabolizing,isozyme,cytochrome 1.0 0.000716743119266 0 5 -5
metabolizing,enzymes,such 1.0 0.000286697247706 0 2 -2
metabolizing,enzymes,and 1.0 0.000143348623853 0 1 -1
metabolizes,may,experience 1.0 0.000143348623853 0 1 -1
metabolizers,with,regard 1.0 0.000286697247706 0 2 -2
metabolizers,which,is 1.0 0.000143348623853 0 1 -1
metabolizers,resemble,poor 1.0 0.000143348623853 0 1 -1
metabolizers,of,such 1.0 0.000286697247706 0 2 -2
metabolizers,have,higher 1.0 0.000716743119266 0 5 -5
metabolizers,had,a 1.0 0.000143348623853 0 1 -1
metabolizers,and,extensive 1.0 0.000143348623853 0 1 -1
metabolizers,after,multiple-dose 1.0 0.000143348623853 0 1 -1
metabolized,via,the 1.0 0.000143348623853 0 1 -1
metabolized,via,a 1.0 0.000143348623853 0 1 -1
metabolized,to,the 1.0 0.000143348623853 0 1 -1
metabolized,to,by 1.0 0.00043004587156 0 3 -3
metabolized,to,a 1.0 0.000143348623853 0 1 -1
metabolized,through,various 1.0 0.000143348623853 0 1 -1
metabolized,through,the 1.0 0.000143348623853 0 1 -1
metabolized,through,cyp3a4 1.0 0.000143348623853 0 1 -1
metabolized,the,coadministration 1.0 0.000143348623853 0 1 -1
metabolized,primarily,by 1.0 0.000143348623853 0 1 -1
metabolized,predominantly,by 1.0 0.000143348623853 0 1 -1
metabolized,particularly,those 1.0 0.000143348623853 0 1 -1
metabolized,nor,does 1.0 0.000143348623853 0 1 -1
metabolized,mainly,via 1.0 0.000286697247706 0 2 -2
metabolized,mainly,by 1.0 0.000143348623853 0 1 -1
metabolized,in,the 1.0 0.000286697247706 0 2 -2
metabolized,in,proof 1.0 0.000143348623853 0 1 -1
metabolized,in,part 1.0 0.000143348623853 0 1 -1
metabolized,drugs,results 1.0 0.000143348623853 0 1 -1
metabolized,by,those 1.0 0.000286697247706 0 2 -2
metabolized,by,these 1.0 0.000716743119266 0 5 -5
metabolized,by,p450iid6 1.0 0.000143348623853 0 1 -1
metabolized,by,p450 1.0 0.00143348623853 0 10 -10
metabolized,by,or 1.0 0.000143348623853 0 1 -1
metabolized,by,one 1.0 0.000143348623853 0 1 -1
metabolized,by,nor 1.0 0.000143348623853 0 1 -1
metabolized,by,multiple 1.0 0.000286697247706 0 2 -2
metabolized,by,monoamine 1.0 0.000143348623853 0 1 -1
metabolized,by,glucuronidation 1.0 0.000143348623853 0 1 -1
metabolized,by,cyp3a 1.0 0.000286697247706 0 2 -2
metabolized,by,cyp1a2 1.0 0.000143348623853 0 1 -1
metabolized,by,cyp 1.0 0.000860091743119 0 6 -6
metabolized,by,catechol-o 1.0 0.000143348623853 0 1 -1
metabolized,by,c 1.0 0.000143348623853 0 1 -1
metabolized,by,a 1.0 0.000143348623853 0 1 -1
metabolized,at,least 1.0 0.000143348623853 0 1 -1
metabolized,and,therefore 1.0 0.000143348623853 0 1 -1
metabolized,and,renal 1.0 0.000143348623853 0 1 -1
metabolize,to,active 1.0 0.000143348623853 0 1 -1
metabolites,with,the 1.0 0.000143348623853 0 1 -1
metabolites,with,m-dinitrobenzene 1.0 0.000143348623853 0 1 -1
metabolites,were,studied 1.0 0.000143348623853 0 1 -1
metabolites,were,measured 1.0 0.000143348623853 0 1 -1
metabolites,oxo-desethylzaleplon,and 1.0 0.000143348623853 0 1 -1
metabolites,or,accumulation 1.0 0.000143348623853 0 1 -1
metabolites,n-desmethylclozapine,and 1.0 0.000143348623853 0 1 -1
metabolites,may,color 1.0 0.000143348623853 0 1 -1
metabolites,is,a 1.0 0.000143348623853 0 1 -1
metabolites,interfere,with 1.0 0.000143348623853 0 1 -1
metabolites,induce,or 1.0 0.000143348623853 0 1 -1
metabolites,including,the 1.0 0.000143348623853 0 1 -1
metabolites,in,the 1.0 0.000143348623853 0 1 -1
metabolites,hydroxytolbutamide,and 1.0 0.000143348623853 0 1 -1
metabolites,have,been 1.0 0.000143348623853 0 1 -1
metabolites,has,been 1.0 0.000143348623853 0 1 -1
metabolites,had,no 1.0 0.000143348623853 0 1 -1
metabolites,dfur,fu 1.0 0.000143348623853 0 1 -1
metabolites,are,minimally 1.0 0.000143348623853 0 1 -1
metabolites,appear,to 1.0 0.000143348623853 0 1 -1
metabolite,ucb,l057 1.0 0.000143348623853 0 1 -1
metabolite,or,pharmacokinetics 1.0 0.000143348623853 0 1 -1
metabolite,of,were 1.0 0.000286697247706 0 2 -2
metabolite,of,the 1.0 0.000143348623853 0 1 -1
metabolite,of,does 1.0 0.000143348623853 0 1 -1
metabolite,of,d 1.0 0.000143348623853 0 1 -1
metabolite,of,chloroprocaine 1.0 0.000143348623853 0 1 -1
metabolite,of,associated 1.0 0.000143348623853 0 1 -1
metabolite,norfluoxe-tine,have 1.0 0.000143348623853 0 1 -1
metabolite,mhd,have 1.0 0.000143348623853 0 1 -1
metabolite,metabolite,i 1.0 0.000143348623853 0 1 -1
metabolite,may,result 1.0 0.000143348623853 0 1 -1
metabolite,m1,which 1.0 0.000143348623853 0 1 -1
metabolite,is,mediated 1.0 0.000143348623853 0 1 -1
metabolite,in,patients 1.0 0.000143348623853 0 1 -1
metabolite,i,with 1.0 0.000143348623853 0 1 -1
metabolite,i,suggesting 1.0 0.000143348623853 0 1 -1
metabolite,i,potency 1.0 0.000143348623853 0 1 -1
metabolite,i,alone 1.0 0.000143348623853 0 1 -1
metabolite,hydroxy-estazolam,and 1.0 0.000143348623853 0 1 -1
metabolite,have,been 1.0 0.000143348623853 0 1 -1
metabolite,has,reduced 1.0 0.000143348623853 0 1 -1
metabolite,formation,the 1.0 0.000143348623853 0 1 -1
metabolite,concentrations,were 1.0 0.000143348623853 0 1 -1
metabolite,beta-naltrexol,were 1.0 0.000143348623853 0 1 -1
metabolite,averaged,s 1.0 0.000143348623853 0 1 -1
metabolite,at,concentrations 1.0 0.000143348623853 0 1 -1
metabolite,are,inhibitors 1.0 0.000143348623853 0 1 -1
metabolite,and,the 1.0 0.000143348623853 0 1 -1
metabolite,after,intravenous 1.0 0.000143348623853 0 1 -1
metabolism,were,homozygous 1.0 0.000143348623853 0 1 -1
metabolism,was,tested 1.0 0.000143348623853 0 1 -1
metabolism,via,cytochrome 1.0 0.000286697247706 0 2 -2
metabolism,very,sensitive 1.0 0.000143348623853 0 1 -1
metabolism,using,isoform 1.0 0.000143348623853 0 1 -1
metabolism,studies,indicate 1.0 0.000143348623853 0 1 -1
metabolism,studies,have 1.0 0.000286697247706 0 2 -2
metabolism,studies,and 1.0 0.000143348623853 0 1 -1
metabolism,pharmacokinetics,therapeutic 1.0 0.000143348623853 0 1 -1
metabolism,or,qt 1.0 0.000143348623853 0 1 -1
metabolism,or,on 1.0 0.000143348623853 0 1 -1
metabolism,or,elimination 1.0 0.000143348623853 0 1 -1
metabolism,of,wellbutrin 1.0 0.000143348623853 0 1 -1
metabolism,of,to 1.0 0.000286697247706 0 2 -2
metabolism,of,taxol 1.0 0.000143348623853 0 1 -1
metabolism,of,labetalol 1.0 0.000143348623853 0 1 -1
metabolism,of,is 1.0 0.000286697247706 0 2 -2
metabolism,of,difluoroacetone 1.0 0.000143348623853 0 1 -1
metabolism,of,cytochrome 1.0 0.000143348623853 0 1 -1
metabolism,of,compounds 1.0 0.000143348623853 0 1 -1
metabolism,of,commonly 1.0 0.000143348623853 0 1 -1
metabolism,of,chylomicron-like 1.0 0.000143348623853 0 1 -1
metabolism,of,c 1.0 0.000286697247706 0 2 -2
metabolism,of,antagonists 1.0 0.000143348623853 0 1 -1
metabolism,mediated,by 1.0 0.000286697247706 0 2 -2
metabolism,may,result 1.0 0.000143348623853 0 1 -1
metabolism,may,produce 1.0 0.000143348623853 0 1 -1
metabolism,may,need 1.0 0.000143348623853 0 1 -1
metabolism,is,predominantly 1.0 0.00043004587156 0 3 -3
metabolism,is,hydroxylation 1.0 0.000143348623853 0 1 -1
metabolism,is,dependent 1.0 0.000143348623853 0 1 -1
metabolism,in,normal 1.0 0.000143348623853 0 1 -1
metabolism,in,future 1.0 0.000143348623853 0 1 -1
metabolism,hormone,action 1.0 0.000143348623853 0 1 -1
metabolism,could,contribute 1.0 0.000143348623853 0 1 -1
metabolism,concomitant,use 1.0 0.000143348623853 0 1 -1
metabolism,carbohydrate,metabolism 1.0 0.000143348623853 0 1 -1
metabolism,by,is 1.0 0.000143348623853 0 1 -1
metabolism,by,cyp2d6 1.0 0.000143348623853 0 1 -1
metabolism,are,unlikely 1.0 0.000143348623853 0 1 -1
metabolism,are,not 1.0 0.000143348623853 0 1 -1
metabolism,are,important 1.0 0.000143348623853 0 1 -1
metabolism,and,uptake 1.0 0.000286697247706 0 2 -2
metabolism,and,therefore 1.0 0.000143348623853 0 1 -1
metabolism,and,may 1.0 0.000286697247706 0 2 -2
metabolism,and,elimination 1.0 0.000143348623853 0 1 -1
metabolism,and,diabetes 1.0 0.000143348623853 0 1 -1
metabolism,and,decrease 1.0 0.000143348623853 0 1 -1
metabolism,and,and 1.0 0.000143348623853 0 1 -1
metabolised,therefore,little 1.0 0.000143348623853 0 1 -1
metabolically,active,when 1.0 0.000143348623853 0 1 -1
metabolic,responses,to 1.0 0.000143348623853 0 1 -1
metabolic,reactions,was 1.0 0.000143348623853 0 1 -1
metabolic,reactions,catalyzed 1.0 0.000143348623853 0 1 -1
metabolic,rate,which 1.0 0.000143348623853 0 1 -1
metabolic,profiles,clinically 1.0 0.000143348623853 0 1 -1
metabolic,probe,study 1.0 0.000286697247706 0 2 -2
metabolic,pathway,may 1.0 0.000143348623853 0 1 -1
metabolic,pathway,for 1.0 0.000286697247706 0 2 -2
metabolic,interference,has 1.0 0.000143348623853 0 1 -1
metabolic,interactions,indicate 1.0 0.000143348623853 0 1 -1
metabolic,interactions,caused 1.0 0.000143348623853 0 1 -1
metabolic,enzymes,is 1.0 0.000143348623853 0 1 -1
metabolic,enzymes,and 1.0 0.000143348623853 0 1 -1
metabolic,effects,specifically 1.0 0.000143348623853 0 1 -1
metabolic,disturbances,have 1.0 0.000143348623853 0 1 -1
metabolic,activation,factor 1.0 0.000143348623853 0 1 -1
metabolic,abnormalities,has 1.0 0.000143348623853 0 1 -1
metab-olizers,resemble,poor 1.0 0.000143348623853 0 1 -1
met,acr,criteria 1.0 0.000143348623853 0 1 -1
mesylate,tablets,have 1.0 0.000286697247706 0 2 -2
mesylate,has,no 1.0 0.000143348623853 0 1 -1
mesylate,has,been 1.0 0.000143348623853 0 1 -1
mesylate,did,not 1.0 0.000143348623853 0 1 -1
messages,advise,on 1.0 0.000143348623853 0 1 -1
mesenteric,vasodilation,is 1.0 0.000143348623853 0 1 -1
mesenteric,resistance,arteries 1.0 0.000143348623853 0 1 -1
mesenteric,ganglion,hypogastric 1.0 0.000143348623853 0 1 -1
mesenteric,arteries,preconstricted 1.0 0.000143348623853 0 1 -1
mesenteric,arteries,from 1.0 0.000143348623853 0 1 -1
mesantoin,use,of 1.0 0.000143348623853 0 1 -1
mercapturic,acids,or 1.0 0.000143348623853 0 1 -1
meq,or,duloxetine 1.0 0.000143348623853 0 1 -1
meq,l,were 1.0 0.000143348623853 0 1 -1
mepron,interferes,with 1.0 0.000143348623853 0 1 -1
mepron,concurrently,with 1.0 0.000143348623853 0 1 -1
mephenytoin,mesantoin,use 1.0 0.000143348623853 0 1 -1
mentioned,above,and 1.0 0.000143348623853 0 1 -1
mentax,butenafine,hcl 1.0 0.000143348623853 0 1 -1
mental,status,in 1.0 0.000143348623853 0 1 -1
mental,and,motor 1.0 0.000143348623853 0 1 -1
mental,alertness,such 1.0 0.000143348623853 0 1 -1
menstrual,rhythm,followed 1.0 0.000143348623853 0 1 -1
menstrual,period,immediately 1.0 0.000143348623853 0 1 -1
menstrual,irregularities,have 1.0 0.000286697247706 0 2 -2
menstrual,cycles,and 1.0 0.000143348623853 0 1 -1
menstrual,cycle,irregularities 1.0 0.000143348623853 0 1 -1
men,years,of 1.0 0.000143348623853 0 1 -1
men,with,mild 1.0 0.000143348623853 0 1 -1
men,with,erectile 1.0 0.000143348623853 0 1 -1
men,who,have 1.0 0.000143348623853 0 1 -1
men,n,did 1.0 0.000143348623853 0 1 -1
men,levels,were 1.0 0.000143348623853 0 1 -1
men,for,the 1.0 0.000143348623853 0 1 -1
men,and,women 1.0 0.000143348623853 0 1 -1
memory,that,are 1.0 0.000286697247706 0 2 -2
memory,systems,most 1.0 0.000143348623853 0 1 -1
memory,systems,at 1.0 0.000143348623853 0 1 -1
memory,system,that 1.0 0.000143348623853 0 1 -1
membranes,of,large 1.0 0.000143348623853 0 1 -1
membranes,and,that 1.0 0.000143348623853 0 1 -1
membrane,was,changed 1.0 0.000143348623853 0 1 -1
membrane,sterol,in 1.0 0.000143348623853 0 1 -1
membrane,properties,of 1.0 0.000143348623853 0 1 -1
membrane,properties,during 1.0 0.000143348623853 0 1 -1
membrane,potential,input 1.0 0.000143348623853 0 1 -1
membrane,phospholipids,as 1.0 0.000143348623853 0 1 -1
membrane,and,intracellular 1.0 0.000143348623853 0 1 -1
members,of,the 1.0 0.000143348623853 0 1 -1
mellitus,or,evidence 1.0 0.000143348623853 0 1 -1
mellitus,may,become 1.0 0.000143348623853 0 1 -1
mellitus,ischemic,heart 1.0 0.000143348623853 0 1 -1
mellitus,is,a 1.0 0.000143348623853 0 1 -1
mellitus,certain,neurologic 1.0 0.000143348623853 0 1 -1
mellitus,and,may 1.0 0.000143348623853 0 1 -1
mellaril,stelazine,vesprin 1.0 0.000143348623853 0 1 -1
megakaryocytes,with,the 1.0 0.000143348623853 0 1 -1
mefloquineuine,on,the 1.0 0.000143348623853 0 1 -1
mefloquineuine,causes,a 1.0 0.000143348623853 0 1 -1
mefloquineuine,and,the 1.0 0.000143348623853 0 1 -1
mefloquine,therapy,should 1.0 0.000143348623853 0 1 -1
mefloquine,should,have 1.0 0.000143348623853 0 1 -1
mefloquine,have,not 1.0 0.000143348623853 0 1 -1
mefloquine,administration,should 1.0 0.000143348623853 0 1 -1
mefenamic,acid,and 1.0 0.000143348623853 0 1 -1
medrol,others,prelone 1.0 0.000143348623853 0 1 -1
medline,premedline,and 1.0 0.000143348623853 0 1 -1
medium,rpmi1640,containing 1.0 0.000143348623853 0 1 -1
medium,consisting,of 1.0 0.000143348623853 0 1 -1
medium,blocked,the 1.0 0.000143348623853 0 1 -1
medicines,with,l-tryptophan 1.0 0.000143348623853 0 1 -1
medicines,when,placed 1.0 0.000143348623853 0 1 -1
medicines,should,not 1.0 0.000143348623853 0 1 -1
medicines,may,make 1.0 0.000143348623853 0 1 -1
medicines,may,increase 1.0 0.000716743119266 0 5 -5
medicines,may,be 1.0 0.000143348623853 0 1 -1
medicines,including,may 1.0 0.000143348623853 0 1 -1
medicines,although,certain 1.0 0.000143348623853 0 1 -1
medicine,without,doctor 1.0 0.000143348623853 0 1 -1
medicine,with,thioridizine 1.0 0.000143348623853 0 1 -1
medicine,with,st 1.0 0.000143348623853 0 1 -1
medicine,such,as 1.0 0.000143348623853 0 1 -1
medicine,should,not 1.0 0.000286697247706 0 2 -2
medicine,due,to 1.0 0.000143348623853 0 1 -1
medicine,certain,such 1.0 0.000143348623853 0 1 -1
medicinal,products,that 1.0 0.000143348623853 0 1 -1
medicinal,products,such 1.0 0.000286697247706 0 2 -2
medicinal,products,have 1.0 0.000143348623853 0 1 -1
medicinal,or,dietary 1.0 0.000143348623853 0 1 -1
medications,with,orencia 1.0 0.000143348623853 0 1 -1
medications,with,narrow 1.0 0.000286697247706 0 2 -2
medications,with,a 1.0 0.000143348623853 0 1 -1
medications,which,interfere 1.0 0.000143348623853 0 1 -1
medications,were,mp 1.0 0.000143348623853 0 1 -1
medications,were,grouped 1.0 0.000143348623853 0 1 -1
medications,used,in 1.0 0.000286697247706 0 2 -2
medications,used,concomitantly 1.0 0.000143348623853 0 1 -1
medications,to,predict 1.0 0.000143348623853 0 1 -1
medications,to,interfere 1.0 0.000143348623853 0 1 -1
medications,that,interfere 1.0 0.000286697247706 0 2 -2
medications,should,not 1.0 0.000143348623853 0 1 -1
medications,should,be 1.0 0.000286697247706 0 2 -2
medications,other,especially 1.0 0.000143348623853 0 1 -1
medications,on,clearance 1.0 0.000143348623853 0 1 -1
medications,muscle,relaxants 1.0 0.000143348623853 0 1 -1
medications,motion,sickness 1.0 0.000143348623853 0 1 -1
medications,most,commonly 1.0 0.000143348623853 0 1 -1
medications,may,need 1.0 0.000143348623853 0 1 -1
medications,may,decrease 1.0 0.000143348623853 0 1 -1
medications,including,inhaled 1.0 0.000143348623853 0 1 -1
medications,included,mtx 1.0 0.000143348623853 0 1 -1
medications,in,the 1.0 0.000143348623853 0 1 -1
medications,have,included 1.0 0.000143348623853 0 1 -1
medications,have,been 1.0 0.000286697247706 0 2 -2
medications,for,the 1.0 0.000143348623853 0 1 -1
medications,for,migraines 1.0 0.000143348623853 0 1 -1
medications,especially,central 1.0 0.000143348623853 0 1 -1
medications,concurrent,use 1.0 0.000286697247706 0 2 -2
medications,can,do 1.0 0.000143348623853 0 1 -1
medications,can,cause 1.0 0.000143348623853 0 1 -1
medications,besides,mtx 1.0 0.000143348623853 0 1 -1
medications,at,any 1.0 0.000143348623853 0 1 -1
medications,applied,to 1.0 0.000143348623853 0 1 -1
medications,and,timing 1.0 0.000143348623853 0 1 -1
medications,and,increase 1.0 0.000143348623853 0 1 -1
medications,and,include 1.0 0.000143348623853 0 1 -1
medications,agents,such 1.0 0.000143348623853 0 1 -1
medication,used,to 1.0 0.000143348623853 0 1 -1
medication,tell,your 1.0 0.000143348623853 0 1 -1
medication,should,not 1.0 0.000143348623853 0 1 -1
medication,should,be 1.0 0.000286697247706 0 2 -2
medication,review,in 1.0 0.000143348623853 0 1 -1
medication,patients,want 1.0 0.000143348623853 0 1 -1
medication,on,patients 1.0 0.000143348623853 0 1 -1
medication,monitored,and 1.0 0.000143348623853 0 1 -1
medication,may,antagonise 1.0 0.000143348623853 0 1 -1
medication,iodine-containing,products 1.0 0.000143348623853 0 1 -1
medication,interferes,with 1.0 0.000143348623853 0 1 -1
medication,but,also 1.0 0.000143348623853 0 1 -1
medication,authorization,cards 1.0 0.000143348623853 0 1 -1
medication,and,mefloquine 1.0 0.000143348623853 0 1 -1
medication,and,instruct 1.0 0.000143348623853 0 1 -1
medication,administered,concomitantly 1.0 0.000286697247706 0 2 -2
medicated,or,abrasive 1.0 0.000143348623853 0 1 -1
medical,supervision,for 1.0 0.000143348623853 0 1 -1
medical,literature,contains 1.0 0.000143348623853 0 1 -1
medical,intervention,in 1.0 0.000143348623853 0 1 -1
medical,examinations,for 1.0 0.000143348623853 0 1 -1
medical,considerations,are 1.0 0.000143348623853 0 1 -1
medical,complications,of 1.0 0.000143348623853 0 1 -1
medical,backgrounds,of 1.0 0.000143348623853 0 1 -1
medical,attention,and 1.0 0.000143348623853 0 1 -1
mediation,of,influence 1.0 0.000143348623853 0 1 -1
mediating,stimulus-induced,neural 1.0 0.000143348623853 0 1 -1
mediated,via,cytochrome 1.0 0.000143348623853 0 1 -1
mediated,via,cyp 1.0 0.000143348623853 0 1 -1
mediated,transport,of 1.0 0.000143348623853 0 1 -1
mediated,signalling,or 1.0 0.000143348623853 0 1 -1
mediated,reduction,in 1.0 0.000143348623853 0 1 -1
mediated,primarily,by 1.0 0.000143348623853 0 1 -1
mediated,clearance,or 1.0 0.000143348623853 0 1 -1
mediated,by,inhibition 1.0 0.000286697247706 0 2 -2
mediated,by,cytochrome 1.0 0.000143348623853 0 1 -1
mediated,by,any 1.0 0.000143348623853 0 1 -1
mediate,the,metabolism 1.0 0.000143348623853 0 1 -1
mediate,and,xenobiotic 1.0 0.000143348623853 0 1 -1
median,tmax,was 1.0 0.000143348623853 0 1 -1
median,survival,for 1.0 0.000143348623853 0 1 -1
median,follow-up,opportunistic 1.0 0.000143348623853 0 1 -1
median,follow-up,of 1.0 0.000143348623853 0 1 -1
median,fold,accumulation 1.0 0.000143348623853 0 1 -1
medial,survival,of 1.0 0.000143348623853 0 1 -1
media,was,given 1.0 0.000286697247706 0 2 -2
meclofenamate,sodium,does 1.0 0.000143348623853 0 1 -1
mechanisms,with,some 1.0 0.000143348623853 0 1 -1
mechanisms,will,aid 1.0 0.000143348623853 0 1 -1
mechanisms,underlying,the 1.0 0.000286697247706 0 2 -2
mechanisms,similar,to 1.0 0.000143348623853 0 1 -1
mechanisms,of,status 1.0 0.000143348623853 0 1 -1
mechanisms,of,pcp-induced 1.0 0.000143348623853 0 1 -1
mechanisms,of,metal 1.0 0.000143348623853 0 1 -1
mechanisms,of,action 1.0 0.000286697247706 0 2 -2
mechanism,underlying,many 1.0 0.000143348623853 0 1 -1
mechanism,s,of 1.0 0.000286697247706 0 2 -2
mechanism,of,this 1.0 0.000286697247706 0 2 -2
mechanism,of,these 1.0 0.000143348623853 0 1 -1
mechanism,of,the 1.0 0.000143348623853 0 1 -1
mechanism,of,resveratrol-induced 1.0 0.000143348623853 0 1 -1
mechanism,of,milk 1.0 0.000143348623853 0 1 -1
mechanism,of,coagulation 1.0 0.000143348623853 0 1 -1
mechanism,of,clozapine 1.0 0.000143348623853 0 1 -1
mechanism,involved,in 1.0 0.000143348623853 0 1 -1
mechanism,and,seven 1.0 0.000143348623853 0 1 -1
mechanism,and,long-term 1.0 0.000143348623853 0 1 -1
mec,values,of 1.0 0.000143348623853 0 1 -1
measuring,serum,total 1.0 0.000143348623853 0 1 -1
measuring,locomotor,activity 1.0 0.000143348623853 0 1 -1
measures,to,minimise 1.0 0.000143348623853 0 1 -1
measures,should,be 1.0 0.000143348623853 0 1 -1
measures,included,self-reported 1.0 0.000143348623853 0 1 -1
measures,have,been 1.0 0.000143348623853 0 1 -1
measures,for,its 1.0 0.000143348623853 0 1 -1
measurements,with,some 1.0 0.000143348623853 0 1 -1
measurements,should,be 1.0 0.000143348623853 0 1 -1
measurements,porter-silber,test 1.0 0.000143348623853 0 1 -1
measurements,are,necessary 1.0 0.000143348623853 0 1 -1
measurements,and,main 1.0 0.000286697247706 0 2 -2
measurement,of,urinary 1.0 0.000143348623853 0 1 -1
measurement,of,pharmacokinetic 1.0 0.000143348623853 0 1 -1
measurement,of,nociception 1.0 0.000143348623853 0 1 -1
measurement,of,fundus 1.0 0.000143348623853 0 1 -1
measurement,of,creatinine 1.0 0.000143348623853 0 1 -1
measurement,of,and 1.0 0.000143348623853 0 1 -1
measurement,must,be 1.0 0.000143348623853 0 1 -1
measured,using,the 1.0 0.000143348623853 0 1 -1
measured,toxicity,was 1.0 0.000143348623853 0 1 -1
measured,near,the 1.0 0.000143348623853 0 1 -1
measured,in,volunteers 1.0 0.000143348623853 0 1 -1
measured,from,the 1.0 0.000143348623853 0 1 -1
measured,four,times 1.0 0.000143348623853 0 1 -1
measured,during,both 1.0 0.000143348623853 0 1 -1
measured,by,the 1.0 0.000143348623853 0 1 -1
measured,by,prothrombin 1.0 0.000143348623853 0 1 -1
measured,by,protein-bound 1.0 0.000286697247706 0 2 -2
measured,by,plate 1.0 0.000143348623853 0 1 -1
measured,by,pbi 1.0 0.000286697247706 0 2 -2
measured,by,high-performance 1.0 0.000143348623853 0 1 -1
measured,by,fluorimetric 1.0 0.000143348623853 0 1 -1
measured,at,steady 1.0 0.000143348623853 0 1 -1
measure,plasma,concentrations 1.0 0.000143348623853 0 1 -1
measure,over,the 1.0 0.000143348623853 0 1 -1
measure,glucose,levels 1.0 0.000143348623853 0 1 -1
measurable,effect,on 1.0 0.000143348623853 0 1 -1
meant,to,relieve 1.0 0.000143348623853 0 1 -1
means,of,the 1.0 0.000143348623853 0 1 -1
means,of,reducing 1.0 0.000143348623853 0 1 -1
means,of,hydroxytolbutamide 1.0 0.000143348623853 0 1 -1
meaningfully,alter,the 1.0 0.000143348623853 0 1 -1
meaningful,interactions,have 1.0 0.000143348623853 0 1 -1
meaningful,increases,in 1.0 0.000143348623853 0 1 -1
meaningful,changes,in 1.0 0.000286697247706 0 2 -2
mean,values,of 1.0 0.000143348623853 0 1 -1
mean,value,of 1.0 0.000143348623853 0 1 -1
mean,template,bleeding 1.0 0.000143348623853 0 1 -1
mean,steady-state,trough 1.0 0.000143348623853 0 1 -1
mean,sem,to 1.0 0.000143348623853 0 1 -1
mean,sd,cumulative 1.0 0.000143348623853 0 1 -1
mean,reduction,of 1.0 0.000143348623853 0 1 -1
mean,ratios,confidence 1.0 0.000143348623853 0 1 -1
mean,plasma,elimination 1.0 0.000143348623853 0 1 -1
mean,of,to 1.0 0.000143348623853 0 1 -1
mean,of,minutes 1.0 0.000143348623853 0 1 -1
mean,number,of 1.0 0.000143348623853 0 1 -1
mean,minimum,concentration 1.0 0.00043004587156 0 3 -3
mean,inr,values 1.0 0.000143348623853 0 1 -1
mean,drug,level 1.0 0.000143348623853 0 1 -1
mean,distribution,of 1.0 0.000143348623853 0 1 -1
mean,decreases,of 1.0 0.000143348623853 0 1 -1
mean,daily,trough 1.0 0.000143348623853 0 1 -1
mean,concentrations,of 1.0 0.000143348623853 0 1 -1
mean,changes,were 1.0 0.000143348623853 0 1 -1
mean,aucs,and 1.0 0.000143348623853 0 1 -1
mean,auc,values 1.0 0.000286697247706 0 2 -2
mean,auc,or 1.0 0.000143348623853 0 1 -1
mean,auc,c 1.0 0.000143348623853 0 1 -1
mealtime,dosing,and 1.0 0.000143348623853 0 1 -1
meals,was,administered 1.0 0.000286697247706 0 2 -2
meals,for,four 1.0 0.000143348623853 0 1 -1
meals,for,day 1.0 0.000143348623853 0 1 -1
meal,would,not 1.0 0.000143348623853 0 1 -1
meal,or,at 1.0 0.000143348623853 0 1 -1
meal,of,the 1.0 0.000143348623853 0 1 -1
meal,and,the 1.0 0.000143348623853 0 1 -1
mcg,twice,daily 1.0 0.000143348623853 0 1 -1
mcg,per,day 1.0 0.000143348623853 0 1 -1
mcg,once,daily 1.0 0.000286697247706 0 2 -2
mcg,ml,nor 1.0 0.000143348623853 0 1 -1
mcf-7,cells,with 1.0 0.000143348623853 0 1 -1
mcf-7,cells,treated 1.0 0.000143348623853 0 1 -1
mcf-7,cells,resistant 1.0 0.000143348623853 0 1 -1
mcf-7,cells,even 1.0 0.000143348623853 0 1 -1
mcf-7,cells,either 1.0 0.000143348623853 0 1 -1
mc,probably,has 1.0 0.000143348623853 0 1 -1
mc,mg,kg 1.0 0.000143348623853 0 1 -1
mc,has,much 1.0 0.000143348623853 0 1 -1
mc,has,a 1.0 0.000143348623853 0 1 -1
mc,enhance,the 1.0 0.000143348623853 0 1 -1
mc,does,not 1.0 0.000286697247706 0 2 -2
mc,decreases,heart 1.0 0.000143348623853 0 1 -1
mc,decrease,extracellular 1.0 0.000143348623853 0 1 -1
mc,and,have 1.0 0.000143348623853 0 1 -1
mc,and,comparison 1.0 0.000143348623853 0 1 -1
mc,and,are 1.0 0.000143348623853 0 1 -1
mc,a,novel 1.0 0.000143348623853 0 1 -1
maybe,useful,for 1.0 0.000143348623853 0 1 -1
may,wear,off 1.0 0.000143348623853 0 1 -1
may,weaken,or 1.0 0.000143348623853 0 1 -1
may,want,to 1.0 0.000143348623853 0 1 -1
may,vary,in 1.0 0.000716743119266 0 5 -5
may,vary,from 1.0 0.000143348623853 0 1 -1
may,vary,by 1.0 0.000143348623853 0 1 -1
may,vary,and 1.0 0.000143348623853 0 1 -1
may,use,especially 1.0 0.000143348623853 0 1 -1
may,underlie,its 1.0 0.000143348623853 0 1 -1
may,undergo,hydrolysis 1.0 0.000143348623853 0 1 -1
may,under,certain 1.0 0.000143348623853 0 1 -1
may,turn,out 1.0 0.000143348623853 0 1 -1
may,therefore,change 1.0 0.000143348623853 0 1 -1
may,thereby,cause 1.0 0.000143348623853 0 1 -1
may,suppress,reactions 1.0 0.000143348623853 0 1 -1
may,suppress,certain 1.0 0.000143348623853 0 1 -1
may,subsequently,increase 1.0 0.000143348623853 0 1 -1
may,subject,themselves 1.0 0.000143348623853 0 1 -1
may,still,be 1.0 0.000143348623853 0 1 -1
may,sterilize,the 1.0 0.000143348623853 0 1 -1
may,sometimes,be 1.0 0.000286697247706 0 2 -2
may,slow,gastric 1.0 0.000143348623853 0 1 -1
may,significantly,reduce 1.0 0.000143348623853 0 1 -1
may,show,on-treatment 1.0 0.000143348623853 0 1 -1
may,share,or 1.0 0.000143348623853 0 1 -1
may,sensitize,tissues 1.0 0.000143348623853 0 1 -1
may,rise,resulting 1.0 0.000143348623853 0 1 -1
may,reveal,other 1.0 0.000143348623853 0 1 -1
may,result,at 1.0 0.000143348623853 0 1 -1
may,respond,to 1.0 0.000143348623853 0 1 -1
may,require,reduction 1.0 0.000286697247706 0 2 -2
may,require,lower 1.0 0.00100344036697 0 7 -7
may,require,higher 1.0 0.000286697247706 0 2 -2
may,require,dose 1.0 0.00043004587156 0 3 -3
may,require,adjustment 1.0 0.000143348623853 0 1 -1
may,require,a 1.0 0.000143348623853 0 1 -1
may,represent,the 1.0 0.000143348623853 0 1 -1
may,remain,some 1.0 0.000143348623853 0 1 -1
may,reduce,its 1.0 0.000143348623853 0 1 -1
may,reach,toxic 1.0 0.000143348623853 0 1 -1
may,raise,blood 1.0 0.000143348623853 0 1 -1
may,provoke,toxicity 1.0 0.000143348623853 0 1 -1
may,provide,misleading 1.0 0.000143348623853 0 1 -1
may,produce,ventricular 1.0 0.000143348623853 0 1 -1
may,produce,significant 1.0 0.000143348623853 0 1 -1
may,produce,serious 1.0 0.000143348623853 0 1 -1
may,produce,false-positive 1.0 0.000143348623853 0 1 -1
may,produce,additive 1.0 0.000143348623853 0 1 -1
may,produce,a 1.0 0.000860091743119 0 6 -6
may,prevent,absorption 1.0 0.000143348623853 0 1 -1
may,potentiate,and 1.0 0.000286697247706 0 2 -2
may,potentially,interfere 1.0 0.000143348623853 0 1 -1
may,potentially,interact 1.0 0.000143348623853 0 1 -1
may,potentially,alter 1.0 0.000143348623853 0 1 -1
may,possibly,have 1.0 0.000143348623853 0 1 -1
may,play,a 1.0 0.000143348623853 0 1 -1
may,persist,for 1.0 0.000143348623853 0 1 -1
may,or,may 1.0 0.000143348623853 0 1 -1
may,occur,potentiating 1.0 0.000143348623853 0 1 -1
may,occur,due 1.0 0.000143348623853 0 1 -1
may,not,require 1.0 0.000286697247706 0 2 -2
may,not,appreciably 1.0 0.000143348623853 0 1 -1
may,modify,the 1.0 0.000143348623853 0 1 -1
may,mimic,underdosage 1.0 0.000143348623853 0 1 -1
may,mask,the 1.0 0.000143348623853 0 1 -1
may,make,your 1.0 0.000143348623853 0 1 -1
may,make,normal 1.0 0.000286697247706 0 2 -2
may,interact,synergistically 1.0 0.000143348623853 0 1 -1
may,interact,altered 1.0 0.000143348623853 0 1 -1
may,intensify,electrolyte 1.0 0.000143348623853 0 1 -1
may,inhibit,k 1.0 0.000143348623853 0 1 -1
may,inhibit,gastrointestinal 1.0 0.000143348623853 0 1 -1
may,influence,the 1.0 0.000286697247706 0 2 -2
may,induce,toxicity 1.0 0.000143348623853 0 1 -1
may,induce,serious 1.0 0.000143348623853 0 1 -1
may,induce,an 1.0 0.000143348623853 0 1 -1
may,increase,their 1.0 0.000143348623853 0 1 -1
may,increase,susceptibility 1.0 0.000143348623853 0 1 -1
may,increase,metabolism 1.0 0.000143348623853 0 1 -1
may,increase,in 1.0 0.000143348623853 0 1 -1
may,increase,excretion 1.0 0.000143348623853 0 1 -1
may,increase,certain 1.0 0.000143348623853 0 1 -1
may,include,one 1.0 0.000143348623853 0 1 -1
may,impair,liver 1.0 0.000143348623853 0 1 -1
may,impair,intestinal 1.0 0.00043004587156 0 3 -3
may,impair,fertility 1.0 0.000143348623853 0 1 -1
may,if,abruptly 1.0 0.000143348623853 0 1 -1
may,however,be 1.0 0.000143348623853 0 1 -1
may,help,to 1.0 0.000286697247706 0 2 -2
may,have,to 1.0 0.000143348623853 0 1 -1
may,have,several 1.0 0.000143348623853 0 1 -1
may,have,lower 1.0 0.000143348623853 0 1 -1
may,have,higher 1.0 0.000143348623853 0 1 -1
may,have,either 1.0 0.000143348623853 0 1 -1
may,have,decreased 1.0 0.000143348623853 0 1 -1
may,have,contributed 1.0 0.000143348623853 0 1 -1
may,have,allergic 1.0 0.000143348623853 0 1 -1
may,have,a 1.0 0.000860091743119 0 6 -6
may,explain,in 1.0 0.000143348623853 0 1 -1
may,experience,large 1.0 0.000143348623853 0 1 -1
may,experience,increased 1.0 0.000143348623853 0 1 -1
may,even,decrease 1.0 0.000143348623853 0 1 -1
may,enhance,s 1.0 0.000143348623853 0 1 -1
may,enhance,cardiovascular 1.0 0.000143348623853 0 1 -1
may,displace,other 1.0 0.000143348623853 0 1 -1
may,displace,from 1.0 0.000286697247706 0 2 -2
may,develop,higher 1.0 0.000143348623853 0 1 -1
may,depend,upon 1.0 0.000143348623853 0 1 -1
may,depend,on 1.0 0.000143348623853 0 1 -1
may,delay,elimination 1.0 0.000143348623853 0 1 -1
may,decrease,sprycel 1.0 0.000143348623853 0 1 -1
may,decrease,platelet 1.0 0.000143348623853 0 1 -1
may,decrease,metabolism 1.0 0.000143348623853 0 1 -1
may,decrease,in 1.0 0.000143348623853 0 1 -1
may,color,alkaline 1.0 0.000143348623853 0 1 -1
may,change,with 1.0 0.000143348623853 0 1 -1
may,cause,too 1.0 0.000143348623853 0 1 -1
may,cause,myopathy 1.0 0.000143348623853 0 1 -1
may,cause,increases 1.0 0.000143348623853 0 1 -1
may,cause,hypotension 1.0 0.000143348623853 0 1 -1
may,cause,hypoglycemia 1.0 0.000286697247706 0 2 -2
may,cause,bleeding 1.0 0.000143348623853 0 1 -1
may,bring,latent 1.0 0.000143348623853 0 1 -1
may,blunt,the 1.0 0.000143348623853 0 1 -1
may,become,more 1.0 0.000143348623853 0 1 -1
may,become,manifest 1.0 0.000143348623853 0 1 -1
may,become,abruptly 1.0 0.000573394495413 0 4 -4
may,be,worsened 1.0 0.000143348623853 0 1 -1
may,be,warranted 1.0 0.000286697247706 0 2 -2
may,be,unresponsive 1.0 0.000860091743119 0 6 -6
may,be,transiently 1.0 0.000143348623853 0 1 -1
may,be,the 1.0 0.000143348623853 0 1 -1
may,be,superior 1.0 0.000143348623853 0 1 -1
may,be,substrates 1.0 0.000143348623853 0 1 -1
may,be,small 1.0 0.000716743119266 0 5 -5
may,be,similar 1.0 0.000143348623853 0 1 -1
may,be,safely 1.0 0.000286697247706 0 2 -2
may,be,related 1.0 0.00043004587156 0 3 -3
may,be,recommended 1.0 0.000286697247706 0 2 -2
may,be,precipitated 1.0 0.000143348623853 0 1 -1
may,be,potential 1.0 0.000143348623853 0 1 -1
may,be,of 1.0 0.000143348623853 0 1 -1
may,be,no 1.0 0.000143348623853 0 1 -1
may,be,negatively 1.0 0.000143348623853 0 1 -1
may,be,involved 1.0 0.000143348623853 0 1 -1
may,be,induced 1.0 0.000143348623853 0 1 -1
may,be,indicated 1.0 0.000143348623853 0 1 -1
may,be,improved 1.0 0.000143348623853 0 1 -1
may,be,important 1.0 0.000286697247706 0 2 -2
may,be,impaired 1.0 0.000143348623853 0 1 -1
may,be,helpful 1.0 0.000143348623853 0 1 -1
may,be,hazardous 1.0 0.000143348623853 0 1 -1
may,be,extrapolated 1.0 0.000143348623853 0 1 -1
may,be,especially 1.0 0.000143348623853 0 1 -1
may,be,encountered 1.0 0.000143348623853 0 1 -1
may,be,elevated 1.0 0.000286697247706 0 2 -2
may,be,efficacious 1.0 0.000143348623853 0 1 -1
may,be,different 1.0 0.000143348623853 0 1 -1
may,be,detrimental 1.0 0.000143348623853 0 1 -1
may,be,crucial 1.0 0.000143348623853 0 1 -1
may,be,considered 1.0 0.000286697247706 0 2 -2
may,be,at 1.0 0.000716743119266 0 5 -5
may,be,adversely 1.0 0.000143348623853 0 1 -1
may,be,administered 1.0 0.00043004587156 0 3 -3
may,be,achieved 1.0 0.000143348623853 0 1 -1
may,be,a 1.0 0.000573394495413 0 4 -4
may,arise,in 1.0 0.000143348623853 0 1 -1
may,antagonise,the 1.0 0.000143348623853 0 1 -1
may,alter,hormone 1.0 0.000143348623853 0 1 -1
may,also,prolong 1.0 0.000143348623853 0 1 -1
may,also,produce 1.0 0.000143348623853 0 1 -1
may,also,occur 1.0 0.000286697247706 0 2 -2
may,also,interact 1.0 0.000286697247706 0 2 -2
may,also,influence 1.0 0.000143348623853 0 1 -1
may,also,increase 1.0 0.000573394495413 0 4 -4
may,also,contribute 1.0 0.000143348623853 0 1 -1
may,also,cause 1.0 0.000143348623853 0 1 -1
may,also,be 1.0 0.000143348623853 0 1 -1
may,also,affect 1.0 0.000143348623853 0 1 -1
may,affect,the 1.0 0.000573394495413 0 4 -4
may,affect,strategies 1.0 0.000143348623853 0 1 -1
may,affect,renal 1.0 0.000143348623853 0 1 -1
may,affect,patient 1.0 0.000143348623853 0 1 -1
may,affect,metabolism 1.0 0.000143348623853 0 1 -1
may,affect,leukocyte 1.0 0.000143348623853 0 1 -1
may,affect,its 1.0 0.000143348623853 0 1 -1
may,affect,central 1.0 0.000143348623853 0 1 -1
may,affect,bioavailabillty 1.0 0.000143348623853 0 1 -1
may,affect,absorption 1.0 0.000143348623853 0 1 -1
may,activate,the 1.0 0.000143348623853 0 1 -1
maximum,tolerated,dose 1.0 0.000143348623853 0 1 -1
maximum,relaxation,of 1.0 0.000143348623853 0 1 -1
maximum,recommended,human 1.0 0.000286697247706 0 2 -2
maximum,levels,meq 1.0 0.000143348623853 0 1 -1
maximum,human,dose 1.0 0.000143348623853 0 1 -1
maximum,concentration,was 1.0 0.000143348623853 0 1 -1
maximum,concentration,in 1.0 0.000143348623853 0 1 -1
maximum,concentration,cmax 1.0 0.000286697247706 0 2 -2
maximum,concentration,and 1.0 0.000286697247706 0 2 -2
maximum,calculated,clearance 1.0 0.000143348623853 0 1 -1
maximizing,therapy,lies 1.0 0.000143348623853 0 1 -1
maximizing,benefit,while 1.0 0.000143348623853 0 1 -1
maximize,the,therapeutic 1.0 0.000143348623853 0 1 -1
maximize,the,effects 1.0 0.000143348623853 0 1 -1
maximize,benefits,and 1.0 0.000143348623853 0 1 -1
maximally,suppresses,gastric 1.0 0.000143348623853 0 1 -1
maximal,hypotension,was 1.0 0.000143348623853 0 1 -1
maximal,exercise,testing 1.0 0.000143348623853 0 1 -1
maximal,effects,of 1.0 0.000143348623853 0 1 -1
maximal,decrease,between 1.0 0.000143348623853 0 1 -1
max,were,observed 1.0 0.000143348623853 0 1 -1
max,were,noted 1.0 0.000143348623853 0 1 -1
max,t,max 1.0 0.000143348623853 0 1 -1
max,or,t 1.0 0.000143348623853 0 1 -1
max,c,min 1.0 0.000143348623853 0 1 -1
max,by,confidence 1.0 0.000143348623853 0 1 -1
max,auc,hrs 1.0 0.000143348623853 0 1 -1
max,and,mean 1.0 0.000286697247706 0 2 -2
max,and,auc 1.0 0.000286697247706 0 2 -2
max,although,c 1.0 0.000143348623853 0 1 -1
matulane,eldepryl,and 1.0 0.000143348623853 0 1 -1
matrix,protein,reorganization 1.0 0.000143348623853 0 1 -1
mating,caused,a 1.0 0.000143348623853 0 1 -1
mathematical,functions,to 1.0 0.000143348623853 0 1 -1
materials,amino,acids 1.0 0.000143348623853 0 1 -1
materially,different,from 1.0 0.000143348623853 0 1 -1
matched,with,regard 1.0 0.000143348623853 0 1 -1
match,an,increased 1.0 0.000143348623853 0 1 -1
massive,seizures,may 1.0 0.000143348623853 0 1 -1
massive,precipitation,in 1.0 0.000143348623853 0 1 -1
masking,symptoms,of 1.0 0.000143348623853 0 1 -1
mask,the,signs 1.0 0.000143348623853 0 1 -1
mask,the,cardiotoxicity 1.0 0.000143348623853 0 1 -1
mask,or,mimic 1.0 0.000143348623853 0 1 -1
marrow,toxicity,of 1.0 0.000143348623853 0 1 -1
marrow,megakaryocytes,with 1.0 0.000143348623853 0 1 -1
marrow,function,will 1.0 0.000143348623853 0 1 -1
marrow,erythrocytes,in 1.0 0.000143348623853 0 1 -1
marrow,depression,or 1.0 0.000143348623853 0 1 -1
marplan,nardil,matulane 1.0 0.000143348623853 0 1 -1
marker,substrates,and 1.0 0.000143348623853 0 1 -1
markedly,sensitive,and 1.0 0.000143348623853 0 1 -1
markedly,inhibit,cyp450s 1.0 0.000143348623853 0 1 -1
markedly,decreased,the 1.0 0.000143348623853 0 1 -1
marked,reductions,in 1.0 0.000143348623853 0 1 -1
marked,inhibition,in 1.0 0.000143348623853 0 1 -1
marked,has,been 1.0 0.000286697247706 0 2 -2
marine,coelenterates,of 1.0 0.000143348623853 0 1 -1
margin,such,as 1.0 0.000143348623853 0 1 -1
margin,after,spontaneous 1.0 0.000143348623853 0 1 -1
march,citrate,has 1.0 0.000143348623853 0 1 -1
maprotiline,risk,of 1.0 0.000143348623853 0 1 -1
maois,which,may 1.0 0.000143348623853 0 1 -1
maoi,such,as 1.0 0.000143348623853 0 1 -1
mao-b,inhibitor,in 1.0 0.000143348623853 0 1 -1
mao,inhibitors,such 1.0 0.000143348623853 0 1 -1
mao,inhibitors,somatostatin 1.0 0.000286697247706 0 2 -2
mao,inhibitors,serious 1.0 0.000143348623853 0 1 -1
mao,inhibitor,talk 1.0 0.000143348623853 0 1 -1
mao,inhibitor,being 1.0 0.000143348623853 0 1 -1
mao,inhibition,of 1.0 0.000143348623853 0 1 -1
many,without,evidence 1.0 0.000143348623853 0 1 -1
many,used,in 1.0 0.000143348623853 0 1 -1
many,that,are 1.0 0.000716743119266 0 5 -5
many,such,reactions 1.0 0.000143348623853 0 1 -1
many,selective,serotonin 1.0 0.000286697247706 0 2 -2
many,people,use 1.0 0.000143348623853 0 1 -1
many,patients,on 1.0 0.000143348623853 0 1 -1
many,other,medicines 1.0 0.000143348623853 0 1 -1
many,other,and 1.0 0.000716743119266 0 5 -5
many,of,these 1.0 0.000286697247706 0 2 -2
many,like,cannot 1.0 0.000143348623853 0 1 -1
many,including,most 1.0 0.000143348623853 0 1 -1
many,drugs,are 1.0 0.000143348623853 0 1 -1
many,cyp,isozymes 1.0 0.000143348623853 0 1 -1
many,concomitant,were 1.0 0.000143348623853 0 1 -1
many,are,excreted 1.0 0.000143348623853 0 1 -1
many,and,are 1.0 0.000143348623853 0 1 -1
manufacturers,have,not 1.0 0.000143348623853 0 1 -1
manufacturer,or,the 1.0 0.000143348623853 0 1 -1
manner,similar,to 1.0 0.000143348623853 0 1 -1
manner,relative,to 1.0 0.000143348623853 0 1 -1
manifested,significantly,longer 1.0 0.000143348623853 0 1 -1
manifested,by,increased 1.0 0.000143348623853 0 1 -1
manifested,by,alt 1.0 0.000143348623853 0 1 -1
manifested,as,muscle 1.0 0.000143348623853 0 1 -1
manic-depressive,disorder,requires 1.0 0.000143348623853 0 1 -1
mania,whereas,in 1.0 0.000143348623853 0 1 -1
maneuver,often,applied 1.0 0.000143348623853 0 1 -1
management,of,schizophrenia 1.0 0.000143348623853 0 1 -1
management,of,patients 1.0 0.000143348623853 0 1 -1
management,of,infection 1.0 0.000143348623853 0 1 -1
management,of,cutaneous 1.0 0.000143348623853 0 1 -1
management,of,chronic 1.0 0.000143348623853 0 1 -1
management,of,acute 1.0 0.000286697247706 0 2 -2
management,and,progression 1.0 0.000143348623853 0 1 -1
management,and,discusses 1.0 0.000143348623853 0 1 -1
man,we,have 1.0 0.000143348623853 0 1 -1
man,was,admitted 1.0 0.000143348623853 0 1 -1
man,include,and 1.0 0.000143348623853 0 1 -1
man,in,animal 1.0 0.000143348623853 0 1 -1
man,and,presumably 1.0 0.000143348623853 0 1 -1
man,and,is 1.0 0.000143348623853 0 1 -1
mammary,tumor,virus 1.0 0.000143348623853 0 1 -1
mammary,gland,of 1.0 0.000143348623853 0 1 -1
mammary,gland,in 1.0 0.000143348623853 0 1 -1
mammalian,target,of 1.0 0.000143348623853 0 1 -1
mammalian,liver,metabolic 1.0 0.000143348623853 0 1 -1
mammalian,cell,mutation 1.0 0.000143348623853 0 1 -1
maltose,interference,with 1.0 0.000143348623853 0 1 -1
malignant,phenotype,were 1.0 0.000143348623853 0 1 -1
malignant,hyperpyrexia,can 1.0 0.000286697247706 0 2 -2
malignant,disease,in 1.0 0.000143348623853 0 1 -1
malignancy,and,the 1.0 0.000143348623853 0 1 -1
malignancy,and,increasingly 1.0 0.000143348623853 0 1 -1
malignancies,is,higher 1.0 0.000143348623853 0 1 -1
males,who,received 1.0 0.000143348623853 0 1 -1
males,the,systemic 1.0 0.000143348623853 0 1 -1
males,in,separate 1.0 0.000143348623853 0 1 -1
males,dosed,at 1.0 0.000143348623853 0 1 -1
male,wistar,rats 1.0 0.000286697247706 0 2 -2
male,volunteers,were 1.0 0.000143348623853 0 1 -1
male,volunteers,no 1.0 0.000143348623853 0 1 -1
male,volunteers,n 1.0 0.000143348623853 0 1 -1
male,volunteers,in 1.0 0.000143348623853 0 1 -1
male,volunteers,for 1.0 0.000143348623853 0 1 -1
male,volunteers,did 1.0 0.000143348623853 0 1 -1
male,subjects,were 1.0 0.000143348623853 0 1 -1
male,subjects,no 1.0 0.000143348623853 0 1 -1
male,sprague-dawley,rats 1.0 0.000143348623853 0 1 -1
male,rhesus,monkeys 1.0 0.000143348623853 0 1 -1
male,rats,treated 1.0 0.000143348623853 0 1 -1
male,rats,that 1.0 0.000143348623853 0 1 -1
male,rats,of 1.0 0.000143348623853 0 1 -1
male,rats,at 1.0 0.000143348623853 0 1 -1
male,rats,and 1.0 0.000143348623853 0 1 -1
male,partners,of 1.0 0.000143348623853 0 1 -1
male,or,female 1.0 0.000143348623853 0 1 -1
male,n,in 1.0 0.000143348623853 0 1 -1
male,lean,and 1.0 0.000143348623853 0 1 -1
male,fertility,have 1.0 0.000286697247706 0 2 -2
male,dogs,one 1.0 0.000143348623853 0 1 -1
male,animals,were 1.0 0.000143348623853 0 1 -1
male,adult,wistar 1.0 0.000143348623853 0 1 -1
malaria,mefloquine,administration 1.0 0.000143348623853 0 1 -1
makes,use,of 1.0 0.000143348623853 0 1 -1
makes,the,clinical 1.0 0.000143348623853 0 1 -1
make,your,condition 1.0 0.000143348623853 0 1 -1
make,up,a 1.0 0.000143348623853 0 1 -1
make,normal,metabolizers 1.0 0.000860091743119 0 6 -6
make,normal,metab-olizers 1.0 0.000143348623853 0 1 -1
majority,of,these 1.0 0.000143348623853 0 1 -1
majority,of,patients 1.0 0.000286697247706 0 2 -2
majority,of,adverse 1.0 0.000143348623853 0 1 -1
major,subtype,in 1.0 0.000143348623853 0 1 -1
major,serum,constituent 1.0 0.000143348623853 0 1 -1
major,pathophysiologic,abnormality 1.0 0.000143348623853 0 1 -1
major,metabolites,dfur 1.0 0.000143348623853 0 1 -1
major,metabolite,beta-naltrexol 1.0 0.000143348623853 0 1 -1
major,metabolite,at 1.0 0.000143348623853 0 1 -1
major,metabolite,are 1.0 0.000143348623853 0 1 -1
major,metabolic,pathway 1.0 0.000143348623853 0 1 -1
major,membrane,sterol 1.0 0.000143348623853 0 1 -1
major,ingredient,of 1.0 0.000143348623853 0 1 -1
major,enzyme,involved 1.0 0.000143348623853 0 1 -1
major,cytochrome,p450 1.0 0.000573394495413 0 4 -4
major,cyp,enzyme 1.0 0.000143348623853 0 1 -1
major,circulating,metabolite 1.0 0.000143348623853 0 1 -1
major,cause,of 1.0 0.000143348623853 0 1 -1
maintenance,bolus,doses 1.0 0.000143348623853 0 1 -1
maintaining,a,given 1.0 0.000143348623853 0 1 -1
maintained,on,without 1.0 0.000143348623853 0 1 -1
maintained,on,monotherapy 1.0 0.000143348623853 0 1 -1
maintained,in,the 1.0 0.000143348623853 0 1 -1
maintained,at,of 1.0 0.000143348623853 0 1 -1
maintained,at,low 1.0 0.000143348623853 0 1 -1
maintain,twitch,for 1.0 0.000143348623853 0 1 -1
maintain,the,prothrombin 1.0 0.000286697247706 0 2 -2
maintain,the,desired 1.0 0.000143348623853 0 1 -1
maintain,pregnancy,when 1.0 0.000143348623853 0 1 -1
maintain,optimum,therapeutic 1.0 0.000286697247706 0 2 -2
maintain,inhibition,of 1.0 0.000143348623853 0 1 -1
maintain,concentrations,within 1.0 0.000143348623853 0 1 -1
maintain,barpress,response 1.0 0.000143348623853 0 1 -1
maintain,an,adequate 1.0 0.000143348623853 0 1 -1
mainly,via,the 1.0 0.000286697247706 0 2 -2
mainly,receiving,thiazide 1.0 0.000143348623853 0 1 -1
mainly,on,the 1.0 0.000143348623853 0 1 -1
mainly,eliminated,by 1.0 0.000143348623853 0 1 -1
mainly,concerns,the 1.0 0.000143348623853 0 1 -1
mainly,by,cytochrome 1.0 0.000143348623853 0 1 -1
main,route,of 1.0 0.000143348623853 0 1 -1
main,results,in 1.0 0.000143348623853 0 1 -1
main,results,blood 1.0 0.000143348623853 0 1 -1
main,non-infection,unwanted 1.0 0.000143348623853 0 1 -1
main,meal,of 1.0 0.000143348623853 0 1 -1
main,indications,are 1.0 0.000143348623853 0 1 -1
magnitude,or,neuromuscular 1.0 0.000143348623853 0 1 -1
magnitude,of,these 1.0 0.000143348623853 0 1 -1
magnitude,of,response 1.0 0.000143348623853 0 1 -1
magnitude,of,interaction 1.0 0.000860091743119 0 6 -6
magnitude,lower,than 1.0 0.000143348623853 0 1 -1
magnitude,and,the 1.0 0.000143348623853 0 1 -1
magnitude,and,relative 1.0 0.000143348623853 0 1 -1
magnitude,and,prevalence 1.0 0.000143348623853 0 1 -1
magnesium-containing,meq,or 1.0 0.000143348623853 0 1 -1
magnesium-aluminum,hydroxide,cerivastatin 1.0 0.000143348623853 0 1 -1
magnesium,infusions,can 1.0 0.000143348623853 0 1 -1
magnesium,aluminum-containing,antacid 1.0 0.000143348623853 0 1 -1
made,whether,to 1.0 0.00043004587156 0 3 -3
made,when,these 1.0 0.000286697247706 0 2 -2
made,to,pursue 1.0 0.000143348623853 0 1 -1
made,they,should 1.0 0.000143348623853 0 1 -1
made,on,the 1.0 0.000143348623853 0 1 -1
made,of,mg 1.0 0.000143348623853 0 1 -1
made,carefully,and 1.0 0.000143348623853 0 1 -1
made,by,using 1.0 0.000143348623853 0 1 -1
macrolide,or,azoles 1.0 0.000143348623853 0 1 -1
macrolide,immunosuppressant,metabolized 1.0 0.000143348623853 0 1 -1
macrolide,and,hiv 1.0 0.000143348623853 0 1 -1
macrolide,and,azoles 1.0 0.000143348623853 0 1 -1
machinery,or,driving 1.0 0.000143348623853 0 1 -1
mac,with,more 1.0 0.000143348623853 0 1 -1
mac,was,correlated 1.0 0.000143348623853 0 1 -1
mac,out,of 1.0 0.000143348623853 0 1 -1
mac,or,had 1.0 0.000143348623853 0 1 -1
mac,of,the 1.0 0.000143348623853 0 1 -1
maalox,tc,had 1.0 0.000143348623853 0 1 -1
maalox,on,the 1.0 0.000143348623853 0 1 -1
maalox,coadministration,of 1.0 0.000143348623853 0 1 -1
m2,without,indicated 1.0 0.000143348623853 0 1 -1
m2,plus,to 1.0 0.000143348623853 0 1 -1
m2,pegasys,equivalent 1.0 0.000143348623853 0 1 -1
m2,dose,of 1.0 0.000286697247706 0 2 -2
m2,before,dose-limiting 1.0 0.000143348623853 0 1 -1
m2,basis,increased 1.0 0.000143348623853 0 1 -1
m2,basis,did 1.0 0.000143348623853 0 1 -1
m1,which,had 1.0 0.000143348623853 0 1 -1
m1,was,shown 1.0 0.000286697247706 0 2 -2
m1,cmax,values 1.0 0.000143348623853 0 1 -1
m-dinitrobenzene,used,in 1.0 0.000143348623853 0 1 -1
m,was,not 1.0 0.000143348623853 0 1 -1
m,v,to 1.0 0.000143348623853 0 1 -1
m,v,significantly 1.0 0.000143348623853 0 1 -1
m,v,nacmc 1.0 0.000143348623853 0 1 -1
m,v,in 1.0 0.000143348623853 0 1 -1
m,v,did 1.0 0.000143348623853 0 1 -1
m,v,decreased 1.0 0.000143348623853 0 1 -1
m,v,cmc-cys7 1.0 0.000143348623853 0 1 -1
m,the,second 1.0 0.000143348623853 0 1 -1
m,resulted,in 1.0 0.000143348623853 0 1 -1
m,parenteral,except 1.0 0.000143348623853 0 1 -1
m,of,immobilised 1.0 0.000143348623853 0 1 -1
m,m,resulted 1.0 0.000143348623853 0 1 -1
m,m,of 1.0 0.000143348623853 0 1 -1
m,g,m2 1.0 0.000286697247706 0 2 -2
m,g,kg 1.0 0.000286697247706 0 2 -2
m,decins,sans 1.0 0.000143348623853 0 1 -1
m,basis,and 1.0 0.000143348623853 0 1 -1
m,and,c9 1.0 0.000143348623853 0 1 -1
m,and,a4 1.0 0.000143348623853 0 1 -1
m,and,a 1.0 0.000143348623853 0 1 -1
lysing,human,red 1.0 0.000143348623853 0 1 -1
lysate,of,serum-deprived 1.0 0.000143348623853 0 1 -1
lysate,derived,from 1.0 0.000143348623853 0 1 -1
lymphopenia,proper,monitoring 1.0 0.000143348623853 0 1 -1
lymphomas,when,animals 1.0 0.000143348623853 0 1 -1
lymphomas,occur,in 1.0 0.000143348623853 0 1 -1
lymphoma,that,was 1.0 0.000143348623853 0 1 -1
lymphoma,on,combination 1.0 0.000143348623853 0 1 -1
lymphoma,hiv-nhl,the 1.0 0.000143348623853 0 1 -1
lymphoma,cells,and 1.0 0.000143348623853 0 1 -1
lymphoid,malignancy,and 1.0 0.000143348623853 0 1 -1
lymphocytes,mammalian,cell 1.0 0.000143348623853 0 1 -1
lymphocytes,in,vitro 1.0 0.000143348623853 0 1 -1
lymphocytes,either,in 1.0 0.000143348623853 0 1 -1
lymphocyte,disorders,plasmacytic 1.0 0.000143348623853 0 1 -1
lymphocyte,counts,related 1.0 0.000143348623853 0 1 -1
luteinizing,hormone,lh 1.0 0.000143348623853 0 1 -1
luteinizing,hormone,and 1.0 0.000143348623853 0 1 -1
lung,survanta,on 1.0 0.000143348623853 0 1 -1
lung,has,the 1.0 0.000143348623853 0 1 -1
lunch,doses,of 1.0 0.000143348623853 0 1 -1
lumen,to,the 1.0 0.000143348623853 0 1 -1
lumen,at,as 1.0 0.000143348623853 0 1 -1
luciferase,reporter,gene 1.0 0.000143348623853 0 1 -1
lucidum,fr,karst 1.0 0.000143348623853 0 1 -1
lucidum,extract,alone 1.0 0.000143348623853 0 1 -1
lst,short,sedation 1.0 0.000143348623853 0 1 -1
lst,mice,showed 1.0 0.000143348623853 0 1 -1
lst,mice,did 1.0 0.000286697247706 0 2 -2
lowers,serum,concentrations 1.0 0.000143348623853 0 1 -1
lowering,their,blood 1.0 0.000143348623853 0 1 -1
lowering,effect,and 1.0 0.000286697247706 0 2 -2
lowering,effect,agents 1.0 0.000143348623853 0 1 -1
lowered,numbers,of 1.0 0.000143348623853 0 1 -1
lowered,from,microg 1.0 0.000143348623853 0 1 -1
lower,with,than 1.0 0.000143348623853 0 1 -1
lower,total,daily 1.0 0.000143348623853 0 1 -1
lower,the,dose 1.0 0.000143348623853 0 1 -1
lower,than,usual 1.0 0.000143348623853 0 1 -1
lower,than,the 1.0 0.000860091743119 0 6 -6
lower,than,expected 1.0 0.000143348623853 0 1 -1
lower,tablet,volume 1.0 0.000143348623853 0 1 -1
lower,respectively,after 1.0 0.000143348623853 0 1 -1
lower,relative,absorption 1.0 0.000143348623853 0 1 -1
lower,plasma,concentration 1.0 0.000143348623853 0 1 -1
lower,locomotor,activity 1.0 0.000143348623853 0 1 -1
lower,in,the 1.0 0.000286697247706 0 2 -2
lower,doses,than 1.0 0.00100344036697 0 7 -7
lower,concentrations,only 1.0 0.000143348623853 0 1 -1
lower,blood,levels 1.0 0.000286697247706 0 2 -2
lower,auc,for 1.0 0.000143348623853 0 1 -1
lower,affinities,than 1.0 0.000143348623853 0 1 -1
low-levels,of,exposure 1.0 0.000143348623853 0 1 -1
low-dose,plus,were 1.0 0.000143348623853 0 1 -1
low-dose,mg,once 1.0 0.000143348623853 0 1 -1
low-dose,mg,enteric 1.0 0.000143348623853 0 1 -1
low-dose,combination,oral 1.0 0.000143348623853 0 1 -1
low-density,lipoproteins,high-density 1.0 0.000143348623853 0 1 -1
low-density,lipoprotein,cholesterol 1.0 0.000143348623853 0 1 -1
low,uptakes,which 1.0 0.000143348623853 0 1 -1
low,to,measure 1.0 0.000143348623853 0 1 -1
low,therapeutic,ratio 1.0 0.000143348623853 0 1 -1
low,therapeutic,margin 1.0 0.000143348623853 0 1 -1
low,temperatures,on 1.0 0.000143348623853 0 1 -1
low,serum,levels 1.0 0.000143348623853 0 1 -1
low,results,in 1.0 0.000143348623853 0 1 -1
low,molecular,weight 1.0 0.000143348623853 0 1 -1
low,measurement,of 1.0 0.000143348623853 0 1 -1
low,levels,cfu 1.0 0.000143348623853 0 1 -1
low,initial,dosing 1.0 0.000143348623853 0 1 -1
low,hepatic,clearance 1.0 0.000143348623853 0 1 -1
low,for,commonly 1.0 0.000143348623853 0 1 -1
low,dose,unfractionated 1.0 0.000143348623853 0 1 -1
low,dose,did 1.0 0.000143348623853 0 1 -1
low,dose,and 1.0 0.000143348623853 0 1 -1
low,dietary,concentration 1.0 0.000143348623853 0 1 -1
low,compared,to 1.0 0.000143348623853 0 1 -1
low,clinically,significant 1.0 0.000143348623853 0 1 -1
low,clearance,a 1.0 0.000143348623853 0 1 -1
low,cardiac,capacity 1.0 0.000143348623853 0 1 -1
low,as,v 1.0 0.000143348623853 0 1 -1
low,as,mg 1.0 0.000143348623853 0 1 -1
low,as,judged 1.0 0.000143348623853 0 1 -1
low,and,high 1.0 0.000143348623853 0 1 -1
low,affinity,binding 1.0 0.000143348623853 0 1 -1
lovastatin,therapy,has 1.0 0.000143348623853 0 1 -1
lovastatin,is,metabolized 1.0 0.000143348623853 0 1 -1
lotions,or,skin 1.0 0.000143348623853 0 1 -1
lotensin,was,administered 1.0 0.000143348623853 0 1 -1
lotensin,has,been 1.0 0.000143348623853 0 1 -1
loss,were,observed 1.0 0.000143348623853 0 1 -1
loss,results,from 1.0 0.000143348623853 0 1 -1
loss,or,inactivity 1.0 0.000143348623853 0 1 -1
loss,of,virologic 1.0 0.00043004587156 0 3 -3
loss,of,spermatozoa 1.0 0.000143348623853 0 1 -1
loss,of,microtubules 1.0 0.000143348623853 0 1 -1
loss,of,efficacy 1.0 0.000143348623853 0 1 -1
loss,of,control 1.0 0.000143348623853 0 1 -1
loss,of,blood 1.0 0.000286697247706 0 2 -2
loss,of,bar-press 1.0 0.000143348623853 0 1 -1
loss,between,systemic 1.0 0.000143348623853 0 1 -1
lose,the,righting 1.0 0.000143348623853 0 1 -1
losartan,bosentan,has 1.0 0.000143348623853 0 1 -1
lorazepam,coadministration,of 1.0 0.000143348623853 0 1 -1
loratadine,mg,once 1.0 0.000143348623853 0 1 -1
loratadine,mg,in 1.0 0.000143348623853 0 1 -1
loratadine,and,descarboethoxyloratadine 1.0 0.000143348623853 0 1 -1
loop,sparing,thiazide 1.0 0.000143348623853 0 1 -1
loop,diuretics,furosemide 1.0 0.000143348623853 0 1 -1
looks,at,five 1.0 0.000143348623853 0 1 -1
longterm,treatment,of 1.0 0.000143348623853 0 1 -1
longitudinal,studies,on 1.0 0.000143348623853 0 1 -1
longitudinal,stability,in 1.0 0.000143348623853 0 1 -1
longitudinal,assessment,of 1.0 0.000143348623853 0 1 -1
longer,term,therapy 1.0 0.000143348623853 0 1 -1
longer,marketed,in 1.0 0.000143348623853 0 1 -1
longer,latencies,to 1.0 0.000143348623853 0 1 -1
long-term,studies,on 1.0 0.000143348623853 0 1 -1
long-term,studies,are 1.0 0.000143348623853 0 1 -1
long-term,safety,studies 1.0 0.000143348623853 0 1 -1
long-term,consequences,of 1.0 0.000143348623853 0 1 -1
long-term,carcinogenicity,studies 1.0 0.000143348623853 0 1 -1
long-term,administration,of 1.0 0.000143348623853 0 1 -1
long-sedation,time,lst 1.0 0.000143348623853 0 1 -1
long-acting,such,as 1.0 0.000143348623853 0 1 -1
long-acting,is,completely 1.0 0.000143348623853 0 1 -1
long-,and,short-acting 1.0 0.000143348623853 0 1 -1
long,withdrawal,period 1.0 0.000143348623853 0 1 -1
long,periods,of 1.0 0.000143348623853 0 1 -1
long,lasting,inhibition 1.0 0.000143348623853 0 1 -1
long,half-lives,to 1.0 0.000143348623853 0 1 -1
long,and,variable 1.0 0.000143348623853 0 1 -1
long,acting,nitrates 1.0 0.000143348623853 0 1 -1
lomefloxacin,is,unlikely 1.0 0.000143348623853 0 1 -1
logs,of,reduction 1.0 0.000143348623853 0 1 -1
logistic,probability,distribution 1.0 0.000143348623853 0 1 -1
logical,approach,to 1.0 0.000143348623853 0 1 -1
logarithmic,fashion,from 1.0 0.000143348623853 0 1 -1
lodosyn,carbidopa,given 1.0 0.000143348623853 0 1 -1
lodosyn,and,or 1.0 0.000143348623853 0 1 -1
lodine,treatment,is 1.0 0.000143348623853 0 1 -1
lodine,should,not 1.0 0.000143348623853 0 1 -1
lodine,or,any 1.0 0.000143348623853 0 1 -1
lodine,indocin,relafen 1.0 0.000143348623853 0 1 -1
lodine,can,give 1.0 0.000143348623853 0 1 -1
lodine,as,measured 1.0 0.000143348623853 0 1 -1
locomotor,responses,to 1.0 0.000143348623853 0 1 -1
locomotor,and,or 1.0 0.000143348623853 0 1 -1
locomotor,activity,than 1.0 0.000143348623853 0 1 -1
locomotor,activity,induced 1.0 0.000143348623853 0 1 -1
locomotor,activity,and 1.0 0.000143348623853 0 1 -1
locomotor,activities,of 1.0 0.000143348623853 0 1 -1
locomotor,activities,in 1.0 0.000143348623853 0 1 -1
locomotion,and,behavioral 1.0 0.000143348623853 0 1 -1
location,histologic,type 1.0 0.000143348623853 0 1 -1
local,use,of 1.0 0.000143348623853 0 1 -1
local,irritation,in 1.0 0.000143348623853 0 1 -1
local,factor,for 1.0 0.000143348623853 0 1 -1
local,close,supervision 1.0 0.000143348623853 0 1 -1
local,breast,cancer 1.0 0.000143348623853 0 1 -1
local,and,some 1.0 0.000143348623853 0 1 -1
local,agents,when 1.0 0.000143348623853 0 1 -1
local,agents,were 1.0 0.000143348623853 0 1 -1
loads,treated,with 1.0 0.000143348623853 0 1 -1
load,constitutes,the 1.0 0.000143348623853 0 1 -1
lng,were,decreased 1.0 0.000143348623853 0 1 -1
livers,of,genetically 1.0 0.000143348623853 0 1 -1
liver,weight,and 1.0 0.000143348623853 0 1 -1
liver,was,altered 1.0 0.000143348623853 0 1 -1
liver,via,the 1.0 0.000143348623853 0 1 -1
liver,tumors,when 1.0 0.000143348623853 0 1 -1
liver,tumors,seen 1.0 0.000143348623853 0 1 -1
liver,transaminases,have 1.0 0.000143348623853 0 1 -1
liver,to,the 1.0 0.000143348623853 0 1 -1
liver,or,kidney 1.0 0.000143348623853 0 1 -1
liver,microsomes,to 1.0 0.000143348623853 0 1 -1
liver,microsomes,the 1.0 0.000143348623853 0 1 -1
liver,microsomes,suggest 1.0 0.000143348623853 0 1 -1
liver,microsomes,showed 1.0 0.000143348623853 0 1 -1
liver,microsomes,indicate 1.0 0.00043004587156 0 3 -3
liver,microsomes,demonstrated 1.0 0.000143348623853 0 1 -1
liver,microsomes,cyp1a2 1.0 0.000143348623853 0 1 -1
liver,microsomes,appears 1.0 0.000143348623853 0 1 -1
liver,microsome,studies 1.0 0.000143348623853 0 1 -1
liver,metabolic,activation 1.0 0.000143348623853 0 1 -1
liver,injury,as 1.0 0.000143348623853 0 1 -1
liver,increasing,from 1.0 0.000143348623853 0 1 -1
liver,function,testing 1.0 0.000143348623853 0 1 -1
liver,function,secondary 1.0 0.000143348623853 0 1 -1
liver,function,clinical 1.0 0.000143348623853 0 1 -1
liver,function,and 1.0 0.000143348623853 0 1 -1
liver,enzymes,have 1.0 0.000143348623853 0 1 -1
liver,disease,and 1.0 0.000143348623853 0 1 -1
liver,cytochrome,p450 1.0 0.000143348623853 0 1 -1
liver,cytochrome,p-450 1.0 0.000143348623853 0 1 -1
liver,by,the 1.0 0.000143348623853 0 1 -1
liver,by,single 1.0 0.000143348623853 0 1 -1
liver,by,cyp2c19 1.0 0.000143348623853 0 1 -1
liver,but,its 1.0 0.000143348623853 0 1 -1
liver,blood,flow 1.0 0.000143348623853 0 1 -1
liver,biopsy,roegnik 1.0 0.000143348623853 0 1 -1
liver,and,it 1.0 0.000286697247706 0 2 -2
liver,and,bowel 1.0 0.000143348623853 0 1 -1
liver,aminotransferases,was 1.0 0.000143348623853 0 1 -1
live,bacteria,should 1.0 0.000143348623853 0 1 -1
little,work,exists 1.0 0.000143348623853 0 1 -1
little,risk,for 1.0 0.000143348623853 0 1 -1
little,published,information 1.0 0.000143348623853 0 1 -1
little,progression,in 1.0 0.000143348623853 0 1 -1
little,is,known 1.0 0.000143348623853 0 1 -1
little,if,any 1.0 0.000143348623853 0 1 -1
little,has,been 1.0 0.000143348623853 0 1 -1
little,experience,with 1.0 0.000286697247706 0 2 -2
little,consideration,to 1.0 0.000143348623853 0 1 -1
little,adequate,evidence 1.0 0.000143348623853 0 1 -1
lithium-a,interaction,study 1.0 0.000143348623853 0 1 -1
lithium,inhibition,of 1.0 0.000143348623853 0 1 -1
lithium,coadministration,of 1.0 0.000143348623853 0 1 -1
lithium,carbonate,mg 1.0 0.000143348623853 0 1 -1
literature,that,the 1.0 0.000143348623853 0 1 -1
literature,suggests,that 1.0 0.000143348623853 0 1 -1
literature,showing,that 1.0 0.000143348623853 0 1 -1
literature,reports,the 1.0 0.000143348623853 0 1 -1
literature,provides,considerable 1.0 0.000143348623853 0 1 -1
literature,contains,reports 1.0 0.000143348623853 0 1 -1
literature,between,january 1.0 0.000143348623853 0 1 -1
lists,of,multiple 1.0 0.000143348623853 0 1 -1
lists,of,are 1.0 0.000143348623853 0 1 -1
listed,in,table 1.0 0.000143348623853 0 1 -1
listed,in,clinical 1.0 0.000143348623853 0 1 -1
listed,here,may 1.0 0.000143348623853 0 1 -1
listed,below,have 1.0 0.000143348623853 0 1 -1
listed,below,are 1.0 0.000143348623853 0 1 -1
listed,agents,has 1.0 0.000143348623853 0 1 -1
liquid,impinger,for 1.0 0.000143348623853 0 1 -1
liquid,did,not 1.0 0.000143348623853 0 1 -1
liquid,chromatographic,assay 1.0 0.000143348623853 0 1 -1
lipoproteins,high-density,lipoproteins 1.0 0.000143348623853 0 1 -1
lipoproteins,and,triglycerides 1.0 0.000143348623853 0 1 -1
lipoprotein,cholesterol,levels 1.0 0.000143348623853 0 1 -1
lipolysis,and,remnant 1.0 0.000143348623853 0 1 -1
lipids,were,explored 1.0 0.000143348623853 0 1 -1
lipids,should,be 1.0 0.000143348623853 0 1 -1
lipids,pretreatment,and 1.0 0.000143348623853 0 1 -1
lipids,in,clinical 1.0 0.000143348623853 0 1 -1
lipid-lowering,that,can 1.0 0.000143348623853 0 1 -1
lipid-lowering,that,are 1.0 0.000143348623853 0 1 -1
lipid-lowering,activity,of 1.0 0.000143348623853 0 1 -1
lipid,profile,total 1.0 0.000143348623853 0 1 -1
lipid,metabolism,carbohydrate 1.0 0.000143348623853 0 1 -1
lipid,levels,the 1.0 0.000143348623853 0 1 -1
linked,to,carbodiimide 1.0 0.000143348623853 0 1 -1
link,between,smoking 1.0 0.000143348623853 0 1 -1
linezolid,is,a 1.0 0.000143348623853 0 1 -1
lines,showed,variable 1.0 0.000143348623853 0 1 -1
lines,divergently,selected 1.0 0.000143348623853 0 1 -1
linear,regression,and 1.0 0.000143348623853 0 1 -1
linear,logarithmic,fashion 1.0 0.000143348623853 0 1 -1
limits,the,dose 1.0 0.000143348623853 0 1 -1
limits,of,the 1.0 0.000143348623853 0 1 -1
limiting,may,be 1.0 0.000143348623853 0 1 -1
limited,to,the 1.0 0.000143348623853 0 1 -1
limited,to,and 1.0 0.000143348623853 0 1 -1
limited,sampling,the 1.0 0.000143348623853 0 1 -1
limited,renal,excretion 1.0 0.000143348623853 0 1 -1
limited,pk,and 1.0 0.000143348623853 0 1 -1
limited,number,of 1.0 0.000286697247706 0 2 -2
limited,experience,with 1.0 0.000286697247706 0 2 -2
limited,evidence,that 1.0 0.000143348623853 0 1 -1
limited,comparative,data 1.0 0.000143348623853 0 1 -1
limited,as,is 1.0 0.000143348623853 0 1 -1
limit,values,it 1.0 0.000143348623853 0 1 -1
limit,of,the 1.0 0.000286697247706 0 2 -2
lime,should,be 1.0 0.000143348623853 0 1 -1
limbic,system,particularly 1.0 0.000143348623853 0 1 -1
limbic,system,and 1.0 0.000143348623853 0 1 -1
limbic,integration,the 1.0 0.000143348623853 0 1 -1
limb,injury,or 1.0 0.000143348623853 0 1 -1
limb,digital,extensor 1.0 0.000143348623853 0 1 -1
likewise,pharmacokinetics,were 1.0 0.000143348623853 0 1 -1
likewise,further,reduced 1.0 0.000143348623853 0 1 -1
likely,to,occur 1.0 0.000143348623853 0 1 -1
likely,to,inhibit 1.0 0.000143348623853 0 1 -1
likely,to,have 1.0 0.000143348623853 0 1 -1
likely,to,cause 1.0 0.000143348623853 0 1 -1
likely,that,use 1.0 0.000143348623853 0 1 -1
likely,that,experience 1.0 0.000143348623853 0 1 -1
likely,that,a 1.0 0.000143348623853 0 1 -1
likely,and,caution 1.0 0.000286697247706 0 2 -2
likelihood,of,potentially 1.0 0.000143348623853 0 1 -1
likelihood,of,bone 1.0 0.000143348623853 0 1 -1
like,mg,kg 1.0 0.000143348623853 0 1 -1
like,mc,probably 1.0 0.000143348623853 0 1 -1
like,does,not 1.0 0.000143348623853 0 1 -1
like,cannot,be 1.0 0.000143348623853 0 1 -1
like,and,from 1.0 0.000143348623853 0 1 -1
light,zone,in 1.0 0.000143348623853 0 1 -1
light,meal,hour 1.0 0.000143348623853 0 1 -1
light,dark,test 1.0 0.00043004587156 0 3 -3
ligand,binding,activity 1.0 0.000143348623853 0 1 -1
lifestyle,giving,up 1.0 0.000143348623853 0 1 -1
life-threatening,ventricular,arrhythmias 1.0 0.000143348623853 0 1 -1
life-threatening,situations,avoid 1.0 0.000143348623853 0 1 -1
life-threatening,reactions,such 1.0 0.00114678899083 0 8 -8
life,in,patients 1.0 0.000143348623853 0 1 -1
lies,in,individualizing 1.0 0.000143348623853 0 1 -1
lies,both,in 1.0 0.000143348623853 0 1 -1
lie,in,its 1.0 0.000143348623853 0 1 -1
lh,follicle-stimulating,hormone 1.0 0.000143348623853 0 1 -1
lh,and,fsh 1.0 0.000143348623853 0 1 -1
leydig,cell,tumors 1.0 0.000143348623853 0 1 -1
lexapro,and,had 1.0 0.000143348623853 0 1 -1
levosimendan,does,not 1.0 0.000143348623853 0 1 -1
levorotatory,isomer,had 1.0 0.000143348623853 0 1 -1
levonorgestrol,oral,product 1.0 0.000143348623853 0 1 -1
levonorgestrel-treated,rats,and 1.0 0.000143348623853 0 1 -1
levodopa,is,known 1.0 0.000143348623853 0 1 -1
levobupivacaine,and,hydroxy 1.0 0.000143348623853 0 1 -1
levo-dromoran,reported,to 1.0 0.000143348623853 0 1 -1
levetiracetam,had,no 1.0 0.000143348623853 0 1 -1
levetiracetam,circulates,largely 1.0 0.000143348623853 0 1 -1
levetiracetam,and,its 1.0 0.000143348623853 0 1 -1
levels,with,resultant 1.0 0.000143348623853 0 1 -1
levels,whenever,an 1.0 0.000143348623853 0 1 -1
levels,whenever,a 1.0 0.000573394495413 0 4 -4
levels,when,the 1.0 0.000143348623853 0 1 -1
levels,were,within 1.0 0.000143348623853 0 1 -1
levels,were,undetectable 1.0 0.000143348623853 0 1 -1
levels,were,noted 1.0 0.000143348623853 0 1 -1
levels,were,not 1.0 0.00043004587156 0 3 -3
levels,utilizing,commercially 1.0 0.000143348623853 0 1 -1
levels,usually,only 1.0 0.000143348623853 0 1 -1
levels,using,an 1.0 0.000143348623853 0 1 -1
levels,up,to 1.0 0.000143348623853 0 1 -1
levels,thereby,providing 1.0 0.000143348623853 0 1 -1
levels,then,remained 1.0 0.000143348623853 0 1 -1
levels,the,adverse 1.0 0.000143348623853 0 1 -1
levels,significantly,higher 1.0 0.000143348623853 0 1 -1
levels,shown,by 1.0 0.000143348623853 0 1 -1
levels,produced,modest 1.0 0.000143348623853 0 1 -1
levels,or,the 1.0 0.000143348623853 0 1 -1
levels,or,prothrombin 1.0 0.000143348623853 0 1 -1
levels,or,fasting 1.0 0.000143348623853 0 1 -1
levels,or,altering 1.0 0.000143348623853 0 1 -1
levels,of,were 1.0 0.000286697247706 0 2 -2
levels,of,vardenafil 1.0 0.000143348623853 0 1 -1
levels,of,urinary 1.0 0.000143348623853 0 1 -1
levels,of,tmp 1.0 0.000143348623853 0 1 -1
levels,of,should 1.0 0.000286697247706 0 2 -2
levels,of,serotonin 1.0 0.000143348623853 0 1 -1
levels,of,racemic 1.0 0.000143348623853 0 1 -1
levels,of,previously 1.0 0.000143348623853 0 1 -1
levels,of,phenytoin 1.0 0.000143348623853 0 1 -1
levels,of,or 1.0 0.000143348623853 0 1 -1
levels,of,necessary 1.0 0.000143348623853 0 1 -1
levels,of,metabolized 1.0 0.000286697247706 0 2 -2
levels,of,in 1.0 0.000143348623853 0 1 -1
levels,of,homocysteine 1.0 0.000143348623853 0 1 -1
levels,of,has 1.0 0.000143348623853 0 1 -1
levels,of,free 1.0 0.000143348623853 0 1 -1
levels,of,exposure 1.0 0.000286697247706 0 2 -2
levels,of,either 1.0 0.000143348623853 0 1 -1
levels,of,diabetic 1.0 0.000143348623853 0 1 -1
levels,of,cortisol 1.0 0.000143348623853 0 1 -1
levels,of,corticosteroid-binding 1.0 0.000143348623853 0 1 -1
levels,of,anti-factor 1.0 0.000286697247706 0 2 -2
levels,meq,l 1.0 0.000143348623853 0 1 -1
levels,may,rise 1.0 0.000143348623853 0 1 -1
levels,may,occur 1.0 0.000143348623853 0 1 -1
levels,may,change 1.0 0.000143348623853 0 1 -1
levels,may,also 1.0 0.000143348623853 0 1 -1
levels,levodopa,is 1.0 0.000143348623853 0 1 -1
levels,leading,to 1.0 0.000143348623853 0 1 -1
levels,induced,by 1.0 0.000143348623853 0 1 -1
levels,indicating,that 1.0 0.000143348623853 0 1 -1
levels,in,patients 1.0 0.000716743119266 0 5 -5
levels,in,humans 1.0 0.000286697247706 0 2 -2
levels,have,occurred 1.0 0.000143348623853 0 1 -1
levels,generally,by 1.0 0.000143348623853 0 1 -1
levels,for,diagnosis 1.0 0.000143348623853 0 1 -1
levels,following,administration 1.0 0.000143348623853 0 1 -1
levels,fluctuated,there 1.0 0.000143348623853 0 1 -1
levels,effects,of 1.0 0.000143348623853 0 1 -1
levels,did,not 1.0 0.000286697247706 0 2 -2
levels,could,lessen 1.0 0.000143348623853 0 1 -1
levels,could,have 1.0 0.000143348623853 0 1 -1
levels,could,be 1.0 0.000143348623853 0 1 -1
levels,comparable,to 1.0 0.000143348623853 0 1 -1
levels,close,to 1.0 0.000143348623853 0 1 -1
levels,cfu,ml 1.0 0.000143348623853 0 1 -1
levels,by,the 1.0 0.000143348623853 0 1 -1
levels,by,jaffe 1.0 0.000143348623853 0 1 -1
levels,by,displacement 1.0 0.000143348623853 0 1 -1
levels,by,column 1.0 0.000286697247706 0 2 -2
levels,but,changes 1.0 0.000143348623853 0 1 -1
levels,at,different 1.0 0.000143348623853 0 1 -1
levels,as,measured 1.0 0.000286697247706 0 2 -2
levels,are,decreased 1.0 0.000143348623853 0 1 -1
levels,are,being 1.0 0.000143348623853 0 1 -1
levels,are,above 1.0 0.000143348623853 0 1 -1
levels,and,therefore 1.0 0.000143348623853 0 1 -1
levels,and,the 1.0 0.000143348623853 0 1 -1
levels,and,potential 1.0 0.000143348623853 0 1 -1
levels,and,possible 1.0 0.000143348623853 0 1 -1
levels,and,pharmaco-dynamic 1.0 0.000143348623853 0 1 -1
levels,and,lethality 1.0 0.000143348623853 0 1 -1
levels,and,followed 1.0 0.000143348623853 0 1 -1
levels,and,drug 1.0 0.000143348623853 0 1 -1
levels,and,decrease 1.0 0.000143348623853 0 1 -1
levels,and,clearance 1.0 0.000143348623853 0 1 -1
levels,and,cardiac 1.0 0.000143348623853 0 1 -1
levels,and,administration 1.0 0.000143348623853 0 1 -1
levels,aldosterone,excretion 1.0 0.000143348623853 0 1 -1
levels,after,oral 1.0 0.000143348623853 0 1 -1
levels,achieved,within 1.0 0.000143348623853 0 1 -1
levels,achieved,in 1.0 0.000143348623853 0 1 -1
levels,about,times 1.0 0.000143348623853 0 1 -1
level,was,increased 1.0 0.000143348623853 0 1 -1
level,to,prevent 1.0 0.000286697247706 0 2 -2
level,that,was 1.0 0.000143348623853 0 1 -1
level,serum,levels 1.0 0.000143348623853 0 1 -1
level,of,thiobarbituric 1.0 0.000143348623853 0 1 -1
level,of,their 1.0 0.000143348623853 0 1 -1
level,of,the 1.0 0.000143348623853 0 1 -1
level,of,platelet 1.0 0.000143348623853 0 1 -1
level,of,phosphatase 1.0 0.000143348623853 0 1 -1
level,of,ergocalcitriol 1.0 0.00043004587156 0 3 -3
level,of,circulating 1.0 0.000286697247706 0 2 -2
level,of,blood 1.0 0.000143348623853 0 1 -1
level,of,at 1.0 0.000143348623853 0 1 -1
level,of,approximately 1.0 0.000143348623853 0 1 -1
level,is,recommended 1.0 0.000143348623853 0 1 -1
level,is,an 1.0 0.000143348623853 0 1 -1
level,in,humans 1.0 0.000143348623853 0 1 -1
level,hyperlipidaemia,and 1.0 0.000143348623853 0 1 -1
level,cells,mm3 1.0 0.000143348623853 0 1 -1
level,by,the 1.0 0.000143348623853 0 1 -1
leustatin,injection,is 1.0 0.000143348623853 0 1 -1
leukopenia,was,similar 1.0 0.000143348623853 0 1 -1
leukopenia,especially,in 1.0 0.000143348623853 0 1 -1
leukocytes,and,lipids 1.0 0.000143348623853 0 1 -1
leukocyte,production,including 1.0 0.000143348623853 0 1 -1
lethargy,drowsiness,restlessness 1.0 0.000143348623853 0 1 -1
lesser,extent,enhanced 1.0 0.000143348623853 0 1 -1
lesser,but,still 1.0 0.000143348623853 0 1 -1
lessened,active,metabolite 1.0 0.000143348623853 0 1 -1
lessen,the,potential 1.0 0.000143348623853 0 1 -1
lessen,its,efficacy 1.0 0.000143348623853 0 1 -1
less,well,studied 1.0 0.000143348623853 0 1 -1
less,toxic,to 1.0 0.000143348623853 0 1 -1
less,than,the 1.0 0.000143348623853 0 1 -1
less,than,seven 1.0 0.000143348623853 0 1 -1
less,than,second 1.0 0.000143348623853 0 1 -1
less,than,optimal 1.0 0.000143348623853 0 1 -1
less,than,of 1.0 0.000286697247706 0 2 -2
less,than,months 1.0 0.000143348623853 0 1 -1
less,than,minutes 1.0 0.000143348623853 0 1 -1
less,than,mg 1.0 0.000143348623853 0 1 -1
less,suppression,of 1.0 0.000143348623853 0 1 -1
less,specific,regulation 1.0 0.000143348623853 0 1 -1
less,marked,has 1.0 0.000286697247706 0 2 -2
less,enzyme,induction 1.0 0.000286697247706 0 2 -2
less,effective,and 1.0 0.000143348623853 0 1 -1
less,caspase-3,activity 1.0 0.000143348623853 0 1 -1
lesions,resulting,from 1.0 0.000143348623853 0 1 -1
lesions,or,dysfunction 1.0 0.000143348623853 0 1 -1
lesions,of,the 1.0 0.000143348623853 0 1 -1
lesions,have,been 1.0 0.000143348623853 0 1 -1
lesions,characterized,by 1.0 0.000143348623853 0 1 -1
lesions,actually,produced 1.0 0.000143348623853 0 1 -1
lengthening,of,the 1.0 0.000143348623853 0 1 -1
left,ventricular,dysfunction 1.0 0.000143348623853 0 1 -1
led,to,significant 1.0 0.000143348623853 0 1 -1
lectin,which,we 1.0 0.000143348623853 0 1 -1
lectin,and,that 1.0 0.000143348623853 0 1 -1
lectin,and,should 1.0 0.000143348623853 0 1 -1
least,two,hours 1.0 0.000286697247706 0 2 -2
least,the,negative 1.0 0.000143348623853 0 1 -1
least,squares,approach 1.0 0.000143348623853 0 1 -1
least,six,hours 1.0 0.000143348623853 0 1 -1
least,seven,days 1.0 0.000143348623853 0 1 -1
least,one,event 1.0 0.000143348623853 0 1 -1
least,of,which 1.0 0.000143348623853 0 1 -1
least,months,received 1.0 0.000143348623853 0 1 -1
least,months,had 1.0 0.000143348623853 0 1 -1
least,miu,ml 1.0 0.000143348623853 0 1 -1
least,hours,between 1.0 0.000143348623853 0 1 -1
least,four,times 1.0 0.000143348623853 0 1 -1
least,five,different 1.0 0.000143348623853 0 1 -1
least,days,before 1.0 0.000143348623853 0 1 -1
least,days,after 1.0 0.000286697247706 0 2 -2
least,balanced,by 1.0 0.000143348623853 0 1 -1
learning,and,memory 1.0 0.000143348623853 0 1 -1
lean,rats,arteries 1.0 0.000143348623853 0 1 -1
lean,animals,where 1.0 0.000143348623853 0 1 -1
lean,and,dietary-obese 1.0 0.000143348623853 0 1 -1
lean,and,dietary-induced 1.0 0.000143348623853 0 1 -1
leakage,of,nm 1.0 0.000143348623853 0 1 -1
leads,to,a 1.0 0.000143348623853 0 1 -1
leading,to,unique 1.0 0.000143348623853 0 1 -1
leading,to,reduced 1.0 0.000143348623853 0 1 -1
leading,to,increases 1.0 0.000143348623853 0 1 -1
leading,to,in-creased 1.0 0.000143348623853 0 1 -1
leading,to,an 1.0 0.000143348623853 0 1 -1
lead,to,several- 1.0 0.000143348623853 0 1 -1
lead,to,reduced 1.0 0.000716743119266 0 5 -5
lead,to,low 1.0 0.000143348623853 0 1 -1
lead,to,loss 1.0 0.00100344036697 0 7 -7
lead,to,increases 1.0 0.000143348623853 0 1 -1
lead,to,increased 1.0 0.000143348623853 0 1 -1
lead,to,higher 1.0 0.000143348623853 0 1 -1
lead,to,exaggerated 1.0 0.000143348623853 0 1 -1
lead,to,enhanced 1.0 0.000143348623853 0 1 -1
lead,to,b-cell 1.0 0.000143348623853 0 1 -1
lead,to,abnormal 1.0 0.000143348623853 0 1 -1
lead,tml,or 1.0 0.000143348623853 0 1 -1
lead,electrocardiograms,performed 1.0 0.000143348623853 0 1 -1
ldl-c,reduction,were 1.0 0.000143348623853 0 1 -1
ldl,cholesterol,concentration 1.0 0.000286697247706 0 2 -2
ldh,were,experienced 1.0 0.000143348623853 0 1 -1
lcv,infection,is 1.0 0.000143348623853 0 1 -1
layers,iv,and 1.0 0.000143348623853 0 1 -1
latter,might,arise 1.0 0.000143348623853 0 1 -1
later,developmental,acquisition 1.0 0.000143348623853 0 1 -1
later,changed,to 1.0 0.000143348623853 0 1 -1
later,by,gradually 1.0 0.000143348623853 0 1 -1
later,all,animals 1.0 0.000143348623853 0 1 -1
latent,lcv,infection 1.0 0.000143348623853 0 1 -1
latent,diabetes,mellitus 1.0 0.000143348623853 0 1 -1
latent,complications,which 1.0 0.000143348623853 0 1 -1
latency,to,loss 1.0 0.000143348623853 0 1 -1
latency,for,most 1.0 0.000143348623853 0 1 -1
latencies,to,lose 1.0 0.000143348623853 0 1 -1
lastly,local,use 1.0 0.000143348623853 0 1 -1
lasting,inhibition,of 1.0 0.000143348623853 0 1 -1
last,years,on 1.0 0.000143348623853 0 1 -1
last,two,hours 1.0 0.000143348623853 0 1 -1
last,morning,dose 1.0 0.000143348623853 0 1 -1
last,day,of 1.0 0.000143348623853 0 1 -1
last,chapters,cover 1.0 0.000143348623853 0 1 -1
last,act,of 1.0 0.000143348623853 0 1 -1
lasma,concentrations,of 1.0 0.000143348623853 0 1 -1
laser,interferometric,measurement 1.0 0.000143348623853 0 1 -1
larger,when,hydrochloride 1.0 0.000143348623853 0 1 -1
larger,doses,could 1.0 0.000143348623853 0 1 -1
largely,unbound,bound 1.0 0.000143348623853 0 1 -1
large,well,controlled 1.0 0.000143348623853 0 1 -1
large,size,to 1.0 0.000143348623853 0 1 -1
large,quantities,of 1.0 0.000143348623853 0 1 -1
large,placebo-controlled,osteoporosis 1.0 0.000143348623853 0 1 -1
large,numbers,of 1.0 0.000143348623853 0 1 -1
large,number,of 1.0 0.000143348623853 0 1 -1
large,initial,doses 1.0 0.000143348623853 0 1 -1
large,increases,inrifabutin 1.0 0.000143348623853 0 1 -1
large,fold,increase 1.0 0.000716743119266 0 5 -5
large,doses,of 1.0 0.000286697247706 0 2 -2
large,doses,may 1.0 0.000143348623853 0 1 -1
lapatinib,undergoes,extensive 1.0 0.000143348623853 0 1 -1
lapatinib,on,drug 1.0 0.000143348623853 0 1 -1
lapatinib,is,a 1.0 0.000143348623853 0 1 -1
lapatinib,inhibits,cyp3a4 1.0 0.000143348623853 0 1 -1
lapatinib,did,not 1.0 0.000143348623853 0 1 -1
lansoprazole,is,metabolized 1.0 0.000143348623853 0 1 -1
lansoprazole,has,also 1.0 0.000143348623853 0 1 -1
lansoprazole,causes,a 1.0 0.000143348623853 0 1 -1
lamivudine,is,predominantly 1.0 0.000143348623853 0 1 -1
lag,phase,in 1.0 0.000143348623853 0 1 -1
lactic,acidosis,have 1.0 0.000143348623853 0 1 -1
lactating,dams,was 1.0 0.000143348623853 0 1 -1
lacking,kidney,function 1.0 0.000143348623853 0 1 -1
lacking,cyp3a4,inducing 1.0 0.000143348623853 0 1 -1
lack,of,the 1.0 0.000143348623853 0 1 -1
lack,of,platelet 1.0 0.000286697247706 0 2 -2
lack,of,interaction 1.0 0.00043004587156 0 3 -3
lack,of,desired 1.0 0.000143348623853 0 1 -1
lack,of,correlation 1.0 0.000143348623853 0 1 -1
lack,of,anti-platelet 1.0 0.000143348623853 0 1 -1
lack,of,an 1.0 0.000143348623853 0 1 -1
laboratorytest,interactions,dactinomycin 1.0 0.000143348623853 0 1 -1
laboratory,tests,vital 1.0 0.000286697247706 0 2 -2
laboratory,tests,response 1.0 0.000143348623853 0 1 -1
laboratory,tests,pregnancy 1.0 0.000143348623853 0 1 -1
laboratory,tests,performed 1.0 0.000143348623853 0 1 -1
laboratory,tests,interactions 1.0 0.000573394495413 0 4 -4
laboratory,tests,if 1.0 0.000143348623853 0 1 -1
laboratory,tests,have 1.0 0.000573394495413 0 4 -4
laboratory,tests,common 1.0 0.000143348623853 0 1 -1
laboratory,test,or 1.0 0.000143348623853 0 1 -1
laboratory,test,interferences 1.0 0.000143348623853 0 1 -1
laboratory,test,interaction 1.0 0.000716743119266 0 5 -5
laboratory,test,in 1.0 0.000143348623853 0 1 -1
laboratory,test,findings 1.0 0.000143348623853 0 1 -1
laboratory,test,alterations 1.0 0.000143348623853 0 1 -1
laboratory,test,abnormalities 1.0 0.000286697247706 0 2 -2
laboratory,studies,to 1.0 0.000143348623853 0 1 -1
laboratory,results,are 1.0 0.000143348623853 0 1 -1
laboratory,preliminary,whole-cell 1.0 0.000143348623853 0 1 -1
laboratory,parameters,should 1.0 0.000143348623853 0 1 -1
laboratory,monitoring,with 1.0 0.000143348623853 0 1 -1
laboratory,interactions,no 1.0 0.000143348623853 0 1 -1
laboratory,evidence,of 1.0 0.000143348623853 0 1 -1
laboratory,assessments,of 1.0 0.000143348623853 0 1 -1
laboratory,abnormalities,elevated 1.0 0.000143348623853 0 1 -1
laboratories,platelia,aspergillus 1.0 0.000286697247706 0 2 -2
labetalol,hcl,special 1.0 0.000143348623853 0 1 -1
labetalol,hcl,has 1.0 0.000143348623853 0 1 -1
labelling,of,histidine 1.0 0.000143348623853 0 1 -1
labelled,and,in 1.0 0.000143348623853 0 1 -1
labeling,of,progestin-only 1.0 0.000143348623853 0 1 -1
labeling,index,of 1.0 0.000143348623853 0 1 -1
labeling,index,apoptotic 1.0 0.000143348623853 0 1 -1
labeling,can,be 1.0 0.000143348623853 0 1 -1
labeled,with,c-cholesteryl 1.0 0.000143348623853 0 1 -1
l50,mg,bid 1.0 0.000143348623853 0 1 -1
l057,was,approximately 1.0 0.000143348623853 0 1 -1
l057,in,the 1.0 0.000143348623853 0 1 -1
l-type,omega-conotoxin,gvia 1.0 0.000143348623853 0 1 -1
l-tryptophan,may,increase 1.0 0.000143348623853 0 1 -1
l-name,and,micromol 1.0 0.000143348623853 0 1 -1
l-glutamine,was,grams 1.0 0.000143348623853 0 1 -1
l-glutamine,has,orphan 1.0 0.000143348623853 0 1 -1
l-ccg,were,not 1.0 0.000143348623853 0 1 -1
l-ccg,upon,pcp 1.0 0.000143348623853 0 1 -1
l-ccg,on,the 1.0 0.000143348623853 0 1 -1
l,with,increasing 1.0 0.000143348623853 0 1 -1
l,while,corresponding 1.0 0.000143348623853 0 1 -1
l,were,similar 1.0 0.000143348623853 0 1 -1
l,were,investigated 1.0 0.000143348623853 0 1 -1
l,were,carried 1.0 0.000143348623853 0 1 -1
l,or,mg 1.0 0.000286697247706 0 2 -2
l,or,kcl 1.0 0.000143348623853 0 1 -1
l,or,higher 1.0 0.000143348623853 0 1 -1
l,mmol,mmol 1.0 0.000143348623853 0 1 -1
l,induced,concentration-dependent 1.0 0.000143348623853 0 1 -1
l,from,both 1.0 0.000143348623853 0 1 -1
l,for,single 1.0 0.000143348623853 0 1 -1
l,did,not 1.0 0.000143348623853 0 1 -1
l,and,mg 1.0 0.000143348623853 0 1 -1
kytril,have,all 1.0 0.000143348623853 0 1 -1
kt,oruvail,voltaren 1.0 0.000143348623853 0 1 -1
krm-1648,has,a 1.0 0.000143348623853 0 1 -1
krm-1648,either,singly 1.0 0.000143348623853 0 1 -1
krm-1648,either,alone 1.0 0.000143348623853 0 1 -1
known,which,clearance 1.0 0.000143348623853 0 1 -1
known,whether,these 1.0 0.000143348623853 0 1 -1
known,whether,other 1.0 0.000143348623853 0 1 -1
known,whether,or 1.0 0.000143348623853 0 1 -1
known,whether,might 1.0 0.000143348623853 0 1 -1
known,whether,amevive 1.0 0.000143348623853 0 1 -1
known,to,sensitize 1.0 0.000143348623853 0 1 -1
known,to,occasionally 1.0 0.00043004587156 0 3 -3
known,to,interfere 1.0 0.00114678899083 0 8 -8
known,to,influence 1.0 0.000143348623853 0 1 -1
known,to,induce 1.0 0.000860091743119 0 6 -6
known,to,effect 1.0 0.000143348623853 0 1 -1
known,to,depress 1.0 0.000143348623853 0 1 -1
known,to,cause 1.0 0.00043004587156 0 3 -3
known,to,adversely 1.0 0.000143348623853 0 1 -1
known,to,accelerate 1.0 0.000143348623853 0 1 -1
known,that,there 1.0 0.000143348623853 0 1 -1
known,substrates,or 1.0 0.000143348623853 0 1 -1
known,strong,inhibitor 1.0 0.000286697247706 0 2 -2
known,risk,factor 1.0 0.000143348623853 0 1 -1
known,relationships,between 1.0 0.000143348623853 0 1 -1
known,or,suspected 1.0 0.000143348623853 0 1 -1
known,metabolite,of 1.0 0.000143348623853 0 1 -1
known,metabolic,profiles 1.0 0.000143348623853 0 1 -1
known,interference,with 1.0 0.000143348623853 0 1 -1
known,interactions,with 1.0 0.000143348623853 0 1 -1
known,interactions,between 1.0 0.00043004587156 0 3 -3
known,if,regranex 1.0 0.000143348623853 0 1 -1
known,if,other 1.0 0.000143348623853 0 1 -1
known,if,mepron 1.0 0.000143348623853 0 1 -1
known,if,is 1.0 0.000143348623853 0 1 -1
known,if,hormonal 1.0 0.000143348623853 0 1 -1
known,health,care 1.0 0.000143348623853 0 1 -1
known,cytochrome,cyp 1.0 0.000143348623853 0 1 -1
known,clinically,significant 1.0 0.000143348623853 0 1 -1
knowledge,of,the 1.0 0.000143348623853 0 1 -1
know,how,safe 1.0 0.000143348623853 0 1 -1
kits,with,an 1.0 0.000143348623853 0 1 -1
kits,such,as 1.0 0.000143348623853 0 1 -1
kinetics,of,a 1.0 0.000143348623853 0 1 -1
kinetics,equilibrium,and 1.0 0.000143348623853 0 1 -1
kinetic,characteristics,for 1.0 0.000143348623853 0 1 -1
kineret,when,the 1.0 0.000143348623853 0 1 -1
kinds,of,and 1.0 0.000143348623853 0 1 -1
kinase,c,or 1.0 0.000143348623853 0 1 -1
kilometers,of,walking 1.0 0.000143348623853 0 1 -1
killing,relative,to 1.0 0.000143348623853 0 1 -1
killed,at,the 1.0 0.000143348623853 0 1 -1
kidneys,coadministration,of 1.0 0.000143348623853 0 1 -1
kidneys,and,bones 1.0 0.00043004587156 0 3 -3
kidneys,along,with 1.0 0.000143348623853 0 1 -1
kidney,which,was 1.0 0.000143348623853 0 1 -1
kidney,recipients,suggest 1.0 0.000143348623853 0 1 -1
kidney,on,scintigraphy 1.0 0.000143348623853 0 1 -1
kidney,homogenates,supplemented 1.0 0.000143348623853 0 1 -1
kidney,function,the 1.0 0.000143348623853 0 1 -1
kidney,function,and 1.0 0.000143348623853 0 1 -1
kidney,diseases,recent 1.0 0.000143348623853 0 1 -1
kidney,damage,as 1.0 0.000143348623853 0 1 -1
kidney,cell,cultures 1.0 0.000143348623853 0 1 -1
kidney,and,the 1.0 0.000143348623853 0 1 -1
kidney,and,liver 1.0 0.000143348623853 0 1 -1
kidney,allograft,recipients 1.0 0.000143348623853 0 1 -1
ki,values,were 1.0 0.000143348623853 0 1 -1
ki,value,of 1.0 0.000143348623853 0 1 -1
ki,of,um 1.0 0.000143348623853 0 1 -1
kht,tumour,the 1.0 0.000143348623853 0 1 -1
kg,weekly,for 1.0 0.000143348623853 0 1 -1
kg,week,about 1.0 0.000143348623853 0 1 -1
kg,was,investigated 1.0 0.000143348623853 0 1 -1
kg,twice,a 1.0 0.000143348623853 0 1 -1
kg,the,diarrhea-inducing 1.0 0.000143348623853 0 1 -1
kg,such,an 1.0 0.000143348623853 0 1 -1
kg,subcutaneous,injection 1.0 0.000143348623853 0 1 -1
kg,results,in 1.0 0.000143348623853 0 1 -1
kg,resulted,in 1.0 0.000143348623853 0 1 -1
kg,produced,no 1.0 0.000143348623853 0 1 -1
kg,person,based 1.0 0.000143348623853 0 1 -1
kg,person,and 1.0 0.000143348623853 0 1 -1
kg,or,vehicle 1.0 0.000143348623853 0 1 -1
kg,or,to 1.0 0.000143348623853 0 1 -1
kg,or,tmax 1.0 0.000143348623853 0 1 -1
kg,or,repeated 1.0 0.000143348623853 0 1 -1
kg,or,mg 1.0 0.000143348623853 0 1 -1
kg,once,every 1.0 0.000286697247706 0 2 -2
kg,of,metabolite 1.0 0.000143348623853 0 1 -1
kg,of,fe 1.0 0.000143348623853 0 1 -1
kg,of,co 1.0 0.000143348623853 0 1 -1
kg,of,body 1.0 0.000143348623853 0 1 -1
kg,of,alone 1.0 0.000143348623853 0 1 -1
kg,ml,sc 1.0 0.000143348623853 0 1 -1
kg,min,over 1.0 0.000143348623853 0 1 -1
kg,min,dose 1.0 0.000143348623853 0 1 -1
kg,mg,kg 1.0 0.00043004587156 0 3 -3
kg,mc,mg 1.0 0.000143348623853 0 1 -1
kg,m,g 1.0 0.000143348623853 0 1 -1
kg,infused,over 1.0 0.000143348623853 0 1 -1
kg,induced,a 1.0 0.000143348623853 0 1 -1
kg,in,a 1.0 0.000143348623853 0 1 -1
kg,every,weeks 1.0 0.000143348623853 0 1 -1
kg,dose,resulted 1.0 0.000143348623853 0 1 -1
kg,dose,of 1.0 0.000143348623853 0 1 -1
kg,dose,m 1.0 0.000143348623853 0 1 -1
kg,decreases,the 1.0 0.000143348623853 0 1 -1
kg,days,mg 1.0 0.000286697247706 0 2 -2
kg,day,was 1.0 0.000143348623853 0 1 -1
kg,day,twice 1.0 0.000143348623853 0 1 -1
kg,day,showed 1.0 0.000143348623853 0 1 -1
kg,day,or 1.0 0.000286697247706 0 2 -2
kg,day,is 1.0 0.000143348623853 0 1 -1
kg,day,im 1.0 0.000286697247706 0 2 -2
kg,day,for 1.0 0.000143348623853 0 1 -1
kg,day,are 1.0 0.000143348623853 0 1 -1
kg,day,approximately 1.0 0.000573394495413 0 4 -4
kg,day,and 1.0 0.00043004587156 0 3 -3
kg,day,about 1.0 0.000143348623853 0 1 -1
kg,daily,for 1.0 0.000143348623853 0 1 -1
kg,bwt,were 1.0 0.000143348623853 0 1 -1
kg,and,sex 1.0 0.000143348623853 0 1 -1
kg,and,oral 1.0 0.000143348623853 0 1 -1
keys,to,maximizing 1.0 0.000143348623853 0 1 -1
key,to,maximizing 1.0 0.000143348623853 0 1 -1
ketorolac,is,highly 1.0 0.000143348623853 0 1 -1
ketorolac,does,not 1.0 0.000143348623853 0 1 -1
ketoprofen,does,not 1.0 0.000143348623853 0 1 -1
ketoprofen,decreases,platelet 1.0 0.000143348623853 0 1 -1
ketones,in,the 1.0 0.000286697247706 0 2 -2
ketones,and,demonstrates 1.0 0.000143348623853 0 1 -1
ketone,bodies,in 1.0 0.000143348623853 0 1 -1
ketogenic,because,of 1.0 0.000143348623853 0 1 -1
ketoconazole,sensipar,is 1.0 0.000143348623853 0 1 -1
ketoconazole,phenytoin,phenobarbitol 1.0 0.000143348623853 0 1 -1
ketoconazole,mg,daily 1.0 0.000143348623853 0 1 -1
ketoconazole,ketoconazole,mg 1.0 0.000143348623853 0 1 -1
ketoconazole,ketoconazole,and 1.0 0.000143348623853 0 1 -1
ketoconazole,itraconazole,macrolides 1.0 0.000143348623853 0 1 -1
ketoconazole,is,a 1.0 0.000286697247706 0 2 -2
ketoconazole,fexofenadine,has 1.0 0.000143348623853 0 1 -1
ketoconazole,erythromycin,clarithromycin 1.0 0.000143348623853 0 1 -1
ketoconazole,did,not 1.0 0.000143348623853 0 1 -1
ketoconazole,cyp3a4,is 1.0 0.000143348623853 0 1 -1
ketoconazole,concomitant,use 1.0 0.000143348623853 0 1 -1
ketoconazole,and,are 1.0 0.000143348623853 0 1 -1
ketamine,is,clinically 1.0 0.000143348623853 0 1 -1
kerlone,with,the 1.0 0.000143348623853 0 1 -1
kerlone,and,have 1.0 0.000143348623853 0 1 -1
kerastick,for,topical 1.0 0.000143348623853 0 1 -1
keppra,on,was 1.0 0.000143348623853 0 1 -1
keppra,mg,twice 1.0 0.000573394495413 0 4 -4
keppra,mg,daily 1.0 0.000143348623853 0 1 -1
keppra,is,unlikely 1.0 0.000143348623853 0 1 -1
keppra,and,other 1.0 0.000286697247706 0 2 -2
kemstrotm,was,similar 1.0 0.000143348623853 0 1 -1
kemstro,the,most 1.0 0.000143348623853 0 1 -1
keflex,a,false-positive 1.0 0.000143348623853 0 1 -1
kda,adapter,protein 1.0 0.000143348623853 0 1 -1
kd,of,d2 1.0 0.000286697247706 0 2 -2
kd,and,bmax 1.0 0.000143348623853 0 1 -1
kcl,mmol,l 1.0 0.000143348623853 0 1 -1
karst,was,tested 1.0 0.000143348623853 0 1 -1
kappa-selective,was,significantly 1.0 0.000143348623853 0 1 -1
kappa,and,possibly 1.0 0.000143348623853 0 1 -1
kaposi,s,sarcoma 1.0 0.000143348623853 0 1 -1
k,epoxide,reductase 1.0 0.000143348623853 0 1 -1
k,contribution,to 1.0 0.000143348623853 0 1 -1
k,aquamephyton,synkayvite 1.0 0.000143348623853 0 1 -1
k,antagonists,and 1.0 0.000286697247706 0 2 -2
justifies,the,potential 1.0 0.000143348623853 0 1 -1
just,prior,to 1.0 0.000143348623853 0 1 -1
june,and,october 1.0 0.000143348623853 0 1 -1
juices,such,as 1.0 0.000286697247706 0 2 -2
juices,studies,with 1.0 0.000143348623853 0 1 -1
juices,fruit,juices 1.0 0.000143348623853 0 1 -1
juice,with,may 1.0 0.000143348623853 0 1 -1
juice,with,increases 1.0 0.000143348623853 0 1 -1
juice,which,inhibits 1.0 0.000143348623853 0 1 -1
juice,should,not 1.0 0.000143348623853 0 1 -1
juice,resulted,in 1.0 0.000143348623853 0 1 -1
juice,increases,ethinyl 1.0 0.000143348623853 0 1 -1
juice,have,not 1.0 0.000143348623853 0 1 -1
juice,given,to 1.0 0.000143348623853 0 1 -1
juice,co-administration,of 1.0 0.000143348623853 0 1 -1
judged,from,the 1.0 0.000143348623853 0 1 -1
judged,by,increased 1.0 0.000143348623853 0 1 -1
joint,exposure,general 1.0 0.000143348623853 0 1 -1
joint,dose-response,curves 1.0 0.000143348623853 0 1 -1
joint,action,ija 1.0 0.000143348623853 0 1 -1
joint,action,data 1.0 0.000143348623853 0 1 -1
johns,wort,may 1.0 0.000286697247706 0 2 -2
johns,wort,hypericum 1.0 0.000143348623853 0 1 -1
johns,wort,because 1.0 0.000143348623853 0 1 -1
johns,wort,based 1.0 0.000143348623853 0 1 -1
job,appointments,since 1.0 0.000143348623853 0 1 -1
jejunal,net,fluid 1.0 0.000143348623853 0 1 -1
january,and,august 1.0 0.000143348623853 0 1 -1
jaffe,reaction,since 1.0 0.000143348623853 0 1 -1
jaffe,reaction,and 1.0 0.000143348623853 0 1 -1
jaff,reaction,and 1.0 0.000143348623853 0 1 -1
jackfruit,contain,a 1.0 0.000143348623853 0 1 -1
jacalin,is,a 1.0 0.000143348623853 0 1 -1
j,chromatogr,should 1.0 0.000143348623853 0 1 -1
ix,x,xii 1.0 0.000286697247706 0 2 -2
iva-sensitive,p-type,channel 1.0 0.000143348623853 0 1 -1
iva,p-type,in 1.0 0.000143348623853 0 1 -1
iv,was,given 1.0 0.000143348623853 0 1 -1
iv,such,as 1.0 0.000143348623853 0 1 -1
iv,myocardium,versus 1.0 0.000143348623853 0 1 -1
iv,in,relation 1.0 0.000143348623853 0 1 -1
iv,have,been 1.0 0.000143348623853 0 1 -1
iv,has,been 1.0 0.000143348623853 0 1 -1
iv,compared,with 1.0 0.000143348623853 0 1 -1
iv,cannot,be 1.0 0.000143348623853 0 1 -1
iv,and,vi 1.0 0.000143348623853 0 1 -1
iv,ace,inhibitors 1.0 0.000143348623853 0 1 -1
itself,was,not 1.0 0.000143348623853 0 1 -1
itself,could,likewise 1.0 0.000143348623853 0 1 -1
its,vasculature,without 1.0 0.000143348623853 0 1 -1
its,use,with 1.0 0.000143348623853 0 1 -1
its,use,in 1.0 0.000286697247706 0 2 -2
its,two,metabolites 1.0 0.000143348623853 0 1 -1
its,three,metabolites 1.0 0.000143348623853 0 1 -1
its,therapeutic,and 1.0 0.000286697247706 0 2 -2
its,synthetic,analogue 1.0 0.000143348623853 0 1 -1
its,proposed,specific 1.0 0.000143348623853 0 1 -1
its,prevention,in 1.0 0.000143348623853 0 1 -1
its,potential,to 1.0 0.000143348623853 0 1 -1
its,plasma,clearance 1.0 0.000143348623853 0 1 -1
its,pharmacologically,active 1.0 0.000143348623853 0 1 -1
its,permeation,enhancing 1.0 0.000143348623853 0 1 -1
its,n-demethylated,metabolite 1.0 0.000143348623853 0 1 -1
its,metabolites,oxo-desethylzaleplon 1.0 0.000143348623853 0 1 -1
its,metabolites,n-desmethylclozapine 1.0 0.000143348623853 0 1 -1
its,metabolites,is 1.0 0.000286697247706 0 2 -2
its,metabolites,interfere 1.0 0.000143348623853 0 1 -1
its,metabolites,induce 1.0 0.000143348623853 0 1 -1
its,metabolites,have 1.0 0.000143348623853 0 1 -1
its,metabolites,had 1.0 0.000143348623853 0 1 -1
its,metabolites,are 1.0 0.000143348623853 0 1 -1
its,metabolite,may 1.0 0.000143348623853 0 1 -1
its,metabolite,concentrationswere 1.0 0.000143348623853 0 1 -1
its,metabolism,may 1.0 0.000143348623853 0 1 -1
its,metabolism,and 1.0 0.000143348623853 0 1 -1
its,major,metabolite 1.0 0.00043004587156 0 3 -3
its,lack,of 1.0 0.00043004587156 0 3 -3
its,inhibitory,effects 1.0 0.000143348623853 0 1 -1
its,epoxide,metabolite 1.0 0.000143348623853 0 1 -1
its,enantiomer,nanm 1.0 0.000143348623853 0 1 -1
its,efficacy,safety 1.0 0.000143348623853 0 1 -1
its,efficacy,as 1.0 0.000143348623853 0 1 -1
its,effects,on 1.0 0.000143348623853 0 1 -1
its,effects,concomitant 1.0 0.000143348623853 0 1 -1
its,effectiveness,in 1.0 0.000143348623853 0 1 -1
its,effect,on 1.0 0.000143348623853 0 1 -1
its,effect,by 1.0 0.000143348623853 0 1 -1
its,congeners,and 1.0 0.000143348623853 0 1 -1
its,components,are 1.0 0.000143348623853 0 1 -1
its,clinical,significance 1.0 0.000143348623853 0 1 -1
its,approval,by 1.0 0.000143348623853 0 1 -1
its,antidiuretic,activity 1.0 0.000143348623853 0 1 -1
its,affinity,for 1.0 0.00043004587156 0 3 -3
its,adverse,effects 1.0 0.000143348623853 0 1 -1
its,activity,was 1.0 0.000143348623853 0 1 -1
its,activity,and 1.0 0.000143348623853 0 1 -1
its,active,metabolites 1.0 0.000143348623853 0 1 -1
its,acid,metabolite 1.0 0.000143348623853 0 1 -1
itraconazole,mg,b 1.0 0.000143348623853 0 1 -1
itraconazole,ketoconazole,erythromycin 1.0 0.000143348623853 0 1 -1
itraconazole,co-administration,of 1.0 0.000143348623853 0 1 -1
itraconazole,and,primarily 1.0 0.000143348623853 0 1 -1
itching,mouth,sores 1.0 0.000143348623853 0 1 -1
italy,from,april 1.0 0.000143348623853 0 1 -1
it,was,possible 1.0 0.000143348623853 0 1 -1
it,was,noted 1.0 0.000143348623853 0 1 -1
it,was,independent 1.0 0.000143348623853 0 1 -1
it,was,established 1.0 0.000143348623853 0 1 -1
it,was,demonstrated 1.0 0.000143348623853 0 1 -1
it,was,combined 1.0 0.000143348623853 0 1 -1
it,was,administered 1.0 0.000143348623853 0 1 -1
it,substituted,for 1.0 0.000143348623853 0 1 -1
it,should,also 1.0 0.000143348623853 0 1 -1
it,reduced,the 1.0 0.000143348623853 0 1 -1
it,palliates,deficiencies 1.0 0.000143348623853 0 1 -1
it,may,impair 1.0 0.00043004587156 0 3 -3
it,may,have 1.0 0.000143348623853 0 1 -1
it,may,decrease 1.0 0.000143348623853 0 1 -1
it,may,also 1.0 0.000286697247706 0 2 -2
it,is,unlikely 1.0 0.000716743119266 0 5 -5
it,is,unknown 1.0 0.00043004587156 0 3 -3
it,is,taken 1.0 0.000286697247706 0 2 -2
it,is,subject 1.0 0.000143348623853 0 1 -1
it,is,structurally 1.0 0.000143348623853 0 1 -1
it,is,proposed 1.0 0.000286697247706 0 2 -2
it,is,probable 1.0 0.000143348623853 0 1 -1
it,is,presently 1.0 0.000143348623853 0 1 -1
it,is,potentially 1.0 0.000143348623853 0 1 -1
it,is,postulated 1.0 0.000143348623853 0 1 -1
it,is,particularly 1.0 0.000143348623853 0 1 -1
it,is,of 1.0 0.000143348623853 0 1 -1
it,is,now 1.0 0.000286697247706 0 2 -2
it,is,notable 1.0 0.000143348623853 0 1 -1
it,is,indicated 1.0 0.000143348623853 0 1 -1
it,is,important 1.0 0.000573394495413 0 4 -4
it,is,extensively 1.0 0.000143348623853 0 1 -1
it,is,essentially 1.0 0.000143348623853 0 1 -1
it,is,difficult 1.0 0.000143348623853 0 1 -1
it,is,desirable 1.0 0.000716743119266 0 5 -5
it,is,critically 1.0 0.000143348623853 0 1 -1
it,is,considered 1.0 0.000143348623853 0 1 -1
it,is,conceived 1.0 0.000143348623853 0 1 -1
it,is,assumed 1.0 0.000143348623853 0 1 -1
it,is,also 1.0 0.000143348623853 0 1 -1
it,interfere,with 1.0 0.000143348623853 0 1 -1
it,increased,the 1.0 0.000143348623853 0 1 -1
it,has,recently 1.0 0.000143348623853 0 1 -1
it,has,greater 1.0 0.000143348623853 0 1 -1
it,has,generally 1.0 0.000143348623853 0 1 -1
it,from,other 1.0 0.000143348623853 0 1 -1
it,enhances,the 1.0 0.000143348623853 0 1 -1
it,does,not 1.0 0.000143348623853 0 1 -1
it,combines,with 1.0 0.000143348623853 0 1 -1
it,can,prolong 1.0 0.000143348623853 0 1 -1
it,by,a 1.0 0.000143348623853 0 1 -1
it,as,much 1.0 0.000143348623853 0 1 -1
it,alter,the 1.0 0.000143348623853 0 1 -1
it,affect,the 1.0 0.000143348623853 0 1 -1
isozymes,may,result 1.0 0.000143348623853 0 1 -1
isozymes,may,increase 1.0 0.000143348623853 0 1 -1
isozymes,including,cyp1a2 1.0 0.000143348623853 0 1 -1
isozymes,in,the 1.0 0.000143348623853 0 1 -1
isozymes,in,particular 1.0 0.000143348623853 0 1 -1
isozymes,evaluated,cyps 1.0 0.000143348623853 0 1 -1
isozymes,a2,a6 1.0 0.000143348623853 0 1 -1
isozymes,a1,a2 1.0 0.000143348623853 0 1 -1
isozyme,which,metabolizes 1.0 0.000143348623853 0 1 -1
isozyme,including,many 1.0 0.000143348623853 0 1 -1
isozyme,cytochrome,p450 1.0 0.000716743119266 0 5 -5
isozyme,cyp2c9,and 1.0 0.000143348623853 0 1 -1
isozyme,and,thus 1.0 0.000143348623853 0 1 -1
isozyme,and,make 1.0 0.000716743119266 0 5 -5
isozyme,activity,among 1.0 0.000716743119266 0 5 -5
isosorbide,dinitrate,chloride 1.0 0.000143348623853 0 1 -1
isoproterenol,alone,at 1.0 0.000143348623853 0 1 -1
isoniazid,should,not 1.0 0.000143348623853 0 1 -1
isomers,of,were 1.0 0.000143348623853 0 1 -1
isomer,on,the 1.0 0.000143348623853 0 1 -1
isomer,had,opioid-antagonist 1.0 0.000143348623853 0 1 -1
isolates,synergy,was 1.0 0.000143348623853 0 1 -1
isolates,and,a 1.0 0.000143348623853 0 1 -1
isolated,single,pancreatic 1.0 0.000143348623853 0 1 -1
isolated,rabbit,gastric 1.0 0.000143348623853 0 1 -1
isolated,from,marine 1.0 0.000143348623853 0 1 -1
isoforms,tested,was 1.0 0.000143348623853 0 1 -1
isoforms,epoxide,hydrolase 1.0 0.000143348623853 0 1 -1
isoforms,cyp3a4,cyp2d6 1.0 0.000143348623853 0 1 -1
isoforms,cyp2c8,c9 1.0 0.000143348623853 0 1 -1
isoforms,cyp1a2,cyp2a6 1.0 0.000143348623853 0 1 -1
isoforms,a4,and 1.0 0.000143348623853 0 1 -1
isoforms,a2,c9 1.0 0.000143348623853 0 1 -1
isoform,selective,marker 1.0 0.000143348623853 0 1 -1
isoform,mediate,the 1.0 0.000143348623853 0 1 -1
isoform,and,cyp1a2 1.0 0.000143348623853 0 1 -1
isoenzymes,will,be 1.0 0.000143348623853 0 1 -1
isoenzymes,tested,cyp1a2 1.0 0.000143348623853 0 1 -1
isoenzymes,may,increase 1.0 0.000143348623853 0 1 -1
isoenzymes,may,decrease 1.0 0.000143348623853 0 1 -1
isoenzymes,has,not 1.0 0.000143348623853 0 1 -1
isoenzymes,cyp2c9,cyp2d6 1.0 0.000143348623853 0 1 -1
isoenzymes,cyp1a2,c8 1.0 0.000143348623853 0 1 -1
isoenzymes,carbamazepine,is 1.0 0.000143348623853 0 1 -1
isoenzymes,and,therefore 1.0 0.000143348623853 0 1 -1
isoenzymes,and,or 1.0 0.000143348623853 0 1 -1
isoenzyme,system,fentanyl 1.0 0.000143348623853 0 1 -1
isoenzyme,system,cyp3a4 1.0 0.000143348623853 0 1 -1
isoenzyme,of,the 1.0 0.000143348623853 0 1 -1
isoenzyme,is,present 1.0 0.000143348623853 0 1 -1
isoenzyme,including,many 1.0 0.000143348623853 0 1 -1
isoenzyme,family,may 1.0 0.000143348623853 0 1 -1
isoenzyme,cyp3a4,responsible 1.0 0.000143348623853 0 1 -1
isoenzyme,cyp3a4,activity 1.0 0.000143348623853 0 1 -1
isoenzyme,cyp2d6,activity 1.0 0.000143348623853 0 1 -1
isoenzyme,could,increase 1.0 0.000143348623853 0 1 -1
isoenzyme,and,thus 1.0 0.000143348623853 0 1 -1
isoenzyme,and,are 1.0 0.000143348623853 0 1 -1
isocarboxazid,may,persist 1.0 0.000143348623853 0 1 -1
isocarboxazid,and,begin 1.0 0.000143348623853 0 1 -1
iso-sensitest,broth,using 1.0 0.000143348623853 0 1 -1
isis-2,currently,do 1.0 0.000143348623853 0 1 -1
ischemia,of,the 1.0 0.000286697247706 0 2 -2
is,within,the 1.0 0.000143348623853 0 1 -1
is,virtually,complete 1.0 0.000143348623853 0 1 -1
is,via,the 1.0 0.000143348623853 0 1 -1
is,very,unlikely 1.0 0.000143348623853 0 1 -1
is,very,low 1.0 0.000143348623853 0 1 -1
is,useful,in 1.0 0.000143348623853 0 1 -1
is,unusual,and 1.0 0.000143348623853 0 1 -1
is,unlikely,to 1.0 0.00172018348624 0 12 -12
is,unlikely,that 1.0 0.00043004587156 0 3 -3
is,unlikely,for 1.0 0.000143348623853 0 1 -1
is,unknown,whether 1.0 0.000286697247706 0 2 -2
is,unknown,how 1.0 0.000143348623853 0 1 -1
is,unknown,but 1.0 0.00043004587156 0 3 -3
is,unknown,at 1.0 0.000143348623853 0 1 -1
is,unknown,amevive 1.0 0.000143348623853 0 1 -1
is,understandable,because 1.0 0.000143348623853 0 1 -1
is,unclear,patients 1.0 0.000143348623853 0 1 -1
is,unavailable,a 1.0 0.000143348623853 0 1 -1
is,unaltered,impaired 1.0 0.000143348623853 0 1 -1
is,unaffected,by 1.0 0.000286697247706 0 2 -2
is,truly,hypothyroid 1.0 0.000143348623853 0 1 -1
is,totally,atoxic 1.0 0.000143348623853 0 1 -1
is,too,small 1.0 0.000143348623853 0 1 -1
is,therefore,necessary 1.0 0.000143348623853 0 1 -1
is,the,risk 1.0 0.000143348623853 0 1 -1
is,the,rate-limiting 1.0 0.000143348623853 0 1 -1
is,the,possibility 1.0 0.000143348623853 0 1 -1
is,the,only 1.0 0.000143348623853 0 1 -1
is,the,first 1.0 0.000143348623853 0 1 -1
is,the,chosen 1.0 0.000143348623853 0 1 -1
is,the,binding 1.0 0.000143348623853 0 1 -1
is,the,best 1.0 0.000143348623853 0 1 -1
is,that,the 1.0 0.000143348623853 0 1 -1
is,susceptible,to 1.0 0.000143348623853 0 1 -1
is,summarized,in 1.0 0.000143348623853 0 1 -1
is,suitable,for 1.0 0.000286697247706 0 2 -2
is,suggested,while 1.0 0.000143348623853 0 1 -1
is,such,a 1.0 0.000143348623853 0 1 -1
is,subject,to 1.0 0.000286697247706 0 2 -2
is,structurally,similar 1.0 0.000143348623853 0 1 -1
is,structurally,distinct 1.0 0.000143348623853 0 1 -1
is,strong,evidence 1.0 0.000143348623853 0 1 -1
is,still,valid 1.0 0.000143348623853 0 1 -1
is,still,unknown 1.0 0.000143348623853 0 1 -1
is,stable,on 1.0 0.000716743119266 0 5 -5
is,small,with 1.0 0.000143348623853 0 1 -1
is,significantly,bound 1.0 0.000143348623853 0 1 -1
is,sensitive,to 1.0 0.000143348623853 0 1 -1
is,seen,in 1.0 0.000143348623853 0 1 -1
is,running,a 1.0 0.000143348623853 0 1 -1
is,required,since 1.0 0.000286697247706 0 2 -2
is,required,if 1.0 0.000286697247706 0 2 -2
is,required,for 1.0 0.000573394495413 0 4 -4
is,related,to 1.0 0.000143348623853 0 1 -1
is,reduced,significantly 1.0 0.000143348623853 0 1 -1
is,reduced,in 1.0 0.000716743119266 0 5 -5
is,recommended,depending 1.0 0.000143348623853 0 1 -1
is,recommended,at 1.0 0.000143348623853 0 1 -1
is,reaching,epidemic 1.0 0.000143348623853 0 1 -1
is,rapidly,and 1.0 0.000143348623853 0 1 -1
is,rapid,while 1.0 0.000143348623853 0 1 -1
is,rapid,equilibration 1.0 0.000143348623853 0 1 -1
is,proposed,that 1.0 0.000286697247706 0 2 -2
is,prone,to 1.0 0.000143348623853 0 1 -1
is,prolonged,because 1.0 0.000143348623853 0 1 -1
is,probably,the 1.0 0.000143348623853 0 1 -1
is,probably,accomplished 1.0 0.000143348623853 0 1 -1
is,probable,that 1.0 0.000143348623853 0 1 -1
is,principally,metabolized 1.0 0.000143348623853 0 1 -1
is,primarily,metabolized 1.0 0.000716743119266 0 5 -5
is,primarily,eliminated 1.0 0.000143348623853 0 1 -1
is,primarily,degraded 1.0 0.000143348623853 0 1 -1
is,primarily,a 1.0 0.000143348623853 0 1 -1
is,presently,not 1.0 0.000143348623853 0 1 -1
is,presented,of 1.0 0.000143348623853 0 1 -1
is,present,whether 1.0 0.000143348623853 0 1 -1
is,present,in 1.0 0.000143348623853 0 1 -1
is,predominantly,metabolized 1.0 0.000143348623853 0 1 -1
is,predominantly,mediated 1.0 0.00043004587156 0 3 -3
is,predominantly,eliminated 1.0 0.000143348623853 0 1 -1
is,potentially,toxic 1.0 0.000143348623853 0 1 -1
is,postulated,that 1.0 0.000143348623853 0 1 -1
is,patient,in 1.0 0.000143348623853 0 1 -1
is,particularly,susceptible 1.0 0.000143348623853 0 1 -1
is,particularly,important 1.0 0.000143348623853 0 1 -1
is,ordinarily,a 1.0 0.000143348623853 0 1 -1
is,only,about 1.0 0.000143348623853 0 1 -1
is,only,a 1.0 0.000143348623853 0 1 -1
is,offset,by 1.0 0.000143348623853 0 1 -1
is,of,importance 1.0 0.000143348623853 0 1 -1
is,of,great 1.0 0.000143348623853 0 1 -1
is,of,clinical 1.0 0.000286697247706 0 2 -2
is,obtained,by 1.0 0.000143348623853 0 1 -1
is,observed,it 1.0 0.000143348623853 0 1 -1
is,now,strong 1.0 0.000143348623853 0 1 -1
is,now,difficult 1.0 0.000143348623853 0 1 -1
is,now,clear 1.0 0.000143348623853 0 1 -1
is,notable,that 1.0 0.000143348623853 0 1 -1
is,not,sufficient 1.0 0.000286697247706 0 2 -2
is,not,significantly 1.0 0.00043004587156 0 3 -3
is,not,required 1.0 0.000143348623853 0 1 -1
is,not,related 1.0 0.000143348623853 0 1 -1
is,not,possible 1.0 0.000286697247706 0 2 -2
is,not,particularly 1.0 0.000143348623853 0 1 -1
is,not,metabolized 1.0 0.000286697247706 0 2 -2
is,not,meant 1.0 0.000143348623853 0 1 -1
is,not,indicated 1.0 0.000143348623853 0 1 -1
is,not,impaired 1.0 0.000143348623853 0 1 -1
is,not,highly 1.0 0.00043004587156 0 3 -3
is,not,higher 1.0 0.000143348623853 0 1 -1
is,not,extensively 1.0 0.000143348623853 0 1 -1
is,not,clear 1.0 0.000286697247706 0 2 -2
is,not,associated 1.0 0.000143348623853 0 1 -1
is,not,approved 1.0 0.000286697247706 0 2 -2
is,not,appreciably 1.0 0.000143348623853 0 1 -1
is,not,antagonized 1.0 0.000143348623853 0 1 -1
is,not,an 1.0 0.00043004587156 0 3 -3
is,not,all 1.0 0.000143348623853 0 1 -1
is,not,affected 1.0 0.000286697247706 0 2 -2
is,no,significant 1.0 0.00043004587156 0 3 -3
is,no,pharmacokinetic 1.0 0.000286697247706 0 2 -2
is,no,or 1.0 0.000143348623853 0 1 -1
is,no,known 1.0 0.000143348623853 0 1 -1
is,no,information 1.0 0.000286697247706 0 2 -2
is,no,experience 1.0 0.000143348623853 0 1 -1
is,no,evidence 1.0 0.00043004587156 0 3 -3
is,no,doubt 1.0 0.000143348623853 0 1 -1
is,no,documentation 1.0 0.000143348623853 0 1 -1
is,no,clinical 1.0 0.000286697247706 0 2 -2
is,nevertheless,associated 1.0 0.000143348623853 0 1 -1
is,neither,metabolized 1.0 0.000143348623853 0 1 -1
is,negligible,interactions 1.0 0.000143348623853 0 1 -1
is,needed,when 1.0 0.000143348623853 0 1 -1
is,needed,should 1.0 0.000143348623853 0 1 -1
is,needed,careful 1.0 0.000143348623853 0 1 -1
is,necessary,careful 1.0 0.00043004587156 0 3 -3
is,necessary,but 1.0 0.000143348623853 0 1 -1
is,narrow,serum 1.0 0.000143348623853 0 1 -1
is,moderately,reduced 1.0 0.000143348623853 0 1 -1
is,mmol,l 1.0 0.000143348623853 0 1 -1
is,mixed,with 1.0 0.000143348623853 0 1 -1
is,minimized,to 1.0 0.000143348623853 0 1 -1
is,mg,with 1.0 0.000143348623853 0 1 -1
is,metabolized,to 1.0 0.00043004587156 0 3 -3
is,metabolized,through 1.0 0.000143348623853 0 1 -1
is,metabolized,primarily 1.0 0.000143348623853 0 1 -1
is,metabolized,mainly 1.0 0.00043004587156 0 3 -3
is,metabolized,in 1.0 0.00043004587156 0 3 -3
is,metabolized,by 1.0 0.00157683486239 0 11 -11
is,metabolized,at 1.0 0.000143348623853 0 1 -1
is,mediated,primarily 1.0 0.000143348623853 0 1 -1
is,mediated,by 1.0 0.000143348623853 0 1 -1
is,manifested,as 1.0 0.000143348623853 0 1 -1
is,maintained,by 1.0 0.000143348623853 0 1 -1
is,made,to 1.0 0.000143348623853 0 1 -1
is,lower,than 1.0 0.000143348623853 0 1 -1
is,low,clinically 1.0 0.000143348623853 0 1 -1
is,little,risk 1.0 0.000143348623853 0 1 -1
is,little,published 1.0 0.000143348623853 0 1 -1
is,little,if 1.0 0.000143348623853 0 1 -1
is,limited,experience 1.0 0.000286697247706 0 2 -2
is,limited,evidence 1.0 0.000143348623853 0 1 -1
is,limited,as 1.0 0.000143348623853 0 1 -1
is,less,well 1.0 0.000143348623853 0 1 -1
is,known,about 1.0 0.000143348623853 0 1 -1
is,involved,in 1.0 0.000716743119266 0 5 -5
is,intricately,associated 1.0 0.000143348623853 0 1 -1
is,initiated,a 1.0 0.000143348623853 0 1 -1
is,indicated,when 1.0 0.000143348623853 0 1 -1
is,indicated,they 1.0 0.000286697247706 0 2 -2
is,indicated,that 1.0 0.000143348623853 0 1 -1
is,indicated,dosing 1.0 0.000143348623853 0 1 -1
is,indicated,because 1.0 0.00043004587156 0 3 -3
is,increased,with 1.0 0.000143348623853 0 1 -1
is,inadequate,systematic 1.0 0.000143348623853 0 1 -1
is,in,cardiovascular 1.0 0.000143348623853 0 1 -1
is,important,when 1.0 0.000143348623853 0 1 -1
is,important,to 1.0 0.000143348623853 0 1 -1
is,important,that 1.0 0.000286697247706 0 2 -2
is,important,for 1.0 0.000286697247706 0 2 -2
is,hydroxylation,catalyzed 1.0 0.000143348623853 0 1 -1
is,however,currently 1.0 0.000143348623853 0 1 -1
is,highly,protein-bound 1.0 0.000143348623853 0 1 -1
is,highly,protein 1.0 0.000286697247706 0 2 -2
is,group,therapy 1.0 0.000143348623853 0 1 -1
is,greatest,in 1.0 0.000286697247706 0 2 -2
is,going,to 1.0 0.000716743119266 0 5 -5
is,given,or 1.0 0.000143348623853 0 1 -1
is,given,in 1.0 0.000143348623853 0 1 -1
is,given,for 1.0 0.000143348623853 0 1 -1
is,given,exclusively 1.0 0.000143348623853 0 1 -1
is,generally,asymptomatic 1.0 0.000143348623853 0 1 -1
is,further,metabolized 1.0 0.000143348623853 0 1 -1
is,frequently,co-administered 1.0 0.000143348623853 0 1 -1
is,frequent,the 1.0 0.000143348623853 0 1 -1
is,found,in 1.0 0.000143348623853 0 1 -1
is,formed,after 1.0 0.000143348623853 0 1 -1
is,followed,by 1.0 0.000143348623853 0 1 -1
is,feasible,and 1.0 0.000143348623853 0 1 -1
is,far,greater 1.0 0.000143348623853 0 1 -1
is,extensively,bound 1.0 0.000143348623853 0 1 -1
is,expected,based 1.0 0.000143348623853 0 1 -1
is,excreted,via 1.0 0.000143348623853 0 1 -1
is,excreted,slowly 1.0 0.000143348623853 0 1 -1
is,excreted,in 1.0 0.000286697247706 0 2 -2
is,evidently,a 1.0 0.000143348623853 0 1 -1
is,evidence,that 1.0 0.000286697247706 0 2 -2
is,essentially,completely 1.0 0.000143348623853 0 1 -1
is,essential,to 1.0 0.000143348623853 0 1 -1
is,essential,the 1.0 0.000143348623853 0 1 -1
is,essential,conduct 1.0 0.000143348623853 0 1 -1
is,essential,close 1.0 0.000143348623853 0 1 -1
is,especially,true 1.0 0.000143348623853 0 1 -1
is,especially,so 1.0 0.000143348623853 0 1 -1
is,erroneous,and 1.0 0.000143348623853 0 1 -1
is,encountered,in 1.0 0.000143348623853 0 1 -1
is,eliminated,in 1.0 0.000143348623853 0 1 -1
is,eliminated,by 1.0 0.000143348623853 0 1 -1
is,either,unchanged 1.0 0.000143348623853 0 1 -1
is,either,initiated 1.0 0.000143348623853 0 1 -1
is,easy,and 1.0 0.000143348623853 0 1 -1
is,difficult,to 1.0 0.000143348623853 0 1 -1
is,desired,this 1.0 0.000143348623853 0 1 -1
is,desirable,to 1.0 0.000716743119266 0 5 -5
is,dependent,upon 1.0 0.000286697247706 0 2 -2
is,dependent,on 1.0 0.000143348623853 0 1 -1
is,demonstrated,for 1.0 0.000143348623853 0 1 -1
is,defined,as 1.0 0.000143348623853 0 1 -1
is,decreasing,according 1.0 0.000143348623853 0 1 -1
is,decreased,reflecting 1.0 0.000573394495413 0 4 -4
is,decreased,in 1.0 0.000143348623853 0 1 -1
is,dealt,with 1.0 0.000143348623853 0 1 -1
is,currently,underway 1.0 0.000143348623853 0 1 -1
is,currently,little 1.0 0.000143348623853 0 1 -1
is,critically,important 1.0 0.000143348623853 0 1 -1
is,critical,for 1.0 0.000143348623853 0 1 -1
is,continued,these 1.0 0.000143348623853 0 1 -1
is,continued,serum 1.0 0.000143348623853 0 1 -1
is,contemplated,the 1.0 0.000716743119266 0 5 -5
is,consistent,with 1.0 0.000143348623853 0 1 -1
is,considered,to 1.0 0.000573394495413 0 4 -4
is,considered,in 1.0 0.000143348623853 0 1 -1
is,considerable,evidence 1.0 0.000143348623853 0 1 -1
is,concurrently,administered 1.0 0.000143348623853 0 1 -1
is,concluded,from 1.0 0.000143348623853 0 1 -1
is,conceived,that 1.0 0.000143348623853 0 1 -1
is,completely,cleared 1.0 0.000143348623853 0 1 -1
is,comparable,to 1.0 0.000143348623853 0 1 -1
is,coadministered,prescribers 1.0 0.000143348623853 0 1 -1
is,co,administered 1.0 0.000143348623853 0 1 -1
is,clinically,significant 1.0 0.000143348623853 0 1 -1
is,clinically,compatible 1.0 0.000143348623853 0 1 -1
is,cleared,primarily 1.0 0.000143348623853 0 1 -1
is,characterised,by 1.0 0.000143348623853 0 1 -1
is,changed,the 1.0 0.000143348623853 0 1 -1
is,catalyzed,by 1.0 0.00043004587156 0 3 -3
is,cas,a 1.0 0.000143348623853 0 1 -1
is,bound,to 1.0 0.000143348623853 0 1 -1
is,both,a 1.0 0.000286697247706 0 2 -2
is,being,developed 1.0 0.000143348623853 0 1 -1
is,begun,in 1.0 0.000143348623853 0 1 -1
is,becoming,increasingly 1.0 0.000143348623853 0 1 -1
is,based,on 1.0 0.000143348623853 0 1 -1
is,available,about 1.0 0.000286697247706 0 2 -2
is,at,the 1.0 0.000143348623853 0 1 -1
is,at,least 1.0 0.00043004587156 0 3 -3
is,assumed,that 1.0 0.000143348623853 0 1 -1
is,associated,with 1.0 0.00043004587156 0 3 -3
is,applicable,across 1.0 0.000143348623853 0 1 -1
is,an,used 1.0 0.000143348623853 0 1 -1
is,an,interactive 1.0 0.000286697247706 0 2 -2
is,an,inhibitor 1.0 0.000716743119266 0 5 -5
is,an,inducer 1.0 0.000143348623853 0 1 -1
is,an,increased 1.0 0.000143348623853 0 1 -1
is,an,effective 1.0 0.000143348623853 0 1 -1
is,an,anion 1.0 0.000143348623853 0 1 -1
is,altered,before 1.0 0.000143348623853 0 1 -1
is,also,to 1.0 0.000143348623853 0 1 -1
is,also,shown 1.0 0.000143348623853 0 1 -1
is,also,prolonged 1.0 0.000143348623853 0 1 -1
is,also,known 1.0 0.000143348623853 0 1 -1
is,also,increased 1.0 0.000143348623853 0 1 -1
is,also,important 1.0 0.000143348623853 0 1 -1
is,also,an 1.0 0.000143348623853 0 1 -1
is,almost,always 1.0 0.000143348623853 0 1 -1
is,advised,to 1.0 0.000286697247706 0 2 -2
is,advised,nonetheless 1.0 0.000143348623853 0 1 -1
is,advised,if 1.0 0.000573394495413 0 4 -4
is,advised,especially 1.0 0.000143348623853 0 1 -1
is,advised,digoxin 1.0 0.000143348623853 0 1 -1
is,advisable,not 1.0 0.000143348623853 0 1 -1
is,administered,together 1.0 0.000143348623853 0 1 -1
is,administered,parenterally 1.0 0.000286697247706 0 2 -2
is,administered,hours 1.0 0.000143348623853 0 1 -1
is,administered,have 1.0 0.000143348623853 0 1 -1
is,administered,before 1.0 0.000143348623853 0 1 -1
is,active,renal 1.0 0.000143348623853 0 1 -1
is,acidified,in 1.0 0.000143348623853 0 1 -1
is,about,times 1.0 0.000143348623853 0 1 -1
is,about,of 1.0 0.000143348623853 0 1 -1
is,a,useful 1.0 0.000143348623853 0 1 -1
is,a,time-dependent 1.0 0.000143348623853 0 1 -1
is,a,substrate 1.0 0.00129013761468 0 9 -9
is,a,study 1.0 0.000143348623853 0 1 -1
is,a,second 1.0 0.000143348623853 0 1 -1
is,a,reversible 1.0 0.000143348623853 0 1 -1
is,a,relatively 1.0 0.000143348623853 0 1 -1
is,a,prostaglandin 1.0 0.000143348623853 0 1 -1
is,a,presynaptic 1.0 0.000143348623853 0 1 -1
is,a,poor 1.0 0.000143348623853 0 1 -1
is,a,pharmacokinetic 1.0 0.000286697247706 0 2 -2
is,a,peptide 1.0 0.000143348623853 0 1 -1
is,a,newly 1.0 0.000143348623853 0 1 -1
is,a,necessary 1.0 0.000143348623853 0 1 -1
is,a,more 1.0 0.000286697247706 0 2 -2
is,a,moderate 1.0 0.000573394495413 0 4 -4
is,a,minor 1.0 0.000286697247706 0 2 -2
is,a,major 1.0 0.00043004587156 0 3 -3
is,a,known 1.0 0.00043004587156 0 3 -3
is,a,high 1.0 0.000143348623853 0 1 -1
is,a,helpful 1.0 0.000143348623853 0 1 -1
is,a,growing 1.0 0.000143348623853 0 1 -1
is,a,frequent 1.0 0.000143348623853 0 1 -1
is,a,decrease 1.0 0.000143348623853 0 1 -1
is,a,d-gal 1.0 0.000143348623853 0 1 -1
is,a,cyp 1.0 0.00043004587156 0 3 -3
is,a,common 1.0 0.000143348623853 0 1 -1
is,a,blocker 1.0 0.000143348623853 0 1 -1
irritation,subjects,received 1.0 0.000143348623853 0 1 -1
irritation,in,some 1.0 0.000143348623853 0 1 -1
irritating,topical,products 1.0 0.000143348623853 0 1 -1
irrespective,of,cause 1.0 0.000143348623853 0 1 -1
irregularities,were,accompanied 1.0 0.000143348623853 0 1 -1
irregularities,have,been 1.0 0.000286697247706 0 2 -2
irradiation,was,delayed 1.0 0.000143348623853 0 1 -1
irradiation,has,not 1.0 0.000143348623853 0 1 -1
irradiation,are,at 1.0 0.000143348623853 0 1 -1
ironing,kilometers,of 1.0 0.000143348623853 0 1 -1
ironically,are,often 1.0 0.000143348623853 0 1 -1
iron-fortified,infant,formula 1.0 0.000143348623853 0 1 -1
iron-fortified,breakfast,cereals 1.0 0.000143348623853 0 1 -1
irinotecan,concentrations,were 1.0 0.000143348623853 0 1 -1
ip,injections,of 1.0 0.000143348623853 0 1 -1
ions,in,platelets 1.0 0.000143348623853 0 1 -1
ions,are,intimately 1.0 0.000143348623853 0 1 -1
ionized,concurrent,treatment 1.0 0.000143348623853 0 1 -1
iodometric,titration,of 1.0 0.000143348623853 0 1 -1
iodine-containing,products,h2-antagonists 1.0 0.000143348623853 0 1 -1
iodine-containing,preparations,and 1.0 0.000143348623853 0 1 -1
iodinated,cholestographic,agents 1.0 0.000143348623853 0 1 -1
iodide,i,and 1.0 0.000143348623853 0 1 -1
involving,six-healthy,male 1.0 0.000143348623853 0 1 -1
involving,otherwise,healthy 1.0 0.000143348623853 0 1 -1
involving,levo-dromoran,reported 1.0 0.000143348623853 0 1 -1
involving,healthy,adults 1.0 0.000143348623853 0 1 -1
involving,even,though 1.0 0.000286697247706 0 2 -2
involving,either,healthy 1.0 0.000143348623853 0 1 -1
involving,concomitant,administration 1.0 0.000143348623853 0 1 -1
involving,adult,volunteers 1.0 0.000143348623853 0 1 -1
involves,depression,anxiety 1.0 0.000143348623853 0 1 -1
involvement,of,reactive 1.0 0.000143348623853 0 1 -1
involvement,labeling,index 1.0 0.000143348623853 0 1 -1
involved,the,administration 1.0 0.000143348623853 0 1 -1
involved,in,the 1.0 0.00100344036697 0 7 -7
involved,in,nociception 1.0 0.000143348623853 0 1 -1
involved,in,metabolism 1.0 0.000143348623853 0 1 -1
involved,in,its 1.0 0.000143348623853 0 1 -1
involved,in,functional 1.0 0.000143348623853 0 1 -1
involved,in,disposition 1.0 0.000143348623853 0 1 -1
involved,in,chemical 1.0 0.000143348623853 0 1 -1
involved,in,both 1.0 0.000143348623853 0 1 -1
involved,in,antiapoptotic 1.0 0.000143348623853 0 1 -1
involved,either,the 1.0 0.000143348623853 0 1 -1
involve,individual,and 1.0 0.000143348623853 0 1 -1
invirase,or,to 1.0 0.000143348623853 0 1 -1
invirase,or,fortovase 1.0 0.000143348623853 0 1 -1
invirase,and,are 1.0 0.000143348623853 0 1 -1
investigator,found,no 1.0 0.000286697247706 0 2 -2
investigations,into,the 1.0 0.000143348623853 0 1 -1
investigations,indicate,that 1.0 0.000143348623853 0 1 -1
investigation,was,undertaken 1.0 0.000143348623853 0 1 -1
investigation,of,chronic 1.0 0.000143348623853 0 1 -1
investigating,possible,interactions 1.0 0.000143348623853 0 1 -1
investigated,whether,these 1.0 0.000143348623853 0 1 -1
investigated,whether,also 1.0 0.000143348623853 0 1 -1
investigated,the,role 1.0 0.000143348623853 0 1 -1
investigated,the,possibility 1.0 0.000143348623853 0 1 -1
investigated,the,mechanism 1.0 0.000143348623853 0 1 -1
investigated,the,effects 1.0 0.000286697247706 0 2 -2
investigated,the,effect 1.0 0.000143348623853 0 1 -1
investigated,simulect,use 1.0 0.000143348623853 0 1 -1
investigated,in,vivo 1.0 0.000143348623853 0 1 -1
investigated,in,the 1.0 0.000286697247706 0 2 -2
investigated,in,patients 1.0 0.000143348623853 0 1 -1
investigated,in,male 1.0 0.000143348623853 0 1 -1
investigated,in,a 1.0 0.000143348623853 0 1 -1
investigated,as,one 1.0 0.000143348623853 0 1 -1
investigated,against,cercariae 1.0 0.000143348623853 0 1 -1
investigate,the,potential 1.0 0.000143348623853 0 1 -1
investigate,the,possibility 1.0 0.000143348623853 0 1 -1
investigate,the,effects 1.0 0.000286697247706 0 2 -2
investigate,the,effect 1.0 0.000143348623853 0 1 -1
inventory,the,profile 1.0 0.000143348623853 0 1 -1
invalidate,folic,acid 1.0 0.000143348623853 0 1 -1
inulin,method,and 1.0 0.000143348623853 0 1 -1
introductory,chapter,discusses 1.0 0.000143348623853 0 1 -1
introduced,atypical,antipsychotic 1.0 0.000143348623853 0 1 -1
intrinsic,value,prescribed 1.0 0.000143348623853 0 1 -1
intricately,associated,with 1.0 0.000143348623853 0 1 -1
intraventricular,and,was 1.0 0.000143348623853 0 1 -1
intraventricular,and,elicit 1.0 0.000143348623853 0 1 -1
intravenously,over,three 1.0 0.000143348623853 0 1 -1
intravenously,or,orally 1.0 0.000143348623853 0 1 -1
intravenously,injected,a 1.0 0.000143348623853 0 1 -1
intravenous,use,were 1.0 0.000143348623853 0 1 -1
intravenous,topical,or 1.0 0.00043004587156 0 3 -3
intravenous,route,may 1.0 0.000143348623853 0 1 -1
intravenous,prodrug,form 1.0 0.000143348623853 0 1 -1
intravenous,prodrug,are 1.0 0.000143348623853 0 1 -1
intravenous,placebo,oral 1.0 0.000143348623853 0 1 -1
intravenous,pentamidine,treatment 1.0 0.000143348623853 0 1 -1
intravenous,mg,x 1.0 0.000143348623853 0 1 -1
intravenous,mg,kg 1.0 0.000143348623853 0 1 -1
intravenous,mg,clo-4 1.0 0.000143348623853 0 1 -1
intravenous,infusion,of 1.0 0.000573394495413 0 4 -4
intravenous,in,ontario 1.0 0.000143348623853 0 1 -1
intravenous,hydration,sodium 1.0 0.000143348623853 0 1 -1
intravenous,has,been 1.0 0.000143348623853 0 1 -1
intravenous,dose,of 1.0 0.000286697247706 0 2 -2
intravenous,bolus,injections 1.0 0.000143348623853 0 1 -1
intravenous,at,mg 1.0 0.000143348623853 0 1 -1
intravenous,application,of 1.0 0.000143348623853 0 1 -1
intravenous,agents,and 1.0 0.000143348623853 0 1 -1
intravenous,administration,the 1.0 0.000143348623853 0 1 -1
intravenous,administration,of 1.0 0.000286697247706 0 2 -2
intravenous,adenocard,has 1.0 0.000143348623853 0 1 -1
intravascular,catabolism,has 1.0 0.000143348623853 0 1 -1
intrathecal,on,the 1.0 0.000143348623853 0 1 -1
intrathecal,on,blocking 1.0 0.000143348623853 0 1 -1
intraperitoneal,injections,of 1.0 0.000143348623853 0 1 -1
intraocular,pressure,may 1.0 0.000143348623853 0 1 -1
intramuscularly,injected,and 1.0 0.000143348623853 0 1 -1
intramuscular,doses,of 1.0 0.000286697247706 0 2 -2
intraluminally,was,only 1.0 0.000143348623853 0 1 -1
intraluminal,concentrations,have 1.0 0.000143348623853 0 1 -1
intracellular,resistance,to 1.0 0.000143348623853 0 1 -1
intracellular,mobilization,of 1.0 0.000143348623853 0 1 -1
intracellular,ca,release 1.0 0.000143348623853 0 1 -1
intracellular,and,extracellular 1.0 0.000143348623853 0 1 -1
intoxication,plasma,levels 1.0 0.000143348623853 0 1 -1
intoxication,appropriate,adjustment 1.0 0.000143348623853 0 1 -1
intoxication,after,administration 1.0 0.000143348623853 0 1 -1
intolerance,prior,to 1.0 0.000143348623853 0 1 -1
intolerance,and,those 1.0 0.000143348623853 0 1 -1
intolerance,and,serum 1.0 0.000143348623853 0 1 -1
into,three,equal 1.0 0.000143348623853 0 1 -1
into,the,effect 1.0 0.000143348623853 0 1 -1
into,the,biogen 1.0 0.000143348623853 0 1 -1
into,question,the 1.0 0.000143348623853 0 1 -1
into,patients,receiving 1.0 0.000143348623853 0 1 -1
into,mice,induced 1.0 0.000143348623853 0 1 -1
into,light,and 1.0 0.000143348623853 0 1 -1
into,consideration,in 1.0 0.000143348623853 0 1 -1
into,consideration,before 1.0 0.000143348623853 0 1 -1
into,account,when 1.0 0.000143348623853 0 1 -1
into,account,variations 1.0 0.000143348623853 0 1 -1
into,account,the 1.0 0.000286697247706 0 2 -2
into,account,for 1.0 0.000143348623853 0 1 -1
into,a,complex 1.0 0.000143348623853 0 1 -1
intimately,related,to 1.0 0.000143348623853 0 1 -1
intestine,kidneys,and 1.0 0.00043004587156 0 3 -3
intestinal,tumors,and 1.0 0.000143348623853 0 1 -1
intestinal,transits,or 1.0 0.000143348623853 0 1 -1
intestinal,permeation,of 1.0 0.000286697247706 0 2 -2
intestinal,mucosa,the 1.0 0.000143348623853 0 1 -1
intestinal,mucosa,mounted 1.0 0.000143348623853 0 1 -1
intestinal,lumen,to 1.0 0.000143348623853 0 1 -1
intestinal,first,pass 1.0 0.000143348623853 0 1 -1
intestinal,carcinogenesis,by 1.0 0.000143348623853 0 1 -1
intestinal,cancers,were 1.0 0.000143348623853 0 1 -1
intestinal,cancers,it 1.0 0.000143348623853 0 1 -1
intestinal,beta-glucuronidase,are 1.0 0.000143348623853 0 1 -1
interventions,each,subject 1.0 0.000143348623853 0 1 -1
intervals,usually,recommended 1.0 0.000143348623853 0 1 -1
intervals,until,the 1.0 0.000286697247706 0 2 -2
intervals,until,stable 1.0 0.000143348623853 0 1 -1
intervals,or,in 1.0 0.000143348623853 0 1 -1
intervals,during,administration 1.0 0.000143348623853 0 1 -1
intervals,caution,should 1.0 0.000143348623853 0 1 -1
intervals,and,no 1.0 0.000143348623853 0 1 -1
interval,were,observed 1.0 0.000143348623853 0 1 -1
interval,were,measured 1.0 0.000143348623853 0 1 -1
interval,prolongation,cardiac 1.0 0.000143348623853 0 1 -1
interval,may,occur 1.0 0.000143348623853 0 1 -1
interval,have,an 1.0 0.000143348623853 0 1 -1
interval,has,elapsed 1.0 0.000143348623853 0 1 -1
interval,for,placebo 1.0 0.000143348623853 0 1 -1
interval,for,coadministration 1.0 0.000143348623853 0 1 -1
interval,decrease,mean 1.0 0.000143348623853 0 1 -1
interval,clinical,laboratory 1.0 0.000143348623853 0 1 -1
interval,caution,should 1.0 0.000143348623853 0 1 -1
interval,between,the 1.0 0.000143348623853 0 1 -1
interval,between,administration 1.0 0.000143348623853 0 1 -1
interval,as,possible 1.0 0.000143348623853 0 1 -1
interval,and,thus 1.0 0.000143348623853 0 1 -1
interval,and,decrease 1.0 0.000143348623853 0 1 -1
interruption,of,tarceva 1.0 0.000143348623853 0 1 -1
interrupted,when,the 1.0 0.000143348623853 0 1 -1
interrupted,or,discontinued 1.0 0.000143348623853 0 1 -1
interrupted,in,order 1.0 0.000143348623853 0 1 -1
interresponse,times,as 1.0 0.000143348623853 0 1 -1
interpreting,the,results 1.0 0.000143348623853 0 1 -1
interpreted,with,caution 1.0 0.000286697247706 0 2 -2
interpreted,cautiously,and 1.0 0.000143348623853 0 1 -1
interpretation,of,t4 1.0 0.000143348623853 0 1 -1
interpretation,of,serum 1.0 0.000143348623853 0 1 -1
interpretation,glucose,and 1.0 0.000143348623853 0 1 -1
international,pharmaceutical,abstracts 1.0 0.000143348623853 0 1 -1
international,literature,between 1.0 0.000143348623853 0 1 -1
internal,application,of 1.0 0.000143348623853 0 1 -1
intermittent,hemodialysis,until 1.0 0.000143348623853 0 1 -1
interindividual,pharmacokinetic,variability 1.0 0.000143348623853 0 1 -1
interferons,such,as 1.0 0.000143348623853 0 1 -1
interferon,induction,tool 1.0 0.000143348623853 0 1 -1
interferon,beta,to 1.0 0.000143348623853 0 1 -1
interferometric,measurement,of 1.0 0.000143348623853 0 1 -1
interferes,with,serum 1.0 0.000143348623853 0 1 -1
interferes,with,nutrition 1.0 0.000143348623853 0 1 -1
interferes,with,clinical 1.0 0.000143348623853 0 1 -1
interferes,with,all 1.0 0.000143348623853 0 1 -1
interferences,dicumarol,and 1.0 0.000143348623853 0 1 -1
interferences,between,solvents 1.0 0.000143348623853 0 1 -1
interferences,and,the 1.0 0.000143348623853 0 1 -1
interference,with,urine 1.0 0.000143348623853 0 1 -1
interference,with,standard 1.0 0.000143348623853 0 1 -1
interference,with,expected 1.0 0.000143348623853 0 1 -1
interference,of,with 1.0 0.000286697247706 0 2 -2
interference,of,biocytin 1.0 0.000143348623853 0 1 -1
interference,may,result 1.0 0.000143348623853 0 1 -1
interference,has,sometimes 1.0 0.000143348623853 0 1 -1
interference,has,resulted 1.0 0.000143348623853 0 1 -1
interference,by,chloral 1.0 0.000143348623853 0 1 -1
interference,between,solvents 1.0 0.000143348623853 0 1 -1
interfere,with,your 1.0 0.000143348623853 0 1 -1
interfere,with,subsequent 1.0 0.000143348623853 0 1 -1
interfere,with,spectrophotometrically 1.0 0.000143348623853 0 1 -1
interfere,with,some 1.0 0.000143348623853 0 1 -1
interfere,with,platelet 1.0 0.00043004587156 0 3 -3
interfere,with,one-stage 1.0 0.000286697247706 0 2 -2
interfere,with,normal 1.0 0.000143348623853 0 1 -1
interfere,with,neuromuscular 1.0 0.000143348623853 0 1 -1
interfere,with,measurement 1.0 0.00043004587156 0 3 -3
interfere,with,laboratory 1.0 0.000143348623853 0 1 -1
interfere,with,hemostasis 1.0 0.000143348623853 0 1 -1
interfere,with,enzymatic-based 1.0 0.000143348623853 0 1 -1
interfere,with,desirable 1.0 0.000143348623853 0 1 -1
interfere,with,cyp2c19 1.0 0.000143348623853 0 1 -1
interfere,with,commonly 1.0 0.00043004587156 0 3 -3
interfere,with,clinical 1.0 0.000143348623853 0 1 -1
interfere,with,cholesterol 1.0 0.000143348623853 0 1 -1
interfere,with,chemical 1.0 0.000143348623853 0 1 -1
interfere,with,bioassay 1.0 0.000143348623853 0 1 -1
interfere,with,biliary 1.0 0.000143348623853 0 1 -1
interfere,with,any 1.0 0.000143348623853 0 1 -1
interest,to,study 1.0 0.000143348623853 0 1 -1
interest,in,administering 1.0 0.000143348623853 0 1 -1
interest,from,a 1.0 0.000143348623853 0 1 -1
intercurrent,use,was 1.0 0.000143348623853 0 1 -1
intercurrent,illnesses,dose 1.0 0.000143348623853 0 1 -1
intercourse,without,using 1.0 0.000143348623853 0 1 -1
intercourse,with,a 1.0 0.000143348623853 0 1 -1
interconversion,between,and 1.0 0.000143348623853 0 1 -1
interacts,with,other 1.0 0.000143348623853 0 1 -1
interacts,with,any 1.0 0.000143348623853 0 1 -1
interactive,effect,on 1.0 0.00043004587156 0 3 -3
interactions,would,not 1.0 0.000286697247706 0 2 -2
interactions,with,the 1.0 0.000143348623853 0 1 -1
interactions,with,that 1.0 0.000143348623853 0 1 -1
interactions,with,systemic 1.0 0.000143348623853 0 1 -1
interactions,with,sustiva 1.0 0.000143348623853 0 1 -1
interactions,with,oral 1.0 0.000143348623853 0 1 -1
interactions,with,noted 1.0 0.000143348623853 0 1 -1
interactions,with,natrecor 1.0 0.000143348623853 0 1 -1
interactions,with,mtx 1.0 0.000143348623853 0 1 -1
interactions,with,metabolized 1.0 0.000286697247706 0 2 -2
interactions,with,mefloquine 1.0 0.000143348623853 0 1 -1
interactions,with,lipid-lowering 1.0 0.000143348623853 0 1 -1
interactions,with,isosorbide 1.0 0.000143348623853 0 1 -1
interactions,with,in 1.0 0.000143348623853 0 1 -1
interactions,with,have 1.0 0.000286697247706 0 2 -2
interactions,with,fruit 1.0 0.000143348623853 0 1 -1
interactions,with,fentanyl 1.0 0.000143348623853 0 1 -1
interactions,with,emtriva 1.0 0.000143348623853 0 1 -1
interactions,with,drugs 1.0 0.000143348623853 0 1 -1
interactions,with,concomitantly 1.0 0.000143348623853 0 1 -1
interactions,with,commonly 1.0 0.000143348623853 0 1 -1
interactions,with,clomiphene 1.0 0.000143348623853 0 1 -1
interactions,when,was 1.0 0.000143348623853 0 1 -1
interactions,when,serious 1.0 0.000143348623853 0 1 -1
interactions,were,studied 1.0 0.000143348623853 0 1 -1
interactions,were,seen 1.0 0.000143348623853 0 1 -1
interactions,were,observed 1.0 0.00043004587156 0 3 -3
interactions,were,noted 1.0 0.000143348623853 0 1 -1
interactions,were,not 1.0 0.000143348623853 0 1 -1
interactions,were,found 1.0 0.000143348623853 0 1 -1
interactions,were,detected 1.0 0.000143348623853 0 1 -1
interactions,were,assessed 1.0 0.000143348623853 0 1 -1
interactions,vardenafil,had 1.0 0.000143348623853 0 1 -1
interactions,use,with 1.0 0.000143348623853 0 1 -1
interactions,under,clinical 1.0 0.000143348623853 0 1 -1
interactions,to,date 1.0 0.000143348623853 0 1 -1
interactions,thiazides,should 1.0 0.000143348623853 0 1 -1
interactions,there,may 1.0 0.000143348623853 0 1 -1
interactions,there,have 1.0 0.000143348623853 0 1 -1
interactions,there,are 1.0 0.00100344036697 0 7 -7
interactions,the,urine 1.0 0.000143348623853 0 1 -1
interactions,the,presence 1.0 0.000143348623853 0 1 -1
interactions,the,pharmacokinetic 1.0 0.000143348623853 0 1 -1
interactions,the,mechanism 1.0 0.000143348623853 0 1 -1
interactions,the,following 1.0 0.000143348623853 0 1 -1
interactions,the,dosage 1.0 0.000143348623853 0 1 -1
interactions,the,bioavailability 1.0 0.000143348623853 0 1 -1
interactions,the,administration 1.0 0.00043004587156 0 3 -3
interactions,that,are 1.0 0.000143348623853 0 1 -1
interactions,should,be 1.0 0.000143348623853 0 1 -1
interactions,serum,salicylate 1.0 0.000143348623853 0 1 -1
interactions,see,clinical 1.0 0.000143348623853 0 1 -1
interactions,resulting,in 1.0 0.000143348623853 0 1 -1
interactions,prolongation,of 1.0 0.000143348623853 0 1 -1
interactions,positive,direct 1.0 0.000143348623853 0 1 -1
interactions,posed,by 1.0 0.000143348623853 0 1 -1
interactions,pi,classified 1.0 0.000143348623853 0 1 -1
interactions,phenytoin,may 1.0 0.000143348623853 0 1 -1
interactions,particularly,in 1.0 0.000143348623853 0 1 -1
interactions,oral,contraceptives 1.0 0.000143348623853 0 1 -1
interactions,on,mean 1.0 0.000143348623853 0 1 -1
interactions,of,taxotere 1.0 0.000143348623853 0 1 -1
interactions,of,herbal 1.0 0.000143348623853 0 1 -1
interactions,of,clolar 1.0 0.000143348623853 0 1 -1
interactions,of,clinical 1.0 0.000286697247706 0 2 -2
interactions,occurred,when 1.0 0.000286697247706 0 2 -2
interactions,noted,above 1.0 0.000143348623853 0 1 -1
interactions,no,pharmacokinetic 1.0 0.000143348623853 0 1 -1
interactions,no,laboratory 1.0 0.000143348623853 0 1 -1
interactions,no,formal 1.0 0.000143348623853 0 1 -1
interactions,no,clinically 1.0 0.00043004587156 0 3 -3
interactions,naproxen,may 1.0 0.000143348623853 0 1 -1
interactions,might,be 1.0 0.000143348623853 0 1 -1
interactions,mediated,by 1.0 0.000286697247706 0 2 -2
interactions,measurement,of 1.0 0.000143348623853 0 1 -1
interactions,may,also 1.0 0.000143348623853 0 1 -1
interactions,listed,below 1.0 0.000143348623853 0 1 -1
interactions,it,is 1.0 0.000143348623853 0 1 -1
interactions,is,summarized 1.0 0.000143348623853 0 1 -1
interactions,is,of 1.0 0.000143348623853 0 1 -1
interactions,interactions,between 1.0 0.000143348623853 0 1 -1
interactions,indicate,that 1.0 0.000143348623853 0 1 -1
interactions,increases,in 1.0 0.000143348623853 0 1 -1
interactions,in,vitro 1.0 0.000143348623853 0 1 -1
interactions,in,individuals 1.0 0.000143348623853 0 1 -1
interactions,in,clinical 1.0 0.000143348623853 0 1 -1
interactions,in,chronic 1.0 0.000143348623853 0 1 -1
interactions,implications,for 1.0 0.000143348623853 0 1 -1
interactions,hyperaminotransferasemia,significant 1.0 0.000143348623853 0 1 -1
interactions,how,to 1.0 0.000143348623853 0 1 -1
interactions,have,yet 1.0 0.000143348623853 0 1 -1
interactions,have,previously 1.0 0.000143348623853 0 1 -1
interactions,have,not 1.0 0.000716743119266 0 5 -5
interactions,have,also 1.0 0.000143348623853 0 1 -1
interactions,has,been 1.0 0.000143348623853 0 1 -1
interactions,general,although 1.0 0.000143348623853 0 1 -1
interactions,frova,is 1.0 0.000143348623853 0 1 -1
interactions,for,any 1.0 0.000143348623853 0 1 -1
interactions,following,administration 1.0 0.000143348623853 0 1 -1
interactions,finasteride,had 1.0 0.000143348623853 0 1 -1
interactions,false,elevations 1.0 0.000143348623853 0 1 -1
interactions,exists,not 1.0 0.000143348623853 0 1 -1
interactions,effect,on 1.0 0.000286697247706 0 2 -2
interactions,due,to 1.0 0.000286697247706 0 2 -2
interactions,dofetilide,is 1.0 0.000143348623853 0 1 -1
interactions,dactinomycin,may 1.0 0.000143348623853 0 1 -1
interactions,could,occur 1.0 0.000143348623853 0 1 -1
interactions,corticosteroids,may 1.0 0.000143348623853 0 1 -1
interactions,clozapine,is 1.0 0.000143348623853 0 1 -1
interactions,cimetidine,concomitant 1.0 0.000143348623853 0 1 -1
interactions,cimetidine,and 1.0 0.000143348623853 0 1 -1
interactions,certain,endocrine 1.0 0.000143348623853 0 1 -1
interactions,certain,could 1.0 0.000143348623853 0 1 -1
interactions,cephalosporins,including 1.0 0.000143348623853 0 1 -1
interactions,cephalosporins,are 1.0 0.000143348623853 0 1 -1
interactions,caused,by 1.0 0.000286697247706 0 2 -2
interactions,by,protein-binding 1.0 0.000143348623853 0 1 -1
interactions,blood,glucose 1.0 0.000143348623853 0 1 -1
interactions,between,vidaza 1.0 0.000143348623853 0 1 -1
interactions,between,uroxatral 1.0 0.000143348623853 0 1 -1
interactions,between,trisenox 1.0 0.000143348623853 0 1 -1
interactions,between,trileptal 1.0 0.000143348623853 0 1 -1
interactions,between,treatments 1.0 0.000143348623853 0 1 -1
interactions,between,these 1.0 0.000143348623853 0 1 -1
interactions,between,theraputic 1.0 0.000143348623853 0 1 -1
interactions,between,the 1.0 0.000143348623853 0 1 -1
interactions,between,taxol 1.0 0.000143348623853 0 1 -1
interactions,between,revia 1.0 0.000143348623853 0 1 -1
interactions,between,oh 1.0 0.000143348623853 0 1 -1
interactions,between,neupogen 1.0 0.000143348623853 0 1 -1
interactions,between,mentax 1.0 0.000143348623853 0 1 -1
interactions,between,keppra 1.0 0.000286697247706 0 2 -2
interactions,between,homopolyribonucleotides 1.0 0.000143348623853 0 1 -1
interactions,between,ellence 1.0 0.000143348623853 0 1 -1
interactions,between,copaxone 1.0 0.000286697247706 0 2 -2
interactions,between,camptosar 1.0 0.000143348623853 0 1 -1
interactions,between,betaseron 1.0 0.000143348623853 0 1 -1
interactions,between,argatroban 1.0 0.000143348623853 0 1 -1
interactions,between,apokyn 1.0 0.000143348623853 0 1 -1
interactions,because,it 1.0 0.000143348623853 0 1 -1
interactions,because,false 1.0 0.000143348623853 0 1 -1
interactions,associated,with 1.0 0.000143348623853 0 1 -1
interactions,as,with 1.0 0.000286697247706 0 2 -2
interactions,as,a 1.0 0.000286697247706 0 2 -2
interactions,are,possible 1.0 0.000143348623853 0 1 -1
interactions,are,not 1.0 0.000143348623853 0 1 -1
interactions,and,socioeconomic 1.0 0.000143348623853 0 1 -1
interactions,and,dosage 1.0 0.000143348623853 0 1 -1
interactions,and,central 1.0 0.000143348623853 0 1 -1
interactions,among,co-administered 1.0 0.000143348623853 0 1 -1
interactions,amerge,tablets 1.0 0.000143348623853 0 1 -1
interactions,alteration,in 1.0 0.000286697247706 0 2 -2
interactions,allows,the 1.0 0.000143348623853 0 1 -1
interactions,acetaminophen,may 1.0 0.000143348623853 0 1 -1
interactions,a,false-positive 1.0 0.00043004587156 0 3 -3
interactions,a,false 1.0 0.000143348623853 0 1 -1
interactions,a,drugs 1.0 0.000143348623853 0 1 -1
interaction,would,occur 1.0 0.000143348623853 0 1 -1
interaction,would,be 1.0 0.000143348623853 0 1 -1
interaction,within,the 1.0 0.000143348623853 0 1 -1
interaction,with,tikosyn 1.0 0.000143348623853 0 1 -1
interaction,with,the 1.0 0.000286697247706 0 2 -2
interaction,with,that 1.0 0.000143348623853 0 1 -1
interaction,with,multiple 1.0 0.000143348623853 0 1 -1
interaction,with,monoamine 1.0 0.000143348623853 0 1 -1
interaction,with,may 1.0 0.000143348623853 0 1 -1
interaction,with,has 1.0 0.000143348623853 0 1 -1
interaction,with,food 1.0 0.000143348623853 0 1 -1
interaction,with,fluoxetine 1.0 0.000143348623853 0 1 -1
interaction,with,erythromycin 1.0 0.000143348623853 0 1 -1
interaction,with,either 1.0 0.000143348623853 0 1 -1
interaction,with,drugs 1.0 0.000286697247706 0 2 -2
interaction,with,concomitant 1.0 0.000143348623853 0 1 -1
interaction,with,central 1.0 0.000143348623853 0 1 -1
interaction,with,affected 1.0 0.000143348623853 0 1 -1
interaction,when,is 1.0 0.000143348623853 0 1 -1
interaction,when,administered 1.0 0.000143348623853 0 1 -1
interaction,was,pharmacodynamic 1.0 0.000286697247706 0 2 -2
interaction,was,observed 1.0 0.000143348623853 0 1 -1
interaction,was,noted 1.0 0.000143348623853 0 1 -1
interaction,was,not 1.0 0.000286697247706 0 2 -2
interaction,trials,have 1.0 0.000143348623853 0 1 -1
interaction,to,patients 1.0 0.000143348623853 0 1 -1
interaction,study,was 1.0 0.00043004587156 0 3 -3
interaction,study,the 1.0 0.000143348623853 0 1 -1
interaction,study,tambocor 1.0 0.000143348623853 0 1 -1
interaction,study,of 1.0 0.00043004587156 0 3 -3
interaction,study,in 1.0 0.000286697247706 0 2 -2
interaction,study,evaluated 1.0 0.000143348623853 0 1 -1
interaction,study,comparing 1.0 0.000143348623853 0 1 -1
interaction,studies,with 1.0 0.00229357798165 0 16 -16
interaction,studies,when 1.0 0.000143348623853 0 1 -1
interaction,studies,other 1.0 0.000143348623853 0 1 -1
interaction,studies,or 1.0 0.000286697247706 0 2 -2
interaction,studies,of 1.0 0.000716743119266 0 5 -5
interaction,studies,no 1.0 0.000143348623853 0 1 -1
interaction,studies,intravenous 1.0 0.000143348623853 0 1 -1
interaction,studies,including 1.0 0.000143348623853 0 1 -1
interaction,studies,in 1.0 0.000860091743119 0 6 -6
interaction,studies,however 1.0 0.000143348623853 0 1 -1
interaction,studies,did 1.0 0.000143348623853 0 1 -1
interaction,studies,demonstrate 1.0 0.000143348623853 0 1 -1
interaction,studies,conducted 1.0 0.000143348623853 0 1 -1
interaction,studies,caution 1.0 0.000143348623853 0 1 -1
interaction,sites,between 1.0 0.000143348623853 0 1 -1
interaction,of,these 1.0 0.000143348623853 0 1 -1
interaction,of,the 1.0 0.000143348623853 0 1 -1
interaction,of,procrit 1.0 0.000143348623853 0 1 -1
interaction,of,levulan 1.0 0.000143348623853 0 1 -1
interaction,of,intramuscularly 1.0 0.000143348623853 0 1 -1
interaction,of,gabitril 1.0 0.000286697247706 0 2 -2
interaction,of,exjade 1.0 0.000143348623853 0 1 -1
interaction,of,aprepitant 1.0 0.000143348623853 0 1 -1
interaction,of,activase 1.0 0.000143348623853 0 1 -1
interaction,occurs,with 1.0 0.000143348623853 0 1 -1
interaction,occurred,when 1.0 0.000143348623853 0 1 -1
interaction,may,result 1.0 0.000143348623853 0 1 -1
interaction,may,occur 1.0 0.000143348623853 0 1 -1
interaction,may,be 1.0 0.00043004587156 0 3 -3
interaction,is,unlikely 1.0 0.000286697247706 0 2 -2
interaction,is,not 1.0 0.000286697247706 0 2 -2
interaction,information,digoxin 1.0 0.000143348623853 0 1 -1
interaction,including,the 1.0 0.000143348623853 0 1 -1
interaction,include,the 1.0 0.000286697247706 0 2 -2
interaction,in,preterm 1.0 0.000143348623853 0 1 -1
interaction,has,been 1.0 0.000286697247706 0 2 -2
interaction,fosinopril,may 1.0 0.000143348623853 0 1 -1
interaction,effects,of 1.0 0.000143348623853 0 1 -1
interaction,during,pregnancy 1.0 0.000143348623853 0 1 -1
interaction,depends,on 1.0 0.000143348623853 0 1 -1
interaction,data,described 1.0 0.00043004587156 0 3 -3
interaction,data,are 1.0 0.000143348623853 0 1 -1
interaction,captopril,may 1.0 0.000143348623853 0 1 -1
interaction,can,the 1.0 0.000143348623853 0 1 -1
interaction,can,potentially 1.0 0.000143348623853 0 1 -1
interaction,between,zdv 1.0 0.000143348623853 0 1 -1
interaction,between,two 1.0 0.000143348623853 0 1 -1
interaction,between,toradoliv 1.0 0.000143348623853 0 1 -1
interaction,between,ssris 1.0 0.000143348623853 0 1 -1
interaction,between,novoseven 1.0 0.000143348623853 0 1 -1
interaction,between,intravenous 1.0 0.000143348623853 0 1 -1
interaction,between,h-spiroperidol 1.0 0.000286697247706 0 2 -2
interaction,between,exogenous 1.0 0.000143348623853 0 1 -1
interaction,between,brevibloc 1.0 0.000143348623853 0 1 -1
interaction,between,both 1.0 0.000143348623853 0 1 -1
interaction,between,a 1.0 0.000143348623853 0 1 -1
interaction,began,within 1.0 0.000143348623853 0 1 -1
interaction,because,xigris 1.0 0.000143348623853 0 1 -1
interaction,at,other 1.0 0.000286697247706 0 2 -2
interaction,as,a 1.0 0.000143348623853 0 1 -1
interaction,appears,to 1.0 0.000286697247706 0 2 -2
interaction,and,potential 1.0 0.000286697247706 0 2 -2
interaction,also,occurs 1.0 0.00043004587156 0 3 -3
interaction,after,treatment 1.0 0.000143348623853 0 1 -1
interacting,with,which 1.0 0.000143348623853 0 1 -1
interacting,which,leads 1.0 0.000143348623853 0 1 -1
interacting,simultaneously,it 1.0 0.000143348623853 0 1 -1
interacting,mechanisms,with 1.0 0.000143348623853 0 1 -1
interact,with,wthionamide 1.0 0.000143348623853 0 1 -1
interact,with,that 1.0 0.000286697247706 0 2 -2
interact,with,skin 1.0 0.000143348623853 0 1 -1
interact,with,other 1.0 0.000573394495413 0 4 -4
interact,with,medication 1.0 0.000143348623853 0 1 -1
interact,with,known 1.0 0.000143348623853 0 1 -1
interact,with,cefamandole 1.0 0.000143348623853 0 1 -1
interact,with,addictive 1.0 0.000143348623853 0 1 -1
interact,synergistically,to 1.0 0.000143348623853 0 1 -1
interact,significantly,with 1.0 0.000143348623853 0 1 -1
interact,altered,hypo-prothrombinemic 1.0 0.000143348623853 0 1 -1
inter-patient,variability,and 1.0 0.000143348623853 0 1 -1
intensive,monitoring,of 1.0 0.000143348623853 0 1 -1
intensive,control,of 1.0 0.000143348623853 0 1 -1
intensive,care,units 1.0 0.000143348623853 0 1 -1
intensity,uniformity,and 1.0 0.000143348623853 0 1 -1
intensify,electrolyte,imbalance 1.0 0.000143348623853 0 1 -1
intensified,electrolyte,depletion 1.0 0.000286697247706 0 2 -2
integrity,of,the 1.0 0.000143348623853 0 1 -1
integrifolia,jackfruit,contain 1.0 0.000143348623853 0 1 -1
integration,the,interaction 1.0 0.000143348623853 0 1 -1
intake,which,only 1.0 0.000143348623853 0 1 -1
intake,of,this 1.0 0.000143348623853 0 1 -1
intake,of,these 1.0 0.000143348623853 0 1 -1
intake,of,supplemental 1.0 0.000143348623853 0 1 -1
intake,of,grapefruit 1.0 0.000143348623853 0 1 -1
intake,of,additional 1.0 0.00043004587156 0 3 -3
intake,and,pharmacological 1.0 0.000143348623853 0 1 -1
intact,subjects,with 1.0 0.000143348623853 0 1 -1
intact,liver,blood 1.0 0.000143348623853 0 1 -1
intables,and,are 1.0 0.000143348623853 0 1 -1
insurances,and,job 1.0 0.000143348623853 0 1 -1
insulins,ability,to 1.0 0.000143348623853 0 1 -1
insulin-sensitizing,effects,of 1.0 0.000143348623853 0 1 -1
insulin-induced,hypoglycemia,and 1.0 0.000143348623853 0 1 -1
insulin-dependent,diabetic,patients 1.0 0.000143348623853 0 1 -1
insulin-dependent,diabetes,mellitus 1.0 0.000143348623853 0 1 -1
insulin,sulfonylureas,requirements 1.0 0.000143348623853 0 1 -1
insulin,requirements,in 1.0 0.000143348623853 0 1 -1
insulin,parameters,were 1.0 0.000143348623853 0 1 -1
insulin,increased,renal 1.0 0.000143348623853 0 1 -1
insulin,a,clinical 1.0 0.000143348623853 0 1 -1
insufficient,intake,which 1.0 0.000143348623853 0 1 -1
insufficiency,was,documented 1.0 0.000143348623853 0 1 -1
insufficiency,resulted,in 1.0 0.000143348623853 0 1 -1
insufficiency,or,those 1.0 0.000143348623853 0 1 -1
insufficiency,or,renal 1.0 0.000143348623853 0 1 -1
insufficiency,in,patients 1.0 0.000143348623853 0 1 -1
insufficiency,especially,in 1.0 0.000143348623853 0 1 -1
insufficiency,are,anticipated 1.0 0.000143348623853 0 1 -1
insufficiency,and,administration 1.0 0.000143348623853 0 1 -1
instructions,for,appropriate 1.0 0.000143348623853 0 1 -1
instructions,and,instructions 1.0 0.000143348623853 0 1 -1
instruct,the,patient 1.0 0.000143348623853 0 1 -1
instances,of,rash 1.0 0.000143348623853 0 1 -1
instances,of,dyspnea 1.0 0.000143348623853 0 1 -1
instances,in,the 1.0 0.000143348623853 0 1 -1
instances,however,and 1.0 0.000143348623853 0 1 -1
instances,has,to 1.0 0.000143348623853 0 1 -1
inspra,should,not 1.0 0.000143348623853 0 1 -1
insp,or,its 1.0 0.000143348623853 0 1 -1
insp,microm,increased 1.0 0.000143348623853 0 1 -1
insp,mediated,responses 1.0 0.000143348623853 0 1 -1
inserts,of,medication 1.0 0.000143348623853 0 1 -1
insertion,of,a 1.0 0.000143348623853 0 1 -1
inserted,between,the 1.0 0.000143348623853 0 1 -1
insertable,hormonal,birth 1.0 0.000143348623853 0 1 -1
insert,of,medication 1.0 0.000143348623853 0 1 -1
insert,labeling,of 1.0 0.000143348623853 0 1 -1
inrifabutin,exposure,and 1.0 0.000143348623853 0 1 -1
inr,were,observed 1.0 0.000143348623853 0 1 -1
inr,was,not 1.0 0.000143348623853 0 1 -1
inr,values,were 1.0 0.000143348623853 0 1 -1
inr,or,due 1.0 0.000143348623853 0 1 -1
inr,or,dose 1.0 0.000143348623853 0 1 -1
inr,determinations,are 1.0 0.000143348623853 0 1 -1
inr,at,the 1.0 0.000143348623853 0 1 -1
inr,and,prothrombin 1.0 0.000143348623853 0 1 -1
input,impedance,and 1.0 0.000143348623853 0 1 -1
inpatient,and,or 1.0 0.000143348623853 0 1 -1
inotropic,and,or 1.0 0.000143348623853 0 1 -1
inositol,trisphosphate-induced,responses 1.0 0.000143348623853 0 1 -1
inositol,trisphosphate,the 1.0 0.000143348623853 0 1 -1
inositol,trisphosphate,insp 1.0 0.000143348623853 0 1 -1
inomax,has,been 1.0 0.000143348623853 0 1 -1
innovar,on,tolerance 1.0 0.000143348623853 0 1 -1
inn,when,coadministered 1.0 0.000143348623853 0 1 -1
injury,should,be 1.0 0.000143348623853 0 1 -1
injury,or,when 1.0 0.000143348623853 0 1 -1
injury,as,manifested 1.0 0.000143348623853 0 1 -1
injectionsite,reaction,injection 1.0 0.000143348623853 0 1 -1
injections,of,trimethyl 1.0 0.000143348623853 0 1 -1
injections,of,saline 1.0 0.000143348623853 0 1 -1
injections,of,or 1.0 0.000143348623853 0 1 -1
injections,of,microg 1.0 0.000143348623853 0 1 -1
injections,of,m 1.0 0.000143348623853 0 1 -1
injections,of,aom 1.0 0.000143348623853 0 1 -1
injections,of,amevive 1.0 0.000143348623853 0 1 -1
injection,who,were 1.0 0.000143348623853 0 1 -1
injection,usp,has 1.0 0.000143348623853 0 1 -1
injection,use,resulted 1.0 0.000143348623853 0 1 -1
injection,there,is 1.0 0.000143348623853 0 1 -1
injection,site,reactions 1.0 0.000143348623853 0 1 -1
injection,site,reaction 1.0 0.000143348623853 0 1 -1
injection,should,not 1.0 0.000143348623853 0 1 -1
injection,should,be 1.0 0.000143348623853 0 1 -1
injection,q12h,for 1.0 0.000143348623853 0 1 -1
injection,produced,some 1.0 0.000143348623853 0 1 -1
injection,of,would 1.0 0.000143348623853 0 1 -1
injection,of,vehicle 1.0 0.000143348623853 0 1 -1
injection,of,these 1.0 0.000143348623853 0 1 -1
injection,of,pcp 1.0 0.000286697247706 0 2 -2
injection,medicine,for 1.0 0.000143348623853 0 1 -1
injection,is,administered 1.0 0.000143348623853 0 1 -1
injected,and,its 1.0 0.000143348623853 0 1 -1
injected,a,chylomicron-like 1.0 0.000143348623853 0 1 -1
injectables,are,adequate 1.0 0.000143348623853 0 1 -1
injectable,implantable,insertable 1.0 0.000143348623853 0 1 -1
initiation,of,soriatane 1.0 0.000143348623853 0 1 -1
initiation,of,or 1.0 0.000143348623853 0 1 -1
initiation,of,lovenox 1.0 0.000143348623853 0 1 -1
initiation,of,hormone 1.0 0.000143348623853 0 1 -1
initiation,of,felbatol 1.0 0.000143348623853 0 1 -1
initiation,of,argatroban 1.0 0.000143348623853 0 1 -1
initiation,is,considered 1.0 0.000143348623853 0 1 -1
initiating,tca,treatment 1.0 0.000573394495413 0 4 -4
initiating,replacement,therapy 1.0 0.000143348623853 0 1 -1
initiated,or,withdrawn 1.0 0.000143348623853 0 1 -1
initiated,or,discontinued 1.0 0.000143348623853 0 1 -1
initiated,cells,that 1.0 0.000143348623853 0 1 -1
initiated,cell,the 1.0 0.000143348623853 0 1 -1
initiated,at,a 1.0 0.000143348623853 0 1 -1
initiated,and,repeated 1.0 0.000143348623853 0 1 -1
initiated,after,cessation 1.0 0.000143348623853 0 1 -1
initiated,a,reduction 1.0 0.000143348623853 0 1 -1
initially,and,returned 1.0 0.000143348623853 0 1 -1
initial,treatment,of 1.0 0.000143348623853 0 1 -1
initial,treatment,occurred 1.0 0.000143348623853 0 1 -1
initial,therapy,with 1.0 0.000143348623853 0 1 -1
initial,step,in 1.0 0.000143348623853 0 1 -1
initial,positive,tests 1.0 0.000143348623853 0 1 -1
initial,or,prolonged 1.0 0.000143348623853 0 1 -1
initial,or,maintenance 1.0 0.000143348623853 0 1 -1
initial,dosing,and 1.0 0.000143348623853 0 1 -1
initial,doses,or 1.0 0.000143348623853 0 1 -1
initial,dose,should 1.0 0.000143348623853 0 1 -1
initial,dose,of 1.0 0.00043004587156 0 3 -3
initial,dose,modification 1.0 0.000143348623853 0 1 -1
initial,dose,for 1.0 0.000143348623853 0 1 -1
initial,clinical,data 1.0 0.000143348623853 0 1 -1
inhibits,the,growth 1.0 0.000143348623853 0 1 -1
inhibits,the,ermbt 1.0 0.000143348623853 0 1 -1
inhibits,the,cytochrome 1.0 0.000143348623853 0 1 -1
inhibits,or,induces 1.0 0.000143348623853 0 1 -1
inhibits,o-glucuronidation,ki 1.0 0.000143348623853 0 1 -1
inhibits,hepatic,enzymes 1.0 0.000143348623853 0 1 -1
inhibits,cyp3a4,cyp2c9 1.0 0.000143348623853 0 1 -1
inhibits,cyp3a4,activity 1.0 0.000143348623853 0 1 -1
inhibits,cyp2d6,is 1.0 0.000143348623853 0 1 -1
inhibits,cyp1a2,weak 1.0 0.000143348623853 0 1 -1
inhibits,cancer,metastasis 1.0 0.000143348623853 0 1 -1
inhibits,c9,c19 1.0 0.000143348623853 0 1 -1
inhibits,adp,and 1.0 0.000143348623853 0 1 -1
inhibitory,towards,the 1.0 0.000143348623853 0 1 -1
inhibitory,potential,of 1.0 0.000143348623853 0 1 -1
inhibitory,or,induction 1.0 0.000143348623853 0 1 -1
inhibitory,interactions,because 1.0 0.000143348623853 0 1 -1
inhibitory,effects,toward 1.0 0.000143348623853 0 1 -1
inhibitory,effects,in 1.0 0.000143348623853 0 1 -1
inhibitory,concentrations,of 1.0 0.000143348623853 0 1 -1
inhibitory,concentrations,mics 1.0 0.000143348623853 0 1 -1
inhibitory,concentration,mic 1.0 0.000143348623853 0 1 -1
inhibitory,concentration,index 1.0 0.000143348623853 0 1 -1
inhibitory,concentration,greater 1.0 0.000143348623853 0 1 -1
inhibitory,concentration,as 1.0 0.000143348623853 0 1 -1
inhibitory,activity,was 1.0 0.000143348623853 0 1 -1
inhibitory,action,of 1.0 0.000286697247706 0 2 -2
inhibitors,without,any 1.0 0.000143348623853 0 1 -1
inhibitors,warning,potential 1.0 0.000143348623853 0 1 -1
inhibitors,to,pms 1.0 0.000143348623853 0 1 -1
inhibitors,the,effect 1.0 0.000143348623853 0 1 -1
inhibitors,ssris,seriraline 1.0 0.000143348623853 0 1 -1
inhibitors,simvastatin,cyp3a4 1.0 0.000143348623853 0 1 -1
inhibitors,serious,side 1.0 0.000143348623853 0 1 -1
inhibitors,protease,inhibitors 1.0 0.000143348623853 0 1 -1
inhibitors,prostaglandin,synthetase 1.0 0.000143348623853 0 1 -1
inhibitors,oral,channel 1.0 0.000143348623853 0 1 -1
inhibitors,or,other 1.0 0.000143348623853 0 1 -1
inhibitors,or,inducers 1.0 0.00100344036697 0 7 -7
inhibitors,or,concomitant 1.0 0.000143348623853 0 1 -1
inhibitors,or,angiotensin 1.0 0.000143348623853 0 1 -1
inhibitors,on,male 1.0 0.000143348623853 0 1 -1
inhibitors,of,these 1.0 0.000286697247706 0 2 -2
inhibitors,of,renal 1.0 0.000143348623853 0 1 -1
inhibitors,of,p450 1.0 0.000286697247706 0 2 -2
inhibitors,of,p-glycoprotein 1.0 0.000143348623853 0 1 -1
inhibitors,of,nor 1.0 0.000143348623853 0 1 -1
inhibitors,of,hmg-coa 1.0 0.000143348623853 0 1 -1
inhibitors,of,either 1.0 0.000143348623853 0 1 -1
inhibitors,of,cyp450 1.0 0.000143348623853 0 1 -1
inhibitors,of,cyp3a4-eplerenone 1.0 0.000143348623853 0 1 -1
inhibitors,of,cyp3a 1.0 0.000143348623853 0 1 -1
inhibitors,nefazodone,cyclosporine 1.0 0.000143348623853 0 1 -1
inhibitors,monoamine,oxidase 1.0 0.000143348623853 0 1 -1
inhibitors,may,cause 1.0 0.000143348623853 0 1 -1
inhibitors,mao,inhibitors 1.0 0.000143348623853 0 1 -1
inhibitors,macrolide,antibiotics 1.0 0.000143348623853 0 1 -1
inhibitors,it,is 1.0 0.000143348623853 0 1 -1
inhibitors,intravenous,and 1.0 0.000143348623853 0 1 -1
inhibitors,interfere,with 1.0 0.000143348623853 0 1 -1
inhibitors,inhibitors,of 1.0 0.000143348623853 0 1 -1
inhibitors,including,acetylsalicylic 1.0 0.000143348623853 0 1 -1
inhibitors,include,azole 1.0 0.000143348623853 0 1 -1
inhibitors,in,subjects 1.0 0.000143348623853 0 1 -1
inhibitors,has,not 1.0 0.000143348623853 0 1 -1
inhibitors,guanethidine,or 1.0 0.000143348623853 0 1 -1
inhibitors,for,most 1.0 0.000143348623853 0 1 -1
inhibitors,felodipine,is 1.0 0.000143348623853 0 1 -1
inhibitors,elevated,blood 1.0 0.000143348623853 0 1 -1
inhibitors,eg,grapefruit 1.0 0.000143348623853 0 1 -1
inhibitors,dasatinib,is 1.0 0.000143348623853 0 1 -1
inhibitors,concomitantly,should 1.0 0.000143348623853 0 1 -1
inhibitors,concomitant,use 1.0 0.000286697247706 0 2 -2
inhibitors,calcium-channel,blockers 1.0 0.000143348623853 0 1 -1
inhibitors,but,which 1.0 0.000143348623853 0 1 -1
inhibitors,beta,blockers 1.0 0.000143348623853 0 1 -1
inhibitors,atomoxetine,is 1.0 0.000143348623853 0 1 -1
inhibitors,as,systemic 1.0 0.000143348623853 0 1 -1
inhibitors,are,known 1.0 0.000143348623853 0 1 -1
inhibitors,and,which 1.0 0.000143348623853 0 1 -1
inhibitors,and,various 1.0 0.000143348623853 0 1 -1
inhibitors,and,should 1.0 0.000143348623853 0 1 -1
inhibitors,and,others 1.0 0.000286697247706 0 2 -2
inhibitors,and,one 1.0 0.000143348623853 0 1 -1
inhibitors,and,leading 1.0 0.000143348623853 0 1 -1
inhibitors,and,inducers 1.0 0.000143348623853 0 1 -1
inhibitors,and,cyp1a2 1.0 0.000143348623853 0 1 -1
inhibitors,and,both 1.0 0.000143348623853 0 1 -1
inhibitors,and,agents 1.0 0.000143348623853 0 1 -1
inhibitors,also,referred 1.0 0.000143348623853 0 1 -1
inhibitors,acetylsalicylic,acid 1.0 0.000143348623853 0 1 -1
inhibitor,to,prevent 1.0 0.000143348623853 0 1 -1
inhibitor,to,be 1.0 0.000143348623853 0 1 -1
inhibitor,talk,to 1.0 0.000143348623853 0 1 -1
inhibitor,resulted,in 1.0 0.000143348623853 0 1 -1
inhibitor,pi,related 1.0 0.000143348623853 0 1 -1
inhibitor,or,channel 1.0 0.000143348623853 0 1 -1
inhibitor,on,the 1.0 0.000143348623853 0 1 -1
inhibitor,of,cyp3a 1.0 0.000143348623853 0 1 -1
inhibitor,of,cyp2c9 1.0 0.000143348623853 0 1 -1
inhibitor,of,cyp 1.0 0.000286697247706 0 2 -2
inhibitor,of,cyclic 1.0 0.000143348623853 0 1 -1
inhibitor,of,breast 1.0 0.000143348623853 0 1 -1
inhibitor,of,any 1.0 0.000143348623853 0 1 -1
inhibitor,of,aldehyde 1.0 0.000143348623853 0 1 -1
inhibitor,nnrti,based 1.0 0.000143348623853 0 1 -1
inhibitor,maoi,such 1.0 0.000143348623853 0 1 -1
inhibitor,is,withdrawn 1.0 0.000286697247706 0 2 -2
inhibitor,in,two 1.0 0.000143348623853 0 1 -1
inhibitor,hydrogen-3,revealed 1.0 0.000143348623853 0 1 -1
inhibitor,however,and 1.0 0.000143348623853 0 1 -1
inhibitor,due,to 1.0 0.000143348623853 0 1 -1
inhibitor,does,not 1.0 0.000143348623853 0 1 -1
inhibitor,being,used 1.0 0.000143348623853 0 1 -1
inhibitor,because,of 1.0 0.000143348623853 0 1 -1
inhibitor,at,steady 1.0 0.000143348623853 0 1 -1
inhibitor,and,an 1.0 0.000143348623853 0 1 -1
inhibitor,added,in 1.0 0.000143348623853 0 1 -1
inhibition,while,gallic 1.0 0.000143348623853 0 1 -1
inhibition,was,observed 1.0 0.000143348623853 0 1 -1
inhibition,of,this 1.0 0.000143348623853 0 1 -1
inhibition,of,these 1.0 0.000143348623853 0 1 -1
inhibition,of,p-glycoprotein 1.0 0.000143348623853 0 1 -1
inhibition,of,other 1.0 0.000143348623853 0 1 -1
inhibition,of,on 1.0 0.000143348623853 0 1 -1
inhibition,of,isoform 1.0 0.000143348623853 0 1 -1
inhibition,of,gastric 1.0 0.000143348623853 0 1 -1
inhibition,of,fibrinolysis 1.0 0.000143348623853 0 1 -1
inhibition,of,cytochrome 1.0 0.00043004587156 0 3 -3
inhibition,of,cyp3a4 1.0 0.000143348623853 0 1 -1
inhibition,of,cyp-2c19 1.0 0.000143348623853 0 1 -1
inhibition,of,cyp 1.0 0.000286697247706 0 2 -2
inhibition,of,cholino- 1.0 0.000143348623853 0 1 -1
inhibition,of,ca 1.0 0.000143348623853 0 1 -1
inhibition,of,both 1.0 0.000286697247706 0 2 -2
inhibition,of,arachidonate- 1.0 0.000143348623853 0 1 -1
inhibition,of,any 1.0 0.000143348623853 0 1 -1
inhibition,of,a 1.0 0.000143348623853 0 1 -1
inhibition,linezolid,is 1.0 0.000143348623853 0 1 -1
inhibition,inhibition,at 1.0 0.000143348623853 0 1 -1
inhibition,in,platelet 1.0 0.000143348623853 0 1 -1
inhibition,can,result 1.0 0.000143348623853 0 1 -1
inhibition,at,microm 1.0 0.000143348623853 0 1 -1
inhibition,and,suggest 1.0 0.000143348623853 0 1 -1
inhibition,and,stimulation 1.0 0.000143348623853 0 1 -1
inhibiting,effects,of 1.0 0.000143348623853 0 1 -1
inhibiting,cyp3a,to 1.0 0.000143348623853 0 1 -1
inhibiting,activity,against 1.0 0.000143348623853 0 1 -1
inhibited,to,an 1.0 0.000143348623853 0 1 -1
inhibited,the,cyp 1.0 0.000143348623853 0 1 -1
inhibited,in,vitro 1.0 0.000143348623853 0 1 -1
inhibited,high,threshold 1.0 0.000143348623853 0 1 -1
inhibited,gastric,acid 1.0 0.000143348623853 0 1 -1
inhibited,cyp,enzymes 1.0 0.000143348623853 0 1 -1
inhibited,by,some 1.0 0.000143348623853 0 1 -1
inhibited,by,mug 1.0 0.000286697247706 0 2 -2
inhibited,by,ergosterol 1.0 0.000143348623853 0 1 -1
inhibited,by,concentrations 1.0 0.000143348623853 0 1 -1
inhibited,by,added 1.0 0.000143348623853 0 1 -1
inhibited,at,a 1.0 0.000143348623853 0 1 -1
inhibit,this,metabolic 1.0 0.000143348623853 0 1 -1
inhibit,these,isoenzymes 1.0 0.000143348623853 0 1 -1
inhibit,the,production 1.0 0.000143348623853 0 1 -1
inhibit,the,major 1.0 0.000286697247706 0 2 -2
inhibit,the,following 1.0 0.000143348623853 0 1 -1
inhibit,the,cyp450 1.0 0.000143348623853 0 1 -1
inhibit,the,biotransformation 1.0 0.000143348623853 0 1 -1
inhibit,the,antitumor 1.0 0.000143348623853 0 1 -1
inhibit,the,activity 1.0 0.00143348623853 0 10 -10
inhibit,platelet,activation 1.0 0.000143348623853 0 1 -1
inhibit,pgp,increased 1.0 0.000143348623853 0 1 -1
inhibit,p450,d6 1.0 0.000716743119266 0 5 -5
inhibit,p450,a6 1.0 0.000143348623853 0 1 -1
inhibit,p-glycoprotein,mediated 1.0 0.000143348623853 0 1 -1
inhibit,or,induce 1.0 0.000716743119266 0 5 -5
inhibit,neuronal,reuptake 1.0 0.000143348623853 0 1 -1
inhibit,metabolism,via 1.0 0.000143348623853 0 1 -1
inhibit,metabolism,mediated 1.0 0.000143348623853 0 1 -1
inhibit,k,epoxide 1.0 0.000143348623853 0 1 -1
inhibit,high,threshold 1.0 0.000143348623853 0 1 -1
inhibit,gastrointestinal,absorption 1.0 0.000143348623853 0 1 -1
inhibit,drug,transport 1.0 0.000143348623853 0 1 -1
inhibit,cytochrome,p450 1.0 0.00157683486239 0 11 -11
inhibit,cyps,a2 1.0 0.000143348623853 0 1 -1
inhibit,cyp450s,cyp1a2 1.0 0.000143348623853 0 1 -1
inhibit,cyp3a4,to 1.0 0.000143348623853 0 1 -1
inhibit,cyp3a4,may 1.0 0.000143348623853 0 1 -1
inhibit,cyp3a4,ketoconazole 1.0 0.000143348623853 0 1 -1
inhibit,cyp3a4,cyp3a4 1.0 0.000143348623853 0 1 -1
inhibit,cyp3a4,activity 1.0 0.000143348623853 0 1 -1
inhibit,cyp3a,may 1.0 0.000143348623853 0 1 -1
inhibit,cyp2e1,but 1.0 0.000143348623853 0 1 -1
inhibit,cyp2d6,cyp1a2 1.0 0.000143348623853 0 1 -1
inhibit,cyp2d6,and 1.0 0.000143348623853 0 1 -1
inhibit,cyp2c19,and 1.0 0.000143348623853 0 1 -1
inhibit,cyp1a2,or 1.0 0.000143348623853 0 1 -1
inhibit,cyp,enzymes 1.0 0.000143348623853 0 1 -1
inhibit,c9,should 1.0 0.000143348623853 0 1 -1
inhibit,alprazolam,metabolism 1.0 0.000143348623853 0 1 -1
inhibit,aldehyde,oxidase 1.0 0.000143348623853 0 1 -1
inhaled,with,no 1.0 0.000143348623853 0 1 -1
inhaled,such,as 1.0 0.000143348623853 0 1 -1
inhaled,medications,should 1.0 0.000143348623853 0 1 -1
inhaled,and,or 1.0 0.000143348623853 0 1 -1
inhalations,than,usual 1.0 0.000143348623853 0 1 -1
inhalational,muscle,relaxants 1.0 0.000143348623853 0 1 -1
inhalation,device,and 1.0 0.000143348623853 0 1 -1
inhalation,aerosol,has 1.0 0.000143348623853 0 1 -1
inhalation,aerosol,and 1.0 0.000143348623853 0 1 -1
ingredient,of,the 1.0 0.000143348623853 0 1 -1
ingestion,should,be 1.0 0.000143348623853 0 1 -1
ingestion,of,grapefruit 1.0 0.000143348623853 0 1 -1
ingesting,the,steadystate 1.0 0.000143348623853 0 1 -1
ingested,or,from 1.0 0.000143348623853 0 1 -1
infusions,of,flolan 1.0 0.000143348623853 0 1 -1
infusions,of,activase 1.0 0.000143348623853 0 1 -1
infusions,must,be 1.0 0.000143348623853 0 1 -1
infusions,can,only 1.0 0.000143348623853 0 1 -1
infusion,was,continued 1.0 0.000143348623853 0 1 -1
infusion,to,maintain 1.0 0.000143348623853 0 1 -1
infusion,than,with 1.0 0.000143348623853 0 1 -1
infusion,solutions,until 1.0 0.000143348623853 0 1 -1
infusion,site,for 1.0 0.000143348623853 0 1 -1
infusion,reactions,compared 1.0 0.000143348623853 0 1 -1
infusion,rate,requirement 1.0 0.000143348623853 0 1 -1
infusion,pumps,for 1.0 0.000143348623853 0 1 -1
infusion,or,was 1.0 0.000143348623853 0 1 -1
infusion,of,had 1.0 0.000143348623853 0 1 -1
infusion,of,amicar 1.0 0.000143348623853 0 1 -1
infusion,of,alone 1.0 0.000143348623853 0 1 -1
infusion,in,horses 1.0 0.000143348623853 0 1 -1
infused,over,minutes 1.0 0.000143348623853 0 1 -1
infrequent,reports,of 1.0 0.000143348623853 0 1 -1
informed,when,a 1.0 0.000143348623853 0 1 -1
informed,that,the 1.0 0.000143348623853 0 1 -1
information,was,obtained 1.0 0.000286697247706 0 2 -2
information,to,the 1.0 0.000143348623853 0 1 -1
information,to,be 1.0 0.000143348623853 0 1 -1
information,that,can 1.0 0.000143348623853 0 1 -1
information,should,be 1.0 0.000143348623853 0 1 -1
information,regarding,the 1.0 0.000143348623853 0 1 -1
information,processing,functions 1.0 0.000143348623853 0 1 -1
information,on,the 1.0 0.000286697247706 0 2 -2
information,on,precautions 1.0 0.000143348623853 0 1 -1
information,on,how 1.0 0.000143348623853 0 1 -1
information,on,efficacy 1.0 0.000143348623853 0 1 -1
information,on,concurrent 1.0 0.000143348623853 0 1 -1
information,on,concomitant 1.0 0.000143348623853 0 1 -1
information,is,available 1.0 0.000286697247706 0 2 -2
information,for,the 1.0 0.00043004587156 0 3 -3
information,for,regarding 1.0 0.000143348623853 0 1 -1
information,digoxin,studies 1.0 0.000143348623853 0 1 -1
information,concerning,laboratory 1.0 0.000143348623853 0 1 -1
information,assists,in 1.0 0.000143348623853 0 1 -1
influenced,the,pharmacodynamics 1.0 0.000143348623853 0 1 -1
influence,through,the 1.0 0.000143348623853 0 1 -1
influence,the,response 1.0 0.000143348623853 0 1 -1
influence,the,pharmacokinetics 1.0 0.00043004587156 0 3 -3
influence,the,hypoprothrombinemia 1.0 0.000143348623853 0 1 -1
influence,the,development 1.0 0.000143348623853 0 1 -1
influence,the,bioavailability 1.0 0.000143348623853 0 1 -1
influence,serum,concentrations 1.0 0.000143348623853 0 1 -1
influence,recovery,time 1.0 0.000143348623853 0 1 -1
influence,on,the 1.0 0.000286697247706 0 2 -2
influence,of,trileptal 1.0 0.000143348623853 0 1 -1
influence,of,the 1.0 0.000286697247706 0 2 -2
influence,of,sympatholytic 1.0 0.000286697247706 0 2 -2
influence,of,coadministration 1.0 0.000143348623853 0 1 -1
influence,of,calcium-channel 1.0 0.000143348623853 0 1 -1
influence,of,angiotensin 1.0 0.000143348623853 0 1 -1
influence,of,and 1.0 0.000286697247706 0 2 -2
influence,of,aed 1.0 0.000143348623853 0 1 -1
influence,limbic,integration 1.0 0.000143348623853 0 1 -1
influence,in,vitro 1.0 0.000143348623853 0 1 -1
inflammatory,recall,reaction 1.0 0.000143348623853 0 1 -1
inflammation,is,an 1.0 0.000143348623853 0 1 -1
infinity,auc,and 1.0 0.000143348623853 0 1 -1
infiltration,of,perivascular 1.0 0.000143348623853 0 1 -1
inferior,mesenteric,ganglion 1.0 0.000143348623853 0 1 -1
inference,is,that 1.0 0.000143348623853 0 1 -1
infectious,complications,that 1.0 0.000143348623853 0 1 -1
infections,have,not 1.0 0.000143348623853 0 1 -1
infections,caused,by 1.0 0.000143348623853 0 1 -1
infections,because,it 1.0 0.000143348623853 0 1 -1
infections,and,certain 1.0 0.000143348623853 0 1 -1
infection,with,this 1.0 0.000143348623853 0 1 -1
infection,oi,rates 1.0 0.000143348623853 0 1 -1
infection,is,generally 1.0 0.000143348623853 0 1 -1
infection,is,dealt 1.0 0.000143348623853 0 1 -1
infection,and,produce 1.0 0.000143348623853 0 1 -1
infarction,there,may 1.0 0.000143348623853 0 1 -1
infarction,patients,who 1.0 0.000143348623853 0 1 -1
infarction,liver,disease 1.0 0.000143348623853 0 1 -1
infarction,in,ephesus 1.0 0.000143348623853 0 1 -1
infarction,during,sexual 1.0 0.000143348623853 0 1 -1
infants,which,are 1.0 0.000143348623853 0 1 -1
infants,has,specifically 1.0 0.000143348623853 0 1 -1
infants,from,amevive 1.0 0.000143348623853 0 1 -1
infants,a,decision 1.0 0.000286697247706 0 2 -2
infant,has,not 1.0 0.000143348623853 0 1 -1
infant,formula,mg 1.0 0.000143348623853 0 1 -1
ineffective,in,preventing 1.0 0.000143348623853 0 1 -1
ineffective,in,altering 1.0 0.000143348623853 0 1 -1
industrial,workers,involved 1.0 0.000143348623853 0 1 -1
induration,skin,exfoliation 1.0 0.000143348623853 0 1 -1
induction,tool,for 1.0 0.000143348623853 0 1 -1
induction,potential,should 1.0 0.000286697247706 0 2 -2
induction,potential,on 1.0 0.000143348623853 0 1 -1
induction,or,inhibition 1.0 0.000286697247706 0 2 -2
induction,of,tumors 1.0 0.000143348623853 0 1 -1
induction,of,such 1.0 0.000143348623853 0 1 -1
induction,of,phosphorylation 1.0 0.000143348623853 0 1 -1
induction,of,its 1.0 0.000143348623853 0 1 -1
induction,of,cytochrome 1.0 0.000143348623853 0 1 -1
induction,of,apoptosis 1.0 0.000143348623853 0 1 -1
induction,data,obtained 1.0 0.000143348623853 0 1 -1
induction,by,a 1.0 0.000143348623853 0 1 -1
inducing,activity,should 1.0 0.000143348623853 0 1 -1
inducible,vana,antisense 1.0 0.000143348623853 0 1 -1
induces,the,cytochrome 1.0 0.000143348623853 0 1 -1
induces,or,inhibits 1.0 0.000143348623853 0 1 -1
induces,or,does 1.0 0.000143348623853 0 1 -1
induces,apoptosis,in 1.0 0.000143348623853 0 1 -1
induces,a,more 1.0 0.000143348623853 0 1 -1
inducers,or,inhibitors 1.0 0.000143348623853 0 1 -1
inducers,of,these 1.0 0.000143348623853 0 1 -1
inducers,of,the 1.0 0.000143348623853 0 1 -1
inducers,of,hepatic 1.0 0.000143348623853 0 1 -1
inducers,may,decrease 1.0 0.000143348623853 0 1 -1
inducers,iodinated,cholestographic 1.0 0.000143348623853 0 1 -1
inducers,include,but 1.0 0.000143348623853 0 1 -1
inducers,eg,are 1.0 0.000143348623853 0 1 -1
inducers,drugs,that 1.0 0.000143348623853 0 1 -1
inducers,cyp3a4,inducers 1.0 0.000143348623853 0 1 -1
inducers,are,unlikely 1.0 0.000143348623853 0 1 -1
inducers,are,indicated 1.0 0.000143348623853 0 1 -1
inducers,and,cyp1a2 1.0 0.000143348623853 0 1 -1
inducer,such,as 1.0 0.000143348623853 0 1 -1
inducer,of,udp-glucuronyl 1.0 0.000143348623853 0 1 -1
inducer,of,microsomal 1.0 0.000143348623853 0 1 -1
inducer,of,drug-metabolizing 1.0 0.000143348623853 0 1 -1
inducer,of,cyp3a4 1.0 0.000143348623853 0 1 -1
inducer,although,not 1.0 0.000143348623853 0 1 -1
inducer,a,dose 1.0 0.000143348623853 0 1 -1
induced,therapeutic,hypermagnesaemia 1.0 0.000143348623853 0 1 -1
induced,skin,wheals 1.0 0.000143348623853 0 1 -1
induced,significant,alterations 1.0 0.000143348623853 0 1 -1
induced,resulting,in 1.0 0.000143348623853 0 1 -1
induced,responses,were 1.0 0.000143348623853 0 1 -1
induced,lower,locomotor 1.0 0.000143348623853 0 1 -1
induced,locomotion,and 1.0 0.000143348623853 0 1 -1
induced,in,mcf-7 1.0 0.000143348623853 0 1 -1
induced,hypotension,because 1.0 0.000143348623853 0 1 -1
induced,hypertension,were 1.0 0.000143348623853 0 1 -1
induced,diarrhea,was 1.0 0.000143348623853 0 1 -1
induced,diarrhea,but 1.0 0.000143348623853 0 1 -1
induced,concentration-dependent,relaxation 1.0 0.000143348623853 0 1 -1
induced,by,suggest 1.0 0.000143348623853 0 1 -1
induced,by,serum 1.0 0.000143348623853 0 1 -1
induced,by,pcp 1.0 0.000143348623853 0 1 -1
induced,by,nonlethal 1.0 0.000143348623853 0 1 -1
induced,by,meth 1.0 0.000143348623853 0 1 -1
induced,by,concomitant 1.0 0.000143348623853 0 1 -1
induced,by,aom 1.0 0.000143348623853 0 1 -1
induced,by,administration 1.0 0.000143348623853 0 1 -1
induced,by,acute 1.0 0.000143348623853 0 1 -1
induced,by,a 1.0 0.000286697247706 0 2 -2
induced,arc,mrna 1.0 0.000143348623853 0 1 -1
induced,a,watery 1.0 0.000143348623853 0 1 -1
induced,a,soft 1.0 0.000143348623853 0 1 -1
induce,toxicity,since 1.0 0.000143348623853 0 1 -1
induce,the,major 1.0 0.000143348623853 0 1 -1
induce,the,cyp3a4 1.0 0.000143348623853 0 1 -1
induce,p-450iie1,a 1.0 0.000143348623853 0 1 -1
induce,or,inhibit 1.0 0.000286697247706 0 2 -2
induce,metabolic,enzymes 1.0 0.000143348623853 0 1 -1
induce,hypercalcemia,by 1.0 0.00043004587156 0 3 -3
induce,early,and 1.0 0.000143348623853 0 1 -1
induce,cytochromes,particularly 1.0 0.000143348623853 0 1 -1
induce,cyp3a4,with 1.0 0.000143348623853 0 1 -1
induce,cyp3a4,rifampin 1.0 0.000143348623853 0 1 -1
induce,cyp3a,may 1.0 0.000143348623853 0 1 -1
induce,cyp1a2,activity 1.0 0.000143348623853 0 1 -1
induce,cyp,enzymes 1.0 0.000143348623853 0 1 -1
induce,cyp,d6 1.0 0.000143348623853 0 1 -1
induce,both,hyperthyroidism 1.0 0.000143348623853 0 1 -1
induce,an,inflammatory 1.0 0.000143348623853 0 1 -1
induce,abnormalities,in 1.0 0.000143348623853 0 1 -1
induce,a4,activity 1.0 0.000143348623853 0 1 -1
induce,a,subgroup 1.0 0.000143348623853 0 1 -1
induce,a,positive 1.0 0.00043004587156 0 3 -3
indomethacin,was,also 1.0 0.000143348623853 0 1 -1
indomethacin,may,also 1.0 0.000143348623853 0 1 -1
indomethacin,are,used 1.0 0.000143348623853 0 1 -1
indocyanine,green,as 1.0 0.000143348623853 0 1 -1
indocin,relafen,daypro 1.0 0.000143348623853 0 1 -1
indocin,reduces,basal 1.0 0.000143348623853 0 1 -1
indocin,may,produce 1.0 0.000143348623853 0 1 -1
indocin,does,not 1.0 0.000143348623853 0 1 -1
indocin,are,made 1.0 0.000143348623853 0 1 -1
individuals,with,a 1.0 0.000143348623853 0 1 -1
individuals,who,consume 1.0 0.000143348623853 0 1 -1
individuals,were,treated 1.0 0.000143348623853 0 1 -1
individuals,may,have 1.0 0.000143348623853 0 1 -1
individuals,may,develop 1.0 0.000143348623853 0 1 -1
individuals,known,or 1.0 0.000143348623853 0 1 -1
individuals,discontinuing,in 1.0 0.000143348623853 0 1 -1
individuals,because,of 1.0 0.000143348623853 0 1 -1
individuals,are,referred 1.0 0.000286697247706 0 2 -2
individualizing,it,as 1.0 0.000143348623853 0 1 -1
individualized,when,patients 1.0 0.000143348623853 0 1 -1
individualized,fixed,daily 1.0 0.000143348623853 0 1 -1
individual,who,is 1.0 0.000716743119266 0 5 -5
individual,simulect,clearance 1.0 0.000143348623853 0 1 -1
individual,patient,response 1.0 0.000143348623853 0 1 -1
individual,levels,fluctuated 1.0 0.000143348623853 0 1 -1
individual,isoform,is 1.0 0.000143348623853 0 1 -1
individual,inr,values 1.0 0.000143348623853 0 1 -1
individual,compounds,rather 1.0 0.000143348623853 0 1 -1
individual,cases,is 1.0 0.000143348623853 0 1 -1
individual,case,to 1.0 0.000143348623853 0 1 -1
individual,and,joint 1.0 0.000143348623853 0 1 -1
individual,and,family 1.0 0.000143348623853 0 1 -1
individual,and,combined 1.0 0.000143348623853 0 1 -1
indirect,antiglobulin,coombs 1.0 0.000143348623853 0 1 -1
indinavir-based,regimens,has 1.0 0.000143348623853 0 1 -1
indinavir,is,metabolized 1.0 0.000143348623853 0 1 -1
indinavir,is,an 1.0 0.000143348623853 0 1 -1
indices,should,be 1.0 0.000286697247706 0 2 -2
indicators,differs,from 1.0 0.000143348623853 0 1 -1
indications,use,instructions 1.0 0.000143348623853 0 1 -1
indications,specific,for 1.0 0.000143348623853 0 1 -1
indications,of,the 1.0 0.000143348623853 0 1 -1
indications,for,and 1.0 0.000143348623853 0 1 -1
indications,are,eclampsia 1.0 0.000143348623853 0 1 -1
indications,and,the 1.0 0.000143348623853 0 1 -1
indication,of,physiological 1.0 0.000143348623853 0 1 -1
indicating,that,this 1.0 0.000143348623853 0 1 -1
indicating,that,the 1.0 0.000143348623853 0 1 -1
indicating,that,several 1.0 0.000143348623853 0 1 -1
indicating,that,impairment 1.0 0.000143348623853 0 1 -1
indicating,no,potential 1.0 0.000143348623853 0 1 -1
indicating,no,change 1.0 0.000143348623853 0 1 -1
indicating,induction,of 1.0 0.000143348623853 0 1 -1
indicating,an,action 1.0 0.000143348623853 0 1 -1
indicates,that,this 1.0 0.000143348623853 0 1 -1
indicates,that,the 1.0 0.000143348623853 0 1 -1
indicates,that,does 1.0 0.000286697247706 0 2 -2
indicates,that,a 1.0 0.000143348623853 0 1 -1
indicates,either,poor 1.0 0.000143348623853 0 1 -1
indicates,deterioration,of 1.0 0.000143348623853 0 1 -1
indicated,when,is 1.0 0.000143348623853 0 1 -1
indicated,they,should 1.0 0.000286697247706 0 2 -2
indicated,the,presence 1.0 0.000143348623853 0 1 -1
indicated,that,there 1.0 0.000286697247706 0 2 -2
indicated,that,the 1.0 0.000286697247706 0 2 -2
indicated,that,pulmozyme 1.0 0.000143348623853 0 1 -1
indicated,that,may 1.0 0.000143348623853 0 1 -1
indicated,that,hydrochloride 1.0 0.000143348623853 0 1 -1
indicated,that,epa 1.0 0.000143348623853 0 1 -1
indicated,that,cyp3a4 1.0 0.000143348623853 0 1 -1
indicated,in,patients 1.0 0.000143348623853 0 1 -1
indicated,dosing,should 1.0 0.000143348623853 0 1 -1
indicated,by,the 1.0 0.000143348623853 0 1 -1
indicated,by,a 1.0 0.000143348623853 0 1 -1
indicated,because,of 1.0 0.00043004587156 0 3 -3
indicated,alternative,therapeutic 1.0 0.000143348623853 0 1 -1
indicated,alternative,agents 1.0 0.000143348623853 0 1 -1
indicate,that,they 1.0 0.000143348623853 0 1 -1
indicate,that,starlix 1.0 0.000143348623853 0 1 -1
indicate,that,platelet 1.0 0.000143348623853 0 1 -1
indicate,that,no 1.0 0.000143348623853 0 1 -1
indicate,that,mesylate 1.0 0.000143348623853 0 1 -1
indicate,that,m 1.0 0.000143348623853 0 1 -1
indicate,that,keppra 1.0 0.000143348623853 0 1 -1
indicate,that,is 1.0 0.000573394495413 0 4 -4
indicate,that,homocysteine 1.0 0.000143348623853 0 1 -1
indicate,that,has 1.0 0.000143348623853 0 1 -1
indicate,that,dosage 1.0 0.000143348623853 0 1 -1
indicate,that,does 1.0 0.000573394495413 0 4 -4
indicate,that,binds 1.0 0.000143348623853 0 1 -1
indicate,that,as 1.0 0.000143348623853 0 1 -1
indicate,that,an 1.0 0.000143348623853 0 1 -1
indicate,that,although 1.0 0.000143348623853 0 1 -1
indicate,that,administration 1.0 0.000143348623853 0 1 -1
indicate,that,a 1.0 0.000286697247706 0 2 -2
indicate,no,discernible 1.0 0.000143348623853 0 1 -1
indicate,important,relationships 1.0 0.000143348623853 0 1 -1
indicate,cyp3a4,isoform 1.0 0.000143348623853 0 1 -1
index,or,tumor 1.0 0.000143348623853 0 1 -1
index,of,the 1.0 0.000286697247706 0 2 -2
index,of,intestinal 1.0 0.000143348623853 0 1 -1
index,of,hepatic 1.0 0.000143348623853 0 1 -1
index,fici,was 1.0 0.000143348623853 0 1 -1
index,digoxin,sonata 1.0 0.000143348623853 0 1 -1
index,digoxin,a 1.0 0.000143348623853 0 1 -1
index,apoptotic,index 1.0 0.000143348623853 0 1 -1
index,and,most 1.0 0.000143348623853 0 1 -1
inderal,tenormin,sectral 1.0 0.000143348623853 0 1 -1
independent,of,the 1.0 0.000143348623853 0 1 -1
independent,joint,action 1.0 0.000143348623853 0 1 -1
indeed,agents,and 1.0 0.000143348623853 0 1 -1
indanedione,including,or 1.0 0.000143348623853 0 1 -1
indanavir,ketoconazole,phenytoin 1.0 0.000143348623853 0 1 -1
incubation,in,the 1.0 0.000143348623853 0 1 -1
incubation,at,degrees 1.0 0.000143348623853 0 1 -1
incubated,at,various 1.0 0.000143348623853 0 1 -1
increasingly,those,with 1.0 0.000143348623853 0 1 -1
increasingly,popular,in 1.0 0.000143348623853 0 1 -1
increasingly,important,causes 1.0 0.000143348623853 0 1 -1
increasing,use,of 1.0 0.000143348623853 0 1 -1
increasing,their,effect 1.0 0.000286697247706 0 2 -2
increasing,the,rate 1.0 0.000143348623853 0 1 -1
increasing,the,force 1.0 0.000143348623853 0 1 -1
increasing,the,bound 1.0 0.000143348623853 0 1 -1
increasing,overall,response 1.0 0.000143348623853 0 1 -1
increasing,metal,concentration 1.0 0.000143348623853 0 1 -1
increasing,incidence,of 1.0 0.000143348623853 0 1 -1
increasing,from,a 1.0 0.000143348623853 0 1 -1
increasing,concentration,to 1.0 0.000143348623853 0 1 -1
increases,will,occur 1.0 0.000143348623853 0 1 -1
increases,the,serum 1.0 0.000143348623853 0 1 -1
increases,the,prothrombin 1.0 0.000143348623853 0 1 -1
increases,the,bioavailability 1.0 0.000143348623853 0 1 -1
increases,serum,concentration 1.0 0.000143348623853 0 1 -1
increases,ranging,from 1.0 0.000286697247706 0 2 -2
increases,qt,prolongation 1.0 0.000143348623853 0 1 -1
increases,platelet,aggregation 1.0 0.000143348623853 0 1 -1
increases,plasma,concentrations 1.0 0.000143348623853 0 1 -1
increases,of,with 1.0 0.000143348623853 0 1 -1
increases,of,modest 1.0 0.000286697247706 0 2 -2
increases,of,and 1.0 0.000143348623853 0 1 -1
increases,metabolic,rate 1.0 0.000143348623853 0 1 -1
increases,inrifabutin,exposure 1.0 0.000143348623853 0 1 -1
increases,in,resorptions 1.0 0.000143348623853 0 1 -1
increases,in,placental 1.0 0.000143348623853 0 1 -1
increases,in,or 1.0 0.000143348623853 0 1 -1
increases,in,lymphocyte 1.0 0.000143348623853 0 1 -1
increases,in,half-life 1.0 0.000143348623853 0 1 -1
increases,in,concentration 1.0 0.000143348623853 0 1 -1
increases,in,clotting 1.0 0.000143348623853 0 1 -1
increases,in,circulating 1.0 0.000143348623853 0 1 -1
increases,in,auc 1.0 0.000143348623853 0 1 -1
increases,extracellular,levels 1.0 0.000143348623853 0 1 -1
increases,ethinyl,estradiol 1.0 0.000143348623853 0 1 -1
increases,enterohepatic,elimination 1.0 0.000143348623853 0 1 -1
increases,bioavailability,by 1.0 0.000143348623853 0 1 -1
increased,with,increasing 1.0 0.000143348623853 0 1 -1
increased,with,coadministration 1.0 0.000143348623853 0 1 -1
increased,when,taken 1.0 0.000143348623853 0 1 -1
increased,volume,of 1.0 0.000286697247706 0 2 -2
increased,urinary,values 1.0 0.000143348623853 0 1 -1
increased,toxicity,cns 1.0 0.000143348623853 0 1 -1
increased,total,circulating 1.0 0.000286697247706 0 2 -2
increased,to,micrograms 1.0 0.00043004587156 0 3 -3
increased,thyroid-binding,globulin 1.0 0.00043004587156 0 3 -3
increased,thioether,excretion 1.0 0.000143348623853 0 1 -1
increased,the,number 1.0 0.00043004587156 0 3 -3
increased,the,extent 1.0 0.000143348623853 0 1 -1
increased,the,amplitudes 1.0 0.000143348623853 0 1 -1
increased,systematically,between 1.0 0.000143348623853 0 1 -1
increased,synaptic,concentration 1.0 0.000143348623853 0 1 -1
increased,susceptibility,to 1.0 0.000143348623853 0 1 -1
increased,steady-state,levels 1.0 0.000143348623853 0 1 -1
increased,stability,of 1.0 0.000286697247706 0 2 -2
increased,side,effects 1.0 0.000143348623853 0 1 -1
increased,sgot,elevated 1.0 0.000143348623853 0 1 -1
increased,serum,triglyceride 1.0 0.000286697247706 0 2 -2
increased,serum,enzyme 1.0 0.000143348623853 0 1 -1
increased,serum,and 1.0 0.000143348623853 0 1 -1
increased,sedation,with 1.0 0.000143348623853 0 1 -1
increased,sedation,or 1.0 0.000286697247706 0 2 -2
increased,risk,relative 1.0 0.000143348623853 0 1 -1
increased,responsiveness,to 1.0 0.000286697247706 0 2 -2
increased,renal,plasma 1.0 0.000143348623853 0 1 -1
increased,regional,perfusion 1.0 0.000143348623853 0 1 -1
increased,prothrombin,and 1.0 0.000286697247706 0 2 -2
increased,potential,for 1.0 0.000286697247706 0 2 -2
increased,plasminogen,antigen 1.0 0.000286697247706 0 2 -2
increased,plasma,hdl 1.0 0.000286697247706 0 2 -2
increased,phenytoin,levels 1.0 0.000143348623853 0 1 -1
increased,or,decreased 1.0 0.000143348623853 0 1 -1
increased,norepinephrine-induced,platel 1.0 0.000143348623853 0 1 -1
increased,lipid,levels 1.0 0.000143348623853 0 1 -1
increased,levels,of 1.0 0.00043004587156 0 3 -3
increased,its,effectiveness 1.0 0.000143348623853 0 1 -1
increased,intraocular,pressure 1.0 0.000143348623853 0 1 -1
increased,intracellular,ca 1.0 0.000143348623853 0 1 -1
increased,interaction,should 1.0 0.000143348623853 0 1 -1
increased,interaction,between 1.0 0.000143348623853 0 1 -1
increased,initially,and 1.0 0.000143348623853 0 1 -1
increased,indicating,induction 1.0 0.000143348623853 0 1 -1
increased,in,hyperthyroid 1.0 0.000143348623853 0 1 -1
increased,in,failing 1.0 0.000143348623853 0 1 -1
increased,in,cocaine-treated 1.0 0.000143348623853 0 1 -1
increased,his,risk 1.0 0.000143348623853 0 1 -1
increased,gastric,ph 1.0 0.000143348623853 0 1 -1
increased,frequency,of 1.0 0.000143348623853 0 1 -1
increased,free,concentrations 1.0 0.000143348623853 0 1 -1
increased,fold,and 1.0 0.000143348623853 0 1 -1
increased,factors,ii 1.0 0.000286697247706 0 2 -2
increased,exposures,in 1.0 0.000143348623853 0 1 -1
increased,exposure,tonevirapine 1.0 0.000143348623853 0 1 -1
increased,effects,of 1.0 0.000143348623853 0 1 -1
increased,effects,lower 1.0 0.000143348623853 0 1 -1
increased,dramatically,from 1.0 0.000143348623853 0 1 -1
increased,dose,of 1.0 0.000860091743119 0 6 -6
increased,deet,toxicity 1.0 0.000143348623853 0 1 -1
increased,concentrations,of 1.0 0.000286697247706 0 2 -2
increased,concentrations,has 1.0 0.000143348623853 0 1 -1
increased,concentrations,and 1.0 0.000143348623853 0 1 -1
increased,clearance,of 1.0 0.000143348623853 0 1 -1
increased,circulating,total 1.0 0.00043004587156 0 3 -3
increased,catabloism,of 1.0 0.000143348623853 0 1 -1
increased,by,when 1.0 0.000143348623853 0 1 -1
increased,by,qtc 1.0 0.000286697247706 0 2 -2
increased,by,co-administration 1.0 0.000143348623853 0 1 -1
increased,by,a 1.0 0.000143348623853 0 1 -1
increased,breakthrough,bleeding 1.0 0.000143348623853 0 1 -1
increased,both,resorptions 1.0 0.000143348623853 0 1 -1
increased,both,in 1.0 0.000143348623853 0 1 -1
increased,blood,at 1.0 0.000143348623853 0 1 -1
increased,bioavailability,and 1.0 0.000143348623853 0 1 -1
increased,binding,globulin 1.0 0.000143348623853 0 1 -1
increased,because,active 1.0 0.000143348623853 0 1 -1
increased,availability,of 1.0 0.000143348623853 0 1 -1
increased,auc,by 1.0 0.000286697247706 0 2 -2
increased,at,the 1.0 0.000143348623853 0 1 -1
increased,as,required 1.0 0.000143348623853 0 1 -1
increased,appetite,and 1.0 0.000143348623853 0 1 -1
increased,anticoagulation,effects 1.0 0.000286697247706 0 2 -2
increased,angiotensinogen,renin 1.0 0.000286697247706 0 2 -2
increased,and,the 1.0 0.00043004587156 0 3 -3
increased,amounts,may 1.0 0.000143348623853 0 1 -1
increased,all,the 1.0 0.000143348623853 0 1 -1
increase,with,the 1.0 0.000143348623853 0 1 -1
increase,was,seen 1.0 0.000143348623853 0 1 -1
increase,toxicity,and 1.0 0.000143348623853 0 1 -1
increase,to,mg 1.0 0.000143348623853 0 1 -1
increase,their,clearance 1.0 0.000143348623853 0 1 -1
increase,their,capacity 1.0 0.000143348623853 0 1 -1
increase,the,unbound 1.0 0.000143348623853 0 1 -1
increase,the,therapeutic 1.0 0.000143348623853 0 1 -1
increase,the,side 1.0 0.000143348623853 0 1 -1
increase,the,potential 1.0 0.000143348623853 0 1 -1
increase,the,need 1.0 0.000143348623853 0 1 -1
increase,the,marrow 1.0 0.000143348623853 0 1 -1
increase,the,levels 1.0 0.000143348623853 0 1 -1
increase,the,impairment 1.0 0.000143348623853 0 1 -1
increase,the,formation 1.0 0.000143348623853 0 1 -1
increase,the,degree 1.0 0.000143348623853 0 1 -1
increase,the,cns 1.0 0.000143348623853 0 1 -1
increase,the,blood-glucose 1.0 0.000286697247706 0 2 -2
increase,the,blood 1.0 0.000286697247706 0 2 -2
increase,susceptibility,to 1.0 0.000143348623853 0 1 -1
increase,steady-state,plasma 1.0 0.000143348623853 0 1 -1
increase,serum,thyroxine-binding 1.0 0.000143348623853 0 1 -1
increase,serum,levels 1.0 0.000143348623853 0 1 -1
increase,risk,of 1.0 0.000143348623853 0 1 -1
increase,over,time 1.0 0.000286697247706 0 2 -2
increase,or,for 1.0 0.000143348623853 0 1 -1
increase,or,enhance 1.0 0.000143348623853 0 1 -1
increase,of,in 1.0 0.000143348623853 0 1 -1
increase,of,glycemia 1.0 0.000143348623853 0 1 -1
increase,metabolism,and 1.0 0.000143348623853 0 1 -1
increase,may,be 1.0 0.000143348623853 0 1 -1
increase,levels,of 1.0 0.000143348623853 0 1 -1
increase,is,greatest 1.0 0.000286697247706 0 2 -2
increase,increase,decrease 1.0 0.000143348623853 0 1 -1
increase,in,uremic 1.0 0.000143348623853 0 1 -1
increase,in,thyroxine 1.0 0.000143348623853 0 1 -1
increase,in,thedosage 1.0 0.000286697247706 0 2 -2
increase,in,symptomatic 1.0 0.000143348623853 0 1 -1
increase,in,sprycel 1.0 0.000143348623853 0 1 -1
increase,in,sn38 1.0 0.000143348623853 0 1 -1
increase,in,renal 1.0 0.000143348623853 0 1 -1
increase,in,mortality 1.0 0.000143348623853 0 1 -1
increase,in,local 1.0 0.000143348623853 0 1 -1
increase,in,levels 1.0 0.000286697247706 0 2 -2
increase,in,glycemia 1.0 0.000143348623853 0 1 -1
increase,in,cortisol 1.0 0.000143348623853 0 1 -1
increase,in,both 1.0 0.000143348623853 0 1 -1
increase,in,bleeding 1.0 0.000143348623853 0 1 -1
increase,in,bioavailability 1.0 0.000143348623853 0 1 -1
increase,in,adverse 1.0 0.000286697247706 0 2 -2
increase,in,a 1.0 0.000143348623853 0 1 -1
increase,high-density,lipoprotein 1.0 0.000143348623853 0 1 -1
increase,generation,of 1.0 0.000143348623853 0 1 -1
increase,gastrointestinal,motility 1.0 0.000143348623853 0 1 -1
increase,for,the 1.0 0.000143348623853 0 1 -1
increase,fi,responding 1.0 0.000143348623853 0 1 -1
increase,excretion,of 1.0 0.000143348623853 0 1 -1
increase,decrease,ci 1.0 0.000143348623853 0 1 -1
increase,daily,dose 1.0 0.000143348623853 0 1 -1
increase,ci,increase 1.0 0.000143348623853 0 1 -1
increase,certain,actions 1.0 0.000143348623853 0 1 -1
increase,catabolism,of 1.0 0.000143348623853 0 1 -1
increase,and,may 1.0 0.000143348623853 0 1 -1
incorporate,the,principles 1.0 0.000143348623853 0 1 -1
incoordination,hyperthermia,shivering 1.0 0.000143348623853 0 1 -1
inconsistent,reports,regarding 1.0 0.000143348623853 0 1 -1
inconcomitant,administration,and 1.0 0.000143348623853 0 1 -1
inconclusive,with,regard 1.0 0.000143348623853 0 1 -1
incompletely,responsive,to 1.0 0.000143348623853 0 1 -1
incomplete,depletion,which 1.0 0.000143348623853 0 1 -1
incompatible,with,and 1.0 0.000143348623853 0 1 -1
incompatibility,of,these 1.0 0.000143348623853 0 1 -1
incombination,with,with 1.0 0.000143348623853 0 1 -1
inclusive,viracept,may 1.0 0.000143348623853 0 1 -1
inclusion,on,responses 1.0 0.000143348623853 0 1 -1
including,were,concurrently 1.0 0.000143348623853 0 1 -1
including,ventricular,tachycardia 1.0 0.000143348623853 0 1 -1
including,those,with 1.0 0.000143348623853 0 1 -1
including,those,undergoing 1.0 0.000143348623853 0 1 -1
including,those,resulting 1.0 0.000143348623853 0 1 -1
including,the,corrected 1.0 0.000143348623853 0 1 -1
including,the,concurrent 1.0 0.000143348623853 0 1 -1
including,the,administration 1.0 0.000143348623853 0 1 -1
including,the,active 1.0 0.000143348623853 0 1 -1
including,robust,induction 1.0 0.000143348623853 0 1 -1
including,reactions,secondary 1.0 0.000143348623853 0 1 -1
including,protease,inhibitors 1.0 0.000143348623853 0 1 -1
including,preparations,glyceryl 1.0 0.000143348623853 0 1 -1
including,oral,inhaled 1.0 0.000143348623853 0 1 -1
including,or,their 1.0 0.000143348623853 0 1 -1
including,or,non-opioid 1.0 0.000143348623853 0 1 -1
including,normal,healthy 1.0 0.000143348623853 0 1 -1
including,most,ssris 1.0 0.000143348623853 0 1 -1
including,more,convenient 1.0 0.000143348623853 0 1 -1
including,may,lead 1.0 0.000143348623853 0 1 -1
including,may,cause 1.0 0.000143348623853 0 1 -1
including,many,selective 1.0 0.000286697247706 0 2 -2
including,man,and 1.0 0.000143348623853 0 1 -1
including,interactions,with 1.0 0.000143348623853 0 1 -1
including,inhaled,and 1.0 0.000143348623853 0 1 -1
including,immune,system 1.0 0.000143348623853 0 1 -1
including,herbal,preparations 1.0 0.000143348623853 0 1 -1
including,gastrointestinal,and 1.0 0.000143348623853 0 1 -1
including,eye,drops 1.0 0.000143348623853 0 1 -1
including,electrocardiographic,qt 1.0 0.000143348623853 0 1 -1
including,cyp1a2,cyp2c9 1.0 0.000286697247706 0 2 -2
including,continuous,and 1.0 0.000143348623853 0 1 -1
including,complete,heart 1.0 0.000143348623853 0 1 -1
including,combined,with 1.0 0.000143348623853 0 1 -1
including,central,obesity 1.0 0.000143348623853 0 1 -1
including,cefotaxime,sodium 1.0 0.000143348623853 0 1 -1
including,blood,pressure 1.0 0.000143348623853 0 1 -1
including,biocytin,in 1.0 0.000143348623853 0 1 -1
including,antiparkinsonism,agents 1.0 0.000143348623853 0 1 -1
including,anti-arrhythmic,agents 1.0 0.000143348623853 0 1 -1
including,and,these 1.0 0.000143348623853 0 1 -1
including,and,have 1.0 0.000143348623853 0 1 -1
including,and,either 1.0 0.000143348623853 0 1 -1
including,and,commonly 1.0 0.000143348623853 0 1 -1
including,anaphylaxis,have 1.0 0.000143348623853 0 1 -1
including,anafranil,is 1.0 0.000143348623853 0 1 -1
including,an,omega-conotoxin 1.0 0.000143348623853 0 1 -1
including,adverse,effects 1.0 0.000143348623853 0 1 -1
including,acetylsalicylic,acid 1.0 0.000143348623853 0 1 -1
includes,most,genotoxic 1.0 0.000143348623853 0 1 -1
includes,longer,term 1.0 0.000143348623853 0 1 -1
includes,anafranil,with 1.0 0.000143348623853 0 1 -1
included,with,combination 1.0 0.000143348623853 0 1 -1
included,seven,cerebrovascular 1.0 0.000143348623853 0 1 -1
included,self-reported,mood 1.0 0.000143348623853 0 1 -1
included,post,myocardial 1.0 0.000143348623853 0 1 -1
included,mtx,in 1.0 0.000143348623853 0 1 -1
included,into,a 1.0 0.000143348623853 0 1 -1
included,in,this 1.0 0.000143348623853 0 1 -1
included,in,the 1.0 0.000143348623853 0 1 -1
included,brovana,doses 1.0 0.000143348623853 0 1 -1
included,beta-adrenergic,receptor 1.0 0.000143348623853 0 1 -1
included,as,proof 1.0 0.000143348623853 0 1 -1
included,a,mcg 1.0 0.000143348623853 0 1 -1
include,the,following 1.0 0.00043004587156 0 3 -3
include,the,and 1.0 0.000573394495413 0 4 -4
include,sufficient,numbers 1.0 0.000143348623853 0 1 -1
include,such,considerations 1.0 0.000143348623853 0 1 -1
include,some,that 1.0 0.000716743119266 0 5 -5
include,regular,reevaluations 1.0 0.000143348623853 0 1 -1
include,optimal,pharmacokinetics 1.0 0.000143348623853 0 1 -1
include,one,or 1.0 0.000143348623853 0 1 -1
include,medications,such 1.0 0.000143348623853 0 1 -1
include,fever,chills 1.0 0.000143348623853 0 1 -1
include,but,are 1.0 0.000286697247706 0 2 -2
include,azole,antifungals 1.0 0.000143348623853 0 1 -1
include,and,some 1.0 0.000143348623853 0 1 -1
include,and,and 1.0 0.000143348623853 0 1 -1
include,a,variety 1.0 0.000143348623853 0 1 -1
incisive,by,therapeutic 1.0 0.000143348623853 0 1 -1
incidence,of,upper 1.0 0.000573394495413 0 4 -4
incidence,of,transient 1.0 0.000143348623853 0 1 -1
incidence,of,tbg 1.0 0.000143348623853 0 1 -1
incidence,of,reaction 1.0 0.000143348623853 0 1 -1
incidence,of,peritoneal 1.0 0.000143348623853 0 1 -1
incidence,of,neurological 1.0 0.000143348623853 0 1 -1
incidence,of,intestinal 1.0 0.000143348623853 0 1 -1
incidence,of,infections 1.0 0.000143348623853 0 1 -1
incidence,of,hypertriglyceridemia 1.0 0.000286697247706 0 2 -2
incidence,of,grade 1.0 0.000143348623853 0 1 -1
incidence,of,fetal 1.0 0.000286697247706 0 2 -2
incidence,of,endoscopic 1.0 0.000143348623853 0 1 -1
incidence,of,cardiovascular 1.0 0.000143348623853 0 1 -1
incidence,of,cancer 1.0 0.000143348623853 0 1 -1
incidence,of,breakthrough 1.0 0.000286697247706 0 2 -2
incidence,of,benign 1.0 0.000143348623853 0 1 -1
incidence,of,atherosclerotic 1.0 0.000143348623853 0 1 -1
incidence,of,are 1.0 0.000143348623853 0 1 -1
inapsine,required,will 1.0 0.000143348623853 0 1 -1
inappropriate,being,either 1.0 0.000143348623853 0 1 -1
inadequate,to,fully 1.0 0.000143348623853 0 1 -1
inadequate,systematic,experience 1.0 0.000143348623853 0 1 -1
inactive,metabolites,has 1.0 0.000143348623853 0 1 -1
inactivation,of,the 1.0 0.000143348623853 0 1 -1
inactivated,by,reaction 1.0 0.000143348623853 0 1 -1
inability,to,ejaculate 1.0 0.000143348623853 0 1 -1
in-vitro,studies,is 1.0 0.000143348623853 0 1 -1
in,zollinger-ellison,ze 1.0 0.000143348623853 0 1 -1
in,women,with 1.0 0.000143348623853 0 1 -1
in,women,who 1.0 0.000143348623853 0 1 -1
in,women,receiving 1.0 0.000143348623853 0 1 -1
in,women,of 1.0 0.000143348623853 0 1 -1
in,whom,this 1.0 0.000143348623853 0 1 -1
in,whom,renal 1.0 0.000143348623853 0 1 -1
in,whom,either 1.0 0.000143348623853 0 1 -1
in,whom,cyp3a4 1.0 0.000143348623853 0 1 -1
in,which,plasma 1.0 0.000286697247706 0 2 -2
in,which,it 1.0 0.000143348623853 0 1 -1
in,which,inflammation 1.0 0.000143348623853 0 1 -1
in,which,erbitux 1.0 0.000143348623853 0 1 -1
in,which,eight 1.0 0.000143348623853 0 1 -1
in,which,concurrent 1.0 0.000143348623853 0 1 -1
in,water,orange 1.0 0.000143348623853 0 1 -1
in,water,from 1.0 0.000143348623853 0 1 -1
in,volunteers,with 1.0 0.000143348623853 0 1 -1
in,vivo,to 1.0 0.000143348623853 0 1 -1
in,vivo,tests 1.0 0.000143348623853 0 1 -1
in,vivo,rodent 1.0 0.000143348623853 0 1 -1
in,vivo,resulted 1.0 0.000143348623853 0 1 -1
in,vivo,particularly 1.0 0.000143348623853 0 1 -1
in,vivo,micronucleus 1.0 0.000143348623853 0 1 -1
in,vivo,metabolic 1.0 0.000286697247706 0 2 -2
in,vivo,it 1.0 0.000143348623853 0 1 -1
in,vivo,interaction 1.0 0.000860091743119 0 6 -6
in,vivo,evidence 1.0 0.000143348623853 0 1 -1
in,vivo,effects 1.0 0.000143348623853 0 1 -1
in,vivo,clinically 1.0 0.000143348623853 0 1 -1
in,vivo,by 1.0 0.000143348623853 0 1 -1
in,vitro,was 1.0 0.000286697247706 0 2 -2
in,vitro,to 1.0 0.000143348623853 0 1 -1
in,vitro,therefore 1.0 0.000143348623853 0 1 -1
in,vitro,the 1.0 0.000286697247706 0 2 -2
in,vitro,tests 1.0 0.000143348623853 0 1 -1
in,vitro,sodium 1.0 0.000143348623853 0 1 -1
in,vitro,showed 1.0 0.000143348623853 0 1 -1
in,vitro,show 1.0 0.000143348623853 0 1 -1
in,vitro,results 1.0 0.000143348623853 0 1 -1
in,vitro,perfused 1.0 0.000143348623853 0 1 -1
in,vitro,on 1.0 0.000143348623853 0 1 -1
in,vitro,metabolism 1.0 0.000716743119266 0 5 -5
in,vitro,metabolic 1.0 0.000143348623853 0 1 -1
in,vitro,inhibitor 1.0 0.000143348623853 0 1 -1
in,vitro,human 1.0 0.000143348623853 0 1 -1
in,vitro,however 1.0 0.000143348623853 0 1 -1
in,vitro,have 1.0 0.000143348623853 0 1 -1
in,vitro,glucuronidation 1.0 0.000143348623853 0 1 -1
in,vitro,gleevec 1.0 0.000286697247706 0 2 -2
in,vitro,finding 1.0 0.000286697247706 0 2 -2
in,vitro,experiments 1.0 0.000143348623853 0 1 -1
in,vitro,excystment 1.0 0.000286697247706 0 2 -2
in,vitro,evaluation 1.0 0.000143348623853 0 1 -1
in,vitro,effect 1.0 0.000143348623853 0 1 -1
in,vitro,does 1.0 0.000143348623853 0 1 -1
in,vitro,displacement 1.0 0.000143348623853 0 1 -1
in,vitro,cytogenetics 1.0 0.000143348623853 0 1 -1
in,vitro,concentrations 1.0 0.000143348623853 0 1 -1
in,vitro,chromosomal 1.0 0.000143348623853 0 1 -1
in,vitro,at 1.0 0.000286697247706 0 2 -2
in,vitro,aspirin-mediated 1.0 0.000143348623853 0 1 -1
in,vitro,anti-cryptosporidial 1.0 0.000143348623853 0 1 -1
in,vitro,against 1.0 0.000286697247706 0 2 -2
in,vitro,activity 1.0 0.000143348623853 0 1 -1
in,visual,cortex 1.0 0.000143348623853 0 1 -1
in,view,however 1.0 0.000143348623853 0 1 -1
in,vertigo,syncope 1.0 0.000143348623853 0 1 -1
in,ventricular,fibrillation 1.0 0.000143348623853 0 1 -1
in,utero,serum 1.0 0.000143348623853 0 1 -1
in,utero,exposure 1.0 0.000143348623853 0 1 -1
in,using,preparations 1.0 0.000143348623853 0 1 -1
in,using,duloxetine 1.0 0.000143348623853 0 1 -1
in,using,concomitant 1.0 0.000143348623853 0 1 -1
in,users,of 1.0 0.000143348623853 0 1 -1
in,users,causes 1.0 0.000143348623853 0 1 -1
in,urine,using 1.0 0.000143348623853 0 1 -1
in,urine,has 1.0 0.000143348623853 0 1 -1
in,urine,allow 1.0 0.000143348623853 0 1 -1
in,urine,after 1.0 0.000143348623853 0 1 -1
in,urinary,homocysteine 1.0 0.000143348623853 0 1 -1
in,uremic,patients 1.0 0.000143348623853 0 1 -1
in,uptake-1,occurs 1.0 0.000143348623853 0 1 -1
in,uptake-1,carrier 1.0 0.000143348623853 0 1 -1
in,unexpectedly,high 1.0 0.000143348623853 0 1 -1
in,unconjugated,nacmc 1.0 0.000143348623853 0 1 -1
in,two-lever,discrimination 1.0 0.000143348623853 0 1 -1
in,two,sequential 1.0 0.000143348623853 0 1 -1
in,two,multiple-dose 1.0 0.000143348623853 0 1 -1
in,two,controlled 1.0 0.000143348623853 0 1 -1
in,two,combined 1.0 0.000143348623853 0 1 -1
in,turn,discussing 1.0 0.000143348623853 0 1 -1
in,turn,controls 1.0 0.000143348623853 0 1 -1
in,tumor,cells 1.0 0.000143348623853 0 1 -1
in,treatment-naive,patients 1.0 0.000143348623853 0 1 -1
in,treatment-experienced,patients 1.0 0.000286697247706 0 2 -2
in,treatment,practices 1.0 0.000143348623853 0 1 -1
in,transfusion,cross-matching 1.0 0.000143348623853 0 1 -1
in,transferring,the 1.0 0.000143348623853 0 1 -1
in,tmax,of 1.0 0.000143348623853 0 1 -1
in,thyroxine,output 1.0 0.000143348623853 0 1 -1
in,three,well-controlled 1.0 0.000143348623853 0 1 -1
in,three,separate 1.0 0.000143348623853 0 1 -1
in,three,pharmacokinetic 1.0 0.000143348623853 0 1 -1
in,those,such 1.0 0.000143348623853 0 1 -1
in,those,receiving 1.0 0.000143348623853 0 1 -1
in,this,test 1.0 0.000143348623853 0 1 -1
in,this,strain 1.0 0.000143348623853 0 1 -1
in,this,situation 1.0 0.000143348623853 0 1 -1
in,this,setting 1.0 0.000143348623853 0 1 -1
in,this,section 1.0 0.000573394495413 0 4 -4
in,this,patient 1.0 0.000143348623853 0 1 -1
in,this,paper 1.0 0.00043004587156 0 3 -3
in,this,formal 1.0 0.000143348623853 0 1 -1
in,this,class 1.0 0.000143348623853 0 1 -1
in,these,trials 1.0 0.000143348623853 0 1 -1
in,these,subjects 1.0 0.000286697247706 0 2 -2
in,these,six 1.0 0.000143348623853 0 1 -1
in,these,monkeys 1.0 0.000143348623853 0 1 -1
in,these,instances 1.0 0.000143348623853 0 1 -1
in,these,in 1.0 0.000143348623853 0 1 -1
in,these,cases 1.0 0.000143348623853 0 1 -1
in,these,areas 1.0 0.000143348623853 0 1 -1
in,therapy,of 1.0 0.000143348623853 0 1 -1
in,therapy,depends 1.0 0.000143348623853 0 1 -1
in,therapeutic,effect 1.0 0.000143348623853 0 1 -1
in,their,serum 1.0 0.000143348623853 0 1 -1
in,their,potential 1.0 0.000143348623853 0 1 -1
in,their,effectiveness 1.0 0.000143348623853 0 1 -1
in,thedosage,of 1.0 0.000286697247706 0 2 -2
in,the,year 1.0 0.000143348623853 0 1 -1
in,the,vehicle-controlled 1.0 0.000143348623853 0 1 -1
in,the,usual 1.0 0.000143348623853 0 1 -1
in,the,user 1.0 0.000143348623853 0 1 -1
in,the,use 1.0 0.000286697247706 0 2 -2
in,the,us 1.0 0.000143348623853 0 1 -1
in,the,urine 1.0 0.00286697247706 0 20 -20
in,the,treated 1.0 0.000143348623853 0 1 -1
in,the,transport 1.0 0.000143348623853 0 1 -1
in,the,toxicity 1.0 0.000143348623853 0 1 -1
in,the,three 1.0 0.000143348623853 0 1 -1
in,the,testes 1.0 0.000143348623853 0 1 -1
in,the,synthesis 1.0 0.000143348623853 0 1 -1
in,the,sympathetic 1.0 0.000143348623853 0 1 -1
in,the,suppression 1.0 0.000286697247706 0 2 -2
in,the,study 1.0 0.00043004587156 0 3 -3
in,the,str 1.0 0.000286697247706 0 2 -2
in,the,steady 1.0 0.000143348623853 0 1 -1
in,the,sst 1.0 0.000143348623853 0 1 -1
in,the,sleeping 1.0 0.000143348623853 0 1 -1
in,the,skin 1.0 0.000143348623853 0 1 -1
in,the,same 1.0 0.000286697247706 0 2 -2
in,the,safety 1.0 0.000286697247706 0 2 -2
in,the,roughly 1.0 0.000143348623853 0 1 -1
in,the,results 1.0 0.000286697247706 0 2 -2
in,the,remainder 1.0 0.000143348623853 0 1 -1
in,the,release 1.0 0.000143348623853 0 1 -1
in,the,relation 1.0 0.000143348623853 0 1 -1
in,the,reduced 1.0 0.000286697247706 0 2 -2
in,the,recording 1.0 0.000143348623853 0 1 -1
in,the,range 1.0 0.00043004587156 0 3 -3
in,the,rabbit 1.0 0.000143348623853 0 1 -1
in,the,qt0 1.0 0.000143348623853 0 1 -1
in,the,promotion 1.0 0.000143348623853 0 1 -1
in,the,production 1.0 0.000143348623853 0 1 -1
in,the,prevention 1.0 0.000143348623853 0 1 -1
in,the,present 1.0 0.000573394495413 0 4 -4
in,the,prescribing 1.0 0.000143348623853 0 1 -1
in,the,placebo-controlled 1.0 0.000143348623853 0 1 -1
in,the,picr 1.0 0.000143348623853 0 1 -1
in,the,phase 1.0 0.000143348623853 0 1 -1
in,the,pharmacokinetic 1.0 0.000143348623853 0 1 -1
in,the,peak 1.0 0.000286697247706 0 2 -2
in,the,patch 1.0 0.000143348623853 0 1 -1
in,the,parietal 1.0 0.000143348623853 0 1 -1
in,the,parameters 1.0 0.000143348623853 0 1 -1
in,the,offspring 1.0 0.000143348623853 0 1 -1
in,the,occurrence 1.0 0.000143348623853 0 1 -1
in,the,nucleus 1.0 0.000143348623853 0 1 -1
in,the,nonfailing 1.0 0.000143348623853 0 1 -1
in,the,non-myelinated 1.0 0.000143348623853 0 1 -1
in,the,ninds 1.0 0.000143348623853 0 1 -1
in,the,next 1.0 0.000143348623853 0 1 -1
in,the,neuronal 1.0 0.000143348623853 0 1 -1
in,the,nervous 1.0 0.000143348623853 0 1 -1
in,the,nac 1.0 0.000286697247706 0 2 -2
in,the,metabolism 1.0 0.000143348623853 0 1 -1
in,the,mesenteric 1.0 0.000143348623853 0 1 -1
in,the,medium 1.0 0.000143348623853 0 1 -1
in,the,medication 1.0 0.000143348623853 0 1 -1
in,the,maximum 1.0 0.000143348623853 0 1 -1
in,the,management 1.0 0.000716743119266 0 5 -5
in,the,male 1.0 0.000143348623853 0 1 -1
in,the,magnitude 1.0 0.000143348623853 0 1 -1
in,the,lysate 1.0 0.000143348623853 0 1 -1
in,the,long-term 1.0 0.000143348623853 0 1 -1
in,the,large 1.0 0.000143348623853 0 1 -1
in,the,kidneys 1.0 0.000143348623853 0 1 -1
in,the,kidney 1.0 0.000286697247706 0 2 -2
in,the,kd 1.0 0.000286697247706 0 2 -2
in,the,interpretation 1.0 0.000143348623853 0 1 -1
in,the,international 1.0 0.000143348623853 0 1 -1
in,the,initial 1.0 0.000143348623853 0 1 -1
in,the,in 1.0 0.000143348623853 0 1 -1
in,the,ibandronate 1.0 0.000143348623853 0 1 -1
in,the,hormone 1.0 0.000143348623853 0 1 -1
in,the,high 1.0 0.000143348623853 0 1 -1
in,the,half- 1.0 0.00043004587156 0 3 -3
in,the,guinea-pig 1.0 0.000143348623853 0 1 -1
in,the,group 1.0 0.000286697247706 0 2 -2
in,the,germinal 1.0 0.000143348623853 0 1 -1
in,the,general 1.0 0.000286697247706 0 2 -2
in,the,frontal 1.0 0.000143348623853 0 1 -1
in,the,following 1.0 0.000286697247706 0 2 -2
in,the,ferricyanide 1.0 0.000286697247706 0 2 -2
in,the,failing 1.0 0.000286697247706 0 2 -2
in,the,experiments 1.0 0.000143348623853 0 1 -1
in,the,event 1.0 0.000143348623853 0 1 -1
in,the,european 1.0 0.000143348623853 0 1 -1
in,the,environment 1.0 0.000143348623853 0 1 -1
in,the,embryogenesis 1.0 0.000143348623853 0 1 -1
in,the,e-strain 1.0 0.000143348623853 0 1 -1
in,the,duodenum 1.0 0.000143348623853 0 1 -1
in,the,duloxetine 1.0 0.000143348623853 0 1 -1
in,the,district 1.0 0.000143348623853 0 1 -1
in,the,digitalized 1.0 0.000143348623853 0 1 -1
in,the,differential 1.0 0.000143348623853 0 1 -1
in,the,diamond 1.0 0.000286697247706 0 2 -2
in,the,diabetics 1.0 0.000143348623853 0 1 -1
in,the,diabectics 1.0 0.000143348623853 0 1 -1
in,the,design 1.0 0.000143348623853 0 1 -1
in,the,degree 1.0 0.000143348623853 0 1 -1
in,the,cytochrome 1.0 0.000143348623853 0 1 -1
in,the,current 1.0 0.000143348623853 0 1 -1
in,the,cumulative 1.0 0.000143348623853 0 1 -1
in,the,course 1.0 0.000143348623853 0 1 -1
in,the,control 1.0 0.000286697247706 0 2 -2
in,the,context 1.0 0.000286697247706 0 2 -2
in,the,contents 1.0 0.000143348623853 0 1 -1
in,the,concurrent 1.0 0.000143348623853 0 1 -1
in,the,community 1.0 0.000143348623853 0 1 -1
in,the,cocaine-treated 1.0 0.000143348623853 0 1 -1
in,the,cmax 1.0 0.000143348623853 0 1 -1
in,the,clinic 1.0 0.000143348623853 0 1 -1
in,the,chop-haart 1.0 0.000286697247706 0 2 -2
in,the,chop 1.0 0.000143348623853 0 1 -1
in,the,chick 1.0 0.000143348623853 0 1 -1
in,the,brain 1.0 0.000143348623853 0 1 -1
in,the,body 1.0 0.000143348623853 0 1 -1
in,the,behavioral 1.0 0.000143348623853 0 1 -1
in,the,appearance 1.0 0.000143348623853 0 1 -1
in,the,antidepressant 1.0 0.000143348623853 0 1 -1
in,the,animal 1.0 0.000143348623853 0 1 -1
in,the,ames 1.0 0.000286697247706 0 2 -2
in,the,adverse 1.0 0.000143348623853 0 1 -1
in,the,acute 1.0 0.000286697247706 0 2 -2
in,the,acquired 1.0 0.000143348623853 0 1 -1
in,that,same 1.0 0.000143348623853 0 1 -1
in,terms,of 1.0 0.00043004587156 0 3 -3
in,temperature,began 1.0 0.000143348623853 0 1 -1
in,tbg,concentrations 1.0 0.000143348623853 0 1 -1
in,tbg,concentration 1.0 0.000143348623853 0 1 -1
in,tambocor,clinical 1.0 0.000143348623853 0 1 -1
in,table,table 1.0 0.000143348623853 0 1 -1
in,table,additional 1.0 0.000143348623853 0 1 -1
in,t24,human 1.0 0.000143348623853 0 1 -1
in,symptomatic,hypotension 1.0 0.000143348623853 0 1 -1
in,survanta,a 1.0 0.000143348623853 0 1 -1
in,surgery,or 1.0 0.000143348623853 0 1 -1
in,supporting,blood 1.0 0.000143348623853 0 1 -1
in,such,users 1.0 0.000143348623853 0 1 -1
in,such,concurrent 1.0 0.000143348623853 0 1 -1
in,such,cases 1.0 0.00043004587156 0 3 -3
in,such,a 1.0 0.000143348623853 0 1 -1
in,subjects,with 1.0 0.000143348623853 0 1 -1
in,subjects,treated 1.0 0.000143348623853 0 1 -1
in,subjects,on 1.0 0.000143348623853 0 1 -1
in,subcortical,structures 1.0 0.000143348623853 0 1 -1
in,study,patients 1.0 0.000286697247706 0 2 -2
in,study,one 1.0 0.000143348623853 0 1 -1
in,studies,of 1.0 0.000143348623853 0 1 -1
in,studies,in 1.0 0.000286697247706 0 2 -2
in,strains,of 1.0 0.000143348623853 0 1 -1
in,states,of 1.0 0.000143348623853 0 1 -1
in,sprycel,should 1.0 0.000143348623853 0 1 -1
in,spite,of 1.0 0.00043004587156 0 3 -3
in,special,populations 1.0 0.000143348623853 0 1 -1
in,some,cases 1.0 0.000286697247706 0 2 -2
in,sn38,levels 1.0 0.000143348623853 0 1 -1
in,small,groups 1.0 0.000143348623853 0 1 -1
in,slow,metabolizers 1.0 0.000143348623853 0 1 -1
in,six,patients 1.0 0.000143348623853 0 1 -1
in,situations,when 1.0 0.000286697247706 0 2 -2
in,situations,in 1.0 0.000143348623853 0 1 -1
in,situ,ligated 1.0 0.000143348623853 0 1 -1
in,situ,and 1.0 0.000143348623853 0 1 -1
in,significant,increases 1.0 0.000143348623853 0 1 -1
in,sheep,interactions 1.0 0.000143348623853 0 1 -1
in,several,well-controlled 1.0 0.000143348623853 0 1 -1
in,several,human 1.0 0.000143348623853 0 1 -1
in,several,dose 1.0 0.000143348623853 0 1 -1
in,several,clinical 1.0 0.000143348623853 0 1 -1
in,seven,experiments 1.0 0.000143348623853 0 1 -1
in,serum-supplemented,nih-3t3 1.0 0.000143348623853 0 1 -1
in,serum-deprived,serum 1.0 0.000143348623853 0 1 -1
in,serum-deprived,ras-transformed 1.0 0.000143348623853 0 1 -1
in,serum,with 1.0 0.000143348623853 0 1 -1
in,serum,uric 1.0 0.000143348623853 0 1 -1
in,serum,reverse 1.0 0.000143348623853 0 1 -1
in,serum,i 1.0 0.000286697247706 0 2 -2
in,serum,hormone 1.0 0.000143348623853 0 1 -1
in,serum,have 1.0 0.000143348623853 0 1 -1
in,serum,endogenous 1.0 0.00043004587156 0 3 -3
in,serum,activity 1.0 0.000143348623853 0 1 -1
in,serious,or 1.0 0.000143348623853 0 1 -1
in,serious,and 1.0 0.000143348623853 0 1 -1
in,separate,studies 1.0 0.000286697247706 0 2 -2
in,separate,single 1.0 0.000143348623853 0 1 -1
in,separate,randomized 1.0 0.000143348623853 0 1 -1
in,sensitivity,to 1.0 0.000143348623853 0 1 -1
in,secretions,such 1.0 0.000143348623853 0 1 -1
in,screening,patients 1.0 0.000143348623853 0 1 -1
in,saline,was 1.0 0.000143348623853 0 1 -1
in,safety,or 1.0 0.000143348623853 0 1 -1
in,s,effects 1.0 0.000143348623853 0 1 -1
in,rodent,studies 1.0 0.000143348623853 0 1 -1
in,rodent,pups 1.0 0.000143348623853 0 1 -1
in,rheumatoid,arthritis 1.0 0.00043004587156 0 3 -3
in,reversing,resistance 1.0 0.000143348623853 0 1 -1
in,response,to 1.0 0.000716743119266 0 5 -5
in,respect,of 1.0 0.000143348623853 0 1 -1
in,resorptions,or 1.0 0.000143348623853 0 1 -1
in,resistance,mesenteric 1.0 0.000143348623853 0 1 -1
in,renally,impaired 1.0 0.000143348623853 0 1 -1
in,renal,retention 1.0 0.000143348623853 0 1 -1
in,renal,function 1.0 0.000143348623853 0 1 -1
in,renal,blood 1.0 0.000143348623853 0 1 -1
in,relationship,to 1.0 0.000143348623853 0 1 -1
in,relation,to 1.0 0.00043004587156 0 3 -3
in,regimens,where 1.0 0.000143348623853 0 1 -1
in,regard,to 1.0 0.000143348623853 0 1 -1
in,reference,to 1.0 0.000143348623853 0 1 -1
in,rats,to 1.0 0.000143348623853 0 1 -1
in,rats,the 1.0 0.000143348623853 0 1 -1
in,rats,tarsal 1.0 0.000143348623853 0 1 -1
in,rats,did 1.0 0.000143348623853 0 1 -1
in,rat,milk 1.0 0.000143348623853 0 1 -1
in,rat,liver 1.0 0.000143348623853 0 1 -1
in,rat,bone 1.0 0.000143348623853 0 1 -1
in,rare,cases 1.0 0.000143348623853 0 1 -1
in,rabbits,dosed 1.0 0.000143348623853 0 1 -1
in,rabbits,backwards 1.0 0.000143348623853 0 1 -1
in,ra,clinical 1.0 0.000143348623853 0 1 -1
in,r-values,of 1.0 0.000143348623853 0 1 -1
in,psychopathology,rating 1.0 0.000143348623853 0 1 -1
in,psoriatic,arthritis 1.0 0.000143348623853 0 1 -1
in,prothrombin,times 1.0 0.000143348623853 0 1 -1
in,prothrombin,test 1.0 0.000286697247706 0 2 -2
in,prothrombin,measures 1.0 0.000143348623853 0 1 -1
in,prothrombin,and 1.0 0.000143348623853 0 1 -1
in,proteins,interacting 1.0 0.000143348623853 0 1 -1
in,proportion,to 1.0 0.000143348623853 0 1 -1
in,proof,by 1.0 0.000143348623853 0 1 -1
in,proliferating,cell 1.0 0.000143348623853 0 1 -1
in,preventing,erythro-fluorocitrate 1.0 0.000143348623853 0 1 -1
in,preterm,neonates 1.0 0.000143348623853 0 1 -1
in,premenopausal,women 1.0 0.000143348623853 0 1 -1
in,preclinical,or 1.0 0.000143348623853 0 1 -1
in,practice,the 1.0 0.000143348623853 0 1 -1
in,poor,metabolizers 1.0 0.000143348623853 0 1 -1
in,platelets,leukocytes 1.0 0.000143348623853 0 1 -1
in,platelets,and 1.0 0.000143348623853 0 1 -1
in,platelet,count 1.0 0.000143348623853 0 1 -1
in,platelet,aggregation 1.0 0.000143348623853 0 1 -1
in,plasma,samples 1.0 0.000286697247706 0 2 -2
in,plasma,or 1.0 0.000143348623853 0 1 -1
in,plasma,concentration 1.0 0.000860091743119 0 6 -6
in,placental,weight 1.0 0.000143348623853 0 1 -1
in,pigeons,nanm 1.0 0.000143348623853 0 1 -1
in,pigeons,did 1.0 0.000143348623853 0 1 -1
in,pigeons,and 1.0 0.00043004587156 0 3 -3
in,phase,was 1.0 0.000143348623853 0 1 -1
in,pharmacokinetics,were 1.0 0.000143348623853 0 1 -1
in,pharmacokinetics,or 1.0 0.000143348623853 0 1 -1
in,pharmacokinetics,auc 1.0 0.000143348623853 0 1 -1
in,pharmacokinetic,studies 1.0 0.000143348623853 0 1 -1
in,pharmacodynamic,effect 1.0 0.000143348623853 0 1 -1
in,period,b 1.0 0.000143348623853 0 1 -1
in,period,a 1.0 0.000143348623853 0 1 -1
in,peak,latency 1.0 0.000143348623853 0 1 -1
in,pcp,discrimination 1.0 0.000143348623853 0 1 -1
in,patients,whose 1.0 0.000286697247706 0 2 -2
in,patients,where 1.0 0.000143348623853 0 1 -1
in,patients,requiring 1.0 0.000143348623853 0 1 -1
in,patients,lacking 1.0 0.000143348623853 0 1 -1
in,patients,in 1.0 0.000143348623853 0 1 -1
in,patients,experiencing 1.0 0.000143348623853 0 1 -1
in,patients,either 1.0 0.000143348623853 0 1 -1
in,patients,concurrently 1.0 0.000143348623853 0 1 -1
in,patients,below 1.0 0.000143348623853 0 1 -1
in,particular,has 1.0 0.00043004587156 0 3 -3
in,particular,and 1.0 0.000143348623853 0 1 -1
in,particular,a2 1.0 0.000143348623853 0 1 -1
in,part,from 1.0 0.000143348623853 0 1 -1
in,part,a 1.0 0.000143348623853 0 1 -1
in,parietal,cell 1.0 0.000143348623853 0 1 -1
in,parentheses,were 1.0 0.000143348623853 0 1 -1
in,overall,improvements 1.0 0.000143348623853 0 1 -1
in,our,laboratory 1.0 0.000143348623853 0 1 -1
in,other,treatment 1.0 0.000143348623853 0 1 -1
in,other,cases 1.0 0.000143348623853 0 1 -1
in,or,of 1.0 0.000143348623853 0 1 -1
in,or,dosage 1.0 0.000143348623853 0 1 -1
in,or,concentrations 1.0 0.000143348623853 0 1 -1
in,opioid-dependent,patients 1.0 0.000143348623853 0 1 -1
in,ontario,the 1.0 0.000143348623853 0 1 -1
in,ontario,alone 1.0 0.000143348623853 0 1 -1
in,one,study 1.0 0.000716743119266 0 5 -5
in,older,men 1.0 0.000143348623853 0 1 -1
in,of,those 1.0 0.000143348623853 0 1 -1
in,of,patients 1.0 0.000143348623853 0 1 -1
in,occasional,susceptible 1.0 0.000143348623853 0 1 -1
in,oa,patients 1.0 0.000143348623853 0 1 -1
in,nursing,infants 1.0 0.00043004587156 0 3 -3
in,nucleoside-experienced,patients 1.0 0.000143348623853 0 1 -1
in,north,american 1.0 0.000143348623853 0 1 -1
in,normal,healthy 1.0 0.000143348623853 0 1 -1
in,normal,and 1.0 0.000143348623853 0 1 -1
in,noradrenaline-precontracted,arteries 1.0 0.000143348623853 0 1 -1
in,non-specialist,hospitals 1.0 0.000143348623853 0 1 -1
in,non-myelinated,axons 1.0 0.000143348623853 0 1 -1
in,non-human,primates 1.0 0.000143348623853 0 1 -1
in,non-diabetics,with 1.0 0.000143348623853 0 1 -1
in,nociception,and 1.0 0.000143348623853 0 1 -1
in,no,significant 1.0 0.000143348623853 0 1 -1
in,no,effect 1.0 0.000143348623853 0 1 -1
in,no,difference 1.0 0.000143348623853 0 1 -1
in,no,clinically 1.0 0.000143348623853 0 1 -1
in,no,apparent 1.0 0.000143348623853 0 1 -1
in,nnrti-na,ve 1.0 0.000143348623853 0 1 -1
in,nine,otherwise 1.0 0.000143348623853 0 1 -1
in,nih-3t3,cells 1.0 0.000143348623853 0 1 -1
in,niddm,subjects 1.0 0.000143348623853 0 1 -1
in,nephrosis,acromegaly 1.0 0.000143348623853 0 1 -1
in,neonates,with 1.0 0.000143348623853 0 1 -1
in,neonates,whose 1.0 0.000143348623853 0 1 -1
in,neonates,and 1.0 0.000143348623853 0 1 -1
in,neither,case 1.0 0.000143348623853 0 1 -1
in,myopathy,and 1.0 0.000143348623853 0 1 -1
in,myocardium,in 1.0 0.000143348623853 0 1 -1
in,multiple,sclerosis 1.0 0.000143348623853 0 1 -1
in,multiple,in 1.0 0.000143348623853 0 1 -1
in,mouse,lymphoma 1.0 0.000143348623853 0 1 -1
in,most,common 1.0 0.000143348623853 0 1 -1
in,mortality,was 1.0 0.000143348623853 0 1 -1
in,moribund,condition 1.0 0.000143348623853 0 1 -1
in,more,than 1.0 0.000143348623853 0 1 -1
in,monkeys,nanm 1.0 0.000143348623853 0 1 -1
in,monkeys,and 1.0 0.000143348623853 0 1 -1
in,mind,when 1.0 0.00043004587156 0 3 -3
in,mice,selectively 1.0 0.000143348623853 0 1 -1
in,mice,on 1.0 0.000143348623853 0 1 -1
in,mice,and 1.0 0.000143348623853 0 1 -1
in,mice,after 1.0 0.000286697247706 0 2 -2
in,mice,a 1.0 0.000143348623853 0 1 -1
in,metabolite,or 1.0 0.000143348623853 0 1 -1
in,metabolism,may 1.0 0.000143348623853 0 1 -1
in,metabolism,is 1.0 0.000143348623853 0 1 -1
in,metabolism,concomitant 1.0 0.000143348623853 0 1 -1
in,men,years 1.0 0.000143348623853 0 1 -1
in,men,with 1.0 0.000286697247706 0 2 -2
in,mediating,stimulus-induced 1.0 0.000143348623853 0 1 -1
in,mcf-7,cells 1.0 0.000143348623853 0 1 -1
in,march,citrate 1.0 0.000143348623853 0 1 -1
in,many,of 1.0 0.000143348623853 0 1 -1
in,man,we 1.0 0.000143348623853 0 1 -1
in,man,in 1.0 0.000143348623853 0 1 -1
in,man,and 1.0 0.000143348623853 0 1 -1
in,males,the 1.0 0.000143348623853 0 1 -1
in,male,wistar 1.0 0.000143348623853 0 1 -1
in,male,sprague-dawley 1.0 0.000143348623853 0 1 -1
in,male,rhesus 1.0 0.000143348623853 0 1 -1
in,male,rats 1.0 0.000143348623853 0 1 -1
in,mac,was 1.0 0.000143348623853 0 1 -1
in,lysing,human 1.0 0.000143348623853 0 1 -1
in,lymphocyte,counts 1.0 0.000143348623853 0 1 -1
in,luteinizing,hormone 1.0 0.000143348623853 0 1 -1
in,lowered,plasma 1.0 0.000143348623853 0 1 -1
in,low-density,lipoprotein 1.0 0.000143348623853 0 1 -1
in,locomotor,responses 1.0 0.000143348623853 0 1 -1
in,locomotor,activity 1.0 0.000143348623853 0 1 -1
in,local,breast 1.0 0.000143348623853 0 1 -1
in,livers,of 1.0 0.000143348623853 0 1 -1
in,liver,transaminases 1.0 0.000143348623853 0 1 -1
in,liver,increasing 1.0 0.000143348623853 0 1 -1
in,liver,function 1.0 0.000143348623853 0 1 -1
in,liver,by 1.0 0.000143348623853 0 1 -1
in,life-threatening,situations 1.0 0.000143348623853 0 1 -1
in,levels,in 1.0 0.000286697247706 0 2 -2
in,levels,comparable 1.0 0.000143348623853 0 1 -1
in,lean,animals 1.0 0.000143348623853 0 1 -1
in,layers,iv 1.0 0.000143348623853 0 1 -1
in,large,well 1.0 0.000143348623853 0 1 -1
in,large,doses 1.0 0.000143348623853 0 1 -1
in,laboratory,parameters 1.0 0.000143348623853 0 1 -1
in,laboratory,assessments 1.0 0.000143348623853 0 1 -1
in,kidney,recipients 1.0 0.000143348623853 0 1 -1
in,its,use 1.0 0.000143348623853 0 1 -1
in,isolated,single 1.0 0.000143348623853 0 1 -1
in,isolated,rabbit 1.0 0.000143348623853 0 1 -1
in,iso-sensitest,broth 1.0 0.000143348623853 0 1 -1
in,interpreting,the 1.0 0.000143348623853 0 1 -1
in,interaction,studies 1.0 0.000286697247706 0 2 -2
in,intensive,care 1.0 0.000143348623853 0 1 -1
in,intact,subjects 1.0 0.000143348623853 0 1 -1
in,insulin-dependent,diabetic 1.0 0.000143348623853 0 1 -1
in,inr,or 1.0 0.000143348623853 0 1 -1
in,inhibiting,yeast 1.0 0.000143348623853 0 1 -1
in,infants,has 1.0 0.000143348623853 0 1 -1
in,individuals,who 1.0 0.000143348623853 0 1 -1
in,individuals,known 1.0 0.000143348623853 0 1 -1
in,individualizing,it 1.0 0.000143348623853 0 1 -1
in,individual,inr 1.0 0.000143348623853 0 1 -1
in,increasing,the 1.0 0.000143348623853 0 1 -1
in,increased,urinary 1.0 0.000143348623853 0 1 -1
in,increased,risk 1.0 0.000143348623853 0 1 -1
in,incomplete,depletion 1.0 0.000143348623853 0 1 -1
in,in,vivo 1.0 0.000143348623853 0 1 -1
in,in,vitro 1.0 0.000573394495413 0 4 -4
in,immune,function 1.0 0.000143348623853 0 1 -1
in,hypothyroid,patients 1.0 0.00043004587156 0 3 -3
in,hyperuricemic,patients 1.0 0.000143348623853 0 1 -1
in,hyperthyroidism,or 1.0 0.000143348623853 0 1 -1
in,hyperthyroid,patients 1.0 0.000143348623853 0 1 -1
in,hypertensive,patients 1.0 0.000143348623853 0 1 -1
in,hypercholesterolemic,noninsulin 1.0 0.000143348623853 0 1 -1
in,humans,was 1.0 0.000143348623853 0 1 -1
in,humans,two 1.0 0.000143348623853 0 1 -1
in,humans,that 1.0 0.000143348623853 0 1 -1
in,humans,taking 1.0 0.000143348623853 0 1 -1
in,humans,remain 1.0 0.000143348623853 0 1 -1
in,humans,metabolism 1.0 0.000143348623853 0 1 -1
in,humans,is 1.0 0.000143348623853 0 1 -1
in,humans,have 1.0 0.000573394495413 0 4 -4
in,humans,demonstrated 1.0 0.000143348623853 0 1 -1
in,human,plasma 1.0 0.000286697247706 0 2 -2
in,human,milk 1.0 0.000286697247706 0 2 -2
in,human,lymphocytes 1.0 0.000286697247706 0 2 -2
in,human,immunodeficiency 1.0 0.000143348623853 0 1 -1
in,human,heart 1.0 0.000286697247706 0 2 -2
in,human,cells 1.0 0.000143348623853 0 1 -1
in,how,it 1.0 0.000143348623853 0 1 -1
in,hospitals,resulting 1.0 0.000143348623853 0 1 -1
in,hormone,levels 1.0 0.000143348623853 0 1 -1
in,hiv-infected,subjects 1.0 0.000143348623853 0 1 -1
in,hiv-infected,individuals 1.0 0.000143348623853 0 1 -1
in,hiv-1,seropositive 1.0 0.000286697247706 0 2 -2
in,his,logical 1.0 0.000143348623853 0 1 -1
in,hippocampal,adenylate 1.0 0.000143348623853 0 1 -1
in,high,concentrations 1.0 0.000143348623853 0 1 -1
in,hepatic,function 1.0 0.000143348623853 0 1 -1
in,hematologic,studies 1.0 0.000143348623853 0 1 -1
in,healthy,young 1.0 0.000143348623853 0 1 -1
in,healthy,women 1.0 0.000143348623853 0 1 -1
in,healthy,normal 1.0 0.000143348623853 0 1 -1
in,healthy,non-smoking 1.0 0.000143348623853 0 1 -1
in,healthy,males 1.0 0.000143348623853 0 1 -1
in,hazardous,activities 1.0 0.000143348623853 0 1 -1
in,gonadotropin,levels 1.0 0.000143348623853 0 1 -1
in,glycemia,after 1.0 0.000143348623853 0 1 -1
in,glutamatergic,activation 1.0 0.000143348623853 0 1 -1
in,glomerular,filtration 1.0 0.000143348623853 0 1 -1
in,geriatric,subjects 1.0 0.000143348623853 0 1 -1
in,genetically,predisposed 1.0 0.000143348623853 0 1 -1
in,general,these 1.0 0.000143348623853 0 1 -1
in,general,most 1.0 0.000143348623853 0 1 -1
in,general,if 1.0 0.000143348623853 0 1 -1
in,general,cognitive 1.0 0.000143348623853 0 1 -1
in,general,caution 1.0 0.000143348623853 0 1 -1
in,general,are 1.0 0.000143348623853 0 1 -1
in,general,any 1.0 0.000143348623853 0 1 -1
in,general,and 1.0 0.000143348623853 0 1 -1
in,gene,expression 1.0 0.000143348623853 0 1 -1
in,functional,or 1.0 0.000143348623853 0 1 -1
in,functional,classes 1.0 0.000286697247706 0 2 -2
in,function,were 1.0 0.000143348623853 0 1 -1
in,free,concentrations 1.0 0.000143348623853 0 1 -1
in,free,concentration 1.0 0.000143348623853 0 1 -1
in,four,subjects 1.0 0.000143348623853 0 1 -1
in,fluoride,levels 1.0 0.000143348623853 0 1 -1
in,five,men 1.0 0.000143348623853 0 1 -1
in,fertility,and 1.0 0.000143348623853 0 1 -1
in,females,dosed 1.0 0.000143348623853 0 1 -1
in,female,rats 1.0 0.00043004587156 0 3 -3
in,female,fertility 1.0 0.000143348623853 0 1 -1
in,female,cynomolgus 1.0 0.000143348623853 0 1 -1
in,female,animals 1.0 0.000143348623853 0 1 -1
in,female,and 1.0 0.000143348623853 0 1 -1
in,fat,and 1.0 0.000143348623853 0 1 -1
in,falsely,elevated 1.0 0.000143348623853 0 1 -1
in,false-positive,findings 1.0 0.000143348623853 0 1 -1
in,failing,hearts 1.0 0.000143348623853 0 1 -1
in,extremely,acidic 1.0 0.000143348623853 0 1 -1
in,extrapolating,these 1.0 0.000143348623853 0 1 -1
in,external,subcutaneous 1.0 0.000143348623853 0 1 -1
in,exposure,were 1.0 0.000143348623853 0 1 -1
in,exposure,and 1.0 0.000143348623853 0 1 -1
in,experiments,on 1.0 0.000143348623853 0 1 -1
in,excess,of 1.0 0.000143348623853 0 1 -1
in,evaluating,the 1.0 0.000143348623853 0 1 -1
in,evaluating,abnormal 1.0 0.000143348623853 0 1 -1
in,establishing,the 1.0 0.000143348623853 0 1 -1
in,escalating,doses 1.0 0.000143348623853 0 1 -1
in,erythro-fluorocitrate,synthesis 1.0 0.000143348623853 0 1 -1
in,ephesus,patients 1.0 0.000143348623853 0 1 -1
in,enterococcus,faecalis 1.0 0.000143348623853 0 1 -1
in,enhancing,efficacious 1.0 0.000143348623853 0 1 -1
in,ems,selective 1.0 0.000143348623853 0 1 -1
in,elucidating,the 1.0 0.000143348623853 0 1 -1
in,elevated,creatinine 1.0 0.000143348623853 0 1 -1
in,electrically,stimulated 1.0 0.000143348623853 0 1 -1
in,either,the 1.0 0.000143348623853 0 1 -1
in,either,striatum 1.0 0.000143348623853 0 1 -1
in,either,procedure 1.0 0.000143348623853 0 1 -1
in,either,pharmacokinetics 1.0 0.000143348623853 0 1 -1
in,either,erythro-fluorocitrate 1.0 0.000143348623853 0 1 -1
in,either,diabetics 1.0 0.000143348623853 0 1 -1
in,eight,experiments 1.0 0.000143348623853 0 1 -1
in,effects,on 1.0 0.000143348623853 0 1 -1
in,effect,of 1.0 0.000143348623853 0 1 -1
in,ecg,heart 1.0 0.000143348623853 0 1 -1
in,eagles,minimal 1.0 0.000143348623853 0 1 -1
in,each,task 1.0 0.000143348623853 0 1 -1
in,each,subject 1.0 0.000143348623853 0 1 -1
in,each,study 1.0 0.000286697247706 0 2 -2
in,each,preparation 1.0 0.000143348623853 0 1 -1
in,each,of 1.0 0.000286697247706 0 2 -2
in,dosing,and 1.0 0.000143348623853 0 1 -1
in,dose,should 1.0 0.000143348623853 0 1 -1
in,dose,selection 1.0 0.000143348623853 0 1 -1
in,dose,or 1.0 0.000286697247706 0 2 -2
in,dose,of 1.0 0.000143348623853 0 1 -1
in,dose,for 1.0 0.000143348623853 0 1 -1
in,dosage,will 1.0 0.000143348623853 0 1 -1
in,dosage,may 1.0 0.000143348623853 0 1 -1
in,dosage,and 1.0 0.000143348623853 0 1 -1
in,dogs,unchanged 1.0 0.000143348623853 0 1 -1
in,dogs,treated 1.0 0.000143348623853 0 1 -1
in,dogs,approximately 1.0 0.000143348623853 0 1 -1
in,dmpge2,mg 1.0 0.000143348623853 0 1 -1
in,divided,doses 1.0 0.000143348623853 0 1 -1
in,disposition,may 1.0 0.000143348623853 0 1 -1
in,dietary-obese,rats 1.0 0.000143348623853 0 1 -1
in,diabetics,blood-sugar 1.0 0.000143348623853 0 1 -1
in,diabetic,and 1.0 0.000286697247706 0 2 -2
in,diabetes,longitudinal 1.0 0.000143348623853 0 1 -1
in,development,of 1.0 0.000143348623853 0 1 -1
in,determining,the 1.0 0.000143348623853 0 1 -1
in,detecting,alterations 1.0 0.000143348623853 0 1 -1
in,desloratadine,and 1.0 0.000143348623853 0 1 -1
in,dependence,on 1.0 0.000143348623853 0 1 -1
in,dentistry,cannot 1.0 0.000143348623853 0 1 -1
in,density,bmax 1.0 0.000143348623853 0 1 -1
in,deficits,in 1.0 0.000143348623853 0 1 -1
in,decreasing,responding 1.0 0.000143348623853 0 1 -1
in,decreases,in 1.0 0.000143348623853 0 1 -1
in,decreased,psychomotor 1.0 0.000143348623853 0 1 -1
in,december,the 1.0 0.000143348623853 0 1 -1
in,de,novo 1.0 0.000286697247706 0 2 -2
in,day-old,embryos 1.0 0.000143348623853 0 1 -1
in,cyp3a4,mediated 1.0 0.000143348623853 0 1 -1
in,cyp2d6,activity 1.0 0.000143348623853 0 1 -1
in,cynomolgus,monkeys 1.0 0.000286697247706 0 2 -2
in,cpk,were 1.0 0.000143348623853 0 1 -1
in,cortisol,does 1.0 0.000143348623853 0 1 -1
in,corrected,qt 1.0 0.000143348623853 0 1 -1
in,coombs,testing 1.0 0.000143348623853 0 1 -1
in,controlled,clinical 1.0 0.000573394495413 0 4 -4
in,control,rats 1.0 0.000286697247706 0 2 -2
in,contrast,to 1.0 0.000286697247706 0 2 -2
in,contrast,the 1.0 0.000143348623853 0 1 -1
in,contrast,preliminary 1.0 0.000143348623853 0 1 -1
in,contrast,nucleophosmin 1.0 0.000143348623853 0 1 -1
in,contrast,increased 1.0 0.000143348623853 0 1 -1
in,contrast,in 1.0 0.000286697247706 0 2 -2
in,contrast,acute 1.0 0.000143348623853 0 1 -1
in,conditions,for 1.0 0.000143348623853 0 1 -1
in,concurrent,or 1.0 0.000286697247706 0 2 -2
in,concert,with 1.0 0.000143348623853 0 1 -1
in,concentration,may 1.0 0.000143348623853 0 1 -1
in,comparative,data 1.0 0.000143348623853 0 1 -1
in,combinations,were 1.0 0.000143348623853 0 1 -1
in,combination,see 1.0 0.000143348623853 0 1 -1
in,combination,lies 1.0 0.000143348623853 0 1 -1
in,coffee,and 1.0 0.000143348623853 0 1 -1
in,cocaine-treated,groups 1.0 0.000143348623853 0 1 -1
in,clotting,time 1.0 0.000286697247706 0 2 -2
in,clotting,factor 1.0 0.000143348623853 0 1 -1
in,close,collaboration 1.0 0.000143348623853 0 1 -1
in,clinically,significant 1.0 0.00043004587156 0 3 -3
in,clinically,normal 1.0 0.000143348623853 0 1 -1
in,clinical,pharmacokinetic 1.0 0.000286697247706 0 2 -2
in,clinical,interaction 1.0 0.000143348623853 0 1 -1
in,clearance,value 1.0 0.000143348623853 0 1 -1
in,clearance,does 1.0 0.000143348623853 0 1 -1
in,clearance,between 1.0 0.000143348623853 0 1 -1
in,class,a 1.0 0.000143348623853 0 1 -1
in,citrate,and 1.0 0.000143348623853 0 1 -1
in,circulating,concentrations 1.0 0.000143348623853 0 1 -1
in,ci,of 1.0 0.000143348623853 0 1 -1
in,chronic,treatments 1.0 0.000143348623853 0 1 -1
in,children,has 1.0 0.000143348623853 0 1 -1
in,chick,embryos 1.0 0.000143348623853 0 1 -1
in,chemotherapy,or 1.0 0.000143348623853 0 1 -1
in,chapter,including 1.0 0.000143348623853 0 1 -1
in,cervical,mucus 1.0 0.000143348623853 0 1 -1
in,certain,tumor 1.0 0.000143348623853 0 1 -1
in,cell,type 1.0 0.000143348623853 0 1 -1
in,cell,cultures 1.0 0.000143348623853 0 1 -1
in,cecectomized,than 1.0 0.000286697247706 0 2 -2
in,cecectomized,rats 1.0 0.000286697247706 0 2 -2
in,cecectomized,and 1.0 0.00043004587156 0 3 -3
in,caution,in 1.0 0.000143348623853 0 1 -1
in,cat,inferior 1.0 0.000143348623853 0 1 -1
in,cases,with 1.0 0.000143348623853 0 1 -1
in,cases,and 1.0 0.000143348623853 0 1 -1
in,cardiovascular,disease 1.0 0.000143348623853 0 1 -1
in,cardioplegic,solutions 1.0 0.000143348623853 0 1 -1
in,breast,cancer 1.0 0.000143348623853 0 1 -1
in,bovine,chromaffin 1.0 0.000286697247706 0 2 -2
in,both,tissues 1.0 0.000143348623853 0 1 -1
in,both,the 1.0 0.00043004587156 0 3 -3
in,both,renal 1.0 0.000143348623853 0 1 -1
in,both,plasma 1.0 0.000143348623853 0 1 -1
in,both,periods 1.0 0.000143348623853 0 1 -1
in,both,instances 1.0 0.000143348623853 0 1 -1
in,both,groups 1.0 0.000286697247706 0 2 -2
in,both,dose 1.0 0.000143348623853 0 1 -1
in,bleeding,time 1.0 0.000143348623853 0 1 -1
in,bioavailability,studies 1.0 0.000143348623853 0 1 -1
in,bioavailability,or 1.0 0.000143348623853 0 1 -1
in,basal,small 1.0 0.000143348623853 0 1 -1
in,balance,were 1.0 0.000143348623853 0 1 -1
in,b-cell,dependent 1.0 0.000143348623853 0 1 -1
in,auc,vs 1.0 0.000143348623853 0 1 -1
in,auc,cmax 1.0 0.000143348623853 0 1 -1
in,arthritic,patients 1.0 0.000143348623853 0 1 -1
in,arteries,from 1.0 0.000143348623853 0 1 -1
in,areas,where 1.0 0.000143348623853 0 1 -1
in,approximately,half 1.0 0.000143348623853 0 1 -1
in,approximately,fold 1.0 0.000286697247706 0 2 -2
in,aortic,rings 1.0 0.000143348623853 0 1 -1
in,any,unexpected 1.0 0.000143348623853 0 1 -1
in,any,statistically 1.0 0.000143348623853 0 1 -1
in,any,significant 1.0 0.000143348623853 0 1 -1
in,any,of 1.0 0.000143348623853 0 1 -1
in,any,changes 1.0 0.000286697247706 0 2 -2
in,antiapoptotic,effect 1.0 0.000143348623853 0 1 -1
in,anti-apoptotic,effect 1.0 0.000143348623853 0 1 -1
in,another,female 1.0 0.000143348623853 0 1 -1
in,animals,to 1.0 0.000143348623853 0 1 -1
in,animal,or 1.0 0.000143348623853 0 1 -1
in,animal,models 1.0 0.000143348623853 0 1 -1
in,angina,patients 1.0 0.000143348623853 0 1 -1
in,and,two 1.0 0.000143348623853 0 1 -1
in,and,there 1.0 0.000143348623853 0 1 -1
in,and,of 1.0 0.000286697247706 0 2 -2
in,and,may 1.0 0.000143348623853 0 1 -1
in,and,epoxide 1.0 0.000143348623853 0 1 -1
in,an,uncontrolled 1.0 0.000143348623853 0 1 -1
in,an,regimen 1.0 0.000143348623853 0 1 -1
in,an,open-label 1.0 0.000143348623853 0 1 -1
in,an,open 1.0 0.000143348623853 0 1 -1
in,an,interaction 1.0 0.000143348623853 0 1 -1
in,an,elisa 1.0 0.000143348623853 0 1 -1
in,an,effort 1.0 0.000143348623853 0 1 -1
in,an,area 1.0 0.000143348623853 0 1 -1
in,an,apparent 1.0 0.000143348623853 0 1 -1
in,an,adolescent 1.0 0.000143348623853 0 1 -1
in,an,adequate 1.0 0.000143348623853 0 1 -1
in,amiodarone-treated,patients 1.0 0.000143348623853 0 1 -1
in,ambulatory,patients 1.0 0.000143348623853 0 1 -1
in,altering,activity 1.0 0.000143348623853 0 1 -1
in,altered,plasma 1.0 0.000143348623853 0 1 -1
in,altered,pharmacoktnetics 1.0 0.000143348623853 0 1 -1
in,almost,complete 1.0 0.000143348623853 0 1 -1
in,all,animal 1.0 0.000143348623853 0 1 -1
in,adverse,reactions 1.0 0.000143348623853 0 1 -1
in,adverse,events 1.0 0.00043004587156 0 3 -3
in,adverse,effects 1.0 0.000143348623853 0 1 -1
in,adults,were 1.0 0.000143348623853 0 1 -1
in,administering,compounds 1.0 0.000143348623853 0 1 -1
in,adjuvant,trials 1.0 0.000143348623853 0 1 -1
in,adequate,numbers 1.0 0.000143348623853 0 1 -1
in,adequate,and 1.0 0.000143348623853 0 1 -1
in,addressing,information 1.0 0.000143348623853 0 1 -1
in,addition,we 1.0 0.000143348623853 0 1 -1
in,addition,under 1.0 0.000286697247706 0 2 -2
in,addition,studies 1.0 0.000143348623853 0 1 -1
in,addition,steady 1.0 0.000143348623853 0 1 -1
in,addition,reduced 1.0 0.000143348623853 0 1 -1
in,addition,patients 1.0 0.000143348623853 0 1 -1
in,addition,new 1.0 0.000286697247706 0 2 -2
in,addition,neuromuscular 1.0 0.000143348623853 0 1 -1
in,addition,is 1.0 0.000143348623853 0 1 -1
in,addition,fondaparinux 1.0 0.000143348623853 0 1 -1
in,addition,does 1.0 0.000143348623853 0 1 -1
in,addition,certain 1.0 0.00100344036697 0 7 -7
in,addition,based 1.0 0.000143348623853 0 1 -1
in,addition,and 1.0 0.000143348623853 0 1 -1
in,addition,administration 1.0 0.000286697247706 0 2 -2
in,accordance,with 1.0 0.000573394495413 0 4 -4
in,absorption,results 1.0 0.000143348623853 0 1 -1
in,about,of 1.0 0.000143348623853 0 1 -1
in,a-chloralose,anesthetized 1.0 0.000143348623853 0 1 -1
in,a,year 1.0 0.000143348623853 0 1 -1
in,a,well-controlled 1.0 0.000286697247706 0 2 -2
in,a,week 1.0 0.000143348623853 0 1 -1
in,a,total 1.0 0.000143348623853 0 1 -1
in,a,temporary 1.0 0.000143348623853 0 1 -1
in,a,systemic 1.0 0.000143348623853 0 1 -1
in,a,supine 1.0 0.000143348623853 0 1 -1
in,a,subset 1.0 0.000860091743119 0 6 -6
in,a,statistically 1.0 0.000143348623853 0 1 -1
in,a,short-term 1.0 0.000143348623853 0 1 -1
in,a,separate 1.0 0.000286697247706 0 2 -2
in,a,randomized 1.0 0.000286697247706 0 2 -2
in,a,rabbit 1.0 0.000143348623853 0 1 -1
in,a,prospective 1.0 0.000143348623853 0 1 -1
in,a,parallel 1.0 0.000143348623853 0 1 -1
in,a,p53 1.0 0.000143348623853 0 1 -1
in,a,mouse 1.0 0.000143348623853 0 1 -1
in,a,month 1.0 0.000286697247706 0 2 -2
in,a,manner 1.0 0.000143348623853 0 1 -1
in,a,lower 1.0 0.000143348623853 0 1 -1
in,a,literature 1.0 0.000143348623853 0 1 -1
in,a,linear 1.0 0.000143348623853 0 1 -1
in,a,limited 1.0 0.000143348623853 0 1 -1
in,a,light 1.0 0.000286697247706 0 2 -2
in,a,less 1.0 0.000143348623853 0 1 -1
in,a,large 1.0 0.000143348623853 0 1 -1
in,a,kg 1.0 0.000143348623853 0 1 -1
in,a,interaction 1.0 0.000143348623853 0 1 -1
in,a,highly 1.0 0.000143348623853 0 1 -1
in,a,high 1.0 0.000143348623853 0 1 -1
in,a,group 1.0 0.000143348623853 0 1 -1
in,a,given 1.0 0.000143348623853 0 1 -1
in,a,genetically 1.0 0.000143348623853 0 1 -1
in,a,four-session 1.0 0.000143348623853 0 1 -1
in,a,follow-up 1.0 0.000143348623853 0 1 -1
in,a,first 1.0 0.000143348623853 0 1 -1
in,a,female 1.0 0.000143348623853 0 1 -1
in,a,false-positive 1.0 0.000716743119266 0 5 -5
in,a,false 1.0 0.000143348623853 0 1 -1
in,a,double-blind 1.0 0.000286697247706 0 2 -2
in,a,double 1.0 0.000143348623853 0 1 -1
in,a,defined 1.0 0.000143348623853 0 1 -1
in,a,complex 1.0 0.000143348623853 0 1 -1
in,a,compensatory 1.0 0.000143348623853 0 1 -1
in,a,chronic 1.0 0.000143348623853 0 1 -1
in,a,cell-free 1.0 0.000143348623853 0 1 -1
in,a,broad 1.0 0.000143348623853 0 1 -1
in,a,basic 1.0 0.000143348623853 0 1 -1
improving,the,adequacy 1.0 0.000143348623853 0 1 -1
improves,the,intestinal 1.0 0.000143348623853 0 1 -1
improves,quality,of 1.0 0.000143348623853 0 1 -1
improvements,in,psychopathology 1.0 0.000143348623853 0 1 -1
improvements,in,general 1.0 0.000143348623853 0 1 -1
improved,when,d2o 1.0 0.000143348623853 0 1 -1
improved,the,transport 1.0 0.000143348623853 0 1 -1
improved,permeation,was 1.0 0.000143348623853 0 1 -1
improved,glucose,utilization 1.0 0.000143348623853 0 1 -1
improved,and,the 1.0 0.000143348623853 0 1 -1
improve,this,metabolism 1.0 0.000143348623853 0 1 -1
improve,the,permeation 1.0 0.000143348623853 0 1 -1
improve,the,general 1.0 0.000143348623853 0 1 -1
improve,sensitivity,and 1.0 0.000143348623853 0 1 -1
impotence,inability,to 1.0 0.000143348623853 0 1 -1
importantly,we,demonstrate 1.0 0.000143348623853 0 1 -1
important,when,using 1.0 0.000143348623853 0 1 -1
important,to,identify 1.0 0.000143348623853 0 1 -1
important,that,physicians 1.0 0.000143348623853 0 1 -1
important,that,patients 1.0 0.000143348623853 0 1 -1
important,that,health 1.0 0.000143348623853 0 1 -1
important,relationships,among 1.0 0.000143348623853 0 1 -1
important,regulation,of 1.0 0.000143348623853 0 1 -1
important,potentiation,of 1.0 0.000143348623853 0 1 -1
important,pharmacokinetic,interactions 1.0 0.000573394495413 0 4 -4
important,interactions,to 1.0 0.000143348623853 0 1 -1
important,interactions,have 1.0 0.000286697247706 0 2 -2
important,interactions,between 1.0 0.000143348623853 0 1 -1
important,interaction,with 1.0 0.000143348623853 0 1 -1
important,in,the 1.0 0.000143348623853 0 1 -1
important,in,supporting 1.0 0.000143348623853 0 1 -1
important,in,patients 1.0 0.000143348623853 0 1 -1
important,for,women 1.0 0.000143348623853 0 1 -1
important,for,the 1.0 0.000143348623853 0 1 -1
important,for,older 1.0 0.000143348623853 0 1 -1
important,for,drugs 1.0 0.000143348623853 0 1 -1
important,factors,in 1.0 0.000143348623853 0 1 -1
important,effects,on 1.0 0.00043004587156 0 3 -3
important,effect,on 1.0 0.000860091743119 0 6 -6
important,causes,of 1.0 0.000143348623853 0 1 -1
important,alterations,of 1.0 0.000143348623853 0 1 -1
important,also,in 1.0 0.000143348623853 0 1 -1
importance,to,all 1.0 0.000143348623853 0 1 -1
importance,of,topoisomerases 1.0 0.000143348623853 0 1 -1
importance,of,the 1.0 0.00043004587156 0 3 -3
importance,of,pharmacogenetics 1.0 0.000143348623853 0 1 -1
importance,of,a 1.0 0.000143348623853 0 1 -1
importance,in,the 1.0 0.000143348623853 0 1 -1
implications,of,these 1.0 0.000143348623853 0 1 -1
implications,for,management 1.0 0.000143348623853 0 1 -1
implications,for,decreased 1.0 0.000143348623853 0 1 -1
implants,and,injectables 1.0 0.000143348623853 0 1 -1
implantable,insertable,hormonal 1.0 0.000143348623853 0 1 -1
implant,have,not 1.0 0.000143348623853 0 1 -1
impedance,and,the 1.0 0.000143348623853 0 1 -1
impairment,there,are 1.0 0.000286697247706 0 2 -2
impairment,particularly,in 1.0 0.000143348623853 0 1 -1
impairment,of,mental 1.0 0.000143348623853 0 1 -1
impairment,of,fertility 1.0 0.000573394495413 0 4 -4
impairment,of,efficacy 1.0 0.000143348623853 0 1 -1
impairment,may,require 1.0 0.000286697247706 0 2 -2
impairment,in,vitro 1.0 0.000143348623853 0 1 -1
impairment,and,patients 1.0 0.000143348623853 0 1 -1
impaired,when,hypothyroid 1.0 0.000143348623853 0 1 -1
impaired,vs,spared 1.0 0.000143348623853 0 1 -1
impaired,ventricular,function 1.0 0.000143348623853 0 1 -1
impaired,suppression,of 1.0 0.000143348623853 0 1 -1
impaired,liver,function 1.0 0.000143348623853 0 1 -1
impaired,fertility,or 1.0 0.000143348623853 0 1 -1
impaired,cardiac,function 1.0 0.000143348623853 0 1 -1
impaired,by,all 1.0 0.000143348623853 0 1 -1
impaired,but,not 1.0 0.000143348623853 0 1 -1
impair,liver,function 1.0 0.000143348623853 0 1 -1
impair,intestinal,absorption 1.0 0.00043004587156 0 3 -3
impair,glomerular,filtration 1.0 0.000143348623853 0 1 -1
impactor,for,characterization 1.0 0.000143348623853 0 1 -1
impacted,by,concomitant 1.0 0.000143348623853 0 1 -1
impact,of,the 1.0 0.000143348623853 0 1 -1
impact,of,renal 1.0 0.000143348623853 0 1 -1
impact,of,chemotherapy 1.0 0.000143348623853 0 1 -1
immunosuppressives,cyclosporine,cyp3a4 1.0 0.000143348623853 0 1 -1
immunosuppressive,drugs,fibric 1.0 0.000143348623853 0 1 -1
immunosuppression,are,now 1.0 0.000143348623853 0 1 -1
immunosuppressant,metabolized,by 1.0 0.000143348623853 0 1 -1
immunoreactive,concentrations,were 1.0 0.000143348623853 0 1 -1
immunoreactive,after,concurrent 1.0 0.000143348623853 0 1 -1
immunogenicity,re-exposure,in 1.0 0.000143348623853 0 1 -1
immunodepressant--the,sandimmune--on,hepatic 1.0 0.000143348623853 0 1 -1
immunodeficiency-associated,lymphocyte,disorders 1.0 0.000143348623853 0 1 -1
immunodeficiency,virus-positive,patients 1.0 0.000143348623853 0 1 -1
immunodeficiency,virus,hiv 1.0 0.000143348623853 0 1 -1
immunodeficiencies,including,those 1.0 0.000143348623853 0 1 -1
immunoanalytical,methods,to 1.0 0.000143348623853 0 1 -1
immune,system,development 1.0 0.000286697247706 0 2 -2
immune,system,are 1.0 0.000143348623853 0 1 -1
immune,system,and 1.0 0.000143348623853 0 1 -1
immune,response,to 1.0 0.000143348623853 0 1 -1
immune,response,suggest 1.0 0.000143348623853 0 1 -1
immune,function,in 1.0 0.000143348623853 0 1 -1
immune,function,and 1.0 0.000143348623853 0 1 -1
immobilised,cmc-cys7,from 1.0 0.000143348623853 0 1 -1
immediately,preceding,the 1.0 0.000143348623853 0 1 -1
immediately,if,any 1.0 0.000143348623853 0 1 -1
immediately,before,injection 1.0 0.000143348623853 0 1 -1
immediate-early,genes,iegs 1.0 0.000143348623853 0 1 -1
immediate,side,effects 1.0 0.000143348623853 0 1 -1
immediate,medical,attention 1.0 0.000143348623853 0 1 -1
immediate,discontinuation,of 1.0 0.000143348623853 0 1 -1
imitrex,talk,to 1.0 0.000143348623853 0 1 -1
imitrex,nasal,spray 1.0 0.000143348623853 0 1 -1
imipramine,mg,kg 1.0 0.000143348623853 0 1 -1
imipramine,and,did 1.0 0.000143348623853 0 1 -1
imidazole,and,triazole 1.0 0.000143348623853 0 1 -1
im,was,given 1.0 0.000143348623853 0 1 -1
im,twice,the 1.0 0.000143348623853 0 1 -1
im,has,been 1.0 0.000143348623853 0 1 -1
im,approximately,one-tenth 1.0 0.000143348623853 0 1 -1
im,and,nondepolarizing 1.0 0.000143348623853 0 1 -1
illustrated,information,for 1.0 0.000143348623853 0 1 -1
illustrated,by,six 1.0 0.000143348623853 0 1 -1
illnesses,dose,of 1.0 0.000143348623853 0 1 -1
ill,and,to 1.0 0.000143348623853 0 1 -1
ija,models,for 1.0 0.000143348623853 0 1 -1
iii,decreased,antithrombin 1.0 0.000286697247706 0 2 -2
iii,and,iv 1.0 0.000286697247706 0 2 -2
ii-vii,x,complex 1.0 0.000286697247706 0 2 -2
ii,vii,antigen 1.0 0.000286697247706 0 2 -2
ii,v,vii 1.0 0.000143348623853 0 1 -1
ii,to,iii 1.0 0.000286697247706 0 2 -2
ii,the,effects 1.0 0.000143348623853 0 1 -1
ii,showed,moderate 1.0 0.000143348623853 0 1 -1
ii,or,its 1.0 0.000143348623853 0 1 -1
ii,alone,and 1.0 0.000286697247706 0 2 -2
igm,can,be 1.0 0.000143348623853 0 1 -1
igg,or,igm 1.0 0.000143348623853 0 1 -1
iga,is,the 1.0 0.000143348623853 0 1 -1
iga,is,probably 1.0 0.000143348623853 0 1 -1
if,you,think 1.0 0.000143348623853 0 1 -1
if,withdrawn,within 1.0 0.000143348623853 0 1 -1
if,used,in 1.0 0.000143348623853 0 1 -1
if,tykerb,is 1.0 0.000286697247706 0 2 -2
if,treatment,is 1.0 0.000143348623853 0 1 -1
if,tranxene,tablets 1.0 0.000143348623853 0 1 -1
if,tranxene,is 1.0 0.000143348623853 0 1 -1
if,this,is 1.0 0.00043004587156 0 3 -3
if,they,occur 1.0 0.000143348623853 0 1 -1
if,they,do 1.0 0.000143348623853 0 1 -1
if,they,can 1.0 0.000143348623853 0 1 -1
if,they,are 1.0 0.000143348623853 0 1 -1
if,these,products 1.0 0.000143348623853 0 1 -1
if,these,preparations 1.0 0.000143348623853 0 1 -1
if,these,patients 1.0 0.000143348623853 0 1 -1
if,these,are 1.0 0.000573394495413 0 4 -4
if,there,is 1.0 0.000573394495413 0 4 -4
if,the,usual 1.0 0.000143348623853 0 1 -1
if,the,treatment 1.0 0.000143348623853 0 1 -1
if,the,supplements 1.0 0.000143348623853 0 1 -1
if,the,porter-silber 1.0 0.000143348623853 0 1 -1
if,the,patients 1.0 0.000143348623853 0 1 -1
if,the,neutrophil 1.0 0.000143348623853 0 1 -1
if,the,is 1.0 0.000143348623853 0 1 -1
if,the,dose 1.0 0.000143348623853 0 1 -1
if,the,concomitant 1.0 0.000286697247706 0 2 -2
if,the,are 1.0 0.000143348623853 0 1 -1
if,the,antagonist 1.0 0.000143348623853 0 1 -1
if,taken,hour 1.0 0.000143348623853 0 1 -1
if,systemic,administration 1.0 0.000143348623853 0 1 -1
if,such,treatment 1.0 0.000143348623853 0 1 -1
if,such,measurements 1.0 0.000143348623853 0 1 -1
if,such,drugs 1.0 0.000143348623853 0 1 -1
if,such,are 1.0 0.000143348623853 0 1 -1
if,such,an 1.0 0.000286697247706 0 2 -2
if,sprycel,must 1.0 0.000143348623853 0 1 -1
if,significant,abnormal 1.0 0.000143348623853 0 1 -1
if,resumed,during 1.0 0.000143348623853 0 1 -1
if,replacement,is 1.0 0.000143348623853 0 1 -1
if,renal,function 1.0 0.000143348623853 0 1 -1
if,regranex,gel 1.0 0.000143348623853 0 1 -1
if,rebif,is 1.0 0.000143348623853 0 1 -1
if,prosom,is 1.0 0.000143348623853 0 1 -1
if,pregnancy,occurs 1.0 0.000286697247706 0 2 -2
if,possible,or 1.0 0.000143348623853 0 1 -1
if,plasma,levels 1.0 0.000143348623853 0 1 -1
if,patients,receive 1.0 0.000143348623853 0 1 -1
if,other,produce 1.0 0.000143348623853 0 1 -1
if,other,muscle 1.0 0.000143348623853 0 1 -1
if,other,alternatives 1.0 0.000143348623853 0 1 -1
if,oral,are 1.0 0.000143348623853 0 1 -1
if,or,are 1.0 0.000143348623853 0 1 -1
if,novolog,is 1.0 0.000143348623853 0 1 -1
if,necessary,should 1.0 0.000143348623853 0 1 -1
if,necessary,receive 1.0 0.000143348623853 0 1 -1
if,necessary,for 1.0 0.000143348623853 0 1 -1
if,necessary,can 1.0 0.000143348623853 0 1 -1
if,mepron,interferes 1.0 0.000143348623853 0 1 -1
if,leustatin,injection 1.0 0.000143348623853 0 1 -1
if,is,to 1.0 0.000143348623853 0 1 -1
if,is,excreted 1.0 0.000143348623853 0 1 -1
if,is,added 1.0 0.000143348623853 0 1 -1
if,hypotension,occurs 1.0 0.000143348623853 0 1 -1
if,hormonal,differ 1.0 0.000143348623853 0 1 -1
if,higher,dosages 1.0 0.000143348623853 0 1 -1
if,given,concomitantly 1.0 0.000143348623853 0 1 -1
if,concomitant,use 1.0 0.000860091743119 0 6 -6
if,concomitant,administration 1.0 0.000143348623853 0 1 -1
if,combination,therapy 1.0 0.000286697247706 0 2 -2
if,co-administration,is 1.0 0.000286697247706 0 2 -2
if,changes,in 1.0 0.000143348623853 0 1 -1
if,b12,deficiency 1.0 0.000143348623853 0 1 -1
if,argatroban,is 1.0 0.000143348623853 0 1 -1
if,any,on 1.0 0.000143348623853 0 1 -1
if,any,of 1.0 0.000286697247706 0 2 -2
if,any,clinically 1.0 0.000143348623853 0 1 -1
if,and,such 1.0 0.000143348623853 0 1 -1
if,an,interaction 1.0 0.000143348623853 0 1 -1
if,an,alternative 1.0 0.000143348623853 0 1 -1
if,administered,rapidly 1.0 0.000143348623853 0 1 -1
if,abruptly,discontinued 1.0 0.000143348623853 0 1 -1
iegs,has,been 1.0 0.000143348623853 0 1 -1
iegs,are,thought 1.0 0.000143348623853 0 1 -1
ieg,response,induced 1.0 0.000143348623853 0 1 -1
ieg,arc,activity-regulated 1.0 0.000143348623853 0 1 -1
ie,timi-ii,isis-2 1.0 0.000143348623853 0 1 -1
ie,recall,has 1.0 0.000143348623853 0 1 -1
ie,from,ml 1.0 0.000143348623853 0 1 -1
idv,exposure,despite 1.0 0.000143348623853 0 1 -1
idv,does,not 1.0 0.000143348623853 0 1 -1
identity,of,the 1.0 0.000143348623853 0 1 -1
identify,the,pharmacological 1.0 0.000143348623853 0 1 -1
identify,the,medications 1.0 0.000143348623853 0 1 -1
identify,characteristics,related 1.0 0.000143348623853 0 1 -1
identify,any,clinically 1.0 0.000143348623853 0 1 -1
identifies,clinically,important 1.0 0.000143348623853 0 1 -1
identified,through,searches 1.0 0.000143348623853 0 1 -1
identified,that,would 1.0 0.000143348623853 0 1 -1
identified,case,of 1.0 0.000143348623853 0 1 -1
identified,as,causally 1.0 0.000143348623853 0 1 -1
identified,and,new 1.0 0.000143348623853 0 1 -1
identification,of,limit 1.0 0.000143348623853 0 1 -1
identification,of,interactions 1.0 0.000143348623853 0 1 -1
identical,whether,the 1.0 0.000143348623853 0 1 -1
identical,but,endogenous 1.0 0.000143348623853 0 1 -1
identical,and,release 1.0 0.000143348623853 0 1 -1
ic50,g,ml 1.0 0.000143348623853 0 1 -1
ic50,from,to 1.0 0.000143348623853 0 1 -1
ic,was,about 1.0 0.000143348623853 0 1 -1
ibuprofen,is,known 1.0 0.000143348623853 0 1 -1
ibuprofen,ibuprofen,is 1.0 0.000143348623853 0 1 -1
ibogaine,produces,whole 1.0 0.000143348623853 0 1 -1
ibogaine,but,not 1.0 0.000143348623853 0 1 -1
iboga,alkaloid,congener 1.0 0.000143348623853 0 1 -1
ibandronate,was,similar 1.0 0.000143348623853 0 1 -1
ibandronate,osteoporosis,treatment 1.0 0.000143348623853 0 1 -1
ibandronate,mg,once 1.0 0.000143348623853 0 1 -1
iatrogenic,alteration,caused 1.0 0.000143348623853 0 1 -1
i-labelled,antigen,were 1.0 0.000143348623853 0 1 -1
i-labelled,antigen,validation 1.0 0.000143348623853 0 1 -1
i,without,alterations 1.0 0.000143348623853 0 1 -1
i,with,was 1.0 0.000143348623853 0 1 -1
i,v,as 1.0 0.000143348623853 0 1 -1
i,trial,in 1.0 0.000143348623853 0 1 -1
i,tranexamic,acid 1.0 0.000143348623853 0 1 -1
i,these,polyene 1.0 0.000143348623853 0 1 -1
i,the,number 1.0 0.000143348623853 0 1 -1
i,suggesting,a 1.0 0.000143348623853 0 1 -1
i,such,as 1.0 0.000143348623853 0 1 -1
i,sodium,pertechnetate 1.0 0.000143348623853 0 1 -1
i,relational,the 1.0 0.000143348623853 0 1 -1
i,p,dmpge2 1.0 0.000143348623853 0 1 -1
i,neurotransmitter,systems 1.0 0.000143348623853 0 1 -1
i,insulin-dependent,diabetes 1.0 0.000143348623853 0 1 -1
i,expression,in 1.0 0.000143348623853 0 1 -1
i,d,have 1.0 0.000143348623853 0 1 -1
i,d,had 1.0 0.000143348623853 0 1 -1
i,corticosteroid,binding 1.0 0.000143348623853 0 1 -1
i,cigarettes,and 1.0 0.000143348623853 0 1 -1
i,binding,globulin 1.0 0.000143348623853 0 1 -1
i,and,with 1.0 0.000143348623853 0 1 -1
i,and,i 1.0 0.000143348623853 0 1 -1
i,and,have 1.0 0.000143348623853 0 1 -1
i,and,activated 1.0 0.000143348623853 0 1 -1
i,alone,produced 1.0 0.000143348623853 0 1 -1
i,acute,pharmacological 1.0 0.000143348623853 0 1 -1
hz,degrees,c 1.0 0.000143348623853 0 1 -1
hypoxic,respiratory,failure 1.0 0.000143348623853 0 1 -1
hypothyroidism,may,interfere 1.0 0.000143348623853 0 1 -1
hypothyroidism,in,spite 1.0 0.000143348623853 0 1 -1
hypothyroid,patients,with 1.0 0.000143348623853 0 1 -1
hypothyroid,patients,and 1.0 0.000286697247706 0 2 -2
hypothyroid,it,is 1.0 0.000143348623853 0 1 -1
hypothesis,there,is 1.0 0.000143348623853 0 1 -1
hypothesis,that,such 1.0 0.000143348623853 0 1 -1
hypothesis,of,gibaldi 1.0 0.000143348623853 0 1 -1
hypothermia,as,an 1.0 0.000143348623853 0 1 -1
hypothalamic-pituitary,testicular,axis 1.0 0.000143348623853 0 1 -1
hypotensive,response,is 1.0 0.000143348623853 0 1 -1
hypotension,was,more 1.0 0.000143348623853 0 1 -1
hypotension,was,found 1.0 0.000143348623853 0 1 -1
hypotension,requiring,treatment 1.0 0.000143348623853 0 1 -1
hypotension,or,tachycardia 1.0 0.000143348623853 0 1 -1
hypotension,or,marked 1.0 0.000286697247706 0 2 -2
hypotension,oliguria,tachycardia 1.0 0.000143348623853 0 1 -1
hypotension,occurs,the 1.0 0.000143348623853 0 1 -1
hypotension,in,patients 1.0 0.000286697247706 0 2 -2
hypotension,could,result 1.0 0.000143348623853 0 1 -1
hypotension,bradycardia,and 1.0 0.000286697247706 0 2 -2
hypotension,because,of 1.0 0.000143348623853 0 1 -1
hypotension,and,occurred 1.0 0.000143348623853 0 1 -1
hypoprothrombinemic,effect,of 1.0 0.000143348623853 0 1 -1
hypomania,restlessness,loss 1.0 0.000143348623853 0 1 -1
hypomagnesemia,should,have 1.0 0.000143348623853 0 1 -1
hypokalemia,they,should 1.0 0.00043004587156 0 3 -3
hypokalemia,or,hypomagnesemia 1.0 0.000143348623853 0 1 -1
hypokalemia,may,increase 1.0 0.000143348623853 0 1 -1
hypokalemia,and,then 1.0 0.000143348623853 0 1 -1
hypoglycemics,initiating,replacement 1.0 0.000143348623853 0 1 -1
hypoglycemics,diclofenac,does 1.0 0.000143348623853 0 1 -1
hypoglycemics,bepridil,has 1.0 0.000143348623853 0 1 -1
hypoglycemic,agents,may 1.0 0.000143348623853 0 1 -1
hypoglycemia,which,may 1.0 0.000286697247706 0 2 -2
hypoglycemia,oral,products 1.0 0.000143348623853 0 1 -1
hypoglycemia,oral,antidiabetes 1.0 0.000143348623853 0 1 -1
hypoglycemia,may,be 1.0 0.000286697247706 0 2 -2
hypoglycemia,and,mask 1.0 0.000143348623853 0 1 -1
hypoglycemia,and,hyperglycemia 1.0 0.000143348623853 0 1 -1
hypogastric,nerve,preparations 1.0 0.000143348623853 0 1 -1
hypo-thyroxine,binding-globulinemias,have 1.0 0.000143348623853 0 1 -1
hypo-prothrombinemic,effect,and 1.0 0.000143348623853 0 1 -1
hypo-,and,hyperglycemic 1.0 0.000143348623853 0 1 -1
hypnotics,contraindicated,due 1.0 0.000143348623853 0 1 -1
hypertriglyceridemia,was,hypercholesterolemia 1.0 0.000143348623853 0 1 -1
hypertriglyceridemia,is,patient 1.0 0.000143348623853 0 1 -1
hyperthyroidism,or,when 1.0 0.000143348623853 0 1 -1
hyperthyroidism,hypertension,and 1.0 0.000143348623853 0 1 -1
hyperthyroid,patients,and 1.0 0.000143348623853 0 1 -1
hyperthermia,shivering,pupillary 1.0 0.000143348623853 0 1 -1
hypertensive,patients,addition 1.0 0.000143348623853 0 1 -1
hypertensive,nephropathy,were 1.0 0.000143348623853 0 1 -1
hypertension,where,the 1.0 0.000143348623853 0 1 -1
hypertension,were,examined 1.0 0.000143348623853 0 1 -1
hypertension,patients,should 1.0 0.000143348623853 0 1 -1
hypertension,hypercoagulation,vasculopathy 1.0 0.000143348623853 0 1 -1
hypertension,have,been 1.0 0.000143348623853 0 1 -1
hypertension,did,not 1.0 0.000143348623853 0 1 -1
hypertension,and,that 1.0 0.000143348623853 0 1 -1
hypersensitivity,reactions,when 1.0 0.000143348623853 0 1 -1
hypersensitivity,reactions,should 1.0 0.000143348623853 0 1 -1
hypersensitivity,reactions,all 1.0 0.000143348623853 0 1 -1
hyperreflexia,ataxia,dysarthria 1.0 0.000143348623853 0 1 -1
hyperpyrexia,eight,poisonings 1.0 0.000143348623853 0 1 -1
hyperpyrexia,can,occur 1.0 0.000286697247706 0 2 -2
hyperprolactinaemia,as,seen 1.0 0.000143348623853 0 1 -1
hyperpolarized,by,selective 1.0 0.000143348623853 0 1 -1
hyperpolarized,by,mu- 1.0 0.000143348623853 0 1 -1
hyperpolarization,and,membrane 1.0 0.000143348623853 0 1 -1
hyperplasia,polymorphic,proliferation 1.0 0.000143348623853 0 1 -1
hyperplasia,of,the 1.0 0.000143348623853 0 1 -1
hyperplasia,observed,in 1.0 0.000143348623853 0 1 -1
hyperplasia,bph,psa 1.0 0.000143348623853 0 1 -1
hypermagnesaemia,high,oral 1.0 0.000143348623853 0 1 -1
hyperlipidaemia,and,obesity 1.0 0.000143348623853 0 1 -1
hyperlactatemia,lactic,acidosis 1.0 0.000143348623853 0 1 -1
hyperinsulinaemia,on,the 1.0 0.000143348623853 0 1 -1
hypericum,perforatum,warning 1.0 0.000143348623853 0 1 -1
hypericum,perforatum,may 1.0 0.000143348623853 0 1 -1
hyperglycemic,effects,have 1.0 0.000143348623853 0 1 -1
hyperglycemia,were,reported 1.0 0.000143348623853 0 1 -1
hyperglycemia,has,also 1.0 0.000143348623853 0 1 -1
hyperglycemia,but,also 1.0 0.000143348623853 0 1 -1
hyperglycemia,and,may 1.0 0.000573394495413 0 4 -4
hyperglycaemic,clamps,mmol 1.0 0.000143348623853 0 1 -1
hyperglycaemia,increased,all 1.0 0.000143348623853 0 1 -1
hyperglycaemia,and,hyperinsulinaemia 1.0 0.000143348623853 0 1 -1
hypercoagulation,vasculopathy,and 1.0 0.000143348623853 0 1 -1
hypercholesterolemic,noninsulin,dependent 1.0 0.000143348623853 0 1 -1
hypercholesterolemia,was,and 1.0 0.000143348623853 0 1 -1
hypercholesterolemia,concomitant,administration 1.0 0.000143348623853 0 1 -1
hypercalcemia,by,the 1.0 0.00043004587156 0 3 -3
hyperaminotransferasemia,significant,elevations 1.0 0.000143348623853 0 1 -1
hyper-,or,hypo-thyroxine 1.0 0.000143348623853 0 1 -1
hydroxytolbutamide,and,was 1.0 0.000143348623853 0 1 -1
hydroxytolbutamide,and,by 1.0 0.000143348623853 0 1 -1
hydroxytamoxifen,tam,which 1.0 0.000143348623853 0 1 -1
hydroxylation,during,treatment 1.0 0.000143348623853 0 1 -1
hydroxylation,catalyzed,by 1.0 0.000143348623853 0 1 -1
hydroxylase,is,reduced 1.0 0.000716743119266 0 5 -5
hydroxylamine,dha,was 1.0 0.000143348623853 0 1 -1
hydroxylamine,a,metabolite 1.0 0.000143348623853 0 1 -1
hydroxydesloratadine,were,observed 1.0 0.000143348623853 0 1 -1
hydroxydesloratadine,pharmacokinetics,in 1.0 0.000143348623853 0 1 -1
hydroxy-estazolam,and,the 1.0 0.000143348623853 0 1 -1
hydroxy-corticosteroids,by,the 1.0 0.000143348623853 0 1 -1
hydroxy-corticosteroid,measurements,porter-silber 1.0 0.000143348623853 0 1 -1
hydroxy-3,methylglutaryl,coenzyme 1.0 0.000143348623853 0 1 -1
hydroxides,does,not 1.0 0.000143348623853 0 1 -1
hydroxides,and,did 1.0 0.000143348623853 0 1 -1
hydroxide-containing,maalox,on 1.0 0.000143348623853 0 1 -1
hydroxide-,and,hydroxide-containing 1.0 0.000143348623853 0 1 -1
hydroxide,does,not 1.0 0.000143348623853 0 1 -1
hydroxide,cerivastatin,plasma 1.0 0.000143348623853 0 1 -1
hydrophobic,side,chain 1.0 0.000143348623853 0 1 -1
hydrophilic,molecule,naflu 1.0 0.000143348623853 0 1 -1
hydrolase,inhibitors,it 1.0 0.000143348623853 0 1 -1
hydrolase,carbamazepine,is 1.0 0.000143348623853 0 1 -1
hydrogen-3,revealed,a 1.0 0.000143348623853 0 1 -1
hydrogen,breath,test 1.0 0.000143348623853 0 1 -1
hydrocortisone,mg,and 1.0 0.000143348623853 0 1 -1
hydrocortisone,elevated,salivary 1.0 0.000143348623853 0 1 -1
hydrocodone,coadministration,of 1.0 0.000143348623853 0 1 -1
hydrochlorothiazide,hctz,alone 1.0 0.000143348623853 0 1 -1
hydrochlorothiazide,a,study 1.0 0.000143348623853 0 1 -1
hydrochloride,was,administered 1.0 0.000286697247706 0 2 -2
hydrochloride,mg,twice 1.0 0.000143348623853 0 1 -1
hydrochloride,mg,every 1.0 0.000143348623853 0 1 -1
hydrochloride,is,an 1.0 0.000143348623853 0 1 -1
hydrochloride,including,anti-arrhythmic 1.0 0.000143348623853 0 1 -1
hydrochloride,does,not 1.0 0.000143348623853 0 1 -1
hydrochloride,could,pose 1.0 0.000143348623853 0 1 -1
hydrochloride,binds,a 1.0 0.000143348623853 0 1 -1
hydrochloride,before,each 1.0 0.000143348623853 0 1 -1
hydrochloride,and,therapy 1.0 0.000143348623853 0 1 -1
hydrochloride,and,is 1.0 0.000143348623853 0 1 -1
hydrochloride,and,and 1.0 0.000143348623853 0 1 -1
hydrochloride,alone,or 1.0 0.000143348623853 0 1 -1
hydrochloride,a,channel 1.0 0.000143348623853 0 1 -1
hydrochloric,acid,secretion 1.0 0.000143348623853 0 1 -1
hydroalcoholic,solutions,with 1.0 0.000143348623853 0 1 -1
hydroalcoholic,solutions,containing 1.0 0.000143348623853 0 1 -1
hydration,sodium,bicarbonate 1.0 0.000143348623853 0 1 -1
hydrate,and,were 1.0 0.000143348623853 0 1 -1
hydrate,and,may 1.0 0.000143348623853 0 1 -1
hydrate,and,agonists 1.0 0.000143348623853 0 1 -1
hunger,can,be 1.0 0.000143348623853 0 1 -1
hunger,and,anxiety 1.0 0.000143348623853 0 1 -1
hundred,mg,of 1.0 0.000143348623853 0 1 -1
hump,peripheral,wasting 1.0 0.000143348623853 0 1 -1
humira,has,not 1.0 0.000143348623853 0 1 -1
humira,has,been 1.0 0.000143348623853 0 1 -1
humans,was,noted 1.0 0.000143348623853 0 1 -1
humans,two,inhibitors 1.0 0.000143348623853 0 1 -1
humans,that,resemble 1.0 0.000143348623853 0 1 -1
humans,taking,the 1.0 0.000143348623853 0 1 -1
humans,remain,to 1.0 0.000143348623853 0 1 -1
humans,metabolism,is 1.0 0.000143348623853 0 1 -1
humans,is,unknown 1.0 0.000143348623853 0 1 -1
humans,is,not 1.0 0.000143348623853 0 1 -1
humans,have,shown 1.0 0.000286697247706 0 2 -2
humans,have,demonstrated 1.0 0.000143348623853 0 1 -1
humans,have,been 1.0 0.000143348623853 0 1 -1
humans,demonstrated,that 1.0 0.000143348623853 0 1 -1
humans,and,the 1.0 0.000143348623853 0 1 -1
humans,and,experimental 1.0 0.000143348623853 0 1 -1
human,weekly,dose 1.0 0.000143348623853 0 1 -1
human,volunteers,co-administration 1.0 0.000143348623853 0 1 -1
human,ventricular,cardiac 1.0 0.000143348623853 0 1 -1
human,subjects,have 1.0 0.000143348623853 0 1 -1
human,studies,that 1.0 0.000143348623853 0 1 -1
human,studies,have 1.0 0.000143348623853 0 1 -1
human,serum,proteins 1.0 0.000143348623853 0 1 -1
human,serum,in 1.0 0.000143348623853 0 1 -1
human,serum,at 1.0 0.000143348623853 0 1 -1
human,serum,and 1.0 0.000143348623853 0 1 -1
human,response,and 1.0 0.000143348623853 0 1 -1
human,red,blood 1.0 0.000143348623853 0 1 -1
human,recommended,dose 1.0 0.000286697247706 0 2 -2
human,plasma,proteins 1.0 0.000143348623853 0 1 -1
human,plasma,protein 1.0 0.000143348623853 0 1 -1
human,plasma,is 1.0 0.000143348623853 0 1 -1
human,plasma,indicate 1.0 0.000143348623853 0 1 -1
human,plasma,in 1.0 0.000143348623853 0 1 -1
human,plasma,area-under 1.0 0.000143348623853 0 1 -1
human,novolog,should 1.0 0.000143348623853 0 1 -1
human,milk,and 1.0 0.000286697247706 0 2 -2
human,lymphocytes,mammalian 1.0 0.000143348623853 0 1 -1
human,lymphocytes,in 1.0 0.000143348623853 0 1 -1
human,lymphocytes,either 1.0 0.000143348623853 0 1 -1
human,liver,microsome 1.0 0.000143348623853 0 1 -1
human,liver,cytochrome 1.0 0.000286697247706 0 2 -2
human,liver,are 1.0 0.000143348623853 0 1 -1
human,interaction,studies 1.0 0.00043004587156 0 3 -3
human,in,vitro 1.0 0.000143348623853 0 1 -1
human,immunodeficiency,virus-related 1.0 0.000143348623853 0 1 -1
human,immunodeficiency,virus-positive 1.0 0.000143348623853 0 1 -1
human,immunodeficiency,virus 1.0 0.000143348623853 0 1 -1
human,immediately,before 1.0 0.000143348623853 0 1 -1
human,heart,failure 1.0 0.000286697247706 0 2 -2
human,fungal,infections 1.0 0.000143348623853 0 1 -1
human,dose,on 1.0 0.000716743119266 0 5 -5
human,dose,of 1.0 0.000286697247706 0 2 -2
human,dose,had 1.0 0.000143348623853 0 1 -1
human,dose,for 1.0 0.000143348623853 0 1 -1
human,dose,based 1.0 0.00043004587156 0 3 -3
human,cytochrome,p450 1.0 0.000286697247706 0 2 -2
human,cyp,enzymes 1.0 0.000143348623853 0 1 -1
human,cells,whereas 1.0 0.000143348623853 0 1 -1
human,bladder,cancer 1.0 0.000143348623853 0 1 -1
human,b,cells 1.0 0.000143348623853 0 1 -1
human,auc,based 1.0 0.000143348623853 0 1 -1
human,african,trypanosomiasis 1.0 0.000143348623853 0 1 -1
http,www,rxlist 1.0 0.000143348623853 0 1 -1
ht3,zofran,and 1.0 0.000143348623853 0 1 -1
ht3,antagonists,in 1.0 0.000143348623853 0 1 -1
ht2a,than,for 1.0 0.000143348623853 0 1 -1
ht1,agonists,has 1.0 0.000143348623853 0 1 -1
hrs,of,loratadine 1.0 0.000143348623853 0 1 -1
hrs,of,and 1.0 0.000286697247706 0 2 -2
hrs,c,max 1.0 0.000143348623853 0 1 -1
hr,should,achieve 1.0 0.000143348623853 0 1 -1
hplc,peak,as 1.0 0.000143348623853 0 1 -1
however,when,the 1.0 0.000143348623853 0 1 -1
however,when,addiction 1.0 0.000143348623853 0 1 -1
however,were,increased 1.0 0.000143348623853 0 1 -1
however,was,increased 1.0 0.000143348623853 0 1 -1
however,usually,give 1.0 0.000143348623853 0 1 -1
however,up,to 1.0 0.000143348623853 0 1 -1
however,under,certain 1.0 0.000143348623853 0 1 -1
however,total,mucosal 1.0 0.000143348623853 0 1 -1
however,to,predict 1.0 0.000143348623853 0 1 -1
however,this,sample 1.0 0.000143348623853 0 1 -1
however,these,studies 1.0 0.000143348623853 0 1 -1
however,there,were 1.0 0.000143348623853 0 1 -1
however,there,was 1.0 0.000143348623853 0 1 -1
however,the,use 1.0 0.000143348623853 0 1 -1
however,the,total 1.0 0.000143348623853 0 1 -1
however,the,second 1.0 0.000143348623853 0 1 -1
however,the,relationship 1.0 0.000143348623853 0 1 -1
however,the,recommendation 1.0 0.000143348623853 0 1 -1
however,the,pharmacodynamics 1.0 0.000143348623853 0 1 -1
however,the,pharmacodynamic 1.0 0.000286697247706 0 2 -2
however,the,effects 1.0 0.000143348623853 0 1 -1
however,the,clinical 1.0 0.00043004587156 0 3 -3
however,the,cause 1.0 0.000143348623853 0 1 -1
however,the,absolute 1.0 0.000143348623853 0 1 -1
however,somepatients,may 1.0 0.000143348623853 0 1 -1
however,since,there 1.0 0.000143348623853 0 1 -1
however,severe,reactions 1.0 0.000143348623853 0 1 -1
however,serious,opportunistic 1.0 0.000143348623853 0 1 -1
however,prudent,evaluation 1.0 0.000143348623853 0 1 -1
however,pretreatment,did 1.0 0.000143348623853 0 1 -1
however,preliminary,results 1.0 0.000143348623853 0 1 -1
however,plasma,concentrations 1.0 0.000143348623853 0 1 -1
however,pharmacokinetic,studies 1.0 0.000143348623853 0 1 -1
however,patients,who 1.0 0.000143348623853 0 1 -1
however,patients,receiving 1.0 0.000286697247706 0 2 -2
however,on,a 1.0 0.000143348623853 0 1 -1
however,oh,metabolite 1.0 0.000143348623853 0 1 -1
however,numerous,potentiation 1.0 0.000143348623853 0 1 -1
however,no,specific 1.0 0.000143348623853 0 1 -1
however,no,significant 1.0 0.000143348623853 0 1 -1
however,no,related 1.0 0.000143348623853 0 1 -1
however,no,deleterious 1.0 0.000143348623853 0 1 -1
however,no,clinically 1.0 0.000143348623853 0 1 -1
however,no,adverse 1.0 0.000143348623853 0 1 -1
however,neuromuscular,paralysis 1.0 0.000143348623853 0 1 -1
however,neither,nor 1.0 0.000143348623853 0 1 -1
however,modification,abolished 1.0 0.000143348623853 0 1 -1
however,may,still 1.0 0.000143348623853 0 1 -1
however,l-name,and 1.0 0.000143348623853 0 1 -1
however,its,effects 1.0 0.000143348623853 0 1 -1
however,it,was 1.0 0.000143348623853 0 1 -1
however,it,should 1.0 0.000143348623853 0 1 -1
however,it,may 1.0 0.000143348623853 0 1 -1
however,it,is 1.0 0.000286697247706 0 2 -2
however,is,within 1.0 0.000143348623853 0 1 -1
however,is,useful 1.0 0.000143348623853 0 1 -1
however,is,advised 1.0 0.000286697247706 0 2 -2
however,initial,dose 1.0 0.000143348623853 0 1 -1
however,increasing,use 1.0 0.000143348623853 0 1 -1
however,in,vivo 1.0 0.00043004587156 0 3 -3
however,in,vitro 1.0 0.000143348623853 0 1 -1
however,in,clinical 1.0 0.000143348623853 0 1 -1
however,if,the 1.0 0.000143348623853 0 1 -1
however,if,argatroban 1.0 0.000143348623853 0 1 -1
however,higher,plasma 1.0 0.000143348623853 0 1 -1
however,did,not 1.0 0.000143348623853 0 1 -1
however,decreases,in 1.0 0.000143348623853 0 1 -1
however,currently,no 1.0 0.000143348623853 0 1 -1
however,current,evidence 1.0 0.000143348623853 0 1 -1
however,cohort,data 1.0 0.000143348623853 0 1 -1
however,coadministration,of 1.0 0.000143348623853 0 1 -1
however,co-administration,of 1.0 0.000143348623853 0 1 -1
however,caution,must 1.0 0.000143348623853 0 1 -1
however,can,decrease 1.0 0.000143348623853 0 1 -1
however,beta,blockers 1.0 0.000143348623853 0 1 -1
however,because,nafarelin 1.0 0.000143348623853 0 1 -1
however,because,higher 1.0 0.000143348623853 0 1 -1
however,because,both 1.0 0.000143348623853 0 1 -1
however,be,administered 1.0 0.000143348623853 0 1 -1
however,at,that 1.0 0.000143348623853 0 1 -1
however,at,lower 1.0 0.000143348623853 0 1 -1
however,are,not 1.0 0.000143348623853 0 1 -1
however,appear,to 1.0 0.000143348623853 0 1 -1
however,and,are 1.0 0.000143348623853 0 1 -1
however,and,all 1.0 0.000143348623853 0 1 -1
however,administration,of 1.0 0.000143348623853 0 1 -1
however,adenocard,should 1.0 0.000143348623853 0 1 -1
however,a,significantly 1.0 0.000143348623853 0 1 -1
however,a,comparison 1.0 0.000143348623853 0 1 -1
how,to,use 1.0 0.000143348623853 0 1 -1
how,the,effect 1.0 0.000143348623853 0 1 -1
how,safe,sexual 1.0 0.000143348623853 0 1 -1
how,it,should 1.0 0.000286697247706 0 2 -2
how,age,may 1.0 0.000143348623853 0 1 -1
hours,two,times 1.0 0.000143348623853 0 1 -1
hours,subsequent,to 1.0 0.000143348623853 0 1 -1
hours,or,mg 1.0 0.00043004587156 0 3 -3
hours,or,follow 1.0 0.000143348623853 0 1 -1
hours,of,frova 1.0 0.000143348623853 0 1 -1
hours,of,administration 1.0 0.000143348623853 0 1 -1
hours,most,commonly 1.0 0.000143348623853 0 1 -1
hours,for,days 1.0 0.000286697247706 0 2 -2
hours,for,cmax 1.0 0.000143348623853 0 1 -1
hours,for,and 1.0 0.000143348623853 0 1 -1
hours,following,the 1.0 0.000286697247706 0 2 -2
hours,following,symptom 1.0 0.000143348623853 0 1 -1
hours,following,an 1.0 0.000143348623853 0 1 -1
hours,concurrently,with 1.0 0.000143348623853 0 1 -1
hours,between,intake 1.0 0.000286697247706 0 2 -2
hours,before,adrenal 1.0 0.000143348623853 0 1 -1
hours,based,on 1.0 0.000143348623853 0 1 -1
hours,apart,so 1.0 0.000143348623853 0 1 -1
hours,and,until 1.0 0.000143348623853 0 1 -1
hours,after,dosing 1.0 0.000143348623853 0 1 -1
hours,after,colestid 1.0 0.000143348623853 0 1 -1
hours,after,cholestyramine 1.0 0.000143348623853 0 1 -1
hours,after,at 1.0 0.000143348623853 0 1 -1
hours,after,administration 1.0 0.000143348623853 0 1 -1
hourly,diuresis,electrocardiogram 1.0 0.000143348623853 0 1 -1
hour,then,mg 1.0 0.000143348623853 0 1 -1
hour,period,before 1.0 0.000143348623853 0 1 -1
hour,of,taxol 1.0 0.000143348623853 0 1 -1
hour,observation,period 1.0 0.000143348623853 0 1 -1
hour,lag,phase 1.0 0.000143348623853 0 1 -1
hour,infusion,than 1.0 0.000143348623853 0 1 -1
hour,before,idv 1.0 0.000143348623853 0 1 -1
hour,and,then 1.0 0.000143348623853 0 1 -1
hour,after,the 1.0 0.000143348623853 0 1 -1
hour,after,starting 1.0 0.000143348623853 0 1 -1
hot,kidney,on 1.0 0.000143348623853 0 1 -1
hot,drinks,may 1.0 0.000143348623853 0 1 -1
host,of,other 1.0 0.000143348623853 0 1 -1
host,defense,may 1.0 0.000143348623853 0 1 -1
hospitals,usually,in 1.0 0.000143348623853 0 1 -1
hospitals,resulting,in 1.0 0.000143348623853 0 1 -1
hospital,for,worsening 1.0 0.000143348623853 0 1 -1
horses,from,anaesthesia 1.0 0.000143348623853 0 1 -1
hormones,were,investigated 1.0 0.000143348623853 0 1 -1
hormones,complex,anions 1.0 0.000143348623853 0 1 -1
hormones,appear,to 1.0 0.000143348623853 0 1 -1
hormone-binding,globulin,shbg 1.0 0.000143348623853 0 1 -1
hormone,therapy,oral 1.0 0.000143348623853 0 1 -1
hormone,synthesis,secretion 1.0 0.000286697247706 0 2 -2
hormone,replacement,therapy 1.0 0.000143348623853 0 1 -1
hormone,or,tsh 1.0 0.000143348623853 0 1 -1
hormone,or,nor 1.0 0.000143348623853 0 1 -1
hormone,may,accelerate 1.0 0.000143348623853 0 1 -1
hormone,lh,follicle-stimulating 1.0 0.000143348623853 0 1 -1
hormone,levels,levodopa 1.0 0.000143348623853 0 1 -1
hormone,levels,induced 1.0 0.000143348623853 0 1 -1
hormone,levels,as 1.0 0.000286697247706 0 2 -2
hormone,levels,and 1.0 0.000143348623853 0 1 -1
hormone,indicating,that 1.0 0.000143348623853 0 1 -1
hormone,fsh,or 1.0 0.000143348623853 0 1 -1
hormone,concentrations,may 1.0 0.000286697247706 0 2 -2
hormone,binding,globulin 1.0 0.000143348623853 0 1 -1
hormone,as,measured 1.0 0.000143348623853 0 1 -1
hormone,and,levels 1.0 0.000143348623853 0 1 -1
hormone,and,its 1.0 0.000143348623853 0 1 -1
hormone,activity,may 1.0 0.000143348623853 0 1 -1
hormone,action,or 1.0 0.000143348623853 0 1 -1
hormonal,who,also 1.0 0.000286697247706 0 2 -2
hormonal,since,some 1.0 0.000143348623853 0 1 -1
hormonal,replacement,increases 1.0 0.000143348623853 0 1 -1
hormonal,evidence,of 1.0 0.000143348623853 0 1 -1
hormonal,differ,in 1.0 0.000143348623853 0 1 -1
hormonal,contraceptives,it 1.0 0.000143348623853 0 1 -1
hormonal,contraception,alone 1.0 0.000143348623853 0 1 -1
hormonal,by,inducing 1.0 0.000143348623853 0 1 -1
hormonal,are,highly 1.0 0.000143348623853 0 1 -1
hormonal,and,the 1.0 0.000143348623853 0 1 -1
hoof,twitch,allowed 1.0 0.000143348623853 0 1 -1
homozygous,for,the 1.0 0.000143348623853 0 1 -1
homopolyribonucleotides,and,complexes 1.0 0.000143348623853 0 1 -1
homogenates,supplemented,with 1.0 0.000143348623853 0 1 -1
homodimeric,structure,of 1.0 0.000143348623853 0 1 -1
homodimeric,disintegrin,was 1.0 0.000143348623853 0 1 -1
homodimeric,disintegrin,and 1.0 0.000143348623853 0 1 -1
homocysteine,may,be 1.0 0.000143348623853 0 1 -1
homocysteine,in,the 1.0 0.000143348623853 0 1 -1
homocysteine,following,synthetic 1.0 0.000143348623853 0 1 -1
homocysteine,excretion,rate 1.0 0.000143348623853 0 1 -1
homocysteine,by,forming 1.0 0.000143348623853 0 1 -1
hmgcoa,reductase,inhibitors 1.0 0.000143348623853 0 1 -1
hmgcoa,reductase,inhibitor 1.0 0.000143348623853 0 1 -1
hmg-coa,reductase,may 1.0 0.000143348623853 0 1 -1
hivid,with,that 1.0 0.000143348623853 0 1 -1
hivid,should,have 1.0 0.000143348623853 0 1 -1
hivid,should,be 1.0 0.000143348623853 0 1 -1
hivid,and,zdv 1.0 0.000143348623853 0 1 -1
hiv-related,systemic,non-hodgkin 1.0 0.000143348623853 0 1 -1
hiv-nhl,who,were 1.0 0.000143348623853 0 1 -1
hiv-nhl,the,authors 1.0 0.000143348623853 0 1 -1
hiv-infected,subjects,to 1.0 0.000143348623853 0 1 -1
hiv-infected,individuals,with 1.0 0.000143348623853 0 1 -1
hiv-infected,individuals,were 1.0 0.000143348623853 0 1 -1
hiv-1,seropositive,subjects 1.0 0.000286697247706 0 2 -2
hiv,status,and 1.0 0.000143348623853 0 1 -1
hiv,disease,and 1.0 0.000143348623853 0 1 -1
hits,are,required 1.0 0.000143348623853 0 1 -1
hitherto,unrecognized,interactions 1.0 0.000143348623853 0 1 -1
hit,may,vary 1.0 0.000143348623853 0 1 -1
hit,in,a 1.0 0.000143348623853 0 1 -1
history,prior,to 1.0 0.000143348623853 0 1 -1
history,of,neuropathy 1.0 0.000143348623853 0 1 -1
history,of,neoplasia 1.0 0.000143348623853 0 1 -1
history,of,injection 1.0 0.000143348623853 0 1 -1
history,of,diabetes 1.0 0.000143348623853 0 1 -1
history,of,anaphylactic 1.0 0.000143348623853 0 1 -1
histology,of,the 1.0 0.000143348623853 0 1 -1
histologic,type,depth 1.0 0.000143348623853 0 1 -1
histidines,on,a 1.0 0.000143348623853 0 1 -1
histidine,residues,on 1.0 0.000286697247706 0 2 -2
histidine,residues,may 1.0 0.000143348623853 0 1 -1
histidine,residues,abolishes 1.0 0.000143348623853 0 1 -1
histidine,modification,had 1.0 0.000143348623853 0 1 -1
histaminergic,and,serotoninergic 1.0 0.000143348623853 0 1 -1
histamine,h2-receptor,antagonists 1.0 0.000143348623853 0 1 -1
his,risk,for 1.0 0.000143348623853 0 1 -1
his,own,pre- 1.0 0.000143348623853 0 1 -1
his,logical,approach 1.0 0.000143348623853 0 1 -1
his,her,and 1.0 0.000143348623853 0 1 -1
his,death,from 1.0 0.000143348623853 0 1 -1
hippocampus,would,play 1.0 0.000143348623853 0 1 -1
hippocampus,is,involved 1.0 0.000143348623853 0 1 -1
hippocampus,as,interaction 1.0 0.000143348623853 0 1 -1
hippocampus,and,to 1.0 0.000143348623853 0 1 -1
hippocampal,lesions,or 1.0 0.000143348623853 0 1 -1
hippocampal,lesions,actually 1.0 0.000143348623853 0 1 -1
hippocampal,adenylate,cyclase 1.0 0.000143348623853 0 1 -1
hind,paw,at 1.0 0.000143348623853 0 1 -1
hind,limb,digital 1.0 0.000143348623853 0 1 -1
highly,unstable,with 1.0 0.000143348623853 0 1 -1
highly,susceptible,to 1.0 0.000143348623853 0 1 -1
highly,sensitive,assay 1.0 0.000143348623853 0 1 -1
highly,protein-bound,would 1.0 0.000143348623853 0 1 -1
highly,protein-bound,such 1.0 0.000143348623853 0 1 -1
highly,protein-bound,have 1.0 0.000143348623853 0 1 -1
highly,plasma,protein- 1.0 0.000143348623853 0 1 -1
highly,plasma,protein 1.0 0.000143348623853 0 1 -1
highly,lethal,dose 1.0 0.000143348623853 0 1 -1
highly,fortified,with 1.0 0.000143348623853 0 1 -1
highly,effective,there 1.0 0.000143348623853 0 1 -1
highly,bound,such 1.0 0.000143348623853 0 1 -1
highly,active,therapy 1.0 0.000286697247706 0 2 -2
highlights,novel,targets 1.0 0.000143348623853 0 1 -1
highintersubject,variability,however 1.0 0.000143348623853 0 1 -1
highest,level,of 1.0 0.000143348623853 0 1 -1
highest,dose,of 1.0 0.000143348623853 0 1 -1
higher,was,significantly 1.0 0.000143348623853 0 1 -1
higher,virologic,response 1.0 0.000143348623853 0 1 -1
higher,than,the 1.0 0.000286697247706 0 2 -2
higher,than,peak 1.0 0.000143348623853 0 1 -1
higher,than,mg 1.0 0.000286697247706 0 2 -2
higher,than,for 1.0 0.000143348623853 0 1 -1
higher,risk,of 1.0 0.000286697247706 0 2 -2
higher,respectively,in 1.0 0.000143348623853 0 1 -1
higher,rate,of 1.0 0.000143348623853 0 1 -1
higher,proportion,of 1.0 0.000143348623853 0 1 -1
higher,plasma,concentrations 1.0 0.000143348623853 0 1 -1
higher,in,the 1.0 0.000143348623853 0 1 -1
higher,frequency,of 1.0 0.000143348623853 0 1 -1
higher,free,fractions 1.0 0.000143348623853 0 1 -1
higher,end,of 1.0 0.000143348623853 0 1 -1
higher,doses,up 1.0 0.000143348623853 0 1 -1
higher,doses,decreased 1.0 0.000143348623853 0 1 -1
higher,dose,mg 1.0 0.000143348623853 0 1 -1
higher,dose,and 1.0 0.000143348623853 0 1 -1
higher,dosages,of 1.0 0.000143348623853 0 1 -1
higher,dosage,of 1.0 0.000143348623853 0 1 -1
higher,daily,acquisition 1.0 0.000143348623853 0 1 -1
higher,changes,were 1.0 0.000143348623853 0 1 -1
higher,approximately,fold 1.0 0.000143348623853 0 1 -1
higher,and,in 1.0 0.000143348623853 0 1 -1
higher,and,excretion 1.0 0.000143348623853 0 1 -1
higher,absolute,but 1.0 0.000143348623853 0 1 -1
high-dose,may,impair 1.0 0.000143348623853 0 1 -1
high-density,lipoproteins,and 1.0 0.000143348623853 0 1 -1
high-density,lipoprotein,cholesterol 1.0 0.000143348623853 0 1 -1
high,viral,loads 1.0 0.000143348623853 0 1 -1
high,threshold,voltage-dependent 1.0 0.00043004587156 0 3 -3
high,plasma,levels 1.0 0.000143348623853 0 1 -1
high,performance,liquid 1.0 0.000143348623853 0 1 -1
high,percentage,of 1.0 0.000143348623853 0 1 -1
high,oral,doses 1.0 0.000286697247706 0 2 -2
high,oral,bioavailability 1.0 0.000143348623853 0 1 -1
high,or,too 1.0 0.000143348623853 0 1 -1
high,intraluminal,concentrations 1.0 0.000143348623853 0 1 -1
high,inter-patient,variability 1.0 0.000143348623853 0 1 -1
high,doses,or 1.0 0.000143348623853 0 1 -1
high,doses,nanm 1.0 0.000143348623853 0 1 -1
high,dose,group 1.0 0.000143348623853 0 1 -1
high,degree,of 1.0 0.000286697247706 0 2 -2
high,concentrations,of 1.0 0.000716743119266 0 5 -5
high,concentrations,mmol 1.0 0.000143348623853 0 1 -1
high,concentrations,it 1.0 0.000143348623853 0 1 -1
high,concentrations,ic50 1.0 0.000143348623853 0 1 -1
high,as,mug 1.0 0.000143348623853 0 1 -1
high,as,in 1.0 0.000143348623853 0 1 -1
high,affinity,substrates 1.0 0.000143348623853 0 1 -1
high,affinity,binding 1.0 0.000286697247706 0 2 -2
high,acquisition,cost 1.0 0.000143348623853 0 1 -1
hg,higher,respectively 1.0 0.000143348623853 0 1 -1
hexokinase,method,be 1.0 0.000286697247706 0 2 -2
herein,with,emphasis 1.0 0.000143348623853 0 1 -1
here,we,show 1.0 0.000143348623853 0 1 -1
here,we,have 1.0 0.000143348623853 0 1 -1
here,we,examined 1.0 0.000143348623853 0 1 -1
here,may,also 1.0 0.000143348623853 0 1 -1
here,demonstrate,that 1.0 0.000143348623853 0 1 -1
here,commonly,showed 1.0 0.000143348623853 0 1 -1
herbs,do,not 1.0 0.000143348623853 0 1 -1
herbal,therapy,and 1.0 0.000143348623853 0 1 -1
herbal,supplement,st 1.0 0.000143348623853 0 1 -1
herbal,remedy,use 1.0 0.000286697247706 0 2 -2
herbal,remedies,with 1.0 0.000143348623853 0 1 -1
herbal,remedies,nephropathies 1.0 0.000143348623853 0 1 -1
herbal,remedies,may 1.0 0.000143348623853 0 1 -1
herbal,remedies,is 1.0 0.000143348623853 0 1 -1
herbal,products,st 1.0 0.000286697247706 0 2 -2
herbal,product,interactions 1.0 0.000143348623853 0 1 -1
herbal,preparations,st 1.0 0.000143348623853 0 1 -1
herb,nutraceutical,st 1.0 0.000143348623853 0 1 -1
herb,interactions,have 1.0 0.000143348623853 0 1 -1
hepatotoxicity,asymptomatic,increases 1.0 0.000143348623853 0 1 -1
hepatotoxic,medications,such 1.0 0.000143348623853 0 1 -1
hepatotoxic,drugs,increased 1.0 0.000143348623853 0 1 -1
hepatitis,c,treated 1.0 0.000143348623853 0 1 -1
hepatitis,and,other 1.0 0.000143348623853 0 1 -1
hepatic,tissues,of 1.0 0.000143348623853 0 1 -1
hepatic,there,is 1.0 0.000143348623853 0 1 -1
hepatic,microsomal,monooxygenase 1.0 0.000143348623853 0 1 -1
hepatic,microsomal,ethoxycoumarine 1.0 0.000143348623853 0 1 -1
hepatic,microsomal,enzymes 1.0 0.000143348623853 0 1 -1
hepatic,metabolism,are 1.0 0.000143348623853 0 1 -1
hepatic,metabolic,clearance 1.0 0.000143348623853 0 1 -1
hepatic,insufficiency,resulted 1.0 0.000143348623853 0 1 -1
hepatic,injury,should 1.0 0.000143348623853 0 1 -1
hepatic,injury,or 1.0 0.000143348623853 0 1 -1
hepatic,impairment,there 1.0 0.000143348623853 0 1 -1
hepatic,impairment,may 1.0 0.000286697247706 0 2 -2
hepatic,impairment,in 1.0 0.000143348623853 0 1 -1
hepatic,function,induced 1.0 0.000143348623853 0 1 -1
hepatic,failure,as 1.0 0.000143348623853 0 1 -1
hepatic,extraction,has 1.0 0.000143348623853 0 1 -1
hepatic,enzymes,capable 1.0 0.000143348623853 0 1 -1
hepatic,cytochrome,p450 1.0 0.000143348623853 0 1 -1
hepatic,cytochrome,p- 1.0 0.000143348623853 0 1 -1
hepatic,cyp,drug-metabolizing 1.0 0.000143348623853 0 1 -1
hepatic,clearance,or 1.0 0.000143348623853 0 1 -1
hepatic,blood,flow 1.0 0.000143348623853 0 1 -1
hepatic,and,the 1.0 0.000143348623853 0 1 -1
heparins,effect,on 1.0 0.000143348623853 0 1 -1
heparins,as,indicated 1.0 0.000143348623853 0 1 -1
heparin-induced,thrombocytopenia,the 1.0 0.000143348623853 0 1 -1
heparin,sodium,may 1.0 0.000143348623853 0 1 -1
heparin,sodium,injection 1.0 0.000143348623853 0 1 -1
heparin,since,is 1.0 0.000143348623853 0 1 -1
heparin,other,and 1.0 0.000143348623853 0 1 -1
heparin,no,human 1.0 0.000143348623853 0 1 -1
heparin,effect,oral 1.0 0.000143348623853 0 1 -1
hen,f1,that 1.0 0.000143348623853 0 1 -1
hemostasis,nsaids,aspirin 1.0 0.000143348623853 0 1 -1
hemostasis,and,regulation 1.0 0.000143348623853 0 1 -1
hemorrhages,edema,and 1.0 0.000143348623853 0 1 -1
hemorrhage,was,seen 1.0 0.000143348623853 0 1 -1
hemorrhage,should,be 1.0 0.000286697247706 0 2 -2
hemorrhage,and,optic 1.0 0.000143348623853 0 1 -1
hemoptysis,hematemesis,hematuria 1.0 0.000143348623853 0 1 -1
hemodynamic,and,electrophysiologic 1.0 0.000143348623853 0 1 -1
hemodialysis,until,his 1.0 0.000143348623853 0 1 -1
hemiballismus,hyperreflexia,ataxia 1.0 0.000143348623853 0 1 -1
hematuria,and,blood 1.0 0.000143348623853 0 1 -1
hematopoietic,system,should 1.0 0.000143348623853 0 1 -1
hematology,taxol,therapy 1.0 0.000143348623853 0 1 -1
hematologic,studies,or 1.0 0.000143348623853 0 1 -1
hematemesis,hematuria,and 1.0 0.000143348623853 0 1 -1
helpful,when,possible 1.0 0.000143348623853 0 1 -1
helpful,means,of 1.0 0.000143348623853 0 1 -1
help,to,trace 1.0 0.000143348623853 0 1 -1
help,to,regulate 1.0 0.000143348623853 0 1 -1
help,to,explain 1.0 0.000143348623853 0 1 -1
hearts,new,york 1.0 0.000143348623853 0 1 -1
heart,rate,or 1.0 0.000286697247706 0 2 -2
heart,rate,increased 1.0 0.000143348623853 0 1 -1
heart,rate,at 1.0 0.000143348623853 0 1 -1
heart,failure,who 1.0 0.000143348623853 0 1 -1
heart,failure,where 1.0 0.000143348623853 0 1 -1
heart,failure,were 1.0 0.000143348623853 0 1 -1
heart,failure,there 1.0 0.000143348623853 0 1 -1
heart,failure,post-myocardial 1.0 0.000143348623853 0 1 -1
heart,failure,nyha 1.0 0.000143348623853 0 1 -1
heart,failure,during 1.0 0.000143348623853 0 1 -1
heart,failure,as 1.0 0.000143348623853 0 1 -1
heart,failure,are 1.0 0.000143348623853 0 1 -1
heart,disease,treated 1.0 0.000143348623853 0 1 -1
heart,disease,spinal 1.0 0.000143348623853 0 1 -1
heart,disease,is 1.0 0.000143348623853 0 1 -1
heart,disease,in 1.0 0.000143348623853 0 1 -1
heart,can,be 1.0 0.000143348623853 0 1 -1
heart,block,were 1.0 0.000143348623853 0 1 -1
heart,block,produced 1.0 0.000143348623853 0 1 -1
heart,association,functional 1.0 0.000143348623853 0 1 -1
healthy,women,of 1.0 0.000143348623853 0 1 -1
healthy,white,female 1.0 0.000143348623853 0 1 -1
healthy,volunteers,who 1.0 0.000143348623853 0 1 -1
healthy,volunteers,when 1.0 0.000143348623853 0 1 -1
healthy,volunteers,were 1.0 0.000143348623853 0 1 -1
healthy,volunteers,under 1.0 0.000143348623853 0 1 -1
healthy,volunteers,treatment 1.0 0.000143348623853 0 1 -1
healthy,volunteers,there 1.0 0.000143348623853 0 1 -1
healthy,volunteers,show 1.0 0.000143348623853 0 1 -1
healthy,volunteers,resulting 1.0 0.000143348623853 0 1 -1
healthy,volunteers,or 1.0 0.000143348623853 0 1 -1
healthy,volunteers,no 1.0 0.000143348623853 0 1 -1
healthy,volunteers,n 1.0 0.000143348623853 0 1 -1
healthy,volunteers,increased 1.0 0.000143348623853 0 1 -1
healthy,volunteers,hormone 1.0 0.000143348623853 0 1 -1
healthy,volunteers,have 1.0 0.00043004587156 0 3 -3
healthy,volunteers,exjade 1.0 0.000143348623853 0 1 -1
healthy,volunteers,did 1.0 0.000143348623853 0 1 -1
healthy,volunteers,administration 1.0 0.000143348623853 0 1 -1
healthy,subjects,with 1.0 0.000286697247706 0 2 -2
healthy,subjects,who 1.0 0.00043004587156 0 3 -3
healthy,subjects,were 1.0 0.000143348623853 0 1 -1
healthy,subjects,to 1.0 0.000143348623853 0 1 -1
healthy,subjects,there 1.0 0.000143348623853 0 1 -1
healthy,subjects,the 1.0 0.000143348623853 0 1 -1
healthy,subjects,or 1.0 0.000143348623853 0 1 -1
healthy,subjects,on 1.0 0.000286697247706 0 2 -2
healthy,subjects,no 1.0 0.000143348623853 0 1 -1
healthy,subjects,clearance 1.0 0.000143348623853 0 1 -1
healthy,subject,n 1.0 0.000143348623853 0 1 -1
healthy,normal,volunteers 1.0 0.000143348623853 0 1 -1
healthy,men,n 1.0 0.000143348623853 0 1 -1
healthy,males,who 1.0 0.000143348623853 0 1 -1
healthy,males,in 1.0 0.000143348623853 0 1 -1
healthy,male,n 1.0 0.000143348623853 0 1 -1
healthy,male,and 1.0 0.00043004587156 0 3 -3
healthy,female,subjects 1.0 0.000286697247706 0 2 -2
healthy,adults,and 1.0 0.000143348623853 0 1 -1
healthcare,prescribers,are 1.0 0.000143348623853 0 1 -1
health,organization,criteria 1.0 0.000143348623853 0 1 -1
health,objectives,to 1.0 0.000143348623853 0 1 -1
health,care,providers 1.0 0.000143348623853 0 1 -1
health,care,professionals 1.0 0.000143348623853 0 1 -1
headaches,and,other 1.0 0.000286697247706 0 2 -2
he,was,treated 1.0 0.000143348623853 0 1 -1
hdl2,cholesterol,subfraction 1.0 0.000286697247706 0 2 -2
hdl,and,hdl2 1.0 0.000286697247706 0 2 -2
hctz,mg,qd 1.0 0.000143348623853 0 1 -1
hctz,hydrodiuril,diuril 1.0 0.000143348623853 0 1 -1
hctz,alone,or 1.0 0.000143348623853 0 1 -1
hcl,special,care 1.0 0.000143348623853 0 1 -1
hcl,is,given 1.0 0.000143348623853 0 1 -1
hcl,has,also 1.0 0.000143348623853 0 1 -1
hcl,cream,cream 1.0 0.000143348623853 0 1 -1
hcl,and,a 1.0 0.000143348623853 0 1 -1
hcl,an,increased 1.0 0.000143348623853 0 1 -1
hcl,a,specific 1.0 0.000143348623853 0 1 -1
hazards,of,herbal 1.0 0.000143348623853 0 1 -1
hazardous,when,taken 1.0 0.000143348623853 0 1 -1
hazardous,activities,requiring 1.0 0.000143348623853 0 1 -1
having,a,well-known 1.0 0.000143348623853 0 1 -1
having,a,vitamin 1.0 0.000143348623853 0 1 -1
having,a,pheochromocytoma 1.0 0.000143348623853 0 1 -1
have,varied,from 1.0 0.000143348623853 0 1 -1
have,used,in 1.0 0.000143348623853 0 1 -1
have,used,combined 1.0 0.000143348623853 0 1 -1
have,to,be 1.0 0.000143348623853 0 1 -1
have,their,dose 1.0 0.000143348623853 0 1 -1
have,the,condition 1.0 0.000143348623853 0 1 -1
have,the,blood 1.0 0.000143348623853 0 1 -1
have,suggested,that 1.0 0.000143348623853 0 1 -1
have,specifically,been 1.0 0.000143348623853 0 1 -1
have,some,of 1.0 0.000143348623853 0 1 -1
have,similar,effects 1.0 0.00043004587156 0 3 -3
have,similar,affinities 1.0 0.000143348623853 0 1 -1
have,significant,interactions 1.0 0.000143348623853 0 1 -1
have,shown,to 1.0 0.000143348623853 0 1 -1
have,shown,no 1.0 0.00043004587156 0 3 -3
have,shown,increased 1.0 0.000143348623853 0 1 -1
have,several,advantages 1.0 0.000143348623853 0 1 -1
have,selected,a 1.0 0.000143348623853 0 1 -1
have,revealed,no 1.0 0.000143348623853 0 1 -1
have,reported,that 1.0 0.000143348623853 0 1 -1
have,renal,clearance 1.0 0.000143348623853 0 1 -1
have,received,such 1.0 0.000143348623853 0 1 -1
have,received,general 1.0 0.000143348623853 0 1 -1
have,received,cephalosporin 1.0 0.000143348623853 0 1 -1
have,pulse,and 1.0 0.000143348623853 0 1 -1
have,previously,been 1.0 0.000143348623853 0 1 -1
have,potentially,favorable 1.0 0.000143348623853 0 1 -1
have,one,or 1.0 0.000143348623853 0 1 -1
have,occurred,when 1.0 0.000286697247706 0 2 -2
have,occasionally,been 1.0 0.000286697247706 0 2 -2
have,noted,that 1.0 0.000143348623853 0 1 -1
have,not,reported 1.0 0.000143348623853 0 1 -1
have,not,demonstrated 1.0 0.000286697247706 0 2 -2
have,not,altered 1.0 0.000143348623853 0 1 -1
have,no,significant 1.0 0.000286697247706 0 2 -2
have,no,inhibitory 1.0 0.000143348623853 0 1 -1
have,no,influence 1.0 0.000143348623853 0 1 -1
have,no,detectable 1.0 0.000143348623853 0 1 -1
have,no,clinically 1.0 0.000143348623853 0 1 -1
have,negative,results 1.0 0.000143348623853 0 1 -1
have,more,frequent 1.0 0.000143348623853 0 1 -1
have,lower,than 1.0 0.000143348623853 0 1 -1
have,long,half-lives 1.0 0.000143348623853 0 1 -1
have,little,or 1.0 0.000143348623853 0 1 -1
have,led,to 1.0 0.000143348623853 0 1 -1
have,involved,either 1.0 0.000143348623853 0 1 -1
have,investigated,whether 1.0 0.000143348623853 0 1 -1
have,investigated,simulect 1.0 0.000143348623853 0 1 -1
have,indicated,that 1.0 0.000286697247706 0 2 -2
have,increased,his 1.0 0.000143348623853 0 1 -1
have,included,beta-adrenergic 1.0 0.000143348623853 0 1 -1
have,higher,virologic 1.0 0.000143348623853 0 1 -1
have,higher,than 1.0 0.000860091743119 0 6 -6
have,generally,not 1.0 0.000143348623853 0 1 -1
have,frequently,been 1.0 0.000143348623853 0 1 -1
have,frequent,clinical 1.0 0.000143348623853 0 1 -1
have,focused,on 1.0 0.000143348623853 0 1 -1
have,failed,to 1.0 0.000143348623853 0 1 -1
have,experienced,problems 1.0 0.000286697247706 0 2 -2
have,experienced,elevated 1.0 0.000143348623853 0 1 -1
have,expanded,our 1.0 0.000143348623853 0 1 -1
have,excluded,patients 1.0 0.000286697247706 0 2 -2
have,examined,whether 1.0 0.000143348623853 0 1 -1
have,essentially,no 1.0 0.000143348623853 0 1 -1
have,either,protective 1.0 0.000143348623853 0 1 -1
have,effects,on 1.0 0.000143348623853 0 1 -1
have,discontinued,that 1.0 0.000143348623853 0 1 -1
have,developed,severe 1.0 0.000143348623853 0 1 -1
have,detrimental,effects 1.0 0.000286697247706 0 2 -2
have,demonstrated,the 1.0 0.000143348623853 0 1 -1
have,demonstrated,marked 1.0 0.000143348623853 0 1 -1
have,demonstrated,efficacy 1.0 0.000143348623853 0 1 -1
have,decreased,renal 1.0 0.000143348623853 0 1 -1
have,contributed,to 1.0 0.000143348623853 0 1 -1
have,congenital,or 1.0 0.000143348623853 0 1 -1
have,confirmed,these 1.0 0.000143348623853 0 1 -1
have,cns,effects 1.0 0.000143348623853 0 1 -1
have,clinically,significant 1.0 0.000286697247706 0 2 -2
have,clinically,important 1.0 0.000286697247706 0 2 -2
have,centroblast,proliferation 1.0 0.000143348623853 0 1 -1
have,carried,out 1.0 0.000143348623853 0 1 -1
have,benign,prostatic 1.0 0.000143348623853 0 1 -1
have,been,tested 1.0 0.000143348623853 0 1 -1
have,been,taking 1.0 0.000143348623853 0 1 -1
have,been,studied 1.0 0.000143348623853 0 1 -1
have,been,started 1.0 0.000143348623853 0 1 -1
have,been,safely 1.0 0.000286697247706 0 2 -2
have,been,recognized 1.0 0.000143348623853 0 1 -1
have,been,receiving 1.0 0.000143348623853 0 1 -1
have,been,received 1.0 0.000286697247706 0 2 -2
have,been,proposed 1.0 0.000143348623853 0 1 -1
have,been,prescribed 1.0 0.000143348623853 0 1 -1
have,been,performed 1.0 0.00172018348624 0 12 -12
have,been,obtained 1.0 0.000143348623853 0 1 -1
have,been,no 1.0 0.00114678899083 0 8 -8
have,been,more 1.0 0.000143348623853 0 1 -1
have,been,inconsistent 1.0 0.000143348623853 0 1 -1
have,been,frequently 1.0 0.000143348623853 0 1 -1
have,been,extensively 1.0 0.000143348623853 0 1 -1
have,been,exploited 1.0 0.000143348623853 0 1 -1
have,been,established 1.0 0.000143348623853 0 1 -1
have,been,drawn 1.0 0.000143348623853 0 1 -1
have,been,diagnosed 1.0 0.000286697247706 0 2 -2
have,been,demonstrated 1.0 0.000143348623853 0 1 -1
have,been,completed 1.0 0.000143348623853 0 1 -1
have,been,compared 1.0 0.000143348623853 0 1 -1
have,been,collected 1.0 0.000143348623853 0 1 -1
have,been,coadministered 1.0 0.000143348623853 0 1 -1
have,been,cited 1.0 0.000143348623853 0 1 -1
have,been,characterized 1.0 0.000143348623853 0 1 -1
have,been,case 1.0 0.000143348623853 0 1 -1
have,been,carried 1.0 0.000286697247706 0 2 -2
have,any,effect 1.0 0.000286697247706 0 2 -2
have,any,clinically 1.0 0.000573394495413 0 4 -4
have,an,increased 1.0 0.000286697247706 0 2 -2
have,an,effect 1.0 0.000143348623853 0 1 -1
have,an,acceptable 1.0 0.000143348623853 0 1 -1
have,allergic,or 1.0 0.000143348623853 0 1 -1
have,all,been 1.0 0.000143348623853 0 1 -1
have,a,synergistic 1.0 0.000143348623853 0 1 -1
have,a,substantially 1.0 0.000143348623853 0 1 -1
have,a,strong 1.0 0.000286697247706 0 2 -2
have,a,statistically 1.0 0.000143348623853 0 1 -1
have,a,specific 1.0 0.000143348623853 0 1 -1
have,a,significant 1.0 0.00043004587156 0 3 -3
have,a,profound 1.0 0.000143348623853 0 1 -1
have,a,positive 1.0 0.000143348623853 0 1 -1
have,a,negative 1.0 0.000143348623853 0 1 -1
have,a,more 1.0 0.000143348623853 0 1 -1
have,a,mild 1.0 0.000143348623853 0 1 -1
have,a,higher 1.0 0.000143348623853 0 1 -1
have,a,dramatic 1.0 0.000143348623853 0 1 -1
have,a,delayed 1.0 0.000143348623853 0 1 -1
have,a,clinically 1.0 0.00043004587156 0 3 -3
hatching,survival,and 1.0 0.000143348623853 0 1 -1
hatching,of,miracidia 1.0 0.000143348623853 0 1 -1
has,the,best 1.0 0.000143348623853 0 1 -1
has,suggested,may 1.0 0.000143348623853 0 1 -1
has,sufficient,function 1.0 0.000143348623853 0 1 -1
has,stabilized,see 1.0 0.000143348623853 0 1 -1
has,stabilized,for 1.0 0.000143348623853 0 1 -1
has,specifically,been 1.0 0.000143348623853 0 1 -1
has,sometimes,been 1.0 0.000143348623853 0 1 -1
has,slight,effects 1.0 0.000143348623853 0 1 -1
has,shown,no 1.0 0.000143348623853 0 1 -1
has,revealed,no 1.0 0.000143348623853 0 1 -1
has,reduced,activity 1.0 0.00043004587156 0 3 -3
has,recently,been 1.0 0.000143348623853 0 1 -1
has,proven,efficacy 1.0 0.000143348623853 0 1 -1
has,orphan,status 1.0 0.000143348623853 0 1 -1
has,occurred,more 1.0 0.000143348623853 0 1 -1
has,not,demonstrated 1.0 0.000143348623853 0 1 -1
has,no,effects 1.0 0.000143348623853 0 1 -1
has,no,effect 1.0 0.000716743119266 0 5 -5
has,no,cyp3a4 1.0 0.000143348623853 0 1 -1
has,no,clinically 1.0 0.000286697247706 0 2 -2
has,no,apparent 1.0 0.000573394495413 0 4 -4
has,much,lower 1.0 0.000143348623853 0 1 -1
has,increased,after 1.0 0.000143348623853 0 1 -1
has,importance,in 1.0 0.000143348623853 0 1 -1
has,greater,affinity 1.0 0.000143348623853 0 1 -1
has,generally,been 1.0 0.000143348623853 0 1 -1
has,focused,on 1.0 0.000143348623853 0 1 -1
has,emerged,from 1.0 0.000143348623853 0 1 -1
has,demonstrated,superiority 1.0 0.000143348623853 0 1 -1
has,demonstrated,effectiveness 1.0 0.000143348623853 0 1 -1
has,benefits,against 1.0 0.000143348623853 0 1 -1
has,been,well 1.0 0.000143348623853 0 1 -1
has,been,used 1.0 0.00114678899083 0 8 -8
has,been,treated 1.0 0.000143348623853 0 1 -1
has,been,too 1.0 0.000143348623853 0 1 -1
has,been,tested 1.0 0.000143348623853 0 1 -1
has,been,termed 1.0 0.000143348623853 0 1 -1
has,been,studied 1.0 0.00100344036697 0 7 -7
has,been,safely 1.0 0.000573394495413 0 4 -4
has,been,noted 1.0 0.000143348623853 0 1 -1
has,been,no 1.0 0.000143348623853 0 1 -1
has,been,little 1.0 0.000143348623853 0 1 -1
has,been,investigated 1.0 0.000143348623853 0 1 -1
has,been,extensively 1.0 0.000143348623853 0 1 -1
has,been,excreted 1.0 0.000143348623853 0 1 -1
has,been,evaluated 1.0 0.000143348623853 0 1 -1
has,been,effectively 1.0 0.000143348623853 0 1 -1
has,been,documented 1.0 0.000143348623853 0 1 -1
has,been,determined 1.0 0.000143348623853 0 1 -1
has,been,described 1.0 0.000143348623853 0 1 -1
has,been,definitely 1.0 0.000143348623853 0 1 -1
has,been,coadministered 1.0 0.000286697247706 0 2 -2
has,been,co-administered 1.0 0.000143348623853 0 1 -1
has,been,characterized 1.0 0.000143348623853 0 1 -1
has,been,attributed 1.0 0.00114678899083 0 8 -8
has,been,analysed 1.0 0.000143348623853 0 1 -1
has,an,enteric 1.0 0.000143348623853 0 1 -1
has,a,well-defined 1.0 0.000143348623853 0 1 -1
has,a,narrower 1.0 0.000143348623853 0 1 -1
has,a,great 1.0 0.000143348623853 0 1 -1
has,a,direct 1.0 0.000143348623853 0 1 -1
harmonic,mean,elimination 1.0 0.000143348623853 0 1 -1
harm,to,the 1.0 0.000143348623853 0 1 -1
hard,gelatin,capsules 1.0 0.000143348623853 0 1 -1
hansten,into,light 1.0 0.000143348623853 0 1 -1
handling,of,in 1.0 0.000143348623853 0 1 -1
hand,the,enhanced 1.0 0.000143348623853 0 1 -1
hand,the,density 1.0 0.000143348623853 0 1 -1
hand,surprisingly,green 1.0 0.000143348623853 0 1 -1
hand,promoted,significant 1.0 0.000143348623853 0 1 -1
hand,had,effects 1.0 0.000143348623853 0 1 -1
hamsters,show,subnormal 1.0 0.000143348623853 0 1 -1
hamsters,in,response 1.0 0.000143348623853 0 1 -1
hamster,s,alpha 1.0 0.000143348623853 0 1 -1
hamster,responds,excessively 1.0 0.000143348623853 0 1 -1
hallucinations,paresthesia,muscle 1.0 0.000143348623853 0 1 -1
half-lives,to,days 1.0 0.000143348623853 0 1 -1
half-lives,of,for 1.0 0.000143348623853 0 1 -1
half-life,was,and 1.0 0.000143348623853 0 1 -1
half-life,of,sulfoxide 1.0 0.000143348623853 0 1 -1
half-life,of,potential 1.0 0.000143348623853 0 1 -1
half-life,of,elimination 1.0 0.000143348623853 0 1 -1
half-life,multiple-dose,pharmacokinetic 1.0 0.000143348623853 0 1 -1
half-life,leading,to 1.0 0.000143348623853 0 1 -1
half-life,increased,from 1.0 0.000143348623853 0 1 -1
half-life,and,enhanced 1.0 0.000143348623853 0 1 -1
half,returned,to 1.0 0.000143348623853 0 1 -1
half,of,the 1.0 0.00043004587156 0 3 -3
half,of,that 1.0 0.000143348623853 0 1 -1
haldol,has,not 1.0 0.000143348623853 0 1 -1
haemodynamic,effects,of 1.0 0.000143348623853 0 1 -1
had,treatment-emergent,positive 1.0 0.000143348623853 0 1 -1
had,to,be 1.0 0.000143348623853 0 1 -1
had,opioid-antagonist,and 1.0 0.000143348623853 0 1 -1
had,not,recovered 1.0 0.000143348623853 0 1 -1
had,no,substantive 1.0 0.000143348623853 0 1 -1
had,no,relevant 1.0 0.000286697247706 0 2 -2
had,no,measurable 1.0 0.000143348623853 0 1 -1
had,no,influence 1.0 0.000143348623853 0 1 -1
had,no,effects 1.0 0.000143348623853 0 1 -1
had,no,clinically 1.0 0.000716743119266 0 5 -5
had,minimal,effects 1.0 0.000143348623853 0 1 -1
had,liver,injury 1.0 0.000143348623853 0 1 -1
had,little,or 1.0 0.000143348623853 0 1 -1
had,intoxication,after 1.0 0.000143348623853 0 1 -1
had,initial,positive 1.0 0.000143348623853 0 1 -1
had,increased,systematically 1.0 0.000143348623853 0 1 -1
had,had,a 1.0 0.000143348623853 0 1 -1
had,effects,similar 1.0 0.000143348623853 0 1 -1
had,depleting,added 1.0 0.000143348623853 0 1 -1
had,chemotherapy,interrupted 1.0 0.000143348623853 0 1 -1
had,been,receiving 1.0 0.000143348623853 0 1 -1
had,already,responded 1.0 0.000143348623853 0 1 -1
had,achieved,steady-state 1.0 0.000143348623853 0 1 -1
had,a,synergistic 1.0 0.000143348623853 0 1 -1
had,a,small 1.0 0.000286697247706 0 2 -2
had,a,similar 1.0 0.000143348623853 0 1 -1
had,a,non-significantly 1.0 0.000143348623853 0 1 -1
had,a,new 1.0 0.000143348623853 0 1 -1
had,a,ki 1.0 0.000143348623853 0 1 -1
had,a,higher 1.0 0.000286697247706 0 2 -2
had,a,dramatic 1.0 0.000143348623853 0 1 -1
haca,titers,may 1.0 0.000143348623853 0 1 -1
habituation,or,cns 1.0 0.000143348623853 0 1 -1
habituating,potential,prolonged 1.0 0.000143348623853 0 1 -1
haart,with,a 1.0 0.000143348623853 0 1 -1
haart,was,included 1.0 0.000143348623853 0 1 -1
haart,treatment,on 1.0 0.000143348623853 0 1 -1
haart,on,the 1.0 0.000143348623853 0 1 -1
haart,is,still 1.0 0.000143348623853 0 1 -1
haart,is,feasible 1.0 0.000143348623853 0 1 -1
h2-receptor,antagonists,histamine 1.0 0.000143348623853 0 1 -1
h2-receptor,antagonists,appear 1.0 0.000143348623853 0 1 -1
h2-antagonists,and,proton 1.0 0.000143348623853 0 1 -1
h2,blockers,and 1.0 0.000143348623853 0 1 -1
h2,antagonists,such 1.0 0.000143348623853 0 1 -1
h2,antagonists,hmg-coa 1.0 0.000143348623853 0 1 -1
h-triolein,at,baseline 1.0 0.000143348623853 0 1 -1
h-spiroperidol,binding,with 1.0 0.000143348623853 0 1 -1
h-spiroperidol,binding,after 1.0 0.000143348623853 0 1 -1
h-spiroperidol,and,low 1.0 0.000143348623853 0 1 -1
h-spiroperidol,and,high 1.0 0.000143348623853 0 1 -1
h-2,antagonists,in 1.0 0.000143348623853 0 1 -1
h,was,discontinued 1.0 0.000143348623853 0 1 -1
h,up,to 1.0 0.000143348623853 0 1 -1
h,this,number 1.0 0.000143348623853 0 1 -1
h,period,demonstrated 1.0 0.000143348623853 0 1 -1
h,or,mycophenolate 1.0 0.000143348623853 0 1 -1
h,in,the 1.0 0.000143348623853 0 1 -1
h,extent,of 1.0 0.000143348623853 0 1 -1
h,exposures,of 1.0 0.000143348623853 0 1 -1
h,did,not 1.0 0.000143348623853 0 1 -1
h,concomitant,administration 1.0 0.000143348623853 0 1 -1
h,by,infusion 1.0 0.000143348623853 0 1 -1
h,antagonists,the 1.0 0.000143348623853 0 1 -1
h,also,indicated 1.0 0.000143348623853 0 1 -1
gvia-sensitive,n-type,channel 1.0 0.000143348623853 0 1 -1
gvia,omega-agatoxin,via-resistant 1.0 0.000143348623853 0 1 -1
gvia,n-type,or 1.0 0.000143348623853 0 1 -1
guinea,pig,small 1.0 0.000143348623853 0 1 -1
guidelines,are,provided 1.0 0.000143348623853 0 1 -1
guardians,should,be 1.0 0.000143348623853 0 1 -1
guardians,of,children 1.0 0.000143348623853 0 1 -1
guardians,carefully,about 1.0 0.000143348623853 0 1 -1
guardian,see,illustrated 1.0 0.000143348623853 0 1 -1
guanethidine,or,similarly 1.0 0.000143348623853 0 1 -1
gtp-binding,proteins,of 1.0 0.000143348623853 0 1 -1
gst,activity,however 1.0 0.000143348623853 0 1 -1
gsh,and,elevation 1.0 0.000143348623853 0 1 -1
growth,to,those 1.0 0.000143348623853 0 1 -1
growth,of,several 1.0 0.000143348623853 0 1 -1
growth,of,pseudomonas 1.0 0.000143348623853 0 1 -1
growth,factor,treatment 1.0 0.000143348623853 0 1 -1
growth,caused,by 1.0 0.000143348623853 0 1 -1
growth,both,in 1.0 0.000143348623853 0 1 -1
grown,in,mm 1.0 0.000143348623853 0 1 -1
growing,problem,not 1.0 0.000143348623853 0 1 -1
growing,class,of 1.0 0.000143348623853 0 1 -1
groups,without,change 1.0 0.000143348623853 0 1 -1
groups,which,were 1.0 0.000143348623853 0 1 -1
groups,were,well 1.0 0.000143348623853 0 1 -1
groups,were,observed 1.0 0.000143348623853 0 1 -1
groups,then,took 1.0 0.000143348623853 0 1 -1
groups,sh,da 1.0 0.000143348623853 0 1 -1
groups,of,rats 1.0 0.000143348623853 0 1 -1
groups,of,patients 1.0 0.000143348623853 0 1 -1
groups,of,agents 1.0 0.00043004587156 0 3 -3
groups,is,decreasing 1.0 0.000143348623853 0 1 -1
groups,ie,from 1.0 0.000143348623853 0 1 -1
groups,fed,further 1.0 0.000143348623853 0 1 -1
groups,developed,b-cell 1.0 0.000143348623853 0 1 -1
groups,but,colony 1.0 0.000143348623853 0 1 -1
groups,and,were 1.0 0.000143348623853 0 1 -1
groups,achieving,a 1.0 0.000143348623853 0 1 -1
grouped,as,ace 1.0 0.000143348623853 0 1 -1
group,took,either 1.0 0.000143348623853 0 1 -1
group,therapy,with 1.0 0.000143348623853 0 1 -1
group,the,dose 1.0 0.000143348623853 0 1 -1
group,that,received 1.0 0.000286697247706 0 2 -2
group,than,in 1.0 0.000143348623853 0 1 -1
group,specifically,cytochromes 1.0 0.000143348623853 0 1 -1
group,sh,ea 1.0 0.000143348623853 0 1 -1
group,served,as 1.0 0.000143348623853 0 1 -1
group,of,patients 1.0 0.000286697247706 0 2 -2
group,of,nonsmoking 1.0 0.000143348623853 0 1 -1
group,of,newly 1.0 0.000143348623853 0 1 -1
group,of,healthy 1.0 0.000143348623853 0 1 -1
group,is,currently 1.0 0.000143348623853 0 1 -1
group,interaction,study 1.0 0.000143348623853 0 1 -1
group,did,not 1.0 0.000143348623853 0 1 -1
group,developed,a 1.0 0.000143348623853 0 1 -1
group,clinical,pharmacology 1.0 0.000143348623853 0 1 -1
gross,motor,skills 1.0 0.000143348623853 0 1 -1
green,tea,polyphenols 1.0 0.000143348623853 0 1 -1
green,tea,gallocatechins 1.0 0.000143348623853 0 1 -1
green,as,an 1.0 0.000143348623853 0 1 -1
greatest,value,of 1.0 0.000143348623853 0 1 -1
greater,understanding,of 1.0 0.000143348623853 0 1 -1
greater,than,the 1.0 0.000286697247706 0 2 -2
greater,than,or 1.0 0.000143348623853 0 1 -1
greater,than,mug 1.0 0.000143348623853 0 1 -1
greater,than,mm 1.0 0.000143348623853 0 1 -1
greater,than,changes 1.0 0.000143348623853 0 1 -1
greater,risk,of 1.0 0.000286697247706 0 2 -2
greater,in,the 1.0 0.000286697247706 0 2 -2
greater,for,the 1.0 0.000143348623853 0 1 -1
greater,for,pseudomonas 1.0 0.000143348623853 0 1 -1
greater,fecal,blood 1.0 0.000143348623853 0 1 -1
greater,extent,than 1.0 0.000286697247706 0 2 -2
greater,eaca,inhibits 1.0 0.000143348623853 0 1 -1
greater,antitumour,activity 1.0 0.000143348623853 0 1 -1
greater,after,than 1.0 0.000143348623853 0 1 -1
greater,affinity,for 1.0 0.000143348623853 0 1 -1
great,potential,in 1.0 0.000143348623853 0 1 -1
great,interest,from 1.0 0.000143348623853 0 1 -1
great,extent,with 1.0 0.000143348623853 0 1 -1
great,an,interval 1.0 0.000143348623853 0 1 -1
grapefruit,orange,and 1.0 0.000143348623853 0 1 -1
grapefruit,or,orange 1.0 0.000143348623853 0 1 -1
grapefruit,or,grapefruit 1.0 0.000143348623853 0 1 -1
grapefruit,juice,with 1.0 0.000286697247706 0 2 -2
grapefruit,juice,which 1.0 0.000143348623853 0 1 -1
grapefruit,juice,resulted 1.0 0.000143348623853 0 1 -1
grapefruit,juice,increases 1.0 0.000143348623853 0 1 -1
grapefruit,juice,have 1.0 0.000143348623853 0 1 -1
grapefruit,juice,given 1.0 0.000143348623853 0 1 -1
grapefruit,juice,co-administration 1.0 0.000143348623853 0 1 -1
grapefruit,and,orange 1.0 0.000143348623853 0 1 -1
granulosa,cell,tumors 1.0 0.000143348623853 0 1 -1
granulomata,subacute,hepatitis 1.0 0.000143348623853 0 1 -1
grams,daily,taken 1.0 0.000143348623853 0 1 -1
gram-negative,organisms,but 1.0 0.000143348623853 0 1 -1
gram-negative,and,some 1.0 0.000143348623853 0 1 -1
gram,positive,and 1.0 0.000143348623853 0 1 -1
gram,negative,bacteria 1.0 0.000143348623853 0 1 -1
gradually,returned,to 1.0 0.000143348623853 0 1 -1
gradual,withdrawal,of 1.0 0.000143348623853 0 1 -1
gradual,dose,increases 1.0 0.000143348623853 0 1 -1
grade,i,roegnik 1.0 0.000143348623853 0 1 -1
grade,according,to 1.0 0.000143348623853 0 1 -1
gout,and,renal 1.0 0.000143348623853 0 1 -1
good,with,few 1.0 0.000143348623853 0 1 -1
good,inhibition,while 1.0 0.000143348623853 0 1 -1
gonadotropin-releasing,hormone,indicating 1.0 0.000143348623853 0 1 -1
gonadotropin,levels,may 1.0 0.000143348623853 0 1 -1
gonadotropin,levels,caused 1.0 0.000143348623853 0 1 -1
gold,salts,medicine 1.0 0.000143348623853 0 1 -1
gold,is,excreted 1.0 0.000143348623853 0 1 -1
going,to,be 1.0 0.000716743119266 0 5 -5
goal-directed,behavior,in 1.0 0.000143348623853 0 1 -1
goal,of,this 1.0 0.000143348623853 0 1 -1
goal,of,enhancing 1.0 0.000143348623853 0 1 -1
glycosides,therapeutic,effects 1.0 0.000143348623853 0 1 -1
glycosides,patients,on 1.0 0.000143348623853 0 1 -1
glycosides,may,be 1.0 0.000143348623853 0 1 -1
glycosides,inducers,of 1.0 0.000143348623853 0 1 -1
glycosides,in,patients 1.0 0.000143348623853 0 1 -1
glycosides,in,a 1.0 0.000143348623853 0 1 -1
glycosides,concurrent,use 1.0 0.000143348623853 0 1 -1
glyceryl,trinitrate,isosorbide 1.0 0.000143348623853 0 1 -1
glycemic,levels,at 1.0 0.000143348623853 0 1 -1
glycemic,control,with 1.0 0.000143348623853 0 1 -1
glycemic,control,in 1.0 0.000143348623853 0 1 -1
glycemia,induced,by 1.0 0.000143348623853 0 1 -1
glycemia,in,diabetic 1.0 0.000143348623853 0 1 -1
glycemia,after,overload 1.0 0.000143348623853 0 1 -1
glyburide,is,a 1.0 0.000143348623853 0 1 -1
glyburide,in,a 1.0 0.000143348623853 0 1 -1
glyburide,glyburide,is 1.0 0.000143348623853 0 1 -1
glyburide,etodolac,has 1.0 0.000143348623853 0 1 -1
glyburide,an,increased 1.0 0.000143348623853 0 1 -1
gly-buride,and,did 1.0 0.000143348623853 0 1 -1
glutathione-s,transferase,gst 1.0 0.000143348623853 0 1 -1
glutathione,total,gsh 1.0 0.000143348623853 0 1 -1
glutathione,or,other 1.0 0.000143348623853 0 1 -1
glutamatergic,activation,of 1.0 0.000143348623853 0 1 -1
glutamate,mglur,agonists 1.0 0.000143348623853 0 1 -1
glucuronide,account,for 1.0 0.000143348623853 0 1 -1
glucuronidation,is,unlikely 1.0 0.000143348623853 0 1 -1
glucuronidation,being,a 1.0 0.000143348623853 0 1 -1
glucuronidation,and,intestinal 1.0 0.000143348623853 0 1 -1
glucosylation,of,the 1.0 0.000143348623853 0 1 -1
glucosyl,transferase,enzyme 1.0 0.000143348623853 0 1 -1
glucose-specific,method,to 1.0 0.000143348623853 0 1 -1
glucose,when,was 1.0 0.000143348623853 0 1 -1
glucose,was,determined 1.0 0.000143348623853 0 1 -1
glucose,utilization,with 1.0 0.000143348623853 0 1 -1
glucose,tolerance,secretion 1.0 0.000143348623853 0 1 -1
glucose,tests,based 1.0 0.000860091743119 0 6 -6
glucose,some,patients 1.0 0.000143348623853 0 1 -1
glucose,oxidase,reactions 1.0 0.000716743119266 0 5 -5
glucose,oxidase,or 1.0 0.000286697247706 0 2 -2
glucose,monitoring,devices 1.0 0.000143348623853 0 1 -1
glucose,metabolism,in 1.0 0.000143348623853 0 1 -1
glucose,metabolism,and 1.0 0.000286697247706 0 2 -2
glucose,measurement,must 1.0 0.000143348623853 0 1 -1
glucose,levels,usually 1.0 0.000143348623853 0 1 -1
glucose,levels,of 1.0 0.000143348623853 0 1 -1
glucose,levels,in 1.0 0.00043004587156 0 3 -3
glucose,levels,have 1.0 0.000143348623853 0 1 -1
glucose,is,recommended 1.0 0.000286697247706 0 2 -2
glucose,intolerance,prior 1.0 0.000143348623853 0 1 -1
glucose,intolerance,and 1.0 0.000286697247706 0 2 -2
glucose,in,urine 1.0 0.000143348623853 0 1 -1
glucose,in,the 1.0 0.00172018348624 0 12 -12
glucose,enzymatic,test 1.0 0.000143348623853 0 1 -1
glucose,dehydrogenase,pyrroloquinolinequinone 1.0 0.000143348623853 0 1 -1
glucose,control,in 1.0 0.000143348623853 0 1 -1
glucose,blood,glucose 1.0 0.000143348623853 0 1 -1
glucose,and,exert 1.0 0.000143348623853 0 1 -1
glucose,and,concentrations 1.0 0.000143348623853 0 1 -1
glucose,and,can 1.0 0.000143348623853 0 1 -1
glucose,alone,and 1.0 0.000143348623853 0 1 -1
glucose,alkaline,phosphatase 1.0 0.000143348623853 0 1 -1
glucocorticoid-induced,mouse,mammary 1.0 0.000143348623853 0 1 -1
glucocorticoid-induced,gene,transcription 1.0 0.000143348623853 0 1 -1
glucocorticoid-induced,gene,expression 1.0 0.000286697247706 0 2 -2
glomerular,filtration,rate 1.0 0.000143348623853 0 1 -1
glomerular,filtration,or 1.0 0.000143348623853 0 1 -1
glomerular,filtration,may 1.0 0.000143348623853 0 1 -1
globulin,thereby,increasing 1.0 0.000143348623853 0 1 -1
globulin,tbg,levels 1.0 0.000143348623853 0 1 -1
globulin,tbg,leading 1.0 0.00043004587156 0 3 -3
globulin,shbg,leading 1.0 0.000286697247706 0 2 -2
globulin,cbg,sex 1.0 0.000286697247706 0 2 -2
gliftor,difluoro-2,propanol 1.0 0.000143348623853 0 1 -1
gleevec,inhibits,the 1.0 0.000143348623853 0 1 -1
gleevec,inhibits,o-glucuronidation 1.0 0.000143348623853 0 1 -1
glatiramer,acetate,were 1.0 0.000143348623853 0 1 -1
glands,with,synergistically 1.0 0.000143348623853 0 1 -1
glands,with,cytochalasin 1.0 0.000143348623853 0 1 -1
glands,was,monitored 1.0 0.000143348623853 0 1 -1
gland,has,sufficient 1.0 0.000143348623853 0 1 -1
gl,was,the 1.0 0.000143348623853 0 1 -1
gl,the,aqueous 1.0 0.000143348623853 0 1 -1
giving,up,smoking 1.0 0.000143348623853 0 1 -1
giving,these,together 1.0 0.000143348623853 0 1 -1
giving,these,concomitantly 1.0 0.000143348623853 0 1 -1
given,without,the 1.0 0.000143348623853 0 1 -1
given,without,difficulty 1.0 0.000143348623853 0 1 -1
given,within,weeks 1.0 0.000143348623853 0 1 -1
given,with,two 1.0 0.000143348623853 0 1 -1
given,with,to 1.0 0.000143348623853 0 1 -1
given,with,the 1.0 0.000143348623853 0 1 -1
given,with,it 1.0 0.000143348623853 0 1 -1
given,with,caution 1.0 0.000286697247706 0 2 -2
given,with,agents 1.0 0.000143348623853 0 1 -1
given,when,administering 1.0 0.000143348623853 0 1 -1
given,weekly,subcutaneous 1.0 0.000143348623853 0 1 -1
given,tot,the 1.0 0.000143348623853 0 1 -1
given,together,with 1.0 0.000143348623853 0 1 -1
given,together,as 1.0 0.000143348623853 0 1 -1
given,to,rats 1.0 0.000143348623853 0 1 -1
given,to,possible 1.0 0.000143348623853 0 1 -1
given,to,electrolyte 1.0 0.000143348623853 0 1 -1
given,to,adult 1.0 0.000143348623853 0 1 -1
given,the,time 1.0 0.000143348623853 0 1 -1
given,the,properties 1.0 0.000143348623853 0 1 -1
given,the,possibility 1.0 0.000143348623853 0 1 -1
given,the,increased 1.0 0.000143348623853 0 1 -1
given,the,following 1.0 0.000143348623853 0 1 -1
given,the,abundance 1.0 0.000143348623853 0 1 -1
given,situation,has 1.0 0.000143348623853 0 1 -1
given,singly,and 1.0 0.000143348623853 0 1 -1
given,several,months 1.0 0.000143348623853 0 1 -1
given,sc,injections 1.0 0.000143348623853 0 1 -1
given,plasma,concentration 1.0 0.000143348623853 0 1 -1
given,oral,h2-antagonists 1.0 0.000143348623853 0 1 -1
given,or,times 1.0 0.000143348623853 0 1 -1
given,only,for 1.0 0.000143348623853 0 1 -1
given,one,of 1.0 0.000716743119266 0 5 -5
given,number,of 1.0 0.000143348623853 0 1 -1
given,mg,day 1.0 0.000143348623853 0 1 -1
given,lodine,or 1.0 0.000143348623853 0 1 -1
given,intravenously,over 1.0 0.000143348623853 0 1 -1
given,intraluminally,was 1.0 0.000143348623853 0 1 -1
given,injections,of 1.0 0.000143348623853 0 1 -1
given,in,combination 1.0 0.00043004587156 0 3 -3
given,i,p 1.0 0.000143348623853 0 1 -1
given,fu,bolus-ifl 1.0 0.000143348623853 0 1 -1
given,for,long 1.0 0.000143348623853 0 1 -1
given,for,each 1.0 0.000143348623853 0 1 -1
given,exclusively,by 1.0 0.000143348623853 0 1 -1
given,doses,of 1.0 0.000143348623853 0 1 -1
given,dose,of 1.0 0.000716743119266 0 5 -5
given,did,not 1.0 0.000143348623853 0 1 -1
given,concurrently,the 1.0 0.000286697247706 0 2 -2
given,concurrently,it 1.0 0.000143348623853 0 1 -1
given,concurrently,and 1.0 0.000143348623853 0 1 -1
given,concomitantly,only 1.0 0.000143348623853 0 1 -1
given,concomitantly,including 1.0 0.000143348623853 0 1 -1
given,compensatory,increases 1.0 0.000143348623853 0 1 -1
given,by,infusion 1.0 0.000143348623853 0 1 -1
given,before,the 1.0 0.000143348623853 0 1 -1
given,at,least 1.0 0.000143348623853 0 1 -1
given,at,bedtime 1.0 0.000143348623853 0 1 -1
given,as,tablets 1.0 0.000143348623853 0 1 -1
given,as,antiemetic 1.0 0.000143348623853 0 1 -1
given,and,hours 1.0 0.000143348623853 0 1 -1
given,alone,or 1.0 0.000143348623853 0 1 -1
given,alone,in 1.0 0.000143348623853 0 1 -1
given,after,multiple 1.0 0.000143348623853 0 1 -1
give,you,more 1.0 0.000143348623853 0 1 -1
give,little,consideration 1.0 0.000143348623853 0 1 -1
give,a,false-positive 1.0 0.000143348623853 0 1 -1
girdle,and,pre-sacral 1.0 0.000143348623853 0 1 -1
ginsenosides-induced,inhibition,of 1.0 0.000143348623853 0 1 -1
gi,motility,agents 1.0 0.000143348623853 0 1 -1
gi,motility,agent 1.0 0.000143348623853 0 1 -1
gi,bleeding,a 1.0 0.000143348623853 0 1 -1
get,the,most 1.0 0.000143348623853 0 1 -1
germinal,centers,of 1.0 0.000143348623853 0 1 -1
geriatric,use,younger 1.0 0.000143348623853 0 1 -1
geriatric,use,when 1.0 0.000143348623853 0 1 -1
geriatric,subjects,n 1.0 0.000143348623853 0 1 -1
geriatric,population,who 1.0 0.000143348623853 0 1 -1
geriatric,population,is 1.0 0.000143348623853 0 1 -1
geometric,mean,ratios 1.0 0.000143348623853 0 1 -1
gentamycin,reduced,twitch 1.0 0.000143348623853 0 1 -1
gentamicin,is,an 1.0 0.000143348623853 0 1 -1
gentamicin,did,not 1.0 0.000143348623853 0 1 -1
genotypes,of,cyp2c9 1.0 0.000143348623853 0 1 -1
genotoxic,compounds--can,be 1.0 0.000143348623853 0 1 -1
genomes,have,been 1.0 0.000143348623853 0 1 -1
genitourinary,symptoms,may 1.0 0.000143348623853 0 1 -1
genetically,predisposed,mice 1.0 0.000286697247706 0 2 -2
genetically,nervous,e-strain 1.0 0.000143348623853 0 1 -1
genetically,initiated,cell 1.0 0.000143348623853 0 1 -1
genetically,diabetic,cinese 1.0 0.000143348623853 0 1 -1
genetic,variation,in 1.0 0.000143348623853 0 1 -1
genetic,variation,also 1.0 0.000143348623853 0 1 -1
genetic,factors,may 1.0 0.000143348623853 0 1 -1
genetic,data,in 1.0 0.000143348623853 0 1 -1
genes,iegs,are 1.0 0.000143348623853 0 1 -1
generation,of,vasodilator 1.0 0.000143348623853 0 1 -1
generation,of,three 1.0 0.000143348623853 0 1 -1
generation,more,people 1.0 0.000143348623853 0 1 -1
generation,atypical,antipsychotic 1.0 0.000143348623853 0 1 -1
generated,to,date 1.0 0.000143348623853 0 1 -1
generated,from,an 1.0 0.000143348623853 0 1 -1
generate,the,toxic 1.0 0.000143348623853 0 1 -1
generally,this,phenomenon 1.0 0.000143348623853 0 1 -1
generally,not,been 1.0 0.000143348623853 0 1 -1
generally,good,with 1.0 0.000143348623853 0 1 -1
generally,do,not 1.0 0.000143348623853 0 1 -1
generally,by,effects 1.0 0.000143348623853 0 1 -1
generally,believed,to 1.0 0.000143348623853 0 1 -1
generally,been,suggested 1.0 0.000143348623853 0 1 -1
generally,be,given 1.0 0.000143348623853 0 1 -1
generally,asymptomatic,but 1.0 0.000143348623853 0 1 -1
generalized,urticaria,require 1.0 0.000143348623853 0 1 -1
general,utilizing,a 1.0 0.000143348623853 0 1 -1
general,these,are 1.0 0.000143348623853 0 1 -1
general,the,anesthesiologist 1.0 0.000143348623853 0 1 -1
general,significant,interactions 1.0 0.000143348623853 0 1 -1
general,public,feels 1.0 0.000143348623853 0 1 -1
general,population,plasma 1.0 0.000143348623853 0 1 -1
general,population,of 1.0 0.000143348623853 0 1 -1
general,population,is 1.0 0.000143348623853 0 1 -1
general,no,clinical 1.0 0.000143348623853 0 1 -1
general,most,patients 1.0 0.000143348623853 0 1 -1
general,may,result 1.0 0.000143348623853 0 1 -1
general,local,like 1.0 0.000143348623853 0 1 -1
general,interactions,certain 1.0 0.000143348623853 0 1 -1
general,in,vitro 1.0 0.000143348623853 0 1 -1
general,in,humans 1.0 0.000143348623853 0 1 -1
general,if,a 1.0 0.000143348623853 0 1 -1
general,conditions,of 1.0 0.000143348623853 0 1 -1
general,concern,regarding 1.0 0.000143348623853 0 1 -1
general,cognitive,function 1.0 0.000143348623853 0 1 -1
general,caution,should 1.0 0.000143348623853 0 1 -1
general,any,added 1.0 0.000143348623853 0 1 -1
general,antianxiety,and 1.0 0.000143348623853 0 1 -1
general,and,local 1.0 0.000143348623853 0 1 -1
general,and,during 1.0 0.000143348623853 0 1 -1
general,although,there 1.0 0.000143348623853 0 1 -1
general,agents,and 1.0 0.000143348623853 0 1 -1
gene,which,may 1.0 0.000143348623853 0 1 -1
gene,under,the 1.0 0.000143348623853 0 1 -1
gene,transfer,to 1.0 0.000143348623853 0 1 -1
gene,transcription,was 1.0 0.000143348623853 0 1 -1
gene,expression,was 1.0 0.000143348623853 0 1 -1
gene,expression,that 1.0 0.000143348623853 0 1 -1
gene,expression,by 1.0 0.000143348623853 0 1 -1
gene,cassette,fully 1.0 0.000143348623853 0 1 -1
gender,race,intercurrent 1.0 0.000143348623853 0 1 -1
gemzar,and,in 1.0 0.000143348623853 0 1 -1
gemfibrozil,other,niacin 1.0 0.000143348623853 0 1 -1
gelatinosa,neurons,including 1.0 0.000143348623853 0 1 -1
gelatin,capsules,at 1.0 0.000143348623853 0 1 -1
gel,with,other 1.0 0.000143348623853 0 1 -1
gel,until,the 1.0 0.000143348623853 0 1 -1
gel,on,the 1.0 0.000143348623853 0 1 -1
gel,interacts,with 1.0 0.000143348623853 0 1 -1
gel,in,combination 1.0 0.000143348623853 0 1 -1
gel,has,the 1.0 0.000143348623853 0 1 -1
gel,and,systemic 1.0 0.000143348623853 0 1 -1
ge,nerally,classified 1.0 0.000143348623853 0 1 -1
gdh,pqq-based,methods 1.0 0.000143348623853 0 1 -1
gdh,pqq,based 1.0 0.000143348623853 0 1 -1
gathered,for,every 1.0 0.000143348623853 0 1 -1
gastrointestinal,tract,where 1.0 0.000143348623853 0 1 -1
gastrointestinal,ph,may 1.0 0.000143348623853 0 1 -1
gastrointestinal,motility,may 1.0 0.000143348623853 0 1 -1
gastrointestinal,events,in 1.0 0.000143348623853 0 1 -1
gastrointestinal,disturbances,such 1.0 0.000143348623853 0 1 -1
gastrointestinal,and,non-gastrointestinal 1.0 0.000143348623853 0 1 -1
gastrointestinal,adverse,experiences 1.0 0.000286697247706 0 2 -2
gastrointestinal,adverse,events 1.0 0.000143348623853 0 1 -1
gastroduodenal,ulcers,in 1.0 0.000143348623853 0 1 -1
gastric,secretion,chronic 1.0 0.000143348623853 0 1 -1
gastric,ph,on 1.0 0.000143348623853 0 1 -1
gastric,ph,in 1.0 0.000143348623853 0 1 -1
gastric,hydrochloric,acid 1.0 0.000143348623853 0 1 -1
gastric,glands,was 1.0 0.000143348623853 0 1 -1
gastric,fistulas,were 1.0 0.000143348623853 0 1 -1
gastric,emptying,by 1.0 0.000143348623853 0 1 -1
gastric,acidity,duloxetine 1.0 0.000143348623853 0 1 -1
garlic,capsules,should 1.0 0.000143348623853 0 1 -1
garlic,capsules,garlic 1.0 0.000143348623853 0 1 -1
ganoderma,lucidum,fr 1.0 0.000143348623853 0 1 -1
ganoderma,lucidum,extract 1.0 0.000143348623853 0 1 -1
ganglionic,or,peripheral 1.0 0.000143348623853 0 1 -1
ganglion,hypogastric,nerve 1.0 0.000143348623853 0 1 -1
ganglion,blocking,compounds 1.0 0.000143348623853 0 1 -1
ganciclovir,the,pharmacokinetics 1.0 0.000143348623853 0 1 -1
gammaherpes,virus,also 1.0 0.000143348623853 0 1 -1
galloyl,esters,on 1.0 0.000143348623853 0 1 -1
gallocatechins,epigallocatechin-3,o-gallate 1.0 0.000143348623853 0 1 -1
gallic,acid,itself 1.0 0.000143348623853 0 1 -1
gallates,is,of 1.0 0.000143348623853 0 1 -1
gallate,showed,the 1.0 0.000143348623853 0 1 -1
gallate,also,showed 1.0 0.000143348623853 0 1 -1
gain,somnolence,dizziness 1.0 0.000143348623853 0 1 -1
gain,occurred,significantly 1.0 0.000143348623853 0 1 -1
gain,and,increased 1.0 0.000143348623853 0 1 -1
gabitril,with,other 1.0 0.000143348623853 0 1 -1
gabitril,with,highly 1.0 0.000143348623853 0 1 -1
gabitril,on,other 1.0 0.000143348623853 0 1 -1
gabitril,is,considered 1.0 0.000143348623853 0 1 -1
gabapentin,pharmacokinetic,parameters 1.0 0.000143348623853 0 1 -1
gabapentin,is,not 1.0 0.000143348623853 0 1 -1
gabapentin,had,no 1.0 0.000143348623853 0 1 -1
gaba-positive,be,included 1.0 0.000143348623853 0 1 -1
g,sometimes,mcg 1.0 0.000143348623853 0 1 -1
g,per,day 1.0 0.000143348623853 0 1 -1
g,ml,or 1.0 0.000143348623853 0 1 -1
g,m2,pegasys 1.0 0.000143348623853 0 1 -1
g,m2,dose 1.0 0.000286697247706 0 2 -2
g,kg,min 1.0 0.000143348623853 0 1 -1
g,kg,mg 1.0 0.000143348623853 0 1 -1
g,kg,m 1.0 0.000143348623853 0 1 -1
g,kg,dose 1.0 0.000143348623853 0 1 -1
g,kg,body 1.0 0.000143348623853 0 1 -1
g,hr,should 1.0 0.000143348623853 0 1 -1
g,bolus,of 1.0 0.000143348623853 0 1 -1
g,bolus,followed 1.0 0.000143348623853 0 1 -1
future,trends,are 1.0 0.000143348623853 0 1 -1
future,studies,should 1.0 0.000143348623853 0 1 -1
furthermore,whenever,one 1.0 0.000716743119266 0 5 -5
furthermore,no,significant 1.0 0.000143348623853 0 1 -1
furthermore,caution,should 1.0 0.000143348623853 0 1 -1
furthermore,and,do 1.0 0.000143348623853 0 1 -1
further,they,bring 1.0 0.000143348623853 0 1 -1
further,these,results 1.0 0.000143348623853 0 1 -1
further,reduced,the 1.0 0.000143348623853 0 1 -1
further,no,effects 1.0 0.000143348623853 0 1 -1
further,metabolized,to 1.0 0.000143348623853 0 1 -1
further,kidney,damage 1.0 0.000143348623853 0 1 -1
further,is,reported 1.0 0.000143348623853 0 1 -1
further,in,rabbits 1.0 0.000143348623853 0 1 -1
further,in,clinical 1.0 0.000143348623853 0 1 -1
further,in,a 1.0 0.000143348623853 0 1 -1
further,if,is 1.0 0.000143348623853 0 1 -1
further,fe,abstract 1.0 0.000143348623853 0 1 -1
further,doses,which 1.0 0.000143348623853 0 1 -1
further,designs,can 1.0 0.000143348623853 0 1 -1
further,data,are 1.0 0.000286697247706 0 2 -2
furosemide-stimulated,diuresis,natriuresis 1.0 0.000143348623853 0 1 -1
furosemide,in,normal 1.0 0.000143348623853 0 1 -1
furosemide,administered,concurrently 1.0 0.000143348623853 0 1 -1
fungal,infections,because 1.0 0.000143348623853 0 1 -1
fundus,pulsation,amplitude 1.0 0.000143348623853 0 1 -1
functions,transcription,replication 1.0 0.000143348623853 0 1 -1
functions,to,model 1.0 0.000143348623853 0 1 -1
functions,i,relational 1.0 0.000143348623853 0 1 -1
functions,as,a 1.0 0.000143348623853 0 1 -1
functionally,distinguishes,it 1.0 0.000143348623853 0 1 -1
functional,or,structural 1.0 0.000143348623853 0 1 -1
functional,integrity,of 1.0 0.000143348623853 0 1 -1
functional,coupling,between 1.0 0.000143348623853 0 1 -1
functional,consequences,following 1.0 0.000286697247706 0 2 -2
functional,classes,ii 1.0 0.000286697247706 0 2 -2
functional,class,iv 1.0 0.000286697247706 0 2 -2
function,will,increase 1.0 0.000143348623853 0 1 -1
function,were,not 1.0 0.000143348623853 0 1 -1
function,the,value 1.0 0.000143348623853 0 1 -1
function,the,decreased 1.0 0.000143348623853 0 1 -1
function,tests,since 1.0 0.000143348623853 0 1 -1
function,tests,should 1.0 0.000143348623853 0 1 -1
function,tests,may 1.0 0.000286697247706 0 2 -2
function,tests,elevations 1.0 0.000143348623853 0 1 -1
function,tests,are 1.0 0.000143348623853 0 1 -1
function,testing,transaminases 1.0 0.000143348623853 0 1 -1
function,studies,in 1.0 0.000143348623853 0 1 -1
function,since,a 1.0 0.000143348623853 0 1 -1
function,simultaneous,use 1.0 0.000143348623853 0 1 -1
function,seen,with 1.0 0.000143348623853 0 1 -1
function,secondary,to 1.0 0.000286697247706 0 2 -2
function,or,in 1.0 0.000143348623853 0 1 -1
function,or,compete 1.0 0.000143348623853 0 1 -1
function,or,coagulation 1.0 0.000143348623853 0 1 -1
function,or,cardiac 1.0 0.000143348623853 0 1 -1
function,of,either 1.0 0.000143348623853 0 1 -1
function,normally,with 1.0 0.000143348623853 0 1 -1
function,may,reduce 1.0 0.000143348623853 0 1 -1
function,may,also 1.0 0.000143348623853 0 1 -1
function,is,recommended 1.0 0.000143348623853 0 1 -1
function,is,not 1.0 0.000143348623853 0 1 -1
function,induced,by 1.0 0.000143348623853 0 1 -1
function,in,the 1.0 0.000143348623853 0 1 -1
function,in,humans 1.0 0.000143348623853 0 1 -1
function,hmg-coa,reductase 1.0 0.000143348623853 0 1 -1
function,have,not 1.0 0.000143348623853 0 1 -1
function,for,normal 1.0 0.000143348623853 0 1 -1
function,clinical,studies 1.0 0.000286697247706 0 2 -2
function,care,should 1.0 0.000143348623853 0 1 -1
function,as,inhibitors 1.0 0.000143348623853 0 1 -1
function,as,has 1.0 0.000143348623853 0 1 -1
function,as,co-activator 1.0 0.000143348623853 0 1 -1
function,are,considerably 1.0 0.000143348623853 0 1 -1
function,and,the 1.0 0.000143348623853 0 1 -1
function,and,or 1.0 0.000143348623853 0 1 -1
function,and,one 1.0 0.000143348623853 0 1 -1
function,and,increase 1.0 0.000143348623853 0 1 -1
function,and,host 1.0 0.000143348623853 0 1 -1
function,and,consequently 1.0 0.000143348623853 0 1 -1
function,and,arachidonic 1.0 0.00043004587156 0 3 -3
fumarate,seroquel,is 1.0 0.000143348623853 0 1 -1
fumarate,did,not 1.0 0.000143348623853 0 1 -1
fumarate,capsules,with 1.0 0.000143348623853 0 1 -1
fulvestrant-treated,lactating,dams 1.0 0.000143348623853 0 1 -1
fulvestrant,was,not 1.0 0.000143348623853 0 1 -1
fulvestrant,was,associated 1.0 0.000143348623853 0 1 -1
fulvestrant,is,metabolized 1.0 0.000143348623853 0 1 -1
fulvestrant,is,found 1.0 0.000143348623853 0 1 -1
fulvestrant,caused,an 1.0 0.000143348623853 0 1 -1
fully,restored,susceptibility 1.0 0.000143348623853 0 1 -1
fully,formed,cysts 1.0 0.000143348623853 0 1 -1
fully,evaluating,the 1.0 0.000143348623853 0 1 -1
fully,define,the 1.0 0.000143348623853 0 1 -1
full,recovery,in 1.0 0.000143348623853 0 1 -1
full,duration,of 1.0 0.000143348623853 0 1 -1
full,dose,range 1.0 0.000143348623853 0 1 -1
fulfils,the,function 1.0 0.000143348623853 0 1 -1
fu,bolus-ifl,with 1.0 0.000143348623853 0 1 -1
fsh,to,gonadotropin-releasing 1.0 0.000143348623853 0 1 -1
fsh,or,prolactin 1.0 0.000143348623853 0 1 -1
fruit,juices,such 1.0 0.000286697247706 0 2 -2
fruit,juices,fruit 1.0 0.000143348623853 0 1 -1
frova,treatment,is 1.0 0.000143348623853 0 1 -1
frova,is,not 1.0 0.000143348623853 0 1 -1
fronti,res,is 1.0 0.000143348623853 0 1 -1
frontal,cortex,and 1.0 0.000143348623853 0 1 -1
from,working,properly 1.0 0.000143348623853 0 1 -1
from,women,who 1.0 0.000143348623853 0 1 -1
from,what,would 1.0 0.000143348623853 0 1 -1
from,week,intraperitoneal 1.0 0.000143348623853 0 1 -1
from,vasodilating,effects 1.0 0.000143348623853 0 1 -1
from,urine,or 1.0 0.000143348623853 0 1 -1
from,trials,using 1.0 0.000143348623853 0 1 -1
from,treatment,of 1.0 0.000143348623853 0 1 -1
from,to,mm 1.0 0.000143348623853 0 1 -1
from,to,ml 1.0 0.000143348623853 0 1 -1
from,to,micrograms 1.0 0.000143348623853 0 1 -1
from,to,microg 1.0 0.00043004587156 0 3 -3
from,to,mg 1.0 0.000143348623853 0 1 -1
from,to,hours 1.0 0.000143348623853 0 1 -1
from,time,zero 1.0 0.000143348623853 0 1 -1
from,those,that 1.0 0.000143348623853 0 1 -1
from,this,study 1.0 0.000143348623853 0 1 -1
from,this,hit 1.0 0.000143348623853 0 1 -1
from,these,results 1.0 0.000143348623853 0 1 -1
from,these,problems 1.0 0.000143348623853 0 1 -1
from,these,groups 1.0 0.000143348623853 0 1 -1
from,therapy,with 1.0 0.000143348623853 0 1 -1
from,their,binding 1.0 0.000286697247706 0 2 -2
from,the,visual 1.0 0.000143348623853 0 1 -1
from,the,use 1.0 0.00043004587156 0 3 -3
from,the,therapeutic 1.0 0.000143348623853 0 1 -1
from,the,th 1.0 0.000143348623853 0 1 -1
from,the,soluble 1.0 0.000286697247706 0 2 -2
from,the,seminiferous 1.0 0.000143348623853 0 1 -1
from,the,review 1.0 0.000143348623853 0 1 -1
from,the,proposed 1.0 0.000143348623853 0 1 -1
from,the,peritoneal 1.0 0.000143348623853 0 1 -1
from,the,other 1.0 0.000143348623853 0 1 -1
from,the,mucosal 1.0 0.000143348623853 0 1 -1
from,the,mg 1.0 0.000143348623853 0 1 -1
from,the,lumen 1.0 0.000143348623853 0 1 -1
from,the,intestinal 1.0 0.000143348623853 0 1 -1
from,the,in 1.0 0.000286697247706 0 2 -2
from,the,fraction 1.0 0.000143348623853 0 1 -1
from,the,dog 1.0 0.000143348623853 0 1 -1
from,the,cytosol 1.0 0.000143348623853 0 1 -1
from,the,currently 1.0 0.000143348623853 0 1 -1
from,the,carpophores 1.0 0.000143348623853 0 1 -1
from,the,beginning 1.0 0.000143348623853 0 1 -1
from,study,to 1.0 0.000143348623853 0 1 -1
from,studies,to 1.0 0.000143348623853 0 1 -1
from,studies,involving 1.0 0.000286697247706 0 2 -2
from,studies,in 1.0 0.000143348623853 0 1 -1
from,spontaneous,reports 1.0 0.000143348623853 0 1 -1
from,smoking,cessation 1.0 0.000143348623853 0 1 -1
from,single,doses 1.0 0.000143348623853 0 1 -1
from,several,studies 1.0 0.000143348623853 0 1 -1
from,serum-deprived,ras-3t3 1.0 0.000143348623853 0 1 -1
from,results,obtained 1.0 0.000143348623853 0 1 -1
from,receiving,growth 1.0 0.000143348623853 0 1 -1
from,prospective,clinical 1.0 0.000143348623853 0 1 -1
from,prefrontal,cortical 1.0 0.000143348623853 0 1 -1
from,plasma,proteins 1.0 0.000143348623853 0 1 -1
from,patients,with 1.0 0.000143348623853 0 1 -1
from,patients,treated 1.0 0.000143348623853 0 1 -1
from,patients,receiving 1.0 0.000286697247706 0 2 -2
from,patients,in 1.0 0.000143348623853 0 1 -1
from,other,monomeric 1.0 0.000143348623853 0 1 -1
from,one,to 1.0 0.000143348623853 0 1 -1
from,ois,in 1.0 0.000143348623853 0 1 -1
from,normal,subjects 1.0 0.000143348623853 0 1 -1
from,ng,ml 1.0 0.000143348623853 0 1 -1
from,neuromuscular,blockade 1.0 0.000143348623853 0 1 -1
from,nerves,and 1.0 0.000143348623853 0 1 -1
from,muscle,cells 1.0 0.000143348623853 0 1 -1
from,multiple,exposure 1.0 0.000143348623853 0 1 -1
from,midcycle,day 1.0 0.000143348623853 0 1 -1
from,membrane,phospholipids 1.0 0.000143348623853 0 1 -1
from,mean,sem 1.0 0.000143348623853 0 1 -1
from,masking,symptoms 1.0 0.000143348623853 0 1 -1
from,marine,coelenterates 1.0 0.000143348623853 0 1 -1
from,male,lean 1.0 0.000143348623853 0 1 -1
from,m,v 1.0 0.000143348623853 0 1 -1
from,lean,and 1.0 0.000143348623853 0 1 -1
from,intravenous,use 1.0 0.000143348623853 0 1 -1
from,interactions,is 1.0 0.000143348623853 0 1 -1
from,interaction,studies 1.0 0.000143348623853 0 1 -1
from,inhibition,of 1.0 0.000143348623853 0 1 -1
from,infectious,complications 1.0 0.000143348623853 0 1 -1
from,in,the 1.0 0.000286697247706 0 2 -2
from,human,in 1.0 0.000143348623853 0 1 -1
from,healthy,subjects 1.0 0.000143348623853 0 1 -1
from,grapefruit,and 1.0 0.000143348623853 0 1 -1
from,fulvestrant-treated,lactating 1.0 0.000143348623853 0 1 -1
from,faslodex,in 1.0 0.000143348623853 0 1 -1
from,existing,clinical 1.0 0.000143348623853 0 1 -1
from,eggs,was 1.0 0.000143348623853 0 1 -1
from,displacement,of 1.0 0.000143348623853 0 1 -1
from,dietary-obese,rats 1.0 0.00043004587156 0 3 -3
from,dependence,usually 1.0 0.000143348623853 0 1 -1
from,cotherapy,an 1.0 0.000143348623853 0 1 -1
from,controlled,clinical 1.0 0.000143348623853 0 1 -1
from,control,values 1.0 0.000143348623853 0 1 -1
from,concomitant,use 1.0 0.000143348623853 0 1 -1
from,concomitant,administration 1.0 0.000143348623853 0 1 -1
from,co-therapy,an 1.0 0.000573394495413 0 4 -4
from,clinical,trials 1.0 0.000143348623853 0 1 -1
from,breast,milk 1.0 0.000143348623853 0 1 -1
from,bovine,lung 1.0 0.000143348623853 0 1 -1
from,both,lean 1.0 0.000286697247706 0 2 -2
from,at,least 1.0 0.000143348623853 0 1 -1
from,an,week 1.0 0.000286697247706 0 2 -2
from,an,solution 1.0 0.000143348623853 0 1 -1
from,amevive,a 1.0 0.000143348623853 0 1 -1
from,alterations,in 1.0 0.000143348623853 0 1 -1
from,albumin,binding 1.0 0.000143348623853 0 1 -1
from,addicts,was 1.0 0.000143348623853 0 1 -1
from,addicts,vs 1.0 0.000143348623853 0 1 -1
from,a,urine 1.0 0.000143348623853 0 1 -1
from,a,therapeutic 1.0 0.000143348623853 0 1 -1
from,a,stock 1.0 0.000143348623853 0 1 -1
from,a,pulse 1.0 0.000143348623853 0 1 -1
from,a,patient 1.0 0.000860091743119 0 6 -6
from,a,number 1.0 0.000143348623853 0 1 -1
from,a,level 1.0 0.000143348623853 0 1 -1
from,a,hit 1.0 0.000143348623853 0 1 -1
from,a,cns 1.0 0.000143348623853 0 1 -1
from,a,bioequivalence 1.0 0.000143348623853 0 1 -1
frequently,with,the 1.0 0.000143348623853 0 1 -1
frequently,with,in 1.0 0.000143348623853 0 1 -1
frequently,to,maintain 1.0 0.000143348623853 0 1 -1
frequently,observed,during 1.0 0.000143348623853 0 1 -1
frequently,limits,the 1.0 0.000143348623853 0 1 -1
frequently,in,patients 1.0 0.000143348623853 0 1 -1
frequently,complex,and 1.0 0.000143348623853 0 1 -1
frequently,co-administered,with 1.0 0.000143348623853 0 1 -1
frequently,been,reported 1.0 0.000143348623853 0 1 -1
frequently,and,monitored 1.0 0.000143348623853 0 1 -1
frequently,administered,concomitantly 1.0 0.000143348623853 0 1 -1
frequent,vital,sign 1.0 0.000143348623853 0 1 -1
frequent,the,development 1.0 0.000143348623853 0 1 -1
frequent,prothrombin,time 1.0 0.000143348623853 0 1 -1
frequent,prothrombin,determinations 1.0 0.000143348623853 0 1 -1
frequent,peripheral,blood 1.0 0.000143348623853 0 1 -1
frequent,occurrence,of 1.0 0.000143348623853 0 1 -1
frequent,monitoring,of 1.0 0.000573394495413 0 4 -4
frequent,laboratory,monitoring 1.0 0.000143348623853 0 1 -1
frequent,for,women 1.0 0.000143348623853 0 1 -1
frequent,dosing,may 1.0 0.000143348623853 0 1 -1
frequent,doses,of 1.0 0.000143348623853 0 1 -1
frequent,determination,of 1.0 0.000143348623853 0 1 -1
frequent,condition,in 1.0 0.000143348623853 0 1 -1
frequent,clinical,and 1.0 0.000143348623853 0 1 -1
frequency,on,placebo 1.0 0.000143348623853 0 1 -1
frequency,of,rejection 1.0 0.000143348623853 0 1 -1
frequency,of,monitoring 1.0 0.000143348623853 0 1 -1
frequency,of,dosing 1.0 0.000143348623853 0 1 -1
frequency,of,adverse 1.0 0.000286697247706 0 2 -2
frequency,of,admissions 1.0 0.000143348623853 0 1 -1
french,non-governmental,organisation 1.0 0.000143348623853 0 1 -1
free,will,result 1.0 0.000143348623853 0 1 -1
free,t4,concentration 1.0 0.000286697247706 0 2 -2
free,t4,and 1.0 0.000286697247706 0 2 -2
free,t3,uptake 1.0 0.000286697247706 0 2 -2
free,t3,concentrations 1.0 0.000143348623853 0 1 -1
free,ions,in 1.0 0.000143348623853 0 1 -1
free,hormone,should 1.0 0.000143348623853 0 1 -1
free,hormone,concentrations 1.0 0.000286697247706 0 2 -2
free,had,no 1.0 0.000143348623853 0 1 -1
free,fractions,of 1.0 0.000143348623853 0 1 -1
free,fraction,of 1.0 0.000286697247706 0 2 -2
free,concentrations,of 1.0 0.000286697247706 0 2 -2
free,concentration,of 1.0 0.000143348623853 0 1 -1
free,concentration,may 1.0 0.000143348623853 0 1 -1
free,cmin,concentrations 1.0 0.000143348623853 0 1 -1
fractions,on,the 1.0 0.000143348623853 0 1 -1
fractions,of,either 1.0 0.000143348623853 0 1 -1
fractional,transfer,to 1.0 0.000143348623853 0 1 -1
fractional,mucosal,cell 1.0 0.000143348623853 0 1 -1
fractional,inhibitory,concentration 1.0 0.000143348623853 0 1 -1
fraction,suggesting,a 1.0 0.000143348623853 0 1 -1
fraction,of,stadol 1.0 0.000143348623853 0 1 -1
fraction,of,rat 1.0 0.000143348623853 0 1 -1
fraction,of,metabolized 1.0 0.00043004587156 0 3 -3
fraction,of,excreted 1.0 0.000143348623853 0 1 -1
fraction,of,drug 1.0 0.000143348623853 0 1 -1
fraction,of,at 1.0 0.000143348623853 0 1 -1
fraction,of,and 1.0 0.000143348623853 0 1 -1
fraction,in,a 1.0 0.000143348623853 0 1 -1
fraction,containing,membranes 1.0 0.000143348623853 0 1 -1
fr,schedule,of 1.0 0.000143348623853 0 1 -1
fr,responding,in 1.0 0.000143348623853 0 1 -1
fr,karst,was 1.0 0.000143348623853 0 1 -1
fourth,group,served 1.0 0.000143348623853 0 1 -1
fourteen,days,later 1.0 0.000143348623853 0 1 -1
four-session,placebo-controlled,within-subject 1.0 0.000143348623853 0 1 -1
four,times,weekly 1.0 0.000143348623853 0 1 -1
four,times,as 1.0 0.000143348623853 0 1 -1
four,times,a 1.0 0.000143348623853 0 1 -1
four,subjects,with 1.0 0.000143348623853 0 1 -1
four,male,wistar 1.0 0.000143348623853 0 1 -1
four,kinds,of 1.0 0.000143348623853 0 1 -1
four,hours,after 1.0 0.000143348623853 0 1 -1
four,educational,messages 1.0 0.000143348623853 0 1 -1
four,doses,did 1.0 0.000143348623853 0 1 -1
four,diets,containing 1.0 0.000143348623853 0 1 -1
four,days,in 1.0 0.000143348623853 0 1 -1
four,chemotherapeutic,agents 1.0 0.000143348623853 0 1 -1
found,with,at 1.0 0.000143348623853 0 1 -1
found,to,interact 1.0 0.000143348623853 0 1 -1
found,to,induce 1.0 0.000143348623853 0 1 -1
found,to,exhibit 1.0 0.00043004587156 0 3 -3
found,to,be 1.0 0.00100344036697 0 7 -7
found,to,affect 1.0 0.000143348623853 0 1 -1
found,to,accompany 1.0 0.000143348623853 0 1 -1
found,no,increase 1.0 0.000286697247706 0 2 -2
found,minutes,post 1.0 0.000143348623853 0 1 -1
found,in,rat 1.0 0.000143348623853 0 1 -1
found,in,most 1.0 0.000143348623853 0 1 -1
found,in,interaction 1.0 0.000286697247706 0 2 -2
found,in,coffee 1.0 0.000143348623853 0 1 -1
found,but,ki 1.0 0.000143348623853 0 1 -1
found,between,the 1.0 0.000143348623853 0 1 -1
fosinopril,may,cause 1.0 0.000143348623853 0 1 -1
foscavir,decreases,serum 1.0 0.000143348623853 0 1 -1
fortovase,may,not 1.0 0.000143348623853 0 1 -1
fortovase,as,the 1.0 0.000143348623853 0 1 -1
fortified,with,elemental 1.0 0.000143348623853 0 1 -1
formulation,the,potential 1.0 0.000143348623853 0 1 -1
formulation,of,with 1.0 0.000143348623853 0 1 -1
formulation,of,was 1.0 0.000143348623853 0 1 -1
formulation,of,fluorescence 1.0 0.000143348623853 0 1 -1
formula,mg,elemental 1.0 0.000143348623853 0 1 -1
forms,of,memory 1.0 0.000143348623853 0 1 -1
forms,of,fat-soluble 1.0 0.000143348623853 0 1 -1
forms,of,effective 1.0 0.000143348623853 0 1 -1
forms,of,deficit 1.0 0.000143348623853 0 1 -1
forming,a,radioactive 1.0 0.000143348623853 0 1 -1
formed,via,cyp3a4 1.0 0.000143348623853 0 1 -1
formed,often,appear 1.0 0.000143348623853 0 1 -1
formed,cysts,had 1.0 0.000143348623853 0 1 -1
formed,by,cytochrome 1.0 0.000143348623853 0 1 -1
formed,after,the 1.0 0.000143348623853 0 1 -1
formation,the,clinical 1.0 0.000143348623853 0 1 -1
formation,that,affect 1.0 0.000143348623853 0 1 -1
formation,of,oxidized 1.0 0.000143348623853 0 1 -1
formation,of,hydroxylamine 1.0 0.000143348623853 0 1 -1
formally,evaluated,in 1.0 0.000143348623853 0 1 -1
formal,studies,to 1.0 0.000143348623853 0 1 -1
formal,studies,of 1.0 0.000143348623853 0 1 -1
formal,studies,fully 1.0 0.000143348623853 0 1 -1
formal,pharmacokinetic,studies 1.0 0.000143348623853 0 1 -1
formal,laboratory,test 1.0 0.000143348623853 0 1 -1
formal,interaction,study 1.0 0.000143348623853 0 1 -1
formal,interaction,studies 1.0 0.0024369266055 0 17 -17
formal,drug-interaction,studies 1.0 0.000286697247706 0 2 -2
formal,drug-drug,interaction 1.0 0.000286697247706 0 2 -2
formal,drug,interaction 1.0 0.00043004587156 0 3 -3
formal,drug,drug 1.0 0.000143348623853 0 1 -1
formal,clinical,studies 1.0 0.00043004587156 0 3 -3
formal,clinical,interaction 1.0 0.000143348623853 0 1 -1
formal,assessments,of 1.0 0.000286697247706 0 2 -2
form,unless,absolute 1.0 0.000143348623853 0 1 -1
form,of,therapy 1.0 0.000143348623853 0 1 -1
form,of,st 1.0 0.000286697247706 0 2 -2
form,of,contraception 1.0 0.000143348623853 0 1 -1
form,of,at 1.0 0.000143348623853 0 1 -1
form,chelates,with 1.0 0.00043004587156 0 3 -3
force,of,contraction 1.0 0.000143348623853 0 1 -1
foradil,should,not 1.0 0.000286697247706 0 2 -2
foradil,other,inhaled 1.0 0.000143348623853 0 1 -1
foradil,is,not 1.0 0.000143348623853 0 1 -1
foradil,fumarate,capsules 1.0 0.000143348623853 0 1 -1
for,yeast,and 1.0 0.000143348623853 0 1 -1
for,worsening,renal 1.0 0.000143348623853 0 1 -1
for,women,who 1.0 0.000143348623853 0 1 -1
for,women,of 1.0 0.000143348623853 0 1 -1
for,which,they 1.0 0.000143348623853 0 1 -1
for,which,the 1.0 0.000143348623853 0 1 -1
for,which,is 1.0 0.000143348623853 0 1 -1
for,which,effectiveness 1.0 0.000143348623853 0 1 -1
for,which,alterations 1.0 0.000143348623853 0 1 -1
for,when,screening 1.0 0.000143348623853 0 1 -1
for,were,determined 1.0 0.000143348623853 0 1 -1
for,weeks,with 1.0 0.000143348623853 0 1 -1
for,weeks,prior 1.0 0.000286697247706 0 2 -2
for,weeks,following 1.0 0.000143348623853 0 1 -1
for,week,following 1.0 0.000143348623853 0 1 -1
for,virtually,all 1.0 0.000143348623853 0 1 -1
for,varying,durations 1.0 0.000143348623853 0 1 -1
for,using,these 1.0 0.000143348623853 0 1 -1
for,use,of 1.0 0.000143348623853 0 1 -1
for,use,by 1.0 0.000143348623853 0 1 -1
for,urinary,tract 1.0 0.000143348623853 0 1 -1
for,urinary,protein 1.0 0.000143348623853 0 1 -1
for,urinary,bilirubin 1.0 0.000143348623853 0 1 -1
for,uptake-1,were 1.0 0.000143348623853 0 1 -1
for,type,diabetes 1.0 0.000143348623853 0 1 -1
for,triacylglycerol,synthesis 1.0 0.000143348623853 0 1 -1
for,total,were 1.0 0.000143348623853 0 1 -1
for,topical,solution 1.0 0.000143348623853 0 1 -1
for,to,interact 1.0 0.000286697247706 0 2 -2
for,three,strains 1.0 0.000143348623853 0 1 -1
for,those,concomitant 1.0 0.000143348623853 0 1 -1
for,this,disease 1.0 0.000143348623853 0 1 -1
for,this,combination 1.0 0.00114678899083 0 8 -8
for,these,purposes 1.0 0.000143348623853 0 1 -1
for,therapy,and 1.0 0.000143348623853 0 1 -1
for,therapeutic,efficacy 1.0 0.000143348623853 0 1 -1
for,therapeutic,advantage 1.0 0.000143348623853 0 1 -1
for,the,wild-type 1.0 0.000143348623853 0 1 -1
for,the,welfare 1.0 0.000143348623853 0 1 -1
for,the,understanding 1.0 0.000143348623853 0 1 -1
for,the,training 1.0 0.000143348623853 0 1 -1
for,the,selective 1.0 0.000143348623853 0 1 -1
for,the,secretion 1.0 0.000143348623853 0 1 -1
for,the,same 1.0 0.000143348623853 0 1 -1
for,the,purpose 1.0 0.000143348623853 0 1 -1
for,the,purification 1.0 0.000143348623853 0 1 -1
for,the,presence 1.0 0.000143348623853 0 1 -1
for,the,predominant 1.0 0.000143348623853 0 1 -1
for,the,potentiation 1.0 0.000143348623853 0 1 -1
for,the,plasma 1.0 0.000143348623853 0 1 -1
for,the,pharmacokinetics 1.0 0.000143348623853 0 1 -1
for,the,patient 1.0 0.000286697247706 0 2 -2
for,the,p-glycoprotein 1.0 0.000143348623853 0 1 -1
for,the,other 1.0 0.000143348623853 0 1 -1
for,the,oral 1.0 0.000143348623853 0 1 -1
for,the,metabolism 1.0 0.000286697247706 0 2 -2
for,the,management 1.0 0.000143348623853 0 1 -1
for,the,maintenance 1.0 0.000143348623853 0 1 -1
for,the,induction 1.0 0.000143348623853 0 1 -1
for,the,individual 1.0 0.000143348623853 0 1 -1
for,the,identification 1.0 0.000143348623853 0 1 -1
for,the,human 1.0 0.000143348623853 0 1 -1
for,the,group 1.0 0.000143348623853 0 1 -1
for,the,full 1.0 0.000143348623853 0 1 -1
for,the,elimination 1.0 0.000143348623853 0 1 -1
for,the,development 1.0 0.000143348623853 0 1 -1
for,the,determination 1.0 0.000143348623853 0 1 -1
for,the,detection 1.0 0.000143348623853 0 1 -1
for,the,control 1.0 0.000143348623853 0 1 -1
for,the,cocaine-treated 1.0 0.000143348623853 0 1 -1
for,the,coadministration 1.0 0.000143348623853 0 1 -1
for,the,clinician 1.0 0.000143348623853 0 1 -1
for,the,classes 1.0 0.000143348623853 0 1 -1
for,the,case 1.0 0.000143348623853 0 1 -1
for,the,calcium-entry 1.0 0.000143348623853 0 1 -1
for,the,association 1.0 0.000143348623853 0 1 -1
for,the,appropriate 1.0 0.000143348623853 0 1 -1
for,the,ability 1.0 0.000143348623853 0 1 -1
for,that,may 1.0 0.000143348623853 0 1 -1
for,that,can 1.0 0.000143348623853 0 1 -1
for,sustiva,and 1.0 0.000143348623853 0 1 -1
for,such,patients 1.0 0.000286697247706 0 2 -2
for,such,interactions 1.0 0.000143348623853 0 1 -1
for,such,interaction 1.0 0.000143348623853 0 1 -1
for,subsequent,courses 1.0 0.000143348623853 0 1 -1
for,subjects,had 1.0 0.000143348623853 0 1 -1
for,studying,of 1.0 0.000143348623853 0 1 -1
for,strains,from 1.0 0.000143348623853 0 1 -1
for,some,strains 1.0 0.000143348623853 0 1 -1
for,single,metal 1.0 0.000143348623853 0 1 -1
for,seven,days 1.0 0.000143348623853 0 1 -1
for,serotonin,ht2a 1.0 0.000143348623853 0 1 -1
for,serious,reactions 1.0 0.000286697247706 0 2 -2
for,serious,events 1.0 0.000143348623853 0 1 -1
for,serious,adverse 1.0 0.00043004587156 0 3 -3
for,seizures,when 1.0 0.000286697247706 0 2 -2
for,results,that 1.0 0.000143348623853 0 1 -1
for,response,to 1.0 0.000143348623853 0 1 -1
for,relief,of 1.0 0.000143348623853 0 1 -1
for,regarding,interactions 1.0 0.000143348623853 0 1 -1
for,reduction,of 1.0 0.000143348623853 0 1 -1
for,recovery,from 1.0 0.000143348623853 0 1 -1
for,realization,of 1.0 0.000143348623853 0 1 -1
for,pseudomonas,strains 1.0 0.000143348623853 0 1 -1
for,protein,mna 1.0 0.000143348623853 0 1 -1
for,protein,may 1.0 0.000143348623853 0 1 -1
for,protein,binding 1.0 0.000286697247706 0 2 -2
for,proper,interpretation 1.0 0.000143348623853 0 1 -1
for,prolonged,use 1.0 0.000143348623853 0 1 -1
for,preservation,of 1.0 0.000143348623853 0 1 -1
for,preparation,before 1.0 0.000143348623853 0 1 -1
for,possible,infiltration 1.0 0.000143348623853 0 1 -1
for,possible,diminished 1.0 0.000143348623853 0 1 -1
for,possible,combined 1.0 0.000286697247706 0 2 -2
for,plasma,and 1.0 0.000143348623853 0 1 -1
for,placebo,were 1.0 0.000143348623853 0 1 -1
for,pharmacokinetic,drug-drug 1.0 0.000143348623853 0 1 -1
for,peroral,administration 1.0 0.000143348623853 0 1 -1
for,periods,of 1.0 0.000143348623853 0 1 -1
for,patients,who 1.0 0.000286697247706 0 2 -2
for,patients,taking 1.0 0.000143348623853 0 1 -1
for,patients,receiving 1.0 0.000286697247706 0 2 -2
for,p450,d6 1.0 0.000716743119266 0 5 -5
for,p-glycoprotein,and 1.0 0.000143348623853 0 1 -1
for,other,that 1.0 0.000143348623853 0 1 -1
for,other,interactions 1.0 0.000143348623853 0 1 -1
for,other,drugs 1.0 0.000286697247706 0 2 -2
for,other,centrally 1.0 0.000143348623853 0 1 -1
for,other,and 1.0 0.000143348623853 0 1 -1
for,oral,suspension 1.0 0.000286697247706 0 2 -2
for,oral,increased 1.0 0.000143348623853 0 1 -1
for,oral,includes 1.0 0.000143348623853 0 1 -1
for,or,oral 1.0 0.000286697247706 0 2 -2
for,optimal,pulmonary 1.0 0.000143348623853 0 1 -1
for,only,of 1.0 0.000143348623853 0 1 -1
for,one,month 1.0 0.000143348623853 0 1 -1
for,one,day 1.0 0.000143348623853 0 1 -1
for,on,dopamine2- 1.0 0.000143348623853 0 1 -1
for,older,patients 1.0 0.000143348623853 0 1 -1
for,older,adults 1.0 0.000143348623853 0 1 -1
for,occult,blood 1.0 0.000143348623853 0 1 -1
for,nsclc,patients 1.0 0.000143348623853 0 1 -1
for,novolog,should 1.0 0.000143348623853 0 1 -1
for,normal,rates 1.0 0.000143348623853 0 1 -1
for,nmda,and 1.0 0.000143348623853 0 1 -1
for,neurons,recorded 1.0 0.000143348623853 0 1 -1
for,multiple,forms 1.0 0.000143348623853 0 1 -1
for,most,of 1.0 0.000286697247706 0 2 -2
for,more,inhalations 1.0 0.000143348623853 0 1 -1
for,months,at 1.0 0.000286697247706 0 2 -2
for,minutes,at 1.0 0.000143348623853 0 1 -1
for,migraines,such 1.0 0.000143348623853 0 1 -1
for,metabolite,m1 1.0 0.000143348623853 0 1 -1
for,metabolism,were 1.0 0.000143348623853 0 1 -1
for,medications,to 1.0 0.000143348623853 0 1 -1
for,mec,values 1.0 0.000143348623853 0 1 -1
for,measurement,of 1.0 0.000286697247706 0 2 -2
for,many,cyp 1.0 0.000143348623853 0 1 -1
for,mania,whereas 1.0 0.000143348623853 0 1 -1
for,management,and 1.0 0.000143348623853 0 1 -1
for,maintenance,of 1.0 0.000143348623853 0 1 -1
for,longitudinal,stability 1.0 0.000143348623853 0 1 -1
for,long,periods 1.0 0.000143348623853 0 1 -1
for,liver,biopsy 1.0 0.000143348623853 0 1 -1
for,less,than 1.0 0.000286697247706 0 2 -2
for,l-glutamine,was 1.0 0.000143348623853 0 1 -1
for,ketones,in 1.0 0.000286697247706 0 2 -2
for,ketones,and 1.0 0.000143348623853 0 1 -1
for,ketogenic,because 1.0 0.000143348623853 0 1 -1
for,kappa,and 1.0 0.000143348623853 0 1 -1
for,its,prevention 1.0 0.000143348623853 0 1 -1
for,is,recommended 1.0 0.000143348623853 0 1 -1
for,interactions,among 1.0 0.000143348623853 0 1 -1
for,interaction,between 1.0 0.00043004587156 0 3 -3
for,insurances,and 1.0 0.000143348623853 0 1 -1
for,initial,or 1.0 0.000143348623853 0 1 -1
for,information,on 1.0 0.000143348623853 0 1 -1
for,individual,and 1.0 0.000143348623853 0 1 -1
for,increased,lipid 1.0 0.000143348623853 0 1 -1
for,increased,both 1.0 0.000143348623853 0 1 -1
for,increased,activity 1.0 0.000143348623853 0 1 -1
for,incombination,with 1.0 0.000143348623853 0 1 -1
for,in,the 1.0 0.000143348623853 0 1 -1
for,in,subcortical 1.0 0.000143348623853 0 1 -1
for,in,patients 1.0 0.000143348623853 0 1 -1
for,in,combination 1.0 0.000143348623853 0 1 -1
for,in,aortic 1.0 0.000143348623853 0 1 -1
for,hypertension,and 1.0 0.000143348623853 0 1 -1
for,human,liver 1.0 0.000143348623853 0 1 -1
for,hours,before 1.0 0.000143348623853 0 1 -1
for,hours,after 1.0 0.000143348623853 0 1 -1
for,hepatic,injury 1.0 0.000143348623853 0 1 -1
for,heparins,effect 1.0 0.000143348623853 0 1 -1
for,heart,failure 1.0 0.000143348623853 0 1 -1
for,h,this 1.0 0.000143348623853 0 1 -1
for,h,concomitant 1.0 0.000143348623853 0 1 -1
for,h,by 1.0 0.000286697247706 0 2 -2
for,gout,and 1.0 0.000143348623853 0 1 -1
for,glucose,intolerance 1.0 0.000143348623853 0 1 -1
for,glucose,in 1.0 0.00186353211009 0 13 -13
for,further,kidney 1.0 0.000143348623853 0 1 -1
for,free,cmin 1.0 0.000143348623853 0 1 -1
for,four,doses 1.0 0.000143348623853 0 1 -1
for,four,days 1.0 0.000143348623853 0 1 -1
for,five,days 1.0 0.000143348623853 0 1 -1
for,extravasation,reactions 1.0 0.000143348623853 0 1 -1
for,example,the 1.0 0.000143348623853 0 1 -1
for,example,sparing 1.0 0.000143348623853 0 1 -1
for,example,may 1.0 0.000143348623853 0 1 -1
for,example,complications 1.0 0.000143348623853 0 1 -1
for,every,mac 1.0 0.000143348623853 0 1 -1
for,evaluating,the 1.0 0.000143348623853 0 1 -1
for,estimation,of 1.0 0.000143348623853 0 1 -1
for,establishing,interactions 1.0 0.000143348623853 0 1 -1
for,erectile,dysfunction 1.0 0.000143348623853 0 1 -1
for,either,toxicities 1.0 0.000143348623853 0 1 -1
for,either,the 1.0 0.000860091743119 0 6 -6
for,either,or 1.0 0.000143348623853 0 1 -1
for,early,evidence 1.0 0.000143348623853 0 1 -1
for,duloxetine,to 1.0 0.000143348623853 0 1 -1
for,drugs,associated 1.0 0.000143348623853 0 1 -1
for,drug-induced,renal 1.0 0.000143348623853 0 1 -1
for,drug-drug,interaction 1.0 0.000143348623853 0 1 -1
for,drug,interactions 1.0 0.000143348623853 0 1 -1
for,dose,adjustment 1.0 0.000286697247706 0 2 -2
for,dosage,modifications 1.0 0.000143348623853 0 1 -1
for,documented,hypokalemia 1.0 0.000143348623853 0 1 -1
for,diagnosis,or 1.0 0.000143348623853 0 1 -1
for,diagnosis,of 1.0 0.000143348623853 0 1 -1
for,diabetic,individuals 1.0 0.000143348623853 0 1 -1
for,developing,rhabdomyolysis 1.0 0.000143348623853 0 1 -1
for,determining,synergism 1.0 0.000143348623853 0 1 -1
for,deriving,experimental 1.0 0.000143348623853 0 1 -1
for,decreased,dosing 1.0 0.000143348623853 0 1 -1
for,days,to 1.0 0.000286697247706 0 2 -2
for,days,there 1.0 0.000143348623853 0 1 -1
for,days,received 1.0 0.000143348623853 0 1 -1
for,days,oral 1.0 0.000143348623853 0 1 -1
for,days,n 1.0 0.000143348623853 0 1 -1
for,days,into 1.0 0.000143348623853 0 1 -1
for,days,had 1.0 0.000573394495413 0 4 -4
for,days,following 1.0 0.000143348623853 0 1 -1
for,days,followed 1.0 0.000573394495413 0 4 -4
for,days,does 1.0 0.000143348623853 0 1 -1
for,days,did 1.0 0.00114678899083 0 8 -8
for,days,day 1.0 0.000143348623853 0 1 -1
for,days,after 1.0 0.000143348623853 0 1 -1
for,day,in 1.0 0.000143348623853 0 1 -1
for,cytochrome,p450 1.0 0.000143348623853 0 1 -1
for,cyp3a4,there 1.0 0.000143348623853 0 1 -1
for,cyp3a4,and 1.0 0.000143348623853 0 1 -1
for,cyp1a2,inhibit 1.0 0.000143348623853 0 1 -1
for,creatinine,if 1.0 0.000143348623853 0 1 -1
for,comprehensive,information 1.0 0.000143348623853 0 1 -1
for,commonly,used 1.0 0.000143348623853 0 1 -1
for,combined,exposure 1.0 0.000143348623853 0 1 -1
for,colazal,however 1.0 0.000143348623853 0 1 -1
for,coadministration,with 1.0 0.000286697247706 0 2 -2
for,cmax,tmax 1.0 0.000143348623853 0 1 -1
for,clinically,significant 1.0 0.000143348623853 0 1 -1
for,clinically,important 1.0 0.000143348623853 0 1 -1
for,clinical,use 1.0 0.000143348623853 0 1 -1
for,clinical,evidence 1.0 0.000143348623853 0 1 -1
for,clindamycin-sensitive,isolates 1.0 0.000143348623853 0 1 -1
for,cigarette,smokers 1.0 0.000143348623853 0 1 -1
for,chronic,indications 1.0 0.000143348623853 0 1 -1
for,chop-haart,patients 1.0 0.000143348623853 0 1 -1
for,chelation,and 1.0 0.000143348623853 0 1 -1
for,characterization,or 1.0 0.000143348623853 0 1 -1
for,changes,in 1.0 0.00043004587156 0 3 -3
for,both,cyp2d6 1.0 0.000143348623853 0 1 -1
for,blood,pressure 1.0 0.000143348623853 0 1 -1
for,bleeding,is 1.0 0.000143348623853 0 1 -1
for,binding,of 1.0 0.000143348623853 0 1 -1
for,bacterial,infection 1.0 0.000143348623853 0 1 -1
for,auc,was 1.0 0.000143348623853 0 1 -1
for,auc,infinity 1.0 0.000143348623853 0 1 -1
for,as,well 1.0 0.000143348623853 0 1 -1
for,arrhythmias,including 1.0 0.000143348623853 0 1 -1
for,appropriate,actions 1.0 0.000143348623853 0 1 -1
for,any,significant 1.0 0.000143348623853 0 1 -1
for,any,patient 1.0 0.000143348623853 0 1 -1
for,any,of 1.0 0.000143348623853 0 1 -1
for,any,interaction 1.0 0.000143348623853 0 1 -1
for,any,evidence 1.0 0.000143348623853 0 1 -1
for,any,dose 1.0 0.000143348623853 0 1 -1
for,any,conclusions 1.0 0.000143348623853 0 1 -1
for,antipsychotic,activity 1.0 0.000143348623853 0 1 -1
for,anions,other 1.0 0.000143348623853 0 1 -1
for,and,were 1.0 0.000143348623853 0 1 -1
for,and,urine 1.0 0.000143348623853 0 1 -1
for,and,the 1.0 0.000143348623853 0 1 -1
for,and,respectively 1.0 0.000286697247706 0 2 -2
for,and,placebo 1.0 0.000143348623853 0 1 -1
for,and,on 1.0 0.000143348623853 0 1 -1
for,and,mg 1.0 0.000143348623853 0 1 -1
for,and,its 1.0 0.000143348623853 0 1 -1
for,and,and 1.0 0.00043004587156 0 3 -3
for,anaphylactic,reaction 1.0 0.000143348623853 0 1 -1
for,an,interval 1.0 0.000143348623853 0 1 -1
for,an,interaction 1.0 0.000143348623853 0 1 -1
for,an,increase 1.0 0.000143348623853 0 1 -1
for,an,in 1.0 0.000143348623853 0 1 -1
for,an,endemic 1.0 0.000143348623853 0 1 -1
for,altering,cyp1a2-mediated 1.0 0.000143348623853 0 1 -1
for,altering,concentrations 1.0 0.000143348623853 0 1 -1
for,all,subsequentcourses 1.0 0.000143348623853 0 1 -1
for,albumin,may 1.0 0.000143348623853 0 1 -1
for,aerobic,facultative 1.0 0.000143348623853 0 1 -1
for,adverse,events 1.0 0.000143348623853 0 1 -1
for,adverse,effects 1.0 0.000143348623853 0 1 -1
for,additive,or 1.0 0.000143348623853 0 1 -1
for,accutane,a 1.0 0.000143348623853 0 1 -1
for,abilify,to 1.0 0.000143348623853 0 1 -1
for,a,week 1.0 0.00043004587156 0 3 -3
for,a,using 1.0 0.000143348623853 0 1 -1
for,a,third 1.0 0.000143348623853 0 1 -1
for,a,substantial 1.0 0.000143348623853 0 1 -1
for,a,second 1.0 0.000143348623853 0 1 -1
for,a,role 1.0 0.000143348623853 0 1 -1
for,a,nondrug 1.0 0.000143348623853 0 1 -1
for,a,kg 1.0 0.000143348623853 0 1 -1
for,a,fold 1.0 0.000143348623853 0 1 -1
for,a,continuing 1.0 0.000143348623853 0 1 -1
foods,highly,fortified 1.0 0.000143348623853 0 1 -1
food,see,clinical 1.0 0.000143348623853 0 1 -1
food,or,milk 1.0 0.000143348623853 0 1 -1
food,or,herb 1.0 0.000286697247706 0 2 -2
food,on,the 1.0 0.000143348623853 0 1 -1
food,isoniazid,should 1.0 0.000143348623853 0 1 -1
food,interactions,the 1.0 0.000143348623853 0 1 -1
food,in,the 1.0 0.000143348623853 0 1 -1
food,has,no 1.0 0.000143348623853 0 1 -1
food,and,drug 1.0 0.000143348623853 0 1 -1
fondaparinux,the,concomitant 1.0 0.000143348623853 0 1 -1
fondaparinux,neither,influenced 1.0 0.000143348623853 0 1 -1
following,was,gathered 1.0 0.000143348623853 0 1 -1
following,varying,degrees 1.0 0.000143348623853 0 1 -1
following,ultracentrifugation,indicated 1.0 0.000143348623853 0 1 -1
following,treatment,with 1.0 0.000286697247706 0 2 -2
following,the,concomitant 1.0 0.000143348623853 0 1 -1
following,table,effects 1.0 0.000143348623853 0 1 -1
following,table,aed 1.0 0.000143348623853 0 1 -1
following,synthetic,steroidal 1.0 0.000143348623853 0 1 -1
following,symptoms,excitement 1.0 0.000143348623853 0 1 -1
following,symptom,onset 1.0 0.000143348623853 0 1 -1
following,subcutaneous,injections 1.0 0.000143348623853 0 1 -1
following,specific,interactions 1.0 0.000143348623853 0 1 -1
following,six,cytochrome 1.0 0.000143348623853 0 1 -1
following,situations,occur 1.0 0.000143348623853 0 1 -1
following,single,dose 1.0 0.000143348623853 0 1 -1
following,similar,changes 1.0 0.000286697247706 0 2 -2
following,protease,inhibitors 1.0 0.000143348623853 0 1 -1
following,other,drugs 1.0 0.000143348623853 0 1 -1
following,oral,and 1.0 0.000143348623853 0 1 -1
following,oral,administration 1.0 0.000143348623853 0 1 -1
following,or,moieties 1.0 0.000143348623853 0 1 -1
following,observations,i 1.0 0.000143348623853 0 1 -1
following,multiple,doses 1.0 0.000143348623853 0 1 -1
following,mptp,administration 1.0 0.000143348623853 0 1 -1
following,methyl-4,phenyl-1 1.0 0.000143348623853 0 1 -1
following,medications,have 1.0 0.000143348623853 0 1 -1
following,mating,caused 1.0 0.000143348623853 0 1 -1
following,lipid-lowering,that 1.0 0.000143348623853 0 1 -1
following,laboratory,tests 1.0 0.000143348623853 0 1 -1
following,ip,injections 1.0 0.000143348623853 0 1 -1
following,intravenous,bolus 1.0 0.000143348623853 0 1 -1
following,interactions,were 1.0 0.000143348623853 0 1 -1
following,initial,or 1.0 0.000143348623853 0 1 -1
following,infusions,of 1.0 0.000143348623853 0 1 -1
following,information,was 1.0 0.000286697247706 0 2 -2
following,immunosuppressives,cyclosporine 1.0 0.000143348623853 0 1 -1
following,have,been 1.0 0.000143348623853 0 1 -1
following,enzymes,in 1.0 0.000143348623853 0 1 -1
following,eight,target 1.0 0.000143348623853 0 1 -1
following,drug,interactions 1.0 0.000143348623853 0 1 -1
following,dosing,of 1.0 0.000143348623853 0 1 -1
following,days,of 1.0 0.000143348623853 0 1 -1
following,cyclosporine,a 1.0 0.000143348623853 0 1 -1
following,concomitant,use 1.0 0.000143348623853 0 1 -1
following,concomitant,medications 1.0 0.000143348623853 0 1 -1
following,completion,of 1.0 0.000143348623853 0 1 -1
following,co-administration,of 1.0 0.000143348623853 0 1 -1
following,chronic,administration 1.0 0.000143348623853 0 1 -1
following,blood,thinners 1.0 0.000143348623853 0 1 -1
following,beta-adrenergic,blocking 1.0 0.000143348623853 0 1 -1
following,are,administered 1.0 0.000143348623853 0 1 -1
following,antibiotics,rifampin 1.0 0.000143348623853 0 1 -1
following,anti-anxiety,used 1.0 0.000143348623853 0 1 -1
following,an,initial 1.0 0.000143348623853 0 1 -1
following,agents,highly 1.0 0.000143348623853 0 1 -1
following,a,g 1.0 0.000143348623853 0 1 -1
following,a,day 1.0 0.000286697247706 0 2 -2
followed,for,estimation 1.0 0.000143348623853 0 1 -1
followed,by,to 1.0 0.000143348623853 0 1 -1
followed,by,the 1.0 0.000143348623853 0 1 -1
followed,by,such 1.0 0.000143348623853 0 1 -1
followed,by,in 1.0 0.000143348623853 0 1 -1
followed,by,either 1.0 0.000143348623853 0 1 -1
followed,by,determination 1.0 0.000143348623853 0 1 -1
followed,and,the 1.0 0.000143348623853 0 1 -1
follow-up,study,in 1.0 0.000143348623853 0 1 -1
follow-up,opportunistic,infection 1.0 0.000143348623853 0 1 -1
follow-up,of,months 1.0 0.000143348623853 0 1 -1
follow-up,measurements,should 1.0 0.000143348623853 0 1 -1
follow-up,liver,function 1.0 0.000143348623853 0 1 -1
follow-up,blood,lipids 1.0 0.000143348623853 0 1 -1
follow,dosing,by 1.0 0.000143348623853 0 1 -1
follicle-stimulating,hormone,fsh 1.0 0.000143348623853 0 1 -1
folic,acid,will 1.0 0.000143348623853 0 1 -1
folic,acid,supplements 1.0 0.000143348623853 0 1 -1
folic,acid,should 1.0 0.000143348623853 0 1 -1
folic,acid,from 1.0 0.000143348623853 0 1 -1
folic,acid,and 1.0 0.000286697247706 0 2 -2
fold,the,systemic 1.0 0.000143348623853 0 1 -1
fold,than,plasma 1.0 0.000143348623853 0 1 -1
fold,range,of 1.0 0.000143348623853 0 1 -1
fold,prolongation,in 1.0 0.000286697247706 0 2 -2
fold,increase,was 1.0 0.000143348623853 0 1 -1
fold,in,males 1.0 0.000143348623853 0 1 -1
fold,in,females 1.0 0.000143348623853 0 1 -1
fold,greater,for 1.0 0.000286697247706 0 2 -2
fold,accumulation,of 1.0 0.000143348623853 0 1 -1
folate,may,also 1.0 0.000143348623853 0 1 -1
focuses,on,metabolic 1.0 0.000143348623853 0 1 -1
focused,on,developing 1.0 0.000143348623853 0 1 -1
focused,on,aspects 1.0 0.000143348623853 0 1 -1
focus,on,specific 1.0 0.000143348623853 0 1 -1
focus,on,investigation 1.0 0.000143348623853 0 1 -1
focus,is,given 1.0 0.000143348623853 0 1 -1
fo,these,hormones 1.0 0.000143348623853 0 1 -1
fo,the,experiment 1.0 0.000143348623853 0 1 -1
fluvoxamine,is,a 1.0 0.000286697247706 0 2 -2
fluvastatin,is,the 1.0 0.000143348623853 0 1 -1
flushing,skin,reactions 1.0 0.000143348623853 0 1 -1
flushing,rash,peripheral 1.0 0.000143348623853 0 1 -1
flushing,and,pruritus 1.0 0.000143348623853 0 1 -1
fluoxetine,ocs,macrolide 1.0 0.000143348623853 0 1 -1
fluoxetine,indanavir,ketoconazole 1.0 0.000143348623853 0 1 -1
fluoxetine,does,not 1.0 0.000143348623853 0 1 -1
fluoxetine,and,its 1.0 0.000143348623853 0 1 -1
fluoxetine,and,increased 1.0 0.000143348623853 0 1 -1
fluoxetine,a,multiple-dose 1.0 0.000143348623853 0 1 -1
fluoroquinolones,macrolide,and 1.0 0.000143348623853 0 1 -1
fluoride,or,citrate 1.0 0.000143348623853 0 1 -1
fluoride,levels,and 1.0 0.000143348623853 0 1 -1
fluoride,accumulation,characteristic 1.0 0.000143348623853 0 1 -1
fluorescence,labelled,and 1.0 0.000143348623853 0 1 -1
fluorescein,naflu,and 1.0 0.000143348623853 0 1 -1
fluids,might,be 1.0 0.000286697247706 0 2 -2
fluid,transfers,were 1.0 0.000143348623853 0 1 -1
fluid,contents,and 1.0 0.000143348623853 0 1 -1
fluid,by,dmpge2 1.0 0.000143348623853 0 1 -1
fluctuated,there,were 1.0 0.000143348623853 0 1 -1
flucoxacillin,and,demonstrated 1.0 0.000143348623853 0 1 -1
fluconazole,fluoxetine,indanavir 1.0 0.000143348623853 0 1 -1
fluconazole,and,the 1.0 0.000143348623853 0 1 -1
fluconazole,and,ketoconazole 1.0 0.000143348623853 0 1 -1
flu-like,effects,may 1.0 0.000143348623853 0 1 -1
flow,were,measured 1.0 0.000143348623853 0 1 -1
flow,seen,in 1.0 0.000143348623853 0 1 -1
flow,or,enzyme 1.0 0.000143348623853 0 1 -1
flow,glomerular,filtration 1.0 0.000143348623853 0 1 -1
flow,caused,by 1.0 0.000143348623853 0 1 -1
flow,and,fundus 1.0 0.000143348623853 0 1 -1
flow,and,function 1.0 0.000143348623853 0 1 -1
flolan,in,clinical 1.0 0.000143348623853 0 1 -1
flexure,of,the 1.0 0.000143348623853 0 1 -1
flexible,and,involve 1.0 0.000143348623853 0 1 -1
flecainide,is,not 1.0 0.000143348623853 0 1 -1
flavonoids,alone,significantly 1.0 0.000143348623853 0 1 -1
flares,coupled,with 1.0 0.000143348623853 0 1 -1
flare,were,significantly 1.0 0.000143348623853 0 1 -1
fixed-ratio,fi,fr 1.0 0.000143348623853 0 1 -1
fixed-interval,fixed-ratio,fi 1.0 0.000143348623853 0 1 -1
fixed,g,m2 1.0 0.000143348623853 0 1 -1
fixed,daily,dose 1.0 0.000143348623853 0 1 -1
fivefold,increase,in 1.0 0.000143348623853 0 1 -1
five,or,mg 1.0 0.000143348623853 0 1 -1
five,men,levels 1.0 0.000143348623853 0 1 -1
five,lacking,kidney 1.0 0.000143348623853 0 1 -1
five,different,ca 1.0 0.000143348623853 0 1 -1
five,days,of 1.0 0.000286697247706 0 2 -2
five,days,in 1.0 0.000143348623853 0 1 -1
five,commonly,used 1.0 0.000143348623853 0 1 -1
fistulas,were,carried 1.0 0.000143348623853 0 1 -1
fischer-344,strain,were 1.0 0.000143348623853 0 1 -1
first-pass,metabolism,are 1.0 0.000143348623853 0 1 -1
first-pass,metabolism,and 1.0 0.000143348623853 0 1 -1
first-line,therapy,for 1.0 0.000143348623853 0 1 -1
first-line,option,in 1.0 0.000143348623853 0 1 -1
first,test,is 1.0 0.000143348623853 0 1 -1
first,synthetic,hydroxy-3 1.0 0.000143348623853 0 1 -1
first,study,both 1.0 0.000143348623853 0 1 -1
first,step,of 1.0 0.000143348623853 0 1 -1
first,response,was 1.0 0.000143348623853 0 1 -1
first,rapid,contraction 1.0 0.000143348623853 0 1 -1
first,post-transplant,year 1.0 0.000143348623853 0 1 -1
first,phase,of 1.0 0.000143348623853 0 1 -1
first,pass,secondary 1.0 0.000143348623853 0 1 -1
first,month,and 1.0 0.000143348623853 0 1 -1
first,hours,following 1.0 0.000143348623853 0 1 -1
first,hour,of 1.0 0.000143348623853 0 1 -1
first,experiment,male 1.0 0.000143348623853 0 1 -1
first,double-blind,comparative 1.0 0.000143348623853 0 1 -1
first,days,of 1.0 0.000143348623853 0 1 -1
first,day,of 1.0 0.000143348623853 0 1 -1
first,contractile,response 1.0 0.000143348623853 0 1 -1
first,cervical,vertebra 1.0 0.000143348623853 0 1 -1
fired,spontaneous,action 1.0 0.000143348623853 0 1 -1
findings,to,the 1.0 0.000143348623853 0 1 -1
findings,these,results 1.0 0.000143348623853 0 1 -1
findings,suggest,that 1.0 0.000573394495413 0 4 -4
findings,should,be 1.0 0.000143348623853 0 1 -1
findings,on,endometrial 1.0 0.000143348623853 0 1 -1
findings,of,these 1.0 0.000143348623853 0 1 -1
findings,indicate,that 1.0 0.000143348623853 0 1 -1
findings,in,some 1.0 0.000143348623853 0 1 -1
findings,has,not 1.0 0.000143348623853 0 1 -1
findings,asymptomatic,transitory 1.0 0.000143348623853 0 1 -1
findings,are,summarized 1.0 0.000143348623853 0 1 -1
findings,and,no 1.0 0.000143348623853 0 1 -1
finding,to,humans 1.0 0.000143348623853 0 1 -1
finding,that,neither 1.0 0.000143348623853 0 1 -1
finding,no,interactive 1.0 0.000143348623853 0 1 -1
find,out,whether 1.0 0.000143348623853 0 1 -1
finasteride,had,no 1.0 0.000143348623853 0 1 -1
finasteride,does,not 1.0 0.000143348623853 0 1 -1
finally,it,is 1.0 0.000143348623853 0 1 -1
filtration,rate,and 1.0 0.000143348623853 0 1 -1
filtration,or,tubular 1.0 0.000143348623853 0 1 -1
filtration,may,prolong 1.0 0.000143348623853 0 1 -1
fifteen,to,minutes 1.0 0.000143348623853 0 1 -1
fifteen,species,of 1.0 0.000143348623853 0 1 -1
fici,was,determined 1.0 0.000143348623853 0 1 -1
fibrosis,therapies,including 1.0 0.000143348623853 0 1 -1
fibrosis,have,been 1.0 0.000143348623853 0 1 -1
fibroblast,y1,cells 1.0 0.000143348623853 0 1 -1
fibrinolysis,is,mmol 1.0 0.000143348623853 0 1 -1
fibrinogen,to,the 1.0 0.000143348623853 0 1 -1
fibrillation,and,cardiovascular 1.0 0.000143348623853 0 1 -1
fibric,acid,derivatives 1.0 0.000286697247706 0 2 -2
fibers,in,clinically 1.0 0.000143348623853 0 1 -1
fi,responding,significantly 1.0 0.000143348623853 0 1 -1
fi,responding,in 1.0 0.000143348623853 0 1 -1
fi,fr,schedule 1.0 0.000143348623853 0 1 -1
fi,and,fr 1.0 0.000143348623853 0 1 -1
fexofenadine,has,been 1.0 0.000143348623853 0 1 -1
fexofenadine,had,no 1.0 0.000143348623853 0 1 -1
fewer,interactions,and 1.0 0.000143348623853 0 1 -1
fewer,infusion,reactions 1.0 0.000143348623853 0 1 -1
fewer,extrapyramidal,symptoms 1.0 0.000143348623853 0 1 -1
few,systemic,data 1.0 0.000143348623853 0 1 -1
few,patients,receiving 1.0 0.000143348623853 0 1 -1
few,individuals,discontinuing 1.0 0.000143348623853 0 1 -1
few,data,regarding 1.0 0.000143348623853 0 1 -1
few,data,exist 1.0 0.000143348623853 0 1 -1
fever,chills,nausea 1.0 0.000143348623853 0 1 -1
fetal,variations,in 1.0 0.000143348623853 0 1 -1
fetal,toxicity,including 1.0 0.000143348623853 0 1 -1
fetal,immune,system 1.0 0.000143348623853 0 1 -1
fetal,development,including 1.0 0.000143348623853 0 1 -1
fetal,development,consistent 1.0 0.000143348623853 0 1 -1
fetal,development,at 1.0 0.000143348623853 0 1 -1
fetal,abnormalities,in 1.0 0.000143348623853 0 1 -1
fertility,were,observed 1.0 0.000143348623853 0 1 -1
fertility,to,values 1.0 0.000143348623853 0 1 -1
fertility,pegasys,may 1.0 0.000143348623853 0 1 -1
fertility,or,harm 1.0 0.000143348623853 0 1 -1
fertility,of,male 1.0 0.000143348623853 0 1 -1
fertility,of,humans 1.0 0.000143348623853 0 1 -1
fertility,of,female 1.0 0.000143348623853 0 1 -1
fertility,no,long-term 1.0 0.000143348623853 0 1 -1
fertility,have,not 1.0 0.000286697247706 0 2 -2
fertility,carcinogenesis,pegasys 1.0 0.000143348623853 0 1 -1
fertility,as,well 1.0 0.000143348623853 0 1 -1
fertility,and,embryonic 1.0 0.000143348623853 0 1 -1
fertility,a,two-year 1.0 0.000143348623853 0 1 -1
ferricyanide,test,it 1.0 0.000286697247706 0 2 -2
fentanyl,is,metabolized 1.0 0.000143348623853 0 1 -1
fentanyl,cyp3a4,substrate 1.0 0.000143348623853 0 1 -1
fenofibric,acid,were 1.0 0.000143348623853 0 1 -1
fenofibric,acid,are 1.0 0.000143348623853 0 1 -1
fenbufen,is,not 1.0 0.000286697247706 0 2 -2
femara,with,these 1.0 0.000143348623853 0 1 -1
femara,in,combination 1.0 0.000143348623853 0 1 -1
females,dosed,at 1.0 0.000143348623853 0 1 -1
females,and,and 1.0 0.000143348623853 0 1 -1
female,volunteers,in 1.0 0.000143348623853 0 1 -1
female,volunteers,established 1.0 0.000143348623853 0 1 -1
female,subjects,received 1.0 0.000286697247706 0 2 -2
female,rats,was 1.0 0.000143348623853 0 1 -1
female,rats,received 1.0 0.000143348623853 0 1 -1
female,rats,at 1.0 0.000143348623853 0 1 -1
female,rats,appear 1.0 0.000143348623853 0 1 -1
female,rats,administered 1.0 0.000143348623853 0 1 -1
female,patients,of 1.0 0.000143348623853 0 1 -1
female,patient,receiving 1.0 0.000143348623853 0 1 -1
female,n,in 1.0 0.000143348623853 0 1 -1
female,have,not 1.0 0.000143348623853 0 1 -1
female,fertility,to 1.0 0.000143348623853 0 1 -1
female,fertility,as 1.0 0.000143348623853 0 1 -1
female,fertility,and 1.0 0.000143348623853 0 1 -1
female,dog,treated 1.0 0.000143348623853 0 1 -1
female,dog,that 1.0 0.000143348623853 0 1 -1
female,cynomolgus,monkeys 1.0 0.000143348623853 0 1 -1
female,animals,dosed 1.0 0.000143348623853 0 1 -1
female,and,male 1.0 0.000143348623853 0 1 -1
felodipine,may,increase 1.0 0.000143348623853 0 1 -1
felodipine,is,metabolized 1.0 0.000143348623853 0 1 -1
fell,to,plus 1.0 0.000143348623853 0 1 -1
felbatol,therapy,resulted 1.0 0.000143348623853 0 1 -1
felbatol,the,rate 1.0 0.000143348623853 0 1 -1
felbatol,the,coadministration 1.0 0.000143348623853 0 1 -1
felbatol,on,low-dose 1.0 0.000143348623853 0 1 -1
felbatol,as,monotherapy 1.0 0.000143348623853 0 1 -1
fehlings,solution,or 1.0 0.00043004587156 0 3 -3
fehling,s,solutions 1.0 0.000286697247706 0 2 -2
fehling,s,solution 1.0 0.000143348623853 0 1 -1
feels,that,is 1.0 0.000143348623853 0 1 -1
feels,better,after 1.0 0.000143348623853 0 1 -1
feeding,and,effective 1.0 0.000143348623853 0 1 -1
feedback,alterations,in 1.0 0.000143348623853 0 1 -1
fed,further,fe 1.0 0.000143348623853 0 1 -1
fecal,loss,or 1.0 0.000143348623853 0 1 -1
fecal,excretion,too 1.0 0.000143348623853 0 1 -1
fecal,blood,loss 1.0 0.000143348623853 0 1 -1
fecal,as,well 1.0 0.000143348623853 0 1 -1
fecal,and,urinary 1.0 0.000143348623853 0 1 -1
fec-100,chemotherapies,breast 1.0 0.000143348623853 0 1 -1
feasible,as,specific 1.0 0.000143348623853 0 1 -1
feasible,and,may 1.0 0.000143348623853 0 1 -1
feasibility,and,efficacy 1.0 0.000143348623853 0 1 -1
fe,over,a 1.0 0.000143348623853 0 1 -1
fe,abstract,truncated 1.0 0.000143348623853 0 1 -1
fda,have,involved 1.0 0.000143348623853 0 1 -1
favorable,effects,on 1.0 0.000143348623853 0 1 -1
fatty,acids,and 1.0 0.000143348623853 0 1 -1
fatigue,hypotension,oliguria 1.0 0.000143348623853 0 1 -1
fatal,interactions,may 1.0 0.000143348623853 0 1 -1
fatal,hepatic,failure 1.0 0.000143348623853 0 1 -1
fatal,cardiac,arrests 1.0 0.000143348623853 0 1 -1
fatal,adverse,events 1.0 0.000143348623853 0 1 -1
fat,soluble,such 1.0 0.000143348623853 0 1 -1
fat,redistribution,redistribution 1.0 0.000143348623853 0 1 -1
fat,including,central 1.0 0.000143348623853 0 1 -1
fat,enlargement,buffalo 1.0 0.000143348623853 0 1 -1
fat,digestion,and 1.0 0.000143348623853 0 1 -1
fat,and,like 1.0 0.000143348623853 0 1 -1
fasting,conditions,or 1.0 0.000143348623853 0 1 -1
fasted,for,h 1.0 0.000143348623853 0 1 -1
fasted,and,the 1.0 0.000143348623853 0 1 -1
faslodex,in,the 1.0 0.000143348623853 0 1 -1
faslodex,in,pediatric 1.0 0.000143348623853 0 1 -1
faslodex,in,nursing 1.0 0.000143348623853 0 1 -1
fashion,to,receive 1.0 0.000143348623853 0 1 -1
fashion,from,to 1.0 0.000143348623853 0 1 -1
fashion,at,a 1.0 0.000143348623853 0 1 -1
fashion,and,may 1.0 0.000143348623853 0 1 -1
far,more,potent 1.0 0.000143348623853 0 1 -1
far,greater,than 1.0 0.000143348623853 0 1 -1
far,greater,extent 1.0 0.000143348623853 0 1 -1
family,may,potentially 1.0 0.000143348623853 0 1 -1
family,education,on 1.0 0.000143348623853 0 1 -1
family,cyp3a4,and 1.0 0.000143348623853 0 1 -1
familial,hyper-,or 1.0 0.000143348623853 0 1 -1
falsely,identify,characteristics 1.0 0.000143348623853 0 1 -1
falsely,elevated,with 1.0 0.000143348623853 0 1 -1
falsely,elevated,levels 1.0 0.000143348623853 0 1 -1
falsely,elevated,glucose 1.0 0.000143348623853 0 1 -1
false-positive,urine,test 1.0 0.000143348623853 0 1 -1
false-positive,test,results 1.0 0.000143348623853 0 1 -1
false-positive,reaction,for 1.0 0.00200688073394 0 14 -14
false-positive,findings,in 1.0 0.000143348623853 0 1 -1
false-positive,direct,coombs 1.0 0.000286697247706 0 2 -2
false-negative,results,in 1.0 0.000286697247706 0 2 -2
false-negative,result,may 1.0 0.000286697247706 0 2 -2
false,positive,test 1.0 0.000143348623853 0 1 -1
false,positive,readings 1.0 0.000143348623853 0 1 -1
false,positive,reaction 1.0 0.000286697247706 0 2 -2
false,low,measurement 1.0 0.000143348623853 0 1 -1
false,increases,of 1.0 0.000286697247706 0 2 -2
false,increases,in 1.0 0.000143348623853 0 1 -1
false,elevations,of 1.0 0.000143348623853 0 1 -1
fall,in,the 1.0 0.000143348623853 0 1 -1
fall,in,blood 1.0 0.000143348623853 0 1 -1
failure,who,are 1.0 0.000143348623853 0 1 -1
failure,where,and 1.0 0.000143348623853 0 1 -1
failure,were,not 1.0 0.000143348623853 0 1 -1
failure,there,is 1.0 0.000143348623853 0 1 -1
failure,secondary,to 1.0 0.000143348623853 0 1 -1
failure,post-myocardial,infarction 1.0 0.000143348623853 0 1 -1
failure,of,to 1.0 0.000143348623853 0 1 -1
failure,nyha,class 1.0 0.000143348623853 0 1 -1
failure,may,be 1.0 0.000143348623853 0 1 -1
failure,elevated,creatine 1.0 0.000143348623853 0 1 -1
failure,during,which 1.0 0.000143348623853 0 1 -1
failure,cannot,be 1.0 0.000143348623853 0 1 -1
failure,as,a 1.0 0.000143348623853 0 1 -1
failure,and,av 1.0 0.000143348623853 0 1 -1
failing,hearts,new 1.0 0.000143348623853 0 1 -1
failing,heart,can 1.0 0.000143348623853 0 1 -1
failed,to,wshow 1.0 0.000286697247706 0 2 -2
failed,to,show 1.0 0.000143348623853 0 1 -1
failed,to,maintain 1.0 0.000143348623853 0 1 -1
failed,to,increase 1.0 0.000143348623853 0 1 -1
failed,to,identify 1.0 0.000143348623853 0 1 -1
failed,to,alter 1.0 0.000143348623853 0 1 -1
faecium,to,the 1.0 0.000143348623853 0 1 -1
faecalis,by,antiresistance 1.0 0.000143348623853 0 1 -1
faecalis,atcc,showed 1.0 0.000143348623853 0 1 -1
faecalis,and,enterococcus 1.0 0.000143348623853 0 1 -1
facultative,and,anaerobic 1.0 0.000143348623853 0 1 -1
facts,should,be 1.0 0.000143348623853 0 1 -1
factrel,test,should 1.0 0.000143348623853 0 1 -1
factors,when,administered 1.0 0.000143348623853 0 1 -1
factors,vii,viii 1.0 0.000286697247706 0 2 -2
factors,v,and 1.0 0.000143348623853 0 1 -1
factors,that,could 1.0 0.000143348623853 0 1 -1
factors,such,as 1.0 0.00043004587156 0 3 -3
factors,of,and 1.0 0.000143348623853 0 1 -1
factors,may,play 1.0 0.000143348623853 0 1 -1
factors,may,interact 1.0 0.000143348623853 0 1 -1
factors,may,increase 1.0 0.000143348623853 0 1 -1
factors,like,smoking 1.0 0.000143348623853 0 1 -1
factors,is,also 1.0 0.000143348623853 0 1 -1
factors,involved,in 1.0 0.000143348623853 0 1 -1
factors,in,hemostasis 1.0 0.000143348623853 0 1 -1
factors,in,concert 1.0 0.000143348623853 0 1 -1
factors,ii,vii 1.0 0.000286697247706 0 2 -2
factors,as,age 1.0 0.000143348623853 0 1 -1
factor,viii,ix 1.0 0.000143348623853 0 1 -1
factor,vii,when 1.0 0.000143348623853 0 1 -1
factor,treatment,for 1.0 0.000143348623853 0 1 -1
factor,support,was 1.0 0.000143348623853 0 1 -1
factor,in,the 1.0 0.000143348623853 0 1 -1
factor,ii,v 1.0 0.000143348623853 0 1 -1
factor,iegs,has 1.0 0.000143348623853 0 1 -1
factor,for,realization 1.0 0.000143348623853 0 1 -1
factor,for,altering 1.0 0.000143348623853 0 1 -1
factor,concentration,that 1.0 0.000143348623853 0 1 -1
factor,concentrates,has 1.0 0.000143348623853 0 1 -1
factor,bacterial,mutation 1.0 0.000143348623853 0 1 -1
factor,assays,based 1.0 0.000143348623853 0 1 -1
factive,had,no 1.0 0.000286697247706 0 2 -2
facilitation,or,an 1.0 0.000143348623853 0 1 -1
facilitates,acquisition,of 1.0 0.000143348623853 0 1 -1
facilitated,by,hippocampal 1.0 0.000143348623853 0 1 -1
facilitate,the,action 1.0 0.000143348623853 0 1 -1
facilitate,and,reinstate 1.0 0.000143348623853 0 1 -1
facial,wasting,breast 1.0 0.000143348623853 0 1 -1
fa,were,submitted 1.0 0.000143348623853 0 1 -1
f2alpha,and,synthetic 1.0 0.000143348623853 0 1 -1
f1,that,received 1.0 0.000143348623853 0 1 -1
eye,drops,unless 1.0 0.000143348623853 0 1 -1
eye,drops,containing 1.0 0.000143348623853 0 1 -1
extrusion,of,from 1.0 0.000143348623853 0 1 -1
extremely,acidic,conditions 1.0 0.000143348623853 0 1 -1
extreme,caution,only 1.0 0.000143348623853 0 1 -1
extravasation,were,usually 1.0 0.000143348623853 0 1 -1
extravasation,reactions,is 1.0 0.000143348623853 0 1 -1
extravasation,it,is 1.0 0.000143348623853 0 1 -1
extravasation,following,administration 1.0 0.000143348623853 0 1 -1
extrarenal,mechanisms,of 1.0 0.000143348623853 0 1 -1
extrapolating,these,findings 1.0 0.000143348623853 0 1 -1
extrapolated,to,other 1.0 0.000143348623853 0 1 -1
extraneals,effects,on 1.0 0.000143348623853 0 1 -1
extraneal,on,absorption 1.0 0.000143348623853 0 1 -1
extraction,j,chromatogr 1.0 0.000143348623853 0 1 -1
extraction,has,been 1.0 0.000143348623853 0 1 -1
extract,from,the 1.0 0.000143348623853 0 1 -1
extract,from,bovine 1.0 0.000143348623853 0 1 -1
extract,alone,and 1.0 0.000143348623853 0 1 -1
extracellular,levels,of 1.0 0.000143348623853 0 1 -1
extracellular,ca,and 1.0 0.000143348623853 0 1 -1
extracellular,application,of 1.0 0.000143348623853 0 1 -1
extra,doses,should 1.0 0.000143348623853 0 1 -1
external,subcutaneous,infusion 1.0 0.000143348623853 0 1 -1
extent,with,that 1.0 0.000143348623853 0 1 -1
extent,than,the 1.0 0.000143348623853 0 1 -1
extent,than,and 1.0 0.000143348623853 0 1 -1
extent,of,plasma 1.0 0.000143348623853 0 1 -1
extent,of,interaction 1.0 0.000143348623853 0 1 -1
extent,of,dissolution 1.0 0.000286697247706 0 2 -2
extent,of,bioavailability 1.0 0.00043004587156 0 3 -3
extent,of,binding 1.0 0.000143348623853 0 1 -1
extent,enhanced,the 1.0 0.000143348623853 0 1 -1
extent,by,the 1.0 0.000143348623853 0 1 -1
extent,and,the 1.0 0.000143348623853 0 1 -1
extensor,tension,hoof 1.0 0.000143348623853 0 1 -1
extensively,used,in 1.0 0.000143348623853 0 1 -1
extensively,studied,and 1.0 0.000286697247706 0 2 -2
extensively,metabolized,the 1.0 0.000143348623853 0 1 -1
extensively,metabolized,predominantly 1.0 0.000143348623853 0 1 -1
extensively,metabolized,in 1.0 0.000143348623853 0 1 -1
extensively,bound,to 1.0 0.000286697247706 0 2 -2
extensive,metabolism,by 1.0 0.000143348623853 0 1 -1
extensive,intake,of 1.0 0.000143348623853 0 1 -1
extensive,cyp2d6,metabolizers 1.0 0.000143348623853 0 1 -1
extensive,concomitant,use 1.0 0.000143348623853 0 1 -1
extended,sodium,capsules 1.0 0.000143348623853 0 1 -1
extended,release,mg 1.0 0.000143348623853 0 1 -1
extended,release,formulation 1.0 0.000143348623853 0 1 -1
extend,outside,the 1.0 0.000143348623853 0 1 -1
expression,was,evaluated 1.0 0.000143348623853 0 1 -1
expression,that,may 1.0 0.000143348623853 0 1 -1
expression,of,subpopulations 1.0 0.000143348623853 0 1 -1
expression,of,an 1.0 0.000143348623853 0 1 -1
expression,in,certain 1.0 0.000143348623853 0 1 -1
expression,by,the 1.0 0.000143348623853 0 1 -1
expressed,in,terms 1.0 0.000143348623853 0 1 -1
expressed,by,minimal 1.0 0.000143348623853 0 1 -1
express,the,d 1.0 0.000143348623853 0 1 -1
exposures,similar,to 1.0 0.000143348623853 0 1 -1
exposures,proposed,by 1.0 0.000143348623853 0 1 -1
exposures,of,fully 1.0 0.000143348623853 0 1 -1
exposures,in,terms 1.0 0.000143348623853 0 1 -1
exposure-response,relationships,between 1.0 0.000143348623853 0 1 -1
exposure-response,relationships,and 1.0 0.000143348623853 0 1 -1
exposure,were,assessed 1.0 0.000143348623853 0 1 -1
exposure,were,as 1.0 0.000143348623853 0 1 -1
exposure,tonevirapine,caution 1.0 0.000143348623853 0 1 -1
exposure,to,substrates 1.0 0.000143348623853 0 1 -1
exposure,to,substances 1.0 0.000143348623853 0 1 -1
exposure,to,solvents 1.0 0.000143348623853 0 1 -1
exposure,to,one 1.0 0.000143348623853 0 1 -1
exposure,to,mac 1.0 0.000143348623853 0 1 -1
exposure,to,electrophilic 1.0 0.000143348623853 0 1 -1
exposure,to,either 1.0 0.000143348623853 0 1 -1
exposure,the,toxicokinetic 1.0 0.000143348623853 0 1 -1
exposure,or,the 1.0 0.000143348623853 0 1 -1
exposure,or,renal 1.0 0.000143348623853 0 1 -1
exposure,may,be 1.0 0.000143348623853 0 1 -1
exposure,levels,close 1.0 0.000143348623853 0 1 -1
exposure,is,limited 1.0 0.000143348623853 0 1 -1
exposure,in,which 1.0 0.000143348623853 0 1 -1
exposure,in,these 1.0 0.000286697247706 0 2 -2
exposure,in,the 1.0 0.000143348623853 0 1 -1
exposure,in,rodent 1.0 0.000143348623853 0 1 -1
exposure,in,mice 1.0 0.000143348623853 0 1 -1
exposure,general,logistic 1.0 0.000143348623853 0 1 -1
exposure,from,the 1.0 0.000143348623853 0 1 -1
exposure,for,the 1.0 0.000143348623853 0 1 -1
exposure,for,oral 1.0 0.000143348623853 0 1 -1
exposure,during,the 1.0 0.000143348623853 0 1 -1
exposure,despite,persistent 1.0 0.000143348623853 0 1 -1
exposure,compared,with 1.0 0.000143348623853 0 1 -1
exposure,be,considered 1.0 0.000143348623853 0 1 -1
exposure,auc0-30,days 1.0 0.000286697247706 0 2 -2
exposure,auc0-12,of 1.0 0.000143348623853 0 1 -1
exposure,approximately,times 1.0 0.000143348623853 0 1 -1
exposure,and,the 1.0 0.000143348623853 0 1 -1
exposure,and,may 1.0 0.000143348623853 0 1 -1
exposed,to,the 1.0 0.000143348623853 0 1 -1
exposed,to,cadmium 1.0 0.000143348623853 0 1 -1
exposed,to,a 1.0 0.000143348623853 0 1 -1
exposed,histidines,on 1.0 0.000143348623853 0 1 -1
exposed,histidine,residues 1.0 0.000143348623853 0 1 -1
explored,with,the 1.0 0.000143348623853 0 1 -1
explored,further,in 1.0 0.000143348623853 0 1 -1
exploited,in,the 1.0 0.000143348623853 0 1 -1
explanation,for,the 1.0 0.000143348623853 0 1 -1
explained,either,by 1.0 0.000143348623853 0 1 -1
explain,the,increased 1.0 0.000143348623853 0 1 -1
explain,in,part 1.0 0.000143348623853 0 1 -1
experiments,we,noted 1.0 0.000143348623853 0 1 -1
experiments,using,the 1.0 0.000143348623853 0 1 -1
experiments,the,perfusion 1.0 0.000143348623853 0 1 -1
experiments,reported,here 1.0 0.000143348623853 0 1 -1
experiments,reactions,to 1.0 0.000143348623853 0 1 -1
experiments,on,white 1.0 0.000143348623853 0 1 -1
experiments,on,dogs 1.0 0.000143348623853 0 1 -1
experiments,for,assessing 1.0 0.000143348623853 0 1 -1
experiments,demonstrated,a 1.0 0.000143348623853 0 1 -1
experimental,designs,for 1.0 0.000143348623853 0 1 -1
experimental,designs,can 1.0 0.000143348623853 0 1 -1
experimental,animals,male 1.0 0.000143348623853 0 1 -1
experiment,rats,were 1.0 0.000143348623853 0 1 -1
experiment,non-diabetic,and 1.0 0.000143348623853 0 1 -1
experiment,male,adult 1.0 0.000143348623853 0 1 -1
experiencing,severe,or 1.0 0.000143348623853 0 1 -1
experiencing,breakthrough,bleeding 1.0 0.000143348623853 0 1 -1
experiences,in,the 1.0 0.000286697247706 0 2 -2
experiences,have,been 1.0 0.000143348623853 0 1 -1
experiences,eg,dizziness 1.0 0.000143348623853 0 1 -1
experiences,are,related 1.0 0.000143348623853 0 1 -1
experienced,problems,with 1.0 0.000143348623853 0 1 -1
experienced,problems,in 1.0 0.000143348623853 0 1 -1
experienced,by,approximately 1.0 0.000143348623853 0 1 -1
experience,with,use 1.0 0.000143348623853 0 1 -1
experience,with,the 1.0 0.00043004587156 0 3 -3
experience,with,concomitant 1.0 0.000286697247706 0 2 -2
experience,to,date 1.0 0.000143348623853 0 1 -1
experience,significantly,underestimates 1.0 0.000143348623853 0 1 -1
experience,profile,seen 1.0 0.000143348623853 0 1 -1
experience,on,the 1.0 0.000143348623853 0 1 -1
experience,may,reveal 1.0 0.000143348623853 0 1 -1
experience,large,increases 1.0 0.000143348623853 0 1 -1
experience,increased,concentrations 1.0 0.000143348623853 0 1 -1
experience,in,the 1.0 0.000143348623853 0 1 -1
experience,gained,may 1.0 0.000143348623853 0 1 -1
experience,fewer,infusion 1.0 0.000143348623853 0 1 -1
experience,as,they 1.0 0.000143348623853 0 1 -1
experience,an,increased 1.0 0.000143348623853 0 1 -1
expensive,or,to 1.0 0.000143348623853 0 1 -1
expected,with,whose 1.0 0.000143348623853 0 1 -1
expected,with,other 1.0 0.000143348623853 0 1 -1
expected,with,larger 1.0 0.000286697247706 0 2 -2
expected,to,substantially 1.0 0.000143348623853 0 1 -1
expected,to,significantly 1.0 0.000143348623853 0 1 -1
expected,to,occur 1.0 0.000143348623853 0 1 -1
expected,to,cause 1.0 0.000286697247706 0 2 -2
expected,to,affect 1.0 0.000286697247706 0 2 -2
expected,that,no 1.0 0.000143348623853 0 1 -1
expected,that,a 1.0 0.000143348623853 0 1 -1
expected,since,the 1.0 0.000143348623853 0 1 -1
expected,plasma,levels 1.0 0.000143348623853 0 1 -1
expected,plasma,concentrations 1.0 0.000860091743119 0 6 -6
expected,physiologic,effects 1.0 0.000143348623853 0 1 -1
expected,magnitude,of 1.0 0.000286697247706 0 2 -2
expected,lasma,concentrations 1.0 0.000143348623853 0 1 -1
expected,in,patients 1.0 0.000143348623853 0 1 -1
expected,changes,in 1.0 0.000143348623853 0 1 -1
expected,between,viracept 1.0 0.000143348623853 0 1 -1
expected,because,is 1.0 0.000143348623853 0 1 -1
expected,based,on 1.0 0.000143348623853 0 1 -1
expanded,our,understanding 1.0 0.000143348623853 0 1 -1
exogenous,respiration,was 1.0 0.000143348623853 0 1 -1
exogenous,respiration,becomes 1.0 0.000143348623853 0 1 -1
exogenous,on,the 1.0 0.000143348623853 0 1 -1
exogenous,enhancement,of 1.0 0.000143348623853 0 1 -1
exogenous,co-factors,could 1.0 0.000143348623853 0 1 -1
exogenous,and,endogenous 1.0 0.000143348623853 0 1 -1
exjade,with,has 1.0 0.000143348623853 0 1 -1
exjade,tablets,for 1.0 0.000143348623853 0 1 -1
exjade,pharmacokinetics,has 1.0 0.000143348623853 0 1 -1
exjade,had,no 1.0 0.000143348623853 0 1 -1
exjade,and,vitamin 1.0 0.000143348623853 0 1 -1
exjade,and,aluminum-containing 1.0 0.000143348623853 0 1 -1
exists,the,potential 1.0 0.000143348623853 0 1 -1
exists,not,only 1.0 0.000143348623853 0 1 -1
exists,in,regard 1.0 0.000143348623853 0 1 -1
exists,for,interaction 1.0 0.000573394495413 0 4 -4
exists,between,the 1.0 0.000143348623853 0 1 -1
existing,therapy,did 1.0 0.000143348623853 0 1 -1
existing,clinical,trials 1.0 0.000143348623853 0 1 -1
existence,of,pi 1.0 0.000143348623853 0 1 -1
exist,on,interactions 1.0 0.000143348623853 0 1 -1
exist,comparing,the 1.0 0.000143348623853 0 1 -1
exhibiting,m,m 1.0 0.000143348623853 0 1 -1
exhibited,similar,temporal 1.0 0.000143348623853 0 1 -1
exhibited,no,platelet 1.0 0.000143348623853 0 1 -1
exhibited,dose-proportional,stable 1.0 0.000143348623853 0 1 -1
exhibit,doubling,times 1.0 0.000143348623853 0 1 -1
exhibit,characteristic,apoptotic 1.0 0.000143348623853 0 1 -1
exhibit,binding,to 1.0 0.000143348623853 0 1 -1
exhibit,additive,effects 1.0 0.00043004587156 0 3 -3
exfoliation,necrosis,and 1.0 0.000143348623853 0 1 -1
exerts,its,effect 1.0 0.000143348623853 0 1 -1
exert,direct,effects 1.0 0.000143348623853 0 1 -1
exert,additive,vasodilator 1.0 0.000143348623853 0 1 -1
exert,additive,ocular 1.0 0.000143348623853 0 1 -1
exercised,with,these 1.0 0.000143348623853 0 1 -1
exercised,with,simultaneous 1.0 0.000143348623853 0 1 -1
exercised,when,using 1.0 0.000286697247706 0 2 -2
exercised,when,treating 1.0 0.000286697247706 0 2 -2
exercised,when,these 1.0 0.000143348623853 0 1 -1
exercised,when,the 1.0 0.000143348623853 0 1 -1
exercised,when,taking 1.0 0.000143348623853 0 1 -1
exercised,when,prescribing 1.0 0.000143348623853 0 1 -1
exercised,when,known 1.0 0.000143348623853 0 1 -1
exercised,when,hydrochloride 1.0 0.000143348623853 0 1 -1
exercised,when,combining 1.0 0.000143348623853 0 1 -1
exercised,in,using 1.0 0.000143348623853 0 1 -1
exercised,in,patients 1.0 0.000143348623853 0 1 -1
exercised,in,extrapolating 1.0 0.000143348623853 0 1 -1
exercised,if,leustatin 1.0 0.000143348623853 0 1 -1
exercised,because,unexpected 1.0 0.000143348623853 0 1 -1
exercised,and,dose 1.0 0.000143348623853 0 1 -1
exercise,that,produces 1.0 0.000143348623853 0 1 -1
exercise,testing,a 1.0 0.000143348623853 0 1 -1
exemestane,is,extensively 1.0 0.000143348623853 0 1 -1
excystment,rates,over 1.0 0.000143348623853 0 1 -1
excystment,rates,of 1.0 0.000143348623853 0 1 -1
excystment,of,parorchis 1.0 0.000143348623853 0 1 -1
excystment,in,vitro 1.0 0.000143348623853 0 1 -1
excretion,was,enhanced 1.0 0.000143348623853 0 1 -1
excretion,was,due 1.0 0.000143348623853 0 1 -1
excretion,was,decreased 1.0 0.000143348623853 0 1 -1
excretion,too,was 1.0 0.000143348623853 0 1 -1
excretion,of,unchanged 1.0 0.000286697247706 0 2 -2
excretion,of,thioethers 1.0 0.000143348623853 0 1 -1
excretion,of,the 1.0 0.000143348623853 0 1 -1
excretion,of,meclofenamate 1.0 0.000143348623853 0 1 -1
excretion,of,immunoreactive 1.0 0.000143348623853 0 1 -1
excretion,is,via 1.0 0.000143348623853 0 1 -1
excretion,is,observed 1.0 0.000143348623853 0 1 -1
excretion,ibuprofen,ibuprofen 1.0 0.000143348623853 0 1 -1
excretion,glucuronidation,and 1.0 0.000143348623853 0 1 -1
excretion,as,well 1.0 0.000143348623853 0 1 -1
excretion,and,renin 1.0 0.000143348623853 0 1 -1
excretion,and,renal 1.0 0.000143348623853 0 1 -1
excretion,a,study 1.0 0.000143348623853 0 1 -1
excreted,via,the 1.0 0.000143348623853 0 1 -1
excreted,unchanged,in 1.0 0.000143348623853 0 1 -1
excreted,slowly,from 1.0 0.000143348623853 0 1 -1
excreted,levels,of 1.0 0.000143348623853 0 1 -1
excreted,in,order 1.0 0.000143348623853 0 1 -1
excreted,in,human 1.0 0.000286697247706 0 2 -2
excreted,by,the 1.0 0.000143348623853 0 1 -1
exclusively,by,the 1.0 0.000143348623853 0 1 -1
excluded,patients,with 1.0 0.000286697247706 0 2 -2
excluded,from,clinical 1.0 0.000143348623853 0 1 -1
excluded,based,on 1.0 0.000143348623853 0 1 -1
excitement,hypomania,restlessness 1.0 0.000143348623853 0 1 -1
excitement,depression,hallucinations 1.0 0.000143348623853 0 1 -1
exchange,it,may 1.0 0.000143348623853 0 1 -1
excessively,to,as 1.0 0.000143348623853 0 1 -1
excessive,release,in 1.0 0.000143348623853 0 1 -1
excessive,release,but 1.0 0.000143348623853 0 1 -1
excessive,perspiration,weight 1.0 0.000143348623853 0 1 -1
excessive,ingestion,should 1.0 0.000143348623853 0 1 -1
excessive,increase,in 1.0 0.000143348623853 0 1 -1
excessive,fecal,loss 1.0 0.000143348623853 0 1 -1
excessive,concurrent,use 1.0 0.000143348623853 0 1 -1
excessive,bradycardia,vertigo 1.0 0.000143348623853 0 1 -1
excess,of,plasma 1.0 0.000143348623853 0 1 -1
exception,of,there 1.0 0.000143348623853 0 1 -1
exception,of,ssri-associated 1.0 0.000143348623853 0 1 -1
exception,of,cyp2c19 1.0 0.000143348623853 0 1 -1
except,with,the 1.0 0.000143348623853 0 1 -1
except,in,life-threatening 1.0 0.000143348623853 0 1 -1
except,for,three 1.0 0.000143348623853 0 1 -1
except,for,patients 1.0 0.000143348623853 0 1 -1
except,for,increased 1.0 0.000143348623853 0 1 -1
except,for,clindamycin-sensitive 1.0 0.000143348623853 0 1 -1
except,for,an 1.0 0.000143348623853 0 1 -1
except,at,concentrations 1.0 0.000143348623853 0 1 -1
exceeded,of,the 1.0 0.000143348623853 0 1 -1
exceed,micrograms,g 1.0 0.000143348623853 0 1 -1
examples,of,this 1.0 0.000286697247706 0 2 -2
examples,of,substances 1.0 0.000573394495413 0 4 -4
examples,of,drugs 1.0 0.000286697247706 0 2 -2
examples,include,the 1.0 0.000143348623853 0 1 -1
example,the,plasma 1.0 0.000143348623853 0 1 -1
example,sparing,pharmacological 1.0 0.000143348623853 0 1 -1
example,may,activate 1.0 0.000143348623853 0 1 -1
example,inhibitors,include 1.0 0.000143348623853 0 1 -1
example,complications,of 1.0 0.000143348623853 0 1 -1
examining,the,addition 1.0 0.000143348623853 0 1 -1
examining,potential,interactions 1.0 0.000143348623853 0 1 -1
examines,the,effects 1.0 0.000143348623853 0 1 -1
examined,whether,meth 1.0 0.000143348623853 0 1 -1
examined,the,interactions 1.0 0.000143348623853 0 1 -1
examined,the,effect 1.0 0.000286697247706 0 2 -2
examine,the,interaction 1.0 0.000143348623853 0 1 -1
examine,the,insp 1.0 0.000143348623853 0 1 -1
examine,the,effects 1.0 0.000286697247706 0 2 -2
examine,some,molecular 1.0 0.000143348623853 0 1 -1
examine,interactions,have 1.0 0.000143348623853 0 1 -1
examinations,for,insurances 1.0 0.000143348623853 0 1 -1
exaggerated,leukopenia,especially 1.0 0.000143348623853 0 1 -1
exaggerate,the,degree 1.0 0.000143348623853 0 1 -1
exact,place,of 1.0 0.000143348623853 0 1 -1
exact,length,of 1.0 0.000143348623853 0 1 -1
exacerbation,of,tachyarrhythmias 1.0 0.000143348623853 0 1 -1
exacerbated,in,patients 1.0 0.000143348623853 0 1 -1
ex,vivo,platelet 1.0 0.000143348623853 0 1 -1
evoked,potentials,were 1.0 0.000286697247706 0 2 -2
evoked,potentials,in 1.0 0.000143348623853 0 1 -1
evoked,potential,components 1.0 0.000286697247706 0 2 -2
evoked,hind,limb 1.0 0.000143348623853 0 1 -1
evidently,a,later 1.0 0.000143348623853 0 1 -1
evident,on,excystment 1.0 0.000143348623853 0 1 -1
evident,in,females 1.0 0.000143348623853 0 1 -1
evident,in,female 1.0 0.000143348623853 0 1 -1
evident,following,a 1.0 0.000143348623853 0 1 -1
evident,by,the 1.0 0.000143348623853 0 1 -1
evidenced,by,the 1.0 0.000143348623853 0 1 -1
evidence,was,obtained 1.0 0.000143348623853 0 1 -1
evidence,to,suggest 1.0 0.000143348623853 0 1 -1
evidence,to,date 1.0 0.000143348623853 0 1 -1
evidence,that,the 1.0 0.000286697247706 0 2 -2
evidence,that,resistance 1.0 0.000143348623853 0 1 -1
evidence,that,intensive 1.0 0.000143348623853 0 1 -1
evidence,that,increased 1.0 0.000143348623853 0 1 -1
evidence,that,epa 1.0 0.000143348623853 0 1 -1
evidence,that,and 1.0 0.000143348623853 0 1 -1
evidence,suggesting,that 1.0 0.000143348623853 0 1 -1
evidence,suggest,that 1.0 0.000143348623853 0 1 -1
evidence,on,either 1.0 0.000143348623853 0 1 -1
evidence,of,ovulation 1.0 0.000143348623853 0 1 -1
evidence,of,neurological 1.0 0.000143348623853 0 1 -1
evidence,of,mutagenicity 1.0 0.000143348623853 0 1 -1
evidence,of,interactions 1.0 0.000286697247706 0 2 -2
evidence,of,interaction 1.0 0.000286697247706 0 2 -2
evidence,of,induction 1.0 0.000143348623853 0 1 -1
evidence,of,increased 1.0 0.000143348623853 0 1 -1
evidence,of,incompatibility 1.0 0.000286697247706 0 2 -2
evidence,of,impaired 1.0 0.000143348623853 0 1 -1
evidence,of,hypothyroidism 1.0 0.000143348623853 0 1 -1
evidence,of,hypotension 1.0 0.000573394495413 0 4 -4
evidence,of,glucose 1.0 0.000143348623853 0 1 -1
evidence,of,fetal 1.0 0.000143348623853 0 1 -1
evidence,of,cytochrome 1.0 0.000143348623853 0 1 -1
evidence,of,clinically 1.0 0.000860091743119 0 6 -6
evidence,of,circulating 1.0 0.000143348623853 0 1 -1
evidence,of,any 1.0 0.000143348623853 0 1 -1
evidence,of,an 1.0 0.000286697247706 0 2 -2
evidence,of,allergic 1.0 0.000143348623853 0 1 -1
evidence,of,a 1.0 0.000286697247706 0 2 -2
evidence,indicating,that 1.0 0.000143348623853 0 1 -1
evidence,in,the 1.0 0.000143348623853 0 1 -1
evidence,in,clinical 1.0 0.000143348623853 0 1 -1
evidence,in,animal 1.0 0.000143348623853 0 1 -1
evidence,for,reduction 1.0 0.000143348623853 0 1 -1
evidence,for,longitudinal 1.0 0.000143348623853 0 1 -1
evidence,for,a 1.0 0.000143348623853 0 1 -1
every,weeks,were 1.0 0.000143348623853 0 1 -1
every,other,week 1.0 0.000143348623853 0 1 -1
every,other,day 1.0 0.00043004587156 0 3 -3
every,mac,with 1.0 0.000143348623853 0 1 -1
every,hours,two 1.0 0.000143348623853 0 1 -1
every,hours,or 1.0 0.000286697247706 0 2 -2
every,hours,for 1.0 0.000286697247706 0 2 -2
everolimus,steady,state 1.0 0.000143348623853 0 1 -1
everolimus,exposure-response,relationships 1.0 0.000143348623853 0 1 -1
everolimus,exhibited,dose-proportional 1.0 0.000143348623853 0 1 -1
everolimus,dose-proportionality,and 1.0 0.000143348623853 0 1 -1
events,with,nnrtis 1.0 0.000143348623853 0 1 -1
events,when,was 1.0 0.000143348623853 0 1 -1
events,when,baraclude 1.0 0.000143348623853 0 1 -1
events,were,reported 1.0 0.000143348623853 0 1 -1
events,were,also 1.0 0.000143348623853 0 1 -1
events,was,similar 1.0 0.000143348623853 0 1 -1
events,such,as 1.0 0.000286697247706 0 2 -2
events,should,be 1.0 0.000143348623853 0 1 -1
events,required,medical 1.0 0.000143348623853 0 1 -1
events,reported,significantly 1.0 0.000143348623853 0 1 -1
events,or,qtc 1.0 0.000143348623853 0 1 -1
events,or,loss 1.0 0.000143348623853 0 1 -1
events,or,hits 1.0 0.000143348623853 0 1 -1
events,occurred,with 1.0 0.000143348623853 0 1 -1
events,is,unknown 1.0 0.000143348623853 0 1 -1
events,involving,levo-dromoran 1.0 0.000143348623853 0 1 -1
events,including,gastrointestinal 1.0 0.000143348623853 0 1 -1
events,including,electrocardiographic 1.0 0.000143348623853 0 1 -1
events,in,subjects 1.0 0.000143348623853 0 1 -1
events,in,patients 1.0 0.000286697247706 0 2 -2
events,and,therapeutic 1.0 0.000143348623853 0 1 -1
events,and,the 1.0 0.000143348623853 0 1 -1
event,profile,between 1.0 0.000143348623853 0 1 -1
event,of,relevant 1.0 0.000143348623853 0 1 -1
event,in,the 1.0 0.000143348623853 0 1 -1
evening,should,not 1.0 0.000143348623853 0 1 -1
evening,meal,would 1.0 0.000143348623853 0 1 -1
evening,meal,or 1.0 0.000143348623853 0 1 -1
even,when,tested 1.0 0.000143348623853 0 1 -1
even,when,parenteral 1.0 0.000143348623853 0 1 -1
even,when,grown 1.0 0.000143348623853 0 1 -1
even,when,co-administered 1.0 0.000143348623853 0 1 -1
even,though,such 1.0 0.000286697247706 0 2 -2
even,though,has 1.0 0.000286697247706 0 2 -2
even,if,the 1.0 0.000143348623853 0 1 -1
even,if,an 1.0 0.000143348623853 0 1 -1
even,decrease,the 1.0 0.000143348623853 0 1 -1
even,death,have 1.0 0.000143348623853 0 1 -1
even,after,was 1.0 0.000143348623853 0 1 -1
evaluation,of,the 1.0 0.000143348623853 0 1 -1
evaluation,of,prothrombin 1.0 0.000143348623853 0 1 -1
evaluation,of,its 1.0 0.000286697247706 0 2 -2
evaluation,of,individual 1.0 0.000143348623853 0 1 -1
evaluation,of,extraneals 1.0 0.000143348623853 0 1 -1
evaluation,and,laboratory 1.0 0.000143348623853 0 1 -1
evaluating,the,use 1.0 0.000143348623853 0 1 -1
evaluating,the,serum 1.0 0.000143348623853 0 1 -1
evaluating,the,potential 1.0 0.000143348623853 0 1 -1
evaluating,the,minimum 1.0 0.000143348623853 0 1 -1
evaluating,the,interaction 1.0 0.000143348623853 0 1 -1
evaluating,the,antidiarrheal 1.0 0.000143348623853 0 1 -1
evaluating,serum,levels 1.0 0.000143348623853 0 1 -1
evaluating,plasma,renin 1.0 0.000143348623853 0 1 -1
evaluated,using,comparisons 1.0 0.000143348623853 0 1 -1
evaluated,to,determine 1.0 0.000143348623853 0 1 -1
evaluated,these,were 1.0 0.000143348623853 0 1 -1
evaluated,the,interference 1.0 0.000143348623853 0 1 -1
evaluated,the,effect 1.0 0.000143348623853 0 1 -1
evaluated,in,vitro 1.0 0.000143348623853 0 1 -1
evaluated,in,preclinical 1.0 0.000143348623853 0 1 -1
evaluated,in,men 1.0 0.000143348623853 0 1 -1
evaluated,in,in 1.0 0.000143348623853 0 1 -1
evaluated,in,human 1.0 0.000143348623853 0 1 -1
evaluated,in,healthy 1.0 0.00043004587156 0 3 -3
evaluated,in,combination 1.0 0.000143348623853 0 1 -1
evaluated,in,an 1.0 0.000143348623853 0 1 -1
evaluated,in,a 1.0 0.000286697247706 0 2 -2
evaluated,cyps,a1 1.0 0.000143348623853 0 1 -1
evaluated,cyp1a2,cyp2a6 1.0 0.000143348623853 0 1 -1
evaluated,by,using 1.0 0.000143348623853 0 1 -1
evaluated,as,a 1.0 0.000143348623853 0 1 -1
evaluated,and,patients 1.0 0.000143348623853 0 1 -1
evaluated,and,compared 1.0 0.000143348623853 0 1 -1
evaluate,the,pharmacokinetic 1.0 0.000143348623853 0 1 -1
evaluate,the,interactions 1.0 0.000143348623853 0 1 -1
evaluate,the,impact 1.0 0.000143348623853 0 1 -1
evaluate,the,effect 1.0 0.00043004587156 0 3 -3
evaluate,the,antianginal 1.0 0.000143348623853 0 1 -1
evaluate,possible,interactions 1.0 0.000143348623853 0 1 -1
evaluate,interactions,with 1.0 0.000143348623853 0 1 -1
european,and,north 1.0 0.000143348623853 0 1 -1
euphoria,excitement,depression 1.0 0.000143348623853 0 1 -1
etodolac,is,highly 1.0 0.000143348623853 0 1 -1
etodolac,is,characterised 1.0 0.000143348623853 0 1 -1
etodolac,has,no 1.0 0.00043004587156 0 3 -3
ethynyl,and,to 1.0 0.000143348623853 0 1 -1
ethyl,is,known 1.0 0.000143348623853 0 1 -1
ethoxycoumarine,deethylase,in 1.0 0.000143348623853 0 1 -1
ethinyl,estradiol,were 1.0 0.000143348623853 0 1 -1
ethinyl,estradiol,the 1.0 0.000143348623853 0 1 -1
ethinyl,estradiol,substrate 1.0 0.000143348623853 0 1 -1
ethinyl,estradiol,mg 1.0 0.000143348623853 0 1 -1
ethinyl,estradiol,following 1.0 0.000143348623853 0 1 -1
ethinyl,estradiol,concentrations 1.0 0.000143348623853 0 1 -1
ethanol-drug,reaction,is 1.0 0.000143348623853 0 1 -1
ethanol,or,triazolam 1.0 0.000143348623853 0 1 -1
ethanol,depressed,the 1.0 0.000143348623853 0 1 -1
ethacrynic,acid,and 1.0 0.000143348623853 0 1 -1
etc,should,be 1.0 0.000143348623853 0 1 -1
etc,and,the 1.0 0.000143348623853 0 1 -1
eszopiclone,mg,administered 1.0 0.000143348623853 0 1 -1
eszopiclone,is,not 1.0 0.000143348623853 0 1 -1
estrogens,tend,to 1.0 0.000143348623853 0 1 -1
estrogenic,component,in 1.0 0.000143348623853 0 1 -1
estrogen-containing,oral,increase 1.0 0.000143348623853 0 1 -1
estrogen,oral,contraceptives 1.0 0.000143348623853 0 1 -1
estrogen,increased,levels 1.0 0.000143348623853 0 1 -1
estradiol,were,similar 1.0 0.000143348623853 0 1 -1
estradiol,the,estrogenic 1.0 0.000143348623853 0 1 -1
estradiol,substrate,of 1.0 0.000143348623853 0 1 -1
estradiol,mg,mcg 1.0 0.000143348623853 0 1 -1
estradiol,following,administration 1.0 0.000143348623853 0 1 -1
estradiol,concentrations,and 1.0 0.000143348623853 0 1 -1
estradiol,and,levels 1.0 0.000143348623853 0 1 -1
estimation,of,tolerance 1.0 0.000143348623853 0 1 -1
estimates,of,the 1.0 0.000716743119266 0 5 -5
estimates,of,steady-state 1.0 0.000143348623853 0 1 -1
estimated,number,of 1.0 0.000143348623853 0 1 -1
estimated,as,of 1.0 0.000143348623853 0 1 -1
esters,on,glucocorticoid-induced 1.0 0.000143348623853 0 1 -1
ester,fractional,clearance 1.0 0.000143348623853 0 1 -1
estazolam,interaction,with 1.0 0.000286697247706 0 2 -2
establishing,the,dose 1.0 0.000143348623853 0 1 -1
established,that,both 1.0 0.000143348623853 0 1 -1
established,on,an 1.0 0.000143348623853 0 1 -1
established,interactions,there 1.0 0.000143348623853 0 1 -1
established,in,experiments 1.0 0.000143348623853 0 1 -1
established,if,there 1.0 0.000143348623853 0 1 -1
established,drug,interactions 1.0 0.000143348623853 0 1 -1
established,but,should 1.0 0.000143348623853 0 1 -1
established,but,an 1.0 0.000286697247706 0 2 -2
established,and,other 1.0 0.000143348623853 0 1 -1
established,and,discontinuation 1.0 0.000143348623853 0 1 -1
establish,whether,the 1.0 0.000143348623853 0 1 -1
establish,strategies,to 1.0 0.000143348623853 0 1 -1
establish,corrective,measures 1.0 0.000143348623853 0 1 -1
essentially,no,effect 1.0 0.000143348623853 0 1 -1
essentially,completely,metabolised 1.0 0.000143348623853 0 1 -1
essentially,completely,absorbed 1.0 0.000143348623853 0 1 -1
essential,to,the 1.0 0.000143348623853 0 1 -1
essential,to,ascertain 1.0 0.000143348623853 0 1 -1
essential,tissue,culture 1.0 0.000143348623853 0 1 -1
essential,the,possibility 1.0 0.000143348623853 0 1 -1
essential,conduct,close 1.0 0.000143348623853 0 1 -1
essential,close,monitoring 1.0 0.000143348623853 0 1 -1
especially,with,respect 1.0 0.000143348623853 0 1 -1
especially,with,repeated 1.0 0.000143348623853 0 1 -1
especially,true,in 1.0 0.000143348623853 0 1 -1
especially,so,for 1.0 0.000143348623853 0 1 -1
especially,resistant,to 1.0 0.000143348623853 0 1 -1
especially,patients,with 1.0 0.000143348623853 0 1 -1
especially,or,preanesthetic 1.0 0.000143348623853 0 1 -1
especially,of,amphotericin 1.0 0.000143348623853 0 1 -1
especially,neglect,of 1.0 0.000143348623853 0 1 -1
especially,in,renal 1.0 0.000143348623853 0 1 -1
especially,important,in 1.0 0.000286697247706 0 2 -2
especially,important,for 1.0 0.000143348623853 0 1 -1
especially,if,these 1.0 0.000143348623853 0 1 -1
especially,if,higher 1.0 0.000143348623853 0 1 -1
especially,hematologic,and 1.0 0.000143348623853 0 1 -1
especially,conduction,disturbances 1.0 0.000143348623853 0 1 -1
especially,central,nervous 1.0 0.000143348623853 0 1 -1
especially,at,arterial 1.0 0.000143348623853 0 1 -1
especially,and,have 1.0 0.000143348623853 0 1 -1
esophageal,motility,dysfunction 1.0 0.000143348623853 0 1 -1
esomeprazole,may,potentially 1.0 0.000143348623853 0 1 -1
esomeprazole,is,extensively 1.0 0.000143348623853 0 1 -1
esomeprazole,inhibits,gastric 1.0 0.000143348623853 0 1 -1
esmolol,hcl,and 1.0 0.000143348623853 0 1 -1
escherichia,coli,in 1.0 0.000286697247706 0 2 -2
escherichia,coli,and 1.0 0.000143348623853 0 1 -1
escalating,use,of 1.0 0.000143348623853 0 1 -1
escalating,doses,up 1.0 0.000143348623853 0 1 -1
escalating,doses,from 1.0 0.000143348623853 0 1 -1
escalate,the,dose 1.0 0.000143348623853 0 1 -1
erythromycin,on,felbatol 1.0 0.000143348623853 0 1 -1
erythromycin,co-administration,of 1.0 0.000143348623853 0 1 -1
erythromycin,clarithromycin,telithromycin 1.0 0.000143348623853 0 1 -1
erythromycin,azole,antifungals 1.0 0.000143348623853 0 1 -1
erythromycin,and,ketoconazole 1.0 0.000143348623853 0 1 -1
erythrocytes,in,vivo 1.0 0.000143348623853 0 1 -1
erythro-fluorocitrate,synthesis,or 1.0 0.000143348623853 0 1 -1
erythro-fluorocitrate,synthesis,in 1.0 0.000143348623853 0 1 -1
erythro-fluorocitrate,synthesis,and 1.0 0.000143348623853 0 1 -1
erythema,tenderness,skin 1.0 0.000143348623853 0 1 -1
erythema,pruritus,and 1.0 0.000143348623853 0 1 -1
error,structures,and 1.0 0.000143348623853 0 1 -1
erroneous,and,cannot 1.0 0.000143348623853 0 1 -1
ermbt,and,and 1.0 0.000143348623853 0 1 -1
ermbt,after,weeks 1.0 0.000143348623853 0 1 -1
ergotamine,or,acute 1.0 0.000143348623853 0 1 -1
ergot-containing,have,been 1.0 0.000286697247706 0 2 -2
ergot-containing,drugs,these 1.0 0.000143348623853 0 1 -1
ergot,toxicity,characterized 1.0 0.000143348623853 0 1 -1
ergot,derivatives,dihydroergotamine 1.0 0.000143348623853 0 1 -1
ergosterol,the,major 1.0 0.000143348623853 0 1 -1
ergocalcitriol,will,be 1.0 0.00043004587156 0 3 -3
erection-supporting,medication,patients 1.0 0.000143348623853 0 1 -1
erection,disorders,in 1.0 0.000143348623853 0 1 -1
erection,disorder,attention 1.0 0.000143348623853 0 1 -1
erectile,dysfunction,is 1.0 0.000143348623853 0 1 -1
erectile,dysfunction,associated 1.0 0.000143348623853 0 1 -1
erbitux,was,administered 1.0 0.000143348623853 0 1 -1
er,extended,release 1.0 0.000143348623853 0 1 -1
equivalent,volume,of 1.0 0.000143348623853 0 1 -1
equivalent,to,to 1.0 0.000143348623853 0 1 -1
equivalent,to,approximately 1.0 0.000143348623853 0 1 -1
equivalent,in,their 1.0 0.000143348623853 0 1 -1
equivalent,amount,of 1.0 0.000143348623853 0 1 -1
equipotent,inducers,of 1.0 0.000143348623853 0 1 -1
equipment,for,measurement 1.0 0.000143348623853 0 1 -1
equilibrium,and,the 1.0 0.000143348623853 0 1 -1
equilibration,of,between 1.0 0.000143348623853 0 1 -1
equetrotm,to,a 1.0 0.000143348623853 0 1 -1
equetrotm,may,reduce 1.0 0.000143348623853 0 1 -1
equal,to,the 1.0 0.000143348623853 0 1 -1
equal,to,micrograms 1.0 0.000143348623853 0 1 -1
equal,groups,and 1.0 0.000143348623853 0 1 -1
equal,concentrations,of 1.0 0.000143348623853 0 1 -1
epsilon,and,mu 1.0 0.000143348623853 0 1 -1
eprosartan,up,to 1.0 0.000143348623853 0 1 -1
eprosartan,has,been 1.0 0.000143348623853 0 1 -1
eprosartan,doses,of 1.0 0.000143348623853 0 1 -1
epoxide,which,is 1.0 0.000143348623853 0 1 -1
epoxide,steady-state,cmin 1.0 0.000143348623853 0 1 -1
epoxide,reductase,resulting 1.0 0.000143348623853 0 1 -1
epoxide,metabolite,in 1.0 0.000143348623853 0 1 -1
epoxide,hydrolase,or 1.0 0.000143348623853 0 1 -1
epoxide,hydrolase,inhibitors 1.0 0.000143348623853 0 1 -1
epoxide,hydrolase,carbamazepine 1.0 0.000143348623853 0 1 -1
epoxide,concentrations,were 1.0 0.000143348623853 0 1 -1
epithelium,proliferates,in 1.0 0.000143348623853 0 1 -1
episodes,permit,reductions 1.0 0.000143348623853 0 1 -1
episodes,of,concomitant 1.0 0.000143348623853 0 1 -1
episodes,and,induced 1.0 0.000143348623853 0 1 -1
episode,of,migraine 1.0 0.000143348623853 0 1 -1
episode,despite,seemingly 1.0 0.000143348623853 0 1 -1
epirubicin-containing,cef-120,or 1.0 0.000143348623853 0 1 -1
epirubicin-based,chemotherapy,concomitantly 1.0 0.000143348623853 0 1 -1
epirubicin,is,extensively 1.0 0.000143348623853 0 1 -1
epinephrine,should,be 1.0 0.000143348623853 0 1 -1
epileptic,patients,who 1.0 0.000143348623853 0 1 -1
epileptic,patients,n 1.0 0.000143348623853 0 1 -1
epilepsy,ingesting,the 1.0 0.00043004587156 0 3 -3
epilepsy,also,receiving 1.0 0.000143348623853 0 1 -1
epigallocatechin-3,o-gallate,and 1.0 0.000143348623853 0 1 -1
epididymides,had,not 1.0 0.000143348623853 0 1 -1
epidermal,necrolysis,has 1.0 0.000143348623853 0 1 -1
epidemics,of,arsenical 1.0 0.000143348623853 0 1 -1
epidemic,proportions,in 1.0 0.000143348623853 0 1 -1
ephesus,patients,receiving 1.0 0.000143348623853 0 1 -1
epa,supplements,should 1.0 0.000143348623853 0 1 -1
epa,supplements,on 1.0 0.000143348623853 0 1 -1
epa,supplements,might 1.0 0.000143348623853 0 1 -1
epa,supplements,have 1.0 0.000143348623853 0 1 -1
epa,dose,should 1.0 0.000143348623853 0 1 -1
enzymes,would,therefore 1.0 0.000143348623853 0 1 -1
enzymes,would,not 1.0 0.000143348623853 0 1 -1
enzymes,were,investigated 1.0 0.000143348623853 0 1 -1
enzymes,showed,that 1.0 0.000143348623853 0 1 -1
enzymes,responsible,for 1.0 0.000286697247706 0 2 -2
enzymes,primarily,cyp3a4 1.0 0.000143348623853 0 1 -1
enzymes,or,the 1.0 0.000143348623853 0 1 -1
enzymes,or,other 1.0 0.000143348623853 0 1 -1
enzymes,may,not 1.0 0.000143348623853 0 1 -1
enzymes,may,decrease 1.0 0.000143348623853 0 1 -1
enzymes,may,change 1.0 0.000143348623853 0 1 -1
enzymes,lapatinib,undergoes 1.0 0.000143348623853 0 1 -1
enzymes,is,an 1.0 0.000143348623853 0 1 -1
enzymes,involved,in 1.0 0.000143348623853 0 1 -1
enzymes,interactions,with 1.0 0.000143348623853 0 1 -1
enzymes,inducers,or 1.0 0.000143348623853 0 1 -1
enzymes,including,cyp1a2 1.0 0.000143348623853 0 1 -1
enzymes,in,vitro 1.0 0.000143348623853 0 1 -1
enzymes,in,human 1.0 0.000143348623853 0 1 -1
enzymes,i,and 1.0 0.000143348623853 0 1 -1
enzymes,have,been 1.0 0.000143348623853 0 1 -1
enzymes,evaluated,cyp1a2 1.0 0.000143348623853 0 1 -1
enzymes,d6,c9 1.0 0.000143348623853 0 1 -1
enzymes,d6,a4 1.0 0.000143348623853 0 1 -1
enzymes,cyp1a2,cyp2a6 1.0 0.000143348623853 0 1 -1
enzymes,carbamazepine,is 1.0 0.000143348623853 0 1 -1
enzymes,capable,of 1.0 0.000143348623853 0 1 -1
enzymes,are,expected 1.0 0.000143348623853 0 1 -1
enzymes,and,the 1.0 0.000143348623853 0 1 -1
enzymes,and,is 1.0 0.000143348623853 0 1 -1
enzymes,and,drug 1.0 0.000143348623853 0 1 -1
enzymes,a2,a6 1.0 0.000143348623853 0 1 -1
enzyme-based,tests,such 1.0 0.000143348623853 0 1 -1
enzyme-based,tests,for 1.0 0.000143348623853 0 1 -1
enzyme,would,not 1.0 0.000143348623853 0 1 -1
enzyme,that,appears 1.0 0.000143348623853 0 1 -1
enzyme,systems,responsible 1.0 0.000143348623853 0 1 -1
enzyme,systems,may 1.0 0.000143348623853 0 1 -1
enzyme,systems,inhibition 1.0 0.000143348623853 0 1 -1
enzyme,system,probably 1.0 0.000143348623853 0 1 -1
enzyme,system,may 1.0 0.00043004587156 0 3 -3
enzyme,system,leading 1.0 0.000286697247706 0 2 -2
enzyme,system,is 1.0 0.000143348623853 0 1 -1
enzyme,supplements,oral 1.0 0.000143348623853 0 1 -1
enzyme,prolongs,and 1.0 0.000143348623853 0 1 -1
enzyme,oxidation,system 1.0 0.000143348623853 0 1 -1
enzyme,may,not 1.0 0.000143348623853 0 1 -1
enzyme,involved,in 1.0 0.000143348623853 0 1 -1
enzyme,inhibitors,without 1.0 0.000143348623853 0 1 -1
enzyme,inhibitors,intravenous 1.0 0.000143348623853 0 1 -1
enzyme,inhibitors,concomitantly 1.0 0.000143348623853 0 1 -1
enzyme,induction,potential 1.0 0.000286697247706 0 2 -2
enzyme,inducers,iodinated 1.0 0.000143348623853 0 1 -1
enzyme,inducer,although 1.0 0.000143348623853 0 1 -1
enzyme,in,the 1.0 0.000143348623853 0 1 -1
enzyme,group,specifically 1.0 0.000143348623853 0 1 -1
enzyme,function,may 1.0 0.000143348623853 0 1 -1
enzyme,based,tests 1.0 0.000143348623853 0 1 -1
enzyme,activities,and 1.0 0.000143348623853 0 1 -1
enzyme,ace,inhibitors 1.0 0.000286697247706 0 2 -2
enzyme,a4,as 1.0 0.000143348623853 0 1 -1
enzymatic-based,assays,resulting 1.0 0.000143348623853 0 1 -1
enzymatic,glucose,oxidase 1.0 0.000860091743119 0 6 -6
envisaged,in,intensive 1.0 0.000143348623853 0 1 -1
environment,and,seem 1.0 0.000143348623853 0 1 -1
enuresis,urinary,retention 1.0 0.000143348623853 0 1 -1
enterohepatic,elimination,of 1.0 0.000143348623853 0 1 -1
enterococcus,three,strains 1.0 0.000143348623853 0 1 -1
enterococcus,faecium,to 1.0 0.000143348623853 0 1 -1
enterococcus,faecalis,by 1.0 0.000143348623853 0 1 -1
enterococcus,faecalis,and 1.0 0.000143348623853 0 1 -1
enterococci,were,lowered 1.0 0.000143348623853 0 1 -1
enterococci,vre,is 1.0 0.000143348623853 0 1 -1
enterococci,highlights,novel 1.0 0.000143348623853 0 1 -1
enterobacteriaceae,and,pseudomonas 1.0 0.000143348623853 0 1 -1
enteric,coating,that 1.0 0.000143348623853 0 1 -1
enteric,coating,may 1.0 0.000143348623853 0 1 -1
enteric,coated,plus 1.0 0.000143348623853 0 1 -1
enter,the,csf 1.0 0.000143348623853 0 1 -1
entacapone,is,highly 1.0 0.000143348623853 0 1 -1
ensure,that,their 1.0 0.000143348623853 0 1 -1
enrolled,in,two 1.0 0.000143348623853 0 1 -1
enrolled,in,the 1.0 0.000143348623853 0 1 -1
enrolled,in,a 1.0 0.000143348623853 0 1 -1
enroll,patients,currently 1.0 0.000143348623853 0 1 -1
enoxaparin,dosed,as 1.0 0.000143348623853 0 1 -1
enoxacin,does,not 1.0 0.000143348623853 0 1 -1
enough,to,affect 1.0 0.000143348623853 0 1 -1
enlargement,buffalo,hump 1.0 0.000143348623853 0 1 -1
enlargement,and,cushingoid 1.0 0.000143348623853 0 1 -1
enhancing,the,rate 1.0 0.000143348623853 0 1 -1
enhancing,selective,tumor 1.0 0.000143348623853 0 1 -1
enhancing,heparin,effect 1.0 0.000143348623853 0 1 -1
enhancing,efficacious,effects 1.0 0.000143348623853 0 1 -1
enhancing,effects,of 1.0 0.000143348623853 0 1 -1
enhances,the,effects 1.0 0.000143348623853 0 1 -1
enhancement,of,intestinal 1.0 0.000143348623853 0 1 -1
enhancement,of,growth 1.0 0.000143348623853 0 1 -1
enhanced,when,it 1.0 0.000143348623853 0 1 -1
enhanced,the,translocating 1.0 0.000143348623853 0 1 -1
enhanced,the,activity 1.0 0.000143348623853 0 1 -1
enhanced,secretion,of 1.0 0.000143348623853 0 1 -1
enhanced,possibility,of 1.0 0.000143348623853 0 1 -1
enhanced,or,prolonged 1.0 0.000143348623853 0 1 -1
enhanced,learning,and 1.0 0.000143348623853 0 1 -1
enhanced,drug,effect 1.0 0.000143348623853 0 1 -1
enhanced,by,known 1.0 0.000143348623853 0 1 -1
enhanced,by,general 1.0 0.000143348623853 0 1 -1
enhanced,absorption,or 1.0 0.000143348623853 0 1 -1
enhance,toxicity,and 1.0 0.000143348623853 0 1 -1
enhance,the,risk 1.0 0.00043004587156 0 3 -3
enhance,the,psychostimulant 1.0 0.000143348623853 0 1 -1
enhance,the,occurrence 1.0 0.000143348623853 0 1 -1
enhance,the,locomotor 1.0 0.000143348623853 0 1 -1
enhance,s,nephrotoxicity 1.0 0.000143348623853 0 1 -1
enhance,cardiovascular,depression 1.0 0.000143348623853 0 1 -1
engaging,in,hazardous 1.0 0.000143348623853 0 1 -1
enflurane,than,when 1.0 0.000143348623853 0 1 -1
endotoxin-treated,rats,did 1.0 0.000143348623853 0 1 -1
endotoxin-induced,changes,in 1.0 0.000143348623853 0 1 -1
endothelium,were,used 1.0 0.000143348623853 0 1 -1
endothelial,function,is 1.0 0.000143348623853 0 1 -1
endothelial,dysfunction,as 1.0 0.000143348623853 0 1 -1
endothelial,dysfunction,and 1.0 0.000143348623853 0 1 -1
endothelial,denudation,indicating 1.0 0.000143348623853 0 1 -1
endoscopy,study,conducted 1.0 0.000143348623853 0 1 -1
endoscopic,gastroduodenal,ulcers 1.0 0.000143348623853 0 1 -1
endorphinergic,system,is 1.0 0.000143348623853 0 1 -1
endorphinergic,system,by 1.0 0.000143348623853 0 1 -1
endometrium,and,the 1.0 0.000143348623853 0 1 -1
endometrial,ovarian,cervical 1.0 0.000143348623853 0 1 -1
endogenous,vitamin,d 1.0 0.00043004587156 0 3 -3
endogenous,secretion,was 1.0 0.000143348623853 0 1 -1
endogenous,respiration,was 1.0 0.000143348623853 0 1 -1
endogenous,and,vasopressin 1.0 0.000143348623853 0 1 -1
endocrine,status,of 1.0 0.000143348623853 0 1 -1
endocrine,function,hmg-coa 1.0 0.000143348623853 0 1 -1
endocrine,feedback,alterations 1.0 0.000143348623853 0 1 -1
endocrine,and,liver 1.0 0.000286697247706 0 2 -2
endemic,primate,gammaherpes 1.0 0.000143348623853 0 1 -1
end,fo,the 1.0 0.000143348623853 0 1 -1
encystment,at,concentrations 1.0 0.000143348623853 0 1 -1
encystment,and,in 1.0 0.000143348623853 0 1 -1
encouraged,to,enroll 1.0 0.000143348623853 0 1 -1
encountered,such,arrhythmias 1.0 0.000143348623853 0 1 -1
encountered,during,the 1.0 0.000143348623853 0 1 -1
encodes,a,protein 1.0 0.000143348623853 0 1 -1
encephalopathy,in,the 1.0 0.000143348623853 0 1 -1
encephalopathy,are,occurred 1.0 0.000143348623853 0 1 -1
enbrel,was,unaltered 1.0 0.000143348623853 0 1 -1
enantiomers,or,the 1.0 0.000143348623853 0 1 -1
enantiomer,pharmacokinetics,were 1.0 0.000143348623853 0 1 -1
enantiomer,nanm,failed 1.0 0.000143348623853 0 1 -1
enalapril,iv,has 1.0 0.000143348623853 0 1 -1
enable,cells,to 1.0 0.000143348623853 0 1 -1
emulsions,in,patients 1.0 0.000143348623853 0 1 -1
emulsion,model,in 1.0 0.000143348623853 0 1 -1
emulsion,doubly,labeled 1.0 0.000143348623853 0 1 -1
emtriva,has,been 1.0 0.000143348623853 0 1 -1
ems,selective,inhibitors 1.0 0.000143348623853 0 1 -1
emptying,by,could 1.0 0.000143348623853 0 1 -1
empty,stomach,minutes 1.0 0.000143348623853 0 1 -1
employing,mtc-mdp,as 1.0 0.000143348623853 0 1 -1
employed,when,xigris 1.0 0.000143348623853 0 1 -1
employed,in,determining 1.0 0.000143348623853 0 1 -1
employed,for,the 1.0 0.000143348623853 0 1 -1
employed,cautiously,as 1.0 0.000143348623853 0 1 -1
empiric,adjustment,of 1.0 0.000143348623853 0 1 -1
emphasize,that,apoptosis 1.0 0.000143348623853 0 1 -1
emphasis,on,those 1.0 0.000143348623853 0 1 -1
emit-d,a,u 1.0 0.000143348623853 0 1 -1
emerging,roles,of 1.0 0.000143348623853 0 1 -1
emerged,from,the 1.0 0.000143348623853 0 1 -1
embryos,was,ineffective 1.0 0.000143348623853 0 1 -1
embryos,similarly,as 1.0 0.000143348623853 0 1 -1
embryonic,survival,were 1.0 0.000143348623853 0 1 -1
embryogenesis,of,nmda-ergic 1.0 0.000143348623853 0 1 -1
embryocidal,effects,have 1.0 0.000143348623853 0 1 -1
embryo,fetal,development 1.0 0.000143348623853 0 1 -1
emboli,rises,that 1.0 0.000143348623853 0 1 -1
elucidating,the,role 1.0 0.000143348623853 0 1 -1
elucidate,metal,toxicity 1.0 0.000143348623853 0 1 -1
ellence,when,used 1.0 0.000143348623853 0 1 -1
ellence,after,previous 1.0 0.000143348623853 0 1 -1
elixir,was,administered 1.0 0.000143348623853 0 1 -1
elisa,and,reduced 1.0 0.000143348623853 0 1 -1
elimination,was,prolonged 1.0 0.000143348623853 0 1 -1
elimination,rate,constant 1.0 0.000286697247706 0 2 -2
elimination,or,altered 1.0 0.000143348623853 0 1 -1
elimination,of,each 1.0 0.000143348623853 0 1 -1
elimination,of,concomitant 1.0 0.000143348623853 0 1 -1
elimination,of,because 1.0 0.000143348623853 0 1 -1
elimination,of,and 1.0 0.000143348623853 0 1 -1
elimination,of,after 1.0 0.000143348623853 0 1 -1
elimination,of,a 1.0 0.000143348623853 0 1 -1
elimination,may,alter 1.0 0.000143348623853 0 1 -1
elimination,is,dependent 1.0 0.000143348623853 0 1 -1
elimination,is,active 1.0 0.000143348623853 0 1 -1
elimination,half-life,was 1.0 0.000143348623853 0 1 -1
elimination,and,increases 1.0 0.000143348623853 0 1 -1
elimination,and,distribution 1.0 0.000143348623853 0 1 -1
eliminated,or,are 1.0 0.000143348623853 0 1 -1
eliminated,in,the 1.0 0.000286697247706 0 2 -2
eliminated,by,the 1.0 0.000143348623853 0 1 -1
eliminated,by,conjugation 1.0 0.000143348623853 0 1 -1
elicit,their,pharmacological 1.0 0.000143348623853 0 1 -1
elevations,with,evidence 1.0 0.000143348623853 0 1 -1
elevations,returned,to 1.0 0.000143348623853 0 1 -1
elevations,resolved,with 1.0 0.000143348623853 0 1 -1
elevations,of,urinary 1.0 0.000143348623853 0 1 -1
elevations,of,pra 1.0 0.000143348623853 0 1 -1
elevations,of,liver 1.0 0.000143348623853 0 1 -1
elevations,of,ast 1.0 0.000143348623853 0 1 -1
elevations,of,aminotransferase 1.0 0.000143348623853 0 1 -1
elevations,in,prothrombin 1.0 0.000143348623853 0 1 -1
elevations,in,cpk 1.0 0.000143348623853 0 1 -1
elevations,and,infrequent 1.0 0.000143348623853 0 1 -1
elevation,of,the 1.0 0.000143348623853 0 1 -1
elevation,of,serum 1.0 0.000143348623853 0 1 -1
elevation,of,conjugated 1.0 0.000143348623853 0 1 -1
elevation,in,fluoride 1.0 0.000143348623853 0 1 -1
elevated,with,some 1.0 0.000143348623853 0 1 -1
elevated,with,by 1.0 0.000143348623853 0 1 -1
elevated,salivary,cortisol 1.0 0.000143348623853 0 1 -1
elevated,liver,aminotransferases 1.0 0.000143348623853 0 1 -1
elevated,levels,of 1.0 0.000143348623853 0 1 -1
elevated,international,normalized 1.0 0.000143348623853 0 1 -1
elevated,in,serum 1.0 0.000286697247706 0 2 -2
elevated,glucose,levels 1.0 0.000143348623853 0 1 -1
elevated,creatinine,despite 1.0 0.000143348623853 0 1 -1
elevated,creatine,phosphokinase 1.0 0.000143348623853 0 1 -1
elevated,by,minimally 1.0 0.000143348623853 0 1 -1
elevated,by,and 1.0 0.000143348623853 0 1 -1
elevated,blood,levels 1.0 0.000143348623853 0 1 -1
elevated,alkaline,phosphatase 1.0 0.000143348623853 0 1 -1
elements,were,determined 1.0 0.000143348623853 0 1 -1
elements,only,take 1.0 0.000143348623853 0 1 -1
elements,had,already 1.0 0.000143348623853 0 1 -1
elemental,primarily,iron-fortified 1.0 0.000143348623853 0 1 -1
elemental,oz,has 1.0 0.000143348623853 0 1 -1
electrophysiologic,interactions,have 1.0 0.000143348623853 0 1 -1
electrophilic,agents--a,class 1.0 0.000143348623853 0 1 -1
electrophilic,agents,or 1.0 0.000143348623853 0 1 -1
electron,microscopy,were 1.0 0.000143348623853 0 1 -1
electrolyte,disturbances,patients 1.0 0.000143348623853 0 1 -1
electrolyte,and,acid-base 1.0 0.000143348623853 0 1 -1
electrolyte,alterations,were 1.0 0.000143348623853 0 1 -1
electroconvulsive,therapy,ect 1.0 0.000143348623853 0 1 -1
electrocardiographic,qt,qtc 1.0 0.000143348623853 0 1 -1
electrocardiographic,qt,c 1.0 0.000143348623853 0 1 -1
electrocardiographic,parameters,including 1.0 0.000143348623853 0 1 -1
electrocardiographic,parameters,clinical 1.0 0.000143348623853 0 1 -1
electrocardiograms,were,done 1.0 0.000143348623853 0 1 -1
electrocardiograms,performed,at 1.0 0.000143348623853 0 1 -1
electrically,stimulated,hz 1.0 0.000143348623853 0 1 -1
elderly,population,in 1.0 0.000143348623853 0 1 -1
elderly,patients,with 1.0 0.000143348623853 0 1 -1
elderly,patients,those 1.0 0.000143348623853 0 1 -1
elderly,patients,are 1.0 0.000143348623853 0 1 -1
elderly,basic,science 1.0 0.000143348623853 0 1 -1
elderly,and,implications 1.0 0.000143348623853 0 1 -1
elderly,and,caution 1.0 0.000143348623853 0 1 -1
eldepryl,and,parnate 1.0 0.000143348623853 0 1 -1
elapse,before,these 1.0 0.000143348623853 0 1 -1
ejection,by,vasopressin 1.0 0.000143348623853 0 1 -1
ejection,by,the 1.0 0.000143348623853 0 1 -1
either,was,observed 1.0 0.000143348623853 0 1 -1
either,unchanged,or 1.0 0.000143348623853 0 1 -1
either,toxicities,or 1.0 0.000143348623853 0 1 -1
either,too,high 1.0 0.000143348623853 0 1 -1
either,the,tricyclic 1.0 0.00043004587156 0 3 -3
either,the,str 1.0 0.000143348623853 0 1 -1
either,the,safety 1.0 0.00043004587156 0 3 -3
either,the,presence 1.0 0.000143348623853 0 1 -1
either,the,pharmacokinetics 1.0 0.000286697247706 0 2 -2
either,the,or 1.0 0.000286697247706 0 2 -2
either,the,normal 1.0 0.000143348623853 0 1 -1
either,the,glucose 1.0 0.000286697247706 0 2 -2
either,the,dose 1.0 0.000143348623853 0 1 -1
either,the,antidepressant 1.0 0.000143348623853 0 1 -1
either,the,administration 1.0 0.000143348623853 0 1 -1
either,striatum,str 1.0 0.000143348623853 0 1 -1
either,singly,or 1.0 0.000143348623853 0 1 -1
either,single,or 1.0 0.000143348623853 0 1 -1
either,single,mg 1.0 0.000143348623853 0 1 -1
either,s,bioavailability 1.0 0.000143348623853 0 1 -1
either,protein,kinase 1.0 0.000143348623853 0 1 -1
either,protective,or 1.0 0.000143348623853 0 1 -1
either,prophylactic,low 1.0 0.000143348623853 0 1 -1
either,procedure,even 1.0 0.000143348623853 0 1 -1
either,poor,patient 1.0 0.000143348623853 0 1 -1
either,or,with 1.0 0.000143348623853 0 1 -1
either,or,micrograms 1.0 0.000143348623853 0 1 -1
either,or,kineret 1.0 0.000143348623853 0 1 -1
either,or,its 1.0 0.000143348623853 0 1 -1
either,or,h 1.0 0.000143348623853 0 1 -1
either,or,compounds 1.0 0.000143348623853 0 1 -1
either,or,biocytin 1.0 0.000143348623853 0 1 -1
either,on,alone 1.0 0.000143348623853 0 1 -1
either,of,these 1.0 0.000286697247706 0 2 -2
either,occurred,during 1.0 0.000143348623853 0 1 -1
either,mg,or 1.0 0.000143348623853 0 1 -1
either,mg,once 1.0 0.000143348623853 0 1 -1
either,mg,every 1.0 0.000143348623853 0 1 -1
either,mask,or 1.0 0.000143348623853 0 1 -1
either,long-acting,such 1.0 0.000143348623853 0 1 -1
either,levels,or 1.0 0.000143348623853 0 1 -1
either,is,recommended 1.0 0.000143348623853 0 1 -1
either,interaction,studies 1.0 0.000143348623853 0 1 -1
either,initiated,or 1.0 0.000143348623853 0 1 -1
either,inhibitors,or 1.0 0.000143348623853 0 1 -1
either,in,the 1.0 0.000143348623853 0 1 -1
either,healthy,subjects 1.0 0.000143348623853 0 1 -1
either,h2,antagonist 1.0 0.000143348623853 0 1 -1
either,grapefruit,or 1.0 0.000143348623853 0 1 -1
either,erythro-fluorocitrate,synthesis 1.0 0.000143348623853 0 1 -1
either,due,to 1.0 0.000143348623853 0 1 -1
either,dose,had 1.0 0.000143348623853 0 1 -1
either,dosage,reduction 1.0 0.000143348623853 0 1 -1
either,concomitant,therapy 1.0 0.000143348623853 0 1 -1
either,class,of 1.0 0.000286697247706 0 2 -2
either,by,repeated 1.0 0.000143348623853 0 1 -1
either,by,overcoming 1.0 0.000143348623853 0 1 -1
either,by,enhanced 1.0 0.000143348623853 0 1 -1
either,by,activation 1.0 0.000143348623853 0 1 -1
either,before,or 1.0 0.000143348623853 0 1 -1
either,are,metabolized 1.0 0.000143348623853 0 1 -1
either,alpha-,or 1.0 0.000143348623853 0 1 -1
either,alone,or 1.0 0.00043004587156 0 3 -3
either,agent,or 1.0 0.000143348623853 0 1 -1
either,agent,additional 1.0 0.000143348623853 0 1 -1
either,accidental,diagnostic 1.0 0.000716743119266 0 5 -5
either,a,facilitation 1.0 0.000143348623853 0 1 -1
eight,target,added 1.0 0.000143348623853 0 1 -1
eight,poisonings,of 1.0 0.000143348623853 0 1 -1
eight,hiv-infected,individuals 1.0 0.000143348623853 0 1 -1
eight,experiments,the 1.0 0.000143348623853 0 1 -1
eia,test,in 1.0 0.000143348623853 0 1 -1
eia,test,have 1.0 0.000143348623853 0 1 -1
eggs,was,inhibited 1.0 0.000143348623853 0 1 -1
egf,ng,ml 1.0 0.000143348623853 0 1 -1
eg,selective,serotonin 1.0 0.000143348623853 0 1 -1
eg,rt-pa,or 1.0 0.000143348623853 0 1 -1
eg,implants,injectables 1.0 0.000143348623853 0 1 -1
eg,have,occasionally 1.0 0.000143348623853 0 1 -1
eg,grapefruit,juice 1.0 0.000143348623853 0 1 -1
eg,flu-like,effects 1.0 0.000143348623853 0 1 -1
eg,esophageal,motility 1.0 0.000143348623853 0 1 -1
eg,dizziness,nausea 1.0 0.000143348623853 0 1 -1
eg,are,indicated 1.0 0.000143348623853 0 1 -1
effort,to,screen 1.0 0.000143348623853 0 1 -1
effort,optimal,and 1.0 0.000143348623853 0 1 -1
efflux,transporter,p-glycoprotein 1.0 0.000143348623853 0 1 -1
efficiently,inhibited,by 1.0 0.000143348623853 0 1 -1
efficient,substrate,for 1.0 0.000143348623853 0 1 -1
efficient,labeling,can 1.0 0.000143348623853 0 1 -1
efficacy,were,observed 1.0 0.000143348623853 0 1 -1
efficacy,toxicity,and 1.0 0.000143348623853 0 1 -1
efficacy,the,clinical 1.0 0.000143348623853 0 1 -1
efficacy,should,be 1.0 0.000143348623853 0 1 -1
efficacy,safety,contraindications 1.0 0.000143348623853 0 1 -1
efficacy,physicians,should 1.0 0.000143348623853 0 1 -1
efficacy,on,measures 1.0 0.000143348623853 0 1 -1
efficacy,of,xigris 1.0 0.000143348623853 0 1 -1
efficacy,of,used 1.0 0.000143348623853 0 1 -1
efficacy,of,proleukin 1.0 0.000143348623853 0 1 -1
efficacy,of,its 1.0 0.000143348623853 0 1 -1
efficacy,of,in 1.0 0.00043004587156 0 3 -3
efficacy,of,future 1.0 0.000143348623853 0 1 -1
efficacy,of,faslodex 1.0 0.000143348623853 0 1 -1
efficacy,of,amevive 1.0 0.000143348623853 0 1 -1
efficacy,in,the 1.0 0.000143348623853 0 1 -1
efficacy,in,patients 1.0 0.000143348623853 0 1 -1
efficacy,in,nnrti-na 1.0 0.000143348623853 0 1 -1
efficacy,has,not 1.0 0.000143348623853 0 1 -1
efficacy,has,emerged 1.0 0.000143348623853 0 1 -1
efficacy,ectopic,pregnancies 1.0 0.000143348623853 0 1 -1
efficacy,data,available 1.0 0.00043004587156 0 3 -3
efficacy,compared,with 1.0 0.000143348623853 0 1 -1
efficacy,benefit,when 1.0 0.000143348623853 0 1 -1
efficacy,as,a 1.0 0.000143348623853 0 1 -1
efficacy,and,side 1.0 0.000143348623853 0 1 -1
efficacy,and,safety 1.0 0.00100344036697 0 7 -7
efficacy,and,pregnancy 1.0 0.000143348623853 0 1 -1
efficacy,and,increased 1.0 0.000286697247706 0 2 -2
efficacy,although,these 1.0 0.000143348623853 0 1 -1
efficacy,against,the 1.0 0.000143348623853 0 1 -1
efficacious,effects,and 1.0 0.000143348623853 0 1 -1
efficacious,a,second 1.0 0.000143348623853 0 1 -1
effects,would,be 1.0 0.000143348623853 0 1 -1
effects,with,these 1.0 0.000143348623853 0 1 -1
effects,with,other 1.0 0.000143348623853 0 1 -1
effects,when,the 1.0 0.000143348623853 0 1 -1
effects,were,short-lasting 1.0 0.000143348623853 0 1 -1
effects,were,seen 1.0 0.000286697247706 0 2 -2
effects,were,noted 1.0 0.000143348623853 0 1 -1
effects,were,not 1.0 0.000286697247706 0 2 -2
effects,were,evident 1.0 0.000143348623853 0 1 -1
effects,were,antagonized 1.0 0.000143348623853 0 1 -1
effects,were,already 1.0 0.000143348623853 0 1 -1
effects,ways,to 1.0 0.000143348623853 0 1 -1
effects,vioxx,is 1.0 0.000143348623853 0 1 -1
effects,toward,other 1.0 0.000143348623853 0 1 -1
effects,specifically,lipid 1.0 0.000143348623853 0 1 -1
effects,similar,to 1.0 0.000143348623853 0 1 -1
effects,seen,are 1.0 0.000143348623853 0 1 -1
effects,reported,with 1.0 0.000143348623853 0 1 -1
effects,reduced,by 1.0 0.000143348623853 0 1 -1
effects,potentially,increased 1.0 0.000143348623853 0 1 -1
effects,on,steady-state 1.0 0.000143348623853 0 1 -1
effects,on,qtc 1.0 0.000143348623853 0 1 -1
effects,on,positive 1.0 0.000143348623853 0 1 -1
effects,on,plasma 1.0 0.00043004587156 0 3 -3
effects,on,pharmacokinetics 1.0 0.000143348623853 0 1 -1
effects,on,p450 1.0 0.000143348623853 0 1 -1
effects,on,other 1.0 0.000143348623853 0 1 -1
effects,on,metabolism 1.0 0.000143348623853 0 1 -1
effects,on,in 1.0 0.000143348623853 0 1 -1
effects,on,immune 1.0 0.000143348623853 0 1 -1
effects,on,hormone 1.0 0.000143348623853 0 1 -1
effects,on,glucose 1.0 0.000143348623853 0 1 -1
effects,on,fetal 1.0 0.000143348623853 0 1 -1
effects,on,fertility 1.0 0.000143348623853 0 1 -1
effects,on,female 1.0 0.000143348623853 0 1 -1
effects,on,evoked 1.0 0.000143348623853 0 1 -1
effects,on,embryo 1.0 0.000143348623853 0 1 -1
effects,on,either 1.0 0.000286697247706 0 2 -2
effects,on,dosing 1.0 0.000143348623853 0 1 -1
effects,on,discrimination 1.0 0.000143348623853 0 1 -1
effects,on,cycle 1.0 0.000143348623853 0 1 -1
effects,on,blood 1.0 0.000286697247706 0 2 -2
effects,of,zinecard 1.0 0.000143348623853 0 1 -1
effects,of,xanthine 1.0 0.000143348623853 0 1 -1
effects,of,vardenafil 1.0 0.000143348623853 0 1 -1
effects,of,use 1.0 0.000143348623853 0 1 -1
effects,of,uptake 1.0 0.000143348623853 0 1 -1
effects,of,upon 1.0 0.000286697247706 0 2 -2
effects,of,triazo 1.0 0.000143348623853 0 1 -1
effects,of,this 1.0 0.000143348623853 0 1 -1
effects,of,supplementary 1.0 0.000143348623853 0 1 -1
effects,of,stress 1.0 0.000143348623853 0 1 -1
effects,of,stimulation 1.0 0.000143348623853 0 1 -1
effects,of,should 1.0 0.000143348623853 0 1 -1
effects,of,ruthenium 1.0 0.000286697247706 0 2 -2
effects,of,romazicon 1.0 0.000143348623853 0 1 -1
effects,of,prinivil 1.0 0.000143348623853 0 1 -1
effects,of,pegasys 1.0 0.000143348623853 0 1 -1
effects,of,pcp 1.0 0.000143348623853 0 1 -1
effects,of,oleate 1.0 0.000143348623853 0 1 -1
effects,of,nephrotoxic 1.0 0.000143348623853 0 1 -1
effects,of,n-allylnormetazocine 1.0 0.000143348623853 0 1 -1
effects,of,mixing 1.0 0.000143348623853 0 1 -1
effects,of,metabotropic 1.0 0.000143348623853 0 1 -1
effects,of,mefloquineuine 1.0 0.000143348623853 0 1 -1
effects,of,low 1.0 0.000286697247706 0 2 -2
effects,of,lapatinib 1.0 0.000143348623853 0 1 -1
effects,of,l-ccg 1.0 0.000143348623853 0 1 -1
effects,of,it 1.0 0.000143348623853 0 1 -1
effects,of,isocarboxazid 1.0 0.000143348623853 0 1 -1
effects,of,hmg-coa 1.0 0.000143348623853 0 1 -1
effects,of,have 1.0 0.000286697247706 0 2 -2
effects,of,has 1.0 0.000286697247706 0 2 -2
effects,of,gabitril 1.0 0.000143348623853 0 1 -1
effects,of,flushing 1.0 0.000143348623853 0 1 -1
effects,of,erythromycin 1.0 0.000143348623853 0 1 -1
effects,of,epa 1.0 0.000143348623853 0 1 -1
effects,of,during 1.0 0.000143348623853 0 1 -1
effects,of,duloxetine 1.0 0.000143348623853 0 1 -1
effects,of,dmpge2 1.0 0.000143348623853 0 1 -1
effects,of,diethyl 1.0 0.000143348623853 0 1 -1
effects,of,competitive 1.0 0.000143348623853 0 1 -1
effects,of,combined 1.0 0.000143348623853 0 1 -1
effects,of,coadministered 1.0 0.000143348623853 0 1 -1
effects,of,both 1.0 0.000143348623853 0 1 -1
effects,of,blockers 1.0 0.000143348623853 0 1 -1
effects,of,biocytin 1.0 0.000143348623853 0 1 -1
effects,of,b 1.0 0.000143348623853 0 1 -1
effects,of,atrovent 1.0 0.000143348623853 0 1 -1
effects,of,antimicrobial 1.0 0.000143348623853 0 1 -1
effects,of,antagonists 1.0 0.000143348623853 0 1 -1
effects,of,antacids 1.0 0.000143348623853 0 1 -1
effects,of,anafranil 1.0 0.000143348623853 0 1 -1
effects,of,aliskiren 1.0 0.000143348623853 0 1 -1
effects,of,agents 1.0 0.000143348623853 0 1 -1
effects,of,acute 1.0 0.000143348623853 0 1 -1
effects,noted,below 1.0 0.000143348623853 0 1 -1
effects,not,only 1.0 0.000143348623853 0 1 -1
effects,may,result 1.0 0.000143348623853 0 1 -1
effects,may,occur 1.0 0.000143348623853 0 1 -1
effects,may,depend 1.0 0.000143348623853 0 1 -1
effects,may,become 1.0 0.000143348623853 0 1 -1
effects,makes,the 1.0 0.000143348623853 0 1 -1
effects,lower,blood 1.0 0.000143348623853 0 1 -1
effects,kemstro,the 1.0 0.000143348623853 0 1 -1
effects,in,the 1.0 0.000143348623853 0 1 -1
effects,in,slow 1.0 0.000143348623853 0 1 -1
effects,in,pigeons 1.0 0.000143348623853 0 1 -1
effects,in,humans 1.0 0.000143348623853 0 1 -1
effects,in,human 1.0 0.000143348623853 0 1 -1
effects,in,each 1.0 0.000143348623853 0 1 -1
effects,in,clinical 1.0 0.000143348623853 0 1 -1
effects,if,any 1.0 0.000143348623853 0 1 -1
effects,have,frequently 1.0 0.000143348623853 0 1 -1
effects,following,the 1.0 0.000143348623853 0 1 -1
effects,especially,with 1.0 0.000143348623853 0 1 -1
effects,especially,conduction 1.0 0.000143348623853 0 1 -1
effects,did,not 1.0 0.000143348623853 0 1 -1
effects,deriving,from 1.0 0.000143348623853 0 1 -1
effects,constipation,and 1.0 0.000143348623853 0 1 -1
effects,conditioning,processes 1.0 0.000143348623853 0 1 -1
effects,concomitant,use 1.0 0.000143348623853 0 1 -1
effects,celebrex,is 1.0 0.000143348623853 0 1 -1
effects,caution,is 1.0 0.000143348623853 0 1 -1
effects,caution,and 1.0 0.000143348623853 0 1 -1
effects,by,the 1.0 0.000143348623853 0 1 -1
effects,breast,feeding 1.0 0.000143348623853 0 1 -1
effects,both,therapeutic 1.0 0.000143348623853 0 1 -1
effects,blood,and 1.0 0.000143348623853 0 1 -1
effects,and,these 1.0 0.000143348623853 0 1 -1
effects,and,therefore 1.0 0.000143348623853 0 1 -1
effects,and,need 1.0 0.000143348623853 0 1 -1
effects,and,malignant 1.0 0.000286697247706 0 2 -2
effects,and,interactions 1.0 0.000143348623853 0 1 -1
effects,and,in 1.0 0.000143348623853 0 1 -1
effects,and,had 1.0 0.000143348623853 0 1 -1
effects,and,even 1.0 0.000143348623853 0 1 -1
effects,and,avoidance 1.0 0.000143348623853 0 1 -1
effects,an,additive 1.0 0.000143348623853 0 1 -1
effects,although,theophylline-induced 1.0 0.000143348623853 0 1 -1
effects,administered,concurrently 1.0 0.000143348623853 0 1 -1
effects,addiction,research 1.0 0.000143348623853 0 1 -1
effector,immediate-early,gene 1.0 0.000143348623853 0 1 -1
effector,ieg,arc 1.0 0.000143348623853 0 1 -1
effectiveness,when,used 1.0 0.000143348623853 0 1 -1
effectiveness,of,the 1.0 0.000286697247706 0 2 -2
effectiveness,of,polyenes 1.0 0.000143348623853 0 1 -1
effectiveness,of,pegasys 1.0 0.000143348623853 0 1 -1
effectiveness,of,in 1.0 0.000286697247706 0 2 -2
effectiveness,of,combination 1.0 0.000143348623853 0 1 -1
effectiveness,of,argatroban 1.0 0.000143348623853 0 1 -1
effectiveness,may,be 1.0 0.000143348623853 0 1 -1
effectiveness,is,reported 1.0 0.000143348623853 0 1 -1
effectiveness,in,transferring 1.0 0.000143348623853 0 1 -1
effectiveness,in,men 1.0 0.000143348623853 0 1 -1
effectiveness,in,children 1.0 0.000143348623853 0 1 -1
effectiveness,by,increasing 1.0 0.000143348623853 0 1 -1
effectiveness,against,multidrug-resistant 1.0 0.000143348623853 0 1 -1
effectively,and,safely 1.0 0.000143348623853 0 1 -1
effectively,administered,in 1.0 0.000143348623853 0 1 -1
effective,use,of 1.0 0.000143348623853 0 1 -1
effective,treatment,is 1.0 0.000143348623853 0 1 -1
effective,there,have 1.0 0.000143348623853 0 1 -1
effective,than,to 1.0 0.000143348623853 0 1 -1
effective,in,women 1.0 0.000143348623853 0 1 -1
effective,first-line,therapy 1.0 0.000143348623853 0 1 -1
effective,dose,and 1.0 0.000143348623853 0 1 -1
effective,contraception,simultaneously 1.0 0.000143348623853 0 1 -1
effective,but,can 1.0 0.000143348623853 0 1 -1
effective,as,intravenous 1.0 0.000143348623853 0 1 -1
effective,and,increased 1.0 0.000143348623853 0 1 -1
effected,by,endothelial 1.0 0.000143348623853 0 1 -1
effect,would,be 1.0 0.000143348623853 0 1 -1
effect,with,this 1.0 0.000143348623853 0 1 -1
effect,when,used 1.0 0.000143348623853 0 1 -1
effect,was,shown 1.0 0.000143348623853 0 1 -1
effect,was,present 1.0 0.000143348623853 0 1 -1
effect,the,functional 1.0 0.000143348623853 0 1 -1
effect,seen,in 1.0 0.000143348623853 0 1 -1
effect,reduction,in 1.0 0.000143348623853 0 1 -1
effect,oral,heparin 1.0 0.000143348623853 0 1 -1
effect,on,that 1.0 0.000143348623853 0 1 -1
effect,on,target 1.0 0.000143348623853 0 1 -1
effect,on,safety 1.0 0.000143348623853 0 1 -1
effect,on,prothrombin 1.0 0.000286697247706 0 2 -2
effect,on,protein 1.0 0.000143348623853 0 1 -1
effect,on,plasma 1.0 0.000860091743119 0 6 -6
effect,on,phosphate 1.0 0.00043004587156 0 3 -3
effect,on,other 1.0 0.000143348623853 0 1 -1
effect,on,metabolism 1.0 0.00043004587156 0 3 -3
effect,on,its 1.0 0.000143348623853 0 1 -1
effect,on,insp 1.0 0.000143348623853 0 1 -1
effect,on,in 1.0 0.000143348623853 0 1 -1
effect,on,hepatic 1.0 0.000143348623853 0 1 -1
effect,on,felbatol 1.0 0.000143348623853 0 1 -1
effect,on,exposure 1.0 0.000143348623853 0 1 -1
effect,on,excystment 1.0 0.000143348623853 0 1 -1
effect,on,either 1.0 0.000573394495413 0 4 -4
effect,on,cytochrome 1.0 0.000143348623853 0 1 -1
effect,on,cyp1a2 1.0 0.000286697247706 0 2 -2
effect,on,cure 1.0 0.000143348623853 0 1 -1
effect,on,concentration 1.0 0.000143348623853 0 1 -1
effect,on,clearance 1.0 0.000143348623853 0 1 -1
effect,on,circulating 1.0 0.000143348623853 0 1 -1
effect,on,bone 1.0 0.000286697247706 0 2 -2
effect,on,bleeding 1.0 0.000143348623853 0 1 -1
effect,on,bioavailability 1.0 0.000143348623853 0 1 -1
effect,on,any 1.0 0.000143348623853 0 1 -1
effect,on,an 1.0 0.000143348623853 0 1 -1
effect,on,a 1.0 0.000143348623853 0 1 -1
effect,of,zebeta 1.0 0.000143348623853 0 1 -1
effect,of,which 1.0 0.000143348623853 0 1 -1
effect,of,was 1.0 0.000143348623853 0 1 -1
effect,of,treatment 1.0 0.000143348623853 0 1 -1
effect,of,these 1.0 0.00043004587156 0 3 -3
effect,of,temperature 1.0 0.000143348623853 0 1 -1
effect,of,strong 1.0 0.000143348623853 0 1 -1
effect,of,steady-state 1.0 0.000143348623853 0 1 -1
effect,of,sensipar 1.0 0.000143348623853 0 1 -1
effect,of,refludan 1.0 0.000143348623853 0 1 -1
effect,of,ras 1.0 0.000286697247706 0 2 -2
effect,of,probenecid 1.0 0.000143348623853 0 1 -1
effect,of,panretin 1.0 0.000143348623853 0 1 -1
effect,of,other 1.0 0.000860091743119 0 6 -6
effect,of,orally 1.0 0.000143348623853 0 1 -1
effect,of,oral 1.0 0.000143348623853 0 1 -1
effect,of,natural 1.0 0.000143348623853 0 1 -1
effect,of,keppra 1.0 0.000143348623853 0 1 -1
effect,of,induction 1.0 0.000143348623853 0 1 -1
effect,of,increased 1.0 0.000286697247706 0 2 -2
effect,of,foods 1.0 0.000143348623853 0 1 -1
effect,of,food 1.0 0.000143348623853 0 1 -1
effect,of,extraneal 1.0 0.000143348623853 0 1 -1
effect,of,exogenous 1.0 0.000143348623853 0 1 -1
effect,of,dmpge2 1.0 0.000143348623853 0 1 -1
effect,of,disease 1.0 0.000143348623853 0 1 -1
effect,of,different 1.0 0.000143348623853 0 1 -1
effect,of,combined 1.0 0.000143348623853 0 1 -1
effect,of,coadministered 1.0 0.000143348623853 0 1 -1
effect,of,clonazepam 1.0 0.000143348623853 0 1 -1
effect,of,caused 1.0 0.000143348623853 0 1 -1
effect,of,brevibloc 1.0 0.000143348623853 0 1 -1
effect,of,beta-receptor 1.0 0.000143348623853 0 1 -1
effect,of,as 1.0 0.000143348623853 0 1 -1
effect,of,an 1.0 0.000286697247706 0 2 -2
effect,of,amevive 1.0 0.000143348623853 0 1 -1
effect,of,agents 1.0 0.000143348623853 0 1 -1
effect,of,administration 1.0 0.000143348623853 0 1 -1
effect,of,administering 1.0 0.000286697247706 0 2 -2
effect,of,administered 1.0 0.000143348623853 0 1 -1
effect,occurs,when 1.0 0.000143348623853 0 1 -1
effect,measured,by 1.0 0.000143348623853 0 1 -1
effect,is,small 1.0 0.000143348623853 0 1 -1
effect,is,at 1.0 0.000143348623853 0 1 -1
effect,increased,by 1.0 0.000286697247706 0 2 -2
effect,in,the 1.0 0.000286697247706 0 2 -2
effect,for,which 1.0 0.000143348623853 0 1 -1
effect,did,not 1.0 0.000143348623853 0 1 -1
effect,compared,with 1.0 0.000143348623853 0 1 -1
effect,by,the 1.0 0.000143348623853 0 1 -1
effect,and,susceptibility 1.0 0.000286697247706 0 2 -2
effect,and,products 1.0 0.000143348623853 0 1 -1
effect,and,other 1.0 0.000143348623853 0 1 -1
effect,and,in 1.0 0.000143348623853 0 1 -1
effect,although,the 1.0 0.000143348623853 0 1 -1
effect,agents,derivatives 1.0 0.000143348623853 0 1 -1
efavirenz,has,demonstrated 1.0 0.000143348623853 0 1 -1
efavirenz,has,been 1.0 0.000143348623853 0 1 -1
ee,were,decreased 1.0 0.000143348623853 0 1 -1
educational,messages,advise 1.0 0.000143348623853 0 1 -1
education,on,recovery 1.0 0.000143348623853 0 1 -1
editorials,concerning,published 1.0 0.000143348623853 0 1 -1
edema,excessive,perspiration 1.0 0.000143348623853 0 1 -1
edema,and,mononuclear 1.0 0.000143348623853 0 1 -1
ectopic,pregnancies,the 1.0 0.000143348623853 0 1 -1
ect,there,are 1.0 0.000143348623853 0 1 -1
ect,and,antidepressant 1.0 0.000143348623853 0 1 -1
eclampsia,some,dysrhythmias 1.0 0.000143348623853 0 1 -1
ecg,taken,at 1.0 0.000143348623853 0 1 -1
ecg,of,given 1.0 0.000143348623853 0 1 -1
ecg,intervals,caution 1.0 0.000143348623853 0 1 -1
ecg,heart,rate 1.0 0.000143348623853 0 1 -1
ec50,values,for 1.0 0.000143348623853 0 1 -1
easy,and,can 1.0 0.000143348623853 0 1 -1
earth,and,transition 1.0 0.000143348623853 0 1 -1
early-phase,schizophrenia,were 1.0 0.000143348623853 0 1 -1
early,studies,indicated 1.0 0.000143348623853 0 1 -1
early,evidence,of 1.0 0.000143348623853 0 1 -1
early,and,numerous 1.0 0.000143348623853 0 1 -1
eagles,minimal,essential 1.0 0.000143348623853 0 1 -1
each,year,indicating 1.0 0.000143348623853 0 1 -1
each,would,coincide 1.0 0.000143348623853 0 1 -1
each,volunteer,was 1.0 0.000143348623853 0 1 -1
each,volunteer,received 1.0 0.000143348623853 0 1 -1
each,treatment,period 1.0 0.000143348623853 0 1 -1
each,task,it 1.0 0.000143348623853 0 1 -1
each,task,induced 1.0 0.000143348623853 0 1 -1
each,successive,generation 1.0 0.000143348623853 0 1 -1
each,subject,was 1.0 0.000143348623853 0 1 -1
each,subject,received 1.0 0.000143348623853 0 1 -1
each,subject,before 1.0 0.000143348623853 0 1 -1
each,study,volunteers 1.0 0.000143348623853 0 1 -1
each,study,there 1.0 0.000143348623853 0 1 -1
each,study,a 1.0 0.000143348623853 0 1 -1
each,significantly,altered 1.0 0.000143348623853 0 1 -1
each,serum,without 1.0 0.000143348623853 0 1 -1
each,preparation,was 1.0 0.000143348623853 0 1 -1
each,of,these 1.0 0.00043004587156 0 3 -3
each,of,the 1.0 0.000143348623853 0 1 -1
each,of,male 1.0 0.000143348623853 0 1 -1
each,month,prior 1.0 0.000143348623853 0 1 -1
each,month,of 1.0 0.000143348623853 0 1 -1
each,may,be 1.0 0.000143348623853 0 1 -1
each,healthy,subject 1.0 0.000143348623853 0 1 -1
each,group,took 1.0 0.000143348623853 0 1 -1
each,found,to 1.0 0.000143348623853 0 1 -1
each,dose,administered 1.0 0.000143348623853 0 1 -1
each,agent,on 1.0 0.000143348623853 0 1 -1
eaca,inhibits,adp 1.0 0.000143348623853 0 1 -1
ea,was,treated 1.0 0.000143348623853 0 1 -1
e2-induced,diarrhea,in 1.0 0.000143348623853 0 1 -1
e2,dmpge2,induced 1.0 0.000143348623853 0 1 -1
e1,and,cyp 1.0 0.000143348623853 0 1 -1
e1,and,a4 1.0 0.000143348623853 0 1 -1
e1,and,a 1.0 0.000143348623853 0 1 -1
e-strain,subjects,to 1.0 0.000143348623853 0 1 -1
e-strain,subjects,but 1.0 0.000143348623853 0 1 -1
dysuria,impotence,inability 1.0 0.000143348623853 0 1 -1
dystonia,ataxia,blurred 1.0 0.000143348623853 0 1 -1
dysrhythmias,torsades,de 1.0 0.000143348623853 0 1 -1
dysregulation,of,the 1.0 0.000143348623853 0 1 -1
dyspnea,requiring,angioedema 1.0 0.000143348623853 0 1 -1
dyspnea,palpitation,chest 1.0 0.000143348623853 0 1 -1
dyspnea,hypotension,or 1.0 0.000143348623853 0 1 -1
dysphoria,and,reduced 1.0 0.000143348623853 0 1 -1
dyslipidemia,hypertension,hypercoagulation 1.0 0.000143348623853 0 1 -1
dysfunction,with,the 1.0 0.000143348623853 0 1 -1
dysfunction,or,cardiac 1.0 0.000143348623853 0 1 -1
dysfunction,may,also 1.0 0.000143348623853 0 1 -1
dysfunction,is,nevertheless 1.0 0.000143348623853 0 1 -1
dysfunction,is,a 1.0 0.000143348623853 0 1 -1
dysfunction,eg,esophageal 1.0 0.000143348623853 0 1 -1
dysfunction,associated,with 1.0 0.000143348623853 0 1 -1
dysfunction,as,indicated 1.0 0.000143348623853 0 1 -1
dysfunction,and,b 1.0 0.000143348623853 0 1 -1
dysarthria,incoordination,hyperthermia 1.0 0.000143348623853 0 1 -1
dynamic,and,release 1.0 0.000143348623853 0 1 -1
dynacirc,has,been 1.0 0.000143348623853 0 1 -1
dynacirc,and,in 1.0 0.000143348623853 0 1 -1
dynacirc,and,does 1.0 0.000143348623853 0 1 -1
dynacirc,an,increased 1.0 0.000143348623853 0 1 -1
during,whole-cell,tight 1.0 0.000143348623853 0 1 -1
during,which,blood 1.0 0.000143348623853 0 1 -1
during,videx,therapy 1.0 0.000143348623853 0 1 -1
during,use,of 1.0 0.000143348623853 0 1 -1
during,up-titration,presumably 1.0 0.000143348623853 0 1 -1
during,treatment,or 1.0 0.000143348623853 0 1 -1
during,transfer,to 1.0 0.000143348623853 0 1 -1
during,this,period 1.0 0.000143348623853 0 1 -1
during,therapy,such 1.0 0.000143348623853 0 1 -1
during,therapy,including 1.0 0.000143348623853 0 1 -1
during,the,trials 1.0 0.000286697247706 0 2 -2
during,the,same 1.0 0.000286697247706 0 2 -2
during,the,months 1.0 0.000143348623853 0 1 -1
during,the,longterm 1.0 0.000143348623853 0 1 -1
during,the,hour 1.0 0.000143348623853 0 1 -1
during,the,coadministration 1.0 0.000143348623853 0 1 -1
during,the,above 1.0 0.000143348623853 0 1 -1
during,simultaneous,administration 1.0 0.000143348623853 0 1 -1
during,sexual,activity 1.0 0.000143348623853 0 1 -1
during,pregnancy,only 1.0 0.000286697247706 0 2 -2
during,pregnancy,cromolyn 1.0 0.000143348623853 0 1 -1
during,placebo,or 1.0 0.000143348623853 0 1 -1
during,photic,stimulation 1.0 0.000143348623853 0 1 -1
during,muscle,relaxants 1.0 0.000143348623853 0 1 -1
during,multiple-dose,suggesting 1.0 0.000143348623853 0 1 -1
during,initiation,of 1.0 0.000143348623853 0 1 -1
during,initial,treatment 1.0 0.000143348623853 0 1 -1
during,days,of 1.0 0.000143348623853 0 1 -1
during,conversion,from 1.0 0.000143348623853 0 1 -1
during,continuous,intravenous 1.0 0.000143348623853 0 1 -1
during,concurrent,administration 1.0 0.000143348623853 0 1 -1
during,co-administration,systemic 1.0 0.000143348623853 0 1 -1
during,clinical,trials 1.0 0.00043004587156 0 3 -3
during,clinical,studies 1.0 0.000143348623853 0 1 -1
during,both,periods 1.0 0.000143348623853 0 1 -1
during,any,of 1.0 0.000143348623853 0 1 -1
during,and,treatment 1.0 0.000143348623853 0 1 -1
during,accutane,therapy 1.0 0.000143348623853 0 1 -1
during,a,prolonged 1.0 0.000143348623853 0 1 -1
during,a,course 1.0 0.000143348623853 0 1 -1
durations,of,sleep 1.0 0.000143348623853 0 1 -1
duration,or,reproductive 1.0 0.000143348623853 0 1 -1
duration,of,therapy 1.0 0.000143348623853 0 1 -1
duration,of,the 1.0 0.000286697247706 0 2 -2
duration,of,succinylcholine-induced 1.0 0.000143348623853 0 1 -1
duration,of,sleep 1.0 0.000143348623853 0 1 -1
duration,of,hexanal-induced 1.0 0.000143348623853 0 1 -1
duration,of,administration 1.0 0.000143348623853 0 1 -1
duragesic,is,given 1.0 0.000143348623853 0 1 -1
duodenum,and,no 1.0 0.000143348623853 0 1 -1
duloxetine-treated,patients,had 1.0 0.000143348623853 0 1 -1
duloxetine,with,had 1.0 0.000143348623853 0 1 -1
duloxetine,with,aluminum- 1.0 0.000143348623853 0 1 -1
duloxetine,unprotected,by 1.0 0.000143348623853 0 1 -1
duloxetine,to,affect 1.0 0.000143348623853 0 1 -1
duloxetine,may,have 1.0 0.000143348623853 0 1 -1
duloxetine,it,should 1.0 0.000143348623853 0 1 -1
duloxetine,is,a 1.0 0.000143348623853 0 1 -1
duloxetine,in,patients 1.0 0.000143348623853 0 1 -1
duloxetine,has,an 1.0 0.000143348623853 0 1 -1
duloxetine,did,not 1.0 0.000143348623853 0 1 -1
duloxetine,clinical,trials 1.0 0.000143348623853 0 1 -1
duloxetine,both,cyp1a2 1.0 0.000143348623853 0 1 -1
duloxetine,and,were 1.0 0.000143348623853 0 1 -1
due,to,reductions 1.0 0.000143348623853 0 1 -1
due,to,potential 1.0 0.00143348623853 0 10 -10
due,to,nonlethal 1.0 0.000143348623853 0 1 -1
due,to,limited 1.0 0.000143348623853 0 1 -1
due,to,interference 1.0 0.000143348623853 0 1 -1
due,to,interactions 1.0 0.000143348623853 0 1 -1
due,to,increased 1.0 0.000143348623853 0 1 -1
due,to,highintersubject 1.0 0.000143348623853 0 1 -1
due,to,high 1.0 0.000143348623853 0 1 -1
due,to,exposure 1.0 0.000143348623853 0 1 -1
due,to,effects 1.0 0.000143348623853 0 1 -1
due,to,displacement 1.0 0.000143348623853 0 1 -1
due,to,changes 1.0 0.000143348623853 0 1 -1
due,to,an 1.0 0.00043004587156 0 3 -3
due,to,adverse 1.0 0.000143348623853 0 1 -1
due,to,accident 1.0 0.000143348623853 0 1 -1
dual-memory,theories,have 1.0 0.000143348623853 0 1 -1
dual,effect,of 1.0 0.000143348623853 0 1 -1
dst,should,be 1.0 0.000286697247706 0 2 -2
dst,in,patients 1.0 0.000286697247706 0 2 -2
dst,false-negative,results 1.0 0.000143348623853 0 1 -1
dryness,of,mouth 1.0 0.000143348623853 0 1 -1
drying,effect,and 1.0 0.000143348623853 0 1 -1
dry,mouth,bodyweight 1.0 0.000143348623853 0 1 -1
dry,mouth,anorexia 1.0 0.000143348623853 0 1 -1
drugs,within,class 1.0 0.000143348623853 0 1 -1
drugs,with,parasympathomimetic 1.0 0.000143348623853 0 1 -1
drugs,with,nephrotoxic 1.0 0.000143348623853 0 1 -1
drugs,with,a 1.0 0.000286697247706 0 2 -2
drugs,which,impair 1.0 0.000143348623853 0 1 -1
drugs,to,affect 1.0 0.000286697247706 0 2 -2
drugs,these,drugs 1.0 0.000143348623853 0 1 -1
drugs,that,suppress 1.0 0.000143348623853 0 1 -1
drugs,that,raise 1.0 0.000143348623853 0 1 -1
drugs,that,interfere 1.0 0.000143348623853 0 1 -1
drugs,that,are 1.0 0.000573394495413 0 4 -4
drugs,that,affect 1.0 0.000143348623853 0 1 -1
drugs,tend,to 1.0 0.000143348623853 0 1 -1
drugs,substances,that 1.0 0.000143348623853 0 1 -1
drugs,results,from 1.0 0.000143348623853 0 1 -1
drugs,prolonging,the 1.0 0.000143348623853 0 1 -1
drugs,possessing,properties 1.0 0.000143348623853 0 1 -1
drugs,other,than 1.0 0.000143348623853 0 1 -1
drugs,or,substances 1.0 0.000143348623853 0 1 -1
drugs,on,the 1.0 0.000143348623853 0 1 -1
drugs,on,aliskiren 1.0 0.000143348623853 0 1 -1
drugs,nsaids,a 1.0 0.000143348623853 0 1 -1
drugs,increased,side 1.0 0.000143348623853 0 1 -1
drugs,include,the 1.0 0.000143348623853 0 1 -1
drugs,in,which 1.0 0.000286697247706 0 2 -2
drugs,in,vitro 1.0 0.000143348623853 0 1 -1
drugs,in,small 1.0 0.000143348623853 0 1 -1
drugs,in,healthy 1.0 0.000143348623853 0 1 -1
drugs,highly,bound 1.0 0.00043004587156 0 3 -3
drugs,have,been 1.0 0.000143348623853 0 1 -1
drugs,has,not 1.0 0.000143348623853 0 1 -1
drugs,given,the 1.0 0.000286697247706 0 2 -2
drugs,given,concurrently 1.0 0.000143348623853 0 1 -1
drugs,fibric,acid 1.0 0.000143348623853 0 1 -1
drugs,enhancing,heparin 1.0 0.000143348623853 0 1 -1
drugs,drugs,such 1.0 0.000143348623853 0 1 -1
drugs,drugs,metabolized 1.0 0.000143348623853 0 1 -1
drugs,clonazepam,does 1.0 0.000143348623853 0 1 -1
drugs,cimetidine,co-administration 1.0 0.000143348623853 0 1 -1
drugs,based,on 1.0 0.000143348623853 0 1 -1
drugs,at,least 1.0 0.000143348623853 0 1 -1
drugs,associated,with 1.0 0.000286697247706 0 2 -2
drugs,aripiprazole,is 1.0 0.000143348623853 0 1 -1
drugs,are,withdrawn 1.0 0.000143348623853 0 1 -1
drugs,are,needed 1.0 0.000143348623853 0 1 -1
drugs,are,excreted 1.0 0.000143348623853 0 1 -1
drugs,are,administered 1.0 0.000143348623853 0 1 -1
drugs,and,no 1.0 0.000143348623853 0 1 -1
drugs,aliskiren,does 1.0 0.000143348623853 0 1 -1
drugs,alcohol,when 1.0 0.000143348623853 0 1 -1
drugs,affecting,hepatic 1.0 0.000143348623853 0 1 -1
drugs,aeds,phenytoin 1.0 0.000286697247706 0 2 -2
drugs,administered,after 1.0 0.000143348623853 0 1 -1
drug-specific,interactions,were 1.0 0.000143348623853 0 1 -1
drug-metabolizing,enzymes,inducers 1.0 0.000143348623853 0 1 -1
drug-laboratory,test,interactions 1.0 0.000573394495413 0 4 -4
drug-lab,interactions,implications 1.0 0.000143348623853 0 1 -1
drug-interaction,studies,performed 1.0 0.000143348623853 0 1 -1
drug-interaction,studies,have 1.0 0.000143348623853 0 1 -1
drug-induced,renal,toxicity 1.0 0.000143348623853 0 1 -1
drug-drug,pharmacokinetic,or 1.0 0.000143348623853 0 1 -1
drug-drug,pharmacokinetic,interactions 1.0 0.000143348623853 0 1 -1
drug-drug,interactions,with 1.0 0.000286697247706 0 2 -2
drug-drug,interactions,the 1.0 0.000143348623853 0 1 -1
drug-drug,interactions,posed 1.0 0.000143348623853 0 1 -1
drug-drug,interactions,no 1.0 0.000143348623853 0 1 -1
drug-drug,interactions,in 1.0 0.000143348623853 0 1 -1
drug-drug,interactions,have 1.0 0.00043004587156 0 3 -3
drug-drug,interactions,cimetidine 1.0 0.000143348623853 0 1 -1
drug-drug,interactions,between 1.0 0.000716743119266 0 5 -5
drug-drug,interactions,and 1.0 0.000143348623853 0 1 -1
drug-drug,interaction,with 1.0 0.000143348623853 0 1 -1
drug-drug,interaction,was 1.0 0.000143348623853 0 1 -1
drug,treatment,of 1.0 0.000143348623853 0 1 -1
drug,transport,systems 1.0 0.000286697247706 0 2 -2
drug,toxicity,is 1.0 0.000143348623853 0 1 -1
drug,taking,into 1.0 0.000143348623853 0 1 -1
drug,side,effects 1.0 0.000143348623853 0 1 -1
drug,should,be 1.0 0.000143348623853 0 1 -1
drug,regimens,in 1.0 0.000143348623853 0 1 -1
drug,or,to 1.0 0.000143348623853 0 1 -1
drug,or,herbal 1.0 0.000143348623853 0 1 -1
drug,nutritional,supplement 1.0 0.000143348623853 0 1 -1
drug,monitoring,may 1.0 0.000143348623853 0 1 -1
drug,metabolizing,isozyme 1.0 0.000143348623853 0 1 -1
drug,metabolizing,enzymes 1.0 0.000143348623853 0 1 -1
drug,metabolized,by 1.0 0.000143348623853 0 1 -1
drug,may,be 1.0 0.000143348623853 0 1 -1
drug,levels,about 1.0 0.000143348623853 0 1 -1
drug,level,in 1.0 0.000143348623853 0 1 -1
drug,laboratorytest,interactions 1.0 0.000143348623853 0 1 -1
drug,laboratory,tests 1.0 0.000573394495413 0 4 -4
drug,laboratory,test-interactions 1.0 0.000143348623853 0 1 -1
drug,laboratory,interactions 1.0 0.000143348623853 0 1 -1
drug,known,to 1.0 0.000143348623853 0 1 -1
drug,is,prescribed 1.0 0.000143348623853 0 1 -1
drug,interactions,would 1.0 0.000143348623853 0 1 -1
drug,interactions,were 1.0 0.000143348623853 0 1 -1
drug,interactions,use 1.0 0.000143348623853 0 1 -1
drug,interactions,under 1.0 0.000143348623853 0 1 -1
drug,interactions,oral 1.0 0.000143348623853 0 1 -1
drug,interactions,no 1.0 0.000143348623853 0 1 -1
drug,interactions,how 1.0 0.000143348623853 0 1 -1
drug,interactions,general 1.0 0.000143348623853 0 1 -1
drug,interactions,exists 1.0 0.000143348623853 0 1 -1
drug,interactions,dofetilide 1.0 0.000143348623853 0 1 -1
drug,interactions,caused 1.0 0.000143348623853 0 1 -1
drug,interactions,between 1.0 0.000143348623853 0 1 -1
drug,interactions,alteration 1.0 0.000286697247706 0 2 -2
drug,interactions,a 1.0 0.000143348623853 0 1 -1
drug,interaction,studies 1.0 0.0024369266055 0 17 -17
drug,interaction,information 1.0 0.000143348623853 0 1 -1
drug,interaction,has 1.0 0.000143348623853 0 1 -1
drug,interaction,during 1.0 0.000143348623853 0 1 -1
drug,interaction,data 1.0 0.000143348623853 0 1 -1
drug,food,interactions 1.0 0.000143348623853 0 1 -1
drug,exposure,in 1.0 0.000143348623853 0 1 -1
drug,effects,both 1.0 0.000143348623853 0 1 -1
drug,drug,interaction 1.0 0.000143348623853 0 1 -1
drug,concentrations,fold 1.0 0.000143348623853 0 1 -1
drug,clearance,with 1.0 0.000143348623853 0 1 -1
drug,classes,that 1.0 0.000143348623853 0 1 -1
drug,class,examples 1.0 0.000143348623853 0 1 -1
drug,class,drug 1.0 0.000286697247706 0 2 -2
drug,at,the 1.0 0.000143348623853 0 1 -1
drug,and,laboratory 1.0 0.000143348623853 0 1 -1
drug,administration,in 1.0 0.000143348623853 0 1 -1
drowsiness-causing,any,other 1.0 0.000143348623853 0 1 -1
drowsiness,was,observed 1.0 0.000143348623853 0 1 -1
drowsiness,restlessness,muscle 1.0 0.000143348623853 0 1 -1
drowsiness,may,occur 1.0 0.000143348623853 0 1 -1
drops,unless,there 1.0 0.000143348623853 0 1 -1
drops,containing,are 1.0 0.000143348623853 0 1 -1
driving,a,car 1.0 0.000143348623853 0 1 -1
drinks,may,increase 1.0 0.000143348623853 0 1 -1
dried,and,collected 1.0 0.000143348623853 0 1 -1
drawn,up,and 1.0 0.000143348623853 0 1 -1
drawn,regarding,the 1.0 0.000143348623853 0 1 -1
drawn,into,the 1.0 0.000143348623853 0 1 -1
drawn,either,before 1.0 0.000143348623853 0 1 -1
drawn,at,and 1.0 0.000143348623853 0 1 -1
drawn,and,lead 1.0 0.000143348623853 0 1 -1
dramatically,from,to 1.0 0.000143348623853 0 1 -1
dramatic,effect,on 1.0 0.000286697247706 0 2 -2
dpcpx,in,a 1.0 0.000143348623853 0 1 -1
doxil,may,interact 1.0 0.000143348623853 0 1 -1
doxil,be,mixed 1.0 0.000143348623853 0 1 -1
doxepin,is,primarily 1.0 0.000143348623853 0 1 -1
doxazosin,mesylate,tablets 1.0 0.000143348623853 0 1 -1
doxazosin,mesylate,has 1.0 0.000143348623853 0 1 -1
downstream,of,cleavable 1.0 0.000143348623853 0 1 -1
down-regulation,of,nucleophosmin 1.0 0.000143348623853 0 1 -1
doubt,complex,and 1.0 0.000143348623853 0 1 -1
doubly,labeled,with 1.0 0.000143348623853 0 1 -1
doubling,times,comparable 1.0 0.000143348623853 0 1 -1
doubling,the,dose 1.0 0.000143348623853 0 1 -1
doubled,in,the 1.0 0.000286697247706 0 2 -2
double-blind,study,of 1.0 0.000143348623853 0 1 -1
double-blind,randomized,balanced 1.0 0.000143348623853 0 1 -1
double-blind,placebo-controlled,study 1.0 0.000143348623853 0 1 -1
double-blind,fashion,to 1.0 0.000143348623853 0 1 -1
double-blind,comparative,study 1.0 0.000143348623853 0 1 -1
double,strength,mg 1.0 0.000143348623853 0 1 -1
dosing,with,would 1.0 0.000143348623853 0 1 -1
dosing,with,m 1.0 0.000143348623853 0 1 -1
dosing,with,failed 1.0 0.000143348623853 0 1 -1
dosing,should,be 1.0 0.000143348623853 0 1 -1
dosing,schedule,of 1.0 0.000143348623853 0 1 -1
dosing,regimens,prediction 1.0 0.000143348623853 0 1 -1
dosing,regimens,of 1.0 0.000143348623853 0 1 -1
dosing,reduced,as 1.0 0.000143348623853 0 1 -1
dosing,recommendations,for 1.0 0.000143348623853 0 1 -1
dosing,or,chronic 1.0 0.000143348623853 0 1 -1
dosing,of,the 1.0 0.000143348623853 0 1 -1
dosing,of,mg 1.0 0.000143348623853 0 1 -1
dosing,may,be 1.0 0.000143348623853 0 1 -1
dosing,is,required 1.0 0.000143348623853 0 1 -1
dosing,interval,for 1.0 0.000143348623853 0 1 -1
dosing,has,been 1.0 0.000143348623853 0 1 -1
dosing,effects,of 1.0 0.000143348623853 0 1 -1
dosing,concurrently,with 1.0 0.000143348623853 0 1 -1
dosing,by,hours 1.0 0.000143348623853 0 1 -1
dosing,by,at 1.0 0.000143348623853 0 1 -1
dosing,at,mg 1.0 0.000143348623853 0 1 -1
dosing,and,small 1.0 0.000143348623853 0 1 -1
dosing,and,pharmacokinetics 1.0 0.000143348623853 0 1 -1
dosing,adjustments,are 1.0 0.000143348623853 0 1 -1
doses,will,be 1.0 0.000143348623853 0 1 -1
doses,which,can 1.0 0.000143348623853 0 1 -1
doses,were,to 1.0 0.000143348623853 0 1 -1
doses,trough,concentrations 1.0 0.000143348623853 0 1 -1
doses,three,times 1.0 0.000143348623853 0 1 -1
doses,there,were 1.0 0.000143348623853 0 1 -1
doses,that,produced 1.0 0.000143348623853 0 1 -1
doses,than,usually 1.0 0.00100344036697 0 7 -7
doses,should,not 1.0 0.000143348623853 0 1 -1
doses,or,too 1.0 0.000143348623853 0 1 -1
doses,or,mg 1.0 0.000143348623853 0 1 -1
doses,or,infusions 1.0 0.000143348623853 0 1 -1
doses,on,the 1.0 0.000143348623853 0 1 -1
doses,of,vitamin 1.0 0.000286697247706 0 2 -2
doses,of,vardenafil 1.0 0.000143348623853 0 1 -1
doses,of,used 1.0 0.000860091743119 0 6 -6
doses,of,up 1.0 0.000143348623853 0 1 -1
doses,of,u 1.0 0.000143348623853 0 1 -1
doses,of,tmp 1.0 0.000143348623853 0 1 -1
doses,of,these 1.0 0.000143348623853 0 1 -1
doses,of,the 1.0 0.000286697247706 0 2 -2
doses,of,starlix 1.0 0.000143348623853 0 1 -1
doses,of,sodium 1.0 0.000143348623853 0 1 -1
doses,of,short-acting 1.0 0.000143348623853 0 1 -1
doses,of,rocaltrol 1.0 0.00043004587156 0 3 -3
doses,of,oral 1.0 0.000143348623853 0 1 -1
doses,of,or 1.0 0.00043004587156 0 3 -3
doses,of,of 1.0 0.000143348623853 0 1 -1
doses,of,nanm 1.0 0.000143348623853 0 1 -1
doses,of,mcg 1.0 0.000143348623853 0 1 -1
doses,of,low 1.0 0.000143348623853 0 1 -1
doses,of,intravenous 1.0 0.000143348623853 0 1 -1
doses,of,increased 1.0 0.000286697247706 0 2 -2
doses,of,hmg-coa 1.0 0.000143348623853 0 1 -1
doses,of,have 1.0 0.000143348623853 0 1 -1
doses,of,had 1.0 0.000143348623853 0 1 -1
doses,of,factive 1.0 0.000143348623853 0 1 -1
doses,of,er 1.0 0.000143348623853 0 1 -1
doses,of,desmopressin 1.0 0.000143348623853 0 1 -1
doses,of,cefditoren 1.0 0.000143348623853 0 1 -1
doses,of,but 1.0 0.000143348623853 0 1 -1
doses,of,b6 1.0 0.000143348623853 0 1 -1
doses,of,at 1.0 0.000143348623853 0 1 -1
doses,of,agents 1.0 0.000143348623853 0 1 -1
doses,nanm,decreased 1.0 0.000143348623853 0 1 -1
doses,mg,kg 1.0 0.00043004587156 0 3 -3
doses,may,inhibit 1.0 0.000143348623853 0 1 -1
doses,higher,than 1.0 0.000286697247706 0 2 -2
doses,have,been 1.0 0.000143348623853 0 1 -1
doses,greater,than 1.0 0.000286697247706 0 2 -2
doses,from,to 1.0 0.000143348623853 0 1 -1
doses,for,this 1.0 0.00114678899083 0 8 -8
doses,did,not 1.0 0.000143348623853 0 1 -1
doses,decreased,fi 1.0 0.000143348623853 0 1 -1
doses,could,have 1.0 0.000143348623853 0 1 -1
doses,corresponding,to 1.0 0.000143348623853 0 1 -1
doses,correspond,to 1.0 0.000286697247706 0 2 -2
doses,besides,their 1.0 0.000143348623853 0 1 -1
doses,as,low 1.0 0.000143348623853 0 1 -1
doses,are,lower 1.0 0.000143348623853 0 1 -1
dosed,with,mg 1.0 0.000143348623853 0 1 -1
dosed,with,difluoroacetone 1.0 0.000143348623853 0 1 -1
dosed,weekly,for 1.0 0.000143348623853 0 1 -1
dosed,subjects,with 1.0 0.000143348623853 0 1 -1
dosed,at,mg 1.0 0.00043004587156 0 3 -3
dosed,as,a 1.0 0.000143348623853 0 1 -1
dose-time,effects,of 1.0 0.000143348623853 0 1 -1
dose-response,models,based 1.0 0.000143348623853 0 1 -1
dose-response,curves,relatively 1.0 0.000143348623853 0 1 -1
dose-proportionality,and,stability 1.0 0.000143348623853 0 1 -1
dose-proportional,stable,exposure 1.0 0.000143348623853 0 1 -1
dose-limiting,organ,may 1.0 0.000143348623853 0 1 -1
dose-dependently,increased,the 1.0 0.000143348623853 0 1 -1
dose-dependent,manner,relative 1.0 0.000143348623853 0 1 -1
dose-dependent,fashion,at 1.0 0.000143348623853 0 1 -1
dose,was,times 1.0 0.000143348623853 0 1 -1
dose,was,not 1.0 0.000143348623853 0 1 -1
dose,was,increased 1.0 0.000143348623853 0 1 -1
dose,was,co-administered 1.0 0.000143348623853 0 1 -1
dose,used,for 1.0 0.000143348623853 0 1 -1
dose,unfractionated,up 1.0 0.000143348623853 0 1 -1
dose,to,maintain 1.0 0.000286697247706 0 2 -2
dose,that,produced 1.0 0.000143348623853 0 1 -1
dose,that,maximally 1.0 0.000143348623853 0 1 -1
dose,study,in 1.0 0.000143348623853 0 1 -1
dose,selection,and 1.0 0.000143348623853 0 1 -1
dose,required,for 1.0 0.000143348623853 0 1 -1
dose,relationship,has 1.0 0.000143348623853 0 1 -1
dose,reduction,should 1.0 0.000143348623853 0 1 -1
dose,reduction,or 1.0 0.000143348623853 0 1 -1
dose,reduction,for 1.0 0.000143348623853 0 1 -1
dose,reduction,as 1.0 0.000143348623853 0 1 -1
dose,ranges,of 1.0 0.000143348623853 0 1 -1
dose,range,when 1.0 0.000143348623853 0 1 -1
dose,range,are 1.0 0.000143348623853 0 1 -1
dose,proportional,over 1.0 0.000143348623853 0 1 -1
dose,pharmacokinetics,of 1.0 0.000286697247706 0 2 -2
dose,pharmacokinetic,interaction 1.0 0.000143348623853 0 1 -1
dose,or,the 1.0 0.000143348623853 0 1 -1
dose,or,regimen 1.0 0.000286697247706 0 2 -2
dose,or,other 1.0 0.000143348623853 0 1 -1
dose,or,mg 1.0 0.000286697247706 0 2 -2
dose,or,at 1.0 0.000143348623853 0 1 -1
dose,once,daily 1.0 0.000143348623853 0 1 -1
dose,on,bsa 1.0 0.000573394495413 0 4 -4
dose,on,a 1.0 0.000143348623853 0 1 -1
dose,of,when 1.0 0.000286697247706 0 2 -2
dose,of,was 1.0 0.000573394495413 0 4 -4
dose,of,tricyclic 1.0 0.000143348623853 0 1 -1
dose,of,tml 1.0 0.000143348623853 0 1 -1
dose,of,theophylline 1.0 0.000143348623853 0 1 -1
dose,of,tcamay 1.0 0.000143348623853 0 1 -1
dose,of,tca 1.0 0.000573394495413 0 4 -4
dose,of,such 1.0 0.000143348623853 0 1 -1
dose,of,subutex 1.0 0.000143348623853 0 1 -1
dose,of,sonata 1.0 0.000143348623853 0 1 -1
dose,of,serious 1.0 0.000143348623853 0 1 -1
dose,of,reduced 1.0 0.000143348623853 0 1 -1
dose,of,prostigmin 1.0 0.000143348623853 0 1 -1
dose,of,pegasys 1.0 0.000143348623853 0 1 -1
dose,of,pcp 1.0 0.000143348623853 0 1 -1
dose,of,one 1.0 0.000716743119266 0 5 -5
dose,of,liquid 1.0 0.000143348623853 0 1 -1
dose,of,itraconazole 1.0 0.000143348623853 0 1 -1
dose,of,is 1.0 0.00043004587156 0 3 -3
dose,of,indocin 1.0 0.000143348623853 0 1 -1
dose,of,inapsine 1.0 0.000143348623853 0 1 -1
dose,of,had 1.0 0.000286697247706 0 2 -2
dose,of,g 1.0 0.000143348623853 0 1 -1
dose,of,escherichia 1.0 0.000143348623853 0 1 -1
dose,of,elixir 1.0 0.000143348623853 0 1 -1
dose,of,either 1.0 0.000286697247706 0 2 -2
dose,of,did 1.0 0.000143348623853 0 1 -1
dose,of,but 1.0 0.000143348623853 0 1 -1
dose,of,bronchodilator 1.0 0.000143348623853 0 1 -1
dose,of,arimidex 1.0 0.000143348623853 0 1 -1
dose,of,antidepressant 1.0 0.00043004587156 0 3 -3
dose,of,aed 1.0 0.000143348623853 0 1 -1
dose,mu,kg 1.0 0.000143348623853 0 1 -1
dose,modification,is 1.0 0.000286697247706 0 2 -2
dose,mg,tid 1.0 0.000143348623853 0 1 -1
dose,mg,day 1.0 0.000143348623853 0 1 -1
dose,mg,and 1.0 0.000143348623853 0 1 -1
dose,may,under 1.0 0.000143348623853 0 1 -1
dose,may,need 1.0 0.000143348623853 0 1 -1
dose,m,g 1.0 0.000143348623853 0 1 -1
dose,limiting,may 1.0 0.000143348623853 0 1 -1
dose,levels,thereby 1.0 0.000143348623853 0 1 -1
dose,levels,of 1.0 0.000143348623853 0 1 -1
dose,level,p 1.0 0.000143348623853 0 1 -1
dose,is,about 1.0 0.000143348623853 0 1 -1
dose,increases,should 1.0 0.000286697247706 0 2 -2
dose,increased,as 1.0 0.000143348623853 0 1 -1
dose,increase,to 1.0 0.000143348623853 0 1 -1
dose,increase,in 1.0 0.000143348623853 0 1 -1
dose,in,regimens 1.0 0.000143348623853 0 1 -1
dose,in,pcp 1.0 0.000143348623853 0 1 -1
dose,in,healthy 1.0 0.000143348623853 0 1 -1
dose,in,accordance 1.0 0.000143348623853 0 1 -1
dose,have,not 1.0 0.000143348623853 0 1 -1
dose,had,no 1.0 0.00043004587156 0 3 -3
dose,had,little 1.0 0.000143348623853 0 1 -1
dose,groups,developed 1.0 0.000143348623853 0 1 -1
dose,group,developed 1.0 0.000143348623853 0 1 -1
dose,greater,than 1.0 0.000143348623853 0 1 -1
dose,fractions,on 1.0 0.000143348623853 0 1 -1
dose,for,this 1.0 0.000143348623853 0 1 -1
dose,for,subsequent 1.0 0.000143348623853 0 1 -1
dose,for,incombination 1.0 0.000143348623853 0 1 -1
dose,for,at 1.0 0.000143348623853 0 1 -1
dose,for,a 1.0 0.000143348623853 0 1 -1
dose,even,when 1.0 0.000143348623853 0 1 -1
dose,during,the 1.0 0.000143348623853 0 1 -1
dose,did,not 1.0 0.000143348623853 0 1 -1
dose,bioavailability,studies 1.0 0.000143348623853 0 1 -1
dose,baseline,vs 1.0 0.000143348623853 0 1 -1
dose,based,on 1.0 0.00043004587156 0 3 -3
dose,at,the 1.0 0.000143348623853 0 1 -1
dose,at,h 1.0 0.000143348623853 0 1 -1
dose,and,until 1.0 0.000143348623853 0 1 -1
dose,and,type 1.0 0.000143348623853 0 1 -1
dose,and,the 1.0 0.000143348623853 0 1 -1
dose,and,pharmacological 1.0 0.000143348623853 0 1 -1
dose,and,long 1.0 0.000143348623853 0 1 -1
dose,administration,mg 1.0 0.000143348623853 0 1 -1
dose,administered,once 1.0 0.000143348623853 0 1 -1
dose,adjustments,of 1.0 0.00043004587156 0 3 -3
dose,adjustments,may 1.0 0.000143348623853 0 1 -1
dose,adjustment,and 1.0 0.000286697247706 0 2 -2
dose,achieves,a 1.0 0.000143348623853 0 1 -1
dosages,of,the 1.0 0.000143348623853 0 1 -1
dosages,and,plasma 1.0 0.000143348623853 0 1 -1
dosage,was,inappropriate 1.0 0.000143348623853 0 1 -1
dosage,replacement,indicates 1.0 0.000143348623853 0 1 -1
dosage,reduction,with 1.0 0.000143348623853 0 1 -1
dosage,reduction,of 1.0 0.000143348623853 0 1 -1
dosage,or,monitoring 1.0 0.000143348623853 0 1 -1
dosage,one,or 1.0 0.000143348623853 0 1 -1
dosage,of,upward 1.0 0.000143348623853 0 1 -1
dosage,of,these 1.0 0.000286697247706 0 2 -2
dosage,of,phosphate-binding 1.0 0.00043004587156 0 3 -3
dosage,of,one 1.0 0.000143348623853 0 1 -1
dosage,of,indocin 1.0 0.000143348623853 0 1 -1
dosage,of,equetrotm 1.0 0.000143348623853 0 1 -1
dosage,of,and 1.0 0.000143348623853 0 1 -1
dosage,of,adjusted 1.0 0.00043004587156 0 3 -3
dosage,modifications,in 1.0 0.000143348623853 0 1 -1
dosage,modifications,based 1.0 0.000143348623853 0 1 -1
dosage,may,be 1.0 0.000573394495413 0 4 -4
dosage,is,required 1.0 0.000143348623853 0 1 -1
dosage,is,recommended 1.0 0.000143348623853 0 1 -1
dosage,inhibited,cyp 1.0 0.000143348623853 0 1 -1
dosage,and,permit 1.0 0.000143348623853 0 1 -1
dosage,and,duration 1.0 0.000143348623853 0 1 -1
dosage,and,administration-dosage 1.0 0.000143348623853 0 1 -1
dosage,adjustments,may 1.0 0.000716743119266 0 5 -5
dosage,adjustments,made 1.0 0.00043004587156 0 3 -3
dosage,adjustment,when 1.0 0.000143348623853 0 1 -1
dosage,adjustment,or 1.0 0.000143348623853 0 1 -1
dosage,adjustment,may 1.0 0.000286697247706 0 2 -2
dosage,adjustment,is 1.0 0.000573394495413 0 4 -4
dosage,adjustment,for 1.0 0.000143348623853 0 1 -1
dosage,adjustment,as 1.0 0.000143348623853 0 1 -1
dosage,accordingly,if 1.0 0.000143348623853 0 1 -1
dorsocervical,fat,enlargement 1.0 0.000143348623853 0 1 -1
dopamine2-,and,serotonin2-receptors 1.0 0.000143348623853 0 1 -1
dopamine-induced,renal,and 1.0 0.000143348623853 0 1 -1
dopamine,da,levels 1.0 0.000143348623853 0 1 -1
dopa,decarboxylase,inhibitor 1.0 0.000143348623853 0 1 -1
dong,quai,and 1.0 0.000143348623853 0 1 -1
done,with,extreme 1.0 0.000143348623853 0 1 -1
done,with,a 1.0 0.000143348623853 0 1 -1
done,it,was 1.0 0.000143348623853 0 1 -1
done,during,the 1.0 0.000143348623853 0 1 -1
done,at,least 1.0 0.000143348623853 0 1 -1
done,at,baseline 1.0 0.000143348623853 0 1 -1
domestic,studies,suggest 1.0 0.000143348623853 0 1 -1
domain,decoy,and 1.0 0.000143348623853 0 1 -1
dolasetron,mesylate,did 1.0 0.000143348623853 0 1 -1
dolasetron,has,been 1.0 0.000143348623853 0 1 -1
dolasetron,does,not 1.0 0.000143348623853 0 1 -1
dogs,with,gastric 1.0 0.000143348623853 0 1 -1
dogs,unchanged,the 1.0 0.000143348623853 0 1 -1
dogs,treated,with 1.0 0.000143348623853 0 1 -1
dogs,one,treated 1.0 0.000143348623853 0 1 -1
dogs,in,a 1.0 0.000143348623853 0 1 -1
dogs,have,demonstrated 1.0 0.000143348623853 0 1 -1
dogs,deprived,of 1.0 0.000143348623853 0 1 -1
dogs,approximately,equal 1.0 0.000143348623853 0 1 -1
dog,treated,for 1.0 0.000143348623853 0 1 -1
dog,that,was 1.0 0.000143348623853 0 1 -1
dofetilide,is,not 1.0 0.000143348623853 0 1 -1
dofetilide,is,metabolized 1.0 0.000143348623853 0 1 -1
dofetilide,is,eliminated 1.0 0.000143348623853 0 1 -1
does,not,undergo 1.0 0.000286697247706 0 2 -2
does,not,significantly 1.0 0.000286697247706 0 2 -2
does,not,result 1.0 0.000286697247706 0 2 -2
does,not,reduce 1.0 0.000143348623853 0 1 -1
does,not,produce 1.0 0.000286697247706 0 2 -2
does,not,predispose 1.0 0.000143348623853 0 1 -1
does,not,necessitate 1.0 0.000286697247706 0 2 -2
does,not,markedly 1.0 0.000143348623853 0 1 -1
does,not,interfere 1.0 0.000716743119266 0 5 -5
does,not,interact 1.0 0.000143348623853 0 1 -1
does,not,inhibit 1.0 0.000860091743119 0 6 -6
does,not,influence 1.0 0.000573394495413 0 4 -4
does,not,induce 1.0 0.000286697247706 0 2 -2
does,not,increase 1.0 0.000143348623853 0 1 -1
does,not,however 1.0 0.000143348623853 0 1 -1
does,not,have 1.0 0.00043004587156 0 3 -3
does,not,greatly 1.0 0.000143348623853 0 1 -1
does,not,displace 1.0 0.000143348623853 0 1 -1
does,not,change 1.0 0.000143348623853 0 1 -1
does,not,cause 1.0 0.000143348623853 0 1 -1
does,not,bind 1.0 0.000143348623853 0 1 -1
does,not,appear 1.0 0.00100344036697 0 7 -7
does,not,affect 1.0 0.0021502293578 0 15 -15
does,it,interfere 1.0 0.000143348623853 0 1 -1
does,it,alter 1.0 0.000143348623853 0 1 -1
does,induce,p-450iie1 1.0 0.000143348623853 0 1 -1
does,affect,the 1.0 0.000143348623853 0 1 -1
documented,prothrombin,times 1.0 0.000143348623853 0 1 -1
documented,hypokalemia,and 1.0 0.000143348623853 0 1 -1
documented,however,the 1.0 0.000143348623853 0 1 -1
documentation,of,such 1.0 0.000143348623853 0 1 -1
document,no,clinically 1.0 0.000143348623853 0 1 -1
doctor,or,pharmacist 1.0 0.000286697247706 0 2 -2
doctor,may,want 1.0 0.000143348623853 0 1 -1
doctor,before,taking 1.0 0.000143348623853 0 1 -1
doctor,before,starting 1.0 0.000143348623853 0 1 -1
doctor,and,pharmacist 1.0 0.000143348623853 0 1 -1
do,to,help 1.0 0.000143348623853 0 1 -1
do,occur,the 1.0 0.000143348623853 0 1 -1
do,not,vary 1.0 0.000143348623853 0 1 -1
do,not,take 1.0 0.000286697247706 0 2 -2
do,not,suggest 1.0 0.000286697247706 0 2 -2
do,not,suffer 1.0 0.000143348623853 0 1 -1
do,not,start 1.0 0.000143348623853 0 1 -1
do,not,require 1.0 0.000143348623853 0 1 -1
do,not,mix 1.0 0.000143348623853 0 1 -1
do,not,metabolize 1.0 0.000143348623853 0 1 -1
do,not,influence 1.0 0.000143348623853 0 1 -1
do,not,affect 1.0 0.000286697247706 0 2 -2
do,not,act 1.0 0.000143348623853 0 1 -1
dna-damaging,agents,in 1.0 0.000143348623853 0 1 -1
dna,damage,when 1.0 0.000143348623853 0 1 -1
dmpge2-induced,jejunal,net 1.0 0.000143348623853 0 1 -1
dmpge2,were,more 1.0 0.000143348623853 0 1 -1
dmpge2,induces,a 1.0 0.000143348623853 0 1 -1
dmpge2,induced,diarrhea 1.0 0.000143348623853 0 1 -1
dmpge2,in,cecectomized 1.0 0.000143348623853 0 1 -1
dmpge2,given,intraluminally 1.0 0.000143348623853 0 1 -1
dl,were,observed 1.0 0.000143348623853 0 1 -1
dl,triglycerides,mg 1.0 0.000143348623853 0 1 -1
dl,submitted,to 1.0 0.000143348623853 0 1 -1
dizziness,nausea,paresthesia 1.0 0.000143348623853 0 1 -1
dizziness,effects,constipation 1.0 0.000143348623853 0 1 -1
dizziness,during,up-titration 1.0 0.000143348623853 0 1 -1
division,of,miles 1.0 0.000143348623853 0 1 -1
divided,doses,three 1.0 0.000143348623853 0 1 -1
divergently,selected,for 1.0 0.000143348623853 0 1 -1
divalent,or,trivalent 1.0 0.000286697247706 0 2 -2
diuretics,furosemide,administered 1.0 0.000143348623853 0 1 -1
diuretics,etodolac,has 1.0 0.000143348623853 0 1 -1
diuresis,electrocardiogram,and 1.0 0.000143348623853 0 1 -1
disulfiram-like,reaction,to 1.0 0.000143348623853 0 1 -1
disulfiram-like,reaction,may 1.0 0.000143348623853 0 1 -1
disulfiram-ethanol,reaction,in 1.0 0.000143348623853 0 1 -1
disulfiram,appears,to 1.0 0.000143348623853 0 1 -1
disulfiram,alone,in 1.0 0.000143348623853 0 1 -1
disturbances,such,as 1.0 0.000143348623853 0 1 -1
disturbances,patients,with 1.0 0.000143348623853 0 1 -1
disturbances,including,complete 1.0 0.000143348623853 0 1 -1
disturbances,have,led 1.0 0.000143348623853 0 1 -1
disturbances,and,exacerbation 1.0 0.000143348623853 0 1 -1
distribution,was,not 1.0 0.000143348623853 0 1 -1
distribution,pathways,and 1.0 0.000143348623853 0 1 -1
distribution,or,total 1.0 0.000143348623853 0 1 -1
distribution,of,with 1.0 0.000143348623853 0 1 -1
distribution,of,was 1.0 0.000143348623853 0 1 -1
distribution,of,phosphatases 1.0 0.000143348623853 0 1 -1
distribution,of,concentrations 1.0 0.000143348623853 0 1 -1
distribution,metabolism,hormone 1.0 0.000143348623853 0 1 -1
distribution,have,been 1.0 0.000143348623853 0 1 -1
distribution,effect,on 1.0 0.000143348623853 0 1 -1
distribution,and,a 1.0 0.000143348623853 0 1 -1
distinguishes,it,from 1.0 0.000143348623853 0 1 -1
distinctive,effects,in 1.0 0.000143348623853 0 1 -1
distinct,from,the 1.0 0.000143348623853 0 1 -1
distilled,and,fermented 1.0 0.000143348623853 0 1 -1
dissolution,until,reaching 1.0 0.000143348623853 0 1 -1
dissolution,rate,of 1.0 0.000286697247706 0 2 -2
dissolution,of,in 1.0 0.000143348623853 0 1 -1
dissolution,of,aerosol 1.0 0.000143348623853 0 1 -1
dissolution,of,administered 1.0 0.000143348623853 0 1 -1
dissolution,in,a 1.0 0.000143348623853 0 1 -1
dissociation,of,the 1.0 0.000143348623853 0 1 -1
disrupts,the,behavioral 1.0 0.000143348623853 0 1 -1
disposition,of,was 1.0 0.000143348623853 0 1 -1
disposition,of,the 1.0 0.000143348623853 0 1 -1
disposition,of,other 1.0 0.000143348623853 0 1 -1
disposition,of,is 1.0 0.000286697247706 0 2 -2
disposition,of,in 1.0 0.000143348623853 0 1 -1
disposition,of,compounds 1.0 0.000143348623853 0 1 -1
disposition,of,and 1.0 0.000143348623853 0 1 -1
displays,both,and 1.0 0.000143348623853 0 1 -1
displaying,transient,outward 1.0 0.000143348623853 0 1 -1
display,the,hour 1.0 0.000143348623853 0 1 -1
displacing,effect,of 1.0 0.000143348623853 0 1 -1
displacement,studies,with 1.0 0.000143348623853 0 1 -1
displacement,of,the 1.0 0.000143348623853 0 1 -1
displacement,of,protein-bound 1.0 0.000143348623853 0 1 -1
displacement,of,more 1.0 0.000143348623853 0 1 -1
displacement,of,in 1.0 0.000143348623853 0 1 -1
displacement,of,by 1.0 0.000143348623853 0 1 -1
displacement,from,albumin 1.0 0.000143348623853 0 1 -1
displacement,between,and 1.0 0.000143348623853 0 1 -1
displace,tightly,bound 1.0 0.000143348623853 0 1 -1
displace,other,protein-bound 1.0 0.000143348623853 0 1 -1
displace,from,their 1.0 0.000286697247706 0 2 -2
dispersed,in,water 1.0 0.000143348623853 0 1 -1
disorientation,anxiety,agitation 1.0 0.000143348623853 0 1 -1
disorders,unrelated,to 1.0 0.000143348623853 0 1 -1
disorders,plasmacytic,hyperplasia 1.0 0.000143348623853 0 1 -1
disorders,in,patients 1.0 0.000143348623853 0 1 -1
disorders,can,exaggerate 1.0 0.000143348623853 0 1 -1
disorders,and,therapy 1.0 0.000143348623853 0 1 -1
disorder,tremor,rigidity 1.0 0.000143348623853 0 1 -1
disorder,requires,more 1.0 0.000143348623853 0 1 -1
disorder,attention,should 1.0 0.000143348623853 0 1 -1
disorder,and,anticipation 1.0 0.000143348623853 0 1 -1
disorder,abdominal,pain 1.0 0.000143348623853 0 1 -1
disopyramide,increases,qt 1.0 0.000143348623853 0 1 -1
disoproxil,fumarate,did 1.0 0.000143348623853 0 1 -1
disintegrins,and,for 1.0 0.000143348623853 0 1 -1
disintegrin,was,compared 1.0 0.000143348623853 0 1 -1
disintegrin,and,monomeric 1.0 0.000143348623853 0 1 -1
diseases,such,as 1.0 0.000143348623853 0 1 -1
diseases,recent,radiation 1.0 0.000143348623853 0 1 -1
diseases,of,the 1.0 0.000143348623853 0 1 -1
disease,who,received 1.0 0.000143348623853 0 1 -1
disease,treated,concomitantly 1.0 0.000143348623853 0 1 -1
disease,states,underlying 1.0 0.000143348623853 0 1 -1
disease,states,or 1.0 0.000143348623853 0 1 -1
disease,states,careful 1.0 0.000143348623853 0 1 -1
disease,states,associated 1.0 0.000143348623853 0 1 -1
disease,spinal,cord 1.0 0.000143348623853 0 1 -1
disease,requires,maintaining 1.0 0.000143348623853 0 1 -1
disease,rather,than 1.0 0.000143348623853 0 1 -1
disease,patients,in 1.0 0.000143348623853 0 1 -1
disease,on,the 1.0 0.000143348623853 0 1 -1
disease,medications,were 1.0 0.000143348623853 0 1 -1
disease,is,intricately 1.0 0.000143348623853 0 1 -1
disease,is,considered 1.0 0.000143348623853 0 1 -1
disease,is,a 1.0 0.000286697247706 0 2 -2
disease,including,or 1.0 0.000143348623853 0 1 -1
disease,in,which 1.0 0.000143348623853 0 1 -1
disease,in,general 1.0 0.000143348623853 0 1 -1
disease,erectile,dysfunction 1.0 0.000143348623853 0 1 -1
disease,clinical,studies 1.0 0.000143348623853 0 1 -1
disease,can,be 1.0 0.000143348623853 0 1 -1
disease,are,frequently 1.0 0.000143348623853 0 1 -1
disease,and,screening 1.0 0.000143348623853 0 1 -1
disease,and,pulmonary 1.0 0.000143348623853 0 1 -1
disease,and,poor-risk 1.0 0.000143348623853 0 1 -1
disease,and,disorder 1.0 0.000143348623853 0 1 -1
disease,aged,years 1.0 0.000143348623853 0 1 -1
discussing,the,main 1.0 0.000143348623853 0 1 -1
discusses,the,advantages 1.0 0.000143348623853 0 1 -1
discusses,the,actions 1.0 0.000143348623853 0 1 -1
discusses,current,information 1.0 0.000143348623853 0 1 -1
discussed,in,the 1.0 0.000143348623853 0 1 -1
discussed,in,relationship 1.0 0.000143348623853 0 1 -1
discussed,in,reference 1.0 0.000143348623853 0 1 -1
discussed,in,chapter 1.0 0.000143348623853 0 1 -1
discussed,herein,with 1.0 0.000143348623853 0 1 -1
discussed,especially,with 1.0 0.000143348623853 0 1 -1
discuss,the,use 1.0 0.000143348623853 0 1 -1
discrimination,and,mixed 1.0 0.000143348623853 0 1 -1
discrimination,and,it 1.0 0.000143348623853 0 1 -1
discrimination,and,behavioral 1.0 0.000143348623853 0 1 -1
discriminates,among,the 1.0 0.000143348623853 0 1 -1
discriminate,between,deficiency 1.0 0.000143348623853 0 1 -1
discrete,responses,alternative 1.0 0.000143348623853 0 1 -1
discontinuing,in,clinical 1.0 0.000143348623853 0 1 -1
discontinuing,hydrochloride,could 1.0 0.000143348623853 0 1 -1
discontinued,that,and 1.0 0.000143348623853 0 1 -1
discontinued,several,days 1.0 0.000143348623853 0 1 -1
discontinued,promptly,if 1.0 0.000143348623853 0 1 -1
discontinued,prior,to 1.0 0.000286697247706 0 2 -2
discontinued,increase,the 1.0 0.000143348623853 0 1 -1
discontinued,in,such 1.0 0.000143348623853 0 1 -1
discontinued,in,patients 1.0 0.000143348623853 0 1 -1
discontinued,if,such 1.0 0.000143348623853 0 1 -1
discontinued,hours,before 1.0 0.000143348623853 0 1 -1
discontinued,before,parathyroid-function 1.0 0.000143348623853 0 1 -1
discontinued,before,carrying 1.0 0.000286697247706 0 2 -2
discontinued,because,of 1.0 0.000143348623853 0 1 -1
discontinued,and,should 1.0 0.000143348623853 0 1 -1
discontinued,and,hoof 1.0 0.000143348623853 0 1 -1
discontinue,the,use 1.0 0.000143348623853 0 1 -1
discontinue,the,taking 1.0 0.000143348623853 0 1 -1
discontinue,pegasys,and 1.0 0.000143348623853 0 1 -1
discontinue,nursing,while 1.0 0.000143348623853 0 1 -1
discontinue,nursing,or 1.0 0.000286697247706 0 2 -2
discontinuation,ordinarily,should 1.0 0.000143348623853 0 1 -1
discontinuation,of,the 1.0 0.000143348623853 0 1 -1
discontinuation,of,taxol 1.0 0.000143348623853 0 1 -1
discontinuation,is,recommended 1.0 0.000143348623853 0 1 -1
discoloration,or,swelling 1.0 0.000143348623853 0 1 -1
discernible,changes,in 1.0 0.000143348623853 0 1 -1
disadvantages,of,pocs 1.0 0.000143348623853 0 1 -1
directly,to,the 1.0 0.000143348623853 0 1 -1
directly,affect,the 1.0 0.000143348623853 0 1 -1
directly,affect,renal 1.0 0.000143348623853 0 1 -1
direction,of,the 1.0 0.000143348623853 0 1 -1
direction,and,degree 1.0 0.000143348623853 0 1 -1
directed,and,proquin 1.0 0.000143348623853 0 1 -1
direct,treatment,costs 1.0 0.000143348623853 0 1 -1
direct,pharmacokinetic,captopril-digoxin 1.0 0.000143348623853 0 1 -1
direct,effects,on 1.0 0.000143348623853 0 1 -1
direct,effect,on 1.0 0.000143348623853 0 1 -1
direct,coombs,tests 1.0 0.000286697247706 0 2 -2
direct,coombs,test 1.0 0.000143348623853 0 1 -1
direct,coombs,reactions 1.0 0.000143348623853 0 1 -1
direct,and,indirect 1.0 0.000143348623853 0 1 -1
dipstick,test,for 1.0 0.000143348623853 0 1 -1
dipropylxanthine,dpcpx,in 1.0 0.000143348623853 0 1 -1
diplococcus,pneumoniae,streptococcus 1.0 0.000143348623853 0 1 -1
dipivoxil,or,tenofovir 1.0 0.000143348623853 0 1 -1
diphenhydramine,is,reported 1.0 0.000143348623853 0 1 -1
diphenhydramine,diphenhydramine,is 1.0 0.000143348623853 0 1 -1
diphen-hydramine,and,h2 1.0 0.000143348623853 0 1 -1
dip-stick,methodology,used 1.0 0.000143348623853 0 1 -1
dinitrate,chloride,folic 1.0 0.000143348623853 0 1 -1
diminution,is,not 1.0 0.000286697247706 0 2 -2
diminished,effect,of 1.0 0.000143348623853 0 1 -1
diminished,by,a 1.0 0.000143348623853 0 1 -1
diminish,fluoride,or 1.0 0.000143348623853 0 1 -1
dimethylprostaglandin,e2-induced,diarrhea 1.0 0.000143348623853 0 1 -1
dimethylprostaglandin,e2,dmpge2 1.0 0.000143348623853 0 1 -1
dilution,method,and 1.0 0.000143348623853 0 1 -1
dilute,solutions,should 1.0 0.000143348623853 0 1 -1
diltiazem,plasma,levels 1.0 0.000143348623853 0 1 -1
diltiazem,is,both 1.0 0.000143348623853 0 1 -1
dilation,diaphoresis,emesis 1.0 0.000143348623853 0 1 -1
dihydroxyflavone,with,may 1.0 0.000143348623853 0 1 -1
dihydroxycholecalciferol,d3,oh 1.0 0.000143348623853 0 1 -1
dihydropyridine,derivative,while 1.0 0.000143348623853 0 1 -1
dihydroergotamine,contraindicated,due 1.0 0.000143348623853 0 1 -1
digoxin,when,starlix 1.0 0.000143348623853 0 1 -1
digoxin,when,given 1.0 0.000143348623853 0 1 -1
digoxin,volume,of 1.0 0.000143348623853 0 1 -1
digoxin,the,concomitant 1.0 0.000143348623853 0 1 -1
digoxin,supraventricular,arrhythmias 1.0 0.000143348623853 0 1 -1
digoxin,studies,of 1.0 0.000143348623853 0 1 -1
digoxin,studies,in 1.0 0.000143348623853 0 1 -1
digoxin,sonata,mg 1.0 0.000143348623853 0 1 -1
digoxin,rofecoxib,mg 1.0 0.000143348623853 0 1 -1
digoxin,plasma,levels 1.0 0.000143348623853 0 1 -1
digoxin,nimodipine,and 1.0 0.000143348623853 0 1 -1
digoxin,methotrexate,cyclosporine 1.0 0.000143348623853 0 1 -1
digoxin,keppra,mg 1.0 0.000143348623853 0 1 -1
digoxin,interaction,studies 1.0 0.000143348623853 0 1 -1
digoxin,in,subjects 1.0 0.000143348623853 0 1 -1
digoxin,in,patients 1.0 0.000143348623853 0 1 -1
digoxin,in,a 1.0 0.000143348623853 0 1 -1
digoxin,half-life,of 1.0 0.000143348623853 0 1 -1
digoxin,did,not 1.0 0.000143348623853 0 1 -1
digoxin,a,single 1.0 0.000143348623853 0 1 -1
digitalized,patient,slow 1.0 0.000143348623853 0 1 -1
digitalis,glycosides,therapeutic 1.0 0.000143348623853 0 1 -1
digitalis,glycosides,patients 1.0 0.000143348623853 0 1 -1
digitalis,enhanced,possibility 1.0 0.000143348623853 0 1 -1
digital,extensor,tension 1.0 0.000143348623853 0 1 -1
digi-,tab,ria 1.0 0.000143348623853 0 1 -1
digestion,and,absorption 1.0 0.000143348623853 0 1 -1
diftitox,had,no 1.0 0.000143348623853 0 1 -1
difluoroacetone,to,erythro-fluorocitrate 1.0 0.000143348623853 0 1 -1
difluoroacetone,mg,kg 1.0 0.000286697247706 0 2 -2
difluoroacetone,did,not 1.0 0.000143348623853 0 1 -1
difluoroacetone,by,an 1.0 0.000143348623853 0 1 -1
difluoroacetone,a,known 1.0 0.000143348623853 0 1 -1
difluoro-2,propanol,was 1.0 0.000143348623853 0 1 -1
diffusible,treatment,during 1.0 0.000143348623853 0 1 -1
diffuse,muscle,pain 1.0 0.000143348623853 0 1 -1
diffraction,differential,scanning 1.0 0.000143348623853 0 1 -1
difficulty,once,the 1.0 0.000143348623853 0 1 -1
difficult,to,situate 1.0 0.000143348623853 0 1 -1
difficult,to,predict 1.0 0.000143348623853 0 1 -1
difficile,a,displays 1.0 0.000143348623853 0 1 -1
differs,in,the 1.0 0.000143348623853 0 1 -1
differs,from,what 1.0 0.000143348623853 0 1 -1
differin,gel,until 1.0 0.000143348623853 0 1 -1
differin,gel,has 1.0 0.000143348623853 0 1 -1
differently,than,and 1.0 0.000143348623853 0 1 -1
differently,from,the 1.0 0.000143348623853 0 1 -1
differential-reinforcement,of-low,rates 1.0 0.000143348623853 0 1 -1
differential,thermal,analysis 1.0 0.000143348623853 0 1 -1
differential,scanning,calorimetry 1.0 0.000143348623853 0 1 -1
differential,regulation,of 1.0 0.000143348623853 0 1 -1
differential,effects,on 1.0 0.000286697247706 0 2 -2
differential,diagnosis,of 1.0 0.000143348623853 0 1 -1
differential,actions,of 1.0 0.000143348623853 0 1 -1
different,way,crossover 1.0 0.000143348623853 0 1 -1
different,types,of 1.0 0.000143348623853 0 1 -1
different,times,and 1.0 0.000143348623853 0 1 -1
different,times,after 1.0 0.000143348623853 0 1 -1
different,tasks,in 1.0 0.000143348623853 0 1 -1
different,site,ie 1.0 0.000143348623853 0 1 -1
different,route,than 1.0 0.000143348623853 0 1 -1
different,responses,in 1.0 0.000143348623853 0 1 -1
different,on,glycemia 1.0 0.000143348623853 0 1 -1
different,medicines,may 1.0 0.000143348623853 0 1 -1
different,levels,of 1.0 0.000143348623853 0 1 -1
different,in,poor 1.0 0.000143348623853 0 1 -1
different,from,the 1.0 0.000143348623853 0 1 -1
different,from,results 1.0 0.000143348623853 0 1 -1
different,for,the 1.0 0.000143348623853 0 1 -1
different,descending,pain 1.0 0.000286697247706 0 2 -2
different,days,for 1.0 0.000143348623853 0 1 -1
different,ca,channel 1.0 0.000143348623853 0 1 -1
different,botulinum,neurotoxin 1.0 0.000286697247706 0 2 -2
different,before,and 1.0 0.000143348623853 0 1 -1
different,and,neither 1.0 0.000143348623853 0 1 -1
differences,were,reflected 1.0 0.000143348623853 0 1 -1
differences,were,observed 1.0 0.00043004587156 0 3 -3
differences,were,between 1.0 0.000143348623853 0 1 -1
differences,may,be 1.0 0.000143348623853 0 1 -1
differences,in,the 1.0 0.000143348623853 0 1 -1
differences,in,sensitivity 1.0 0.000143348623853 0 1 -1
differences,in,safety 1.0 0.000143348623853 0 1 -1
differences,in,prothrombin 1.0 0.000143348623853 0 1 -1
differences,in,locomotor 1.0 0.000143348623853 0 1 -1
differences,in,effect 1.0 0.000143348623853 0 1 -1
differences,in,dosing 1.0 0.000143348623853 0 1 -1
differences,in,clearance 1.0 0.000143348623853 0 1 -1
differences,in,balance 1.0 0.000143348623853 0 1 -1
differences,in,adverse 1.0 0.000286697247706 0 2 -2
differences,can,occur 1.0 0.000143348623853 0 1 -1
differences,between,tumor 1.0 0.000143348623853 0 1 -1
differences,between,treatment 1.0 0.000143348623853 0 1 -1
differences,between,the 1.0 0.000143348623853 0 1 -1
differences,between,cecectomized 1.0 0.000143348623853 0 1 -1
differences,are,being 1.0 0.000143348623853 0 1 -1
differences,among,the 1.0 0.000143348623853 0 1 -1
difference,was,not 1.0 0.000143348623853 0 1 -1
difference,was,found 1.0 0.000143348623853 0 1 -1
difference,p,in 1.0 0.000143348623853 0 1 -1
difference,in,the 1.0 0.000573394495413 0 4 -4
difference,in,pharmacodynamic 1.0 0.000143348623853 0 1 -1
difference,exists,between 1.0 0.000143348623853 0 1 -1
difference,between,the 1.0 0.000143348623853 0 1 -1
difference,between,coadministered 1.0 0.000143348623853 0 1 -1
differ,significantly,in 1.0 0.000143348623853 0 1 -1
differ,in,their 1.0 0.000143348623853 0 1 -1
differ,from,control 1.0 0.000143348623853 0 1 -1
differ,and,they 1.0 0.000143348623853 0 1 -1
diets,no,effect 1.0 0.000143348623853 0 1 -1
diets,containing,either 1.0 0.000143348623853 0 1 -1
diethylnitrosamine,during,the 1.0 0.000143348623853 0 1 -1
diethyl,pyrocarbonate,revealed 1.0 0.000143348623853 0 1 -1
diethyl,pyrocarbonate,could 1.0 0.000143348623853 0 1 -1
diethyl,pyrocarbonate,at 1.0 0.000143348623853 0 1 -1
diethyl,pyrocarbonate,abolished 1.0 0.000143348623853 0 1 -1
dietary-obese,rats,showed 1.0 0.000143348623853 0 1 -1
dietary-obese,rats,responses 1.0 0.000143348623853 0 1 -1
dietary-obese,rats,giving 1.0 0.000143348623853 0 1 -1
dietary-obese,rats,are 1.0 0.000143348623853 0 1 -1
dietary,treatments,with 1.0 0.000143348623853 0 1 -1
dietary,interferes,with 1.0 0.000143348623853 0 1 -1
dietary,concentrations,showing 1.0 0.000143348623853 0 1 -1
dietary,concentration,as 1.0 0.000143348623853 0 1 -1
diet,or,with 1.0 0.000143348623853 0 1 -1
diet,did,not 1.0 0.000143348623853 0 1 -1
diet,and,more 1.0 0.000143348623853 0 1 -1
dienes,approximately,in 1.0 0.000143348623853 0 1 -1
died,compared,to 1.0 0.000143348623853 0 1 -1
die,from,macrovascular 1.0 0.000143348623853 0 1 -1
didanosine,it,is 1.0 0.000143348623853 0 1 -1
didanosine,fluconazole,fluoxetine 1.0 0.000143348623853 0 1 -1
did,produce,inhibition 1.0 0.000143348623853 0 1 -1
did,occur,at 1.0 0.000143348623853 0 1 -1
did,not,systematically 1.0 0.000143348623853 0 1 -1
did,not,show 1.0 0.000860091743119 0 6 -6
did,not,seem 1.0 0.000143348623853 0 1 -1
did,not,reveal 1.0 0.000143348623853 0 1 -1
did,not,report 1.0 0.000143348623853 0 1 -1
did,not,produce 1.0 0.000286697247706 0 2 -2
did,not,modify 1.0 0.000286697247706 0 2 -2
did,not,meaningfully 1.0 0.000143348623853 0 1 -1
did,not,lead 1.0 0.000143348623853 0 1 -1
did,not,interfere 1.0 0.000716743119266 0 5 -5
did,not,interact 1.0 0.000143348623853 0 1 -1
did,not,inhibit 1.0 0.000573394495413 0 4 -4
did,not,influence 1.0 0.000860091743119 0 6 -6
did,not,induce 1.0 0.000286697247706 0 2 -2
did,not,increase 1.0 0.00043004587156 0 3 -3
did,not,include 1.0 0.000143348623853 0 1 -1
did,not,have 1.0 0.00143348623853 0 10 -10
did,not,extend 1.0 0.000143348623853 0 1 -1
did,not,experience 1.0 0.000143348623853 0 1 -1
did,not,display 1.0 0.000143348623853 0 1 -1
did,not,diminish 1.0 0.000143348623853 0 1 -1
did,not,differ 1.0 0.000286697247706 0 2 -2
did,not,detect 1.0 0.000143348623853 0 1 -1
did,not,depend 1.0 0.000143348623853 0 1 -1
did,not,demonstrate 1.0 0.000286697247706 0 2 -2
did,not,correlate 1.0 0.000143348623853 0 1 -1
did,not,confirm 1.0 0.000143348623853 0 1 -1
did,not,change 1.0 0.00043004587156 0 3 -3
did,not,cause 1.0 0.000286697247706 0 2 -2
did,not,appear 1.0 0.00043004587156 0 3 -3
did,not,alter 1.0 0.0024369266055 0 17 -17
did,it,affect 1.0 0.000143348623853 0 1 -1
dicumarol,and,may 1.0 0.000143348623853 0 1 -1
dicumarol,and,indanedione 1.0 0.000143348623853 0 1 -1
diclofenac,like,other 1.0 0.000143348623853 0 1 -1
diclofenac,is,a 1.0 0.000143348623853 0 1 -1
diclofenac,increases,platelet 1.0 0.000143348623853 0 1 -1
diclofenac,does,not 1.0 0.000143348623853 0 1 -1
diclofenac,administration,of 1.0 0.000143348623853 0 1 -1
diazepam,valium,is 1.0 0.000143348623853 0 1 -1
diazepam,diazepam,valium 1.0 0.000143348623853 0 1 -1
diastolic,or,systolic 1.0 0.000143348623853 0 1 -1
diarrhea-inducing,effects,of 1.0 0.000143348623853 0 1 -1
diarrhea,was,analyzed 1.0 0.000143348623853 0 1 -1
diarrhea,or,in 1.0 0.000143348623853 0 1 -1
diarrhea,model,is 1.0 0.000143348623853 0 1 -1
diarrhea,in,cecectomized 1.0 0.000143348623853 0 1 -1
diarrhea,hypotension,edema 1.0 0.000143348623853 0 1 -1
diarrhea,but,did 1.0 0.000143348623853 0 1 -1
diarrhea,and,positive 1.0 0.000143348623853 0 1 -1
diamond,trials,the 1.0 0.000143348623853 0 1 -1
diamond,trials,patients 1.0 0.000143348623853 0 1 -1
dialyzed,were,and 1.0 0.000143348623853 0 1 -1
dialyzable,may,be 1.0 0.000143348623853 0 1 -1
dialysis,solutions,blood 1.0 0.000143348623853 0 1 -1
diagnostic,treatment,and 1.0 0.000143348623853 0 1 -1
diagnostic,serum,tests 1.0 0.000143348623853 0 1 -1
diagnostic,or,therapeutic 1.0 0.000286697247706 0 2 -2
diagnostic,interference,with 1.0 0.000143348623853 0 1 -1
diagnostic,dip-stick,methodology 1.0 0.000143348623853 0 1 -1
diagnostic,challenge,and 1.0 0.000143348623853 0 1 -1
diagnosis,or,monitoring 1.0 0.000143348623853 0 1 -1
diagnosis,of,myocardial 1.0 0.000143348623853 0 1 -1
diagnosis,of,deficiency 1.0 0.000143348623853 0 1 -1
diagnosed,subjects,with 1.0 0.000143348623853 0 1 -1
diagnosed,during,therapy 1.0 0.000143348623853 0 1 -1
diagnosed,during,accutane 1.0 0.000143348623853 0 1 -1
diabinese,the,patient 1.0 0.000573394495413 0 4 -4
diabetics,who,were 1.0 0.000143348623853 0 1 -1
diabetics,who,take 1.0 0.000143348623853 0 1 -1
diabetics,should,discuss 1.0 0.000143348623853 0 1 -1
diabetics,die,from 1.0 0.000143348623853 0 1 -1
diabetics,blood-sugar,levels 1.0 0.000143348623853 0 1 -1
diabetics,and,undetectable 1.0 0.000143348623853 0 1 -1
diabetic,rats,were 1.0 0.000143348623853 0 1 -1
diabetic,patients,without 1.0 0.000143348623853 0 1 -1
diabetic,patients,under 1.0 0.000143348623853 0 1 -1
diabetic,patients,there 1.0 0.000143348623853 0 1 -1
diabetic,patients,receiving 1.0 0.000143348623853 0 1 -1
diabetic,patients,must 1.0 0.000143348623853 0 1 -1
diabetic,patients,may 1.0 0.000143348623853 0 1 -1
diabetic,patients,have 1.0 0.000143348623853 0 1 -1
diabetic,patients,demonstrated 1.0 0.000143348623853 0 1 -1
diabetic,individuals,because 1.0 0.000143348623853 0 1 -1
diabetic,cinese,hamsters 1.0 0.000143348623853 0 1 -1
diabetic,chinese,hamsters 1.0 0.000143348623853 0 1 -1
diabetic,chinese,hamster 1.0 0.000286697247706 0 2 -2
diabetes,were,administered 1.0 0.000143348623853 0 1 -1
diabetes,there,were 1.0 0.000143348623853 0 1 -1
diabetes,mellitus,the 1.0 0.000143348623853 0 1 -1
diabetes,mellitus,or 1.0 0.000143348623853 0 1 -1
diabetes,mellitus,may 1.0 0.000143348623853 0 1 -1
diabetes,mellitus,ischemic 1.0 0.000143348623853 0 1 -1
diabetes,mellitus,is 1.0 0.000143348623853 0 1 -1
diabetes,mellitus,certain 1.0 0.000143348623853 0 1 -1
diabetes,mellitus,and 1.0 0.000143348623853 0 1 -1
diabetes,longitudinal,studies 1.0 0.000143348623853 0 1 -1
diabetes,have,been 1.0 0.000286697247706 0 2 -2
diabetes,coagulation,factors 1.0 0.000143348623853 0 1 -1
diabectics,than,in 1.0 0.000143348623853 0 1 -1
dha,was,more 1.0 0.000143348623853 0 1 -1
dextrorotatory,isomer,on 1.0 0.000143348623853 0 1 -1
dextromethorphan,is,primarily 1.0 0.000143348623853 0 1 -1
dextromethorphan,is,a 1.0 0.000143348623853 0 1 -1
dextromethorphan,dextromethorphan,is 1.0 0.000143348623853 0 1 -1
dexrazoxane,was,not 1.0 0.000143348623853 0 1 -1
dexamethasone,suppression,test 1.0 0.000143348623853 0 1 -1
dexamethasone,is,a 1.0 0.000143348623853 0 1 -1
dexamethasone,had,a 1.0 0.000143348623853 0 1 -1
devices,and,test 1.0 0.000143348623853 0 1 -1
device,and,how 1.0 0.000143348623853 0 1 -1
developments,in,these 1.0 0.000143348623853 0 1 -1
developmental,acquisition,after 1.0 0.000143348623853 0 1 -1
development,was,observed 1.0 0.000143348623853 0 1 -1
development,of,withdrawal 1.0 0.000143348623853 0 1 -1
development,of,the 1.0 0.00043004587156 0 3 -3
development,of,severe 1.0 0.000143348623853 0 1 -1
development,of,selective 1.0 0.000143348623853 0 1 -1
development,of,safe 1.0 0.000143348623853 0 1 -1
development,of,not 1.0 0.000143348623853 0 1 -1
development,of,drug-induced 1.0 0.000143348623853 0 1 -1
development,of,dependence 1.0 0.000286697247706 0 2 -2
development,of,clinical 1.0 0.000143348623853 0 1 -1
development,of,a 1.0 0.000143348623853 0 1 -1
development,is,not 1.0 0.000143348623853 0 1 -1
development,including,immune 1.0 0.000143348623853 0 1 -1
development,essential,to 1.0 0.000143348623853 0 1 -1
development,consistent,with 1.0 0.000143348623853 0 1 -1
development,at,clinically 1.0 0.000143348623853 0 1 -1
developing,rhabdomyolysis,including 1.0 0.000143348623853 0 1 -1
developing,renal,failure 1.0 0.000143348623853 0 1 -1
developing,mathematical,functions 1.0 0.000143348623853 0 1 -1
developed,severe,hypersensitivity 1.0 0.000143348623853 0 1 -1
developed,severe,autonomic 1.0 0.000143348623853 0 1 -1
developed,regarding,interactions 1.0 0.000143348623853 0 1 -1
developed,b-cell,hyperplasia 1.0 0.000143348623853 0 1 -1
developed,as,a 1.0 0.000143348623853 0 1 -1
developed,a,b-cell 1.0 0.000143348623853 0 1 -1
develop,physiological,tolerance 1.0 0.000143348623853 0 1 -1
develop,higher,than 1.0 0.000143348623853 0 1 -1
detrimental,for,the 1.0 0.000143348623853 0 1 -1
detrimental,effects,on 1.0 0.000143348623853 0 1 -1
detrimental,effects,in 1.0 0.000143348623853 0 1 -1
determining,the,magnitude 1.0 0.000143348623853 0 1 -1
determining,synergism,with 1.0 0.000143348623853 0 1 -1
determined,that,the 1.0 0.000143348623853 0 1 -1
determined,on,different 1.0 0.000143348623853 0 1 -1
determined,in,iso-sensitest 1.0 0.000143348623853 0 1 -1
determined,definitely,that 1.0 0.000143348623853 0 1 -1
determined,by,using 1.0 0.000143348623853 0 1 -1
determined,by,their 1.0 0.000143348623853 0 1 -1
determined,by,the 1.0 0.000143348623853 0 1 -1
determined,by,consulting 1.0 0.000143348623853 0 1 -1
determined,by,checkerboard 1.0 0.000143348623853 0 1 -1
determined,by,a 1.0 0.000143348623853 0 1 -1
determined,after,a 1.0 0.000143348623853 0 1 -1
determine,whether,would 1.0 0.000143348623853 0 1 -1
determine,whether,they 1.0 0.000143348623853 0 1 -1
determine,whether,injection 1.0 0.000143348623853 0 1 -1
determine,whether,has 1.0 0.000143348623853 0 1 -1
determine,the,presence 1.0 0.000143348623853 0 1 -1
determine,the,extent 1.0 0.000143348623853 0 1 -1
determine,the,effects 1.0 0.000143348623853 0 1 -1
determine,the,effect 1.0 0.000143348623853 0 1 -1
determine,its,capacity 1.0 0.000143348623853 0 1 -1
determine,if,they 1.0 0.000143348623853 0 1 -1
determine,if,there 1.0 0.000143348623853 0 1 -1
determine,blood,plasma 1.0 0.000286697247706 0 2 -2
determinations,of,serum 1.0 0.000143348623853 0 1 -1
determinations,are,important 1.0 0.000143348623853 0 1 -1
determinations,are,advisable 1.0 0.000286697247706 0 2 -2
determination,of,the 1.0 0.000286697247706 0 2 -2
determination,of,prothrombin 1.0 0.000143348623853 0 1 -1
determination,of,creatinine 1.0 0.000143348623853 0 1 -1
determinants,of,cellular 1.0 0.000143348623853 0 1 -1
determinants,downstream,of 1.0 0.000143348623853 0 1 -1
determinant,of,sensitivity 1.0 0.000143348623853 0 1 -1
deterioration,of,asthma 1.0 0.000143348623853 0 1 -1
deterioration,in,renal 1.0 0.000143348623853 0 1 -1
detection,of,exposure 1.0 0.000143348623853 0 1 -1
detecting,alterations,in 1.0 0.000143348623853 0 1 -1
detected,in,in 1.0 0.000143348623853 0 1 -1
detected,in,ci 1.0 0.000143348623853 0 1 -1
detected,except,for 1.0 0.000143348623853 0 1 -1
detected,although,the 1.0 0.000143348623853 0 1 -1
detected,after,weeks 1.0 0.000143348623853 0 1 -1
detectable,effect,on 1.0 0.000143348623853 0 1 -1
detect,ketone,bodies 1.0 0.000143348623853 0 1 -1
detect,an,effect 1.0 0.000143348623853 0 1 -1
despite,the,several-fold 1.0 0.000143348623853 0 1 -1
despite,seemingly,adequate 1.0 0.000143348623853 0 1 -1
despite,reduction,in 1.0 0.000143348623853 0 1 -1
desmopressin,tablets,should 1.0 0.000143348623853 0 1 -1
desmopressin,is,very 1.0 0.000143348623853 0 1 -1
desloratadine,and,hydroxydesloratadine 1.0 0.000143348623853 0 1 -1
desired,this,combination 1.0 0.000143348623853 0 1 -1
desired,therapeutic,effect 1.0 0.000143348623853 0 1 -1
desired,level,to 1.0 0.000286697247706 0 2 -2
desirable,to,monitor 1.0 0.000716743119266 0 5 -5
desirable,or,undesirable 1.0 0.000286697247706 0 2 -2
desirable,antimuscarinic,effects 1.0 0.000143348623853 0 1 -1
designs,for,the 1.0 0.000286697247706 0 2 -2
designs,can,be 1.0 0.000286697247706 0 2 -2
designing,experiments,for 1.0 0.000143348623853 0 1 -1
designed,to,investigate 1.0 0.000143348623853 0 1 -1
designed,to,examine 1.0 0.000143348623853 0 1 -1
designed,to,evaluate 1.0 0.000143348623853 0 1 -1
designed,studies,have 1.0 0.000143348623853 0 1 -1
design,open-label,three-phase 1.0 0.000143348623853 0 1 -1
design,of,new 1.0 0.000143348623853 0 1 -1
desethylzaleplon,formed,via 1.0 0.000143348623853 0 1 -1
describes,a,recently 1.0 0.000143348623853 0 1 -1
described,little,is 1.0 0.000143348623853 0 1 -1
described,in,this 1.0 0.00043004587156 0 3 -3
described,in,a 1.0 0.000143348623853 0 1 -1
described,as,strong 1.0 0.000143348623853 0 1 -1
describe,the,escalating 1.0 0.000143348623853 0 1 -1
describe,a,simple 1.0 0.000143348623853 0 1 -1
descending,epsilon,and 1.0 0.000143348623853 0 1 -1
descarboethoxyloratadine,after,days 1.0 0.000143348623853 0 1 -1
desbutyl,levobupivacaine,and 1.0 0.000143348623853 0 1 -1
dermatologist,and,their 1.0 0.000143348623853 0 1 -1
deriving,from,multiple 1.0 0.000143348623853 0 1 -1
deriving,experimental,designs 1.0 0.000143348623853 0 1 -1
derived,from,serum-deprived 1.0 0.000143348623853 0 1 -1
derivatives,nicotinic,acid 1.0 0.000143348623853 0 1 -1
derivatives,niacin,nicotinic 1.0 0.000143348623853 0 1 -1
derivatives,k,antagonists 1.0 0.000143348623853 0 1 -1
derivatives,in,a 1.0 0.000143348623853 0 1 -1
derivatives,dihydroergotamine,contraindicated 1.0 0.000143348623853 0 1 -1
derivative,while,left 1.0 0.000143348623853 0 1 -1
derivative,of,this 1.0 0.000143348623853 0 1 -1
derivative,is,a 1.0 0.000143348623853 0 1 -1
derivative,implications,for 1.0 0.000143348623853 0 1 -1
depth,of,involvement 1.0 0.000143348623853 0 1 -1
deprived,of,water 1.0 0.000143348623853 0 1 -1
depressive,symptoms,support 1.0 0.000143348623853 0 1 -1
depressive,symptoms,p 1.0 0.000143348623853 0 1 -1
depressive,symptoms,but 1.0 0.000143348623853 0 1 -1
depressive,and,negative 1.0 0.000143348623853 0 1 -1
depression,than,the 1.0 0.000143348623853 0 1 -1
depression,producing,medications 1.0 0.000286697247706 0 2 -2
depression,or,other 1.0 0.000143348623853 0 1 -1
depression,is,reaching 1.0 0.000143348623853 0 1 -1
depression,in,diabetic 1.0 0.000143348623853 0 1 -1
depression,hallucinations,paresthesia 1.0 0.000143348623853 0 1 -1
depression,cns,depressants 1.0 0.000143348623853 0 1 -1
depression,and,bradyarrhythmias 1.0 0.000143348623853 0 1 -1
depresses,bone,marrow 1.0 0.000143348623853 0 1 -1
depressed,the,amplitudes 1.0 0.000143348623853 0 1 -1
depressed,at,a 1.0 0.000143348623853 0 1 -1
depressants,with,habituating 1.0 0.000143348623853 0 1 -1
depressants,other,than 1.0 0.000143348623853 0 1 -1
depressants,but,regular 1.0 0.000143348623853 0 1 -1
depressant,effects,on 1.0 0.000143348623853 0 1 -1
depressant,effect,on 1.0 0.000143348623853 0 1 -1
depressant,cns,including 1.0 0.000143348623853 0 1 -1
depressant,and,cautioned 1.0 0.000143348623853 0 1 -1
depress,prolactin,secretion 1.0 0.000143348623853 0 1 -1
depletor,should,therefore 1.0 0.00043004587156 0 3 -3
depletion,which,becomes 1.0 0.000143348623853 0 1 -1
depletion,related,to 1.0 0.000143348623853 0 1 -1
depletion,are,tricky 1.0 0.000143348623853 0 1 -1
depleting,added,to 1.0 0.000143348623853 0 1 -1
depends,on,the 1.0 0.000143348623853 0 1 -1
depends,on,clinical 1.0 0.000143348623853 0 1 -1
depends,not,only 1.0 0.000143348623853 0 1 -1
depending,on,the 1.0 0.00114678899083 0 8 -8
dependent,upon,the 1.0 0.000143348623853 0 1 -1
dependent,upon,cytochrome 1.0 0.000143348623853 0 1 -1
dependent,oxidation,is 1.0 0.000143348623853 0 1 -1
dependent,on,the 1.0 0.000143348623853 0 1 -1
dependent,measures,included 1.0 0.000143348623853 0 1 -1
dependent,labelling,of 1.0 0.000143348623853 0 1 -1
dependent,diabetic,patients 1.0 0.000143348623853 0 1 -1
dependent,areas,in 1.0 0.000143348623853 0 1 -1
dependency,of,the 1.0 0.000143348623853 0 1 -1
dependence,usually,involves 1.0 0.000143348623853 0 1 -1
dependence,on,application 1.0 0.000143348623853 0 1 -1
dependence,of,each 1.0 0.000143348623853 0 1 -1
dependence,may,be 1.0 0.000143348623853 0 1 -1
depend,upon,the 1.0 0.000143348623853 0 1 -1
depend,upon,a 1.0 0.000143348623853 0 1 -1
depakene,use,of 1.0 0.000143348623853 0 1 -1
deoxy,to,is 1.0 0.000143348623853 0 1 -1
denudation,indicating,an 1.0 0.000143348623853 0 1 -1
dentistry,cannot,be 1.0 0.000143348623853 0 1 -1
density,of,d2 1.0 0.000143348623853 0 1 -1
density,in,functional 1.0 0.000143348623853 0 1 -1
density,bmax,in 1.0 0.000143348623853 0 1 -1
denileukin,diftitox,had 1.0 0.000143348623853 0 1 -1
demonstrates,the,importance 1.0 0.000143348623853 0 1 -1
demonstrated,widespread,effects 1.0 0.000143348623853 0 1 -1
demonstrated,the,following 1.0 0.000143348623853 0 1 -1
demonstrated,that,pretreatment 1.0 0.000143348623853 0 1 -1
demonstrated,that,mixing 1.0 0.000143348623853 0 1 -1
demonstrated,that,inhibits 1.0 0.000143348623853 0 1 -1
demonstrated,that,has 1.0 0.000143348623853 0 1 -1
demonstrated,that,did 1.0 0.000143348623853 0 1 -1
demonstrated,that,administration 1.0 0.000143348623853 0 1 -1
demonstrated,superiority,over 1.0 0.000143348623853 0 1 -1
demonstrated,superior,antipsychotic 1.0 0.000143348623853 0 1 -1
demonstrated,similar,efficacy 1.0 0.000143348623853 0 1 -1
demonstrated,renal,precipitation 1.0 0.000143348623853 0 1 -1
demonstrated,only,in 1.0 0.000143348623853 0 1 -1
demonstrated,no,significant 1.0 0.000143348623853 0 1 -1
demonstrated,no,evidence 1.0 0.00043004587156 0 3 -3
demonstrated,no,effect 1.0 0.000143348623853 0 1 -1
demonstrated,marked,reductions 1.0 0.000143348623853 0 1 -1
demonstrated,large,numbers 1.0 0.000143348623853 0 1 -1
demonstrated,in,view 1.0 0.000143348623853 0 1 -1
demonstrated,in,all 1.0 0.000143348623853 0 1 -1
demonstrated,hypokalemia,they 1.0 0.00043004587156 0 3 -3
demonstrated,for,cigarette 1.0 0.000143348623853 0 1 -1
demonstrated,efficacy,in 1.0 0.000143348623853 0 1 -1
demonstrated,efficacy,and 1.0 0.000143348623853 0 1 -1
demonstrated,effectiveness,in 1.0 0.000143348623853 0 1 -1
demonstrated,clinical,evidence 1.0 0.000143348623853 0 1 -1
demonstrated,by,the 1.0 0.000286697247706 0 2 -2
demonstrated,between,argatroban 1.0 0.000143348623853 0 1 -1
demonstrated,any,significant 1.0 0.000143348623853 0 1 -1
demonstrated,any,effect 1.0 0.000143348623853 0 1 -1
demonstrated,a,rapid 1.0 0.000143348623853 0 1 -1
demonstrated,a,lack 1.0 0.000143348623853 0 1 -1
demonstrate,very,little 1.0 0.000143348623853 0 1 -1
demonstrate,that,with 1.0 0.000143348623853 0 1 -1
demonstrate,that,iga 1.0 0.000143348623853 0 1 -1
demonstrate,that,does 1.0 0.000286697247706 0 2 -2
demonstrate,that,and 1.0 0.000143348623853 0 1 -1
demonstrate,any,efficacy 1.0 0.000143348623853 0 1 -1
demonstrate,any,alterations 1.0 0.000143348623853 0 1 -1
demonstrate,a,high 1.0 0.000143348623853 0 1 -1
demographics,nhl,characteristics 1.0 0.000143348623853 0 1 -1
deltasone,orasone,others 1.0 0.000143348623853 0 1 -1
delta,and,kappa-selective 1.0 0.000143348623853 0 1 -1
deletion,of,any 1.0 0.000143348623853 0 1 -1
deleterious,interactions,were 1.0 0.000143348623853 0 1 -1
deleterious,effects,following 1.0 0.000143348623853 0 1 -1
delayed,until,the 1.0 0.000143348623853 0 1 -1
delayed,until,after 1.0 0.000143348623853 0 1 -1
delayed,elimination,and 1.0 0.000143348623853 0 1 -1
delayed,by,a 1.0 0.000143348623853 0 1 -1
delayed,at,least 1.0 0.000143348623853 0 1 -1
delay,premature,atherosclerotic 1.0 0.000143348623853 0 1 -1
delay,elimination,of 1.0 0.000143348623853 0 1 -1
dehydrogenase,pyrroloquinolinequinone,gdh 1.0 0.000143348623853 0 1 -1
degrees,of,recovery 1.0 0.000143348623853 0 1 -1
degrees,of,locomotor 1.0 0.000143348623853 0 1 -1
degrees,c,the 1.0 0.000143348623853 0 1 -1
degrees,c,human 1.0 0.000143348623853 0 1 -1
degrees,c,for 1.0 0.000143348623853 0 1 -1
degree,when,it 1.0 0.000143348623853 0 1 -1
degree,should,be 1.0 0.000143348623853 0 1 -1
degree,of,variability 1.0 0.000143348623853 0 1 -1
degree,of,the 1.0 0.000143348623853 0 1 -1
degree,of,stereoselectivity 1.0 0.000143348623853 0 1 -1
degree,of,qtc 1.0 0.000143348623853 0 1 -1
degree,of,protein 1.0 0.000143348623853 0 1 -1
degree,of,heart 1.0 0.000143348623853 0 1 -1
degree,of,enhancement 1.0 0.000143348623853 0 1 -1
degree,of,anticoagulation 1.0 0.000143348623853 0 1 -1
degree,of,accumulation 1.0 0.000143348623853 0 1 -1
degree,in,the 1.0 0.000286697247706 0 2 -2
degraded,by,peptidase 1.0 0.000143348623853 0 1 -1
degenerative,changes,in 1.0 0.000143348623853 0 1 -1
degeneration,wallerian,degeneration 1.0 0.000143348623853 0 1 -1
degeneration,of,retinogeniculate 1.0 0.000143348623853 0 1 -1
definitely,that,the 1.0 0.000143348623853 0 1 -1
definitely,determined,that 1.0 0.000143348623853 0 1 -1
definite,nondepolarizing,blocking 1.0 0.000143348623853 0 1 -1
defined,physical,dependency 1.0 0.000143348623853 0 1 -1
defined,medium,consisting 1.0 0.000143348623853 0 1 -1
defined,as,compulsion 1.0 0.000143348623853 0 1 -1
define,the,possible 1.0 0.000143348623853 0 1 -1
define,the,changes 1.0 0.000143348623853 0 1 -1
define,positive,and 1.0 0.000143348623853 0 1 -1
deficits,in,learning 1.0 0.000143348623853 0 1 -1
deficit,i,acute 1.0 0.000143348623853 0 1 -1
deficit,and,to 1.0 0.000143348623853 0 1 -1
deficient,in,cyp2d6 1.0 0.000143348623853 0 1 -1
deficiency,due,to 1.0 0.000143348623853 0 1 -1
deficiency,and,the 1.0 0.000143348623853 0 1 -1
deficiencies,constitute,the 1.0 0.000143348623853 0 1 -1
deficiencies,by,simply 1.0 0.000143348623853 0 1 -1
deferasirox,should,be 1.0 0.000143348623853 0 1 -1
defense,may,help 1.0 0.000143348623853 0 1 -1
defects,occur,in 1.0 0.000143348623853 0 1 -1
defect,is,not 1.0 0.000143348623853 0 1 -1
defect,in,the 1.0 0.000286697247706 0 2 -2
defect,in,cytochrome 1.0 0.000143348623853 0 1 -1
defecation,episodes,and 1.0 0.000143348623853 0 1 -1
deethylase,in,male 1.0 0.000143348623853 0 1 -1
deet,was,included 1.0 0.000143348623853 0 1 -1
deet,toxicity,when 1.0 0.000143348623853 0 1 -1
deep-seated,infection,with 1.0 0.000143348623853 0 1 -1
deep,tendon,reflexes 1.0 0.000143348623853 0 1 -1
decreasing,the,concentration 1.0 0.000143348623853 0 1 -1
decreasing,responding,whereas 1.0 0.000143348623853 0 1 -1
decreasing,components,n1 1.0 0.000143348623853 0 1 -1
decreasing,according,to 1.0 0.000143348623853 0 1 -1
decreases,the,intravenous 1.0 0.000143348623853 0 1 -1
decreases,stomach,acidity 1.0 0.000143348623853 0 1 -1
decreases,serum,concentrations 1.0 0.000143348623853 0 1 -1
decreases,platelet,adhesion 1.0 0.000143348623853 0 1 -1
decreases,of,to 1.0 0.000143348623853 0 1 -1
decreases,in,tmax 1.0 0.000143348623853 0 1 -1
decreases,in,tbg 1.0 0.000143348623853 0 1 -1
decreases,in,exposure 1.0 0.000143348623853 0 1 -1
decreases,in,cmax 1.0 0.000143348623853 0 1 -1
decreases,in,auc 1.0 0.000143348623853 0 1 -1
decreases,heart,rate 1.0 0.000143348623853 0 1 -1
decreases,aldosterone,production 1.0 0.000143348623853 0 1 -1
decreased,when,used 1.0 0.000286697247706 0 2 -2
decreased,when,tracleer 1.0 0.000143348623853 0 1 -1
decreased,urinary,levels 1.0 0.000143348623853 0 1 -1
decreased,thiazides,should 1.0 0.000143348623853 0 1 -1
decreased,the,time 1.0 0.000143348623853 0 1 -1
decreased,the,results 1.0 0.000143348623853 0 1 -1
decreased,the,r-value 1.0 0.000143348623853 0 1 -1
decreased,the,amount 1.0 0.000143348623853 0 1 -1
decreased,significantly,without 1.0 0.000143348623853 0 1 -1
decreased,response,to 1.0 0.000286697247706 0 2 -2
decreased,renal,function 1.0 0.000286697247706 0 2 -2
decreased,reflecting,the 1.0 0.000573394495413 0 4 -4
decreased,psychomotor,performance 1.0 0.000143348623853 0 1 -1
decreased,prothrombin,time 1.0 0.000143348623853 0 1 -1
decreased,probably,related 1.0 0.000143348623853 0 1 -1
decreased,plasma,concentrations 1.0 0.000286697247706 0 2 -2
decreased,levels,of 1.0 0.000286697247706 0 2 -2
decreased,levels,in 1.0 0.000143348623853 0 1 -1
decreased,in,relation 1.0 0.000143348623853 0 1 -1
decreased,in,hypothyroid 1.0 0.000143348623853 0 1 -1
decreased,in,hyperthyroidism 1.0 0.000143348623853 0 1 -1
decreased,from,ng 1.0 0.000143348623853 0 1 -1
decreased,free,will 1.0 0.000143348623853 0 1 -1
decreased,fi,and 1.0 0.000286697247706 0 2 -2
decreased,effectiveness,of 1.0 0.000143348623853 0 1 -1
decreased,effect,of 1.0 0.000143348623853 0 1 -1
decreased,core,temperature 1.0 0.000143348623853 0 1 -1
decreased,by,during 1.0 0.000143348623853 0 1 -1
decreased,by,co-administration 1.0 0.000143348623853 0 1 -1
decreased,by,ci 1.0 0.000286697247706 0 2 -2
decreased,by,as 1.0 0.000143348623853 0 1 -1
decreased,along,with 1.0 0.000143348623853 0 1 -1
decreased,activity,because 1.0 0.000143348623853 0 1 -1
decrease,the,rate 1.0 0.000143348623853 0 1 -1
decrease,the,peak 1.0 0.000143348623853 0 1 -1
decrease,the,overall 1.0 0.000143348623853 0 1 -1
decrease,the,k 1.0 0.000143348623853 0 1 -1
decrease,the,dose 1.0 0.000286697247706 0 2 -2
decrease,sprycel,plasma 1.0 0.000143348623853 0 1 -1
decrease,prior,to 1.0 0.000143348623853 0 1 -1
decrease,platelet,nucleotide 1.0 0.000143348623853 0 1 -1
decrease,platelet,aggregation 1.0 0.000143348623853 0 1 -1
decrease,overall,treatment 1.0 0.000143348623853 0 1 -1
decrease,of,total 1.0 0.000143348623853 0 1 -1
decrease,of,the 1.0 0.000143348623853 0 1 -1
decrease,of,phosphorylated 1.0 0.000143348623853 0 1 -1
decrease,of,nucleophosmin 1.0 0.000143348623853 0 1 -1
decrease,of,nucleolin 1.0 0.000143348623853 0 1 -1
decrease,of,ci 1.0 0.000143348623853 0 1 -1
decrease,mean,trough 1.0 0.000143348623853 0 1 -1
decrease,mean,c 1.0 0.000143348623853 0 1 -1
decrease,in,temperature 1.0 0.000143348623853 0 1 -1
decrease,in,renal 1.0 0.000143348623853 0 1 -1
decrease,in,prothrombin 1.0 0.000143348623853 0 1 -1
decrease,in,hypothyroid 1.0 0.000143348623853 0 1 -1
decrease,in,absorption 1.0 0.000143348623853 0 1 -1
decrease,first,pass 1.0 0.000143348623853 0 1 -1
decrease,extracellular,levels 1.0 0.000143348623853 0 1 -1
decrease,effectiveness,by 1.0 0.000143348623853 0 1 -1
decrease,by,approximately 1.0 0.000143348623853 0 1 -1
decrease,between,and 1.0 0.000143348623853 0 1 -1
decrease,and,delay 1.0 0.000143348623853 0 1 -1
decoy,and,inducible 1.0 0.000143348623853 0 1 -1
declining,to,about 1.0 0.000143348623853 0 1 -1
decline,in,glomerular 1.0 0.000143348623853 0 1 -1
decision,to,prescribe 1.0 0.000143348623853 0 1 -1
decision,should,be 1.0 0.000286697247706 0 2 -2
decision,must,be 1.0 0.000143348623853 0 1 -1
decision,is,made 1.0 0.000143348623853 0 1 -1
decins,sans,fronti 1.0 0.000143348623853 0 1 -1
december,the,following 1.0 0.000143348623853 0 1 -1
decarboxylase,inhibitor,does 1.0 0.000143348623853 0 1 -1
debrisoquin,hydroxylase,is 1.0 0.000143348623853 0 1 -1
deaths,three,cases 1.0 0.000143348623853 0 1 -1
deaths,is,far 1.0 0.000143348623853 0 1 -1
deaths,induced,by 1.0 0.000143348623853 0 1 -1
deaths,in,users 1.0 0.000143348623853 0 1 -1
deaths,due,to 1.0 0.000143348623853 0 1 -1
deaths,associated,with 1.0 0.000143348623853 0 1 -1
deaths,among,the 1.0 0.000143348623853 0 1 -1
death,in,users 1.0 0.000143348623853 0 1 -1
death,have,been 1.0 0.000143348623853 0 1 -1
death,from,infectious 1.0 0.000143348623853 0 1 -1
dealt,with,as 1.0 0.000143348623853 0 1 -1
deals,with,the 1.0 0.000143348623853 0 1 -1
dea,concentrations,were 1.0 0.000143348623853 0 1 -1
de,pointes-type,ventricular 1.0 0.000143348623853 0 1 -1
de,pointes,have 1.0 0.000143348623853 0 1 -1
de,pointes,and 1.0 0.000143348623853 0 1 -1
de,pointe,particularly 1.0 0.000143348623853 0 1 -1
de,novo,renal 1.0 0.000143348623853 0 1 -1
de,novo,kidney 1.0 0.000143348623853 0 1 -1
dcg-iv,and,l-ccg 1.0 0.00043004587156 0 3 -3
days,with,coadministration 1.0 0.000286697247706 0 2 -2
days,to,of 1.0 0.000143348623853 0 1 -1
days,to,healthy 1.0 0.000143348623853 0 1 -1
days,there,was 1.0 0.000143348623853 0 1 -1
days,the,dose 1.0 0.000143348623853 0 1 -1
days,showed,a 1.0 0.000143348623853 0 1 -1
days,received,mg 1.0 0.000143348623853 0 1 -1
days,produced,no 1.0 0.000143348623853 0 1 -1
days,prior,to 1.0 0.000143348623853 0 1 -1
days,plus,mg 1.0 0.000143348623853 0 1 -1
days,oral,administration 1.0 0.000143348623853 0 1 -1
days,or,more 1.0 0.000143348623853 0 1 -1
days,or,mg 1.0 0.000143348623853 0 1 -1
days,of,use 1.0 0.000143348623853 0 1 -1
days,of,treatment 1.0 0.000143348623853 0 1 -1
days,of,the 1.0 0.000143348623853 0 1 -1
days,of,multipledose 1.0 0.000143348623853 0 1 -1
days,of,general 1.0 0.000143348623853 0 1 -1
days,of,daily 1.0 0.000143348623853 0 1 -1
days,of,coadministration 1.0 0.000143348623853 0 1 -1
days,of,co-administration 1.0 0.000286697247706 0 2 -2
days,of,both 1.0 0.000143348623853 0 1 -1
days,of,beginning 1.0 0.000143348623853 0 1 -1
days,n,under 1.0 0.000143348623853 0 1 -1
days,n,or 1.0 0.000143348623853 0 1 -1
days,mg,times 1.0 0.000143348623853 0 1 -1
days,mg,rat 1.0 0.000286697247706 0 2 -2
days,later,by 1.0 0.000143348623853 0 1 -1
days,later,all 1.0 0.000143348623853 0 1 -1
days,into,mice 1.0 0.000143348623853 0 1 -1
days,increases,plasma 1.0 0.000143348623853 0 1 -1
days,in,combination 1.0 0.000143348623853 0 1 -1
days,in,a 1.0 0.000286697247706 0 2 -2
days,had,no 1.0 0.000573394495413 0 4 -4
days,for,that 1.0 0.000143348623853 0 1 -1
days,for,evidence 1.0 0.000143348623853 0 1 -1
days,following,days 1.0 0.000143348623853 0 1 -1
days,followed,by 1.0 0.000573394495413 0 4 -4
days,does,not 1.0 0.000143348623853 0 1 -1
days,did,not 1.0 0.00114678899083 0 8 -8
days,and,to 1.0 0.000143348623853 0 1 -1
days,and,titrated 1.0 0.000143348623853 0 1 -1
days,and,then 1.0 0.000143348623853 0 1 -1
days,and,the 1.0 0.000286697247706 0 2 -2
days,and,mmol 1.0 0.000143348623853 0 1 -1
days,and,males 1.0 0.000143348623853 0 1 -1
days,and,for 1.0 0.000143348623853 0 1 -1
days,and,cohort 1.0 0.000143348623853 0 1 -1
days,and,and 1.0 0.000143348623853 0 1 -1
days,after,a 1.0 0.000143348623853 0 1 -1
days,achieved,in 1.0 0.000143348623853 0 1 -1
daypro,and,anaprox 1.0 0.000143348623853 0 1 -1
day-to,day,variability 1.0 0.000143348623853 0 1 -1
day-old,embryos,was 1.0 0.000143348623853 0 1 -1
day,withdrawal,the 1.0 0.000286697247706 0 2 -2
day,withdrawal,period 1.0 0.000143348623853 0 1 -1
day,with,a 1.0 0.000143348623853 0 1 -1
day,washout,period 1.0 0.000143348623853 0 1 -1
day,was,superior 1.0 0.000143348623853 0 1 -1
day,was,studied 1.0 0.000143348623853 0 1 -1
day,was,similar 1.0 0.000143348623853 0 1 -1
day,was,significantly 1.0 0.000143348623853 0 1 -1
day,variability,in 1.0 0.000143348623853 0 1 -1
day,until,the 1.0 0.000143348623853 0 1 -1
day,twice,the 1.0 0.000143348623853 0 1 -1
day,to,prevent 1.0 0.000143348623853 0 1 -1
day,to,patients 1.0 0.000143348623853 0 1 -1
day,to,midcycle 1.0 0.000143348623853 0 1 -1
day,to,mg 1.0 0.00043004587156 0 3 -3
day,there,were 1.0 0.000143348623853 0 1 -1
day,the,rats 1.0 0.000143348623853 0 1 -1
day,showed,that 1.0 0.000143348623853 0 1 -1
day,racemic,for 1.0 0.000143348623853 0 1 -1
day,qd,cohort 1.0 0.000143348623853 0 1 -1
day,proved,to 1.0 0.000143348623853 0 1 -1
day,pretreatment,period 1.0 0.000143348623853 0 1 -1
day,preferably,the 1.0 0.000143348623853 0 1 -1
day,or,prophylactic 1.0 0.000143348623853 0 1 -1
day,or,placebo 1.0 0.000143348623853 0 1 -1
day,or,mg 1.0 0.000143348623853 0 1 -1
day,or,in 1.0 0.000286697247706 0 2 -2
day,on,weeks 1.0 0.000143348623853 0 1 -1
day,of,was 1.0 0.000143348623853 0 1 -1
day,of,two 1.0 0.000143348623853 0 1 -1
day,of,the 1.0 0.000143348623853 0 1 -1
day,of,n 1.0 0.000143348623853 0 1 -1
day,of,incubation 1.0 0.000143348623853 0 1 -1
day,of,from 1.0 0.000143348623853 0 1 -1
day,of,each 1.0 0.000143348623853 0 1 -1
day,of,concomitant 1.0 0.000143348623853 0 1 -1
day,n,for 1.0 0.000143348623853 0 1 -1
day,monotherapy,did 1.0 0.000143348623853 0 1 -1
day,microg,kg 1.0 0.000143348623853 0 1 -1
day,is,easy 1.0 0.000143348623853 0 1 -1
day,in,the 1.0 0.000143348623853 0 1 -1
day,in,overall 1.0 0.000143348623853 0 1 -1
day,in,otherwise 1.0 0.000143348623853 0 1 -1
day,in,combination 1.0 0.000143348623853 0 1 -1
day,in,a 1.0 0.000143348623853 0 1 -1
day,im,twice 1.0 0.000143348623853 0 1 -1
day,im,approximately 1.0 0.000143348623853 0 1 -1
day,has,not 1.0 0.000143348623853 0 1 -1
day,for,one 1.0 0.000143348623853 0 1 -1
day,for,a 1.0 0.00043004587156 0 3 -3
day,fecal,as 1.0 0.000143348623853 0 1 -1
day,each,volunteer 1.0 0.000143348623853 0 1 -1
day,dosing,with 1.0 0.000143348623853 0 1 -1
day,doses,of 1.0 0.000143348623853 0 1 -1
day,did,not 1.0 0.000143348623853 0 1 -1
day,days,plus 1.0 0.000143348623853 0 1 -1
day,course,of 1.0 0.000143348623853 0 1 -1
day,before,meals 1.0 0.000143348623853 0 1 -1
day,as,well 1.0 0.000143348623853 0 1 -1
day,are,used 1.0 0.000143348623853 0 1 -1
day,are,advisable 1.0 0.000143348623853 0 1 -1
day,approximately,times 1.0 0.000286697247706 0 2 -2
day,approximately,one-thousandth 1.0 0.000143348623853 0 1 -1
day,approximately,one-hundredth 1.0 0.000143348623853 0 1 -1
day,and,or 1.0 0.000143348623853 0 1 -1
day,and,one 1.0 0.000143348623853 0 1 -1
day,and,from 1.0 0.000286697247706 0 2 -2
day,and,every 1.0 0.000143348623853 0 1 -1
day,and,above 1.0 0.000143348623853 0 1 -1
day,against,positive 1.0 0.000143348623853 0 1 -1
day,after,weeks 1.0 0.000143348623853 0 1 -1
day,administration,for 1.0 0.000143348623853 0 1 -1
day,about,one-half 1.0 0.000143348623853 0 1 -1
date,show,that 1.0 0.000143348623853 0 1 -1
date,on,the 1.0 0.000286697247706 0 2 -2
date,levosimendan,does 1.0 0.000143348623853 0 1 -1
date,in,clinical 1.0 0.000143348623853 0 1 -1
date,has,not 1.0 0.000143348623853 0 1 -1
database,three,duloxetine-treated 1.0 0.000143348623853 0 1 -1
data,to,exclude 1.0 0.000143348623853 0 1 -1
data,that,conclusively 1.0 0.000143348623853 0 1 -1
data,suggest,these 1.0 0.000143348623853 0 1 -1
data,suggest,the 1.0 0.000143348623853 0 1 -1
data,suggest,similar 1.0 0.000143348623853 0 1 -1
data,showed,that 1.0 0.000143348623853 0 1 -1
data,relating,to 1.0 0.000143348623853 0 1 -1
data,regarding,the 1.0 0.000143348623853 0 1 -1
data,raise,the 1.0 0.000143348623853 0 1 -1
data,presented,here 1.0 0.000143348623853 0 1 -1
data,on,the 1.0 0.000716743119266 0 5 -5
data,on,metabolic 1.0 0.000143348623853 0 1 -1
data,on,concomitant 1.0 0.000143348623853 0 1 -1
data,obtained,in 1.0 0.000143348623853 0 1 -1
data,no,interaction 1.0 0.000143348623853 0 1 -1
data,is,very 1.0 0.000143348623853 0 1 -1
data,intables,and 1.0 0.000143348623853 0 1 -1
data,indicated,that 1.0 0.000143348623853 0 1 -1
data,including,continuous 1.0 0.000143348623853 0 1 -1
data,in,these 1.0 0.000143348623853 0 1 -1
data,in,kidney 1.0 0.000143348623853 0 1 -1
data,in,human 1.0 0.000143348623853 0 1 -1
data,in,angina 1.0 0.000143348623853 0 1 -1
data,in,a 1.0 0.000143348623853 0 1 -1
data,have,been 1.0 0.000143348623853 0 1 -1
data,from,this 1.0 0.000143348623853 0 1 -1
data,from,studies 1.0 0.000143348623853 0 1 -1
data,from,several 1.0 0.000143348623853 0 1 -1
data,from,prospective 1.0 0.000143348623853 0 1 -1
data,from,patients 1.0 0.000143348623853 0 1 -1
data,from,grapefruit 1.0 0.000143348623853 0 1 -1
data,exist,on 1.0 0.000143348623853 0 1 -1
data,emphasize,that 1.0 0.000143348623853 0 1 -1
data,do,not 1.0 0.000143348623853 0 1 -1
data,described,in 1.0 0.00043004587156 0 3 -3
data,demonstrate,that 1.0 0.000143348623853 0 1 -1
data,beyond,days 1.0 0.000143348623853 0 1 -1
data,available,from 1.0 0.00043004587156 0 3 -3
data,are,not 1.0 0.000286697247706 0 2 -2
data,are,neither 1.0 0.000143348623853 0 1 -1
data,are,discussed 1.0 0.000143348623853 0 1 -1
data,are,developed 1.0 0.000143348623853 0 1 -1
data,are,available 1.0 0.00100344036697 0 7 -7
data,appeared,well 1.0 0.000143348623853 0 1 -1
data,and,selected 1.0 0.000143348623853 0 1 -1
dasatinib,is,a 1.0 0.000286697247706 0 2 -2
dasatinib,and,its 1.0 0.000143348623853 0 1 -1
dark,test,in 1.0 0.000143348623853 0 1 -1
dantrium,is,metabolized 1.0 0.000143348623853 0 1 -1
dangerous,machinery,while 1.0 0.000143348623853 0 1 -1
dangerous,because,it 1.0 0.000143348623853 0 1 -1
dams,was,estimated 1.0 0.000143348623853 0 1 -1
damage,when,tested 1.0 0.000143348623853 0 1 -1
damage,could,theoretically 1.0 0.000143348623853 0 1 -1
damage,as,well 1.0 0.000143348623853 0 1 -1
daily,with,mg 1.0 0.000143348623853 0 1 -1
daily,was,similar 1.0 0.000143348623853 0 1 -1
daily,was,coadministered 1.0 0.000143348623853 0 1 -1
daily,under,steady-state 1.0 0.000143348623853 0 1 -1
daily,trough,serum 1.0 0.000143348623853 0 1 -1
daily,treatment,with 1.0 0.000143348623853 0 1 -1
daily,to,patients 1.0 0.000143348623853 0 1 -1
daily,to,healthy 1.0 0.000143348623853 0 1 -1
daily,taken,in 1.0 0.000143348623853 0 1 -1
daily,should,be 1.0 0.000143348623853 0 1 -1
daily,oral,dose 1.0 0.000143348623853 0 1 -1
daily,or,placebo 1.0 0.000143348623853 0 1 -1
daily,of,brovana 1.0 0.000143348623853 0 1 -1
daily,morning,and 1.0 0.000143348623853 0 1 -1
daily,mg,total 1.0 0.000143348623853 0 1 -1
daily,mcg,twice 1.0 0.000143348623853 0 1 -1
daily,has,been 1.0 0.000143348623853 0 1 -1
daily,had,no 1.0 0.000286697247706 0 2 -2
daily,for,the 1.0 0.000143348623853 0 1 -1
daily,dosing,regimens 1.0 0.000143348623853 0 1 -1
daily,dose,was 1.0 0.000143348623853 0 1 -1
daily,dose,once 1.0 0.000143348623853 0 1 -1
daily,dose,in 1.0 0.000143348623853 0 1 -1
daily,dose,and 1.0 0.000143348623853 0 1 -1
daily,dosage,of 1.0 0.000286697247706 0 2 -2
daily,did,not 1.0 0.00114678899083 0 8 -8
daily,brovana,dose 1.0 0.000143348623853 0 1 -1
daily,before,meals 1.0 0.000286697247706 0 2 -2
daily,as,assessed 1.0 0.000143348623853 0 1 -1
daily,and,mg 1.0 0.000143348623853 0 1 -1
daily,and,mcg 1.0 0.000143348623853 0 1 -1
daily,alternating,therapy 1.0 0.000143348623853 0 1 -1
daily,administration,of 1.0 0.000286697247706 0 2 -2
daily,activities,such 1.0 0.000143348623853 0 1 -1
daily,acquisition,cost 1.0 0.000143348623853 0 1 -1
dactinomycin,may,interfere 1.0 0.000143348623853 0 1 -1
da,sh,fa 1.0 0.000143348623853 0 1 -1
da,levels,did 1.0 0.000143348623853 0 1 -1
d6,they,may 1.0 0.000716743119266 0 5 -5
d6,the,increase 1.0 0.000716743119266 0 5 -5
d6,the,biochemical 1.0 0.000716743119266 0 5 -5
d6,metabolizers,had 1.0 0.000143348623853 0 1 -1
d6,may,require 1.0 0.000860091743119 0 6 -6
d6,many,other 1.0 0.000716743119266 0 5 -5
d6,isozyme,activity 1.0 0.000716743119266 0 5 -5
d6,include,some 1.0 0.000716743119266 0 5 -5
d6,in,human 1.0 0.000143348623853 0 1 -1
d6,ic50,g 1.0 0.000143348623853 0 1 -1
d6,hydroxylase,is 1.0 0.000573394495413 0 4 -4
d6,e1,and 1.0 0.00043004587156 0 3 -3
d6,debrisoquin,hydroxylase 1.0 0.000143348623853 0 1 -1
d6,cyp2d6,sensipar 1.0 0.000143348623853 0 1 -1
d6,c9,c19 1.0 0.000143348623853 0 1 -1
d6,and,to 1.0 0.000143348623853 0 1 -1
d6,and,or 1.0 0.000143348623853 0 1 -1
d6,and,cyp 1.0 0.000143348623853 0 1 -1
d6,a4,were 1.0 0.000143348623853 0 1 -1
d6,a4,c9 1.0 0.000143348623853 0 1 -1
d6,a4,and 1.0 0.000143348623853 0 1 -1
d3,the,active 1.0 0.000143348623853 0 1 -1
d3,oh,d3 1.0 0.000143348623853 0 1 -1
d3,exhibit,characteristic 1.0 0.000143348623853 0 1 -1
d3,and,the 1.0 0.000143348623853 0 1 -1
d2o,was,present 1.0 0.000143348623853 0 1 -1
d2,in,the 1.0 0.000286697247706 0 2 -2
d2,binding,sites 1.0 0.000143348623853 0 1 -1
d1,receptors,are 1.0 0.000143348623853 0 1 -1
d-penicillamine,or,did 1.0 0.000143348623853 0 1 -1
d-gal,binding,lectin 1.0 0.000143348623853 0 1 -1
d-ala2,metenkephalinamide,or 1.0 0.000143348623853 0 1 -1
d,the,coadministration 1.0 0.00043004587156 0 3 -3
d,redistributed,type 1.0 0.000143348623853 0 1 -1
d,of,compared 1.0 0.000143348623853 0 1 -1
d,is,a 1.0 0.000143348623853 0 1 -1
d,have,not 1.0 0.00043004587156 0 3 -3
d,have,been 1.0 0.000143348623853 0 1 -1
d,had,no 1.0 0.000143348623853 0 1 -1
d,doses,have 1.0 0.000143348623853 0 1 -1
d,concentrations,have 1.0 0.00043004587156 0 3 -3
d,but,the 1.0 0.000143348623853 0 1 -1
d,and,mg 1.0 0.000143348623853 0 1 -1
d,and,exhibit 1.0 0.000143348623853 0 1 -1
d,analogues,should 1.0 0.00043004587156 0 3 -3
d,also,has 1.0 0.00043004587156 0 3 -3
cytosol,to,the 1.0 0.000143348623853 0 1 -1
cytoskeleton-associated,that,encodes 1.0 0.000143348623853 0 1 -1
cytoprotective,properties,of 1.0 0.000143348623853 0 1 -1
cytoplasmic,condensation,nuclear 1.0 0.000143348623853 0 1 -1
cytokines,have,been 1.0 0.000143348623853 0 1 -1
cytokines,cytokines,have 1.0 0.000143348623853 0 1 -1
cytogenetics,study,in 1.0 0.000143348623853 0 1 -1
cytochromes,p450,a4 1.0 0.000143348623853 0 1 -1
cytochromes,p450,a2 1.0 0.000143348623853 0 1 -1
cytochrome,p450iid6,may 1.0 0.000143348623853 0 1 -1
cytochrome,p450iid6,cyp2d6 1.0 0.000143348623853 0 1 -1
cytochrome,p4502d6,in 1.0 0.000143348623853 0 1 -1
cytochrome,p450-mediated,metabolism 1.0 0.000143348623853 0 1 -1
cytochrome,p450-mediated,interactions 1.0 0.000143348623853 0 1 -1
cytochrome,p450-linked,drug-metabolizing 1.0 0.000143348623853 0 1 -1
cytochrome,p450,with 1.0 0.000143348623853 0 1 -1
cytochrome,p450,substrates 1.0 0.000143348623853 0 1 -1
cytochrome,p450,pathway 1.0 0.000143348623853 0 1 -1
cytochrome,p450,metabolism 1.0 0.000143348623853 0 1 -1
cytochrome,p450,isozymes 1.0 0.000573394495413 0 4 -4
cytochrome,p450,isozyme 1.0 0.000286697247706 0 2 -2
cytochrome,p450,isoforms 1.0 0.000286697247706 0 2 -2
cytochrome,p450,isoenzymes 1.0 0.000716743119266 0 5 -5
cytochrome,p450,isoenzyme 1.0 0.000286697247706 0 2 -2
cytochrome,p450,isoen-zymes 1.0 0.000143348623853 0 1 -1
cytochrome,p450,inhibitors 1.0 0.000286697247706 0 2 -2
cytochrome,p450,d6 1.0 0.0024369266055 0 17 -17
cytochrome,p450,cyp450 1.0 0.000143348623853 0 1 -1
cytochrome,p450,cyp 1.0 0.000716743119266 0 5 -5
cytochrome,p450,c9 1.0 0.000286697247706 0 2 -2
cytochrome,p450,c 1.0 0.000143348623853 0 1 -1
cytochrome,p450,a2 1.0 0.000143348623853 0 1 -1
cytochrome,p450,a 1.0 0.00043004587156 0 3 -3
cytochrome,p-450,linked 1.0 0.000143348623853 0 1 -1
cytochrome,p-450,is 1.0 0.000143348623853 0 1 -1
cytochrome,p-450,enzymes 1.0 0.000143348623853 0 1 -1
cytochrome,p-450,a4 1.0 0.000143348623853 0 1 -1
cytochrome,p-,by 1.0 0.000143348623853 0 1 -1
cytochrome,isozymes,are 1.0 0.000143348623853 0 1 -1
cytochrome,cyp,p450 1.0 0.000143348623853 0 1 -1
cytochrome,cyp,c9 1.0 0.000143348623853 0 1 -1
cytochalasin,d,redistributed 1.0 0.000143348623853 0 1 -1
cysts,had,no 1.0 0.000143348623853 0 1 -1
cystic,fibrosis,therapies 1.0 0.000143348623853 0 1 -1
cysteine,was,covalently 1.0 0.000143348623853 0 1 -1
cysteine,conjugation,at 1.0 0.000143348623853 0 1 -1
cyps,a2,a6 1.0 0.000143348623853 0 1 -1
cyps,a1,c9 1.0 0.000143348623853 0 1 -1
cyp4a9,and,cyp4a11 1.0 0.000143348623853 0 1 -1
cyp4a11,with,the 1.0 0.000143348623853 0 1 -1
cyp450s,cyp1a2,cyp2a6 1.0 0.000143348623853 0 1 -1
cyp450,metabolized,drugs 1.0 0.000143348623853 0 1 -1
cyp450,isoenzymes,has 1.0 0.000143348623853 0 1 -1
cyp450,isoenzymes,cyp1a2 1.0 0.000143348623853 0 1 -1
cyp450,enzymes,including 1.0 0.000143348623853 0 1 -1
cyp450,enzyme,would 1.0 0.000143348623853 0 1 -1
cyp450,enzyme,group 1.0 0.000143348623853 0 1 -1
cyp450,a4,especially 1.0 0.000143348623853 0 1 -1
cyp3a5,responsible,for 1.0 0.000143348623853 0 1 -1
cyp3a4-eplerenone,metabolism,is 1.0 0.000143348623853 0 1 -1
cyp3a4,would,be 1.0 0.000286697247706 0 2 -2
cyp3a4,with,potentially 1.0 0.000143348623853 0 1 -1
cyp3a4,which,is 1.0 0.000143348623853 0 1 -1
cyp3a4,therefore,potential 1.0 0.000143348623853 0 1 -1
cyp3a4,there,is 1.0 0.000143348623853 0 1 -1
cyp3a4,that,mediate 1.0 0.000143348623853 0 1 -1
cyp3a4,substrates,dasatinib 1.0 0.000143348623853 0 1 -1
cyp3a4,substrates,and 1.0 0.000143348623853 0 1 -1
cyp3a4,substrate,single 1.0 0.000143348623853 0 1 -1
cyp3a4,substrate,response 1.0 0.000143348623853 0 1 -1
cyp3a4,substrate,in 1.0 0.000286697247706 0 2 -2
cyp3a4,substrate,given 1.0 0.000143348623853 0 1 -1
cyp3a4,substrate,administered 1.0 0.000143348623853 0 1 -1
cyp3a4,rifampin,cyp3a4 1.0 0.000143348623853 0 1 -1
cyp3a4,responsible,for 1.0 0.000143348623853 0 1 -1
cyp3a4,patients,who 1.0 0.000143348623853 0 1 -1
cyp3a4,or,potentially 1.0 0.000143348623853 0 1 -1
cyp3a4,or,epoxide 1.0 0.000143348623853 0 1 -1
cyp3a4,nor,of 1.0 0.000143348623853 0 1 -1
cyp3a4,metabolic,reactions 1.0 0.000143348623853 0 1 -1
cyp3a4,mediated,metabolism 1.0 0.000143348623853 0 1 -1
cyp3a4,may,result 1.0 0.000143348623853 0 1 -1
cyp3a4,may,have 1.0 0.000143348623853 0 1 -1
cyp3a4,may,decrease 1.0 0.000143348623853 0 1 -1
cyp3a4,ketoconazole,cyp3a4 1.0 0.000143348623853 0 1 -1
cyp3a4,isoform,and 1.0 0.000143348623853 0 1 -1
cyp3a4,isoenzyme,of 1.0 0.000143348623853 0 1 -1
cyp3a4,isoenzyme,is 1.0 0.000143348623853 0 1 -1
cyp3a4,isoenzyme,could 1.0 0.000143348623853 0 1 -1
cyp3a4,is,ordinarily 1.0 0.000143348623853 0 1 -1
cyp3a4,is,a 1.0 0.000286697247706 0 2 -2
cyp3a4,inhibitors,may 1.0 0.000143348623853 0 1 -1
cyp3a4,inhibitors,felodipine 1.0 0.000143348623853 0 1 -1
cyp3a4,inhibitors,eg 1.0 0.000143348623853 0 1 -1
cyp3a4,inhibitors,dasatinib 1.0 0.000143348623853 0 1 -1
cyp3a4,inhibitors,but 1.0 0.000143348623853 0 1 -1
cyp3a4,inhibitors,are 1.0 0.000143348623853 0 1 -1
cyp3a4,inhibitor,or 1.0 0.000143348623853 0 1 -1
cyp3a4,inhibitor,is 1.0 0.000143348623853 0 1 -1
cyp3a4,inhibitor,cannot 1.0 0.000143348623853 0 1 -1
cyp3a4,inhibitor,because 1.0 0.000143348623853 0 1 -1
cyp3a4,ingestion,of 1.0 0.000143348623853 0 1 -1
cyp3a4,inducing,activity 1.0 0.000143348623853 0 1 -1
cyp3a4,inducers,may 1.0 0.000143348623853 0 1 -1
cyp3a4,inducers,include 1.0 0.000143348623853 0 1 -1
cyp3a4,inducers,eg 1.0 0.000143348623853 0 1 -1
cyp3a4,inducers,drugs 1.0 0.000143348623853 0 1 -1
cyp3a4,inducers,cyp3a4 1.0 0.000143348623853 0 1 -1
cyp3a4,inducers,are 1.0 0.000143348623853 0 1 -1
cyp3a4,inducer,such 1.0 0.000143348623853 0 1 -1
cyp3a4,inducer,a 1.0 0.000143348623853 0 1 -1
cyp3a4,have,not 1.0 0.000143348623853 0 1 -1
cyp3a4,enzyme,inducer 1.0 0.000143348623853 0 1 -1
cyp3a4,did,not 1.0 0.000143348623853 0 1 -1
cyp3a4,cyp3a4,is 1.0 0.000143348623853 0 1 -1
cyp3a4,cyp2d6,cyp2e1 1.0 0.000143348623853 0 1 -1
cyp3a4,can,increase 1.0 0.000143348623853 0 1 -1
cyp3a4,but,has 1.0 0.000143348623853 0 1 -1
cyp3a4,below,increase 1.0 0.000143348623853 0 1 -1
cyp3a4,as,it 1.0 0.000143348623853 0 1 -1
cyp3a4,and,the 1.0 0.000143348623853 0 1 -1
cyp3a4,and,protease 1.0 0.000143348623853 0 1 -1
cyp3a4,and,or 1.0 0.000286697247706 0 2 -2
cyp3a4,and,mg 1.0 0.000143348623853 0 1 -1
cyp3a4,and,cyp3a5 1.0 0.000143348623853 0 1 -1
cyp3a4,and,cyp2d6 1.0 0.000143348623853 0 1 -1
cyp3a4,and,cyp2c8 1.0 0.000286697247706 0 2 -2
cyp3a4,and,concomitant 1.0 0.000143348623853 0 1 -1
cyp3a4,and,c19 1.0 0.000143348623853 0 1 -1
cyp3a4,activity,would 1.0 0.000143348623853 0 1 -1
cyp3a4,activity,predominantly 1.0 0.000143348623853 0 1 -1
cyp3a4,activity,increase 1.0 0.000143348623853 0 1 -1
cyp3a3,also,inhibit 1.0 0.000143348623853 0 1 -1
cyp3a,to,a 1.0 0.000143348623853 0 1 -1
cyp3a,the,metabolism 1.0 0.000143348623853 0 1 -1
cyp3a,results,of 1.0 0.000143348623853 0 1 -1
cyp3a,may,increase 1.0 0.000143348623853 0 1 -1
cyp3a,may,decrease 1.0 0.000143348623853 0 1 -1
cyp3a,channel,blockers 1.0 0.000143348623853 0 1 -1
cyp3a,and,c9 1.0 0.000143348623853 0 1 -1
cyp2e1,or,uridine 1.0 0.000143348623853 0 1 -1
cyp2e1,or,cyp3a4 1.0 0.000143348623853 0 1 -1
cyp2e1,cyp4a9,and 1.0 0.000143348623853 0 1 -1
cyp2e1,but,did 1.0 0.000143348623853 0 1 -1
cyp2e1,and,cyp3a4 1.0 0.000143348623853 0 1 -1
cyp2d6,with,cyp1a2 1.0 0.000143348623853 0 1 -1
cyp2d6,was,co-administered 1.0 0.000143348623853 0 1 -1
cyp2d6,the,need 1.0 0.000143348623853 0 1 -1
cyp2d6,sensipar,is 1.0 0.000143348623853 0 1 -1
cyp2d6,or,ugt 1.0 0.000143348623853 0 1 -1
cyp2d6,metabolizers,after 1.0 0.000143348623853 0 1 -1
cyp2d6,may,result 1.0 0.000143348623853 0 1 -1
cyp2d6,many,including 1.0 0.000143348623853 0 1 -1
cyp2d6,is,unlikely 1.0 0.000143348623853 0 1 -1
cyp2d6,is,involved 1.0 0.000143348623853 0 1 -1
cyp2d6,is,expected 1.0 0.000143348623853 0 1 -1
cyp2d6,inhibitors,atomoxetine 1.0 0.000143348623853 0 1 -1
cyp2d6,inhibitor,is 1.0 0.000143348623853 0 1 -1
cyp2d6,increase,steady-state 1.0 0.000143348623853 0 1 -1
cyp2d6,has,not 1.0 0.000143348623853 0 1 -1
cyp2d6,duloxetine,is 1.0 0.000143348623853 0 1 -1
cyp2d6,cyp2e1,or 1.0 0.000143348623853 0 1 -1
cyp2d6,cyp2e1,cyp4a9 1.0 0.000143348623853 0 1 -1
cyp2d6,cyp2e1,and 1.0 0.000143348623853 0 1 -1
cyp2d6,cyp2c9,cyp2c19 1.0 0.000143348623853 0 1 -1
cyp2d6,cyp1a2,cyp2c9 1.0 0.000143348623853 0 1 -1
cyp2d6,because,cyp2d6 1.0 0.000143348623853 0 1 -1
cyp2d6,are,responsible 1.0 0.000286697247706 0 2 -2
cyp2d6,and,is 1.0 0.000143348623853 0 1 -1
cyp2d6,and,have 1.0 0.000143348623853 0 1 -1
cyp2d6,and,cyp3a3 1.0 0.000143348623853 0 1 -1
cyp2d6,activity,based 1.0 0.000143348623853 0 1 -1
cyp2d6,activity,at 1.0 0.000143348623853 0 1 -1
cyp2c9,cyp2d6,cyp2e1 1.0 0.000143348623853 0 1 -1
cyp2c9,cyp2d6,and 1.0 0.000143348623853 0 1 -1
cyp2c9,cyp2c19,or 1.0 0.000143348623853 0 1 -1
cyp2c9,cyp2c19,cyp2e1 1.0 0.000143348623853 0 1 -1
cyp2c9,cyp2c19,cyp2d6 1.0 0.000573394495413 0 4 -4
cyp2c9,cyp2c19,and 1.0 0.000286697247706 0 2 -2
cyp2c9,and,to 1.0 0.000143348623853 0 1 -1
cyp2c9,and,cyp3a4 1.0 0.000286697247706 0 2 -2
cyp2c9,and,c19 1.0 0.000143348623853 0 1 -1
cyp2c8,in,vitro 1.0 0.000143348623853 0 1 -1
cyp2c8,drugs,substances 1.0 0.000143348623853 0 1 -1
cyp2c8,cyp2c9,cyp2c19 1.0 0.000143348623853 0 1 -1
cyp2c8,c9,c19 1.0 0.000143348623853 0 1 -1
cyp2c19,the,major 1.0 0.000143348623853 0 1 -1
cyp2c19,cyp2e1,or 1.0 0.000143348623853 0 1 -1
cyp2c19,cyp2d6,cyp2e1 1.0 0.00043004587156 0 3 -3
cyp2c19,and,induce 1.0 0.000143348623853 0 1 -1
cyp2c19,and,cyp2d6 1.0 0.000143348623853 0 1 -1
cyp2c19,and,cyp2a6 1.0 0.000143348623853 0 1 -1
cyp2b6,cyp2c8,cyp2c9 1.0 0.000143348623853 0 1 -1
cyp2a6,cyp2c9,cyp2d6 1.0 0.000143348623853 0 1 -1
cyp2a6,cyp2c9,cyp2c19 1.0 0.00043004587156 0 3 -3
cyp2a6,cyp2b6,cyp2c8 1.0 0.000143348623853 0 1 -1
cyp2a6,and,mild-to 1.0 0.000143348623853 0 1 -1
cyp1a2,weak,b6 1.0 0.000143348623853 0 1 -1
cyp1a2,was,explored 1.0 0.000143348623853 0 1 -1
cyp1a2,substrate,single 1.0 0.000143348623853 0 1 -1
cyp1a2,isoform,mediate 1.0 0.000143348623853 0 1 -1
cyp1a2,is,known 1.0 0.000143348623853 0 1 -1
cyp1a2,inhibitors,as 1.0 0.000143348623853 0 1 -1
cyp1a2,inhibit,cyp1a2 1.0 0.000143348623853 0 1 -1
cyp1a2,inducers,and 1.0 0.000143348623853 0 1 -1
cyp1a2,in,vitro 1.0 0.000143348623853 0 1 -1
cyp1a2,cyp2c9,cyp2d6 1.0 0.000143348623853 0 1 -1
cyp1a2,cyp2c9,cyp2c19 1.0 0.000573394495413 0 4 -4
cyp1a2,cyp2a6,cyp2c9 1.0 0.000573394495413 0 4 -4
cyp1a2,cyp2a6,cyp2b6 1.0 0.000143348623853 0 1 -1
cyp1a2,c8,c9 1.0 0.000143348623853 0 1 -1
cyp1a2,and,cyp3a4 1.0 0.000143348623853 0 1 -1
cyp1a2,and,cyp2d6 1.0 0.000143348623853 0 1 -1
cyp1a2,and,also 1.0 0.000143348623853 0 1 -1
cyp1a2,activity,and 1.0 0.000143348623853 0 1 -1
cyp1a2,a6,and 1.0 0.000143348623853 0 1 -1
cyp1a1,cyp1a2,cyp2a6 1.0 0.000143348623853 0 1 -1
cyp-mediated,drug,clearance 1.0 0.000143348623853 0 1 -1
cyp-450,inhibitor,resulted 1.0 0.000143348623853 0 1 -1
cyp-2c19,by,oxc 1.0 0.000143348623853 0 1 -1
cyp,p450,isoforms 1.0 0.000143348623853 0 1 -1
cyp,isozymes,in 1.0 0.000143348623853 0 1 -1
cyp,isoforms,a4 1.0 0.000143348623853 0 1 -1
cyp,isoforms,a2 1.0 0.000143348623853 0 1 -1
cyp,isoenzymes,therefore 1.0 0.000143348623853 0 1 -1
cyp,isoenzymes,tested 1.0 0.000143348623853 0 1 -1
cyp,enzymes,would 1.0 0.000143348623853 0 1 -1
cyp,enzymes,showed 1.0 0.000143348623853 0 1 -1
cyp,enzymes,e1 1.0 0.000143348623853 0 1 -1
cyp,enzymes,d6 1.0 0.000286697247706 0 2 -2
cyp,enzymes,a2 1.0 0.000286697247706 0 2 -2
cyp,enzyme,a4 1.0 0.000143348623853 0 1 -1
cyp,drug-metabolizing,enzymes 1.0 0.000143348623853 0 1 -1
cyp,drug,metabolizing 1.0 0.000143348623853 0 1 -1
cyp,d6,or 1.0 0.000143348623853 0 1 -1
cyp,d6,ic50 1.0 0.000143348623853 0 1 -1
cyp,d6,and 1.0 0.000286697247706 0 2 -2
cyp,c9,substrates 1.0 0.000143348623853 0 1 -1
cyp,c9,human 1.0 0.000143348623853 0 1 -1
cyp,c9,cyp 1.0 0.000143348623853 0 1 -1
cyp,c9,and 1.0 0.000143348623853 0 1 -1
cyp,c19,substrate 1.0 0.000143348623853 0 1 -1
cyp,c19,ic50 1.0 0.000143348623853 0 1 -1
cyp,c19,cyp 1.0 0.000143348623853 0 1 -1
cyp,at,clinically 1.0 0.000143348623853 0 1 -1
cyp,a4,to 1.0 0.000143348623853 0 1 -1
cyp,a4,substrate 1.0 0.000143348623853 0 1 -1
cyp,a4,may 1.0 0.000286697247706 0 2 -2
cyp,a4,inhibitors 1.0 0.000286697247706 0 2 -2
cyp,a4,has 1.0 0.000143348623853 0 1 -1
cyp,a4,by 1.0 0.000143348623853 0 1 -1
cyp,a4,but 1.0 0.000143348623853 0 1 -1
cyp,a4,and 1.0 0.00043004587156 0 3 -3
cyp,a,or 1.0 0.000143348623853 0 1 -1
cynomolgus,monkeys,were 1.0 0.000143348623853 0 1 -1
cynomolgus,monkeys,given 1.0 0.000143348623853 0 1 -1
cynomolgus,monkeys,following 1.0 0.000143348623853 0 1 -1
cynomolgus,monkeys,at 1.0 0.000143348623853 0 1 -1
cyclosporine,large,quantities 1.0 0.000143348623853 0 1 -1
cyclosporine,doses,trough 1.0 0.000143348623853 0 1 -1
cyclosporine,diclofenac,like 1.0 0.000143348623853 0 1 -1
cyclosporine,cyp3a4,substrate 1.0 0.000143348623853 0 1 -1
cyclosporine,concomitant,administration 1.0 0.000143348623853 0 1 -1
cyclosporine,a,during 1.0 0.000143348623853 0 1 -1
cyclopentyl-1,dipropylxanthine,dpcpx 1.0 0.000143348623853 0 1 -1
cyclooxygenase-2,cox-2,inhibitor 1.0 0.000143348623853 0 1 -1
cyclic,in,turn 1.0 0.000143348623853 0 1 -1
cycles,of,taxol 1.0 0.000143348623853 0 1 -1
cycles,and,or 1.0 0.000143348623853 0 1 -1
cycle,irregularities,were 1.0 0.000143348623853 0 1 -1
cycle,duration,or 1.0 0.000143348623853 0 1 -1
cyclase,activity,but 1.0 0.000143348623853 0 1 -1
cushingoid,appearance,have 1.0 0.000143348623853 0 1 -1
curves,relatively,little 1.0 0.000143348623853 0 1 -1
curve,was,also 1.0 0.000143348623853 0 1 -1
curve,of,these 1.0 0.000143348623853 0 1 -1
curve,of,and 1.0 0.000143348623853 0 1 -1
curve,from,time 1.0 0.000143348623853 0 1 -1
curve,auc,and 1.0 0.000143348623853 0 1 -1
currents,in,a 1.0 0.000143348623853 0 1 -1
currents,discriminates,among 1.0 0.000143348623853 0 1 -1
currently,underway,to 1.0 0.000143348623853 0 1 -1
currently,there,are 1.0 0.00043004587156 0 3 -3
currently,taking,amevive 1.0 0.000143348623853 0 1 -1
currently,no,data 1.0 0.000143348623853 0 1 -1
currently,no,clinical 1.0 0.000286697247706 0 2 -2
currently,little,adequate 1.0 0.000143348623853 0 1 -1
currently,it,is 1.0 0.000143348623853 0 1 -1
currently,exist,comparing 1.0 0.000143348623853 0 1 -1
currently,do,not 1.0 0.000143348623853 0 1 -1
currently,available,hmgcoa 1.0 0.000143348623853 0 1 -1
currently,available,and 1.0 0.000143348623853 0 1 -1
current,therapies,are 1.0 0.000143348623853 0 1 -1
current,theories,assume 1.0 0.000143348623853 0 1 -1
current,study,the 1.0 0.000143348623853 0 1 -1
current,information,on 1.0 0.000143348623853 0 1 -1
cure,rates,and 1.0 0.000143348623853 0 1 -1
cure,and,to 1.0 0.000143348623853 0 1 -1
cups,of,american 1.0 0.000143348623853 0 1 -1
cumulative,urinary,excretion 1.0 0.000143348623853 0 1 -1
cumulative,incidence,of 1.0 0.000143348623853 0 1 -1
cultures,superinduced,by 1.0 0.000143348623853 0 1 -1
cultures,stimulated,with 1.0 0.000143348623853 0 1 -1
cssmax,of,the 1.0 0.000143348623853 0 1 -1
csf,primarily,as 1.0 0.000143348623853 0 1 -1
crystalline,preparations,novolog 1.0 0.000143348623853 0 1 -1
cryptosporidium,parvum,in 1.0 0.000143348623853 0 1 -1
crucial,to,the 1.0 0.000143348623853 0 1 -1
crossover,study,to 1.0 0.000143348623853 0 1 -1
crossover,study,patients 1.0 0.000143348623853 0 1 -1
crossover,study,of 1.0 0.000143348623853 0 1 -1
crossover,studies,in 1.0 0.000143348623853 0 1 -1
crossover,double-blind,placebo-controlled 1.0 0.000143348623853 0 1 -1
crossover,design,with 1.0 0.000143348623853 0 1 -1
crossover,clinical,pharmacology 1.0 0.000143348623853 0 1 -1
cross-reactions,with,non-aspergillus 1.0 0.000143348623853 0 1 -1
cross-matching,procedures,when 1.0 0.000143348623853 0 1 -1
cromolyn,sodium,and 1.0 0.000143348623853 0 1 -1
cromolyn,sodium,alone 1.0 0.000143348623853 0 1 -1
crohn,s,disease 1.0 0.000573394495413 0 4 -4
crixivan,or,to 1.0 0.000286697247706 0 2 -2
crixivan,and,primarily 1.0 0.000143348623853 0 1 -1
crixivan,and,other 1.0 0.000143348623853 0 1 -1
crixivan,and,are 1.0 0.000143348623853 0 1 -1
critically,reviews,the 1.0 0.000143348623853 0 1 -1
critically,important,for 1.0 0.000143348623853 0 1 -1
critical,role,in 1.0 0.000143348623853 0 1 -1
critical,for,determining 1.0 0.000143348623853 0 1 -1
critical,fall,in 1.0 0.000143348623853 0 1 -1
criteria,was,significantly 1.0 0.000143348623853 0 1 -1
criteria,for,liver 1.0 0.000143348623853 0 1 -1
crisis,may,mimic 1.0 0.000143348623853 0 1 -1
creatinine,values,by 1.0 0.000143348623853 0 1 -1
creatinine,makes,use 1.0 0.000143348623853 0 1 -1
creatinine,levels,should 1.0 0.000143348623853 0 1 -1
creatinine,levels,by 1.0 0.000286697247706 0 2 -2
creatinine,if,withdrawn 1.0 0.000143348623853 0 1 -1
creatinine,have,occurred 1.0 0.000143348623853 0 1 -1
creatinine,despite,reduction 1.0 0.000143348623853 0 1 -1
creatinine,concentration,times 1.0 0.000143348623853 0 1 -1
creatinine,clearance,ml 1.0 0.000143348623853 0 1 -1
creatinine,by,the 1.0 0.000143348623853 0 1 -1
creatine,phosphokinase,diffuse 1.0 0.000143348623853 0 1 -1
create,possible,additive 1.0 0.00043004587156 0 3 -3
creams,ointments,or 1.0 0.000143348623853 0 1 -1
creams,lotions,or 1.0 0.000143348623853 0 1 -1
cream,cream,and 1.0 0.000143348623853 0 1 -1
cream,and,other 1.0 0.000143348623853 0 1 -1
cramps,muscular,fatigue 1.0 0.000143348623853 0 1 -1
cpk,were,observed 1.0 0.000143348623853 0 1 -1
cpk,some,patients 1.0 0.000143348623853 0 1 -1
cpk,elevations,returned 1.0 0.000143348623853 0 1 -1
cox-2,inhibitor,at 1.0 0.000143348623853 0 1 -1
covers,pharmacology,pharmacokinetics 1.0 0.000143348623853 0 1 -1
cover,interactions,with 1.0 0.000143348623853 0 1 -1
covalently,linked,to 1.0 0.000143348623853 0 1 -1
courses,of,zmax 1.0 0.000143348623853 0 1 -1
courses,of,therapy 1.0 0.000143348623853 0 1 -1
course,of,taxol 1.0 0.000143348623853 0 1 -1
course,of,septic 1.0 0.000143348623853 0 1 -1
course,of,patients 1.0 0.000143348623853 0 1 -1
course,of,interference 1.0 0.000143348623853 0 1 -1
coupling,between,the 1.0 0.000143348623853 0 1 -1
coupled,with,population 1.0 0.000143348623853 0 1 -1
coupled,to,three 1.0 0.000143348623853 0 1 -1
coupled,to,activation 1.0 0.000143348623853 0 1 -1
counts,were,determined 1.0 0.000143348623853 0 1 -1
counts,related,to 1.0 0.000143348623853 0 1 -1
counts,of,less 1.0 0.000143348623853 0 1 -1
counts,for,type 1.0 0.000143348623853 0 1 -1
counts,be,performed 1.0 0.000143348623853 0 1 -1
counts,and,the 1.0 0.000143348623853 0 1 -1
counter,medicines,including 1.0 0.000143348623853 0 1 -1
counter,cough,cold 1.0 0.000143348623853 0 1 -1
count,ria,kit 1.0 0.000143348623853 0 1 -1
count,prothrombin,time 1.0 0.000143348623853 0 1 -1
count,is,at 1.0 0.000143348623853 0 1 -1
coumarin-type,has,been 1.0 0.000143348623853 0 1 -1
coumarin-type,anticoagulants,several 1.0 0.000143348623853 0 1 -1
coumarin-derivative,should,be 1.0 0.000143348623853 0 1 -1
coumarin,type,revealed 1.0 0.000143348623853 0 1 -1
coumarin,anticoagulants,in 1.0 0.000143348623853 0 1 -1
coumadin,other,tegretol 1.0 0.000143348623853 0 1 -1
could,theoretically,occur 1.0 0.000143348623853 0 1 -1
could,theoretically,interfere 1.0 0.000143348623853 0 1 -1
could,result,in 1.0 0.000286697247706 0 2 -2
could,result,from 1.0 0.000143348623853 0 1 -1
could,occur,following 1.0 0.000143348623853 0 1 -1
could,observe,that 1.0 0.000143348623853 0 1 -1
could,not,be 1.0 0.000286697247706 0 2 -2
could,lessen,its 1.0 0.000143348623853 0 1 -1
could,have,increased 1.0 0.000143348623853 0 1 -1
could,have,a 1.0 0.00043004587156 0 3 -3
could,facilitate,the 1.0 0.000143348623853 0 1 -1
could,decrease,first 1.0 0.000143348623853 0 1 -1
could,create,possible 1.0 0.00043004587156 0 3 -3
could,contribute,to 1.0 0.000143348623853 0 1 -1
could,contribute,in 1.0 0.000143348623853 0 1 -1
could,be,the 1.0 0.000143348623853 0 1 -1
could,be,reversed 1.0 0.000143348623853 0 1 -1
could,be,involved 1.0 0.000143348623853 0 1 -1
could,be,explained 1.0 0.000143348623853 0 1 -1
could,be,due 1.0 0.000143348623853 0 1 -1
could,be,considered 1.0 0.000143348623853 0 1 -1
could,be,avoided 1.0 0.000143348623853 0 1 -1
could,be,ascertained 1.0 0.000143348623853 0 1 -1
could,be,an 1.0 0.000143348623853 0 1 -1
could,be,affected 1.0 0.000143348623853 0 1 -1
could,affect,the 1.0 0.000143348623853 0 1 -1
cough,cold,allergy 1.0 0.000143348623853 0 1 -1
cotherapy,an,increased 1.0 0.000143348623853 0 1 -1
costs,of,schizophrenia 1.0 0.000143348623853 0 1 -1
costs,inpatient,and 1.0 0.000143348623853 0 1 -1
costs,despite,the 1.0 0.000143348623853 0 1 -1
cost-risk,benefit,balance 1.0 0.000143348623853 0 1 -1
cost,of,is 1.0 0.000143348623853 0 1 -1
cosmetics,that,have 1.0 0.000143348623853 0 1 -1
cortisol,thyroid-stimulating,hormone 1.0 0.000143348623853 0 1 -1
cortisol,levels,produced 1.0 0.000143348623853 0 1 -1
cortisol,does,not 1.0 0.000143348623853 0 1 -1
cortisol,concentration,or 1.0 0.000143348623853 0 1 -1
corticosteroids,systemic,are 1.0 0.000143348623853 0 1 -1
corticosteroids,may,suppress 1.0 0.000143348623853 0 1 -1
corticosteroids,may,affect 1.0 0.000143348623853 0 1 -1
corticosteroids,acth,intensified 1.0 0.000286697247706 0 2 -2
corticosteroid-binding,globulin,thereby 1.0 0.000143348623853 0 1 -1
corticosteroid,binding,globulin 1.0 0.000143348623853 0 1 -1
cortical,tissues,of 1.0 0.000143348623853 0 1 -1
cortex,which,are 1.0 0.000143348623853 0 1 -1
cortex,of,the 1.0 0.000143348623853 0 1 -1
cortex,of,chronically 1.0 0.000143348623853 0 1 -1
cortex,and,subcortical 1.0 0.000143348623853 0 1 -1
corresponding,values,for 1.0 0.000286697247706 0 2 -2
corresponding,to,relevant 1.0 0.000143348623853 0 1 -1
correspond,to,approximately 1.0 0.000286697247706 0 2 -2
correlative,clinical,studies 1.0 0.000143348623853 0 1 -1
correlation,between,blood 1.0 0.000143348623853 0 1 -1
correlated,with,brain 1.0 0.000143348623853 0 1 -1
correlated,with,at 1.0 0.000143348623853 0 1 -1
correlate,with,release 1.0 0.000143348623853 0 1 -1
corrective,measures,to 1.0 0.000143348623853 0 1 -1
corrective,measures,for 1.0 0.000143348623853 0 1 -1
corrected,whenever,possible 1.0 0.000143348623853 0 1 -1
corrected,qt,intervals 1.0 0.000286697247706 0 2 -2
corrected,qt,interval 1.0 0.000143348623853 0 1 -1
correct,the,anemia 1.0 0.000143348623853 0 1 -1
correct,changes,in 1.0 0.000143348623853 0 1 -1
coronary,oral,cough 1.0 0.000143348623853 0 1 -1
coronary,insufficiency,in 1.0 0.000143348623853 0 1 -1
coronary,insufficiency,especially 1.0 0.000143348623853 0 1 -1
coronary,artery,disease 1.0 0.000286697247706 0 2 -2
corn,oil,ml 1.0 0.000143348623853 0 1 -1
core,temperature,returned 1.0 0.000143348623853 0 1 -1
core,temperature,in 1.0 0.000143348623853 0 1 -1
cordarone,i,v 1.0 0.000143348623853 0 1 -1
cordarone,administration,impairs 1.0 0.000143348623853 0 1 -1
copper,sulfate,tests 1.0 0.000143348623853 0 1 -1
copper,reduction,tests 1.0 0.000286697247706 0 2 -2
copegus,therapy,is 1.0 0.000143348623853 0 1 -1
copegus,should,not 1.0 0.000143348623853 0 1 -1
copegus,pegasys,treatment 1.0 0.000143348623853 0 1 -1
copegus,in,patients 1.0 0.000143348623853 0 1 -1
copegus,did,not 1.0 0.000143348623853 0 1 -1
copegus,are,excreted 1.0 0.000143348623853 0 1 -1
copd,symptoms,and 1.0 0.000143348623853 0 1 -1
copd,should,not 1.0 0.000143348623853 0 1 -1
copd,medications,they 1.0 0.000143348623853 0 1 -1
copaxone,has,not 1.0 0.000143348623853 0 1 -1
copaxone,did,not 1.0 0.000143348623853 0 1 -1
copaxone,and,other 1.0 0.000286697247706 0 2 -2
coordination,disorder,tremor 1.0 0.000143348623853 0 1 -1
coombs,tests,have 1.0 0.000286697247706 0 2 -2
coombs,testing,of 1.0 0.000143348623853 0 1 -1
coombs,test,may 1.0 0.000286697247706 0 2 -2
coombs,test,has 1.0 0.000143348623853 0 1 -1
coombs,test,could 1.0 0.000143348623853 0 1 -1
coombs,reactions,in 1.0 0.000143348623853 0 1 -1
cooling,the,nerves 1.0 0.000143348623853 0 1 -1
convulsions,occurring,in 1.0 0.000143348623853 0 1 -1
convulsion,was,seen 1.0 0.000143348623853 0 1 -1
converting,enzyme,ace 1.0 0.000143348623853 0 1 -1
converted,difluoroacetone,to 1.0 0.000143348623853 0 1 -1
conversion,to,inactive 1.0 0.000143348623853 0 1 -1
conversion,of,to 1.0 0.000286697247706 0 2 -2
conversion,of,deoxy 1.0 0.000143348623853 0 1 -1
conversion,from,one 1.0 0.000143348623853 0 1 -1
conversion,could,be 1.0 0.000143348623853 0 1 -1
conversely,the,administration 1.0 0.000143348623853 0 1 -1
conversely,at,exposure 1.0 0.000143348623853 0 1 -1
conversely,adverse,effects 1.0 0.000143348623853 0 1 -1
conventional,it,has 1.0 0.000143348623853 0 1 -1
convenient,administration,regimens 1.0 0.000143348623853 0 1 -1
controls,was,evident 1.0 0.000143348623853 0 1 -1
controls,levels,of 1.0 0.000143348623853 0 1 -1
controlled,trials,that 1.0 0.000143348623853 0 1 -1
controlled,trials,in 1.0 0.000143348623853 0 1 -1
controlled,trial,that 1.0 0.000143348623853 0 1 -1
controlled,study,suggested 1.0 0.000143348623853 0 1 -1
controlled,study,of 1.0 0.000286697247706 0 2 -2
controlled,study,in 1.0 0.000143348623853 0 1 -1
controlled,studies,to 1.0 0.000143348623853 0 1 -1
controlled,studies,failed 1.0 0.000286697247706 0 2 -2
controlled,parallel,group 1.0 0.000143348623853 0 1 -1
controlled,crossover,clinical 1.0 0.000143348623853 0 1 -1
controlled,clinical,trials 1.0 0.00043004587156 0 3 -3
controlled,clinical,trial 1.0 0.000143348623853 0 1 -1
controlled,clinical,studies 1.0 0.000143348623853 0 1 -1
controlled,clinical,pharmacology 1.0 0.000143348623853 0 1 -1
controlled,and,uncontrolled 1.0 0.000143348623853 0 1 -1
control,with,reduced 1.0 0.000143348623853 0 1 -1
control,values,for 1.0 0.000143348623853 0 1 -1
control,symptoms,indicates 1.0 0.000143348623853 0 1 -1
control,side,effects 1.0 0.000143348623853 0 1 -1
control,rbc,were 1.0 0.000143348623853 0 1 -1
control,rats,with 1.0 0.000143348623853 0 1 -1
control,rats,whereas 1.0 0.000143348623853 0 1 -1
control,rats,probably 1.0 0.000143348623853 0 1 -1
control,rats,in 1.0 0.000143348623853 0 1 -1
control,rats,at 1.0 0.000143348623853 0 1 -1
control,program,of 1.0 0.000143348623853 0 1 -1
control,pills,sleeping 1.0 0.000143348623853 0 1 -1
control,of,their 1.0 0.000143348623853 0 1 -1
control,of,naflu 1.0 0.000143348623853 0 1 -1
control,of,blood 1.0 0.000143348623853 0 1 -1
control,of,acute 1.0 0.000143348623853 0 1 -1
control,mechanisms,of 1.0 0.000143348623853 0 1 -1
control,in,patients 1.0 0.000143348623853 0 1 -1
control,in,non-diabetics 1.0 0.000143348623853 0 1 -1
control,group,vs 1.0 0.000143348623853 0 1 -1
control,blood,glucose 1.0 0.000143348623853 0 1 -1
control,at,h 1.0 0.000143348623853 0 1 -1
control,and,the 1.0 0.000143348623853 0 1 -1
control,and,received 1.0 0.000143348623853 0 1 -1
control,and,levonorgestrel-treated 1.0 0.000143348623853 0 1 -1
control,and,continued 1.0 0.000143348623853 0 1 -1
contribution,to,the 1.0 0.000143348623853 0 1 -1
contribution,of,receptors 1.0 0.000143348623853 0 1 -1
contribution,of,each 1.0 0.000143348623853 0 1 -1
contributed,to,the 1.0 0.000143348623853 0 1 -1
contributed,to,hyperglycemia 1.0 0.000143348623853 0 1 -1
contribute,to,regimen 1.0 0.000143348623853 0 1 -1
contribute,to,decrease 1.0 0.000143348623853 0 1 -1
contribute,in,part 1.0 0.000143348623853 0 1 -1
contrast,to,the 1.0 0.000143348623853 0 1 -1
contrast,to,its 1.0 0.000143348623853 0 1 -1
contrast,the,potency 1.0 0.000143348623853 0 1 -1
contrast,reactions,after 1.0 0.000143348623853 0 1 -1
contrast,preliminary,results 1.0 0.000143348623853 0 1 -1
contrast,nucleophosmin,b23 1.0 0.000143348623853 0 1 -1
contrast,mm,and 1.0 0.000143348623853 0 1 -1
contrast,media,was 1.0 0.000286697247706 0 2 -2
contrast,increased,the 1.0 0.000143348623853 0 1 -1
contrast,in,ontario 1.0 0.000143348623853 0 1 -1
contrast,in,isolated 1.0 0.000143348623853 0 1 -1
contrast,acute,toxicity 1.0 0.000143348623853 0 1 -1
contraindications,significant,teratogenic 1.0 0.000143348623853 0 1 -1
contraindications,indications,use 1.0 0.000143348623853 0 1 -1
contraindication,to,further 1.0 0.000143348623853 0 1 -1
contraindicated,specifically,due 1.0 0.000143348623853 0 1 -1
contraindicated,since,the 1.0 0.000143348623853 0 1 -1
contraindicated,in,women 1.0 0.000143348623853 0 1 -1
contraindicated,due,to 1.0 0.00143348623853 0 10 -10
contraction,was,decreased 1.0 0.000143348623853 0 1 -1
contraction,of,guinea-pig 1.0 0.000143348623853 0 1 -1
contraction,followed,by 1.0 0.000143348623853 0 1 -1
contraction,and,release 1.0 0.000143348623853 0 1 -1
contractile,response,to 1.0 0.000143348623853 0 1 -1
contraceptives,valdecoxib,mg 1.0 0.000143348623853 0 1 -1
contraceptives,the,effect 1.0 0.000143348623853 0 1 -1
contraceptives,rofecoxib,did 1.0 0.000143348623853 0 1 -1
contraceptives,multiple,doses 1.0 0.000143348623853 0 1 -1
contraceptives,multiple,dose 1.0 0.000143348623853 0 1 -1
contraceptives,may,be 1.0 0.000143348623853 0 1 -1
contraceptives,keppra,mg 1.0 0.000143348623853 0 1 -1
contraceptives,it,has 1.0 0.000143348623853 0 1 -1
contraceptives,estrogens,tend 1.0 0.000143348623853 0 1 -1
contraceptives,a,group 1.0 0.000143348623853 0 1 -1
contraceptive,based,on 1.0 0.000143348623853 0 1 -1
contraceptive,agents,ethinyl 1.0 0.000143348623853 0 1 -1
contraception,simultaneously,at 1.0 0.000143348623853 0 1 -1
contraception,is,suggested 1.0 0.000143348623853 0 1 -1
contraception,and,not 1.0 0.000143348623853 0 1 -1
contraception,alone,when 1.0 0.000143348623853 0 1 -1
continuous,intravenous,infusion 1.0 0.000143348623853 0 1 -1
continuous,cardiac,monitoring 1.0 0.000143348623853 0 1 -1
continuous,and,discrete 1.0 0.000143348623853 0 1 -1
continuing,surveillance,of 1.0 0.000143348623853 0 1 -1
continues,to,be 1.0 0.000143348623853 0 1 -1
continued,use,of 1.0 0.000143348623853 0 1 -1
continued,use,in 1.0 0.000143348623853 0 1 -1
continued,to,receive 1.0 0.000143348623853 0 1 -1
continued,these,patients 1.0 0.000143348623853 0 1 -1
continued,serum,levels 1.0 0.000143348623853 0 1 -1
continued,need,for 1.0 0.000143348623853 0 1 -1
continued,for,a 1.0 0.000143348623853 0 1 -1
continued,admistration,of 1.0 0.000143348623853 0 1 -1
continue,to,be 1.0 0.000143348623853 0 1 -1
continue,the,provide 1.0 0.000143348623853 0 1 -1
continuation,of,both 1.0 0.000286697247706 0 2 -2
context,of,linear 1.0 0.000143348623853 0 1 -1
contents,of,the 1.0 0.000143348623853 0 1 -1
contents,and,transits 1.0 0.000143348623853 0 1 -1
content,after,perfusion 1.0 0.000143348623853 0 1 -1
contemplated,the,dose 1.0 0.000573394495413 0 4 -4
contemplated,the,dosage 1.0 0.000143348623853 0 1 -1
contains,reports,of 1.0 0.000143348623853 0 1 -1
contains,dehydrated,usp 1.0 0.000143348623853 0 1 -1
contains,a,carbonic 1.0 0.000143348623853 0 1 -1
containing,side,chains 1.0 0.000143348623853 0 1 -1
containing,should,also 1.0 0.000143348623853 0 1 -1
containing,or,salicylic 1.0 0.000143348623853 0 1 -1
containing,microgram,ml 1.0 0.000143348623853 0 1 -1
containing,mg,ethinyl 1.0 0.000286697247706 0 2 -2
containing,membranes,of 1.0 0.000143348623853 0 1 -1
containing,may,lead 1.0 0.000143348623853 0 1 -1
containing,iodine-containing,preparations 1.0 0.000143348623853 0 1 -1
containing,higher,and 1.0 0.000143348623853 0 1 -1
containing,either,or 1.0 0.000143348623853 0 1 -1
containing,a,vanh 1.0 0.000143348623853 0 1 -1
contained,plus,or 1.0 0.000143348623853 0 1 -1
contain,a,lectin 1.0 0.000143348623853 0 1 -1
contact,and,with 1.0 0.000143348623853 0 1 -1
consumption,of,at 1.0 0.000143348623853 0 1 -1
consume,greater,than 1.0 0.000143348623853 0 1 -1
consulting,the,physician 1.0 0.000143348623853 0 1 -1
consulting,the,appropriate 1.0 0.000143348623853 0 1 -1
consult,the,package 1.0 0.000286697247706 0 2 -2
constructive,alternatives,in 1.0 0.000143348623853 0 1 -1
constriction,were,unaffected 1.0 0.000143348623853 0 1 -1
constitutes,the,best 1.0 0.000143348623853 0 1 -1
constitute,the,sole 1.0 0.000143348623853 0 1 -1
constituents,of,alcoholic 1.0 0.000143348623853 0 1 -1
constituent,precipitated,by 1.0 0.000143348623853 0 1 -1
constipation,and,dry 1.0 0.000143348623853 0 1 -1
constant,while,fractional 1.0 0.000143348623853 0 1 -1
constant,was,significantly 1.0 0.000143348623853 0 1 -1
constant,volume,of 1.0 0.000143348623853 0 1 -1
constant,values,being 1.0 0.000143348623853 0 1 -1
consisting,of,basal 1.0 0.000143348623853 0 1 -1
consistent,with,the 1.0 0.00043004587156 0 3 -3
consistent,with,its 1.0 0.000286697247706 0 2 -2
consistent,effects,with 1.0 0.000143348623853 0 1 -1
consisted,of,two 1.0 0.000143348623853 0 1 -1
consisted,of,erythema 1.0 0.000286697247706 0 2 -2
considers,the,mode 1.0 0.000143348623853 0 1 -1
considering,that,the 1.0 0.000143348623853 0 1 -1
considered,whenever,these 1.0 0.000143348623853 0 1 -1
considered,when,treatment 1.0 0.000143348623853 0 1 -1
considered,when,rebif 1.0 0.000143348623853 0 1 -1
considered,when,ponstel 1.0 0.000143348623853 0 1 -1
considered,when,evaluating 1.0 0.000143348623853 0 1 -1
considered,when,dosing 1.0 0.000143348623853 0 1 -1
considered,when,changing 1.0 0.000143348623853 0 1 -1
considered,to,result 1.0 0.000143348623853 0 1 -1
considered,to,have 1.0 0.000143348623853 0 1 -1
considered,the,same 1.0 0.000143348623853 0 1 -1
considered,particularly,when 1.0 0.000143348623853 0 1 -1
considered,particularly,for 1.0 0.000143348623853 0 1 -1
considered,in,the 1.0 0.000286697247706 0 2 -2
considered,in,patients 1.0 0.00043004587156 0 3 -3
considered,if,systemic 1.0 0.000143348623853 0 1 -1
considered,if,changes 1.0 0.000143348623853 0 1 -1
considered,for,the 1.0 0.000143348623853 0 1 -1
considered,for,pancreatic 1.0 0.000143348623853 0 1 -1
considered,for,nsclc 1.0 0.000143348623853 0 1 -1
considered,clinically,significant 1.0 0.000143348623853 0 1 -1
considered,by,age 1.0 0.000143348623853 0 1 -1
considered,and,dosage 1.0 0.00043004587156 0 3 -3
considered,although,they 1.0 0.000143348623853 0 1 -1
considerations,as,the 1.0 0.000143348623853 0 1 -1
considerations,are,discussed 1.0 0.000143348623853 0 1 -1
consideration,to,the 1.0 0.000143348623853 0 1 -1
consideration,of,appropriate 1.0 0.000143348623853 0 1 -1
consideration,in,the 1.0 0.000143348623853 0 1 -1
consideration,before,such 1.0 0.000143348623853 0 1 -1
considerably,lower,than 1.0 0.000143348623853 0 1 -1
considerably,enhance,the 1.0 0.000143348623853 0 1 -1
considerable,variability,of 1.0 0.000143348623853 0 1 -1
considerable,segment,of 1.0 0.000143348623853 0 1 -1
considerable,evidence,suggesting 1.0 0.000143348623853 0 1 -1
considerable,evidence,indicating 1.0 0.000143348623853 0 1 -1
consider,starting,other 1.0 0.000143348623853 0 1 -1
consider,monitoring,levels 1.0 0.000143348623853 0 1 -1
consider,doubling,the 1.0 0.000143348623853 0 1 -1
conservative,approach,to 1.0 0.000143348623853 0 1 -1
consequently,with,a 1.0 0.000143348623853 0 1 -1
consequently,tracleer,is 1.0 0.000143348623853 0 1 -1
consequently,prothrombin,time 1.0 0.000143348623853 0 1 -1
consequently,plasma,concentrations 1.0 0.000143348623853 0 1 -1
consequently,interactions,with 1.0 0.000143348623853 0 1 -1
consequently,caution,is 1.0 0.000286697247706 0 2 -2
consequently,alter,the 1.0 0.000143348623853 0 1 -1
consequences,of,these 1.0 0.000143348623853 0 1 -1
consequences,of,concomitant 1.0 0.000286697247706 0 2 -2
consequences,hunger,can 1.0 0.000143348623853 0 1 -1
consequences,following,mptp 1.0 0.000143348623853 0 1 -1
consequences,following,methyl-4 1.0 0.000143348623853 0 1 -1
consequences,could,be 1.0 0.000143348623853 0 1 -1
consensus,reports,have 1.0 0.000143348623853 0 1 -1
consciousness,confusion,disorientation 1.0 0.000143348623853 0 1 -1
conjunction,with,the 1.0 0.000143348623853 0 1 -1
conjunction,with,standard 1.0 0.000143348623853 0 1 -1
conjunction,with,one 1.0 0.000143348623853 0 1 -1
conjunction,with,demonstrated 1.0 0.000143348623853 0 1 -1
conjunction,with,an 1.0 0.000143348623853 0 1 -1
conjugation,through,udp-glucuronyl 1.0 0.000143348623853 0 1 -1
conjugation,at,nacmc 1.0 0.000143348623853 0 1 -1
conjugation,at,and 1.0 0.000143348623853 0 1 -1
conjugates,was,used 1.0 0.000143348623853 0 1 -1
conjugates,so,formed 1.0 0.000143348623853 0 1 -1
conjugates,on,the 1.0 0.000143348623853 0 1 -1
conjugated,with,further 1.0 0.000143348623853 0 1 -1
conjugated,system,maybe 1.0 0.000143348623853 0 1 -1
conjugated,dienes,approximately 1.0 0.000143348623853 0 1 -1
conjugated,and,and 1.0 0.000143348623853 0 1 -1
congenital,or,acquired 1.0 0.000143348623853 0 1 -1
congeners,and,coexisting 1.0 0.000143348623853 0 1 -1
congener,is,being 1.0 0.000143348623853 0 1 -1
confusion,disorientation,anxiety 1.0 0.000143348623853 0 1 -1
conflicting,results,have 1.0 0.000143348623853 0 1 -1
confirms,the,identity 1.0 0.000143348623853 0 1 -1
confirmed,these,effects 1.0 0.000143348623853 0 1 -1
confirmed,interactions,have 1.0 0.000143348623853 0 1 -1
confirmed,for,in 1.0 0.000143348623853 0 1 -1
confirmed,by,other 1.0 0.000143348623853 0 1 -1
confirmation,test,should 1.0 0.000143348623853 0 1 -1
confirmation,should,be 1.0 0.000143348623853 0 1 -1
confirm,the,significant 1.0 0.000143348623853 0 1 -1
confirm,that,the 1.0 0.000286697247706 0 2 -2
confidence,limit,decrease 1.0 0.000143348623853 0 1 -1
confidence,interval,for 1.0 0.000143348623853 0 1 -1
confidence,interval,decrease 1.0 0.000143348623853 0 1 -1
confidence,interval,and 1.0 0.000143348623853 0 1 -1
conference,reviews,recent 1.0 0.000143348623853 0 1 -1
conduction,disturbances,including 1.0 0.000143348623853 0 1 -1
conduction,abnormalities,also 1.0 0.000143348623853 0 1 -1
conducted,with,persantine 1.0 0.000143348623853 0 1 -1
conducted,with,and 1.0 0.000143348623853 0 1 -1
conducted,to,investigate 1.0 0.000143348623853 0 1 -1
conducted,to,evaluate 1.0 0.000143348623853 0 1 -1
conducted,to,date 1.0 0.000143348623853 0 1 -1
conducted,to,assess 1.0 0.00043004587156 0 3 -3
conducted,the,most 1.0 0.000143348623853 0 1 -1
conducted,on,plasma 1.0 0.000143348623853 0 1 -1
conducted,on,days 1.0 0.000143348623853 0 1 -1
conducted,no,interactions 1.0 0.000143348623853 0 1 -1
conducted,in,vivo 1.0 0.000143348623853 0 1 -1
conducted,in,vitro 1.0 0.000286697247706 0 2 -2
conducted,in,the 1.0 0.000143348623853 0 1 -1
conducted,in,oa 1.0 0.000143348623853 0 1 -1
conducted,in,hiv-infected 1.0 0.000143348623853 0 1 -1
conducted,in,hiv-1 1.0 0.000143348623853 0 1 -1
conducted,in,female 1.0 0.000143348623853 0 1 -1
conducted,in,cases 1.0 0.000143348623853 0 1 -1
conducted,for,the 1.0 0.000143348623853 0 1 -1
conducted,for,colazal 1.0 0.000143348623853 0 1 -1
conducted,at,intermediate 1.0 0.000143348623853 0 1 -1
conducted,although,many 1.0 0.000143348623853 0 1 -1
conduct,close,clinical 1.0 0.000143348623853 0 1 -1
conditions,to,normal 1.0 0.000143348623853 0 1 -1
conditions,to,healthy 1.0 0.000143348623853 0 1 -1
conditions,that,may 1.0 0.000143348623853 0 1 -1
conditions,such,as 1.0 0.000143348623853 0 1 -1
conditions,produce,toxicity 1.0 0.000143348623853 0 1 -1
conditions,or,with 1.0 0.000143348623853 0 1 -1
conditions,or,was 1.0 0.000143348623853 0 1 -1
conditions,of,patients 1.0 0.000143348623853 0 1 -1
conditions,kinetics,equilibrium 1.0 0.000143348623853 0 1 -1
conditions,had,no 1.0 0.000143348623853 0 1 -1
conditions,for,which 1.0 0.000143348623853 0 1 -1
conditions,duloxetine,unprotected 1.0 0.000143348623853 0 1 -1
conditions,concentrations,were 1.0 0.000143348623853 0 1 -1
conditions,and,concomitantly 1.0 0.000143348623853 0 1 -1
conditioning,processes,automatic 1.0 0.000143348623853 0 1 -1
conditioning,and,a 1.0 0.000143348623853 0 1 -1
condition,worse,and 1.0 0.000143348623853 0 1 -1
condition,may,be 1.0 0.000143348623853 0 1 -1
condition,corrected,whenever 1.0 0.000143348623853 0 1 -1
condition,after,weeks 1.0 0.000143348623853 0 1 -1
condensation,nuclear,matrix 1.0 0.000143348623853 0 1 -1
concurrently,without,any 1.0 0.000143348623853 0 1 -1
concurrently,with,such 1.0 0.000143348623853 0 1 -1
concurrently,with,mg 1.0 0.000143348623853 0 1 -1
concurrently,with,medications 1.0 0.000286697247706 0 2 -2
concurrently,with,iopidine 1.0 0.000143348623853 0 1 -1
concurrently,with,in 1.0 0.000143348623853 0 1 -1
concurrently,with,escalating 1.0 0.000143348623853 0 1 -1
concurrently,with,does 1.0 0.000143348623853 0 1 -1
concurrently,with,cardiac 1.0 0.000143348623853 0 1 -1
concurrently,with,can 1.0 0.000143348623853 0 1 -1
concurrently,with,brevibloc 1.0 0.000143348623853 0 1 -1
concurrently,with,agents 1.0 0.000286697247706 0 2 -2
concurrently,with,a 1.0 0.000143348623853 0 1 -1
concurrently,taking,metabolized 1.0 0.000143348623853 0 1 -1
concurrently,taking,medications 1.0 0.000143348623853 0 1 -1
concurrently,taking,antiseizure 1.0 0.000143348623853 0 1 -1
concurrently,patient,should 1.0 0.000143348623853 0 1 -1
concurrently,it,is 1.0 0.000143348623853 0 1 -1
concurrently,did,not 1.0 0.000143348623853 0 1 -1
concurrently,and,to 1.0 0.000143348623853 0 1 -1
concurrently,and,that 1.0 0.000143348623853 0 1 -1
concurrently,administered,with 1.0 0.000286697247706 0 2 -2
concurrently,administered,in 1.0 0.000143348623853 0 1 -1
concurrent,use,to 1.0 0.000143348623853 0 1 -1
concurrent,use,should 1.0 0.000143348623853 0 1 -1
concurrent,use,may 1.0 0.000573394495413 0 4 -4
concurrent,usage,of 1.0 0.000143348623853 0 1 -1
concurrent,therapy,is 1.0 0.00043004587156 0 3 -3
concurrent,or,serial 1.0 0.000286697247706 0 2 -2
concurrent,dosing,of 1.0 0.000143348623853 0 1 -1
concurrent,and,avastin 1.0 0.000143348623853 0 1 -1
concomitantly,without,a 1.0 0.000143348623853 0 1 -1
concomitantly,with,without 1.0 0.000143348623853 0 1 -1
concomitantly,with,sustained-release 1.0 0.000143348623853 0 1 -1
concomitantly,with,radiation 1.0 0.000143348623853 0 1 -1
concomitantly,with,plendil 1.0 0.000143348623853 0 1 -1
concomitantly,with,many 1.0 0.000143348623853 0 1 -1
concomitantly,with,lodosyn 1.0 0.000143348623853 0 1 -1
concomitantly,with,increases 1.0 0.000286697247706 0 2 -2
concomitantly,with,hormonal 1.0 0.000143348623853 0 1 -1
concomitantly,with,coly-mycin 1.0 0.000143348623853 0 1 -1
concomitantly,with,beta-adrenergic 1.0 0.000143348623853 0 1 -1
concomitantly,with,beta 1.0 0.000143348623853 0 1 -1
concomitantly,with,angiotensin- 1.0 0.000143348623853 0 1 -1
concomitantly,used,in 1.0 0.000143348623853 0 1 -1
concomitantly,taking,or 1.0 0.000143348623853 0 1 -1
concomitantly,showed,that 1.0 0.000143348623853 0 1 -1
concomitantly,should,be 1.0 0.000286697247706 0 2 -2
concomitantly,receiving,velcade 1.0 0.000143348623853 0 1 -1
concomitantly,prothrombin,time 1.0 0.000573394495413 0 4 -4
concomitantly,prothrombin,or 1.0 0.000143348623853 0 1 -1
concomitantly,plasma,levels 1.0 0.000143348623853 0 1 -1
concomitantly,only,with 1.0 0.000286697247706 0 2 -2
concomitantly,of,whom 1.0 0.000143348623853 0 1 -1
concomitantly,given,did 1.0 0.000143348623853 0 1 -1
concomitantly,closely,monitor 1.0 0.000143348623853 0 1 -1
concomitantly,careful,monitoring 1.0 0.000143348623853 0 1 -1
concomitantly,administered,with 1.0 0.000143348623853 0 1 -1
concomitantly,administered,tagamet 1.0 0.000143348623853 0 1 -1
concomitantly,administered,mg 1.0 0.000143348623853 0 1 -1
concomitantly,administered,metabolized 1.0 0.000143348623853 0 1 -1
concomitantly,administered,iron-fortified 1.0 0.000143348623853 0 1 -1
concomitantly,administered,highly 1.0 0.000143348623853 0 1 -1
concomitantly,administered,due 1.0 0.000143348623853 0 1 -1
concomitantly,administered,did 1.0 0.000143348623853 0 1 -1
concomitant,were,used 1.0 0.000143348623853 0 1 -1
concomitant,use,unless 1.0 0.000143348623853 0 1 -1
concomitant,use,should 1.0 0.000143348623853 0 1 -1
concomitant,use,is 1.0 0.000143348623853 0 1 -1
concomitant,use,however 1.0 0.000143348623853 0 1 -1
concomitant,use,cannot 1.0 0.000143348623853 0 1 -1
concomitant,treatment,in 1.0 0.000286697247706 0 2 -2
concomitant,therapy,or 1.0 0.000143348623853 0 1 -1
concomitant,therapy,may 1.0 0.000143348623853 0 1 -1
concomitant,therapy,in 1.0 0.000143348623853 0 1 -1
concomitant,therapy,although 1.0 0.000286697247706 0 2 -2
concomitant,therapies,may 1.0 0.000143348623853 0 1 -1
concomitant,therapies,in 1.0 0.000143348623853 0 1 -1
concomitant,supplementation,with 1.0 0.000143348623853 0 1 -1
concomitant,such,as 1.0 0.000143348623853 0 1 -1
concomitant,substrate,should 1.0 0.000143348623853 0 1 -1
concomitant,strong,inhibitors 1.0 0.000143348623853 0 1 -1
concomitant,strong,inducers 1.0 0.000143348623853 0 1 -1
concomitant,or,hot 1.0 0.000143348623853 0 1 -1
concomitant,on,the 1.0 0.000143348623853 0 1 -1
concomitant,medications,with 1.0 0.000286697247706 0 2 -2
concomitant,medications,were 1.0 0.000143348623853 0 1 -1
concomitant,medications,such 1.0 0.000286697247706 0 2 -2
concomitant,medications,should 1.0 0.000143348623853 0 1 -1
concomitant,medications,on 1.0 0.000143348623853 0 1 -1
concomitant,medications,may 1.0 0.000143348623853 0 1 -1
concomitant,medications,included 1.0 0.000143348623853 0 1 -1
concomitant,medications,in 1.0 0.000143348623853 0 1 -1
concomitant,medications,besides 1.0 0.000143348623853 0 1 -1
concomitant,medications,and 1.0 0.00043004587156 0 3 -3
concomitant,medication,on 1.0 0.000143348623853 0 1 -1
concomitant,medication,but 1.0 0.000143348623853 0 1 -1
concomitant,intake,of 1.0 0.000143348623853 0 1 -1
concomitant,in,rheumatoid 1.0 0.000143348623853 0 1 -1
concomitant,hydrochloride,and 1.0 0.000143348623853 0 1 -1
concomitant,crohn,s 1.0 0.000143348623853 0 1 -1
concomitant,compared,with 1.0 0.000143348623853 0 1 -1
concomitant,chemotherapy,and 1.0 0.000143348623853 0 1 -1
concomitant,beta-1a,avonex 1.0 0.000143348623853 0 1 -1
concomitant,augmentin,xr 1.0 0.000143348623853 0 1 -1
concomitant,and,chemotherapy 1.0 0.000143348623853 0 1 -1
concomitant,agents,such 1.0 0.000143348623853 0 1 -1
concomitant,administration,trough 1.0 0.000143348623853 0 1 -1
concomitant,administration,on 1.0 0.000286697247706 0 2 -2
conclusively,establish,whether 1.0 0.000143348623853 0 1 -1
conclusions,to,be 1.0 0.000143348623853 0 1 -1
conclusions,the,combination 1.0 0.000143348623853 0 1 -1
conclusions,sildenafil,is 1.0 0.000143348623853 0 1 -1
conclusions,olanzapine,demonstrated 1.0 0.000143348623853 0 1 -1
conclusions,it,is 1.0 0.000143348623853 0 1 -1
conclusions,interpretation,glucose 1.0 0.000143348623853 0 1 -1
conclusions,in,contrast 1.0 0.000143348623853 0 1 -1
conclusions,everolimus,exhibited 1.0 0.000143348623853 0 1 -1
conclusions,are,given 1.0 0.000143348623853 0 1 -1
conclusions,and,the 1.0 0.000143348623853 0 1 -1
conclusion,these,findings 1.0 0.000143348623853 0 1 -1
conclusion,fluvoxamine,is 1.0 0.000143348623853 0 1 -1
conclusion,cisapride,can 1.0 0.000143348623853 0 1 -1
concluded,that,oral 1.0 0.000143348623853 0 1 -1
concluded,that,may 1.0 0.000143348623853 0 1 -1
concluded,that,chloral 1.0 0.000143348623853 0 1 -1
concluded,from,these 1.0 0.000143348623853 0 1 -1
conclude,that,there 1.0 0.000143348623853 0 1 -1
conclude,that,an 1.0 0.000143348623853 0 1 -1
concert,with,age-dependent 1.0 0.000143348623853 0 1 -1
concerns,the,obstetrical 1.0 0.000143348623853 0 1 -1
concerns,regarding,protease 1.0 0.000143348623853 0 1 -1
concerning,published,in 1.0 0.000143348623853 0 1 -1
concerning,laboratory,test 1.0 0.000143348623853 0 1 -1
concerned,variable,elevations 1.0 0.000143348623853 0 1 -1
concern,thus,could 1.0 0.000143348623853 0 1 -1
concern,regarding,asthma 1.0 0.000143348623853 0 1 -1
concentrations,within,the 1.0 0.000143348623853 0 1 -1
concentrations,which,have 1.0 0.000143348623853 0 1 -1
concentrations,when,compared 1.0 0.000143348623853 0 1 -1
concentrations,when,coadministered 1.0 0.000143348623853 0 1 -1
concentrations,were,unchanged 1.0 0.000143348623853 0 1 -1
concentrations,were,similar 1.0 0.000143348623853 0 1 -1
concentrations,were,reduced 1.0 0.000143348623853 0 1 -1
concentrations,were,not 1.0 0.000573394495413 0 4 -4
concentrations,were,increased 1.0 0.000143348623853 0 1 -1
concentrations,were,found 1.0 0.000143348623853 0 1 -1
concentrations,were,collected 1.0 0.000143348623853 0 1 -1
concentrations,were,and 1.0 0.000143348623853 0 1 -1
concentrations,were,also 1.0 0.000143348623853 0 1 -1
concentrations,well,above 1.0 0.000143348623853 0 1 -1
concentrations,was,dialyzed 1.0 0.000143348623853 0 1 -1
concentrations,up,to 1.0 0.000286697247706 0 2 -2
concentrations,to,exposures 1.0 0.000143348623853 0 1 -1
concentrations,that,affect 1.0 0.000143348623853 0 1 -1
concentrations,tested,to 1.0 0.000143348623853 0 1 -1
concentrations,substances,that 1.0 0.000143348623853 0 1 -1
concentrations,showing,a 1.0 0.000143348623853 0 1 -1
concentrations,resulted,in 1.0 0.000143348623853 0 1 -1
concentrations,reduced,ldl 1.0 0.000286697247706 0 2 -2
concentrations,recognition,and 1.0 0.000143348623853 0 1 -1
concentrations,ranging,from 1.0 0.00043004587156 0 3 -3
concentrations,producing,of 1.0 0.000143348623853 0 1 -1
concentrations,prior,to 1.0 0.000143348623853 0 1 -1
concentrations,or,the 1.0 0.000143348623853 0 1 -1
concentrations,or,clinical 1.0 0.000143348623853 0 1 -1
concentrations,of,when 1.0 0.00043004587156 0 3 -3
concentrations,of,tricyclic 1.0 0.000143348623853 0 1 -1
concentrations,of,tcas 1.0 0.000573394495413 0 4 -4
concentrations,of,sn38 1.0 0.000143348623853 0 1 -1
concentrations,of,patients 1.0 0.000143348623853 0 1 -1
concentrations,of,one 1.0 0.000143348623853 0 1 -1
concentrations,of,mmol 1.0 0.000143348623853 0 1 -1
concentrations,of,micrograms 1.0 0.000143348623853 0 1 -1
concentrations,of,microg 1.0 0.00043004587156 0 3 -3
concentrations,of,metabolized 1.0 0.00043004587156 0 3 -3
concentrations,of,mcg 1.0 0.000143348623853 0 1 -1
concentrations,of,ionized 1.0 0.000143348623853 0 1 -1
concentrations,of,glucose 1.0 0.000143348623853 0 1 -1
concentrations,of,either 1.0 0.000143348623853 0 1 -1
concentrations,of,each 1.0 0.000143348623853 0 1 -1
concentrations,of,do 1.0 0.000143348623853 0 1 -1
concentrations,of,dialyzable 1.0 0.000143348623853 0 1 -1
concentrations,of,coadministered 1.0 0.000143348623853 0 1 -1
concentrations,of,at 1.0 0.000143348623853 0 1 -1
concentrations,of,astringents 1.0 0.000143348623853 0 1 -1
concentrations,of,andtolbutamide 1.0 0.000143348623853 0 1 -1
concentrations,of,amicar 1.0 0.000143348623853 0 1 -1
concentrations,of,after 1.0 0.000143348623853 0 1 -1
concentrations,observed,with 1.0 0.000143348623853 0 1 -1
concentrations,mmol,l 1.0 0.000143348623853 0 1 -1
concentrations,mics,and 1.0 0.000143348623853 0 1 -1
concentrations,mg,bid 1.0 0.000143348623853 0 1 -1
concentrations,lower,than 1.0 0.000143348623853 0 1 -1
concentrations,just,prior 1.0 0.000143348623853 0 1 -1
concentrations,it,is 1.0 0.000143348623853 0 1 -1
concentrations,increased,from 1.0 0.000143348623853 0 1 -1
concentrations,in,vitro 1.0 0.000143348623853 0 1 -1
concentrations,in,serum 1.0 0.000143348623853 0 1 -1
concentrations,ic50,from 1.0 0.000143348623853 0 1 -1
concentrations,have,not 1.0 0.000143348623853 0 1 -1
concentrations,have,been 1.0 0.00043004587156 0 3 -3
concentrations,has,not 1.0 0.000143348623853 0 1 -1
concentrations,has,no 1.0 0.000143348623853 0 1 -1
concentrations,has,been 1.0 0.000143348623853 0 1 -1
concentrations,has,also 1.0 0.000143348623853 0 1 -1
concentrations,greater,than 1.0 0.000143348623853 0 1 -1
concentrations,found,to 1.0 0.000143348623853 0 1 -1
concentrations,fold,higher 1.0 0.000143348623853 0 1 -1
concentrations,fo,these 1.0 0.000143348623853 0 1 -1
concentrations,did,not 1.0 0.000143348623853 0 1 -1
concentrations,cyp3a4,inhibitors 1.0 0.000143348623853 0 1 -1
concentrations,cyp3a4,inducers 1.0 0.000143348623853 0 1 -1
concentrations,c,max 1.0 0.000143348623853 0 1 -1
concentrations,at,the 1.0 0.000143348623853 0 1 -1
concentrations,as,high 1.0 0.000143348623853 0 1 -1
concentrations,are,observed 1.0 0.000143348623853 0 1 -1
concentrations,appeared,to 1.0 0.000143348623853 0 1 -1
concentrations,and,would 1.0 0.000143348623853 0 1 -1
concentrations,and,reduce 1.0 0.000143348623853 0 1 -1
concentrations,and,prothrombin 1.0 0.000143348623853 0 1 -1
concentrations,and,possible 1.0 0.000143348623853 0 1 -1
concentrations,and,pharmacologic 1.0 0.000143348623853 0 1 -1
concentrations,and,ldl-c 1.0 0.000143348623853 0 1 -1
concentrations,and,enhance 1.0 0.000143348623853 0 1 -1
concentrations,and,effects 1.0 0.000143348623853 0 1 -1
concentrations,and,decreased 1.0 0.000143348623853 0 1 -1
concentrations,and,auc 1.0 0.000143348623853 0 1 -1
concentrations,and,appropriate 1.0 0.000143348623853 0 1 -1
concentration-time,curve,was 1.0 0.000143348623853 0 1 -1
concentration-time,curve,of 1.0 0.000143348623853 0 1 -1
concentration-time,curve,from 1.0 0.000143348623853 0 1 -1
concentration-time,curve,auc 1.0 0.000143348623853 0 1 -1
concentration-dependent,relaxation,of 1.0 0.000143348623853 0 1 -1
concentration,which,was 1.0 0.000143348623853 0 1 -1
concentration,were,not 1.0 0.000143348623853 0 1 -1
concentration,was,delayed 1.0 0.000143348623853 0 1 -1
concentration,to,suppression 1.0 0.000143348623853 0 1 -1
concentration,times,the 1.0 0.000143348623853 0 1 -1
concentration,that,may 1.0 0.000143348623853 0 1 -1
concentration,that,is 1.0 0.000143348623853 0 1 -1
concentration,reached,by 1.0 0.000143348623853 0 1 -1
concentration,ranges,within 1.0 0.000143348623853 0 1 -1
concentration,profile,or 1.0 0.000143348623853 0 1 -1
concentration,or,impair 1.0 0.000143348623853 0 1 -1
concentration,or,activity 1.0 0.000143348623853 0 1 -1
concentration,of,was 1.0 0.000143348623853 0 1 -1
concentration,of,predisposing 1.0 0.000143348623853 0 1 -1
concentration,of,other 1.0 0.000143348623853 0 1 -1
concentration,of,or 1.0 0.000143348623853 0 1 -1
concentration,of,one 1.0 0.000143348623853 0 1 -1
concentration,of,novolog 1.0 0.000143348623853 0 1 -1
concentration,of,nevirapine 1.0 0.000143348623853 0 1 -1
concentration,of,krm-1648 1.0 0.000143348623853 0 1 -1
concentration,of,increased 1.0 0.000143348623853 0 1 -1
concentration,of,following 1.0 0.000143348623853 0 1 -1
concentration,of,cmc-cys 1.0 0.000143348623853 0 1 -1
concentration,of,as 1.0 0.000143348623853 0 1 -1
concentration,of,approximately 1.0 0.000143348623853 0 1 -1
concentration,of,amicar 1.0 0.000143348623853 0 1 -1
concentration,mm,is 1.0 0.000143348623853 0 1 -1
concentration,mic,of 1.0 0.000143348623853 0 1 -1
concentration,mean,change 1.0 0.000286697247706 0 2 -2
concentration,may,lead 1.0 0.000286697247706 0 2 -2
concentration,may,be 1.0 0.000716743119266 0 5 -5
concentration,is,unaltered 1.0 0.000143348623853 0 1 -1
concentration,is,of 1.0 0.000143348623853 0 1 -1
concentration,index,fici 1.0 0.000143348623853 0 1 -1
concentration,increased,to 1.0 0.000143348623853 0 1 -1
concentration,increased,and 1.0 0.00043004587156 0 3 -3
concentration,in,plasma 1.0 0.000143348623853 0 1 -1
concentration,greater,than 1.0 0.000143348623853 0 1 -1
concentration,for,optimal 1.0 0.000143348623853 0 1 -1
concentration,except,at 1.0 0.000143348623853 0 1 -1
concentration,dependent,labelling 1.0 0.000143348623853 0 1 -1
concentration,data,from 1.0 0.000143348623853 0 1 -1
concentration,cmax,of 1.0 0.000286697247706 0 2 -2
concentration,by,after 1.0 0.000286697247706 0 2 -2
concentration,as,well 1.0 0.000143348623853 0 1 -1
concentration,as,high 1.0 0.000143348623853 0 1 -1
concentration,as,compared 1.0 0.000143348623853 0 1 -1
concentrating,as,effective 1.0 0.000143348623853 0 1 -1
concentrates,or,prothrombin 1.0 0.000143348623853 0 1 -1
concentrates,has,not 1.0 0.000143348623853 0 1 -1
conceived,while,using 1.0 0.000143348623853 0 1 -1
conceived,that,a 1.0 0.000143348623853 0 1 -1
comt,hormone,levels 1.0 0.000143348623853 0 1 -1
compulsion,loss,of 1.0 0.000143348623853 0 1 -1
compromised,uptake-1,in 1.0 0.000143348623853 0 1 -1
compromised,cardiovascular,system 1.0 0.000143348623853 0 1 -1
compromise,the,limbic 1.0 0.000143348623853 0 1 -1
comprehensive,review,was 1.0 0.000143348623853 0 1 -1
comprehensive,information,concerning 1.0 0.000143348623853 0 1 -1
compounds--can,be,inactivated 1.0 0.000143348623853 0 1 -1
compounds,which,inhibit 1.0 0.000143348623853 0 1 -1
compounds,was,assessed 1.0 0.000143348623853 0 1 -1
compounds,that,have 1.0 0.000143348623853 0 1 -1
compounds,tested,in 1.0 0.000143348623853 0 1 -1
compounds,rather,than 1.0 0.000143348623853 0 1 -1
compounds,metabolized,by 1.0 0.000143348623853 0 1 -1
compounds,may,be 1.0 0.000143348623853 0 1 -1
compounds,interfere,with 1.0 0.000143348623853 0 1 -1
compounds,in,urine 1.0 0.000143348623853 0 1 -1
compounds,in,combination 1.0 0.000143348623853 0 1 -1
compounds,have,not 1.0 0.000143348623853 0 1 -1
compounds,have,cns 1.0 0.000143348623853 0 1 -1
compounds,for,antipsychotic 1.0 0.000143348623853 0 1 -1
compounds,enhanced,tendency 1.0 0.000143348623853 0 1 -1
compounds,caution,should 1.0 0.000143348623853 0 1 -1
compounds,block,pcp-induced 1.0 0.000143348623853 0 1 -1
compounds,because,a 1.0 0.000143348623853 0 1 -1
compounds,attenuate,morphine-induced 1.0 0.000143348623853 0 1 -1
compounds,are,metabolized 1.0 0.000143348623853 0 1 -1
compound,is,administered 1.0 0.000143348623853 0 1 -1
compound,and,sodium 1.0 0.000143348623853 0 1 -1
components,with,only 1.0 0.000143348623853 0 1 -1
components,of,the 1.0 0.000143348623853 0 1 -1
components,n1,n2 1.0 0.000143348623853 0 1 -1
components,may,help 1.0 0.000143348623853 0 1 -1
components,in,comparison 1.0 0.000143348623853 0 1 -1
components,are,representations 1.0 0.000143348623853 0 1 -1
components,are,excreted 1.0 0.000143348623853 0 1 -1
component,p2,may 1.0 0.000143348623853 0 1 -1
component,p2,however 1.0 0.000143348623853 0 1 -1
complications,which,may 1.0 0.000143348623853 0 1 -1
complications,that,occurred 1.0 0.000143348623853 0 1 -1
complications,related,to 1.0 0.000143348623853 0 1 -1
complications,of,retinopathy 1.0 0.000143348623853 0 1 -1
complications,in,neonates 1.0 0.000143348623853 0 1 -1
complications,have,specifically 1.0 0.000143348623853 0 1 -1
complications,considerably,enhance 1.0 0.000143348623853 0 1 -1
complications,careful,monitoring 1.0 0.000143348623853 0 1 -1
complications,and,lack 1.0 0.000143348623853 0 1 -1
complication,of,treatment 1.0 0.000143348623853 0 1 -1
complicated,or,uncomplicated 1.0 0.000143348623853 0 1 -1
compliance,poor,absorption 1.0 0.000143348623853 0 1 -1
compliance,especially,neglect 1.0 0.000143348623853 0 1 -1
compliance,and,efficacy 1.0 0.000143348623853 0 1 -1
complexometric,methods,commonly 1.0 0.000143348623853 0 1 -1
complexes,thereof,are 1.0 0.000143348623853 0 1 -1
complex,overallactivity,against 1.0 0.000143348623853 0 1 -1
complex,of,treatment 1.0 0.000143348623853 0 1 -1
complex,ii-vii,x 1.0 0.000286697247706 0 2 -2
complex,formation,that 1.0 0.000143348623853 0 1 -1
complex,fashion,and 1.0 0.000143348623853 0 1 -1
complex,concentrates,should 1.0 0.000143348623853 0 1 -1
complex,concentrates,or 1.0 0.000143348623853 0 1 -1
complex,anions,antithyroid 1.0 0.000143348623853 0 1 -1
complex,and,multifaceted 1.0 0.000143348623853 0 1 -1
complex,and,can 1.0 0.000143348623853 0 1 -1
completely,metabolised,therefore 1.0 0.000143348623853 0 1 -1
completely,evaluated,to 1.0 0.000143348623853 0 1 -1
completely,cleared,from 1.0 0.000143348623853 0 1 -1
completely,absorbed,from 1.0 0.000143348623853 0 1 -1
completed,with,both 1.0 0.000143348623853 0 1 -1
completed,at,least 1.0 0.000143348623853 0 1 -1
complete,prescribing,information 1.0 0.000143348623853 0 1 -1
complete,mental,alertness 1.0 0.000143348623853 0 1 -1
complete,loss,of 1.0 0.000143348623853 0 1 -1
complete,heart,block 1.0 0.000143348623853 0 1 -1
complete,after,a 1.0 0.000143348623853 0 1 -1
complete,across,all 1.0 0.000143348623853 0 1 -1
competitive,suppression,of 1.0 0.000143348623853 0 1 -1
competitive,inhibition,of 1.0 0.000143348623853 0 1 -1
competitive,displacement,of 1.0 0.000143348623853 0 1 -1
competition,for,protein 1.0 0.000286697247706 0 2 -2
competing,memory,systems 1.0 0.000143348623853 0 1 -1
compete,for,the 1.0 0.000143348623853 0 1 -1
compete,for,active 1.0 0.000143348623853 0 1 -1
compensatory,increases,in 1.0 0.000143348623853 0 1 -1
compensatory,increase,in 1.0 0.000143348623853 0 1 -1
compelling,reasons,for 1.0 0.000143348623853 0 1 -1
compazine,sparine,phenergan 1.0 0.000143348623853 0 1 -1
compatible,with,the 1.0 0.000143348623853 0 1 -1
compatibility,of,novolog 1.0 0.000143348623853 0 1 -1
compatibility,data,are 1.0 0.000143348623853 0 1 -1
comparison,to,saline 1.0 0.000143348623853 0 1 -1
comparison,study,and 1.0 0.000143348623853 0 1 -1
comparison,of,the 1.0 0.000143348623853 0 1 -1
comparison,of,pharmacokinetics 1.0 0.000143348623853 0 1 -1
comparison,of,antiaddictive 1.0 0.000143348623853 0 1 -1
comparison,of,administration 1.0 0.000143348623853 0 1 -1
comparing,the,intravenous 1.0 0.000143348623853 0 1 -1
comparing,the,approved 1.0 0.000143348623853 0 1 -1
comparing,once-monthly,with 1.0 0.000143348623853 0 1 -1
compared,with,the 1.0 0.000286697247706 0 2 -2
compared,with,single 1.0 0.000143348623853 0 1 -1
compared,with,recordings 1.0 0.000143348623853 0 1 -1
compared,with,only 1.0 0.000143348623853 0 1 -1
compared,with,neurons 1.0 0.000143348623853 0 1 -1
compared,with,lean 1.0 0.000143348623853 0 1 -1
compared,with,in 1.0 0.000286697247706 0 2 -2
compared,with,has 1.0 0.000143348623853 0 1 -1
compared,with,conventional 1.0 0.000143348623853 0 1 -1
compared,with,and 1.0 0.000143348623853 0 1 -1
compared,to,triple 1.0 0.000143348623853 0 1 -1
compared,to,those 1.0 0.000143348623853 0 1 -1
compared,to,similar 1.0 0.000143348623853 0 1 -1
compared,to,prinivil 1.0 0.000143348623853 0 1 -1
compared,to,of 1.0 0.000143348623853 0 1 -1
compared,to,its 1.0 0.000143348623853 0 1 -1
compared,to,deaths 1.0 0.000143348623853 0 1 -1
compared,to,co-administration 1.0 0.000143348623853 0 1 -1
compared,retrospectively,a 1.0 0.000143348623853 0 1 -1
compared,pharmacokinetics,and 1.0 0.000143348623853 0 1 -1
compared,directly,to 1.0 0.000143348623853 0 1 -1
comparative,study,week 1.0 0.000143348623853 0 1 -1
comparative,data,in 1.0 0.000286697247706 0 2 -2
comparative,analysis,of 1.0 0.000143348623853 0 1 -1
comparable,to,those 1.0 0.000286697247706 0 2 -2
comparable,to,the 1.0 0.000143348623853 0 1 -1
comparable,to,that 1.0 0.000143348623853 0 1 -1
comparable,in,effects 1.0 0.000143348623853 0 1 -1
comparable,cognitive,enhancing 1.0 0.000143348623853 0 1 -1
comparable,activity,to 1.0 0.000143348623853 0 1 -1
company,division,of 1.0 0.000143348623853 0 1 -1
comorbidity,and,a 1.0 0.000143348623853 0 1 -1
community,or,seen 1.0 0.000143348623853 0 1 -1
commonly,used,such 1.0 0.000143348623853 0 1 -1
commonly,used,preanesthetic 1.0 0.000143348623853 0 1 -1
commonly,used,in 1.0 0.000860091743119 0 6 -6
commonly,used,general 1.0 0.000143348623853 0 1 -1
commonly,to,hours 1.0 0.000143348623853 0 1 -1
commonly,showed,anxiogenic 1.0 0.000143348623853 0 1 -1
commonly,involved,in 1.0 0.000143348623853 0 1 -1
commonly,found,in 1.0 0.000143348623853 0 1 -1
commonly,employed,clinical 1.0 0.00043004587156 0 3 -3
commonly,associated,with 1.0 0.000143348623853 0 1 -1
common,transport,pathway 1.0 0.000143348623853 0 1 -1
common,side,effects 1.0 0.000143348623853 0 1 -1
common,phenotypic,subset 1.0 0.000143348623853 0 1 -1
common,pathogens,of 1.0 0.000143348623853 0 1 -1
common,medications,used 1.0 0.000143348623853 0 1 -1
common,distilled,and 1.0 0.000143348623853 0 1 -1
common,comorbidity,and 1.0 0.000143348623853 0 1 -1
common,adverse,reactions 1.0 0.000143348623853 0 1 -1
common,adverse,reaction 1.0 0.000143348623853 0 1 -1
common,adverse,effects 1.0 0.000143348623853 0 1 -1
commit,to,use 1.0 0.000143348623853 0 1 -1
commercially,available,kits 1.0 0.000143348623853 0 1 -1
commercially,available,assay 1.0 0.000143348623853 0 1 -1
comments,about,possible 1.0 0.000143348623853 0 1 -1
commentaries,and,editorials 1.0 0.000143348623853 0 1 -1
combining,with,any 1.0 0.000143348623853 0 1 -1
combining,these,agents 1.0 0.000143348623853 0 1 -1
combines,with,membranes 1.0 0.000143348623853 0 1 -1
combined,with,local 1.0 0.000143348623853 0 1 -1
combined,with,either 1.0 0.000143348623853 0 1 -1
combined,week,placebo 1.0 0.000143348623853 0 1 -1
combined,treatment,the 1.0 0.000143348623853 0 1 -1
combined,transcriptional,activator 1.0 0.000143348623853 0 1 -1
combined,therapy,should 1.0 0.000143348623853 0 1 -1
combined,therapy,is 1.0 0.000573394495413 0 4 -4
combined,oral,as 1.0 0.000143348623853 0 1 -1
combined,hyperglycaemia,and 1.0 0.000143348623853 0 1 -1
combined,hormonal,who 1.0 0.000286697247706 0 2 -2
combined,exposures,proposed 1.0 0.000143348623853 0 1 -1
combined,exposure,to 1.0 0.000143348623853 0 1 -1
combined,data,from 1.0 0.000143348623853 0 1 -1
combined,chemotherapy,plus 1.0 0.000143348623853 0 1 -1
combined,actions,desirable 1.0 0.000286697247706 0 2 -2
combinations,were,determined 1.0 0.000143348623853 0 1 -1
combinations,should,be 1.0 0.000286697247706 0 2 -2
combinations,or,with 1.0 0.000143348623853 0 1 -1
combinations,of,mm 1.0 0.000143348623853 0 1 -1
combinations,has,not 1.0 0.000143348623853 0 1 -1
combinations,are,sometimes 1.0 0.000143348623853 0 1 -1
combinational,action,in 1.0 0.000143348623853 0 1 -1
combination,with,was 1.0 0.000143348623853 0 1 -1
combination,with,very 1.0 0.000143348623853 0 1 -1
combination,with,uricosuric 1.0 0.000143348623853 0 1 -1
combination,with,triamterene 1.0 0.000143348623853 0 1 -1
combination,with,sustiva 1.0 0.000143348623853 0 1 -1
combination,with,sulfamethoxazole 1.0 0.000143348623853 0 1 -1
combination,with,should 1.0 0.000143348623853 0 1 -1
combination,with,respect 1.0 0.000716743119266 0 5 -5
combination,with,produced 1.0 0.000143348623853 0 1 -1
combination,with,oral 1.0 0.000143348623853 0 1 -1
combination,with,or 1.0 0.00043004587156 0 3 -3
combination,with,humira 1.0 0.000143348623853 0 1 -1
combination,with,has 1.0 0.000143348623853 0 1 -1
combination,with,hard 1.0 0.000143348623853 0 1 -1
combination,with,double 1.0 0.000143348623853 0 1 -1
combination,with,cyp3a4 1.0 0.000143348623853 0 1 -1
combination,with,copegus 1.0 0.00043004587156 0 3 -3
combination,with,cns-active 1.0 0.000143348623853 0 1 -1
combination,with,avastin 1.0 0.000143348623853 0 1 -1
combination,with,any 1.0 0.000143348623853 0 1 -1
combination,with,and 1.0 0.000716743119266 0 5 -5
combination,with,an 1.0 0.000143348623853 0 1 -1
combination,with,against 1.0 0.000143348623853 0 1 -1
combination,with,a 1.0 0.000573394495413 0 4 -4
combination,was,associated 1.0 0.000143348623853 0 1 -1
combination,therapy,should 1.0 0.000143348623853 0 1 -1
combination,therapy,is 1.0 0.00043004587156 0 3 -3
combination,therapy,did 1.0 0.000143348623853 0 1 -1
combination,therapy,any 1.0 0.000143348623853 0 1 -1
combination,therapies,that 1.0 0.000143348623853 0 1 -1
combination,see,drug 1.0 0.000143348623853 0 1 -1
combination,products,should 1.0 0.000143348623853 0 1 -1
combination,procedures,in 1.0 0.000143348623853 0 1 -1
combination,oral,ethinyl 1.0 0.000143348623853 0 1 -1
combination,oral,contraceptives 1.0 0.000143348623853 0 1 -1
combination,of,therapeutic 1.0 0.000143348623853 0 1 -1
combination,of,the 1.0 0.000143348623853 0 1 -1
combination,of,or 1.0 0.000143348623853 0 1 -1
combination,of,hivid 1.0 0.000143348623853 0 1 -1
combination,of,conjugated 1.0 0.000143348623853 0 1 -1
combination,of,chop 1.0 0.000143348623853 0 1 -1
combination,of,arimidex 1.0 0.000143348623853 0 1 -1
combination,lies,both 1.0 0.000143348623853 0 1 -1
combination,in,ameliorating 1.0 0.000143348623853 0 1 -1
combination,hormonal,by 1.0 0.000143348623853 0 1 -1
combination,have,not 1.0 0.000143348623853 0 1 -1
combination,arenot,established 1.0 0.000286697247706 0 2 -2
com,cgi,generic3 1.0 0.000143348623853 0 1 -1
column,or,t4 1.0 0.000286697247706 0 2 -2
column,or,by 1.0 0.000286697247706 0 2 -2
colostrum,iga,is 1.0 0.000143348623853 0 1 -1
colorimetric,complexometric,methods 1.0 0.000143348623853 0 1 -1
colorectal,cancer,were 1.0 0.000143348623853 0 1 -1
color,reverses,when 1.0 0.000143348623853 0 1 -1
color,development,essential 1.0 0.000143348623853 0 1 -1
color,alkaline,urine 1.0 0.000143348623853 0 1 -1
colony,stimulating,factor 1.0 0.000143348623853 0 1 -1
colonic,transit-enhancing,effect 1.0 0.000143348623853 0 1 -1
colonic,fluid,contents 1.0 0.000143348623853 0 1 -1
colonic,fluid,by 1.0 0.000143348623853 0 1 -1
collected,through,hours 1.0 0.000143348623853 0 1 -1
collected,on,the 1.0 0.000143348623853 0 1 -1
collected,for,quantitation 1.0 0.000143348623853 0 1 -1
collected,by,a 1.0 0.000143348623853 0 1 -1
collapse,respiratory,arrest 1.0 0.000143348623853 0 1 -1
collapse,in,patients 1.0 0.000143348623853 0 1 -1
collapse,in,association 1.0 0.000143348623853 0 1 -1
collapse,and,respiratory 1.0 0.000143348623853 0 1 -1
collagen-induced,platelet,aggregation 1.0 0.000143348623853 0 1 -1
coli,in,vitro 1.0 0.000143348623853 0 1 -1
coli,in,male 1.0 0.000143348623853 0 1 -1
coli,and,one 1.0 0.000143348623853 0 1 -1
colestld,tablets,may 1.0 0.000143348623853 0 1 -1
colestid,tablets,to 1.0 0.000143348623853 0 1 -1
colestid,tablets,and 1.0 0.000143348623853 0 1 -1
cold,preparations,nsaids 1.0 0.000143348623853 0 1 -1
cold,binding,of 1.0 0.000143348623853 0 1 -1
cold,allergy,or 1.0 0.000143348623853 0 1 -1
colazal,however,the 1.0 0.000143348623853 0 1 -1
coincide,duloxetine,did 1.0 0.000143348623853 0 1 -1
cohort,then,received 1.0 0.000143348623853 0 1 -1
cohort,received,plus 1.0 0.000143348623853 0 1 -1
cohort,or,mg 1.0 0.000143348623853 0 1 -1
cohort,data,and 1.0 0.000143348623853 0 1 -1
cognitive,function,seen 1.0 0.000143348623853 0 1 -1
cognitive,enhancing,effects 1.0 0.000143348623853 0 1 -1
coffee,was,administered 1.0 0.000143348623853 0 1 -1
coexisting,in,the 1.0 0.000143348623853 0 1 -1
coenzyme,a,hmgcoa 1.0 0.000143348623853 0 1 -1
coenzyme,a,atp 1.0 0.000143348623853 0 1 -1
coelenterates,of,palythoa 1.0 0.000143348623853 0 1 -1
cocaine-treated,sst,and 1.0 0.000143348623853 0 1 -1
cocaine-treated,groups,without 1.0 0.000143348623853 0 1 -1
cocaine-treated,animals,to 1.0 0.000143348623853 0 1 -1
cobalt,excretion,was 1.0 0.000143348623853 0 1 -1
coating,that,resists 1.0 0.000143348623853 0 1 -1
coating,may,undergo 1.0 0.000143348623853 0 1 -1
coated,plus,vioxx 1.0 0.000143348623853 0 1 -1
coat-a,count,ria 1.0 0.000143348623853 0 1 -1
coagulation,times,were 1.0 0.000143348623853 0 1 -1
coagulation,tests,should 1.0 0.000573394495413 0 4 -4
coagulation,system,or 1.0 0.000143348623853 0 1 -1
coagulation,should,have 1.0 0.000143348623853 0 1 -1
coagulation,parameters,should 1.0 0.000143348623853 0 1 -1
coagulation,ketoprofen,decreases 1.0 0.000143348623853 0 1 -1
coagulation,indices,should 1.0 0.000286697247706 0 2 -2
coagulation,factors,and 1.0 0.000143348623853 0 1 -1
coagulation,factor,concentrates 1.0 0.000143348623853 0 1 -1
coagulation,diclofenac,increases 1.0 0.000143348623853 0 1 -1
coagulation,assays,based 1.0 0.000143348623853 0 1 -1
coagulation,alterations,is 1.0 0.000143348623853 0 1 -1
coagulant,activity,ix 1.0 0.000286697247706 0 2 -2
coadminstration,with,agents 1.0 0.000143348623853 0 1 -1
coadministration,with,videx 1.0 0.000143348623853 0 1 -1
coadministration,with,of 1.0 0.000143348623853 0 1 -1
coadministration,with,invirase 1.0 0.000143348623853 0 1 -1
coadministration,of,welchol 1.0 0.000143348623853 0 1 -1
coadministration,of,videx 1.0 0.000143348623853 0 1 -1
coadministration,of,this 1.0 0.000286697247706 0 2 -2
coadministration,of,the 1.0 0.000143348623853 0 1 -1
coadministration,of,tambocor 1.0 0.000286697247706 0 2 -2
coadministration,of,radiation 1.0 0.000143348623853 0 1 -1
coadministration,of,racemic 1.0 0.000143348623853 0 1 -1
coadministration,of,on 1.0 0.000143348623853 0 1 -1
coadministration,of,neurontin 1.0 0.000143348623853 0 1 -1
coadministration,of,maalox 1.0 0.000143348623853 0 1 -1
coadministration,of,lexapro 1.0 0.000143348623853 0 1 -1
coadministration,of,invirase 1.0 0.000143348623853 0 1 -1
coadministration,of,has 1.0 0.000143348623853 0 1 -1
coadministration,of,had 1.0 0.000143348623853 0 1 -1
coadministration,of,grapefruit 1.0 0.000143348623853 0 1 -1
coadministration,of,gly-buride 1.0 0.000143348623853 0 1 -1
coadministration,of,did 1.0 0.00043004587156 0 3 -3
coadministration,of,cytochrome 1.0 0.000143348623853 0 1 -1
coadministration,of,channel 1.0 0.000143348623853 0 1 -1
coadministration,of,bextra 1.0 0.000143348623853 0 1 -1
coadministration,of,beta-adrenergic 1.0 0.000143348623853 0 1 -1
coadministration,of,baraclude 1.0 0.000286697247706 0 2 -2
coadministration,of,any 1.0 0.000573394495413 0 4 -4
coadministration,may,lead 1.0 0.000143348623853 0 1 -1
coadministration,loratadine,mg 1.0 0.000143348623853 0 1 -1
coadministration,in,hiv-infected 1.0 0.000143348623853 0 1 -1
coadministering,medications,that 1.0 0.000143348623853 0 1 -1
coadministered,with,used 1.0 0.000143348623853 0 1 -1
coadministered,with,therapeutic 1.0 0.000143348623853 0 1 -1
coadministered,with,sustiva 1.0 0.000143348623853 0 1 -1
coadministered,with,mg 1.0 0.00043004587156 0 3 -3
coadministered,with,kerlone 1.0 0.000143348623853 0 1 -1
coadministered,with,dopa 1.0 0.000143348623853 0 1 -1
coadministered,with,caution 1.0 0.000286697247706 0 2 -2
coadministered,with,as 1.0 0.000143348623853 0 1 -1
coadministered,with,another 1.0 0.000143348623853 0 1 -1
coadministered,prescribers,should 1.0 0.000143348623853 0 1 -1
coadministered,in,de 1.0 0.000143348623853 0 1 -1
coadministered,and,on 1.0 0.000286697247706 0 2 -2
coadministered,although,the 1.0 0.000143348623853 0 1 -1
coad-ministered,with,caution 1.0 0.000143348623853 0 1 -1
co-therapy,an,increased 1.0 0.000573394495413 0 4 -4
co-infected,with,tuberculosis 1.0 0.000143348623853 0 1 -1
co-factors,could,be 1.0 0.000143348623853 0 1 -1
co-administration,with,should 1.0 0.000143348623853 0 1 -1
co-administration,with,other 1.0 0.000143348623853 0 1 -1
co-administration,with,hydrochloride 1.0 0.000143348623853 0 1 -1
co-administration,with,antifungal 1.0 0.000143348623853 0 1 -1
co-administration,systemic,levels 1.0 0.000143348623853 0 1 -1
co-administration,or,overlapping 1.0 0.000143348623853 0 1 -1
co-administration,of,two 1.0 0.000143348623853 0 1 -1
co-administration,of,tca5 1.0 0.000143348623853 0 1 -1
co-administration,of,single 1.0 0.000143348623853 0 1 -1
co-administration,of,plendil 1.0 0.000143348623853 0 1 -1
co-administration,of,or 1.0 0.000143348623853 0 1 -1
co-administration,of,natrecor 1.0 0.000143348623853 0 1 -1
co-administration,of,multiple 1.0 0.000143348623853 0 1 -1
co-administration,of,did 1.0 0.000143348623853 0 1 -1
co-administration,of,cyp3a4 1.0 0.000143348623853 0 1 -1
co-administration,of,argatroban 1.0 0.000143348623853 0 1 -1
co-administration,of,another 1.0 0.000143348623853 0 1 -1
co-administration,mean,trough 1.0 0.000143348623853 0 1 -1
co-administration,is,essential 1.0 0.000286697247706 0 2 -2
co-administered,with,that 1.0 0.000143348623853 0 1 -1
co-administered,with,slow-release 1.0 0.000143348623853 0 1 -1
co-administered,with,potent 1.0 0.000143348623853 0 1 -1
co-administered,with,natrecor 1.0 0.000143348623853 0 1 -1
co-administered,with,it 1.0 0.000143348623853 0 1 -1
co-administered,with,either 1.0 0.000143348623853 0 1 -1
co-administered,with,but 1.0 0.000143348623853 0 1 -1
co-administered,with,brovana 1.0 0.000143348623853 0 1 -1
co-administered,with,another 1.0 0.000573394495413 0 4 -4
co-administered,drug,may 1.0 0.000143348623853 0 1 -1
co-administered,dose,level 1.0 0.000143348623853 0 1 -1
co-administered,but,not 1.0 0.000143348623853 0 1 -1
co-administered,avonex,indicates 1.0 0.000143348623853 0 1 -1
co-administered,avonex,and 1.0 0.000143348623853 0 1 -1
co-administered,antiepilepsy,aeds 1.0 0.000143348623853 0 1 -1
co-activator,in,glutamatergic 1.0 0.000143348623853 0 1 -1
co-,administration,of 1.0 0.000143348623853 0 1 -1
co,and,or 1.0 0.000143348623853 0 1 -1
co,administered,with 1.0 0.000143348623853 0 1 -1
cns-active,has,not 1.0 0.000286697247706 0 2 -2
cns,vascular,lesions 1.0 0.000143348623853 0 1 -1
cns,toxicity,brain 1.0 0.000143348623853 0 1 -1
cns,lesions,have 1.0 0.000143348623853 0 1 -1
cns,including,blood 1.0 0.000143348623853 0 1 -1
cns,effects,an 1.0 0.000143348623853 0 1 -1
cns,drugs,given 1.0 0.000143348623853 0 1 -1
cns,depression,producing 1.0 0.000286697247706 0 2 -2
cns,depression,cns 1.0 0.000143348623853 0 1 -1
cns,depressants,with 1.0 0.000143348623853 0 1 -1
cns,cardiac,and 1.0 0.000143348623853 0 1 -1
cns,and,other 1.0 0.000143348623853 0 1 -1
cns,and,genitourinary 1.0 0.000143348623853 0 1 -1
cns,acting,drugs 1.0 0.000143348623853 0 1 -1
cmin,plasma,concentration 1.0 0.000286697247706 0 2 -2
cmin,increased,to 1.0 0.000286697247706 0 2 -2
cmin,concentrations,were 1.0 0.000143348623853 0 1 -1
cmin,concentrations,increased 1.0 0.000143348623853 0 1 -1
cmin,concentration,increased 1.0 0.000143348623853 0 1 -1
cmin,auc,ci 1.0 0.000143348623853 0 1 -1
cmin,are,summarized 1.0 0.000143348623853 0 1 -1
cmc-cys7,from,m 1.0 0.000143348623853 0 1 -1
cmc-cys7,a,significantly 1.0 0.000143348623853 0 1 -1
cmc-cys,exhibiting,m 1.0 0.000143348623853 0 1 -1
cmc-cys,conjugates,on 1.0 0.000143348623853 0 1 -1
cmax,were,observed 1.0 0.000143348623853 0 1 -1
cmax,was,observed 1.0 0.000143348623853 0 1 -1
cmax,vs,and 1.0 0.000143348623853 0 1 -1
cmax,values,were 1.0 0.000143348623853 0 1 -1
cmax,values,after 1.0 0.000143348623853 0 1 -1
cmax,tmax,and 1.0 0.000143348623853 0 1 -1
cmax,the,geometric 1.0 0.000143348623853 0 1 -1
cmax,respectively,of 1.0 0.000143348623853 0 1 -1
cmax,of,when 1.0 0.000143348623853 0 1 -1
cmax,of,however 1.0 0.000143348623853 0 1 -1
cmax,of,both 1.0 0.000143348623853 0 1 -1
cmax,of,an 1.0 0.000143348623853 0 1 -1
cmax,of,a 1.0 0.000143348623853 0 1 -1
cmax,levels,achieved 1.0 0.000143348623853 0 1 -1
cmax,is,also 1.0 0.000143348623853 0 1 -1
cmax,differences,were 1.0 0.000143348623853 0 1 -1
cmax,cmin,auc 1.0 0.000143348623853 0 1 -1
cmax,by,resulting 1.0 0.000143348623853 0 1 -1
cmax,but,no 1.0 0.000143348623853 0 1 -1
cmax,and,were 1.0 0.000143348623853 0 1 -1
cmax,and,fold 1.0 0.000143348623853 0 1 -1
cmax,and,decreases 1.0 0.000143348623853 0 1 -1
cmax,and,about 1.0 0.000143348623853 0 1 -1
cluster,of,metabolic 1.0 0.000143348623853 0 1 -1
clozapine,should,not 1.0 0.000143348623853 0 1 -1
clozapine,is,a 1.0 0.000143348623853 0 1 -1
clozapine,induced,agranulocytosis 1.0 0.000143348623853 0 1 -1
clozapine,in,combination 1.0 0.000143348623853 0 1 -1
clozapine,dose,should 1.0 0.000143348623853 0 1 -1
clotting,time,was 1.0 0.000143348623853 0 1 -1
clotting,time,plasma 1.0 0.000143348623853 0 1 -1
clotting,time,have 1.0 0.000143348623853 0 1 -1
clotting,factors,when 1.0 0.000143348623853 0 1 -1
clotting,factor,vii 1.0 0.000143348623853 0 1 -1
clotting,factor,synthesis 1.0 0.000143348623853 0 1 -1
clostridium,were,inhibited 1.0 0.000143348623853 0 1 -1
clostridium,three,strains 1.0 0.000143348623853 0 1 -1
clostridium,difficile,a 1.0 0.000143348623853 0 1 -1
closely,watched,during 1.0 0.000143348623853 0 1 -1
closely,particularly,if 1.0 0.000143348623853 0 1 -1
closely,monitor,the 1.0 0.000143348623853 0 1 -1
closely,monitor,serum 1.0 0.000143348623853 0 1 -1
closely,monitor,cardiovascular 1.0 0.000143348623853 0 1 -1
closely,for,several 1.0 0.000143348623853 0 1 -1
closely,for,nevirapine-associated 1.0 0.000143348623853 0 1 -1
closely,for,loss 1.0 0.00043004587156 0 3 -3
closely,for,early 1.0 0.000143348623853 0 1 -1
closely,for,changes 1.0 0.000143348623853 0 1 -1
closely,for,any 1.0 0.000143348623853 0 1 -1
closely,for,adverse 1.0 0.000143348623853 0 1 -1
closely,associated,with 1.0 0.000143348623853 0 1 -1
close,to,the 1.0 0.000143348623853 0 1 -1
close,monitoring,may 1.0 0.000143348623853 0 1 -1
close,monitoring,allows 1.0 0.000143348623853 0 1 -1
close,collaboration,with 1.0 0.000143348623853 0 1 -1
close,clinical,and 1.0 0.000143348623853 0 1 -1
clonidines,analgesic,actions 1.0 0.000143348623853 0 1 -1
clonidine,therapy,can 1.0 0.000143348623853 0 1 -1
clonazepam,would,be 1.0 0.000143348623853 0 1 -1
clonazepam,on,the 1.0 0.000143348623853 0 1 -1
clonazepam,literature,reports 1.0 0.000143348623853 0 1 -1
clonazepam,does,not 1.0 0.000143348623853 0 1 -1
clomiphene,citrate,tablets 1.0 0.000143348623853 0 1 -1
clolar,with,other 1.0 0.000143348623853 0 1 -1
clo-4,simultaneously,or 1.0 0.000143348623853 0 1 -1
clinitest,tablets,but 1.0 0.000573394495413 0 4 -4
clinitest,tablets,benedicts 1.0 0.000143348623853 0 1 -1
clinitest,benedicts,solution 1.0 0.000143348623853 0 1 -1
clinitest,benedict,s 1.0 0.000286697247706 0 2 -2
clinistix,or,tes-tape 1.0 0.000573394495413 0 4 -4
clinistix,and,glucose 1.0 0.000143348623853 0 1 -1
clinicians,have,noted 1.0 0.000143348623853 0 1 -1
clinician,to,offer 1.0 0.000143348623853 0 1 -1
clinician,responsible,for 1.0 0.000143348623853 0 1 -1
clinician,in,his 1.0 0.000143348623853 0 1 -1
clinician,depends,on 1.0 0.000143348623853 0 1 -1
clinically,significant,when 1.0 0.000143348623853 0 1 -1
clinically,significant,symptoms 1.0 0.000143348623853 0 1 -1
clinically,significant,qtc 1.0 0.000143348623853 0 1 -1
clinically,significant,pharmacokinetic 1.0 0.000143348623853 0 1 -1
clinically,significant,only 1.0 0.000143348623853 0 1 -1
clinically,significant,interactions 1.0 0.00143348623853 0 10 -10
clinically,significant,interaction 1.0 0.00043004587156 0 3 -3
clinically,significant,inhibition 1.0 0.000143348623853 0 1 -1
clinically,significant,hyperprolactinaemia 1.0 0.000143348623853 0 1 -1
clinically,significant,effect 1.0 0.00114678899083 0 8 -8
clinically,significant,drug-drug 1.0 0.000143348623853 0 1 -1
clinically,significant,drug 1.0 0.000143348623853 0 1 -1
clinically,significant,differences 1.0 0.000143348623853 0 1 -1
clinically,significant,degree 1.0 0.000143348623853 0 1 -1
clinically,significant,changes 1.0 0.000573394495413 0 4 -4
clinically,significant,and 1.0 0.000286697247706 0 2 -2
clinically,significant,adverse 1.0 0.000143348623853 0 1 -1
clinically,relevant,pharmacokinetic 1.0 0.000286697247706 0 2 -2
clinically,relevant,laboratory 1.0 0.000143348623853 0 1 -1
clinically,relevant,interactions 1.0 0.000286697247706 0 2 -2
clinically,relevant,effects 1.0 0.000143348623853 0 1 -1
clinically,relevant,drug-drug 1.0 0.000143348623853 0 1 -1
clinically,relevant,concentrations 1.0 0.000143348623853 0 1 -1
clinically,relevant,changes 1.0 0.00100344036697 0 7 -7
clinically,relevant,as 1.0 0.000143348623853 0 1 -1
clinically,relevant,alterations 1.0 0.000143348623853 0 1 -1
clinically,or,statistically 1.0 0.000143348623853 0 1 -1
clinically,normal,dogs 1.0 0.000143348623853 0 1 -1
clinically,meaningful,interactions 1.0 0.000286697247706 0 2 -2
clinically,meaningful,increases 1.0 0.000143348623853 0 1 -1
clinically,meaningful,changes 1.0 0.000286697247706 0 2 -2
clinically,in,patients 1.0 0.000143348623853 0 1 -1
clinically,important,potentiation 1.0 0.000143348623853 0 1 -1
clinically,important,pharmacokinetic 1.0 0.000573394495413 0 4 -4
clinically,important,interactions 1.0 0.00043004587156 0 3 -3
clinically,important,interaction 1.0 0.000143348623853 0 1 -1
clinically,important,effects 1.0 0.000286697247706 0 2 -2
clinically,important,effect 1.0 0.000860091743119 0 6 -6
clinically,important,alterations 1.0 0.000143348623853 0 1 -1
clinically,compatible,with 1.0 0.000143348623853 0 1 -1
clinically,because,they 1.0 0.000143348623853 0 1 -1
clinical,vancomycin-resistant,strains 1.0 0.000143348623853 0 1 -1
clinical,use,and 1.0 0.000143348623853 0 1 -1
clinical,trials,were 1.0 0.000286697247706 0 2 -2
clinical,trials,was 1.0 0.000143348623853 0 1 -1
clinical,trials,to 1.0 0.000143348623853 0 1 -1
clinical,trials,the 1.0 0.000286697247706 0 2 -2
clinical,trials,suggest 1.0 0.000286697247706 0 2 -2
clinical,trials,similar 1.0 0.000143348623853 0 1 -1
clinical,trials,showed 1.0 0.000143348623853 0 1 -1
clinical,trials,patients 1.0 0.000143348623853 0 1 -1
clinical,trials,no 1.0 0.000286697247706 0 2 -2
clinical,trials,mesylate 1.0 0.000143348623853 0 1 -1
clinical,trials,mean 1.0 0.000143348623853 0 1 -1
clinical,trials,hypoglycemia 1.0 0.000143348623853 0 1 -1
clinical,trials,however 1.0 0.000143348623853 0 1 -1
clinical,trials,have 1.0 0.00043004587156 0 3 -3
clinical,trials,database 1.0 0.000143348623853 0 1 -1
clinical,trials,currently 1.0 0.000143348623853 0 1 -1
clinical,trials,concomitant 1.0 0.000143348623853 0 1 -1
clinical,trials,and 1.0 0.00043004587156 0 3 -3
clinical,trials,a 1.0 0.000143348623853 0 1 -1
clinical,trial,there 1.0 0.000143348623853 0 1 -1
clinical,trial,of 1.0 0.000143348623853 0 1 -1
clinical,trial,in 1.0 0.000143348623853 0 1 -1
clinical,trial,a 1.0 0.000143348623853 0 1 -1
clinical,toxicity,of 1.0 0.000143348623853 0 1 -1
clinical,study,in 1.0 0.000286697247706 0 2 -2
clinical,studies,without 1.0 0.000143348623853 0 1 -1
clinical,studies,where 1.0 0.000143348623853 0 1 -1
clinical,studies,were 1.0 0.000143348623853 0 1 -1
clinical,studies,using 1.0 0.000143348623853 0 1 -1
clinical,studies,to 1.0 0.000143348623853 0 1 -1
clinical,studies,tilade 1.0 0.000143348623853 0 1 -1
clinical,studies,the 1.0 0.000286697247706 0 2 -2
clinical,studies,some 1.0 0.000143348623853 0 1 -1
clinical,studies,sodium 1.0 0.000143348623853 0 1 -1
clinical,studies,received 1.0 0.000286697247706 0 2 -2
clinical,studies,performed 1.0 0.000143348623853 0 1 -1
clinical,studies,in 1.0 0.00043004587156 0 3 -3
clinical,studies,had 1.0 0.000143348623853 0 1 -1
clinical,studies,did 1.0 0.000143348623853 0 1 -1
clinical,studies,coadministration 1.0 0.000143348623853 0 1 -1
clinical,studies,case 1.0 0.000143348623853 0 1 -1
clinical,studies,beta-receptor 1.0 0.000143348623853 0 1 -1
clinical,studies,and 1.0 0.000286697247706 0 2 -2
clinical,situation,and 1.0 0.000143348623853 0 1 -1
clinical,significance,these 1.0 0.000143348623853 0 1 -1
clinical,significance,the 1.0 0.000143348623853 0 1 -1
clinical,significance,if 1.0 0.000143348623853 0 1 -1
clinical,significance,as 1.0 0.000143348623853 0 1 -1
clinical,response,and 1.0 0.000143348623853 0 1 -1
clinical,relevance,picr 1.0 0.000143348623853 0 1 -1
clinical,relevance,of 1.0 0.000860091743119 0 6 -6
clinical,presentation,and 1.0 0.000143348623853 0 1 -1
clinical,pharmacology-pharmacokinetics,drug-drug 1.0 0.000143348623853 0 1 -1
clinical,pharmacology,studies 1.0 0.00043004587156 0 3 -3
clinical,pharmacology,pharmacokinetics 1.0 0.000286697247706 0 2 -2
clinical,pharmacology,drug- 1.0 0.000143348623853 0 1 -1
clinical,pharmacokinetic,studies 1.0 0.000286697247706 0 2 -2
clinical,patterns,of 1.0 0.000143348623853 0 1 -1
clinical,or,interaction 1.0 0.000143348623853 0 1 -1
clinical,monitoring,of 1.0 0.000143348623853 0 1 -1
clinical,monitoring,may 1.0 0.000143348623853 0 1 -1
clinical,laboratory,tests 1.0 0.000573394495413 0 4 -4
clinical,laboratory,test 1.0 0.000143348623853 0 1 -1
clinical,isolates,of 1.0 0.000143348623853 0 1 -1
clinical,isolates,and 1.0 0.000143348623853 0 1 -1
clinical,interest,to 1.0 0.000143348623853 0 1 -1
clinical,interaction,study 1.0 0.000286697247706 0 2 -2
clinical,interaction,studies 1.0 0.000860091743119 0 6 -6
clinical,interaction,between 1.0 0.000143348623853 0 1 -1
clinical,importance,have 1.0 0.000143348623853 0 1 -1
clinical,experiences,eg 1.0 0.000143348623853 0 1 -1
clinical,experience,with 1.0 0.000143348623853 0 1 -1
clinical,experience,to 1.0 0.000143348623853 0 1 -1
clinical,experience,may 1.0 0.000143348623853 0 1 -1
clinical,experience,in 1.0 0.000143348623853 0 1 -1
clinical,evidence,to 1.0 0.000286697247706 0 2 -2
clinical,evidence,of 1.0 0.000143348623853 0 1 -1
clinical,evidence,in 1.0 0.000143348623853 0 1 -1
clinical,evaluation,and 1.0 0.000143348623853 0 1 -1
clinical,effects,of 1.0 0.000143348623853 0 1 -1
clinical,drug-drug,interaction 1.0 0.000143348623853 0 1 -1
clinical,dose,of 1.0 0.000143348623853 0 1 -1
clinical,differences,indicated 1.0 0.000143348623853 0 1 -1
clinical,data,relating 1.0 0.000143348623853 0 1 -1
clinical,data,on 1.0 0.000143348623853 0 1 -1
clinical,data,in 1.0 0.000286697247706 0 2 -2
clinical,data,are 1.0 0.000143348623853 0 1 -1
clinical,course,of 1.0 0.000143348623853 0 1 -1
clinical,comments,about 1.0 0.000143348623853 0 1 -1
clinical,basis,of 1.0 0.000143348623853 0 1 -1
clinical,and,paraclinical 1.0 0.000143348623853 0 1 -1
clinical,and,laboratory 1.0 0.000286697247706 0 2 -2
clinical,acumen,but 1.0 0.000143348623853 0 1 -1
clinic,is,now 1.0 0.000143348623853 0 1 -1
clindamycin-sensitive,isolates,synergy 1.0 0.000143348623853 0 1 -1
climbing,paperhanging,playing 1.0 0.000143348623853 0 1 -1
cleavable,complex,formation 1.0 0.000143348623853 0 1 -1
clearly,show,that 1.0 0.000143348623853 0 1 -1
cleared,primarily,by 1.0 0.000143348623853 0 1 -1
clearance,with,the 1.0 0.000143348623853 0 1 -1
clearance,was,reduced 1.0 0.000143348623853 0 1 -1
clearance,was,decreased 1.0 0.000286697247706 0 2 -2
clearance,values,in 1.0 0.000143348623853 0 1 -1
clearance,value,is 1.0 0.000143348623853 0 1 -1
clearance,this,interaction 1.0 0.000143348623853 0 1 -1
clearance,resulting,in 1.0 0.000143348623853 0 1 -1
clearance,rate,was 1.0 0.000143348623853 0 1 -1
clearance,ranged,from 1.0 0.000143348623853 0 1 -1
clearance,prolongation,of 1.0 0.000143348623853 0 1 -1
clearance,or,volume 1.0 0.000143348623853 0 1 -1
clearance,or,toxicologic 1.0 0.000143348623853 0 1 -1
clearance,or,no 1.0 0.000143348623853 0 1 -1
clearance,or,cyp-mediated 1.0 0.000143348623853 0 1 -1
clearance,of,ucb 1.0 0.000143348623853 0 1 -1
clearance,of,the 1.0 0.000143348623853 0 1 -1
clearance,of,metabolized 1.0 0.000143348623853 0 1 -1
clearance,of,drugs 1.0 0.000143348623853 0 1 -1
clearance,of,as 1.0 0.000143348623853 0 1 -1
clearance,of,adrenocorticoids 1.0 0.000143348623853 0 1 -1
clearance,ml,min 1.0 0.000143348623853 0 1 -1
clearance,mechanisms,similar 1.0 0.000143348623853 0 1 -1
clearance,mechanism,involved 1.0 0.000143348623853 0 1 -1
clearance,may,decrease 1.0 0.000143348623853 0 1 -1
clearance,leading,to 1.0 0.000286697247706 0 2 -2
clearance,is,not 1.0 0.000143348623853 0 1 -1
clearance,has,not 1.0 0.000143348623853 0 1 -1
clearance,from,to 1.0 0.000143348623853 0 1 -1
clearance,does,not 1.0 0.000143348623853 0 1 -1
clearance,by,means 1.0 0.000143348623853 0 1 -1
clearance,between,patients 1.0 0.000143348623853 0 1 -1
clearance,at,steady-state 1.0 0.000143348623853 0 1 -1
clearance,and,concentration 1.0 0.000143348623853 0 1 -1
clearance,a,small 1.0 0.000143348623853 0 1 -1
clear,within,a 1.0 0.000143348623853 0 1 -1
clear,whether,this 1.0 0.000286697247706 0 2 -2
clear,that,topoisomerase 1.0 0.000143348623853 0 1 -1
clear,reproducible,pattern 1.0 0.000143348623853 0 1 -1
cleansers,soaps,and 1.0 0.000143348623853 0 1 -1
clastogenic,to,human 1.0 0.000143348623853 0 1 -1
clastogenic,in,multiple 1.0 0.000143348623853 0 1 -1
classified,using,the 1.0 0.000143348623853 0 1 -1
classes,that,are 1.0 0.000143348623853 0 1 -1
classes,of,listed 1.0 0.000143348623853 0 1 -1
classes,of,cardiovascular 1.0 0.000143348623853 0 1 -1
classes,ii,to 1.0 0.000286697247706 0 2 -2
class,which,includes 1.0 0.000143348623853 0 1 -1
class,produced,optic 1.0 0.000143348623853 0 1 -1
class,of,with 1.0 0.000143348623853 0 1 -1
class,of,protease 1.0 0.000143348623853 0 1 -1
class,of,oral 1.0 0.000143348623853 0 1 -1
class,of,include 1.0 0.000143348623853 0 1 -1
class,of,chemicals 1.0 0.000143348623853 0 1 -1
class,of,agents 1.0 0.000286697247706 0 2 -2
class,not,to 1.0 0.000143348623853 0 1 -1
class,may,reduce 1.0 0.000143348623853 0 1 -1
class,iv,in 1.0 0.000143348623853 0 1 -1
class,iv,cannot 1.0 0.000143348623853 0 1 -1
class,is,increased 1.0 0.000143348623853 0 1 -1
class,including,anafranil 1.0 0.000143348623853 0 1 -1
class,i,such 1.0 0.000143348623853 0 1 -1
class,drug,name 1.0 0.000286697247706 0 2 -2
class,a,vana 1.0 0.000143348623853 0 1 -1
clarithromycin,telithromycin,hiv 1.0 0.000143348623853 0 1 -1
clamps,mmol,l 1.0 0.000143348623853 0 1 -1
citrate,tablets,usp 1.0 0.000143348623853 0 1 -1
citrate,has,been 1.0 0.000143348623853 0 1 -1
citrate,and,fluoride 1.0 0.000143348623853 0 1 -1
cite,primary,sources 1.0 0.000143348623853 0 1 -1
cisplatin,was,administered 1.0 0.000143348623853 0 1 -1
cisapride,was,well 1.0 0.000143348623853 0 1 -1
cisapride,is,metabolized 1.0 0.000143348623853 0 1 -1
cisapride,can,be 1.0 0.000143348623853 0 1 -1
circumstances,as,prophylaxis 1.0 0.000143348623853 0 1 -1
circulating,total,hormone 1.0 0.00043004587156 0 3 -3
circulating,metabolite,hydroxy-estazolam 1.0 0.000143348623853 0 1 -1
circulating,levels,of 1.0 0.000143348623853 0 1 -1
circulating,fluids,might 1.0 0.000286697247706 0 2 -2
circulating,concentrations,and 1.0 0.000143348623853 0 1 -1
circulating,catecholamines,after 1.0 0.000143348623853 0 1 -1
circulating,after,alphagan 1.0 0.000143348623853 0 1 -1
circulating,active,metabolites 1.0 0.000143348623853 0 1 -1
circulates,largely,unbound 1.0 0.000143348623853 0 1 -1
circulars,for,preparations 1.0 0.00043004587156 0 3 -3
circulars,for,preparation 1.0 0.000143348623853 0 1 -1
cinese,hamsters,show 1.0 0.000143348623853 0 1 -1
cimetldine,cerivastatin,plasma 1.0 0.000143348623853 0 1 -1
cimetidine,mg,b 1.0 0.000143348623853 0 1 -1
cimetidine,increased,auc 1.0 0.000143348623853 0 1 -1
cimetidine,does,not 1.0 0.000143348623853 0 1 -1
cimetidine,concomitant,use 1.0 0.000143348623853 0 1 -1
cimetidine,co-administration,of 1.0 0.000286697247706 0 2 -2
cimetidine,cimetidine,does 1.0 0.000143348623853 0 1 -1
cimetidine,atorvastatin,plasma 1.0 0.000143348623853 0 1 -1
cimetidine,and,had 1.0 0.000143348623853 0 1 -1
cilexetil,given,with 1.0 0.000143348623853 0 1 -1
cigarettes,and,other 1.0 0.000143348623853 0 1 -1
cigarette,smokers,and 1.0 0.000143348623853 0 1 -1
ci,were,picr 1.0 0.000143348623853 0 1 -1
ci,of,the 1.0 0.000286697247706 0 2 -2
ci,kg,or 1.0 0.000143348623853 0 1 -1
ci,increase,increase 1.0 0.000143348623853 0 1 -1
ci,in,one 1.0 0.000286697247706 0 2 -2
ci,by,monitoring 1.0 0.000143348623853 0 1 -1
chylomicron-like,emulsions,in 1.0 0.000143348623853 0 1 -1
chylomicron-like,emulsion,model 1.0 0.000143348623853 0 1 -1
chylomicron-like,emulsion,doubly 1.0 0.000143348623853 0 1 -1
chylomicron,metabolism,was 1.0 0.000143348623853 0 1 -1
chylomicron,lipolysis,and 1.0 0.000143348623853 0 1 -1
chylomicron,intravascular,catabolism 1.0 0.000143348623853 0 1 -1
chronically,receiving,resulted 1.0 0.000143348623853 0 1 -1
chronically,receiving,and 1.0 0.000143348623853 0 1 -1
chronically,ill,and 1.0 0.000143348623853 0 1 -1
chronic,weeks,oral 1.0 0.000143348623853 0 1 -1
chronic,treatments,corrective 1.0 0.000143348623853 0 1 -1
chronic,treatment,for 1.0 0.000143348623853 0 1 -1
chronic,toxicity,study 1.0 0.000143348623853 0 1 -1
chronic,therapy,had 1.0 0.000143348623853 0 1 -1
chronic,indications,and 1.0 0.000143348623853 0 1 -1
chronic,hepatitis,c 1.0 0.000143348623853 0 1 -1
chronic,experiments,on 1.0 0.000143348623853 0 1 -1
chronic,dosing,is 1.0 0.000143348623853 0 1 -1
chronic,dosing,effects 1.0 0.000143348623853 0 1 -1
chronic,activation,of 1.0 0.000143348623853 0 1 -1
chromosomal,aberration,assay 1.0 0.000143348623853 0 1 -1
chromatography,procedure,for 1.0 0.000143348623853 0 1 -1
chromatographic,assay,with 1.0 0.000143348623853 0 1 -1
chromatographic,assay,and 1.0 0.000143348623853 0 1 -1
chromatogr,should,be 1.0 0.000143348623853 0 1 -1
chromatin,and,cytoplasmic 1.0 0.000143348623853 0 1 -1
chromaffin,cell,including 1.0 0.000143348623853 0 1 -1
chromaffin,cell,could 1.0 0.000143348623853 0 1 -1
chosen,method,or 1.0 0.000143348623853 0 1 -1
choroidal,blood,flow 1.0 0.000143348623853 0 1 -1
chop-like,regimen,i 1.0 0.000143348623853 0 1 -1
chop-haart,patients,was 1.0 0.000143348623853 0 1 -1
chop-haart,patients,than 1.0 0.000143348623853 0 1 -1
chop-haart,patients,developed 1.0 0.000143348623853 0 1 -1
chop-haart,group,than 1.0 0.000143348623853 0 1 -1
chop-haart,compared,with 1.0 0.000143348623853 0 1 -1
chop,plus,haart 1.0 0.000143348623853 0 1 -1
chop,patients,was 1.0 0.000143348623853 0 1 -1
chop,patients,vs 1.0 0.000143348623853 0 1 -1
chop,patients,developed 1.0 0.000143348623853 0 1 -1
chop,chemotherapy,regimen 1.0 0.000143348623853 0 1 -1
chop,chemotherapy,or 1.0 0.000143348623853 0 1 -1
chop,alone,vs 1.0 0.000143348623853 0 1 -1
choose,particular,low 1.0 0.000143348623853 0 1 -1
cholino-,and,adrenoreceptors 1.0 0.000143348623853 0 1 -1
cholinergic,stimulation,is 1.0 0.000143348623853 0 1 -1
cholinergic,role,in 1.0 0.000143348623853 0 1 -1
cholinergic,reactions,of 1.0 0.000143348623853 0 1 -1
cholinergic,crisis,may 1.0 0.000143348623853 0 1 -1
cholestyramine,the,influence 1.0 0.000143348623853 0 1 -1
cholestyramine,resin,or 1.0 0.000143348623853 0 1 -1
cholestyramine,resin,may 1.0 0.000143348623853 0 1 -1
cholestyramine,increases,enterohepatic 1.0 0.000143348623853 0 1 -1
cholestographic,agents,iodine-containing 1.0 0.000143348623853 0 1 -1
cholesterol,the,major 1.0 0.000143348623853 0 1 -1
cholesterol,synthesis,and 1.0 0.000143348623853 0 1 -1
cholesterol,subfraction,concentrations 1.0 0.000286697247706 0 2 -2
cholesterol,mg,dl 1.0 0.000143348623853 0 1 -1
cholesterol,low-density,lipoproteins 1.0 0.000143348623853 0 1 -1
cholesterol,levels,could 1.0 0.000143348623853 0 1 -1
cholesterol,concentration,increased 1.0 0.000286697247706 0 2 -2
cholesterol,and,triglyceride 1.0 0.000143348623853 0 1 -1
cholecystokinin--of,h-spiroperidol,binding 1.0 0.000143348623853 0 1 -1
cholecystokinin,octapeptide,was 1.0 0.000143348623853 0 1 -1
cholecystokinin,octapeptide,is 1.0 0.000143348623853 0 1 -1
choice,of,as 1.0 0.000143348623853 0 1 -1
choice,for,prolonged 1.0 0.000143348623853 0 1 -1
chloroprocaine,inhibits,the 1.0 0.000143348623853 0 1 -1
chirocaine,that,are 1.0 0.000143348623853 0 1 -1
chinese,hamsters,in 1.0 0.000143348623853 0 1 -1
chinese,hamster,s 1.0 0.000143348623853 0 1 -1
chinese,hamster,responds 1.0 0.000143348623853 0 1 -1
chills,nausea,vomiting 1.0 0.000143348623853 0 1 -1
children,who,have 1.0 0.000143348623853 0 1 -1
children,has,not 1.0 0.000143348623853 0 1 -1
childbearing,potential,to 1.0 0.000143348623853 0 1 -1
childbearing,potential,only 1.0 0.000143348623853 0 1 -1
childbearing,potential,must 1.0 0.000143348623853 0 1 -1
childbearing,potential,make 1.0 0.000143348623853 0 1 -1
chiefly,with,the 1.0 0.000143348623853 0 1 -1
chick,embryos,similarly 1.0 0.000143348623853 0 1 -1
chick,by,means 1.0 0.000143348623853 0 1 -1
chemotherapy,regimen,plus 1.0 0.000143348623853 0 1 -1
chemotherapy,plus,highly 1.0 0.000143348623853 0 1 -1
chemotherapy,plus,haart 1.0 0.000286697247706 0 2 -2
chemotherapy,or,surgery 1.0 0.000143348623853 0 1 -1
chemotherapy,or,a 1.0 0.000143348623853 0 1 -1
chemotherapy,interrupted,in 1.0 0.000143348623853 0 1 -1
chemotherapy,in,the 1.0 0.000143348623853 0 1 -1
chemotherapy,concomitantly,with 1.0 0.000143348623853 0 1 -1
chemotherapy,can,have 1.0 0.000143348623853 0 1 -1
chemotherapy,and,highly 1.0 0.000143348623853 0 1 -1
chemotherapy,agents,no 1.0 0.000143348623853 0 1 -1
chemotherapy,agents,in 1.0 0.000143348623853 0 1 -1
chemotherapies,breast,irradiation 1.0 0.000143348623853 0 1 -1
chemotherapeutic,agents,in 1.0 0.000143348623853 0 1 -1
chemicals,that,includes 1.0 0.000143348623853 0 1 -1
chemically,similar,in 1.0 0.000143348623853 0 1 -1
chemically,modify,exposed 1.0 0.000143348623853 0 1 -1
chemical,or,laboratory 1.0 0.000143348623853 0 1 -1
chemical,i,neurotransmitter 1.0 0.000143348623853 0 1 -1
chemical,color,development 1.0 0.000143348623853 0 1 -1
chemical,carcinogen,may 1.0 0.000143348623853 0 1 -1
chelator,therapies,as 1.0 0.000143348623853 0 1 -1
chelation,and,these 1.0 0.000143348623853 0 1 -1
chelates,with,alkaline 1.0 0.000286697247706 0 2 -2
chelated,extracellular,ca 1.0 0.000143348623853 0 1 -1
checkerboard,assay,for 1.0 0.000143348623853 0 1 -1
check,your,b12 1.0 0.000143348623853 0 1 -1
check,serum,levels 1.0 0.000143348623853 0 1 -1
characterized,to,define 1.0 0.000143348623853 0 1 -1
characterized,by,perivascular 1.0 0.000143348623853 0 1 -1
characterized,by,peripheral 1.0 0.000286697247706 0 2 -2
characterized,by,flushing 1.0 0.000143348623853 0 1 -1
characterize,the,steady-state 1.0 0.000143348623853 0 1 -1
characterize,the,aerosol 1.0 0.000143348623853 0 1 -1
characterization,or,by 1.0 0.000143348623853 0 1 -1
characteristics,related,to 1.0 0.000143348623853 0 1 -1
characteristics,of,the 1.0 0.000143348623853 0 1 -1
characteristics,in,the 1.0 0.000143348623853 0 1 -1
characteristics,hiv,status 1.0 0.000143348623853 0 1 -1
characteristics,for,and 1.0 0.000143348623853 0 1 -1
characteristic,of,animals 1.0 0.000143348623853 0 1 -1
characteristic,apoptotic,morphology 1.0 0.000143348623853 0 1 -1
characterised,by,a 1.0 0.000143348623853 0 1 -1
chapters,cover,interactions 1.0 0.000143348623853 0 1 -1
chapter,presents,information 1.0 0.000143348623853 0 1 -1
chapter,presents,findings 1.0 0.000143348623853 0 1 -1
chapter,including,persistent 1.0 0.000143348623853 0 1 -1
chapter,focuses,on 1.0 0.000143348623853 0 1 -1
chapter,discusses,the 1.0 0.000143348623853 0 1 -1
chapter,covers,pharmacology 1.0 0.000143348623853 0 1 -1
chapter,considers,the 1.0 0.000143348623853 0 1 -1
chapter,and,chapter 1.0 0.000143348623853 0 1 -1
channels,in,bovine 1.0 0.000143348623853 0 1 -1
channels,and,the 1.0 0.000143348623853 0 1 -1
channel-blockers,ace,inhibitors 1.0 0.000143348623853 0 1 -1
channel,subtypes,using 1.0 0.000143348623853 0 1 -1
channel,subtypes,in 1.0 0.000286697247706 0 2 -2
channel,subtypes,although 1.0 0.000143348623853 0 1 -1
channel,blocking,agents 1.0 0.000286697247706 0 2 -2
channel,blockers,sustained-release 1.0 0.000143348623853 0 1 -1
channel,blockers,nonsteroidal 1.0 0.000143348623853 0 1 -1
channel,blockers,l-type 1.0 0.000143348623853 0 1 -1
channel,blockers,did 1.0 0.000143348623853 0 1 -1
channel,blockers,beta 1.0 0.000143348623853 0 1 -1
channel,blocker,was 1.0 0.000143348623853 0 1 -1
channel,blocker,on 1.0 0.000143348623853 0 1 -1
channel,antagonists,cyp1a2 1.0 0.000143348623853 0 1 -1
channel,antagonists,angiotensin 1.0 0.000143348623853 0 1 -1
channel,antagonists,a 1.0 0.000143348623853 0 1 -1
channel,and,omega-conotoxin 1.0 0.000143348623853 0 1 -1
channel,an,omega-agatoxin 1.0 0.000143348623853 0 1 -1
changing,from,intravenous 1.0 0.000143348623853 0 1 -1
changes,were,observed 1.0 0.00043004587156 0 3 -3
changes,were,noted 1.0 0.000143348623853 0 1 -1
changes,were,not 1.0 0.000143348623853 0 1 -1
changes,to,the 1.0 0.000143348623853 0 1 -1
changes,that,occur 1.0 0.000143348623853 0 1 -1
changes,seen,with 1.0 0.000143348623853 0 1 -1
changes,resulting,from 1.0 0.000143348623853 0 1 -1
changes,on,the 1.0 0.000143348623853 0 1 -1
changes,of,mice 1.0 0.000143348623853 0 1 -1
changes,occurred,in 1.0 0.000143348623853 0 1 -1
changes,northern,blot 1.0 0.000143348623853 0 1 -1
changes,may,be 1.0 0.00043004587156 0 3 -3
changes,induced,by 1.0 0.000143348623853 0 1 -1
changes,in,urinary 1.0 0.000143348623853 0 1 -1
changes,in,tbg 1.0 0.000143348623853 0 1 -1
changes,in,serum 1.0 0.000286697247706 0 2 -2
changes,in,prothrombin 1.0 0.000860091743119 0 6 -6
changes,in,platelets 1.0 0.000143348623853 0 1 -1
changes,in,pharmacokinetics 1.0 0.00043004587156 0 3 -3
changes,in,or 1.0 0.000143348623853 0 1 -1
changes,in,luteinizing 1.0 0.000143348623853 0 1 -1
changes,in,liver 1.0 0.000143348623853 0 1 -1
changes,in,laboratory 1.0 0.000286697247706 0 2 -2
changes,in,inr 1.0 0.000143348623853 0 1 -1
changes,in,hormone 1.0 0.000143348623853 0 1 -1
changes,in,hepatic 1.0 0.000143348623853 0 1 -1
changes,in,gene 1.0 0.000143348623853 0 1 -1
changes,in,function 1.0 0.000143348623853 0 1 -1
changes,in,either 1.0 0.000143348623853 0 1 -1
changes,in,ecg 1.0 0.000143348623853 0 1 -1
changes,in,desloratadine 1.0 0.000143348623853 0 1 -1
changes,in,density 1.0 0.000143348623853 0 1 -1
changes,in,corrected 1.0 0.000143348623853 0 1 -1
changes,in,clotting 1.0 0.000143348623853 0 1 -1
changes,in,cervical 1.0 0.000143348623853 0 1 -1
changes,in,and 1.0 0.000143348623853 0 1 -1
changes,has,not 1.0 0.000143348623853 0 1 -1
changes,are,not 1.0 0.000143348623853 0 1 -1
changes,are,listed 1.0 0.000143348623853 0 1 -1
changes,and,its 1.0 0.000143348623853 0 1 -1
changed,to,mg 1.0 0.000143348623853 0 1 -1
changed,the,same 1.0 0.000143348623853 0 1 -1
changed,as,evidenced 1.0 0.000143348623853 0 1 -1
changed,and,they 1.0 0.000143348623853 0 1 -1
change,with,the 1.0 0.000143348623853 0 1 -1
change,was,not 1.0 0.000143348623853 0 1 -1
change,the,pharmacokinetics 1.0 0.000143348623853 0 1 -1
change,the,pharmacokinetic 1.0 0.000143348623853 0 1 -1
change,the,dose 1.0 0.000286697247706 0 2 -2
change,significantly,while 1.0 0.000143348623853 0 1 -1
change,of,lifestyle 1.0 0.000143348623853 0 1 -1
change,in,prothrombin 1.0 0.000143348623853 0 1 -1
change,in,platelet 1.0 0.000143348623853 0 1 -1
change,in,phase 1.0 0.000143348623853 0 1 -1
change,in,meclofenamate 1.0 0.000143348623853 0 1 -1
change,in,dose 1.0 0.000143348623853 0 1 -1
change,in,clotting 1.0 0.000143348623853 0 1 -1
change,in,clearance 1.0 0.000143348623853 0 1 -1
change,in,auc 1.0 0.000143348623853 0 1 -1
change,fasting,or 1.0 0.000143348623853 0 1 -1
change,after,a 1.0 0.000143348623853 0 1 -1
challenged,with,a 1.0 0.000143348623853 0 1 -1
challenge,or,accidental 1.0 0.000143348623853 0 1 -1
challenge,either,accidental 1.0 0.000716743119266 0 5 -5
challenge,and,the 1.0 0.000143348623853 0 1 -1
chains,of,n-methylthiotetrazole 1.0 0.000143348623853 0 1 -1
chain,is,important 1.0 0.000143348623853 0 1 -1
cfus,were,maintained 1.0 0.000143348623853 0 1 -1
cfu,ml,for 1.0 0.000143348623853 0 1 -1
cevimeline,might,interfere 1.0 0.000143348623853 0 1 -1
cessation,with,or 1.0 0.000143348623853 0 1 -1
cessation,such,cases 1.0 0.000143348623853 0 1 -1
cessation,of,therapy 1.0 0.000143348623853 0 1 -1
cervical,vertebra,at 1.0 0.000143348623853 0 1 -1
cervical,mucus,the 1.0 0.000143348623853 0 1 -1
cervical,breast,and 1.0 0.000143348623853 0 1 -1
cerulein--an,analog,of 1.0 0.000143348623853 0 1 -1
cerubidine,may,be 1.0 0.000143348623853 0 1 -1
certain,tumor,types 1.0 0.000143348623853 0 1 -1
certain,that,are 1.0 0.000286697247706 0 2 -2
certain,tend,to 1.0 0.00043004587156 0 3 -3
certain,other,and 1.0 0.000143348623853 0 1 -1
certain,neurologic,disorders 1.0 0.000143348623853 0 1 -1
certain,metabolizing,enzymes 1.0 0.000286697247706 0 2 -2
certain,medicines,should 1.0 0.000143348623853 0 1 -1
certain,malignancies,is 1.0 0.000143348623853 0 1 -1
certain,inhibit,the 1.0 0.000716743119266 0 5 -5
certain,factors,such 1.0 0.000143348623853 0 1 -1
certain,especially,and 1.0 0.000143348623853 0 1 -1
certain,endocrine,and 1.0 0.000286697247706 0 2 -2
certain,drugs,tend 1.0 0.000143348623853 0 1 -1
certain,cyp450,enzymes 1.0 0.000143348623853 0 1 -1
certain,could,increase 1.0 0.000143348623853 0 1 -1
certain,conditions,produce 1.0 0.000143348623853 0 1 -1
certain,concomitant,medications 1.0 0.000286697247706 0 2 -2
certain,circumstances,as 1.0 0.000143348623853 0 1 -1
certain,brain,chemical 1.0 0.000143348623853 0 1 -1
certain,are,metabolized 1.0 0.000143348623853 0 1 -1
certain,antipsychotic,medications 1.0 0.000143348623853 0 1 -1
certain,actions,or 1.0 0.000143348623853 0 1 -1
cerivastatin,plasma,concentrations 1.0 0.00043004587156 0 3 -3
cerebyx,with,other 1.0 0.000143348623853 0 1 -1
cerebyx,were,concurrently 1.0 0.000143348623853 0 1 -1
cerebyx,are,expected 1.0 0.000143348623853 0 1 -1
cerebrovascular,accidents,six 1.0 0.000143348623853 0 1 -1
cerebroactive,drugs,has 1.0 0.000143348623853 0 1 -1
cerebral,memory,systems 1.0 0.000143348623853 0 1 -1
cereals,on,absorption 1.0 0.000143348623853 0 1 -1
cercarial,encystment,at 1.0 0.000143348623853 0 1 -1
cercariae,exposed,to 1.0 0.000143348623853 0 1 -1
cercariae,and,metacercariae 1.0 0.000143348623853 0 1 -1
cephalothin,sodium,sulfate 1.0 0.000143348623853 0 1 -1
cephalosporins-cephalosporins,containing,side 1.0 0.000143348623853 0 1 -1
cephalosporins,including,cefotaxime 1.0 0.000143348623853 0 1 -1
cephalosporins,are,known 1.0 0.000286697247706 0 2 -2
cephalosporin,before,parturition 1.0 0.000143348623853 0 1 -1
centroblast,proliferation,in 1.0 0.000143348623853 0 1 -1
centrally,acting,including 1.0 0.000143348623853 0 1 -1
central,pathways,are 1.0 0.000143348623853 0 1 -1
central,obesity,dorsocervical 1.0 0.000143348623853 0 1 -1
central,importance,of 1.0 0.000143348623853 0 1 -1
centers,of,the 1.0 0.000143348623853 0 1 -1
center,italy,from 1.0 0.000143348623853 0 1 -1
center,inventory,the 1.0 0.000143348623853 0 1 -1
cellulitis,induration,skin 1.0 0.000143348623853 0 1 -1
cellular,sensitivity,to 1.0 0.000143348623853 0 1 -1
cellular,permeability,and 1.0 0.000143348623853 0 1 -1
cellular,basis,of 1.0 0.000143348623853 0 1 -1
cellular,and,molecular 1.0 0.000143348623853 0 1 -1
cells,with,tam 1.0 0.000143348623853 0 1 -1
cells,with,nucleophosmin 1.0 0.000143348623853 0 1 -1
cells,whereas,the 1.0 0.000143348623853 0 1 -1
cells,whereas,b 1.0 0.000143348623853 0 1 -1
cells,were,also 1.0 0.000143348623853 0 1 -1
cells,was,found 1.0 0.000143348623853 0 1 -1
cells,was,as 1.0 0.000143348623853 0 1 -1
cells,treated,with 1.0 0.000143348623853 0 1 -1
cells,to,topo 1.0 0.000143348623853 0 1 -1
cells,to,the 1.0 0.000143348623853 0 1 -1
cells,to,increase 1.0 0.000143348623853 0 1 -1
cells,that,result 1.0 0.000143348623853 0 1 -1
cells,that,are 1.0 0.000143348623853 0 1 -1
cells,stably,transfected 1.0 0.000143348623853 0 1 -1
cells,rr,had 1.0 0.000143348623853 0 1 -1
cells,respond,normally 1.0 0.000143348623853 0 1 -1
cells,resistant,to 1.0 0.000143348623853 0 1 -1
cells,mm3,for 1.0 0.000143348623853 0 1 -1
cells,mm3,and 1.0 0.000143348623853 0 1 -1
cells,including,robust 1.0 0.000143348623853 0 1 -1
cells,in,response 1.0 0.000143348623853 0 1 -1
cells,from,healthy 1.0 0.000143348623853 0 1 -1
cells,for,the 1.0 0.000143348623853 0 1 -1
cells,express,the 1.0 0.000143348623853 0 1 -1
cells,even,when 1.0 0.000143348623853 0 1 -1
cells,either,by 1.0 0.000143348623853 0 1 -1
cells,compared,with 1.0 0.000143348623853 0 1 -1
cells,by,a 1.0 0.000143348623853 0 1 -1
cells,at,low 1.0 0.000143348623853 0 1 -1
cells,are,being 1.0 0.000143348623853 0 1 -1
cells,and,may 1.0 0.000143348623853 0 1 -1
cells,and,in 1.0 0.000143348623853 0 1 -1
cell-independent,activator,of 1.0 0.000143348623853 0 1 -1
cell-free,system,derived 1.0 0.000143348623853 0 1 -1
cell,type-specific,differences 1.0 0.000143348623853 0 1 -1
cell,type,and 1.0 0.000143348623853 0 1 -1
cell,tumors,was 1.0 0.000143348623853 0 1 -1
cell,tumors,and 1.0 0.000143348623853 0 1 -1
cell,the,result 1.0 0.000143348623853 0 1 -1
cell,resistance,or 1.0 0.000143348623853 0 1 -1
cell,permeable,caspase-3 1.0 0.000143348623853 0 1 -1
cell,permeability,of 1.0 0.000143348623853 0 1 -1
cell,or,to 1.0 0.000143348623853 0 1 -1
cell,of,the 1.0 0.000143348623853 0 1 -1
cell,mutation,assay 1.0 0.000143348623853 0 1 -1
cell,mitogen,and 1.0 0.000143348623853 0 1 -1
cell,membrane,was 1.0 0.000143348623853 0 1 -1
cell,killing,relative 1.0 0.000143348623853 0 1 -1
cell,infiltration,of 1.0 0.000143348623853 0 1 -1
cell,including,an 1.0 0.000143348623853 0 1 -1
cell,growth,both 1.0 0.000143348623853 0 1 -1
cell,functions,transcription 1.0 0.000143348623853 0 1 -1
cell,from,the 1.0 0.000143348623853 0 1 -1
cell,cultures,superinduced 1.0 0.000143348623853 0 1 -1
cell,cultures,stimulated 1.0 0.000143348623853 0 1 -1
cell,counts,be 1.0 0.000143348623853 0 1 -1
cell,could,be 1.0 0.000143348623853 0 1 -1
cell,body,and 1.0 0.000143348623853 0 1 -1
cell,and,was 1.0 0.000143348623853 0 1 -1
cell,activation,and 1.0 0.000143348623853 0 1 -1
cell,accumulation,of 1.0 0.000143348623853 0 1 -1
celecoxib,metabolism,is 1.0 0.000143348623853 0 1 -1
celebrex,is,not 1.0 0.000143348623853 0 1 -1
celebrex,did,not 1.0 0.000143348623853 0 1 -1
cefuroxime,does,not 1.0 0.000143348623853 0 1 -1
cefotaxime,sodium,are 1.0 0.000143348623853 0 1 -1
cefotan,may,result 1.0 0.000143348623853 0 1 -1
cefditoren,pivoxil,had 1.0 0.000143348623853 0 1 -1
cefamandole,naftate,cephalothin 1.0 0.000143348623853 0 1 -1
cef-120,or,fec-100 1.0 0.000143348623853 0 1 -1
cecum,in,the 1.0 0.000143348623853 0 1 -1
cecum,and,its 1.0 0.000143348623853 0 1 -1
cecectomized,than,in 1.0 0.000286697247706 0 2 -2
cecectomized,rats,was 1.0 0.000143348623853 0 1 -1
cecectomized,rats,prepared 1.0 0.000143348623853 0 1 -1
cecectomized,and,in 1.0 0.000286697247706 0 2 -2
cecectomized,and,control 1.0 0.000286697247706 0 2 -2
ccnu,was,times 1.0 0.000143348623853 0 1 -1
ccnu,is,given 1.0 0.000143348623853 0 1 -1
ccnu,either,alone 1.0 0.000143348623853 0 1 -1
cbg,sex,hormone-binding 1.0 0.000143348623853 0 1 -1
cbg,sex,hormone 1.0 0.000143348623853 0 1 -1
cavity,or,on 1.0 0.000143348623853 0 1 -1
caverject,the,potential 1.0 0.000143348623853 0 1 -1
cautiously,if,at 1.0 0.000143348623853 0 1 -1
cautiously,as,toxic 1.0 0.000143348623853 0 1 -1
cautiously,and,perhaps 1.0 0.000143348623853 0 1 -1
cautiously,and,confirmed 1.0 0.000143348623853 0 1 -1
cautious,in,patients 1.0 0.000143348623853 0 1 -1
cautious,and,this 1.0 0.000143348623853 0 1 -1
cautioned,that,the 1.0 0.000143348623853 0 1 -1
cautioned,regarding,potential 1.0 0.000143348623853 0 1 -1
cautioned,against,engaging 1.0 0.000143348623853 0 1 -1
cautioned,against,driving 1.0 0.000143348623853 0 1 -1
cautioned,about,the 1.0 0.000143348623853 0 1 -1
caution,when,it 1.0 0.000143348623853 0 1 -1
caution,when,giving 1.0 0.000143348623853 0 1 -1
caution,since,they 1.0 0.000143348623853 0 1 -1
caution,should,also 1.0 0.000286697247706 0 2 -2
caution,only,if 1.0 0.000143348623853 0 1 -1
caution,must,be 1.0 0.000143348623853 0 1 -1
caution,may,be 1.0 0.000143348623853 0 1 -1
caution,in,the 1.0 0.000143348623853 0 1 -1
caution,in,prothrombin 1.0 0.000143348623853 0 1 -1
caution,in,individuals 1.0 0.000143348623853 0 1 -1
caution,however,is 1.0 0.000286697247706 0 2 -2
caution,especially,in 1.0 0.000143348623853 0 1 -1
caution,dose,adjustment 1.0 0.000143348623853 0 1 -1
caution,and,with 1.0 0.00043004587156 0 3 -3
caution,and,the 1.0 0.000286697247706 0 2 -2
caution,and,frequent 1.0 0.00043004587156 0 3 -3
caution,and,consideration 1.0 0.000143348623853 0 1 -1
caution,and,careful 1.0 0.000143348623853 0 1 -1
caution,and,be 1.0 0.000143348623853 0 1 -1
causing,no,significant 1.0 0.000143348623853 0 1 -1
causes,of,at 1.0 0.000143348623853 0 1 -1
causes,no,more 1.0 0.000143348623853 0 1 -1
causes,a,significant 1.0 0.000143348623853 0 1 -1
causes,a,profound 1.0 0.000143348623853 0 1 -1
caused,the,release 1.0 0.000143348623853 0 1 -1
caused,subnormal,release 1.0 0.000143348623853 0 1 -1
caused,no,systematic 1.0 0.000143348623853 0 1 -1
caused,no,change 1.0 0.000143348623853 0 1 -1
caused,identical,and 1.0 0.000143348623853 0 1 -1
caused,excessive,release 1.0 0.000286697247706 0 2 -2
caused,by,two 1.0 0.000143348623853 0 1 -1
caused,by,therapy 1.0 0.000143348623853 0 1 -1
caused,by,sodium 1.0 0.000143348623853 0 1 -1
caused,by,inhibition 1.0 0.000143348623853 0 1 -1
caused,by,gram-negative 1.0 0.000143348623853 0 1 -1
caused,by,an 1.0 0.000143348623853 0 1 -1
caused,by,administration 1.0 0.000143348623853 0 1 -1
caused,an,increased 1.0 0.000143348623853 0 1 -1
caused,a,three- 1.0 0.000143348623853 0 1 -1
caused,a,reversible 1.0 0.000143348623853 0 1 -1
caused,a,reduction 1.0 0.000143348623853 0 1 -1
caused,a,first 1.0 0.000143348623853 0 1 -1
cause,transient,increase 1.0 0.000143348623853 0 1 -1
cause,too,much 1.0 0.000143348623853 0 1 -1
cause,significant,increases 1.0 0.000143348623853 0 1 -1
cause,renal,and 1.0 0.000143348623853 0 1 -1
cause,qt,prolongation 1.0 0.000143348623853 0 1 -1
cause,peripheral,neuropathy 1.0 0.000143348623853 0 1 -1
cause,pancreatitis,may 1.0 0.000143348623853 0 1 -1
cause,or,be 1.0 0.000143348623853 0 1 -1
cause,of,the 1.0 0.000143348623853 0 1 -1
cause,of,mortality 1.0 0.000143348623853 0 1 -1
cause,of,contrast 1.0 0.000143348623853 0 1 -1
cause,neutropenia,and 1.0 0.000143348623853 0 1 -1
cause,myopathy,which 1.0 0.000143348623853 0 1 -1
cause,myopathy,when 1.0 0.000286697247706 0 2 -2
cause,much,more 1.0 0.000143348623853 0 1 -1
cause,k,deficiency 1.0 0.000143348623853 0 1 -1
cause,induction,or 1.0 0.000143348623853 0 1 -1
cause,increases,ranging 1.0 0.000286697247706 0 2 -2
cause,increases,in 1.0 0.000143348623853 0 1 -1
cause,increased,serum 1.0 0.000143348623853 0 1 -1
cause,increased,free 1.0 0.000143348623853 0 1 -1
cause,increased,blood 1.0 0.000143348623853 0 1 -1
cause,in,vivo 1.0 0.000143348623853 0 1 -1
cause,hypotension,bradycardia 1.0 0.000143348623853 0 1 -1
cause,hypoglycemia,which 1.0 0.000286697247706 0 2 -2
cause,headaches,and 1.0 0.000286697247706 0 2 -2
cause,dna,damage 1.0 0.000143348623853 0 1 -1
cause,direct,coombs 1.0 0.000143348623853 0 1 -1
cause,clinically,important 1.0 0.000143348623853 0 1 -1
cause,bleeding,complications 1.0 0.000143348623853 0 1 -1
cause,arrhythmias,in 1.0 0.000143348623853 0 1 -1
cause,are,dryness 1.0 0.000143348623853 0 1 -1
cause,an,excessive 1.0 0.000143348623853 0 1 -1
cause,an,alteration 1.0 0.000143348623853 0 1 -1
cause,a,sudden 1.0 0.000143348623853 0 1 -1
cause,a,false-positive 1.0 0.000143348623853 0 1 -1
cause,a,false 1.0 0.000143348623853 0 1 -1
cause,a,clinically 1.0 0.000143348623853 0 1 -1
causative,factors,may 1.0 0.000143348623853 0 1 -1
causally,related,to 1.0 0.000143348623853 0 1 -1
causal,relationship,between 1.0 0.000143348623853 0 1 -1
caucasians,are,so-called 1.0 0.000286697247706 0 2 -2
caucasians,are,so 1.0 0.00043004587156 0 3 -3
caucasian,population,about 1.0 0.000573394495413 0 4 -4
cations,multivitamins,quinolones 1.0 0.000143348623853 0 1 -1
cationic,secretion,are 1.0 0.000143348623853 0 1 -1
category,x,use 1.0 0.000143348623853 0 1 -1
category,c,pegasys 1.0 0.000143348623853 0 1 -1
catecholamines,in,response 1.0 0.000143348623853 0 1 -1
catecholamines,after,withdrawal 1.0 0.000143348623853 0 1 -1
catecholamine,levels,may 1.0 0.000143348623853 0 1 -1
catecholamine,depletor,should 1.0 0.00043004587156 0 3 -3
catechol-o,methyltransferase,comt 1.0 0.000143348623853 0 1 -1
catalyzed,by,xanthine 1.0 0.000286697247706 0 2 -2
catalyzed,by,cytochromes 1.0 0.000143348623853 0 1 -1
catalyzed,by,cytochrome 1.0 0.000286697247706 0 2 -2
cataflam,lodine,indocin 1.0 0.000143348623853 0 1 -1
catabolism,of,k-dependent 1.0 0.000143348623853 0 1 -1
catabolism,has,been 1.0 0.000143348623853 0 1 -1
catabloism,of,k-dependent 1.0 0.000143348623853 0 1 -1
cat,inferior,mesenteric 1.0 0.000143348623853 0 1 -1
castor,oil,ml 1.0 0.000143348623853 0 1 -1
cassette,fully,restored 1.0 0.000143348623853 0 1 -1
caspofungin,is,not 1.0 0.000143348623853 0 1 -1
caspofungin,acetate,is 1.0 0.000143348623853 0 1 -1
caspase-3,inhibitor,added 1.0 0.000143348623853 0 1 -1
caspase-3,and,induction 1.0 0.000143348623853 0 1 -1
caspase-3,activity,was 1.0 0.000143348623853 0 1 -1
cases,your,doctor 1.0 0.000143348623853 0 1 -1
cases,with,potential 1.0 0.000143348623853 0 1 -1
cases,where,serious 1.0 0.000143348623853 0 1 -1
cases,was,misused 1.0 0.000143348623853 0 1 -1
cases,two,were 1.0 0.000143348623853 0 1 -1
cases,two,different 1.0 0.000143348623853 0 1 -1
cases,therefore,more 1.0 0.000143348623853 0 1 -1
cases,the,unbound 1.0 0.000143348623853 0 1 -1
cases,the,onset 1.0 0.000143348623853 0 1 -1
cases,should,be 1.0 0.000143348623853 0 1 -1
cases,presented,with 1.0 0.000143348623853 0 1 -1
cases,of,serious 1.0 0.000286697247706 0 2 -2
cases,of,rhabdomyolysis 1.0 0.000286697247706 0 2 -2
cases,of,medical 1.0 0.000143348623853 0 1 -1
cases,of,hyperpyrexia 1.0 0.000143348623853 0 1 -1
cases,of,elevated 1.0 0.000143348623853 0 1 -1
cases,of,diabetes 1.0 0.000286697247706 0 2 -2
cases,of,combined 1.0 0.000143348623853 0 1 -1
cases,of,collapse 1.0 0.000143348623853 0 1 -1
cases,of,a 1.0 0.000143348623853 0 1 -1
cases,occurred,between 1.0 0.000143348623853 0 1 -1
cases,it,was 1.0 0.000143348623853 0 1 -1
cases,is,warranted 1.0 0.000143348623853 0 1 -1
cases,from,spontaneous 1.0 0.000143348623853 0 1 -1
cases,approximately,case 1.0 0.000143348623853 0 1 -1
cases,and,this 1.0 0.000143348623853 0 1 -1
case,were,the 1.0 0.000143348623853 0 1 -1
case,to,maintain 1.0 0.000143348623853 0 1 -1
case,the,peripheral 1.0 0.000143348623853 0 1 -1
case,summary,a 1.0 0.000143348623853 0 1 -1
case,reports,indicates 1.0 0.000143348623853 0 1 -1
case,reports,and 1.0 0.000143348623853 0 1 -1
case,per,patients 1.0 0.000143348623853 0 1 -1
case,of,serum 1.0 0.000143348623853 0 1 -1
case,of,rhabdomyolysis 1.0 0.000143348623853 0 1 -1
case,of,other 1.0 0.000143348623853 0 1 -1
case,of,medical 1.0 0.000143348623853 0 1 -1
case,of,interference 1.0 0.000143348623853 0 1 -1
case,in,which 1.0 0.000143348623853 0 1 -1
cascade,impactor,for 1.0 0.000143348623853 0 1 -1
cas,a,kda 1.0 0.000143348623853 0 1 -1
carrying,out,tests 1.0 0.000286697247706 0 2 -2
carrier,density,in 1.0 0.000143348623853 0 1 -1
carried,out,with 1.0 0.000143348623853 0 1 -1
carried,out,two 1.0 0.000143348623853 0 1 -1
carried,out,to 1.0 0.000143348623853 0 1 -1
carried,out,studies 1.0 0.000143348623853 0 1 -1
carried,out,mainly 1.0 0.000143348623853 0 1 -1
carried,out,in 1.0 0.000286697247706 0 2 -2
carried,out,during 1.0 0.000143348623853 0 1 -1
carried,out,as 1.0 0.000143348623853 0 1 -1
carried,out,and 1.0 0.000143348623853 0 1 -1
carpophores,of,ganoderma 1.0 0.000143348623853 0 1 -1
carotid,cannulation,decreased 1.0 0.000143348623853 0 1 -1
carefully,monitored,see 1.0 0.000143348623853 0 1 -1
carefully,monitored,especially 1.0 0.000143348623853 0 1 -1
carefully,in,order 1.0 0.000143348623853 0 1 -1
carefully,and,in 1.0 0.000143348623853 0 1 -1
carefully,about,and 1.0 0.000143348623853 0 1 -1
careful,titration,should 1.0 0.000143348623853 0 1 -1
careful,titration,are 1.0 0.000143348623853 0 1 -1
careful,tapering,of 1.0 0.000143348623853 0 1 -1
careful,supervision,of 1.0 0.000143348623853 0 1 -1
cared,for,in 1.0 0.000143348623853 0 1 -1
care,units,with 1.0 0.000143348623853 0 1 -1
care,providers,are 1.0 0.000143348623853 0 1 -1
care,professionals,be 1.0 0.000143348623853 0 1 -1
care,is,required 1.0 0.000143348623853 0 1 -1
care,in,the 1.0 0.000143348623853 0 1 -1
care,and,observation 1.0 0.000143348623853 0 1 -1
cards,mac,of 1.0 0.000143348623853 0 1 -1
cardiovasculars,cardiac,glycosides 1.0 0.000143348623853 0 1 -1
cardiovascular,system,have 1.0 0.000143348623853 0 1 -1
cardiovascular,status,at 1.0 0.000143348623853 0 1 -1
cardiovascular,safety,of 1.0 0.000143348623853 0 1 -1
cardiovascular,risk,than 1.0 0.000143348623853 0 1 -1
cardiovascular,morbidity,and 1.0 0.000143348623853 0 1 -1
cardiovascular,in,patients 1.0 0.000143348623853 0 1 -1
cardiovascular,hypotension,bradycardia 1.0 0.000143348623853 0 1 -1
cardiovascular,effects,such 1.0 0.000143348623853 0 1 -1
cardiovascular,effects,of 1.0 0.000143348623853 0 1 -1
cardiovascular,effects,can 1.0 0.000286697247706 0 2 -2
cardiovascular,disease,morbidity 1.0 0.000143348623853 0 1 -1
cardiovascular,disease,is 1.0 0.000286697247706 0 2 -2
cardiovascular,disease,in 1.0 0.000143348623853 0 1 -1
cardiovascular,disease,erectile 1.0 0.000143348623853 0 1 -1
cardiovascular,disease,are 1.0 0.000143348623853 0 1 -1
cardiovascular,directly,affect 1.0 0.000143348623853 0 1 -1
cardiovascular,depression,and 1.0 0.000143348623853 0 1 -1
cardiovascular,concurrently,with 1.0 0.000143348623853 0 1 -1
cardiovascular,collapse,in 1.0 0.000286697247706 0 2 -2
cardiovascular,are,also 1.0 0.000143348623853 0 1 -1
cardiovascular,and,identifies 1.0 0.000143348623853 0 1 -1
cardiovascular,agents,enalapril 1.0 0.000143348623853 0 1 -1
cardiovascular,adverse,events 1.0 0.000143348623853 0 1 -1
cardiotoxicity,associated,with 1.0 0.000143348623853 0 1 -1
cardioselective,could,be 1.0 0.000143348623853 0 1 -1
cardiopulmonary,stimulation,is 1.0 0.000143348623853 0 1 -1
cardiopulmonary,arrest,with 1.0 0.000143348623853 0 1 -1
cardioplegic,solutions,and 1.0 0.000143348623853 0 1 -1
cardioactive,or,cerebroactive 1.0 0.000143348623853 0 1 -1
cardioactive,drugs,such 1.0 0.000143348623853 0 1 -1
cardiac,two,hepatic 1.0 0.000143348623853 0 1 -1
cardiac,preparations,and 1.0 0.000143348623853 0 1 -1
cardiac,patients,does 1.0 0.000143348623853 0 1 -1
cardiac,monitoring,is 1.0 0.000143348623853 0 1 -1
cardiac,h2,antagonists 1.0 0.000143348623853 0 1 -1
cardiac,glycosides,inducers 1.0 0.000143348623853 0 1 -1
cardiac,glycosides,in 1.0 0.000286697247706 0 2 -2
cardiac,function,simultaneous 1.0 0.000143348623853 0 1 -1
cardiac,function,should 1.0 0.000143348623853 0 1 -1
cardiac,deaths,three 1.0 0.000143348623853 0 1 -1
cardiac,contractility,and 1.0 0.000143348623853 0 1 -1
cardiac,conduction,abnormalities 1.0 0.000143348623853 0 1 -1
cardiac,channel,blockers 1.0 0.000143348623853 0 1 -1
cardiac,capacity,should 1.0 0.000143348623853 0 1 -1
cardiac,arrhythmias,in 1.0 0.000143348623853 0 1 -1
cardiac,arrests,have 1.0 0.000143348623853 0 1 -1
cardiac,arrest,torsades 1.0 0.000143348623853 0 1 -1
cardiac,arrest,during 1.0 0.000143348623853 0 1 -1
cardiac,and,systemic 1.0 0.000143348623853 0 1 -1
cardiac,and,others 1.0 0.000143348623853 0 1 -1
cardiac,and,coronary 1.0 0.000143348623853 0 1 -1
carcinogenicity,study,at 1.0 0.000143348623853 0 1 -1
carcinogenicity,studies,have 1.0 0.000143348623853 0 1 -1
carcinogenicity,or,fertility 1.0 0.000143348623853 0 1 -1
carcinogenic,potential,of 1.0 0.000286697247706 0 2 -2
carcinogenesis,study,was 1.0 0.000143348623853 0 1 -1
carcinogenesis,pegasys,has 1.0 0.000143348623853 0 1 -1
carcinogenesis,mutagenesis,impairment 1.0 0.000286697247706 0 2 -2
carcinogenesis,mutagenesis,and 1.0 0.000143348623853 0 1 -1
carcinogenesis,by,or 1.0 0.000143348623853 0 1 -1
carcinogen,may,depend 1.0 0.000143348623853 0 1 -1
carcinogen,can,induce 1.0 0.000143348623853 0 1 -1
carboxymethylcellulose,nacmc,and 1.0 0.000143348623853 0 1 -1
carboxymethylcellulose,in,vitro 1.0 0.000143348623853 0 1 -1
carbonate,mg,bid 1.0 0.000143348623853 0 1 -1
carbohydrate,metabolism,and 1.0 0.000143348623853 0 1 -1
carbidopa-levodopa,combination,products 1.0 0.000143348623853 0 1 -1
carbidopa,given,with 1.0 0.000143348623853 0 1 -1
carbamazepine,tiagabine,had 1.0 0.000143348623853 0 1 -1
carbamazepine,steady-state,trough 1.0 0.000143348623853 0 1 -1
carbamazepine,overdose,recognized 1.0 0.000143348623853 0 1 -1
carbamazepine,is,not 1.0 0.000143348623853 0 1 -1
carbamazepine,is,metabolized 1.0 0.000286697247706 0 2 -2
carbamazepine,is,known 1.0 0.000143348623853 0 1 -1
carbamazepine,has,been 1.0 0.000143348623853 0 1 -1
carbamazepine,epoxide,steady-state 1.0 0.000143348623853 0 1 -1
carbamazepine,due,to 1.0 0.000143348623853 0 1 -1
carbamazepine,combined,administration 1.0 0.000143348623853 0 1 -1
car,or,operating 1.0 0.000143348623853 0 1 -1
captopril-digoxin,interaction,could 1.0 0.000143348623853 0 1 -1
captopril,may,cause 1.0 0.000143348623853 0 1 -1
capsules,with,the 1.0 0.000143348623853 0 1 -1
capsules,twice,daily 1.0 0.000143348623853 0 1 -1
capsules,should,not 1.0 0.000143348623853 0 1 -1
capsules,mg,tid 1.0 0.000143348623853 0 1 -1
capsules,garlic,capsules 1.0 0.000143348623853 0 1 -1
capsules,at,the 1.0 0.000143348623853 0 1 -1
capsule,twice,daily 1.0 0.000143348623853 0 1 -1
capacity,to,function 1.0 0.000143348623853 0 1 -1
capacity,should,be 1.0 0.000143348623853 0 1 -1
capacity,for,triacylglycerol 1.0 0.000143348623853 0 1 -1
capable,of,producing 1.0 0.000143348623853 0 1 -1
capable,of,metabolizing 1.0 0.000143348623853 0 1 -1
capable,of,inducing 1.0 0.000143348623853 0 1 -1
cannulation,decreased,along 1.0 0.000143348623853 0 1 -1
cannot,be,used 1.0 0.000143348623853 0 1 -1
cannot,be,taken 1.0 0.000143348623853 0 1 -1
cannot,be,further 1.0 0.000143348623853 0 1 -1
cannot,be,excluded 1.0 0.000143348623853 0 1 -1
cannot,be,avoided 1.0 0.000143348623853 0 1 -1
cannot,be,advocated 1.0 0.000143348623853 0 1 -1
candida,albicans,one 1.0 0.000143348623853 0 1 -1
candesartan,cilexetil,given 1.0 0.000143348623853 0 1 -1
cancidas,has,no 1.0 0.000143348623853 0 1 -1
cancidas,did,not 1.0 0.000143348623853 0 1 -1
cancidas,are,not 1.0 0.000143348623853 0 1 -1
cancers,were,investigated 1.0 0.000143348623853 0 1 -1
cancers,it,significantly 1.0 0.000143348623853 0 1 -1
cancer,were,given 1.0 0.000143348623853 0 1 -1
cancer,res,have 1.0 0.000143348623853 0 1 -1
cancer,recurrence,relative 1.0 0.000143348623853 0 1 -1
cancer,metastasis,to 1.0 0.000143348623853 0 1 -1
cancer,metastasis,through 1.0 0.000143348623853 0 1 -1
cancer,increases,progressively 1.0 0.000143348623853 0 1 -1
cancer,in,the 1.0 0.000143348623853 0 1 -1
cancer,diabetes,mellitus 1.0 0.000143348623853 0 1 -1
cancer,center,italy 1.0 0.000143348623853 0 1 -1
cancer,cells,including 1.0 0.000143348623853 0 1 -1
cancer,cells,in 1.0 0.000143348623853 0 1 -1
cancer,cell,growth 1.0 0.000143348623853 0 1 -1
can,then,be 1.0 0.000143348623853 0 1 -1
can,the,therapeutic 1.0 0.000143348623853 0 1 -1
can,take,to 1.0 0.000143348623853 0 1 -1
can,speed-up,this 1.0 0.000143348623853 0 1 -1
can,significantly,reduce 1.0 0.000143348623853 0 1 -1
can,prolong,bleeding 1.0 0.000143348623853 0 1 -1
can,progress,very 1.0 0.000143348623853 0 1 -1
can,prevent,or 1.0 0.000143348623853 0 1 -1
can,potentially,lead 1.0 0.000143348623853 0 1 -1
can,only,be 1.0 0.000143348623853 0 1 -1
can,occur,sometimes 1.0 0.000286697247706 0 2 -2
can,occur,in 1.0 0.000143348623853 0 1 -1
can,inhibit,cytochrome 1.0 0.000716743119266 0 5 -5
can,inhibit,cyp2c19 1.0 0.000143348623853 0 1 -1
can,induce,early 1.0 0.000143348623853 0 1 -1
can,increase,plasma 1.0 0.000143348623853 0 1 -1
can,in,rare 1.0 0.000143348623853 0 1 -1
can,have,a 1.0 0.000143348623853 0 1 -1
can,give,you 1.0 0.000143348623853 0 1 -1
can,give,a 1.0 0.000143348623853 0 1 -1
can,generally,be 1.0 0.000143348623853 0 1 -1
can,exert,additive 1.0 0.000143348623853 0 1 -1
can,exaggerate,the 1.0 0.000143348623853 0 1 -1
can,enhance,toxicity 1.0 0.000143348623853 0 1 -1
can,either,mask 1.0 0.000143348623853 0 1 -1
can,do,to 1.0 0.000143348623853 0 1 -1
can,decrease,the 1.0 0.000143348623853 0 1 -1
can,correct,the 1.0 0.000143348623853 0 1 -1
can,continue,to 1.0 0.000143348623853 0 1 -1
can,cause,myopathy 1.0 0.000286697247706 0 2 -2
can,cause,k 1.0 0.000143348623853 0 1 -1
can,cause,in 1.0 0.000143348623853 0 1 -1
can,cause,hypothyroidism 1.0 0.000143348623853 0 1 -1
can,cause,headaches 1.0 0.000286697247706 0 2 -2
can,blunt,the 1.0 0.000143348623853 0 1 -1
can,be,significantly 1.0 0.000143348623853 0 1 -1
can,be,seen 1.0 0.000143348623853 0 1 -1
can,be,safely 1.0 0.000143348623853 0 1 -1
can,be,rationalized 1.0 0.000143348623853 0 1 -1
can,be,monitored 1.0 0.000143348623853 0 1 -1
can,be,mimicked 1.0 0.000143348623853 0 1 -1
can,be,initiated 1.0 0.000143348623853 0 1 -1
can,be,induced 1.0 0.000143348623853 0 1 -1
can,be,given 1.0 0.000143348623853 0 1 -1
can,be,expressed 1.0 0.000143348623853 0 1 -1
can,be,explained 1.0 0.000143348623853 0 1 -1
can,be,expected 1.0 0.000143348623853 0 1 -1
can,be,employed 1.0 0.000143348623853 0 1 -1
can,be,effectively 1.0 0.000143348623853 0 1 -1
can,be,dispersed 1.0 0.000143348623853 0 1 -1
can,be,detected 1.0 0.000143348623853 0 1 -1
can,be,carried 1.0 0.000143348623853 0 1 -1
can,be,associated 1.0 0.000143348623853 0 1 -1
can,be,applied 1.0 0.000143348623853 0 1 -1
can,be,administered 1.0 0.00043004587156 0 3 -3
can,be,achieved 1.0 0.000143348623853 0 1 -1
can,affect,the 1.0 0.00043004587156 0 3 -3
camptosar,with,irradiation 1.0 0.000143348623853 0 1 -1
campath,may,interfere 1.0 0.000143348623853 0 1 -1
camp,in,parietal 1.0 0.000143348623853 0 1 -1
calorimetry,differential,thermal 1.0 0.000143348623853 0 1 -1
call,that,is 1.0 0.000143348623853 0 1 -1
calculi,the,experience 1.0 0.000143348623853 0 1 -1
calculated,clearance,ranged 1.0 0.000143348623853 0 1 -1
calculated,by,the 1.0 0.000143348623853 0 1 -1
calcium-entry,blocking,agents 1.0 0.000143348623853 0 1 -1
calcium-containing,preparations,should 1.0 0.00043004587156 0 3 -3
calcium-containing,medicines,including 1.0 0.000143348623853 0 1 -1
calcium-channel,blocking,agents 1.0 0.000143348623853 0 1 -1
calcium-channel,blockers,on 1.0 0.000143348623853 0 1 -1
calcium-channel,blockers,cardiac 1.0 0.000143348623853 0 1 -1
calcium-channel,blockers,and 1.0 0.000143348623853 0 1 -1
calcium-blocking,agents,and 1.0 0.000143348623853 0 1 -1
calcium,supplements,uncontrolled 1.0 0.00043004587156 0 3 -3
calcium,particularly,if 1.0 0.000143348623853 0 1 -1
calcium,channel,blocking 1.0 0.000286697247706 0 2 -2
calcium,channel,antagonists 1.0 0.000143348623853 0 1 -1
caffeine,two,hundred 1.0 0.000143348623853 0 1 -1
cadmium,mixtures,at 1.0 0.000286697247706 0 2 -2
cadmium,and,to 1.0 0.000286697247706 0 2 -2
cadmium,and,had 1.0 0.000143348623853 0 1 -1
cadmium,and,cadmium 1.0 0.000286697247706 0 2 -2
ca,subtypes,by 1.0 0.000143348623853 0 1 -1
ca,store,and 1.0 0.000143348623853 0 1 -1
ca,release,by 1.0 0.000143348623853 0 1 -1
ca,i,and 1.0 0.000143348623853 0 1 -1
ca,currents,in 1.0 0.000143348623853 0 1 -1
ca,currents,discriminates 1.0 0.000143348623853 0 1 -1
ca,channels,in 1.0 0.000143348623853 0 1 -1
ca,channel,subtypes 1.0 0.00043004587156 0 3 -3
ca,channel,blockers 1.0 0.000143348623853 0 1 -1
ca,and,to 1.0 0.000143348623853 0 1 -1
c9,with,glucuronidation 1.0 0.000143348623853 0 1 -1
c9,should,be 1.0 0.000143348623853 0 1 -1
c9,respectively,have 1.0 0.000143348623853 0 1 -1
c9,ic50,g 1.0 0.000143348623853 0 1 -1
c9,human,hepatic 1.0 0.000143348623853 0 1 -1
c9,have,not 1.0 0.000143348623853 0 1 -1
c9,d6,e1 1.0 0.000143348623853 0 1 -1
c9,cyp,c19 1.0 0.000143348623853 0 1 -1
c9,c19,e1 1.0 0.000143348623853 0 1 -1
c9,c19,d6 1.0 0.000860091743119 0 6 -6
c9,c19,and 1.0 0.000143348623853 0 1 -1
c9,and,not 1.0 0.000143348623853 0 1 -1
c9,and,cyp 1.0 0.000143348623853 0 1 -1
c8,c9,c19 1.0 0.000143348623853 0 1 -1
c8,and,a4 1.0 0.000143348623853 0 1 -1
c57bl,n,x 1.0 0.000143348623853 0 1 -1
c57bl,n,was 1.0 0.000143348623853 0 1 -1
c57bl,n,demonstrated 1.0 0.000143348623853 0 1 -1
c3h,hen,f1 1.0 0.000143348623853 0 1 -1
c23,in,nih-3t3 1.0 0.000143348623853 0 1 -1
c23,down-regulation,of 1.0 0.000143348623853 0 1 -1
c19,the,enzymes 1.0 0.000143348623853 0 1 -1
c19,inhibitors,in 1.0 0.000143348623853 0 1 -1
c19,ic50,g 1.0 0.000143348623853 0 1 -1
c19,d6,e1 1.0 0.000573394495413 0 4 -4
c19,d6,a4 1.0 0.000286697247706 0 2 -2
c19,cyp,d6 1.0 0.000143348623853 0 1 -1
c19,are,the 1.0 0.000143348623853 0 1 -1
c19,and,a4 1.0 0.000143348623853 0 1 -1
c129h223n3o54,isolated,from 1.0 0.000143348623853 0 1 -1
c-cholesteryl,oleate,and 1.0 0.000143348623853 0 1 -1
c-cholesterol,ester,fractional 1.0 0.000143348623853 0 1 -1
c-17,alkylated,such 1.0 0.000143348623853 0 1 -1
c,up,to 1.0 0.000143348623853 0 1 -1
c,treated,with 1.0 0.000143348623853 0 1 -1
c,the,non-myelinated 1.0 0.000143348623853 0 1 -1
c,pegasys,has 1.0 0.000143348623853 0 1 -1
c,or,calmodulin 1.0 0.000143348623853 0 1 -1
c,min,or 1.0 0.000143348623853 0 1 -1
c,max,were 1.0 0.000143348623853 0 1 -1
c,max,t 1.0 0.000143348623853 0 1 -1
c,max,or 1.0 0.000286697247706 0 2 -2
c,max,increased 1.0 0.000143348623853 0 1 -1
c,max,c 1.0 0.000143348623853 0 1 -1
c,max,auc 1.0 0.000143348623853 0 1 -1
c,max,and 1.0 0.000143348623853 0 1 -1
c,interval,were 1.0 0.000143348623853 0 1 -1
c,human,ventricular 1.0 0.000143348623853 0 1 -1
c,has,not 1.0 0.000143348623853 0 1 -1
c,for,h 1.0 0.000143348623853 0 1 -1
c,drug,interactions 1.0 0.000143348623853 0 1 -1
c,diethyl,pyrocarbonate 1.0 0.000143348623853 0 1 -1
by,xanthine,oxidase 1.0 0.000143348623853 0 1 -1
by,which,could 1.0 0.000143348623853 0 1 -1
by,when,extended 1.0 0.000143348623853 0 1 -1
by,using,rat 1.0 0.000143348623853 0 1 -1
by,using,more 1.0 0.000143348623853 0 1 -1
by,using,four 1.0 0.000143348623853 0 1 -1
by,users,of 1.0 0.000286697247706 0 2 -2
by,use,of 1.0 0.000143348623853 0 1 -1
by,to,several 1.0 0.000143348623853 0 1 -1
by,to,g 1.0 0.000143348623853 0 1 -1
by,to,but 1.0 0.000143348623853 0 1 -1
by,thyroxine-binding,prealbumin 1.0 0.000143348623853 0 1 -1
by,through,the 1.0 0.000143348623853 0 1 -1
by,those,enzymes 1.0 0.000143348623853 0 1 -1
by,this,procedure 1.0 0.000143348623853 0 1 -1
by,this,enzyme 1.0 0.00043004587156 0 3 -3
by,this,class 1.0 0.000143348623853 0 1 -1
by,these,two 1.0 0.000143348623853 0 1 -1
by,these,isozymes 1.0 0.000143348623853 0 1 -1
by,these,enzyme 1.0 0.000143348623853 0 1 -1
by,these,cyp 1.0 0.000143348623853 0 1 -1
by,therapy,can 1.0 0.000143348623853 0 1 -1
by,therapeutic,monitoring 1.0 0.000143348623853 0 1 -1
by,their,relative 1.0 0.000143348623853 0 1 -1
by,the,was 1.0 0.000143348623853 0 1 -1
by,the,use 1.0 0.000143348623853 0 1 -1
by,the,us 1.0 0.000143348623853 0 1 -1
by,the,stimulant 1.0 0.000143348623853 0 1 -1
by,the,slow 1.0 0.000143348623853 0 1 -1
by,the,same 1.0 0.000286697247706 0 2 -2
by,the,reduction 1.0 0.00043004587156 0 3 -3
by,the,presence 1.0 0.000286697247706 0 2 -2
by,the,prescriber 1.0 0.000143348623853 0 1 -1
by,the,porter-silber 1.0 0.000143348623853 0 1 -1
by,the,plasma 1.0 0.000143348623853 0 1 -1
by,the,pathway 1.0 0.000143348623853 0 1 -1
by,the,oral 1.0 0.000143348623853 0 1 -1
by,the,nonlinear 1.0 0.000143348623853 0 1 -1
by,the,major 1.0 0.000143348623853 0 1 -1
by,the,liver 1.0 0.000286697247706 0 2 -2
by,the,lectin 1.0 0.000143348623853 0 1 -1
by,the,leakage 1.0 0.000143348623853 0 1 -1
by,the,lack 1.0 0.000143348623853 0 1 -1
by,the,kidneys 1.0 0.000143348623853 0 1 -1
by,the,kidney 1.0 0.000143348623853 0 1 -1
by,the,jaffe 1.0 0.000143348623853 0 1 -1
by,the,jaff 1.0 0.000143348623853 0 1 -1
by,the,intravenous 1.0 0.000143348623853 0 1 -1
by,the,hepatic 1.0 0.000143348623853 0 1 -1
by,the,glucosylation 1.0 0.000143348623853 0 1 -1
by,the,following 1.0 0.000286697247706 0 2 -2
by,the,enteric 1.0 0.000143348623853 0 1 -1
by,the,elevation 1.0 0.000143348623853 0 1 -1
by,the,effects 1.0 0.000143348623853 0 1 -1
by,the,dermatologist 1.0 0.000143348623853 0 1 -1
by,the,dependence 1.0 0.000143348623853 0 1 -1
by,the,cyp3a4 1.0 0.000143348623853 0 1 -1
by,the,cyp2d6 1.0 0.000143348623853 0 1 -1
by,the,comparative 1.0 0.000143348623853 0 1 -1
by,the,coadministration 1.0 0.000286697247706 0 2 -2
by,the,clinical 1.0 0.000143348623853 0 1 -1
by,the,balance 1.0 0.000143348623853 0 1 -1
by,the,at 1.0 0.000143348623853 0 1 -1
by,the,antioxidative 1.0 0.000143348623853 0 1 -1
by,the,alveoli 1.0 0.000143348623853 0 1 -1
by,the,alkaline 1.0 0.000143348623853 0 1 -1
by,the,activation 1.0 0.000143348623853 0 1 -1
by,the,accumulation 1.0 0.000143348623853 0 1 -1
by,suggest,that 1.0 0.000143348623853 0 1 -1
by,such,without 1.0 0.000143348623853 0 1 -1
by,such,factors 1.0 0.000143348623853 0 1 -1
by,such,an 1.0 0.000143348623853 0 1 -1
by,stimulating,the 1.0 0.000143348623853 0 1 -1
by,some,of 1.0 0.000143348623853 0 1 -1
by,sodium,should 1.0 0.000143348623853 0 1 -1
by,sodium,following 1.0 0.000143348623853 0 1 -1
by,six,typical 1.0 0.000143348623853 0 1 -1
by,single,dose 1.0 0.000143348623853 0 1 -1
by,simply,normalizing 1.0 0.000143348623853 0 1 -1
by,similar,personality 1.0 0.000143348623853 0 1 -1
by,serum,deprivation 1.0 0.000143348623853 0 1 -1
by,serial,broth 1.0 0.000143348623853 0 1 -1
by,separate,brain 1.0 0.000143348623853 0 1 -1
by,self-injection,of 1.0 0.000143348623853 0 1 -1
by,selective,agonists 1.0 0.000143348623853 0 1 -1
by,resecting,the 1.0 0.000143348623853 0 1 -1
by,repeated,challenge 1.0 0.000143348623853 0 1 -1
by,reductions,in 1.0 0.000143348623853 0 1 -1
by,reaction,with 1.0 0.000143348623853 0 1 -1
by,rats,treated 1.0 0.000143348623853 0 1 -1
by,radioimmunoassay,or 1.0 0.000286697247706 0 2 -2
by,qtc,increase 1.0 0.000286697247706 0 2 -2
by,prothrombin,time 1.0 0.000143348623853 0 1 -1
by,protein-bound,pbi 1.0 0.000286697247706 0 2 -2
by,protein-binding,displacement 1.0 0.000143348623853 0 1 -1
by,profound,collapse 1.0 0.000143348623853 0 1 -1
by,platelets,plays 1.0 0.000143348623853 0 1 -1
by,plate,counts 1.0 0.000143348623853 0 1 -1
by,perivascular,hemorrhages 1.0 0.000143348623853 0 1 -1
by,peripheral,vasospasm 1.0 0.000286697247706 0 2 -2
by,peptidase,and 1.0 0.000143348623853 0 1 -1
by,pbi,t4 1.0 0.000286697247706 0 2 -2
by,patients,receiving 1.0 0.000143348623853 0 1 -1
by,p450iid6,a 1.0 0.000143348623853 0 1 -1
by,p450,d6 1.0 0.00143348623853 0 10 -10
by,p450,c9 1.0 0.000143348623853 0 1 -1
by,oxc,and 1.0 0.000286697247706 0 2 -2
by,overcoming,tumor 1.0 0.000143348623853 0 1 -1
by,other,manufacturers 1.0 0.000143348623853 0 1 -1
by,or,salicylic 1.0 0.000143348623853 0 1 -1
by,or,on 1.0 0.000143348623853 0 1 -1
by,or,inhibit 1.0 0.000143348623853 0 1 -1
by,one-third,when 1.0 0.000143348623853 0 1 -1
by,one-third,to 1.0 0.000143348623853 0 1 -1
by,one-half,depending 1.0 0.000143348623853 0 1 -1
by,one,or 1.0 0.000143348623853 0 1 -1
by,observations,now 1.0 0.000143348623853 0 1 -1
by,nor,inhibits 1.0 0.000143348623853 0 1 -1
by,nonlethal,mg 1.0 0.000143348623853 0 1 -1
by,multiple,enzyme 1.0 0.000143348623853 0 1 -1
by,multiple,cytochrome 1.0 0.000143348623853 0 1 -1
by,mug,or 1.0 0.000286697247706 0 2 -2
by,mu-,delta 1.0 0.000143348623853 0 1 -1
by,mouth,or 1.0 0.000143348623853 0 1 -1
by,monitoring,and 1.0 0.000143348623853 0 1 -1
by,minimally,elevated 1.0 0.000143348623853 0 1 -1
by,minimal,inhibitory 1.0 0.000143348623853 0 1 -1
by,millions,of 1.0 0.000143348623853 0 1 -1
by,mg,once 1.0 0.000143348623853 0 1 -1
by,meth,has 1.0 0.000143348623853 0 1 -1
by,measuring,serum 1.0 0.000143348623853 0 1 -1
by,measuring,locomotor 1.0 0.000143348623853 0 1 -1
by,lesions,of 1.0 0.000143348623853 0 1 -1
by,known,to 1.0 0.000143348623853 0 1 -1
by,jaffe,reaction 1.0 0.000143348623853 0 1 -1
by,is,expected 1.0 0.000143348623853 0 1 -1
by,intraventricular,and 1.0 0.000286697247706 0 2 -2
by,intrathecal,on 1.0 0.000143348623853 0 1 -1
by,injection,medicine 1.0 0.000143348623853 0 1 -1
by,infusion,to 1.0 0.000143348623853 0 1 -1
by,infusion,in 1.0 0.000143348623853 0 1 -1
by,induction,data 1.0 0.000143348623853 0 1 -1
by,indicating,no 1.0 0.000143348623853 0 1 -1
by,increasing,metal 1.0 0.000143348623853 0 1 -1
by,increased,susceptibility 1.0 0.000143348623853 0 1 -1
by,increased,serum 1.0 0.000143348623853 0 1 -1
by,increased,catabloism 1.0 0.000143348623853 0 1 -1
by,in,combination 1.0 0.000143348623853 0 1 -1
by,in,bovine 1.0 0.000143348623853 0 1 -1
by,hours,or 1.0 0.000143348623853 0 1 -1
by,his,her 1.0 0.000143348623853 0 1 -1
by,hippocampal,lesions 1.0 0.000143348623853 0 1 -1
by,hepatic,cytochrome 1.0 0.000143348623853 0 1 -1
by,gram-negative,organisms 1.0 0.000143348623853 0 1 -1
by,gradually,decreasing 1.0 0.000143348623853 0 1 -1
by,glucuronidation,is 1.0 0.000143348623853 0 1 -1
by,general,local 1.0 0.000143348623853 0 1 -1
by,forming,a 1.0 0.000143348623853 0 1 -1
by,flushing,rash 1.0 0.000143348623853 0 1 -1
by,fluorimetric,or 1.0 0.000143348623853 0 1 -1
by,factors,of 1.0 0.000143348623853 0 1 -1
by,ex,vivo 1.0 0.000143348623853 0 1 -1
by,evaluating,the 1.0 0.000143348623853 0 1 -1
by,ergosterol,the 1.0 0.000143348623853 0 1 -1
by,enhanced,absorption 1.0 0.000143348623853 0 1 -1
by,endothelial,dysfunction 1.0 0.000143348623853 0 1 -1
by,endothelial,denudation 1.0 0.000143348623853 0 1 -1
by,electrocardiographic,parameters 1.0 0.000286697247706 0 2 -2
by,either,mg 1.0 0.000143348623853 0 1 -1
by,either,alpha- 1.0 0.000143348623853 0 1 -1
by,effects,on 1.0 0.000143348623853 0 1 -1
by,ecg,changes 1.0 0.000143348623853 0 1 -1
by,during,this 1.0 0.000143348623853 0 1 -1
by,during,august 1.0 0.000143348623853 0 1 -1
by,dmpge2,given 1.0 0.000143348623853 0 1 -1
by,displacement,from 1.0 0.000143348623853 0 1 -1
by,determination,of 1.0 0.000286697247706 0 2 -2
by,cytochromes,p450 1.0 0.000143348623853 0 1 -1
by,cytochrome,p450iid6 1.0 0.000286697247706 0 2 -2
by,cytochrome,p4502d6 1.0 0.000143348623853 0 1 -1
by,cyp3a4,substrates 1.0 0.000143348623853 0 1 -1
by,cyp3a4,may 1.0 0.000143348623853 0 1 -1
by,cyp3a4,but 1.0 0.000143348623853 0 1 -1
by,cyp3a4,as 1.0 0.000143348623853 0 1 -1
by,cyp3a4,and 1.0 0.000286697247706 0 2 -2
by,cyp3a,results 1.0 0.000143348623853 0 1 -1
by,cyp3a,channel 1.0 0.000143348623853 0 1 -1
by,cyp2d6,with 1.0 0.000143348623853 0 1 -1
by,cyp2d6,the 1.0 0.000143348623853 0 1 -1
by,cyp2d6,has 1.0 0.000143348623853 0 1 -1
by,cyp2d6,duloxetine 1.0 0.000143348623853 0 1 -1
by,cyp2d6,cyp2c9 1.0 0.000143348623853 0 1 -1
by,cyp2c9,and 1.0 0.000143348623853 0 1 -1
by,cyp1a2,in 1.0 0.000143348623853 0 1 -1
by,cyp,d6 1.0 0.000143348623853 0 1 -1
by,cyp,c9 1.0 0.000143348623853 0 1 -1
by,cyp,a4 1.0 0.00043004587156 0 3 -3
by,could,affect 1.0 0.000143348623853 0 1 -1
by,contrast,mm 1.0 0.000143348623853 0 1 -1
by,consulting,the 1.0 0.000143348623853 0 1 -1
by,conjugation,through 1.0 0.000143348623853 0 1 -1
by,confidence,limit 1.0 0.000143348623853 0 1 -1
by,confidence,interval 1.0 0.000143348623853 0 1 -1
by,concurrent,dosing 1.0 0.000143348623853 0 1 -1
by,concomitant,therapies 1.0 0.000143348623853 0 1 -1
by,concomitant,in 1.0 0.000143348623853 0 1 -1
by,concentrations,of 1.0 0.000143348623853 0 1 -1
by,column,or 1.0 0.000573394495413 0 4 -4
by,coadministration,with 1.0 0.000143348623853 0 1 -1
by,co-administration,or 1.0 0.000143348623853 0 1 -1
by,co-administration,of 1.0 0.000143348623853 0 1 -1
by,ci,in 1.0 0.000286697247706 0 2 -2
by,cholinergic,stimulation 1.0 0.000143348623853 0 1 -1
by,chloral,hydrate 1.0 0.000143348623853 0 1 -1
by,checkerboard,assay 1.0 0.000143348623853 0 1 -1
by,cerulein--an,analog 1.0 0.000143348623853 0 1 -1
by,cercariae,exposed 1.0 0.000143348623853 0 1 -1
by,catechol-o,methyltransferase 1.0 0.000143348623853 0 1 -1
by,both,a 1.0 0.000143348623853 0 1 -1
by,baseline,use 1.0 0.000143348623853 0 1 -1
by,barton,braunberg 1.0 0.000143348623853 0 1 -1
by,as,much 1.0 0.000143348623853 0 1 -1
by,approximately,to 1.0 0.000143348623853 0 1 -1
by,approximately,or 1.0 0.000143348623853 0 1 -1
by,aom,and 1.0 0.000143348623853 0 1 -1
by,antiresistance,determinant 1.0 0.000143348623853 0 1 -1
by,and,that 1.0 0.000143348623853 0 1 -1
by,and,suppressed 1.0 0.000143348623853 0 1 -1
by,and,cmax 1.0 0.000143348623853 0 1 -1
by,and,clotibrate 1.0 0.000143348623853 0 1 -1
by,and,appears 1.0 0.000143348623853 0 1 -1
by,an,nad 1.0 0.000143348623853 0 1 -1
by,an,elevation 1.0 0.000143348623853 0 1 -1
by,an,effect 1.0 0.000143348623853 0 1 -1
by,an,alteration 1.0 0.000143348623853 0 1 -1
by,alveoli,of 1.0 0.000143348623853 0 1 -1
by,alterations,in 1.0 0.000286697247706 0 2 -2
by,alt,and 1.0 0.000143348623853 0 1 -1
by,agents,used 1.0 0.000143348623853 0 1 -1
by,age,objective 1.0 0.000143348623853 0 1 -1
by,after,to 1.0 0.000143348623853 0 1 -1
by,administration,or 1.0 0.000143348623853 0 1 -1
by,administration,however 1.0 0.000143348623853 0 1 -1
by,adl,and 1.0 0.000143348623853 0 1 -1
by,added,cholesterol 1.0 0.000143348623853 0 1 -1
by,acute,and 1.0 0.000143348623853 0 1 -1
by,active,organic 1.0 0.000143348623853 0 1 -1
by,activation,of 1.0 0.000143348623853 0 1 -1
by,about,three-fold 1.0 0.000143348623853 0 1 -1
by,about,but 1.0 0.000143348623853 0 1 -1
by,a,week 1.0 0.000143348623853 0 1 -1
by,a,variety 1.0 0.000286697247706 0 2 -2
by,a,type 1.0 0.000143348623853 0 1 -1
by,a,nonlethal 1.0 0.000143348623853 0 1 -1
by,a,microdilution 1.0 0.000143348623853 0 1 -1
by,a,liquid 1.0 0.000143348623853 0 1 -1
by,a,increase 1.0 0.000143348623853 0 1 -1
by,a,homodimeric 1.0 0.000143348623853 0 1 -1
by,a,high 1.0 0.000143348623853 0 1 -1
by,a,day 1.0 0.000573394495413 0 4 -4
by,a,combination 1.0 0.000143348623853 0 1 -1
by,a,cascade 1.0 0.000143348623853 0 1 -1
bwt,were,given 1.0 0.000143348623853 0 1 -1
butenafine,hcl,cream 1.0 0.000143348623853 0 1 -1
but,would,be 1.0 0.000143348623853 0 1 -1
but,which,can 1.0 0.000143348623853 0 1 -1
but,was,found 1.0 0.000143348623853 0 1 -1
but,these,changes 1.0 0.000143348623853 0 1 -1
but,there,were 1.0 0.000286697247706 0 2 -2
but,the,rate 1.0 0.000143348623853 0 1 -1
but,the,possibility 1.0 0.000143348623853 0 1 -1
but,the,lst 1.0 0.000143348623853 0 1 -1
but,the,difference 1.0 0.000143348623853 0 1 -1
but,that,the 1.0 0.000143348623853 0 1 -1
but,still,significant 1.0 0.000143348623853 0 1 -1
but,returned,to 1.0 0.000143348623853 0 1 -1
but,regular,users 1.0 0.000143348623853 0 1 -1
but,presumably,to 1.0 0.000143348623853 0 1 -1
but,only,increases 1.0 0.000143348623853 0 1 -1
but,only,at 1.0 0.000286697247706 0 2 -2
but,one,volunteer 1.0 0.000143348623853 0 1 -1
but,not,with 1.0 0.00100344036697 0 7 -7
but,not,under 1.0 0.000143348623853 0 1 -1
but,not,these 1.0 0.000143348623853 0 1 -1
but,not,sufficient 1.0 0.000286697247706 0 2 -2
but,not,on 1.0 0.000143348623853 0 1 -1
but,not,morphine-induced 1.0 0.000143348623853 0 1 -1
but,not,mc 1.0 0.000143348623853 0 1 -1
but,not,at 1.0 0.000143348623853 0 1 -1
but,not,all 1.0 0.000143348623853 0 1 -1
but,no,prolongation 1.0 0.000143348623853 0 1 -1
but,no,effect 1.0 0.000143348623853 0 1 -1
but,nearly,normal 1.0 0.000143348623853 0 1 -1
but,may,represent 1.0 0.000143348623853 0 1 -1
but,ki,values 1.0 0.000143348623853 0 1 -1
but,its,inhibitory 1.0 0.000143348623853 0 1 -1
but,increased,the 1.0 0.000143348623853 0 1 -1
but,increased,effects 1.0 0.000143348623853 0 1 -1
but,in,a 1.0 0.000143348623853 0 1 -1
but,have,no 1.0 0.000143348623853 0 1 -1
but,has,no 1.0 0.000143348623853 0 1 -1
but,had,chemotherapy 1.0 0.000143348623853 0 1 -1
but,had,a 1.0 0.000143348623853 0 1 -1
but,given,the 1.0 0.000143348623853 0 1 -1
but,generally,do 1.0 0.000143348623853 0 1 -1
but,endogenous,secretion 1.0 0.000143348623853 0 1 -1
but,did,produce 1.0 0.000143348623853 0 1 -1
but,definite,nondepolarizing 1.0 0.000143348623853 0 1 -1
but,colony,stimulating 1.0 0.000143348623853 0 1 -1
but,coadministration,of 1.0 0.000143348623853 0 1 -1
but,changes,in 1.0 0.000143348623853 0 1 -1
but,caused,no 1.0 0.000143348623853 0 1 -1
but,can,lead 1.0 0.000143348623853 0 1 -1
but,can,be 1.0 0.000143348623853 0 1 -1
but,available,data 1.0 0.000143348623853 0 1 -1
but,are,relatively 1.0 0.000143348623853 0 1 -1
but,are,not 1.0 0.000286697247706 0 2 -2
but,an,increase 1.0 0.000286697247706 0 2 -2
but,an,active 1.0 0.000143348623853 0 1 -1
but,also,with 1.0 0.000143348623853 0 1 -1
but,also,results 1.0 0.000143348623853 0 1 -1
but,also,on 1.0 0.000143348623853 0 1 -1
but,also,have 1.0 0.000143348623853 0 1 -1
but,also,dyslipidemia 1.0 0.000143348623853 0 1 -1
but,also,across 1.0 0.000143348623853 0 1 -1
but,a,lower 1.0 0.000143348623853 0 1 -1
buprenorphine,is,metabolized 1.0 0.000143348623853 0 1 -1
buforin,ii,showed 1.0 0.000143348623853 0 1 -1
buforin,ii,alone 1.0 0.000286697247706 0 2 -2
buffalo,hump,peripheral 1.0 0.000143348623853 0 1 -1
bsa,when,administered 1.0 0.000286697247706 0 2 -2
bsa,increases,in 1.0 0.000143348623853 0 1 -1
bsa,for,weeks 1.0 0.000143348623853 0 1 -1
bsa,during,the 1.0 0.000143348623853 0 1 -1
bsa,caused,a 1.0 0.000143348623853 0 1 -1
bsa,and,non-ossification 1.0 0.000143348623853 0 1 -1
bruising,nosebleeds,hemoptysis 1.0 0.000143348623853 0 1 -1
brovana,treated,subjects 1.0 0.000286697247706 0 2 -2
brovana,has,not 1.0 0.000143348623853 0 1 -1
brovana,doses,of 1.0 0.000143348623853 0 1 -1
brovana,dose,of 1.0 0.000143348623853 0 1 -1
brovana,at,steady-state 1.0 0.000143348623853 0 1 -1
brovana,are,not 1.0 0.000143348623853 0 1 -1
broth,using,a 1.0 0.000143348623853 0 1 -1
broth,dilution,method 1.0 0.000143348623853 0 1 -1
bronchodilator,effect,of 1.0 0.000143348623853 0 1 -1
broadly,the,same 1.0 0.000143348623853 0 1 -1
broadening,indications,for 1.0 0.000143348623853 0 1 -1
broad-spectrum,antibiotics-broad,spectrum 1.0 0.000143348623853 0 1 -1
broad,spectrum,of 1.0 0.000143348623853 0 1 -1
broad,range,of 1.0 0.000143348623853 0 1 -1
broad,population,of 1.0 0.000143348623853 0 1 -1
bring,latent,complications 1.0 0.000143348623853 0 1 -1
bring,into,question 1.0 0.000143348623853 0 1 -1
briefly,reduced,the 1.0 0.000143348623853 0 1 -1
briefly,exposed,to 1.0 0.000143348623853 0 1 -1
brevibloc,on,the 1.0 0.000143348623853 0 1 -1
brevibloc,esmolol,hcl 1.0 0.000143348623853 0 1 -1
brevibloc,and,showed 1.0 0.000143348623853 0 1 -1
brevibloc,and,does 1.0 0.000143348623853 0 1 -1
bretylium,tosylate,these 1.0 0.000143348623853 0 1 -1
bred,for,differential 1.0 0.000143348623853 0 1 -1
bred,control,rbc 1.0 0.000143348623853 0 1 -1
breath,test,was 1.0 0.000143348623853 0 1 -1
breast,milk,on 1.0 0.000143348623853 0 1 -1
breast,irradiation,was 1.0 0.000143348623853 0 1 -1
breast,feeding,and 1.0 0.000143348623853 0 1 -1
breast,enlargement,and 1.0 0.000143348623853 0 1 -1
breast,cancer,recurrence 1.0 0.000143348623853 0 1 -1
breast,cancer,cell 1.0 0.000143348623853 0 1 -1
breakthrough,bleeding,shortly 1.0 0.000143348623853 0 1 -1
breakthrough,bleeding,has 1.0 0.000143348623853 0 1 -1
breakthrough,bleeding,and 1.0 0.000286697247706 0 2 -2
breakfast,cereals,on 1.0 0.000143348623853 0 1 -1
breadth,of,systemic 1.0 0.000143348623853 0 1 -1
brain,systems,and 1.0 0.000143348623853 0 1 -1
brain,sites,produced 1.0 0.000143348623853 0 1 -1
brain,memory,system 1.0 0.000143348623853 0 1 -1
brain,levels,of 1.0 0.000143348623853 0 1 -1
brain,hemorrhage,was 1.0 0.000143348623853 0 1 -1
brain,hemorrhage,and 1.0 0.000143348623853 0 1 -1
brain,chemical,i 1.0 0.000143348623853 0 1 -1
brain,although,they 1.0 0.000143348623853 0 1 -1
bradycardia,vertigo,syncope 1.0 0.000143348623853 0 1 -1
bradycardia,sinus,arrest 1.0 0.000143348623853 0 1 -1
bradycardia,has,been 1.0 0.000143348623853 0 1 -1
bradycardia,and,hypertension 1.0 0.000143348623853 0 1 -1
bradycardia,and,decreased 1.0 0.000143348623853 0 1 -1
bpm,and,mm 1.0 0.000143348623853 0 1 -1
bph,psa,levels 1.0 0.000143348623853 0 1 -1
bowel,disease,in 1.0 0.000143348623853 0 1 -1
bowel,and,decrease 1.0 0.000143348623853 0 1 -1
bovine,thyroglobulin,in 1.0 0.000143348623853 0 1 -1
bovine,lung,survanta 1.0 0.000143348623853 0 1 -1
bovine,chromaffin,cell 1.0 0.000286697247706 0 2 -2
bound,would,not 1.0 0.000143348623853 0 1 -1
bound,with,narrow 1.0 0.000143348623853 0 1 -1
bound,to,the 1.0 0.000143348623853 0 1 -1
bound,to,plasma 1.0 0.000860091743119 0 6 -6
bound,to,human 1.0 0.000286697247706 0 2 -2
bound,to,albumin 1.0 0.000143348623853 0 1 -1
bound,such,as 1.0 0.000143348623853 0 1 -1
bound,should,not 1.0 0.000286697247706 0 2 -2
bound,like,and 1.0 0.000143348623853 0 1 -1
bound,from,plasma 1.0 0.000143348623853 0 1 -1
bound,drugs,in 1.0 0.000143348623853 0 1 -1
bound,and,this 1.0 0.000143348623853 0 1 -1
botulinum,neurotoxin,serotypes 1.0 0.000286697247706 0 2 -2
both,with,and 1.0 0.000143348623853 0 1 -1
both,which,are 1.0 0.000143348623853 0 1 -1
both,were,thus 1.0 0.000143348623853 0 1 -1
both,to,pressor 1.0 0.000143348623853 0 1 -1
both,tissues,either 1.0 0.000143348623853 0 1 -1
both,therapies,standard 1.0 0.000143348623853 0 1 -1
both,therapeutic,and 1.0 0.000286697247706 0 2 -2
both,the,toxicity 1.0 0.000143348623853 0 1 -1
both,the,r 1.0 0.000143348623853 0 1 -1
both,the,mucosal 1.0 0.000143348623853 0 1 -1
both,the,liver 1.0 0.000143348623853 0 1 -1
both,than,from 1.0 0.000143348623853 0 1 -1
both,steady-state,maximum 1.0 0.000143348623853 0 1 -1
both,should,be 1.0 0.000286697247706 0 2 -2
both,renal,clearance 1.0 0.000143348623853 0 1 -1
both,products,are 1.0 0.000143348623853 0 1 -1
both,possibly,due 1.0 0.000143348623853 0 1 -1
both,plasma,and 1.0 0.000143348623853 0 1 -1
both,periods,with 1.0 0.000143348623853 0 1 -1
both,periods,blood 1.0 0.000143348623853 0 1 -1
both,parental,and 1.0 0.000143348623853 0 1 -1
both,or,its 1.0 0.000143348623853 0 1 -1
both,minimal,inhibitory 1.0 0.000143348623853 0 1 -1
both,mc,and 1.0 0.000143348623853 0 1 -1
both,lean,and 1.0 0.000286697247706 0 2 -2
both,its,therapeutic 1.0 0.000143348623853 0 1 -1
both,its,activity 1.0 0.000143348623853 0 1 -1
both,instances,however 1.0 0.000143348623853 0 1 -1
both,in,vivo 1.0 0.000143348623853 0 1 -1
both,in,the 1.0 0.000143348623853 0 1 -1
both,in,enhancing 1.0 0.000143348623853 0 1 -1
both,in,diabetic 1.0 0.000143348623853 0 1 -1
both,hypo-,and 1.0 0.000143348623853 0 1 -1
both,human,serum 1.0 0.000143348623853 0 1 -1
both,groups,of 1.0 0.00043004587156 0 3 -3
both,groups,ie 1.0 0.000143348623853 0 1 -1
both,ethynyl,and 1.0 0.000143348623853 0 1 -1
both,elements,had 1.0 0.000143348623853 0 1 -1
both,dose,groups 1.0 0.000143348623853 0 1 -1
both,dietary,concentrations 1.0 0.000143348623853 0 1 -1
both,cyp3a4,and 1.0 0.000143348623853 0 1 -1
both,cyp2c9,and 1.0 0.000143348623853 0 1 -1
both,cyp1a2,and 1.0 0.000143348623853 0 1 -1
both,crixivan,and 1.0 0.000143348623853 0 1 -1
both,control,and 1.0 0.000143348623853 0 1 -1
both,compounds,attenuate 1.0 0.000143348623853 0 1 -1
both,chylomicron,lipolysis 1.0 0.000143348623853 0 1 -1
both,at,the 1.0 0.000143348623853 0 1 -1
both,angiotensins,inhibited 1.0 0.000143348623853 0 1 -1
both,and,under 1.0 0.000143348623853 0 1 -1
both,and,organoleads 1.0 0.000143348623853 0 1 -1
both,and,i 1.0 0.000143348623853 0 1 -1
both,and,have 1.0 0.000143348623853 0 1 -1
both,and,after 1.0 0.000286697247706 0 2 -2
both,alone,at 1.0 0.000143348623853 0 1 -1
both,agents,was 1.0 0.000143348623853 0 1 -1
both,agents,should 1.0 0.000860091743119 0 6 -6
both,agents,did 1.0 0.000143348623853 0 1 -1
both,agents,demonstrated 1.0 0.000143348623853 0 1 -1
both,a,substrate 1.0 0.000143348623853 0 1 -1
both,a,potent 1.0 0.000143348623853 0 1 -1
both,a,decrease 1.0 0.000143348623853 0 1 -1
both,a,cyp3a4 1.0 0.000143348623853 0 1 -1
bosentan,is,metabolized 1.0 0.000143348623853 0 1 -1
bosentan,is,an 1.0 0.000143348623853 0 1 -1
bosentan,has,no 1.0 0.000143348623853 0 1 -1
bosentan,had,no 1.0 0.000143348623853 0 1 -1
borderline,statistical,significance 1.0 0.000143348623853 0 1 -1
bones,the,dosage 1.0 0.00043004587156 0 3 -3
bone,scintigraphy,employing 1.0 0.000143348623853 0 1 -1
bone,marrow,megakaryocytes 1.0 0.000143348623853 0 1 -1
bone,marrow,function 1.0 0.000143348623853 0 1 -1
bone,marrow,erythrocytes 1.0 0.000143348623853 0 1 -1
bone,loss,between 1.0 0.000286697247706 0 2 -2
bombesin,significantly,increased 1.0 0.000143348623853 0 1 -1
bolus-ifl,with,or 1.0 0.000143348623853 0 1 -1
bolus-ifl,plus,avastin 1.0 0.000143348623853 0 1 -1
bolus-ifl,in,combination 1.0 0.000143348623853 0 1 -1
bolus-ifl,alone,and 1.0 0.000143348623853 0 1 -1
bolus,of,amicar 1.0 0.000143348623853 0 1 -1
bolus,injections,of 1.0 0.000143348623853 0 1 -1
bolus,followed,by 1.0 0.000143348623853 0 1 -1
bodyweight,gain,somnolence 1.0 0.000143348623853 0 1 -1
bodyweight,gain,occurred 1.0 0.000143348623853 0 1 -1
bodyweight,gain,and 1.0 0.000143348623853 0 1 -1
bodys,ability,to 1.0 0.000143348623853 0 1 -1
body,weight,were 1.0 0.000143348623853 0 1 -1
body,weight,for 1.0 0.000143348623853 0 1 -1
body,weight,every 1.0 0.000143348623853 0 1 -1
body,weight,approximately 1.0 0.000143348623853 0 1 -1
body,weight,and 1.0 0.000286697247706 0 2 -2
body,tremors,and 1.0 0.000143348623853 0 1 -1
body,surface,area 1.0 0.00043004587156 0 3 -3
body,it,is 1.0 0.000143348623853 0 1 -1
body,increase,in 1.0 0.000143348623853 0 1 -1
body,fat,including 1.0 0.000143348623853 0 1 -1
body,clearance,is 1.0 0.000143348623853 0 1 -1
body,by,the 1.0 0.000143348623853 0 1 -1
body,and,of 1.0 0.000143348623853 0 1 -1
bodies,in,urine 1.0 0.000143348623853 0 1 -1
bmax,of,d2 1.0 0.000143348623853 0 1 -1
bmax,in,the 1.0 0.000143348623853 0 1 -1
bmax,in,either 1.0 0.000143348623853 0 1 -1
blurred,vision,nystagmus 1.0 0.000143348623853 0 1 -1
blunt,the,bronchodilator 1.0 0.000143348623853 0 1 -1
blunt,adrenal,and 1.0 0.000143348623853 0 1 -1
blot,analysis,of 1.0 0.000143348623853 0 1 -1
blood-sugar,levels,should 1.0 0.000143348623853 0 1 -1
blood-glucose,lowering,effect 1.0 0.000573394495413 0 4 -4
blood,thinners,coumadin 1.0 0.000143348623853 0 1 -1
blood,sugar,some 1.0 0.000143348623853 0 1 -1
blood,sugar,level 1.0 0.000143348623853 0 1 -1
blood,sampling,for 1.0 0.000143348623853 0 1 -1
blood,samples,were 1.0 0.000286697247706 0 2 -2
blood,samples,also 1.0 0.000143348623853 0 1 -1
blood,pressure,were 1.0 0.000143348623853 0 1 -1
blood,pressure,strattera 1.0 0.000143348623853 0 1 -1
blood,pressure,should 1.0 0.000143348623853 0 1 -1
blood,pressure,response 1.0 0.000143348623853 0 1 -1
blood,pressure,or 1.0 0.00043004587156 0 3 -3
blood,pressure,medications 1.0 0.000143348623853 0 1 -1
blood,pressure,in 1.0 0.000143348623853 0 1 -1
blood,pressure,has 1.0 0.00043004587156 0 3 -3
blood,pressure,control 1.0 0.000143348623853 0 1 -1
blood,pressure,carotid 1.0 0.000143348623853 0 1 -1
blood,pressure,beyond 1.0 0.000143348623853 0 1 -1
blood,pressure,and 1.0 0.00043004587156 0 3 -3
blood,plasma,glucose 1.0 0.000286697247706 0 2 -2
blood,or,urine 1.0 0.000143348623853 0 1 -1
blood,loss,results 1.0 0.000143348623853 0 1 -1
blood,liver,or 1.0 0.000143348623853 0 1 -1
blood,lipids,should 1.0 0.000143348623853 0 1 -1
blood,levels,in 1.0 0.000143348623853 0 1 -1
blood,levels,could 1.0 0.000143348623853 0 1 -1
blood,level,of 1.0 0.000573394495413 0 4 -4
blood,glucose,when 1.0 0.000143348623853 0 1 -1
blood,glucose,was 1.0 0.000143348623853 0 1 -1
blood,glucose,monitoring 1.0 0.000143348623853 0 1 -1
blood,glucose,measurement 1.0 0.000143348623853 0 1 -1
blood,glucose,is 1.0 0.000286697247706 0 2 -2
blood,glucose,blood 1.0 0.000143348623853 0 1 -1
blood,flow,were 1.0 0.000143348623853 0 1 -1
blood,flow,seen 1.0 0.000143348623853 0 1 -1
blood,flow,or 1.0 0.000143348623853 0 1 -1
blood,flow,caused 1.0 0.000143348623853 0 1 -1
blood,flow,and 1.0 0.000143348623853 0 1 -1
blood,concentrations,of 1.0 0.000286697247706 0 2 -2
blood,concentrations,and 1.0 0.000143348623853 0 1 -1
blood,concentration-time,curve 1.0 0.000143348623853 0 1 -1
blood,concentration,should 1.0 0.000143348623853 0 1 -1
blood,coagulation,system 1.0 0.000143348623853 0 1 -1
blood,coagulation,ketoprofen 1.0 0.000143348623853 0 1 -1
blood,coagulation,diclofenac 1.0 0.000143348623853 0 1 -1
blood,cells,whereas 1.0 0.000143348623853 0 1 -1
blood,cell,counts 1.0 0.000143348623853 0 1 -1
blood,can,significantly 1.0 0.000143348623853 0 1 -1
blood,at,different 1.0 0.000143348623853 0 1 -1
blood,and,urine 1.0 0.000286697247706 0 2 -2
blocking,the,tail-flick 1.0 0.000143348623853 0 1 -1
blocking,compounds,because 1.0 0.000143348623853 0 1 -1
blocking,agents,without 1.0 0.000143348623853 0 1 -1
blocking,agents,to 1.0 0.000143348623853 0 1 -1
blocking,agents,these 1.0 0.000143348623853 0 1 -1
blocking,agents,or 1.0 0.000143348623853 0 1 -1
blocking,agents,now 1.0 0.000143348623853 0 1 -1
blocking,agents,did 1.0 0.000286697247706 0 2 -2
blocking,agents,concurrent 1.0 0.000143348623853 0 1 -1
blocking,agents,coadministration 1.0 0.000286697247706 0 2 -2
blocking,agents,chloral 1.0 0.000143348623853 0 1 -1
blocking,agents,calcium-channel 1.0 0.000143348623853 0 1 -1
blocking,agents,calcium 1.0 0.000143348623853 0 1 -1
blocking,agents,actions 1.0 0.000143348623853 0 1 -1
blocking,agents,a 1.0 0.000143348623853 0 1 -1
blocking,agent,plus 1.0 0.000143348623853 0 1 -1
blocking,agent,administered 1.0 0.000143348623853 0 1 -1
blocking,action,which 1.0 0.000143348623853 0 1 -1
blocking,action,is 1.0 0.000143348623853 0 1 -1
blockers,sustained-release,with 1.0 0.000143348623853 0 1 -1
blockers,patients,with 1.0 0.000286697247706 0 2 -2
blockers,on,platelet 1.0 0.000286697247706 0 2 -2
blockers,nonsteroidal,antiinflammatories 1.0 0.000143348623853 0 1 -1
blockers,may,weaken 1.0 0.000143348623853 0 1 -1
blockers,may,result 1.0 0.000143348623853 0 1 -1
blockers,l-type,omega-conotoxin 1.0 0.000143348623853 0 1 -1
blockers,including,were 1.0 0.000143348623853 0 1 -1
blockers,including,eye 1.0 0.000143348623853 0 1 -1
blockers,in,the 1.0 0.000143348623853 0 1 -1
blockers,in,one 1.0 0.000143348623853 0 1 -1
blockers,have,been 1.0 0.000143348623853 0 1 -1
blockers,did,not 1.0 0.000143348623853 0 1 -1
blockers,concurrently,did 1.0 0.000143348623853 0 1 -1
blockers,cardiac,h2 1.0 0.000143348623853 0 1 -1
blockers,cardiac,glycosides 1.0 0.000143348623853 0 1 -1
blockers,calcium-channel,blockers 1.0 0.000143348623853 0 1 -1
blockers,calcium,channel 1.0 0.000143348623853 0 1 -1
blockers,beta,blockers 1.0 0.000143348623853 0 1 -1
blockers,antagonists,and 1.0 0.000143348623853 0 1 -1
blockers,and,proton 1.0 0.000143348623853 0 1 -1
blockers,and,nonsteroidal 1.0 0.000143348623853 0 1 -1
blockers,also,increase 1.0 0.000143348623853 0 1 -1
blocker,was,studied 1.0 0.000143348623853 0 1 -1
blocker,on,the 1.0 0.000143348623853 0 1 -1
blocker,of,renal 1.0 0.000143348623853 0 1 -1
blocked,the,decrease 1.0 0.000143348623853 0 1 -1
blockade,will,be 1.0 0.000143348623853 0 1 -1
blockade,was,studied 1.0 0.000143348623853 0 1 -1
blockade,of,diverse 1.0 0.000143348623853 0 1 -1
block,with,and 1.0 0.000143348623853 0 1 -1
block,were,more 1.0 0.000143348623853 0 1 -1
block,produced,by 1.0 0.000143348623853 0 1 -1
block,pcp-induced,behaviors 1.0 0.000143348623853 0 1 -1
block,following,initial 1.0 0.000143348623853 0 1 -1
block,angiotensin,ii 1.0 0.000143348623853 0 1 -1
bleedings,have,been 1.0 0.000143348623853 0 1 -1
bleeding,with,xigris 1.0 0.000143348623853 0 1 -1
bleeding,time,pt 1.0 0.000143348623853 0 1 -1
bleeding,time,plasma 1.0 0.000143348623853 0 1 -1
bleeding,time,of 1.0 0.000143348623853 0 1 -1
bleeding,time,has 1.0 0.000143348623853 0 1 -1
bleeding,time,caused 1.0 0.000143348623853 0 1 -1
bleeding,time,by 1.0 0.000143348623853 0 1 -1
bleeding,shortly,after 1.0 0.000143348623853 0 1 -1
bleeding,or,with 1.0 0.000143348623853 0 1 -1
bleeding,is,advised 1.0 0.000143348623853 0 1 -1
bleeding,international,normalized 1.0 0.000143348623853 0 1 -1
bleeding,from,a 1.0 0.000143348623853 0 1 -1
bleeding,events,including 1.0 0.000143348623853 0 1 -1
bleeding,complications,considerably 1.0 0.000143348623853 0 1 -1
bleeding,complications,careful 1.0 0.000143348623853 0 1 -1
bleeding,and,menstrual 1.0 0.000286697247706 0 2 -2
bleeding,a,complication 1.0 0.000143348623853 0 1 -1
bladder,cancer,cells 1.0 0.000143348623853 0 1 -1
biweekly,intervals,until 1.0 0.000286697247706 0 2 -2
bisphosphonates,are,known 1.0 0.000143348623853 0 1 -1
birth,control,pills 1.0 0.000286697247706 0 2 -2
biotransformation,of,other 1.0 0.000143348623853 0 1 -1
biopsy,roegnik,grade 1.0 0.000143348623853 0 1 -1
biopsy,revealed,necrotizing 1.0 0.000143348623853 0 1 -1
biopharmaceutical,properties,relative 1.0 0.000143348623853 0 1 -1
biological,levels,have 1.0 0.000143348623853 0 1 -1
biological,indicators,differs 1.0 0.000143348623853 0 1 -1
biological,half-lives,of 1.0 0.000143348623853 0 1 -1
biogen,pregnancy,registry 1.0 0.000143348623853 0 1 -1
bioequivalent,when,proquin 1.0 0.000143348623853 0 1 -1
bioequivalent,to,the 1.0 0.000143348623853 0 1 -1
bioequivalence,study,the 1.0 0.000143348623853 0 1 -1
biodistribution,may,provide 1.0 0.000143348623853 0 1 -1
biocytin,with,whole-cell 1.0 0.000143348623853 0 1 -1
biocytin,with,opioid-evoked 1.0 0.000143348623853 0 1 -1
biocytin,was,included 1.0 0.000143348623853 0 1 -1
biocytin,inclusion,on 1.0 0.000143348623853 0 1 -1
biocytin,in,the 1.0 0.000143348623853 0 1 -1
biocytin,compared,to 1.0 0.000143348623853 0 1 -1
biochemical,toxicology,of 1.0 0.000143348623853 0 1 -1
biochemical,activity,of 1.0 0.000716743119266 0 5 -5
bioavailabillty,and,may 1.0 0.000143348623853 0 1 -1
bioavailability,studies,with 1.0 0.000143348623853 0 1 -1
bioavailability,studies,in 1.0 0.000143348623853 0 1 -1
bioavailability,parameters,the 1.0 0.000143348623853 0 1 -1
bioavailability,or,due 1.0 0.000143348623853 0 1 -1
bioavailability,of,valproic 1.0 0.000143348623853 0 1 -1
bioavailability,of,unbound 1.0 0.000143348623853 0 1 -1
bioavailability,of,the 1.0 0.000286697247706 0 2 -2
bioavailability,of,relative 1.0 0.000143348623853 0 1 -1
bioavailability,of,novolog 1.0 0.000143348623853 0 1 -1
bioavailability,low,clearance 1.0 0.000143348623853 0 1 -1
bioavailability,auc,or 1.0 0.000143348623853 0 1 -1
bioavailability,auc,and 1.0 0.000286697247706 0 2 -2
bioavailability,area,under 1.0 0.000143348623853 0 1 -1
bioavailability,and,whether 1.0 0.000143348623853 0 1 -1
bioassay,procedures,for 1.0 0.000143348623853 0 1 -1
bio-rad,laboratories,platelia 1.0 0.000286697247706 0 2 -2
binds,differently,than 1.0 0.000143348623853 0 1 -1
binds,bile,acids 1.0 0.000143348623853 0 1 -1
binding,with,high 1.0 0.000143348623853 0 1 -1
binding,to,plasma 1.0 0.000573394495413 0 4 -4
binding,to,human 1.0 0.000143348623853 0 1 -1
binding,studies,with 1.0 0.000143348623853 0 1 -1
binding,sites,other 1.0 0.000286697247706 0 2 -2
binding,sites,in 1.0 0.000143348623853 0 1 -1
binding,sites,for 1.0 0.000286697247706 0 2 -2
binding,sites,are 1.0 0.000143348623853 0 1 -1
binding,proteins,may 1.0 0.000286697247706 0 2 -2
binding,of,these 1.0 0.000143348623853 0 1 -1
binding,of,therapeutic 1.0 0.000286697247706 0 2 -2
binding,of,of 1.0 0.000143348623853 0 1 -1
binding,of,mhd 1.0 0.000143348623853 0 1 -1
binding,of,is 1.0 0.000143348623853 0 1 -1
binding,of,in 1.0 0.000286697247706 0 2 -2
binding,of,hcl 1.0 0.000143348623853 0 1 -1
binding,of,fibrinogen 1.0 0.000143348623853 0 1 -1
binding,of,and 1.0 0.000143348623853 0 1 -1
binding,of,affected 1.0 0.000143348623853 0 1 -1
binding,of,acetylsalicylic 1.0 0.000143348623853 0 1 -1
binding,lectin,and 1.0 0.000143348623853 0 1 -1
binding,is,not 1.0 0.000143348623853 0 1 -1
binding,in,each 1.0 0.000143348623853 0 1 -1
binding,globulin,tbg 1.0 0.000143348623853 0 1 -1
binding,globulin,shbg 1.0 0.000143348623853 0 1 -1
binding,globulin,cbg 1.0 0.000286697247706 0 2 -2
binding,experiments,using 1.0 0.000143348623853 0 1 -1
binding,entacapone,is 1.0 0.000143348623853 0 1 -1
binding,domain,decoy 1.0 0.000143348623853 0 1 -1
binding,displacement,between 1.0 0.000143348623853 0 1 -1
binding,and,the 1.0 0.000143348623853 0 1 -1
binding,and,serum 1.0 0.000143348623853 0 1 -1
binding,after,the 1.0 0.000143348623853 0 1 -1
binding,activity,in 1.0 0.000143348623853 0 1 -1
bind,significantly,to 1.0 0.000143348623853 0 1 -1
bind,other,drugs 1.0 0.000143348623853 0 1 -1
bilirubin,urobilin,due 1.0 0.000143348623853 0 1 -1
bilirubin,times,the 1.0 0.000143348623853 0 1 -1
bilirubin,levels,by 1.0 0.000143348623853 0 1 -1
bilirubin,elevations,with 1.0 0.000143348623853 0 1 -1
bilirubin,and,alkaline 1.0 0.000143348623853 0 1 -1
biliary,route,with 1.0 0.000143348623853 0 1 -1
biliary,excretion,glucuronidation 1.0 0.000143348623853 0 1 -1
bile-acidsequestering,agent,on 1.0 0.000143348623853 0 1 -1
bile,caution,should 1.0 0.000143348623853 0 1 -1
bile,acids,may 1.0 0.000143348623853 0 1 -1
bilateral,ovariectomy,female 1.0 0.000143348623853 0 1 -1
bid,were,not 1.0 0.000143348623853 0 1 -1
bid,on,the 1.0 0.000286697247706 0 2 -2
bid,n,vs 1.0 0.000143348623853 0 1 -1
bid,have,not 1.0 0.000143348623853 0 1 -1
bid,did,not 1.0 0.00043004587156 0 3 -3
beyond,those,changes 1.0 0.000143348623853 0 1 -1
beyond,days,are 1.0 0.000143348623853 0 1 -1
bextra,mg,bid 1.0 0.000143348623853 0 1 -1
bextra,is,either 1.0 0.000143348623853 0 1 -1
bexarotene,oxidative,metabolites 1.0 0.000143348623853 0 1 -1
beverages,in,the 1.0 0.000143348623853 0 1 -1
beverages,are,not 1.0 0.000143348623853 0 1 -1
between,zdv,and 1.0 0.000143348623853 0 1 -1
between,vidaza,and 1.0 0.000143348623853 0 1 -1
between,uroxatral,and 1.0 0.000143348623853 0 1 -1
between,two,or 1.0 0.000143348623853 0 1 -1
between,tumor,and 1.0 0.000143348623853 0 1 -1
between,trisenox,and 1.0 0.000143348623853 0 1 -1
between,trileptal,and 1.0 0.000143348623853 0 1 -1
between,treatments,with 1.0 0.000143348623853 0 1 -1
between,treatment,groups 1.0 0.000143348623853 0 1 -1
between,toradoliv,im 1.0 0.000143348623853 0 1 -1
between,these,events 1.0 0.000143348623853 0 1 -1
between,these,and 1.0 0.000143348623853 0 1 -1
between,theraputic,agents 1.0 0.000143348623853 0 1 -1
between,the,th 1.0 0.000143348623853 0 1 -1
between,the,survanta 1.0 0.000143348623853 0 1 -1
between,the,mean 1.0 0.000143348623853 0 1 -1
between,the,liver 1.0 0.000143348623853 0 1 -1
between,the,excreted 1.0 0.000143348623853 0 1 -1
between,the,ca 1.0 0.000143348623853 0 1 -1
between,the,and 1.0 0.000143348623853 0 1 -1
between,the,administration 1.0 0.000143348623853 0 1 -1
between,taxol,a 1.0 0.000143348623853 0 1 -1
between,study,without 1.0 0.000143348623853 0 1 -1
between,ssris,and 1.0 0.000143348623853 0 1 -1
between,solvents,have 1.0 0.000143348623853 0 1 -1
between,solvents,can 1.0 0.000143348623853 0 1 -1
between,revia,and 1.0 0.000143348623853 0 1 -1
between,prostin,vr 1.0 0.000143348623853 0 1 -1
between,plasma,levels 1.0 0.000143348623853 0 1 -1
between,patients,on 1.0 0.000143348623853 0 1 -1
between,older,and 1.0 0.000143348623853 0 1 -1
between,oh,d3 1.0 0.000143348623853 0 1 -1
between,novoseven,and 1.0 0.000143348623853 0 1 -1
between,neupogen,and 1.0 0.000143348623853 0 1 -1
between,mentax,butenafine 1.0 0.000143348623853 0 1 -1
between,mealtime,dosing 1.0 0.000143348623853 0 1 -1
between,keppra,and 1.0 0.000286697247706 0 2 -2
between,june,and 1.0 0.000143348623853 0 1 -1
between,january,and 1.0 0.000143348623853 0 1 -1
between,intravenous,and 1.0 0.000143348623853 0 1 -1
between,intake,of 1.0 0.000286697247706 0 2 -2
between,homopolyribonucleotides,and 1.0 0.000143348623853 0 1 -1
between,h-spiroperidol,and 1.0 0.000286697247706 0 2 -2
between,given,singly 1.0 0.000143348623853 0 1 -1
between,folic,acid 1.0 0.000143348623853 0 1 -1
between,exogenous,and 1.0 0.000143348623853 0 1 -1
between,ellence,and 1.0 0.000143348623853 0 1 -1
between,deficiency,due 1.0 0.000143348623853 0 1 -1
between,copaxone,and 1.0 0.000286697247706 0 2 -2
between,coadministered,with 1.0 0.000143348623853 0 1 -1
between,cerebral,memory 1.0 0.000143348623853 0 1 -1
between,cecectomized,and 1.0 0.000143348623853 0 1 -1
between,camptosar,and 1.0 0.000143348623853 0 1 -1
between,brevibloc,and 1.0 0.000143348623853 0 1 -1
between,both,dietary 1.0 0.000143348623853 0 1 -1
between,both,at 1.0 0.000143348623853 0 1 -1
between,blood,levels 1.0 0.000143348623853 0 1 -1
between,betaseron,and 1.0 0.000143348623853 0 1 -1
between,argatroban,and 1.0 0.000286697247706 0 2 -2
between,area,under 1.0 0.000143348623853 0 1 -1
between,apokyn,and 1.0 0.000143348623853 0 1 -1
between,and,were 1.0 0.000143348623853 0 1 -1
between,and,to 1.0 0.000143348623853 0 1 -1
between,and,racemic 1.0 0.000143348623853 0 1 -1
between,and,pharmacokinetics 1.0 0.000143348623853 0 1 -1
between,and,or 1.0 0.000143348623853 0 1 -1
between,and,more 1.0 0.000143348623853 0 1 -1
between,and,mg 1.0 0.000143348623853 0 1 -1
between,and,laboratory 1.0 0.000143348623853 0 1 -1
between,and,following 1.0 0.000286697247706 0 2 -2
between,and,both 1.0 0.000143348623853 0 1 -1
between,and,beta 1.0 0.000143348623853 0 1 -1
between,and,any 1.0 0.00043004587156 0 3 -3
between,and,antidiuretic 1.0 0.000143348623853 0 1 -1
between,and,an 1.0 0.000143348623853 0 1 -1
between,and,acetylsalicylic 1.0 0.000143348623853 0 1 -1
between,a,macrolide 1.0 0.000143348623853 0 1 -1
better,designed,studies 1.0 0.000143348623853 0 1 -1
better,after,initiating 1.0 0.000143348623853 0 1 -1
betaseron,and,other 1.0 0.000143348623853 0 1 -1
beta-receptor,blockers,have 1.0 0.000143348623853 0 1 -1
beta-receptor,blockers,antagonists 1.0 0.000143348623853 0 1 -1
beta-receptor,agonist,in 1.0 0.000143348623853 0 1 -1
beta-naltrexol,were,unaffected 1.0 0.000143348623853 0 1 -1
beta-glucuronidase,are,given 1.0 0.000143348623853 0 1 -1
beta-blocking,agents,the 1.0 0.000143348623853 0 1 -1
beta-blocking,agents,has 1.0 0.000143348623853 0 1 -1
beta-blocking,agents,a 1.0 0.000143348623853 0 1 -1
beta-blockers,serum,concentrations 1.0 0.000143348623853 0 1 -1
beta-blockers,in,controlled 1.0 0.000143348623853 0 1 -1
beta-adrenergic,stimulating,properties 1.0 0.000143348623853 0 1 -1
beta-adrenergic,receptor,blockers 1.0 0.000143348623853 0 1 -1
beta-adrenergic,neuroeffector,defects 1.0 0.000143348623853 0 1 -1
beta,to,copaxone 1.0 0.000143348623853 0 1 -1
beta,cells,respond 1.0 0.000143348623853 0 1 -1
beta,blockers,patients 1.0 0.000286697247706 0 2 -2
beta,blockers,including 1.0 0.000143348623853 0 1 -1
beta,blockers,in 1.0 0.000143348623853 0 1 -1
beta,blockers,concurrently 1.0 0.000143348623853 0 1 -1
beta,blockers,cardiac 1.0 0.000143348623853 0 1 -1
beta,blockers,calcium-channel 1.0 0.000143348623853 0 1 -1
beta,adrenergic-blocking,agents 1.0 0.000143348623853 0 1 -1
best,tool,for 1.0 0.000143348623853 0 1 -1
best,choice,for 1.0 0.000143348623853 0 1 -1
best,approach,in 1.0 0.000143348623853 0 1 -1
best,adaptive,value 1.0 0.000143348623853 0 1 -1
besides,their,action 1.0 0.000143348623853 0 1 -1
besides,mtx,were 1.0 0.000143348623853 0 1 -1
bepridil,with,long- 1.0 0.000143348623853 0 1 -1
bepridil,has,been 1.0 0.000143348623853 0 1 -1
bepridil,and,beta-blocking 1.0 0.000143348623853 0 1 -1
benzylpenicillin,and,have 1.0 0.000143348623853 0 1 -1
benzyl,has,been 1.0 0.000143348623853 0 1 -1
benzodiazepines,were,administered 1.0 0.000143348623853 0 1 -1
benzodiazepines,gi,motility 1.0 0.000143348623853 0 1 -1
benign,prostatic,hyperplasia 1.0 0.000143348623853 0 1 -1
benign,ovarian,granulosa 1.0 0.000143348623853 0 1 -1
benefits,of,mefloquine 1.0 0.000143348623853 0 1 -1
benefits,of,medications 1.0 0.000143348623853 0 1 -1
benefits,and,get 1.0 0.000143348623853 0 1 -1
benefits,against,symptoms 1.0 0.000143348623853 0 1 -1
benefit,while,avoiding 1.0 0.000143348623853 0 1 -1
benefit,when,compared 1.0 0.000143348623853 0 1 -1
benefit,of,while 1.0 0.000143348623853 0 1 -1
benefit,justifies,the 1.0 0.000143348623853 0 1 -1
benefit,balance,patient 1.0 0.000143348623853 0 1 -1
benedicts,solution,or 1.0 0.000286697247706 0 2 -2
benedicts,solution,fehlings 1.0 0.000286697247706 0 2 -2
benedicts,or,fehlings 1.0 0.000143348623853 0 1 -1
benedict,s,solution 1.0 0.000286697247706 0 2 -2
benedict,s,or 1.0 0.000143348623853 0 1 -1
benedict,s,and 1.0 0.000286697247706 0 2 -2
below,the,therapeutic 1.0 0.000143348623853 0 1 -1
below,the,age 1.0 0.000143348623853 0 1 -1
below,increase,the 1.0 0.000143348623853 0 1 -1
below,have,not 1.0 0.000143348623853 0 1 -1
below,are,potentially 1.0 0.000143348623853 0 1 -1
below,are,likely 1.0 0.000143348623853 0 1 -1
below,a,sub- 1.0 0.000143348623853 0 1 -1
believed,to,be 1.0 0.000143348623853 0 1 -1
being,used,the 1.0 0.000143348623853 0 1 -1
being,used,many 1.0 0.000143348623853 0 1 -1
being,reached,after 1.0 0.000143348623853 0 1 -1
being,rapidly,identified 1.0 0.000143348623853 0 1 -1
being,observed,with 1.0 0.000143348623853 0 1 -1
being,monitored,they 1.0 0.000143348623853 0 1 -1
being,metabolized,through 1.0 0.000143348623853 0 1 -1
being,homocysteine,by 1.0 0.000143348623853 0 1 -1
being,given,compensatory 1.0 0.000143348623853 0 1 -1
being,either,too 1.0 0.000143348623853 0 1 -1
being,dosed,at 1.0 0.000143348623853 0 1 -1
being,developed,as 1.0 0.000143348623853 0 1 -1
being,a,further 1.0 0.000143348623853 0 1 -1
behaviour,when,briefly 1.0 0.000143348623853 0 1 -1
behaviour,of,the 1.0 0.000286697247706 0 2 -2
behaviour,of,schistosoma 1.0 0.000143348623853 0 1 -1
behaviors,which,are 1.0 0.000143348623853 0 1 -1
behaviors,most,closely 1.0 0.000143348623853 0 1 -1
behavioral,sensitization,similar 1.0 0.000143348623853 0 1 -1
behavioral,responses,to 1.0 0.000143348623853 0 1 -1
behavioral,response,of 1.0 0.000286697247706 0 2 -2
behavioral,or,subjective 1.0 0.000143348623853 0 1 -1
behavioral,mechanisms,underlying 1.0 0.000143348623853 0 1 -1
behavioral,effects,of 1.0 0.000716743119266 0 5 -5
behavioral,changes,of 1.0 0.000143348623853 0 1 -1
behavioral,changes,northern 1.0 0.000143348623853 0 1 -1
behavioral,changes,may 1.0 0.000143348623853 0 1 -1
behavioral,changes,induced 1.0 0.000143348623853 0 1 -1
behavior,in,normal 1.0 0.000143348623853 0 1 -1
behavior,and,stress 1.0 0.000143348623853 0 1 -1
begun,in,a 1.0 0.000143348623853 0 1 -1
beginning,of,the 1.0 0.000143348623853 0 1 -1
begin,therapy,with 1.0 0.000143348623853 0 1 -1
began,within,minutes 1.0 0.000143348623853 0 1 -1
began,within,five 1.0 0.000143348623853 0 1 -1
before,you,take 1.0 0.000143348623853 0 1 -1
before,using,this 1.0 0.000143348623853 0 1 -1
before,to,attenuate 1.0 0.000286697247706 0 2 -2
before,these,determinations 1.0 0.000143348623853 0 1 -1
before,there,is 1.0 0.000143348623853 0 1 -1
before,the,first 1.0 0.000143348623853 0 1 -1
before,the,analysis 1.0 0.000143348623853 0 1 -1
before,taking,any 1.0 0.000143348623853 0 1 -1
before,such,are 1.0 0.000143348623853 0 1 -1
before,starting,treatment 1.0 0.000143348623853 0 1 -1
before,receiving,the 1.0 0.000143348623853 0 1 -1
before,prescribing,a 1.0 0.000143348623853 0 1 -1
before,parturition,it 1.0 0.000143348623853 0 1 -1
before,parathyroid-function,tests 1.0 0.000143348623853 0 1 -1
before,or,within 1.0 0.000143348623853 0 1 -1
before,or,to 1.0 0.000143348623853 0 1 -1
before,or,four 1.0 0.000143348623853 0 1 -1
before,or,for 1.0 0.000143348623853 0 1 -1
before,or,at 1.0 0.000143348623853 0 1 -1
before,one,should 1.0 0.000143348623853 0 1 -1
before,morning,doses 1.0 0.000143348623853 0 1 -1
before,meals,was 1.0 0.000286697247706 0 2 -2
before,meals,for 1.0 0.000286697247706 0 2 -2
before,injection,produced 1.0 0.000143348623853 0 1 -1
before,initiating,tca 1.0 0.000573394495413 0 4 -4
before,idv,does 1.0 0.000143348623853 0 1 -1
before,dose-limiting,toxicities 1.0 0.000143348623853 0 1 -1
before,day,with 1.0 0.000143348623853 0 1 -1
before,carrying,out 1.0 0.000286697247706 0 2 -2
before,being,treated 1.0 0.000143348623853 0 1 -1
before,and,after 1.0 0.000286697247706 0 2 -2
before,after,or 1.0 0.000143348623853 0 1 -1
before,adrenal,function 1.0 0.000143348623853 0 1 -1
before,a,long-acting 1.0 0.000143348623853 0 1 -1
been,well,tolerated 1.0 0.000143348623853 0 1 -1
been,well,studied 1.0 0.000143348623853 0 1 -1
been,used,with 1.0 0.000143348623853 0 1 -1
been,used,successfully 1.0 0.000286697247706 0 2 -2
been,used,it 1.0 0.000143348623853 0 1 -1
been,used,in 1.0 0.000143348623853 0 1 -1
been,used,concurrently 1.0 0.000143348623853 0 1 -1
been,used,by 1.0 0.000143348623853 0 1 -1
been,too,little 1.0 0.000143348623853 0 1 -1
been,tested,in 1.0 0.000143348623853 0 1 -1
been,tested,for 1.0 0.000143348623853 0 1 -1
been,tested,and 1.0 0.000143348623853 0 1 -1
been,termed,the 1.0 0.000143348623853 0 1 -1
been,taking,on 1.0 0.000143348623853 0 1 -1
been,suggested,with 1.0 0.00043004587156 0 3 -3
been,suggested,in 1.0 0.000143348623853 0 1 -1
been,studied,of 1.0 0.000143348623853 0 1 -1
been,studied,in 1.0 0.00114678899083 0 8 -8
been,studied,for 1.0 0.000143348623853 0 1 -1
been,studied,extensively 1.0 0.000143348623853 0 1 -1
been,studied,as 1.0 0.000143348623853 0 1 -1
been,started,on 1.0 0.000143348623853 0 1 -1
been,shown,on 1.0 0.000143348623853 0 1 -1
been,shown,not 1.0 0.000143348623853 0 1 -1
been,seen,in 1.0 0.000143348623853 0 1 -1
been,safely,used 1.0 0.00043004587156 0 3 -3
been,safely,tolerated 1.0 0.000143348623853 0 1 -1
been,safely,coadministered 1.0 0.000143348623853 0 1 -1
been,reported,regarding 1.0 0.000143348623853 0 1 -1
been,reported,pretreatment 1.0 0.000143348623853 0 1 -1
been,reported,itraconazole 1.0 0.000143348623853 0 1 -1
been,reported,for 1.0 0.000286697247706 0 2 -2
been,reported,chiefly 1.0 0.000143348623853 0 1 -1
been,reported,by 1.0 0.000286697247706 0 2 -2
been,reported,between 1.0 0.000286697247706 0 2 -2
been,recognized,as 1.0 0.000143348623853 0 1 -1
been,receiving,treatment 1.0 0.000143348623853 0 1 -1
been,receiving,for 1.0 0.000143348623853 0 1 -1
been,received,as 1.0 0.000143348623853 0 1 -1
been,received,among 1.0 0.000143348623853 0 1 -1
been,proposed,in 1.0 0.000143348623853 0 1 -1
been,proposed,as 1.0 0.000143348623853 0 1 -1
been,prescribed,foradil 1.0 0.000143348623853 0 1 -1
been,performed,with 1.0 0.00043004587156 0 3 -3
been,performed,to 1.0 0.000143348623853 0 1 -1
been,performed,in 1.0 0.000286697247706 0 2 -2
been,performed,examining 1.0 0.000143348623853 0 1 -1
been,performed,and 1.0 0.00043004587156 0 3 -3
been,obtained,in 1.0 0.000143348623853 0 1 -1
been,observed,with 1.0 0.00157683486239 0 11 -11
been,observed,more 1.0 0.000143348623853 0 1 -1
been,observed,between 1.0 0.000286697247706 0 2 -2
been,observed,and 1.0 0.000286697247706 0 2 -2
been,observed,after 1.0 0.000143348623853 0 1 -1
been,noted,that 1.0 0.000143348623853 0 1 -1
been,no,reported 1.0 0.000143348623853 0 1 -1
been,no,formal 1.0 0.000716743119266 0 5 -5
been,no,experience 1.0 0.000143348623853 0 1 -1
been,no,controlled 1.0 0.000143348623853 0 1 -1
been,no,chemical 1.0 0.000143348623853 0 1 -1
been,more,than 1.0 0.000143348623853 0 1 -1
been,little,experience 1.0 0.000143348623853 0 1 -1
been,investigated,in 1.0 0.000143348623853 0 1 -1
been,inconsistent,reports 1.0 0.000143348623853 0 1 -1
been,identified,that 1.0 0.000143348623853 0 1 -1
been,frequently,administered 1.0 0.000143348623853 0 1 -1
been,found,with 1.0 0.000286697247706 0 2 -2
been,found,in 1.0 0.000286697247706 0 2 -2
been,formally,evaluated 1.0 0.000143348623853 0 1 -1
been,extensively,studied 1.0 0.000286697247706 0 2 -2
been,exploited,in 1.0 0.000143348623853 0 1 -1
been,excreted,in 1.0 0.000143348623853 0 1 -1
been,evaluated,these 1.0 0.000143348623853 0 1 -1
been,evaluated,in 1.0 0.000716743119266 0 5 -5
been,established,in 1.0 0.000143348623853 0 1 -1
been,established,if 1.0 0.000143348623853 0 1 -1
been,established,and 1.0 0.000143348623853 0 1 -1
been,effectively,administered 1.0 0.000143348623853 0 1 -1
been,drawn,up 1.0 0.000143348623853 0 1 -1
been,done,it 1.0 0.000143348623853 0 1 -1
been,documented,prothrombin 1.0 0.000143348623853 0 1 -1
been,diagnosed,during 1.0 0.000286697247706 0 2 -2
been,determined,definitely 1.0 0.000143348623853 0 1 -1
been,described,little 1.0 0.000143348623853 0 1 -1
been,described,in 1.0 0.000143348623853 0 1 -1
been,definitely,determined 1.0 0.000143348623853 0 1 -1
been,conducted,to 1.0 0.000573394495413 0 4 -4
been,conducted,the 1.0 0.000143348623853 0 1 -1
been,conducted,no 1.0 0.000143348623853 0 1 -1
been,conducted,in 1.0 0.000286697247706 0 2 -2
been,conducted,for 1.0 0.000286697247706 0 2 -2
been,conducted,at 1.0 0.000143348623853 0 1 -1
been,completely,evaluated 1.0 0.000143348623853 0 1 -1
been,completed,with 1.0 0.000143348623853 0 1 -1
been,compared,to 1.0 0.000143348623853 0 1 -1
been,collected,on 1.0 0.000143348623853 0 1 -1
been,coadministered,with 1.0 0.00043004587156 0 3 -3
been,co-administered,with 1.0 0.000143348623853 0 1 -1
been,cited,in 1.0 0.000143348623853 0 1 -1
been,characterized,to 1.0 0.000143348623853 0 1 -1
been,characterized,by 1.0 0.000143348623853 0 1 -1
been,case,reports 1.0 0.000143348623853 0 1 -1
been,carried,out 1.0 0.000286697247706 0 2 -2
been,attributed,to 1.0 0.00143348623853 0 10 -10
been,assessed,in 1.0 0.000143348623853 0 1 -1
been,as,effective 1.0 0.000143348623853 0 1 -1
been,analysed,using 1.0 0.000143348623853 0 1 -1
been,administered,without 1.0 0.000143348623853 0 1 -1
been,administered,with 1.0 0.000143348623853 0 1 -1
been,administered,safely 1.0 0.000143348623853 0 1 -1
been,administered,concurrently 1.0 0.000143348623853 0 1 -1
been,administered,concomitantly 1.0 0.000143348623853 0 1 -1
been,administered,and 1.0 0.000143348623853 0 1 -1
been,adequately,studied 1.0 0.000143348623853 0 1 -1
been,adequately,evaluated 1.0 0.000143348623853 0 1 -1
bedtime,has,revealed 1.0 0.000143348623853 0 1 -1
bedtime,and,given 1.0 0.000143348623853 0 1 -1
becoming,more,severely 1.0 0.000143348623853 0 1 -1
becoming,increasingly,popular 1.0 0.000143348623853 0 1 -1
becomes,sensitive,to 1.0 0.000143348623853 0 1 -1
becomes,metabolically,active 1.0 0.000143348623853 0 1 -1
becomes,complete,after 1.0 0.000143348623853 0 1 -1
become,pregnant,into 1.0 0.000143348623853 0 1 -1
become,more,pronounced 1.0 0.000143348623853 0 1 -1
become,more,feasible 1.0 0.000143348623853 0 1 -1
become,abruptly,toxic 1.0 0.000716743119266 0 5 -5
because,xigris,may 1.0 0.000143348623853 0 1 -1
because,unexpected,hypotension 1.0 0.000143348623853 0 1 -1
because,they,are 1.0 0.000143348623853 0 1 -1
because,there,exists 1.0 0.000143348623853 0 1 -1
because,there,are 1.0 0.000143348623853 0 1 -1
because,the,sum 1.0 0.000143348623853 0 1 -1
because,the,small 1.0 0.000143348623853 0 1 -1
because,the,risk 1.0 0.000143348623853 0 1 -1
because,the,incidence 1.0 0.000143348623853 0 1 -1
because,the,geriatric 1.0 0.000143348623853 0 1 -1
because,the,ccnu 1.0 0.000143348623853 0 1 -1
because,pregnancy,could 1.0 0.000143348623853 0 1 -1
because,or,activase 1.0 0.000143348623853 0 1 -1
because,of,this 1.0 0.000143348623853 0 1 -1
because,of,reduced 1.0 0.000143348623853 0 1 -1
because,of,lessened 1.0 0.000143348623853 0 1 -1
because,of,initial 1.0 0.000143348623853 0 1 -1
because,of,demonstrated 1.0 0.00043004587156 0 3 -3
because,of,alkalinization 1.0 0.000143348623853 0 1 -1
because,of,a 1.0 0.000143348623853 0 1 -1
because,nafarelin,acetate 1.0 0.000143348623853 0 1 -1
because,many,drugs 1.0 0.000143348623853 0 1 -1
because,many,are 1.0 0.000143348623853 0 1 -1
because,it,is 1.0 0.000286697247706 0 2 -2
because,it,does 1.0 0.000143348623853 0 1 -1
because,is,primarily 1.0 0.000143348623853 0 1 -1
because,is,not 1.0 0.000286697247706 0 2 -2
because,is,metabolized 1.0 0.000573394495413 0 4 -4
because,is,extensively 1.0 0.000143348623853 0 1 -1
because,is,coadministered 1.0 0.000143348623853 0 1 -1
because,higher,doses 1.0 0.000143348623853 0 1 -1
because,false,positive 1.0 0.000143348623853 0 1 -1
because,elderly,patients 1.0 0.000143348623853 0 1 -1
because,efficient,labeling 1.0 0.000143348623853 0 1 -1
because,does,not 1.0 0.000143348623853 0 1 -1
because,cyp2d6,is 1.0 0.000143348623853 0 1 -1
because,cyp,a4 1.0 0.000143348623853 0 1 -1
because,binds,bile 1.0 0.000143348623853 0 1 -1
because,active,metabolite 1.0 0.000143348623853 0 1 -1
because,a,psychotic 1.0 0.000143348623853 0 1 -1
because,a,critical 1.0 0.000143348623853 0 1 -1
be,worsened,by 1.0 0.000143348623853 0 1 -1
be,well,acquainted 1.0 0.000143348623853 0 1 -1
be,warranted,when 1.0 0.000286697247706 0 2 -2
be,useful,to 1.0 0.000143348623853 0 1 -1
be,useful,for 1.0 0.000143348623853 0 1 -1
be,used,while 1.0 0.000143348623853 0 1 -1
be,used,only 1.0 0.000286697247706 0 2 -2
be,used,inconcomitant 1.0 0.000143348623853 0 1 -1
be,used,for 1.0 0.000286697247706 0 2 -2
be,used,during 1.0 0.00043004587156 0 3 -3
be,used,clinically 1.0 0.000143348623853 0 1 -1
be,used,and 1.0 0.000143348623853 0 1 -1
be,used,after 1.0 0.000143348623853 0 1 -1
be,unresponsive,to 1.0 0.000860091743119 0 6 -6
be,unlikely,to 1.0 0.000143348623853 0 1 -1
be,unlikely,that 1.0 0.000143348623853 0 1 -1
be,unaffected,by 1.0 0.000143348623853 0 1 -1
be,transiently,elevated 1.0 0.000143348623853 0 1 -1
be,titrated,to 1.0 0.000143348623853 0 1 -1
be,the,smallest 1.0 0.000143348623853 0 1 -1
be,the,potential 1.0 0.000143348623853 0 1 -1
be,the,major 1.0 0.000143348623853 0 1 -1
be,the,cellular 1.0 0.000143348623853 0 1 -1
be,tested,more 1.0 0.000143348623853 0 1 -1
be,taken,on 1.0 0.000143348623853 0 1 -1
be,taken,in 1.0 0.000573394495413 0 4 -4
be,taken,for 1.0 0.000143348623853 0 1 -1
be,taken,concomitantly 1.0 0.000286697247706 0 2 -2
be,taken,as 1.0 0.000143348623853 0 1 -1
be,susceptible,to 1.0 0.000143348623853 0 1 -1
be,superior,to 1.0 0.000143348623853 0 1 -1
be,substrates,inhibitors 1.0 0.000143348623853 0 1 -1
be,subject,to 1.0 0.000286697247706 0 2 -2
be,stopped,without 1.0 0.000143348623853 0 1 -1
be,small,or 1.0 0.000716743119266 0 5 -5
be,significantly,more 1.0 0.000143348623853 0 1 -1
be,significantly,affected 1.0 0.000143348623853 0 1 -1
be,sensitive,to 1.0 0.000286697247706 0 2 -2
be,seen,as 1.0 0.000143348623853 0 1 -1
be,safely,coadministered 1.0 0.000143348623853 0 1 -1
be,safely,co-administered 1.0 0.000143348623853 0 1 -1
be,reviewed,after 1.0 0.000143348623853 0 1 -1
be,restricted,and 1.0 0.000143348623853 0 1 -1
be,reserved,for 1.0 0.000143348623853 0 1 -1
be,required,with 1.0 0.000143348623853 0 1 -1
be,required,when 1.0 0.00043004587156 0 3 -3
be,required,in 1.0 0.000143348623853 0 1 -1
be,required,if 1.0 0.00043004587156 0 3 -3
be,reported,to 1.0 0.000143348623853 0 1 -1
be,repeated,each 1.0 0.000143348623853 0 1 -1
be,related,with 1.0 0.000143348623853 0 1 -1
be,related,to 1.0 0.000286697247706 0 2 -2
be,related,both 1.0 0.000143348623853 0 1 -1
be,reflective,of 1.0 0.000143348623853 0 1 -1
be,reduced,in 1.0 0.000286697247706 0 2 -2
be,reduced,higher 1.0 0.00043004587156 0 3 -3
be,reduced,and 1.0 0.000286697247706 0 2 -2
be,recommended,based 1.0 0.000286697247706 0 2 -2
be,recognized,that 1.0 0.00043004587156 0 3 -3
be,reassessed,periodically 1.0 0.000143348623853 0 1 -1
be,reassessed,and 1.0 0.000143348623853 0 1 -1
be,re-treated,with 1.0 0.000143348623853 0 1 -1
be,rationalized,at 1.0 0.000143348623853 0 1 -1
be,provided,to 1.0 0.000143348623853 0 1 -1
be,provided,for 1.0 0.000143348623853 0 1 -1
be,produced,by 1.0 0.000286697247706 0 2 -2
be,prepared,to 1.0 0.000143348623853 0 1 -1
be,premedicated,with 1.0 0.000143348623853 0 1 -1
be,precipitated,by 1.0 0.000143348623853 0 1 -1
be,potentiated,apparently 1.0 0.000143348623853 0 1 -1
be,potential,pharmacokinetic 1.0 0.000143348623853 0 1 -1
be,placed,in 1.0 0.000143348623853 0 1 -1
be,performed,weekly 1.0 0.000143348623853 0 1 -1
be,performed,prior 1.0 0.000143348623853 0 1 -1
be,performed,on 1.0 0.000143348623853 0 1 -1
be,performed,at 1.0 0.000286697247706 0 2 -2
be,patient,specific 1.0 0.000143348623853 0 1 -1
be,particularly,cautious 1.0 0.000143348623853 0 1 -1
be,particularly,carefully 1.0 0.000143348623853 0 1 -1
be,paid,to 1.0 0.000143348623853 0 1 -1
be,of,assistance 1.0 0.000143348623853 0 1 -1
be,obtained,under 1.0 0.000286697247706 0 2 -2
be,obtained,before 1.0 0.000143348623853 0 1 -1
be,notified,immediately 1.0 0.000143348623853 0 1 -1
be,noted,when 1.0 0.000143348623853 0 1 -1
be,no,pharmacokinetic 1.0 0.000143348623853 0 1 -1
be,no,acceptable 1.0 0.000143348623853 0 1 -1
be,negatively,impacted 1.0 0.000143348623853 0 1 -1
be,needed,due 1.0 0.000143348623853 0 1 -1
be,necessary,in 1.0 0.000143348623853 0 1 -1
be,necessary,if 1.0 0.00043004587156 0 3 -3
be,more,susceptible 1.0 0.000143348623853 0 1 -1
be,more,severe 1.0 0.000143348623853 0 1 -1
be,more,reactive 1.0 0.000573394495413 0 4 -4
be,monitored,with 1.0 0.000286697247706 0 2 -2
be,monitored,by 1.0 0.000286697247706 0 2 -2
be,monitored,appropriately 1.0 0.000143348623853 0 1 -1
be,modified,if 1.0 0.000143348623853 0 1 -1
be,modified,given 1.0 0.000143348623853 0 1 -1
be,mixed,with 1.0 0.000573394495413 0 4 -4
be,mimicked,by 1.0 0.000143348623853 0 1 -1
be,mediated,through 1.0 0.000143348623853 0 1 -1
be,manifested,by 1.0 0.000143348623853 0 1 -1
be,maintained,in 1.0 0.000143348623853 0 1 -1
be,made,whether 1.0 0.00043004587156 0 3 -3
be,made,on 1.0 0.000143348623853 0 1 -1
be,made,immediately 1.0 0.000143348623853 0 1 -1
be,made,carefully 1.0 0.000143348623853 0 1 -1
be,made,by 1.0 0.000143348623853 0 1 -1
be,lower,than 1.0 0.000143348623853 0 1 -1
be,lower,in 1.0 0.000143348623853 0 1 -1
be,low,for 1.0 0.000143348623853 0 1 -1
be,longer,in 1.0 0.000143348623853 0 1 -1
be,less,than 1.0 0.000143348623853 0 1 -1
be,involved,in 1.0 0.00043004587156 0 3 -3
be,interrupted,when 1.0 0.000143348623853 0 1 -1
be,interrupted,or 1.0 0.000143348623853 0 1 -1
be,interpreted,with 1.0 0.000286697247706 0 2 -2
be,interpreted,cautiously 1.0 0.000143348623853 0 1 -1
be,initiated,and 1.0 0.000143348623853 0 1 -1
be,initiated,after 1.0 0.000143348623853 0 1 -1
be,inhibited,in 1.0 0.000143348623853 0 1 -1
be,informed,when 1.0 0.000143348623853 0 1 -1
be,informed,that 1.0 0.000143348623853 0 1 -1
be,induced,resulting 1.0 0.000143348623853 0 1 -1
be,induced,in 1.0 0.000143348623853 0 1 -1
be,individualized,when 1.0 0.000143348623853 0 1 -1
be,indicated,in 1.0 0.000143348623853 0 1 -1
be,increased,serum 1.0 0.000143348623853 0 1 -1
be,increased,decreased 1.0 0.000286697247706 0 2 -2
be,increased,at 1.0 0.000143348623853 0 1 -1
be,increased,angiotensinogen 1.0 0.000286697247706 0 2 -2
be,included,into 1.0 0.000143348623853 0 1 -1
be,inactivated,by 1.0 0.000143348623853 0 1 -1
be,improved,and 1.0 0.000143348623853 0 1 -1
be,important,determinants 1.0 0.000143348623853 0 1 -1
be,important,also 1.0 0.000143348623853 0 1 -1
be,impaired,when 1.0 0.000143348623853 0 1 -1
be,highly,unstable 1.0 0.000143348623853 0 1 -1
be,highly,susceptible 1.0 0.000143348623853 0 1 -1
be,helpful,when 1.0 0.000143348623853 0 1 -1
be,hazardous,when 1.0 0.000143348623853 0 1 -1
be,guided,by 1.0 0.000143348623853 0 1 -1
be,given,without 1.0 0.000286697247706 0 2 -2
be,given,when 1.0 0.000143348623853 0 1 -1
be,given,tot 1.0 0.000143348623853 0 1 -1
be,given,together 1.0 0.000143348623853 0 1 -1
be,given,only 1.0 0.000143348623853 0 1 -1
be,given,concomitantly 1.0 0.000286697247706 0 2 -2
be,given,at 1.0 0.000143348623853 0 1 -1
be,further,increased 1.0 0.000143348623853 0 1 -1
be,free,of 1.0 0.000143348623853 0 1 -1
be,formed,by 1.0 0.000143348623853 0 1 -1
be,followed,and 1.0 0.000143348623853 0 1 -1
be,flexible,and 1.0 0.000143348623853 0 1 -1
be,falsely,elevated 1.0 0.000143348623853 0 1 -1
be,extrapolated,to 1.0 0.000143348623853 0 1 -1
be,expressed,in 1.0 0.000143348623853 0 1 -1
be,explained,either 1.0 0.000143348623853 0 1 -1
be,expected,with 1.0 0.000573394495413 0 4 -4
be,expected,since 1.0 0.000143348623853 0 1 -1
be,exercised,with 1.0 0.000286697247706 0 2 -2
be,exercised,and 1.0 0.000143348623853 0 1 -1
be,excluded,based 1.0 0.000143348623853 0 1 -1
be,exacerbated,in 1.0 0.000143348623853 0 1 -1
be,evaluated,in 1.0 0.000143348623853 0 1 -1
be,especially,important 1.0 0.000143348623853 0 1 -1
be,envisaged,in 1.0 0.000143348623853 0 1 -1
be,enhanced,or 1.0 0.000143348623853 0 1 -1
be,encountered,with 1.0 0.000143348623853 0 1 -1
be,employed,when 1.0 0.000143348623853 0 1 -1
be,employed,in 1.0 0.000143348623853 0 1 -1
be,employed,for 1.0 0.000143348623853 0 1 -1
be,employed,cautiously 1.0 0.000143348623853 0 1 -1
be,elevated,in 1.0 0.000286697247706 0 2 -2
be,efficacious,a 1.0 0.000143348623853 0 1 -1
be,effectively,and 1.0 0.000143348623853 0 1 -1
be,drawn,regarding 1.0 0.000143348623853 0 1 -1
be,drawn,into 1.0 0.000143348623853 0 1 -1
be,drawn,either 1.0 0.000143348623853 0 1 -1
be,done,with 1.0 0.000286697247706 0 2 -2
be,done,during 1.0 0.000143348623853 0 1 -1
be,done,at 1.0 0.000143348623853 0 1 -1
be,dispersed,in 1.0 0.000143348623853 0 1 -1
be,discontinued,several 1.0 0.000143348623853 0 1 -1
be,discontinued,prior 1.0 0.000286697247706 0 2 -2
be,discontinued,in 1.0 0.000143348623853 0 1 -1
be,discontinued,if 1.0 0.000143348623853 0 1 -1
be,discontinued,before 1.0 0.00043004587156 0 3 -3
be,discontinued,and 1.0 0.000143348623853 0 1 -1
be,different,for 1.0 0.000143348623853 0 1 -1
be,detrimental,for 1.0 0.000143348623853 0 1 -1
be,determined,on 1.0 0.000143348623853 0 1 -1
be,determined,by 1.0 0.000286697247706 0 2 -2
be,detected,in 1.0 0.000143348623853 0 1 -1
be,demonstrated,by 1.0 0.000143348623853 0 1 -1
be,delayed,until 1.0 0.000143348623853 0 1 -1
be,delayed,at 1.0 0.000143348623853 0 1 -1
be,deficient,in 1.0 0.000143348623853 0 1 -1
be,decreased,thiazides 1.0 0.000143348623853 0 1 -1
be,decreased,by 1.0 0.000286697247706 0 2 -2
be,decreased,activity 1.0 0.000143348623853 0 1 -1
be,crucial,to 1.0 0.000143348623853 0 1 -1
be,consistent,with 1.0 0.000143348623853 0 1 -1
be,considered,whenever 1.0 0.000143348623853 0 1 -1
be,considered,particularly 1.0 0.000286697247706 0 2 -2
be,considered,for 1.0 0.00043004587156 0 3 -3
be,considered,as 1.0 0.000143348623853 0 1 -1
be,considered,and 1.0 0.00043004587156 0 3 -3
be,considered,although 1.0 0.000143348623853 0 1 -1
be,confirmed,for 1.0 0.000143348623853 0 1 -1
be,conducted,in 1.0 0.000143348623853 0 1 -1
be,concomitantly,administered 1.0 0.000143348623853 0 1 -1
be,completed,at 1.0 0.000143348623853 0 1 -1
be,coad-ministered,with 1.0 0.000143348623853 0 1 -1
be,closely,watched 1.0 0.000143348623853 0 1 -1
be,clinically,relevant 1.0 0.000143348623853 0 1 -1
be,clastogenic,to 1.0 0.000143348623853 0 1 -1
be,changed,and 1.0 0.000143348623853 0 1 -1
be,cautioned,regarding 1.0 0.000143348623853 0 1 -1
be,cautioned,against 1.0 0.000143348623853 0 1 -1
be,cautioned,about 1.0 0.000143348623853 0 1 -1
be,caused,by 1.0 0.000143348623853 0 1 -1
be,catalyzed,by 1.0 0.000143348623853 0 1 -1
be,carried,out 1.0 0.000143348623853 0 1 -1
be,based,on 1.0 0.000143348623853 0 1 -1
be,aware,of 1.0 0.000286697247706 0 2 -2
be,avoided,while 1.0 0.000143348623853 0 1 -1
be,avoided,serum 1.0 0.000143348623853 0 1 -1
be,avoided,at 1.0 0.000143348623853 0 1 -1
be,avoided,as 1.0 0.00043004587156 0 3 -3
be,at,risk 1.0 0.000143348623853 0 1 -1
be,at,increased 1.0 0.000286697247706 0 2 -2
be,at,higher 1.0 0.000143348623853 0 1 -1
be,at,a 1.0 0.000143348623853 0 1 -1
be,assumed,to 1.0 0.000143348623853 0 1 -1
be,ascertained,between 1.0 0.000143348623853 0 1 -1
be,as,long 1.0 0.000143348623853 0 1 -1
be,artifactually,altered 1.0 0.000143348623853 0 1 -1
be,approximately,half 1.0 0.000143348623853 0 1 -1
be,approved,for 1.0 0.000143348623853 0 1 -1
be,applied,to 1.0 0.000143348623853 0 1 -1
be,applied,for 1.0 0.000143348623853 0 1 -1
be,anticipated,alternative 1.0 0.000143348623853 0 1 -1
be,analyzed,for 1.0 0.000143348623853 0 1 -1
be,an,inhibitor 1.0 0.000860091743119 0 6 -6
be,an,inducer 1.0 0.000286697247706 0 2 -2
be,an,increased 1.0 0.000143348623853 0 1 -1
be,an,increase 1.0 0.000143348623853 0 1 -1
be,altered,so 1.0 0.000143348623853 0 1 -1
be,alerted,to 1.0 0.000143348623853 0 1 -1
be,alert,for 1.0 0.000286697247706 0 2 -2
be,advocated,on 1.0 0.000143348623853 0 1 -1
be,adversely,affected 1.0 0.000143348623853 0 1 -1
be,administered,safely 1.0 0.000286697247706 0 2 -2
be,administered,or 1.0 0.000143348623853 0 1 -1
be,administered,on 1.0 0.000143348623853 0 1 -1
be,administered,cautiously 1.0 0.000143348623853 0 1 -1
be,administered,alternately 1.0 0.000286697247706 0 2 -2
be,administered,a 1.0 0.000143348623853 0 1 -1
be,adjusted,when 1.0 0.000143348623853 0 1 -1
be,adjusted,in 1.0 0.000573394495413 0 4 -4
be,additive,when 1.0 0.000143348623853 0 1 -1
be,achieved,with 1.0 0.000143348623853 0 1 -1
be,achieved,either 1.0 0.000143348623853 0 1 -1
be,accompanied,by 1.0 0.00043004587156 0 3 -3
be,above,the 1.0 0.000143348623853 0 1 -1
be,abnormal,in 1.0 0.000143348623853 0 1 -1
be,a,weak 1.0 0.000143348623853 0 1 -1
be,a,useful 1.0 0.000143348623853 0 1 -1
be,a,sign 1.0 0.000143348623853 0 1 -1
be,a,result 1.0 0.000143348623853 0 1 -1
be,a,primary 1.0 0.000143348623853 0 1 -1
be,a,precipitating 1.0 0.000143348623853 0 1 -1
be,a,non-enzyme 1.0 0.000143348623853 0 1 -1
be,a,complication 1.0 0.000143348623853 0 1 -1
basis,this,dose 1.0 0.000143348623853 0 1 -1
basis,of,this 1.0 0.00043004587156 0 3 -3
basis,of,therapeutic 1.0 0.000143348623853 0 1 -1
basis,of,hippocampal 1.0 0.000143348623853 0 1 -1
basis,of,antistress 1.0 0.000143348623853 0 1 -1
basis,it,is 1.0 0.000143348623853 0 1 -1
basis,increased,both 1.0 0.000143348623853 0 1 -1
basis,for,the 1.0 0.000286697247706 0 2 -2
basis,did,not 1.0 0.000143348623853 0 1 -1
basis,and,as 1.0 0.000143348623853 0 1 -1
basic,science,and 1.0 0.000143348623853 0 1 -1
basic,area,of 1.0 0.000143348623853 0 1 -1
baseline,vs,end 1.0 0.000143348623853 0 1 -1
baseline,use,of 1.0 0.000143348623853 0 1 -1
baseline,to,ng 1.0 0.000143348623853 0 1 -1
baseline,neutrophil,counts 1.0 0.000143348623853 0 1 -1
baseline,for,h 1.0 0.000143348623853 0 1 -1
baseline,and,on 1.0 0.000143348623853 0 1 -1
based,tests,such 1.0 0.000143348623853 0 1 -1
based,regimens,for 1.0 0.000143348623853 0 1 -1
based,on,this 1.0 0.000143348623853 0 1 -1
based,on,some 1.0 0.000143348623853 0 1 -1
based,on,previous 1.0 0.000143348623853 0 1 -1
based,on,known 1.0 0.000143348623853 0 1 -1
based,on,in-vitro 1.0 0.000143348623853 0 1 -1
based,on,enzymatic 1.0 0.000860091743119 0 6 -6
based,on,either 1.0 0.000286697247706 0 2 -2
based,on,drug 1.0 0.000286697247706 0 2 -2
based,on,body 1.0 0.000573394495413 0 4 -4
based,on,auc 1.0 0.000143348623853 0 1 -1
based,methods,gdh 1.0 0.000143348623853 0 1 -1
basal,small,intestinal 1.0 0.000143348623853 0 1 -1
basal,plasma,renin 1.0 0.000143348623853 0 1 -1
basal,plasma,cortisol 1.0 0.000143348623853 0 1 -1
basal,medium,rpmi1640 1.0 0.000143348623853 0 1 -1
basal,colonic,fluid 1.0 0.000143348623853 0 1 -1
basal,and,dmpge2-induced 1.0 0.000143348623853 0 1 -1
barrier,form,of 1.0 0.000143348623853 0 1 -1
barpress,response,in 1.0 0.000143348623853 0 1 -1
baraclude,with,that 1.0 0.000143348623853 0 1 -1
baraclude,with,other 1.0 0.000143348623853 0 1 -1
baraclude,is,coadministered 1.0 0.000143348623853 0 1 -1
bar-press,response,in 1.0 0.000143348623853 0 1 -1
bar-press,conditioning,and 1.0 0.000143348623853 0 1 -1
bar-press,behavior,in 1.0 0.000143348623853 0 1 -1
balanced,by,decreased 1.0 0.000143348623853 0 1 -1
balance,were,only 1.0 0.000143348623853 0 1 -1
balance,technique,and 1.0 0.000143348623853 0 1 -1
balance,patient,access 1.0 0.000143348623853 0 1 -1
balance,in,patients 1.0 0.000143348623853 0 1 -1
bactrim,septra,gantrisin 1.0 0.000143348623853 0 1 -1
bactericidal,concentration,of 1.0 0.000143348623853 0 1 -1
bactericidal,activity,is 1.0 0.000143348623853 0 1 -1
bacterial,mutation,assay 1.0 0.000143348623853 0 1 -1
bacterial,mutagenicity,assay 1.0 0.000143348623853 0 1 -1
bacterial,infection,and 1.0 0.000143348623853 0 1 -1
bacteria,tested,the 1.0 0.000143348623853 0 1 -1
bacteria,should,therefore 1.0 0.000143348623853 0 1 -1
bacteria,except,for 1.0 0.000143348623853 0 1 -1
bacteria,by,serial 1.0 0.000143348623853 0 1 -1
backwards,displacement,of 1.0 0.000143348623853 0 1 -1
background,the,pharmacokinetic 1.0 0.000143348623853 0 1 -1
background,the,feasibility 1.0 0.000143348623853 0 1 -1
background,the,effects 1.0 0.000143348623853 0 1 -1
background,since,its 1.0 0.000143348623853 0 1 -1
back,pain,arthralgia 1.0 0.000143348623853 0 1 -1
baboons,given,doses 1.0 0.000143348623853 0 1 -1
b6,weak,c19 1.0 0.000143348623853 0 1 -1
b6,physiological,doses 1.0 0.000143348623853 0 1 -1
b6,d6,e1 1.0 0.000143348623853 0 1 -1
b23,was,thus 1.0 0.000143348623853 0 1 -1
b23,is,involved 1.0 0.000143348623853 0 1 -1
b23,in,serum-deprived 1.0 0.000286697247706 0 2 -2
b23,in,anti-apoptotic 1.0 0.000143348623853 0 1 -1
b23,antisense,oligomer 1.0 0.000143348623853 0 1 -1
b23,and,apoptosis 1.0 0.000143348623853 0 1 -1
b23,activation,of 1.0 0.000143348623853 0 1 -1
b12,status,before 1.0 0.000143348623853 0 1 -1
b12,deficiency,is 1.0 0.000143348623853 0 1 -1
b12,because,they 1.0 0.000143348623853 0 1 -1
b-cell,lymphomas,when 1.0 0.000143348623853 0 1 -1
b-cell,lymphomas,occur 1.0 0.000143348623853 0 1 -1
b-cell,lymphoma,that 1.0 0.000143348623853 0 1 -1
b-cell,hyperplasia,of 1.0 0.000143348623853 0 1 -1
b-cell,dependent,areas 1.0 0.000143348623853 0 1 -1
b-adrenergic,blocking,agents 1.0 0.000286697247706 0 2 -2
b,were,more 1.0 0.000143348623853 0 1 -1
b,was,more 1.0 0.000143348623853 0 1 -1
b,this,table 1.0 0.000143348623853 0 1 -1
b,the,volunteers 1.0 0.000143348623853 0 1 -1
b,the,effects 1.0 0.000143348623853 0 1 -1
b,the,clearance 1.0 0.000143348623853 0 1 -1
b,or,the 1.0 0.000143348623853 0 1 -1
b,or,potassium-depleting 1.0 0.000143348623853 0 1 -1
b,or,corticosteroids 1.0 0.000143348623853 0 1 -1
b,however,is 1.0 0.000143348623853 0 1 -1
b,for,yeast 1.0 0.000143348623853 0 1 -1
b,estradiol,and 1.0 0.000143348623853 0 1 -1
b,cells,for 1.0 0.000143348623853 0 1 -1
b,can,be 1.0 0.000143348623853 0 1 -1
azopt,ophthalmic,suspension 1.0 0.000143348623853 0 1 -1
azoles,are,known 1.0 0.000143348623853 0 1 -1
azole,antifungals,the 1.0 0.000143348623853 0 1 -1
azole,antifungals,protease 1.0 0.000143348623853 0 1 -1
azithromycin,did,not 1.0 0.000143348623853 0 1 -1
axons,of,post-ganglionic 1.0 0.000143348623853 0 1 -1
axons,has,been 1.0 0.000143348623853 0 1 -1
axons,contained,plus 1.0 0.000143348623853 0 1 -1
axis,in,premenopausal 1.0 0.000143348623853 0 1 -1
axert,is,not 1.0 0.000143348623853 0 1 -1
aware,of,the 1.0 0.000286697247706 0 2 -2
avonex,indicates,that 1.0 0.000143348623853 0 1 -1
avonex,and,study 1.0 0.000143348623853 0 1 -1
avoided,while,taking 1.0 0.000143348623853 0 1 -1
avoided,serum,levels 1.0 0.000143348623853 0 1 -1
avoided,in,the 1.0 0.000143348623853 0 1 -1
avoided,in,connection 1.0 0.000143348623853 0 1 -1
avoided,because,a 1.0 0.000143348623853 0 1 -1
avoided,at,the 1.0 0.000143348623853 0 1 -1
avoided,as,this 1.0 0.00043004587156 0 3 -3
avoidance,behaviour,when 1.0 0.000143348623853 0 1 -1
avoidance,behaviour,of 1.0 0.000143348623853 0 1 -1
avoid,use,if 1.0 0.000143348623853 0 1 -1
avoid,them,and 1.0 0.000143348623853 0 1 -1
avoid,the,occurrence 1.0 0.000143348623853 0 1 -1
avoid,saw,palmetto 1.0 0.000143348623853 0 1 -1
avoid,potentiation,the 1.0 0.000143348623853 0 1 -1
avoid,intoxication,plasma 1.0 0.000143348623853 0 1 -1
avoid,intoxication,appropriate 1.0 0.000143348623853 0 1 -1
avoid,dong,quai 1.0 0.000143348623853 0 1 -1
avoid,concomitant,use 1.0 0.000143348623853 0 1 -1
avoid,administration,of 1.0 0.000143348623853 0 1 -1
avidities,for,the 1.0 0.000143348623853 0 1 -1
aviano,cancer,center 1.0 0.000143348623853 0 1 -1
average,infusion,rate 1.0 0.000143348623853 0 1 -1
average,higher,in 1.0 0.000143348623853 0 1 -1
average,for,the 1.0 0.000143348623853 0 1 -1
avastin,when,compared 1.0 0.000143348623853 0 1 -1
avastin,had,a 1.0 0.000143348623853 0 1 -1
available,uncontrolled,data 1.0 0.000143348623853 0 1 -1
available,to,direct 1.0 0.000143348623853 0 1 -1
available,regarding,the 1.0 0.000143348623853 0 1 -1
available,regarding,interactions 1.0 0.000143348623853 0 1 -1
available,on,potential 1.0 0.000143348623853 0 1 -1
available,on,concomitant 1.0 0.000143348623853 0 1 -1
available,kits,with 1.0 0.000143348623853 0 1 -1
available,it,is 1.0 0.000143348623853 0 1 -1
available,in,the 1.0 0.000143348623853 0 1 -1
available,hmgcoa,reductase 1.0 0.000143348623853 0 1 -1
available,from,the 1.0 0.00043004587156 0 3 -3
available,for,use 1.0 0.000143348623853 0 1 -1
available,for,the 1.0 0.000143348623853 0 1 -1
available,for,chelation 1.0 0.000143348623853 0 1 -1
available,data,suggest 1.0 0.000143348623853 0 1 -1
available,data,indicate 1.0 0.000143348623853 0 1 -1
available,data,are 1.0 0.00043004587156 0 3 -3
available,assay,methods 1.0 0.000143348623853 0 1 -1
available,and,only 1.0 0.000143348623853 0 1 -1
available,and,except 1.0 0.000143348623853 0 1 -1
available,about,the 1.0 0.000286697247706 0 2 -2
availability,of,relevant 1.0 0.000143348623853 0 1 -1
availability,of,potent 1.0 0.000143348623853 0 1 -1
av,nodes,however 1.0 0.000143348623853 0 1 -1
autonomic,neurotoxicity,whereas 1.0 0.000143348623853 0 1 -1
automatic,behavior,and 1.0 0.000143348623853 0 1 -1
automated,equipment,for 1.0 0.000143348623853 0 1 -1
autoinduction,has,been 1.0 0.000143348623853 0 1 -1
authors,investigated,the 1.0 0.000143348623853 0 1 -1
authors,examined,the 1.0 0.000143348623853 0 1 -1
authors,compared,retrospectively 1.0 0.000143348623853 0 1 -1
authorization,cards,mac 1.0 0.000143348623853 0 1 -1
aureus,to,survive 1.0 0.000143348623853 0 1 -1
aureus,diplococcus,pneumoniae 1.0 0.000143348623853 0 1 -1
august,were,identified 1.0 0.000143348623853 0 1 -1
augmentin,xr,patients 1.0 0.000143348623853 0 1 -1
augmented,the,response 1.0 0.000143348623853 0 1 -1
augmentation,persisted,even 1.0 0.000143348623853 0 1 -1
augmentation,of,component 1.0 0.000143348623853 0 1 -1
aucss,h,extent 1.0 0.000143348623853 0 1 -1
aucs,of,unbound 1.0 0.000143348623853 0 1 -1
aucs,of,the 1.0 0.000143348623853 0 1 -1
aucs,and,cmin 1.0 0.000143348623853 0 1 -1
aucasian,population,about 1.0 0.000143348623853 0 1 -1
auc0-30,days,achieved 1.0 0.000286697247706 0 2 -2
auc0-12,of,hydroxylamine 1.0 0.000143348623853 0 1 -1
auc,with,the 1.0 0.000143348623853 0 1 -1
auc,were,seen 1.0 0.000143348623853 0 1 -1
auc,were,not 1.0 0.000143348623853 0 1 -1
auc,were,dose 1.0 0.000143348623853 0 1 -1
auc,was,reduced 1.0 0.000143348623853 0 1 -1
auc,was,and 1.0 0.000143348623853 0 1 -1
auc,vs,cmax 1.0 0.000143348623853 0 1 -1
auc,values,are 1.0 0.000143348623853 0 1 -1
auc,or,maximum 1.0 0.000143348623853 0 1 -1
auc,of,on 1.0 0.000143348623853 0 1 -1
auc,of,during 1.0 0.000143348623853 0 1 -1
auc,more,than 1.0 0.000143348623853 0 1 -1
auc,infinity,auc 1.0 0.000143348623853 0 1 -1
auc,hrs,c 1.0 0.000143348623853 0 1 -1
auc,hours,based 1.0 0.000143348623853 0 1 -1
auc,for,total 1.0 0.000143348623853 0 1 -1
auc,exhibited,similar 1.0 0.000143348623853 0 1 -1
auc,ci,kg 1.0 0.000143348623853 0 1 -1
auc,c,max 1.0 0.000286697247706 0 2 -2
auc,by,about 1.0 0.000143348623853 0 1 -1
auc,based,on 1.0 0.000143348623853 0 1 -1
auc,and,maximum 1.0 0.000143348623853 0 1 -1
auc,and,increases 1.0 0.000143348623853 0 1 -1
auc,and,half-life 1.0 0.000143348623853 0 1 -1
auc,and,changes 1.0 0.000143348623853 0 1 -1
atypical,antipsychotic,with 1.0 0.000143348623853 0 1 -1
atypical,antipsychotic,was 1.0 0.000143348623853 0 1 -1
atypical,antipsychotic,agent 1.0 0.000143348623853 0 1 -1
attributed,to,inhibition 1.0 0.00143348623853 0 10 -10
attenuation,in,the 1.0 0.000143348623853 0 1 -1
attenuated,live,bacteria 1.0 0.000143348623853 0 1 -1
attenuated,by,endothelial 1.0 0.000143348623853 0 1 -1
attenuate,some,of 1.0 0.000286697247706 0 2 -2
attenuate,morphine-induced,locomotion 1.0 0.000143348623853 0 1 -1
attention,should,be 1.0 0.000286697247706 0 2 -2
attention,and,may 1.0 0.000143348623853 0 1 -1
attempts,to,provide 1.0 0.000143348623853 0 1 -1
attempting,to,replicate 1.0 0.000143348623853 0 1 -1
atropine-like,effects,may 1.0 0.000143348623853 0 1 -1
atropine,either,alone 1.0 0.000143348623853 0 1 -1
atrophy,was,seen 1.0 0.000143348623853 0 1 -1
atrophy,and,degenerative 1.0 0.000143348623853 0 1 -1
atracurium,was,again 1.0 0.000143348623853 0 1 -1
atracurium,infusion,was 1.0 0.000143348623853 0 1 -1
atp,oxaloacetate,and 1.0 0.000143348623853 0 1 -1
atp,and,serotonin 1.0 0.000143348623853 0 1 -1
atoxic,since,it 1.0 0.000143348623853 0 1 -1
atovaquone,is,highly 1.0 0.000143348623853 0 1 -1
atorvastatin,plasma,concentrations 1.0 0.000143348623853 0 1 -1
atorvastatin,had,no 1.0 0.000143348623853 0 1 -1
atomoxetine,is,primarily 1.0 0.000143348623853 0 1 -1
atiii,no,interactions 1.0 0.000143348623853 0 1 -1
atherosclerotic,risk,factors 1.0 0.000143348623853 0 1 -1
atherosclerotic,disease,is 1.0 0.000143348623853 0 1 -1
atherosclerotic,cardiovascular,disease 1.0 0.000143348623853 0 1 -1
atg,alg,mycophenolate 1.0 0.000143348623853 0 1 -1
atcc,showed,the 1.0 0.000143348623853 0 1 -1
ataxia,dysarthria,incoordination 1.0 0.000143348623853 0 1 -1
ataxia,blurred,vision 1.0 0.000143348623853 0 1 -1
ataxia,a,typical 1.0 0.000143348623853 0 1 -1
at,which,certain 1.0 0.000143348623853 0 1 -1
at,weekly,or 1.0 0.000286697247706 0 2 -2
at,very,high 1.0 0.000143348623853 0 1 -1
at,various,temperatures 1.0 0.000143348623853 0 1 -1
at,total,drug 1.0 0.000143348623853 0 1 -1
at,to,week 1.0 0.000143348623853 0 1 -1
at,three,different 1.0 0.000143348623853 0 1 -1
at,three,concentrations 1.0 0.000143348623853 0 1 -1
at,therapeutic,levels 1.0 0.000143348623853 0 1 -1
at,their,usual 1.0 0.000143348623853 0 1 -1
at,the,time 1.0 0.000286697247706 0 2 -2
at,the,three 1.0 0.000143348623853 0 1 -1
at,the,site 1.0 0.000286697247706 0 2 -2
at,the,outset 1.0 0.000143348623853 0 1 -1
at,the,intervals 1.0 0.000143348623853 0 1 -1
at,the,insp 1.0 0.000143348623853 0 1 -1
at,the,highest 1.0 0.000286697247706 0 2 -2
at,the,higher 1.0 0.000143348623853 0 1 -1
at,the,end 1.0 0.000286697247706 0 2 -2
at,the,dose 1.0 0.000143348623853 0 1 -1
at,the,desired 1.0 0.000286697247706 0 2 -2
at,the,clinical 1.0 0.000143348623853 0 1 -1
at,the,cellular 1.0 0.000143348623853 0 1 -1
at,the,cardiac 1.0 0.000143348623853 0 1 -1
at,the,aviano 1.0 0.000143348623853 0 1 -1
at,the,absorption 1.0 0.000143348623853 0 1 -1
at,that,time 1.0 0.000143348623853 0 1 -1
at,steady-state,were 1.0 0.000143348623853 0 1 -1
at,steady-state,in 1.0 0.000143348623853 0 1 -1
at,steady-state,exposure 1.0 0.000143348623853 0 1 -1
at,stable,as 1.0 0.000143348623853 0 1 -1
at,specified,time 1.0 0.000143348623853 0 1 -1
at,similar,median 1.0 0.000143348623853 0 1 -1
at,similar,concentrations 1.0 0.000143348623853 0 1 -1
at,risk,for 1.0 0.000143348623853 0 1 -1
at,ph,was 1.0 0.000143348623853 0 1 -1
at,other,doses 1.0 0.000286697247706 0 2 -2
at,of,baseline 1.0 0.000143348623853 0 1 -1
at,nacmc,with 1.0 0.000143348623853 0 1 -1
at,min,after 1.0 0.000143348623853 0 1 -1
at,microm,which 1.0 0.000143348623853 0 1 -1
at,mg,rat 1.0 0.000143348623853 0 1 -1
at,mg,kg 1.0 0.00129013761468 0 9 -9
at,m,v 1.0 0.000143348623853 0 1 -1
at,lower,concentrations 1.0 0.000143348623853 0 1 -1
at,low-levels,of 1.0 0.000143348623853 0 1 -1
at,low,levels 1.0 0.000143348623853 0 1 -1
at,low,as 1.0 0.000143348623853 0 1 -1
at,levels,significantly 1.0 0.000143348623853 0 1 -1
at,least,the 1.0 0.000143348623853 0 1 -1
at,least,six 1.0 0.000143348623853 0 1 -1
at,least,seven 1.0 0.000143348623853 0 1 -1
at,least,of 1.0 0.000143348623853 0 1 -1
at,least,months 1.0 0.000286697247706 0 2 -2
at,least,miu 1.0 0.000143348623853 0 1 -1
at,least,four 1.0 0.000143348623853 0 1 -1
at,least,five 1.0 0.000143348623853 0 1 -1
at,least,balanced 1.0 0.000143348623853 0 1 -1
at,least,an 1.0 0.000143348623853 0 1 -1
at,intramuscular,doses 1.0 0.000143348623853 0 1 -1
at,intervals,as 1.0 0.000143348623853 0 1 -1
at,hr,p 1.0 0.000143348623853 0 1 -1
at,high,doses 1.0 0.000286697247706 0 2 -2
at,high,concentrations 1.0 0.000286697247706 0 2 -2
at,h,up 1.0 0.000143348623853 0 1 -1
at,h,for 1.0 0.000143348623853 0 1 -1
at,h,also 1.0 0.000143348623853 0 1 -1
at,greater,risk 1.0 0.000143348623853 0 1 -1
at,five,commonly 1.0 0.000143348623853 0 1 -1
at,exposure,levels 1.0 0.000143348623853 0 1 -1
at,either,dose 1.0 0.000143348623853 0 1 -1
at,doses,up 1.0 0.000573394495413 0 4 -4
at,doses,mg 1.0 0.00043004587156 0 3 -3
at,doses,as 1.0 0.000143348623853 0 1 -1
at,dosages,exceeding 1.0 0.000143348623853 0 1 -1
at,different,times 1.0 0.000286697247706 0 2 -2
at,different,levels 1.0 0.000143348623853 0 1 -1
at,degrees,c 1.0 0.000286697247706 0 2 -2
at,daily,doses 1.0 0.000143348623853 0 1 -1
at,concentrations,well 1.0 0.000143348623853 0 1 -1
at,concentrations,up 1.0 0.000143348623853 0 1 -1
at,concentrations,ranging 1.0 0.000286697247706 0 2 -2
at,concentrations,of 1.0 0.00043004587156 0 3 -3
at,concentrations,in 1.0 0.000286697247706 0 2 -2
at,concentrations,as 1.0 0.000143348623853 0 1 -1
at,clinically,relevant 1.0 0.000143348623853 0 1 -1
at,c,drug 1.0 0.000143348623853 0 1 -1
at,but,not 1.0 0.000143348623853 0 1 -1
at,bedtime,has 1.0 0.000143348623853 0 1 -1
at,bedtime,and 1.0 0.000143348623853 0 1 -1
at,baseline,to 1.0 0.000143348623853 0 1 -1
at,baseline,and 1.0 0.000286697247706 0 2 -2
at,as,v 1.0 0.000143348623853 0 1 -1
at,as,great 1.0 0.000143348623853 0 1 -1
at,approximately,to 1.0 0.000143348623853 0 1 -1
at,any,time 1.0 0.000143348623853 0 1 -1
at,any,occasion 1.0 0.000143348623853 0 1 -1
at,and,min 1.0 0.000143348623853 0 1 -1
at,and,m 1.0 0.000143348623853 0 1 -1
at,all,in 1.0 0.000286697247706 0 2 -2
at,a,site 1.0 0.000143348623853 0 1 -1
at,a,plasma 1.0 0.000143348623853 0 1 -1
at,a,median 1.0 0.000143348623853 0 1 -1
at,a,lower 1.0 0.000143348623853 0 1 -1
at,a,low 1.0 0.000286697247706 0 2 -2
at,a,later 1.0 0.000143348623853 0 1 -1
at,a,higher 1.0 0.000286697247706 0 2 -2
at,a,greater 1.0 0.000143348623853 0 1 -1
at,a,different 1.0 0.000143348623853 0 1 -1
at,a,concentration 1.0 0.00043004587156 0 3 -3
asymptomatic,transitory,changes 1.0 0.000143348623853 0 1 -1
asymptomatic,increases,in 1.0 0.000143348623853 0 1 -1
asymptomatic,but,can 1.0 0.000143348623853 0 1 -1
astringents,spices,or 1.0 0.000143348623853 0 1 -1
asthma,therapy,compliance 1.0 0.000143348623853 0 1 -1
asthma,or,copd 1.0 0.000286697247706 0 2 -2
asthma,decreased,effectiveness 1.0 0.000143348623853 0 1 -1
asthma,control,and 1.0 0.000143348623853 0 1 -1
ast,times,the 1.0 0.000143348623853 0 1 -1
ast,sgot,alt 1.0 0.000143348623853 0 1 -1
assumed,to,have 1.0 0.000143348623853 0 1 -1
assumed,that,increased 1.0 0.000143348623853 0 1 -1
assume,that,there 1.0 0.000143348623853 0 1 -1
association,with,reported 1.0 0.000143348623853 0 1 -1
association,with,anaesthesia 1.0 0.000143348623853 0 1 -1
association,though,less 1.0 0.000286697247706 0 2 -2
association,of,deep-seated 1.0 0.000143348623853 0 1 -1
association,has,not 1.0 0.000143348623853 0 1 -1
association,functional,class 1.0 0.000143348623853 0 1 -1
association,between,and 1.0 0.000143348623853 0 1 -1
associated,with,torsades 1.0 0.000143348623853 0 1 -1
associated,with,strenuous 1.0 0.000143348623853 0 1 -1
associated,with,somatic 1.0 0.000143348623853 0 1 -1
associated,with,significantly 1.0 0.000143348623853 0 1 -1
associated,with,significant 1.0 0.000143348623853 0 1 -1
associated,with,serotonin 1.0 0.000143348623853 0 1 -1
associated,with,serious 1.0 0.000143348623853 0 1 -1
associated,with,resistance 1.0 0.000286697247706 0 2 -2
associated,with,reports 1.0 0.000143348623853 0 1 -1
associated,with,qt-interval 1.0 0.000143348623853 0 1 -1
associated,with,prostatectomy 1.0 0.000143348623853 0 1 -1
associated,with,physicians 1.0 0.000143348623853 0 1 -1
associated,with,peripheral 1.0 0.000286697247706 0 2 -2
associated,with,other 1.0 0.000143348623853 0 1 -1
associated,with,myopathy 1.0 0.000143348623853 0 1 -1
associated,with,joint 1.0 0.000143348623853 0 1 -1
associated,with,indirect 1.0 0.000143348623853 0 1 -1
associated,with,in 1.0 0.000143348623853 0 1 -1
associated,with,hepatic 1.0 0.000143348623853 0 1 -1
associated,with,depression 1.0 0.000143348623853 0 1 -1
associated,with,coronary 1.0 0.000143348623853 0 1 -1
associated,with,concomitant 1.0 0.00043004587156 0 3 -3
associated,with,bleeding 1.0 0.000143348623853 0 1 -1
associated,with,acute 1.0 0.000143348623853 0 1 -1
associated,side-effect,profiles 1.0 0.000143348623853 0 1 -1
associated,in,intact 1.0 0.000143348623853 0 1 -1
associated,adverse,event 1.0 0.000143348623853 0 1 -1
assists,in,development 1.0 0.000143348623853 0 1 -1
assistance,in,detecting 1.0 0.000143348623853 0 1 -1
assist,the,clinician 1.0 0.000143348623853 0 1 -1
assigned,to,receive 1.0 0.000143348623853 0 1 -1
assigned,to,one 1.0 0.000143348623853 0 1 -1
assigned,in,a 1.0 0.000143348623853 0 1 -1
assessments,of,pt 1.0 0.000143348623853 0 1 -1
assessments,of,pharmacokinetic 1.0 0.000143348623853 0 1 -1
assessments,of,drug-drug 1.0 0.000143348623853 0 1 -1
assessment,of,in 1.0 0.000143348623853 0 1 -1
assessed,the,ability 1.0 0.000143348623853 0 1 -1
assessed,on,day 1.0 0.000143348623853 0 1 -1
assessed,in,various 1.0 0.000143348623853 0 1 -1
assessed,in,two 1.0 0.000143348623853 0 1 -1
assessed,in,the 1.0 0.00043004587156 0 3 -3
assessed,in,clinical 1.0 0.000143348623853 0 1 -1
assessed,by,ex 1.0 0.000143348623853 0 1 -1
assessed,by,evaluating 1.0 0.000143348623853 0 1 -1
assessed,by,electrocardiographic 1.0 0.000286697247706 0 2 -2
assess,the,potential 1.0 0.000143348623853 0 1 -1
assess,the,effect 1.0 0.000143348623853 0 1 -1
assess,the,carcinogenic 1.0 0.000143348623853 0 1 -1
assess,if,there 1.0 0.000286697247706 0 2 -2
assays,using,red 1.0 0.000143348623853 0 1 -1
assays,resulting,in 1.0 0.000143348623853 0 1 -1
assays,of,hydroxy 1.0 0.000143348623853 0 1 -1
assays,caution,should 1.0 0.000143348623853 0 1 -1
assays,based,on 1.0 0.000286697247706 0 2 -2
assay,xigris,present 1.0 0.000143348623853 0 1 -1
assay,with,solid 1.0 0.000143348623853 0 1 -1
assay,system,of 1.0 0.000143348623853 0 1 -1
assay,result,is 1.0 0.000143348623853 0 1 -1
assay,of,thio 1.0 0.000143348623853 0 1 -1
assay,of,serum 1.0 0.000143348623853 0 1 -1
assay,methods,toxi-lab 1.0 0.000143348623853 0 1 -1
assay,in,strains 1.0 0.000143348623853 0 1 -1
assay,in,mouse 1.0 0.000143348623853 0 1 -1
assay,in,human 1.0 0.000143348623853 0 1 -1
assay,as,a 1.0 0.000143348623853 0 1 -1
assay,appears,to 1.0 0.000143348623853 0 1 -1
assay,and,the 1.0 0.000143348623853 0 1 -1
assay,and,in 1.0 0.000143348623853 0 1 -1
assay,and,emit-d 1.0 0.000143348623853 0 1 -1
aspirin-mediated,inhibition,of 1.0 0.000143348623853 0 1 -1
aspirin,vardenafil,mg 1.0 0.000143348623853 0 1 -1
aspirin,nonsteroidal,antiinflammatory 1.0 0.000143348623853 0 1 -1
aspirin,ketoprofen,does 1.0 0.000143348623853 0 1 -1
aspirin,and,have 1.0 0.000143348623853 0 1 -1
aspirin,acetaminophen,pharmacokinetic 1.0 0.000143348623853 0 1 -1
aspergillus,eia,test 1.0 0.000286697247706 0 2 -2
aspects,that,impact 1.0 0.000143348623853 0 1 -1
aspects,of,learning 1.0 0.000143348623853 0 1 -1
aspecific,treatments,of 1.0 0.000143348623853 0 1 -1
ask,your,physician 1.0 0.000143348623853 0 1 -1
asian,african,and 1.0 0.000716743119266 0 5 -5
ascorbic,acid,may 1.0 0.000143348623853 0 1 -1
ascorbic,acid,in 1.0 0.000143348623853 0 1 -1
ascorbic,acid,for 1.0 0.000143348623853 0 1 -1
ascorbic,acid,and 1.0 0.000143348623853 0 1 -1
ascorbic,acid,although 1.0 0.000143348623853 0 1 -1
ascertained,between,mealtime 1.0 0.000143348623853 0 1 -1
ascertain,when,adjustment 1.0 0.000143348623853 0 1 -1
asa,and,may 1.0 0.000143348623853 0 1 -1
as,with,high 1.0 0.000143348623853 0 1 -1
as,with,all 1.0 0.000286697247706 0 2 -2
as,well,and 1.0 0.000143348623853 0 1 -1
as,was,evident 1.0 0.000143348623853 0 1 -1
as,v,remains 1.0 0.000143348623853 0 1 -1
as,v,readily 1.0 0.000143348623853 0 1 -1
as,v,has 1.0 0.000143348623853 0 1 -1
as,v,concentrations 1.0 0.000286697247706 0 2 -2
as,v,concentration 1.0 0.000143348623853 0 1 -1
as,v,and 1.0 0.000143348623853 0 1 -1
as,urinary,excretion 1.0 0.000143348623853 0 1 -1
as,uncompromised,elderly 1.0 0.000143348623853 0 1 -1
as,triple,combination 1.0 0.000143348623853 0 1 -1
as,toxic,epidermal 1.0 0.000143348623853 0 1 -1
as,topical,injectable 1.0 0.000143348623853 0 1 -1
as,tolerance,and 1.0 0.000143348623853 0 1 -1
as,to,provide 1.0 0.000143348623853 0 1 -1
as,to,establish 1.0 0.000143348623853 0 1 -1
as,those,used 1.0 0.000143348623853 0 1 -1
as,those,found 1.0 0.000143348623853 0 1 -1
as,those,elevations 1.0 0.000143348623853 0 1 -1
as,thorazine,prolixin 1.0 0.000143348623853 0 1 -1
as,this,may 1.0 0.000143348623853 0 1 -1
as,this,could 1.0 0.00043004587156 0 3 -3
as,they,relate 1.0 0.000143348623853 0 1 -1
as,these,disorders 1.0 0.000143348623853 0 1 -1
as,there,is 1.0 0.000143348623853 0 1 -1
as,the,was 1.0 0.000143348623853 0 1 -1
as,the,sole 1.0 0.000143348623853 0 1 -1
as,the,serum 1.0 0.000143348623853 0 1 -1
as,the,retention 1.0 0.000143348623853 0 1 -1
as,the,physician 1.0 0.000143348623853 0 1 -1
as,the,interaction 1.0 0.000143348623853 0 1 -1
as,the,geriatric 1.0 0.000143348623853 0 1 -1
as,the,cytochrome 1.0 0.000286697247706 0 2 -2
as,the,cyp 1.0 0.000143348623853 0 1 -1
as,the,cost-risk 1.0 0.000143348623853 0 1 -1
as,the,coat-a 1.0 0.000143348623853 0 1 -1
as,that,in 1.0 0.000143348623853 0 1 -1
as,tablets,was 1.0 0.000143348623853 0 1 -1
as,systemic,levels 1.0 0.000143348623853 0 1 -1
as,sulfamethoxazole-trimethoprim,bactrim 1.0 0.000143348623853 0 1 -1
as,such,it 1.0 0.00043004587156 0 3 -3
as,such,a 1.0 0.000143348623853 0 1 -1
as,subsequent,synthesis 1.0 0.000143348623853 0 1 -1
as,strong,inhibitors 1.0 0.000143348623853 0 1 -1
as,stadol,ns 1.0 0.000286697247706 0 2 -2
as,stable,as 1.0 0.000143348623853 0 1 -1
as,specific,molecular 1.0 0.000143348623853 0 1 -1
as,sole,protease 1.0 0.000143348623853 0 1 -1
as,should,be 1.0 0.000143348623853 0 1 -1
as,seen,with 1.0 0.000143348623853 0 1 -1
as,safety,of 1.0 0.000143348623853 0 1 -1
as,risk,of 1.0 0.000286697247706 0 2 -2
as,retention,in 1.0 0.000143348623853 0 1 -1
as,required,to 1.0 0.000143348623853 0 1 -1
as,renal,vascular 1.0 0.000143348623853 0 1 -1
as,reinforcing,effects 1.0 0.000143348623853 0 1 -1
as,recommended,in 1.0 0.000143348623853 0 1 -1
as,psoriasis,rheumatoid 1.0 0.000143348623853 0 1 -1
as,prophylaxis,after 1.0 0.000143348623853 0 1 -1
as,proof,of 1.0 0.000143348623853 0 1 -1
as,prolonged,or 1.0 0.000286697247706 0 2 -2
as,potent,of 1.0 0.000143348623853 0 1 -1
as,possible,when 1.0 0.000143348623853 0 1 -1
as,possible,to 1.0 0.000143348623853 0 1 -1
as,poor,metabolizers 1.0 0.000286697247706 0 2 -2
as,platelet,inhibitors 1.0 0.000143348623853 0 1 -1
as,plasma,protein 1.0 0.000143348623853 0 1 -1
as,phlebitis,cellulitis 1.0 0.000143348623853 0 1 -1
as,peripheral,neuropathy 1.0 0.000143348623853 0 1 -1
as,part,of 1.0 0.000286697247706 0 2 -2
as,palpitations,or 1.0 0.000143348623853 0 1 -1
as,oral,parenteral 1.0 0.000143348623853 0 1 -1
as,or,would 1.0 0.000143348623853 0 1 -1
as,or,or 1.0 0.000143348623853 0 1 -1
as,or,large 1.0 0.000143348623853 0 1 -1
as,or,iv 1.0 0.000143348623853 0 1 -1
as,or,is 1.0 0.000143348623853 0 1 -1
as,or,concurrent 1.0 0.000143348623853 0 1 -1
as,or,a 1.0 0.000143348623853 0 1 -1
as,operating,machinery 1.0 0.000143348623853 0 1 -1
as,one,possible 1.0 0.000143348623853 0 1 -1
as,of,the 1.0 0.000143348623853 0 1 -1
as,nsaids,and 1.0 0.000143348623853 0 1 -1
as,noted,below 1.0 0.000143348623853 0 1 -1
as,nonsteroidal,agents 1.0 0.000143348623853 0 1 -1
as,muscle,pain 1.0 0.000143348623853 0 1 -1
as,mug,ml 1.0 0.000143348623853 0 1 -1
as,motrin,advil 1.0 0.000143348623853 0 1 -1
as,most,excretion 1.0 0.000143348623853 0 1 -1
as,monotherapy,given 1.0 0.000143348623853 0 1 -1
as,minimal,bactericidal 1.0 0.000143348623853 0 1 -1
as,mhd,the 1.0 0.000143348623853 0 1 -1
as,mg,was 1.0 0.000143348623853 0 1 -1
as,mg,of 1.0 0.000143348623853 0 1 -1
as,mg,kg 1.0 0.000143348623853 0 1 -1
as,methyltetrahydro-folate,and 1.0 0.000143348623853 0 1 -1
as,mercapturic,acids 1.0 0.000143348623853 0 1 -1
as,may,also 1.0 0.000143348623853 0 1 -1
as,marplan,parnate 1.0 0.000143348623853 0 1 -1
as,marplan,nardil 1.0 0.000143348623853 0 1 -1
as,manifested,by 1.0 0.000143348623853 0 1 -1
as,low,as 1.0 0.000143348623853 0 1 -1
as,k,antagonists 1.0 0.000143348623853 0 1 -1
as,judged,from 1.0 0.000143348623853 0 1 -1
as,judged,by 1.0 0.000143348623853 0 1 -1
as,it,had 1.0 0.000143348623853 0 1 -1
as,is,subject 1.0 0.000143348623853 0 1 -1
as,is,seen 1.0 0.000143348623853 0 1 -1
as,is,a 1.0 0.000143348623853 0 1 -1
as,ironing,kilometers 1.0 0.000143348623853 0 1 -1
as,intravenous,mg 1.0 0.000143348623853 0 1 -1
as,interaction,sites 1.0 0.000143348623853 0 1 -1
as,initial,therapy 1.0 0.000143348623853 0 1 -1
as,inhibitors,for 1.0 0.000143348623853 0 1 -1
as,indicated,in 1.0 0.000143348623853 0 1 -1
as,inderal,tenormin 1.0 0.000143348623853 0 1 -1
as,increasingly,important 1.0 0.000143348623853 0 1 -1
as,increasing,overall 1.0 0.000143348623853 0 1 -1
as,in,the 1.0 0.000286697247706 0 2 -2
as,impulsivity,and 1.0 0.000143348623853 0 1 -1
as,implants,and 1.0 0.000143348623853 0 1 -1
as,immediate-early,genes 1.0 0.000143348623853 0 1 -1
as,imitrex,talk 1.0 0.000143348623853 0 1 -1
as,hypotension,requiring 1.0 0.000143348623853 0 1 -1
as,his,own 1.0 0.000143348623853 0 1 -1
as,high-dose,may 1.0 0.000143348623853 0 1 -1
as,high,as 1.0 0.00043004587156 0 3 -3
as,hctz,hydrodiuril 1.0 0.000143348623853 0 1 -1
as,have,not 1.0 0.000143348623853 0 1 -1
as,great,an 1.0 0.000143348623853 0 1 -1
as,grapefruit,orange 1.0 0.000143348623853 0 1 -1
as,for,weeks 1.0 0.000143348623853 0 1 -1
as,for,the 1.0 0.000143348623853 0 1 -1
as,flushing,skin 1.0 0.000143348623853 0 1 -1
as,factor,viii 1.0 0.000143348623853 0 1 -1
as,factor,ii 1.0 0.000143348623853 0 1 -1
as,effects,on 1.0 0.000143348623853 0 1 -1
as,effective,in 1.0 0.000143348623853 0 1 -1
as,effective,as 1.0 0.000143348623853 0 1 -1
as,dose,and 1.0 0.000143348623853 0 1 -1
as,directed,by 1.0 0.000143348623853 0 1 -1
as,directed,and 1.0 0.000143348623853 0 1 -1
as,diphen-hydramine,and 1.0 0.000143348623853 0 1 -1
as,differin,gel 1.0 0.000143348623853 0 1 -1
as,determined,by 1.0 0.000143348623853 0 1 -1
as,demonstrated,by 1.0 0.000143348623853 0 1 -1
as,deltasone,orasone 1.0 0.000143348623853 0 1 -1
as,control,and 1.0 0.000143348623853 0 1 -1
as,compulsion,loss 1.0 0.000143348623853 0 1 -1
as,complications,related 1.0 0.000143348623853 0 1 -1
as,common,pathogens 1.0 0.000143348623853 0 1 -1
as,colostrum,iga 1.0 0.000143348623853 0 1 -1
as,co-activator,in 1.0 0.000143348623853 0 1 -1
as,cns,cardiac 1.0 0.000143348623853 0 1 -1
as,clinistix,or 1.0 0.000573394495413 0 4 -4
as,clinistix,and 1.0 0.000143348623853 0 1 -1
as,channel-blockers,ace 1.0 0.000143348623853 0 1 -1
as,causally,related 1.0 0.000143348623853 0 1 -1
as,binding,of 1.0 0.000143348623853 0 1 -1
as,beta-adrenergic,blocking 1.0 0.000143348623853 0 1 -1
as,being,homocysteine 1.0 0.000143348623853 0 1 -1
as,back,pain 1.0 0.000143348623853 0 1 -1
as,assessed,by 1.0 0.00043004587156 0 3 -3
as,appropriate,in 1.0 0.000143348623853 0 1 -1
as,and,which 1.0 0.000143348623853 0 1 -1
as,and,the 1.0 0.000286697247706 0 2 -2
as,and,similar 1.0 0.000143348623853 0 1 -1
as,and,respectively 1.0 0.000143348623853 0 1 -1
as,and,oral 1.0 0.000143348623853 0 1 -1
as,and,inhibit 1.0 0.000143348623853 0 1 -1
as,and,in 1.0 0.000143348623853 0 1 -1
as,and,cardiac 1.0 0.000143348623853 0 1 -1
as,an,open 1.0 0.000143348623853 0 1 -1
as,an,index 1.0 0.000286697247706 0 2 -2
as,an,expression 1.0 0.000143348623853 0 1 -1
as,an,agent 1.0 0.000143348623853 0 1 -1
as,age,gender 1.0 0.000143348623853 0 1 -1
as,adverse,experiences 1.0 0.000143348623853 0 1 -1
as,acute,toxicity 1.0 0.000286697247706 0 2 -2
as,ace,inhibitors 1.0 0.000143348623853 0 1 -1
as,a,tool 1.0 0.000143348623853 0 1 -1
as,a,substitute 1.0 0.000143348623853 0 1 -1
as,a,single 1.0 0.00043004587156 0 3 -3
as,a,premedication 1.0 0.000143348623853 0 1 -1
as,a,precursor 1.0 0.000143348623853 0 1 -1
as,a,potential 1.0 0.000143348623853 0 1 -1
as,a,possible 1.0 0.000143348623853 0 1 -1
as,a,moderate 1.0 0.000143348623853 0 1 -1
as,a,method 1.0 0.000286697247706 0 2 -2
as,a,local 1.0 0.000143348623853 0 1 -1
as,a,high 1.0 0.000143348623853 0 1 -1
as,a,gas 1.0 0.000143348623853 0 1 -1
as,a,function 1.0 0.000143348623853 0 1 -1
as,a,first-line 1.0 0.000143348623853 0 1 -1
as,a,false-negative 1.0 0.000286697247706 0 2 -2
as,a,d 1.0 0.000143348623853 0 1 -1
as,a,class 1.0 0.000143348623853 0 1 -1
as,a,change 1.0 0.000143348623853 0 1 -1
artocarpus,integrifolia,jackfruit 1.0 0.000143348623853 0 1 -1
artifactually,low,results 1.0 0.000143348623853 0 1 -1
artifactually,altered,it 1.0 0.000143348623853 0 1 -1
article,will,describe 1.0 0.000143348623853 0 1 -1
article,reviews,the 1.0 0.000143348623853 0 1 -1
article,review,papers 1.0 0.000143348623853 0 1 -1
article,looks,at 1.0 0.000143348623853 0 1 -1
arthritis,patients,taking 1.0 0.000286697247706 0 2 -2
arthritis,or,crohn 1.0 0.000143348623853 0 1 -1
arthritis,n,as 1.0 0.000143348623853 0 1 -1
arthritis,concomitant,medications 1.0 0.000143348623853 0 1 -1
arthritis,clinical,trials 1.0 0.000143348623853 0 1 -1
arthritis,and,liver 1.0 0.000143348623853 0 1 -1
arthritic,patients,receiving 1.0 0.000143348623853 0 1 -1
arthralgia,limb,injury 1.0 0.000143348623853 0 1 -1
artery,disease,and 1.0 0.000143348623853 0 1 -1
artery,disease,aged 1.0 0.000143348623853 0 1 -1
arteries,preconstricted,with 1.0 0.000143348623853 0 1 -1
arteries,of,lean 1.0 0.000143348623853 0 1 -1
arteries,from,male 1.0 0.000143348623853 0 1 -1
arteries,from,lean 1.0 0.000143348623853 0 1 -1
arteries,from,dietary-obese 1.0 0.00043004587156 0 3 -3
arteries,from,both 1.0 0.000143348623853 0 1 -1
arterial,pressure,deep 1.0 0.000143348623853 0 1 -1
arterial,hypertension,did 1.0 0.000143348623853 0 1 -1
arsenical,reactive,encephalopathy 1.0 0.000143348623853 0 1 -1
arsenical,encephalopathy,in 1.0 0.000143348623853 0 1 -1
arrival,of,oral 1.0 0.000143348623853 0 1 -1
arrhythmias,who,are 1.0 0.000143348623853 0 1 -1
arrhythmias,qt,prolongation 1.0 0.000143348623853 0 1 -1
arrhythmias,or,toxicity 1.0 0.000143348623853 0 1 -1
arrhythmias,may,respond 1.0 0.000143348623853 0 1 -1
arrhythmias,may,mask 1.0 0.000143348623853 0 1 -1
arrhythmias,including,ventricular 1.0 0.000143348623853 0 1 -1
arrhythmias,in,the 1.0 0.000143348623853 0 1 -1
arrhythmias,in,patients 1.0 0.000143348623853 0 1 -1
arrests,have,occurred 1.0 0.000143348623853 0 1 -1
arrest,with,full 1.0 0.000143348623853 0 1 -1
arrest,torsades,de 1.0 0.000143348623853 0 1 -1
arrest,during,initial 1.0 0.000143348623853 0 1 -1
arrest,cardiac,arrest 1.0 0.000143348623853 0 1 -1
arrangements,in,an 1.0 0.000143348623853 0 1 -1
arm,was,discontinued 1.0 0.000143348623853 0 1 -1
arise,in,association 1.0 0.000143348623853 0 1 -1
arise,from,a 1.0 0.000143348623853 0 1 -1
aripiprazole,is,unlikely 1.0 0.000143348623853 0 1 -1
aripiprazole,is,not 1.0 0.000143348623853 0 1 -1
aripiprazole,also,does 1.0 0.000143348623853 0 1 -1
arimidex,with,other 1.0 0.000143348623853 0 1 -1
arimidex,and,did 1.0 0.000143348623853 0 1 -1
arginine,in,the 1.0 0.000286697247706 0 2 -2
argatroban,with,thrombolytic 1.0 0.000143348623853 0 1 -1
argatroban,is,to 1.0 0.000143348623853 0 1 -1
argatroban,g,kg 1.0 0.000143348623853 0 1 -1
argatroban,and,is 1.0 0.000143348623853 0 1 -1
argatroban,and,concomitantly 1.0 0.000143348623853 0 1 -1
arenot,established,but 1.0 0.000286697247706 0 2 -2
areas,where,abuse 1.0 0.000143348623853 0 1 -1
areas,of,your 1.0 0.000143348623853 0 1 -1
areas,in,the 1.0 0.000143348623853 0 1 -1
areas,examines,the 1.0 0.000143348623853 0 1 -1
area-under,the-curve,auc 1.0 0.000143348623853 0 1 -1
area,of,the 1.0 0.000143348623853 0 1 -1
area,of,scotland 1.0 0.000143348623853 0 1 -1
area,of,rural 1.0 0.000143348623853 0 1 -1
area,bsa,for 1.0 0.000143348623853 0 1 -1
area,bsa,caused 1.0 0.000143348623853 0 1 -1
area,basis,this 1.0 0.000143348623853 0 1 -1
area,and,may 1.0 0.000143348623853 0 1 -1
are,years,of 1.0 0.000143348623853 0 1 -1
are,withdrawn,from 1.0 0.00100344036697 0 7 -7
are,weak,inhibitors 1.0 0.000143348623853 0 1 -1
are,warranted,in 1.0 0.000143348623853 0 1 -1
are,using,effective 1.0 0.000143348623853 0 1 -1
are,used,to 1.0 0.000143348623853 0 1 -1
are,used,they 1.0 0.000143348623853 0 1 -1
are,used,physiological 1.0 0.000143348623853 0 1 -1
are,used,on 1.0 0.000143348623853 0 1 -1
are,used,during 1.0 0.000143348623853 0 1 -1
are,unlikely,to 1.0 0.00043004587156 0 3 -3
are,unchanged,when 1.0 0.000143348623853 0 1 -1
are,unaltered,in 1.0 0.000143348623853 0 1 -1
are,typically,nonlinear 1.0 0.000143348623853 0 1 -1
are,types,of 1.0 0.000143348623853 0 1 -1
are,tricky,using 1.0 0.000143348623853 0 1 -1
are,tolerated,in 1.0 0.000143348623853 0 1 -1
are,to,lower 1.0 0.000143348623853 0 1 -1
are,thought,to 1.0 0.000286697247706 0 2 -2
are,the,primary 1.0 0.000143348623853 0 1 -1
are,that,have 1.0 0.000143348623853 0 1 -1
are,taking,medications 1.0 0.000143348623853 0 1 -1
are,taking,certain 1.0 0.000143348623853 0 1 -1
are,taking,an 1.0 0.000143348623853 0 1 -1
are,taking,a 1.0 0.000143348623853 0 1 -1
are,supported,by 1.0 0.000143348623853 0 1 -1
are,summarized,in 1.0 0.000286697247706 0 2 -2
are,suggested,by 1.0 0.000143348623853 0 1 -1
are,suddenly,exceeded 1.0 0.000143348623853 0 1 -1
are,substrates,of 1.0 0.000573394495413 0 4 -4
are,substrates,inhibitors 1.0 0.000143348623853 0 1 -1
are,substrates,for 1.0 0.00114678899083 0 8 -8
are,substrates,and 1.0 0.000143348623853 0 1 -1
are,strong,central 1.0 0.000143348623853 0 1 -1
are,specific,substrates 1.0 0.000143348623853 0 1 -1
are,sometimes,used 1.0 0.000143348623853 0 1 -1
are,so,called 1.0 0.00043004587156 0 3 -3
are,several,instances 1.0 0.000143348623853 0 1 -1
are,sequestered,in 1.0 0.000143348623853 0 1 -1
are,required,for 1.0 0.000143348623853 0 1 -1
are,representations,of 1.0 0.000143348623853 0 1 -1
are,reported,in 1.0 0.000143348623853 0 1 -1
are,renally,eliminated 1.0 0.000143348623853 0 1 -1
are,related,to 1.0 0.000143348623853 0 1 -1
are,referred,to 1.0 0.000286697247706 0 2 -2
are,receiving,concomitant 1.0 0.000143348623853 0 1 -1
are,provided,to 1.0 0.000143348623853 0 1 -1
are,present,in 1.0 0.000143348623853 0 1 -1
are,pregnant,and 1.0 0.000143348623853 0 1 -1
are,predominantly,cyp 1.0 0.000143348623853 0 1 -1
are,predictable,and 1.0 0.000143348623853 0 1 -1
are,possible,with 1.0 0.000143348623853 0 1 -1
are,poorly,understood 1.0 0.000143348623853 0 1 -1
are,performed,on 1.0 0.000143348623853 0 1 -1
are,performed,if 1.0 0.000143348623853 0 1 -1
are,part,of 1.0 0.000143348623853 0 1 -1
are,overly,cautious 1.0 0.000143348623853 0 1 -1
are,other,agents 1.0 0.000143348623853 0 1 -1
are,often,used 1.0 0.000143348623853 0 1 -1
are,often,administered 1.0 0.000143348623853 0 1 -1
are,occurred,in 1.0 0.000143348623853 0 1 -1
are,obtained,either 1.0 0.000143348623853 0 1 -1
are,observed,in 1.0 0.000143348623853 0 1 -1
are,now,cared 1.0 0.000143348623853 0 1 -1
are,not,sufficient 1.0 0.000286697247706 0 2 -2
are,not,readily 1.0 0.000143348623853 0 1 -1
are,not,potent 1.0 0.000143348623853 0 1 -1
are,not,necessary 1.0 0.000143348623853 0 1 -1
are,not,metabolized 1.0 0.000716743119266 0 5 -5
are,not,limited 1.0 0.000286697247706 0 2 -2
are,not,known 1.0 0.000143348623853 0 1 -1
are,not,inhibitors 1.0 0.000143348623853 0 1 -1
are,not,expected 1.0 0.000286697247706 0 2 -2
are,not,equivalent 1.0 0.000143348623853 0 1 -1
are,not,effected 1.0 0.000143348623853 0 1 -1
are,not,clinically 1.0 0.000143348623853 0 1 -1
are,not,available 1.0 0.000143348623853 0 1 -1
are,not,always 1.0 0.000143348623853 0 1 -1
are,not,altered 1.0 0.000286697247706 0 2 -2
are,no,significant 1.0 0.000143348623853 0 1 -1
are,no,safety 1.0 0.00043004587156 0 3 -3
are,no,reported 1.0 0.00043004587156 0 3 -3
are,no,known 1.0 0.000860091743119 0 6 -6
are,no,formal 1.0 0.000143348623853 0 1 -1
are,no,data 1.0 0.000286697247706 0 2 -2
are,no,clinical 1.0 0.000286697247706 0 2 -2
are,no,adequate 1.0 0.000286697247706 0 2 -2
are,neither,sufficient 1.0 0.000143348623853 0 1 -1
are,neither,inhibitors 1.0 0.000143348623853 0 1 -1
are,negatively,coupled 1.0 0.000143348623853 0 1 -1
are,needed,to 1.0 0.000143348623853 0 1 -1
are,needed,they 1.0 0.000143348623853 0 1 -1
are,needed,their 1.0 0.000143348623853 0 1 -1
are,necessary,the 1.0 0.000143348623853 0 1 -1
are,necessary,during 1.0 0.000143348623853 0 1 -1
are,multiple,forms 1.0 0.000143348623853 0 1 -1
are,more,likely 1.0 0.000143348623853 0 1 -1
are,more,frequent 1.0 0.000143348623853 0 1 -1
are,minimally,excreted 1.0 0.000143348623853 0 1 -1
are,metabolized,via 1.0 0.000143348623853 0 1 -1
are,metabolized,through 1.0 0.000143348623853 0 1 -1
are,metabolized,and 1.0 0.000143348623853 0 1 -1
are,mainly,eliminated 1.0 0.000143348623853 0 1 -1
are,made,they 1.0 0.000143348623853 0 1 -1
are,lower,than 1.0 0.000143348623853 0 1 -1
are,listed,in 1.0 0.000143348623853 0 1 -1
are,likely,and 1.0 0.000286697247706 0 2 -2
are,involved,in 1.0 0.000143348623853 0 1 -1
are,intimately,related 1.0 0.000143348623853 0 1 -1
are,inhibitors,or 1.0 0.000143348623853 0 1 -1
are,inducers,of 1.0 0.000286697247706 0 2 -2
are,indicated,alternative 1.0 0.000286697247706 0 2 -2
are,indeed,agents 1.0 0.000143348623853 0 1 -1
are,incompletely,responsive 1.0 0.000143348623853 0 1 -1
are,incompatible,with 1.0 0.000143348623853 0 1 -1
are,important,in 1.0 0.000143348623853 0 1 -1
are,important,factors 1.0 0.000143348623853 0 1 -1
are,impaired,vs 1.0 0.000143348623853 0 1 -1
are,illustrated,by 1.0 0.000143348623853 0 1 -1
are,identical,whether 1.0 0.000143348623853 0 1 -1
are,highly,effective 1.0 0.000143348623853 0 1 -1
are,given,the 1.0 0.000143348623853 0 1 -1
are,given,lodine 1.0 0.000143348623853 0 1 -1
are,given,for 1.0 0.000143348623853 0 1 -1
are,given,concurrently 1.0 0.000143348623853 0 1 -1
are,generally,believed 1.0 0.000143348623853 0 1 -1
are,ge,nerally 1.0 0.000143348623853 0 1 -1
are,frequently,observed 1.0 0.000143348623853 0 1 -1
are,frequently,complex 1.0 0.000143348623853 0 1 -1
are,few,data 1.0 0.000143348623853 0 1 -1
are,facilitated,by 1.0 0.000143348623853 0 1 -1
are,excreted,in 1.0 0.00043004587156 0 3 -3
are,excreted,by 1.0 0.000143348623853 0 1 -1
are,equipotent,inducers 1.0 0.000143348623853 0 1 -1
are,encouraged,to 1.0 0.000143348623853 0 1 -1
are,either,inhibitors 1.0 0.000143348623853 0 1 -1
are,effective,but 1.0 0.000143348623853 0 1 -1
are,eclampsia,some 1.0 0.000143348623853 0 1 -1
are,dryness,of 1.0 0.000143348623853 0 1 -1
are,dose,limiting 1.0 0.000143348623853 0 1 -1
are,dizziness,weakness 1.0 0.000143348623853 0 1 -1
are,discussed,in 1.0 0.000286697247706 0 2 -2
are,discussed,herein 1.0 0.000143348623853 0 1 -1
are,discussed,especially 1.0 0.000143348623853 0 1 -1
are,developed,regarding 1.0 0.000143348623853 0 1 -1
are,determined,by 1.0 0.000143348623853 0 1 -1
are,currently,no 1.0 0.000286697247706 0 2 -2
are,critical,to 1.0 0.000143348623853 0 1 -1
are,coupled,to 1.0 0.000143348623853 0 1 -1
are,contraindicated,specifically 1.0 0.000143348623853 0 1 -1
are,consistent,with 1.0 0.000143348623853 0 1 -1
are,considerably,lower 1.0 0.000143348623853 0 1 -1
are,concurrently,taking 1.0 0.000143348623853 0 1 -1
are,concomitantly,receiving 1.0 0.000143348623853 0 1 -1
are,concomitantly,being 1.0 0.000143348623853 0 1 -1
are,compelling,reasons 1.0 0.000143348623853 0 1 -1
are,commonly,found 1.0 0.000143348623853 0 1 -1
are,carried,out 1.0 0.000143348623853 0 1 -1
are,capable,of 1.0 0.000286697247706 0 2 -2
are,bodyweight,gain 1.0 0.000143348623853 0 1 -1
are,being,used 1.0 0.000143348623853 0 1 -1
are,being,rapidly 1.0 0.000143348623853 0 1 -1
are,being,monitored 1.0 0.000143348623853 0 1 -1
are,being,designed 1.0 0.000143348623853 0 1 -1
are,becoming,more 1.0 0.000143348623853 0 1 -1
are,based,on 1.0 0.000286697247706 0 2 -2
are,available,to 1.0 0.000143348623853 0 1 -1
are,available,regarding 1.0 0.000286697247706 0 2 -2
are,available,on 1.0 0.000286697247706 0 2 -2
are,available,it 1.0 0.000143348623853 0 1 -1
are,available,for 1.0 0.000286697247706 0 2 -2
are,at,least 1.0 0.000143348623853 0 1 -1
are,at,greater 1.0 0.000143348623853 0 1 -1
are,at,a 1.0 0.000143348623853 0 1 -1
are,associated,with 1.0 0.000573394495413 0 4 -4
are,anticipated,due 1.0 0.000143348623853 0 1 -1
are,analgesic,adjuvants 1.0 0.000143348623853 0 1 -1
are,also,regulated 1.0 0.000143348623853 0 1 -1
are,also,receiving 1.0 0.000143348623853 0 1 -1
are,also,extensively 1.0 0.000143348623853 0 1 -1
are,also,discussed 1.0 0.000143348623853 0 1 -1
are,also,albumin 1.0 0.000143348623853 0 1 -1
are,also,affected 1.0 0.000143348623853 0 1 -1
are,advisable,until 1.0 0.000286697247706 0 2 -2
are,advisable,for 1.0 0.000143348623853 0 1 -1
are,administered,to 1.0 0.00114678899083 0 8 -8
are,administered,dilute 1.0 0.000143348623853 0 1 -1
are,administered,as 1.0 0.000143348623853 0 1 -1
are,administered,alone 1.0 0.000143348623853 0 1 -1
are,adequate,methods 1.0 0.000143348623853 0 1 -1
are,added,to 1.0 0.000143348623853 0 1 -1
are,activated,during 1.0 0.000143348623853 0 1 -1
are,above,or 1.0 0.000143348623853 0 1 -1
are,a,rapidly 1.0 0.000143348623853 0 1 -1
are,a,number 1.0 0.000143348623853 0 1 -1
are,a,family 1.0 0.000143348623853 0 1 -1
arc,mrna,in 1.0 0.000143348623853 0 1 -1
arc,gene,which 1.0 0.000143348623853 0 1 -1
arc,activity-regulated,cytoskeleton-associated 1.0 0.000143348623853 0 1 -1
arachidonic,acid,metabolism 1.0 0.000286697247706 0 2 -2
arachidonic,acid,from 1.0 0.000143348623853 0 1 -1
arachidonate-,or,collagen-stimulated 1.0 0.000143348623853 0 1 -1
aqueous,extract,from 1.0 0.000143348623853 0 1 -1
aquamephyton,synkayvite,use 1.0 0.000143348623853 0 1 -1
aptt,to,decrease 1.0 0.000143348623853 0 1 -1
aptt,such,as 1.0 0.000143348623853 0 1 -1
aptt,assay,xigris 1.0 0.000143348623853 0 1 -1
aprepitant,with,in 1.0 0.000143348623853 0 1 -1
aprepitant,was,given 1.0 0.000143348623853 0 1 -1
aprepitant,is,unlikely 1.0 0.000143348623853 0 1 -1
aprepitant,is,also 1.0 0.000143348623853 0 1 -1
aprepitant,is,a 1.0 0.00043004587156 0 3 -3
approximately,twofold,at 1.0 0.000143348623853 0 1 -1
approximately,to,times 1.0 0.000143348623853 0 1 -1
approximately,to,minutes 1.0 0.000143348623853 0 1 -1
approximately,the,same 1.0 0.000143348623853 0 1 -1
approximately,or,more 1.0 0.000143348623853 0 1 -1
approximately,one-thousandth,of 1.0 0.000143348623853 0 1 -1
approximately,one-tenth,of 1.0 0.000143348623853 0 1 -1
approximately,one-hundredth,of 1.0 0.000286697247706 0 2 -2
approximately,of,the 1.0 0.000143348623853 0 1 -1
approximately,of,that 1.0 0.000143348623853 0 1 -1
approximately,ml,of 1.0 0.000143348623853 0 1 -1
approximately,in,uptake-1 1.0 0.000143348623853 0 1 -1
approximately,in,patients 1.0 0.000143348623853 0 1 -1
approximately,in,liver 1.0 0.000143348623853 0 1 -1
approximately,half,of 1.0 0.00043004587156 0 3 -3
approximately,fold,than 1.0 0.000143348623853 0 1 -1
approximately,fold,increase 1.0 0.000286697247706 0 2 -2
approximately,equal,to 1.0 0.000143348623853 0 1 -1
approximately,doubled,in 1.0 0.000143348623853 0 1 -1
approximately,case,per 1.0 0.000143348623853 0 1 -1
approximately,bpm,and 1.0 0.000143348623853 0 1 -1
approximately,and,fold 1.0 0.000286697247706 0 2 -2
approximate,the,steady 1.0 0.000143348623853 0 1 -1
approved,in,the 1.0 0.000286697247706 0 2 -2
approved,for,clinical 1.0 0.000143348623853 0 1 -1
approval,by,the 1.0 0.000143348623853 0 1 -1
appropriately,regardless,of 1.0 0.000143348623853 0 1 -1
appropriate,package,insert 1.0 0.000143348623853 0 1 -1
appropriate,interval,between 1.0 0.000143348623853 0 1 -1
appropriate,in,patients 1.0 0.000143348623853 0 1 -1
appropriate,doses,for 1.0 0.00114678899083 0 8 -8
appropriate,dose,for 1.0 0.000143348623853 0 1 -1
appropriate,adjustment,to 1.0 0.000143348623853 0 1 -1
appropriate,actions,after 1.0 0.000143348623853 0 1 -1
approach,to,treatment 1.0 0.000143348623853 0 1 -1
approach,to,the 1.0 0.000143348623853 0 1 -1
approach,to,dosing 1.0 0.000143348623853 0 1 -1
approach,is,applicable 1.0 0.000143348623853 0 1 -1
approach,can,be 1.0 0.000143348623853 0 1 -1
appreciably,metabolized,nor 1.0 0.000143348623853 0 1 -1
appointments,since,some 1.0 0.000143348623853 0 1 -1
apply,to,administration 1.0 0.000143348623853 0 1 -1
applied,to,supraspinal 1.0 0.000143348623853 0 1 -1
applied,to,cardiac 1.0 0.000143348623853 0 1 -1
applied,to,any 1.0 0.000143348623853 0 1 -1
applied,for,other 1.0 0.000143348623853 0 1 -1
applications,of,the 1.0 0.000143348623853 0 1 -1
application,of,rr 1.0 0.000143348623853 0 1 -1
application,of,offers 1.0 0.000143348623853 0 1 -1
application,of,insp 1.0 0.000143348623853 0 1 -1
applicable,across,a 1.0 0.000143348623853 0 1 -1
apple,may,reduce 1.0 0.000143348623853 0 1 -1
appetite,and,compared 1.0 0.000143348623853 0 1 -1
appears,to,lie 1.0 0.000143348623853 0 1 -1
appears,to,generate 1.0 0.000143348623853 0 1 -1
appears,to,decrease 1.0 0.000143348623853 0 1 -1
appears,to,affect 1.0 0.000143348623853 0 1 -1
appears,generally,good 1.0 0.000143348623853 0 1 -1
appearing,on,the 1.0 0.000143348623853 0 1 -1
appeared,well,correlated 1.0 0.000143348623853 0 1 -1
appeared,well,after 1.0 0.000143348623853 0 1 -1
appeared,to,function 1.0 0.000143348623853 0 1 -1
appearance,of,unchanged 1.0 0.000143348623853 0 1 -1
appearance,of,a 1.0 0.000143348623853 0 1 -1
appearance,have,been 1.0 0.000143348623853 0 1 -1
appear,to,share 1.0 0.000143348623853 0 1 -1
appear,to,overlap 1.0 0.000143348623853 0 1 -1
appear,to,induce 1.0 0.000286697247706 0 2 -2
appear,to,have 1.0 0.000143348623853 0 1 -1
appear,to,cause 1.0 0.000143348623853 0 1 -1
appear,to,alter 1.0 0.000143348623853 0 1 -1
appear,to,affect 1.0 0.00043004587156 0 3 -3
appear,in,the 1.0 0.000143348623853 0 1 -1
appear,before,there 1.0 0.000143348623853 0 1 -1
apparently,t,cell-independent 1.0 0.000143348623853 0 1 -1
apparently,by,increased 1.0 0.000143348623853 0 1 -1
apparent,volume,of 1.0 0.000143348623853 0 1 -1
apparent,pharmacokinetic,interaction 1.0 0.000573394495413 0 4 -4
apparent,increase,in 1.0 0.000143348623853 0 1 -1
apparent,factor,concentration 1.0 0.000143348623853 0 1 -1
apparent,effect,on 1.0 0.000143348623853 0 1 -1
apparent,decrease,in 1.0 0.000143348623853 0 1 -1
apparatus,of,spontaneous 1.0 0.000143348623853 0 1 -1
app,polymer,p 1.0 0.000143348623853 0 1 -1
app,control,of 1.0 0.000143348623853 0 1 -1
apoptotic,morphology,pyknotic 1.0 0.000143348623853 0 1 -1
apoptotic,index,or 1.0 0.000143348623853 0 1 -1
apoptosis,induced,by 1.0 0.000286697247706 0 2 -2
apoptosis,in,breast 1.0 0.000143348623853 0 1 -1
apoptosis,can,be 1.0 0.000143348623853 0 1 -1
apart,so,that 1.0 0.000143348623853 0 1 -1
aom,mg,kg 1.0 0.000143348623853 0 1 -1
aom,and,the 1.0 0.000143348623853 0 1 -1
any,unexpected,adverse 1.0 0.000143348623853 0 1 -1
any,time,point 1.0 0.000143348623853 0 1 -1
any,that,may 1.0 0.000143348623853 0 1 -1
any,statistically,or 1.0 0.000143348623853 0 1 -1
any,significant,changes 1.0 0.000143348623853 0 1 -1
any,significant,change 1.0 0.000143348623853 0 1 -1
any,serious,and 1.0 0.000143348623853 0 1 -1
any,procedure,in 1.0 0.000143348623853 0 1 -1
any,prescription,or 1.0 0.000143348623853 0 1 -1
any,pharmacokinetic,interactions 1.0 0.000143348623853 0 1 -1
any,patient,in 1.0 0.000143348623853 0 1 -1
any,other,that 1.0 0.000143348623853 0 1 -1
any,other,medication 1.0 0.000143348623853 0 1 -1
any,other,drugs 1.0 0.000143348623853 0 1 -1
any,on,the 1.0 0.000143348623853 0 1 -1
any,of,these 1.0 0.000286697247706 0 2 -2
any,occasion,in 1.0 0.000143348623853 0 1 -1
any,nonlinear,regression 1.0 0.000143348623853 0 1 -1
any,new,rashes 1.0 0.000143348623853 0 1 -1
any,medicine,without 1.0 0.000143348623853 0 1 -1
any,mechanism,of 1.0 0.000143348623853 0 1 -1
any,interaction,on 1.0 0.000143348623853 0 1 -1
any,interaction,between 1.0 0.000143348623853 0 1 -1
any,great,extent 1.0 0.000143348623853 0 1 -1
any,from,the 1.0 0.000143348623853 0 1 -1
any,form,of 1.0 0.000143348623853 0 1 -1
any,evidence,of 1.0 0.000286697247706 0 2 -2
any,enzyme,in 1.0 0.000143348623853 0 1 -1
any,efficacy,benefit 1.0 0.000143348623853 0 1 -1
any,effect,on 1.0 0.00043004587156 0 3 -3
any,dose,or 1.0 0.000143348623853 0 1 -1
any,cyp,isoenzymes 1.0 0.000143348623853 0 1 -1
any,conclusions,to 1.0 0.000143348623853 0 1 -1
any,combination,of 1.0 0.000143348623853 0 1 -1
any,clinically,significant 1.0 0.000286697247706 0 2 -2
any,clinically,important 1.0 0.000573394495413 0 4 -4
any,clinical,interaction 1.0 0.000143348623853 0 1 -1
any,changes,in 1.0 0.000573394495413 0 4 -4
any,change,in 1.0 0.000143348623853 0 1 -1
any,antineoplastic,agents 1.0 0.000143348623853 0 1 -1
any,alterations,in 1.0 0.000143348623853 0 1 -1
any,agent,that 1.0 0.00043004587156 0 3 -3
any,agent,metabolized 1.0 0.000143348623853 0 1 -1
any,added,drug 1.0 0.000143348623853 0 1 -1
anxiogenic,effects,in 1.0 0.000143348623853 0 1 -1
anxiety,depressive,symptoms 1.0 0.000143348623853 0 1 -1
anxiety,associated,with 1.0 0.000143348623853 0 1 -1
anxiety,agitation,motor 1.0 0.000143348623853 0 1 -1
antitumour,activity,for 1.0 0.000143348623853 0 1 -1
antitumour,activity,acute 1.0 0.000143348623853 0 1 -1
antitumor,activity,of 1.0 0.000143348623853 0 1 -1
antitubercular,serum,concentrations 1.0 0.000143348623853 0 1 -1
antithyroid,b-adrenergic,blocking 1.0 0.000143348623853 0 1 -1
antithyroid,agents,medicine 1.0 0.000143348623853 0 1 -1
antithrombotics,aspirin,and 1.0 0.000143348623853 0 1 -1
antithrombin,iii,decreased 1.0 0.000286697247706 0 2 -2
antisense,oligomer,significantly 1.0 0.000143348623853 0 1 -1
antisense,gene,cassette 1.0 0.000143348623853 0 1 -1
antiseizure,medication,monitored 1.0 0.000143348623853 0 1 -1
antiseizure,medication,and 1.0 0.000143348623853 0 1 -1
antiretroviral,regimens,consisted 1.0 0.000143348623853 0 1 -1
antiretroviral,plasma,and 1.0 0.000143348623853 0 1 -1
antiretroviral,medications,have 1.0 0.000143348623853 0 1 -1
antiretroviral,agents,no 1.0 0.000143348623853 0 1 -1
antiretroviral,agents,including 1.0 0.000143348623853 0 1 -1
antipyrine,pharmacokinetics,were 1.0 0.000143348623853 0 1 -1
antipyrine,because,does 1.0 0.000143348623853 0 1 -1
antipyrine,antipyrine,pharmacokinetics 1.0 0.000143348623853 0 1 -1
antipsychotic,with,demonstrated 1.0 0.000143348623853 0 1 -1
antipsychotic,was,tested 1.0 0.000143348623853 0 1 -1
antipsychotic,efficacy,compared 1.0 0.000143348623853 0 1 -1
antipsychotic,agent,which 1.0 0.000143348623853 0 1 -1
antipsychotic,activity,preclinical 1.0 0.000143348623853 0 1 -1
antipsychotic,action,of 1.0 0.000143348623853 0 1 -1
antiprothrombinemic,effect,of 1.0 0.000143348623853 0 1 -1
antiplatelet,therapies,should 1.0 0.000143348623853 0 1 -1
antiparkinsonism,agents,in 1.0 0.000143348623853 0 1 -1
antioxidative,gallates,is 1.0 0.000143348623853 0 1 -1
antinonciceptive,effect,of 1.0 0.000143348623853 0 1 -1
antinociception,was,measured 1.0 0.000143348623853 0 1 -1
antineoplastic,agents,nitrogen 1.0 0.000143348623853 0 1 -1
antineoplastic,agents,have 1.0 0.000143348623853 0 1 -1
antimycobacterial,agents,contraindicated 1.0 0.000143348623853 0 1 -1
antimuscarinic,effects,of 1.0 0.000143348623853 0 1 -1
antimicrobial,effect,of 1.0 0.000143348623853 0 1 -1
antimicrobial,agents,available 1.0 0.000143348623853 0 1 -1
antimicrobial,activity,was 1.0 0.000143348623853 0 1 -1
antimicrobial,activity,of 1.0 0.00043004587156 0 3 -3
antihypertensives,amiodarone,should 1.0 0.000143348623853 0 1 -1
antihypertensive,medications,other 1.0 0.000143348623853 0 1 -1
antihypertensive,effect,although 1.0 0.000143348623853 0 1 -1
antihypertensive,additive,effect 1.0 0.000143348623853 0 1 -1
antihistamines,contraindicated,due 1.0 0.000143348623853 0 1 -1
antihistamines,benzodiazepines,gi 1.0 0.000143348623853 0 1 -1
antigout,oral,and 1.0 0.000143348623853 0 1 -1
antigout,medications,may 1.0 0.000143348623853 0 1 -1
antiglobulin,coombs,tests 1.0 0.000143348623853 0 1 -1
antigen,were,precise 1.0 0.000143348623853 0 1 -1
antigen,viii,coagulant 1.0 0.000286697247706 0 2 -2
antigen,viii,antigen 1.0 0.000286697247706 0 2 -2
antigen,validation,of 1.0 0.000143348623853 0 1 -1
antigen,psa,decreased 1.0 0.000143348623853 0 1 -1
antifungals,the,effect 1.0 0.000143348623853 0 1 -1
antifungal,agents,such 1.0 0.000143348623853 0 1 -1
antifibrinolytic,therapies,i 1.0 0.000143348623853 0 1 -1
antiepileptic,the,more 1.0 0.000143348623853 0 1 -1
antiepileptic,potential,interactions 1.0 0.000143348623853 0 1 -1
antiepileptic,drugs,aeds 1.0 0.000143348623853 0 1 -1
antiepilepsy,aeds,whether 1.0 0.000143348623853 0 1 -1
antiemetic,prophylaxis,contributed 1.0 0.000143348623853 0 1 -1
antidiuretic,hormone,and 1.0 0.000143348623853 0 1 -1
antidiuretic,activity,large 1.0 0.000143348623853 0 1 -1
antidiabetic,requirements,i 1.0 0.000143348623853 0 1 -1
antidiabetic,oral,agents 1.0 0.000573394495413 0 4 -4
antidiabetic,agents,insulin 1.0 0.000143348623853 0 1 -1
antidiabetes,products,ace 1.0 0.000143348623853 0 1 -1
antidepressants,or,other 1.0 0.000143348623853 0 1 -1
antidepressants,concurrent,use 1.0 0.000143348623853 0 1 -1
antidepressant,was,shown 1.0 0.000143348623853 0 1 -1
antidepressant,or,the 1.0 0.000143348623853 0 1 -1
antidepressant,class,which 1.0 0.000143348623853 0 1 -1
antidepressant,class,including 1.0 0.000143348623853 0 1 -1
antidepressant,agent,or 1.0 0.000143348623853 0 1 -1
antidepressant,agent,may 1.0 0.000143348623853 0 1 -1
anticoagulents,may,be 1.0 0.000143348623853 0 1 -1
anticoagulation,should,receive 1.0 0.000143348623853 0 1 -1
anticoagulation,should,be 1.0 0.000143348623853 0 1 -1
anticoagulation,may,if 1.0 0.000143348623853 0 1 -1
anticoagulation,effects,due 1.0 0.000286697247706 0 2 -2
anticoagulants,thyroid,hormones 1.0 0.000143348623853 0 1 -1
anticoagulants,ten,patients 1.0 0.000143348623853 0 1 -1
anticoagulants,should,be 1.0 0.000143348623853 0 1 -1
anticoagulants,several,short-term 1.0 0.000143348623853 0 1 -1
anticoagulants,predispose,a 1.0 0.000143348623853 0 1 -1
anticoagulants,potentiation,of 1.0 0.000143348623853 0 1 -1
anticoagulants,oral,the 1.0 0.000143348623853 0 1 -1
anticoagulants,oral,in 1.0 0.000143348623853 0 1 -1
anticoagulants,interaction,studies 1.0 0.000286697247706 0 2 -2
anticoagulants,in,a 1.0 0.000143348623853 0 1 -1
anticoagulants,coagulation,parameters 1.0 0.000143348623853 0 1 -1
anticoagulant,inhibition,was 1.0 0.000143348623853 0 1 -1
anticipated,due,to 1.0 0.000143348623853 0 1 -1
anticipated,alternative,therapy 1.0 0.000143348623853 0 1 -1
anticholinesterases,neostgmine,can 1.0 0.000143348623853 0 1 -1
anticholinesterase,treatment,should 1.0 0.000143348623853 0 1 -1
anticholinesterase,overdose,cholinergic 1.0 0.000143348623853 0 1 -1
anticholinergics,antagonize,the 1.0 0.000143348623853 0 1 -1
anticholinergic,in,the 1.0 0.000143348623853 0 1 -1
antibiotics-broad,spectrum,may 1.0 0.000143348623853 0 1 -1
antibiotics,rifampin,is 1.0 0.000143348623853 0 1 -1
antibiotics,pregnancy,has 1.0 0.000143348623853 0 1 -1
antibiotics,no,human 1.0 0.000143348623853 0 1 -1
antibiotics,and,azole 1.0 0.000143348623853 0 1 -1
antiasthmatic,dose,of 1.0 0.000143348623853 0 1 -1
antiarrhythmics,other,such 1.0 0.000143348623853 0 1 -1
antiarrhythmics,amiodarone,contraindicated 1.0 0.000143348623853 0 1 -1
antiarrhythmic,agents,class 1.0 0.000143348623853 0 1 -1
antiapoptotic,effect,of 1.0 0.000143348623853 0 1 -1
antianginal,effectiveness,of 1.0 0.000143348623853 0 1 -1
antiaggregant,prostacyclin,which 1.0 0.000143348623853 0 1 -1
antiaddictive,efficacy,toxicity 1.0 0.000143348623853 0 1 -1
antiacid,didanosine,fluconazole 1.0 0.000143348623853 0 1 -1
anti-platelet,effect,is 1.0 0.000143348623853 0 1 -1
anti-platelet,activity,of 1.0 0.000143348623853 0 1 -1
anti-peptic,agents,primarily 1.0 0.000143348623853 0 1 -1
anti-neoplastic,agents,have 1.0 0.000143348623853 0 1 -1
anti-inflammatory,nsaids,without 1.0 0.000143348623853 0 1 -1
anti-inflammatory,but,not 1.0 0.000143348623853 0 1 -1
anti-inflammatory,agents,may 1.0 0.000143348623853 0 1 -1
anti-infectives,without,evidence 1.0 0.000143348623853 0 1 -1
anti-hiv,protease,inhibitors 1.0 0.000143348623853 0 1 -1
anti-globulin,tests,are 1.0 0.000143348623853 0 1 -1
anti-glaucoma,and,miotic 1.0 0.000143348623853 0 1 -1
anti-factor,xa,and 1.0 0.000286697247706 0 2 -2
anti-cryptosporidial,activity,of 1.0 0.000143348623853 0 1 -1
anti-coagulant,effect,of 1.0 0.000143348623853 0 1 -1
anti-asthma,medications,including 1.0 0.000143348623853 0 1 -1
anti-arrhythmic,agents,such 1.0 0.000143348623853 0 1 -1
anti-apoptotic,effect,of 1.0 0.000143348623853 0 1 -1
anti-anxiety,used,to 1.0 0.000143348623853 0 1 -1
anti,platelet,agents 1.0 0.000143348623853 0 1 -1
antagonized,by,either 1.0 0.000143348623853 0 1 -1
antagonized,by,an 1.0 0.000143348623853 0 1 -1
antagonized,by,agents 1.0 0.000143348623853 0 1 -1
antagonists,the,effect 1.0 0.000143348623853 0 1 -1
antagonists,tested,here 1.0 0.000143348623853 0 1 -1
antagonists,phenyltheophylline,and 1.0 0.000143348623853 0 1 -1
antagonists,in,studies 1.0 0.000143348623853 0 1 -1
antagonists,in,clinical 1.0 0.000143348623853 0 1 -1
antagonists,hmg-coa,reductase 1.0 0.000143348623853 0 1 -1
antagonists,histamine,h2-receptor 1.0 0.000143348623853 0 1 -1
antagonists,decreased,the 1.0 0.000143348623853 0 1 -1
antagonists,cyp1a2,inducers 1.0 0.000143348623853 0 1 -1
antagonists,congestive,heart 1.0 0.000143348623853 0 1 -1
antagonists,appear,to 1.0 0.000143348623853 0 1 -1
antagonists,angiotensin,converting 1.0 0.000143348623853 0 1 -1
antagonists,and,that 1.0 0.000143348623853 0 1 -1
antagonists,and,oral 1.0 0.000143348623853 0 1 -1
antagonists,and,loop 1.0 0.000143348623853 0 1 -1
antagonists,and,could 1.0 0.000143348623853 0 1 -1
antagonists,administered,in 1.0 0.000143348623853 0 1 -1
antagonists,a,cyp3a4 1.0 0.000143348623853 0 1 -1
antagonist,were,a 1.0 0.000143348623853 0 1 -1
antagonist,may,precipitate 1.0 0.000143348623853 0 1 -1
antagonist,effect,should 1.0 0.000143348623853 0 1 -1
antagonism,in,vivo 1.0 0.000143348623853 0 1 -1
antagonise,the,effect 1.0 0.000143348623853 0 1 -1
antagonise,the,anti-glaucoma 1.0 0.000143348623853 0 1 -1
antacids,the,concomitant 1.0 0.000143348623853 0 1 -1
antacids,sucralfate,metal 1.0 0.000143348623853 0 1 -1
antacids,on,felbatol 1.0 0.000143348623853 0 1 -1
antacids,nonclinical,data 1.0 0.000143348623853 0 1 -1
antacid,the,effect 1.0 0.000143348623853 0 1 -1
antacid,products,absorption 1.0 0.000143348623853 0 1 -1
antacid,magnesium-aluminum,hydroxide 1.0 0.000143348623853 0 1 -1
another,that,is 1.0 0.00043004587156 0 3 -3
another,study,with 1.0 0.000143348623853 0 1 -1
another,study,toradoliv 1.0 0.000143348623853 0 1 -1
another,study,showed 1.0 0.000143348623853 0 1 -1
another,positively-charged,bile 1.0 0.000143348623853 0 1 -1
another,known,to 1.0 0.000573394495413 0 4 -4
another,is,structurally 1.0 0.000143348623853 0 1 -1
another,investigator,found 1.0 0.000286697247706 0 2 -2
another,female,dog 1.0 0.000143348623853 0 1 -1
another,extended,release 1.0 0.000143348623853 0 1 -1
another,drug,known 1.0 0.000143348623853 0 1 -1
another,drug,is 1.0 0.000143348623853 0 1 -1
another,agent,should 1.0 0.000143348623853 0 1 -1
anorexia,taste,disorder 1.0 0.000143348623853 0 1 -1
ankle,edema,excessive 1.0 0.000143348623853 0 1 -1
anions,other,than 1.0 0.000143348623853 0 1 -1
anions,antithyroid,b-adrenergic 1.0 0.000143348623853 0 1 -1
anion,itself,could 1.0 0.000143348623853 0 1 -1
anion,exchange,it 1.0 0.000143348623853 0 1 -1
anion,because,of 1.0 0.000143348623853 0 1 -1
animals,where,endothelial 1.0 0.000143348623853 0 1 -1
animals,were,not 1.0 0.000143348623853 0 1 -1
animals,were,killed 1.0 0.000143348623853 0 1 -1
animals,were,challenged 1.0 0.000143348623853 0 1 -1
animals,to,their 1.0 0.000143348623853 0 1 -1
animals,to,screen 1.0 0.000143348623853 0 1 -1
animals,than,in 1.0 0.000143348623853 0 1 -1
animals,studies,on 1.0 0.000143348623853 0 1 -1
animals,male,or 1.0 0.000143348623853 0 1 -1
animals,in,the 1.0 0.000143348623853 0 1 -1
animals,in,both 1.0 0.000143348623853 0 1 -1
animals,dosed,with 1.0 0.000143348623853 0 1 -1
animals,dosed,at 1.0 0.000143348623853 0 1 -1
animal,toxicology,studies 1.0 0.000143348623853 0 1 -1
animal,source,or 1.0 0.000143348623853 0 1 -1
animal,reproduction,studies 1.0 0.000143348623853 0 1 -1
animal,or,human 1.0 0.000143348623853 0 1 -1
animal,models,and 1.0 0.000143348623853 0 1 -1
animal,literature,showing 1.0 0.000143348623853 0 1 -1
animal,in,the 1.0 0.000143348623853 0 1 -1
animal,data,indicated 1.0 0.000143348623853 0 1 -1
animal,and,human 1.0 0.000143348623853 0 1 -1
anhydrase,inhibitors,concomitant 1.0 0.000143348623853 0 1 -1
angiotensins,inhibited,gastric 1.0 0.000143348623853 0 1 -1
angiotensinogen,renin,substrate 1.0 0.000286697247706 0 2 -2
angiotensin-converting,enzyme,ace 1.0 0.000143348623853 0 1 -1
angiotensin-,converting,enzyme 1.0 0.000143348623853 0 1 -1
angiotensin,on,pentagastrin- 1.0 0.000143348623853 0 1 -1
angiotensin,ii,or 1.0 0.000143348623853 0 1 -1
angiotensin,and,angiotensin 1.0 0.000143348623853 0 1 -1
angiomax,should,be 1.0 0.000143348623853 0 1 -1
angiomax,in,clinical 1.0 0.000143348623853 0 1 -1
angiomax,exhibited,no 1.0 0.000143348623853 0 1 -1
angiomax,does,not 1.0 0.000143348623853 0 1 -1
angiomax,and,plasma 1.0 0.000143348623853 0 1 -1
angioedema,or,generalized 1.0 0.000143348623853 0 1 -1
angina,patients,receiving 1.0 0.000143348623853 0 1 -1
angina,myocardial,infarction 1.0 0.000143348623853 0 1 -1
angina,attacks,during 1.0 0.000143348623853 0 1 -1
anesthetized,swine,has 1.0 0.000143348623853 0 1 -1
anesthesiologist,should,be 1.0 0.000143348623853 0 1 -1
anemia,grade,according 1.0 0.000143348623853 0 1 -1
anemia,associated,with 1.0 0.000143348623853 0 1 -1
andusing,a,containing 1.0 0.000143348623853 0 1 -1
andtolbutamide,did,not 1.0 0.000143348623853 0 1 -1
androgens,may,increase 1.0 0.000286697247706 0 2 -2
and,zdv,has 1.0 0.000143348623853 0 1 -1
and,younger,patients 1.0 0.000143348623853 0 1 -1
and,xenobiotic,metabolism 1.0 0.000143348623853 0 1 -1
and,women,were 1.0 0.000143348623853 0 1 -1
and,without,the 1.0 0.000143348623853 0 1 -1
and,without,mg 1.0 0.000143348623853 0 1 -1
and,without,evidence 1.0 0.000286697247706 0 2 -2
and,without,coadministration 1.0 0.000143348623853 0 1 -1
and,without,and 1.0 0.000143348623853 0 1 -1
and,with,plus 1.0 0.000143348623853 0 1 -1
and,with,frequent 1.0 0.00043004587156 0 3 -3
and,with,diagnostic 1.0 0.000143348623853 0 1 -1
and,with,coadministration 1.0 0.000143348623853 0 1 -1
and,with,at 1.0 0.000143348623853 0 1 -1
and,will,have 1.0 0.000143348623853 0 1 -1
and,wide,distribution 1.0 0.000143348623853 0 1 -1
and,which,may 1.0 0.000143348623853 0 1 -1
and,which,has 1.0 0.000143348623853 0 1 -1
and,which,affect 1.0 0.000143348623853 0 1 -1
and,whether,similar 1.0 0.000143348623853 0 1 -1
and,where,appropriate 1.0 0.000143348623853 0 1 -1
and,when,amitriptyline 1.0 0.000143348623853 0 1 -1
and,what,to 1.0 0.000143348623853 0 1 -1
and,were,variable 1.0 0.000143348623853 0 1 -1
and,were,unchanged 1.0 0.000143348623853 0 1 -1
and,were,tested 1.0 0.000143348623853 0 1 -1
and,were,systematically 1.0 0.000143348623853 0 1 -1
and,were,studied 1.0 0.000143348623853 0 1 -1
and,were,not 1.0 0.000286697247706 0 2 -2
and,were,increased 1.0 0.000143348623853 0 1 -1
and,were,in 1.0 0.000143348623853 0 1 -1
and,were,given 1.0 0.000143348623853 0 1 -1
and,were,each 1.0 0.000143348623853 0 1 -1
and,were,concomitantly 1.0 0.000143348623853 0 1 -1
and,were,also 1.0 0.000143348623853 0 1 -1
and,were,administered 1.0 0.000286697247706 0 2 -2
and,were,additive 1.0 0.000143348623853 0 1 -1
and,well-controlled,studies 1.0 0.000286697247706 0 2 -2
and,watery,stool 1.0 0.000143348623853 0 1 -1
and,was,resistant 1.0 0.000143348623853 0 1 -1
and,was,potentiated 1.0 0.000143348623853 0 1 -1
and,was,performed 1.0 0.000143348623853 0 1 -1
and,was,evaluated 1.0 0.000143348623853 0 1 -1
and,was,comparable 1.0 0.000143348623853 0 1 -1
and,vitamin,c 1.0 0.000143348623853 0 1 -1
and,vitamin,b12 1.0 0.000143348623853 0 1 -1
and,viable,counts 1.0 0.000143348623853 0 1 -1
and,vi,of 1.0 0.000143348623853 0 1 -1
and,ventral,tubercle 1.0 0.000143348623853 0 1 -1
and,vasopressin,was 1.0 0.000143348623853 0 1 -1
and,various,chemotherapy 1.0 0.000143348623853 0 1 -1
and,variable,half-life 1.0 0.000143348623853 0 1 -1
and,vanillylmandelic,acid 1.0 0.000143348623853 0 1 -1
and,use,as 1.0 0.000143348623853 0 1 -1
and,urine,were 1.0 0.000143348623853 0 1 -1
and,urine,was 1.0 0.000143348623853 0 1 -1
and,urine,sampling 1.0 0.000143348623853 0 1 -1
and,urine,samples 1.0 0.000143348623853 0 1 -1
and,urine,immunoreactive 1.0 0.000143348623853 0 1 -1
and,urine,glucose 1.0 0.000143348623853 0 1 -1
and,urine,creatinine 1.0 0.00043004587156 0 3 -3
and,uptake,of 1.0 0.000286697247706 0 2 -2
and,until,blood 1.0 0.000286697247706 0 2 -2
and,unexpected,adverse 1.0 0.000143348623853 0 1 -1
and,undetectable,release 1.0 0.000143348623853 0 1 -1
and,understanding,of 1.0 0.000143348623853 0 1 -1
and,uncontrolled,domestic 1.0 0.000143348623853 0 1 -1
and,ultimately,atherosclerotic 1.0 0.000143348623853 0 1 -1
and,type,of 1.0 0.000143348623853 0 1 -1
and,two,outbreaks 1.0 0.000143348623853 0 1 -1
and,twice-a,day 1.0 0.000143348623853 0 1 -1
and,tumour,total 1.0 0.000143348623853 0 1 -1
and,triglycerides,or 1.0 0.000143348623853 0 1 -1
and,triglyceride,plasma 1.0 0.000143348623853 0 1 -1
and,triazole,have 1.0 0.000143348623853 0 1 -1
and,treatments,and 1.0 0.000143348623853 0 1 -1
and,treatment,of 1.0 0.000143348623853 0 1 -1
and,treatment,in 1.0 0.000143348623853 0 1 -1
and,treatment,i 1.0 0.000143348623853 0 1 -1
and,treatment,discontinued 1.0 0.000143348623853 0 1 -1
and,treatment,ataxia 1.0 0.000143348623853 0 1 -1
and,transport,were 1.0 0.000143348623853 0 1 -1
and,transits,were 1.0 0.000143348623853 0 1 -1
and,transient,asymptomatic 1.0 0.000143348623853 0 1 -1
and,toxicokinetic,studies 1.0 0.000143348623853 0 1 -1
and,toxic,effects 1.0 0.000143348623853 0 1 -1
and,total,body 1.0 0.000143348623853 0 1 -1
and,total,bilirubin 1.0 0.000143348623853 0 1 -1
and,to,times 1.0 0.000143348623853 0 1 -1
and,to,mouse 1.0 0.000143348623853 0 1 -1
and,to,miracidia 1.0 0.000143348623853 0 1 -1
and,to,mg 1.0 0.000143348623853 0 1 -1
and,to,lower 1.0 0.000143348623853 0 1 -1
and,to,inhibitors 1.0 0.000143348623853 0 1 -1
and,to,improve 1.0 0.000143348623853 0 1 -1
and,to,healthy 1.0 0.00043004587156 0 3 -3
and,to,groups 1.0 0.000143348623853 0 1 -1
and,to,establish 1.0 0.000143348623853 0 1 -1
and,to,encystment 1.0 0.000143348623853 0 1 -1
and,to,discriminate 1.0 0.000143348623853 0 1 -1
and,to,determine 1.0 0.000143348623853 0 1 -1
and,to,decrease 1.0 0.000143348623853 0 1 -1
and,to,confirm 1.0 0.000143348623853 0 1 -1
and,to,broadly 1.0 0.000143348623853 0 1 -1
and,to,beta-adrenergic 1.0 0.000143348623853 0 1 -1
and,to,alter 1.0 0.000143348623853 0 1 -1
and,tnf,blocking 1.0 0.000143348623853 0 1 -1
and,tmax,vs 1.0 0.000143348623853 0 1 -1
and,titrated,to 1.0 0.000286697247706 0 2 -2
and,time,course 1.0 0.000143348623853 0 1 -1
and,thus,this 1.0 0.000143348623853 0 1 -1
and,through,pharmacokinetic 1.0 0.000143348623853 0 1 -1
and,those,with 1.0 0.000143348623853 0 1 -1
and,those,used 1.0 0.000143348623853 0 1 -1
and,those,off 1.0 0.000143348623853 0 1 -1
and,those,of 1.0 0.000143348623853 0 1 -1
and,this,strategy 1.0 0.000143348623853 0 1 -1
and,this,should 1.0 0.000143348623853 0 1 -1
and,this,may 1.0 0.000286697247706 0 2 -2
and,they,should 1.0 0.000143348623853 0 1 -1
and,they,do 1.0 0.000143348623853 0 1 -1
and,these,with 1.0 0.000143348623853 0 1 -1
and,these,patients 1.0 0.000143348623853 0 1 -1
and,these,medicines 1.0 0.000143348623853 0 1 -1
and,these,imidazole 1.0 0.000143348623853 0 1 -1
and,these,have 1.0 0.000143348623853 0 1 -1
and,these,data 1.0 0.000143348623853 0 1 -1
and,these,compounds 1.0 0.000143348623853 0 1 -1
and,these,combinations 1.0 0.000143348623853 0 1 -1
and,these,are 1.0 0.000143348623853 0 1 -1
and,these,aeds 1.0 0.000143348623853 0 1 -1
and,therefore,subtle 1.0 0.000143348623853 0 1 -1
and,therefore,signs 1.0 0.000143348623853 0 1 -1
and,therefore,should 1.0 0.000286697247706 0 2 -2
and,therefore,potentiate 1.0 0.000143348623853 0 1 -1
and,therefore,no 1.0 0.000143348623853 0 1 -1
and,therefore,may 1.0 0.000286697247706 0 2 -2
and,therefore,has 1.0 0.000143348623853 0 1 -1
and,thereafter,at 1.0 0.000143348623853 0 1 -1
and,there,were 1.0 0.000143348623853 0 1 -1
and,there,are 1.0 0.000143348623853 0 1 -1
and,therapy,were 1.0 0.000143348623853 0 1 -1
and,therapy,indicate 1.0 0.000143348623853 0 1 -1
and,therapy,eg 1.0 0.000143348623853 0 1 -1
and,therapeutic,superiority 1.0 0.000143348623853 0 1 -1
and,theoretically,might 1.0 0.000143348623853 0 1 -1
and,then,with 1.0 0.000143348623853 0 1 -1
and,then,hoof 1.0 0.000143348623853 0 1 -1
and,then,analysing 1.0 0.000143348623853 0 1 -1
and,then,allowed 1.0 0.000143348623853 0 1 -1
and,their,reappearance 1.0 0.000143348623853 0 1 -1
and,their,o-desacetyl 1.0 0.000143348623853 0 1 -1
and,their,dosages 1.0 0.000143348623853 0 1 -1
and,their,associated 1.0 0.000143348623853 0 1 -1
and,theasinensin,a 1.0 0.000143348623853 0 1 -1
and,the,types 1.0 0.000143348623853 0 1 -1
and,the,type 1.0 0.000716743119266 0 5 -5
and,the,two 1.0 0.000143348623853 0 1 -1
and,the,total 1.0 0.000143348623853 0 1 -1
and,the,time 1.0 0.000143348623853 0 1 -1
and,the,therapy 1.0 0.000143348623853 0 1 -1
and,the,therapeutic 1.0 0.000143348623853 0 1 -1
and,the,th 1.0 0.000143348623853 0 1 -1
and,the,signs 1.0 0.000286697247706 0 2 -2
and,the,serum 1.0 0.000143348623853 0 1 -1
and,the,same 1.0 0.000143348623853 0 1 -1
and,the,risk 1.0 0.000143348623853 0 1 -1
and,the,result 1.0 0.000143348623853 0 1 -1
and,the,rest 1.0 0.000143348623853 0 1 -1
and,the,renal 1.0 0.00043004587156 0 3 -3
and,the,remaining 1.0 0.000143348623853 0 1 -1
and,the,relevance 1.0 0.000143348623853 0 1 -1
and,the,reductions 1.0 0.000143348623853 0 1 -1
and,the,rbc 1.0 0.000143348623853 0 1 -1
and,the,proportion 1.0 0.000143348623853 0 1 -1
and,the,prolonged 1.0 0.000143348623853 0 1 -1
and,the,prolongation 1.0 0.000143348623853 0 1 -1
and,the,possible 1.0 0.000143348623853 0 1 -1
and,the,possibility 1.0 0.000143348623853 0 1 -1
and,the,plasma 1.0 0.000143348623853 0 1 -1
and,the,pharmacodynamics 1.0 0.000143348623853 0 1 -1
and,the,patients 1.0 0.000143348623853 0 1 -1
and,the,patient 1.0 0.000286697247706 0 2 -2
and,the,parenteral 1.0 0.000143348623853 0 1 -1
and,the,numerous 1.0 0.000143348623853 0 1 -1
and,the,number 1.0 0.000143348623853 0 1 -1
and,the,need 1.0 0.000286697247706 0 2 -2
and,the,nature 1.0 0.000143348623853 0 1 -1
and,the,model 1.0 0.000143348623853 0 1 -1
and,the,metabolism 1.0 0.000143348623853 0 1 -1
and,the,management 1.0 0.000143348623853 0 1 -1
and,the,magnitude 1.0 0.000143348623853 0 1 -1
and,the,levels 1.0 0.000143348623853 0 1 -1
and,the,lack 1.0 0.000143348623853 0 1 -1
and,the,labeling 1.0 0.000143348623853 0 1 -1
and,the,is 1.0 0.000286697247706 0 2 -2
and,the,intracellular 1.0 0.000143348623853 0 1 -1
and,the,inr 1.0 0.000143348623853 0 1 -1
and,the,immune 1.0 0.000143348623853 0 1 -1
and,the,hyperplasia 1.0 0.000143348623853 0 1 -1
and,the,hydroxytamoxifen 1.0 0.000143348623853 0 1 -1
and,the,ht3 1.0 0.000143348623853 0 1 -1
and,the,herbal 1.0 0.000143348623853 0 1 -1
and,the,hazards 1.0 0.000143348623853 0 1 -1
and,the,frequency 1.0 0.000143348623853 0 1 -1
and,the,fractional 1.0 0.000143348623853 0 1 -1
and,the,following 1.0 0.000143348623853 0 1 -1
and,the,first 1.0 0.000143348623853 0 1 -1
and,the,extent 1.0 0.000143348623853 0 1 -1
and,the,excretion 1.0 0.000143348623853 0 1 -1
and,the,electrocardiographic 1.0 0.000143348623853 0 1 -1
and,the,dosage 1.0 0.000143348623853 0 1 -1
and,the,direction 1.0 0.000143348623853 0 1 -1
and,the,development 1.0 0.000143348623853 0 1 -1
and,the,derivative 1.0 0.000143348623853 0 1 -1
and,the,decreased 1.0 0.000143348623853 0 1 -1
and,the,deaths 1.0 0.000143348623853 0 1 -1
and,the,cyp3a4 1.0 0.000143348623853 0 1 -1
and,the,cyp1a2 1.0 0.000143348623853 0 1 -1
and,the,contribution 1.0 0.000143348623853 0 1 -1
and,the,clinician 1.0 0.000143348623853 0 1 -1
and,the,channel 1.0 0.000143348623853 0 1 -1
and,the,bmax 1.0 0.000143348623853 0 1 -1
and,the,bioavailability 1.0 0.000143348623853 0 1 -1
and,the,binding 1.0 0.000143348623853 0 1 -1
and,the,behaviour 1.0 0.000286697247706 0 2 -2
and,the,bactec 1.0 0.000143348623853 0 1 -1
and,the,appearance 1.0 0.000286697247706 0 2 -2
and,the,antimicrobial 1.0 0.000143348623853 0 1 -1
and,the,above 1.0 0.000286697247706 0 2 -2
and,the,ability 1.0 0.000143348623853 0 1 -1
and,the,aberrant 1.0 0.000143348623853 0 1 -1
and,that,transferred 1.0 0.000143348623853 0 1 -1
and,that,these 1.0 0.000143348623853 0 1 -1
and,that,tests 1.0 0.000143348623853 0 1 -1
and,that,polyamines 1.0 0.000143348623853 0 1 -1
and,that,of 1.0 0.000286697247706 0 2 -2
and,that,no 1.0 0.000143348623853 0 1 -1
and,that,is 1.0 0.000143348623853 0 1 -1
and,that,induce 1.0 0.000143348623853 0 1 -1
and,that,functional 1.0 0.000143348623853 0 1 -1
and,that,caution 1.0 0.000143348623853 0 1 -1
and,that,can 1.0 0.000143348623853 0 1 -1
and,that,are 1.0 0.000143348623853 0 1 -1
and,th,days 1.0 0.000143348623853 0 1 -1
and,testicular,leydig 1.0 0.000143348623853 0 1 -1
and,test,strips 1.0 0.000143348623853 0 1 -1
and,t3,concentrations 1.0 0.000143348623853 0 1 -1
and,systolic,blood 1.0 0.000143348623853 0 1 -1
and,systemic,eg 1.0 0.000143348623853 0 1 -1
and,synthetic,on 1.0 0.000143348623853 0 1 -1
and,synthetic,galloyl 1.0 0.000143348623853 0 1 -1
and,symptomatic,hyperlactatemia 1.0 0.000143348623853 0 1 -1
and,sustiva,mg 1.0 0.000143348623853 0 1 -1
and,sustain,plasma 1.0 0.000143348623853 0 1 -1
and,susceptibility,to 1.0 0.00043004587156 0 3 -3
and,suppressed,by 1.0 0.000143348623853 0 1 -1
and,such,are 1.0 0.000143348623853 0 1 -1
and,subsequent,recovery 1.0 0.000143348623853 0 1 -1
and,subjective,effects 1.0 0.000143348623853 0 1 -1
and,subcutaneous,injections 1.0 0.000143348623853 0 1 -1
and,subcortical,structures 1.0 0.000143348623853 0 1 -1
and,study,with 1.0 0.000143348623853 0 1 -1
and,studies,involving 1.0 0.000143348623853 0 1 -1
and,stress,may 1.0 0.000143348623853 0 1 -1
and,streptozotocin-induced,diabetic 1.0 0.000143348623853 0 1 -1
and,stimulation,of 1.0 0.000143348623853 0 1 -1
and,stability,over 1.0 0.000143348623853 0 1 -1
and,squirrel,monkeys 1.0 0.000143348623853 0 1 -1
and,specific,activity 1.0 0.000143348623853 0 1 -1
and,some,gram-positive 1.0 0.000143348623853 0 1 -1
and,some,general 1.0 0.000143348623853 0 1 -1
and,some,are 1.0 0.000143348623853 0 1 -1
and,sodium,the 1.0 0.000143348623853 0 1 -1
and,sodium,levels 1.0 0.000143348623853 0 1 -1
and,sodium,an 1.0 0.000143348623853 0 1 -1
and,socioeconomic,factors 1.0 0.000143348623853 0 1 -1
and,smx,were 1.0 0.000143348623853 0 1 -1
and,six,clinical 1.0 0.000143348623853 0 1 -1
and,single,dose 1.0 0.000143348623853 0 1 -1
and,similar,compounds 1.0 0.000143348623853 0 1 -1
and,sigma-2,receptors 1.0 0.000143348623853 0 1 -1
and,side,effect 1.0 0.000143348623853 0 1 -1
and,showed,that 1.0 0.000143348623853 0 1 -1
and,showed,no 1.0 0.000143348623853 0 1 -1
and,should,have 1.0 0.000143348623853 0 1 -1
and,shorter,durations 1.0 0.000143348623853 0 1 -1
and,short-acting,has 1.0 0.000143348623853 0 1 -1
and,sgpt,s-alt 1.0 0.000143348623853 0 1 -1
and,sex,men 1.0 0.000143348623853 0 1 -1
and,several,with 1.0 0.000143348623853 0 1 -1
and,seven,cases 1.0 0.000143348623853 0 1 -1
and,served,as 1.0 0.000143348623853 0 1 -1
and,serum,uric 1.0 0.000143348623853 0 1 -1
and,serum,txb2 1.0 0.000143348623853 0 1 -1
and,serum,bilirubin 1.0 0.000143348623853 0 1 -1
and,serotoninergic,central 1.0 0.000143348623853 0 1 -1
and,serotonin2-receptors,underlies 1.0 0.000143348623853 0 1 -1
and,serotonin,and 1.0 0.000143348623853 0 1 -1
and,serosal,surfaces 1.0 0.000143348623853 0 1 -1
and,sensitization,to 1.0 0.000143348623853 0 1 -1
and,selected,patient 1.0 0.000143348623853 0 1 -1
and,seem,to 1.0 0.000143348623853 0 1 -1
and,secondary,deficiencies 1.0 0.000143348623853 0 1 -1
and,screening,for 1.0 0.000143348623853 0 1 -1
and,scanning,electron 1.0 0.000143348623853 0 1 -1
and,safety,profiles 1.0 0.000143348623853 0 1 -1
and,safety,of 1.0 0.000143348623853 0 1 -1
and,safety,have 1.0 0.000716743119266 0 5 -5
and,safely,used 1.0 0.000143348623853 0 1 -1
and,s,isomers 1.0 0.000143348623853 0 1 -1
and,rhabdomyolysis,particularly 1.0 0.000143348623853 0 1 -1
and,rhabdomyolysis,have 1.0 0.000143348623853 0 1 -1
and,returned,to 1.0 0.000286697247706 0 2 -2
and,return,toward 1.0 0.000143348623853 0 1 -1
and,retard,the 1.0 0.000143348623853 0 1 -1
and,respiratory,and 1.0 0.000143348623853 0 1 -1
and,respectively,which 1.0 0.000143348623853 0 1 -1
and,respectively,in 1.0 0.000286697247706 0 2 -2
and,resistant,mcf-7 1.0 0.000143348623853 0 1 -1
and,requires,a 1.0 0.000143348623853 0 1 -1
and,repeated,if 1.0 0.000143348623853 0 1 -1
and,repeat,testing 1.0 0.000143348623853 0 1 -1
and,renal,vasodilator 1.0 0.000143348623853 0 1 -1
and,renal,excretion 1.0 0.000143348623853 0 1 -1
and,renal,calculi 1.0 0.000143348623853 0 1 -1
and,remnant,removal 1.0 0.000143348623853 0 1 -1
and,reliable,affinity 1.0 0.000143348623853 0 1 -1
and,release,was 1.0 0.000143348623853 0 1 -1
and,release,of 1.0 0.000286697247706 0 2 -2
and,release,in 1.0 0.000286697247706 0 2 -2
and,relative,importance 1.0 0.000143348623853 0 1 -1
and,related,psychoses 1.0 0.000143348623853 0 1 -1
and,related,ethacrynic 1.0 0.000143348623853 0 1 -1
and,reinstate,psychostimulant 1.0 0.000143348623853 0 1 -1
and,regulation,of 1.0 0.000143348623853 0 1 -1
and,reduced,subjects 1.0 0.000143348623853 0 1 -1
and,reduced,ligand 1.0 0.000143348623853 0 1 -1
and,recurred,when 1.0 0.000143348623853 0 1 -1
and,received,an 1.0 0.000143348623853 0 1 -1
and,rarely,euphoria 1.0 0.000143348623853 0 1 -1
and,rarely,enuresis 1.0 0.000143348623853 0 1 -1
and,rarely,dry 1.0 0.000143348623853 0 1 -1
and,randomly,bred 1.0 0.000143348623853 0 1 -1
and,racemic,was 1.0 0.000143348623853 0 1 -1
and,quinolones,form 1.0 0.000143348623853 0 1 -1
and,qualitative,differences 1.0 0.000143348623853 0 1 -1
and,qtc,intervals 1.0 0.000143348623853 0 1 -1
and,pupil,constriction 1.0 0.000286697247706 0 2 -2
and,pulsatile,choroidal 1.0 0.000143348623853 0 1 -1
and,pulmonary,emboli 1.0 0.000143348623853 0 1 -1
and,pseudomonas,aeruginosa 1.0 0.000143348623853 0 1 -1
and,pruritus,and 1.0 0.000143348623853 0 1 -1
and,proton,pump 1.0 0.000143348623853 0 1 -1
and,protein,binding 1.0 0.000143348623853 0 1 -1
and,protease,inhibitors 1.0 0.000143348623853 0 1 -1
and,proquin,xr 1.0 0.000143348623853 0 1 -1
and,proposed,as 1.0 0.000143348623853 0 1 -1
and,properties,of 1.0 0.000143348623853 0 1 -1
and,prolonged,thrombocytopenia 1.0 0.000143348623853 0 1 -1
and,prolong,and 1.0 0.000143348623853 0 1 -1
and,progression,of 1.0 0.000143348623853 0 1 -1
and,progestogen,administration 1.0 0.000143348623853 0 1 -1
and,products,with 1.0 0.000143348623853 0 1 -1
and,produced,in 1.0 0.000143348623853 0 1 -1
and,produced,an 1.0 0.000143348623853 0 1 -1
and,produce,false 1.0 0.00043004587156 0 3 -3
and,probably,for 1.0 0.000143348623853 0 1 -1
and,primarily,metabolized 1.0 0.000573394495413 0 4 -4
and,prevention,studies 1.0 0.000143348623853 0 1 -1
and,prevent,the 1.0 0.000143348623853 0 1 -1
and,prevalence,of 1.0 0.000143348623853 0 1 -1
and,presumably,a 1.0 0.000143348623853 0 1 -1
and,pregnancy,outcomes 1.0 0.000143348623853 0 1 -1
and,pre-sacral,vertebrae 1.0 0.000143348623853 0 1 -1
and,potentiates,the 1.0 0.000143348623853 0 1 -1
and,potentiate,sulfate 1.0 0.000143348623853 0 1 -1
and,potential,for 1.0 0.000286697247706 0 2 -2
and,potential,decrease 1.0 0.000143348623853 0 1 -1
and,potential,bleeding 1.0 0.000143348623853 0 1 -1
and,potent,inhibitors 1.0 0.000143348623853 0 1 -1
and,potency,and 1.0 0.000143348623853 0 1 -1
and,potassium-sparing,each 1.0 0.000143348623853 0 1 -1
and,postnatal,immune 1.0 0.000143348623853 0 1 -1
and,post-implantation,loss 1.0 0.000143348623853 0 1 -1
and,possibly,nicotinic 1.0 0.000143348623853 0 1 -1
and,possible,toxicity 1.0 0.000143348623853 0 1 -1
and,possible,resistance 1.0 0.00043004587156 0 3 -3
and,possible,adjustment 1.0 0.000143348623853 0 1 -1
and,positive,test 1.0 0.000143348623853 0 1 -1
and,poor-risk,aids-related 1.0 0.000143348623853 0 1 -1
and,polyfuranoses,with 1.0 0.000143348623853 0 1 -1
and,platelets,recover 1.0 0.000143348623853 0 1 -1
and,platelet,antiaggregant 1.0 0.000143348623853 0 1 -1
and,plasma,expanders 1.0 0.000143348623853 0 1 -1
and,placebo,coadministered 1.0 0.000143348623853 0 1 -1
and,phase,days 1.0 0.000143348623853 0 1 -1
and,pharmacotherapy,of 1.0 0.000143348623853 0 1 -1
and,pharmacological,therapy 1.0 0.000143348623853 0 1 -1
and,pharmacological,interactions 1.0 0.000143348623853 0 1 -1
and,pharmacologic,effects 1.0 0.000143348623853 0 1 -1
and,pharmacokinetics,of 1.0 0.000143348623853 0 1 -1
and,pharmacokinetics,at 1.0 0.000143348623853 0 1 -1
and,pharmacodynamics,ecg 1.0 0.000143348623853 0 1 -1
and,pharmacodynamic,interactions 1.0 0.000143348623853 0 1 -1
and,pharmaco-dynamic,effects 1.0 0.000143348623853 0 1 -1
and,pharmacist,before 1.0 0.000143348623853 0 1 -1
and,perhaps,other 1.0 0.000143348623853 0 1 -1
and,perhaps,at 1.0 0.000143348623853 0 1 -1
and,patients,with 1.0 0.000143348623853 0 1 -1
and,patients,observed 1.0 0.000143348623853 0 1 -1
and,particularly,those 1.0 0.000143348623853 0 1 -1
and,partial,thromboplastin 1.0 0.000143348623853 0 1 -1
and,parnate,using 1.0 0.000143348623853 0 1 -1
and,paraclinical,pattern 1.0 0.000143348623853 0 1 -1
and,p2,while 1.0 0.000143348623853 0 1 -1
and,oxo-desethylzaleplon,glucuronide 1.0 0.000143348623853 0 1 -1
and,ototoxicity,were 1.0 0.000143348623853 0 1 -1
and,others,plasma 1.0 0.000143348623853 0 1 -1
and,others,or 1.0 0.000286697247706 0 2 -2
and,others,may 1.0 0.000286697247706 0 2 -2
and,other,ventricular 1.0 0.000143348623853 0 1 -1
and,other,thyroid 1.0 0.000143348623853 0 1 -1
and,other,therapies 1.0 0.000143348623853 0 1 -1
and,other,than 1.0 0.000143348623853 0 1 -1
and,other,similarly 1.0 0.000143348623853 0 1 -1
and,other,similar 1.0 0.000143348623853 0 1 -1
and,other,signs 1.0 0.000286697247706 0 2 -2
and,other,products 1.0 0.000286697247706 0 2 -2
and,other,populations 1.0 0.000716743119266 0 5 -5
and,other,phe-nothiazines 1.0 0.000143348623853 0 1 -1
and,other,nondepolarizing 1.0 0.000143348623853 0 1 -1
and,other,myelosuppressive 1.0 0.000143348623853 0 1 -1
and,other,monoamines 1.0 0.000286697247706 0 2 -2
and,other,membrane 1.0 0.000143348623853 0 1 -1
and,other,medicinal 1.0 0.000143348623853 0 1 -1
and,other,likely 1.0 0.000143348623853 0 1 -1
and,other,lesions 1.0 0.000143348623853 0 1 -1
and,other,highly 1.0 0.000143348623853 0 1 -1
and,other,have 1.0 0.000716743119266 0 5 -5
and,other,had 1.0 0.000143348623853 0 1 -1
and,other,drug 1.0 0.000143348623853 0 1 -1
and,other,complications 1.0 0.000143348623853 0 1 -1
and,other,commonly 1.0 0.000143348623853 0 1 -1
and,other,are 1.0 0.000143348623853 0 1 -1
and,other,antiepileptic 1.0 0.000143348623853 0 1 -1
and,other,aeds 1.0 0.000286697247706 0 2 -2
and,organoleads,are 1.0 0.000143348623853 0 1 -1
and,orange,juices 1.0 0.000143348623853 0 1 -1
and,oral,resulting 1.0 0.000143348623853 0 1 -1
and,oral,in 1.0 0.000143348623853 0 1 -1
and,oral,and 1.0 0.000143348623853 0 1 -1
and,oral,an 1.0 0.000143348623853 0 1 -1
and,oral,administration 1.0 0.000143348623853 0 1 -1
and,oral,adl 1.0 0.000143348623853 0 1 -1
and,or,without 1.0 0.000143348623853 0 1 -1
and,or,were 1.0 0.000143348623853 0 1 -1
and,or,total 1.0 0.000143348623853 0 1 -1
and,or,stereotypic 1.0 0.000143348623853 0 1 -1
and,or,pharmacodynamics 1.0 0.000143348623853 0 1 -1
and,or,pgp 1.0 0.000143348623853 0 1 -1
and,or,pd 1.0 0.000143348623853 0 1 -1
and,or,parenteral 1.0 0.000143348623853 0 1 -1
and,or,outpatient 1.0 0.000143348623853 0 1 -1
and,or,ototoxicity 1.0 0.000143348623853 0 1 -1
and,or,nephrotoxic 1.0 0.000143348623853 0 1 -1
and,or,hepatic 1.0 0.000286697247706 0 2 -2
and,or,gonadal 1.0 0.000143348623853 0 1 -1
and,or,excessive 1.0 0.000143348623853 0 1 -1
and,or,epoxide 1.0 0.000143348623853 0 1 -1
and,or,embryocidal 1.0 0.000143348623853 0 1 -1
and,or,drug 1.0 0.000143348623853 0 1 -1
and,or,cardiac 1.0 0.000143348623853 0 1 -1
and,or,carbidopa-levodopa 1.0 0.000143348623853 0 1 -1
and,or,ast 1.0 0.000143348623853 0 1 -1
and,or,anticoagulation 1.0 0.000143348623853 0 1 -1
and,or,amenorrhea 1.0 0.000143348623853 0 1 -1
and,optic,nerve 1.0 0.000143348623853 0 1 -1
and,only,if 1.0 0.000143348623853 0 1 -1
and,one,with 1.0 0.000143348623853 0 1 -1
and,one,strain 1.0 0.000143348623853 0 1 -1
and,one,at 1.0 0.000143348623853 0 1 -1
and,on,intestinal 1.0 0.000143348623853 0 1 -1
and,on,days 1.0 0.000143348623853 0 1 -1
and,on,bar-press 1.0 0.000143348623853 0 1 -1
and,on,antinociceptive 1.0 0.000143348623853 0 1 -1
and,omega-conotoxin,gvia 1.0 0.000143348623853 0 1 -1
and,older,who 1.0 0.000143348623853 0 1 -1
and,of,pseudomonas 1.0 0.000143348623853 0 1 -1
and,of,protein 1.0 0.000143348623853 0 1 -1
and,of,patients 1.0 0.000143348623853 0 1 -1
and,of,on 1.0 0.000143348623853 0 1 -1
and,of,innovar 1.0 0.000143348623853 0 1 -1
and,of,ergot-type 1.0 0.000143348623853 0 1 -1
and,ocular,blood 1.0 0.000143348623853 0 1 -1
and,october,of 1.0 0.000143348623853 0 1 -1
and,occurred,within 1.0 0.000143348623853 0 1 -1
and,observations,on 1.0 0.000143348623853 0 1 -1
and,obesity,as 1.0 0.000143348623853 0 1 -1
and,numerous,liver 1.0 0.000143348623853 0 1 -1
and,nrtis,other 1.0 0.000143348623853 0 1 -1
and,note,if 1.0 0.000143348623853 0 1 -1
and,not,rely 1.0 0.000143348623853 0 1 -1
and,not,materially 1.0 0.000143348623853 0 1 -1
and,not,by 1.0 0.000143348623853 0 1 -1
and,north,american 1.0 0.000143348623853 0 1 -1
and,normal,cells 1.0 0.000143348623853 0 1 -1
and,nor,the 1.0 0.000143348623853 0 1 -1
and,nonsteroidal,were 1.0 0.000286697247706 0 2 -2
and,nonsteroidal,anti-inflammatory 1.0 0.000143348623853 0 1 -1
and,nonrenal,clearance 1.0 0.000143348623853 0 1 -1
and,nonprescription,products 1.0 0.000143348623853 0 1 -1
and,nondepolarizing,muscle 1.0 0.000143348623853 0 1 -1
and,nonclinical,studies 1.0 0.000143348623853 0 1 -1
and,nonadditive,independent 1.0 0.000143348623853 0 1 -1
and,non-ossification,of 1.0 0.000143348623853 0 1 -1
and,non-opioid,agonist 1.0 0.000143348623853 0 1 -1
and,non-gastrointestinal,bleedings 1.0 0.000143348623853 0 1 -1
and,no,treatment-related 1.0 0.000143348623853 0 1 -1
and,no,reports 1.0 0.000143348623853 0 1 -1
and,no,potentiation 1.0 0.000143348623853 0 1 -1
and,no,evidence 1.0 0.000143348623853 0 1 -1
and,no,effect 1.0 0.000143348623853 0 1 -1
and,no,drug-specific 1.0 0.000143348623853 0 1 -1
and,no,dose 1.0 0.000286697247706 0 2 -2
and,no,differential 1.0 0.000143348623853 0 1 -1
and,no,complications 1.0 0.000143348623853 0 1 -1
and,no,clinically 1.0 0.000143348623853 0 1 -1
and,no,clear 1.0 0.000143348623853 0 1 -1
and,new,combination 1.0 0.000143348623853 0 1 -1
and,neither,were 1.0 0.000143348623853 0 1 -1
and,negative,symptoms 1.0 0.00043004587156 0 3 -3
and,need,similar 1.0 0.000143348623853 0 1 -1
and,natural,history 1.0 0.000143348623853 0 1 -1
and,n3,for 1.0 0.000143348623853 0 1 -1
and,n1,and 1.0 0.000143348623853 0 1 -1
and,n-oxide,were 1.0 0.000143348623853 0 1 -1
and,n-cetyl,gallate 1.0 0.000143348623853 0 1 -1
and,n-acetyl,by 1.0 0.000143348623853 0 1 -1
and,must,be 1.0 0.000143348623853 0 1 -1
and,muscle,relaxant 1.0 0.000143348623853 0 1 -1
and,multiple,doses 1.0 0.000143348623853 0 1 -1
and,multifaceted,and 1.0 0.000143348623853 0 1 -1
and,mu,systems 1.0 0.000143348623853 0 1 -1
and,motor,skills 1.0 0.000143348623853 0 1 -1
and,most,may 1.0 0.000143348623853 0 1 -1
and,mortality,were 1.0 0.000143348623853 0 1 -1
and,mortality,is 1.0 0.000143348623853 0 1 -1
and,more,than 1.0 0.000143348623853 0 1 -1
and,mononuclear,cell 1.0 0.000143348623853 0 1 -1
and,monitored,regularly 1.0 0.000143348623853 0 1 -1
and,molecular,level 1.0 0.000143348623853 0 1 -1
and,mmol,day 1.0 0.000143348623853 0 1 -1
and,mm,hg 1.0 0.000143348623853 0 1 -1
and,mm,had 1.0 0.000143348623853 0 1 -1
and,mixed--pharmacological,and 1.0 0.000143348623853 0 1 -1
and,mixed,signalled-unsignalled 1.0 0.000143348623853 0 1 -1
and,mixed,agonist-antagonist 1.0 0.000143348623853 0 1 -1
and,miotic,actions 1.0 0.000143348623853 0 1 -1
and,minutes,to 1.0 0.000143348623853 0 1 -1
and,minor,adverse 1.0 0.000143348623853 0 1 -1
and,minimal,inhibitory 1.0 0.000143348623853 0 1 -1
and,minimal,experimental 1.0 0.000143348623853 0 1 -1
and,min,following 1.0 0.000143348623853 0 1 -1
and,mild-to,moderate 1.0 0.000143348623853 0 1 -1
and,micromol,l 1.0 0.000143348623853 0 1 -1
and,micrograms,ml 1.0 0.000286697247706 0 2 -2
and,mhd,induce 1.0 0.000143348623853 0 1 -1
and,mhd,however 1.0 0.000143348623853 0 1 -1
and,mhd,did 1.0 0.000143348623853 0 1 -1
and,mg2,converted 1.0 0.000143348623853 0 1 -1
and,mg,with 1.0 0.000143348623853 0 1 -1
and,mg,when 1.0 0.000143348623853 0 1 -1
and,mg,were 1.0 0.000143348623853 0 1 -1
and,mg,single 1.0 0.000286697247706 0 2 -2
and,mg,or 1.0 0.000143348623853 0 1 -1
and,mg,l 1.0 0.000143348623853 0 1 -1
and,mg,iv 1.0 0.000143348623853 0 1 -1
and,mg,for 1.0 0.000143348623853 0 1 -1
and,mg,did 1.0 0.00043004587156 0 3 -3
and,mg,b 1.0 0.000143348623853 0 1 -1
and,mg,a 1.0 0.000143348623853 0 1 -1
and,metacercariae,of 1.0 0.000143348623853 0 1 -1
and,menstrual,irregularities 1.0 0.000286697247706 0 2 -2
and,memory,that 1.0 0.000143348623853 0 1 -1
and,membrane,properties 1.0 0.000143348623853 0 1 -1
and,mefloquine,should 1.0 0.000143348623853 0 1 -1
and,medical,backgrounds 1.0 0.000143348623853 0 1 -1
and,mean,plasma 1.0 0.000143348623853 0 1 -1
and,mean,c 1.0 0.000143348623853 0 1 -1
and,mcg,once 1.0 0.000143348623853 0 1 -1
and,mcg,of 1.0 0.000143348623853 0 1 -1
and,mc,enhance 1.0 0.000143348623853 0 1 -1
and,mc,decrease 1.0 0.000143348623853 0 1 -1
and,mc,ameliorate 1.0 0.000143348623853 0 1 -1
and,may,vary 1.0 0.000143348623853 0 1 -1
and,may,therefore 1.0 0.000143348623853 0 1 -1
and,may,thereby 1.0 0.000143348623853 0 1 -1
and,may,subsequently 1.0 0.000143348623853 0 1 -1
and,may,possibly 1.0 0.000143348623853 0 1 -1
and,may,or 1.0 0.000143348623853 0 1 -1
and,may,lead 1.0 0.000573394495413 0 4 -4
and,may,include 1.0 0.000143348623853 0 1 -1
and,may,explain 1.0 0.000143348623853 0 1 -1
and,may,even 1.0 0.000143348623853 0 1 -1
and,may,also 1.0 0.000143348623853 0 1 -1
and,mask,the 1.0 0.000143348623853 0 1 -1
and,many,that 1.0 0.000716743119266 0 5 -5
and,manageable,without 1.0 0.000143348623853 0 1 -1
and,malignant,hyperpyrexia 1.0 0.000286697247706 0 2 -2
and,males,dosed 1.0 0.000143348623853 0 1 -1
and,male,rats 1.0 0.000143348623853 0 1 -1
and,make,normal 1.0 0.000716743119266 0 5 -5
and,main,results 1.0 0.000286697247706 0 2 -2
and,magnesium-containing,meq 1.0 0.000143348623853 0 1 -1
and,m,v 1.0 0.000143348623853 0 1 -1
and,m,m 1.0 0.000143348623853 0 1 -1
and,lymphopenia,proper 1.0 0.000143348623853 0 1 -1
and,lunch,doses 1.0 0.000143348623853 0 1 -1
and,lower,auc 1.0 0.000143348623853 0 1 -1
and,low,hepatic 1.0 0.000143348623853 0 1 -1
and,low,affinity 1.0 0.000143348623853 0 1 -1
and,losartan,bosentan 1.0 0.000143348623853 0 1 -1
and,loop,and 1.0 0.000143348623853 0 1 -1
and,long-term,consequences 1.0 0.000143348623853 0 1 -1
and,long,withdrawal 1.0 0.000143348623853 0 1 -1
and,long,lasting 1.0 0.000143348623853 0 1 -1
and,lodine,should 1.0 0.000143348623853 0 1 -1
and,local,agents 1.0 0.000286697247706 0 2 -2
and,liver,function 1.0 0.00043004587156 0 3 -3
and,liver,and 1.0 0.000143348623853 0 1 -1
and,lipids,were 1.0 0.000143348623853 0 1 -1
and,limited,sampling 1.0 0.000143348623853 0 1 -1
and,like,mc 1.0 0.000143348623853 0 1 -1
and,life-threatening,reactions 1.0 0.000143348623853 0 1 -1
and,levonorgestrel-treated,rats 1.0 0.000143348623853 0 1 -1
and,levels,indicating 1.0 0.000143348623853 0 1 -1
and,levels,following 1.0 0.000143348623853 0 1 -1
and,lethality,in 1.0 0.000143348623853 0 1 -1
and,less,suppression 1.0 0.000143348623853 0 1 -1
and,lead,electrocardiograms 1.0 0.000143348623853 0 1 -1
and,ldl-c,reduction 1.0 0.000143348623853 0 1 -1
and,lack,of 1.0 0.000143348623853 0 1 -1
and,laboratory,tests 1.0 0.000286697247706 0 2 -2
and,laboratory,studies 1.0 0.000143348623853 0 1 -1
and,laboratory,monitoring 1.0 0.000143348623853 0 1 -1
and,laboratory,evidence 1.0 0.000143348623853 0 1 -1
and,laboratory,abnormalities 1.0 0.000143348623853 0 1 -1
and,l-ccg,was 1.0 0.000143348623853 0 1 -1
and,l-ccg,upon 1.0 0.000143348623853 0 1 -1
and,l-ccg,on 1.0 0.000143348623853 0 1 -1
and,kytril,have 1.0 0.000143348623853 0 1 -1
and,kht,tumour 1.0 0.000143348623853 0 1 -1
and,ketoconazole,ketoconazole 1.0 0.000143348623853 0 1 -1
and,ketoconazole,fexofenadine 1.0 0.000143348623853 0 1 -1
and,kappa-selective,was 1.0 0.000143348623853 0 1 -1
and,joint,exposure 1.0 0.000143348623853 0 1 -1
and,job,appointments 1.0 0.000143348623853 0 1 -1
and,iv,myocardium 1.0 0.000143348623853 0 1 -1
and,iv,have 1.0 0.000143348623853 0 1 -1
and,iv,compared 1.0 0.000143348623853 0 1 -1
and,its,vasculature 1.0 0.000143348623853 0 1 -1
and,its,two 1.0 0.000143348623853 0 1 -1
and,its,pharmacologically 1.0 0.000143348623853 0 1 -1
and,its,n-demethylated 1.0 0.000143348623853 0 1 -1
and,its,metabolite 1.0 0.000143348623853 0 1 -1
and,its,major 1.0 0.00043004587156 0 3 -3
and,its,clinical 1.0 0.000143348623853 0 1 -1
and,its,acid 1.0 0.000143348623853 0 1 -1
and,it,may 1.0 0.000143348623853 0 1 -1
and,it,increased 1.0 0.000143348623853 0 1 -1
and,it,enhances 1.0 0.000143348623853 0 1 -1
and,ischemia,of 1.0 0.000286697247706 0 2 -2
and,is,usually 1.0 0.000143348623853 0 1 -1
and,is,unlikely 1.0 0.000143348623853 0 1 -1
and,is,prone 1.0 0.000143348623853 0 1 -1
and,is,probably 1.0 0.000143348623853 0 1 -1
and,is,particularly 1.0 0.000143348623853 0 1 -1
and,is,dependent 1.0 0.000143348623853 0 1 -1
and,is,comparable 1.0 0.000143348623853 0 1 -1
and,is,a 1.0 0.000143348623853 0 1 -1
and,involve,individual 1.0 0.000143348623853 0 1 -1
and,invalidate,folic 1.0 0.000143348623853 0 1 -1
and,intravenous,placebo 1.0 0.000143348623853 0 1 -1
and,intravenous,mg 1.0 0.000286697247706 0 2 -2
and,intravenous,administration 1.0 0.000143348623853 0 1 -1
and,intraindividual,interoccasion 1.0 0.000143348623853 0 1 -1
and,intracellular,mobilization 1.0 0.000143348623853 0 1 -1
and,intestinal,beta-glucuronidase 1.0 0.000143348623853 0 1 -1
and,international,pharmaceutical 1.0 0.000143348623853 0 1 -1
and,interactions,and 1.0 0.000143348623853 0 1 -1
and,interactions,allows 1.0 0.000143348623853 0 1 -1
and,instructions,for 1.0 0.000143348623853 0 1 -1
and,instruct,the 1.0 0.000143348623853 0 1 -1
and,inr,were 1.0 0.000143348623853 0 1 -1
and,inn,when 1.0 0.000143348623853 0 1 -1
and,injectables,are 1.0 0.000143348623853 0 1 -1
and,inhibition,of 1.0 0.000143348623853 0 1 -1
and,inhibited,to 1.0 0.000143348623853 0 1 -1
and,inhibit,platelet 1.0 0.000143348623853 0 1 -1
and,inhibit,p450 1.0 0.000716743119266 0 5 -5
and,inhaled,with 1.0 0.000143348623853 0 1 -1
and,infrequent,reports 1.0 0.000143348623853 0 1 -1
and,infants,which 1.0 0.000143348623853 0 1 -1
and,industrial,workers 1.0 0.000143348623853 0 1 -1
and,inducible,vana 1.0 0.000143348623853 0 1 -1
and,inducers,are 1.0 0.000143348623853 0 1 -1
and,induced,a 1.0 0.000143348623853 0 1 -1
and,induce,cyp3a4 1.0 0.000143348623853 0 1 -1
and,indirect,antiglobulin 1.0 0.000143348623853 0 1 -1
and,indicated,that 1.0 0.000143348623853 0 1 -1
and,indanedione,including 1.0 0.000143348623853 0 1 -1
and,increasingly,those 1.0 0.000143348623853 0 1 -1
and,increases,of 1.0 0.000143348623853 0 1 -1
and,increased,its 1.0 0.000143348623853 0 1 -1
and,increased,incidence 1.0 0.00043004587156 0 3 -3
and,increased,in 1.0 0.000143348623853 0 1 -1
and,increased,breakthrough 1.0 0.000143348623853 0 1 -1
and,increased,blood 1.0 0.000143348623853 0 1 -1
and,increased,appetite 1.0 0.000143348623853 0 1 -1
and,increased,amounts 1.0 0.000143348623853 0 1 -1
and,increase,serum 1.0 0.000143348623853 0 1 -1
and,increase,growth 1.0 0.000143348623853 0 1 -1
and,including,or 1.0 0.000143348623853 0 1 -1
and,include,but 1.0 0.000143348623853 0 1 -1
and,in,unconjugated 1.0 0.000143348623853 0 1 -1
and,in,treatment-experienced 1.0 0.000143348623853 0 1 -1
and,in,limiting 1.0 0.000143348623853 0 1 -1
and,in,controlled 1.0 0.000143348623853 0 1 -1
and,in,combinations 1.0 0.000143348623853 0 1 -1
and,in,combination 1.0 0.000860091743119 0 6 -6
and,in,and 1.0 0.000143348623853 0 1 -1
and,in,a-chloralose 1.0 0.000143348623853 0 1 -1
and,in,a 1.0 0.000143348623853 0 1 -1
and,implications,for 1.0 0.000143348623853 0 1 -1
and,impairment,of 1.0 0.000143348623853 0 1 -1
and,impaired,suppression 1.0 0.000143348623853 0 1 -1
and,imitrex,nasal 1.0 0.000143348623853 0 1 -1
and,ii,the 1.0 0.000143348623853 0 1 -1
and,if,they 1.0 0.000143348623853 0 1 -1
and,identifies,clinically 1.0 0.000143348623853 0 1 -1
and,identifications,of 1.0 0.000143348623853 0 1 -1
and,i,sodium 1.0 0.000143348623853 0 1 -1
and,i,cigarettes 1.0 0.000143348623853 0 1 -1
and,hypotension,and 1.0 0.000143348623853 0 1 -1
and,hypertension,have 1.0 0.000143348623853 0 1 -1
and,hyperinsulinaemia,on 1.0 0.000143348623853 0 1 -1
and,hyperglycemic,effects 1.0 0.000143348623853 0 1 -1
and,hyperglycemia,were 1.0 0.000143348623853 0 1 -1
and,hydroxydesloratadine,were 1.0 0.000143348623853 0 1 -1
and,hydroxydesloratadine,pharmacokinetics 1.0 0.000143348623853 0 1 -1
and,hydroxides,does 1.0 0.000143348623853 0 1 -1
and,hydroxides,and 1.0 0.000143348623853 0 1 -1
and,hydroxide-containing,maalox 1.0 0.000143348623853 0 1 -1
and,hydroxide,does 1.0 0.000143348623853 0 1 -1
and,hydrochloride,a 1.0 0.000143348623853 0 1 -1
and,human,studies 1.0 0.000143348623853 0 1 -1
and,human,liver 1.0 0.000143348623853 0 1 -1
and,how,it 1.0 0.000143348623853 0 1 -1
and,hours,subsequent 1.0 0.000143348623853 0 1 -1
and,hours,prior 1.0 0.000143348623853 0 1 -1
and,hours,for 1.0 0.000286697247706 0 2 -2
and,host,defense 1.0 0.000143348623853 0 1 -1
and,hoof,twitch 1.0 0.000143348623853 0 1 -1
and,hiv,protease 1.0 0.000143348623853 0 1 -1
and,histamine-induced,gastric 1.0 0.000143348623853 0 1 -1
and,highly,active 1.0 0.000143348623853 0 1 -1
and,high,doses 1.0 0.000143348623853 0 1 -1
and,high,affinity 1.0 0.000143348623853 0 1 -1
and,hepatitis,has 1.0 0.000143348623853 0 1 -1
and,hepatic,enzyme 1.0 0.000143348623853 0 1 -1
and,healthy,subjects 1.0 0.000143348623853 0 1 -1
and,hdl2,cholesterol 1.0 0.000286697247706 0 2 -2
and,have,similar 1.0 0.000143348623853 0 1 -1
and,have,revealed 1.0 0.000143348623853 0 1 -1
and,have,no 1.0 0.000143348623853 0 1 -1
and,have,demonstrated 1.0 0.000143348623853 0 1 -1
and,have,also 1.0 0.000143348623853 0 1 -1
and,have,a 1.0 0.000286697247706 0 2 -2
and,has,no 1.0 0.000143348623853 0 1 -1
and,has,importance 1.0 0.000143348623853 0 1 -1
and,has,also 1.0 0.000143348623853 0 1 -1
and,half-life,multiple-dose 1.0 0.000143348623853 0 1 -1
and,half,returned 1.0 0.000143348623853 0 1 -1
and,haldol,has 1.0 0.000143348623853 0 1 -1
and,had,no 1.0 0.000860091743119 0 6 -6
and,had,an 1.0 0.000143348623853 0 1 -1
and,had,a 1.0 0.000143348623853 0 1 -1
and,h2,antagonists 1.0 0.000143348623853 0 1 -1
and,h-triolein,at 1.0 0.000143348623853 0 1 -1
and,greater,than 1.0 0.000143348623853 0 1 -1
and,greater,eaca 1.0 0.000143348623853 0 1 -1
and,gram,negative 1.0 0.000143348623853 0 1 -1
and,glycemic,control 1.0 0.000143348623853 0 1 -1
and,glucose,enzymatic 1.0 0.000143348623853 0 1 -1
and,given,before 1.0 0.000143348623853 0 1 -1
and,gi,bleeding 1.0 0.000143348623853 0 1 -1
and,get,the 1.0 0.000143348623853 0 1 -1
and,genitourinary,symptoms 1.0 0.000143348623853 0 1 -1
and,gastrointestinal,disturbances 1.0 0.000143348623853 0 1 -1
and,gastric,ph 1.0 0.000143348623853 0 1 -1
and,gamma,glutamyl 1.0 0.000143348623853 0 1 -1
and,fundus,pulsation 1.0 0.000143348623853 0 1 -1
and,functional,consequences 1.0 0.000286697247706 0 2 -2
and,function,for 1.0 0.000143348623853 0 1 -1
and,fsh,to 1.0 0.000143348623853 0 1 -1
and,from,week 1.0 0.000143348623853 0 1 -1
and,from,ml 1.0 0.000143348623853 0 1 -1
and,frequent,monitoring 1.0 0.00043004587156 0 3 -3
and,free,t3 1.0 0.000143348623853 0 1 -1
and,fr,responding 1.0 0.000143348623853 0 1 -1
and,for,week 1.0 0.000143348623853 0 1 -1
and,for,the 1.0 0.000286697247706 0 2 -2
and,for,preservation 1.0 0.000143348623853 0 1 -1
and,for,mec 1.0 0.000143348623853 0 1 -1
and,for,and 1.0 0.000286697247706 0 2 -2
and,following,treatment 1.0 0.000143348623853 0 1 -1
and,following,the 1.0 0.000143348623853 0 1 -1
and,following,single 1.0 0.000143348623853 0 1 -1
and,following,multiple 1.0 0.000143348623853 0 1 -1
and,following,infusions 1.0 0.000143348623853 0 1 -1
and,followed,by 1.0 0.000143348623853 0 1 -1
and,follow-up,measurements 1.0 0.000143348623853 0 1 -1
and,follow-up,liver 1.0 0.000143348623853 0 1 -1
and,follow-up,blood 1.0 0.000143348623853 0 1 -1
and,fold,the 1.0 0.000143348623853 0 1 -1
and,fold,prolongation 1.0 0.000143348623853 0 1 -1
and,fold,in 1.0 0.000143348623853 0 1 -1
and,fluoride,accumulation 1.0 0.000143348623853 0 1 -1
and,flares,coupled 1.0 0.000143348623853 0 1 -1
and,flare,were 1.0 0.000143348623853 0 1 -1
and,fibrosis,have 1.0 0.000143348623853 0 1 -1
and,fetal,development 1.0 0.000143348623853 0 1 -1
and,fenofibric,acid 1.0 0.000143348623853 0 1 -1
and,fehling,s 1.0 0.000286697247706 0 2 -2
and,family,education 1.0 0.000143348623853 0 1 -1
and,failed,to 1.0 0.000143348623853 0 1 -1
and,factors,vii 1.0 0.000286697247706 0 2 -2
and,facilitate,and 1.0 0.000143348623853 0 1 -1
and,extracellular,application 1.0 0.000143348623853 0 1 -1
and,extra,doses 1.0 0.000143348623853 0 1 -1
and,extent,of 1.0 0.000573394495413 0 4 -4
and,extensive,cyp2d6 1.0 0.000143348623853 0 1 -1
and,experimental,animals 1.0 0.000143348623853 0 1 -1
and,exhibit,doubling 1.0 0.000143348623853 0 1 -1
and,exert,direct 1.0 0.000143348623853 0 1 -1
and,exert,additive 1.0 0.000143348623853 0 1 -1
and,excretion,was 1.0 0.000143348623853 0 1 -1
and,except,for 1.0 0.000143348623853 0 1 -1
and,exacerbation,of 1.0 0.000143348623853 0 1 -1
and,evening,should 1.0 0.000143348623853 0 1 -1
and,even,death 1.0 0.000143348623853 0 1 -1
and,estrogen-containing,oral 1.0 0.000143348623853 0 1 -1
and,essentially,completely 1.0 0.000143348623853 0 1 -1
and,escherichia,coli 1.0 0.000143348623853 0 1 -1
and,epoxide,concentrations 1.0 0.000143348623853 0 1 -1
and,epididymides,had 1.0 0.000143348623853 0 1 -1
and,enterococcus,faecium 1.0 0.000143348623853 0 1 -1
and,enhanced,effects 1.0 0.000143348623853 0 1 -1
and,endogenous,and 1.0 0.000143348623853 0 1 -1
and,endocrine,status 1.0 0.000143348623853 0 1 -1
and,enable,cells 1.0 0.000143348623853 0 1 -1
and,emit-d,a 1.0 0.000143348623853 0 1 -1
and,embryonic,survival 1.0 0.000143348623853 0 1 -1
and,elimination,of 1.0 0.000143348623853 0 1 -1
and,elicit,their 1.0 0.000143348623853 0 1 -1
and,elevation,of 1.0 0.000286697247706 0 2 -2
and,electrophysiologic,interactions 1.0 0.000143348623853 0 1 -1
and,electrolyte,alterations 1.0 0.000143348623853 0 1 -1
and,either,or 1.0 0.000143348623853 0 1 -1
and,efficacy,should 1.0 0.000143348623853 0 1 -1
and,efficacy,has 1.0 0.000143348623853 0 1 -1
and,efficacy,ectopic 1.0 0.000143348623853 0 1 -1
and,efficacy,data 1.0 0.00043004587156 0 3 -3
and,effects,potentially 1.0 0.000143348623853 0 1 -1
and,effects,on 1.0 0.000143348623853 0 1 -1
and,effects,especially 1.0 0.000143348623853 0 1 -1
and,effectiveness,of 1.0 0.00043004587156 0 3 -3
and,effectiveness,in 1.0 0.000143348623853 0 1 -1
and,effective,use 1.0 0.000143348623853 0 1 -1
and,editorials,concerning 1.0 0.000143348623853 0 1 -1
and,during,use 1.0 0.000143348623853 0 1 -1
and,during,concomitant 1.0 0.000286697247706 0 2 -2
and,dry,mouth 1.0 0.000143348623853 0 1 -1
and,drug,transport 1.0 0.000143348623853 0 1 -1
and,drug,effects 1.0 0.000143348623853 0 1 -1
and,drug,administration 1.0 0.000143348623853 0 1 -1
and,doses,should 1.0 0.000143348623853 0 1 -1
and,dose,reduction 1.0 0.000143348623853 0 1 -1
and,dosage,of 1.0 0.00043004587156 0 3 -3
and,dosage,and 1.0 0.000143348623853 0 1 -1
and,dosage,adjustments 1.0 0.000143348623853 0 1 -1
and,dosage,adjustment 1.0 0.000286697247706 0 2 -2
and,does,not 1.0 0.00043004587156 0 3 -3
and,do,not 1.0 0.000286697247706 0 2 -2
and,dna-damaging,agents 1.0 0.000143348623853 0 1 -1
and,dmpge2-induced,jejunal 1.0 0.000143348623853 0 1 -1
and,distribution,of 1.0 0.000143348623853 0 1 -1
and,disorder,and 1.0 0.000143348623853 0 1 -1
and,discusses,current 1.0 0.000143348623853 0 1 -1
and,discrete,responses 1.0 0.000143348623853 0 1 -1
and,discontinuation,ordinarily 1.0 0.000143348623853 0 1 -1
and,disadvantages,of 1.0 0.000143348623853 0 1 -1
and,differed,from 1.0 0.000143348623853 0 1 -1
and,dietary-obese,rats 1.0 0.000143348623853 0 1 -1
and,diabetic,chinese 1.0 0.000143348623853 0 1 -1
and,diabetes,coagulation 1.0 0.000143348623853 0 1 -1
and,descarboethoxyloratadine,after 1.0 0.000143348623853 0 1 -1
and,depressive,symptoms 1.0 0.000286697247706 0 2 -2
and,depletion,related 1.0 0.000143348623853 0 1 -1
and,depend,upon 1.0 0.000143348623853 0 1 -1
and,demonstrates,the 1.0 0.000143348623853 0 1 -1
and,demonstrated,no 1.0 0.000143348623853 0 1 -1
and,delay,in 1.0 0.000143348623853 0 1 -1
and,degree,of 1.0 0.000143348623853 0 1 -1
and,degenerative,changes 1.0 0.000143348623853 0 1 -1
and,define,positive 1.0 0.000143348623853 0 1 -1
and,decreased,prothrombin 1.0 0.000143348623853 0 1 -1
and,decreased,efficacy 1.0 0.000143348623853 0 1 -1
and,decrease,platelet 1.0 0.000143348623853 0 1 -1
and,decrease,mean 1.0 0.000143348623853 0 1 -1
and,decrease,its 1.0 0.000143348623853 0 1 -1
and,cytoprotective,properties 1.0 0.000143348623853 0 1 -1
and,cytoplasmic,condensation 1.0 0.000143348623853 0 1 -1
and,cyp4a11,with 1.0 0.000143348623853 0 1 -1
and,cyp3a5,responsible 1.0 0.000143348623853 0 1 -1
and,cyp3a4,that 1.0 0.000143348623853 0 1 -1
and,cyp3a4,substrate 1.0 0.000143348623853 0 1 -1
and,cyp3a4,patients 1.0 0.000143348623853 0 1 -1
and,cyp3a4,as 1.0 0.000143348623853 0 1 -1
and,cyp3a3,also 1.0 0.000143348623853 0 1 -1
and,cyp2d6,or 1.0 0.000143348623853 0 1 -1
and,cyp2d6,are 1.0 0.000286697247706 0 2 -2
and,cyp2c8,in 1.0 0.000143348623853 0 1 -1
and,cyp2c8,drugs 1.0 0.000143348623853 0 1 -1
and,cyp2a6,and 1.0 0.000143348623853 0 1 -1
and,cyp1a2,isoform 1.0 0.000143348623853 0 1 -1
and,cyp1a2,inhibitors 1.0 0.000143348623853 0 1 -1
and,cyp,c19 1.0 0.000143348623853 0 1 -1
and,cyp,a4 1.0 0.000143348623853 0 1 -1
and,cyp,a 1.0 0.000143348623853 0 1 -1
and,cyclopentyl-1,dipropylxanthine 1.0 0.000143348623853 0 1 -1
and,cushingoid,appearance 1.0 0.000143348623853 0 1 -1
and,crystalline,preparations 1.0 0.000143348623853 0 1 -1
and,could,have 1.0 0.000143348623853 0 1 -1
and,cosmetics,that 1.0 0.000143348623853 0 1 -1
and,coronary,oral 1.0 0.000143348623853 0 1 -1
and,copegus,should 1.0 0.000143348623853 0 1 -1
and,copegus,are 1.0 0.000143348623853 0 1 -1
and,control,rats 1.0 0.000286697247706 0 2 -2
and,contraindications,indications 1.0 0.000143348623853 0 1 -1
and,continued,use 1.0 0.000143348623853 0 1 -1
and,constructive,alternatives 1.0 0.000143348623853 0 1 -1
and,consisted,of 1.0 0.000143348623853 0 1 -1
and,consideration,of 1.0 0.000143348623853 0 1 -1
and,consequently,alter 1.0 0.000143348623853 0 1 -1
and,consensus,reports 1.0 0.000143348623853 0 1 -1
and,confirmed,by 1.0 0.000143348623853 0 1 -1
and,concomitantly,of 1.0 0.000143348623853 0 1 -1
and,concomitantly,administered 1.0 0.000286697247706 0 2 -2
and,concomitant,beta-1a 1.0 0.000143348623853 0 1 -1
and,concomitant,administration 1.0 0.000143348623853 0 1 -1
and,concerns,regarding 1.0 0.000143348623853 0 1 -1
and,concentrations,and 1.0 0.000143348623853 0 1 -1
and,concentration,were 1.0 0.000143348623853 0 1 -1
and,complexes,thereof 1.0 0.000143348623853 0 1 -1
and,comparison,of 1.0 0.000143348623853 0 1 -1
and,compared,with 1.0 0.000143348623853 0 1 -1
and,compared,to 1.0 0.000143348623853 0 1 -1
and,commonly,used 1.0 0.000143348623853 0 1 -1
and,commit,to 1.0 0.000143348623853 0 1 -1
and,commentaries,and 1.0 0.000143348623853 0 1 -1
and,combined,exposures 1.0 0.000143348623853 0 1 -1
and,collected,by 1.0 0.000143348623853 0 1 -1
and,collagen-induced,platelet 1.0 0.000143348623853 0 1 -1
and,cohort,received 1.0 0.000143348623853 0 1 -1
and,coexisting,in 1.0 0.000143348623853 0 1 -1
and,coagulation,factor 1.0 0.000143348623853 0 1 -1
and,cmin,are 1.0 0.000143348623853 0 1 -1
and,cmc-cys,conjugates 1.0 0.000143348623853 0 1 -1
and,cmax,were 1.0 0.000143348623853 0 1 -1
and,cmax,was 1.0 0.000143348623853 0 1 -1
and,cmax,the 1.0 0.000143348623853 0 1 -1
and,cmax,respectively 1.0 0.000143348623853 0 1 -1
and,cmax,differences 1.0 0.000143348623853 0 1 -1
and,cmax,but 1.0 0.000143348623853 0 1 -1
and,cmax,and 1.0 0.000286697247706 0 2 -2
and,clotibrate,and 1.0 0.000143348623853 0 1 -1
and,close,monitoring 1.0 0.000143348623853 0 1 -1
and,clinically,important 1.0 0.000143348623853 0 1 -1
and,clinical,response 1.0 0.000143348623853 0 1 -1
and,clinical,monitoring 1.0 0.000143348623853 0 1 -1
and,clearance,at 1.0 0.000143348623853 0 1 -1
and,cleansers,soaps 1.0 0.000143348623853 0 1 -1
and,ci,in 1.0 0.000286697247706 0 2 -2
and,chronic,activation 1.0 0.000143348623853 0 1 -1
and,chop,chemotherapy 1.0 0.000143348623853 0 1 -1
and,chemotherapy,plus 1.0 0.000143348623853 0 1 -1
and,chapter,presents 1.0 0.000143348623853 0 1 -1
and,channel,antagonists 1.0 0.000143348623853 0 1 -1
and,changes,in 1.0 0.000286697247706 0 2 -2
and,certain,malignancies 1.0 0.000143348623853 0 1 -1
and,cerebyx,were 1.0 0.000143348623853 0 1 -1
and,central,nervous 1.0 0.000143348623853 0 1 -1
and,cell,permeability 1.0 0.000143348623853 0 1 -1
and,cautioned,that 1.0 0.000143348623853 0 1 -1
and,cautioned,against 1.0 0.000143348623853 0 1 -1
and,caution,should 1.0 0.00043004587156 0 3 -3
and,caused,excessive 1.0 0.000143348623853 0 1 -1
and,cause,renal 1.0 0.000143348623853 0 1 -1
and,cause,qt 1.0 0.000143348623853 0 1 -1
and,cause,cardio 1.0 0.000143348623853 0 1 -1
and,careful,titration 1.0 0.000143348623853 0 1 -1
and,cardiovascular,safety 1.0 0.000143348623853 0 1 -1
and,cardiovascular,collapse 1.0 0.000143348623853 0 1 -1
and,cardiac,function 1.0 0.000143348623853 0 1 -1
and,cancer,metastasis 1.0 0.000143348623853 0 1 -1
and,can,exert 1.0 0.000143348623853 0 1 -1
and,cadmium,mixtures 1.0 0.000286697247706 0 2 -2
and,c9,with 1.0 0.000143348623853 0 1 -1
and,c9,respectively 1.0 0.000143348623853 0 1 -1
and,c9,ic50 1.0 0.000143348623853 0 1 -1
and,c19,the 1.0 0.000143348623853 0 1 -1
and,c19,inhibitors 1.0 0.000143348623853 0 1 -1
and,c19,are 1.0 0.000143348623853 0 1 -1
and,by,the 1.0 0.000143348623853 0 1 -1
and,by,observations 1.0 0.000143348623853 0 1 -1
and,by,means 1.0 0.000143348623853 0 1 -1
and,by,maximum 1.0 0.000286697247706 0 2 -2
and,bretylium,tosylate 1.0 0.000143348623853 0 1 -1
and,bowel,disease 1.0 0.000143348623853 0 1 -1
and,both,thiazide-like 1.0 0.000143348623853 0 1 -1
and,both,or 1.0 0.000143348623853 0 1 -1
and,both,alone 1.0 0.000143348623853 0 1 -1
and,bones,the 1.0 0.00043004587156 0 3 -3
and,bone,scintigraphy 1.0 0.000143348623853 0 1 -1
and,body,weight 1.0 0.000143348623853 0 1 -1
and,bmax,in 1.0 0.000143348623853 0 1 -1
and,blood,sugar 1.0 0.000143348623853 0 1 -1
and,blood,pressures 1.0 0.000143348623853 0 1 -1
and,blood,in 1.0 0.000143348623853 0 1 -1
and,blood,glucose 1.0 0.000143348623853 0 1 -1
and,black,cohosh 1.0 0.000143348623853 0 1 -1
and,between,given 1.0 0.000143348623853 0 1 -1
and,beta-blocking,agents 1.0 0.000143348623853 0 1 -1
and,beta,cells 1.0 0.000143348623853 0 1 -1
and,beta,blockers 1.0 0.000143348623853 0 1 -1
and,being,treated 1.0 0.000143348623853 0 1 -1
and,behavioral,inhibition 1.0 0.000143348623853 0 1 -1
and,behavioral,effects 1.0 0.000143348623853 0 1 -1
and,behavioral,changes 1.0 0.000143348623853 0 1 -1
and,begin,therapy 1.0 0.000143348623853 0 1 -1
and,because,they 1.0 0.000143348623853 0 1 -1
and,because,there 1.0 0.000143348623853 0 1 -1
and,be,prepared 1.0 0.000143348623853 0 1 -1
and,background,the 1.0 0.000143348623853 0 1 -1
and,b12,because 1.0 0.000143348623853 0 1 -1
and,b-cell,lymphomas 1.0 0.000143348623853 0 1 -1
and,b,the 1.0 0.000143348623853 0 1 -1
and,azoles,are 1.0 0.000143348623853 0 1 -1
and,azole,antifungals 1.0 0.000143348623853 0 1 -1
and,avoidance,of 1.0 0.000143348623853 0 1 -1
and,avoidance,behaviour 1.0 0.000143348623853 0 1 -1
and,av,nodes 1.0 0.000143348623853 0 1 -1
and,av,conduction 1.0 0.000143348623853 0 1 -1
and,august,were 1.0 0.000143348623853 0 1 -1
and,auc,were 1.0 0.00043004587156 0 3 -3
and,auc,hrs 1.0 0.000143348623853 0 1 -1
and,auc,exhibited 1.0 0.000143348623853 0 1 -1
and,at,therapeutic 1.0 0.000143348623853 0 1 -1
and,at,steady-state 1.0 0.000143348623853 0 1 -1
and,at,high 1.0 0.000143348623853 0 1 -1
and,at,concentrations 1.0 0.000143348623853 0 1 -1
and,aspecific,treatments 1.0 0.000143348623853 0 1 -1
and,asa,and 1.0 0.000143348623853 0 1 -1
and,as,well 1.0 0.000143348623853 0 1 -1
and,as,such 1.0 0.000143348623853 0 1 -1
and,as,low 1.0 0.000143348623853 0 1 -1
and,are,unlikely 1.0 0.000143348623853 0 1 -1
and,are,sequestered 1.0 0.000143348623853 0 1 -1
and,are,predominantly 1.0 0.000143348623853 0 1 -1
and,are,predictable 1.0 0.000143348623853 0 1 -1
and,are,metabolized 1.0 0.000143348623853 0 1 -1
and,are,inhibitors 1.0 0.000143348623853 0 1 -1
and,are,ge 1.0 0.000143348623853 0 1 -1
and,are,equipotent 1.0 0.000143348623853 0 1 -1
and,are,based 1.0 0.000143348623853 0 1 -1
and,are,associated 1.0 0.000143348623853 0 1 -1
and,arachidonic,acid 1.0 0.000286697247706 0 2 -2
and,apple,may 1.0 0.000143348623853 0 1 -1
and,appears,to 1.0 0.000143348623853 0 1 -1
and,apoptosis,induced 1.0 0.000143348623853 0 1 -1
and,aortic,rings 1.0 0.000143348623853 0 1 -1
and,any,other 1.0 0.000143348623853 0 1 -1
and,any,mechanism 1.0 0.000143348623853 0 1 -1
and,any,deficit 1.0 0.000143348623853 0 1 -1
and,any,agent 1.0 0.00043004587156 0 3 -3
and,anxiety,during 1.0 0.000143348623853 0 1 -1
and,anxiety,depressive 1.0 0.000143348623853 0 1 -1
and,antithrombin,iii 1.0 0.000286697247706 0 2 -2
and,antidiuretic,hormone 1.0 0.000143348623853 0 1 -1
and,anti-infectives,without 1.0 0.000143348623853 0 1 -1
and,anti,platelet 1.0 0.000143348623853 0 1 -1
and,angiotensin,on 1.0 0.000143348623853 0 1 -1
and,angiotensin,converting 1.0 0.000143348623853 0 1 -1
and,and,which 1.0 0.000143348623853 0 1 -1
and,and,twice-a 1.0 0.000143348623853 0 1 -1
and,and,these 1.0 0.000143348623853 0 1 -1
and,and,their 1.0 0.000143348623853 0 1 -1
and,and,the 1.0 0.000286697247706 0 2 -2
and,and,probably 1.0 0.000143348623853 0 1 -1
and,and,potent 1.0 0.000143348623853 0 1 -1
and,and,on 1.0 0.000143348623853 0 1 -1
and,and,no 1.0 0.000143348623853 0 1 -1
and,and,hydroxides 1.0 0.000143348623853 0 1 -1
and,and,hours 1.0 0.000143348623853 0 1 -1
and,and,have 1.0 0.000143348623853 0 1 -1
and,and,has 1.0 0.000143348623853 0 1 -1
and,and,fold 1.0 0.000143348623853 0 1 -1
and,and,are 1.0 0.000143348623853 0 1 -1
and,anaerobic,bacteria 1.0 0.000143348623853 0 1 -1
and,an,inhibitor 1.0 0.000143348623853 0 1 -1
and,an,inducer 1.0 0.000143348623853 0 1 -1
and,an,increased 1.0 0.00043004587156 0 3 -3
and,an,in 1.0 0.000143348623853 0 1 -1
and,an,apparently 1.0 0.000143348623853 0 1 -1
and,an,agent 1.0 0.000143348623853 0 1 -1
and,an,adjustment 1.0 0.000143348623853 0 1 -1
and,aluminum-containing,preparations 1.0 0.000143348623853 0 1 -1
and,also,with 1.0 0.000143348623853 0 1 -1
and,also,inhibits 1.0 0.000143348623853 0 1 -1
and,alone,and 1.0 0.000143348623853 0 1 -1
and,all,that 1.0 0.000143348623853 0 1 -1
and,alkaline,phosphatase 1.0 0.000143348623853 0 1 -1
and,agonists,hepatic 1.0 0.000143348623853 0 1 -1
and,agitation,while 1.0 0.000143348623853 0 1 -1
and,agents,used 1.0 0.000143348623853 0 1 -1
and,agents,and 1.0 0.000143348623853 0 1 -1
and,against,cryptosporidium 1.0 0.000143348623853 0 1 -1
and,aftercare,approaches 1.0 0.000143348623853 0 1 -1
and,after,oral 1.0 0.000143348623853 0 1 -1
and,aetiopathogenic--,for 1.0 0.000143348623853 0 1 -1
and,adverse,events 1.0 0.000143348623853 0 1 -1
and,adult,patients 1.0 0.000143348623853 0 1 -1
and,adrenoreceptors,on 1.0 0.000143348623853 0 1 -1
and,administration,to 1.0 0.000143348623853 0 1 -1
and,administration,of 1.0 0.000143348623853 0 1 -1
and,administered,with 1.0 0.000143348623853 0 1 -1
and,activity,at 1.0 0.000143348623853 0 1 -1
and,activated,the 1.0 0.000143348623853 0 1 -1
and,acid-base,balance 1.0 0.000143348623853 0 1 -1
and,acamprosate,does 1.0 0.000143348623853 0 1 -1
and,absorption,and 1.0 0.000143348623853 0 1 -1
and,above,this 1.0 0.000143348623853 0 1 -1
and,about,fold 1.0 0.000143348623853 0 1 -1
and,a4,were 1.0 0.000143348623853 0 1 -1
and,a4,isozymes 1.0 0.000143348623853 0 1 -1
and,a4,ic50 1.0 0.000143348623853 0 1 -1
and,a4,but 1.0 0.000143348623853 0 1 -1
and,a,weak 1.0 0.000143348623853 0 1 -1
and,a,type 1.0 0.000143348623853 0 1 -1
and,a,trend 1.0 0.000143348623853 0 1 -1
and,a,sprycel 1.0 0.000143348623853 0 1 -1
and,a,spatial 1.0 0.000143348623853 0 1 -1
and,a,shorter 1.0 0.000143348623853 0 1 -1
and,a,series 1.0 0.000143348623853 0 1 -1
and,a,rapidly 1.0 0.000143348623853 0 1 -1
and,a,precipitate 1.0 0.000143348623853 0 1 -1
and,a,or 1.0 0.000143348623853 0 1 -1
and,a,only 1.0 0.000143348623853 0 1 -1
and,a,new 1.0 0.000143348623853 0 1 -1
and,a,major 1.0 0.000143348623853 0 1 -1
and,a,laser 1.0 0.000143348623853 0 1 -1
and,a,cyp3a4 1.0 0.000143348623853 0 1 -1
and,a,comparison 1.0 0.000143348623853 0 1 -1
and,a,clinically 1.0 0.000143348623853 0 1 -1
and,a,catecholamine 1.0 0.000143348623853 0 1 -1
ancobon,does,not 1.0 0.000143348623853 0 1 -1
anastrozole,inhibited,in 1.0 0.000143348623853 0 1 -1
anastrozole,did,not 1.0 0.000286697247706 0 2 -2
anaphylaxis,have,been 1.0 0.000143348623853 0 1 -1
anaphylactic,reactions,and 1.0 0.000143348623853 0 1 -1
anaphylactic,reaction,while 1.0 0.00043004587156 0 3 -3
anaphylactic,reaction,to 1.0 0.000716743119266 0 5 -5
analyzed,in,cecectomized 1.0 0.000143348623853 0 1 -1
analyzed,for,creatinine 1.0 0.000143348623853 0 1 -1
analyzed,for,and 1.0 0.000143348623853 0 1 -1
analyte,is,altered 1.0 0.000143348623853 0 1 -1
analysis,of,total 1.0 0.000143348623853 0 1 -1
analysis,of,side 1.0 0.000143348623853 0 1 -1
analysis,of,dimethylprostaglandin 1.0 0.000143348623853 0 1 -1
analysis,and,therefore 1.0 0.000143348623853 0 1 -1
analysis,and,scanning 1.0 0.000143348623853 0 1 -1
analysing,the,resulting 1.0 0.000143348623853 0 1 -1
analyses,were,conducted 1.0 0.000143348623853 0 1 -1
analyses,revealed,that 1.0 0.000143348623853 0 1 -1
analyses,of,this 1.0 0.000143348623853 0 1 -1
analysed,using,two 1.0 0.000143348623853 0 1 -1
analogues,should,be 1.0 0.00043004587156 0 3 -3
analogue,scales,vital 1.0 0.000143348623853 0 1 -1
analogue,d-ala2,metenkephalinamide 1.0 0.000143348623853 0 1 -1
analog,of,the 1.0 0.000143348623853 0 1 -1
analog,of,cholecystokinin 1.0 0.000143348623853 0 1 -1
analgesics,was,similar 1.0 0.000143348623853 0 1 -1
analgesic,actions,are 1.0 0.000143348623853 0 1 -1
analgesia,and,pupil 1.0 0.000286697247706 0 2 -2
anagrelide,is,metabolized 1.0 0.000143348623853 0 1 -1
anagrelide,is,an 1.0 0.000143348623853 0 1 -1
anafranil,with,that 1.0 0.000143348623853 0 1 -1
anafranil,is,going 1.0 0.000143348623853 0 1 -1
anafranil,in,combination 1.0 0.000143348623853 0 1 -1
anafranil,caution,is 1.0 0.000143348623853 0 1 -1
anafranil,by,other 1.0 0.000143348623853 0 1 -1
anaesthetic,agents,which 1.0 0.000143348623853 0 1 -1
anaesthesia,and,the 1.0 0.000143348623853 0 1 -1
anaerobic,bacteria,except 1.0 0.000143348623853 0 1 -1
anabolin,anavar,anadrol 1.0 0.000143348623853 0 1 -1
anabolic,particularly,c-17 1.0 0.000143348623853 0 1 -1
anabolic,hormones,complex 1.0 0.000143348623853 0 1 -1
anabolic,anabolin,anavar 1.0 0.000143348623853 0 1 -1
an,week,trial 1.0 0.000143348623853 0 1 -1
an,week,controlled 1.0 0.000143348623853 0 1 -1
an,used,to 1.0 0.000143348623853 0 1 -1
an,updated,review 1.0 0.000143348623853 0 1 -1
an,uncontrolled,study 1.0 0.000143348623853 0 1 -1
an,solution,dried 1.0 0.000143348623853 0 1 -1
an,regimen,reduces 1.0 0.000143348623853 0 1 -1
an,overactive,pain 1.0 0.000143348623853 0 1 -1
an,organophosphorous,compound 1.0 0.000143348623853 0 1 -1
an,oral,regimen 1.0 0.000143348623853 0 1 -1
an,oral,overload 1.0 0.000143348623853 0 1 -1
an,oral,mg 1.0 0.000143348623853 0 1 -1
an,open-label,two-way 1.0 0.000143348623853 0 1 -1
an,open,three-period 1.0 0.000143348623853 0 1 -1
an,open,randomized 1.0 0.000143348623853 0 1 -1
an,omega-conotoxin,gvia-sensitive 1.0 0.000143348623853 0 1 -1
an,omega-agatoxin,iva-sensitive 1.0 0.000143348623853 0 1 -1
an,nsaid,has 1.0 0.000143348623853 0 1 -1
an,nad,dependent 1.0 0.000143348623853 0 1 -1
an,levonorgestrol,oral 1.0 0.000143348623853 0 1 -1
an,intravenous,infusion 1.0 0.000143348623853 0 1 -1
an,intravenous,dose 1.0 0.000143348623853 0 1 -1
an,interval,as 1.0 0.000143348623853 0 1 -1
an,interactive,effect 1.0 0.000286697247706 0 2 -2
an,interaction,with 1.0 0.000286697247706 0 2 -2
an,interaction,were 1.0 0.000286697247706 0 2 -2
an,interaction,of 1.0 0.000143348623853 0 1 -1
an,interaction,can 1.0 0.000143348623853 0 1 -1
an,interacting,which 1.0 0.000143348623853 0 1 -1
an,insufficient,intake 1.0 0.000143348623853 0 1 -1
an,initial,dose 1.0 0.000286697247706 0 2 -2
an,inhibitory,effect 1.0 0.000143348623853 0 1 -1
an,inflammatory,recall 1.0 0.000143348623853 0 1 -1
an,individualized,fixed 1.0 0.000143348623853 0 1 -1
an,individual,who 1.0 0.000716743119266 0 5 -5
an,individual,isoform 1.0 0.000143348623853 0 1 -1
an,indication,for 1.0 0.000143348623853 0 1 -1
an,index,of 1.0 0.000286697247706 0 2 -2
an,increasing,incidence 1.0 0.000143348623853 0 1 -1
an,increased,volume 1.0 0.000286697247706 0 2 -2
an,increased,synaptic 1.0 0.000143348623853 0 1 -1
an,increased,potential 1.0 0.000286697247706 0 2 -2
an,increased,clearance 1.0 0.000143348623853 0 1 -1
an,increased,availability 1.0 0.000143348623853 0 1 -1
an,increase,or 1.0 0.000143348623853 0 1 -1
an,in,vivo 1.0 0.000573394495413 0 4 -4
an,improved,glucose 1.0 0.000143348623853 0 1 -1
an,immune,response 1.0 0.000143348623853 0 1 -1
an,i-labelled,antigen 1.0 0.000286697247706 0 2 -2
an,expression,of 1.0 0.000143348623853 0 1 -1
an,excessive,increase 1.0 0.000143348623853 0 1 -1
an,evaluation,of 1.0 0.000143348623853 0 1 -1
an,erection,disorder 1.0 0.000143348623853 0 1 -1
an,equivalent,volume 1.0 0.000143348623853 0 1 -1
an,equivalent,amount 1.0 0.000143348623853 0 1 -1
an,enteric,coating 1.0 0.000143348623853 0 1 -1
an,endemic,primate 1.0 0.000143348623853 0 1 -1
an,empty,stomach 1.0 0.000143348623853 0 1 -1
an,elisa,and 1.0 0.000143348623853 0 1 -1
an,elevation,in 1.0 0.000143348623853 0 1 -1
an,effort,to 1.0 0.000143348623853 0 1 -1
an,effector,immediate-early 1.0 0.000143348623853 0 1 -1
an,effector,ieg 1.0 0.000143348623853 0 1 -1
an,effective,first-line 1.0 0.000143348623853 0 1 -1
an,effect,of 1.0 0.00043004587156 0 3 -3
an,effect,is 1.0 0.000143348623853 0 1 -1
an,area,of 1.0 0.000143348623853 0 1 -1
an,apparently,t 1.0 0.000143348623853 0 1 -1
an,apparent,factor 1.0 0.000143348623853 0 1 -1
an,apparent,decrease 1.0 0.000143348623853 0 1 -1
an,anion,exchange 1.0 0.000143348623853 0 1 -1
an,analog,of 1.0 0.000143348623853 0 1 -1
an,an,organophosphorous 1.0 0.000143348623853 0 1 -1
an,aluminum-containing,had 1.0 0.000143348623853 0 1 -1
an,aluminum,hydroxide- 1.0 0.000143348623853 0 1 -1
an,alternative,treatment 1.0 0.000143348623853 0 1 -1
an,alternative,or 1.0 0.000143348623853 0 1 -1
an,alternative,non-cyp3a4 1.0 0.000143348623853 0 1 -1
an,altered,biodistribution 1.0 0.000143348623853 0 1 -1
an,alteration,of 1.0 0.000143348623853 0 1 -1
an,alteration,in 1.0 0.000286697247706 0 2 -2
an,agent,that 1.0 0.000143348623853 0 1 -1
an,agent,of 1.0 0.000286697247706 0 2 -2
an,agent,administered 1.0 0.000143348623853 0 1 -1
an,aed,induces 1.0 0.000143348623853 0 1 -1
an,adverse,interaction 1.0 0.000143348623853 0 1 -1
an,adolescent,presents 1.0 0.000143348623853 0 1 -1
an,adjustment,of 1.0 0.000143348623853 0 1 -1
an,adjustment,in 1.0 0.00043004587156 0 3 -3
an,adequate,respiratory 1.0 0.000143348623853 0 1 -1
an,adequate,period 1.0 0.000143348623853 0 1 -1
an,adequate,degree 1.0 0.000143348623853 0 1 -1
an,adequate,and 1.0 0.000143348623853 0 1 -1
an,additive,pharmacodynamic 1.0 0.000143348623853 0 1 -1
an,acute,increase 1.0 0.000143348623853 0 1 -1
an,active,metabolite 1.0 0.000143348623853 0 1 -1
an,active,dose 1.0 0.000143348623853 0 1 -1
an,action,should 1.0 0.000143348623853 0 1 -1
an,action,independent 1.0 0.000143348623853 0 1 -1
an,ability,of 1.0 0.000143348623853 0 1 -1
amylase,an,apparent 1.0 0.000143348623853 0 1 -1
amprenavir,is,metabolized 1.0 0.000143348623853 0 1 -1
amprenavir,is,an 1.0 0.000143348623853 0 1 -1
amprenavir,inhibits,the 1.0 0.000143348623853 0 1 -1
amprenavir,does,not 1.0 0.000143348623853 0 1 -1
amprenavir,decreased,the 1.0 0.000143348623853 0 1 -1
amplitudes,of,most 1.0 0.000143348623853 0 1 -1
amplitudes,of,components 1.0 0.000286697247706 0 2 -2
amplitude,of,most 1.0 0.000143348623853 0 1 -1
amplitude,data,from 1.0 0.000143348623853 0 1 -1
amplitude,but,not 1.0 0.000143348623853 0 1 -1
amphotericin,b,or 1.0 0.00043004587156 0 3 -3
amphotericin,b,non-steroidal 1.0 0.000143348623853 0 1 -1
amphetamines,may,interfere 1.0 0.000286697247706 0 2 -2
amounts,of,these 1.0 0.000143348623853 0 1 -1
amounts,of,nondepolarizing 1.0 0.000143348623853 0 1 -1
amounts,may,be 1.0 0.000143348623853 0 1 -1
amount,of,placebo 1.0 0.000143348623853 0 1 -1
amount,of,mna 1.0 0.000143348623853 0 1 -1
amount,of,extractable 1.0 0.000143348623853 0 1 -1
amount,absorbed,when 1.0 0.000143348623853 0 1 -1
among,these,patients 1.0 0.000286697247706 0 2 -2
among,the,various 1.0 0.000143348623853 0 1 -1
among,the,proteins 1.0 0.000143348623853 0 1 -1
among,the,polyene 1.0 0.000143348623853 0 1 -1
among,the,pd2 1.0 0.000143348623853 0 1 -1
among,the,patients 1.0 0.000143348623853 0 1 -1
among,subjects,who 1.0 0.000143348623853 0 1 -1
among,ras,nucleophosmin 1.0 0.000143348623853 0 1 -1
among,patients,on 1.0 0.000143348623853 0 1 -1
among,or,nsaid 1.0 0.000143348623853 0 1 -1
among,fifteen,species 1.0 0.000143348623853 0 1 -1
among,co-administered,antiepilepsy 1.0 0.000143348623853 0 1 -1
among,bosentan-,and 1.0 0.000143348623853 0 1 -1
among,asian,african 1.0 0.000716743119266 0 5 -5
amiodarone-treated,patients,who 1.0 0.000143348623853 0 1 -1
amiodarone,therapy,alone 1.0 0.000143348623853 0 1 -1
amiodarone,taken,concomitantly 1.0 0.00043004587156 0 3 -3
amiodarone,should,be 1.0 0.000143348623853 0 1 -1
amiodarone,may,suppress 1.0 0.000143348623853 0 1 -1
amiodarone,is,metabolized 1.0 0.000143348623853 0 1 -1
amiodarone,is,also 1.0 0.000143348623853 0 1 -1
amiodarone,contraindicated,due 1.0 0.000143348623853 0 1 -1
amiodarone,caused,a 1.0 0.000143348623853 0 1 -1
amiodarone,amiodarone,therapy 1.0 0.000143348623853 0 1 -1
aminotransferases,was,observed 1.0 0.000143348623853 0 1 -1
aminotransferase,sgot,s-ast 1.0 0.000143348623853 0 1 -1
aminotransferase,determinations,are 1.0 0.000143348623853 0 1 -1
amino,acids,proteins 1.0 0.000143348623853 0 1 -1
amino,acid,and 1.0 0.000143348623853 0 1 -1
amines,possible,decreased 1.0 0.000286697247706 0 2 -2
amines,but,not 1.0 0.000286697247706 0 2 -2
amicar,transient,peak 1.0 0.000143348623853 0 1 -1
amicar,necessary,to 1.0 0.000143348623853 0 1 -1
amicar,may,occur 1.0 0.000143348623853 0 1 -1
amicar,at,dosages 1.0 0.000143348623853 0 1 -1
amevive,who,become 1.0 0.000143348623853 0 1 -1
amevive,underwent,trans-placental 1.0 0.000143348623853 0 1 -1
amevive,should,be 1.0 0.000143348623853 0 1 -1
amevive,on,pregnancy 1.0 0.000143348623853 0 1 -1
amevive,is,not 1.0 0.000143348623853 0 1 -1
amevive,is,excreted 1.0 0.000143348623853 0 1 -1
amevive,in,the 1.0 0.000143348623853 0 1 -1
amevive,in,pediatric 1.0 0.000143348623853 0 1 -1
amevive,in,clinical 1.0 0.000143348623853 0 1 -1
amevive,continued,use 1.0 0.000143348623853 0 1 -1
amevive,before,one 1.0 0.000143348623853 0 1 -1
amevive,administered,weekly 1.0 0.000143348623853 0 1 -1
amevive,a,decision 1.0 0.000143348623853 0 1 -1
ames,test,but 1.0 0.000143348623853 0 1 -1
ames,n-multistix,sg 1.0 0.000143348623853 0 1 -1
ames,company,division 1.0 0.000143348623853 0 1 -1
ames,bacterial,mutagenicity 1.0 0.000143348623853 0 1 -1
american,coffee,was 1.0 0.000143348623853 0 1 -1
amerge,tablets,are 1.0 0.000143348623853 0 1 -1
amenorrhea,were,observed 1.0 0.000143348623853 0 1 -1
amenorrhea,the,second 1.0 0.000143348623853 0 1 -1
ambulatory,patients,the 1.0 0.000143348623853 0 1 -1
always,seen,in 1.0 0.000143348623853 0 1 -1
always,predictive,of 1.0 0.000143348623853 0 1 -1
alveoli,of,the 1.0 0.000286697247706 0 2 -2
aluminum-containing,preparations,has 1.0 0.000143348623853 0 1 -1
aluminum-containing,had,no 1.0 0.000143348623853 0 1 -1
aluminum-containing,antacid,products 1.0 0.000143348623853 0 1 -1
aluminum-,and,magnesium-containing 1.0 0.000143348623853 0 1 -1
aluminum,hydroxide-,and 1.0 0.000143348623853 0 1 -1
although,they,should 1.0 0.000143348623853 0 1 -1
although,they,may 1.0 0.000143348623853 0 1 -1
although,these,effects 1.0 0.000143348623853 0 1 -1
although,there,may 1.0 0.000143348623853 0 1 -1
although,there,is 1.0 0.00043004587156 0 3 -3
although,theophylline-induced,anxiogenic 1.0 0.000143348623853 0 1 -1
although,the,specific 1.0 0.000143348623853 0 1 -1
although,the,relevance 1.0 0.000143348623853 0 1 -1
although,the,proposed 1.0 0.000143348623853 0 1 -1
although,the,pressor 1.0 0.000143348623853 0 1 -1
although,the,pattern 1.0 0.000143348623853 0 1 -1
although,the,dose-limiting 1.0 0.000143348623853 0 1 -1
although,the,difference 1.0 0.000143348623853 0 1 -1
although,the,daily 1.0 0.000143348623853 0 1 -1
although,the,aerosol 1.0 0.000143348623853 0 1 -1
although,studies,designed 1.0 0.000143348623853 0 1 -1
although,results,have 1.0 0.000143348623853 0 1 -1
although,other,hormonal 1.0 0.000143348623853 0 1 -1
although,one,study 1.0 0.000143348623853 0 1 -1
although,not,posing 1.0 0.000143348623853 0 1 -1
although,no,drug-drug 1.0 0.000143348623853 0 1 -1
although,no,causal 1.0 0.000143348623853 0 1 -1
although,much,statistical 1.0 0.000143348623853 0 1 -1
although,minimal,alterations 1.0 0.000143348623853 0 1 -1
although,many,such 1.0 0.000143348623853 0 1 -1
although,many,concomitant 1.0 0.000143348623853 0 1 -1
although,is,not 1.0 0.000143348623853 0 1 -1
although,inhibition,of 1.0 0.000143348623853 0 1 -1
although,increased,plasma 1.0 0.000286697247706 0 2 -2
although,hydroxy-corticosteroid,measurements 1.0 0.000143348623853 0 1 -1
although,consistent,with 1.0 0.000143348623853 0 1 -1
although,combining,these 1.0 0.000143348623853 0 1 -1
although,combinations,are 1.0 0.000143348623853 0 1 -1
although,clinical,evidence 1.0 0.000143348623853 0 1 -1
although,certain,medicines 1.0 0.000143348623853 0 1 -1
although,c,max 1.0 0.000143348623853 0 1 -1
although,administered,at 1.0 0.000143348623853 0 1 -1
although,additional,interaction 1.0 0.000143348623853 0 1 -1
although,activation,of 1.0 0.000143348623853 0 1 -1
alters,the,cellular 1.0 0.000143348623853 0 1 -1
alters,hormone,synthesis 1.0 0.000143348623853 0 1 -1
alternatives,to,the 1.0 0.000143348623853 0 1 -1
alternatives,to,such 1.0 0.000286697247706 0 2 -2
alternatives,in,dealing 1.0 0.000143348623853 0 1 -1
alternatives,are,not 1.0 0.000143348623853 0 1 -1
alternatively,the,effect 1.0 0.000143348623853 0 1 -1
alternatively,provide,medical 1.0 0.000143348623853 0 1 -1
alternative,treatment,is 1.0 0.000143348623853 0 1 -1
alternative,therapeutic,agents 1.0 0.000143348623853 0 1 -1
alternative,or,additional 1.0 0.000143348623853 0 1 -1
alternative,non-cyp3a4,substrate 1.0 0.000143348623853 0 1 -1
alternative,error,structures 1.0 0.000143348623853 0 1 -1
alternative,agents,with 1.0 0.000143348623853 0 1 -1
alternating,therapy,for 1.0 0.000143348623853 0 1 -1
alternately,when,the 1.0 0.000143348623853 0 1 -1
alternately,provided,a 1.0 0.000143348623853 0 1 -1
alternate,treatments,lacking 1.0 0.000143348623853 0 1 -1
alternate,or,additional 1.0 0.000143348623853 0 1 -1
altering,their,need 1.0 0.000143348623853 0 1 -1
altering,cyp1a2-mediated,metabolism 1.0 0.000143348623853 0 1 -1
altering,concentrations,of 1.0 0.000143348623853 0 1 -1
altering,activity,in 1.0 0.000143348623853 0 1 -1
altered,when,and 1.0 0.000143348623853 0 1 -1
altered,tsh,secretion 1.0 0.000143348623853 0 1 -1
altered,topo,i 1.0 0.000143348623853 0 1 -1
altered,to,a 1.0 0.000143348623853 0 1 -1
altered,so,as 1.0 0.000143348623853 0 1 -1
altered,safety,and 1.0 0.000143348623853 0 1 -1
altered,responsiveness,to 1.0 0.000143348623853 0 1 -1
altered,renal,function 1.0 0.000143348623853 0 1 -1
altered,plasma,concentrations 1.0 0.000143348623853 0 1 -1
altered,mental,status 1.0 0.000143348623853 0 1 -1
altered,it,is 1.0 0.000143348623853 0 1 -1
altered,in,the 1.0 0.000143348623853 0 1 -1
altered,in,patients 1.0 0.000143348623853 0 1 -1
altered,hypo-prothrombinemic,effect 1.0 0.000143348623853 0 1 -1
altered,for,neurons 1.0 0.000143348623853 0 1 -1
altered,by,the 1.0 0.000286697247706 0 2 -2
altered,by,cyp3a4 1.0 0.000143348623853 0 1 -1
altered,by,coadministration 1.0 0.000143348623853 0 1 -1
altered,by,amphotericin 1.0 0.000143348623853 0 1 -1
altered,biodistribution,may 1.0 0.000143348623853 0 1 -1
altered,before,the 1.0 0.000143348623853 0 1 -1
alterations,were,not 1.0 0.000143348623853 0 1 -1
alterations,underlying,neural 1.0 0.000143348623853 0 1 -1
alterations,of,status 1.0 0.000143348623853 0 1 -1
alterations,of,clearance 1.0 0.000143348623853 0 1 -1
alterations,of,blood 1.0 0.000143348623853 0 1 -1
alterations,might,reflect 1.0 0.000143348623853 0 1 -1
alterations,is,unclear 1.0 0.000143348623853 0 1 -1
alterations,in,the 1.0 0.000573394495413 0 4 -4
alterations,in,serum 1.0 0.000143348623853 0 1 -1
alterations,in,immune 1.0 0.000143348623853 0 1 -1
alterations,in,hippocampal 1.0 0.000143348623853 0 1 -1
alterations,in,gonadotropin 1.0 0.000143348623853 0 1 -1
alterations,in,blood 1.0 0.000143348623853 0 1 -1
alterations,associated,with 1.0 0.000143348623853 0 1 -1
alteration,of,the 1.0 0.000286697247706 0 2 -2
alteration,of,ph 1.0 0.000143348623853 0 1 -1
alteration,of,hepatic 1.0 0.000143348623853 0 1 -1
alteration,of,either 1.0 0.000143348623853 0 1 -1
alteration,in,uptake-1 1.0 0.000143348623853 0 1 -1
alteration,in,the 1.0 0.000286697247706 0 2 -2
alteration,in,dose 1.0 0.000286697247706 0 2 -2
alteration,in,clearance 1.0 0.000143348623853 0 1 -1
alteration,caused,by 1.0 0.000143348623853 0 1 -1
alter,the,serum 1.0 0.000143348623853 0 1 -1
alter,the,response 1.0 0.000143348623853 0 1 -1
alter,the,pharmacological 1.0 0.000143348623853 0 1 -1
alter,the,pharmacokinetics 1.0 0.00157683486239 0 11 -11
alter,the,pharmacokinetic 1.0 0.000143348623853 0 1 -1
alter,the,optimal 1.0 0.000143348623853 0 1 -1
alter,the,mean 1.0 0.000143348623853 0 1 -1
alter,the,effects 1.0 0.00043004587156 0 3 -3
alter,the,effect 1.0 0.000143348623853 0 1 -1
alter,the,clearance 1.0 0.000143348623853 0 1 -1
alter,the,bioavailability 1.0 0.000143348623853 0 1 -1
alter,the,behavioral 1.0 0.000143348623853 0 1 -1
alter,the,adverse 1.0 0.000143348623853 0 1 -1
alter,the,absorption 1.0 0.000143348623853 0 1 -1
alter,renal,excretion 1.0 0.000143348623853 0 1 -1
alter,hormone,or 1.0 0.000143348623853 0 1 -1
alter,glucose,metabolism 1.0 0.000143348623853 0 1 -1
alter,behaviors,which 1.0 0.000143348623853 0 1 -1
alt,sgpt,or 1.0 0.000143348623853 0 1 -1
alt,and,total 1.0 0.000143348623853 0 1 -1
alt,and,or 1.0 0.000143348623853 0 1 -1
also,with,drugs 1.0 0.000143348623853 0 1 -1
also,were,taken 1.0 0.000143348623853 0 1 -1
also,was,no 1.0 0.000143348623853 0 1 -1
also,verified,by 1.0 0.000143348623853 0 1 -1
also,used,some 1.0 0.000286697247706 0 2 -2
also,to,be 1.0 0.000143348623853 0 1 -1
also,there,were 1.0 0.000143348623853 0 1 -1
also,the,potential 1.0 0.000143348623853 0 1 -1
also,suggest,an 1.0 0.000286697247706 0 2 -2
also,shown,to 1.0 0.000143348623853 0 1 -1
also,showed,good 1.0 0.000143348623853 0 1 -1
also,see,warnings 1.0 0.000143348623853 0 1 -1
also,results,in 1.0 0.000143348623853 0 1 -1
also,resolved,with 1.0 0.000143348623853 0 1 -1
also,regulated,by 1.0 0.000143348623853 0 1 -1
also,referred,to 1.0 0.000143348623853 0 1 -1
also,refer,to 1.0 0.000143348623853 0 1 -1
also,reduced,to 1.0 0.000143348623853 0 1 -1
also,receiving,mg 1.0 0.000143348623853 0 1 -1
also,receiving,a 1.0 0.000143348623853 0 1 -1
also,received,ace 1.0 0.000143348623853 0 1 -1
also,prolong,the 1.0 0.000143348623853 0 1 -1
also,produce,artifactually 1.0 0.000143348623853 0 1 -1
also,on,the 1.0 0.000143348623853 0 1 -1
also,occurs,with 1.0 0.00043004587156 0 3 -3
also,occurs,in 1.0 0.000143348623853 0 1 -1
also,occur,with 1.0 0.000143348623853 0 1 -1
also,occur,in 1.0 0.000143348623853 0 1 -1
also,not,affected 1.0 0.000143348623853 0 1 -1
also,modify,the 1.0 0.000143348623853 0 1 -1
also,lowers,serum 1.0 0.000143348623853 0 1 -1
also,known,to 1.0 0.000143348623853 0 1 -1
also,known,as 1.0 0.000143348623853 0 1 -1
also,interact,with 1.0 0.000286697247706 0 2 -2
also,inhibits,cyp3a4 1.0 0.000143348623853 0 1 -1
also,inhibit,the 1.0 0.000143348623853 0 1 -1
also,ineffective,in 1.0 0.000143348623853 0 1 -1
also,induces,apoptosis 1.0 0.000143348623853 0 1 -1
also,induced,diarrhea 1.0 0.000143348623853 0 1 -1
also,indicated,the 1.0 0.000143348623853 0 1 -1
also,indicate,that 1.0 0.000143348623853 0 1 -1
also,increased,rate 1.0 0.000143348623853 0 1 -1
also,increased,by 1.0 0.000143348623853 0 1 -1
also,increase,the 1.0 0.00043004587156 0 3 -3
also,increase,risk 1.0 0.000143348623853 0 1 -1
also,increase,generation 1.0 0.000143348623853 0 1 -1
also,included,in 1.0 0.000143348623853 0 1 -1
also,in,vitro 1.0 0.000143348623853 0 1 -1
also,in,case 1.0 0.000143348623853 0 1 -1
also,important,regulation 1.0 0.000143348623853 0 1 -1
also,have,potentially 1.0 0.000143348623853 0 1 -1
also,has,an 1.0 0.00043004587156 0 3 -3
also,fulfils,the 1.0 0.000143348623853 0 1 -1
also,extensively,used 1.0 0.000143348623853 0 1 -1
also,dyslipidemia,hypertension 1.0 0.000143348623853 0 1 -1
also,does,not 1.0 0.000286697247706 0 2 -2
also,discussed,in 1.0 0.000143348623853 0 1 -1
also,diminished,by 1.0 0.000143348623853 0 1 -1
also,conducted,with 1.0 0.000143348623853 0 1 -1
also,concurrent,use 1.0 0.000143348623853 0 1 -1
also,compromise,the 1.0 0.000143348623853 0 1 -1
also,collected,for 1.0 0.000143348623853 0 1 -1
also,chronically,receiving 1.0 0.000143348623853 0 1 -1
also,cause,increased 1.0 0.000143348623853 0 1 -1
also,been,reported 1.0 0.000860091743119 0 6 -6
also,been,observed 1.0 0.000143348623853 0 1 -1
also,been,assessed 1.0 0.000143348623853 0 1 -1
also,be,used 1.0 0.000143348623853 0 1 -1
also,be,taken 1.0 0.000143348623853 0 1 -1
also,be,increased 1.0 0.000143348623853 0 1 -1
also,be,avoided 1.0 0.000143348623853 0 1 -1
also,be,applied 1.0 0.000143348623853 0 1 -1
also,assessed,by 1.0 0.000143348623853 0 1 -1
also,appears,to 1.0 0.000143348623853 0 1 -1
also,an,inducer 1.0 0.000143348623853 0 1 -1
also,although,minimal 1.0 0.000143348623853 0 1 -1
also,albumin,bound 1.0 0.000143348623853 0 1 -1
also,affect,plasma 1.0 0.000143348623853 0 1 -1
already,seen,with 1.0 0.000143348623853 0 1 -1
already,responded,to 1.0 0.000143348623853 0 1 -1
already,receiving,n 1.0 0.000143348623853 0 1 -1
already,receiving,a 1.0 0.000143348623853 0 1 -1
already,on,cyp 1.0 0.000143348623853 0 1 -1
alprazolam,metabolism,via 1.0 0.000143348623853 0 1 -1
alphagan,p,administration 1.0 0.000143348623853 0 1 -1
alpha-agonists,as,a 1.0 0.000143348623853 0 1 -1
alpha-,or,beta-adrenergic 1.0 0.000143348623853 0 1 -1
alpha,interferons,such 1.0 0.000143348623853 0 1 -1
alpha,cell,of 1.0 0.000143348623853 0 1 -1
alpha,and,beta 1.0 0.000143348623853 0 1 -1
alosetron,does,not 1.0 0.000143348623853 0 1 -1
alosetron,also,does 1.0 0.000143348623853 0 1 -1
along,with,the 1.0 0.000143348623853 0 1 -1
along,with,another 1.0 0.000143348623853 0 1 -1
along,with,an 1.0 0.000143348623853 0 1 -1
alone,were,compared 1.0 0.000143348623853 0 1 -1
alone,versus,mg 1.0 0.000143348623853 0 1 -1
alone,significantly,lowered 1.0 0.000143348623853 0 1 -1
alone,produced,less 1.0 0.000143348623853 0 1 -1
alone,produced,a 1.0 0.000143348623853 0 1 -1
alone,or,when 1.0 0.000143348623853 0 1 -1
alone,or,or 1.0 0.000143348623853 0 1 -1
alone,or,in 1.0 0.00129013761468 0 9 -9
alone,mg,twice 1.0 0.000143348623853 0 1 -1
alone,markedly,decreased 1.0 0.000143348623853 0 1 -1
alone,in,the 1.0 0.000143348623853 0 1 -1
alone,in,doses 1.0 0.000143348623853 0 1 -1
alone,in,and 1.0 0.000143348623853 0 1 -1
alone,caused,identical 1.0 0.000143348623853 0 1 -1
alone,can,cause 1.0 0.000143348623853 0 1 -1
alone,at,therapeutic 1.0 0.000143348623853 0 1 -1
alone,at,a 1.0 0.000143348623853 0 1 -1
alone,and,minutes 1.0 0.000143348623853 0 1 -1
alone,and,in 1.0 0.000860091743119 0 6 -6
alone,and,following 1.0 0.000143348623853 0 1 -1
alone,and,administered 1.0 0.000143348623853 0 1 -1
almost,complete,loss 1.0 0.000143348623853 0 1 -1
almost,always,seen 1.0 0.000143348623853 0 1 -1
allows,the,clinician 1.0 0.000143348623853 0 1 -1
allows,physicians,to 1.0 0.000143348623853 0 1 -1
allowed,to,recover 1.0 0.000143348623853 0 1 -1
allowed,in,clinical 1.0 0.000143348623853 0 1 -1
allow,sufficient,time 1.0 0.000143348623853 0 1 -1
allow,for,any 1.0 0.000143348623853 0 1 -1
allow,for,an 1.0 0.000143348623853 0 1 -1
allow,development,of 1.0 0.000143348623853 0 1 -1
allopurinol,increased,possibility 1.0 0.000143348623853 0 1 -1
allopurinol,in,a 1.0 0.000143348623853 0 1 -1
allograft,recipients,during 1.0 0.000143348623853 0 1 -1
allergy,or,weight 1.0 0.000143348623853 0 1 -1
allergic,reactions,including 1.0 0.000143348623853 0 1 -1
allergic,or,hypersensitivity 1.0 0.000143348623853 0 1 -1
allergic,or,anaphylactic 1.0 0.000143348623853 0 1 -1
allergens,may,have 1.0 0.000143348623853 0 1 -1
allergens,may,be 1.0 0.000573394495413 0 4 -4
allergens,either,by 1.0 0.000143348623853 0 1 -1
allegra,should,be 1.0 0.000143348623853 0 1 -1
all,volunteers,took 1.0 0.000143348623853 0 1 -1
all,three,agents 1.0 0.000143348623853 0 1 -1
all,the,selective 1.0 0.000716743119266 0 5 -5
all,the,renal 1.0 0.000143348623853 0 1 -1
all,the,potential 1.0 0.000143348623853 0 1 -1
all,the,animals 1.0 0.000143348623853 0 1 -1
all,that,inhibit 1.0 0.000143348623853 0 1 -1
all,subjects,received 1.0 0.000286697247706 0 2 -2
all,strains,of 1.0 0.000286697247706 0 2 -2
all,species,including 1.0 0.000143348623853 0 1 -1
all,research,specific 1.0 0.000143348623853 0 1 -1
all,prescription,and 1.0 0.000143348623853 0 1 -1
all,physciains,it 1.0 0.000143348623853 0 1 -1
all,patients,were 1.0 0.000143348623853 0 1 -1
all,patients,receiving 1.0 0.000143348623853 0 1 -1
all,patients,in 1.0 0.000143348623853 0 1 -1
all,patients,as 1.0 0.000143348623853 0 1 -1
all,of,these 1.0 0.000143348623853 0 1 -1
all,inclusive,viracept 1.0 0.000143348623853 0 1 -1
all,in,vivo 1.0 0.000143348623853 0 1 -1
all,in,patients 1.0 0.000143348623853 0 1 -1
all,in,other 1.0 0.000143348623853 0 1 -1
all,elevations,resolved 1.0 0.000143348623853 0 1 -1
all,care,should 1.0 0.000143348623853 0 1 -1
all,been,used 1.0 0.000143348623853 0 1 -1
all,are,indeed 1.0 0.000143348623853 0 1 -1
all,antagonists,decreased 1.0 0.000143348623853 0 1 -1
all,animals,were 1.0 0.000143348623853 0 1 -1
all,animals,in 1.0 0.000143348623853 0 1 -1
all,animal,species 1.0 0.000143348623853 0 1 -1
all,agents,to 1.0 0.000143348623853 0 1 -1
alkylated,such,as 1.0 0.000143348623853 0 1 -1
alkaloid,congener,is 1.0 0.000143348623853 0 1 -1
alkalinizing,agents,increase 1.0 0.000143348623853 0 1 -1
alkalinizers,decrease,effectiveness 1.0 0.000143348623853 0 1 -1
alkaline,urine,red-orange 1.0 0.000143348623853 0 1 -1
alkaline,phosphatase,should 1.0 0.000143348623853 0 1 -1
alkaline,phosphatase,and 1.0 0.000286697247706 0 2 -2
alkaline,earth,and 1.0 0.000286697247706 0 2 -2
aliskiren,on,other 1.0 0.000143348623853 0 1 -1
aliskiren,does,not 1.0 0.000143348623853 0 1 -1
aliskiren,based,on 1.0 0.000143348623853 0 1 -1
alg,mycophenolate,mofetil 1.0 0.000143348623853 0 1 -1
alfenta,doses,will 1.0 0.000143348623853 0 1 -1
alfa-2a,treatment,of 1.0 0.000143348623853 0 1 -1
alfa-2a,for,months 1.0 0.000143348623853 0 1 -1
alertness,such,as 1.0 0.000143348623853 0 1 -1
alerted,to,the 1.0 0.000143348623853 0 1 -1
alert,for,possible 1.0 0.000286697247706 0 2 -2
aldosterone,production,elevation 1.0 0.000143348623853 0 1 -1
aldosterone,excretion,and 1.0 0.000143348623853 0 1 -1
aldehyde,oxidase,the 1.0 0.000143348623853 0 1 -1
aldehyde,oxidase,enzyme 1.0 0.000143348623853 0 1 -1
alcoholic,beverages,in 1.0 0.000143348623853 0 1 -1
alcoholic,beverages,are 1.0 0.000143348623853 0 1 -1
alcohol-related,deaths,is 1.0 0.000143348623853 0 1 -1
alcohol,when,duloxetine 1.0 0.000143348623853 0 1 -1
alcohol,there,was 1.0 0.000143348623853 0 1 -1
alcohol,or,potentiation 1.0 0.000286697247706 0 2 -2
alcohol,increases,bioavailability 1.0 0.000143348623853 0 1 -1
alcohol,in,particular 1.0 0.00043004587156 0 3 -3
alcohol,g,kg 1.0 0.000143348623853 0 1 -1
alcohol,alcohol,g 1.0 0.000143348623853 0 1 -1
albumin,may,displace 1.0 0.000143348623853 0 1 -1
albumin,could,increase 1.0 0.000143348623853 0 1 -1
albumin,bound,and 1.0 0.000143348623853 0 1 -1
albumin,binding,and 1.0 0.000143348623853 0 1 -1
albicans,one,of 1.0 0.000143348623853 0 1 -1
albendazole,sulfoxide,plasma 1.0 0.000143348623853 0 1 -1
akathisia,however,is 1.0 0.000143348623853 0 1 -1
aims,hypothesis,there 1.0 0.000143348623853 0 1 -1
aim,of,this 1.0 0.000286697247706 0 2 -2
aim,and,background 1.0 0.000143348623853 0 1 -1
aids-related,kaposi,s 1.0 0.000143348623853 0 1 -1
aid,sleep,drowsiness-causing 1.0 0.000143348623853 0 1 -1
aid,in,elucidating 1.0 0.000143348623853 0 1 -1
agranulocytosis,as,seen 1.0 0.000143348623853 0 1 -1
agonists,hepatic,enzyme 1.0 0.000143348623853 0 1 -1
agonists,has,not 1.0 0.000143348623853 0 1 -1
agonists,dcg-iv,and 1.0 0.000143348623853 0 1 -1
agonists,compared,with 1.0 0.000143348623853 0 1 -1
agonist,in,patients 1.0 0.000143348623853 0 1 -1
agonist,effects,in 1.0 0.000143348623853 0 1 -1
agonist,antagonist,may 1.0 0.000143348623853 0 1 -1
agitation,while,other 1.0 0.000143348623853 0 1 -1
agitation,motor,weakness 1.0 0.000143348623853 0 1 -1
aggressively,with,intravenous 1.0 0.000143348623853 0 1 -1
aggressively,is,understandable 1.0 0.000143348623853 0 1 -1
aggression,and,agitation 1.0 0.000143348623853 0 1 -1
aggregation,time,but 1.0 0.000143348623853 0 1 -1
aggregation,the,release 1.0 0.000143348623853 0 1 -1
aggregation,response,against 1.0 0.000143348623853 0 1 -1
aggregation,and,serum 1.0 0.000143348623853 0 1 -1
aggregation,and,prolong 1.0 0.000143348623853 0 1 -1
agents--a,class,of 1.0 0.000143348623853 0 1 -1
agents,with,less 1.0 0.000286697247706 0 2 -2
agents,with,decreased 1.0 0.000143348623853 0 1 -1
agents,with,can 1.0 0.000143348623853 0 1 -1
agents,which,prolong 1.0 0.000143348623853 0 1 -1
agents,which,may 1.0 0.000143348623853 0 1 -1
agents,were,reported 1.0 0.000143348623853 0 1 -1
agents,was,not 1.0 0.000143348623853 0 1 -1
agents,was,evaluated 1.0 0.000143348623853 0 1 -1
agents,used,to 1.0 0.000143348623853 0 1 -1
agents,used,in 1.0 0.000143348623853 0 1 -1
agents,to,treat 1.0 0.000143348623853 0 1 -1
agents,these,medicines 1.0 0.000143348623853 0 1 -1
agents,the,safety 1.0 0.000143348623853 0 1 -1
agents,the,possibility 1.0 0.000143348623853 0 1 -1
agents,the,metabolism 1.0 0.000143348623853 0 1 -1
agents,the,effect 1.0 0.000143348623853 0 1 -1
agents,the,concomitant 1.0 0.000143348623853 0 1 -1
agents,that,may 1.0 0.000286697247706 0 2 -2
agents,that,lower 1.0 0.000143348623853 0 1 -1
agents,that,inhibit 1.0 0.000143348623853 0 1 -1
agents,that,affect 1.0 0.000143348623853 0 1 -1
agents,since,vitamin 1.0 0.00043004587156 0 3 -3
agents,should,precede 1.0 0.000143348623853 0 1 -1
agents,should,generally 1.0 0.000716743119266 0 5 -5
agents,produced,reliable 1.0 0.000143348623853 0 1 -1
agents,prinivil,has 1.0 0.000143348623853 0 1 -1
agents,primarily,h2 1.0 0.000143348623853 0 1 -1
agents,possible,increased 1.0 0.000143348623853 0 1 -1
agents,pharmacokinetic,drug-drug 1.0 0.000143348623853 0 1 -1
agents,or,radiation 1.0 0.000143348623853 0 1 -1
agents,or,including 1.0 0.000143348623853 0 1 -1
agents,or,glycosides 1.0 0.000143348623853 0 1 -1
agents,or,adrenergic 1.0 0.000143348623853 0 1 -1
agents,only,with 1.0 0.000143348623853 0 1 -1
agents,on,the 1.0 0.000143348623853 0 1 -1
agents,of,class 1.0 0.000143348623853 0 1 -1
agents,now,available 1.0 0.000143348623853 0 1 -1
agents,no,interactions 1.0 0.000143348623853 0 1 -1
agents,no,effect 1.0 0.000143348623853 0 1 -1
agents,nitrogen,mustard 1.0 0.000143348623853 0 1 -1
agents,must,be 1.0 0.000573394495413 0 4 -4
agents,medicine,for 1.0 0.000143348623853 0 1 -1
agents,may,represent 1.0 0.000143348623853 0 1 -1
agents,may,potentially 1.0 0.000143348623853 0 1 -1
agents,may,alter 1.0 0.000143348623853 0 1 -1
agents,lower,blood 1.0 0.000286697247706 0 2 -2
agents,likely,to 1.0 0.000143348623853 0 1 -1
agents,is,indicated 1.0 0.000860091743119 0 6 -6
agents,iodine-containing,compounds 1.0 0.000143348623853 0 1 -1
agents,into,patients 1.0 0.000143348623853 0 1 -1
agents,insulin,sulfonylureas 1.0 0.000143348623853 0 1 -1
agents,increase,blood 1.0 0.000286697247706 0 2 -2
agents,including,protease 1.0 0.000143348623853 0 1 -1
agents,including,and 1.0 0.000143348623853 0 1 -1
agents,include,medications 1.0 0.000143348623853 0 1 -1
agents,in,pharmacokinetic 1.0 0.000143348623853 0 1 -1
agents,in,one 1.0 0.000143348623853 0 1 -1
agents,in,general 1.0 0.000143348623853 0 1 -1
agents,in,four 1.0 0.000143348623853 0 1 -1
agents,in,addition 1.0 0.000143348623853 0 1 -1
agents,in,a 1.0 0.000143348623853 0 1 -1
agents,highly,bound 1.0 0.000143348623853 0 1 -1
agents,having,vasodilator 1.0 0.000143348623853 0 1 -1
agents,having,a 1.0 0.000143348623853 0 1 -1
agents,have,not 1.0 0.000286697247706 0 2 -2
agents,have,also 1.0 0.000143348623853 0 1 -1
agents,has,not 1.0 0.000143348623853 0 1 -1
agents,has,an 1.0 0.000143348623853 0 1 -1
agents,given,concomitantly 1.0 0.000143348623853 0 1 -1
agents,for,the 1.0 0.000143348623853 0 1 -1
agents,folic,acid 1.0 0.000143348623853 0 1 -1
agents,ethinyl,estradiol 1.0 0.000143348623853 0 1 -1
agents,enalapril,and 1.0 0.000143348623853 0 1 -1
agents,dynamic,and 1.0 0.000143348623853 0 1 -1
agents,did,not 1.0 0.00043004587156 0 3 -3
agents,derivatives,hormones 1.0 0.000286697247706 0 2 -2
agents,demonstrated,similar 1.0 0.000143348623853 0 1 -1
agents,contribute,to 1.0 0.000143348623853 0 1 -1
agents,contraindicated,since 1.0 0.000143348623853 0 1 -1
agents,coadministration,of 1.0 0.000286697247706 0 2 -2
agents,co-administration,of 1.0 0.000143348623853 0 1 -1
agents,class,i 1.0 0.000143348623853 0 1 -1
agents,chloral,hydrate 1.0 0.000143348623853 0 1 -1
agents,calcium-channel,blocking 1.0 0.000143348623853 0 1 -1
agents,calcium-blocking,agents 1.0 0.000143348623853 0 1 -1
agents,calcium,channel 1.0 0.000143348623853 0 1 -1
agents,because,of 1.0 0.000143348623853 0 1 -1
agents,available,for 1.0 0.000143348623853 0 1 -1
agents,are,associated 1.0 0.000143348623853 0 1 -1
agents,are,added 1.0 0.000143348623853 0 1 -1
agents,and,without 1.0 0.000286697247706 0 2 -2
agents,and,some 1.0 0.000143348623853 0 1 -1
agents,and,should 1.0 0.000143348623853 0 1 -1
agents,and,local 1.0 0.000143348623853 0 1 -1
agents,and,hypoglycemia 1.0 0.000143348623853 0 1 -1
agents,and,dosage 1.0 0.000286697247706 0 2 -2
agents,and,angiotensin 1.0 0.000143348623853 0 1 -1
agents,affecting,sympathetic 1.0 0.000286697247706 0 2 -2
agents,affecting,myelopoesis 1.0 0.000143348623853 0 1 -1
agents,affecting,cytochrome 1.0 0.000143348623853 0 1 -1
agents,actions,of 1.0 0.000143348623853 0 1 -1
agents,a,pharmacokinetic 1.0 0.000143348623853 0 1 -1
agents,a,cyp3a4 1.0 0.000143348623853 0 1 -1
agent,which,has 1.0 0.000143348623853 0 1 -1
agent,was,found 1.0 0.000143348623853 0 1 -1
agent,that,inhibits 1.0 0.000143348623853 0 1 -1
agent,that,decreases 1.0 0.000143348623853 0 1 -1
agent,that,alters 1.0 0.000143348623853 0 1 -1
agent,should,include 1.0 0.000143348623853 0 1 -1
agent,should,allow 1.0 0.000143348623853 0 1 -1
agent,plus,a 1.0 0.000143348623853 0 1 -1
agent,or,the 1.0 0.000143348623853 0 1 -1
agent,or,incompletely 1.0 0.000143348623853 0 1 -1
agent,on,the 1.0 0.000143348623853 0 1 -1
agent,on,intact 1.0 0.000143348623853 0 1 -1
agent,of,the 1.0 0.000143348623853 0 1 -1
agent,metabolized,by 1.0 0.000143348623853 0 1 -1
agent,may,be 1.0 0.000143348623853 0 1 -1
agent,known,to 1.0 0.000143348623853 0 1 -1
agent,has,slight 1.0 0.000143348623853 0 1 -1
agent,contraindicated,due 1.0 0.000143348623853 0 1 -1
agent,and,should 1.0 0.000143348623853 0 1 -1
agent,administered,at 1.0 0.000143348623853 0 1 -1
agent,additional,concomitant 1.0 0.000143348623853 0 1 -1
aged,years,total 1.0 0.000143348623853 0 1 -1
aged,or,over 1.0 0.000143348623853 0 1 -1
age-dependent,alterations,in 1.0 0.000143348623853 0 1 -1
age,the,mean 1.0 0.000143348623853 0 1 -1
age,sex,number 1.0 0.000143348623853 0 1 -1
age,range,years 1.0 0.000143348623853 0 1 -1
age,or,older 1.0 0.000143348623853 0 1 -1
age,of,years 1.0 0.000143348623853 0 1 -1
age,objective,responses 1.0 0.000143348623853 0 1 -1
age,may,influence 1.0 0.000143348623853 0 1 -1
age,gender,race 1.0 0.000143348623853 0 1 -1
age,and,older 1.0 0.000143348623853 0 1 -1
age,and,is 1.0 0.000143348623853 0 1 -1
age,and,in 1.0 0.000143348623853 0 1 -1
against,two,type 1.0 0.000143348623853 0 1 -1
against,this,pathogen 1.0 0.000143348623853 0 1 -1
against,the,simultaneous 1.0 0.000143348623853 0 1 -1
against,the,potential 1.0 0.000143348623853 0 1 -1
against,the,possibility 1.0 0.000143348623853 0 1 -1
against,the,positive 1.0 0.000143348623853 0 1 -1
against,symptoms,of 1.0 0.000143348623853 0 1 -1
against,sera,from 1.0 0.000143348623853 0 1 -1
against,positive,and 1.0 0.000143348623853 0 1 -1
against,of,resistant 1.0 0.000143348623853 0 1 -1
against,mycobacteriumavium-intracellulare,complex 1.0 0.000143348623853 0 1 -1
against,multidrug-resistant,organisms 1.0 0.000143348623853 0 1 -1
against,micrococcus,luteus 1.0 0.000143348623853 0 1 -1
against,hepatic,microsomal 1.0 0.000143348623853 0 1 -1
against,gram-negative,and 1.0 0.000143348623853 0 1 -1
against,gram,positive 1.0 0.000143348623853 0 1 -1
against,engaging,in 1.0 0.000143348623853 0 1 -1
against,driving,a 1.0 0.000143348623853 0 1 -1
against,cryptosporidium,parvum 1.0 0.000143348623853 0 1 -1
against,cercariae,and 1.0 0.000143348623853 0 1 -1
again,neutralized,the 1.0 0.000143348623853 0 1 -1
again,given,by 1.0 0.000143348623853 0 1 -1
again,allowed,to 1.0 0.000143348623853 0 1 -1
after,withdrawal,the 1.0 0.000143348623853 0 1 -1
after,weeks,of 1.0 0.000286697247706 0 2 -2
after,was,washed 1.0 0.000143348623853 0 1 -1
after,treatment,with 1.0 0.000143348623853 0 1 -1
after,treatment,there 1.0 0.000143348623853 0 1 -1
after,treatment,cessation 1.0 0.000143348623853 0 1 -1
after,to,days 1.0 0.000143348623853 0 1 -1
after,the,long-term 1.0 0.000143348623853 0 1 -1
after,the,interaction 1.0 0.000143348623853 0 1 -1
after,the,first 1.0 0.000143348623853 0 1 -1
after,the,effects 1.0 0.000143348623853 0 1 -1
after,starting,the 1.0 0.000143348623853 0 1 -1
after,starting,st 1.0 0.000143348623853 0 1 -1
after,remained,the 1.0 0.000143348623853 0 1 -1
after,prolonged,administration 1.0 0.000143348623853 0 1 -1
after,previous,radiation 1.0 0.000143348623853 0 1 -1
after,perfusion,did 1.0 0.000143348623853 0 1 -1
after,overload,both 1.0 0.000143348623853 0 1 -1
after,oral,mg 1.0 0.000143348623853 0 1 -1
after,oral,administration 1.0 0.000143348623853 0 1 -1
after,or,in 1.0 0.000143348623853 0 1 -1
after,one,day 1.0 0.000143348623853 0 1 -1
after,myocardial,infarction 1.0 0.000143348623853 0 1 -1
after,multiple-dose,administration 1.0 0.000143348623853 0 1 -1
after,multiple,doses 1.0 0.000143348623853 0 1 -1
after,missing,a 1.0 0.000143348623853 0 1 -1
after,min,fasting 1.0 0.000143348623853 0 1 -1
after,mefloquineuine,causes 1.0 0.000143348623853 0 1 -1
after,intravenous,administration 1.0 0.000143348623853 0 1 -1
after,insertion,of 1.0 0.000143348623853 0 1 -1
after,initiating,treatment 1.0 0.000143348623853 0 1 -1
after,inhalational,muscle 1.0 0.000143348623853 0 1 -1
after,incubation,at 1.0 0.000143348623853 0 1 -1
after,h,was 1.0 0.000143348623853 0 1 -1
after,extensive,intake 1.0 0.000143348623853 0 1 -1
after,exposure,to 1.0 0.000286697247706 0 2 -2
after,dosing,at 1.0 0.000143348623853 0 1 -1
after,discontinuation,of 1.0 0.000143348623853 0 1 -1
after,days,of 1.0 0.000573394495413 0 4 -4
after,day,of 1.0 0.000143348623853 0 1 -1
after,consumption,of 1.0 0.000143348623853 0 1 -1
after,concurrent,treatment 1.0 0.000143348623853 0 1 -1
after,concomitant,administration 1.0 0.000143348623853 0 1 -1
after,colestid,tablets 1.0 0.000143348623853 0 1 -1
after,coadministration,of 1.0 0.000143348623853 0 1 -1
after,clinical,patterns 1.0 0.000143348623853 0 1 -1
after,chronic,treatment 1.0 0.000143348623853 0 1 -1
after,cholestyramine,resin 1.0 0.000143348623853 0 1 -1
after,cessation,of 1.0 0.000143348623853 0 1 -1
after,bilateral,ovariectomy 1.0 0.000143348623853 0 1 -1
after,being,dosed 1.0 0.000143348623853 0 1 -1
after,at,the 1.0 0.000143348623853 0 1 -1
after,an,mg 1.0 0.000143348623853 0 1 -1
after,alphagan,p 1.0 0.000143348623853 0 1 -1
after,administration,reaching 1.0 0.000143348623853 0 1 -1
after,administration,but 1.0 0.000143348623853 0 1 -1
after,a,second 1.0 0.000143348623853 0 1 -1
after,a,day 1.0 0.000143348623853 0 1 -1
african-american,man,was 1.0 0.000143348623853 0 1 -1
african,trypanosomiasis,in 1.0 0.000143348623853 0 1 -1
african,and,other 1.0 0.000716743119266 0 5 -5
affinity,substrates,for 1.0 0.000143348623853 0 1 -1
affinity,kd,of 1.0 0.000143348623853 0 1 -1
affinity,for,serotonin 1.0 0.000143348623853 0 1 -1
affinity,for,protein 1.0 0.000286697247706 0 2 -2
affinity,for,anions 1.0 0.000143348623853 0 1 -1
affinity,for,albumin 1.0 0.000143348623853 0 1 -1
affinity,chromatography,procedure 1.0 0.000143348623853 0 1 -1
affinity,binding,sites 1.0 0.000286697247706 0 2 -2
affinities,than,for 1.0 0.000143348623853 0 1 -1
affinities,for,kappa 1.0 0.000143348623853 0 1 -1
affects,prothrombin,times 1.0 0.000143348623853 0 1 -1
affects,expression,of 1.0 0.000143348623853 0 1 -1
affecting,sympathetic,activity 1.0 0.000286697247706 0 2 -2
affecting,patients,ci 1.0 0.000143348623853 0 1 -1
affecting,myelopoesis,drugs 1.0 0.000143348623853 0 1 -1
affecting,hepatic,blood 1.0 0.000143348623853 0 1 -1
affecting,cytochrome,p450 1.0 0.000143348623853 0 1 -1
affected,when,administered 1.0 0.000143348623853 0 1 -1
affected,significantly,with 1.0 0.000143348623853 0 1 -1
affected,prothrombin,times 1.0 0.000143348623853 0 1 -1
affected,during,multiple-dose 1.0 0.000143348623853 0 1 -1
affected,during,concomitant 1.0 0.000143348623853 0 1 -1
affected,by,such 1.0 0.000143348623853 0 1 -1
affected,by,or 1.0 0.000143348623853 0 1 -1
affected,by,multiple-dose 1.0 0.000143348623853 0 1 -1
affected,by,his 1.0 0.000143348623853 0 1 -1
affected,by,cytochrome 1.0 0.000143348623853 0 1 -1
affected,by,concomitant 1.0 0.000143348623853 0 1 -1
affected,by,coadministration 1.0 0.000286697247706 0 2 -2
affected,by,co-administration 1.0 0.000143348623853 0 1 -1
affected,by,cercariae 1.0 0.000143348623853 0 1 -1
affected,by,alterations 1.0 0.000286697247706 0 2 -2
affected,by,administration 1.0 0.000143348623853 0 1 -1
affect,this,activity 1.0 0.000143348623853 0 1 -1
affect,the,steady-state 1.0 0.000143348623853 0 1 -1
affect,the,sensitivity 1.0 0.000143348623853 0 1 -1
affect,the,results 1.0 0.000143348623853 0 1 -1
affect,the,relative 1.0 0.000143348623853 0 1 -1
affect,the,rate 1.0 0.000143348623853 0 1 -1
affect,the,prothrombin 1.0 0.000143348623853 0 1 -1
affect,the,plasma 1.0 0.00043004587156 0 3 -3
affect,the,pk 1.0 0.000143348623853 0 1 -1
affect,the,pituitary 1.0 0.000143348623853 0 1 -1
affect,the,pharmacokinetics 1.0 0.0024369266055 0 17 -17
affect,the,peak 1.0 0.000143348623853 0 1 -1
affect,the,nitrobluetetrazolium 1.0 0.000143348623853 0 1 -1
affect,the,metabolism 1.0 0.000286697247706 0 2 -2
affect,the,mediated 1.0 0.000143348623853 0 1 -1
affect,the,mechanism 1.0 0.000143348623853 0 1 -1
affect,the,in 1.0 0.000143348623853 0 1 -1
affect,the,hematopoietic 1.0 0.000143348623853 0 1 -1
affect,the,growth 1.0 0.000143348623853 0 1 -1
affect,the,extent 1.0 0.000143348623853 0 1 -1
affect,the,cytochrome 1.0 0.000143348623853 0 1 -1
affect,the,course 1.0 0.000143348623853 0 1 -1
affect,the,conversion 1.0 0.000143348623853 0 1 -1
affect,the,concentration 1.0 0.000143348623853 0 1 -1
affect,the,clearance 1.0 0.000143348623853 0 1 -1
affect,the,c 1.0 0.000143348623853 0 1 -1
affect,the,blood 1.0 0.000143348623853 0 1 -1
affect,the,bioavailability 1.0 0.000143348623853 0 1 -1
affect,the,aptt 1.0 0.000143348623853 0 1 -1
affect,subjective,responses 1.0 0.000143348623853 0 1 -1
affect,strategies,during 1.0 0.000143348623853 0 1 -1
affect,steady-state,pharmacokinetic 1.0 0.000143348623853 0 1 -1
affect,safety,however 1.0 0.000143348623853 0 1 -1
affect,responding,for 1.0 0.000143348623853 0 1 -1
affect,renal,prostaglandins 1.0 0.000143348623853 0 1 -1
affect,renal,nonrenal 1.0 0.000143348623853 0 1 -1
affect,renal,function 1.0 0.00043004587156 0 3 -3
affect,protein,tyrosine 1.0 0.000143348623853 0 1 -1
affect,plasma,renin 1.0 0.000143348623853 0 1 -1
affect,patient,response 1.0 0.000143348623853 0 1 -1
affect,other,drugs 1.0 0.000286697247706 0 2 -2
affect,metabolism,pharmacokinetics 1.0 0.000143348623853 0 1 -1
affect,leukocyte,production 1.0 0.000143348623853 0 1 -1
affect,its,metabolism 1.0 0.000143348623853 0 1 -1
affect,idv,exposure 1.0 0.000143348623853 0 1 -1
affect,hepatic,microsomal 1.0 0.000143348623853 0 1 -1
affect,glucose,metabolism 1.0 0.000286697247706 0 2 -2
affect,gastric,acidity 1.0 0.000143348623853 0 1 -1
affect,either,the 1.0 0.000143348623853 0 1 -1
affect,duloxetine,both 1.0 0.000143348623853 0 1 -1
affect,cyp3a4,and 1.0 0.000143348623853 0 1 -1
affect,cardiac,contractility 1.0 0.000143348623853 0 1 -1
affect,bleeding,time 1.0 0.000143348623853 0 1 -1
affect,bioavailabillty,and 1.0 0.000143348623853 0 1 -1
affect,behaviors,most 1.0 0.000143348623853 0 1 -1
affect,any,of 1.0 0.000143348623853 0 1 -1
affect,abilify,aripiprazole 1.0 0.000143348623853 0 1 -1
aetiopathogenic--,for,example 1.0 0.000143348623853 0 1 -1
aeruginosa,were,inhibited 1.0 0.000143348623853 0 1 -1
aeruginosa,serotype,o11 1.0 0.000286697247706 0 2 -2
aeruginosa,particularly,serotype 1.0 0.000143348623853 0 1 -1
aeruginosa,as,common 1.0 0.000143348623853 0 1 -1
aerosolized,has,not 1.0 0.000143348623853 0 1 -1
aerosol,particles,of 1.0 0.00043004587156 0 3 -3
aerosol,particles,in 1.0 0.000143348623853 0 1 -1
aerosol,particles,appeared 1.0 0.000143348623853 0 1 -1
aerosol,particles,and 1.0 0.000143348623853 0 1 -1
aerosol,of,the 1.0 0.000143348623853 0 1 -1
aerosol,has,been 1.0 0.000143348623853 0 1 -1
aerosol,and,these 1.0 0.000143348623853 0 1 -1
aerolizertm,inhalation,device 1.0 0.000143348623853 0 1 -1
aerobic,facultative,and 1.0 0.000143348623853 0 1 -1
aeds,whether,or 1.0 0.000143348623853 0 1 -1
aeds,were,assessed 1.0 0.000143348623853 0 1 -1
aeds,phenytoin,tiagabine 1.0 0.000143348623853 0 1 -1
aeds,phenytoin,keppra 1.0 0.000143348623853 0 1 -1
aeds,during,placebo-controlled 1.0 0.000143348623853 0 1 -1
aeds,do,not 1.0 0.000143348623853 0 1 -1
aeds,and,were 1.0 0.000143348623853 0 1 -1
aeds,and,that 1.0 0.000143348623853 0 1 -1
aed,on,mhd 1.0 0.000143348623853 0 1 -1
aed,induces,or 1.0 0.000143348623853 0 1 -1
aed,concentration,mean 1.0 0.000143348623853 0 1 -1
advocated,on,the 1.0 0.000143348623853 0 1 -1
advised,to,refrain 1.0 0.000143348623853 0 1 -1
advised,to,monitor 1.0 0.000286697247706 0 2 -2
advised,to,consult 1.0 0.000286697247706 0 2 -2
advised,nonetheless,since 1.0 0.000143348623853 0 1 -1
advised,if,the 1.0 0.000286697247706 0 2 -2
advised,if,patients 1.0 0.000143348623853 0 1 -1
advised,if,and 1.0 0.000143348623853 0 1 -1
advised,especially,at 1.0 0.000143348623853 0 1 -1
advise,on,over 1.0 0.000143348623853 0 1 -1
advisable,until,it 1.0 0.000286697247706 0 2 -2
advisable,to,closely 1.0 0.000143348623853 0 1 -1
advisable,to,be 1.0 0.000143348623853 0 1 -1
advisable,not,to 1.0 0.000143348623853 0 1 -1
advisable,for,chronic 1.0 0.000143348623853 0 1 -1
advil,nuprin,others 1.0 0.000143348623853 0 1 -1
adversely,affected,by 1.0 0.000143348623853 0 1 -1
adversely,affect,the 1.0 0.000143348623853 0 1 -1
adverse,reactions,thought 1.0 0.000143348623853 0 1 -1
adverse,reactions,related 1.0 0.000143348623853 0 1 -1
adverse,reactions,in 1.0 0.000286697247706 0 2 -2
adverse,reactions,from 1.0 0.000286697247706 0 2 -2
adverse,reactions,atg 1.0 0.000143348623853 0 1 -1
adverse,reactions,are 1.0 0.000143348623853 0 1 -1
adverse,reaction,profile 1.0 0.000143348623853 0 1 -1
adverse,reaction,is 1.0 0.000143348623853 0 1 -1
adverse,reaction,during 1.0 0.000143348623853 0 1 -1
adverse,reaction,and 1.0 0.000143348623853 0 1 -1
adverse,interactions,with 1.0 0.000143348623853 0 1 -1
adverse,interaction,to 1.0 0.000143348623853 0 1 -1
adverse,experiences,are 1.0 0.000143348623853 0 1 -1
adverse,experience,profile 1.0 0.000143348623853 0 1 -1
adverse,events,with 1.0 0.000143348623853 0 1 -1
adverse,events,when 1.0 0.000286697247706 0 2 -2
adverse,events,was 1.0 0.000143348623853 0 1 -1
adverse,events,such 1.0 0.000143348623853 0 1 -1
adverse,events,should 1.0 0.000143348623853 0 1 -1
adverse,events,reported 1.0 0.000143348623853 0 1 -1
adverse,events,or 1.0 0.000286697247706 0 2 -2
adverse,events,occurred 1.0 0.000143348623853 0 1 -1
adverse,events,involving 1.0 0.000143348623853 0 1 -1
adverse,events,including 1.0 0.000143348623853 0 1 -1
adverse,events,in 1.0 0.000286697247706 0 2 -2
adverse,events,from 1.0 0.000143348623853 0 1 -1
adverse,events,are 1.0 0.000143348623853 0 1 -1
adverse,events,and 1.0 0.000143348623853 0 1 -1
adverse,event,profile 1.0 0.000143348623853 0 1 -1
adverse,effects,reported 1.0 0.000143348623853 0 1 -1
adverse,effects,reduced 1.0 0.000143348623853 0 1 -1
adverse,effects,or 1.0 0.000143348623853 0 1 -1
adverse,effects,on 1.0 0.000573394495413 0 4 -4
adverse,effects,may 1.0 0.000143348623853 0 1 -1
adverse,effects,in 1.0 0.000286697247706 0 2 -2
adverse,effects,especially 1.0 0.000143348623853 0 1 -1
adverse,consequences,hunger 1.0 0.000143348623853 0 1 -1
adverse,clinical,experiences 1.0 0.000143348623853 0 1 -1
adverse,cardiovascular,effects 1.0 0.000143348623853 0 1 -1
advantages,over,pi-based 1.0 0.000143348623853 0 1 -1
advantages,offered,by 1.0 0.000143348623853 0 1 -1
advantages,and,disadvantages 1.0 0.000143348623853 0 1 -1
advantage,when,used 1.0 0.000143348623853 0 1 -1
advantage,of,these 1.0 0.000143348623853 0 1 -1
advanced,hiv,disease 1.0 0.000143348623853 0 1 -1
adults,were,conducted 1.0 0.000143348623853 0 1 -1
adults,to,be 1.0 0.000143348623853 0 1 -1
adults,and,adult 1.0 0.000143348623853 0 1 -1
adult,wistar,rats 1.0 0.000143348623853 0 1 -1
adult,volunteers,toradoloral 1.0 0.000143348623853 0 1 -1
adult,diabetics,who 1.0 0.000143348623853 0 1 -1
adrenoreceptors,on,this 1.0 0.000143348623853 0 1 -1
adrenocorticoids,metabolic,clearance 1.0 0.000143348623853 0 1 -1
adrenocorticoids,is,decreased 1.0 0.000143348623853 0 1 -1
adrenergic-blocking,agents,calcium-blocking 1.0 0.000143348623853 0 1 -1
adrenergic,stimulant,type 1.0 0.000143348623853 0 1 -1
adrenergic,neuron,blocking 1.0 0.000143348623853 0 1 -1
adrenergic,from,working 1.0 0.000143348623853 0 1 -1
adrenergic,blockers,may 1.0 0.000143348623853 0 1 -1
adrenergic,blockers,including 1.0 0.000143348623853 0 1 -1
adrenal,function,tests 1.0 0.000143348623853 0 1 -1
adrenal,and,or 1.0 0.000143348623853 0 1 -1
adp-induced,increases,in 1.0 0.000143348623853 0 1 -1
adp,and,collagen-induced 1.0 0.000143348623853 0 1 -1
adolescent,presents,a 1.0 0.000143348623853 0 1 -1
admitted,to,the 1.0 0.000143348623853 0 1 -1
admistration,of,the 1.0 0.000143348623853 0 1 -1
admissions,for,mania 1.0 0.000143348623853 0 1 -1
admission,the,patient 1.0 0.000143348623853 0 1 -1
administrative,arrangements,in 1.0 0.000143348623853 0 1 -1
administration,with,the 1.0 0.000143348623853 0 1 -1
administration,with,other 1.0 0.000143348623853 0 1 -1
administration,twice,a 1.0 0.000143348623853 0 1 -1
administration,trough,concentrations 1.0 0.000143348623853 0 1 -1
administration,to,the 1.0 0.000143348623853 0 1 -1
administration,the,effect 1.0 0.000143348623853 0 1 -1
administration,should,be 1.0 0.000143348623853 0 1 -1
administration,regimens,lower 1.0 0.000143348623853 0 1 -1
administration,reaching,a 1.0 0.000143348623853 0 1 -1
administration,or,salt 1.0 0.000143348623853 0 1 -1
administration,one,hour 1.0 0.000143348623853 0 1 -1
administration,on,the 1.0 0.000143348623853 0 1 -1
administration,on,day 1.0 0.000143348623853 0 1 -1
administration,on,a 1.0 0.000143348623853 0 1 -1
administration,of,withdrawal 1.0 0.000143348623853 0 1 -1
administration,of,was 1.0 0.000143348623853 0 1 -1
administration,of,vioxx 1.0 0.000143348623853 0 1 -1
administration,of,two 1.0 0.000143348623853 0 1 -1
administration,of,that 1.0 0.000143348623853 0 1 -1
administration,of,taxol 1.0 0.000286697247706 0 2 -2
administration,of,suprax 1.0 0.000143348623853 0 1 -1
administration,of,suggesting 1.0 0.000143348623853 0 1 -1
administration,of,substrates 1.0 0.000143348623853 0 1 -1
administration,of,strong 1.0 0.000143348623853 0 1 -1
administration,of,stadol 1.0 0.000143348623853 0 1 -1
administration,of,single 1.0 0.000143348623853 0 1 -1
administration,of,should 1.0 0.000286697247706 0 2 -2
administration,of,several 1.0 0.000143348623853 0 1 -1
administration,of,revia 1.0 0.000143348623853 0 1 -1
administration,of,repeat 1.0 0.000143348623853 0 1 -1
administration,of,proton 1.0 0.000143348623853 0 1 -1
administration,of,precedex 1.0 0.000143348623853 0 1 -1
administration,of,pipracil 1.0 0.000143348623853 0 1 -1
administration,of,peptide 1.0 0.000143348623853 0 1 -1
administration,of,pegasys 1.0 0.000143348623853 0 1 -1
administration,of,panretin 1.0 0.000143348623853 0 1 -1
administration,of,on 1.0 0.000143348623853 0 1 -1
administration,of,neurontin 1.0 0.000143348623853 0 1 -1
administration,of,morning 1.0 0.000143348623853 0 1 -1
administration,of,mefloquineuine 1.0 0.000143348623853 0 1 -1
administration,of,lower 1.0 0.000143348623853 0 1 -1
administration,of,large 1.0 0.000143348623853 0 1 -1
administration,of,known 1.0 0.000286697247706 0 2 -2
administration,of,kerlone 1.0 0.000143348623853 0 1 -1
administration,of,keflex 1.0 0.000143348623853 0 1 -1
administration,of,it 1.0 0.000143348623853 0 1 -1
administration,of,hydroxide 1.0 0.000143348623853 0 1 -1
administration,of,had 1.0 0.000143348623853 0 1 -1
administration,of,for 1.0 0.000143348623853 0 1 -1
administration,of,fibric 1.0 0.000143348623853 0 1 -1
administration,of,exjade 1.0 0.000286697247706 0 2 -2
administration,of,equetrotm 1.0 0.000143348623853 0 1 -1
administration,of,ellence 1.0 0.000143348623853 0 1 -1
administration,of,either 1.0 0.000143348623853 0 1 -1
administration,of,ect 1.0 0.000143348623853 0 1 -1
administration,of,dynacirc 1.0 0.000286697247706 0 2 -2
administration,of,dmpge2 1.0 0.000143348623853 0 1 -1
administration,of,difluoroacetone 1.0 0.000143348623853 0 1 -1
administration,of,diffusible 1.0 0.000143348623853 0 1 -1
administration,of,different 1.0 0.000143348623853 0 1 -1
administration,of,did 1.0 0.000143348623853 0 1 -1
administration,of,d-penicillamine 1.0 0.000143348623853 0 1 -1
administration,of,colestid 1.0 0.000143348623853 0 1 -1
administration,of,cerebyx 1.0 0.000143348623853 0 1 -1
administration,of,cefotan 1.0 0.000143348623853 0 1 -1
administration,of,camptosar 1.0 0.000143348623853 0 1 -1
administration,of,brevibloc 1.0 0.000143348623853 0 1 -1
administration,of,both 1.0 0.000286697247706 0 2 -2
administration,mg,and 1.0 0.000143348623853 0 1 -1
administration,in,march 1.0 0.000143348623853 0 1 -1
administration,impairs,metabolism 1.0 0.000143348623853 0 1 -1
administration,however,the 1.0 0.000143348623853 0 1 -1
administration,hour,before 1.0 0.000143348623853 0 1 -1
administration,for,days 1.0 0.000286697247706 0 2 -2
administration,even,when 1.0 0.000143348623853 0 1 -1
administration,does,not 1.0 0.000143348623853 0 1 -1
administration,but,these 1.0 0.000143348623853 0 1 -1
administration,at,doses 1.0 0.000143348623853 0 1 -1
administration,appeared,well 1.0 0.000143348623853 0 1 -1
administration,and,the 1.0 0.000143348623853 0 1 -1
administration,and,patients 1.0 0.000143348623853 0 1 -1
administration,affects,expression 1.0 0.000143348623853 0 1 -1
administering,this,to 1.0 0.000143348623853 0 1 -1
administering,taxol,to 1.0 0.000143348623853 0 1 -1
administering,taxol,concomitantly 1.0 0.000143348623853 0 1 -1
administering,other,that 1.0 0.000143348623853 0 1 -1
administering,other,for 1.0 0.000143348623853 0 1 -1
administering,mepron,concurrently 1.0 0.000143348623853 0 1 -1
administering,different,botulinum 1.0 0.000286697247706 0 2 -2
administering,cyp3a4,inhibitors 1.0 0.000143348623853 0 1 -1
administering,compounds,in 1.0 0.000143348623853 0 1 -1
administering,cerebyx,with 1.0 0.000143348623853 0 1 -1
administered,without,any 1.0 0.000143348623853 0 1 -1
administered,with,that 1.0 0.000286697247706 0 2 -2
administered,with,lodine 1.0 0.000143348623853 0 1 -1
administered,with,iron-fortified 1.0 0.000143348623853 0 1 -1
administered,with,g 1.0 0.000143348623853 0 1 -1
administered,with,either 1.0 0.000143348623853 0 1 -1
administered,with,cyp3a4 1.0 0.000143348623853 0 1 -1
administered,with,chirocaine 1.0 0.000143348623853 0 1 -1
administered,with,any 1.0 0.000286697247706 0 2 -2
administered,with,an 1.0 0.000143348623853 0 1 -1
administered,with,a 1.0 0.00043004587156 0 3 -3
administered,weekly,during 1.0 0.000143348623853 0 1 -1
administered,twice,daily 1.0 0.000143348623853 0 1 -1
administered,together,the 1.0 0.000143348623853 0 1 -1
administered,to,treated 1.0 0.000143348623853 0 1 -1
administered,to,or 1.0 0.000143348623853 0 1 -1
administered,to,normal 1.0 0.000143348623853 0 1 -1
administered,to,mice 1.0 0.000143348623853 0 1 -1
administered,to,individuals 1.0 0.000286697247706 0 2 -2
administered,to,hypertensive 1.0 0.000143348623853 0 1 -1
administered,tagamet,to 1.0 0.000143348623853 0 1 -1
administered,starlix,mg 1.0 0.000143348623853 0 1 -1
administered,several,hours 1.0 0.000143348623853 0 1 -1
administered,safely,without 1.0 0.000143348623853 0 1 -1
administered,safely,with 1.0 0.000143348623853 0 1 -1
administered,safely,to 1.0 0.000143348623853 0 1 -1
administered,rapidly,by 1.0 0.000143348623853 0 1 -1
administered,parenterally,special 1.0 0.000286697247706 0 2 -2
administered,over,the 1.0 0.000143348623853 0 1 -1
administered,orally,to 1.0 0.000143348623853 0 1 -1
administered,orally,has 1.0 0.000143348623853 0 1 -1
administered,or,if 1.0 0.000143348623853 0 1 -1
administered,one,mg 1.0 0.000143348623853 0 1 -1
administered,on,day 1.0 0.000143348623853 0 1 -1
administered,on,an 1.0 0.000143348623853 0 1 -1
administered,neonatally,to 1.0 0.000143348623853 0 1 -1
administered,mg,starlix 1.0 0.000143348623853 0 1 -1
administered,mg,orally 1.0 0.000143348623853 0 1 -1
administered,metabolized,by 1.0 0.000143348623853 0 1 -1
administered,iron-fortified,infant 1.0 0.000143348623853 0 1 -1
administered,in,the 1.0 0.000143348623853 0 1 -1
administered,in,single 1.0 0.000143348623853 0 1 -1
administered,in,order 1.0 0.000143348623853 0 1 -1
administered,in,conjunction 1.0 0.000143348623853 0 1 -1
administered,hydrochloride,alone 1.0 0.000143348623853 0 1 -1
administered,highly,protein-bound 1.0 0.000143348623853 0 1 -1
administered,have,also 1.0 0.000143348623853 0 1 -1
administered,following,varying 1.0 0.000143348623853 0 1 -1
administered,enter,the 1.0 0.000143348623853 0 1 -1
administered,during,the 1.0 0.000286697247706 0 2 -2
administered,during,days 1.0 0.000143348623853 0 1 -1
administered,due,to 1.0 0.000143348623853 0 1 -1
administered,dilute,solutions 1.0 0.000143348623853 0 1 -1
administered,did,not 1.0 0.000143348623853 0 1 -1
administered,daily,for 1.0 0.000143348623853 0 1 -1
administered,could,theoretically 1.0 0.000143348623853 0 1 -1
administered,concurrently,without 1.0 0.000143348623853 0 1 -1
administered,concurrently,should 1.0 0.000143348623853 0 1 -1
administered,concomitantly,without 1.0 0.000143348623853 0 1 -1
administered,concomitantly,showed 1.0 0.000143348623853 0 1 -1
administered,concomitantly,prothrombin 1.0 0.000716743119266 0 5 -5
administered,cautiously,and 1.0 0.000143348623853 0 1 -1
administered,by,patients 1.0 0.000143348623853 0 1 -1
administered,but,an 1.0 0.000143348623853 0 1 -1
administered,before,after 1.0 0.000143348623853 0 1 -1
administered,at,either 1.0 0.000143348623853 0 1 -1
administered,at,doses 1.0 0.000143348623853 0 1 -1
administered,as,stadol 1.0 0.000286697247706 0 2 -2
administered,as,oral 1.0 0.000143348623853 0 1 -1
administered,and,the 1.0 0.000143348623853 0 1 -1
administered,alternately,when 1.0 0.000143348623853 0 1 -1
administered,alternately,provided 1.0 0.000143348623853 0 1 -1
administered,agents,should 1.0 0.000143348623853 0 1 -1
administered,after,inhalational 1.0 0.000143348623853 0 1 -1
administered,a,fixed 1.0 0.000143348623853 0 1 -1
adl,mg,or 1.0 0.000143348623853 0 1 -1
adl,mg,and 1.0 0.000143348623853 0 1 -1
adl,and,differed 1.0 0.000143348623853 0 1 -1
adjuvant,trials,of 1.0 0.000143348623853 0 1 -1
adjustments,of,either 1.0 0.000286697247706 0 2 -2
adjustments,of,concomitant 1.0 0.000143348623853 0 1 -1
adjustments,of,brovana 1.0 0.000143348623853 0 1 -1
adjustments,may,be 1.0 0.000143348623853 0 1 -1
adjustments,made,when 1.0 0.000286697247706 0 2 -2
adjustments,are,necessary 1.0 0.000143348623853 0 1 -1
adjustment,when,starting 1.0 0.000286697247706 0 2 -2
adjustment,to,the 1.0 0.000286697247706 0 2 -2
adjustment,or,special 1.0 0.000143348623853 0 1 -1
adjustment,of,sustiva 1.0 0.000143348623853 0 1 -1
adjustment,of,should 1.0 0.000143348623853 0 1 -1
adjustment,of,may 1.0 0.000143348623853 0 1 -1
adjustment,of,either 1.0 0.000286697247706 0 2 -2
adjustment,of,doses 1.0 0.000143348623853 0 1 -1
adjustment,of,dosages 1.0 0.000143348623853 0 1 -1
adjustment,of,concomitant 1.0 0.000143348623853 0 1 -1
adjustment,of,co-administered 1.0 0.000143348623853 0 1 -1
adjustment,of,by 1.0 0.000143348623853 0 1 -1
adjustment,of,antigout 1.0 0.000143348623853 0 1 -1
adjustment,may,be 1.0 0.000286697247706 0 2 -2
adjustment,is,required 1.0 0.00043004587156 0 3 -3
adjustment,is,recommended 1.0 0.000143348623853 0 1 -1
adjustment,is,needed 1.0 0.000143348623853 0 1 -1
adjustment,is,necessary 1.0 0.000143348623853 0 1 -1
adjustment,in,the 1.0 0.000286697247706 0 2 -2
adjustment,in,dose 1.0 0.000143348623853 0 1 -1
adjustment,for,is 1.0 0.000143348623853 0 1 -1
adjustment,for,any 1.0 0.000143348623853 0 1 -1
adjustment,as,appropriate 1.0 0.000143348623853 0 1 -1
adjustment,and,particularly 1.0 0.000286697247706 0 2 -2
adjusted,when,these 1.0 0.000143348623853 0 1 -1
adjusted,in,patients 1.0 0.000143348623853 0 1 -1
adjusted,in,accordance 1.0 0.00043004587156 0 3 -3
adjust,dosage,of 1.0 0.000143348623853 0 1 -1
adjust,dosage,accordingly 1.0 0.000143348623853 0 1 -1
adequately,studied,and 1.0 0.000143348623853 0 1 -1
adequately,evaluated,in 1.0 0.000143348623853 0 1 -1
adequate,respiratory,exchange 1.0 0.000143348623853 0 1 -1
adequate,period,of 1.0 0.000143348623853 0 1 -1
adequate,methods,of 1.0 0.000143348623853 0 1 -1
adequate,evidence,on 1.0 0.000143348623853 0 1 -1
adequate,dosage,replacement 1.0 0.000143348623853 0 1 -1
adequate,degree,of 1.0 0.000143348623853 0 1 -1
adequate,and,well-controlled 1.0 0.000573394495413 0 4 -4
adequacy,of,the 1.0 0.000143348623853 0 1 -1
adenylate,cyclase,activity 1.0 0.000143348623853 0 1 -1
adenosine,cyclic,in 1.0 0.000143348623853 0 1 -1
adenocard,should,be 1.0 0.000143348623853 0 1 -1
adenocard,has,been 1.0 0.000143348623853 0 1 -1
adefovir,dipivoxil,or 1.0 0.000143348623853 0 1 -1
adds,to,the 1.0 0.000143348623853 0 1 -1
addressing,information,to 1.0 0.000143348623853 0 1 -1
additive,when,was 1.0 0.000143348623853 0 1 -1
additive,when,the 1.0 0.000143348623853 0 1 -1
additive,vasodilator,properties 1.0 0.000143348623853 0 1 -1
additive,toxicity,especially 1.0 0.000143348623853 0 1 -1
additive,potentiation,synergistic 1.0 0.000143348623853 0 1 -1
additive,pharmacodynamic,effect 1.0 0.000143348623853 0 1 -1
additive,or,synergistic 1.0 0.000143348623853 0 1 -1
additive,ocular,and 1.0 0.000143348623853 0 1 -1
additive,inotropic,and 1.0 0.000143348623853 0 1 -1
additive,effects,caution 1.0 0.000143348623853 0 1 -1
additive,depressant,effect 1.0 0.000143348623853 0 1 -1
additive,and,nonadditive 1.0 0.000143348623853 0 1 -1
additionally,there,is 1.0 0.000143348623853 0 1 -1
additionally,is,a 1.0 0.000143348623853 0 1 -1
additionally,did,not 1.0 0.000143348623853 0 1 -1
additionally,and,did 1.0 0.000143348623853 0 1 -1
additional,therapy,the 1.0 0.000143348623853 0 1 -1
additional,that,are 1.0 0.000143348623853 0 1 -1
additional,stimulus,of 1.0 0.000143348623853 0 1 -1
additional,research,is 1.0 0.000143348623853 0 1 -1
additional,pharmacokinetic,studies 1.0 0.000143348623853 0 1 -1
additional,patients,who 1.0 0.000143348623853 0 1 -1
additional,methods,of 1.0 0.000143348623853 0 1 -1
additional,method,of 1.0 0.000143348623853 0 1 -1
additional,measures,should 1.0 0.000143348623853 0 1 -1
additional,interaction,studies 1.0 0.000286697247706 0 2 -2
additional,dose,increases 1.0 0.000143348623853 0 1 -1
additional,concomitant,medications 1.0 0.000143348623853 0 1 -1
additional,clinical,monitoring 1.0 0.000143348623853 0 1 -1
additional,clinical,experience 1.0 0.000143348623853 0 1 -1
additional,caution,in 1.0 0.000143348623853 0 1 -1
additional,calcium-containing,preparations 1.0 0.00043004587156 0 3 -3
additional,at,three 1.0 0.000143348623853 0 1 -1
additional,animals,in 1.0 0.000143348623853 0 1 -1
addition,we,have 1.0 0.000143348623853 0 1 -1
addition,under,the 1.0 0.000286697247706 0 2 -2
addition,to,the 1.0 0.000143348623853 0 1 -1
addition,to,its 1.0 0.000143348623853 0 1 -1
addition,to,established 1.0 0.000143348623853 0 1 -1
addition,there,was 1.0 0.000143348623853 0 1 -1
addition,the,use 1.0 0.000143348623853 0 1 -1
addition,the,transfusion 1.0 0.000143348623853 0 1 -1
addition,the,frequency 1.0 0.000143348623853 0 1 -1
addition,the,atropine-like 1.0 0.000143348623853 0 1 -1
addition,studies,in 1.0 0.000143348623853 0 1 -1
addition,steady,state 1.0 0.000143348623853 0 1 -1
addition,several,cardiovascular 1.0 0.000143348623853 0 1 -1
addition,reduced,kidney 1.0 0.000143348623853 0 1 -1
addition,patients,taking 1.0 0.000143348623853 0 1 -1
addition,or,deletion 1.0 0.000143348623853 0 1 -1
addition,of,is 1.0 0.000143348623853 0 1 -1
addition,of,in 1.0 0.000143348623853 0 1 -1
addition,of,given 1.0 0.000143348623853 0 1 -1
addition,of,a 1.0 0.000143348623853 0 1 -1
addition,new,cases 1.0 0.000286697247706 0 2 -2
addition,neuromuscular,blocking 1.0 0.000143348623853 0 1 -1
addition,is,not 1.0 0.000143348623853 0 1 -1
addition,fondaparinux,neither 1.0 0.000143348623853 0 1 -1
addition,does,not 1.0 0.000143348623853 0 1 -1
addition,certain,that 1.0 0.000286697247706 0 2 -2
addition,certain,inhibit 1.0 0.000716743119266 0 5 -5
addition,based,on 1.0 0.000143348623853 0 1 -1
addition,and,mhd 1.0 0.000143348623853 0 1 -1
addition,administration,to 1.0 0.000143348623853 0 1 -1
addition,administration,of 1.0 0.000143348623853 0 1 -1
addicts,was,especially 1.0 0.000143348623853 0 1 -1
addicts,vs,logs 1.0 0.000143348623853 0 1 -1
addicts,in,areas 1.0 0.000143348623853 0 1 -1
addictive,medications,especially 1.0 0.000143348623853 0 1 -1
addiction,while,they 1.0 0.000143348623853 0 1 -1
addiction,research,center 1.0 0.000143348623853 0 1 -1
addiction,is,defined 1.0 0.000143348623853 0 1 -1
addiction,after,withdrawal 1.0 0.000143348623853 0 1 -1
added,to,triple-immunosuppression 1.0 0.000143348623853 0 1 -1
added,to,their 1.0 0.000143348623853 0 1 -1
added,to,pooled 1.0 0.000143348623853 0 1 -1
added,to,other 1.0 0.000143348623853 0 1 -1
added,to,human 1.0 0.000143348623853 0 1 -1
added,one,additional 1.0 0.000143348623853 0 1 -1
added,in,the 1.0 0.000143348623853 0 1 -1
added,in,and 1.0 0.000143348623853 0 1 -1
added,drug,should 1.0 0.000143348623853 0 1 -1
added,drug,combinations 1.0 0.000143348623853 0 1 -1
added,concentration,which 1.0 0.000143348623853 0 1 -1
added,cholesterol,the 1.0 0.000143348623853 0 1 -1
added,as,well 1.0 0.000143348623853 0 1 -1
adaptive,value,abstract 1.0 0.000143348623853 0 1 -1
adapting,of,diet 1.0 0.000143348623853 0 1 -1
adapter,protein,involved 1.0 0.000143348623853 0 1 -1
aczone,gel,in 1.0 0.000143348623853 0 1 -1
acute,toxicity,was 1.0 0.000143348623853 0 1 -1
acute,toxicity,tests 1.0 0.000143348623853 0 1 -1
acute,toxicity,and 1.0 0.000143348623853 0 1 -1
acute,symptoms,should 1.0 0.000143348623853 0 1 -1
acute,release,or 1.0 0.000143348623853 0 1 -1
acute,pretreatment,on 1.0 0.000143348623853 0 1 -1
acute,phase,schizophrenia 1.0 0.000143348623853 0 1 -1
acute,phase,and 1.0 0.000143348623853 0 1 -1
acute,pharmacological,i 1.0 0.000143348623853 0 1 -1
acute,myocardial,infarction 1.0 0.000143348623853 0 1 -1
acute,ischemic,stroke 1.0 0.000143348623853 0 1 -1
acute,increase,in 1.0 0.000143348623853 0 1 -1
acute,ergot,toxicity 1.0 0.000143348623853 0 1 -1
acute,episode,despite 1.0 0.000143348623853 0 1 -1
acute,effect,of 1.0 0.000143348623853 0 1 -1
acute,dosing,with 1.0 0.000286697247706 0 2 -2
acute,asthma,or 1.0 0.000143348623853 0 1 -1
acute,angina,attacks 1.0 0.000143348623853 0 1 -1
acute,and,repeated 1.0 0.000143348623853 0 1 -1
acute,administration,does 1.0 0.000143348623853 0 1 -1
acumen,but,also 1.0 0.000143348623853 0 1 -1
actually,produced,enhanced 1.0 0.000143348623853 0 1 -1
activity-regulated,cytoskeleton-associated,that 1.0 0.000143348623853 0 1 -1
activity,would,be 1.0 0.000143348623853 0 1 -1
activity,while,on 1.0 0.000143348623853 0 1 -1
activity,which,increased 1.0 0.000143348623853 0 1 -1
activity,was,observed 1.0 0.000143348623853 0 1 -1
activity,was,noted 1.0 0.000143348623853 0 1 -1
activity,was,expressed 1.0 0.000143348623853 0 1 -1
activity,was,enhanced 1.0 0.000143348623853 0 1 -1
activity,to,pi-based 1.0 0.000143348623853 0 1 -1
activity,they,should 1.0 0.000143348623853 0 1 -1
activity,the,sympathetic 1.0 0.000143348623853 0 1 -1
activity,than,that 1.0 0.000143348623853 0 1 -1
activity,predominantly,in 1.0 0.000143348623853 0 1 -1
activity,preclinical,researchers 1.0 0.000143348623853 0 1 -1
activity,pra,as 1.0 0.000143348623853 0 1 -1
activity,of,within 1.0 0.000143348623853 0 1 -1
activity,of,this 1.0 0.00100344036697 0 7 -7
activity,of,these 1.0 0.000143348623853 0 1 -1
activity,of,the 1.0 0.00114678899083 0 8 -8
activity,of,mixed-function 1.0 0.000143348623853 0 1 -1
activity,of,low-dose 1.0 0.000143348623853 0 1 -1
activity,of,liver 1.0 0.000143348623853 0 1 -1
activity,of,krm-1648 1.0 0.000143348623853 0 1 -1
activity,of,gl 1.0 0.000286697247706 0 2 -2
activity,of,ganoderma 1.0 0.000143348623853 0 1 -1
activity,of,four 1.0 0.000143348623853 0 1 -1
activity,of,desmopressin 1.0 0.000143348623853 0 1 -1
activity,of,cytochrome 1.0 0.000143348623853 0 1 -1
activity,of,clostridium 1.0 0.000143348623853 0 1 -1
activity,of,certain 1.0 0.000286697247706 0 2 -2
activity,of,buforin 1.0 0.000286697247706 0 2 -2
activity,may,reduce 1.0 0.000143348623853 0 1 -1
activity,may,increase 1.0 0.000143348623853 0 1 -1
activity,may,decrease 1.0 0.000286697247706 0 2 -2
activity,may,also 1.0 0.000143348623853 0 1 -1
activity,level,is 1.0 0.000143348623853 0 1 -1
activity,large,doses 1.0 0.000143348623853 0 1 -1
activity,ix,x 1.0 0.000286697247706 0 2 -2
activity,is,not 1.0 0.000143348623853 0 1 -1
activity,is,in 1.0 0.000143348623853 0 1 -1
activity,is,desired 1.0 0.000143348623853 0 1 -1
activity,induced,by 1.0 0.000143348623853 0 1 -1
activity,increase,the 1.0 0.000143348623853 0 1 -1
activity,in,association 1.0 0.000143348623853 0 1 -1
activity,in,arteries 1.0 0.000143348623853 0 1 -1
activity,in,a 1.0 0.000143348623853 0 1 -1
activity,however,did 1.0 0.000143348623853 0 1 -1
activity,has,been 1.0 0.000143348623853 0 1 -1
activity,ganglionic,blocking 1.0 0.000143348623853 0 1 -1
activity,for,the 1.0 0.000143348623853 0 1 -1
activity,enough,to 1.0 0.000143348623853 0 1 -1
activity,data,on 1.0 0.000143348623853 0 1 -1
activity,but,in 1.0 0.000143348623853 0 1 -1
activity,but,given 1.0 0.000143348623853 0 1 -1
activity,because,of 1.0 0.000143348623853 0 1 -1
activity,based,on 1.0 0.000143348623853 0 1 -1
activity,at,similar 1.0 0.000143348623853 0 1 -1
activity,are,associated 1.0 0.000143348623853 0 1 -1
activity,and,to 1.0 0.000143348623853 0 1 -1
activity,and,the 1.0 0.000143348623853 0 1 -1
activity,and,it 1.0 0.000143348623853 0 1 -1
activity,and,activity 1.0 0.000143348623853 0 1 -1
activity,among,asian 1.0 0.000716743119266 0 5 -5
activity,against,mycobacteriumavium-intracellulare 1.0 0.000143348623853 0 1 -1
activity,against,hepatic 1.0 0.000143348623853 0 1 -1
activity,against,gram-negative 1.0 0.000143348623853 0 1 -1
activity,acute,toxicity 1.0 0.000143348623853 0 1 -1
activities,such,as 1.0 0.000143348623853 0 1 -1
activities,similar,to 1.0 0.000143348623853 0 1 -1
activities,requiring,complete 1.0 0.000143348623853 0 1 -1
activities,of,the 1.0 0.000143348623853 0 1 -1
activities,and,increased 1.0 0.000143348623853 0 1 -1
actively,concentrating,as 1.0 0.000143348623853 0 1 -1
active,when,it 1.0 0.000143348623853 0 1 -1
active,triphosphate,metabolite 1.0 0.000143348623853 0 1 -1
active,therapy,in 1.0 0.000143348623853 0 1 -1
active,therapy,haart 1.0 0.000143348623853 0 1 -1
active,suggesting,that 1.0 0.000143348623853 0 1 -1
active,s-isomer,and 1.0 0.000143348623853 0 1 -1
active,renal,secretion 1.0 0.000143348623853 0 1 -1
active,monohydroxy,metabolite 1.0 0.000143348623853 0 1 -1
active,metabolites,were 1.0 0.000143348623853 0 1 -1
active,metabolites,or 1.0 0.000143348623853 0 1 -1
active,metabolite,of 1.0 0.000286697247706 0 2 -2
active,metabolite,norfluoxe-tine 1.0 0.000143348623853 0 1 -1
active,metabolite,is 1.0 0.000143348623853 0 1 -1
active,metabolite,have 1.0 0.000143348623853 0 1 -1
active,metabolite,has 1.0 0.000143348623853 0 1 -1
active,metabolite,formation 1.0 0.000143348623853 0 1 -1
active,metabolite,averaged 1.0 0.000143348623853 0 1 -1
active,metabolite,after 1.0 0.000143348623853 0 1 -1
active,epoxide,which 1.0 0.000143348623853 0 1 -1
active,dose,of 1.0 0.000143348623853 0 1 -1
activator,of,human 1.0 0.000143348623853 0 1 -1
activator,binding,domain 1.0 0.000143348623853 0 1 -1
activation,of,vitamin-d 1.0 0.000143348623853 0 1 -1
activation,of,these 1.0 0.000143348623853 0 1 -1
activation,of,several 1.0 0.000143348623853 0 1 -1
activation,of,nmda 1.0 0.000143348623853 0 1 -1
activation,of,different 1.0 0.000286697247706 0 2 -2
activation,of,caspase-3 1.0 0.000143348623853 0 1 -1
activation,of,arc 1.0 0.000143348623853 0 1 -1
activation,of,an 1.0 0.000143348623853 0 1 -1
activation,in,vitro 1.0 0.000143348623853 0 1 -1
activation,factor,bacterial 1.0 0.000143348623853 0 1 -1
activation,and,that 1.0 0.000143348623853 0 1 -1
activation,and,release 1.0 0.000143348623853 0 1 -1
activated,the,ca 1.0 0.000143348623853 0 1 -1
activated,prothrombin,complex 1.0 0.000143348623853 0 1 -1
activated,during,photic 1.0 0.000143348623853 0 1 -1
activate,the,renin-angiotensin 1.0 0.000143348623853 0 1 -1
activase,with,other 1.0 0.000143348623853 0 1 -1
activase,may,cause 1.0 0.000143348623853 0 1 -1
activase,in,the 1.0 0.000143348623853 0 1 -1
activase,for,the 1.0 0.000143348623853 0 1 -1
actions,via,the 1.0 0.000143348623853 0 1 -1
actions,that,do 1.0 0.000143348623853 0 1 -1
actions,or,side 1.0 0.000143348623853 0 1 -1
actions,of,some 1.0 0.000143348623853 0 1 -1
actions,of,ophthalmic 1.0 0.000143348623853 0 1 -1
actions,of,intrathecal 1.0 0.000143348623853 0 1 -1
actions,desirable,or 1.0 0.000286697247706 0 2 -2
actions,and,will 1.0 0.000143348623853 0 1 -1
actions,and,the 1.0 0.000143348623853 0 1 -1
actions,after,missing 1.0 0.000143348623853 0 1 -1
action,which,may 1.0 0.000143348623853 0 1 -1
action,should,be 1.0 0.000143348623853 0 1 -1
action,potentials,with 1.0 0.000143348623853 0 1 -1
action,or,elimination 1.0 0.000143348623853 0 1 -1
action,or,dosing 1.0 0.000143348623853 0 1 -1
action,on,smooth 1.0 0.000143348623853 0 1 -1
action,of,suggested 1.0 0.000143348623853 0 1 -1
action,of,rr 1.0 0.000143348623853 0 1 -1
action,of,ptx 1.0 0.000143348623853 0 1 -1
action,of,oleate 1.0 0.000143348623853 0 1 -1
action,of,fatty 1.0 0.000143348623853 0 1 -1
action,of,effect 1.0 0.000143348623853 0 1 -1
action,of,are 1.0 0.000143348623853 0 1 -1
action,of,alfenta 1.0 0.000143348623853 0 1 -1
action,of,after 1.0 0.000143348623853 0 1 -1
action,may,bring 1.0 0.000143348623853 0 1 -1
action,is,enhanced 1.0 0.000143348623853 0 1 -1
action,independent,of 1.0 0.000143348623853 0 1 -1
action,in,reversing 1.0 0.000143348623853 0 1 -1
action,ija,models 1.0 0.000143348623853 0 1 -1
action,data,including 1.0 0.000143348623853 0 1 -1
action,are,frequently 1.0 0.000143348623853 0 1 -1
acting,on,the 1.0 0.000286697247706 0 2 -2
acting,nitrates,nifedipine 1.0 0.000143348623853 0 1 -1
acting,including,those 1.0 0.000143348623853 0 1 -1
acting,drugs,given 1.0 0.000143348623853 0 1 -1
acth,treatment,of 1.0 0.000143348623853 0 1 -1
acth,intensified,electrolyte 1.0 0.000286697247706 0 2 -2
acth,induced,hypertension 1.0 0.000286697247706 0 2 -2
act,of,unprotected 1.0 0.000143348623853 0 1 -1
across,all,species 1.0 0.000143348623853 0 1 -1
across,a,wide 1.0 0.000143348623853 0 1 -1
acromegaly,and,after 1.0 0.000143348623853 0 1 -1
acr,criteria,for 1.0 0.000143348623853 0 1 -1
acquisition,of,tasks 1.0 0.000143348623853 0 1 -1
acquisition,of,goal-directed 1.0 0.000143348623853 0 1 -1
acquisition,cost,of 1.0 0.000143348623853 0 1 -1
acquisition,after,day 1.0 0.000143348623853 0 1 -1
acquired,immunodeficiencies,including 1.0 0.000143348623853 0 1 -1
acquired,behavioral,response 1.0 0.000143348623853 0 1 -1
acquainted,with,the 1.0 0.000143348623853 0 1 -1
acne,transient,elevations 1.0 0.000143348623853 0 1 -1
acinar,cells,rr 1.0 0.000143348623853 0 1 -1
acids,proteins,and 1.0 0.000143348623853 0 1 -1
acids,or,other 1.0 0.000143348623853 0 1 -1
acids,may,interfere 1.0 0.000143348623853 0 1 -1
acids,and,enable 1.0 0.000143348623853 0 1 -1
acidosis,have,been 1.0 0.000143348623853 0 1 -1
acidity,duloxetine,has 1.0 0.000143348623853 0 1 -1
acidity,does,not 1.0 0.000143348623853 0 1 -1
acidified,in,vitro 1.0 0.000143348623853 0 1 -1
acidic,conditions,duloxetine 1.0 0.000143348623853 0 1 -1
acid-catalyzed,ethanol-drug,reaction 1.0 0.000143348623853 0 1 -1
acid-base,balance,in 1.0 0.000143348623853 0 1 -1
acid,will,not 1.0 0.000143348623853 0 1 -1
acid,when,measured 1.0 0.000143348623853 0 1 -1
acid,were,not 1.0 0.000143348623853 0 1 -1
acid,were,added 1.0 0.000143348623853 0 1 -1
acid,the,mean 1.0 0.000143348623853 0 1 -1
acid,sympathomimet-ics,channel 1.0 0.000143348623853 0 1 -1
acid,supplements,can 1.0 0.000143348623853 0 1 -1
acid,should,not 1.0 0.000143348623853 0 1 -1
acid,sequestrants,have 1.0 0.000143348623853 0 1 -1
acid,secretion,stimulated 1.0 0.000143348623853 0 1 -1
acid,secretion,in 1.0 0.000143348623853 0 1 -1
acid,secretion,are 1.0 0.000143348623853 0 1 -1
acid,sali-cylates,nsaids 1.0 0.000143348623853 0 1 -1
acid,reactive,substances 1.0 0.000143348623853 0 1 -1
acid,precipitation,procedure 1.0 0.000143348623853 0 1 -1
acid,nsaids,and 1.0 0.000143348623853 0 1 -1
acid,metabolite,of 1.0 0.000286697247706 0 2 -2
acid,metabolite,and 1.0 0.000143348623853 0 1 -1
acid,metabolism,could 1.0 0.000143348623853 0 1 -1
acid,metabolism,are 1.0 0.000143348623853 0 1 -1
acid,may,be 1.0 0.000143348623853 0 1 -1
acid,levels,may 1.0 0.000143348623853 0 1 -1
acid,itself,was 1.0 0.000143348623853 0 1 -1
acid,indicating,no 1.0 0.000143348623853 0 1 -1
acid,in,the 1.0 0.000143348623853 0 1 -1
acid,in,combination 1.0 0.000143348623853 0 1 -1
acid,from,membrane 1.0 0.000143348623853 0 1 -1
acid,from,masking 1.0 0.000143348623853 0 1 -1
acid,for,these 1.0 0.000143348623853 0 1 -1
acid,erythromycin,azole 1.0 0.000143348623853 0 1 -1
acid,did,not 1.0 0.000143348623853 0 1 -1
acid,derivatives,nicotinic 1.0 0.000143348623853 0 1 -1
acid,derivatives,niacin 1.0 0.000143348623853 0 1 -1
acid,depakene,use 1.0 0.000143348623853 0 1 -1
acid,concentrations,prior 1.0 0.000143348623853 0 1 -1
acid,calcium,channel-blocking 1.0 0.000143348623853 0 1 -1
acid,are,not 1.0 0.000143348623853 0 1 -1
acid,and,vitamin 1.0 0.000143348623853 0 1 -1
acid,and,these 1.0 0.000143348623853 0 1 -1
acid,and,then 1.0 0.000143348623853 0 1 -1
acid,and,the 1.0 0.000143348623853 0 1 -1
acid,and,showed 1.0 0.000143348623853 0 1 -1
acid,and,related 1.0 0.000143348623853 0 1 -1
acid,and,nor 1.0 0.000143348623853 0 1 -1
acid,and,b12 1.0 0.000143348623853 0 1 -1
acid,aminocaproic,acid 1.0 0.000143348623853 0 1 -1
acid,although,many 1.0 0.000143348623853 0 1 -1
acid,a-blockers,angiotensin-converting 1.0 0.000143348623853 0 1 -1
achlorhydria,and,those 1.0 0.000143348623853 0 1 -1
achieving,a,maximum 1.0 0.000143348623853 0 1 -1
achieves,a,highest 1.0 0.000143348623853 0 1 -1
achieved,within,the 1.0 0.000143348623853 0 1 -1
achieved,with,biocytin 1.0 0.000143348623853 0 1 -1
achieved,steady-state,blood 1.0 0.000143348623853 0 1 -1
achieved,indicating,that 1.0 0.000143348623853 0 1 -1
achieved,in,women 1.0 0.000143348623853 0 1 -1
achieved,in,adequate 1.0 0.000143348623853 0 1 -1
achieved,either,by 1.0 0.000143348623853 0 1 -1
achieve,or,maintain 1.0 0.000143348623853 0 1 -1
achieve,and,sustain 1.0 0.000143348623853 0 1 -1
acetylsalicylic,acid,sali-cylates 1.0 0.000143348623853 0 1 -1
acetylsalicylic,acid,nsaids 1.0 0.000143348623853 0 1 -1
acetylsalicylic,acid,did 1.0 0.000143348623853 0 1 -1
acetylsalicylic,acid,a-blockers 1.0 0.000143348623853 0 1 -1
acetylcysteine,interference,with 1.0 0.000143348623853 0 1 -1
acetate,were,inconclusive 1.0 0.000143348623853 0 1 -1
acetate,is,not 1.0 0.000143348623853 0 1 -1
acetate,is,a 1.0 0.000143348623853 0 1 -1
acetate,and,mcg 1.0 0.000143348623853 0 1 -1
acetaminophen,pharmacokinetic,or 1.0 0.000143348623853 0 1 -1
acetaminophen,may,produce 1.0 0.000143348623853 0 1 -1
acetaminophen,had,no 1.0 0.000143348623853 0 1 -1
acetaminophen,and,valproic 1.0 0.000143348623853 0 1 -1
acebutolol,and,low 1.0 0.000143348623853 0 1 -1
ace,inhibitors,oral 1.0 0.000143348623853 0 1 -1
ace,inhibitors,or 1.0 0.000143348623853 0 1 -1
ace,inhibitors,monoamine 1.0 0.000143348623853 0 1 -1
ace,inhibitors,mao 1.0 0.000143348623853 0 1 -1
ace,inhibitors,concomitant 1.0 0.000143348623853 0 1 -1
ace,inhibitors,calcium-channel 1.0 0.000143348623853 0 1 -1
ace,inhibitors,beta 1.0 0.000143348623853 0 1 -1
accutane,use,is 1.0 0.000143348623853 0 1 -1
accutane,therapy,have 1.0 0.000143348623853 0 1 -1
accutane,therapy,although 1.0 0.000143348623853 0 1 -1
accutane,have,experienced 1.0 0.000143348623853 0 1 -1
accutane,has,not 1.0 0.000143348623853 0 1 -1
accumulation,that,might 1.0 0.000143348623853 0 1 -1
accumulation,of,exposure 1.0 0.000143348623853 0 1 -1
accumulation,of,body 1.0 0.000143348623853 0 1 -1
accumulation,of,as 1.0 0.000286697247706 0 2 -2
accumulation,characteristic,of 1.0 0.000143348623853 0 1 -1
accumbens,nac,for 1.0 0.000143348623853 0 1 -1
accumbens,but,only 1.0 0.000143348623853 0 1 -1
accounts,for,less 1.0 0.000143348623853 0 1 -1
account,when,evaluating 1.0 0.000143348623853 0 1 -1
account,variations,of 1.0 0.000143348623853 0 1 -1
account,the,importance 1.0 0.000286697247706 0 2 -2
account,for,proper 1.0 0.000143348623853 0 1 -1
account,for,only 1.0 0.000143348623853 0 1 -1
accordingly,renal,function 1.0 0.000143348623853 0 1 -1
accordingly,if,effect 1.0 0.000143348623853 0 1 -1
according,to,gibaldi 1.0 0.000143348623853 0 1 -1
according,to,a 1.0 0.000143348623853 0 1 -1
accordance,with,the 1.0 0.00043004587156 0 3 -3
accordance,with,standard 1.0 0.000143348623853 0 1 -1
accomplished,through,redundancy 1.0 0.000143348623853 0 1 -1
accompanied,by,similar 1.0 0.000143348623853 0 1 -1
accompanied,by,profound 1.0 0.000143348623853 0 1 -1
accompanied,by,ecg 1.0 0.000143348623853 0 1 -1
accompanied,by,detailed 1.0 0.000143348623853 0 1 -1
accompanied,by,both 1.0 0.000143348623853 0 1 -1
accidents,six,sudden 1.0 0.000143348623853 0 1 -1
accidental,contact,and 1.0 0.000143348623853 0 1 -1
access,distribution,pathways 1.0 0.000143348623853 0 1 -1
acceptable,alternatives,to 1.0 0.000143348623853 0 1 -1
acceleration,of,gastric 1.0 0.000143348623853 0 1 -1
accelerated,prothrombin,time 1.0 0.000286697247706 0 2 -2
accelerate,the,metabolism 1.0 0.000143348623853 0 1 -1
acarbose,was,bioequivalent 1.0 0.000143348623853 0 1 -1
acarbose,the,patient 1.0 0.000143348623853 0 1 -1
acarbose,may,affect 1.0 0.000143348623853 0 1 -1
acarbose,in,combination 1.0 0.000143348623853 0 1 -1
acarbose,has,no 1.0 0.000143348623853 0 1 -1
acarbose,did,not 1.0 0.000143348623853 0 1 -1
acanthus,obtained,from 1.0 0.000143348623853 0 1 -1
acamprosate,does,not 1.0 0.000143348623853 0 1 -1
abuse,of,this 1.0 0.000143348623853 0 1 -1
abundance,and,wide 1.0 0.000143348623853 0 1 -1
abstracts,using,the 1.0 0.000143348623853 0 1 -1
abstinence,is,the 1.0 0.000143348623853 0 1 -1
absorption,site,fecal 1.0 0.000143348623853 0 1 -1
absorption,results,in 1.0 0.000143348623853 0 1 -1
absorption,or,its 1.0 0.000143348623853 0 1 -1
absorption,or,disposition 1.0 0.000143348623853 0 1 -1
absorption,or,by 1.0 0.000143348623853 0 1 -1
absorption,of,was 1.0 0.000143348623853 0 1 -1
absorption,of,other 1.0 0.000143348623853 0 1 -1
absorption,of,any 1.0 0.00043004587156 0 3 -3
absorption,of,also 1.0 0.000143348623853 0 1 -1
absorption,of,administered 1.0 0.000143348623853 0 1 -1
absorption,metabolism,and 1.0 0.000143348623853 0 1 -1
absorption,is,sensitive 1.0 0.000143348623853 0 1 -1
absorption,has,not 1.0 0.000143348623853 0 1 -1
absorption,excessive,fecal 1.0 0.000143348623853 0 1 -1
absorption,but,had 1.0 0.000143348623853 0 1 -1
absorption,as,well 1.0 0.000143348623853 0 1 -1
absorption,and,thus 1.0 0.000143348623853 0 1 -1
absorption,after,administration 1.0 0.000143348623853 0 1 -1
absorbing,materials,amino 1.0 0.000143348623853 0 1 -1
absorbed,while,taking 1.0 0.000143348623853 0 1 -1
absorbed,when,taking 1.0 0.000143348623853 0 1 -1
absorbed,is,unaffected 1.0 0.000143348623853 0 1 -1
absorbed,from,the 1.0 0.000143348623853 0 1 -1
absolute,number,of 1.0 0.000143348623853 0 1 -1
absolute,in,a 1.0 0.000143348623853 0 1 -1
absolute,but,a 1.0 0.000143348623853 0 1 -1
absolute,abstinence,is 1.0 0.000143348623853 0 1 -1
absence,of,severe 1.0 0.000143348623853 0 1 -1
absence,of,serious 1.0 0.000143348623853 0 1 -1
absence,of,other 1.0 0.000143348623853 0 1 -1
absence,of,or 1.0 0.000143348623853 0 1 -1
absence,of,kidney 1.0 0.000143348623853 0 1 -1
absence,of,formal 1.0 0.000143348623853 0 1 -1
absence,of,did 1.0 0.000143348623853 0 1 -1
absence,of,a 1.0 0.000143348623853 0 1 -1
abruptly,toxic,when 1.0 0.000716743119266 0 5 -5
abruptly,discontinued,increase 1.0 0.000143348623853 0 1 -1
abrasive,soaps,and 1.0 0.000143348623853 0 1 -1
above,this,study 1.0 0.000143348623853 0 1 -1
above,the,usual 1.0 0.000143348623853 0 1 -1
above,or,suspected 1.0 0.000143348623853 0 1 -1
above,or,herbs 1.0 0.000143348623853 0 1 -1
above,listed,agents 1.0 0.000143348623853 0 1 -1
above,findings,are 1.0 0.000143348623853 0 1 -1
above,experiments,we 1.0 0.000143348623853 0 1 -1
above,data,from 1.0 0.000143348623853 0 1 -1
above,cmax,levels 1.0 0.000143348623853 0 1 -1
above,chronic,weeks 1.0 0.000143348623853 0 1 -1
above,behavioral,changes 1.0 0.000143348623853 0 1 -1
above,and,other 1.0 0.000143348623853 0 1 -1
about,to,of 1.0 0.000286697247706 0 2 -2
about,times,the 1.0 0.000143348623853 0 1 -1
about,times,more 1.0 0.000143348623853 0 1 -1
about,times,higher 1.0 0.000286697247706 0 2 -2
about,three-fold,compared 1.0 0.000143348623853 0 1 -1
about,three,weeks 1.0 0.000143348623853 0 1 -1
about,the,use 1.0 0.000286697247706 0 2 -2
about,possible,dosage 1.0 0.000143348623853 0 1 -1
about,one-half,the 1.0 0.000143348623853 0 1 -1
about,of,that 1.0 0.000143348623853 0 1 -1
about,of,patients 1.0 0.000143348623853 0 1 -1
about,of,caucasians 1.0 0.00043004587156 0 3 -3
about,fold,prolongation 1.0 0.000143348623853 0 1 -1
about,fold,greater 1.0 0.000143348623853 0 1 -1
about,but,caused 1.0 0.000143348623853 0 1 -1
about,bound,to 1.0 0.000143348623853 0 1 -1
about,and,use 1.0 0.000143348623853 0 1 -1
abortifacient,or,teratogenic 1.0 0.000143348623853 0 1 -1
abolishes,the,activity 1.0 0.000143348623853 0 1 -1
abolished,the,cold 1.0 0.000143348623853 0 1 -1
abolished,both,its 1.0 0.000143348623853 0 1 -1
abnormalities,were,identified 1.0 0.000143348623853 0 1 -1
abnormalities,related,to 1.0 0.000143348623853 0 1 -1
abnormalities,in,rats 1.0 0.000143348623853 0 1 -1
abnormalities,in,platelet 1.0 0.000143348623853 0 1 -1
abnormalities,has,been 1.0 0.000143348623853 0 1 -1
abnormalities,also,see 1.0 0.000143348623853 0 1 -1
abnormal,topoisomerase,quantity 1.0 0.000143348623853 0 1 -1
abnormal,laboratory,results 1.0 0.000143348623853 0 1 -1
abnormal,in,a 1.0 0.000143348623853 0 1 -1
abnormal,handling,of 1.0 0.000143348623853 0 1 -1
abnormal,bleeding,and 1.0 0.000143348623853 0 1 -1
ability,to,use 1.0 0.000143348623853 0 1 -1
ability,to,control 1.0 0.000143348623853 0 1 -1
ability,to,affect 1.0 0.000143348623853 0 1 -1
ability,of,the 1.0 0.000143348623853 0 1 -1
ability,of,gene 1.0 0.000143348623853 0 1 -1
abilify,to,affect 1.0 0.000143348623853 0 1 -1
abilify,aripiprazole,is 1.0 0.000143348623853 0 1 -1
aberration,assay,in 1.0 0.000143348623853 0 1 -1
aberrant,and,chronic 1.0 0.000143348623853 0 1 -1
abdominal,symptoms,appear 1.0 0.000143348623853 0 1 -1
abdominal,pain,vomiting 1.0 0.000143348623853 0 1 -1
abdominal,irradiation,are 1.0 0.000143348623853 0 1 -1
abciximab,have,not 1.0 0.000143348623853 0 1 -1
abciximab,has,been 1.0 0.000143348623853 0 1 -1
a6,or,the 1.0 0.000143348623853 0 1 -1
a6,c9,d6 1.0 0.000143348623853 0 1 -1
a6,c9,c19 1.0 0.000286697247706 0 2 -2
a6,b6,d6 1.0 0.000143348623853 0 1 -1
a6,and,e1 1.0 0.000143348623853 0 1 -1
a4,were,not 1.0 0.000143348623853 0 1 -1
a4,were,found 1.0 0.000143348623853 0 1 -1
a4,to,the 1.0 0.000143348623853 0 1 -1
a4,substrate,and 1.0 0.000143348623853 0 1 -1
a4,should,be 1.0 0.000143348623853 0 1 -1
a4,may,increase 1.0 0.000143348623853 0 1 -1
a4,may,affect 1.0 0.000143348623853 0 1 -1
a4,isozymes,in 1.0 0.000143348623853 0 1 -1
a4,isozyme,which 1.0 0.000143348623853 0 1 -1
a4,isoenzyme,system 1.0 0.000143348623853 0 1 -1
a4,inhibitors,on 1.0 0.000143348623853 0 1 -1
a4,inhibitors,may 1.0 0.000143348623853 0 1 -1
a4,inhibitors,elevated 1.0 0.000143348623853 0 1 -1
a4,ic50,g 1.0 0.000143348623853 0 1 -1
a4,has,no 1.0 0.000143348623853 0 1 -1
a4,had,no 1.0 0.000143348623853 0 1 -1
a4,especially,patients 1.0 0.000143348623853 0 1 -1
a4,enzymes,lapatinib 1.0 0.000143348623853 0 1 -1
a4,by,oxc 1.0 0.000143348623853 0 1 -1
a4,but,only 1.0 0.000143348623853 0 1 -1
a4,but,coadministration 1.0 0.000143348623853 0 1 -1
a4,as,well 1.0 0.000143348623853 0 1 -1
a4,and,to 1.0 0.000143348623853 0 1 -1
a4,and,cyp 1.0 0.000143348623853 0 1 -1
a4,and,c9 1.0 0.000286697247706 0 2 -2
a4,activity,may 1.0 0.000143348623853 0 1 -1
a2,cyp1a2,is 1.0 0.000143348623853 0 1 -1
a2,c9,c19 1.0 0.000143348623853 0 1 -1
a2,c8,and 1.0 0.000143348623853 0 1 -1
a2,are,also 1.0 0.000143348623853 0 1 -1
a2,a6,c9 1.0 0.00043004587156 0 3 -3
a2,a6,b6 1.0 0.000143348623853 0 1 -1
a1,c9,c19 1.0 0.000143348623853 0 1 -1
a1,a2,a6 1.0 0.000143348623853 0 1 -1
a-chloralose,anesthetized,swine 1.0 0.000143348623853 0 1 -1
a-blockers,angiotensin-converting,enzyme 1.0 0.000143348623853 0 1 -1
a,year-old,african-american 1.0 0.000143348623853 0 1 -1
a,year,controlled 1.0 0.000143348623853 0 1 -1
a,with,metabolism 1.0 0.000143348623853 0 1 -1
a,with,diethyl 1.0 0.000143348623853 0 1 -1
a,with,c 1.0 0.000143348623853 0 1 -1
a,wide,variety 1.0 0.000286697247706 0 2 -2
a,were,not 1.0 0.000143348623853 0 1 -1
a,well-known,potential 1.0 0.000143348623853 0 1 -1
a,well-defined,pharmacokinetic-pharmacodynamic 1.0 0.000143348623853 0 1 -1
a,well-controlled,study 1.0 0.000143348623853 0 1 -1
a,well,defined 1.0 0.000143348623853 0 1 -1
a,week,to 1.0 0.000573394495413 0 4 -4
a,week,leaving 1.0 0.000143348623853 0 1 -1
a,week,endoscopy 1.0 0.000143348623853 0 1 -1
a,weak,inducer 1.0 0.000143348623853 0 1 -1
a,watery,stool 1.0 0.000286697247706 0 2 -2
a,water,pill 1.0 0.000143348623853 0 1 -1
a,volatile,agent 1.0 0.000143348623853 0 1 -1
a,very,low 1.0 0.000143348623853 0 1 -1
a,variety,of 1.0 0.00200688073394 0 14 -14
a,vanh,promoter-vana 1.0 0.000143348623853 0 1 -1
a,vana,glycopeptide-resistant 1.0 0.000143348623853 0 1 -1
a,useful,tool 1.0 0.000143348623853 0 1 -1
a,useful,pharmacological 1.0 0.000143348623853 0 1 -1
a,urine,or 1.0 0.000143348623853 0 1 -1
a,typical,side 1.0 0.000143348623853 0 1 -1
a,type,strain 1.0 0.000143348623853 0 1 -1
a,two-year,carcinogenesis 1.0 0.000143348623853 0 1 -1
a,tumor,that 1.0 0.000143348623853 0 1 -1
a,true,decrease 1.0 0.000143348623853 0 1 -1
a,trend,to 1.0 0.000143348623853 0 1 -1
a,total,of 1.0 0.000143348623853 0 1 -1
a,tool,for 1.0 0.000143348623853 0 1 -1
a,time-dependent,inhibitor 1.0 0.000143348623853 0 1 -1
a,three-,to 1.0 0.000143348623853 0 1 -1
a,thorough,medication 1.0 0.000143348623853 0 1 -1
a,third,hour 1.0 0.000143348623853 0 1 -1
a,thin-layer,chromatographic 1.0 0.000143348623853 0 1 -1
a,thienobenzodiazepine,derivative 1.0 0.000143348623853 0 1 -1
a,therapeutic,point 1.0 0.000143348623853 0 1 -1
a,the,maximal 1.0 0.000143348623853 0 1 -1
a,the,initial 1.0 0.000143348623853 0 1 -1
a,that,is 1.0 0.000286697247706 0 2 -2
a,that,inhibits 1.0 0.000143348623853 0 1 -1
a,that,has 1.0 0.000143348623853 0 1 -1
a,test,agent 1.0 0.000143348623853 0 1 -1
a,tendency,toward 1.0 0.000143348623853 0 1 -1
a,temporary,decrease 1.0 0.000143348623853 0 1 -1
a,tarceva,dose 1.0 0.000143348623853 0 1 -1
a,talk,to 1.0 0.000143348623853 0 1 -1
a,systemic,exposure 1.0 0.000143348623853 0 1 -1
a,synergistic,or 1.0 0.000143348623853 0 1 -1
a,symptomatic,pharmaceutical 1.0 0.000143348623853 0 1 -1
a,survey,of 1.0 0.000143348623853 0 1 -1
a,supplement,that 1.0 0.000143348623853 0 1 -1
a,supine,position 1.0 0.000143348623853 0 1 -1
a,sulfa-based,such 1.0 0.000143348623853 0 1 -1
a,sudden,extrusion 1.0 0.000143348623853 0 1 -1
a,substrates,is 1.0 0.000143348623853 0 1 -1
a,substrate,of 1.0 0.00043004587156 0 3 -3
a,substrate,is 1.0 0.000143348623853 0 1 -1
a,substrate,and 1.0 0.000143348623853 0 1 -1
a,substrate,a 1.0 0.000143348623853 0 1 -1
a,substitute,for 1.0 0.000573394495413 0 4 -4
a,substantially,greater 1.0 0.000143348623853 0 1 -1
a,substantial,period 1.0 0.000143348623853 0 1 -1
a,subset,to 1.0 0.000143348623853 0 1 -1
a,subset,of 1.0 0.00100344036697 0 7 -7
a,subgroup,of 1.0 0.000143348623853 0 1 -1
a,subclone,of 1.0 0.000143348623853 0 1 -1
a,sub-,for 1.0 0.000143348623853 0 1 -1
a,study,with 1.0 0.000143348623853 0 1 -1
a,study,which 1.0 0.000143348623853 0 1 -1
a,study,comparing 1.0 0.000143348623853 0 1 -1
a,strong,in 1.0 0.000143348623853 0 1 -1
a,strong,drying 1.0 0.000143348623853 0 1 -1
a,strong,affinity 1.0 0.000143348623853 0 1 -1
a,steady,partner 1.0 0.000143348623853 0 1 -1
a,starting,daily 1.0 0.000143348623853 0 1 -1
a,stable,prothrombin 1.0 0.000143348623853 0 1 -1
a,sprycel,dose 1.0 0.000143348623853 0 1 -1
a,spinal,naloxone-sensitive 1.0 0.000143348623853 0 1 -1
a,specific,treatment 1.0 0.000143348623853 0 1 -1
a,specific,rare 1.0 0.000143348623853 0 1 -1
a,specific,method 1.0 0.000143348623853 0 1 -1
a,solution,was 1.0 0.000143348623853 0 1 -1
a,soft,and 1.0 0.000143348623853 0 1 -1
a,smaller,week 1.0 0.000143348623853 0 1 -1
a,small,yet 1.0 0.000143348623853 0 1 -1
a,small,volume 1.0 0.000143348623853 0 1 -1
a,small,study 1.0 0.000143348623853 0 1 -1
a,small,number 1.0 0.000143348623853 0 1 -1
a,small,increase 1.0 0.000143348623853 0 1 -1
a,small,extent 1.0 0.000143348623853 0 1 -1
a,small,effect 1.0 0.000143348623853 0 1 -1
a,small,clinical 1.0 0.000143348623853 0 1 -1
a,slight,degree 1.0 0.000143348623853 0 1 -1
a,site,of 1.0 0.000143348623853 0 1 -1
a,single-dose,study 1.0 0.000143348623853 0 1 -1
a,single-dose,pharmacokinetic 1.0 0.000143348623853 0 1 -1
a,single-dose,interaction 1.0 0.000143348623853 0 1 -1
a,single,tonic 1.0 0.000143348623853 0 1 -1
a,single,small 1.0 0.000143348623853 0 1 -1
a,single,method 1.0 0.000143348623853 0 1 -1
a,single,intravenous 1.0 0.000143348623853 0 1 -1
a,single,in 1.0 0.000143348623853 0 1 -1
a,single,enzyme 1.0 0.000143348623853 0 1 -1
a,single,dosage 1.0 0.000143348623853 0 1 -1
a,single,daily 1.0 0.000143348623853 0 1 -1
a,single,compound 1.0 0.000143348623853 0 1 -1
a,single,agent 1.0 0.000143348623853 0 1 -1
a,simple,and 1.0 0.000143348623853 0 1 -1
a,similar,metabolism 1.0 0.000143348623853 0 1 -1
a,similar,mechanism 1.0 0.000143348623853 0 1 -1
a,similar,effect 1.0 0.00043004587156 0 3 -3
a,similar,association 1.0 0.000286697247706 0 2 -2
a,significantly,smaller 1.0 0.000143348623853 0 1 -1
a,significantly,improved 1.0 0.000143348623853 0 1 -1
a,significantly,higher 1.0 0.000143348623853 0 1 -1
a,significant,lengthening 1.0 0.000143348623853 0 1 -1
a,significant,impact 1.0 0.000143348623853 0 1 -1
a,significant,effect 1.0 0.00043004587156 0 3 -3
a,significant,difference 1.0 0.000143348623853 0 1 -1
a,significant,deterioration 1.0 0.000143348623853 0 1 -1
a,sign,of 1.0 0.000143348623853 0 1 -1
a,shorter,withdrawal 1.0 0.000143348623853 0 1 -1
a,short-term,controlled 1.0 0.000143348623853 0 1 -1
a,short-acting,inhaled 1.0 0.000143348623853 0 1 -1
a,series,of 1.0 0.000143348623853 0 1 -1
a,separate,study 1.0 0.000286697247706 0 2 -2
a,sensitivity,of 1.0 0.000143348623853 0 1 -1
a,segment,of 1.0 0.000143348623853 0 1 -1
a,second,study 1.0 0.000143348623853 0 1 -1
a,second,hour 1.0 0.000143348623853 0 1 -1
a,second,generation 1.0 0.000143348623853 0 1 -1
a,safety,concern 1.0 0.000143348623853 0 1 -1
a,routine,dosage 1.0 0.000143348623853 0 1 -1
a,role,of 1.0 0.000143348623853 0 1 -1
a,role,in 1.0 0.000286697247706 0 2 -2
a,role,for 1.0 0.000143348623853 0 1 -1
a,review,is 1.0 0.000143348623853 0 1 -1
a,reversible,reduction 1.0 0.000143348623853 0 1 -1
a,reversible,nonselective 1.0 0.000143348623853 0 1 -1
a,return,to 1.0 0.000143348623853 0 1 -1
a,result,when 1.0 0.000143348623853 0 1 -1
a,result,that 1.0 0.000143348623853 0 1 -1
a,renal,tubular 1.0 0.000143348623853 0 1 -1
a,release,of 1.0 0.000143348623853 0 1 -1
a,relatively,unexplored 1.0 0.000143348623853 0 1 -1
a,relatively,specific 1.0 0.000143348623853 0 1 -1
a,regular,basis 1.0 0.000143348623853 0 1 -1
a,reduction,that 1.0 0.000143348623853 0 1 -1
a,reduced,clozapine 1.0 0.000143348623853 0 1 -1
a,reduced,antihypertensive 1.0 0.000143348623853 0 1 -1
a,recently,identified 1.0 0.000143348623853 0 1 -1
a,rapidly,hydrolyzed 1.0 0.000143348623853 0 1 -1
a,rapidly,growing 1.0 0.000143348623853 0 1 -1
a,rapid,avoidance 1.0 0.000143348623853 0 1 -1
a,randomized,multiple-dose 1.0 0.000143348623853 0 1 -1
a,randomized,crossover 1.0 0.000143348623853 0 1 -1
a,radioactive,derivative 1.0 0.000143348623853 0 1 -1
a,rabbit,erythrocyte 1.0 0.000143348623853 0 1 -1
a,pulse,of 1.0 0.000143348623853 0 1 -1
a,pulmonary,extract 1.0 0.000143348623853 0 1 -1
a,psychotic,reaction 1.0 0.000143348623853 0 1 -1
a,protein,with 1.0 0.000143348623853 0 1 -1
a,prostaglandin,synthetase 1.0 0.000143348623853 0 1 -1
a,prospective,study 1.0 0.000143348623853 0 1 -1
a,proposed,mechanism 1.0 0.000143348623853 0 1 -1
a,proper,interval 1.0 0.000143348623853 0 1 -1
a,prolonged,infusion 1.0 0.000143348623853 0 1 -1
a,profound,effect 1.0 0.000143348623853 0 1 -1
a,profound,and 1.0 0.000143348623853 0 1 -1
a,primary,form 1.0 0.000143348623853 0 1 -1
a,presynaptic,defect 1.0 0.000143348623853 0 1 -1
a,premedication,for 1.0 0.000143348623853 0 1 -1
a,pregnancy,test 1.0 0.000143348623853 0 1 -1
a,predisposition,for 1.0 0.000143348623853 0 1 -1
a,precursor,to 1.0 0.000143348623853 0 1 -1
a,precipitating,factor 1.0 0.000143348623853 0 1 -1
a,potently,enhanced 1.0 0.000143348623853 0 1 -1
a,potential,treatment 1.0 0.000143348623853 0 1 -1
a,potent,t 1.0 0.000143348623853 0 1 -1
a,potent,effect 1.0 0.000143348623853 0 1 -1
a,potent,cyp 1.0 0.000143348623853 0 1 -1
a,possible,lack 1.0 0.000143348623853 0 1 -1
a,possible,explanation 1.0 0.000143348623853 0 1 -1
a,positive,urine 1.0 0.000143348623853 0 1 -1
a,positive,direct 1.0 0.00043004587156 0 3 -3
a,positive,coombs 1.0 0.00043004587156 0 3 -3
a,poor,substrate 1.0 0.000143348623853 0 1 -1
a,plasma,concentration 1.0 0.000143348623853 0 1 -1
a,placebo-controlled,phase 1.0 0.000143348623853 0 1 -1
a,pheochromocytoma,and 1.0 0.000143348623853 0 1 -1
a,pharmacological,interaction 1.0 0.000143348623853 0 1 -1
a,pharmacological,analysis 1.0 0.000143348623853 0 1 -1
a,peptide,that 1.0 0.000143348623853 0 1 -1
a,patient,to 1.0 0.000143348623853 0 1 -1
a,patient,taking 1.0 0.00043004587156 0 3 -3
a,patient,shows 1.0 0.000143348623853 0 1 -1
a,patient,s 1.0 0.000143348623853 0 1 -1
a,patient,population 1.0 0.000286697247706 0 2 -2
a,patient,or 1.0 0.000143348623853 0 1 -1
a,patient,is 1.0 0.000286697247706 0 2 -2
a,patient,had 1.0 0.000143348623853 0 1 -1
a,patient,during 1.0 0.000143348623853 0 1 -1
a,patient,already 1.0 0.000286697247706 0 2 -2
a,partially,impaired 1.0 0.000143348623853 0 1 -1
a,parallel,group 1.0 0.000143348623853 0 1 -1
a,pacemaker,in 1.0 0.000143348623853 0 1 -1
a,p53,mouse 1.0 0.000143348623853 0 1 -1
a,or,should 1.0 0.000143348623853 0 1 -1
a,or,induce 1.0 0.000143348623853 0 1 -1
a,only,at 1.0 0.000143348623853 0 1 -1
a,novel,purification 1.0 0.000143348623853 0 1 -1
a,novel,iboga 1.0 0.000143348623853 0 1 -1
a,nonsteroidal,nsaid 1.0 0.000143348623853 0 1 -1
a,nonlinear,weighted 1.0 0.000143348623853 0 1 -1
a,nonhormonal,product 1.0 0.000860091743119 0 6 -6
a,non-specific,cyp-450 1.0 0.000143348623853 0 1 -1
a,non-significantly,reduced 1.0 0.000143348623853 0 1 -1
a,newly,introduced 1.0 0.000143348623853 0 1 -1
a,new,class 1.0 0.000143348623853 0 1 -1
a,new,acute 1.0 0.000143348623853 0 1 -1
a,negative,result 1.0 0.000143348623853 0 1 -1
a,necessary,factor 1.0 0.000143348623853 0 1 -1
a,nd,series 1.0 0.000143348623853 0 1 -1
a,nd,female 1.0 0.000143348623853 0 1 -1
a,nasal,vasoconstrictor 1.0 0.000143348623853 0 1 -1
a,narrower,spectrum 1.0 0.000143348623853 0 1 -1
a,muscle,biopsy 1.0 0.000143348623853 0 1 -1
a,multiple,fixed-interval 1.0 0.000143348623853 0 1 -1
a,multicenter,randomized 1.0 0.000143348623853 0 1 -1
a,mouse,model 1.0 0.000143348623853 0 1 -1
a,more,severe 1.0 0.000143348623853 0 1 -1
a,more,rapid 1.0 0.000143348623853 0 1 -1
a,more,pronounced 1.0 0.000286697247706 0 2 -2
a,more,efficient 1.0 0.000143348623853 0 1 -1
a,month,washout 1.0 0.000143348623853 0 1 -1
a,month,toxicology 1.0 0.000143348623853 0 1 -1
a,month,controlled 1.0 0.000143348623853 0 1 -1
a,monoamine,oxidase 1.0 0.000143348623853 0 1 -1
a,modest,inhibition 1.0 0.000143348623853 0 1 -1
a,moderate,inhibitor 1.0 0.000716743119266 0 5 -5
a,moderate,inducer 1.0 0.000143348623853 0 1 -1
a,mixed-function,oxidase 1.0 0.000143348623853 0 1 -1
a,minor,metabolizing 1.0 0.000143348623853 0 1 -1
a,minor,metabolic 1.0 0.000143348623853 0 1 -1
a,minor,contribution 1.0 0.000143348623853 0 1 -1
a,mild,but 1.0 0.000143348623853 0 1 -1
a,microdilution,method 1.0 0.000143348623853 0 1 -1
a,mg,once-daily 1.0 0.000143348623853 0 1 -1
a,mg,m 1.0 0.000143348623853 0 1 -1
a,mg,kg 1.0 0.000143348623853 0 1 -1
a,mg,intravenous 1.0 0.000143348623853 0 1 -1
a,method,to 1.0 0.000286697247706 0 2 -2
a,method,for 1.0 0.000143348623853 0 1 -1
a,metabolized,by 1.0 0.000143348623853 0 1 -1
a,metabolite,i 1.0 0.000143348623853 0 1 -1
a,metabolism,and 1.0 0.000143348623853 0 1 -1
a,medicine,such 1.0 0.000143348623853 0 1 -1
a,median,follow-up 1.0 0.000143348623853 0 1 -1
a,median,fold 1.0 0.000143348623853 0 1 -1
a,mean,template 1.0 0.000143348623853 0 1 -1
a,meal,and 1.0 0.000143348623853 0 1 -1
a,mcg,once 1.0 0.000143348623853 0 1 -1
a,maximum,relaxation 1.0 0.000143348623853 0 1 -1
a,maximal,decrease 1.0 0.000143348623853 0 1 -1
a,massive,precipitation 1.0 0.000143348623853 0 1 -1
a,marked,inhibition 1.0 0.000143348623853 0 1 -1
a,manner,similar 1.0 0.000143348623853 0 1 -1
a,maneuver,often 1.0 0.000143348623853 0 1 -1
a,mammalian,liver 1.0 0.000143348623853 0 1 -1
a,major,pathophysiologic 1.0 0.000143348623853 0 1 -1
a,major,metabolic 1.0 0.000143348623853 0 1 -1
a,major,cause 1.0 0.000286697247706 0 2 -2
a,main,meal 1.0 0.000143348623853 0 1 -1
a,macrolide,immunosuppressant 1.0 0.000143348623853 0 1 -1
a,luciferase,reporter 1.0 0.000143348623853 0 1 -1
a,lower,total 1.0 0.000143348623853 0 1 -1
a,lower,than 1.0 0.000143348623853 0 1 -1
a,lower,relative 1.0 0.000143348623853 0 1 -1
a,lower,plasma 1.0 0.000143348623853 0 1 -1
a,low,therapeutic 1.0 0.000143348623853 0 1 -1
a,low,dose 1.0 0.000143348623853 0 1 -1
a,loss,of 1.0 0.000143348623853 0 1 -1
a,long-acting,is 1.0 0.000143348623853 0 1 -1
a,local,factor 1.0 0.000143348623853 0 1 -1
a,liquid,impinger 1.0 0.000143348623853 0 1 -1
a,linear,logarithmic 1.0 0.000143348623853 0 1 -1
a,limited,number 1.0 0.000286697247706 0 2 -2
a,light,dark 1.0 0.000286697247706 0 2 -2
a,level,that 1.0 0.000143348623853 0 1 -1
a,level,of 1.0 0.000143348623853 0 1 -1
a,level,cells 1.0 0.000143348623853 0 1 -1
a,lesser,degree 1.0 0.000143348623853 0 1 -1
a,lesser,but 1.0 0.000143348623853 0 1 -1
a,lectin,which 1.0 0.000143348623853 0 1 -1
a,later,time 1.0 0.000143348623853 0 1 -1
a,later,developmental 1.0 0.000143348623853 0 1 -1
a,laser,interferometric 1.0 0.000143348623853 0 1 -1
a,large,number 1.0 0.000143348623853 0 1 -1
a,large,decrease 1.0 0.000143348623853 0 1 -1
a,lack,of 1.0 0.000143348623853 0 1 -1
a,krm-1648,either 1.0 0.000143348623853 0 1 -1
a,known,strong 1.0 0.000286697247706 0 2 -2
a,known,risk 1.0 0.000143348623853 0 1 -1
a,known,metabolite 1.0 0.000143348623853 0 1 -1
a,ki,of 1.0 0.000143348623853 0 1 -1
a,kg,person 1.0 0.000286697247706 0 2 -2
a,kda,adapter 1.0 0.000143348623853 0 1 -1
a,interaction,with 1.0 0.000143348623853 0 1 -1
a,interaction,study 1.0 0.00043004587156 0 3 -3
a,interaction,cannot 1.0 0.000143348623853 0 1 -1
a,hypothyroid,patient 1.0 0.000143348623853 0 1 -1
a,hot,kidney 1.0 0.000143348623853 0 1 -1
a,host,of 1.0 0.000143348623853 0 1 -1
a,homodimeric,disintegrin 1.0 0.000143348623853 0 1 -1
a,hmgcoa,reductase 1.0 0.000143348623853 0 1 -1
a,hit,in 1.0 0.000143348623853 0 1 -1
a,highly,sensitive 1.0 0.000143348623853 0 1 -1
a,highly,lethal 1.0 0.000143348623853 0 1 -1
a,highest,level 1.0 0.000143348623853 0 1 -1
a,higher,risk 1.0 0.000286697247706 0 2 -2
a,higher,rate 1.0 0.000143348623853 0 1 -1
a,higher,frequency 1.0 0.000143348623853 0 1 -1
a,higher,dose 1.0 0.000286697247706 0 2 -2
a,higher,absolute 1.0 0.000143348623853 0 1 -1
a,high,performance 1.0 0.000143348623853 0 1 -1
a,high,percentage 1.0 0.000143348623853 0 1 -1
a,high,oral 1.0 0.000143348623853 0 1 -1
a,high,degree 1.0 0.000286697247706 0 2 -2
a,helpful,means 1.0 0.000143348623853 0 1 -1
a,half-life,less 1.0 0.000143348623853 0 1 -1
a,h,period 1.0 0.000143348623853 0 1 -1
a,growing,problem 1.0 0.000143348623853 0 1 -1
a,group,of 1.0 0.000716743119266 0 5 -5
a,greater,understanding 1.0 0.000143348623853 0 1 -1
a,greater,risk 1.0 0.000143348623853 0 1 -1
a,greater,extent 1.0 0.000143348623853 0 1 -1
a,great,potential 1.0 0.000143348623853 0 1 -1
a,glucose-specific,method 1.0 0.000143348623853 0 1 -1
a,given,situation 1.0 0.000143348623853 0 1 -1
a,given,plasma 1.0 0.000143348623853 0 1 -1
a,given,dose 1.0 0.000716743119266 0 5 -5
a,genetically,initiated 1.0 0.000143348623853 0 1 -1
a,genetic,predisposition 1.0 0.000143348623853 0 1 -1
a,gas,chromatographic-mass 1.0 0.000143348623853 0 1 -1
a,g,bolus 1.0 0.000286697247706 0 2 -2
a,further,route 1.0 0.000143348623853 0 1 -1
a,function,of 1.0 0.000143348623853 0 1 -1
a,frequent,condition 1.0 0.000143348623853 0 1 -1
a,four-session,placebo-controlled 1.0 0.000143348623853 0 1 -1
a,follow-up,study 1.0 0.000143348623853 0 1 -1
a,fold,range 1.0 0.000143348623853 0 1 -1
a,focus,on 1.0 0.000143348623853 0 1 -1
a,fixed,g 1.0 0.000143348623853 0 1 -1
a,first-line,option 1.0 0.000143348623853 0 1 -1
a,first,rapid 1.0 0.000143348623853 0 1 -1
a,first,experiment 1.0 0.000143348623853 0 1 -1
a,female,dog 1.0 0.000143348623853 0 1 -1
a,far,greater 1.0 0.000143348623853 0 1 -1
a,family,cyp3a4 1.0 0.000143348623853 0 1 -1
a,false-positive,urine 1.0 0.000143348623853 0 1 -1
a,false-positive,reaction 1.0 0.00200688073394 0 14 -14
a,false-positive,direct 1.0 0.000143348623853 0 1 -1
a,false-negative,result 1.0 0.000286697247706 0 2 -2
a,false,positive 1.0 0.00043004587156 0 3 -3
a,false,low 1.0 0.000143348623853 0 1 -1
a,fall,in 1.0 0.000143348623853 0 1 -1
a,facilitation,or 1.0 0.000143348623853 0 1 -1
a,facilitates,acquisition 1.0 0.000143348623853 0 1 -1
a,exerts,its 1.0 0.000143348623853 0 1 -1
a,euthyroid,state 1.0 0.000143348623853 0 1 -1
a,dysregulation,of 1.0 0.000143348623853 0 1 -1
a,during,the 1.0 0.000143348623853 0 1 -1
a,drugs,that 1.0 0.000143348623853 0 1 -1
a,drugs,enhancing 1.0 0.000143348623853 0 1 -1
a,dramatic,effect 1.0 0.000286697247706 0 2 -2
a,double-blind,randomized 1.0 0.000143348623853 0 1 -1
a,double-blind,fashion 1.0 0.000143348623853 0 1 -1
a,double,blind 1.0 0.000143348623853 0 1 -1
a,dosing,schedule 1.0 0.000143348623853 0 1 -1
a,dose,that 1.0 0.000143348623853 0 1 -1
a,dosage,adjustment 1.0 0.000143348623853 0 1 -1
a,dopa,decarboxylase 1.0 0.000143348623853 0 1 -1
a,disulfiram-like,reaction 1.0 0.000286697247706 0 2 -2
a,dissociation,of 1.0 0.000143348623853 0 1 -1
a,displays,both 1.0 0.000143348623853 0 1 -1
a,direct,pharmacokinetic 1.0 0.000143348623853 0 1 -1
a,direct,effect 1.0 0.000143348623853 0 1 -1
a,dihydropyridine,derivative 1.0 0.000143348623853 0 1 -1
a,different,site 1.0 0.000143348623853 0 1 -1
a,different,route 1.0 0.000143348623853 0 1 -1
a,diagnostic,challenge 1.0 0.000143348623853 0 1 -1
a,delayed,elimination 1.0 0.000143348623853 0 1 -1
a,defined,medium 1.0 0.000143348623853 0 1 -1
a,decrease,of 1.0 0.000286697247706 0 2 -2
a,decrease,and 1.0 0.000143348623853 0 1 -1
a,decline,in 1.0 0.000143348623853 0 1 -1
a,decision,should 1.0 0.000286697247706 0 2 -2
a,decision,must 1.0 0.000143348623853 0 1 -1
a,day,withdrawal 1.0 0.00043004587156 0 3 -3
a,day,washout 1.0 0.000143348623853 0 1 -1
a,day,qd 1.0 0.000143348623853 0 1 -1
a,day,pretreatment 1.0 0.000143348623853 0 1 -1
a,day,for 1.0 0.000573394495413 0 4 -4
a,day,did 1.0 0.000143348623853 0 1 -1
a,day,course 1.0 0.000143348623853 0 1 -1
a,day,before 1.0 0.000143348623853 0 1 -1
a,d-gal,binding 1.0 0.000143348623853 0 1 -1
a,d,e 1.0 0.000143348623853 0 1 -1
a,cyp3a4,inducer 1.0 0.000143348623853 0 1 -1
a,cyp3a,the 1.0 0.000143348623853 0 1 -1
a,cyp,c9 1.0 0.000143348623853 0 1 -1
a,cyp,a4 1.0 0.000286697247706 0 2 -2
a,critical,role 1.0 0.000143348623853 0 1 -1
a,critical,fall 1.0 0.000143348623853 0 1 -1
a,controlled,clinical 1.0 0.000143348623853 0 1 -1
a,control,program 1.0 0.000143348623853 0 1 -1
a,contraindication,to 1.0 0.000143348623853 0 1 -1
a,continuing,rise 1.0 0.000143348623853 0 1 -1
a,containing,regimen 1.0 0.000143348623853 0 1 -1
a,considerable,segment 1.0 0.000143348623853 0 1 -1
a,conservative,approach 1.0 0.000143348623853 0 1 -1
a,confirmation,test 1.0 0.000143348623853 0 1 -1
a,concentration,of 1.0 0.000286697247706 0 2 -2
a,concentration,as 1.0 0.000143348623853 0 1 -1
a,comprehensive,review 1.0 0.000143348623853 0 1 -1
a,complication,of 1.0 0.000143348623853 0 1 -1
a,complex,of 1.0 0.000143348623853 0 1 -1
a,complex,fashion 1.0 0.000143348623853 0 1 -1
a,compensatory,increase 1.0 0.000143348623853 0 1 -1
a,common,transport 1.0 0.000143348623853 0 1 -1
a,common,phenotypic 1.0 0.000143348623853 0 1 -1
a,common,comorbidity 1.0 0.000143348623853 0 1 -1
a,combined,transcriptional 1.0 0.000143348623853 0 1 -1
a,combination,of 1.0 0.00043004587156 0 3 -3
a,clinically,significant 1.0 0.000716743119266 0 5 -5
a,clinically,important 1.0 0.000286697247706 0 2 -2
a,clinical,interaction 1.0 0.000286697247706 0 2 -2
a,class,may 1.0 0.000143348623853 0 1 -1
a,chylomicron-like,emulsion 1.0 0.000286697247706 0 2 -2
a,chronic,toxicity 1.0 0.000143348623853 0 1 -1
a,chop-like,regimen 1.0 0.000143348623853 0 1 -1
a,chemically,similar 1.0 0.000143348623853 0 1 -1
a,chemical,carcinogen 1.0 0.000143348623853 0 1 -1
a,channel,blocker 1.0 0.000143348623853 0 1 -1
a,change,of 1.0 0.000143348623853 0 1 -1
a,cetaminophen,hepatoxicity 1.0 0.000143348623853 0 1 -1
a,cell-free,system 1.0 0.000143348623853 0 1 -1
a,causal,relationship 1.0 0.000286697247706 0 2 -2
a,catecholamine,depletor 1.0 0.00043004587156 0 3 -3
a,case,the 1.0 0.000143348623853 0 1 -1
a,cascade,impactor 1.0 0.000143348623853 0 1 -1
a,cardioselective,could 1.0 0.000143348623853 0 1 -1
a,car,or 1.0 0.000143348623853 0 1 -1
a,broad,spectrum 1.0 0.000143348623853 0 1 -1
a,broad,range 1.0 0.000143348623853 0 1 -1
a,broad,population 1.0 0.000143348623853 0 1 -1
a,body,surface 1.0 0.000143348623853 0 1 -1
a,blunting,of 1.0 0.000143348623853 0 1 -1
a,blocker,of 1.0 0.000143348623853 0 1 -1
a,bioequivalence,study 1.0 0.000143348623853 0 1 -1
a,basis,for 1.0 0.000143348623853 0 1 -1
a,basic,area 1.0 0.000143348623853 0 1 -1
a,bar-press,conditioning 1.0 0.000143348623853 0 1 -1
a,balanced,technique 1.0 0.000143348623853 0 1 -1
a,b-cell,lymphoma 1.0 0.000143348623853 0 1 -1
a,atp,oxaloacetate 1.0 0.000143348623853 0 1 -1
a,are,critical 1.0 0.000143348623853 0 1 -1
a,are,available 1.0 0.000143348623853 0 1 -1
a,and,lower 1.0 0.000143348623853 0 1 -1
a,all,volunteers 1.0 0.000143348623853 0 1 -1
drug,laboratory,test 0.960784313725 0.00702408256881 1 50 -49
laboratory,test,interactions 0.957446808511 0.00645068807339 1 46 -45
interaction,studies,have 0.944444444444 0.00487385321101 1 35 -34
on,the,pharmacokinetics 0.942857142857 0.00473050458716 1 34 -33
not,affect,the 0.939393939394 0.00444380733945 1 32 -31
the,auc,of 0.916666666667 0.00315366972477 23 1 22
a,increase,in 0.909090909091 0.00286697247706 21 1 20
significant,effect,on 0.909090909091 0.00286697247706 1 21 -20
there,are,no 0.904761904762 0.00272362385321 1 20 -19
there,were,no 0.9 0.00258027522936 1 19 -18
not,alter,the 0.9 0.00258027522936 1 19 -18
there,is,no 0.882352941176 0.0021502293578 1 16 -15
no,significant,effect 0.882352941176 0.0021502293578 1 16 -15
the,cytochrome,p450 0.866666666667 0.00372706422018 2 28 -26
significance,of,this 0.866666666667 0.00186353211009 1 14 -13
drugs,metabolized,by 0.866666666667 0.00186353211009 1 14 -13
studies,have,been 0.862068965517 0.00358371559633 2 27 -25
effects,on,the 0.857142857143 0.00172018348624 1 13 -12
of,may,be 0.851851851852 0.00329701834862 25 2 23
did,not,affect 0.851851851852 0.00329701834862 2 25 -23
result,in,an 0.846153846154 0.00157683486239 12 1 11
and,resulted,in 0.846153846154 0.00157683486239 12 1 11
the,extent,of 0.846153846154 0.00157683486239 1 12 -11
one,of,these 0.846153846154 0.00157683486239 1 12 -11
no,clinically,relevant 0.846153846154 0.00157683486239 1 12 -11
may,enhance,the 0.837837837838 0.00444380733945 34 3 31
resulted,in,an 0.833333333333 0.00143348623853 11 1 10
in,plasma,levels 0.833333333333 0.00143348623853 11 1 10
there,was,no 0.833333333333 0.00286697247706 2 22 -20
clinical,significance,of 0.833333333333 0.00286697247706 2 22 -20
not,result,in 0.833333333333 0.00143348623853 1 11 -10
not,appear,to 0.833333333333 0.00143348623853 1 11 -10
inhibition,of,renal 0.833333333333 0.00143348623853 1 11 -10
resulted,in,a 0.823529411765 0.00401376146789 31 3 28
of,resulting,in 0.818181818182 0.00258027522936 20 2 18
increase,in,auc 0.818181818182 0.00129013761468 10 1 9
be,potentiated,by 0.818181818182 0.00129013761468 10 1 9
the,increase,in 0.818181818182 0.00129013761468 1 10 -9
specific,interaction,studies 0.818181818182 0.00129013761468 1 10 -9
serious,and,or 0.818181818182 0.00129013761468 1 10 -9
other,metabolized,by 0.818181818182 0.00129013761468 1 10 -9
or,in,combination 0.818181818182 0.00129013761468 1 10 -9
known,to,be 0.818181818182 0.00129013761468 1 10 -9
had,no,significant 0.818181818182 0.00129013761468 1 10 -9
for,serious,and 0.818181818182 0.00129013761468 1 10 -9
and,did,not 0.818181818182 0.00129013761468 1 10 -9
a,substrate,for 0.818181818182 0.00129013761468 1 10 -9
monoamine,oxidase,inhibitors 0.809523809524 0.0024369266055 19 2 17
serum,levels,and 0.8 0.00114678899083 9 1 8
up,to,mg 0.8 0.00114678899083 1 9 -8
not,significantly,affect 0.8 0.00114678899083 1 9 -8
is,not,expected 0.8 0.00114678899083 1 9 -8
is,not,a 0.8 0.00114678899083 1 9 -8
increased,incidence,of 0.8 0.00114678899083 1 9 -8
human,liver,microsomes 0.8 0.00114678899083 1 9 -8
highly,bound,to 0.8 0.00114678899083 1 9 -8
cytochrome,p450,enzymes 0.8 0.00114678899083 1 9 -8
adjustment,of,dosage 0.8 0.00114678899083 1 9 -8
the,pharmacokinetics,of 0.79381443299 0.0110378440367 10 87 -77
the,clinical,significance 0.793103448276 0.00329701834862 3 26 -23
metabolized,by,the 0.789473684211 0.0021502293578 2 17 -15
are,known,to 0.789473684211 0.0021502293578 2 17 -15
tubular,secretion,of 0.777777777778 0.00100344036697 8 1 7
reports,suggest,that 0.777777777778 0.00100344036697 8 1 7
reported,to,decrease 0.777777777778 0.00100344036697 8 1 7
combination,hormonal,may 0.777777777778 0.00100344036697 8 1 7
and,auc,of 0.777777777778 0.00100344036697 8 1 7
potential,for,serious 0.777777777778 0.00200688073394 2 16 -14
to,plasma,proteins 0.777777777778 0.00100344036697 1 8 -7
the,mechanism,of 0.777777777778 0.00100344036697 1 8 -7
primarily,metabolized,by 0.777777777778 0.00100344036697 1 8 -7
or,mg,kg 0.777777777778 0.00100344036697 1 8 -7
not,expected,to 0.777777777778 0.00100344036697 1 8 -7
in,the,pharmacokinetics 0.777777777778 0.00100344036697 1 8 -7
in,human,liver 0.777777777778 0.00100344036697 1 8 -7
did,not,result 0.777777777778 0.00100344036697 1 8 -7
been,observed,in 0.777777777778 0.00100344036697 1 8 -7
and,or,life-threatening 0.777777777778 0.00100344036697 1 8 -7
has,been,associated 0.764705882353 0.00186353211009 15 2 13
decrease,in,the 0.764705882353 0.00186353211009 15 2 13
have,been,conducted 0.764705882353 0.00186353211009 2 15 -13
effect,on,the 0.761194029851 0.00731077981651 8 59 -51
may,lead,to 0.76 0.00272362385321 3 22 -19
effect,of,and 0.75 0.00172018348624 14 2 12
the,desired,effect 0.75 0.000860091743119 7 1 6
should,be,approached 0.75 0.000860091743119 7 1 6
of,the,dose 0.75 0.000860091743119 7 1 6
of,and,resulted 0.75 0.000860091743119 7 1 6
may,be,additive 0.75 0.000860091743119 7 1 6
levels,of,have 0.75 0.000860091743119 7 1 6
increase,the,clearance 0.75 0.000860091743119 7 1 6
in,cmax,and 0.75 0.000860091743119 7 1 6
effects,of,may 0.75 0.000860091743119 7 1 6
auc,of,was 0.75 0.000860091743119 7 1 6
after,initiation,of 0.75 0.000860091743119 7 1 6
studies,have,shown 0.75 0.00172018348624 2 14 -12
vitro,studies,indicate 0.75 0.000860091743119 1 7 -6
to,have,no 0.75 0.000860091743119 1 7 -6
to,evaluate,the 0.75 0.000860091743119 1 7 -6
the,management,of 0.75 0.000860091743119 1 7 -6
that,are,not 0.75 0.000860091743119 1 7 -6
significantly,affect,the 0.75 0.000860091743119 1 7 -6
pharmacokinetics,of,were 0.75 0.000860091743119 1 7 -6
on,the,metabolism 0.75 0.000860091743119 1 7 -6
of,one,or 0.75 0.000860091743119 1 7 -6
monitoring,of,plasma 0.75 0.000860091743119 1 7 -6
may,be,more 0.75 0.000860091743119 1 7 -6
john,s,wort 0.75 0.000860091743119 1 7 -6
is,withdrawn,from 0.75 0.000860091743119 1 7 -6
interactions,between,and 0.75 0.000860091743119 1 7 -6
in,the,extent 0.75 0.000860091743119 1 7 -6
higher,than,expected 0.75 0.000860091743119 1 7 -6
drug-drug,interaction,studies 0.75 0.000860091743119 1 7 -6
doses,up,to 0.75 0.000860091743119 1 7 -6
cytochrome,p450,system 0.75 0.000860091743119 1 7 -6
closely,observed,for 0.75 0.000860091743119 1 7 -6
be,closely,observed 0.75 0.000860091743119 1 7 -6
as,a,result 0.75 0.000860091743119 1 7 -6
appropriate,dosage,adjustments 0.75 0.000860091743119 1 7 -6
and,its,metabolites 0.75 0.000860091743119 1 7 -6
in,an,increase 0.733333333333 0.00157683486239 13 2 11
did,not,significantly 0.733333333333 0.00157683486239 2 13 -11
based,on,the 0.733333333333 0.00157683486239 2 13 -11
in,clinical,studies 0.727272727273 0.00229357798165 3 19 -16
a,decrease,in 0.724137931034 0.00301032110092 25 4 21
with,concomitant,use 0.714285714286 0.000716743119266 6 1 5
when,is,administered 0.714285714286 0.000716743119266 6 1 5
viracept,resulted,in 0.714285714286 0.000716743119266 6 1 5
used,cautiously,in 0.714285714286 0.000716743119266 6 1 5
the,neuromuscular,blocking 0.714285714286 0.000716743119266 6 1 5
the,natriuretic,effect 0.714285714286 0.000716743119266 6 1 5
the,cmax,and 0.714285714286 0.000716743119266 6 1 5
the,area,under 0.714285714286 0.000716743119266 6 1 5
reported,following,concomitant 0.714285714286 0.000716743119266 6 1 5
proton,pump,inhibitors 0.714285714286 0.000716743119266 6 1 5
natriuretic,effect,of 0.714285714286 0.000716743119266 6 1 5
interferes,with,the 0.714285714286 0.000716743119266 6 1 5
inhibitors,should,be 0.714285714286 0.000716743119266 6 1 5
in,the,steady-state 0.714285714286 0.000716743119266 6 1 5
hepatic,metabolism,of 0.714285714286 0.000716743119266 6 1 5
healthy,subjects,receiving 0.714285714286 0.000716743119266 6 1 5
degree,of,inhibition 0.714285714286 0.000716743119266 6 1 5
concomitantly,the,patient 0.714285714286 0.000716743119266 6 1 5
combined,use,of 0.714285714286 0.000716743119266 6 1 5
clinical,studies,as 0.714285714286 0.000716743119266 6 1 5
been,reported,that 0.714285714286 0.000716743119266 6 1 5
and,may,result 0.714285714286 0.000716743119266 6 1 5
administered,with,caution 0.714285714286 0.000716743119266 6 1 5
the,development,of 0.714285714286 0.00143348623853 2 12 -10
by,the,cytochrome 0.714285714286 0.00143348623853 2 12 -10
use,of,the 0.714285714286 0.000716743119266 1 6 -5
this,isozyme,and 0.714285714286 0.000716743119266 1 6 -5
the,magnitude,of 0.714285714286 0.000716743119266 1 6 -5
the,course,of 0.714285714286 0.000716743119266 1 6 -5
that,is,not 0.714285714286 0.000716743119266 1 6 -5
that,inhibit,cytochrome 0.714285714286 0.000716743119266 1 6 -5
st,john,s 0.714285714286 0.000716743119266 1 6 -5
similar,to,that 0.714285714286 0.000716743119266 1 6 -5
significance,of,these 0.714285714286 0.000716743119266 1 6 -5
should,be,made 0.714285714286 0.000716743119266 1 6 -5
or,both,agents 0.714285714286 0.000716743119266 1 6 -5
of,serum,levels 0.714285714286 0.000716743119266 1 6 -5
of,action,of 0.714285714286 0.000716743119266 1 6 -5
of,a,mg 0.714285714286 0.000716743119266 1 6 -5
not,been,conducted 0.714285714286 0.000716743119266 1 6 -5
for,the,treatment 0.714285714286 0.000716743119266 1 6 -5
effects,have,been 0.714285714286 0.000716743119266 1 6 -5
during,the,first 0.714285714286 0.000716743119266 1 6 -5
does,not,alter 0.714285714286 0.000716743119266 1 6 -5
concomitant,use,with 0.714285714286 0.000716743119266 1 6 -5
be,considered,in 0.714285714286 0.000716743119266 1 6 -5
as,measured,by 0.714285714286 0.000716743119266 1 6 -5
and,in,vivo 0.714285714286 0.000716743119266 1 6 -5
an,increased,dose 0.714285714286 0.000716743119266 1 6 -5
a,result,of 0.714285714286 0.000716743119266 1 6 -5
the,action,of 0.7 0.00200688073394 17 3 14
of,and,in 0.7 0.00200688073394 17 3 14
in,clinical,trials 0.7 0.00200688073394 3 17 -14
have,been,observed 0.7 0.00200688073394 3 17 -14
had,no,effect 0.695652173913 0.0045871559633 7 39 -32
to,mg,day 0.692307692308 0.00129013761468 2 11 -9
effects,of,on 0.692307692308 0.00129013761468 2 11 -9
no,effect,on 0.672131147541 0.00587729357798 10 51 -41
in,patients,with 0.671232876712 0.00702408256881 12 61 -49
reported,in,patients 0.666666666667 0.00229357798165 20 4 16
other,cns,depressants 0.666666666667 0.00114678899083 10 2 8
of,and,may 0.666666666667 0.00114678899083 10 2 8
with,has,been 0.666666666667 0.000573394495413 5 1 4
with,and,other 0.666666666667 0.000573394495413 5 1 4
used,concomitantly,the 0.666666666667 0.000573394495413 5 1 4
to,result,in 0.666666666667 0.000573394495413 5 1 4
to,reduce,the 0.666666666667 0.000573394495413 5 1 4
to,be,increased 0.666666666667 0.000573394495413 5 1 4
the,extent,to 0.666666666667 0.000573394495413 5 1 4
the,elimination,of 0.666666666667 0.000573394495413 5 1 4
the,combined,use 0.666666666667 0.000573394495413 5 1 4
some,patients,with 0.666666666667 0.000573394495413 5 1 4
significantly,increased,the 0.666666666667 0.000573394495413 5 1 4
significantly,decreased,the 0.666666666667 0.000573394495413 5 1 4
reported,with,the 0.666666666667 0.000573394495413 5 1 4
reported,with,concomitant 0.666666666667 0.000573394495413 5 1 4
of,to,patients 0.666666666667 0.000573394495413 5 1 4
of,blood,pressure 0.666666666667 0.000573394495413 5 1 4
of,and,or 0.666666666667 0.000573394495413 5 1 4
metabolism,of,and 0.666666666667 0.000573394495413 5 1 4
levels,and,a 0.666666666667 0.000573394495413 5 1 4
is,used,concomitantly 0.666666666667 0.000573394495413 5 1 4
is,reduced,by 0.666666666667 0.000573394495413 5 1 4
is,likely,to 0.666666666667 0.000573394495413 5 1 4
in,the,clearance 0.666666666667 0.000573394495413 5 1 4
in,patients,concomitantly 0.666666666667 0.000573394495413 5 1 4
if,therapy,is 0.666666666667 0.000573394495413 5 1 4
gastrointestinal,absorption,of 0.666666666667 0.000573394495413 5 1 4
extent,to,which 0.666666666667 0.000573394495413 5 1 4
excretion,of,and 0.666666666667 0.000573394495413 5 1 4
day,regimen,of 0.666666666667 0.000573394495413 5 1 4
by,concomitant,administration 0.666666666667 0.000573394495413 5 1 4
be,used,concomitantly 0.666666666667 0.000573394495413 5 1 4
be,reduced,to 0.666666666667 0.000573394495413 5 1 4
at,doses,of 0.666666666667 0.000573394495413 5 1 4
a,significant,increase 0.666666666667 0.000573394495413 5 1 4
with,caution,and 0.666666666667 0.00114678899083 2 10 -8
to,inhibition,of 0.666666666667 0.00114678899083 2 10 -8
they,should,be 0.666666666667 0.00114678899083 2 10 -8
patients,with,a 0.666666666667 0.00114678899083 2 10 -8
interactions,with,other 0.666666666667 0.00114678899083 2 10 -8
was,no,effect 0.666666666667 0.000573394495413 1 5 -4
vitro,and,in 0.666666666667 0.000573394495413 1 5 -4
to,have,a 0.666666666667 0.000573394495413 1 5 -4
to,determine,whether 0.666666666667 0.000573394495413 1 5 -4
therefore,the,potential 0.666666666667 0.000573394495413 1 5 -4
therefore,caution,should 0.666666666667 0.000573394495413 1 5 -4
the,other,hand 0.666666666667 0.000573394495413 1 5 -4
the,following,are 0.666666666667 0.000573394495413 1 5 -4
taken,concomitantly,with 0.666666666667 0.000573394495413 1 5 -4
studies,were,conducted 0.666666666667 0.000573394495413 1 5 -4
studies,of,the 0.666666666667 0.000573394495413 1 5 -4
plasma,concentrations,were 0.666666666667 0.000573394495413 1 5 -4
plasma,auc,of 0.666666666667 0.000573394495413 1 5 -4
pharmacokinetic,interactions,between 0.666666666667 0.000573394495413 1 5 -4
on,the,other 0.666666666667 0.000573394495413 1 5 -4
of,when,given 0.666666666667 0.000573394495413 1 5 -4
of,in,patients 0.666666666667 0.000573394495413 1 5 -4
of,either,or 0.666666666667 0.000573394495413 1 5 -4
observed,in,patients 0.666666666667 0.000573394495413 1 5 -4
not,sufficient,to 0.666666666667 0.000573394495413 1 5 -4
not,known,if 0.666666666667 0.000573394495413 1 5 -4
measurement,of,serum 0.666666666667 0.000573394495413 1 5 -4
kg,body,weight 0.666666666667 0.000573394495413 1 5 -4
is,highly,bound 0.666666666667 0.000573394495413 1 5 -4
is,extensively,metabolized 0.666666666667 0.000573394495413 1 5 -4
interaction,with,other 0.666666666667 0.000573394495413 1 5 -4
inducers,of,cyp3a4 0.666666666667 0.000573394495413 1 5 -4
in,this,study 0.666666666667 0.000573394495413 1 5 -4
in,the,development 0.666666666667 0.000573394495413 1 5 -4
has,also,been 0.666666666667 0.000573394495413 1 5 -4
half-life,of,the 0.666666666667 0.000573394495413 1 5 -4
for,patients,with 0.666666666667 0.000573394495413 1 5 -4
for,evidence,of 0.666666666667 0.000573394495413 1 5 -4
for,at,least 0.666666666667 0.000573394495413 1 5 -4
dosage,of,the 0.666666666667 0.000573394495413 1 5 -4
cyp3a4,activity,may 0.666666666667 0.000573394495413 1 5 -4
concurrently,with,other 0.666666666667 0.000573394495413 1 5 -4
between,the,two 0.666666666667 0.000573394495413 1 5 -4
an,increased,incidence 0.666666666667 0.000573394495413 1 5 -4
agents,should,not 0.666666666667 0.000573394495413 1 5 -4
effect,of,on 0.659574468085 0.00444380733945 8 39 -31
not,be,administered 0.652173913043 0.0021502293578 19 4 15
an,increase,in 0.636363636364 0.00401376146789 36 8 28
resulting,in,a 0.636363636364 0.00100344036697 9 2 7
in,patients,on 0.636363636364 0.00100344036697 9 2 7
concentrations,should,be 0.636363636364 0.00100344036697 9 2 7
and,has,been 0.636363636364 0.00100344036697 9 2 7
a,fold,increase 0.636363636364 0.00100344036697 9 2 7
safety,and,efficacy 0.636363636364 0.00100344036697 2 9 -7
has,been,reported 0.632183908046 0.00788417431193 71 16 55
use,of,and 0.625 0.00143348623853 13 3 10
patients,who,are 0.625 0.00143348623853 13 3 10
may,potentiate,the 0.615384615385 0.00229357798165 21 5 16
in,vitro,studies 0.615384615385 0.0045871559633 10 42 -32
the,treatment,of 0.615384615385 0.00229357798165 5 21 -16
administration,of,with 0.6 0.00258027522936 24 6 18
plasma,levels,and 0.6 0.00172018348624 16 4 12
reported,to,increase 0.6 0.000860091743119 8 2 6
and,is,not 0.6 0.000860091743119 8 2 6
with,viracept,resulted 0.6 0.00043004587156 4 1 3
with,the,metabolism 0.6 0.00043004587156 4 1 3
with,the,effect 0.6 0.00043004587156 4 1 3
with,alone,and 0.6 0.00043004587156 4 1 3
who,are,receiving 0.6 0.00043004587156 4 1 3
which,may,enhance 0.6 0.00043004587156 4 1 3
when,compared,to 0.6 0.00043004587156 4 1 3
weakness,hyperreflexia,and 0.6 0.00043004587156 4 1 3
volunteers,has,shown 0.6 0.00043004587156 4 1 3
vardenafil,mg,and 0.6 0.00043004587156 4 1 3
to,patients,taking 0.6 0.00043004587156 4 1 3
to,mg,every 0.6 0.00043004587156 4 1 3
the,ssris,and 0.6 0.00043004587156 4 1 3
the,possibility,that 0.6 0.00043004587156 4 1 3
the,liver,and 0.6 0.00043004587156 4 1 3
the,inhibition,of 0.6 0.00043004587156 4 1 3
the,gastrointestinal,absorption 0.6 0.00043004587156 4 1 3
the,dose,to 0.6 0.00043004587156 4 1 3
the,antinociceptive,effect 0.6 0.00043004587156 4 1 3
that,coadministration,of 0.6 0.00043004587156 4 1 3
switching,from,one 0.6 0.00043004587156 4 1 3
study,in,which 0.6 0.00043004587156 4 1 3
ssris,and,also 0.6 0.00043004587156 4 1 3
shown,that,the 0.6 0.00043004587156 4 1 3
should,not,exceed 0.6 0.00043004587156 4 1 3
sensitize,the,myocardium 0.6 0.00043004587156 4 1 3
resulting,in,increased 0.6 0.00043004587156 4 1 3
regimen,of,aprepitant 0.6 0.00043004587156 4 1 3
reduced,by,approximately 0.6 0.00043004587156 4 1 3
reduce,the,efficacy 0.6 0.00043004587156 4 1 3
reduce,the,absorption 0.6 0.00043004587156 4 1 3
receiving,monoamine,oxidase 0.6 0.00043004587156 4 1 3
potentiate,the,effects 0.6 0.00043004587156 4 1 3
potent,cyp3a4,inhibitor 0.6 0.00043004587156 4 1 3
percentage,increase,in 0.6 0.00043004587156 4 1 3
patients,taking,and 0.6 0.00043004587156 4 1 3
patients,receiving,monoamine 0.6 0.00043004587156 4 1 3
patients,on,concomitant 0.6 0.00043004587156 4 1 3
one,class,to 0.6 0.00043004587156 4 1 3
of,therapy,with 0.6 0.00043004587156 4 1 3
of,the,ssris 0.6 0.00043004587156 4 1 3
of,the,oral 0.6 0.00043004587156 4 1 3
of,patients,treated 0.6 0.00043004587156 4 1 3
of,less,than 0.6 0.00043004587156 4 1 3
of,and,has 0.6 0.00043004587156 4 1 3
muscle,relaxants,and 0.6 0.00043004587156 4 1 3
mesylate,injection,usp 0.6 0.00043004587156 4 1 3
least,hours,before 0.6 0.00043004587156 4 1 3
it,is,given 0.6 0.00043004587156 4 1 3
is,recommended,during 0.6 0.00043004587156 4 1 3
is,enhanced,by 0.6 0.00043004587156 4 1 3
interfere,with,absorption 0.6 0.00043004587156 4 1 3
increases,the,risk 0.6 0.00043004587156 4 1 3
increases,in,plasma 0.6 0.00043004587156 4 1 3
in,the,co-administration 0.6 0.00043004587156 4 1 3
in,switching,from 0.6 0.00043004587156 4 1 3
in,post-marketing,experience 0.6 0.00043004587156 4 1 3
in,a,fold 0.6 0.00043004587156 4 1 3
hyperreflexia,and,incoordination 0.6 0.00043004587156 4 1 3
hours,after,a 0.6 0.00043004587156 4 1 3
hepatic,enzyme,inducers 0.6 0.00043004587156 4 1 3
healthy,volunteers,has 0.6 0.00043004587156 4 1 3
have,a,narrow 0.6 0.00043004587156 4 1 3
greater,in,patients 0.6 0.00043004587156 4 1 3
from,one,class 0.6 0.00043004587156 4 1 3
effects,of,or 0.6 0.00043004587156 4 1 3
e,mesylate,injection 0.6 0.00043004587156 4 1 3
dose,to,mg 0.6 0.00043004587156 4 1 3
decrease,the,clearance 0.6 0.00043004587156 4 1 3
concurrent,therapy,with 0.6 0.00043004587156 4 1 3
compared,to,patients 0.6 0.00043004587156 4 1 3
blood,levels,of 0.6 0.00043004587156 4 1 3
been,rare,reports 0.6 0.00043004587156 4 1 3
been,observed,when 0.6 0.00043004587156 4 1 3
be,observed,carefully 0.6 0.00043004587156 4 1 3
be,administered,concurrently 0.6 0.00043004587156 4 1 3
be,administered,at 0.6 0.00043004587156 4 1 3
and,ethinyl,estradiol 0.6 0.00043004587156 4 1 3
and,also,in 0.6 0.00043004587156 4 1 3
also,in,switching 0.6 0.00043004587156 4 1 3
administration,of,or 0.6 0.00043004587156 4 1 3
administered,at,least 0.6 0.00043004587156 4 1 3
additive,effects,with 0.6 0.00043004587156 4 1 3
action,of,may 0.6 0.00043004587156 4 1 3
a,reduction,of 0.6 0.00043004587156 4 1 3
a,potential,interaction 0.6 0.00043004587156 4 1 3
of,these,agents 0.6 0.00129013761468 3 12 -9
vitro,studies,have 0.6 0.000860091743119 2 8 -6
use,of,such 0.6 0.000860091743119 2 8 -6
the,number,of 0.6 0.000860091743119 2 8 -6
the,absence,of 0.6 0.000860091743119 2 8 -6
has,been,administered 0.6 0.000860091743119 2 8 -6
following,the,administration 0.6 0.000860091743119 2 8 -6
drugs,that,inhibit 0.6 0.000860091743119 2 8 -6
withdrawn,from,given 0.6 0.00043004587156 1 4 -3
with,and,without 0.6 0.00043004587156 1 4 -3
when,used,concurrently 0.6 0.00043004587156 1 4 -3
were,treated,with 0.6 0.00043004587156 1 4 -3
was,seen,in 0.6 0.00043004587156 1 4 -3
treated,with,mg 0.6 0.00043004587156 1 4 -3
to,micrograms,ml 0.6 0.00043004587156 1 4 -3
time,must,elapse 0.6 0.00043004587156 1 4 -3
therefore,has,the 0.6 0.00043004587156 1 4 -3
the,potential,exists 0.6 0.00043004587156 1 4 -3
the,parent,and 0.6 0.00043004587156 1 4 -3
the,occurrence,of 0.6 0.00043004587156 1 4 -3
the,long,half-life 0.6 0.00043004587156 1 4 -3
the,initial,dose 0.6 0.00043004587156 1 4 -3
the,conversion,of 0.6 0.00043004587156 1 4 -3
the,concurrent,administration 0.6 0.00043004587156 1 4 -3
the,and,other 0.6 0.00043004587156 1 4 -3
that,there,is 0.6 0.00043004587156 1 4 -3
that,may,be 0.6 0.00043004587156 1 4 -3
that,inhibit,cyp3a4 0.6 0.00043004587156 1 4 -3
sufficient,time,must 0.6 0.00043004587156 1 4 -3
such,combined,therapy 0.6 0.00043004587156 1 4 -3
st,johns,wort 0.6 0.00043004587156 1 4 -3
should,be,done 0.6 0.00043004587156 1 4 -3
result,in,clinically 0.6 0.00043004587156 1 4 -3
prolongation,of,its 0.6 0.00043004587156 1 4 -3
potential,exists,for 0.6 0.00043004587156 1 4 -3
patient,receiving,the 0.6 0.00043004587156 1 4 -3
patient,being,withdrawn 0.6 0.00043004587156 1 4 -3
particular,importance,sufficient 0.6 0.00043004587156 1 4 -3
parent,and,active 0.6 0.00043004587156 1 4 -3
order,to,maintain 0.6 0.00043004587156 1 4 -3
oral,administration,of 0.6 0.00043004587156 1 4 -3
one,of,the 0.6 0.00043004587156 1 4 -3
of,with,that 0.6 0.00043004587156 1 4 -3
of,upper,gastrointestinal 0.6 0.00043004587156 1 4 -3
of,the,parent 0.6 0.00043004587156 1 4 -3
of,the,effects 0.6 0.00043004587156 1 4 -3
of,patients,who 0.6 0.00043004587156 1 4 -3
of,particular,importance 0.6 0.00043004587156 1 4 -3
of,coadministration,of 0.6 0.00043004587156 1 4 -3
of,ascorbic,acid 0.6 0.00043004587156 1 4 -3
of,a,potent 0.6 0.00043004587156 1 4 -3
observed,in,the 0.6 0.00043004587156 1 4 -3
not,likely,to 0.6 0.00043004587156 1 4 -3
no,clinical,studies 0.6 0.00043004587156 1 4 -3
must,elapse,before 0.6 0.00043004587156 1 4 -3
monitoring,of,blood 0.6 0.00043004587156 1 4 -3
mg,kg,body 0.6 0.00043004587156 1 4 -3
metabolite,at,least 0.6 0.00043004587156 1 4 -3
may,be,due 0.6 0.00043004587156 1 4 -3
long,half-life,of 0.6 0.00043004587156 1 4 -3
liver,function,tests 0.6 0.00043004587156 1 4 -3
least,weeks,may 0.6 0.00043004587156 1 4 -3
is,recommended,in 0.6 0.00043004587156 1 4 -3
is,not,likely 0.6 0.00043004587156 1 4 -3
interaction,studies,were 0.6 0.00043004587156 1 4 -3
inhibitors,ssris,and 0.6 0.00043004587156 1 4 -3
inhibitors,of,the 0.6 0.00043004587156 1 4 -3
increase,or,prolong 0.6 0.00043004587156 1 4 -3
in,vivo,and 0.6 0.00043004587156 1 4 -3
in,the,united 0.6 0.00043004587156 1 4 -3
in,the,elderly 0.6 0.00043004587156 1 4 -3
in,addition,the 0.6 0.00043004587156 1 4 -3
importance,sufficient,time 0.6 0.00043004587156 1 4 -3
history,of,severe 0.6 0.00043004587156 1 4 -3
has,no,significant 0.6 0.00043004587156 1 4 -3
has,an,effect 0.6 0.00043004587156 1 4 -3
given,the,long 0.6 0.00043004587156 1 4 -3
from,given,the 0.6 0.00043004587156 1 4 -3
following,are,examples 0.6 0.00043004587156 1 4 -3
following,a,single 0.6 0.00043004587156 1 4 -3
extent,of,the 0.6 0.00043004587156 1 4 -3
expected,to,have 0.6 0.00043004587156 1 4 -3
elapse,before,initiating 0.6 0.00043004587156 1 4 -3
during,the,period 0.6 0.00043004587156 1 4 -3
duration,of,action 0.6 0.00043004587156 1 4 -3
dose,of,should 0.6 0.00043004587156 1 4 -3
could,increase,or 0.6 0.00043004587156 1 4 -3
concentrations,may,be 0.6 0.00043004587156 1 4 -3
clinically,significant,effects 0.6 0.00043004587156 1 4 -3
clinical,trials,of 0.6 0.00043004587156 1 4 -3
between,and,other 0.6 0.00043004587156 1 4 -3
being,withdrawn,from 0.6 0.00043004587156 1 4 -3
been,administered,to 0.6 0.00043004587156 1 4 -3
be,exercised,in 0.6 0.00043004587156 1 4 -3
be,coadministered,with 0.6 0.00043004587156 1 4 -3
be,co-administered,with 0.6 0.00043004587156 1 4 -3
basis,of,the 0.6 0.00043004587156 1 4 -3
are,examples,of 0.6 0.00043004587156 1 4 -3
and,to,a 0.6 0.00043004587156 1 4 -3
and,in,vitro 0.6 0.00043004587156 1 4 -3
and,have,not 0.6 0.00043004587156 1 4 -3
analysis,of,the 0.6 0.00043004587156 1 4 -3
an,inducer,of 0.6 0.00043004587156 1 4 -3
after,the,last 0.6 0.00043004587156 1 4 -3
additive,effects,of 0.6 0.00043004587156 1 4 -3
active,metabolite,at 0.6 0.00043004587156 1 4 -3
a,tca,is 0.6 0.00043004587156 1 4 -3
a,patient,being 0.6 0.00043004587156 1 4 -3
have,not,been 0.589743589744 0.00329701834862 8 31 -23
been,reported,to 0.582089552239 0.00559059633028 53 14 39
prolongation,of,the 0.578947368421 0.00157683486239 15 4 11
in,order,to 0.578947368421 0.00157683486239 4 15 -11
an,inhibitor,of 0.578947368421 0.00157683486239 4 15 -11
the,absorption,of 0.571428571429 0.00229357798165 22 6 16
the,results,of 0.571428571429 0.00114678899083 3 11 -8
of,cytochrome,p450 0.571428571429 0.00114678899083 3 11 -8
of,on,the 0.5625 0.00258027522936 7 25 -18
increase,in,the 0.555555555556 0.0021502293578 21 6 15
coadministration,of,and 0.555555555556 0.00143348623853 14 4 10
within,hours,of 0.555555555556 0.000716743119266 7 2 5
when,was,administered 0.555555555556 0.000716743119266 7 2 5
prolong,and,intensify 0.555555555556 0.000716743119266 7 2 5
or,other,cns 0.555555555556 0.000716743119266 7 2 5
observed,closely,to 0.555555555556 0.000716743119266 7 2 5
interaction,should,be 0.555555555556 0.000716743119266 7 2 5
inhibitors,such,as 0.555555555556 0.000716743119266 7 2 5
if,the,desired 0.555555555556 0.000716743119266 7 2 5
hours,prior,to 0.555555555556 0.000716743119266 7 2 5
following,concomitant,administration 0.555555555556 0.000716743119266 7 2 5
determine,if,the 0.555555555556 0.000716743119266 7 2 5
data,indicate,that 0.555555555556 0.000716743119266 7 2 5
closely,to,determine 0.555555555556 0.000716743119266 7 2 5
been,reported,following 0.555555555556 0.000716743119266 7 2 5
and,intensify,the 0.555555555556 0.000716743119266 7 2 5
interactions,have,been 0.555555555556 0.00143348623853 4 14 -10
to,patients,with 0.555555555556 0.000716743119266 2 7 -5
pharmacokinetic,interaction,between 0.555555555556 0.000716743119266 2 7 -5
one,or,both 0.555555555556 0.000716743119266 2 7 -5
not,known,whether 0.555555555556 0.000716743119266 2 7 -5
may,occur,with 0.555555555556 0.000716743119266 2 7 -5
clinical,studies,with 0.555555555556 0.000716743119266 2 7 -5
been,found,to 0.555555555556 0.000716743119266 2 7 -5
because,of,its 0.555555555556 0.000716743119266 2 7 -5
administered,to,a 0.555555555556 0.000716743119266 2 7 -5
to,increase,the 0.545454545455 0.00172018348624 17 5 12
the,concomitant,use 0.542857142857 0.00272362385321 27 8 19
can,result,in 0.538461538462 0.00100344036697 10 3 7
clinical,studies,have 0.538461538462 0.00100344036697 3 10 -7
the,clearance,of 0.533333333333 0.00229357798165 23 7 16
cmax,and,auc 0.529411764706 0.00129013761468 13 4 9
be,administered,with 0.529411764706 0.00129013761468 13 4 9
in,the,treatment 0.529411764706 0.00129013761468 4 13 -9
a,patient,receiving 0.529411764706 0.00129013761468 4 13 -9
been,reported,with 0.52380952381 0.00157683486239 16 5 11
mg,kg,day 0.52380952381 0.00157683486239 5 16 -11
administered,concomitantly,with 0.52 0.00186353211009 19 6 13
is,not,known 0.52 0.00186353211009 6 19 -13
increase,in,plasma 0.5 0.00200688073394 21 7 14
may,decrease,the 0.5 0.00172018348624 18 6 12
when,coadministered,with 0.5 0.00114678899083 12 4 8
with,the,absorption 0.5 0.000860091743119 9 3 6
with,or,other 0.5 0.000860091743119 9 3 6
when,used,in 0.5 0.000860091743119 9 3 6
should,be,carefully 0.5 0.000860091743119 9 3 6
are,used,concomitantly 0.5 0.000860091743119 9 3 6
patient,should,be 0.5 0.00200688073394 7 21 -14
of,at,mg 0.5 0.000573394495413 6 2 4
not,be,given 0.5 0.000573394495413 6 2 4
may,have,an 0.5 0.000573394495413 6 2 4
is,added,to 0.5 0.000573394495413 6 2 4
doses,of,and 0.5 0.000573394495413 6 2 4
close,monitoring,of 0.5 0.000573394495413 6 2 4
be,carefully,monitored 0.5 0.000573394495413 6 2 4
and,its,active 0.5 0.000573394495413 6 2 4
to,a,patient 0.5 0.00114678899083 4 12 -8
that,are,metabolized 0.5 0.00114678899083 4 12 -8
with,extreme,caution 0.5 0.000286697247706 3 1 2
with,central,nervous 0.5 0.000286697247706 3 1 2
with,a,history 0.5 0.000860091743119 3 9 -6
with,a,higher 0.5 0.000286697247706 3 1 2
when,was,added 0.5 0.000286697247706 3 1 2
when,it,was 0.5 0.000286697247706 3 1 2
when,given,as 0.5 0.000286697247706 3 1 2
when,administered,concomitantly 0.5 0.000286697247706 3 1 2
were,reduced,by 0.5 0.000286697247706 3 1 2
was,added,to 0.5 0.000286697247706 3 1 2
volunteers,resulted,in 0.5 0.000286697247706 3 1 2
vasodilating,effects,of 0.5 0.000286697247706 3 1 2
under,the,curve 0.5 0.000286697247706 3 1 2
total,body,clearance 0.5 0.000286697247706 3 1 2
to,the,administration 0.5 0.000286697247706 3 1 2
to,produce,a 0.5 0.000286697247706 3 1 2
to,patients,who 0.5 0.000286697247706 3 1 2
to,patients,on 0.5 0.000286697247706 3 1 2
to,increase,in 0.5 0.000286697247706 3 1 2
time,should,be 0.5 0.000286697247706 3 1 2
these,agents,are 0.5 0.000286697247706 3 1 2
therefore,should,be 0.5 0.000286697247706 3 1 2
therefore,not,be 0.5 0.000286697247706 3 1 2
there,is,one 0.5 0.000286697247706 3 1 2
the,tail-flick,inhibition 0.5 0.000286697247706 3 1 2
the,potential,effects 0.5 0.000286697247706 3 1 2
the,patient,is 0.5 0.000286697247706 3 1 2
the,myocardium,to 0.5 0.000286697247706 3 1 2
the,hypotensive,effects 0.5 0.000286697247706 3 1 2
the,have,been 0.5 0.000286697247706 3 1 2
the,doses,of 0.5 0.000286697247706 3 1 2
taken,within,hours 0.5 0.000286697247706 3 1 2
suggesting,that,the 0.5 0.000286697247706 3 1 2
strong,cyp3a4,inhibitors 0.5 0.000286697247706 3 1 2
statistically,significant,increase 0.5 0.000286697247706 3 1 2
sonata,mg,and 0.5 0.000286697247706 3 1 2
small,decrease,in 0.5 0.000286697247706 3 1 2
signs,and,symptoms 0.5 0.000286697247706 3 1 2
serum,concentrations,should 0.5 0.000286697247706 3 1 2
resulting,in,elevated 0.5 0.000286697247706 3 1 2
resulting,in,decreased 0.5 0.000286697247706 3 1 2
reports,of,increased 0.5 0.000286697247706 3 1 2
reduced,plasma,concentrations 0.5 0.000286697247706 3 1 2
recommended,not,to 0.5 0.000286697247706 3 1 2
recommended,for,use 0.5 0.000286697247706 3 1 2
prothrombin,time,should 0.5 0.000286697247706 3 1 2
potential,interaction,between 0.5 0.000286697247706 3 1 2
possibly,due,to 0.5 0.000286697247706 3 1 2
patients,undergoing,treatment 0.5 0.000286697247706 3 1 2
other,cns,depressant 0.5 0.000286697247706 3 1 2
other,antiepileptic,drugs 0.5 0.000286697247706 3 1 2
of,with,viracept 0.5 0.000286697247706 3 1 2
of,possible,additive 0.5 0.000286697247706 3 1 2
of,percentage,increase 0.5 0.000286697247706 3 1 2
of,neuromuscular,block 0.5 0.000286697247706 3 1 2
of,mg,in 0.5 0.000286697247706 3 1 2
of,it,is 0.5 0.000286697247706 3 1 2
of,crixivan,to 0.5 0.000286697247706 3 1 2
of,and,ethinyl 0.5 0.000286697247706 3 1 2
not,recommended,for 0.5 0.000286697247706 3 1 2
nonsteroidal,anti-inflammatory,drugs 0.5 0.000286697247706 3 1 2
nonsteroidal,anti-inflammatory,agents 0.5 0.000286697247706 3 1 2
net,change,of 0.5 0.000286697247706 3 1 2
might,increase,the 0.5 0.000286697247706 3 1 2
may,be,anticipated 0.5 0.000286697247706 3 1 2
mao,inhibitors,may 0.5 0.000286697247706 3 1 2
mao,inhibitors,and 0.5 0.000286697247706 3 1 2
levels,in,the 0.5 0.000286697247706 3 1 2
lead,to,an 0.5 0.000286697247706 3 1 2
it,is,possible 0.5 0.000286697247706 3 1 2
is,recommended,not 0.5 0.000286697247706 3 1 2
is,possible,that 0.5 0.000286697247706 3 1 2
is,due,to 0.5 0.000286697247706 3 1 2
is,advised,when 0.5 0.000286697247706 3 1 2
international,normalized,ratio 0.5 0.000286697247706 3 1 2
intake,of,and 0.5 0.000286697247706 3 1 2
increase,in,fdf 0.5 0.000286697247706 3 1 2
in,the,mean 0.5 0.000286697247706 3 1 2
in,the,elimination 0.5 0.000286697247706 3 1 2
in,serum,creatinine 0.5 0.000286697247706 3 1 2
in,mean,auc 0.5 0.000286697247706 3 1 2
in,fdf,at 0.5 0.000286697247706 3 1 2
in,a,significant 0.5 0.000286697247706 3 1 2
if,is,given 0.5 0.000286697247706 3 1 2
hypotensive,effects,of 0.5 0.000286697247706 3 1 2
hours,after,the 0.5 0.000286697247706 3 1 2
given,concurrently,with 0.5 0.000286697247706 3 1 2
given,as,mg 0.5 0.000286697247706 3 1 2
for,alone,and 0.5 0.000286697247706 3 1 2
enhance,the,effect 0.5 0.000286697247706 3 1 2
effects,such,as 0.5 0.000286697247706 3 1 2
due,to,decreased 0.5 0.000286697247706 3 1 2
dosage,should,be 0.5 0.000286697247706 3 1 2
decrease,the,effects 0.5 0.000286697247706 3 1 2
decrease,plasma,levels 0.5 0.000286697247706 3 1 2
days,has,been 0.5 0.000286697247706 3 1 2
days,before,the 0.5 0.000286697247706 3 1 2
crixivan,to,mg 0.5 0.000286697247706 3 1 2
contraindicated,in,patients 0.5 0.000286697247706 3 1 2
concomitant,administration,with 0.5 0.000286697247706 3 1 2
concentrations,of,are 0.5 0.000286697247706 3 1 2
coadministration,of,oral 0.5 0.000286697247706 3 1 2
co-administration,of,mg 0.5 0.000286697247706 3 1 2
change,of,percentage 0.5 0.000286697247706 3 1 2
carbonic,anhydrase,inhibitors 0.5 0.000286697247706 3 1 2
can,be,used 0.5 0.000286697247706 3 1 2
by,monoamine,oxidase 0.5 0.000286697247706 3 1 2
by,cytochrome,p450 0.5 0.000860091743119 3 9 -6
by,a,net 0.5 0.000286697247706 3 1 2
but,should,be 0.5 0.000286697247706 3 1 2
but,not,in 0.5 0.000286697247706 3 1 2
been,reported,rarely 0.5 0.000286697247706 3 1 2
be,taken,during 0.5 0.000286697247706 3 1 2
be,monitored,frequently 0.5 0.000286697247706 3 1 2
be,exercised,if 0.5 0.000286697247706 3 1 2
be,enhanced,by 0.5 0.000286697247706 3 1 2
associated,with,elevations 0.5 0.000286697247706 3 1 2
as,mg,on 0.5 0.000286697247706 3 1 2
are,highly,protein 0.5 0.000286697247706 3 1 2
are,given,concomitantly 0.5 0.000286697247706 3 1 2
and,or,in 0.5 0.000286697247706 3 1 2
and,may,produce 0.5 0.000286697247706 3 1 2
and,may,enhance 0.5 0.000286697247706 3 1 2
and,have,been 0.5 0.000860091743119 3 9 -6
and,decrease,the 0.5 0.000286697247706 3 1 2
and,can,result 0.5 0.000286697247706 3 1 2
analyses,indicate,that 0.5 0.000286697247706 3 1 2
administration,of,tablets 0.5 0.000286697247706 3 1 2
administration,of,other 0.5 0.000286697247706 3 1 2
action,of,nondepolarizing 0.5 0.000286697247706 3 1 2
a,net,change 0.5 0.000286697247706 3 1 2
a,history,of 0.5 0.000860091743119 3 9 -6
used,in,the 0.5 0.000573394495413 2 6 -4
the,safety,and 0.5 0.000573394495413 2 6 -4
studies,in,healthy 0.5 0.000573394495413 2 6 -4
side,effects,of 0.5 0.000573394495413 2 6 -4
should,be,discontinued 0.5 0.000573394495413 2 6 -4
patients,who,were 0.5 0.000573394495413 2 6 -4
of,mg,and 0.5 0.000573394495413 2 6 -4
extent,of,absorption 0.5 0.000573394495413 2 6 -4
combined,administration,of 0.5 0.000573394495413 2 6 -4
approximately,times,the 0.5 0.000573394495413 2 6 -4
appear,to,be 0.5 0.000573394495413 2 6 -4
and,on,the 0.5 0.000573394495413 2 6 -4
an,effect,on 0.5 0.000573394495413 2 6 -4
with,other,medications 0.5 0.000286697247706 1 3 -2
with,other,known 0.5 0.000286697247706 1 3 -2
with,narrow,therapeutic 0.5 0.000286697247706 1 3 -2
with,mg,qd 0.5 0.000286697247706 1 3 -2
which,may,be 0.5 0.000286697247706 1 3 -2
when,mg,day 0.5 0.000286697247706 1 3 -2
when,administered,to 0.5 0.000286697247706 1 3 -2
well,as,the 0.5 0.000286697247706 1 3 -2
was,observed,that 0.5 0.000286697247706 1 3 -2
was,administered,to 0.5 0.000286697247706 1 3 -2
volunteers,have,shown 0.5 0.000286697247706 1 3 -2
use,of,in 0.5 0.000286697247706 1 3 -2
tyrosine,phosphorylation,in 0.5 0.000286697247706 1 3 -2
treatment,with,mg 0.5 0.000286697247706 1 3 -2
to,the,pharmacology 0.5 0.000286697247706 1 3 -2
to,change,the 0.5 0.000286697247706 1 3 -2
to,assess,the 0.5 0.000286697247706 1 3 -2
to,alter,the 0.5 0.000286697247706 1 3 -2
to,a,decrease 0.5 0.000286697247706 1 3 -2
times,the,recommended 0.5 0.000286697247706 1 3 -2
these,should,be 0.5 0.000286697247706 1 3 -2
these,in,vitro 0.5 0.000286697247706 1 3 -2
therefore,be,closely 0.5 0.000286697247706 1 3 -2
there,is,the 0.5 0.000286697247706 1 3 -2
there,is,an 0.5 0.000286697247706 1 3 -2
therapeutic,concentrations,of 0.5 0.000286697247706 1 3 -2
the,serum,concentrations 0.5 0.000286697247706 1 3 -2
the,reduction,of 0.5 0.000286697247706 1 3 -2
the,pharmacology,of 0.5 0.000286697247706 1 3 -2
the,onset,of 0.5 0.000286697247706 1 3 -2
the,maximum,recommended 0.5 0.000286697247706 1 3 -2
the,increased,risk 0.5 0.000286697247706 1 3 -2
the,effect,may 0.5 0.000286697247706 1 3 -2
the,class,of 0.5 0.000286697247706 1 3 -2
the,case,of 0.5 0.000286697247706 1 3 -2
the,appearance,of 0.5 0.000286697247706 1 3 -2
the,active,metabolite 0.5 0.000286697247706 1 3 -2
than,in,the 0.5 0.000286697247706 1 3 -2
strong,inhibitors,of 0.5 0.000286697247706 1 3 -2
some,patients,receiving 0.5 0.000286697247706 1 3 -2
signs,of,toxicity 0.5 0.000286697247706 1 3 -2
show,that,the 0.5 0.000286697247706 1 3 -2
should,be,warned 0.5 0.000286697247706 1 3 -2
should,be,kept 0.5 0.000286697247706 1 3 -2
should,be,employed 0.5 0.000286697247706 1 3 -2
should,be,determined 0.5 0.000286697247706 1 3 -2
serum,levels,may 0.5 0.000286697247706 1 3 -2
replacement,therapy,may 0.5 0.000286697247706 1 3 -2
relevance,of,these 0.5 0.000286697247706 1 3 -2
release,in,the 0.5 0.000286697247706 1 3 -2
relative,to,the 0.5 0.000286697247706 1 3 -2
reduced,by,and 0.5 0.000286697247706 1 3 -2
recommended,dose,of 0.5 0.000286697247706 1 3 -2
receiving,should,be 0.5 0.000286697247706 1 3 -2
prolongation,in,the 0.5 0.000286697247706 1 3 -2
potential,for,interactions 0.5 0.000286697247706 1 3 -2
potent,inhibitors,of 0.5 0.000286697247706 1 3 -2
possibility,of,a 0.5 0.000286697247706 1 3 -2
plasma,proteins,is 0.5 0.000286697247706 1 3 -2
patients,with,chronic 0.5 0.000286697247706 1 3 -2
patients,receiving,should 0.5 0.000286697247706 1 3 -2
patients,receiving,oral 0.5 0.000286697247706 1 3 -2
oral,has,been 0.5 0.000286697247706 1 3 -2
or,on,the 0.5 0.000286697247706 1 3 -2
or,did,not 0.5 0.000286697247706 1 3 -2
on,blood,pressure 0.5 0.000286697247706 1 3 -2
on,a,mg 0.5 0.000286697247706 1 3 -2
of,these,is 0.5 0.000286697247706 1 3 -2
of,racemic,mg 0.5 0.000286697247706 1 3 -2
of,or,mg 0.5 0.000286697247706 1 3 -2
of,mg,on 0.5 0.000286697247706 1 3 -2
of,interaction,between 0.5 0.000286697247706 1 3 -2
of,does,not 0.5 0.000286697247706 1 3 -2
of,concomitant,use 0.5 0.000286697247706 1 3 -2
of,as,a 0.5 0.000286697247706 1 3 -2
of,anaphylactic,reaction 0.5 0.000286697247706 1 3 -2
occur,when,is 0.5 0.000286697247706 1 3 -2
not,be,coadministered 0.5 0.000286697247706 1 3 -2
no,effect,of 0.5 0.000286697247706 1 3 -2
most,of,the 0.5 0.000286697247706 1 3 -2
ml,when,mg 0.5 0.000286697247706 1 3 -2
micrograms,ml,when 0.5 0.000286697247706 1 3 -2
mg,of,per 0.5 0.000286697247706 1 3 -2
mg,kg,dose 0.5 0.000286697247706 1 3 -2
mg,day,was 0.5 0.000286697247706 1 3 -2
mg,day,in 0.5 0.000286697247706 1 3 -2
metabolism,of,other 0.5 0.000286697247706 1 3 -2
medications,that,are 0.5 0.000286697247706 1 3 -2
mechanism,of,action 0.5 0.000286697247706 1 3 -2
mean,c,max 0.5 0.000286697247706 1 3 -2
may,increase,or 0.5 0.000286697247706 1 3 -2
may,be,used 0.5 0.000286697247706 1 3 -2
larger,doses,of 0.5 0.000286697247706 1 3 -2
known,to,affect 0.5 0.000286697247706 1 3 -2
it,was,observed 0.5 0.000286697247706 1 3 -2
is,likely,that 0.5 0.000286697247706 1 3 -2
interval,of,at 0.5 0.000286697247706 1 3 -2
interaction,study,with 0.5 0.000286697247706 1 3 -2
interaction,of,with 0.5 0.000286697247706 1 3 -2
inhibitors,of,cyp2d6 0.5 0.000286697247706 1 3 -2
inhibitors,may,increase 0.5 0.000286697247706 1 3 -2
inhibition,of,metabolism 0.5 0.000286697247706 1 3 -2
inhibit,the,cytochrome 0.5 0.000286697247706 1 3 -2
induce,cytochrome,p450 0.5 0.000286697247706 1 3 -2
in,the,patients 0.5 0.000286697247706 1 3 -2
in,the,liver 0.5 0.000286697247706 1 3 -2
in,the,intestine 0.5 0.000286697247706 1 3 -2
in,the,free 0.5 0.000286697247706 1 3 -2
in,the,case 0.5 0.000286697247706 1 3 -2
in,healthy,male 0.5 0.000286697247706 1 3 -2
in,a,single-dose 0.5 0.000286697247706 1 3 -2
however,in,a 0.5 0.000286697247706 1 3 -2
hiv,protease,inhibitors 0.5 0.000286697247706 1 3 -2
have,been,administered 0.5 0.000286697247706 1 3 -2
has,been,suggested 0.5 0.000286697247706 1 3 -2
greater,than,mg 0.5 0.000286697247706 1 3 -2
found,to,have 0.5 0.000286697247706 1 3 -2
for,loss,of 0.5 0.000286697247706 1 3 -2
failure,as,well 0.5 0.000286697247706 1 3 -2
end,of,the 0.5 0.000286697247706 1 3 -2
effect,of,mg 0.5 0.000286697247706 1 3 -2
effect,of,concomitant 0.5 0.000286697247706 1 3 -2
drugs,that,should 0.5 0.000286697247706 1 3 -2
doses,of,ascorbic 0.5 0.000286697247706 1 3 -2
dose,of,in 0.5 0.000286697247706 1 3 -2
dose,of,administered 0.5 0.000286697247706 1 3 -2
dmpge2,mg,kg 0.5 0.000286697247706 1 3 -2
course,of,treatment 0.5 0.000286697247706 1 3 -2
course,of,the 0.5 0.000286697247706 1 3 -2
concentrations,of,were 0.5 0.000286697247706 1 3 -2
concentrations,of,or 0.5 0.000286697247706 1 3 -2
concentration,should,be 0.5 0.000286697247706 1 3 -2
coadministration,of,viracept 0.5 0.000286697247706 1 3 -2
clearance,of,was 0.5 0.000286697247706 1 3 -2
chloral,hydrate,and 0.5 0.000286697247706 1 3 -2
careful,patient,monitoring 0.5 0.000286697247706 1 3 -2
careful,consideration,should 0.5 0.000286697247706 1 3 -2
c,p,a 0.5 0.000286697247706 1 3 -2
by,this,isoenzyme 0.5 0.000286697247706 1 3 -2
both,of,these 0.5 0.000286697247706 1 3 -2
both,and,mc 0.5 0.000286697247706 1 3 -2
bioavailability,of,was 0.5 0.000286697247706 1 3 -2
between,and,the 0.5 0.000286697247706 1 3 -2
between,and,has 0.5 0.000286697247706 1 3 -2
been,observed,following 0.5 0.000286697247706 1 3 -2
be,warned,of 0.5 0.000286697247706 1 3 -2
be,due,to 0.5 0.000286697247706 1 3 -2
be,decreased,when 0.5 0.000286697247706 1 3 -2
based,on,these 0.5 0.000286697247706 1 3 -2
auc,hrs,of 0.5 0.000286697247706 1 3 -2
at,least,one 0.5 0.000286697247706 1 3 -2
at,least,days 0.5 0.000286697247706 1 3 -2
are,inhibitors,of 0.5 0.000286697247706 1 3 -2
and,other,agents 0.5 0.000286697247706 1 3 -2
and,mg,daily 0.5 0.000286697247706 1 3 -2
and,may,require 0.5 0.000286697247706 1 3 -2
and,a,prolongation 0.5 0.000286697247706 1 3 -2
an,interval,of 0.5 0.000286697247706 1 3 -2
although,specific,interaction 0.5 0.000286697247706 1 3 -2
advised,in,patients 0.5 0.000286697247706 1 3 -2
administration,of,racemic 0.5 0.000286697247706 1 3 -2
a,potential,for 0.5 0.000286697247706 1 3 -2
a,pharmacokinetic,interaction 0.5 0.000286697247706 1 3 -2
in,some,patients 0.481481481481 0.00186353211009 20 7 13
the,patient,should 0.481481481481 0.00186353211009 7 20 -13
the,coadministration,of 0.478260869565 0.00157683486239 6 17 -11
should,be,administered 0.473684210526 0.00129013761468 14 5 9
changes,in,the 0.473684210526 0.00129013761468 5 14 -9
are,metabolized,by 0.473684210526 0.00129013761468 5 14 -9
the,bioavailability,of 0.466666666667 0.00100344036697 4 11 -7
of,should,be 0.466666666667 0.00100344036697 4 11 -7
day,for,days 0.466666666667 0.00100344036697 4 11 -7
may,reduce,the 0.461538461538 0.00172018348624 19 7 12
plasma,levels,of 0.454545454545 0.00286697247706 32 12 20
was,associated,with 0.454545454545 0.000716743119266 8 3 5
urinary,excretion,of 0.454545454545 0.000716743119266 8 3 5
the,concentration,of 0.454545454545 0.000716743119266 8 3 5
of,have,been 0.454545454545 0.000716743119266 8 3 5
may,inhibit,the 0.454545454545 0.000716743119266 8 3 5
in,auc,and 0.454545454545 0.000716743119266 8 3 5
be,used,cautiously 0.454545454545 0.000716743119266 8 3 5
the,level,of 0.454545454545 0.000716743119266 3 8 -5
such,patients,may 0.454545454545 0.000716743119266 3 8 -5
prothrombin,time,or 0.454545454545 0.000716743119266 3 8 -5
protein,binding,of 0.454545454545 0.000716743119266 3 8 -5
of,the,cytochrome 0.454545454545 0.000716743119266 3 8 -5
it,should,be 0.454545454545 0.000716743119266 3 8 -5
is,known,to 0.454545454545 0.000716743119266 3 8 -5
the,use,of 0.450980392157 0.00329701834862 14 37 -23
is,not,recommended 0.444444444444 0.00114678899083 13 5 8
it,is,not 0.44 0.00157683486239 7 18 -11
been,reported,in 0.435897435897 0.0024369266055 28 11 17
has,been,shown 0.428571428571 0.00172018348624 20 8 12
concomitant,treatment,with 0.428571428571 0.000860091743119 10 4 6
the,incidence,of 0.428571428571 0.00129013761468 6 15 -9
that,have,been 0.428571428571 0.00043004587156 5 2 3
systolic,blood,pressure 0.428571428571 0.00043004587156 5 2 3
study,in,healthy 0.428571428571 0.00043004587156 5 2 3
renal,excretion,of 0.428571428571 0.00043004587156 5 2 3
patients,receiving,or 0.428571428571 0.00043004587156 5 2 3
patients,receiving,and 0.428571428571 0.00043004587156 5 2 3
or,other,that 0.428571428571 0.00043004587156 5 2 3
or,hours,after 0.428571428571 0.00043004587156 5 2 3
of,each,other 0.428571428571 0.00043004587156 5 2 3
of,and,and 0.428571428571 0.00043004587156 5 2 3
neuromuscular,blocking,action 0.428571428571 0.00043004587156 5 2 3
metabolic,clearance,of 0.428571428571 0.00043004587156 5 2 3
its,active,metabolite 0.428571428571 0.00043004587156 5 2 3
it,is,suggested 0.428571428571 0.00043004587156 5 2 3
is,co-administered,with 0.428571428571 0.00043004587156 5 2 3
in,plasma,concentrations 0.428571428571 0.00043004587156 5 2 3
if,is,administered 0.428571428571 0.00043004587156 5 2 3
have,been,rare 0.428571428571 0.00043004587156 5 2 3
has,been,demonstrated 0.428571428571 0.00043004587156 5 2 3
h,e,mesylate 0.428571428571 0.00043004587156 5 2 3
drugs,such,as 0.428571428571 0.00043004587156 5 2 3
desired,effect,of 0.428571428571 0.00043004587156 5 2 3
depend,on,the 0.428571428571 0.00043004587156 5 2 3
d,h,e 0.428571428571 0.00043004587156 5 2 3
by,the,concomitant 0.428571428571 0.00043004587156 5 2 3
be,administered,concomitantly 0.428571428571 0.00043004587156 5 2 3
as,and,may 0.428571428571 0.00043004587156 5 2 3
and,may,reduce 0.428571428571 0.00043004587156 5 2 3
administration,of,to 0.428571428571 0.00043004587156 5 2 3
a,cyp3a4,substrate 0.428571428571 0.00043004587156 5 2 3
volume,of,distribution 0.428571428571 0.00043004587156 2 5 -3
twice,daily,for 0.428571428571 0.00043004587156 2 5 -3
the,recommended,dose 0.428571428571 0.00043004587156 2 5 -3
that,induce,cyp3a4 0.428571428571 0.00043004587156 2 5 -3
risk,of,myopathy 0.428571428571 0.00043004587156 2 5 -3
other,suitable,coagulation 0.428571428571 0.00043004587156 2 5 -3
of,the,effect 0.428571428571 0.00043004587156 2 5 -3
of,at,least 0.428571428571 0.00043004587156 2 5 -3
metabolized,by,cyp2d6 0.428571428571 0.00043004587156 2 5 -3
may,be,reduced 0.428571428571 0.00043004587156 2 5 -3
may,be,associated 0.428571428571 0.00043004587156 2 5 -3
in,vivo,studies 0.428571428571 0.00043004587156 2 5 -3
healthy,male,volunteers 0.428571428571 0.00043004587156 2 5 -3
have,demonstrated,that 0.428571428571 0.00043004587156 2 5 -3
for,signs,of 0.428571428571 0.00043004587156 2 5 -3
effects,of,either 0.428571428571 0.00043004587156 2 5 -3
effects,of,concomitant 0.428571428571 0.00043004587156 2 5 -3
concomitant,therapy,with 0.428571428571 0.00043004587156 2 5 -3
care,should,be 0.428571428571 0.00043004587156 2 5 -3
been,used,concomitantly 0.428571428571 0.00043004587156 2 5 -3
and,efficacy,of 0.428571428571 0.00043004587156 2 5 -3
have,been,reported 0.415730337079 0.00530389908257 63 26 37
concurrent,administration,of 0.411764705882 0.00200688073394 24 10 14
to,patients,receiving 0.411764705882 0.00100344036697 12 5 7
the,plasma,levels 0.411764705882 0.00100344036697 12 5 7
in,healthy,subjects 0.411764705882 0.00100344036697 12 5 7
the,co-administration,of 0.4 0.000573394495413 7 3 4
renal,function,should 0.4 0.000573394495413 7 3 4
oral,hypoglycemic,agents 0.4 0.000573394495413 7 3 4
once,daily,for 0.4 0.000573394495413 7 3 4
of,mg,bid 0.4 0.000573394495413 7 3 4
is,administered,with 0.4 0.000573394495413 7 3 4
effect,of,the 0.4 0.000573394495413 7 3 4
co-administration,of,with 0.4 0.000573394495413 7 3 4
as,compared,to 0.4 0.000573394495413 7 3 4
was,found,to 0.4 0.000573394495413 3 7 -4
use,of,a 0.4 0.000573394495413 3 7 -4
the,basis,of 0.4 0.000573394495413 3 7 -4
on,the,basis 0.4 0.000573394495413 3 7 -4
of,patients,with 0.4 0.000573394495413 3 7 -4
metabolized,by,cytochrome 0.4 0.000573394495413 3 7 -4
may,be,decreased 0.4 0.000573394495413 3 7 -4
have,been,found 0.4 0.000573394495413 3 7 -4
dose,adjustment,of 0.4 0.000573394495413 3 7 -4
be,associated,with 0.4 0.000573394495413 3 7 -4
levels,should,be 0.391304347826 0.00129013761468 7 16 -9
in,combination,with 0.384615384615 0.0043004587156 24 54 -30
the,combination,of 0.384615384615 0.000716743119266 9 4 5
be,closely,monitored 0.384615384615 0.000716743119266 9 4 5
adjustment,of,the 0.384615384615 0.000716743119266 9 4 5
result,in,a 0.384615384615 0.000716743119266 4 9 -5
in,vitro,and 0.384615384615 0.000716743119266 4 9 -5
concentrations,of,the 0.384615384615 0.000716743119266 4 9 -5
concomitant,administration,of 0.379310344828 0.00788417431193 100 45 55
been,shown,to 0.377777777778 0.0024369266055 31 14 17
administration,of,and 0.375 0.00258027522936 33 15 18
serum,levels,of 0.375 0.000860091743119 11 5 6
at,least,hours 0.375 0.000860091743119 11 5 6
should,be,considered 0.375 0.00172018348624 10 22 -12
the,activity,of 0.368421052632 0.00100344036697 6 13 -7
the,presence,of 0.348837209302 0.0021502293578 14 29 -15
may,increase,the 0.34328358209 0.00329701834862 45 22 23
such,as,and 0.333333333333 0.00172018348624 24 12 12
has,not,been 0.333333333333 0.0021502293578 15 30 -15
coadministration,of,with 0.333333333333 0.000860091743119 12 6 6
have,been,reports 0.333333333333 0.000716743119266 10 5 5
caution,in,patients 0.333333333333 0.000716743119266 10 5 5
and,should,be 0.333333333333 0.000716743119266 10 5 5
of,and,its 0.333333333333 0.000573394495413 8 4 4
nervous,system,depressants 0.333333333333 0.000573394495413 8 4 4
high,doses,of 0.333333333333 0.000573394495413 8 4 4
associated,with,an 0.333333333333 0.000573394495413 8 4 4
a,dose,of 0.333333333333 0.000573394495413 8 4 4
any,of,the 0.333333333333 0.00100344036697 7 14 -7
with,vitamin,d 0.333333333333 0.00043004587156 6 3 3
vitamin,d,analogues 0.333333333333 0.00043004587156 6 3 3
of,treatment,with 0.333333333333 0.00043004587156 6 3 3
of,and,a 0.333333333333 0.00043004587156 6 3 3
mg,twice,daily 0.333333333333 0.000860091743119 6 12 -6
elevated,plasma,concentrations 0.333333333333 0.00043004587156 6 3 3
concomitantly,with,other 0.333333333333 0.00043004587156 6 3 3
cns,depressant,effects 0.333333333333 0.00043004587156 6 3 3
bid,for,days 0.333333333333 0.00043004587156 6 3 3
with,resulted,in 0.333333333333 0.000286697247706 4 2 2
with,other,that 0.333333333333 0.000573394495413 4 8 -4
with,mg,of 0.333333333333 0.000286697247706 4 2 2
when,administered,with 0.333333333333 0.000286697247706 4 2 2
when,a,single 0.333333333333 0.000286697247706 4 2 2
under,the,plasma 0.333333333333 0.000286697247706 4 2 2
to,be,administered 0.333333333333 0.000286697247706 4 2 2
therapy,is,initiated 0.333333333333 0.000286697247706 4 2 2
the,serum,concentration 0.333333333333 0.000286697247706 4 2 2
the,renal,excretion 0.333333333333 0.000286697247706 4 2 2
the,potential,to 0.333333333333 0.000573394495413 4 8 -4
the,efficacy,of 0.333333333333 0.000286697247706 4 2 2
the,duration,of 0.333333333333 0.000573394495413 4 8 -4
the,amount,of 0.333333333333 0.000286697247706 4 2 2
suggest,that,the 0.333333333333 0.000573394495413 4 8 -4
similar,to,those 0.333333333333 0.000286697247706 4 2 2
side,effects,affecting 0.333333333333 0.000286697247706 4 2 2
serum,levels,should 0.333333333333 0.000573394495413 4 8 -4
renal,tubular,secretion 0.333333333333 0.000286697247706 4 2 2
rare,reports,of 0.333333333333 0.000286697247706 4 2 2
prothrombin,time,in 0.333333333333 0.000286697247706 4 2 2
other,central,nervous 0.333333333333 0.000286697247706 4 2 2
of,has,been 0.333333333333 0.000286697247706 4 2 2
of,both,and 0.333333333333 0.000286697247706 4 2 2
observed,closely,for 0.333333333333 0.000573394495413 4 8 -4
nevertheless,caution,is 0.333333333333 0.000286697247706 4 2 2
mg,on,day 0.333333333333 0.000286697247706 4 2 2
mg,day,for 0.333333333333 0.000573394495413 4 8 -4
mg,bid,for 0.333333333333 0.000286697247706 4 2 2
may,increase,plasma 0.333333333333 0.000286697247706 4 2 2
may,be,enhanced 0.333333333333 0.000286697247706 4 2 2
is,suggested,that 0.333333333333 0.000286697247706 4 2 2
is,indicated,in 0.333333333333 0.000286697247706 4 2 2
interact,with,the 0.333333333333 0.000286697247706 4 2 2
have,occurred,in 0.333333333333 0.000286697247706 4 2 2
effect,may,be 0.333333333333 0.000286697247706 4 2 2
caution,is,recommended 0.333333333333 0.000286697247706 4 2 2
be,given,with 0.333333333333 0.000286697247706 4 2 2
are,to,be 0.333333333333 0.000286697247706 4 2 2
and,the,dose 0.333333333333 0.000286697247706 4 2 2
also,been,shown 0.333333333333 0.000286697247706 4 2 2
absorption,of,is 0.333333333333 0.000286697247706 4 2 2
you,are,taking 0.333333333333 0.00043004587156 3 6 -3
with,that,are 0.333333333333 0.00043004587156 3 6 -3
to,healthy,volunteers 0.333333333333 0.00043004587156 3 6 -3
time,or,other 0.333333333333 0.00043004587156 3 6 -3
of,the,following 0.333333333333 0.00043004587156 3 6 -3
of,and,the 0.333333333333 0.00043004587156 3 6 -3
not,been,evaluated 0.333333333333 0.00043004587156 3 6 -3
mg,day,of 0.333333333333 0.00043004587156 3 6 -3
may,be,required 0.333333333333 0.00043004587156 3 6 -3
inhibitors,of,cyp3a4 0.333333333333 0.00043004587156 3 6 -3
inhibition,of,the 0.333333333333 0.00043004587156 3 6 -3
in,prothrombin,time 0.333333333333 0.00043004587156 3 6 -3
in,diabetic,patients 0.333333333333 0.00043004587156 3 6 -3
if,you,are 0.333333333333 0.00043004587156 3 6 -3
blood,levels,and 0.333333333333 0.00043004587156 3 6 -3
be,given,to 0.333333333333 0.00043004587156 3 6 -3
a,mg,dose 0.333333333333 0.00043004587156 3 6 -3
within,the,first 0.333333333333 0.000143348623853 2 1 1
within,hours,before 0.333333333333 0.000143348623853 2 1 1
with,tikosyn,mcg 0.333333333333 0.000143348623853 2 1 1
with,other,or 0.333333333333 0.000143348623853 2 1 1
with,other,members 0.333333333333 0.000143348623853 2 1 1
with,oral,and 0.333333333333 0.000143348623853 2 1 1
with,or,and 0.333333333333 0.000143348623853 2 1 1
with,neuromuscular,transmission 0.333333333333 0.000143348623853 2 1 1
with,mild,to 0.333333333333 0.000143348623853 2 1 1
with,elevations,in 0.333333333333 0.000143348623853 2 1 1
with,elevated,levels 0.333333333333 0.000143348623853 2 1 1
with,beta-adrenergic,blocking 0.333333333333 0.000143348623853 2 1 1
will,not,affect 0.333333333333 0.000143348623853 2 1 1
who,are,concurrently 0.333333333333 0.000143348623853 2 1 1
while,the,patient 0.333333333333 0.000143348623853 2 1 1
which,may,present 0.333333333333 0.000143348623853 2 1 1
which,could,increase 0.333333333333 0.000143348623853 2 1 1
when,was,taken 0.333333333333 0.000143348623853 2 1 1
when,therapy,is 0.333333333333 0.000143348623853 2 1 1
when,is,co-administered 0.333333333333 0.000143348623853 2 1 1
when,are,administered 0.333333333333 0.000143348623853 2 1 1
when,and,were 0.333333333333 0.000143348623853 2 1 1
were,reported,to 0.333333333333 0.000143348623853 2 1 1
were,increased,by 0.333333333333 0.000143348623853 2 1 1
were,concomitantly,administered 0.333333333333 0.000143348623853 2 1 1
well,as,a 0.333333333333 0.000143348623853 2 1 1
we,conclude,that 0.333333333333 0.000143348623853 2 1 1
was,given,with 0.333333333333 0.000143348623853 2 1 1
was,decreased,by 0.333333333333 0.000143348623853 2 1 1
was,administered,with 0.333333333333 0.000286697247706 2 4 -2
was,administered,concomitantly 0.333333333333 0.000143348623853 2 1 1
warfarin,the,effects 0.333333333333 0.000143348623853 2 1 1
vitro,studies,in 0.333333333333 0.000286697247706 2 4 -2
vitro,data,suggest 0.333333333333 0.000143348623853 2 1 1
vitamin,d,but 0.333333333333 0.000143348623853 2 1 1
variability,in,the 0.333333333333 0.000143348623853 2 1 1
used,in,conjunction 0.333333333333 0.000143348623853 2 1 1
used,cautiously,with 0.333333333333 0.000143348623853 2 1 1
use,of,toradol 0.333333333333 0.000143348623853 2 1 1
transient,elevations,in 0.333333333333 0.000143348623853 2 1 1
to,the,possibility 0.333333333333 0.000143348623853 2 1 1
to,the,increased 0.333333333333 0.000143348623853 2 1 1
to,possible,decrease 0.333333333333 0.000143348623853 2 1 1
to,moderate,hypertension 0.333333333333 0.000143348623853 2 1 1
to,mg,kg 0.333333333333 0.000286697247706 2 4 -2
to,have,decreased 0.333333333333 0.000143348623853 2 1 1
to,cause,weakness 0.333333333333 0.000143348623853 2 1 1
to,be,the 0.333333333333 0.000143348623853 2 1 1
to,be,reduced 0.333333333333 0.000143348623853 2 1 1
to,be,of 0.333333333333 0.000286697247706 2 4 -2
to,a,maintenance 0.333333333333 0.000143348623853 2 1 1
titrated,to,a 0.333333333333 0.000286697247706 2 4 -2
tikosyn,mcg,bid 0.333333333333 0.000143348623853 2 1 1
this,report,describes 0.333333333333 0.000143348623853 2 1 1
these,patients,are 0.333333333333 0.000143348623853 2 1 1
these,agents,with 0.333333333333 0.000143348623853 2 1 1
therefore,the,addition 0.333333333333 0.000143348623853 2 1 1
therefore,close,monitoring 0.333333333333 0.000143348623853 2 1 1
there,may,be 0.333333333333 0.000286697247706 2 4 -2
therapy,with,bextra 0.333333333333 0.000143348623853 2 1 1
therapy,with,and 0.333333333333 0.000143348623853 2 1 1
therapy,in,patients 0.333333333333 0.000143348623853 2 1 1
therapeutic,efficacy,of 0.333333333333 0.000143348623853 2 1 1
the,two,are 0.333333333333 0.000143348623853 2 1 1
the,toxicity,of 0.333333333333 0.000286697247706 2 4 -2
the,should,be 0.333333333333 0.000286697247706 2 4 -2
the,rate,and 0.333333333333 0.000286697247706 2 4 -2
the,qtc,interval 0.333333333333 0.000143348623853 2 1 1
the,prolongation,of 0.333333333333 0.000143348623853 2 1 1
the,pressor,effects 0.333333333333 0.000143348623853 2 1 1
the,potential,benefits 0.333333333333 0.000143348623853 2 1 1
the,physician,should 0.333333333333 0.000286697247706 2 4 -2
the,package,insert 0.333333333333 0.000143348623853 2 1 1
the,induction,of 0.333333333333 0.000143348623853 2 1 1
the,gastrointestinal,tract 0.333333333333 0.000143348623853 2 1 1
the,following,may 0.333333333333 0.000286697247706 2 4 -2
the,excretion,of 0.333333333333 0.000143348623853 2 1 1
the,day,regimen 0.333333333333 0.000143348623853 2 1 1
the,daily,dose 0.333333333333 0.000143348623853 2 1 1
the,concentrations,of 0.333333333333 0.000143348623853 2 1 1
the,capsule,formulation 0.333333333333 0.000143348623853 2 1 1
the,c,max 0.333333333333 0.000143348623853 2 1 1
the,blood-glucose,lowering 0.333333333333 0.000286697247706 2 4 -2
the,adverse,effects 0.333333333333 0.000143348623853 2 1 1
that,may,result 0.333333333333 0.000143348623853 2 1 1
that,may,enhance 0.333333333333 0.000143348623853 2 1 1
that,interfere,with 0.333333333333 0.000286697247706 2 4 -2
that,in,patients 0.333333333333 0.000143348623853 2 1 1
that,concomitant,use 0.333333333333 0.000143348623853 2 1 1
that,co-administration,of 0.333333333333 0.000143348623853 2 1 1
that,are,predominantly 0.333333333333 0.000143348623853 2 1 1
sustained,increases,in 0.333333333333 0.000143348623853 2 1 1
suitable,coagulation,test 0.333333333333 0.000143348623853 2 1 1
suggest,that,may 0.333333333333 0.000143348623853 2 1 1
suggest,that,coadministration 0.333333333333 0.000143348623853 2 1 1
such,as,may 0.333333333333 0.000143348623853 2 1 1
such,as,have 0.333333333333 0.000143348623853 2 1 1
such,as,acetylsalicylic 0.333333333333 0.000143348623853 2 1 1
such,an,effect 0.333333333333 0.000143348623853 2 1 1
study,demonstrated,that 0.333333333333 0.000143348623853 2 1 1
studies,in,humans 0.333333333333 0.000286697247706 2 4 -2
ssris,have,been 0.333333333333 0.000143348623853 2 1 1
spontaneous,reports,of 0.333333333333 0.000143348623853 2 1 1
single,oral,doses 0.333333333333 0.000143348623853 2 1 1
since,interactions,have 0.333333333333 0.000143348623853 2 1 1
simultaneous,use,of 0.333333333333 0.000286697247706 2 4 -2
significant,increases,in 0.333333333333 0.000286697247706 2 4 -2
side,effects,in 0.333333333333 0.000143348623853 2 1 1
should,therefore,be 0.333333333333 0.000286697247706 2 4 -2
should,be,reviewed 0.333333333333 0.000143348623853 2 1 1
should,be,initiated 0.333333333333 0.000143348623853 2 1 1
should,be,adjusted 0.333333333333 0.000143348623853 2 1 1
should,also,be 0.333333333333 0.000286697247706 2 4 -2
severe,peripheral,vasospasm 0.333333333333 0.000143348623853 2 1 1
several,days,after 0.333333333333 0.000143348623853 2 1 1
serum,concentrations,and 0.333333333333 0.000143348623853 2 1 1
risk,of,toxicity 0.333333333333 0.000143348623853 2 1 1
result,in,reduced 0.333333333333 0.000143348623853 2 1 1
response,to,in 0.333333333333 0.000143348623853 2 1 1
reported,to,have 0.333333333333 0.000143348623853 2 1 1
reduction,of,crixivan 0.333333333333 0.000143348623853 2 1 1
reduce,endogenous,plasma 0.333333333333 0.000143348623853 2 1 1
reactions,have,been 0.333333333333 0.000143348623853 2 1 1
rate,of,elimination 0.333333333333 0.000143348623853 2 1 1
rate,and,extent 0.333333333333 0.000286697247706 2 4 -2
rare,instances,of 0.333333333333 0.000143348623853 2 1 1
qt,c,interval 0.333333333333 0.000143348623853 2 1 1
prolong,the,qt 0.333333333333 0.000143348623853 2 1 1
pressor,effects,of 0.333333333333 0.000143348623853 2 1 1
potentiate,the,hypotensive 0.333333333333 0.000143348623853 2 1 1
potential,interaction,of 0.333333333333 0.000143348623853 2 1 1
potential,effects,of 0.333333333333 0.000143348623853 2 1 1
potent,inducer,of 0.333333333333 0.000143348623853 2 1 1
potent,cyp3a4,inhibitors 0.333333333333 0.000143348623853 2 1 1
potent,cyp3a4,inducer 0.333333333333 0.000143348623853 2 1 1
post-marketing,experience,there 0.333333333333 0.000143348623853 2 1 1
possible,interaction,between 0.333333333333 0.000143348623853 2 1 1
plasma,concentrations,to 0.333333333333 0.000143348623853 2 1 1
plasma,concentrations,should 0.333333333333 0.000143348623853 2 1 1
plasma,concentrations,increased 0.333333333333 0.000143348623853 2 1 1
plasma,concentrations,in 0.333333333333 0.000143348623853 2 1 1
physicians,should,consider 0.333333333333 0.000143348623853 2 1 1
phenytoin,phenobarbital,the 0.333333333333 0.000143348623853 2 1 1
phenobarbital,the,coadministration 0.333333333333 0.000143348623853 2 1 1
patients,with,mild 0.333333333333 0.000143348623853 2 1 1
patients,treated,concurrently 0.333333333333 0.000143348623853 2 1 1
patients,receiving,therapy 0.333333333333 0.000143348623853 2 1 1
patients,on,should 0.333333333333 0.000143348623853 2 1 1
patient,has,been 0.333333333333 0.000286697247706 2 4 -2
other,members,of 0.333333333333 0.000143348623853 2 1 1
other,inducers,of 0.333333333333 0.000143348623853 2 1 1
order,to,avoid 0.333333333333 0.000286697247706 2 4 -2
oral,and,can 0.333333333333 0.000143348623853 2 1 1
or,will,not 0.333333333333 0.000143348623853 2 1 1
or,severity,of 0.333333333333 0.000143348623853 2 1 1
or,other,agents 0.333333333333 0.000143348623853 2 1 1
only,in,the 0.333333333333 0.000143348623853 2 1 1
on,the,th 0.333333333333 0.000143348623853 2 1 1
on,the,pharmacokinetic 0.333333333333 0.000143348623853 2 1 1
on,in,vitro 0.333333333333 0.000286697247706 2 4 -2
of,with,has 0.333333333333 0.000143348623853 2 1 1
of,with,an 0.333333333333 0.000143348623853 2 1 1
of,was,increased 0.333333333333 0.000143348623853 2 1 1
of,vardenafil,with 0.333333333333 0.000143348623853 2 1 1
of,these,medicines 0.333333333333 0.000143348623853 2 1 1
of,the,usual 0.333333333333 0.000143348623853 2 1 1
of,the,risk 0.333333333333 0.000143348623853 2 1 1
of,the,prothrombin 0.333333333333 0.000143348623853 2 1 1
of,the,cyp3a4 0.333333333333 0.000143348623853 2 1 1
of,the,capsule 0.333333333333 0.000143348623853 2 1 1
of,oral,ccnu 0.333333333333 0.000143348623853 2 1 1
of,or,will 0.333333333333 0.000143348623853 2 1 1
of,mg,b 0.333333333333 0.000143348623853 2 1 1
of,itraconazole,and 0.333333333333 0.000143348623853 2 1 1
of,is,not 0.333333333333 0.000286697247706 2 4 -2
of,healthy,volunteers 0.333333333333 0.000143348623853 2 1 1
of,felbatol,at 0.333333333333 0.000143348623853 2 1 1
of,felbatol,as 0.333333333333 0.000143348623853 2 1 1
of,ergocalcitriol,by 0.333333333333 0.000143348623853 2 1 1
of,equivalent,to 0.333333333333 0.000143348623853 2 1 1
of,either,these 0.333333333333 0.000286697247706 2 4 -2
of,distribution,of 0.333333333333 0.000143348623853 2 1 1
of,concomitantly,with 0.333333333333 0.000143348623853 2 1 1
of,changes,in 0.333333333333 0.000143348623853 2 1 1
of,caution,should 0.333333333333 0.000143348623853 2 1 1
of,caused,by 0.333333333333 0.000143348623853 2 1 1
of,and,respectively 0.333333333333 0.000143348623853 2 1 1
occurred,in,a 0.333333333333 0.000143348623853 2 1 1
observed,for,signs 0.333333333333 0.000143348623853 2 1 1
not,been,reported 0.333333333333 0.000143348623853 2 1 1
not,affect,plasma 0.333333333333 0.000143348623853 2 1 1
normal,volunteers,the 0.333333333333 0.000143348623853 2 1 1
nonsteroidal,anti-inflammatory,nsaids 0.333333333333 0.000143348623853 2 1 1
nanm,or,pcp 0.333333333333 0.000143348623853 2 1 1
monitoring,of,serum 0.333333333333 0.000286697247706 2 4 -2
monitored,in,patients 0.333333333333 0.000143348623853 2 1 1
min,for,alone 0.333333333333 0.000143348623853 2 1 1
mild,to,moderate 0.333333333333 0.000143348623853 2 1 1
mg,with,mg 0.333333333333 0.000143348623853 2 1 1
mg,q,d 0.333333333333 0.000143348623853 2 1 1
mg,per,day 0.333333333333 0.000143348623853 2 1 1
mg,of,the 0.333333333333 0.000143348623853 2 1 1
method,of,contraception 0.333333333333 0.000143348623853 2 1 1
metabolized,by,cyp3a4 0.333333333333 0.000286697247706 2 4 -2
metabolism,of,by 0.333333333333 0.000143348623853 2 1 1
mean,elimination,half-life 0.333333333333 0.000143348623853 2 1 1
mean,auc,and 0.333333333333 0.000143348623853 2 1 1
mcg,bid,for 0.333333333333 0.000143348623853 2 1 1
may,reduce,plasma 0.333333333333 0.000143348623853 2 1 1
may,reduce,endogenous 0.333333333333 0.000143348623853 2 1 1
may,not,be 0.333333333333 0.000286697247706 2 4 -2
may,increase,serum 0.333333333333 0.000143348623853 2 1 1
may,decrease,serum 0.333333333333 0.000143348623853 2 1 1
may,cause,an 0.333333333333 0.000143348623853 2 1 1
may,be,an 0.333333333333 0.000143348623853 2 1 1
like,other,nsaids 0.333333333333 0.000143348623853 2 1 1
levels,of,ergocalcitriol 0.333333333333 0.000143348623853 2 1 1
left,ventricular,failure 0.333333333333 0.000143348623853 2 1 1
least,hours,after 0.333333333333 0.000143348623853 2 1 1
least,hour,before 0.333333333333 0.000143348623853 2 1 1
leading,to,a 0.333333333333 0.000143348623853 2 1 1
known,to,prolong 0.333333333333 0.000143348623853 2 1 1
it,is,likely 0.333333333333 0.000286697247706 2 4 -2
it,is,known 0.333333333333 0.000143348623853 2 1 1
it,is,administered 0.333333333333 0.000143348623853 2 1 1
is,used,in 0.333333333333 0.000143348623853 2 1 1
is,recommended,and 0.333333333333 0.000143348623853 2 1 1
is,one,report 0.333333333333 0.000143348623853 2 1 1
is,known,that 0.333333333333 0.000143348623853 2 1 1
is,given,to 0.333333333333 0.000286697247706 2 4 -2
is,given,concurrently 0.333333333333 0.000143348623853 2 1 1
is,an,important 0.333333333333 0.000143348623853 2 1 1
is,also,used 0.333333333333 0.000143348623853 2 1 1
intraventricular,injection,of 0.333333333333 0.000143348623853 2 1 1
inhibitors,ssris,have 0.333333333333 0.000143348623853 2 1 1
inhibit,this,enzyme 0.333333333333 0.000143348623853 2 1 1
induce,the,metabolism 0.333333333333 0.000143348623853 2 1 1
increasing,serum,potassium 0.333333333333 0.000143348623853 2 1 1
increased,when,coadministered 0.333333333333 0.000143348623853 2 1 1
increased,rate,of 0.333333333333 0.000143348623853 2 1 1
increased,possibility,of 0.333333333333 0.000143348623853 2 1 1
increase,in,exposure 0.333333333333 0.000143348623853 2 1 1
incoordination,when,coadministered 0.333333333333 0.000143348623853 2 1 1
in,vitro,interaction 0.333333333333 0.000143348623853 2 1 1
in,those,patients 0.333333333333 0.000143348623853 2 1 1
in,the,stomach 0.333333333333 0.000143348623853 2 1 1
in,the,frequency 0.333333333333 0.000143348623853 2 1 1
in,the,first 0.333333333333 0.000143348623853 2 1 1
in,the,coadministration 0.333333333333 0.000143348623853 2 1 1
in,the,blood 0.333333333333 0.000143348623853 2 1 1
in,peripheral,blood 0.333333333333 0.000143348623853 2 1 1
in,hemostasis,and 0.333333333333 0.000143348623853 2 1 1
in,heart,rate 0.333333333333 0.000143348623853 2 1 1
in,dose,to 0.333333333333 0.000143348623853 2 1 1
in,a,placebo-controlled 0.333333333333 0.000143348623853 2 1 1
in,a,mean 0.333333333333 0.000143348623853 2 1 1
in,a,few 0.333333333333 0.000143348623853 2 1 1
important,determinant,of 0.333333333333 0.000143348623853 2 1 1
if,a,is 0.333333333333 0.000143348623853 2 1 1
higher,in,patients 0.333333333333 0.000143348623853 2 1 1
higher,concentrations,of 0.333333333333 0.000143348623853 2 1 1
hepatic,enzyme,inhibitors 0.333333333333 0.000143348623853 2 1 1
healthy,volunteers,the 0.333333333333 0.000143348623853 2 1 1
have,been,used 0.333333333333 0.000286697247706 2 4 -2
have,been,seen 0.333333333333 0.000143348623853 2 1 1
has,been,titrated 0.333333333333 0.000286697247706 2 4 -2
has,been,found 0.333333333333 0.000286697247706 2 4 -2
given,to,the 0.333333333333 0.000286697247706 2 4 -2
given,to,patients 0.333333333333 0.000286697247706 2 4 -2
given,to,healthy 0.333333333333 0.000143348623853 2 1 1
ganglionic,blocking,agents 0.333333333333 0.000143348623853 2 1 1
for,interaction,with 0.333333333333 0.000286697247706 2 4 -2
for,additive,effects 0.333333333333 0.000143348623853 2 1 1
felbatol,at,steady 0.333333333333 0.000143348623853 2 1 1
events,have,been 0.333333333333 0.000143348623853 2 1 1
endogenous,plasma,levels 0.333333333333 0.000143348623853 2 1 1
elimination,half-life,of 0.333333333333 0.000143348623853 2 1 1
elevations,in,serum 0.333333333333 0.000143348623853 2 1 1
effects,of,such 0.333333333333 0.000143348623853 2 1 1
effects,of,nanm 0.333333333333 0.000143348623853 2 1 1
effects,of,caution 0.333333333333 0.000143348623853 2 1 1
effects,in,patients 0.333333333333 0.000143348623853 2 1 1
effect,of,is 0.333333333333 0.000143348623853 2 1 1
drugs,that,have 0.333333333333 0.000143348623853 2 1 1
doses,of,sonata 0.333333333333 0.000143348623853 2 1 1
dose,of,on 0.333333333333 0.000143348623853 2 1 1
dose,of,felbatol 0.333333333333 0.000143348623853 2 1 1
dose,of,a 0.333333333333 0.000143348623853 2 1 1
dosage,are,required 0.333333333333 0.000143348623853 2 1 1
delay,in,the 0.333333333333 0.000143348623853 2 1 1
decrease,in,auc 0.333333333333 0.000143348623853 2 1 1
data,from,in 0.333333333333 0.000143348623853 2 1 1
d,but,may 0.333333333333 0.000143348623853 2 1 1
considered,when,these 0.333333333333 0.000143348623853 2 1 1
concurrently,the,following 0.333333333333 0.000286697247706 2 4 -2
concentrations,of,vitamin 0.333333333333 0.000143348623853 2 1 1
concentrations,of,resulting 0.333333333333 0.000143348623853 2 1 1
concentrations,of,a 0.333333333333 0.000143348623853 2 1 1
compounds,that,are 0.333333333333 0.000143348623853 2 1 1
combinations,of,and 0.333333333333 0.000143348623853 2 1 1
combination,with,is 0.333333333333 0.000143348623853 2 1 1
combination,of,with 0.333333333333 0.000143348623853 2 1 1
coagulation,test,should 0.333333333333 0.000143348623853 2 1 1
coadministration,of,or 0.333333333333 0.000143348623853 2 1 1
coadministration,of,itraconazole 0.333333333333 0.000143348623853 2 1 1
co-administration,of,may 0.333333333333 0.000286697247706 2 4 -2
co-administered,with,tikosyn 0.333333333333 0.000143348623853 2 1 1
co-administered,with,mg 0.333333333333 0.000143348623853 2 1 1
clearance,of,resulting 0.333333333333 0.000143348623853 2 1 1
clearance,of,felbatol 0.333333333333 0.000143348623853 2 1 1
characterized,by,severe 0.333333333333 0.000143348623853 2 1 1
cerebral,and,hepatic 0.333333333333 0.000143348623853 2 1 1
caution,is,warranted 0.333333333333 0.000143348623853 2 1 1
cause,weakness,hyperreflexia 0.333333333333 0.000143348623853 2 1 1
by,this,isozyme 0.333333333333 0.000143348623853 2 1 1
by,severe,peripheral 0.333333333333 0.000143348623853 2 1 1
by,a,decrease 0.333333333333 0.000143348623853 2 1 1
but,may,reduce 0.333333333333 0.000143348623853 2 1 1
but,did,not 0.333333333333 0.000143348623853 2 1 1
both,and,its 0.333333333333 0.000143348623853 2 1 1
blunting,of,the 0.333333333333 0.000143348623853 2 1 1
blood,glucose,and 0.333333333333 0.000143348623853 2 1 1
blockers,adrenergic,blockers 0.333333333333 0.000143348623853 2 1 1
blockade,of,the 0.333333333333 0.000143348623853 2 1 1
binding,of,to 0.333333333333 0.000143348623853 2 1 1
binding,of,by 0.333333333333 0.000143348623853 2 1 1
before,use,of 0.333333333333 0.000286697247706 2 4 -2
been,titrated,to 0.333333333333 0.000286697247706 2 4 -2
been,seen,with 0.333333333333 0.000143348623853 2 1 1
been,administered,in 0.333333333333 0.000143348623853 2 1 1
be,used,together 0.333333333333 0.000143348623853 2 1 1
be,taken,with 0.333333333333 0.000286697247706 2 4 -2
be,taken,when 0.333333333333 0.000286697247706 2 4 -2
be,taken,into 0.333333333333 0.000286697247706 2 4 -2
be,potentiated,when 0.333333333333 0.000286697247706 2 4 -2
be,noted,that 0.333333333333 0.000143348623853 2 1 1
be,monitored,and 0.333333333333 0.000286697247706 2 4 -2
be,inhibited,by 0.333333333333 0.000143348623853 2 1 1
be,increased,when 0.333333333333 0.000143348623853 2 1 1
be,increased,by 0.333333333333 0.000143348623853 2 1 1
be,avoided,because 0.333333333333 0.000143348623853 2 1 1
be,advised,against 0.333333333333 0.000143348623853 2 1 1
avoided,in,patients 0.333333333333 0.000143348623853 2 1 1
auc,by,and 0.333333333333 0.000143348623853 2 1 1
at,mg,bid 0.333333333333 0.000143348623853 2 1 1
at,least,minutes 0.333333333333 0.000143348623853 2 1 1
at,least,hour 0.333333333333 0.000143348623853 2 1 1
as,acetylsalicylic,acid 0.333333333333 0.000143348623853 2 1 1
are,required,when 0.333333333333 0.000143348623853 2 1 1
are,predominantly,metabolized 0.333333333333 0.000143348623853 2 1 1
are,at,increased 0.333333333333 0.000143348623853 2 1 1
are,antagonized,by 0.333333333333 0.000143348623853 2 1 1
approximately,when,coadministered 0.333333333333 0.000143348623853 2 1 1
appears,to,be 0.333333333333 0.000286697247706 2 4 -2
antagonize,the,effects 0.333333333333 0.000143348623853 2 1 1
and,which,are 0.333333333333 0.000143348623853 2 1 1
and,valproic,acid 0.333333333333 0.000143348623853 2 1 1
and,urinary,excretion 0.333333333333 0.000143348623853 2 1 1
and,therefore,the 0.333333333333 0.000143348623853 2 1 1
and,the,oral 0.333333333333 0.000143348623853 2 1 1
and,the,effects 0.333333333333 0.000143348623853 2 1 1
and,sustained,increases 0.333333333333 0.000143348623853 2 1 1
and,result,in 0.333333333333 0.000143348623853 2 1 1
and,or,marked 0.333333333333 0.000143348623853 2 1 1
and,may,have 0.333333333333 0.000143348623853 2 1 1
and,may,decrease 0.333333333333 0.000143348623853 2 1 1
and,incoordination,when 0.333333333333 0.000143348623853 2 1 1
and,in,patients 0.333333333333 0.000143348623853 2 1 1
and,blood,pressure 0.333333333333 0.000143348623853 2 1 1
and,because,of 0.333333333333 0.000143348623853 2 1 1
and,appropriate,dosage 0.333333333333 0.000286697247706 2 4 -2
and,active,metabolite 0.333333333333 0.000286697247706 2 4 -2
an,mao,inhibitor 0.333333333333 0.000143348623853 2 1 1
an,interaction,between 0.333333333333 0.000143348623853 2 1 1
an,inhibition,of 0.333333333333 0.000143348623853 2 1 1
an,important,role 0.333333333333 0.000143348623853 2 1 1
an,important,determinant 0.333333333333 0.000143348623853 2 1 1
although,there,was 0.333333333333 0.000143348623853 2 1 1
although,the,clinical 0.333333333333 0.000143348623853 2 1 1
although,clinical,studies 0.333333333333 0.000143348623853 2 1 1
agonists,within,hours 0.333333333333 0.000143348623853 2 1 1
agents,may,increase 0.333333333333 0.000143348623853 2 1 1
agents,increasing,serum 0.333333333333 0.000143348623853 2 1 1
agents,have,been 0.333333333333 0.000143348623853 2 1 1
agents,has,been 0.333333333333 0.000143348623853 2 1 1
agent,has,been 0.333333333333 0.000143348623853 2 1 1
after,administration,of 0.333333333333 0.000286697247706 2 4 -2
affect,plasma,concentrations 0.333333333333 0.000143348623853 2 1 1
adrenergic,blockers,adrenergic 0.333333333333 0.000143348623853 2 1 1
administration,of,wellbutrin 0.333333333333 0.000143348623853 2 1 1
administration,of,itraconazole 0.333333333333 0.000143348623853 2 1 1
administered,on,the 0.333333333333 0.000143348623853 2 1 1
administered,hours,before 0.333333333333 0.000143348623853 2 1 1
action,of,the 0.333333333333 0.000143348623853 2 1 1
action,of,on 0.333333333333 0.000143348623853 2 1 1
accompanied,by,a 0.333333333333 0.000143348623853 2 1 1
absorption,of,oral 0.333333333333 0.000143348623853 2 1 1
absorption,of,fat 0.333333333333 0.000143348623853 2 1 1
absorption,from,the 0.333333333333 0.000143348623853 2 1 1
a,small,decrease 0.333333333333 0.000143348623853 2 1 1
a,risk,of 0.333333333333 0.000143348623853 2 1 1
a,period,of 0.333333333333 0.000143348623853 2 1 1
a,patient,who 0.333333333333 0.000143348623853 2 1 1
a,metabolite,of 0.333333333333 0.000143348623853 2 1 1
a,is,also 0.333333333333 0.000143348623853 2 1 1
a,few,patients 0.333333333333 0.000143348623853 2 1 1
a,dose-dependent,manner 0.333333333333 0.000143348623853 2 1 1
a,dose,adjustment 0.333333333333 0.000143348623853 2 1 1
your,doctor,if 0.333333333333 0.000143348623853 1 2 -1
withdrawn,from,the 0.333333333333 0.000143348623853 1 2 -1
with,such,as 0.333333333333 0.000143348623853 1 2 -1
with,other,highly 0.333333333333 0.000143348623853 1 2 -1
with,one,of 0.333333333333 0.000143348623853 1 2 -1
with,may,be 0.333333333333 0.000143348623853 1 2 -1
with,hivid,should 0.333333333333 0.000143348623853 1 2 -1
with,high,concentrations 0.333333333333 0.000143348623853 1 2 -1
with,equetrotm,it 0.333333333333 0.000143348623853 1 2 -1
with,either,or 0.333333333333 0.000143348623853 1 2 -1
with,congestive,heart 0.333333333333 0.000143348623853 1 2 -1
with,blood,glucose 0.333333333333 0.000143348623853 1 2 -1
with,and,a 0.333333333333 0.000143348623853 1 2 -1
who,were,treated 0.333333333333 0.000143348623853 1 2 -1
when,was,given 0.333333333333 0.000143348623853 1 2 -1
were,studied,in 0.333333333333 0.000143348623853 1 2 -1
were,added,to 0.333333333333 0.000143348623853 1 2 -1
well,as,to 0.333333333333 0.000143348623853 1 2 -1
weekly,for,weeks 0.333333333333 0.000143348623853 1 2 -1
was,significantly,reduced 0.333333333333 0.000143348623853 1 2 -1
was,given,to 0.333333333333 0.000143348623853 1 2 -1
was,decreased,in 0.333333333333 0.000143348623853 1 2 -1
volunteers,there,was 0.333333333333 0.000143348623853 1 2 -1
vitro,studies,with 0.333333333333 0.000143348623853 1 2 -1
vital,signs,and 0.333333333333 0.000143348623853 1 2 -1
valdecoxib,mg,bid 0.333333333333 0.000143348623853 1 2 -1
use,may,increase 0.333333333333 0.000143348623853 1 2 -1
use,may,be 0.333333333333 0.000143348623853 1 2 -1
until,blood,pressure 0.333333333333 0.000143348623853 1 2 -1
tubular,secretion,may 0.333333333333 0.000143348623853 1 2 -1
treatment,with,equetrotm 0.333333333333 0.000143348623853 1 2 -1
transient,increases,in 0.333333333333 0.000143348623853 1 2 -1
torsades,de,pointes 0.333333333333 0.000143348623853 1 2 -1
to,occur,with 0.333333333333 0.000143348623853 1 2 -1
to,human,serum 0.333333333333 0.000143348623853 1 2 -1
to,healthy,subjects 0.333333333333 0.000143348623853 1 2 -1
to,have,an 0.333333333333 0.000143348623853 1 2 -1
to,alterations,in 0.333333333333 0.000143348623853 1 2 -1
to,a,single 0.333333333333 0.000143348623853 1 2 -1
times,the,maximum 0.333333333333 0.000143348623853 1 2 -1
times,higher,than 0.333333333333 0.000143348623853 1 2 -1
times,a,day 0.333333333333 0.000143348623853 1 2 -1
three,times,daily 0.333333333333 0.000143348623853 1 2 -1
this,is,not 0.333333333333 0.000143348623853 1 2 -1
this,increase,is 0.333333333333 0.000143348623853 1 2 -1
this,enzyme,system 0.333333333333 0.000143348623853 1 2 -1
this,category,and 0.333333333333 0.000143348623853 1 2 -1
these,agents,may 0.333333333333 0.000143348623853 1 2 -1
therapeutic,doses,of 0.333333333333 0.000143348623853 1 2 -1
the,time,to 0.333333333333 0.000143348623853 1 2 -1
the,therapeutic,range 0.333333333333 0.000143348623853 1 2 -1
the,steady,state 0.333333333333 0.000143348623853 1 2 -1
the,simultaneous,administration 0.333333333333 0.000143348623853 1 2 -1
the,signs,of 0.333333333333 0.000143348623853 1 2 -1
the,same,time 0.333333333333 0.000143348623853 1 2 -1
the,relevance,of 0.333333333333 0.000143348623853 1 2 -1
the,plasma,concentration-time 0.333333333333 0.000143348623853 1 2 -1
the,pharmacokinetic,parameters 0.333333333333 0.000143348623853 1 2 -1
the,pharmacodynamic,effects 0.333333333333 0.000143348623853 1 2 -1
the,percentage,of 0.333333333333 0.000143348623853 1 2 -1
the,mechanism,for 0.333333333333 0.000143348623853 1 2 -1
the,levels,of 0.333333333333 0.000143348623853 1 2 -1
the,hepatic,microsomal 0.333333333333 0.000143348623853 1 2 -1
the,formation,of 0.333333333333 0.000143348623853 1 2 -1
the,evening,meal 0.333333333333 0.000143348623853 1 2 -1
the,enzyme,system 0.333333333333 0.000143348623853 1 2 -1
the,combination,therapy 0.333333333333 0.000143348623853 1 2 -1
the,agents,in 0.333333333333 0.000143348623853 1 2 -1
the,activation,of 0.333333333333 0.000143348623853 1 2 -1
the,ability,of 0.333333333333 0.000143348623853 1 2 -1
that,the,prothrombin 0.333333333333 0.000143348623853 1 2 -1
that,are,mainly 0.333333333333 0.000143348623853 1 2 -1
that,affect,the 0.333333333333 0.000143348623853 1 2 -1
tell,your,doctor 0.333333333333 0.000143348623853 1 2 -1
taking,should,be 0.333333333333 0.000143348623853 1 2 -1
taking,any,of 0.333333333333 0.000143348623853 1 2 -1
taken,into,consideration 0.333333333333 0.000143348623853 1 2 -1
taken,into,account 0.333333333333 0.000143348623853 1 2 -1
taken,in,combination 0.333333333333 0.000143348623853 1 2 -1
substances,that,are 0.333333333333 0.000143348623853 1 2 -1
subjects,who,received 0.333333333333 0.000143348623853 1 2 -1
study,did,not 0.333333333333 0.000143348623853 1 2 -1
studies,with,have 0.333333333333 0.000143348623853 1 2 -1
studies,in,normal 0.333333333333 0.000143348623853 1 2 -1
studies,also,suggest 0.333333333333 0.000143348623853 1 2 -1
steady-state,trough,cmin 0.333333333333 0.000143348623853 1 2 -1
state,plasma,concentrations 0.333333333333 0.000143348623853 1 2 -1
spontaneous,motility,in 0.333333333333 0.000143348623853 1 2 -1
specific,studies,have 0.333333333333 0.000143348623853 1 2 -1
since,it,has 0.333333333333 0.000143348623853 1 2 -1
since,is,a 0.333333333333 0.000143348623853 1 2 -1
signs,of,renal 0.333333333333 0.000143348623853 1 2 -1
significant,inhibition,of 0.333333333333 0.000143348623853 1 2 -1
significant,effects,have 0.333333333333 0.000143348623853 1 2 -1
side,effects,and 0.333333333333 0.000143348623853 1 2 -1
shown,to,decrease 0.333333333333 0.000143348623853 1 2 -1
shown,to,be 0.333333333333 0.000143348623853 1 2 -1
should,have,their 0.333333333333 0.000143348623853 1 2 -1
should,generally,not 0.333333333333 0.000143348623853 1 2 -1
should,be,treated 0.333333333333 0.000143348623853 1 2 -1
should,be,performed 0.333333333333 0.000143348623853 1 2 -1
should,be,delayed 0.333333333333 0.000143348623853 1 2 -1
severe,persistent,hypertension 0.333333333333 0.000143348623853 1 2 -1
severe,hypersensitivity,reactions 0.333333333333 0.000143348623853 1 2 -1
serum,potassium,levels 0.333333333333 0.000143348623853 1 2 -1
risks,of,using 0.333333333333 0.000143348623853 1 2 -1
risk,of,anaphylactic 0.333333333333 0.000143348623853 1 2 -1
reverse,transcriptase,inhibitors 0.333333333333 0.000143348623853 1 2 -1
results,from,a 0.333333333333 0.000143348623853 1 2 -1
resulted,in,the 0.333333333333 0.000143348623853 1 2 -1
resulted,in,decreased 0.333333333333 0.000143348623853 1 2 -1
resulted,in,approximately 0.333333333333 0.000143348623853 1 2 -1
response,to,pressor 0.333333333333 0.000143348623853 1 2 -1
require,dosage,adjustment 0.333333333333 0.000143348623853 1 2 -1
reported,to,occur 0.333333333333 0.000143348623853 1 2 -1
renal,function,and 0.333333333333 0.000143348623853 1 2 -1
renal,failure,as 0.333333333333 0.000143348623853 1 2 -1
recommended,in,patients 0.333333333333 0.000143348623853 1 2 -1
recommended,daily,inhalation 0.333333333333 0.000143348623853 1 2 -1
received,mg,of 0.333333333333 0.000143348623853 1 2 -1
rats,treated,with 0.333333333333 0.000143348623853 1 2 -1
prothrombin,time,inr 0.333333333333 0.000143348623853 1 2 -1
protein,binding,sites 0.333333333333 0.000143348623853 1 2 -1
protease,inhibitors,and 0.333333333333 0.000143348623853 1 2 -1
products,such,as 0.333333333333 0.000143348623853 1 2 -1
presence,of,m 0.333333333333 0.000143348623853 1 2 -1
potential,for,an 0.333333333333 0.000143348623853 1 2 -1
possible,interactions,between 0.333333333333 0.000143348623853 1 2 -1
possible,clinical,significance 0.333333333333 0.000143348623853 1 2 -1
poor,metabolizers,of 0.333333333333 0.000143348623853 1 2 -1
plus,or,minus 0.333333333333 0.000143348623853 1 2 -1
plasma,levels,may 0.333333333333 0.000143348623853 1 2 -1
plasma,concentration-time,curve 0.333333333333 0.000143348623853 1 2 -1
pharmacokinetic,parameters,of 0.333333333333 0.000143348623853 1 2 -1
persistent,hypertension,or 0.333333333333 0.000143348623853 1 2 -1
patients,with,ischemic 0.333333333333 0.000143348623853 1 2 -1
patients,with,congestive 0.333333333333 0.000143348623853 1 2 -1
patients,there,was 0.333333333333 0.000143348623853 1 2 -1
patients,taking,these 0.333333333333 0.000143348623853 1 2 -1
patients,taking,should 0.333333333333 0.000143348623853 1 2 -1
patients,taking,other 0.333333333333 0.000143348623853 1 2 -1
patients,receiving,the 0.333333333333 0.000143348623853 1 2 -1
patients,receiving,concurrent 0.333333333333 0.000143348623853 1 2 -1
particularly,in,patients 0.333333333333 0.000143348623853 1 2 -1
paroxetine,coadministration,of 0.333333333333 0.000143348623853 1 2 -1
p450,a4,enzyme 0.333333333333 0.000143348623853 1 2 -1
oxytocic,may,cause 0.333333333333 0.000143348623853 1 2 -1
other,highly,plasma 0.333333333333 0.000143348623853 1 2 -1
other,has,not 0.333333333333 0.000143348623853 1 2 -1
other,drug,interactions 0.333333333333 0.000143348623853 1 2 -1
or,prolongation,of 0.333333333333 0.000143348623853 1 2 -1
or,other,central 0.333333333333 0.000143348623853 1 2 -1
or,mg,of 0.333333333333 0.000143348623853 1 2 -1
or,during,the 0.333333333333 0.000143348623853 1 2 -1
on,the,same 0.333333333333 0.000143348623853 1 2 -1
on,replacement,therapy 0.333333333333 0.000143348623853 1 2 -1
on,platelet,function 0.333333333333 0.000143348623853 1 2 -1
on,one,of 0.333333333333 0.000143348623853 1 2 -1
of,this,combination 0.333333333333 0.000143348623853 1 2 -1
of,these,two 0.333333333333 0.000143348623853 1 2 -1
of,these,findings 0.333333333333 0.000143348623853 1 2 -1
of,these,effects 0.333333333333 0.000143348623853 1 2 -1
of,the,treatment 0.333333333333 0.000143348623853 1 2 -1
of,the,total 0.333333333333 0.000143348623853 1 2 -1
of,the,that 0.333333333333 0.000143348623853 1 2 -1
of,the,pressor 0.333333333333 0.000143348623853 1 2 -1
of,the,possible 0.333333333333 0.000143348623853 1 2 -1
of,the,plasma 0.333333333333 0.000143348623853 1 2 -1
of,the,elimination 0.333333333333 0.000143348623853 1 2 -1
of,such,preparations 0.333333333333 0.000143348623853 1 2 -1
of,r,or 0.333333333333 0.000143348623853 1 2 -1
of,possible,clinical 0.333333333333 0.000143348623853 1 2 -1
of,plasma,concentrations 0.333333333333 0.000143348623853 1 2 -1
of,other,agents 0.333333333333 0.000143348623853 1 2 -1
of,on,day 0.333333333333 0.000143348623853 1 2 -1
of,mg,twice 0.333333333333 0.000143348623853 1 2 -1
of,known,to 0.333333333333 0.000143348623853 1 2 -1
of,inhibition,of 0.333333333333 0.000143348623853 1 2 -1
of,high,doses 0.333333333333 0.000143348623853 1 2 -1
of,given,as 0.333333333333 0.000143348623853 1 2 -1
of,exposure,to 0.333333333333 0.000143348623853 1 2 -1
of,crixivan,and 0.333333333333 0.000143348623853 1 2 -1
of,c,p 0.333333333333 0.000143348623853 1 2 -1
of,and,have 0.333333333333 0.000143348623853 1 2 -1
of,absorption,of 0.333333333333 0.000143348623853 1 2 -1
occur,in,the 0.333333333333 0.000143348623853 1 2 -1
observed,with,the 0.333333333333 0.000143348623853 1 2 -1
not,potentiate,the 0.333333333333 0.000143348623853 1 2 -1
normal,volunteers,there 0.333333333333 0.000143348623853 1 2 -1
non-nucleoside,reverse,transcriptase 0.333333333333 0.000143348623853 1 2 -1
no,studies,have 0.333333333333 0.000143348623853 1 2 -1
nephrotoxicity,and,ototoxicity 0.333333333333 0.000143348623853 1 2 -1
monitored,regularly,for 0.333333333333 0.000143348623853 1 2 -1
monitored,and,appropriate 0.333333333333 0.000143348623853 1 2 -1
mg,of,kg 0.333333333333 0.000143348623853 1 2 -1
mg,m2,basis 0.333333333333 0.000143348623853 1 2 -1
mg,day,racemic 0.333333333333 0.000143348623853 1 2 -1
methods,of,contraception 0.333333333333 0.000143348623853 1 2 -1
metabolism,may,be 0.333333333333 0.000143348623853 1 2 -1
medications,such,as 0.333333333333 0.000143348623853 1 2 -1
mediated,by,the 0.333333333333 0.000143348623853 1 2 -1
mechanism,for,this 0.333333333333 0.000143348623853 1 2 -1
mean,trough,concentrations 0.333333333333 0.000143348623853 1 2 -1
mean,t,max 0.333333333333 0.000143348623853 1 2 -1
may,change,the 0.333333333333 0.000143348623853 1 2 -1
may,be,useful 0.333333333333 0.000143348623853 1 2 -1
may,be,clinically 0.333333333333 0.000143348623853 1 2 -1
maximum,recommended,daily 0.333333333333 0.000143348623853 1 2 -1
lipid,response,to 0.333333333333 0.000143348623853 1 2 -1
levels,may,increase 0.333333333333 0.000143348623853 1 2 -1
least,one,hour 0.333333333333 0.000143348623853 1 2 -1
least,in,part 0.333333333333 0.000143348623853 1 2 -1
lead,to,a 0.333333333333 0.000143348623853 1 2 -1
known,inhibition,of 0.333333333333 0.000143348623853 1 2 -1
kept,in,mind 0.333333333333 0.000143348623853 1 2 -1
it,may,be 0.333333333333 0.000143348623853 1 2 -1
is,taken,in 0.333333333333 0.000143348623853 1 2 -1
is,reported,to 0.333333333333 0.000143348623853 1 2 -1
is,recommended,for 0.333333333333 0.000143348623853 1 2 -1
is,especially,important 0.333333333333 0.000143348623853 1 2 -1
interactions,with,and 0.333333333333 0.000143348623853 1 2 -1
interactions,of,with 0.333333333333 0.000143348623853 1 2 -1
interaction,between,the 0.333333333333 0.000143348623853 1 2 -1
initial,doses,of 0.333333333333 0.000143348623853 1 2 -1
inhibits,cyp3a4,and 0.333333333333 0.000143348623853 1 2 -1
inhibitory,effects,of 0.333333333333 0.000143348623853 1 2 -1
inhibitory,effect,on 0.333333333333 0.000143348623853 1 2 -1
inhaled,and,oral 0.333333333333 0.000143348623853 1 2 -1
inhalation,dose,in 0.333333333333 0.000143348623853 1 2 -1
ingesting,the,steady-state 0.333333333333 0.000143348623853 1 2 -1
influence,the,plasma 0.333333333333 0.000143348623853 1 2 -1
inducers,of,cytochrome 0.333333333333 0.000143348623853 1 2 -1
induced,by,intraventricular 0.333333333333 0.000143348623853 1 2 -1
increased,serum,concentrations 0.333333333333 0.000143348623853 1 2 -1
increase,the,toxicity 0.333333333333 0.000143348623853 1 2 -1
increase,sensitivity,to 0.333333333333 0.000143348623853 1 2 -1
increase,in,free 0.333333333333 0.000143348623853 1 2 -1
increase,blood,levels 0.333333333333 0.000143348623853 1 2 -1
in,which,was 0.333333333333 0.000143348623853 1 2 -1
in,which,the 0.333333333333 0.000143348623853 1 2 -1
in,this,category 0.333333333333 0.000143348623853 1 2 -1
in,the,rate 0.333333333333 0.000143348623853 1 2 -1
in,the,pharmacodynamic 0.333333333333 0.000143348623853 1 2 -1
in,the,light 0.333333333333 0.000143348623853 1 2 -1
in,the,levels 0.333333333333 0.000143348623853 1 2 -1
in,the,clinical 0.333333333333 0.000143348623853 1 2 -1
in,the,bioavailability 0.333333333333 0.000143348623853 1 2 -1
in,subjects,who 0.333333333333 0.000143348623853 1 2 -1
in,subjects,receiving 0.333333333333 0.000143348623853 1 2 -1
in,studies,with 0.333333333333 0.000143348623853 1 2 -1
in,serum,concentrations 0.333333333333 0.000143348623853 1 2 -1
in,pediatric,patients 0.333333333333 0.000143348623853 1 2 -1
in,patients,using 0.333333333333 0.000143348623853 1 2 -1
in,otherwise,healthy 0.333333333333 0.000143348623853 1 2 -1
in,normal,subjects 0.333333333333 0.000143348623853 1 2 -1
in,comparison,to 0.333333333333 0.000143348623853 1 2 -1
in,cerebral,and 0.333333333333 0.000143348623853 1 2 -1
in,another,study 0.333333333333 0.000143348623853 1 2 -1
in,an,in 0.333333333333 0.000143348623853 1 2 -1
in,adults,on 0.333333333333 0.000143348623853 1 2 -1
in,a,small 0.333333333333 0.000143348623853 1 2 -1
impact,on,the 0.333333333333 0.000143348623853 1 2 -1
hypoglycemic,agents,in 0.333333333333 0.000143348623853 1 2 -1
hoof,twitch,was 0.333333333333 0.000143348623853 1 2 -1
hepatic,microsomal,enzyme 0.333333333333 0.000143348623853 1 2 -1
healthy,male,subjects 0.333333333333 0.000143348623853 1 2 -1
have,been,attributed 0.333333333333 0.000143348623853 1 2 -1
grapefruit,juice,should 0.333333333333 0.000143348623853 1 2 -1
given,with,or 0.333333333333 0.000143348623853 1 2 -1
generally,not,be 0.333333333333 0.000143348623853 1 2 -1
from,the,combination 0.333333333333 0.000143348623853 1 2 -1
found,to,produce 0.333333333333 0.000143348623853 1 2 -1
for,interactions,with 0.333333333333 0.000143348623853 1 2 -1
for,days,of 0.333333333333 0.000143348623853 1 2 -1
following,interactions,have 0.333333333333 0.000143348623853 1 2 -1
exposure,to,and 0.333333333333 0.000143348623853 1 2 -1
estradiol,and,mg 0.333333333333 0.000143348623853 1 2 -1
especially,in,patients 0.333333333333 0.000143348623853 1 2 -1
ergot-type,oxytocic,may 0.333333333333 0.000143348623853 1 2 -1
equetrotm,it,is 0.333333333333 0.000143348623853 1 2 -1
enzymes,such,as 0.333333333333 0.000143348623853 1 2 -1
effects,due,to 0.333333333333 0.000143348623853 1 2 -1
effect,has,been 0.333333333333 0.000143348623853 1 2 -1
during,the,course 0.333333333333 0.000143348623853 1 2 -1
during,concomitant,therapy 0.333333333333 0.000143348623853 1 2 -1
drugs,which,inhibit 0.333333333333 0.000143348623853 1 2 -1
dose,should,then 0.333333333333 0.000143348623853 1 2 -1
dose,resulted,in 0.333333333333 0.000143348623853 1 2 -1
dose,of,to 0.333333333333 0.000143348623853 1 2 -1
dose,of,and 0.333333333333 0.000143348623853 1 2 -1
dose,in,adults 0.333333333333 0.000143348623853 1 2 -1
dosage,on,one 0.333333333333 0.000143348623853 1 2 -1
dosage,of,should 0.333333333333 0.000143348623853 1 2 -1
dosage,of,oral 0.333333333333 0.000143348623853 1 2 -1
doctor,if,you 0.333333333333 0.000143348623853 1 2 -1
do,not,appear 0.333333333333 0.000143348623853 1 2 -1
did,not,potentiate 0.333333333333 0.000143348623853 1 2 -1
depressants,may,have 0.333333333333 0.000143348623853 1 2 -1
demonstrated,that,a 0.333333333333 0.000143348623853 1 2 -1
demonstrate,that,the 0.333333333333 0.000143348623853 1 2 -1
decrease,in,serum 0.333333333333 0.000143348623853 1 2 -1
days,with,mg 0.333333333333 0.000143348623853 1 2 -1
days,of,mg 0.333333333333 0.000143348623853 1 2 -1
daily,inhalation,dose 0.333333333333 0.000143348623853 1 2 -1
cyp3a4,in,vitro 0.333333333333 0.000143348623853 1 2 -1
could,increase,the 0.333333333333 0.000143348623853 1 2 -1
converting,enzyme,inhibitors 0.333333333333 0.000143348623853 1 2 -1
considered,to,be 0.333333333333 0.000143348623853 1 2 -1
concurrently,should,be 0.333333333333 0.000143348623853 1 2 -1
concurrent,treatment,with 0.333333333333 0.000143348623853 1 2 -1
concentrations,of,may 0.333333333333 0.000143348623853 1 2 -1
concentrations,of,in 0.333333333333 0.000143348623853 1 2 -1
concentrations,in,the 0.333333333333 0.000143348623853 1 2 -1
concentrations,auc,hrs 0.333333333333 0.000143348623853 1 2 -1
components,p1,and 0.333333333333 0.000143348623853 1 2 -1
compared,with,those 0.333333333333 0.000143348623853 1 2 -1
compared,with,that 0.333333333333 0.000143348623853 1 2 -1
combination,with,mg 0.333333333333 0.000143348623853 1 2 -1
combination,therapy,dose 0.333333333333 0.000143348623853 1 2 -1
coadministration,of,crixivan 0.333333333333 0.000143348623853 1 2 -1
coadministered,with,a 0.333333333333 0.000143348623853 1 2 -1
coadministered,medicinal,products 0.333333333333 0.000143348623853 1 2 -1
clinical,significance,is 0.333333333333 0.000143348623853 1 2 -1
cause,severe,persistent 0.333333333333 0.000143348623853 1 2 -1
causal,relationship,has 0.333333333333 0.000143348623853 1 2 -1
category,and,then 0.333333333333 0.000143348623853 1 2 -1
can,increase,the 0.333333333333 0.000143348623853 1 2 -1
by,the,known 0.333333333333 0.000143348623853 1 2 -1
by,means,of 0.333333333333 0.000143348623853 1 2 -1
by,approximately,in 0.333333333333 0.000143348623853 1 2 -1
but,may,be 0.333333333333 0.000143348623853 1 2 -1
but,it,is 0.333333333333 0.000143348623853 1 2 -1
body,weight,was 0.333333333333 0.000143348623853 1 2 -1
body,weight,to 0.333333333333 0.000143348623853 1 2 -1
blood,levels,were 0.333333333333 0.000143348623853 1 2 -1
blocking,agents,and 0.333333333333 0.000143348623853 1 2 -1
been,observed,during 0.333333333333 0.000143348623853 1 2 -1
be,weighed,against 0.333333333333 0.000143348623853 1 2 -1
be,used,as 0.333333333333 0.000143348623853 1 2 -1
be,treated,with 0.333333333333 0.000143348623853 1 2 -1
be,monitored,regularly 0.333333333333 0.000143348623853 1 2 -1
be,kept,in 0.333333333333 0.000143348623853 1 2 -1
be,considered,if 0.333333333333 0.000143348623853 1 2 -1
auc,values,of 0.333333333333 0.000143348623853 1 2 -1
atrovent,inhalation,aerosol 0.333333333333 0.000143348623853 1 2 -1
at,therapeutic,concentrations 0.333333333333 0.000143348623853 1 2 -1
at,the,same 0.333333333333 0.000143348623853 1 2 -1
at,the,recommended 0.333333333333 0.000143348623853 1 2 -1
at,least,two 0.333333333333 0.000143348623853 1 2 -1
at,least,in 0.333333333333 0.000143348623853 1 2 -1
at,and,hours 0.333333333333 0.000143348623853 1 2 -1
as,they,may 0.333333333333 0.000143348623853 1 2 -1
as,much,as 0.333333333333 0.000143348623853 1 2 -1
as,and,have 0.333333333333 0.000143348623853 1 2 -1
as,a,mg 0.333333333333 0.000143348623853 1 2 -1
are,taking,any 0.333333333333 0.000143348623853 1 2 -1
are,advised,to 0.333333333333 0.000143348623853 1 2 -1
aprepitant,with,that 0.333333333333 0.000143348623853 1 2 -1
animal,studies,also 0.333333333333 0.000143348623853 1 2 -1
and,prothrombin,time 0.333333333333 0.000143348623853 1 2 -1
and,or,mg 0.333333333333 0.000143348623853 1 2 -1
and,no,significant 0.333333333333 0.000143348623853 1 2 -1
and,increases,in 0.333333333333 0.000143348623853 1 2 -1
and,if,necessary 0.333333333333 0.000143348623853 1 2 -1
an,interaction,study 0.333333333333 0.000143348623853 1 2 -1
an,increase,of 0.333333333333 0.000143348623853 1 2 -1
although,there,have 0.333333333333 0.000143348623853 1 2 -1
although,it,is 0.333333333333 0.000143348623853 1 2 -1
alter,the,plasma 0.333333333333 0.000143348623853 1 2 -1
agents,that,induce 0.333333333333 0.000143348623853 1 2 -1
agents,may,be 0.333333333333 0.000143348623853 1 2 -1
agents,may,also 0.333333333333 0.000143348623853 1 2 -1
agents,in,this 0.333333333333 0.000143348623853 1 2 -1
after,a,single 0.333333333333 0.000143348623853 1 2 -1
advised,in,using 0.333333333333 0.000143348623853 1 2 -1
adverse,experiences,in 0.333333333333 0.000143348623853 1 2 -1
adverse,effects,and 0.333333333333 0.000143348623853 1 2 -1
adults,on,a 0.333333333333 0.000143348623853 1 2 -1
administration,to,a 0.333333333333 0.000143348623853 1 2 -1
administration,of,in 0.333333333333 0.000143348623853 1 2 -1
administration,of,high 0.333333333333 0.000143348623853 1 2 -1
administration,of,has 0.333333333333 0.000143348623853 1 2 -1
administered,together,with 0.333333333333 0.000143348623853 1 2 -1
activity,may,result 0.333333333333 0.000143348623853 1 2 -1
according,to,the 0.333333333333 0.000143348623853 1 2 -1
absorption,of,a 0.333333333333 0.000143348623853 1 2 -1
a4,enzyme,system 0.333333333333 0.000143348623853 1 2 -1
a,weak,inhibitor 0.333333333333 0.000143348623853 1 2 -1
a,synergistic,effect 0.333333333333 0.000143348623853 1 2 -1
a,such,as 0.333333333333 0.000143348623853 1 2 -1
a,study,involving 0.333333333333 0.000143348623853 1 2 -1
a,similar,interaction 0.333333333333 0.000143348623853 1 2 -1
a,mg,m2 0.333333333333 0.000143348623853 1 2 -1
a,mean,of 0.333333333333 0.000143348623853 1 2 -1
a,lesser,extent 0.333333333333 0.000143348623853 1 2 -1
a,comparison,of 0.333333333333 0.000143348623853 1 2 -1
a,clinical,trial 0.333333333333 0.000143348623853 1 2 -1
the,potential,for 0.314285714286 0.00157683486239 12 23 -11
a,reduction,in 0.3 0.000860091743119 13 7 6
the,metabolism,of 0.296296296296 0.00229357798165 35 19 16
as,with,other 0.294117647059 0.000716743119266 11 6 5
doses,of,mg 0.294117647059 0.000716743119266 6 11 -5
auc,and,cmax 0.294117647059 0.000716743119266 6 11 -5
and,in,the 0.294117647059 0.000716743119266 6 11 -5
the,plasma,concentrations 0.285714285714 0.000573394495413 9 5 4
plasma,concentration,of 0.285714285714 0.000573394495413 9 5 4
effects,of,and 0.285714285714 0.000573394495413 9 5 4
being,treated,with 0.285714285714 0.000573394495413 9 5 4
been,reports,of 0.285714285714 0.000573394495413 9 5 4
area,under,the 0.285714285714 0.000573394495413 9 5 4
use,of,these 0.285714285714 0.000573394495413 5 9 -4
has,been,observed 0.285714285714 0.000573394495413 5 9 -4
the,effect,of 0.284210526316 0.00387041284404 34 61 -27
in,patients,taking 0.282051282051 0.00157683486239 25 14 11
concurrent,use,of 0.277777777778 0.00143348623853 23 13 10
when,it,is 0.272727272727 0.00043004587156 7 4 3
to,determine,if 0.272727272727 0.00043004587156 7 4 3
to,decrease,the 0.272727272727 0.00043004587156 7 4 3
may,occur,when 0.272727272727 0.00043004587156 7 4 3
may,need,to 0.272727272727 0.00043004587156 7 4 3
function,should,be 0.272727272727 0.00043004587156 7 4 3
associated,with,a 0.272727272727 0.00043004587156 7 4 3
a,study,of 0.272727272727 0.00043004587156 7 4 3
with,a,single 0.272727272727 0.00043004587156 4 7 -3
use,of,other 0.272727272727 0.00043004587156 4 7 -3
the,in,vitro 0.272727272727 0.00043004587156 4 7 -3
the,auc,and 0.272727272727 0.00043004587156 4 7 -3
likely,to,be 0.272727272727 0.00043004587156 4 7 -3
in,increased,plasma 0.272727272727 0.00043004587156 4 7 -3
has,the,potential 0.272727272727 0.00043004587156 4 7 -3
for,days,and 0.272727272727 0.00043004587156 4 7 -3
administered,to,patients 0.272727272727 0.00043004587156 4 7 -3
may,be,potentiated 0.263157894737 0.000716743119266 12 7 5
beta-adrenergic,blocking,agents 0.263157894737 0.000716743119266 12 7 5
in,patients,receiving 0.260273972603 0.00272362385321 46 27 19
the,dose,of 0.257142857143 0.00129013761468 13 22 -9
not,be,used 0.25 0.00114678899083 20 12 8
such,as,or 0.25 0.000860091743119 15 9 6
the,dosage,of 0.25 0.000573394495413 6 10 -4
studies,have,not 0.25 0.000573394495413 6 10 -4
of,a,single 0.25 0.000573394495413 6 10 -4
with,or,without 0.25 0.000286697247706 5 3 2
when,co-administered,with 0.25 0.000286697247706 5 3 2
the,renal,clearance 0.25 0.000286697247706 5 3 2
reported,to,cause 0.25 0.000286697247706 5 3 2
reported,to,be 0.25 0.000286697247706 5 3 2
prior,to,the 0.25 0.000286697247706 5 3 2
on,day,and 0.25 0.000286697247706 5 3 2
inhibitor,of,the 0.25 0.000286697247706 5 3 2
effects,of,other 0.25 0.000286697247706 5 3 2
effects,of,in 0.25 0.000286697247706 5 3 2
dose,reduction,of 0.25 0.000286697247706 5 3 2
at,a,dose 0.25 0.000286697247706 5 3 2
with,the,following 0.25 0.000286697247706 3 5 -2
with,other,agents 0.25 0.000286697247706 3 5 -2
to,interact,with 0.25 0.000286697247706 3 5 -2
the,interaction,between 0.25 0.000286697247706 3 5 -2
shown,to,have 0.25 0.000286697247706 3 5 -2
patients,with,renal 0.25 0.000286697247706 3 5 -2
patients,with,impaired 0.25 0.000286697247706 3 5 -2
or,other,suitable 0.25 0.000286697247706 3 5 -2
no,change,in 0.25 0.000286697247706 3 5 -2
metabolized,by,this 0.25 0.000286697247706 3 5 -2
is,advised,in 0.25 0.000286697247706 3 5 -2
intestinal,absorption,of 0.25 0.000286697247706 3 5 -2
increases,in,the 0.25 0.000286697247706 3 5 -2
in,the,absence 0.25 0.000286697247706 3 5 -2
in,a,clinical 0.25 0.000286697247706 3 5 -2
highly,protein,bound 0.25 0.000286697247706 3 5 -2
have,been,associated 0.25 0.000286697247706 3 5 -2
have,also,been 0.25 0.000286697247706 3 5 -2
expected,to,be 0.25 0.000286697247706 3 5 -2
consideration,should,be 0.25 0.000286697247706 3 5 -2
be,used,to 0.25 0.000286697247706 3 5 -2
and,increase,the 0.25 0.000286697247706 3 5 -2
affected,by,the 0.25 0.000286697247706 3 5 -2
interfere,with,the 0.243243243243 0.00129013761468 23 14 9
because,of,the 0.241379310345 0.00100344036697 18 11 7
the,concomitant,administration 0.238095238095 0.00143348623853 26 16 10
of,mg,kg 0.238095238095 0.000716743119266 8 13 -5
the,effects,of 0.234042553191 0.00315366972477 36 58 -22
been,associated,with 0.230769230769 0.000860091743119 16 10 6
interaction,between,and 0.230769230769 0.000860091743119 10 16 -6
the,degree,of 0.230769230769 0.00043004587156 8 5 3
of,mg,of 0.230769230769 0.00043004587156 8 5 3
is,recommended,when 0.230769230769 0.00043004587156 8 5 3
dose,should,be 0.230769230769 0.00043004587156 8 5 3
clearance,of,and 0.230769230769 0.00043004587156 8 5 3
result,in,increased 0.230769230769 0.00043004587156 5 8 -3
patients,who,have 0.230769230769 0.00043004587156 5 8 -3
may,be,increased 0.230769230769 0.00043004587156 5 8 -3
combination,with,other 0.230769230769 0.00043004587156 5 8 -3
single,mg,dose 0.222222222222 0.000573394495413 11 7 4
it,has,been 0.222222222222 0.000573394495413 11 7 4
in,normal,volunteers 0.222222222222 0.000573394495413 11 7 4
cytochrome,p450,a4 0.222222222222 0.000573394495413 7 11 -4
should,be,taken 0.217391304348 0.000716743119266 9 14 -5
be,observed,closely 0.214285714286 0.000860091743119 11 17 -6
there,have,been 0.2 0.00129013761468 27 18 9
administration,of,mg 0.2 0.000716743119266 15 10 5
in,the,presence 0.2 0.00100344036697 14 21 -7
dose,of,mg 0.2 0.00100344036697 14 21 -7
have,shown,that 0.2 0.000860091743119 12 18 -6
used,in,combination 0.2 0.00043004587156 9 6 3
the,addition,of 0.2 0.00043004587156 9 6 3
of,the,potential 0.2 0.00043004587156 9 6 3
coadministration,of,mg 0.2 0.00043004587156 9 6 3
due,to,the 0.2 0.000573394495413 8 12 -4
studies,indicate,that 0.2 0.00043004587156 6 9 -3
selective,serotonin,reuptake 0.2 0.00043004587156 6 9 -3
patients,being,treated 0.2 0.000286697247706 6 4 2
of,the,patient 0.2 0.000286697247706 6 4 2
mg,b,i 0.2 0.000286697247706 6 4 2
caution,is,advised 0.2 0.00043004587156 6 9 -3
been,reported,during 0.2 0.000286697247706 6 4 2
b,i,d 0.2 0.000286697247706 6 4 2
used,concurrently,with 0.2 0.000286697247706 4 6 -2
these,results,suggest 0.2 0.000286697247706 4 6 -2
of,and,other 0.2 0.000286697247706 4 6 -2
monoamine,oxidase,mao 0.2 0.000286697247706 4 6 -2
in,vitro,data 0.2 0.000286697247706 4 6 -2
with,should,be 0.2 0.000143348623853 3 2 1
with,oral,has 0.2 0.000143348623853 3 2 1
with,multiple,doses 0.2 0.000143348623853 3 2 1
with,mg,once 0.2 0.000143348623853 3 2 1
with,an,increase 0.2 0.000143348623853 3 2 1
when,they,are 0.2 0.000143348623853 3 2 1
were,decreased,by 0.2 0.000143348623853 3 2 1
used,when,administering 0.2 0.000143348623853 3 2 1
treatment,should,be 0.2 0.000143348623853 3 2 1
to,prolong,the 0.2 0.000143348623853 3 2 1
therapy,may,require 0.2 0.000143348623853 3 2 1
the,potential,of 0.2 0.000143348623853 3 2 1
the,likelihood,of 0.2 0.000143348623853 3 2 1
the,cytochrome,p-450 0.2 0.000143348623853 3 2 1
that,may,decrease 0.2 0.000143348623853 3 2 1
that,concomitant,administration 0.2 0.000143348623853 3 2 1
tail-flick,inhibition,induced 0.2 0.000143348623853 3 2 1
steady,state,plasma 0.2 0.000143348623853 3 2 1
skeletal,muscle,relaxants 0.2 0.000143348623853 3 2 1
single,doses,of 0.2 0.000143348623853 3 2 1
significant,decrease,in 0.2 0.000143348623853 3 2 1
should,be,advised 0.2 0.000143348623853 3 2 1
risk,of,bleeding 0.2 0.000143348623853 3 2 1
results,in,a 0.2 0.000143348623853 3 2 1
renal,clearance,of 0.2 0.000143348623853 3 2 1
reduction,in,the 0.2 0.000143348623853 3 2 1
population,pharmacokinetic,analyses 0.2 0.000143348623853 3 2 1
plasma,concentrations,auc 0.2 0.000143348623853 3 2 1
of,was,reduced 0.2 0.000143348623853 3 2 1
of,these,should 0.2 0.000143348623853 3 2 1
of,the,and 0.2 0.000143348623853 3 2 1
of,sonata,mg 0.2 0.000143348623853 3 2 1
of,hypotension,and 0.2 0.000143348623853 3 2 1
of,hepatic,metabolism 0.2 0.000143348623853 3 2 1
of,ethinyl,estradiol 0.2 0.000143348623853 3 2 1
of,cyp3a4,activity 0.2 0.000143348623853 3 2 1
of,a,patient 0.2 0.000143348623853 3 2 1
occurred,in,patients 0.2 0.000143348623853 3 2 1
not,been,established 0.2 0.000143348623853 3 2 1
mg,day,on 0.2 0.000143348623853 3 2 1
may,cause,severe 0.2 0.000143348623853 3 2 1
interaction,of,and 0.2 0.000143348623853 3 2 1
inhibition,induced,by 0.2 0.000143348623853 3 2 1
in,such,patients 0.2 0.000143348623853 3 2 1
in,a,dose-dependent 0.2 0.000143348623853 3 2 1
hypotension,and,or 0.2 0.000143348623853 3 2 1
has,shown,that 0.2 0.000143348623853 3 2 1
for,up,to 0.2 0.000143348623853 3 2 1
exercised,when,administering 0.2 0.000143348623853 3 2 1
effect,of,may 0.2 0.000143348623853 3 2 1
during,concomitant,administration 0.2 0.000143348623853 3 2 1
concurrently,with,and 0.2 0.000143348623853 3 2 1
concomitantly,with,a 0.2 0.000143348623853 3 2 1
compared,to,the 0.2 0.000143348623853 3 2 1
coadministration,of,single 0.2 0.000143348623853 3 2 1
co-administration,of,a 0.2 0.000143348623853 3 2 1
can,lead,to 0.2 0.000143348623853 3 2 1
be,taken,within 0.2 0.000143348623853 3 2 1
be,administered,to 0.2 0.000143348623853 3 2 1
associated,with,the 0.2 0.000143348623853 3 2 1
are,likely,to 0.2 0.000143348623853 3 2 1
are,expected,to 0.2 0.000143348623853 3 2 1
antinociceptive,effect,of 0.2 0.000143348623853 3 2 1
angiotensin,converting,enzyme 0.2 0.000143348623853 3 2 1
and,other,that 0.2 0.000143348623853 3 2 1
and,monoamine,oxidase 0.2 0.000143348623853 3 2 1
and,it,is 0.2 0.000143348623853 3 2 1
agents,and,other 0.2 0.000143348623853 3 2 1
administration,of,hydrochloride 0.2 0.000143348623853 3 2 1
a,possible,interaction 0.2 0.000143348623853 3 2 1
a,dose,reduction 0.2 0.000143348623853 3 2 1
with,mg,kg 0.2 0.000143348623853 2 3 -1
with,activity,effects 0.2 0.000143348623853 2 3 -1
who,have,been 0.2 0.000143348623853 2 3 -1
when,these,medications 0.2 0.000143348623853 2 3 -1
when,these,agents 0.2 0.000143348623853 2 3 -1
weeks,prior,to 0.2 0.000143348623853 2 3 -1
was,co-administered,with 0.2 0.000143348623853 2 3 -1
vertigo,syncope,or 0.2 0.000143348623853 2 3 -1
use,of,or 0.2 0.000143348623853 2 3 -1
toxicity,characterized,by 0.2 0.000143348623853 2 3 -1
to,expect,that 0.2 0.000143348623853 2 3 -1
to,a,stable 0.2 0.000143348623853 2 3 -1
thus,if,a 0.2 0.000143348623853 2 3 -1
these,medications,are 0.2 0.000143348623853 2 3 -1
therefore,it,is 0.2 0.000143348623853 2 3 -1
there,has,been 0.2 0.000143348623853 2 3 -1
then,begins,a 0.2 0.000143348623853 2 3 -1
the,systemic,exposure 0.2 0.000143348623853 2 3 -1
the,steady-state,plasma 0.2 0.000143348623853 2 3 -1
the,steady-state,cmin 0.2 0.000143348623853 2 3 -1
the,side,effects 0.2 0.000143348623853 2 3 -1
the,production,of 0.2 0.000143348623853 2 3 -1
the,primary,cns 0.2 0.000143348623853 2 3 -1
the,need,for 0.2 0.000143348623853 2 3 -1
the,initiation,of 0.2 0.000143348623853 2 3 -1
the,following,interactions 0.2 0.000143348623853 2 3 -1
the,cns,depressant 0.2 0.000143348623853 2 3 -1
the,central,nervous 0.2 0.000143348623853 2 3 -1
the,blood,pressure 0.2 0.000143348623853 2 3 -1
that,may,increase 0.2 0.000143348623853 2 3 -1
that,are,known 0.2 0.000143348623853 2 3 -1
that,a,dose 0.2 0.000143348623853 2 3 -1
supervision,and,careful 0.2 0.000143348623853 2 3 -1
study,of,healthy 0.2 0.000143348623853 2 3 -1
studies,suggest,that 0.2 0.000143348623853 2 3 -1
single,oral,dose 0.2 0.000143348623853 2 3 -1
reported,to,produce 0.2 0.000143348623853 2 3 -1
reduction,of,the 0.2 0.000143348623853 2 3 -1
reasonable,to,expect 0.2 0.000143348623853 2 3 -1
primary,cns,effects 0.2 0.000143348623853 2 3 -1
preparations,before,use 0.2 0.000143348623853 2 3 -1
potentiated,when,these 0.2 0.000143348623853 2 3 -1
potential,for,interaction 0.2 0.000143348623853 2 3 -1
physician,should,be 0.2 0.000143348623853 2 3 -1
patients,receiving,both 0.2 0.000143348623853 2 3 -1
other,medications,with 0.2 0.000143348623853 2 3 -1
other,known,to 0.2 0.000143348623853 2 3 -1
oral,dose,of 0.2 0.000143348623853 2 3 -1
or,other,medications 0.2 0.000143348623853 2 3 -1
or,marked,bradycardia 0.2 0.000143348623853 2 3 -1
or,inhibitors,of 0.2 0.000143348623853 2 3 -1
on,days,and 0.2 0.000143348623853 2 3 -1
of,therapy,and 0.2 0.000143348623853 2 3 -1
of,the,should 0.2 0.000143348623853 2 3 -1
of,the,agents 0.2 0.000143348623853 2 3 -1
of,single,doses 0.2 0.000143348623853 2 3 -1
of,per,day 0.2 0.000143348623853 2 3 -1
of,blood,glucose 0.2 0.000143348623853 2 3 -1
of,aprepitant,was 0.2 0.000143348623853 2 3 -1
of,agents,may 0.2 0.000143348623853 2 3 -1
occur,in,patients 0.2 0.000143348623853 2 3 -1
not,been,performed 0.2 0.000143348623853 2 3 -1
narrow,therapeutic,index 0.2 0.000143348623853 2 3 -1
monitoring,of,patients 0.2 0.000143348623853 2 3 -1
mg,or,mg 0.2 0.000143348623853 2 3 -1
medications,are,used 0.2 0.000143348623853 2 3 -1
may,decrease,plasma 0.2 0.000143348623853 2 3 -1
may,be,affected 0.2 0.000143348623853 2 3 -1
marked,bradycardia,which 0.2 0.000143348623853 2 3 -1
known,to,inhibit 0.2 0.000143348623853 2 3 -1
it,is,reasonable 0.2 0.000143348623853 2 3 -1
it,is,concluded 0.2 0.000143348623853 2 3 -1
it,is,advisable 0.2 0.000143348623853 2 3 -1
is,reasonable,to 0.2 0.000143348623853 2 3 -1
is,given,with 0.2 0.000143348623853 2 3 -1
is,a,potential 0.2 0.000143348623853 2 3 -1
interference,with,the 0.2 0.000143348623853 2 3 -1
induce,cyp3a4,activity 0.2 0.000143348623853 2 3 -1
increase,plasma,concentrations 0.2 0.000143348623853 2 3 -1
in,these,patients 0.2 0.000143348623853 2 3 -1
in,the,dose 0.2 0.000143348623853 2 3 -1
in,serum,levels 0.2 0.000143348623853 2 3 -1
in,a,pharmacokinetic 0.2 0.000143348623853 2 3 -1
hour,before,or 0.2 0.000143348623853 2 3 -1
have,no,effect 0.2 0.000143348623853 2 3 -1
has,resulted,in 0.2 0.000143348623853 2 3 -1
given,the,primary 0.2 0.000143348623853 2 3 -1
given,as,a 0.2 0.000143348623853 2 3 -1
for,preparations,before 0.2 0.000143348623853 2 3 -1
for,days,with 0.2 0.000143348623853 2 3 -1
expect,that,a 0.2 0.000143348623853 2 3 -1
effects,of,these 0.2 0.000143348623853 2 3 -1
effect,on,blood 0.2 0.000143348623853 2 3 -1
drugs,that,induce 0.2 0.000143348623853 2 3 -1
drug,interactions,with 0.2 0.000143348623853 2 3 -1
dose,adjustment,is 0.2 0.000143348623853 2 3 -1
depressant,effects,of 0.2 0.000143348623853 2 3 -1
daily,doses,of 0.2 0.000143348623853 2 3 -1
concomitantly,with,and 0.2 0.000143348623853 2 3 -1
concentrations,of,other 0.2 0.000143348623853 2 3 -1
close,supervision,and 0.2 0.000143348623853 2 3 -1
change,in,the 0.2 0.000143348623853 2 3 -1
careful,adjustment,of 0.2 0.000143348623853 2 3 -1
bradycardia,which,may 0.2 0.000143348623853 2 3 -1
begins,a,course 0.2 0.000143348623853 2 3 -1
been,demonstrated,in 0.2 0.000143348623853 2 3 -1
be,observed,for 0.2 0.000143348623853 2 3 -1
be,monitored,for 0.2 0.000143348623853 2 3 -1
at,increased,risk 0.2 0.000143348623853 2 3 -1
associated,with,increased 0.2 0.000143348623853 2 3 -1
and,thus,may 0.2 0.000143348623853 2 3 -1
and,then,begins 0.2 0.000143348623853 2 3 -1
and,careful,adjustment 0.2 0.000143348623853 2 3 -1
and,can,be 0.2 0.000143348623853 2 3 -1
administration,of,the 0.2 0.000143348623853 2 3 -1
activity,effects,may 0.2 0.000143348623853 2 3 -1
acetylsalicylic,acid,and 0.2 0.000143348623853 2 3 -1
ace,inhibitors,and 0.2 0.000143348623853 2 3 -1
a,statistically,significant 0.2 0.000143348623853 2 3 -1
a,stable,dosage 0.2 0.000143348623853 2 3 -1
a,single,oral 0.2 0.000143348623853 2 3 -1
a,significant,decrease 0.2 0.000143348623853 2 3 -1
a,prolongation,of 0.2 0.000143348623853 2 3 -1
a,potent,cyp3a4 0.2 0.000143348623853 2 3 -1
a,pharmacokinetic,study 0.2 0.000143348623853 2 3 -1
central,nervous,system 0.181818181818 0.000573394495413 13 9 4
a,study,in 0.181818181818 0.000573394495413 13 9 4
to,interfere,with 0.176470588235 0.00043004587156 7 10 -3
may,interact,with 0.166666666667 0.000573394495413 14 10 4
be,used,when 0.166666666667 0.000286697247706 7 5 2
administered,concurrently,with 0.166666666667 0.000286697247706 7 5 2
in,patients,treated 0.166666666667 0.000286697247706 5 7 -2
in,conjunction,with 0.166666666667 0.000286697247706 5 7 -2
concurrent,use,with 0.166666666667 0.000286697247706 5 7 -2
concomitant,use,of 0.163265306122 0.00229357798165 57 41 16
be,expected,to 0.157894736842 0.00043004587156 8 11 -3
should,not,be 0.148936170213 0.00200688073394 54 40 14
in,a,study 0.142857142857 0.000573394495413 16 12 4
in,patients,who 0.142857142857 0.00043004587156 12 9 3
administration,of,a 0.142857142857 0.00043004587156 12 9 3
in,healthy,volunteers 0.142857142857 0.00043004587156 9 12 -3
potent,inhibitor,of 0.142857142857 0.000286697247706 8 6 2
have,been,shown 0.142857142857 0.000286697247706 8 6 2
a,potent,inhibitor 0.142857142857 0.000286697247706 8 6 2
serotonin,reuptake,inhibitors 0.142857142857 0.000286697247706 6 8 -2
mg,once,daily 0.142857142857 0.000286697247706 6 8 -2
may,be,necessary 0.142857142857 0.000286697247706 6 8 -2
effects,may,be 0.142857142857 0.000286697247706 6 8 -2
was,administered,on 0.142857142857 0.000143348623853 4 3 1
the,plasma,concentration 0.142857142857 0.000143348623853 4 3 1
simultaneous,administration,of 0.142857142857 0.000143348623853 4 3 1
plasma,levels,were 0.142857142857 0.000143348623853 4 3 1
patients,receiving,concomitant 0.142857142857 0.000143348623853 4 3 1
oral,doses,of 0.142857142857 0.000143348623853 4 3 1
may,alter,the 0.142857142857 0.000143348623853 4 3 1
indicated,in,the 0.142857142857 0.000143348623853 4 3 1
increase,in,serum 0.142857142857 0.000143348623853 4 3 1
in,the,plasma 0.142857142857 0.000143348623853 4 3 1
in,patients,being 0.142857142857 0.000143348623853 4 3 1
in,a,single 0.142857142857 0.000143348623853 4 3 1
ethinyl,estradiol,and 0.142857142857 0.000143348623853 4 3 1
decrease,plasma,concentrations 0.142857142857 0.000143348623853 4 3 1
cns,effects,of 0.142857142857 0.000143348623853 4 3 1
chance,of,side 0.142857142857 0.000143348623853 4 3 1
caution,is,indicated 0.142857142857 0.000143348623853 4 3 1
before,or,hours 0.142857142857 0.000143348623853 4 3 1
and,mg,kg 0.142857142857 0.000143348623853 4 3 1
and,cmax,of 0.142857142857 0.000143348623853 4 3 1
administered,in,combination 0.142857142857 0.000143348623853 4 3 1
added,to,the 0.142857142857 0.000143348623853 4 3 1
a,narrow,therapeutic 0.142857142857 0.000143348623853 4 3 1
a,dose,increase 0.142857142857 0.000143348623853 4 3 1
when,is,given 0.142857142857 0.000143348623853 3 4 -1
the,response,to 0.142857142857 0.000143348623853 3 4 -1
the,frequency,of 0.142857142857 0.000143348623853 3 4 -1
the,effectiveness,of 0.142857142857 0.000143348623853 3 4 -1
test,should,be 0.142857142857 0.000143348623853 3 4 -1
study,in,normal 0.142857142857 0.000143348623853 3 4 -1
studies,have,demonstrated 0.142857142857 0.000143348623853 3 4 -1
or,should,be 0.142857142857 0.000143348623853 3 4 -1
of,may,result 0.142857142857 0.000143348623853 3 4 -1
of,and,to 0.142857142857 0.000143348623853 3 4 -1
may,occur,in 0.142857142857 0.000143348623853 3 4 -1
may,cause,a 0.142857142857 0.000143348623853 3 4 -1
levels,have,been 0.142857142857 0.000143348623853 3 4 -1
is,given,concomitantly 0.142857142857 0.000143348623853 3 4 -1
interact,with,or 0.142857142857 0.000143348623853 3 4 -1
following,administration,of 0.142857142857 0.000143348623853 3 4 -1
effect,of,a 0.142857142857 0.000143348623853 3 4 -1
during,treatment,with 0.142857142857 0.000143348623853 3 4 -1
by,inhibition,of 0.142857142857 0.000143348623853 3 4 -1
be,necessary,when 0.142857142857 0.000143348623853 3 4 -1
be,affected,by 0.142857142857 0.000143348623853 3 4 -1
at,least,weeks 0.142857142857 0.000143348623853 3 4 -1
and,mg,day 0.142857142857 0.000143348623853 3 4 -1
and,has,not 0.142857142857 0.000143348623853 3 4 -1
administration,of,these 0.142857142857 0.000143348623853 3 4 -1
administration,of,may 0.142857142857 0.000143348623853 3 4 -1
a,patient,has 0.142857142857 0.000143348623853 3 4 -1
a,course,of 0.142857142857 0.000143348623853 3 4 -1
be,exercised,when 0.130434782609 0.00043004587156 10 13 -3
in,a,patient 0.125 0.000286697247706 9 7 2
given,concomitantly,with 0.125 0.000286697247706 7 9 -2
should,be,given 0.12 0.00043004587156 11 14 -3
mg,dose,of 0.111111111111 0.00043004587156 15 12 3
may,interfere,with 0.111111111111 0.00043004587156 15 12 3
the,possibility,of 0.111111111111 0.00043004587156 12 15 -3
with,caution,in 0.111111111111 0.000286697247706 10 8 2
would,be,expected 0.111111111111 0.000286697247706 8 10 -2
with,coadministration,of 0.111111111111 0.000143348623853 5 4 1
with,any,of 0.111111111111 0.000143348623853 5 4 1
there,was,a 0.111111111111 0.000143348623853 5 4 1
plasma,concentrations,and 0.111111111111 0.000143348623853 5 4 1
of,the,may 0.111111111111 0.000143348623853 5 4 1
of,side,effects 0.111111111111 0.000143348623853 5 4 1
levels,of,and 0.111111111111 0.000143348623853 5 4 1
hours,before,or 0.111111111111 0.000143348623853 5 4 1
due,to,a 0.111111111111 0.000143348623853 5 4 1
drugs,that,may 0.111111111111 0.000143348623853 5 4 1
used,in,patients 0.111111111111 0.000143348623853 4 5 -1
use,with,may 0.111111111111 0.000143348623853 4 5 -1
to,inhibit,the 0.111111111111 0.000143348623853 4 5 -1
the,binding,of 0.111111111111 0.000143348623853 4 5 -1
such,as,the 0.111111111111 0.000143348623853 4 5 -1
possible,additive,effects 0.111111111111 0.000143348623853 4 5 -1
oxidase,mao,inhibitors 0.111111111111 0.000143348623853 4 5 -1
levels,may,be 0.111111111111 0.000143348623853 4 5 -1
in,plasma,auc 0.111111111111 0.000143348623853 4 5 -1
higher,doses,of 0.111111111111 0.000143348623853 4 5 -1
expected,to,increase 0.111111111111 0.000143348623853 4 5 -1
coadministration,of,a 0.111111111111 0.000143348623853 4 5 -1
because,of,possible 0.111111111111 0.000143348623853 4 5 -1
at,steady,state 0.111111111111 0.000143348623853 4 5 -1
should,be,exercised 0.105263157895 0.000573394495413 17 21 -4
as,well,as 0.105263157895 0.000573394495413 17 21 -4
patients,should,be 0.1 0.000286697247706 9 11 -2
be,used,with 0.0967741935484 0.00043004587156 17 14 3
plasma,concentrations,of 0.0958904109589 0.00100344036697 40 33 7
should,be,avoided 0.0909090909091 0.000286697247706 12 10 2
mg,and,mg 0.0909090909091 0.000286697247706 12 10 2
be,used,in 0.0909090909091 0.000286697247706 10 12 -2
therapy,should,be 0.0909090909091 0.000143348623853 6 5 1
responsible,for,the 0.0909090909091 0.000143348623853 6 5 1
not,been,studied 0.0909090909091 0.000143348623853 6 5 1
mg,every,hours 0.0909090909091 0.000143348623853 6 5 1
in,the,auc 0.0909090909091 0.000143348623853 6 5 1
be,monitored,closely 0.0909090909091 0.000143348623853 6 5 1
to,initiation,of 0.0909090909091 0.000143348623853 5 6 -1
reuptake,inhibitors,ssris 0.0909090909091 0.000143348623853 5 6 -1
results,suggest,that 0.0909090909091 0.000143348623853 5 6 -1
multiple,doses,of 0.0909090909091 0.000143348623853 5 6 -1
if,a,patient 0.0909090909091 0.000143348623853 5 6 -1
are,administered,concomitantly 0.0909090909091 0.000143348623853 5 6 -1
patients,treated,with 0.0833333333333 0.000286697247706 13 11 2
increased,risk,of 0.0833333333333 0.000286697247706 11 13 -2
it,is,recommended 0.0810810810811 0.00043004587156 20 17 3
the,administration,of 0.08 0.000573394495413 27 23 4
the,prothrombin,time 0.0769230769231 0.000143348623853 7 6 1
the,concurrent,use 0.0769230769231 0.000143348623853 6 7 -1
of,plasma,levels 0.0769230769231 0.000143348623853 6 7 -1
dosage,adjustment,of 0.0769230769231 0.000143348623853 6 7 -1
may,result,in 0.0740740740741 0.000573394495413 29 25 4
should,be,monitored 0.0697674418605 0.00043004587156 20 23 -3
a,single,dose 0.0666666666667 0.000286697247706 14 16 -2
not,be,taken 0.0666666666667 0.000143348623853 8 7 1
data,suggest,that 0.0666666666667 0.000143348623853 7 8 -1
concentrations,of,and 0.0666666666667 0.000143348623853 7 8 -1
agents,such,as 0.0666666666667 0.000143348623853 7 8 -1
should,be,reduced 0.0588235294118 0.000143348623853 9 8 1
serum,concentrations,of 0.0588235294118 0.000143348623853 9 8 1
other,that,are 0.0588235294118 0.000143348623853 8 9 -1
of,mg,day 0.0588235294118 0.000143348623853 8 9 -1
used,with,caution 0.047619047619 0.000143348623853 11 10 1
used,concomitantly,with 0.047619047619 0.000143348623853 11 10 1
daily,for,days 0.047619047619 0.000143348623853 10 11 -1
the,risk,of 0.04 0.000286697247706 24 26 -2
a,single,mg 0.037037037037 0.000143348623853 14 13 1
use,of,with 0.0344827586207 0.000143348623853 15 14 1
should,be,used 0.027027027027 0.000286697247706 36 38 -2
should,be,observed 0.0243902439024 0.000143348623853 20 21 -1
caution,should,be 0.0153846153846 0.000143348623853 32 33 -1
is,recommended,that 0.0 0.0 16 16 0
increase,the,risk 0.0 0.0 15 15 0
single,dose,of 0.0 0.0 14 14 0
should,be,closely 0.0 0.0 9 9 0
fold,increase,in 0.0 0.0 9 9 0
there,is,a 0.0 0.0 8 8 0
of,with,other 0.0 0.0 7 7 0
increased,plasma,concentrations 0.0 0.0 7 7 0
be,considered,when 0.0 0.0 7 7 0
an,increased,risk 0.0 0.0 7 7 0
hmg-coa,reductase,inhibitors 0.0 0.0 6 6 0
effects,of,the 0.0 0.0 6 6 0
the,rate,of 0.0 0.0 5 5 0
the,chance,of 0.0 0.0 5 5 0
prior,to,initiation 0.0 0.0 5 5 0
of,concomitant,administration 0.0 0.0 5 5 0
leading,to,increased 0.0 0.0 5 5 0
increase,the,plasma 0.0 0.0 5 5 0
increase,the,chance 0.0 0.0 5 5 0
co-administration,of,and 0.0 0.0 5 5 0
be,reduced,by 0.0 0.0 5 5 0
agents,should,be 0.0 0.0 5 5 0
a,number,of 0.0 0.0 5 5 0
with,concomitant,administration 0.0 0.0 4 4 0
was,coadministered,with 0.0 0.0 4 4 0
steady-state,plasma,concentrations 0.0 0.0 4 4 0
of,aprepitant,with 0.0 0.0 4 4 0
of,and,were 0.0 0.0 4 4 0
is,to,be 0.0 0.0 4 4 0
is,a,potent 0.0 0.0 4 4 0
inhibitor,of,cytochrome 0.0 0.0 4 4 0
inhibitor,of,cyp3a4 0.0 0.0 4 4 0
dose,of,the 0.0 0.0 4 4 0
day,and,mg 0.0 0.0 4 4 0
with,co-administration,of 0.0 0.0 3 3 0
with,an,increased 0.0 0.0 3 3 0
was,reduced,by 0.0 0.0 3 3 0
was,observed,when 0.0 0.0 3 3 0
trough,concentrations,of 0.0 0.0 3 3 0
the,steady-state,trough 0.0 0.0 3 3 0
the,following,agents 0.0 0.0 3 3 0
the,dose,may 0.0 0.0 3 3 0
that,should,not 0.0 0.0 3 3 0
serum,and,urine 0.0 0.0 3 3 0
see,clinical,pharmacology 0.0 0.0 3 3 0
of,with,vitamin 0.0 0.0 3 3 0
of,prothrombin,time 0.0 0.0 3 3 0
of,in,a 0.0 0.0 3 3 0
need,to,be 0.0 0.0 3 3 0
medications,with,activity 0.0 0.0 3 3 0
little,or,no 0.0 0.0 3 3 0
interactions,may,occur 0.0 0.0 3 3 0
in,association,with 0.0 0.0 3 3 0
in,addition,to 0.0 0.0 3 3 0
followed,by,a 0.0 0.0 3 3 0
days,after,the 0.0 0.0 3 3 0
daily,dose,of 0.0 0.0 3 3 0
congestive,heart,failure 0.0 0.0 3 3 0
clinical,studies,of 0.0 0.0 3 3 0
careful,monitoring,of 0.0 0.0 3 3 0
be,avoided,in 0.0 0.0 3 3 0
and,may,be 0.0 0.0 3 3 0
with,may,prolong 0.0 0.0 2 2 0
with,careful,monitoring 0.0 0.0 2 2 0
with,and,monoamine 0.0 0.0 2 2 0
who,have,received 0.0 0.0 2 2 0
which,may,produce 0.0 0.0 2 2 0
when,was,coadministered 0.0 0.0 2 2 0
when,the,two 0.0 0.0 2 2 0
when,administered,concurrently 0.0 0.0 2 2 0
was,shown,to 0.0 0.0 2 2 0
was,increased,by 0.0 0.0 2 2 0
vitro,studies,of 0.0 0.0 2 2 0
treated,with,the 0.0 0.0 2 2 0
treated,concurrently,with 0.0 0.0 2 2 0
to,avoid,impeding 0.0 0.0 2 2 0
to,an,increase 0.0 0.0 2 2 0
time,in,patients 0.0 0.0 2 2 0
these,medications,or 0.0 0.0 2 2 0
these,effects,may 0.0 0.0 2 2 0
therapy,dose,should 0.0 0.0 2 2 0
the,th,day 0.0 0.0 2 2 0
the,risks,of 0.0 0.0 2 2 0
the,protein,binding 0.0 0.0 2 2 0
the,magnitude,and 0.0 0.0 2 2 0
the,intracellular,phosphorylation 0.0 0.0 2 2 0
the,and,cns 0.0 0.0 2 2 0
that,may,reduce 0.0 0.0 2 2 0
taken,concurrently,with 0.0 0.0 2 2 0
system,may,be 0.0 0.0 2 2 0
system,depressants,may 0.0 0.0 2 2 0
stable,dosage,on 0.0 0.0 2 2 0
should,be,noted 0.0 0.0 2 2 0
should,be,alert 0.0 0.0 2 2 0
refer,to,the 0.0 0.0 2 2 0
reduction,in,dosage 0.0 0.0 2 2 0
rate,of,absorption 0.0 0.0 2 2 0
ranging,from,to 0.0 0.0 2 2 0
produce,vertigo,syncope 0.0 0.0 2 2 0
prior,administration,of 0.0 0.0 2 2 0
predominantly,metabolized,by 0.0 0.0 2 2 0
potentiation,of,the 0.0 0.0 2 2 0
potentiate,the,cns 0.0 0.0 2 2 0
potential,for,additive 0.0 0.0 2 2 0
pharmacokinetic,studies,have 0.0 0.0 2 2 0
peak,plasma,concentrations 0.0 0.0 2 2 0
other,such,as 0.0 0.0 2 2 0
or,or,other 0.0 0.0 2 2 0
on,the,plasma 0.0 0.0 2 2 0
on,the,central 0.0 0.0 2 2 0
of,with,a 0.0 0.0 2 2 0
of,was,decreased 0.0 0.0 2 2 0
of,vitamin,d 0.0 0.0 2 2 0
of,to,mg 0.0 0.0 2 2 0
of,the,dosage 0.0 0.0 2 2 0
of,the,day 0.0 0.0 2 2 0
of,such,as 0.0 0.0 2 2 0
of,stadol,ns 0.0 0.0 2 2 0
of,spontaneous,motility 0.0 0.0 2 2 0
of,renal,failure 0.0 0.0 2 2 0
of,or,other 0.0 0.0 2 2 0
of,or,its 0.0 0.0 2 2 0
of,mg,was 0.0 0.0 2 2 0
of,hmg-coa,reductase 0.0 0.0 2 2 0
of,amphotericin,b 0.0 0.0 2 2 0
of,a,day 0.0 0.0 2 2 0
not,recommended,that 0.0 0.0 2 2 0
not,limited,to 0.0 0.0 2 2 0
mg,three,times 0.0 0.0 2 2 0
mg,kg,and 0.0 0.0 2 2 0
metabolized,by,cyp2c9 0.0 0.0 2 2 0
medications,or,or 0.0 0.0 2 2 0
may,prolong,the 0.0 0.0 2 2 0
may,prolong,and 0.0 0.0 2 2 0
may,produce,vertigo 0.0 0.0 2 2 0
may,increase,sensitivity 0.0 0.0 2 2 0
may,be,mediated 0.0 0.0 2 2 0
may,be,expected 0.0 0.0 2 2 0
mao,inhibitors,concurrent 0.0 0.0 2 2 0
kg,and,mg 0.0 0.0 2 2 0
it,has,not 0.0 0.0 2 2 0
ischemic,heart,disease 0.0 0.0 2 2 0
is,used,with 0.0 0.0 2 2 0
is,contraindicated,in 0.0 0.0 2 2 0
is,concluded,that 0.0 0.0 2 2 0
is,advisable,to 0.0 0.0 2 2 0
intracellular,phosphorylation,of 0.0 0.0 2 2 0
intensify,the,and 0.0 0.0 2 2 0
inhibitors,concurrent,use 0.0 0.0 2 2 0
inhibition,of,hepatic 0.0 0.0 2 2 0
indicate,that,the 0.0 0.0 2 2 0
indicate,that,and 0.0 0.0 2 2 0
increases,in,serum 0.0 0.0 2 2 0
increased,plasma,levels 0.0 0.0 2 2 0
increased,by,the 0.0 0.0 2 2 0
increase,the,likelihood 0.0 0.0 2 2 0
increase,or,decrease 0.0 0.0 2 2 0
in,epileptic,patients 0.0 0.0 2 2 0
in,blood,pressure 0.0 0.0 2 2 0
in,a,dose 0.0 0.0 2 2 0
impaired,renal,function 0.0 0.0 2 2 0
have,the,potential 0.0 0.0 2 2 0
gastrointestinal,transit,time 0.0 0.0 2 2 0
from,in,vitro 0.0 0.0 2 2 0
for,this,interaction 0.0 0.0 2 2 0
following,may,interact 0.0 0.0 2 2 0
following,agents,may 0.0 0.0 2 2 0
extensively,metabolized,by 0.0 0.0 2 2 0
experience,there,have 0.0 0.0 2 2 0
either,these,medications 0.0 0.0 2 2 0
effects,of,oral 0.0 0.0 2 2 0
during,administration,of 0.0 0.0 2 2 0
drugs,which,may 0.0 0.0 2 2 0
drug,interaction,with 0.0 0.0 2 2 0
doses,of,to 0.0 0.0 2 2 0
dose,of,aprepitant 0.0 0.0 2 2 0
dosage,adjustments,of 0.0 0.0 2 2 0
depressants,may,potentiate 0.0 0.0 2 2 0
demonstrated,that,the 0.0 0.0 2 2 0
decrease,the,plasma 0.0 0.0 2 2 0
decrease,the,effectiveness 0.0 0.0 2 2 0
days,and,mg 0.0 0.0 2 2 0
day,on,days 0.0 0.0 2 2 0
cyp3a4,substrate,and 0.0 0.0 2 2 0
concomitantly,with,the 0.0 0.0 2 2 0
concomitantly,with,that 0.0 0.0 2 2 0
combined,with,other 0.0 0.0 2 2 0
coadministration,of,aprepitant 0.0 0.0 2 2 0
cns,depressants,may 0.0 0.0 2 2 0
closely,monitored,and 0.0 0.0 2 2 0
closely,for,signs 0.0 0.0 2 2 0
chronic,administration,of 0.0 0.0 2 2 0
cause,a,significant 0.0 0.0 2 2 0
by,coadministration,of 0.0 0.0 2 2 0
but,not,the 0.0 0.0 2 2 0
blood,glucose,levels 0.0 0.0 2 2 0
be,more,pronounced 0.0 0.0 2 2 0
be,mediated,by 0.0 0.0 2 2 0
be,combined,with 0.0 0.0 2 2 0
based,on,in 0.0 0.0 2 2 0
as,indicated,by 0.0 0.0 2 2 0
are,used,concurrently 0.0 0.0 2 2 0
aprepitant,was,administered 0.0 0.0 2 2 0
antacids,concomitant,administration 0.0 0.0 2 2 0
and,would,be 0.0 0.0 2 2 0
and,patients,should 0.0 0.0 2 2 0
and,mg,respectively 0.0 0.0 2 2 0
and,inhibitors,of 0.0 0.0 2 2 0
and,duration,of 0.0 0.0 2 2 0
and,cns,depressant 0.0 0.0 2 2 0
and,auc,values 0.0 0.0 2 2 0
and,and,mg 0.0 0.0 2 2 0
an,in,vitro 0.0 0.0 2 2 0
after,a,mg 0.0 0.0 2 2 0
adverse,effects,of 0.0 0.0 2 2 0
administration,of,g 0.0 0.0 2 2 0
administration,of,aprepitant 0.0 0.0 2 2 0
administration,of,an 0.0 0.0 2 2 0
administered,with,and 0.0 0.0 2 2 0
administered,once,daily 0.0 0.0 2 2 0
administered,concurrently,the 0.0 0.0 2 2 0
adjustment,of,is 0.0 0.0 2 2 0
addition,of,to 0.0 0.0 2 2 0
acute,toxicity,characterized 0.0 0.0 2 2 0
a,potent,inducer 0.0 0.0 2 2 0
a,clinical,study 0.0 0.0 2 2 0
wort,may,significantly 0.0 0.0 1 1 0
within,days,of 0.0 0.0 1 1 0
with,therapeutic,doses 0.0 0.0 1 1 0
with,the,specific 0.0 0.0 1 1 0
with,the,patient 0.0 0.0 1 1 0
with,the,mg 0.0 0.0 1 1 0
with,the,antidepressant 0.0 0.0 1 1 0
with,that,have 0.0 0.0 1 1 0
with,strong,cyp3a4 0.0 0.0 1 1 0
with,other,the 0.0 0.0 1 1 0
with,other,such 0.0 0.0 1 1 0
with,other,coadministered 0.0 0.0 1 1 0
with,other,cns-active 0.0 0.0 1 1 0
with,other,cardioactive 0.0 0.0 1 1 0
with,other,antiretroviral 0.0 0.0 1 1 0
with,oral,or 0.0 0.0 1 1 0
with,or,did 0.0 0.0 1 1 0
with,nephrotoxic,potential 0.0 0.0 1 1 0
with,mg,day 0.0 0.0 1 1 0
with,mg,daily 0.0 0.0 1 1 0
with,mg,and 0.0 0.0 1 1 0
with,may,produce 0.0 0.0 1 1 0
with,may,lead 0.0 0.0 1 1 0
with,may,also 0.0 0.0 1 1 0
with,long-term,high-dose 0.0 0.0 1 1 0
with,ischemic,heart 0.0 0.0 1 1 0
with,is,not 0.0 0.0 1 1 0
with,in,the 0.0 0.0 1 1 0
with,impaired,renal 0.0 0.0 1 1 0
with,can,be 0.0 0.0 1 1 0
with,because,of 0.0 0.0 1 1 0
with,agents,or 0.0 0.0 1 1 0
with,a,light 0.0 0.0 1 1 0
widening,of,the 0.0 0.0 1 1 0
who,were,subsequently 0.0 0.0 1 1 0
who,have,previously 0.0 0.0 1 1 0
who,had,received 0.0 0.0 1 1 0
while,those,of 0.0 0.0 1 1 0
which,may,result 0.0 0.0 1 1 0
which,are,metabolized 0.0 0.0 1 1 0
whether,the,concurrent 0.0 0.0 1 1 0
when,was,co-administered 0.0 0.0 1 1 0
when,therapy,with 0.0 0.0 1 1 0
when,the,is 0.0 0.0 1 1 0
when,sustiva,is 0.0 0.0 1 1 0
when,hydrochloride,is 0.0 0.0 1 1 0
when,either,is 0.0 0.0 1 1 0
when,amitriptyline,hcl 0.0 0.0 1 1 0
were,within,the 0.0 0.0 1 1 0
were,seen,when 0.0 0.0 1 1 0
were,observed,following 0.0 0.0 1 1 0
were,not,sufficient 0.0 0.0 1 1 0
were,not,reported 0.0 0.0 1 1 0
were,in,the 0.0 0.0 1 1 0
well,tolerated,but 0.0 0.0 1 1 0
well,as,those 0.0 0.0 1 1 0
was,unaffected,by 0.0 0.0 1 1 0
was,significantly,decreased 0.0 0.0 1 1 0
was,shown,that 0.0 0.0 1 1 0
was,seen,with 0.0 0.0 1 1 0
was,prolonged,from 0.0 0.0 1 1 0
was,no,change 0.0 0.0 1 1 0
was,given,hours 0.0 0.0 1 1 0
was,given,after 0.0 0.0 1 1 0
was,concluded,that 0.0 0.0 1 1 0
was,combined,with 0.0 0.0 1 1 0
was,a,small 0.0 0.0 1 1 0
was,a,slight 0.0 0.0 1 1 0
warranted,when,is 0.0 0.0 1 1 0
warranted,in,patients 0.0 0.0 1 1 0
warned,of,the 0.0 0.0 1 1 0
volunteers,the,pharmacokinetics 0.0 0.0 1 1 0
volunteers,the,concomitant 0.0 0.0 1 1 0
vivo,studies,have 0.0 0.0 1 1 0
vitro,studies,suggest 0.0 0.0 1 1 0
vioxx,and,mg 0.0 0.0 1 1 0
view,of,the 0.0 0.0 1 1 0
videx,should,be 0.0 0.0 1 1 0
very,high,doses 0.0 0.0 1 1 0
values,for,and 0.0 0.0 1 1 0
valproic,acid,and 0.0 0.0 1 1 0
usually,well,tolerated 0.0 0.0 1 1 0
using,these,medicines 0.0 0.0 1 1 0
using,it,concomitantly 0.0 0.0 1 1 0
used,the,risk 0.0 0.0 1 1 0
use,of,should 0.0 0.0 1 1 0
use,of,oral 0.0 0.0 1 1 0
use,of,nsaids 0.0 0.0 1 1 0
use,of,mao 0.0 0.0 1 1 0
use,of,injection 0.0 0.0 1 1 0
use,of,hivid 0.0 0.0 1 1 0
urinary,alkalinizing,agents 0.0 0.0 1 1 0
up,to,days 0.0 0.0 1 1 0
under,treatment,with 0.0 0.0 1 1 0
two,were,administered 0.0 0.0 1 1 0
two,or,more 0.0 0.0 1 1 0
twice,daily,and 0.0 0.0 1 1 0
tubular,organic,cation 0.0 0.0 1 1 0
trough,cmin,concentration 0.0 0.0 1 1 0
trials,in,patients 0.0 0.0 1 1 0
trials,have,been 0.0 0.0 1 1 0
treatment,with,or 0.0 0.0 1 1 0
treatment,with,one 0.0 0.0 1 1 0
treatment,with,hivid 0.0 0.0 1 1 0
treatment,with,a 0.0 0.0 1 1 0
treatment,of,patients 0.0 0.0 1 1 0
treatment,of,hypotension 0.0 0.0 1 1 0
treated,with,should 0.0 0.0 1 1 0
treated,concomitantly,with 0.0 0.0 1 1 0
transit,time,from 0.0 0.0 1 1 0
toxicity,associated,with 0.0 0.0 1 1 0
toxic,effects,of 0.0 0.0 1 1 0
towards,cyp1a2,which 0.0 0.0 1 1 0
too,much,in 0.0 0.0 1 1 0
to,treat,pneumocystis 0.0 0.0 1 1 0
to,the,treatment 0.0 0.0 1 1 0
to,the,risk 0.0 0.0 1 1 0
to,the,regimen 0.0 0.0 1 1 0
to,the,potential 0.0 0.0 1 1 0
to,the,has 0.0 0.0 1 1 0
to,the,effects 0.0 0.0 1 1 0
to,that,of 0.0 0.0 1 1 0
to,that,observed 0.0 0.0 1 1 0
to,significant,increases 0.0 0.0 1 1 0
to,sensitize,the 0.0 0.0 1 1 0
to,result,from 0.0 0.0 1 1 0
to,produce,significant 0.0 0.0 1 1 0
to,or,withdrawn 0.0 0.0 1 1 0
to,obstetric,blocks 0.0 0.0 1 1 0
to,ng,ml 0.0 0.0 1 1 0
to,ml,min 0.0 0.0 1 1 0
to,ml,h 0.0 0.0 1 1 0
to,mg,qd 0.0 0.0 1 1 0
to,mg,for 0.0 0.0 1 1 0
to,induction,of 0.0 0.0 1 1 0
to,induce,the 0.0 0.0 1 1 0
to,increase,their 0.0 0.0 1 1 0
to,increase,blood 0.0 0.0 1 1 0
to,health,if 0.0 0.0 1 1 0
to,ensure,that 0.0 0.0 1 1 0
to,control,blood 0.0 0.0 1 1 0
to,continue,the 0.0 0.0 1 1 0
to,cause,a 0.0 0.0 1 1 0
to,be,well 0.0 0.0 1 1 0
to,be,metabolized 0.0 0.0 1 1 0
to,be,discontinued 0.0 0.0 1 1 0
to,be,combined 0.0 0.0 1 1 0
to,avoid,the 0.0 0.0 1 1 0
to,and,may 0.0 0.0 1 1 0
to,achieve,the 0.0 0.0 1 1 0
to,a,reduction 0.0 0.0 1 1 0
to,a,interaction 0.0 0.0 1 1 0
to,a,greater 0.0 0.0 1 1 0
to,a,direct 0.0 0.0 1 1 0
times,should,be 0.0 0.0 1 1 0
time,spent,in 0.0 0.0 1 1 0
time,from,to 0.0 0.0 1 1 0
three,weeks,prior 0.0 0.0 1 1 0
three,times,a 0.0 0.0 1 1 0
those,with,a 0.0 0.0 1 1 0
those,found,in 0.0 0.0 1 1 0
this,reason,the 0.0 0.0 1 1 0
this,may,indicate 0.0 0.0 1 1 0
this,isozyme,including 0.0 0.0 1 1 0
this,isoenzyme,including 0.0 0.0 1 1 0
this,effect,was 0.0 0.0 1 1 0
this,effect,may 0.0 0.0 1 1 0
this,decrease,in 0.0 0.0 1 1 0
they,do,not 0.0 0.0 1 1 0
these,pharmacokinetic,effects 0.0 0.0 1 1 0
these,pharmacokinetic,changes 0.0 0.0 1 1 0
these,or,other 0.0 0.0 1 1 0
these,medicines,with 0.0 0.0 1 1 0
these,increased,exposures 0.0 0.0 1 1 0
these,findings,to 0.0 0.0 1 1 0
these,agents,have 0.0 0.0 1 1 0
therefore,when,using 0.0 0.0 1 1 0
therefore,when,indocin 0.0 0.0 1 1 0
therefore,should,not 0.0 0.0 1 1 0
therefore,concomitant,use 0.0 0.0 1 1 0
therefore,coadministration,of 0.0 0.0 1 1 0
there,is,thus 0.0 0.0 1 1 0
therapy,with,another 0.0 0.0 1 1 0
therapy,is,needed 0.0 0.0 1 1 0
therapies,should,not 0.0 0.0 1 1 0
therapeutic,indices,as 0.0 0.0 1 1 0
therapeutic,effects,of 0.0 0.0 1 1 0
theoretically,possible,that 0.0 0.0 1 1 0
theoretical,potential,for 0.0 0.0 1 1 0
theophylline-induced,anxiogenic,effects 0.0 0.0 1 1 0
their,plasma,concentration 0.0 0.0 1 1 0
their,blood,glucose 0.0 0.0 1 1 0
the,urinary,excretion 0.0 0.0 1 1 0
the,two,were 0.0 0.0 1 1 0
the,two,agents 0.0 0.0 1 1 0
the,treatment,regimen 0.0 0.0 1 1 0
the,time,spent 0.0 0.0 1 1 0
the,time,of 0.0 0.0 1 1 0
the,therapeutic,effect 0.0 0.0 1 1 0
the,tail-flick,response 0.0 0.0 1 1 0
the,successive,application 0.0 0.0 1 1 0
the,simultaneous,use 0.0 0.0 1 1 0
the,second,study 0.0 0.0 1 1 0
the,retention,of 0.0 0.0 1 1 0
the,regimen,of 0.0 0.0 1 1 0
the,reduction,in 0.0 0.0 1 1 0
the,qrs,complex 0.0 0.0 1 1 0
the,potential,risk 0.0 0.0 1 1 0
the,potential,interaction 0.0 0.0 1 1 0
the,possible,additive 0.0 0.0 1 1 0
the,plasma,exposure 0.0 0.0 1 1 0
the,plasma,auc 0.0 0.0 1 1 0
the,plasma,and 0.0 0.0 1 1 0
the,period,of 0.0 0.0 1 1 0
the,period,following 0.0 0.0 1 1 0
the,patient,has 0.0 0.0 1 1 0
the,nervous,system 0.0 0.0 1 1 0
the,modulation,of 0.0 0.0 1 1 0
the,major,enzyme 0.0 0.0 1 1 0
the,light,zone 0.0 0.0 1 1 0
the,is,given 0.0 0.0 1 1 0
the,involvement,of 0.0 0.0 1 1 0
the,intravenous,self-administration 0.0 0.0 1 1 0
the,intestinal,mucosa 0.0 0.0 1 1 0
the,increase,of 0.0 0.0 1 1 0
the,geometric,mean 0.0 0.0 1 1 0
the,following,medications 0.0 0.0 1 1 0
the,first,study 0.0 0.0 1 1 0
the,first,hour 0.0 0.0 1 1 0
the,exposure,of 0.0 0.0 1 1 0
the,enteric,coating 0.0 0.0 1 1 0
the,enhancement,of 0.0 0.0 1 1 0
the,elevation,of 0.0 0.0 1 1 0
the,desired,and 0.0 0.0 1 1 0
the,cyp2d6,isoenzyme 0.0 0.0 1 1 0
the,curve,of 0.0 0.0 1 1 0
the,cure,and 0.0 0.0 1 1 0
the,concomitant,agent 0.0 0.0 1 1 0
the,combination,is 0.0 0.0 1 1 0
the,clinically,effective 0.0 0.0 1 1 0
the,clinical,use 0.0 0.0 1 1 0
the,blood,levels 0.0 0.0 1 1 0
the,bioavailability,auc 0.0 0.0 1 1 0
the,benefits,of 0.0 0.0 1 1 0
the,antitumour,activity 0.0 0.0 1 1 0
the,antihypertensive,action 0.0 0.0 1 1 0
the,acute,toxicity 0.0 0.0 1 1 0
the,actions,of 0.0 0.0 1 1 0
that,the,toxicity 0.0 0.0 1 1 0
that,the,dosage 0.0 0.0 1 1 0
that,no,significant 0.0 0.0 1 1 0
that,may,have 0.0 0.0 1 1 0
that,is,a 0.0 0.0 1 1 0
that,inhibit,prostaglandin 0.0 0.0 1 1 0
that,have,a 0.0 0.0 1 1 0
that,do,not 0.0 0.0 1 1 0
that,cefditoren,pivoxil 0.0 0.0 1 1 0
that,an,interaction 0.0 0.0 1 1 0
than,with,the 0.0 0.0 1 1 0
than,that,of 0.0 0.0 1 1 0
th,day,of 0.0 0.0 1 1 0
test,interactions,amphetamines 0.0 0.0 1 1 0
taking,other,that 0.0 0.0 1 1 0
taking,chronically,had 0.0 0.0 1 1 0
taken,with,a 0.0 0.0 1 1 0
taken,at,and 0.0 0.0 1 1 0
t4,and,t3 0.0 0.0 1 1 0
systemic,exposure,to 0.0 0.0 1 1 0
systemic,administration,of 0.0 0.0 1 1 0
system,cns,depressants 0.0 0.0 1 1 0
synergistic,effect,with 0.0 0.0 1 1 0
synergism,with,camp 0.0 0.0 1 1 0
supplements,or,potassium-containing 0.0 0.0 1 1 0
supervision,after,the 0.0 0.0 1 1 0
suggest,that,oral 0.0 0.0 1 1 0
suggest,that,in 0.0 0.0 1 1 0
suggest,that,concomitant 0.0 0.0 1 1 0
such,as,ophthalmic 0.0 0.0 1 1 0
such,as,imitrex 0.0 0.0 1 1 0
successive,application,of 0.0 0.0 1 1 0
substrates,of,cyp2d6 0.0 0.0 1 1 0
substitutes,may,lead 0.0 0.0 1 1 0
subjects,who,have 0.0 0.0 1 1 0
subjects,who,had 0.0 0.0 1 1 0
subjects,receiving,both 0.0 0.0 1 1 0
study,or,was 0.0 0.0 1 1 0
study,of,schizophrenic 0.0 0.0 1 1 0
study,in,human 0.0 0.0 1 1 0
study,conducted,in 0.0 0.0 1 1 0
study,concomitant,administration 0.0 0.0 1 1 0
study,co-administration,of 0.0 0.0 1 1 0
studies,with,the 0.0 0.0 1 1 0
studies,of,patients 0.0 0.0 1 1 0
studies,in,rats 0.0 0.0 1 1 0
studied,in,patients 0.0 0.0 1 1 0
strong,inhibitor,of 0.0 0.0 1 1 0
strattera,should,be 0.0 0.0 1 1 0
strains,of,staphylococcus 0.0 0.0 1 1 0
steady-state,with,a 0.0 0.0 1 1 0
standard,monitoring,of 0.0 0.0 1 1 0
stabilized,on,oral 0.0 0.0 1 1 0
spent,in,the 0.0 0.0 1 1 0
special,care,should 0.0 0.0 1 1 0
some,limited,inhibitory 0.0 0.0 1 1 0
sodium,capsules,mg 0.0 0.0 1 1 0
small,effect,on 0.0 0.0 1 1 0
single,dose,study 0.0 0.0 1 1 0
single,dose,administration 0.0 0.0 1 1 0
since,the,concomitant 0.0 0.0 1 1 0
since,both,and 0.0 0.0 1 1 0
significantly,alter,the 0.0 0.0 1 1 0
significant,interaction,between 0.0 0.0 1 1 0
significant,impact,on 0.0 0.0 1 1 0
significant,elevation,in 0.0 0.0 1 1 0
significance,is,not 0.0 0.0 1 1 0
side,effects,caused 0.0 0.0 1 1 0
shown,to,inhibit 0.0 0.0 1 1 0
shown,that,concomitant 0.0 0.0 1 1 0
should,elapse,before 0.0 0.0 1 1 0
should,be,titrated 0.0 0.0 1 1 0
should,be,separated 0.0 0.0 1 1 0
should,be,borne 0.0 0.0 1 1 0
shorter,durations,of 0.0 0.0 1 1 0
serum,uric,acid 0.0 0.0 1 1 0
serum,levels,with 0.0 0.0 1 1 0
serum,concentration,of 0.0 0.0 1 1 0
serious,ventricular,arrhythmias 0.0 0.0 1 1 0
serious,cardiovascular,adverse 0.0 0.0 1 1 0
secondary,to,a 0.0 0.0 1 1 0
second,contractile,responses 0.0 0.0 1 1 0
salt,substitutes,may 0.0 0.0 1 1 0
s,wort,may 0.0 0.0 1 1 0
s,response,to 0.0 0.0 1 1 0
s,d,and 0.0 0.0 1 1 0
risk,of,using 0.0 0.0 1 1 0
risk,of,severe 0.0 0.0 1 1 0
risk,of,renal 0.0 0.0 1 1 0
risk,of,developing 0.0 0.0 1 1 0
risk,of,a 0.0 0.0 1 1 0
reversal,of,the 0.0 0.0 1 1 0
results,of,studies 0.0 0.0 1 1 0
results,in,an 0.0 0.0 1 1 0
resulting,in,serum 0.0 0.0 1 1 0
resulting,in,lowered 0.0 0.0 1 1 0
resulting,from,concomitant 0.0 0.0 1 1 0
resulted,in,significant 0.0 0.0 1 1 0
resulted,from,a 0.0 0.0 1 1 0
result,in,the 0.0 0.0 1 1 0
result,in,higher 0.0 0.0 1 1 0
responses,to,ptx 0.0 0.0 1 1 0
response,induced,by 0.0 0.0 1 1 0
respiratory,depression,may 0.0 0.0 1 1 0
respiratory,depression,hypotension 0.0 0.0 1 1 0
resistant,to,the 0.0 0.0 1 1 0
reported,with,oral 0.0 0.0 1 1 0
reported,to,induce 0.0 0.0 1 1 0
reported,rarely,to 0.0 0.0 1 1 0
reported,in,the 0.0 0.0 1 1 0
report,describes,a 0.0 0.0 1 1 0
renal,and,mesenteric 0.0 0.0 1 1 0
relationship,has,not 0.0 0.0 1 1 0
related,to,obstetric 0.0 0.0 1 1 0
related,anabolic,hormones 0.0 0.0 1 1 0
regimen,of,a 0.0 0.0 1 1 0
regarding,the,effect 0.0 0.0 1 1 0
reduction,in,dose 0.0 0.0 1 1 0
reductase,inhibitors,and 0.0 0.0 1 1 0
reduced,by,to 0.0 0.0 1 1 0
reduced,approximately,when 0.0 0.0 1 1 0
reduce,the,bioavailability 0.0 0.0 1 1 0
reduce,pulse,and 0.0 0.0 1 1 0
recommended,when,sustiva 0.0 0.0 1 1 0
recommended,that,cefditoren 0.0 0.0 1 1 0
recommended,that,be 0.0 0.0 1 1 0
recommended,dose,may 0.0 0.0 1 1 0
receiving,the,initial 0.0 0.0 1 1 0
received,days,of 0.0 0.0 1 1 0
reason,the,dose 0.0 0.0 1 1 0
ratio,inr,elevations 0.0 0.0 1 1 0
rarely,to,cause 0.0 0.0 1 1 0
rare,postmarketing,reports 0.0 0.0 1 1 0
range,of,mg 0.0 0.0 1 1 0
racemic,combined,administration 0.0 0.0 1 1 0
r,or,s 0.0 0.0 1 1 0
qrs,complex,and 0.0 0.0 1 1 0
qd,days,with 0.0 0.0 1 1 0
q24h,for,days 0.0 0.0 1 1 0
pulse,and,blood 0.0 0.0 1 1 0
provide,close,medical 0.0 0.0 1 1 0
prothrombin,times,when 0.0 0.0 1 1 0
prothrombin,times,should 0.0 0.0 1 1 0
prothrombin,time,when 0.0 0.0 1 1 0
protein,binding,and 0.0 0.0 1 1 0
protease,inhibitors,in 0.0 0.0 1 1 0
prostaglandin,f2alpha,and 0.0 0.0 1 1 0
propanol,to,difluoroacetone 0.0 0.0 1 1 0
prolonged,gastrointestinal,transit 0.0 0.0 1 1 0
prolongation,of,plasma 0.0 0.0 1 1 0
prolong,the,qtc 0.0 0.0 1 1 0
prolong,the,clinically 0.0 0.0 1 1 0
profound,sedation,or 0.0 0.0 1 1 0
profile,of,either 0.0 0.0 1 1 0
products,sharing,that 0.0 0.0 1 1 0
produced,a,decrease 0.0 0.0 1 1 0
probenecid,probenecid,is 0.0 0.0 1 1 0
primary,and,secondary 0.0 0.0 1 1 0
present,a,theoretical 0.0 0.0 1 1 0
presence,of,carbamazepine 0.0 0.0 1 1 0
preparations,containing,or 0.0 0.0 1 1 0
predominantly,in,the 0.0 0.0 1 1 0
potential,to,decrease 0.0 0.0 1 1 0
potent,inducers,of 0.0 0.0 1 1 0
potassium-sparing,or,supplements 0.0 0.0 1 1 0
potassium-containing,salt,substitutes 0.0 0.0 1 1 0
postmarketing,reports,of 0.0 0.0 1 1 0
possible,decrease,in 0.0 0.0 1 1 0
pose,a,hazard 0.0 0.0 1 1 0
plasma,levels,in 0.0 0.0 1 1 0
plasma,half-life,and 0.0 0.0 1 1 0
plasma,concentrations,when 0.0 0.0 1 1 0
plasma,concentration,altered 0.0 0.0 1 1 0
pivoxil,be,taken 0.0 0.0 1 1 0
phase,i,trial 0.0 0.0 1 1 0
pharmacology,of,the 0.0 0.0 1 1 0
pharmacokinetic,profile,of 0.0 0.0 1 1 0
pharmacokinetic,data,suggest 0.0 0.0 1 1 0
peritoneal,metastasis,of 0.0 0.0 1 1 0
per,day,and 0.0 0.0 1 1 0
pcp,in,pigeons 0.0 0.0 1 1 0
patients,with,normal 0.0 0.0 1 1 0
patients,taking,when 0.0 0.0 1 1 0
patients,taking,vioxx 0.0 0.0 1 1 0
patients,taking,tricyclic 0.0 0.0 1 1 0
patients,taking,chronically 0.0 0.0 1 1 0
patients,taking,celebrex 0.0 0.0 1 1 0
patients,should,take 0.0 0.0 1 1 0
patients,receiving,either 0.0 0.0 1 1 0
patients,on,a 0.0 0.0 1 1 0
patients,in,the 0.0 0.0 1 1 0
patients,exposed,to 0.0 0.0 1 1 0
patient,s,response 0.0 0.0 1 1 0
patient,is,receiving 0.0 0.0 1 1 0
particularly,during,the 0.0 0.0 1 1 0
particular,caution,should 0.0 0.0 1 1 0
p1,and,n1 0.0 0.0 1 1 0
p-450,the,enzyme 0.0 0.0 1 1 0
oxidative,stress,in 0.0 0.0 1 1 0
other,that,have 0.0 0.0 1 1 0
other,nsaids,may 0.0 0.0 1 1 0
other,nonsteroidal,agents 0.0 0.0 1 1 0
other,nondepolarizing,neuromuscular 0.0 0.0 1 1 0
other,metabolized,via 0.0 0.0 1 1 0
other,medications,that 0.0 0.0 1 1 0
other,ht1b,d 0.0 0.0 1 1 0
other,ht1,agonists 0.0 0.0 1 1 0
other,drugs,that 0.0 0.0 1 1 0
other,coadministered,medicinal 0.0 0.0 1 1 0
other,antiepilepsy,drugs 0.0 0.0 1 1 0
other,agents,has 0.0 0.0 1 1 0
orally,inhaled,and 0.0 0.0 1 1 0
oral,may,be 0.0 0.0 1 1 0
or,within,weeks 0.0 0.0 1 1 0
or,withdrawn,from 0.0 0.0 1 1 0
or,supplements,or 0.0 0.0 1 1 0
or,reduce,the 0.0 0.0 1 1 0
or,potassium-containing,salt 0.0 0.0 1 1 0
or,oral,hypoglycemics 0.0 0.0 1 1 0
or,no,effect 0.0 0.0 1 1 0
or,may,not 0.0 0.0 1 1 0
or,inhibit,the 0.0 0.0 1 1 0
or,h,antagonists 0.0 0.0 1 1 0
or,effect,of 0.0 0.0 1 1 0
or,discontinued,in 0.0 0.0 1 1 0
or,decrease,the 0.0 0.0 1 1 0
or,beta-adrenergic,blocking 0.0 0.0 1 1 0
or,are,metabolized 0.0 0.0 1 1 0
or,any,other 0.0 0.0 1 1 0
or,activity,of 0.0 0.0 1 1 0
ophthalmic,and,systemic 0.0 0.0 1 1 0
only,if,the 0.0 0.0 1 1 0
one-tenth,of,the 0.0 0.0 1 1 0
one,report,of 0.0 0.0 1 1 0
one,hour,after 0.0 0.0 1 1 0
once,daily,as 0.0 0.0 1 1 0
on,total,concentrations 0.0 0.0 1 1 0
on,the,use 0.0 0.0 1 1 0
on,the,renal 0.0 0.0 1 1 0
on,the,intracellular 0.0 0.0 1 1 0
on,the,availability 0.0 0.0 1 1 0
on,the,antinociceptive 0.0 0.0 1 1 0
on,day,there 0.0 0.0 1 1 0
on,day,on 0.0 0.0 1 1 0
on,chronic,therapy 0.0 0.0 1 1 0
on,blood,levels 0.0 0.0 1 1 0
oh,d3,and 0.0 0.0 1 1 0
of,withdrawal,and 0.0 0.0 1 1 0
of,with,the 0.0 0.0 1 1 0
of,which,were 0.0 0.0 1 1 0
of,using,the 0.0 0.0 1 1 0
of,tubular,secretion 0.0 0.0 1 1 0
of,tubular,organic 0.0 0.0 1 1 0
of,toxicity,may 0.0 0.0 1 1 0
of,toxicity,and 0.0 0.0 1 1 0
of,toradol,on 0.0 0.0 1 1 0
of,this,isoenzyme 0.0 0.0 1 1 0
of,this,enzyme 0.0 0.0 1 1 0
of,these,cyp3a4 0.0 0.0 1 1 0
of,the,two 0.0 0.0 1 1 0
of,the,tail-flick 0.0 0.0 1 1 0
of,the,small 0.0 0.0 1 1 0
of,the,relationship 0.0 0.0 1 1 0
of,the,qrs 0.0 0.0 1 1 0
of,the,or 0.0 0.0 1 1 0
of,the,major 0.0 0.0 1 1 0
of,the,increased 0.0 0.0 1 1 0
of,the,hmg-coa 0.0 0.0 1 1 0
of,the,have 0.0 0.0 1 1 0
of,the,cyp2d6 0.0 0.0 1 1 0
of,the,antihypertensive 0.0 0.0 1 1 0
of,the,active 0.0 0.0 1 1 0
of,tambocor,and 0.0 0.0 1 1 0
of,studies,in 0.0 0.0 1 1 0
of,staphylococcus,aureus 0.0 0.0 1 1 0
of,skin,rash 0.0 0.0 1 1 0
of,severe,hypersensitivity 0.0 0.0 1 1 0
of,schizophrenic,patients 0.0 0.0 1 1 0
of,revia,and 0.0 0.0 1 1 0
of,renal,function 0.0 0.0 1 1 0
of,relative,to 0.0 0.0 1 1 0
of,prostaglandin,f2alpha 0.0 0.0 1 1 0
of,plasma,half-life 0.0 0.0 1 1 0
of,p450,c9 0.0 0.0 1 1 0
of,other,that 0.0 0.0 1 1 0
of,other,such 0.0 0.0 1 1 0
of,other,ht1b 0.0 0.0 1 1 0
of,other,cns 0.0 0.0 1 1 0
of,orally,inhaled 0.0 0.0 1 1 0
of,nsaids,in 0.0 0.0 1 1 0
of,nizoral,tablets 0.0 0.0 1 1 0
of,nimbex,and 0.0 0.0 1 1 0
of,nephrotoxicity,and 0.0 0.0 1 1 0
of,mg,to 0.0 0.0 1 1 0
of,mg,qd 0.0 0.0 1 1 0
of,mg,or 0.0 0.0 1 1 0
of,methylpyrazole,mg 0.0 0.0 1 1 0
of,mefenamic,acid 0.0 0.0 1 1 0
of,may,interfere 0.0 0.0 1 1 0
of,mao,inhibitors 0.0 0.0 1 1 0
of,m,g 0.0 0.0 1 1 0
of,liver,enzymes 0.0 0.0 1 1 0
of,is,reduced 0.0 0.0 1 1 0
of,intravenous,sodium 0.0 0.0 1 1 0
of,intestinal,adenocarcinomas 0.0 0.0 1 1 0
of,interactions,when 0.0 0.0 1 1 0
of,in,vitro 0.0 0.0 1 1 0
of,in,human 0.0 0.0 1 1 0
of,hypotension,related 0.0 0.0 1 1 0
of,hivid,with 0.0 0.0 1 1 0
of,hepatic,cytochrome 0.0 0.0 1 1 0
of,heart,block 0.0 0.0 1 1 0
of,healthy,male 0.0 0.0 1 1 0
of,gl,with 0.0 0.0 1 1 0
of,g,kg 0.0 0.0 1 1 0
of,felbatol,on 0.0 0.0 1 1 0
of,enhancing,the 0.0 0.0 1 1 0
of,endotoxin-treated,rats 0.0 0.0 1 1 0
of,either,and 0.0 0.0 1 1 0
of,duloxetine,with 0.0 0.0 1 1 0
of,dosage,are 0.0 0.0 1 1 0
of,difluoro-2,propanol 0.0 0.0 1 1 0
of,d,h 0.0 0.0 1 1 0
of,cyp3a,and 0.0 0.0 1 1 0
of,cyp2d6,such 0.0 0.0 1 1 0
of,control,and 0.0 0.0 1 1 0
of,combination,hormonal 0.0 0.0 1 1 0
of,cefditoren,pivoxil 0.0 0.0 1 1 0
of,but,may 0.0 0.0 1 1 0
of,brevibloc,and 0.0 0.0 1 1 0
of,breast,cancer 0.0 0.0 1 1 0
of,both,the 0.0 0.0 1 1 0
of,beta-adrenergic,blocking 0.0 0.0 1 1 0
of,atrovent,inhalation 0.0 0.0 1 1 0
of,at,steady-state 0.0 0.0 1 1 0
of,as,compared 0.0 0.0 1 1 0
of,argatroban,with 0.0 0.0 1 1 0
of,argatroban,and 0.0 0.0 1 1 0
of,are,likely 0.0 0.0 1 1 0
of,aprepitant,and 0.0 0.0 1 1 0
of,approximately,in 0.0 0.0 1 1 0
of,and,produced 0.0 0.0 1 1 0
of,and,mg 0.0 0.0 1 1 0
of,and,increase 0.0 0.0 1 1 0
of,and,an 0.0 0.0 1 1 0
of,an,interaction 0.0 0.0 1 1 0
of,an,increase 0.0 0.0 1 1 0
of,a,similar 0.0 0.0 1 1 0
of,a,selective 0.0 0.0 1 1 0
of,a,cyp 0.0 0.0 1 1 0
occur,with,the 0.0 0.0 1 1 0
obstetric,blocks,and 0.0 0.0 1 1 0
observed,it,is 0.0 0.0 1 1 0
observed,for,the 0.0 0.0 1 1 0
observed,between,and 0.0 0.0 1 1 0
noted,with,the 0.0 0.0 1 1 0
not,significantly,inhibit 0.0 0.0 1 1 0
not,reported,in 0.0 0.0 1 1 0
not,observed,in 0.0 0.0 1 1 0
not,known,it 0.0 0.0 1 1 0
not,enhance,the 0.0 0.0 1 1 0
not,due,to 0.0 0.0 1 1 0
not,been,shown 0.0 0.0 1 1 0
not,been,done 0.0 0.0 1 1 0
not,be,effective 0.0 0.0 1 1 0
not,be,combined 0.0 0.0 1 1 0
normalized,ratio,inr 0.0 0.0 1 1 0
normal,volunteers,n 0.0 0.0 1 1 0
normal,volunteers,have 0.0 0.0 1 1 0
nonselective,inhibitor,of 0.0 0.0 1 1 0
nonlethal,dose,of 0.0 0.0 1 1 0
nonetheless,since,interactions 0.0 0.0 1 1 0
nondepolarizing,muscle,relaxants 0.0 0.0 1 1 0
nizoral,tablets,and 0.0 0.0 1 1 0
neuromuscular,blockade,was 0.0 0.0 1 1 0
nervous,system,depression 0.0 0.0 1 1 0
nervous,system,cns 0.0 0.0 1 1 0
need,to,change 0.0 0.0 1 1 0
necessary,to,maintain 0.0 0.0 1 1 0
necessary,to,continue 0.0 0.0 1 1 0
narrow,therapeutic,indices 0.0 0.0 1 1 0
nad,dependent,oxidation 0.0 0.0 1 1 0
n-methyllevallorphan,mg,kg 0.0 0.0 1 1 0
must,be,administered 0.0 0.0 1 1 0
multiple-dose,administration,of 0.0 0.0 1 1 0
multiple,oral,doses 0.0 0.0 1 1 0
much,in,the 0.0 0.0 1 1 0
morphine,prolonged,gastrointestinal 0.0 0.0 1 1 0
monitoring,for,toxicity 0.0 0.0 1 1 0
monitored,for,a 0.0 0.0 1 1 0
monitored,closely,in 0.0 0.0 1 1 0
monitored,closely,and 0.0 0.0 1 1 0
monitored,at,the 0.0 0.0 1 1 0
monitored,and,the 0.0 0.0 1 1 0
molecular,basis,for 0.0 0.0 1 1 0
ml,min,p 0.0 0.0 1 1 0
ml,h,to 0.0 0.0 1 1 0
mixed,agonist,antagonist 0.0 0.0 1 1 0
microsomal,enzyme,systems 0.0 0.0 1 1 0
microg,kg,day 0.0 0.0 1 1 0
mg,was,given 0.0 0.0 1 1 0
mg,to,mg 0.0 0.0 1 1 0
mg,times,daily 0.0 0.0 1 1 0
mg,qd,for 0.0 0.0 1 1 0
mg,qd,days 0.0 0.0 1 1 0
mg,of,had 0.0 0.0 1 1 0
mg,kg,produced 0.0 0.0 1 1 0
mg,kg,per 0.0 0.0 1 1 0
mg,kg,p 0.0 0.0 1 1 0
mg,kg,on 0.0 0.0 1 1 0
mg,daily,as 0.0 0.0 1 1 0
mg,daily,and 0.0 0.0 1 1 0
mg,bid,day 0.0 0.0 1 1 0
methylpyrazole,mg,kg 0.0 0.0 1 1 0
metastasis,of,intestinal 0.0 0.0 1 1 0
metabolized,by,hepatic 0.0 0.0 1 1 0
metabolism,of,the 0.0 0.0 1 1 0
metabolism,by,cyp3a4 0.0 0.0 1 1 0
metabolism,and,the 0.0 0.0 1 1 0
metabolism,and,increase 0.0 0.0 1 1 0
medicinal,products,sharing 0.0 0.0 1 1 0
medications,may,be 0.0 0.0 1 1 0
medication,such,as 0.0 0.0 1 1 0
medical,supervision,after 0.0 0.0 1 1 0
meclofenamate,sodium,is 0.0 0.0 1 1 0
mechanism,for,the 0.0 0.0 1 1 0
measured,by,auc0-24hr 0.0 0.0 1 1 0
mean,area,under 0.0 0.0 1 1 0
mcg,of,ethinyl 0.0 0.0 1 1 0
mcg,im,once 0.0 0.0 1 1 0
may,result,from 0.0 0.0 1 1 0
may,require,dosage 0.0 0.0 1 1 0
may,reduce,pulse 0.0 0.0 1 1 0
may,raise,the 0.0 0.0 1 1 0
may,present,a 0.0 0.0 1 1 0
may,indicate,that 0.0 0.0 1 1 0
may,increase,toxicity 0.0 0.0 1 1 0
may,impair,the 0.0 0.0 1 1 0
may,have,their 0.0 0.0 1 1 0
may,delay,or 0.0 0.0 1 1 0
may,decrease,hepatic 0.0 0.0 1 1 0
may,contribute,to 0.0 0.0 1 1 0
may,bind,other 0.0 0.0 1 1 0
may,be,taken 0.0 0.0 1 1 0
may,be,produced 0.0 0.0 1 1 0
may,be,needed 0.0 0.0 1 1 0
may,be,less 0.0 0.0 1 1 0
may,be,greater 0.0 0.0 1 1 0
may,be,exacerbated 0.0 0.0 1 1 0
may,also,have 0.0 0.0 1 1 0
max,increased,by 0.0 0.0 1 1 0
mao,inhibitors,including 0.0 0.0 1 1 0
male,and,female 0.0 0.0 1 1 0
maintenance,level,while 0.0 0.0 1 1 0
maintenance,doses,of 0.0 0.0 1 1 0
macrolide,such,as 0.0 0.0 1 1 0
macrolide,antibiotics,and 0.0 0.0 1 1 0
lowering,effect,of 0.0 0.0 1 1 0
lower,doses,of 0.0 0.0 1 1 0
lower,blood,pressure 0.0 0.0 1 1 0
loss,of,the 0.0 0.0 1 1 0
loss,of,consciousness 0.0 0.0 1 1 0
loperamide,and,and 0.0 0.0 1 1 0
longer,in,the 0.0 0.0 1 1 0
literature,reports,suggest 0.0 0.0 1 1 0
limited,inhibitory,activity 0.0 0.0 1 1 0
limited,clinical,data 0.0 0.0 1 1 0
levulan,kerastick,for 0.0 0.0 1 1 0
levels,with,the 0.0 0.0 1 1 0
levels,of,other 0.0 0.0 1 1 0
levels,is,recommended 0.0 0.0 1 1 0
levels,and,auc 0.0 0.0 1 1 0
levels,and,adjust 0.0 0.0 1 1 0
level,while,the 0.0 0.0 1 1 0
less,than,and 0.0 0.0 1 1 0
length,of,time 0.0 0.0 1 1 0
least,hours,should 0.0 0.0 1 1 0
lead,to,significant 0.0 0.0 1 1 0
ldl-c,reduction,was 0.0 0.0 1 1 0
known,whether,this 0.0 0.0 1 1 0
known,whether,the 0.0 0.0 1 1 0
known,to,interact 0.0 0.0 1 1 0
known,to,have 0.0 0.0 1 1 0
known,it,is 0.0 0.0 1 1 0
kg,per,day 0.0 0.0 1 1 0
kg,p,o 0.0 0.0 1 1 0
kg,for,days 0.0 0.0 1 1 0
kg,dose,or 0.0 0.0 1 1 0
kg,day,in 0.0 0.0 1 1 0
ketoconazole,when,a 0.0 0.0 1 1 0
juice,should,be 0.0 0.0 1 1 0
its,metabolites,with 0.0 0.0 1 1 0
its,capacity,to 0.0 0.0 1 1 0
it,would,be 0.0 0.0 1 1 0
it,was,shown 0.0 0.0 1 1 0
it,was,concluded 0.0 0.0 1 1 0
it,significantly,decreased 0.0 0.0 1 1 0
it,may,increase 0.0 0.0 1 1 0
it,is,therefore 0.0 0.0 1 1 0
it,is,theoretically 0.0 0.0 1 1 0
it,is,necessary 0.0 0.0 1 1 0
it,is,expected 0.0 0.0 1 1 0
it,is,especially 0.0 0.0 1 1 0
it,had,no 0.0 0.0 1 1 0
it,concomitantly,with 0.0 0.0 1 1 0
is,warranted,in 0.0 0.0 1 1 0
is,warranted,and 0.0 0.0 1 1 0
is,usually,well 0.0 0.0 1 1 0
is,thus,an 0.0 0.0 1 1 0
is,theoretically,possible 0.0 0.0 1 1 0
is,the,primary 0.0 0.0 1 1 0
is,the,potential 0.0 0.0 1 1 0
is,taken,concurrently 0.0 0.0 1 1 0
is,required,when 0.0 0.0 1 1 0
is,required,to 0.0 0.0 1 1 0
is,recommended,to 0.0 0.0 1 1 0
is,needed,the 0.0 0.0 1 1 0
is,necessary,when 0.0 0.0 1 1 0
is,necessary,to 0.0 0.0 1 1 0
is,initiated,or 0.0 0.0 1 1 0
is,higher,in 0.0 0.0 1 1 0
is,expected,to 0.0 0.0 1 1 0
is,expected,that 0.0 0.0 1 1 0
is,administered,shortly 0.0 0.0 1 1 0
is,a,strong 0.0 0.0 1 1 0
iopidine,ophthalmic,solution 0.0 0.0 1 1 0
intravenous,sodium,and 0.0 0.0 1 1 0
intravenous,self-administration,of 0.0 0.0 1 1 0
intracellular,ca,concentration 0.0 0.0 1 1 0
intestinal,adenocarcinomas,induced 0.0 0.0 1 1 0
intermediate,doses,of 0.0 0.0 1 1 0
interactions,when,and 0.0 0.0 1 1 0
interactions,have,occurred 0.0 0.0 1 1 0
interactions,are,listed 0.0 0.0 1 1 0
interactions,amphetamines,can 0.0 0.0 1 1 0
interaction,with,and 0.0 0.0 1 1 0
interaction,study,co-administration 0.0 0.0 1 1 0
interaction,on,the 0.0 0.0 1 1 0
interaction,of,prostaglandin 0.0 0.0 1 1 0
interaction,has,not 0.0 0.0 1 1 0
insulin,or,oral 0.0 0.0 1 1 0
inspra,to,mg 0.0 0.0 1 1 0
insp,induced,responses 0.0 0.0 1 1 0
inr,elevations,and 0.0 0.0 1 1 0
injection,of,and 0.0 0.0 1 1 0
injection,in,combination 0.0 0.0 1 1 0
initial,dose,and 0.0 0.0 1 1 0
inhibitory,effect,of 0.0 0.0 1 1 0
inhibitory,activity,towards 0.0 0.0 1 1 0
inhibitors,on,the 0.0 0.0 1 1 0
inhibitors,of,tubular 0.0 0.0 1 1 0
inhibitors,of,hepatic 0.0 0.0 1 1 0
inhibitors,of,cytochrome 0.0 0.0 1 1 0
inhibitors,of,cyp2c9 0.0 0.0 1 1 0
inhibitors,of,cyp2c19 0.0 0.0 1 1 0
inhibitors,including,sulfate 0.0 0.0 1 1 0
inhibitors,in,vitro 0.0 0.0 1 1 0
inhibitors,grapefruit,juice 0.0 0.0 1 1 0
inhibitors,and,angiotensin 0.0 0.0 1 1 0
inhibitor,of,p450 0.0 0.0 1 1 0
inhibitor,of,cyp2d6 0.0 0.0 1 1 0
inhibitor,of,cyp1a2 0.0 0.0 1 1 0
inhibitor,in,combination 0.0 0.0 1 1 0
inhibition,of,tubular 0.0 0.0 1 1 0
inhibit,the,hepatic 0.0 0.0 1 1 0
inhibit,prostaglandin,synthesis 0.0 0.0 1 1 0
inhibit,or,are 0.0 0.0 1 1 0
inducer,of,hepatic 0.0 0.0 1 1 0
indocin,and,potassium-sparing 0.0 0.0 1 1 0
indices,as,competition 0.0 0.0 1 1 0
indicate,that,inhibits 0.0 0.0 1 1 0
increases,should,be 0.0 0.0 1 1 0
increases,in,their 0.0 0.0 1 1 0
increases,in,peak 0.0 0.0 1 1 0
increases,in,liver 0.0 0.0 1 1 0
increases,in,inr 0.0 0.0 1 1 0
increases,in,fi 0.0 0.0 1 1 0
increases,in,dose 0.0 0.0 1 1 0
increased,with,concurrent 0.0 0.0 1 1 0
increased,the,incidence 0.0 0.0 1 1 0
increased,risks,of 0.0 0.0 1 1 0
increased,plasma,concentration 0.0 0.0 1 1 0
increased,in,patients 0.0 0.0 1 1 0
increased,from,to 0.0 0.0 1 1 0
increased,blood,levels 0.0 0.0 1 1 0
increased,and,decreased 0.0 0.0 1 1 0
increased,activity,of 0.0 0.0 1 1 0
increase,the,metabolism 0.0 0.0 1 1 0
increase,the,dose 0.0 0.0 1 1 0
increase,serum,concentrations 0.0 0.0 1 1 0
increase,of,approximately 0.0 0.0 1 1 0
increase,in,blood 0.0 0.0 1 1 0
including,sulfate,sulfate 0.0 0.0 1 1 0
incidence,of,akathisia 0.0 0.0 1 1 0
in,which,healthy 0.0 0.0 1 1 0
in,which,a 0.0 0.0 1 1 0
in,vivo,drug-drug 0.0 0.0 1 1 0
in,vitro,study 0.0 0.0 1 1 0
in,vitro,in 0.0 0.0 1 1 0
in,vitro,has 0.0 0.0 1 1 0
in,vitro,binding 0.0 0.0 1 1 0
in,view,of 0.0 0.0 1 1 0
in,using,it 0.0 0.0 1 1 0
in,two,of 0.0 0.0 1 1 0
in,total,body 0.0 0.0 1 1 0
in,the,second 0.0 0.0 1 1 0
in,the,rat 0.0 0.0 1 1 0
in,the,literature 0.0 0.0 1 1 0
in,the,level 0.0 0.0 1 1 0
in,the,intestinal 0.0 0.0 1 1 0
in,the,groups 0.0 0.0 1 1 0
in,the,diet 0.0 0.0 1 1 0
in,susceptible,patients 0.0 0.0 1 1 0
in,serum,concentration 0.0 0.0 1 1 0
in,serum,and 0.0 0.0 1 1 0
in,reduced,plasma 0.0 0.0 1 1 0
in,rats,at 0.0 0.0 1 1 0
in,previous,reports 0.0 0.0 1 1 0
in,postmarketing,experience 0.0 0.0 1 1 0
in,patients,to 0.0 0.0 1 1 0
in,patients,given 0.0 0.0 1 1 0
in,patients,exposed 0.0 0.0 1 1 0
in,part,to 0.0 0.0 1 1 0
in,one,controlled 0.0 0.0 1 1 0
in,ms,patients 0.0 0.0 1 1 0
in,man,include 0.0 0.0 1 1 0
in,inr,and 0.0 0.0 1 1 0
in,humans,and 0.0 0.0 1 1 0
in,human,subjects 0.0 0.0 1 1 0
in,functional,class 0.0 0.0 1 1 0
in,fi,responding 0.0 0.0 1 1 0
in,females,and 0.0 0.0 1 1 0
in,elderly,patients 0.0 0.0 1 1 0
in,doses,up 0.0 0.0 1 1 0
in,decreased,plasma 0.0 0.0 1 1 0
in,comparison,with 0.0 0.0 1 1 0
in,clinically,meaningful 0.0 0.0 1 1 0
in,case,of 0.0 0.0 1 1 0
in,blood,levels 0.0 0.0 1 1 0
in,auc,of 0.0 0.0 1 1 0
in,all,patients 0.0 0.0 1 1 0
in,addition,there 0.0 0.0 1 1 0
in,addition,several 0.0 0.0 1 1 0
in,a,similar 0.0 0.0 1 1 0
in,a,controlled 0.0 0.0 1 1 0
in,a,and 0.0 0.0 1 1 0
implicated,in,the 0.0 0.0 1 1 0
im,once,weekly 0.0 0.0 1 1 0
ii,receptor,antagonists 0.0 0.0 1 1 0
if,used,concomitantly 0.0 0.0 1 1 0
if,the,potential 0.0 0.0 1 1 0
if,the,patient 0.0 0.0 1 1 0
if,it,is 0.0 0.0 1 1 0
if,at,all 0.0 0.0 1 1 0
if,a,potentially 0.0 0.0 1 1 0
i,d,or 0.0 0.0 1 1 0
i,d,and 0.0 0.0 1 1 0
hypotension,related,to 0.0 0.0 1 1 0
hypotension,and,profound 0.0 0.0 1 1 0
hydroxide,and,hydroxide 0.0 0.0 1 1 0
hydrochloride,is,used 0.0 0.0 1 1 0
hydrochloride,concomitantly,with 0.0 0.0 1 1 0
ht1b,d,agonists 0.0 0.0 1 1 0
however,there,are 0.0 0.0 1 1 0
however,ldl-c,reduction 0.0 0.0 1 1 0
however,in,the 0.0 0.0 1 1 0
however,concomitant,administration 0.0 0.0 1 1 0
hours,should,elapse 0.0 0.0 1 1 0
hormonal,may,also 0.0 0.0 1 1 0
higher,incidence,of 0.0 0.0 1 1 0
hepatitis,has,been 0.0 0.0 1 1 0
hepatic,toxicity,in 0.0 0.0 1 1 0
hepatic,cytochrome,p-450 0.0 0.0 1 1 0
heart,rate,and 0.0 0.0 1 1 0
healthy,volunteers,resulted 0.0 0.0 1 1 0
healthy,subjects,by 0.0 0.0 1 1 0
health,if,a 0.0 0.0 1 1 0
hazard,to,health 0.0 0.0 1 1 0
having,vasodilator,activity 0.0 0.0 1 1 0
have,their,prothrombin 0.0 0.0 1 1 0
have,their,plasma 0.0 0.0 1 1 0
have,previously,received 0.0 0.0 1 1 0
have,occurred,with 0.0 0.0 1 1 0
have,not,shown 0.0 0.0 1 1 0
have,decreased,plasma 0.0 0.0 1 1 0
have,clinically,relevant 0.0 0.0 1 1 0
have,been,identified 0.0 0.0 1 1 0
has,been,proposed 0.0 0.0 1 1 0
has,been,implicated 0.0 0.0 1 1 0
has,been,established 0.0 0.0 1 1 0
had,received,days 0.0 0.0 1 1 0
h,to,ml 0.0 0.0 1 1 0
glucose,levels,or 0.0 0.0 1 1 0
gl,with,four 0.0 0.0 1 1 0
given,with,other 0.0 0.0 1 1 0
given,prior,to 0.0 0.0 1 1 0
given,in,a 0.0 0.0 1 1 0
given,hours,after 0.0 0.0 1 1 0
give,rise,to 0.0 0.0 1 1 0
gastric,acid,secretion 0.0 0.0 1 1 0
function,of,the 0.0 0.0 1 1 0
from,ml,h 0.0 0.0 1 1 0
from,clinical,studies 0.0 0.0 1 1 0
from,a,study 0.0 0.0 1 1 0
fractional,clearance,rate 0.0 0.0 1 1 0
foradil,should,be 0.0 0.0 1 1 0
for,weeks,in 0.0 0.0 1 1 0
for,use,in 0.0 0.0 1 1 0
for,toxicity,and 0.0 0.0 1 1 0
for,this,reason 0.0 0.0 1 1 0
for,the,first-pass 0.0 0.0 1 1 0
for,the,concomitant 0.0 0.0 1 1 0
for,several,hours 0.0 0.0 1 1 0
for,of,the 0.0 0.0 1 1 0
for,increases,in 0.0 0.0 1 1 0
for,equetrotm,may 0.0 0.0 1 1 0
for,days,produced 0.0 0.0 1 1 0
for,days,in 0.0 0.0 1 1 0
for,binding,sites 0.0 0.0 1 1 0
for,adverse,reactions 0.0 0.0 1 1 0
for,active,tubular 0.0 0.0 1 1 0
following,the,use 0.0 0.0 1 1 0
following,doses,of 0.0 0.0 1 1 0
following,coadministration,of 0.0 0.0 1 1 0
followed,by,mg 0.0 0.0 1 1 0
fold,increases,in 0.0 0.0 1 1 0
fold,higher,than 0.0 0.0 1 1 0
flurbiprofen,did,not 0.0 0.0 1 1 0
first,and,second 0.0 0.0 1 1 0
extreme,caution,should 0.0 0.0 1 1 0
exposure,of,the 0.0 0.0 1 1 0
explained,by,a 0.0 0.0 1 1 0
experience,with,co-administration 0.0 0.0 1 1 0
exjade,should,not 0.0 0.0 1 1 0
exercised,in,the 0.0 0.0 1 1 0
excretion,of,both 0.0 0.0 1 1 0
excessive,widening,of 0.0 0.0 1 1 0
evidence,suggests,that 0.0 0.0 1 1 0
every,hours,should 0.0 0.0 1 1 0
equetrotm,and,then 0.0 0.0 1 1 0
epa,supplements,and 0.0 0.0 1 1 0
enhancement,of,the 0.0 0.0 1 1 0
enhance,the,potential 0.0 0.0 1 1 0
enalapril,and,iv 0.0 0.0 1 1 0
either,and,the 0.0 0.0 1 1 0
eight,healthy,volunteers 0.0 0.0 1 1 0
efficacy,of,concomitant 0.0 0.0 1 1 0
effects,were,observed 0.0 0.0 1 1 0
effects,of,were 0.0 0.0 1 1 0
effects,of,felbatol 0.0 0.0 1 1 0
effects,of,dcg-iv 0.0 0.0 1 1 0
effects,of,coadministration 0.0 0.0 1 1 0
effects,may,induce 0.0 0.0 1 1 0
effects,caused,by 0.0 0.0 1 1 0
effects,can,be 0.0 0.0 1 1 0
effectiveness,of,these 0.0 0.0 1 1 0
effective,duration,of 0.0 0.0 1 1 0
effective,due,to 0.0 0.0 1 1 0
effect,was,observed 0.0 0.0 1 1 0
effect,should,be 0.0 0.0 1 1 0
effect,on,pharmacokinetics 0.0 0.0 1 1 0
effect,of,various 0.0 0.0 1 1 0
effect,of,toradol 0.0 0.0 1 1 0
effect,of,sodium 0.0 0.0 1 1 0
effect,of,or 0.0 0.0 1 1 0
effect,of,in 0.0 0.0 1 1 0
effect,of,has 0.0 0.0 1 1 0
effect,is,not 0.0 0.0 1 1 0
ecg,changes,and 0.0 0.0 1 1 0
during,the,cure 0.0 0.0 1 1 0
during,the,administration 0.0 0.0 1 1 0
during,concomitant,use 0.0 0.0 1 1 0
duration,of,neuromuscular 0.0 0.0 1 1 0
due,to,their 0.0 0.0 1 1 0
due,to,possible 0.0 0.0 1 1 0
due,to,its 0.0 0.0 1 1 0
due,to,induction 0.0 0.0 1 1 0
dry,mouth,and 0.0 0.0 1 1 0
drugs,whose,absorption 0.0 0.0 1 1 0
drugs,that,alter 0.0 0.0 1 1 0
drug-drug,interaction,study 0.0 0.0 1 1 0
drug,interactions,have 0.0 0.0 1 1 0
doses,should,be 0.0 0.0 1 1 0
doses,of,nimbex 0.0 0.0 1 1 0
dose,of,oral 0.0 0.0 1 1 0
dose,of,may 0.0 0.0 1 1 0
dose,increase,for 0.0 0.0 1 1 0
dose,and,a 0.0 0.0 1 1 0
dose,administration,of 0.0 0.0 1 1 0
dose,adjustment,may 0.0 0.0 1 1 0
dose,adjustment,for 0.0 0.0 1 1 0
dosages,may,be 0.0 0.0 1 1 0
dosage,of,may 0.0 0.0 1 1 0
dosage,of,is 0.0 0.0 1 1 0
does,not,exhibit 0.0 0.0 1 1 0
does,not,enhance 0.0 0.0 1 1 0
divided,into,three 0.0 0.0 1 1 0
distribution,of,the 0.0 0.0 1 1 0
discontinued,at,least 0.0 0.0 1 1 0
direct,action,on 0.0 0.0 1 1 0
digoxin,concomitant,administration 0.0 0.0 1 1 0
difluoro-2,propanol,to 0.0 0.0 1 1 0
diet,high,in 0.0 0.0 1 1 0
determine,whether,the 0.0 0.0 1 1 0
desired,and,or 0.0 0.0 1 1 0
depression,may,be 0.0 0.0 1 1 0
depression,hypotension,and 0.0 0.0 1 1 0
depressant,effect,when 0.0 0.0 1 1 0
demonstrates,some,limited 0.0 0.0 1 1 0
demonstrated,that,and 0.0 0.0 1 1 0
demonstrated,in,patients 0.0 0.0 1 1 0
delay,or,reduce 0.0 0.0 1 1 0
decreases,in,serum 0.0 0.0 1 1 0
decreased,the,incidence 0.0 0.0 1 1 0
decreased,plasma,levels 0.0 0.0 1 1 0
decreased,in,the 0.0 0.0 1 1 0
decrease,the,metabolism 0.0 0.0 1 1 0
decrease,the,levels 0.0 0.0 1 1 0
decrease,metabolism,and 0.0 0.0 1 1 0
decrease,in,total 0.0 0.0 1 1 0
decrease,in,maximal 0.0 0.0 1 1 0
decrease,hepatic,toxicity 0.0 0.0 1 1 0
day,racemic,combined 0.0 0.0 1 1 0
data,in,patients 0.0 0.0 1 1 0
data,from,clinical 0.0 0.0 1 1 0
data,from,a 0.0 0.0 1 1 0
daily,for,one 0.0 0.0 1 1 0
daily,as,compared 0.0 0.0 1 1 0
d,or,mg 0.0 0.0 1 1 0
d,and,s 0.0 0.0 1 1 0
d,agonists,within 0.0 0.0 1 1 0
cytochrome,p-450,the 0.0 0.0 1 1 0
cytochrome,p-450,isoenzymes 0.0 0.0 1 1 0
cyp3a4,inhibitors,should 0.0 0.0 1 1 0
cyp3a4,inhibitors,and 0.0 0.0 1 1 0
cyp3a4,inducers,such 0.0 0.0 1 1 0
cyp2d6,such,as 0.0 0.0 1 1 0
cyp1a2,which,may 0.0 0.0 1 1 0
current,evidence,suggests 0.0 0.0 1 1 0
course,of,mg 0.0 0.0 1 1 0
could,pose,a 0.0 0.0 1 1 0
could,lead,to 0.0 0.0 1 1 0
could,enhance,the 0.0 0.0 1 1 0
cough,and,cold 0.0 0.0 1 1 0
convulsions,have,been 0.0 0.0 1 1 0
conversion,of,difluoro-2 0.0 0.0 1 1 0
contribute,to,the 0.0 0.0 1 1 0
contractile,responses,to 0.0 0.0 1 1 0
containing,mg,of 0.0 0.0 1 1 0
considered,for,patients 0.0 0.0 1 1 0
conjunction,with,other 0.0 0.0 1 1 0
conduction,disturbances,and 0.0 0.0 1 1 0
concurrently,with,because 0.0 0.0 1 1 0
concomitantly,with,potent 0.0 0.0 1 1 0
concomitantly,with,oral 0.0 0.0 1 1 0
concomitantly,with,known 0.0 0.0 1 1 0
concomitantly,with,in 0.0 0.0 1 1 0
concomitantly,with,for 0.0 0.0 1 1 0
concomitantly,administered,in 0.0 0.0 1 1 0
concomitant,medications,that 0.0 0.0 1 1 0
concomitant,agent,may 0.0 0.0 1 1 0
concentrations,of,these 0.0 0.0 1 1 0
concentrations,of,have 0.0 0.0 1 1 0
concentrations,of,endotoxin-treated 0.0 0.0 1 1 0
concentrations,of,by 0.0 0.0 1 1 0
concentrations,in,patients 0.0 0.0 1 1 0
concentration,has,been 0.0 0.0 1 1 0
concentration,ca,i 0.0 0.0 1 1 0
concentration,and,auc 0.0 0.0 1 1 0
concentration,and,area 0.0 0.0 1 1 0
concentration,altered,by 0.0 0.0 1 1 0
complex,and,or 0.0 0.0 1 1 0
competition,for,binding 0.0 0.0 1 1 0
comparison,with,the 0.0 0.0 1 1 0
compared,with,mg 0.0 0.0 1 1 0
compared,to,a 0.0 0.0 1 1 0
combined,effects,may 0.0 0.0 1 1 0
combinations,of,gl 0.0 0.0 1 1 0
combination,with,may 0.0 0.0 1 1 0
coly-mycin,m,parenteral 0.0 0.0 1 1 0
coadministration,of,other 0.0 0.0 1 1 0
coadministration,of,nizoral 0.0 0.0 1 1 0
coadministration,of,femara 0.0 0.0 1 1 0
coadministered,with,on 0.0 0.0 1 1 0
coadministered,with,and 0.0 0.0 1 1 0
co-medications,that,induce 0.0 0.0 1 1 0
co-administration,of,orally 0.0 0.0 1 1 0
co-administration,of,duloxetine 0.0 0.0 1 1 0
co-administration,of,at 0.0 0.0 1 1 0
co-administration,of,angiomax 0.0 0.0 1 1 0
co-administered,with,other 0.0 0.0 1 1 0
cns,depressant,and 0.0 0.0 1 1 0
cmin,concentration,was 0.0 0.0 1 1 0
closely,monitored,in 0.0 0.0 1 1 0
closely,monitored,for 0.0 0.0 1 1 0
closely,in,patients 0.0 0.0 1 1 0
closely,for,evidence 0.0 0.0 1 1 0
closely,and,appropriate 0.0 0.0 1 1 0
close,monitoring,for 0.0 0.0 1 1 0
close,medical,supervision 0.0 0.0 1 1 0
clinically,significant,increases 0.0 0.0 1 1 0
clinically,effective,duration 0.0 0.0 1 1 0
clinical,use,of 0.0 0.0 1 1 0
clinical,trials,with 0.0 0.0 1 1 0
clinical,pharmacology,study 0.0 0.0 1 1 0
clearance,in,patients 0.0 0.0 1 1 0
chronically,had,no 0.0 0.0 1 1 0
channel,blockers,may 0.0 0.0 1 1 0
changes,in,plasma 0.0 0.0 1 1 0
cevimeline,should,be 0.0 0.0 1 1 0
cefditoren,pivoxil,be 0.0 0.0 1 1 0
cautiously,in,patients 0.0 0.0 1 1 0
caution,in,using 0.0 0.0 1 1 0
caused,by,the 0.0 0.0 1 1 0
case,reports,of 0.0 0.0 1 1 0
case,of,severe 0.0 0.0 1 1 0
carefully,observed,for 0.0 0.0 1 1 0
carefully,monitored,for 0.0 0.0 1 1 0
careful,monitoring,or 0.0 0.0 1 1 0
careful,monitoring,for 0.0 0.0 1 1 0
careful,attention,must 0.0 0.0 1 1 0
capsule,formulation,of 0.0 0.0 1 1 0
capacity,to,inhibit 0.0 0.0 1 1 0
can,give,rise 0.0 0.0 1 1 0
can,cause,a 0.0 0.0 1 1 0
ca,concentration,ca 0.0 0.0 1 1 0
c,max,by 0.0 0.0 1 1 0
by,the,addition 0.0 0.0 1 1 0
by,resulting,in 0.0 0.0 1 1 0
by,reducing,the 0.0 0.0 1 1 0
by,increasing,the 0.0 0.0 1 1 0
by,cytochrome,p-450 0.0 0.0 1 1 0
by,cyp2d6,and 0.0 0.0 1 1 0
by,auc0-24hr,in 0.0 0.0 1 1 0
by,any,of 0.0 0.0 1 1 0
by,administration,of 0.0 0.0 1 1 0
by,a,mean 0.0 0.0 1 1 0
by,a,highly 0.0 0.0 1 1 0
but,there,have 0.0 0.0 1 1 0
but,does,not 0.0 0.0 1 1 0
breast,cancer,cells 0.0 0.0 1 1 0
bound,to,serum 0.0 0.0 1 1 0
both,the,rate 0.0 0.0 1 1 0
borne,in,mind 0.0 0.0 1 1 0
bone,marrow,suppression 0.0 0.0 1 1 0
bone,marrow,depression 0.0 0.0 1 1 0
blocks,and,ergot-type 0.0 0.0 1 1 0
blocking,agents,the 0.0 0.0 1 1 0
blocking,agents,such 0.0 0.0 1 1 0
blocking,agents,should 0.0 0.0 1 1 0
blockers,such,as 0.0 0.0 1 1 0
bioavailability,of,is 0.0 0.0 1 1 0
bioavailability,of,and 0.0 0.0 1 1 0
bioavailability,auc,of 0.0 0.0 1 1 0
binding,of,was 0.0 0.0 1 1 0
bile,acid,sequestrants 0.0 0.0 1 1 0
bid,day,and 0.0 0.0 1 1 0
between,and,and 0.0 0.0 1 1 0
between,administration,of 0.0 0.0 1 1 0
beta-adrenergic,blocking,agent 0.0 0.0 1 1 0
beta-1a,avonex,mcg 0.0 0.0 1 1 0
before,the,evening 0.0 0.0 1 1 0
been,treated,with 0.0 0.0 1 1 0
been,shown,in 0.0 0.0 1 1 0
been,rare,postmarketing 0.0 0.0 1 1 0
been,implicated,in 0.0 0.0 1 1 0
been,evaluated,and 0.0 0.0 1 1 0
been,established,but 0.0 0.0 1 1 0
been,demonstrated,that 0.0 0.0 1 1 0
been,demonstrated,between 0.0 0.0 1 1 0
been,conducted,with 0.0 0.0 1 1 0
because,they,may 0.0 0.0 1 1 0
because,of,an 0.0 0.0 1 1 0
because,is,eliminated 0.0 0.0 1 1 0
because,both,of 0.0 0.0 1 1 0
be,useful,in 0.0 0.0 1 1 0
be,temporarily,discontinued 0.0 0.0 1 1 0
be,taken,if 0.0 0.0 1 1 0
be,required,to 0.0 0.0 1 1 0
be,required,and 0.0 0.0 1 1 0
be,reduced,if 0.0 0.0 1 1 0
be,performed,when 0.0 0.0 1 1 0
be,necessary,to 0.0 0.0 1 1 0
be,monitored,to 0.0 0.0 1 1 0
be,monitored,in 0.0 0.0 1 1 0
be,monitored,at 0.0 0.0 1 1 0
be,metabolized,by 0.0 0.0 1 1 0
be,less,effective 0.0 0.0 1 1 0
be,initiated,at 0.0 0.0 1 1 0
be,increased,in 0.0 0.0 1 1 0
be,increased,during 0.0 0.0 1 1 0
be,greater,in 0.0 0.0 1 1 0
be,given,the 0.0 0.0 1 1 0
be,explained,by 0.0 0.0 1 1 0
be,expected,that 0.0 0.0 1 1 0
be,exercised,because 0.0 0.0 1 1 0
be,effective,due 0.0 0.0 1 1 0
be,discontinued,at 0.0 0.0 1 1 0
be,decreased,in 0.0 0.0 1 1 0
be,clinically,significant 0.0 0.0 1 1 0
be,carefully,observed 0.0 0.0 1 1 0
be,borne,in 0.0 0.0 1 1 0
be,avoided,by 0.0 0.0 1 1 0
be,advised,to 0.0 0.0 1 1 0
azithromycin,had,no 0.0 0.0 1 1 0
avonex,mcg,im 0.0 0.0 1 1 0
averaged,s,d 0.0 0.0 1 1 0
av,conduction,disturbances 0.0 0.0 1 1 0
auc0-24hr,in,patients 0.0 0.0 1 1 0
auc,values,in 0.0 0.0 1 1 0
auc,of,the 0.0 0.0 1 1 0
auc,for,and 0.0 0.0 1 1 0
auc,and,the 0.0 0.0 1 1 0
attention,must,be 0.0 0.0 1 1 0
at,the,initiation 0.0 0.0 1 1 0
at,steady-state,with 0.0 0.0 1 1 0
at,approximately,times 0.0 0.0 1 1 0
associated,with,may 0.0 0.0 1 1 0
associated,with,elevated 0.0 0.0 1 1 0
as,or,should 0.0 0.0 1 1 0
as,or,in 0.0 0.0 1 1 0
as,ophthalmic,and 0.0 0.0 1 1 0
as,has,been 0.0 0.0 1 1 0
as,evidenced,by 0.0 0.0 1 1 0
as,competition,for 0.0 0.0 1 1 0
as,antiemetic,prophylaxis 0.0 0.0 1 1 0
argatroban,and,mg 0.0 0.0 1 1 0
are,used,together 0.0 0.0 1 1 0
are,not,recommended 0.0 0.0 1 1 0
are,mainly,metabolized 0.0 0.0 1 1 0
are,also,being 0.0 0.0 1 1 0
aprepitant,with,strong 0.0 0.0 1 1 0
aprepitant,and,on 0.0 0.0 1 1 0
approximately,in,the 0.0 0.0 1 1 0
appropriate,dose,adjustments 0.0 0.0 1 1 0
appropriate,adjustment,of 0.0 0.0 1 1 0
applied,to,the 0.0 0.0 1 1 0
application,of,or 0.0 0.0 1 1 0
appears,to,have 0.0 0.0 1 1 0
appeared,to,be 0.0 0.0 1 1 0
appear,to,increase 0.0 0.0 1 1 0
aortic,rings,with 0.0 0.0 1 1 0
any,other,nsaid 0.0 0.0 1 1 0
anxiogenic,effects,were 0.0 0.0 1 1 0
antimicrobial,combinations,of 0.0 0.0 1 1 0
antiepilepsy,drugs,aeds 0.0 0.0 1 1 0
anticholinergic,agents,may 0.0 0.0 1 1 0
anti-inflammatory,drugs,nsaids 0.0 0.0 1 1 0
antacids,or,h 0.0 0.0 1 1 0
antacids,administration,of 0.0 0.0 1 1 0
angiotensin,ii,receptor 0.0 0.0 1 1 0
angiotensin,ii,antagonists 0.0 0.0 1 1 0
and,was,significantly 0.0 0.0 1 1 0
and,torsades,de 0.0 0.0 1 1 0
and,to,increase 0.0 0.0 1 1 0
and,thus,the 0.0 0.0 1 1 0
and,their,dose 0.0 0.0 1 1 0
and,the,mechanism 0.0 0.0 1 1 0
and,the,effect 0.0 0.0 1 1 0
and,the,duration 0.0 0.0 1 1 0
and,the,concomitant 0.0 0.0 1 1 0
and,that,inhibit 0.0 0.0 1 1 0
and,that,affect 0.0 0.0 1 1 0
and,systemic,and 0.0 0.0 1 1 0
and,suggest,that 0.0 0.0 1 1 0
and,small,gradual 0.0 0.0 1 1 0
and,serum,levels 0.0 0.0 1 1 0
and,serotonergic,agents 0.0 0.0 1 1 0
and,second,contractile 0.0 0.0 1 1 0
and,renal,clearance 0.0 0.0 1 1 0
and,related,anabolic 0.0 0.0 1 1 0
and,reduce,its 0.0 0.0 1 1 0
and,prothrombin,times 0.0 0.0 1 1 0
and,profound,sedation 0.0 0.0 1 1 0
and,produced,a 0.0 0.0 1 1 0
and,plasma,levels 0.0 0.0 1 1 0
and,plasma,concentrations 0.0 0.0 1 1 0
and,other,potentially 0.0 0.0 1 1 0
and,other,inducers 0.0 0.0 1 1 0
and,or,severity 0.0 0.0 1 1 0
and,or,prolongation 0.0 0.0 1 1 0
and,or,its 0.0 0.0 1 1 0
and,or,inhibitors 0.0 0.0 1 1 0
and,or,effect 0.0 0.0 1 1 0
and,multiple,dose 0.0 0.0 1 1 0
and,mg,qd 0.0 0.0 1 1 0
and,mg,each 0.0 0.0 1 1 0
and,mesenteric,vasodilation 0.0 0.0 1 1 0
and,may,alter 0.0 0.0 1 1 0
and,maximum,concentration 0.0 0.0 1 1 0
and,leading,to 0.0 0.0 1 1 0
and,its,effect 0.0 0.0 1 1 0
and,in,humans 0.0 0.0 1 1 0
and,hours,after 0.0 0.0 1 1 0
and,hepatic,tissues 0.0 0.0 1 1 0
and,female,volunteers 0.0 0.0 1 1 0
and,ergot-type,oxytocic 0.0 0.0 1 1 0
and,enhance,the 0.0 0.0 1 1 0
and,decreases,in 0.0 0.0 1 1 0
and,d,h 0.0 0.0 1 1 0
and,concomitant,use 0.0 0.0 1 1 0
and,cold,preparations 0.0 0.0 1 1 0
and,cmax,by 0.0 0.0 1 1 0
and,cardiac,glycosides 0.0 0.0 1 1 0
and,area,under 0.0 0.0 1 1 0
and,angiotensin,ii 0.0 0.0 1 1 0
and,acetylsalicylic,acid 0.0 0.0 1 1 0
and,a,potent 0.0 0.0 1 1 0
anagrelide,demonstrates,some 0.0 0.0 1 1 0
an,oral,containing 0.0 0.0 1 1 0
an,association,between 0.0 0.0 1 1 0
amprenavir,plus,was 0.0 0.0 1 1 0
amphetamines,can,cause 0.0 0.0 1 1 0
amount,of,absorbed 0.0 0.0 1 1 0
amitriptyline,hcl,is 0.0 0.0 1 1 0
although,the,occurrence 0.0 0.0 1 1 0
although,not,studied 0.0 0.0 1 1 0
although,not,a 0.0 0.0 1 1 0
although,no,clinical 0.0 0.0 1 1 0
alternative,therapy,should 0.0 0.0 1 1 0
alter,the,renal 0.0 0.0 1 1 0
also,used,the 0.0 0.0 1 1 0
also,suggest,that 0.0 0.0 1 1 0
also,shown,that 0.0 0.0 1 1 0
also,reported,to 0.0 0.0 1 1 0
also,has,no 0.0 0.0 1 1 0
also,being,given 0.0 0.0 1 1 0
already,stabilized,on 0.0 0.0 1 1 0
all,patients,treated 0.0 0.0 1 1 0
aldehyde,oxidase,in 0.0 0.0 1 1 0
agents,which,are 0.0 0.0 1 1 0
agents,when,an 0.0 0.0 1 1 0
agents,known,to 0.0 0.0 1 1 0
agents,in,the 0.0 0.0 1 1 0
agents,concurrent,use 0.0 0.0 1 1 0
agents,and,has 0.0 0.0 1 1 0
agent,should,be 0.0 0.0 1 1 0
after,the,initial 0.0 0.0 1 1 0
after,the,addition 0.0 0.0 1 1 0
affect,the,pharmacokinetic 0.0 0.0 1 1 0
affect,platelet,function 0.0 0.0 1 1 0
advised,when,administering 0.0 0.0 1 1 0
advised,against,the 0.0 0.0 1 1 0
adverse,reactions,to 0.0 0.0 1 1 0
administration,of,vasopressor 0.0 0.0 1 1 0
administration,of,sonata 0.0 0.0 1 1 0
administration,of,oral 0.0 0.0 1 1 0
administration,of,methylpyrazole 0.0 0.0 1 1 0
administration,of,drugs 0.0 0.0 1 1 0
administration,of,concomitantly 0.0 0.0 1 1 0
administration,of,at 0.0 0.0 1 1 0
administration,of,alone 0.0 0.0 1 1 0
administered,with,food 0.0 0.0 1 1 0
administered,shortly,after 0.0 0.0 1 1 0
administered,on,day5 0.0 0.0 1 1 0
administered,in,clinical 0.0 0.0 1 1 0
administered,at,a 0.0 0.0 1 1 0
administered,alone,and 0.0 0.0 1 1 0
adjustments,of,should 0.0 0.0 1 1 0
adjustment,is,not 0.0 0.0 1 1 0
adenocarcinomas,induced,by 0.0 0.0 1 1 0
activity,towards,cyp1a2 0.0 0.0 1 1 0
active,tubular,secretion 0.0 0.0 1 1 0
activation,of,spontaneous 0.0 0.0 1 1 0
actions,of,the 0.0 0.0 1 1 0
action,of,initial 0.0 0.0 1 1 0
act,on,the 0.0 0.0 1 1 0
acid-base,and,electrolyte 0.0 0.0 1 1 0
acetazolamide,may,increase 0.0 0.0 1 1 0
ace,inhibitors,may 0.0 0.0 1 1 0
ace,inhibitors,has 0.0 0.0 1 1 0
acamprosate,concomitantly,with 0.0 0.0 1 1 0
absorption,of,some 0.0 0.0 1 1 0
absorption,of,in 0.0 0.0 1 1 0
absorption,of,concomitant 0.0 0.0 1 1 0
absorption,of,as 0.0 0.0 1 1 0
about,the,interaction 0.0 0.0 1 1 0
a4,inhibitors,such 0.0 0.0 1 1 0
a,theoretical,potential 0.0 0.0 1 1 0
a,similar,study 0.0 0.0 1 1 0
a,significant,elevation 0.0 0.0 1 1 0
a,selective,serotonin 0.0 0.0 1 1 0
a,potentially,toxic 0.0 0.0 1 1 0
a,nonlethal,dose 0.0 0.0 1 1 0
a,multiple-dose,study 0.0 0.0 1 1 0
a,maintenance,level 0.0 0.0 1 1 0
a,light,meal 0.0 0.0 1 1 0
a,less,than 0.0 0.0 1 1 0
a,higher,incidence 0.0 0.0 1 1 0
a,hazard,to 0.0 0.0 1 1 0
a,drug-drug,interaction 0.0 0.0 1 1 0
a,dose-dependent,fashion 0.0 0.0 1 1 0
a,direct,action 0.0 0.0 1 1 0
a,daily,dose 0.0 0.0 1 1 0
a,cyp3a4,inhibitor 0.0 0.0 1 1 0
a,clinical,pharmacology 0.0 0.0 1 1 0
a,change,in 0.0 0.0 1 1 0
a,case,of 0.0 0.0 1 1 0
a,beta-adrenergic,blocking 0.0 0.0 1 1 0
